NCT001403090	NCT00140309_0_T0	GENE	2	2	27
NCT001403090	NCT00140309_0_T1	COMPOUND	0	0	TBTC
NCT001403093	NCT00140309_3_T0	PHENOTYPE	18	18	affects
NCT001403095	NCT00140309_5_T0	COMPOUND	20	20	moxifloxacin
NCT001403098	NCT00140309_8_T0	PHENOTYPE	5	5	tuberculosis
NCT001403098	NCT00140309_8_T1	PHENOTYPE	10	11	pulmonary disease
NCT0014030910	NCT00140309_10_T0	PHENOTYPE	3	3	HIV
NCT0014030910	NCT00140309_10_T1	PHENOTYPE	7	7	HIV
NCT0014030910	NCT00140309_10_T2	PHENOTYPE	17	19	negative HIV test
NCT0014030911	NCT00140309_11_T0	PHENOTYPE	5	5	tuberculosis
NCT0014030920	NCT00140309_20_T0	COMPOUND	4	4	fluoroquinolone
NCT0014030920	NCT00140309_20_T1	PHENOTYPE	1	1	allergy
NCT0014030922	NCT00140309_22_T0	PHENOTYPE	11	11	tuberculosis
NCT001403222	NCT00140322_2_T0	PHENOTYPE	16	16	strategies
NCT001403225	NCT00140322_5_T0	PHENOTYPE	18	18	falling
NCT001403225	NCT00140322_5_T1	PHENOTYPE	16	17	fear of
NCT001403352	NCT00140335_2_T0	PHENOTYPE	4	4	diseases
NCT001403353	NCT00140335_3_T0	COMPOUND	7	7	1st
NCT001403353	NCT00140335_3_T1	PHENOTYPE	27	27	attitudes
NCT001403357	NCT00140335_7_T0	PHENOTYPE	5	5	attitudes
NCT001403357	NCT00140335_7_T1	PHENOTYPE	7	7	practices
NCT001403613	NCT00140361_3_T0	PHENOTYPE	1	1	fever
NCT001403613	NCT00140361_3_T1	PHENOTYPE	14	14	fever
NCT001403613	NCT00140361_3_T2	PHENOTYPE	56	56	malaria
NCT001403613	NCT00140361_3_T3	PHENOTYPE	32	32	asexual
NCT001403613	NCT00140361_3_T4	PHENOTYPE	19	19	chronic
NCT001403614	NCT00140361_4_T0	COMPOUND	9	9	artemisinin
NCT001403614	NCT00140361_4_T1	PHENOTYPE	1	1	allergy
NCT001403741	NCT00140374_1_T0	PHENOTYPE	12	12	toxicity
NCT001403871	NCT00140387_1_T0	PHENOTYPE	12	12	toxicity
NCT001404135	NCT00140413_5_T0	PHENOTYPE	6	6	endocrinopathies
NCT0014041317	NCT00140413_17_T0	GENE	22	22	MRI
NCT0014041320	NCT00140413_20_T0	GENE	7	7	GH
NCT0014041320	NCT00140413_20_T1	GENE	12	12	GH
NCT0014041322	NCT00140413_22_T0	TISSUE	15	16	body fat
NCT001404261	NCT00140426_1_T0	COMPOUND	4	4	risperidone
NCT001404261	NCT00140426_1_T1	COMPOUND	1	1	1
NCT001404261	NCT00140426_1_T2	COMPOUND	19	19	2
NCT001404261	NCT00140426_1_T3	PHENOTYPE	14	14	distortion
NCT001404261	NCT00140426_1_T4	PHENOTYPE	16	17	Eating Disorder
NCT001404261	NCT00140426_1_T5	PHENOTYPE	12	13	body image
NCT001404262	NCT00140426_2_T0	COMPOUND	1	1	2
NCT001404262	NCT00140426_2_T1	COMPOUND	4	4	risperidone
NCT001404265	NCT00140426_5_T0	PHENOTYPE	18	18	symptoms
NCT001404265	NCT00140426_5_T1	COMPOUND	6	6	risperidone
NCT001404265	NCT00140426_5_T2	COMPOUND	12	12	risperidone
NCT001404265	NCT00140426_5_T3	PHENOTYPE	20	21	anorexia nervosa
NCT001404266	NCT00140426_6_T0	COMPOUND	3	3	risperidone
NCT001404266	NCT00140426_6_T1	PHENOTYPE	16	17	Tardive Dyskinesia
NCT001404266	NCT00140426_6_T2	PHENOTYPE	14	15	Extrapyramidal Symptoms
NCT001404266	NCT00140426_6_T3	PHENOTYPE	22	23	liver enzymes
NCT001404266	NCT00140426_6_T4	PHENOTYPE	20	21	Energy Expenditure
NCT001404267	NCT00140426_7_T0	PHENOTYPE	18	18	symptoms
NCT001404267	NCT00140426_7_T1	GENE	15	15	leptin
NCT001404390	NCT00140439_0_T0	PHENOTYPE	1	1	Asthma
NCT001404392	NCT00140439_2_T0	PHENOTYPE	20	20	asthma
NCT001404393	NCT00140439_3_T0	PHENOTYPE	14	14	asthma
NCT001404393	NCT00140439_3_T1	PHENOTYPE	17	17	asthma
NCT001404393	NCT00140439_3_T2	PHENOTYPE	18	20	quality of life
NCT001404395	NCT00140439_5_T0	PHENOTYPE	9	9	physiology
NCT001404395	NCT00140439_5_T1	PHENOTYPE	11	11	asthma
NCT001404395	NCT00140439_5_T2	PHENOTYPE	0	0	Asthma
NCT0014043914	NCT00140439_14_T0	PHENOTYPE	22	22	asthma
NCT0014043917	NCT00140439_17_T0	PHENOTYPE	5	5	asthma
NCT0014043917	NCT00140439_17_T1	PHENOTYPE	15	15	asthma
NCT0014043918	NCT00140439_18_T0	COMPOUND	2	2	1
NCT0014043918	NCT00140439_18_T1	COMPOUND	10	10	2
NCT001404650	NCT00140465_0_T0	GENE	8	8	PCI
NCT001404652	NCT00140465_2_T0	GENE	24	24	PCI
NCT001404653	NCT00140465_3_T0	PHENOTYPE	8	8	chronic
NCT001404654	NCT00140465_4_T0	GENE	5	5	has
NCT001404656	NCT00140465_6_T0	COMPOUND	18	18	clopidogrel
NCT001404784	NCT00140478_4_T0	PHENOTYPE	13	14	hormone levels
NCT001404785	NCT00140478_5_T0	GENE	20	20	MRI
NCT001404910	NCT00140491_0_T0	PHENOTYPE	7	10	Anterior Ischemic Optic Neuropathy
NCT001404914	NCT00140491_4_T0	PHENOTYPE	13	16	altitudinal visual field defect
NCT001404915	NCT00140491_5_T0	PHENOTYPE	10	11	depth perception
NCT001404916	NCT00140491_6_T0	PHENOTYPE	16	16	secondary
NCT001404916	NCT00140491_6_T1	PHENOTYPE	2	2	enlargement
NCT001404916	NCT00140491_6_T2	GENE	7	7	has
NCT001404916	NCT00140491_6_T3	ORGAN	22	23	visual pathways
NCT001404916	NCT00140491_6_T4	PHENOTYPE	4	6	visual field defects
NCT001404917	NCT00140491_7_T0	GENE	11	11	has
NCT001404918	NCT00140491_8_T0	PHENOTYPE	9	10	homonymous hemianopia
NCT0014049110	NCT00140491_10_T0	CELL	4	4	neurons
NCT0014049111	NCT00140491_11_T0	PHENOTYPE	21	22	optic neuropathies
NCT0014049112	NCT00140491_12_T0	PHENOTYPE	20	20	unilateral
NCT0014049112	NCT00140491_12_T1	PHENOTYPE	22	22	bilateral
NCT0014049112	NCT00140491_12_T2	PHENOTYPE	34	36	visual field defects
NCT0014049113	NCT00140491_13_T0	GENE	16	16	24.2
NCT0014049113	NCT00140491_13_T1	PHENOTYPE	27	29	quality of life
NCT0014049119	NCT00140491_19_T0	GENE	9	9	has
NCT001405040	NCT00140504_0_T0	PHENOTYPE	1	3	Adverse Drug Events
NCT001405171	NCT00140517_1_T0	PHENOTYPE	12	12	malaria
NCT001405171	NCT00140517_1_T1	GENE	2	2	SP
NCT001405172	NCT00140517_2_T0	PHENOTYPE	13	13	resistant
NCT001405172	NCT00140517_2_T1	PHENOTYPE	14	14	malaria
NCT001405172	NCT00140517_2_T2	PHENOTYPE	16	16	strains
NCT001405173	NCT00140517_3_T0	PHENOTYPE	18	20	malaria in pregnancy
NCT001405174	NCT00140517_4_T0	PHENOTYPE	35	35	resistant
NCT001405174	NCT00140517_4_T1	PHENOTYPE	36	36	strains
NCT001405174	NCT00140517_4_T2	GENE	28	28	SP
NCT001405178	NCT00140517_8_T0	PHENOTYPE	26	26	malaria
NCT001405178	NCT00140517_8_T1	GENE	18	18	SP
NCT001405179	NCT00140517_9_T0	PHENOTYPE	14	14	centre
NCT001405179	NCT00140517_9_T1	PHENOTYPE	20	20	malaria
NCT001405179	NCT00140517_9_T2	GENE	29	29	SP
NCT0014051711	NCT00140517_11_T0	PHENOTYPE	21	21	cord
NCT0014051711	NCT00140517_11_T1	PHENOTYPE	19	19	peripheral
NCT0014051711	NCT00140517_11_T2	GENE	16	16	SP
NCT0014051712	NCT00140517_12_T0	PHENOTYPE	16	16	anaemia
NCT0014051712	NCT00140517_12_T1	PHENOTYPE	9	9	resistant
NCT0014051712	NCT00140517_12_T2	PHENOTYPE	10	10	strains
NCT0014051712	NCT00140517_12_T3	PHENOTYPE	12	12	malaria
NCT0014051713	NCT00140517_13_T0	GENE	10	10	SP
NCT0014051714	NCT00140517_14_T0	PHENOTYPE	10	10	peripheral
NCT0014051714	NCT00140517_14_T1	PHENOTYPE	12	12	centre
NCT0014051716	NCT00140517_16_T0	PHENOTYPE	0	0	Malaria
NCT0014051717	NCT00140517_17_T0	PHENOTYPE	0	0	Malaria
NCT0014051717	NCT00140517_17_T1	PHENOTYPE	8	8	illnesses
NCT0014051717	NCT00140517_17_T2	GENE	46	46	has
NCT0014051717	NCT00140517_17_T3	PHENOTYPE	7	7	febrile
NCT0014051717	NCT00140517_17_T4	GENE	45	45	SP
NCT0014051717	NCT00140517_17_T5	PHENOTYPE	17	17	centres
NCT0014051719	NCT00140517_19_T0	PHENOTYPE	0	0	Malaria
NCT0014051719	NCT00140517_19_T1	PHENOTYPE	21	21	malaria
NCT0014051720	NCT00140517_20_T0	GENE	0	0	ANC
NCT0014051720	NCT00140517_20_T1	PHENOTYPE	4	4	centres
NCT0014051721	NCT00140517_21_T0	GENE	6	6	VI
NCT0014051721	NCT00140517_21_T1	PHENOTYPE	2	2	centre
NCT0014051721	NCT00140517_21_T2	GENE	5	5	Paul
NCT0014051726	NCT00140517_26_T0	PHENOTYPE	23	23	centre
NCT0014051726	NCT00140517_26_T1	PHENOTYPE	39	39	reflecting
NCT0014051726	NCT00140517_26_T2	COMPOUND	31	31	chloroquine
NCT0014051726	NCT00140517_26_T3	GENE	24	25	group D
NCT0014051728	NCT00140517_28_T0	COMPOUND	2	2	1
NCT0014051728	NCT00140517_28_T1	COMPOUND	15	15	2
NCT0014051728	NCT00140517_28_T2	GENE	29	29	Hb
NCT0014051728	NCT00140517_28_T3	GENE	36	36	PCR
NCT0014051729	NCT00140517_29_T0	GENE	5	5	SP
NCT0014051730	NCT00140517_30_T0	PHENOTYPE	16	17	feel sick
NCT0014051731	NCT00140517_31_T0	COMPOUND	12	12	1
NCT0014051732	NCT00140517_32_T0	COMPOUND	11	11	2
NCT0014051732	NCT00140517_32_T1	GENE	10	10	Hb
NCT0014051733	NCT00140517_33_T0	PHENOTYPE	20	20	peripheral
NCT0014051733	NCT00140517_33_T1	COMPOUND	8	8	1
NCT0014051733	NCT00140517_33_T2	COMPOUND	18	18	2
NCT0014051733	NCT00140517_33_T3	COMPOUND	32	32	3
NCT0014051733	NCT00140517_33_T4	GENE	26	26	Hb
NCT0014051733	NCT00140517_33_T5	GENE	31	31	PCR
NCT0014051733	NCT00140517_33_T6	GENE	45	45	PCR
NCT0014051733	NCT00140517_33_T7	ORGAN	47	48	cord blood
NCT0014051734	NCT00140517_34_T0	GENE	24	24	SP
NCT0014051734	NCT00140517_34_T1	GENE	10	10	PCR
NCT0014051735	NCT00140517_35_T0	PHENOTYPE	8	8	malaria
NCT0014051735	NCT00140517_35_T1	GENE	17	17	SP
NCT0014051736	NCT00140517_36_T0	COMPOUND	10	10	chloroquine
NCT0014051736	NCT00140517_36_T1	GENE	14	14	DHFR
NCT0014051736	NCT00140517_36_T2	GENE	15	15	DHPS
NCT0014051736	NCT00140517_36_T3	GENE	11	11	PfCRT
NCT0014051737	NCT00140517_37_T0	GENE	11	11	SP
NCT0014051739	NCT00140517_39_T0	PHENOTYPE	10	10	peripheral
NCT0014051740	NCT00140517_40_T0	COMPOUND	89	89	chloroquine
NCT0014051740	NCT00140517_40_T1	GENE	48	48	SP
NCT0014051742	NCT00140517_42_T0	GENE	10	10	ANC
NCT0014051746	NCT00140517_46_T0	PHENOTYPE	3	3	peripheral
NCT0014051746	NCT00140517_46_T1	PHENOTYPE	0	0	Cord
NCT0014051746	NCT00140517_46_T2	GENE	12	12	PCR
NCT0014051748	NCT00140517_48_T0	PHENOTYPE	25	25	immersion
NCT0014051748	NCT00140517_48_T1	COMPOUND	12	12	phosphate
NCT0014051748	NCT00140517_48_T2	GENE	15	15	7.2
NCT0014051748	NCT00140517_48_T3	COMPOUND	6	6	methanol
NCT0014051748	NCT00140517_48_T4	GENE	14	14	pH
NCT0014051749	NCT00140517_49_T0	CELL	44	44	leukocyte
NCT0014051749	NCT00140517_49_T1	CELL	29	29	leukocytes
NCT0014051749	NCT00140517_49_T2	PHENOTYPE	24	24	asexual
NCT0014051749	NCT00140517_49_T3	PHENOTYPE	25	25	P.falciparum
NCT0014051752	NCT00140517_52_T0	GENE	12	12	ANC
NCT0014051754	NCT00140517_54_T0	GENE	28	28	Hb
NCT0014051754	NCT00140517_54_T1	PHENOTYPE	21	22	haemoglobin concentration
NCT0014051757	NCT00140517_57_T0	PHENOTYPE	14	15	falciparum malaria
NCT0014051760	NCT00140517_60_T0	PHENOTYPE	27	27	concentrations
NCT0014051760	NCT00140517_60_T1	PHENOTYPE	36	36	malaria
NCT0014051761	NCT00140517_61_T0	COMPOUND	22	22	LBW
NCT0014051761	NCT00140517_61_T1	PHENOTYPE	16	16	peripheral
NCT0014051761	NCT00140517_61_T2	PHENOTYPE	25	25	resistant
NCT0014051761	NCT00140517_61_T3	PHENOTYPE	26	26	strains
NCT0014051761	NCT00140517_61_T4	ORGAN	19	20	cord blood
NCT0014051762	NCT00140517_62_T0	PHENOTYPE	4	4	concentrations
NCT001405300	NCT00140530_0_T0	PHENOTYPE	6	6	Restenosis
NCT001405304	NCT00140530_4_T0	GENE	3	3	reduced
NCT001405305	NCT00140530_5_T0	GENE	17	17	has
NCT001405307	NCT00140530_7_T0	GENE	3	3	has
NCT001405308	NCT00140530_8_T0	PHENOTYPE	7	7	enables
NCT001405309	NCT00140530_9_T0	PHENOTYPE	6	6	restenosis
NCT001405309	NCT00140530_9_T1	PHENOTYPE	24	24	proliferation
NCT001405309	NCT00140530_9_T2	COMPOUND	12	12	rapamycin
NCT0014053010	NCT00140530_10_T0	PHENOTYPE	33	33	restenosis
NCT0014053010	NCT00140530_10_T1	COMPOUND	14	14	rapamycin
NCT0014053010	NCT00140530_10_T2	COMPOUND	23	23	rapamycin
NCT0014053011	NCT00140530_11_T0	GENE	29	29	has
NCT001405431	NCT00140543_1_T0	PHENOTYPE	10	10	immunosuppression
NCT001405431	NCT00140543_1_T1	ORGAN	28	28	allograft
NCT001405433	NCT00140543_3_T0	PHENOTYPE	12	12	complications
NCT001405433	NCT00140543_3_T1	PHENOTYPE	15	15	complications
NCT001405436	NCT00140543_6_T0	GENE	0	1	Group 1
NCT001405439	NCT00140543_9_T0	GENE	14	14	1.1
NCT0014054312	NCT00140543_12_T0	PHENOTYPE	16	16	nephropathy
NCT0014054314	NCT00140543_14_T0	PHENOTYPE	8	10	negative pregnancy test
NCT0014054318	NCT00140543_18_T0	ORGAN	14	14	bladder
NCT0014054318	NCT00140543_18_T1	ORGAN	9	9	transplant
NCT0014054318	NCT00140543_18_T2	GENE	17	17	portal
NCT0014054318	NCT00140543_18_T3	GENE	7	7	SPK
NCT0014054322	NCT00140543_22_T0	COMPOUND	12	12	macrolides
NCT0014054324	NCT00140543_24_T0	GENE	1	1	has
NCT0014054324	NCT00140543_24_T1	ORGAN	10	10	serum
NCT0014054324	NCT00140543_24_T2	CELL	4	4	T-cell
NCT0014054330	NCT00140543_30_T0	GENE	1	1	has
NCT0014054332	NCT00140543_32_T0	GENE	1	1	has
NCT0014054332	NCT00140543_32_T1	PHENOTYPE	7	8	psychiatric disorder
NCT0014054332	NCT00140543_32_T2	PHENOTYPE	5	6	substance abuse
NCT0014054334	NCT00140543_34_T0	ORGAN	17	17	kidney
NCT0014054334	NCT00140543_34_T1	ORGAN	4	4	transplant
NCT0014054334	NCT00140543_34_T2	ORGAN	13	13	transplant
NCT0014054334	NCT00140543_34_T3	ORGAN	18	18	transplant
NCT0014054334	NCT00140543_34_T4	GENE	3	3	SPK
NCT0014054336	NCT00140543_36_T0	PHENOTYPE	2	2	occlusion
NCT0014054336	NCT00140543_36_T1	GENE	4	4	10
NCT0014054336	NCT00140543_36_T2	ORGAN	0	1	Pancreatic duct
NCT001405560	NCT00140556_0_T0	PHENOTYPE	6	6	Chemoradiation
NCT001405560	NCT00140556_0_T1	GENE	2	2	EGFR
NCT001405560	NCT00140556_0_T2	PHENOTYPE	9	12	Head and Neck Cancer
NCT001405564	NCT00140556_4_T0	GENE	4	4	reduced
NCT001405566	NCT00140556_6_T0	GENE	6	6	RT
NCT001405566	NCT00140556_6_T1	GENE	3	3	EGFR
NCT001405567	NCT00140556_7_T0	GENE	1	1	VEGF
NCT001405567	NCT00140556_7_T1	GENE	3	3	EGFR
NCT001405567	NCT00140556_7_T2	PHENOTYPE	20	23	head and neck cancer
NCT001405569	NCT00140556_9_T0	COMPOUND	19	19	cisplatin
NCT0014055613	NCT00140556_13_T0	GENE	14	14	EGF
NCT0014055613	NCT00140556_13_T1	GENE	10	10	VEGF
NCT0014055613	NCT00140556_13_T2	GENE	12	12	IL-8
NCT001405822	NCT00140582_2_T0	COMPOUND	9	9	1st
NCT001405953	NCT00140595_3_T0	PHENOTYPE	6	6	toxicity
NCT001405953	NCT00140595_3_T1	GENE	2	2	had
NCT001405955	NCT00140595_5_T0	GENE	22	22	EFS
NCT001405955	NCT00140595_5_T1	PHENOTYPE	17	17	remission
NCT001405955	NCT00140595_5_T2	GENE	6	6	CHOP
NCT001405955	NCT00140595_5_T3	GENE	8	8	has
NCT001405955	NCT00140595_5_T4	GENE	19	19	CR
NCT001405956	NCT00140595_6_T0	GENE	12	12	EFS
NCT001405956	NCT00140595_6_T1	GENE	25	25	CHOP
NCT0014059510	NCT00140595_10_T0	GENE	8	8	LDH
NCT0014059510	NCT00140595_10_T1	GENE	10	10	OR
NCT0014059510	NCT00140595_10_T2	GENE	13	13	OR
NCT0014059513	NCT00140595_13_T0	PHENOTYPE	1	1	HIV
NCT0014059513	NCT00140595_13_T1	COMPOUND	4	4	HCV
NCT0014059513	NCT00140595_13_T2	PHENOTYPE	2	2	HBV
NCT0014059515	NCT00140595_15_T0	PHENOTYPE	7	7	lymphoma
NCT0014059516	NCT00140595_16_T0	PHENOTYPE	7	7	lymphoma
NCT0014059518	NCT00140595_18_T0	PHENOTYPE	7	7	lymphoma
NCT0014059518	NCT00140595_18_T1	ORGAN	0	2	Central nervous system
NCT0014059521	NCT00140595_21_T0	PHENOTYPE	22	22	lymphoma
NCT0014059521	NCT00140595_21_T1	PHENOTYPE	8	9	total bilirubin
NCT0014059522	NCT00140595_22_T0	GENE	12	12	100
NCT0014059522	NCT00140595_22_T1	GENE	8	8	1.5
NCT0014059522	NCT00140595_22_T2	CELL	7	7	neutrophils
NCT0014059522	NCT00140595_22_T3	CELL	11	11	platelets
NCT0014059522	NCT00140595_22_T4	PHENOTYPE	19	19	infiltration
NCT0014059522	NCT00140595_22_T5	ORGAN	1	2	bone marrow
NCT0014059522	NCT00140595_22_T6	ORGAN	17	18	bone marrow
NCT0014059523	NCT00140595_23_T0	PHENOTYPE	15	15	tumors
NCT0014059523	NCT00140595_23_T1	PHENOTYPE	13	14	melanoma skin
NCT0014059523	NCT00140595_23_T2	PHENOTYPE	21	22	cervical carcinoma
NCT0014059523	NCT00140595_23_T3	PHENOTYPE	17	18	stage 0
NCT001406472	NCT00140647_2_T0	GENE	7	7	DREAM
NCT001406472	NCT00140647_2_T1	COMPOUND	14	14	rosiglitazone
NCT001406472	NCT00140647_2_T2	PHENOTYPE	8	8	Diabetes
NCT001406472	NCT00140647_2_T3	COMPOUND	12	12	ramipril
NCT001406474	NCT00140647_4_T0	PHENOTYPE	24	24	atherosclerosis
NCT001406474	NCT00140647_4_T1	COMPOUND	2	2	THE
NCT001406474	NCT00140647_4_T2	PHENOTYPE	27	27	inference
NCT001406474	NCT00140647_4_T3	COMPOUND	8	8	ramipril
NCT001406474	NCT00140647_4_T4	MOLECULAR_FUNCTION	20	21	ACE inhibitor
NCT001406603	NCT00140660_3_T0	PHENOTYPE	16	16	relapse
NCT001406604	NCT00140660_4_T0	GENE	14	14	CHOP
NCT001406604	NCT00140660_4_T1	GENE	32	32	CHOP
NCT001406604	NCT00140660_4_T2	GENE	4	4	al
NCT001406604	NCT00140660_4_T3	GENE	3	3	et
NCT0014066014	NCT00140660_14_T0	PHENOTYPE	14	14	toxicity
NCT0014066014	NCT00140660_14_T1	GENE	9	9	66
NCT0014066018	NCT00140660_18_T0	PHENOTYPE	6	7	indolent lymphoma
NCT001406730	NCT00140673_0_T0	GENE	13	13	thy
NCT001406732	NCT00140673_2_T0	PHENOTYPE	21	21	intussusception
NCT001406732	NCT00140673_2_T1	COMPOUND	4	4	N
NCT001406732	NCT00140673_2_T2	GENE	13	13	GSK
NCT001406735	NCT00140673_5_T0	GENE	1	1	EPI
NCT001406738	NCT00140673_8_T0	COMPOUND	2	2	N
NCT001406863	NCT00140686_3_T0	GENE	1	1	EPI
NCT001406867	NCT00140686_7_T0	GENE	8	9	group C
NCT001406869	NCT00140686_9_T0	GENE	9	10	group C
NCT001406990	NCT00140699_0_T0	PHENOTYPE	3	3	Maturation
NCT001406993	NCT00140699_3_T0	PHENOTYPE	22	23	balance disorders
NCT001406995	NCT00140699_5_T0	COMPOUND	0	0	2
NCT0014069911	NCT00140699_11_T0	PHENOTYPE	3	4	balance disorders
NCT0014069912	NCT00140699_12_T0	PHENOTYPE	11	11	acute
NCT0014069912	NCT00140699_12_T1	GENE	18	18	al
NCT0014069912	NCT00140699_12_T2	GENE	17	17	et
NCT0014069912	NCT00140699_12_T3	PHENOTYPE	13	15	chronic otitis media
NCT0014069915	NCT00140699_15_T0	GENE	2	2	DP
NCT0014069918	NCT00140699_18_T0	COMPOUND	0	0	2
NCT0014069918	NCT00140699_18_T1	PHENOTYPE	9	10	balance disorders
NCT0014069922	NCT00140699_22_T0	GENE	15	15	DP
NCT001407250	NCT00140725_0_T0	GENE	2	2	Interferon
NCT001407250	NCT00140725_0_T1	PHENOTYPE	15	15	HBV
NCT001407250	NCT00140725_0_T2	PHENOTYPE	11	13	Chronic Hepatitis B
NCT001407385	NCT00140738_5_T0	GENE	14	14	Act
NCT001407385	NCT00140738_5_T1	GENE	3	3	has
NCT001407385	NCT00140738_5_T2	GENE	15	15	Sep
NCT0014073812	NCT00140738_12_T0	PHENOTYPE	5	5	centers
NCT0014073815	NCT00140738_15_T0	TISSUE	5	6	lymph nodes
NCT0014073815	NCT00140738_15_T1	PHENOTYPE	14	15	metastatic disease
NCT0014073817	NCT00140738_17_T0	COMPOUND	5	5	3
NCT0014073821	NCT00140738_21_T0	PHENOTYPE	11	11	impairment
NCT0014073821	NCT00140738_21_T1	PHENOTYPE	6	7	lung metastases
NCT0014073823	NCT00140738_23_T0	PHENOTYPE	13	14	lung metastases
NCT001407511	NCT00140751_1_T0	PHENOTYPE	17	17	suppression
NCT001407511	NCT00140751_1_T1	GENE	29	29	PI
NCT001407511	NCT00140751_1_T2	ORGAN	23	23	plasma
NCT001407511	NCT00140751_1_T3	GENE	18	18	met
NCT001407511	NCT00140751_1_T4	BIOLOGICAL_PROCESS	35	36	viral replication
NCT001407511	NCT00140751_1_T5	GENE	4	5	protease inhibitor
NCT001407511	NCT00140751_1_T6	GENE	10	11	reverse transcriptase
NCT001407512	NCT00140751_2_T0	COMPOUND	9	9	LPV/r
NCT001407512	NCT00140751_2_T1	COMPOUND	4	4	lopinavir
NCT001407512	NCT00140751_2_T2	COMPOUND	1	1	ritonavir
NCT001407512	NCT00140751_2_T3	ORGAN	5	5	plasma
NCT001407513	NCT00140751_3_T0	COMPOUND	1	1	lopinavir
NCT001407514	NCT00140751_4_T0	COMPOUND	0	0	LPV/r
NCT001407514	NCT00140751_4_T1	COMPOUND	26	26	lopinavir
NCT001407514	NCT00140751_4_T2	PHENOTYPE	11	11	pharmacokinetics
NCT001407514	NCT00140751_4_T3	BIOLOGICAL_PROCESS	19	20	viral replication
NCT001407641	NCT00140764_1_T0	PHENOTYPE	13	13	symptoms
NCT001407643	NCT00140764_3_T0	PHENOTYPE	6	6	HIV
NCT001407903	NCT00140790_3_T0	COMPOUND	4	4	valsartan
NCT001407903	NCT00140790_3_T1	PHENOTYPE	10	11	urine albumin
NCT001407904	NCT00140790_4_T0	COMPOUND	3	3	valsartan
NCT001408030	NCT00140803_0_T0	PHENOTYPE	9	9	Secondary
NCT001408030	NCT00140803_0_T1	PHENOTYPE	11	13	Age-Related Macular Degeneration
NCT001408032	NCT00140803_2_T0	COMPOUND	2	2	triamcinolone
NCT001408033	NCT00140803_3_T0	COMPOUND	8	8	Visudyne
NCT001408033	NCT00140803_3_T1	COMPOUND	14	14	triamcinolone
NCT001408036	NCT00140803_6_T0	COMPOUND	19	19	fluorescein
NCT001408036	NCT00140803_6_T1	PHENOTYPE	15	15	leakage
NCT001408038	NCT00140803_8_T0	COMPOUND	16	16	fluorescein
NCT0014080311	NCT00140803_11_T0	PHENOTYPE	0	1	Adverse events
NCT0014080317	NCT00140803_17_T0	PHENOTYPE	4	4	chronic
NCT0014080318	NCT00140803_18_T0	PHENOTYPE	0	0	Chronic
NCT0014080319	NCT00140803_19_T0	COMPOUND	10	10	aspirin
NCT0014080319	NCT00140803_19_T1	GENE	11	11	ASA
NCT0014080319	NCT00140803_19_T2	GENE	7	7	po
NCT0014080324	NCT00140803_24_T0	COMPOUND	20	20	fluorescein
NCT0014080325	NCT00140803_25_T0	COMPOUND	15	15	fluorescein
NCT0014080325	NCT00140803_25_T1	GENE	16	16	dye
NCT0014080325	NCT00140803_25_T2	PHENOTYPE	13	13	allergy
NCT0014080325	NCT00140803_25_T3	PHENOTYPE	12	12	opacity
NCT0014080327	NCT00140803_27_T0	PHENOTYPE	1	1	cataracts
NCT001408162	NCT00140816_2_T0	GENE	17	17	extended
NCT001408290	NCT00140829_0_T0	PHENOTYPE	9	10	Spastic Paraplegias
NCT001408290	NCT00140829_0_T1	PHENOTYPE	6	7	Cerebellar Ataxias
NCT001408293	NCT00140829_3_T0	PHENOTYPE	2	2	disorders
NCT001408293	NCT00140829_3_T1	PHENOTYPE	1	1	progressive
NCT001408294	NCT00140829_4_T0	PHENOTYPE	16	16	diseases
NCT001408295	NCT00140829_5_T0	PHENOTYPE	18	18	initiation
NCT001408296	NCT00140829_6_T0	PHENOTYPE	44	44	disorders
NCT0014082912	NCT00140829_12_T0	PHENOTYPE	16	16	pathophysiology
NCT001408420	NCT00140842_0_T0	PHENOTYPE	6	6	Overweight
NCT001408420	NCT00140842_0_T1	PHENOTYPE	3	4	Metabolic Effects
NCT001408422	NCT00140842_2_T0	GENE	16	16	ghrelin
NCT001408422	NCT00140842_2_T1	GENE	20	20	ghrelin
NCT001408422	NCT00140842_2_T2	PHENOTYPE	27	27	hunger
NCT001408427	NCT00140842_7_T0	PHENOTYPE	6	7	insulin resistance
NCT001408428	NCT00140842_8_T0	GENE	7	7	ghrelin
NCT001408428	NCT00140842_8_T1	PHENOTYPE	26	26	hunger
NCT0014084212	NCT00140842_12_T0	PHENOTYPE	0	0	Obese
NCT0014084212	NCT00140842_12_T1	COMPOUND	2	2	BMI
NCT0014084213	NCT00140842_13_T0	COMPOUND	2	2	BMI
NCT0014084217	NCT00140842_17_T0	PHENOTYPE	2	3	substance abuse
NCT0014084219	NCT00140842_19_T0	PHENOTYPE	3	3	obesity
NCT0014084220	NCT00140842_20_T0	COMPOUND	7	7	aspartame
NCT0014084220	NCT00140842_20_T1	GENE	6	6	peanut
NCT001408552	NCT00140855_2_T0	PHENOTYPE	1	1	tumor
NCT001408552	NCT00140855_2_T1	ORGAN	13	13	lungs
NCT001408555	NCT00140855_5_T0	GENE	8	8	CTLA4
NCT001408555	NCT00140855_5_T1	ORGAN	20	21	immune system
NCT001408555	NCT00140855_5_T2	PHENOTYPE	25	27	recurrent synovial sarcoma
NCT001408556	NCT00140855_6_T0	PHENOTYPE	4	4	tumor
NCT001408556	NCT00140855_6_T1	GENE	24	24	CTLA4
NCT001408556	NCT00140855_6_T2	CELL	20	21	T cells
NCT001408557	NCT00140855_7_T0	ORGAN	6	7	immune system
NCT001408558	NCT00140855_8_T0	ORGAN	11	12	immune system
NCT001408559	NCT00140855_9_T0	PHENOTYPE	5	5	tumor
NCT001408559	NCT00140855_9_T1	GENE	26	26	CTLA4
NCT001408559	NCT00140855_9_T2	PHENOTYPE	41	41	sarcomas
NCT001408559	NCT00140855_9_T3	PHENOTYPE	37	38	synovial sarcoma
NCT001408682	NCT00140868_2_T0	PHENOTYPE	35	36	treatment complications
NCT001408682	NCT00140868_2_T1	PHENOTYPE	32	33	bowel obstruction
NCT001408682	NCT00140868_2_T2	PHENOTYPE	7	9	large bowel obstruction
NCT001408682	NCT00140868_2_T3	PHENOTYPE	26	28	quality of life
NCT001408683	NCT00140868_3_T0	PHENOTYPE	4	6	quality of life
NCT001408684	NCT00140868_4_T0	PHENOTYPE	2	3	bowel obstruction
NCT001409073	NCT00140907_3_T0	PHENOTYPE	7	7	Other
NCT001409981	NCT00140998_1_T0	ORGAN	9	9	ovaries
NCT001409982	NCT00140998_2_T0	COMPOUND	13	13	estrogen
NCT001409982	NCT00140998_2_T1	COMPOUND	22	22	estrogen
NCT001409982	NCT00140998_2_T2	BIOLOGICAL_PROCESS	8	8	metabolism
NCT001409983	NCT00140998_3_T0	GENE	9	9	GH
NCT001409986	NCT00140998_6_T0	COMPOUND	10	10	leucine
NCT001409986	NCT00140998_6_T1	COMPOUND	13	13	glucose
NCT001409986	NCT00140998_6_T2	BIOLOGICAL_PROCESS	23	23	metabolism
NCT001409986	NCT00140998_6_T3	COMPOUND	11	11	glycerol
NCT001409987	NCT00140998_7_T0	PHENOTYPE	11	12	energy expenditure
NCT001409989	NCT00140998_9_T0	COMPOUND	13	13	estrogen
NCT0014099810	NCT00140998_10_T0	COMPOUND	4	4	estrogen
NCT0014099811	NCT00140998_11_T0	COMPOUND	10	10	estrogen
NCT001410245	NCT00141024_5_T0	GENE	4	4	EP
NCT001410245	NCT00141024_5_T1	PHENOTYPE	11	11	HIV
NCT001410247	NCT00141024_7_T0	GENE	5	5	EP
NCT001410248	NCT00141024_8_T0	GENE	15	15	0.5
NCT001410248	NCT00141024_8_T1	GENE	17	17	1.5
NCT001410248	NCT00141024_8_T2	GENE	19	19	3.5
NCT001410248	NCT00141024_8_T3	GENE	21	21	6.5
NCT0014102410	NCT00141024_10_T0	PHENOTYPE	7	7	experiences
NCT001410372	NCT00141037_2_T0	ORGAN	24	24	kidney
NCT001410372	NCT00141037_2_T1	ORGAN	26	26	transplants
NCT001410378	NCT00141037_8_T0	ORGAN	21	21	kidney
NCT001410378	NCT00141037_8_T1	ORGAN	22	22	transplants
NCT001410379	NCT00141037_9_T0	ORGAN	15	15	kidney
NCT001410379	NCT00141037_9_T1	PHENOTYPE	9	11	end-stage kidney disease
NCT0014103711	NCT00141037_11_T0	GENE	4	4	1.1
NCT0014103714	NCT00141037_14_T0	ORGAN	9	9	kidney
NCT001410765	NCT00141076_5_T0	PHENOTYPE	2	3	insulin sensitivity
NCT001410765	NCT00141076_5_T1	PHENOTYPE	12	13	Glucose Tolerance
NCT001410766	NCT00141076_6_T0	PHENOTYPE	2	2	CVD
NCT001410766	NCT00141076_6_T1	PHENOTYPE	8	9	oxidative stress
NCT001410890	NCT00141089_0_T0	PHENOTYPE	11	12	Chronic Constipation
NCT001410892	NCT00141089_2_T0	GENE	15	15	bowel
NCT001410892	NCT00141089_2_T1	COMPOUND	13	13	tegaserod
NCT001410892	NCT00141089_2_T2	PHENOTYPE	21	22	chronic constipation
NCT001411151	NCT00141115_1_T0	PHENOTYPE	21	21	symptoms
NCT001411151	NCT00141115_1_T1	PHENOTYPE	19	20	sleep disturbance
NCT001411153	NCT00141115_3_T0	PHENOTYPE	4	4	suffering
NCT001411153	NCT00141115_3_T1	PHENOTYPE	7	8	alcohol dependence
NCT001411154	NCT00141115_4_T0	PHENOTYPE	9	10	alcohol withdrawal
NCT001411155	NCT00141115_5_T0	BIOLOGICAL_PROCESS	9	9	drinking
NCT001411155	NCT00141115_5_T1	BIOLOGICAL_PROCESS	15	15	drinking
NCT001411155	NCT00141115_5_T2	PHENOTYPE	2	2	seizure
NCT001411156	NCT00141115_6_T0	PHENOTYPE	4	4	seizure
NCT001411156	NCT00141115_6_T1	PHENOTYPE	14	14	seizure
NCT001411157	NCT00141115_7_T0	PHENOTYPE	19	19	epilepsy
NCT001411157	NCT00141115_7_T1	PHENOTYPE	13	13	seizure
NCT001411157	NCT00141115_7_T2	GENE	6	6	has
NCT001411157	NCT00141115_7_T3	COMPOUND	8	8	levetiracetam
NCT001411158	NCT00141115_8_T0	PHENOTYPE	9	9	seizure
NCT001411158	NCT00141115_8_T1	BIOLOGICAL_PROCESS	1	1	metabolism
NCT001411158	NCT00141115_8_T2	COMPOUND	3	3	levetiracetam
NCT001411159	NCT00141115_9_T0	GENE	1	1	has
NCT001411159	NCT00141115_9_T1	PHENOTYPE	14	15	alcohol withdrawal
NCT0014111510	NCT00141115_10_T0	GENE	2	2	had
NCT0014111511	NCT00141115_11_T0	PHENOTYPE	3	3	seizure
NCT0014111511	NCT00141115_11_T1	COMPOUND	16	16	levetiracetam
NCT0014111511	NCT00141115_11_T2	COMPOUND	30	30	levetiracetam
NCT0014111511	NCT00141115_11_T3	PHENOTYPE	59	60	anxiety disorders
NCT0014111511	NCT00141115_11_T4	PHENOTYPE	13	14	alcohol dependence
NCT0014111511	NCT00141115_11_T5	PHENOTYPE	41	42	alcohol dependence
NCT001411800	NCT00141180_0_T0	PHENOTYPE	2	2	Allergy
NCT001411800	NCT00141180_0_T1	COMPOUND	1	1	Nickel
NCT001412450	NCT00141245_0_T0	GENE	13	13	al
NCT001412450	NCT00141245_0_T1	PHENOTYPE	14	14	Seizures
NCT001412450	NCT00141245_0_T2	PHENOTYPE	11	12	Partial Seizures
NCT001412580	NCT00141258_0_T0	PHENOTYPE	1	1	Epilepsy
NCT001412710	NCT00141271_0_T0	PHENOTYPE	18	18	Depression
NCT001412712	NCT00141271_2_T0	GENE	16	16	med
NCT001412840	NCT00141284_0_T0	PHENOTYPE	15	15	HIV
NCT001412840	NCT00141284_0_T1	PHENOTYPE	17	18	Hepatitis C
NCT001412971	NCT00141297_1_T0	GENE	10	10	kinase
NCT001412971	NCT00141297_1_T1	GENE	9	9	cyclin
NCT001412971	NCT00141297_1_T2	GENE	11	11	CDK
NCT001413100	NCT00141310_0_T0	PHENOTYPE	7	7	Pre-Eclampsia
NCT001413360	NCT00141336_0_T0	GENE	14	14	al
NCT001413360	NCT00141336_0_T1	PHENOTYPE	15	15	Seizures
NCT001413360	NCT00141336_0_T2	PHENOTYPE	12	13	Partial Seizures
NCT001413492	NCT00141349_2_T0	GENE	7	7	PDE5
NCT001413751	NCT00141375_1_T0	PHENOTYPE	1	1	Injury
NCT001413751	NCT00141375_1_T1	PHENOTYPE	0	0	Cord
NCT001414010	NCT00141401_0_T0	PHENOTYPE	8	10	Diabetic Peripheral Neuropathy
NCT001414140	NCT00141414_0_T0	PHENOTYPE	12	12	Epilepsy
NCT001414140	NCT00141414_0_T1	GENE	11	11	al
NCT001414140	NCT00141414_0_T2	PHENOTYPE	9	10	Partial Epilepsy
NCT001414270	NCT00141427_0_T0	PHENOTYPE	2	3	Partial Seizures
NCT001414662	NCT00141466_2_T0	PHENOTYPE	10	10	strategies
NCT001414926	NCT00141492_6_T0	PHENOTYPE	2	2	hypogonadism
NCT001414926	NCT00141492_6_T1	PHENOTYPE	4	5	low testosterone
NCT001414927	NCT00141492_7_T0	GENE	1	1	insulin
NCT001414928	NCT00141492_8_T0	COMPOUND	2	2	testosterone
NCT001414929	NCT00141492_9_T0	PHENOTYPE	0	2	Male breast cancer
NCT001415316	NCT00141531_6_T0	ORGAN	9	9	bladder
NCT001415317	NCT00141531_7_T0	ORGAN	1	1	bladder
NCT0014153111	NCT00141531_11_T0	PHENOTYPE	23	24	progressive disease
NCT0014153112	NCT00141531_12_T0	PHENOTYPE	3	3	recurrence
NCT0014153116	NCT00141531_16_T0	PHENOTYPE	4	4	anesthesia
NCT0014153117	NCT00141531_17_T0	PHENOTYPE	3	5	urinary tract tumor
NCT0014153118	NCT00141531_18_T0	GENE	6	6	0.2
NCT0014153118	NCT00141531_18_T1	ORGAN	8	8	Appendix
NCT0014153122	NCT00141531_22_T0	GENE	4	4	T2
NCT0014153124	NCT00141531_24_T0	PHENOTYPE	7	7	recurrent
NCT0014153124	NCT00141531_24_T1	PHENOTYPE	9	10	bacterial cystitis
NCT0014153124	NCT00141531_24_T2	PHENOTYPE	3	5	urinary tract infection
NCT0014153128	NCT00141531_28_T0	PHENOTYPE	31	31	disorders
NCT001415830	NCT00141583_0_T0	PHENOTYPE	4	5	Essential Hypertension
NCT001415960	NCT00141596_0_T0	PHENOTYPE	4	4	Hypertension
NCT001415960	NCT00141596_0_T1	PHENOTYPE	3	3	Resistant
NCT001415960	NCT00141596_0_T2	CELL	0	1	Extracellular Fluid
NCT001415962	NCT00141596_2_T0	PHENOTYPE	8	8	resistant
NCT001415962	NCT00141596_2_T1	PHENOTYPE	9	9	hypertension
NCT001415962	NCT00141596_2_T2	CELL	16	17	extracellular fluid
NCT001415963	NCT00141596_3_T0	PHENOTYPE	1	1	secondary
NCT001415963	NCT00141596_3_T1	PHENOTYPE	18	18	resistant
NCT001415963	NCT00141596_3_T2	PHENOTYPE	19	19	hypertension
NCT001416091	NCT00141609_1_T0	PHENOTYPE	10	10	strokes
NCT001416091	NCT00141609_1_T1	PHENOTYPE	7	8	cardiovascular disease
NCT001416091	NCT00141609_1_T2	PHENOTYPE	14	15	heart failure
NCT001416091	NCT00141609_1_T3	PHENOTYPE	11	12	heart attacks
NCT001416091	NCT00141609_1_T4	PHENOTYPE	0	2	High blood pressure
NCT001416095	NCT00141609_5_T0	GENE	2	2	has
NCT001416096	NCT00141609_6_T0	GENE	3	3	has
NCT001416097	NCT00141609_7_T0	PHENOTYPE	7	7	thirst
NCT001416097	NCT00141609_7_T1	PHENOTYPE	6	6	affects
NCT001416098	NCT00141609_8_T0	ORGAN	9	10	blood vessel
NCT001416098	NCT00141609_8_T1	ORGAN	16	17	blood vessel
NCT0014160910	NCT00141609_10_T0	GENE	20	20	BP
NCT0014160912	NCT00141609_12_T0	PHENOTYPE	5	5	thirst
NCT0014160912	NCT00141609_12_T1	ORGAN	13	14	blood vessel
NCT0014160914	NCT00141609_14_T0	PHENOTYPE	12	12	hypertension
NCT0014160915	NCT00141609_15_T0	PHENOTYPE	7	7	thirst
NCT0014160915	NCT00141609_15_T1	PHENOTYPE	18	18	chronic
NCT0014160915	NCT00141609_15_T2	CELL	21	22	extracellular fluid
NCT0014160915	NCT00141609_15_T3	PHENOTYPE	12	13	weight gains
NCT0014160915	NCT00141609_15_T4	PHENOTYPE	26	28	high blood pressure
NCT0014160916	NCT00141609_16_T0	GENE	15	15	has
NCT0014160916	NCT00141609_16_T1	PHENOTYPE	12	13	endothelial dysfunction
NCT0014160917	NCT00141609_17_T0	COMPOUND	24	24	dimethylarginine
NCT0014160917	NCT00141609_17_T1	PHENOTYPE	0	0	Abnormalities
NCT0014160917	NCT00141609_17_T2	PHENOTYPE	14	14	hypertension
NCT0014160917	NCT00141609_17_T3	GENE	21	22	NO synthase
NCT0014160917	NCT00141609_17_T4	COMPOUND	3	4	nitric oxide
NCT0014160918	NCT00141609_18_T0	ORGAN	0	0	Plasma
NCT0014160918	NCT00141609_18_T1	PHENOTYPE	2	2	concentrations
NCT0014160918	NCT00141609_18_T2	PHENOTYPE	24	24	concentrations
NCT0014160919	NCT00141609_19_T0	PHENOTYPE	25	25	affects
NCT0014160919	NCT00141609_19_T1	GENE	26	26	BP
NCT0014160921	NCT00141609_21_T0	GENE	10	10	BP
NCT0014160922	NCT00141609_22_T0	PHENOTYPE	13	13	thirst
NCT0014160922	NCT00141609_22_T1	GENE	8	8	BP
NCT0014160922	NCT00141609_22_T2	PHENOTYPE	16	17	weight gains
NCT0014160923	NCT00141609_23_T0	PHENOTYPE	14	14	concentrations
NCT0014160923	NCT00141609_23_T1	ORGAN	12	12	plasma
NCT0014160923	NCT00141609_23_T2	GENE	26	26	BP
NCT0014160923	NCT00141609_23_T3	PHENOTYPE	28	30	systemic vascular resistance
NCT001416222	NCT00141622_2_T0	COMPOUND	27	27	sodium
NCT001416222	NCT00141622_2_T1	PHENOTYPE	0	0	Abnormalities
NCT001416222	NCT00141622_2_T2	PHENOTYPE	29	29	affects
NCT001416222	NCT00141622_2_T3	GENE	24	24	has
NCT001416223	NCT00141622_3_T0	COMPOUND	11	11	sodium
NCT001416223	NCT00141622_3_T1	ORGAN	20	21	blood vessel
NCT001416223	NCT00141622_3_T2	PHENOTYPE	26	27	kidney disease
NCT001416228	NCT00141622_8_T0	GENE	20	20	DDAH
NCT001416228	NCT00141622_8_T1	COMPOUND	8	8	dimethylamine
NCT001416228	NCT00141622_8_T2	GENE	9	9	DMA
NCT001416229	NCT00141622_9_T0	GENE	6	6	DMA
NCT001416229	NCT00141622_9_T1	PHENOTYPE	15	16	venous occlusion
NCT001416351	NCT00141635_1_T0	PHENOTYPE	16	18	quality of life
NCT001416355	NCT00141635_5_T0	PHENOTYPE	11	12	breast cancer
NCT0014163516	NCT00141635_16_T0	PHENOTYPE	7	7	fatigue
NCT001416483	NCT00141648_3_T0	COMPOUND	9	9	vincristine
NCT001416483	NCT00141648_3_T1	COMPOUND	7	7	doxorubicin
NCT001416485	NCT00141648_5_T0	GENE	3	3	has
NCT001416487	NCT00141648_7_T0	GENE	23	23	Gy
NCT001416487	NCT00141648_7_T1	GENE	9	9	CHOP
NCT001416742	NCT00141674_2_T0	GENE	2	2	has
NCT001416745	NCT00141674_5_T0	GENE	12	12	reduced
NCT001416745	NCT00141674_5_T1	COMPOUND	9	9	oxygen
NCT001416746	NCT00141674_6_T0	PHENOTYPE	10	11	brain injury
NCT001416747	NCT00141674_7_T0	PHENOTYPE	38	38	suffered
NCT001416747	NCT00141674_7_T1	COMPOUND	33	33	oxygen
NCT0014167412	NCT00141674_12_T0	COMPOUND	11	11	oxygen
NCT0014167414	NCT00141674_14_T0	PHENOTYPE	18	18	secondary
NCT0014167414	NCT00141674_14_T1	PHENOTYPE	21	21	hypotensive
NCT0014167414	NCT00141674_14_T2	PHENOTYPE	19	19	hypoxic
NCT0014167416	NCT00141674_16_T0	TISSUE	18	18	tissues
NCT0014167416	NCT00141674_16_T1	COMPOUND	15	15	oxygen
NCT0014167416	NCT00141674_16_T2	CELL	9	11	red blood cells
NCT0014167418	NCT00141674_18_T0	PHENOTYPE	16	16	trauma
NCT0014167419	NCT00141674_19_T0	PHENOTYPE	14	14	wasting
NCT0014167419	NCT00141674_19_T1	PHENOTYPE	11	11	centers
NCT0014167420	NCT00141674_20_T0	GENE	18	18	has
NCT0014167422	NCT00141674_22_T0	PHENOTYPE	3	3	secondary
NCT0014167422	NCT00141674_22_T1	PHENOTYPE	7	7	hypotension
NCT0014167422	NCT00141674_22_T2	PHENOTYPE	9	9	hypoxia
NCT0014167422	NCT00141674_22_T3	GENE	10	10	has
NCT0014167422	NCT00141674_22_T4	PHENOTYPE	17	18	adverse effect
NCT0014167423	NCT00141674_23_T0	PHENOTYPE	15	15	severely
NCT0014167426	NCT00141674_26_T0	GENE	6	6	has
NCT0014167429	NCT00141674_29_T0	PHENOTYPE	26	27	oxygen extraction
NCT0014167430	NCT00141674_30_T0	PHENOTYPE	12	13	oxygen extraction
NCT0014167430	NCT00141674_30_T1	PHENOTYPE	17	19	traumatic brain injury
NCT0014167431	NCT00141674_31_T0	PHENOTYPE	6	6	centre
NCT0014167431	NCT00141674_31_T1	PHENOTYPE	10	10	severely
NCT0014167436	NCT00141674_36_T0	PHENOTYPE	3	5	traumatic brain injury
NCT0014167440	NCT00141674_40_T0	GENE	1	1	bulb
NCT0014167444	NCT00141674_44_T0	CELL	2	4	Red Blood Cells
NCT0014167445	NCT00141674_45_T0	PHENOTYPE	0	1	Multiple trauma
NCT0014167447	NCT00141674_47_T0	PHENOTYPE	0	2	Chronic renal failure
NCT0014167448	NCT00141674_48_T0	PHENOTYPE	3	4	septic shock
NCT0014167448	NCT00141674_48_T1	PHENOTYPE	0	1	Severe sepsis
NCT001416875	NCT00141687_5_T0	PHENOTYPE	3	4	breech presentation
NCT001416878	NCT00141687_8_T0	TISSUE	21	21	membranes
NCT001416878	NCT00141687_8_T1	PHENOTYPE	25	25	polyhydramnios
NCT001416878	NCT00141687_8_T2	PHENOTYPE	23	23	oligohydramnios
NCT001416878	NCT00141687_8_T3	PHENOTYPE	19	19	rupture
NCT001416878	NCT00141687_8_T4	PHENOTYPE	14	15	uterine anomalies
NCT001416878	NCT00141687_8_T5	ORGAN	4	5	fetal heart
NCT001416878	NCT00141687_8_T6	PHENOTYPE	8	9	abruptio placenta
NCT001416879	NCT00141687_9_T0	PHENOTYPE	8	9	preterm labour
NCT001416879	NCT00141687_9_T1	PHENOTYPE	15	16	preterm labour
NCT001416879	NCT00141687_9_T2	PHENOTYPE	29	30	maternal hypertension
NCT001416879	NCT00141687_9_T3	PHENOTYPE	25	26	abruptio placenta
NCT0014168710	NCT00141687_10_T0	GENE	11	11	CS
NCT0014168710	NCT00141687_10_T1	PHENOTYPE	7	8	placenta previa
NCT0014168711	NCT00141687_11_T0	GENE	4	4	CS
NCT0014168713	NCT00141687_13_T0	GENE	7	7	eg
NCT001417008	NCT00141700_8_T0	PHENOTYPE	5	5	peripheral
NCT001417008	NCT00141700_8_T1	CELL	0	0	Granulocyte
NCT001417008	NCT00141700_8_T2	GENE	3	3	G-CSF
NCT001417008	NCT00141700_8_T3	CELL	7	8	progenitor cells
NCT001417009	NCT00141700_9_T0	COMPOUND	4	4	cyclophosphamide
NCT001417009	NCT00141700_9_T1	ORGAN	12	12	transplant
NCT001417130	NCT00141713_0_T0	PHENOTYPE	9	9	Acute
NCT001417130	NCT00141713_0_T1	PHENOTYPE	10	11	Graft-Versus-Host Disease
NCT001417134	NCT00141713_4_T0	PHENOTYPE	13	13	GVHD
NCT001417134	NCT00141713_4_T1	GENE	2	2	has
NCT001417136	NCT00141713_6_T0	PHENOTYPE	5	5	blocks
NCT001417136	NCT00141713_6_T1	GENE	12	12	TNF
NCT001417136	NCT00141713_6_T2	MOLECULAR_FUNCTION	9	11	Tumor Necrosis Factor
NCT001417137	NCT00141713_7_T0	PHENOTYPE	16	16	GVHD
NCT001417137	NCT00141713_7_T1	PHENOTYPE	14	15	graft-versus-host disease
NCT001417139	NCT00141713_9_T0	PHENOTYPE	14	15	graft-versus-host disease
NCT0014171310	NCT00141713_10_T0	PHENOTYPE	15	15	GVHD
NCT0014171312	NCT00141713_12_T0	PHENOTYPE	10	10	GVHD
NCT001417261	NCT00141726_1_T0	PHENOTYPE	6	6	toxicity
NCT001417261	NCT00141726_1_T1	PHENOTYPE	19	21	quality of life
NCT001417266	NCT00141726_6_T0	ORGAN	13	13	transplant
NCT001417266	NCT00141726_6_T1	PHENOTYPE	1	2	lung injury
NCT001417266	NCT00141726_6_T2	ORGAN	11	12	bone marrow
NCT001417267	NCT00141726_7_T0	PHENOTYPE	11	11	fatigue
NCT001417267	NCT00141726_7_T1	PHENOTYPE	9	9	wheezing
NCT001417267	NCT00141726_7_T2	PHENOTYPE	8	8	cough
NCT001417267	NCT00141726_7_T3	PHENOTYPE	5	7	shortness of breath
NCT0014172610	NCT00141726_10_T0	PHENOTYPE	5	5	infections
NCT0014172610	NCT00141726_10_T1	ORGAN	11	11	lungs
NCT001417393	NCT00141739_3_T0	GENE	8	8	56
NCT001417393	NCT00141739_3_T1	ORGAN	12	12	transplant
NCT001417395	NCT00141739_5_T0	PHENOTYPE	21	21	acute
NCT001417395	NCT00141739_5_T1	PHENOTYPE	24	24	GVHD
NCT001417395	NCT00141739_5_T2	PHENOTYPE	22	23	graft-vs-host disease
NCT001417396	NCT00141739_6_T0	PHENOTYPE	4	4	complication
NCT001417396	NCT00141739_6_T1	ORGAN	9	9	transplant
NCT001417396	NCT00141739_6_T2	PHENOTYPE	0	0	GVHD
NCT001417396	NCT00141739_6_T3	ORGAN	7	8	bone marrow
NCT001417397	NCT00141739_7_T0	ORGAN	3	3	transplant
NCT001417397	NCT00141739_7_T1	PHENOTYPE	0	0	GVHD
NCT001417397	NCT00141739_7_T2	CELL	7	8	blood cells
NCT001417398	NCT00141739_8_T0	TISSUE	13	13	tissues
NCT001417398	NCT00141739_8_T1	ORGAN	17	17	liver
NCT0014173911	NCT00141739_11_T0	COMPOUND	23	23	cyclosporine
NCT0014173911	NCT00141739_11_T1	PHENOTYPE	4	4	acute
NCT0014173911	NCT00141739_11_T2	COMPOUND	21	21	tacrolimus
NCT0014173911	NCT00141739_11_T3	PHENOTYPE	5	5	GVHD
NCT0014173911	NCT00141739_11_T4	ORGAN	17	18	immune system
NCT0014173912	NCT00141739_12_T0	PHENOTYPE	5	5	blocks
NCT0014173912	NCT00141739_12_T1	GENE	12	12	TNF
NCT0014173912	NCT00141739_12_T2	MOLECULAR_FUNCTION	9	11	Tumor Necrosis Factor
NCT0014173913	NCT00141739_13_T0	PHENOTYPE	14	14	GVHD
NCT0014173914	NCT00141739_14_T0	PHENOTYPE	13	13	GVHD
NCT001417521	NCT00141752_1_T0	PHENOTYPE	11	11	dysphagia
NCT001417522	NCT00141752_2_T0	PHENOTYPE	12	12	acute
NCT001417523	NCT00141752_3_T0	PHENOTYPE	33	33	acute
NCT001417523	NCT00141752_3_T1	PHENOTYPE	26	26	dysphagia
NCT001417525	NCT00141752_5_T0	PHENOTYPE	24	24	dysphagia
NCT001417526	NCT00141752_6_T0	PHENOTYPE	16	16	dysphagia
NCT001417655	NCT00141765_5_T0	ORGAN	11	11	transplant
NCT001417656	NCT00141765_6_T0	PHENOTYPE	5	6	progressive disease
NCT001417781	NCT00141778_1_T0	GENE	18	18	bypass
NCT001417781	NCT00141778_1_T1	GENE	19	19	CPB
NCT001417781	NCT00141778_1_T2	GENE	1	1	AF
NCT001417783	NCT00141778_3_T0	GENE	19	19	AF
NCT001417783	NCT00141778_3_T1	PHENOTYPE	8	8	inflammation
NCT001417783	NCT00141778_3_T2	PHENOTYPE	9	10	atrial remodeling
NCT001417784	NCT00141778_4_T0	PHENOTYPE	12	12	inflammation
NCT001417784	NCT00141778_4_T1	COMPOUND	21	21	aldosterone
NCT001417784	NCT00141778_4_T2	CELL	13	13	myocyte
NCT001417784	NCT00141778_4_T3	PHENOTYPE	19	19	fibrosis
NCT001417784	NCT00141778_4_T4	PHENOTYPE	16	17	electrical remodeling
NCT001417786	NCT00141778_6_T0	GENE	18	18	CPB
NCT001417788	NCT00141778_8_T0	GENE	19	19	AF
NCT001417788	NCT00141778_8_T1	PHENOTYPE	8	8	inflammation
NCT001417788	NCT00141778_8_T2	PHENOTYPE	9	10	atrial remodeling
NCT001417789	NCT00141778_9_T0	PHENOTYPE	12	12	inflammation
NCT001417789	NCT00141778_9_T1	COMPOUND	21	21	aldosterone
NCT001417789	NCT00141778_9_T2	CELL	13	13	myocyte
NCT001417789	NCT00141778_9_T3	PHENOTYPE	19	19	fibrosis
NCT001417789	NCT00141778_9_T4	PHENOTYPE	16	17	electrical remodeling
NCT0014177812	NCT00141778_12_T0	GENE	7	7	bypass
NCT0014177812	NCT00141778_12_T1	ORGAN	3	3	heart
NCT0014177812	NCT00141778_12_T2	ORGAN	5	6	coronary artery
NCT0014177814	NCT00141778_14_T0	GENE	2	2	AF
NCT0014177814	NCT00141778_14_T1	GENE	7	7	AF
NCT0014177816	NCT00141778_16_T0	GENE	6	6	1.7
NCT0014177816	NCT00141778_16_T1	PHENOTYPE	2	2	coagulopathy
NCT0014177816	NCT00141778_16_T2	GENE	3	3	INR
NCT0014177816	NCT00141778_16_T3	COMPOUND	8	8	warfarin
NCT0014177818	NCT00141778_18_T0	PHENOTYPE	4	4	angioedema
NCT0014177818	NCT00141778_18_T1	MOLECULAR_FUNCTION	2	3	ACE inhibitor
NCT0014177819	NCT00141778_19_T0	PHENOTYPE	13	13	hypoperfusion
NCT0014177819	NCT00141778_19_T1	PHENOTYPE	0	2	Low blood pressure
NCT0014177820	NCT00141778_20_T0	PHENOTYPE	0	0	Hyperkalemia
NCT0014177820	NCT00141778_20_T1	COMPOUND	1	1	potassium
NCT0014177820	NCT00141778_20_T2	GENE	5	5	5.0
NCT0014177821	NCT00141778_21_T0	ORGAN	1	1	kidney
NCT0014177821	NCT00141778_21_T1	COMPOUND	4	4	creatinine
NCT0014177821	NCT00141778_21_T2	GENE	8	8	1/6
NCT0014177821	NCT00141778_21_T3	ORGAN	3	3	serum
NCT0014177822	NCT00141778_22_T0	PHENOTYPE	12	12	complications
NCT0014177822	NCT00141778_22_T1	PHENOTYPE	3	4	acute disease
NCT001418042	NCT00141804_2_T0	PHENOTYPE	6	6	centre
NCT001418043	NCT00141804_3_T0	PHENOTYPE	7	7	5-10
NCT001418430	NCT00141843_0_T0	GENE	6	6	AF
NCT001418430	NCT00141843_0_T1	PHENOTYPE	12	13	Hemophilia A
NCT001418560	NCT00141856_0_T0	ORGAN	2	2	Heart
NCT001418560	NCT00141856_0_T1	PHENOTYPE	10	11	Heart Failure
NCT001418562	NCT00141856_2_T0	ORGAN	12	12	Heart
NCT001418562	NCT00141856_2_T1	PHENOTYPE	1	1	secondary
NCT001418565	NCT00141856_5_T0	PHENOTYPE	17	17	CHF
NCT0014185610	NCT00141856_10_T0	GENE	18	18	1.1
NCT0014185611	NCT00141856_11_T0	PHENOTYPE	48	50	signs and symptoms
NCT0014185613	NCT00141856_13_T0	PHENOTYPE	11	12	heart failure
NCT0014185615	NCT00141856_15_T0	PHENOTYPE	8	8	practices
NCT0014185616	NCT00141856_16_T0	PHENOTYPE	6	6	sorts
NCT0014185619	NCT00141856_19_T0	PHENOTYPE	13	14	heart failure
NCT0014185619	NCT00141856_19_T1	PHENOTYPE	30	31	Heart Disease
NCT0014185621	NCT00141856_21_T0	PHENOTYPE	9	11	congestive heart failure
NCT001418692	NCT00141869_2_T0	GENE	22	22	TS
NCT001418692	NCT00141869_2_T1	GENE	25	25	TS
NCT001418692	NCT00141869_2_T2	PHENOTYPE	5	6	brain activity
NCT001418692	NCT00141869_2_T3	PHENOTYPE	15	16	brain activity
NCT001418693	NCT00141869_3_T0	GENE	6	6	TS
NCT001418694	NCT00141869_4_T0	PHENOTYPE	4	4	tics
NCT001418697	NCT00141869_7_T0	GENE	9	9	MEG
NCT001418699	NCT00141869_9_T0	ORGAN	16	16	jaw
NCT0014186915	NCT00141869_15_T0	ORGAN	8	8	scalp
NCT0014186917	NCT00141869_17_T0	PHENOTYPE	22	23	adverse events
NCT0014186919	NCT00141869_19_T0	PHENOTYPE	9	10	sensory gating
NCT0014186929	NCT00141869_29_T0	GENE	12	12	TS
NCT0014186930	NCT00141869_30_T0	PHENOTYPE	4	4	tics
NCT0014186930	NCT00141869_30_T1	PHENOTYPE	14	14	tics
NCT0014186930	NCT00141869_30_T2	PHENOTYPE	2	2	bilateral
NCT0014186930	NCT00141869_30_T3	PHENOTYPE	12	12	unilateral
NCT0014186930	NCT00141869_30_T4	GENE	7	7	contrasted
NCT0014186933	NCT00141869_33_T0	PHENOTYPE	2	3	sensory gating
NCT0014186934	NCT00141869_34_T0	PHENOTYPE	11	11	tics
NCT0014186941	NCT00141869_41_T0	PHENOTYPE	12	12	Disorders
NCT0014186944	NCT00141869_44_T0	PHENOTYPE	3	3	tics
NCT0014186946	NCT00141869_46_T0	ORGAN	4	4	eyes
NCT0014186947	NCT00141869_47_T0	GENE	2	2	pins
NCT0014186952	NCT00141869_52_T0	PHENOTYPE	7	8	bipolar disorder
NCT0014186952	NCT00141869_52_T1	PHENOTYPE	11	12	psychotic disorder
NCT0014186952	NCT00141869_52_T2	PHENOTYPE	4	5	major depression
NCT0014186954	NCT00141869_54_T0	PHENOTYPE	3	3	acute
NCT0014186954	NCT00141869_54_T1	GENE	18	18	extended
NCT0014186954	NCT00141869_54_T2	PHENOTYPE	35	35	discomfort
NCT0014186954	NCT00141869_54_T3	PHENOTYPE	5	6	chronic illness
NCT0014186955	NCT00141869_55_T0	GENE	12	12	al
NCT0014186955	NCT00141869_55_T1	GENE	11	11	et
NCT001418950	NCT00141895_0_T0	PHENOTYPE	13	15	Intrauterine Fetal Death
NCT001418952	NCT00141895_2_T0	COMPOUND	14	14	misoprostol
NCT001418952	NCT00141895_2_T1	COMPOUND	41	41	mifepristone
NCT001418952	NCT00141895_2_T2	PHENOTYPE	2	2	focused
NCT001418952	NCT00141895_2_T3	GENE	15	15	has
NCT001418955	NCT00141895_5_T0	COMPOUND	4	4	misoprostol
NCT001418955	NCT00141895_5_T1	COMPOUND	27	27	misoprostol
NCT001418955	NCT00141895_5_T2	GENE	9	9	has
NCT001418957	NCT00141895_7_T0	COMPOUND	13	13	misoprostol
NCT001418957	NCT00141895_7_T1	GENE	1	1	has
NCT001418957	NCT00141895_7_T2	PHENOTYPE	26	28	intrauterine fetal death
NCT001418958	NCT00141895_8_T0	COMPOUND	11	11	misoprostol
NCT0014189510	NCT00141895_10_T0	GENE	7	7	has
NCT0014189510	NCT00141895_10_T1	PHENOTYPE	24	25	side effect
NCT0014189510	NCT00141895_10_T2	COMPOUND	5	6	prostaglandin E1
NCT0014189511	NCT00141895_11_T0	COMPOUND	3	3	misoprostol
NCT0014189511	NCT00141895_11_T1	GENE	4	4	has
NCT0014189512	NCT00141895_12_T0	COMPOUND	1	1	misoprostol
NCT0014189512	NCT00141895_12_T1	GENE	2	2	has
NCT0014189515	NCT00141895_15_T0	COMPOUND	8	8	misoprostol
NCT0014189517	NCT00141895_17_T0	PHENOTYPE	11	11	pharmacokinetics
NCT0014189518	NCT00141895_18_T0	COMPOUND	11	11	misoprostol
NCT0014189518	NCT00141895_18_T1	GENE	2	2	al
NCT0014189518	NCT00141895_18_T2	GENE	1	1	et
NCT0014189519	NCT00141895_19_T0	ORGAN	0	0	Plasma
NCT0014189519	NCT00141895_19_T1	PHENOTYPE	1	1	concentrations
NCT0014189519	NCT00141895_19_T2	BIOLOGICAL_PROCESS	56	56	metabolism
NCT0014189519	NCT00141895_19_T3	COMPOUND	5	6	misoprostol acid
NCT0014189520	NCT00141895_20_T0	ORGAN	17	17	cervix
NCT0014189521	NCT00141895_21_T0	GENE	5	5	has
NCT0014189522	NCT00141895_22_T0	COMPOUND	20	20	misoprostol
NCT0014189524	NCT00141895_24_T0	COMPOUND	11	11	misoprostol
NCT0014189524	NCT00141895_24_T1	PHENOTYPE	36	38	intrauterine fetal death
NCT0014189526	NCT00141895_26_T0	COMPOUND	12	12	misoprostol
NCT0014189526	NCT00141895_26_T1	GENE	25	25	has
NCT0014189526	NCT00141895_26_T2	PHENOTYPE	18	20	intrauterine fetal death
NCT0014189527	NCT00141895_27_T0	COMPOUND	21	21	misoprostol
NCT0014189528	NCT00141895_28_T0	PHENOTYPE	20	20	Bucks
NCT0014189528	NCT00141895_28_T1	COMPOUND	16	16	misoprostol
NCT0014189528	NCT00141895_28_T2	PHENOTYPE	42	44	intrauterine fetal death
NCT0014189530	NCT00141895_30_T0	COMPOUND	11	11	misoprostol
NCT0014189530	NCT00141895_30_T1	COMPOUND	37	37	misoprostol
NCT0014189530	NCT00141895_30_T2	GENE	24	24	mid
NCT0014189531	NCT00141895_31_T0	COMPOUND	8	8	misoprostol
NCT0014189531	NCT00141895_31_T1	GENE	27	27	had
NCT0014189532	NCT00141895_32_T0	COMPOUND	6	6	misoprostol
NCT0014189534	NCT00141895_34_T0	PHENOTYPE	27	27	Bucks
NCT0014189534	NCT00141895_34_T1	COMPOUND	23	23	misoprostol
NCT0014189535	NCT00141895_35_T0	PHENOTYPE	26	26	initiation
NCT0014189540	NCT00141895_40_T0	GENE	9	9	Chi
NCT001419081	NCT00141908_1_T0	PHENOTYPE	18	19	preterm birth
NCT001419081	NCT00141908_1_T1	PHENOTYPE	11	12	preterm births
NCT001419084	NCT00141908_4_T0	PHENOTYPE	9	10	preterm labor
NCT001419085	NCT00141908_5_T0	BIOLOGICAL_PROCESS	22	22	gestation
NCT001419086	NCT00141908_6_T0	GENE	10	10	has
NCT001419086	NCT00141908_6_T1	PHENOTYPE	8	9	preterm birth
NCT001419088	NCT00141908_8_T0	COMPOUND	1	1	progesterone
NCT001419088	NCT00141908_8_T1	GENE	2	2	has
NCT001419088	NCT00141908_8_T2	PHENOTYPE	10	11	preterm birth
NCT001419088	NCT00141908_8_T3	PHENOTYPE	16	17	preterm births
NCT0014190810	NCT00141908_10_T0	COMPOUND	22	22	progesterone
NCT0014190810	NCT00141908_10_T1	BIOLOGICAL_PROCESS	32	32	gestation
NCT0014190810	NCT00141908_10_T2	BIOLOGICAL_PROCESS	48	48	gestation
NCT0014190811	NCT00141908_11_T0	PHENOTYPE	21	22	preterm labor
NCT0014190814	NCT00141908_14_T0	PHENOTYPE	27	27	bleeding
NCT0014190814	NCT00141908_14_T1	GENE	23	23	50
NCT0014190814	NCT00141908_14_T2	PHENOTYPE	17	18	preterm delivery
NCT0014190814	NCT00141908_14_T3	PHENOTYPE	30	32	sexually transmitted diseases
NCT0014190815	NCT00141908_15_T0	GENE	15	15	has
NCT0014190815	NCT00141908_15_T1	PHENOTYPE	13	14	preterm delivery
NCT0014190816	NCT00141908_16_T0	GENE	6	6	has
NCT0014190816	NCT00141908_16_T1	PHENOTYPE	3	4	preterm birth
NCT0014190818	NCT00141908_18_T0	PHENOTYPE	8	9	preterm labor
NCT0014190819	NCT00141908_19_T0	COMPOUND	7	7	progesterone
NCT0014190819	NCT00141908_19_T1	PHENOTYPE	9	10	preterm labor
NCT0014190820	NCT00141908_20_T0	PHENOTYPE	13	14	preterm delivery
NCT0014190822	NCT00141908_22_T0	PHENOTYPE	20	21	preterm delivery
NCT0014190823	NCT00141908_23_T0	GENE	30	30	37
NCT0014190823	NCT00141908_23_T1	PHENOTYPE	44	44	recurrent
NCT0014190823	NCT00141908_23_T2	BIOLOGICAL_PROCESS	33	33	gestation
NCT0014190823	NCT00141908_23_T3	PHENOTYPE	13	14	preterm birth
NCT0014190823	NCT00141908_23_T4	PHENOTYPE	28	29	preterm birth
NCT0014190823	NCT00141908_23_T5	PHENOTYPE	45	46	preterm birth
NCT0014190824	NCT00141908_24_T0	COMPOUND	7	7	progesterone
NCT0014190825	NCT00141908_25_T0	GENE	4	4	has
NCT0014190828	NCT00141908_28_T0	COMPOUND	3	3	progesterone
NCT0014190828	NCT00141908_28_T1	COMPOUND	26	26	progesterone
NCT0014190828	NCT00141908_28_T2	BIOLOGICAL_PROCESS	13	13	gestation
NCT0014190829	NCT00141908_29_T0	COMPOUND	5	5	progesterone
NCT0014190829	NCT00141908_29_T1	PHENOTYPE	19	20	preterm delivery
NCT0014190830	NCT00141908_30_T0	COMPOUND	10	10	progesterone
NCT0014190830	NCT00141908_30_T1	COMPOUND	38	38	progesterone
NCT0014190830	NCT00141908_30_T2	COMPOUND	65	65	progesterone
NCT0014190830	NCT00141908_30_T3	BIOLOGICAL_PROCESS	31	31	gestation
NCT0014190830	NCT00141908_30_T4	PHENOTYPE	17	18	preterm birth
NCT0014190830	NCT00141908_30_T5	PHENOTYPE	22	23	preterm birth
NCT0014190830	NCT00141908_30_T6	PHENOTYPE	68	69	preterm birth
NCT0014190831	NCT00141908_31_T0	GENE	46	46	fibronectin
NCT0014190831	NCT00141908_31_T1	COMPOUND	24	24	progesterone
NCT0014190832	NCT00141908_32_T0	BIOLOGICAL_PROCESS	10	10	gestation
NCT0014190834	NCT00141908_34_T0	COMPOUND	17	17	estrogen
NCT0014190834	NCT00141908_34_T1	PHENOTYPE	30	30	initiation
NCT0014190834	NCT00141908_34_T2	ORGAN	21	21	decidua
NCT0014190834	NCT00141908_34_T3	COMPOUND	15	15	progesterone
NCT0014190834	NCT00141908_34_T4	TISSUE	23	24	fetal membranes
NCT0014190834	NCT00141908_34_T5	PHENOTYPE	9	10	progesterone level
NCT0014190835	NCT00141908_35_T0	PHENOTYPE	11	11	soreness
NCT0014190835	NCT00141908_35_T1	PHENOTYPE	13	13	itching
NCT0014190835	NCT00141908_35_T2	PHENOTYPE	15	15	bruising
NCT0014190835	NCT00141908_35_T3	PHENOTYPE	28	29	teratogenic effects
NCT0014190838	NCT00141908_38_T0	BIOLOGICAL_PROCESS	37	37	gestation
NCT0014190838	NCT00141908_38_T1	PHENOTYPE	24	25	preterm delivery
NCT0014190839	NCT00141908_39_T0	PHENOTYPE	33	34	preterm delivery
NCT0014190840	NCT00141908_40_T0	PHENOTYPE	17	18	preterm delivery
NCT0014190847	NCT00141908_47_T0	GENE	16	16	OPD
NCT0014190847	NCT00141908_47_T1	GENE	27	27	OPD
NCT0014190848	NCT00141908_48_T0	GENE	14	14	RA
NCT0014190851	NCT00141908_51_T0	BIOLOGICAL_PROCESS	15	15	gestation
NCT0014190854	NCT00141908_54_T0	GENE	15	15	Chi
NCT0014190860	NCT00141908_60_T0	PHENOTYPE	2	2	regression
NCT0014190861	NCT00141908_61_T0	GENE	27	27	twins
NCT0014190861	NCT00141908_61_T1	GENE	26	26	reduced
NCT0014190861	NCT00141908_61_T2	COMPOUND	13	13	BMI
NCT0014190861	NCT00141908_61_T3	PHENOTYPE	19	20	preterm delivery
NCT0014190863	NCT00141908_63_T0	BIOLOGICAL_PROCESS	29	29	gestation
NCT001419340	NCT00141934_0_T0	GENE	8	8	AD
NCT001419340	NCT00141934_0_T1	GENE	11	11	RA
NCT001419341	NCT00141934_1_T0	GENE	0	0	RA
NCT001419343	NCT00141934_3_T0	PHENOTYPE	18	18	symptoms
NCT001419343	NCT00141934_3_T1	GENE	4	4	AD
NCT001419343	NCT00141934_3_T2	GENE	28	28	AD
NCT001419343	NCT00141934_3_T3	GENE	12	12	RA
NCT001419343	NCT00141934_3_T4	GENE	17	17	RA
NCT001419344	NCT00141934_4_T0	COMPOUND	9	9	methotrexate
NCT001419344	NCT00141934_4_T1	COMPOUND	18	18	methotrexate
NCT001419344	NCT00141934_4_T2	GENE	12	12	RA
NCT001419345	NCT00141934_5_T0	GENE	20	20	AD
NCT001419345	NCT00141934_5_T1	PHENOTYPE	15	15	pharmacokinetics
NCT001419345	NCT00141934_5_T2	GENE	8	8	RA
NCT001419346	NCT00141934_6_T0	PHENOTYPE	10	11	adverse events
NCT001419472	NCT00141947_2_T0	COMPOUND	10	10	bexarotene
NCT001419472	NCT00141947_2_T1	PHENOTYPE	26	26	schizophrenia
NCT001419602	NCT00141960_2_T0	PHENOTYPE	11	11	GERD
NCT001419602	NCT00141960_2_T1	GENE	3	3	has
NCT001419603	NCT00141960_3_T0	PHENOTYPE	14	14	GERD
NCT001419603	NCT00141960_3_T1	COMPOUND	9	9	famotidine
NCT001419732	NCT00141973_2_T0	GENE	14	14	procalcitonin
NCT001419732	NCT00141973_2_T1	PHENOTYPE	7	7	sepsis
NCT001419732	NCT00141973_2_T2	PHENOTYPE	23	23	sepsis
NCT001419862	NCT00141986_2_T0	GENE	4	4	insulin
NCT001419862	NCT00141986_2_T1	PHENOTYPE	19	19	complications
NCT001419862	NCT00141986_2_T2	PHENOTYPE	22	22	blindness
NCT001419862	NCT00141986_2_T3	PHENOTYPE	24	25	kidney failure
NCT001419864	NCT00141986_4_T0	COMPOUND	20	21	vitamin D
NCT001419990	NCT00141999_0_T0	PHENOTYPE	5	6	Hepatitis B
NCT001419992	NCT00141999_2_T0	PHENOTYPE	6	6	immunity
NCT001419992	NCT00141999_2_T1	PHENOTYPE	24	24	HBV
NCT001419992	NCT00141999_2_T2	PHENOTYPE	4	5	hepatitis B
NCT001419992	NCT00141999_2_T3	PHENOTYPE	21	22	hepatitis B
NCT001419993	NCT00141999_3_T0	PHENOTYPE	9	9	HBV
NCT001419993	NCT00141999_3_T1	PHENOTYPE	17	18	hepatitis B
NCT001419994	NCT00141999_4_T0	PHENOTYPE	19	20	hepatitis B
NCT001419994	NCT00141999_4_T1	PHENOTYPE	36	37	hepatitis B
NCT001419994	NCT00141999_4_T2	BIOLOGICAL_PROCESS	10	11	immune response
NCT001419995	NCT00141999_5_T0	ORGAN	23	23	serum
NCT001419995	NCT00141999_5_T1	PHENOTYPE	5	6	hepatitis B
NCT001419998	NCT00141999_8_T0	GENE	8	8	booster
NCT001419999	NCT00141999_9_T0	GENE	16	16	booster
NCT001419999	NCT00141999_9_T1	PHENOTYPE	19	20	hepatitis B
NCT001420124	NCT00142012_4_T0	BIOLOGICAL_PROCESS	22	22	Eating
NCT001420126	NCT00142012_6_T0	PHENOTYPE	27	27	diseases
NCT001420126	NCT00142012_6_T1	BIOLOGICAL_PROCESS	14	14	eating
NCT001420126	NCT00142012_6_T2	PHENOTYPE	24	24	overweight
NCT001420129	NCT00142012_9_T0	PHENOTYPE	8	9	eating disorder
NCT001420252	NCT00142025_2_T0	PHENOTYPE	3	3	asthma
NCT001420252	NCT00142025_2_T1	PHENOTYPE	6	7	inflammatory disorder
NCT001420253	NCT00142025_3_T0	PHENOTYPE	4	4	asthma
NCT001420254	NCT00142025_4_T0	PHENOTYPE	1	1	asthma
NCT001420254	NCT00142025_4_T1	PHENOTYPE	18	18	asthma
NCT001420255	NCT00142025_5_T0	PHENOTYPE	13	13	asthma
NCT001420255	NCT00142025_5_T1	PHENOTYPE	6	7	neurogenic inflammation
NCT001420259	NCT00142025_9_T0	COMPOUND	10	10	oxcarbazepine
NCT001420259	NCT00142025_9_T1	PHENOTYPE	15	16	bronchial asthma
NCT0014202510	NCT00142025_10_T0	COMPOUND	22	22	carbamazepine
NCT001420381	NCT00142038_1_T0	COMPOUND	15	15	docetaxel
NCT001420381	NCT00142038_1_T1	GENE	4	4	al
NCT001420381	NCT00142038_1_T2	GENE	3	3	et
NCT001420384	NCT00142038_4_T0	COMPOUND	15	15	capecitabine
NCT001420384	NCT00142038_4_T1	COMPOUND	34	34	capecitabine
NCT001420384	NCT00142038_4_T2	COMPOUND	32	32	docetaxel
NCT001420384	NCT00142038_4_T3	PHENOTYPE	42	43	gastric cancer
NCT001420388	NCT00142038_8_T0	GENE	15	15	reduced
NCT001420388	NCT00142038_8_T1	GENE	13	13	has
NCT0014203810	NCT00142038_10_T0	GENE	10	10	pts
NCT0014203811	NCT00142038_11_T0	PHENOTYPE	5	6	tumor progression
NCT0014203812	NCT00142038_12_T0	PHENOTYPE	9	10	tumor progression
NCT001420512	NCT00142051_2_T0	PHENOTYPE	11	11	pathophysiology
NCT001420517	NCT00142051_7_T0	PHENOTYPE	0	0	Secondary
NCT0014205110	NCT00142051_10_T0	GENE	6	6	SC
NCT0014205110	NCT00142051_10_T1	GENE	10	10	hemoglobin
NCT0014205110	NCT00142051_10_T2	PHENOTYPE	0	1	Hemoglobin SS
NCT0014205123	NCT00142051_23_T0	COMPOUND	6	6	hydroxyurea
NCT0014205127	NCT00142051_27_T0	PHENOTYPE	2	2	acute
NCT0014205127	NCT00142051_27_T1	PHENOTYPE	4	4	chronic
NCT0014205127	NCT00142051_27_T2	PHENOTYPE	6	6	dysfunction
NCT0014205129	NCT00142051_29_T0	PHENOTYPE	0	0	Acute
NCT0014205129	NCT00142051_29_T1	PHENOTYPE	1	1	priapism
NCT0014205131	NCT00142051_31_T0	PHENOTYPE	1	1	focal
NCT0014205131	NCT00142051_31_T1	PHENOTYPE	2	3	neurologic symptoms
NCT0014205133	NCT00142051_33_T0	PHENOTYPE	6	7	parvovirus infection
NCT0014205137	NCT00142051_37_T0	PHENOTYPE	5	5	chronic
NCT001420645	NCT00142064_5_T0	PHENOTYPE	9	9	analgesia
NCT0014206412	NCT00142064_12_T0	PHENOTYPE	10	10	analgesia
NCT001420773	NCT00142077_3_T0	PHENOTYPE	3	3	influenza
NCT001420775	NCT00142077_5_T0	PHENOTYPE	20	20	influenza
NCT001420775	NCT00142077_5_T1	PHENOTYPE	28	28	influenza
NCT001420775	NCT00142077_5_T2	PHENOTYPE	16	16	attitudes
NCT0014207714	NCT00142077_14_T0	GENE	2	2	has
NCT0014207717	NCT00142077_17_T0	PHENOTYPE	20	20	influenza
NCT0014207717	NCT00142077_17_T1	PHENOTYPE	7	7	allergy
NCT001420901	NCT00142090_1_T0	PHENOTYPE	16	16	concussion
NCT001420901	NCT00142090_1_T1	PHENOTYPE	21	21	vomiting
NCT001420901	NCT00142090_1_T2	PHENOTYPE	20	20	nausea
NCT001420901	NCT00142090_1_T3	PHENOTYPE	9	10	other symptoms
NCT001420902	NCT00142090_2_T0	GENE	17	17	has
NCT001420902	NCT00142090_2_T1	PHENOTYPE	28	29	brain injury
NCT001420904	NCT00142090_4_T0	PHENOTYPE	4	4	pathophysiology
NCT001420907	NCT00142090_7_T0	PHENOTYPE	17	17	symptoms
NCT001420907	NCT00142090_7_T1	PHENOTYPE	34	34	complication
NCT001420907	NCT00142090_7_T2	PHENOTYPE	23	23	progression
NCT001420907	NCT00142090_7_T3	PHENOTYPE	8	9	intracranial injury
NCT001420909	NCT00142090_9_T0	PHENOTYPE	28	28	amnesia
NCT001420909	NCT00142090_9_T1	PHENOTYPE	13	13	headaches
NCT001420909	NCT00142090_9_T2	PHENOTYPE	23	23	vomiting
NCT001420909	NCT00142090_9_T3	PHENOTYPE	21	21	nausea
NCT0014209012	NCT00142090_12_T0	GENE	28	28	AD
NCT0014209012	NCT00142090_12_T1	GENE	30	30	has
NCT0014209012	NCT00142090_12_T2	PHENOTYPE	8	9	head injury
NCT0014209012	NCT00142090_12_T3	PHENOTYPE	15	16	head injury
NCT0014209013	NCT00142090_13_T0	PHENOTYPE	9	9	shaking
NCT0014209014	NCT00142090_14_T0	GENE	11	11	enigma
NCT0014209014	NCT00142090_14_T1	PHENOTYPE	27	27	diffuse
NCT0014209014	NCT00142090_14_T2	CELL	51	51	neurons
NCT0014209014	NCT00142090_14_T3	PHENOTYPE	6	6	symptoms
NCT0014209014	NCT00142090_14_T4	CELL	53	53	axons
NCT0014209014	NCT00142090_14_T5	GENE	28	28	structural
NCT0014209014	NCT00142090_14_T6	PHENOTYPE	19	19	concussion
NCT0014209014	NCT00142090_14_T7	PHENOTYPE	33	35	traumatic brain injury
NCT0014209015	NCT00142090_15_T0	PHENOTYPE	5	6	metabolic profiles
NCT0014209018	NCT00142090_18_T0	PHENOTYPE	12	12	trauma
NCT0014209018	NCT00142090_18_T1	PHENOTYPE	28	28	symptoms
NCT0014209019	NCT00142090_19_T0	COMPOUND	26	26	ondansetron
NCT0014209019	NCT00142090_19_T1	PHENOTYPE	16	16	analgesia
NCT0014209019	NCT00142090_19_T2	PHENOTYPE	7	9	traumatic brain injuries
NCT0014209021	NCT00142090_21_T0	PHENOTYPE	1	1	symptoms
NCT0014209028	NCT00142090_28_T0	PHENOTYPE	19	19	demyelination
NCT0014209028	NCT00142090_28_T1	PHENOTYPE	14	15	pulmonary edema
NCT0014209028	NCT00142090_28_T2	PHENOTYPE	5	6	adverse effects
NCT0014209028	NCT00142090_28_T3	PHENOTYPE	12	13	renal failure
NCT0014209029	NCT00142090_29_T0	PHENOTYPE	33	33	secondary
NCT0014209029	NCT00142090_29_T1	GENE	32	32	ICP
NCT0014209029	NCT00142090_29_T2	PHENOTYPE	16	16	centers
NCT0014209029	NCT00142090_29_T3	GENE	10	10	has
NCT0014209029	NCT00142090_29_T4	PHENOTYPE	7	9	traumatic brain injury
NCT0014209029	NCT00142090_29_T5	PHENOTYPE	36	38	traumatic brain injury
NCT0014209030	NCT00142090_30_T0	GENE	3	3	ICP
NCT0014209033	NCT00142090_33_T0	PHENOTYPE	23	23	vasospasm
NCT0014209033	NCT00142090_33_T1	PHENOTYPE	3	3	symptoms
NCT0014209033	NCT00142090_33_T2	PHENOTYPE	20	21	cerebral edema
NCT0014209033	NCT00142090_33_T3	PHENOTYPE	6	9	mild traumatic brain injury
NCT0014209034	NCT00142090_34_T0	PHENOTYPE	8	8	symptoms
NCT0014209034	NCT00142090_34_T1	PHENOTYPE	20	20	symptoms
NCT0014209034	NCT00142090_34_T2	PHENOTYPE	10	10	concussion
NCT0014209038	NCT00142090_38_T0	PHENOTYPE	2	3	skull fractures
NCT001421030	NCT00142103_0_T0	COMPOUND	14	14	HCV
NCT001421030	NCT00142103_0_T1	PHENOTYPE	7	8	Hepatitis C
NCT001421030	NCT00142103_0_T2	PHENOTYPE	11	12	Hepatitis C
NCT001421032	NCT00142103_2_T0	GENE	7	7	SC
NCT001421032	NCT00142103_2_T1	COMPOUND	14	14	ribavirin
NCT001421032	NCT00142103_2_T2	COMPOUND	20	20	ribavirin
NCT001421032	NCT00142103_2_T3	COMPOUND	29	29	HCV
NCT001421032	NCT00142103_2_T4	GENE	13	13	interferon
NCT001421032	NCT00142103_2_T5	GENE	18	18	interferon
NCT001421036	NCT00142103_6_T0	COMPOUND	0	0	HCV
NCT0014210312	NCT00142103_12_T0	GENE	37	37	has
NCT0014210312	NCT00142103_12_T1	PHENOTYPE	0	2	Negative pregnancy test
NCT0014210313	NCT00142103_13_T0	GENE	4	4	IFN
NCT0014210320	NCT00142103_20_T0	COMPOUND	34	34	ribavirin
NCT0014210320	NCT00142103_20_T1	PHENOTYPE	29	29	allergy
NCT0014210320	NCT00142103_20_T2	GENE	33	33	interferon
NCT001421163	NCT00142116_3_T0	COMPOUND	5	5	thalidomide
NCT001421163	NCT00142116_3_T1	COMPOUND	14	14	thalidomide
NCT001421165	NCT00142116_5_T0	ORGAN	8	9	bone marrow
NCT001421294	NCT00142129_4_T0	COMPOUND	0	0	DAY
NCT001421295	NCT00142129_5_T0	COMPOUND	0	0	DAY
NCT001421684	NCT00142168_4_T0	PHENOTYPE	8	8	pulse
NCT001421686	NCT00142168_6_T0	ORGAN	8	9	bone marrow
NCT001421817	NCT00142181_7_T0	PHENOTYPE	4	4	aspirations
NCT001421817	NCT00142181_7_T1	ORGAN	0	1	Bone marrow
NCT001421940	NCT00142194_0_T0	PHENOTYPE	2	3	Oxidative Stress
NCT001421940	NCT00142194_0_T1	PHENOTYPE	10	11	Atrial Fibrillation
NCT001421942	NCT00142194_2_T0	ORGAN	13	13	heart
NCT001421943	NCT00142194_3_T0	PHENOTYPE	5	5	relapse
NCT001421943	NCT00142194_3_T1	PHENOTYPE	18	19	atrial fibrillation
NCT001421944	NCT00142194_4_T0	PHENOTYPE	6	7	atrial fibrillation
NCT001421944	NCT00142194_4_T1	PHENOTYPE	12	13	oxidative stress
NCT001421945	NCT00142194_5_T0	COMPOUND	6	6	oxygen
NCT001421946	NCT00142194_6_T0	CELL	4	4	cells
NCT001421946	NCT00142194_6_T1	ORGAN	7	7	heart
NCT001421947	NCT00142194_7_T0	GENE	8	8	pig
NCT001421947	NCT00142194_7_T1	PHENOTYPE	13	14	atrial fibrillation
NCT001421947	NCT00142194_7_T2	PHENOTYPE	5	6	oxidative stress
NCT001421948	NCT00142194_8_T0	PHENOTYPE	13	14	atrial fibrillation
NCT001421948	NCT00142194_8_T1	PHENOTYPE	6	7	oxidative stress
NCT001421949	NCT00142194_9_T0	PHENOTYPE	16	17	atrial fibrillation
NCT001421949	NCT00142194_9_T1	PHENOTYPE	9	10	oxidative stress
NCT0014219410	NCT00142194_10_T0	PHENOTYPE	7	8	atrial fibrillation
NCT0014219410	NCT00142194_10_T1	PHENOTYPE	16	17	atrial fibrillation
NCT0014219413	NCT00142194_13_T0	ORGAN	13	13	heart
NCT0014219414	NCT00142194_14_T0	PHENOTYPE	5	5	relapse
NCT0014219414	NCT00142194_14_T1	PHENOTYPE	18	19	atrial fibrillation
NCT0014219415	NCT00142194_15_T0	ORGAN	23	23	heart
NCT0014219415	NCT00142194_15_T1	PHENOTYPE	5	6	atrial fibrillation
NCT0014219415	NCT00142194_15_T2	ORGAN	26	27	atrial appendage
NCT0014219415	NCT00142194_15_T3	PHENOTYPE	11	12	oxidative stress
NCT0014219416	NCT00142194_16_T0	COMPOUND	7	7	oxygen
NCT0014219416	NCT00142194_16_T1	PHENOTYPE	0	1	Oxidative stress
NCT0014219417	NCT00142194_17_T0	CELL	4	4	cells
NCT0014219417	NCT00142194_17_T1	ORGAN	7	7	heart
NCT0014219418	NCT00142194_18_T0	ORGAN	5	5	heart
NCT0014219418	NCT00142194_18_T1	PHENOTYPE	13	14	blood clots
NCT0014219422	NCT00142194_22_T0	PHENOTYPE	18	19	atrial fibrillation
NCT0014219422	NCT00142194_22_T1	PHENOTYPE	11	12	oxidative stress
NCT0014219423	NCT00142194_23_T0	PHENOTYPE	7	8	atrial fibrillation
NCT0014219423	NCT00142194_23_T1	PHENOTYPE	15	16	atrial fibrillation
NCT0014219425	NCT00142194_25_T0	PHENOTYPE	22	23	atrial fibrillation
NCT001422070	NCT00142207_0_T0	PHENOTYPE	1	1	Malaria
NCT001422075	NCT00142207_5_T0	PHENOTYPE	5	5	malaria
NCT001422077	NCT00142207_7_T0	PHENOTYPE	10	10	malaria
NCT001422078	NCT00142207_8_T0	PHENOTYPE	15	15	malaria
NCT001422079	NCT00142207_9_T0	GENE	2	2	has
NCT0014220710	NCT00142207_10_T0	PHENOTYPE	8	8	malaria
NCT0014220711	NCT00142207_11_T0	PHENOTYPE	12	12	strategies
NCT0014220711	NCT00142207_11_T1	PHENOTYPE	17	17	malaria
NCT0014220716	NCT00142207_16_T0	PHENOTYPE	9	9	strategies
NCT001422200	NCT00142220_0_T0	PHENOTYPE	10	11	Critically Ill
NCT0014223311	NCT00142233_11_T0	PHENOTYPE	4	4	symptoms
NCT0014223311	NCT00142233_11_T1	GENE	3	3	had
NCT0014223311	NCT00142233_11_T2	PHENOTYPE	6	6	pancreatitis
NCT0014223318	NCT00142233_18_T0	GENE	15	15	PRSS1
NCT0014223318	NCT00142233_18_T1	GENE	30	30	PRSS1
NCT0014223318	NCT00142233_18_T2	GENE	5	5	HP
NCT0014223318	NCT00142233_18_T3	GENE	23	23	ICP
NCT0014223318	NCT00142233_18_T4	PHENOTYPE	3	4	Hereditary Pancreatitis
NCT0014223318	NCT00142233_18_T5	PHENOTYPE	26	27	mutations detected
NCT0014223318	NCT00142233_18_T6	PHENOTYPE	21	22	Chronic Pancreatitis
NCT0014223325	NCT00142233_25_T0	COMPOUND	6	6	3
NCT0014223325	NCT00142233_25_T1	COMPOUND	16	16	magnesium
NCT0014223325	NCT00142233_25_T2	GENE	3	3	had
NCT0014223327	NCT00142233_27_T0	COMPOUND	5	5	3
NCT0014223327	NCT00142233_27_T1	GENE	3	3	had
NCT0014223327	NCT00142233_27_T2	PHENOTYPE	17	18	pancreatic disease
NCT0014223329	NCT00142233_29_T0	COMPOUND	5	5	creatinine
NCT0014223329	NCT00142233_29_T1	ORGAN	4	4	serum
NCT0014223329	NCT00142233_29_T2	PHENOTYPE	2	3	renal failure
NCT0014223333	NCT00142233_33_T0	ORGAN	0	0	Serum
NCT0014223337	NCT00142233_37_T0	PHENOTYPE	7	7	analgesia
NCT0014223337	NCT00142233_37_T1	COMPOUND	8	8	morphine
NCT0014223338	NCT00142233_38_T0	PHENOTYPE	8	8	impairment
NCT0014223338	NCT00142233_38_T1	PHENOTYPE	3	5	chronic hepatic failure
NCT001422460	NCT00142246_0_T0	PHENOTYPE	11	11	Malaria
NCT001422460	NCT00142246_0_T1	PHENOTYPE	12	12	Anaemia
NCT001422463	NCT00142246_3_T0	COMPOUND	7	7	amodiaquine
NCT001422463	NCT00142246_3_T1	GENE	0	0	SP
NCT001422465	NCT00142246_5_T0	GENE	22	22	al
NCT001422465	NCT00142246_5_T1	PHENOTYPE	19	19	malaria
NCT001422465	NCT00142246_5_T2	GENE	21	21	et
NCT001422466	NCT00142246_6_T0	PHENOTYPE	0	0	Malaria
NCT001422466	NCT00142246_6_T1	GENE	18	18	al
NCT001422466	NCT00142246_6_T2	GENE	17	17	et
NCT0014224611	NCT00142246_11_T0	PHENOTYPE	24	24	anaemia
NCT0014224611	NCT00142246_11_T1	PHENOTYPE	6	6	malaria
NCT001422721	NCT00142272_1_T0	COMPOUND	16	16	erythromycin
NCT001422721	NCT00142272_1_T1	COMPOUND	5	5	ciprofloxacin
NCT001422723	NCT00142272_3_T0	PHENOTYPE	4	4	dehydrated
NCT001422723	NCT00142272_3_T1	PHENOTYPE	20	20	dehydration
NCT001422724	NCT00142272_4_T0	COMPOUND	16	16	sodium
NCT001422724	NCT00142272_4_T1	COMPOUND	17	17	potassium
NCT001422724	NCT00142272_4_T2	GENE	23	23	3.4
NCT001422724	NCT00142272_4_T3	COMPOUND	18	18	chloride
NCT001422724	NCT00142272_4_T4	COMPOUND	20	20	bicarbonate
NCT001422726	NCT00142272_6_T0	GENE	33	33	Period
NCT001422729	NCT00142272_9_T0	PHENOTYPE	9	9	initiation
NCT001422729	NCT00142272_9_T1	PHENOTYPE	18	18	diarrhoea
NCT0014227212	NCT00142272_12_T0	GENE	8	8	MRI
NCT0014227213	NCT00142272_13_T0	GENE	19	19	has
NCT0014227213	NCT00142272_13_T1	GENE	37	37	has
NCT0014227213	NCT00142272_13_T2	GENE	22	22	orb
NCT0014227213	NCT00142272_13_T3	PHENOTYPE	21	21	resolved
NCT0014227213	NCT00142272_13_T4	PHENOTYPE	17	18	adverse event
NCT0014227215	NCT00142272_15_T0	PHENOTYPE	11	11	initiation
NCT0014227216	NCT00142272_16_T0	ORGAN	0	0	Blood
NCT0014227217	NCT00142272_17_T0	PHENOTYPE	9	9	initiation
NCT0014227219	NCT00142272_19_T0	COMPOUND	6	6	creatinine
NCT0014227219	NCT00142272_19_T1	PHENOTYPE	17	17	initiation
NCT0014227219	NCT00142272_19_T2	ORGAN	3	3	serum
NCT0014227219	NCT00142272_19_T3	PHENOTYPE	7	8	total bilirubin
NCT0014227219	NCT00142272_19_T4	GENE	11	12	alkaline phosphatase
NCT0014227221	NCT00142272_21_T0	ORGAN	0	0	Serum
NCT0014227221	NCT00142272_21_T1	COMPOUND	3	3	ciprofloxacin
NCT0014227224	NCT00142272_24_T0	GENE	3	3	24
NCT0014227226	NCT00142272_26_T0	PHENOTYPE	0	1	Severe dehydration
NCT0014227231	NCT00142272_31_T0	PHENOTYPE	3	5	chronic renal insufficiency
NCT001422853	NCT00142285_3_T0	PHENOTYPE	3	3	pneumonia
NCT001422854	NCT00142285_4_T0	PHENOTYPE	8	8	acute
NCT001422854	NCT00142285_4_T1	PHENOTYPE	18	18	pneumonia
NCT001422854	NCT00142285_4_T2	COMPOUND	3	3	zinc
NCT001422856	NCT00142285_6_T0	COMPOUND	11	11	zinc
NCT001422858	NCT00142285_8_T0	PHENOTYPE	20	20	pneumonia
NCT001422858	NCT00142285_8_T1	COMPOUND	6	6	zinc
NCT001422982	NCT00142298_2_T0	GENE	26	26	had
NCT0014229813	NCT00142298_13_T0	COMPOUND	4	4	telbivudine
NCT0014229813	NCT00142298_13_T1	COMPOUND	17	17	telbivudine
NCT0014229814	NCT00142298_14_T0	COMPOUND	25	25	telbivudine
NCT0014229814	NCT00142298_14_T1	COMPOUND	4	4	lamivudine
NCT0014229816	NCT00142298_16_T0	COMPOUND	3	3	telbivudine
NCT0014229816	NCT00142298_16_T1	COMPOUND	15	15	telbivudine
NCT0014229817	NCT00142298_17_T0	COMPOUND	15	15	telbivudine
NCT0014229817	NCT00142298_17_T1	COMPOUND	4	4	lamivudine
NCT0014229818	NCT00142298_18_T0	GENE	12	12	had
NCT0014229818	NCT00142298_18_T1	PHENOTYPE	9	10	hepatitis B
NCT0014229818	NCT00142298_18_T2	PHENOTYPE	8	9	chronic hepatitis
NCT0014229820	NCT00142298_20_T0	GENE	4	5	group C
NCT0014229821	NCT00142298_21_T0	COMPOUND	8	8	telbivudine
NCT0014229821	NCT00142298_21_T1	GENE	5	6	group C
NCT001423111	NCT00142311_1_T0	GENE	22	22	Parkin
NCT001423111	NCT00142311_1_T1	PHENOTYPE	35	36	isolated cases
NCT001423112	NCT00142311_2_T0	PHENOTYPE	14	14	secondary
NCT001423112	NCT00142311_2_T1	PHENOTYPE	21	21	mutation
NCT001423112	NCT00142311_2_T2	GENE	3	3	has
NCT001423112	NCT00142311_2_T3	GENE	19	19	Parkin
NCT001423115	NCT00142311_5_T0	GENE	4	4	Parkin
NCT001423115	NCT00142311_5_T1	CELL	16	17	dopaminergic neurons
NCT001423115	NCT00142311_5_T2	ORGAN	20	23	substantia nigra pars compacta
NCT001423116	NCT00142311_6_T0	COMPOUND	12	12	levodopa
NCT001423116	NCT00142311_6_T1	PHENOTYPE	22	22	attitudes
NCT001423116	NCT00142311_6_T2	PHENOTYPE	15	16	cognitive deficit
NCT001423117	NCT00142311_7_T0	PHENOTYPE	11	11	centers
NCT001423117	NCT00142311_7_T1	PHENOTYPE	32	32	centers
NCT001423117	NCT00142311_7_T2	GENE	34	34	TEP
NCT001423117	NCT00142311_7_T3	GENE	4	4	Parkin
NCT0014231110	NCT00142311_10_T0	GENE	23	23	coil
NCT0014231111	NCT00142311_11_T0	BIOLOGICAL_PROCESS	13	14	menstrual cycle
NCT001423373	NCT00142337_3_T0	COMPOUND	3	3	nevirapine
NCT001423375	NCT00142337_5_T0	GENE	11	12	reverse transcriptase
NCT001423377	NCT00142337_7_T0	COMPOUND	18	18	nevirapine
NCT001423377	NCT00142337_7_T1	ORGAN	1	1	plasma
NCT001423378	NCT00142337_8_T0	COMPOUND	9	9	nevirapine
NCT001423378	NCT00142337_8_T1	COMPOUND	24	24	nevirapine
NCT001423501	NCT00142350_1_T0	COMPOUND	18	18	fluoropyrimidine
NCT001423501	NCT00142350_1_T1	COMPOUND	9	9	irinotecan
NCT001423501	NCT00142350_1_T2	COMPOUND	24	24	5_fluorouracil
NCT001423501	NCT00142350_1_T3	COMPOUND	11	11	cisplatin
NCT001423631	NCT00142363_1_T0	GENE	5	5	has
NCT001423631	NCT00142363_1_T1	PHENOTYPE	17	18	psychiatric disorders
NCT001423633	NCT00142363_3_T0	PHENOTYPE	15	15	epilepsies
NCT001423635	NCT00142363_5_T0	PHENOTYPE	1	1	epilepsies
NCT001423761	NCT00142376_1_T0	PHENOTYPE	8	8	ventilation
NCT001423764	NCT00142376_4_T0	GENE	8	8	met
NCT001423764	NCT00142376_4_T1	PHENOTYPE	13	13	ARDS
NCT001423767	NCT00142376_7_T0	GENE	3	3	met
NCT001423769	NCT00142376_9_T0	PHENOTYPE	13	13	ventilation
NCT0014237611	NCT00142376_11_T0	PHENOTYPE	10	10	ARDS
NCT0014237612	NCT00142376_12_T0	PHENOTYPE	13	13	ARDS
NCT001424025	NCT00142402_5_T0	GENE	11	12	group 2
NCT001424027	NCT00142402_7_T0	COMPOUND	9	9	EDSS
NCT001424029	NCT00142402_9_T0	GENE	0	1	Group 1
NCT0014240218	NCT00142402_18_T0	GENE	17	17	MS
NCT0014240218	NCT00142402_18_T1	PHENOTYPE	14	15	cognitive symptoms
NCT0014240222	NCT00142402_22_T0	GENE	26	26	3.5
NCT0014240222	NCT00142402_22_T1	GENE	6	6	has
NCT0014240222	NCT00142402_22_T2	PHENOTYPE	21	21	encoding
NCT0014240222	NCT00142402_22_T3	BIOLOGICAL_PROCESS	11	12	long-term potentiation
NCT0014240228	NCT00142402_28_T0	GENE	1	1	has
NCT0014240230	NCT00142402_30_T0	GENE	2	2	has
NCT0014240230	NCT00142402_30_T1	PHENOTYPE	9	12	Attention Deficit Hyperactivity Disorder
NCT0014240231	NCT00142402_31_T0	PHENOTYPE	10	10	impairment
NCT0014240235	NCT00142402_35_T0	PHENOTYPE	11	12	language comprehension
NCT0014240237	NCT00142402_37_T0	ORGAN	6	6	Appendix
NCT0014240238	NCT00142402_38_T0	GENE	9	9	MS
NCT0014240238	NCT00142402_38_T1	ORGAN	20	20	Appendix
NCT0014240241	NCT00142402_41_T0	PHENOTYPE	1	1	impairment
NCT0014240241	NCT00142402_41_T1	GENE	9	9	1.5
NCT0014240243	NCT00142402_43_T0	ORGAN	8	8	Appendix
NCT0014240245	NCT00142402_45_T0	GENE	11	12	group 2
NCT0014240247	NCT00142402_47_T0	GENE	10	10	Dr
NCT0014240247	NCT00142402_47_T1	COMPOUND	22	22	EDSS
NCT0014240249	NCT00142402_49_T0	COMPOUND	9	9	EDSS
NCT0014240251	NCT00142402_51_T0	GENE	0	1	Group 1
NCT0014240258	NCT00142402_58_T0	ORGAN	6	6	Appendix
NCT0014240259	NCT00142402_59_T0	GENE	16	16	ANOVA
NCT0014240261	NCT00142402_61_T0	COMPOUND	8	8	1st
NCT0014240261	NCT00142402_61_T1	GENE	27	28	group 2
NCT0014240262	NCT00142402_62_T0	GENE	15	15	NP
NCT0014240262	NCT00142402_62_T1	GENE	18	19	Group 1
NCT0014240262	NCT00142402_62_T2	PHENOTYPE	7	8	cognitive functioning
NCT0014240262	NCT00142402_62_T3	GENE	27	28	group 2
NCT001424150	NCT00142415_0_T0	PHENOTYPE	11	12	Renal Cancer
NCT001424154	NCT00142415_4_T0	PHENOTYPE	1	1	secondary
NCT001424154	NCT00142415_4_T1	GENE	19	19	1.0
NCT001424154	NCT00142415_4_T2	PHENOTYPE	6	6	tumor
NCT001424154	NCT00142415_4_T3	PHENOTYPE	15	16	Solid Tumors
NCT001424159	NCT00142415_9_T0	PHENOTYPE	10	10	toxicity
NCT001424159	NCT00142415_9_T1	PHENOTYPE	4	5	disease progression
NCT0014241510	NCT00142415_10_T0	PHENOTYPE	4	4	pharmacokinetics
NCT0014241512	NCT00142415_12_T0	PHENOTYPE	6	6	toxicity
NCT0014241523	NCT00142415_23_T0	ORGAN	10	10	serum
NCT0014241523	NCT00142415_23_T1	PHENOTYPE	0	2	Negative pregnancy test
NCT0014241529	NCT00142415_29_T0	PHENOTYPE	1	1	metastases
NCT0014241531	NCT00142415_31_T0	PHENOTYPE	1	1	hypercalcemia
NCT0014241533	NCT00142415_33_T0	PHENOTYPE	0	1	Metastatic disease
NCT0014241538	NCT00142415_38_T0	PHENOTYPE	7	8	pathological fractures
NCT0014241540	NCT00142415_40_T0	ORGAN	5	5	Heart
NCT0014241540	NCT00142415_40_T1	GENE	9	9	III
NCT0014241540	NCT00142415_40_T2	GENE	11	11	IV
NCT0014241544	NCT00142415_44_T0	PHENOTYPE	15	15	judgement
NCT0014241544	NCT00142415_44_T1	PHENOTYPE	6	6	inflammation
NCT0014241544	NCT00142415_44_T2	PHENOTYPE	10	11	laboratory abnormality
NCT001424286	NCT00142428_6_T0	PHENOTYPE	4	4	tumor
NCT001424286	NCT00142428_6_T1	PHENOTYPE	25	25	tumor
NCT001424286	NCT00142428_6_T2	GENE	6	6	EGFR
NCT0014242814	NCT00142428_14_T0	GENE	10	10	MRI
NCT0014242814	NCT00142428_14_T1	PHENOTYPE	17	17	tumor
NCT0014242816	NCT00142428_16_T0	PHENOTYPE	11	12	disease progression
NCT001424543	NCT00142454_3_T0	GENE	19	19	NY-ESO-1
NCT001424545	NCT00142454_5_T0	ORGAN	14	14	extremities
NCT001424545	NCT00142454_5_T1	GENE	27	27	NY-ESO-1
NCT001424546	NCT00142454_6_T0	GENE	7	7	NY-ESO-1
NCT001424546	NCT00142454_6_T1	CELL	5	5	T-cell
NCT001424546	NCT00142454_6_T2	PHENOTYPE	9	10	antibody titers
NCT001424804	NCT00142480_4_T0	COMPOUND	46	46	capecitabine
NCT001424804	NCT00142480_4_T1	COMPOUND	62	62	capecitabine
NCT001424804	NCT00142480_4_T2	COMPOUND	69	69	capecitabine
NCT001424804	NCT00142480_4_T3	GENE	24	24	29
NCT001424804	NCT00142480_4_T4	GENE	45	45	29
NCT001424804	NCT00142480_4_T5	COMPOUND	3	3	oxaliplatin
NCT001424808	NCT00142480_8_T0	PHENOTYPE	15	15	tumors
NCT001424808	NCT00142480_8_T1	GENE	14	14	had
NCT0014248017	NCT00142480_17_T0	PHENOTYPE	27	27	tumor
NCT0014248017	NCT00142480_17_T1	ORGAN	24	24	abdomen
NCT001424932	NCT00142493_2_T0	COMPOUND	10	10	dexmedetomidine
NCT001424932	NCT00142493_2_T1	COMPOUND	8	8	midazolam
NCT001424932	NCT00142493_2_T2	COMPOUND	7	7	thiopental
NCT001424938	NCT00142493_8_T0	GENE	25	25	CRT
NCT001425063	NCT00142506_3_T0	PHENOTYPE	30	31	erectile dysfunction
NCT001425067	NCT00142506_7_T0	PHENOTYPE	21	21	QOL
NCT001425191	NCT00142519_1_T0	COMPOUND	16	16	methadone
NCT001425191	NCT00142519_1_T1	COMPOUND	14	14	morphine
NCT001425326	NCT00142532_6_T0	GENE	3	3	1.3
NCT0014253213	NCT00142532_13_T0	PHENOTYPE	9	10	lung cancer
NCT001425452	NCT00142545_2_T0	COMPOUND	17	17	apomorphine
NCT001425452	NCT00142545_2_T1	COMPOUND	20	20	apomorphine
NCT001425452	NCT00142545_2_T2	GENE	8	8	had
NCT001425454	NCT00142545_4_T0	COMPOUND	12	12	apomorphine
NCT001425459	NCT00142545_9_T0	COMPOUND	5	5	levodopa_carbidopa
NCT001425459	NCT00142545_9_T1	COMPOUND	20	20	dopamine
NCT001425713	NCT00142571_3_T0	GENE	4	4	III
NCT001425715	NCT00142571_5_T0	COMPOUND	12	12	docetaxel
NCT001425715	NCT00142571_5_T1	COMPOUND	5	5	gemcitabine
NCT001425715	NCT00142571_5_T2	COMPOUND	10	10	gemcitabine
NCT001425715	NCT00142571_5_T3	PHENOTYPE	24	24	sarcomas
NCT001425716	NCT00142571_6_T0	PHENOTYPE	13	13	tumors
NCT001425716	NCT00142571_6_T1	PHENOTYPE	12	12	sarcoma
NCT001425716	NCT00142571_6_T2	COMPOUND	6	6	gemcitabine
NCT001425718	NCT00142571_8_T0	COMPOUND	16	16	docetaxel
NCT001425718	NCT00142571_8_T1	GENE	10	10	Is
NCT001425718	NCT00142571_8_T2	COMPOUND	14	14	gemcitabine
NCT001425718	NCT00142571_8_T3	COMPOUND	21	21	gemcitabine
NCT001425719	NCT00142571_9_T0	GENE	5	5	III
NCT001425719	NCT00142571_9_T1	PHENOTYPE	15	17	soft tissue sarcoma
NCT0014257112	NCT00142571_12_T0	PHENOTYPE	7	7	Sarcoma
NCT0014257112	NCT00142571_12_T1	PHENOTYPE	14	14	Oncology
NCT0014257112	NCT00142571_12_T2	TISSUE	12	13	Connective Tissue
NCT0014257114	NCT00142571_14_T0	PHENOTYPE	0	1	Measurable disease
NCT0014257114	NCT00142571_14_T1	PHENOTYPE	9	10	measurable lesion
NCT0014257115	NCT00142571_15_T0	GENE	8	8	solitary
NCT0014257115	NCT00142571_15_T1	PHENOTYPE	2	3	measurable disease
NCT001425840	NCT00142584_0_T0	PHENOTYPE	14	14	Hypertension
NCT001425846	NCT00142584_6_T0	COMPOUND	6	6	nebivolol
NCT001425846	NCT00142584_6_T1	COMPOUND	8	8	metoprolol
NCT001425849	NCT00142584_9_T0	COMPOUND	19	19	nebivolol
NCT001425849	NCT00142584_9_T1	GENE	5	5	1.3
NCT001425849	NCT00142584_9_T2	COMPOUND	21	21	metoprolol
NCT001425973	NCT00142597_3_T0	PHENOTYPE	0	0	Fibromyalgia
NCT0014259717	NCT00142597_17_T0	ORGAN	9	9	thumb
NCT0014259717	NCT00142597_17_T1	COMPOUND	25	25	oxygen
NCT0014259721	NCT00142597_21_T0	MOLECULAR_FUNCTION	14	16	mu-opioid receptor activity
NCT0014259723	NCT00142597_23_T0	GENE	11	11	Ann
NCT0014259723	NCT00142597_23_T1	PHENOTYPE	23	23	Center
NCT001426104	NCT00142610_4_T0	CELL	11	11	cells
NCT001426105	NCT00142610_5_T0	ORGAN	7	7	lungs
NCT001426107	NCT00142610_7_T0	COMPOUND	5	5	ascorbate
NCT001426107	NCT00142610_7_T1	PHENOTYPE	11	11	asthma
NCT001426107	NCT00142610_7_T2	COMPOUND	17	17	ozone
NCT001426108	NCT00142610_8_T0	PHENOTYPE	20	20	allergies
NCT001426108	NCT00142610_8_T1	ORGAN	9	9	lungs
NCT001426108	NCT00142610_8_T2	PHENOTYPE	16	17	respiratory diseases
NCT001426109	NCT00142610_9_T0	PHENOTYPE	9	9	asthmatics
NCT001426109	NCT00142610_9_T1	COMPOUND	16	17	vitamin E
NCT0014261010	NCT00142610_10_T0	COMPOUND	17	17	ascorbate
NCT0014261012	NCT00142610_12_T0	CELL	10	10	cells
NCT0014261012	NCT00142610_12_T1	COMPOUND	16	16	methacholine
NCT0014261012	NCT00142610_12_T2	PHENOTYPE	13	14	respiratory symptoms
NCT0014261012	NCT00142610_12_T3	PHENOTYPE	11	12	lung function
NCT0014261014	NCT00142610_14_T0	COMPOUND	21	21	methacholine
NCT001426235	NCT00142623_5_T0	PHENOTYPE	18	18	self-assessments
NCT0014262310	NCT00142623_10_T0	COMPOUND	38	38	cotinine
NCT0014262310	NCT00142623_10_T1	COMPOUND	50	50	cotinine
NCT0014262310	NCT00142623_10_T2	GENE	14	14	UC
NCT0014262310	NCT00142623_10_T3	GENE	37	37	saliva
NCT0014262310	NCT00142623_10_T4	GENE	49	49	saliva
NCT0014262310	NCT00142623_10_T5	COMPOUND	2	2	1
NCT0014262310	NCT00142623_10_T6	BIOLOGICAL_PROCESS	35	35	gestation
NCT0014262311	NCT00142623_11_T0	PHENOTYPE	38	38	concentrations
NCT0014262311	NCT00142623_11_T1	COMPOUND	37	37	cotinine
NCT0014262311	NCT00142623_11_T2	COMPOUND	56	56	cotinine
NCT0014262311	NCT00142623_11_T3	GENE	10	10	UC
NCT0014262311	NCT00142623_11_T4	GENE	36	36	saliva
NCT0014262311	NCT00142623_11_T5	GENE	55	55	saliva
NCT0014262311	NCT00142623_11_T6	COMPOUND	2	2	2
NCT0014262311	NCT00142623_11_T7	BIOLOGICAL_PROCESS	34	34	gestation
NCT001426495	NCT00142649_5_T0	PHENOTYPE	1	1	diseases
NCT001426496	NCT00142649_6_T0	PHENOTYPE	6	6	overweight
NCT0014264910	NCT00142649_10_T0	PHENOTYPE	11	12	weight loss
NCT0014264916	NCT00142649_16_T0	PHENOTYPE	43	43	hypertension
NCT001426622	NCT00142662_2_T0	PHENOTYPE	2	2	obesity
NCT001426624	NCT00142662_4_T0	GENE	2	2	has
NCT001426626	NCT00142662_6_T0	PHENOTYPE	22	22	Obesity
NCT0014266212	NCT00142662_12_T0	COMPOUND	4	4	BMI
NCT0014266212	NCT00142662_12_T1	PHENOTYPE	17	18	weight gain
NCT0014266214	NCT00142662_14_T0	GENE	30	30	reduced
NCT0014266215	NCT00142662_15_T0	PHENOTYPE	5	6	individual differences
NCT0014266217	NCT00142662_17_T0	PHENOTYPE	24	24	self-efficacy
NCT0014266217	NCT00142662_17_T1	PHENOTYPE	22	22	overeating
NCT0014266217	NCT00142662_17_T2	PHENOTYPE	27	29	quality of life
NCT001426754	NCT00142675_4_T0	PHENOTYPE	13	14	chronic disease
NCT001426885	NCT00142688_5_T0	PHENOTYPE	26	26	self-efficacy
NCT001426886	NCT00142688_6_T0	GENE	18	18	mediator
NCT001427015	NCT00142701_5_T0	GENE	26	26	CLM
NCT001427273	NCT00142727_3_T0	PHENOTYPE	7	8	physical dependence
NCT001427274	NCT00142727_4_T0	COMPOUND	15	15	methadone
NCT001427275	NCT00142727_5_T0	GENE	27	27	has
NCT001427402	NCT00142740_2_T0	GENE	2	2	ml
NCT001427403	NCT00142740_3_T0	GENE	9	9	amp
NCT001427403	NCT00142740_3_T1	GENE	21	21	polymerase
NCT001427403	NCT00142740_3_T2	PHENOTYPE	0	0	Peripheral
NCT001427403	NCT00142740_3_T3	CELL	3	3	cells
NCT001427403	NCT00142740_3_T4	GENE	11	11	kit
NCT001427532	NCT00142753_2_T0	PHENOTYPE	23	23	persistence
NCT001427532	NCT00142753_2_T1	PHENOTYPE	32	33	hepatitis B
NCT001427532	NCT00142753_2_T2	BIOLOGICAL_PROCESS	4	6	cellular immune response
NCT001427535	NCT00142753_5_T0	COMPOUND	14	14	Engerix-B
NCT001427535	NCT00142753_5_T1	GENE	1	1	10
NCT001427538	NCT00142753_8_T0	PHENOTYPE	7	7	HBV
NCT001427538	NCT00142753_8_T1	PHENOTYPE	10	10	HBV
NCT001427538	NCT00142753_8_T2	PHENOTYPE	14	14	HBV
NCT0014275310	NCT00142753_10_T0	PHENOTYPE	5	5	HBV
NCT0014275311	NCT00142753_11_T0	PHENOTYPE	34	34	HIV
NCT0014275311	NCT00142753_11_T1	PHENOTYPE	30	30	HBV
NCT0014275311	NCT00142753_11_T2	PHENOTYPE	27	28	antibody response
NCT0014275311	NCT00142753_11_T3	PHENOTYPE	14	15	hepatitis B
NCT0014275311	NCT00142753_11_T4	BIOLOGICAL_PROCESS	10	12	cellular immune response
NCT0014275312	NCT00142753_12_T0	PHENOTYPE	3	3	peripheral
NCT0014275312	NCT00142753_12_T1	CELL	5	5	cells
NCT0014275312	NCT00142753_12_T2	BIOLOGICAL_PROCESS	0	1	Cytokine production
NCT0014275312	NCT00142753_12_T3	CELL	13	14	antibody-secreting cells
NCT001427660	NCT00142766_0_T0	PHENOTYPE	8	8	Ventilation
NCT001427662	NCT00142766_2_T0	PHENOTYPE	30	30	ventilation
NCT001427662	NCT00142766_2_T1	PHENOTYPE	37	37	ventilation
NCT001427667	NCT00142766_7_T0	GENE	2	2	has
NCT001427667	NCT00142766_7_T1	PHENOTYPE	8	8	practices
NCT001427669	NCT00142766_9_T0	PHENOTYPE	16	17	decision making
NCT0014276612	NCT00142766_12_T0	PHENOTYPE	27	27	ventilation
NCT0014276618	NCT00142766_18_T0	PHENOTYPE	13	14	problem solving
NCT0014276619	NCT00142766_19_T0	PHENOTYPE	11	11	practices
NCT0014276622	NCT00142766_22_T0	GENE	9	9	pre
NCT0014276625	NCT00142766_25_T0	PHENOTYPE	12	13	opioid withdrawal
NCT0014276627	NCT00142766_27_T0	PHENOTYPE	7	8	opioid withdrawal
NCT0014276629	NCT00142766_29_T0	PHENOTYPE	33	33	self-assessment
NCT0014276634	NCT00142766_34_T0	PHENOTYPE	3	3	vigilance
NCT0014276634	NCT00142766_34_T1	PHENOTYPE	30	30	decision-making
NCT001427791	NCT00142779_1_T0	PHENOTYPE	19	20	cocaine use
NCT001427791	NCT00142779_1_T1	PHENOTYPE	11	12	anxiety disorders
NCT001427791	NCT00142779_1_T2	PHENOTYPE	25	26	cocaine addiction
NCT001427792	NCT00142779_2_T0	COMPOUND	7	7	fluoxetine
NCT001427792	NCT00142779_2_T1	COMPOUND	23	23	methadone
NCT001427792	NCT00142779_2_T2	PHENOTYPE	10	11	cocaine use
NCT001427792	NCT00142779_2_T3	PHENOTYPE	14	16	addicted to cocaine
NCT001427795	NCT00142779_5_T0	PHENOTYPE	11	12	drug use
NCT001427795	NCT00142779_5_T1	PHENOTYPE	6	7	depressive symptoms
NCT001427796	NCT00142779_6_T0	PHENOTYPE	11	12	panic attacks
NCT001427796	NCT00142779_6_T1	PHENOTYPE	17	18	cocaine use
NCT001427796	NCT00142779_6_T2	PHENOTYPE	21	23	addicted to cocaine
NCT001427797	NCT00142779_7_T0	GENE	15	15	lessen
NCT001427797	NCT00142779_7_T1	COMPOUND	13	13	fluoxetine
NCT001427797	NCT00142779_7_T2	COMPOUND	24	24	cocaine
NCT001427797	NCT00142779_7_T3	PHENOTYPE	16	17	depressive symptoms
NCT001427798	NCT00142779_8_T0	PHENOTYPE	12	12	reward
NCT001427798	NCT00142779_8_T1	PHENOTYPE	22	23	substance abuse
NCT001427799	NCT00142779_9_T0	COMPOUND	5	5	fluoxetine
NCT001427799	NCT00142779_9_T1	GENE	2	2	has
NCT001427799	NCT00142779_9_T2	PHENOTYPE	18	19	cocaine use
NCT0014277910	NCT00142779_10_T0	COMPOUND	9	9	fluoxetine
NCT0014277910	NCT00142779_10_T1	COMPOUND	11	11	cocaine
NCT0014277911	NCT00142779_11_T0	COMPOUND	11	11	fluoxetine
NCT0014277911	NCT00142779_11_T1	COMPOUND	25	25	cocaine
NCT0014277911	NCT00142779_11_T2	PHENOTYPE	21	22	cocaine use
NCT0014277912	NCT00142779_12_T0	COMPOUND	9	9	cocaine
NCT0014277912	NCT00142779_12_T1	COMPOUND	18	18	methadone
NCT0014277913	NCT00142779_13_T0	COMPOUND	11	11	fluoxetine
NCT0014277915	NCT00142779_15_T0	PHENOTYPE	12	13	cocaine use
NCT0014277915	NCT00142779_15_T1	PHENOTYPE	8	10	medication side effects
NCT0014277918	NCT00142779_18_T0	COMPOUND	25	25	cocaine
NCT001427922	NCT00142792_2_T0	PHENOTYPE	14	14	impairment
NCT001427925	NCT00142792_5_T0	TISSUE	19	19	muscles
NCT001427925	NCT00142792_5_T1	PHENOTYPE	12	12	EDC
NCT001427925	NCT00142792_5_T2	GENE	14	14	ECR
NCT001427925	NCT00142792_5_T3	ORGAN	17	17	wrist
NCT0014279217	NCT00142792_17_T0	PHENOTYPE	21	21	impairment
NCT0014279217	NCT00142792_17_T1	PHENOTYPE	42	42	impairment
NCT0014279218	NCT00142792_18_T0	PHENOTYPE	4	5	acute stroke
NCT0014279224	NCT00142792_24_T0	PHENOTYPE	20	20	impairment
NCT0014279224	NCT00142792_24_T1	GENE	15	15	FMA
NCT0014279224	NCT00142792_24_T2	ORGAN	7	8	upper extremity
NCT001428052	NCT00142805_2_T0	GENE	10	10	AD
NCT001428052	NCT00142805_2_T1	GENE	5	5	reduced
NCT001428052	NCT00142805_2_T2	GENE	12	12	met
NCT001428052	NCT00142805_2_T3	PHENOTYPE	7	8	metabolic rates
NCT001428053	NCT00142805_3_T0	COMPOUND	8	8	glucose
NCT001428053	NCT00142805_3_T1	GENE	2	2	AD
NCT001428053	NCT00142805_3_T2	GENE	10	10	insulin
NCT001428055	NCT00142805_5_T0	COMPOUND	19	19	glucose
NCT001428055	NCT00142805_5_T1	GENE	21	21	insulin
NCT001428181	NCT00142818_1_T0	PHENOTYPE	12	13	alcohol addiction
NCT001428182	NCT00142818_2_T0	PHENOTYPE	18	19	substance abuse
NCT001428183	NCT00142818_3_T0	COMPOUND	13	13	naltrexone
NCT001428183	NCT00142818_3_T1	COMPOUND	11	11	modafinil
NCT001428183	NCT00142818_3_T2	PHENOTYPE	26	28	addicted to cocaine
NCT001428185	NCT00142818_5_T0	COMPOUND	11	11	cocaine
NCT001428185	NCT00142818_5_T1	GENE	2	2	has
NCT001428185	NCT00142818_5_T2	PHENOTYPE	19	20	substance abuse
NCT001428186	NCT00142818_6_T0	GENE	2	2	has
NCT001428187	NCT00142818_7_T0	PHENOTYPE	12	13	alcohol addiction
NCT001428188	NCT00142818_8_T0	PHENOTYPE	5	6	high feeling
NCT001428189	NCT00142818_9_T0	PHENOTYPE	13	13	narcolepsy
NCT0014281810	NCT00142818_10_T0	PHENOTYPE	16	16	symptoms
NCT0014281810	NCT00142818_10_T1	COMPOUND	11	11	cocaine
NCT0014281810	NCT00142818_10_T2	GENE	2	2	has
NCT0014281810	NCT00142818_10_T3	PHENOTYPE	18	19	cocaine withdrawal
NCT0014281813	NCT00142818_13_T0	COMPOUND	9	9	cocaine
NCT0014281814	NCT00142818_14_T0	COMPOUND	18	18	cocaine
NCT0014281814	NCT00142818_14_T1	BIOLOGICAL_PROCESS	13	13	detoxification
NCT0014281818	NCT00142818_18_T0	COMPOUND	13	13	naltrexone
NCT0014281818	NCT00142818_18_T1	COMPOUND	19	19	naltrexone
NCT0014281818	NCT00142818_18_T2	COMPOUND	12	12	modafinil
NCT0014281818	NCT00142818_18_T3	COMPOUND	17	17	modafinil
NCT0014281822	NCT00142818_22_T0	PHENOTYPE	16	16	severity
NCT0014281822	NCT00142818_22_T1	PHENOTYPE	20	21	withdrawal symptoms
NCT0014281823	NCT00142818_23_T0	PHENOTYPE	16	17	adverse events
NCT0014281828	NCT00142818_28_T0	COMPOUND	7	7	cocaine
NCT0014281828	NCT00142818_28_T1	PHENOTYPE	9	10	alcohol dependence
NCT0014281832	NCT00142818_32_T0	PHENOTYPE	21	21	Withdrawal
NCT0014281837	NCT00142818_37_T0	GENE	6	6	TRC
NCT0014281839	NCT00142818_39_T0	PHENOTYPE	1	1	understands
NCT0014281841	NCT00142818_41_T0	COMPOUND	2	2	cocaine
NCT0014281843	NCT00142818_43_T0	COMPOUND	15	15	nicotine
NCT0014281843	NCT00142818_43_T1	COMPOUND	11	11	cocaine
NCT0014281843	NCT00142818_43_T2	GENE	2	2	IV
NCT0014281843	NCT00142818_43_T3	PHENOTYPE	19	19	SCID
NCT0014281843	NCT00142818_43_T4	PHENOTYPE	5	6	dependence on
NCT0014281845	NCT00142818_45_T0	PHENOTYPE	8	8	seizure
NCT0014281845	NCT00142818_45_T1	COMPOUND	14	14	diphenhydramine
NCT0014281847	NCT00142818_47_T0	PHENOTYPE	7	7	schizophrenia
NCT0014281847	NCT00142818_47_T1	PHENOTYPE	10	11	psychotic disorder
NCT0014281847	NCT00142818_47_T2	PHENOTYPE	13	15	organic mental disorder
NCT0014281848	NCT00142818_48_T0	PHENOTYPE	10	11	psychiatric disorder
NCT0014281850	NCT00142818_50_T0	PHENOTYPE	28	28	hypertension
NCT0014281850	NCT00142818_50_T1	PHENOTYPE	19	20	myocardial infarction
NCT0014281850	NCT00142818_50_T2	PHENOTYPE	13	14	gastrointestinal disease
NCT0014281850	NCT00142818_50_T3	PHENOTYPE	21	23	mitral valve prolapse
NCT0014281850	NCT00142818_50_T4	PHENOTYPE	24	26	left ventricular hypertrophy
NCT0014281852	NCT00142818_52_T0	GENE	30	30	AST
NCT0014281852	NCT00142818_52_T1	GENE	20	20	1.3
NCT0014281852	NCT00142818_52_T2	PHENOTYPE	4	4	illnesses
NCT0014281852	NCT00142818_52_T3	PHENOTYPE	9	9	hepatitis
NCT0014281852	NCT00142818_52_T4	ORGAN	32	32	serum
NCT0014281852	NCT00142818_52_T5	PHENOTYPE	18	19	bilirubin levels
NCT0014281852	NCT00142818_52_T6	PHENOTYPE	11	12	hepatocellular injury
NCT0014281852	NCT00142818_52_T7	GENE	28	29	aspartate aminotransferase
NCT0014281852	NCT00142818_52_T8	PHENOTYPE	16	18	elevated total bilirubin
NCT0014281857	NCT00142818_57_T0	COMPOUND	14	14	naltrexone
NCT0014281857	NCT00142818_57_T1	COMPOUND	12	12	modafinil
NCT0014281857	NCT00142818_57_T2	COMPOUND	16	16	propranolol
NCT0014281857	NCT00142818_57_T3	COMPOUND	17	17	phenytoin
NCT0014281857	NCT00142818_57_T4	PHENOTYPE	1	1	chronic
NCT0014281857	NCT00142818_57_T5	COMPOUND	18	18	warfarin
NCT0014281858	NCT00142818_58_T0	GENE	2	3	monoamine oxidase
NCT0014281859	NCT00142818_59_T0	GENE	0	0	Is
NCT001428311	NCT00142831_1_T0	PHENOTYPE	7	8	nicotine dependence
NCT001428317	NCT00142831_7_T0	COMPOUND	7	7	bupropion
NCT001428318	NCT00142831_8_T0	COMPOUND	12	12	bupropion
NCT0014283115	NCT00142831_15_T0	PHENOTYPE	16	16	judgement
NCT001428442	NCT00142844_2_T0	COMPOUND	12	12	naltrexone
NCT001428442	NCT00142844_2_T1	COMPOUND	28	28	cocaine
NCT001428442	NCT00142844_2_T2	COMPOUND	14	14	disulfiram
NCT001428442	NCT00142844_2_T3	PHENOTYPE	30	31	alcohol dependence
NCT001428445	NCT00142844_5_T0	COMPOUND	2	2	disulfiram
NCT001428445	NCT00142844_5_T1	PHENOTYPE	9	10	alcohol dependence
NCT001428447	NCT00142844_7_T0	COMPOUND	12	12	cocaine
NCT001428447	NCT00142844_7_T1	PHENOTYPE	14	15	alcohol dependence
NCT001428448	NCT00142844_8_T0	COMPOUND	12	12	naltrexone
NCT001428448	NCT00142844_8_T1	COMPOUND	28	28	cocaine
NCT001428448	NCT00142844_8_T2	COMPOUND	14	14	disulfiram
NCT001428449	NCT00142844_9_T0	COMPOUND	13	13	naltrexone
NCT001428449	NCT00142844_9_T1	COMPOUND	12	12	disulfiram
NCT0014284410	NCT00142844_10_T0	PHENOTYPE	10	11	cocaine use
NCT0014284413	NCT00142844_13_T0	COMPOUND	19	19	acetate
NCT0014284413	NCT00142844_13_T1	COMPOUND	13	13	progesterone
NCT0014284413	NCT00142844_13_T2	ORGAN	7	7	diaphragm
NCT0014284413	NCT00142844_13_T3	COMPOUND	16	16	levonorgestrel
NCT001428700	NCT00142870_0_T0	PHENOTYPE	5	5	Marijuana
NCT001428702	NCT00142870_2_T0	PHENOTYPE	9	10	withdrawal symptoms
NCT001428703	NCT00142870_3_T0	COMPOUND	9	9	bupropion
NCT001428706	NCT00142870_6_T0	PHENOTYPE	3	4	withdrawal symptoms
NCT001428707	NCT00142870_7_T0	COMPOUND	9	9	nicotine
NCT001428707	NCT00142870_7_T1	GENE	1	1	has
NCT001428707	NCT00142870_7_T2	COMPOUND	19	19	bupropion
NCT001428708	NCT00142870_8_T0	COMPOUND	6	6	bupropion
NCT001428708	NCT00142870_8_T1	PHENOTYPE	8	9	withdrawal symptoms
NCT001428708	NCT00142870_8_T2	PHENOTYPE	12	13	marijuana abuse
NCT001428709	NCT00142870_9_T0	COMPOUND	13	13	bupropion
NCT0014287010	NCT00142870_10_T0	COMPOUND	2	2	bupropion
NCT001428832	NCT00142883_2_T0	COMPOUND	16	16	cocaine
NCT001428832	NCT00142883_2_T1	GENE	9	9	GABA
NCT001428832	NCT00142883_2_T2	COMPOUND	8	8	dopamine
NCT001428833	NCT00142883_3_T0	COMPOUND	13	13	cocaine
NCT001428833	NCT00142883_3_T1	GENE	16	16	GABA
NCT001428833	NCT00142883_3_T2	PHENOTYPE	21	23	addicted to cocaine
NCT001428834	NCT00142883_4_T0	GENE	8	8	GABA
NCT001428834	NCT00142883_4_T1	PHENOTYPE	12	13	cocaine addiction
NCT001428836	NCT00142883_6_T0	COMPOUND	25	25	cocaine
NCT001428836	NCT00142883_6_T1	GENE	1	1	GABA
NCT001428836	NCT00142883_6_T2	COMPOUND	8	8	dopamine
NCT001428836	NCT00142883_6_T3	PHENOTYPE	26	27	drug addiction
NCT001428838	NCT00142883_8_T0	PHENOTYPE	8	9	cocaine addiction
NCT001428839	NCT00142883_9_T0	COMPOUND	8	8	tiagabine
NCT001428839	NCT00142883_9_T1	COMPOUND	14	14	progesterone
NCT001428839	NCT00142883_9_T2	GENE	5	5	GABA
NCT001428839	NCT00142883_9_T3	COMPOUND	12	12	baclofen
NCT001428839	NCT00142883_9_T4	COMPOUND	9	9	topiramate
NCT0014288310	NCT00142883_10_T0	COMPOUND	14	14	cocaine
NCT0014288310	NCT00142883_10_T1	GENE	11	11	GABA
NCT0014288311	NCT00142883_11_T0	COMPOUND	7	7	cocaine
NCT0014288314	NCT00142883_14_T0	GENE	11	11	GABA
NCT0014288315	NCT00142883_15_T0	GENE	1	1	GABA
NCT0014288316	NCT00142883_16_T0	COMPOUND	2	2	cocaine
NCT0014288316	NCT00142883_16_T1	GENE	24	24	GABA
NCT0014288317	NCT00142883_17_T0	COMPOUND	3	3	cocaine
NCT0014288317	NCT00142883_17_T1	GENE	13	13	separated
NCT0014288318	NCT00142883_18_T0	COMPOUND	10	10	cocaine
NCT0014288319	NCT00142883_19_T0	ORGAN	7	7	heart
NCT0014288320	NCT00142883_20_T0	COMPOUND	15	15	cocaine
NCT0014288320	NCT00142883_20_T1	PHENOTYPE	29	30	adverse events
NCT0014288320	NCT00142883_20_T2	PHENOTYPE	34	35	withdrawal symptoms
NCT0014288321	NCT00142883_21_T0	PHENOTYPE	4	4	closed
NCT001428962	NCT00142896_2_T0	COMPOUND	7	7	tramadol
NCT001428962	NCT00142896_2_T1	PHENOTYPE	10	11	withdrawal symptoms
NCT001428966	NCT00142896_6_T0	COMPOUND	5	5	tramadol
NCT001428966	NCT00142896_6_T1	PHENOTYPE	12	13	opioid withdrawal
NCT001428967	NCT00142896_7_T0	COMPOUND	9	9	tramadol
NCT001428968	NCT00142896_8_T0	COMPOUND	11	11	tramadol
NCT001428968	NCT00142896_8_T1	PHENOTYPE	15	16	withdrawal symptoms
NCT001428968	NCT00142896_8_T2	PHENOTYPE	14	15	opioid withdrawal
NCT0014289611	NCT00142896_11_T0	COMPOUND	4	4	morphine
NCT0014289612	NCT00142896_12_T0	COMPOUND	23	23	tramadol
NCT0014289612	NCT00142896_12_T1	COMPOUND	24	24	naloxone
NCT0014289612	NCT00142896_12_T2	COMPOUND	25	25	morphine
NCT0014289613	NCT00142896_13_T0	COMPOUND	7	7	tramadol
NCT0014289613	NCT00142896_13_T1	PHENOTYPE	11	12	withdrawal symptoms
NCT0014289613	NCT00142896_13_T2	PHENOTYPE	10	11	opioid withdrawal
NCT0014289614	NCT00142896_14_T0	PHENOTYPE	9	10	cognitive functioning
NCT0014289615	NCT00142896_15_T0	ORGAN	0	0	Heart
NCT0014289616	NCT00142896_16_T0	ORGAN	13	13	eyes
NCT0014289617	NCT00142896_17_T0	PHENOTYPE	11	12	withdrawal symptoms
NCT0014289618	NCT00142896_18_T0	PHENOTYPE	12	13	drug abuse
NCT001429093	NCT00142909_3_T0	GENE	17	17	1.0
NCT001429093	NCT00142909_3_T1	GENE	19	19	1.2
NCT001429093	NCT00142909_3_T2	GENE	6	6	0.4
NCT001429093	NCT00142909_3_T3	PHENOTYPE	4	4	initiation
NCT001429093	NCT00142909_3_T4	GENE	8	8	bid
NCT001429093	NCT00142909_3_T5	GENE	21	21	bid
NCT001429093	NCT00142909_3_T6	GENE	29	29	bid
NCT001429094	NCT00142909_4_T0	GENE	3	3	tapered
NCT001429095	NCT00142909_5_T0	GENE	6	6	2.4
NCT001429095	NCT00142909_5_T1	GENE	13	13	reduced
NCT001429097	NCT00142909_7_T0	PHENOTYPE	1	1	blocks
NCT001429097	NCT00142909_7_T1	PHENOTYPE	3	3	euphoric
NCT001429098	NCT00142909_8_T0	COMPOUND	1	1	naltrexone
NCT001429098	NCT00142909_8_T1	PHENOTYPE	3	3	suffers
NCT001429098	NCT00142909_8_T2	PHENOTYPE	10	10	relapse
NCT001429099	NCT00142909_9_T0	PHENOTYPE	17	18	opiate dependence
NCT0014290913	NCT00142909_13_T0	COMPOUND	21	21	naltrexone
NCT0014290913	NCT00142909_13_T1	COMPOUND	14	14	lofexidine
NCT0014290914	NCT00142909_14_T0	GENE	9	9	0.4
NCT0014290914	NCT00142909_14_T1	GENE	14	14	0.8
NCT0014290915	NCT00142909_15_T0	GENE	6	6	1.2
NCT0014290916	NCT00142909_16_T0	GENE	7	7	tapered
NCT0014290916	NCT00142909_16_T1	COMPOUND	3	3	lofexidine
NCT0014290917	NCT00142909_17_T0	PHENOTYPE	17	18	withdrawal symptoms
NCT0014290917	NCT00142909_17_T1	PHENOTYPE	13	15	medication side effects
NCT0014290918	NCT00142909_18_T0	ORGAN	0	0	Blood
NCT0014290919	NCT00142909_19_T0	COMPOUND	2	2	naltrexone
NCT0014290920	NCT00142909_20_T0	COMPOUND	12	12	lofexidine
NCT001429352	NCT00142935_2_T0	PHENOTYPE	17	18	substance abuse
NCT001429353	NCT00142935_3_T0	PHENOTYPE	22	22	HIV
NCT001429353	NCT00142935_3_T1	PHENOTYPE	27	27	relapse
NCT001429356	NCT00142935_6_T0	GENE	0	0	MMT
NCT0014293510	NCT00142935_10_T0	GENE	6	6	MMT
NCT0014293512	NCT00142935_12_T0	PHENOTYPE	22	22	overdose
NCT0014293512	NCT00142935_12_T1	PHENOTYPE	13	13	HIV
NCT0014293512	NCT00142935_12_T2	PHENOTYPE	20	20	relapse
NCT0014293513	NCT00142935_13_T0	PHENOTYPE	20	20	HIV
NCT0014293513	NCT00142935_13_T1	PHENOTYPE	28	28	relapse
NCT0014293513	NCT00142935_13_T2	PHENOTYPE	27	27	addiction
NCT0014293513	NCT00142935_13_T3	GENE	15	15	has
NCT0014293513	NCT00142935_13_T4	PHENOTYPE	25	26	drug use
NCT0014293514	NCT00142935_14_T0	PHENOTYPE	22	22	HIV
NCT0014293514	NCT00142935_14_T1	PHENOTYPE	27	27	relapse
NCT0014293517	NCT00142935_17_T0	COMPOUND	6	6	methadone
NCT0014293517	NCT00142935_17_T1	GENE	3	4	Group 1
NCT0014293518	NCT00142935_18_T0	COMPOUND	4	4	methadone
NCT0014293519	NCT00142935_19_T0	COMPOUND	9	9	methadone
NCT0014293521	NCT00142935_21_T0	GENE	2	2	had
NCT0014293522	NCT00142935_22_T0	GENE	5	5	1.5
NCT001429481	NCT00142948_1_T0	BIOLOGICAL_PROCESS	17	17	detoxification
NCT001429481	NCT00142948_1_T1	PHENOTYPE	11	12	withdrawal symptoms
NCT001429482	NCT00142948_2_T0	COMPOUND	11	11	heroin
NCT001429482	NCT00142948_2_T1	PHENOTYPE	15	17	addicted to heroin
NCT001429483	NCT00142948_3_T0	COMPOUND	7	7	naltrexone
NCT001429483	NCT00142948_3_T1	COMPOUND	16	16	heroin
NCT001429483	NCT00142948_3_T2	COMPOUND	19	19	heroin
NCT001429483	NCT00142948_3_T3	COMPOUND	9	9	guanfacine
NCT001429485	NCT00142948_5_T0	PHENOTYPE	10	11	substance addiction
NCT001429486	NCT00142948_6_T0	PHENOTYPE	5	6	high feeling
NCT001429487	NCT00142948_7_T0	BIOLOGICAL_PROCESS	16	16	detoxification
NCT001429487	NCT00142948_7_T1	PHENOTYPE	10	11	withdrawal symptoms
NCT001429488	NCT00142948_8_T0	PHENOTYPE	11	12	heroin addiction
NCT001429489	NCT00142948_9_T0	COMPOUND	11	11	naltrexone
NCT001429489	NCT00142948_9_T1	COMPOUND	17	17	naltrexone
NCT001429489	NCT00142948_9_T2	COMPOUND	25	25	heroin
NCT001429489	NCT00142948_9_T3	PHENOTYPE	23	23	relapse
NCT001429489	NCT00142948_9_T4	COMPOUND	12	12	guanfacine
NCT001429489	NCT00142948_9_T5	COMPOUND	19	19	guanfacine
NCT0014294810	NCT00142948_10_T0	PHENOTYPE	19	19	addiction
NCT0014294810	NCT00142948_10_T1	BIOLOGICAL_PROCESS	13	13	detoxification
NCT0014294810	NCT00142948_10_T2	PHENOTYPE	5	7	addicted to heroin
NCT0014294811	NCT00142948_11_T0	BIOLOGICAL_PROCESS	3	3	detoxification
NCT0014294812	NCT00142948_12_T0	COMPOUND	2	2	3
NCT0014294814	NCT00142948_14_T0	COMPOUND	23	23	naltrexone
NCT0014294814	NCT00142948_14_T1	COMPOUND	32	32	naltrexone
NCT0014294814	NCT00142948_14_T2	COMPOUND	37	37	naltrexone
NCT0014294814	NCT00142948_14_T3	COMPOUND	44	44	naltrexone
NCT0014294814	NCT00142948_14_T4	GENE	27	27	1.0
NCT0014294814	NCT00142948_14_T5	GENE	39	39	1.0
NCT0014294814	NCT00142948_14_T6	COMPOUND	25	25	guanfacine
NCT0014294814	NCT00142948_14_T7	COMPOUND	30	30	guanfacine
NCT0014294814	NCT00142948_14_T8	COMPOUND	42	42	guanfacine
NCT0014294814	NCT00142948_14_T9	COMPOUND	47	47	guanfacine
NCT0014294818	NCT00142948_18_T0	PHENOTYPE	10	10	HIV
NCT0014294818	NCT00142948_18_T1	PHENOTYPE	5	5	relapse
NCT0014294818	NCT00142948_18_T2	PHENOTYPE	14	15	psychiatric symptoms
NCT0014294818	NCT00142948_18_T3	PHENOTYPE	8	9	withdrawal symptoms
NCT001429611	NCT00142961_1_T0	PHENOTYPE	20	20	ADHD
NCT001429611	NCT00142961_1_T1	COMPOUND	11	11	atomoxetine
NCT001429611	NCT00142961_1_T2	PHENOTYPE	16	17	abuse marijuana
NCT001429612	NCT00142961_2_T0	PHENOTYPE	10	10	symptoms
NCT001429612	NCT00142961_2_T1	PHENOTYPE	9	9	ADHD
NCT001429612	NCT00142961_2_T2	COMPOUND	7	7	atomoxetine
NCT001429615	NCT00142961_5_T0	PHENOTYPE	12	12	ADHD
NCT001429615	NCT00142961_5_T1	PHENOTYPE	14	15	marijuana dependence
NCT001429616	NCT00142961_6_T0	PHENOTYPE	9	9	ADHD
NCT001429617	NCT00142961_7_T0	PHENOTYPE	24	24	ADHD
NCT001429617	NCT00142961_7_T1	COMPOUND	12	12	atomoxetine
NCT001429617	NCT00142961_7_T2	PHENOTYPE	20	21	abuse marijuana
NCT001429618	NCT00142961_8_T0	PHENOTYPE	10	10	symptoms
NCT001429618	NCT00142961_8_T1	PHENOTYPE	9	9	ADHD
NCT001429618	NCT00142961_8_T2	COMPOUND	7	7	atomoxetine
NCT0014296110	NCT00142961_10_T0	COMPOUND	12	12	atomoxetine
NCT0014296112	NCT00142961_12_T0	PHENOTYPE	7	9	medication side effects
NCT0014296114	NCT00142961_14_T0	PHENOTYPE	11	11	symptoms
NCT0014296114	NCT00142961_14_T1	PHENOTYPE	10	10	ADHD
NCT0014296116	NCT00142961_16_T0	PHENOTYPE	13	13	ADHD
NCT0014296116	NCT00142961_16_T1	GENE	8	8	has
NCT0014296117	NCT00142961_17_T0	PHENOTYPE	27	27	symptoms
NCT0014296117	NCT00142961_17_T1	PHENOTYPE	32	32	ADHD
NCT0014296117	NCT00142961_17_T2	PHENOTYPE	21	22	drug use
NCT0014296119	NCT00142961_19_T0	PHENOTYPE	24	24	symptoms
NCT0014296119	NCT00142961_19_T1	PHENOTYPE	23	23	ADHD
NCT001429740	NCT00142974_0_T0	PHENOTYPE	15	15	Symptoms
NCT001429740	NCT00142974_0_T1	PHENOTYPE	20	20	Symptoms
NCT001429740	NCT00142974_0_T2	PHENOTYPE	22	23	Diabetic Gastropathy
NCT001429870	NCT00142987_0_T0	PHENOTYPE	19	19	Diarrhea
NCT001429870	NCT00142987_0_T1	PHENOTYPE	14	14	IBS
NCT001429870	NCT00142987_0_T2	PHENOTYPE	20	20	IBS
NCT001429870	NCT00142987_0_T3	PHENOTYPE	6	6	Symptoms
NCT001429870	NCT00142987_0_T4	PHENOTYPE	11	13	Irritable Bowel Syndrome
NCT001429872	NCT00142987_2_T0	GENE	19	19	bowel
NCT001429872	NCT00142987_2_T1	PHENOTYPE	16	16	IBS
NCT001429872	NCT00142987_2_T2	PHENOTYPE	25	25	diarrhea
NCT001429872	NCT00142987_2_T3	COMPOUND	9	9	tegaserod
NCT001430138	NCT00143013_8_T0	TISSUE	5	6	adipose tissue
NCT001430138	NCT00143013_8_T1	TISSUE	2	3	skeletal muscle
NCT001430139	NCT00143013_9_T0	TISSUE	14	15	adipose tissue
NCT001430139	NCT00143013_9_T1	TISSUE	17	18	skeletal muscle
NCT001430260	NCT00143026_0_T0	PHENOTYPE	17	18	Parkinson's Disease
NCT001430260	NCT00143026_0_T1	PHENOTYPE	11	13	Quality of Life
NCT001430263	NCT00143026_3_T0	COMPOUND	11	11	levodopa_carbidopa
NCT001430395	NCT00143039_5_T0	GENE	34	34	demise
NCT001430521	NCT00143052_1_T0	GENE	3	3	hormone
NCT001430528	NCT00143052_8_T0	GENE	8	8	has
NCT001430528	NCT00143052_8_T1	PHENOTYPE	19	19	osteoporosis
NCT001430654	NCT00143065_4_T0	CELL	11	11	cells
NCT001430655	NCT00143065_5_T0	COMPOUND	9	9	fludarabine
NCT001430656	NCT00143065_6_T0	PHENOTYPE	20	20	leukemia
NCT001430656	NCT00143065_6_T1	CELL	18	18	B-cells
NCT001430656	NCT00143065_6_T2	GENE	7	8	CD20 antigen
NCT001430657	NCT00143065_7_T0	CELL	14	14	B-cells
NCT001430657	NCT00143065_7_T1	ORGAN	7	8	immune system
NCT001430658	NCT00143065_8_T0	GENE	14	14	has
NCT001430658	NCT00143065_8_T1	GENE	19	19	p53
NCT001430658	NCT00143065_8_T2	GENE	10	11	CD25 antigen
NCT001430659	NCT00143065_9_T0	PHENOTYPE	13	14	lymphocytic leukemia
NCT0014306510	NCT00143065_10_T0	COMPOUND	5	5	fludarabine
NCT0014306510	NCT00143065_10_T1	GENE	1	1	has
NCT0014306511	NCT00143065_11_T0	COMPOUND	2	2	fludarabine
NCT0014306512	NCT00143065_12_T0	COMPOUND	16	16	fludarabine
NCT0014306513	NCT00143065_13_T0	COMPOUND	9	9	fludarabine
NCT0014306513	NCT00143065_13_T1	PHENOTYPE	23	24	lymphocytic leukemia
NCT0014306513	NCT00143065_13_T2	PHENOTYPE	18	20	B-cell lymphocytic leukemia
NCT0014306515	NCT00143065_15_T0	COMPOUND	6	6	fludarabine
NCT001430781	NCT00143078_1_T0	PHENOTYPE	19	20	weight loss
NCT001430781	NCT00143078_1_T1	PHENOTYPE	22	23	reproductive function
NCT001430784	NCT00143078_4_T0	GENE	10	10	GI
NCT001430784	NCT00143078_4_T1	PHENOTYPE	16	17	reproductive function
NCT001430786	NCT00143078_6_T0	PHENOTYPE	11	12	weight loss
NCT001430786	NCT00143078_6_T1	PHENOTYPE	18	19	reproductive function
NCT001430787	NCT00143078_7_T0	PHENOTYPE	19	20	reproductive function
NCT0014307810	NCT00143078_10_T0	CELL	20	20	sperm
NCT0014307810	NCT00143078_10_T1	PHENOTYPE	12	12	libido
NCT0014307810	NCT00143078_10_T2	PHENOTYPE	2	2	obesity
NCT0014307810	NCT00143078_10_T3	PHENOTYPE	14	15	erectile dysfunction
NCT0014307810	NCT00143078_10_T4	PHENOTYPE	5	6	reproductive function
NCT0014307811	NCT00143078_11_T0	PHENOTYPE	27	28	weight loss
NCT0014307811	NCT00143078_11_T1	PHENOTYPE	15	16	severe obesity
NCT0014307811	NCT00143078_11_T2	PHENOTYPE	18	19	reproductive function
NCT001431821	NCT00143182_1_T0	PHENOTYPE	1	1	symptoms
NCT001431821	NCT00143182_1_T1	PHENOTYPE	6	6	mania
NCT001431822	NCT00143182_2_T0	PHENOTYPE	9	9	manic
NCT001431822	NCT00143182_2_T1	PHENOTYPE	14	15	bipolar disorder
NCT001431823	NCT00143182_3_T0	COMPOUND	25	25	olanzapine
NCT001431823	NCT00143182_3_T1	COMPOUND	23	23	asenapine
NCT001431823	NCT00143182_3_T2	PHENOTYPE	35	35	mania
NCT001432080	NCT00143208_0_T0	PHENOTYPE	10	10	Poag
NCT001432080	NCT00143208_0_T1	COMPOUND	6	6	Xalacom
NCT001432080	NCT00143208_0_T2	PHENOTYPE	2	3	Intraocular Pressure
NCT001432081	NCT00143208_1_T0	PHENOTYPE	0	0	Poag
NCT001432084	NCT00143208_4_T0	PHENOTYPE	3	3	hypotensive
NCT001432085	NCT00143208_5_T0	COMPOUND	10	10	Xalacom
NCT001432473	NCT00143247_3_T0	GENE	14	14	insulin
NCT001433120	NCT00143312_0_T0	PHENOTYPE	2	2	Secondary
NCT001433120	NCT00143312_0_T1	ORGAN	13	14	Cell Transplants
NCT001433120	NCT00143312_0_T2	CELL	12	13	Stem Cell
NCT001433120	NCT00143312_0_T3	PHENOTYPE	5	7	Invasive Fungal Infections
NCT001433511	NCT00143351_1_T0	PHENOTYPE	6	7	malignant disease
NCT001433511	NCT00143351_1_T1	PHENOTYPE	16	17	skin cancer
NCT001433902	NCT00143390_2_T0	PHENOTYPE	8	8	progressive
NCT001433902	NCT00143390_2_T1	PHENOTYPE	11	11	recurrent
NCT001433902	NCT00143390_2_T2	PHENOTYPE	13	14	breast cancer
NCT001435070	NCT00143507_0_T0	PHENOTYPE	10	12	Coronary Artery Disease
NCT001435070	NCT00143507_0_T1	PHENOTYPE	14	17	Left Ventricular Systolic Dysfunction
NCT001435201	NCT00143520_1_T0	COMPOUND	3	3	rivoglitazone
NCT001435330	NCT00143533_0_T0	PHENOTYPE	2	2	Diarrhea
NCT001435330	NCT00143533_0_T1	GENE	6	6	IV
NCT001435330	NCT00143533_0_T2	PHENOTYPE	15	16	Solid Tumors
NCT001435333	NCT00143533_3_T0	PHENOTYPE	12	12	toxicity
NCT001435333	NCT00143533_3_T1	COMPOUND	17	17	irinotecan
NCT001435333	NCT00143533_3_T2	COMPOUND	23	23	irinotecan
NCT001435333	NCT00143533_3_T3	COMPOUND	19	19	cefpodoxime
NCT001435333	NCT00143533_3_T4	COMPOUND	27	27	cefpodoxime
NCT001435333	NCT00143533_3_T5	PHENOTYPE	21	21	pharmacokinetics
NCT001435336	NCT00143533_6_T0	GENE	5	5	has
NCT001435337	NCT00143533_7_T0	COMPOUND	17	17	2
NCT001435337	NCT00143533_7_T1	COMPOUND	33	33	2
NCT001435339	NCT00143533_9_T0	COMPOUND	22	22	irinotecan
NCT001435339	NCT00143533_9_T1	GENE	9	9	BID
NCT001435461	NCT00143546_1_T0	PHENOTYPE	7	7	toxicity
NCT001435461	NCT00143546_1_T1	ORGAN	24	24	liver
NCT001435461	NCT00143546_1_T2	PHENOTYPE	8	8	secondary
NCT001435461	NCT00143546_1_T3	PHENOTYPE	12	13	radiation damage
NCT001435461	NCT00143546_1_T4	ORGAN	20	21	blood vessels
NCT001435461	NCT00143546_1_T5	CELL	16	17	epithelial cells
NCT001435462	NCT00143546_2_T0	PHENOTYPE	0	0	VOD
NCT001435463	NCT00143546_3_T0	GENE	2	2	has
NCT001435465	NCT00143546_5_T0	PHENOTYPE	14	14	VOD
NCT001435466	NCT00143546_6_T0	GENE	3	3	has
NCT001435466	NCT00143546_6_T1	GENE	19	19	IND
NCT001435469	NCT00143546_9_T0	PHENOTYPE	4	4	VOD
NCT0014354613	NCT00143546_13_T0	PHENOTYPE	0	0	Hyperbilirubinemia
NCT0014354613	NCT00143546_13_T1	GENE	25	25	OR
NCT0014354613	NCT00143546_13_T2	PHENOTYPE	13	13	ascites
NCT0014354613	NCT00143546_13_T3	PHENOTYPE	12	12	hepatomegaly
NCT0014354613	NCT00143546_13_T4	PHENOTYPE	15	16	weight gain
NCT001435590	NCT00143559_0_T0	PHENOTYPE	6	7	Hematologic Malignancies
NCT001435590	NCT00143559_0_T1	CELL	0	1	Stem Cell
NCT001435593	NCT00143559_3_T0	ORGAN	4	4	transplant
NCT001435594	NCT00143559_4_T0	PHENOTYPE	19	19	toxicity
NCT001435594	NCT00143559_4_T1	PHENOTYPE	16	16	complications
NCT001435594	NCT00143559_4_T2	ORGAN	2	2	transplant
NCT001435594	NCT00143559_4_T3	PHENOTYPE	21	21	GVHD
NCT001435594	NCT00143559_4_T4	GENE	3	3	has
NCT001435594	NCT00143559_4_T5	GENE	11	11	has
NCT001435596	NCT00143559_6_T0	CELL	21	21	cells
NCT001435596	NCT00143559_6_T1	TISSUE	10	10	tissues
NCT001435596	NCT00143559_6_T2	PHENOTYPE	0	0	GVHD
NCT001435596	NCT00143559_6_T3	CELL	5	6	T cells
NCT001435597	NCT00143559_7_T0	ORGAN	23	23	graft
NCT001435597	NCT00143559_7_T1	PHENOTYPE	9	9	GVHD
NCT001435597	NCT00143559_7_T2	GENE	10	11	too few
NCT001435597	NCT00143559_7_T3	ORGAN	16	17	immune system
NCT001435597	NCT00143559_7_T4	CELL	3	4	T cells
NCT0014355910	NCT00143559_10_T0	PHENOTYPE	14	14	toxicity
NCT0014355910	NCT00143559_10_T1	GENE	1	1	reduced
NCT0014355912	NCT00143559_12_T0	ORGAN	22	22	transplant
NCT0014355912	NCT00143559_12_T1	PHENOTYPE	6	7	hematologic malignancies
NCT0014355912	NCT00143559_12_T2	PHENOTYPE	16	17	hematologic malignancies
NCT0014355913	NCT00143559_13_T0	PHENOTYPE	10	10	relapse
NCT0014355913	NCT00143559_13_T1	ORGAN	28	28	transplant
NCT0014355913	NCT00143559_13_T2	PHENOTYPE	21	22	hematologic malignancies
NCT0014355914	NCT00143559_14_T0	PHENOTYPE	12	12	secondary
NCT0014355915	NCT00143559_15_T0	ORGAN	21	21	graft
NCT0014355915	NCT00143559_15_T1	PHENOTYPE	3	3	closed
NCT0014355915	NCT00143559_15_T2	GENE	11	11	met
NCT001435720	NCT00143572_0_T0	PHENOTYPE	9	11	Sickle Cell Disease
NCT001435723	NCT00143572_3_T0	GENE	10	10	0.6
NCT001435726	NCT00143572_6_T0	COMPOUND	8	8	hydroxyurea
NCT001435727	NCT00143572_7_T0	PHENOTYPE	26	26	toxicity
NCT001435727	NCT00143572_7_T1	COMPOUND	35	35	hydroxyurea
NCT001435727	NCT00143572_7_T2	COMPOUND	9	9	magnesium
NCT001435727	NCT00143572_7_T3	COMPOUND	29	29	magnesium
NCT001435727	NCT00143572_7_T4	GENE	22	22	MTD
NCT001435727	NCT00143572_7_T5	GENE	27	27	DLT
NCT001435729	NCT00143572_9_T0	PHENOTYPE	3	3	toxicity
NCT001435729	NCT00143572_9_T1	PHENOTYPE	7	9	drug side effects
NCT0014357212	NCT00143572_12_T0	PHENOTYPE	7	8	beta thalassemia
NCT0014357212	NCT00143572_12_T1	PHENOTYPE	2	3	Hb SS
NCT0014357212	NCT00143572_12_T2	PHENOTYPE	5	6	Hb S
NCT0014357214	NCT00143572_14_T0	GENE	3	3	HU
NCT0014357217	NCT00143572_17_T0	COMPOUND	6	6	creatinine
NCT0014357217	NCT00143572_17_T1	GENE	9	9	1.5
NCT0014357217	NCT00143572_17_T2	ORGAN	5	5	serum
NCT0014357217	NCT00143572_17_T3	PHENOTYPE	1	1	dysfunction
NCT0014357219	NCT00143572_19_T0	COMPOUND	8	8	hydroxyurea
NCT0014357221	NCT00143572_21_T0	GENE	5	5	ferritin
NCT0014357221	NCT00143572_21_T1	ORGAN	4	4	serum
NCT0014357221	NCT00143572_21_T2	PHENOTYPE	0	1	Iron deficiency
NCT001435984	NCT00143598_4_T0	GENE	2	2	PTS
NCT001435985	NCT00143598_5_T0	GENE	9	9	PTS
NCT001436113	NCT00143611_3_T0	PHENOTYPE	30	30	dysfunction
NCT001436113	NCT00143611_3_T1	PHENOTYPE	9	10	severe sepsis
NCT001436113	NCT00143611_3_T2	PHENOTYPE	24	25	severe sepsis
NCT001436119	NCT00143611_9_T0	COMPOUND	9	9	resatorvid
NCT001436119	NCT00143611_9_T1	PHENOTYPE	17	18	severe sepsis
NCT0014361110	NCT00143611_10_T0	PHENOTYPE	11	12	cytokine suppression
NCT001436242	NCT00143624_2_T0	BIOLOGICAL_PROCESS	22	22	metabolism
NCT001436242	NCT00143624_2_T1	ORGAN	16	17	blood vessel
NCT001436242	NCT00143624_2_T2	TISSUE	28	29	body fat
NCT001436372	NCT00143637_2_T0	CELL	33	33	cells
NCT001436372	NCT00143637_2_T1	PHENOTYPE	18	19	lung function
NCT001436374	NCT00143637_4_T0	PHENOTYPE	11	11	exposures
NCT001436374	NCT00143637_4_T1	COMPOUND	1	1	1
NCT001436374	NCT00143637_4_T2	PHENOTYPE	20	21	inflammatory responses
NCT001436376	NCT00143637_6_T0	PHENOTYPE	20	20	exposures
NCT001436378	NCT00143637_8_T0	PHENOTYPE	8	8	regression
NCT001436379	NCT00143637_9_T0	PHENOTYPE	27	27	exposures
NCT001436379	NCT00143637_9_T1	PHENOTYPE	6	6	atopic
NCT001436379	NCT00143637_9_T2	COMPOUND	9	9	histamine
NCT0014363713	NCT00143637_13_T0	GENE	14	14	hoc
NCT0014363715	NCT00143637_15_T0	PHENOTYPE	10	10	exposures
NCT0014363717	NCT00143637_17_T0	GENE	16	16	condensed
NCT0014363723	NCT00143637_23_T0	PHENOTYPE	4	4	atopic
NCT0014363724	NCT00143637_24_T0	GENE	34	34	TSP
NCT0014363724	NCT00143637_24_T1	GENE	42	42	TSP
NCT0014363724	NCT00143637_24_T2	GENE	12	12	IMA
NCT0014363727	NCT00143637_27_T0	PHENOTYPE	3	3	exposures
NCT0014363728	NCT00143637_28_T0	PHENOTYPE	13	13	exposures
NCT0014363729	NCT00143637_29_T0	COMPOUND	13	13	2
NCT0014363729	NCT00143637_29_T1	PHENOTYPE	5	5	repetitions
NCT001436506	NCT00143650_6_T0	PHENOTYPE	11	11	symptoms
NCT001436506	NCT00143650_6_T1	PHENOTYPE	6	6	perceptions
NCT001436508	NCT00143650_8_T0	COMPOUND	9	9	IAQ
NCT001436508	NCT00143650_8_T1	PHENOTYPE	7	7	affects
NCT0014365012	NCT00143650_12_T0	PHENOTYPE	10	10	exposures
NCT0014365012	NCT00143650_12_T1	GENE	0	0	Is
NCT0014365013	NCT00143650_13_T0	PHENOTYPE	10	10	exposures
NCT0014365017	NCT00143650_17_T0	PHENOTYPE	5	5	exposures
NCT0014365018	NCT00143650_18_T0	PHENOTYPE	6	6	exposures
NCT0014365022	NCT00143650_22_T0	PHENOTYPE	16	16	exposures
NCT0014365024	NCT00143650_24_T0	GENE	5	5	3.4
NCT001436630	NCT00143663_0_T0	PHENOTYPE	6	7	Cholesterol Levels
NCT001436630	NCT00143663_0_T1	PHENOTYPE	11	12	Elevated Cholesterol
NCT001436634	NCT00143663_4_T0	COMPOUND	16	16	acetate
NCT001436634	NCT00143663_4_T1	COMPOUND	15	15	lapaquistat
NCT001436763	NCT00143676_3_T0	GENE	19	19	11.1
NCT001436763	NCT00143676_3_T1	GENE	4	4	7.2
NCT001436763	NCT00143676_3_T2	GENE	2	2	CHD
NCT001436763	NCT00143676_3_T3	GENE	14	14	CHD
NCT001436764	NCT00143676_4_T0	PHENOTYPE	12	12	dyslipidemia
NCT001436764	NCT00143676_4_T1	PHENOTYPE	10	10	hypercholesterolemia
NCT001436766	NCT00143676_6_T0	GENE	7	7	lipoprotein
NCT001436766	NCT00143676_6_T1	PHENOTYPE	4	4	hypercholesterolemia
NCT001436767	NCT00143676_7_T0	PHENOTYPE	14	14	concentrations
NCT001436767	NCT00143676_7_T1	GENE	11	11	lipoprotein
NCT001436767	NCT00143676_7_T2	GENE	5	5	has
NCT001436767	NCT00143676_7_T3	ORGAN	13	13	plasma
NCT001436767	NCT00143676_7_T4	PHENOTYPE	17	18	cardiovascular morbidity
NCT001436768	NCT00143676_8_T0	GENE	15	15	lipoprotein
NCT001436768	NCT00143676_8_T1	GENE	8	8	III
NCT001436768	NCT00143676_8_T2	GENE	9	9	has
NCT001436768	NCT00143676_8_T3	GENE	25	25	CHD
NCT001436769	NCT00143676_9_T0	GENE	19	19	lipoprotein
NCT001436769	NCT00143676_9_T1	GENE	28	28	lipoprotein
NCT001436769	NCT00143676_9_T2	GENE	13	13	III
NCT001436769	NCT00143676_9_T3	PHENOTYPE	15	16	elevated triglycerides
NCT0014367610	NCT00143676_10_T0	PHENOTYPE	13	13	atherosclerosis
NCT0014367610	NCT00143676_10_T1	PHENOTYPE	46	46	concentrations
NCT0014367610	NCT00143676_10_T2	GENE	7	7	lipoprotein
NCT0014367610	NCT00143676_10_T3	GENE	21	21	lipoprotein
NCT0014367610	NCT00143676_10_T4	GENE	29	29	lipoprotein
NCT0014367610	NCT00143676_10_T5	BIOLOGICAL_PROCESS	31	31	transport
NCT0014367610	NCT00143676_10_T6	PHENOTYPE	42	45	low high-density lipoprotein cholesterol
NCT0014367611	NCT00143676_11_T0	PHENOTYPE	8	8	dyslipidemia
NCT0014367612	NCT00143676_12_T0	GENE	17	17	lipoprotein
NCT0014367612	NCT00143676_12_T1	GENE	1	4	3-hydroxy-3-methylglutaryl coenzyme A reductase
NCT0014367613	NCT00143676_13_T0	GENE	21	21	lipoprotein
NCT0014367613	NCT00143676_13_T1	GENE	16	16	III
NCT0014367616	NCT00143676_16_T0	GENE	30	30	lipoprotein
NCT0014367616	NCT00143676_16_T1	GENE	23	23	has
NCT0014367616	NCT00143676_16_T2	ORGAN	28	28	serum
NCT0014367617	NCT00143676_17_T0	COMPOUND	11	11	acetate
NCT0014367617	NCT00143676_17_T1	COMPOUND	10	10	lapaquistat
NCT0014367617	NCT00143676_17_T2	PHENOTYPE	16	16	dyslipidemia
NCT0014367617	NCT00143676_17_T3	GENE	6	7	squalene synthase
NCT0014367619	NCT00143676_19_T0	COMPOUND	10	10	acetate
NCT0014367619	NCT00143676_19_T1	COMPOUND	9	9	lapaquistat
NCT0014367619	NCT00143676_19_T2	COMPOUND	12	12	atorvastatin
NCT0014367619	NCT00143676_19_T3	PHENOTYPE	31	31	hypercholesterolemia
NCT001437021	NCT00143702_1_T0	COMPOUND	4	4	abacavir
NCT001437022	NCT00143702_2_T0	COMPOUND	3	3	thiamine
NCT001437022	NCT00143702_2_T1	COMPOUND	1	1	riboflavin
NCT001437150	NCT00143715_0_T0	PHENOTYPE	6	6	Coagulopathy
NCT001437152	NCT00143715_2_T0	PHENOTYPE	12	12	bleeding
NCT001437152	NCT00143715_2_T1	GENE	4	4	INR
NCT001437152	NCT00143715_2_T2	GENE	22	22	INR
NCT001437152	NCT00143715_2_T3	PHENOTYPE	26	27	therapeutic range
NCT001437153	NCT00143715_3_T0	PHENOTYPE	21	21	bleeding
NCT001437153	NCT00143715_3_T1	PHENOTYPE	2	2	strategies
NCT001437153	NCT00143715_3_T2	GENE	11	11	INR
NCT001437154	NCT00143715_4_T0	GENE	8	8	4.5
NCT001437154	NCT00143715_4_T1	GENE	5	5	INR
NCT001437154	NCT00143715_4_T2	GENE	24	24	INR
NCT001437154	NCT00143715_4_T3	GENE	28	28	INR
NCT001437154	NCT00143715_4_T4	COMPOUND	16	17	vitamin K
NCT001437155	NCT00143715_5_T0	GENE	18	18	INR
NCT001437155	NCT00143715_5_T1	COMPOUND	1	1	warfarin
NCT001437155	NCT00143715_5_T2	COMPOUND	7	8	vitamin K
NCT001437156	NCT00143715_6_T0	COMPOUND	1	2	vitamin K
NCT001437157	NCT00143715_7_T0	COMPOUND	32	32	warfarin
NCT001437157	NCT00143715_7_T1	COMPOUND	22	23	vitamin K
NCT001437158	NCT00143715_8_T0	GENE	9	9	INR
NCT001437158	NCT00143715_8_T1	GENE	18	18	INR
NCT001437158	NCT00143715_8_T2	COMPOUND	14	14	warfarin
NCT001437158	NCT00143715_8_T3	PHENOTYPE	23	24	therapeutic range
NCT001437159	NCT00143715_9_T0	GENE	7	7	has
NCT0014371510	NCT00143715_10_T0	PHENOTYPE	26	26	bleeding
NCT0014371510	NCT00143715_10_T1	GENE	13	13	6.0
NCT0014371510	NCT00143715_10_T2	GENE	8	8	INR
NCT0014371510	NCT00143715_10_T3	GENE	38	38	INR
NCT0014371510	NCT00143715_10_T4	COMPOUND	19	19	warfarin
NCT0014371511	NCT00143715_11_T0	PHENOTYPE	12	12	bleeding
NCT0014371511	NCT00143715_11_T1	PHENOTYPE	36	36	bleeding
NCT0014371511	NCT00143715_11_T2	GENE	15	15	has
NCT0014371511	NCT00143715_11_T3	GENE	19	19	INR
NCT0014371511	NCT00143715_11_T4	COMPOUND	8	9	vitamin K
NCT0014371511	NCT00143715_11_T5	COMPOUND	33	34	vitamin K
NCT0014371512	NCT00143715_12_T0	PHENOTYPE	10	10	thrombosis
NCT0014371512	NCT00143715_12_T1	COMPOUND	6	7	vitamin K
NCT0014371513	NCT00143715_13_T0	COMPOUND	6	6	warfarin
NCT0014371513	NCT00143715_13_T1	COMPOUND	9	10	vitamin K
NCT0014371513	NCT00143715_13_T2	COMPOUND	26	27	vitamin K
NCT0014371514	NCT00143715_14_T0	PHENOTYPE	29	29	bleeds
NCT0014371514	NCT00143715_14_T1	GENE	18	18	INR
NCT0014371514	NCT00143715_14_T2	COMPOUND	11	12	vitamin K
NCT0014371517	NCT00143715_17_T0	PHENOTYPE	26	26	bleeding
NCT0014371517	NCT00143715_17_T1	GENE	11	11	10.0
NCT0014371517	NCT00143715_17_T2	GENE	9	9	4.5
NCT0014371517	NCT00143715_17_T3	GENE	6	6	INR
NCT0014371517	NCT00143715_17_T4	PHENOTYPE	28	28	thrombosis
NCT0014371517	NCT00143715_17_T5	COMPOUND	18	19	vitamin K
NCT0014371518	NCT00143715_18_T0	GENE	7	7	10.0
NCT0014371518	NCT00143715_18_T1	GENE	2	2	INR
NCT0014371518	NCT00143715_18_T2	COMPOUND	17	18	vitamin K
NCT0014371519	NCT00143715_19_T0	GENE	31	31	INR
NCT0014371519	NCT00143715_19_T1	COMPOUND	24	24	warfarin
NCT0014371521	NCT00143715_21_T0	PHENOTYPE	9	9	bleeding
NCT0014371521	NCT00143715_21_T1	COMPOUND	1	1	warfarin
NCT0014371522	NCT00143715_22_T0	PHENOTYPE	3	3	bleeding
NCT0014371522	NCT00143715_22_T1	PHENOTYPE	19	19	hemorrhage
NCT0014371523	NCT00143715_23_T0	GENE	15	15	INR
NCT0014371523	NCT00143715_23_T1	PHENOTYPE	6	6	hemorrhage
NCT0014371524	NCT00143715_24_T0	PHENOTYPE	30	30	thrombosis
NCT0014371524	NCT00143715_24_T1	GENE	13	13	INR
NCT0014371524	NCT00143715_24_T2	PHENOTYPE	24	24	hemorrhage
NCT0014371524	NCT00143715_24_T3	COMPOUND	6	7	vitamin K
NCT0014371525	NCT00143715_25_T0	PHENOTYPE	26	26	bleeding
NCT0014371525	NCT00143715_25_T1	PHENOTYPE	29	29	thrombosis
NCT0014371525	NCT00143715_25_T2	GENE	39	39	4.5
NCT0014371525	NCT00143715_25_T3	GENE	34	34	INR
NCT0014371525	NCT00143715_25_T4	COMPOUND	12	13	vitamin K
NCT0014371526	NCT00143715_26_T0	PHENOTYPE	8	8	toxicity
NCT0014371526	NCT00143715_26_T1	GENE	41	41	1.2
NCT0014371526	NCT00143715_26_T2	COMPOUND	10	10	warfarin
NCT0014371526	NCT00143715_26_T3	PHENOTYPE	33	33	recurrent
NCT0014371526	NCT00143715_26_T4	PHENOTYPE	34	35	arterial thrombosis
NCT0014371526	NCT00143715_26_T5	PHENOTYPE	18	20	recurrent venous thrombosis
NCT0014371527	NCT00143715_27_T0	COMPOUND	9	9	warfarin
NCT0014371527	NCT00143715_27_T1	COMPOUND	22	22	warfarin
NCT0014371528	NCT00143715_28_T0	PHENOTYPE	2	2	toxicity
NCT0014371528	NCT00143715_28_T1	PHENOTYPE	6	6	bleeding
NCT0014371528	NCT00143715_28_T2	COMPOUND	4	4	warfarin
NCT0014371529	NCT00143715_29_T0	PHENOTYPE	1	1	bleeding
NCT0014371529	NCT00143715_29_T1	GENE	15	15	2.0
NCT0014371529	NCT00143715_29_T2	GENE	17	17	3.0
NCT0014371529	NCT00143715_29_T3	GENE	9	9	INR
NCT0014371529	NCT00143715_29_T4	GENE	27	27	INR
NCT0014371529	NCT00143715_29_T5	PHENOTYPE	24	24	bleed
NCT0014371529	NCT00143715_29_T6	PHENOTYPE	13	14	therapeutic range
NCT0014371530	NCT00143715_30_T0	GENE	43	43	6.0
NCT0014371530	NCT00143715_30_T1	PHENOTYPE	20	20	anticoagulation
NCT0014371530	NCT00143715_30_T2	GENE	36	36	had
NCT0014371530	NCT00143715_30_T3	GENE	22	22	has
NCT0014371530	NCT00143715_30_T4	GENE	16	16	INR
NCT0014371530	NCT00143715_30_T5	GENE	40	40	INR
NCT0014371531	NCT00143715_31_T0	GENE	14	14	1.0
NCT0014371531	NCT00143715_31_T1	GENE	12	12	INR
NCT0014371531	NCT00143715_31_T2	GENE	16	16	4.7
NCT0014371531	NCT00143715_31_T3	PHENOTYPE	4	4	hemorrhage
NCT0014371532	NCT00143715_32_T0	GENE	22	22	has
NCT0014371532	NCT00143715_32_T1	PHENOTYPE	21	21	coagulopathy
NCT0014371532	NCT00143715_32_T2	GENE	11	11	INR
NCT0014371532	NCT00143715_32_T3	PHENOTYPE	15	15	hemorrhage
NCT0014371532	NCT00143715_32_T4	COMPOUND	20	20	warfarin
NCT0014371533	NCT00143715_33_T0	GENE	13	13	6.0
NCT0014371533	NCT00143715_33_T1	GENE	15	15	had
NCT0014371533	NCT00143715_33_T2	GENE	22	22	had
NCT0014371533	NCT00143715_33_T3	GENE	8	8	INR
NCT0014371533	NCT00143715_33_T4	GENE	21	21	INR
NCT0014371533	NCT00143715_33_T5	COMPOUND	17	17	warfarin
NCT0014371534	NCT00143715_34_T0	PHENOTYPE	19	19	bleeding
NCT0014371534	NCT00143715_34_T1	GENE	16	16	14.0
NCT0014371534	NCT00143715_34_T2	PHENOTYPE	26	26	bleeds
NCT0014371534	NCT00143715_34_T3	GENE	13	13	CI
NCT0014371535	NCT00143715_35_T0	GENE	12	12	CI
NCT0014371535	NCT00143715_35_T1	GENE	18	18	CI
NCT0014371535	NCT00143715_35_T2	GENE	20	20	4.2
NCT0014371535	NCT00143715_35_T3	GENE	13	13	0.6
NCT0014371535	NCT00143715_35_T4	GENE	14	14	8-1
NCT0014371535	NCT00143715_35_T5	PHENOTYPE	5	5	hemorrhage
NCT0014371535	NCT00143715_35_T6	PHENOTYPE	8	8	hemorrhage
NCT0014371537	NCT00143715_37_T0	PHENOTYPE	11	11	bleeding
NCT0014371537	NCT00143715_37_T1	PHENOTYPE	24	24	bleeding
NCT0014371537	NCT00143715_37_T2	GENE	7	7	INR
NCT0014371537	NCT00143715_37_T3	GENE	21	21	INR
NCT0014371538	NCT00143715_38_T0	PHENOTYPE	7	7	coagulopathy
NCT0014371538	NCT00143715_38_T1	GENE	16	16	INR
NCT0014371538	NCT00143715_38_T2	GENE	31	31	INR
NCT0014371538	NCT00143715_38_T3	COMPOUND	5	5	warfarin
NCT0014371538	NCT00143715_38_T4	COMPOUND	12	12	warfarin
NCT0014371542	NCT00143715_42_T0	PHENOTYPE	24	24	bleeding
NCT0014371542	NCT00143715_42_T1	PHENOTYPE	16	16	thrombosis
NCT0014371542	NCT00143715_42_T2	PHENOTYPE	11	11	complications
NCT0014371542	NCT00143715_42_T3	PHENOTYPE	14	14	allergy
NCT0014371542	NCT00143715_42_T4	GENE	18	18	has
NCT0014371543	NCT00143715_43_T0	PHENOTYPE	15	15	bleeding
NCT0014371543	NCT00143715_43_T1	GENE	12	12	INR
NCT0014371546	NCT00143715_46_T0	PHENOTYPE	7	7	bleeding
NCT0014371546	NCT00143715_46_T1	GENE	20	20	10.0
NCT0014371546	NCT00143715_46_T2	GENE	18	18	4.5
NCT0014371546	NCT00143715_46_T3	GENE	15	15	INR
NCT0014371546	NCT00143715_46_T4	COMPOUND	11	11	warfarin
NCT0014371546	NCT00143715_46_T5	COMPOUND	1	2	vitamin K
NCT0014371548	NCT00143715_48_T0	PHENOTYPE	10	10	thrombosis
NCT0014371548	NCT00143715_48_T1	COMPOUND	2	3	vitamin K
NCT0014371551	NCT00143715_51_T0	PHENOTYPE	21	21	bleeding
NCT0014371551	NCT00143715_51_T1	PHENOTYPE	40	40	bleeding
NCT0014371551	NCT00143715_51_T2	GENE	15	15	INR
NCT0014371551	NCT00143715_51_T3	GENE	34	34	INR
NCT0014371551	NCT00143715_51_T4	GENE	22	22	4-8
NCT0014371551	NCT00143715_51_T5	COMPOUND	29	30	vitamin K
NCT0014371551	NCT00143715_51_T6	COMPOUND	49	50	vitamin K
NCT0014371552	NCT00143715_52_T0	GENE	17	17	INR
NCT0014371552	NCT00143715_52_T1	COMPOUND	12	13	vitamin K
NCT0014371554	NCT00143715_54_T0	PHENOTYPE	13	13	bleeding
NCT0014371554	NCT00143715_54_T1	COMPOUND	18	18	warfarin
NCT0014371554	NCT00143715_54_T2	COMPOUND	23	24	vitamin K
NCT0014371555	NCT00143715_55_T0	PHENOTYPE	8	8	attributable
NCT0014371555	NCT00143715_55_T1	GENE	17	17	has
NCT0014371555	NCT00143715_55_T2	PHENOTYPE	28	28	hemorrhage
NCT0014371555	NCT00143715_55_T3	COMPOUND	5	6	vitamin K
NCT0014371555	NCT00143715_55_T4	COMPOUND	22	23	vitamin K
NCT0014371556	NCT00143715_56_T0	PHENOTYPE	9	9	bleeding
NCT0014371556	NCT00143715_56_T1	PHENOTYPE	17	17	bleeding
NCT0014371556	NCT00143715_56_T2	PHENOTYPE	36	36	attributable
NCT0014371556	NCT00143715_56_T3	COMPOUND	14	15	vitamin K
NCT0014371557	NCT00143715_57_T0	PHENOTYPE	19	19	thrombosis
NCT0014371557	NCT00143715_57_T1	GENE	23	23	INR
NCT0014371557	NCT00143715_57_T2	COMPOUND	11	12	vitamin K
NCT0014371558	NCT00143715_58_T0	PHENOTYPE	18	18	thrombosis
NCT0014371558	NCT00143715_58_T1	GENE	24	24	has
NCT0014371558	NCT00143715_58_T2	PHENOTYPE	15	16	warfarin resistance
NCT0014371558	NCT00143715_58_T3	COMPOUND	11	12	vitamin K
NCT0014371559	NCT00143715_59_T0	COMPOUND	7	7	warfarin
NCT0014371560	NCT00143715_60_T0	COMPOUND	7	8	vitamin K
NCT0014371560	NCT00143715_60_T1	COMPOUND	24	25	vitamin K
NCT0014371562	NCT00143715_62_T0	GENE	12	12	10.0
NCT0014371562	NCT00143715_62_T1	GENE	10	10	4.5
NCT0014371562	NCT00143715_62_T2	GENE	7	7	INR
NCT0014371563	NCT00143715_63_T0	GENE	12	12	10.0
NCT0014371563	NCT00143715_63_T1	GENE	7	7	INR
NCT0014371566	NCT00143715_66_T0	GENE	15	15	INR
NCT0014371567	NCT00143715_67_T0	COMPOUND	3	3	warfarin
NCT0014371568	NCT00143715_68_T0	GENE	14	14	INR
NCT0014371569	NCT00143715_69_T0	GENE	18	18	kit
NCT0014371569	NCT00143715_69_T1	COMPOUND	26	27	vitamin K
NCT0014371570	NCT00143715_70_T0	GENE	10	10	INR
NCT0014371570	NCT00143715_70_T1	GENE	13	13	INR
NCT0014371571	NCT00143715_71_T0	PHENOTYPE	7	7	centres
NCT0014371572	NCT00143715_72_T0	GENE	12	12	INR
NCT0014371573	NCT00143715_73_T0	GENE	24	24	INR
NCT0014371574	NCT00143715_74_T0	GENE	19	19	4.5
NCT0014371574	NCT00143715_74_T1	GENE	15	15	INR
NCT0014371576	NCT00143715_76_T0	PHENOTYPE	17	17	centre
NCT0014371578	NCT00143715_78_T0	PHENOTYPE	17	17	centre
NCT0014371579	NCT00143715_79_T0	PHENOTYPE	7	7	centres
NCT0014371579	NCT00143715_79_T1	PHENOTYPE	21	21	centres
NCT0014371579	NCT00143715_79_T2	GENE	19	20	group 2
NCT0014371580	NCT00143715_80_T0	GENE	15	15	10.0
NCT0014371580	NCT00143715_80_T1	GENE	10	10	INR
NCT0014371580	NCT00143715_80_T2	PHENOTYPE	7	7	centres
NCT0014371580	NCT00143715_80_T3	GENE	5	6	group 2
NCT0014371580	NCT00143715_80_T4	COMPOUND	27	28	vitamin K
NCT0014371581	NCT00143715_81_T0	PHENOTYPE	11	11	centres
NCT0014371583	NCT00143715_83_T0	GENE	3	3	INR
NCT0014371583	NCT00143715_83_T1	GENE	9	9	INR
NCT0014371584	NCT00143715_84_T0	GENE	6	6	INR
NCT0014371585	NCT00143715_85_T0	GENE	5	5	has
NCT0014371589	NCT00143715_89_T0	COMPOUND	7	7	warfarin
NCT0014371590	NCT00143715_90_T0	GENE	9	9	INR
NCT0014371590	NCT00143715_90_T1	GENE	18	18	INR
NCT0014371590	NCT00143715_90_T2	COMPOUND	13	13	warfarin
NCT0014371591	NCT00143715_91_T0	GENE	19	19	4.5
NCT0014371591	NCT00143715_91_T1	GENE	15	15	INR
NCT0014371592	NCT00143715_92_T0	GENE	12	12	INR
NCT0014371593	NCT00143715_93_T0	PHENOTYPE	13	13	centre
NCT0014371594	NCT00143715_94_T0	GENE	0	1	Group 1
NCT0014371594	NCT00143715_94_T1	GENE	3	4	group 2
NCT0014371595	NCT00143715_95_T0	PHENOTYPE	42	42	centre
NCT0014371595	NCT00143715_95_T1	GENE	9	10	group 2
NCT0014371595	NCT00143715_95_T2	GENE	29	30	group 2
NCT0014371598	NCT00143715_98_T0	GENE	19	19	4.5
NCT0014371598	NCT00143715_98_T1	GENE	17	17	INR
NCT00143715103	NCT00143715_103_T0	PHENOTYPE	11	11	centre
NCT00143715104	NCT00143715_104_T0	PHENOTYPE	20	20	centre
NCT00143715104	NCT00143715_104_T1	COMPOUND	12	13	vitamin K
NCT00143715109	NCT00143715_109_T0	GENE	3	3	INR
NCT00143715111	NCT00143715_111_T0	PHENOTYPE	8	8	bleeding
NCT00143715113	NCT00143715_113_T0	PHENOTYPE	21	21	bleeding
NCT00143715113	NCT00143715_113_T1	PHENOTYPE	11	11	coagulopathy
NCT00143715113	NCT00143715_113_T2	COMPOUND	10	10	warfarin
NCT00143715113	NCT00143715_113_T3	PHENOTYPE	16	16	hemorrhage
NCT00143715114	NCT00143715_114_T0	GENE	5	5	has
NCT00143715114	NCT00143715_114_T1	PHENOTYPE	4	4	hemorrhage
NCT00143715114	NCT00143715_114_T2	PHENOTYPE	24	24	hemorrhage
NCT00143715115	NCT00143715_115_T0	PHENOTYPE	11	11	acute
NCT00143715115	NCT00143715_115_T1	PHENOTYPE	19	19	acute
NCT00143715115	NCT00143715_115_T2	PHENOTYPE	12	12	thrombosis
NCT00143715115	NCT00143715_115_T3	PHENOTYPE	20	20	thrombosis
NCT00143715116	NCT00143715_116_T0	PHENOTYPE	4	4	acute
NCT00143715116	NCT00143715_116_T1	PHENOTYPE	18	18	bleeding
NCT00143715116	NCT00143715_116_T2	PHENOTYPE	5	5	thrombosis
NCT00143715116	NCT00143715_116_T3	PHENOTYPE	24	24	complications
NCT00143715117	NCT00143715_117_T0	PHENOTYPE	13	13	acute
NCT00143715117	NCT00143715_117_T1	PHENOTYPE	20	20	bleeding
NCT00143715117	NCT00143715_117_T2	PHENOTYPE	16	16	thrombosis
NCT00143715118	NCT00143715_118_T0	PHENOTYPE	9	9	bleeding
NCT00143715118	NCT00143715_118_T1	GENE	27	27	INR
NCT00143715118	NCT00143715_118_T2	PHENOTYPE	13	13	bruising
NCT00143715118	NCT00143715_118_T3	COMPOUND	4	4	warfarin
NCT00143715118	NCT00143715_118_T4	PHENOTYPE	14	14	epistaxis
NCT00143715118	NCT00143715_118_T5	PHENOTYPE	18	19	blood loss
NCT00143715119	NCT00143715_119_T0	PHENOTYPE	6	6	bleeding
NCT00143715119	NCT00143715_119_T1	PHENOTYPE	26	26	bleeding
NCT00143715119	NCT00143715_119_T2	PHENOTYPE	7	7	complications
NCT00143715119	NCT00143715_119_T3	COMPOUND	18	18	warfarin
NCT00143715120	NCT00143715_120_T0	PHENOTYPE	14	14	bleeding
NCT00143715121	NCT00143715_121_T0	PHENOTYPE	0	0	Secondary
NCT00143715121	NCT00143715_121_T1	PHENOTYPE	22	22	bleeding
NCT00143715121	NCT00143715_121_T2	PHENOTYPE	33	33	bleeds
NCT00143715121	NCT00143715_121_T3	PHENOTYPE	4	4	Hemorrhage
NCT00143715121	NCT00143715_121_T4	COMPOUND	18	19	vitamin K
NCT00143715122	NCT00143715_122_T0	PHENOTYPE	1	1	bleeding
NCT00143715122	NCT00143715_122_T1	PHENOTYPE	13	13	bleeding
NCT00143715122	NCT00143715_122_T2	ORGAN	23	23	appendix
NCT00143715123	NCT00143715_123_T0	PHENOTYPE	9	11	signs and symptoms
NCT00143715125	NCT00143715_125_T0	ORGAN	12	12	appendix
NCT00143715129	NCT00143715_129_T0	PHENOTYPE	13	13	bleeding
NCT00143715129	NCT00143715_129_T1	PHENOTYPE	7	7	symptoms
NCT00143715129	NCT00143715_129_T2	PHENOTYPE	15	15	thrombosis
NCT00143715130	NCT00143715_130_T0	PHENOTYPE	1	1	bleeding
NCT00143715130	NCT00143715_130_T1	PHENOTYPE	3	3	thrombosis
NCT00143715131	NCT00143715_131_T0	PHENOTYPE	1	1	bleeding
NCT00143715131	NCT00143715_131_T1	PHENOTYPE	14	14	bleeding
NCT00143715132	NCT00143715_132_T0	PHENOTYPE	14	14	bleeding
NCT00143715132	NCT00143715_132_T1	GENE	8	8	10.0
NCT00143715132	NCT00143715_132_T2	GENE	6	6	4.5
NCT00143715132	NCT00143715_132_T3	GENE	5	5	INR
NCT00143715132	NCT00143715_132_T4	GENE	25	25	INR
NCT00143715132	NCT00143715_132_T5	COMPOUND	21	21	warfarin
NCT00143715132	NCT00143715_132_T6	COMPOUND	29	29	warfarin
NCT00143715133	NCT00143715_133_T0	PHENOTYPE	23	23	bleeding
NCT00143715133	NCT00143715_133_T1	COMPOUND	16	17	vitamin K
NCT00143715134	NCT00143715_134_T0	PHENOTYPE	6	6	bleeding
NCT00143715134	NCT00143715_134_T1	COMPOUND	20	21	vitamin K
NCT00143715136	NCT00143715_136_T0	PHENOTYPE	55	55	bleeding
NCT00143715136	NCT00143715_136_T1	GENE	56	56	4.7
NCT00143715136	NCT00143715_136_T2	GENE	20	20	2.9
NCT00143715136	NCT00143715_136_T3	GENE	25	25	INR
NCT00143715136	NCT00143715_136_T4	GENE	50	50	INR
NCT00143715136	NCT00143715_136_T5	GENE	32	32	fold
NCT00143715136	NCT00143715_136_T6	PHENOTYPE	38	38	hemorrhage
NCT00143715136	NCT00143715_136_T7	COMPOUND	15	16	vitamin K
NCT00143715137	NCT00143715_137_T0	GENE	16	16	fold
NCT00143715137	NCT00143715_137_T1	PHENOTYPE	22	22	hemorrhage
NCT00143715141	NCT00143715_141_T0	GENE	8	8	has
NCT00143715143	NCT00143715_143_T0	COMPOUND	13	14	vitamin K
NCT00143715144	NCT00143715_144_T0	GENE	9	9	had
NCT00143715144	NCT00143715_144_T1	COMPOUND	16	17	vitamin K
NCT00143715145	NCT00143715_145_T0	COMPOUND	48	48	warfarin
NCT00143715145	NCT00143715_145_T1	COMPOUND	58	58	warfarin
NCT00143715147	NCT00143715_147_T0	PHENOTYPE	11	11	Thromboembolism
NCT00143715148	NCT00143715_148_T0	PHENOTYPE	5	5	centre
NCT00143715148	NCT00143715_148_T1	PHENOTYPE	33	33	centre
NCT00143715151	NCT00143715_151_T0	PHENOTYPE	28	28	centres
NCT00143715152	NCT00143715_152_T0	PHENOTYPE	12	12	centre
NCT00143715153	NCT00143715_153_T0	COMPOUND	10	11	vitamin K
NCT00143715154	NCT00143715_154_T0	COMPOUND	16	17	vitamin K
NCT00143715155	NCT00143715_155_T0	COMPOUND	3	4	vitamin K
NCT00143715156	NCT00143715_156_T0	COMPOUND	9	10	vitamin K
NCT00143715157	NCT00143715_157_T0	COMPOUND	12	12	lactose
NCT00143715157	NCT00143715_157_T1	COMPOUND	14	14	lactose
NCT00143715157	NCT00143715_157_T2	COMPOUND	19	20	vitamin K
NCT00143715158	NCT00143715_158_T0	PHENOTYPE	26	26	centre
NCT00143715158	NCT00143715_158_T1	PHENOTYPE	36	36	centre
NCT00143715159	NCT00143715_159_T0	PHENOTYPE	9	9	centre
NCT00143715159	NCT00143715_159_T1	PHENOTYPE	14	14	centre
NCT00143715160	NCT00143715_160_T0	GENE	5	5	Dr
NCT00143715166	NCT00143715_166_T0	PHENOTYPE	59	59	thromboembolism
NCT00143715166	NCT00143715_166_T1	GENE	42	42	di
NCT00143715166	NCT00143715_166_T2	GENE	13	13	Dr
NCT00143715166	NCT00143715_166_T3	GENE	18	18	Dr
NCT00143715166	NCT00143715_166_T4	GENE	23	23	Dr
NCT00143715166	NCT00143715_166_T5	GENE	30	30	Dr
NCT00143715166	NCT00143715_166_T6	GENE	38	38	Dr
NCT00143715166	NCT00143715_166_T7	GENE	44	44	Dr
NCT00143715166	NCT00143715_166_T8	GENE	48	48	Dr
NCT00143715166	NCT00143715_166_T9	PHENOTYPE	1	1	centres
NCT00143715167	NCT00143715_167_T0	PHENOTYPE	14	14	bleeds
NCT00143715168	NCT00143715_168_T0	PHENOTYPE	6	6	hemorrhage
NCT00143715170	NCT00143715_170_T0	PHENOTYPE	30	30	bleeding
NCT00143715173	NCT00143715_173_T0	PHENOTYPE	6	6	Thromboembolism
NCT00143715173	NCT00143715_173_T1	PHENOTYPE	16	16	Thromboembolism
NCT00143715173	NCT00143715_173_T2	GENE	3	3	Dr
NCT00143715173	NCT00143715_173_T3	GENE	13	13	Dr
NCT00143715175	NCT00143715_175_T0	PHENOTYPE	15	15	bleeds
NCT00143715175	NCT00143715_175_T1	PHENOTYPE	17	17	thrombi
NCT00143715178	NCT00143715_178_T0	PHENOTYPE	2	2	thromboembolism
NCT00143715179	NCT00143715_179_T0	PHENOTYPE	21	21	bleeding
NCT00143715179	NCT00143715_179_T1	PHENOTYPE	51	51	closed
NCT00143715181	NCT00143715_181_T0	GENE	10	10	Chi
NCT00143715182	NCT00143715_182_T0	PHENOTYPE	0	0	Secondary
NCT00143715182	NCT00143715_182_T1	PHENOTYPE	20	20	thromboembolism
NCT00143715182	NCT00143715_182_T2	GENE	30	30	Chi
NCT00143715182	NCT00143715_182_T3	PHENOTYPE	12	12	thrombosis
NCT00143715182	NCT00143715_182_T4	PHENOTYPE	11	11	hemorrhage
NCT00143715182	NCT00143715_182_T5	PHENOTYPE	24	24	hemorrhage
NCT00143715183	NCT00143715_183_T0	PHENOTYPE	1	1	regression
NCT00143715183	NCT00143715_183_T1	PHENOTYPE	33	34	adverse events
NCT00143715184	NCT00143715_184_T0	GENE	13	13	ANOVA
NCT00143715184	NCT00143715_184_T1	GENE	3	3	INR
NCT00143715185	NCT00143715_185_T0	PHENOTYPE	13	13	bleeds
NCT00143715185	NCT00143715_185_T1	GENE	8	8	INR
NCT00143715188	NCT00143715_188_T0	PHENOTYPE	16	16	bleeding
NCT00143715189	NCT00143715_189_T0	GENE	10	10	5.7
NCT00143715195	NCT00143715_195_T0	PHENOTYPE	17	17	suffering
NCT00143715195	NCT00143715_195_T1	PHENOTYPE	21	21	hemorrhage
NCT00143715199	NCT00143715_199_T0	PHENOTYPE	16	16	hemorrhage
NCT00143715200	NCT00143715_200_T0	GENE	7	7	CI
NCT00143715200	NCT00143715_200_T1	PHENOTYPE	12	12	hemorrhage
NCT00143715200	NCT00143715_200_T2	PHENOTYPE	39	39	hemorrhage
NCT00143715202	NCT00143715_202_T0	BIOLOGICAL_PROCESS	4	7	response to vitamin K
NCT00143715203	NCT00143715_203_T0	PHENOTYPE	11	11	thrombosis
NCT00143715203	NCT00143715_203_T1	GENE	23	23	INR
NCT00143715203	NCT00143715_203_T2	PHENOTYPE	13	13	hemorrhage
NCT00143715204	NCT00143715_204_T0	GENE	33	33	INR
NCT00143715204	NCT00143715_204_T1	COMPOUND	39	40	vitamin K
NCT00143715205	NCT00143715_205_T0	GENE	5	5	INR
NCT00143715205	NCT00143715_205_T1	GENE	15	15	INR
NCT00143715205	NCT00143715_205_T2	GENE	38	38	INR
NCT00143715205	NCT00143715_205_T3	GENE	56	56	INR
NCT00143715205	NCT00143715_205_T4	BIOLOGICAL_PROCESS	41	44	response to vitamin K
NCT00143715206	NCT00143715_206_T0	GENE	22	22	INR
NCT00143715206	NCT00143715_206_T1	COMPOUND	25	25	warfarin
NCT00143715206	NCT00143715_206_T2	COMPOUND	31	31	warfarin
NCT00143715207	NCT00143715_207_T0	GENE	10	10	INR
NCT00143715207	NCT00143715_207_T1	COMPOUND	14	15	vitamin K
NCT00143715208	NCT00143715_208_T0	BIOLOGICAL_PROCESS	20	23	response to vitamin K
NCT00143715209	NCT00143715_209_T0	COMPOUND	13	14	vitamin K
NCT001437280	NCT00143728_0_T0	PHENOTYPE	8	8	Resistance
NCT001437280	NCT00143728_0_T1	PHENOTYPE	5	5	HIV
NCT001437411	NCT00143741_1_T0	ORGAN	9	9	kidneys
NCT001437412	NCT00143741_2_T0	ORGAN	21	21	transplant
NCT001437412	NCT00143741_2_T1	ORGAN	22	22	kidneys
NCT001437416	NCT00143741_6_T0	ORGAN	11	11	kidney
NCT001437416	NCT00143741_6_T1	GENE	14	14	3.5
NCT001437416	NCT00143741_6_T2	ORGAN	12	12	transplant
NCT001437417	NCT00143741_7_T0	ORGAN	14	14	kidney
NCT001437417	NCT00143741_7_T1	ORGAN	15	15	transplants
NCT001437419	NCT00143741_9_T0	ORGAN	9	9	kidneys
NCT0014374110	NCT00143741_10_T0	ORGAN	29	29	transplant
NCT0014374110	NCT00143741_10_T1	ORGAN	30	30	kidneys
NCT0014374111	NCT00143741_11_T0	ORGAN	21	21	kidney
NCT0014374111	NCT00143741_11_T1	ORGAN	22	22	transplant
NCT0014374111	NCT00143741_11_T2	COMPOUND	2	2	atorvastatin
NCT0014374115	NCT00143741_15_T0	ORGAN	6	6	kidney
NCT0014374115	NCT00143741_15_T1	ORGAN	7	7	transplant
NCT0014374120	NCT00143741_20_T0	GENE	4	4	PRA
NCT001437541	NCT00143754_1_T0	PHENOTYPE	22	22	syncope
NCT001437541	NCT00143754_1_T1	PHENOTYPE	5	5	chronic
NCT001437541	NCT00143754_1_T2	PHENOTYPE	21	21	recurrent
NCT001437541	NCT00143754_1_T3	PHENOTYPE	13	13	tolerance
NCT001437671	NCT00143767_1_T0	PHENOTYPE	7	7	ADHD
NCT001437671	NCT00143767_1_T1	GENE	14	14	MRI
NCT001437675	NCT00143767_5_T0	GENE	3	3	has
NCT001437676	NCT00143767_6_T0	PHENOTYPE	7	7	symptoms
NCT001437679	NCT00143767_9_T0	PHENOTYPE	17	17	ADHD
NCT001437679	NCT00143767_9_T1	ORGAN	27	28	gray matter
NCT001437800	NCT00143780_0_T0	PHENOTYPE	0	0	Pneumonia
NCT001437800	NCT00143780_0_T1	ORGAN	5	5	Transplant
NCT001437800	NCT00143780_0_T2	ORGAN	3	4	Bone Marrow
NCT001437802	NCT00143780_2_T0	GENE	1	1	has
NCT001437803	NCT00143780_3_T0	GENE	9	9	has
NCT001437804	NCT00143780_4_T0	ORGAN	6	6	transplant
NCT001437804	NCT00143780_4_T1	ORGAN	17	17	transplant
NCT001437804	NCT00143780_4_T2	BIOLOGICAL_PROCESS	11	12	immune response
NCT001437804	NCT00143780_4_T3	ORGAN	2	3	bone marrow
NCT001437805	NCT00143780_5_T0	ORGAN	19	20	immune system
NCT001437807	NCT00143780_7_T0	ORGAN	9	9	transplant
NCT001437807	NCT00143780_7_T1	ORGAN	13	13	transplant
NCT0014378013	NCT00143780_13_T0	CELL	9	9	T-cell
NCT0014378015	NCT00143780_15_T0	ORGAN	3	3	marrow
NCT0014378018	NCT00143780_18_T0	GENE	4	4	eg
NCT0014378019	NCT00143780_19_T0	GENE	11	11	eg
NCT0014378019	NCT00143780_19_T1	PHENOTYPE	15	15	sarcoidosis
NCT0014378019	NCT00143780_19_T2	PHENOTYPE	16	17	rheumatoid arthritis
NCT0014378019	NCT00143780_19_T3	PHENOTYPE	12	14	systemic lupus erythematosus
NCT001438062	NCT00143806_2_T0	COMPOUND	8	8	cyclosporine
NCT001438064	NCT00143806_4_T0	COMPOUND	13	13	cyclosporine
NCT001438322	NCT00143832_2_T0	PHENOTYPE	0	0	ADHD
NCT001438322	NCT00143832_2_T1	PHENOTYPE	4	5	heritable disorder
NCT001438323	NCT00143832_3_T0	PHENOTYPE	12	12	ADHD
NCT001438324	NCT00143832_4_T0	PHENOTYPE	8	8	ADHD
NCT001438324	NCT00143832_4_T1	PHENOTYPE	3	4	cognitive functioning
NCT001438325	NCT00143832_5_T0	PHENOTYPE	11	11	ADHD
NCT001438325	NCT00143832_5_T1	PHENOTYPE	39	39	ADHD
NCT001438325	NCT00143832_5_T2	PHENOTYPE	54	54	ADHD
NCT001438325	NCT00143832_5_T3	PHENOTYPE	33	34	cognitive functions
NCT001438327	NCT00143832_7_T0	PHENOTYPE	0	0	ADHD
NCT001438327	NCT00143832_7_T1	PHENOTYPE	4	5	heritable disorder
NCT001438329	NCT00143832_9_T0	PHENOTYPE	15	16	cognitive deficits
NCT0014383210	NCT00143832_10_T0	PHENOTYPE	15	15	ADHD
NCT0014383210	NCT00143832_10_T1	GENE	5	5	has
NCT0014383211	NCT00143832_11_T0	PHENOTYPE	12	13	cognitive deficits
NCT0014383211	NCT00143832_11_T1	PHENOTYPE	16	17	psychiatric disorders
NCT0014383212	NCT00143832_12_T0	PHENOTYPE	20	20	ADHD
NCT0014383212	NCT00143832_12_T1	GENE	3	3	MRI
NCT0014383212	NCT00143832_12_T2	GENE	4	4	has
NCT0014383213	NCT00143832_13_T0	PHENOTYPE	23	23	ADHD
NCT0014383214	NCT00143832_14_T0	PHENOTYPE	13	13	ADHD
NCT0014383215	NCT00143832_15_T0	PHENOTYPE	8	8	ADHD
NCT0014383215	NCT00143832_15_T1	PHENOTYPE	16	17	cognitive deficits
NCT0014383217	NCT00143832_17_T0	PHENOTYPE	8	8	ADHD
NCT0014383217	NCT00143832_17_T1	PHENOTYPE	3	4	cognitive functioning
NCT0014383218	NCT00143832_18_T0	PHENOTYPE	11	11	ADHD
NCT0014383218	NCT00143832_18_T1	PHENOTYPE	39	39	ADHD
NCT0014383218	NCT00143832_18_T2	PHENOTYPE	54	54	ADHD
NCT0014383218	NCT00143832_18_T3	PHENOTYPE	33	34	cognitive functions
NCT0014383219	NCT00143832_19_T0	PHENOTYPE	7	7	ADHD
NCT0014383219	NCT00143832_19_T1	PHENOTYPE	13	13	ADHD
NCT0014383219	NCT00143832_19_T2	PHENOTYPE	34	34	ADHD
NCT0014383219	NCT00143832_19_T3	PHENOTYPE	28	29	cognitive functions
NCT0014383221	NCT00143832_21_T0	GENE	10	10	nogo
NCT0014383226	NCT00143832_26_T0	PHENOTYPE	11	11	anxious
NCT001438452	NCT00143845_2_T0	PHENOTYPE	9	9	immunosuppression
NCT001438452	NCT00143845_2_T1	PHENOTYPE	25	25	GVHD
NCT001438452	NCT00143845_2_T2	CELL	14	14	cells
NCT001438452	NCT00143845_2_T3	PHENOTYPE	26	29	Graft Versus Host Disease
NCT001438454	NCT00143845_4_T0	ORGAN	8	9	bone marrow
NCT001438455	NCT00143845_5_T0	PHENOTYPE	25	25	complications
NCT001438455	NCT00143845_5_T1	PHENOTYPE	29	29	relapse
NCT001438455	NCT00143845_5_T2	PHENOTYPE	27	27	GVHD
NCT001438457	NCT00143845_7_T0	COMPOUND	2	2	1
NCT001438457	NCT00143845_7_T1	COMPOUND	23	23	2
NCT001438457	NCT00143845_7_T2	GENE	33	33	FISH
NCT001438457	NCT00143845_7_T3	PHENOTYPE	17	17	pulse
NCT001438457	NCT00143845_7_T4	PHENOTYPE	0	1	Multiple myeloma
NCT001438457	NCT00143845_7_T5	PHENOTYPE	24	25	chromosomal abnormality
NCT0014384516	NCT00143845_16_T0	PHENOTYPE	3	3	FVC
NCT0014384521	NCT00143845_21_T0	CELL	17	17	Leukocyte
NCT0014384521	NCT00143845_21_T1	GENE	4	4	mid
NCT0014384521	NCT00143845_21_T2	PHENOTYPE	19	20	class I
NCT0014384522	NCT00143845_22_T0	PHENOTYPE	20	20	infections
NCT001438580	NCT00143858_0_T0	PHENOTYPE	8	8	Peripheral
NCT001438580	NCT00143858_0_T1	PHENOTYPE	11	11	Pulse
NCT001438584	NCT00143858_4_T0	ORGAN	1	1	limb
NCT001438584	NCT00143858_4_T1	ORGAN	13	13	limb
NCT001438585	NCT00143858_5_T0	ORGAN	9	9	limb
NCT001438585	NCT00143858_5_T1	ORGAN	3	3	heart
NCT001438587	NCT00143858_7_T0	PHENOTYPE	27	27	pulse
NCT001438588	NCT00143858_8_T0	PHENOTYPE	2	2	pulse
NCT001438588	NCT00143858_8_T1	ORGAN	11	12	lower extremities
NCT001438589	NCT00143858_9_T0	PHENOTYPE	2	2	occluding
NCT001438589	NCT00143858_9_T1	GENE	5	5	strap
NCT0014385810	NCT00143858_10_T0	PHENOTYPE	20	21	electrical impedance
NCT0014385811	NCT00143858_11_T0	GENE	15	15	strap
NCT0014385811	NCT00143858_11_T1	ORGAN	13	14	lower extremity
NCT001438715	NCT00143871_5_T0	PHENOTYPE	17	17	strategies
NCT001438716	NCT00143871_6_T0	PHENOTYPE	9	9	lymphoma
NCT001438717	NCT00143871_7_T0	PHENOTYPE	16	16	lymphoma
NCT001438717	NCT00143871_7_T1	ORGAN	6	7	immune system
NCT001438717	NCT00143871_7_T2	ORGAN	12	13	immune system
NCT001438843	NCT00143884_3_T0	CELL	20	20	cells
NCT001438843	NCT00143884_3_T1	ORGAN	6	6	transplant
NCT001438843	NCT00143884_3_T2	CELL	28	29	stem cells
NCT001438843	NCT00143884_3_T3	ORGAN	4	5	bone marrow
NCT001438843	NCT00143884_3_T4	ORGAN	26	27	bone marrow
NCT001438843	NCT00143884_3_T5	ORGAN	36	37	bone marrow
NCT001438845	NCT00143884_5_T0	PHENOTYPE	8	9	high-risk cancer
NCT0014388410	NCT00143884_10_T0	CELL	13	13	cells
NCT0014388410	NCT00143884_10_T1	CELL	18	18	cells
NCT0014388411	NCT00143884_11_T0	PHENOTYPE	7	7	conditioning
NCT0014388411	NCT00143884_11_T1	PHENOTYPE	25	25	conditioning
NCT0014388411	NCT00143884_11_T2	PHENOTYPE	30	30	conditioning
NCT0014388411	NCT00143884_11_T3	ORGAN	11	11	transplant
NCT0014388413	NCT00143884_13_T0	PHENOTYPE	0	2	Chronic myelogenous leukemia
NCT0014388415	NCT00143884_15_T0	PHENOTYPE	0	1	Blast phase
NCT0014388416	NCT00143884_16_T0	PHENOTYPE	0	2	Acute myelogenous leukemia
NCT0014388417	NCT00143884_17_T0	CELL	11	11	chromosomes
NCT0014388417	NCT00143884_17_T1	PHENOTYPE	4	4	remission
NCT0014388422	NCT00143884_22_T0	PHENOTYPE	0	2	Acute lymphoblastic leukemia
NCT0014388423	NCT00143884_23_T0	PHENOTYPE	2	2	remission
NCT0014388424	NCT00143884_24_T0	PHENOTYPE	4	4	relapse
NCT0014388424	NCT00143884_24_T1	PHENOTYPE	2	2	remission
NCT0014388425	NCT00143884_25_T0	PHENOTYPE	4	4	remission
NCT0014388429	NCT00143884_29_T0	PHENOTYPE	1	1	syndromes
NCT0014388430	NCT00143884_30_T0	PHENOTYPE	0	0	RAEB
NCT0014388432	NCT00143884_32_T0	PHENOTYPE	1	1	Lymphoma
NCT0014388433	NCT00143884_33_T0	PHENOTYPE	15	15	tumor
NCT0014388433	NCT00143884_33_T1	GENE	19	19	cm
NCT0014388435	NCT00143884_35_T0	PHENOTYPE	2	3	rapidly progressive
NCT0014388435	NCT00143884_35_T1	PHENOTYPE	3	4	progressive disease
NCT0014388437	NCT00143884_37_T0	GENE	28	28	OR
NCT0014388437	NCT00143884_37_T1	COMPOUND	14	14	1
NCT0014388437	NCT00143884_37_T2	COMPOUND	29	29	2
NCT0014388437	NCT00143884_37_T3	GENE	35	35	FISH
NCT0014388437	NCT00143884_37_T4	PHENOTYPE	23	23	pulse
NCT0014388437	NCT00143884_37_T5	PHENOTYPE	0	1	Multiple myeloma
NCT0014388437	NCT00143884_37_T6	PHENOTYPE	30	31	chromosomal abnormality
NCT0014388439	NCT00143884_39_T0	PHENOTYPE	0	2	Chronic lymphoblastic leukemia
NCT0014388447	NCT00143884_47_T0	PHENOTYPE	1	2	stage 3
NCT0014388448	NCT00143884_48_T0	PHENOTYPE	0	0	Lymphadenopathy
NCT0014388448	NCT00143884_48_T1	GENE	5	5	cm
NCT0014388449	NCT00143884_49_T0	PHENOTYPE	10	10	conditioning
NCT0014388449	NCT00143884_49_T1	PHENOTYPE	14	14	dysfunction
NCT0014388453	NCT00143884_53_T0	GENE	2	2	1.5
NCT0014388455	NCT00143884_55_T0	PHENOTYPE	3	3	FVC
NCT0014388457	NCT00143884_57_T0	GENE	3	3	2.0
NCT0014388457	NCT00143884_57_T1	COMPOUND	6	6	3
NCT0014388457	NCT00143884_57_T2	GENE	1	2	Total bilirubin
NCT0014388459	NCT00143884_59_T0	GENE	8	8	60
NCT0014388459	NCT00143884_59_T1	GENE	19	19	60
NCT0014388459	NCT00143884_59_T2	GENE	10	10	pts
NCT001439102	NCT00143910_2_T0	PHENOTYPE	2	2	closed
NCT001439230	NCT00143923_0_T0	PHENOTYPE	1	1	Strategies
NCT001439230	NCT00143923_0_T1	PHENOTYPE	4	5	Heart Disease
NCT001439235	NCT00143923_5_T0	PHENOTYPE	10	11	cardiovascular disease
NCT0014392310	NCT00143923_10_T0	PHENOTYPE	32	32	Center
NCT001439362	NCT00143936_2_T0	GENE	12	12	has
NCT001439365	NCT00143936_5_T0	PHENOTYPE	25	25	tolerance
NCT001439490	NCT00143949_0_T0	GENE	0	0	Renin
NCT001439493	NCT00143949_3_T0	PHENOTYPE	18	20	diabetic kidney disease
NCT001439495	NCT00143949_5_T0	PHENOTYPE	15	15	progression
NCT001439496	NCT00143949_6_T0	GENE	5	5	has
NCT001439498	NCT00143949_8_T0	GENE	2	2	has
NCT001439499	NCT00143949_9_T0	COMPOUND	32	32	enalapril
NCT001439499	NCT00143949_9_T1	COMPOUND	30	30	losartan
NCT0014394913	NCT00143949_13_T0	GENE	9	9	structural
NCT001439620	NCT00143962_0_T0	PHENOTYPE	5	6	Weight Loss
NCT001439625	NCT00143962_5_T0	COMPOUND	7	7	glucose
NCT001439625	NCT00143962_5_T1	BIOLOGICAL_PROCESS	12	12	eating
NCT001439625	NCT00143962_5_T2	PHENOTYPE	5	6	cholesterol levels
NCT001439625	NCT00143962_5_T3	PHENOTYPE	9	10	insulin levels
NCT001439750	NCT00143975_0_T0	PHENOTYPE	8	8	AML
NCT001439753	NCT00143975_3_T0	COMPOUND	19	19	cytarabine
NCT001439753	NCT00143975_3_T1	COMPOUND	30	30	1
NCT001439753	NCT00143975_3_T2	COMPOUND	18	18	idarubicin
NCT001439753	NCT00143975_3_T3	COMPOUND	20	20	etoposide
NCT001439753	NCT00143975_3_T4	GENE	17	17	ICE
NCT001439753	NCT00143975_3_T5	GENE	21	21	had
NCT001439754	NCT00143975_4_T0	GENE	6	6	had
NCT001439755	NCT00143975_5_T0	COMPOUND	15	15	3
NCT001439756	NCT00143975_6_T0	GENE	12	12	PR
NCT001439756	NCT00143975_6_T1	PHENOTYPE	16	16	remission
NCT001439756	NCT00143975_6_T2	GENE	15	15	CR
NCT001439757	NCT00143975_7_T0	PHENOTYPE	22	22	conditioning
NCT001439757	NCT00143975_7_T1	GENE	21	21	reduced
NCT001439757	NCT00143975_7_T2	ORGAN	2	2	transplant
NCT001439758	NCT00143975_8_T0	PHENOTYPE	10	10	strategies
NCT001439758	NCT00143975_8_T1	GENE	11	11	had
NCT0014397510	NCT00143975_10_T0	GENE	40	40	14
NCT0014397511	NCT00143975_11_T0	PHENOTYPE	6	6	strategies
NCT0014397512	NCT00143975_12_T0	GENE	8	8	ICE
NCT0014397512	NCT00143975_12_T1	GENE	15	15	ICE
NCT0014397513	NCT00143975_13_T0	GENE	13	13	PR
NCT0014397513	NCT00143975_13_T1	GENE	11	11	CR
NCT0014397515	NCT00143975_15_T0	COMPOUND	1	1	ozogamicin
NCT0014397515	NCT00143975_15_T1	GENE	6	6	CD33
NCT0014397519	NCT00143975_19_T0	PHENOTYPE	20	20	toxicity
NCT0014397519	NCT00143975_19_T1	ORGAN	19	19	liver
NCT0014397519	NCT00143975_19_T2	GENE	39	39	17
NCT0014397519	NCT00143975_19_T3	GENE	2	2	MRC
NCT0014397520	NCT00143975_20_T0	GENE	14	14	II
NCT0014397521	NCT00143975_21_T0	PHENOTYPE	3	3	toxicity
NCT0014397521	NCT00143975_21_T1	GENE	8	8	MRC
NCT0014397522	NCT00143975_22_T0	PHENOTYPE	11	12	adult AML
NCT0014397524	NCT00143975_24_T0	GENE	20	20	18
NCT0014397524	NCT00143975_24_T1	PHENOTYPE	8	8	VOD
NCT0014397525	NCT00143975_25_T0	GENE	20	20	21.6
NCT0014397525	NCT00143975_25_T1	GENE	14	14	3.5
NCT0014397525	NCT00143975_25_T2	PHENOTYPE	7	7	VOD
NCT0014397527	NCT00143975_27_T0	PHENOTYPE	7	7	VOD
NCT001439883	NCT00143988_3_T0	ORGAN	9	9	heart
NCT001439884	NCT00143988_4_T0	PHENOTYPE	5	5	hypertension
NCT001440011	NCT00144001_1_T0	PHENOTYPE	24	24	epilepsy
NCT001440015	NCT00144001_5_T0	PHENOTYPE	16	16	epilepsy
NCT001440018	NCT00144001_8_T0	PHENOTYPE	50	50	epilepsy
NCT0014400110	NCT00144001_10_T0	PHENOTYPE	12	12	fractures
NCT0014400110	NCT00144001_10_T1	PHENOTYPE	9	10	fall injuries
NCT0014400111	NCT00144001_11_T0	PHENOTYPE	18	18	epilepsy
NCT0014400111	NCT00144001_11_T1	PHENOTYPE	41	41	chronic
NCT0014400115	NCT00144001_15_T0	PHENOTYPE	21	21	epilepsy
NCT0014400115	NCT00144001_15_T1	PHENOTYPE	33	33	epilepsy
NCT0014400115	NCT00144001_15_T2	GENE	0	0	IMPACT
NCT0014400115	NCT00144001_15_T3	PHENOTYPE	36	36	chronic
NCT0014400116	NCT00144001_16_T0	PHENOTYPE	26	26	epilepsy
NCT001440144	NCT00144014_4_T0	PHENOTYPE	16	16	initiation
NCT001440144	NCT00144014_4_T1	PHENOTYPE	0	0	Onset
NCT0014401411	NCT00144014_11_T0	PHENOTYPE	0	0	Coma
NCT0014401413	NCT00144014_13_T0	PHENOTYPE	2	2	symptoms
NCT0014401415	NCT00144014_15_T0	GENE	5	5	20
NCT0014401415	NCT00144014_15_T1	PHENOTYPE	2	4	symptoms and signs
NCT0014401417	NCT00144014_17_T0	PHENOTYPE	2	3	brain tumours
NCT0014401421	NCT00144014_21_T0	BIOLOGICAL_PROCESS	4	4	lactation
NCT0014401421	NCT00144014_21_T1	BIOLOGICAL_PROCESS	6	6	parturition
NCT0014401422	NCT00144014_22_T0	GENE	1	1	135
NCT001440274	NCT00144027_4_T0	GENE	4	4	BFM
NCT001440274	NCT00144027_4_T1	GENE	17	17	BFM
NCT001440274	NCT00144027_4_T2	GENE	27	27	List
NCT001440275	NCT00144027_5_T0	PHENOTYPE	19	19	schizophrenia
NCT001440276	NCT00144027_6_T0	PHENOTYPE	17	17	schizophrenia
NCT001440277	NCT00144027_7_T0	GENE	7	7	BFM
NCT001440277	NCT00144027_7_T1	GENE	20	20	BFM
NCT001440277	NCT00144027_7_T2	PHENOTYPE	16	17	mental health
NCT001440278	NCT00144027_8_T0	GENE	21	21	BFM
NCT0014402710	NCT00144027_10_T0	PHENOTYPE	18	18	severity
NCT0014402710	NCT00144027_10_T1	GENE	5	5	BFM
NCT0014402710	NCT00144027_10_T2	PHENOTYPE	16	16	schizophrenia
NCT0014402711	NCT00144027_11_T0	PHENOTYPE	17	17	severity
NCT0014402711	NCT00144027_11_T1	PHENOTYPE	15	15	schizophrenia
NCT0014402713	NCT00144027_13_T0	GENE	7	7	BFM
NCT0014402713	NCT00144027_13_T1	PHENOTYPE	17	19	quality of life
NCT0014402714	NCT00144027_14_T0	PHENOTYPE	10	12	quality of life
NCT0014402717	NCT00144027_17_T0	PHENOTYPE	31	31	strategies
NCT0014402717	NCT00144027_17_T1	GENE	11	11	BFM
NCT0014402717	NCT00144027_17_T2	PHENOTYPE	24	24	schizophrenia
NCT0014402718	NCT00144027_18_T0	PHENOTYPE	6	7	mental health
NCT0014402719	NCT00144027_19_T0	GENE	7	7	BFM
NCT0014402720	NCT00144027_20_T0	GENE	19	19	BFM
NCT0014402722	NCT00144027_22_T0	GENE	0	0	BFM
NCT0014402722	NCT00144027_22_T1	GENE	12	12	BFM
NCT0014402723	NCT00144027_23_T0	GENE	0	0	BFM
NCT001440402	NCT00144040_2_T0	PHENOTYPE	13	13	acute
NCT001440402	NCT00144040_2_T1	PHENOTYPE	14	16	respiratory tract infections
NCT001440403	NCT00144040_3_T0	PHENOTYPE	29	29	acute
NCT001440403	NCT00144040_3_T1	GENE	32	32	eg
NCT001440403	NCT00144040_3_T2	PHENOTYPE	38	38	centers
NCT001440403	NCT00144040_3_T3	GENE	14	14	has
NCT001440403	NCT00144040_3_T4	GENE	51	51	has
NCT001440404	NCT00144040_4_T0	PHENOTYPE	16	16	acute
NCT001440404	NCT00144040_4_T1	BIOLOGICAL_PROCESS	0	0	Translation
NCT001440404	NCT00144040_4_T2	PHENOTYPE	8	8	practices
NCT001440406	NCT00144040_6_T0	PHENOTYPE	21	21	acute
NCT001440406	NCT00144040_6_T1	COMPOUND	2	2	2
NCT001440406	NCT00144040_6_T2	PHENOTYPE	22	22	cough
NCT001440409	NCT00144040_9_T0	GENE	9	9	hub
NCT0014404014	NCT00144040_14_T0	BIOLOGICAL_PROCESS	16	16	translation
NCT001440533	NCT00144053_3_T0	PHENOTYPE	10	10	NSCLC
NCT001440534	NCT00144053_4_T0	PHENOTYPE	9	9	Oncology
NCT001440534	NCT00144053_4_T1	GENE	1	1	had
NCT001440534	NCT00144053_4_T2	PHENOTYPE	4	5	measurable disease
NCT001440535	NCT00144053_5_T0	ORGAN	5	5	liver
NCT001440535	NCT00144053_5_T1	ORGAN	6	6	heart
NCT001440535	NCT00144053_5_T2	ORGAN	2	3	bone marrow
NCT001440793	NCT00144079_3_T0	GENE	12	12	RIT
NCT001440795	NCT00144079_5_T0	PHENOTYPE	23	23	recurrence
NCT001440795	NCT00144079_5_T1	PHENOTYPE	7	7	basalioma
NCT001440795	NCT00144079_5_T2	PHENOTYPE	13	14	psychiatric disorder
NCT001440795	NCT00144079_5_T3	PHENOTYPE	4	5	secondary malignancy
NCT001440796	NCT00144079_6_T0	GENE	20	20	TNM
NCT0014407911	NCT00144079_11_T0	GENE	10	10	nodal
NCT0014407914	NCT00144079_14_T0	GENE	0	0	RT
NCT0014407914	NCT00144079_14_T1	PHENOTYPE	6	6	unilateral
NCT0014407914	NCT00144079_14_T2	GENE	17	17	Gy
NCT0014407914	NCT00144079_14_T3	GENE	20	20	Gy
NCT0014407914	NCT00144079_14_T4	GENE	58	58	Gy
NCT0014407914	NCT00144079_14_T5	GENE	61	61	Gy
NCT0014407914	NCT00144079_14_T6	PHENOTYPE	7	7	tumors
NCT0014407914	NCT00144079_14_T7	ORGAN	3	3	thyroid
NCT0014407914	NCT00144079_14_T8	ORGAN	45	45	mandible
NCT0014407914	NCT00144079_14_T9	ORGAN	37	37	mediastinum
NCT0014407914	NCT00144079_14_T10	GENE	24	24	R1
NCT0014407914	NCT00144079_14_T11	ORGAN	47	48	mastoid process
NCT0014407914	NCT00144079_14_T12	TISSUE	30	31	lymph nodes
NCT0014407915	NCT00144079_15_T0	GENE	3	3	1.8
NCT0014407919	NCT00144079_19_T0	PHENOTYPE	5	5	toxicity
NCT0014407919	NCT00144079_19_T1	GENE	21	21	3.0
NCT0014407919	NCT00144079_19_T2	PHENOTYPE	13	15	quality of life
NCT001441051	NCT00144105_1_T0	GENE	0	0	BID
NCT001441052	NCT00144105_2_T0	GENE	0	0	BID
NCT0014410516	NCT00144105_16_T0	GENE	11	11	has
NCT0014410516	NCT00144105_16_T1	GENE	16	16	has
NCT0014410516	NCT00144105_16_T2	PHENOTYPE	12	12	resolved
NCT0014410516	NCT00144105_16_T3	PHENOTYPE	22	23	opportunistic infection
NCT001441182	NCT00144118_2_T0	COMPOUND	6	6	sevoflurane
NCT001441182	NCT00144118_2_T1	COMPOUND	19	19	sevoflurane
NCT001441183	NCT00144118_3_T0	GENE	1	1	has
NCT001441183	NCT00144118_3_T1	COMPOUND	13	13	isoflurane
NCT001441183	NCT00144118_3_T2	PHENOTYPE	11	11	anaesthesia
NCT001441187	NCT00144118_7_T0	ORGAN	6	6	kidney
NCT0014411810	NCT00144118_10_T0	COMPOUND	15	15	creatinine
NCT0014411810	NCT00144118_10_T1	GENE	9	9	has
NCT0014411810	NCT00144118_10_T2	ORGAN	14	14	plasma
NCT0014411811	NCT00144118_11_T0	COMPOUND	13	13	creatinine
NCT0014411811	NCT00144118_11_T1	COMPOUND	3	3	sevoflurane
NCT0014411811	NCT00144118_11_T2	COMPOUND	7	7	sevoflurane
NCT0014411811	NCT00144118_11_T3	GENE	4	4	has
NCT0014411811	NCT00144118_11_T4	ORGAN	12	12	plasma
NCT0014411812	NCT00144118_12_T0	PHENOTYPE	5	5	Anaesthesia
NCT0014411812	NCT00144118_12_T1	COMPOUND	16	16	sevoflurane
NCT0014411812	NCT00144118_12_T2	GENE	6	6	has
NCT0014411812	NCT00144118_12_T3	PHENOTYPE	13	13	anaesthesia
NCT0014411813	NCT00144118_13_T0	COMPOUND	13	13	creatinine
NCT0014411813	NCT00144118_13_T1	COMPOUND	7	7	propofol
NCT0014411813	NCT00144118_13_T2	COMPOUND	5	5	sevoflurane
NCT0014411813	NCT00144118_13_T3	COMPOUND	4	4	isoflurane
NCT0014411820	NCT00144118_20_T0	COMPOUND	6	6	creatinine
NCT0014411822	NCT00144118_22_T0	PHENOTYPE	3	4	renal impairment
NCT0014411823	NCT00144118_23_T0	PHENOTYPE	1	2	renal impairment
NCT0014411824	NCT00144118_24_T0	COMPOUND	4	4	creatinine
NCT0014411824	NCT00144118_24_T1	COMPOUND	6	6	sevoflurane
NCT0014411824	NCT00144118_24_T2	PHENOTYPE	17	18	renal impairment
NCT0014411825	NCT00144118_25_T0	COMPOUND	8	8	sevoflurane
NCT0014411825	NCT00144118_25_T1	GENE	5	5	has
NCT0014411825	NCT00144118_25_T2	PHENOTYPE	11	12	renal impairment
NCT0014411826	NCT00144118_26_T0	PHENOTYPE	8	8	Anaesthesia
NCT0014411828	NCT00144118_28_T0	PHENOTYPE	9	10	renal impairment
NCT0014411829	NCT00144118_29_T0	PHENOTYPE	27	27	anesthesia
NCT0014411829	NCT00144118_29_T1	COMPOUND	9	9	sevoflurane
NCT0014411829	NCT00144118_29_T2	COMPOUND	17	17	isoflurane
NCT0014411829	NCT00144118_29_T3	PHENOTYPE	22	23	renal impairment
NCT0014411834	NCT00144118_34_T0	COMPOUND	16	16	1
NCT0014411834	NCT00144118_34_T1	COMPOUND	24	24	2
NCT0014411834	NCT00144118_34_T2	COMPOUND	33	33	creatinine
NCT0014411834	NCT00144118_34_T3	COMPOUND	28	28	3
NCT0014411834	NCT00144118_34_T4	ORGAN	32	32	serum
NCT0014411834	NCT00144118_34_T5	PHENOTYPE	27	27	anaesthesia
NCT0014411841	NCT00144118_41_T0	PHENOTYPE	10	10	anaesthesia
NCT0014411847	NCT00144118_47_T0	GENE	1	1	OR
NCT0014411850	NCT00144118_50_T0	COMPOUND	11	11	sevoflurane
NCT0014411850	NCT00144118_50_T1	COMPOUND	9	9	isoflurane
NCT0014411853	NCT00144118_53_T0	COMPOUND	10	10	sevoflurane
NCT0014411853	NCT00144118_53_T1	COMPOUND	8	8	isoflurane
NCT0014411854	NCT00144118_54_T0	COMPOUND	14	14	creatinine
NCT0014411854	NCT00144118_54_T1	ORGAN	13	13	serum
NCT0014411855	NCT00144118_55_T0	COMPOUND	7	7	creatinine
NCT0014411855	NCT00144118_55_T1	COMPOUND	9	9	urea
NCT0014411857	NCT00144118_57_T0	COMPOUND	10	10	creatinine
NCT0014411857	NCT00144118_57_T1	COMPOUND	19	19	creatinine
NCT0014411857	NCT00144118_57_T2	PHENOTYPE	6	7	renal impairment
NCT0014411862	NCT00144118_62_T0	PHENOTYPE	15	15	Anaesthesia
NCT0014411863	NCT00144118_63_T0	COMPOUND	29	29	1
NCT0014411863	NCT00144118_63_T1	COMPOUND	47	47	2
NCT0014411863	NCT00144118_63_T2	COMPOUND	24	24	creatinine
NCT0014411863	NCT00144118_63_T3	COMPOUND	36	36	creatinine
NCT0014411863	NCT00144118_63_T4	COMPOUND	11	11	sevoflurane
NCT0014411863	NCT00144118_63_T5	COMPOUND	9	9	isoflurane
NCT0014411863	NCT00144118_63_T6	GENE	19	19	met
NCT0014411864	NCT00144118_64_T0	GENE	12	13	group 2
NCT0014411870	NCT00144118_70_T0	COMPOUND	17	17	creatinine
NCT0014411870	NCT00144118_70_T1	COMPOUND	14	14	sevoflurane
NCT0014411870	NCT00144118_70_T2	GENE	32	32	unpaired
NCT0014411870	NCT00144118_70_T3	COMPOUND	12	12	isoflurane
NCT0014411871	NCT00144118_71_T0	COMPOUND	22	22	creatinine
NCT0014411871	NCT00144118_71_T1	COMPOUND	16	16	sevoflurane
NCT0014411871	NCT00144118_71_T2	COMPOUND	14	14	isoflurane
NCT0014411872	NCT00144118_72_T0	GENE	27	27	Chi
NCT0014411873	NCT00144118_73_T0	COMPOUND	14	14	creatinine
NCT0014411873	NCT00144118_73_T1	GENE	30	30	unpaired
NCT0014411873	NCT00144118_73_T2	COMPOUND	16	16	urea
NCT0014411874	NCT00144118_74_T0	PHENOTYPE	0	1	Adverse events
NCT0014411878	NCT00144118_78_T0	COMPOUND	23	23	creatinine
NCT0014411878	NCT00144118_78_T1	COMPOUND	16	16	sevoflurane
NCT0014411878	NCT00144118_78_T2	COMPOUND	25	25	isoflurane
NCT0014411878	NCT00144118_78_T3	PHENOTYPE	30	31	renal impairment
NCT0014411879	NCT00144118_79_T0	GENE	35	35	had
NCT0014411879	NCT00144118_79_T1	COMPOUND	20	20	sevoflurane
NCT0014411879	NCT00144118_79_T2	COMPOUND	18	18	isoflurane
NCT001441310	NCT00144131_0_T0	PHENOTYPE	13	13	Malignancies
NCT001441310	NCT00144131_0_T1	PHENOTYPE	15	15	Anemia
NCT001441570	NCT00144157_0_T0	PHENOTYPE	16	16	HIV
NCT001441573	NCT00144157_3_T0	COMPOUND	31	31	nevirapine
NCT001441573	NCT00144157_3_T1	PHENOTYPE	25	25	HIV
NCT001441574	NCT00144157_4_T0	PHENOTYPE	14	14	withdrawn
NCT001441574	NCT00144157_4_T1	PHENOTYPE	10	10	resistant
NCT001441575	NCT00144157_5_T0	GENE	14	14	retained
NCT001441575	NCT00144157_5_T1	COMPOUND	55	55	nevirapine
NCT001441575	NCT00144157_5_T2	COMPOUND	72	72	nevirapine
NCT001441575	NCT00144157_5_T3	PHENOTYPE	9	9	resistant
NCT001441575	NCT00144157_5_T4	PHENOTYPE	21	21	resistant
NCT001441702	NCT00144170_2_T0	GENE	1	1	CD4
NCT0014417027	NCT00144170_27_T0	GENE	1	1	aminotransferase
NCT0014417027	NCT00144170_27_T1	GENE	8	9	aspartate aminotransferase
NCT0014417030	NCT00144170_30_T0	COMPOUND	1	1	tipranavir
NCT0014417034	NCT00144170_34_T0	COMPOUND	17	17	hydroxyurea
NCT0014417034	NCT00144170_34_T1	COMPOUND	16	16	cyclosporin
NCT0014417034	NCT00144170_34_T2	GENE	15	15	interferon
NCT0014417034	NCT00144170_34_T3	GENE	18	19	interleukin 2
NCT0014417036	NCT00144170_36_T0	PHENOTYPE	11	12	substance abuse
NCT001441837	NCT00144183_7_T0	COMPOUND	21	21	nevirapine
NCT001441837	NCT00144183_7_T1	COMPOUND	32	32	nevirapine
NCT001441838	NCT00144183_8_T0	COMPOUND	13	13	nevirapine
NCT001441838	NCT00144183_8_T1	COMPOUND	33	33	nevirapine
NCT001441838	NCT00144183_8_T2	PHENOTYPE	14	14	resistant
NCT0014418310	NCT00144183_10_T0	COMPOUND	41	41	nevirapine
NCT0014418310	NCT00144183_10_T1	COMPOUND	55	55	nevirapine
NCT001441963	NCT00144196_3_T0	GENE	8	8	0.2
NCT001441963	NCT00144196_3_T1	COMPOUND	5	5	salbutamol
NCT001441963	NCT00144196_3_T2	GENE	10	10	prn
NCT001441965	NCT00144196_5_T0	COMPOUND	4	4	2
NCT001441965	NCT00144196_5_T1	GENE	30	30	has
NCT0014419612	NCT00144196_12_T0	COMPOUND	11	11	tiotropium
NCT0014419612	NCT00144196_12_T1	COMPOUND	12	12	Spiriva
NCT0014419615	NCT00144196_15_T0	GENE	11	11	GCP
NCT0014419615	NCT00144196_15_T1	GENE	10	10	ICH
NCT0014419622	NCT00144196_22_T0	GENE	14	14	10
NCT0014419628	NCT00144196_28_T0	PHENOTYPE	6	7	renal insufficiency
NCT0014419630	NCT00144196_30_T0	PHENOTYPE	15	16	myocardial infarction
NCT0014419632	NCT00144196_32_T0	PHENOTYPE	17	17	arrhythmia
NCT0014419632	NCT00144196_32_T1	BIOLOGICAL_PROCESS	46	46	AICD
NCT0014419632	NCT00144196_32_T2	PHENOTYPE	7	8	cardiac arrhythmia
NCT0014419632	NCT00144196_32_T3	PHENOTYPE	31	32	cardiac arrhythmia
NCT0014419634	NCT00144196_34_T0	COMPOUND	4	4	oxygen
NCT0014419636	NCT00144196_36_T0	PHENOTYPE	3	4	active tuberculosis
NCT0014419641	NCT00144196_41_T0	PHENOTYPE	8	8	obstruction
NCT0014419641	NCT00144196_41_T1	PHENOTYPE	18	18	bronchiectasis
NCT0014419641	NCT00144196_41_T2	PHENOTYPE	13	14	cystic fibrosis
NCT0014419646	NCT00144196_46_T0	PHENOTYPE	4	4	hyperplasia
NCT0014419646	NCT00144196_46_T1	PHENOTYPE	6	8	bladder neck obstruction
NCT0014419647	NCT00144196_47_T0	PHENOTYPE	9	9	symptoms
NCT0014419647	NCT00144196_47_T1	PHENOTYPE	4	5	prostatic hyperplasia
NCT001442092	NCT00144209_2_T0	COMPOUND	11	11	pramipexole
NCT001442092	NCT00144209_2_T1	COMPOUND	13	13	levodopa
NCT001442092	NCT00144209_2_T2	PHENOTYPE	19	21	quality of life
NCT001442220	NCT00144222_0_T0	PHENOTYPE	18	19	Essential Hypertension
NCT001442223	NCT00144222_3_T0	COMPOUND	19	19	telmisartan
NCT001442225	NCT00144222_5_T0	COMPOUND	7	7	telmisartan
NCT001442225	NCT00144222_5_T1	COMPOUND	25	25	telmisartan
NCT001442225	NCT00144222_5_T2	COMPOUND	35	35	telmisartan
NCT001442226	NCT00144222_6_T0	GENE	29	29	pat
NCT001442226	NCT00144222_6_T1	COMPOUND	11	11	telmisartan
NCT001442226	NCT00144222_6_T2	COMPOUND	24	24	telmisartan
NCT001442226	NCT00144222_6_T3	COMPOUND	40	40	telmisartan
NCT001442226	NCT00144222_6_T4	PHENOTYPE	32	33	essential hypertension
NCT001442227	NCT00144222_7_T0	GENE	13	13	DBP
NCT001442351	NCT00144235_1_T0	GENE	0	0	PHL
NCT001442351	NCT00144235_1_T1	PHENOTYPE	4	5	cognitive function
NCT001442351	NCT00144235_1_T2	PHENOTYPE	11	12	physical stress
NCT001442356	NCT00144235_6_T0	GENE	4	4	2.1
NCT001442358	NCT00144235_8_T0	GENE	0	0	H1
NCT0014423512	NCT00144235_12_T0	GENE	12	12	ts
NCT0014423514	NCT00144235_14_T0	GENE	9	9	GCP
NCT0014423515	NCT00144235_15_T0	PHENOTYPE	6	7	clinical depression
NCT0014423516	NCT00144235_16_T0	PHENOTYPE	4	4	dementia
NCT0014423519	NCT00144235_19_T0	PHENOTYPE	4	5	alcohol abuse
NCT0014423521	NCT00144235_21_T0	COMPOUND	15	15	nicotine
NCT0014423521	NCT00144235_21_T1	COMPOUND	21	21	nicotine
NCT0014423521	NCT00144235_21_T2	COMPOUND	23	23	nicotine
NCT0014423521	NCT00144235_21_T3	BIOLOGICAL_PROCESS	19	19	chewing
NCT0014423522	NCT00144235_22_T0	PHENOTYPE	8	9	drug allergies
NCT001442482	NCT00144248_2_T0	PHENOTYPE	16	16	reflected
NCT001442482	NCT00144248_2_T1	PHENOTYPE	22	23	hepatic fibrosis
NCT001442482	NCT00144248_2_T2	PHENOTYPE	12	14	chronic liver disease
NCT001442483	NCT00144248_3_T0	COMPOUND	0	0	2
NCT001442484	NCT00144248_4_T0	COMPOUND	4	4	nevirapine
NCT001442485	NCT00144248_5_T0	COMPOUND	2	2	nevirapine
NCT001442487	NCT00144248_7_T0	PHENOTYPE	15	15	pathology
NCT001442488	NCT00144248_8_T0	ORGAN	6	6	liver
NCT001442488	NCT00144248_8_T1	PHENOTYPE	15	15	cirrhosis
NCT001442489	NCT00144248_9_T0	ORGAN	9	9	liver
NCT001442489	NCT00144248_9_T1	PHENOTYPE	3	3	cirrhosis
NCT0014424811	NCT00144248_11_T0	PHENOTYPE	6	6	HIV
NCT0014424814	NCT00144248_14_T0	COMPOUND	4	4	fluconazole
NCT0014424814	NCT00144248_14_T1	COMPOUND	6	6	ketoconazole
NCT0014424814	NCT00144248_14_T2	COMPOUND	5	5	itraconazole
NCT0014424820	NCT00144248_20_T0	PHENOTYPE	10	11	Grade 1
NCT0014424820	NCT00144248_20_T1	PHENOTYPE	7	8	other encephalopathy
NCT0014424821	NCT00144248_21_T0	PHENOTYPE	2	3	renal failure
NCT001442610	NCT00144261_0_T0	ORGAN	13	13	Plasma
NCT001442610	NCT00144261_0_T1	GENE	14	14	HDL
NCT001442610	NCT00144261_0_T2	PHENOTYPE	16	16	HIV
NCT001442612	NCT00144261_2_T0	GENE	21	21	Apo
NCT001442612	NCT00144261_2_T1	GENE	11	11	HDL
NCT001442612	NCT00144261_2_T2	GENE	19	19	HDL
NCT001442612	NCT00144261_2_T3	PHENOTYPE	28	28	initiation
NCT001442612	NCT00144261_2_T4	PHENOTYPE	10	10	affects
NCT001442612	NCT00144261_2_T5	BIOLOGICAL_PROCESS	12	12	metabolism
NCT001442617	NCT00144261_7_T0	GENE	20	20	GCP
NCT0014426111	NCT00144261_11_T0	ORGAN	2	2	plasma
NCT0014426113	NCT00144261_13_T0	ORGAN	2	2	plasma
NCT0014426122	NCT00144261_22_T0	GENE	3	3	155
NCT0014426122	NCT00144261_22_T1	GENE	7	7	95
NCT0014426122	NCT00144261_22_T2	PHENOTYPE	1	1	hypertension
NCT0014426124	NCT00144261_24_T0	PHENOTYPE	1	1	hypertriglyceridemia
NCT0014426128	NCT00144261_28_T0	PHENOTYPE	2	3	hepatitis B
NCT0014426128	NCT00144261_28_T1	PHENOTYPE	0	2	Chronic active hepatitis
NCT0014426130	NCT00144261_30_T0	PHENOTYPE	0	0	Anemia
NCT0014426130	NCT00144261_30_T1	GENE	7	7	hematocrit
NCT0014426130	NCT00144261_30_T2	GENE	1	1	Hb
NCT0014426132	NCT00144261_32_T0	PHENOTYPE	4	4	neoplasm
NCT0014426132	NCT00144261_32_T1	PHENOTYPE	22	23	progressive disease
NCT0014426132	NCT00144261_32_T2	PHENOTYPE	1	2	opportunistic infection
NCT0014426132	NCT00144261_32_T3	PHENOTYPE	17	18	Kaposi's sarcoma
NCT0014426134	NCT00144261_34_T0	PHENOTYPE	5	5	infarction
NCT0014426134	NCT00144261_34_T1	PHENOTYPE	6	7	heart failure
NCT0014426134	NCT00144261_34_T2	PHENOTYPE	3	4	cardiovascular disease
NCT0014426134	NCT00144261_34_T3	PHENOTYPE	8	10	peripheral vascular disease
NCT0014426135	NCT00144261_35_T0	ORGAN	3	3	thyroid
NCT0014426137	NCT00144261_37_T0	COMPOUND	3	3	coumarin
NCT0014426137	NCT00144261_37_T1	PHENOTYPE	1	1	anticoagulation
NCT0014426139	NCT00144261_39_T0	GENE	3	3	CD4
NCT0014426139	NCT00144261_39_T1	GENE	5	5	250
NCT0014426140	NCT00144261_40_T0	GENE	3	3	CD4
NCT0014426140	NCT00144261_40_T1	GENE	5	5	400
NCT001442746	NCT00144274_6_T0	COMPOUND	21	21	1st
NCT001442748	NCT00144274_8_T0	PHENOTYPE	6	6	acute
NCT001442748	NCT00144274_8_T1	PHENOTYPE	3	4	sore throat
NCT001442748	NCT00144274_8_T2	PHENOTYPE	7	8	viral pharyngitis
NCT0014427423	NCT00144274_23_T0	GENE	5	5	NOT
NCT0014427423	NCT00144274_23_T1	GENE	14	14	NOT
NCT0014427427	NCT00144274_27_T0	PHENOTYPE	2	2	symptoms
NCT0014427427	NCT00144274_27_T1	PHENOTYPE	12	13	clinical findings
NCT0014427427	NCT00144274_27_T2	PHENOTYPE	5	6	bacterial pharyngitis
NCT0014427429	NCT00144274_29_T0	PHENOTYPE	3	3	symptoms
NCT0014427429	NCT00144274_29_T1	PHENOTYPE	8	9	sore throat
NCT0014427429	NCT00144274_29_T2	PHENOTYPE	5	6	acute pharyngitis
NCT0014427431	NCT00144274_31_T0	PHENOTYPE	4	4	acute
NCT0014427431	NCT00144274_31_T1	PHENOTYPE	2	2	suffered
NCT0014427431	NCT00144274_31_T2	PHENOTYPE	7	8	bacterial pharyngitis
NCT0014427433	NCT00144274_33_T0	GENE	21	21	fo
NCT0014427434	NCT00144274_34_T0	GENE	2	2	ical
NCT0014427440	NCT00144274_40_T0	PHENOTYPE	3	3	tumour
NCT001442874	NCT00144287_4_T0	COMPOUND	17	17	tipranavir
NCT001442874	NCT00144287_4_T1	COMPOUND	21	21	ritonavir
NCT001442874	NCT00144287_4_T2	COMPOUND	26	26	ritonavir
NCT001442874	NCT00144287_4_T3	GENE	27	27	BID
NCT001442877	NCT00144287_7_T0	GENE	13	13	had
NCT0014428717	NCT00144287_17_T0	PHENOTYPE	11	11	initiation
NCT001443000	NCT00144300_0_T0	PHENOTYPE	12	13	Parkinson's Disease
NCT001443004	NCT00144300_4_T0	COMPOUND	32	32	levodopa
NCT001443004	NCT00144300_4_T1	COMPOUND	34	34	dopamine
NCT001443004	NCT00144300_4_T2	PHENOTYPE	3	4	Parkinson's disease
NCT001443005	NCT00144300_5_T0	COMPOUND	3	3	dopamine
NCT001443009	NCT00144300_9_T0	ORGAN	8	8	serum
NCT0014430011	NCT00144300_11_T0	GENE	19	19	has
NCT0014430016	NCT00144300_16_T0	PHENOTYPE	6	6	complications
NCT0014430016	NCT00144300_16_T1	PHENOTYPE	3	4	allergic response
NCT0014430017	NCT00144300_17_T0	PHENOTYPE	2	2	syndromes
NCT0014430019	NCT00144300_19_T0	PHENOTYPE	1	2	hepatitis B
NCT0014430019	NCT00144300_19_T1	PHENOTYPE	6	7	hepatitis C
NCT0014430022	NCT00144300_22_T0	PHENOTYPE	3	3	epilepsy
NCT0014430022	NCT00144300_22_T1	PHENOTYPE	4	4	seizure
NCT0014430024	NCT00144300_24_T0	GENE	4	4	III
NCT0014430024	NCT00144300_24_T1	PHENOTYPE	0	2	Congestive heart failure
NCT0014430026	NCT00144300_26_T0	PHENOTYPE	1	1	orthostatic
NCT0014430027	NCT00144300_27_T0	PHENOTYPE	2	3	liver disease
NCT0014430028	NCT00144300_28_T0	PHENOTYPE	0	1	Malignant melanoma
NCT0014430029	NCT00144300_29_T0	COMPOUND	27	27	rasagiline
NCT0014430029	NCT00144300_29_T1	GENE	48	48	Q10
NCT0014430029	NCT00144300_29_T2	GENE	24	24	MAO
NCT0014430029	NCT00144300_29_T3	COMPOUND	29	29	selegiline
NCT0014430029	NCT00144300_29_T4	COMPOUND	47	47	Coenzyme
NCT0014430029	NCT00144300_29_T5	PHENOTYPE	39	40	Parkinson's disease
NCT0014430031	NCT00144300_31_T0	PHENOTYPE	2	2	glaucoma
NCT0014430032	NCT00144300_32_T0	PHENOTYPE	3	3	retinopathy
NCT0014430032	NCT00144300_32_T1	PHENOTYPE	7	8	macular degeneration
NCT0014430034	NCT00144300_34_T0	GENE	9	9	insulin
NCT0014430034	NCT00144300_34_T1	PHENOTYPE	0	1	Diabetes mellitus
NCT0014430036	NCT00144300_36_T0	PHENOTYPE	0	1	Refractive error
NCT0014430037	NCT00144300_37_T0	PHENOTYPE	0	1	Abnormal electroretinogram
NCT001443133	NCT00144313_3_T0	PHENOTYPE	10	10	acute
NCT001443133	NCT00144313_3_T1	PHENOTYPE	14	14	infections
NCT001443133	NCT00144313_3_T2	PHENOTYPE	12	12	chronic
NCT001443133	NCT00144313_3_T3	PHENOTYPE	13	13	HBV
NCT001443133	NCT00144313_3_T4	PHENOTYPE	22	23	chronic infections
NCT001443133	NCT00144313_3_T5	PHENOTYPE	0	1	Hepatitis B
NCT001443134	NCT00144313_4_T0	PHENOTYPE	14	14	Practices
NCT001443134	NCT00144313_4_T1	GENE	7	7	AAP
NCT001443134	NCT00144313_4_T2	COMPOUND	15	15	ACIP
NCT001443134	NCT00144313_4_T3	PHENOTYPE	18	19	hepatitis B
NCT001443135	NCT00144313_5_T0	PHENOTYPE	11	11	immunity
NCT001443135	NCT00144313_5_T1	PHENOTYPE	8	8	HBV
NCT001443135	NCT00144313_5_T2	PHENOTYPE	13	13	HBV
NCT001443135	NCT00144313_5_T3	PHENOTYPE	36	37	drug use
NCT001443137	NCT00144313_7_T0	PHENOTYPE	6	7	hepatitis B
NCT001443139	NCT00144313_9_T0	PHENOTYPE	1	1	5-10
NCT001443139	NCT00144313_9_T1	PHENOTYPE	8	8	concentrations
NCT001443139	NCT00144313_9_T2	PHENOTYPE	14	14	concentrations
NCT0014431310	NCT00144313_10_T0	PHENOTYPE	4	4	concentrations
NCT0014431310	NCT00144313_10_T1	PHENOTYPE	6	6	infections
NCT0014431310	NCT00144313_10_T2	PHENOTYPE	5	5	HBV
NCT0014431310	NCT00144313_10_T3	PHENOTYPE	18	19	hepatitis B
NCT0014431310	NCT00144313_10_T4	PHENOTYPE	26	27	hepatitis B
NCT0014431316	NCT00144313_16_T0	PHENOTYPE	29	29	concentrations
NCT0014431317	NCT00144313_17_T0	GENE	19	19	retained
NCT0014431318	NCT00144313_18_T0	GENE	14	14	booster
NCT0014431319	NCT00144313_19_T0	PHENOTYPE	8	8	concentrations
NCT0014431319	NCT00144313_19_T1	GENE	10	10	booster
NCT0014431319	NCT00144313_19_T2	PHENOTYPE	19	20	hepatitis B
NCT0014431320	NCT00144313_20_T0	PHENOTYPE	23	23	HBV
NCT0014431320	NCT00144313_20_T1	PHENOTYPE	7	8	hepatitis B
NCT0014431320	NCT00144313_20_T2	PHENOTYPE	32	33	drug use
NCT0014431321	NCT00144313_21_T0	PHENOTYPE	9	9	HBV
NCT0014431321	NCT00144313_21_T1	GENE	19	19	booster
NCT0014431323	NCT00144313_23_T0	PHENOTYPE	3	3	concentrations
NCT0014431323	NCT00144313_23_T1	PHENOTYPE	18	19	hepatitis B
NCT0014431325	NCT00144313_25_T0	GENE	7	7	booster
NCT0014431325	NCT00144313_25_T1	PHENOTYPE	11	12	hepatitis B
NCT0014431325	NCT00144313_25_T2	PHENOTYPE	29	30	hepatitis B
NCT0014431328	NCT00144313_28_T0	PHENOTYPE	0	0	Secondary
NCT0014431329	NCT00144313_29_T0	GENE	6	6	booster
NCT0014431329	NCT00144313_29_T1	GENE	30	30	booster
NCT0014431329	NCT00144313_29_T2	COMPOUND	13	13	1
NCT0014431329	NCT00144313_29_T3	COMPOUND	20	20	2
NCT0014431329	NCT00144313_29_T4	PHENOTYPE	9	10	hepatitis B
NCT0014431331	NCT00144313_31_T0	PHENOTYPE	11	12	hepatitis B
NCT0014431333	NCT00144313_33_T0	PHENOTYPE	22	22	HBV
NCT001443262	NCT00144326_2_T0	COMPOUND	12	12	tiotropium
NCT001443266	NCT00144326_6_T0	GENE	3	3	null
NCT001443266	NCT00144326_6_T1	COMPOUND	13	13	Spiriva
NCT001443266	NCT00144326_6_T2	COMPOUND	12	12	tiotropium
NCT001443267	NCT00144326_7_T0	COMPOUND	11	11	Spiriva
NCT001443267	NCT00144326_7_T1	COMPOUND	10	10	tiotropium
NCT0014432612	NCT00144326_12_T0	PHENOTYPE	2	3	eosinophil count
NCT001443522	NCT00144352_2_T0	PHENOTYPE	7	7	HIV
NCT001443523	NCT00144352_3_T0	PHENOTYPE	16	16	infections
NCT001443523	NCT00144352_3_T1	PHENOTYPE	7	7	malaria
NCT001443525	NCT00144352_5_T0	PHENOTYPE	18	18	HIV
NCT001443525	NCT00144352_5_T1	PHENOTYPE	13	13	infections
NCT001443525	NCT00144352_5_T2	PHENOTYPE	34	34	infections
NCT001443525	NCT00144352_5_T3	PHENOTYPE	12	12	malaria
NCT0014435211	NCT00144352_11_T0	COMPOUND	7	7	quinine
NCT0014435211	NCT00144352_11_T1	PHENOTYPE	10	10	parasitemia
NCT0014435212	NCT00144352_12_T0	PHENOTYPE	9	9	pharmacokinetics
NCT0014435216	NCT00144352_16_T0	PHENOTYPE	4	4	fever
NCT0014435217	NCT00144352_17_T0	PHENOTYPE	22	22	peripheral
NCT0014435217	NCT00144352_17_T1	PHENOTYPE	11	11	asexual
NCT0014435219	NCT00144352_19_T0	PHENOTYPE	3	6	allergy to sulfa drugs
NCT0014435220	NCT00144352_20_T0	PHENOTYPE	2	2	HIV
NCT0014435221	NCT00144352_21_T0	GENE	5	5	yrs
NCT0014435223	NCT00144352_23_T0	PHENOTYPE	2	3	allergic reactions
NCT0014435224	NCT00144352_24_T0	PHENOTYPE	4	4	malaria
NCT0014435225	NCT00144352_25_T0	PHENOTYPE	3	3	fever
NCT001443651	NCT00144365_1_T0	PHENOTYPE	12	12	HIV
NCT001443651	NCT00144365_1_T1	PHENOTYPE	10	10	strategies
NCT001443652	NCT00144365_2_T0	PHENOTYPE	15	15	HIV
NCT001443652	NCT00144365_2_T1	PHENOTYPE	9	10	disease progression
NCT001443654	NCT00144365_4_T0	PHENOTYPE	13	13	HIV
NCT001443654	NCT00144365_4_T1	PHENOTYPE	10	10	strategies
NCT001443654	NCT00144365_4_T2	ORGAN	12	12	plasma
NCT001443655	NCT00144365_5_T0	PHENOTYPE	15	15	HIV
NCT001443655	NCT00144365_5_T1	PHENOTYPE	9	10	disease progression
NCT001443783	NCT00144378_3_T0	COMPOUND	5	5	irinotecan
NCT001443911	NCT00144391_1_T0	PHENOTYPE	1	1	secondary
NCT001443911	NCT00144391_1_T1	COMPOUND	9	9	testosterone
NCT001443915	NCT00144391_5_T0	PHENOTYPE	19	19	libido
NCT001443916	NCT00144391_6_T0	COMPOUND	17	17	testosterone
NCT001443916	NCT00144391_6_T1	GENE	6	6	hormone
NCT001443918	NCT00144391_8_T0	GENE	6	6	gel
NCT0014439110	NCT00144391_10_T0	COMPOUND	16	16	3
NCT0014439111	NCT00144391_11_T0	GENE	28	28	insulin
NCT0014439111	NCT00144391_11_T1	COMPOUND	37	37	cortisol
NCT0014439111	NCT00144391_11_T2	PHENOTYPE	19	20	cardiovascular disease
NCT0014439111	NCT00144391_11_T3	PHENOTYPE	13	14	insulin tolerance
NCT0014439111	NCT00144391_11_T4	PHENOTYPE	46	47	glucose level
NCT0014439111	NCT00144391_11_T5	PHENOTYPE	58	59	adrenal insufficiency
NCT0014439112	NCT00144391_12_T0	GENE	44	44	GH
NCT0014439112	NCT00144391_12_T1	GENE	19	19	had
NCT0014439114	NCT00144391_14_T0	PHENOTYPE	14	14	oligomenorrhea
NCT0014439114	NCT00144391_14_T1	COMPOUND	17	17	estrogen
NCT0014439114	NCT00144391_14_T2	GENE	11	11	had
NCT0014439114	NCT00144391_14_T3	PHENOTYPE	12	12	amenorrhea
NCT0014439115	NCT00144391_15_T0	GENE	1	1	FAH
NCT0014439116	NCT00144391_16_T0	GENE	17	17	LHRH
NCT0014439116	NCT00144391_16_T1	GENE	26	26	LHRH
NCT0014439116	NCT00144391_16_T2	PHENOTYPE	47	48	gonadotropin insufficiency
NCT0014439123	NCT00144391_23_T0	PHENOTYPE	7	7	hypopituitarism
NCT001444041	NCT00144404_1_T0	PHENOTYPE	22	22	hypopituitarism
NCT001444041	NCT00144404_1_T1	PHENOTYPE	8	9	laboratory abnormalities
NCT001444043	NCT00144404_3_T0	COMPOUND	4	4	testosterone
NCT001444043	NCT00144404_3_T1	PHENOTYPE	10	10	understood
NCT001444045	NCT00144404_5_T0	COMPOUND	10	10	testosterone
NCT001444045	NCT00144404_5_T1	COMPOUND	21	21	testosterone
NCT001444046	NCT00144404_6_T0	COMPOUND	3	3	testosterone
NCT001444047	NCT00144404_7_T0	PHENOTYPE	5	6	androgen deficiency
NCT001444049	NCT00144404_9_T0	COMPOUND	20	20	androgen
NCT001444049	NCT00144404_9_T1	ORGAN	29	29	ovaries
NCT001444049	NCT00144404_9_T2	PHENOTYPE	2	2	hypopituitarism
NCT001444049	NCT00144404_9_T3	PHENOTYPE	18	18	severely
NCT001444049	NCT00144404_9_T4	ORGAN	25	26	adrenal glands
NCT0014440411	NCT00144404_11_T0	COMPOUND	21	21	DHEA
NCT0014440411	NCT00144404_11_T1	COMPOUND	13	13	testosterone
NCT0014440411	NCT00144404_11_T2	BIOLOGICAL_PROCESS	23	23	androstenedione
NCT0014440411	NCT00144404_11_T3	PHENOTYPE	27	27	hypopituitarism
NCT0014440411	NCT00144404_11_T4	COMPOUND	20	20	dehydroepiandrosterone
NCT0014440411	NCT00144404_11_T5	GENE	16	16	DHEAS
NCT0014440411	NCT00144404_11_T6	COMPOUND	14	15	dehydroepiandrosterone sulfate
NCT0014440412	NCT00144404_12_T0	PHENOTYPE	21	21	symptoms
NCT0014440412	NCT00144404_12_T1	PHENOTYPE	8	8	hypopituitarism
NCT0014440412	NCT00144404_12_T2	PHENOTYPE	25	26	androgen deficiency
NCT0014440412	NCT00144404_12_T3	PHENOTYPE	11	12	decreased libido
NCT0014440412	NCT00144404_12_T4	PHENOTYPE	18	20	quality of life
NCT0014440413	NCT00144404_13_T0	PHENOTYPE	15	15	hypopituitarism
NCT0014440414	NCT00144404_14_T0	COMPOUND	17	17	testosterone
NCT0014440414	NCT00144404_14_T1	PHENOTYPE	14	14	hypopituitarism
NCT0014440415	NCT00144404_15_T0	COMPOUND	3	3	testosterone
NCT0014440415	NCT00144404_15_T1	COMPOUND	26	26	testosterone
NCT0014440415	NCT00144404_15_T2	PHENOTYPE	12	12	hypopituitarism
NCT0014440416	NCT00144404_16_T0	PHENOTYPE	25	25	toxicity
NCT0014440416	NCT00144404_16_T1	COMPOUND	6	6	testosterone
NCT0014440416	NCT00144404_16_T2	COMPOUND	14	14	testosterone
NCT0014440416	NCT00144404_16_T3	ORGAN	24	24	liver
NCT0014440418	NCT00144404_18_T0	COMPOUND	5	5	testosterone
NCT0014440418	NCT00144404_18_T1	ORGAN	4	4	serum
NCT0014440419	NCT00144404_19_T0	COMPOUND	7	7	testosterone
NCT0014440419	NCT00144404_19_T1	COMPOUND	12	12	testosterone
NCT0014440419	NCT00144404_19_T2	COMPOUND	21	21	testosterone
NCT0014440419	NCT00144404_19_T3	ORGAN	20	20	serum
NCT0014440419	NCT00144404_19_T4	GENE	13	13	gel
NCT0014440420	NCT00144404_20_T0	COMPOUND	4	4	testosterone
NCT0014440420	NCT00144404_20_T1	GENE	5	5	gel
NCT0014440425	NCT00144404_25_T0	COMPOUND	5	5	testosterone
NCT0014440425	NCT00144404_25_T1	COMPOUND	15	15	testosterone
NCT0014440425	NCT00144404_25_T2	GENE	6	6	gel
NCT0014440430	NCT00144404_30_T0	PHENOTYPE	7	7	hypopituitarism
NCT001444170	NCT00144417_0_T0	GENE	2	2	28
NCT001444170	NCT00144417_0_T1	COMPOUND	0	0	TBTC
NCT001444173	NCT00144417_3_T0	PHENOTYPE	3	4	antimicrobial activity
NCT001444174	NCT00144417_4_T0	COMPOUND	22	22	moxifloxacin
NCT001444177	NCT00144417_7_T0	COMPOUND	1	1	fluoroquinolone
NCT001444177	NCT00144417_7_T1	PHENOTYPE	8	8	tuberculosis
NCT001444177	NCT00144417_7_T2	PHENOTYPE	10	10	tuberculosis
NCT001444178	NCT00144417_8_T0	GENE	22	22	half-life
NCT001444178	NCT00144417_8_T1	PHENOTYPE	16	16	tuberculosis
NCT001444178	NCT00144417_8_T2	GENE	6	6	has
NCT001444178	NCT00144417_8_T3	ORGAN	21	21	serum
NCT001444178	NCT00144417_8_T4	COMPOUND	5	5	moxifloxacin
NCT001444178	NCT00144417_8_T5	PHENOTYPE	39	40	hepatic insufficiency
NCT001444179	NCT00144417_9_T0	COMPOUND	13	13	isoniazid
NCT001444179	NCT00144417_9_T1	COMPOUND	36	36	isoniazid
NCT001444179	NCT00144417_9_T2	PHENOTYPE	7	7	tuberculosis
NCT001444179	NCT00144417_9_T3	COMPOUND	38	38	pyrazinamide
NCT001444179	NCT00144417_9_T4	COMPOUND	11	11	moxifloxacin
NCT0014441710	NCT00144417_10_T0	PHENOTYPE	10	10	tuberculosis
NCT0014441710	NCT00144417_10_T1	GENE	2	2	has
NCT0014441710	NCT00144417_10_T2	COMPOUND	1	1	moxifloxacin
NCT0014441712	NCT00144417_12_T0	PHENOTYPE	14	14	tuberculosis
NCT0014441713	NCT00144417_13_T0	COMPOUND	2	2	pyrazinamide
NCT0014441714	NCT00144417_14_T0	COMPOUND	16	16	moxifloxacin
NCT0014441714	NCT00144417_14_T1	PHENOTYPE	13	14	antimicrobial activity
NCT0014441717	NCT00144417_17_T0	PHENOTYPE	5	5	tuberculosis
NCT0014441717	NCT00144417_17_T1	PHENOTYPE	10	11	pulmonary disease
NCT001444301	NCT00144430_1_T0	CELL	18	18	lymphocytes
NCT001444301	NCT00144430_1_T1	COMPOUND	19	19	pentostatin
NCT001444301	NCT00144430_1_T2	PHENOTYPE	31	31	GVHD
NCT001444301	NCT00144430_1_T3	PHENOTYPE	30	30	chronic
NCT001444302	NCT00144430_2_T0	PHENOTYPE	7	7	toxicity
NCT001444302	NCT00144430_2_T1	PHENOTYPE	0	0	Secondary
NCT001444302	NCT00144430_2_T2	PHENOTYPE	28	28	GVHD
NCT001444302	NCT00144430_2_T3	PHENOTYPE	32	32	QOL
NCT001444302	NCT00144430_2_T4	COMPOUND	10	10	pentostatin
NCT001444302	NCT00144430_2_T5	PHENOTYPE	33	33	impairment
NCT001444302	NCT00144430_2_T6	PHENOTYPE	27	27	chronic
NCT001444302	NCT00144430_2_T7	PHENOTYPE	21	22	severe myelosuppression
NCT001444303	NCT00144430_3_T0	COMPOUND	13	13	pentostatin
NCT001444303	NCT00144430_3_T1	PHENOTYPE	11	11	GVHD
NCT001444303	NCT00144430_3_T2	PHENOTYPE	10	10	chronic
NCT001444307	NCT00144430_7_T0	COMPOUND	5	5	pentostatin
NCT001444308	NCT00144430_8_T0	GENE	4	4	had
NCT001444308	NCT00144430_8_T1	GENE	3	3	has
NCT001444309	NCT00144430_9_T0	COMPOUND	19	19	pentostatin
NCT001444309	NCT00144430_9_T1	GENE	4	4	had
NCT001444309	NCT00144430_9_T2	GENE	3	3	has
NCT0014443013	NCT00144430_13_T0	PHENOTYPE	4	4	centers
NCT0014443013	NCT00144430_13_T1	PHENOTYPE	15	15	GVHD
NCT0014443014	NCT00144430_14_T0	PHENOTYPE	9	9	sclerosis
NCT0014443014	NCT00144430_14_T1	GENE	34	34	ROM
NCT0014443014	NCT00144430_14_T2	PHENOTYPE	11	13	poor wound healing
NCT0014443015	NCT00144430_15_T0	PHENOTYPE	2	2	GVHD
NCT0014443016	NCT00144430_16_T0	PHENOTYPE	11	11	remission
NCT0014443016	NCT00144430_16_T1	PHENOTYPE	19	19	GVHD
NCT0014443021	NCT00144430_21_T0	PHENOTYPE	9	9	acute
NCT0014443021	NCT00144430_21_T1	PHENOTYPE	21	21	erythema
NCT0014443021	NCT00144430_21_T2	PHENOTYPE	10	10	GVHD
NCT0014443021	NCT00144430_21_T3	PHENOTYPE	29	29	GVHD
NCT0014443021	NCT00144430_21_T4	PHENOTYPE	28	28	chronic
NCT001444433	NCT00144443_3_T0	PHENOTYPE	20	20	asthma
NCT001444433	NCT00144443_3_T1	PHENOTYPE	18	19	lead poisoning
NCT001444433	NCT00144443_3_T2	PHENOTYPE	22	23	home injuries
NCT001444434	NCT00144443_4_T0	PHENOTYPE	16	16	strategies
NCT001444435	NCT00144443_5_T0	PHENOTYPE	22	22	asthma
NCT001444435	NCT00144443_5_T1	PHENOTYPE	24	24	asthma
NCT001444435	NCT00144443_5_T2	PHENOTYPE	45	45	asthma
NCT0014444310	NCT00144443_10_T0	PHENOTYPE	17	17	CMH
NCT0014444311	NCT00144443_11_T0	PHENOTYPE	11	12	respiratory problems
NCT0014444315	NCT00144443_15_T0	PHENOTYPE	17	17	strategies
NCT0014444317	NCT00144443_17_T0	PHENOTYPE	40	40	Center
NCT0014444322	NCT00144443_22_T0	PHENOTYPE	33	33	Allergy
NCT0014444322	NCT00144443_22_T1	PHENOTYPE	28	28	CMH
NCT0014444322	NCT00144443_22_T2	PHENOTYPE	32	32	CMH
NCT0014444322	NCT00144443_22_T3	PHENOTYPE	36	36	CMH
NCT0014444322	NCT00144443_22_T4	PHENOTYPE	0	0	Recruitment
NCT0014444324	NCT00144443_24_T0	PHENOTYPE	5	5	CMH
NCT0014444329	NCT00144443_29_T0	GENE	28	28	structural
NCT0014444339	NCT00144443_39_T0	COMPOUND	2	2	1
NCT0014444339	NCT00144443_39_T1	COMPOUND	15	15	1
NCT0014444339	NCT00144443_39_T2	PHENOTYPE	9	9	chronic
NCT0014444339	NCT00144443_39_T3	PHENOTYPE	10	12	symptoms in children
NCT0014444341	NCT00144443_41_T0	PHENOTYPE	1	1	severity
NCT0014444341	NCT00144443_41_T1	PHENOTYPE	0	0	Asthma
NCT0014444343	NCT00144443_43_T0	PHENOTYPE	1	2	lead level
NCT0014444348	NCT00144443_48_T0	PHENOTYPE	0	2	Quality of life
NCT0014444349	NCT00144443_49_T0	COMPOUND	10	10	2
NCT0014444349	NCT00144443_49_T1	GENE	8	8	al
NCT0014444349	NCT00144443_49_T2	PHENOTYPE	0	0	Asthma
NCT0014444349	NCT00144443_49_T3	GENE	7	7	et
NCT0014444349	NCT00144443_49_T4	PHENOTYPE	2	4	quality of life
NCT0014444353	NCT00144443_53_T0	GENE	6	6	trap
NCT0014444353	NCT00144443_53_T1	CELL	1	1	spore
NCT0014444353	NCT00144443_53_T2	CELL	5	5	spore
NCT0014444354	NCT00144443_54_T0	COMPOUND	10	10	3
NCT0014444355	NCT00144443_55_T0	PHENOTYPE	2	3	environmental exposure
NCT0014444357	NCT00144443_57_T0	GENE	11	11	allergen
NCT0014444363	NCT00144443_63_T0	GENE	6	6	trap
NCT0014444363	NCT00144443_63_T1	CELL	1	1	spore
NCT0014444363	NCT00144443_63_T2	CELL	5	5	spore
NCT0014444366	NCT00144443_66_T0	GENE	28	28	structural
NCT001444560	NCT00144456_0_T0	PHENOTYPE	7	7	Osteoporosis
NCT001444690	NCT00144469_0_T0	PHENOTYPE	12	14	Chronic Hepatitis C
NCT001445080	NCT00144508_0_T0	GENE	1	1	III
NCT001445080	NCT00144508_0_T1	PHENOTYPE	5	5	MRA
NCT001445085	NCT00144508_5_T0	ORGAN	1	1	Plasma
NCT001445213	NCT00144521_3_T0	GENE	8	8	MTX
NCT001445214	NCT00144521_4_T0	COMPOUND	7	7	prednisolone
NCT001445216	NCT00144521_6_T0	ORGAN	0	0	Plasma
NCT001446254	NCT00144625_4_T0	ORGAN	0	0	Plasma
NCT001446381	NCT00144638_1_T0	GENE	3	3	som
NCT001446381	NCT00144638_1_T1	GENE	1	1	has
NCT001446381	NCT00144638_1_T2	PHENOTYPE	21	21	sepsis
NCT001446383	NCT00144638_3_T0	COMPOUND	1	1	Procalcitonin
NCT001446385	NCT00144638_5_T0	PHENOTYPE	11	11	sepsis
NCT001446385	NCT00144638_5_T1	PHENOTYPE	18	18	sepsis
NCT001446385	NCT00144638_5_T2	PHENOTYPE	20	20	dysfunction
NCT0014463812	NCT00144638_12_T0	PHENOTYPE	25	25	severity
NCT0014463812	NCT00144638_12_T1	GENE	11	11	procalcitonin
NCT0014463812	NCT00144638_12_T2	GENE	4	4	al
NCT0014463812	NCT00144638_12_T3	ORGAN	10	10	serum
NCT0014463812	NCT00144638_12_T4	GENE	3	3	et
NCT0014463812	NCT00144638_12_T5	PHENOTYPE	19	20	bacterial infection
NCT0014463819	NCT00144638_19_T0	PHENOTYPE	33	33	secondary
NCT0014463822	NCT00144638_22_T0	PHENOTYPE	1	1	sepsis
NCT0014463826	NCT00144638_26_T0	PHENOTYPE	6	6	secondary
NCT0014463829	NCT00144638_29_T0	ORGAN	7	7	serum
NCT0014463834	NCT00144638_34_T0	PHENOTYPE	32	32	tolerance
NCT0014463834	NCT00144638_34_T1	PHENOTYPE	8	8	sepsis
NCT0014463834	NCT00144638_34_T2	PHENOTYPE	41	41	foci
NCT0014463834	NCT00144638_34_T3	PHENOTYPE	29	30	clinical findings
NCT001446514	NCT00144651_4_T0	ORGAN	0	0	Plasma
NCT001446771	NCT00144677_1_T0	PHENOTYPE	22	22	toxicity
NCT001446771	NCT00144677_1_T1	ORGAN	21	21	transplant
NCT001446771	NCT00144677_1_T2	COMPOUND	11	11	methotrexate
NCT001446771	NCT00144677_1_T3	PHENOTYPE	30	30	GVHD
NCT001446771	NCT00144677_1_T4	PHENOTYPE	9	9	elimination
NCT001446901	NCT00144690_1_T0	PHENOTYPE	1	1	secondary
NCT001446901	NCT00144690_1_T1	PHENOTYPE	12	12	pharmacokinetics
NCT001446904	NCT00144690_4_T0	ORGAN	6	6	serum
NCT001446904	NCT00144690_4_T1	COMPOUND	8	9	chorionic gonadotropin
NCT001446908	NCT00144690_8_T0	PHENOTYPE	11	11	seizures
NCT001446908	NCT00144690_8_T1	GENE	7	7	had
NCT001447033	NCT00144703_3_T0	PHENOTYPE	14	14	GVHD
NCT001447164	NCT00144716_4_T0	COMPOUND	21	21	lotion
NCT001447164	NCT00144716_4_T1	GENE	16	16	has
NCT001447165	NCT00144716_5_T0	PHENOTYPE	6	6	malaria
NCT001447165	NCT00144716_5_T1	PHENOTYPE	12	12	malaria
NCT001447168	NCT00144716_8_T0	PHENOTYPE	12	12	susceptible
NCT0014471619	NCT00144716_19_T0	PHENOTYPE	0	0	Recruitment
NCT0014471630	NCT00144716_30_T0	PHENOTYPE	9	9	centre
NCT0014471632	NCT00144716_32_T0	PHENOTYPE	40	40	centres
NCT001447552	NCT00144755_2_T0	GENE	20	20	EFS
NCT001447552	NCT00144755_2_T1	PHENOTYPE	15	15	remission
NCT001447552	NCT00144755_2_T2	GENE	6	6	CHOP
NCT001447552	NCT00144755_2_T3	GENE	8	8	has
NCT001447552	NCT00144755_2_T4	GENE	17	17	CR
NCT001447554	NCT00144755_4_T0	PHENOTYPE	0	0	Anemia
NCT001447554	NCT00144755_4_T1	PHENOTYPE	10	11	aggressive lymphoma
NCT001447555	NCT00144755_5_T0	GENE	11	11	had
NCT001447555	NCT00144755_5_T1	PHENOTYPE	16	17	hemoglobin level
NCT001447556	NCT00144755_6_T0	GENE	9	9	had
NCT001447556	NCT00144755_6_T1	PHENOTYPE	11	12	hemoglobin level
NCT001447557	NCT00144755_7_T0	PHENOTYPE	3	3	anemia
NCT001447558	NCT00144755_8_T0	PHENOTYPE	12	12	tumor
NCT001447559	NCT00144755_9_T0	PHENOTYPE	1	1	hypoxia
NCT001447559	NCT00144755_9_T1	PHENOTYPE	8	8	anemia
NCT0014475511	NCT00144755_11_T0	PHENOTYPE	9	9	inhibition
NCT0014475514	NCT00144755_14_T0	PHENOTYPE	24	27	head and neck cancer
NCT0014475515	NCT00144755_15_T0	TISSUE	7	7	tissues
NCT0014475516	NCT00144755_16_T0	BIOLOGICAL_PROCESS	8	8	erythropoiesis
NCT0014475517	NCT00144755_17_T0	GENE	12	12	CR
NCT0014475517	NCT00144755_17_T1	GENE	14	14	EFS
NCT0014475517	NCT00144755_17_T2	PHENOTYPE	21	24	diffuse large B-cell lymphoma
NCT0014475522	NCT00144755_22_T0	GENE	0	0	Ann
NCT0014475522	NCT00144755_22_T1	GENE	3	3	II
NCT0014475522	NCT00144755_22_T2	GENE	4	4	III
NCT0014475522	NCT00144755_22_T3	GENE	5	5	IV
NCT0014475528	NCT00144755_28_T0	PHENOTYPE	7	7	lymphoma
NCT0014475529	NCT00144755_29_T0	PHENOTYPE	7	7	lymphoma
NCT0014475531	NCT00144755_31_T0	PHENOTYPE	7	7	lymphoma
NCT0014475531	NCT00144755_31_T1	ORGAN	0	2	Central nervous system
NCT0014475536	NCT00144755_36_T0	PHENOTYPE	15	15	tumors
NCT0014475536	NCT00144755_36_T1	PHENOTYPE	13	14	melanoma skin
NCT0014475536	NCT00144755_36_T2	PHENOTYPE	21	22	cervical carcinoma
NCT0014475536	NCT00144755_36_T3	PHENOTYPE	17	18	stage 0
NCT0014475537	NCT00144755_37_T0	PHENOTYPE	1	1	hypertension
NCT0014475539	NCT00144755_39_T0	PHENOTYPE	0	1	Myocardial infarction
NCT0014475539	NCT00144755_39_T1	PHENOTYPE	8	9	coronary disease
NCT0014475539	NCT00144755_39_T2	PHENOTYPE	12	13	cardiac insufficiency
NCT0014475540	NCT00144755_40_T0	PHENOTYPE	0	1	Venous thrombosis
NCT0014475540	NCT00144755_40_T1	PHENOTYPE	3	4	pulmonary embolism
NCT001447810	NCT00144781_0_T0	PHENOTYPE	13	13	Disease
NCT001447810	NCT00144781_0_T1	PHENOTYPE	9	10	Mucopolysaccharidosis I
NCT001447810	NCT00144781_0_T2	PHENOTYPE	11	12	MPS I
NCT001447940	NCT00144794_0_T0	PHENOTYPE	0	1	Mucopolysaccharidosis I
NCT001447940	NCT00144794_0_T1	PHENOTYPE	2	3	MPS I
NCT001447942	NCT00144794_2_T0	PHENOTYPE	18	18	progression
NCT001447942	NCT00144794_2_T1	PHENOTYPE	5	6	MPS I
NCT001447942	NCT00144794_2_T2	PHENOTYPE	20	21	MPS I
NCT001448071	NCT00144807_1_T0	GENE	18	18	2.3
NCT001448072	NCT00144807_2_T0	PHENOTYPE	13	13	remission
NCT001448073	NCT00144807_3_T0	PHENOTYPE	20	20	toxicity
NCT001448073	NCT00144807_3_T1	PHENOTYPE	16	16	remission
NCT001448073	NCT00144807_3_T2	COMPOUND	9	9	cyclophosphamide
NCT001448073	NCT00144807_3_T3	COMPOUND	5	5	etoposide
NCT001448073	NCT00144807_3_T4	COMPOUND	7	7	doxorubicin
NCT001448076	NCT00144807_6_T0	PHENOTYPE	33	33	toxicities
NCT001448076	NCT00144807_6_T1	GENE	15	15	CR
NCT001448076	NCT00144807_6_T2	GENE	29	29	CHOP
NCT001448076	NCT00144807_6_T3	GENE	1	1	has
NCT001448076	NCT00144807_6_T4	COMPOUND	10	11	CHOP regimen
NCT001448076	NCT00144807_6_T5	PHENOTYPE	24	25	B-cell lymphoma
NCT0014480712	NCT00144807_12_T0	ORGAN	8	8	transplant
NCT0014480716	NCT00144807_16_T0	PHENOTYPE	8	9	indolent lymphoma
NCT0014480718	NCT00144807_18_T0	PHENOTYPE	7	7	lymphoma
NCT0014480718	NCT00144807_18_T1	ORGAN	0	2	Central nervous system
NCT0014480721	NCT00144807_21_T0	GENE	12	12	100
NCT0014480721	NCT00144807_21_T1	GENE	8	8	1.5
NCT0014480721	NCT00144807_21_T2	CELL	7	7	neutrophils
NCT0014480721	NCT00144807_21_T3	CELL	11	11	platelets
NCT0014480721	NCT00144807_21_T4	PHENOTYPE	19	19	infiltration
NCT0014480721	NCT00144807_21_T5	ORGAN	1	2	bone marrow
NCT0014480721	NCT00144807_21_T6	ORGAN	17	18	bone marrow
NCT0014480722	NCT00144807_22_T0	PHENOTYPE	15	15	tumors
NCT0014480722	NCT00144807_22_T1	PHENOTYPE	13	14	melanoma skin
NCT0014480722	NCT00144807_22_T2	PHENOTYPE	21	22	cervical carcinoma
NCT0014480722	NCT00144807_22_T3	PHENOTYPE	17	18	stage 0
NCT001448203	NCT00144820_3_T0	TISSUE	5	5	cartilage
NCT001448203	NCT00144820_3_T1	BIOLOGICAL_PROCESS	6	6	degradation
NCT001448330	NCT00144833_0_T0	PHENOTYPE	16	16	HIV
NCT001448332	NCT00144833_2_T0	COMPOUND	18	18	fosamprenavir
NCT001448332	NCT00144833_2_T1	COMPOUND	24	24	fosamprenavir
NCT001448460	NCT00144846_0_T0	PHENOTYPE	4	4	Acute
NCT001448460	NCT00144846_0_T1	PHENOTYPE	5	5	Wheezing
NCT001448460	NCT00144846_0_T2	PHENOTYPE	9	10	Airways Disease
NCT001448462	NCT00144846_2_T0	PHENOTYPE	16	16	acute
NCT001448462	NCT00144846_2_T1	PHENOTYPE	17	17	wheezing
NCT001448462	NCT00144846_2_T2	PHENOTYPE	21	22	airways disease
NCT001448465	NCT00144846_5_T0	COMPOUND	8	8	glucose
NCT001448465	NCT00144846_5_T1	COMPOUND	18	18	glucose
NCT001448465	NCT00144846_5_T2	COMPOUND	13	13	potassium
NCT001448465	NCT00144846_5_T3	PHENOTYPE	4	5	serum potassium
NCT001448724	NCT00144872_4_T0	PHENOTYPE	14	14	seizure
NCT001448724	NCT00144872_4_T1	PHENOTYPE	19	19	hyperventilation
NCT001448726	NCT00144872_6_T0	PHENOTYPE	5	5	seizure
NCT001448729	NCT00144872_9_T0	COMPOUND	12	12	lamotrigine
NCT001448729	NCT00144872_9_T1	ORGAN	11	11	serum
NCT001448729	NCT00144872_9_T2	PHENOTYPE	6	7	adverse events
NCT001448850	NCT00144885_0_T0	PHENOTYPE	6	6	Acute
NCT001448850	NCT00144885_0_T1	PHENOTYPE	9	9	Endocarditis
NCT001448853	NCT00144885_3_T0	ORGAN	5	5	abdomen
NCT001448854	NCT00144885_4_T0	GENE	14	14	pre
NCT001448981	NCT00144898_1_T0	PHENOTYPE	25	26	sentinel node
NCT001449110	NCT00144911_0_T0	PHENOTYPE	14	17	Chronic Obstructive Pulmonary Disease
NCT001449111	NCT00144911_1_T0	GENE	11	11	GSK
NCT001449375	NCT00144937_5_T0	COMPOUND	14	14	1
NCT001449375	NCT00144937_5_T1	COMPOUND	19	19	2
NCT001449379	NCT00144937_9_T0	GENE	19	19	Parc
NCT0014493711	NCT00144937_11_T0	PHENOTYPE	23	23	secondary
NCT0014493711	NCT00144937_11_T1	GENE	14	14	2.4
NCT001449634	NCT00144963_4_T0	GENE	11	11	MTD
NCT001449637	NCT00144963_7_T0	PHENOTYPE	9	9	symptoms
NCT001449637	NCT00144963_7_T1	PHENOTYPE	6	6	progression
NCT001449893	NCT00144989_3_T0	GENE	12	12	EP
NCT001449893	NCT00144989_3_T1	GENE	2	2	12/8
NCT001449894	NCT00144989_4_T0	GENE	11	11	EP
NCT001450023	NCT00145002_3_T0	PHENOTYPE	23	23	peripheral
NCT001450023	NCT00145002_3_T1	PHENOTYPE	25	25	malignancy
NCT001450023	NCT00145002_3_T2	BIOLOGICAL_PROCESS	17	17	agglutination
NCT001450023	NCT00145002_3_T3	GENE	2	2	ATL
NCT001450023	NCT00145002_3_T4	CELL	24	24	T-cell
NCT001450024	NCT00145002_4_T0	PHENOTYPE	3	3	acute
NCT001450024	NCT00145002_4_T1	PHENOTYPE	4	4	lymphoma
NCT001450024	NCT00145002_4_T2	GENE	1	1	ATL
NCT001450024	NCT00145002_4_T3	GENE	8	8	ATL
NCT001450027	NCT00145002_7_T0	PHENOTYPE	15	15	hypercalcemia
NCT001450027	NCT00145002_7_T1	GENE	8	8	0.3
NCT001450027	NCT00145002_7_T2	PHENOTYPE	2	2	Oncology
NCT001450028	NCT00145002_8_T0	ORGAN	5	5	kidney
NCT001450028	NCT00145002_8_T1	ORGAN	4	4	liver
NCT001450028	NCT00145002_8_T2	ORGAN	6	6	heart
NCT001450028	NCT00145002_8_T3	ORGAN	2	3	bone marrow
NCT0014500210	NCT00145002_10_T0	GENE	5	5	insulin
NCT0014500210	NCT00145002_10_T1	PHENOTYPE	0	1	Diabetes mellitus
NCT0014500211	NCT00145002_11_T0	PHENOTYPE	1	2	systemic infection
NCT0014500212	NCT00145002_12_T0	PHENOTYPE	0	1	Cardiac disorders
NCT0014500213	NCT00145002_13_T0	PHENOTYPE	2	3	chronic hepatitis
NCT0014500213	NCT00145002_13_T1	PHENOTYPE	0	1	Acute hepatitis
NCT0014500213	NCT00145002_13_T2	PHENOTYPE	5	6	liver cirrhosis
NCT0014500214	NCT00145002_14_T0	COMPOUND	5	5	HCV
NCT0014500215	NCT00145002_15_T0	PHENOTYPE	2	2	malignancy
NCT001450152	NCT00145015_2_T0	PHENOTYPE	14	14	cancers
NCT001450152	NCT00145015_2_T1	ORGAN	17	18	GI tract
NCT001450154	NCT00145015_4_T0	PHENOTYPE	23	24	colon cancer
NCT001450154	NCT00145015_4_T1	PHENOTYPE	20	21	ulcerative colitis
NCT001450156	NCT00145015_6_T0	GENE	9	9	salmon
NCT001450415	NCT00145041_5_T0	PHENOTYPE	0	0	Secondary
NCT001450542	NCT00145054_2_T0	GENE	6	6	has
NCT001450548	NCT00145054_8_T0	GENE	6	6	has
NCT001450936	NCT00145093_6_T0	PHENOTYPE	5	5	toxicity
NCT001450936	NCT00145093_6_T1	PHENOTYPE	12	12	toxicity
NCT001450937	NCT00145093_7_T0	GENE	5	5	has
NCT001450937	NCT00145093_7_T1	PHENOTYPE	8	9	drug intolerance
NCT001450938	NCT00145093_8_T0	PHENOTYPE	5	6	side effect
NCT001450939	NCT00145093_9_T0	PHENOTYPE	5	6	side effect
NCT0014509312	NCT00145093_12_T0	COMPOUND	17	17	chromium
NCT0014509320	NCT00145093_20_T0	COMPOUND	3	3	chromium
NCT0014509321	NCT00145093_21_T0	COMPOUND	8	8	chromium
NCT0014509322	NCT00145093_22_T0	PHENOTYPE	4	4	ingest
NCT0014509324	NCT00145093_24_T0	TISSUE	0	1	Body fat
NCT0014509325	NCT00145093_25_T0	ORGAN	8	8	feet
NCT0014509326	NCT00145093_26_T0	ORGAN	7	7	feet
NCT0014509327	NCT00145093_27_T0	COMPOUND	9	9	glucose
NCT0014509327	NCT00145093_27_T1	GENE	11	11	insulin
NCT0014509327	NCT00145093_27_T2	GENE	16	16	HDL
NCT0014509327	NCT00145093_27_T3	COMPOUND	1	1	creatinine
NCT0014509327	NCT00145093_27_T4	GENE	15	15	LDL
NCT0014509327	NCT00145093_27_T5	ORGAN	0	0	Serum
NCT0014509327	NCT00145093_27_T6	GENE	7	7	Hb
NCT0014509327	NCT00145093_27_T7	ORGAN	12	12	serum
NCT0014509328	NCT00145093_28_T0	COMPOUND	8	8	chromium
NCT0014509328	NCT00145093_28_T1	ORGAN	7	7	serum
NCT0014509329	NCT00145093_29_T0	COMPOUND	1	1	citrate
NCT0014509329	NCT00145093_29_T1	ORGAN	3	3	serum
NCT0014509330	NCT00145093_30_T0	COMPOUND	14	14	creatinine
NCT0014509330	NCT00145093_30_T1	GENE	17	17	albumin
NCT0014509331	NCT00145093_31_T0	GENE	5	5	cc
NCT0014509334	NCT00145093_34_T0	GENE	9	9	had
NCT0014509339	NCT00145093_39_T0	GENE	6	6	Hb
NCT0014509341	NCT00145093_41_T0	PHENOTYPE	6	6	withdrawn
NCT001451063	NCT00145106_3_T0	GENE	1	1	reduced
NCT001451067	NCT00145106_7_T0	PHENOTYPE	19	19	acne
NCT0014510610	NCT00145106_10_T0	COMPOUND	10	10	tazarotene
NCT0014510610	NCT00145106_10_T1	COMPOUND	15	15	tazarotene
NCT0014510610	NCT00145106_10_T2	COMPOUND	28	28	tazarotene
NCT0014510610	NCT00145106_10_T3	COMPOUND	12	12	minocycline
NCT0014510610	NCT00145106_10_T4	COMPOUND	18	18	minocycline
NCT0014510610	NCT00145106_10_T5	COMPOUND	31	31	minocycline
NCT001451453	NCT00145145_3_T0	PHENOTYPE	0	0	Tumor
NCT001451454	NCT00145145_4_T0	GENE	0	0	PBL
NCT001451455	NCT00145145_5_T0	CELL	4	5	T lymphocytes
NCT001451456	NCT00145145_6_T0	PHENOTYPE	10	11	tumor progression
NCT001451458	NCT00145145_8_T0	PHENOTYPE	3	3	progression
NCT0014514516	NCT00145145_16_T0	PHENOTYPE	0	0	Melanoma
NCT0014514518	NCT00145145_18_T0	PHENOTYPE	8	8	tumor
NCT0014514518	NCT00145145_18_T1	GENE	15	15	7.3
NCT0014514518	NCT00145145_18_T2	PHENOTYPE	11	12	leptomeningeal metastasis
NCT0014514531	NCT00145145_31_T0	COMPOUND	16	17	mitomycin C
NCT0014514533	NCT00145145_33_T0	GENE	19	19	CTL
NCT0014514535	NCT00145145_35_T0	GENE	6	6	III
NCT0014514535	NCT00145145_35_T1	GENE	8	8	IV
NCT0014514535	NCT00145145_35_T2	PHENOTYPE	2	3	heart disease
NCT0014514541	NCT00145145_41_T0	PHENOTYPE	2	2	acute
NCT0014514541	NCT00145145_41_T1	PHENOTYPE	8	8	infections
NCT0014514541	NCT00145145_41_T2	PHENOTYPE	11	12	bleeding disorders
NCT0014514541	NCT00145145_41_T3	PHENOTYPE	4	5	chronic illnesses
NCT0014514543	NCT00145145_43_T0	PHENOTYPE	1	1	malignancy
NCT0014514543	NCT00145145_43_T1	PHENOTYPE	14	16	melanoma skin cancer
NCT0014514543	NCT00145145_43_T2	PHENOTYPE	18	21	cervical carcinoma in situ
NCT001451585	NCT00145158_5_T0	PHENOTYPE	0	0	Tumor
NCT001451586	NCT00145158_6_T0	GENE	0	0	PBL
NCT001451587	NCT00145158_7_T0	CELL	4	5	T lymphocytes
NCT001451588	NCT00145158_8_T0	PHENOTYPE	9	9	tumor
NCT001451588	NCT00145158_8_T1	GENE	4	4	PCR
NCT001451589	NCT00145158_9_T0	PHENOTYPE	11	11	tumor
NCT001451589	NCT00145158_9_T1	PHENOTYPE	21	22	tumor progression
NCT0014515811	NCT00145158_11_T0	PHENOTYPE	3	3	progression
NCT0014515812	NCT00145158_12_T0	BIOLOGICAL_PROCESS	1	2	immune response
NCT0014515813	NCT00145158_13_T0	GENE	19	19	CTL
NCT0014515813	NCT00145158_13_T1	CELL	18	18	lymphocyte
NCT0014515814	NCT00145158_14_T0	GENE	31	31	CTL
NCT0014515814	NCT00145158_14_T1	GENE	18	18	has
NCT0014515815	NCT00145158_15_T0	PHENOTYPE	14	14	tumor
NCT0014515815	NCT00145158_15_T1	PHENOTYPE	15	15	regressions
NCT0014515823	NCT00145158_23_T0	PHENOTYPE	2	2	tumor
NCT0014515823	NCT00145158_23_T1	GENE	10	10	PCR
NCT0014515825	NCT00145158_25_T0	PHENOTYPE	8	8	tumor
NCT0014515838	NCT00145158_38_T0	COMPOUND	16	17	mitomycin C
NCT0014515840	NCT00145158_40_T0	GENE	6	6	III
NCT0014515840	NCT00145158_40_T1	GENE	8	8	IV
NCT0014515840	NCT00145158_40_T2	PHENOTYPE	2	3	heart disease
NCT0014515846	NCT00145158_46_T0	PHENOTYPE	2	2	acute
NCT0014515846	NCT00145158_46_T1	PHENOTYPE	8	8	infections
NCT0014515846	NCT00145158_46_T2	PHENOTYPE	11	12	bleeding disorders
NCT0014515846	NCT00145158_46_T3	PHENOTYPE	4	5	chronic illnesses
NCT0014515848	NCT00145158_48_T0	PHENOTYPE	1	1	malignancy
NCT0014515848	NCT00145158_48_T1	PHENOTYPE	14	16	melanoma skin cancer
NCT0014515848	NCT00145158_48_T2	PHENOTYPE	18	21	cervical carcinoma in situ
NCT001451710	NCT00145171_0_T0	PHENOTYPE	8	9	Adverse Events
NCT001451713	NCT00145171_3_T0	PHENOTYPE	19	20	adverse events
NCT001451714	NCT00145171_4_T0	COMPOUND	9	9	apomorphine
NCT001451717	NCT00145171_7_T0	PHENOTYPE	3	3	acute
NCT001451717	NCT00145171_7_T1	COMPOUND	12	12	apomorphine
NCT0014517117	NCT00145171_17_T0	PHENOTYPE	18	18	diseases
NCT0014517121	NCT00145171_21_T0	PHENOTYPE	4	4	fluctuations
NCT0014517125	NCT00145171_25_T0	PHENOTYPE	3	3	discomfort
NCT0014517127	NCT00145171_27_T0	PHENOTYPE	2	2	dystonias
NCT0014517131	NCT00145171_31_T0	PHENOTYPE	0	1	Swallowing difficulties
NCT0014517133	NCT00145171_33_T0	PHENOTYPE	2	3	visual hallucinations
NCT0014517135	NCT00145171_35_T0	PHENOTYPE	2	2	dyskinesia
NCT0014517138	NCT00145171_38_T0	GENE	36	36	catechol-O-methyltransferase
NCT0014517138	NCT00145171_38_T1	GENE	33	33	MAOB
NCT0014517138	NCT00145171_38_T2	COMPOUND	5	5	levodopa_carbidopa
NCT0014517138	NCT00145171_38_T3	GENE	38	38	COMT
NCT0014517138	NCT00145171_38_T4	COMPOUND	27	27	dopamine
NCT0014517138	NCT00145171_38_T5	GENE	30	31	monoamine oxidase
NCT0014517142	NCT00145171_42_T0	COMPOUND	5	5	apomorphine
NCT0014517142	NCT00145171_42_T1	COMPOUND	16	16	apomorphine
NCT0014517147	NCT00145171_47_T0	PHENOTYPE	9	9	dementia
NCT0014517147	NCT00145171_47_T1	PHENOTYPE	7	7	psychoses
NCT0014517149	NCT00145171_49_T0	PHENOTYPE	7	8	alcohol dependency
NCT0014517153	NCT00145171_53_T0	COMPOUND	2	2	methyldopa
NCT001451840	NCT00145184_0_T0	PHENOTYPE	11	11	Tuberculosis
NCT001451842	NCT00145184_2_T0	PHENOTYPE	12	12	tuberculosis
NCT001451849	NCT00145184_9_T0	PHENOTYPE	20	20	tuberculosis
NCT0014518410	NCT00145184_10_T0	PHENOTYPE	23	23	tuberculosis
NCT0014518410	NCT00145184_10_T1	PHENOTYPE	30	30	tuberculosis
NCT0014518410	NCT00145184_10_T2	PHENOTYPE	19	20	weight gain
NCT0014518412	NCT00145184_12_T0	GENE	8	8	CD4
NCT0014518412	NCT00145184_12_T1	CELL	10	10	lymphocyte
NCT0014518412	NCT00145184_12_T2	PHENOTYPE	17	18	weight gain
NCT0014518413	NCT00145184_13_T0	BIOLOGICAL_PROCESS	8	9	immune response
NCT001451970	NCT00145197_0_T0	PHENOTYPE	4	5	Breast Cancer
NCT001451973	NCT00145197_3_T0	PHENOTYPE	10	12	stage breast cancer
NCT001451974	NCT00145197_4_T0	GENE	22	22	has
NCT001451976	NCT00145197_6_T0	GENE	3	3	has
NCT001451977	NCT00145197_7_T0	GENE	4	4	has
NCT001451977	NCT00145197_7_T1	GENE	33	33	has
NCT0014519711	NCT00145197_11_T0	PHENOTYPE	1	1	elimination
NCT0014519711	NCT00145197_11_T1	PHENOTYPE	25	27	early-stage breast cancer
NCT0014519714	NCT00145197_14_T0	PHENOTYPE	2	3	breast cancer
NCT0014519714	NCT00145197_14_T1	PHENOTYPE	13	14	breast cancer
NCT0014519719	NCT00145197_19_T0	PHENOTYPE	12	14	early-stage breast cancer
NCT001452106	NCT00145210_6_T0	PHENOTYPE	18	18	hypertension
NCT001452233	NCT00145223_3_T0	PHENOTYPE	11	11	filariasis
NCT001452235	NCT00145223_5_T0	PHENOTYPE	6	6	filariasis
NCT001452235	NCT00145223_5_T1	PHENOTYPE	13	13	filariasis
NCT001452235	NCT00145223_5_T2	PHENOTYPE	14	14	elimination
NCT001452239	NCT00145223_9_T0	PHENOTYPE	11	12	lymphatic filariasis
NCT0014522310	NCT00145223_10_T0	GENE	17	17	DEC
NCT0014522310	NCT00145223_10_T1	PHENOTYPE	20	20	filariasis
NCT0014522310	NCT00145223_10_T2	PHENOTYPE	31	31	filariasis
NCT0014522310	NCT00145223_10_T3	GENE	14	14	ALB
NCT0014522310	NCT00145223_10_T4	COMPOUND	16	16	diethylcarbamazine
NCT0014522311	NCT00145223_11_T0	PHENOTYPE	14	14	filariasis
NCT0014522317	NCT00145223_17_T0	COMPOUND	11	11	albendazole
NCT0014522320	NCT00145223_20_T0	PHENOTYPE	9	9	intensities
NCT0014522321	NCT00145223_21_T0	PHENOTYPE	8	8	filariasis
NCT0014522321	NCT00145223_21_T1	PHENOTYPE	6	6	elimination
NCT001452360	NCT00145236_0_T0	PHENOTYPE	14	14	Mild
NCT001452360	NCT00145236_0_T1	PHENOTYPE	17	17	Hypertension
NCT001452365	NCT00145236_5_T0	GENE	1	1	had
NCT001452491	NCT00145249_1_T0	COMPOUND	17	17	fluconazole
NCT001452491	NCT00145249_1_T1	COMPOUND	7	8	amphotericin B
NCT001452492	NCT00145249_2_T0	COMPOUND	34	34	fluconazole
NCT001452495	NCT00145249_5_T0	GENE	4	4	extended
NCT001452497	NCT00145249_7_T0	GENE	8	8	II
NCT001452497	NCT00145249_7_T1	PHENOTYPE	18	18	acute
NCT001452497	NCT00145249_7_T2	PHENOTYPE	19	20	cryptococcal meningitis
NCT0014524914	NCT00145249_14_T0	COMPOUND	15	15	fluconazole
NCT0014524914	NCT00145249_14_T1	PHENOTYPE	10	10	chronic
NCT0014524917	NCT00145249_17_T0	GENE	13	13	3.5
NCT0014524917	NCT00145249_17_T1	PHENOTYPE	10	10	experiences
NCT0014524918	NCT00145249_18_T0	PHENOTYPE	23	23	secondary
NCT0014524918	NCT00145249_18_T1	GENE	10	10	3.5
NCT0014524918	NCT00145249_18_T2	GENE	28	28	3.5
NCT0014524918	NCT00145249_18_T3	PHENOTYPE	12	12	experiences
NCT0014524918	NCT00145249_18_T4	PHENOTYPE	30	30	experiences
NCT0014524919	NCT00145249_19_T0	PHENOTYPE	1	1	secondary
NCT0014524919	NCT00145249_19_T1	PHENOTYPE	10	10	toxicities
NCT0014524920	NCT00145249_20_T0	GENE	25	25	CSF
NCT0014524923	NCT00145249_23_T0	GENE	0	0	OR
NCT0014524924	NCT00145249_24_T0	GENE	11	11	blot
NCT0014524924	NCT00145249_24_T1	PHENOTYPE	17	17	HIV
NCT0014524924	NCT00145249_24_T2	PHENOTYPE	13	14	positive HIV
NCT0014524926	NCT00145249_26_T0	PHENOTYPE	59	59	nocardiosis
NCT0014524926	NCT00145249_26_T1	PHENOTYPE	54	54	bartonellosis
NCT0014524926	NCT00145249_26_T2	GENE	29	29	10
NCT0014524926	NCT00145249_26_T3	PHENOTYPE	55	55	microsporidiosis
NCT0014524926	NCT00145249_26_T4	COMPOUND	56	56	1
NCT0014524926	NCT00145249_26_T5	PHENOTYPE	23	23	Pneumocystis
NCT0014524926	NCT00145249_26_T6	PHENOTYPE	37	38	Chagas disease
NCT0014524926	NCT00145249_26_T7	PHENOTYPE	47	48	Hodgkin's lymphoma
NCT0014524926	NCT00145249_26_T8	PHENOTYPE	52	53	Hodgkin's lymphoma
NCT0014524926	NCT00145249_26_T9	PHENOTYPE	27	28	herpes zoster
NCT0014524926	NCT00145249_26_T10	PHENOTYPE	35	36	American trypanosomiasis
NCT0014524926	NCT00145249_26_T11	PHENOTYPE	60	61	invasive aspergillosis
NCT0014524926	NCT00145249_26_T12	PHENOTYPE	45	46	visceral leishmaniasis
NCT0014524931	NCT00145249_31_T0	PHENOTYPE	9	9	IUD
NCT001452621	NCT00145262_1_T0	ORGAN	24	24	limbs
NCT001452751	NCT00145275_1_T0	PHENOTYPE	5	5	fever
NCT001452751	NCT00145275_1_T1	PHENOTYPE	9	9	pains
NCT001452751	NCT00145275_1_T2	PHENOTYPE	4	4	headache
NCT001452751	NCT00145275_1_T3	PHENOTYPE	0	1	Side effects
NCT001452751	NCT00145275_1_T4	PHENOTYPE	6	7	muscle aches
NCT001452752	NCT00145275_2_T0	PHENOTYPE	12	12	symptoms
NCT001452881	NCT00145288_1_T0	PHENOTYPE	2	2	hirsutism
NCT001452881	NCT00145288_1_T1	BIOLOGICAL_PROCESS	8	8	metabolism
NCT001452881	NCT00145288_1_T2	PHENOTYPE	5	5	overweight
NCT001452881	NCT00145288_1_T3	PHENOTYPE	11	12	insulin resistance
NCT001452881	NCT00145288_1_T4	PHENOTYPE	14	16	impaired glucose tolerance
NCT001452883	NCT00145288_3_T0	PHENOTYPE	0	0	Hyperinsulinemia
NCT001452883	NCT00145288_3_T1	PHENOTYPE	6	6	dyslipidemia
NCT001452883	NCT00145288_3_T2	PHENOTYPE	8	9	cardiovascular diseases
NCT001452887	NCT00145288_7_T0	COMPOUND	12	12	androgen
NCT001452887	NCT00145288_7_T1	PHENOTYPE	0	0	Hirsutism
NCT0014528812	NCT00145288_12_T0	PHENOTYPE	2	2	hirsutism
NCT0014528812	NCT00145288_12_T1	BIOLOGICAL_PROCESS	8	8	metabolism
NCT0014528812	NCT00145288_12_T2	PHENOTYPE	5	5	overweight
NCT0014528812	NCT00145288_12_T3	PHENOTYPE	11	12	insulin resistance
NCT0014528812	NCT00145288_12_T4	PHENOTYPE	14	16	impaired glucose tolerance
NCT0014528814	NCT00145288_14_T0	PHENOTYPE	0	0	Hyperinsulinemia
NCT0014528814	NCT00145288_14_T1	PHENOTYPE	6	6	dyslipidemia
NCT0014528814	NCT00145288_14_T2	PHENOTYPE	8	9	cardiovascular diseases
NCT0014528818	NCT00145288_18_T0	COMPOUND	12	12	androgen
NCT0014528818	NCT00145288_18_T1	PHENOTYPE	0	0	Hirsutism
NCT0014528822	NCT00145288_22_T0	GENE	4	4	had
NCT0014528824	NCT00145288_24_T0	GENE	5	5	had
NCT0014528824	NCT00145288_24_T1	PHENOTYPE	17	18	glucose tolerance
NCT0014528857	NCT00145288_57_T0	PHENOTYPE	8	9	polycystic ovary
NCT0014528857	NCT00145288_57_T1	PHENOTYPE	2	4	abnormal glucose tolerance
NCT0014528866	NCT00145288_66_T0	COMPOUND	0	0	O
NCT0014528870	NCT00145288_70_T0	ORGAN	2	2	ovaries
NCT0014528870	NCT00145288_70_T1	PHENOTYPE	7	8	cardiovascular disease
NCT0014528870	NCT00145288_70_T2	PHENOTYPE	12	13	polycystic ovary
NCT0014528877	NCT00145288_77_T0	PHENOTYPE	8	9	polycystic ovary
NCT0014528885	NCT00145288_85_T0	PHENOTYPE	15	15	hirsutism
NCT0014528885	NCT00145288_85_T1	PHENOTYPE	2	3	endocrine diseases
NCT0014528885	NCT00145288_85_T2	PHENOTYPE	6	7	glucose tolerance
NCT001453403	NCT00145340_3_T0	PHENOTYPE	8	9	insulin sensitivity
NCT001453404	NCT00145340_4_T0	GENE	13	13	insulin
NCT001453404	NCT00145340_4_T1	PHENOTYPE	17	17	hirsute
NCT001453405	NCT00145340_5_T0	GENE	8	8	reduced
NCT001453405	NCT00145340_5_T1	PHENOTYPE	4	6	male sex hormones
NCT001453407	NCT00145340_7_T0	PHENOTYPE	6	6	hirsute
NCT0014534011	NCT00145340_11_T0	GENE	11	11	hormone
NCT0014534012	NCT00145340_12_T0	PHENOTYPE	14	15	glucose tolerance
NCT0014534013	NCT00145340_13_T0	COMPOUND	10	10	pioglitazone
NCT0014534015	NCT00145340_15_T0	PHENOTYPE	14	14	hirsute
NCT001453662	NCT00145366_2_T0	PHENOTYPE	6	6	acute
NCT001453662	NCT00145366_2_T1	ORGAN	11	11	thyroid
NCT001453662	NCT00145366_2_T2	PHENOTYPE	24	26	nontoxic nodular goiter
NCT001453668	NCT00145366_8_T0	GENE	7	7	TSH
NCT001453668	NCT00145366_8_T1	GENE	3	3	0.9
NCT001453668	NCT00145366_8_T2	PHENOTYPE	9	10	thyroid function
NCT0014536611	NCT00145366_11_T0	GENE	3	3	0.3
NCT0014536611	NCT00145366_11_T1	GENE	7	7	TSH
NCT0014536611	NCT00145366_11_T2	PHENOTYPE	9	10	thyroid function
NCT0014536611	NCT00145366_11_T3	PHENOTYPE	20	22	multinodular toxic goiter
NCT001453793	NCT00145379_3_T0	GENE	3	3	insulin
NCT001453793	NCT00145379_3_T1	GENE	12	12	insulin
NCT001453793	NCT00145379_3_T2	GENE	17	17	insulin
NCT001453795	NCT00145379_5_T0	COMPOUND	8	8	glucose
NCT001453795	NCT00145379_5_T1	PHENOTYPE	16	17	weight loss
NCT0014537915	NCT00145379_15_T0	GENE	11	11	insulin
NCT0014537918	NCT00145379_18_T0	GENE	8	8	insulin
NCT0014537922	NCT00145379_22_T0	COMPOUND	11	11	glucose
NCT0014537923	NCT00145379_23_T0	GENE	9	9	insulin
NCT0014537923	NCT00145379_23_T1	GENE	22	22	insulin
NCT0014537924	NCT00145379_24_T0	COMPOUND	21	21	glucose
NCT0014537925	NCT00145379_25_T0	COMPOUND	12	12	glucose
NCT001453923	NCT00145392_3_T0	PHENOTYPE	9	9	diseases
NCT001453923	NCT00145392_3_T1	PHENOTYPE	12	12	overweight
NCT001453925	NCT00145392_5_T0	PHENOTYPE	13	13	overweight
NCT001453926	NCT00145392_6_T0	PHENOTYPE	5	5	overweight
NCT001453926	NCT00145392_6_T1	PHENOTYPE	14	16	male sex hormone
NCT001453928	NCT00145392_8_T0	GENE	11	11	hormone
NCT001454057	NCT00145405_7_T0	GENE	13	13	OCT
NCT001454057	NCT00145405_7_T1	GENE	18	18	GH
NCT001454057	NCT00145405_7_T2	GENE	20	20	IGF-I
NCT001454057	NCT00145405_7_T3	GENE	15	15	LAN
NCT001454058	NCT00145405_8_T0	GENE	15	15	GH
NCT001454058	NCT00145405_8_T1	GENE	13	13	IGF-I
NCT0014540515	NCT00145405_15_T0	GENE	13	13	OCT
NCT0014540515	NCT00145405_15_T1	GENE	18	18	GH
NCT0014540515	NCT00145405_15_T2	GENE	20	20	IGF-I
NCT0014540515	NCT00145405_15_T3	GENE	15	15	LAN
NCT0014540516	NCT00145405_16_T0	GENE	15	15	GH
NCT0014540516	NCT00145405_16_T1	GENE	13	13	IGF-I
NCT0014540520	NCT00145405_20_T0	GENE	7	7	OCT
NCT0014540520	NCT00145405_20_T1	GENE	32	32	OCT
NCT0014540520	NCT00145405_20_T2	GENE	9	9	LAN
NCT0014540520	NCT00145405_20_T3	GENE	34	34	LAN
NCT0014540521	NCT00145405_21_T0	GENE	0	0	OCT
NCT0014540521	NCT00145405_21_T1	GENE	6	6	LAN
NCT0014540523	NCT00145405_23_T0	GENE	4	4	OCT
NCT0014540523	NCT00145405_23_T1	GENE	10	10	OCT
NCT0014540523	NCT00145405_23_T2	GENE	16	16	OCT
NCT0014540523	NCT00145405_23_T3	GENE	22	22	LAN
NCT0014540524	NCT00145405_24_T0	GENE	2	2	OCT
NCT0014540524	NCT00145405_24_T1	GENE	14	14	IGF-I
NCT0014540524	NCT00145405_24_T2	GENE	18	18	0.4
NCT0014540525	NCT00145405_25_T0	GENE	8	8	OCT
NCT0014540525	NCT00145405_25_T1	GENE	14	14	OCT
NCT0014540525	NCT00145405_25_T2	GENE	21	21	OCT
NCT0014540525	NCT00145405_25_T3	GENE	28	28	OCT
NCT0014540525	NCT00145405_25_T4	GENE	1	1	LAN
NCT0014540525	NCT00145405_25_T5	GENE	18	18	LAN
NCT0014540525	NCT00145405_25_T6	GENE	25	25	LAN
NCT0014540525	NCT00145405_25_T7	GENE	32	32	LAN
NCT0014540527	NCT00145405_27_T0	GENE	1	1	GH
NCT0014540527	NCT00145405_27_T1	GENE	4	4	prolactin
NCT0014540527	NCT00145405_27_T2	COMPOUND	8	8	testosterone
NCT0014540527	NCT00145405_27_T3	GENE	17	17	hemoglobin
NCT0014540527	NCT00145405_27_T4	GENE	6	6	hormone
NCT0014540527	NCT00145405_27_T5	GENE	3	3	IGF-I
NCT0014540527	NCT00145405_27_T6	ORGAN	5	5	thyroid
NCT0014540527	NCT00145405_27_T7	GENE	11	11	FSH
NCT0014540527	NCT00145405_27_T8	PHENOTYPE	19	20	enzymes levels
NCT0014540527	NCT00145405_27_T9	PHENOTYPE	13	14	plasma glucose
NCT0014540527	NCT00145405_27_T10	PHENOTYPE	18	19	liver enzymes
NCT0014540532	NCT00145405_32_T0	PHENOTYPE	4	4	acromegaly
NCT0014540534	NCT00145405_34_T0	PHENOTYPE	6	6	acromegaly
NCT0014540537	NCT00145405_37_T0	PHENOTYPE	8	8	chronic
NCT0014540548	NCT00145405_48_T0	GENE	3	3	Bex
NCT0014540549	NCT00145405_49_T0	COMPOUND	1	1	lanreotide
NCT0014540549	NCT00145405_49_T1	PHENOTYPE	6	6	acromegaly
NCT001454182	NCT00145418_2_T0	GENE	3	3	has
NCT001454183	NCT00145418_3_T0	COMPOUND	2	2	docetaxel
NCT001454183	NCT00145418_3_T1	PHENOTYPE	10	11	lung cancer
NCT001454184	NCT00145418_4_T0	PHENOTYPE	16	16	toxicity
NCT001454184	NCT00145418_4_T1	COMPOUND	12	12	docetaxel
NCT001454184	NCT00145418_4_T2	COMPOUND	9	9	oxaliplatin
NCT001454184	NCT00145418_4_T3	GENE	13	13	has
NCT001454187	NCT00145418_7_T0	PHENOTYPE	11	11	toxicity
NCT001454187	NCT00145418_7_T1	PHENOTYPE	1	1	secondary
NCT001454187	NCT00145418_7_T2	PHENOTYPE	6	6	progression
NCT001454310	NCT00145431_0_T0	PHENOTYPE	13	13	Disorder
NCT001454310	NCT00145431_0_T1	PHENOTYPE	15	15	Disorder
NCT001454310	NCT00145431_0_T2	GENE	14	14	ol
NCT001454441	NCT00145444_1_T0	PHENOTYPE	31	31	schizophrenia
NCT001454441	NCT00145444_1_T1	PHENOTYPE	19	20	cognitive function
NCT001454834	NCT00145483_4_T0	PHENOTYPE	4	4	symptoms
NCT001454835	NCT00145483_5_T0	PHENOTYPE	19	19	symptoms
NCT001454835	NCT00145483_5_T1	PHENOTYPE	22	22	acute
NCT001454835	NCT00145483_5_T2	COMPOUND	13	13	sildenafil
NCT001454960	NCT00145496_0_T0	PHENOTYPE	15	15	Schizophrenia
NCT001454960	NCT00145496_0_T1	PHENOTYPE	13	13	Symptoms
NCT001454962	NCT00145496_2_T0	PHENOTYPE	16	16	symptoms
NCT001454962	NCT00145496_2_T1	PHENOTYPE	18	18	acute
NCT001454962	NCT00145496_2_T2	COMPOUND	7	7	olanzapine
NCT001454962	NCT00145496_2_T3	GENE	2	2	atypical
NCT001454962	NCT00145496_2_T4	GENE	8	8	has
NCT001454963	NCT00145496_3_T0	PHENOTYPE	26	26	symptoms
NCT001454963	NCT00145496_3_T1	COMPOUND	16	16	olanzapine
NCT001454963	NCT00145496_3_T2	PHENOTYPE	28	28	schizophrenia
NCT001454963	NCT00145496_3_T3	COMPOUND	11	11	asenapine
NCT001454965	NCT00145496_5_T0	PHENOTYPE	6	6	symptoms
NCT001455090	NCT00145509_0_T0	COMPOUND	12	12	Lithium
NCT001455090	NCT00145509_0_T1	PHENOTYPE	19	20	Bipolar Disorder
NCT001455092	NCT00145509_2_T0	COMPOUND	8	8	lithium
NCT001455092	NCT00145509_2_T1	COMPOUND	17	17	lithium
NCT001455092	NCT00145509_2_T2	COMPOUND	21	21	asenapine
NCT001455092	NCT00145509_2_T3	COMPOUND	31	31	benzodiazepine
NCT001455353	NCT00145535_3_T0	PHENOTYPE	10	11	open-angle glaucoma
NCT001455482	NCT00145548_2_T0	PHENOTYPE	6	6	airflow
NCT001455482	NCT00145548_2_T1	PHENOTYPE	28	28	emphysema
NCT001455486	NCT00145548_6_T0	PHENOTYPE	5	5	emphysema
NCT001455488	NCT00145548_8_T0	ORGAN	10	10	transplant
NCT0014554810	NCT00145548_10_T0	PHENOTYPE	4	4	centers
NCT001455612	NCT00145561_2_T0	PHENOTYPE	23	23	HIV
NCT001455612	NCT00145561_2_T1	COMPOUND	10	10	saquinavir
NCT001455612	NCT00145561_2_T2	PHENOTYPE	3	3	experiences
NCT001455613	NCT00145561_3_T0	COMPOUND	10	10	ritonavir
NCT001455613	NCT00145561_3_T1	COMPOUND	7	7	saquinavir
NCT001455613	NCT00145561_3_T2	COMPOUND	41	41	saquinavir
NCT001455613	NCT00145561_3_T3	GENE	2	2	bid
NCT001455873	NCT00145587_3_T0	PHENOTYPE	6	7	rapid progression
NCT001455877	NCT00145587_7_T0	ORGAN	31	31	graft
NCT001455877	NCT00145587_7_T1	PHENOTYPE	20	20	conditioning
NCT001455877	NCT00145587_7_T2	ORGAN	29	30	bone marrow
NCT001455878	NCT00145587_8_T0	ORGAN	4	4	transplant
NCT001456003	NCT00145600_3_T0	GENE	8	8	VAMP
NCT001456003	NCT00145600_3_T1	GENE	27	27	VAMP
NCT001456003	NCT00145600_3_T2	PHENOTYPE	16	17	Hodgkin's disease
NCT001456005	NCT00145600_5_T0	GENE	12	12	RT
NCT001456005	NCT00145600_5_T1	GENE	7	7	VAMP
NCT001456005	NCT00145600_5_T2	GENE	29	29	VAMP
NCT001456005	NCT00145600_5_T3	PHENOTYPE	18	19	Hodgkin's disease
NCT001456007	NCT00145600_7_T0	GENE	19	19	RT
NCT001456007	NCT00145600_7_T1	PHENOTYPE	25	26	Hodgkin's disease
NCT001456009	NCT00145600_9_T0	GENE	14	14	RT
NCT001456009	NCT00145600_9_T1	PHENOTYPE	20	21	Hodgkin's disease
NCT001456009	NCT00145600_9_T2	COMPOUND	8	9	Stanford V
NCT0014560010	NCT00145600_10_T0	PHENOTYPE	0	0	Secondary
NCT0014560011	NCT00145600_11_T0	PHENOTYPE	3	5	quality of life
NCT0014560016	NCT00145600_16_T0	GENE	11	11	ray
NCT0014560016	NCT00145600_16_T1	PHENOTYPE	1	2	mediastinal disease
NCT001456130	NCT00145613_0_T0	PHENOTYPE	7	8	Hematological Malignancies
NCT001456130	NCT00145613_0_T1	CELL	1	2	Stem Cell
NCT001456130	NCT00145613_0_T2	ORGAN	2	3	Cell Transplant
NCT001456135	NCT00145613_5_T0	ORGAN	9	9	transplant
NCT001456137	NCT00145613_7_T0	ORGAN	1	1	marrow
NCT001456137	NCT00145613_7_T1	CELL	23	24	blood cells
NCT001456137	NCT00145613_7_T2	ORGAN	16	17	bone marrow
NCT001456138	NCT00145613_8_T0	ORGAN	14	15	immune system
NCT0014561311	NCT00145613_11_T0	ORGAN	5	5	transplant
NCT0014561311	NCT00145613_11_T1	CELL	7	8	stem cells
NCT0014561312	NCT00145613_12_T0	PHENOTYPE	19	19	toxicity
NCT0014561312	NCT00145613_12_T1	PHENOTYPE	16	16	complications
NCT0014561312	NCT00145613_12_T2	PHENOTYPE	25	25	GVHD
NCT0014561312	NCT00145613_12_T3	ORGAN	2	2	transplant
NCT0014561312	NCT00145613_12_T4	GENE	3	3	has
NCT0014561312	NCT00145613_12_T5	GENE	11	11	has
NCT0014561312	NCT00145613_12_T6	PHENOTYPE	21	24	graft versus host disease
NCT0014561314	NCT00145613_14_T0	CELL	19	19	cells
NCT0014561314	NCT00145613_14_T1	TISSUE	13	13	tissues
NCT0014561314	NCT00145613_14_T2	PHENOTYPE	0	0	GVHD
NCT0014561314	NCT00145613_14_T3	CELL	5	6	T cells
NCT0014561315	NCT00145613_15_T0	ORGAN	23	23	graft
NCT0014561315	NCT00145613_15_T1	PHENOTYPE	9	9	GVHD
NCT0014561315	NCT00145613_15_T2	GENE	10	11	too few
NCT0014561315	NCT00145613_15_T3	ORGAN	16	17	immune system
NCT0014561315	NCT00145613_15_T4	CELL	3	4	T cells
NCT0014561320	NCT00145613_20_T0	PHENOTYPE	10	10	toxicity
NCT0014561320	NCT00145613_20_T1	GENE	1	1	reduced
NCT001456260	NCT00145626_0_T0	PHENOTYPE	17	18	Hematologic Malignancies
NCT001456260	NCT00145626_0_T1	CELL	1	2	Stem Cell
NCT001456260	NCT00145626_0_T2	CELL	4	6	Natural Killer Cell
NCT001456264	NCT00145626_4_T0	PHENOTYPE	19	19	toxicity
NCT001456264	NCT00145626_4_T1	PHENOTYPE	16	16	complications
NCT001456264	NCT00145626_4_T2	PHENOTYPE	27	27	GVHD
NCT001456264	NCT00145626_4_T3	GENE	3	3	has
NCT001456264	NCT00145626_4_T4	GENE	11	11	has
NCT001456264	NCT00145626_4_T5	PHENOTYPE	23	26	graft versus host disease
NCT001456265	NCT00145626_5_T0	ORGAN	12	12	graft
NCT001456265	NCT00145626_5_T1	CELL	15	16	T lymphocytes
NCT001456266	NCT00145626_6_T0	PHENOTYPE	40	40	toxicity
NCT001456266	NCT00145626_6_T1	ORGAN	34	34	graft
NCT001456266	NCT00145626_6_T2	CELL	23	23	cells
NCT001456266	NCT00145626_6_T3	ORGAN	4	4	transplant
NCT001456266	NCT00145626_6_T4	PHENOTYPE	35	36	disease relapse
NCT001456266	NCT00145626_6_T5	CELL	16	18	white blood cells
NCT001456267	NCT00145626_7_T0	PHENOTYPE	17	18	hematologic malignancies
NCT001456269	NCT00145626_9_T0	CELL	12	12	cells
NCT001456269	NCT00145626_9_T1	CELL	14	15	NK cells
NCT001456390	NCT00145639_0_T0	PHENOTYPE	6	6	Osteosarcoma
NCT001456392	NCT00145639_2_T0	COMPOUND	1	1	methotrexate
NCT001456392	NCT00145639_2_T1	PHENOTYPE	18	19	localized disease
NCT001456393	NCT00145639_3_T0	COMPOUND	14	14	ifosfamide
NCT001456393	NCT00145639_3_T1	COMPOUND	22	22	ifosfamide
NCT001456393	NCT00145639_3_T2	COMPOUND	15	15	doxorubicin
NCT001456393	NCT00145639_3_T3	PHENOTYPE	36	36	osteosarcoma
NCT001456396	NCT00145639_6_T0	PHENOTYPE	24	24	tumor
NCT001456396	NCT00145639_6_T1	PHENOTYPE	3	3	Plan
NCT001456397	NCT00145639_7_T0	GENE	4	4	0.12
NCT001456399	NCT00145639_9_T0	GENE	4	4	GFR
NCT001456399	NCT00145639_9_T1	COMPOUND	58	58	doxorubicin
NCT001456399	NCT00145639_9_T2	GENE	14	14	IV
NCT001456399	NCT00145639_9_T3	GENE	30	30	IV
NCT001456521	NCT00145652_1_T0	PHENOTYPE	12	12	Disorders
NCT001456521	NCT00145652_1_T1	PHENOTYPE	9	10	Lymphoproliferative Disorders
NCT001456523	NCT00145652_3_T0	GENE	27	27	LPD
NCT001456523	NCT00145652_3_T1	PHENOTYPE	6	6	anemia
NCT001456526	NCT00145652_6_T0	PHENOTYPE	2	2	recruitment
NCT0014565213	NCT00145652_13_T0	GENE	21	21	epoetin
NCT0014565213	NCT00145652_13_T1	GENE	4	4	Hb
NCT0014565213	NCT00145652_13_T2	GENE	22	22	beta
NCT0014565214	NCT00145652_14_T0	GENE	8	8	epoetin
NCT0014565214	NCT00145652_14_T1	GENE	2	2	Hb
NCT0014565214	NCT00145652_14_T2	GENE	9	9	beta
NCT0014565215	NCT00145652_15_T0	PHENOTYPE	9	9	falls
NCT0014565215	NCT00145652_15_T1	GENE	7	7	Hb
NCT0014565217	NCT00145652_17_T0	PHENOTYPE	17	17	falls
NCT0014565217	NCT00145652_17_T1	COMPOUND	9	9	sucrose
NCT001456652	NCT00145665_2_T0	PHENOTYPE	8	8	recurrence
NCT001456654	NCT00145665_4_T0	PHENOTYPE	35	35	metastases
NCT001456654	NCT00145665_4_T1	PHENOTYPE	27	28	proliferation index
NCT001456654	NCT00145665_4_T2	PHENOTYPE	21	22	liver metastases
NCT001456655	NCT00145665_5_T0	PHENOTYPE	10	10	recurrence
NCT001456655	NCT00145665_5_T1	PHENOTYPE	8	8	proliferation
NCT001456656	NCT00145665_6_T0	PHENOTYPE	5	6	liver metastases
NCT001456658	NCT00145665_8_T0	PHENOTYPE	11	12	liver metastases
NCT001456659	NCT00145665_9_T0	PHENOTYPE	6	7	proliferation index
NCT001456659	NCT00145665_9_T1	PHENOTYPE	10	11	liver metastases
NCT0014566510	NCT00145665_10_T0	PHENOTYPE	4	4	proliferation
NCT0014566512	NCT00145665_12_T0	PHENOTYPE	6	6	proliferation
NCT0014566512	NCT00145665_12_T1	PHENOTYPE	39	39	proliferation
NCT0014566512	NCT00145665_12_T2	PHENOTYPE	25	26	liver metastases
NCT0014566513	NCT00145665_13_T0	PHENOTYPE	6	6	proliferation
NCT0014566513	NCT00145665_13_T1	PHENOTYPE	16	16	proliferation
NCT0014566513	NCT00145665_13_T2	GENE	0	0	FLT
NCT0014566514	NCT00145665_14_T0	PHENOTYPE	10	11	liver metastases
NCT0014566517	NCT00145665_17_T0	GENE	11	11	extended
NCT0014566519	NCT00145665_19_T0	PHENOTYPE	27	27	proliferation
NCT001456780	NCT00145678_0_T0	PHENOTYPE	8	10	Alcohol Use Disorder
NCT001456780	NCT00145678_0_T1	PHENOTYPE	4	6	Borderline Personality Disorder
NCT001456784	NCT00145678_4_T0	PHENOTYPE	19	19	BPD
NCT001456784	NCT00145678_4_T1	GENE	11	11	has
NCT001456784	NCT00145678_4_T2	PHENOTYPE	4	4	psychodynamic
NCT001456784	NCT00145678_4_T3	PHENOTYPE	24	26	substance use disorders
NCT0014567813	NCT00145678_13_T0	PHENOTYPE	18	18	BPD
NCT001457040	NCT00145704_0_T0	MOLECULAR_FUNCTION	5	6	Growth Hormone
NCT001457040	NCT00145704_0_T1	PHENOTYPE	9	10	Childhood Cancer
NCT001457043	NCT00145704_3_T0	GENE	21	21	collagen
NCT001457043	NCT00145704_3_T1	ORGAN	11	11	serum
NCT001457043	NCT00145704_3_T2	GENE	16	16	BSAP
NCT001457043	NCT00145704_3_T3	GENE	14	15	alkaline phosphatase
NCT001457044	NCT00145704_4_T0	PHENOTYPE	27	27	osteopenia
NCT001457044	NCT00145704_4_T1	PHENOTYPE	10	10	Oncology
NCT001457044	NCT00145704_4_T2	PHENOTYPE	12	12	Endocrine
NCT001457172	NCT00145717_2_T0	GENE	18	18	has
NCT001457175	NCT00145717_5_T0	COMPOUND	10	10	sterol
NCT001457176	NCT00145717_6_T0	PHENOTYPE	9	10	cholesterol levels
NCT001457305	NCT00145730_5_T0	PHENOTYPE	31	31	withdrawn
NCT001457305	NCT00145730_5_T1	COMPOUND	11	11	aspirin
NCT001457309	NCT00145730_9_T0	PHENOTYPE	8	8	centre
NCT0014573011	NCT00145730_11_T0	PHENOTYPE	0	0	Secondary
NCT0014573011	NCT00145730_11_T1	PHENOTYPE	4	6	quality of life
NCT001457431	NCT00145743_1_T0	PHENOTYPE	16	18	quality of life
NCT001457433	NCT00145743_3_T0	PHENOTYPE	16	17	breast cancer
NCT001457436	NCT00145743_6_T0	GENE	13	13	has
NCT001457439	NCT00145743_9_T0	PHENOTYPE	4	5	breast cancer
NCT0014574315	NCT00145743_15_T0	PHENOTYPE	7	7	insights
NCT0014574315	NCT00145743_15_T1	PHENOTYPE	26	27	breast cancer
NCT0014574315	NCT00145743_15_T2	PHENOTYPE	19	21	quality of life
NCT001457563	NCT00145756_3_T0	PHENOTYPE	18	19	cardiovascular disease
NCT001457568	NCT00145756_8_T0	COMPOUND	1	1	sodium
NCT0014575611	NCT00145756_11_T0	COMPOUND	2	2	sodium
NCT0014575611	NCT00145756_11_T1	COMPOUND	7	7	sodium
NCT0014575611	NCT00145756_11_T2	COMPOUND	20	20	sodium
NCT0014575611	NCT00145756_11_T3	COMPOUND	4	4	potassium
NCT0014575611	NCT00145756_11_T4	COMPOUND	14	14	sulphate
NCT0014575611	NCT00145756_11_T5	COMPOUND	8	8	chloride
NCT0014575611	NCT00145756_11_T6	COMPOUND	21	21	chloride
NCT0014575611	NCT00145756_11_T7	COMPOUND	13	13	magnesium
NCT0014575611	NCT00145756_11_T8	COMPOUND	10	11	potassium chloride
NCT001457827	NCT00145782_7_T0	COMPOUND	19	19	BMI
NCT0014578217	NCT00145782_17_T0	GENE	21	21	GP
NCT001457953	NCT00145795_3_T0	GENE	16	16	PI
NCT001457953	NCT00145795_3_T1	COMPOUND	10	10	Kaletra
NCT001457953	NCT00145795_3_T2	BIOLOGICAL_PROCESS	33	34	immune response
NCT001457955	NCT00145795_5_T0	BIOLOGICAL_PROCESS	5	6	viral replication
NCT001457956	NCT00145795_6_T0	GENE	14	14	thymic
NCT0014579510	NCT00145795_10_T0	PHENOTYPE	14	14	HIV
NCT0014579510	NCT00145795_10_T1	ORGAN	13	13	plasma
NCT0014579510	NCT00145795_10_T2	BIOLOGICAL_PROCESS	0	1	Viral replication
NCT0014579513	NCT00145795_13_T0	PHENOTYPE	30	30	strategies
NCT0014579513	NCT00145795_13_T1	PHENOTYPE	18	19	virologic failure
NCT0014579514	NCT00145795_14_T0	PHENOTYPE	16	16	suppression
NCT0014579514	NCT00145795_14_T1	COMPOUND	0	0	Kaletra
NCT0014579515	NCT00145795_15_T0	GENE	20	20	polymerase
NCT0014579515	NCT00145795_15_T1	PHENOTYPE	7	7	suppression
NCT0014579515	NCT00145795_15_T2	ORGAN	19	19	plasma
NCT0014579515	NCT00145795_15_T3	GENE	23	23	PCR
NCT0014579515	NCT00145795_15_T4	COMPOUND	0	0	Kaletra
NCT0014579515	NCT00145795_15_T5	BIOLOGICAL_PROCESS	9	10	viral replication
NCT001458081	NCT00145808_1_T0	PHENOTYPE	13	13	pathology
NCT001458081	NCT00145808_1_T1	GENE	12	12	bowel
NCT001458081	NCT00145808_1_T2	GENE	18	18	UC
NCT001458082	NCT00145808_2_T0	PHENOTYPE	10	10	IBD
NCT001458084	NCT00145808_4_T0	GENE	7	7	GI
NCT001458089	NCT00145808_9_T0	ORGAN	19	19	abdomen
NCT0014580810	NCT00145808_10_T0	PHENOTYPE	13	13	fitted
NCT0014580811	NCT00145808_11_T0	GENE	2	2	swallow
NCT0014580812	NCT00145808_12_T0	ORGAN	6	7	digestive tract
NCT0014580814	NCT00145808_14_T0	PHENOTYPE	3	3	ingestion
NCT0014580817	NCT00145808_17_T0	GENE	10	10	DCAM
NCT0014580818	NCT00145808_18_T0	PHENOTYPE	6	6	ingested
NCT0014580818	NCT00145808_18_T1	BIOLOGICAL_PROCESS	9	9	drinking
NCT0014580818	NCT00145808_18_T2	PHENOTYPE	18	18	discomfort
NCT0014580818	NCT00145808_18_T3	BIOLOGICAL_PROCESS	7	7	eating
NCT0014580820	NCT00145808_20_T0	GENE	16	16	abdominal
NCT0014580820	NCT00145808_20_T1	GENE	27	27	has
NCT0014580821	NCT00145808_21_T0	PHENOTYPE	23	24	Ulcerative Colitis
NCT0014580827	NCT00145808_27_T0	PHENOTYPE	6	6	fistula
NCT0014580827	NCT00145808_27_T1	COMPOUND	29	29	aspirin
NCT0014580827	NCT00145808_27_T2	PHENOTYPE	8	8	stricture
NCT0014580827	NCT00145808_27_T3	PHENOTYPE	45	46	ileal disease
NCT0014580827	NCT00145808_27_T4	PHENOTYPE	56	57	gastrointestinal bleeding
NCT0014580827	NCT00145808_27_T5	PHENOTYPE	18	19	swallowing disorder
NCT0014580827	NCT00145808_27_T6	PHENOTYPE	4	5	bowel obstruction
NCT0014580827	NCT00145808_27_T7	PHENOTYPE	41	42	celiac disease
NCT001458471	NCT00145847_1_T0	PHENOTYPE	32	32	severity
NCT001458471	NCT00145847_1_T1	COMPOUND	22	22	naltrexone
NCT001458471	NCT00145847_1_T2	PHENOTYPE	46	46	Severity
NCT001458471	NCT00145847_1_T3	COMPOUND	5	5	1
NCT001458471	NCT00145847_1_T4	COMPOUND	18	18	2
NCT001458471	NCT00145847_1_T5	COMPOUND	45	45	3
NCT001458471	NCT00145847_1_T6	PHENOTYPE	34	35	psychiatric symptoms
NCT001458471	NCT00145847_1_T7	PHENOTYPE	48	49	psychiatric symptoms
NCT001458471	NCT00145847_1_T8	PHENOTYPE	41	42	emergency psychiatric
NCT001458473	NCT00145847_3_T0	PHENOTYPE	9	10	mental illness
NCT001458473	NCT00145847_3_T1	PHENOTYPE	0	2	Alcohol use disorders
NCT001458474	NCT00145847_4_T0	PHENOTYPE	21	21	disorders
NCT001458474	NCT00145847_4_T1	PHENOTYPE	18	18	schizophrenia
NCT001458476	NCT00145847_6_T0	PHENOTYPE	17	20	alcohol abuse or dependence
NCT001458478	NCT00145847_8_T0	COMPOUND	12	12	naltrexone
NCT001458478	NCT00145847_8_T1	PHENOTYPE	20	20	schizophrenia
NCT001458478	NCT00145847_8_T2	PHENOTYPE	22	23	schizoaffective disorder
NCT001458478	NCT00145847_8_T3	PHENOTYPE	27	30	alcohol abuse or dependence
NCT001458479	NCT00145847_9_T0	COMPOUND	4	4	1
NCT0014584710	NCT00145847_10_T0	BIOLOGICAL_PROCESS	9	9	drinking
NCT0014584711	NCT00145847_11_T0	PHENOTYPE	8	8	severity
NCT0014584712	NCT00145847_12_T0	PHENOTYPE	18	18	severity
NCT0014584712	NCT00145847_12_T1	COMPOUND	8	8	naltrexone
NCT0014584712	NCT00145847_12_T2	COMPOUND	4	4	2
NCT0014584712	NCT00145847_12_T3	PHENOTYPE	20	21	psychiatric symptoms
NCT0014584712	NCT00145847_12_T4	PHENOTYPE	27	28	emergency psychiatric
NCT0014584713	NCT00145847_13_T0	PHENOTYPE	14	14	severity
NCT0014584714	NCT00145847_14_T0	COMPOUND	4	4	3
NCT0014584714	NCT00145847_14_T1	PHENOTYPE	5	5	Severity
NCT0014584714	NCT00145847_14_T2	PHENOTYPE	7	8	psychiatric symptoms
NCT0014584716	NCT00145847_16_T0	COMPOUND	14	14	naltrexone
NCT0014584719	NCT00145847_19_T0	PHENOTYPE	19	19	severity
NCT0014584721	NCT00145847_21_T0	PHENOTYPE	12	12	Schizophrenia
NCT0014584721	NCT00145847_21_T1	PHENOTYPE	14	15	Schizoaffective Disorder
NCT0014584722	NCT00145847_22_T0	PHENOTYPE	3	4	Alcohol Abuse
NCT0014584722	NCT00145847_22_T1	PHENOTYPE	6	7	Alcohol Dependence
NCT0014584723	NCT00145847_23_T0	BIOLOGICAL_PROCESS	8	8	drinking
NCT0014584723	NCT00145847_23_T1	BIOLOGICAL_PROCESS	2	2	Drinking
NCT0014584725	NCT00145847_25_T0	PHENOTYPE	14	14	Center
NCT0014584725	NCT00145847_25_T1	PHENOTYPE	19	19	Center
NCT0014584725	NCT00145847_25_T2	PHENOTYPE	22	22	Center
NCT0014584728	NCT00145847_28_T0	COMPOUND	5	5	naltrexone
NCT0014584728	NCT00145847_28_T1	COMPOUND	2	2	disulfiram
NCT0014584729	NCT00145847_29_T0	PHENOTYPE	7	8	Opioid Abuse
NCT0014584729	NCT00145847_29_T1	PHENOTYPE	4	5	Opioid Dependence
NCT0014584730	NCT00145847_30_T0	COMPOUND	2	2	ibuprofen
NCT0014584730	NCT00145847_30_T1	PHENOTYPE	24	25	hepatic injury
NCT0014584731	NCT00145847_31_T0	COMPOUND	12	12	codeine
NCT0014584731	NCT00145847_31_T1	COMPOUND	13	13	heroin
NCT0014584731	NCT00145847_31_T2	COMPOUND	10	10	methadone
NCT0014584731	NCT00145847_31_T3	COMPOUND	14	14	meperidine
NCT0014584731	NCT00145847_31_T4	COMPOUND	11	11	morphine
NCT0014584733	NCT00145847_33_T0	PHENOTYPE	10	10	sterile
NCT0014584735	NCT00145847_35_T0	PHENOTYPE	8	9	psychiatric disorders
NCT0014584737	NCT00145847_37_T0	GENE	0	0	AST
NCT0014584740	NCT00145847_40_T0	PHENOTYPE	3	3	acute
NCT0014584740	NCT00145847_40_T1	PHENOTYPE	22	22	Withdrawal
NCT0014584740	NCT00145847_40_T2	BIOLOGICAL_PROCESS	5	5	detoxification
NCT001458600	NCT00145860_0_T0	PHENOTYPE	3	4	Colorectal Cancer
NCT001458603	NCT00145860_3_T0	PHENOTYPE	6	7	colorectal cancer
NCT001458607	NCT00145860_7_T0	PHENOTYPE	6	7	colorectal cancer
NCT0014586011	NCT00145860_11_T0	PHENOTYPE	27	27	learned
NCT0014586011	NCT00145860_11_T1	PHENOTYPE	17	18	colon cancer
NCT0014586012	NCT00145860_12_T0	GENE	3	3	has
NCT0014586014	NCT00145860_14_T0	PHENOTYPE	8	9	colon cancer
NCT0014586016	NCT00145860_16_T0	GENE	38	38	had
NCT0014586016	NCT00145860_16_T1	PHENOTYPE	22	23	colon cancer
NCT001458731	NCT00145873_1_T0	ORGAN	12	12	veins
NCT001458731	NCT00145873_1_T1	COMPOUND	1	1	Natrecor
NCT001458731	NCT00145873_1_T2	ORGAN	14	14	arteries
NCT001458731	NCT00145873_1_T3	GENE	9	9	hormone
NCT001458732	NCT00145873_2_T0	COMPOUND	1	1	Natrecor
NCT001458732	NCT00145873_2_T1	GENE	8	8	IV
NCT001458732	NCT00145873_2_T2	PHENOTYPE	13	15	chronic heart failure
NCT001458734	NCT00145873_4_T0	PHENOTYPE	17	19	chronic heart failure
NCT001458735	NCT00145873_5_T0	PHENOTYPE	13	13	symptoms
NCT001458735	NCT00145873_5_T1	PHENOTYPE	21	22	Heart Failure
NCT001458736	NCT00145873_6_T0	GENE	14	14	BNP
NCT001458736	NCT00145873_6_T1	COMPOUND	13	13	N
NCT001458736	NCT00145873_6_T2	COMPOUND	17	18	cyclic GMP
NCT0014587313	NCT00145873_13_T0	PHENOTYPE	21	21	severity
NCT0014587313	NCT00145873_13_T1	GENE	53	53	IV
NCT0014587313	NCT00145873_13_T2	GENE	71	71	IV
NCT0014587313	NCT00145873_13_T3	PHENOTYPE	24	24	symptoms
NCT0014587313	NCT00145873_13_T4	PHENOTYPE	41	41	symptoms
NCT0014587313	NCT00145873_13_T5	PHENOTYPE	13	14	heart failure
NCT0014587313	NCT00145873_13_T6	PHENOTYPE	19	20	heart failure
NCT0014587313	NCT00145873_13_T7	PHENOTYPE	39	40	heart failure
NCT0014587313	NCT00145873_13_T8	PHENOTYPE	34	35	Heart Failure
NCT0014587322	NCT00145873_22_T0	GENE	3	3	ER
NCT0014587323	NCT00145873_23_T0	GENE	18	18	IV
NCT0014587323	NCT00145873_23_T1	PHENOTYPE	16	16	chronic
NCT0014587325	NCT00145873_25_T0	GENE	2	2	24
NCT0014587327	NCT00145873_27_T0	GENE	9	9	II
NCT0014587327	NCT00145873_27_T1	PHENOTYPE	1	3	chronic heart failure
NCT0014587331	NCT00145873_31_T0	PHENOTYPE	0	1	Hypertrophic cardiomyopathy
NCT0014587333	NCT00145873_33_T0	PHENOTYPE	4	5	cor pulmonale
NCT0014587333	NCT00145873_33_T1	PHENOTYPE	1	3	right heart failure
NCT0014587344	NCT00145873_44_T0	GENE	4	4	IV
NCT001458863	NCT00145886_3_T0	GENE	12	13	parathyroid hormone
NCT001458864	NCT00145886_4_T0	COMPOUND	15	15	calcium
NCT001458864	NCT00145886_4_T1	BIOLOGICAL_PROCESS	16	16	metabolism
NCT001458866	NCT00145886_6_T0	COMPOUND	9	9	calcium
NCT001458866	NCT00145886_6_T1	GENE	5	5	PTH
NCT001458866	NCT00145886_6_T2	BIOLOGICAL_PROCESS	10	10	metabolism
NCT001458866	NCT00145886_6_T3	GENE	6	7	parathyroid hormone
NCT0014588610	NCT00145886_10_T0	COMPOUND	8	8	calcium
NCT0014588610	NCT00145886_10_T1	COMPOUND	23	23	calcium
NCT0014588612	NCT00145886_12_T0	GENE	34	34	PTH
NCT0014588612	NCT00145886_12_T1	PHENOTYPE	22	23	serum calcium
NCT0014588613	NCT00145886_13_T0	COMPOUND	16	16	calcium
NCT0014588621	NCT00145886_21_T0	CELL	8	8	cells
NCT0014588621	NCT00145886_21_T1	CELL	36	36	cells
NCT0014588630	NCT00145886_30_T0	GENE	32	32	0.3
NCT0014588630	NCT00145886_30_T1	GENE	24	24	cm
NCT0014588630	NCT00145886_30_T2	GENE	33	33	cm
NCT0014588630	NCT00145886_30_T3	COMPOUND	34	34	1_10
NCT0014588634	NCT00145886_34_T0	GENE	3	3	had
NCT0014588639	NCT00145886_39_T0	PHENOTYPE	26	26	osteomalacia
NCT0014588639	NCT00145886_39_T1	PHENOTYPE	22	23	bone disease
NCT001459256	NCT00145925_6_T0	COMPOUND	24	24	glucose
NCT001459256	NCT00145925_6_T1	COMPOUND	22	22	gliclazide
NCT001459259	NCT00145925_9_T0	GENE	8	8	5.5
NCT0014592510	NCT00145925_10_T0	PHENOTYPE	7	7	centres
NCT0014592511	NCT00145925_11_T0	COMPOUND	22	22	glucose
NCT0014592511	NCT00145925_11_T1	PHENOTYPE	35	36	glucose levels
NCT0014592517	NCT00145925_17_T0	COMPOUND	11	11	thiazide
NCT0014592517	NCT00145925_17_T1	MOLECULAR_FUNCTION	7	8	ACE inhibitor
NCT0014592518	NCT00145925_18_T0	COMPOUND	21	21	thiazide
NCT0014592518	NCT00145925_18_T1	GENE	12	12	2.4
NCT0014592518	NCT00145925_18_T2	COMPOUND	11	11	perindopril
NCT0014592518	NCT00145925_18_T3	MOLECULAR_FUNCTION	7	8	ACE inhibitor
NCT0014592519	NCT00145925_19_T0	COMPOUND	8	8	gliclazide
NCT0014592520	NCT00145925_20_T0	COMPOUND	6	6	gliclazide
NCT0014592521	NCT00145925_21_T0	GENE	8	8	insulin
NCT001459381	NCT00145938_1_T0	GENE	2	2	PTPH
NCT001459381	NCT00145938_1_T1	PHENOTYPE	1	1	hypertension
NCT001459381	NCT00145938_1_T2	PHENOTYPE	8	9	pulmonary hypertension
NCT001459382	NCT00145938_2_T0	ORGAN	23	23	lungs
NCT001459382	NCT00145938_2_T1	ORGAN	20	20	heart
NCT001459382	NCT00145938_2_T2	ORGAN	16	17	right ventricle
NCT001459382	NCT00145938_2_T3	ORGAN	8	9	pulmonary arteries
NCT001459382	NCT00145938_2_T4	PHENOTYPE	0	1	Pulmonary hypertension
NCT001459382	NCT00145938_2_T5	PHENOTYPE	3	5	high blood pressure
NCT001459383	NCT00145938_3_T0	PHENOTYPE	4	4	constriction
NCT001459383	NCT00145938_3_T1	ORGAN	16	16	lungs
NCT001459383	NCT00145938_3_T2	ORGAN	9	10	blood vessels
NCT001459383	NCT00145938_3_T3	PHENOTYPE	0	1	Pulmonary hypertension
NCT001459384	NCT00145938_4_T0	ORGAN	10	10	lungs
NCT001459384	NCT00145938_4_T1	ORGAN	16	16	heart
NCT001459387	NCT00145938_7_T0	COMPOUND	14	14	sildenafil
NCT001459387	NCT00145938_7_T1	PHENOTYPE	18	20	primary pulmonary hypertension
NCT0014593810	NCT00145938_10_T0	GENE	5	5	PTPH
NCT0014593810	NCT00145938_10_T1	ORGAN	11	11	heart
NCT0014593812	NCT00145938_12_T0	COMPOUND	28	28	sildenafil
NCT0014593812	NCT00145938_12_T1	COMPOUND	23	24	nitric oxide
NCT0014593815	NCT00145938_15_T0	PHENOTYPE	22	22	hypoxemia
NCT0014593815	NCT00145938_15_T1	PHENOTYPE	15	15	chronic
NCT0014593815	NCT00145938_15_T2	PHENOTYPE	18	18	chronic
NCT0014593815	NCT00145938_15_T3	PHENOTYPE	21	21	chronic
NCT0014593815	NCT00145938_15_T4	PHENOTYPE	46	46	cirrhosis
NCT0014593815	NCT00145938_15_T5	GENE	6	6	PH
NCT0014593815	NCT00145938_15_T6	PHENOTYPE	5	5	hypertension
NCT0014593815	NCT00145938_15_T7	PHENOTYPE	16	17	lung disease
NCT0014593815	NCT00145938_15_T8	PHENOTYPE	19	20	thromboembolic disease
NCT0014593815	NCT00145938_15_T9	PHENOTYPE	42	43	portal hypertension
NCT0014593815	NCT00145938_15_T10	PHENOTYPE	9	11	left ventricular dysfunction
NCT0014593815	NCT00145938_15_T11	PHENOTYPE	12	14	valvular heart disease
NCT0014593815	NCT00145938_15_T12	PHENOTYPE	28	30	obstructive sleep apnea
NCT0014593816	NCT00145938_16_T0	GENE	28	28	35
NCT0014593816	NCT00145938_16_T1	ORGAN	14	14	heart
NCT0014593816	NCT00145938_16_T2	GENE	18	18	PH
NCT0014593816	NCT00145938_16_T3	PHENOTYPE	3	4	pulmonary hypertension
NCT0014593816	NCT00145938_16_T4	PHENOTYPE	24	26	pulmonary artery pressure
NCT0014593817	NCT00145938_17_T0	PHENOTYPE	10	10	dilation
NCT0014593817	NCT00145938_17_T1	GENE	5	5	RV
NCT0014593817	NCT00145938_17_T2	GENE	9	9	RV
NCT0014593817	NCT00145938_17_T3	GENE	12	12	RV
NCT0014593817	NCT00145938_17_T4	GENE	18	18	RV
NCT0014593817	NCT00145938_17_T5	GENE	11	11	reduced
NCT0014593817	NCT00145938_17_T6	GENE	4	4	ventricular
NCT0014593817	NCT00145938_17_T7	PHENOTYPE	6	6	dysfunction
NCT0014593817	NCT00145938_17_T8	GENE	21	21	10
NCT0014593818	NCT00145938_18_T0	ORGAN	18	18	liver
NCT0014593818	NCT00145938_18_T1	ORGAN	19	19	transplant
NCT0014593818	NCT00145938_18_T2	PHENOTYPE	13	14	pulmonary hypertension
NCT0014593822	NCT00145938_22_T0	GENE	12	12	PTPH
NCT0014593822	NCT00145938_22_T1	COMPOUND	26	26	sildenafil
NCT0014593823	NCT00145938_23_T0	PHENOTYPE	4	4	syndromes
NCT0014593823	NCT00145938_23_T1	PHENOTYPE	13	14	myocardial ischemia
NCT0014593823	NCT00145938_23_T2	PHENOTYPE	9	11	coronary artery disease
NCT001459516	NCT00145951_6_T0	PHENOTYPE	15	16	depressive disorders
NCT001459641	NCT00145964_1_T0	ORGAN	13	13	liver
NCT001459641	NCT00145964_1_T1	ORGAN	14	14	transplant
NCT001459641	NCT00145964_1_T2	PHENOTYPE	9	10	liver failure
NCT001459641	NCT00145964_1_T3	PHENOTYPE	4	5	liver disease
NCT001459641	NCT00145964_1_T4	PHENOTYPE	2	3	slowly progressive
NCT001459644	NCT00145964_4_T0	BIOLOGICAL_PROCESS	11	12	immune response
NCT001459648	NCT00145964_8_T0	GENE	1	1	PTPN22
NCT001459648	NCT00145964_8_T1	GENE	4	4	has
NCT001459648	NCT00145964_8_T2	PHENOTYPE	23	24	autoimmune diseases
NCT001459770	NCT00145977_0_T0	PHENOTYPE	3	4	Postmenopausal Osteoporosis
NCT001459774	NCT00145977_4_T0	PHENOTYPE	40	40	osteoporosis
NCT001459774	NCT00145977_4_T1	PHENOTYPE	29	29	fragility
NCT001459774	NCT00145977_4_T2	TISSUE	19	20	trabecular bone
NCT001459775	NCT00145977_5_T0	PHENOTYPE	23	23	osteoporosis
NCT001459776	NCT00145977_6_T0	PHENOTYPE	4	4	osteoporosis
NCT001459777	NCT00145977_7_T0	GENE	11	11	has
NCT001459777	NCT00145977_7_T1	COMPOUND	9	9	DXA
NCT001459777	NCT00145977_7_T2	PHENOTYPE	17	18	radiation exposure
NCT0014597713	NCT00145977_13_T0	TISSUE	23	24	trabecular bone
NCT0014597714	NCT00145977_14_T0	GENE	2	2	has
NCT0014597714	NCT00145977_14_T1	GENE	0	0	Dr
NCT0014597715	NCT00145977_15_T0	GENE	37	37	FMP
NCT0014597715	NCT00145977_15_T1	TISSUE	26	27	trabecular bone
NCT0014597718	NCT00145977_18_T0	TISSUE	10	11	trabecular bone
NCT0014597722	NCT00145977_22_T0	GENE	12	12	has
NCT0014597729	NCT00145977_29_T0	PHENOTYPE	8	8	fragility
NCT0014597733	NCT00145977_33_T0	PHENOTYPE	27	27	suffers
NCT0014597734	NCT00145977_34_T0	PHENOTYPE	6	6	peripheral
NCT0014597735	NCT00145977_35_T0	COMPOUND	2	2	DXA
NCT0014597737	NCT00145977_37_T0	GENE	13	13	has
NCT0014597737	NCT00145977_37_T1	PHENOTYPE	37	37	osteoporosis
NCT0014597740	NCT00145977_40_T0	PHENOTYPE	16	16	fractures
NCT0014597743	NCT00145977_43_T0	COMPOUND	10	10	calcium
NCT0014597743	NCT00145977_43_T1	GENE	30	30	PEPI
NCT0014597744	NCT00145977_44_T0	COMPOUND	14	14	calcium
NCT0014597744	NCT00145977_44_T1	PHENOTYPE	6	6	questioning
NCT0014597744	NCT00145977_44_T2	COMPOUND	16	16	alendronate
NCT0014597748	NCT00145977_48_T0	ORGAN	22	22	spine
NCT0014597748	NCT00145977_48_T1	PHENOTYPE	16	16	deformities
NCT001459902	NCT00145990_2_T0	COMPOUND	5	5	methacholine
NCT001459904	NCT00145990_4_T0	COMPOUND	4	4	methacholine
NCT001459904	NCT00145990_4_T1	COMPOUND	18	18	methacholine
NCT0014599010	NCT00145990_10_T0	PHENOTYPE	14	14	asthma
NCT0014599010	NCT00145990_10_T1	COMPOUND	9	9	methacholine
NCT0014599011	NCT00145990_11_T0	COMPOUND	9	9	methacholine
NCT0014599013	NCT00145990_13_T0	COMPOUND	7	7	methacholine
NCT0014599014	NCT00145990_14_T0	GENE	12	12	paired
NCT001460032	NCT00146003_2_T0	PHENOTYPE	6	6	pathophysiology
NCT001460292	NCT00146029_2_T0	COMPOUND	18	18	docetaxel
NCT001460293	NCT00146029_3_T0	PHENOTYPE	9	9	tumor
NCT001460293	NCT00146029_3_T1	GENE	17	17	CYP
NCT001460293	NCT00146029_3_T2	GENE	36	36	CYP
NCT001460422	NCT00146042_2_T0	ORGAN	23	23	liver
NCT001460425	NCT00146042_5_T0	COMPOUND	3	3	docetaxel
NCT001460426	NCT00146042_6_T0	COMPOUND	2	2	docetaxel
NCT001460426	NCT00146042_6_T1	PHENOTYPE	21	23	metastatic breast cancer
NCT001460429	NCT00146042_9_T0	ORGAN	23	23	liver
NCT0014604212	NCT00146042_12_T0	COMPOUND	3	3	docetaxel
NCT0014604213	NCT00146042_13_T0	COMPOUND	2	2	docetaxel
NCT0014604213	NCT00146042_13_T1	PHENOTYPE	21	23	metastatic breast cancer
NCT0014604213	NCT00146042_13_T2	PHENOTYPE	34	36	metastatic breast cancer
NCT0014604216	NCT00146042_16_T0	GENE	18	18	MRI
NCT0014604216	NCT00146042_16_T1	PHENOTYPE	8	9	primary tumor
NCT0014604217	NCT00146042_17_T0	COMPOUND	19	19	docetaxel
NCT0014604220	NCT00146042_20_T0	COMPOUND	5	5	docetaxel
NCT0014604220	NCT00146042_20_T1	COMPOUND	16	16	docetaxel
NCT0014604222	NCT00146042_22_T0	GENE	15	15	6.5
NCT0014604226	NCT00146042_26_T0	PHENOTYPE	15	15	osteoporosis
NCT001460553	NCT00146055_3_T0	CELL	7	7	cells
NCT001460554	NCT00146055_4_T0	CELL	8	8	cells
NCT001460554	NCT00146055_4_T1	CELL	15	15	cells
NCT001460555	NCT00146055_5_T0	PHENOTYPE	3	3	damages
NCT001460555	NCT00146055_5_T1	PHENOTYPE	2	2	severely
NCT001460555	NCT00146055_5_T2	CELL	19	20	blood cells
NCT001460555	NCT00146055_5_T3	ORGAN	6	7	bone marrow
NCT001460557	NCT00146055_7_T0	PHENOTYPE	5	5	complications
NCT0014605520	NCT00146055_20_T0	PHENOTYPE	18	18	tumor
NCT0014605520	NCT00146055_20_T1	PHENOTYPE	4	5	Hodgkin's lymphoma
NCT0014605524	NCT00146055_24_T0	PHENOTYPE	7	7	macroglobulinemia
NCT0014605524	NCT00146055_24_T1	PHENOTYPE	2	4	chronic lymphocytic leukemia
NCT0014605538	NCT00146055_38_T0	GENE	8	8	blot
NCT0014605538	NCT00146055_38_T1	PHENOTYPE	4	5	HIV infection
NCT0014605540	NCT00146055_40_T0	ORGAN	7	7	transplant
NCT0014605540	NCT00146055_40_T1	PHENOTYPE	15	16	personality disorder
NCT0014605540	NCT00146055_40_T2	PHENOTYPE	11	12	substance abuse
NCT001460688	NCT00146068_8_T0	GENE	7	7	IFNB
NCT001460688	NCT00146068_8_T1	BIOLOGICAL_PROCESS	16	17	antigen presentation
NCT001460688	NCT00146068_8_T2	BIOLOGICAL_PROCESS	3	4	T-cell activation
NCT001460688	NCT00146068_8_T3	GENE	9	11	MHC class II
NCT0014606810	NCT00146068_10_T0	GENE	16	16	RR
NCT0014606810	NCT00146068_10_T1	GENE	17	17	MS
NCT0014606818	NCT00146068_18_T0	GENE	1	1	has
NCT0014606818	NCT00146068_18_T1	GENE	9	9	5.5
NCT0014606818	NCT00146068_18_T2	COMPOUND	4	4	EDSS
NCT0014606820	NCT00146068_20_T0	GENE	0	0	MRI
NCT0014606820	NCT00146068_20_T1	GENE	21	21	T2
NCT0014606822	NCT00146068_22_T0	GENE	1	1	has
NCT0014606824	NCT00146068_24_T0	PHENOTYPE	16	16	secondary
NCT0014606824	NCT00146068_24_T1	GENE	5	5	CD
NCT0014606824	NCT00146068_24_T2	GENE	12	12	MS
NCT0014606824	NCT00146068_24_T3	GENE	21	21	MS
NCT0014606824	NCT00146068_24_T4	PHENOTYPE	17	17	progressive
NCT0014606824	NCT00146068_24_T5	PHENOTYPE	20	20	progressive
NCT0014606824	NCT00146068_24_T6	GENE	1	1	has
NCT0014606826	NCT00146068_26_T0	GENE	1	1	has
NCT0014606827	NCT00146068_27_T0	GENE	1	1	has
NCT0014606829	NCT00146068_29_T0	PHENOTYPE	12	12	septicemia
NCT0014606829	NCT00146068_29_T1	PHENOTYPE	11	11	pneumonia
NCT0014606829	NCT00146068_29_T2	GENE	2	2	had
NCT0014606829	NCT00146068_29_T3	GENE	1	1	has
NCT0014606829	NCT00146068_29_T4	PHENOTYPE	10	10	abscess
NCT0014606829	NCT00146068_29_T5	PHENOTYPE	9	9	cellulitis
NCT0014606831	NCT00146068_31_T0	GENE	1	1	has
NCT0014606831	NCT00146068_31_T1	PHENOTYPE	7	8	laboratory results
NCT0014606842	NCT00146068_42_T0	GENE	1	1	has
NCT0014606842	NCT00146068_42_T1	PHENOTYPE	5	6	alcohol abuse
NCT0014606843	NCT00146068_43_T0	PHENOTYPE	14	14	sterile
NCT0014606846	NCT00146068_46_T0	GENE	2	2	had
NCT0014606846	NCT00146068_46_T1	GENE	1	1	has
NCT001460813	NCT00146081_3_T0	PHENOTYPE	6	6	obesity
NCT001460816	NCT00146081_6_T0	PHENOTYPE	41	42	Group B
NCT001460816	NCT00146081_6_T1	PHENOTYPE	8	9	weight loss
NCT001460817	NCT00146081_7_T0	PHENOTYPE	15	16	weight loss
NCT001460817	NCT00146081_7_T1	PHENOTYPE	26	27	weight loss
NCT001460818	NCT00146081_8_T0	COMPOUND	4	4	1
NCT001460818	NCT00146081_8_T1	COMPOUND	28	28	2
NCT001460818	NCT00146081_8_T2	COMPOUND	46	46	3
NCT001460818	NCT00146081_8_T3	PHENOTYPE	5	6	weight loss
NCT001460818	NCT00146081_8_T4	PHENOTYPE	47	48	weight loss
NCT001460818	NCT00146081_8_T5	PHENOTYPE	26	27	Group B
NCT001460818	NCT00146081_8_T6	PHENOTYPE	44	45	Group B
NCT001460819	NCT00146081_9_T0	PHENOTYPE	18	18	CVD
NCT001460819	NCT00146081_9_T1	PHENOTYPE	0	0	Secondary
NCT001460943	NCT00146094_3_T0	PHENOTYPE	17	17	osteopenia
NCT001460943	NCT00146094_3_T1	PHENOTYPE	19	19	osteoporosis
NCT001461201	NCT00146120_1_T0	PHENOTYPE	9	9	AML
NCT001461201	NCT00146120_1_T1	PHENOTYPE	31	31	remission
NCT001461201	NCT00146120_1_T2	PHENOTYPE	47	47	remission
NCT001461203	NCT00146120_3_T0	GENE	8	8	ICE
NCT001461203	NCT00146120_3_T1	GENE	14	14	ICE
NCT001461208	NCT00146120_8_T0	PHENOTYPE	19	19	conditioning
NCT001461334	NCT00146133_4_T0	PHENOTYPE	8	9	weight loss
NCT001461463	NCT00146146_3_T0	COMPOUND	15	15	androgen
NCT001461463	NCT00146146_3_T1	COMPOUND	11	11	testosterone
NCT001461465	NCT00146146_5_T0	COMPOUND	13	13	testosterone
NCT001461466	NCT00146146_6_T0	COMPOUND	9	9	androgen
NCT001461469	NCT00146146_9_T0	COMPOUND	12	12	testosterone
NCT001461469	NCT00146146_9_T1	COMPOUND	15	15	estradiol
NCT0014614610	NCT00146146_10_T0	COMPOUND	15	15	letrozole
NCT0014614610	NCT00146146_10_T1	GENE	17	17	aromatase
NCT0014614610	NCT00146146_10_T2	COMPOUND	6	7	testosterone undecanoate
NCT0014614610	NCT00146146_10_T3	PHENOTYPE	19	20	Group B
NCT0014614611	NCT00146146_11_T0	COMPOUND	12	12	dutasteride
NCT0014614617	NCT00146146_17_T0	PHENOTYPE	7	7	fulfillment
NCT0014614620	NCT00146146_20_T0	PHENOTYPE	11	12	pulse rate
NCT0014614625	NCT00146146_25_T0	ORGAN	0	0	Serum
NCT0014614625	NCT00146146_25_T1	GENE	4	4	ml
NCT0014614626	NCT00146146_26_T0	PHENOTYPE	17	17	acne
NCT0014614626	NCT00146146_26_T1	PHENOTYPE	19	19	gynecomastia
NCT0014614626	NCT00146146_26_T2	PHENOTYPE	7	8	external genitalia
NCT0014614629	NCT00146146_29_T0	GENE	11	11	SR
NCT001461720	NCT00146172_0_T0	PHENOTYPE	4	4	Tumors
NCT001461722	NCT00146172_2_T0	PHENOTYPE	14	14	tumor
NCT001461850	NCT00146185_0_T0	PHENOTYPE	10	10	Needle-Stick
NCT001461853	NCT00146185_3_T0	GENE	22	22	2.3
NCT001461853	NCT00146185_3_T1	PHENOTYPE	20	20	analgesia
NCT001461853	NCT00146185_3_T2	COMPOUND	13	13	lidocaine
NCT001461853	NCT00146185_3_T3	TISSUE	16	16	epidermis
NCT001461854	NCT00146185_4_T0	PHENOTYPE	35	35	peripheral
NCT001461854	NCT00146185_4_T1	GENE	5	5	III
NCT001461855	NCT00146185_5_T0	PHENOTYPE	9	9	centers
NCT001461857	NCT00146185_7_T0	PHENOTYPE	9	9	analgesia
NCT001461859	NCT00146185_9_T0	GENE	18	18	painless
NCT001461859	NCT00146185_9_T1	PHENOTYPE	12	12	anesthesia
NCT0014618511	NCT00146185_11_T0	PHENOTYPE	38	38	peripheral
NCT0014618511	NCT00146185_11_T1	GENE	5	5	III
NCT0014618512	NCT00146185_12_T0	PHENOTYPE	9	9	centers
NCT0014618513	NCT00146185_13_T0	GENE	5	5	3.7
NCT0014618514	NCT00146185_14_T0	GENE	11	11	0.5
NCT0014618526	NCT00146185_26_T0	PHENOTYPE	1	1	sterile
NCT001462240	NCT00146224_0_T0	PHENOTYPE	9	9	Anemia
NCT001462240	NCT00146224_0_T1	PHENOTYPE	13	15	Chronic Kidney Disease
NCT001462372	NCT00146237_2_T0	PHENOTYPE	22	22	strategies
NCT001462374	NCT00146237_4_T0	COMPOUND	10	10	lithium
NCT001462374	NCT00146237_4_T1	GENE	14	14	al
NCT001462374	NCT00146237_4_T2	GENE	13	13	et
NCT001462375	NCT00146237_5_T0	COMPOUND	2	2	lithium
NCT001462375	NCT00146237_5_T1	GENE	7	7	3.4
NCT001462376	NCT00146237_6_T0	COMPOUND	12	12	lithium
NCT001462377	NCT00146237_7_T0	COMPOUND	14	14	valproate
NCT001462377	NCT00146237_7_T1	COMPOUND	0	0	Lithium
NCT001462377	NCT00146237_7_T2	GENE	4	4	has
NCT001462377	NCT00146237_7_T3	COMPOUND	12	12	carbamazepine
NCT001462378	NCT00146237_8_T0	GENE	24	24	al
NCT001462378	NCT00146237_8_T1	GENE	34	34	al
NCT001462378	NCT00146237_8_T2	GENE	30	30	BP
NCT001462378	NCT00146237_8_T3	GENE	23	23	et
NCT001462378	NCT00146237_8_T4	GENE	33	33	et
NCT001462378	NCT00146237_8_T5	PHENOTYPE	21	21	manic
NCT001462378	NCT00146237_8_T6	GENE	11	11	has
NCT001462379	NCT00146237_9_T0	COMPOUND	6	6	lithium
NCT001462379	NCT00146237_9_T1	GENE	13	13	sparse
NCT0014623710	NCT00146237_10_T0	COMPOUND	6	6	valproate
NCT0014623710	NCT00146237_10_T1	GENE	3	3	al
NCT0014623710	NCT00146237_10_T2	GENE	9	9	al
NCT0014623710	NCT00146237_10_T3	GENE	2	2	et
NCT0014623710	NCT00146237_10_T4	GENE	8	8	et
NCT0014623711	NCT00146237_11_T0	COMPOUND	19	19	lithium
NCT0014623711	NCT00146237_11_T1	GENE	13	13	al
NCT0014623711	NCT00146237_11_T2	COMPOUND	29	29	phenytoin
NCT0014623711	NCT00146237_11_T3	PHENOTYPE	9	10	unipolar depression
NCT0014623712	NCT00146237_12_T0	GENE	23	23	al
NCT0014623713	NCT00146237_13_T0	GENE	33	33	2.3
NCT0014623713	NCT00146237_13_T1	PHENOTYPE	19	19	reluctant
NCT0014623715	NCT00146237_15_T0	COMPOUND	33	33	lithium
NCT0014623715	NCT00146237_15_T1	COMPOUND	10	10	phenytoin
NCT0014623715	NCT00146237_15_T2	COMPOUND	22	22	phenytoin
NCT0014623715	NCT00146237_15_T3	COMPOUND	26	26	phenytoin
NCT0014623715	NCT00146237_15_T4	GENE	5	5	Li
NCT0014623717	NCT00146237_17_T0	PHENOTYPE	22	22	strategies
NCT0014623719	NCT00146237_19_T0	COMPOUND	10	10	lithium
NCT0014623719	NCT00146237_19_T1	GENE	14	14	al
NCT0014623719	NCT00146237_19_T2	GENE	13	13	et
NCT0014623720	NCT00146237_20_T0	COMPOUND	2	2	lithium
NCT0014623720	NCT00146237_20_T1	GENE	7	7	3.4
NCT0014623721	NCT00146237_21_T0	COMPOUND	12	12	lithium
NCT0014623722	NCT00146237_22_T0	COMPOUND	14	14	valproate
NCT0014623722	NCT00146237_22_T1	COMPOUND	0	0	Lithium
NCT0014623722	NCT00146237_22_T2	GENE	4	4	has
NCT0014623722	NCT00146237_22_T3	COMPOUND	12	12	carbamazepine
NCT0014623723	NCT00146237_23_T0	GENE	24	24	al
NCT0014623723	NCT00146237_23_T1	GENE	34	34	al
NCT0014623723	NCT00146237_23_T2	GENE	30	30	BP
NCT0014623723	NCT00146237_23_T3	GENE	23	23	et
NCT0014623723	NCT00146237_23_T4	GENE	33	33	et
NCT0014623723	NCT00146237_23_T5	PHENOTYPE	21	21	manic
NCT0014623723	NCT00146237_23_T6	GENE	11	11	has
NCT0014623724	NCT00146237_24_T0	COMPOUND	6	6	lithium
NCT0014623724	NCT00146237_24_T1	GENE	13	13	sparse
NCT0014623725	NCT00146237_25_T0	COMPOUND	6	6	valproate
NCT0014623725	NCT00146237_25_T1	GENE	3	3	al
NCT0014623725	NCT00146237_25_T2	GENE	9	9	al
NCT0014623725	NCT00146237_25_T3	GENE	2	2	et
NCT0014623725	NCT00146237_25_T4	GENE	8	8	et
NCT0014623726	NCT00146237_26_T0	COMPOUND	19	19	lithium
NCT0014623726	NCT00146237_26_T1	GENE	13	13	al
NCT0014623726	NCT00146237_26_T2	COMPOUND	29	29	phenytoin
NCT0014623726	NCT00146237_26_T3	PHENOTYPE	9	10	unipolar depression
NCT0014623727	NCT00146237_27_T0	GENE	23	23	al
NCT0014623728	NCT00146237_28_T0	GENE	33	33	2.3
NCT0014623728	NCT00146237_28_T1	PHENOTYPE	19	19	reluctant
NCT0014623730	NCT00146237_30_T0	COMPOUND	33	33	lithium
NCT0014623730	NCT00146237_30_T1	COMPOUND	10	10	phenytoin
NCT0014623730	NCT00146237_30_T2	COMPOUND	22	22	phenytoin
NCT0014623730	NCT00146237_30_T3	COMPOUND	26	26	phenytoin
NCT0014623730	NCT00146237_30_T4	GENE	5	5	Li
NCT0014623731	NCT00146237_31_T0	GENE	2	2	has
NCT0014623732	NCT00146237_32_T0	PHENOTYPE	12	13	major depression
NCT0014623734	NCT00146237_34_T0	PHENOTYPE	11	11	illnesses
NCT0014623734	NCT00146237_34_T1	PHENOTYPE	2	5	alcohol or drug abuse
NCT0014623737	NCT00146237_37_T0	COMPOUND	5	5	phenytoin
NCT0014623741	NCT00146237_41_T0	COMPOUND	3	3	phenytoin
NCT0014623743	NCT00146237_43_T0	PHENOTYPE	17	18	gingival hyperplasia
NCT0014623744	NCT00146237_44_T0	PHENOTYPE	2	2	epilepsy
NCT0014623744	NCT00146237_44_T1	PHENOTYPE	6	7	side effect
NCT0014623745	NCT00146237_45_T0	GENE	14	14	al
NCT0014623745	NCT00146237_45_T1	GENE	18	18	al
NCT0014623745	NCT00146237_45_T2	GENE	13	13	et
NCT0014623745	NCT00146237_45_T3	GENE	17	17	et
NCT0014623746	NCT00146237_46_T0	PHENOTYPE	9	9	toxicity
NCT0014623746	NCT00146237_46_T1	PHENOTYPE	1	1	pharmacokinetics
NCT0014623747	NCT00146237_47_T0	PHENOTYPE	6	6	toxicity
NCT0014623750	NCT00146237_50_T0	PHENOTYPE	46	46	ideas
NCT0014623750	NCT00146237_50_T1	COMPOUND	4	4	phenytoin
NCT0014623750	NCT00146237_50_T2	COMPOUND	25	25	phenytoin
NCT0014623750	NCT00146237_50_T3	COMPOUND	36	36	lithium
NCT0014623755	NCT00146237_55_T0	GENE	7	7	al
NCT0014623755	NCT00146237_55_T1	GENE	6	6	et
NCT0014623756	NCT00146237_56_T0	COMPOUND	5	5	fluoxetine
NCT0014623756	NCT00146237_56_T1	COMPOUND	0	0	Lithium
NCT0014623756	NCT00146237_56_T2	PHENOTYPE	8	8	resistant
NCT0014623756	NCT00146237_56_T3	PHENOTYPE	9	10	major depression
NCT0014623758	NCT00146237_58_T0	GENE	7	7	RH
NCT0014623763	NCT00146237_63_T0	COMPOUND	3	3	phenytoin
NCT0014623763	NCT00146237_63_T1	GENE	5	5	BP
NCT0014623764	NCT00146237_64_T0	PHENOTYPE	0	1	Bipolar Disorder
NCT0014623765	NCT00146237_65_T0	GENE	5	5	RH
NCT0014623768	NCT00146237_68_T0	GENE	7	7	RH
NCT0014623771	NCT00146237_71_T0	PHENOTYPE	3	3	Transmission
NCT0014623773	NCT00146237_73_T0	COMPOUND	4	4	fluoxetine
NCT0014623773	NCT00146237_73_T1	PHENOTYPE	6	7	unipolar depression
NCT0014623774	NCT00146237_74_T0	GENE	7	7	Eap
NCT0014623776	NCT00146237_76_T0	COMPOUND	7	7	citalopram
NCT001462502	NCT00146250_2_T0	GENE	1	1	has
NCT001462502	NCT00146250_2_T1	COMPOUND	11	11	oxygen
NCT001462503	NCT00146250_3_T0	COMPOUND	19	19	oxygen
NCT001462503	NCT00146250_3_T1	COMPOUND	28	29	nitrous oxide
NCT001462504	NCT00146250_4_T0	COMPOUND	12	12	oxygen
NCT001462504	NCT00146250_4_T1	COMPOUND	6	7	nitrous oxide
NCT001462508	NCT00146250_8_T0	PHENOTYPE	7	7	atelectasis
NCT001462509	NCT00146250_9_T0	GENE	5	5	bypass
NCT001462509	NCT00146250_9_T1	PHENOTYPE	26	26	anesthesia
NCT001462509	NCT00146250_9_T2	ORGAN	10	11	coronary artery
NCT001462632	NCT00146263_2_T0	PHENOTYPE	17	17	impairment
NCT001462632	NCT00146263_2_T1	PHENOTYPE	20	20	dementia
NCT001462632	NCT00146263_2_T2	GENE	2	2	has
NCT001462632	NCT00146263_2_T3	PHENOTYPE	10	11	cognitive function
NCT0014626311	NCT00146263_11_T0	PHENOTYPE	10	10	suffering
NCT0014626311	NCT00146263_11_T1	PHENOTYPE	12	12	diseases
NCT0014626311	NCT00146263_11_T2	PHENOTYPE	22	22	dementia
NCT0014626311	NCT00146263_11_T3	GENE	2	2	has
NCT0014626312	NCT00146263_12_T0	PHENOTYPE	4	4	dementia
NCT0014626313	NCT00146263_13_T0	PHENOTYPE	8	9	cognitive function
NCT0014626315	NCT00146263_15_T0	PHENOTYPE	26	26	suffering
NCT0014626315	NCT00146263_15_T1	PHENOTYPE	29	29	dementia
NCT0014626315	NCT00146263_15_T2	GENE	13	13	has
NCT0014626315	NCT00146263_15_T3	GENE	20	20	has
NCT0014626320	NCT00146263_20_T0	PHENOTYPE	19	19	suffering
NCT0014626320	NCT00146263_20_T1	PHENOTYPE	22	22	dementia
NCT0014626320	NCT00146263_20_T2	PHENOTYPE	14	15	cognitive function
NCT0014626325	NCT00146263_25_T0	PHENOTYPE	11	11	dementia
NCT0014626325	NCT00146263_25_T1	PHENOTYPE	7	8	cognitive impairment
NCT0014626326	NCT00146263_26_T0	GENE	8	8	Corp
NCT001462892	NCT00146289_2_T0	GENE	12	12	GCP
NCT001462896	NCT00146289_6_T0	COMPOUND	3	3	BMI
NCT0014628920	NCT00146289_20_T0	COMPOUND	6	6	thiazide
NCT0014628920	NCT00146289_20_T1	COMPOUND	22	22	niacin
NCT0014628920	NCT00146289_20_T2	PHENOTYPE	16	17	insulin sensitivity
NCT0014628920	NCT00146289_20_T3	COMPOUND	23	24	nicotinic acid
NCT0014628921	NCT00146289_21_T0	GENE	4	4	OTC
NCT0014628925	NCT00146289_25_T0	PHENOTYPE	5	6	atrial flutter
NCT0014628925	NCT00146289_25_T1	PHENOTYPE	3	4	atrial fibrillation
NCT0014628925	NCT00146289_25_T2	PHENOTYPE	11	12	cardiac arrhythmias
NCT0014628925	NCT00146289_25_T3	PHENOTYPE	0	2	Sustained ventricular tachycardia
NCT0014628931	NCT00146289_31_T0	GENE	0	0	PCI
NCT0014628939	NCT00146289_39_T0	COMPOUND	17	17	estrogen
NCT0014628939	NCT00146289_39_T1	PHENOTYPE	10	10	IUD
NCT0014628943	NCT00146289_43_T0	COMPOUND	1	1	fructose
NCT0014628944	NCT00146289_44_T0	PHENOTYPE	4	5	alcohol dependency
NCT0014628945	NCT00146289_45_T0	PHENOTYPE	4	5	weight loss
NCT001463020	NCT00146302_0_T0	GENE	8	8	BCG
NCT001463020	NCT00146302_0_T1	PHENOTYPE	1	3	Low Birth Weight
NCT001463022	NCT00146302_2_T0	PHENOTYPE	0	0	Pre-term
NCT001463023	NCT00146302_3_T0	GENE	13	13	BCG
NCT001463025	NCT00146302_5_T0	GENE	0	0	BCG
NCT001463025	NCT00146302_5_T1	GENE	17	17	BCG
NCT001463025	NCT00146302_5_T2	GENE	1	1	has
NCT001463027	NCT00146302_7_T0	COMPOUND	10	10	LBW
NCT001463027	NCT00146302_7_T1	GENE	4	4	BCG
NCT001463027	NCT00146302_7_T2	PHENOTYPE	7	9	low birth weight
NCT001463029	NCT00146302_9_T0	COMPOUND	2	2	LBW
NCT001463029	NCT00146302_9_T1	PHENOTYPE	0	0	Recruitment
NCT0014630210	NCT00146302_10_T0	GENE	16	16	BCG
NCT0014630210	NCT00146302_10_T1	PHENOTYPE	21	21	centres
NCT0014630211	NCT00146302_11_T0	COMPOUND	3	3	LBW
NCT0014630212	NCT00146302_12_T0	GENE	16	16	BCG
NCT0014630213	NCT00146302_13_T0	PHENOTYPE	25	25	infections
NCT0014630213	NCT00146302_13_T1	PHENOTYPE	28	28	malaria
NCT0014630214	NCT00146302_14_T0	PHENOTYPE	27	27	centre
NCT0014630215	NCT00146302_15_T0	COMPOUND	8	8	LBW
NCT0014630216	NCT00146302_16_T0	GENE	19	19	had
NCT0014630217	NCT00146302_17_T0	PHENOTYPE	22	22	centre
NCT0014630217	NCT00146302_17_T1	GENE	28	28	has
NCT0014630217	NCT00146302_17_T2	PHENOTYPE	29	30	gained weight
NCT0014630218	NCT00146302_18_T0	GENE	22	22	BCG
NCT0014630218	NCT00146302_18_T1	GENE	31	31	had
NCT0014630219	NCT00146302_19_T0	GENE	23	23	BCG
NCT0014630219	NCT00146302_19_T1	PHENOTYPE	17	17	centres
NCT0014630224	NCT00146302_24_T0	GENE	3	3	has
NCT0014630228	NCT00146302_28_T0	COMPOUND	11	11	LBW
NCT0014630228	NCT00146302_28_T1	PHENOTYPE	7	7	complications
NCT0014630228	NCT00146302_28_T2	GENE	9	9	BCG
NCT0014630229	NCT00146302_29_T0	PHENOTYPE	4	4	complications
NCT0014630231	NCT00146302_31_T0	COMPOUND	13	13	LBW
NCT0014630231	NCT00146302_31_T1	GENE	5	5	BCG
NCT0014630231	NCT00146302_31_T2	GENE	26	26	BCG
NCT0014630231	NCT00146302_31_T3	PHENOTYPE	31	31	centre
NCT0014630232	NCT00146302_32_T0	COMPOUND	7	7	LBW
NCT0014630232	NCT00146302_32_T1	GENE	5	5	BCG
NCT001463150	NCT00146315_0_T0	PHENOTYPE	6	8	Coronary Heart Disease
NCT001463153	NCT00146315_3_T0	GENE	2	2	has
NCT001463153	NCT00146315_3_T1	GENE	8	8	CHD
NCT001463156	NCT00146315_6_T0	GENE	53	53	HR
NCT001463156	NCT00146315_6_T1	PHENOTYPE	42	42	stationary
NCT001463156	NCT00146315_6_T2	PHENOTYPE	34	34	centers
NCT001463156	NCT00146315_6_T3	GENE	11	11	CHD
NCT001463156	NCT00146315_6_T4	PHENOTYPE	18	20	quality of life
NCT001463157	NCT00146315_7_T0	PHENOTYPE	11	11	centers
NCT001463157	NCT00146315_7_T1	GENE	5	5	CHD
NCT001463158	NCT00146315_8_T0	PHENOTYPE	19	19	complication
NCT001463158	NCT00146315_8_T1	PHENOTYPE	14	16	cardiovascular risk factor
NCT001463284	NCT00146328_4_T0	PHENOTYPE	15	16	virologic failure
NCT001463289	NCT00146328_9_T0	PHENOTYPE	3	3	Immunodeficiency
NCT001463289	NCT00146328_9_T1	GENE	24	24	Blot
NCT001463289	NCT00146328_9_T2	PHENOTYPE	33	33	HIV
NCT001463289	NCT00146328_9_T3	GENE	19	19	kit
NCT001463289	NCT00146328_9_T4	ORGAN	32	32	plasma
NCT0014632818	NCT00146328_18_T0	PHENOTYPE	28	28	impairment
NCT0014632818	NCT00146328_18_T1	PHENOTYPE	16	17	narcotic use
NCT0014632818	NCT00146328_18_T2	PHENOTYPE	8	10	other substance abuse
NCT0014632822	NCT00146328_22_T0	PHENOTYPE	5	6	drug allergy
NCT0014632826	NCT00146328_26_T0	PHENOTYPE	1	1	HIV
NCT0014632826	NCT00146328_26_T1	PHENOTYPE	4	4	HIV
NCT0014632827	NCT00146328_27_T0	COMPOUND	19	19	tipranavir
NCT0014632827	NCT00146328_27_T1	GENE	32	32	has
NCT0014632827	NCT00146328_27_T2	PHENOTYPE	33	33	resolved
NCT0014632833	NCT00146328_33_T0	COMPOUND	16	16	tipranavir
NCT001463413	NCT00146341_3_T0	GENE	15	15	DBP
NCT001463413	NCT00146341_3_T1	GENE	19	19	Hg
NCT001463414	NCT00146341_4_T0	GENE	15	15	DBP
NCT001463414	NCT00146341_4_T1	GENE	19	19	Hg
NCT001463415	NCT00146341_5_T0	GENE	1	1	BP
NCT001463417	NCT00146341_7_T0	COMPOUND	16	16	telmisartan
NCT001463419	NCT00146341_9_T0	GENE	3	3	null
NCT0014634110	NCT00146341_10_T0	GENE	13	13	DBP
NCT0014634113	NCT00146341_13_T0	GENE	9	9	DBP
NCT0014634113	NCT00146341_13_T1	PHENOTYPE	3	3	hypertension
NCT0014634114	NCT00146341_14_T0	GENE	11	11	DBP
NCT0014634114	NCT00146341_14_T1	COMPOUND	7	7	telmisartan
NCT0014634122	NCT00146341_22_T0	PHENOTYPE	2	2	hypokalaemia
NCT0014634122	NCT00146341_22_T1	PHENOTYPE	4	4	hyperkalaemia
NCT0014634123	NCT00146341_23_T0	PHENOTYPE	1	2	volume depletion
NCT0014634124	NCT00146341_24_T0	PHENOTYPE	1	2	sodium depletion
NCT0014634125	NCT00146341_25_T0	PHENOTYPE	0	1	Primary aldosteronism
NCT0014634126	NCT00146341_26_T0	COMPOUND	1	1	fructose
NCT0014634127	NCT00146341_27_T0	PHENOTYPE	2	2	disorders
NCT0014634127	NCT00146341_27_T1	PHENOTYPE	3	3	cholestasis
NCT0014634128	NCT00146341_28_T0	PHENOTYPE	3	3	secondary
NCT0014634130	NCT00146341_30_T0	PHENOTYPE	6	6	CHF
NCT0014634130	NCT00146341_30_T1	PHENOTYPE	0	2	Congestive heart failure
NCT0014634133	NCT00146341_33_T0	PHENOTYPE	0	1	Myocardial infarction
NCT001463544	NCT00146354_4_T0	COMPOUND	42	42	MGH
NCT001463671	NCT00146367_1_T0	COMPOUND	10	10	ALED
NCT001463671	NCT00146367_1_T1	COMPOUND	25	25	ALED
NCT001463671	NCT00146367_1_T2	PHENOTYPE	14	14	arthritis
NCT001463674	NCT00146367_4_T0	COMPOUND	20	20	ALED
NCT001463674	NCT00146367_4_T1	PHENOTYPE	22	23	cardiovascular disease
NCT001463675	NCT00146367_5_T0	COMPOUND	5	5	ALED
NCT001463675	NCT00146367_5_T1	PHENOTYPE	11	11	arthritis
NCT001463676	NCT00146367_6_T0	COMPOUND	22	22	ALED
NCT001463676	NCT00146367_6_T1	PHENOTYPE	26	26	arthritis
NCT001463677	NCT00146367_7_T0	BIOLOGICAL_PROCESS	24	24	Aging
NCT001463678	NCT00146367_8_T0	COMPOUND	10	10	ALED
NCT001463678	NCT00146367_8_T1	COMPOUND	25	25	ALED
NCT001463678	NCT00146367_8_T2	PHENOTYPE	14	14	arthritis
NCT0014636712	NCT00146367_12_T0	PHENOTYPE	9	9	arthritis
NCT0014636712	NCT00146367_12_T1	GENE	8	8	has
NCT0014636714	NCT00146367_14_T0	GENE	14	14	NC
NCT001463803	NCT00146380_3_T0	PHENOTYPE	3	3	HIV
NCT001463804	NCT00146380_4_T0	PHENOTYPE	16	16	HIV
NCT001463805	NCT00146380_5_T0	PHENOTYPE	13	13	HIV
NCT001463807	NCT00146380_7_T0	GENE	10	10	II
NCT001463807	NCT00146380_7_T1	GENE	18	18	CD4
NCT001463807	NCT00146380_7_T2	PHENOTYPE	42	42	HIV
NCT001463807	NCT00146380_7_T3	PHENOTYPE	28	28	tolerance
NCT001463808	NCT00146380_8_T0	PHENOTYPE	12	12	HIV
NCT001463808	NCT00146380_8_T1	PHENOTYPE	1	1	Transmission
NCT0014638010	NCT00146380_10_T0	PHENOTYPE	6	6	HIV
NCT0014638010	NCT00146380_10_T1	BIOLOGICAL_PROCESS	12	12	gestation
NCT0014638016	NCT00146380_16_T0	GENE	10	10	O12
NCT0014638016	NCT00146380_16_T1	PHENOTYPE	31	31	Transmission
NCT0014638016	NCT00146380_16_T2	PHENOTYPE	15	15	malaria
NCT0014638016	NCT00146380_16_T3	PHENOTYPE	16	17	vertical transmission
NCT0014638018	NCT00146380_18_T0	COMPOUND	6	6	ARVs
NCT0014638020	NCT00146380_20_T0	PHENOTYPE	3	3	HIV
NCT0014638020	NCT00146380_20_T1	PHENOTYPE	46	46	HIV
NCT0014638020	NCT00146380_20_T2	GENE	12	12	has
NCT0014638020	NCT00146380_20_T3	BIOLOGICAL_PROCESS	10	10	gestation
NCT0014638027	NCT00146380_27_T0	PHENOTYPE	18	18	anemia
NCT0014638030	NCT00146380_30_T0	COMPOUND	1	1	creatinine
NCT0014638030	NCT00146380_30_T1	GENE	2	2	1.5
NCT0014638030	NCT00146380_30_T2	ORGAN	0	0	Serum
NCT0014638031	NCT00146380_31_T0	PHENOTYPE	0	0	Hgb
NCT0014638033	NCT00146380_33_T0	PHENOTYPE	0	1	Platelet count
NCT0014638035	NCT00146380_35_T0	GENE	2	2	CD4
NCT0014638036	NCT00146380_36_T0	PHENOTYPE	13	14	Hepatitis C
NCT0014638036	NCT00146380_36_T1	PHENOTYPE	2	3	Hepatitis B
NCT0014638036	NCT00146380_36_T2	PHENOTYPE	8	9	Hepatitis B
NCT0014638037	NCT00146380_37_T0	GENE	19	19	34.36
NCT0014638037	NCT00146380_37_T1	GENE	4	4	met
NCT0014638037	NCT00146380_37_T2	BIOLOGICAL_PROCESS	21	21	gestation
NCT0014638039	NCT00146380_39_T0	PHENOTYPE	4	4	HIV
NCT0014638039	NCT00146380_39_T1	GENE	0	0	Is
NCT0014638043	NCT00146380_43_T0	PHENOTYPE	8	9	allergic reaction
NCT0014638045	NCT00146380_45_T0	COMPOUND	16	16	sulfate
NCT0014638045	NCT00146380_45_T1	COMPOUND	15	15	magnesium
NCT0014638046	NCT00146380_46_T0	COMPOUND	13	13	quinidine
NCT0014638046	NCT00146380_46_T1	COMPOUND	23	23	simvastatin
NCT0014638046	NCT00146380_46_T2	COMPOUND	26	26	triazolam
NCT0014638046	NCT00146380_46_T3	COMPOUND	18	18	pimozide
NCT0014638046	NCT00146380_46_T4	COMPOUND	12	12	amiodarone
NCT0014638046	NCT00146380_46_T5	COMPOUND	24	24	midazolam
NCT0014638046	NCT00146380_46_T6	COMPOUND	22	22	lovastatin
NCT0014638050	NCT00146380_50_T0	PHENOTYPE	17	17	malignancy
NCT0014638054	NCT00146380_54_T0	PHENOTYPE	0	0	Chronic
NCT0014638054	NCT00146380_54_T1	PHENOTYPE	4	5	drug use
NCT0014638056	NCT00146380_56_T0	GENE	10	10	NOT
NCT001463936	NCT00146393_6_T0	GENE	7	7	PACE
NCT001463937	NCT00146393_7_T0	GENE	6	6	The
NCT001463938	NCT00146393_8_T0	GENE	4	4	PACE
NCT001463938	NCT00146393_8_T1	GENE	15	15	PACE
NCT0014639310	NCT00146393_10_T0	GENE	6	6	AF
NCT0014639310	NCT00146393_10_T1	GENE	23	23	PACE
NCT0014639312	NCT00146393_12_T0	GENE	12	12	PACE
NCT0014639312	NCT00146393_12_T1	GENE	20	20	PACE
NCT0014639314	NCT00146393_14_T0	PHENOTYPE	5	5	arthritis
NCT0014639314	NCT00146393_14_T1	GENE	9	9	PACE
NCT0014639314	NCT00146393_14_T2	GENE	16	16	PACE
NCT0014639316	NCT00146393_16_T0	PHENOTYPE	11	11	arthritis
NCT0014639316	NCT00146393_16_T1	GENE	6	6	PACE
NCT0014639318	NCT00146393_18_T0	GENE	5	5	PACE
NCT0014639320	NCT00146393_20_T0	GENE	9	9	PACE
NCT001464192	NCT00146419_2_T0	PHENOTYPE	16	16	HIV
NCT001464192	NCT00146419_2_T1	GENE	1	1	SUN
NCT001464194	NCT00146419_4_T0	PHENOTYPE	14	14	complications
NCT001464194	NCT00146419_4_T1	GENE	3	3	has
NCT001464195	NCT00146419_5_T0	PHENOTYPE	23	23	cancers
NCT001464195	NCT00146419_5_T1	PHENOTYPE	21	21	diseases
NCT001464196	NCT00146419_6_T0	PHENOTYPE	8	8	HIV
NCT001464196	NCT00146419_6_T1	PHENOTYPE	31	31	HIV
NCT001464196	NCT00146419_6_T2	PHENOTYPE	39	39	practices
NCT001464198	NCT00146419_8_T0	PHENOTYPE	20	20	HIV
NCT001464198	NCT00146419_8_T1	PHENOTYPE	23	23	HIV
NCT001464198	NCT00146419_8_T2	PHENOTYPE	26	26	centers
NCT001464198	NCT00146419_8_T3	GENE	1	1	SUN
NCT0014641911	NCT00146419_11_T0	PHENOTYPE	14	14	HIV
NCT0014641913	NCT00146419_13_T0	PHENOTYPE	9	9	complications
NCT0014641913	NCT00146419_13_T1	PHENOTYPE	24	24	complications
NCT001464452	NCT00146445_2_T0	COMPOUND	8	8	1
NCT001464452	NCT00146445_2_T1	COMPOUND	23	23	2
NCT001464452	NCT00146445_2_T2	COMPOUND	35	35	3
NCT001464452	NCT00146445_2_T3	PHENOTYPE	30	30	HIV
NCT001464452	NCT00146445_2_T4	PHENOTYPE	39	39	HIV
NCT001464452	NCT00146445_2_T5	PHENOTYPE	21	22	HIV infection
NCT001464455	NCT00146445_5_T0	GENE	9	9	CD4
NCT001464582	NCT00146458_2_T0	TISSUE	17	18	lymph nodes
NCT001464583	NCT00146458_3_T0	GENE	3	3	MRI
NCT001464583	NCT00146458_3_T1	PHENOTYPE	11	13	enlarged lymph nodes
NCT001464584	NCT00146458_4_T0	TISSUE	5	6	lymph node
NCT001464584	NCT00146458_4_T1	PHENOTYPE	20	21	reactive hyperplasia
NCT001464585	NCT00146458_5_T0	PHENOTYPE	14	14	malignancy
NCT001464585	NCT00146458_5_T1	PHENOTYPE	21	21	malignancy
NCT001464585	NCT00146458_5_T2	GENE	2	2	MRI
NCT001464585	NCT00146458_5_T3	COMPOUND	3	3	18F-FDG
NCT001464585	NCT00146458_5_T4	PHENOTYPE	18	19	benign tumor
NCT001464586	NCT00146458_6_T0	GENE	26	26	MRI
NCT001464586	NCT00146458_6_T1	PHENOTYPE	12	12	metastasis
NCT001464586	NCT00146458_6_T2	PHENOTYPE	19	19	cancers
NCT001464587	NCT00146458_7_T0	PHENOTYPE	11	12	cervical carcinoma
NCT001464589	NCT00146458_9_T0	PHENOTYPE	11	11	metastases
NCT0014645810	NCT00146458_10_T0	GENE	6	6	II
NCT0014645810	NCT00146458_10_T1	PHENOTYPE	18	19	Cervical Cancer
NCT0014645810	NCT00146458_10_T2	TISSUE	24	25	Lymph Nodes
NCT0014645811	NCT00146458_11_T0	PHENOTYPE	6	6	metastasis
NCT0014645813	NCT00146458_13_T0	GENE	18	18	III
NCT0014645813	NCT00146458_13_T1	PHENOTYPE	6	6	Oncology
NCT0014645813	NCT00146458_13_T2	GENE	14	14	has
NCT0014645814	NCT00146458_14_T0	PHENOTYPE	19	19	initiation
NCT0014645814	NCT00146458_14_T1	GENE	8	8	MRI
NCT0014645814	NCT00146458_14_T2	TISSUE	4	5	lymph node
NCT001464711	NCT00146471_1_T0	COMPOUND	13	13	diazepam
NCT001464711	NCT00146471_1_T1	PHENOTYPE	20	21	withdrawal symptoms
NCT001464711	NCT00146471_1_T2	PHENOTYPE	18	20	acute alcohol withdrawal
NCT001464714	NCT00146471_4_T0	PHENOTYPE	4	5	physical disorder
NCT001464971	NCT00146497_1_T0	PHENOTYPE	1	1	inflammation
NCT001464974	NCT00146497_4_T0	COMPOUND	4	4	dexamethasone
NCT001464974	NCT00146497_4_T1	PHENOTYPE	13	13	sepsis
NCT0014649711	NCT00146497_11_T0	GENE	27	27	0.5
NCT0014649711	NCT00146497_11_T1	GENE	25	25	Ltd
NCT0014649715	NCT00146497_15_T0	COMPOUND	4	4	dexamethasone
NCT0014649715	NCT00146497_15_T1	PHENOTYPE	13	13	sepsis
NCT0014649717	NCT00146497_17_T0	COMPOUND	9	9	dexamethasone
NCT0014649718	NCT00146497_18_T0	GENE	1	1	has
NCT0014649719	NCT00146497_19_T0	CELL	10	10	cells
NCT0014649719	NCT00146497_19_T1	PHENOTYPE	20	20	asthma
NCT0014649721	NCT00146497_21_T0	PHENOTYPE	18	19	lung inflammation
NCT001465102	NCT00146510_2_T0	PHENOTYPE	41	42	weight loss
NCT001465231	NCT00146523_1_T0	COMPOUND	3	3	cortisol
NCT001465231	NCT00146523_1_T1	PHENOTYPE	22	23	stress response
NCT001465231	NCT00146523_1_T2	PHENOTYPE	17	18	emotional stress
NCT001465232	NCT00146523_2_T0	PHENOTYPE	36	36	thoughts
NCT001465232	NCT00146523_2_T1	PHENOTYPE	32	32	psychosis
NCT001465232	NCT00146523_2_T2	PHENOTYPE	30	30	symptoms
NCT001465232	NCT00146523_2_T3	COMPOUND	13	13	cortisol
NCT001465232	NCT00146523_2_T4	PHENOTYPE	38	38	hallucinations
NCT001465232	NCT00146523_2_T5	PHENOTYPE	21	22	cortisol levels
NCT001465232	NCT00146523_2_T6	PHENOTYPE	25	26	stress response
NCT001465232	NCT00146523_2_T7	PHENOTYPE	5	6	major depression
NCT001465491	NCT00146549_1_T0	COMPOUND	29	29	vinorelbine
NCT001465491	NCT00146549_1_T1	COMPOUND	16	16	paclitaxel
NCT001465491	NCT00146549_1_T2	COMPOUND	18	18	docetaxel
NCT001465752	NCT00146575_2_T0	PHENOTYPE	13	13	restenosis
NCT001465753	NCT00146575_3_T0	PHENOTYPE	27	27	restenosis
NCT001465753	NCT00146575_3_T1	PHENOTYPE	17	19	coronary artery disease
NCT001465755	NCT00146575_5_T0	COMPOUND	15	15	paclitaxel
NCT001465756	NCT00146575_6_T0	PHENOTYPE	29	29	restenosis
NCT001465756	NCT00146575_6_T1	ORGAN	14	15	coronary arteries
NCT001465756	NCT00146575_6_T2	ORGAN	50	51	coronary arteries
NCT001465757	NCT00146575_7_T0	COMPOUND	20	20	paclitaxel
NCT001465757	NCT00146575_7_T1	PHENOTYPE	15	15	restenosis
NCT001465757	NCT00146575_7_T2	ORGAN	26	27	coronary vessels
NCT001465759	NCT00146575_9_T0	COMPOUND	25	25	paclitaxel
NCT001465759	NCT00146575_9_T1	PHENOTYPE	21	21	restenosis
NCT0014657511	NCT00146575_11_T0	ORGAN	17	18	coronary vessels
NCT0014657512	NCT00146575_12_T0	ORGAN	12	13	coronary vessels
NCT001466014	NCT00146601_4_T0	PHENOTYPE	14	14	severity
NCT001466014	NCT00146601_4_T1	PHENOTYPE	7	8	hot flash
NCT001466014	NCT00146601_4_T2	PHENOTYPE	16	17	hot flashes
NCT001466016	NCT00146601_6_T0	PHENOTYPE	4	5	disease progression
NCT001466017	NCT00146601_7_T0	PHENOTYPE	12	13	disease progression
NCT001466143	NCT00146614_3_T0	COMPOUND	6	6	fludarabine
NCT001466146	NCT00146614_6_T0	CELL	16	16	cells
NCT001466146	NCT00146614_6_T1	ORGAN	6	7	bone marrow
NCT001466146	NCT00146614_6_T2	ORGAN	19	20	bone marrow
NCT001466147	NCT00146614_7_T0	GENE	19	19	3.4
NCT001466147	NCT00146614_7_T1	ORGAN	22	22	transplant
NCT001466147	NCT00146614_7_T2	ORGAN	16	17	bone marrow
NCT001466272	NCT00146627_2_T0	PHENOTYPE	8	8	encephalopathy
NCT001466276	NCT00146627_6_T0	PHENOTYPE	35	35	toxicity
NCT001466276	NCT00146627_6_T1	PHENOTYPE	24	24	toxic
NCT001466276	NCT00146627_6_T2	GENE	33	33	HAT
NCT001466277	NCT00146627_7_T0	PHENOTYPE	24	24	toxicity
NCT001466277	NCT00146627_7_T1	GENE	14	14	has
NCT001466279	NCT00146627_9_T0	COMPOUND	17	17	melarsoprol
NCT001466279	NCT00146627_9_T1	COMPOUND	22	22	melarsoprol
NCT001466532	NCT00146653_2_T0	COMPOUND	12	12	heparin
NCT001466532	NCT00146653_2_T1	COMPOUND	21	21	heparin
NCT001466532	NCT00146653_2_T2	PHENOTYPE	13	13	concentrations
NCT001466532	NCT00146653_2_T3	PHENOTYPE	22	22	concentrations
NCT001466535	NCT00146653_5_T0	COMPOUND	9	9	heparin
NCT001466535	NCT00146653_5_T1	COMPOUND	19	19	heparin
NCT001466535	NCT00146653_5_T2	GENE	31	31	CPB
NCT001466536	NCT00146653_6_T0	GENE	12	12	bypass
NCT001466536	NCT00146653_6_T1	GENE	1	1	ACT
NCT001466537	NCT00146653_7_T0	COMPOUND	12	12	heparin
NCT001466537	NCT00146653_7_T1	GENE	2	2	ACT
NCT001466537	NCT00146653_7_T2	GENE	18	18	ACT
NCT001466538	NCT00146653_8_T0	COMPOUND	5	5	heparin
NCT001466538	NCT00146653_8_T1	GENE	4	4	CPB
NCT001466538	NCT00146653_8_T2	GENE	17	17	protamine
NCT001466539	NCT00146653_9_T0	COMPOUND	12	12	heparin
NCT001466539	NCT00146653_9_T1	COMPOUND	21	21	heparin
NCT001466539	NCT00146653_9_T2	PHENOTYPE	13	13	concentrations
NCT001466539	NCT00146653_9_T3	PHENOTYPE	22	22	concentrations
NCT0014665314	NCT00146653_14_T0	COMPOUND	1	1	heparin
NCT0014665314	NCT00146653_14_T1	COMPOUND	17	17	heparin
NCT0014665314	NCT00146653_14_T2	PHENOTYPE	19	19	falls
NCT0014665315	NCT00146653_15_T0	COMPOUND	12	12	heparin
NCT0014665315	NCT00146653_15_T1	GENE	17	17	CPB
NCT0014665315	NCT00146653_15_T2	GENE	7	7	protamine
NCT0014665316	NCT00146653_16_T0	COMPOUND	14	14	heparin
NCT0014665316	NCT00146653_16_T1	COMPOUND	32	32	heparin
NCT0014665316	NCT00146653_16_T2	GENE	18	18	ACT
NCT0014665316	NCT00146653_16_T3	PHENOTYPE	38	38	initiation
NCT0014665316	NCT00146653_16_T4	GENE	40	40	CPB
NCT0014665316	NCT00146653_16_T5	GENE	52	52	CPB
NCT0014665318	NCT00146653_18_T0	COMPOUND	25	25	heparin
NCT0014665318	NCT00146653_18_T1	PHENOTYPE	16	16	initiation
NCT0014665318	NCT00146653_18_T2	GENE	18	18	CPB
NCT0014665318	NCT00146653_18_T3	GENE	32	32	CPB
NCT0014665318	NCT00146653_18_T4	GENE	34	34	protamine
NCT0014665319	NCT00146653_19_T0	GENE	12	12	1.2
NCT0014665319	NCT00146653_19_T1	GENE	10	10	prothrombin
NCT0014665319	NCT00146653_19_T2	GENE	11	11	fragment
NCT0014665319	NCT00146653_19_T3	GENE	25	25	beta-thromboglobulin
NCT0014665319	NCT00146653_19_T4	GENE	23	23	VIII
NCT0014665319	NCT00146653_19_T5	COMPOUND	13	14	fibrinopeptide A
NCT0014665319	NCT00146653_19_T6	GENE	16	19	tissue factor pathway inhibitor
NCT0014665320	NCT00146653_20_T0	GENE	16	16	protamine
NCT0014665320	NCT00146653_20_T1	GENE	23	23	protamine
NCT0014665323	NCT00146653_23_T0	GENE	9	9	ACT
NCT0014665323	NCT00146653_23_T1	GENE	17	17	protamine
NCT0014665325	NCT00146653_25_T0	GENE	7	7	CPB
NCT001466664	NCT00146666_4_T0	PHENOTYPE	0	2	Peripheral arterial disease
NCT001466668	NCT00146666_8_T0	PHENOTYPE	1	1	claudication
NCT0014666610	NCT00146666_10_T0	GENE	8	8	eg
NCT0014666610	NCT00146666_10_T1	COMPOUND	9	9	cilostazol
NCT0014666610	NCT00146666_10_T2	GENE	19	19	has
NCT0014666610	NCT00146666_10_T3	PHENOTYPE	5	5	claudication
NCT0014666612	NCT00146666_12_T0	GENE	17	17	has
NCT0014666614	NCT00146666_14_T0	ORGAN	3	3	heart
NCT0014666614	NCT00146666_14_T1	PHENOTYPE	9	10	pulmonary disease
NCT0014666616	NCT00146666_16_T0	ORGAN	2	2	arteries
NCT0014666617	NCT00146666_17_T0	PHENOTYPE	3	3	acute
NCT0014666617	NCT00146666_17_T1	PHENOTYPE	5	5	subacute
NCT0014666617	NCT00146666_17_T2	ORGAN	18	18	extremity
NCT0014666617	NCT00146666_17_T3	PHENOTYPE	8	10	deep venous thrombosis
NCT0014666619	NCT00146666_19_T0	PHENOTYPE	1	2	venous insufficiency
NCT0014666623	NCT00146666_23_T0	ORGAN	3	4	lower extremity
NCT0014666625	NCT00146666_25_T0	PHENOTYPE	0	0	Ulcer
NCT0014666625	NCT00146666_25_T1	PHENOTYPE	1	1	cellulitis
NCT0014666625	NCT00146666_25_T2	PHENOTYPE	5	6	superficial thrombophlebitis
NCT0014666625	NCT00146666_25_T3	PHENOTYPE	2	3	skin conditions
NCT0014666627	NCT00146666_27_T0	PHENOTYPE	0	0	Acute
NCT0014666627	NCT00146666_27_T1	PHENOTYPE	1	2	pulmonary embolism
NCT0014666629	NCT00146666_29_T0	PHENOTYPE	0	0	Osteomyelitis
NCT0014666630	NCT00146666_30_T0	PHENOTYPE	0	0	Gangrene
NCT0014666631	NCT00146666_31_T0	ORGAN	1	1	limb
NCT0014666631	NCT00146666_31_T1	PHENOTYPE	0	0	Acute
NCT001466794	NCT00146679_4_T0	PHENOTYPE	12	12	symptoms
NCT001466794	NCT00146679_4_T1	PHENOTYPE	9	9	adaptation
NCT0014667911	NCT00146679_11_T0	PHENOTYPE	8	8	acute
NCT0014667912	NCT00146679_12_T0	GENE	1	1	booster
NCT001466925	NCT00146692_5_T0	GENE	14	14	has
NCT001466926	NCT00146692_6_T0	PHENOTYPE	22	22	malaria
NCT001466927	NCT00146692_7_T0	GENE	29	29	II
NCT001466928	NCT00146692_8_T0	PHENOTYPE	4	4	anaemia
NCT0014669210	NCT00146692_10_T0	PHENOTYPE	1	1	perceptions
NCT0014669210	NCT00146692_10_T1	BIOLOGICAL_PROCESS	4	4	behaviour
NCT0014669211	NCT00146692_11_T0	PHENOTYPE	35	35	malaria
NCT0014669214	NCT00146692_14_T0	PHENOTYPE	5	5	anaemia
NCT0014669216	NCT00146692_16_T0	PHENOTYPE	9	9	malaria
NCT0014669220	NCT00146692_20_T0	PHENOTYPE	10	10	febrile
NCT0014669220	NCT00146692_20_T1	PHENOTYPE	12	12	malaria
NCT0014669222	NCT00146692_22_T0	PHENOTYPE	11	11	malaria
NCT0014669223	NCT00146692_23_T0	PHENOTYPE	32	32	malaria
NCT0014669225	NCT00146692_25_T0	PHENOTYPE	39	39	secondary
NCT0014669227	NCT00146692_27_T0	PHENOTYPE	0	0	Recruitment
NCT0014669230	NCT00146692_30_T0	PHENOTYPE	18	18	centre
NCT0014669232	NCT00146692_32_T0	ORGAN	1	1	heads
NCT0014669243	NCT00146692_43_T0	PHENOTYPE	25	25	secondary
NCT0014669247	NCT00146692_47_T0	GENE	7	7	Alpha
NCT001467051	NCT00146705_1_T0	GENE	10	10	has
NCT001467051	NCT00146705_1_T1	GENE	7	7	interferon
NCT001467051	NCT00146705_1_T2	PHENOTYPE	3	3	HBV
NCT001467051	NCT00146705_1_T3	PHENOTYPE	20	21	chronic hepatitis
NCT001467051	NCT00146705_1_T4	PHENOTYPE	21	22	hepatitis B
NCT001467052	NCT00146705_2_T0	COMPOUND	14	14	lamivudine
NCT001467053	NCT00146705_3_T0	GENE	12	12	had
NCT001467053	NCT00146705_3_T1	ORGAN	14	14	serum
NCT001467184	NCT00146718_4_T0	PHENOTYPE	19	19	malaria
NCT001467187	NCT00146718_7_T0	PHENOTYPE	18	18	blocked
NCT0014671811	NCT00146718_11_T0	GENE	13	13	SP
NCT0014671813	NCT00146718_13_T0	GENE	17	17	D7
NCT0014671813	NCT00146718_13_T1	GENE	18	18	D14
NCT0014671813	NCT00146718_13_T2	GENE	20	20	D28
NCT0014671813	NCT00146718_13_T3	GENE	16	16	D3
NCT0014671815	NCT00146718_15_T0	PHENOTYPE	8	8	withdrawn
NCT0014671816	NCT00146718_16_T0	PHENOTYPE	9	9	prick
NCT0014671818	NCT00146718_18_T0	ORGAN	6	6	plasma
NCT0014671818	NCT00146718_18_T1	PHENOTYPE	15	16	drug level
NCT001467312	NCT00146731_2_T0	GENE	26	26	SP
NCT001467314	NCT00146731_4_T0	PHENOTYPE	16	16	malaria
NCT001467315	NCT00146731_5_T0	GENE	13	13	SP
NCT001467318	NCT00146731_8_T0	PHENOTYPE	0	0	Secondary
NCT001467318	NCT00146731_8_T1	GENE	12	12	viability
NCT0014673111	NCT00146731_11_T0	GENE	0	0	SP
NCT0014673115	NCT00146731_15_T0	PHENOTYPE	69	69	fever
NCT0014673115	NCT00146731_15_T1	PHENOTYPE	95	95	malaria
NCT0014673115	NCT00146731_15_T2	GENE	31	31	Hb
NCT0014673115	NCT00146731_15_T3	GENE	52	52	Hb
NCT0014673115	NCT00146731_15_T4	GENE	56	56	Hb
NCT0014673115	NCT00146731_15_T5	PHENOTYPE	94	94	recurrent
NCT0014673115	NCT00146731_15_T6	GENE	74	74	32
NCT0014673115	NCT00146731_15_T7	GENE	98	98	14
NCT0014673115	NCT00146731_15_T8	GENE	105	105	14
NCT0014673115	NCT00146731_15_T9	COMPOUND	7	7	1
NCT0014673115	NCT00146731_15_T10	COMPOUND	66	66	2
NCT0014673115	NCT00146731_15_T11	COMPOUND	75	75	3
NCT0014673115	NCT00146731_15_T12	COMPOUND	81	81	3
NCT0014673115	NCT00146731_15_T13	PHENOTYPE	21	21	convulsions
NCT0014673115	NCT00146731_15_T14	PHENOTYPE	67	67	persistence
NCT0014673115	NCT00146731_15_T15	PHENOTYPE	24	25	renal impairment
NCT0014673115	NCT00146731_15_T16	PHENOTYPE	22	23	persistent vomiting
NCT0014673115	NCT00146731_15_T17	PHENOTYPE	26	27	respiratory distress
NCT0014673116	NCT00146731_16_T0	PHENOTYPE	0	0	Secondary
NCT0014673116	NCT00146731_16_T1	PHENOTYPE	2	2	Secondary
NCT0014673117	NCT00146731_17_T0	PHENOTYPE	2	3	foetal death
NCT0014673118	NCT00146731_18_T0	PHENOTYPE	0	0	Hypoglycaemia
NCT0014673122	NCT00146731_22_T0	PHENOTYPE	0	0	Fever
NCT0014673125	NCT00146731_25_T0	PHENOTYPE	1	1	malaria
NCT0014673126	NCT00146731_26_T0	PHENOTYPE	0	1	Preterm delivery
NCT0014673127	NCT00146731_27_T0	PHENOTYPE	1	2	adverse events
NCT0014673130	NCT00146731_30_T0	GENE	3	3	DOT
NCT0014673131	NCT00146731_31_T0	PHENOTYPE	4	4	blister
NCT0014673133	NCT00146731_33_T0	GENE	27	27	MCH
NCT0014673133	NCT00146731_33_T1	PHENOTYPE	2	2	Withdrawal
NCT0014673133	NCT00146731_33_T2	GENE	20	20	ANC
NCT0014673133	NCT00146731_33_T3	PHENOTYPE	11	12	falciparum malaria
NCT0014673135	NCT00146731_35_T0	GENE	24	24	probable
NCT0014673135	NCT00146731_35_T1	PHENOTYPE	19	19	fever
NCT0014673135	NCT00146731_35_T2	PHENOTYPE	27	27	malaria
NCT0014673135	NCT00146731_35_T3	PHENOTYPE	7	7	febrile
NCT0014673136	NCT00146731_36_T0	PHENOTYPE	5	5	anaemia
NCT0014673138	NCT00146731_38_T0	GENE	12	12	pH
NCT0014673138	NCT00146731_38_T1	GENE	13	13	7.2
NCT0014673141	NCT00146731_41_T0	PHENOTYPE	34	34	toxaemia
NCT0014673141	NCT00146731_41_T1	PHENOTYPE	11	11	malaria
NCT0014673141	NCT00146731_41_T2	COMPOUND	5	5	1
NCT0014673141	NCT00146731_41_T3	COMPOUND	17	17	2
NCT0014673141	NCT00146731_41_T4	COMPOUND	23	23	3
NCT0014673141	NCT00146731_41_T5	PHENOTYPE	29	30	complicated pregnancy
NCT0014673144	NCT00146731_44_T0	GENE	0	0	11
NCT0014673144	NCT00146731_44_T1	GENE	5	5	twins
NCT0014673144	NCT00146731_44_T2	BIOLOGICAL_PROCESS	2	2	gestation
NCT0014673145	NCT00146731_45_T0	PHENOTYPE	8	8	malaria
NCT0014673146	NCT00146731_46_T0	COMPOUND	9	9	quinine
NCT0014673146	NCT00146731_46_T1	GENE	17	17	SP
NCT0014673147	NCT00146731_47_T0	PHENOTYPE	0	0	Withdrawal
NCT0014673147	NCT00146731_47_T1	PHENOTYPE	2	2	Withdrawal
NCT0014673147	NCT00146731_47_T2	COMPOUND	6	6	1
NCT0014673147	NCT00146731_47_T3	COMPOUND	16	16	2
NCT0014673147	NCT00146731_47_T4	COMPOUND	23	23	3
NCT0014673147	NCT00146731_47_T5	PHENOTYPE	24	24	vomiting
NCT0014673149	NCT00146731_49_T0	COMPOUND	6	6	quinine
NCT0014673153	NCT00146731_53_T0	GENE	19	19	GMP
NCT0014673156	NCT00146731_56_T0	COMPOUND	1	1	sulfadoxine
NCT0014673156	NCT00146731_56_T1	GENE	0	0	SP
NCT0014673158	NCT00146731_58_T0	GENE	1	1	1.2
NCT0014673158	NCT00146731_58_T1	GENE	4	4	2.4
NCT0014673161	NCT00146731_61_T0	GENE	13	13	OPD
NCT0014673161	NCT00146731_61_T1	GENE	10	10	ANC
NCT0014673161	NCT00146731_61_T2	GENE	0	0	Is
NCT0014673163	NCT00146731_63_T0	GENE	0	0	Is
NCT0014673164	NCT00146731_64_T0	GENE	0	0	Is
NCT0014673167	NCT00146731_67_T0	PHENOTYPE	5	5	malaria
NCT0014673170	NCT00146731_70_T0	PHENOTYPE	5	5	toxaemia
NCT0014673170	NCT00146731_70_T1	PHENOTYPE	0	1	Complicated pregnancy
NCT0014673171	NCT00146731_71_T0	PHENOTYPE	5	5	stillbirths
NCT0014673173	NCT00146731_73_T0	COMPOUND	8	8	tetracycline
NCT0014673178	NCT00146731_78_T0	BIOLOGICAL_PROCESS	1	1	gestation
NCT001467442	NCT00146744_2_T0	PHENOTYPE	29	30	miliary tuberculosis
NCT001467442	NCT00146744_2_T1	PHENOTYPE	26	27	meningeal tuberculosis
NCT001467444	NCT00146744_4_T0	PHENOTYPE	17	17	adult-onset
NCT001467444	NCT00146744_4_T1	GENE	6	6	BCG
NCT001467444	NCT00146744_4_T2	PHENOTYPE	18	18	tuberculosis
NCT001467444	NCT00146744_4_T3	GENE	22	22	has
NCT001467445	NCT00146744_5_T0	PHENOTYPE	12	12	tuberculosis
NCT001467445	NCT00146744_5_T1	GENE	6	6	polyprotein
NCT001467570	NCT00146757_0_T0	PHENOTYPE	6	6	Pharmacokinetics
NCT001467570	NCT00146757_0_T1	PHENOTYPE	11	12	MPS I
NCT001467700	NCT00146770_0_T0	PHENOTYPE	13	14	Mucopolysaccharidosis I
NCT001467700	NCT00146770_0_T1	PHENOTYPE	15	16	MPS I
NCT001467831	NCT00146783_1_T0	GENE	7	7	has
NCT001467831	NCT00146783_1_T1	PHENOTYPE	18	20	malaria in pregnancy
NCT001467832	NCT00146783_2_T0	GENE	1	1	has
NCT001467833	NCT00146783_3_T0	COMPOUND	32	32	IPTp
NCT001467833	NCT00146783_3_T1	GENE	7	7	SP
NCT001467835	NCT00146783_5_T0	COMPOUND	18	18	chloroquine
NCT001467835	NCT00146783_5_T1	GENE	1	1	has
NCT001467835	NCT00146783_5_T2	GENE	27	27	has
NCT001467835	NCT00146783_5_T3	PHENOTYPE	13	13	malaria
NCT001467835	NCT00146783_5_T4	GENE	26	26	SP
NCT001467838	NCT00146783_8_T0	COMPOUND	39	39	IPTp
NCT001467838	NCT00146783_8_T1	COMPOUND	23	23	amodiaquine
NCT001467838	NCT00146783_8_T2	COMPOUND	30	30	amodiaquine
NCT001467838	NCT00146783_8_T3	GENE	8	8	SP
NCT001467838	NCT00146783_8_T4	GENE	35	35	SP
NCT0014678310	NCT00146783_10_T0	PHENOTYPE	13	13	malaria
NCT0014678310	NCT00146783_10_T1	PHENOTYPE	4	6	malaria in pregnancy
NCT0014678311	NCT00146783_11_T0	PHENOTYPE	8	8	peripheral
NCT0014678311	NCT00146783_11_T1	PHENOTYPE	24	24	peripheral
NCT0014678312	NCT00146783_12_T0	COMPOUND	18	18	IPTp
NCT0014678313	NCT00146783_13_T0	COMPOUND	3	3	IPTp
NCT0014678313	NCT00146783_13_T1	GENE	4	4	has
NCT0014678314	NCT00146783_14_T0	COMPOUND	0	0	IPTp
NCT0014678314	NCT00146783_14_T1	GENE	1	1	has
NCT0014678315	NCT00146783_15_T0	COMPOUND	31	31	IPTp
NCT0014678315	NCT00146783_15_T1	PHENOTYPE	15	15	intensities
NCT0014678316	NCT00146783_16_T0	COMPOUND	0	0	IPTp
NCT0014678316	NCT00146783_16_T1	PHENOTYPE	12	12	anaemia
NCT0014678316	NCT00146783_16_T2	GENE	3	3	has
NCT0014678316	NCT00146783_16_T3	GENE	2	2	SP
NCT0014678316	NCT00146783_16_T4	PHENOTYPE	21	23	low birth weight
NCT0014678317	NCT00146783_17_T0	GENE	0	0	SP
NCT0014678317	NCT00146783_17_T1	PHENOTYPE	18	18	tolerance
NCT0014678319	NCT00146783_19_T0	GENE	5	5	SP
NCT0014678321	NCT00146783_21_T0	COMPOUND	21	21	IPTp
NCT0014678321	NCT00146783_21_T1	COMPOUND	15	15	amodiaquine
NCT0014678321	NCT00146783_21_T2	COMPOUND	18	18	amodiaquine
NCT0014678321	NCT00146783_21_T3	GENE	30	30	34.36
NCT0014678322	NCT00146783_22_T0	PHENOTYPE	1	1	secondary
NCT0014678324	NCT00146783_24_T0	PHENOTYPE	4	4	malaria
NCT0014678325	NCT00146783_25_T0	PHENOTYPE	3	3	anaemia
NCT0014678325	NCT00146783_25_T1	GENE	4	4	Hb
NCT0014678327	NCT00146783_27_T0	PHENOTYPE	3	3	peripheral
NCT0014678327	NCT00146783_27_T1	GENE	7	7	34.36
NCT0014678328	NCT00146783_28_T0	PHENOTYPE	4	4	peripheral
NCT0014678329	NCT00146783_29_T0	GENE	8	8	SP
NCT0014678330	NCT00146783_30_T0	PHENOTYPE	18	18	malaria
NCT0014678330	NCT00146783_30_T1	GENE	12	12	SP
NCT0014678331	NCT00146783_31_T0	GENE	9	9	ANC
NCT0014678335	NCT00146783_35_T0	PHENOTYPE	17	17	centre
NCT0014678335	NCT00146783_35_T1	GENE	2	2	has
NCT0014678335	NCT00146783_35_T2	PHENOTYPE	5	5	centres
NCT0014678336	NCT00146783_36_T0	GENE	21	21	ANC
NCT0014678336	NCT00146783_36_T1	GENE	28	28	2.7
NCT0014678338	NCT00146783_38_T0	GENE	6	6	had
NCT0014678338	NCT00146783_38_T1	PHENOTYPE	7	8	haemoglobin levels
NCT0014678339	NCT00146783_39_T0	BIOLOGICAL_PROCESS	8	8	gestation
NCT0014678339	NCT00146783_39_T1	PHENOTYPE	24	24	centres
NCT0014678339	NCT00146783_39_T2	GENE	6	6	32
NCT0014678341	NCT00146783_41_T0	PHENOTYPE	19	19	attitudes
NCT0014678341	NCT00146783_41_T1	PHENOTYPE	21	21	practices
NCT0014678344	NCT00146783_44_T0	GENE	8	8	ANC
NCT0014678344	NCT00146783_44_T1	GENE	27	27	ANC
NCT0014678345	NCT00146783_45_T0	GENE	11	11	ANC
NCT0014678346	NCT00146783_46_T0	GENE	7	7	ANC
NCT0014678349	NCT00146783_49_T0	PHENOTYPE	9	9	malaria
NCT0014678351	NCT00146783_51_T0	GENE	4	4	envelope
NCT0014678352	NCT00146783_52_T0	COMPOUND	34	34	IPTp
NCT0014678352	NCT00146783_52_T1	GENE	14	14	envelope
NCT0014678357	NCT00146783_57_T0	COMPOUND	20	20	IPTp
NCT0014678357	NCT00146783_57_T1	PHENOTYPE	31	31	malaria
NCT0014678357	NCT00146783_57_T2	GENE	15	15	SP
NCT0014678359	NCT00146783_59_T0	PHENOTYPE	3	3	tolerance
NCT0014678359	NCT00146783_59_T1	PHENOTYPE	24	25	adverse events
NCT0014678359	NCT00146783_59_T2	PHENOTYPE	5	7	adverse drug reactions
NCT0014678361	NCT00146783_61_T0	PHENOTYPE	3	3	severity
NCT0014678361	NCT00146783_61_T1	PHENOTYPE	8	9	adverse events
NCT0014678363	NCT00146783_63_T0	PHENOTYPE	3	4	adverse events
NCT0014678364	NCT00146783_64_T0	PHENOTYPE	23	23	symptoms
NCT0014678364	NCT00146783_64_T1	COMPOUND	5	5	IPTp
NCT0014678364	NCT00146783_64_T2	GENE	10	10	36
NCT0014678364	NCT00146783_64_T3	PHENOTYPE	22	22	malaria
NCT0014678365	NCT00146783_65_T0	COMPOUND	8	8	IPTp
NCT0014678365	NCT00146783_65_T1	GENE	39	39	ANC
NCT0014678366	NCT00146783_66_T0	PHENOTYPE	16	16	peripheral
NCT0014678366	NCT00146783_66_T1	GENE	2	2	36
NCT0014678366	NCT00146783_66_T2	GENE	14	14	Hb
NCT0014678366	NCT00146783_66_T3	PHENOTYPE	12	13	haemoglobin levels
NCT0014678367	NCT00146783_67_T0	PHENOTYPE	3	3	anaemia
NCT0014678367	NCT00146783_67_T1	GENE	4	4	Hb
NCT0014678368	NCT00146783_68_T0	GENE	8	8	ANC
NCT0014678370	NCT00146783_70_T0	GENE	21	21	Hb
NCT0014678371	NCT00146783_71_T0	PHENOTYPE	13	13	peripheral
NCT0014678371	NCT00146783_71_T1	PHENOTYPE	5	5	centre
NCT0014678373	NCT00146783_73_T0	PHENOTYPE	4	4	estimation
NCT0014678373	NCT00146783_73_T1	PHENOTYPE	11	11	centre
NCT0014678374	NCT00146783_74_T0	PHENOTYPE	14	14	complications
NCT0014678374	NCT00146783_74_T1	PHENOTYPE	52	52	centre
NCT0014678374	NCT00146783_74_T2	PHENOTYPE	18	18	haemorrhage
NCT0014678374	NCT00146783_74_T3	GENE	55	55	TBA
NCT0014678374	NCT00146783_74_T4	GENE	2	2	Hb
NCT0014678374	NCT00146783_74_T5	GENE	61	61	Hb
NCT0014678374	NCT00146783_74_T6	PHENOTYPE	41	42	haemoglobin levels
NCT0014678375	NCT00146783_75_T0	PHENOTYPE	8	8	centre
NCT0014678376	NCT00146783_76_T0	BIOLOGICAL_PROCESS	21	21	gestation
NCT0014678377	NCT00146783_77_T0	GENE	8	8	CKI
NCT0014678382	NCT00146783_82_T0	PHENOTYPE	25	25	miscarriages
NCT0014678382	NCT00146783_82_T1	PHENOTYPE	11	11	attributable
NCT001467961	NCT00146796_1_T0	PHENOTYPE	5	5	malaria
NCT001467962	NCT00146796_2_T0	PHENOTYPE	8	8	malaria
NCT001467963	NCT00146796_3_T0	GENE	27	27	has
NCT001467965	NCT00146796_5_T0	PHENOTYPE	15	15	malaria
NCT001467965	NCT00146796_5_T1	PHENOTYPE	7	7	P.falciparum
NCT001467967	NCT00146796_7_T0	PHENOTYPE	8	8	malaria
NCT001467969	NCT00146796_9_T0	PHENOTYPE	13	13	malaria
NCT001467969	NCT00146796_9_T1	PHENOTYPE	22	22	malaria
NCT0014679611	NCT00146796_11_T0	PHENOTYPE	19	19	malaria
NCT0014679611	NCT00146796_11_T1	PHENOTYPE	26	26	P.falciparum
NCT0014679617	NCT00146796_17_T0	PHENOTYPE	5	5	Malaria
NCT0014679618	NCT00146796_18_T0	PHENOTYPE	16	16	malaria
NCT0014679622	NCT00146796_22_T0	PHENOTYPE	43	43	distressed
NCT0014679624	NCT00146796_24_T0	PHENOTYPE	11	11	malaria
NCT0014679626	NCT00146796_26_T0	PHENOTYPE	1	1	recruitment
NCT0014679628	NCT00146796_28_T0	PHENOTYPE	24	26	main presenting symptom
NCT0014679629	NCT00146796_29_T0	GENE	13	13	has
NCT0014679629	NCT00146796_29_T1	GENE	24	24	has
NCT0014679629	NCT00146796_29_T2	PHENOTYPE	22	22	malaria
NCT0014679631	NCT00146796_31_T0	GENE	10	10	has
NCT0014679631	NCT00146796_31_T1	PHENOTYPE	8	8	malaria
NCT0014679635	NCT00146796_35_T0	GENE	2	2	envelope
NCT0014679640	NCT00146796_40_T0	PHENOTYPE	13	13	judgement
NCT0014679641	NCT00146796_41_T0	GENE	3	3	has
NCT0014679642	NCT00146796_42_T0	GENE	20	20	retained
NCT0014679654	NCT00146796_54_T0	GENE	24	24	had
NCT0014679659	NCT00146796_59_T0	PHENOTYPE	6	6	malaria
NCT001468093	NCT00146809_3_T0	GENE	13	13	atypical
NCT001468093	NCT00146809_3_T1	PHENOTYPE	15	15	syndromes
NCT001468093	NCT00146809_3_T2	PHENOTYPE	3	4	Parkinson's disease
NCT001468095	NCT00146809_5_T0	PHENOTYPE	15	15	diseases
NCT001468096	NCT00146809_6_T0	GENE	15	15	atypical
NCT001468096	NCT00146809_6_T1	PHENOTYPE	17	17	Syndromes
NCT0014680911	NCT00146809_11_T0	PHENOTYPE	18	19	rheumatoid arthritis
NCT0014680913	NCT00146809_13_T0	PHENOTYPE	2	2	focal
NCT0014680913	NCT00146809_13_T1	GENE	12	12	reduced
NCT0014680915	NCT00146809_15_T0	GENE	30	30	Van
NCT0014680915	NCT00146809_15_T1	GENE	16	16	al
NCT0014680915	NCT00146809_15_T2	GENE	20	20	al
NCT0014680915	NCT00146809_15_T3	GENE	24	24	al
NCT0014680915	NCT00146809_15_T4	GENE	28	28	al
NCT0014680915	NCT00146809_15_T5	GENE	34	34	al
NCT0014680915	NCT00146809_15_T6	GENE	38	38	al
NCT0014680915	NCT00146809_15_T7	GENE	31	31	Den
NCT0014680915	NCT00146809_15_T8	PHENOTYPE	13	13	experiences
NCT0014680915	NCT00146809_15_T9	GENE	15	15	et
NCT0014680915	NCT00146809_15_T10	GENE	19	19	et
NCT0014680915	NCT00146809_15_T11	GENE	23	23	et
NCT0014680915	NCT00146809_15_T12	GENE	27	27	et
NCT0014680915	NCT00146809_15_T13	GENE	33	33	et
NCT0014680915	NCT00146809_15_T14	GENE	37	37	et
NCT0014680915	NCT00146809_15_T15	PHENOTYPE	40	42	amyotrophic lateral sclerosis
NCT0014680917	NCT00146809_17_T0	BIOLOGICAL_PROCESS	8	8	neuroprotection
NCT0014680920	NCT00146809_20_T0	CELL	8	8	microglia
NCT0014680923	NCT00146809_23_T0	PHENOTYPE	9	9	peripheral
NCT0014680923	NCT00146809_23_T1	GENE	15	15	al
NCT0014680923	NCT00146809_23_T2	GENE	14	14	et
NCT0014680925	NCT00146809_25_T0	PHENOTYPE	16	16	Chorea
NCT0014680925	NCT00146809_25_T1	PHENOTYPE	19	21	amyotrophic lateral sclerosis
NCT001468353	NCT00146835_3_T0	GENE	14	14	Act
NCT001468353	NCT00146835_3_T1	GENE	3	3	has
NCT001468353	NCT00146835_3_T2	GENE	15	15	Sep
NCT0014683513	NCT00146835_13_T0	PHENOTYPE	15	15	centers
NCT001468486	NCT00146848_6_T0	PHENOTYPE	7	8	heart failure
NCT001468487	NCT00146848_7_T0	GENE	8	8	has
NCT001468487	NCT00146848_7_T1	PHENOTYPE	14	15	heart failure
NCT001468612	NCT00146861_2_T0	GENE	5	5	CI
NCT001468613	NCT00146861_3_T0	GENE	9	9	CI
NCT001468740	NCT00146874_0_T0	GENE	0	0	CRT
NCT001468876	NCT00146887_6_T0	PHENOTYPE	0	1	Atrial fibrillation
NCT001468877	NCT00146887_7_T0	GENE	2	2	beta
NCT001468878	NCT00146887_8_T0	PHENOTYPE	1	2	pulmonary disease
NCT001468879	NCT00146887_9_T0	PHENOTYPE	1	3	peripheral vascular disease
NCT0014688712	NCT00146887_12_T0	GENE	6	6	Hg
NCT0014688715	NCT00146887_15_T0	PHENOTYPE	0	0	Allergy
NCT0014688717	NCT00146887_17_T0	COMPOUND	13	13	metoprolol
NCT0014688717	NCT00146887_17_T1	ORGAN	2	2	heart
NCT0014688719	NCT00146887_19_T0	COMPOUND	14	14	metoprolol
NCT0014688719	NCT00146887_19_T1	GENE	13	13	IV
NCT0014688719	NCT00146887_19_T2	ORGAN	6	6	heart
NCT0014688720	NCT00146887_20_T0	GENE	19	19	0.5
NCT0014688720	NCT00146887_20_T1	GENE	23	23	0.42
NCT0014688723	NCT00146887_23_T0	ORGAN	18	18	heart
NCT0014688724	NCT00146887_24_T0	ORGAN	10	10	heart
NCT0014688725	NCT00146887_25_T0	ORGAN	13	13	artery
NCT0014688725	NCT00146887_25_T1	PHENOTYPE	8	8	enables
NCT0014688727	NCT00146887_27_T0	PHENOTYPE	3	3	plaque
NCT0014688727	NCT00146887_27_T1	PHENOTYPE	12	12	plaque
NCT0014688728	NCT00146887_28_T0	ORGAN	24	24	heart
NCT0014688731	NCT00146887_31_T0	BIOLOGICAL_PROCESS	8	9	cardiac contraction
NCT0014688734	NCT00146887_34_T0	ORGAN	6	6	heart
NCT0014688735	NCT00146887_35_T0	GENE	0	0	MPR
NCT0014688735	NCT00146887_35_T1	ORGAN	8	8	heart
NCT0014688737	NCT00146887_37_T0	GENE	24	24	RAO
NCT0014688737	NCT00146887_37_T1	GENE	26	26	RAO
NCT0014688737	NCT00146887_37_T2	GENE	27	27	caudal
NCT0014688737	NCT00146887_37_T3	GENE	35	35	caudal
NCT0014688737	NCT00146887_37_T4	GENE	31	31	LAO
NCT0014688737	NCT00146887_37_T5	GENE	34	34	LAO
NCT0014688738	NCT00146887_38_T0	GENE	4	4	caudal
NCT0014688740	NCT00146887_40_T0	PHENOTYPE	11	11	strategies
NCT0014688742	NCT00146887_42_T0	PHENOTYPE	2	2	projections
NCT0014688742	NCT00146887_42_T1	GENE	16	16	RAO
NCT0014688742	NCT00146887_42_T2	GENE	17	17	LAO
NCT0014688742	NCT00146887_42_T3	GENE	19	19	spider
NCT0014688747	NCT00146887_47_T0	PHENOTYPE	21	21	atherosclerosis
NCT0014688747	NCT00146887_47_T1	PHENOTYPE	24	24	calcification
NCT0014688747	NCT00146887_47_T2	PHENOTYPE	26	26	narrowing
NCT0014688750	NCT00146887_50_T0	GENE	11	11	mid
NCT0014688750	NCT00146887_50_T1	PHENOTYPE	46	46	cavity
NCT0014688750	NCT00146887_50_T2	GENE	12	12	ventricular
NCT0014688750	NCT00146887_50_T3	GENE	45	45	ventricular
NCT0014688750	NCT00146887_50_T4	PHENOTYPE	31	31	constriction
NCT0014688750	NCT00146887_50_T5	ORGAN	15	16	papillary muscles
NCT0014688752	NCT00146887_52_T0	GENE	6	6	axis
NCT0014688756	NCT00146887_56_T0	PHENOTYPE	0	1	Atrial fibrillation
NCT0014688757	NCT00146887_57_T0	GENE	2	2	beta
NCT0014688758	NCT00146887_58_T0	PHENOTYPE	1	2	pulmonary disease
NCT0014688759	NCT00146887_59_T0	PHENOTYPE	1	3	peripheral vascular disease
NCT0014688762	NCT00146887_62_T0	GENE	6	6	Hg
NCT001469133	NCT00146913_3_T0	GENE	4	4	IM
NCT001469521	NCT00146952_1_T0	PHENOTYPE	33	33	syndromes
NCT001469781	NCT00146978_1_T0	PHENOTYPE	15	15	resistant
NCT001469781	NCT00146978_1_T1	PHENOTYPE	19	19	GVHD
NCT001469783	NCT00146978_3_T0	GENE	13	13	GI
NCT001469783	NCT00146978_3_T1	ORGAN	17	17	liver
NCT001469783	NCT00146978_3_T2	PHENOTYPE	7	7	affects
NCT001469783	NCT00146978_3_T3	PHENOTYPE	0	0	GVHD
NCT001469784	NCT00146978_4_T0	COMPOUND	13	13	tacrolimus
NCT001469784	NCT00146978_4_T1	COMPOUND	12	12	cyclosporin
NCT001469784	NCT00146978_4_T2	COMPOUND	14	14	methotrexate
NCT001469784	NCT00146978_4_T3	PHENOTYPE	3	3	GVHD
NCT001469784	NCT00146978_4_T4	CELL	16	16	lymphocyte
NCT001469787	NCT00146978_7_T0	PHENOTYPE	11	11	resistant
NCT001469787	NCT00146978_7_T1	PHENOTYPE	12	12	GVHD
NCT001469789	NCT00146978_9_T0	PHENOTYPE	8	8	GVHD
NCT001469789	NCT00146978_9_T1	PHENOTYPE	11	12	blood supply
NCT001469789	NCT00146978_9_T2	ORGAN	1	2	bile ducts
NCT001469789	NCT00146978_9_T3	ORGAN	16	17	hepatic artery
NCT0014697811	NCT00146978_11_T0	GENE	23	23	GI
NCT0014697811	NCT00146978_11_T1	PHENOTYPE	24	24	GVHD
NCT0014697811	NCT00146978_11_T2	GENE	2	2	al
NCT0014697811	NCT00146978_11_T3	GENE	1	1	et
NCT0014697811	NCT00146978_11_T4	PHENOTYPE	17	17	remission
NCT0014697811	NCT00146978_11_T5	ORGAN	13	15	inferior mesenteric arteries
NCT0014697812	NCT00146978_12_T0	ORGAN	10	10	liver
NCT0014697812	NCT00146978_12_T1	PHENOTYPE	11	11	GVHD
NCT0014697812	NCT00146978_12_T2	GENE	2	2	has
NCT0014697813	NCT00146978_13_T0	PHENOTYPE	14	14	resistant
NCT0014697813	NCT00146978_13_T1	PHENOTYPE	18	18	GVHD
NCT0014697814	NCT00146978_14_T0	GENE	12	12	GI
NCT0014697814	NCT00146978_14_T1	GENE	25	25	MP
NCT0014697814	NCT00146978_14_T2	GENE	9	9	3.4
NCT0014697814	NCT00146978_14_T3	COMPOUND	24	24	methylprednisolone
NCT0014697814	NCT00146978_14_T4	COMPOUND	19	19	cyclosporin
NCT0014697814	NCT00146978_14_T5	PHENOTYPE	13	13	GVHD
NCT0014697814	NCT00146978_14_T6	GENE	18	18	IV
NCT0014697814	NCT00146978_14_T7	GENE	23	23	IV
NCT0014697815	NCT00146978_15_T0	PHENOTYPE	0	0	GVHD
NCT0014697816	NCT00146978_16_T0	PHENOTYPE	8	8	severity
NCT0014697816	NCT00146978_16_T1	PHENOTYPE	0	0	GVHD
NCT0014697817	NCT00146978_17_T0	GENE	19	19	MP
NCT0014697817	NCT00146978_17_T1	COMPOUND	14	14	methotrexate
NCT0014697817	NCT00146978_17_T2	PHENOTYPE	3	3	GVHD
NCT0014697817	NCT00146978_17_T3	ORGAN	10	11	hepatic artery
NCT0014697818	NCT00146978_18_T0	GENE	14	14	MP
NCT0014697818	NCT00146978_18_T1	COMPOUND	10	10	methotrexate
NCT0014697820	NCT00146978_20_T0	GENE	4	4	GI
NCT0014697820	NCT00146978_20_T1	GENE	9	9	MP
NCT0014697820	NCT00146978_20_T2	GENE	16	16	GDA
NCT0014697820	NCT00146978_20_T3	PHENOTYPE	5	5	GVHD
NCT0014697820	NCT00146978_20_T4	ORGAN	15	15	artery
NCT0014697822	NCT00146978_22_T0	PHENOTYPE	6	6	sterile
NCT0014697822	NCT00146978_22_T1	COMPOUND	11	11	lidocaine
NCT0014697822	NCT00146978_22_T2	PHENOTYPE	14	14	conscious
NCT0014697822	NCT00146978_22_T3	PHENOTYPE	9	9	anesthesia
NCT0014697823	NCT00146978_23_T0	PHENOTYPE	12	14	arterial blood supply
NCT0014697826	NCT00146978_26_T0	GENE	3	3	Rim
NCT0014697828	NCT00146978_28_T0	GENE	1	1	SP
NCT0014697829	NCT00146978_29_T0	ORGAN	12	12	artery
NCT0014697830	NCT00146978_30_T0	BIOLOGICAL_PROCESS	18	18	hemostasis
NCT0014697831	NCT00146978_31_T0	GENE	10	10	extended
NCT0014697831	NCT00146978_31_T1	ORGAN	9	9	extremity
NCT0014697837	NCT00146978_37_T0	ORGAN	2	2	liver
NCT0014697837	NCT00146978_37_T1	GENE	8	8	2.4
NCT0014697837	NCT00146978_37_T2	ORGAN	5	6	GI tract
NCT0014697838	NCT00146978_38_T0	PHENOTYPE	0	0	Resistant
NCT001470042	NCT00147004_2_T0	COMPOUND	9	9	hydrocortisone
NCT001470042	NCT00147004_2_T1	PHENOTYPE	16	17	septic shock
NCT001470044	NCT00147004_4_T0	PHENOTYPE	0	0	Secondary
NCT001470045	NCT00147004_5_T0	GENE	7	7	1.1
NCT001470046	NCT00147004_6_T0	GENE	6	6	tapered
NCT001470048	NCT00147004_8_T0	PHENOTYPE	14	14	Sepsis
NCT001470048	NCT00147004_8_T1	GENE	18	18	Med
NCT001470048	NCT00147004_8_T2	PHENOTYPE	9	10	septic shock
NCT001470048	NCT00147004_8_T3	PHENOTYPE	6	7	severe sepsis
NCT001470049	NCT00147004_9_T0	PHENOTYPE	2	3	adverse events
NCT0014700410	NCT00147004_10_T0	PHENOTYPE	1	2	adverse events
NCT0014700411	NCT00147004_11_T0	PHENOTYPE	1	2	adverse events
NCT0014700412	NCT00147004_12_T0	PHENOTYPE	8	8	hyperglycemia
NCT0014700412	NCT00147004_12_T1	PHENOTYPE	7	7	superinfection
NCT0014700412	NCT00147004_12_T2	PHENOTYPE	9	9	hypernatremia
NCT0014700412	NCT00147004_12_T3	PHENOTYPE	10	11	muscular weakness
NCT0014700412	NCT00147004_12_T4	PHENOTYPE	4	5	gastrointestinal bleeding
NCT0014700413	NCT00147004_13_T0	PHENOTYPE	11	11	peripheral
NCT0014700413	NCT00147004_13_T1	PHENOTYPE	12	12	ischemia
NCT0014700413	NCT00147004_13_T2	PHENOTYPE	7	9	acute myocardial infarction
NCT0014700414	NCT00147004_14_T0	COMPOUND	7	7	cortisol
NCT0014700414	NCT00147004_14_T1	PHENOTYPE	25	25	weakness
NCT0014700414	NCT00147004_14_T2	GENE	24	24	neuromuscular
NCT0014700414	NCT00147004_14_T3	PHENOTYPE	10	11	cortisol levels
NCT0014700417	NCT00147004_17_T0	CELL	3	3	cells
NCT0014700417	NCT00147004_17_T1	PHENOTYPE	7	7	sterile
NCT0014700418	NCT00147004_18_T0	PHENOTYPE	10	10	sterile
NCT0014700419	NCT00147004_19_T0	PHENOTYPE	8	8	ruptured
NCT0014700419	NCT00147004_19_T1	ORGAN	21	21	abdomen
NCT0014700419	NCT00147004_19_T2	GENE	9	9	bowel
NCT0014700419	NCT00147004_19_T3	GENE	17	17	bowel
NCT0014700425	NCT00147004_25_T0	PHENOTYPE	0	0	Tachycardia
NCT0014700425	NCT00147004_25_T1	GENE	4	4	90
NCT0014700425	NCT00147004_25_T2	ORGAN	1	1	heart
NCT0014700427	NCT00147004_27_T0	GENE	3	3	WBC
NCT0014700427	NCT00147004_27_T1	CELL	12	12	neutrophils
NCT0014700436	NCT00147004_36_T0	PHENOTYPE	12	12	pneumonia
NCT0014700436	NCT00147004_36_T1	PHENOTYPE	0	1	Arterial hypoxemia
NCT0014700443	NCT00147004_43_T0	PHENOTYPE	0	1	Cortisol level
NCT0014700451	NCT00147004_51_T0	PHENOTYPE	1	1	immunosuppression
NCT0014700453	NCT00147004_53_T0	PHENOTYPE	10	10	acute
NCT0014700453	NCT00147004_53_T1	PHENOTYPE	2	2	chronic
NCT0014700456	NCT00147004_56_T0	PHENOTYPE	0	0	HIV
NCT0014700460	NCT00147004_60_T0	PHENOTYPE	0	1	Advanced cancer
NCT0014700461	NCT00147004_61_T0	PHENOTYPE	0	2	Acute myocardial infarction
NCT001470174	NCT00147017_4_T0	CELL	3	3	macrophages
NCT001470175	NCT00147017_5_T0	PHENOTYPE	8	11	carcinoma of the lung
NCT0014701722	NCT00147017_22_T0	CELL	3	3	macrophages
NCT0014701723	NCT00147017_23_T0	CELL	1	1	cells
NCT0014701723	NCT00147017_23_T1	GENE	12	12	mediator
NCT0014701726	NCT00147017_26_T0	CELL	9	9	cells
NCT0014701726	NCT00147017_26_T1	MOLECULAR_FUNCTION	0	1	Enzyme activity
NCT0014701727	NCT00147017_27_T0	GENE	12	12	FACS
NCT0014701728	NCT00147017_28_T0	CELL	2	2	macrophages
NCT0014701728	NCT00147017_28_T1	GENE	11	11	FACS
NCT001470301	NCT00147030_1_T0	PHENOTYPE	30	30	suffering
NCT001470301	NCT00147030_1_T1	PHENOTYPE	33	33	encephalopathy
NCT001470305	NCT00147030_5_T0	PHENOTYPE	14	15	perinatal asphyxia
NCT001470306	NCT00147030_6_T0	PHENOTYPE	19	20	congenital abnormalities
NCT001470309	NCT00147030_9_T0	PHENOTYPE	5	5	recruitment
NCT001470309	NCT00147030_9_T1	PHENOTYPE	6	6	closed
NCT001470309	NCT00147030_9_T2	GENE	9	9	had
NCT0014703013	NCT00147030_13_T0	PHENOTYPE	17	17	seizures
NCT001470432	NCT00147043_2_T0	PHENOTYPE	6	6	toxicities
NCT001470434	NCT00147043_4_T0	CELL	4	4	hepatocyte
NCT001470434	NCT00147043_4_T1	PHENOTYPE	26	27	liver mass
NCT001470434	NCT00147043_4_T2	PHENOTYPE	15	16	virus infection
NCT001470434	NCT00147043_4_T3	PHENOTYPE	16	18	infection or inflammation
NCT001470438	NCT00147043_8_T0	ORGAN	16	16	liver
NCT001470438	NCT00147043_8_T1	GENE	2	2	abstract
NCT001470438	NCT00147043_8_T2	CELL	28	28	hepatocytes
NCT001470438	NCT00147043_8_T3	GENE	3	3	has
NCT001470438	NCT00147043_8_T4	PHENOTYPE	33	33	cirrhosis
NCT001470438	NCT00147043_8_T5	CELL	11	13	bone marrow cells
NCT001470438	NCT00147043_8_T6	CELL	20	22	bone marrow cells
NCT0014704310	NCT00147043_10_T0	PHENOTYPE	5	5	toxicity
NCT0014704310	NCT00147043_10_T1	PHENOTYPE	11	13	chronic liver disease
NCT001470564	NCT00147056_4_T0	GENE	11	11	MRI
NCT001470566	NCT00147056_6_T0	ORGAN	12	12	skull
NCT001470568	NCT00147056_8_T0	PHENOTYPE	10	10	tumor
NCT001470568	NCT00147056_8_T1	PHENOTYPE	18	18	tumor
NCT0014705616	NCT00147056_16_T0	GENE	14	14	has
NCT0014705616	NCT00147056_16_T1	PHENOTYPE	5	5	recurrent
NCT0014705616	NCT00147056_16_T2	PHENOTYPE	6	7	metastatic cancer
NCT0014705619	NCT00147056_19_T0	PHENOTYPE	4	4	tumor
NCT0014705619	NCT00147056_19_T1	PHENOTYPE	10	10	tumor
NCT0014705621	NCT00147056_21_T0	GENE	8	8	MRI
NCT0014705624	NCT00147056_24_T0	PHENOTYPE	2	2	tumor
NCT0014705626	NCT00147056_26_T0	ORGAN	4	4	Appendix
NCT0014705628	NCT00147056_28_T0	GENE	0	0	ASA
NCT0014705633	NCT00147056_33_T0	PHENOTYPE	1	2	myocardial infarction
NCT0014705636	NCT00147056_36_T0	PHENOTYPE	0	2	Congestive heart disease
NCT0014705644	NCT00147056_44_T0	PHENOTYPE	9	9	hemorrhage
NCT0014705645	NCT00147056_45_T0	PHENOTYPE	0	0	TIA
NCT0014705647	NCT00147056_47_T0	PHENOTYPE	0	0	Immunosuppression
NCT0014705647	NCT00147056_47_T1	PHENOTYPE	4	5	brain edema
NCT0014705649	NCT00147056_49_T0	GENE	2	2	MRI
NCT0014705650	NCT00147056_50_T0	GENE	7	7	MRI
NCT0014705651	NCT00147056_51_T0	GENE	12	12	MRI
NCT0014705653	NCT00147056_53_T0	PHENOTYPE	4	4	menopausal
NCT0014705653	NCT00147056_53_T1	PHENOTYPE	0	2	Positive pregnancy test
NCT0014705656	NCT00147056_56_T0	PHENOTYPE	2	3	abnormal bleeding
NCT001470692	NCT00147069_2_T0	PHENOTYPE	15	15	imbalance
NCT001470692	NCT00147069_2_T1	CELL	2	2	cells
NCT001470694	NCT00147069_4_T0	CELL	8	8	monocytes
NCT001470694	NCT00147069_4_T1	CELL	0	0	Monocytes
NCT001470694	NCT00147069_4_T2	CELL	10	10	neutrophils
NCT001470694	NCT00147069_4_T3	CELL	4	5	alveolar macrophages
NCT001470695	NCT00147069_5_T0	PHENOTYPE	5	5	inflammation
NCT001470696	NCT00147069_6_T0	CELL	2	2	cells
NCT001470696	NCT00147069_6_T1	CELL	11	12	alveolar macrophages
NCT001470697	NCT00147069_7_T0	CELL	9	9	macrophage
NCT001470697	NCT00147069_7_T1	CELL	11	11	monocyte
NCT001470697	NCT00147069_7_T2	CELL	13	13	neutrophils
NCT001470699	NCT00147069_9_T0	CELL	16	16	cells
NCT001470699	NCT00147069_9_T1	PHENOTYPE	13	13	recruitment
NCT001470699	NCT00147069_9_T2	CELL	6	6	lymphocyte
NCT0014706910	NCT00147069_10_T0	CELL	27	27	monocytes
NCT0014706910	NCT00147069_10_T1	CELL	29	29	neutrophils
NCT0014706911	NCT00147069_11_T0	ORGAN	17	17	lungs
NCT0014706914	NCT00147069_14_T0	GENE	3	3	had
NCT0014706915	NCT00147069_15_T0	PHENOTYPE	0	0	Recruitment
NCT0014706922	NCT00147069_22_T0	PHENOTYPE	31	31	asthmatics
NCT0014706932	NCT00147069_32_T0	PHENOTYPE	9	9	Asthma
NCT0014706937	NCT00147069_37_T0	PHENOTYPE	23	23	spitting
NCT0014706937	NCT00147069_37_T1	GENE	17	17	saliva
NCT0014706938	NCT00147069_38_T0	PHENOTYPE	5	6	chest discomfort
NCT0014706938	NCT00147069_38_T1	PHENOTYPE	8	10	shortness of breath
NCT0014706941	NCT00147069_41_T0	GENE	6	6	TNF-alpha
NCT0014706941	NCT00147069_41_T1	GENE	7	7	IL-8
NCT0014706946	NCT00147069_46_T0	CELL	6	6	leukocyte
NCT0014706946	NCT00147069_46_T1	BIOLOGICAL_PROCESS	9	9	chemotaxis
NCT0014706952	NCT00147069_52_T0	COMPOUND	4	4	salbutamol
NCT0014706952	NCT00147069_52_T1	GENE	10	10	1L
NCT0014706956	NCT00147069_56_T0	PHENOTYPE	5	6	respiratory disease
NCT0014706960	NCT00147069_60_T0	PHENOTYPE	1	2	lung function
NCT0014706961	NCT00147069_61_T0	PHENOTYPE	2	4	respiratory tract infection
NCT0014706962	NCT00147069_62_T0	PHENOTYPE	5	6	respiratory disease
NCT0014706966	NCT00147069_66_T0	PHENOTYPE	1	2	lung function
NCT0014706969	NCT00147069_69_T0	PHENOTYPE	0	1	Alcohol abuse
NCT0014706970	NCT00147069_70_T0	PHENOTYPE	8	9	renal disease
NCT0014706972	NCT00147069_72_T0	PHENOTYPE	0	1	Drug abuse
NCT0014706975	NCT00147069_75_T0	PHENOTYPE	3	4	lung diseases
NCT0014706976	NCT00147069_76_T0	PHENOTYPE	0	2	Upper respiratory infection
NCT001470824	NCT00147082_4_T0	CELL	5	5	cells
NCT001470824	NCT00147082_4_T1	CELL	12	12	cells
NCT001470828	NCT00147082_8_T0	CELL	2	2	cells
NCT001470953	NCT00147095_3_T0	CELL	6	6	macrophages
NCT001470953	NCT00147095_3_T1	CELL	22	22	cells
NCT001470954	NCT00147095_4_T0	CELL	4	4	leukocyte
NCT001470955	NCT00147095_5_T0	CELL	19	19	cells
NCT001470957	NCT00147095_7_T0	CELL	6	6	macrophages
NCT001470959	NCT00147095_9_T0	CELL	20	20	cells
NCT001470959	NCT00147095_9_T1	CELL	2	2	leukocytes
NCT0014709512	NCT00147095_12_T0	CELL	14	14	leukocytes
NCT0014709512	NCT00147095_12_T1	GENE	11	11	mediator
NCT0014709515	NCT00147095_15_T0	CELL	10	10	leukocyte
NCT0014709528	NCT00147095_28_T0	GENE	8	8	Dr
NCT0014709529	NCT00147095_29_T0	GENE	8	8	am
NCT0014709530	NCT00147095_30_T0	PHENOTYPE	11	11	5-10
NCT0014709530	NCT00147095_30_T1	COMPOUND	10	10	midazolam
NCT0014709530	NCT00147095_30_T2	GENE	6	6	0.6
NCT0014709530	NCT00147095_30_T3	COMPOUND	5	5	atropine
NCT0014709531	NCT00147095_31_T0	COMPOUND	13	13	oxygen
NCT0014709532	NCT00147095_32_T0	ORGAN	11	11	larynx
NCT0014709532	NCT00147095_32_T1	ORGAN	27	27	trachea
NCT0014709532	NCT00147095_32_T2	COMPOUND	4	4	lidocaine
NCT0014709532	NCT00147095_32_T3	PHENOTYPE	2	2	anaesthesia
NCT0014709535	NCT00147095_35_T0	PHENOTYPE	14	14	fever
NCT0014709538	NCT00147095_38_T0	GENE	4	4	ml
NCT001471083	NCT00147108_3_T0	GENE	15	15	lump
NCT001471084	NCT00147108_4_T0	PHENOTYPE	21	21	fibroadenoma
NCT001471084	NCT00147108_4_T1	PHENOTYPE	23	24	breast cancer
NCT0014710810	NCT00147108_10_T0	PHENOTYPE	14	14	recruitment
NCT0014710811	NCT00147108_11_T0	GENE	12	12	MRI
NCT001471211	NCT00147121_1_T0	GENE	13	13	CHOP
NCT001471211	NCT00147121_1_T1	GENE	16	16	G-CSF
NCT001471215	NCT00147121_5_T0	GENE	0	0	Ann
NCT001471215	NCT00147121_5_T1	GENE	2	2	CS
NCT001471215	NCT00147121_5_T2	GENE	3	3	III
NCT001471215	NCT00147121_5_T3	GENE	5	5	IV
NCT001471218	NCT00147121_8_T0	GENE	2	2	0.2
NCT001471219	NCT00147121_9_T0	PHENOTYPE	1	2	measurable disease
NCT0014712114	NCT00147121_14_T0	PHENOTYPE	0	0	Glaucoma
NCT0014712115	NCT00147121_15_T0	GENE	3	3	insulin
NCT0014712116	NCT00147121_16_T0	GENE	1	1	HT
NCT0014712117	NCT00147121_17_T0	PHENOTYPE	1	1	AMI
NCT0014712118	NCT00147121_18_T0	PHENOTYPE	10	10	HIV
NCT0014712118	NCT00147121_18_T1	COMPOUND	6	6	HCV
NCT0014712119	NCT00147121_19_T0	PHENOTYPE	2	3	pulmonary fibrosis
NCT0014712119	NCT00147121_19_T1	PHENOTYPE	0	1	Interstitial pneumonitis
NCT001471344	NCT00147134_4_T0	PHENOTYPE	2	3	colorectal carcinoma
NCT001471345	NCT00147134_5_T0	ORGAN	11	11	colon
NCT001471345	NCT00147134_5_T1	PHENOTYPE	0	0	Tumor
NCT001471345	NCT00147134_5_T2	ORGAN	4	4	cecum
NCT001471345	NCT00147134_5_T3	ORGAN	5	6	ascending colon
NCT001471345	NCT00147134_5_T4	ORGAN	7	8	sigmoid colon
NCT001471346	NCT00147134_6_T0	GENE	0	0	T3
NCT001471347	NCT00147134_7_T0	PHENOTYPE	5	7	carcinoma in situ
NCT001471348	NCT00147134_8_T0	GENE	9	9	TNM
NCT0014713410	NCT00147134_10_T0	PHENOTYPE	1	2	bowel obstruction
NCT0014713416	NCT00147134_16_T0	PHENOTYPE	6	6	malignancy
NCT0014713416	NCT00147134_16_T1	PHENOTYPE	9	11	carcinoma in situ
NCT0014713417	NCT00147134_17_T0	PHENOTYPE	1	2	pulmonary emphysema
NCT0014713417	NCT00147134_17_T1	PHENOTYPE	3	4	interstitial pneumonitis
NCT0014713417	NCT00147134_17_T2	PHENOTYPE	6	8	ischemic heart disease
NCT0014713419	NCT00147134_19_T0	PHENOTYPE	1	2	mental disease
NCT001471470	NCT00147147_0_T0	PHENOTYPE	12	13	Gastric Cancer
NCT001471473	NCT00147147_3_T0	GENE	16	16	pts
NCT001471473	NCT00147147_3_T1	GENE	21	21	pts
NCT001471474	NCT00147147_4_T0	COMPOUND	21	21	5_fluorouracil
NCT001471474	NCT00147147_4_T1	ORGAN	10	10	abdomen
NCT001471474	NCT00147147_4_T2	COMPOUND	4	4	cisplatin
NCT001471474	NCT00147147_4_T3	COMPOUND	15	15	cisplatin
NCT001471474	NCT00147147_4_T4	GENE	30	30	FU
NCT001471476	NCT00147147_6_T0	PHENOTYPE	6	6	recurrence
NCT001471476	NCT00147147_6_T1	PHENOTYPE	8	8	secondary
NCT001471477	NCT00147147_7_T0	GENE	3	3	D2
NCT001471477	NCT00147147_7_T1	PHENOTYPE	19	20	gastric cancer
NCT001471477	NCT00147147_7_T2	TISSUE	6	7	lymph node
NCT001471479	NCT00147147_9_T0	GENE	3	3	D2
NCT001471479	NCT00147147_9_T1	TISSUE	6	7	lymph node
NCT0014714710	NCT00147147_10_T0	PHENOTYPE	2	3	gastric adenocarcinoma
NCT0014714715	NCT00147147_15_T0	GENE	3	3	WBC
NCT001471862	NCT00147186_2_T0	PHENOTYPE	7	7	exhausted
NCT001471863	NCT00147186_3_T0	GENE	1	1	G/F
NCT001471867	NCT00147186_7_T0	GENE	9	9	G/F
NCT001471869	NCT00147186_9_T0	GENE	8	8	has
NCT0014718611	NCT00147186_11_T0	ORGAN	13	14	knee joint
NCT0014718611	NCT00147186_11_T1	ORGAN	8	9	synovial fluid
NCT0014718614	NCT00147186_14_T0	GENE	14	14	G/F
NCT0014718615	NCT00147186_15_T0	GENE	10	10	G/F
NCT0014718615	NCT00147186_15_T1	GENE	32	32	G/F
NCT001471993	NCT00147199_3_T0	COMPOUND	9	9	treprostinil
NCT001471997	NCT00147199_7_T0	GENE	3	3	has
NCT001472250	NCT00147225_0_T0	PHENOTYPE	6	6	Malignancy
NCT001472250	NCT00147225_0_T1	GENE	0	0	AMG
NCT001472252	NCT00147225_2_T0	GENE	10	10	AMG
NCT001472254	NCT00147225_4_T0	PHENOTYPE	17	17	malignancy
NCT001472254	NCT00147225_4_T1	GENE	8	8	AMG
NCT001472255	NCT00147225_5_T0	COMPOUND	6	6	OBD
NCT001472255	NCT00147225_5_T1	PHENOTYPE	19	19	thrombocytopenia
NCT001472255	NCT00147225_5_T2	GENE	8	8	AMG
NCT001472256	NCT00147225_6_T0	PHENOTYPE	19	19	Secondary
NCT001472256	NCT00147225_6_T1	PHENOTYPE	13	13	thrombocytopenia
NCT001472256	NCT00147225_6_T2	CELL	15	15	platelet
NCT001472256	NCT00147225_6_T3	GENE	5	5	AMG
NCT001472258	NCT00147225_8_T0	COMPOUND	5	5	OBD
NCT001472258	NCT00147225_8_T1	GENE	22	22	pre
NCT001472258	NCT00147225_8_T2	GENE	16	16	AMG
NCT0014722512	NCT00147225_12_T0	CELL	7	7	platelet
NCT0014722512	NCT00147225_12_T1	GENE	0	0	AMG
NCT0014722514	NCT00147225_14_T0	GENE	3	3	AMG
NCT0014722516	NCT00147225_16_T0	GENE	17	17	AMG
NCT0014722517	NCT00147225_17_T0	GENE	0	0	AMG
NCT0014722518	NCT00147225_18_T0	GENE	0	0	AMG
NCT0014722520	NCT00147225_20_T0	GENE	32	32	AMG
NCT0014722520	NCT00147225_20_T1	PHENOTYPE	12	12	tolerance
NCT0014722522	NCT00147225_22_T0	CELL	21	21	platelet
NCT0014722522	NCT00147225_22_T1	GENE	3	3	AMG
NCT0014722525	NCT00147225_25_T0	GENE	13	13	AMG
NCT0014722530	NCT00147225_30_T0	GENE	0	0	AMG
NCT0014722535	NCT00147225_35_T0	PHENOTYPE	15	15	thrombocytopenia
NCT0014722535	NCT00147225_35_T1	GENE	25	25	AI
NCT0014722535	NCT00147225_35_T2	PHENOTYPE	5	6	solid tumors
NCT0014722542	NCT00147225_42_T0	PHENOTYPE	7	7	menopausal
NCT0014722542	NCT00147225_42_T1	PHENOTYPE	19	21	negative pregnancy test
NCT0014722545	NCT00147225_45_T0	PHENOTYPE	11	11	ascites
NCT0014722545	NCT00147225_45_T1	PHENOTYPE	2	3	rapidly progressive
NCT0014722545	NCT00147225_45_T2	PHENOTYPE	3	4	progressive disease
NCT0014722545	NCT00147225_45_T3	PHENOTYPE	13	14	pleural effusion
NCT0014722547	NCT00147225_47_T0	PHENOTYPE	2	3	hematologic malignancies
NCT0014722551	NCT00147225_51_T0	PHENOTYPE	6	6	metastasis
NCT0014722551	NCT00147225_51_T1	ORGAN	2	4	central nervous system
NCT0014722553	NCT00147225_53_T0	GENE	11	11	III
NCT0014722553	NCT00147225_53_T1	GENE	13	13	IV
NCT0014722553	NCT00147225_53_T2	PHENOTYPE	28	28	CVA
NCT0014722553	NCT00147225_53_T3	PHENOTYPE	21	21	ischemia
NCT0014722553	NCT00147225_53_T4	PHENOTYPE	3	4	cardiac disease
NCT0014722553	NCT00147225_53_T5	PHENOTYPE	26	27	cerebrovascular accident
NCT0014722553	NCT00147225_53_T6	PHENOTYPE	22	24	transient ischemic attack
NCT0014722555	NCT00147225_55_T0	PHENOTYPE	12	12	DVT
NCT0014722555	NCT00147225_55_T1	PHENOTYPE	14	15	pulmonary embolus
NCT0014722555	NCT00147225_55_T2	PHENOTYPE	5	6	thromboembolic events
NCT0014722555	NCT00147225_55_T3	PHENOTYPE	9	11	deep venous thrombosis
NCT0014722558	NCT00147225_58_T0	PHENOTYPE	28	28	toxicity
NCT0014722558	NCT00147225_58_T1	PHENOTYPE	27	27	acute
NCT0014722558	NCT00147225_58_T2	GENE	20	20	has
NCT0014722562	NCT00147225_62_T0	GENE	5	5	RT
NCT0014722563	NCT00147225_63_T0	PHENOTYPE	19	19	thrombocytopenia
NCT0014722563	NCT00147225_63_T1	CELL	21	21	platelet
NCT001472384	NCT00147238_4_T0	TISSUE	9	10	lymph nodes
NCT001472386	NCT00147238_6_T0	GENE	20	20	MRI
NCT001472386	NCT00147238_6_T1	GENE	23	23	MRI
NCT001472386	NCT00147238_6_T2	TISSUE	17	18	lymph nodes
NCT001472389	NCT00147238_9_T0	GENE	8	8	MRI
NCT0014723810	NCT00147238_10_T0	GENE	8	8	MRI
NCT0014723812	NCT00147238_12_T0	GENE	10	10	MRI
NCT0014723812	NCT00147238_12_T1	GENE	26	26	MRI
NCT0014723813	NCT00147238_13_T0	GENE	16	16	MRI
NCT0014723814	NCT00147238_14_T0	GENE	9	9	MRI
NCT0014723814	NCT00147238_14_T1	GENE	23	23	MRI
NCT0014723817	NCT00147238_17_T0	GENE	6	6	MRI
NCT0014723819	NCT00147238_19_T0	PHENOTYPE	14	14	tolerance
NCT0014723822	NCT00147238_22_T0	GENE	6	6	MRI
NCT0014723824	NCT00147238_24_T0	GENE	10	10	has
NCT0014723832	NCT00147238_32_T0	TISSUE	11	12	lymph node
NCT0014723835	NCT00147238_35_T0	GENE	2	2	MRI
NCT0014723836	NCT00147238_36_T0	PHENOTYPE	0	0	Claustrophobia
NCT0014723836	NCT00147238_36_T1	ORGAN	4	4	pelvis
NCT0014723839	NCT00147238_39_T0	PHENOTYPE	6	7	penile cancer
NCT0014723839	NCT00147238_39_T1	PHENOTYPE	0	1	Penile Cancer
NCT0014723840	NCT00147238_40_T0	GENE	9	9	NOT
NCT0014723840	NCT00147238_40_T1	PHENOTYPE	6	7	bladder cancer
NCT0014723840	NCT00147238_40_T2	TISSUE	25	26	lymph node
NCT0014723840	NCT00147238_40_T3	PHENOTYPE	0	1	Bladder Cancer
NCT0014723842	NCT00147238_42_T0	ORGAN	9	9	bladder
NCT001472512	NCT00147251_2_T0	PHENOTYPE	31	31	strokes
NCT001472512	NCT00147251_2_T1	PHENOTYPE	22	23	cardiovascular disease
NCT001472512	NCT00147251_2_T2	PHENOTYPE	28	29	heart attacks
NCT001472512	NCT00147251_2_T3	ORGAN	12	13	carotid artery
NCT001472513	NCT00147251_3_T0	PHENOTYPE	6	6	secondary
NCT001472513	NCT00147251_3_T1	ORGAN	22	22	kidney
NCT001472513	NCT00147251_3_T2	ORGAN	13	13	heart
NCT001472516	NCT00147251_6_T0	PHENOTYPE	5	5	CVD
NCT001472516	NCT00147251_6_T1	PHENOTYPE	0	0	Diabetes
NCT001472517	NCT00147251_7_T0	PHENOTYPE	6	6	hyperlipidemia
NCT001472517	NCT00147251_7_T1	PHENOTYPE	12	12	progression
NCT001472517	NCT00147251_7_T2	PHENOTYPE	8	8	hypertension
NCT001472517	NCT00147251_7_T3	PHENOTYPE	15	16	vascular disease
NCT0014725111	NCT00147251_11_T0	GENE	2	2	BP
NCT0014725112	NCT00147251_12_T0	PHENOTYPE	5	5	atherosclerosis
NCT0014725112	NCT00147251_12_T1	PHENOTYPE	3	3	progression
NCT0014725113	NCT00147251_13_T0	ORGAN	10	11	carotid artery
NCT0014725115	NCT00147251_15_T0	GENE	12	12	CRP
NCT0014725115	NCT00147251_15_T1	PHENOTYPE	4	4	plaque
NCT0014725115	NCT00147251_15_T2	PHENOTYPE	0	0	Secondary
NCT0014725115	NCT00147251_15_T3	ORGAN	11	11	serum
NCT0014725115	NCT00147251_15_T4	GENE	7	7	ventricular
NCT0014725116	NCT00147251_16_T0	PHENOTYPE	24	24	CVD
NCT0014725117	NCT00147251_17_T0	PHENOTYPE	15	15	atherosclerosis
NCT0014725117	NCT00147251_17_T1	GENE	36	36	BP
NCT0014725120	NCT00147251_20_T0	COMPOUND	27	27	glucose
NCT0014725120	NCT00147251_20_T1	GENE	31	31	200
NCT0014725120	NCT00147251_20_T2	GENE	29	29	11.0
NCT0014725120	NCT00147251_20_T3	GENE	6	6	ADA
NCT0014725120	NCT00147251_20_T4	GENE	13	13	ADA
NCT0014725120	NCT00147251_20_T5	PHENOTYPE	18	19	plasma glucose
NCT0014725120	NCT00147251_20_T6	PHENOTYPE	37	38	glucose tolerance
NCT0014725122	NCT00147251_22_T0	GENE	0	0	LDL
NCT0014725124	NCT00147251_24_T0	GENE	1	1	BP
NCT0014725124	NCT00147251_24_T1	GENE	5	5	Hg
NCT0014725126	NCT00147251_26_T0	ORGAN	2	2	Heart
NCT0014725126	NCT00147251_26_T1	GENE	5	5	III
NCT0014725126	NCT00147251_26_T2	GENE	6	6	IV
NCT0014725126	NCT00147251_26_T3	PHENOTYPE	7	9	congestive heart failure
NCT0014725128	NCT00147251_28_T0	GENE	0	0	SBP
NCT0014725128	NCT00147251_28_T1	GENE	1	1	180
NCT0014725128	NCT00147251_28_T2	PHENOTYPE	12	12	hypertension
NCT0014725130	NCT00147251_30_T0	PHENOTYPE	2	2	angioedema
NCT0014725134	NCT00147251_34_T0	PHENOTYPE	3	4	cognitive impairment
NCT0014725136	NCT00147251_36_T0	ORGAN	0	0	Serum
NCT0014725142	NCT00147251_42_T0	PHENOTYPE	3	3	hyperlipidemia
NCT0014725144	NCT00147251_44_T0	ORGAN	5	5	thyroid
NCT0014725145	NCT00147251_45_T0	PHENOTYPE	2	2	malignancy
NCT0014725145	NCT00147251_45_T1	PHENOTYPE	9	10	skin cancer
NCT0014725146	NCT00147251_46_T0	BIOLOGICAL_PROCESS	2	2	lactation
NCT0014725149	NCT00147251_49_T0	COMPOUND	26	26	nelfinavir
NCT0014725149	NCT00147251_49_T1	COMPOUND	9	9	erythromycin
NCT0014725149	NCT00147251_49_T2	COMPOUND	23	23	ritonavir
NCT0014725149	NCT00147251_49_T3	COMPOUND	16	16	clarithromycin
NCT0014725150	NCT00147251_50_T0	PHENOTYPE	0	1	Orthostatic hypotension
NCT0014725151	NCT00147251_51_T0	GENE	11	11	BP
NCT0014725151	NCT00147251_51_T1	GENE	32	32	BP
NCT0014725151	NCT00147251_51_T2	PHENOTYPE	16	16	symptoms
NCT0014725151	NCT00147251_51_T3	PHENOTYPE	24	24	symptoms
NCT0014725151	NCT00147251_51_T4	GENE	2	2	has
NCT0014725151	NCT00147251_51_T5	GENE	7	7	20
NCT0014725153	NCT00147251_53_T0	GENE	2	2	350
NCT0014725153	NCT00147251_53_T1	PHENOTYPE	0	1	Triglyceride level
NCT001472648	NCT00147264_8_T0	GENE	12	12	RAS
NCT001472648	NCT00147264_8_T1	GENE	8	8	putative
NCT001472648	NCT00147264_8_T2	GENE	19	20	angiotensin receptor
NCT001472648	NCT00147264_8_T3	PHENOTYPE	30	31	abdominal obesity
NCT0014726412	NCT00147264_12_T0	PHENOTYPE	22	23	insulin sensitivity
NCT0014726416	NCT00147264_16_T0	GENE	0	0	11
NCT0014726416	NCT00147264_16_T1	GENE	5	5	12
NCT001472902	NCT00147290_2_T0	GENE	8	8	RV
NCT001472902	NCT00147290_2_T1	GENE	11	11	has
NCT001472902	NCT00147290_2_T2	GENE	4	4	ATP
NCT001472902	NCT00147290_2_T3	COMPOUND	10	10	BIV
NCT001473033	NCT00147303_3_T0	PHENOTYPE	6	6	embolism
NCT001473033	NCT00147303_3_T1	PHENOTYPE	0	1	Cerebral infarction
NCT001473035	NCT00147303_5_T0	PHENOTYPE	3	3	symptoms
NCT001473036	NCT00147303_6_T0	GENE	2	2	MRI
NCT0014730312	NCT00147303_12_T0	PHENOTYPE	7	8	cerebral infarction
NCT0014730313	NCT00147303_13_T0	PHENOTYPE	2	3	intracranial hemorrhage
NCT0014730314	NCT00147303_14_T0	PHENOTYPE	3	3	bleeding
NCT0014730314	NCT00147303_14_T1	PHENOTYPE	11	11	coagulopathy
NCT0014730314	NCT00147303_14_T2	PHENOTYPE	8	9	bleeding diathesis
NCT0014730315	NCT00147303_15_T0	PHENOTYPE	2	2	complications
NCT0014730315	NCT00147303_15_T1	PHENOTYPE	8	9	heart failure
NCT0014730315	NCT00147303_15_T2	PHENOTYPE	6	7	hepatic insufficiency
NCT0014730316	NCT00147303_16_T0	PHENOTYPE	1	2	malignant tumor
NCT0014730318	NCT00147303_18_T0	COMPOUND	2	2	sarpogrelate
NCT001473164	NCT00147316_4_T0	GENE	15	15	rt-PA
NCT001473164	NCT00147316_4_T1	PHENOTYPE	10	11	Neurological Disorders
NCT001473166	NCT00147316_6_T0	ORGAN	24	26	middle cerebral artery
NCT001473292	NCT00147329_2_T0	PHENOTYPE	10	10	bloodstream
NCT001473292	NCT00147329_2_T1	GENE	7	7	AFP
NCT001473293	NCT00147329_3_T0	GENE	3	3	AFP
NCT001473295	NCT00147329_5_T0	GENE	6	6	AFP
NCT0014732910	NCT00147329_10_T0	GENE	3	3	had
NCT001473422	NCT00147342_2_T0	GENE	4	4	insulin
NCT001473422	NCT00147342_2_T1	GENE	14	14	insulin
NCT001473423	NCT00147342_3_T0	GENE	10	10	insulin
NCT001473423	NCT00147342_3_T1	PHENOTYPE	21	21	hypoglycemia
NCT001473424	NCT00147342_4_T0	PHENOTYPE	14	14	hyperglycemia
NCT001473424	NCT00147342_4_T1	PHENOTYPE	11	11	hypoglycemia
NCT001473424	NCT00147342_4_T2	PHENOTYPE	15	17	high blood sugar
NCT001473428	NCT00147342_8_T0	GENE	5	5	insulin
NCT0014734213	NCT00147342_13_T0	GENE	18	18	hemoglobin
NCT0014734216	NCT00147342_16_T0	COMPOUND	15	15	glucose
NCT0014734216	NCT00147342_16_T1	PHENOTYPE	9	11	blood sugar level
NCT0014734217	NCT00147342_17_T0	COMPOUND	8	8	glucose
NCT0014734218	NCT00147342_18_T0	ORGAN	10	10	buttock
NCT0014734219	NCT00147342_19_T0	GENE	7	7	numb
NCT0014734221	NCT00147342_21_T0	COMPOUND	11	11	glucose
NCT0014734223	NCT00147342_23_T0	GENE	7	7	numb
NCT0014734234	NCT00147342_34_T0	GENE	13	13	insulin
NCT0014734235	NCT00147342_35_T0	GENE	2	2	insulin
NCT0014734243	NCT00147342_43_T0	PHENOTYPE	11	11	hypoglycemia
NCT0014734249	NCT00147342_49_T0	COMPOUND	7	7	glucose
NCT0014734250	NCT00147342_50_T0	GENE	21	21	log
NCT001473550	NCT00147355_0_T0	PHENOTYPE	0	0	Toxicity
NCT001473553	NCT00147355_3_T0	COMPOUND	39	39	phosphate
NCT001473553	NCT00147355_3_T1	GENE	10	10	1/6
NCT001473553	NCT00147355_3_T2	COMPOUND	5	5	ibuprofen
NCT001473553	NCT00147355_3_T3	COMPOUND	38	38	codeine
NCT001473553	NCT00147355_3_T4	COMPOUND	30	30	ondansetron
NCT001473553	NCT00147355_3_T5	COMPOUND	32	32	metoclopramide
NCT001473553	NCT00147355_3_T6	COMPOUND	7	7	paracetamol
NCT0014735510	NCT00147355_10_T0	GENE	11	11	CD4
NCT0014735510	NCT00147355_10_T1	PHENOTYPE	0	0	Secondary
NCT0014735510	NCT00147355_10_T2	CELL	12	12	T-cell
NCT0014735510	NCT00147355_10_T3	PHENOTYPE	15	17	quality of life
NCT0014735512	NCT00147355_12_T0	GENE	3	3	CD4
NCT0014735512	NCT00147355_12_T1	CELL	4	4	T-cell
NCT0014735514	NCT00147355_14_T0	PHENOTYPE	4	4	upset
NCT0014735514	NCT00147355_14_T1	GENE	3	3	GI
NCT0014735519	NCT00147355_19_T0	PHENOTYPE	1	1	allergy
NCT0014735521	NCT00147355_21_T0	GENE	4	4	cyclooxygenase-2
NCT0014735521	NCT00147355_21_T1	GENE	5	5	COX-2
NCT001473682	NCT00147368_2_T0	COMPOUND	12	12	arginine
NCT001473682	NCT00147368_2_T1	PHENOTYPE	14	15	falciparum malaria
NCT001473684	NCT00147368_4_T0	COMPOUND	4	4	arginine
NCT001473684	NCT00147368_4_T1	COMPOUND	14	14	arginine
NCT001473684	NCT00147368_4_T2	PHENOTYPE	39	39	malaria
NCT001473684	NCT00147368_4_T3	ORGAN	13	13	plasma
NCT001473684	NCT00147368_4_T4	PHENOTYPE	9	10	falciparum malaria
NCT001473687	NCT00147368_7_T0	PHENOTYPE	2	2	parasitemia
NCT0014736810	NCT00147368_10_T0	COMPOUND	11	11	arginine
NCT0014736810	NCT00147368_10_T1	COMPOUND	2	2	quinine
NCT0014736813	NCT00147368_13_T0	BIOLOGICAL_PROCESS	2	2	lactation
NCT0014736816	NCT00147368_16_T0	PHENOTYPE	3	3	malaria
NCT0014736817	NCT00147368_17_T0	PHENOTYPE	0	0	Diabetes
NCT0014736819	NCT00147368_19_T0	ORGAN	5	5	kidney
NCT0014736822	NCT00147368_22_T0	PHENOTYPE	1	1	allergy
NCT001473813	NCT00147381_3_T0	PHENOTYPE	11	11	acute
NCT001473944	NCT00147394_4_T0	PHENOTYPE	2	2	disorders
NCT001473945	NCT00147394_5_T0	PHENOTYPE	3	3	PDD
NCT001473945	NCT00147394_5_T1	PHENOTYPE	17	17	sequelae
NCT001473945	NCT00147394_5_T2	PHENOTYPE	19	20	tardive dyskinesia
NCT0014742010	NCT00147420_10_T0	PHENOTYPE	23	23	dilation
NCT0014742010	NCT00147420_10_T1	COMPOUND	4	4	misoprostol
NCT0014742010	NCT00147420_10_T2	COMPOUND	26	26	misoprostol
NCT0014742011	NCT00147420_11_T0	PHENOTYPE	12	13	blood loss
NCT001474331	NCT00147433_1_T0	ORGAN	13	13	thyroid
NCT001474331	NCT00147433_1_T1	PHENOTYPE	10	11	thyroid function
NCT001474331	NCT00147433_1_T2	PHENOTYPE	15	16	hormone levels
NCT001474332	NCT00147433_2_T0	GENE	10	10	FT4
NCT001474332	NCT00147433_2_T1	GENE	24	24	FT4
NCT001474332	NCT00147433_2_T2	GENE	31	31	FT4
NCT001474332	NCT00147433_2_T3	GENE	3	3	has
NCT001474333	NCT00147433_3_T0	GENE	23	23	FT4
NCT001474334	NCT00147433_4_T0	PHENOTYPE	30	30	strategies
NCT001474339	NCT00147433_9_T0	ORGAN	5	5	thyroid
NCT001474339	NCT00147433_9_T1	GENE	7	7	TSH
NCT001474339	NCT00147433_9_T2	GENE	6	6	hormone
NCT0014743310	NCT00147433_10_T0	GENE	6	6	TSH
NCT0014743311	NCT00147433_11_T0	GENE	1	1	T4
NCT0014743311	NCT00147433_11_T1	GENE	9	9	sera
NCT0014743312	NCT00147433_12_T0	GENE	2	2	nested
NCT0014743313	NCT00147433_13_T0	PHENOTYPE	24	25	congenital anomalies
NCT0014743315	NCT00147433_15_T0	GENE	4	4	T4
NCT0014743315	NCT00147433_15_T1	GENE	22	22	T4
NCT0014743319	NCT00147433_19_T0	GENE	12	12	T4
NCT0014743319	NCT00147433_19_T1	GENE	4	4	1.4
NCT0014743319	NCT00147433_19_T2	GENE	9	9	TSH
NCT0014743319	NCT00147433_19_T3	GENE	21	21	TSH
NCT0014743319	NCT00147433_19_T4	PHENOTYPE	2	2	Recruitment
NCT0014743321	NCT00147433_21_T0	GENE	19	19	T4
NCT0014743321	NCT00147433_21_T1	GENE	15	15	TSH
NCT0014743321	NCT00147433_21_T2	ORGAN	23	23	serum
NCT0014743321	NCT00147433_21_T3	PHENOTYPE	1	1	Recruitment
NCT0014743323	NCT00147433_23_T0	GENE	18	18	T4
NCT0014743323	NCT00147433_23_T1	GENE	32	32	T4
NCT0014743325	NCT00147433_25_T0	COMPOUND	15	15	3
NCT0014743325	NCT00147433_25_T1	PHENOTYPE	18	18	hypothyroidism
NCT0014743327	NCT00147433_27_T0	GENE	13	13	T4
NCT0014743327	NCT00147433_27_T1	ORGAN	10	10	thyroid
NCT0014743327	NCT00147433_27_T2	ORGAN	16	16	thyroid
NCT0014743327	NCT00147433_27_T3	GENE	14	14	T3
NCT0014743331	NCT00147433_31_T0	ORGAN	15	15	thyroid
NCT0014743331	NCT00147433_31_T1	GENE	16	16	hormone
NCT0014743333	NCT00147433_33_T0	PHENOTYPE	14	14	strategies
NCT001474464	NCT00147446_4_T0	GENE	1	1	met
NCT001474465	NCT00147446_5_T0	PHENOTYPE	4	4	focused
NCT001474465	NCT00147446_5_T1	PHENOTYPE	7	8	problem solving
NCT001474468	NCT00147446_8_T0	GENE	6	6	has
NCT0014744610	NCT00147446_10_T0	GENE	16	16	MS
NCT0014744610	NCT00147446_10_T1	GENE	32	32	MS
NCT0014744610	NCT00147446_10_T2	PHENOTYPE	24	25	brain lesions
NCT0014744611	NCT00147446_11_T0	GENE	7	7	MRI
NCT0014744611	NCT00147446_11_T1	GENE	6	6	Gd
NCT0014744611	NCT00147446_11_T2	PHENOTYPE	8	9	brain lesion
NCT0014744613	NCT00147446_13_T0	GENE	23	23	condensed
NCT0014744614	NCT00147446_14_T0	GENE	2	2	MRI
NCT0014744615	NCT00147446_15_T0	PHENOTYPE	28	28	inflammation
NCT0014744615	NCT00147446_15_T1	GENE	27	27	MS
NCT001474591	NCT00147459_1_T0	PHENOTYPE	6	6	HBV
NCT001474594	NCT00147459_4_T0	PHENOTYPE	11	11	HBV
NCT001474597	NCT00147459_7_T0	PHENOTYPE	6	6	HBV
NCT001474597	NCT00147459_7_T1	PHENOTYPE	15	15	HBV
NCT001474598	NCT00147459_8_T0	PHENOTYPE	8	8	HBV
NCT001474598	NCT00147459_8_T1	GENE	5	5	booster
NCT001474599	NCT00147459_9_T0	GENE	7	7	booster
NCT0014745910	NCT00147459_10_T0	PHENOTYPE	13	13	HBV
NCT0014745910	NCT00147459_10_T1	PHENOTYPE	7	8	antibody titer
NCT0014745912	NCT00147459_12_T0	ORGAN	16	16	liver
NCT0014745913	NCT00147459_13_T0	PHENOTYPE	15	15	HBV
NCT0014745913	NCT00147459_13_T1	GENE	16	16	booster
NCT0014745918	NCT00147459_18_T0	PHENOTYPE	9	9	HBV
NCT0014745919	NCT00147459_19_T0	ORGAN	13	13	liver
NCT0014745919	NCT00147459_19_T1	PHENOTYPE	26	26	immunosuppression
NCT0014745919	NCT00147459_19_T2	PHENOTYPE	22	22	HBV
NCT0014745919	NCT00147459_19_T3	GENE	23	23	booster
NCT0014745923	NCT00147459_23_T0	PHENOTYPE	9	9	HBV
NCT001474720	NCT00147472_0_T0	PHENOTYPE	13	13	Tumours
NCT001474723	NCT00147472_3_T0	GENE	13	13	MRI
NCT001474723	NCT00147472_3_T1	PHENOTYPE	19	20	radiation disease
NCT001474725	NCT00147472_5_T0	PHENOTYPE	4	4	tumours
NCT001474728	NCT00147472_8_T0	PHENOTYPE	13	13	tumours
NCT001474729	NCT00147472_9_T0	PHENOTYPE	12	12	tumours
NCT0014747212	NCT00147472_12_T0	PHENOTYPE	7	9	of skin cancer
NCT0014747215	NCT00147472_15_T0	PHENOTYPE	3	3	adenopathy
NCT0014747215	NCT00147472_15_T1	GENE	8	8	IV
NCT0014747217	NCT00147472_17_T0	GENE	3	3	N2
NCT0014747217	NCT00147472_17_T1	GENE	5	5	N3
NCT0014747217	NCT00147472_17_T2	PHENOTYPE	6	7	neck disease
NCT0014747221	NCT00147472_21_T0	PHENOTYPE	3	3	metastasis
NCT0014747222	NCT00147472_22_T0	PHENOTYPE	1	1	tumour
NCT0014747222	NCT00147472_22_T1	PHENOTYPE	0	0	Recurrent
NCT0014747225	NCT00147472_25_T0	PHENOTYPE	2	2	malignancy
NCT0014747226	NCT00147472_26_T0	PHENOTYPE	2	3	neck disease
NCT001474851	NCT00147485_1_T0	GENE	13	13	kinase
NCT001474851	NCT00147485_1_T1	GENE	12	12	cyclin
NCT001474851	NCT00147485_1_T2	GENE	14	14	CDK
NCT001475110	NCT00147511_0_T0	PHENOTYPE	4	4	Onset
NCT001475241	NCT00147524_1_T0	PHENOTYPE	13	13	hypertension
NCT001475241	NCT00147524_1_T1	PHENOTYPE	15	17	congestive heart failure
NCT001475242	NCT00147524_2_T0	GENE	7	7	ventricular
NCT001475242	NCT00147524_2_T1	PHENOTYPE	15	16	cardiovascular disorders
NCT001475245	NCT00147524_5_T0	COMPOUND	2	2	quinapril
NCT001475246	NCT00147524_6_T0	COMPOUND	9	9	quinapril
NCT001475246	NCT00147524_6_T1	PHENOTYPE	14	14	menopausal
NCT001475246	NCT00147524_6_T2	PHENOTYPE	20	20	hypertension
NCT001475246	NCT00147524_6_T3	PHENOTYPE	11	12	endothelial dysfunction
NCT001475502	NCT00147550_2_T0	CELL	13	13	cells
NCT001475503	NCT00147550_3_T0	PHENOTYPE	20	20	melanoma
NCT001475503	NCT00147550_3_T1	PHENOTYPE	15	16	colon cancer
NCT001475503	NCT00147550_3_T2	PHENOTYPE	17	18	breast cancer
NCT001475504	NCT00147550_4_T0	PHENOTYPE	24	24	tumor
NCT0014755010	NCT00147550_10_T0	GENE	4	4	erythropoietin
NCT0014755010	NCT00147550_10_T1	PHENOTYPE	8	9	hemoglobin level
NCT001475760	NCT00147576_0_T0	GENE	16	16	nt
NCT001475890	NCT00147589_0_T0	PHENOTYPE	14	14	Hypertension
NCT001476672	NCT00147667_2_T0	PHENOTYPE	4	4	symptoms
NCT001476673	NCT00147667_3_T0	PHENOTYPE	9	9	inflammation
NCT001476802	NCT00147680_2_T0	PHENOTYPE	43	43	recurrence
NCT001476802	NCT00147680_2_T1	GENE	24	24	Gy
NCT001476802	NCT00147680_2_T2	ORGAN	21	21	pelvis
NCT001476809	NCT00147680_9_T0	GENE	1	1	43
NCT0014768011	NCT00147680_11_T0	GENE	1	1	64
NCT0014768015	NCT00147680_15_T0	GENE	15	15	has
NCT001476930	NCT00147693_0_T0	GENE	11	11	nt
NCT001476930	NCT00147693_0_T1	PHENOTYPE	6	6	Dementia
NCT001476935	NCT00147693_5_T0	GENE	10	10	scant
NCT001476935	NCT00147693_5_T1	PHENOTYPE	1	1	inhibition
NCT001476936	NCT00147693_6_T0	GENE	14	14	Van
NCT001476936	NCT00147693_6_T1	GENE	17	17	al
NCT001476936	NCT00147693_6_T2	GENE	16	16	et
NCT001476937	NCT00147693_7_T0	PHENOTYPE	13	13	transformed
NCT001476937	NCT00147693_7_T1	GENE	11	11	has
NCT001476937	NCT00147693_7_T2	GENE	9	9	al
NCT001476937	NCT00147693_7_T3	GENE	8	8	et
NCT001476938	NCT00147693_8_T0	GENE	54	54	al
NCT001476938	NCT00147693_8_T1	GENE	53	53	et
NCT0014769311	NCT00147693_11_T0	PHENOTYPE	28	28	recruitment
NCT0014769311	NCT00147693_11_T1	PHENOTYPE	4	5	mental health
NCT0014769312	NCT00147693_12_T0	PHENOTYPE	15	16	mental health
NCT0014769317	NCT00147693_17_T0	PHENOTYPE	1	1	secondary
NCT0014769317	NCT00147693_17_T1	PHENOTYPE	4	6	quality of life
NCT0014769318	NCT00147693_18_T0	COMPOUND	10	10	SCQ
NCT0014769318	NCT00147693_18_T1	PHENOTYPE	1	3	quality of life
NCT0014769318	NCT00147693_18_T2	PHENOTYPE	15	17	quality of life
NCT0014769319	NCT00147693_19_T0	PHENOTYPE	5	6	behavioral problems
NCT0014769319	NCT00147693_19_T1	PHENOTYPE	1	3	quality of life
NCT001477060	NCT00147706_0_T0	GENE	11	11	se
NCT001477060	NCT00147706_0_T1	PHENOTYPE	8	9	Chronic Disease
NCT001477064	NCT00147706_4_T0	PHENOTYPE	48	48	self-efficacy
NCT001477064	NCT00147706_4_T1	GENE	4	4	portal
NCT001477064	NCT00147706_4_T2	GENE	14	14	portal
NCT001477321	NCT00147732_1_T0	PHENOTYPE	26	26	tumour
NCT001477321	NCT00147732_1_T1	COMPOUND	8	8	nicotinamide
NCT001477321	NCT00147732_1_T2	COMPOUND	6	6	carbogen
NCT001477321	NCT00147732_1_T3	PHENOTYPE	21	22	laryngeal carcinoma
NCT001477711	NCT00147771_1_T0	PHENOTYPE	20	20	plaques
NCT001477711	NCT00147771_1_T1	PHENOTYPE	19	19	morphea
NCT001477711	NCT00147771_1_T2	GENE	8	8	has
NCT001477713	NCT00147771_3_T0	PHENOTYPE	20	21	plaque morphea
NCT001477840	NCT00147784_0_T0	GENE	15	15	MMT
NCT001477840	NCT00147784_0_T1	GENE	18	18	MMT
NCT001477840	NCT00147784_0_T2	PHENOTYPE	10	11	Hepatitis C
NCT001477843	NCT00147784_3_T0	GENE	5	5	MMT
NCT001477843	NCT00147784_3_T1	PHENOTYPE	23	24	hepatitis C
NCT001477845	NCT00147784_5_T0	COMPOUND	17	17	HCV
NCT001477845	NCT00147784_5_T1	PHENOTYPE	7	8	psychological disorders
NCT001477846	NCT00147784_6_T0	GENE	3	3	MMT
NCT001477846	NCT00147784_6_T1	PHENOTYPE	11	12	Hepatitis C
NCT001477848	NCT00147784_8_T0	GENE	15	15	MMT
NCT001477848	NCT00147784_8_T1	COMPOUND	21	21	HCV
NCT001477975	NCT00147797_5_T0	PHENOTYPE	19	19	HIV
NCT001477975	NCT00147797_5_T1	COMPOUND	11	11	pravastatin
NCT001477975	NCT00147797_5_T2	PHENOTYPE	15	16	aortic stiffness
NCT001477979	NCT00147797_9_T0	COMPOUND	11	11	pravastatin
NCT001477979	NCT00147797_9_T1	GENE	5	5	al
NCT001477979	NCT00147797_9_T2	GENE	4	4	et
NCT001478100	NCT00147810_0_T0	PHENOTYPE	1	1	Asthma
NCT001478102	NCT00147810_2_T0	PHENOTYPE	10	10	severity
NCT001478102	NCT00147810_2_T1	PHENOTYPE	8	8	asthma
NCT001478104	NCT00147810_4_T0	PHENOTYPE	16	17	acute asthma
NCT001478104	NCT00147810_4_T1	PHENOTYPE	21	23	quality of life
NCT001478105	NCT00147810_5_T0	PHENOTYPE	19	19	acute
NCT001478105	NCT00147810_5_T1	PHENOTYPE	11	11	asthma
NCT001478105	NCT00147810_5_T2	PHENOTYPE	24	24	asthma
NCT001478105	NCT00147810_5_T3	PHENOTYPE	3	4	speech recognition
NCT001478108	NCT00147810_8_T0	PHENOTYPE	16	16	asthma
NCT001478108	NCT00147810_8_T1	PHENOTYPE	27	27	KPC
NCT0014781013	NCT00147810_13_T0	PHENOTYPE	19	19	asthma
NCT0014781013	NCT00147810_13_T1	PHENOTYPE	29	29	asthma
NCT0014781013	NCT00147810_13_T2	PHENOTYPE	39	39	asthma
NCT0014781013	NCT00147810_13_T3	GENE	23	23	had
NCT0014781017	NCT00147810_17_T0	PHENOTYPE	25	25	asthma
NCT0014781017	NCT00147810_17_T1	PHENOTYPE	31	31	asthma
NCT0014781017	NCT00147810_17_T2	PHENOTYPE	45	45	asthma
NCT0014781019	NCT00147810_19_T0	PHENOTYPE	0	0	Feedback
NCT0014781023	NCT00147810_23_T0	PHENOTYPE	21	21	pushing
NCT0014781023	NCT00147810_23_T1	PHENOTYPE	7	8	speech recognition
NCT0014781026	NCT00147810_26_T0	PHENOTYPE	10	10	acute
NCT0014781028	NCT00147810_28_T0	PHENOTYPE	13	15	quality of life
NCT0014781029	NCT00147810_29_T0	PHENOTYPE	1	1	secondary
NCT001478230	NCT00147823_0_T0	PHENOTYPE	11	12	Bone Lesions
NCT001478230	NCT00147823_0_T1	ORGAN	8	9	Bone Marrow
NCT001478234	NCT00147823_4_T0	TISSUE	9	9	tissues
NCT001478234	NCT00147823_4_T1	PHENOTYPE	4	5	blood supply
NCT001478235	NCT00147823_5_T0	PHENOTYPE	15	15	complications
NCT001478235	NCT00147823_5_T1	ORGAN	13	13	graft
NCT001478236	NCT00147823_6_T0	ORGAN	24	24	graft
NCT001478236	NCT00147823_6_T1	GENE	13	13	scaffold
NCT001478236	NCT00147823_6_T2	GENE	12	12	structural
NCT001478236	NCT00147823_6_T3	PHENOTYPE	9	10	bone lesions
NCT001478237	NCT00147823_7_T0	ORGAN	10	10	allografts
NCT001478237	NCT00147823_7_T1	ORGAN	28	28	graft
NCT0014782310	NCT00147823_10_T0	ORGAN	4	4	graft
NCT0014782310	NCT00147823_10_T1	PHENOTYPE	1	1	persistence
NCT0014782310	NCT00147823_10_T2	PHENOTYPE	20	21	late effects
NCT0014782311	NCT00147823_11_T0	ORGAN	15	15	graft
NCT0014782311	NCT00147823_11_T1	ORGAN	8	8	grafts
NCT0014782311	NCT00147823_11_T2	ORGAN	21	22	bone marrow
NCT0014782312	NCT00147823_12_T0	COMPOUND	17	17	phosphate
NCT0014782312	NCT00147823_12_T1	PHENOTYPE	28	29	benign tumors
NCT0014782312	NCT00147823_12_T2	ORGAN	19	20	bone marrow
NCT0014782315	NCT00147823_15_T0	PHENOTYPE	6	7	bone lesion
NCT0014782317	NCT00147823_17_T0	ORGAN	31	31	autograft
NCT0014782317	NCT00147823_17_T1	ORGAN	29	29	graft
NCT0014782317	NCT00147823_17_T2	ORGAN	36	36	graft
NCT0014782317	NCT00147823_17_T3	ORGAN	37	37	allograft
NCT0014782317	NCT00147823_17_T4	PHENOTYPE	5	5	disorders
NCT0014782317	NCT00147823_17_T5	ORGAN	3	4	bone marrow
NCT0014782317	NCT00147823_17_T6	ORGAN	16	17	bone marrow
NCT0014782320	NCT00147823_20_T0	TISSUE	22	22	tissues
NCT0014782320	NCT00147823_20_T1	BIOLOGICAL_PROCESS	47	47	trabeculation
NCT0014782320	NCT00147823_20_T2	ORGAN	18	18	graft
NCT0014782320	NCT00147823_20_T3	ORGAN	44	44	graft
NCT0014782320	NCT00147823_20_T4	ORGAN	55	55	graft
NCT0014782320	NCT00147823_20_T5	COMPOUND	15	15	1
NCT0014782320	NCT00147823_20_T6	COMPOUND	23	23	2
NCT0014782320	NCT00147823_20_T7	COMPOUND	34	34	3
NCT0014782320	NCT00147823_20_T8	GENE	27	27	rim
NCT0014782320	NCT00147823_20_T9	GENE	38	38	rim
NCT0014782320	NCT00147823_20_T10	PHENOTYPE	53	53	persistence
NCT001478362	NCT00147836_2_T0	PHENOTYPE	6	6	progressive
NCT001478362	NCT00147836_2_T1	PHENOTYPE	4	5	insulin resistance
NCT001478363	NCT00147836_3_T0	PHENOTYPE	0	0	Hyperglycemia
NCT001478363	NCT00147836_3_T1	GENE	1	1	has
NCT001478366	NCT00147836_6_T0	GENE	11	11	insulin
NCT001478366	NCT00147836_6_T1	GENE	22	23	type 2
NCT001478492	NCT00147849_2_T0	PHENOTYPE	4	4	strategies
NCT001478492	NCT00147849_2_T1	PHENOTYPE	1	1	Strategies
NCT001478494	NCT00147849_4_T0	GENE	1	1	null
NCT001478494	NCT00147849_4_T1	PHENOTYPE	9	9	strategies
NCT001478496	NCT00147849_6_T0	PHENOTYPE	0	0	Secondary
NCT001478496	NCT00147849_6_T1	PHENOTYPE	9	9	strategies
NCT001478497	NCT00147849_7_T0	PHENOTYPE	9	9	strategies
NCT001478497	NCT00147849_7_T1	PHENOTYPE	32	32	strategies
NCT0014784911	NCT00147849_11_T0	PHENOTYPE	1	1	Plan
NCT0014784912	NCT00147849_12_T0	PHENOTYPE	35	35	practices
NCT0014784915	NCT00147849_15_T0	PHENOTYPE	48	48	Association
NCT0014784917	NCT00147849_17_T0	PHENOTYPE	16	16	strategies
NCT0014784923	NCT00147849_23_T0	PHENOTYPE	19	19	strategies
NCT0014784923	NCT00147849_23_T1	PHENOTYPE	38	38	strategies
NCT001478620	NCT00147862_0_T0	PHENOTYPE	5	6	Blood Loss
NCT001478623	NCT00147862_3_T0	PHENOTYPE	17	17	recurrence
NCT001478623	NCT00147862_3_T1	PHENOTYPE	23	23	cancers
NCT001478627	NCT00147862_7_T0	ORGAN	12	12	liver
NCT001478627	NCT00147862_7_T1	PHENOTYPE	14	14	scoliosis
NCT001478627	NCT00147862_7_T2	GENE	1	1	has
NCT001478627	NCT00147862_7_T3	PHENOTYPE	6	7	blood loss
NCT001478629	NCT00147862_9_T0	PHENOTYPE	14	15	thromboembolic events
NCT0014786213	NCT00147862_13_T0	PHENOTYPE	18	19	blood loss
NCT0014786214	NCT00147862_14_T0	PHENOTYPE	13	13	complications
NCT0014786214	NCT00147862_14_T1	GENE	7	7	reduced
NCT001478752	NCT00147875_2_T0	PHENOTYPE	11	12	Hodgkin's lymphoma
NCT001478884	NCT00147888_4_T0	PHENOTYPE	16	16	obstruction
NCT001478884	NCT00147888_4_T1	PHENOTYPE	14	14	unilateral
NCT001478884	NCT00147888_4_T2	ORGAN	2	3	nasal cavity
NCT001478885	NCT00147888_5_T0	PHENOTYPE	5	5	ingestion
NCT001479141	NCT00147914_1_T0	PHENOTYPE	21	23	quality of life
NCT001479403	NCT00147940_3_T0	ORGAN	14	15	nasal cavity
NCT001479404	NCT00147940_4_T0	GENE	2	2	has
NCT001479408	NCT00147940_8_T0	GENE	6	6	pre
NCT001479408	NCT00147940_8_T1	COMPOUND	11	11	oxymetazoline
NCT0014794011	NCT00147940_11_T0	ORGAN	22	23	nasal cavity
NCT0014794014	NCT00147940_14_T0	PHENOTYPE	3	3	distortion
NCT0014794018	NCT00147940_18_T0	GENE	2	2	Kay
NCT0014794018	NCT00147940_18_T1	GENE	4	4	Corp
NCT0014794018	NCT00147940_18_T2	GENE	6	6	Park
NCT0014794018	NCT00147940_18_T3	ORGAN	24	25	nasal cavity
NCT0014794019	NCT00147940_19_T0	GENE	7	7	separated
NCT0014794020	NCT00147940_20_T0	ORGAN	19	20	oral cavity
NCT0014794021	NCT00147940_21_T0	PHENOTYPE	7	7	pathology
NCT0014794023	NCT00147940_23_T0	GENE	1	1	has
NCT0014794023	NCT00147940_23_T1	PHENOTYPE	18	19	velopharyngeal incompetence
NCT0014794023	NCT00147940_23_T2	PHENOTYPE	15	16	cleft palate
NCT0014794024	NCT00147940_24_T0	GENE	3	3	relaxed
NCT0014794024	NCT00147940_24_T1	PHENOTYPE	6	6	fitted
NCT0014794025	NCT00147940_25_T0	GENE	15	15	midway
NCT0014794030	NCT00147940_30_T0	GENE	3	3	has
NCT0014794030	NCT00147940_30_T1	GENE	11	11	has
NCT001479534	NCT00147953_4_T0	PHENOTYPE	16	16	toxicity
NCT001479534	NCT00147953_4_T1	PHENOTYPE	13	13	symptoms
NCT001479535	NCT00147953_5_T0	PHENOTYPE	9	9	toxicity
NCT001479536	NCT00147953_6_T0	PHENOTYPE	25	26	Hodgkin's lymphoma
NCT001479660	NCT00147966_0_T0	GENE	6	6	The
NCT001479790	NCT00147979_0_T0	COMPOUND	11	11	PTFE
NCT001479790	NCT00147979_0_T1	COMPOUND	15	15	PTFE
NCT001479920	NCT00147992_0_T0	ORGAN	10	10	Jaw
NCT001479921	NCT00147992_1_T0	PHENOTYPE	15	15	Satisfaction
NCT001480050	NCT00148005_0_T0	BIOLOGICAL_PROCESS	5	5	Micturition
NCT001480050	NCT00148005_0_T1	PHENOTYPE	6	6	Disorders
NCT001480052	NCT00148005_2_T0	ORGAN	10	10	bladder
NCT001480056	NCT00148005_6_T0	PHENOTYPE	5	5	adaptation
NCT001480056	NCT00148005_6_T1	BIOLOGICAL_PROCESS	8	8	micturition
NCT001480056	NCT00148005_6_T2	BIOLOGICAL_PROCESS	10	11	drinking behaviour
NCT001480182	NCT00148018_2_T0	PHENOTYPE	9	9	lymphoma
NCT001480311	NCT00148031_1_T0	COMPOUND	9	9	HCV
NCT001480311	NCT00148031_1_T1	COMPOUND	24	24	HCV
NCT001480311	NCT00148031_1_T2	PHENOTYPE	16	16	SVR
NCT001480311	NCT00148031_1_T3	PHENOTYPE	29	30	substance abuse
NCT001480313	NCT00148031_3_T0	COMPOUND	14	14	HCV
NCT001480313	NCT00148031_3_T1	PHENOTYPE	21	21	SVR
NCT001480314	NCT00148031_4_T0	COMPOUND	7	7	HCV
NCT001480314	NCT00148031_4_T1	PHENOTYPE	12	13	substance abuse
NCT001480315	NCT00148031_5_T0	COMPOUND	0	0	HCV
NCT001480316	NCT00148031_6_T0	COMPOUND	7	7	HCV
NCT001480317	NCT00148031_7_T0	COMPOUND	8	8	HCV
NCT001480317	NCT00148031_7_T1	COMPOUND	29	29	HCV
NCT001480318	NCT00148031_8_T0	PHENOTYPE	9	10	psychiatric symptoms
NCT001480318	NCT00148031_8_T1	PHENOTYPE	17	18	Hepatitis C
NCT001480318	NCT00148031_8_T2	PHENOTYPE	6	7	psychiatric disorders
NCT001480319	NCT00148031_9_T0	GENE	24	24	MMT
NCT001480319	NCT00148031_9_T1	COMPOUND	17	17	HCV
NCT001480319	NCT00148031_9_T2	COMPOUND	21	21	methadone
NCT0014803110	NCT00148031_10_T0	GENE	29	29	GI
NCT0014803110	NCT00148031_10_T1	GENE	21	21	MMT
NCT0014803110	NCT00148031_10_T2	COMPOUND	1	1	HCV
NCT0014803110	NCT00148031_10_T3	COMPOUND	15	15	HCV
NCT0014803111	NCT00148031_11_T0	GENE	34	34	GI
NCT0014803111	NCT00148031_11_T1	GENE	3	3	MMT
NCT0014803111	NCT00148031_11_T2	GENE	25	25	MMT
NCT0014803111	NCT00148031_11_T3	COMPOUND	0	0	HCV
NCT0014803111	NCT00148031_11_T4	COMPOUND	12	12	HCV
NCT0014803111	NCT00148031_11_T5	PHENOTYPE	1	2	antibody positive
NCT0014803112	NCT00148031_12_T0	COMPOUND	13	13	HCV
NCT0014803112	NCT00148031_12_T1	COMPOUND	21	21	HCV
NCT0014803112	NCT00148031_12_T2	PHENOTYPE	9	9	SVR
NCT0014803112	NCT00148031_12_T3	PHENOTYPE	25	27	quality of life
NCT0014803114	NCT00148031_14_T0	PHENOTYPE	17	17	severity
NCT0014803114	NCT00148031_14_T1	PHENOTYPE	13	13	SCID
NCT0014803114	NCT00148031_14_T2	PHENOTYPE	26	26	psychosis
NCT0014803114	NCT00148031_14_T3	PHENOTYPE	23	23	mania
NCT0014803114	NCT00148031_14_T4	PHENOTYPE	0	1	Psychiatric diagnosis
NCT0014803115	NCT00148031_15_T0	PHENOTYPE	0	1	Drug use
NCT0014803115	NCT00148031_15_T1	PHENOTYPE	4	6	quality of life
NCT0014803116	NCT00148031_16_T0	PHENOTYPE	18	19	substance abuse
NCT0014803117	NCT00148031_17_T0	COMPOUND	13	13	HCV
NCT0014803117	NCT00148031_17_T1	COMPOUND	20	20	HCV
NCT0014803117	NCT00148031_17_T2	COMPOUND	32	32	HCV
NCT0014803117	NCT00148031_17_T3	COMPOUND	45	45	HCV
NCT0014803117	NCT00148031_17_T4	PHENOTYPE	39	40	psychiatric symptoms
NCT0014803118	NCT00148031_18_T0	COMPOUND	19	19	HCV
NCT0014803118	NCT00148031_18_T1	PHENOTYPE	27	27	SVR
NCT0014803118	NCT00148031_18_T2	PHENOTYPE	11	12	psychiatric symptoms
NCT0014803122	NCT00148031_22_T0	COMPOUND	3	3	methadone
NCT0014803124	NCT00148031_24_T0	PHENOTYPE	0	1	Hepatitis C
NCT0014803126	NCT00148031_26_T0	COMPOUND	3	3	HCV
NCT0014803128	NCT00148031_28_T0	GENE	1	1	has
NCT0014803128	NCT00148031_28_T1	PHENOTYPE	18	19	Hepatitis C
NCT0014803130	NCT00148031_30_T0	BIOLOGICAL_PROCESS	7	7	detoxification
NCT0014803132	NCT00148031_32_T0	PHENOTYPE	4	5	Hepatitis C
NCT0014803135	NCT00148031_35_T0	COMPOUND	8	8	HCV
NCT0014803137	NCT00148031_37_T0	COMPOUND	20	20	HCV
NCT0014803137	NCT00148031_37_T1	GENE	3	3	has
NCT0014803139	NCT00148031_39_T0	GENE	6	6	has
NCT0014803141	NCT00148031_41_T0	GENE	1	1	has
NCT0014803145	NCT00148031_45_T0	GENE	1	1	has
NCT001480572	NCT00148057_2_T0	GENE	3	3	has
NCT001480574	NCT00148057_4_T0	PHENOTYPE	22	23	breast cancer
NCT001480577	NCT00148057_7_T0	GENE	4	4	has
NCT001480577	NCT00148057_7_T1	PHENOTYPE	0	0	Recruitment
NCT001480578	NCT00148057_8_T0	PHENOTYPE	26	27	breast cancer
NCT001480579	NCT00148057_9_T0	PHENOTYPE	18	19	breast cancer
NCT001480579	NCT00148057_9_T1	PHENOTYPE	45	46	breast cancer
NCT0014805711	NCT00148057_11_T0	GENE	0	0	II
NCT0014805714	NCT00148057_14_T0	PHENOTYPE	15	15	cancers
NCT0014805722	NCT00148057_22_T0	GENE	5	5	27
NCT0014805722	NCT00148057_22_T1	GENE	3	3	19
NCT0014805725	NCT00148057_25_T0	PHENOTYPE	7	8	skin cancer
NCT001480702	NCT00148070_2_T0	ORGAN	23	23	liver
NCT001480705	NCT00148070_5_T0	COMPOUND	3	3	docetaxel
NCT001480709	NCT00148070_9_T0	ORGAN	23	23	liver
NCT0014807012	NCT00148070_12_T0	COMPOUND	3	3	docetaxel
NCT0014807013	NCT00148070_13_T0	PHENOTYPE	10	12	metastatic breast cancer
NCT0014807014	NCT00148070_14_T0	COMPOUND	7	7	docetaxel
NCT0014807014	NCT00148070_14_T1	PHENOTYPE	10	11	breast cancer
NCT0014807016	NCT00148070_16_T0	GENE	17	17	MRI
NCT0014807016	NCT00148070_16_T1	PHENOTYPE	7	8	primary tumor
NCT0014807017	NCT00148070_17_T0	COMPOUND	18	18	docetaxel
NCT0014807020	NCT00148070_20_T0	PHENOTYPE	11	11	nausea/vomiting
NCT0014807020	NCT00148070_20_T1	COMPOUND	34	34	docetaxel
NCT0014807020	NCT00148070_20_T2	GENE	10	10	prn
NCT0014807020	NCT00148070_20_T3	GENE	6	6	po
NCT0014807021	NCT00148070_21_T0	GENE	15	15	6.5
NCT0014807025	NCT00148070_25_T0	PHENOTYPE	15	15	osteoporosis
NCT0014807028	NCT00148070_28_T0	COMPOUND	6	6	docetaxel
NCT001480832	NCT00148083_2_T0	GENE	17	17	atypical
NCT001480833	NCT00148083_3_T0	PHENOTYPE	1	1	secondary
NCT001480833	NCT00148083_3_T1	PHENOTYPE	19	20	cognitive functioning
NCT001480838	NCT00148083_8_T0	COMPOUND	9	9	risperidone
NCT001480838	NCT00148083_8_T1	PHENOTYPE	18	19	adverse effects
NCT001480839	NCT00148083_9_T0	COMPOUND	9	9	risperidone
NCT001480839	NCT00148083_9_T1	GENE	13	13	tapered
NCT0014808313	NCT00148083_13_T0	PHENOTYPE	18	19	adverse events
NCT0014808323	NCT00148083_23_T0	PHENOTYPE	12	12	focused
NCT0014808329	NCT00148083_29_T0	PHENOTYPE	1	1	secondary
NCT0014808330	NCT00148083_30_T0	COMPOUND	22	22	risperidone
NCT0014808330	NCT00148083_30_T1	PHENOTYPE	17	17	schizophrenia
NCT0014808330	NCT00148083_30_T2	GENE	11	11	has
NCT0014808332	NCT00148083_32_T0	PHENOTYPE	1	1	secondary
NCT0014808332	NCT00148083_32_T1	GENE	12	12	al
NCT0014808332	NCT00148083_32_T2	GENE	11	11	et
NCT0014808334	NCT00148083_34_T0	GENE	2	2	has
NCT0014808336	NCT00148083_36_T0	PHENOTYPE	2	2	secondary
NCT0014808336	NCT00148083_36_T1	PHENOTYPE	29	29	schizophrenia
NCT0014808339	NCT00148083_39_T0	PHENOTYPE	18	18	symptoms
NCT0014808339	NCT00148083_39_T1	PHENOTYPE	10	10	Syndrome
NCT0014808340	NCT00148083_40_T0	PHENOTYPE	2	3	Side effects
NCT0014808340	NCT00148083_40_T1	PHENOTYPE	5	6	adverse events
NCT0014808340	NCT00148083_40_T2	PHENOTYPE	0	1	Adverse Events
NCT0014808342	NCT00148083_42_T0	PHENOTYPE	0	1	Adverse events
NCT0014808343	NCT00148083_43_T0	GENE	22	22	3.5
NCT0014808343	NCT00148083_43_T1	PHENOTYPE	6	7	adverse events
NCT0014808343	NCT00148083_43_T2	PHENOTYPE	0	1	Side effects
NCT0014808344	NCT00148083_44_T0	PHENOTYPE	1	2	adverse events
NCT0014808345	NCT00148083_45_T0	PHENOTYPE	1	2	adverse events
NCT0014808346	NCT00148083_46_T0	PHENOTYPE	11	12	side effect
NCT0014808346	NCT00148083_46_T1	PHENOTYPE	2	3	adverse events
NCT0014808347	NCT00148083_47_T0	PHENOTYPE	27	27	withdrawn
NCT0014808347	NCT00148083_47_T1	PHENOTYPE	18	19	adverse events
NCT0014808350	NCT00148083_50_T0	PHENOTYPE	28	28	dystonia
NCT0014808350	NCT00148083_50_T1	PHENOTYPE	20	20	Akathisia
NCT0014808350	NCT00148083_50_T2	PHENOTYPE	10	11	Involuntary Movement
NCT0014808350	NCT00148083_50_T3	PHENOTYPE	17	18	tardive dyskinesia
NCT0014808352	NCT00148083_52_T0	PHENOTYPE	2	2	akathisia
NCT0014808352	NCT00148083_52_T1	GENE	5	5	reduced
NCT0014808352	NCT00148083_52_T2	GENE	8	8	reduced
NCT0014808357	NCT00148083_57_T0	COMPOUND	5	5	creatinine
NCT0014808357	NCT00148083_57_T1	COMPOUND	10	10	glucose
NCT0014808357	NCT00148083_57_T2	ORGAN	6	6	liver
NCT0014808360	NCT00148083_60_T0	GENE	7	7	HDL
NCT0014808360	NCT00148083_60_T1	GENE	5	5	LDL
NCT0014808362	NCT00148083_62_T0	GENE	5	5	prolactin
NCT0014808362	NCT00148083_62_T1	GENE	0	0	Prolactin
NCT0014808362	NCT00148083_62_T2	PHENOTYPE	14	14	osteoporosis
NCT0014808362	NCT00148083_62_T3	PHENOTYPE	10	11	sexual dysfunction
NCT0014808366	NCT00148083_66_T0	PHENOTYPE	5	5	hypothyroidism
NCT0014808366	NCT00148083_66_T1	GENE	22	22	TSH
NCT0014808369	NCT00148083_69_T0	COMPOUND	8	8	glucose
NCT0014808369	NCT00148083_69_T1	GENE	12	12	2.3
NCT0014808374	NCT00148083_74_T0	PHENOTYPE	0	0	Schizophrenia
NCT0014808374	NCT00148083_74_T1	PHENOTYPE	2	3	schizoaffective disorder
NCT0014808377	NCT00148083_77_T0	PHENOTYPE	6	6	chronic
NCT0014808383	NCT00148083_83_T0	PHENOTYPE	16	16	symptoms
NCT0014808383	NCT00148083_83_T1	PHENOTYPE	21	21	symptoms
NCT0014808383	NCT00148083_83_T2	PHENOTYPE	8	8	impairment
NCT0014808383	NCT00148083_83_T3	PHENOTYPE	23	23	schizophrenia
NCT0014808383	NCT00148083_83_T4	PHENOTYPE	39	39	experiences
NCT0014808386	NCT00148083_86_T0	PHENOTYPE	1	1	dependency
NCT0014808387	NCT00148083_87_T0	PHENOTYPE	2	2	dementia
NCT0014808388	NCT00148083_88_T0	PHENOTYPE	5	6	brain injury
NCT0014808388	NCT00148083_88_T1	PHENOTYPE	9	10	cognitive impairment
NCT0014808388	NCT00148083_88_T2	PHENOTYPE	1	2	head injury
NCT0014808391	NCT00148083_91_T0	PHENOTYPE	0	0	Allergy
NCT0014808391	NCT00148083_91_T1	COMPOUND	7	7	risperidone
NCT0014808391	NCT00148083_91_T2	PHENOTYPE	4	5	adverse reaction
NCT001480961	NCT00148096_1_T0	PHENOTYPE	3	3	asthma
NCT001480962	NCT00148096_2_T0	PHENOTYPE	1	1	ventilation
NCT001480962	NCT00148096_2_T1	GENE	5	5	has
NCT001480963	NCT00148096_3_T0	PHENOTYPE	11	11	asthma
NCT001480964	NCT00148096_4_T0	PHENOTYPE	22	22	ventilation
NCT001480964	NCT00148096_4_T1	PHENOTYPE	12	12	allergy
NCT001480967	NCT00148096_7_T0	PHENOTYPE	10	10	inflammation
NCT001480967	NCT00148096_7_T1	PHENOTYPE	6	6	asthma
NCT0014809610	NCT00148096_10_T0	PHENOTYPE	11	11	asthma
NCT0014809611	NCT00148096_11_T0	PHENOTYPE	8	8	ventilation
NCT0014809612	NCT00148096_12_T0	PHENOTYPE	25	25	ventilation
NCT0014809612	NCT00148096_12_T1	PHENOTYPE	15	15	avoidance
NCT0014809615	NCT00148096_15_T0	PHENOTYPE	3	3	asthma
NCT0014809615	NCT00148096_15_T1	PHENOTYPE	5	8	house dust mite allergy
NCT0014809617	NCT00148096_17_T0	PHENOTYPE	5	7	peak flow rate
NCT0014809618	NCT00148096_18_T0	PHENOTYPE	0	0	Secondary
NCT0014809618	NCT00148096_18_T1	PHENOTYPE	9	9	quality-of-life
NCT001481093	NCT00148109_3_T0	PHENOTYPE	15	15	sarcoma
NCT001481096	NCT00148109_6_T0	PHENOTYPE	0	0	Sarcomas
NCT001481096	NCT00148109_6_T1	PHENOTYPE	2	2	heterogeneous
NCT001481097	NCT00148109_7_T0	PHENOTYPE	7	7	sarcomas
NCT001481098	NCT00148109_8_T0	PHENOTYPE	5	5	sarcomas
NCT0014810911	NCT00148109_11_T0	PHENOTYPE	1	1	sarcomas
NCT0014810912	NCT00148109_12_T0	GENE	12	12	fusion
NCT0014810912	NCT00148109_12_T1	PHENOTYPE	18	19	synovial sarcoma
NCT0014810912	NCT00148109_12_T2	PHENOTYPE	15	16	Ewing sarcoma
NCT0014810912	NCT00148109_12_T3	PHENOTYPE	21	22	alveolar rhabdomyosarcoma
NCT0014810912	NCT00148109_12_T4	PHENOTYPE	25	26	myxoid liposarcomas
NCT0014810913	NCT00148109_13_T0	PHENOTYPE	7	7	sarcomas
NCT0014810914	NCT00148109_14_T0	PHENOTYPE	11	11	symptoms
NCT0014810914	NCT00148109_14_T1	PHENOTYPE	0	0	Sarcomas
NCT0014810914	NCT00148109_14_T2	ORGAN	14	14	extremity
NCT0014810915	NCT00148109_15_T0	PHENOTYPE	1	1	tumor
NCT0014810915	NCT00148109_15_T1	PHENOTYPE	14	14	sarcomas
NCT0014810916	NCT00148109_16_T0	BIOLOGICAL_PROCESS	11	11	necrosis
NCT0014810916	NCT00148109_16_T1	PHENOTYPE	0	0	Tumor
NCT0014810917	NCT00148109_17_T0	PHENOTYPE	13	14	metastatic disease
NCT0014810917	NCT00148109_17_T1	PHENOTYPE	5	6	high grade
NCT0014810917	NCT00148109_17_T2	PHENOTYPE	7	9	soft tissue sarcoma
NCT0014810918	NCT00148109_18_T0	PHENOTYPE	0	0	Sarcomas
NCT0014810918	NCT00148109_18_T1	ORGAN	15	15	liver
NCT0014810919	NCT00148109_19_T0	PHENOTYPE	5	5	sarcoma
NCT0014810919	NCT00148109_19_T1	PHENOTYPE	13	14	metastatic disease
NCT0014810923	NCT00148109_23_T0	PHENOTYPE	12	12	sarcoma
NCT0014810923	NCT00148109_23_T1	PHENOTYPE	7	9	soft tissue sarcoma
NCT0014810925	NCT00148109_25_T0	PHENOTYPE	2	2	tumor
NCT0014810925	NCT00148109_25_T1	GENE	8	8	EGFR
NCT0014810927	NCT00148109_27_T0	GENE	5	5	0.2
NCT0014810931	NCT00148109_31_T0	PHENOTYPE	16	18	negative pregnancy test
NCT0014810932	NCT00148109_32_T0	PHENOTYPE	12	12	sterile
NCT0014810932	NCT00148109_32_T1	PHENOTYPE	18	18	bilateral
NCT0014810932	NCT00148109_32_T2	PHENOTYPE	22	22	bilateral
NCT0014810936	NCT00148109_36_T0	GENE	6	6	ANC
NCT0014810936	NCT00148109_36_T1	CELL	4	4	neutrophil
NCT0014810936	NCT00148109_36_T2	CELL	8	8	platelets
NCT0014810936	NCT00148109_36_T3	ORGAN	0	1	Bone marrow
NCT0014810938	NCT00148109_38_T0	COMPOUND	2	2	creatinine
NCT0014810938	NCT00148109_38_T1	GENE	3	3	2.0
NCT0014810941	NCT00148109_41_T0	GENE	10	10	has
NCT0014810942	NCT00148109_42_T0	PHENOTYPE	7	7	progression
NCT0014810944	NCT00148109_44_T0	PHENOTYPE	3	4	measurable disease
NCT0014810945	NCT00148109_45_T0	PHENOTYPE	12	12	progression
NCT0014810945	NCT00148109_45_T1	PHENOTYPE	1	2	measurable lesion
NCT0014810947	NCT00148109_47_T0	PHENOTYPE	4	4	HIV
NCT0014810947	NCT00148109_47_T1	PHENOTYPE	0	1	Acute hepatitis
NCT0014810953	NCT00148109_53_T0	GENE	8	8	EGFR
NCT001481220	NCT00148122_0_T0	PHENOTYPE	15	18	Head and Neck Cancer
NCT001481222	NCT00148122_2_T0	PHENOTYPE	4	8	recurrent head and neck cancer
NCT001481223	NCT00148122_3_T0	PHENOTYPE	5	9	recurrent head and neck cancer
NCT001481225	NCT00148122_5_T0	COMPOUND	12	12	docetaxel
NCT001481225	NCT00148122_5_T1	GENE	4	4	has
NCT001481228	NCT00148122_8_T0	PHENOTYPE	9	9	metastases
NCT001481228	NCT00148122_8_T1	PHENOTYPE	12	13	recurrent disease
NCT0014812212	NCT00148122_12_T0	BIOLOGICAL_PROCESS	6	7	microtubule stabilization
NCT0014812213	NCT00148122_13_T0	GENE	2	2	II
NCT0014812213	NCT00148122_13_T1	COMPOUND	11	11	docetaxel
NCT0014812213	NCT00148122_13_T2	PHENOTYPE	13	16	head and neck cancer
NCT0014812215	NCT00148122_15_T0	COMPOUND	12	12	5_fluorouracil
NCT0014812215	NCT00148122_15_T1	GENE	1	1	has
NCT0014812215	NCT00148122_15_T2	COMPOUND	8	8	cisplatin
NCT0014812215	NCT00148122_15_T3	COMPOUND	10	10	cisplatin
NCT0014812216	NCT00148122_16_T0	COMPOUND	15	15	docetaxel
NCT0014812216	NCT00148122_16_T1	PHENOTYPE	20	20	toxicities
NCT0014812217	NCT00148122_17_T0	COMPOUND	3	3	fluoropyrimidine
NCT0014812217	NCT00148122_17_T1	TISSUE	14	14	tissues
NCT0014812217	NCT00148122_17_T2	COMPOUND	16	16	5_fluorouracil
NCT0014812217	NCT00148122_17_T3	PHENOTYPE	13	13	tumor
NCT0014812217	NCT00148122_17_T4	COMPOUND	4	4	carbamate
NCT0014812218	NCT00148122_18_T0	GENE	2	2	has
NCT0014812218	NCT00148122_18_T1	PHENOTYPE	8	9	colorectal cancers
NCT0014812219	NCT00148122_19_T0	COMPOUND	23	23	capecitabine
NCT0014812219	NCT00148122_19_T1	PHENOTYPE	19	19	tumors
NCT0014812219	NCT00148122_19_T2	COMPOUND	1	1	5_fluorouracil
NCT0014812219	NCT00148122_19_T3	GENE	2	2	has
NCT0014812219	NCT00148122_19_T4	PHENOTYPE	8	11	head and neck cancer
NCT0014812220	NCT00148122_20_T0	COMPOUND	8	8	capecitabine
NCT0014812220	NCT00148122_20_T1	PHENOTYPE	15	18	head and neck cancer
NCT0014812222	NCT00148122_22_T0	COMPOUND	7	7	capecitabine
NCT0014812222	NCT00148122_22_T1	COMPOUND	9	9	docetaxel
NCT0014812222	NCT00148122_22_T2	GENE	10	10	has
NCT0014812223	NCT00148122_23_T0	COMPOUND	22	22	capecitabine
NCT0014812223	NCT00148122_23_T1	COMPOUND	8	8	docetaxel
NCT0014812223	NCT00148122_23_T2	COMPOUND	26	26	5_fluorouracil
NCT0014812223	NCT00148122_23_T3	PHENOTYPE	10	10	tumor
NCT0014812223	NCT00148122_23_T4	COMPOUND	24	24	5'-dFUrd
NCT0014812223	NCT00148122_23_T5	GENE	13	14	thymidine phosphorylase
NCT0014812224	NCT00148122_24_T0	GENE	3	3	al
NCT0014812224	NCT00148122_24_T1	GENE	2	2	et
NCT0014812224	NCT00148122_24_T2	PHENOTYPE	15	17	metastatic breast cancer
NCT0014812225	NCT00148122_25_T0	COMPOUND	13	13	paclitaxel
NCT0014812225	NCT00148122_25_T1	COMPOUND	18	18	capecitabine
NCT0014812225	NCT00148122_25_T2	COMPOUND	27	27	docetaxel
NCT0014812225	NCT00148122_25_T3	COMPOUND	37	37	docetaxel
NCT0014812225	NCT00148122_25_T4	GENE	3	3	III
NCT0014812227	NCT00148122_27_T0	PHENOTYPE	24	24	toxicity
NCT0014812227	NCT00148122_27_T1	PHENOTYPE	29	29	toxicity
NCT0014812227	NCT00148122_27_T2	COMPOUND	3	3	docetaxel
NCT0014812227	NCT00148122_27_T3	GENE	9	9	reduced
NCT0014812228	NCT00148122_28_T0	PHENOTYPE	16	16	symptoms
NCT0014812228	NCT00148122_28_T1	PHENOTYPE	6	9	head and neck cancer
NCT0014812229	NCT00148122_29_T0	COMPOUND	0	0	Platinum
NCT0014812229	NCT00148122_29_T1	PHENOTYPE	9	9	strategies
NCT0014812229	NCT00148122_29_T2	COMPOUND	2	2	5_fluorouracil
NCT0014812230	NCT00148122_30_T0	PHENOTYPE	24	25	metastatic disease
NCT0014812231	NCT00148122_31_T0	COMPOUND	24	24	capecitabine
NCT0014812231	NCT00148122_31_T1	COMPOUND	2	2	docetaxel
NCT0014812231	NCT00148122_31_T2	COMPOUND	22	22	docetaxel
NCT0014812231	NCT00148122_31_T3	GENE	3	3	has
NCT0014812231	NCT00148122_31_T4	PHENOTYPE	8	11	head and neck cancer
NCT0014812231	NCT00148122_31_T5	PHENOTYPE	37	40	head and neck cancer
NCT0014812232	NCT00148122_32_T0	COMPOUND	1	1	capecitabine
NCT0014812232	NCT00148122_32_T1	COMPOUND	3	3	docetaxel
NCT0014812232	NCT00148122_32_T2	PHENOTYPE	14	14	toxicities
NCT0014812233	NCT00148122_33_T0	PHENOTYPE	18	18	toxicity
NCT0014812233	NCT00148122_33_T1	GENE	8	8	al
NCT0014812233	NCT00148122_33_T2	GENE	7	7	et
NCT0014812233	NCT00148122_33_T3	COMPOUND	32	32	capecitabine
NCT0014812233	NCT00148122_33_T4	COMPOUND	20	20	docetaxel
NCT0014812233	NCT00148122_33_T5	PHENOTYPE	10	12	metastatic breast cancer
NCT0014812234	NCT00148122_34_T0	COMPOUND	20	20	capecitabine
NCT0014812234	NCT00148122_34_T1	COMPOUND	10	10	docetaxel
NCT0014812234	NCT00148122_34_T2	GENE	8	8	al
NCT0014812234	NCT00148122_34_T3	GENE	7	7	et
NCT0014812235	NCT00148122_35_T0	ORGAN	8	8	colon
NCT0014812235	NCT00148122_35_T1	PHENOTYPE	10	11	bladder cancers
NCT0014812236	NCT00148122_36_T0	COMPOUND	21	21	capecitabine
NCT0014812236	NCT00148122_36_T1	COMPOUND	19	19	docetaxel
NCT0014812236	NCT00148122_36_T2	PHENOTYPE	11	14	head and neck cancer
NCT0014812237	NCT00148122_37_T0	PHENOTYPE	5	5	toxicity
NCT0014812239	NCT00148122_39_T0	COMPOUND	8	8	capecitabine
NCT0014812239	NCT00148122_39_T1	COMPOUND	25	25	capecitabine
NCT0014812240	NCT00148122_40_T0	GENE	14	14	am
NCT0014812241	NCT00148122_41_T0	COMPOUND	3	3	capecitabine
NCT0014812241	NCT00148122_41_T1	PHENOTYPE	18	19	breast cancer
NCT0014812242	NCT00148122_42_T0	GENE	5	5	al
NCT0014812242	NCT00148122_42_T1	GENE	4	4	et
NCT0014812242	NCT00148122_42_T2	COMPOUND	25	25	capecitabine
NCT0014812242	NCT00148122_42_T3	COMPOUND	12	12	docetaxel
NCT0014812242	NCT00148122_42_T4	PHENOTYPE	27	29	metastatic breast cancer
NCT0014812243	NCT00148122_43_T0	COMPOUND	17	17	capecitabine
NCT0014812243	NCT00148122_43_T1	GENE	11	11	TP
NCT0014812244	NCT00148122_44_T0	GENE	26	26	1.7
NCT0014812246	NCT00148122_46_T0	COMPOUND	17	17	capecitabine
NCT0014812247	NCT00148122_47_T0	PHENOTYPE	13	13	malignancies
NCT0014812247	NCT00148122_47_T1	PHENOTYPE	11	12	solid tumor
NCT0014812248	NCT00148122_48_T0	GENE	14	14	had
NCT0014812248	NCT00148122_48_T1	GENE	26	26	had
NCT0014812248	NCT00148122_48_T2	GENE	19	19	lines
NCT0014812249	NCT00148122_49_T0	PHENOTYPE	7	10	head and neck cancer
NCT001481350	NCT00148135_0_T0	PHENOTYPE	9	12	Carcinoma of Unknown Primary
NCT001481353	NCT00148135_3_T0	PHENOTYPE	4	4	tumor
NCT001481356	NCT00148135_6_T0	PHENOTYPE	5	5	centers
NCT0014813516	NCT00148135_16_T0	COMPOUND	0	0	Platinum
NCT0014813516	NCT00148135_16_T1	PHENOTYPE	30	30	carcinomas
NCT0014813516	NCT00148135_16_T2	PHENOTYPE	24	25	endometrial carcinomas
NCT0014813516	NCT00148135_16_T3	PHENOTYPE	14	15	solid tumors
NCT0014813518	NCT00148135_18_T0	PHENOTYPE	16	16	nephrotoxicity
NCT0014813518	NCT00148135_18_T1	PHENOTYPE	18	18	ototoxicity
NCT0014813518	NCT00148135_18_T2	GENE	1	1	has
NCT0014813518	NCT00148135_18_T3	COMPOUND	8	8	cisplatin
NCT0014813518	NCT00148135_18_T4	PHENOTYPE	14	15	peripheral neuropathy
NCT0014813518	NCT00148135_18_T5	PHENOTYPE	11	13	nausea and vomiting
NCT0014813519	NCT00148135_19_T0	PHENOTYPE	8	8	malignancies
NCT0014813521	NCT00148135_21_T0	COMPOUND	8	8	cytosine
NCT0014813521	NCT00148135_21_T1	COMPOUND	3	3	deoxycytidine
NCT0014813521	NCT00148135_21_T2	COMPOUND	9	9	arabinoside
NCT0014813522	NCT00148135_22_T0	BIOLOGICAL_PROCESS	10	10	phosphorylation
NCT0014813522	NCT00148135_22_T1	GENE	4	5	deoxycytidine kinase
NCT0014813522	NCT00148135_22_T2	COMPOUND	12	13	difluorodeoxycytidine triphosphate
NCT0014813524	NCT00148135_24_T0	PHENOTYPE	4	4	toxicity
NCT0014813524	NCT00148135_24_T1	COMPOUND	6	6	gemcitabine
NCT0014813524	NCT00148135_24_T2	GENE	7	7	has
NCT0014813525	NCT00148135_25_T0	COMPOUND	14	14	platinum
NCT0014813525	NCT00148135_25_T1	COMPOUND	11	11	gemcitabine
NCT0014813526	NCT00148135_26_T0	COMPOUND	5	5	fluoropyrimidine
NCT0014813526	NCT00148135_26_T1	PHENOTYPE	14	14	pharmacokinetics
NCT0014813528	NCT00148135_28_T0	COMPOUND	6	6	capecitabine
NCT0014813528	NCT00148135_28_T1	GENE	18	18	has
NCT0014813528	NCT00148135_28_T2	GENE	14	14	TP
NCT0014813528	NCT00148135_28_T3	GENE	12	13	thymidine phosphorylase
NCT0014813528	NCT00148135_28_T4	PHENOTYPE	26	27	colorectal tumors
NCT0014813529	NCT00148135_29_T0	PHENOTYPE	11	11	concentrations
NCT0014813529	NCT00148135_29_T1	CELL	16	16	cells
NCT0014813529	NCT00148135_29_T2	PHENOTYPE	2	2	tumor
NCT0014813529	NCT00148135_29_T3	PHENOTYPE	15	15	tumor
NCT0014813529	NCT00148135_29_T4	PHENOTYPE	23	23	tumor
NCT0014813529	NCT00148135_29_T5	GENE	4	4	has
NCT0014813530	NCT00148135_30_T0	GENE	14	14	has
NCT0014813530	NCT00148135_30_T1	PHENOTYPE	11	12	breast carcinoma
NCT0014813530	NCT00148135_30_T2	PHENOTYPE	19	20	colorectal carcinoma
NCT0014813531	NCT00148135_31_T0	PHENOTYPE	14	14	toxicity
NCT0014813531	NCT00148135_31_T1	PHENOTYPE	23	23	toxicity
NCT0014813532	NCT00148135_32_T0	GENE	1	1	has
NCT0014813537	NCT00148135_37_T0	GENE	8	8	has
NCT0014813540	NCT00148135_40_T0	PHENOTYPE	26	26	toxicity
NCT0014813540	NCT00148135_40_T1	COMPOUND	23	23	capecitabine
NCT0014813540	NCT00148135_40_T2	PHENOTYPE	4	4	tumor
NCT0014813546	NCT00148135_46_T0	TISSUE	11	12	lymph nodes
NCT0014813546	NCT00148135_46_T1	PHENOTYPE	3	4	squamous carcinoma
NCT0014813547	NCT00148135_47_T0	PHENOTYPE	4	5	axillary lymphadenopathy
NCT0014813548	NCT00148135_48_T0	PHENOTYPE	4	5	peritoneal carcinomatosis
NCT001481482	NCT00148148_2_T0	CELL	10	10	granulocytes
NCT001481482	NCT00148148_2_T1	PHENOTYPE	5	5	profound
NCT001481482	NCT00148148_2_T2	PHENOTYPE	6	6	granulocytopenia
NCT001481482	NCT00148148_2_T3	CELL	9	9	neutrophil
NCT001481482	NCT00148148_2_T4	PHENOTYPE	14	15	recurrent fever
NCT001481484	NCT00148148_4_T0	COMPOUND	3	4	amphotericin B
NCT001481485	NCT00148148_5_T0	ORGAN	1	1	plasma
NCT001481486	NCT00148148_6_T0	PHENOTYPE	2	2	tolerance
NCT001481488	NCT00148148_8_T0	CELL	20	20	granulocytes
NCT001481488	NCT00148148_8_T1	PHENOTYPE	13	13	toxicity
NCT001481488	NCT00148148_8_T2	PHENOTYPE	16	16	engraftment
NCT001481488	NCT00148148_8_T3	GENE	33	33	probable
NCT001481488	NCT00148148_8_T4	CELL	19	19	neutrophil
NCT001481488	NCT00148148_8_T5	COMPOUND	8	8	1
NCT001481488	NCT00148148_8_T6	COMPOUND	14	14	2
NCT001481488	NCT00148148_8_T7	COMPOUND	28	28	3
NCT001481488	NCT00148148_8_T8	PHENOTYPE	37	38	fungal infection
NCT001481489	NCT00148148_9_T0	GENE	4	4	probable
NCT001481489	NCT00148148_9_T1	PHENOTYPE	0	0	Febrile
NCT001481489	NCT00148148_9_T2	PHENOTYPE	7	9	invasive fungal infections
NCT0014814810	NCT00148148_10_T0	GENE	4	4	probable
NCT0014814811	NCT00148148_11_T0	PHENOTYPE	1	1	infections
NCT0014814811	NCT00148148_11_T1	GENE	5	5	probable
NCT0014814811	NCT00148148_11_T2	PHENOTYPE	8	10	invasive fungal infections
NCT0014814813	NCT00148148_13_T0	PHENOTYPE	18	18	pharmacokinetics
NCT0014814813	NCT00148148_13_T1	PHENOTYPE	16	16	tolerance
NCT0014814814	NCT00148148_14_T0	PHENOTYPE	5	5	secondary
NCT0014814815	NCT00148148_15_T0	COMPOUND	2	2	1
NCT0014814815	NCT00148148_15_T1	COMPOUND	14	14	2
NCT001481611	NCT00148161_1_T0	GENE	6	6	MEG
NCT001481612	NCT00148161_2_T0	PHENOTYPE	11	11	pathology
NCT001481612	NCT00148161_2_T1	PHENOTYPE	7	8	speech perception
NCT001481613	NCT00148161_3_T0	PHENOTYPE	3	3	stuttering
NCT001481613	NCT00148161_3_T1	PHENOTYPE	8	8	blocks
NCT001481613	NCT00148161_3_T2	PHENOTYPE	5	5	repetitions
NCT001481614	NCT00148161_4_T0	PHENOTYPE	3	3	stuttering
NCT001481619	NCT00148161_9_T0	PHENOTYPE	9	9	stuttering
NCT0014816110	NCT00148161_10_T0	PHENOTYPE	6	7	auditory feedback
NCT0014816112	NCT00148161_12_T0	PHENOTYPE	13	13	stuttering
NCT001481741	NCT00148174_1_T0	PHENOTYPE	7	7	focused
NCT001481741	NCT00148174_1_T1	ORGAN	17	17	transplant
NCT001481742	NCT00148174_2_T0	PHENOTYPE	7	7	acute
NCT001481742	NCT00148174_2_T1	PHENOTYPE	15	15	chronic
NCT001481742	NCT00148174_2_T2	PHENOTYPE	18	19	graft loss
NCT001481745	NCT00148174_5_T0	PHENOTYPE	36	37	adverse events
NCT001481871	NCT00148187_1_T0	ORGAN	3	3	transplant
NCT001481874	NCT00148187_4_T0	ORGAN	19	19	transplant
NCT001481874	NCT00148187_4_T1	ORGAN	23	23	transplant
NCT001482009	NCT00148200_9_T0	GENE	9	9	al
NCT001482009	NCT00148200_9_T1	GENE	8	8	et
NCT0014820011	NCT00148200_11_T0	BIOLOGICAL_PROCESS	6	6	translation
NCT0014820020	NCT00148200_20_T0	GENE	17	17	al
NCT0014820020	NCT00148200_20_T1	GENE	16	16	et
NCT0014820020	NCT00148200_20_T2	PHENOTYPE	23	24	sexual dysfunction
NCT001482131	NCT00148213_1_T0	GENE	5	5	Tg
NCT001482131	NCT00148213_1_T1	GENE	16	16	Tg
NCT001482131	NCT00148213_1_T2	ORGAN	21	21	thyroid
NCT001482131	NCT00148213_1_T3	GENE	22	22	hormone
NCT001482133	NCT00148213_3_T0	GENE	5	5	Tg
NCT001482134	NCT00148213_4_T0	GENE	26	26	hormone
NCT001482134	NCT00148213_4_T1	GENE	15	15	Tg
NCT001482134	NCT00148213_4_T2	ORGAN	25	25	thyroid
NCT001482134	NCT00148213_4_T3	ORGAN	18	18	serum
NCT001482134	NCT00148213_4_T4	PHENOTYPE	20	21	thyroid cancer
NCT001482137	NCT00148213_7_T0	GENE	7	7	pts
NCT001482138	NCT00148213_8_T0	PHENOTYPE	4	4	separation
NCT0014821310	NCT00148213_10_T0	GENE	19	19	San
NCT0014821310	NCT00148213_10_T1	GENE	0	0	Tg
NCT0014821310	NCT00148213_10_T2	PHENOTYPE	4	4	concentrations
NCT0014821311	NCT00148213_11_T0	GENE	14	14	Tg
NCT0014821312	NCT00148213_12_T0	GENE	2	2	Tg
NCT0014821312	NCT00148213_12_T1	GENE	17	17	AG
NCT0014821312	NCT00148213_12_T2	GENE	21	21	TSH
NCT001482261	NCT00148226_1_T0	PHENOTYPE	11	11	practices
NCT001482397	NCT00148239_7_T0	PHENOTYPE	22	24	quality of life
NCT0014823912	NCT00148239_12_T0	PHENOTYPE	5	5	complications
NCT0014823914	NCT00148239_14_T0	PHENOTYPE	22	23	physical symptoms
NCT0014823916	NCT00148239_16_T0	PHENOTYPE	13	13	separation
NCT0014823916	NCT00148239_16_T1	GENE	16	16	al
NCT0014823916	NCT00148239_16_T2	GENE	15	15	et
NCT001482523	NCT00148252_3_T0	PHENOTYPE	7	8	drug withdrawal
NCT001482524	NCT00148252_4_T0	PHENOTYPE	2	2	dyslipidemia
NCT001482524	NCT00148252_4_T1	PHENOTYPE	5	6	drug withdrawal
NCT001482525	NCT00148252_5_T0	PHENOTYPE	2	2	hypertension
NCT001482525	NCT00148252_5_T1	PHENOTYPE	5	6	drug withdrawal
NCT001482526	NCT00148252_6_T0	PHENOTYPE	2	3	glucose tolerance
NCT001482526	NCT00148252_6_T1	PHENOTYPE	5	6	drug withdrawal
NCT001482527	NCT00148252_7_T0	PHENOTYPE	4	4	infections
NCT001482528	NCT00148252_8_T0	GENE	0	0	Sub
NCT0014825210	NCT00148252_10_T0	PHENOTYPE	9	9	ESRD
NCT0014825210	NCT00148252_10_T1	GENE	17	17	extended
NCT0014825210	NCT00148252_10_T2	PHENOTYPE	5	7	Quality of life
NCT0014825217	NCT00148252_17_T0	ORGAN	18	18	transplant
NCT0014825221	NCT00148252_21_T0	PHENOTYPE	4	4	acute
NCT0014825221	NCT00148252_21_T1	PHENOTYPE	3	3	resistant
NCT0014825223	NCT00148252_23_T0	PHENOTYPE	6	6	acute
NCT0014825233	NCT00148252_33_T0	PHENOTYPE	3	3	acute
NCT0014825233	NCT00148252_33_T1	PHENOTYPE	0	1	Acute illness
NCT001482654	NCT00148265_4_T0	COMPOUND	16	16	triamcinolone
NCT001482654	NCT00148265_4_T1	PHENOTYPE	21	23	diabetic macular edema
NCT001482655	NCT00148265_5_T0	GENE	10	10	has
NCT001482655	NCT00148265_5_T1	PHENOTYPE	22	23	macular oedema
NCT0014826512	NCT00148265_12_T0	PHENOTYPE	19	19	blindness
NCT001482780	NCT00148278_0_T0	PHENOTYPE	10	11	Septic Shock
NCT001482782	NCT00148278_2_T0	COMPOUND	4	4	norepinephrine
NCT001482782	NCT00148278_2_T1	GENE	12	12	III
NCT001482782	NCT00148278_2_T2	COMPOUND	9	9	epinephrine
NCT001482783	NCT00148278_3_T0	COMPOUND	11	11	norepinephrine
NCT001482783	NCT00148278_3_T1	COMPOUND	13	13	dobutamine
NCT001482783	NCT00148278_3_T2	COMPOUND	17	17	epinephrine
NCT001482783	NCT00148278_3_T3	PHENOTYPE	21	22	septic shock
NCT001482785	NCT00148278_5_T0	COMPOUND	18	18	norepinephrine
NCT001482785	NCT00148278_5_T1	COMPOUND	16	16	dobutamine
NCT001482785	NCT00148278_5_T2	COMPOUND	22	22	epinephrine
NCT001482785	NCT00148278_5_T3	PHENOTYPE	27	28	septic shock
NCT001482786	NCT00148278_6_T0	COMPOUND	12	12	norepinephrine
NCT001482786	NCT00148278_6_T1	COMPOUND	14	14	dobutamine
NCT001482786	NCT00148278_6_T2	COMPOUND	10	10	epinephrine
NCT001482912	NCT00148291_2_T0	GENE	11	11	II
NCT001482912	NCT00148291_2_T1	GENE	1	1	has
NCT001482913	NCT00148291_3_T0	COMPOUND	16	16	vinorelbine
NCT001482913	NCT00148291_3_T1	PHENOTYPE	22	22	NSCLC
NCT001482913	NCT00148291_3_T2	COMPOUND	10	10	docetaxel
NCT001482913	NCT00148291_3_T3	GENE	5	5	III
NCT001482915	NCT00148291_5_T0	GENE	1	1	had
NCT001482917	NCT00148291_7_T0	PHENOTYPE	9	9	dementia
NCT001482917	NCT00148291_7_T1	PHENOTYPE	5	6	brain metastasis
NCT001483042	NCT00148304_2_T0	PHENOTYPE	20	20	complications
NCT001483042	NCT00148304_2_T1	PHENOTYPE	8	9	insulin resistance
NCT001483043	NCT00148304_3_T0	GENE	24	24	insulin
NCT001483044	NCT00148304_4_T0	PHENOTYPE	42	42	strategies
NCT001483045	NCT00148304_5_T0	GENE	26	26	insulin
NCT001483045	NCT00148304_5_T1	PHENOTYPE	11	11	decision-making
NCT001483046	NCT00148304_6_T0	COMPOUND	1	1	1
NCT001483046	NCT00148304_6_T1	GENE	12	12	insulin
NCT001483046	NCT00148304_6_T2	GENE	23	23	insulin
NCT001483046	NCT00148304_6_T3	PHENOTYPE	14	14	decision-making
NCT001483047	NCT00148304_7_T0	COMPOUND	1	1	2
NCT001483049	NCT00148304_9_T0	COMPOUND	1	1	3
NCT0014830410	NCT00148304_10_T0	GENE	27	27	nested
NCT0014830411	NCT00148304_11_T0	PHENOTYPE	12	12	associations
NCT0014830411	NCT00148304_11_T1	PHENOTYPE	15	15	strategies
NCT0014830412	NCT00148304_12_T0	GENE	36	36	nested
NCT001483172	NCT00148317_2_T0	COMPOUND	18	18	dexamethasone
NCT001483172	NCT00148317_2_T1	COMPOUND	26	26	cyclophosphamide
NCT001483172	NCT00148317_2_T2	COMPOUND	16	16	bortezomib
NCT001483172	NCT00148317_2_T3	PHENOTYPE	32	33	multiple myeloma
NCT001483175	NCT00148317_5_T0	PHENOTYPE	15	15	plasmacytoma
NCT001483175	NCT00148317_5_T1	ORGAN	10	10	serum
NCT001483304	NCT00148330_4_T0	GENE	2	2	insulin
NCT001483306	NCT00148330_6_T0	COMPOUND	11	11	triamcinolone
NCT001483306	NCT00148330_6_T1	PHENOTYPE	20	22	diabetic macular edema
NCT001483307	NCT00148330_7_T0	PHENOTYPE	13	14	macular oedema
NCT0014833016	NCT00148330_16_T0	GENE	19	19	had
NCT0014833016	NCT00148330_16_T1	ORGAN	10	10	eyes
NCT0014833016	NCT00148330_16_T2	PHENOTYPE	20	21	reduced vision
NCT0014833016	NCT00148330_16_T3	PHENOTYPE	23	25	diabetic macular oedema
NCT001483430	NCT00148343_0_T0	PHENOTYPE	6	6	Hemiparesis
NCT001483430	NCT00148343_0_T1	PHENOTYPE	4	4	Footdrop
NCT001483432	NCT00148343_2_T0	PHENOTYPE	12	14	quality of life
NCT001483433	NCT00148343_3_T0	PHENOTYPE	18	18	hemiparesis
NCT001483433	NCT00148343_3_T1	ORGAN	16	17	lower limb
NCT001483437	NCT00148343_7_T0	PHENOTYPE	0	0	Foot-drop
NCT001483437	NCT00148343_7_T1	GENE	27	27	reduced
NCT001483437	NCT00148343_7_T2	ORGAN	7	7	ankle
NCT001483437	NCT00148343_7_T3	ORGAN	15	15	ankle
NCT001483437	NCT00148343_7_T4	COMPOUND	4	4	dorsiflex
NCT001483437	NCT00148343_7_T5	PHENOTYPE	22	23	gait abnormalities
NCT001483438	NCT00148343_8_T0	GENE	17	17	AFO
NCT001483439	NCT00148343_9_T0	PHENOTYPE	17	17	relearning
NCT0014834310	NCT00148343_10_T0	PHENOTYPE	1	1	relearning
NCT0014834310	NCT00148343_10_T1	PHENOTYPE	12	14	nervous system injury
NCT0014834310	NCT00148343_10_T2	ORGAN	11	13	central nervous system
NCT0014834311	NCT00148343_11_T0	GENE	3	3	AFO
NCT0014834312	NCT00148343_12_T0	GENE	11	11	neuromuscular
NCT0014834312	NCT00148343_12_T1	PHENOTYPE	17	17	relearning
NCT0014834313	NCT00148343_13_T0	PHENOTYPE	17	17	foot-drop
NCT0014834313	NCT00148343_13_T1	GENE	32	32	AFO
NCT0014834313	NCT00148343_13_T2	PHENOTYPE	7	7	chronic
NCT0014834313	NCT00148343_13_T3	ORGAN	13	14	peroneal nerve
NCT0014834313	NCT00148343_13_T4	ORGAN	27	28	peroneal nerve
NCT0014834314	NCT00148343_14_T0	PHENOTYPE	13	13	relearning
NCT0014834314	NCT00148343_14_T1	ORGAN	19	20	peroneal nerve
NCT0014834315	NCT00148343_15_T0	PHENOTYPE	21	21	relearning
NCT0014834315	NCT00148343_15_T1	PHENOTYPE	23	23	chronic
NCT0014834315	NCT00148343_15_T2	ORGAN	18	19	lower limb
NCT0014834315	NCT00148343_15_T3	ORGAN	14	15	peroneal nerve
NCT0014834316	NCT00148343_16_T0	PHENOTYPE	1	1	secondary
NCT0014834316	NCT00148343_16_T1	ORGAN	14	15	lower limb
NCT0014834316	NCT00148343_16_T2	ORGAN	10	11	peroneal nerve
NCT0014834316	NCT00148343_16_T3	PHENOTYPE	20	22	quality of life
NCT0014834317	NCT00148343_17_T0	GENE	38	38	AFO
NCT0014834317	NCT00148343_17_T1	PHENOTYPE	22	22	chronic
NCT0014834317	NCT00148343_17_T2	ORGAN	18	19	peroneal nerve
NCT0014834319	NCT00148343_19_T0	PHENOTYPE	13	13	relearning
NCT0014834319	NCT00148343_19_T1	ORGAN	7	8	peroneal nerve
NCT0014834319	NCT00148343_19_T2	PHENOTYPE	19	21	quality of life
NCT0014834320	NCT00148343_20_T0	PHENOTYPE	22	22	foot-drop
NCT0014834320	NCT00148343_20_T1	COMPOUND	17	17	AFOs
NCT001483561	NCT00148356_1_T0	GENE	14	14	has
NCT001483563	NCT00148356_3_T0	PHENOTYPE	7	8	cardiovascular disease
NCT001483567	NCT00148356_7_T0	PHENOTYPE	8	8	restenosis
NCT001483567	NCT00148356_7_T1	GENE	10	10	balloon
NCT001483568	NCT00148356_8_T0	PHENOTYPE	17	17	restenosis
NCT001483568	NCT00148356_8_T1	GENE	12	12	had
NCT0014835610	NCT00148356_10_T0	PHENOTYPE	13	13	concentrations
NCT001483822	NCT00148382_2_T0	GENE	3	3	lipase
NCT001483822	NCT00148382_2_T1	PHENOTYPE	19	20	weight reduction
NCT001483953	NCT00148395_3_T0	PHENOTYPE	17	17	strategies
NCT001483958	NCT00148395_8_T0	GENE	9	9	IV
NCT001483958	NCT00148395_8_T1	PHENOTYPE	4	6	malignant pleural effusion
NCT001483959	NCT00148395_9_T0	PHENOTYPE	0	0	Tumor
NCT0014839512	NCT00148395_12_T0	PHENOTYPE	3	3	tumor
NCT0014839513	NCT00148395_13_T0	PHENOTYPE	4	4	NSCLC
NCT0014839522	NCT00148395_22_T0	PHENOTYPE	4	4	tumors
NCT0014839522	NCT00148395_22_T1	PHENOTYPE	1	2	lung cancer
NCT0014839523	NCT00148395_23_T0	PHENOTYPE	3	4	stage III
NCT0014839524	NCT00148395_24_T0	PHENOTYPE	5	5	diseases
NCT0014839525	NCT00148395_25_T0	PHENOTYPE	5	5	tumor
NCT0014839526	NCT00148395_26_T0	ORGAN	16	16	cervix
NCT0014839526	NCT00148395_26_T1	PHENOTYPE	22	22	melanoma
NCT0014839526	NCT00148395_26_T2	PHENOTYPE	8	9	secondary malignancy
NCT0014839526	NCT00148395_26_T3	PHENOTYPE	11	15	carcinoma in situ of the
NCT0014839527	NCT00148395_27_T0	PHENOTYPE	0	1	Respiratory insufficiency
NCT0014839528	NCT00148395_28_T0	GENE	3	3	III
NCT0014839528	NCT00148395_28_T1	GENE	5	5	IV
NCT0014839528	NCT00148395_28_T2	PHENOTYPE	0	1	Heart insufficiency
NCT0014839529	NCT00148395_29_T0	GENE	5	5	IV
NCT0014839529	NCT00148395_29_T1	PHENOTYPE	2	3	stage III
NCT0014839529	NCT00148395_29_T2	PHENOTYPE	0	1	Peripheral arteriosclerosis
NCT0014839530	NCT00148395_30_T0	PHENOTYPE	3	3	diseases
NCT0014839533	NCT00148395_33_T0	GENE	4	4	C13
NCT0014839533	NCT00148395_33_T1	PHENOTYPE	1	2	hepatitis B
NCT0014839534	NCT00148395_34_T0	PHENOTYPE	1	2	infectious diseases
NCT001484082	NCT00148408_2_T0	PHENOTYPE	15	15	asthma
NCT001484082	NCT00148408_2_T1	GENE	8	8	Is
NCT001484210	NCT00148421_0_T0	PHENOTYPE	10	10	Malignancies
NCT001484210	NCT00148421_0_T1	PHENOTYPE	5	5	Anemia
NCT001484342	NCT00148434_2_T0	COMPOUND	53	53	aspirin
NCT001484342	NCT00148434_2_T1	PHENOTYPE	11	11	hypertension
NCT001484343	NCT00148434_3_T0	PHENOTYPE	9	9	hypertension
NCT001484344	NCT00148434_4_T0	COMPOUND	30	30	aspirin
NCT001484347	NCT00148434_7_T0	GENE	14	14	al
NCT001484347	NCT00148434_7_T1	GENE	26	26	has
NCT001484347	NCT00148434_7_T2	PHENOTYPE	8	8	hypertension
NCT001484347	NCT00148434_7_T3	GENE	13	13	et
NCT001484348	NCT00148434_8_T0	GENE	22	22	al
NCT001484348	NCT00148434_8_T1	GENE	39	39	al
NCT001484348	NCT00148434_8_T2	GENE	43	43	al
NCT001484348	NCT00148434_8_T3	PHENOTYPE	27	27	reluctant
NCT001484348	NCT00148434_8_T4	PHENOTYPE	9	9	hypertension
NCT001484348	NCT00148434_8_T5	PHENOTYPE	17	17	hypertension
NCT001484348	NCT00148434_8_T6	PHENOTYPE	31	31	hypertension
NCT001484348	NCT00148434_8_T7	PHENOTYPE	33	33	hypertension
NCT001484348	NCT00148434_8_T8	GENE	21	21	et
NCT001484348	NCT00148434_8_T9	GENE	38	38	et
NCT001484348	NCT00148434_8_T10	GENE	42	42	et
NCT001484349	NCT00148434_9_T0	GENE	23	23	al
NCT001484349	NCT00148434_9_T1	GENE	22	22	et
NCT0014843412	NCT00148434_12_T0	GENE	21	21	GP
NCT0014843412	NCT00148434_12_T1	GENE	24	24	al
NCT0014843412	NCT00148434_12_T2	GENE	23	23	et
NCT0014843413	NCT00148434_13_T0	GENE	14	14	al
NCT0014843413	NCT00148434_13_T1	GENE	13	13	et
NCT0014843414	NCT00148434_14_T0	BIOLOGICAL_PROCESS	21	21	behaviour
NCT0014843414	NCT00148434_14_T1	GENE	10	10	has
NCT0014843414	NCT00148434_14_T2	GENE	18	18	has
NCT0014843415	NCT00148434_15_T0	GENE	3	3	has
NCT0014843419	NCT00148434_19_T0	PHENOTYPE	33	33	hypertension
NCT0014843421	NCT00148434_21_T0	PHENOTYPE	20	20	hypertension
NCT0014843423	NCT00148434_23_T0	PHENOTYPE	3	3	hypertension
NCT0014843426	NCT00148434_26_T0	PHENOTYPE	10	10	hypertension
NCT0014843429	NCT00148434_29_T0	COMPOUND	20	20	aspirin
NCT0014843429	NCT00148434_29_T1	COMPOUND	37	37	urea
NCT0014843438	NCT00148434_38_T0	GENE	15	15	has
NCT0014843444	NCT00148434_44_T0	PHENOTYPE	16	16	Hypertension
NCT0014843445	NCT00148434_45_T0	PHENOTYPE	8	8	Hypertension
NCT0014843450	NCT00148434_50_T0	GENE	23	23	envelope
NCT0014843453	NCT00148434_53_T0	GENE	13	13	BP
NCT0014843454	NCT00148434_54_T0	PHENOTYPE	14	14	estimation
NCT0014843454	NCT00148434_54_T1	COMPOUND	24	24	aspirin
NCT0014843454	NCT00148434_54_T2	GENE	8	8	BP
NCT0014843454	NCT00148434_54_T3	PHENOTYPE	27	28	cholesterol level
NCT0014843454	NCT00148434_54_T4	COMPOUND	18	19	cholesterol lowering
NCT0014843456	NCT00148434_56_T0	PHENOTYPE	20	20	perceived
NCT0014843456	NCT00148434_56_T1	PHENOTYPE	28	28	perceived
NCT0014843456	NCT00148434_56_T2	PHENOTYPE	33	33	empowered
NCT0014843459	NCT00148434_59_T0	GENE	27	27	2.3
NCT0014843459	NCT00148434_59_T1	GENE	7	7	has
NCT0014843459	NCT00148434_59_T2	GENE	39	39	BP
NCT0014843459	NCT00148434_59_T3	GENE	29	29	Hg
NCT0014843460	NCT00148434_60_T0	GENE	8	8	Rob
NCT0014843460	NCT00148434_60_T1	GENE	7	7	Dr
NCT0014843470	NCT00148434_70_T0	BIOLOGICAL_PROCESS	4	4	transcription
NCT0014843472	NCT00148434_72_T0	GENE	2	2	al
NCT0014843472	NCT00148434_72_T1	GENE	1	1	et
NCT0014843478	NCT00148434_78_T0	PHENOTYPE	10	10	hypertension
NCT0014843479	NCT00148434_79_T0	PHENOTYPE	23	23	Hypertension
NCT0014843479	NCT00148434_79_T1	PHENOTYPE	12	12	hypertension
NCT0014843483	NCT00148434_83_T0	PHENOTYPE	10	10	practices
NCT0014843484	NCT00148434_84_T0	COMPOUND	11	11	N
NCT0014843487	NCT00148434_87_T0	COMPOUND	3	3	N
NCT0014843490	NCT00148434_90_T0	GENE	4	4	1.5
NCT0014843491	NCT00148434_91_T0	PHENOTYPE	20	21	atrial fibrillation
NCT0014843492	NCT00148434_92_T0	GENE	4	4	CD
NCT0014843492	NCT00148434_92_T1	PHENOTYPE	16	16	hypertension
NCT0014843493	NCT00148434_93_T0	GENE	3	3	AD
NCT0014843493	NCT00148434_93_T1	GENE	9	9	al
NCT0014843493	NCT00148434_93_T2	GENE	8	8	et
NCT0014843494	NCT00148434_94_T0	GENE	9	9	al
NCT0014843494	NCT00148434_94_T1	GENE	8	8	et
NCT0014843495	NCT00148434_95_T0	PHENOTYPE	1	1	Hypertension
NCT0014843495	NCT00148434_95_T1	PHENOTYPE	18	18	Hypertension
NCT0014843495	NCT00148434_95_T2	PHENOTYPE	8	8	hypertension
NCT0014843496	NCT00148434_96_T0	PHENOTYPE	6	6	Hypertension
NCT0014843497	NCT00148434_97_T0	PHENOTYPE	11	11	perceptions
NCT0014843498	NCT00148434_98_T0	GENE	1	1	Med
NCT0014843499	NCT00148434_99_T0	PHENOTYPE	6	6	strategies
NCT001484472	NCT00148447_2_T0	PHENOTYPE	17	17	symptoms
NCT001484602	NCT00148460_2_T0	PHENOTYPE	8	8	secondary
NCT001484603	NCT00148460_3_T0	GENE	30	30	rt-PA
NCT001484603	NCT00148460_3_T1	GENE	6	6	met
NCT001484607	NCT00148460_7_T0	PHENOTYPE	6	6	progressive
NCT0014846011	NCT00148460_11_T0	GENE	22	22	rt-PA
NCT0014846011	NCT00148460_11_T1	GENE	3	3	null
NCT0014846018	NCT00148460_18_T0	PHENOTYPE	1	1	discomfort
NCT0014846020	NCT00148460_20_T0	PHENOTYPE	6	6	symptoms
NCT0014846020	NCT00148460_20_T1	PHENOTYPE	5	5	AMI
NCT0014846020	NCT00148460_20_T2	PHENOTYPE	0	0	Onset
NCT0014846020	NCT00148460_20_T3	PHENOTYPE	2	4	acute myocardial infarction
NCT0014846026	NCT00148460_26_T0	GENE	3	3	bypass
NCT0014846026	NCT00148460_26_T1	ORGAN	1	2	coronary artery
NCT0014846030	NCT00148460_30_T0	GENE	3	3	SBP
NCT0014846030	NCT00148460_30_T1	GENE	11	11	DBP
NCT0014846034	NCT00148460_34_T0	PHENOTYPE	1	2	bleeding disorder
NCT0014846036	NCT00148460_36_T0	PHENOTYPE	9	9	trauma
NCT0014846038	NCT00148460_38_T0	PHENOTYPE	7	7	trauma
NCT0014846038	NCT00148460_38_T1	PHENOTYPE	2	3	head trauma
NCT0014846038	NCT00148460_38_T2	PHENOTYPE	14	15	myocardial infarction
NCT0014846040	NCT00148460_40_T0	COMPOUND	2	2	heparin
NCT0014846042	NCT00148460_42_T0	PHENOTYPE	17	17	aneurysm
NCT0014846042	NCT00148460_42_T1	GENE	13	13	structural
NCT0014846042	NCT00148460_42_T2	PHENOTYPE	16	16	neoplasm
NCT0014846042	NCT00148460_42_T3	PHENOTYPE	6	8	transient ischemic attack
NCT0014846042	NCT00148460_42_T4	ORGAN	10	12	central nervous system
NCT0014846044	NCT00148460_44_T0	BIOLOGICAL_PROCESS	1	1	lactation
NCT0014846044	NCT00148460_44_T1	BIOLOGICAL_PROCESS	3	3	parturition
NCT0014846045	NCT00148460_45_T0	GENE	6	6	had
NCT0014846045	NCT00148460_45_T1	PHENOTYPE	8	10	negative pregnancy test
NCT0014846048	NCT00148460_48_T0	PHENOTYPE	0	1	Drug abuse
NCT001484733	NCT00148473_3_T0	ORGAN	16	16	cervix
NCT001484733	NCT00148473_3_T1	PHENOTYPE	6	6	ripening
NCT001484734	NCT00148473_4_T0	PHENOTYPE	14	14	ulcers
NCT001484735	NCT00148473_5_T0	GENE	12	12	has
NCT001484736	NCT00148473_6_T0	COMPOUND	1	1	misoprostol
NCT001484736	NCT00148473_6_T1	GENE	9	9	has
NCT001484739	NCT00148473_9_T0	COMPOUND	12	12	misoprostol
NCT001484739	NCT00148473_9_T1	COMPOUND	15	15	misoprostol
NCT0014847311	NCT00148473_11_T0	GENE	8	8	41
NCT001484863	NCT00148486_3_T0	COMPOUND	1	1	levodopa
NCT001484995	NCT00148499_5_T0	COMPOUND	14	14	ambroxol
NCT001484996	NCT00148499_6_T0	COMPOUND	26	26	benzocaine
NCT001484996	NCT00148499_6_T1	GENE	19	19	am
NCT001484997	NCT00148499_7_T0	PHENOTYPE	13	13	secondary
NCT001484997	NCT00148499_7_T1	COMPOUND	16	16	benzocaine
NCT001484999	NCT00148499_9_T0	PHENOTYPE	6	6	acute
NCT001484999	NCT00148499_9_T1	PHENOTYPE	3	4	sore throat
NCT001484999	NCT00148499_9_T2	PHENOTYPE	7	8	viral pharyngitis
NCT0014849919	NCT00148499_19_T0	GENE	29	29	ts
NCT0014849924	NCT00148499_24_T0	GENE	0	0	NOT
NCT0014849924	NCT00148499_24_T1	GENE	8	8	NOT
NCT0014849927	NCT00148499_27_T0	PHENOTYPE	2	2	symptoms
NCT0014849927	NCT00148499_27_T1	PHENOTYPE	12	13	clinical findings
NCT0014849927	NCT00148499_27_T2	PHENOTYPE	5	6	bacterial pharyngitis
NCT0014849929	NCT00148499_29_T0	PHENOTYPE	3	3	symptoms
NCT0014849929	NCT00148499_29_T1	PHENOTYPE	8	9	sore throat
NCT0014849929	NCT00148499_29_T2	PHENOTYPE	5	6	acute pharyngitis
NCT0014849931	NCT00148499_31_T0	PHENOTYPE	4	4	acute
NCT0014849931	NCT00148499_31_T1	PHENOTYPE	2	2	suffered
NCT0014849931	NCT00148499_31_T2	PHENOTYPE	7	8	bacterial pharyngitis
NCT0014849941	NCT00148499_41_T0	PHENOTYPE	1	1	tumour
NCT001485120	NCT00148512_0_T0	PHENOTYPE	38	38	Fluctuations
NCT001485120	NCT00148512_0_T1	GENE	22	22	1.0
NCT001485120	NCT00148512_0_T2	GENE	12	12	NS
NCT001485120	NCT00148512_0_T3	GENE	19	19	0.5
NCT001485124	NCT00148512_4_T0	GENE	18	18	1.0
NCT001485124	NCT00148512_4_T1	COMPOUND	12	12	tesofensine
NCT001485125	NCT00148512_5_T0	GENE	27	27	null
NCT001485125	NCT00148512_5_T1	COMPOUND	38	38	tesofensine
NCT001485125	NCT00148512_5_T2	PHENOTYPE	16	17	Parkinson Disease
NCT001485126	NCT00148512_6_T0	COMPOUND	7	7	tesofensine
NCT001485127	NCT00148512_7_T0	GENE	46	46	II
NCT001485127	NCT00148512_7_T1	GENE	55	55	III
NCT001485127	NCT00148512_7_T2	COMPOUND	27	27	3
NCT001485127	NCT00148512_7_T3	PHENOTYPE	14	14	waking
NCT001485127	NCT00148512_7_T4	COMPOUND	6	6	tesofensine
NCT0014852510	NCT00148525_10_T0	GENE	21	21	hr
NCT001485382	NCT00148538_2_T0	PHENOTYPE	0	0	Secondary
NCT001485382	NCT00148538_2_T1	PHENOTYPE	28	28	hypoglycemia
NCT001485382	NCT00148538_2_T2	GENE	32	33	C-reactive protein
NCT001485382	NCT00148538_2_T3	PHENOTYPE	35	37	quality of life
NCT001485384	NCT00148538_4_T0	GENE	7	7	AR
NCT001485386	NCT00148538_6_T0	GENE	7	7	AR
NCT001485387	NCT00148538_7_T0	PHENOTYPE	18	18	secondary
NCT001485387	NCT00148538_7_T1	PHENOTYPE	0	0	Secondary
NCT0014853812	NCT00148538_12_T0	PHENOTYPE	20	20	understood
NCT0014853816	NCT00148538_16_T0	GENE	4	5	insulin receptor
NCT0014853823	NCT00148538_23_T0	GENE	16	16	AR
NCT0014853827	NCT00148538_27_T0	PHENOTYPE	32	34	quality of life
NCT001485510	NCT00148551_0_T0	PHENOTYPE	8	8	ARMD
NCT001485511	NCT00148551_1_T0	PHENOTYPE	2	2	ARMD
NCT001485641	NCT00148564_1_T0	COMPOUND	16	16	olanzapine
NCT001485641	NCT00148564_1_T1	PHENOTYPE	2	2	schizophrenia
NCT001485641	NCT00148564_1_T2	COMPOUND	14	14	ziprasidone
NCT001485641	NCT00148564_1_T3	PHENOTYPE	4	5	schizoaffective disorders
NCT001485773	NCT00148577_3_T0	GENE	9	9	VAS
NCT001485901	NCT00148590_1_T0	PHENOTYPE	9	9	Syndrome
NCT0014859010	NCT00148590_10_T0	PHENOTYPE	4	4	parkinsonism
NCT0014859010	NCT00148590_10_T1	PHENOTYPE	21	21	suffering
NCT0014859010	NCT00148590_10_T2	PHENOTYPE	23	24	sleep disorders
NCT0014859012	NCT00148590_12_T0	COMPOUND	14	14	2
NCT0014859014	NCT00148590_14_T0	PHENOTYPE	15	16	adverse effects
NCT0014859014	NCT00148590_14_T1	PHENOTYPE	2	3	adverse events
NCT001486030	NCT00148603_0_T0	PHENOTYPE	6	6	Eosinophilia
NCT001486032	NCT00148603_2_T0	ORGAN	9	9	duodenum
NCT0014860311	NCT00148603_11_T0	PHENOTYPE	16	16	dyspepsia
NCT0014860311	NCT00148603_11_T1	PHENOTYPE	5	5	eosinophilia
NCT0014860312	NCT00148603_12_T0	CELL	1	1	eosinophil
NCT0014860312	NCT00148603_12_T1	CELL	12	12	eosinophil
NCT0014860312	NCT00148603_12_T2	BIOLOGICAL_PROCESS	8	9	eosinophil activation
NCT0014860313	NCT00148603_13_T0	GENE	21	21	had
NCT0014860313	NCT00148603_13_T1	CELL	24	24	eosinophil
NCT0014860313	NCT00148603_13_T2	BIOLOGICAL_PROCESS	12	13	eosinophil degranulation
NCT0014860315	NCT00148603_15_T0	COMPOUND	11	11	montelukast
NCT0014860315	NCT00148603_15_T1	PHENOTYPE	15	16	eosinophilic gastroenteritis
NCT0014860316	NCT00148603_16_T0	PHENOTYPE	13	13	constipation
NCT0014860316	NCT00148603_16_T1	PHENOTYPE	23	23	symptoms
NCT0014860316	NCT00148603_16_T2	COMPOUND	25	25	montelukast
NCT0014860316	NCT00148603_16_T3	PHENOTYPE	21	21	remission
NCT0014860316	NCT00148603_16_T4	PHENOTYPE	10	10	dysphagia
NCT0014860316	NCT00148603_16_T5	PHENOTYPE	17	17	eosinophilia
NCT0014860316	NCT00148603_16_T6	GENE	19	19	had
NCT0014860316	NCT00148603_16_T7	PHENOTYPE	11	11	diarrhea
NCT0014860317	NCT00148603_17_T0	COMPOUND	12	12	montelukast
NCT0014860317	NCT00148603_17_T1	PHENOTYPE	18	18	eosinophilia
NCT0014860320	NCT00148603_20_T0	COMPOUND	11	11	montelukast
NCT0014860320	NCT00148603_20_T1	PHENOTYPE	12	12	pharmacokinetics
NCT0014860321	NCT00148603_21_T0	COMPOUND	7	7	montelukast
NCT0014860321	NCT00148603_21_T1	GENE	22	22	3.4
NCT0014860321	NCT00148603_21_T2	GENE	11	11	1.8
NCT0014860321	NCT00148603_21_T3	PHENOTYPE	4	4	elimination
NCT0014860321	NCT00148603_21_T4	PHENOTYPE	29	30	intestinal disease
NCT0014860322	NCT00148603_22_T0	COMPOUND	17	17	montelukast
NCT0014860322	NCT00148603_22_T1	BIOLOGICAL_PROCESS	18	18	metabolism
NCT0014860322	NCT00148603_22_T2	ORGAN	22	23	small intestine
NCT0014860324	NCT00148603_24_T0	COMPOUND	10	10	montelukast
NCT0014860324	NCT00148603_24_T1	GENE	14	14	has
NCT0014860325	NCT00148603_25_T0	CELL	29	29	cells
NCT0014860325	NCT00148603_25_T1	CELL	26	26	eosinophils
NCT0014860325	NCT00148603_25_T2	CELL	14	14	eosinophil
NCT0014860325	NCT00148603_25_T3	BIOLOGICAL_PROCESS	19	20	eosinophil activation
NCT0014860329	NCT00148603_29_T0	PHENOTYPE	11	11	duodenitis
NCT0014860329	NCT00148603_29_T1	COMPOUND	6	6	montelukast
NCT0014860329	NCT00148603_29_T2	CELL	22	22	eosinophils
NCT0014860332	NCT00148603_32_T0	PHENOTYPE	18	18	duodenitis
NCT0014860332	NCT00148603_32_T1	COMPOUND	5	5	montelukast
NCT0014860332	NCT00148603_32_T2	PHENOTYPE	21	21	dyspepsia
NCT0014860332	NCT00148603_32_T3	CELL	8	8	eosinophil
NCT0014860334	NCT00148603_34_T0	CELL	16	16	eosinophil
NCT0014860339	NCT00148603_39_T0	GENE	19	19	met
NCT0014860343	NCT00148603_43_T0	PHENOTYPE	25	25	pathology
NCT0014860343	NCT00148603_43_T1	CELL	7	7	eosinophils
NCT0014860343	NCT00148603_43_T2	ORGAN	17	17	duodenum
NCT0014860348	NCT00148603_48_T0	COMPOUND	8	8	montelukast
NCT0014860348	NCT00148603_48_T1	GENE	3	3	has
NCT0014860352	NCT00148603_52_T0	PHENOTYPE	11	12	liver disease
NCT0014860354	NCT00148603_54_T0	GENE	7	7	CYP3A4
NCT0014860361	NCT00148603_61_T0	COMPOUND	11	11	montelukast
NCT0014860363	NCT00148603_63_T0	COMPOUND	4	4	1
NCT0014860371	NCT00148603_71_T0	COMPOUND	0	0	2
NCT0014860372	NCT00148603_72_T0	CELL	1	1	Eosinophils
NCT0014860373	NCT00148603_73_T0	COMPOUND	16	17	2 antral
NCT0014860375	NCT00148603_75_T0	CELL	4	4	eosinophil
NCT0014860377	NCT00148603_77_T0	COMPOUND	0	0	3
NCT0014860378	NCT00148603_78_T0	ORGAN	22	22	serum
NCT0014860378	NCT00148603_78_T1	PHENOTYPE	25	26	protein concentration
NCT0014860378	NCT00148603_78_T2	GENE	23	25	eosinophil cationic protein
NCT0014860379	NCT00148603_79_T0	PHENOTYPE	26	26	concentrations
NCT0014860379	NCT00148603_79_T1	ORGAN	0	0	Serum
NCT0014860379	NCT00148603_79_T2	ORGAN	24	24	serum
NCT0014860381	NCT00148603_81_T0	GENE	11	11	GI
NCT0014860385	NCT00148603_85_T0	ORGAN	0	0	Plasma
NCT0014860387	NCT00148603_87_T0	COMPOUND	29	29	montelukast
NCT0014860387	NCT00148603_87_T1	GENE	19	19	has
NCT0014860387	NCT00148603_87_T2	ORGAN	1	1	serum
NCT0014860389	NCT00148603_89_T0	PHENOTYPE	11	11	concentrations
NCT0014860389	NCT00148603_89_T1	GENE	10	10	ECP
NCT0014860389	NCT00148603_89_T2	CELL	5	5	eosinophil
NCT0014860389	NCT00148603_89_T3	GENE	17	17	paired
NCT0014860391	NCT00148603_91_T0	COMPOUND	17	17	montelukast
NCT0014860392	NCT00148603_92_T0	GENE	4	4	eg
NCT0014860392	NCT00148603_92_T1	PHENOTYPE	7	7	concentrations
NCT0014860392	NCT00148603_92_T2	GENE	6	6	ECP
NCT0014860392	NCT00148603_92_T3	PHENOTYPE	15	15	regression
NCT0014860394	NCT00148603_94_T0	GENE	14	14	eg
NCT0014860394	NCT00148603_94_T1	PHENOTYPE	2	2	regression
NCT0014860394	NCT00148603_94_T2	PHENOTYPE	17	17	pharmacodynamic
NCT0014860394	NCT00148603_94_T3	CELL	23	23	eosinophil
NCT0014860397	NCT00148603_97_T0	CELL	10	10	eosinophil
NCT0014860398	NCT00148603_98_T0	COMPOUND	13	13	montelukast
NCT0014860398	NCT00148603_98_T1	CELL	3	3	eosinophil
NCT0014860399	NCT00148603_99_T0	GENE	10	10	paired
NCT00148603100	NCT00148603_100_T0	COMPOUND	16	16	N
NCT001486168	NCT00148616_8_T0	PHENOTYPE	4	4	parkinsonism
NCT001486168	NCT00148616_8_T1	PHENOTYPE	21	21	suffering
NCT001486168	NCT00148616_8_T2	PHENOTYPE	23	24	sleep disorders
NCT0014861610	NCT00148616_10_T0	COMPOUND	14	14	2
NCT0014861612	NCT00148616_12_T0	PHENOTYPE	15	16	adverse effects
NCT0014861612	NCT00148616_12_T1	PHENOTYPE	2	3	adverse events
NCT001486292	NCT00148629_2_T0	COMPOUND	5	5	1
NCT001486292	NCT00148629_2_T1	PHENOTYPE	27	28	severe anemia
NCT001486294	NCT00148629_4_T0	COMPOUND	1	1	2
NCT001486294	NCT00148629_4_T1	PHENOTYPE	21	22	severe anemia
NCT001486295	NCT00148629_5_T0	COMPOUND	1	1	3
NCT001486295	NCT00148629_5_T1	PHENOTYPE	23	24	severe anemia
NCT001486296	NCT00148629_6_T0	PHENOTYPE	21	22	severe anemia
NCT001486683	NCT00148668_3_T0	PHENOTYPE	10	10	tumor
NCT001486683	NCT00148668_3_T1	GENE	1	1	clip
NCT001486689	NCT00148668_9_T0	COMPOUND	17	17	navelbine
NCT001486813	NCT00148681_3_T0	COMPOUND	17	17	navelbine
NCT001486816	NCT00148681_6_T0	PHENOTYPE	12	12	tumor
NCT001486818	NCT00148681_8_T0	COMPOUND	10	10	cyclophosphamide
NCT001486818	NCT00148681_8_T1	COMPOUND	7	7	doxorubicin
NCT0014868111	NCT00148681_11_T0	COMPOUND	11	11	navelbine
NCT0014868111	NCT00148681_11_T1	GENE	7	8	Group 1
NCT0014868112	NCT00148681_12_T0	COMPOUND	5	5	paclitaxel
NCT0014868113	NCT00148681_13_T0	COMPOUND	21	21	paclitaxel
NCT0014868116	NCT00148681_16_T0	COMPOUND	11	11	MUGA
NCT0014868118	NCT00148681_18_T0	COMPOUND	4	4	MUGA
NCT001486942	NCT00148694_2_T0	COMPOUND	3	3	cisplatin
NCT001486943	NCT00148694_3_T0	CELL	23	23	cells
NCT001486943	NCT00148694_3_T1	PHENOTYPE	11	11	tumor
NCT001486943	NCT00148694_3_T2	PHENOTYPE	22	22	tumor
NCT001486943	NCT00148694_3_T3	COMPOUND	3	3	cisplatin
NCT001486945	NCT00148694_5_T0	PHENOTYPE	11	11	toxicity
NCT001487333	NCT00148733_3_T0	COMPOUND	17	17	zinc
NCT001487333	NCT00148733_3_T1	ORGAN	25	26	immune system
NCT001487337	NCT00148733_7_T0	PHENOTYPE	10	10	acute
NCT001487337	NCT00148733_7_T1	GENE	2	2	has
NCT001487337	NCT00148733_7_T2	COMPOUND	1	1	zinc
NCT001487337	NCT00148733_7_T3	PHENOTYPE	12	13	persistent diarrhea
NCT001487338	NCT00148733_8_T0	COMPOUND	3	3	zinc
NCT001487339	NCT00148733_9_T0	COMPOUND	24	24	zinc
NCT0014873310	NCT00148733_10_T0	COMPOUND	11	11	zinc
NCT0014873310	NCT00148733_10_T1	COMPOUND	14	14	zinc
NCT0014873311	NCT00148733_11_T0	COMPOUND	16	16	zinc
NCT0014873312	NCT00148733_12_T0	PHENOTYPE	5	5	perceived
NCT0014873313	NCT00148733_13_T0	PHENOTYPE	10	10	pneumonia
NCT0014873313	NCT00148733_13_T1	COMPOUND	5	5	zinc
NCT0014873314	NCT00148733_14_T0	PHENOTYPE	9	9	pneumonia
NCT0014873314	NCT00148733_14_T1	GENE	15	15	had
NCT0014873314	NCT00148733_14_T2	COMPOUND	13	13	zinc
NCT0014873316	NCT00148733_16_T0	GENE	2	2	has
NCT0014873316	NCT00148733_16_T1	GENE	8	8	has
NCT0014873316	NCT00148733_16_T2	COMPOUND	1	1	zinc
NCT0014873316	NCT00148733_16_T3	PHENOTYPE	6	7	respiratory infections
NCT0014873317	NCT00148733_17_T0	PHENOTYPE	4	4	infections
NCT0014873317	NCT00148733_17_T1	COMPOUND	1	1	zinc
NCT0014873317	NCT00148733_17_T2	COMPOUND	18	18	zinc
NCT0014873318	NCT00148733_18_T0	COMPOUND	4	4	zinc
NCT0014873321	NCT00148733_21_T0	PHENOTYPE	12	12	pneumonia
NCT0014873323	NCT00148733_23_T0	TISSUE	5	5	thymus
NCT0014873324	NCT00148733_24_T0	PHENOTYPE	14	14	inflammation
NCT0014873324	NCT00148733_24_T1	PHENOTYPE	15	15	fever
NCT0014873324	NCT00148733_24_T2	COMPOUND	4	4	zinc
NCT001487460	NCT00148746_0_T0	GENE	1	1	Time
NCT001487460	NCT00148746_0_T1	PHENOTYPE	9	10	Atopic Dermatitis
NCT001487464	NCT00148746_4_T0	PHENOTYPE	3	5	quality of life
NCT001487595	NCT00148759_5_T0	COMPOUND	11	11	ARVs
NCT001487595	NCT00148759_5_T1	PHENOTYPE	32	32	HIV
NCT001487596	NCT00148759_6_T0	PHENOTYPE	35	35	HIV/AIDS
NCT001487596	NCT00148759_6_T1	PHENOTYPE	14	14	toxicities
NCT001487596	NCT00148759_6_T2	GENE	15	15	has
NCT001487598	NCT00148759_8_T0	PHENOTYPE	13	13	HIV
NCT001487598	NCT00148759_8_T1	PHENOTYPE	26	27	adverse effects
NCT001487599	NCT00148759_9_T0	COMPOUND	10	10	ARVs
NCT0014875910	NCT00148759_10_T0	COMPOUND	20	20	ARVs
NCT0014875910	NCT00148759_10_T1	COMPOUND	32	32	ARVs
NCT0014875910	NCT00148759_10_T2	PHENOTYPE	33	33	pharmacokinetics
NCT0014875911	NCT00148759_11_T0	PHENOTYPE	45	45	HIV
NCT0014875912	NCT00148759_12_T0	COMPOUND	28	28	LPV/r
NCT0014875912	NCT00148759_12_T1	PHENOTYPE	13	13	pharmacokinetics
NCT0014875913	NCT00148759_13_T0	PHENOTYPE	3	3	toxicity
NCT0014875913	NCT00148759_13_T1	PHENOTYPE	6	6	diarrhea
NCT0014875913	NCT00148759_13_T2	PHENOTYPE	10	12	quality of life
NCT001487723	NCT00148772_3_T0	GENE	7	7	hormone
NCT001487725	NCT00148772_5_T0	PHENOTYPE	4	4	tumor
NCT001487729	NCT00148772_9_T0	PHENOTYPE	10	10	cancers
NCT001487729	NCT00148772_9_T1	GENE	1	1	has
NCT0014877210	NCT00148772_10_T0	COMPOUND	6	6	erlotinib
NCT0014877210	NCT00148772_10_T1	PHENOTYPE	14	15	lung cancer
NCT0014877212	NCT00148772_12_T0	COMPOUND	16	16	erlotinib
NCT001487851	NCT00148785_1_T0	PHENOTYPE	13	13	HIV
NCT001487852	NCT00148785_2_T0	GENE	29	29	protease
NCT001487852	NCT00148785_2_T1	PHENOTYPE	6	6	HIV
NCT001487852	NCT00148785_2_T2	PHENOTYPE	16	16	HIV
NCT001487852	NCT00148785_2_T3	PHENOTYPE	12	12	resistant
NCT001487855	NCT00148785_5_T0	COMPOUND	20	20	fosamprenavir
NCT001487855	NCT00148785_5_T1	PHENOTYPE	31	31	HIV
NCT001487855	NCT00148785_5_T2	COMPOUND	17	17	indinavir
NCT001487857	NCT00148785_7_T0	GENE	17	17	PI
NCT001487857	NCT00148785_7_T1	COMPOUND	15	15	Kaletra
NCT001487857	NCT00148785_7_T2	COMPOUND	26	26	Kaletra
NCT001487859	NCT00148785_9_T0	PHENOTYPE	33	34	HIV infection
NCT0014878510	NCT00148785_10_T0	PHENOTYPE	3	3	HIV
NCT0014878510	NCT00148785_10_T1	GENE	24	24	IDP
NCT0014878510	NCT00148785_10_T2	PHENOTYPE	21	22	Infectious Disease
NCT0014878511	NCT00148785_11_T0	PHENOTYPE	45	46	drug levels
NCT0014878512	NCT00148785_12_T0	PHENOTYPE	3	4	blood concentrations
NCT0014878515	NCT00148785_15_T0	PHENOTYPE	7	8	drug levels
NCT0014878517	NCT00148785_17_T0	PHENOTYPE	15	15	mutation
NCT0014878517	NCT00148785_17_T1	PHENOTYPE	12	12	resistant
NCT0014878517	NCT00148785_17_T2	GENE	4	4	has
NCT0014878518	NCT00148785_18_T0	COMPOUND	20	20	ritonavir
NCT0014878518	NCT00148785_18_T1	PHENOTYPE	10	10	resistant
NCT0014878518	NCT00148785_18_T2	GENE	24	24	PI
NCT0014878518	NCT00148785_18_T3	PHENOTYPE	12	12	strains
NCT0014878520	NCT00148785_20_T0	PHENOTYPE	6	6	suppression
NCT0014878520	NCT00148785_20_T1	PHENOTYPE	2	2	pharmacokinetics
NCT0014878520	NCT00148785_20_T2	PHENOTYPE	11	11	strains
NCT0014878520	NCT00148785_20_T3	BIOLOGICAL_PROCESS	8	9	viral replication
NCT0014878521	NCT00148785_21_T0	PHENOTYPE	16	16	mutation
NCT0014878521	NCT00148785_21_T1	GENE	3	3	PI
NCT0014878521	NCT00148785_21_T2	GENE	55	55	PI
NCT0014878522	NCT00148785_22_T0	PHENOTYPE	20	21	side effect
NCT0014878523	NCT00148785_23_T0	PHENOTYPE	29	29	mutation
NCT0014878523	NCT00148785_23_T1	COMPOUND	5	5	indinavir
NCT0014878523	NCT00148785_23_T2	PHENOTYPE	28	28	resistant
NCT0014878524	NCT00148785_24_T0	COMPOUND	13	13	LPV/r
NCT0014878525	NCT00148785_25_T0	PHENOTYPE	20	20	concentrations
NCT0014878525	NCT00148785_25_T1	COMPOUND	23	23	lopinavir
NCT0014878525	NCT00148785_25_T2	GENE	11	11	bid
NCT0014878527	NCT00148785_27_T0	PHENOTYPE	24	24	concentrations
NCT0014878527	NCT00148785_27_T1	PHENOTYPE	28	28	concentrations
NCT0014878527	NCT00148785_27_T2	GENE	32	32	half-life
NCT0014878527	NCT00148785_27_T3	PHENOTYPE	50	50	HIV
NCT0014878527	NCT00148785_27_T4	ORGAN	22	22	plasma
NCT0014878527	NCT00148785_27_T5	PHENOTYPE	31	31	elimination
NCT0014878528	NCT00148785_28_T0	PHENOTYPE	2	2	HIV
NCT0014878528	NCT00148785_28_T1	GENE	24	24	IDP
NCT0014878528	NCT00148785_28_T2	GENE	14	14	bid
NCT0014878528	NCT00148785_28_T3	PHENOTYPE	21	22	Infectious Disease
NCT0014878529	NCT00148785_29_T0	PHENOTYPE	23	23	pharmacokinetics
NCT0014878530	NCT00148785_30_T0	GENE	3	3	bid
NCT0014878532	NCT00148785_32_T0	ORGAN	2	2	Plasma
NCT0014878532	NCT00148785_32_T1	PHENOTYPE	3	3	concentrations
NCT0014878534	NCT00148785_34_T0	GENE	21	21	paired
NCT001488240	NCT00148824_0_T0	PHENOTYPE	0	1	Antibody Responses
NCT001488245	NCT00148824_5_T0	GENE	11	11	CD4
NCT001488245	NCT00148824_5_T1	GENE	4	4	PPV
NCT001488247	NCT00148824_7_T0	GENE	22	22	PCV
NCT001488247	NCT00148824_7_T1	GENE	6	6	CD4
NCT001488247	NCT00148824_7_T2	GENE	28	28	PPV
NCT001488247	NCT00148824_7_T3	GENE	33	33	PPV
NCT001488249	NCT00148824_9_T0	COMPOUND	15	15	polysaccharides
NCT001488249	NCT00148824_9_T1	GENE	9	9	had
NCT001488249	NCT00148824_9_T2	PHENOTYPE	10	11	antibody responses
NCT0014882410	NCT00148824_10_T0	PHENOTYPE	0	0	Secondary
NCT0014882410	NCT00148824_10_T1	PHENOTYPE	4	4	persistence
NCT0014882410	NCT00148824_10_T2	PHENOTYPE	6	7	antibody responses
NCT001488371	NCT00148837_1_T0	PHENOTYPE	21	21	fibrosis
NCT001488371	NCT00148837_1_T1	COMPOUND	7	7	prazosin
NCT001488371	NCT00148837_1_T2	PHENOTYPE	17	18	hepatitis C
NCT001488371	NCT00148837_1_T3	PHENOTYPE	16	17	chronic hepatitis
NCT001488371	NCT00148837_1_T4	PHENOTYPE	10	11	hepatic fibrosis
NCT001488373	NCT00148837_3_T0	PHENOTYPE	11	11	fibrosis
NCT001488373	NCT00148837_3_T1	PHENOTYPE	18	18	cirrhosis
NCT001488373	NCT00148837_3_T2	PHENOTYPE	0	1	Viral hepatitis
NCT001488373	NCT00148837_3_T3	PHENOTYPE	1	2	hepatitis C
NCT001488373	NCT00148837_3_T4	PHENOTYPE	20	21	hepatic cancer
NCT001488379	NCT00148837_9_T0	PHENOTYPE	12	12	fibrosis
NCT0014883710	NCT00148837_10_T0	PHENOTYPE	0	0	Secondary
NCT001488500	NCT00148850_0_T0	PHENOTYPE	10	10	Blind
NCT001488500	NCT00148850_0_T1	PHENOTYPE	6	6	Lipoatrophy
NCT001488504	NCT00148850_4_T0	PHENOTYPE	1	1	pathophysiology
NCT001488504	NCT00148850_4_T1	PHENOTYPE	6	6	understood
NCT001488504	NCT00148850_4_T2	PHENOTYPE	3	3	lipodystrophy
NCT001488507	NCT00148850_7_T0	GENE	1	1	PPARG
NCT001488507	NCT00148850_7_T1	ORGAN	12	12	plasma
NCT001488507	NCT00148850_7_T2	CELL	9	9	adipocytes
NCT001488508	NCT00148850_8_T0	PHENOTYPE	1	1	HIV
NCT001488508	NCT00148850_8_T1	TISSUE	14	15	subcutaneous fat
NCT001488509	NCT00148850_9_T0	COMPOUND	12	12	rosiglitazone
NCT001488630	NCT00148863_0_T0	GENE	4	4	Alpha
NCT001488630	NCT00148863_0_T1	GENE	0	0	Interferon
NCT001488630	NCT00148863_0_T2	GENE	5	5	2a
NCT001488630	NCT00148863_0_T3	PHENOTYPE	13	15	Chronic Hepatitis C
NCT001488634	NCT00148863_4_T0	PHENOTYPE	11	12	hepatitis C
NCT001488635	NCT00148863_5_T0	GENE	0	0	Interferon
NCT001488635	NCT00148863_5_T1	PHENOTYPE	5	5	fibrosis
NCT001488635	NCT00148863_5_T2	GENE	2	2	has
NCT001488635	NCT00148863_5_T3	GENE	1	1	gamma
NCT001488637	NCT00148863_7_T0	GENE	27	28	interferon gamma
NCT001488760	NCT00148876_0_T0	GENE	0	0	TBP
NCT001488769	NCT00148876_9_T0	PHENOTYPE	2	5	carcinoma of the breast
NCT0014887613	NCT00148876_13_T0	COMPOUND	12	12	3
NCT0014887613	NCT00148876_13_T1	GENE	18	18	FISH
NCT0014887613	NCT00148876_13_T2	PHENOTYPE	5	6	metastatic tumor
NCT0014887618	NCT00148876_18_T0	ORGAN	15	15	Appendix
NCT0014887620	NCT00148876_20_T0	GENE	9	9	portal
NCT0014887620	NCT00148876_20_T1	PHENOTYPE	17	18	progressive disease
NCT0014887620	NCT00148876_20_T2	PHENOTYPE	1	2	measurable disease
NCT0014887622	NCT00148876_22_T0	PHENOTYPE	3	3	tumor
NCT0014887624	NCT00148876_24_T0	GENE	1	1	18
NCT0014887637	NCT00148876_37_T0	PHENOTYPE	14	14	symptoms
NCT0014887637	NCT00148876_37_T1	PHENOTYPE	1	2	brain metastases
NCT0014887641	NCT00148876_41_T0	PHENOTYPE	4	5	psychiatric illness
NCT0014887643	NCT00148876_43_T0	PHENOTYPE	9	10	cardiac disease
NCT0014887643	NCT00148876_43_T1	PHENOTYPE	2	4	congestive heart failure
NCT0014887645	NCT00148876_45_T0	PHENOTYPE	3	3	malignancy
NCT0014887645	NCT00148876_45_T1	PHENOTYPE	17	18	breast cancer
NCT0014887655	NCT00148876_55_T0	PHENOTYPE	13	13	centre
NCT001488892	NCT00148889_2_T0	PHENOTYPE	3	3	chronic
NCT001488894	NCT00148889_4_T0	COMPOUND	6	6	dopamine
NCT001488895	NCT00148889_5_T0	GENE	3	3	CD
NCT001488896	NCT00148889_6_T0	PHENOTYPE	12	12	bilateral
NCT001488896	NCT00148889_6_T1	PHENOTYPE	21	22	generalized dystonia
NCT001488897	NCT00148889_7_T0	GENE	6	6	1.1
NCT001488899	NCT00148889_9_T0	PHENOTYPE	5	6	movement disorders
NCT0014888910	NCT00148889_10_T0	PHENOTYPE	13	13	dystonia
NCT001489288	NCT00148928_8_T0	GENE	14	14	Act
NCT001489288	NCT00148928_8_T1	GENE	3	3	has
NCT001489288	NCT00148928_8_T2	GENE	15	15	Sep
NCT001489413	NCT00148941_3_T0	PHENOTYPE	5	5	influenza
NCT001489801	NCT00148980_1_T0	CELL	0	1	Stem cells
NCT001489803	NCT00148980_3_T0	GENE	28	28	has
NCT001489803	NCT00148980_3_T1	PHENOTYPE	37	37	cavity
NCT001489803	NCT00148980_3_T2	TISSUE	18	19	trabecular bone
NCT001489803	NCT00148980_3_T3	ORGAN	35	36	bone marrow
NCT001489930	NCT00148993_0_T0	PHENOTYPE	1	1	Tumor
NCT001489930	NCT00148993_0_T1	PHENOTYPE	7	8	Solid Tumors
NCT001490060	NCT00149006_0_T0	GENE	11	11	Interleukin-2
NCT001490060	NCT00149006_0_T1	CELL	7	7	Lymphocytes
NCT001490060	NCT00149006_0_T2	PHENOTYPE	15	16	Solid Tumors
NCT001490062	NCT00149006_2_T0	CELL	42	42	lymphocytes
NCT001490062	NCT00149006_2_T1	PHENOTYPE	5	5	resistant
NCT001490062	NCT00149006_2_T2	GENE	30	30	interferon
NCT001490062	NCT00149006_2_T3	COMPOUND	26	26	fludarabine
NCT001490062	NCT00149006_2_T4	PHENOTYPE	3	4	solid tumors
NCT001490190	NCT00149019_0_T0	CELL	5	5	Lymphocytes
NCT001490193	NCT00149019_3_T0	CELL	26	26	lymphocytes
NCT001490193	NCT00149019_3_T1	GENE	2	2	NST
NCT001490193	NCT00149019_3_T2	GENE	20	20	NST
NCT001490193	NCT00149019_3_T3	CELL	8	8	cells
NCT001490193	NCT00149019_3_T4	PHENOTYPE	7	7	tumor
NCT001490193	NCT00149019_3_T5	PHENOTYPE	17	18	recurrent disease
NCT001490194	NCT00149019_4_T0	CELL	19	19	lymphocytes
NCT001490194	NCT00149019_4_T1	CELL	25	25	lymphocytes
NCT001490194	NCT00149019_4_T2	CELL	12	12	cells
NCT001490194	NCT00149019_4_T3	PHENOTYPE	11	11	tumor
NCT001490194	NCT00149019_4_T4	PHENOTYPE	29	29	tumor
NCT001490322	NCT00149032_2_T0	CELL	15	15	lymphocytes
NCT001490322	NCT00149032_2_T1	PHENOTYPE	20	20	relapse
NCT001490322	NCT00149032_2_T2	PHENOTYPE	19	19	resistant
NCT001490322	NCT00149032_2_T3	PHENOTYPE	22	22	resistant
NCT001490581	NCT00149058_1_T0	GENE	7	7	EPO
NCT001490581	NCT00149058_1_T1	GENE	27	27	reduced
NCT001490581	NCT00149058_1_T2	ORGAN	16	16	heart
NCT001490581	NCT00149058_1_T3	GENE	8	8	has
NCT001490581	NCT00149058_1_T4	COMPOUND	24	24	oxygen
NCT001490581	NCT00149058_1_T5	PHENOTYPE	28	29	blood supply
NCT001490582	NCT00149058_2_T0	GENE	19	19	EPO
NCT001490582	NCT00149058_2_T1	PHENOTYPE	14	15	heart attack
NCT001490582	NCT00149058_2_T2	PHENOTYPE	26	27	heart attack
NCT001490584	NCT00149058_4_T0	GENE	4	4	null
NCT001490584	NCT00149058_4_T1	GENE	13	13	EPO
NCT001490584	NCT00149058_4_T2	GENE	23	23	EPO
NCT001490584	NCT00149058_4_T3	PHENOTYPE	16	16	infarct
NCT001490584	NCT00149058_4_T4	PHENOTYPE	26	26	infarct
NCT001490585	NCT00149058_5_T0	PHENOTYPE	3	3	acute
NCT001490586	NCT00149058_6_T0	GENE	8	8	PCI
NCT001490587	NCT00149058_7_T0	GENE	8	8	EPO
NCT001490587	NCT00149058_7_T1	GENE	14	14	PCI
NCT001490589	NCT00149058_9_T0	GENE	5	5	EPO
NCT0014905810	NCT00149058_10_T0	GENE	2	2	PCI
NCT0014905811	NCT00149058_11_T0	GENE	28	28	CMR
NCT0014905811	NCT00149058_11_T1	PHENOTYPE	34	34	infarct
NCT0014905811	NCT00149058_11_T2	COMPOUND	23	23	gadolinium
NCT0014905812	NCT00149058_12_T0	GENE	20	20	CMR
NCT0014905814	NCT00149058_14_T0	GENE	15	15	1.5
NCT0014905814	NCT00149058_14_T1	GENE	0	0	CMR
NCT0014905815	NCT00149058_15_T0	GENE	15	15	ventricular
NCT0014905816	NCT00149058_16_T0	COMPOUND	8	8	gadolinium
NCT0014905816	NCT00149058_16_T1	PHENOTYPE	0	1	Myocardial infarcts
NCT0014905817	NCT00149058_17_T0	COMPOUND	0	0	Gadolinium
NCT0014905817	NCT00149058_17_T1	PHENOTYPE	22	22	headache
NCT0014905817	NCT00149058_17_T2	PHENOTYPE	24	24	nausea
NCT001490711	NCT00149071_1_T0	COMPOUND	17	17	rTMS
NCT001490712	NCT00149071_2_T0	COMPOUND	16	16	escitalopram
NCT001490712	NCT00149071_2_T1	COMPOUND	22	22	escitalopram
NCT001490712	NCT00149071_2_T2	COMPOUND	13	13	rTMS
NCT001490712	NCT00149071_2_T3	COMPOUND	19	19	rTMS
NCT001490713	NCT00149071_3_T0	COMPOUND	0	0	rTMS
NCT001490714	NCT00149071_4_T0	PHENOTYPE	5	5	relapse
NCT001490714	NCT00149071_4_T1	COMPOUND	22	22	escitalopram
NCT001490846	NCT00149084_6_T0	COMPOUND	17	17	S-mephenytoin
NCT001490846	NCT00149084_6_T1	COMPOUND	5	5	omeprazole
NCT001490846	NCT00149084_6_T2	COMPOUND	3	3	lansoprazole
NCT001490846	NCT00149084_6_T3	ORGAN	11	11	liver
NCT001490846	NCT00149084_6_T4	GENE	19	19	CYP2C19
NCT001490847	NCT00149084_7_T0	ORGAN	0	0	Plasma
NCT001490847	NCT00149084_7_T1	PHENOTYPE	1	1	concentrations
NCT001490847	NCT00149084_7_T2	PHENOTYPE	9	9	inhibition
NCT001490849	NCT00149084_9_T0	GENE	5	5	CYP2C19
NCT0014908416	NCT00149084_16_T0	PHENOTYPE	22	22	blocked
NCT0014908418	NCT00149084_18_T0	PHENOTYPE	10	10	strain
NCT0014908418	NCT00149084_18_T1	PHENOTYPE	62	62	strain
NCT0014908418	NCT00149084_18_T2	COMPOUND	25	25	amoxicillin
NCT0014908418	NCT00149084_18_T3	COMPOUND	73	73	amoxicillin
NCT0014908418	NCT00149084_18_T4	COMPOUND	34	34	lansoprazole
NCT0014908418	NCT00149084_18_T5	COMPOUND	82	82	lansoprazole
NCT0014908418	NCT00149084_18_T6	COMPOUND	21	21	clarithromycin
NCT0014908418	NCT00149084_18_T7	GENE	24	24	tid
NCT0014908418	NCT00149084_18_T8	GENE	28	28	tid
NCT0014908418	NCT00149084_18_T9	GENE	39	39	tid
NCT0014908418	NCT00149084_18_T10	GENE	44	44	tid
NCT0014908418	NCT00149084_18_T11	GENE	50	50	bid
NCT0014908418	NCT00149084_18_T12	GENE	97	97	bid
NCT001491104	NCT00149110_4_T0	GENE	26	26	has
NCT001491104	NCT00149110_4_T1	PHENOTYPE	21	22	major depression
NCT001491105	NCT00149110_5_T0	GENE	15	15	has
NCT001491107	NCT00149110_7_T0	PHENOTYPE	7	7	ambition
NCT001491107	NCT00149110_7_T1	PHENOTYPE	29	29	remission
NCT0014911010	NCT00149110_10_T0	GENE	2	2	has
NCT0014911011	NCT00149110_11_T0	COMPOUND	7	7	duloxetine
NCT0014911012	NCT00149110_12_T0	PHENOTYPE	19	19	remission
NCT0014911012	NCT00149110_12_T1	GENE	9	9	has
NCT0014911015	NCT00149110_15_T0	PHENOTYPE	25	25	profound
NCT0014911020	NCT00149110_20_T0	PHENOTYPE	20	20	remission
NCT0014911020	NCT00149110_20_T1	GENE	7	7	has
NCT0014911021	NCT00149110_21_T0	PHENOTYPE	5	5	remission
NCT0014911022	NCT00149110_22_T0	PHENOTYPE	20	20	remission
NCT0014911022	NCT00149110_22_T1	PHENOTYPE	32	32	remission
NCT0014911022	NCT00149110_22_T2	COMPOUND	14	14	duloxetine
NCT0014911024	NCT00149110_24_T0	COMPOUND	16	16	duloxetine
NCT0014911025	NCT00149110_25_T0	COMPOUND	8	8	duloxetine
NCT0014911035	NCT00149110_35_T0	GENE	3	3	has
NCT0014911045	NCT00149110_45_T0	GENE	6	6	am
NCT0014911046	NCT00149110_46_T0	PHENOTYPE	7	7	agitation
NCT0014911046	NCT00149110_46_T1	PHENOTYPE	9	10	sleep disturbances
NCT0014911047	NCT00149110_47_T0	PHENOTYPE	4	5	major depression
NCT0014911048	NCT00149110_48_T0	PHENOTYPE	31	31	self-assessment
NCT0014911048	NCT00149110_48_T1	PHENOTYPE	0	0	Severity
NCT0014911048	NCT00149110_48_T2	GENE	23	23	al
NCT0014911048	NCT00149110_48_T3	GENE	22	22	et
NCT0014911050	NCT00149110_50_T0	PHENOTYPE	0	1	Side effects
NCT0014911054	NCT00149110_54_T0	PHENOTYPE	9	9	remission
NCT0014911055	NCT00149110_55_T0	PHENOTYPE	0	0	Secondary
NCT0014911057	NCT00149110_57_T0	GENE	11	11	has
NCT0014911059	NCT00149110_59_T0	PHENOTYPE	12	13	Adverse Reactions
NCT0014911059	NCT00149110_59_T1	PHENOTYPE	5	7	Adverse drug reactions
NCT0014911060	NCT00149110_60_T0	PHENOTYPE	0	1	Side effects
NCT001491231	NCT00149123_1_T0	PHENOTYPE	9	10	septic shock
NCT001491232	NCT00149123_2_T0	GENE	18	18	reduced
NCT001491232	NCT00149123_2_T1	PHENOTYPE	3	3	hypovolemic
NCT001491232	NCT00149123_2_T2	PHENOTYPE	8	8	burns
NCT001491233	NCT00149123_3_T0	COMPOUND	11	11	hydrocortisone
NCT001491233	NCT00149123_3_T1	PHENOTYPE	3	4	septic shock
NCT001491362	NCT00149136_2_T0	PHENOTYPE	9	9	blocks
NCT001491362	NCT00149136_2_T1	PHENOTYPE	17	17	blocks
NCT001491362	NCT00149136_2_T2	COMPOUND	19	19	imatinib
NCT001491362	NCT00149136_2_T3	GENE	4	4	CR
NCT001491363	NCT00149136_3_T0	COMPOUND	12	12	methotrexate
NCT001491363	NCT00149136_3_T1	PHENOTYPE	3	6	central nervous system leukemia
NCT001491620	NCT00149162_0_T0	GENE	8	8	Interleukin-2
NCT001491620	NCT00149162_0_T1	PHENOTYPE	3	7	Childhood Acute Myeloid Leukemia With
NCT001491625	NCT00149162_5_T0	GENE	6	6	interleukin-2
NCT001491625	NCT00149162_5_T1	PHENOTYPE	12	12	remission
NCT001491751	NCT00149175_1_T0	GENE	28	28	de
NCT001491751	NCT00149175_1_T1	GENE	31	31	IFR
NCT001491753	NCT00149175_3_T0	PHENOTYPE	2	2	disorders
NCT001491753	NCT00149175_3_T1	GENE	6	6	has
NCT001491754	NCT00149175_4_T0	GENE	8	8	APP
NCT001491754	NCT00149175_4_T1	GENE	11	11	PSEN2
NCT001491754	NCT00149175_4_T2	GENE	9	9	PSEN1
NCT001491754	NCT00149175_4_T3	PHENOTYPE	1	2	Alzheimer's disease
NCT001491755	NCT00149175_5_T0	GENE	4	4	tau
NCT001491755	NCT00149175_5_T1	PHENOTYPE	1	2	frontotemporal dementias
NCT001491755	NCT00149175_5_T2	PHENOTYPE	16	18	autosomal dominant inheritance
NCT001491758	NCT00149175_8_T0	PHENOTYPE	18	18	localizing
NCT001491759	NCT00149175_9_T0	PHENOTYPE	1	1	strategies
NCT0014917510	NCT00149175_10_T0	PHENOTYPE	15	15	tolerance
NCT0014917511	NCT00149175_11_T0	PHENOTYPE	13	13	dementia
NCT0014917512	NCT00149175_12_T0	PHENOTYPE	8	8	dementias
NCT0014917512	NCT00149175_12_T1	PHENOTYPE	19	20	neurological disorders
NCT001492012	NCT00149201_2_T0	GENE	20	20	II
NCT001492012	NCT00149201_2_T1	PHENOTYPE	16	16	metastasis
NCT001492012	NCT00149201_2_T2	PHENOTYPE	12	13	gastric cancer
NCT001492013	NCT00149201_3_T0	PHENOTYPE	16	16	metastasis
NCT001492013	NCT00149201_3_T1	GENE	4	4	III
NCT001492013	NCT00149201_3_T2	PHENOTYPE	12	13	gastric cancer
NCT001492274	NCT00149227_4_T0	GENE	15	15	has
NCT001492274	NCT00149227_4_T1	PHENOTYPE	10	11	cardiovascular disease
NCT001492275	NCT00149227_5_T0	COMPOUND	11	11	valsartan
NCT001492275	NCT00149227_5_T1	PHENOTYPE	26	26	hypertension
NCT001492661	NCT00149266_1_T0	PHENOTYPE	5	5	metastasis
NCT001492661	NCT00149266_1_T1	GENE	4	4	nodal
NCT001492664	NCT00149266_4_T0	COMPOUND	5	5	3
NCT001492664	NCT00149266_4_T1	GENE	30	30	cm
NCT001492664	NCT00149266_4_T2	COMPOUND	17	17	oxygen
NCT001492665	NCT00149266_5_T0	PHENOTYPE	0	0	Carcinoma
NCT001492665	NCT00149266_5_T1	ORGAN	3	4	remnant stomach
NCT001492795	NCT00149279_5_T0	COMPOUND	26	26	creatinine
NCT001492795	NCT00149279_5_T1	COMPOUND	5	5	3
NCT001492795	NCT00149279_5_T2	COMPOUND	17	17	oxygen
NCT001492797	NCT00149279_7_T0	GENE	7	7	T4
NCT001492797	NCT00149279_7_T1	CELL	33	33	cells
NCT001492797	NCT00149279_7_T2	PHENOTYPE	17	17	metastasis
NCT001492797	NCT00149279_7_T3	GENE	5	5	T3
NCT001492798	NCT00149279_8_T0	PHENOTYPE	0	0	Carcinoma
NCT001492798	NCT00149279_8_T1	ORGAN	3	4	remnant stomach
NCT001492921	NCT00149292_1_T0	PHENOTYPE	27	27	schizophrenia
NCT001493051	NCT00149305_1_T0	PHENOTYPE	14	14	hyperoxaluria
NCT001493051	NCT00149305_1_T1	PHENOTYPE	10	10	nephrolithiasis
NCT001493051	NCT00149305_1_T2	PHENOTYPE	28	28	nephrolithiasis
NCT001493051	NCT00149305_1_T3	PHENOTYPE	15	15	cystinuria
NCT001493051	NCT00149305_1_T4	PHENOTYPE	13	13	hypercalciuria
NCT001493051	NCT00149305_1_T5	GENE	3	3	has
NCT001493051	NCT00149305_1_T6	PHENOTYPE	16	18	renal tubular acidosis
NCT001493052	NCT00149305_2_T0	GENE	7	7	di
NCT001493058	NCT00149305_8_T0	GENE	13	13	5.5
NCT001493058	NCT00149305_8_T1	GENE	12	12	pH
NCT001493058	NCT00149305_8_T2	COMPOUND	3	4	uric acid
NCT001493058	NCT00149305_8_T3	PHENOTYPE	6	8	calcium oxalate nephrolithiasis
NCT001493059	NCT00149305_9_T0	PHENOTYPE	0	0	Hyperuricemia
NCT001493059	NCT00149305_9_T1	PHENOTYPE	1	1	hypertriglyceridemia
NCT001493059	NCT00149305_9_T2	PHENOTYPE	6	7	gouty arthritis
NCT0014930511	NCT00149305_11_T0	PHENOTYPE	1	1	acidity
NCT0014930511	NCT00149305_11_T1	PHENOTYPE	10	11	primary gout
NCT0014930511	NCT00149305_11_T2	PHENOTYPE	17	19	uric acid nephrolithiasis
NCT0014930513	NCT00149305_13_T0	COMPOUND	22	22	sulfate
NCT0014930513	NCT00149305_13_T1	PHENOTYPE	16	16	hyperoxaluria
NCT0014930513	NCT00149305_13_T2	PHENOTYPE	17	17	hyperuricosuria
NCT0014930513	NCT00149305_13_T3	PHENOTYPE	18	18	hypocitraturia
NCT0014930513	NCT00149305_13_T4	COMPOUND	28	28	sodium
NCT0014930513	NCT00149305_13_T5	PHENOTYPE	5	5	nephrolithiasis
NCT0014930513	NCT00149305_13_T6	GENE	36	36	pH
NCT0014930513	NCT00149305_13_T7	PHENOTYPE	29	29	cystinuria
NCT0014930513	NCT00149305_13_T8	PHENOTYPE	15	15	hypercalciuria
NCT0014930513	NCT00149305_13_T9	PHENOTYPE	12	13	kidney stones
NCT0014930514	NCT00149305_14_T0	PHENOTYPE	20	20	nephrolithiasis
NCT0014930514	NCT00149305_14_T1	GENE	3	3	has
NCT0014930515	NCT00149305_15_T0	GENE	21	21	UAN
NCT0014930515	NCT00149305_15_T1	PHENOTYPE	18	20	Uric Acid Nephrolithiasis
NCT0014930516	NCT00149305_16_T0	GENE	9	9	UAN
NCT0014930516	NCT00149305_16_T1	GENE	30	30	UAN
NCT0014930517	NCT00149305_17_T0	GENE	5	5	UAN
NCT0014930517	NCT00149305_17_T1	GENE	11	11	ZNF365
NCT0014930518	NCT00149305_18_T0	GENE	7	7	di
NCT0014930518	NCT00149305_18_T1	PHENOTYPE	17	17	nephrolithiasis
NCT0014930521	NCT00149305_21_T0	PHENOTYPE	14	14	attitudes
NCT0014930521	NCT00149305_21_T1	PHENOTYPE	33	33	progression
NCT0014930521	NCT00149305_21_T2	PHENOTYPE	27	28	renal disease
NCT0014930523	NCT00149305_23_T0	GENE	40	40	di
NCT0014930523	NCT00149305_23_T1	PHENOTYPE	9	9	nephrolithiasis
NCT001493183	NCT00149318_3_T0	PHENOTYPE	3	3	opacities
NCT001493184	NCT00149318_4_T0	PHENOTYPE	11	11	hypertension
NCT001493184	NCT00149318_4_T1	PHENOTYPE	0	0	Proteinuria
NCT001493185	NCT00149318_5_T0	PHENOTYPE	1	4	end stage renal disease
NCT001493187	NCT00149318_7_T0	ORGAN	10	10	kidney
NCT001493187	NCT00149318_7_T1	ORGAN	8	8	heart
NCT0014931810	NCT00149318_10_T0	PHENOTYPE	16	17	Fabry disease
NCT0014931815	NCT00149318_15_T0	COMPOUND	11	11	globotriaosylceramide
NCT0014931815	NCT00149318_15_T1	CELL	25	25	cells
NCT0014931815	NCT00149318_15_T2	GENE	12	12	Gb3
NCT0014931815	NCT00149318_15_T3	CELL	19	19	lysosomes
NCT0014931815	NCT00149318_15_T4	ORGAN	27	28	blood vessels
NCT0014931816	NCT00149318_16_T0	CELL	4	5	ganglion cells
NCT0014931818	NCT00149318_18_T0	PHENOTYPE	3	3	opacities
NCT0014931819	NCT00149318_19_T0	PHENOTYPE	11	11	uremia
NCT0014931819	NCT00149318_19_T1	PHENOTYPE	3	3	proteinuria
NCT0014931819	NCT00149318_19_T2	PHENOTYPE	9	9	hypertension
NCT0014931819	NCT00149318_19_T3	PHENOTYPE	5	6	renal impairment
NCT0014931820	NCT00149318_20_T0	PHENOTYPE	14	14	chronic
NCT0014931820	NCT00149318_20_T1	PHENOTYPE	0	1	Renal failure
NCT0014931821	NCT00149318_21_T0	ORGAN	20	20	heart
NCT0014931822	NCT00149318_22_T0	GENE	4	4	has
NCT0014931823	NCT00149318_23_T0	PHENOTYPE	22	22	dystrophy
NCT0014931825	NCT00149318_25_T0	ORGAN	2	2	kidney
NCT0014931825	NCT00149318_25_T1	PHENOTYPE	30	30	distal
NCT0014931825	NCT00149318_25_T2	CELL	36	36	histiocytes
NCT0014931825	NCT00149318_25_T3	TISSUE	22	22	epithelium
NCT0014931825	NCT00149318_25_T4	PHENOTYPE	33	33	proximal
NCT0014931825	NCT00149318_25_T5	CELL	13	14	epithelial cells
NCT0014931826	NCT00149318_26_T0	PHENOTYPE	1	1	distal
NCT0014931826	NCT00149318_26_T1	CELL	3	4	epithelial cells
NCT0014931827	NCT00149318_27_T0	ORGAN	1	2	blood vessels
NCT0014931829	NCT00149318_29_T0	PHENOTYPE	7	7	sclerosis
NCT0014931829	NCT00149318_29_T1	PHENOTYPE	13	13	proliferation
NCT0014931829	NCT00149318_29_T2	PHENOTYPE	9	9	atrophy
NCT0014931829	NCT00149318_29_T3	PHENOTYPE	11	11	fibrosis
NCT0014931829	NCT00149318_29_T4	TISSUE	17	17	epithelium
NCT0014931829	NCT00149318_29_T5	PHENOTYPE	21	21	diffuse
NCT0014931829	NCT00149318_29_T6	PHENOTYPE	18	19	tubular atrophy
NCT0014931829	NCT00149318_29_T7	PHENOTYPE	22	23	interstitial fibrosis
NCT0014931830	NCT00149318_30_T0	PHENOTYPE	22	23	Fabry disease
NCT0014931831	NCT00149318_31_T0	PHENOTYPE	19	20	Fabry disease
NCT001493313	NCT00149331_3_T0	GENE	17	17	insulin
NCT001493314	NCT00149331_4_T0	GENE	29	29	insulin
NCT001493314	NCT00149331_4_T1	PHENOTYPE	16	16	feelings
NCT0014934410	NCT00149344_10_T0	GENE	32	32	BRAVO
NCT0014934410	NCT00149344_10_T1	GENE	14	14	2.3
NCT0014934410	NCT00149344_10_T2	PHENOTYPE	2	4	quality of life
NCT0014934412	NCT00149344_12_T0	PHENOTYPE	6	6	self-evaluation
NCT0014934418	NCT00149344_18_T0	GENE	11	11	displaced
NCT0014934418	NCT00149344_18_T1	GENE	14	14	ml
NCT0014934419	NCT00149344_19_T0	GENE	5	5	displaced
NCT001493701	NCT00149370_1_T0	PHENOTYPE	18	18	denials
NCT001493701	NCT00149370_1_T1	COMPOUND	28	28	BMI
NCT001493703	NCT00149370_3_T0	PHENOTYPE	7	8	breast hypertrophy
NCT001493704	NCT00149370_4_T0	GENE	21	21	BRAVO
NCT001493832	NCT00149383_2_T0	PHENOTYPE	11	12	falciparum malaria
NCT001493833	NCT00149383_3_T0	PHENOTYPE	19	19	parasitemia
NCT001493833	NCT00149383_3_T1	PHENOTYPE	28	28	infections
NCT001493833	NCT00149383_3_T2	PHENOTYPE	21	21	fever
NCT001493833	NCT00149383_3_T3	COMPOUND	10	10	rosiglitazone
NCT001493833	NCT00149383_3_T4	COMPOUND	38	38	rosiglitazone
NCT001493836	NCT00149383_6_T0	PHENOTYPE	3	4	Tropical Diseases
NCT001493961	NCT00149396_1_T0	GENE	1	1	has
NCT001493962	NCT00149396_2_T0	ORGAN	33	33	liver
NCT001493962	NCT00149396_2_T1	PHENOTYPE	25	26	herpes simplex
NCT001493967	NCT00149396_7_T0	PHENOTYPE	18	19	stage 2
NCT001493967	NCT00149396_7_T1	PHENOTYPE	7	8	stage 1
NCT0014939611	NCT00149396_11_T0	GENE	25	25	has
NCT0014939612	NCT00149396_12_T0	GENE	4	4	log
NCT0014939612	NCT00149396_12_T1	GENE	18	18	MTD
NCT0014939613	NCT00149396_13_T0	PHENOTYPE	1	1	toxicity
NCT0014939613	NCT00149396_13_T1	COMPOUND	6	6	NCI
NCT0014939615	NCT00149396_15_T0	PHENOTYPE	30	31	colorectal cancer
NCT0014939621	NCT00149396_21_T0	PHENOTYPE	0	1	Colorectal adenocarcinoma
NCT0014939623	NCT00149396_23_T0	PHENOTYPE	7	7	tumors
NCT0014939623	NCT00149396_23_T1	COMPOUND	16	16	irinotecan
NCT0014939623	NCT00149396_23_T2	COMPOUND	18	18	oxaliplatin
NCT0014939623	NCT00149396_23_T3	PHENOTYPE	4	5	metastatic disease
NCT0014939627	NCT00149396_27_T0	PHENOTYPE	2	3	herpes simplex
NCT0014939630	NCT00149396_30_T0	PHENOTYPE	12	12	metastases
NCT0014939630	NCT00149396_30_T1	PHENOTYPE	7	8	malignant ascites
NCT0014939630	NCT00149396_30_T2	PHENOTYPE	4	5	cerebral metastases
NCT0014939631	NCT00149396_31_T0	PHENOTYPE	0	0	Seronegative
NCT0014939635	NCT00149396_35_T0	ORGAN	6	6	liver
NCT0014939641	NCT00149396_41_T0	PHENOTYPE	0	0	Acute
NCT0014939641	NCT00149396_41_T1	PHENOTYPE	1	1	HSV
NCT0014939641	NCT00149396_41_T2	PHENOTYPE	11	11	HSV
NCT0014939642	NCT00149396_42_T0	PHENOTYPE	1	2	viral hepatitis
NCT0014939642	NCT00149396_42_T1	PHENOTYPE	7	8	hepatitis A
NCT0014939646	NCT00149396_46_T0	PHENOTYPE	5	5	cirrhosis
NCT0014939646	NCT00149396_46_T1	PHENOTYPE	3	4	hepatic fibrosis
NCT0014939647	NCT00149396_47_T0	PHENOTYPE	2	2	malignancy
NCT0014939647	NCT00149396_47_T1	PHENOTYPE	5	6	colorectal cancer
NCT001494353	NCT00149435_3_T0	PHENOTYPE	8	8	CVD
NCT001494358	NCT00149435_8_T0	GENE	16	16	yrs
NCT001494358	NCT00149435_8_T1	GENE	11	11	CHD
NCT001494359	NCT00149435_9_T0	GENE	8	8	CHD
NCT0014943510	NCT00149435_10_T0	GENE	5	5	CHD
NCT0014943512	NCT00149435_12_T0	GENE	15	15	CHD
NCT0014943513	NCT00149435_13_T0	GENE	29	29	CHD
NCT0014943514	NCT00149435_14_T0	PHENOTYPE	10	10	CVD
NCT001494481	NCT00149448_1_T0	PHENOTYPE	7	7	enabling
NCT001494481	NCT00149448_1_T1	PHENOTYPE	2	2	focused
NCT001494614	NCT00149461_4_T0	PHENOTYPE	3	3	affects
NCT001494614	NCT00149461_4_T1	PHENOTYPE	1	1	asthma
NCT001494614	NCT00149461_4_T2	PHENOTYPE	32	32	asthma
NCT001494618	NCT00149461_8_T0	PHENOTYPE	1	1	asthma
NCT001494619	NCT00149461_9_T0	PHENOTYPE	18	18	asthma
NCT0014946113	NCT00149461_13_T0	PHENOTYPE	16	16	asthma
NCT0014946113	NCT00149461_13_T1	PHENOTYPE	28	28	asthma
NCT0014946113	NCT00149461_13_T2	PHENOTYPE	32	34	quality of life
NCT0014946115	NCT00149461_15_T0	PHENOTYPE	14	14	asthma
NCT0014946115	NCT00149461_15_T1	PHENOTYPE	3	3	secondary
NCT001494740	NCT00149474_0_T0	PHENOTYPE	7	7	Asthma
NCT001494743	NCT00149474_3_T0	PHENOTYPE	5	5	asthma
NCT001494743	NCT00149474_3_T1	PHENOTYPE	17	17	asthma
NCT001494743	NCT00149474_3_T2	GENE	29	29	50
NCT001494870	NCT00149487_0_T0	PHENOTYPE	5	5	Asthma
NCT001494870	NCT00149487_0_T1	PHENOTYPE	8	9	Problem Solving
NCT001494873	NCT00149487_3_T0	PHENOTYPE	1	1	asthma
NCT001494873	NCT00149487_3_T1	PHENOTYPE	4	5	chronic illness
NCT001494874	NCT00149487_4_T0	PHENOTYPE	4	4	asthma
NCT001494875	NCT00149487_5_T0	PHENOTYPE	39	39	asthma
NCT001494875	NCT00149487_5_T1	PHENOTYPE	15	16	problem solving
NCT001494876	NCT00149487_6_T0	PHENOTYPE	7	8	Problem Solving
NCT001495001	NCT00149500_1_T0	PHENOTYPE	7	7	asthma
NCT001495001	NCT00149500_1_T1	PHENOTYPE	12	12	asthma
NCT001495001	NCT00149500_1_T2	GENE	45	45	stops
NCT001495002	NCT00149500_2_T0	PHENOTYPE	14	14	asthma
NCT001495002	NCT00149500_2_T1	PHENOTYPE	24	24	asthma
NCT001495004	NCT00149500_4_T0	PHENOTYPE	15	15	asthma
NCT001495008	NCT00149500_8_T0	PHENOTYPE	23	23	symptoms
NCT001495008	NCT00149500_8_T1	PHENOTYPE	21	22	acute asthma
NCT001495009	NCT00149500_9_T0	PHENOTYPE	1	1	secondary
NCT0014950012	NCT00149500_12_T0	PHENOTYPE	12	13	acute asthma
NCT0014950014	NCT00149500_14_T0	PHENOTYPE	3	3	asthma
NCT0014950015	NCT00149500_15_T0	PHENOTYPE	23	23	perceived
NCT0014950015	NCT00149500_15_T1	PHENOTYPE	11	11	attitudes
NCT0014950015	NCT00149500_15_T2	PHENOTYPE	13	13	asthma
NCT0014950017	NCT00149500_17_T0	PHENOTYPE	9	9	asthma
NCT0014950017	NCT00149500_17_T1	PHENOTYPE	22	22	asthma
NCT0014950017	NCT00149500_17_T2	GENE	5	5	has
NCT0014950017	NCT00149500_17_T3	GENE	31	31	has
NCT0014950017	NCT00149500_17_T4	PHENOTYPE	35	35	wheezing
NCT0014950019	NCT00149500_19_T0	PHENOTYPE	13	13	asthma
NCT0014950020	NCT00149500_20_T0	PHENOTYPE	10	10	wheezing
NCT0014950024	NCT00149500_24_T0	GENE	2	2	has
NCT0014950027	NCT00149500_27_T0	GENE	2	2	has
NCT0014950029	NCT00149500_29_T0	PHENOTYPE	7	7	practices
NCT0014950029	NCT00149500_29_T1	PHENOTYPE	10	10	practices
NCT0014950031	NCT00149500_31_T0	GENE	9	9	metro
NCT0014950035	NCT00149500_35_T0	GENE	10	10	metro
NCT0014950037	NCT00149500_37_T0	PHENOTYPE	8	8	asthma
NCT0014950037	NCT00149500_37_T1	GENE	2	2	has
NCT0014950037	NCT00149500_37_T2	PHENOTYPE	12	12	wheezing
NCT0014950037	NCT00149500_37_T3	PHENOTYPE	14	15	respiratory symptoms
NCT0014950037	NCT00149500_37_T4	PHENOTYPE	4	5	chronic illness
NCT001495130	NCT00149513_0_T0	PHENOTYPE	11	11	Ventilation
NCT001495133	NCT00149513_3_T0	PHENOTYPE	19	19	complications
NCT0014951310	NCT00149513_10_T0	PHENOTYPE	13	13	ventilation
NCT0014951311	NCT00149513_11_T0	PHENOTYPE	8	8	blocks
NCT0014951316	NCT00149513_16_T0	PHENOTYPE	1	1	secondary
NCT001495260	NCT00149526_0_T0	GENE	6	6	ma
NCT001495260	NCT00149526_0_T1	PHENOTYPE	4	4	Asthma
NCT001495262	NCT00149526_2_T0	PHENOTYPE	8	8	asthma
NCT001495262	NCT00149526_2_T1	PHENOTYPE	6	6	decision-making
NCT001495262	NCT00149526_2_T2	PHENOTYPE	29	30	persistent asthma
NCT001495264	NCT00149526_4_T0	PHENOTYPE	12	12	decisions
NCT001495265	NCT00149526_5_T0	PHENOTYPE	19	19	decision-making
NCT001495265	NCT00149526_5_T1	PHENOTYPE	32	33	persistent asthma
NCT001495266	NCT00149526_6_T0	PHENOTYPE	19	19	asthma
NCT001495266	NCT00149526_6_T1	PHENOTYPE	2	2	decision-making
NCT001495266	NCT00149526_6_T2	GENE	26	26	UC
NCT001495267	NCT00149526_7_T0	PHENOTYPE	23	23	asthma
NCT001495267	NCT00149526_7_T1	GENE	9	9	has
NCT001495267	NCT00149526_7_T2	PHENOTYPE	7	7	decision-making
NCT001495267	NCT00149526_7_T3	PHENOTYPE	21	22	chronic disease
NCT001495268	NCT00149526_8_T0	PHENOTYPE	6	6	Asthma
NCT0014952610	NCT00149526_10_T0	PHENOTYPE	2	2	asthma
NCT0014952611	NCT00149526_11_T0	PHENOTYPE	15	15	asthma
NCT0014952612	NCT00149526_12_T0	PHENOTYPE	15	15	attributable
NCT0014952613	NCT00149526_13_T0	GENE	8	8	UC
NCT0014952617	NCT00149526_17_T0	GENE	11	11	UC
NCT0014952617	NCT00149526_17_T1	GENE	14	14	UC
NCT001495392	NCT00149539_2_T0	COMPOUND	6	6	buprenorphine
NCT001495392	NCT00149539_2_T1	COMPOUND	19	19	buprenorphine
NCT001495393	NCT00149539_3_T0	COMPOUND	15	15	buprenorphine_naloxone
NCT001495395	NCT00149539_5_T0	COMPOUND	5	5	buprenorphine
NCT001495396	NCT00149539_6_T0	COMPOUND	13	13	buprenorphine
NCT001495396	NCT00149539_6_T1	COMPOUND	2	2	buprenorphine_naloxone
NCT001495397	NCT00149539_7_T0	PHENOTYPE	12	12	acute
NCT001495397	NCT00149539_7_T1	COMPOUND	15	15	buprenorphine_naloxone
NCT001495397	NCT00149539_7_T2	COMPOUND	27	27	buprenorphine_naloxone
NCT001495398	NCT00149539_8_T0	COMPOUND	11	11	buprenorphine_naloxone
NCT001495399	NCT00149539_9_T0	COMPOUND	9	9	buprenorphine_naloxone
NCT001495522	NCT00149552_2_T0	PHENOTYPE	16	16	HIV
NCT001495522	NCT00149552_2_T1	ORGAN	25	25	plasma
NCT001495522	NCT00149552_2_T2	COMPOUND	9	9	zinc
NCT001495522	NCT00149552_2_T3	COMPOUND	26	26	zinc
NCT001495524	NCT00149552_4_T0	PHENOTYPE	4	4	susceptible
NCT001495524	NCT00149552_4_T1	PHENOTYPE	6	7	zinc deficiency
NCT001495525	NCT00149552_5_T0	PHENOTYPE	18	18	HIV
NCT001495525	NCT00149552_5_T1	COMPOUND	11	11	zinc
NCT001495527	NCT00149552_7_T0	COMPOUND	8	8	zinc
NCT001495528	NCT00149552_8_T0	COMPOUND	7	7	zinc
NCT001495528	NCT00149552_8_T1	COMPOUND	16	16	zinc
NCT0014956511	NCT00149565_11_T0	GENE	2	2	1.1
NCT0014956511	NCT00149565_11_T1	GENE	15	15	1.2
NCT0014956511	NCT00149565_11_T2	PHENOTYPE	1	1	PLAN
NCT0014956517	NCT00149565_17_T0	GENE	18	18	II
NCT0014956517	NCT00149565_17_T1	ORGAN	17	17	Appendix
NCT0014956517	NCT00149565_17_T2	PHENOTYPE	12	13	adverse events
NCT0014956518	NCT00149565_18_T0	PHENOTYPE	54	54	toxicity
NCT0014956518	NCT00149565_18_T1	GENE	35	35	II
NCT0014956518	NCT00149565_18_T2	ORGAN	34	34	Appendix
NCT0014956518	NCT00149565_18_T3	PHENOTYPE	4	5	adverse events
NCT0014956518	NCT00149565_18_T4	PHENOTYPE	29	30	adverse events
NCT0014956522	NCT00149565_22_T0	PHENOTYPE	21	21	constipation
NCT0014956522	NCT00149565_22_T1	PHENOTYPE	18	20	spontaneous bacterial peritonitis
NCT0014956526	NCT00149565_26_T0	PHENOTYPE	19	19	withdrawn
NCT0014956527	NCT00149565_27_T0	PHENOTYPE	1	1	Recurrent
NCT0014956533	NCT00149565_33_T0	PHENOTYPE	3	3	Center
NCT0014956533	NCT00149565_33_T1	COMPOUND	8	8	A191
NCT0014956533	NCT00149565_33_T2	GENE	23	23	Fax
NCT0014956535	NCT00149565_35_T0	GENE	0	0	Tel
NCT0014956535	NCT00149565_35_T1	GENE	2	2	Fax
NCT0014956540	NCT00149565_40_T0	PHENOTYPE	2	2	toxicity
NCT0014956540	NCT00149565_40_T1	PHENOTYPE	9	9	toxicity
NCT0014956540	NCT00149565_40_T2	GENE	13	13	2.0
NCT0014956540	NCT00149565_40_T3	PHENOTYPE	26	26	initiation
NCT0014956540	NCT00149565_40_T4	PHENOTYPE	41	41	initiation
NCT0014956540	NCT00149565_40_T5	GENE	12	12	III
NCT0014956540	NCT00149565_40_T6	ORGAN	11	11	Appendix
NCT0014956541	NCT00149565_41_T0	GENE	0	0	2.1
NCT0014956544	NCT00149565_44_T0	ORGAN	5	5	liver
NCT0014956544	NCT00149565_44_T1	GENE	0	0	2.2
NCT0014956544	NCT00149565_44_T2	GENE	14	14	albumin
NCT0014956544	NCT00149565_44_T3	COMPOUND	8	8	bilirubin
NCT0014956547	NCT00149565_47_T0	GENE	2	2	PA
NCT0014956547	NCT00149565_47_T1	GENE	0	0	2.3
NCT0014956548	NCT00149565_48_T0	PHENOTYPE	13	13	recurrence
NCT0014956548	NCT00149565_48_T1	GENE	0	0	2.4
NCT0014956548	NCT00149565_48_T2	PHENOTYPE	7	8	cardiac disease
NCT0014956553	NCT00149565_53_T0	GENE	10	10	abdominal
NCT0014956553	NCT00149565_53_T1	GENE	0	0	2.7
NCT0014956553	NCT00149565_53_T2	PHENOTYPE	14	14	recurrent
NCT0014956554	NCT00149565_54_T0	GENE	6	6	abdominal
NCT0014956554	NCT00149565_54_T1	GENE	0	0	2.8
NCT0014956555	NCT00149565_55_T0	PHENOTYPE	8	8	bleeding
NCT0014956555	NCT00149565_55_T1	PHENOTYPE	10	10	dyspepsia
NCT0014956555	NCT00149565_55_T2	GENE	0	0	2.9
NCT0014956557	NCT00149565_57_T0	PHENOTYPE	8	8	symptoms
NCT0014956557	NCT00149565_57_T1	PHENOTYPE	13	14	bony metastases
NCT0014956558	NCT00149565_58_T0	GENE	0	0	2.11
NCT0014956558	NCT00149565_58_T1	ORGAN	1	1	Serum
NCT0014956558	NCT00149565_58_T2	COMPOUND	5	5	HCV
NCT0014956558	NCT00149565_58_T3	PHENOTYPE	3	3	HBV
NCT0014956559	NCT00149565_59_T0	GENE	0	0	2.12
NCT0014956561	NCT00149565_61_T0	GENE	0	0	2.13
NCT0014956562	NCT00149565_62_T0	GENE	0	0	3.0
NCT0014956562	NCT00149565_62_T1	GENE	3	3	3-1
NCT0014956564	NCT00149565_64_T0	GENE	0	0	3/12
NCT0014956565	NCT00149565_65_T0	GENE	0	0	3-2
NCT0014956565	NCT00149565_65_T1	PHENOTYPE	3	4	tumor recurrence
NCT0014956566	NCT00149565_66_T0	GENE	0	0	3.3
NCT0014956567	NCT00149565_67_T0	GENE	0	0	3.4
NCT0014956568	NCT00149565_68_T0	GENE	0	0	3.5
NCT0014956577	NCT00149565_77_T0	PHENOTYPE	6	6	tolerance
NCT0014956580	NCT00149565_80_T0	PHENOTYPE	9	9	recurrence
NCT0014956580	NCT00149565_80_T1	PHENOTYPE	14	14	recurrence
NCT0014956582	NCT00149565_82_T0	GENE	17	17	130
NCT0014956584	NCT00149565_84_T0	GENE	5	5	132
NCT0014956588	NCT00149565_88_T0	GENE	1	1	a1
NCT0014956589	NCT00149565_89_T0	GENE	8	8	Lan
NCT0014956589	NCT00149565_89_T1	GENE	12	12	Li
NCT0014956590	NCT00149565_90_T0	PHENOTYPE	16	16	tumors
NCT0014956591	NCT00149565_91_T0	PHENOTYPE	1	1	toxicity
NCT0014956595	NCT00149565_95_T0	PHENOTYPE	2	3	hepatocellular carcinoma
NCT00149565105	NCT00149565_105_T0	ORGAN	4	4	liver
NCT00149565119	NCT00149565_119_T0	COMPOUND	3	3	HCV
NCT00149565119	NCT00149565_119_T1	PHENOTYPE	1	1	HBV
NCT00149565128	NCT00149565_128_T0	PHENOTYPE	4	4	diseases
NCT00149565130	NCT00149565_130_T0	PHENOTYPE	5	5	malignancy
NCT00149565134	NCT00149565_134_T0	PHENOTYPE	3	4	cardiopulmonary diseases
NCT00149565136	NCT00149565_136_T0	PHENOTYPE	4	5	psychiatric disorder
NCT001495781	NCT00149578_1_T0	GENE	10	10	shifted
NCT001495781	NCT00149578_1_T1	PHENOTYPE	6	7	progressive disease
NCT001495782	NCT00149578_2_T0	GENE	14	14	3.4
NCT001495786	NCT00149578_6_T0	PHENOTYPE	20	20	toxicity
NCT001495786	NCT00149578_6_T1	PHENOTYPE	16	17	disease progression
NCT001495788	NCT00149578_8_T0	COMPOUND	8	8	oxaliplatin
NCT001495788	NCT00149578_8_T1	COMPOUND	7	7	gemcitabine
NCT001495788	NCT00149578_8_T2	COMPOUND	11	11	leucovorin
NCT001495788	NCT00149578_8_T3	PHENOTYPE	1	2	adverse events
NCT0014957810	NCT00149578_10_T0	PHENOTYPE	22	22	malignancy
NCT0014957810	NCT00149578_10_T1	PHENOTYPE	17	17	intent
NCT0014957811	NCT00149578_11_T0	COMPOUND	33	33	oxaliplatin
NCT0014957811	NCT00149578_11_T1	COMPOUND	15	15	gemcitabine
NCT0014957811	NCT00149578_11_T2	COMPOUND	43	43	leucovorin
NCT0014957812	NCT00149578_12_T0	COMPOUND	9	9	dexamethasone
NCT0014957812	NCT00149578_12_T1	COMPOUND	11	11	histamine
NCT0014957813	NCT00149578_13_T0	GENE	0	0	4.2
NCT0014957813	NCT00149578_13_T1	GENE	5	5	G-CSF
NCT0014957813	NCT00149578_13_T2	GENE	7	7	GM-CSF
NCT0014957814	NCT00149578_14_T0	PHENOTYPE	3	4	febrile neutropenia
NCT0014957815	NCT00149578_15_T0	GENE	11	11	4.3
NCT0014957815	NCT00149578_15_T1	GENE	1	1	G-CSF
NCT0014957815	NCT00149578_15_T2	PHENOTYPE	41	42	Disease progression
NCT0014957815	NCT00149578_15_T3	PHENOTYPE	24	25	adverse events
NCT0014957817	NCT00149578_17_T0	PHENOTYPE	9	9	metastasis
NCT0014957817	NCT00149578_17_T1	PHENOTYPE	12	12	progression
NCT0014957817	NCT00149578_17_T2	PHENOTYPE	3	4	progressive disease
NCT0014957818	NCT00149578_18_T0	PHENOTYPE	4	4	remission
NCT0014957818	NCT00149578_18_T1	PHENOTYPE	6	6	remission
NCT0014957818	NCT00149578_18_T2	GENE	21	21	3.4
NCT0014957820	NCT00149578_20_T0	GENE	17	17	RT
NCT0014957822	NCT00149578_22_T0	COMPOUND	8	8	dexamethasone
NCT0014957822	NCT00149578_22_T1	GENE	15	15	tid
NCT0014957823	NCT00149578_23_T0	COMPOUND	2	2	dexamethasone
NCT0014957823	NCT00149578_23_T1	GENE	9	9	had
NCT0014957824	NCT00149578_24_T0	COMPOUND	12	12	dexamethasone
NCT0014957825	NCT00149578_25_T0	COMPOUND	8	8	prochlorperazine
NCT0014957825	NCT00149578_25_T1	PHENOTYPE	17	19	nausea and vomiting
NCT0014957830	NCT00149578_30_T0	PHENOTYPE	0	0	Tumor
NCT0014957832	NCT00149578_32_T0	ORGAN	1	2	spinal cord
NCT0014957833	NCT00149578_33_T0	ORGAN	2	2	kidney
NCT0014957833	NCT00149578_33_T1	ORGAN	16	16	kidney
NCT0014957835	NCT00149578_35_T0	PHENOTYPE	5	5	tumor
NCT0014957835	NCT00149578_35_T1	PHENOTYPE	9	10	primary tumor
NCT0014957836	NCT00149578_36_T0	PHENOTYPE	9	9	tumor
NCT0014957838	NCT00149578_38_T0	GENE	2	2	nodal
NCT0014957840	NCT00149578_40_T0	GENE	0	0	4.5
NCT0014957841	NCT00149578_41_T0	PHENOTYPE	6	6	metastasis
NCT0014957842	NCT00149578_42_T0	GENE	17	17	MRI
NCT0014957842	NCT00149578_42_T1	GENE	14	14	abdominal
NCT0014957845	NCT00149578_45_T0	PHENOTYPE	5	5	tumor
NCT0014957847	NCT00149578_47_T0	GENE	13	13	bypass
NCT0014957847	NCT00149578_47_T1	GENE	12	12	eg
NCT0014957848	NCT00149578_48_T0	PHENOTYPE	30	31	tumor progression
NCT0014957849	NCT00149578_49_T0	GENE	14	14	3.4
NCT0014957850	NCT00149578_50_T0	PHENOTYPE	5	6	disease progression
NCT0014957851	NCT00149578_51_T0	PHENOTYPE	3	4	progressive disease
NCT0014957853	NCT00149578_53_T0	PHENOTYPE	7	9	adenocarcinoma of pancreas
NCT0014957855	NCT00149578_55_T0	PHENOTYPE	5	6	pancreatic cancer
NCT0014957859	NCT00149578_59_T0	PHENOTYPE	7	8	measurable disease
NCT0014957861	NCT00149578_61_T0	GENE	1	1	20
NCT0014957862	NCT00149578_62_T0	GENE	18	18	20
NCT0014957862	NCT00149578_62_T1	PHENOTYPE	4	5	adverse event
NCT0014957864	NCT00149578_64_T0	GENE	3	3	0.2
NCT0014957864	NCT00149578_64_T1	ORGAN	5	5	Appendix
NCT0014957874	NCT00149578_74_T0	PHENOTYPE	3	3	metastases
NCT0014957878	NCT00149578_78_T0	GENE	3	3	had
NCT0014957880	NCT00149578_80_T0	PHENOTYPE	2	3	allergic reactions
NCT0014957882	NCT00149578_82_T0	GENE	5	5	II
NCT0014957882	NCT00149578_82_T1	PHENOTYPE	6	7	peripheral neuropathy
NCT0014957884	NCT00149578_84_T0	PHENOTYPE	6	6	malignancy
NCT0014957884	NCT00149578_84_T1	GENE	2	2	had
NCT0014957888	NCT00149578_88_T0	GENE	11	11	has
NCT0014957888	NCT00149578_88_T1	PHENOTYPE	17	18	abortifacient effects
NCT0014957891	NCT00149578_91_T0	PHENOTYPE	11	11	infections
NCT0014957891	NCT00149578_91_T1	PHENOTYPE	3	4	immune deficiency
NCT001495910	NCT00149591_0_T0	GENE	7	7	The
NCT001495910	NCT00149591_0_T1	PHENOTYPE	4	4	Acute
NCT001495913	NCT00149591_3_T0	PHENOTYPE	15	15	infarction
NCT001495913	NCT00149591_3_T1	PHENOTYPE	14	14	recurrent
NCT001495913	NCT00149591_3_T2	PHENOTYPE	17	18	anginal attacks
NCT001495915	NCT00149591_5_T0	ORGAN	25	25	artery
NCT001495915	NCT00149591_5_T1	PHENOTYPE	24	24	infarct
NCT001495915	NCT00149591_5_T2	PHENOTYPE	14	15	myocardial infarction
NCT001495917	NCT00149591_7_T0	GENE	8	8	viability
NCT001495917	NCT00149591_7_T1	PHENOTYPE	18	20	acute myocardial infarction
NCT001495918	NCT00149591_8_T0	GENE	25	25	viability
NCT001495918	NCT00149591_8_T1	PHENOTYPE	12	14	acute myocardial infarction
NCT001495919	NCT00149591_9_T0	GENE	5	5	viability
NCT0014959110	NCT00149591_10_T0	GENE	14	14	balloon
NCT0014959110	NCT00149591_10_T1	CELL	29	29	platelet
NCT0014959110	NCT00149591_10_T2	PHENOTYPE	20	20	infarct
NCT0014959110	NCT00149591_10_T3	ORGAN	21	22	coronary artery
NCT0014959111	NCT00149591_11_T0	PHENOTYPE	17	17	recurrent
NCT0014959111	NCT00149591_11_T1	PHENOTYPE	18	18	ischemia
NCT0014959111	NCT00149591_11_T2	PHENOTYPE	14	15	impending infarction
NCT0014959112	NCT00149591_12_T0	GENE	4	4	balloon
NCT0014959113	NCT00149591_13_T0	GENE	2	2	viability
NCT001496042	NCT00149604_2_T0	COMPOUND	23	23	estrogen
NCT001496042	NCT00149604_2_T1	COMPOUND	33	33	estrogen
NCT001496042	NCT00149604_2_T2	COMPOUND	7	7	raloxifene
NCT001496042	NCT00149604_2_T3	PHENOTYPE	28	28	osteoporosis
NCT001496042	NCT00149604_2_T4	GENE	10	11	estrogen receptor
NCT001496045	NCT00149604_5_T0	TISSUE	7	8	visceral fat
NCT001496046	NCT00149604_6_T0	COMPOUND	7	7	raloxifene
NCT001496046	NCT00149604_6_T1	GENE	6	6	HT
NCT001496172	NCT00149617_2_T0	PHENOTYPE	13	14	marijuana dependence
NCT001496173	NCT00149617_3_T0	GENE	1	1	has
NCT001496173	NCT00149617_3_T1	PHENOTYPE	9	10	affective disorders
NCT001496173	NCT00149617_3_T2	PHENOTYPE	4	5	marijuana abuse
NCT001496175	NCT00149617_5_T0	PHENOTYPE	14	15	marijuana dependence
NCT001496176	NCT00149617_6_T0	GENE	3	3	has
NCT001496177	NCT00149617_7_T0	COMPOUND	5	5	buspirone
NCT001496177	NCT00149617_7_T1	PHENOTYPE	21	22	marijuana dependence
NCT001496178	NCT00149617_8_T0	COMPOUND	10	10	buspirone
NCT001496178	NCT00149617_8_T1	PHENOTYPE	18	19	marijuana dependence
NCT0014961710	NCT00149617_10_T0	COMPOUND	8	8	buspirone
NCT0014961713	NCT00149617_13_T0	PHENOTYPE	14	14	affects
NCT0014961713	NCT00149617_13_T1	PHENOTYPE	17	18	substance use
NCT0014961714	NCT00149617_14_T0	PHENOTYPE	8	9	withdrawal symptom
NCT0014961716	NCT00149617_16_T0	COMPOUND	8	8	cocaine
NCT0014961719	NCT00149617_19_T0	COMPOUND	20	20	buspirone
NCT0014961719	NCT00149617_19_T1	PHENOTYPE	1	4	perceived quality of life
NCT001496301	NCT00149630_1_T0	COMPOUND	23	23	cocaine
NCT001496301	NCT00149630_1_T1	PHENOTYPE	21	21	discomfort
NCT001496301	NCT00149630_1_T2	COMPOUND	8	8	disulfiram
NCT001496301	NCT00149630_1_T3	GENE	7	7	DBH
NCT001496301	NCT00149630_1_T4	COMPOUND	12	12	dopamine
NCT001496301	NCT00149630_1_T5	GENE	4	6	dopamine beta hydroxylase
NCT001496302	NCT00149630_2_T0	PHENOTYPE	11	11	relapse
NCT001496302	NCT00149630_2_T1	COMPOUND	13	13	cocaine
NCT001496302	NCT00149630_2_T2	COMPOUND	7	7	disulfiram
NCT001496302	NCT00149630_2_T3	GENE	22	22	DBH
NCT001496306	NCT00149630_6_T0	COMPOUND	14	14	cocaine
NCT001496306	NCT00149630_6_T1	COMPOUND	3	3	dopamine
NCT001496307	NCT00149630_7_T0	COMPOUND	2	2	cocaine
NCT001496307	NCT00149630_7_T1	COMPOUND	4	4	dopamine
NCT001496308	NCT00149630_8_T0	COMPOUND	6	6	cocaine
NCT001496308	NCT00149630_8_T1	PHENOTYPE	16	16	discomfort
NCT001496308	NCT00149630_8_T2	COMPOUND	2	2	disulfiram
NCT001496308	NCT00149630_8_T3	COMPOUND	9	9	dopamine
NCT001496309	NCT00149630_9_T0	GENE	0	0	DBH
NCT001496309	NCT00149630_9_T1	COMPOUND	7	7	dopamine
NCT0014963011	NCT00149630_11_T0	COMPOUND	1	1	cocaine
NCT0014963011	NCT00149630_11_T1	GENE	5	5	DBH
NCT0014963012	NCT00149630_12_T0	PHENOTYPE	14	14	relapse
NCT0014963012	NCT00149630_12_T1	COMPOUND	21	21	cocaine
NCT0014963012	NCT00149630_12_T2	COMPOUND	11	11	disulfiram
NCT0014963012	NCT00149630_12_T3	GENE	28	28	DBH
NCT0014963013	NCT00149630_13_T0	COMPOUND	8	8	methadone
NCT0014963014	NCT00149630_14_T0	COMPOUND	16	16	disulfiram
NCT0014963014	NCT00149630_14_T1	COMPOUND	25	25	methadone
NCT0014963015	NCT00149630_15_T0	BIOLOGICAL_PROCESS	19	19	detoxification
NCT0014963015	NCT00149630_15_T1	COMPOUND	18	18	methadone
NCT0014963016	NCT00149630_16_T0	COMPOUND	3	3	cocaine
NCT0014963016	NCT00149630_16_T1	COMPOUND	12	12	cocaine
NCT0014963016	NCT00149630_16_T2	PHENOTYPE	6	7	drug use
NCT0014963018	NCT00149630_18_T0	GENE	1	1	DBH
NCT001496431	NCT00149643_1_T0	PHENOTYPE	15	17	major depressive disorder
NCT001496432	NCT00149643_2_T0	COMPOUND	11	11	fluoxetine
NCT001496432	NCT00149643_2_T1	PHENOTYPE	25	26	marijuana dependence
NCT001496432	NCT00149643_2_T2	PHENOTYPE	21	23	major depressive disorder
NCT001496434	NCT00149643_4_T0	COMPOUND	12	12	fluoxetine
NCT001496437	NCT00149643_7_T0	PHENOTYPE	0	2	Major depressive disorder
NCT001496438	NCT00149643_8_T0	PHENOTYPE	8	9	major depression
NCT001496439	NCT00149643_9_T0	COMPOUND	11	11	fluoxetine
NCT001496439	NCT00149643_9_T1	PHENOTYPE	25	26	marijuana dependence
NCT001496439	NCT00149643_9_T2	PHENOTYPE	21	23	major depressive disorder
NCT0014964310	NCT00149643_10_T0	COMPOUND	12	12	fluoxetine
NCT0014964311	NCT00149643_11_T0	COMPOUND	12	12	fluoxetine
NCT0014964313	NCT00149643_13_T0	COMPOUND	26	26	fluoxetine
NCT0014964314	NCT00149643_14_T0	PHENOTYPE	10	11	depressive symptoms
NCT0014964317	NCT00149643_17_T0	GENE	29	29	aminotransferase
NCT0014964317	NCT00149643_17_T1	PHENOTYPE	19	20	liver enzymes
NCT0014964317	NCT00149643_17_T2	GENE	24	25	Aspartate aminotransferase
NCT0014964318	NCT00149643_18_T0	BIOLOGICAL_PROCESS	7	8	drinking behavior
NCT0014964319	NCT00149643_19_T0	PHENOTYPE	2	2	acute
NCT001496560	NCT00149656_0_T0	PHENOTYPE	9	9	HIV
NCT001496560	NCT00149656_0_T1	PHENOTYPE	6	7	Drug Abuse
NCT001496562	NCT00149656_2_T0	PHENOTYPE	6	7	drug abuse
NCT001496562	NCT00149656_2_T1	PHENOTYPE	15	16	HIV disease
NCT001496562	NCT00149656_2_T2	PHENOTYPE	16	17	disease progression
NCT001496564	NCT00149656_4_T0	GENE	4	4	has
NCT001496564	NCT00149656_4_T1	PHENOTYPE	2	3	drug abuse
NCT001496565	NCT00149656_5_T0	COMPOUND	6	6	selenium
NCT001496565	NCT00149656_5_T1	PHENOTYPE	10	10	progression
NCT001496565	NCT00149656_5_T2	PHENOTYPE	12	13	HIV disease
NCT001496566	NCT00149656_6_T0	COMPOUND	15	15	selenium
NCT001496566	NCT00149656_6_T1	PHENOTYPE	17	17	HIV
NCT001496568	NCT00149656_8_T0	COMPOUND	13	13	selenium
NCT001496568	NCT00149656_8_T1	COMPOUND	16	16	selenium
NCT001496691	NCT00149669_1_T0	COMPOUND	8	8	naltrexone
NCT001496691	NCT00149669_1_T1	BIOLOGICAL_PROCESS	6	6	detoxification
NCT001496692	NCT00149669_2_T0	COMPOUND	4	4	naltrexone
NCT001496693	NCT00149669_3_T0	COMPOUND	13	13	naltrexone
NCT001496695	NCT00149669_5_T0	COMPOUND	10	10	naltrexone
NCT001496695	NCT00149669_5_T1	PHENOTYPE	9	9	ingest
NCT001496697	NCT00149669_7_T0	COMPOUND	17	17	naltrexone
NCT001496697	NCT00149669_7_T1	PHENOTYPE	18	18	ingestion
NCT001496697	NCT00149669_7_T2	PHENOTYPE	38	39	HIV infection
NCT001496698	NCT00149669_8_T0	COMPOUND	19	19	naltrexone
NCT001496698	NCT00149669_8_T1	PHENOTYPE	8	8	ingestion
NCT001496699	NCT00149669_9_T0	COMPOUND	12	12	naltrexone
NCT0014966917	NCT00149669_17_T0	COMPOUND	14	14	naltrexone
NCT0014966917	NCT00149669_17_T1	COMPOUND	28	28	naltrexone
NCT0014966917	NCT00149669_17_T2	PHENOTYPE	17	18	drug use
NCT0014966919	NCT00149669_19_T0	COMPOUND	26	26	nicotine
NCT0014966919	NCT00149669_19_T1	COMPOUND	23	23	cocaine
NCT0014966919	NCT00149669_19_T2	PHENOTYPE	6	6	Severity
NCT0014966919	NCT00149669_19_T3	PHENOTYPE	5	5	Addiction
NCT0014966919	NCT00149669_19_T4	PHENOTYPE	36	37	psychiatric disorders
NCT0014966921	NCT00149669_21_T0	ORGAN	11	11	liver
NCT0014966921	NCT00149669_21_T1	PHENOTYPE	6	7	hepatic damage
NCT0014966922	NCT00149669_22_T0	ORGAN	15	15	liver
NCT0014966922	NCT00149669_22_T1	GENE	17	17	aminotransferase
NCT0014966923	NCT00149669_23_T0	GENE	23	23	aminotransferase
NCT0014966926	NCT00149669_26_T0	COMPOUND	13	13	cocaine
NCT0014966926	NCT00149669_26_T1	COMPOUND	14	14	benzoylecgonine
NCT0014966926	NCT00149669_26_T2	COMPOUND	10	10	morphine
NCT0014966927	NCT00149669_27_T0	COMPOUND	16	16	naltrexone
NCT0014966927	NCT00149669_27_T1	COMPOUND	11	11	buprenorphine
NCT0014966927	NCT00149669_27_T2	COMPOUND	13	13	amphetamine
NCT0014966927	NCT00149669_27_T3	COMPOUND	12	12	methadone
NCT0014966928	NCT00149669_28_T0	COMPOUND	5	5	naltrexone
NCT0014966928	NCT00149669_28_T1	COMPOUND	20	20	naltrexone
NCT0014966928	NCT00149669_28_T2	GENE	23	23	MD
NCT0014966930	NCT00149669_30_T0	PHENOTYPE	9	10	adverse events
NCT0014966931	NCT00149669_31_T0	PHENOTYPE	12	13	adverse event
NCT0014966932	NCT00149669_32_T0	PHENOTYPE	11	12	adverse event
NCT0014966932	NCT00149669_32_T1	PHENOTYPE	3	4	adverse events
NCT0014966933	NCT00149669_33_T0	PHENOTYPE	8	9	adverse events
NCT0014966933	NCT00149669_33_T1	PHENOTYPE	18	19	adverse events
NCT0014966935	NCT00149669_35_T0	COMPOUND	22	22	naltrexone
NCT0014966935	NCT00149669_35_T1	BIOLOGICAL_PROCESS	9	9	detoxification
NCT0014966936	NCT00149669_36_T0	COMPOUND	4	4	naltrexone
NCT0014966936	NCT00149669_36_T1	BIOLOGICAL_PROCESS	2	2	detoxification
NCT0014966937	NCT00149669_37_T0	PHENOTYPE	11	11	overdose
NCT0014966937	NCT00149669_37_T1	COMPOUND	15	15	naltrexone
NCT0014966937	NCT00149669_37_T2	GENE	19	19	extended
NCT0014966938	NCT00149669_38_T0	COMPOUND	25	25	naltrexone
NCT0014966939	NCT00149669_39_T0	PHENOTYPE	0	0	Overdose
NCT0014966940	NCT00149669_40_T0	PHENOTYPE	3	3	overdose
NCT0014966941	NCT00149669_41_T0	COMPOUND	14	14	naltrexone
NCT0014966941	NCT00149669_41_T1	PHENOTYPE	9	9	ingest
NCT0014966942	NCT00149669_42_T0	COMPOUND	3	3	naltrexone
NCT0014966943	NCT00149669_43_T0	COMPOUND	28	28	naltrexone
NCT0014966944	NCT00149669_44_T0	PHENOTYPE	7	8	drug abuse
NCT0014966945	NCT00149669_45_T0	COMPOUND	33	33	1
NCT0014966945	NCT00149669_45_T1	GENE	14	14	1.1
NCT0014966947	NCT00149669_47_T0	COMPOUND	23	23	naltrexone
NCT0014966947	NCT00149669_47_T1	PHENOTYPE	22	22	ingest
NCT0014966952	NCT00149669_52_T0	COMPOUND	10	10	naltrexone
NCT0014966952	NCT00149669_52_T1	COMPOUND	23	23	naltrexone
NCT0014966952	NCT00149669_52_T2	PHENOTYPE	24	24	ingestion
NCT0014966953	NCT00149669_53_T0	COMPOUND	7	7	naltrexone
NCT0014966953	NCT00149669_53_T1	PHENOTYPE	5	5	ingest
NCT0014966954	NCT00149669_54_T0	COMPOUND	5	5	naltrexone
NCT0014966954	NCT00149669_54_T1	COMPOUND	20	20	naltrexone
NCT001496822	NCT00149682_2_T0	GENE	9	9	has
NCT001496823	NCT00149682_3_T0	PHENOTYPE	22	23	behavioral changes
NCT001496824	NCT00149682_4_T0	PHENOTYPE	8	8	overweight
NCT001496952	NCT00149695_2_T0	PHENOTYPE	11	12	pediatric obesity
NCT001496953	NCT00149695_3_T0	GENE	3	3	has
NCT001497082	NCT00149708_2_T0	GENE	12	12	had
NCT001497082	NCT00149708_2_T1	PHENOTYPE	15	16	pituitary diseases
NCT001497085	NCT00149708_5_T0	GENE	2	2	GH
NCT001497085	NCT00149708_5_T1	GENE	4	4	IGHD
NCT001497085	NCT00149708_5_T2	PHENOTYPE	7	8	rare disease
NCT001497086	NCT00149708_6_T0	GENE	18	18	GH
NCT001497086	NCT00149708_6_T1	GENE	12	12	IGHD
NCT001497087	NCT00149708_7_T0	PHENOTYPE	17	17	mutation
NCT001497087	NCT00149708_7_T1	GENE	21	21	GHRHR
NCT001497087	NCT00149708_7_T2	GENE	12	12	IGHD
NCT001497089	NCT00149708_9_T0	GENE	15	15	GH
NCT0014970810	NCT00149708_10_T0	PHENOTYPE	15	15	mutation
NCT0014970811	NCT00149708_11_T0	GENE	15	15	GH
NCT0014970811	NCT00149708_11_T1	GENE	47	47	GH
NCT0014970811	NCT00149708_11_T2	ORGAN	26	26	thyroid
NCT0014970811	NCT00149708_11_T3	BIOLOGICAL_PROCESS	32	32	metabolism
NCT0014970812	NCT00149708_12_T0	PHENOTYPE	13	13	mutation
NCT0014970812	NCT00149708_12_T1	GENE	12	12	GHRHR
NCT0014970813	NCT00149708_13_T0	GENE	8	8	GHRHR
NCT0014970813	NCT00149708_13_T1	GENE	27	27	GHRHR
NCT0014970815	NCT00149708_15_T0	COMPOUND	2	2	2
NCT0014970815	NCT00149708_15_T1	GENE	1	1	AIM
NCT0014970816	NCT00149708_16_T0	PHENOTYPE	11	11	mutation
NCT0014970816	NCT00149708_16_T1	GENE	10	10	GHRHR
NCT0014970816	NCT00149708_16_T2	COMPOUND	2	2	3
NCT0014970816	NCT00149708_16_T3	GENE	1	1	AIM
NCT0014970817	NCT00149708_17_T0	GENE	34	34	GHRHR
NCT0014970817	NCT00149708_17_T1	PHENOTYPE	35	35	mutation
NCT0014970818	NCT00149708_18_T0	GENE	31	31	GHRHR
NCT0014970818	NCT00149708_18_T1	GENE	11	11	GH
NCT001497211	NCT00149721_1_T0	GENE	10	10	ICP
NCT001497211	NCT00149721_1_T1	PHENOTYPE	23	23	hypopituitarism
NCT001497211	NCT00149721_1_T2	GENE	17	17	axis
NCT001497212	NCT00149721_2_T0	PHENOTYPE	16	16	hydrocephalus
NCT001497212	NCT00149721_2_T1	PHENOTYPE	11	11	hypopituitarism
NCT001497214	NCT00149721_4_T0	GENE	23	23	Dr
NCT001497214	NCT00149721_4_T1	GENE	28	28	Dr
NCT001497215	NCT00149721_5_T0	PHENOTYPE	11	11	hydrocephalus
NCT001497216	NCT00149721_6_T0	PHENOTYPE	33	34	pituitary failure
NCT001497218	NCT00149721_8_T0	PHENOTYPE	15	15	Hydrocephalus
NCT001497219	NCT00149721_9_T0	PHENOTYPE	2	2	hydrocephalus
NCT0014972111	NCT00149721_11_T0	PHENOTYPE	22	22	libido
NCT0014972114	NCT00149721_14_T0	GENE	10	10	T4
NCT0014972114	NCT00149721_14_T1	GENE	14	14	GH
NCT0014972114	NCT00149721_14_T2	GENE	16	16	prolactin
NCT0014972114	NCT00149721_14_T3	COMPOUND	24	24	testosterone
NCT0014972114	NCT00149721_14_T4	GENE	11	11	FT4
NCT0014972114	NCT00149721_14_T5	GENE	12	12	TSH
NCT0014972114	NCT00149721_14_T6	COMPOUND	13	13	cortisol
NCT0014972114	NCT00149721_14_T7	GENE	18	18	FSH
NCT0014972114	NCT00149721_14_T8	ORGAN	8	8	serum
NCT0014972114	NCT00149721_14_T9	GENE	15	15	IGF-1
NCT0014972115	NCT00149721_15_T0	BIOLOGICAL_PROCESS	6	7	follicular phase
NCT0014972116	NCT00149721_16_T0	COMPOUND	2	2	testosterone
NCT0014972116	NCT00149721_16_T1	ORGAN	0	0	Serum
NCT0014972116	NCT00149721_16_T2	GENE	1	1	IGF-1
NCT0014972116	NCT00149721_16_T3	COMPOUND	3	3	estradiol
NCT0014972118	NCT00149721_18_T0	GENE	4	4	GH
NCT0014972118	NCT00149721_18_T1	COMPOUND	15	15	arginine
NCT0014972118	NCT00149721_18_T2	GENE	23	23	gm
NCT0014972118	NCT00149721_18_T3	GENE	10	10	GHRH
NCT0014972118	NCT00149721_18_T4	GENE	16	16	0.5
NCT0014972118	NCT00149721_18_T5	GENE	19	19	30
NCT0014972118	NCT00149721_18_T6	GENE	22	22	30
NCT0014972119	NCT00149721_19_T0	GENE	13	13	GHRH
NCT0014972119	NCT00149721_19_T1	GENE	8	8	90
NCT0014972119	NCT00149721_19_T2	GENE	7	7	60
NCT0014972119	NCT00149721_19_T3	GENE	6	6	30
NCT0014972119	NCT00149721_19_T4	GENE	10	10	120
NCT0014972120	NCT00149721_20_T0	GENE	11	11	GH
NCT0014972122	NCT00149721_22_T0	COMPOUND	3	3	arginine
NCT0014972122	NCT00149721_22_T1	PHENOTYPE	19	19	itching
NCT0014972122	NCT00149721_22_T2	GENE	1	1	GHRH
NCT0014972122	NCT00149721_22_T3	GENE	15	15	GHRH
NCT0014972122	NCT00149721_22_T4	PHENOTYPE	21	21	flushing
NCT0014972124	NCT00149721_24_T0	COMPOUND	2	2	cortisol
NCT0014972124	NCT00149721_24_T1	PHENOTYPE	11	12	adrenal insufficiency
NCT0014972126	NCT00149721_26_T0	COMPOUND	2	2	cortisol
NCT0014972126	NCT00149721_26_T1	GENE	21	21	ACTH
NCT0014972126	NCT00149721_26_T2	ORGAN	1	1	serum
NCT0014972127	NCT00149721_27_T0	COMPOUND	3	3	cortisol
NCT0014972127	NCT00149721_27_T1	GENE	14	14	ACTH
NCT0014972127	NCT00149721_27_T2	ORGAN	2	2	serum
NCT0014972127	NCT00149721_27_T3	GENE	12	12	30
NCT0014972131	NCT00149721_31_T0	PHENOTYPE	22	22	dementia
NCT0014972133	NCT00149721_33_T0	PHENOTYPE	25	25	suppression
NCT0014972133	NCT00149721_33_T1	GENE	28	28	axis
NCT0014972133	NCT00149721_33_T2	GENE	7	7	GC
NCT0014972133	NCT00149721_33_T3	GENE	22	22	GC
NCT0014972134	NCT00149721_34_T0	GENE	7	7	T4
NCT0014972134	NCT00149721_34_T1	GENE	21	21	T4
NCT0014972134	NCT00149721_34_T2	COMPOUND	5	5	phenytoin
NCT0014972134	NCT00149721_34_T3	COMPOUND	15	15	phenytoin
NCT001497342	NCT00149734_2_T0	GENE	1	1	atypical
NCT001497342	NCT00149734_2_T1	COMPOUND	6	6	aripiprazole
NCT001497344	NCT00149734_4_T0	PHENOTYPE	3	3	schizophrenia
NCT001497347	NCT00149734_7_T0	COMPOUND	3	3	ondansetron
NCT001497347	NCT00149734_7_T1	GENE	12	12	P50
NCT001497348	NCT00149734_8_T0	COMPOUND	1	1	ondansetron
NCT001497348	NCT00149734_8_T1	GENE	11	11	atypical
NCT001497348	NCT00149734_8_T2	GENE	2	2	has
NCT001497349	NCT00149734_9_T0	COMPOUND	8	8	ondansetron
NCT001497349	NCT00149734_9_T1	GENE	11	11	atypical
NCT001497349	NCT00149734_9_T2	GENE	15	15	P50
NCT0014973410	NCT00149734_10_T0	COMPOUND	12	12	ondansetron
NCT0014973412	NCT00149734_12_T0	COMPOUND	10	10	olanzapine
NCT0014973412	NCT00149734_12_T1	GENE	6	6	atypical
NCT0014973412	NCT00149734_12_T2	COMPOUND	11	11	quetiapine
NCT0014973412	NCT00149734_12_T3	COMPOUND	13	13	aripiprazole
NCT0014973415	NCT00149734_15_T0	PHENOTYPE	1	1	symptoms
NCT0014973415	NCT00149734_15_T1	COMPOUND	14	14	ondansetron
NCT001497474	NCT00149747_4_T0	PHENOTYPE	11	12	psychiatric disorders
NCT001497476	NCT00149747_6_T0	PHENOTYPE	19	20	difficulty sleeping
NCT0014974712	NCT00149747_12_T0	PHENOTYPE	5	7	quality of life
NCT001497603	NCT00149760_3_T0	PHENOTYPE	6	6	impairment
NCT001497605	NCT00149760_5_T0	PHENOTYPE	12	12	strategies
NCT001497605	NCT00149760_5_T1	PHENOTYPE	2	3	somatization disorder
NCT001497606	NCT00149760_6_T0	GENE	6	6	has
NCT001497607	NCT00149760_7_T0	PHENOTYPE	13	14	physical symptoms
NCT001497607	NCT00149760_7_T1	PHENOTYPE	23	24	somatization disorder
NCT0014976010	NCT00149760_10_T0	PHENOTYPE	5	5	impairment
NCT001497732	NCT00149773_2_T0	PHENOTYPE	23	24	depressive illness
NCT001497733	NCT00149773_3_T0	PHENOTYPE	11	11	focused
NCT001497733	NCT00149773_3_T1	PHENOTYPE	7	7	ideation
NCT001497733	NCT00149773_3_T2	GENE	10	10	has
NCT001497737	NCT00149773_7_T0	PHENOTYPE	12	12	ideation
NCT0014977310	NCT00149773_10_T0	PHENOTYPE	13	13	hopelessness
NCT0014977310	NCT00149773_10_T1	PHENOTYPE	12	12	ideation
NCT0014977311	NCT00149773_11_T0	PHENOTYPE	18	18	ideation
NCT001497863	NCT00149786_3_T0	PHENOTYPE	12	12	focused
NCT001497863	NCT00149786_3_T1	PHENOTYPE	7	8	anorexia nervosa
NCT001497864	NCT00149786_4_T0	PHENOTYPE	10	11	anorexia nervosa
NCT001497865	NCT00149786_5_T0	PHENOTYPE	18	19	anorexia nervosa
NCT001497866	NCT00149786_6_T0	PHENOTYPE	10	11	weight gain
NCT0014978610	NCT00149786_10_T0	PHENOTYPE	20	21	Eating Disorder
NCT0014978610	NCT00149786_10_T1	PHENOTYPE	2	3	weight gain
NCT001497993	NCT00149799_3_T0	PHENOTYPE	0	0	BDD
NCT001497993	NCT00149799_3_T1	PHENOTYPE	18	20	body image disorder
NCT001497994	NCT00149799_4_T0	PHENOTYPE	8	8	impairment
NCT001497994	NCT00149799_4_T1	PHENOTYPE	12	14	quality of life
NCT001497995	NCT00149799_5_T0	PHENOTYPE	11	11	BDD
NCT001497995	NCT00149799_5_T1	PHENOTYPE	15	15	BDD
NCT001497996	NCT00149799_6_T0	GENE	9	9	SRI
NCT001497997	NCT00149799_7_T0	PHENOTYPE	2	2	relapse
NCT001497998	NCT00149799_8_T0	PHENOTYPE	13	13	BDD
NCT001497998	NCT00149799_8_T1	PHENOTYPE	18	18	chronic
NCT001497999	NCT00149799_9_T0	PHENOTYPE	10	10	relapse
NCT001497999	NCT00149799_9_T1	PHENOTYPE	20	20	relapse
NCT001497999	NCT00149799_9_T2	GENE	12	12	SRI
NCT001497999	NCT00149799_9_T3	GENE	17	17	SRI
NCT0014979910	NCT00149799_10_T0	COMPOUND	12	12	escitalopram
NCT0014979910	NCT00149799_10_T1	COMPOUND	14	14	escitalopram
NCT0014979910	NCT00149799_10_T2	COMPOUND	25	25	escitalopram
NCT0014979911	NCT00149799_11_T0	PHENOTYPE	15	15	acute
NCT0014979911	NCT00149799_11_T1	PHENOTYPE	8	8	relapse
NCT0014979911	NCT00149799_11_T2	PHENOTYPE	10	10	relapse
NCT0014979911	NCT00149799_11_T3	COMPOUND	16	16	escitalopram
NCT0014979911	NCT00149799_11_T4	COMPOUND	27	27	escitalopram
NCT0014979912	NCT00149799_12_T0	PHENOTYPE	14	14	secondary
NCT0014979912	NCT00149799_12_T1	PHENOTYPE	28	28	symptoms
NCT0014979912	NCT00149799_12_T2	PHENOTYPE	39	39	Acute
NCT0014979912	NCT00149799_12_T3	COMPOUND	10	10	escitalopram
NCT0014979912	NCT00149799_12_T4	COMPOUND	32	32	escitalopram
NCT0014979912	NCT00149799_12_T5	PHENOTYPE	18	20	quality of life
NCT0014979913	NCT00149799_13_T0	PHENOTYPE	12	12	BDD
NCT0014979913	NCT00149799_13_T1	PHENOTYPE	21	21	BDD
NCT0014979913	NCT00149799_13_T2	PHENOTYPE	8	8	relapse
NCT0014979914	NCT00149799_14_T0	PHENOTYPE	24	24	symptoms
NCT0014979914	NCT00149799_14_T1	PHENOTYPE	7	7	relapse
NCT0014979914	NCT00149799_14_T2	PHENOTYPE	20	20	relapse
NCT0014979914	NCT00149799_14_T3	GENE	14	14	SRI
NCT001498126	NCT00149812_6_T0	PHENOTYPE	6	7	mental health
NCT001498126	NCT00149812_6_T1	PHENOTYPE	23	24	depressive episode
NCT001498253	NCT00149825_3_T0	PHENOTYPE	17	17	recurrence
NCT001498253	NCT00149825_3_T1	PHENOTYPE	4	4	insomnia
NCT001498254	NCT00149825_4_T0	PHENOTYPE	12	12	symptoms
NCT001498254	NCT00149825_4_T1	PHENOTYPE	14	14	insomnia
NCT001498254	NCT00149825_4_T2	PHENOTYPE	8	10	major depressive disorder
NCT001498255	NCT00149825_5_T0	PHENOTYPE	16	17	sleep difficulties
NCT001498256	NCT00149825_6_T0	PHENOTYPE	20	20	insomnia
NCT001498257	NCT00149825_7_T0	COMPOUND	5	5	escitalopram
NCT001498257	NCT00149825_7_T1	COMPOUND	6	6	oxalate
NCT001498259	NCT00149825_9_T0	PHENOTYPE	1	1	severity
NCT001498259	NCT00149825_9_T1	PHENOTYPE	6	6	insomnia
NCT001498386	NCT00149838_6_T0	GENE	10	10	has
NCT001498386	NCT00149838_6_T1	PHENOTYPE	15	17	symptoms of depression
NCT001498389	NCT00149838_9_T0	GENE	1	1	has
NCT001498389	NCT00149838_9_T1	COMPOUND	0	0	rTMS
NCT0014983811	NCT00149838_11_T0	COMPOUND	9	9	rTMS
NCT0014983813	NCT00149838_13_T0	COMPOUND	11	11	rTMS
NCT0014983817	NCT00149838_17_T0	GENE	2	2	II
NCT0014983817	NCT00149838_17_T1	COMPOUND	14	14	rTMS
NCT0014983819	NCT00149838_19_T0	ORGAN	21	21	skull
NCT0014983819	NCT00149838_19_T1	PHENOTYPE	16	17	individual differences
NCT0014983820	NCT00149838_20_T0	PHENOTYPE	9	9	remission
NCT0014983820	NCT00149838_20_T1	GENE	1	1	III
NCT0014983822	NCT00149838_22_T0	PHENOTYPE	4	6	symptoms of depression
NCT001498511	NCT00149851_1_T0	ORGAN	7	7	esophagus
NCT001498511	NCT00149851_1_T1	ORGAN	16	16	esophagus
NCT001498512	NCT00149851_2_T0	PHENOTYPE	1	1	symptoms
NCT001498512	NCT00149851_2_T1	PHENOTYPE	26	26	symptoms
NCT001498512	NCT00149851_2_T2	PHENOTYPE	3	3	GERD
NCT001498512	NCT00149851_2_T3	COMPOUND	20	20	omeprazole
NCT001498512	NCT00149851_2_T4	PHENOTYPE	8	8	regurgitation
NCT001498512	NCT00149851_2_T5	PHENOTYPE	5	5	heartburn
NCT001498512	NCT00149851_2_T6	PHENOTYPE	28	28	heartburn
NCT001498640	NCT00149864_0_T0	COMPOUND	7	7	Sodium
NCT001498642	NCT00149864_2_T0	COMPOUND	14	14	sodium
NCT001498642	NCT00149864_2_T1	COMPOUND	25	25	sodium
NCT001498642	NCT00149864_2_T2	COMPOUND	32	32	sodium
NCT001498770	NCT00149877_0_T0	PHENOTYPE	9	10	Chronic Constipation
NCT001498772	NCT00149877_2_T0	GENE	21	21	CC
NCT001498772	NCT00149877_2_T1	GENE	16	16	bowel
NCT001498772	NCT00149877_2_T2	COMPOUND	14	14	tegaserod
NCT001498901	NCT00149890_1_T0	COMPOUND	27	27	cyclosporine
NCT001498901	NCT00149890_1_T1	GENE	32	32	de
NCT001498901	NCT00149890_1_T2	ORGAN	34	34	liver
NCT001498901	NCT00149890_1_T3	ORGAN	35	35	transplant
NCT001498901	NCT00149890_1_T4	PHENOTYPE	11	12	systemic infections
NCT001499160	NCT00149916_0_T0	COMPOUND	7	7	Sodium
NCT001499162	NCT00149916_2_T0	COMPOUND	15	15	sodium
NCT001499290	NCT00149929_0_T0	COMPOUND	7	7	Sodium
NCT001499292	NCT00149929_2_T0	COMPOUND	14	14	sodium
NCT001499292	NCT00149929_2_T1	COMPOUND	25	25	sodium
NCT001499292	NCT00149929_2_T2	COMPOUND	33	33	sodium
NCT001499420	NCT00149942_0_T0	GENE	18	18	GI
NCT001499420	NCT00149942_0_T1	COMPOUND	9	9	Sodium
NCT001499420	NCT00149942_0_T2	PHENOTYPE	15	15	Suffering
NCT001499420	NCT00149942_0_T3	PHENOTYPE	19	20	Adverse Events
NCT001499941	NCT00149994_1_T0	COMPOUND	12	12	cyclosporine
NCT001499941	NCT00149994_1_T1	COMPOUND	24	24	tacrolimus
NCT001500200	NCT00150020_0_T0	GENE	13	13	GI
NCT001500200	NCT00150020_0_T1	COMPOUND	6	6	Sodium
NCT001500200	NCT00150020_0_T2	ORGAN	10	10	Transplant
NCT001500205	NCT00150020_5_T0	PHENOTYPE	4	4	secondary
NCT001500205	NCT00150020_5_T1	ORGAN	11	11	kidney
NCT001500205	NCT00150020_5_T2	ORGAN	12	12	transplant
NCT001500209	NCT00150020_9_T0	COMPOUND	8	8	cyclosporine
NCT001500209	NCT00150020_9_T1	COMPOUND	13	13	cyclosporine
NCT001500209	NCT00150020_9_T2	GENE	14	14	USP
NCT001500209	NCT00150020_9_T3	COMPOUND	17	17	tacrolimus
NCT0015002013	NCT00150020_13_T0	PHENOTYPE	16	16	secondary
NCT0015002013	NCT00150020_13_T1	ORGAN	3	3	kidney
NCT0015002013	NCT00150020_13_T2	ORGAN	15	15	kidney
NCT0015002013	NCT00150020_13_T3	ORGAN	17	17	kidney
NCT0015002013	NCT00150020_13_T4	ORGAN	5	5	pancreas
NCT0015002013	NCT00150020_13_T5	ORGAN	8	8	transplant
NCT0015002013	NCT00150020_13_T6	ORGAN	18	18	transplant
NCT0015002015	NCT00150020_15_T0	PHENOTYPE	6	6	acute
NCT0015002015	NCT00150020_15_T1	ORGAN	2	2	graft
NCT001500331	NCT00150033_1_T0	PHENOTYPE	7	7	enlargement
NCT001500331	NCT00150033_1_T1	PHENOTYPE	8	8	goitre
NCT001500332	NCT00150033_2_T0	PHENOTYPE	4	4	suspicion
NCT001500332	NCT00150033_2_T1	GENE	14	14	reduced
NCT001500332	NCT00150033_2_T2	PHENOTYPE	8	9	life quality
NCT001500333	NCT00150033_3_T0	PHENOTYPE	10	12	quality of life
NCT001500334	NCT00150033_4_T0	PHENOTYPE	6	7	thyroid disease
NCT001500336	NCT00150033_6_T0	PHENOTYPE	4	6	quality of life
NCT001500337	NCT00150033_7_T0	PHENOTYPE	15	15	suffering
NCT001500337	NCT00150033_7_T1	PHENOTYPE	17	18	thyroid diseases
NCT001500337	NCT00150033_7_T2	PHENOTYPE	10	12	quality of life
NCT0015003311	NCT00150033_11_T0	GENE	15	15	structural
NCT001500464	NCT00150046_4_T0	ORGAN	9	10	organ transplants
NCT001500464	NCT00150046_4_T1	ORGAN	15	16	organ transplants
NCT001500468	NCT00150046_8_T0	GENE	5	5	ABO
NCT001500468	NCT00150046_8_T1	ORGAN	7	7	transplants
NCT001500468	NCT00150046_8_T2	PHENOTYPE	10	11	platelet count
NCT0015004610	NCT00150046_10_T0	PHENOTYPE	0	1	Laboratory results
NCT001500590	NCT00150059_0_T0	PHENOTYPE	15	15	Mild
NCT001500590	NCT00150059_0_T1	PHENOTYPE	18	19	Atopic Dermatitis
NCT001500722	NCT00150072_2_T0	PHENOTYPE	4	4	tumour
NCT001500722	NCT00150072_2_T1	PHENOTYPE	23	24	solid tumors
NCT001500724	NCT00150072_4_T0	PHENOTYPE	3	3	chordoma
NCT001500726	NCT00150072_6_T0	GENE	13	13	PDGFB
NCT001500726	NCT00150072_6_T1	COMPOUND	6	6	mesylate
NCT001500728	NCT00150072_8_T0	GENE	47	47	Blot
NCT0015007210	NCT00150072_10_T0	PHENOTYPE	9	9	centers
NCT0015007212	NCT00150072_12_T0	PHENOTYPE	2	3	evaluable disease
NCT0015007213	NCT00150072_13_T0	PHENOTYPE	3	4	local disease
NCT0015007213	NCT00150072_13_T1	PHENOTYPE	27	28	metastatic disease
NCT0015007216	NCT00150072_16_T0	GENE	10	10	8-1
NCT0015007220	NCT00150072_20_T0	GENE	13	13	100
NCT0015007220	NCT00150072_20_T1	GENE	8	8	ANC
NCT0015007220	NCT00150072_20_T2	GENE	9	9	1.5
NCT0015007220	NCT00150072_20_T3	GENE	16	16	Hb
NCT0015007220	NCT00150072_20_T4	CELL	12	12	platelets
NCT0015007220	NCT00150072_20_T5	ORGAN	1	2	bone marrow
NCT0015007221	NCT00150072_21_T0	GENE	9	9	Hb
NCT0015007223	NCT00150072_23_T0	PHENOTYPE	14	14	initiation
NCT0015007223	NCT00150072_23_T1	PHENOTYPE	7	9	negative pregnancy test
NCT0015007224	NCT00150072_24_T0	PHENOTYPE	1	1	menopausal
NCT0015007233	NCT00150072_33_T0	ORGAN	10	10	Heart
NCT0015007233	NCT00150072_33_T1	PHENOTYPE	17	18	myocardial infarction
NCT0015007233	NCT00150072_33_T2	PHENOTYPE	14	16	congestive heart failure
NCT0015007236	NCT00150072_36_T0	PHENOTYPE	1	2	brain metastasis
NCT0015007238	NCT00150072_38_T0	PHENOTYPE	9	9	cirrhosis
NCT0015007238	NCT00150072_38_T1	PHENOTYPE	1	3	chronic liver disease
NCT0015007238	NCT00150072_38_T2	PHENOTYPE	5	7	chronic active hepatitis
NCT0015007242	NCT00150072_42_T0	ORGAN	7	8	bone marrow
NCT001500852	NCT00150085_2_T0	COMPOUND	15	15	cyclosporine
NCT001500852	NCT00150085_2_T1	ORGAN	22	22	kidney
NCT001500852	NCT00150085_2_T2	ORGAN	24	24	liver
NCT001500852	NCT00150085_2_T3	COMPOUND	13	13	tacrolimus
NCT001500981	NCT00150098_1_T0	PHENOTYPE	22	22	HIV
NCT001500983	NCT00150098_3_T0	PHENOTYPE	7	7	HIV
NCT001500983	NCT00150098_3_T1	PHENOTYPE	16	16	HIV
NCT001500983	NCT00150098_3_T2	PHENOTYPE	9	9	HBV
NCT001500983	NCT00150098_3_T3	PHENOTYPE	23	23	HBV
NCT001500983	NCT00150098_3_T4	PHENOTYPE	20	21	hepatitis B
NCT001500984	NCT00150098_4_T0	PHENOTYPE	18	18	HIV
NCT001500986	NCT00150098_6_T0	PHENOTYPE	7	7	HBV
NCT001500986	NCT00150098_6_T1	PHENOTYPE	5	5	susceptible
NCT001500986	NCT00150098_6_T2	PHENOTYPE	10	11	hepatitis B
NCT001500989	NCT00150098_9_T0	GENE	2	2	sera
NCT001500989	NCT00150098_9_T1	PHENOTYPE	4	4	HIV
NCT0015009812	NCT00150098_12_T0	PHENOTYPE	2	2	HIV
NCT0015009815	NCT00150098_15_T0	PHENOTYPE	11	11	Centers
NCT0015009815	NCT00150098_15_T1	PHENOTYPE	6	6	HIV
NCT001501112	NCT00150111_2_T0	GENE	4	4	IgG1
NCT001501112	NCT00150111_2_T1	GENE	5	5	kappa
NCT001501112	NCT00150111_2_T2	GENE	17	18	constant region
NCT001501112	NCT00150111_2_T3	GENE	10	13	heavy chain variable region
NCT001501113	NCT00150111_3_T0	CELL	11	12	B lymphocytes
NCT001501113	NCT00150111_3_T1	GENE	8	9	CD20 antigen
NCT001501115	NCT00150111_5_T0	PHENOTYPE	9	9	autoimmune
NCT001501115	NCT00150111_5_T1	PHENOTYPE	10	10	cytopenias
NCT001501116	NCT00150111_6_T0	PHENOTYPE	3	3	peripheral
NCT001501116	NCT00150111_6_T1	CELL	5	6	B cells
NCT001501117	NCT00150111_7_T0	GENE	7	7	CD20
NCT001501117	NCT00150111_7_T1	CELL	25	25	cells
NCT001501117	NCT00150111_7_T2	CELL	13	13	macrophage
NCT001501117	NCT00150111_7_T3	GENE	2	2	has
NCT001501117	NCT00150111_7_T4	CELL	21	22	blood cells
NCT001501117	NCT00150111_7_T5	CELL	8	9	B cells
NCT001501118	NCT00150111_8_T0	CELL	5	5	clones
NCT001501118	NCT00150111_8_T1	CELL	4	4	B-cell
NCT001501118	NCT00150111_8_T2	PHENOTYPE	0	0	Suppression
NCT0015011113	NCT00150111_13_T0	PHENOTYPE	20	20	hyperthyroidism
NCT0015011113	NCT00150111_13_T1	ORGAN	1	1	thyroid
NCT0015011113	NCT00150111_13_T2	ORGAN	4	4	thyroid
NCT0015011113	NCT00150111_13_T3	ORGAN	11	11	thyroid
NCT0015011113	NCT00150111_13_T4	PHENOTYPE	6	6	hypertrophy
NCT0015011113	NCT00150111_13_T5	PHENOTYPE	8	8	hyperplasia
NCT0015011113	NCT00150111_13_T6	PHENOTYPE	15	16	diffuse goiter
NCT0015011114	NCT00150111_14_T0	ORGAN	3	3	thyroid
NCT0015011114	NCT00150111_14_T1	GENE	6	6	thyroglobulin
NCT0015011114	NCT00150111_14_T2	GENE	8	9	thyroid peroxidase
NCT0015011117	NCT00150111_17_T0	COMPOUND	9	9	iodine
NCT0015011118	NCT00150111_18_T0	PHENOTYPE	7	8	adverse effects
NCT0015011119	NCT00150111_19_T0	PHENOTYPE	3	3	complication
NCT0015011119	NCT00150111_19_T1	PHENOTYPE	18	18	vasculitis
NCT0015011119	NCT00150111_19_T2	PHENOTYPE	8	8	agranulocytosis
NCT0015011119	NCT00150111_19_T3	PHENOTYPE	15	16	cholestatic hepatitis
NCT0015011119	NCT00150111_19_T4	PHENOTYPE	12	14	acute hepatic necrosis
NCT0015011120	NCT00150111_20_T0	PHENOTYPE	10	10	ophthalmopathy
NCT0015011120	NCT00150111_20_T1	COMPOUND	5	5	iodine
NCT0015011121	NCT00150111_21_T0	PHENOTYPE	7	7	hypothyroidism
NCT0015011123	NCT00150111_23_T0	GENE	7	7	II
NCT0015011124	NCT00150111_24_T0	GENE	10	10	T4
NCT0015011124	NCT00150111_24_T1	GENE	16	16	TPO
NCT0015011124	NCT00150111_24_T2	GENE	13	13	TSH
NCT0015011124	NCT00150111_24_T3	COMPOUND	33	33	methimazole
NCT0015011124	NCT00150111_24_T4	GENE	12	12	T3
NCT0015011127	NCT00150111_27_T0	GENE	26	26	T4
NCT0015011127	NCT00150111_27_T1	PHENOTYPE	4	4	relapse
NCT0015011127	NCT00150111_27_T2	PHENOTYPE	18	18	relapse
NCT0015011127	NCT00150111_27_T3	GENE	29	29	TSH
NCT0015011127	NCT00150111_27_T4	GENE	32	32	TPO
NCT0015011127	NCT00150111_27_T5	PHENOTYPE	5	5	remission
NCT0015011127	NCT00150111_27_T6	GENE	28	28	T3
NCT0015011129	NCT00150111_29_T0	COMPOUND	2	2	paracetamol
NCT001501242	NCT00150124_2_T0	PHENOTYPE	9	10	thyroid storm
NCT001501244	NCT00150124_4_T0	PHENOTYPE	14	16	toxic nodular goiter
NCT001501246	NCT00150124_6_T0	COMPOUND	22	22	methimazole
NCT001501246	NCT00150124_6_T1	PHENOTYPE	19	20	adverse effect
NCT001501249	NCT00150124_9_T0	ORGAN	12	12	thyroid
NCT001501249	NCT00150124_9_T1	PHENOTYPE	21	21	discomfort
NCT0015012414	NCT00150124_14_T0	GENE	20	20	had
NCT0015012414	NCT00150124_14_T1	COMPOUND	14	14	methimazole
NCT0015012415	NCT00150124_15_T0	PHENOTYPE	12	12	hyperthyroid
NCT0015012415	NCT00150124_15_T1	COMPOUND	29	29	methimazole
NCT0015012416	NCT00150124_16_T0	PHENOTYPE	5	5	suffering
NCT0015012416	NCT00150124_16_T1	PHENOTYPE	7	7	recurrent
NCT0015012416	NCT00150124_16_T2	PHENOTYPE	13	15	toxic nodular goiter
NCT0015012419	NCT00150124_19_T0	GENE	14	14	half-life
NCT0015012419	NCT00150124_19_T1	ORGAN	17	17	thyroid
NCT0015012419	NCT00150124_19_T2	GENE	5	5	max
NCT0015012420	NCT00150124_20_T0	PHENOTYPE	11	12	thyroid function
NCT001501374	NCT00150137_4_T0	PHENOTYPE	14	16	toxic nodular goiter
NCT001501376	NCT00150137_6_T0	COMPOUND	22	22	methimazole
NCT001501376	NCT00150137_6_T1	PHENOTYPE	19	20	adverse effect
NCT001501379	NCT00150137_9_T0	ORGAN	12	12	thyroid
NCT001501379	NCT00150137_9_T1	PHENOTYPE	21	21	discomfort
NCT0015013714	NCT00150137_14_T0	GENE	20	20	had
NCT0015013714	NCT00150137_14_T1	COMPOUND	14	14	methimazole
NCT0015013715	NCT00150137_15_T0	COMPOUND	11	11	methimazole
NCT0015013715	NCT00150137_15_T1	COMPOUND	30	30	methimazole
NCT0015013716	NCT00150137_16_T0	PHENOTYPE	6	6	suffering
NCT0015013716	NCT00150137_16_T1	PHENOTYPE	8	8	recurrent
NCT0015013716	NCT00150137_16_T2	PHENOTYPE	13	15	toxic nodular goiter
NCT0015013717	NCT00150137_17_T0	COMPOUND	6	6	methimazole
NCT0015013718	NCT00150137_18_T0	GENE	14	14	half-life
NCT0015013718	NCT00150137_18_T1	ORGAN	17	17	thyroid
NCT0015013718	NCT00150137_18_T2	GENE	5	5	max
NCT0015013719	NCT00150137_19_T0	PHENOTYPE	11	12	thyroid function
NCT001501502	NCT00150150_2_T0	PHENOTYPE	9	9	hyperthermia
NCT001501502	NCT00150150_2_T1	GENE	3	3	ILP
NCT001501502	NCT00150150_2_T2	PHENOTYPE	17	18	benign tumors
NCT001501502	NCT00150150_2_T3	PHENOTYPE	20	21	thyroid nodules
NCT001501503	NCT00150150_3_T0	PHENOTYPE	36	36	toxic
NCT001501503	NCT00150150_3_T1	GENE	9	9	ILP
NCT001501503	NCT00150150_3_T2	PHENOTYPE	37	38	thyroid nodules
NCT001501503	NCT00150150_3_T3	PHENOTYPE	23	24	thyroid function
NCT001501503	NCT00150150_3_T4	PHENOTYPE	19	21	benign thyroid nodule
NCT001501506	NCT00150150_6_T0	GENE	8	8	solitary
NCT001501506	NCT00150150_6_T1	PHENOTYPE	10	11	thyroid nodules
NCT001501507	NCT00150150_7_T0	ORGAN	5	5	thyroid
NCT001501507	NCT00150150_7_T1	PHENOTYPE	6	6	cystadenomas
NCT001501631	NCT00150163_1_T0	COMPOUND	13	13	estrone
NCT001501631	NCT00150163_1_T1	COMPOUND	6	6	testosterone
NCT001501631	NCT00150163_1_T2	COMPOUND	7	7	dihydrotestosterone
NCT001501631	NCT00150163_1_T3	BIOLOGICAL_PROCESS	8	8	androstenedione
NCT001501631	NCT00150163_1_T4	ORGAN	4	4	serum
NCT001501631	NCT00150163_1_T5	ORGAN	10	10	serum
NCT001501631	NCT00150163_1_T6	COMPOUND	12	12	estradiol
NCT001501636	NCT00150163_6_T0	BIOLOGICAL_PROCESS	5	5	metabolism
NCT001501638	NCT00150163_8_T0	TISSUE	2	3	visceral fat
NCT0015016310	NCT00150163_10_T0	BIOLOGICAL_PROCESS	5	6	glucocorticoid metabolism
NCT0015016310	NCT00150163_10_T1	BIOLOGICAL_PROCESS	2	3	glucose metabolism
NCT0015016313	NCT00150163_13_T0	PHENOTYPE	11	12	chronic disease
NCT0015016313	NCT00150163_13_T1	PHENOTYPE	6	7	drug addiction
NCT0015016320	NCT00150163_20_T0	GENE	16	16	AR
NCT0015016320	NCT00150163_20_T1	GENE	13	13	IGF-1
NCT0015016320	NCT00150163_20_T2	ORGAN	9	9	serum
NCT0015016320	NCT00150163_20_T3	GENE	11	11	hormone
NCT0015016322	NCT00150163_22_T0	COMPOUND	0	0	2
NCT0015016322	NCT00150163_22_T1	PHENOTYPE	2	3	chronic disease
NCT0015016323	NCT00150163_23_T0	COMPOUND	0	0	3
NCT001501762	NCT00150176_2_T0	PHENOTYPE	17	17	symptoms
NCT001501762	NCT00150176_2_T1	PHENOTYPE	6	6	acute
NCT001501762	NCT00150176_2_T2	PHENOTYPE	16	16	acute
NCT001501762	NCT00150176_2_T3	PHENOTYPE	13	13	remission
NCT001501762	NCT00150176_2_T4	PHENOTYPE	7	8	psychotic episodes
NCT001501763	NCT00150176_3_T0	PHENOTYPE	10	10	symptoms
NCT001501763	NCT00150176_3_T1	PHENOTYPE	28	28	symptoms
NCT001501763	NCT00150176_3_T2	PHENOTYPE	9	9	acute
NCT001501763	NCT00150176_3_T3	PHENOTYPE	27	27	acute
NCT001501763	NCT00150176_3_T4	PHENOTYPE	19	19	relapse
NCT001501763	NCT00150176_3_T5	PHENOTYPE	3	3	schizophrenia
NCT001501764	NCT00150176_4_T0	PHENOTYPE	16	16	acute
NCT001501764	NCT00150176_4_T1	GENE	12	12	1.2
NCT001501764	NCT00150176_4_T2	PHENOTYPE	10	10	relapse
NCT001501764	NCT00150176_4_T3	PHENOTYPE	19	19	schizophrenia
NCT001501765	NCT00150176_5_T0	PHENOTYPE	28	28	imbalance
NCT001501765	NCT00150176_5_T1	PHENOTYPE	10	10	relapse
NCT001501765	NCT00150176_5_T2	PHENOTYPE	18	18	relapse
NCT001501765	NCT00150176_5_T3	PHENOTYPE	22	22	schizophrenia
NCT001501765	NCT00150176_5_T4	PHENOTYPE	20	20	symptoms
NCT001501765	NCT00150176_5_T5	CELL	41	41	cells
NCT001501765	NCT00150176_5_T6	COMPOUND	35	35	dopamine
NCT001501765	NCT00150176_5_T7	PHENOTYPE	39	39	enables
NCT001501766	NCT00150176_6_T0	PHENOTYPE	6	6	imbalance
NCT001501766	NCT00150176_6_T1	COMPOUND	8	8	dopamine
NCT001501767	NCT00150176_7_T0	PHENOTYPE	31	31	symptoms
NCT001501767	NCT00150176_7_T1	PHENOTYPE	16	16	relapse
NCT001501767	NCT00150176_7_T2	PHENOTYPE	21	21	relapse
NCT001501767	NCT00150176_7_T3	PHENOTYPE	33	33	schizophrenia
NCT001501767	NCT00150176_7_T4	COMPOUND	12	12	asenapine
NCT001501767	NCT00150176_7_T5	COMPOUND	29	29	asenapine
NCT001501768	NCT00150176_8_T0	COMPOUND	9	9	asenapine
NCT001501894	NCT00150189_4_T0	ORGAN	21	22	dorsal horn
NCT001501894	NCT00150189_4_T1	PHENOTYPE	2	4	mechanism of action
NCT001502540	NCT00150254_0_T0	PHENOTYPE	11	11	Strategies
NCT001502670	NCT00150267_0_T0	PHENOTYPE	14	15	Ocular Hypertension
NCT001502670	NCT00150267_0_T1	PHENOTYPE	10	12	Open Angle Glaucoma
NCT001502930	NCT00150293_0_T0	GENE	13	13	al
NCT001502930	NCT00150293_0_T1	PHENOTYPE	14	14	Seizures
NCT001502930	NCT00150293_0_T2	PHENOTYPE	11	12	Partial Seizures
NCT001503191	NCT00150319_1_T0	GENE	14	14	had
NCT001503451	NCT00150345_1_T0	PHENOTYPE	4	4	neutropenia
NCT001503451	NCT00150345_1_T1	PHENOTYPE	8	10	predisposition to infections
NCT001503453	NCT00150345_3_T0	PHENOTYPE	22	22	fungi
NCT001503454	NCT00150345_4_T0	COMPOUND	13	13	voriconazole
NCT001503455	NCT00150345_5_T0	COMPOUND	7	7	voriconazole
NCT001503455	NCT00150345_5_T1	PHENOTYPE	12	12	fever
NCT001503456	NCT00150345_6_T0	PHENOTYPE	11	12	fungal infections
NCT001504230	NCT00150423_0_T0	PHENOTYPE	12	14	Diabetic Peripheral Neuropathy
NCT001504360	NCT00150436_0_T0	PHENOTYPE	11	12	Postherpetic Neuralgia
NCT001504361	NCT00150436_1_T0	PHENOTYPE	1	1	Neuralgia
NCT001504490	NCT00150449_0_T0	PHENOTYPE	13	13	Disorders
NCT001504490	NCT00150449_0_T1	PHENOTYPE	10	11	Anxiety Disorders
NCT001504620	NCT00150462_0_T0	PHENOTYPE	13	14	Hematological Malignancies
NCT001504622	NCT00150462_2_T0	GENE	3	3	proteasome
NCT001504628	NCT00150462_8_T0	GENE	8	8	0.2
NCT001504628	NCT00150462_8_T1	PHENOTYPE	2	2	Oncology
NCT001504629	NCT00150462_9_T0	PHENOTYPE	5	5	ischemia
NCT001504629	NCT00150462_9_T1	PHENOTYPE	13	14	myocardial infarction
NCT001504629	NCT00150462_9_T2	PHENOTYPE	6	7	conduction abnormalities
NCT0015046212	NCT00150462_12_T0	COMPOUND	2	2	creatinine
NCT0015046213	NCT00150462_13_T0	COMPOUND	1	1	creatinine
NCT0015046213	NCT00150462_13_T1	GENE	3	3	2.0
NCT0015046213	NCT00150462_13_T2	ORGAN	0	0	Serum
NCT0015046215	NCT00150462_15_T0	ORGAN	17	17	serum
NCT0015046222	NCT00150462_22_T0	COMPOUND	7	7	dexamethasone
NCT0015046229	NCT00150462_29_T0	PHENOTYPE	3	3	CHF
NCT0015046229	NCT00150462_29_T1	ORGAN	6	6	Heart
NCT0015046229	NCT00150462_29_T2	PHENOTYPE	8	9	class III
NCT0015046229	NCT00150462_29_T3	PHENOTYPE	0	2	Congestive heart failure
NCT0015046230	NCT00150462_30_T0	PHENOTYPE	0	0	Acute
NCT0015046232	NCT00150462_32_T0	PHENOTYPE	1	2	hepatitis A
NCT0015046232	NCT00150462_32_T1	PHENOTYPE	16	17	hepatitis B
NCT0015046232	NCT00150462_32_T2	PHENOTYPE	10	11	Hepatitis C
NCT0015046235	NCT00150462_35_T0	PHENOTYPE	3	4	brain metastasis
NCT0015046235	NCT00150462_35_T1	ORGAN	6	8	central nervous system
NCT0015047514	NCT00150475_14_T0	GENE	30	30	PPE
NCT0015047514	NCT00150475_14_T1	GENE	37	37	PAPR
NCT0015047518	NCT00150475_18_T0	GENE	17	17	PAPR
NCT0015047519	NCT00150475_19_T0	GENE	13	13	PAPR
NCT0015047519	NCT00150475_19_T1	PHENOTYPE	0	0	Recruitment
NCT0015047523	NCT00150475_23_T0	GENE	5	5	don
NCT0015047523	NCT00150475_23_T1	GENE	10	10	PPE
NCT0015047523	NCT00150475_23_T2	GENE	8	8	PAPR
NCT0015047524	NCT00150475_24_T0	GENE	17	17	has
NCT0015047526	NCT00150475_26_T0	GENE	12	12	PPE
NCT0015047526	NCT00150475_26_T1	GENE	3	3	has
NCT0015047527	NCT00150475_27_T0	GENE	12	12	PPE
NCT0015047532	NCT00150475_32_T0	GENE	8	8	PPE
NCT0015047535	NCT00150475_35_T0	GENE	11	11	PAPR
NCT0015047535	NCT00150475_35_T1	GENE	2	2	has
NCT0015047536	NCT00150475_36_T0	GENE	17	17	PPE
NCT0015047537	NCT00150475_37_T0	PHENOTYPE	1	1	intent
NCT0015047539	NCT00150475_39_T0	GENE	38	38	PPE
NCT0015047539	NCT00150475_39_T1	PHENOTYPE	25	25	practices
NCT0015047541	NCT00150475_41_T0	GENE	19	19	PAPR
NCT0015047542	NCT00150475_42_T0	GENE	11	11	PPE
NCT0015047542	NCT00150475_42_T1	GENE	13	13	PAPR
NCT0015047544	NCT00150475_44_T0	GENE	17	17	PPE
NCT0015047544	NCT00150475_44_T1	GENE	27	27	PAPR
NCT0015047545	NCT00150475_45_T0	GENE	2	2	cease
NCT0015047548	NCT00150475_48_T0	COMPOUND	8	8	fluorescein
NCT0015047548	NCT00150475_48_T1	PHENOTYPE	17	17	sterile
NCT0015047550	NCT00150475_50_T0	PHENOTYPE	29	29	coughing
NCT0015047552	NCT00150475_52_T0	ORGAN	17	17	umbilicus
NCT0015047554	NCT00150475_54_T0	PHENOTYPE	8	8	closed
NCT0015047554	NCT00150475_54_T1	ORGAN	5	5	eyes
NCT0015047558	NCT00150475_58_T0	ORGAN	9	9	forearms
NCT0015047562	NCT00150475_62_T0	GENE	16	16	PPE
NCT0015047562	NCT00150475_62_T1	GENE	26	26	PAPR
NCT0015047563	NCT00150475_63_T0	GENE	9	9	lamp
NCT0015047564	NCT00150475_64_T0	GENE	2	2	cease
NCT0015047567	NCT00150475_67_T0	GENE	7	7	lamp
NCT0015047568	NCT00150475_68_T0	GENE	2	2	PPE
NCT0015047568	NCT00150475_68_T1	GENE	15	15	PPE
NCT0015047568	NCT00150475_68_T2	PHENOTYPE	20	20	sterile
NCT0015047568	NCT00150475_68_T3	PHENOTYPE	23	23	resistant
NCT0015047568	NCT00150475_68_T4	GENE	9	9	lamp
NCT0015047568	NCT00150475_68_T5	PHENOTYPE	19	19	fitted
NCT0015047569	NCT00150475_69_T0	GENE	9	9	PPE
NCT0015047569	NCT00150475_69_T1	PHENOTYPE	20	20	sterile
NCT0015047569	NCT00150475_69_T2	PHENOTYPE	19	19	fitted
NCT0015047570	NCT00150475_70_T0	GENE	2	2	PAPR
NCT0015047570	NCT00150475_70_T1	GENE	15	15	PAPR
NCT0015047570	NCT00150475_70_T2	GENE	18	18	PAPR
NCT0015047570	NCT00150475_70_T3	PHENOTYPE	33	33	sterile
NCT0015047570	NCT00150475_70_T4	PHENOTYPE	25	25	resistant
NCT0015047570	NCT00150475_70_T5	GENE	9	9	lamp
NCT0015047570	NCT00150475_70_T6	PHENOTYPE	32	32	fitted
NCT0015047571	NCT00150475_71_T0	GENE	10	10	PAPR
NCT0015047571	NCT00150475_71_T1	PHENOTYPE	16	16	sterile
NCT0015047571	NCT00150475_71_T2	PHENOTYPE	17	17	fitted
NCT0015047572	NCT00150475_72_T0	GENE	9	9	PAPR
NCT0015047572	NCT00150475_72_T1	PHENOTYPE	19	19	sterile
NCT0015047572	NCT00150475_72_T2	PHENOTYPE	20	20	fitted
NCT0015047576	NCT00150475_76_T0	PHENOTYPE	13	13	cm2
NCT001504881	NCT00150488_1_T0	PHENOTYPE	13	14	adverse events
NCT001504884	NCT00150488_4_T0	PHENOTYPE	0	0	Secondary
NCT001504885	NCT00150488_5_T0	PHENOTYPE	4	4	symptoms
NCT0015048810	NCT00150488_10_T0	GENE	2	2	PUF
NCT0015048816	NCT00150488_16_T0	PHENOTYPE	3	4	interstitial cystitis
NCT0015048819	NCT00150488_19_T0	PHENOTYPE	1	1	sterile
NCT0015048821	NCT00150488_21_T0	GENE	11	11	VAS
NCT0015048825	NCT00150488_25_T0	COMPOUND	13	13	heparin
NCT0015048825	NCT00150488_25_T1	GENE	10	10	eg
NCT0015048825	NCT00150488_25_T2	GENE	15	15	BCG
NCT0015048825	NCT00150488_25_T3	GENE	4	4	had
NCT0015048829	NCT00150488_29_T0	PHENOTYPE	1	1	symptoms
NCT0015048830	NCT00150488_30_T0	ORGAN	0	0	Bladder
NCT0015048830	NCT00150488_30_T1	GENE	6	6	ml
NCT0015048831	NCT00150488_31_T0	ORGAN	3	3	bladder
NCT0015048831	NCT00150488_31_T1	ORGAN	12	12	bladder
NCT0015048832	NCT00150488_32_T0	PHENOTYPE	1	3	urinary tract infection
NCT0015048833	NCT00150488_33_T0	PHENOTYPE	4	4	tuberculous
NCT0015048834	NCT00150488_34_T0	ORGAN	2	2	bladder
NCT0015048835	NCT00150488_35_T0	PHENOTYPE	12	13	melanoma skin
NCT0015048836	NCT00150488_36_T0	PHENOTYPE	2	2	transmitted
NCT001505148	NCT00150514_8_T0	PHENOTYPE	5	6	skin prick
NCT001505148	NCT00150514_8_T1	GENE	3	4	pollen specific
NCT0015051412	NCT00150514_12_T0	PHENOTYPE	1	3	perennial allergic rhinitis
NCT0015051413	NCT00150514_13_T0	PHENOTYPE	27	27	symptoms
NCT0015051413	NCT00150514_13_T1	GENE	7	7	allergen
NCT0015051413	NCT00150514_13_T2	PHENOTYPE	2	2	allergy
NCT0015051413	NCT00150514_13_T3	PHENOTYPE	31	31	allergy
NCT0015051415	NCT00150514_15_T0	PHENOTYPE	1	3	seasonal allergic rhinitis
NCT0015051417	NCT00150514_17_T0	ORGAN	10	11	nasal cavity
NCT0015051421	NCT00150514_21_T0	PHENOTYPE	5	6	skin prick
NCT0015051421	NCT00150514_21_T1	GENE	3	4	pollen specific
NCT001505272	NCT00150527_2_T0	COMPOUND	3	3	escitalopram
NCT001505272	NCT00150527_2_T1	GENE	4	4	has
NCT001505275	NCT00150527_5_T0	COMPOUND	14	14	escitalopram
NCT001505275	NCT00150527_5_T1	COMPOUND	24	24	escitalopram
NCT001505275	NCT00150527_5_T2	GENE	2	2	has
NCT001505275	NCT00150527_5_T3	COMPOUND	12	12	R-citalopram
NCT001505275	NCT00150527_5_T4	PHENOTYPE	21	22	anxiolytic effects
NCT001505660	NCT00150566_0_T0	ORGAN	7	7	Serum
NCT001505660	NCT00150566_0_T1	ORGAN	27	27	Blood
NCT001505660	NCT00150566_0_T2	PHENOTYPE	13	16	End Stage Renal Disease
NCT001505791	NCT00150579_1_T0	PHENOTYPE	8	8	affects
NCT001505791	NCT00150579_1_T1	PHENOTYPE	16	18	quality of life
NCT001506311	NCT00150631_1_T0	COMPOUND	8	9	candesartan cilexetil
NCT001506313	NCT00150631_3_T0	GENE	13	13	blocker
NCT001506313	NCT00150631_3_T1	PHENOTYPE	21	21	progression
NCT001506313	NCT00150631_3_T2	PHENOTYPE	23	23	hypertension
NCT001506313	NCT00150631_3_T3	GENE	11	12	angiotensin receptor
NCT001506314	NCT00150631_4_T0	PHENOTYPE	0	0	Secondary
NCT001506314	NCT00150631_4_T1	ORGAN	26	27	left ventricle
NCT001506316	NCT00150631_6_T0	PHENOTYPE	4	4	hypertension
NCT001506317	NCT00150631_7_T0	PHENOTYPE	3	3	hypertension
NCT001506318	NCT00150631_8_T0	PHENOTYPE	7	7	blocks
NCT0015063111	NCT00150631_11_T0	GENE	13	13	blocker
NCT0015063111	NCT00150631_11_T1	PHENOTYPE	21	21	progression
NCT0015063111	NCT00150631_11_T2	PHENOTYPE	23	23	hypertension
NCT0015063111	NCT00150631_11_T3	GENE	11	12	angiotensin receptor
NCT0015063112	NCT00150631_12_T0	PHENOTYPE	0	0	Secondary
NCT0015063112	NCT00150631_12_T1	ORGAN	26	27	left ventricle
NCT0015063113	NCT00150631_13_T0	PHENOTYPE	16	17	essential hypertension
NCT0015063115	NCT00150631_15_T0	PHENOTYPE	3	3	hypertension
NCT0015063116	NCT00150631_16_T0	COMPOUND	14	15	candesartan cilexetil
NCT0015063117	NCT00150631_17_T0	BIOLOGICAL_PROCESS	8	9	glomerular filtration
NCT0015063117	NCT00150631_17_T1	PHENOTYPE	12	13	vascular resistance
NCT0015063118	NCT00150631_18_T0	GENE	4	4	0.5
NCT0015063122	NCT00150631_22_T0	PHENOTYPE	0	0	Secondary
NCT0015063122	NCT00150631_22_T1	GENE	30	30	ventricular
NCT0015063122	NCT00150631_22_T2	PHENOTYPE	26	27	vascular resistance
NCT0015063125	NCT00150631_25_T0	PHENOTYPE	3	4	essential hypertension
NCT0015063129	NCT00150631_29_T0	GENE	5	5	ot
NCT0015063130	NCT00150631_30_T0	ORGAN	7	7	kidney
NCT0015063130	NCT00150631_30_T1	ORGAN	8	8	liver
NCT001506440	NCT00150644_0_T0	PHENOTYPE	11	12	Uterine Fibroids
NCT001506445	NCT00150644_5_T0	TISSUE	22	22	myometrium
NCT001506445	NCT00150644_5_T1	ORGAN	20	20	endometrium
NCT001506445	NCT00150644_5_T2	COMPOUND	17	17	asoprisnil
NCT001506445	NCT00150644_5_T3	PHENOTYPE	25	26	uterine fibroids
NCT001506831	NCT00150683_1_T0	PHENOTYPE	1	1	Injury
NCT001506831	NCT00150683_1_T1	PHENOTYPE	0	0	Cord
NCT001506961	NCT00150696_1_T0	PHENOTYPE	1	1	Injury
NCT001506961	NCT00150696_1_T1	PHENOTYPE	0	0	Cord
NCT001507221	NCT00150722_1_T0	GENE	9	9	HDL
NCT001507221	NCT00150722_1_T1	GENE	3	3	has
NCT0015072210	NCT00150722_10_T0	PHENOTYPE	7	7	secondary
NCT0015072210	NCT00150722_10_T1	PHENOTYPE	9	9	strategies
NCT0015072210	NCT00150722_10_T2	PHENOTYPE	5	6	coronary atherosclerosis
NCT0015072212	NCT00150722_12_T0	GENE	17	17	HDL
NCT0015072212	NCT00150722_12_T1	GENE	10	10	has
NCT0015072213	NCT00150722_13_T0	PHENOTYPE	0	1	Low HDL
NCT0015072214	NCT00150722_14_T0	GENE	0	0	HDL
NCT0015072214	NCT00150722_14_T1	TISSUE	13	13	tissues
NCT0015072214	NCT00150722_14_T2	BIOLOGICAL_PROCESS	4	6	reverse cholesterol transport
NCT0015072215	NCT00150722_15_T0	GENE	2	2	HDL
NCT0015072215	NCT00150722_15_T1	GENE	3	3	has
NCT0015072216	NCT00150722_16_T0	GENE	7	7	HDL
NCT0015072216	NCT00150722_16_T1	COMPOUND	10	10	niacin
NCT0015072219	NCT00150722_19_T0	PHENOTYPE	11	11	atherosclerosis
NCT0015072219	NCT00150722_19_T1	TISSUE	3	3	endothelium
NCT0015072219	NCT00150722_19_T2	PHENOTYPE	0	0	Dysfunction
NCT0015072222	NCT00150722_22_T0	GENE	7	7	has
NCT0015072223	NCT00150722_23_T0	COMPOUND	3	3	niacin
NCT0015072223	NCT00150722_23_T1	GENE	7	7	has
NCT0015072225	NCT00150722_25_T0	COMPOUND	9	9	atorvastatin
NCT0015072225	NCT00150722_25_T1	COMPOUND	24	24	atorvastatin
NCT0015072227	NCT00150722_27_T0	COMPOUND	2	2	atorvastatin
NCT0015072228	NCT00150722_28_T0	COMPOUND	17	17	niacin
NCT0015072228	NCT00150722_28_T1	GENE	16	16	ER
NCT0015072232	NCT00150722_32_T0	ORGAN	5	5	gallbladder
NCT0015072232	NCT00150722_32_T1	PHENOTYPE	20	20	initiation
NCT0015072232	NCT00150722_32_T2	PHENOTYPE	4	4	gout
NCT0015072232	NCT00150722_32_T3	COMPOUND	24	24	niacin
NCT0015072232	NCT00150722_32_T4	PHENOTYPE	7	9	peptic ulcer disease
NCT0015072236	NCT00150722_36_T0	GENE	8	8	LDL
NCT0015072237	NCT00150722_37_T0	GENE	0	0	HDL
NCT0015072237	NCT00150722_37_T1	GENE	1	1	has
NCT0015072238	NCT00150722_38_T0	PHENOTYPE	17	17	atherosclerosis
NCT0015072238	NCT00150722_38_T1	GENE	8	8	HDL
NCT001507483	NCT00150748_3_T0	PHENOTYPE	0	0	Concentration
NCT001507870	NCT00150787_0_T0	PHENOTYPE	9	9	Epilepsy
NCT001507870	NCT00150787_0_T1	PHENOTYPE	11	11	Epilepsy
NCT001507870	NCT00150787_0_T2	PHENOTYPE	7	7	Suffering
NCT001507870	NCT00150787_0_T3	GENE	10	10	om
NCT001508003	NCT00150800_3_T0	PHENOTYPE	0	0	Concentration
NCT001508130	NCT00150813_0_T0	PHENOTYPE	7	7	Epilepsy
NCT001508130	NCT00150813_0_T1	PHENOTYPE	9	9	Epilepsy
NCT001508130	NCT00150813_0_T2	PHENOTYPE	5	5	Suffering
NCT001508130	NCT00150813_0_T3	GENE	8	8	om
NCT001508265	NCT00150826_5_T0	GENE	6	6	CFR
NCT001508265	NCT00150826_5_T1	GENE	13	13	CFR
NCT001508266	NCT00150826_6_T0	PHENOTYPE	14	14	Angina
NCT001508266	NCT00150826_6_T1	PHENOTYPE	7	8	chest discomfort
NCT001508267	NCT00150826_7_T0	PHENOTYPE	8	8	pulse
NCT001508267	NCT00150826_7_T1	PHENOTYPE	14	15	adverse events
NCT001508268	NCT00150826_8_T0	GENE	15	15	has
NCT0015082615	NCT00150826_15_T0	COMPOUND	11	11	SAQ
NCT0015082615	NCT00150826_15_T1	GENE	19	19	3.0
NCT0015082615	NCT00150826_15_T2	GENE	14	14	reduced
NCT0015082615	NCT00150826_15_T3	PHENOTYPE	9	9	Angina
NCT0015082615	NCT00150826_15_T4	GENE	1	1	WISE
NCT0015082615	NCT00150826_15_T5	COMPOUND	29	29	quinapril
NCT0015082618	NCT00150826_18_T0	PHENOTYPE	4	5	chest discomfort
NCT0015082622	NCT00150826_22_T0	GENE	4	4	3.0
NCT0015082627	NCT00150826_27_T0	PHENOTYPE	14	14	withdrawn
NCT0015082631	NCT00150826_31_T0	PHENOTYPE	2	2	hypertension
NCT0015082633	NCT00150826_33_T0	ORGAN	7	7	Heart
NCT0015082633	NCT00150826_33_T1	GENE	11	11	III
NCT0015082633	NCT00150826_33_T2	GENE	13	13	IV
NCT0015082633	NCT00150826_33_T3	PHENOTYPE	1	2	heart failure
NCT0015082635	NCT00150826_35_T0	GENE	6	6	bypass
NCT0015082635	NCT00150826_35_T1	ORGAN	4	5	coronary artery
NCT0015082637	NCT00150826_37_T0	GENE	12	12	3.0
NCT0015082637	NCT00150826_37_T1	PHENOTYPE	7	7	IHD
NCT0015082637	NCT00150826_37_T2	COMPOUND	11	11	creatinine
NCT0015082637	NCT00150826_37_T3	PHENOTYPE	14	15	hepatic disease
NCT0015082637	NCT00150826_37_T4	PHENOTYPE	21	23	valvular heart disease
NCT0015082643	NCT00150826_43_T0	PHENOTYPE	2	2	hypertrophic
NCT0015082645	NCT00150826_45_T0	PHENOTYPE	1	1	dysfunction
NCT0015082646	NCT00150826_46_T0	COMPOUND	2	2	cocaine
NCT0015082646	NCT00150826_46_T1	COMPOUND	4	4	amphetamine
NCT001508391	NCT00150839_1_T0	PHENOTYPE	9	9	diseases
NCT001508391	NCT00150839_1_T1	PHENOTYPE	0	1	Depressive disorder
NCT001508392	NCT00150839_2_T0	PHENOTYPE	4	5	depressive disorders
NCT001508394	NCT00150839_4_T0	PHENOTYPE	16	16	suffering
NCT001508394	NCT00150839_4_T1	PHENOTYPE	8	8	remission
NCT001508395	NCT00150839_5_T0	PHENOTYPE	1	3	treatment resistant depression
NCT001508397	NCT00150839_7_T0	PHENOTYPE	31	31	secondary
NCT001508397	NCT00150839_7_T1	PHENOTYPE	16	16	remission
NCT001508397	NCT00150839_7_T2	PHENOTYPE	41	41	remission
NCT001508397	NCT00150839_7_T3	PHENOTYPE	18	19	depressive symptoms
NCT001508398	NCT00150839_8_T0	COMPOUND	17	17	mirtazapine
NCT001508398	NCT00150839_8_T1	COMPOUND	21	21	venlafaxine
NCT0015083912	NCT00150839_12_T0	COMPOUND	13	13	mirtazapine
NCT0015083913	NCT00150839_13_T0	COMPOUND	20	20	venlafaxine
NCT0015083914	NCT00150839_14_T0	PHENOTYPE	10	10	strategies
NCT0015083914	NCT00150839_14_T1	PHENOTYPE	5	6	therapy-resistant depression
NCT0015083915	NCT00150839_15_T0	COMPOUND	22	22	mirtazapine
NCT0015083915	NCT00150839_15_T1	GENE	15	15	al
NCT0015083915	NCT00150839_15_T2	GENE	38	38	al
NCT0015083915	NCT00150839_15_T3	GENE	14	14	et
NCT0015083915	NCT00150839_15_T4	GENE	37	37	et
NCT0015083916	NCT00150839_16_T0	COMPOUND	13	13	citalopram
NCT0015083916	NCT00150839_16_T1	COMPOUND	15	15	reboxetine
NCT0015083917	NCT00150839_17_T0	COMPOUND	12	12	mirtazapine
NCT0015083917	NCT00150839_17_T1	COMPOUND	10	10	venlafaxine
NCT0015083917	NCT00150839_17_T2	GENE	2	2	al
NCT0015083917	NCT00150839_17_T3	GENE	16	16	al
NCT0015083917	NCT00150839_17_T4	GENE	1	1	et
NCT0015083917	NCT00150839_17_T5	GENE	15	15	et
NCT0015083917	NCT00150839_17_T6	COMPOUND	7	7	reboxetine
NCT0015083918	NCT00150839_18_T0	COMPOUND	13	13	mirtazapine
NCT0015083918	NCT00150839_18_T1	COMPOUND	8	8	venlafaxine
NCT0015083918	NCT00150839_18_T2	GENE	2	2	al
NCT0015083918	NCT00150839_18_T3	GENE	1	1	et
NCT0015083920	NCT00150839_20_T0	GENE	6	6	al
NCT0015083920	NCT00150839_20_T1	GENE	5	5	et
NCT0015083922	NCT00150839_22_T0	PHENOTYPE	22	22	OCD
NCT0015083922	NCT00150839_22_T1	COMPOUND	12	12	mirtazapine
NCT0015083922	NCT00150839_22_T2	GENE	2	2	al
NCT0015083922	NCT00150839_22_T3	GENE	25	25	al
NCT0015083922	NCT00150839_22_T4	GENE	1	1	et
NCT0015083922	NCT00150839_22_T5	GENE	24	24	et
NCT0015083930	NCT00150839_30_T0	COMPOUND	4	4	mirtazapine
NCT0015083930	NCT00150839_30_T1	GENE	5	5	has
NCT0015083940	NCT00150839_40_T0	GENE	28	28	AMG
NCT0015083942	NCT00150839_42_T0	PHENOTYPE	5	6	depressive disorder
NCT0015083945	NCT00150839_45_T0	GENE	6	6	5.7
NCT0015083946	NCT00150839_46_T0	GENE	6	7	monoamine oxidase
NCT0015083953	NCT00150839_53_T0	COMPOUND	32	32	lorazepam
NCT0015083954	NCT00150839_54_T0	COMPOUND	16	16	lorazepam
NCT0015083955	NCT00150839_55_T0	GENE	11	11	SPC
NCT0015083956	NCT00150839_56_T0	GENE	16	16	MAO
NCT0015083960	NCT00150839_60_T0	GENE	6	6	BAI
NCT0015083962	NCT00150839_62_T0	GENE	5	5	BAI
NCT0015083963	NCT00150839_63_T0	GENE	15	15	13
NCT001508520	NCT00150852_0_T0	PHENOTYPE	3	4	Wound Infection
NCT001508524	NCT00150852_4_T0	PHENOTYPE	14	14	complication
NCT001508524	NCT00150852_4_T1	GENE	8	8	has
NCT001508526	NCT00150852_6_T0	GENE	12	12	PEG
NCT001508526	NCT00150852_6_T1	GENE	10	10	extended
NCT001508528	NCT00150852_8_T0	PHENOTYPE	7	7	gastrostomy
NCT001508528	NCT00150852_8_T1	ORGAN	13	13	oropharynx
NCT0015085210	NCT00150852_10_T0	PHENOTYPE	10	10	toxicity
NCT0015085210	NCT00150852_10_T1	GENE	4	4	PEG
NCT0015085210	NCT00150852_10_T2	COMPOUND	9	9	vancomycin
NCT001508652	NCT00150865_2_T0	PHENOTYPE	12	12	anesthesia
NCT001508782	NCT00150878_2_T0	GENE	2	2	II
NCT001508784	NCT00150878_4_T0	PHENOTYPE	13	13	remission
NCT001508784	NCT00150878_4_T1	GENE	9	9	had
NCT001508785	NCT00150878_5_T0	PHENOTYPE	25	25	AML
NCT001508785	NCT00150878_5_T1	GENE	18	18	Gy
NCT001508785	NCT00150878_5_T2	PHENOTYPE	10	10	conditioning
NCT001508785	NCT00150878_5_T3	PHENOTYPE	28	28	remission
NCT001508786	NCT00150878_6_T0	ORGAN	14	14	marrow
NCT001508786	NCT00150878_6_T1	PHENOTYPE	31	31	conditioning
NCT001508786	NCT00150878_6_T2	PHENOTYPE	4	4	remission
NCT001508787	NCT00150878_7_T0	PHENOTYPE	5	5	relapse
NCT001508789	NCT00150878_9_T0	GENE	4	4	0.8
NCT001508911	NCT00150891_1_T0	PHENOTYPE	21	21	acute
NCT001508911	NCT00150891_1_T1	ORGAN	30	30	graft
NCT001508911	NCT00150891_1_T2	GENE	42	42	al
NCT001508911	NCT00150891_1_T3	GENE	41	41	et
NCT001508911	NCT00150891_1_T4	COMPOUND	27	27	1
NCT001508911	NCT00150891_1_T5	GENE	7	7	CD4
NCT001508911	NCT00150891_1_T6	GENE	13	13	IL-10
NCT001508911	NCT00150891_1_T7	GENE	34	34	Th1
NCT001508912	NCT00150891_2_T0	GENE	6	6	CD4
NCT001508912	NCT00150891_2_T1	GENE	11	11	IL-10
NCT001508912	NCT00150891_2_T2	ORGAN	1	1	liver
NCT001508912	NCT00150891_2_T3	ORGAN	2	2	transplant
NCT001508912	NCT00150891_2_T4	GENE	21	21	al
NCT001508912	NCT00150891_2_T5	GENE	20	20	et
NCT001508913	NCT00150891_3_T0	GENE	24	24	CD4
NCT001508913	NCT00150891_3_T1	GENE	29	29	IL-10
NCT001508913	NCT00150891_3_T2	ORGAN	18	18	graft
NCT001508913	NCT00150891_3_T3	ORGAN	9	9	transplant
NCT001508916	NCT00150891_6_T0	ORGAN	18	18	graft
NCT001508918	NCT00150891_8_T0	PHENOTYPE	21	21	acute
NCT001508918	NCT00150891_8_T1	ORGAN	30	30	graft
NCT001508918	NCT00150891_8_T2	GENE	42	42	al
NCT001508918	NCT00150891_8_T3	GENE	41	41	et
NCT001508918	NCT00150891_8_T4	COMPOUND	27	27	1
NCT001508918	NCT00150891_8_T5	GENE	7	7	CD4
NCT001508918	NCT00150891_8_T6	GENE	13	13	IL-10
NCT001508918	NCT00150891_8_T7	GENE	34	34	Th1
NCT001508919	NCT00150891_9_T0	GENE	6	6	CD4
NCT001508919	NCT00150891_9_T1	GENE	11	11	IL-10
NCT001508919	NCT00150891_9_T2	ORGAN	1	1	liver
NCT001508919	NCT00150891_9_T3	ORGAN	2	2	transplant
NCT001508919	NCT00150891_9_T4	GENE	21	21	al
NCT001508919	NCT00150891_9_T5	GENE	20	20	et
NCT0015089110	NCT00150891_10_T0	GENE	24	24	CD4
NCT0015089110	NCT00150891_10_T1	GENE	29	29	IL-10
NCT0015089110	NCT00150891_10_T2	ORGAN	18	18	graft
NCT0015089110	NCT00150891_10_T3	ORGAN	9	9	transplant
NCT0015089112	NCT00150891_12_T0	PHENOTYPE	48	48	acute
NCT0015089112	NCT00150891_12_T1	COMPOUND	19	19	azathioprine
NCT0015089112	NCT00150891_12_T2	PHENOTYPE	50	50	chronic
NCT0015089114	NCT00150891_14_T0	ORGAN	0	0	Serum
NCT0015089114	NCT00150891_14_T1	COMPOUND	7	7	neopterin
NCT0015089116	NCT00150891_16_T0	PHENOTYPE	12	12	estimation
NCT0015089118	NCT00150891_18_T0	ORGAN	20	20	graft
NCT0015089118	NCT00150891_18_T1	ORGAN	24	24	graft
NCT0015089118	NCT00150891_18_T2	PHENOTYPE	28	28	chronic
NCT0015089118	NCT00150891_18_T3	ORGAN	29	29	allograft
NCT0015089120	NCT00150891_20_T0	ORGAN	11	11	graft
NCT0015089120	NCT00150891_20_T1	GENE	2	2	suppressor
NCT0015089120	NCT00150891_20_T2	ORGAN	6	6	transplant
NCT0015089123	NCT00150891_23_T0	GENE	1	1	Proc
NCT0015089123	NCT00150891_23_T1	ORGAN	0	0	Transplant
NCT0015089125	NCT00150891_25_T0	GENE	10	10	Carl
NCT0015089126	NCT00150891_26_T0	ORGAN	11	11	kidney
NCT0015089126	NCT00150891_26_T1	PHENOTYPE	10	10	acute
NCT0015089126	NCT00150891_26_T2	GENE	1	1	CD4
NCT0015089126	NCT00150891_26_T3	GENE	5	5	IL-10
NCT0015089126	NCT00150891_26_T4	ORGAN	12	12	graft
NCT0015089129	NCT00150891_29_T0	GENE	1	1	Proc
NCT0015089129	NCT00150891_29_T1	GENE	11	11	Carl
NCT0015089129	NCT00150891_29_T2	ORGAN	0	0	Transplant
NCT001509041	NCT00150904_1_T0	COMPOUND	8	8	ribavirin
NCT001509041	NCT00150904_1_T1	COMPOUND	16	16	HCV
NCT001509046	NCT00150904_6_T0	PHENOTYPE	6	6	HIV
NCT001509046	NCT00150904_6_T1	COMPOUND	8	8	HCV
NCT001509046	NCT00150904_6_T2	PHENOTYPE	4	4	coinfection
NCT001509047	NCT00150904_7_T0	PHENOTYPE	3	3	progression
NCT001509047	NCT00150904_7_T1	PHENOTYPE	8	8	cirrhosis
NCT001509047	NCT00150904_7_T2	PHENOTYPE	11	12	liver disease
NCT001509047	NCT00150904_7_T3	PHENOTYPE	24	25	hepatitis C
NCT001509047	NCT00150904_7_T4	PHENOTYPE	5	6	liver fibrosis
NCT001509048	NCT00150904_8_T0	COMPOUND	9	9	HCV
NCT001509049	NCT00150904_9_T0	PHENOTYPE	7	7	understood
NCT0015090410	NCT00150904_10_T0	GENE	15	15	EVR
NCT0015090410	NCT00150904_10_T1	COMPOUND	5	5	HCV
NCT0015090410	NCT00150904_10_T2	COMPOUND	19	19	HCV
NCT0015090414	NCT00150904_14_T0	COMPOUND	4	4	HCV
NCT0015090414	NCT00150904_14_T1	GENE	6	6	has
NCT0015090415	NCT00150904_15_T0	CELL	9	9	cells
NCT0015090415	NCT00150904_15_T1	GENE	8	8	CD8
NCT0015090415	NCT00150904_15_T2	GENE	11	11	defective
NCT0015090415	NCT00150904_15_T3	COMPOUND	6	6	HCV
NCT0015090415	NCT00150904_15_T4	BIOLOGICAL_PROCESS	3	4	interferon production
NCT0015090416	NCT00150904_16_T0	COMPOUND	16	16	ribavirin
NCT0015090416	NCT00150904_16_T1	CELL	9	9	cells
NCT0015090416	NCT00150904_16_T2	GENE	8	8	CD8
NCT0015090416	NCT00150904_16_T3	COMPOUND	7	7	HCV
NCT0015090417	NCT00150904_17_T0	PHENOTYPE	14	14	proliferation
NCT0015090417	NCT00150904_17_T1	CELL	5	5	T-cells
NCT0015090418	NCT00150904_18_T0	PHENOTYPE	21	21	peripheral
NCT0015090418	NCT00150904_18_T1	GENE	9	9	CD4
NCT0015090418	NCT00150904_18_T2	CELL	12	12	cells
NCT0015090418	NCT00150904_18_T3	ORGAN	15	15	liver
NCT0015090418	NCT00150904_18_T4	GENE	11	11	CD8
NCT0015090418	NCT00150904_18_T5	COMPOUND	8	8	HCV
NCT0015090420	NCT00150904_20_T0	GENE	12	12	EVR
NCT0015090420	NCT00150904_20_T1	GENE	40	40	EVR
NCT0015090420	NCT00150904_20_T2	COMPOUND	74	74	ribavirin
NCT0015090420	NCT00150904_20_T3	PHENOTYPE	64	64	proliferation
NCT0015090420	NCT00150904_20_T4	GENE	68	68	interferon
NCT0015090420	NCT00150904_20_T5	GENE	57	57	CD4
NCT0015090420	NCT00150904_20_T6	CELL	60	60	cells
NCT0015090420	NCT00150904_20_T7	GENE	59	59	CD8
NCT0015090420	NCT00150904_20_T8	COMPOUND	28	28	HCV
NCT0015090420	NCT00150904_20_T9	COMPOUND	55	55	HCV
NCT0015090421	NCT00150904_21_T0	COMPOUND	27	27	ribavirin
NCT0015090421	NCT00150904_21_T1	PHENOTYPE	6	6	proliferation
NCT0015090421	NCT00150904_21_T2	COMPOUND	11	11	HCV
NCT0015090421	NCT00150904_21_T3	PHENOTYPE	10	10	chronic
NCT0015090421	NCT00150904_21_T4	CELL	2	3	T cells
NCT0015090421	NCT00150904_21_T5	CELL	18	19	T cells
NCT0015090422	NCT00150904_22_T0	GENE	1	1	wich
NCT0015090422	NCT00150904_22_T1	CELL	13	13	cells
NCT0015090422	NCT00150904_22_T2	ORGAN	16	16	liver
NCT0015090422	NCT00150904_22_T3	GENE	12	12	CD8
NCT0015090422	NCT00150904_22_T4	COMPOUND	10	10	HCV
NCT001509171	NCT00150917_1_T0	PHENOTYPE	9	9	perceived
NCT001509178	NCT00150917_8_T0	PHENOTYPE	9	10	breast cancer
NCT001509179	NCT00150917_9_T0	PHENOTYPE	11	11	perceived
NCT0015091711	NCT00150917_11_T0	PHENOTYPE	40	41	breast cancer
NCT0015091713	NCT00150917_13_T0	PHENOTYPE	18	18	Oncology
NCT0015091713	NCT00150917_13_T1	PHENOTYPE	28	29	Regional Cancer
NCT0015091715	NCT00150917_15_T0	GENE	2	2	has
NCT0015091715	NCT00150917_15_T1	PHENOTYPE	8	9	Breast Cancer
NCT0015091717	NCT00150917_17_T0	PHENOTYPE	7	7	recruitment
NCT0015091721	NCT00150917_21_T0	GENE	3	3	has
NCT0015091721	NCT00150917_21_T1	GENE	26	26	has
NCT0015091723	NCT00150917_23_T0	PHENOTYPE	12	12	decision-making
NCT001509304	NCT00150930_4_T0	GENE	8	8	UVB
NCT001509304	NCT00150930_4_T1	GENE	22	22	UVB
NCT001509305	NCT00150930_5_T0	PHENOTYPE	0	2	Quality of life
NCT0015093017	NCT00150930_17_T0	GENE	5	5	UVB
NCT0015093017	NCT00150930_17_T1	GENE	12	12	UVB
NCT0015093018	NCT00150930_18_T0	GENE	7	7	UVB
NCT0015093019	NCT00150930_19_T0	GENE	9	9	UVB
NCT0015093020	NCT00150930_20_T0	GENE	18	18	UVB
NCT0015093022	NCT00150930_22_T0	GENE	10	10	UVB
NCT0015093022	NCT00150930_22_T1	GENE	24	24	UVB
NCT0015093023	NCT00150930_23_T0	PHENOTYPE	0	2	Quality of life
NCT0015093024	NCT00150930_24_T0	GENE	32	32	PDI
NCT0015093024	NCT00150930_24_T1	PHENOTYPE	26	28	Quality of life
NCT001509433	NCT00150943_3_T0	PHENOTYPE	5	6	vascular disease
NCT001509436	NCT00150943_6_T0	PHENOTYPE	7	7	progression
NCT001509436	NCT00150943_6_T1	PHENOTYPE	5	6	renal failure
NCT001509438	NCT00150943_8_T0	ORGAN	9	10	renal artery
NCT0015094311	NCT00150943_11_T0	GENE	5	5	yrs
NCT0015094311	NCT00150943_11_T1	GENE	11	11	yrs
NCT0015094311	NCT00150943_11_T2	GENE	7	7	extended
NCT0015094317	NCT00150943_17_T0	GENE	16	16	cm
NCT0015094317	NCT00150943_17_T1	ORGAN	29	29	aorta
NCT0015094317	NCT00150943_17_T2	ORGAN	12	13	renal artery
NCT0015094319	NCT00150943_19_T0	ORGAN	5	5	serum
NCT0015094319	NCT00150943_19_T1	COMPOUND	19	19	atorvastatin
NCT0015094320	NCT00150943_20_T0	COMPOUND	10	10	atorvastatin
NCT0015094321	NCT00150943_21_T0	PHENOTYPE	0	0	Hypertension
NCT0015094321	NCT00150943_21_T1	COMPOUND	7	7	thiazide
NCT0015094321	NCT00150943_21_T2	COMPOUND	9	9	calcium
NCT0015094323	NCT00150943_23_T0	GENE	2	2	BP
NCT0015094324	NCT00150943_24_T0	COMPOUND	5	5	aspirin
NCT0015094324	NCT00150943_24_T1	CELL	3	3	platelet
NCT0015094327	NCT00150943_27_T0	COMPOUND	8	8	aspirin
NCT0015094331	NCT00150943_31_T0	PHENOTYPE	7	7	bilateral
NCT0015094331	NCT00150943_31_T1	GENE	25	25	yrs
NCT0015094332	NCT00150943_32_T0	GENE	13	13	yrs
NCT0015094333	NCT00150943_33_T0	GENE	16	16	mth
NCT0015094333	NCT00150943_33_T1	GENE	23	23	yrs
NCT0015094333	NCT00150943_33_T2	PHENOTYPE	0	2	Quality of life
NCT0015094334	NCT00150943_34_T0	GENE	12	12	balloon
NCT0015094334	NCT00150943_34_T1	PHENOTYPE	78	78	renovascular
NCT0015094334	NCT00150943_34_T2	GENE	56	56	hr
NCT0015094334	NCT00150943_34_T3	GENE	38	38	BP
NCT0015094334	NCT00150943_34_T4	GENE	50	50	BP
NCT0015094334	NCT00150943_34_T5	GENE	58	58	BP
NCT0015094334	NCT00150943_34_T6	PHENOTYPE	77	77	bilateral
NCT0015094334	NCT00150943_34_T7	PHENOTYPE	33	33	hypertension
NCT0015094334	NCT00150943_34_T8	PHENOTYPE	71	72	pulmonary edema
NCT0015094334	NCT00150943_34_T9	PHENOTYPE	109	110	malignant hypertension
NCT0015094334	NCT00150943_34_T10	PHENOTYPE	85	88	impaired left ventricular function
NCT0015094336	NCT00150943_36_T0	GENE	10	10	CI
NCT001509692	NCT00150969_2_T0	PHENOTYPE	18	18	fragility
NCT001509692	NCT00150969_2_T1	PHENOTYPE	24	24	fractures
NCT001509692	NCT00150969_2_T2	PHENOTYPE	3	4	systemic disease
NCT001509693	NCT00150969_3_T0	PHENOTYPE	10	10	osteoporosis
NCT001509694	NCT00150969_4_T0	PHENOTYPE	5	6	osteoporotic fracture
NCT001509695	NCT00150969_5_T0	PHENOTYPE	6	7	osteoporotic fractures
NCT001509696	NCT00150969_6_T0	PHENOTYPE	13	13	fractures
NCT001509696	NCT00150969_6_T1	COMPOUND	4	5	vitamin K
NCT001509696	NCT00150969_6_T2	PHENOTYPE	9	10	bone loss
NCT001509697	NCT00150969_7_T0	GENE	24	24	osteocalcin
NCT001509697	NCT00150969_7_T1	COMPOUND	15	16	glutamic acid
NCT001509697	NCT00150969_7_T2	TISSUE	19	20	bone matrix
NCT001509697	NCT00150969_7_T3	GENE	6	7	gamma-glutamyl carboxylase
NCT001509699	NCT00150969_9_T0	PHENOTYPE	8	8	osteoporosis
NCT001509699	NCT00150969_9_T1	PHENOTYPE	13	14	osteoporotic fractures
NCT0015096911	NCT00150969_11_T0	PHENOTYPE	22	22	osteopenia
NCT0015096911	NCT00150969_11_T1	COMPOUND	10	11	vitamin K
NCT0015096912	NCT00150969_12_T0	PHENOTYPE	1	1	secondary
NCT0015096912	NCT00150969_12_T1	PHENOTYPE	31	31	affects
NCT0015096912	NCT00150969_12_T2	PHENOTYPE	24	24	fractures
NCT0015096912	NCT00150969_12_T3	PHENOTYPE	8	9	adverse effects
NCT0015096912	NCT00150969_12_T4	COMPOUND	12	13	vitamin K
NCT0015096912	NCT00150969_12_T5	COMPOUND	18	19	vitamin K
NCT0015096912	NCT00150969_12_T6	COMPOUND	29	30	vitamin K
NCT0015096912	NCT00150969_12_T7	PHENOTYPE	32	34	quality of life
NCT0015096913	NCT00150969_13_T0	PHENOTYPE	19	20	adverse effects
NCT0015096913	NCT00150969_13_T1	COMPOUND	4	5	vitamin K
NCT0015096913	NCT00150969_13_T2	COMPOUND	22	23	vitamin K
NCT0015096916	NCT00150969_16_T0	GENE	3	3	had
NCT0015096916	NCT00150969_16_T1	GENE	9	9	40
NCT0015096916	NCT00150969_16_T2	PHENOTYPE	5	5	fragility
NCT0015096916	NCT00150969_16_T3	PHENOTYPE	6	6	fracture
NCT0015096918	NCT00150969_18_T0	GENE	8	8	calcitonin
NCT0015096918	NCT00150969_18_T1	COMPOUND	6	6	bisphosphonates
NCT0015096918	NCT00150969_18_T2	COMPOUND	5	5	raloxifene
NCT0015096918	NCT00150969_18_T3	GENE	2	2	hormone
NCT0015096920	NCT00150969_20_T0	PHENOTYPE	7	7	hyperthyroidism
NCT0015096920	NCT00150969_20_T1	PHENOTYPE	6	6	hyperparathyroidism
NCT0015096920	NCT00150969_20_T2	PHENOTYPE	4	5	Paget's disease
NCT0015096920	NCT00150969_20_T3	PHENOTYPE	10	12	metabolic bone diseases
NCT0015096921	NCT00150969_21_T0	ORGAN	7	7	kidney
NCT0015096921	NCT00150969_21_T1	ORGAN	8	8	pancreas
NCT0015096921	NCT00150969_21_T2	ORGAN	11	11	heart
NCT0015096921	NCT00150969_21_T3	PHENOTYPE	3	6	diseases of the liver
NCT001510086	NCT00151008_6_T0	PHENOTYPE	21	21	initiation
NCT001510086	NCT00151008_6_T1	GENE	40	40	gel
NCT001510211	NCT00151021_1_T0	BIOLOGICAL_PROCESS	28	29	walking behavior
NCT001510341	NCT00151034_1_T0	PHENOTYPE	19	19	tumors
NCT001510341	NCT00151034_1_T1	GENE	17	17	HER2
NCT001510471	NCT00151047_1_T0	PHENOTYPE	21	21	tumor
NCT001510471	NCT00151047_1_T1	PHENOTYPE	10	10	affects
NCT001510471	NCT00151047_1_T2	PHENOTYPE	14	15	other cancer
NCT001510604	NCT00151060_4_T0	COMPOUND	8	8	paclitaxel
NCT001510604	NCT00151060_4_T1	COMPOUND	6	6	etoposide
NCT001510604	NCT00151060_4_T2	COMPOUND	5	5	estramustine
NCT001510607	NCT00151060_7_T0	CELL	17	17	cells
NCT001510607	NCT00151060_7_T1	CELL	24	24	cells
NCT001510607	NCT00151060_7_T2	PHENOTYPE	16	16	tumor
NCT001510608	NCT00151060_8_T0	PHENOTYPE	17	17	tumors
NCT001510608	NCT00151060_8_T1	GENE	11	11	has
NCT0015106011	NCT00151060_11_T0	PHENOTYPE	3	3	metastases
NCT0015106011	NCT00151060_11_T1	PHENOTYPE	15	15	metastases
NCT0015106011	NCT00151060_11_T2	GENE	8	8	D1
NCT0015106011	NCT00151060_11_T3	TISSUE	6	7	lymph nodes
NCT001510732	NCT00151073_2_T0	GENE	1	1	hormone
NCT001510733	NCT00151073_3_T0	GENE	4	4	has
NCT001510735	NCT00151073_5_T0	PHENOTYPE	10	10	complications
NCT001510735	NCT00151073_5_T1	PHENOTYPE	13	14	bone metastases
NCT001510863	NCT00151086_3_T0	GENE	1	1	hormone
NCT001510864	NCT00151086_4_T0	GENE	4	4	has
NCT001510868	NCT00151086_8_T0	PHENOTYPE	9	11	quality of life
NCT001511252	NCT00151125_2_T0	PHENOTYPE	18	20	Von Willebrand disease
NCT001511380	NCT00151138_0_T0	PHENOTYPE	3	3	HTN
NCT001511388	NCT00151138_8_T0	BIOLOGICAL_PROCESS	6	6	drinking
NCT001511388	NCT00151138_8_T1	BIOLOGICAL_PROCESS	19	19	drinking
NCT001511388	NCT00151138_8_T2	BIOLOGICAL_PROCESS	4	4	eating
NCT001511388	NCT00151138_8_T3	GENE	2	2	BP
NCT001511389	NCT00151138_9_T0	GENE	16	16	2.3
NCT001511389	NCT00151138_9_T1	GENE	10	10	separated
NCT001511389	NCT00151138_9_T2	GENE	5	5	BP
NCT0015113810	NCT00151138_10_T0	PHENOTYPE	6	6	pulse
NCT0015113812	NCT00151138_12_T0	GENE	9	9	BP
NCT0015113813	NCT00151138_13_T0	PHENOTYPE	10	10	hypertension
NCT0015113816	NCT00151138_16_T0	PHENOTYPE	8	8	secondary
NCT0015113816	NCT00151138_16_T1	PHENOTYPE	33	33	hyperaldosteronism
NCT0015113816	NCT00151138_16_T2	PHENOTYPE	11	11	hypertension
NCT0015113816	NCT00151138_16_T3	PHENOTYPE	29	30	renal failure
NCT0015113820	NCT00151138_20_T0	GENE	22	22	blocker
NCT0015113820	NCT00151138_20_T1	PHENOTYPE	33	33	asthma
NCT0015113820	NCT00151138_20_T2	GENE	21	21	beta
NCT0015113820	NCT00151138_20_T3	PHENOTYPE	25	26	adverse reaction
NCT0015113820	NCT00151138_20_T4	MOLECULAR_FUNCTION	18	19	ACE inhibitor
NCT0015113820	NCT00151138_20_T5	PHENOTYPE	28	31	chronic obstructive lung disease
NCT0015113821	NCT00151138_21_T0	GENE	9	9	SBP
NCT0015113821	NCT00151138_21_T1	PHENOTYPE	29	29	allergy
NCT0015113821	NCT00151138_21_T2	GENE	10	10	180
NCT0015113821	NCT00151138_21_T3	GENE	16	16	110
NCT0015113821	NCT00151138_21_T4	GENE	15	15	DBP
NCT0015113821	NCT00151138_21_T5	GENE	31	31	beta
NCT0015113821	NCT00151138_21_T6	PHENOTYPE	26	27	adverse reaction
NCT0015113826	NCT00151138_26_T0	PHENOTYPE	9	9	seizures
NCT0015113826	NCT00151138_26_T1	PHENOTYPE	17	18	multiple sclerosis
NCT0015113826	NCT00151138_26_T2	PHENOTYPE	12	13	alcoholic dementia
NCT0015113826	NCT00151138_26_T3	PHENOTYPE	14	15	Parkinson's disease
NCT0015113826	NCT00151138_26_T4	PHENOTYPE	7	8	head injury
NCT0015113826	NCT00151138_26_T5	PHENOTYPE	4	5	neurological disorders
NCT0015113827	NCT00151138_27_T0	GENE	3	3	MRI
NCT0015113829	NCT00151138_29_T0	PHENOTYPE	6	6	peri-menopausal
NCT001511513	NCT00151151_3_T0	GENE	6	6	CAMI
NCT001511513	NCT00151151_3_T1	PHENOTYPE	26	26	STDs
NCT001511518	NCT00151151_8_T0	GENE	15	15	has
NCT001511519	NCT00151151_9_T0	GENE	32	32	DEC
NCT001511519	NCT00151151_9_T1	GENE	26	26	CAMI
NCT0015115110	NCT00151151_10_T0	GENE	1	1	CAMI
NCT0015115115	NCT00151151_15_T0	GENE	19	19	DEC
NCT0015115115	NCT00151151_15_T1	GENE	14	14	CAMI
NCT0015115115	NCT00151151_15_T2	PHENOTYPE	33	33	STDs
NCT0015115116	NCT00151151_16_T0	PHENOTYPE	20	20	STDs
NCT0015115116	NCT00151151_16_T1	PHENOTYPE	30	30	STDs
NCT0015115117	NCT00151151_17_T0	GENE	6	6	CAMI
NCT0015115117	NCT00151151_17_T1	PHENOTYPE	26	26	STDs
NCT0015115118	NCT00151151_18_T0	GENE	9	9	CAMI
NCT0015115119	NCT00151151_19_T0	GENE	6	6	CAMI
NCT0015115120	NCT00151151_20_T0	PHENOTYPE	22	22	STDs
NCT001511772	NCT00151177_2_T0	GENE	1	1	CPAP
NCT001511772	NCT00151177_2_T1	PHENOTYPE	16	16	initiation
NCT001511773	NCT00151177_3_T0	GENE	13	13	CPAP
NCT001511774	NCT00151177_4_T0	PHENOTYPE	3	3	acute
NCT001511774	NCT00151177_4_T1	GENE	16	16	CPAP
NCT001511774	NCT00151177_4_T2	PHENOTYPE	4	5	ischemic stroke
NCT001511775	NCT00151177_5_T0	GENE	9	9	CPAP
NCT001511778	NCT00151177_8_T0	GENE	11	11	MRI
NCT001511778	NCT00151177_8_T1	PHENOTYPE	22	22	infarction
NCT0015117711	NCT00151177_11_T0	GENE	1	1	CPAP
NCT0015117712	NCT00151177_12_T0	GENE	7	7	CPAP
NCT0015117712	NCT00151177_12_T1	PHENOTYPE	12	13	acute stroke
NCT0015117713	NCT00151177_13_T0	PHENOTYPE	12	12	infarctions
NCT0015117713	NCT00151177_13_T1	PHENOTYPE	0	0	Secondary
NCT0015117713	NCT00151177_13_T2	GENE	14	14	MRI
NCT0015117715	NCT00151177_15_T0	ORGAN	2	2	arteries
NCT0015117716	NCT00151177_16_T0	ORGAN	33	33	arteries
NCT0015117716	NCT00151177_16_T1	PHENOTYPE	13	13	DVA
NCT0015117717	NCT00151177_17_T0	GENE	4	4	hoc
NCT0015117718	NCT00151177_18_T0	PHENOTYPE	7	7	DVA
NCT0015117718	NCT00151177_18_T1	PHENOTYPE	12	13	sleep apnea
NCT001511900	NCT00151190_0_T0	PHENOTYPE	1	1	Diabetes
NCT001512033	NCT00151203_3_T0	COMPOUND	21	21	1
NCT001512167	NCT00151216_7_T0	PHENOTYPE	9	9	progressive
NCT001512167	NCT00151216_7_T1	PHENOTYPE	3	3	LINCL
NCT001512167	NCT00151216_7_T2	PHENOTYPE	5	6	chronically ill
NCT001512167	NCT00151216_7_T3	PHENOTYPE	10	11	CNS disorder
NCT0015121612	NCT00151216_12_T0	PHENOTYPE	0	1	Group B
NCT0015121613	NCT00151216_13_T0	PHENOTYPE	14	14	LINCL
NCT0015121614	NCT00151216_14_T0	PHENOTYPE	44	44	progression
NCT0015121614	NCT00151216_14_T1	PHENOTYPE	29	29	LINCL
NCT0015121614	NCT00151216_14_T2	ORGAN	50	52	central nervous system
NCT0015121617	NCT00151216_17_T0	PHENOTYPE	2	2	malignancy
NCT0015121617	NCT00151216_17_T1	ORGAN	10	10	liver
NCT0015121617	NCT00151216_17_T2	PHENOTYPE	17	17	HIV
NCT0015121617	NCT00151216_17_T3	PHENOTYPE	5	6	skin cancer
NCT0015121617	NCT00151216_17_T4	PHENOTYPE	12	13	renal failure
NCT0015121617	NCT00151216_17_T5	PHENOTYPE	7	9	congenital heart disease
NCT001512294	NCT00151229_4_T0	PHENOTYPE	32	32	estimation
NCT001512295	NCT00151229_5_T0	PHENOTYPE	25	26	systolic hypertension
NCT001512686	NCT00151268_6_T0	PHENOTYPE	10	10	LINCL
NCT001512687	NCT00151268_7_T0	GENE	13	13	al
NCT001512687	NCT00151268_7_T1	GENE	12	12	et
NCT001512812	NCT00151281_2_T0	PHENOTYPE	0	0	Secondary
NCT001512819	NCT00151281_9_T0	GENE	1	1	ANC
NCT001512819	NCT00151281_9_T1	GENE	6	6	PEPC
NCT0015128110	NCT00151281_10_T0	GENE	5	5	PEPC
NCT001512942	NCT00151294_2_T0	PHENOTYPE	14	15	emotional instability
NCT001512942	NCT00151294_2_T1	PHENOTYPE	22	23	depressive symptoms
NCT001513073	NCT00151307_3_T0	COMPOUND	9	9	oxygen
NCT001513074	NCT00151307_4_T0	COMPOUND	4	4	oxygen
NCT001513077	NCT00151307_7_T0	ORGAN	14	14	forehead
NCT001513077	NCT00151307_7_T1	COMPOUND	9	9	oxygen
NCT001513078	NCT00151307_8_T0	PHENOTYPE	8	8	floppy
NCT001513079	NCT00151307_9_T0	COMPOUND	16	16	oxygen
NCT0015130710	NCT00151307_10_T0	COMPOUND	8	8	oxygen
NCT0015130711	NCT00151307_11_T0	COMPOUND	7	7	oxygen
NCT001513202	NCT00151320_2_T0	GENE	8	8	CHOP
NCT001513205	NCT00151320_5_T0	GENE	19	19	18
NCT001513205	NCT00151320_5_T1	PHENOTYPE	39	40	disease progression
NCT001513206	NCT00151320_6_T0	PHENOTYPE	3	4	disease progression
NCT001513330	NCT00151333_0_T0	PHENOTYPE	4	4	Mild
NCT001513330	NCT00151333_0_T1	GENE	9	9	AD
NCT001513330	NCT00151333_0_T2	PHENOTYPE	7	8	Alzheimer's Disease
NCT001513464	NCT00151346_4_T0	PHENOTYPE	17	17	hypotension
NCT001513464	NCT00151346_4_T1	GENE	4	4	CSE
NCT001513464	NCT00151346_4_T2	GENE	23	23	CSE
NCT001513464	NCT00151346_4_T3	PHENOTYPE	19	20	fetal bradycardia
NCT001513594	NCT00151359_4_T0	PHENOTYPE	16	18	loss of sensation
NCT001513597	NCT00151359_7_T0	PHENOTYPE	19	19	discomfort
NCT001513722	NCT00151372_2_T0	PHENOTYPE	31	31	ideation
NCT001513722	NCT00151372_2_T1	PHENOTYPE	28	29	depressive symptoms
NCT001513724	NCT00151372_4_T0	PHENOTYPE	31	31	ideation
NCT001513724	NCT00151372_4_T1	PHENOTYPE	28	29	depressive symptoms
NCT001513850	NCT00151385_0_T0	PHENOTYPE	5	6	Hemophilia A
NCT001513852	NCT00151385_2_T0	GENE	15	15	FVIII
NCT001513852	NCT00151385_2_T1	PHENOTYPE	5	6	hemophilia A
NCT001513980	NCT00151398_0_T0	PHENOTYPE	5	5	Mild
NCT001513980	NCT00151398_0_T1	GENE	10	10	AD
NCT001513980	NCT00151398_0_T2	GENE	3	3	SR
NCT001513980	NCT00151398_0_T3	PHENOTYPE	8	9	Alzheimer's Disease
NCT001514113	NCT00151411_3_T0	PHENOTYPE	0	0	PCOS
NCT001514113	NCT00151411_3_T1	PHENOTYPE	8	8	hyperinsulinemia
NCT001514113	NCT00151411_3_T2	PHENOTYPE	5	6	insulin resistance
NCT001514114	NCT00151411_4_T0	PHENOTYPE	19	19	anovulation
NCT001514114	NCT00151411_4_T1	PHENOTYPE	18	18	chronic
NCT001514115	NCT00151411_5_T0	PHENOTYPE	7	7	PCOS
NCT001514115	NCT00151411_5_T1	PHENOTYPE	30	30	PCOS
NCT001514115	NCT00151411_5_T2	PHENOTYPE	2	3	insulin sensitivity
NCT001514117	NCT00151411_7_T0	PHENOTYPE	0	0	Secondary
NCT001514117	NCT00151411_7_T1	PHENOTYPE	8	9	insulin sensitivity
NCT001514119	NCT00151411_9_T0	PHENOTYPE	0	0	Secondary
NCT001514119	NCT00151411_9_T1	PHENOTYPE	8	9	insulin sensitivity
NCT001514243	NCT00151424_3_T0	GENE	3	3	reduced
NCT001514243	NCT00151424_3_T1	PHENOTYPE	0	1	Other symptoms
NCT001514243	NCT00151424_3_T2	PHENOTYPE	13	14	problem solving
NCT001514244	NCT00151424_4_T0	PHENOTYPE	9	9	imbalance
NCT001514244	NCT00151424_4_T1	PHENOTYPE	3	3	schizophrenia
NCT001514244	NCT00151424_4_T2	PHENOTYPE	1	1	symptoms
NCT001514244	NCT00151424_4_T3	CELL	22	22	cells
NCT001514244	NCT00151424_4_T4	COMPOUND	16	16	dopamine
NCT001514244	NCT00151424_4_T5	PHENOTYPE	20	20	enables
NCT001514245	NCT00151424_5_T0	PHENOTYPE	11	11	imbalance
NCT001514245	NCT00151424_5_T1	COMPOUND	13	13	dopamine
NCT001514246	NCT00151424_6_T0	COMPOUND	18	18	olanzapine
NCT001514246	NCT00151424_6_T1	PHENOTYPE	25	25	schizophrenia
NCT001514246	NCT00151424_6_T2	COMPOUND	13	13	asenapine
NCT001514631	NCT00151463_1_T0	COMPOUND	43	43	citrate
NCT001514631	NCT00151463_1_T1	COMPOUND	42	42	sildenafil
NCT001514890	NCT00151489_0_T0	PHENOTYPE	7	7	Fibromyalgia
NCT001515020	NCT00151502_0_T0	GENE	13	13	AD
NCT001515020	NCT00151502_0_T1	GENE	10	10	Cholinesterase
NCT001515021	NCT00151502_1_T0	GENE	0	0	AD
NCT001515151	NCT00151515_1_T0	PHENOTYPE	1	1	secondary
NCT001515151	NCT00151515_1_T1	COMPOUND	12	12	minoxidil
NCT001515151	NCT00151515_1_T2	PHENOTYPE	25	26	hair loss
NCT001515153	NCT00151515_3_T0	COMPOUND	7	7	minoxidil
NCT001515154	NCT00151515_4_T0	COMPOUND	10	10	minoxidil
NCT001515154	NCT00151515_4_T1	COMPOUND	27	27	minoxidil
NCT001515155	NCT00151515_5_T0	COMPOUND	2	2	minoxidil
NCT001515155	NCT00151515_5_T1	PHENOTYPE	14	15	androgenetic alopecia
NCT001515157	NCT00151515_7_T0	PHENOTYPE	12	12	secondary
NCT001515157	NCT00151515_7_T1	COMPOUND	4	4	minoxidil
NCT001515158	NCT00151515_8_T0	ORGAN	32	32	scalp
NCT001515158	NCT00151515_8_T1	COMPOUND	2	2	minoxidil
NCT001515158	NCT00151515_8_T2	PHENOTYPE	11	12	adverse events
NCT001515280	NCT00151528_0_T0	PHENOTYPE	8	8	Fibromyalgia
NCT001515415	NCT00151541_5_T0	PHENOTYPE	1	1	Acne
NCT001515415	NCT00151541_5_T1	PHENOTYPE	7	8	Adverse Reaction
NCT001515417	NCT00151541_7_T0	ORGAN	0	0	Plasma
NCT001515417	NCT00151541_7_T1	COMPOUND	15	15	dapsone
NCT001515417	NCT00151541_7_T2	ORGAN	16	16	plasma
NCT001515418	NCT00151541_8_T0	PHENOTYPE	0	1	Adverse events
NCT0015154129	NCT00151541_29_T0	PHENOTYPE	7	8	mental health
NCT0015154131	NCT00151541_31_T0	BIOLOGICAL_PROCESS	7	7	swimming
NCT0015154137	NCT00151541_37_T0	PHENOTYPE	9	9	acne
NCT0015154137	NCT00151541_37_T1	PHENOTYPE	16	16	acne
NCT0015154140	NCT00151541_40_T0	COMPOUND	20	20	THE
NCT0015154140	NCT00151541_40_T1	COMPOUND	28	28	THE
NCT0015154140	NCT00151541_40_T2	GENE	24	24	NOT
NCT0015154148	NCT00151541_48_T0	PHENOTYPE	21	21	acne
NCT0015154148	NCT00151541_48_T1	PHENOTYPE	23	24	inflammatory responses
NCT0015154152	NCT00151541_52_T0	COMPOUND	4	4	isotretinoin
NCT0015154154	NCT00151541_54_T0	COMPOUND	14	14	dapsone
NCT0015154154	NCT00151541_54_T1	GENE	16	16	gel
NCT0015154160	NCT00151541_60_T0	PHENOTYPE	3	4	cystic acne
NCT0015154160	NCT00151541_60_T1	PHENOTYPE	6	7	acne conglobata
NCT0015154162	NCT00151541_62_T0	PHENOTYPE	6	6	nodules
NCT0015154165	NCT00151541_65_T0	GENE	14	14	hormone
NCT001515541	NCT00151554_1_T0	GENE	25	25	abdominal
NCT001515541	NCT00151554_1_T1	ORGAN	19	19	heart
NCT001515542	NCT00151554_2_T0	PHENOTYPE	17	17	discomfort
NCT001515547	NCT00151554_7_T0	GENE	20	20	abdominal
NCT0015155412	NCT00151554_12_T0	PHENOTYPE	10	10	experiences
NCT0015155414	NCT00151554_14_T0	GENE	4	4	abdominal
NCT0015155414	NCT00151554_14_T1	COMPOUND	1	1	N
NCT001515671	NCT00151567_1_T0	PHENOTYPE	38	38	ureterolithiasis
NCT001515671	NCT00151567_1_T1	ORGAN	37	37	pelvis
NCT001515671	NCT00151567_1_T2	COMPOUND	12	12	tamsulosin
NCT001515671	NCT00151567_1_T3	PHENOTYPE	30	30	elimination
NCT001515671	NCT00151567_1_T4	PHENOTYPE	21	24	lower urinary tract symptoms
NCT001515674	NCT00151567_4_T0	ORGAN	24	25	urinary tract
NCT001515674	NCT00151567_4_T1	PHENOTYPE	14	16	benign prostatic hyperplasia
NCT001515675	NCT00151567_5_T0	PHENOTYPE	23	23	ureterolithiasis
NCT001515675	NCT00151567_5_T1	ORGAN	22	22	pelvis
NCT001515675	NCT00151567_5_T2	COMPOUND	9	9	tamsulosin
NCT001515675	NCT00151567_5_T3	PHENOTYPE	15	15	elimination
NCT001515676	NCT00151567_6_T0	COMPOUND	6	6	tamsulosin
NCT001515676	NCT00151567_6_T1	PHENOTYPE	17	17	elimination
NCT001515801	NCT00151580_1_T0	ORGAN	0	0	Transplant
NCT001515801	NCT00151580_1_T1	PHENOTYPE	3	4	hepatitis C
NCT001515802	NCT00151580_2_T0	PHENOTYPE	1	1	recurrence
NCT001515802	NCT00151580_2_T1	PHENOTYPE	4	6	chronic liver disease
NCT001515803	NCT00151580_3_T0	COMPOUND	7	7	ribavirin
NCT001515803	NCT00151580_3_T1	GENE	11	11	has
NCT001515807	NCT00151580_7_T0	COMPOUND	16	16	ribavirin
NCT001515808	NCT00151580_8_T0	COMPOUND	16	16	ribavirin
NCT001515936	NCT00151593_6_T0	ORGAN	15	15	liver
NCT001515936	NCT00151593_6_T1	ORGAN	16	16	transplant
NCT001516063	NCT00151606_3_T0	COMPOUND	10	10	methicillin
NCT001516063	NCT00151606_3_T1	PHENOTYPE	8	8	resistant
NCT001516063	NCT00151606_3_T2	PHENOTYPE	6	6	strains
NCT001516064	NCT00151606_4_T0	PHENOTYPE	8	8	resistant
NCT001516192	NCT00151619_2_T0	PHENOTYPE	17	17	symptoms
NCT001516192	NCT00151619_2_T1	PHENOTYPE	5	7	coronary heart disease
NCT001516193	NCT00151619_3_T0	GENE	18	18	blocker
NCT001516193	NCT00151619_3_T1	COMPOUND	19	19	amlodipine
NCT001516193	NCT00151619_3_T2	PHENOTYPE	23	25	chronic heart failure
NCT001516195	NCT00151619_5_T0	PHENOTYPE	7	7	symptoms
NCT001516196	NCT00151619_6_T0	GENE	6	7	calcium channel
NCT001516196	NCT00151619_6_T1	PHENOTYPE	12	14	chronic heart failure
NCT001516196	NCT00151619_6_T2	PHENOTYPE	25	28	left ventricular diastolic dysfunction
NCT001516197	NCT00151619_7_T0	COMPOUND	28	28	amlodipine
NCT001516197	NCT00151619_7_T1	PHENOTYPE	19	19	tolerance
NCT001516198	NCT00151619_8_T0	COMPOUND	14	14	enalapril
NCT001516198	NCT00151619_8_T1	COMPOUND	17	17	digoxin
NCT001516198	NCT00151619_8_T2	COMPOUND	23	23	amlodipine
NCT001516198	NCT00151619_8_T3	COMPOUND	15	15	furosemide
NCT001516198	NCT00151619_8_T4	PHENOTYPE	3	5	chronic heart failure
NCT001516325	NCT00151632_5_T0	COMPOUND	3	3	tacrolimus
NCT001516325	NCT00151632_5_T1	PHENOTYPE	0	1	Adverse effects
NCT001516326	NCT00151632_6_T0	COMPOUND	11	11	tacrolimus
NCT001516326	NCT00151632_6_T1	GENE	8	8	reduced
NCT001516326	NCT00151632_6_T2	COMPOUND	16	17	mycophenolate mofetil
NCT001516327	NCT00151632_7_T0	PHENOTYPE	11	11	pharmacokinetics
NCT001516327	NCT00151632_7_T1	COMPOUND	13	14	mycophenolate mofetil
NCT001516328	NCT00151632_8_T0	ORGAN	2	2	liver
NCT001516328	NCT00151632_8_T1	COMPOUND	8	8	tacrolimus
NCT001516328	NCT00151632_8_T2	COMPOUND	17	17	tacrolimus
NCT001516328	NCT00151632_8_T3	COMPOUND	22	23	mycophenolate mofetil
NCT001516450	NCT00151645_0_T0	PHENOTYPE	9	9	Carcinoma
NCT001516450	NCT00151645_0_T1	CELL	3	3	Lymphocytes
NCT001516450	NCT00151645_0_T2	PHENOTYPE	5	7	Renal Cell Carcinoma
NCT001516452	NCT00151645_2_T0	PHENOTYPE	9	9	metastasis
NCT001516454	NCT00151645_4_T0	CELL	20	20	lymphocytes
NCT001516454	NCT00151645_4_T1	GENE	28	28	interleukin-2
NCT001516457	NCT00151645_7_T0	CELL	20	20	lymphocytes
NCT001516457	NCT00151645_7_T1	GENE	28	28	interleukin-2
NCT001516712	NCT00151671_2_T0	PHENOTYPE	6	7	hepatic insufficiency
NCT001516713	NCT00151671_3_T0	GENE	10	10	ORL
NCT001516714	NCT00151671_4_T0	ORGAN	20	20	liver
NCT001516714	NCT00151671_4_T1	PHENOTYPE	29	30	liver cancer
NCT001516717	NCT00151671_7_T0	PHENOTYPE	1	1	complications
NCT001516717	NCT00151671_7_T1	GENE	11	11	reduced
NCT001516717	NCT00151671_7_T2	PHENOTYPE	6	7	hepatic insufficiency
NCT001516717	NCT00151671_7_T3	PHENOTYPE	19	20	reperfusion injury
NCT001516717	NCT00151671_7_T4	PHENOTYPE	14	15	oxidative stress
NCT001516718	NCT00151671_8_T0	PHENOTYPE	10	10	complications
NCT001516718	NCT00151671_8_T1	GENE	5	5	has
NCT0015167111	NCT00151671_11_T0	ORGAN	14	14	liver
NCT0015167111	NCT00151671_11_T1	PHENOTYPE	20	20	infections
NCT0015167111	NCT00151671_11_T2	PHENOTYPE	16	16	immunity
NCT001516841	NCT00151684_1_T0	PHENOTYPE	0	0	Obesity
NCT001516841	NCT00151684_1_T1	ORGAN	6	6	plasma
NCT001516841	NCT00151684_1_T2	PHENOTYPE	7	8	insulin levels
NCT001516845	NCT00151684_5_T0	GENE	9	9	IIa
NCT001516846	NCT00151684_6_T0	PHENOTYPE	25	26	glucose levels
NCT001516971	NCT00151697_1_T0	COMPOUND	19	19	glucose
NCT001516971	NCT00151697_1_T1	GENE	14	14	insulin
NCT001516971	NCT00151697_1_T2	COMPOUND	11	11	glimepiride
NCT001516972	NCT00151697_2_T0	GENE	35	35	insulin
NCT001516972	NCT00151697_2_T1	GENE	42	42	insulin
NCT001516973	NCT00151697_3_T0	COMPOUND	4	4	glucose
NCT001516973	NCT00151697_3_T1	PHENOTYPE	7	8	weight gain
NCT001516976	NCT00151697_6_T0	GENE	21	21	insulin
NCT001516976	NCT00151697_6_T1	PHENOTYPE	14	15	insulin resistance
NCT001516976	NCT00151697_6_T2	TISSUE	7	8	body fat
NCT001516977	NCT00151697_7_T0	GENE	6	6	insulin
NCT001516978	NCT00151697_8_T0	COMPOUND	33	33	Lantus
NCT0015169710	NCT00151697_10_T0	GENE	27	27	C-peptide
NCT0015169710	NCT00151697_10_T1	ORGAN	21	21	plasma
NCT0015169710	NCT00151697_10_T2	PHENOTYPE	30	31	adverse effects
NCT001517100	NCT00151710_0_T0	PHENOTYPE	4	6	Congenital Adrenal Hyperplasia
NCT001517102	NCT00151710_2_T0	PHENOTYPE	19	19	obesity
NCT001517102	NCT00151710_2_T1	PHENOTYPE	7	8	insulin resistance
NCT001517104	NCT00151710_4_T0	PHENOTYPE	10	11	insulin sensitivity
NCT001517230	NCT00151723_0_T0	PHENOTYPE	12	12	Hyperthyroidism
NCT001517230	NCT00151723_0_T1	PHENOTYPE	7	8	Bone Loss
NCT001517230	NCT00151723_0_T2	PHENOTYPE	4	5	Atrial Fibrillation
NCT001517232	NCT00151723_2_T0	GENE	5	5	has
NCT001517362	NCT00151736_2_T0	PHENOTYPE	28	29	disease progression
NCT001517363	NCT00151736_3_T0	PHENOTYPE	7	8	B-cell CLL
NCT001517366	NCT00151736_6_T0	COMPOUND	14	14	NCI
NCT001517366	NCT00151736_6_T1	PHENOTYPE	2	3	B-cell CLL
NCT0015173610	NCT00151736_10_T0	PHENOTYPE	4	4	CLL
NCT0015173614	NCT00151736_14_T0	GENE	7	7	0.2
NCT0015173614	NCT00151736_14_T1	ORGAN	8	8	Appendix
NCT0015173618	NCT00151736_18_T0	COMPOUND	13	13	creatinine
NCT0015173618	NCT00151736_18_T1	GENE	3	3	1.5
NCT0015173618	NCT00151736_18_T2	ORGAN	12	12	serum
NCT0015173618	NCT00151736_18_T3	COMPOUND	9	9	urea
NCT0015173631	NCT00151736_31_T0	PHENOTYPE	6	6	CLL
NCT0015173637	NCT00151736_37_T0	COMPOUND	14	14	aspirin
NCT0015173637	NCT00151736_37_T1	PHENOTYPE	18	20	acute myocardial infarction
NCT0015177512	NCT00151775_12_T0	GENE	21	21	has
NCT0015177512	NCT00151775_12_T1	GENE	26	26	has
NCT0015177512	NCT00151775_12_T2	PHENOTYPE	31	31	hypertension
NCT0015177512	NCT00151775_12_T3	PHENOTYPE	23	24	kidney disease
NCT0015177513	NCT00151775_13_T0	PHENOTYPE	3	3	hypertension
NCT0015177516	NCT00151775_16_T0	GENE	17	17	has
NCT0015177516	NCT00151775_16_T1	GENE	22	22	has
NCT0015177516	NCT00151775_16_T2	PHENOTYPE	27	27	hypertension
NCT0015177516	NCT00151775_16_T3	PHENOTYPE	19	20	kidney disease
NCT0015177517	NCT00151775_17_T0	GENE	9	10	calcium channel
NCT0015177518	NCT00151775_18_T0	PHENOTYPE	3	3	hypertension
NCT0015177520	NCT00151775_20_T0	COMPOUND	8	8	1
NCT0015177522	NCT00151775_22_T0	GENE	1	1	II
NCT0015177523	NCT00151775_23_T0	COMPOUND	11	11	olmesartan
NCT0015177525	NCT00151775_25_T0	GENE	1	1	III
NCT0015177526	NCT00151775_26_T0	GENE	5	5	II
NCT0015177527	NCT00151775_27_T0	GENE	1	1	IV
NCT001517880	NCT00151788_0_T0	PHENOTYPE	12	12	Progression
NCT001517880	NCT00151788_0_T1	GENE	5	5	ACAT
NCT001517880	NCT00151788_0_T2	PHENOTYPE	14	16	Carotid Artery Disease
NCT001518010	NCT00151801_0_T0	GENE	9	9	MS
NCT001518016	NCT00151801_6_T0	PHENOTYPE	4	6	relapsing-remitting multiple sclerosis
NCT001518018	NCT00151801_8_T0	GENE	13	13	MRI
NCT001518019	NCT00151801_9_T0	COMPOUND	5	5	EDSS
NCT0015180110	NCT00151801_10_T0	GENE	0	0	MRI
NCT0015180111	NCT00151801_11_T0	GENE	5	5	MRI
NCT0015180111	NCT00151801_11_T1	BIOLOGICAL_PROCESS	24	25	luteal phase
NCT0015180111	NCT00151801_11_T2	BIOLOGICAL_PROCESS	29	30	menstrual cycle
NCT0015180112	NCT00151801_12_T0	GENE	17	17	24
NCT0015180112	NCT00151801_12_T1	GENE	24	24	24
NCT0015180112	NCT00151801_12_T2	GENE	32	32	24
NCT0015180112	NCT00151801_12_T3	GENE	40	40	24
NCT0015180112	NCT00151801_12_T4	GENE	50	50	24
NCT0015180112	NCT00151801_12_T5	PHENOTYPE	25	25	Fatigue
NCT0015180112	NCT00151801_12_T6	PHENOTYPE	26	26	Severity
NCT0015180112	NCT00151801_12_T7	PHENOTYPE	41	43	Quality of Life
NCT001518140	NCT00151814_0_T0	GENE	3	3	PK
NCT001518271	NCT00151827_1_T0	COMPOUND	9	9	losartan
NCT001518271	NCT00151827_1_T1	COMPOUND	4	5	olmesartan medoxomil
NCT001518404	NCT00151840_4_T0	BIOLOGICAL_PROCESS	3	4	donor selection
NCT001518530	NCT00151853_0_T0	GENE	14	14	CPB
NCT001518530	NCT00151853_0_T1	PHENOTYPE	13	13	Acute
NCT001518533	NCT00151853_3_T0	PHENOTYPE	19	19	secondary
NCT001518533	NCT00151853_3_T1	PHENOTYPE	14	15	atrial fibrillation
NCT001518533	NCT00151853_3_T2	PHENOTYPE	9	10	cerebral infarction
NCT001518533	NCT00151853_3_T3	PHENOTYPE	22	23	myocardial infarction
NCT001518538	NCT00151853_8_T0	PHENOTYPE	11	11	acute
NCT001518538	NCT00151853_8_T1	GENE	14	14	CPB
NCT001518539	NCT00151853_9_T0	GENE	9	9	ml
NCT0015185311	NCT00151853_11_T0	GENE	24	24	INR
NCT0015185311	NCT00151853_11_T1	GENE	28	28	INR
NCT0015185311	NCT00151853_11_T2	PHENOTYPE	6	6	enables
NCT0015185312	NCT00151853_12_T0	GENE	14	14	INR
NCT001518662	NCT00151866_2_T0	GENE	16	16	II
NCT001518662	NCT00151866_2_T1	GENE	18	18	II
NCT001518662	NCT00151866_2_T2	GENE	31	31	II
NCT001518662	NCT00151866_2_T3	CELL	13	13	Platelet
NCT001518662	NCT00151866_2_T4	GENE	17	17	PAS
NCT001518662	NCT00151866_2_T5	GENE	30	30	PAS
NCT001518662	NCT00151866_2_T6	ORGAN	20	20	plasma
NCT001518662	NCT00151866_2_T7	CELL	10	10	platelets
NCT001518662	NCT00151866_2_T8	CELL	27	27	platelets
NCT001518663	NCT00151866_3_T0	CELL	16	16	platelet
NCT001518664	NCT00151866_4_T0	GENE	13	13	II
NCT001518664	NCT00151866_4_T1	GENE	12	12	PAS
NCT001518664	NCT00151866_4_T2	ORGAN	15	15	plasma
NCT001518664	NCT00151866_4_T3	CELL	9	9	platelets
NCT001518664	NCT00151866_4_T4	PHENOTYPE	22	23	increased platelet
NCT001518666	NCT00151866_6_T0	COMPOUND	0	0	1
NCT001518666	NCT00151866_6_T1	GENE	3	3	CCI
NCT001518667	NCT00151866_7_T0	PHENOTYPE	0	0	Secondary
NCT001518667	NCT00151866_7_T1	PHENOTYPE	8	8	bleeding
NCT001518667	NCT00151866_7_T2	PHENOTYPE	9	9	complications
NCT001518667	NCT00151866_7_T3	PHENOTYPE	5	6	adverse reactions
NCT001518791	NCT00151879_1_T0	PHENOTYPE	6	6	SPM
NCT001518794	NCT00151879_4_T0	PHENOTYPE	16	16	seizure
NCT001518795	NCT00151879_5_T0	PHENOTYPE	15	15	SPM
NCT001518922	NCT00151892_2_T0	PHENOTYPE	7	8	ulcerative colitis
NCT001518923	NCT00151892_3_T0	GENE	15	15	bowel
NCT001518923	NCT00151892_3_T1	PHENOTYPE	18	19	ulcerative colitis
NCT001518924	NCT00151892_4_T0	COMPOUND	9	9	mesalazine
NCT001518924	NCT00151892_4_T1	PHENOTYPE	14	15	in remission
NCT001518924	NCT00151892_4_T2	PHENOTYPE	12	13	ulcerative colitis
NCT001519053	NCT00151905_3_T0	GENE	9	9	has
NCT001519053	NCT00151905_3_T1	PHENOTYPE	18	19	lung disease
NCT001519054	NCT00151905_4_T0	PHENOTYPE	16	16	bronchiolitis
NCT001519058	NCT00151905_8_T0	GENE	3	3	has
NCT001519058	NCT00151905_8_T1	PHENOTYPE	13	14	cystic fibrosis
NCT001519059	NCT00151905_9_T0	GENE	1	1	has
NCT001519059	NCT00151905_9_T1	PHENOTYPE	15	15	bronchiolitis
NCT0015190510	NCT00151905_10_T0	PHENOTYPE	28	28	bronchiolitis
NCT001519440	NCT00151944_0_T0	PHENOTYPE	14	14	Colitis
NCT001519440	NCT00151944_0_T1	PHENOTYPE	11	12	Ulcerative Colitis
NCT001519702	NCT00151970_2_T0	PHENOTYPE	28	28	ADHD
NCT001519832	NCT00151983_2_T0	COMPOUND	25	25	methylphenidate
NCT001520220	NCT00152022_0_T0	PHENOTYPE	10	10	ADHD
NCT001520220	NCT00152022_0_T1	PHENOTYPE	12	12	ADHD
NCT001520222	NCT00152022_2_T0	PHENOTYPE	8	8	affects
NCT001520222	NCT00152022_2_T1	PHENOTYPE	17	19	quality of life
NCT001520350	NCT00152035_0_T0	PHENOTYPE	7	7	ADHD
NCT001520350	NCT00152035_0_T1	PHENOTYPE	10	10	ADHD
NCT001520352	NCT00152035_2_T0	PHENOTYPE	8	8	affects
NCT001520613	NCT00152061_3_T0	GENE	48	48	CD4
NCT001520613	NCT00152061_3_T1	PHENOTYPE	30	30	resistant
NCT001520613	NCT00152061_3_T2	GENE	34	34	has
NCT001520744	NCT00152074_4_T0	GENE	11	11	has
NCT001520745	NCT00152074_5_T0	PHENOTYPE	42	42	proteinuria
NCT001520745	NCT00152074_5_T1	PHENOTYPE	37	37	progression
NCT001520745	NCT00152074_5_T2	PHENOTYPE	39	40	renal disease
NCT001520745	NCT00152074_5_T3	PHENOTYPE	34	36	left ventricular hypertrophy
NCT001520746	NCT00152074_6_T0	GENE	13	13	has
NCT001520746	NCT00152074_6_T1	PHENOTYPE	25	26	cardiovascular disease
NCT001520748	NCT00152074_8_T0	GENE	6	6	reduced
NCT001520872	NCT00152087_2_T0	PHENOTYPE	2	2	hepatoma
NCT001520874	NCT00152087_4_T0	ORGAN	21	21	liver
NCT001521003	NCT00152100_3_T0	CELL	2	2	cells
NCT001521003	NCT00152100_3_T1	GENE	9	9	has
NCT001521003	NCT00152100_3_T2	PHENOTYPE	19	19	SCID
NCT001521003	NCT00152100_3_T3	ORGAN	12	13	immune system
NCT001521005	NCT00152100_5_T0	PHENOTYPE	4	4	infections
NCT001521005	NCT00152100_5_T1	ORGAN	11	11	transplant
NCT001521005	NCT00152100_5_T2	PHENOTYPE	5	8	graft versus host disease
NCT001521131	NCT00152113_1_T0	PHENOTYPE	10	12	abnormal blood flow
NCT001521132	NCT00152113_2_T0	PHENOTYPE	18	18	complications
NCT001521132	NCT00152113_2_T1	PHENOTYPE	3	3	chronic
NCT001521132	NCT00152113_2_T2	PHENOTYPE	9	10	iron overload
NCT001521135	NCT00152113_5_T0	ORGAN	11	11	transplant
NCT001521135	NCT00152113_5_T1	CELL	0	1	Stem cells
NCT001521136	NCT00152113_6_T0	PHENOTYPE	18	18	cancers
NCT001521136	NCT00152113_6_T1	ORGAN	3	3	transplant
NCT001521136	NCT00152113_6_T2	GENE	4	4	has
NCT0015211311	NCT00152113_11_T0	PHENOTYPE	12	12	toxicity
NCT0015211312	NCT00152113_12_T0	PHENOTYPE	11	11	acute
NCT0015211312	NCT00152113_12_T1	ORGAN	7	7	graft
NCT0015211312	NCT00152113_12_T2	PHENOTYPE	0	0	Toxicity
NCT0015211312	NCT00152113_12_T3	PHENOTYPE	12	12	GVHD
NCT0015211313	NCT00152113_13_T0	ORGAN	20	20	graft
NCT0015211313	NCT00152113_13_T1	ORGAN	25	25	graft
NCT0015211313	NCT00152113_13_T2	PHENOTYPE	5	5	closed
NCT0015211313	NCT00152113_13_T3	GENE	13	13	had
NCT0015211313	NCT00152113_13_T4	GENE	14	14	met
NCT0015211313	NCT00152113_13_T5	PHENOTYPE	22	23	graft failure
NCT001521262	NCT00152126_2_T0	CELL	12	12	cells
NCT001521262	NCT00152126_2_T1	CELL	23	23	cells
NCT001521262	NCT00152126_2_T2	GENE	1	1	CD133
NCT001521263	NCT00152126_3_T0	CELL	9	9	cells
NCT001521263	NCT00152126_3_T1	PHENOTYPE	11	11	neuroblastoma
NCT001521266	NCT00152126_6_T0	PHENOTYPE	6	6	engraftment
NCT001521266	NCT00152126_6_T1	ORGAN	0	0	Transplants
NCT001521266	NCT00152126_6_T2	CELL	12	12	neutrophil
NCT001521390	NCT00152139_0_T0	PHENOTYPE	6	7	Hematologic Malignancies
NCT001521390	NCT00152139_0_T1	CELL	0	1	Stem Cell
NCT001521393	NCT00152139_3_T0	PHENOTYPE	26	26	toxicity
NCT001521393	NCT00152139_3_T1	PHENOTYPE	21	22	disease relapse
NCT001521393	NCT00152139_3_T2	CELL	4	6	hematopoietic stem cells
NCT001521399	NCT00152139_9_T0	ORGAN	23	23	graft
NCT001521399	NCT00152139_9_T1	PHENOTYPE	6	6	strategies
NCT0015213910	NCT00152139_10_T0	ORGAN	27	27	marrow
NCT0015213910	NCT00152139_10_T1	PHENOTYPE	13	13	acute
NCT0015213910	NCT00152139_10_T2	ORGAN	28	28	graft
NCT0015213910	NCT00152139_10_T3	PHENOTYPE	14	14	GVHD
NCT0015213910	NCT00152139_10_T4	PHENOTYPE	19	20	hematologic malignancies
NCT0015213915	NCT00152139_15_T0	GENE	1	1	midway
NCT0015213915	NCT00152139_15_T1	PHENOTYPE	14	14	acute
NCT0015213915	NCT00152139_15_T2	CELL	17	17	T-cell
NCT0015213915	NCT00152139_15_T3	ORGAN	32	33	bone marrow
NCT0015213917	NCT00152139_17_T0	PHENOTYPE	13	13	acute
NCT0015213918	NCT00152139_18_T0	PHENOTYPE	14	14	centers
NCT0015213918	NCT00152139_18_T1	ORGAN	22	23	bone marrow
NCT0015213921	NCT00152139_21_T0	GENE	5	5	had
NCT0015213921	NCT00152139_21_T1	ORGAN	7	8	bone marrow
NCT0015213922	NCT00152139_22_T0	PHENOTYPE	15	15	peripheral
NCT0015213922	NCT00152139_22_T1	ORGAN	12	13	bone marrow
NCT0015213922	NCT00152139_22_T2	CELL	9	11	hematopoietic stem cells
NCT001521521	NCT00152152_1_T0	ORGAN	13	13	spine
NCT001521523	NCT00152152_3_T0	PHENOTYPE	16	16	bending
NCT001521526	NCT00152152_6_T0	ORGAN	10	10	spine
NCT001521529	NCT00152152_9_T0	COMPOUND	8	8	tantalum
NCT0015215210	NCT00152152_10_T0	GENE	10	10	op
NCT0015215210	NCT00152152_10_T1	GENE	16	16	op
NCT0015215211	NCT00152152_11_T0	PHENOTYPE	7	7	5-10
NCT001521651	NCT00152165_1_T0	GENE	16	16	fusion
NCT001521651	NCT00152165_1_T1	GENE	17	17	PLIF
NCT001521653	NCT00152165_3_T0	GENE	14	14	fusion
NCT001521653	NCT00152165_3_T1	ORGAN	8	8	vertebra
NCT001521653	NCT00152165_3_T2	COMPOUND	1	1	tantalum
NCT001521655	NCT00152165_5_T0	PHENOTYPE	6	6	bending
NCT001521655	NCT00152165_5_T1	ORGAN	26	26	vertebrae
NCT001521656	NCT00152165_6_T0	GENE	21	21	fusion
NCT0015216510	NCT00152165_10_T0	GENE	4	4	has
NCT0015216511	NCT00152165_11_T0	PHENOTYPE	14	14	bending
NCT0015216512	NCT00152165_12_T0	GENE	1	1	has
NCT0015216517	NCT00152165_17_T0	GENE	9	9	1.2
NCT0015216518	NCT00152165_18_T0	GENE	1	1	has
NCT0015216519	NCT00152165_19_T0	GENE	13	13	has
NCT0015216520	NCT00152165_20_T0	ORGAN	15	15	spine
NCT0015216522	NCT00152165_22_T0	ORGAN	12	12	spine
NCT0015216525	NCT00152165_25_T0	PHENOTYPE	17	17	bending
NCT0015216525	NCT00152165_25_T1	ORGAN	6	6	spine
NCT0015216526	NCT00152165_26_T0	GENE	2	2	fusion
NCT0015216528	NCT00152165_28_T0	PHENOTYPE	17	17	bending
NCT0015216528	NCT00152165_28_T1	GENE	35	35	fusion
NCT0015216528	NCT00152165_28_T2	ORGAN	23	23	spine
NCT0015216529	NCT00152165_29_T0	GENE	15	15	fusion
NCT0015216529	NCT00152165_29_T1	GENE	16	16	PLIF
NCT0015216531	NCT00152165_31_T0	GENE	10	10	fusion
NCT0015216533	NCT00152165_33_T0	GENE	19	19	fusion
NCT0015216533	NCT00152165_33_T1	ORGAN	11	11	spine
NCT0015216533	NCT00152165_33_T2	COMPOUND	6	6	tantalum
NCT001521782	NCT00152178_2_T0	PHENOTYPE	6	6	recurrence
NCT001521783	NCT00152178_3_T0	PHENOTYPE	6	7	adverse events
NCT001521912	NCT00152191_2_T0	PHENOTYPE	6	6	recurrence
NCT001521913	NCT00152191_3_T0	PHENOTYPE	5	6	adverse events
NCT001522046	NCT00152204_6_T0	PHENOTYPE	10	10	fever
NCT001522048	NCT00152204_8_T0	PHENOTYPE	13	13	anaemia
NCT001522048	NCT00152204_8_T1	PHENOTYPE	10	10	malaria
NCT001522048	NCT00152204_8_T2	GENE	24	24	EPI
NCT001522049	NCT00152204_9_T0	GENE	40	40	EPI
NCT001522172	NCT00152217_2_T0	PHENOTYPE	6	6	recurrence
NCT001522173	NCT00152217_3_T0	PHENOTYPE	5	6	adverse events
NCT001522302	NCT00152230_2_T0	PHENOTYPE	6	6	recurrence
NCT001522303	NCT00152230_3_T0	PHENOTYPE	23	24	colon cancer
NCT001522303	NCT00152230_3_T1	PHENOTYPE	26	27	rectal cancer
NCT001522303	NCT00152230_3_T2	PHENOTYPE	5	6	adverse events
NCT001522432	NCT00152243_2_T0	PHENOTYPE	6	6	recurrence
NCT001522433	NCT00152243_3_T0	PHENOTYPE	5	6	adverse events
NCT001522690	NCT00152269_0_T0	PHENOTYPE	2	3	Uterine Fibroids
NCT001522693	NCT00152269_3_T0	COMPOUND	13	13	asoprisnil
NCT001522693	NCT00152269_3_T1	COMPOUND	41	41	asoprisnil
NCT001522693	NCT00152269_3_T2	PHENOTYPE	32	33	uterine bleeding
NCT001522693	NCT00152269_3_T3	PHENOTYPE	36	37	uterine fibroids
NCT001522694	NCT00152269_4_T0	PHENOTYPE	5	6	uterine bleeding
NCT001522694	NCT00152269_4_T1	ORGAN	15	16	uterine artery
NCT001522822	NCT00152282_2_T0	PHENOTYPE	6	6	bleeding
NCT001522951	NCT00152295_1_T0	PHENOTYPE	6	7	uterine bleeding
NCT001522952	NCT00152295_2_T0	PHENOTYPE	5	6	laboratory results
NCT001522952	NCT00152295_2_T1	PHENOTYPE	19	20	adverse events
NCT001523081	NCT00152308_1_T0	COMPOUND	3	3	paclitaxel
NCT001523081	NCT00152308_1_T1	PHENOTYPE	19	19	restenosis
NCT001523081	NCT00152308_1_T2	PHENOTYPE	12	12	proliferation
NCT001523081	NCT00152308_1_T3	PHENOTYPE	11	11	neointima
NCT001523082	NCT00152308_2_T0	PHENOTYPE	11	11	restenosis
NCT001523086	NCT00152308_6_T0	PHENOTYPE	4	4	inference
NCT001523088	NCT00152308_8_T0	PHENOTYPE	20	20	restenosis
NCT001523212	NCT00152321_2_T0	PHENOTYPE	0	0	Fractures
NCT001523212	NCT00152321_2_T1	PHENOTYPE	3	3	deformity
NCT001523215	NCT00152321_5_T0	COMPOUND	1	1	bisphosphonates
NCT001523215	NCT00152321_5_T1	PHENOTYPE	12	12	fractures
NCT001523218	NCT00152321_8_T0	PHENOTYPE	25	25	osteoporosis
NCT001523218	NCT00152321_8_T1	PHENOTYPE	9	10	wrist fracture
NCT0015232110	NCT00152321_10_T0	PHENOTYPE	10	10	osteoporosis
NCT0015232110	NCT00152321_10_T1	ORGAN	12	12	wrist
NCT0015232110	NCT00152321_10_T2	PHENOTYPE	13	13	fractures
NCT0015232111	NCT00152321_11_T0	PHENOTYPE	22	22	osteoporosis
NCT0015232115	NCT00152321_15_T0	PHENOTYPE	3	3	osteoporosis
NCT0015232117	NCT00152321_17_T0	PHENOTYPE	18	18	Fracture
NCT0015232118	NCT00152321_18_T0	COMPOUND	16	16	bisphosphonates
NCT0015232118	NCT00152321_18_T1	GENE	4	4	50
NCT0015232118	NCT00152321_18_T2	PHENOTYPE	10	11	wrist fracture
NCT0015232119	NCT00152321_19_T0	PHENOTYPE	14	14	fracture
NCT0015232120	NCT00152321_20_T0	PHENOTYPE	2	2	secondary
NCT0015232120	NCT00152321_20_T1	GENE	11	11	calcitonin
NCT0015232120	NCT00152321_20_T2	COMPOUND	10	10	bisphosphonates
NCT0015232120	NCT00152321_20_T3	COMPOUND	12	12	raloxifene
NCT0015232120	NCT00152321_20_T4	PHENOTYPE	8	8	osteoporosis
NCT0015232120	NCT00152321_20_T5	GENE	14	14	hormone
NCT0015232127	NCT00152321_27_T0	PHENOTYPE	1	1	distal
NCT0015232127	NCT00152321_27_T1	PHENOTYPE	2	3	forearm fracture
NCT0015232132	NCT00152321_32_T0	PHENOTYPE	2	2	osteoporosis
NCT0015232133	NCT00152321_33_T0	PHENOTYPE	2	2	allergy
NCT001523341	NCT00152334_1_T0	PHENOTYPE	22	22	clubfoot
NCT001523471	NCT00152347_1_T0	GENE	1	1	null
NCT001523471	NCT00152347_1_T1	PHENOTYPE	17	17	clubfoot
NCT001523472	NCT00152347_2_T0	PHENOTYPE	16	16	clubfoot
NCT001523474	NCT00152347_4_T0	PHENOTYPE	33	33	recurrences
NCT001523474	NCT00152347_4_T1	PHENOTYPE	49	49	recurrences
NCT001523474	NCT00152347_4_T2	GENE	50	50	Rec2
NCT001523474	NCT00152347_4_T3	GENE	30	30	NR1
NCT001523474	NCT00152347_4_T4	GENE	46	46	NR2
NCT001523475	NCT00152347_5_T0	PHENOTYPE	19	19	clubfoot
NCT0015234710	NCT00152347_10_T0	GENE	3	3	has
NCT0015234710	NCT00152347_10_T1	PHENOTYPE	4	5	bilateral clubfoot
NCT0015234711	NCT00152347_11_T0	GENE	15	15	4.5
NCT001523604	NCT00152360_4_T0	PHENOTYPE	31	31	hypertension
NCT001523604	NCT00152360_4_T1	PHENOTYPE	6	7	weight loss
NCT001523604	NCT00152360_4_T2	PHENOTYPE	33	34	plasma glucose
NCT001523604	NCT00152360_4_T3	PHENOTYPE	14	15	heart disease
NCT001523608	NCT00152360_8_T0	COMPOUND	19	19	glucose
NCT001523608	NCT00152360_8_T1	PHENOTYPE	0	1	Weight loss
NCT001523608	NCT00152360_8_T2	PHENOTYPE	13	14	cholesterol levels
NCT001523608	NCT00152360_8_T3	TISSUE	5	6	body fat
NCT001523609	NCT00152360_9_T0	COMPOUND	1	1	orlistat
NCT001523609	NCT00152360_9_T1	GENE	5	5	lipase
NCT0015236011	NCT00152360_11_T0	PHENOTYPE	6	7	cholesterol levels
NCT0015236012	NCT00152360_12_T0	COMPOUND	12	12	sulfonylurea
NCT0015236012	NCT00152360_12_T1	COMPOUND	19	19	sulfonylurea
NCT0015236012	NCT00152360_12_T2	COMPOUND	25	25	sulfonylurea
NCT0015236013	NCT00152360_13_T0	PHENOTYPE	13	13	CVD
NCT0015236013	NCT00152360_13_T1	GENE	8	8	has
NCT0015236018	NCT00152360_18_T0	PHENOTYPE	4	5	weight loss
NCT001523732	NCT00152373_2_T0	COMPOUND	0	0	3
NCT001523733	NCT00152373_3_T0	GENE	3	3	has
NCT001523734	NCT00152373_4_T0	GENE	3	3	MRI
NCT001523734	NCT00152373_4_T1	PHENOTYPE	14	14	progressive
NCT001523734	NCT00152373_4_T2	PHENOTYPE	13	13	neoplasia
NCT001523734	NCT00152373_4_T3	PHENOTYPE	21	22	neurodegenerative disease
NCT001523735	NCT00152373_5_T0	COMPOUND	2	2	1
NCT001523735	NCT00152373_5_T1	COMPOUND	62	62	1
NCT001523735	NCT00152373_5_T2	COMPOUND	15	15	2
NCT001523735	NCT00152373_5_T3	COMPOUND	37	37	3
NCT001523735	NCT00152373_5_T4	PHENOTYPE	18	18	seizures
NCT001523735	NCT00152373_5_T5	PHENOTYPE	5	6	status epilepticus
NCT001523735	NCT00152373_5_T6	ORGAN	50	52	central nervous system
NCT001523736	NCT00152373_6_T0	COMPOUND	2	2	amitriptyline
NCT001523736	NCT00152373_6_T1	COMPOUND	5	5	fluoxetine
NCT001523736	NCT00152373_6_T2	COMPOUND	3	3	mianserin
NCT001524250	NCT00152425_0_T0	PHENOTYPE	11	12	Crohn's Disease
NCT001524382	NCT00152438_2_T0	TISSUE	10	10	endothelium
NCT001524382	NCT00152438_2_T1	COMPOUND	4	4	progesterone
NCT001524382	NCT00152438_2_T2	ORGAN	11	11	forearm
NCT001524382	NCT00152438_2_T3	PHENOTYPE	7	8	hot flushes
NCT001524385	NCT00152438_5_T0	PHENOTYPE	11	11	symptoms
NCT001524386	NCT00152438_6_T0	ORGAN	0	0	Forearm
NCT001524386	NCT00152438_6_T1	PHENOTYPE	7	8	venous occlusion
NCT0015243816	NCT00152438_16_T0	BIOLOGICAL_PROCESS	1	1	menstruation
NCT0015243820	NCT00152438_20_T0	COMPOUND	9	9	androgen
NCT0015243820	NCT00152438_20_T1	COMPOUND	5	5	estrogen
NCT0015243820	NCT00152438_20_T2	COMPOUND	7	7	progesterone
NCT0015243820	NCT00152438_20_T3	COMPOUND	17	17	raloxifene
NCT0015243820	NCT00152438_20_T4	COMPOUND	19	19	tamoxifen
NCT0015243820	NCT00152438_20_T5	GENE	3	3	hormone
NCT0015243820	NCT00152438_20_T6	GENE	12	13	estrogen receptor
NCT0015243822	NCT00152438_22_T0	COMPOUND	3	3	BMI
NCT001524512	NCT00152451_2_T0	PHENOTYPE	0	1	Status epilepticus
NCT001524641	NCT00152464_1_T0	COMPOUND	10	10	levocetirizine
NCT001524641	NCT00152464_1_T1	PHENOTYPE	17	17	asthma
NCT001524773	NCT00152477_3_T0	COMPOUND	7	7	paclitaxel
NCT001524776	NCT00152477_6_T0	COMPOUND	7	7	paclitaxel
NCT001524777	NCT00152477_7_T0	COMPOUND	13	13	carboplatin_paclitaxel
NCT001524779	NCT00152477_9_T0	COMPOUND	7	7	carboplatin_paclitaxel
NCT0015247710	NCT00152477_10_T0	PHENOTYPE	13	13	tumor
NCT001524903	NCT00152490_3_T0	GENE	28	28	tapered
NCT001525032	NCT00152503_2_T0	PHENOTYPE	0	1	Status epilepticus
NCT001525296	NCT00152529_6_T0	PHENOTYPE	22	22	Secondary
NCT001525296	NCT00152529_6_T1	PHENOTYPE	42	42	opinions
NCT001525297	NCT00152529_7_T0	PHENOTYPE	13	13	5-10
NCT001525554	NCT00152555_4_T0	PHENOTYPE	6	6	Lupus
NCT001525556	NCT00152555_6_T0	COMPOUND	8	8	prednisone
NCT001525556	NCT00152555_6_T1	ORGAN	12	12	heart
NCT0015255513	NCT00152555_13_T0	ORGAN	10	10	shoulders
NCT0015255513	NCT00152555_13_T1	ORGAN	29	29	feet
NCT0015255513	NCT00152555_13_T2	ORGAN	25	25	thighs
NCT0015255513	NCT00152555_13_T3	ORGAN	4	4	hands
NCT0015255513	NCT00152555_13_T4	ORGAN	19	19	forehead
NCT0015255513	NCT00152555_13_T5	ORGAN	6	6	wrists
NCT0015255513	NCT00152555_13_T6	ORGAN	16	16	eyes
NCT0015255513	NCT00152555_13_T7	GENE	22	22	abdominal
NCT0015255513	NCT00152555_13_T8	ORGAN	32	32	toes
NCT0015255516	NCT00152555_16_T0	ORGAN	20	20	heart
NCT0015255518	NCT00152555_18_T0	ORGAN	0	0	Heart
NCT0015255520	NCT00152555_20_T0	GENE	12	12	stops
NCT0015255522	NCT00152555_22_T0	PHENOTYPE	10	11	pulmonary disease
NCT0015255522	NCT00152555_22_T1	PHENOTYPE	13	15	coronary artery disease
NCT0015255523	NCT00152555_23_T0	GENE	4	4	structural
NCT0015255523	NCT00152555_23_T1	PHENOTYPE	11	12	avascular necrosis
NCT001525684	NCT00152568_4_T0	PHENOTYPE	0	2	Motor vehicle injury
NCT0015256815	NCT00152568_15_T0	GENE	9	9	booster
NCT001525810	NCT00152581_0_T0	COMPOUND	11	11	HCV
NCT001525819	NCT00152581_9_T0	COMPOUND	0	0	HCV
NCT001525819	NCT00152581_9_T1	ORGAN	4	4	serum
NCT001525819	NCT00152581_9_T2	GENE	10	10	PCR
NCT0015258110	NCT00152581_10_T0	GENE	14	14	12
NCT0015258110	NCT00152581_10_T1	COMPOUND	3	3	HCV
NCT0015258110	NCT00152581_10_T2	GENE	12	12	4-8
NCT0015258112	NCT00152581_12_T0	PHENOTYPE	20	20	withdrawn
NCT0015258112	NCT00152581_12_T1	COMPOUND	9	9	HCV
NCT001525941	NCT00152594_1_T0	PHENOTYPE	10	11	lung infiltrates
NCT001525943	NCT00152594_3_T0	GENE	4	4	de
NCT001525943	NCT00152594_3_T1	PHENOTYPE	7	8	secondary AML
NCT001525948	NCT00152594_8_T0	GENE	2	2	probable
NCT001525948	NCT00152594_8_T1	PHENOTYPE	6	7	fungal infection
NCT001525949	NCT00152594_9_T0	GENE	25	25	MSG
NCT001525949	NCT00152594_9_T1	PHENOTYPE	30	30	infiltrate
NCT001525949	NCT00152594_9_T2	GENE	33	33	al
NCT001525949	NCT00152594_9_T3	GENE	32	32	et
NCT001525949	NCT00152594_9_T4	PHENOTYPE	8	9	fungal infection
NCT0015259410	NCT00152594_10_T0	PHENOTYPE	2	2	fever
NCT0015259415	NCT00152594_15_T0	COMPOUND	24	24	rifampicin
NCT0015259415	NCT00152594_15_T1	COMPOUND	21	21	voriconazole
NCT0015259415	NCT00152594_15_T2	COMPOUND	25	25	carbamazepine
NCT0015259417	NCT00152594_17_T0	GENE	1	1	has
NCT0015259417	NCT00152594_17_T1	PHENOTYPE	8	8	cirrhosis
NCT0015259417	NCT00152594_17_T2	PHENOTYPE	5	6	acute hepatitis
NCT0015259420	NCT00152594_20_T0	PHENOTYPE	0	0	Diseases
NCT001526076	NCT00152607_6_T0	PHENOTYPE	1	1	estimation
NCT001526076	NCT00152607_6_T1	ORGAN	6	6	liver
NCT001526077	NCT00152607_7_T0	GENE	8	8	IV
NCT001526078	NCT00152607_8_T0	ORGAN	4	4	liver
NCT001526079	NCT00152607_9_T0	ORGAN	13	13	liver
NCT0015260711	NCT00152607_11_T0	ORGAN	7	7	liver
NCT0015260713	NCT00152607_13_T0	GENE	10	10	has
NCT0015260714	NCT00152607_14_T0	GENE	11	11	cc
NCT0015260714	NCT00152607_14_T1	ORGAN	4	4	liver
NCT0015260721	NCT00152607_21_T0	ORGAN	14	14	kidney
NCT0015260721	NCT00152607_21_T1	ORGAN	15	15	transplant
NCT0015260722	NCT00152607_22_T0	ORGAN	7	7	liver
NCT0015260723	NCT00152607_23_T0	GENE	22	22	prn
NCT0015260725	NCT00152607_25_T0	ORGAN	12	12	transplant
NCT0015260730	NCT00152607_30_T0	ORGAN	10	10	liver
NCT0015260732	NCT00152607_32_T0	PHENOTYPE	47	47	HIV
NCT0015260732	NCT00152607_32_T1	GENE	49	49	CXR
NCT0015260732	NCT00152607_32_T2	PHENOTYPE	41	42	hepatitis B
NCT0015260732	NCT00152607_32_T3	PHENOTYPE	45	46	hepatitis C
NCT0015260732	NCT00152607_32_T4	PHENOTYPE	5	6	concomitant disease
NCT0015260732	NCT00152607_32_T5	PHENOTYPE	22	23	platelet count
NCT0015260732	NCT00152607_32_T6	PHENOTYPE	37	38	Hepatitis B
NCT0015260733	NCT00152607_33_T0	PHENOTYPE	1	1	estimation
NCT0015260733	NCT00152607_33_T1	GENE	8	8	lobe
NCT0015260733	NCT00152607_33_T2	PHENOTYPE	5	7	right and left
NCT0015260734	NCT00152607_34_T0	GENE	7	7	IV
NCT0015260735	NCT00152607_35_T0	ORGAN	4	4	liver
NCT0015260736	NCT00152607_36_T0	ORGAN	13	13	liver
NCT0015260738	NCT00152607_38_T0	ORGAN	9	9	liver
NCT0015260746	NCT00152607_46_T0	ORGAN	7	7	liver
NCT0015260746	NCT00152607_46_T1	ORGAN	8	8	transplants
NCT0015260751	NCT00152607_51_T0	ORGAN	8	8	liver
NCT0015260751	NCT00152607_51_T1	ORGAN	9	9	transplant
NCT0015260755	NCT00152607_55_T0	PHENOTYPE	14	14	reluctance
NCT0015260755	NCT00152607_55_T1	ORGAN	25	25	transplant
NCT0015260761	NCT00152607_61_T0	ORGAN	7	7	transplant
NCT0015260764	NCT00152607_64_T0	ORGAN	21	21	liver
NCT0015260764	NCT00152607_64_T1	GENE	12	12	has
NCT0015260764	NCT00152607_64_T2	GENE	13	13	met
NCT0015260768	NCT00152607_68_T0	GENE	11	11	lobe
NCT0015260768	NCT00152607_68_T1	ORGAN	2	2	liver
NCT0015260770	NCT00152607_70_T0	ORGAN	4	4	liver
NCT0015260770	NCT00152607_70_T1	PHENOTYPE	9	9	steatosis
NCT0015260776	NCT00152607_76_T0	ORGAN	8	9	hepatic arteries
NCT0015260776	NCT00152607_76_T1	PHENOTYPE	5	7	right and left
NCT0015260779	NCT00152607_79_T0	GENE	8	8	lobe
NCT0015260781	NCT00152607_81_T0	PHENOTYPE	1	1	anastomosis
NCT0015260783	NCT00152607_83_T0	ORGAN	11	11	liver
NCT0015260783	NCT00152607_83_T1	ORGAN	12	12	transplant
NCT0015260786	NCT00152607_86_T0	ORGAN	6	6	heart
NCT0015260788	NCT00152607_88_T0	PHENOTYPE	3	4	liver disease
NCT0015260794	NCT00152607_94_T0	PHENOTYPE	5	7	negative pregnancy test
NCT0015260798	NCT00152607_98_T0	ORGAN	26	26	liver
NCT0015260798	NCT00152607_98_T1	GENE	11	11	abdominal
NCT0015260798	NCT00152607_98_T2	PHENOTYPE	8	9	liver mass
NCT0015260799	NCT00152607_99_T0	ORGAN	11	11	graft
NCT0015260799	NCT00152607_99_T1	ORGAN	27	27	graft
NCT0015260799	NCT00152607_99_T2	ORGAN	32	32	liver
NCT00152607104	NCT00152607_104_T0	PHENOTYPE	4	4	infections
NCT00152607106	NCT00152607_106_T0	ORGAN	4	5	organ transplants
NCT00152607108	NCT00152607_108_T0	PHENOTYPE	1	2	pulmonary disease
NCT001526330	NCT00152633_0_T0	PHENOTYPE	10	11	Essential Hypertension
NCT001526332	NCT00152633_2_T0	ORGAN	19	21	internal carotid artery
NCT001526461	NCT00152646_1_T0	PHENOTYPE	17	17	arteriopathy
NCT001526598	NCT00152659_8_T0	PHENOTYPE	29	29	epilepsy
NCT001526598	NCT00152659_8_T1	PHENOTYPE	2	2	hoping
NCT001526598	NCT00152659_8_T2	PHENOTYPE	27	27	tumors
NCT001526850	NCT00152685_0_T0	PHENOTYPE	10	10	Acute
NCT001526850	NCT00152685_0_T1	ORGAN	3	3	Serum
NCT001526850	NCT00152685_0_T2	PHENOTYPE	14	15	Head Injury
NCT001526983	NCT00152698_3_T0	PHENOTYPE	0	0	Hypercholesterolemia
NCT001526983	NCT00152698_3_T1	PHENOTYPE	10	10	impairment
NCT001526983	NCT00152698_3_T2	GENE	14	14	has
NCT001526983	NCT00152698_3_T3	ORGAN	29	29	forearm
NCT001526983	NCT00152698_3_T4	PHENOTYPE	7	8	ischemic stroke
NCT001526984	NCT00152698_4_T0	GENE	13	13	has
NCT001526984	NCT00152698_4_T1	PHENOTYPE	12	12	hypercholesterolemia
NCT001526985	NCT00152698_5_T0	GENE	7	8	angiotensin-converting enzyme
NCT001526985	NCT00152698_5_T1	PHENOTYPE	8	9	enzyme inhibition
NCT001527111	NCT00152711_1_T0	PHENOTYPE	8	9	liver enzymes
NCT001527372	NCT00152737_2_T0	PHENOTYPE	25	25	suffering
NCT001527372	NCT00152737_2_T1	PHENOTYPE	22	22	ischemia
NCT001527372	NCT00152737_2_T2	PHENOTYPE	21	21	distal
NCT001527372	NCT00152737_2_T3	PHENOTYPE	16	16	proximal
NCT001527372	NCT00152737_2_T4	PHENOTYPE	19	19	proximal
NCT001527372	NCT00152737_2_T5	PHENOTYPE	30	31	arterial disease
NCT001527372	NCT00152737_2_T6	ORGAN	28	29	lower extremity
NCT001527373	NCT00152737_3_T0	PHENOTYPE	13	13	proximal
NCT001527373	NCT00152737_3_T1	PHENOTYPE	14	14	ischemia
NCT001527374	NCT00152737_4_T0	PHENOTYPE	21	21	symptoms
NCT001527374	NCT00152737_4_T1	PHENOTYPE	20	20	distal
NCT001527374	NCT00152737_4_T2	PHENOTYPE	18	18	proximal
NCT001527374	NCT00152737_4_T3	PHENOTYPE	23	23	ischemia
NCT001527375	NCT00152737_5_T0	ORGAN	20	21	iliac artery
NCT001527376	NCT00152737_6_T0	GENE	19	19	bypass
NCT001527376	NCT00152737_6_T1	PHENOTYPE	22	22	proximal
NCT001527508	NCT00152750_8_T0	PHENOTYPE	4	5	mental health
NCT001527509	NCT00152750_9_T0	COMPOUND	8	8	clonidine
NCT0015275011	NCT00152750_11_T0	PHENOTYPE	6	7	mental health
NCT0015276315	NCT00152763_15_T0	PHENOTYPE	15	16	psychological function
NCT0015276315	NCT00152763_15_T1	PHENOTYPE	18	20	quality of life
NCT001528024	NCT00152802_4_T0	ORGAN	21	21	liver
NCT001528024	NCT00152802_4_T1	ORGAN	22	22	transplant
NCT001528029	NCT00152802_9_T0	ORGAN	6	6	liver
NCT001528029	NCT00152802_9_T1	ORGAN	7	7	transplant
NCT001528029	NCT00152802_9_T2	ORGAN	12	12	transplant
NCT001528029	NCT00152802_9_T3	PHENOTYPE	1	1	PLAN
NCT0015280210	NCT00152802_10_T0	GENE	3	3	had
NCT0015280213	NCT00152802_13_T0	ORGAN	0	0	Serum
NCT0015280215	NCT00152802_15_T0	GENE	6	6	sera
NCT0015280216	NCT00152802_16_T0	PHENOTYPE	14	14	pneumoniae
NCT0015280217	NCT00152802_17_T0	PHENOTYPE	1	1	recruitment
NCT0015280222	NCT00152802_22_T0	ORGAN	23	24	organ transplant
NCT0015280223	NCT00152802_23_T0	ORGAN	20	20	transplant
NCT0015280223	NCT00152802_23_T1	ORGAN	57	57	transplant
NCT0015280223	NCT00152802_23_T2	PHENOTYPE	37	37	practices
NCT0015280223	NCT00152802_23_T3	BIOLOGICAL_PROCESS	50	51	immune response
NCT0015280224	NCT00152802_24_T0	ORGAN	14	15	organ transplant
NCT001528412	NCT00152841_2_T0	PHENOTYPE	2	2	anaemia
NCT001528412	NCT00152841_2_T1	COMPOUND	10	11	ferrous fumarate
NCT001528414	NCT00152841_4_T0	PHENOTYPE	2	2	anaemia
NCT001528414	NCT00152841_4_T1	COMPOUND	9	10	ferrous fumarate
NCT001528547	NCT00152854_7_T0	PHENOTYPE	18	18	analgesia
NCT001528547	NCT00152854_7_T1	PHENOTYPE	10	12	mechanism of action
NCT0015285419	NCT00152854_19_T0	GENE	3	3	0.2
NCT0015285419	NCT00152854_19_T1	PHENOTYPE	8	8	Oncology
NCT0015285420	NCT00152854_20_T0	GENE	11	11	BPI
NCT0015285426	NCT00152854_26_T0	GENE	1	1	has
NCT0015285428	NCT00152854_28_T0	GENE	4	4	had
NCT0015285428	NCT00152854_28_T1	GENE	1	1	has
NCT0015285430	NCT00152854_30_T0	GENE	1	1	has
NCT0015285430	NCT00152854_30_T1	GENE	5	5	hormone
NCT0015285434	NCT00152854_34_T0	GENE	1	1	has
NCT001528670	NCT00152867_0_T0	PHENOTYPE	4	6	Quality of Life
NCT001528673	NCT00152867_3_T0	COMPOUND	14	14	dexamethasone
NCT001528673	NCT00152867_3_T1	PHENOTYPE	8	10	nausea and vomiting
NCT001528674	NCT00152867_4_T0	COMPOUND	20	20	dexamethasone
NCT001528674	NCT00152867_4_T1	PHENOTYPE	13	15	nausea and vomiting
NCT001528675	NCT00152867_5_T0	COMPOUND	1	1	dexamethasone
NCT001528675	NCT00152867_5_T1	PHENOTYPE	12	12	indigestion
NCT001528675	NCT00152867_5_T2	PHENOTYPE	4	4	nausea
NCT001528675	NCT00152867_5_T3	PHENOTYPE	11	11	insomnia
NCT001528675	NCT00152867_5_T4	PHENOTYPE	15	16	mood changes
NCT001528676	NCT00152867_6_T0	COMPOUND	35	35	dexamethasone
NCT001528676	NCT00152867_6_T1	PHENOTYPE	20	20	nausea
NCT001528676	NCT00152867_6_T2	PHENOTYPE	40	40	nausea
NCT001528676	NCT00152867_6_T3	PHENOTYPE	15	15	QOL
NCT001528676	NCT00152867_6_T4	PHENOTYPE	24	24	QOL
NCT001528676	NCT00152867_6_T5	PHENOTYPE	22	22	vomiting
NCT001528676	NCT00152867_6_T6	PHENOTYPE	12	14	quality of life
NCT001528676	NCT00152867_6_T7	PHENOTYPE	4	6	vomiting and nausea
NCT001528677	NCT00152867_7_T0	PHENOTYPE	22	22	nausea/vomiting
NCT001528678	NCT00152867_8_T0	PHENOTYPE	3	3	acute
NCT001528678	NCT00152867_8_T1	PHENOTYPE	4	4	nausea/vomiting
NCT001528678	NCT00152867_8_T2	PHENOTYPE	17	17	nausea
NCT001528679	NCT00152867_9_T0	COMPOUND	10	10	dexamethasone
NCT0015286710	NCT00152867_10_T0	COMPOUND	5	5	dexamethasone
NCT0015286710	NCT00152867_10_T1	PHENOTYPE	15	15	nausea/vomiting
NCT0015286710	NCT00152867_10_T2	PHENOTYPE	3	3	QOL
NCT0015286710	NCT00152867_10_T3	PHENOTYPE	8	10	nausea and vomiting
NCT0015286711	NCT00152867_11_T0	COMPOUND	10	10	dexamethasone
NCT0015286711	NCT00152867_11_T1	COMPOUND	24	24	dexamethasone
NCT0015286711	NCT00152867_11_T2	PHENOTYPE	31	31	QOL
NCT0015286711	NCT00152867_11_T3	PHENOTYPE	12	14	nausea and vomiting
NCT0015286711	NCT00152867_11_T4	PHENOTYPE	27	29	nausea and vomiting
NCT0015286712	NCT00152867_12_T0	COMPOUND	10	10	dexamethasone
NCT0015286712	NCT00152867_12_T1	COMPOUND	25	25	dexamethasone
NCT0015286712	NCT00152867_12_T2	PHENOTYPE	18	18	QOL
NCT0015286713	NCT00152867_13_T0	PHENOTYPE	13	13	severity
NCT0015286713	NCT00152867_13_T1	COMPOUND	41	41	dexamethasone
NCT0015286713	NCT00152867_13_T2	COMPOUND	50	50	dexamethasone
NCT0015286713	NCT00152867_13_T3	PHENOTYPE	15	15	nausea
NCT0015286713	NCT00152867_13_T4	PHENOTYPE	42	42	insomnia
NCT0015286713	NCT00152867_13_T5	PHENOTYPE	28	28	QOL
NCT0015286713	NCT00152867_13_T6	PHENOTYPE	1	1	secondary
NCT0015286713	NCT00152867_13_T7	PHENOTYPE	35	35	symptoms
NCT0015286713	NCT00152867_13_T8	PHENOTYPE	44	44	agitation
NCT0015286713	NCT00152867_13_T9	PHENOTYPE	11	11	vomiting
NCT0015286713	NCT00152867_13_T10	PHENOTYPE	24	26	nausea and vomiting
NCT0015286714	NCT00152867_14_T0	COMPOUND	12	12	dexamethasone
NCT0015286714	NCT00152867_14_T1	PHENOTYPE	15	17	nausea and vomiting
NCT0015286714	NCT00152867_14_T2	PHENOTYPE	32	34	nausea and vomiting
NCT0015286719	NCT00152867_19_T0	COMPOUND	12	12	dexamethasone
NCT0015286719	NCT00152867_19_T1	PHENOTYPE	14	14	fatigue
NCT0015286719	NCT00152867_19_T2	PHENOTYPE	7	7	indigestion
NCT0015286719	NCT00152867_19_T3	PHENOTYPE	4	4	insomnia
NCT0015286720	NCT00152867_20_T0	PHENOTYPE	4	4	symptoms
NCT0015286720	NCT00152867_20_T1	GENE	7	7	has
NCT0015286721	NCT00152867_21_T0	PHENOTYPE	24	24	vomiting
NCT0015286721	NCT00152867_21_T1	PHENOTYPE	22	22	nausea
NCT0015286721	NCT00152867_21_T2	PHENOTYPE	15	15	QOL
NCT0015286721	NCT00152867_21_T3	PHENOTYPE	17	17	QOL
NCT0015286721	NCT00152867_21_T4	PHENOTYPE	12	14	quality of life
NCT0015286721	NCT00152867_21_T5	PHENOTYPE	4	6	vomiting and nausea
NCT0015286722	NCT00152867_22_T0	PHENOTYPE	17	19	quality of life
NCT0015286722	NCT00152867_22_T1	PHENOTYPE	8	10	nausea and vomiting
NCT0015286723	NCT00152867_23_T0	COMPOUND	6	6	dexamethasone
NCT0015286723	NCT00152867_23_T1	PHENOTYPE	37	39	Quality of Life
NCT0015286723	NCT00152867_23_T2	PHENOTYPE	22	24	quality of life
NCT0015286723	NCT00152867_23_T3	PHENOTYPE	13	15	nausea and vomiting
NCT0015286725	NCT00152867_25_T0	COMPOUND	17	17	dexamethasone
NCT0015286725	NCT00152867_25_T1	PHENOTYPE	24	24	QOL
NCT0015286725	NCT00152867_25_T2	PHENOTYPE	5	7	nausea and vomiting
NCT0015286725	NCT00152867_25_T3	PHENOTYPE	20	22	nausea and vomiting
NCT0015286726	NCT00152867_26_T0	COMPOUND	12	12	dexamethasone
NCT0015286726	NCT00152867_26_T1	PHENOTYPE	2	2	acute
NCT0015286726	NCT00152867_26_T2	COMPOUND	10	10	granisetron
NCT0015286726	NCT00152867_26_T3	COMPOUND	18	18	granisetron
NCT0015286726	NCT00152867_26_T4	PHENOTYPE	3	3	emesis
NCT0015286728	NCT00152867_28_T0	PHENOTYPE	7	7	symptoms
NCT0015286728	NCT00152867_28_T1	PHENOTYPE	28	28	symptoms
NCT0015286728	NCT00152867_28_T2	COMPOUND	10	10	dexamethasone
NCT0015286728	NCT00152867_28_T3	PHENOTYPE	6	6	QOL
NCT0015286728	NCT00152867_28_T4	PHENOTYPE	12	14	nausea and vomiting
NCT0015286729	NCT00152867_29_T0	PHENOTYPE	9	9	QOL
NCT0015286730	NCT00152867_30_T0	PHENOTYPE	13	13	severity
NCT0015286730	NCT00152867_30_T1	COMPOUND	19	19	dexamethasone
NCT0015286730	NCT00152867_30_T2	COMPOUND	40	40	dexamethasone
NCT0015286730	NCT00152867_30_T3	COMPOUND	57	57	dexamethasone
NCT0015286730	NCT00152867_30_T4	COMPOUND	66	66	dexamethasone
NCT0015286730	NCT00152867_30_T5	PHENOTYPE	15	15	nausea
NCT0015286730	NCT00152867_30_T6	PHENOTYPE	58	58	insomnia
NCT0015286730	NCT00152867_30_T7	PHENOTYPE	36	36	QOL
NCT0015286730	NCT00152867_30_T8	PHENOTYPE	1	1	secondary
NCT0015286730	NCT00152867_30_T9	PHENOTYPE	51	51	symptoms
NCT0015286730	NCT00152867_30_T10	PHENOTYPE	60	60	agitation
NCT0015286730	NCT00152867_30_T11	PHENOTYPE	11	11	vomiting
NCT0015286730	NCT00152867_30_T12	PHENOTYPE	32	34	nausea and vomiting
NCT0015286731	NCT00152867_31_T0	COMPOUND	9	9	dexamethasone
NCT0015286733	NCT00152867_33_T0	COMPOUND	6	6	dexamethasone
NCT0015286733	NCT00152867_33_T1	PHENOTYPE	2	2	QOL
NCT0015286734	NCT00152867_34_T0	COMPOUND	5	5	dexamethasone
NCT0015286734	NCT00152867_34_T1	GENE	3	3	reduced
NCT0015286734	NCT00152867_34_T2	PHENOTYPE	32	32	emesis
NCT0015286734	NCT00152867_34_T3	PHENOTYPE	1	1	QOL
NCT001528800	NCT00152880_0_T0	BIOLOGICAL_PROCESS	0	0	Apoptosis
NCT001528800	NCT00152880_0_T1	BIOLOGICAL_PROCESS	7	7	Apoptosis
NCT001528800	NCT00152880_0_T2	PHENOTYPE	2	3	Hepatitis B
NCT001528802	NCT00152880_2_T0	PHENOTYPE	19	19	complications
NCT001528802	NCT00152880_2_T1	BIOLOGICAL_PROCESS	8	9	viral replication
NCT001528803	NCT00152880_3_T0	PHENOTYPE	27	27	HBV
NCT001528803	NCT00152880_3_T1	PHENOTYPE	23	24	liver enzymes
NCT001528804	NCT00152880_4_T0	PHENOTYPE	10	10	fibrosis
NCT001528804	NCT00152880_4_T1	PHENOTYPE	7	8	liver inflammation
NCT0015288015	NCT00152880_15_T0	GENE	35	35	caspase-9
NCT0015288015	NCT00152880_15_T1	ORGAN	18	18	liver
NCT0015288015	NCT00152880_15_T2	GENE	34	34	caspase-3
NCT0015288015	NCT00152880_15_T3	GENE	42	42	caspase
NCT0015288019	NCT00152880_19_T0	ORGAN	2	2	liver
NCT0015288023	NCT00152880_23_T0	PHENOTYPE	7	7	hepatitis
NCT0015288023	NCT00152880_23_T1	PHENOTYPE	28	29	hepatic fibrosis
NCT0015288025	NCT00152880_25_T0	GENE	6	6	ANOVA
NCT0015288036	NCT00152880_36_T0	ORGAN	11	11	liver
NCT0015288036	NCT00152880_36_T1	PHENOTYPE	0	0	HBV
NCT0015288036	NCT00152880_36_T2	GENE	5	5	PCR
NCT0015288038	NCT00152880_38_T0	PHENOTYPE	0	0	Coinfection
NCT0015288038	NCT00152880_38_T1	PHENOTYPE	2	3	viral hepatitis
NCT0015288038	NCT00152880_38_T2	PHENOTYPE	3	4	hepatitis A
NCT0015288040	NCT00152880_40_T0	PHENOTYPE	0	0	Coinfection
NCT0015288040	NCT00152880_40_T1	PHENOTYPE	2	2	HIV
NCT0015288042	NCT00152880_42_T0	PHENOTYPE	2	2	Hepatoma
NCT0015288044	NCT00152880_44_T0	PHENOTYPE	4	4	malignancy
NCT001528931	NCT00152893_1_T0	COMPOUND	6	6	chromium
NCT001528931	NCT00152893_1_T1	PHENOTYPE	19	19	HIV
NCT001528931	NCT00152893_1_T2	COMPOUND	7	7	nicotinate
NCT001528931	NCT00152893_1_T3	PHENOTYPE	16	17	insulin resistance
NCT001528933	NCT00152893_3_T0	COMPOUND	5	5	chromium
NCT001528933	NCT00152893_3_T1	COMPOUND	9	9	chromium
NCT001528933	NCT00152893_3_T2	GENE	2	2	gel
NCT001528934	NCT00152893_4_T0	COMPOUND	16	16	chromium
NCT001528934	NCT00152893_4_T1	COMPOUND	3	3	phosphate
NCT001528934	NCT00152893_4_T2	GENE	7	7	gel
NCT001528937	NCT00152893_7_T0	PHENOTYPE	4	4	concentrations
NCT001528937	NCT00152893_7_T1	GENE	6	6	2.0
NCT001528937	NCT00152893_7_T2	PHENOTYPE	0	0	Hypertriglyceridemia
NCT001528937	NCT00152893_7_T3	PHENOTYPE	17	18	cardiac disease
NCT001529062	NCT00152906_2_T0	PHENOTYPE	27	27	localize
NCT001529062	NCT00152906_2_T1	GENE	6	6	CRT
NCT001529062	NCT00152906_2_T2	ORGAN	39	39	liver
NCT001529062	NCT00152906_2_T3	PHENOTYPE	41	41	tolerance
NCT001529062	NCT00152906_2_T4	PHENOTYPE	30	31	liver tumors
NCT001529062	NCT00152906_2_T5	PHENOTYPE	16	17	liver cancer
NCT001529063	NCT00152906_3_T0	PHENOTYPE	24	24	toxicity
NCT001529063	NCT00152906_3_T1	ORGAN	15	15	liver
NCT001529063	NCT00152906_3_T2	PHENOTYPE	3	4	liver tumors
NCT001529320	NCT00152932_0_T0	PHENOTYPE	5	5	Glaucoma
NCT001529324	NCT00152932_4_T0	PHENOTYPE	20	20	glaucoma
NCT001529329	NCT00152932_9_T0	PHENOTYPE	12	12	glaucoma
NCT001529329	NCT00152932_9_T1	PHENOTYPE	1	2	intraocular pressure
NCT0015293211	NCT00152932_11_T0	PHENOTYPE	13	13	vasospasm
NCT0015293211	NCT00152932_11_T1	PHENOTYPE	20	21	vascular disorders
NCT0015293211	NCT00152932_11_T2	PHENOTYPE	24	26	low blood pressure
NCT0015293214	NCT00152932_14_T0	GENE	2	2	has
NCT0015293215	NCT00152932_15_T0	ORGAN	20	20	eyes
NCT0015293216	NCT00152932_16_T0	PHENOTYPE	18	18	POAG
NCT0015293217	NCT00152932_17_T0	COMPOUND	1	1	hydrochloride
NCT0015293217	NCT00152932_17_T1	PHENOTYPE	13	13	IOP
NCT0015293217	NCT00152932_17_T2	PHENOTYPE	11	12	intraocular pressure
NCT0015293217	NCT00152932_17_T3	GENE	6	7	carbonic anhydrase
NCT0015293227	NCT00152932_27_T0	GENE	12	12	HRF
NCT0015293231	NCT00152932_31_T0	PHENOTYPE	7	7	Uveitis
NCT0015293231	NCT00152932_31_T1	PHENOTYPE	5	6	ocular infections
NCT0015293232	NCT00152932_32_T0	PHENOTYPE	1	1	allergy
NCT0015293234	NCT00152932_34_T0	PHENOTYPE	19	19	progressive
NCT0015293234	NCT00152932_34_T1	PHENOTYPE	2	4	visual field loss
NCT0015293234	NCT00152932_34_T2	PHENOTYPE	20	22	visual field loss
NCT0015293236	NCT00152932_36_T0	PHENOTYPE	8	8	hypotensive
NCT0015293236	NCT00152932_36_T1	PHENOTYPE	1	1	chronic
NCT0015293239	NCT00152932_39_T0	PHENOTYPE	5	5	traumas
NCT001529450	NCT00152945_0_T0	ORGAN	11	11	Plasma
NCT001529450	NCT00152945_0_T1	GENE	5	5	Lipoprotein
NCT001529452	NCT00152945_2_T0	ORGAN	1	1	intestine
NCT001529452	NCT00152945_2_T1	GENE	13	13	lipoprotein
NCT001529452	NCT00152945_2_T2	GENE	17	17	lipoprotein
NCT001529452	NCT00152945_2_T3	GENE	2	2	has
NCT001529452	NCT00152945_2_T4	PHENOTYPE	24	24	ingestion
NCT001529453	NCT00152945_3_T0	PHENOTYPE	22	22	fed
NCT001529454	NCT00152945_4_T0	GENE	17	17	lipoprotein
NCT001529454	NCT00152945_4_T1	ORGAN	10	10	plasma
NCT001529459	NCT00152945_9_T0	GENE	13	13	lipoprotein
NCT0015294510	NCT00152945_10_T0	COMPOUND	17	17	heparin
NCT0015294510	NCT00152945_10_T1	COMPOUND	26	26	glycerol
NCT0015294510	NCT00152945_10_T2	COMPOUND	39	39	glycerol
NCT0015294510	NCT00152945_10_T3	GENE	20	21	lipoprotein lipase
NCT0015294512	NCT00152945_12_T0	COMPOUND	7	7	heparin
NCT0015294512	NCT00152945_12_T1	GENE	31	31	lipoprotein
NCT0015294512	NCT00152945_12_T2	ORGAN	17	17	plasma
NCT0015294514	NCT00152945_14_T0	COMPOUND	5	5	glycerol
NCT0015294514	NCT00152945_14_T1	COMPOUND	20	20	glycerol
NCT0015294517	NCT00152945_17_T0	GENE	2	2	am
NCT0015294517	NCT00152945_17_T1	PHENOTYPE	16	16	ingest
NCT0015294518	NCT00152945_18_T0	GENE	22	22	HBE
NCT0015294518	NCT00152945_18_T1	GENE	15	15	On
NCT0015294521	NCT00152945_21_T0	COMPOUND	9	9	heparin
NCT0015294521	NCT00152945_21_T1	GENE	5	5	IV
NCT0015294521	NCT00152945_21_T2	COMPOUND	15	15	glycerol
NCT0015294522	NCT00152945_22_T0	COMPOUND	17	17	leucine
NCT0015294522	NCT00152945_22_T1	COMPOUND	16	16	deuterium
NCT0015294522	NCT00152945_22_T2	GENE	30	30	0.6
NCT0015294522	NCT00152945_22_T3	GENE	38	38	0.6
NCT0015294522	NCT00152945_22_T4	GENE	2	2	am
NCT0015294522	NCT00152945_22_T5	PHENOTYPE	8	8	ingestion
NCT0015294523	NCT00152945_23_T0	GENE	3	3	IV
NCT0015294524	NCT00152945_24_T0	BIOLOGICAL_PROCESS	9	10	lipoprotein metabolism
NCT0015294525	NCT00152945_25_T0	CELL	12	12	cells
NCT0015294525	NCT00152945_25_T1	PHENOTYPE	18	18	blocks
NCT0015294525	NCT00152945_25_T2	COMPOUND	5	5	glycerol
NCT0015294526	NCT00152945_26_T0	COMPOUND	3	3	leucine
NCT0015294526	NCT00152945_26_T1	COMPOUND	10	10	leucine
NCT0015294526	NCT00152945_26_T2	COMPOUND	33	33	hydrogen
NCT0015294526	NCT00152945_26_T3	GENE	22	22	has
NCT0015294526	NCT00152945_26_T4	COMPOUND	18	18	glycerol
NCT0015294527	NCT00152945_27_T0	COMPOUND	1	1	leucine
NCT0015294527	NCT00152945_27_T1	COMPOUND	31	31	leucine
NCT0015294527	NCT00152945_27_T2	COMPOUND	3	3	glycerol
NCT0015294527	NCT00152945_27_T3	COMPOUND	33	33	glycerol
NCT0015294528	NCT00152945_28_T0	PHENOTYPE	5	5	sterile
NCT0015294530	NCT00152945_30_T0	GENE	4	4	ml
NCT0015294540	NCT00152945_40_T0	GENE	1	1	has
NCT0015294540	NCT00152945_40_T1	GENE	8	8	has
NCT0015294550	NCT00152945_50_T0	PHENOTYPE	14	14	allergies
NCT0015294550	NCT00152945_50_T1	PHENOTYPE	3	3	allergy
NCT0015294550	NCT00152945_50_T2	PHENOTYPE	24	25	anaphylactic reactions
NCT0015294552	NCT00152945_52_T0	PHENOTYPE	1	1	addiction
NCT001529580	NCT00152958_0_T0	GENE	24	24	0.5
NCT001529580	NCT00152958_0_T1	PHENOTYPE	4	4	Suffering
NCT001529580	NCT00152958_0_T2	PHENOTYPE	7	9	Restless Legs Syndrome
NCT001529583	NCT00152958_3_T0	PHENOTYPE	1	1	secondary
NCT001529710	NCT00152971_0_T0	PHENOTYPE	7	8	Venous Thromboembolism
NCT001529712	NCT00152971_2_T0	PHENOTYPE	6	6	unilateral
NCT0015297110	NCT00152971_10_T0	PHENOTYPE	2	3	bleeding diathesis
NCT0015297116	NCT00152971_16_T0	PHENOTYPE	7	7	hypertension
NCT0015297116	NCT00152971_16_T1	PHENOTYPE	2	3	cardiovascular disease
NCT0015297116	NCT00152971_16_T2	PHENOTYPE	18	19	myocardial infarction
NCT0015297118	NCT00152971_18_T0	PHENOTYPE	3	3	anesthesia
NCT0015297121	NCT00152971_21_T0	PHENOTYPE	18	18	aneurysm
NCT0015297121	NCT00152971_21_T1	PHENOTYPE	12	12	bleeding
NCT0015297121	NCT00152971_21_T2	GENE	15	15	AV
NCT0015297121	NCT00152971_21_T3	PHENOTYPE	16	16	malformation
NCT0015297121	NCT00152971_21_T4	PHENOTYPE	13	13	neoplasm
NCT0015297121	NCT00152971_21_T5	PHENOTYPE	3	4	hemorrhagic stroke
NCT0015297125	NCT00152971_25_T0	PHENOTYPE	2	2	bleeding
NCT0015297125	NCT00152971_25_T1	PHENOTYPE	9	9	bleeding
NCT0015297127	NCT00152971_27_T0	PHENOTYPE	2	3	duodenal ulcer
NCT0015297131	NCT00152971_31_T0	COMPOUND	6	6	creatinine
NCT0015297131	NCT00152971_31_T1	COMPOUND	16	16	creatinine
NCT0015297131	NCT00152971_31_T2	ORGAN	15	15	serum
NCT0015297131	NCT00152971_31_T3	PHENOTYPE	20	21	renal insufficiency
NCT001529972	NCT00152997_2_T0	ORGAN	5	5	legs
NCT001529972	NCT00152997_2_T1	ORGAN	16	16	legs
NCT0015299712	NCT00152997_12_T0	PHENOTYPE	15	15	akathisia
NCT0015299718	NCT00152997_18_T0	PHENOTYPE	2	3	microcytic anemia
NCT001530103	NCT00153010_3_T0	PHENOTYPE	13	15	negative pregnancy test
NCT001530105	NCT00153010_5_T0	PHENOTYPE	29	29	Disorders
NCT001530105	NCT00153010_5_T1	GENE	2	2	probable
NCT001530105	NCT00153010_5_T2	PHENOTYPE	6	6	Dementia
NCT001530105	NCT00153010_5_T3	PHENOTYPE	25	26	Alzheimer's Disease
NCT001530105	NCT00153010_5_T4	PHENOTYPE	19	20	Communicative Disorders
NCT0015301010	NCT00153010_10_T0	GENE	6	6	MRI
NCT0015301010	NCT00153010_10_T1	PHENOTYPE	12	12	Dementia
NCT0015301010	NCT00153010_10_T2	ORGAN	0	2	Central nervous system
NCT0015301021	NCT00153010_21_T0	PHENOTYPE	1	1	disorders
NCT0015301021	NCT00153010_21_T1	PHENOTYPE	0	0	Secondary
NCT0015301021	NCT00153010_21_T2	PHENOTYPE	10	10	hyperthyroidism
NCT0015301021	NCT00153010_21_T3	PHENOTYPE	3	3	dementia
NCT0015301021	NCT00153010_21_T4	PHENOTYPE	6	6	neurosyphilis
NCT0015301021	NCT00153010_21_T5	PHENOTYPE	7	8	craniocerebral trauma
NCT0015301021	NCT00153010_21_T6	PHENOTYPE	12	14	folic acid deficiency
NCT0015301027	NCT00153010_27_T0	COMPOUND	32	32	heroin
NCT0015301027	NCT00153010_27_T1	COMPOUND	31	31	cocaine
NCT0015301027	NCT00153010_27_T2	GENE	13	13	IV
NCT0015301027	NCT00153010_27_T3	PHENOTYPE	3	4	drug dependence
NCT0015301027	NCT00153010_27_T4	PHENOTYPE	26	29	positive urine drug screen
NCT0015301029	NCT00153010_29_T0	PHENOTYPE	0	1	HIV positive
NCT0015301031	NCT00153010_31_T0	PHENOTYPE	2	3	Hepatitis C
NCT0015301033	NCT00153010_33_T0	PHENOTYPE	5	5	anesthesia
NCT0015301035	NCT00153010_35_T0	GENE	4	4	NS
NCT0015301039	NCT00153010_39_T0	COMPOUND	4	4	rivastigmine
NCT0015301039	NCT00153010_39_T1	COMPOUND	6	6	tacrine
NCT0015301039	NCT00153010_39_T2	COMPOUND	2	2	donepezil
NCT0015301039	NCT00153010_39_T3	COMPOUND	3	3	galantamine
NCT0015301040	NCT00153010_40_T0	GENE	10	10	II
NCT0015301040	NCT00153010_40_T1	GENE	5	5	CYP
NCT0015301040	NCT00153010_40_T2	ORGAN	9	9	Appendix
NCT0015301041	NCT00153010_41_T0	ORGAN	13	13	Appendix
NCT0015301042	NCT00153010_42_T0	GENE	2	3	monoamine oxidase
NCT001530230	NCT00153023_0_T0	PHENOTYPE	18	18	Nephropathy
NCT001530232	NCT00153023_2_T0	COMPOUND	10	10	telmisartan
NCT001530232	NCT00153023_2_T1	PHENOTYPE	32	32	proteinuria
NCT001530232	NCT00153023_2_T2	COMPOUND	25	25	valsartan
NCT001530237	NCT00153023_7_T0	PHENOTYPE	7	8	oxidative stress
NCT0015302310	NCT00153023_10_T0	PHENOTYPE	14	14	centre
NCT001530490	NCT00153049_0_T0	PHENOTYPE	12	13	Essential Hypertension
NCT001530492	NCT00153049_2_T0	PHENOTYPE	17	18	Essential Hypertension
NCT001530496	NCT00153049_6_T0	COMPOUND	20	20	telmisartan
NCT001530496	NCT00153049_6_T1	COMPOUND	22	22	hydrochlorothiazide
NCT001530496	NCT00153049_6_T2	GENE	8	8	Period
NCT001530496	NCT00153049_6_T3	GENE	35	35	Period
NCT001530496	NCT00153049_6_T4	COMPOUND	28	30	telmisartan and hydrochlorothiazide
NCT001530497	NCT00153049_7_T0	CELL	4	4	cells
NCT001530497	NCT00153049_7_T1	COMPOUND	6	6	telmisartan
NCT001530497	NCT00153049_7_T2	COMPOUND	13	13	hydrochlorothiazide
NCT001530497	NCT00153049_7_T3	GENE	7	7	TEL
NCT001530497	NCT00153049_7_T4	GENE	10	10	TEL
NCT001530497	NCT00153049_7_T5	GENE	20	20	TEL
NCT001530497	NCT00153049_7_T6	GENE	25	25	TEL
NCT001530497	NCT00153049_7_T7	GENE	30	30	TEL
NCT001530497	NCT00153049_7_T8	GENE	36	36	TEL
NCT001530498	NCT00153049_8_T0	PHENOTYPE	40	40	regression
NCT001530498	NCT00153049_8_T1	PHENOTYPE	15	16	essential hypertension
NCT001530499	NCT00153049_9_T0	GENE	28	28	Period
NCT0015304915	NCT00153049_15_T0	GENE	0	0	The
NCT0015304915	NCT00153049_15_T1	GENE	4	4	SBP
NCT0015304915	NCT00153049_15_T2	GENE	2	2	DBP
NCT0015304924	NCT00153049_24_T0	GENE	12	12	GCP
NCT0015304927	NCT00153049_27_T0	PHENOTYPE	9	9	melanocytoma
NCT0015304927	NCT00153049_27_T1	PHENOTYPE	3	4	secondary hypertension
NCT0015304927	NCT00153049_27_T2	PHENOTYPE	7	8	primary aldosteronism
NCT0015304927	NCT00153049_27_T3	PHENOTYPE	5	6	renovascular hypertension
NCT0015304933	NCT00153049_33_T0	PHENOTYPE	3	4	heart failure
NCT0015304935	NCT00153049_35_T0	PHENOTYPE	0	1	Myocardial infarction
NCT0015304937	NCT00153049_37_T0	GENE	2	2	bypass
NCT0015304937	NCT00153049_37_T1	ORGAN	0	1	Coronary artery
NCT0015304943	NCT00153049_43_T0	PHENOTYPE	2	4	transient ischemic attack
NCT0015307514	NCT00153075_14_T0	GENE	39	39	null
NCT0015307514	NCT00153075_14_T1	GENE	36	36	0.5
NCT001530883	NCT00153088_3_T0	GENE	22	22	II
NCT001530883	NCT00153088_3_T1	PHENOTYPE	29	29	microalbuminuria
NCT001530883	NCT00153088_3_T2	PHENOTYPE	40	40	nephropathy
NCT001530883	NCT00153088_3_T3	GENE	30	30	has
NCT001530883	NCT00153088_3_T4	PHENOTYPE	26	27	diabetic nephropathy
NCT001530884	NCT00153088_4_T0	PHENOTYPE	13	13	nephropathy
NCT001530885	NCT00153088_5_T0	COMPOUND	17	17	creatinine
NCT001530885	NCT00153088_5_T1	GENE	15	15	albumin
NCT001530885	NCT00153088_5_T2	PHENOTYPE	10	10	nephropathy
NCT001530887	NCT00153088_7_T0	PHENOTYPE	15	15	closed
NCT001530889	NCT00153088_9_T0	GENE	12	13	period 2
NCT0015308816	NCT00153088_16_T0	GENE	16	16	GCP
NCT0015308821	NCT00153088_21_T0	GENE	1	1	SBP
NCT0015308821	NCT00153088_21_T1	GENE	5	5	DBP
NCT0015308822	NCT00153088_22_T0	PHENOTYPE	21	21	complication
NCT0015308822	NCT00153088_22_T1	PHENOTYPE	20	20	haematuria
NCT0015308822	NCT00153088_22_T2	PHENOTYPE	3	4	renal disease
NCT0015308822	NCT00153088_22_T3	PHENOTYPE	7	8	diabetic nephropathy
NCT0015308822	NCT00153088_22_T4	PHENOTYPE	16	18	diabetic renal disease
NCT0015308822	NCT00153088_22_T5	PHENOTYPE	23	25	urinary tract infection
NCT0015308824	NCT00153088_24_T0	PHENOTYPE	2	2	angioedema
NCT0015308832	NCT00153088_32_T0	COMPOUND	1	1	sodium
NCT0015308835	NCT00153088_35_T0	PHENOTYPE	1	1	tumour
NCT0015308835	NCT00153088_35_T1	PHENOTYPE	4	4	diseases
NCT001531013	NCT00153101_3_T0	PHENOTYPE	12	13	Cardiovascular Disease
NCT001531014	NCT00153101_4_T0	PHENOTYPE	39	39	CHF
NCT001531014	NCT00153101_4_T1	COMPOUND	13	13	telmisartan
NCT001531014	NCT00153101_4_T2	PHENOTYPE	28	29	Myocardial Infarction
NCT001531014	NCT00153101_4_T3	PHENOTYPE	36	38	Congestive Heart Failure
NCT0015310110	NCT00153101_10_T0	GENE	5	5	II
NCT0015310110	NCT00153101_10_T1	PHENOTYPE	18	18	albuminuria
NCT0015310110	NCT00153101_10_T2	PHENOTYPE	11	11	retinopathy
NCT0015310110	NCT00153101_10_T3	PHENOTYPE	0	1	Diabetes Mellitus
NCT0015310110	NCT00153101_10_T4	PHENOTYPE	26	27	vascular disease
NCT0015310110	NCT00153101_10_T5	PHENOTYPE	12	14	Left ventricular hypertrophy
NCT0015310115	NCT00153101_15_T0	GENE	6	6	ACE
NCT0015310115	NCT00153101_15_T1	GENE	11	11	receptor
NCT0015310120	NCT00153101_20_T0	PHENOTYPE	0	1	Cardiovascular disease
NCT0015310121	NCT00153101_21_T0	PHENOTYPE	1	3	congestive heart failure
NCT0015310125	NCT00153101_25_T0	PHENOTYPE	0	1	Constrictive pericarditis
NCT0015310127	NCT00153101_27_T0	PHENOTYPE	1	3	congenital heart disease
NCT0015310135	NCT00153101_35_T0	ORGAN	0	0	Heart
NCT0015310135	NCT00153101_35_T1	ORGAN	1	1	transplant
NCT0015310137	NCT00153101_37_T0	PHENOTYPE	0	0	Strokes
NCT0015310137	NCT00153101_37_T1	PHENOTYPE	3	4	subarachnoid hemorrhage
NCT0015310139	NCT00153101_39_T0	PHENOTYPE	1	2	renal disease
NCT0015310144	NCT00153101_44_T0	PHENOTYPE	0	0	Proteinuria
NCT0015310148	NCT00153101_48_T0	PHENOTYPE	4	5	sodium depletion
NCT0015310148	NCT00153101_48_T1	PHENOTYPE	1	2	volume depletion
NCT0015310150	NCT00153101_50_T0	PHENOTYPE	0	1	Primary aldosteronism
NCT0015310152	NCT00153101_52_T0	PHENOTYPE	0	2	Hereditary fructose intolerance
NCT0015310160	NCT00153101_60_T0	GENE	1	1	has
NCT001531270	NCT00153127_0_T0	PHENOTYPE	10	10	Constipating
NCT001531270	NCT00153127_0_T1	PHENOTYPE	8	8	Constipation
NCT001531400	NCT00153140_0_T0	PHENOTYPE	8	9	Chronic Constipation
NCT001531665	NCT00153166_5_T0	PHENOTYPE	15	15	atherosclerosis
NCT001531665	NCT00153166_5_T1	PHENOTYPE	1	1	inflammation
NCT001531665	NCT00153166_5_T2	PHENOTYPE	3	4	insulin resistance
NCT001531666	NCT00153166_6_T0	GENE	14	14	insulin
NCT001531666	NCT00153166_6_T1	COMPOUND	31	31	atorvastatin
NCT001531666	NCT00153166_6_T2	COMPOUND	40	40	pioglitazone
NCT001531666	NCT00153166_6_T3	PHENOTYPE	38	38	inflammation
NCT001531666	NCT00153166_6_T4	PHENOTYPE	8	9	intermittent claudication
NCT001531666	NCT00153166_6_T5	PHENOTYPE	48	49	insulin sensitivity
NCT001531793	NCT00153179_3_T0	GENE	6	7	type 2
NCT001531794	NCT00153179_4_T0	PHENOTYPE	6	6	atherosclerosis
NCT001531794	NCT00153179_4_T1	PHENOTYPE	0	0	Diabetes
NCT001531794	NCT00153179_4_T2	PHENOTYPE	9	10	cardiovascular morbidity
NCT001531799	NCT00153179_9_T0	PHENOTYPE	9	9	atherosclerosis
NCT001531799	NCT00153179_9_T1	PHENOTYPE	16	16	hyperglycemia
NCT001531799	NCT00153179_9_T2	PHENOTYPE	4	5	insulin resistance
NCT0015317912	NCT00153179_12_T0	PHENOTYPE	15	15	withdrawn
NCT0015317912	NCT00153179_12_T1	PHENOTYPE	1	3	blood pressure rises
NCT0015319225	NCT00153192_25_T0	GENE	7	7	am
NCT0015319227	NCT00153192_27_T0	GENE	15	15	ml
NCT0015319232	NCT00153192_32_T0	PHENOTYPE	6	6	analgesia
NCT0015319237	NCT00153192_37_T0	GENE	12	12	had
NCT001532052	NCT00153205_2_T0	BIOLOGICAL_PROCESS	27	27	transcription
NCT001532054	NCT00153205_4_T0	BIOLOGICAL_PROCESS	25	25	transcription
NCT001532055	NCT00153205_5_T0	GENE	8	8	pre
NCT001532311	NCT00153231_1_T0	PHENOTYPE	9	9	centres
NCT001532313	NCT00153231_3_T0	PHENOTYPE	1	1	severity
NCT001532313	NCT00153231_3_T1	PHENOTYPE	0	0	Prolapse
NCT001532314	NCT00153231_4_T0	PHENOTYPE	6	8	quality of life
NCT001532442	NCT00153244_2_T0	PHENOTYPE	3	3	asthma
NCT001532442	NCT00153244_2_T1	PHENOTYPE	6	7	inflammatory disorder
NCT001532443	NCT00153244_3_T0	PHENOTYPE	4	4	asthma
NCT001532444	NCT00153244_4_T0	PHENOTYPE	1	1	asthma
NCT001532444	NCT00153244_4_T1	PHENOTYPE	18	18	asthma
NCT001532445	NCT00153244_5_T0	PHENOTYPE	13	13	asthma
NCT001532445	NCT00153244_5_T1	PHENOTYPE	6	7	neurogenic inflammation
NCT001532449	NCT00153244_9_T0	COMPOUND	9	9	lamotrigine
NCT001532449	NCT00153244_9_T1	PHENOTYPE	16	17	bronchial asthma
NCT001532571	NCT00153257_1_T0	PHENOTYPE	17	17	erosions
NCT001532571	NCT00153257_1_T1	PHENOTYPE	13	13	complications
NCT001532571	NCT00153257_1_T2	PHENOTYPE	19	19	dyspareunia
NCT001532572	NCT00153257_2_T0	PHENOTYPE	27	27	prolapse
NCT001532572	NCT00153257_2_T1	COMPOUND	17	17	polypropylene
NCT001532572	NCT00153257_2_T2	GENE	18	18	mesh
NCT001532573	NCT00153257_3_T0	PHENOTYPE	9	9	centres
NCT001532574	NCT00153257_4_T0	GENE	23	23	mesh
NCT001532575	NCT00153257_5_T0	COMPOUND	14	14	polypropylene
NCT001532575	NCT00153257_5_T1	GENE	16	16	mesh
NCT001532576	NCT00153257_6_T0	COMPOUND	14	14	glycerol
NCT001532576	NCT00153257_6_T1	GENE	1	1	mesh
NCT001532576	NCT00153257_6_T2	COMPOUND	11	12	polyethylene glycol
NCT001532577	NCT00153257_7_T0	PHENOTYPE	11	11	acute
NCT001532577	NCT00153257_7_T1	PHENOTYPE	12	12	inflammation
NCT001532577	NCT00153257_7_T2	ORGAN	6	6	viscera
NCT001532578	NCT00153257_8_T0	PHENOTYPE	1	1	severity
NCT001532578	NCT00153257_8_T1	PHENOTYPE	0	0	Prolapse
NCT001532579	NCT00153257_9_T0	PHENOTYPE	6	8	quality of life
NCT0015325710	NCT00153257_10_T0	GENE	18	18	mesh
NCT001532702	NCT00153270_2_T0	PHENOTYPE	3	3	asthma
NCT001532702	NCT00153270_2_T1	PHENOTYPE	6	7	inflammatory disorder
NCT001532703	NCT00153270_3_T0	PHENOTYPE	4	4	asthma
NCT001532704	NCT00153270_4_T0	PHENOTYPE	1	1	asthma
NCT001532704	NCT00153270_4_T1	PHENOTYPE	18	18	asthma
NCT001532705	NCT00153270_5_T0	PHENOTYPE	13	13	asthma
NCT001532705	NCT00153270_5_T1	PHENOTYPE	6	7	neurogenic inflammation
NCT001532709	NCT00153270_9_T0	COMPOUND	10	10	sodium
NCT001532709	NCT00153270_9_T1	COMPOUND	11	11	valproate
NCT001532709	NCT00153270_9_T2	PHENOTYPE	16	17	bronchial asthma
NCT0015327010	NCT00153270_10_T0	COMPOUND	0	0	Sodium
NCT001532832	NCT00153283_2_T0	PHENOTYPE	3	3	asthma
NCT001532832	NCT00153283_2_T1	PHENOTYPE	6	7	inflammatory disorder
NCT001532833	NCT00153283_3_T0	PHENOTYPE	4	4	asthma
NCT001532834	NCT00153283_4_T0	PHENOTYPE	1	1	asthma
NCT001532834	NCT00153283_4_T1	PHENOTYPE	18	18	asthma
NCT001532835	NCT00153283_5_T0	PHENOTYPE	13	13	asthma
NCT001532835	NCT00153283_5_T1	PHENOTYPE	6	7	neurogenic inflammation
NCT001532839	NCT00153283_9_T0	COMPOUND	10	10	gabapentin
NCT001532839	NCT00153283_9_T1	PHENOTYPE	15	16	bronchial asthma
NCT001532962	NCT00153296_2_T0	PHENOTYPE	3	3	asthma
NCT001532962	NCT00153296_2_T1	PHENOTYPE	6	7	inflammatory disorder
NCT001532963	NCT00153296_3_T0	PHENOTYPE	4	4	asthma
NCT001532964	NCT00153296_4_T0	PHENOTYPE	1	1	asthma
NCT001532964	NCT00153296_4_T1	PHENOTYPE	18	18	asthma
NCT001532965	NCT00153296_5_T0	PHENOTYPE	13	13	asthma
NCT001532965	NCT00153296_5_T1	PHENOTYPE	6	7	neurogenic inflammation
NCT001532969	NCT00153296_9_T0	COMPOUND	10	10	carbamazepine
NCT001532969	NCT00153296_9_T1	PHENOTYPE	15	16	bronchial asthma
NCT001533095	NCT00153309_5_T0	PHENOTYPE	21	21	arthritis
NCT001533095	NCT00153309_5_T1	GENE	0	0	PACE
NCT001533095	NCT00153309_5_T2	GENE	1	1	has
NCT001533096	NCT00153309_6_T0	GENE	14	14	PACE
NCT001533096	NCT00153309_6_T1	GENE	2	2	has
NCT001533097	NCT00153309_7_T0	PHENOTYPE	26	26	recruitment
NCT001533097	NCT00153309_7_T1	GENE	14	14	AF
NCT001533097	NCT00153309_7_T2	GENE	6	6	PACE
NCT001533097	NCT00153309_7_T3	GENE	15	15	PACE
NCT0015330910	NCT00153309_10_T0	GENE	12	12	PACE
NCT0015330911	NCT00153309_11_T0	GENE	8	8	PACE
NCT001533222	NCT00153322_2_T0	PHENOTYPE	9	9	obesity
NCT001533223	NCT00153322_3_T0	PHENOTYPE	26	26	strategies
NCT001533226	NCT00153322_6_T0	COMPOUND	6	6	BMI
NCT001533226	NCT00153322_6_T1	COMPOUND	37	37	BMI
NCT001533227	NCT00153322_7_T0	PHENOTYPE	20	20	obesity
NCT001533356	NCT00153335_6_T0	PHENOTYPE	31	31	strategies
NCT001533356	NCT00153335_6_T1	PHENOTYPE	37	37	decisions
NCT001533610	NCT00153361_0_T0	GENE	1	1	MIX
NCT001533612	NCT00153361_2_T0	PHENOTYPE	9	9	HIV
NCT001533612	NCT00153361_2_T1	COMPOUND	28	28	AOD
NCT001533614	NCT00153361_4_T0	COMPOUND	12	12	AOD
NCT001533615	NCT00153361_5_T0	PHENOTYPE	16	16	focused
NCT001533615	NCT00153361_5_T1	PHENOTYPE	9	10	AOD use
NCT001533618	NCT00153361_8_T0	PHENOTYPE	9	9	HIV
NCT0015336110	NCT00153361_10_T0	COMPOUND	22	22	AOD
NCT0015336110	NCT00153361_10_T1	PHENOTYPE	1	1	intent
NCT001534524	NCT00153452_4_T0	PHENOTYPE	20	21	violent behavior
NCT001534527	NCT00153452_7_T0	PHENOTYPE	34	34	stalkings
NCT001534527	NCT00153452_7_T1	GENE	26	26	3-2
NCT001534527	NCT00153452_7_T2	PHENOTYPE	31	31	assaults
NCT001534529	NCT00153452_9_T0	GENE	5	5	toll
NCT0015345211	NCT00153452_11_T0	PHENOTYPE	16	16	focused
NCT0015345213	NCT00153452_13_T0	PHENOTYPE	19	19	empowering
NCT0015345223	NCT00153452_23_T0	PHENOTYPE	1	1	self-assessment
NCT0015345225	NCT00153452_25_T0	PHENOTYPE	8	8	arthritis
NCT0015345228	NCT00153452_28_T0	PHENOTYPE	11	11	fatigued
NCT0015345228	NCT00153452_28_T1	GENE	13	13	distracted
NCT0015345235	NCT00153452_35_T0	GENE	15	15	has
NCT0015345236	NCT00153452_36_T0	PHENOTYPE	24	25	domestic violence
NCT0015345242	NCT00153452_42_T0	PHENOTYPE	25	25	generalized
NCT0015345242	NCT00153452_42_T1	GENE	10	10	has
NCT0015345242	NCT00153452_42_T2	GENE	49	49	has
NCT0015345243	NCT00153452_43_T0	GENE	12	12	has
NCT0015345245	NCT00153452_45_T0	GENE	35	35	had
NCT0015345246	NCT00153452_46_T0	GENE	2	2	has
NCT0015345252	NCT00153452_52_T0	GENE	2	2	toll
NCT0015345254	NCT00153452_54_T0	PHENOTYPE	1	1	initiatives
NCT0015345254	NCT00153452_54_T1	PHENOTYPE	8	8	affects
NCT0015345254	NCT00153452_54_T2	PHENOTYPE	6	7	domestic abuse
NCT0015345255	NCT00153452_55_T0	PHENOTYPE	12	12	affects
NCT0015345255	NCT00153452_55_T1	PHENOTYPE	23	23	affects
NCT0015345255	NCT00153452_55_T2	PHENOTYPE	10	11	domestic violence
NCT0015345258	NCT00153452_58_T0	PHENOTYPE	15	15	self-assessment
NCT001534784	NCT00153478_4_T0	GENE	18	18	AEP
NCT001534785	NCT00153478_5_T0	GENE	34	34	pros
NCT001534785	NCT00153478_5_T1	BIOLOGICAL_PROCESS	39	39	drinking
NCT001534785	NCT00153478_5_T2	GENE	16	16	AEP
NCT001534786	NCT00153478_6_T0	GENE	10	10	AEP
NCT001534787	NCT00153478_7_T0	PHENOTYPE	30	31	alcohol abuse
NCT001535043	NCT00153504_3_T0	PHENOTYPE	22	22	HIV
NCT001535045	NCT00153504_5_T0	PHENOTYPE	18	18	Centers
NCT001535046	NCT00153504_6_T0	PHENOTYPE	17	17	HIV
NCT001535046	NCT00153504_6_T1	PHENOTYPE	35	35	HIV
NCT001535046	NCT00153504_6_T2	PHENOTYPE	29	30	disease progression
NCT001535047	NCT00153504_7_T0	PHENOTYPE	7	7	HIV
NCT0015350410	NCT00153504_10_T0	GENE	20	20	CD4
NCT0015350411	NCT00153504_11_T0	PHENOTYPE	14	14	HIV
NCT0015350411	NCT00153504_11_T1	PHENOTYPE	27	27	HIV
NCT001535172	NCT00153517_2_T0	COMPOUND	12	12	metronidazole
NCT001535174	NCT00153517_4_T0	COMPOUND	8	8	metronidazole
NCT001535175	NCT00153517_5_T0	COMPOUND	8	8	metronidazole
NCT001535175	NCT00153517_5_T1	PHENOTYPE	19	19	chorioamnionitis
NCT001535175	NCT00153517_5_T2	PHENOTYPE	20	21	preterm delivery
NCT001535177	NCT00153517_7_T0	COMPOUND	20	20	metronidazole
NCT001535177	NCT00153517_7_T1	COMPOUND	31	31	metronidazole
NCT001535177	NCT00153517_7_T2	GENE	35	35	BID
NCT001535177	NCT00153517_7_T3	BIOLOGICAL_PROCESS	10	10	gestation
NCT001535177	NCT00153517_7_T4	GENE	23	23	TID
NCT001535177	NCT00153517_7_T5	GENE	34	34	gel
NCT001535306	NCT00153530_6_T0	GENE	14	14	MTX
NCT001535308	NCT00153530_8_T0	GENE	11	11	MTX
NCT001535308	NCT00153530_8_T1	COMPOUND	1	1	dexamethasone
NCT0015353011	NCT00153530_11_T0	GENE	19	19	MTX
NCT0015353012	NCT00153530_12_T0	GENE	14	14	MTX
NCT0015353012	NCT00153530_12_T1	GENE	0	0	MRI
NCT0015353017	NCT00153530_17_T0	PHENOTYPE	2	2	remission
NCT0015353021	NCT00153530_21_T0	GENE	8	8	IV
NCT0015353028	NCT00153530_28_T0	GENE	17	17	A1
NCT0015353028	NCT00153530_28_T1	COMPOUND	19	19	WBI
NCT0015353033	NCT00153530_33_T0	ORGAN	16	17	spinal cord
NCT0015353034	NCT00153530_34_T0	CELL	11	11	lymphocytes
NCT0015353034	NCT00153530_34_T1	GENE	5	5	CSF
NCT001535432	NCT00153543_2_T0	GENE	16	16	old-1
NCT001535433	NCT00153543_3_T0	PHENOTYPE	2	3	pneumococcal infection
NCT001535434	NCT00153543_4_T0	GENE	6	6	has
NCT001535435	NCT00153543_5_T0	PHENOTYPE	6	6	Practices
NCT001535435	NCT00153543_5_T1	COMPOUND	7	7	ACIP
NCT001535436	NCT00153543_6_T0	PHENOTYPE	15	15	meningitis
NCT001535436	NCT00153543_6_T1	PHENOTYPE	24	24	chronic
NCT001535436	NCT00153543_6_T2	PHENOTYPE	13	13	bacteremia
NCT001535438	NCT00153543_8_T0	GENE	1	1	has
NCT001535439	NCT00153543_9_T0	PHENOTYPE	18	18	pneumonia
NCT001535439	NCT00153543_9_T1	PHENOTYPE	16	16	bronchitis
NCT001535439	NCT00153543_9_T2	GENE	21	21	has
NCT001535439	NCT00153543_9_T3	PHENOTYPE	20	20	bacteremia
NCT001535439	NCT00153543_9_T4	PHENOTYPE	11	12	pneumococcal infection
NCT001535439	NCT00153543_9_T5	PHENOTYPE	12	15	infection in the elderly
NCT0015354310	NCT00153543_10_T0	COMPOUND	4	4	polysaccharides
NCT0015354310	NCT00153543_10_T1	PHENOTYPE	13	13	concentrations
NCT0015354311	NCT00153543_11_T0	PHENOTYPE	20	21	pneumococcal infection
NCT0015354313	NCT00153543_13_T0	COMPOUND	5	5	ACIP
NCT0015354316	NCT00153543_16_T0	COMPOUND	5	5	polysaccharides
NCT0015354316	NCT00153543_16_T1	CELL	0	0	T-cell
NCT0015354316	NCT00153543_16_T2	GENE	9	9	booster
NCT0015354319	NCT00153543_19_T0	GENE	8	8	has
NCT0015354321	NCT00153543_21_T0	PHENOTYPE	15	15	resistant
NCT0015354322	NCT00153543_22_T0	PHENOTYPE	9	9	immunity
NCT0015354322	NCT00153543_22_T1	GENE	21	21	has
NCT0015354322	NCT00153543_22_T2	ORGAN	16	17	respiratory tract
NCT0015354324	NCT00153543_24_T0	PHENOTYPE	4	5	pneumococcal infections
NCT0015354325	NCT00153543_25_T0	PHENOTYPE	21	22	antibody responses
NCT0015354326	NCT00153543_26_T0	CELL	44	44	T-cell
NCT0015354326	NCT00153543_26_T1	GENE	31	31	booster
NCT0015354326	NCT00153543_26_T2	ORGAN	18	19	immune system
NCT0015354327	NCT00153543_27_T0	PHENOTYPE	11	12	chronic illnesses
NCT001535953	NCT00153595_3_T0	PHENOTYPE	14	15	allergic rhinitis
NCT001535954	NCT00153595_4_T0	GENE	5	5	HDM
NCT001535954	NCT00153595_4_T1	PHENOTYPE	13	14	allergic rhinitis
NCT001535954	NCT00153595_4_T2	PHENOTYPE	10	11	allergic reactions
NCT001535956	NCT00153595_6_T0	GENE	1	1	Dp
NCT001535957	NCT00153595_7_T0	PHENOTYPE	8	9	allergic rhinitis
NCT001535958	NCT00153595_8_T0	PHENOTYPE	11	12	immunologic diseases
NCT001535959	NCT00153595_9_T0	PHENOTYPE	32	32	rhinitis
NCT001535959	NCT00153595_9_T1	GENE	16	16	has
NCT001535959	NCT00153595_9_T2	PHENOTYPE	31	31	recurrent
NCT0015359511	NCT00153595_11_T0	PHENOTYPE	25	27	perennial allergic rhinitis
NCT0015359512	NCT00153595_12_T0	GENE	17	17	1.1
NCT0015359513	NCT00153595_13_T0	PHENOTYPE	19	19	symptoms
NCT0015359513	NCT00153595_13_T1	PHENOTYPE	18	18	rhinitis
NCT0015359515	NCT00153595_15_T0	PHENOTYPE	1	1	intent
NCT0015359519	NCT00153595_19_T0	GENE	4	4	allergen
NCT0015359519	NCT00153595_19_T1	GENE	0	0	AR
NCT0015359519	NCT00153595_19_T2	COMPOUND	11	11	2
NCT0015359519	NCT00153595_19_T3	GENE	9	9	IgE
NCT0015359519	NCT00153595_19_T4	GENE	7	7	Dp
NCT0015359520	NCT00153595_20_T0	PHENOTYPE	6	7	allergic rhinitis
NCT0015359521	NCT00153595_21_T0	PHENOTYPE	22	22	symptoms
NCT0015359521	NCT00153595_21_T1	PHENOTYPE	8	8	impairment
NCT0015359524	NCT00153595_24_T0	PHENOTYPE	1	1	initiation
NCT0015359526	NCT00153595_26_T0	PHENOTYPE	6	6	asthma
NCT0015359527	NCT00153595_27_T0	PHENOTYPE	0	0	Chronic
NCT0015359530	NCT00153595_30_T0	PHENOTYPE	3	3	acute
NCT0015359530	NCT00153595_30_T1	PHENOTYPE	6	7	chronic sinusitis
NCT0015359531	NCT00153595_31_T0	PHENOTYPE	0	0	Chronic
NCT0015359533	NCT00153595_33_T0	PHENOTYPE	0	1	Rhinitis medicamentosa
NCT0015359537	NCT00153595_37_T0	COMPOUND	5	5	creatinine
NCT0015359537	NCT00153595_37_T1	GENE	8	8	1.5
NCT0015359537	NCT00153595_37_T2	PHENOTYPE	1	1	dysfunction
NCT001536214	NCT00153621_4_T0	PHENOTYPE	2	2	HIV
NCT001536216	NCT00153621_6_T0	PHENOTYPE	1	1	Immunodeficiency
NCT001536217	NCT00153621_7_T0	PHENOTYPE	15	15	HIV
NCT0015362111	NCT00153621_11_T0	PHENOTYPE	9	10	opportunistic infections
NCT0015362111	NCT00153621_11_T1	PHENOTYPE	15	16	primary disorders
NCT0015362112	NCT00153621_12_T0	PHENOTYPE	10	10	HIVAN
NCT0015362112	NCT00153621_12_T1	PHENOTYPE	0	0	Proteinuria
NCT0015362112	NCT00153621_12_T2	PHENOTYPE	8	9	HIV nephropathy
NCT0015362113	NCT00153621_13_T0	PHENOTYPE	13	13	HIVAN
NCT0015362114	NCT00153621_14_T0	GENE	8	8	has
NCT0015362114	NCT00153621_14_T1	PHENOTYPE	3	3	HIVAN
NCT0015362115	NCT00153621_15_T0	GENE	8	8	has
NCT0015362115	NCT00153621_15_T1	PHENOTYPE	15	15	HIVAN
NCT0015362116	NCT00153621_16_T0	PHENOTYPE	2	2	HIVAN
NCT0015362117	NCT00153621_17_T0	GENE	16	16	has
NCT0015362117	NCT00153621_17_T1	PHENOTYPE	8	9	HIV infection
NCT0015362118	NCT00153621_18_T0	PHENOTYPE	13	13	ESRD
NCT0015362118	NCT00153621_18_T1	PHENOTYPE	3	3	HIV
NCT0015362118	NCT00153621_18_T2	PHENOTYPE	10	12	end-stage renal disease
NCT0015362119	NCT00153621_19_T0	PHENOTYPE	15	15	ESRD
NCT0015362119	NCT00153621_19_T1	PHENOTYPE	18	18	HIVAN
NCT0015362119	NCT00153621_19_T2	GENE	19	19	has
NCT0015362120	NCT00153621_20_T0	GENE	7	7	has
NCT0015362120	NCT00153621_20_T1	PHENOTYPE	3	4	pediatric AIDS
NCT0015362121	NCT00153621_21_T0	PHENOTYPE	15	15	HIVAN
NCT0015362121	NCT00153621_21_T1	PHENOTYPE	7	8	pediatric AIDS
NCT0015362122	NCT00153621_22_T0	PHENOTYPE	25	25	ESRD
NCT0015362122	NCT00153621_22_T1	PHENOTYPE	1	1	progression
NCT0015362122	NCT00153621_22_T2	PHENOTYPE	4	4	HIVAN
NCT0015362122	NCT00153621_22_T3	PHENOTYPE	13	13	HIVAN
NCT0015362122	NCT00153621_22_T4	PHENOTYPE	23	23	HIVAN
NCT0015362123	NCT00153621_23_T0	PHENOTYPE	6	6	HIV
NCT0015362123	NCT00153621_23_T1	PHENOTYPE	15	15	HIVAN
NCT0015362125	NCT00153621_25_T0	PHENOTYPE	13	13	proteinuria
NCT0015362125	NCT00153621_25_T1	PHENOTYPE	19	19	proteinuria
NCT0015362130	NCT00153621_30_T0	GENE	2	2	GFR
NCT0015362130	NCT00153621_30_T1	COMPOUND	11	11	creatinine
NCT0015362130	NCT00153621_30_T2	ORGAN	10	10	serum
NCT0015362131	NCT00153621_31_T0	PHENOTYPE	0	2	Chronic Kidney Disease
NCT001536345	NCT00153634_5_T0	GENE	4	4	IV
NCT001536472	NCT00153647_2_T0	PHENOTYPE	1	1	secondary
NCT001536472	NCT00153647_2_T1	ORGAN	11	11	ileum
NCT001536472	NCT00153647_2_T2	PHENOTYPE	22	22	complication
NCT001536601	NCT00153660_1_T0	COMPOUND	24	24	esomeprazole
NCT001536601	NCT00153660_1_T1	COMPOUND	15	15	celecoxib
NCT001536601	NCT00153660_1_T2	GENE	14	14	ASA
NCT001536601	NCT00153660_1_T3	COMPOUND	22	22	naproxen
NCT001536601	NCT00153660_1_T4	PHENOTYPE	29	29	recurrent
NCT001536601	NCT00153660_1_T5	PHENOTYPE	9	10	ulcer bleeding
NCT001536601	NCT00153660_1_T6	PHENOTYPE	30	31	ulcer bleeding
NCT001536603	NCT00153660_3_T0	PHENOTYPE	9	10	ulcer bleeding
NCT001536605	NCT00153660_5_T0	GENE	13	13	cyclooxygenase-2
NCT001536605	NCT00153660_5_T1	GENE	14	14	COX-2
NCT001536606	NCT00153660_6_T0	GENE	9	9	COX-2
NCT001536608	NCT00153660_8_T0	PHENOTYPE	16	16	toxicity
NCT001536608	NCT00153660_8_T1	COMPOUND	3	3	aspirin
NCT001536608	NCT00153660_8_T2	GENE	10	10	COX-2
NCT001536609	NCT00153660_9_T0	COMPOUND	18	18	aspirin
NCT001536609	NCT00153660_9_T1	GENE	21	21	COX-2
NCT001536609	NCT00153660_9_T2	PHENOTYPE	13	13	ulcer
NCT001536732	NCT00153673_2_T0	PHENOTYPE	11	11	inflammation
NCT001536732	NCT00153673_2_T1	GENE	9	9	COX-2
NCT001536732	NCT00153673_2_T2	GENE	4	4	COX-1
NCT001536734	NCT00153673_4_T0	COMPOUND	18	18	1
NCT001536734	NCT00153673_4_T1	GENE	8	8	PG
NCT001536734	NCT00153673_4_T2	GENE	2	2	COX-2
NCT001536734	NCT00153673_4_T3	GENE	11	11	COX-2
NCT001536734	NCT00153673_4_T4	PHENOTYPE	0	0	Inhibition
NCT001536734	NCT00153673_4_T5	PHENOTYPE	4	5	ulcer healing
NCT001536736	NCT00153673_6_T0	GENE	8	8	COX-2
NCT001536736	NCT00153673_6_T1	GENE	6	6	COX-1
NCT001536736	NCT00153673_6_T2	PHENOTYPE	15	16	ulcer healing
NCT001536736	NCT00153673_6_T3	PHENOTYPE	14	15	gastric ulcer
NCT001536737	NCT00153673_7_T0	COMPOUND	22	22	2
NCT001536737	NCT00153673_7_T1	GENE	6	6	COX-2
NCT001536737	NCT00153673_7_T2	GENE	15	15	COX-2
NCT001536737	NCT00153673_7_T3	GENE	13	13	COX-1
NCT001536737	NCT00153673_7_T4	PHENOTYPE	2	2	ulcers
NCT001536737	NCT00153673_7_T5	PHENOTYPE	20	21	gastric ulcers
NCT001536738	NCT00153673_8_T0	PHENOTYPE	6	6	inhibition
NCT001536738	NCT00153673_8_T1	GENE	8	8	COX-2
NCT001536738	NCT00153673_8_T2	PHENOTYPE	19	20	ulcer healing
NCT0015367310	NCT00153673_10_T0	PHENOTYPE	11	11	inhibition
NCT0015367310	NCT00153673_10_T1	GENE	2	2	COX-2
NCT0015367310	NCT00153673_10_T2	PHENOTYPE	0	0	Inhibition
NCT0015367310	NCT00153673_10_T3	GENE	14	14	COX
NCT0015367310	NCT00153673_10_T4	PHENOTYPE	7	8	adverse effect
NCT0015367310	NCT00153673_10_T5	PHENOTYPE	17	18	ulcer healing
NCT0015367311	NCT00153673_11_T0	GENE	10	10	COX-2
NCT0015367311	NCT00153673_11_T1	PHENOTYPE	13	14	gastric ulcer
NCT001536863	NCT00153686_3_T0	PHENOTYPE	14	14	bleeding
NCT001536863	NCT00153686_3_T1	GENE	10	10	bowel
NCT001536864	NCT00153686_4_T0	PHENOTYPE	10	10	bleeding
NCT001536993	NCT00153699_3_T0	PHENOTYPE	5	8	acute angle closure glaucoma
NCT001536994	NCT00153699_4_T0	COMPOUND	19	19	topiramate
NCT001537123	NCT00153712_3_T0	GENE	7	7	Hp
NCT001537123	NCT00153712_3_T1	GENE	10	10	had
NCT001537123	NCT00153712_3_T2	GENE	15	15	had
NCT001537123	NCT00153712_3_T3	PHENOTYPE	8	9	bleeding ulcers
NCT001537124	NCT00153712_4_T0	PHENOTYPE	18	18	bleeding
NCT001537124	NCT00153712_4_T1	GENE	17	17	Hp
NCT001537124	NCT00153712_4_T2	PHENOTYPE	15	16	Helicobacter pylori
NCT001537124	NCT00153712_4_T3	PHENOTYPE	19	20	peptic ulcers
NCT001537251	NCT00153725_1_T0	COMPOUND	1	1	aspirin
NCT001537251	NCT00153725_1_T1	PHENOTYPE	4	4	ulcer
NCT001537251	NCT00153725_1_T2	PHENOTYPE	8	9	ulcer bleeding
NCT001537251	NCT00153725_1_T3	PHENOTYPE	7	8	acute ulcer
NCT001537253	NCT00153725_3_T0	GENE	12	12	reduced
NCT001537253	NCT00153725_3_T1	COMPOUND	23	23	aspirin
NCT001537253	NCT00153725_3_T2	PHENOTYPE	16	16	recurrent
NCT001537253	NCT00153725_3_T3	PHENOTYPE	17	18	ulcer bleeding
NCT001537254	NCT00153725_4_T0	COMPOUND	27	27	aspirin
NCT001537254	NCT00153725_4_T1	PHENOTYPE	20	20	recurrent
NCT001537254	NCT00153725_4_T2	PHENOTYPE	21	22	ulcer bleeding
NCT001537381	NCT00153738_1_T0	GENE	9	9	LDL
NCT001537383	NCT00153738_3_T0	GENE	9	9	LDL
NCT001537386	NCT00153738_6_T0	PHENOTYPE	1	1	ingested
NCT001537513	NCT00153751_3_T0	PHENOTYPE	16	16	symptoms
NCT001537513	NCT00153751_3_T1	PHENOTYPE	18	18	IBS
NCT001537515	NCT00153751_5_T0	PHENOTYPE	0	0	IBS
NCT001537517	NCT00153751_7_T0	PHENOTYPE	6	6	IBS
NCT001537518	NCT00153751_8_T0	PHENOTYPE	9	9	IBS
NCT001537518	NCT00153751_8_T1	PHENOTYPE	28	28	IBS
NCT001537519	NCT00153751_9_T0	PHENOTYPE	15	15	IBS
NCT0015375110	NCT00153751_10_T0	GENE	19	19	has
NCT0015375110	NCT00153751_10_T1	PHENOTYPE	11	12	functional disorders
NCT0015375112	NCT00153751_12_T0	PHENOTYPE	14	14	symptoms
NCT0015375112	NCT00153751_12_T1	PHENOTYPE	22	22	IBS
NCT0015375112	NCT00153751_12_T2	PHENOTYPE	16	18	quality of life
NCT0015375113	NCT00153751_13_T0	PHENOTYPE	12	12	constipation
NCT0015375113	NCT00153751_13_T1	PHENOTYPE	14	14	IBS
NCT0015375116	NCT00153751_16_T0	GENE	14	14	HW
NCT0015375117	NCT00153751_17_T0	PHENOTYPE	1	1	IBS
NCT0015375117	NCT00153751_17_T1	PHENOTYPE	4	6	quality of life
NCT001537641	NCT00153764_1_T0	COMPOUND	16	16	homocysteine
NCT001537641	NCT00153764_1_T1	GENE	17	17	LDL
NCT001537641	NCT00153764_1_T2	GENE	20	21	C-reactive protein
NCT001537641	NCT00153764_1_T3	COMPOUND	8	10	omega_3 fatty acid
NCT001537645	NCT00153764_5_T0	COMPOUND	16	16	homocysteine
NCT001537645	NCT00153764_5_T1	GENE	17	17	LDL
NCT001537645	NCT00153764_5_T2	GENE	20	21	C-reactive protein
NCT001537645	NCT00153764_5_T3	COMPOUND	8	10	omega_3 fatty acid
NCT001537770	NCT00153777_0_T0	PHENOTYPE	3	3	HIV
NCT001537770	NCT00153777_0_T1	PHENOTYPE	4	4	Transmission
NCT001537772	NCT00153777_2_T0	PHENOTYPE	1	1	secondary
NCT001537772	NCT00153777_2_T1	PHENOTYPE	10	10	gonorrhea
NCT001537775	NCT00153777_5_T0	PHENOTYPE	8	8	HIV
NCT001537777	NCT00153777_7_T0	COMPOUND	1	1	sulfate
NCT001537777	NCT00153777_7_T1	PHENOTYPE	4	4	HIV
NCT001537777	NCT00153777_7_T2	PHENOTYPE	23	23	transmitted
NCT001537777	NCT00153777_7_T3	COMPOUND	13	13	N
NCT001537904	NCT00153790_4_T0	BIOLOGICAL_PROCESS	13	14	appetite suppression
NCT001537904	NCT00153790_4_T1	PHENOTYPE	10	11	weight loss
NCT001538034	NCT00153803_4_T0	COMPOUND	4	4	erlotinib
NCT001538034	NCT00153803_4_T1	PHENOTYPE	15	17	stage III NSCLC
NCT001538035	NCT00153803_5_T0	PHENOTYPE	23	23	relapse
NCT001538035	NCT00153803_5_T1	PHENOTYPE	7	9	stage III NSCLC
NCT001538161	NCT00153816_1_T0	COMPOUND	22	22	calcium
NCT001538161	NCT00153816_1_T1	COMPOUND	30	30	calcium
NCT001538161	NCT00153816_1_T2	COMPOUND	39	39	calcium
NCT001538161	NCT00153816_1_T3	GENE	18	18	bowel
NCT001538161	NCT00153816_1_T4	COMPOUND	13	14	vitamin D
NCT001538161	NCT00153816_1_T5	COMPOUND	24	25	vitamin D
NCT001538164	NCT00153816_4_T0	PHENOTYPE	7	7	Centers
NCT001538165	NCT00153816_5_T0	PHENOTYPE	23	23	polyps
NCT001538165	NCT00153816_5_T1	GENE	26	26	bowel
NCT001538165	NCT00153816_5_T2	GENE	4	4	had
NCT001538165	NCT00153816_5_T3	PHENOTYPE	8	10	large bowel adenoma
NCT001538166	NCT00153816_6_T0	COMPOUND	17	17	calcium
NCT001538166	NCT00153816_6_T1	COMPOUND	18	18	carbonate
NCT001538166	NCT00153816_6_T2	COMPOUND	13	14	vitamin D
NCT001538168	NCT00153816_8_T0	PHENOTYPE	9	9	recruitment
NCT001538168	NCT00153816_8_T1	COMPOUND	27	28	vitamin D
NCT0015381610	NCT00153816_10_T0	COMPOUND	6	6	calcium
NCT0015381610	NCT00153816_10_T1	COMPOUND	7	7	creatinine
NCT0015381611	NCT00153816_11_T0	COMPOUND	27	27	calcium
NCT0015381611	NCT00153816_11_T1	PHENOTYPE	21	21	illnesses
NCT0015381611	NCT00153816_11_T2	COMPOUND	29	30	vitamin D
NCT0015381612	NCT00153816_12_T0	PHENOTYPE	9	9	adenomas
NCT0015381616	NCT00153816_16_T0	PHENOTYPE	8	8	adenomas
NCT0015381616	NCT00153816_16_T1	COMPOUND	30	30	calcium
NCT0015381616	NCT00153816_16_T2	COMPOUND	41	41	calcium
NCT0015381616	NCT00153816_16_T3	COMPOUND	46	46	calcium
NCT0015381616	NCT00153816_16_T4	COMPOUND	57	57	calcium
NCT0015381616	NCT00153816_16_T5	COMPOUND	68	68	calcium
NCT0015381616	NCT00153816_16_T6	COMPOUND	75	75	calcium
NCT0015381616	NCT00153816_16_T7	COMPOUND	85	85	calcium
NCT0015381616	NCT00153816_16_T8	COMPOUND	93	93	calcium
NCT0015381616	NCT00153816_16_T9	COMPOUND	25	26	vitamin D
NCT0015381616	NCT00153816_16_T10	COMPOUND	36	37	vitamin D
NCT0015381616	NCT00153816_16_T11	COMPOUND	50	51	vitamin D
NCT0015381616	NCT00153816_16_T12	COMPOUND	61	62	vitamin D
NCT0015381616	NCT00153816_16_T13	COMPOUND	87	88	vitamin D
NCT0015381617	NCT00153816_17_T0	PHENOTYPE	1	1	secondary
NCT0015381617	NCT00153816_17_T1	GENE	17	17	VDR
NCT0015381617	NCT00153816_17_T2	COMPOUND	10	11	vitamin D
NCT0015381617	NCT00153816_17_T3	COMPOUND	21	22	vitamin D
NCT0015381617	NCT00153816_17_T4	GENE	14	16	vitamin D receptor
NCT0015381618	NCT00153816_18_T0	PHENOTYPE	3	3	adenomas
NCT0015381618	NCT00153816_18_T1	PHENOTYPE	10	10	secondary
NCT0015381621	NCT00153816_21_T0	PHENOTYPE	7	7	adenomas
NCT001538290	NCT00153829_0_T0	PHENOTYPE	0	1	Chronic Illness
NCT001538296	NCT00153829_6_T0	GENE	22	22	hoc
NCT001538296	NCT00153829_6_T1	PHENOTYPE	17	17	chronic
NCT001538296	NCT00153829_6_T2	PHENOTYPE	6	7	chronically ill
NCT001538297	NCT00153829_7_T0	PHENOTYPE	13	13	chronic
NCT001538298	NCT00153829_8_T0	PHENOTYPE	16	16	desires
NCT001538299	NCT00153829_9_T0	PHENOTYPE	3	4	chronic illness
NCT0015382910	NCT00153829_10_T0	PHENOTYPE	46	47	chronic illness
NCT0015382910	NCT00153829_10_T1	PHENOTYPE	24	26	multiple chronic conditions
NCT001538422	NCT00153842_2_T0	GENE	9	9	II
NCT001538422	NCT00153842_2_T1	COMPOUND	12	12	bexarotene
NCT001538427	NCT00153842_7_T0	GENE	3	3	II
NCT001538427	NCT00153842_7_T1	COMPOUND	12	12	bexarotene
NCT001538427	NCT00153842_7_T2	GENE	28	28	DLT
NCT001538429	NCT00153842_9_T0	GENE	30	30	PR
NCT001538429	NCT00153842_9_T1	PHENOTYPE	25	25	remission
NCT001538429	NCT00153842_9_T2	PHENOTYPE	29	29	remission
NCT001538429	NCT00153842_9_T3	GENE	26	26	CR
NCT001538553	NCT00153855_3_T0	PHENOTYPE	13	14	brain injury
NCT001538554	NCT00153855_4_T0	PHENOTYPE	2	2	PVL
NCT001538554	NCT00153855_4_T1	BIOLOGICAL_PROCESS	7	7	necrosis
NCT001538554	NCT00153855_4_T2	PHENOTYPE	29	30	premature infants
NCT001538554	NCT00153855_4_T3	ORGAN	11	12	white matter
NCT001538554	NCT00153855_4_T4	PHENOTYPE	25	26	brain injury
NCT001538554	NCT00153855_4_T5	PHENOTYPE	0	1	Periventricular leukomalacia
NCT001538555	NCT00153855_5_T0	GENE	0	0	MRI
NCT001538556	NCT00153855_6_T0	GENE	9	9	MRI
NCT001538556	NCT00153855_6_T1	PHENOTYPE	12	13	premature infants
NCT001538680	NCT00153868_0_T0	PHENOTYPE	14	14	Cancer
NCT001538680	NCT00153868_0_T1	PHENOTYPE	4	6	Quality of Life
NCT001538684	NCT00153868_4_T0	GENE	7	7	1.0
NCT001538684	NCT00153868_4_T1	PHENOTYPE	12	12	concentrations
NCT001538684	NCT00153868_4_T2	GENE	11	11	hemoglobin
NCT001538686	NCT00153868_6_T0	GENE	18	18	al
NCT001538686	NCT00153868_6_T1	GENE	23	23	al
NCT001538686	NCT00153868_6_T2	GENE	3	3	has
NCT001538686	NCT00153868_6_T3	PHENOTYPE	11	11	anemia
NCT001538686	NCT00153868_6_T4	GENE	17	17	et
NCT001538686	NCT00153868_6_T5	GENE	22	22	et
NCT001538686	NCT00153868_6_T6	PHENOTYPE	13	14	lung cancer
NCT001538687	NCT00153868_7_T0	PHENOTYPE	25	25	symptoms
NCT001538687	NCT00153868_7_T1	PHENOTYPE	12	12	anemia
NCT001538687	NCT00153868_7_T2	PHENOTYPE	30	32	quality of life
NCT001538688	NCT00153868_8_T0	PHENOTYPE	11	11	symptoms
NCT001538688	NCT00153868_8_T1	PHENOTYPE	15	17	quality of life
NCT0015386810	NCT00153868_10_T0	PHENOTYPE	17	17	symptoms
NCT0015386810	NCT00153868_10_T1	PHENOTYPE	30	32	quality of life
NCT0015386812	NCT00153868_12_T0	PHENOTYPE	18	18	anemia
NCT0015386813	NCT00153868_13_T0	PHENOTYPE	15	17	quality of life
NCT001538816	NCT00153881_6_T0	GENE	13	13	Gy
NCT001538816	NCT00153881_6_T1	COMPOUND	1	1	docetaxel
NCT001538816	NCT00153881_6_T2	COMPOUND	6	6	5_fluorouracil
NCT001538816	NCT00153881_6_T3	GENE	17	17	has
NCT001538816	NCT00153881_6_T4	GENE	31	31	DMS
NCT001538817	NCT00153881_7_T0	COMPOUND	30	30	capecitabine
NCT001538817	NCT00153881_7_T1	COMPOUND	20	20	5_fluorouracil
NCT001538817	NCT00153881_7_T2	GENE	4	4	has
NCT001538818	NCT00153881_8_T0	CELL	6	6	cells
NCT001538818	NCT00153881_8_T1	COMPOUND	2	2	5_fluorouracil
NCT001538818	NCT00153881_8_T2	PHENOTYPE	5	5	tumor
NCT001538819	NCT00153881_9_T0	ORGAN	36	37	gastroesophageal junction
NCT001538819	NCT00153881_9_T1	PHENOTYPE	31	34	cancer of the esophagus
NCT001538949	NCT00153894_9_T0	ORGAN	7	7	heart
NCT0015389413	NCT00153894_13_T0	GENE	6	6	insulin
NCT0015389413	NCT00153894_13_T1	PHENOTYPE	8	9	glucose levels
NCT0015389414	NCT00153894_14_T0	PHENOTYPE	18	18	impedance
NCT001539076	NCT00153907_6_T0	COMPOUND	7	7	navelbine
NCT001539201	NCT00153920_1_T0	GENE	16	16	had
NCT001539201	NCT00153920_1_T1	PHENOTYPE	12	13	multiple myeloma
NCT001539202	NCT00153920_2_T0	CELL	18	19	nerve fiber
NCT001539202	NCT00153920_2_T1	ORGAN	12	13	bone marrow
NCT001539207	NCT00153920_7_T0	COMPOUND	13	13	bortezomib
NCT001539336	NCT00153933_6_T0	COMPOUND	8	8	bortezomib
NCT0015393311	NCT00153933_11_T0	GENE	11	11	1.2
NCT0015393311	NCT00153933_11_T1	COMPOUND	1	1	bortezomib
NCT0015393311	NCT00153933_11_T2	COMPOUND	7	7	bortezomib
NCT0015393314	NCT00153933_14_T0	ORGAN	4	5	bone marrow
NCT001539461	NCT00153946_1_T0	PHENOTYPE	18	18	acute
NCT001539461	NCT00153946_1_T1	PHENOTYPE	19	20	brain infarction
NCT001539462	NCT00153946_2_T0	GENE	9	9	has
NCT001539463	NCT00153946_3_T0	PHENOTYPE	18	18	acute
NCT001539463	NCT00153946_3_T1	PHENOTYPE	22	23	ischemic stroke
NCT001539721	NCT00153972_1_T0	COMPOUND	19	19	levodopa
NCT001539721	NCT00153972_1_T1	COMPOUND	17	17	cabergoline
NCT001539723	NCT00153972_3_T0	COMPOUND	11	11	levodopa
NCT001539723	NCT00153972_3_T1	GENE	12	12	has
NCT001539723	NCT00153972_3_T2	COMPOUND	17	17	dopamine
NCT001539723	NCT00153972_3_T3	COMPOUND	21	21	dopamine
NCT001539723	NCT00153972_3_T4	COMPOUND	26	26	dopamine
NCT001539727	NCT00153972_7_T0	BIOLOGICAL_PROCESS	18	19	dopamine metabolism
NCT001539728	NCT00153972_8_T0	COMPOUND	11	11	levodopa
NCT001539728	NCT00153972_8_T1	GENE	12	12	has
NCT001539728	NCT00153972_8_T2	COMPOUND	17	17	dopamine
NCT001539728	NCT00153972_8_T3	COMPOUND	21	21	dopamine
NCT001539728	NCT00153972_8_T4	COMPOUND	26	26	dopamine
NCT0015397210	NCT00153972_10_T0	COMPOUND	9	9	levodopa
NCT0015397210	NCT00153972_10_T1	COMPOUND	15	15	cabergoline
NCT0015397210	NCT00153972_10_T2	COMPOUND	12	12	dopamine
NCT0015397210	NCT00153972_10_T3	COMPOUND	18	18	dopamine
NCT0015397210	NCT00153972_10_T4	COMPOUND	27	27	dopamine
NCT0015397210	NCT00153972_10_T5	GENE	13	13	D2
NCT0015397211	NCT00153972_11_T0	COMPOUND	19	19	levodopa
NCT0015397211	NCT00153972_11_T1	COMPOUND	17	17	cabergoline
NCT0015397212	NCT00153972_12_T0	GENE	9	9	IV
NCT001539851	NCT00153985_1_T0	PHENOTYPE	5	5	severity
NCT001539851	NCT00153985_1_T1	ORGAN	11	11	graft
NCT001539851	NCT00153985_1_T2	PHENOTYPE	15	15	GVHD
NCT001539981	NCT00153998_1_T0	GENE	9	9	abdominal
NCT001539983	NCT00153998_3_T0	PHENOTYPE	16	17	liver metastases
NCT001539983	NCT00153998_3_T1	PHENOTYPE	33	34	liver metastases
NCT001539985	NCT00153998_5_T0	GENE	18	18	EGFR
NCT001539986	NCT00153998_6_T0	BIOLOGICAL_PROCESS	9	10	gene expression
NCT001539987	NCT00153998_7_T0	GENE	16	16	EGFR
NCT001539987	NCT00153998_7_T1	PHENOTYPE	2	3	primary tumor
NCT0015399811	NCT00153998_11_T0	PHENOTYPE	16	17	tumor progression
NCT001540376	NCT00154037_6_T0	PHENOTYPE	2	2	pulse
NCT001540500	NCT00154050_0_T0	PHENOTYPE	6	6	Restenosis
NCT001540630	NCT00154063_0_T0	PHENOTYPE	7	7	Migraine
NCT001540636	NCT00154063_6_T0	PHENOTYPE	0	0	Migraine
NCT001540636	NCT00154063_6_T1	GENE	5	5	had
NCT0015406311	NCT00154063_11_T0	PHENOTYPE	10	10	unilateral
NCT0015406311	NCT00154063_11_T1	GENE	2	2	has
NCT0015406319	NCT00154063_19_T0	GENE	15	15	eg
NCT0015406319	NCT00154063_19_T1	PHENOTYPE	22	22	IUD
NCT0015406321	NCT00154063_21_T0	COMPOUND	6	6	BMI
NCT0015406326	NCT00154063_26_T0	PHENOTYPE	23	23	Headache
NCT0015406326	NCT00154063_26_T1	PHENOTYPE	17	17	secondary
NCT0015406326	NCT00154063_26_T2	PHENOTYPE	12	12	headaches
NCT0015406326	NCT00154063_26_T3	PHENOTYPE	18	18	headaches
NCT0015406326	NCT00154063_26_T4	PHENOTYPE	14	15	tension-type headache
NCT0015406326	NCT00154063_26_T5	PHENOTYPE	6	8	trigeminal autonomic cephalalgias
NCT0015406326	NCT00154063_26_T6	PHENOTYPE	2	6	cluster headaches and other trigeminal
NCT0015406330	NCT00154063_30_T0	PHENOTYPE	12	12	schizophrenia
NCT0015406330	NCT00154063_30_T1	PHENOTYPE	17	18	bipolar disorder
NCT0015406330	NCT00154063_30_T2	PHENOTYPE	9	10	psychiatric disorders
NCT0015406330	NCT00154063_30_T3	PHENOTYPE	13	15	major depressive disorder
NCT0015406334	NCT00154063_34_T0	PHENOTYPE	4	5	ECG abnormality
NCT0015406335	NCT00154063_35_T0	PHENOTYPE	12	13	gastrointestinal diseases
NCT0015406335	NCT00154063_35_T1	PHENOTYPE	17	18	viral infections
NCT0015406335	NCT00154063_35_T2	PHENOTYPE	5	6	hepatic disease
NCT0015406336	NCT00154063_36_T0	PHENOTYPE	7	7	alcoholism
NCT0015406336	NCT00154063_36_T1	PHENOTYPE	9	10	drug abuse
NCT0015406337	NCT00154063_37_T0	GENE	3	3	had
NCT0015406337	NCT00154063_37_T1	PHENOTYPE	5	6	allergic reactions
NCT0015406338	NCT00154063_38_T0	GENE	14	14	PI
NCT0015406340	NCT00154063_40_T0	PHENOTYPE	6	6	allergy
NCT0015406340	NCT00154063_40_T1	COMPOUND	8	8	lactose
NCT0015406340	NCT00154063_40_T2	COMPOUND	10	10	lactose
NCT0015406341	NCT00154063_41_T0	COMPOUND	25	25	magnesium
NCT0015406341	NCT00154063_41_T1	GENE	44	44	toxin
NCT0015406341	NCT00154063_41_T2	COMPOUND	33	33	riboflavin
NCT0015406341	NCT00154063_41_T3	GENE	17	18	calcium channel
NCT0015406341	NCT00154063_41_T4	GENE	20	21	monoamine oxidase
NCT0015406345	NCT00154063_45_T0	COMPOUND	4	4	BMI
NCT001540765	NCT00154076_5_T0	PHENOTYPE	13	13	seizure
NCT001540765	NCT00154076_5_T1	PHENOTYPE	5	5	seizures
NCT001540765	NCT00154076_5_T2	GENE	1	1	had
NCT001540767	NCT00154076_7_T0	GENE	1	1	had
NCT0015407612	NCT00154076_12_T0	PHENOTYPE	3	3	progressive
NCT0015407613	NCT00154076_13_T0	PHENOTYPE	0	0	Allergy
NCT0015407614	NCT00154076_14_T0	COMPOUND	2	2	acetazolamide
NCT0015407615	NCT00154076_15_T0	PHENOTYPE	0	1	Hemolytic anemia
NCT0015407616	NCT00154076_16_T0	GENE	8	8	GPT
NCT0015407616	NCT00154076_16_T1	PHENOTYPE	3	5	abnormal liver function
NCT0015407618	NCT00154076_18_T0	PHENOTYPE	3	5	abnormal renal function
NCT0015407620	NCT00154076_20_T0	PHENOTYPE	7	8	alcohol abuse
NCT0015407622	NCT00154076_22_T0	GENE	0	1	Glucose-6-phosphate dehydrogenase
NCT0015407623	NCT00154076_23_T0	PHENOTYPE	5	6	renal stones
NCT0015407624	NCT00154076_24_T0	PHENOTYPE	3	3	progressive
NCT0015407625	NCT00154076_25_T0	PHENOTYPE	3	3	progressive
NCT0015407626	NCT00154076_26_T0	PHENOTYPE	3	4	mental retardation
NCT001540892	NCT00154089_2_T0	COMPOUND	10	10	terameprocol
NCT001540892	NCT00154089_2_T1	GENE	2	2	met
NCT001540893	NCT00154089_3_T0	PHENOTYPE	9	9	symptoms
NCT001541022	NCT00154102_2_T0	PHENOTYPE	13	15	metastatic colorectal cancer
NCT001541025	NCT00154102_5_T0	PHENOTYPE	39	39	toxicity
NCT001541025	NCT00154102_5_T1	GENE	3	3	EGF
NCT001541025	NCT00154102_5_T2	PHENOTYPE	33	33	progression
NCT001541029	NCT00154102_9_T0	GENE	18	18	4.5
NCT001541151	NCT00154115_1_T0	ORGAN	17	18	heart valve
NCT001541153	NCT00154115_3_T0	PHENOTYPE	10	10	anesthesia
NCT001541154	NCT00154115_4_T0	PHENOTYPE	10	10	secondary
NCT001541154	NCT00154115_4_T1	GENE	8	8	bypass
NCT001541154	NCT00154115_4_T2	PHENOTYPE	18	19	organ failure
NCT001541288	NCT00154128_8_T0	ORGAN	6	7	masticatory muscles
NCT001541288	NCT00154128_8_T1	PHENOTYPE	19	20	joint noises
NCT0015412812	NCT00154128_12_T0	GENE	25	25	II
NCT0015412812	NCT00154128_12_T1	ORGAN	18	18	spine
NCT001541541	NCT00154154_1_T0	GENE	3	3	DBT
NCT001541542	NCT00154154_2_T0	GENE	19	19	GPM
NCT001541542	NCT00154154_2_T1	GENE	13	13	DBT
NCT001541543	NCT00154154_3_T0	GENE	14	14	GPM
NCT001541543	NCT00154154_3_T1	GENE	10	10	DBT
NCT001541548	NCT00154154_8_T0	PHENOTYPE	12	13	personality disorder
NCT001541548	NCT00154154_8_T1	PHENOTYPE	25	26	personality disorder
NCT001541549	NCT00154154_9_T0	PHENOTYPE	3	3	BPD
NCT001541549	NCT00154154_9_T1	BIOLOGICAL_PROCESS	9	9	behaviour
NCT001541549	NCT00154154_9_T2	PHENOTYPE	0	2	Borderline personality disorder
NCT0015415410	NCT00154154_10_T0	BIOLOGICAL_PROCESS	1	1	behaviour
NCT0015415410	NCT00154154_10_T1	PHENOTYPE	8	9	self-injurious behaviour
NCT0015415410	NCT00154154_10_T2	PHENOTYPE	16	17	completed suicide
NCT0015415412	NCT00154154_12_T0	PHENOTYPE	27	27	BPD
NCT0015415413	NCT00154154_13_T0	PHENOTYPE	6	6	BPD
NCT0015415413	NCT00154154_13_T1	BIOLOGICAL_PROCESS	2	2	behaviour
NCT0015415413	NCT00154154_13_T2	PHENOTYPE	15	16	psychiatric disorders
NCT0015415414	NCT00154154_14_T0	GENE	26	26	sparse
NCT0015415416	NCT00154154_16_T0	GENE	0	0	DBT
NCT0015415417	NCT00154154_17_T0	GENE	7	7	DBT
NCT0015415417	NCT00154154_17_T1	GENE	16	16	DBT
NCT0015415418	NCT00154154_18_T0	GENE	29	29	GPM
NCT0015415418	NCT00154154_18_T1	GENE	14	14	DBT
NCT0015415418	NCT00154154_18_T2	PHENOTYPE	22	22	BPD
NCT0015415421	NCT00154154_21_T0	GENE	2	2	DBT
NCT001541673	NCT00154167_3_T0	COMPOUND	22	22	levonordefrin
NCT001541673	NCT00154167_3_T1	COMPOUND	10	10	articaine
NCT001541673	NCT00154167_3_T2	COMPOUND	12	12	epinephrine
NCT001541673	NCT00154167_3_T3	COMPOUND	15	15	epinephrine
NCT001541673	NCT00154167_3_T4	COMPOUND	18	18	epinephrine
NCT001541673	NCT00154167_3_T5	COMPOUND	16	16	prilocaine
NCT001541673	NCT00154167_3_T6	COMPOUND	20	20	mepivacaine
NCT001541673	NCT00154167_3_T7	COMPOUND	13	13	lidocaine
NCT001541677	NCT00154167_7_T0	GENE	16	16	had
NCT001541677	NCT00154167_7_T1	GENE	7	7	1.8
NCT001542191	NCT00154219_1_T0	COMPOUND	3	3	celecoxib
NCT001542191	NCT00154219_1_T1	GENE	11	11	COX-2
NCT001542191	NCT00154219_1_T2	COMPOUND	1	1	lumiracoxib
NCT001542450	NCT00154245_0_T0	GENE	23	23	de
NCT001542450	NCT00154245_0_T1	COMPOUND	15	15	Sodium
NCT001542450	NCT00154245_0_T2	ORGAN	25	25	Kidney
NCT001542450	NCT00154245_0_T3	ORGAN	26	26	Transplant
NCT001542453	NCT00154245_3_T0	COMPOUND	8	8	cyclosporine
NCT001542453	NCT00154245_3_T1	GENE	16	16	The
NCT001542453	NCT00154245_3_T2	ORGAN	3	3	transplant
NCT001542455	NCT00154245_5_T0	GENE	2	2	de
NCT001542455	NCT00154245_5_T1	ORGAN	10	10	kidney
NCT001542455	NCT00154245_5_T2	ORGAN	17	17	kidney
NCT001542455	NCT00154245_5_T3	ORGAN	19	19	pancreas
NCT001542455	NCT00154245_5_T4	ORGAN	22	22	transplant
NCT001542455	NCT00154245_5_T5	ORGAN	11	11	transplants
NCT001542456	NCT00154245_6_T0	ORGAN	7	7	transplants
NCT001542457	NCT00154245_7_T0	GENE	7	7	PRA
NCT001542458	NCT00154245_8_T0	ORGAN	11	11	transplant
NCT0015424510	NCT00154245_10_T0	PHENOTYPE	3	3	HIV
NCT0015424510	NCT00154245_10_T1	PHENOTYPE	5	6	Hepatitis B
NCT001542581	NCT00154258_1_T0	COMPOUND	14	14	clozapine
NCT001542581	NCT00154258_1_T1	PHENOTYPE	19	19	schizophrenia
NCT001542583	NCT00154258_3_T0	COMPOUND	14	14	clozapine
NCT001542583	NCT00154258_3_T1	PHENOTYPE	19	19	schizophrenia
NCT001542714	NCT00154271_4_T0	GENE	16	16	SBP
NCT001542714	NCT00154271_4_T1	GENE	24	24	DBP
NCT001542714	NCT00154271_4_T2	PHENOTYPE	2	2	hypertension
NCT001542714	NCT00154271_4_T3	GENE	13	13	BP
NCT001542718	NCT00154271_8_T0	GENE	8	8	11.0
NCT0015427110	NCT00154271_10_T0	PHENOTYPE	2	3	secondary hypertension
NCT0015427112	NCT00154271_12_T0	COMPOUND	21	21	thiazide
NCT0015427112	NCT00154271_12_T1	GENE	4	4	ACE
NCT0015427112	NCT00154271_12_T2	COMPOUND	10	10	aldosterone
NCT0015427112	NCT00154271_12_T3	GENE	6	7	angiotensin receptor
NCT001542842	NCT00154284_2_T0	PHENOTYPE	3	3	reflected
NCT001543104	NCT00154310_4_T0	GENE	2	2	de
NCT001543104	NCT00154310_4_T1	ORGAN	10	10	kidney
NCT001543104	NCT00154310_4_T2	ORGAN	11	11	transplants
NCT001543105	NCT00154310_5_T0	GENE	19	19	BL
NCT001543105	NCT00154310_5_T1	PHENOTYPE	58	58	infertility
NCT001543105	NCT00154310_5_T2	GENE	53	53	has
NCT001543105	NCT00154310_5_T3	ORGAN	9	9	serum
NCT001543106	NCT00154310_6_T0	GENE	28	28	BL
NCT001543106	NCT00154310_6_T1	GENE	48	48	BL
NCT001543106	NCT00154310_6_T2	GENE	41	41	had
NCT001543106	NCT00154310_6_T3	GENE	17	17	has
NCT001543107	NCT00154310_7_T0	COMPOUND	20	20	cyclosporine
NCT001543107	NCT00154310_7_T1	GENE	1	1	had
NCT001543108	NCT00154310_8_T0	COMPOUND	5	5	creatinine
NCT001543108	NCT00154310_8_T1	GENE	7	7	3.0
NCT001543108	NCT00154310_8_T2	GENE	20	20	BL
NCT001543108	NCT00154310_8_T3	ORGAN	4	4	serum
NCT0015431010	NCT00154310_10_T0	ORGAN	3	3	kidney
NCT0015431010	NCT00154310_10_T1	ORGAN	15	15	kidney
NCT0015431010	NCT00154310_10_T2	ORGAN	5	5	pancreas
NCT0015431010	NCT00154310_10_T3	ORGAN	8	8	transplant
NCT0015431011	NCT00154310_11_T0	PHENOTYPE	15	15	secondary
NCT0015431011	NCT00154310_11_T1	PHENOTYPE	0	1	Graft loss
NCT0015431012	NCT00154310_12_T0	ORGAN	7	7	transplants
NCT0015431014	NCT00154310_14_T0	ORGAN	11	11	transplant
NCT0015431015	NCT00154310_15_T0	GENE	32	32	BL
NCT0015431015	NCT00154310_15_T1	GENE	48	48	BL
NCT0015431015	NCT00154310_15_T2	GENE	39	39	met
NCT0015431016	NCT00154310_16_T0	PHENOTYPE	0	1	Graft loss
NCT0015431018	NCT00154310_18_T0	GENE	8	8	II
NCT0015431018	NCT00154310_18_T1	PHENOTYPE	9	9	acute
NCT0015431018	NCT00154310_18_T2	PHENOTYPE	12	12	acute
NCT0015431018	NCT00154310_18_T3	PHENOTYPE	17	17	acute
NCT0015431018	NCT00154310_18_T4	PHENOTYPE	2	2	suffered
NCT0015431018	NCT00154310_18_T5	PHENOTYPE	16	16	resistant
NCT0015431018	NCT00154310_18_T6	PHENOTYPE	11	11	recurrent
NCT001543230	NCT00154323_0_T0	GENE	20	20	II
NCT001543230	NCT00154323_0_T1	PHENOTYPE	16	17	Bipolar Disorder
NCT001543232	NCT00154323_2_T0	GENE	21	21	II
NCT001543232	NCT00154323_2_T1	COMPOUND	9	9	oxcarbazepine
NCT001543232	NCT00154323_2_T2	PHENOTYPE	16	17	bipolar disorder
NCT001543360	NCT00154336_0_T0	PHENOTYPE	19	19	Arthritis
NCT001543360	NCT00154336_0_T1	PHENOTYPE	16	17	Rheumatoid Arthritis
NCT001543362	NCT00154336_2_T0	COMPOUND	14	14	imatinib
NCT001543362	NCT00154336_2_T1	COMPOUND	24	24	methotrexate
NCT001543362	NCT00154336_2_T2	COMPOUND	36	36	methotrexate
NCT001543362	NCT00154336_2_T3	PHENOTYPE	19	20	rheumatoid arthritis
NCT001543622	NCT00154362_2_T0	COMPOUND	9	9	oxcarbazepine
NCT001543622	NCT00154362_2_T1	PHENOTYPE	16	17	conduct disorder
NCT001543750	NCT00154375_0_T0	PHENOTYPE	20	20	Progressive
NCT001543750	NCT00154375_0_T1	PHENOTYPE	21	21	Glioblastoma
NCT001543750	NCT00154375_0_T2	PHENOTYPE	19	19	Resistant
NCT001543756	NCT00154375_6_T0	GENE	0	0	MRI
NCT001543757	NCT00154375_7_T0	GENE	16	16	MRI
NCT001543882	NCT00154388_2_T0	PHENOTYPE	1	1	menopausal
NCT001543882	NCT00154388_2_T1	PHENOTYPE	6	6	amenorrhea
NCT001544271	NCT00154427_1_T0	PHENOTYPE	17	17	bleeding
NCT001544400	NCT00154440_0_T0	GENE	9	9	II
NCT001544400	NCT00154440_0_T1	PHENOTYPE	2	2	Lymphoma
NCT001544402	NCT00154440_2_T0	PHENOTYPE	18	19	MALT lymphoma
NCT001544404	NCT00154440_4_T0	GENE	2	2	II
NCT001544404	NCT00154440_4_T1	GENE	17	17	reduced
NCT001544407	NCT00154440_7_T0	PHENOTYPE	31	31	remission
NCT001544407	NCT00154440_7_T1	PHENOTYPE	15	16	MALT lymphoma
NCT0015444012	NCT00154440_12_T0	PHENOTYPE	9	10	MALT lymphoma
NCT0015444015	NCT00154440_15_T0	GENE	5	5	reduced
NCT001544530	NCT00154453_0_T0	TISSUE	11	11	Muscle
NCT001544532	NCT00154453_2_T0	GENE	2	2	has
NCT001544534	NCT00154453_4_T0	GENE	7	7	has
NCT001544537	NCT00154453_7_T0	GENE	25	25	MHC
NCT001544537	NCT00154453_7_T1	TISSUE	32	33	skeletal muscle
NCT001544537	NCT00154453_7_T2	GENE	22	24	myosin heavy chain
NCT001544538	NCT00154453_8_T0	GENE	0	0	MHC
NCT001544538	NCT00154453_8_T1	PHENOTYPE	13	13	contraction
NCT001544539	NCT00154453_9_T0	GENE	4	4	MHC
NCT0015445313	NCT00154453_13_T0	GENE	1	1	gel
NCT001544660	NCT00154466_0_T0	PHENOTYPE	14	15	Heart Failure
NCT001544660	NCT00154466_0_T1	CELL	10	11	Stem Cell
NCT001544662	NCT00154466_2_T0	PHENOTYPE	1	1	reperfusion
NCT001544662	NCT00154466_2_T1	PHENOTYPE	5	7	acute myocardial infarction
NCT001544663	NCT00154466_3_T0	GENE	9	9	ventricular
NCT001544663	NCT00154466_3_T1	ORGAN	4	5	left ventricle
NCT001544665	NCT00154466_5_T0	CELL	10	11	stem cells
NCT0015446611	NCT00154466_11_T0	PHENOTYPE	2	2	focused
NCT0015446611	NCT00154466_11_T1	COMPOUND	13	13	oxygen
NCT0015446611	NCT00154466_11_T2	TISSUE	16	17	skeletal muscle
NCT001544791	NCT00154479_1_T0	PHENOTYPE	11	12	cervical cancer
NCT001544792	NCT00154479_2_T0	PHENOTYPE	9	10	cervical cancer
NCT001544792	NCT00154479_2_T1	PHENOTYPE	21	22	cervical cancer
NCT001544794	NCT00154479_4_T0	PHENOTYPE	21	21	infections
NCT001544794	NCT00154479_4_T1	BIOLOGICAL_PROCESS	7	8	immune response
NCT001544794	NCT00154479_4_T2	PHENOTYPE	3	4	virus diseases
NCT001544797	NCT00154479_7_T0	GENE	9	9	E7
NCT001544797	NCT00154479_7_T1	GENE	13	13	CTL
NCT001544797	NCT00154479_7_T2	PHENOTYPE	14	14	immunity
NCT001544797	NCT00154479_7_T3	CELL	12	12	lymphocyte
NCT0015447910	NCT00154479_10_T0	GENE	6	6	II
NCT0015447910	NCT00154479_10_T1	PHENOTYPE	3	4	class I
NCT0015447910	NCT00154479_10_T2	BIOLOGICAL_PROCESS	14	15	immune response
NCT0015447910	NCT00154479_10_T3	PHENOTYPE	18	19	cervical lesions
NCT0015447911	NCT00154479_11_T0	GENE	19	19	II
NCT0015447911	NCT00154479_11_T1	PHENOTYPE	16	17	class I
NCT0015447911	NCT00154479_11_T2	PHENOTYPE	30	31	cervical cancer
NCT0015447912	NCT00154479_12_T0	GENE	15	15	II
NCT0015447912	NCT00154479_12_T1	PHENOTYPE	16	16	associations
NCT0015447912	NCT00154479_12_T2	PHENOTYPE	22	22	neoplasia
NCT0015447912	NCT00154479_12_T3	PHENOTYPE	12	13	class I
NCT0015447913	NCT00154479_13_T0	GENE	17	17	II
NCT0015447913	NCT00154479_13_T1	GENE	41	41	II
NCT0015447913	NCT00154479_13_T2	COMPOUND	6	6	1
NCT0015447913	NCT00154479_13_T3	COMPOUND	25	25	2
NCT0015447913	NCT00154479_13_T4	PHENOTYPE	14	15	class I
NCT0015447913	NCT00154479_13_T5	PHENOTYPE	38	39	class I
NCT0015447913	NCT00154479_13_T6	PHENOTYPE	22	23	cervical cancer
NCT0015447914	NCT00154479_14_T0	PHENOTYPE	14	14	susceptible
NCT0015447914	NCT00154479_14_T1	PHENOTYPE	21	23	invasive cervical cancer
NCT0015447915	NCT00154479_15_T0	PHENOTYPE	15	16	cervical cancer
NCT0015447918	NCT00154479_18_T0	PHENOTYPE	24	25	cervical cancers
NCT0015447919	NCT00154479_19_T0	PHENOTYPE	5	6	cervical cancer
NCT0015447925	NCT00154479_25_T0	GENE	4	4	II
NCT0015447925	NCT00154479_25_T1	PHENOTYPE	14	14	carcinoma
NCT0015447925	NCT00154479_25_T2	PHENOTYPE	1	2	class I
NCT0015447926	NCT00154479_26_T0	GENE	7	7	II
NCT0015447926	NCT00154479_26_T1	CELL	2	2	leukocyte
NCT0015447926	NCT00154479_26_T2	PHENOTYPE	4	5	class I
NCT0015447926	NCT00154479_26_T3	PHENOTYPE	22	23	hepatitis C
NCT0015447926	NCT00154479_26_T4	PHENOTYPE	24	25	virus infection
NCT0015447926	NCT00154479_26_T5	PHENOTYPE	21	22	chronic hepatitis
NCT0015447926	NCT00154479_26_T6	BIOLOGICAL_PROCESS	13	15	response to interferon-alpha
NCT0015447934	NCT00154479_34_T0	GENE	13	13	II
NCT0015447934	NCT00154479_34_T1	PHENOTYPE	22	22	carcinogenesis
NCT0015447934	NCT00154479_34_T2	PHENOTYPE	24	25	cervical cancer
NCT0015447935	NCT00154479_35_T0	GENE	3	3	has
NCT0015447935	NCT00154479_35_T1	PHENOTYPE	16	17	cervical cancer
NCT0015447937	NCT00154479_37_T0	GENE	16	16	II
NCT0015447937	NCT00154479_37_T1	PHENOTYPE	13	14	class I
NCT0015447937	NCT00154479_37_T2	PHENOTYPE	29	30	cervical cancer
NCT0015447937	NCT00154479_37_T3	BIOLOGICAL_PROCESS	4	5	immune response
NCT0015447938	NCT00154479_38_T0	PHENOTYPE	29	29	carcinogenesis
NCT0015447938	NCT00154479_38_T1	PHENOTYPE	10	10	susceptible
NCT0015447938	NCT00154479_38_T2	PHENOTYPE	31	32	cervical cancer
NCT0015447938	NCT00154479_38_T3	PHENOTYPE	15	17	invasive cervical cancer
NCT0015447940	NCT00154479_40_T0	PHENOTYPE	5	6	cervical cancer
NCT001544921	NCT00154492_1_T0	PHENOTYPE	20	20	bleeding
NCT001544921	NCT00154492_1_T1	PHENOTYPE	15	16	advanced cirrhosis
NCT001545051	NCT00154505_1_T0	PHENOTYPE	18	18	severity
NCT001545051	NCT00154505_1_T1	PHENOTYPE	20	20	scoliosis
NCT001545053	NCT00154505_3_T0	GENE	4	4	has
NCT001545056	NCT00154505_6_T0	ORGAN	3	3	spine
NCT001545057	NCT00154505_7_T0	ORGAN	8	8	spine
NCT001545058	NCT00154505_8_T0	ORGAN	20	20	spine
NCT001545181	NCT00154518_1_T0	ORGAN	9	10	third molars
NCT001545183	NCT00154518_3_T0	PHENOTYPE	6	6	periodontitis
NCT001545183	NCT00154518_3_T1	PHENOTYPE	3	4	dental caries
NCT001545185	NCT00154518_5_T0	BIOLOGICAL_PROCESS	6	7	bone resorption
NCT001545186	NCT00154518_6_T0	BIOLOGICAL_PROCESS	1	2	bone resorption
NCT001545187	NCT00154518_7_T0	BIOLOGICAL_PROCESS	0	1	Bone resorption
NCT001545188	NCT00154518_8_T0	CELL	8	8	osteoclasts
NCT0015451811	NCT00154518_11_T0	PHENOTYPE	7	7	initiation
NCT0015451811	NCT00154518_11_T1	CELL	0	0	Osteoblast
NCT0015451811	NCT00154518_11_T2	BIOLOGICAL_PROCESS	9	10	bone resorption
NCT0015451813	NCT00154518_13_T0	CELL	11	12	cultured cells
NCT0015451814	NCT00154518_14_T0	CELL	12	12	cells
NCT0015451814	NCT00154518_14_T1	GENE	15	15	collagen
NCT0015451814	NCT00154518_14_T2	CELL	11	11	osteocyte
NCT0015451814	NCT00154518_14_T3	GENE	16	16	gel
NCT0015451814	NCT00154518_14_T4	BIOLOGICAL_PROCESS	6	7	bone resorption
NCT0015451817	NCT00154518_17_T0	GENE	11	11	ex
NCT0015451817	NCT00154518_17_T1	GENE	12	12	Beta-actin
NCT0015451817	NCT00154518_17_T2	GENE	14	14	GAPDH
NCT0015451821	NCT00154518_21_T0	ORGAN	9	10	third molars
NCT001545311	NCT00154531_1_T0	PHENOTYPE	10	10	tumor
NCT001545311	NCT00154531_1_T1	GENE	2	2	AFP
NCT0015453114	NCT00154531_14_T0	GENE	1	1	DCP
NCT0015453114	NCT00154531_14_T1	COMPOUND	11	11	3cm
NCT0015453118	NCT00154531_18_T0	GENE	5	5	has
NCT0015453122	NCT00154531_22_T0	GENE	3	3	retained
NCT0015453125	NCT00154531_25_T0	ORGAN	0	0	Blood
NCT001545443	NCT00154544_3_T0	GENE	6	6	DCP
NCT001545443	NCT00154544_3_T1	PHENOTYPE	11	11	tumor
NCT001545443	NCT00154544_3_T2	GENE	2	2	AFP
NCT001545443	NCT00154544_3_T3	GENE	5	5	prothrombin
NCT0015454410	NCT00154544_10_T0	GENE	6	6	clot
NCT0015454410	NCT00154544_10_T1	ORGAN	15	15	serum
NCT0015454412	NCT00154544_12_T0	GENE	5	5	sera
NCT0015454412	NCT00154544_12_T1	GENE	1	1	gel
NCT0015454413	NCT00154544_13_T0	PHENOTYPE	0	0	Spots
NCT001545575	NCT00154557_5_T0	GENE	0	0	And
NCT0015455715	NCT00154557_15_T0	PHENOTYPE	13	13	regression
NCT0015455721	NCT00154557_21_T0	GENE	0	0	And
NCT0015455731	NCT00154557_31_T0	PHENOTYPE	13	13	regression
NCT001545700	NCT00154570_0_T0	PHENOTYPE	10	11	Reflux Esophagitis
NCT001545703	NCT00154570_3_T0	GENE	9	10	proton pump
NCT001545704	NCT00154570_4_T0	GENE	6	6	has
NCT001545704	NCT00154570_4_T1	COMPOUND	4	4	antral
NCT001545704	NCT00154570_4_T2	PHENOTYPE	5	5	dysmotility
NCT001545704	NCT00154570_4_T3	PHENOTYPE	11	12	reflux esophagitis
NCT001545704	NCT00154570_4_T4	BIOLOGICAL_PROCESS	1	2	gastric emptying
NCT001545705	NCT00154570_5_T0	GENE	0	0	EGG
NCT001545705	NCT00154570_5_T1	GENE	44	44	EGG
NCT001545705	NCT00154570_5_T2	GENE	76	76	EGG
NCT001545705	NCT00154570_5_T3	GENE	21	21	GES
NCT001545705	NCT00154570_5_T4	GENE	74	74	pH
NCT001545705	NCT00154570_5_T5	PHENOTYPE	13	13	motility
NCT001545705	NCT00154570_5_T6	GENE	33	33	has
NCT001545705	NCT00154570_5_T7	GENE	78	78	has
NCT001545705	NCT00154570_5_T8	PHENOTYPE	31	32	reflux esophagitis
NCT001545705	NCT00154570_5_T9	PHENOTYPE	60	61	reflux esophagitis
NCT001545705	NCT00154570_5_T10	PHENOTYPE	27	28	motility disorder
NCT001545705	NCT00154570_5_T11	PHENOTYPE	53	54	gastroesophageal reflux
NCT001545705	NCT00154570_5_T12	BIOLOGICAL_PROCESS	26	27	gastric motility
NCT001545705	NCT00154570_5_T13	BIOLOGICAL_PROCESS	50	51	gastric motility
NCT001545706	NCT00154570_6_T0	GENE	5	5	EGG
NCT001545706	NCT00154570_6_T1	GENE	1	1	has
NCT001545706	NCT00154570_6_T2	TISSUE	14	15	smooth muscle
NCT001545706	NCT00154570_6_T3	BIOLOGICAL_PROCESS	21	22	gastric emptying
NCT001545707	NCT00154570_7_T0	GENE	11	11	EGG
NCT001545707	NCT00154570_7_T1	GENE	9	9	pH
NCT001545707	NCT00154570_7_T2	PHENOTYPE	20	21	gastroesophageal reflux
NCT001545708	NCT00154570_8_T0	PHENOTYPE	14	15	gastroesophageal reflux
NCT001545709	NCT00154570_9_T0	GENE	35	35	EGG
NCT001545709	NCT00154570_9_T1	GENE	8	8	pH
NCT001545709	NCT00154570_9_T2	GENE	33	33	pH
NCT001545709	NCT00154570_9_T3	PHENOTYPE	51	52	reflux esophagitis
NCT0015457010	NCT00154570_10_T0	PHENOTYPE	46	46	symptoms
NCT0015457010	NCT00154570_10_T1	PHENOTYPE	53	53	symptoms
NCT0015457010	NCT00154570_10_T2	GENE	45	45	GI
NCT0015457010	NCT00154570_10_T3	GENE	11	11	EGG
NCT0015457010	NCT00154570_10_T4	GENE	8	8	pH
NCT0015457010	NCT00154570_10_T5	GENE	17	17	pH
NCT0015457010	NCT00154570_10_T6	GENE	41	41	pH
NCT0015457010	NCT00154570_10_T7	PHENOTYPE	26	27	gastroesophageal reflux
NCT0015457010	NCT00154570_10_T8	PHENOTYPE	30	31	gastroesophageal reflux
NCT0015457010	NCT00154570_10_T9	PHENOTYPE	57	58	acid reflux
NCT0015457011	NCT00154570_11_T0	PHENOTYPE	10	11	reflux esophagitis
NCT0015457012	NCT00154570_12_T0	PHENOTYPE	8	8	severity
NCT0015457012	NCT00154570_12_T1	PHENOTYPE	2	2	GERD
NCT0015457012	NCT00154570_12_T2	GENE	0	0	GI
NCT0015457017	NCT00154570_17_T0	GENE	2	2	EGG
NCT0015457020	NCT00154570_20_T0	PHENOTYPE	19	19	symptoms
NCT0015457020	NCT00154570_20_T1	GENE	12	12	pH
NCT001545831	NCT00154583_1_T0	PHENOTYPE	8	9	cervical cancer
NCT001545833	NCT00154583_3_T0	PHENOTYPE	10	11	cervical cancer
NCT001545834	NCT00154583_4_T0	PHENOTYPE	9	10	cervical cancer
NCT001545834	NCT00154583_4_T1	PHENOTYPE	26	27	cervical cancer
NCT001545835	NCT00154583_5_T0	TISSUE	11	11	tissues
NCT001545835	NCT00154583_5_T1	PHENOTYPE	9	10	cervical cancer
NCT001545836	NCT00154583_6_T0	PHENOTYPE	23	23	malignancy
NCT001545836	NCT00154583_6_T1	PHENOTYPE	12	12	regression
NCT001545836	NCT00154583_6_T2	PHENOTYPE	18	18	persistence
NCT001545836	NCT00154583_6_T3	PHENOTYPE	20	20	progression
NCT001545836	NCT00154583_6_T4	PHENOTYPE	15	16	cervical abnormality
NCT001545836	NCT00154583_6_T5	BIOLOGICAL_PROCESS	3	4	immune response
NCT001545837	NCT00154583_7_T0	PHENOTYPE	10	10	tumors
NCT001545837	NCT00154583_7_T1	CELL	27	27	cells
NCT001545839	NCT00154583_9_T0	GENE	18	18	E7
NCT001545839	NCT00154583_9_T1	PHENOTYPE	23	23	strategies
NCT001545839	NCT00154583_9_T2	GENE	3	3	Dr
NCT001545839	NCT00154583_9_T3	GENE	4	4	TC
NCT0015458316	NCT00154583_16_T0	PHENOTYPE	8	8	severity
NCT0015458316	NCT00154583_16_T1	GENE	20	20	E7
NCT0015458316	NCT00154583_16_T2	PHENOTYPE	10	11	cervical cancer
NCT0015458319	NCT00154583_19_T0	PHENOTYPE	7	7	tumors
NCT0015458319	NCT00154583_19_T1	PHENOTYPE	13	13	carcinomas
NCT0015458320	NCT00154583_20_T0	PHENOTYPE	29	29	cancers
NCT0015458320	NCT00154583_20_T1	ORGAN	1	1	genital
NCT0015458321	NCT00154583_21_T0	PHENOTYPE	5	6	cervical cancer
NCT0015458323	NCT00154583_23_T0	PHENOTYPE	11	12	cervical cancer
NCT0015458327	NCT00154583_27_T0	PHENOTYPE	18	18	deletion
NCT0015458328	NCT00154583_28_T0	GENE	16	16	E6
NCT0015458328	NCT00154583_28_T1	GENE	18	18	E7
NCT0015458328	NCT00154583_28_T2	GENE	2	2	L1
NCT0015458328	NCT00154583_28_T3	PHENOTYPE	28	28	carcinomas
NCT0015458328	NCT00154583_28_T4	GENE	4	4	L2
NCT0015458328	NCT00154583_28_T5	GENE	9	9	E1
NCT0015458328	NCT00154583_28_T6	GENE	11	11	E2
NCT0015458331	NCT00154583_31_T0	GENE	16	16	E6
NCT0015458331	NCT00154583_31_T1	GENE	18	18	E7
NCT0015458331	NCT00154583_31_T2	PHENOTYPE	5	6	cervical cancers
NCT0015458331	NCT00154583_31_T3	PHENOTYPE	24	25	cervical cancers
NCT0015458333	NCT00154583_33_T0	GENE	2	2	E6
NCT0015458333	NCT00154583_33_T1	GENE	4	4	E7
NCT0015458333	NCT00154583_33_T2	CELL	17	17	cells
NCT0015458333	NCT00154583_33_T3	CELL	18	18	cells
NCT0015458333	NCT00154583_33_T4	BIOLOGICAL_PROCESS	25	26	immune response
NCT0015458333	NCT00154583_33_T5	PHENOTYPE	20	21	cervical cancer
NCT0015458334	NCT00154583_34_T0	GENE	2	2	E6
NCT0015458334	NCT00154583_34_T1	GENE	4	4	E7
NCT0015458334	NCT00154583_34_T2	CELL	6	6	cells
NCT0015458334	NCT00154583_34_T3	GENE	8	8	cease
NCT0015458335	NCT00154583_35_T0	GENE	1	1	E6
NCT0015458335	NCT00154583_35_T1	GENE	3	3	E7
NCT0015458335	NCT00154583_35_T2	PHENOTYPE	15	16	cervical cancer
NCT0015458336	NCT00154583_36_T0	GENE	24	24	E6
NCT0015458336	NCT00154583_36_T1	GENE	26	26	E7
NCT0015458338	NCT00154583_38_T0	GENE	18	18	E7
NCT0015458338	NCT00154583_38_T1	GENE	25	25	E7
NCT0015458338	NCT00154583_38_T2	CELL	13	13	cells
NCT0015458338	NCT00154583_38_T3	CELL	29	29	cells
NCT0015458338	NCT00154583_38_T4	PHENOTYPE	28	28	tumor
NCT0015458338	NCT00154583_38_T5	GENE	4	4	al
NCT0015458338	NCT00154583_38_T6	GENE	3	3	et
NCT0015458339	NCT00154583_39_T0	GENE	9	9	E7
NCT0015458339	NCT00154583_39_T1	GENE	14	14	MHC
NCT0015458339	NCT00154583_39_T2	GENE	5	5	CTL
NCT0015458339	NCT00154583_39_T3	GENE	2	2	al
NCT0015458339	NCT00154583_39_T4	GENE	1	1	et
NCT0015458340	NCT00154583_40_T0	CELL	14	14	cells
NCT0015458340	NCT00154583_40_T1	PHENOTYPE	13	13	tumor
NCT0015458340	NCT00154583_40_T2	PHENOTYPE	6	6	resistant
NCT0015458340	NCT00154583_40_T3	PHENOTYPE	12	12	transformed
NCT0015458341	NCT00154583_41_T0	GENE	32	32	E7
NCT0015458341	NCT00154583_41_T1	PHENOTYPE	34	34	tumors
NCT0015458341	NCT00154583_41_T2	GENE	11	11	al
NCT0015458341	NCT00154583_41_T3	GENE	19	19	al
NCT0015458341	NCT00154583_41_T4	GENE	10	10	et
NCT0015458341	NCT00154583_41_T5	GENE	18	18	et
NCT0015458342	NCT00154583_42_T0	GENE	25	25	E6
NCT0015458342	NCT00154583_42_T1	GENE	27	27	E7
NCT0015458342	NCT00154583_42_T2	PHENOTYPE	21	21	vaccinia
NCT0015458342	NCT00154583_42_T3	PHENOTYPE	14	16	stage cervical cancer
NCT0015458347	NCT00154583_47_T0	PHENOTYPE	4	4	regression
NCT0015458349	NCT00154583_49_T0	PHENOTYPE	13	13	infections
NCT0015458349	NCT00154583_49_T1	PHENOTYPE	23	24	class II
NCT0015458349	NCT00154583_49_T2	GENE	19	21	MHC class I
NCT0015458349	NCT00154583_49_T3	BIOLOGICAL_PROCESS	8	10	T-cell mediated immunity
NCT0015458354	NCT00154583_54_T0	GENE	9	9	has
NCT0015458354	NCT00154583_54_T1	PHENOTYPE	1	1	infiltration
NCT0015458354	NCT00154583_54_T2	PHENOTYPE	3	4	cervical cancer
NCT0015458364	NCT00154583_64_T0	GENE	0	0	CD4
NCT0015458364	NCT00154583_64_T1	CELL	2	3	helper cells
NCT0015458365	NCT00154583_65_T0	GENE	0	0	CD4
NCT0015458365	NCT00154583_65_T1	PHENOTYPE	16	16	malignancies
NCT0015458365	NCT00154583_65_T2	CELL	1	2	T cells
NCT0015458367	NCT00154583_67_T0	PHENOTYPE	8	8	immunity
NCT0015458367	NCT00154583_67_T1	PHENOTYPE	5	5	Immunity
NCT0015458367	NCT00154583_67_T2	GENE	15	15	secreted
NCT0015458367	NCT00154583_67_T3	CELL	18	19	helper cells
NCT0015458369	NCT00154583_69_T0	GENE	9	9	IFN-gamma
NCT0015458369	NCT00154583_69_T1	GENE	7	8	interferon gamma
NCT0015458369	NCT00154583_69_T2	CELL	0	1	Th1 cells
NCT0015458376	NCT00154583_76_T0	PHENOTYPE	29	29	tumors
NCT0015458376	NCT00154583_76_T1	GENE	4	4	TC
NCT0015458381	NCT00154583_81_T0	COMPOUND	7	7	1
NCT0015458381	NCT00154583_81_T1	COMPOUND	22	22	2
NCT0015458381	NCT00154583_81_T2	GENE	19	19	E7
NCT0015458381	NCT00154583_81_T3	GENE	37	37	E7
NCT0015458381	NCT00154583_81_T4	GENE	32	32	Th
NCT001545965	NCT00154596_5_T0	PHENOTYPE	13	13	syndromes
NCT001545965	NCT00154596_5_T1	GENE	11	11	had
NCT001545968	NCT00154596_8_T0	PHENOTYPE	11	11	symptoms
NCT0015459610	NCT00154596_10_T0	PHENOTYPE	6	8	signs and symptoms
NCT0015459611	NCT00154596_11_T0	PHENOTYPE	9	9	symptoms
NCT0015459611	NCT00154596_11_T1	PHENOTYPE	12	13	Kawasaki disease
NCT0015459611	NCT00154596_11_T2	PHENOTYPE	31	32	Kawasaki disease
NCT0015459616	NCT00154596_16_T0	GENE	5	5	atypical
NCT0015459616	NCT00154596_16_T1	PHENOTYPE	2	3	Kawasaki disease
NCT0015459616	NCT00154596_16_T2	PHENOTYPE	6	7	Kawasaki disease
NCT0015459625	NCT00154596_25_T0	GENE	15	15	Kit
NCT0015459626	NCT00154596_26_T0	GENE	2	2	kit
NCT0015459631	NCT00154596_31_T0	COMPOUND	3	3	AW1
NCT0015459631	NCT00154596_31_T1	COMPOUND	24	24	AW2
NCT0015459633	NCT00154596_33_T0	GENE	6	6	AVE
NCT0015459636	NCT00154596_36_T0	COMPOUND	9	9	MgCl2
NCT0015459636	NCT00154596_36_T1	GENE	13	14	RNase inhibitor
NCT0015459636	NCT00154596_36_T2	GENE	15	16	reverse transcriptase
NCT0015459639	NCT00154596_39_T0	GENE	2	2	PCR
NCT0015459640	NCT00154596_40_T0	GENE	11	11	PCR
NCT0015459642	NCT00154596_42_T0	GENE	19	19	VP1
NCT0015459643	NCT00154596_43_T0	GENE	15	15	PCR
NCT0015459643	NCT00154596_43_T1	GENE	20	20	PCR
NCT0015459646	NCT00154596_46_T0	PHENOTYPE	16	16	acute
NCT0015459646	NCT00154596_46_T1	ORGAN	10	10	pharynx
NCT0015459646	NCT00154596_46_T2	GENE	3	3	toxin
NCT0015459646	NCT00154596_46_T3	ORGAN	12	12	rectum
NCT0015459646	NCT00154596_46_T4	GENE	24	24	globulin
NCT0015459650	NCT00154596_50_T0	GENE	1	1	PK
NCT0015459652	NCT00154596_52_T0	PHENOTYPE	9	9	pneumoniae
NCT0015459652	NCT00154596_52_T1	PHENOTYPE	11	11	pneumoniae
NCT0015459652	NCT00154596_52_T2	PHENOTYPE	8	8	Mycoplasma
NCT0015459654	NCT00154596_54_T0	GENE	15	15	IgM
NCT0015459657	NCT00154596_57_T0	GENE	7	7	SAS
NCT0015459657	NCT00154596_57_T1	GENE	12	12	SAS
NCT0015459659	NCT00154596_59_T0	PHENOTYPE	11	11	regression
NCT001546090	NCT00154609_0_T0	PHENOTYPE	11	11	Osteoporosis
NCT001546090	NCT00154609_0_T1	GENE	2	2	BL
NCT001546092	NCT00154609_2_T0	PHENOTYPE	21	21	osteoporosis
NCT001546094	NCT00154609_4_T0	PHENOTYPE	14	15	postmenopausal osteoporosis
NCT001546095	NCT00154609_5_T0	PHENOTYPE	7	7	osteoporosis
NCT001546352	NCT00154635_2_T0	GENE	14	14	III
NCT001546353	NCT00154635_3_T0	PHENOTYPE	11	12	adverse effect
NCT001546357	NCT00154635_7_T0	PHENOTYPE	15	15	weakness
NCT001546357	NCT00154635_7_T1	PHENOTYPE	13	14	premature aging
NCT0015463510	NCT00154635_10_T0	PHENOTYPE	12	13	Alzheimer disease
NCT0015463513	NCT00154635_13_T0	GENE	12	12	AD
NCT0015463513	NCT00154635_13_T1	GENE	11	11	probable
NCT0015463514	NCT00154635_14_T0	PHENOTYPE	13	13	Dementia
NCT0015463515	NCT00154635_15_T0	COMPOUND	9	9	rivastigmine
NCT0015463515	NCT00154635_15_T1	COMPOUND	12	12	memantine
NCT0015463515	NCT00154635_15_T2	GENE	6	6	cholinesterase
NCT0015463515	NCT00154635_15_T3	COMPOUND	10	10	galantamine
NCT0015463515	NCT00154635_15_T4	COMPOUND	8	8	donepezil
NCT0015463515	NCT00154635_15_T5	GENE	16	16	has
NCT0015463517	NCT00154635_17_T0	GENE	9	9	CDR
NCT0015463517	NCT00154635_17_T1	PHENOTYPE	0	0	Secondary
NCT0015463520	NCT00154635_20_T0	GENE	14	14	III
NCT0015463521	NCT00154635_21_T0	PHENOTYPE	6	7	adverse effect
NCT0015463523	NCT00154635_23_T0	PHENOTYPE	3	3	menopausal
NCT0015463525	NCT00154635_25_T0	PHENOTYPE	15	15	dementia
NCT0015463525	NCT00154635_25_T1	GENE	0	0	Probable
NCT0015463525	NCT00154635_25_T2	PHENOTYPE	11	12	Communicative Disorders
NCT0015463527	NCT00154635_27_T0	GENE	7	7	CDR
NCT0015463527	NCT00154635_27_T1	GENE	12	12	CDR
NCT0015463527	NCT00154635_27_T2	GENE	15	15	AD
NCT0015463527	NCT00154635_27_T3	PHENOTYPE	3	3	Dementia
NCT0015463528	NCT00154635_28_T0	GENE	9	9	MRI
NCT0015463531	NCT00154635_31_T0	COMPOUND	7	7	rivastigmine
NCT0015463531	NCT00154635_31_T1	COMPOUND	6	6	donepezil
NCT0015463531	NCT00154635_31_T2	GENE	15	15	has
NCT0015463531	NCT00154635_31_T3	COMPOUND	9	9	galantamine
NCT0015463533	NCT00154635_33_T0	PHENOTYPE	13	13	infarct
NCT0015463533	NCT00154635_33_T1	PHENOTYPE	14	14	progressive
NCT0015463533	NCT00154635_33_T2	PHENOTYPE	15	16	heart failure
NCT0015463533	NCT00154635_33_T3	PHENOTYPE	5	6	systemic disease
NCT0015463533	NCT00154635_33_T4	PHENOTYPE	9	11	coronary artery disease
NCT0015463533	NCT00154635_33_T5	PHENOTYPE	17	20	chronic obstructive pulmonary disease
NCT0015463534	NCT00154635_34_T0	COMPOUND	13	13	creatinine
NCT0015463534	NCT00154635_34_T1	ORGAN	12	12	serum
NCT0015463534	NCT00154635_34_T2	PHENOTYPE	4	5	renal insufficiency
NCT0015463535	NCT00154635_35_T0	PHENOTYPE	16	16	epilepsy
NCT0015463535	NCT00154635_35_T1	GENE	8	8	AD
NCT0015463535	NCT00154635_35_T2	PHENOTYPE	25	26	alcoholic encephalopathy
NCT0015463535	NCT00154635_35_T3	PHENOTYPE	12	13	vascular disease
NCT0015463535	NCT00154635_35_T4	PHENOTYPE	17	19	traumatic brain injury
NCT0015463535	NCT00154635_35_T5	PHENOTYPE	20	23	central nervous system infection
NCT0015463535	NCT00154635_35_T6	PHENOTYPE	2	5	central nervous system disease
NCT0015463537	NCT00154635_37_T0	PHENOTYPE	13	14	skin cancer
NCT0015463543	NCT00154635_43_T0	GENE	5	5	CSF
NCT0015463543	NCT00154635_43_T1	PHENOTYPE	2	2	neurosyphilis
NCT0015463544	NCT00154635_44_T0	GENE	14	14	AD
NCT0015463544	NCT00154635_44_T1	GENE	4	4	MRI
NCT0015463544	NCT00154635_44_T2	GENE	13	13	probable
NCT001546613	NCT00154661_3_T0	PHENOTYPE	10	11	glomerular diseases
NCT001546614	NCT00154661_4_T0	GENE	22	22	MCP-1
NCT001546614	NCT00154661_4_T1	GENE	6	6	PTX
NCT001546614	NCT00154661_4_T2	GENE	27	27	PTX
NCT001546614	NCT00154661_4_T3	GENE	14	14	TNF-a
NCT001546614	NCT00154661_4_T4	GENE	7	7	has
NCT001546615	NCT00154661_5_T0	GENE	13	13	MCP-1
NCT001546615	NCT00154661_5_T1	GENE	7	7	PTX
NCT001546615	NCT00154661_5_T2	GENE	24	24	PTX
NCT001546615	NCT00154661_5_T3	PHENOTYPE	9	9	proteinuria
NCT001546615	NCT00154661_5_T4	PHENOTYPE	30	30	proteinuria
NCT001546615	NCT00154661_5_T5	GENE	14	14	mRNA
NCT001546615	NCT00154661_5_T6	PHENOTYPE	18	18	glomerulonephritis
NCT001546615	NCT00154661_5_T7	PHENOTYPE	38	38	glomerulonephritis
NCT001546615	NCT00154661_5_T8	BIOLOGICAL_PROCESS	34	35	MCP-1 production
NCT001546616	NCT00154661_6_T0	GENE	11	11	MCP-1
NCT001546616	NCT00154661_6_T1	GENE	14	14	PTX
NCT001546616	NCT00154661_6_T2	PHENOTYPE	20	21	glomerular diseases
NCT001546741	NCT00154674_1_T0	PHENOTYPE	33	33	hypothermic
NCT001546742	NCT00154674_2_T0	PHENOTYPE	7	7	hypothermia
NCT001546746	NCT00154674_6_T0	PHENOTYPE	15	15	Hypothermia
NCT001546748	NCT00154674_8_T0	PHENOTYPE	31	31	hypothermia
NCT001546749	NCT00154674_9_T0	PHENOTYPE	17	17	hypothermia
NCT0015467415	NCT00154674_15_T0	PHENOTYPE	2	2	malignancy
NCT0015467416	NCT00154674_16_T0	PHENOTYPE	3	3	coagulopathy
NCT0015467416	NCT00154674_16_T1	PHENOTYPE	0	1	Massive bleeding
NCT001546876	NCT00154687_6_T0	COMPOUND	35	35	cisplatin
NCT001546877	NCT00154687_7_T0	PHENOTYPE	13	13	toxicities
NCT0015468710	NCT00154687_10_T0	PHENOTYPE	0	1	Measurable disease
NCT0015468715	NCT00154687_15_T0	GENE	3	3	2.0
NCT0015468719	NCT00154687_19_T0	GENE	0	0	TG
NCT0015468720	NCT00154687_20_T0	PHENOTYPE	0	1	CNS metastasis
NCT001547002	NCT00154700_2_T0	PHENOTYPE	9	9	toxicity
NCT001547002	NCT00154700_2_T1	PHENOTYPE	1	1	secondary
NCT001547137	NCT00154713_7_T0	GENE	15	15	had
NCT001547139	NCT00154713_9_T0	GENE	4	4	CEA
NCT001547262	NCT00154726_2_T0	COMPOUND	3	3	paclitaxel
NCT001547262	NCT00154726_2_T1	GENE	9	9	had
NCT001547262	NCT00154726_2_T2	GENE	8	8	has
NCT001547262	NCT00154726_2_T3	PHENOTYPE	22	23	gastric cancer
NCT001547263	NCT00154726_3_T0	PHENOTYPE	24	25	gastric cancer
NCT001547263	NCT00154726_3_T1	COMPOUND	5	6	weekly paclitaxel
NCT001547394	NCT00154739_4_T0	COMPOUND	5	5	paclitaxel
NCT001547394	NCT00154739_4_T1	PHENOTYPE	6	6	neurotoxicity
NCT001547394	NCT00154739_4_T2	PHENOTYPE	3	3	suffered
NCT001547397	NCT00154739_7_T0	PHENOTYPE	7	8	life quality
NCT001547399	NCT00154739_9_T0	COMPOUND	6	6	gemcitabine
NCT001547399	NCT00154739_9_T1	COMPOUND	8	8	cisplatin
NCT001547521	NCT00154752_1_T0	ORGAN	9	9	bladder
NCT001547521	NCT00154752_1_T1	PHENOTYPE	11	11	contraction
NCT001547521	NCT00154752_1_T2	BIOLOGICAL_PROCESS	6	7	penile erection
NCT001547524	NCT00154752_4_T0	PHENOTYPE	12	13	rectal cancers
NCT001547526	NCT00154752_6_T0	BIOLOGICAL_PROCESS	21	21	micturition
NCT001547526	NCT00154752_6_T1	BIOLOGICAL_PROCESS	13	14	colonic transit
NCT001547526	NCT00154752_6_T2	BIOLOGICAL_PROCESS	28	29	penile erection
NCT001547527	NCT00154752_7_T0	PHENOTYPE	9	9	tumor
NCT001547527	NCT00154752_7_T1	TISSUE	15	16	lymph node
NCT0015475210	NCT00154752_10_T0	PHENOTYPE	11	12	rectal cancer
NCT0015475211	NCT00154752_11_T0	PHENOTYPE	18	18	tumors
NCT0015475211	NCT00154752_11_T1	PHENOTYPE	9	9	localized
NCT0015475211	NCT00154752_11_T2	PHENOTYPE	22	22	malignancies
NCT0015475211	NCT00154752_11_T3	PHENOTYPE	1	4	adenocarcinoma of the rectum
NCT0015475212	NCT00154752_12_T0	GENE	5	5	has
NCT0015475212	NCT00154752_12_T1	GENE	1	1	extended
NCT0015475213	NCT00154752_13_T0	PHENOTYPE	24	25	rectal cancers
NCT0015475214	NCT00154752_14_T0	ORGAN	32	32	artery
NCT0015475214	NCT00154752_14_T1	GENE	24	24	IMA
NCT0015475214	NCT00154752_14_T2	PHENOTYPE	12	13	rectal cancers
NCT0015475214	NCT00154752_14_T3	ORGAN	21	23	inferior mesenteric artery
NCT0015475215	NCT00154752_15_T0	PHENOTYPE	18	19	rectal cancer
NCT0015475216	NCT00154752_16_T0	GENE	33	33	has
NCT0015475216	NCT00154752_16_T1	GENE	30	30	extended
NCT0015475216	NCT00154752_16_T2	PHENOTYPE	42	43	rectal cancer
NCT0015475218	NCT00154752_18_T0	PHENOTYPE	4	4	complication
NCT0015475219	NCT00154752_19_T0	GENE	11	11	paired
NCT0015475219	NCT00154752_19_T1	GENE	15	15	paired
NCT0015475219	NCT00154752_19_T2	ORGAN	3	4	autonomic nerves
NCT0015475219	NCT00154752_19_T3	ORGAN	17	18	splanchnic nerves
NCT0015475219	NCT00154752_19_T4	ORGAN	26	27	splanchnic nerves
NCT0015475220	NCT00154752_20_T0	ORGAN	12	13	pelvic plexus
NCT0015475220	NCT00154752_20_T1	TISSUE	23	24	lateral ligament
NCT0015475221	NCT00154752_21_T0	PHENOTYPE	10	10	distal
NCT0015475221	NCT00154752_21_T1	ORGAN	11	11	rectum
NCT0015475221	NCT00154752_21_T2	ORGAN	0	1	Pelvic plexus
NCT0015475223	NCT00154752_23_T0	ORGAN	16	16	bladder
NCT0015475223	NCT00154752_23_T1	PHENOTYPE	3	3	neurophysiology
NCT0015475224	NCT00154752_24_T0	ORGAN	9	9	bladder
NCT0015475224	NCT00154752_24_T1	PHENOTYPE	11	11	contraction
NCT0015475224	NCT00154752_24_T2	BIOLOGICAL_PROCESS	6	7	penile erection
NCT0015475227	NCT00154752_27_T0	PHENOTYPE	12	13	rectal cancers
NCT0015475230	NCT00154752_30_T0	PHENOTYPE	9	9	tumor
NCT0015475230	NCT00154752_30_T1	TISSUE	15	16	lymph node
NCT0015475232	NCT00154752_32_T0	GENE	15	15	has
NCT0015475233	NCT00154752_33_T0	PHENOTYPE	18	19	rectal cancer
NCT0015475234	NCT00154752_34_T0	COMPOUND	11	11	oxaliplatin
NCT0015475234	NCT00154752_34_T1	COMPOUND	19	19	leucovorin
NCT0015475235	NCT00154752_35_T0	PHENOTYPE	17	17	dysfunction
NCT0015475238	NCT00154752_38_T0	PHENOTYPE	21	22	rectal cancer
NCT0015475240	NCT00154752_40_T0	PHENOTYPE	1	2	rectal adenocarcinoma
NCT0015475241	NCT00154752_41_T0	GENE	7	7	T4
NCT0015475241	NCT00154752_41_T1	PHENOTYPE	0	0	Tumor
NCT0015475242	NCT00154752_42_T0	GENE	0	0	ASA
NCT0015475246	NCT00154752_46_T0	PHENOTYPE	4	4	metastasis
NCT0015475246	NCT00154752_46_T1	PHENOTYPE	6	7	peritoneal carcinomatosis
NCT0015475246	NCT00154752_46_T2	PHENOTYPE	0	1	Primary tumors
NCT001547657	NCT00154765_7_T0	PHENOTYPE	12	13	knee osteoarthritis
NCT0015476517	NCT00154765_17_T0	GENE	6	6	got
NCT001547783	NCT00154778_3_T0	GENE	9	9	has
NCT001547783	NCT00154778_3_T1	PHENOTYPE	6	7	gastric cancer
NCT001547784	NCT00154778_4_T0	PHENOTYPE	24	24	toxicity
NCT001547787	NCT00154778_7_T0	PHENOTYPE	4	5	gastric adenocarcinoma
NCT001547787	NCT00154778_7_T1	PHENOTYPE	14	15	recurrent disease
NCT001547788	NCT00154778_8_T0	PHENOTYPE	5	6	measurable lesion
NCT0015477810	NCT00154778_10_T0	PHENOTYPE	8	9	metastatic disease
NCT0015477811	NCT00154778_11_T0	ORGAN	7	7	liver
NCT0015477811	NCT00154778_11_T1	GENE	22	22	ALT-3
NCT0015477811	NCT00154778_11_T2	ORGAN	6	6	heart
NCT0015477811	NCT00154778_11_T3	ORGAN	8	8	kidney
NCT0015477811	NCT00154778_11_T4	GENE	16	16	ANC
NCT0015477811	NCT00154778_11_T5	GENE	14	14	WBC
NCT0015477811	NCT00154778_11_T6	GENE	18	18	PLT
NCT0015477811	NCT00154778_11_T7	GENE	20	20	Hb
NCT0015477811	NCT00154778_11_T8	PHENOTYPE	31	32	liver metastasis
NCT0015477811	NCT00154778_11_T9	ORGAN	4	5	bone marrow
NCT0015477811	NCT00154778_11_T10	GENE	34	35	Total bilirubin
NCT0015477814	NCT00154778_14_T0	ORGAN	9	9	plasma
NCT0015477816	NCT00154778_16_T0	PHENOTYPE	2	3	CNS metastasis
NCT0015477819	NCT00154778_19_T0	PHENOTYPE	2	2	symptoms
NCT0015477820	NCT00154778_20_T0	PHENOTYPE	5	6	intestinal obstruction
NCT0015477820	NCT00154778_20_T1	PHENOTYPE	3	4	gastrointestinal bleeding
NCT0015477821	NCT00154778_21_T0	PHENOTYPE	2	2	ascites
NCT0015477821	NCT00154778_21_T1	PHENOTYPE	5	5	affects
NCT0015477822	NCT00154778_22_T0	PHENOTYPE	6	6	neuropathy
NCT001547911	NCT00154791_1_T0	COMPOUND	10	10	oxaliplatin
NCT001547911	NCT00154791_1_T1	COMPOUND	15	15	gemcitabine
NCT001547911	NCT00154791_1_T2	COMPOUND	26	26	leucovorin
NCT001547912	NCT00154791_2_T0	GENE	3	3	II
NCT001547914	NCT00154791_4_T0	GENE	64	64	II
NCT001547914	NCT00154791_4_T1	GENE	80	80	II
NCT001547914	NCT00154791_4_T2	GENE	37	37	DLT
NCT001547914	NCT00154791_4_T3	COMPOUND	8	8	oxaliplatin
NCT001547914	NCT00154791_4_T4	COMPOUND	20	20	oxaliplatin
NCT001547914	NCT00154791_4_T5	GENE	55	55	MTD
NCT001547915	NCT00154791_5_T0	GENE	13	13	II
NCT001547917	NCT00154791_7_T0	PHENOTYPE	3	4	pancreatic adenocarcinoma
NCT001547918	NCT00154791_8_T0	GENE	18	18	CAT
NCT001547919	NCT00154791_9_T0	GENE	3	3	II
NCT001547919	NCT00154791_9_T1	GENE	16	16	CAT
NCT0015479111	NCT00154791_11_T0	PHENOTYPE	19	20	evaluable disease
NCT0015479115	NCT00154791_15_T0	GENE	10	10	WBC
NCT0015479115	NCT00154791_15_T1	CELL	14	14	neutrophil
NCT0015479115	NCT00154791_15_T2	PHENOTYPE	19	20	platelet count
NCT0015479115	NCT00154791_15_T3	ORGAN	5	6	bone marrow
NCT0015479117	NCT00154791_17_T0	PHENOTYPE	4	5	biliary obstruction
NCT001548043	NCT00154804_3_T0	GENE	2	2	SCC
NCT001548043	NCT00154804_3_T1	PHENOTYPE	4	6	adenocarcinoma of esophagus
NCT001548045	NCT00154804_5_T0	GENE	7	7	T3
NCT001548045	NCT00154804_5_T1	PHENOTYPE	2	3	esophageal cancer
NCT001548046	NCT00154804_6_T0	PHENOTYPE	14	15	esophageal cancer
NCT001548046	NCT00154804_6_T1	PHENOTYPE	24	25	esophageal cancer
NCT001548046	NCT00154804_6_T2	TISSUE	9	10	lymph node
NCT001548046	NCT00154804_6_T3	TISSUE	18	19	lymph node
NCT001548049	NCT00154804_9_T0	COMPOUND	0	0	KPS
NCT0015480413	NCT00154804_13_T0	GENE	5	5	T4
NCT0015480415	NCT00154804_15_T0	PHENOTYPE	1	1	metastasis
NCT001548173	NCT00154817_3_T0	COMPOUND	16	16	ethanol
NCT001548176	NCT00154817_6_T0	GENE	4	4	RT
NCT001548178	NCT00154817_8_T0	COMPOUND	27	27	thalidomide
NCT001548178	NCT00154817_8_T1	GENE	3	3	MRI
NCT001548178	NCT00154817_8_T2	PHENOTYPE	20	20	tumor
NCT001548178	NCT00154817_8_T3	ORGAN	5	5	serum
NCT001548179	NCT00154817_9_T0	PHENOTYPE	9	10	disease progression
NCT0015481713	NCT00154817_13_T0	PHENOTYPE	4	4	toxicity
NCT0015481717	NCT00154817_17_T0	GENE	7	7	TACE
NCT0015481717	NCT00154817_17_T1	COMPOUND	12	12	ethanol
NCT0015481717	NCT00154817_17_T2	COMPOUND	9	10	acetic acid
NCT0015481729	NCT00154817_29_T0	PHENOTYPE	2	2	recurrence
NCT0015481729	NCT00154817_29_T1	GENE	4	4	RT
NCT0015481729	NCT00154817_29_T2	GENE	11	11	RT
NCT0015481730	NCT00154817_30_T0	GENE	7	7	RT
NCT0015481730	NCT00154817_30_T1	GENE	11	11	RT
NCT0015481732	NCT00154817_32_T0	GENE	5	5	RT
NCT0015481732	NCT00154817_32_T1	PHENOTYPE	9	9	tumors
NCT0015481732	NCT00154817_32_T2	PHENOTYPE	12	13	tumor liver
NCT0015481733	NCT00154817_33_T0	PHENOTYPE	16	16	severity
NCT0015481733	NCT00154817_33_T1	PHENOTYPE	18	18	cirrhosis
NCT0015481733	NCT00154817_33_T2	PHENOTYPE	20	21	portal hypertension
NCT0015481734	NCT00154817_34_T0	PHENOTYPE	11	11	tumors
NCT0015481734	NCT00154817_34_T1	PHENOTYPE	4	4	enables
NCT0015481734	NCT00154817_34_T2	PHENOTYPE	1	2	cervical cancer
NCT0015481735	NCT00154817_35_T0	PHENOTYPE	0	0	Malignancy
NCT0015481736	NCT00154817_36_T0	COMPOUND	21	21	1st
NCT0015481736	NCT00154817_36_T1	GENE	3	3	al
NCT0015481736	NCT00154817_36_T2	GENE	2	2	et
NCT0015481736	NCT00154817_36_T3	PHENOTYPE	6	7	rectal carcinoma
NCT0015481737	NCT00154817_37_T0	TISSUE	7	8	lymph node
NCT0015481738	NCT00154817_38_T0	GENE	9	9	ADC
NCT0015481738	NCT00154817_38_T1	GENE	16	16	RT
NCT0015481738	NCT00154817_38_T2	PHENOTYPE	14	14	initiation
NCT0015481738	NCT00154817_38_T3	GENE	22	22	had
NCT0015481738	NCT00154817_38_T4	GENE	2	2	al
NCT0015481738	NCT00154817_38_T5	GENE	1	1	et
NCT0015481738	NCT00154817_38_T6	PHENOTYPE	18	19	brain cancer
NCT0015481739	NCT00154817_39_T0	PHENOTYPE	15	15	cancers
NCT0015481742	NCT00154817_42_T0	ORGAN	12	12	serum
NCT0015481742	NCT00154817_42_T1	PHENOTYPE	20	21	hepatocellular carcinoma
NCT0015481749	NCT00154817_49_T0	GENE	0	0	1/6
NCT0015481754	NCT00154817_54_T0	COMPOUND	0	0	1_10
NCT0015481754	NCT00154817_54_T1	PHENOTYPE	8	10	negative pregnancy test
NCT0015481756	NCT00154817_56_T0	PHENOTYPE	4	4	metastasis
NCT0015481758	NCT00154817_58_T0	GENE	6	6	abdominal
NCT0015481760	NCT00154817_60_T0	COMPOUND	4	4	thalidomide
NCT0015481762	NCT00154817_62_T0	GENE	2	2	had
NCT0015481764	NCT00154817_64_T0	COMPOUND	2	2	NCI
NCT0015481764	NCT00154817_64_T1	PHENOTYPE	7	8	peripheral neuropathy
NCT0015481766	NCT00154817_66_T0	PHENOTYPE	4	4	diseases
NCT001548301	NCT00154830_1_T0	PHENOTYPE	5	6	gait abnormality
NCT001548301	NCT00154830_1_T1	PHENOTYPE	10	11	cerebral palsy
NCT001548305	NCT00154830_5_T0	PHENOTYPE	5	6	gait abnormality
NCT001548305	NCT00154830_5_T1	PHENOTYPE	10	11	cerebral palsy
NCT001548308	NCT00154830_8_T0	PHENOTYPE	15	15	pathology
NCT001548308	NCT00154830_8_T1	GENE	4	4	has
NCT001548431	NCT00154843_1_T0	PHENOTYPE	0	0	Secondary
NCT0015484313	NCT00154843_13_T0	PHENOTYPE	8	8	LUTS
NCT001548560	NCT00154856_0_T0	BIOLOGICAL_PROCESS	6	6	Osteogenesis
NCT001548565	NCT00154856_5_T0	ORGAN	22	22	limb
NCT001548565	NCT00154856_5_T1	PHENOTYPE	15	16	bone fracture
NCT001548569	NCT00154856_9_T0	PHENOTYPE	8	8	strain
NCT001548569	NCT00154856_9_T1	BIOLOGICAL_PROCESS	15	15	osteogenesis
NCT0015485611	NCT00154856_11_T0	ORGAN	18	18	limb
NCT0015485611	NCT00154856_11_T1	BIOLOGICAL_PROCESS	11	11	osteogenesis
NCT0015485612	NCT00154856_12_T0	TISSUE	24	24	tissues
NCT0015485612	NCT00154856_12_T1	PHENOTYPE	18	18	transmitted
NCT0015485612	NCT00154856_12_T2	ORGAN	9	10	lower limb
NCT001548690	NCT00154869_0_T0	PHENOTYPE	5	6	Chronic Hepatitis
NCT001548690	NCT00154869_0_T1	PHENOTYPE	11	13	Chronic Hepatitis C
NCT001548692	NCT00154869_2_T0	COMPOUND	16	16	HCV
NCT001548692	NCT00154869_2_T1	COMPOUND	25	25	HCV
NCT001548692	NCT00154869_2_T2	PHENOTYPE	9	9	hepatitis
NCT001548692	NCT00154869_2_T3	PHENOTYPE	19	19	HBV
NCT001548692	NCT00154869_2_T4	PHENOTYPE	32	33	hepatitis C
NCT001548693	NCT00154869_3_T0	GENE	23	23	IFN
NCT001548693	NCT00154869_3_T1	GENE	11	11	has
NCT001548693	NCT00154869_3_T2	PHENOTYPE	29	30	chronic hepatitis
NCT001548693	NCT00154869_3_T3	PHENOTYPE	30	31	hepatitis C
NCT001548694	NCT00154869_4_T0	COMPOUND	12	12	HCV
NCT001548694	NCT00154869_4_T1	PHENOTYPE	14	14	HBV
NCT001548695	NCT00154869_5_T0	COMPOUND	15	15	ribavirin
NCT001548695	NCT00154869_5_T1	GENE	37	37	2.3
NCT001548695	NCT00154869_5_T2	GENE	13	13	IFN
NCT001548695	NCT00154869_5_T3	COMPOUND	33	33	HCV
NCT001548695	NCT00154869_5_T4	PHENOTYPE	20	21	hepatitis B
NCT001548695	NCT00154869_5_T5	PHENOTYPE	28	29	hepatitis C
NCT001548695	NCT00154869_5_T6	PHENOTYPE	19	20	chronic hepatitis
NCT001548695	NCT00154869_5_T7	PHENOTYPE	27	28	chronic hepatitis
NCT001548696	NCT00154869_6_T0	COMPOUND	13	13	HCV
NCT001548696	NCT00154869_6_T1	COMPOUND	27	27	HCV
NCT001548696	NCT00154869_6_T2	GENE	32	32	al
NCT001548696	NCT00154869_6_T3	ORGAN	12	12	serum
NCT001548696	NCT00154869_6_T4	GENE	31	31	et
NCT001548697	NCT00154869_7_T0	GENE	5	5	IFN
NCT001548697	NCT00154869_7_T1	COMPOUND	26	26	HCV
NCT001548697	NCT00154869_7_T2	COMPOUND	31	31	HCV
NCT001548697	NCT00154869_7_T3	GENE	44	44	al
NCT001548697	NCT00154869_7_T4	GENE	49	49	al
NCT001548697	NCT00154869_7_T5	GENE	12	12	has
NCT001548697	NCT00154869_7_T6	ORGAN	25	25	serum
NCT001548697	NCT00154869_7_T7	GENE	43	43	et
NCT001548697	NCT00154869_7_T8	GENE	48	48	et
NCT001548698	NCT00154869_8_T0	GENE	19	19	IFN
NCT001548698	NCT00154869_8_T1	COMPOUND	27	27	HCV
NCT001548698	NCT00154869_8_T2	COMPOUND	37	37	HCV
NCT001548698	NCT00154869_8_T3	COMPOUND	40	40	HCV
NCT001548698	NCT00154869_8_T4	ORGAN	26	26	serum
NCT001548699	NCT00154869_9_T0	GENE	14	14	2.3
NCT001548699	NCT00154869_9_T1	COMPOUND	12	12	HCV
NCT001548699	NCT00154869_9_T2	COMPOUND	29	29	HCV
NCT001548699	NCT00154869_9_T3	COMPOUND	36	36	HCV
NCT001548699	NCT00154869_9_T4	COMPOUND	53	53	HCV
NCT001548699	NCT00154869_9_T5	PHENOTYPE	20	21	hepatitis C
NCT001548699	NCT00154869_9_T6	PHENOTYPE	44	45	hepatitis C
NCT001548699	NCT00154869_9_T7	PHENOTYPE	19	20	chronic hepatitis
NCT001548699	NCT00154869_9_T8	PHENOTYPE	43	44	chronic hepatitis
NCT0015486911	NCT00154869_11_T0	GENE	17	17	al
NCT0015486911	NCT00154869_11_T1	GENE	16	16	et
NCT0015486912	NCT00154869_12_T0	PHENOTYPE	7	8	chronic hepatitis
NCT0015486912	NCT00154869_12_T1	PHENOTYPE	8	9	hepatitis C
NCT0015486913	NCT00154869_13_T0	GENE	8	8	co
NCT0015486913	NCT00154869_13_T1	PHENOTYPE	10	10	HBV
NCT0015486914	NCT00154869_14_T0	PHENOTYPE	13	13	infections
NCT0015486914	NCT00154869_14_T1	GENE	24	24	al
NCT0015486914	NCT00154869_14_T2	GENE	28	28	al
NCT0015486914	NCT00154869_14_T3	GENE	34	34	al
NCT0015486914	NCT00154869_14_T4	GENE	23	23	et
NCT0015486914	NCT00154869_14_T5	GENE	27	27	et
NCT0015486914	NCT00154869_14_T6	GENE	33	33	et
NCT0015486914	NCT00154869_14_T7	PHENOTYPE	1	2	hepatitis B
NCT0015486914	NCT00154869_14_T8	PHENOTYPE	16	17	hepatitis C
NCT0015486915	NCT00154869_15_T0	GENE	18	18	al
NCT0015486915	NCT00154869_15_T1	GENE	33	33	al
NCT0015486915	NCT00154869_15_T2	GENE	17	17	et
NCT0015486915	NCT00154869_15_T3	GENE	32	32	et
NCT0015486915	NCT00154869_15_T4	COMPOUND	4	4	HCV
NCT0015486915	NCT00154869_15_T5	PHENOTYPE	12	12	HBV
NCT0015486915	NCT00154869_15_T6	PHENOTYPE	13	13	chronic
NCT0015486915	NCT00154869_15_T7	PHENOTYPE	14	15	liver diseases
NCT0015486917	NCT00154869_17_T0	GENE	1	1	co
NCT0015486919	NCT00154869_19_T0	COMPOUND	4	4	HCV
NCT0015486919	NCT00154869_19_T1	PHENOTYPE	2	2	HBV
NCT0015486920	NCT00154869_20_T0	COMPOUND	13	13	HCV
NCT0015486920	NCT00154869_20_T1	GENE	20	20	co
NCT0015486920	NCT00154869_20_T2	PHENOTYPE	22	22	HBV
NCT0015486921	NCT00154869_21_T0	PHENOTYPE	15	16	hepatitis C
NCT0015486922	NCT00154869_22_T0	PHENOTYPE	0	0	Sporadic
NCT0015486922	NCT00154869_22_T1	GENE	27	27	al
NCT0015486922	NCT00154869_22_T2	GENE	31	31	al
NCT0015486922	NCT00154869_22_T3	GENE	35	35	al
NCT0015486922	NCT00154869_22_T4	GENE	39	39	al
NCT0015486922	NCT00154869_22_T5	GENE	26	26	et
NCT0015486922	NCT00154869_22_T6	GENE	30	30	et
NCT0015486922	NCT00154869_22_T7	GENE	34	34	et
NCT0015486922	NCT00154869_22_T8	GENE	38	38	et
NCT0015486922	NCT00154869_22_T9	GENE	4	4	IFN
NCT0015486922	NCT00154869_22_T10	COMPOUND	11	11	HCV
NCT0015486922	NCT00154869_22_T11	PHENOTYPE	13	13	HBV
NCT0015486922	NCT00154869_22_T12	PHENOTYPE	19	20	hepatitis B
NCT0015486923	NCT00154869_23_T0	GENE	8	8	IFN
NCT0015486923	NCT00154869_23_T1	COMPOUND	19	19	HCV
NCT0015486923	NCT00154869_23_T2	GENE	27	27	al
NCT0015486923	NCT00154869_23_T3	GENE	26	26	et
NCT0015486925	NCT00154869_25_T0	GENE	25	25	al
NCT0015486925	NCT00154869_25_T1	GENE	29	29	al
NCT0015486925	NCT00154869_25_T2	GENE	33	33	al
NCT0015486925	NCT00154869_25_T3	GENE	37	37	al
NCT0015486925	NCT00154869_25_T4	GENE	41	41	al
NCT0015486925	NCT00154869_25_T5	GENE	45	45	al
NCT0015486925	NCT00154869_25_T6	GENE	49	49	al
NCT0015486925	NCT00154869_25_T7	GENE	24	24	et
NCT0015486925	NCT00154869_25_T8	GENE	28	28	et
NCT0015486925	NCT00154869_25_T9	GENE	32	32	et
NCT0015486925	NCT00154869_25_T10	GENE	36	36	et
NCT0015486925	NCT00154869_25_T11	GENE	40	40	et
NCT0015486925	NCT00154869_25_T12	GENE	44	44	et
NCT0015486925	NCT00154869_25_T13	GENE	48	48	et
NCT0015486925	NCT00154869_25_T14	GENE	2	2	IFN
NCT0015486925	NCT00154869_25_T15	GENE	21	21	IFN
NCT0015486925	NCT00154869_25_T16	GENE	5	5	has
NCT0015486925	NCT00154869_25_T17	PHENOTYPE	62	63	hepatitis B
NCT0015486925	NCT00154869_25_T18	PHENOTYPE	18	19	hepatitis C
NCT0015486925	NCT00154869_25_T19	PHENOTYPE	17	18	chronic hepatitis
NCT0015486926	NCT00154869_26_T0	GENE	10	10	IFN
NCT0015486926	NCT00154869_26_T1	COMPOUND	13	13	ribavirin
NCT0015486926	NCT00154869_26_T2	COMPOUND	20	20	HCV
NCT0015486926	NCT00154869_26_T3	PHENOTYPE	22	22	HBV
NCT0015486927	NCT00154869_27_T0	GENE	5	5	IFN
NCT0015486927	NCT00154869_27_T1	COMPOUND	7	7	ribavirin
NCT0015486927	NCT00154869_27_T2	COMPOUND	9	9	HCV
NCT0015486927	NCT00154869_27_T3	GENE	12	12	9-21
NCT0015486927	NCT00154869_27_T4	PHENOTYPE	19	20	hepatitis B
NCT0015486928	NCT00154869_28_T0	PHENOTYPE	10	11	chronic hepatitis
NCT0015486928	NCT00154869_28_T1	PHENOTYPE	11	12	hepatitis C
NCT0015486930	NCT00154869_30_T0	GENE	27	27	2b
NCT0015486930	NCT00154869_30_T1	GENE	20	20	1b
NCT0015486930	NCT00154869_30_T2	GENE	43	43	1b
NCT0015486930	NCT00154869_30_T3	COMPOUND	11	11	HCV
NCT0015486930	NCT00154869_30_T4	COMPOUND	31	31	HCV
NCT0015486930	NCT00154869_30_T5	COMPOUND	41	41	HCV
NCT0015486930	NCT00154869_30_T6	GENE	25	25	2a
NCT0015486931	NCT00154869_31_T0	COMPOUND	18	18	ribavirin
NCT0015486931	NCT00154869_31_T1	COMPOUND	24	24	HCV
NCT0015486931	NCT00154869_31_T2	COMPOUND	31	31	HCV
NCT0015486931	NCT00154869_31_T3	COMPOUND	35	35	HCV
NCT0015486931	NCT00154869_31_T4	GENE	40	40	al
NCT0015486931	NCT00154869_31_T5	GENE	44	44	al
NCT0015486931	NCT00154869_31_T6	ORGAN	23	23	serum
NCT0015486931	NCT00154869_31_T7	GENE	42	42	Yu
NCT0015486931	NCT00154869_31_T8	GENE	16	16	interferon
NCT0015486931	NCT00154869_31_T9	PHENOTYPE	29	29	HBV
NCT0015486931	NCT00154869_31_T10	GENE	39	39	et
NCT0015486931	NCT00154869_31_T11	GENE	43	43	et
NCT0015486933	NCT00154869_33_T0	COMPOUND	17	17	HCV
NCT0015486934	NCT00154869_34_T0	COMPOUND	10	10	HCV
NCT0015486934	NCT00154869_34_T1	PHENOTYPE	12	12	HBV
NCT0015486936	NCT00154869_36_T0	COMPOUND	8	8	HCV
NCT0015486936	NCT00154869_36_T1	PHENOTYPE	11	11	HBV
NCT0015486938	NCT00154869_38_T0	PHENOTYPE	3	3	hepatitis
NCT0015486938	NCT00154869_38_T1	PHENOTYPE	9	10	hepatitis B
NCT0015486939	NCT00154869_39_T0	GENE	12	12	had
NCT0015486939	NCT00154869_39_T1	COMPOUND	15	15	HCV
NCT0015486939	NCT00154869_39_T2	PHENOTYPE	10	11	hepatitis B
NCT0015486940	NCT00154869_40_T0	ORGAN	18	18	liver
NCT0015486941	NCT00154869_41_T0	GENE	29	29	extended
NCT0015486941	NCT00154869_41_T1	GENE	16	16	IFN
NCT0015486941	NCT00154869_41_T2	COMPOUND	40	40	HCV
NCT0015486941	NCT00154869_41_T3	PHENOTYPE	3	4	hepatitis C
NCT0015486941	NCT00154869_41_T4	PHENOTYPE	11	12	hepatitis C
NCT0015486942	NCT00154869_42_T0	PHENOTYPE	9	9	HBV
NCT0015486943	NCT00154869_43_T0	COMPOUND	5	5	HCV
NCT0015486943	NCT00154869_43_T1	PHENOTYPE	19	20	hepatitis B
NCT0015486943	NCT00154869_43_T2	PHENOTYPE	12	13	hepatitis C
NCT0015486944	NCT00154869_44_T0	COMPOUND	16	16	HCV
NCT0015486944	NCT00154869_44_T1	COMPOUND	25	25	HCV
NCT0015486944	NCT00154869_44_T2	PHENOTYPE	9	9	hepatitis
NCT0015486944	NCT00154869_44_T3	PHENOTYPE	19	19	HBV
NCT0015486944	NCT00154869_44_T4	PHENOTYPE	32	33	hepatitis C
NCT0015486945	NCT00154869_45_T0	GENE	22	22	IFN
NCT0015486945	NCT00154869_45_T1	GENE	10	10	has
NCT0015486945	NCT00154869_45_T2	PHENOTYPE	28	29	chronic hepatitis
NCT0015486945	NCT00154869_45_T3	PHENOTYPE	29	30	hepatitis C
NCT0015486946	NCT00154869_46_T0	COMPOUND	12	12	HCV
NCT0015486946	NCT00154869_46_T1	PHENOTYPE	14	14	HBV
NCT0015486947	NCT00154869_47_T0	GENE	35	35	2.3
NCT0015486947	NCT00154869_47_T1	GENE	12	12	IFN
NCT0015486947	NCT00154869_47_T2	COMPOUND	31	31	HCV
NCT0015486947	NCT00154869_47_T3	PHENOTYPE	18	19	hepatitis B
NCT0015486947	NCT00154869_47_T4	PHENOTYPE	26	27	hepatitis C
NCT0015486947	NCT00154869_47_T5	PHENOTYPE	17	18	chronic hepatitis
NCT0015486947	NCT00154869_47_T6	PHENOTYPE	25	26	chronic hepatitis
NCT0015486948	NCT00154869_48_T0	COMPOUND	13	13	HCV
NCT0015486948	NCT00154869_48_T1	COMPOUND	27	27	HCV
NCT0015486948	NCT00154869_48_T2	GENE	32	32	al
NCT0015486948	NCT00154869_48_T3	ORGAN	12	12	serum
NCT0015486948	NCT00154869_48_T4	GENE	31	31	et
NCT0015486949	NCT00154869_49_T0	GENE	5	5	IFN
NCT0015486949	NCT00154869_49_T1	COMPOUND	26	26	HCV
NCT0015486949	NCT00154869_49_T2	COMPOUND	31	31	HCV
NCT0015486949	NCT00154869_49_T3	GENE	44	44	al
NCT0015486949	NCT00154869_49_T4	GENE	49	49	al
NCT0015486949	NCT00154869_49_T5	GENE	12	12	has
NCT0015486949	NCT00154869_49_T6	ORGAN	25	25	serum
NCT0015486949	NCT00154869_49_T7	GENE	43	43	et
NCT0015486949	NCT00154869_49_T8	GENE	48	48	et
NCT0015486950	NCT00154869_50_T0	GENE	19	19	IFN
NCT0015486950	NCT00154869_50_T1	COMPOUND	27	27	HCV
NCT0015486950	NCT00154869_50_T2	COMPOUND	37	37	HCV
NCT0015486950	NCT00154869_50_T3	COMPOUND	40	40	HCV
NCT0015486950	NCT00154869_50_T4	ORGAN	26	26	serum
NCT0015486951	NCT00154869_51_T0	GENE	14	14	2.3
NCT0015486951	NCT00154869_51_T1	COMPOUND	12	12	HCV
NCT0015486951	NCT00154869_51_T2	COMPOUND	29	29	HCV
NCT0015486951	NCT00154869_51_T3	COMPOUND	36	36	HCV
NCT0015486951	NCT00154869_51_T4	COMPOUND	53	53	HCV
NCT0015486951	NCT00154869_51_T5	PHENOTYPE	20	21	hepatitis C
NCT0015486951	NCT00154869_51_T6	PHENOTYPE	44	45	hepatitis C
NCT0015486951	NCT00154869_51_T7	PHENOTYPE	19	20	chronic hepatitis
NCT0015486951	NCT00154869_51_T8	PHENOTYPE	43	44	chronic hepatitis
NCT001548821	NCT00154882_1_T0	PHENOTYPE	5	5	toxicity
NCT001548821	NCT00154882_1_T1	PHENOTYPE	1	1	secondary
NCT001548821	NCT00154882_1_T2	PHENOTYPE	12	12	progression
NCT001548821	NCT00154882_1_T3	PHENOTYPE	9	11	quality of life
NCT001548823	NCT00154882_3_T0	COMPOUND	7	7	paclitaxel
NCT001548823	NCT00154882_3_T1	COMPOUND	9	9	cisplatin
NCT001548823	NCT00154882_3_T2	PHENOTYPE	20	21	breast cancer
NCT001548824	NCT00154882_4_T0	PHENOTYPE	2	2	acute
NCT001548824	NCT00154882_4_T1	COMPOUND	7	7	paclitaxel
NCT001548824	NCT00154882_4_T2	PHENOTYPE	5	5	toxicities
NCT001548826	NCT00154882_6_T0	COMPOUND	4	4	paclitaxel
NCT001548827	NCT00154882_7_T0	GENE	3	3	II
NCT001548829	NCT00154882_9_T0	PHENOTYPE	11	11	metastasis
NCT001548829	NCT00154882_9_T1	PHENOTYPE	4	5	breast cancer
NCT0015488215	NCT00154882_15_T0	PHENOTYPE	4	5	metastatic disease
NCT0015488216	NCT00154882_16_T0	GENE	11	11	has
NCT0015488217	NCT00154882_17_T0	PHENOTYPE	8	9	metastatic disease
NCT0015488217	NCT00154882_17_T1	PHENOTYPE	16	17	disease progression
NCT0015488218	NCT00154882_18_T0	PHENOTYPE	19	19	tumor
NCT0015488225	NCT00154882_25_T0	COMPOUND	5	5	paclitaxel
NCT0015488225	NCT00154882_25_T1	COMPOUND	7	7	docetaxel
NCT0015488225	NCT00154882_25_T2	COMPOUND	9	9	cisplatin
NCT0015488226	NCT00154882_26_T0	PHENOTYPE	4	5	leptomeningeal metastases
NCT0015488227	NCT00154882_27_T0	PHENOTYPE	4	5	cardiac arrhythmia
NCT0015488227	NCT00154882_27_T1	PHENOTYPE	7	9	acute myocardial infarction
NCT0015488228	NCT00154882_28_T0	PHENOTYPE	5	5	diseases
NCT001548950	NCT00154895_0_T0	PHENOTYPE	7	9	Primary Spontaneous Pneumothorax
NCT001548953	NCT00154895_3_T0	PHENOTYPE	7	7	Thoracic
NCT001548954	NCT00154895_4_T0	COMPOUND	13	13	minocycline
NCT001548954	NCT00154895_4_T1	PHENOTYPE	3	5	primary spontaneous pneumothorax
NCT001548955	NCT00154895_5_T0	PHENOTYPE	8	8	recurrence
NCT001548956	NCT00154895_6_T0	PHENOTYPE	0	0	Secondary
NCT001548956	NCT00154895_6_T1	COMPOUND	12	12	minocycline
NCT0015489510	NCT00154895_10_T0	COMPOUND	21	21	minocycline
NCT0015489510	NCT00154895_10_T1	PHENOTYPE	17	17	allergy
NCT0015489510	NCT00154895_10_T2	COMPOUND	19	19	tetracycline
NCT0015489510	NCT00154895_10_T3	PHENOTYPE	11	12	pulmonary disease
NCT0015489514	NCT00154895_14_T0	PHENOTYPE	9	9	recurrence
NCT0015489514	NCT00154895_14_T1	PHENOTYPE	38	38	anesthesia
NCT0015489516	NCT00154895_16_T0	GENE	4	4	Karl
NCT0015489516	NCT00154895_16_T1	ORGAN	14	15	pleural cavity
NCT0015489518	NCT00154895_18_T0	PHENOTYPE	1	2	pleural adhesions
NCT0015489519	NCT00154895_19_T0	PHENOTYPE	1	1	blebs
NCT0015489520	NCT00154895_20_T0	PHENOTYPE	12	12	bleb
NCT0015489523	NCT00154895_23_T0	PHENOTYPE	14	14	wounds
NCT0015489525	NCT00154895_25_T0	PHENOTYPE	1	1	anesthesia
NCT0015489528	NCT00154895_28_T0	COMPOUND	32	32	minocycline
NCT0015489534	NCT00154895_34_T0	COMPOUND	9	9	minocycline
NCT0015489534	NCT00154895_34_T1	COMPOUND	11	11	minocycline
NCT0015489536	NCT00154895_36_T0	COMPOUND	12	12	minocycline
NCT0015489538	NCT00154895_38_T0	COMPOUND	9	9	hydrochloride
NCT0015489538	NCT00154895_38_T1	COMPOUND	2	2	minocycline
NCT0015489538	NCT00154895_38_T2	COMPOUND	28	28	minocycline
NCT0015489538	NCT00154895_38_T3	COMPOUND	8	8	lidocaine
NCT0015489538	NCT00154895_38_T4	ORGAN	39	40	pleural cavity
NCT0015489540	NCT00154895_40_T0	COMPOUND	9	9	minocycline
NCT0015489541	NCT00154895_41_T0	PHENOTYPE	0	1	Side effects
NCT0015489543	NCT00154895_43_T0	COMPOUND	7	7	minocycline
NCT0015489544	NCT00154895_44_T0	COMPOUND	16	16	minocycline
NCT0015489544	NCT00154895_44_T1	GENE	5	5	had
NCT0015489549	NCT00154895_49_T0	PHENOTYPE	1	1	complications
NCT0015489551	NCT00154895_51_T0	PHENOTYPE	1	1	detachment
NCT0015489551	NCT00154895_51_T1	PHENOTYPE	6	6	pneumothorax
NCT0015489553	NCT00154895_53_T0	PHENOTYPE	38	38	recurrence
NCT0015489558	NCT00154895_58_T0	ORGAN	20	20	Chest
NCT0015489558	NCT00154895_58_T1	PHENOTYPE	3	3	FVC
NCT0015489558	NCT00154895_58_T2	PHENOTYPE	0	2	Forced vital capacity
NCT0015489560	NCT00154895_60_T0	PHENOTYPE	21	21	complications
NCT0015489560	NCT00154895_60_T1	GENE	29	29	VAS
NCT0015489560	NCT00154895_60_T2	COMPOUND	25	25	meperidine
NCT0015489561	NCT00154895_61_T0	GENE	19	19	05
NCT0015489561	NCT00154895_61_T1	GENE	28	28	reduced
NCT0015489561	NCT00154895_61_T2	GENE	25	25	0.8
NCT0015489561	NCT00154895_61_T3	PHENOTYPE	30	30	recurrence
NCT0015489561	NCT00154895_61_T4	COMPOUND	27	27	minocycline
NCT0015489563	NCT00154895_63_T0	PHENOTYPE	17	17	recurrence
NCT0015489563	NCT00154895_63_T1	COMPOUND	21	21	minocycline
NCT0015489563	NCT00154895_63_T2	GENE	14	14	reduced
NCT0015489568	NCT00154895_68_T0	PHENOTYPE	2	2	recurrence
NCT0015489569	NCT00154895_69_T0	GENE	16	16	25
NCT0015489569	NCT00154895_69_T1	PHENOTYPE	68	68	complications
NCT0015489569	NCT00154895_69_T2	PHENOTYPE	8	8	pneumothorax
NCT0015489569	NCT00154895_69_T3	PHENOTYPE	6	6	recurrence
NCT0015489569	NCT00154895_69_T4	PHENOTYPE	31	31	recurrence
NCT0015489569	NCT00154895_69_T5	PHENOTYPE	11	11	regression
NCT0015489569	NCT00154895_69_T6	PHENOTYPE	42	42	blebs
NCT0015489569	NCT00154895_69_T7	COMPOUND	55	55	meperidine
NCT0015489569	NCT00154895_69_T8	COMPOUND	63	63	meperidine
NCT001549216	NCT00154921_6_T0	PHENOTYPE	16	16	centered
NCT0015492115	NCT00154921_15_T0	PHENOTYPE	16	16	centered
NCT001549345	NCT00154934_5_T0	PHENOTYPE	11	11	generalized
NCT001549345	NCT00154934_5_T1	PHENOTYPE	12	13	endothelial dysfunction
NCT001549346	NCT00154934_6_T0	GENE	1	1	IL-10
NCT001549346	NCT00154934_6_T1	GENE	0	0	Interleukin-10
NCT0015493410	NCT00154934_10_T0	PHENOTYPE	11	11	paracrine
NCT0015493410	NCT00154934_10_T1	CELL	14	15	decidual cells
NCT0015493411	NCT00154934_11_T0	GENE	2	2	has
NCT0015493412	NCT00154934_12_T0	GENE	12	12	IL-10
NCT0015493412	NCT00154934_12_T1	GENE	16	16	kit
NCT0015493412	NCT00154934_12_T2	PHENOTYPE	7	7	preeclampsia
NCT0015493412	NCT00154934_12_T3	ORGAN	4	4	serum
NCT0015493413	NCT00154934_13_T0	CELL	3	3	trophoblast
NCT0015493415	NCT00154934_15_T0	GENE	16	16	IL-10
NCT0015493415	NCT00154934_15_T1	GENE	17	17	mRNA
NCT0015493415	NCT00154934_15_T2	CELL	3	3	trophoblast
NCT0015493416	NCT00154934_16_T0	CELL	5	5	trophoblast
NCT0015493416	NCT00154934_16_T1	GENE	24	25	Fas ligand
NCT0015493416	NCT00154934_16_T2	GENE	13	14	matrix metalloproteinase
NCT0015493420	NCT00154934_20_T0	PHENOTYPE	0	0	Hypertension
NCT0015493420	NCT00154934_20_T1	PHENOTYPE	4	4	edema
NCT0015493420	NCT00154934_20_T2	PHENOTYPE	1	1	proteinuria
NCT0015493421	NCT00154934_21_T0	PHENOTYPE	31	31	focal
NCT0015493421	NCT00154934_21_T1	ORGAN	28	28	arteries
NCT0015493421	NCT00154934_21_T2	GENE	34	34	reduced
NCT0015493421	NCT00154934_21_T3	CELL	17	17	trophoblast
NCT0015493422	NCT00154934_22_T0	GENE	1	1	has
NCT0015493422	NCT00154934_22_T1	PHENOTYPE	9	9	ischemia
NCT0015493423	NCT00154934_23_T0	PHENOTYPE	15	15	preeclampsia
NCT0015493424	NCT00154934_24_T0	TISSUE	20	20	endothelium
NCT0015493424	NCT00154934_24_T1	PHENOTYPE	4	5	tumor necrosis
NCT0015493424	NCT00154934_24_T2	PHENOTYPE	28	29	endothelial dysfunction
NCT0015493425	NCT00154934_25_T0	PHENOTYPE	16	17	immune tolerance
NCT0015493426	NCT00154934_26_T0	PHENOTYPE	14	14	disorders
NCT0015493426	NCT00154934_26_T1	GENE	6	6	interleukin-10
NCT0015493428	NCT00154934_28_T0	PHENOTYPE	15	16	immunological tolerance
NCT0015493438	NCT00154934_38_T0	CELL	4	4	granulocytes
NCT0015493438	NCT00154934_38_T1	GENE	0	0	IL-10
NCT0015493438	NCT00154934_38_T2	CELL	5	5	eosinophils
NCT0015493438	NCT00154934_38_T3	CELL	8	9	B cells
NCT0015493438	NCT00154934_38_T4	CELL	6	7	mast cells
NCT0015493438	NCT00154934_38_T5	CELL	10	11	T cells
NCT0015493439	NCT00154934_39_T0	GENE	0	0	IL-10
NCT0015493439	NCT00154934_39_T1	PHENOTYPE	5	6	inflammatory responses
NCT0015493440	NCT00154934_40_T0	GENE	3	3	IL-10
NCT0015493440	NCT00154934_40_T1	BIOLOGICAL_PROCESS	6	7	macrophage activation
NCT0015493443	NCT00154934_43_T0	GENE	3	3	IL-10
NCT0015493446	NCT00154934_46_T0	GENE	7	7	IL-10
NCT0015493446	NCT00154934_46_T1	GENE	6	6	Interleukin-10
NCT0015493446	NCT00154934_46_T2	ORGAN	22	22	endometrium
NCT0015493446	NCT00154934_46_T3	CELL	19	19	leukocytes
NCT0015493446	NCT00154934_46_T4	BIOLOGICAL_PROCESS	4	5	interleukin-10 production
NCT0015493446	NCT00154934_46_T5	CELL	16	17	epithelial cells
NCT0015493447	NCT00154934_47_T0	GENE	7	7	IL-10
NCT0015493449	NCT00154934_49_T0	GENE	0	0	IL-10
NCT0015493449	NCT00154934_49_T1	CELL	7	7	cells
NCT0015493449	NCT00154934_49_T2	CELL	9	9	cells
NCT0015493449	NCT00154934_49_T3	GENE	1	1	has
NCT0015493449	NCT00154934_49_T4	CELL	8	8	trophoblast
NCT0015493449	NCT00154934_49_T5	CELL	14	14	lymphocyte
NCT0015493450	NCT00154934_50_T0	CELL	9	10	NK cells
NCT0015493450	NCT00154934_50_T1	BIOLOGICAL_PROCESS	20	21	IL-10 production
NCT0015493450	NCT00154934_50_T2	CELL	1	3	bone marrow cells
NCT0015493451	NCT00154934_51_T0	GENE	8	8	has
NCT0015493451	NCT00154934_51_T1	PHENOTYPE	17	17	recurrent
NCT0015493451	NCT00154934_51_T2	BIOLOGICAL_PROCESS	6	7	immune response
NCT0015493452	NCT00154934_52_T0	GENE	0	0	IL-10
NCT0015493452	NCT00154934_52_T1	GENE	1	1	has
NCT0015493453	NCT00154934_53_T0	PHENOTYPE	12	12	maturation
NCT0015493453	NCT00154934_53_T1	GENE	0	0	IL-10
NCT0015493453	NCT00154934_53_T2	COMPOUND	14	14	progesterone
NCT0015493453	NCT00154934_53_T3	ORGAN	10	11	corpus luteum
NCT0015493454	NCT00154934_54_T0	GENE	14	14	IL-10
NCT0015493454	NCT00154934_54_T1	GENE	15	15	has
NCT0015493454	NCT00154934_54_T2	PHENOTYPE	9	10	spontaneous abortion
NCT0015493455	NCT00154934_55_T0	PHENOTYPE	15	15	peripheral
NCT0015493455	NCT00154934_55_T1	GENE	13	13	IL-10
NCT0015493455	NCT00154934_55_T2	TISSUE	20	20	spleen
NCT0015493457	NCT00154934_57_T0	COMPOUND	1	1	progesterone
NCT0015493457	NCT00154934_57_T1	GENE	2	2	has
NCT0015493459	NCT00154934_59_T0	GENE	3	3	IL-10
NCT0015493461	NCT00154934_61_T0	GENE	15	15	IL-10
NCT0015493461	NCT00154934_61_T1	CELL	6	6	cells
NCT0015493463	NCT00154934_63_T0	CELL	19	19	cytotrophoblast
NCT0015493463	NCT00154934_63_T1	ORGAN	11	11	decidua
NCT0015493463	NCT00154934_63_T2	GENE	0	0	Interleukin-10
NCT0015493463	NCT00154934_63_T3	GENE	7	7	Interleukin-10
NCT0015493463	NCT00154934_63_T4	PHENOTYPE	3	3	motility
NCT0015493463	NCT00154934_63_T5	CELL	2	2	trophoblast
NCT0015493463	NCT00154934_63_T6	BIOLOGICAL_PROCESS	33	34	immune response
NCT0015493463	NCT00154934_63_T7	GENE	23	24	matrix metalloproteinase
NCT0015493464	NCT00154934_64_T0	CELL	0	0	Cytotrophoblast
NCT0015493464	NCT00154934_64_T1	GENE	10	10	MMP-9
NCT0015493464	NCT00154934_64_T2	GENE	8	9	matrix metalloproteinase-9
NCT0015493465	NCT00154934_65_T0	GENE	11	11	IL-10
NCT0015493465	NCT00154934_65_T1	CELL	8	8	cytotrophoblasts
NCT0015493465	NCT00154934_65_T2	PHENOTYPE	19	19	paracrine
NCT0015493465	NCT00154934_65_T3	GENE	10	10	interleukin-10
NCT0015493465	NCT00154934_65_T4	ORGAN	24	25	immune system
NCT0015493468	NCT00154934_68_T0	GENE	8	8	MMP
NCT0015493468	NCT00154934_68_T1	CELL	12	12	cytotrophoblast
NCT0015493468	NCT00154934_68_T2	GENE	0	0	IL-10
NCT0015493469	NCT00154934_69_T0	CELL	12	12	cytotrophoblast
NCT0015493469	NCT00154934_69_T1	GENE	6	6	IL-10
NCT0015493469	NCT00154934_69_T2	GENE	13	13	MMP-9
NCT0015493472	NCT00154934_72_T0	ORGAN	16	16	liver
NCT0015493472	NCT00154934_72_T1	ORGAN	14	14	kidneys
NCT0015493472	NCT00154934_72_T2	PHENOTYPE	1	2	hypertensive disease
NCT0015493472	NCT00154934_72_T3	PHENOTYPE	2	4	disease of pregnancy
NCT0015493474	NCT00154934_74_T0	GENE	20	20	IL-10
NCT0015493474	NCT00154934_74_T1	GENE	48	48	IL-10
NCT0015493474	NCT00154934_74_T2	GENE	54	54	IL-10
NCT0015493474	NCT00154934_74_T3	TISSUE	24	24	tissues
NCT0015493474	NCT00154934_74_T4	GENE	21	21	mRNA
NCT0015493474	NCT00154934_74_T5	ORGAN	27	27	plasma
NCT0015493474	NCT00154934_74_T6	ORGAN	45	45	plasma
NCT0015493474	NCT00154934_74_T7	ORGAN	51	51	plasma
NCT0015493474	NCT00154934_74_T8	GENE	58	58	163
NCT0015493475	NCT00154934_75_T0	GENE	11	11	CTB
NCT0015493475	NCT00154934_75_T1	GENE	4	4	IL-10
NCT0015493475	NCT00154934_75_T2	GENE	13	13	PE
NCT0015493476	NCT00154934_76_T0	GENE	15	15	CTB
NCT0015493476	NCT00154934_76_T1	GENE	7	7	IL-10
NCT0015493476	NCT00154934_76_T2	GENE	14	14	PE
NCT0015493476	NCT00154934_76_T3	PHENOTYPE	5	5	alternation
NCT0015493478	NCT00154934_78_T0	GENE	0	0	CTB
NCT0015493478	NCT00154934_78_T1	GENE	10	10	IL-10
NCT0015493479	NCT00154934_79_T0	GENE	20	20	CTB
NCT0015493479	NCT00154934_79_T1	TISSUE	9	9	tissues
NCT001549471	NCT00154947_1_T0	PHENOTYPE	7	7	narrowing
NCT001549471	NCT00154947_1_T1	PHENOTYPE	3	4	bone erosion
NCT001549473	NCT00154947_3_T0	PHENOTYPE	22	22	visualization
NCT001549473	NCT00154947_3_T1	GENE	12	12	MRI
NCT001549473	NCT00154947_3_T2	PHENOTYPE	31	31	synovitis
NCT001549473	NCT00154947_3_T3	PHENOTYPE	28	29	bone inflammation
NCT001549473	NCT00154947_3_T4	PHENOTYPE	18	19	bone erosion
NCT001549475	NCT00154947_5_T0	GENE	6	6	CRP
NCT001549475	NCT00154947_5_T1	ORGAN	24	24	joints
NCT001549475	NCT00154947_5_T2	TISSUE	32	32	cartilage
NCT001549475	NCT00154947_5_T3	PHENOTYPE	15	15	inflammation
NCT001549475	NCT00154947_5_T4	GENE	21	21	structural
NCT001549475	NCT00154947_5_T5	ORGAN	3	3	serum
NCT001549475	NCT00154947_5_T6	GENE	4	5	C-reactive protein
NCT001549479	NCT00154947_9_T0	GENE	15	15	COMP
NCT001549479	NCT00154947_9_T1	GENE	22	22	PIIINP
NCT001549479	NCT00154947_9_T2	COMPOUND	20	20	PICP
NCT001549479	NCT00154947_9_T3	GENE	16	16	MMP-3
NCT001549479	NCT00154947_9_T4	GENE	25	25	YKL-40
NCT001549479	NCT00154947_9_T5	ORGAN	12	12	Serum
NCT001549479	NCT00154947_9_T6	ORGAN	14	14	Serum
NCT001549479	NCT00154947_9_T7	ORGAN	17	17	Serum
NCT001549479	NCT00154947_9_T8	ORGAN	19	19	Serum
NCT001549479	NCT00154947_9_T9	ORGAN	24	24	Serum
NCT001549479	NCT00154947_9_T10	GENE	13	13	osteocalcin
NCT0015494712	NCT00154947_12_T0	PHENOTYPE	7	7	narrowing
NCT0015494712	NCT00154947_12_T1	PHENOTYPE	3	4	bone erosion
NCT0015494714	NCT00154947_14_T0	PHENOTYPE	22	22	visualization
NCT0015494714	NCT00154947_14_T1	GENE	12	12	MRI
NCT0015494714	NCT00154947_14_T2	PHENOTYPE	31	31	synovitis
NCT0015494714	NCT00154947_14_T3	PHENOTYPE	28	29	bone inflammation
NCT0015494714	NCT00154947_14_T4	PHENOTYPE	18	19	bone erosion
NCT0015494716	NCT00154947_16_T0	GENE	6	6	CRP
NCT0015494716	NCT00154947_16_T1	ORGAN	24	24	joints
NCT0015494716	NCT00154947_16_T2	TISSUE	32	32	cartilage
NCT0015494716	NCT00154947_16_T3	PHENOTYPE	15	15	inflammation
NCT0015494716	NCT00154947_16_T4	GENE	21	21	structural
NCT0015494716	NCT00154947_16_T5	ORGAN	3	3	serum
NCT0015494716	NCT00154947_16_T6	GENE	4	5	C-reactive protein
NCT001549600	NCT00154960_0_T0	PHENOTYPE	7	7	Diseases
NCT001549601	NCT00154960_1_T0	GENE	0	0	LC
NCT001549603	NCT00154960_3_T0	PHENOTYPE	16	17	internal control
NCT001549604	NCT00154960_4_T0	GENE	7	7	duplicated
NCT001549604	NCT00154960_4_T1	GENE	23	23	PCR
NCT001549607	NCT00154960_7_T0	PHENOTYPE	15	15	deletion
NCT001549607	NCT00154960_7_T1	GENE	26	26	SMN2
NCT001549607	NCT00154960_7_T2	GENE	14	14	SMN1
NCT001549607	NCT00154960_7_T3	GENE	24	24	SMN1
NCT001549609	NCT00154960_9_T0	PHENOTYPE	8	9	colorectal cancer
NCT0015496011	NCT00154960_11_T0	PHENOTYPE	10	10	carcinogenesis
NCT0015496011	NCT00154960_11_T1	PHENOTYPE	8	9	colon cancer
NCT0015496013	NCT00154960_13_T0	PHENOTYPE	27	27	adenoma
NCT0015496013	NCT00154960_13_T1	GENE	9	9	has
NCT0015496016	NCT00154960_16_T0	GENE	5	5	1A1
NCT0015496016	NCT00154960_16_T1	COMPOUND	12	12	bilirubin
NCT0015496016	NCT00154960_16_T2	GENE	9	9	HO-1
NCT0015496016	NCT00154960_16_T3	BIOLOGICAL_PROCESS	13	13	metabolism
NCT0015496016	NCT00154960_16_T4	GENE	7	8	heme oxygenase-1
NCT0015496016	NCT00154960_16_T5	GENE	3	4	UDP-glucuronosyl transferase
NCT0015496018	NCT00154960_18_T0	GENE	9	9	UGT1A1
NCT0015496018	NCT00154960_18_T1	PHENOTYPE	17	18	neonatal hyperbilirubinemia
NCT0015496019	NCT00154960_19_T0	COMPOUND	18	18	biliverdin
NCT0015496019	NCT00154960_19_T1	GENE	1	1	HO-1
NCT0015496019	NCT00154960_19_T2	BIOLOGICAL_PROCESS	14	14	degradation
NCT0015496019	NCT00154960_19_T3	BIOLOGICAL_PROCESS	8	9	heme metabolism
NCT0015496021	NCT00154960_21_T0	GENE	7	7	UGT1A1
NCT0015496021	NCT00154960_21_T1	PHENOTYPE	16	17	unconjugated hyperbilirubinemia
NCT0015496022	NCT00154960_22_T0	PHENOTYPE	14	14	mutation
NCT0015496022	NCT00154960_22_T1	GENE	12	12	UGT1A1
NCT0015496022	NCT00154960_22_T2	PHENOTYPE	10	10	hyperbilirubinemia
NCT0015496023	NCT00154960_23_T0	GENE	7	7	UGT1A1
NCT0015496023	NCT00154960_23_T1	GENE	9	9	HO-1
NCT0015496023	NCT00154960_23_T2	PHENOTYPE	14	15	unconjugated hyperbilirubinemia
NCT001549861	NCT00154986_1_T0	GENE	7	7	IGFBP-3
NCT001549861	NCT00154986_1_T1	PHENOTYPE	9	10	ovarian cancer
NCT0015498610	NCT00154986_10_T0	GENE	12	12	IGFBP-3
NCT0015498610	NCT00154986_10_T1	ORGAN	2	2	xenograft
NCT0015498610	NCT00154986_10_T2	PHENOTYPE	14	15	ovarian cancer
NCT001549992	NCT00154999_2_T0	GENE	7	7	RBC
NCT001549993	NCT00154999_3_T0	GENE	5	5	ROS
NCT001549993	NCT00154999_3_T1	PHENOTYPE	12	13	neonatal hyperbilirubinemia
NCT001549994	NCT00154999_4_T0	GENE	9	9	ROS
NCT001549994	NCT00154999_4_T1	PHENOTYPE	6	7	bilirubin level
NCT001549996	NCT00154999_6_T0	GENE	7	7	RBC
NCT001549996	NCT00154999_6_T1	COMPOUND	1	1	bilirubin
NCT001549998	NCT00154999_8_T0	COMPOUND	2	2	bilirubin
NCT001549998	NCT00154999_8_T1	GENE	3	3	has
NCT001549999	NCT00154999_9_T0	GENE	17	17	ROS
NCT001549999	NCT00154999_9_T1	COMPOUND	12	12	bilirubin
NCT001549999	NCT00154999_9_T2	COMPOUND	15	15	oxygen
NCT0015499914	NCT00154999_14_T0	PHENOTYPE	5	6	neonatal hyperbilirubinemia
NCT001550122	NCT00155012_2_T0	COMPOUND	8	8	calcium
NCT001550123	NCT00155012_3_T0	COMPOUND	12	12	calcium
NCT001550126	NCT00155012_6_T0	COMPOUND	1	1	calcium
NCT001550126	NCT00155012_6_T1	PHENOTYPE	8	10	coronary artery disease
NCT001550128	NCT00155012_8_T0	PHENOTYPE	9	9	visualization
NCT001550128	NCT00155012_8_T1	ORGAN	11	12	coronary artery
NCT001550129	NCT00155012_9_T0	ORGAN	14	14	heart
NCT0015501210	NCT00155012_10_T0	PHENOTYPE	1	1	distal
NCT0015501211	NCT00155012_11_T0	PHENOTYPE	3	3	calcification
NCT0015501212	NCT00155012_12_T0	COMPOUND	5	5	calcium
NCT0015501213	NCT00155012_13_T0	COMPOUND	12	12	calcium
NCT0015501215	NCT00155012_15_T0	COMPOUND	8	8	calcium
NCT0015501216	NCT00155012_16_T0	COMPOUND	12	12	calcium
NCT001550251	NCT00155025_1_T0	PHENOTYPE	4	4	diseases
NCT001550252	NCT00155025_2_T0	GENE	5	5	OPD
NCT001550256	NCT00155025_6_T0	PHENOTYPE	1	1	associations
NCT001550380	NCT00155038_0_T0	GENE	11	11	Age
NCT001550380	NCT00155038_0_T1	PHENOTYPE	3	4	Breast Cancer
NCT001550383	NCT00155038_3_T0	GENE	21	21	has
NCT001550383	NCT00155038_3_T1	PHENOTYPE	2	3	breast cancer
NCT001550383	NCT00155038_3_T2	PHENOTYPE	23	24	breast cancer
NCT001550384	NCT00155038_4_T0	GENE	57	57	has
NCT001550384	NCT00155038_4_T1	PHENOTYPE	30	31	breast cancer
NCT001550384	NCT00155038_4_T2	PHENOTYPE	42	43	breast cancer
NCT001550386	NCT00155038_6_T0	PHENOTYPE	12	13	breast cancer
NCT001550387	NCT00155038_7_T0	PHENOTYPE	15	16	breast cancer
NCT001550387	NCT00155038_7_T1	PHENOTYPE	34	35	breast cancer
NCT001550388	NCT00155038_8_T0	PHENOTYPE	29	29	pathology
NCT001550388	NCT00155038_8_T1	PHENOTYPE	23	23	tumor
NCT001550388	NCT00155038_8_T2	PHENOTYPE	10	11	breast cancers
NCT001550389	NCT00155038_9_T0	PHENOTYPE	30	31	breast cancer
NCT001550510	NCT00155051_0_T0	PHENOTYPE	7	7	Adenomyosis
NCT001550510	NCT00155051_0_T1	CELL	4	5	Stromal Cells
NCT001550512	NCT00155051_2_T0	PHENOTYPE	17	17	dysfunction
NCT001550512	NCT00155051_2_T1	PHENOTYPE	18	19	uterine bleeding
NCT001550512	NCT00155051_2_T2	PHENOTYPE	14	15	endometrial hyperplasia
NCT001550512	NCT00155051_2_T3	PHENOTYPE	12	13	endometrial cancer
NCT001550513	NCT00155051_3_T0	PHENOTYPE	4	4	adenomyosis
NCT001550514	NCT00155051_4_T0	CELL	8	8	cells
NCT001550514	NCT00155051_4_T1	PHENOTYPE	12	12	adenomyosis
NCT001550514	NCT00155051_4_T2	PHENOTYPE	20	20	adenomyosis
NCT001550515	NCT00155051_5_T0	PHENOTYPE	23	23	adenomyosis
NCT001550515	NCT00155051_5_T1	ORGAN	19	19	endometrium
NCT001550515	NCT00155051_5_T2	CELL	13	14	NK cells
NCT001550516	NCT00155051_6_T0	CELL	21	21	cells
NCT001550516	NCT00155051_6_T1	ORGAN	31	31	endometrium
NCT001550516	NCT00155051_6_T2	PHENOTYPE	10	10	cytotoxicity
NCT001550518	NCT00155051_8_T0	PHENOTYPE	17	17	adenomyosis
NCT001550518	NCT00155051_8_T1	PHENOTYPE	15	15	endometriosis
NCT001550518	NCT00155051_8_T2	ORGAN	10	10	endometrium
NCT001550518	NCT00155051_8_T3	ORGAN	24	24	endometrium
NCT001550519	NCT00155051_9_T0	TISSUE	8	8	tissues
NCT001550519	NCT00155051_9_T1	PHENOTYPE	14	14	adenomyosis
NCT001550519	NCT00155051_9_T2	ORGAN	23	23	endometrium
NCT001550519	NCT00155051_9_T3	CELL	20	21	stromal cells
NCT0015505110	NCT00155051_10_T0	COMPOUND	16	16	danazol
NCT0015505110	NCT00155051_10_T1	PHENOTYPE	14	14	MPA
NCT0015505110	NCT00155051_10_T2	CELL	2	3	stromal cells
NCT0015505111	NCT00155051_11_T0	PHENOTYPE	11	11	concentrations
NCT0015505111	NCT00155051_11_T1	CELL	8	8	cells
NCT0015505111	NCT00155051_11_T2	GENE	2	2	IL-6
NCT0015505111	NCT00155051_11_T3	GENE	13	13	IL-6
NCT0015505111	NCT00155051_11_T4	GENE	5	5	mRNA
NCT0015505111	NCT00155051_11_T5	GENE	4	4	IL-8
NCT0015505111	NCT00155051_11_T6	GENE	15	15	IL-8
NCT0015505112	NCT00155051_12_T0	CELL	7	7	cells
NCT0015505114	NCT00155051_14_T0	GENE	9	9	ESC
NCT0015505114	NCT00155051_14_T1	COMPOUND	24	24	danazol
NCT0015505114	NCT00155051_14_T2	PHENOTYPE	22	22	MPA
NCT0015505115	NCT00155051_15_T0	GENE	8	8	TNF-alpha
NCT0015505115	NCT00155051_15_T1	PHENOTYPE	9	9	concentrations
NCT0015505115	NCT00155051_15_T2	GENE	5	5	IL-6
NCT0015505115	NCT00155051_15_T3	GENE	6	6	IL-8
NCT0015505116	NCT00155051_16_T0	GENE	10	10	TNF-alpha
NCT0015505116	NCT00155051_16_T1	GENE	14	14	ESC
NCT0015505116	NCT00155051_16_T2	GENE	7	7	IL-6
NCT0015505116	NCT00155051_16_T3	GENE	8	8	IL-8
NCT001550641	NCT00155064_1_T0	BIOLOGICAL_PROCESS	12	12	metabolism
NCT001550649	NCT00155064_9_T0	PHENOTYPE	8	9	primary hypertension
NCT0015506410	NCT00155064_10_T0	GENE	21	21	al
NCT0015506410	NCT00155064_10_T1	GENE	20	20	et
NCT0015506412	NCT00155064_12_T0	ORGAN	21	22	adrenal gland
NCT0015506414	NCT00155064_14_T0	COMPOUND	11	11	sodium
NCT0015506414	NCT00155064_14_T1	BIOLOGICAL_PROCESS	14	14	metabolism
NCT0015506415	NCT00155064_15_T0	BIOLOGICAL_PROCESS	12	12	metabolism
NCT0015506416	NCT00155064_16_T0	GENE	11	11	II
NCT0015506416	NCT00155064_16_T1	GENE	10	10	Ang
NCT0015506417	NCT00155064_17_T0	GENE	12	12	B2
NCT0015506417	NCT00155064_17_T1	CELL	10	10	cells
NCT0015506417	NCT00155064_17_T2	COMPOUND	6	6	aldosterone
NCT0015506424	NCT00155064_24_T0	GENE	9	9	bradykinin
NCT0015506424	NCT00155064_24_T1	COMPOUND	7	7	angiotensin
NCT0015506424	NCT00155064_24_T2	PHENOTYPE	15	15	hypertension
NCT0015506424	NCT00155064_24_T3	ORGAN	12	13	adrenal gland
NCT001550771	NCT00155077_1_T0	PHENOTYPE	6	7	malignant neoplasm
NCT001550771	NCT00155077_1_T1	PHENOTYPE	0	1	Cervical cancer
NCT001550772	NCT00155077_2_T0	PHENOTYPE	6	7	invasive carcinoma
NCT001550772	NCT00155077_2_T1	PHENOTYPE	7	10	carcinoma of the cervix
NCT001550773	NCT00155077_3_T0	PHENOTYPE	0	1	Cervical cancer
NCT001550774	NCT00155077_4_T0	PHENOTYPE	4	5	cervical cancer
NCT001550775	NCT00155077_5_T0	PHENOTYPE	11	11	progression
NCT001550776	NCT00155077_6_T0	PHENOTYPE	17	18	cervical cancer
NCT001550777	NCT00155077_7_T0	PHENOTYPE	4	5	cervical cancer
NCT001550777	NCT00155077_7_T1	PHENOTYPE	15	16	cervical cancer
NCT0015507713	NCT00155077_13_T0	PHENOTYPE	22	23	cervical cancer
NCT0015507721	NCT00155077_21_T0	ORGAN	25	25	liver
NCT0015507721	NCT00155077_21_T1	PHENOTYPE	8	9	malignant neoplasm
NCT0015507721	NCT00155077_21_T2	PHENOTYPE	2	3	cervical cancer
NCT0015507721	NCT00155077_21_T3	PHENOTYPE	21	24	carcinoma of the lung
NCT0015507722	NCT00155077_22_T0	PHENOTYPE	14	15	invasive carcinoma
NCT0015507722	NCT00155077_22_T1	PHENOTYPE	33	35	carcinoma in situ
NCT0015507722	NCT00155077_22_T2	PHENOTYPE	15	18	carcinoma of the cervix
NCT0015507723	NCT00155077_23_T0	GENE	7	7	has
NCT0015507723	NCT00155077_23_T1	PHENOTYPE	4	6	invasive cervical cancer
NCT0015507724	NCT00155077_24_T0	PHENOTYPE	4	5	cervical cancers
NCT0015507725	NCT00155077_25_T0	TISSUE	19	19	tissues
NCT0015507725	NCT00155077_25_T1	TISSUE	14	15	lymph nodes
NCT0015507725	NCT00155077_25_T2	PHENOTYPE	4	5	cervical lesion
NCT0015507726	NCT00155077_26_T0	CELL	7	7	cells
NCT0015507726	NCT00155077_26_T1	PHENOTYPE	6	6	tumor
NCT0015507727	NCT00155077_27_T0	ORGAN	16	16	pelvis
NCT0015507727	NCT00155077_27_T1	GENE	0	0	7-10
NCT0015507727	NCT00155077_27_T2	PHENOTYPE	4	5	cervical cancer
NCT0015507728	NCT00155077_28_T0	GENE	7	7	has
NCT0015507731	NCT00155077_31_T0	PHENOTYPE	10	10	tumor
NCT0015507732	NCT00155077_32_T0	PHENOTYPE	18	19	primary cancer
NCT0015507732	NCT00155077_32_T1	PHENOTYPE	22	24	lymph node metastases
NCT0015507735	NCT00155077_35_T0	ORGAN	8	8	cervix
NCT0015507735	NCT00155077_35_T1	GENE	4	4	has
NCT0015507735	NCT00155077_35_T2	GENE	5	5	extended
NCT0015507735	NCT00155077_35_T3	PHENOTYPE	2	3	cervical cancer
NCT0015507736	NCT00155077_36_T0	PHENOTYPE	13	13	progression
NCT0015507737	NCT00155077_37_T0	PHENOTYPE	17	18	cervical cancer
NCT0015507738	NCT00155077_38_T0	PHENOTYPE	9	10	cervical cancer
NCT0015507740	NCT00155077_40_T0	GENE	25	25	II
NCT0015507740	NCT00155077_40_T1	PHENOTYPE	38	38	IVA
NCT0015507740	NCT00155077_40_T2	PHENOTYPE	30	31	stage III
NCT0015507741	NCT00155077_41_T0	PHENOTYPE	13	14	primary tumor
NCT0015507742	NCT00155077_42_T0	PHENOTYPE	19	19	recurrence
NCT0015507742	NCT00155077_42_T1	GENE	11	11	reduced
NCT0015507747	NCT00155077_47_T0	GENE	1	1	has
NCT0015507752	NCT00155077_52_T0	PHENOTYPE	23	24	cervical cancer
NCT0015507754	NCT00155077_54_T0	PHENOTYPE	0	1	Cervical cancer
NCT001550904	NCT00155090_4_T0	TISSUE	2	2	tissues
NCT001550905	NCT00155090_5_T0	TISSUE	6	6	tissues
NCT001551033	NCT00155103_3_T0	PHENOTYPE	20	20	associations
NCT001551033	NCT00155103_3_T1	PHENOTYPE	9	10	chronic hepatitis
NCT001551033	NCT00155103_3_T2	PHENOTYPE	12	13	hepatocellular carcinoma
NCT001551162	NCT00155116_2_T0	PHENOTYPE	10	11	lung cancer
NCT001551162	NCT00155116_2_T1	PHENOTYPE	18	19	lung cancer
NCT001551163	NCT00155116_3_T0	PHENOTYPE	19	19	metastasized
NCT001551163	NCT00155116_3_T1	CELL	12	12	cells
NCT001551163	NCT00155116_3_T2	TISSUE	17	17	tissues
NCT001551163	NCT00155116_3_T3	PHENOTYPE	3	4	lung cancer
NCT001551164	NCT00155116_4_T0	GENE	15	15	had
NCT001551164	NCT00155116_4_T1	PHENOTYPE	3	4	lung cancer
NCT001551165	NCT00155116_5_T0	PHENOTYPE	5	6	metastatic disease
NCT001551166	NCT00155116_6_T0	PHENOTYPE	12	12	cancers
NCT001551166	NCT00155116_6_T1	PHENOTYPE	1	2	lung cancers
NCT001551167	NCT00155116_7_T0	TISSUE	16	16	tissues
NCT001551167	NCT00155116_7_T1	GENE	21	21	secreted
NCT001551167	NCT00155116_7_T2	CELL	11	11	cells
NCT001551167	NCT00155116_7_T3	PHENOTYPE	10	10	tumor
NCT001551167	NCT00155116_7_T4	PHENOTYPE	35	36	lung cancer
NCT0015511610	NCT00155116_10_T0	PHENOTYPE	19	19	metastasis
NCT0015511610	NCT00155116_10_T1	ORGAN	25	25	serum
NCT0015511610	NCT00155116_10_T2	GENE	9	9	D1
NCT0015511610	NCT00155116_10_T3	PHENOTYPE	15	16	lung cancer
NCT0015511611	NCT00155116_11_T0	PHENOTYPE	27	27	metastasis
NCT0015511611	NCT00155116_11_T1	GENE	13	13	D1
NCT0015511611	NCT00155116_11_T2	PHENOTYPE	25	26	lung cancer
NCT001551291	NCT00155129_1_T0	GENE	0	0	Nociceptin
NCT001551291	NCT00155129_1_T1	GENE	4	4	mRNA
NCT001551291	NCT00155129_1_T2	GENE	17	17	CGRP
NCT001551291	NCT00155129_1_T3	ORGAN	10	11	trigeminal ganglia
NCT001551295	NCT00155129_5_T0	GENE	0	0	Nociceptin
NCT001551295	NCT00155129_5_T1	GENE	4	4	mRNA
NCT001551295	NCT00155129_5_T2	GENE	17	17	CGRP
NCT001551295	NCT00155129_5_T3	ORGAN	10	11	trigeminal ganglia
NCT001551423	NCT00155142_3_T0	PHENOTYPE	32	32	strategies
NCT001551423	NCT00155142_3_T1	PHENOTYPE	11	11	insights
NCT001551423	NCT00155142_3_T2	BIOLOGICAL_PROCESS	4	4	innervation
NCT001551423	NCT00155142_3_T3	GENE	25	26	type 2
NCT001551423	NCT00155142_3_T4	PHENOTYPE	34	35	diabetic neuropathy
NCT001551423	NCT00155142_3_T5	PHENOTYPE	19	21	small fiber neuropathy
NCT001551429	NCT00155142_9_T0	ORGAN	6	6	limbs
NCT001551429	NCT00155142_9_T1	PHENOTYPE	5	5	distal
NCT001551429	NCT00155142_9_T2	PHENOTYPE	11	11	proximal
NCT0015514210	NCT00155142_10_T0	GENE	8	8	reduced
NCT0015514210	NCT00155142_10_T1	BIOLOGICAL_PROCESS	6	6	innervation
NCT0015514210	NCT00155142_10_T2	GENE	12	13	type 2
NCT0015514212	NCT00155142_12_T0	CELL	28	29	C fibers
NCT0015514213	NCT00155142_13_T0	BIOLOGICAL_PROCESS	17	17	innervation
NCT0015514214	NCT00155142_14_T0	BIOLOGICAL_PROCESS	12	12	innervation
NCT0015514217	NCT00155142_17_T0	PHENOTYPE	2	2	neuropathies
NCT0015514218	NCT00155142_18_T0	PHENOTYPE	8	8	degeneration
NCT0015514220	NCT00155142_20_T0	TISSUE	14	14	tissues
NCT0015514220	NCT00155142_20_T1	ORGAN	17	18	peripheral nerves
NCT0015514220	NCT00155142_20_T2	BIOLOGICAL_PROCESS	25	26	gene expression
NCT0015514221	NCT00155142_21_T0	BIOLOGICAL_PROCESS	33	33	regeneration
NCT0015514221	NCT00155142_21_T1	GENE	5	5	has
NCT0015514221	NCT00155142_21_T2	ORGAN	11	12	peripheral nerves
NCT0015514221	NCT00155142_21_T3	BIOLOGICAL_PROCESS	19	20	neurite outgrowth
NCT0015514227	NCT00155142_27_T0	BIOLOGICAL_PROCESS	3	3	innervation
NCT0015514227	NCT00155142_27_T1	GENE	7	8	type 2
NCT001551550	NCT00155155_0_T0	PHENOTYPE	7	9	Chronic Hepatitis B
NCT001551555	NCT00155155_5_T0	CELL	3	4	T cells
NCT001551556	NCT00155155_6_T0	PHENOTYPE	12	12	HBV
NCT001551556	NCT00155155_6_T1	CELL	5	6	T cells
NCT001551557	NCT00155155_7_T0	PHENOTYPE	4	4	HBV
NCT001551558	NCT00155155_8_T0	PHENOTYPE	2	2	HBV
NCT001551558	NCT00155155_8_T1	PHENOTYPE	12	12	HBV
NCT001551559	NCT00155155_9_T0	GENE	3	3	CD8
NCT001551559	NCT00155155_9_T1	PHENOTYPE	2	2	HBV
NCT001551559	NCT00155155_9_T2	ORGAN	9	10	cord bloods
NCT001551559	NCT00155155_9_T3	CELL	4	5	T cells
NCT0015515517	NCT00155155_17_T0	PHENOTYPE	4	4	HBV
NCT0015515519	NCT00155155_19_T0	PHENOTYPE	8	8	HIV
NCT0015515519	NCT00155155_19_T1	COMPOUND	6	6	HCV
NCT0015515519	NCT00155155_19_T2	GENE	2	2	IgM
NCT0015515520	NCT00155155_20_T0	ORGAN	1	1	serum
NCT0015515520	NCT00155155_20_T1	PHENOTYPE	4	4	HBV
NCT0015515520	NCT00155155_20_T2	GENE	14	14	PCR
NCT0015515521	NCT00155155_21_T0	PHENOTYPE	10	10	HIV
NCT0015515521	NCT00155155_21_T1	COMPOUND	8	8	HCV
NCT0015515525	NCT00155155_25_T0	GENE	3	3	CD8
NCT0015515525	NCT00155155_25_T1	PHENOTYPE	2	2	HBV
NCT0015515525	NCT00155155_25_T2	PHENOTYPE	11	11	HBV
NCT0015515525	NCT00155155_25_T3	PHENOTYPE	10	10	chronic
NCT0015515525	NCT00155155_25_T4	CELL	4	5	T cells
NCT001551680	NCT00155168_0_T0	GENE	5	5	SMN2
NCT001551680	NCT00155168_0_T1	GENE	3	3	SMN1
NCT001551682	NCT00155168_2_T0	GENE	2	2	PCR
NCT001551685	NCT00155168_5_T0	GENE	5	5	SMN
NCT001551685	NCT00155168_5_T1	GENE	8	8	SMN
NCT001551685	NCT00155168_5_T2	GENE	12	12	SMN
NCT001551685	NCT00155168_5_T3	GENE	13	13	SMN2
NCT001551685	NCT00155168_5_T4	GENE	9	9	SMN1
NCT001551686	NCT00155168_6_T0	GENE	2	2	SMN
NCT001551687	NCT00155168_7_T0	PHENOTYPE	6	6	encoded
NCT001551688	NCT00155168_8_T0	GENE	16	16	SMN2
NCT001551688	NCT00155168_8_T1	GENE	10	10	SMN1
NCT0015516813	NCT00155168_13_T0	PHENOTYPE	15	15	deletion
NCT0015516813	NCT00155168_13_T1	GENE	26	26	SMN2
NCT0015516813	NCT00155168_13_T2	GENE	14	14	SMN1
NCT0015516813	NCT00155168_13_T3	GENE	24	24	SMN1
NCT0015516815	NCT00155168_15_T0	PHENOTYPE	23	23	fluctuations
NCT0015516815	NCT00155168_15_T1	GENE	29	29	SMN
NCT0015516815	NCT00155168_15_T2	GENE	12	12	SMN2
NCT0015516815	NCT00155168_15_T3	GENE	10	10	SMN1
NCT0015516815	NCT00155168_15_T4	GENE	5	5	PCR
NCT0015516816	NCT00155168_16_T0	GENE	21	21	SMN2
NCT0015516816	NCT00155168_16_T1	GENE	8	8	KRIT1
NCT0015516816	NCT00155168_16_T2	GENE	5	5	CYBB
NCT0015516816	NCT00155168_16_T3	GENE	19	19	SMN1
NCT0015516816	NCT00155168_16_T4	PHENOTYPE	4	4	X-linked
NCT001551813	NCT00155181_3_T0	PHENOTYPE	1	1	carcinomas
NCT001551813	NCT00155181_3_T1	PHENOTYPE	6	7	nasopharyngeal carcinoma
NCT001551813	NCT00155181_3_T2	PHENOTYPE	9	10	gastric carcinoma
NCT0015518120	NCT00155181_20_T0	PHENOTYPE	17	17	metastasis
NCT0015518120	NCT00155181_20_T1	PHENOTYPE	18	18	progression
NCT0015518120	NCT00155181_20_T2	GENE	10	10	LMP2A
NCT001551943	NCT00155194_3_T0	PHENOTYPE	3	3	immunity
NCT001551943	NCT00155194_3_T1	PHENOTYPE	16	16	immunity
NCT001551943	NCT00155194_3_T2	PHENOTYPE	6	7	biliary atresia
NCT001552074	NCT00155207_4_T0	PHENOTYPE	20	20	schizophrenia
NCT001552076	NCT00155207_6_T0	GENE	4	4	has
NCT001552076	NCT00155207_6_T1	GENE	7	7	lines
NCT0015520711	NCT00155207_11_T0	COMPOUND	34	34	G72
NCT0015520711	NCT00155207_11_T1	GENE	28	28	NOTCH4
NCT0015520711	NCT00155207_11_T2	GENE	36	36	CHRNA7
NCT0015520711	NCT00155207_11_T3	GENE	30	30	NRG1
NCT0015520711	NCT00155207_11_T4	PHENOTYPE	13	13	schizophrenia
NCT0015520711	NCT00155207_11_T5	GENE	22	22	GNPAT
NCT0015520711	NCT00155207_11_T6	GENE	32	32	DAAO
NCT0015520711	NCT00155207_11_T7	GENE	24	24	DISC1
NCT0015520711	NCT00155207_11_T8	GENE	38	38	PRODH
NCT0015520711	NCT00155207_11_T9	GENE	43	43	CACNG2
NCT0015520711	NCT00155207_11_T10	GENE	26	26	MRDS1
NCT0015520713	NCT00155207_13_T0	COMPOUND	2	2	1
NCT0015520714	NCT00155207_14_T0	GENE	15	15	CPT
NCT0015520714	NCT00155207_14_T1	COMPOUND	31	31	niacin
NCT0015520714	NCT00155207_14_T2	PHENOTYPE	32	32	flushing
NCT0015520714	NCT00155207_14_T3	PHENOTYPE	22	22	Sorting
NCT0015520714	NCT00155207_14_T4	PHENOTYPE	16	17	executive function
NCT0015520715	NCT00155207_15_T0	PHENOTYPE	7	7	schizophrenia
NCT0015520715	NCT00155207_15_T1	PHENOTYPE	10	10	heterogeneous
NCT0015520716	NCT00155207_16_T0	COMPOUND	2	2	2
NCT0015520716	NCT00155207_16_T1	PHENOTYPE	33	33	schizophrenia
NCT0015520721	NCT00155207_21_T0	CELL	23	23	cells
NCT0015520721	NCT00155207_21_T1	BIOLOGICAL_PROCESS	34	35	gene expression
NCT0015520722	NCT00155207_22_T0	COMPOUND	14	14	niacin
NCT0015520722	NCT00155207_22_T1	PHENOTYPE	19	19	schizophrenia
NCT0015520722	NCT00155207_22_T2	PHENOTYPE	16	16	flushing
NCT0015520723	NCT00155207_23_T0	CELL	19	19	lymphocytes
NCT0015520723	NCT00155207_23_T1	COMPOUND	7	7	niacin
NCT0015520723	NCT00155207_23_T2	PHENOTYPE	8	8	flushing
NCT0015520723	NCT00155207_23_T3	BIOLOGICAL_PROCESS	15	16	gene expression
NCT0015520727	NCT00155207_27_T0	TISSUE	19	19	tissues
NCT0015520727	NCT00155207_27_T1	PHENOTYPE	43	44	behavioral abnormalities
NCT0015520729	NCT00155207_29_T0	GENE	3	3	4b
NCT0015520735	NCT00155207_35_T0	PHENOTYPE	13	13	Schizophrenia
NCT0015520735	NCT00155207_35_T1	GENE	2	2	has
NCT0015520735	NCT00155207_35_T2	GENE	23	23	has
NCT0015520736	NCT00155207_36_T0	GENE	13	13	al
NCT0015520736	NCT00155207_36_T1	GENE	17	17	al
NCT0015520736	NCT00155207_36_T2	GENE	21	21	al
NCT0015520736	NCT00155207_36_T3	GENE	25	25	al
NCT0015520736	NCT00155207_36_T4	GENE	31	31	al
NCT0015520736	NCT00155207_36_T5	GENE	12	12	et
NCT0015520736	NCT00155207_36_T6	GENE	16	16	et
NCT0015520736	NCT00155207_36_T7	GENE	20	20	et
NCT0015520736	NCT00155207_36_T8	GENE	24	24	et
NCT0015520736	NCT00155207_36_T9	GENE	30	30	et
NCT0015520738	NCT00155207_38_T0	PHENOTYPE	9	9	schizophrenia
NCT0015520738	NCT00155207_38_T1	GENE	17	17	lines
NCT0015520742	NCT00155207_42_T0	GENE	5	5	2.1
NCT0015520742	NCT00155207_42_T1	PHENOTYPE	4	4	Schizophrenia
NCT0015520744	NCT00155207_44_T0	GENE	14	14	al
NCT0015520744	NCT00155207_44_T1	GENE	18	18	al
NCT0015520744	NCT00155207_44_T2	GENE	13	13	et
NCT0015520744	NCT00155207_44_T3	GENE	17	17	et
NCT0015520746	NCT00155207_46_T0	PHENOTYPE	6	6	translocation
NCT0015520746	NCT00155207_46_T1	CELL	1	1	chromosome
NCT0015520746	NCT00155207_46_T2	GENE	25	25	al
NCT0015520746	NCT00155207_46_T3	PHENOTYPE	21	21	schizophrenia
NCT0015520746	NCT00155207_46_T4	GENE	24	24	et
NCT0015520746	NCT00155207_46_T5	COMPOUND	7	7	1
NCT0015520746	NCT00155207_46_T6	PHENOTYPE	18	19	mental illness
NCT0015520752	NCT00155207_52_T0	GENE	46	46	al
NCT0015520752	NCT00155207_52_T1	GENE	66	66	al
NCT0015520752	NCT00155207_52_T2	GENE	45	45	et
NCT0015520752	NCT00155207_52_T3	GENE	65	65	et
NCT0015520752	NCT00155207_52_T4	PHENOTYPE	8	9	internal control
NCT0015520752	NCT00155207_52_T5	PHENOTYPE	25	26	internal control
NCT0015520753	NCT00155207_53_T0	GENE	22	22	van
NCT0015520753	NCT00155207_53_T1	GENE	28	28	van
NCT0015520753	NCT00155207_53_T2	GENE	45	45	NOTCH4
NCT0015520753	NCT00155207_53_T3	GENE	12	12	DTNBP1
NCT0015520753	NCT00155207_53_T4	GENE	8	8	al
NCT0015520753	NCT00155207_53_T5	GENE	16	16	al
NCT0015520753	NCT00155207_53_T6	GENE	20	20	al
NCT0015520753	NCT00155207_53_T7	GENE	26	26	al
NCT0015520753	NCT00155207_53_T8	GENE	32	32	al
NCT0015520753	NCT00155207_53_T9	GENE	39	39	al
NCT0015520753	NCT00155207_53_T10	GENE	43	43	al
NCT0015520753	NCT00155207_53_T11	GENE	53	53	al
NCT0015520753	NCT00155207_53_T12	GENE	57	57	al
NCT0015520753	NCT00155207_53_T13	GENE	61	61	al
NCT0015520753	NCT00155207_53_T14	GENE	65	65	al
NCT0015520753	NCT00155207_53_T15	GENE	71	71	al
NCT0015520753	NCT00155207_53_T16	GENE	76	76	al
NCT0015520753	NCT00155207_53_T17	GENE	80	80	al
NCT0015520753	NCT00155207_53_T18	GENE	86	86	al
NCT0015520753	NCT00155207_53_T19	GENE	91	91	al
NCT0015520753	NCT00155207_53_T20	GENE	97	97	al
NCT0015520753	NCT00155207_53_T21	GENE	103	103	al
NCT0015520753	NCT00155207_53_T22	GENE	107	107	al
NCT0015520753	NCT00155207_53_T23	GENE	113	113	al
NCT0015520753	NCT00155207_53_T24	GENE	29	29	den
NCT0015520753	NCT00155207_53_T25	GENE	23	23	Den
NCT0015520753	NCT00155207_53_T26	GENE	7	7	et
NCT0015520753	NCT00155207_53_T27	GENE	15	15	et
NCT0015520753	NCT00155207_53_T28	GENE	19	19	et
NCT0015520753	NCT00155207_53_T29	GENE	25	25	et
NCT0015520753	NCT00155207_53_T30	GENE	31	31	et
NCT0015520753	NCT00155207_53_T31	GENE	38	38	et
NCT0015520753	NCT00155207_53_T32	GENE	42	42	et
NCT0015520753	NCT00155207_53_T33	GENE	52	52	et
NCT0015520753	NCT00155207_53_T34	GENE	56	56	et
NCT0015520753	NCT00155207_53_T35	GENE	60	60	et
NCT0015520753	NCT00155207_53_T36	GENE	64	64	et
NCT0015520753	NCT00155207_53_T37	GENE	70	70	et
NCT0015520753	NCT00155207_53_T38	GENE	75	75	et
NCT0015520753	NCT00155207_53_T39	GENE	79	79	et
NCT0015520753	NCT00155207_53_T40	GENE	85	85	et
NCT0015520753	NCT00155207_53_T41	GENE	90	90	et
NCT0015520753	NCT00155207_53_T42	GENE	96	96	et
NCT0015520753	NCT00155207_53_T43	GENE	102	102	et
NCT0015520753	NCT00155207_53_T44	GENE	106	106	et
NCT0015520753	NCT00155207_53_T45	GENE	112	112	et
NCT0015520753	NCT00155207_53_T46	GENE	4	4	RGS4
NCT0015520753	NCT00155207_53_T47	GENE	35	35	TNFa
NCT0015520753	NCT00155207_53_T48	GENE	67	67	PPP3CC
NCT0015520753	NCT00155207_53_T49	GENE	10	10	MRDS1
NCT0015520755	NCT00155207_55_T0	GENE	33	33	al
NCT0015520755	NCT00155207_55_T1	GENE	29	29	CACNG2
NCT0015520755	NCT00155207_55_T2	GENE	32	32	et
NCT0015520757	NCT00155207_57_T0	GENE	9	9	al
NCT0015520757	NCT00155207_57_T1	GENE	54	54	al
NCT0015520757	NCT00155207_57_T2	GENE	58	58	al
NCT0015520757	NCT00155207_57_T3	GENE	8	8	et
NCT0015520757	NCT00155207_57_T4	GENE	13	13	et
NCT0015520757	NCT00155207_57_T5	GENE	53	53	et
NCT0015520757	NCT00155207_57_T6	GENE	57	57	et
NCT0015520762	NCT00155207_62_T0	PHENOTYPE	10	10	symptoms
NCT0015520762	NCT00155207_62_T1	GENE	4	4	had
NCT0015520762	NCT00155207_62_T2	GENE	13	13	al
NCT0015520762	NCT00155207_62_T3	GENE	17	17	al
NCT0015520762	NCT00155207_62_T4	GENE	25	25	al
NCT0015520762	NCT00155207_62_T5	GENE	29	29	al
NCT0015520762	NCT00155207_62_T6	GENE	33	33	al
NCT0015520762	NCT00155207_62_T7	GENE	37	37	al
NCT0015520762	NCT00155207_62_T8	GENE	41	41	al
NCT0015520762	NCT00155207_62_T9	GENE	50	50	al
NCT0015520762	NCT00155207_62_T10	GENE	54	54	al
NCT0015520762	NCT00155207_62_T11	GENE	12	12	et
NCT0015520762	NCT00155207_62_T12	GENE	16	16	et
NCT0015520762	NCT00155207_62_T13	GENE	24	24	et
NCT0015520762	NCT00155207_62_T14	GENE	28	28	et
NCT0015520762	NCT00155207_62_T15	GENE	32	32	et
NCT0015520762	NCT00155207_62_T16	GENE	36	36	et
NCT0015520762	NCT00155207_62_T17	GENE	40	40	et
NCT0015520762	NCT00155207_62_T18	GENE	49	49	et
NCT0015520762	NCT00155207_62_T19	GENE	53	53	et
NCT0015520771	NCT00155207_71_T0	COMPOUND	10	10	niacin
NCT0015520771	NCT00155207_71_T1	GENE	14	14	al
NCT0015520771	NCT00155207_71_T2	GENE	18	18	al
NCT0015520771	NCT00155207_71_T3	GENE	13	13	et
NCT0015520771	NCT00155207_71_T4	GENE	17	17	et
NCT0015520772	NCT00155207_72_T0	GENE	10	10	HM74
NCT0015520772	NCT00155207_72_T1	GENE	15	15	HM74a
NCT0015520772	NCT00155207_72_T2	COMPOUND	1	1	niacin
NCT0015520772	NCT00155207_72_T3	GENE	23	23	al
NCT0015520772	NCT00155207_72_T4	GENE	27	27	al
NCT0015520772	NCT00155207_72_T5	GENE	21	21	Wise
NCT0015520772	NCT00155207_72_T6	GENE	22	22	et
NCT0015520772	NCT00155207_72_T7	GENE	26	26	et
NCT0015520772	NCT00155207_72_T8	GENE	25	25	Soga
NCT0015520772	NCT00155207_72_T9	GENE	13	13	receptor
NCT0015520772	NCT00155207_72_T10	GENE	18	18	receptor
NCT0015520772	NCT00155207_72_T11	GENE	35	35	GPCR
NCT0015520772	NCT00155207_72_T12	GENE	7	9	nicotinic acid receptor
NCT0015520773	NCT00155207_73_T0	CELL	7	7	lymphocytes
NCT0015520773	NCT00155207_73_T1	GENE	10	10	al
NCT0015520773	NCT00155207_73_T2	GENE	8	8	Wise
NCT0015520773	NCT00155207_73_T3	GENE	9	9	et
NCT0015520780	NCT00155207_80_T0	CELL	19	19	chromosome
NCT0015520780	NCT00155207_80_T1	PHENOTYPE	15	15	inhibition
NCT0015520780	NCT00155207_80_T2	GENE	14	14	P50
NCT0015520780	NCT00155207_80_T3	GENE	23	23	al
NCT0015520780	NCT00155207_80_T4	GENE	3	3	has
NCT0015520780	NCT00155207_80_T5	GENE	22	22	et
NCT0015520781	NCT00155207_81_T0	GENE	18	18	lod
NCT0015520781	NCT00155207_81_T1	CELL	12	12	chromosome
NCT0015520781	NCT00155207_81_T2	GENE	24	24	al
NCT0015520781	NCT00155207_81_T3	PHENOTYPE	7	7	schizophrenia
NCT0015520781	NCT00155207_81_T4	GENE	8	8	has
NCT0015520781	NCT00155207_81_T5	PHENOTYPE	5	5	dysfunction
NCT0015520781	NCT00155207_81_T6	GENE	23	23	et
NCT0015520784	NCT00155207_84_T0	PHENOTYPE	2	2	Heterogeneity
NCT0015520784	NCT00155207_84_T1	PHENOTYPE	5	6	clinical heterogeneity
NCT0015520786	NCT00155207_86_T0	GENE	3	3	had
NCT0015520791	NCT00155207_91_T0	COMPOUND	10	10	G72
NCT0015520791	NCT00155207_91_T1	GENE	1	1	DAAO
NCT0015520791	NCT00155207_91_T2	GENE	17	17	al
NCT0015520791	NCT00155207_91_T3	GENE	16	16	et
NCT0015520791	NCT00155207_91_T4	GENE	2	3	D-amino-acid oxidase
NCT0015520791	NCT00155207_91_T5	GENE	11	14	D-amino acid oxidase activator
NCT0015520793	NCT00155207_93_T0	COMPOUND	2	2	proline
NCT0015520793	NCT00155207_93_T1	COMPOUND	8	8	proline
NCT0015520793	NCT00155207_93_T2	COMPOUND	19	19	proline
NCT0015520793	NCT00155207_93_T3	GENE	28	28	al
NCT0015520793	NCT00155207_93_T4	GENE	1	1	PRODH
NCT0015520793	NCT00155207_93_T5	GENE	3	3	dehydrogenase
NCT0015520793	NCT00155207_93_T6	GENE	27	27	et
NCT0015520793	NCT00155207_93_T7	GENE	11	11	P5C
NCT0015520794	NCT00155207_94_T0	PHENOTYPE	8	8	hyperprolinemia
NCT0015520794	NCT00155207_94_T1	PHENOTYPE	0	0	Deletion
NCT0015520794	NCT00155207_94_T2	GENE	4	4	has
NCT0015520794	NCT00155207_94_T3	GENE	11	11	al
NCT0015520795	NCT00155207_95_T0	CELL	9	9	cells
NCT0015520795	NCT00155207_95_T1	PHENOTYPE	20	20	schizophrenia
NCT0015520795	NCT00155207_95_T2	PHENOTYPE	17	18	pathological process
NCT001552202	NCT00155220_2_T0	PHENOTYPE	5	6	breast carcinoma
NCT001552204	NCT00155220_4_T0	ORGAN	14	14	lymph
NCT001552204	NCT00155220_4_T1	PHENOTYPE	4	4	lymphedema
NCT001552204	NCT00155220_4_T2	GENE	9	9	DLT
NCT001552205	NCT00155220_5_T0	PHENOTYPE	7	7	lymphedema
NCT0015522011	NCT00155220_11_T0	PHENOTYPE	28	28	lymphedema
NCT0015522011	NCT00155220_11_T1	GENE	13	13	DLT
NCT0015522011	NCT00155220_11_T2	GENE	15	15	DLT
NCT0015522011	NCT00155220_11_T3	GENE	22	22	DLT
NCT0015522013	NCT00155220_13_T0	PHENOTYPE	4	4	lymphedema
NCT0015522020	NCT00155220_20_T0	PHENOTYPE	1	3	breast cancer lymphedema
NCT0015522020	NCT00155220_20_T1	PHENOTYPE	0	2	Female breast cancer
NCT0015522021	NCT00155220_21_T0	PHENOTYPE	1	1	lymphedema
NCT0015522021	NCT00155220_21_T1	PHENOTYPE	0	0	Unilateral
NCT0015522022	NCT00155220_22_T0	PHENOTYPE	0	0	Lymphedema
NCT0015522023	NCT00155220_23_T0	PHENOTYPE	3	3	lymphedema
NCT0015522024	NCT00155220_24_T0	GENE	8	8	cm
NCT0015522026	NCT00155220_26_T0	PHENOTYPE	7	7	adhesion
NCT0015522029	NCT00155220_29_T0	ORGAN	1	2	upper extremity
NCT0015522030	NCT00155220_30_T0	PHENOTYPE	1	1	diseases
NCT001552331	NCT00155233_1_T0	GENE	4	4	receptor
NCT001552331	NCT00155233_1_T1	GENE	8	8	receptor
NCT001552331	NCT00155233_1_T2	GENE	3	3	mu
NCT001552331	NCT00155233_1_T3	GENE	7	7	kappa
NCT001552333	NCT00155233_3_T0	GENE	4	4	receptor
NCT001552333	NCT00155233_3_T1	GENE	8	8	receptor
NCT001552333	NCT00155233_3_T2	GENE	3	3	mu
NCT001552333	NCT00155233_3_T3	GENE	7	7	kappa
NCT001552334	NCT00155233_4_T0	COMPOUND	9	9	nalbuphine
NCT001552334	NCT00155233_4_T1	COMPOUND	11	11	morphine
NCT001552337	NCT00155233_7_T0	GENE	8	8	III
NCT001552337	NCT00155233_7_T1	GENE	3	3	ASA
NCT001552338	NCT00155233_8_T0	GENE	3	3	abdominal
NCT001552338	NCT00155233_8_T1	PHENOTYPE	9	10	ovarian tumor
NCT001552461	NCT00155246_1_T0	COMPOUND	27	27	aldosterone
NCT001552461	NCT00155246_1_T1	PHENOTYPE	12	12	proteinuria
NCT001552461	NCT00155246_1_T2	COMPOUND	2	2	pentoxifylline
NCT001552461	NCT00155246_1_T3	BIOLOGICAL_PROCESS	14	15	glomerular filtration
NCT001552461	NCT00155246_1_T4	PHENOTYPE	18	19	tumor necrosis
NCT001552462	NCT00155246_2_T0	COMPOUND	1	1	pentoxifylline
NCT001552591	NCT00155259_1_T0	PHENOTYPE	5	5	toxicity
NCT001552591	NCT00155259_1_T1	PHENOTYPE	1	1	secondary
NCT001552591	NCT00155259_1_T2	PHENOTYPE	6	6	progression
NCT001552593	NCT00155259_3_T0	PHENOTYPE	13	14	metastatic disease
NCT001552593	NCT00155259_3_T1	PHENOTYPE	22	23	breast cancer
NCT001552595	NCT00155259_5_T0	PHENOTYPE	13	13	initiation
NCT001552595	NCT00155259_5_T1	PHENOTYPE	3	3	strategies
NCT001552595	NCT00155259_5_T2	PHENOTYPE	29	30	lymphatic metastases
NCT001552595	NCT00155259_5_T3	PHENOTYPE	25	26	primary tumor
NCT001552598	NCT00155259_8_T0	COMPOUND	7	7	capecitabine
NCT001552598	NCT00155259_8_T1	COMPOUND	5	5	docetaxel
NCT001552598	NCT00155259_8_T2	GENE	2	2	has
NCT001552598	NCT00155259_8_T3	PHENOTYPE	15	17	metastatic breast cancer
NCT0015525910	NCT00155259_10_T0	COMPOUND	10	10	capecitabine
NCT0015525910	NCT00155259_10_T1	COMPOUND	6	6	docetaxel
NCT0015525910	NCT00155259_10_T2	COMPOUND	8	8	cisplatin
NCT0015525910	NCT00155259_10_T3	PHENOTYPE	17	18	breast cancer
NCT0015525913	NCT00155259_13_T0	PHENOTYPE	0	0	Tumor
NCT0015525913	NCT00155259_13_T1	GENE	4	4	cm
NCT0015525914	NCT00155259_14_T0	PHENOTYPE	17	17	ulceration
NCT0015525914	NCT00155259_14_T1	TISSUE	11	11	muscles
NCT0015525914	NCT00155259_14_T2	PHENOTYPE	16	16	edema
NCT0015525914	NCT00155259_14_T3	PHENOTYPE	20	20	nodules
NCT0015525914	NCT00155259_14_T4	PHENOTYPE	0	0	Tumor
NCT0015525914	NCT00155259_14_T5	ORGAN	5	5	ribs
NCT0015525914	NCT00155259_14_T6	ORGAN	3	4	chest wall
NCT0015525915	NCT00155259_15_T0	PHENOTYPE	2	3	inflammatory carcinoma
NCT001552722	NCT00155272_2_T0	COMPOUND	16	16	ethanol
NCT001552723	NCT00155272_3_T0	GENE	4	4	RT
NCT001552724	NCT00155272_4_T0	GENE	8	8	RT
NCT001552725	NCT00155272_5_T0	PHENOTYPE	10	11	tumor progression
NCT001552726	NCT00155272_6_T0	COMPOUND	25	25	thalidomide
NCT001552726	NCT00155272_6_T1	COMPOUND	31	31	thalidomide
NCT001552726	NCT00155272_6_T2	GENE	3	3	MRI
NCT001552726	NCT00155272_6_T3	PHENOTYPE	18	18	tumor
NCT001552729	NCT00155272_9_T0	PHENOTYPE	4	4	toxicity
NCT0015527217	NCT00155272_17_T0	GENE	0	0	1/6
NCT0015527221	NCT00155272_21_T0	COMPOUND	0	0	1_10
NCT0015527221	NCT00155272_21_T1	PHENOTYPE	8	10	negative pregnancy test
NCT0015527223	NCT00155272_23_T0	PHENOTYPE	4	4	metastasis
NCT0015527225	NCT00155272_25_T0	GENE	6	6	abdominal
NCT0015527227	NCT00155272_27_T0	COMPOUND	4	4	thalidomide
NCT0015527229	NCT00155272_29_T0	GENE	2	2	had
NCT0015527231	NCT00155272_31_T0	COMPOUND	2	2	NCI
NCT0015527231	NCT00155272_31_T1	PHENOTYPE	7	8	peripheral neuropathy
NCT0015527233	NCT00155272_33_T0	PHENOTYPE	4	4	diseases
NCT001553112	NCT00155311_2_T0	ORGAN	9	10	third molars
NCT001553115	NCT00155311_5_T0	PHENOTYPE	6	6	periodontitis
NCT001553115	NCT00155311_5_T1	PHENOTYPE	3	4	dental caries
NCT001553117	NCT00155311_7_T0	BIOLOGICAL_PROCESS	5	6	bone resorption
NCT001553118	NCT00155311_8_T0	BIOLOGICAL_PROCESS	0	1	Bone resorption
NCT001553119	NCT00155311_9_T0	PHENOTYPE	6	6	initiation
NCT001553119	NCT00155311_9_T1	CELL	0	0	Osteoblasts
NCT001553119	NCT00155311_9_T2	BIOLOGICAL_PROCESS	8	9	bone resorption
NCT0015531113	NCT00155311_13_T0	ORGAN	9	10	third molars
NCT001553241	NCT00155324_1_T0	TISSUE	4	4	fascia
NCT001553502	NCT00155350_2_T0	GENE	9	9	insulin
NCT001553502	NCT00155350_2_T1	PHENOTYPE	22	23	myocardial infarction
NCT001553505	NCT00155350_5_T0	PHENOTYPE	9	9	plaques
NCT0015535014	NCT00155350_14_T0	PHENOTYPE	3	3	progression
NCT0015535014	NCT00155350_14_T1	PHENOTYPE	5	6	coronary atherosclerosis
NCT0015535018	NCT00155350_18_T0	PHENOTYPE	9	9	plaque
NCT0015535018	NCT00155350_18_T1	PHENOTYPE	11	11	plaque
NCT0015535018	NCT00155350_18_T2	COMPOUND	25	25	calcium
NCT0015535019	NCT00155350_19_T0	PHENOTYPE	23	23	homeostatic
NCT0015535019	NCT00155350_19_T1	COMPOUND	9	9	calcium
NCT0015535019	NCT00155350_19_T2	PHENOTYPE	1	1	secondary
NCT0015535019	NCT00155350_19_T3	ORGAN	21	21	plasma
NCT0015535019	NCT00155350_19_T4	PHENOTYPE	44	45	myocardial infarction
NCT0015535019	NCT00155350_19_T5	ORGAN	14	15	coronary artery
NCT0015535020	NCT00155350_20_T0	GENE	14	14	insulin
NCT0015535020	NCT00155350_20_T1	PHENOTYPE	21	21	plaques
NCT0015535020	NCT00155350_20_T2	COMPOUND	15	15	sensitizer
NCT0015535021	NCT00155350_21_T0	PHENOTYPE	5	5	insights
NCT0015535021	NCT00155350_21_T1	PHENOTYPE	11	11	plaques
NCT0015535021	NCT00155350_21_T2	ORGAN	22	23	coronary arteries
NCT001553631	NCT00155363_1_T0	GENE	1	1	has
NCT001553632	NCT00155363_2_T0	PHENOTYPE	19	19	homeostatic
NCT001553632	NCT00155363_2_T1	ORGAN	10	10	plasma
NCT001553632	NCT00155363_2_T2	ORGAN	15	15	serum
NCT001553632	NCT00155363_2_T3	GENE	11	11	leptin
NCT001553632	NCT00155363_2_T4	PHENOTYPE	13	14	insulin levels
NCT001553633	NCT00155363_3_T0	GENE	9	9	adiponectin
NCT001553633	NCT00155363_3_T1	PHENOTYPE	7	8	insulin sensitivity
NCT001553633	NCT00155363_3_T2	PHENOTYPE	6	7	increasing insulin
NCT001553634	NCT00155363_4_T0	PHENOTYPE	3	3	ESRD
NCT001553635	NCT00155363_5_T0	GENE	11	11	had
NCT001553637	NCT00155363_7_T0	GENE	3	3	has
NCT001553638	NCT00155363_8_T0	GENE	7	7	adiponectin
NCT001553638	NCT00155363_8_T1	GENE	23	23	adiponectin
NCT001553638	NCT00155363_8_T2	ORGAN	6	6	plasma
NCT001553638	NCT00155363_8_T3	ORGAN	22	22	plasma
NCT001553639	NCT00155363_9_T0	GENE	16	16	adiponectin
NCT001553639	NCT00155363_9_T1	ORGAN	15	15	plasma
NCT001553639	NCT00155363_9_T2	ORGAN	22	22	serum
NCT0015536315	NCT00155363_15_T0	ORGAN	0	0	Plasma
NCT0015536315	NCT00155363_15_T1	GENE	1	1	adiponectin
NCT0015536315	NCT00155363_15_T2	PHENOTYPE	20	20	homeostatic
NCT0015536315	NCT00155363_15_T3	GENE	27	27	Soc
NCT0015536315	NCT00155363_15_T4	GENE	12	12	leptin
NCT0015536315	NCT00155363_15_T5	GENE	32	32	Sci
NCT0015536315	NCT00155363_15_T6	PHENOTYPE	41	41	Diabetes
NCT0015536315	NCT00155363_15_T7	ORGAN	11	11	plasma
NCT0015536315	NCT00155363_15_T8	ORGAN	16	16	serum
NCT0015536315	NCT00155363_15_T9	PHENOTYPE	14	15	insulin levels
NCT0015536316	NCT00155363_16_T0	GENE	9	9	adiponectin
NCT0015536316	NCT00155363_16_T1	PHENOTYPE	7	8	insulin sensitivity
NCT0015536316	NCT00155363_16_T2	PHENOTYPE	6	7	increasing insulin
NCT0015536318	NCT00155363_18_T0	PHENOTYPE	11	11	Diabetes
NCT0015536318	NCT00155363_18_T1	PHENOTYPE	9	10	insulin sensitivity
NCT0015536321	NCT00155363_21_T0	GENE	19	19	Int
NCT0015536321	NCT00155363_21_T1	ORGAN	18	18	Kidney
NCT0015536324	NCT00155363_24_T0	GENE	22	22	Soc
NCT0015536324	NCT00155363_24_T1	GENE	1	1	has
NCT0015536324	NCT00155363_24_T2	ORGAN	30	30	Kidney
NCT0015536324	NCT00155363_24_T3	PHENOTYPE	31	31	Dis
NCT0015536325	NCT00155363_25_T0	GENE	4	4	adiponectin
NCT0015536326	NCT00155363_26_T0	GENE	10	10	adiponectin
NCT0015536327	NCT00155363_27_T0	GENE	8	8	CRP
NCT0015536327	NCT00155363_27_T1	COMPOUND	9	9	homocystine
NCT0015536327	NCT00155363_27_T2	GENE	10	10	insulin
NCT0015536328	NCT00155363_28_T0	GENE	11	11	secreted
NCT0015536328	NCT00155363_28_T1	TISSUE	2	3	adipose tissue
NCT0015536328	NCT00155363_28_T2	TISSUE	13	14	adipose tissue
NCT0015536328	NCT00155363_28_T3	PHENOTYPE	18	19	insulin resistance
NCT0015536330	NCT00155363_30_T0	GENE	4	4	adiponectin
NCT0015536332	NCT00155363_32_T0	PHENOTYPE	8	8	ESRD
NCT0015536332	NCT00155363_32_T1	GENE	6	6	adiponectin
NCT0015536332	NCT00155363_32_T2	PHENOTYPE	14	14	inflammation
NCT0015536336	NCT00155363_36_T0	GENE	7	7	CRP
NCT0015536336	NCT00155363_36_T1	GENE	16	16	adiponectin
NCT0015536336	NCT00155363_36_T2	COMPOUND	8	8	homocystine
NCT0015536336	NCT00155363_36_T3	GENE	9	9	insulin
NCT0015536338	NCT00155363_38_T0	GENE	9	9	adiponectin
NCT001553761	NCT00155376_1_T0	GENE	19	19	glucagon
NCT001553761	NCT00155376_1_T1	COMPOUND	17	17	morphine
NCT001553763	NCT00155376_3_T0	GENE	19	19	glucagon
NCT001553763	NCT00155376_3_T1	COMPOUND	17	17	morphine
NCT001553895	NCT00155389_5_T0	PHENOTYPE	9	9	carcinogenesis
NCT001553895	NCT00155389_5_T1	PHENOTYPE	7	8	gastric cancer
NCT001553896	NCT00155389_6_T0	PHENOTYPE	5	6	gastric cancer
NCT001553898	NCT00155389_8_T0	COMPOUND	23	23	amoxicillin
NCT001553898	NCT00155389_8_T1	COMPOUND	19	19	esomeprazole
NCT001553898	NCT00155389_8_T2	COMPOUND	28	28	levofloxacin
NCT0015538911	NCT00155389_11_T0	PHENOTYPE	18	18	strategies
NCT0015538911	NCT00155389_11_T1	GENE	2	2	has
NCT0015538914	NCT00155389_14_T0	PHENOTYPE	43	44	advanced cancer
NCT0015538915	NCT00155389_15_T0	PHENOTYPE	15	15	premalignant
NCT0015538915	NCT00155389_15_T1	PHENOTYPE	6	6	strains
NCT0015538918	NCT00155389_18_T0	PHENOTYPE	8	8	premalignant
NCT0015538923	NCT00155389_23_T0	PHENOTYPE	6	6	premalignant
NCT0015538923	NCT00155389_23_T1	PHENOTYPE	7	8	gastric lesion
NCT0015538931	NCT00155389_31_T0	PHENOTYPE	3	4	gastric cancer
NCT001554151	NCT00155415_1_T0	PHENOTYPE	12	13	colorectal cancer
NCT001554154	NCT00155415_4_T0	GENE	11	11	bowel
NCT001554154	NCT00155415_4_T1	ORGAN	14	14	colon
NCT001554154	NCT00155415_4_T2	ORGAN	25	25	colon
NCT001554154	NCT00155415_4_T3	COMPOUND	4	5	polyethylene glycol
NCT001554155	NCT00155415_5_T0	PHENOTYPE	24	24	ingested
NCT001554155	NCT00155415_5_T1	PHENOTYPE	3	3	ingesting
NCT001554155	NCT00155415_5_T2	PHENOTYPE	11	11	ingest
NCT001554155	NCT00155415_5_T3	PHENOTYPE	29	29	ingest
NCT001554158	NCT00155415_8_T0	ORGAN	14	14	colon
NCT001554159	NCT00155415_9_T0	ORGAN	11	11	colon
NCT001554159	NCT00155415_9_T1	ORGAN	17	17	colon
NCT0015541510	NCT00155415_10_T0	ORGAN	9	9	colon
NCT0015541510	NCT00155415_10_T1	PHENOTYPE	10	10	neoplasia
NCT0015541516	NCT00155415_16_T0	PHENOTYPE	13	14	colorectal cancer
NCT0015541519	NCT00155415_19_T0	GENE	11	11	bowel
NCT0015541519	NCT00155415_19_T1	ORGAN	14	14	colon
NCT0015541519	NCT00155415_19_T2	ORGAN	25	25	colon
NCT0015541519	NCT00155415_19_T3	COMPOUND	4	5	polyethylene glycol
NCT0015541520	NCT00155415_20_T0	PHENOTYPE	24	24	ingested
NCT0015541520	NCT00155415_20_T1	PHENOTYPE	3	3	ingesting
NCT0015541520	NCT00155415_20_T2	PHENOTYPE	11	11	ingest
NCT0015541520	NCT00155415_20_T3	PHENOTYPE	29	29	ingest
NCT0015541523	NCT00155415_23_T0	ORGAN	14	14	colon
NCT0015541524	NCT00155415_24_T0	ORGAN	11	11	colon
NCT0015541524	NCT00155415_24_T1	ORGAN	17	17	colon
NCT0015541525	NCT00155415_25_T0	ORGAN	9	9	colon
NCT0015541525	NCT00155415_25_T1	PHENOTYPE	10	10	neoplasia
NCT001554411	NCT00155441_1_T0	PHENOTYPE	8	8	insomnia
NCT001554413	NCT00155441_3_T0	PHENOTYPE	13	13	chronic
NCT001554413	NCT00155441_3_T1	PHENOTYPE	10	11	sleep disturbance
NCT001554416	NCT00155441_6_T0	PHENOTYPE	8	8	insomnia
NCT001554417	NCT00155441_7_T0	PHENOTYPE	18	18	alcoholism
NCT001554417	NCT00155441_7_T1	GENE	1	1	has
NCT001554417	NCT00155441_7_T2	PHENOTYPE	12	13	chronic insomnia
NCT001554419	NCT00155441_9_T0	PHENOTYPE	16	16	chronic
NCT001554419	NCT00155441_9_T1	PHENOTYPE	13	14	sleep disturbance
NCT001554542	NCT00155454_2_T0	PHENOTYPE	1	1	hemorrhage
NCT001554543	NCT00155454_3_T0	PHENOTYPE	1	1	complication
NCT001554544	NCT00155454_4_T0	PHENOTYPE	3	3	bleeding
NCT001554545	NCT00155454_5_T0	GENE	30	30	clot
NCT001554545	NCT00155454_5_T1	TISSUE	44	44	tissues
NCT001554545	NCT00155454_5_T2	PHENOTYPE	4	4	proliferation
NCT001554545	NCT00155454_5_T3	PHENOTYPE	29	29	lysed
NCT001554545	NCT00155454_5_T4	PHENOTYPE	20	20	recurrent
NCT001554545	NCT00155454_5_T5	PHENOTYPE	26	26	hemorrhage
NCT001554545	NCT00155454_5_T6	PHENOTYPE	21	22	vitreous hemorrhage
NCT001554545	NCT00155454_5_T7	ORGAN	36	37	retinal vessels
NCT001554546	NCT00155454_6_T0	PHENOTYPE	12	13	vitreous hemorrhage
NCT001554547	NCT00155454_7_T0	PHENOTYPE	4	4	peripheral
NCT001554547	NCT00155454_7_T1	PHENOTYPE	22	22	proliferation
NCT001554547	NCT00155454_7_T2	PHENOTYPE	34	34	recurrent
NCT001554547	NCT00155454_7_T3	PHENOTYPE	35	36	vitreous hemorrhage
NCT001554548	NCT00155454_8_T0	PHENOTYPE	6	7	vitreous hemorrhage
NCT0015545413	NCT00155454_13_T0	PHENOTYPE	14	14	complications
NCT0015545413	NCT00155454_13_T1	PHENOTYPE	16	16	proliferative
NCT0015545413	NCT00155454_13_T2	PHENOTYPE	17	18	diabetic retinopathy
NCT0015545415	NCT00155454_15_T0	PHENOTYPE	31	31	peripheral
NCT0015545415	NCT00155454_15_T1	PHENOTYPE	40	40	peripheral
NCT0015545415	NCT00155454_15_T2	TISSUE	6	6	tissues
NCT0015545415	NCT00155454_15_T3	PHENOTYPE	46	46	spots
NCT0015545415	NCT00155454_15_T4	PHENOTYPE	55	55	spots
NCT0015545415	NCT00155454_15_T5	PHENOTYPE	26	27	blood clots
NCT0015545416	NCT00155454_16_T0	PHENOTYPE	4	5	retinal detachment
NCT0015545416	NCT00155454_16_T1	PHENOTYPE	30	31	retinal detachment
NCT0015545417	NCT00155454_17_T0	PHENOTYPE	17	17	waking
NCT0015545425	NCT00155454_25_T0	PHENOTYPE	10	10	attachment
NCT0015545425	NCT00155454_25_T1	GENE	2	2	had
NCT0015545425	NCT00155454_25_T2	COMPOUND	3	4	silicone oil
NCT001554930	NCT00155493_0_T0	GENE	12	12	Fat
NCT001554930	NCT00155493_0_T1	GENE	14	14	Fat
NCT001554932	NCT00155493_2_T0	BIOLOGICAL_PROCESS	17	17	aging
NCT001554932	NCT00155493_2_T1	GENE	11	11	has
NCT001554932	NCT00155493_2_T2	TISSUE	0	1	Adipose tissue
NCT001554933	NCT00155493_3_T0	CELL	24	24	cells
NCT001554933	NCT00155493_3_T1	PHENOTYPE	15	15	proliferation
NCT001554933	NCT00155493_3_T2	PHENOTYPE	3	3	atrophy
NCT001554933	NCT00155493_3_T3	GENE	22	22	adipose
NCT001554933	NCT00155493_3_T4	TISSUE	7	8	adipose tissue
NCT001554935	NCT00155493_5_T0	GENE	4	4	has
NCT001554938	NCT00155493_8_T0	PHENOTYPE	20	20	proliferation
NCT001554938	NCT00155493_8_T1	TISSUE	16	17	adipose tissue
NCT001554939	NCT00155493_9_T0	GENE	1	1	adipose
NCT0015549310	NCT00155493_10_T0	CELL	10	10	cells
NCT0015549310	NCT00155493_10_T1	PHENOTYPE	18	18	proliferation
NCT0015549311	NCT00155493_11_T0	GENE	20	20	GPDH
NCT0015549311	NCT00155493_11_T1	GENE	18	19	Glycerol-3-phosphate dehydrogenase
NCT0015549312	NCT00155493_12_T0	PHENOTYPE	2	2	regression
NCT0015549313	NCT00155493_13_T0	GENE	24	24	ANOVA
NCT0015549313	NCT00155493_13_T1	GENE	6	6	had
NCT0015549313	NCT00155493_13_T2	PHENOTYPE	8	9	periorbital fat
NCT001555061	NCT00155506_1_T0	PHENOTYPE	7	7	schizophrenia
NCT001555061	NCT00155506_1_T1	GENE	8	8	has
NCT001555063	NCT00155506_3_T0	PHENOTYPE	6	6	schizophrenia
NCT001555067	NCT00155506_7_T0	GENE	7	7	PI
NCT001555067	NCT00155506_7_T1	PHENOTYPE	21	21	schizophrenia
NCT001555069	NCT00155506_9_T0	GENE	2	2	PI
NCT0015550620	NCT00155506_20_T0	GENE	23	23	II
NCT0015550620	NCT00155506_20_T1	GENE	28	28	II
NCT0015550620	NCT00155506_20_T2	GENE	20	20	KS
NCT0015550620	NCT00155506_20_T3	PHENOTYPE	39	39	schizophrenia
NCT0015550622	NCT00155506_22_T0	PHENOTYPE	9	9	schizophrenia
NCT0015550623	NCT00155506_23_T0	PHENOTYPE	3	3	schizophrenia
NCT0015550623	NCT00155506_23_T1	PHENOTYPE	23	23	schizophrenia
NCT0015550625	NCT00155506_25_T0	PHENOTYPE	17	17	schizophrenia
NCT0015550626	NCT00155506_26_T0	PHENOTYPE	6	6	schizophrenia
NCT0015550629	NCT00155506_29_T0	CELL	14	14	chromosome
NCT0015550629	NCT00155506_29_T1	CELL	22	22	chromosome
NCT0015550629	NCT00155506_29_T2	PHENOTYPE	5	5	schizophrenia
NCT0015550630	NCT00155506_30_T0	CELL	4	4	chromosome
NCT0015550630	NCT00155506_30_T1	CELL	16	16	chromosome
NCT0015550632	NCT00155506_32_T0	COMPOUND	9	9	D4
NCT0015550632	NCT00155506_32_T1	GENE	10	10	D5
NCT0015550632	NCT00155506_32_T2	GENE	18	18	had
NCT0015550632	NCT00155506_32_T3	GENE	6	6	D1
NCT0015550632	NCT00155506_32_T4	COMPOUND	5	5	dopamine
NCT0015550632	NCT00155506_32_T5	GENE	7	7	D2
NCT0015550632	NCT00155506_32_T6	GENE	8	8	D3
NCT0015550632	NCT00155506_32_T7	GENE	15	16	Glutamate receptor
NCT0015550634	NCT00155506_34_T0	GENE	10	10	probable
NCT0015550634	NCT00155506_34_T1	PHENOTYPE	7	7	schizophrenia
NCT0015550635	NCT00155506_35_T0	PHENOTYPE	6	6	resolved
NCT0015550638	NCT00155506_38_T0	PHENOTYPE	56	57	internal control
NCT0015550639	NCT00155506_39_T0	PHENOTYPE	17	17	schizophrenia
NCT0015550641	NCT00155506_41_T0	GENE	25	25	NOTCH4
NCT0015550641	NCT00155506_41_T1	CELL	28	28	chromosome
NCT0015550641	NCT00155506_41_T2	PHENOTYPE	14	14	schizophrenia
NCT0015550641	NCT00155506_41_T3	GENE	6	6	has
NCT0015550642	NCT00155506_42_T0	PHENOTYPE	11	11	strategies
NCT0015550642	NCT00155506_42_T1	PHENOTYPE	19	19	schizophrenia
NCT0015550642	NCT00155506_42_T2	PHENOTYPE	29	29	schizophrenia
NCT0015550646	NCT00155506_46_T0	PHENOTYPE	10	10	schizophrenia
NCT0015550646	NCT00155506_46_T1	PHENOTYPE	35	35	dysfunction
NCT0015550647	NCT00155506_47_T0	GENE	15	15	CPT
NCT0015550647	NCT00155506_47_T1	PHENOTYPE	5	5	schizophrenia
NCT0015550647	NCT00155506_47_T2	PHENOTYPE	24	24	Sorting
NCT0015550647	NCT00155506_47_T3	PHENOTYPE	17	18	executive function
NCT0015550648	NCT00155506_48_T0	GENE	4	4	CPT
NCT0015550649	NCT00155506_49_T0	PHENOTYPE	2	2	vigilance
NCT0015550649	NCT00155506_49_T1	GENE	6	6	CPT
NCT0015550651	NCT00155506_51_T0	GENE	2	2	CPT
NCT0015550651	NCT00155506_51_T1	PHENOTYPE	30	30	schizophrenia
NCT0015550652	NCT00155506_52_T0	PHENOTYPE	28	28	symptoms
NCT0015550652	NCT00155506_52_T1	GENE	7	7	CPT
NCT0015550652	NCT00155506_52_T2	GENE	22	22	CPT
NCT0015550653	NCT00155506_53_T0	PHENOTYPE	17	17	symptoms
NCT0015550653	NCT00155506_53_T1	GENE	9	9	CPT
NCT0015550655	NCT00155506_55_T0	PHENOTYPE	10	10	schizophrenia
NCT0015550655	NCT00155506_55_T1	PHENOTYPE	19	20	cognitive deficits
NCT0015550657	NCT00155506_57_T0	PHENOTYPE	14	14	schizophrenia
NCT0015550657	NCT00155506_57_T1	PHENOTYPE	9	10	executive function
NCT0015550658	NCT00155506_58_T0	PHENOTYPE	10	10	schizophrenia
NCT0015550658	NCT00155506_58_T1	PHENOTYPE	21	21	schizophrenia
NCT0015550660	NCT00155506_60_T0	PHENOTYPE	7	7	Schizophrenia
NCT0015550660	NCT00155506_60_T1	PHENOTYPE	22	22	schizophrenia
NCT0015550660	NCT00155506_60_T2	PHENOTYPE	53	54	genetic alteration
NCT0015550660	NCT00155506_60_T3	PHENOTYPE	19	20	genetic heterogeneity
NCT0015550661	NCT00155506_61_T0	GENE	8	8	CPT
NCT0015550661	NCT00155506_61_T1	PHENOTYPE	18	18	schizophrenia
NCT0015550661	NCT00155506_61_T2	PHENOTYPE	3	4	attention deficits
NCT0015550663	NCT00155506_63_T0	PHENOTYPE	13	13	recurrence
NCT0015550663	NCT00155506_63_T1	GENE	23	23	CPT
NCT0015550663	NCT00155506_63_T2	GENE	31	31	CPT
NCT0015550664	NCT00155506_64_T0	PHENOTYPE	18	18	schizophrenia
NCT0015550664	NCT00155506_64_T1	PHENOTYPE	1	2	executive function
NCT0015550666	NCT00155506_66_T0	GENE	2	2	CPT
NCT0015550666	NCT00155506_66_T1	PHENOTYPE	10	10	schizophrenia
NCT0015550666	NCT00155506_66_T2	PHENOTYPE	33	33	schizophrenia
NCT0015550667	NCT00155506_67_T0	CELL	21	21	chromosome
NCT0015550667	NCT00155506_67_T1	PHENOTYPE	17	17	inhibition
NCT0015550667	NCT00155506_67_T2	GENE	16	16	P50
NCT0015550667	NCT00155506_67_T3	PHENOTYPE	13	13	schizophrenia
NCT0015550667	NCT00155506_67_T4	GENE	3	3	has
NCT0015550668	NCT00155506_68_T0	GENE	17	17	lod
NCT0015550668	NCT00155506_68_T1	CELL	28	28	chromosome
NCT0015550668	NCT00155506_68_T2	PHENOTYPE	7	7	inhibition
NCT0015550668	NCT00155506_68_T3	GENE	6	6	P50
NCT0015550668	NCT00155506_68_T4	PHENOTYPE	12	12	schizophrenia
NCT0015550669	NCT00155506_69_T0	GENE	14	14	lod
NCT0015550669	NCT00155506_69_T1	PHENOTYPE	5	5	schizophrenia
NCT0015550671	NCT00155506_71_T0	PHENOTYPE	6	6	schizophrenia
NCT0015550672	NCT00155506_72_T0	PHENOTYPE	23	23	schizophrenics
NCT0015550672	NCT00155506_72_T1	PHENOTYPE	13	13	schizophrenia
NCT0015550672	NCT00155506_72_T2	PHENOTYPE	18	18	schizophrenia
NCT0015550672	NCT00155506_72_T3	PHENOTYPE	44	44	schizophrenia
NCT0015550675	NCT00155506_75_T0	PHENOTYPE	2	2	Schizophrenia
NCT0015550675	NCT00155506_75_T1	PHENOTYPE	15	15	schizophrenia
NCT0015550675	NCT00155506_75_T2	GENE	8	8	has
NCT0015550676	NCT00155506_76_T0	GENE	15	15	sib
NCT0015550676	NCT00155506_76_T1	GENE	19	19	sib
NCT0015550679	NCT00155506_79_T0	PHENOTYPE	6	6	schizophrenia
NCT0015550680	NCT00155506_80_T0	PHENOTYPE	10	10	peripheral
NCT0015550680	NCT00155506_80_T1	CELL	12	12	cells
NCT0015550680	NCT00155506_80_T2	GENE	28	28	sib
NCT0015550682	NCT00155506_82_T0	CELL	5	5	cells
NCT0015550682	NCT00155506_82_T1	PHENOTYPE	3	3	transformed
NCT0015550688	NCT00155506_88_T0	GENE	12	12	SIS
NCT0015550689	NCT00155506_89_T0	GENE	4	4	PAS
NCT0015550689	NCT00155506_89_T1	PHENOTYPE	17	17	schizophrenia
NCT0015550689	NCT00155506_89_T2	PHENOTYPE	18	19	personality disorders
NCT0015550691	NCT00155506_91_T0	PHENOTYPE	8	8	Schizophrenia
NCT0015550691	NCT00155506_91_T1	PHENOTYPE	24	24	schizophrenia
NCT0015550691	NCT00155506_91_T2	GENE	25	25	has
NCT0015550696	NCT00155506_96_T0	PHENOTYPE	4	4	Schizophrenia
NCT0015550696	NCT00155506_96_T1	PHENOTYPE	10	10	schizophrenia
NCT0015550697	NCT00155506_97_T0	PHENOTYPE	9	9	focused
NCT0015550698	NCT00155506_98_T0	GENE	18	18	extended
NCT0015550699	NCT00155506_99_T0	GENE	12	12	probable
NCT0015550699	NCT00155506_99_T1	GENE	10	10	had
NCT0015550699	NCT00155506_99_T2	PHENOTYPE	15	15	schizophrenia
NCT0015550699	NCT00155506_99_T3	GENE	5	6	androgen receptor
NCT00155506100	NCT00155506_100_T0	GENE	8	8	al
NCT00155506100	NCT00155506_100_T1	GENE	7	7	et
NCT00155506101	NCT00155506_101_T0	GENE	0	0	Dr
NCT00155506102	NCT00155506_102_T0	GENE	46	46	had
NCT00155506102	NCT00155506_102_T1	PHENOTYPE	21	21	schizophrenia
NCT00155506102	NCT00155506_102_T2	PHENOTYPE	35	35	schizophrenia
NCT00155506102	NCT00155506_102_T3	PHENOTYPE	25	25	mutation
NCT00155506102	NCT00155506_102_T4	GENE	14	14	receptor
NCT00155506102	NCT00155506_102_T5	GENE	27	27	DRD2
NCT00155506102	NCT00155506_102_T6	GENE	13	13	DRD4
NCT00155506103	NCT00155506_103_T0	PHENOTYPE	10	10	Schizophrenia
NCT00155506103	NCT00155506_103_T1	GENE	7	7	al
NCT00155506103	NCT00155506_103_T2	GENE	18	18	Dr
NCT00155506103	NCT00155506_103_T3	GENE	30	30	Dr
NCT00155506103	NCT00155506_103_T4	GENE	6	6	et
NCT00155506104	NCT00155506_104_T0	CELL	8	8	chromosomes
NCT00155506105	NCT00155506_105_T0	CELL	14	14	chromosome
NCT00155506106	NCT00155506_106_T0	CELL	10	10	chromosome
NCT00155506106	NCT00155506_106_T1	PHENOTYPE	30	31	symptom clusters
NCT00155506106	NCT00155506_106_T2	GENE	5	6	5-HT2 receptor
NCT00155506107	NCT00155506_107_T0	CELL	7	7	chromosome
NCT00155506108	NCT00155506_108_T0	CELL	25	25	chromosome
NCT00155506108	NCT00155506_108_T1	CELL	28	28	chromosome
NCT00155506110	NCT00155506_110_T0	COMPOUND	14	14	D4
NCT00155506110	NCT00155506_110_T1	GENE	15	15	receptor
NCT00155506110	NCT00155506_110_T2	GENE	27	27	al
NCT00155506110	NCT00155506_110_T3	PHENOTYPE	24	24	schizophrenia
NCT00155506110	NCT00155506_110_T4	GENE	4	4	has
NCT00155506110	NCT00155506_110_T5	GENE	16	16	DRD4
NCT00155506110	NCT00155506_110_T6	GENE	26	26	et
NCT00155506111	NCT00155506_111_T0	PHENOTYPE	11	11	schizophrenia
NCT00155506111	NCT00155506_111_T1	GENE	4	6	cytosolic phospholipase A2
NCT00155506113	NCT00155506_113_T0	GENE	15	15	CPT
NCT00155506113	NCT00155506_113_T1	PHENOTYPE	5	5	Schizophrenia
NCT00155506113	NCT00155506_113_T2	PHENOTYPE	21	21	schizophrenia
NCT00155506114	NCT00155506_114_T0	GENE	12	12	CPT
NCT00155506114	NCT00155506_114_T1	PHENOTYPE	17	17	schizophrenia
NCT00155506114	NCT00155506_114_T2	PHENOTYPE	6	7	attention deficits
NCT00155506116	NCT00155506_116_T0	GENE	3	3	CPT
NCT00155506116	NCT00155506_116_T1	PHENOTYPE	10	10	schizophrenia
NCT00155506116	NCT00155506_116_T2	PHENOTYPE	22	23	psychotic symptoms
NCT00155506116	NCT00155506_116_T3	PHENOTYPE	32	33	psychotic symptoms
NCT00155506116	NCT00155506_116_T4	PHENOTYPE	42	44	major depressive disorder
NCT00155506117	NCT00155506_117_T0	GENE	4	4	CPT
NCT00155506117	NCT00155506_117_T1	PHENOTYPE	11	11	schizophrenia
NCT00155506117	NCT00155506_117_T2	PHENOTYPE	16	17	bipolar disorder
NCT00155506117	NCT00155506_117_T3	PHENOTYPE	22	23	major depression
NCT00155506118	NCT00155506_118_T0	GENE	4	4	CPT
NCT00155506118	NCT00155506_118_T1	PHENOTYPE	11	11	schizophrenia
NCT00155506122	NCT00155506_122_T0	PHENOTYPE	25	25	Center
NCT00155506124	NCT00155506_124_T0	PHENOTYPE	7	7	recruitment
NCT00155506126	NCT00155506_126_T0	PHENOTYPE	8	8	schizophrenia
NCT00155506129	NCT00155506_129_T0	PHENOTYPE	28	28	Initiative
NCT00155506130	NCT00155506_130_T0	PHENOTYPE	21	21	symptoms
NCT00155506130	NCT00155506_130_T1	PHENOTYPE	17	18	substance abuse
NCT00155506130	NCT00155506_130_T2	PHENOTYPE	8	10	course of illness
NCT00155506131	NCT00155506_131_T0	PHENOTYPE	12	12	psychoses
NCT00155506131	NCT00155506_131_T1	PHENOTYPE	8	8	schizophrenia
NCT00155506131	NCT00155506_131_T2	PHENOTYPE	13	14	schizoaffective disorders
NCT00155506131	NCT00155506_131_T3	PHENOTYPE	16	18	psychotic mood disorders
NCT00155506135	NCT00155506_135_T0	PHENOTYPE	19	19	Symptoms
NCT00155506136	NCT00155506_136_T0	GENE	4	4	II
NCT00155506139	NCT00155506_139_T0	PHENOTYPE	10	11	psychiatric illness
NCT00155506143	NCT00155506_143_T0	PHENOTYPE	20	20	psychosis
NCT00155506143	NCT00155506_143_T1	PHENOTYPE	17	17	mania
NCT00155506143	NCT00155506_143_T2	PHENOTYPE	18	19	substance abuse
NCT00155506143	NCT00155506_143_T3	PHENOTYPE	23	25	schizotypal personality disorder
NCT00155506155	NCT00155506_155_T0	PHENOTYPE	13	14	psychiatric disorders
NCT00155506158	NCT00155506_158_T0	PHENOTYPE	3	3	familiarity
NCT00155506161	NCT00155506_161_T0	GENE	14	14	SIS
NCT00155506162	NCT00155506_162_T0	GENE	1	1	SIS
NCT00155506162	NCT00155506_162_T1	PHENOTYPE	10	12	schizotypal personality disorder
NCT00155506165	NCT00155506_165_T0	PHENOTYPE	11	11	schizophrenia
NCT00155506167	NCT00155506_167_T0	GENE	6	6	CPT
NCT00155506168	NCT00155506_168_T0	PHENOTYPE	5	5	Sorting
NCT00155506168	NCT00155506_168_T1	PHENOTYPE	1	2	executive functions
NCT00155506171	NCT00155506_171_T0	GENE	13	13	span
NCT00155506178	NCT00155506_178_T0	GENE	4	4	has
NCT00155506178	NCT00155506_178_T1	GENE	6	6	lines
NCT00155506179	NCT00155506_179_T0	GENE	23	23	purple
NCT00155506179	NCT00155506_179_T1	GENE	11	11	ml
NCT00155506180	NCT00155506_180_T0	GENE	4	4	purple
NCT00155506195	NCT00155506_195_T0	GENE	7	7	disc
NCT00155506198	NCT00155506_198_T0	PHENOTYPE	20	20	desires
NCT00155506207	NCT00155506_207_T0	PHENOTYPE	8	8	discomfort
NCT001555190	NCT00155519_0_T0	PHENOTYPE	6	6	Schizophrenia
NCT001555192	NCT00155519_2_T0	PHENOTYPE	14	14	schizophrenia
NCT001555193	NCT00155519_3_T0	PHENOTYPE	9	9	impairment
NCT001555193	NCT00155519_3_T1	PHENOTYPE	0	0	Schizophrenia
NCT001555194	NCT00155519_4_T0	PHENOTYPE	15	15	schizophrenia
NCT001555194	NCT00155519_4_T1	PHENOTYPE	24	24	schizophrenia
NCT001555195	NCT00155519_5_T0	PHENOTYPE	6	6	pathology
NCT001555195	NCT00155519_5_T1	PHENOTYPE	15	15	schizophrenia
NCT001555195	NCT00155519_5_T2	PHENOTYPE	17	18	schizotypal disorder
NCT001555197	NCT00155519_7_T0	PHENOTYPE	6	6	schizophrenia
NCT001555198	NCT00155519_8_T0	PHENOTYPE	14	14	pathology
NCT001555198	NCT00155519_8_T1	PHENOTYPE	22	22	schizophrenia
NCT0015551910	NCT00155519_10_T0	GENE	8	8	yrs
NCT0015551910	NCT00155519_10_T1	GENE	11	11	yrs
NCT0015551911	NCT00155519_11_T0	PHENOTYPE	20	20	pathology
NCT0015551911	NCT00155519_11_T1	PHENOTYPE	27	27	schizophrenia
NCT0015551911	NCT00155519_11_T2	GENE	2	2	neurotic
NCT0015551911	NCT00155519_11_T3	PHENOTYPE	6	7	latent schizophrenia
NCT0015551912	NCT00155519_12_T0	PHENOTYPE	8	8	Schizotaxia
NCT0015551912	NCT00155519_12_T1	PHENOTYPE	21	21	schizophrenia
NCT0015551912	NCT00155519_12_T2	PHENOTYPE	15	16	latent schizophrenia
NCT0015551912	NCT00155519_12_T3	PHENOTYPE	17	18	schizotypal disorder
NCT0015551914	NCT00155519_14_T0	PHENOTYPE	16	17	latent schizophrenia
NCT001555321	NCT00155532_1_T0	PHENOTYPE	16	16	judgement
NCT001555321	NCT00155532_1_T1	PHENOTYPE	10	10	syndromes
NCT001555452	NCT00155545_2_T0	PHENOTYPE	3	3	secondary
NCT001555452	NCT00155545_2_T1	PHENOTYPE	4	4	scoliosis
NCT001555455	NCT00155545_5_T0	ORGAN	12	12	limbs
NCT001555455	NCT00155545_5_T1	GENE	11	11	paired
NCT001555455	NCT00155545_5_T2	PHENOTYPE	0	2	Leg length discrepancy
NCT001555457	NCT00155545_7_T0	GENE	3	3	has
NCT0015554511	NCT00155545_11_T0	PHENOTYPE	17	18	idiopathic scoliosis
NCT0015554512	NCT00155545_12_T0	PHENOTYPE	28	28	scoliosis
NCT0015554512	NCT00155545_12_T1	ORGAN	5	5	spine
NCT0015554512	NCT00155545_12_T2	ORGAN	22	22	spine
NCT0015554512	NCT00155545_12_T3	ORGAN	8	9	lower extremities
NCT0015554512	NCT00155545_12_T4	ORGAN	25	26	lower limbs
NCT0015554515	NCT00155545_15_T0	ORGAN	19	19	spine
NCT0015554515	NCT00155545_15_T1	PHENOTYPE	27	28	idiopathic scoliosis
NCT0015554515	NCT00155545_15_T2	ORGAN	22	23	lower extremities
NCT001555582	NCT00155558_2_T0	GENE	2	2	has
NCT001555583	NCT00155558_3_T0	GENE	11	11	al
NCT001555583	NCT00155558_3_T1	GENE	10	10	et
NCT001555583	NCT00155558_3_T2	PHENOTYPE	6	8	metastatic colorectal cancer
NCT001555584	NCT00155558_4_T0	GENE	8	8	de
NCT001555584	NCT00155558_4_T1	GENE	11	11	al
NCT001555584	NCT00155558_4_T2	GENE	10	10	et
NCT001555584	NCT00155558_4_T3	PHENOTYPE	6	7	colorectal cancer
NCT001555712	NCT00155571_2_T0	TISSUE	12	12	tissues
NCT001555712	NCT00155571_2_T1	GENE	13	13	has
NCT001555712	NCT00155571_2_T2	BIOLOGICAL_PROCESS	9	9	chewing
NCT001555713	NCT00155571_3_T0	ORGAN	15	15	periodontium
NCT001555715	NCT00155571_5_T0	GENE	12	12	has
NCT001555717	NCT00155571_7_T0	PHENOTYPE	10	11	periodontal pockets
NCT0015557111	NCT00155571_11_T0	TISSUE	12	12	tissues
NCT0015557111	NCT00155571_11_T1	GENE	13	13	has
NCT0015557111	NCT00155571_11_T2	BIOLOGICAL_PROCESS	9	9	chewing
NCT0015557112	NCT00155571_12_T0	TISSUE	10	10	tissues
NCT0015557113	NCT00155571_13_T0	PHENOTYPE	3	4	periodontal disease
NCT0015557114	NCT00155571_14_T0	CELL	14	14	fibroblast
NCT0015557114	NCT00155571_14_T1	GENE	8	8	has
NCT0015557118	NCT00155571_18_T0	BIOLOGICAL_PROCESS	22	22	chewing
NCT0015557118	NCT00155571_18_T1	PHENOTYPE	11	12	periodontal index
NCT0015557120	NCT00155571_20_T0	PHENOTYPE	6	7	bleeding gums
NCT0015557124	NCT00155571_24_T0	ORGAN	15	15	periodontium
NCT0015557126	NCT00155571_26_T0	GENE	12	12	has
NCT001555842	NCT00155584_2_T0	PHENOTYPE	18	18	premalignant
NCT001555842	NCT00155584_2_T1	GENE	4	4	LED
NCT001555842	NCT00155584_2_T2	PHENOTYPE	23	23	dysplasia
NCT001555842	NCT00155584_2_T3	ORGAN	29	30	oral cavity
NCT001555842	NCT00155584_2_T4	PHENOTYPE	25	29	carcinoma in situ of oral
NCT001555843	NCT00155584_3_T0	GENE	11	11	LED
NCT001555844	NCT00155584_4_T0	PHENOTYPE	10	10	papilloma
NCT001555844	NCT00155584_4_T1	PHENOTYPE	5	5	papillomas
NCT001555844	NCT00155584_4_T2	PHENOTYPE	0	1	Verruca vulgaris
NCT0015558411	NCT00155584_11_T0	GENE	2	2	ALA
NCT0015558411	NCT00155584_11_T1	GENE	5	5	LED
NCT0015558413	NCT00155584_13_T0	GENE	12	12	LED
NCT0015558420	NCT00155584_20_T0	CELL	22	22	cells
NCT0015558420	NCT00155584_20_T1	PHENOTYPE	21	21	tumor
NCT0015558420	NCT00155584_20_T2	PHENOTYPE	16	16	uptakes
NCT0015558420	NCT00155584_20_T3	GENE	3	3	has
NCT0015558421	NCT00155584_21_T0	GENE	6	6	ALA
NCT0015558421	NCT00155584_21_T1	GENE	12	12	broadened
NCT0015558421	NCT00155584_21_T2	COMPOUND	10	10	PpIX
NCT0015558421	NCT00155584_21_T3	GENE	11	11	has
NCT0015558421	NCT00155584_21_T4	GENE	9	9	IX
NCT0015558421	NCT00155584_21_T5	COMPOUND	4	5	5_aminolevulinic acid
NCT001555973	NCT00155597_3_T0	PHENOTYPE	13	15	quality of life
NCT001555977	NCT00155597_7_T0	GENE	5	5	CEA
NCT0015559715	NCT00155597_15_T0	GENE	11	12	group I
NCT0015559715	NCT00155597_15_T1	GENE	16	17	group II
NCT0015559716	NCT00155597_16_T0	GENE	4	5	group I
NCT0015559720	NCT00155597_20_T0	PHENOTYPE	7	7	fixation
NCT0015559722	NCT00155597_22_T0	PHENOTYPE	9	9	affects
NCT0015559722	NCT00155597_22_T1	PHENOTYPE	11	12	functional recovery
NCT0015559722	NCT00155597_22_T2	PHENOTYPE	16	18	quality of life
NCT0015559730	NCT00155597_30_T0	GENE	2	2	CEA
NCT0015559734	NCT00155597_34_T0	PHENOTYPE	19	19	complication
NCT0015559739	NCT00155597_39_T0	GENE	10	11	group I
NCT0015559739	NCT00155597_39_T1	GENE	15	16	group II
NCT0015559740	NCT00155597_40_T0	GENE	4	5	group I
NCT0015559743	NCT00155597_43_T0	GENE	18	18	CEA
NCT001556103	NCT00155610_3_T0	GENE	4	4	CPT
NCT001556103	NCT00155610_3_T1	PHENOTYPE	12	12	dysfunction
NCT001556106	NCT00155610_6_T0	PHENOTYPE	3	3	secondary
NCT001556106	NCT00155610_6_T1	PHENOTYPE	9	9	obesity
NCT001556106	NCT00155610_6_T2	PHENOTYPE	25	27	fasting blood glucose
NCT001556109	NCT00155610_9_T0	PHENOTYPE	10	10	complications
NCT001556109	NCT00155610_9_T1	PHENOTYPE	3	3	dysfunction
NCT001556109	NCT00155610_9_T2	ORGAN	1	2	urinary tract
NCT0015561011	NCT00155610_11_T0	PHENOTYPE	11	11	dysfunction
NCT0015561012	NCT00155610_12_T0	GENE	0	0	CPT
NCT001556235	NCT00155623_5_T0	PHENOTYPE	24	24	MALT
NCT001556235	NCT00155623_5_T1	PHENOTYPE	22	23	gastric lymphoma
NCT001556235	NCT00155623_5_T2	PHENOTYPE	19	20	gastric cancer
NCT001556235	NCT00155623_5_T3	PHENOTYPE	6	7	chronic gastritis
NCT001556235	NCT00155623_5_T4	PHENOTYPE	13	15	peptic ulcer disease
NCT001556237	NCT00155623_7_T0	PHENOTYPE	13	13	recurrences
NCT001556239	NCT00155623_9_T0	PHENOTYPE	15	15	carcinogenesis
NCT0015562311	NCT00155623_11_T0	PHENOTYPE	35	35	diseases
NCT0015562311	NCT00155623_11_T1	PHENOTYPE	17	19	infection in children
NCT0015562312	NCT00155623_12_T0	PHENOTYPE	10	12	infection in children
NCT0015562322	NCT00155623_22_T0	PHENOTYPE	24	24	strain
NCT0015562322	NCT00155623_22_T1	PHENOTYPE	16	16	pathology
NCT0015562324	NCT00155623_24_T0	GENE	9	9	SAS
NCT001556361	NCT00155636_1_T0	GENE	2	2	has
NCT001556362	NCT00155636_2_T0	GENE	22	22	has
NCT001556362	NCT00155636_2_T1	PHENOTYPE	3	3	fragmented
NCT001556363	NCT00155636_3_T0	GENE	1	1	PPG
NCT001556363	NCT00155636_3_T1	PHENOTYPE	10	10	schizophrenia
NCT001556366	NCT00155636_6_T0	GENE	5	5	PPG
NCT001556366	NCT00155636_6_T1	PHENOTYPE	18	18	Schizophrenia
NCT001556366	NCT00155636_6_T2	PHENOTYPE	33	33	Schizophrenia
NCT001556366	NCT00155636_6_T3	PHENOTYPE	26	26	schizophrenia
NCT001556367	NCT00155636_7_T0	CELL	32	32	chromosome
NCT001556368	NCT00155636_8_T0	PHENOTYPE	8	8	recruitment
NCT0015563610	NCT00155636_10_T0	GENE	1	1	PPG
NCT0015563611	NCT00155636_11_T0	GENE	33	33	PPG
NCT0015563611	NCT00155636_11_T1	GENE	2	2	has
NCT0015563614	NCT00155636_14_T0	PHENOTYPE	7	7	chronic
NCT0015563615	NCT00155636_15_T0	PHENOTYPE	5	5	acute
NCT0015563617	NCT00155636_17_T0	PHENOTYPE	16	16	schizophrenia
NCT0015563618	NCT00155636_18_T0	PHENOTYPE	1	1	schizophrenia
NCT0015563619	NCT00155636_19_T0	PHENOTYPE	8	8	schizophrenia
NCT0015563620	NCT00155636_20_T0	PHENOTYPE	6	6	schizophrenia
NCT0015563621	NCT00155636_21_T0	PHENOTYPE	13	13	schizophrenia
NCT0015563621	NCT00155636_21_T1	GENE	17	17	has
NCT0015563622	NCT00155636_22_T0	PHENOTYPE	7	7	pathology
NCT0015563622	NCT00155636_22_T1	PHENOTYPE	20	20	schizophrenia
NCT0015563622	NCT00155636_22_T2	GENE	8	8	has
NCT0015563623	NCT00155636_23_T0	PHENOTYPE	16	16	schizophrenia
NCT0015563624	NCT00155636_24_T0	PHENOTYPE	7	7	schizophrenia
NCT0015563626	NCT00155636_26_T0	PHENOTYPE	14	14	reflected
NCT0015563626	NCT00155636_26_T1	GENE	11	11	has
NCT0015563627	NCT00155636_27_T0	PHENOTYPE	2	2	schizophrenia
NCT0015563627	NCT00155636_27_T1	GENE	4	4	has
NCT0015563630	NCT00155636_30_T0	PHENOTYPE	7	7	reflecting
NCT0015563631	NCT00155636_31_T0	PHENOTYPE	6	6	schizophrenia
NCT0015563631	NCT00155636_31_T1	PHENOTYPE	16	16	schizophrenia
NCT0015563632	NCT00155636_32_T0	PHENOTYPE	17	17	schizophrenia
NCT0015563632	NCT00155636_32_T1	PHENOTYPE	31	31	schizophrenia
NCT0015563632	NCT00155636_32_T2	PHENOTYPE	37	38	psychological function
NCT0015563632	NCT00155636_32_T3	PHENOTYPE	7	9	psychological defense mechanism
NCT0015563634	NCT00155636_34_T0	PHENOTYPE	5	5	schizophrenia
NCT0015563636	NCT00155636_36_T0	GENE	12	12	PPG
NCT0015563639	NCT00155636_39_T0	PHENOTYPE	12	12	chronic
NCT0015563639	NCT00155636_39_T1	PHENOTYPE	25	26	psychological factors
NCT0015563640	NCT00155636_40_T0	PHENOTYPE	5	6	disease course
NCT0015563644	NCT00155636_44_T0	PHENOTYPE	16	16	schizophrenia
NCT0015563644	NCT00155636_44_T1	PHENOTYPE	25	25	schizophrenia
NCT0015563644	NCT00155636_44_T2	PHENOTYPE	34	34	schizophrenia
NCT0015563645	NCT00155636_45_T0	PHENOTYPE	32	32	schizophrenia
NCT0015563646	NCT00155636_46_T0	PHENOTYPE	26	26	Schizophrenia
NCT0015563647	NCT00155636_47_T0	PHENOTYPE	12	12	schizophrenia
NCT0015563647	NCT00155636_47_T1	PHENOTYPE	21	21	schizophrenia
NCT0015563648	NCT00155636_48_T0	GENE	11	11	CPT
NCT0015563648	NCT00155636_48_T1	PHENOTYPE	3	3	focused
NCT0015563648	NCT00155636_48_T2	PHENOTYPE	9	9	schizophrenia
NCT0015563648	NCT00155636_48_T3	PHENOTYPE	15	15	schizophrenia
NCT0015563649	NCT00155636_49_T0	GENE	0	0	CPT
NCT0015563650	NCT00155636_50_T0	PHENOTYPE	9	9	schizophrenia
NCT0015563651	NCT00155636_51_T0	PHENOTYPE	14	14	schizophrenia
NCT0015563652	NCT00155636_52_T0	GENE	7	7	CPT
NCT0015563652	NCT00155636_52_T1	PHENOTYPE	25	25	schizophrenia
NCT0015563654	NCT00155636_54_T0	PHENOTYPE	4	4	schizophrenia
NCT0015563674	NCT00155636_74_T0	PHENOTYPE	20	20	schizophrenia
NCT0015563677	NCT00155636_77_T0	GENE	13	13	has
NCT0015563682	NCT00155636_82_T0	PHENOTYPE	22	22	schizophrenia
NCT0015563684	NCT00155636_84_T0	GENE	8	8	PPG
NCT0015563685	NCT00155636_85_T0	PHENOTYPE	7	7	schizophrenia
NCT0015563685	NCT00155636_85_T1	PHENOTYPE	13	13	schizophrenia
NCT0015563685	NCT00155636_85_T2	PHENOTYPE	22	22	schizophrenia
NCT0015563685	NCT00155636_85_T3	PHENOTYPE	4	5	symptom clusters
NCT0015563686	NCT00155636_86_T0	PHENOTYPE	4	4	schizophrenia
NCT0015563687	NCT00155636_87_T0	COMPOUND	27	27	EFA
NCT0015563687	NCT00155636_87_T1	PHENOTYPE	40	40	schizophrenia
NCT0015563687	NCT00155636_87_T2	GENE	32	32	CFA
NCT0015563689	NCT00155636_89_T0	COMPOUND	19	19	EFA
NCT0015563690	NCT00155636_90_T0	GENE	1	1	CFA
NCT0015563690	NCT00155636_90_T1	GENE	17	17	CFA
NCT0015563692	NCT00155636_92_T0	PHENOTYPE	8	8	peripheral
NCT0015563692	NCT00155636_92_T1	PHENOTYPE	15	15	schizophrenia
NCT0015563693	NCT00155636_93_T0	PHENOTYPE	12	12	generalized
NCT0015563693	NCT00155636_93_T1	PHENOTYPE	23	23	pathology
NCT0015563693	NCT00155636_93_T2	GENE	15	15	GAP
NCT0015563693	NCT00155636_93_T3	PHENOTYPE	26	26	schizophrenia
NCT0015563694	NCT00155636_94_T0	GENE	2	2	GAP
NCT0015563698	NCT00155636_98_T0	PHENOTYPE	10	10	impairment
NCT0015563698	NCT00155636_98_T1	GENE	19	19	CPT
NCT0015563699	NCT00155636_99_T0	GENE	12	12	CPT
NCT00155636100	NCT00155636_100_T0	GENE	7	7	CPT
NCT00155636100	NCT00155636_100_T1	PHENOTYPE	24	24	schizophrenia
NCT00155636100	NCT00155636_100_T2	PHENOTYPE	2	2	severely
NCT00155636102	NCT00155636_102_T0	GENE	1	1	GAP
NCT00155636106	NCT00155636_106_T0	PHENOTYPE	11	12	symptom cluster
NCT00155636108	NCT00155636_108_T0	PHENOTYPE	6	6	schizophrenia
NCT00155636110	NCT00155636_110_T0	GENE	10	10	GAP
NCT00155636112	NCT00155636_112_T0	PHENOTYPE	33	33	symptoms
NCT00155636112	NCT00155636_112_T1	GENE	7	7	GAP
NCT00155636112	NCT00155636_112_T2	PHENOTYPE	10	11	symptom clusters
NCT00155636113	NCT00155636_113_T0	GENE	22	22	CPT
NCT00155636121	NCT00155636_121_T0	GENE	7	7	CPT
NCT00155636121	NCT00155636_121_T1	PHENOTYPE	13	13	schizophrenia
NCT00155636122	NCT00155636_122_T0	GENE	3	3	CPT
NCT00155636123	NCT00155636_123_T0	GENE	2	2	has
NCT00155636125	NCT00155636_125_T0	GENE	4	4	CPT
NCT00155636125	NCT00155636_125_T1	GENE	8	8	1.9
NCT00155636125	NCT00155636_125_T2	GENE	13	13	1.9
NCT00155636126	NCT00155636_126_T0	GENE	6	6	CPT
NCT00155636126	NCT00155636_126_T1	PHENOTYPE	8	8	reflects
NCT00155636127	NCT00155636_127_T0	GENE	12	12	CPT
NCT00155636127	NCT00155636_127_T1	PHENOTYPE	17	17	schizophrenia
NCT00155636127	NCT00155636_127_T2	PHENOTYPE	6	7	attention deficits
NCT00155636130	NCT00155636_130_T0	PHENOTYPE	4	4	schizophrenia
NCT00155636130	NCT00155636_130_T1	PHENOTYPE	7	7	schizophrenia
NCT00155636130	NCT00155636_130_T2	GENE	27	27	SIS
NCT00155636131	NCT00155636_131_T0	GENE	4	4	PAS
NCT00155636131	NCT00155636_131_T1	PHENOTYPE	17	17	schizophrenia
NCT00155636131	NCT00155636_131_T2	PHENOTYPE	18	19	personality disorders
NCT00155636133	NCT00155636_133_T0	GENE	11	11	PAS
NCT00155636133	NCT00155636_133_T1	PHENOTYPE	4	4	schizophrenia
NCT00155636133	NCT00155636_133_T2	GENE	20	20	SIS
NCT00155636133	NCT00155636_133_T3	PHENOTYPE	5	6	personality disorders
NCT00155636134	NCT00155636_134_T0	PHENOTYPE	1	1	schizophrenia
NCT00155636134	NCT00155636_134_T1	PHENOTYPE	15	15	schizophrenia
NCT00155636134	NCT00155636_134_T2	PHENOTYPE	2	3	personality disorder
NCT00155636139	NCT00155636_139_T0	GENE	1	1	P50
NCT00155636139	NCT00155636_139_T1	PHENOTYPE	20	20	schizophrenia
NCT00155636141	NCT00155636_141_T0	GENE	9	9	P50
NCT00155636145	NCT00155636_145_T0	CELL	9	9	chromosome
NCT00155636146	NCT00155636_146_T0	CELL	26	26	chromosome
NCT00155636146	NCT00155636_146_T1	CELL	29	29	chromosome
NCT00155636146	NCT00155636_146_T2	PHENOTYPE	21	21	spots
NCT00155636146	NCT00155636_146_T3	PHENOTYPE	16	16	schizophrenia
NCT00155636146	NCT00155636_146_T4	PHENOTYPE	23	23	schizophrenia
NCT00155636148	NCT00155636_148_T0	GENE	4	4	PPG
NCT00155636148	NCT00155636_148_T1	PHENOTYPE	27	27	schizophrenia
NCT00155636149	NCT00155636_149_T0	PHENOTYPE	21	21	schizophrenia
NCT00155636150	NCT00155636_150_T0	GENE	7	7	PPG
NCT00155636151	NCT00155636_151_T0	PHENOTYPE	18	18	schizophrenia
NCT00155636151	NCT00155636_151_T1	PHENOTYPE	23	23	schizophrenia
NCT00155636153	NCT00155636_153_T0	COMPOUND	4	4	niacin
NCT00155636153	NCT00155636_153_T1	BIOLOGICAL_PROCESS	22	22	metabolism
NCT00155636154	NCT00155636_154_T0	GENE	6	6	PPG
NCT00155636156	NCT00155636_156_T0	PHENOTYPE	0	1	Expressed emotion
NCT00155636157	NCT00155636_157_T0	PHENOTYPE	25	25	schizophrenia
NCT00155636157	NCT00155636_157_T1	PHENOTYPE	1	2	expressed emotion
NCT00155636158	NCT00155636_158_T0	PHENOTYPE	7	7	schizophrenia
NCT00155636158	NCT00155636_158_T1	PHENOTYPE	16	18	course of illness
NCT00155636160	NCT00155636_160_T0	PHENOTYPE	28	28	schizophrenia
NCT00155636160	NCT00155636_160_T1	GENE	18	18	has
NCT00155636164	NCT00155636_164_T0	GENE	7	7	GAP
NCT00155636164	NCT00155636_164_T1	PHENOTYPE	4	4	Generalized
NCT00155636165	NCT00155636_165_T0	GENE	3	3	fruitful
NCT00155636168	NCT00155636_168_T0	PHENOTYPE	20	20	schizophrenia
NCT00155636169	NCT00155636_169_T0	PHENOTYPE	22	22	schizophrenia
NCT00155636170	NCT00155636_170_T0	PHENOTYPE	10	10	schizophrenia
NCT00155636171	NCT00155636_171_T0	PHENOTYPE	14	14	disorders
NCT00155636171	NCT00155636_171_T1	PHENOTYPE	10	10	schizophrenia
NCT00155636172	NCT00155636_172_T0	PHENOTYPE	17	17	Schizophrenia
NCT00155636172	NCT00155636_172_T1	PHENOTYPE	48	48	schizophrenia
NCT00155636173	NCT00155636_173_T0	GENE	7	7	CPT
NCT00155636175	NCT00155636_175_T0	GENE	12	12	PPG
NCT00155636180	NCT00155636_180_T0	GENE	15	15	PPG
NCT00155636181	NCT00155636_181_T0	PHENOTYPE	15	15	schizophrenia
NCT00155636182	NCT00155636_182_T0	PHENOTYPE	8	8	schizophrenia
NCT00155636183	NCT00155636_183_T0	PHENOTYPE	11	11	strategies
NCT00155636183	NCT00155636_183_T1	PHENOTYPE	5	5	schizophrenia
NCT00155636184	NCT00155636_184_T0	GENE	4	4	has
NCT001556491	NCT00155649_1_T0	GENE	55	55	DRP
NCT001556491	NCT00155649_1_T1	GENE	97	97	NOTCH4
NCT001556491	NCT00155649_1_T2	GENE	31	31	CPT
NCT001556491	NCT00155649_1_T3	CELL	60	60	chromosomes
NCT001556491	NCT00155649_1_T4	PHENOTYPE	127	127	Schizophrenia
NCT001556491	NCT00155649_1_T5	PHENOTYPE	45	45	inhibition
NCT001556491	NCT00155649_1_T6	GENE	47	47	P50
NCT001556491	NCT00155649_1_T7	PHENOTYPE	13	13	schizophrenia
NCT001556491	NCT00155649_1_T8	PHENOTYPE	140	140	schizophrenia
NCT001556491	NCT00155649_1_T9	PHENOTYPE	40	40	Sorting
NCT001556491	NCT00155649_1_T10	PHENOTYPE	34	35	executive function
NCT001556493	NCT00155649_3_T0	GENE	5	5	CPT
NCT001556493	NCT00155649_3_T1	GENE	3	3	had
NCT001556495	NCT00155649_5_T0	PHENOTYPE	16	16	Schizophrenia
NCT0015564914	NCT00155649_14_T0	PHENOTYPE	22	22	recruitment
NCT0015564914	NCT00155649_14_T1	PHENOTYPE	7	7	schizophrenia
NCT0015564930	NCT00155649_30_T0	GENE	18	18	II
NCT0015564930	NCT00155649_30_T1	GENE	23	23	II
NCT0015564930	NCT00155649_30_T2	GENE	15	15	KS
NCT0015564930	NCT00155649_30_T3	GENE	3	3	had
NCT0015564931	NCT00155649_31_T0	GENE	4	4	0.7
NCT0015564933	NCT00155649_33_T0	GENE	19	19	al
NCT0015564933	NCT00155649_33_T1	GENE	23	23	al
NCT0015564933	NCT00155649_33_T2	GENE	16	16	1966
NCT0015564933	NCT00155649_33_T3	GENE	18	18	et
NCT0015564933	NCT00155649_33_T4	GENE	22	22	et
NCT0015564935	NCT00155649_35_T0	PHENOTYPE	19	19	schizophrenia
NCT0015564937	NCT00155649_37_T0	CELL	11	11	chromosomes
NCT0015564937	NCT00155649_37_T1	PHENOTYPE	4	4	Schizophrenia
NCT0015564940	NCT00155649_40_T0	CELL	4	4	chromosome
NCT0015564940	NCT00155649_40_T1	CELL	16	16	chromosome
NCT0015564940	NCT00155649_40_T2	GENE	20	20	al
NCT0015564940	NCT00155649_40_T3	GENE	25	25	al
NCT0015564940	NCT00155649_40_T4	GENE	30	30	al
NCT0015564940	NCT00155649_40_T5	GENE	36	36	al
NCT0015564940	NCT00155649_40_T6	GENE	19	19	et
NCT0015564940	NCT00155649_40_T7	GENE	24	24	et
NCT0015564940	NCT00155649_40_T8	GENE	29	29	et
NCT0015564940	NCT00155649_40_T9	GENE	35	35	et
NCT0015564941	NCT00155649_41_T0	CELL	2	2	chromosome
NCT0015564941	NCT00155649_41_T1	CELL	5	5	chromosome
NCT0015564942	NCT00155649_42_T0	PHENOTYPE	2	2	translocation
NCT0015564942	NCT00155649_42_T1	PHENOTYPE	13	13	schizophrenia
NCT0015564942	NCT00155649_42_T2	GENE	23	23	al
NCT0015564942	NCT00155649_42_T3	GENE	22	22	et
NCT0015564942	NCT00155649_42_T4	COMPOUND	3	3	1
NCT0015564942	NCT00155649_42_T5	PHENOTYPE	10	11	mental illness
NCT0015564943	NCT00155649_43_T0	CELL	16	16	chromosome
NCT0015564943	NCT00155649_43_T1	PHENOTYPE	7	7	Schizophrenia
NCT0015564943	NCT00155649_43_T2	PHENOTYPE	13	13	Schizophrenia
NCT0015564943	NCT00155649_43_T3	GENE	25	25	al
NCT0015564943	NCT00155649_43_T4	GENE	4	4	DISC1
NCT0015564943	NCT00155649_43_T5	GENE	10	10	DISC2
NCT0015564943	NCT00155649_43_T6	GENE	24	24	et
NCT0015564944	NCT00155649_44_T0	GENE	10	10	al
NCT0015564944	NCT00155649_44_T1	GENE	17	17	al
NCT0015564944	NCT00155649_44_T2	GENE	21	21	al
NCT0015564944	NCT00155649_44_T3	GENE	9	9	et
NCT0015564944	NCT00155649_44_T4	GENE	16	16	et
NCT0015564944	NCT00155649_44_T5	GENE	20	20	et
NCT0015564946	NCT00155649_46_T0	PHENOTYPE	9	9	disorders
NCT0015564947	NCT00155649_47_T0	GENE	17	17	al
NCT0015564947	NCT00155649_47_T1	GENE	16	16	et
NCT0015564952	NCT00155649_52_T0	PHENOTYPE	39	40	internal control
NCT0015564953	NCT00155649_53_T0	PHENOTYPE	17	17	schizophrenia
NCT0015564955	NCT00155649_55_T0	GENE	25	25	NOTCH4
NCT0015564955	NCT00155649_55_T1	CELL	28	28	chromosome
NCT0015564955	NCT00155649_55_T2	PHENOTYPE	14	14	schizophrenia
NCT0015564955	NCT00155649_55_T3	GENE	6	6	has
NCT0015564956	NCT00155649_56_T0	PHENOTYPE	20	20	strategies
NCT0015564956	NCT00155649_56_T1	PHENOTYPE	33	33	schizophrenia
NCT0015564960	NCT00155649_60_T0	PHENOTYPE	1	1	impairment
NCT0015564960	NCT00155649_60_T1	GENE	14	14	Kremen
NCT0015564960	NCT00155649_60_T2	GENE	16	16	al
NCT0015564960	NCT00155649_60_T3	PHENOTYPE	22	22	dysfunction
NCT0015564960	NCT00155649_60_T4	GENE	15	15	et
NCT0015564961	NCT00155649_61_T0	GENE	8	8	CPT
NCT0015564961	NCT00155649_61_T1	PHENOTYPE	16	16	Sorting
NCT0015564962	NCT00155649_62_T0	PHENOTYPE	18	18	schizophrenia
NCT0015564963	NCT00155649_63_T0	PHENOTYPE	6	6	symptoms
NCT0015564963	NCT00155649_63_T1	PHENOTYPE	41	41	symptoms
NCT0015564963	NCT00155649_63_T2	GENE	0	0	CPT
NCT0015564963	NCT00155649_63_T3	GENE	9	9	al
NCT0015564963	NCT00155649_63_T4	GENE	13	13	al
NCT0015564963	NCT00155649_63_T5	GENE	21	21	al
NCT0015564963	NCT00155649_63_T6	GENE	29	29	al
NCT0015564963	NCT00155649_63_T7	GENE	33	33	al
NCT0015564963	NCT00155649_63_T8	GENE	37	37	al
NCT0015564963	NCT00155649_63_T9	GENE	44	44	al
NCT0015564963	NCT00155649_63_T10	GENE	8	8	et
NCT0015564963	NCT00155649_63_T11	GENE	12	12	et
NCT0015564963	NCT00155649_63_T12	GENE	20	20	et
NCT0015564963	NCT00155649_63_T13	GENE	28	28	et
NCT0015564963	NCT00155649_63_T14	GENE	32	32	et
NCT0015564963	NCT00155649_63_T15	GENE	36	36	et
NCT0015564963	NCT00155649_63_T16	GENE	43	43	et
NCT0015564964	NCT00155649_64_T0	GENE	18	18	al
NCT0015564964	NCT00155649_64_T1	GENE	22	22	al
NCT0015564964	NCT00155649_64_T2	GENE	17	17	et
NCT0015564964	NCT00155649_64_T3	GENE	21	21	et
NCT0015564964	NCT00155649_64_T4	PHENOTYPE	14	15	cognitive deficits
NCT0015564971	NCT00155649_71_T0	PHENOTYPE	17	17	recurrence
NCT0015564971	NCT00155649_71_T1	GENE	27	27	CPT
NCT0015564971	NCT00155649_71_T2	GENE	35	35	CPT
NCT0015564971	NCT00155649_71_T3	GENE	12	12	al
NCT0015564971	NCT00155649_71_T4	GENE	11	11	et
NCT0015564973	NCT00155649_73_T0	GENE	8	8	CPT
NCT0015564974	NCT00155649_74_T0	GENE	7	7	CPT
NCT0015564974	NCT00155649_74_T1	PHENOTYPE	1	1	intent
NCT0015564976	NCT00155649_76_T0	CELL	21	21	chromosome
NCT0015564976	NCT00155649_76_T1	PHENOTYPE	17	17	inhibition
NCT0015564976	NCT00155649_76_T2	GENE	16	16	P50
NCT0015564976	NCT00155649_76_T3	PHENOTYPE	13	13	schizophrenia
NCT0015564976	NCT00155649_76_T4	GENE	3	3	has
NCT0015564979	NCT00155649_79_T0	GENE	18	18	lod
NCT0015564979	NCT00155649_79_T1	CELL	12	12	chromosome
NCT0015564979	NCT00155649_79_T2	PHENOTYPE	7	7	schizophrenia
NCT0015564979	NCT00155649_79_T3	GENE	8	8	has
NCT0015564979	NCT00155649_79_T4	PHENOTYPE	5	5	dysfunction
NCT0015564980	NCT00155649_80_T0	GENE	20	20	al
NCT0015564980	NCT00155649_80_T1	PHENOTYPE	6	6	schizophrenia
NCT0015564980	NCT00155649_80_T2	GENE	19	19	et
NCT0015564984	NCT00155649_84_T0	PHENOTYPE	2	2	Schizophrenia
NCT0015564984	NCT00155649_84_T1	PHENOTYPE	15	15	schizophrenia
NCT0015564984	NCT00155649_84_T2	GENE	8	8	has
NCT0015564985	NCT00155649_85_T0	GENE	15	15	sib
NCT0015564985	NCT00155649_85_T1	GENE	19	19	sib
NCT0015564988	NCT00155649_88_T0	PHENOTYPE	6	6	schizophrenia
NCT0015564989	NCT00155649_89_T0	PHENOTYPE	10	10	peripheral
NCT0015564989	NCT00155649_89_T1	CELL	12	12	cells
NCT0015564989	NCT00155649_89_T2	GENE	28	28	sib
NCT0015564991	NCT00155649_91_T0	CELL	5	5	cells
NCT0015564991	NCT00155649_91_T1	PHENOTYPE	3	3	transformed
NCT0015564996	NCT00155649_96_T0	PHENOTYPE	11	11	Schizophrenia
NCT0015564996	NCT00155649_96_T1	PHENOTYPE	27	27	schizophrenia
NCT0015564996	NCT00155649_96_T2	GENE	28	28	has
NCT00155649101	NCT00155649_101_T0	GENE	0	0	CPT
NCT00155649103	NCT00155649_103_T0	PHENOTYPE	4	4	Schizophrenia
NCT00155649103	NCT00155649_103_T1	PHENOTYPE	10	10	schizophrenia
NCT00155649104	NCT00155649_104_T0	PHENOTYPE	9	9	focused
NCT00155649105	NCT00155649_105_T0	GENE	18	18	extended
NCT00155649106	NCT00155649_106_T0	GENE	12	12	probable
NCT00155649106	NCT00155649_106_T1	GENE	10	10	had
NCT00155649106	NCT00155649_106_T2	PHENOTYPE	15	15	schizophrenia
NCT00155649106	NCT00155649_106_T3	GENE	18	18	al
NCT00155649106	NCT00155649_106_T4	GENE	17	17	et
NCT00155649106	NCT00155649_106_T5	GENE	5	6	androgen receptor
NCT00155649107	NCT00155649_107_T0	GENE	8	8	al
NCT00155649107	NCT00155649_107_T1	GENE	7	7	et
NCT00155649109	NCT00155649_109_T0	GENE	0	0	Dr
NCT00155649110	NCT00155649_110_T0	GENE	53	53	had
NCT00155649110	NCT00155649_110_T1	GENE	24	24	al
NCT00155649110	NCT00155649_110_T2	PHENOTYPE	21	21	schizophrenia
NCT00155649110	NCT00155649_110_T3	PHENOTYPE	39	39	schizophrenia
NCT00155649110	NCT00155649_110_T4	GENE	23	23	et
NCT00155649110	NCT00155649_110_T5	GENE	41	41	et
NCT00155649110	NCT00155649_110_T6	PHENOTYPE	29	29	mutation
NCT00155649110	NCT00155649_110_T7	GENE	14	14	receptor
NCT00155649110	NCT00155649_110_T8	GENE	31	31	DRD2
NCT00155649110	NCT00155649_110_T9	GENE	13	13	DRD4
NCT00155649112	NCT00155649_112_T0	CELL	8	8	chromosomes
NCT00155649114	NCT00155649_114_T0	CELL	10	10	chromosome
NCT00155649114	NCT00155649_114_T1	CELL	50	50	chromosome
NCT00155649114	NCT00155649_114_T2	GENE	41	41	al
NCT00155649114	NCT00155649_114_T3	GENE	40	40	et
NCT00155649114	NCT00155649_114_T4	GENE	53	53	et
NCT00155649114	NCT00155649_114_T5	GENE	5	6	5-HT2 receptor
NCT00155649115	NCT00155649_115_T0	CELL	25	25	chromosome
NCT00155649115	NCT00155649_115_T1	CELL	28	28	chromosome
NCT00155649117	NCT00155649_117_T0	PHENOTYPE	10	10	schizophrenia
NCT00155649117	NCT00155649_117_T1	GENE	11	11	NPL
NCT00155649117	NCT00155649_117_T2	GENE	19	19	al
NCT00155649117	NCT00155649_117_T3	GENE	18	18	et
NCT00155649118	NCT00155649_118_T0	CELL	9	9	chromosome
NCT00155649118	NCT00155649_118_T1	PHENOTYPE	5	5	schizophrenia
NCT00155649118	NCT00155649_118_T2	GENE	13	13	al
NCT00155649118	NCT00155649_118_T3	GENE	12	12	et
NCT00155649119	NCT00155649_119_T0	GENE	4	4	NOTCH4
NCT00155649119	NCT00155649_119_T1	CELL	8	8	chromosome
NCT00155649119	NCT00155649_119_T2	GENE	10	10	NPL
NCT00155649119	NCT00155649_119_T3	GENE	18	18	al
NCT00155649119	NCT00155649_119_T4	GENE	17	17	et
NCT00155649120	NCT00155649_120_T0	COMPOUND	14	14	D4
NCT00155649120	NCT00155649_120_T1	GENE	15	15	receptor
NCT00155649120	NCT00155649_120_T2	GENE	27	27	al
NCT00155649120	NCT00155649_120_T3	PHENOTYPE	24	24	schizophrenia
NCT00155649120	NCT00155649_120_T4	GENE	4	4	has
NCT00155649120	NCT00155649_120_T5	GENE	16	16	DRD4
NCT00155649120	NCT00155649_120_T6	GENE	26	26	et
NCT00155649121	NCT00155649_121_T0	PHENOTYPE	11	11	schizophrenia
NCT00155649121	NCT00155649_121_T1	GENE	14	14	al
NCT00155649121	NCT00155649_121_T2	GENE	13	13	et
NCT00155649121	NCT00155649_121_T3	GENE	4	6	cytosolic phospholipase A2
NCT00155649123	NCT00155649_123_T0	GENE	15	15	CPT
NCT00155649123	NCT00155649_123_T1	PHENOTYPE	5	5	Schizophrenia
NCT00155649123	NCT00155649_123_T2	PHENOTYPE	21	21	schizophrenia
NCT00155649124	NCT00155649_124_T0	GENE	12	12	CPT
NCT00155649124	NCT00155649_124_T1	PHENOTYPE	17	17	schizophrenia
NCT00155649124	NCT00155649_124_T2	PHENOTYPE	6	7	attention deficits
NCT00155649126	NCT00155649_126_T0	PHENOTYPE	19	19	symptoms
NCT00155649126	NCT00155649_126_T1	GENE	5	5	CPT
NCT00155649126	NCT00155649_126_T2	GENE	25	25	CPT
NCT00155649126	NCT00155649_126_T3	GENE	2	2	al
NCT00155649126	NCT00155649_126_T4	GENE	35	35	al
NCT00155649126	NCT00155649_126_T5	GENE	1	1	et
NCT00155649126	NCT00155649_126_T6	GENE	34	34	et
NCT00155649127	NCT00155649_127_T0	GENE	3	3	CPT
NCT00155649127	NCT00155649_127_T1	GENE	8	8	al
NCT00155649127	NCT00155649_127_T2	PHENOTYPE	14	14	schizophrenia
NCT00155649127	NCT00155649_127_T3	GENE	7	7	et
NCT00155649127	NCT00155649_127_T4	PHENOTYPE	26	27	psychotic symptoms
NCT00155649127	NCT00155649_127_T5	PHENOTYPE	36	37	psychotic symptoms
NCT00155649127	NCT00155649_127_T6	PHENOTYPE	46	48	major depressive disorder
NCT00155649128	NCT00155649_128_T0	GENE	4	4	CPT
NCT00155649128	NCT00155649_128_T1	PHENOTYPE	11	11	schizophrenia
NCT00155649128	NCT00155649_128_T2	PHENOTYPE	16	17	bipolar disorder
NCT00155649128	NCT00155649_128_T3	PHENOTYPE	22	23	major depression
NCT00155649129	NCT00155649_129_T0	GENE	4	4	CPT
NCT00155649129	NCT00155649_129_T1	PHENOTYPE	11	11	schizophrenia
NCT00155649131	NCT00155649_131_T0	PHENOTYPE	5	5	Schizophrenia
NCT00155649131	NCT00155649_131_T1	PHENOTYPE	2	3	Clinical Heterogeneity
NCT00155649132	NCT00155649_132_T0	GENE	4	4	had
NCT00155649133	NCT00155649_133_T0	PHENOTYPE	12	12	Schizophrenia
NCT00155649133	NCT00155649_133_T1	PHENOTYPE	9	9	schizophrenia
NCT00155649134	NCT00155649_134_T0	GENE	4	4	has
NCT00155649134	NCT00155649_134_T1	PHENOTYPE	1	2	clinical heterogeneity
NCT00155649135	NCT00155649_135_T0	GENE	27	27	CPT
NCT00155649135	NCT00155649_135_T1	GENE	3	3	al
NCT00155649135	NCT00155649_135_T2	GENE	9	9	al
NCT00155649135	NCT00155649_135_T3	PHENOTYPE	13	13	schizophrenia
NCT00155649135	NCT00155649_135_T4	GENE	2	2	et
NCT00155649135	NCT00155649_135_T5	GENE	8	8	et
NCT00155649135	NCT00155649_135_T6	PHENOTYPE	25	26	attention impairment
NCT00155649136	NCT00155649_136_T0	GENE	13	13	al
NCT00155649136	NCT00155649_136_T1	GENE	12	12	et
NCT00155649137	NCT00155649_137_T0	PHENOTYPE	6	6	schizophrenia
NCT00155649138	NCT00155649_138_T0	PHENOTYPE	11	11	schizophrenia
NCT00155649140	NCT00155649_140_T0	GENE	1	1	PI
NCT001556624	NCT00155662_4_T0	PHENOTYPE	11	11	impairment
NCT001556625	NCT00155662_5_T0	PHENOTYPE	28	30	quality of life
NCT0015566212	NCT00155662_12_T0	PHENOTYPE	5	5	impairment
NCT0015566219	NCT00155662_19_T0	PHENOTYPE	11	11	impairment
NCT0015566220	NCT00155662_20_T0	PHENOTYPE	28	30	quality of life
NCT0015566227	NCT00155662_27_T0	PHENOTYPE	5	5	impairment
NCT001556752	NCT00155675_2_T0	PHENOTYPE	10	11	postmenopausal osteoporosis
NCT001556753	NCT00155675_3_T0	ORGAN	6	6	kidney
NCT001556753	NCT00155675_3_T1	ORGAN	5	5	liver
NCT001556755	NCT00155675_5_T0	PHENOTYPE	14	14	osteoporosis
NCT001556756	NCT00155675_6_T0	PHENOTYPE	7	7	osteoporosis
NCT001556881	NCT00155688_1_T0	PHENOTYPE	18	18	schizophrenia
NCT001556884	NCT00155688_4_T0	GENE	18	18	Han
NCT001556884	NCT00155688_4_T1	PHENOTYPE	23	23	schizophrenia
NCT001556889	NCT00155688_9_T0	PHENOTYPE	16	16	Initiative
NCT0015568811	NCT00155688_11_T0	GENE	28	28	Han
NCT0015568812	NCT00155688_12_T0	GENE	27	27	PI
NCT0015568812	NCT00155688_12_T1	PHENOTYPE	38	38	schizophrenia
NCT0015568812	NCT00155688_12_T2	GENE	28	28	has
NCT0015568813	NCT00155688_13_T0	GENE	11	11	PhD
NCT0015568815	NCT00155688_15_T0	GENE	7	7	PI
NCT0015568815	NCT00155688_15_T1	PHENOTYPE	17	17	schizophrenia
NCT0015568815	NCT00155688_15_T2	GENE	8	8	has
NCT0015568815	NCT00155688_15_T3	GENE	19	19	has
NCT0015568817	NCT00155688_17_T0	GENE	8	8	has
NCT0015568818	NCT00155688_18_T0	GENE	6	6	had
NCT0015568818	NCT00155688_18_T1	GENE	5	5	has
NCT001557013	NCT00155701_3_T0	PHENOTYPE	23	23	schizophrenia
NCT001557013	NCT00155701_3_T1	GENE	7	7	has
NCT001557013	NCT00155701_3_T2	GENE	12	12	NPL
NCT001557014	NCT00155701_4_T0	PHENOTYPE	11	11	schizophrenia
NCT001557014	NCT00155701_4_T1	GENE	8	8	DISC1
NCT001557014	NCT00155701_4_T2	GENE	12	13	gene 1
NCT001557015	NCT00155701_5_T0	PHENOTYPE	6	6	translocation
NCT001557015	NCT00155701_5_T1	PHENOTYPE	13	13	schizophrenia
NCT001557015	NCT00155701_5_T2	GENE	9	9	has
NCT001557016	NCT00155701_6_T0	PHENOTYPE	4	4	translocation
NCT001557016	NCT00155701_6_T1	GENE	18	18	DISC1
NCT001557017	NCT00155701_7_T0	PHENOTYPE	1	1	translocation
NCT001557018	NCT00155701_8_T0	PHENOTYPE	31	31	schizophrenia
NCT001557018	NCT00155701_8_T1	GENE	9	9	has
NCT001557018	NCT00155701_8_T2	GENE	28	28	DISC1
NCT001557019	NCT00155701_9_T0	GENE	6	6	DISC1
NCT0015570110	NCT00155701_10_T0	PHENOTYPE	16	16	translocation
NCT0015570110	NCT00155701_10_T1	CELL	19	19	chromosome
NCT0015570111	NCT00155701_11_T0	PHENOTYPE	6	6	symptoms
NCT0015570111	NCT00155701_11_T1	PHENOTYPE	18	18	characters
NCT0015570111	NCT00155701_11_T2	PHENOTYPE	22	22	translocation
NCT0015570112	NCT00155701_12_T0	GENE	8	8	DISC1
NCT0015570116	NCT00155701_16_T0	GENE	4	4	has
NCT0015570117	NCT00155701_17_T0	GENE	8	8	had
NCT0015570118	NCT00155701_18_T0	PHENOTYPE	8	8	schizophrenia
NCT0015570118	NCT00155701_18_T1	GENE	3	3	has
NCT0015570118	NCT00155701_18_T2	GENE	1	1	DISC1
NCT0015570119	NCT00155701_19_T0	GENE	5	5	DISC1
NCT0015570120	NCT00155701_20_T0	PHENOTYPE	6	6	translocation
NCT0015570120	NCT00155701_20_T1	PHENOTYPE	11	11	schizophrenia
NCT0015570123	NCT00155701_23_T0	GENE	25	25	DISC1
NCT0015570124	NCT00155701_24_T0	PHENOTYPE	0	0	Translocation
NCT0015570125	NCT00155701_25_T0	CELL	4	5	mononuclear leukocytes
NCT0015570126	NCT00155701_26_T0	COMPOUND	3	3	EDTA
NCT0015570129	NCT00155701_29_T0	CELL	3	3	cells
NCT0015570129	NCT00155701_29_T1	GENE	20	20	al
NCT0015570129	NCT00155701_29_T2	GENE	19	19	et
NCT0015570130	NCT00155701_30_T0	GENE	0	0	PCR
NCT0015570130	NCT00155701_30_T1	GENE	16	17	DNA polymerase
NCT0015570131	NCT00155701_31_T0	COMPOUND	23	23	MgCl2
NCT0015570131	NCT00155701_31_T1	GENE	21	21	1.5
NCT0015570131	NCT00155701_31_T2	COMPOUND	30	30	Tris-HCl
NCT0015570135	NCT00155701_35_T0	GENE	3	3	PCR
NCT0015570135	NCT00155701_35_T1	GENE	12	12	PCR
NCT0015570135	NCT00155701_35_T2	GENE	9	9	gel
NCT0015570137	NCT00155701_37_T0	COMPOUND	18	18	agarose
NCT0015570137	NCT00155701_37_T1	GENE	2	2	1.4
NCT0015570137	NCT00155701_37_T2	GENE	29	29	al
NCT0015570137	NCT00155701_37_T3	GENE	19	19	gel
NCT0015570137	NCT00155701_37_T4	GENE	28	28	et
NCT0015570137	NCT00155701_37_T5	GENE	6	6	fragment
NCT0015570137	NCT00155701_37_T6	GENE	12	12	PCR
NCT0015570139	NCT00155701_39_T0	GENE	32	32	T4
NCT0015570139	NCT00155701_39_T1	GENE	8	8	fragment
NCT0015570139	NCT00155701_39_T2	GENE	28	28	PEG
NCT0015570139	NCT00155701_39_T3	GENE	4	4	1.4
NCT0015570139	NCT00155701_39_T4	GENE	33	33	ligase
NCT0015570140	NCT00155701_40_T0	GENE	9	9	hr
NCT0015570141	NCT00155701_41_T0	GENE	18	18	fragment
NCT0015570141	NCT00155701_41_T1	GENE	24	24	kit
NCT0015570141	NCT00155701_41_T2	GENE	17	17	PCR
NCT0015570143	NCT00155701_43_T0	GENE	12	12	kit
NCT0015570144	NCT00155701_44_T0	CELL	1	1	cells
NCT0015570144	NCT00155701_44_T1	GENE	30	30	shaker
NCT0015570144	NCT00155701_44_T2	GENE	12	12	ml
NCT0015570145	NCT00155701_45_T0	GENE	9	9	ml
NCT0015570145	NCT00155701_45_T1	GENE	16	16	ml
NCT0015570147	NCT00155701_47_T0	GENE	2	2	ml
NCT0015570151	NCT00155701_51_T0	CELL	6	6	cells
NCT0015570152	NCT00155701_52_T0	CELL	1	1	cells
NCT0015570154	NCT00155701_54_T0	CELL	10	10	clones
NCT0015570154	NCT00155701_54_T1	GENE	25	25	lacZ
NCT0015570154	NCT00155701_54_T2	CELL	0	0	Clone
NCT0015570155	NCT00155701_55_T0	GENE	11	11	PCR
NCT0015570159	NCT00155701_59_T0	COMPOUND	11	11	isopropanol
NCT0015570160	NCT00155701_60_T0	COMPOUND	9	9	ethanol
NCT0015570161	NCT00155701_61_T0	CELL	40	40	chromosomes
NCT0015570161	NCT00155701_61_T1	GENE	0	0	PCR
NCT0015570161	NCT00155701_61_T2	GENE	26	26	PCR
NCT0015570162	NCT00155701_62_T0	GENE	0	0	PCR
NCT0015570162	NCT00155701_62_T1	GENE	13	14	DNA polymerase
NCT0015570163	NCT00155701_63_T0	COMPOUND	23	23	MgCl2
NCT0015570163	NCT00155701_63_T1	GENE	21	21	1.5
NCT0015570163	NCT00155701_63_T2	COMPOUND	30	30	Tris-HCl
NCT0015570165	NCT00155701_65_T0	CELL	5	5	chromosome
NCT0015570166	NCT00155701_66_T0	PHENOTYPE	20	20	translocation
NCT0015570166	NCT00155701_66_T1	GENE	9	9	1.4
NCT0015570166	NCT00155701_66_T2	CELL	23	23	chromosome
NCT0015570166	NCT00155701_66_T3	GENE	2	2	PCR
NCT0015570167	NCT00155701_67_T0	PHENOTYPE	14	14	translocation
NCT0015570168	NCT00155701_68_T0	PHENOTYPE	6	6	translocation
NCT0015570170	NCT00155701_70_T0	PHENOTYPE	2	2	translocation
NCT0015570170	NCT00155701_70_T1	GENE	8	8	has
NCT0015570172	NCT00155701_72_T0	PHENOTYPE	2	2	translocation
NCT0015570174	NCT00155701_74_T0	PHENOTYPE	15	15	schizophrenia
NCT0015570174	NCT00155701_74_T1	GENE	12	12	DISC1
NCT0015570176	NCT00155701_76_T0	PHENOTYPE	14	14	mutation
NCT0015570176	NCT00155701_76_T1	CELL	37	37	chromosome
NCT0015570177	NCT00155701_77_T0	GENE	28	28	PCR
NCT0015570177	NCT00155701_77_T1	GENE	36	36	PCR
NCT0015570178	NCT00155701_78_T0	PHENOTYPE	30	30	schizophrenia
NCT0015570179	NCT00155701_79_T0	GENE	0	0	PCR
NCT0015570179	NCT00155701_79_T1	GENE	25	25	PCR
NCT0015570181	NCT00155701_81_T0	GENE	0	0	PCR
NCT0015570181	NCT00155701_81_T1	GENE	13	14	DNA polymerase
NCT0015570182	NCT00155701_82_T0	COMPOUND	23	23	MgCl2
NCT0015570182	NCT00155701_82_T1	GENE	21	21	1.5
NCT0015570182	NCT00155701_82_T2	COMPOUND	30	30	Tris-HCl
NCT0015570184	NCT00155701_84_T0	GENE	9	9	Tm
NCT0015570184	NCT00155701_84_T1	GENE	0	0	PCR
NCT0015570185	NCT00155701_85_T0	GENE	5	5	fragment
NCT0015570185	NCT00155701_85_T1	GENE	8	8	PCR
NCT0015570185	NCT00155701_85_T2	GENE	24	24	PCR
NCT0015570185	NCT00155701_85_T3	GENE	29	29	PCR
NCT0015570186	NCT00155701_86_T0	GENE	17	17	WAVE
NCT0015570186	NCT00155701_86_T1	PHENOTYPE	0	0	Mutation
NCT0015570188	NCT00155701_88_T0	GENE	14	14	al
NCT0015570188	NCT00155701_88_T1	GENE	13	13	et
NCT0015570189	NCT00155701_89_T0	COMPOUND	9	9	acetate
NCT0015570189	NCT00155701_89_T1	COMPOUND	21	21	acetonitrile
NCT0015570189	NCT00155701_89_T2	COMPOUND	8	8	triethylammonium
NCT0015570191	NCT00155701_91_T0	GENE	13	13	fragment
NCT0015570191	NCT00155701_91_T1	PHENOTYPE	3	3	concentrations
NCT0015570193	NCT00155701_93_T0	PHENOTYPE	4	4	mutation
NCT0015570193	NCT00155701_93_T1	GENE	8	8	fragment
NCT0015570193	NCT00155701_93_T2	GENE	24	24	fragment
NCT0015570193	NCT00155701_93_T3	GENE	16	16	Tm
NCT0015570195	NCT00155701_95_T0	PHENOTYPE	7	7	Mutation
NCT0015570196	NCT00155701_96_T0	PHENOTYPE	0	0	RFLP
NCT0015570196	NCT00155701_96_T1	GENE	5	5	PCR
NCT0015570197	NCT00155701_97_T0	PHENOTYPE	2	2	mutation
NCT0015570197	NCT00155701_97_T1	GENE	19	19	fragment
NCT0015570197	NCT00155701_97_T2	PHENOTYPE	22	22	RFLP
NCT00155701100	NCT00155701_100_T0	PHENOTYPE	14	14	mutation
NCT00155701101	NCT00155701_101_T0	PHENOTYPE	25	25	mutation
NCT00155701106	NCT00155701_106_T0	PHENOTYPE	9	9	mutation
NCT00155701108	NCT00155701_108_T0	PHENOTYPE	14	14	mutation
NCT00155701110	NCT00155701_110_T0	PHENOTYPE	12	12	mutation
NCT00155701110	NCT00155701_110_T1	GENE	13	13	has
NCT00155701110	NCT00155701_110_T2	PHENOTYPE	4	4	RFLP
NCT00155701110	NCT00155701_110_T3	PHENOTYPE	0	3	Restriction fragment length polymorphism
NCT001557140	NCT00155714_0_T0	PHENOTYPE	8	10	Secondary Pulmonary Hypertension
NCT001557142	NCT00155714_2_T0	COMPOUND	12	12	sildenafil
NCT001557272	NCT00155727_2_T0	GENE	11	11	has
NCT001557276	NCT00155727_6_T0	GENE	4	4	II
NCT001557276	NCT00155727_6_T1	GENE	6	6	III
NCT001557279	NCT00155727_9_T0	GENE	14	14	has
NCT0015572713	NCT00155727_13_T0	PHENOTYPE	7	7	immunosuppression
NCT0015572713	NCT00155727_13_T1	PHENOTYPE	17	18	colorectal cancer
NCT0015572715	NCT00155727_15_T0	PHENOTYPE	33	34	colorectal cancer
NCT0015572716	NCT00155727_16_T0	PHENOTYPE	22	22	flatus
NCT0015572716	NCT00155727_16_T1	PHENOTYPE	8	9	life quality
NCT0015572718	NCT00155727_18_T0	PHENOTYPE	5	5	pneumoperitoneum
NCT0015572718	NCT00155727_18_T1	PHENOTYPE	16	17	colorectal cancer
NCT0015572719	NCT00155727_19_T0	GENE	10	10	lines
NCT0015572720	NCT00155727_20_T0	GENE	5	5	has
NCT0015572722	NCT00155727_22_T0	GENE	11	11	has
NCT0015572726	NCT00155727_26_T0	GENE	4	4	II
NCT0015572726	NCT00155727_26_T1	GENE	6	6	III
NCT0015572729	NCT00155727_29_T0	GENE	14	14	has
NCT001557401	NCT00155740_1_T0	PHENOTYPE	3	4	ovarian cancer
NCT001557402	NCT00155740_2_T0	PHENOTYPE	3	3	symptoms
NCT001557402	NCT00155740_2_T1	PHENOTYPE	10	10	tumor
NCT001557402	NCT00155740_2_T2	PHENOTYPE	26	27	ovarian cancer
NCT001557402	NCT00155740_2_T3	PHENOTYPE	17	18	ovarian tumor
NCT001557403	NCT00155740_3_T0	PHENOTYPE	13	13	malignancy
NCT001557403	NCT00155740_3_T1	PHENOTYPE	7	7	tumor
NCT001557403	NCT00155740_3_T2	PHENOTYPE	4	5	ovarian carcinomas
NCT001557403	NCT00155740_3_T3	PHENOTYPE	15	16	residual tumor
NCT001557404	NCT00155740_4_T0	PHENOTYPE	9	9	tumor
NCT001557404	NCT00155740_4_T1	PHENOTYPE	12	13	ovarian cancer
NCT001557405	NCT00155740_5_T0	PHENOTYPE	10	11	disease course
NCT001557407	NCT00155740_7_T0	GENE	0	0	CA125
NCT001557407	NCT00155740_7_T1	ORGAN	6	6	serum
NCT001557407	NCT00155740_7_T2	PHENOTYPE	11	12	ovarian carcinoma
NCT001557408	NCT00155740_8_T0	GENE	20	20	CA125
NCT001557408	NCT00155740_8_T1	GENE	22	22	CA125
NCT001557408	NCT00155740_8_T2	GENE	2	2	has
NCT001557408	NCT00155740_8_T3	PHENOTYPE	15	16	ovarian carcinomas
NCT001557408	NCT00155740_8_T4	PHENOTYPE	29	30	inflammatory disease
NCT0015574010	NCT00155740_10_T0	GENE	0	0	Mesothelin
NCT0015574010	NCT00155740_10_T1	GENE	5	5	glycoprotein
NCT0015574012	NCT00155740_12_T0	GENE	19	19	mesothelin
NCT0015574012	NCT00155740_12_T1	PHENOTYPE	9	9	carcinomas
NCT0015574012	NCT00155740_12_T2	PHENOTYPE	26	26	tumor
NCT0015574012	NCT00155740_12_T3	GENE	0	0	Mesothelin
NCT0015574012	NCT00155740_12_T4	GENE	1	1	has
NCT0015574012	NCT00155740_12_T5	PHENOTYPE	13	14	ovarian carcinoma
NCT0015574012	NCT00155740_12_T6	PHENOTYPE	29	30	ovarian carcinoma
NCT0015574012	NCT00155740_12_T7	PHENOTYPE	10	11	gastric carcinoma
NCT0015574015	NCT00155740_15_T0	PHENOTYPE	3	4	ovarian cancer
NCT0015574016	NCT00155740_16_T0	PHENOTYPE	9	9	cancers
NCT0015574016	NCT00155740_16_T1	GENE	2	2	has
NCT0015574016	NCT00155740_16_T2	PHENOTYPE	0	1	Ovarian cancer
NCT0015574017	NCT00155740_17_T0	PHENOTYPE	3	3	symptoms
NCT0015574017	NCT00155740_17_T1	PHENOTYPE	10	10	tumor
NCT0015574017	NCT00155740_17_T2	PHENOTYPE	26	27	ovarian cancer
NCT0015574017	NCT00155740_17_T3	PHENOTYPE	17	18	ovarian tumor
NCT0015574018	NCT00155740_18_T0	PHENOTYPE	13	13	malignancy
NCT0015574018	NCT00155740_18_T1	PHENOTYPE	7	7	tumor
NCT0015574018	NCT00155740_18_T2	PHENOTYPE	4	5	ovarian carcinomas
NCT0015574018	NCT00155740_18_T3	PHENOTYPE	15	16	residual tumor
NCT0015574019	NCT00155740_19_T0	PHENOTYPE	9	9	tumor
NCT0015574019	NCT00155740_19_T1	PHENOTYPE	12	13	ovarian cancer
NCT0015574020	NCT00155740_20_T0	PHENOTYPE	10	11	disease course
NCT0015574021	NCT00155740_21_T0	PHENOTYPE	4	5	ovarian cancer
NCT0015574023	NCT00155740_23_T0	GENE	0	0	CA125
NCT0015574023	NCT00155740_23_T1	ORGAN	6	6	serum
NCT0015574023	NCT00155740_23_T2	PHENOTYPE	11	12	ovarian carcinoma
NCT0015574024	NCT00155740_24_T0	GENE	20	20	CA125
NCT0015574024	NCT00155740_24_T1	GENE	22	22	CA125
NCT0015574024	NCT00155740_24_T2	GENE	2	2	has
NCT0015574024	NCT00155740_24_T3	PHENOTYPE	15	16	ovarian carcinomas
NCT0015574024	NCT00155740_24_T4	PHENOTYPE	29	30	inflammatory disease
NCT0015574026	NCT00155740_26_T0	PHENOTYPE	4	4	tumor
NCT0015574026	NCT00155740_26_T1	GENE	9	9	Mesothelin
NCT0015574026	NCT00155740_26_T2	GENE	14	14	glycoprotein
NCT0015574026	NCT00155740_26_T3	PHENOTYPE	7	8	ovarian cancer
NCT0015574027	NCT00155740_27_T0	GENE	29	29	membrane-bound
NCT0015574027	NCT00155740_27_T1	GENE	20	20	secreted
NCT0015574027	NCT00155740_27_T2	COMPOUND	18	18	N
NCT0015574028	NCT00155740_28_T0	GENE	4	4	has
NCT0015574028	NCT00155740_28_T1	GENE	2	2	secreted
NCT0015574028	NCT00155740_28_T2	GENE	7	9	megakaryocyte potentiating factor
NCT0015574030	NCT00155740_30_T0	GENE	21	21	mesothelin
NCT0015574030	NCT00155740_30_T1	PHENOTYPE	27	27	tumor
NCT0015574030	NCT00155740_30_T2	GENE	0	0	Mesothelin
NCT0015574030	NCT00155740_30_T3	GENE	1	1	has
NCT0015574030	NCT00155740_30_T4	PHENOTYPE	14	15	ovarian carcinoma
NCT0015574030	NCT00155740_30_T5	PHENOTYPE	30	31	ovarian carcinoma
NCT0015574030	NCT00155740_30_T6	PHENOTYPE	10	11	gastric carcinoma
NCT0015574031	NCT00155740_31_T0	ORGAN	10	10	serum
NCT0015574031	NCT00155740_31_T1	GENE	6	6	mesothelin
NCT0015574031	NCT00155740_31_T2	PHENOTYPE	15	17	epithelial ovarian cancer
NCT0015574036	NCT00155740_36_T0	ORGAN	18	18	ovary
NCT0015574036	NCT00155740_36_T1	PHENOTYPE	24	24	ruptured
NCT0015574036	NCT00155740_36_T2	TISSUE	3	4	lymph node
NCT0015574038	NCT00155740_38_T0	PHENOTYPE	5	6	residual tumor
NCT0015574040	NCT00155740_40_T0	PHENOTYPE	2	3	ovarian endometrioma
NCT0015574040	NCT00155740_40_T1	PHENOTYPE	5	7	benign ovarian tumors
NCT001557533	NCT00155753_3_T0	PHENOTYPE	14	15	pathologic myopia
NCT001557534	NCT00155753_4_T0	PHENOTYPE	9	9	myopia
NCT001557534	NCT00155753_4_T1	PHENOTYPE	2	2	myopic
NCT001557535	NCT00155753_5_T0	GENE	16	16	twins
NCT001557535	NCT00155753_5_T1	GENE	26	26	twins
NCT001557535	NCT00155753_5_T2	ORGAN	5	6	anterior chamber
NCT001557535	NCT00155753_5_T3	PHENOTYPE	12	13	refractive errors
NCT001557536	NCT00155753_6_T0	PHENOTYPE	11	11	myopia
NCT001557536	NCT00155753_6_T1	PHENOTYPE	17	18	pathological myopia
NCT001557538	NCT00155753_8_T0	PHENOTYPE	3	3	myopia
NCT001557538	NCT00155753_8_T1	PHENOTYPE	8	9	refractive error
NCT001557660	NCT00155766_0_T0	PHENOTYPE	4	4	Cancers
NCT001557660	NCT00155766_0_T1	PHENOTYPE	2	2	Recurrent
NCT001557660	NCT00155766_0_T2	CELL	6	7	Dendritic Cells
NCT001557663	NCT00155766_3_T0	GENE	12	12	has
NCT001557664	NCT00155766_4_T0	PHENOTYPE	1	1	papilloma
NCT001557664	NCT00155766_4_T1	PHENOTYPE	10	11	cervical cancer
NCT001557664	NCT00155766_4_T2	PHENOTYPE	23	24	cervical cancer
NCT001557665	NCT00155766_5_T0	TISSUE	11	11	tissues
NCT001557665	NCT00155766_5_T1	PHENOTYPE	9	10	cervical cancer
NCT001557667	NCT00155766_7_T0	PHENOTYPE	18	18	tumor
NCT001557667	NCT00155766_7_T1	CELL	20	21	dendritic cells
NCT001557668	NCT00155766_8_T0	PHENOTYPE	2	2	toxicity
NCT001557668	NCT00155766_8_T1	GENE	3	3	has
NCT001557669	NCT00155766_9_T0	PHENOTYPE	32	32	recurrent
NCT001557669	NCT00155766_9_T1	PHENOTYPE	33	34	cervical cancers
NCT001557669	NCT00155766_9_T2	CELL	23	24	dendritic cells
NCT0015576610	NCT00155766_10_T0	GENE	16	16	IL-4
NCT0015576610	NCT00155766_10_T1	GENE	14	14	GM-CSF
NCT0015576610	NCT00155766_10_T2	CELL	6	7	dendritic cells
NCT0015576611	NCT00155766_11_T0	GENE	17	17	E7
NCT0015576611	NCT00155766_11_T1	GENE	11	11	CTL
NCT0015576611	NCT00155766_11_T2	CELL	1	2	dendritic cells
NCT0015576612	NCT00155766_12_T0	CELL	1	2	dendritic cells
NCT0015576612	NCT00155766_12_T1	TISSUE	8	9	lymph nodes
NCT0015576616	NCT00155766_16_T0	GENE	12	12	has
NCT0015576617	NCT00155766_17_T0	PHENOTYPE	1	1	papilloma
NCT0015576617	NCT00155766_17_T1	PHENOTYPE	10	11	cervical cancer
NCT0015576617	NCT00155766_17_T2	PHENOTYPE	23	24	cervical cancer
NCT0015576618	NCT00155766_18_T0	TISSUE	11	11	tissues
NCT0015576618	NCT00155766_18_T1	PHENOTYPE	9	10	cervical cancer
NCT0015576620	NCT00155766_20_T0	PHENOTYPE	18	18	tumor
NCT0015576620	NCT00155766_20_T1	CELL	20	21	dendritic cells
NCT0015576621	NCT00155766_21_T0	PHENOTYPE	2	2	toxicity
NCT0015576621	NCT00155766_21_T1	GENE	3	3	has
NCT0015576622	NCT00155766_22_T0	PHENOTYPE	32	32	recurrent
NCT0015576622	NCT00155766_22_T1	PHENOTYPE	33	34	cervical cancers
NCT0015576622	NCT00155766_22_T2	CELL	23	24	dendritic cells
NCT0015576623	NCT00155766_23_T0	GENE	16	16	IL-4
NCT0015576623	NCT00155766_23_T1	GENE	14	14	GM-CSF
NCT0015576623	NCT00155766_23_T2	CELL	6	7	dendritic cells
NCT0015576624	NCT00155766_24_T0	GENE	17	17	E7
NCT0015576624	NCT00155766_24_T1	GENE	11	11	CTL
NCT0015576624	NCT00155766_24_T2	CELL	1	2	dendritic cells
NCT0015576625	NCT00155766_25_T0	CELL	1	2	dendritic cells
NCT0015576625	NCT00155766_25_T1	TISSUE	8	9	lymph nodes
NCT0015576629	NCT00155766_29_T0	GENE	3	3	ot
NCT0015576629	NCT00155766_29_T1	COMPOUND	2	2	cisplatin
NCT0015576632	NCT00155766_32_T0	GENE	3	3	II
NCT0015576634	NCT00155766_34_T0	ORGAN	1	2	bone marrow
NCT0015576636	NCT00155766_36_T0	PHENOTYPE	0	1	CNS metastasis
NCT0015576637	NCT00155766_37_T0	PHENOTYPE	0	0	Acute
NCT0015576637	NCT00155766_37_T1	PHENOTYPE	2	3	chronic infection
NCT0015576639	NCT00155766_39_T0	PHENOTYPE	0	0	Asthma
NCT0015576641	NCT00155766_41_T0	PHENOTYPE	0	1	Autoimmune disease
NCT001557790	NCT00155779_0_T0	GENE	0	0	ACE
NCT001557790	NCT00155779_0_T1	PHENOTYPE	4	4	ARDS
NCT001557793	NCT00155779_3_T0	GENE	31	31	II
NCT001557793	NCT00155779_3_T1	GENE	29	29	DD
NCT001557793	NCT00155779_3_T2	GENE	1	1	ACE
NCT001557793	NCT00155779_3_T3	PHENOTYPE	14	14	deletion
NCT001557794	NCT00155779_4_T0	GENE	8	8	ACE
NCT001557794	NCT00155779_4_T1	GENE	18	18	ACE
NCT001557794	NCT00155779_4_T2	GENE	1	1	has
NCT001557794	NCT00155779_4_T3	ORGAN	17	17	serum
NCT001557797	NCT00155779_7_T0	GENE	12	12	ACE
NCT001557797	NCT00155779_7_T1	GENE	20	20	ACE
NCT001557797	NCT00155779_7_T2	PHENOTYPE	31	31	ARDS
NCT001557798	NCT00155779_8_T0	PHENOTYPE	4	4	ARDS
NCT001557799	NCT00155779_9_T0	GENE	1	1	ACE
NCT001557799	NCT00155779_9_T1	GENE	32	32	ACE
NCT001557799	NCT00155779_9_T2	GENE	12	12	polymerase
NCT001557799	NCT00155779_9_T3	GENE	20	20	fragment
NCT001557799	NCT00155779_9_T4	PHENOTYPE	7	7	ARDS
NCT001557799	NCT00155779_9_T5	GENE	15	15	PCR
NCT0015577910	NCT00155779_10_T0	PHENOTYPE	5	5	ARDS
NCT0015577912	NCT00155779_12_T0	PHENOTYPE	8	8	ARDS
NCT0015577917	NCT00155779_17_T0	GENE	3	3	had
NCT0015577917	NCT00155779_17_T1	PHENOTYPE	7	7	ARDS
NCT0015577918	NCT00155779_18_T0	PHENOTYPE	3	3	sepsis
NCT0015577921	NCT00155779_21_T0	GENE	3	3	had
NCT0015577921	NCT00155779_21_T1	GENE	19	19	had
NCT0015577921	NCT00155779_21_T2	PHENOTYPE	8	9	respiratory failure
NCT0015577923	NCT00155779_23_T0	GENE	24	24	II
NCT0015577923	NCT00155779_23_T1	PHENOTYPE	20	20	Chronic
NCT0015577923	NCT00155779_23_T2	PHENOTYPE	17	17	Acute
NCT0015577923	NCT00155779_23_T3	PHENOTYPE	18	18	Physiology
NCT0015577923	NCT00155779_23_T4	PHENOTYPE	2	2	ARDS
NCT0015577927	NCT00155779_27_T0	PHENOTYPE	14	14	ventilation
NCT0015577927	NCT00155779_27_T1	PHENOTYPE	0	0	Decisions
NCT0015577927	NCT00155779_27_T2	PHENOTYPE	6	6	ARDS
NCT0015577927	NCT00155779_27_T3	COMPOUND	10	11	nitric oxide
NCT0015577928	NCT00155779_28_T0	PHENOTYPE	14	14	ARDS
NCT0015577929	NCT00155779_29_T0	PHENOTYPE	1	1	secondary
NCT0015577930	NCT00155779_30_T0	GENE	0	0	ACE
NCT0015577931	NCT00155779_31_T0	PHENOTYPE	11	11	peripheral
NCT0015577931	NCT00155779_31_T1	COMPOUND	19	19	EDTA
NCT0015577932	NCT00155779_32_T0	GENE	11	11	Kit
NCT0015577932	NCT00155779_32_T1	GENE	14	14	CA
NCT0015577933	NCT00155779_33_T0	GENE	1	1	ACE
NCT0015577933	NCT00155779_33_T1	GENE	24	24	ACE
NCT0015577933	NCT00155779_33_T2	GENE	7	7	PCR
NCT0015577934	NCT00155779_34_T0	COMPOUND	23	23	MgCl2
NCT0015577934	NCT00155779_34_T1	GENE	32	32	0.2
NCT0015577934	NCT00155779_34_T2	GENE	42	42	polymerase
NCT0015577934	NCT00155779_34_T3	GENE	21	21	1.5
NCT0015577934	NCT00155779_34_T4	COMPOUND	29	29	Tris-HCl
NCT0015577934	NCT00155779_34_T5	GENE	30	30	pH
NCT0015577934	NCT00155779_34_T6	GENE	1	1	PCR
NCT0015577935	NCT00155779_35_T0	GENE	39	39	480
NCT0015577936	NCT00155779_36_T0	COMPOUND	8	8	agarose
NCT0015577936	NCT00155779_36_T1	GENE	1	1	PCR
NCT0015577937	NCT00155779_37_T0	GENE	8	8	DD
NCT0015577937	NCT00155779_37_T1	GENE	15	15	DD
NCT0015577937	NCT00155779_37_T2	GENE	23	23	PCR
NCT0015577938	NCT00155779_38_T0	GENE	3	3	has
NCT0015577938	NCT00155779_38_T1	GENE	1	1	PCR
NCT0015577939	NCT00155779_39_T0	GENE	21	21	DD
NCT0015577941	NCT00155779_41_T0	GENE	5	5	10.1
NCT0015577943	NCT00155779_43_T0	GENE	8	8	ANOVA
NCT0015577944	NCT00155779_44_T0	PHENOTYPE	30	30	ARDS
NCT0015577946	NCT00155779_46_T0	PHENOTYPE	6	6	secondary
NCT001557922	NCT00155792_2_T0	PHENOTYPE	8	9	cervical cancer
NCT001557923	NCT00155792_3_T0	CELL	20	20	cells
NCT001557923	NCT00155792_3_T1	CELL	22	22	cells
NCT001557924	NCT00155792_4_T0	PHENOTYPE	10	11	cervical cancer
NCT001557925	NCT00155792_5_T0	PHENOTYPE	1	1	papilloma
NCT001557925	NCT00155792_5_T1	PHENOTYPE	10	11	cervical cancer
NCT001557925	NCT00155792_5_T2	PHENOTYPE	23	24	cervical cancer
NCT001557926	NCT00155792_6_T0	TISSUE	11	11	tissues
NCT001557926	NCT00155792_6_T1	PHENOTYPE	9	10	cervical cancer
NCT001557927	NCT00155792_7_T0	PHENOTYPE	21	21	malignancy
NCT001557927	NCT00155792_7_T1	PHENOTYPE	12	12	regression
NCT001557927	NCT00155792_7_T2	PHENOTYPE	17	17	persistence
NCT001557927	NCT00155792_7_T3	PHENOTYPE	19	19	progression
NCT001557927	NCT00155792_7_T4	PHENOTYPE	14	15	cervical abnormality
NCT001557927	NCT00155792_7_T5	BIOLOGICAL_PROCESS	3	4	immune response
NCT001557928	NCT00155792_8_T0	PHENOTYPE	10	10	tumors
NCT001557928	NCT00155792_8_T1	CELL	27	27	cells
NCT0015579211	NCT00155792_11_T0	PHENOTYPE	5	6	tumor immunity
NCT0015579212	NCT00155792_12_T0	GENE	16	16	E7
NCT0015579212	NCT00155792_12_T1	PHENOTYPE	21	21	strategies
NCT0015579212	NCT00155792_12_T2	GENE	3	3	Dr
NCT0015579212	NCT00155792_12_T3	GENE	4	4	TC
NCT0015579219	NCT00155792_19_T0	PHENOTYPE	7	7	tumors
NCT0015579219	NCT00155792_19_T1	PHENOTYPE	13	13	carcinomas
NCT0015579220	NCT00155792_20_T0	PHENOTYPE	29	29	cancers
NCT0015579220	NCT00155792_20_T1	ORGAN	1	1	genital
NCT0015579221	NCT00155792_21_T0	COMPOUND	21	21	1
NCT0015579221	NCT00155792_21_T1	PHENOTYPE	5	6	cervical cancer
NCT0015579223	NCT00155792_23_T0	COMPOUND	13	13	2
NCT0015579223	NCT00155792_23_T1	PHENOTYPE	11	12	cervical cancer
NCT0015579227	NCT00155792_27_T0	PHENOTYPE	18	18	deletion
NCT0015579228	NCT00155792_28_T0	GENE	16	16	E6
NCT0015579228	NCT00155792_28_T1	GENE	18	18	E7
NCT0015579228	NCT00155792_28_T2	GENE	2	2	L1
NCT0015579228	NCT00155792_28_T3	PHENOTYPE	28	28	carcinomas
NCT0015579228	NCT00155792_28_T4	GENE	4	4	L2
NCT0015579228	NCT00155792_28_T5	GENE	9	9	E1
NCT0015579228	NCT00155792_28_T6	GENE	11	11	E2
NCT0015579231	NCT00155792_31_T0	GENE	16	16	E6
NCT0015579231	NCT00155792_31_T1	GENE	18	18	E7
NCT0015579231	NCT00155792_31_T2	PHENOTYPE	5	6	cervical cancers
NCT0015579231	NCT00155792_31_T3	PHENOTYPE	24	25	cervical cancers
NCT0015579233	NCT00155792_33_T0	GENE	2	2	E6
NCT0015579233	NCT00155792_33_T1	GENE	4	4	E7
NCT0015579233	NCT00155792_33_T2	CELL	17	17	cells
NCT0015579233	NCT00155792_33_T3	CELL	19	19	cells
NCT0015579233	NCT00155792_33_T4	BIOLOGICAL_PROCESS	26	27	immune response
NCT0015579233	NCT00155792_33_T5	PHENOTYPE	21	22	cervical cancer
NCT0015579234	NCT00155792_34_T0	GENE	2	2	E6
NCT0015579234	NCT00155792_34_T1	GENE	4	4	E7
NCT0015579234	NCT00155792_34_T2	CELL	6	6	cells
NCT0015579234	NCT00155792_34_T3	GENE	8	8	cease
NCT0015579235	NCT00155792_35_T0	GENE	1	1	E6
NCT0015579235	NCT00155792_35_T1	GENE	3	3	E7
NCT0015579235	NCT00155792_35_T2	PHENOTYPE	15	16	cervical cancer
NCT0015579236	NCT00155792_36_T0	GENE	24	24	E6
NCT0015579236	NCT00155792_36_T1	GENE	26	26	E7
NCT0015579236	NCT00155792_36_T2	GENE	29	29	10
NCT0015579238	NCT00155792_38_T0	GENE	30	30	11
NCT0015579238	NCT00155792_38_T1	GENE	18	18	E7
NCT0015579238	NCT00155792_38_T2	GENE	25	25	E7
NCT0015579238	NCT00155792_38_T3	CELL	13	13	cells
NCT0015579238	NCT00155792_38_T4	CELL	29	29	cells
NCT0015579238	NCT00155792_38_T5	PHENOTYPE	28	28	tumor
NCT0015579238	NCT00155792_38_T6	GENE	4	4	al
NCT0015579238	NCT00155792_38_T7	GENE	3	3	et
NCT0015579239	NCT00155792_39_T0	GENE	9	9	E7
NCT0015579239	NCT00155792_39_T1	GENE	14	14	MHC
NCT0015579239	NCT00155792_39_T2	GENE	5	5	CTL
NCT0015579239	NCT00155792_39_T3	GENE	2	2	al
NCT0015579239	NCT00155792_39_T4	GENE	1	1	et
NCT0015579240	NCT00155792_40_T0	GENE	15	15	12
NCT0015579240	NCT00155792_40_T1	CELL	14	14	cells
NCT0015579240	NCT00155792_40_T2	PHENOTYPE	13	13	tumor
NCT0015579240	NCT00155792_40_T3	PHENOTYPE	6	6	resistant
NCT0015579240	NCT00155792_40_T4	PHENOTYPE	12	12	transformed
NCT0015579241	NCT00155792_41_T0	GENE	32	32	E7
NCT0015579241	NCT00155792_41_T1	PHENOTYPE	34	34	tumors
NCT0015579241	NCT00155792_41_T2	GENE	11	11	al
NCT0015579241	NCT00155792_41_T3	GENE	19	19	al
NCT0015579241	NCT00155792_41_T4	GENE	24	24	has
NCT0015579241	NCT00155792_41_T5	GENE	10	10	et
NCT0015579241	NCT00155792_41_T6	GENE	18	18	et
NCT0015579242	NCT00155792_42_T0	GENE	25	25	E6
NCT0015579242	NCT00155792_42_T1	GENE	35	35	13
NCT0015579242	NCT00155792_42_T2	GENE	27	27	E7
NCT0015579242	NCT00155792_42_T3	PHENOTYPE	21	21	vaccinia
NCT0015579242	NCT00155792_42_T4	PHENOTYPE	14	16	stage cervical cancer
NCT0015579243	NCT00155792_43_T0	GENE	15	15	13
NCT0015579247	NCT00155792_47_T0	PHENOTYPE	4	4	regression
NCT0015579252	NCT00155792_52_T0	GENE	9	9	has
NCT0015579252	NCT00155792_52_T1	PHENOTYPE	1	1	infiltration
NCT0015579252	NCT00155792_52_T2	PHENOTYPE	3	4	cervical cancer
NCT0015579262	NCT00155792_62_T0	GENE	0	0	CD4
NCT0015579262	NCT00155792_62_T1	CELL	2	3	helper cells
NCT0015579263	NCT00155792_63_T0	GENE	19	19	49
NCT0015579263	NCT00155792_63_T1	GENE	0	0	CD4
NCT0015579263	NCT00155792_63_T2	PHENOTYPE	16	16	malignancies
NCT0015579263	NCT00155792_63_T3	GENE	20	20	50
NCT0015579263	NCT00155792_63_T4	GENE	24	24	51
NCT0015579263	NCT00155792_63_T5	GENE	25	25	52
NCT0015579263	NCT00155792_63_T6	CELL	1	2	T cells
NCT0015579264	NCT00155792_64_T0	PHENOTYPE	2	2	tumors
NCT0015579264	NCT00155792_64_T1	PHENOTYPE	25	25	tumors
NCT0015579264	NCT00155792_64_T2	GENE	26	26	53
NCT0015579264	NCT00155792_64_T3	GENE	27	27	54
NCT0015579264	NCT00155792_64_T4	PHENOTYPE	22	23	class II
NCT0015579264	NCT00155792_64_T5	GENE	8	10	MHC class II
NCT0015579266	NCT00155792_66_T0	PHENOTYPE	8	8	immunity
NCT0015579266	NCT00155792_66_T1	PHENOTYPE	5	5	Immunity
NCT0015579266	NCT00155792_66_T2	GENE	15	15	secreted
NCT0015579266	NCT00155792_66_T3	CELL	18	19	helper cells
NCT0015579268	NCT00155792_68_T0	GENE	7	8	interferon gamma
NCT0015579268	NCT00155792_68_T1	CELL	0	1	Th1 cells
NCT0015579279	NCT00155792_79_T0	GENE	19	19	E7
NCT0015579279	NCT00155792_79_T1	GENE	36	36	E7
NCT0015579279	NCT00155792_79_T2	GENE	31	31	Th
NCT001558055	NCT00155805_5_T0	PHENOTYPE	6	6	GERD
NCT001558055	NCT00155805_5_T1	PHENOTYPE	21	21	diseases
NCT001558056	NCT00155805_6_T0	PHENOTYPE	0	0	Reflux
NCT001558056	NCT00155805_6_T1	ORGAN	12	12	esophagus
NCT001558056	NCT00155805_6_T2	PHENOTYPE	14	15	esophageal cancer
NCT001558056	NCT00155805_6_T3	PHENOTYPE	9	10	esophageal injury
NCT001558058	NCT00155805_8_T0	PHENOTYPE	12	12	GERD
NCT001558059	NCT00155805_9_T0	PHENOTYPE	14	14	GERD
NCT001558059	NCT00155805_9_T1	ORGAN	17	17	esophagus
NCT001558059	NCT00155805_9_T2	PHENOTYPE	8	9	tumor necrosis
NCT0015580510	NCT00155805_10_T0	PHENOTYPE	12	12	GERD
NCT0015580510	NCT00155805_10_T1	GENE	9	9	Hp
NCT0015580510	NCT00155805_10_T2	GENE	27	27	Hp
NCT0015580510	NCT00155805_10_T3	PHENOTYPE	32	32	reflux
NCT0015580511	NCT00155805_11_T0	PHENOTYPE	15	15	GERD
NCT0015580511	NCT00155805_11_T1	GENE	16	16	has
NCT0015580511	NCT00155805_11_T2	GENE	7	7	LES
NCT0015580511	NCT00155805_11_T3	PHENOTYPE	23	23	experiences
NCT0015580514	NCT00155805_14_T0	GENE	4	4	al
NCT0015580514	NCT00155805_14_T1	GENE	32	32	NERD
NCT0015580514	NCT00155805_14_T2	GENE	3	3	et
NCT0015580514	NCT00155805_14_T3	PHENOTYPE	11	11	GERD
NCT0015580514	NCT00155805_14_T4	ORGAN	37	37	esophagus
NCT0015580514	NCT00155805_14_T5	PHENOTYPE	33	34	reflux esophagitis
NCT0015580517	NCT00155805_17_T0	ORGAN	3	3	diaphragm
NCT0015580517	NCT00155805_17_T1	PHENOTYPE	15	15	reflux
NCT0015580517	NCT00155805_17_T2	GENE	0	0	LES
NCT0015580517	NCT00155805_17_T3	ORGAN	11	11	esophagus
NCT0015580520	NCT00155805_20_T0	ORGAN	6	6	diaphragm
NCT0015580520	NCT00155805_20_T1	GENE	37	37	COX-2
NCT0015580520	NCT00155805_20_T2	GENE	28	28	NERD
NCT0015580520	NCT00155805_20_T3	PHENOTYPE	1	1	dysfunction
NCT0015580520	NCT00155805_20_T4	GENE	3	3	LES
NCT0015580520	NCT00155805_20_T5	GENE	24	24	mediator
NCT0015580520	NCT00155805_20_T6	ORGAN	33	33	esophagus
NCT0015580520	NCT00155805_20_T7	PHENOTYPE	29	30	reflux esophagitis
NCT0015580525	NCT00155805_25_T0	GENE	4	4	Hp
NCT0015580525	NCT00155805_25_T1	GENE	26	26	Hp
NCT0015580525	NCT00155805_25_T2	ORGAN	8	8	esophagus
NCT0015580529	NCT00155805_29_T0	BIOLOGICAL_PROCESS	1	1	necrosis
NCT0015580529	NCT00155805_29_T1	PHENOTYPE	2	3	reflux esophagitis
NCT0015580532	NCT00155805_32_T0	PHENOTYPE	7	7	inflammation
NCT0015580532	NCT00155805_32_T1	PHENOTYPE	20	20	reflux
NCT0015580532	NCT00155805_32_T2	GENE	17	17	LES
NCT0015580532	NCT00155805_32_T3	PHENOTYPE	18	18	dysfunction
NCT0015580534	NCT00155805_34_T0	GENE	0	0	ROS
NCT0015580539	NCT00155805_39_T0	PHENOTYPE	9	9	carcinogenesis
NCT0015580539	NCT00155805_39_T1	GENE	1	1	COX-2
NCT0015580541	NCT00155805_41_T0	GENE	12	12	COX-2
NCT0015580541	NCT00155805_41_T1	GENE	10	10	PGs
NCT0015580541	NCT00155805_41_T2	PHENOTYPE	15	16	reflux esophagitis
NCT0015580543	NCT00155805_43_T0	GENE	7	7	iNOS
NCT0015580543	NCT00155805_43_T1	GENE	13	13	has
NCT0015580546	NCT00155805_46_T0	PHENOTYPE	25	25	complications
NCT0015580546	NCT00155805_46_T1	GENE	4	4	COX-2
NCT0015580546	NCT00155805_46_T2	PHENOTYPE	17	18	reflux esophagitis
NCT0015580549	NCT00155805_49_T0	GENE	1	1	has
NCT0015580555	NCT00155805_55_T0	PHENOTYPE	9	9	severity
NCT0015580555	NCT00155805_55_T1	PHENOTYPE	3	3	GERD
NCT0015580555	NCT00155805_55_T2	PHENOTYPE	13	15	quality of life
NCT0015580559	NCT00155805_59_T0	ORGAN	5	5	cardia
NCT0015580559	NCT00155805_59_T1	GENE	21	21	Hp
NCT0015580559	NCT00155805_59_T2	ORGAN	4	4	esophagus
NCT0015580559	NCT00155805_59_T3	ORGAN	27	27	esophagus
NCT0015580559	NCT00155805_59_T4	PHENOTYPE	18	19	atrophic gastritis
NCT0015580562	NCT00155805_62_T0	GENE	0	0	EIA
NCT0015580562	NCT00155805_62_T1	GENE	2	2	PGs
NCT0015580564	NCT00155805_64_T0	COMPOUND	5	5	antral
NCT0015580564	NCT00155805_64_T1	GENE	9	9	EIA
NCT0015580566	NCT00155805_66_T0	GENE	8	8	PGII
NCT0015580566	NCT00155805_66_T1	GENE	7	7	PGI
NCT0015580566	NCT00155805_66_T2	GENE	12	12	Hp
NCT0015580566	NCT00155805_66_T3	GENE	4	4	EIA
NCT0015580566	NCT00155805_66_T4	ORGAN	3	3	plasma
NCT0015580566	NCT00155805_66_T5	GENE	10	10	gastrin
NCT0015580568	NCT00155805_68_T0	PHENOTYPE	10	10	hypotensive
NCT0015580574	NCT00155805_74_T0	ORGAN	9	9	esophagus
NCT0015580576	NCT00155805_76_T0	PHENOTYPE	14	16	gastroesophageal reflux disease
NCT0015580577	NCT00155805_77_T0	PHENOTYPE	14	14	GERD
NCT0015580577	NCT00155805_77_T1	PHENOTYPE	35	35	GERD
NCT0015580578	NCT00155805_78_T0	GENE	3	3	Hp
NCT0015580578	NCT00155805_78_T1	GENE	13	13	Hp
NCT0015580578	NCT00155805_78_T2	PHENOTYPE	17	18	esophageal diseases
NCT0015580578	NCT00155805_78_T3	PHENOTYPE	16	17	reflux esophageal
NCT001558183	NCT00155818_3_T0	PHENOTYPE	23	23	schizophrenia
NCT001558183	NCT00155818_3_T1	GENE	7	7	has
NCT001558183	NCT00155818_3_T2	GENE	12	12	NPL
NCT001558184	NCT00155818_4_T0	PHENOTYPE	11	11	schizophrenia
NCT001558184	NCT00155818_4_T1	GENE	8	8	DISC1
NCT001558184	NCT00155818_4_T2	GENE	12	13	gene 1
NCT001558185	NCT00155818_5_T0	PHENOTYPE	6	6	translocation
NCT001558185	NCT00155818_5_T1	PHENOTYPE	13	13	schizophrenia
NCT001558185	NCT00155818_5_T2	GENE	9	9	has
NCT001558186	NCT00155818_6_T0	PHENOTYPE	4	4	translocation
NCT001558186	NCT00155818_6_T1	GENE	18	18	DISC1
NCT001558187	NCT00155818_7_T0	PHENOTYPE	1	1	translocation
NCT001558188	NCT00155818_8_T0	PHENOTYPE	31	31	schizophrenia
NCT001558188	NCT00155818_8_T1	GENE	9	9	has
NCT001558188	NCT00155818_8_T2	GENE	28	28	DISC1
NCT001558189	NCT00155818_9_T0	GENE	6	6	DISC1
NCT0015581810	NCT00155818_10_T0	PHENOTYPE	16	16	translocation
NCT0015581810	NCT00155818_10_T1	CELL	19	19	chromosome
NCT0015581811	NCT00155818_11_T0	PHENOTYPE	6	6	symptoms
NCT0015581811	NCT00155818_11_T1	PHENOTYPE	18	18	characters
NCT0015581811	NCT00155818_11_T2	PHENOTYPE	22	22	translocation
NCT0015581812	NCT00155818_12_T0	GENE	8	8	DISC1
NCT0015581816	NCT00155818_16_T0	GENE	4	4	has
NCT0015581817	NCT00155818_17_T0	GENE	8	8	had
NCT0015581818	NCT00155818_18_T0	PHENOTYPE	8	8	schizophrenia
NCT0015581818	NCT00155818_18_T1	GENE	3	3	has
NCT0015581818	NCT00155818_18_T2	GENE	1	1	DISC1
NCT0015581819	NCT00155818_19_T0	GENE	5	5	DISC1
NCT0015581820	NCT00155818_20_T0	PHENOTYPE	6	6	translocation
NCT0015581820	NCT00155818_20_T1	PHENOTYPE	11	11	schizophrenia
NCT0015581823	NCT00155818_23_T0	GENE	25	25	DISC1
NCT0015581824	NCT00155818_24_T0	PHENOTYPE	0	0	Translocation
NCT0015581825	NCT00155818_25_T0	CELL	4	5	mononuclear leukocytes
NCT0015581826	NCT00155818_26_T0	COMPOUND	3	3	EDTA
NCT0015581829	NCT00155818_29_T0	CELL	3	3	cells
NCT0015581829	NCT00155818_29_T1	GENE	20	20	al
NCT0015581829	NCT00155818_29_T2	GENE	19	19	et
NCT0015581830	NCT00155818_30_T0	GENE	0	0	PCR
NCT0015581830	NCT00155818_30_T1	GENE	16	17	DNA polymerase
NCT0015581831	NCT00155818_31_T0	COMPOUND	23	23	MgCl2
NCT0015581831	NCT00155818_31_T1	GENE	21	21	1.5
NCT0015581831	NCT00155818_31_T2	COMPOUND	30	30	Tris-HCl
NCT0015581835	NCT00155818_35_T0	GENE	3	3	PCR
NCT0015581835	NCT00155818_35_T1	GENE	12	12	PCR
NCT0015581835	NCT00155818_35_T2	GENE	9	9	gel
NCT0015581837	NCT00155818_37_T0	COMPOUND	18	18	agarose
NCT0015581837	NCT00155818_37_T1	GENE	2	2	1.4
NCT0015581837	NCT00155818_37_T2	GENE	29	29	al
NCT0015581837	NCT00155818_37_T3	GENE	19	19	gel
NCT0015581837	NCT00155818_37_T4	GENE	28	28	et
NCT0015581837	NCT00155818_37_T5	GENE	6	6	fragment
NCT0015581837	NCT00155818_37_T6	GENE	12	12	PCR
NCT0015581839	NCT00155818_39_T0	GENE	32	32	T4
NCT0015581839	NCT00155818_39_T1	GENE	8	8	fragment
NCT0015581839	NCT00155818_39_T2	GENE	28	28	PEG
NCT0015581839	NCT00155818_39_T3	GENE	4	4	1.4
NCT0015581839	NCT00155818_39_T4	GENE	33	33	ligase
NCT0015581840	NCT00155818_40_T0	GENE	9	9	hr
NCT0015581841	NCT00155818_41_T0	GENE	18	18	fragment
NCT0015581841	NCT00155818_41_T1	GENE	24	24	kit
NCT0015581841	NCT00155818_41_T2	GENE	17	17	PCR
NCT0015581843	NCT00155818_43_T0	GENE	12	12	kit
NCT0015581844	NCT00155818_44_T0	CELL	1	1	cells
NCT0015581844	NCT00155818_44_T1	GENE	30	30	shaker
NCT0015581844	NCT00155818_44_T2	GENE	12	12	ml
NCT0015581845	NCT00155818_45_T0	GENE	9	9	ml
NCT0015581845	NCT00155818_45_T1	GENE	16	16	ml
NCT0015581847	NCT00155818_47_T0	GENE	2	2	ml
NCT0015581851	NCT00155818_51_T0	CELL	6	6	cells
NCT0015581852	NCT00155818_52_T0	CELL	1	1	cells
NCT0015581854	NCT00155818_54_T0	CELL	10	10	clones
NCT0015581854	NCT00155818_54_T1	GENE	25	25	lacZ
NCT0015581854	NCT00155818_54_T2	CELL	0	0	Clone
NCT0015581855	NCT00155818_55_T0	GENE	11	11	PCR
NCT0015581859	NCT00155818_59_T0	COMPOUND	11	11	isopropanol
NCT0015581860	NCT00155818_60_T0	COMPOUND	9	9	ethanol
NCT0015581861	NCT00155818_61_T0	CELL	40	40	chromosomes
NCT0015581861	NCT00155818_61_T1	GENE	0	0	PCR
NCT0015581861	NCT00155818_61_T2	GENE	26	26	PCR
NCT0015581862	NCT00155818_62_T0	GENE	0	0	PCR
NCT0015581862	NCT00155818_62_T1	GENE	13	14	DNA polymerase
NCT0015581863	NCT00155818_63_T0	COMPOUND	23	23	MgCl2
NCT0015581863	NCT00155818_63_T1	GENE	21	21	1.5
NCT0015581863	NCT00155818_63_T2	COMPOUND	30	30	Tris-HCl
NCT0015581865	NCT00155818_65_T0	CELL	5	5	chromosome
NCT0015581866	NCT00155818_66_T0	PHENOTYPE	20	20	translocation
NCT0015581866	NCT00155818_66_T1	GENE	9	9	1.4
NCT0015581866	NCT00155818_66_T2	CELL	23	23	chromosome
NCT0015581866	NCT00155818_66_T3	GENE	2	2	PCR
NCT0015581867	NCT00155818_67_T0	PHENOTYPE	14	14	translocation
NCT0015581868	NCT00155818_68_T0	PHENOTYPE	6	6	translocation
NCT0015581870	NCT00155818_70_T0	PHENOTYPE	2	2	translocation
NCT0015581870	NCT00155818_70_T1	GENE	8	8	has
NCT0015581872	NCT00155818_72_T0	PHENOTYPE	2	2	translocation
NCT0015581874	NCT00155818_74_T0	PHENOTYPE	15	15	schizophrenia
NCT0015581874	NCT00155818_74_T1	GENE	12	12	DISC1
NCT0015581876	NCT00155818_76_T0	PHENOTYPE	14	14	mutation
NCT0015581876	NCT00155818_76_T1	CELL	37	37	chromosome
NCT0015581877	NCT00155818_77_T0	GENE	28	28	PCR
NCT0015581877	NCT00155818_77_T1	GENE	36	36	PCR
NCT0015581878	NCT00155818_78_T0	PHENOTYPE	30	30	schizophrenia
NCT0015581879	NCT00155818_79_T0	GENE	0	0	PCR
NCT0015581879	NCT00155818_79_T1	GENE	25	25	PCR
NCT0015581881	NCT00155818_81_T0	GENE	0	0	PCR
NCT0015581881	NCT00155818_81_T1	GENE	13	14	DNA polymerase
NCT0015581882	NCT00155818_82_T0	COMPOUND	23	23	MgCl2
NCT0015581882	NCT00155818_82_T1	GENE	21	21	1.5
NCT0015581882	NCT00155818_82_T2	COMPOUND	30	30	Tris-HCl
NCT0015581884	NCT00155818_84_T0	GENE	9	9	Tm
NCT0015581884	NCT00155818_84_T1	GENE	0	0	PCR
NCT0015581885	NCT00155818_85_T0	GENE	5	5	fragment
NCT0015581885	NCT00155818_85_T1	GENE	8	8	PCR
NCT0015581885	NCT00155818_85_T2	GENE	24	24	PCR
NCT0015581885	NCT00155818_85_T3	GENE	29	29	PCR
NCT0015581886	NCT00155818_86_T0	GENE	17	17	WAVE
NCT0015581886	NCT00155818_86_T1	PHENOTYPE	0	0	Mutation
NCT0015581888	NCT00155818_88_T0	GENE	14	14	al
NCT0015581888	NCT00155818_88_T1	GENE	13	13	et
NCT0015581889	NCT00155818_89_T0	COMPOUND	9	9	acetate
NCT0015581889	NCT00155818_89_T1	COMPOUND	21	21	acetonitrile
NCT0015581889	NCT00155818_89_T2	COMPOUND	8	8	triethylammonium
NCT0015581891	NCT00155818_91_T0	GENE	13	13	fragment
NCT0015581891	NCT00155818_91_T1	PHENOTYPE	3	3	concentrations
NCT0015581893	NCT00155818_93_T0	PHENOTYPE	4	4	mutation
NCT0015581893	NCT00155818_93_T1	GENE	8	8	fragment
NCT0015581893	NCT00155818_93_T2	GENE	24	24	fragment
NCT0015581893	NCT00155818_93_T3	GENE	16	16	Tm
NCT0015581895	NCT00155818_95_T0	PHENOTYPE	7	7	Mutation
NCT0015581896	NCT00155818_96_T0	PHENOTYPE	0	0	RFLP
NCT0015581896	NCT00155818_96_T1	GENE	5	5	PCR
NCT0015581897	NCT00155818_97_T0	PHENOTYPE	2	2	mutation
NCT0015581897	NCT00155818_97_T1	GENE	19	19	fragment
NCT0015581897	NCT00155818_97_T2	PHENOTYPE	22	22	RFLP
NCT00155818100	NCT00155818_100_T0	PHENOTYPE	14	14	mutation
NCT00155818101	NCT00155818_101_T0	PHENOTYPE	25	25	mutation
NCT00155818106	NCT00155818_106_T0	PHENOTYPE	9	9	mutation
NCT00155818108	NCT00155818_108_T0	PHENOTYPE	14	14	mutation
NCT00155818110	NCT00155818_110_T0	PHENOTYPE	12	12	mutation
NCT00155818110	NCT00155818_110_T1	GENE	13	13	has
NCT00155818110	NCT00155818_110_T2	PHENOTYPE	4	4	RFLP
NCT00155818110	NCT00155818_110_T3	PHENOTYPE	0	3	Restriction fragment length polymorphism
NCT0015583110	NCT00155831_10_T0	PHENOTYPE	5	6	premature infants
NCT0015583116	NCT00155831_16_T0	PHENOTYPE	10	11	Infant Development
NCT0015583118	NCT00155831_18_T0	PHENOTYPE	20	20	pulse
NCT0015583118	NCT00155831_18_T1	PHENOTYPE	0	1	Respiratory disease
NCT0015583118	NCT00155831_18_T2	PHENOTYPE	14	15	Bronchopulmonary Dysplasia
NCT0015583123	NCT00155831_23_T0	PHENOTYPE	18	19	developmental disabilities
NCT0015583125	NCT00155831_25_T0	PHENOTYPE	23	24	premature infants
NCT0015583125	NCT00155831_25_T1	PHENOTYPE	27	28	respiratory disease
NCT001558443	NCT00155844_3_T0	GENE	12	12	PB
NCT001558443	NCT00155844_3_T1	CELL	8	8	cells
NCT001558443	NCT00155844_3_T2	GENE	30	30	axis
NCT001558443	NCT00155844_3_T3	PHENOTYPE	31	31	dysfunction
NCT001558446	NCT00155844_6_T0	PHENOTYPE	14	14	peripheral
NCT001558446	NCT00155844_6_T1	CELL	8	8	cells
NCT001558446	NCT00155844_6_T2	CELL	3	4	progenitor cells
NCT001558449	NCT00155844_9_T0	ORGAN	22	22	marrow
NCT001558449	NCT00155844_9_T1	GENE	11	11	PB
NCT001558449	NCT00155844_9_T2	GENE	19	19	CXCL12
NCT001558449	NCT00155844_9_T3	PHENOTYPE	7	7	HPC
NCT001558449	NCT00155844_9_T4	GENE	25	25	has
NCT001558449	NCT00155844_9_T5	CELL	23	24	stromal cells
NCT0015584411	NCT00155844_11_T0	CELL	13	13	cells
NCT0015584411	NCT00155844_11_T1	GENE	2	2	axis
NCT0015584411	NCT00155844_11_T2	ORGAN	17	18	bone marrow
NCT0015584414	NCT00155844_14_T0	GENE	12	12	PB
NCT0015584414	NCT00155844_14_T1	CELL	8	8	cells
NCT0015584414	NCT00155844_14_T2	GENE	30	30	axis
NCT0015584414	NCT00155844_14_T3	PHENOTYPE	31	31	dysfunction
NCT0015584416	NCT00155844_16_T0	PHENOTYPE	14	14	acute
NCT0015584416	NCT00155844_16_T1	GENE	6	6	CXCL12
NCT0015584416	NCT00155844_16_T2	CELL	10	10	cells
NCT0015584416	NCT00155844_16_T3	GENE	2	2	CXCR4
NCT001558572	NCT00155857_2_T0	PHENOTYPE	16	16	blindness
NCT001558575	NCT00155857_5_T0	PHENOTYPE	5	5	blindness
NCT001558576	NCT00155857_6_T0	PHENOTYPE	6	6	glaucoma
NCT001558577	NCT00155857_7_T0	PHENOTYPE	8	8	glaucoma
NCT001558577	NCT00155857_7_T1	PHENOTYPE	22	22	glaucoma
NCT001558578	NCT00155857_8_T0	GENE	12	12	met
NCT001558579	NCT00155857_9_T0	PHENOTYPE	19	19	glaucoma
NCT0015585710	NCT00155857_10_T0	PHENOTYPE	16	16	projections
NCT0015585710	NCT00155857_10_T1	GENE	11	11	ACG
NCT0015585711	NCT00155857_11_T0	GENE	12	12	ACG
NCT0015585715	NCT00155857_15_T0	PHENOTYPE	1	1	POAG
NCT0015585716	NCT00155857_16_T0	PHENOTYPE	10	10	symptoms
NCT0015585716	NCT00155857_16_T1	GENE	8	8	has
NCT0015585716	NCT00155857_16_T2	PHENOTYPE	6	6	chronic
NCT0015585717	NCT00155857_17_T0	PHENOTYPE	7	7	symptoms
NCT0015585717	NCT00155857_17_T1	GENE	17	17	has
NCT0015585721	NCT00155857_21_T0	PHENOTYPE	31	31	acute
NCT0015585721	NCT00155857_21_T1	GENE	13	13	18
NCT0015585721	NCT00155857_21_T2	PHENOTYPE	12	12	IOP
NCT0015585721	NCT00155857_21_T3	PHENOTYPE	19	19	IOP
NCT0015585721	NCT00155857_21_T4	GENE	15	15	Hg
NCT0015585721	NCT00155857_21_T5	GENE	22	22	Hg
NCT0015585722	NCT00155857_22_T0	GENE	14	14	structural
NCT0015585722	NCT00155857_22_T1	PHENOTYPE	15	16	optic neuropathy
NCT0015585722	NCT00155857_22_T2	PHENOTYPE	10	12	visual field defect
NCT0015585723	NCT00155857_23_T0	PHENOTYPE	6	6	suffering
NCT0015585724	NCT00155857_24_T0	PHENOTYPE	8	8	symptoms
NCT0015585724	NCT00155857_24_T1	PHENOTYPE	11	11	acute
NCT0015585726	NCT00155857_26_T0	PHENOTYPE	13	13	blindness
NCT0015585726	NCT00155857_26_T1	GENE	3	3	has
NCT0015585727	NCT00155857_27_T0	PHENOTYPE	8	8	POAG
NCT0015585727	NCT00155857_27_T1	PHENOTYPE	11	11	glaucoma
NCT0015585730	NCT00155857_30_T0	PHENOTYPE	13	13	mutation
NCT0015585730	NCT00155857_30_T1	GENE	6	6	cDNA
NCT0015585732	NCT00155857_32_T0	GENE	8	8	had
NCT0015585735	NCT00155857_35_T0	COMPOUND	12	12	2
NCT0015585735	NCT00155857_35_T1	PHENOTYPE	1	1	IOP
NCT0015585735	NCT00155857_35_T2	GENE	5	5	Hg
NCT0015585736	NCT00155857_36_T0	PHENOTYPE	14	15	optic neuropathy
NCT0015585736	NCT00155857_36_T1	PHENOTYPE	0	2	Primary angle-closure glaucoma
NCT0015585737	NCT00155857_37_T0	GENE	6	6	CDR
NCT0015585737	NCT00155857_37_T1	GENE	14	14	0.2
NCT0015585737	NCT00155857_37_T2	GENE	8	8	0.7
NCT0015585737	NCT00155857_37_T3	PHENOTYPE	0	1	Optic neuropathy
NCT0015585738	NCT00155857_38_T0	GENE	5	5	CDR
NCT0015585738	NCT00155857_38_T1	GENE	13	13	0.2
NCT0015585738	NCT00155857_38_T2	GENE	7	7	0.7
NCT0015585738	NCT00155857_38_T3	GENE	9	9	0.8
NCT0015585738	NCT00155857_38_T4	PHENOTYPE	16	18	visual field defect
NCT0015585739	NCT00155857_39_T0	GENE	3	3	CDR
NCT0015585739	NCT00155857_39_T1	GENE	6	6	CDR
NCT0015585739	NCT00155857_39_T2	GENE	8	8	0.3
NCT0015585739	NCT00155857_39_T3	PHENOTYPE	12	13	visual loss
NCT001558702	NCT00155870_2_T0	PHENOTYPE	9	9	symptoms
NCT001558702	NCT00155870_2_T1	PHENOTYPE	24	24	QOL
NCT001558702	NCT00155870_2_T2	PHENOTYPE	21	23	quality of life
NCT001558704	NCT00155870_4_T0	ORGAN	9	9	uteri
NCT001558704	NCT00155870_4_T1	ORGAN	22	22	uteri
NCT001558704	NCT00155870_4_T2	PHENOTYPE	12	12	QOL
NCT001558706	NCT00155870_6_T0	PHENOTYPE	11	11	QOL
NCT001558709	NCT00155870_9_T0	PHENOTYPE	18	18	suffering
NCT001558709	NCT00155870_9_T1	PHENOTYPE	8	8	QOL
NCT001558709	NCT00155870_9_T2	PHENOTYPE	22	22	adenomyosis
NCT001558709	NCT00155870_9_T3	PHENOTYPE	20	20	leiomyoma
NCT0015587011	NCT00155870_11_T0	PHENOTYPE	26	26	suffering
NCT0015587011	NCT00155870_11_T1	PHENOTYPE	31	31	adenomyosis
NCT0015587011	NCT00155870_11_T2	GENE	7	7	abdominal
NCT0015587011	NCT00155870_11_T3	GENE	17	17	has
NCT0015587011	NCT00155870_11_T4	PHENOTYPE	28	29	uterine myoma
NCT0015587013	NCT00155870_13_T0	PHENOTYPE	9	9	symptoms
NCT0015587013	NCT00155870_13_T1	PHENOTYPE	24	24	QOL
NCT0015587013	NCT00155870_13_T2	PHENOTYPE	21	23	quality of life
NCT0015587015	NCT00155870_15_T0	ORGAN	9	9	uteri
NCT0015587015	NCT00155870_15_T1	ORGAN	22	22	uteri
NCT0015587015	NCT00155870_15_T2	PHENOTYPE	12	12	QOL
NCT0015587017	NCT00155870_17_T0	PHENOTYPE	11	11	QOL
NCT0015587020	NCT00155870_20_T0	PHENOTYPE	18	18	suffering
NCT0015587020	NCT00155870_20_T1	PHENOTYPE	8	8	QOL
NCT0015587020	NCT00155870_20_T2	PHENOTYPE	22	22	adenomyosis
NCT0015587020	NCT00155870_20_T3	PHENOTYPE	20	20	leiomyoma
NCT001558832	NCT00155883_2_T0	COMPOUND	10	10	5_fluorouracil
NCT001558832	NCT00155883_2_T1	COMPOUND	13	13	leucovorin
NCT001558832	NCT00155883_2_T2	PHENOTYPE	24	25	gastric cancer
NCT001558833	NCT00155883_3_T0	PHENOTYPE	25	25	tumor
NCT001558833	NCT00155883_3_T1	PHENOTYPE	32	32	suppression
NCT001558833	NCT00155883_3_T2	PHENOTYPE	41	41	cytotoxicity
NCT001558833	NCT00155883_3_T3	PHENOTYPE	28	29	gastric cancer
NCT001558833	NCT00155883_3_T4	GENE	34	35	thymidylate synthase
NCT001558834	NCT00155883_4_T0	PHENOTYPE	13	13	tumor
NCT001558834	NCT00155883_4_T1	GENE	4	4	has
NCT001558834	NCT00155883_4_T2	PHENOTYPE	9	10	gastric cancer
NCT001558835	NCT00155883_5_T0	COMPOUND	9	9	docetaxel
NCT001558835	NCT00155883_5_T1	COMPOUND	27	27	docetaxel
NCT001558835	NCT00155883_5_T2	PHENOTYPE	32	32	tumor
NCT001558835	NCT00155883_5_T3	PHENOTYPE	15	15	neutropenia
NCT001558835	NCT00155883_5_T4	PHENOTYPE	17	17	asthenia
NCT001558836	NCT00155883_6_T0	GENE	2	2	II
NCT001558836	NCT00155883_6_T1	PHENOTYPE	11	11	toxicity
NCT001558836	NCT00155883_6_T2	COMPOUND	14	14	docetaxel
NCT001558836	NCT00155883_6_T3	PHENOTYPE	29	30	gastric cancer
NCT001558838	NCT00155883_8_T0	PHENOTYPE	5	6	gastric adenocarcinoma
NCT0015588310	NCT00155883_10_T0	PHENOTYPE	1	2	measurable disease
NCT0015588315	NCT00155883_15_T0	ORGAN	4	4	Appendix
NCT0015588320	NCT00155883_20_T0	ORGAN	0	0	Serum
NCT0015588322	NCT00155883_22_T0	PHENOTYPE	3	4	metastatic disease
NCT0015588323	NCT00155883_23_T0	GENE	12	12	has
NCT0015588333	NCT00155883_33_T0	PHENOTYPE	4	5	leptomeningeal metastases
NCT0015588335	NCT00155883_35_T0	PHENOTYPE	4	5	cardiac arrhythmia
NCT0015588335	NCT00155883_35_T1	PHENOTYPE	7	9	acute myocardial infarction
NCT0015588337	NCT00155883_37_T0	PHENOTYPE	5	5	diseases
NCT001558961	NCT00155896_1_T0	PHENOTYPE	3	4	ovarian cancer
NCT001558962	NCT00155896_2_T0	PHENOTYPE	0	1	Ovarian cancer
NCT001558963	NCT00155896_3_T0	PHENOTYPE	5	5	carcinogenesis
NCT001558963	NCT00155896_3_T1	PHENOTYPE	18	18	strategies
NCT001558963	NCT00155896_3_T2	PHENOTYPE	7	8	ovarian cancer
NCT001558963	NCT00155896_3_T3	PHENOTYPE	24	25	ovarian cancer
NCT001558964	NCT00155896_4_T0	PHENOTYPE	8	8	symptoms
NCT001558964	NCT00155896_4_T1	PHENOTYPE	5	5	malignancy
NCT001558964	NCT00155896_4_T2	PHENOTYPE	13	13	tumor
NCT001558968	NCT00155896_8_T0	PHENOTYPE	4	4	carcinogenesis
NCT001558968	NCT00155896_8_T1	GENE	17	17	BRCA1
NCT001558968	NCT00155896_8_T2	GENE	8	8	has
NCT001558968	NCT00155896_8_T3	GENE	19	19	BRCA2
NCT001558968	NCT00155896_8_T4	PHENOTYPE	6	7	ovarian cancer
NCT001558969	NCT00155896_9_T0	PHENOTYPE	13	13	mutation
NCT001558969	NCT00155896_9_T1	GENE	9	9	BRCA1
NCT001558969	NCT00155896_9_T2	GENE	11	11	BRCA2
NCT0015589610	NCT00155896_10_T0	PHENOTYPE	7	7	mutation
NCT0015589610	NCT00155896_10_T1	GENE	3	3	BRCA1
NCT0015589610	NCT00155896_10_T2	GENE	5	5	BRCA2
NCT0015589610	NCT00155896_10_T3	PHENOTYPE	17	18	ovarian cancer
NCT0015589611	NCT00155896_11_T0	PHENOTYPE	4	4	mutation
NCT0015589611	NCT00155896_11_T1	GENE	2	2	BRCA1
NCT0015589611	NCT00155896_11_T2	PHENOTYPE	22	23	ovarian cancer
NCT0015589611	NCT00155896_11_T3	PHENOTYPE	9	10	breast cancer
NCT0015589612	NCT00155896_12_T0	PHENOTYPE	4	4	mutation
NCT0015589612	NCT00155896_12_T1	GENE	2	2	BRCA2
NCT0015589612	NCT00155896_12_T2	PHENOTYPE	11	12	ovarian cancer
NCT0015589613	NCT00155896_13_T0	GENE	8	8	has
NCT0015589615	NCT00155896_15_T0	GENE	16	16	BRCA1
NCT0015589615	NCT00155896_15_T1	GENE	1	1	has
NCT0015589615	NCT00155896_15_T2	GENE	18	18	BRCA2
NCT0015589615	NCT00155896_15_T3	PHENOTYPE	20	21	breast cancer
NCT0015589618	NCT00155896_18_T0	PHENOTYPE	8	8	malignancy
NCT0015589619	NCT00155896_19_T0	PHENOTYPE	9	9	malignancies
NCT0015589619	NCT00155896_19_T1	PHENOTYPE	0	1	Ovarian cancer
NCT0015589620	NCT00155896_20_T0	PHENOTYPE	3	4	ovarian cancer
NCT0015589621	NCT00155896_21_T0	PHENOTYPE	0	1	Ovarian cancer
NCT0015589622	NCT00155896_22_T0	PHENOTYPE	5	5	carcinogenesis
NCT0015589622	NCT00155896_22_T1	PHENOTYPE	18	18	strategies
NCT0015589622	NCT00155896_22_T2	PHENOTYPE	7	8	ovarian cancer
NCT0015589622	NCT00155896_22_T3	PHENOTYPE	24	25	ovarian cancer
NCT0015589623	NCT00155896_23_T0	PHENOTYPE	8	8	symptoms
NCT0015589623	NCT00155896_23_T1	PHENOTYPE	5	5	malignancy
NCT0015589623	NCT00155896_23_T2	PHENOTYPE	13	13	tumor
NCT0015589627	NCT00155896_27_T0	PHENOTYPE	4	4	carcinogenesis
NCT0015589627	NCT00155896_27_T1	GENE	17	17	BRCA1
NCT0015589627	NCT00155896_27_T2	GENE	8	8	has
NCT0015589627	NCT00155896_27_T3	GENE	19	19	BRCA2
NCT0015589627	NCT00155896_27_T4	PHENOTYPE	6	7	ovarian cancer
NCT0015589628	NCT00155896_28_T0	PHENOTYPE	13	13	mutation
NCT0015589628	NCT00155896_28_T1	GENE	9	9	BRCA1
NCT0015589628	NCT00155896_28_T2	GENE	11	11	BRCA2
NCT0015589629	NCT00155896_29_T0	PHENOTYPE	7	7	mutation
NCT0015589629	NCT00155896_29_T1	GENE	3	3	BRCA1
NCT0015589629	NCT00155896_29_T2	GENE	5	5	BRCA2
NCT0015589629	NCT00155896_29_T3	PHENOTYPE	17	18	ovarian cancer
NCT0015589630	NCT00155896_30_T0	PHENOTYPE	4	4	mutation
NCT0015589630	NCT00155896_30_T1	GENE	2	2	BRCA1
NCT0015589630	NCT00155896_30_T2	PHENOTYPE	22	23	ovarian cancer
NCT0015589630	NCT00155896_30_T3	PHENOTYPE	9	10	breast cancer
NCT0015589631	NCT00155896_31_T0	PHENOTYPE	4	4	mutation
NCT0015589631	NCT00155896_31_T1	GENE	2	2	BRCA2
NCT0015589631	NCT00155896_31_T2	PHENOTYPE	11	12	ovarian cancer
NCT0015589632	NCT00155896_32_T0	GENE	8	8	has
NCT0015589634	NCT00155896_34_T0	GENE	16	16	BRCA1
NCT0015589634	NCT00155896_34_T1	GENE	1	1	has
NCT0015589634	NCT00155896_34_T2	GENE	18	18	BRCA2
NCT0015589634	NCT00155896_34_T3	PHENOTYPE	20	21	breast cancer
NCT001559090	NCT00155909_0_T0	PHENOTYPE	3	4	Radiation Pneumonitis
NCT001559094	NCT00155909_4_T0	GENE	8	8	BWL
NCT001559094	NCT00155909_4_T1	PHENOTYPE	25	26	albumin level
NCT001559094	NCT00155909_4_T2	PHENOTYPE	14	15	primary lesion
NCT001559095	NCT00155909_5_T0	COMPOUND	19	19	V20
NCT001559096	NCT00155909_6_T0	GENE	13	13	RT
NCT001559096	NCT00155909_6_T1	GENE	3	3	IL6
NCT001559096	NCT00155909_6_T2	GENE	4	4	TGFB
NCT001559097	NCT00155909_7_T0	GENE	14	14	RT
NCT001559097	NCT00155909_7_T1	GENE	4	4	IL6
NCT001559097	NCT00155909_7_T2	GENE	5	5	TGFB
NCT001559099	NCT00155909_9_T0	GENE	0	0	RT
NCT0015590910	NCT00155909_10_T0	PHENOTYPE	10	10	toxicity
NCT0015590910	NCT00155909_10_T1	GENE	16	16	RT
NCT0015590910	NCT00155909_10_T2	PHENOTYPE	3	3	fibrosis
NCT0015590910	NCT00155909_10_T3	PHENOTYPE	0	1	Radiation pneumonitis
NCT001559223	NCT00155922_3_T0	PHENOTYPE	5	6	accelerated atherosclerosis
NCT001559224	NCT00155922_4_T0	PHENOTYPE	0	0	Hyperglycemia
NCT001559224	NCT00155922_4_T1	PHENOTYPE	12	12	generalized
NCT001559224	NCT00155922_4_T2	PHENOTYPE	13	13	inflammation
NCT001559224	NCT00155922_4_T3	PHENOTYPE	4	4	hyperinsulinemia
NCT001559224	NCT00155922_4_T4	PHENOTYPE	9	10	oxidative stress
NCT001559226	NCT00155922_6_T0	CELL	0	0	Macrophages
NCT001559227	NCT00155922_7_T0	PHENOTYPE	11	11	inflammation
NCT001559227	NCT00155922_7_T1	CELL	0	0	Macrophages
NCT001559227	NCT00155922_7_T2	PHENOTYPE	8	9	oxidative stress
NCT0015592210	NCT00155922_10_T0	PHENOTYPE	7	7	peripheral
NCT0015592210	NCT00155922_10_T1	PHENOTYPE	19	19	complications
NCT0015592210	NCT00155922_10_T2	PHENOTYPE	15	15	pathophysiology
NCT0015592212	NCT00155922_12_T0	PHENOTYPE	3	4	plasma glucose
NCT001559351	NCT00155935_1_T0	GENE	6	6	has
NCT001559351	NCT00155935_1_T1	PHENOTYPE	4	5	ovarian cancer
NCT001559352	NCT00155935_2_T0	PHENOTYPE	0	1	Ovarian cancer
NCT001559353	NCT00155935_3_T0	ORGAN	11	11	ovaries
NCT001559353	NCT00155935_3_T1	PHENOTYPE	9	9	localized
NCT001559353	NCT00155935_3_T2	PHENOTYPE	2	3	ovarian cancer
NCT001559355	NCT00155935_5_T0	PHENOTYPE	5	6	ovarian cancer
NCT001559358	NCT00155935_8_T0	COMPOUND	1	1	folate
NCT001559358	NCT00155935_8_T1	GENE	2	2	receptor
NCT001559358	NCT00155935_8_T2	PHENOTYPE	16	16	carcinomas
NCT001559358	NCT00155935_8_T3	CELL	9	10	epithelial cells
NCT001559359	NCT00155935_9_T0	GENE	2	2	has
NCT001559359	NCT00155935_9_T1	PHENOTYPE	13	14	ovarian carcinomas
NCT0015593510	NCT00155935_10_T0	COMPOUND	5	5	folate
NCT0015593510	NCT00155935_10_T1	GENE	6	6	receptor
NCT0015593511	NCT00155935_11_T0	COMPOUND	4	4	folate
NCT0015593511	NCT00155935_11_T1	GENE	5	5	receptor
NCT0015593511	NCT00155935_11_T2	PHENOTYPE	15	16	ovarian cancer
NCT0015593513	NCT00155935_13_T0	COMPOUND	7	7	1
NCT0015593513	NCT00155935_13_T1	COMPOUND	22	22	2
NCT0015593513	NCT00155935_13_T2	COMPOUND	19	19	folate
NCT0015593513	NCT00155935_13_T3	COMPOUND	26	26	folate
NCT0015593513	NCT00155935_13_T4	GENE	27	27	receptor
NCT0015593513	NCT00155935_13_T5	PHENOTYPE	34	35	ovarian cancer
NCT0015593515	NCT00155935_15_T0	PHENOTYPE	15	16	ovarian cancer
NCT0015593516	NCT00155935_16_T0	PHENOTYPE	3	3	symptoms
NCT0015593516	NCT00155935_16_T1	PHENOTYPE	10	10	tumor
NCT0015593516	NCT00155935_16_T2	PHENOTYPE	26	27	ovarian cancer
NCT0015593516	NCT00155935_16_T3	PHENOTYPE	17	18	ovarian tumor
NCT0015593517	NCT00155935_17_T0	PHENOTYPE	13	13	malignancy
NCT0015593517	NCT00155935_17_T1	PHENOTYPE	7	7	tumor
NCT0015593517	NCT00155935_17_T2	PHENOTYPE	4	5	ovarian carcinomas
NCT0015593517	NCT00155935_17_T3	PHENOTYPE	15	16	residual tumor
NCT0015593518	NCT00155935_18_T0	PHENOTYPE	9	9	tumor
NCT0015593518	NCT00155935_18_T1	PHENOTYPE	12	13	ovarian cancer
NCT0015593519	NCT00155935_19_T0	PHENOTYPE	10	11	disease course
NCT0015593520	NCT00155935_20_T0	PHENOTYPE	4	5	ovarian cancer
NCT0015593521	NCT00155935_21_T0	PHENOTYPE	11	11	carcinoma
NCT0015593521	NCT00155935_21_T1	PHENOTYPE	2	3	ovarian cancer
NCT0015593521	NCT00155935_21_T2	ORGAN	21	22	peritoneal cavity
NCT0015593521	NCT00155935_21_T3	PHENOTYPE	4	6	Epithelial ovarian cancer
NCT0015593522	NCT00155935_22_T0	PHENOTYPE	5	5	tumors
NCT0015593523	NCT00155935_23_T0	ORGAN	10	10	ovaries
NCT0015593523	NCT00155935_23_T1	PHENOTYPE	8	8	localized
NCT0015593526	NCT00155935_26_T0	COMPOUND	10	10	carboplatin_paclitaxel
NCT0015593527	NCT00155935_27_T0	ORGAN	26	26	ovaries
NCT0015593529	NCT00155935_29_T0	GENE	1	1	BRCA1
NCT0015593529	NCT00155935_29_T1	GENE	3	3	BRCA2
NCT0015593530	NCT00155935_30_T0	PHENOTYPE	9	9	mutation
NCT0015593530	NCT00155935_30_T1	PHENOTYPE	13	14	ovarian cancer
NCT0015593531	NCT00155935_31_T0	GENE	8	8	BRCA1
NCT0015593531	NCT00155935_31_T1	GENE	10	10	BRCA2
NCT0015593531	NCT00155935_31_T2	PHENOTYPE	22	23	ovarian cancer
NCT0015593533	NCT00155935_33_T0	PHENOTYPE	21	22	peritoneal cancer
NCT0015593535	NCT00155935_35_T0	PHENOTYPE	8	8	strategies
NCT0015593535	NCT00155935_35_T1	PHENOTYPE	2	3	ovarian cancer
NCT0015593539	NCT00155935_39_T0	PHENOTYPE	33	33	tumor
NCT0015593542	NCT00155935_42_T0	PHENOTYPE	13	13	carcinomas
NCT0015593542	NCT00155935_42_T1	PHENOTYPE	27	27	malignancies
NCT0015593542	NCT00155935_42_T2	CELL	6	7	epithelial cells
NCT0015593543	NCT00155935_43_T0	TISSUE	5	5	tissues
NCT0015593544	NCT00155935_44_T0	PHENOTYPE	9	9	tumor
NCT0015593545	NCT00155935_45_T0	CELL	19	19	cells
NCT0015593545	NCT00155935_45_T1	PHENOTYPE	17	18	ovarian carcinoma
NCT0015593545	NCT00155935_45_T2	CELL	8	9	T cells
NCT0015593547	NCT00155935_47_T0	GENE	10	10	CD3
NCT0015593547	NCT00155935_47_T1	GENE	12	12	CD28
NCT0015593547	NCT00155935_47_T2	PHENOTYPE	25	26	ovarian cancer
NCT0015593549	NCT00155935_49_T0	PHENOTYPE	16	16	tumors
NCT0015593549	NCT00155935_49_T1	GENE	8	8	receptor
NCT0015593549	NCT00155935_49_T2	CELL	7	7	T-cell
NCT0015593549	NCT00155935_49_T3	CELL	12	12	T-cell
NCT0015593549	NCT00155935_49_T4	COMPOUND	1	2	folic acid
NCT0015593550	NCT00155935_50_T0	COMPOUND	10	10	folate
NCT0015593550	NCT00155935_50_T1	CELL	28	28	cells
NCT0015593550	NCT00155935_50_T2	GENE	17	17	exotoxin
NCT0015593550	NCT00155935_50_T3	PHENOTYPE	8	8	internalization
NCT0015593552	NCT00155935_52_T0	PHENOTYPE	9	9	tumor
NCT0015593553	NCT00155935_53_T0	CELL	9	9	cells
NCT0015593553	NCT00155935_53_T1	CELL	16	16	cells
NCT0015593553	NCT00155935_53_T2	PHENOTYPE	8	8	tumor
NCT0015593553	NCT00155935_53_T3	COMPOUND	21	21	doxorubicin
NCT0015593557	NCT00155935_57_T0	PHENOTYPE	12	12	ascites
NCT0015593557	NCT00155935_57_T1	GENE	5	5	has
NCT0015593557	NCT00155935_57_T2	ORGAN	10	10	serum
NCT0015593557	NCT00155935_57_T3	PHENOTYPE	16	17	ovarian cancer
NCT0015593557	NCT00155935_57_T4	GENE	1	2	soluble form
NCT0015593558	NCT00155935_58_T0	TISSUE	20	20	tissues
NCT0015593558	NCT00155935_58_T1	GENE	2	2	has
NCT0015593558	NCT00155935_58_T2	PHENOTYPE	13	14	ovarian carcinomas
NCT0015593560	NCT00155935_60_T0	PHENOTYPE	14	15	ovarian cancer
NCT0015593561	NCT00155935_61_T0	COMPOUND	2	2	folate
NCT0015593561	NCT00155935_61_T1	GENE	3	3	receptor
NCT0015593563	NCT00155935_63_T0	COMPOUND	5	5	folate
NCT0015593563	NCT00155935_63_T1	GENE	6	6	receptor
NCT0015593564	NCT00155935_64_T0	GENE	7	7	E75
NCT0015593565	NCT00155935_65_T0	COMPOUND	3	3	folate
NCT0015593565	NCT00155935_65_T1	PHENOTYPE	14	15	ovarian cancer
NCT0015593570	NCT00155935_70_T0	COMPOUND	7	7	1
NCT0015593570	NCT00155935_70_T1	COMPOUND	20	20	2
NCT0015593570	NCT00155935_70_T2	COMPOUND	17	17	folate
NCT0015593570	NCT00155935_70_T3	COMPOUND	24	24	folate
NCT0015593570	NCT00155935_70_T4	GENE	25	25	receptor
NCT0015593570	NCT00155935_70_T5	PHENOTYPE	32	33	ovarian cancer
NCT001559482	NCT00155948_2_T0	PHENOTYPE	16	16	progressive
NCT001559482	NCT00155948_2_T1	ORGAN	10	10	multifidus
NCT001559483	NCT00155948_3_T0	ORGAN	7	7	multifidus
NCT001559484	NCT00155948_4_T0	GENE	13	13	C4
NCT001559484	NCT00155948_4_T1	GENE	14	14	C5
NCT001559484	NCT00155948_4_T2	GENE	16	16	C6
NCT001559484	NCT00155948_4_T3	GENE	20	20	MRI
NCT001559484	NCT00155948_4_T4	ORGAN	9	9	multifidus
NCT001559485	NCT00155948_5_T0	PHENOTYPE	6	6	regression
NCT001559488	NCT00155948_8_T0	GENE	0	0	ANOVA
NCT001559488	NCT00155948_8_T1	GENE	5	5	hoc
NCT001559489	NCT00155948_9_T0	GENE	21	21	R2
NCT001559489	NCT00155948_9_T1	GENE	30	30	MRI
NCT001559489	NCT00155948_9_T2	GENE	14	14	cm
NCT0015594811	NCT00155948_11_T0	PHENOTYPE	24	24	estimation
NCT0015594813	NCT00155948_13_T0	GENE	7	7	relaxed
NCT0015594813	NCT00155948_13_T1	GENE	6	6	C6
NCT001559611	NCT00155961_1_T0	BIOLOGICAL_PROCESS	9	9	ageing
NCT001559612	NCT00155961_2_T0	BIOLOGICAL_PROCESS	11	11	ageing
NCT001559612	NCT00155961_2_T1	COMPOUND	16	16	testosterone
NCT001559612	NCT00155961_2_T2	ORGAN	13	13	serum
NCT001559615	NCT00155961_5_T0	GENE	21	21	PP
NCT001559615	NCT00155961_5_T1	COMPOUND	12	12	testosterone
NCT0015596111	NCT00155961_11_T0	GENE	9	9	PP
NCT0015596111	NCT00155961_11_T1	PHENOTYPE	2	2	associations
NCT0015596113	NCT00155961_13_T0	BIOLOGICAL_PROCESS	9	9	ageing
NCT0015596114	NCT00155961_14_T0	BIOLOGICAL_PROCESS	11	11	ageing
NCT0015596114	NCT00155961_14_T1	COMPOUND	16	16	testosterone
NCT0015596114	NCT00155961_14_T2	ORGAN	13	13	serum
NCT0015596117	NCT00155961_17_T0	GENE	21	21	PP
NCT0015596117	NCT00155961_17_T1	COMPOUND	12	12	testosterone
NCT0015596123	NCT00155961_23_T0	GENE	9	9	PP
NCT0015596123	NCT00155961_23_T1	PHENOTYPE	2	2	associations
NCT0015596126	NCT00155961_26_T0	TISSUE	30	30	muscles
NCT0015596126	NCT00155961_26_T1	GENE	21	21	MRI
NCT0015596126	NCT00155961_26_T2	ORGAN	7	8	upper extremities
NCT0015596127	NCT00155961_27_T0	COMPOUND	0	0	MVF
NCT0015596129	NCT00155961_29_T0	COMPOUND	11	11	Oxycon
NCT0015596129	NCT00155961_29_T1	GENE	12	12	Pro
NCT0015596131	NCT00155961_31_T0	GENE	14	14	MRI
NCT0015596131	NCT00155961_31_T1	GENE	9	9	abdominal
NCT0015596131	NCT00155961_31_T2	GENE	19	19	abdominal
NCT0015596132	NCT00155961_32_T0	COMPOUND	1	1	BMI
NCT0015596134	NCT00155961_34_T0	GENE	12	12	had
NCT001559743	NCT00155974_3_T0	GENE	9	9	structural
NCT001559749	NCT00155974_9_T0	PHENOTYPE	19	19	acute
NCT001559749	NCT00155974_9_T1	GENE	21	21	HTR
NCT0015597410	NCT00155974_10_T0	PHENOTYPE	9	9	attitudes
NCT0015597411	NCT00155974_11_T0	GENE	4	4	HTR
NCT0015597414	NCT00155974_14_T0	GENE	26	26	HTR
NCT0015597415	NCT00155974_15_T0	PHENOTYPE	3	3	estimation
NCT0015597417	NCT00155974_17_T0	PHENOTYPE	19	19	influenza
NCT0015597420	NCT00155974_20_T0	PHENOTYPE	28	28	HIV
NCT0015597420	NCT00155974_20_T1	PHENOTYPE	29	29	HBV
NCT0015597424	NCT00155974_24_T0	PHENOTYPE	13	13	influenza
NCT0015597424	NCT00155974_24_T1	PHENOTYPE	18	18	influenza
NCT0015597425	NCT00155974_25_T0	PHENOTYPE	16	16	Practices
NCT0015597425	NCT00155974_25_T1	PHENOTYPE	3	3	influenza
NCT001559878	NCT00155987_8_T0	COMPOUND	8	8	thiopentone
NCT001559878	NCT00155987_8_T1	COMPOUND	11	11	thiopentone
NCT001559878	NCT00155987_8_T2	PHENOTYPE	12	12	coma
NCT0015598713	NCT00155987_13_T0	GENE	12	12	flap
NCT0015598713	NCT00155987_13_T1	GENE	16	16	midline
NCT0015598714	NCT00155987_14_T0	TISSUE	2	2	muscles
NCT0015598714	NCT00155987_14_T1	PHENOTYPE	5	5	reflected
NCT0015598715	NCT00155987_15_T0	ORGAN	25	25	zygoma
NCT0015598717	NCT00155987_17_T0	PHENOTYPE	0	0	Bilateral
NCT0015598717	NCT00155987_17_T1	ORGAN	10	11	skull base
NCT0015598722	NCT00155987_22_T0	GENE	0	0	OR
NCT0015598724	NCT00155987_24_T0	ORGAN	8	9	cerebral veins
NCT0015598725	NCT00155987_25_T0	ORGAN	21	21	scalp
NCT0015598727	NCT00155987_27_T0	GENE	13	13	PO2
NCT0015598727	NCT00155987_27_T1	GENE	6	6	ICP
NCT0015598727	NCT00155987_27_T2	GENE	9	9	ventricular
NCT0015598730	NCT00155987_30_T0	GENE	2	2	flap
NCT0015598730	NCT00155987_30_T1	GENE	8	8	has
NCT0015598730	NCT00155987_30_T2	GENE	13	13	has
NCT0015598730	NCT00155987_30_T3	PHENOTYPE	9	9	resolved
NCT0015598730	NCT00155987_30_T4	PHENOTYPE	6	7	bone swelling
NCT0015598731	NCT00155987_31_T0	GENE	2	2	flap
NCT0015598731	NCT00155987_31_T1	ORGAN	21	22	abdominal wall
NCT0015598731	NCT00155987_31_T2	TISSUE	17	18	subcutaneous tissue
NCT0015598734	NCT00155987_34_T0	GENE	1	1	ICP
NCT0015598734	NCT00155987_34_T1	GENE	14	14	ICP
NCT0015598734	NCT00155987_34_T2	GENE	26	26	Hg
NCT001560003	NCT00156000_3_T0	PHENOTYPE	5	6	preterm delivery
NCT001560005	NCT00156000_5_T0	COMPOUND	12	12	progesterone
NCT001560006	NCT00156000_6_T0	COMPOUND	12	12	progesterone
NCT001560006	NCT00156000_6_T1	COMPOUND	28	28	progesterone
NCT001560006	NCT00156000_6_T2	GENE	3	3	E3
NCT001560008	NCT00156000_8_T0	GENE	7	7	has
NCT001560008	NCT00156000_8_T1	PHENOTYPE	4	5	preterm birth
NCT001560009	NCT00156000_9_T0	PHENOTYPE	10	11	preterm birth
NCT0015600010	NCT00156000_10_T0	PHENOTYPE	12	13	preterm birth
NCT0015600010	NCT00156000_10_T1	PHENOTYPE	8	9	triplet pregnancies
NCT0015600011	NCT00156000_11_T0	PHENOTYPE	26	27	preterm birth
NCT0015600012	NCT00156000_12_T0	COMPOUND	17	17	estriol
NCT0015600012	NCT00156000_12_T1	GENE	14	14	fibronectin
NCT0015600012	NCT00156000_12_T2	PHENOTYPE	6	7	preterm birth
NCT0015600013	NCT00156000_13_T0	GENE	10	10	reduced
NCT0015600013	NCT00156000_13_T1	PHENOTYPE	11	12	preterm delivery
NCT0015600014	NCT00156000_14_T0	COMPOUND	15	15	progesterone
NCT0015600014	NCT00156000_14_T1	GENE	30	30	E3
NCT0015600014	NCT00156000_14_T2	PHENOTYPE	49	50	triplet pregnancies
NCT0015600014	NCT00156000_14_T3	PHENOTYPE	20	22	mechanism of action
NCT0015600015	NCT00156000_15_T0	COMPOUND	15	15	estriol
NCT0015600015	NCT00156000_15_T1	GENE	12	12	fibronectin
NCT0015600018	NCT00156000_18_T0	PHENOTYPE	28	29	Triplet Pregnancy
NCT0015600018	NCT00156000_18_T1	PHENOTYPE	23	24	Preterm Birth
NCT0015600020	NCT00156000_20_T0	BIOLOGICAL_PROCESS	8	8	gestation
NCT0015600020	NCT00156000_20_T1	BIOLOGICAL_PROCESS	11	11	gestation
NCT0015600022	NCT00156000_22_T0	TISSUE	1	2	amniotic membranes
NCT0015600025	NCT00156000_25_T0	GENE	1	1	has
NCT0015600026	NCT00156000_26_T0	PHENOTYPE	2	2	contractions
NCT0015600027	NCT00156000_27_T0	PHENOTYPE	0	1	Placenta previa
NCT0015600028	NCT00156000_28_T0	PHENOTYPE	0	1	Abruptio placenta
NCT0015600029	NCT00156000_29_T0	PHENOTYPE	0	1	Severe preeclampsia
NCT0015600034	NCT00156000_34_T0	PHENOTYPE	3	4	vaginal bleeding
NCT001560131	NCT00156013_1_T0	COMPOUND	3	3	clofarabine
NCT001560132	NCT00156013_2_T0	GENE	6	6	has
NCT001560134	NCT00156013_4_T0	COMPOUND	3	3	clofarabine
NCT001560134	NCT00156013_4_T1	GENE	12	12	has
NCT001560134	NCT00156013_4_T2	GENE	43	43	has
NCT001560134	NCT00156013_4_T3	PHENOTYPE	7	8	solid tumors
NCT001560134	NCT00156013_4_T4	PHENOTYPE	10	11	lymphoproliferative disorders
NCT001560134	NCT00156013_4_T5	PHENOTYPE	27	28	acute leukemia
NCT001560138	NCT00156013_8_T0	CELL	4	4	granulocyte
NCT001560391	NCT00156039_1_T0	PHENOTYPE	10	12	quality of life
NCT001560521	NCT00156052_1_T0	PHENOTYPE	6	6	recurrence
NCT001560521	NCT00156052_1_T1	PHENOTYPE	8	8	secondary
NCT001560523	NCT00156052_3_T0	GENE	3	3	has
NCT001560523	NCT00156052_3_T1	PHENOTYPE	17	18	metastatic disease
NCT001560523	NCT00156052_3_T2	PHENOTYPE	8	12	invasive carcinoma of the breast
NCT001560525	NCT00156052_5_T0	PHENOTYPE	16	16	tumour
NCT001560525	NCT00156052_5_T1	GENE	19	19	rim
NCT001560525	NCT00156052_5_T2	GENE	1	1	had
NCT001560527	NCT00156052_7_T0	GENE	7	7	OR
NCT001560527	NCT00156052_7_T1	GENE	3	3	had
NCT001560527	NCT00156052_7_T2	GENE	12	12	had
NCT001560527	NCT00156052_7_T3	GENE	1	1	has
NCT001560527	NCT00156052_7_T4	PHENOTYPE	21	22	metastatic disease
NCT001560529	NCT00156052_9_T0	GENE	4	4	cm
NCT001560529	NCT00156052_9_T1	PHENOTYPE	0	0	Tumour
NCT0015605211	NCT00156052_11_T0	TISSUE	11	12	surgical margins
NCT0015605211	NCT00156052_11_T1	PHENOTYPE	7	8	breast cancer
NCT0015605213	NCT00156052_13_T0	PHENOTYPE	16	16	edema
NCT0015605213	NCT00156052_13_T1	PHENOTYPE	6	6	infiltration
NCT0015605213	NCT00156052_13_T2	PHENOTYPE	17	17	ulceration
NCT0015605213	NCT00156052_13_T3	PHENOTYPE	22	22	tumour
NCT0015605213	NCT00156052_13_T4	PHENOTYPE	19	19	fixation
NCT0015605213	NCT00156052_13_T5	PHENOTYPE	27	29	inflammatory breast cancer
NCT0015605215	NCT00156052_15_T0	PHENOTYPE	1	1	malignancy
NCT0015605215	NCT00156052_15_T1	PHENOTYPE	0	0	Bilateral
NCT0015605217	NCT00156052_17_T0	PHENOTYPE	5	5	tumour
NCT0015605219	NCT00156052_19_T0	PHENOTYPE	3	4	breast cancer
NCT0015605221	NCT00156052_21_T0	ORGAN	3	3	axilla
NCT0015605227	NCT00156052_27_T0	GENE	3	3	eg
NCT001560653	NCT00156065_3_T0	GENE	3	3	reduced
NCT001560653	NCT00156065_3_T1	PHENOTYPE	0	1	Other symptoms
NCT001560653	NCT00156065_3_T2	PHENOTYPE	13	14	problem solving
NCT001560654	NCT00156065_4_T0	PHENOTYPE	9	9	imbalance
NCT001560654	NCT00156065_4_T1	PHENOTYPE	3	3	schizophrenia
NCT001560654	NCT00156065_4_T2	PHENOTYPE	1	1	symptoms
NCT001560654	NCT00156065_4_T3	CELL	22	22	cells
NCT001560654	NCT00156065_4_T4	COMPOUND	16	16	dopamine
NCT001560654	NCT00156065_4_T5	PHENOTYPE	20	20	enables
NCT001560657	NCT00156065_7_T0	GENE	15	15	BID
NCT001560657	NCT00156065_7_T1	GENE	22	22	BID
NCT001560658	NCT00156065_8_T0	PHENOTYPE	10	10	acute
NCT001560658	NCT00156065_8_T1	PHENOTYPE	13	13	schizophrenia
NCT001560658	NCT00156065_8_T2	GENE	25	25	BID
NCT001560658	NCT00156065_8_T3	COMPOUND	16	16	asenapine
NCT001560913	NCT00156091_3_T0	GENE	3	3	reduced
NCT001560913	NCT00156091_3_T1	PHENOTYPE	0	1	Other symptoms
NCT001560913	NCT00156091_3_T2	PHENOTYPE	13	14	problem solving
NCT001560914	NCT00156091_4_T0	PHENOTYPE	9	9	imbalance
NCT001560914	NCT00156091_4_T1	PHENOTYPE	3	3	schizophrenia
NCT001560914	NCT00156091_4_T2	PHENOTYPE	1	1	symptoms
NCT001560914	NCT00156091_4_T3	CELL	22	22	cells
NCT001560914	NCT00156091_4_T4	COMPOUND	16	16	dopamine
NCT001560914	NCT00156091_4_T5	PHENOTYPE	20	20	enables
NCT001560917	NCT00156091_7_T0	GENE	15	15	BID
NCT001560917	NCT00156091_7_T1	GENE	20	20	BID
NCT001560918	NCT00156091_8_T0	PHENOTYPE	10	10	acute
NCT001560918	NCT00156091_8_T1	PHENOTYPE	13	13	schizophrenia
NCT001560918	NCT00156091_8_T2	GENE	25	25	BID
NCT001560918	NCT00156091_8_T3	COMPOUND	16	16	asenapine
NCT001561042	NCT00156104_2_T0	GENE	3	3	reduced
NCT001561042	NCT00156104_2_T1	PHENOTYPE	0	1	Other symptoms
NCT001561042	NCT00156104_2_T2	PHENOTYPE	13	14	problem solving
NCT001561043	NCT00156104_3_T0	PHENOTYPE	9	9	imbalance
NCT001561043	NCT00156104_3_T1	PHENOTYPE	3	3	schizophrenia
NCT001561043	NCT00156104_3_T2	PHENOTYPE	1	1	symptoms
NCT001561043	NCT00156104_3_T3	CELL	22	22	cells
NCT001561043	NCT00156104_3_T4	COMPOUND	16	16	dopamine
NCT001561043	NCT00156104_3_T5	PHENOTYPE	20	20	enables
NCT001561044	NCT00156104_4_T0	COMPOUND	13	13	dopamine
NCT001561045	NCT00156104_5_T0	PHENOTYPE	29	29	acute
NCT001561045	NCT00156104_5_T1	COMPOUND	21	21	haloperidol
NCT001561045	NCT00156104_5_T2	PHENOTYPE	32	32	schizophrenia
NCT001561045	NCT00156104_5_T3	COMPOUND	12	12	asenapine
NCT001561173	NCT00156117_3_T0	GENE	3	3	reduced
NCT001561173	NCT00156117_3_T1	PHENOTYPE	0	1	Other symptoms
NCT001561173	NCT00156117_3_T2	PHENOTYPE	13	14	problem solving
NCT001561174	NCT00156117_4_T0	PHENOTYPE	9	9	imbalance
NCT001561174	NCT00156117_4_T1	PHENOTYPE	3	3	schizophrenia
NCT001561174	NCT00156117_4_T2	PHENOTYPE	1	1	symptoms
NCT001561174	NCT00156117_4_T3	CELL	22	22	cells
NCT001561174	NCT00156117_4_T4	COMPOUND	16	16	dopamine
NCT001561174	NCT00156117_4_T5	PHENOTYPE	20	20	enables
NCT001561175	NCT00156117_5_T0	PHENOTYPE	11	11	imbalance
NCT001561175	NCT00156117_5_T1	COMPOUND	13	13	dopamine
NCT001561176	NCT00156117_6_T0	COMPOUND	18	18	olanzapine
NCT001561176	NCT00156117_6_T1	PHENOTYPE	25	25	schizophrenia
NCT001561176	NCT00156117_6_T2	COMPOUND	13	13	asenapine
NCT001561301	NCT00156130_1_T0	PHENOTYPE	20	20	recurrence
NCT001561301	NCT00156130_1_T1	PHENOTYPE	8	9	cardiac disease
NCT001561303	NCT00156130_3_T0	PHENOTYPE	19	19	recurrence
NCT001561304	NCT00156130_4_T0	GENE	2	2	has
NCT001561304	NCT00156130_4_T1	ORGAN	28	28	heart
NCT001561306	NCT00156130_6_T0	PHENOTYPE	20	20	recurrence
NCT001561306	NCT00156130_6_T1	PHENOTYPE	8	9	cardiac disease
NCT001561309	NCT00156130_9_T0	GENE	3	3	has
NCT001561309	NCT00156130_9_T1	PHENOTYPE	17	18	metastatic disease
NCT001561309	NCT00156130_9_T2	PHENOTYPE	8	12	invasive carcinoma of the breast
NCT0015613011	NCT00156130_11_T0	PHENOTYPE	16	16	tumour
NCT0015613011	NCT00156130_11_T1	GENE	19	19	rim
NCT0015613011	NCT00156130_11_T2	GENE	1	1	had
NCT0015613013	NCT00156130_13_T0	GENE	7	7	OR
NCT0015613013	NCT00156130_13_T1	GENE	3	3	had
NCT0015613013	NCT00156130_13_T2	GENE	12	12	had
NCT0015613013	NCT00156130_13_T3	GENE	1	1	has
NCT0015613013	NCT00156130_13_T4	PHENOTYPE	21	22	metastatic disease
NCT0015613015	NCT00156130_15_T0	GENE	4	4	cm
NCT0015613015	NCT00156130_15_T1	PHENOTYPE	0	0	Tumour
NCT0015613017	NCT00156130_17_T0	TISSUE	11	12	surgical margins
NCT0015613017	NCT00156130_17_T1	PHENOTYPE	7	8	breast cancer
NCT0015613019	NCT00156130_19_T0	PHENOTYPE	16	16	edema
NCT0015613019	NCT00156130_19_T1	PHENOTYPE	6	6	infiltration
NCT0015613019	NCT00156130_19_T2	PHENOTYPE	17	17	ulceration
NCT0015613019	NCT00156130_19_T3	PHENOTYPE	22	22	tumour
NCT0015613019	NCT00156130_19_T4	PHENOTYPE	19	19	fixation
NCT0015613019	NCT00156130_19_T5	PHENOTYPE	27	29	inflammatory breast cancer
NCT0015613021	NCT00156130_21_T0	PHENOTYPE	1	1	malignancy
NCT0015613021	NCT00156130_21_T1	PHENOTYPE	0	0	Bilateral
NCT0015613023	NCT00156130_23_T0	PHENOTYPE	5	5	tumour
NCT0015613025	NCT00156130_25_T0	PHENOTYPE	3	4	breast cancer
NCT0015613027	NCT00156130_27_T0	ORGAN	3	3	axilla
NCT0015613033	NCT00156130_33_T0	GENE	3	3	eg
NCT001561430	NCT00156143_0_T0	MOLECULAR_FUNCTION	2	3	Growth Hormone
NCT001561430	NCT00156143_0_T1	MOLECULAR_FUNCTION	7	8	Growth Hormone
NCT001561560	NCT00156156_0_T0	PHENOTYPE	10	10	Fibroids
NCT001561560	NCT00156156_0_T1	PHENOTYPE	7	8	Uterine Fibroids
NCT001561563	NCT00156156_3_T0	COMPOUND	13	13	asoprisnil
NCT001561563	NCT00156156_3_T1	COMPOUND	26	26	asoprisnil
NCT001561563	NCT00156156_3_T2	COMPOUND	31	31	asoprisnil
NCT001561564	NCT00156156_4_T0	ORGAN	15	15	ovaries
NCT001561564	NCT00156156_4_T1	ORGAN	14	14	endometrium
NCT001561564	NCT00156156_4_T2	PHENOTYPE	9	9	affects
NCT001561564	NCT00156156_4_T3	COMPOUND	11	11	asoprisnil
NCT001561564	NCT00156156_4_T4	PHENOTYPE	25	26	adverse events
NCT001561565	NCT00156156_5_T0	COMPOUND	3	3	asoprisnil
NCT001561568	NCT00156156_8_T0	COMPOUND	7	7	asoprisnil
NCT001561690	NCT00156169_0_T0	GENE	11	11	9-cis
NCT001561690	NCT00156169_0_T1	GENE	21	21	ed
NCT001561693	NCT00156169_3_T0	GENE	44	44	TG
NCT001561693	NCT00156169_3_T1	GENE	11	11	9-cis
NCT001561693	NCT00156169_3_T2	GENE	23	23	9-cis
NCT001561693	NCT00156169_3_T3	ORGAN	36	36	plasma
NCT001561693	NCT00156169_3_T4	COMPOUND	24	25	retinoic acid
NCT001561694	NCT00156169_4_T0	GENE	11	11	1.1
NCT001561694	NCT00156169_4_T1	GENE	3	3	9-cis
NCT001561694	NCT00156169_4_T2	GENE	1	1	all-trans
NCT001561820	NCT00156182_0_T0	PHENOTYPE	13	13	Fibroids
NCT001561820	NCT00156182_0_T1	PHENOTYPE	10	11	Uterine Fibroids
NCT001561823	NCT00156182_3_T0	COMPOUND	12	12	asoprisnil
NCT001561823	NCT00156182_3_T1	PHENOTYPE	33	34	uterine fibroids
NCT001561824	NCT00156182_4_T0	PHENOTYPE	15	16	adverse events
NCT001561952	NCT00156195_2_T0	COMPOUND	12	12	asoprisnil
NCT001561952	NCT00156195_2_T1	PHENOTYPE	27	28	uterine bleeding
NCT001561952	NCT00156195_2_T2	PHENOTYPE	31	32	uterine fibroids
NCT001561953	NCT00156195_3_T0	ORGAN	13	13	endometrium
NCT001561953	NCT00156195_3_T1	PHENOTYPE	22	23	adverse events
NCT001561953	NCT00156195_3_T2	PHENOTYPE	14	15	ovarian cysts
NCT001561954	NCT00156195_4_T0	COMPOUND	3	3	asoprisnil
NCT001561957	NCT00156195_7_T0	COMPOUND	7	7	asoprisnil
NCT001562082	NCT00156208_2_T0	COMPOUND	12	12	asoprisnil
NCT001562082	NCT00156208_2_T1	PHENOTYPE	26	27	uterine leiomyomata
NCT001562083	NCT00156208_3_T0	ORGAN	13	13	endometrium
NCT001562083	NCT00156208_3_T1	PHENOTYPE	18	19	adverse events
NCT001562083	NCT00156208_3_T2	PHENOTYPE	14	15	ovarian cysts
NCT001562084	NCT00156208_4_T0	COMPOUND	3	3	asoprisnil
NCT001562087	NCT00156208_7_T0	COMPOUND	7	7	asoprisnil
NCT001562211	NCT00156221_1_T0	GENE	58	58	MRI
NCT001562211	NCT00156221_1_T1	GENE	26	26	al
NCT001562211	NCT00156221_1_T2	PHENOTYPE	6	6	autism
NCT001562211	NCT00156221_1_T3	PHENOTYPE	33	33	autism
NCT001562211	NCT00156221_1_T4	GENE	25	25	et
NCT001562211	NCT00156221_1_T5	GENE	56	56	T2
NCT001562211	NCT00156221_1_T6	PHENOTYPE	22	23	atypical autism
NCT001562211	NCT00156221_1_T7	PHENOTYPE	16	17	mental retardation
NCT001562211	NCT00156221_1_T8	PHENOTYPE	36	37	developmental disorders
NCT001562212	NCT00156221_2_T0	PHENOTYPE	9	9	focal
NCT001562212	NCT00156221_2_T1	GENE	0	0	MRI
NCT001562212	NCT00156221_2_T2	BIOLOGICAL_PROCESS	14	14	myelination
NCT001562212	NCT00156221_2_T3	ORGAN	22	22	cerebellum
NCT001562212	NCT00156221_2_T4	ORGAN	27	28	white matter
NCT001562341	NCT00156234_1_T0	ORGAN	20	20	heart
NCT001562341	NCT00156234_1_T1	PHENOTYPE	3	3	dysfunction
NCT001562341	NCT00156234_1_T2	TISSUE	1	2	skeletal muscle
NCT001562342	NCT00156234_2_T0	GENE	6	6	has
NCT001562342	NCT00156234_2_T1	PHENOTYPE	14	14	dysfunction
NCT001562342	NCT00156234_2_T2	TISSUE	12	13	skeletal muscle
NCT001562342	NCT00156234_2_T3	PHENOTYPE	3	5	congestive heart failure
NCT001562472	NCT00156247_2_T0	COMPOUND	4	4	acitretin
NCT001562474	NCT00156247_4_T0	GENE	14	14	PGA
NCT001562601	NCT00156260_1_T0	PHENOTYPE	11	12	breast cancer
NCT001562604	NCT00156260_4_T0	GENE	42	42	had
NCT001562604	NCT00156260_4_T1	PHENOTYPE	6	6	unilateral
NCT001562604	NCT00156260_4_T2	GENE	30	30	has
NCT001562604	NCT00156260_4_T3	PHENOTYPE	20	20	desires
NCT001562604	NCT00156260_4_T4	GENE	56	56	probable
NCT001562604	NCT00156260_4_T5	COMPOUND	4	4	2
NCT001562604	NCT00156260_4_T6	COMPOUND	18	18	3
NCT001562604	NCT00156260_4_T7	PHENOTYPE	57	58	residual disease
NCT001562604	NCT00156260_4_T8	PHENOTYPE	38	39	breast tumor
NCT001562604	NCT00156260_4_T9	PHENOTYPE	7	9	invasive breast cancer
NCT001562604	NCT00156260_4_T10	PHENOTYPE	14	17	ductal carcinoma in situ
NCT001562605	NCT00156260_5_T0	PHENOTYPE	14	14	tumor
NCT001562864	NCT00156286_4_T0	TISSUE	12	13	lymph nodes
NCT001562864	NCT00156286_4_T1	TISSUE	21	22	lymph nodes
NCT001562864	NCT00156286_4_T2	PHENOTYPE	27	28	pleural effusion
NCT0015628611	NCT00156286_11_T0	PHENOTYPE	4	5	measurable lesion
NCT0015628616	NCT00156286_16_T0	PHENOTYPE	7	8	leptomeningeal metastases
NCT0015628623	NCT00156286_23_T0	COMPOUND	3	3	NCI
NCT0015628623	NCT00156286_23_T1	PHENOTYPE	0	1	Peripheral neuropathy
NCT0015628625	NCT00156286_25_T0	PHENOTYPE	1	1	edema
NCT0015628627	NCT00156286_27_T0	PHENOTYPE	1	1	anticoagulation
NCT0015628627	NCT00156286_27_T1	COMPOUND	3	3	warfarin
NCT0015628632	NCT00156286_32_T0	PHENOTYPE	0	0	Acute
NCT0015628632	NCT00156286_32_T1	PHENOTYPE	9	9	cirrhosis
NCT0015628632	NCT00156286_32_T2	PHENOTYPE	2	4	chronic liver disease
NCT0015628632	NCT00156286_32_T3	PHENOTYPE	6	8	chronic active hepatitis
NCT0015628634	NCT00156286_34_T0	PHENOTYPE	2	2	dementia
NCT0015628634	NCT00156286_34_T1	PHENOTYPE	4	5	psychiatric disorder
NCT0015628636	NCT00156286_36_T0	PHENOTYPE	1	1	menopausal
NCT0015628636	NCT00156286_36_T1	PHENOTYPE	3	3	peri-menopausal
NCT001562991	NCT00156299_1_T0	COMPOUND	13	13	choline
NCT001562991	NCT00156299_1_T1	CELL	8	8	cells
NCT001562991	NCT00156299_1_T2	COMPOUND	14	14	magnesium
NCT001562991	NCT00156299_1_T3	COMPOUND	15	15	trisalicylate
NCT001562997	NCT00156299_7_T0	COMPOUND	13	13	dexamethasone
NCT001562997	NCT00156299_7_T1	COMPOUND	3	3	choline
NCT001562997	NCT00156299_7_T2	COMPOUND	21	21	choline
NCT001562997	NCT00156299_7_T3	COMPOUND	4	4	magnesium
NCT001562997	NCT00156299_7_T4	COMPOUND	22	22	magnesium
NCT001562997	NCT00156299_7_T5	COMPOUND	5	5	trisalicylate
NCT001562997	NCT00156299_7_T6	COMPOUND	23	23	trisalicylate
NCT001563120	NCT00156312_0_T0	PHENOTYPE	2	2	Tumor
NCT001563120	NCT00156312_0_T1	PHENOTYPE	5	6	Breast Cancer
NCT001563123	NCT00156312_3_T0	COMPOUND	4	4	capecitabine
NCT001563123	NCT00156312_3_T1	PHENOTYPE	14	14	tumors
NCT001563123	NCT00156312_3_T2	COMPOUND	2	2	docetaxel
NCT001563124	NCT00156312_4_T0	COMPOUND	23	23	capecitabine
NCT001563124	NCT00156312_4_T1	COMPOUND	5	5	docetaxel
NCT001563124	NCT00156312_4_T2	GENE	16	16	TP
NCT001563124	NCT00156312_4_T3	GENE	14	15	thymidine phosphorylase
NCT001563125	NCT00156312_5_T0	PHENOTYPE	11	12	breast cancer
NCT001563126	NCT00156312_6_T0	GENE	15	15	TP
NCT001563126	NCT00156312_6_T1	PHENOTYPE	7	8	breast tumors
NCT001563127	NCT00156312_7_T0	PHENOTYPE	9	9	tumors
NCT0015631210	NCT00156312_10_T0	GENE	8	8	PE
NCT0015631210	NCT00156312_10_T1	GENE	3	3	cm
NCT0015631211	NCT00156312_11_T0	GENE	0	0	OR
NCT0015631211	NCT00156312_11_T1	GENE	3	3	cm
NCT0015631211	NCT00156312_11_T2	GENE	5	5	ER
NCT001563250	NCT00156325_0_T0	PHENOTYPE	6	8	Bipolar II Disorder
NCT001563253	NCT00156325_3_T0	PHENOTYPE	2	2	reflects
NCT001563253	NCT00156325_3_T1	PHENOTYPE	18	19	Bipolar Disorder
NCT001563254	NCT00156325_4_T0	GENE	6	6	II
NCT001563254	NCT00156325_4_T1	GENE	21	21	II
NCT001563254	NCT00156325_4_T2	GENE	10	10	has
NCT001563256	NCT00156325_6_T0	PHENOTYPE	26	26	severity
NCT0015632512	NCT00156325_12_T0	PHENOTYPE	7	9	Bipolar II disorder
NCT0015632513	NCT00156325_13_T0	PHENOTYPE	11	12	Mental Disorders
NCT0015632514	NCT00156325_14_T0	PHENOTYPE	14	15	mood disturbance
NCT0015632515	NCT00156325_15_T0	PHENOTYPE	19	20	psychotic symptoms
NCT0015632516	NCT00156325_16_T0	PHENOTYPE	8	9	personality disorder
NCT0015632516	NCT00156325_16_T1	PHENOTYPE	12	13	drug use
NCT0015632517	NCT00156325_17_T0	PHENOTYPE	21	21	epilepsy
NCT0015632517	NCT00156325_17_T1	PHENOTYPE	23	23	seizures
NCT0015632517	NCT00156325_17_T2	PHENOTYPE	19	20	liver disease
NCT0015632517	NCT00156325_17_T3	PHENOTYPE	17	18	heart disease
NCT0015632519	NCT00156325_19_T0	PHENOTYPE	15	15	Mania
NCT0015635115	NCT00156351_15_T0	PHENOTYPE	27	27	perceived
NCT0015635115	NCT00156351_15_T1	GENE	7	7	mediator
NCT0015635115	NCT00156351_15_T2	PHENOTYPE	22	23	self efficacy
NCT001563642	NCT00156364_2_T0	PHENOTYPE	13	15	diabetic renal disease
NCT001563646	NCT00156364_6_T0	PHENOTYPE	3	3	5-10
NCT001563646	NCT00156364_6_T1	GENE	12	12	structural
NCT001563646	NCT00156364_6_T2	ORGAN	17	17	kidneys
NCT0015636414	NCT00156364_14_T0	PHENOTYPE	33	33	recruitment
NCT0015636414	NCT00156364_14_T1	ORGAN	18	18	transplant
NCT0015636417	NCT00156364_17_T0	GENE	12	12	PI
NCT0015636421	NCT00156364_21_T0	PHENOTYPE	5	5	unilateral
NCT0015636421	NCT00156364_21_T1	ORGAN	1	1	kidneys
NCT0015636421	NCT00156364_21_T2	PHENOTYPE	6	7	renal disease
NCT0015636423	NCT00156364_23_T0	PHENOTYPE	4	5	kidney disease
NCT0015636432	NCT00156364_32_T0	PHENOTYPE	3	3	chronic
NCT0015636434	NCT00156364_34_T0	PHENOTYPE	4	5	kidney disease
NCT001563773	NCT00156377_3_T0	PHENOTYPE	13	13	infections
NCT001563773	NCT00156377_3_T1	PHENOTYPE	39	39	infections
NCT001563774	NCT00156377_4_T0	COMPOUND	11	11	mupirocin
NCT001563774	NCT00156377_4_T1	PHENOTYPE	34	34	infections
NCT001563776	NCT00156377_6_T0	COMPOUND	12	12	mupirocin
NCT001563779	NCT00156377_9_T0	COMPOUND	8	8	mupirocin
NCT001563779	NCT00156377_9_T1	PHENOTYPE	11	12	nosocomial infections
NCT001563902	NCT00156390_2_T0	PHENOTYPE	17	17	attributable
NCT001563902	NCT00156390_2_T1	PHENOTYPE	19	21	sudden cardiac death
NCT001563903	NCT00156390_3_T0	GENE	3	3	has
NCT001563903	NCT00156390_3_T1	COMPOUND	1	1	BIV
NCT001563904	NCT00156390_4_T0	PHENOTYPE	19	19	symptoms
NCT001563904	NCT00156390_4_T1	GENE	5	5	ventricular
NCT001563904	NCT00156390_4_T2	PHENOTYPE	6	7	conduction abnormalities
NCT001563904	NCT00156390_4_T3	PHENOTYPE	9	11	reduced ejection fraction
NCT001563905	NCT00156390_5_T0	COMPOUND	6	6	BIV
NCT001563905	NCT00156390_5_T1	PHENOTYPE	13	15	quality of life
NCT001563906	NCT00156390_6_T0	COMPOUND	14	14	BIV
NCT001563907	NCT00156390_7_T0	GENE	31	31	ventricular
NCT001563908	NCT00156390_8_T0	COMPOUND	10	10	BIV
NCT001563909	NCT00156390_9_T0	COMPOUND	6	6	BIV
NCT001563909	NCT00156390_9_T1	COMPOUND	38	38	BIV
NCT0015639016	NCT00156390_16_T0	COMPOUND	12	12	BIV
NCT0015639017	NCT00156390_17_T0	COMPOUND	20	20	BIV
NCT0015639018	NCT00156390_18_T0	COMPOUND	19	19	BIV
NCT0015639019	NCT00156390_19_T0	PHENOTYPE	12	12	severity
NCT0015639022	NCT00156390_22_T0	COMPOUND	8	8	BIV
NCT0015639027	NCT00156390_27_T0	PHENOTYPE	7	7	acute
NCT0015639027	NCT00156390_27_T1	COMPOUND	14	14	BIV
NCT0015639030	NCT00156390_30_T0	PHENOTYPE	19	19	scaring
NCT0015639030	NCT00156390_30_T1	COMPOUND	33	33	BIV
NCT0015639030	NCT00156390_30_T2	PHENOTYPE	5	5	cardiomyopathy
NCT001564033	NCT00156403_3_T0	GENE	7	7	trypsinogen
NCT001564033	NCT00156403_3_T1	CELL	11	12	acinar cells
NCT001564033	NCT00156403_3_T2	PHENOTYPE	15	16	pancreatic inflammation
NCT001564034	NCT00156403_4_T0	PHENOTYPE	13	13	complications
NCT001564034	NCT00156403_4_T1	PHENOTYPE	6	6	recurrent
NCT001564034	NCT00156403_4_T2	PHENOTYPE	21	22	pancreatic adenocarcinoma
NCT001564034	NCT00156403_4_T3	PHENOTYPE	9	10	chronic pancreatitis
NCT001564034	NCT00156403_4_T4	PHENOTYPE	7	8	acute pancreatitis
NCT001564036	NCT00156403_6_T0	GENE	7	7	trypsinogen
NCT001564038	NCT00156403_8_T0	GENE	17	17	blocker
NCT001564038	NCT00156403_8_T1	GENE	28	28	trypsinogen
NCT001564038	NCT00156403_8_T2	COMPOUND	18	18	amlodipine
NCT001564038	NCT00156403_8_T3	GENE	15	16	calcium channel
NCT001564038	NCT00156403_8_T4	PHENOTYPE	34	35	pancreatic inflammation
NCT001564039	NCT00156403_9_T0	GENE	16	16	PRSS1
NCT001564039	NCT00156403_9_T1	GENE	13	14	cationic trypsinogen
NCT0015640310	NCT00156403_10_T0	PHENOTYPE	6	6	symptoms
NCT0015640310	NCT00156403_10_T1	PHENOTYPE	9	9	symptoms
NCT0015640312	NCT00156403_12_T0	PHENOTYPE	7	7	symptoms
NCT0015640312	NCT00156403_12_T1	PHENOTYPE	21	23	quality of life
NCT0015640313	NCT00156403_13_T0	PHENOTYPE	56	56	severity
NCT0015640313	NCT00156403_13_T1	COMPOUND	12	12	amlodipine
NCT0015640313	NCT00156403_13_T2	PHENOTYPE	54	54	symptoms
NCT0015640313	NCT00156403_13_T3	GENE	2	2	has
NCT001564161	NCT00156416_1_T0	PHENOTYPE	0	1	Menopausal symptoms
NCT001564161	NCT00156416_1_T1	PHENOTYPE	10	12	quality of life
NCT001564163	NCT00156416_3_T0	PHENOTYPE	11	11	mindfulness
NCT001564163	NCT00156416_3_T1	COMPOUND	5	5	1
NCT001564163	NCT00156416_3_T2	PHENOTYPE	12	12	meditation
NCT001564163	NCT00156416_3_T3	PHENOTYPE	21	22	hot flushes
NCT001564163	NCT00156416_3_T4	PHENOTYPE	18	19	menopausal symptoms
NCT001564164	NCT00156416_4_T0	PHENOTYPE	19	19	severity
NCT001564164	NCT00156416_4_T1	PHENOTYPE	7	7	mindfulness
NCT001564164	NCT00156416_4_T2	COMPOUND	37	37	cortisol
NCT001564164	NCT00156416_4_T3	COMPOUND	0	0	2
NCT001564164	NCT00156416_4_T4	PHENOTYPE	8	8	meditation
NCT001564164	NCT00156416_4_T5	PHENOTYPE	21	22	hot flushes
NCT001564164	NCT00156416_4_T6	PHENOTYPE	35	36	stress response
NCT001564164	NCT00156416_4_T7	PHENOTYPE	11	12	menopausal symptom
NCT001564164	NCT00156416_4_T8	PHENOTYPE	30	32	quality of life
NCT001564166	NCT00156416_6_T0	PHENOTYPE	10	10	meditation
NCT001564167	NCT00156416_7_T0	PHENOTYPE	4	4	meditation
NCT001564169	NCT00156416_9_T0	PHENOTYPE	8	9	menopausal symptoms
NCT0015641611	NCT00156416_11_T0	PHENOTYPE	0	1	Menopausal symptoms
NCT0015641611	NCT00156416_11_T1	PHENOTYPE	10	12	quality of life
NCT0015641612	NCT00156416_12_T0	COMPOUND	14	14	estrogen
NCT0015641612	NCT00156416_12_T1	PHENOTYPE	26	26	discomfort
NCT0015641612	NCT00156416_12_T2	PHENOTYPE	21	21	meditation
NCT0015641612	NCT00156416_12_T3	PHENOTYPE	24	25	menopausal symptom
NCT0015641614	NCT00156416_14_T0	PHENOTYPE	11	11	mindfulness
NCT0015641614	NCT00156416_14_T1	COMPOUND	5	5	1
NCT0015641614	NCT00156416_14_T2	PHENOTYPE	12	12	meditation
NCT0015641614	NCT00156416_14_T3	PHENOTYPE	21	22	hot flushes
NCT0015641614	NCT00156416_14_T4	PHENOTYPE	18	19	menopausal symptoms
NCT0015641615	NCT00156416_15_T0	PHENOTYPE	19	19	severity
NCT0015641615	NCT00156416_15_T1	PHENOTYPE	7	7	mindfulness
NCT0015641615	NCT00156416_15_T2	COMPOUND	37	37	cortisol
NCT0015641615	NCT00156416_15_T3	COMPOUND	0	0	2
NCT0015641615	NCT00156416_15_T4	PHENOTYPE	8	8	meditation
NCT0015641615	NCT00156416_15_T5	PHENOTYPE	21	22	hot flushes
NCT0015641615	NCT00156416_15_T6	PHENOTYPE	35	36	stress response
NCT0015641615	NCT00156416_15_T7	PHENOTYPE	11	12	menopausal symptom
NCT0015641615	NCT00156416_15_T8	PHENOTYPE	30	32	quality of life
NCT0015641619	NCT00156416_19_T0	PHENOTYPE	10	10	meditation
NCT0015641620	NCT00156416_20_T0	PHENOTYPE	4	4	meditation
NCT0015641622	NCT00156416_22_T0	PHENOTYPE	8	9	menopausal symptoms
NCT0015641624	NCT00156416_24_T0	PHENOTYPE	21	21	mindfulness
NCT0015641624	NCT00156416_24_T1	PHENOTYPE	22	22	meditation
NCT0015641624	NCT00156416_24_T2	PHENOTYPE	29	30	menopausal symptom
NCT0015641624	NCT00156416_24_T3	PHENOTYPE	35	37	quality of life
NCT0015641626	NCT00156416_26_T0	PHENOTYPE	9	9	menopausal
NCT0015641626	NCT00156416_26_T1	PHENOTYPE	10	11	hot flushes
NCT0015641630	NCT00156416_30_T0	GENE	27	27	beta
NCT0015641630	NCT00156416_30_T1	PHENOTYPE	24	25	hot flush
NCT0015641630	NCT00156416_30_T2	PHENOTYPE	6	7	menopausal symptoms
NCT0015641631	NCT00156416_31_T0	PHENOTYPE	12	12	hypertension
NCT0015641631	NCT00156416_31_T1	PHENOTYPE	15	16	hot flushes
NCT0015641632	NCT00156416_32_T0	PHENOTYPE	11	11	meditation
NCT0015641632	NCT00156416_32_T1	PHENOTYPE	3	4	menopausal symptoms
NCT0015641633	NCT00156416_33_T0	PHENOTYPE	20	20	meditation
NCT0015641633	NCT00156416_33_T1	PHENOTYPE	19	19	mindfulness
NCT0015641633	NCT00156416_33_T2	PHENOTYPE	8	9	breast cancer
NCT0015641633	NCT00156416_33_T3	PHENOTYPE	22	24	quality of life
NCT0015641634	NCT00156416_34_T0	PHENOTYPE	12	12	thoughts
NCT0015641634	NCT00156416_34_T1	GENE	9	9	27
NCT001564292	NCT00156429_2_T0	GENE	16	16	beta-AR
NCT001564292	NCT00156429_2_T1	PHENOTYPE	33	33	LVH
NCT001564295	NCT00156429_5_T0	GENE	16	16	beta-AR
NCT001564295	NCT00156429_5_T1	PHENOTYPE	33	33	LVH
NCT001564421	NCT00156442_1_T0	PHENOTYPE	4	4	severity
NCT001564421	NCT00156442_1_T1	PHENOTYPE	21	22	cleft palate
NCT001564421	NCT00156442_1_T2	PHENOTYPE	6	8	obstructive sleep apnea
NCT001564426	NCT00156442_6_T0	PHENOTYPE	19	20	cleft palate
NCT001564427	NCT00156442_7_T0	PHENOTYPE	16	17	cleft palate
NCT0015644211	NCT00156442_11_T0	PHENOTYPE	16	17	velopharyngeal dysfunction
NCT0015644211	NCT00156442_11_T1	PHENOTYPE	11	12	cleft palate
NCT0015644213	NCT00156442_13_T0	PHENOTYPE	3	3	incompetence
NCT0015644215	NCT00156442_15_T0	PHENOTYPE	12	14	obstructive sleep apnea
NCT0015644216	NCT00156442_16_T0	PHENOTYPE	17	18	cleft palate
NCT0015644216	NCT00156442_16_T1	PHENOTYPE	8	10	obstructive sleep apnea
NCT0015644216	NCT00156442_16_T2	PHENOTYPE	36	38	obstructive sleep apnea
NCT0015644217	NCT00156442_17_T0	PHENOTYPE	13	14	poor speech
NCT0015644217	NCT00156442_17_T1	PHENOTYPE	16	17	sleep apnea
NCT0015644218	NCT00156442_18_T0	PHENOTYPE	21	21	sequelae
NCT0015644218	NCT00156442_18_T1	PHENOTYPE	14	15	cleft palate
NCT0015644218	NCT00156442_18_T2	PHENOTYPE	5	7	obstructive sleep apnea
NCT0015644219	NCT00156442_19_T0	PHENOTYPE	19	19	severity
NCT0015644219	NCT00156442_19_T1	PHENOTYPE	36	37	cleft palate
NCT0015644219	NCT00156442_19_T2	PHENOTYPE	21	23	obstructive sleep apnea
NCT0015644225	NCT00156442_25_T0	PHENOTYPE	5	5	snoring
NCT0015644225	NCT00156442_25_T1	PHENOTYPE	7	7	snoring
NCT0015644228	NCT00156442_28_T0	PHENOTYPE	1	1	snoring
NCT0015644228	NCT00156442_28_T1	PHENOTYPE	12	13	cleft palate
NCT0015644230	NCT00156442_30_T0	PHENOTYPE	22	23	cleft palate
NCT0015644233	NCT00156442_33_T0	ORGAN	14	14	pharynx
NCT0015644233	NCT00156442_33_T1	ORGAN	11	11	glottis
NCT0015644233	NCT00156442_33_T2	PHENOTYPE	31	32	velopharyngeal dysfunction
NCT0015644235	NCT00156442_35_T0	PHENOTYPE	14	15	velopharyngeal dysfunction
NCT0015644236	NCT00156442_36_T0	PHENOTYPE	19	20	cleft palate
NCT0015644240	NCT00156442_40_T0	PHENOTYPE	0	1	Cleft palate
NCT001564552	NCT00156455_2_T0	GENE	10	10	II
NCT001564556	NCT00156455_6_T0	GENE	10	10	II
NCT001564558	NCT00156455_8_T0	PHENOTYPE	7	7	physiology
NCT001564558	NCT00156455_8_T1	PHENOTYPE	5	6	single ventricle
NCT001564558	NCT00156455_8_T2	PHENOTYPE	15	16	vascular resistance
NCT001564559	NCT00156455_9_T0	PHENOTYPE	18	18	circulations
NCT0015645511	NCT00156455_11_T0	PHENOTYPE	19	20	stage III
NCT0015645511	NCT00156455_11_T1	PHENOTYPE	3	5	pulmonary artery pressure
NCT0015645513	NCT00156455_13_T0	PHENOTYPE	8	9	sleep apnea
NCT0015645515	NCT00156455_15_T0	GENE	3	3	has
NCT0015645515	NCT00156455_15_T1	PHENOTYPE	17	18	systemic hypertension
NCT0015645515	NCT00156455_15_T2	PHENOTYPE	0	2	Obstructive sleep apnea
NCT0015645517	NCT00156455_17_T0	COMPOUND	5	5	oxygen
NCT0015645518	NCT00156455_18_T0	PHENOTYPE	27	27	dissociation
NCT0015645518	NCT00156455_18_T1	GENE	14	14	mid
NCT0015645518	NCT00156455_18_T2	COMPOUND	10	10	oxygen
NCT0015645518	NCT00156455_18_T3	PHENOTYPE	3	6	cyanotic congenital heart disease
NCT0015645520	NCT00156455_20_T0	PHENOTYPE	19	19	apneic
NCT0015645521	NCT00156455_21_T0	GENE	26	26	II
NCT0015645521	NCT00156455_21_T1	PHENOTYPE	9	9	apneic
NCT0015645521	NCT00156455_21_T2	ORGAN	17	18	pulmonary artery
NCT0015645525	NCT00156455_25_T0	PHENOTYPE	4	4	hypoxic
NCT0015645525	NCT00156455_25_T1	GENE	17	17	ventricular
NCT0015645525	NCT00156455_25_T2	ORGAN	11	12	cardiovascular system
NCT0015645526	NCT00156455_26_T0	PHENOTYPE	12	12	secondary
NCT0015645526	NCT00156455_26_T1	PHENOTYPE	15	15	arrhythmias
NCT0015645527	NCT00156455_27_T0	PHENOTYPE	9	9	apneic
NCT001564680	NCT00156468_0_T0	PHENOTYPE	1	1	Asthma
NCT001564682	NCT00156468_2_T0	PHENOTYPE	16	16	asthma
NCT001564682	NCT00156468_2_T1	PHENOTYPE	22	22	asthma
NCT001564683	NCT00156468_3_T0	PHENOTYPE	20	20	asthma
NCT001565201	NCT00156520_1_T0	BIOLOGICAL_PROCESS	19	19	hemostasis
NCT001565201	NCT00156520_1_T1	ORGAN	14	15	aortic valve
NCT001565203	NCT00156520_3_T0	CELL	5	5	platelets
NCT001565204	NCT00156520_4_T0	BIOLOGICAL_PROCESS	8	8	hemostasis
NCT001565206	NCT00156520_6_T0	PHENOTYPE	17	17	cavity
NCT001565206	NCT00156520_6_T1	PHENOTYPE	3	4	postoperative bleeding
NCT001565208	NCT00156520_8_T0	PHENOTYPE	7	7	pathology
NCT001565208	NCT00156520_8_T1	PHENOTYPE	6	6	stenotic
NCT001565208	NCT00156520_8_T2	ORGAN	4	5	aortic valve
NCT0015652015	NCT00156520_15_T0	PHENOTYPE	39	39	anesthesia
NCT0015652019	NCT00156520_19_T0	GENE	31	31	ADP
NCT0015652019	NCT00156520_19_T1	GENE	32	32	receptor
NCT0015652019	NCT00156520_19_T2	COMPOUND	19	19	aspirin
NCT0015652019	NCT00156520_19_T3	CELL	16	16	platelet
NCT0015652019	NCT00156520_19_T4	ORGAN	5	6	coronary artery
NCT0015652021	NCT00156520_21_T0	GENE	4	4	1.3
NCT0015652021	NCT00156520_21_T1	GENE	21	21	1.3
NCT0015652023	NCT00156520_23_T0	BIOLOGICAL_PROCESS	12	12	hemostasis
NCT0015652023	NCT00156520_23_T1	COMPOUND	6	6	1
NCT0015652023	NCT00156520_23_T2	COMPOUND	24	24	2
NCT0015652023	NCT00156520_23_T3	COMPOUND	32	32	3
NCT0015652023	NCT00156520_23_T4	CELL	10	10	platelet
NCT0015652023	NCT00156520_23_T5	CELL	22	22	platelet
NCT0015652023	NCT00156520_23_T6	GENE	34	34	VIII
NCT0015652023	NCT00156520_23_T7	PHENOTYPE	26	27	von Willebrand
NCT0015652026	NCT00156520_26_T0	CELL	14	14	platelet
NCT0015652029	NCT00156520_29_T0	COMPOUND	21	21	heparin
NCT0015652029	NCT00156520_29_T1	COMPOUND	8	8	EACA
NCT0015652029	NCT00156520_29_T2	GENE	11	11	has
NCT0015652030	NCT00156520_30_T0	GENE	11	11	bypass
NCT0015652030	NCT00156520_30_T1	GENE	6	6	protamine
NCT0015652032	NCT00156520_32_T0	GENE	5	5	ml
NCT0015652032	NCT00156520_32_T1	GENE	15	15	ml
NCT0015652032	NCT00156520_32_T2	GENE	25	25	ml
NCT0015652037	NCT00156520_37_T0	COMPOUND	6	6	N
NCT001565333	NCT00156533_3_T0	GENE	18	18	receptor
NCT001565333	NCT00156533_3_T1	COMPOUND	17	17	benzodiazepine
NCT001565334	NCT00156533_4_T0	GENE	8	8	fold
NCT001565335	NCT00156533_5_T0	PHENOTYPE	10	10	strategies
NCT001565335	NCT00156533_5_T1	PHENOTYPE	17	17	insomnia
NCT001565336	NCT00156533_6_T0	GENE	10	10	extended
NCT001565337	NCT00156533_7_T0	COMPOUND	2	2	1
NCT001565337	NCT00156533_7_T1	GENE	0	0	Re
NCT0015653312	NCT00156533_12_T0	COMPOUND	2	2	2
NCT0015653312	NCT00156533_12_T1	GENE	0	0	Re
NCT0015653315	NCT00156533_15_T0	GENE	22	22	extended
NCT0015653316	NCT00156533_16_T0	PHENOTYPE	15	16	Primary Insomnia
NCT0015653318	NCT00156533_18_T0	COMPOUND	5	5	zolpidem
NCT001565591	NCT00156559_1_T0	GENE	19	19	29
NCT001565591	NCT00156559_1_T1	BIOLOGICAL_PROCESS	21	21	gestation
NCT001565591	NCT00156559_1_T2	PHENOTYPE	7	7	varicella
NCT001565596	NCT00156559_6_T0	GENE	23	23	29
NCT001565596	NCT00156559_6_T1	BIOLOGICAL_PROCESS	25	25	gestation
NCT001565596	NCT00156559_6_T2	PHENOTYPE	11	11	varicella
NCT001565597	NCT00156559_7_T0	PHENOTYPE	0	0	Measles
NCT001565598	NCT00156559_8_T0	PHENOTYPE	2	2	rubella
NCT001565598	NCT00156559_8_T1	PHENOTYPE	0	0	Mumps
NCT001565599	NCT00156559_9_T0	PHENOTYPE	0	0	Varicella
NCT0015655910	NCT00156559_10_T0	PHENOTYPE	9	10	adverse events
NCT0015655910	NCT00156559_10_T1	PHENOTYPE	18	19	adverse events
NCT0015655923	NCT00156559_23_T0	ORGAN	8	8	radius
NCT0015655931	NCT00156559_31_T0	COMPOUND	1	1	oxygen
NCT001565721	NCT00156572_1_T0	PHENOTYPE	0	0	Hyponatremia
NCT001565721	NCT00156572_1_T1	PHENOTYPE	7	8	side effect
NCT001565722	NCT00156572_2_T0	PHENOTYPE	10	10	hyponatremia
NCT001565723	NCT00156572_3_T0	ORGAN	20	20	lungs
NCT001565724	NCT00156572_4_T0	PHENOTYPE	9	9	VLBW
NCT001565724	NCT00156572_4_T1	PHENOTYPE	23	23	BPD
NCT001565724	NCT00156572_4_T2	PHENOTYPE	4	7	very low birth weight
NCT001565725	NCT00156572_5_T0	PHENOTYPE	21	21	hyponatremic
NCT001565725	NCT00156572_5_T1	ORGAN	24	24	serum
NCT001565725	NCT00156572_5_T2	GENE	26	26	130
NCT0015657210	NCT00156572_10_T0	COMPOUND	7	7	sodium
NCT0015657210	NCT00156572_10_T1	COMPOUND	1	1	Sodium
NCT0015657210	NCT00156572_10_T2	COMPOUND	13	13	NaCl
NCT0015657211	NCT00156572_11_T0	COMPOUND	3	3	sodium
NCT0015657211	NCT00156572_11_T1	COMPOUND	12	12	NaCl
NCT0015657211	NCT00156572_11_T2	ORGAN	2	2	serum
NCT0015657212	NCT00156572_12_T0	COMPOUND	3	3	sodium
NCT0015657212	NCT00156572_12_T1	COMPOUND	12	12	NaCl
NCT0015657212	NCT00156572_12_T2	ORGAN	2	2	serum
NCT0015657213	NCT00156572_13_T0	GENE	9	9	135
NCT0015657213	NCT00156572_13_T1	ORGAN	6	6	serum
NCT0015657218	NCT00156572_18_T0	PHENOTYPE	0	0	Secondary
NCT0015657219	NCT00156572_19_T0	COMPOUND	5	5	creatinine
NCT0015657219	NCT00156572_19_T1	COMPOUND	3	3	calcium
NCT0015657219	NCT00156572_19_T2	PHENOTYPE	1	2	urine sodium
NCT0015657221	NCT00156572_21_T0	ORGAN	2	2	serum
NCT0015657223	NCT00156572_23_T0	ORGAN	2	2	serum
NCT0015657227	NCT00156572_27_T0	GENE	2	2	CPAP
NCT0015657227	NCT00156572_27_T1	GENE	9	9	CPAP
NCT0015657227	NCT00156572_27_T2	PHENOTYPE	5	5	ventilation
NCT0015657229	NCT00156572_29_T0	GENE	33	33	CPAP
NCT0015657229	NCT00156572_29_T1	GENE	5	5	has
NCT0015657230	NCT00156572_30_T0	GENE	35	35	CPAP
NCT0015657234	NCT00156572_34_T0	PHENOTYPE	0	3	Very low birth weight
NCT0015657235	NCT00156572_35_T0	COMPOUND	5	5	oxygen
NCT0015657235	NCT00156572_35_T1	PHENOTYPE	0	1	Bronchopulmonary dysplasia
NCT0015657235	NCT00156572_35_T2	PHENOTYPE	22	24	chronic lung disease
NCT0015657238	NCT00156572_38_T0	PHENOTYPE	0	0	Hyponatremic
NCT0015657238	NCT00156572_38_T1	ORGAN	3	3	serum
NCT0015657238	NCT00156572_38_T2	GENE	5	5	130
NCT0015657240	NCT00156572_40_T0	ORGAN	6	6	lungs
NCT0015657240	NCT00156572_40_T1	ORGAN	7	7	kidneys
NCT0015657240	NCT00156572_40_T2	ORGAN	5	5	heart
NCT0015657240	NCT00156572_40_T3	PHENOTYPE	9	10	chromosomal abnormalities
NCT0015657240	NCT00156572_40_T4	PHENOTYPE	1	2	congenital anomalies
NCT0015657242	NCT00156572_42_T0	GENE	2	2	1.3
NCT001565851	NCT00156585_1_T0	COMPOUND	17	17	Gd-DTPA
NCT001565851	NCT00156585_1_T1	PHENOTYPE	9	10	brain lesions
NCT001565852	NCT00156585_2_T0	GENE	10	10	gamma
NCT001565854	NCT00156585_4_T0	GENE	11	11	MRI
NCT001565854	NCT00156585_4_T1	PHENOTYPE	6	6	tumor
NCT001565982	NCT00156598_2_T0	PHENOTYPE	12	13	adverse effects
NCT001566113	NCT00156611_3_T0	PHENOTYPE	7	7	occlusions
NCT001566113	NCT00156611_3_T1	GENE	11	11	cm
NCT001566242	NCT00156624_2_T0	ORGAN	14	15	femoral artery
NCT001566244	NCT00156624_4_T0	PHENOTYPE	9	9	peripheral
NCT001566244	NCT00156624_4_T1	ORGAN	6	7	coronary arteries
NCT001566245	NCT00156624_5_T0	GENE	17	17	balloon
NCT001566245	NCT00156624_5_T1	GENE	20	20	balloon
NCT001566245	NCT00156624_5_T2	GENE	5	5	135
NCT001566373	NCT00156637_3_T0	PHENOTYPE	15	15	schizophrenia
NCT001566375	NCT00156637_5_T0	PHENOTYPE	0	1	Mental Health
NCT001566376	NCT00156637_6_T0	PHENOTYPE	8	8	learned
NCT001566376	NCT00156637_6_T1	BIOLOGICAL_PROCESS	12	12	translation
NCT001566377	NCT00156637_7_T0	BIOLOGICAL_PROCESS	3	3	translation
NCT001566377	NCT00156637_7_T1	COMPOUND	50	50	clozapine
NCT001566378	NCT00156637_8_T0	PHENOTYPE	21	21	strategies
NCT001566378	NCT00156637_8_T1	BIOLOGICAL_PROCESS	23	23	translation
NCT0015663710	NCT00156637_10_T0	COMPOUND	15	15	clozapine
NCT0015663712	NCT00156637_12_T0	COMPOUND	28	28	clozapine
NCT0015663712	NCT00156637_12_T1	PHENOTYPE	7	8	side effect
NCT0015663714	NCT00156637_14_T0	COMPOUND	25	25	clozapine
NCT0015663714	NCT00156637_14_T1	PHENOTYPE	17	18	side effect
NCT0015663717	NCT00156637_17_T0	PHENOTYPE	0	0	All
NCT0015663718	NCT00156637_18_T0	PHENOTYPE	2	2	recruitment
NCT0015663718	NCT00156637_18_T1	GENE	3	3	had
NCT001566504	NCT00156650_4_T0	CELL	9	9	sperm
NCT001566507	NCT00156650_7_T0	GENE	24	24	reduced
NCT001566507	NCT00156650_7_T1	CELL	20	20	sperm
NCT001566633	NCT00156663_3_T0	PHENOTYPE	7	7	stereotypes
NCT001566633	NCT00156663_3_T1	GENE	31	31	VHA
NCT001566635	NCT00156663_5_T0	GENE	1	1	II
NCT001566636	NCT00156663_6_T0	GENE	2	2	III
NCT0015666312	NCT00156663_12_T0	GENE	25	25	249
NCT0015666312	NCT00156663_12_T1	GENE	12	12	Time
NCT0015666312	NCT00156663_12_T2	GENE	21	21	Time
NCT0015666312	NCT00156663_12_T3	GENE	33	33	Time
NCT001566760	NCT00156676_0_T0	GENE	9	9	ll
NCT001566760	NCT00156676_0_T1	PHENOTYPE	4	5	Multiple Sclerosis
NCT001566762	NCT00156676_2_T0	GENE	9	9	robotic
NCT001566762	NCT00156676_2_T1	ORGAN	13	14	lower limbs
NCT001566764	NCT00156676_4_T0	PHENOTYPE	46	46	impairment
NCT001566764	NCT00156676_4_T1	PHENOTYPE	40	41	multiple sclerosis
NCT001566764	NCT00156676_4_T2	PHENOTYPE	10	12	spinal cord injury
NCT001566764	NCT00156676_4_T3	PHENOTYPE	36	38	quality of life
NCT001566766	NCT00156676_6_T0	GENE	11	11	has
NCT001566767	NCT00156676_7_T0	PHENOTYPE	18	18	fatigue
NCT001566767	NCT00156676_7_T1	PHENOTYPE	20	22	quality of life
NCT001566769	NCT00156676_9_T0	COMPOUND	0	0	EDSS
NCT001566890	NCT00156689_0_T0	PHENOTYPE	11	11	Chronic
NCT001566890	NCT00156689_0_T1	PHENOTYPE	9	9	Suffering
NCT001566890	NCT00156689_0_T2	PHENOTYPE	14	14	Polyneuropathy
NCT001566892	NCT00156689_2_T0	COMPOUND	6	6	levetiracetam
NCT001566892	NCT00156689_2_T1	PHENOTYPE	18	20	mechanism of action
NCT0015668911	NCT00156689_11_T0	GENE	0	0	Max
NCT0015668921	NCT00156689_21_T0	COMPOUND	5	5	valproate
NCT0015668921	NCT00156689_21_T1	PHENOTYPE	7	9	painful diabetic neuropathy
NCT0015668925	NCT00156689_25_T0	PHENOTYPE	30	30	epilepsy
NCT0015668925	NCT00156689_25_T1	COMPOUND	21	21	levetiracetam
NCT0015668926	NCT00156689_26_T0	PHENOTYPE	1	1	hyperalgesia
NCT0015668926	NCT00156689_26_T1	COMPOUND	6	6	levetiracetam
NCT0015668928	NCT00156689_28_T0	ORGAN	5	6	sciatic nerve
NCT0015668931	NCT00156689_31_T0	GENE	29	29	bid
NCT0015668931	NCT00156689_31_T1	PHENOTYPE	1	2	diabetic neuropathy
NCT0015668942	NCT00156689_42_T0	PHENOTYPE	7	7	symptoms
NCT0015668942	NCT00156689_42_T1	COMPOUND	13	13	creatinine
NCT0015668942	NCT00156689_42_T2	GENE	3	3	has
NCT0015668942	NCT00156689_42_T3	PHENOTYPE	9	10	renal impairment
NCT0015668944	NCT00156689_44_T0	PHENOTYPE	4	4	sterile
NCT001567023	NCT00156702_3_T0	COMPOUND	10	10	3
NCT001567023	NCT00156702_3_T1	PHENOTYPE	40	40	dependence
NCT001567029	NCT00156702_9_T0	PHENOTYPE	12	12	dependence
NCT001567029	NCT00156702_9_T1	PHENOTYPE	22	23	nicotine dependence
NCT0015670210	NCT00156702_10_T0	GENE	29	29	SLT
NCT0015670210	NCT00156702_10_T1	GENE	48	48	al
NCT0015670210	NCT00156702_10_T2	GENE	47	47	et
NCT0015670210	NCT00156702_10_T3	PHENOTYPE	0	1	Nicotine dependence
NCT0015670212	NCT00156702_12_T0	PHENOTYPE	18	18	dependence
NCT0015670212	NCT00156702_12_T1	PHENOTYPE	31	32	tobacco dependence
NCT0015670212	NCT00156702_12_T2	PHENOTYPE	16	17	progressing to
NCT0015670216	NCT00156702_16_T0	GENE	26	26	al
NCT0015670216	NCT00156702_16_T1	GENE	34	34	al
NCT0015670216	NCT00156702_16_T2	GENE	38	38	al
NCT0015670216	NCT00156702_16_T3	GENE	9	9	has
NCT0015670216	NCT00156702_16_T4	GENE	25	25	et
NCT0015670216	NCT00156702_16_T5	GENE	33	33	et
NCT0015670216	NCT00156702_16_T6	GENE	37	37	et
NCT0015670217	NCT00156702_17_T0	GENE	2	2	Dr
NCT0015670218	NCT00156702_18_T0	GENE	21	21	al
NCT0015670218	NCT00156702_18_T1	GENE	25	25	al
NCT0015670218	NCT00156702_18_T2	GENE	1	1	has
NCT0015670218	NCT00156702_18_T3	GENE	20	20	et
NCT0015670218	NCT00156702_18_T4	GENE	24	24	et
NCT0015670222	NCT00156702_22_T0	PHENOTYPE	11	11	recruitment
NCT0015670223	NCT00156702_23_T0	COMPOUND	10	10	3
NCT0015670223	NCT00156702_23_T1	PHENOTYPE	40	40	dependence
NCT0015670225	NCT00156702_25_T0	PHENOTYPE	0	0	Recruitment
NCT0015670226	NCT00156702_26_T0	GENE	7	7	ads
NCT0015670227	NCT00156702_27_T0	GENE	3	3	ads
NCT0015670228	NCT00156702_28_T0	PHENOTYPE	21	22	tobacco dependence
NCT0015670231	NCT00156702_31_T0	GENE	12	14	word of mouth
NCT0015670248	NCT00156702_48_T0	GENE	3	3	has
NCT0015670257	NCT00156702_57_T0	PHENOTYPE	11	11	upsetting
NCT0015670259	NCT00156702_59_T0	GENE	36	36	lib
NCT0015670259	NCT00156702_59_T1	GENE	16	16	al
NCT0015670259	NCT00156702_59_T2	GENE	15	15	et
NCT0015670259	NCT00156702_59_T3	GENE	43	43	puff
NCT0015670259	NCT00156702_59_T4	GENE	46	46	puff
NCT0015670259	NCT00156702_59_T5	PHENOTYPE	30	31	tobacco withdrawal
NCT0015670264	NCT00156702_64_T0	GENE	22	22	puff
NCT0015670264	NCT00156702_64_T1	ORGAN	8	8	heart
NCT0015670264	NCT00156702_64_T2	PHENOTYPE	19	20	withdrawal symptoms
NCT0015670264	NCT00156702_64_T3	PHENOTYPE	18	19	tobacco withdrawal
NCT0015670264	NCT00156702_64_T4	COMPOUND	11	12	carbon monoxide
NCT0015670265	NCT00156702_65_T0	COMPOUND	14	14	nicotine
NCT0015670265	NCT00156702_65_T1	COMPOUND	18	18	nicotine
NCT0015670265	NCT00156702_65_T2	COMPOUND	16	16	cotinine
NCT0015670267	NCT00156702_67_T0	PHENOTYPE	0	0	Withdrawal
NCT0015670267	NCT00156702_67_T1	GENE	7	7	al
NCT0015670267	NCT00156702_67_T2	GENE	6	6	et
NCT0015670271	NCT00156702_71_T0	ORGAN	7	7	heart
NCT0015670272	NCT00156702_72_T0	GENE	19	19	KS
NCT0015670272	NCT00156702_72_T1	GENE	1	1	CO
NCT0015670273	NCT00156702_73_T0	GENE	16	16	al
NCT0015670273	NCT00156702_73_T1	GENE	20	20	al
NCT0015670273	NCT00156702_73_T2	GENE	15	15	et
NCT0015670273	NCT00156702_73_T3	GENE	19	19	et
NCT0015670274	NCT00156702_74_T0	COMPOUND	3	3	nicotine
NCT0015670274	NCT00156702_74_T1	COMPOUND	5	5	cotinine
NCT0015670276	NCT00156702_76_T0	GENE	13	13	32
NCT0015670277	NCT00156702_77_T0	GENE	27	27	al
NCT0015670277	NCT00156702_77_T1	GENE	15	15	has
NCT0015670277	NCT00156702_77_T2	GENE	26	26	et
NCT0015670284	NCT00156702_84_T0	GENE	11	11	al
NCT0015670284	NCT00156702_84_T1	GENE	10	10	et
NCT0015670288	NCT00156702_88_T0	PHENOTYPE	29	29	strategies
NCT0015670294	NCT00156702_94_T0	PHENOTYPE	22	22	attitudes
NCT0015670296	NCT00156702_96_T0	COMPOUND	8	8	nicotine
NCT0015670296	NCT00156702_96_T1	COMPOUND	10	10	cotinine
NCT0015670296	NCT00156702_96_T2	GENE	13	13	CO
NCT00156702107	NCT00156702_107_T0	PHENOTYPE	5	5	regressions
NCT00156702115	NCT00156702_115_T0	PHENOTYPE	12	13	cardiovascular disease
NCT00156702117	NCT00156702_117_T0	PHENOTYPE	1	1	Plan
NCT00156702117	NCT00156702_117_T1	PHENOTYPE	0	0	Recruitment
NCT00156702121	NCT00156702_121_T0	GENE	13	13	has
NCT00156702125	NCT00156702_125_T0	PHENOTYPE	0	0	Compensation
NCT00156702125	NCT00156702_125_T1	PHENOTYPE	1	1	Plan
NCT00156702141	NCT00156702_141_T0	GENE	9	9	has
NCT00156702145	NCT00156702_145_T0	GENE	3	3	has
NCT001567150	NCT00156715_0_T0	PHENOTYPE	9	9	Schizophrenia
NCT001567150	NCT00156715_0_T1	PHENOTYPE	13	15	Substance Use Disorder
NCT001567152	NCT00156715_2_T0	COMPOUND	5	5	quetiapine
NCT001567152	NCT00156715_2_T1	PHENOTYPE	14	15	substance use
NCT001567154	NCT00156715_4_T0	GENE	1	1	met
NCT001567156	NCT00156715_6_T0	COMPOUND	5	5	quetiapine
NCT001567158	NCT00156715_8_T0	PHENOTYPE	7	7	symptoms
NCT001567158	NCT00156715_8_T1	PHENOTYPE	9	9	impairment
NCT001567158	NCT00156715_8_T2	PHENOTYPE	13	13	schizophrenia
NCT0015671510	NCT00156715_10_T0	PHENOTYPE	15	15	schizophrenia
NCT0015671511	NCT00156715_11_T0	GENE	11	11	has
NCT0015671511	NCT00156715_11_T1	GENE	19	19	extended
NCT0015671512	NCT00156715_12_T0	COMPOUND	17	17	clozapine
NCT0015671512	NCT00156715_12_T1	PHENOTYPE	14	14	schizophrenia
NCT0015671512	NCT00156715_12_T2	PHENOTYPE	9	10	substance use
NCT0015671513	NCT00156715_13_T0	COMPOUND	10	10	quetiapine
NCT0015671513	NCT00156715_13_T1	PHENOTYPE	14	14	schizophrenia
NCT0015671514	NCT00156715_14_T0	GENE	1	1	receptor
NCT0015671514	NCT00156715_14_T1	GENE	8	8	receptor
NCT0015671514	NCT00156715_14_T2	GENE	7	7	D2
NCT0015671515	NCT00156715_15_T0	COMPOUND	10	10	quetiapine
NCT0015671515	NCT00156715_15_T1	PHENOTYPE	18	18	schizophrenia
NCT0015671515	NCT00156715_15_T2	PHENOTYPE	21	23	substance use disorder
NCT0015671516	NCT00156715_16_T0	COMPOUND	16	16	quetiapine
NCT0015671516	NCT00156715_16_T1	PHENOTYPE	3	3	schizophrenia
NCT0015671516	NCT00156715_16_T2	PHENOTYPE	5	6	schizoaffective disorder
NCT0015671516	NCT00156715_16_T3	PHENOTYPE	10	12	substance use disorder
NCT0015671517	NCT00156715_17_T0	COMPOUND	3	3	quetiapine
NCT0015671517	NCT00156715_17_T1	PHENOTYPE	12	13	substance use
NCT0015671519	NCT00156715_19_T0	COMPOUND	6	6	quetiapine
NCT001567282	NCT00156728_2_T0	GENE	6	6	AF
NCT001567282	NCT00156728_2_T1	GENE	17	17	AF
NCT001567284	NCT00156728_4_T0	GENE	4	4	AF
NCT001567284	NCT00156728_4_T1	PHENOTYPE	3	3	tachycardia
NCT001567284	NCT00156728_4_T2	PHENOTYPE	6	8	congestive heart failure
NCT001567285	NCT00156728_5_T0	GENE	14	14	AF
NCT001567285	NCT00156728_5_T1	GENE	31	31	31
NCT001567285	NCT00156728_5_T2	PHENOTYPE	5	7	congestive heart failure
NCT001567287	NCT00156728_7_T0	GENE	3	3	AF
NCT001567287	NCT00156728_7_T1	GENE	4	4	has
NCT001567287	NCT00156728_7_T2	PHENOTYPE	2	2	chronic
NCT001567287	NCT00156728_7_T3	PHENOTYPE	28	29	heart failure
NCT001567287	NCT00156728_7_T4	BIOLOGICAL_PROCESS	37	38	action potential
NCT001567287	NCT00156728_7_T5	PHENOTYPE	10	12	congestive heart failure
NCT001567287	NCT00156728_7_T6	PHENOTYPE	49	51	congestive heart failure
NCT001567288	NCT00156728_8_T0	GENE	5	5	AF
NCT001567288	NCT00156728_8_T1	PHENOTYPE	7	8	heart failure
NCT001567410	NCT00156741_0_T0	ORGAN	10	10	Heart
NCT001567410	NCT00156741_0_T1	GENE	12	12	rt
NCT001567413	NCT00156741_3_T0	GENE	5	5	ventricular
NCT001567414	NCT00156741_4_T0	GENE	6	6	ventricular
NCT001567416	NCT00156741_6_T0	GENE	7	7	ventricular
NCT0015674113	NCT00156741_13_T0	GENE	10	10	VP
NCT0015674114	NCT00156741_14_T0	PHENOTYPE	0	1	Adverse events
NCT001567673	NCT00156767_3_T0	PHENOTYPE	9	10	adrenal insufficiency
NCT001567673	NCT00156767_3_T1	PHENOTYPE	18	19	adrenal insufficiency
NCT001567673	NCT00156767_3_T2	PHENOTYPE	12	13	critically ill
NCT001567677	NCT00156767_7_T0	PHENOTYPE	9	9	pulse
NCT001567677	NCT00156767_7_T1	ORGAN	17	17	transplant
NCT001567677	NCT00156767_7_T2	ORGAN	15	16	bone marrow
NCT0015676711	NCT00156767_11_T0	PHENOTYPE	9	10	adrenal insufficiency
NCT0015676711	NCT00156767_11_T1	PHENOTYPE	18	19	adrenal insufficiency
NCT0015676711	NCT00156767_11_T2	PHENOTYPE	12	13	critically ill
NCT0015676713	NCT00156767_13_T0	COMPOUND	4	4	cortrosyn
NCT0015676713	NCT00156767_13_T1	PHENOTYPE	10	11	cortisol levels
NCT0015676714	NCT00156767_14_T0	PHENOTYPE	3	4	adrenal insufficiency
NCT0015676717	NCT00156767_17_T0	PHENOTYPE	9	9	pulse
NCT0015676717	NCT00156767_17_T1	ORGAN	17	17	transplant
NCT0015676717	NCT00156767_17_T2	ORGAN	15	16	bone marrow
NCT0015676720	NCT00156767_20_T0	PHENOTYPE	7	7	sepsis
NCT0015676724	NCT00156767_24_T0	PHENOTYPE	9	9	illnesses
NCT0015676726	NCT00156767_26_T0	PHENOTYPE	62	62	complication
NCT0015676726	NCT00156767_26_T1	PHENOTYPE	64	64	CIRRHOSIS
NCT0015676726	NCT00156767_26_T2	ORGAN	33	33	serum
NCT0015676726	NCT00156767_26_T3	PHENOTYPE	2	3	ADRENAL INSUFFICIENCY
NCT0015676726	NCT00156767_26_T4	PHENOTYPE	18	19	ADRENAL INSUFFICIENCY
NCT0015676726	NCT00156767_26_T5	PHENOTYPE	42	43	ADRENAL INSUFFICIENCY
NCT0015676726	NCT00156767_26_T6	PHENOTYPE	34	35	cortisol level
NCT0015676726	NCT00156767_26_T7	PHENOTYPE	66	67	NEPHROTIC SYNDROME
NCT0015676726	NCT00156767_26_T8	PHENOTYPE	11	13	secondary adrenal insufficiency
NCT001567930	NCT00156793_0_T0	PHENOTYPE	12	14	Coronary Artery Disease
NCT001567934	NCT00156793_4_T0	PHENOTYPE	13	13	ischemia
NCT001568060	NCT00156806_0_T0	PHENOTYPE	18	18	Cancer
NCT001568060	NCT00156806_0_T1	PHENOTYPE	15	16	Breast Cancer
NCT001568062	NCT00156806_2_T0	PHENOTYPE	10	10	burning
NCT001568062	NCT00156806_2_T1	PHENOTYPE	8	8	itching
NCT001568062	NCT00156806_2_T2	PHENOTYPE	6	7	skin redness
NCT001568066	NCT00156806_6_T0	GENE	9	9	vera
NCT001568066	NCT00156806_6_T1	GENE	10	10	gel
NCT001568066	NCT00156806_6_T2	GENE	13	13	gel
NCT001568067	NCT00156806_7_T0	GENE	6	6	gel
NCT0015680610	NCT00156806_10_T0	PHENOTYPE	9	9	symptoms
NCT0015680610	NCT00156806_10_T1	GENE	36	36	has
NCT0015680612	NCT00156806_12_T0	PHENOTYPE	9	9	symptoms
NCT001568191	NCT00156819_1_T0	COMPOUND	3	3	fluticasone
NCT001568191	NCT00156819_1_T1	COMPOUND	13	13	fluticasone
NCT001568191	NCT00156819_1_T2	COMPOUND	15	15	salmeterol
NCT001568191	NCT00156819_1_T3	COMPOUND	4	4	montelukast
NCT001568192	NCT00156819_2_T0	COMPOUND	7	7	fluticasone
NCT001568192	NCT00156819_2_T1	COMPOUND	9	9	salmeterol
NCT001568192	NCT00156819_2_T2	COMPOUND	1	1	montelukast
NCT001568192	NCT00156819_2_T3	PHENOTYPE	19	19	asthma
NCT001568193	NCT00156819_3_T0	PHENOTYPE	17	17	severity
NCT001568193	NCT00156819_3_T1	PHENOTYPE	28	28	asthma
NCT001568193	NCT00156819_3_T2	PHENOTYPE	19	20	asthma attacks
NCT001568450	NCT00156845_0_T0	PHENOTYPE	12	14	Coronary Artery Disease
NCT001568454	NCT00156845_4_T0	PHENOTYPE	11	11	ischemia
NCT001568972	NCT00156897_2_T0	GENE	3	3	lipase
NCT001568972	NCT00156897_2_T1	PHENOTYPE	19	20	weight reduction
NCT001568974	NCT00156897_4_T0	COMPOUND	24	24	orlistat
NCT001569362	NCT00156936_2_T0	COMPOUND	5	5	naltrexone
NCT0015693610	NCT00156936_10_T0	COMPOUND	10	10	naloxone
NCT0015693610	NCT00156936_10_T1	PHENOTYPE	7	8	opioid use
NCT0015693611	NCT00156936_11_T0	PHENOTYPE	13	13	symptoms
NCT0015693611	NCT00156936_11_T1	COMPOUND	1	1	naloxone
NCT0015693611	NCT00156936_11_T2	PHENOTYPE	15	16	opioid withdrawal
NCT001569751	NCT00156975_1_T0	PHENOTYPE	17	17	metastases
NCT001569751	NCT00156975_1_T1	PHENOTYPE	12	12	relapse
NCT001569751	NCT00156975_1_T2	PHENOTYPE	15	15	tumour
NCT001569751	NCT00156975_1_T3	PHENOTYPE	21	21	tumour
NCT001569885	NCT00156988_5_T0	PHENOTYPE	38	38	burns
NCT001570012	NCT00157001_2_T0	PHENOTYPE	25	25	symptoms
NCT001570012	NCT00157001_2_T1	PHENOTYPE	0	0	Restenosis
NCT001570012	NCT00157001_2_T2	GENE	18	18	reduced
NCT001570012	NCT00157001_2_T3	ORGAN	14	14	artery
NCT001570012	NCT00157001_2_T4	PHENOTYPE	7	7	narrowing
NCT001570013	NCT00157001_3_T0	COMPOUND	33	33	8_methoxypsoralen
NCT001570013	NCT00157001_3_T1	PHENOTYPE	19	19	separation
NCT001570013	NCT00157001_3_T2	CELL	11	13	white blood cells
NCT001570014	NCT00157001_4_T0	PHENOTYPE	1	1	secondary
NCT001570015	NCT00157001_5_T0	PHENOTYPE	7	8	cardiac events
NCT001570016	NCT00157001_6_T0	PHENOTYPE	22	22	symptoms
NCT001570016	NCT00157001_6_T1	GENE	10	10	bypass
NCT001570016	NCT00157001_6_T2	ORGAN	11	11	graft
NCT001570016	NCT00157001_6_T3	PHENOTYPE	6	7	myocardial infarction
NCT001570016	NCT00157001_6_T4	ORGAN	8	9	coronary artery
NCT001570018	NCT00157001_8_T0	PHENOTYPE	12	12	acute
NCT001570018	NCT00157001_8_T1	PHENOTYPE	16	16	bleeding
NCT001570018	NCT00157001_8_T2	PHENOTYPE	15	15	thrombosis
NCT001570018	NCT00157001_8_T3	PHENOTYPE	14	14	subacute
NCT001570018	NCT00157001_8_T4	PHENOTYPE	19	19	complications
NCT0015700111	NCT00157001_11_T0	PHENOTYPE	16	18	coronary artery disease
NCT0015700112	NCT00157001_12_T0	PHENOTYPE	0	0	Restenosis
NCT0015700113	NCT00157001_13_T0	PHENOTYPE	6	6	restenosis
NCT0015700113	NCT00157001_13_T1	PHENOTYPE	37	37	restenosis
NCT0015700115	NCT00157001_15_T0	COMPOUND	5	5	XTS
NCT0015700116	NCT00157001_16_T0	COMPOUND	2	2	XTS
NCT0015700116	NCT00157001_16_T1	ORGAN	20	20	plasma
NCT0015700116	NCT00157001_16_T2	CELL	16	18	red blood cells
NCT0015700116	NCT00157001_16_T3	CELL	13	15	white blood cells
NCT0015700117	NCT00157001_17_T0	CELL	1	3	red blood cells
NCT0015700120	NCT00157001_20_T0	ORGAN	10	10	plasma
NCT0015700120	NCT00157001_20_T1	BIOLOGICAL_PROCESS	25	26	immune response
NCT0015700120	NCT00157001_20_T2	CELL	6	8	white blood cells
NCT0015700120	NCT00157001_20_T3	CELL	34	36	white blood cells
NCT0015700121	NCT00157001_21_T0	BIOLOGICAL_PROCESS	4	5	immune response
NCT0015700122	NCT00157001_22_T0	CELL	29	29	clones
NCT0015700122	NCT00157001_22_T1	CELL	20	20	cells
NCT0015700122	NCT00157001_22_T2	CELL	34	34	cells
NCT0015700122	NCT00157001_22_T3	ORGAN	24	25	immune system
NCT0015700122	NCT00157001_22_T4	CELL	7	9	white blood cells
NCT0015700125	NCT00157001_25_T0	PHENOTYPE	1	1	diseases
NCT0015700125	NCT00157001_25_T1	PHENOTYPE	12	13	immune dysfunction
NCT0015700127	NCT00157001_27_T0	PHENOTYPE	3	3	diseases
NCT0015700127	NCT00157001_27_T1	CELL	39	39	macrophages
NCT0015700127	NCT00157001_27_T2	PHENOTYPE	17	17	Atherosclerosis
NCT0015700127	NCT00157001_27_T3	GENE	18	18	has
NCT0015700127	NCT00157001_27_T4	CELL	41	42	T lymphocytes
NCT0015700128	NCT00157001_28_T0	CELL	2	2	lymphocytes
NCT0015700128	NCT00157001_28_T1	CELL	13	13	lymphocytes
NCT0015700128	NCT00157001_28_T2	PHENOTYPE	8	8	plaques
NCT0015700128	NCT00157001_28_T3	GENE	31	31	MHC
NCT0015700128	NCT00157001_28_T4	PHENOTYPE	29	30	class II
NCT0015700132	NCT00157001_32_T0	PHENOTYPE	28	28	severity
NCT0015700132	NCT00157001_32_T1	PHENOTYPE	9	9	acute
NCT0015700132	NCT00157001_32_T2	ORGAN	13	13	transplant
NCT0015700132	NCT00157001_32_T3	GENE	1	1	has
NCT0015700132	NCT00157001_32_T4	ORGAN	12	12	heart
NCT0015700135	NCT00157001_35_T0	ORGAN	17	17	transplant
NCT0015700135	NCT00157001_35_T1	ORGAN	23	24	coronary artery
NCT0015700136	NCT00157001_36_T0	COMPOUND	19	19	methoxypsoralen
NCT0015700137	NCT00157001_37_T0	PHENOTYPE	15	15	restenosis
NCT0015700142	NCT00157001_42_T0	COMPOUND	25	25	phenothiazine
NCT0015700142	NCT00157001_42_T1	PHENOTYPE	21	21	photosensitizing
NCT0015700142	NCT00157001_42_T2	COMPOUND	26	26	tetracycline
NCT0015701411	NCT00157014_11_T0	PHENOTYPE	3	4	hepatitis B
NCT0015701411	NCT00157014_11_T1	PHENOTYPE	8	9	hepatitis C
NCT001570272	NCT00157027_2_T0	GENE	17	17	separated
NCT001570272	NCT00157027_2_T1	GENE	4	4	ECP
NCT001570272	NCT00157027_2_T2	CELL	24	24	cells
NCT001570272	NCT00157027_2_T3	ORGAN	22	22	plasma
NCT001570272	NCT00157027_2_T4	GENE	26	26	buffy
NCT001570272	NCT00157027_2_T5	CELL	29	31	red blood cells
NCT001570273	NCT00157027_3_T0	CELL	5	5	cells
NCT001570273	NCT00157027_3_T1	ORGAN	8	8	plasma
NCT001570274	NCT00157027_4_T0	ORGAN	2	2	plasma
NCT001570274	NCT00157027_4_T1	CELL	4	6	red blood cells
NCT001570275	NCT00157027_5_T0	PHENOTYPE	13	13	photosensitizing
NCT001570275	NCT00157027_5_T1	ORGAN	8	8	plasma
NCT001570275	NCT00157027_5_T2	GENE	2	2	buffy
NCT001570275	NCT00157027_5_T3	CELL	4	6	white blood cells
NCT0015702710	NCT00157027_10_T0	GENE	33	33	blot
NCT0015702710	NCT00157027_10_T1	GENE	4	4	ECP
NCT0015702710	NCT00157027_10_T2	COMPOUND	6	6	psoralen
NCT0015702710	NCT00157027_10_T3	GENE	12	12	al
NCT0015702710	NCT00157027_10_T4	GENE	11	11	et
NCT0015702710	NCT00157027_10_T5	PHENOTYPE	18	19	HIV positive
NCT0015702711	NCT00157027_11_T0	GENE	7	7	WR3
NCT0015702713	NCT00157027_13_T0	GENE	4	4	CD4
NCT0015702716	NCT00157027_16_T0	PHENOTYPE	9	9	progression
NCT0015702716	NCT00157027_16_T1	GENE	5	5	has
NCT0015702716	NCT00157027_16_T2	PHENOTYPE	11	12	HIV disease
NCT0015702719	NCT00157027_19_T0	GENE	21	21	1-19
NCT0015702719	NCT00157027_19_T1	GENE	3	3	ECP
NCT0015702719	NCT00157027_19_T2	GENE	15	15	had
NCT0015702721	NCT00157027_21_T0	PHENOTYPE	8	9	opportunistic infection
NCT0015702722	NCT00157027_22_T0	GENE	17	17	ECP
NCT0015702723	NCT00157027_23_T0	COMPOUND	2	2	THE
NCT0015702723	NCT00157027_23_T1	GENE	12	12	ECP
NCT0015702724	NCT00157027_24_T0	GENE	17	17	separated
NCT0015702724	NCT00157027_24_T1	GENE	4	4	ECP
NCT0015702724	NCT00157027_24_T2	CELL	24	24	cells
NCT0015702724	NCT00157027_24_T3	ORGAN	22	22	plasma
NCT0015702724	NCT00157027_24_T4	GENE	26	26	buffy
NCT0015702724	NCT00157027_24_T5	CELL	29	31	red blood cells
NCT0015702725	NCT00157027_25_T0	CELL	5	5	cells
NCT0015702725	NCT00157027_25_T1	ORGAN	8	8	plasma
NCT0015702726	NCT00157027_26_T0	ORGAN	2	2	plasma
NCT0015702726	NCT00157027_26_T1	CELL	4	6	red blood cells
NCT0015702727	NCT00157027_27_T0	PHENOTYPE	13	13	photosensitizing
NCT0015702727	NCT00157027_27_T1	ORGAN	8	8	plasma
NCT0015702727	NCT00157027_27_T2	GENE	2	2	buffy
NCT0015702727	NCT00157027_27_T3	CELL	4	6	white blood cells
NCT0015702730	NCT00157027_30_T0	COMPOUND	5	5	XTS
NCT0015702732	NCT00157027_32_T0	GENE	8	8	buffy
NCT0015702732	NCT00157027_32_T1	GENE	16	16	buffy
NCT0015702737	NCT00157027_37_T0	COMPOUND	28	28	phenothiazine
NCT0015702737	NCT00157027_37_T1	PHENOTYPE	24	24	photosensitizing
NCT001570400	NCT00157040_0_T0	PHENOTYPE	2	2	Pharmacokinetics
NCT001570400	NCT00157040_0_T1	GENE	11	12	Factor VIII
NCT001570400	NCT00157040_0_T2	PHENOTYPE	18	19	Hemophilia A
NCT001571180	NCT00157118_0_T0	PHENOTYPE	13	15	Protein C Deficiency
NCT001571182	NCT00157118_2_T0	PHENOTYPE	23	23	acute
NCT001571442	NCT00157144_2_T0	GENE	7	7	has
NCT001571444	NCT00157144_4_T0	PHENOTYPE	10	10	centres
NCT001571572	NCT00157157_2_T0	PHENOTYPE	3	3	bleeding
NCT001571700	NCT00157170_0_T0	PHENOTYPE	14	14	HIV/AIDS
NCT001571700	NCT00157170_0_T1	PHENOTYPE	16	16	HIV/AIDS
NCT001571700	NCT00157170_0_T2	GENE	15	15	th
NCT001571700	NCT00157170_0_T3	PHENOTYPE	8	9	Self Efficacy
NCT001571704	NCT00157170_4_T0	PHENOTYPE	15	15	HIV
NCT001571704	NCT00157170_4_T1	PHENOTYPE	17	17	strategies
NCT001571704	NCT00157170_4_T2	GENE	8	8	has
NCT001571704	NCT00157170_4_T3	PHENOTYPE	3	3	QOL
NCT001571704	NCT00157170_4_T4	PHENOTYPE	0	2	Quality of life
NCT001571705	NCT00157170_5_T0	PHENOTYPE	21	21	HIV
NCT001571705	NCT00157170_5_T1	PHENOTYPE	17	17	QOL
NCT001571705	NCT00157170_5_T2	PHENOTYPE	10	11	self efficacy
NCT001571706	NCT00157170_6_T0	PHENOTYPE	15	15	HIV
NCT001571706	NCT00157170_6_T1	PHENOTYPE	11	11	self-efficacy
NCT001571706	NCT00157170_6_T2	GENE	9	9	SEP
NCT001571706	NCT00157170_6_T3	GENE	27	27	SEP
NCT001571707	NCT00157170_7_T0	PHENOTYPE	8	8	secondary
NCT001571707	NCT00157170_7_T1	PHENOTYPE	0	0	QOL
NCT0015717011	NCT00157170_11_T0	PHENOTYPE	15	15	HIV
NCT0015717011	NCT00157170_11_T1	GENE	6	6	SEP
NCT0015717011	NCT00157170_11_T2	PHENOTYPE	25	25	QOL
NCT0015717011	NCT00157170_11_T3	PHENOTYPE	20	21	self efficacy
NCT001571830	NCT00157183_0_T0	PHENOTYPE	1	1	Ventilation
NCT001571830	NCT00157183_0_T1	PHENOTYPE	6	7	Cystic Fibrosis
NCT001571834	NCT00157183_4_T0	PHENOTYPE	0	1	Respiratory failure
NCT001571835	NCT00157183_5_T0	PHENOTYPE	3	3	hypoxia
NCT001571835	NCT00157183_5_T1	PHENOTYPE	7	7	hypercapnia
NCT001571835	NCT00157183_5_T2	PHENOTYPE	1	2	respiratory failure
NCT001571837	NCT00157183_7_T0	GENE	1	1	has
NCT001571837	NCT00157183_7_T1	PHENOTYPE	8	9	respiratory failure
NCT001571837	NCT00157183_7_T2	PHENOTYPE	14	16	quality of life
NCT001571838	NCT00157183_8_T0	PHENOTYPE	11	12	respiratory failure
NCT001571962	NCT00157196_2_T0	PHENOTYPE	3	5	Stage IIIA NSCLC
NCT001571963	NCT00157196_3_T0	PHENOTYPE	1	1	secondary
NCT001572092	NCT00157209_2_T0	PHENOTYPE	32	32	Oncology
NCT001572093	NCT00157209_3_T0	GENE	27	27	IV
NCT001572093	NCT00157209_3_T1	GENE	35	35	BSC
NCT001572093	NCT00157209_3_T2	GENE	41	41	BSC
NCT001572093	NCT00157209_3_T3	PHENOTYPE	22	24	malignant pleural effusion
NCT001572221	NCT00157222_1_T0	ORGAN	18	18	limbs
NCT001572221	NCT00157222_1_T1	ORGAN	9	9	joints
NCT001572221	NCT00157222_1_T2	BIOLOGICAL_PROCESS	23	23	innervation
NCT001572221	NCT00157222_1_T3	PHENOTYPE	4	5	progressive disease
NCT001572221	NCT00157222_1_T4	PHENOTYPE	5	7	disease of bone
NCT001572222	NCT00157222_2_T0	PHENOTYPE	3	3	acute
NCT001572222	NCT00157222_2_T1	GENE	9	9	0.2
NCT001572223	NCT00157222_3_T0	PHENOTYPE	6	6	neuropathy
NCT001572227	NCT00157222_7_T0	PHENOTYPE	20	20	trauma
NCT001572227	NCT00157222_7_T1	PHENOTYPE	7	7	acute
NCT001572227	NCT00157222_7_T2	PHENOTYPE	4	4	unilateral
NCT001572228	NCT00157222_8_T0	PHENOTYPE	7	7	oedematous
NCT0015722210	NCT00157222_10_T0	PHENOTYPE	13	13	osteomyelitis
NCT0015722210	NCT00157222_10_T1	GENE	3	3	has
NCT0015722210	NCT00157222_10_T2	PHENOTYPE	5	6	foot ulcer
NCT0015722214	NCT00157222_14_T0	PHENOTYPE	7	7	deformity
NCT0015722214	NCT00157222_14_T1	PHENOTYPE	1	1	chronic
NCT0015722216	NCT00157222_16_T0	PHENOTYPE	3	3	deformity
NCT0015722219	NCT00157222_19_T0	PHENOTYPE	22	22	polyneuropathy
NCT0015722222	NCT00157222_22_T0	PHENOTYPE	22	22	distal
NCT0015722222	NCT00157222_22_T1	PHENOTYPE	33	33	neuropathy
NCT0015722223	NCT00157222_23_T0	PHENOTYPE	33	33	osteomyelitis
NCT0015722223	NCT00157222_23_T1	PHENOTYPE	9	9	ulceration
NCT0015722223	NCT00157222_23_T2	CELL	23	23	leukocyte
NCT0015722223	NCT00157222_23_T3	GENE	3	3	has
NCT0015722235	NCT00157222_35_T0	PHENOTYPE	18	18	complication
NCT001572354	NCT00157235_4_T0	COMPOUND	6	6	tiotropium
NCT001572356	NCT00157235_6_T0	ORGAN	5	6	lower limb
NCT001572358	NCT00157235_8_T0	COMPOUND	20	20	3
NCT0015723510	NCT00157235_10_T0	GENE	3	3	null
NCT0015723510	NCT00157235_10_T1	COMPOUND	20	20	tiotropium
NCT0015723511	NCT00157235_11_T0	COMPOUND	5	5	tiotropium
NCT0015723514	NCT00157235_14_T0	COMPOUND	6	6	tiotropium
NCT0015723515	NCT00157235_15_T0	GENE	18	18	de
NCT0015723515	NCT00157235_15_T1	GENE	2	2	has
NCT0015723515	NCT00157235_15_T2	COMPOUND	16	16	Spiriva
NCT0015723515	NCT00157235_15_T3	COMPOUND	15	15	tiotropium
NCT001572483	NCT00157248_3_T0	GENE	20	20	has
NCT001572483	NCT00157248_3_T1	PHENOTYPE	2	2	anemia
NCT001572483	NCT00157248_3_T2	PHENOTYPE	7	7	anemia
NCT001572483	NCT00157248_3_T3	PHENOTYPE	27	27	anemia
NCT001572483	NCT00157248_3_T4	PHENOTYPE	17	18	GI bleeding
NCT001572614	NCT00157261_4_T0	GENE	8	8	IV
NCT001572615	NCT00157261_5_T0	PHENOTYPE	9	9	5-10
NCT001572615	NCT00157261_5_T1	GENE	6	6	IV
NCT001572616	NCT00157261_6_T0	GENE	0	0	PCI
NCT001572618	NCT00157261_8_T0	PHENOTYPE	13	13	5-10
NCT001572618	NCT00157261_8_T1	GENE	28	28	CPR
NCT001572618	NCT00157261_8_T2	GENE	10	10	IV
NCT001572619	NCT00157261_9_T0	PHENOTYPE	10	10	5-10
NCT001572619	NCT00157261_9_T1	GENE	25	25	CPR
NCT001572619	NCT00157261_9_T2	GENE	7	7	IV
NCT001572619	NCT00157261_9_T3	PHENOTYPE	0	1	Group B
NCT001572741	NCT00157274_1_T0	PHENOTYPE	5	5	toxicity
NCT001572871	NCT00157287_1_T0	GENE	3	3	has
NCT001572872	NCT00157287_2_T0	PHENOTYPE	19	19	ventilation
NCT001573001	NCT00157300_1_T0	GENE	4	4	erythropoietin
NCT001573001	NCT00157300_1_T1	PHENOTYPE	9	11	delayed graft function
NCT001573005	NCT00157300_5_T0	GENE	8	8	Beta
NCT001573006	NCT00157300_6_T0	PHENOTYPE	5	7	delayed graft function
NCT001573132	NCT00157313_2_T0	PHENOTYPE	8	8	schizophrenia
NCT001573132	NCT00157313_2_T1	GENE	12	12	has
NCT001573135	NCT00157313_5_T0	PHENOTYPE	9	9	centre
NCT001573135	NCT00157313_5_T1	PHENOTYPE	7	8	mental health
NCT001573136	NCT00157313_6_T0	PHENOTYPE	18	18	symptoms
NCT001573136	NCT00157313_6_T1	PHENOTYPE	8	8	hallucinations
NCT001573136	NCT00157313_6_T2	PHENOTYPE	16	17	blunted affect
NCT001573139	NCT00157313_9_T0	BIOLOGICAL_PROCESS	16	16	behaviour
NCT001573139	NCT00157313_9_T1	PHENOTYPE	10	12	quality of life
NCT0015731312	NCT00157313_12_T0	PHENOTYPE	16	16	schizophrenia
NCT0015731315	NCT00157313_15_T0	PHENOTYPE	9	9	centre
NCT0015731315	NCT00157313_15_T1	PHENOTYPE	7	8	mental health
NCT0015731316	NCT00157313_16_T0	PHENOTYPE	6	6	symptoms
NCT0015731317	NCT00157313_17_T0	GENE	25	25	0.31
NCT0015731317	NCT00157313_17_T1	PHENOTYPE	5	6	psychotic symptoms
NCT0015731318	NCT00157313_18_T0	PHENOTYPE	1	1	symptoms
NCT0015731319	NCT00157313_19_T0	PHENOTYPE	22	22	symptoms
NCT0015731319	NCT00157313_19_T1	GENE	24	24	0.45
NCT0015731319	NCT00157313_19_T2	GENE	27	27	0.22
NCT0015731319	NCT00157313_19_T3	GENE	14	14	0.32
NCT0015731319	NCT00157313_19_T4	PHENOTYPE	11	12	psychotic symptoms
NCT0015731320	NCT00157313_20_T0	GENE	5	5	had
NCT001573260	NCT00157326_0_T0	PHENOTYPE	4	4	Mild
NCT001573260	NCT00157326_0_T1	PHENOTYPE	7	7	Hypertension
NCT001573782	NCT00157378_2_T0	GENE	11	11	atypical
NCT001573782	NCT00157378_2_T1	GENE	29	29	atypical
NCT001573782	NCT00157378_2_T2	GENE	51	51	max
NCT001573786	NCT00157378_6_T0	PHENOTYPE	5	5	schizophrenia
NCT001573787	NCT00157378_7_T0	PHENOTYPE	9	9	acute
NCT001573789	NCT00157378_9_T0	PHENOTYPE	30	30	symptoms
NCT001573789	NCT00157378_9_T1	COMPOUND	22	22	haloperidol
NCT001573789	NCT00157378_9_T2	COMPOUND	13	13	risperidone
NCT0015737810	NCT00157378_10_T0	GENE	9	9	has
NCT0015737810	NCT00157378_10_T1	PHENOTYPE	16	17	depressive symptoms
NCT0015737810	NCT00157378_10_T2	PHENOTYPE	32	34	quality of life
NCT001574821	NCT00157482_1_T0	PHENOTYPE	1	1	chronic
NCT001574821	NCT00157482_1_T1	PHENOTYPE	4	5	myocardial infarction
NCT001574821	NCT00157482_1_T2	PHENOTYPE	2	3	cardiovascular complications
NCT001574822	NCT00157482_2_T0	GENE	6	6	lipoprotein
NCT001574822	NCT00157482_2_T1	GENE	22	22	reduced
NCT001574822	NCT00157482_2_T2	GENE	7	7	LDL
NCT001574822	NCT00157482_2_T3	PHENOTYPE	15	16	coronary disease
NCT001574823	NCT00157482_3_T0	PHENOTYPE	14	14	proteinuria
NCT001574823	NCT00157482_3_T1	PHENOTYPE	6	6	dyslipidemia
NCT001574824	NCT00157482_4_T0	GENE	11	11	has
NCT001574826	NCT00157482_6_T0	PHENOTYPE	23	23	albuminuria
NCT001574826	NCT00157482_6_T1	COMPOUND	15	15	simvastatin
NCT001574826	NCT00157482_6_T2	COMPOUND	9	9	ezetimibe_simvastatin
NCT001574826	NCT00157482_6_T3	GENE	25	26	type 2
NCT0015748210	NCT00157482_10_T0	PHENOTYPE	15	15	proteinuria
NCT0015748210	NCT00157482_10_T1	PHENOTYPE	7	7	dyslipidemia
NCT0015748211	NCT00157482_11_T0	ORGAN	37	38	small intestine
NCT0015748212	NCT00157482_12_T0	COMPOUND	11	11	ezetimibe
NCT0015748212	NCT00157482_12_T1	GENE	24	25	HMGCoA reductase
NCT0015748213	NCT00157482_13_T0	COMPOUND	14	14	ezetimibe
NCT0015748213	NCT00157482_13_T1	COMPOUND	19	19	simvastatin
NCT0015748213	NCT00157482_13_T2	PHENOTYPE	6	6	hypercholesterolemia
NCT0015748215	NCT00157482_15_T0	PHENOTYPE	8	8	toxicity
NCT0015748215	NCT00157482_15_T1	GENE	1	1	had
NCT0015748216	NCT00157482_16_T0	PHENOTYPE	6	6	hyperlipidemia
NCT0015748216	NCT00157482_16_T1	COMPOUND	13	13	ezetimibe
NCT0015748218	NCT00157482_18_T0	COMPOUND	6	6	ezetimibe_simvastatin
NCT001575080	NCT00157508_0_T0	PHENOTYPE	14	14	Nephropathy
NCT001575080	NCT00157508_0_T1	PHENOTYPE	9	11	Type 2 Diabetes
NCT001575082	NCT00157508_2_T0	PHENOTYPE	11	11	toxicity
NCT001575082	NCT00157508_2_T1	COMPOUND	4	4	aspirin
NCT001575083	NCT00157508_3_T0	COMPOUND	11	11	aspirin
NCT001575083	NCT00157508_3_T1	COMPOUND	6	7	nitric oxide
NCT001575084	NCT00157508_4_T0	GENE	1	1	has
NCT001575086	NCT00157508_6_T0	GENE	12	12	eNOS
NCT001575086	NCT00157508_6_T1	PHENOTYPE	9	10	insulin sensitivity
NCT001575088	NCT00157508_8_T0	COMPOUND	23	23	aspirin
NCT001575088	NCT00157508_8_T1	COMPOUND	27	27	aspirin
NCT0015750810	NCT00157508_10_T0	TISSUE	42	42	mucosa
NCT0015750813	NCT00157508_13_T0	COMPOUND	12	12	aspirin
NCT0015750817	NCT00157508_17_T0	COMPOUND	20	20	aspirin
NCT0015750817	NCT00157508_17_T1	ORGAN	29	29	microvasculature
NCT0015750819	NCT00157508_19_T0	COMPOUND	14	14	aspirin
NCT0015750819	NCT00157508_19_T1	COMPOUND	31	31	aspirin
NCT0015750819	NCT00157508_19_T2	COMPOUND	37	37	aspirin
NCT0015750821	NCT00157508_21_T0	COMPOUND	9	9	glucose
NCT0015750821	NCT00157508_21_T1	ORGAN	32	32	plasma
NCT0015750821	NCT00157508_21_T2	PHENOTYPE	7	8	insulin sensitivity
NCT0015750821	NCT00157508_21_T3	PHENOTYPE	27	28	oxidative stress
NCT001575210	NCT00157521_0_T0	PHENOTYPE	2	2	Pre-Eclampsia
NCT001575212	NCT00157521_2_T0	PHENOTYPE	12	12	symptoms
NCT001575212	NCT00157521_2_T1	PHENOTYPE	0	0	Hypertension
NCT001575212	NCT00157521_2_T2	PHENOTYPE	3	3	edema
NCT001575212	NCT00157521_2_T3	PHENOTYPE	1	1	proteinuria
NCT001575214	NCT00157521_4_T0	PHENOTYPE	0	0	Pre-eclampsia
NCT001575215	NCT00157521_5_T0	PHENOTYPE	1	1	pathophysiology
NCT001575218	NCT00157521_8_T0	GENE	1	1	reduced
NCT001575218	NCT00157521_8_T1	PHENOTYPE	6	7	oxidative stress
NCT001575219	NCT00157521_9_T0	PHENOTYPE	21	21	preeclampsia
NCT0015752112	NCT00157521_12_T0	PHENOTYPE	24	24	cord
NCT0015752112	NCT00157521_12_T1	TISSUE	20	20	endothelium
NCT0015752112	NCT00157521_12_T2	PHENOTYPE	17	17	localized
NCT0015752112	NCT00157521_12_T3	GENE	7	7	ecNOS
NCT0015752112	NCT00157521_12_T4	GENE	8	8	has
NCT0015752112	NCT00157521_12_T5	GENE	4	6	nitric oxide synthase
NCT0015752113	NCT00157521_13_T0	GENE	2	2	ecNOS
NCT0015752113	NCT00157521_13_T1	PHENOTYPE	9	10	vascular resistance
NCT0015752115	NCT00157521_15_T0	PHENOTYPE	26	26	eclampsia
NCT0015752115	NCT00157521_15_T1	BIOLOGICAL_PROCESS	24	24	placentation
NCT0015752115	NCT00157521_15_T2	GENE	11	11	has
NCT0015752115	NCT00157521_15_T3	COMPOUND	5	6	nitric oxide
NCT0015752117	NCT00157521_17_T0	PHENOTYPE	9	9	eclampsia
NCT0015752123	NCT00157521_23_T0	COMPOUND	10	10	nifedipine
NCT0015752123	NCT00157521_23_T1	PHENOTYPE	20	20	maturation
NCT0015752123	NCT00157521_23_T2	COMPOUND	12	12	magnesium
NCT0015752123	NCT00157521_23_T3	PHENOTYPE	16	16	eclampsia
NCT0015752123	NCT00157521_23_T4	PHENOTYPE	22	22	eclampsia
NCT0015752123	NCT00157521_23_T5	COMPOUND	17	17	betamethasone
NCT0015752126	NCT00157521_26_T0	PHENOTYPE	10	10	eclampsia
NCT001575340	NCT00157534_0_T0	PHENOTYPE	18	18	Infection
NCT001575340	NCT00157534_0_T1	PHENOTYPE	13	15	Chronic Hepatitis C
NCT001575471	NCT00157547_1_T0	ORGAN	16	16	scalp
NCT001575475	NCT00157547_5_T0	GENE	20	20	al
NCT001575475	NCT00157547_5_T1	PHENOTYPE	17	17	MDD
NCT001575475	NCT00157547_5_T2	GENE	19	19	et
NCT001575477	NCT00157547_7_T0	PHENOTYPE	7	7	MDD
NCT001575477	NCT00157547_7_T1	GENE	21	21	theta
NCT001575478	NCT00157547_8_T0	PHENOTYPE	12	12	MDD
NCT0015754710	NCT00157547_10_T0	PHENOTYPE	24	24	MDD
NCT0015754711	NCT00157547_11_T0	GENE	30	30	atypical
NCT0015754711	NCT00157547_11_T1	PHENOTYPE	25	27	age of onset
NCT0015754713	NCT00157547_13_T0	PHENOTYPE	21	21	disorders
NCT0015754713	NCT00157547_13_T1	PHENOTYPE	13	13	pathophysiology
NCT0015754713	NCT00157547_13_T2	PHENOTYPE	15	16	major depression
NCT0015754715	NCT00157547_15_T0	PHENOTYPE	4	4	MDD
NCT0015754719	NCT00157547_19_T0	PHENOTYPE	3	3	ideation
NCT0015754722	NCT00157547_22_T0	PHENOTYPE	27	27	IUD
NCT0015754722	NCT00157547_22_T1	ORGAN	25	25	diaphragm
NCT0015754723	NCT00157547_23_T0	PHENOTYPE	16	17	hematological disease
NCT0015754725	NCT00157547_25_T0	PHENOTYPE	13	13	schizophrenia
NCT0015754725	NCT00157547_25_T1	PHENOTYPE	38	38	disorders
NCT0015754725	NCT00157547_25_T2	PHENOTYPE	36	37	substance dependence
NCT0015754725	NCT00157547_25_T3	PHENOTYPE	23	24	bipolar disorder
NCT0015754725	NCT00157547_25_T4	PHENOTYPE	8	9	psychiatric illness
NCT0015754725	NCT00157547_25_T5	PHENOTYPE	16	17	delusional disorder
NCT0015754725	NCT00157547_25_T6	PHENOTYPE	18	19	psychotic disorders
NCT0015754725	NCT00157547_25_T7	PHENOTYPE	14	15	schizoaffective disorder
NCT0015754725	NCT00157547_25_T8	PHENOTYPE	10	12	organic mental disorder
NCT0015754727	NCT00157547_27_T0	PHENOTYPE	3	5	adverse drug reactions
NCT0015754731	NCT00157547_31_T0	PHENOTYPE	12	14	major depressive episode
NCT001575601	NCT00157560_1_T0	COMPOUND	17	17	taxol
NCT001575602	NCT00157560_2_T0	PHENOTYPE	8	8	toxicity
NCT001575602	NCT00157560_2_T1	PHENOTYPE	27	27	carcinoma
NCT001575606	NCT00157560_6_T0	COMPOUND	14	14	taxol
NCT001575606	NCT00157560_6_T1	COMPOUND	8	8	gemcitabine
NCT001575606	NCT00157560_6_T2	COMPOUND	24	24	topotecan
NCT001575608	NCT00157560_8_T0	PHENOTYPE	6	6	carcinoma
NCT001575733	NCT00157573_3_T0	PHENOTYPE	16	16	toxicity
NCT001575733	NCT00157573_3_T1	PHENOTYPE	13	14	disease progression
NCT001575861	NCT00157586_1_T0	PHENOTYPE	0	1	Diabetes mellitus
NCT001575861	NCT00157586_1_T1	PHENOTYPE	8	10	end-stage renal disease
NCT001575862	NCT00157586_2_T0	PHENOTYPE	14	15	cardiovascular complications
NCT001575868	NCT00157586_8_T0	COMPOUND	14	14	manidipine
NCT001575868	NCT00157586_8_T1	PHENOTYPE	1	1	secondary
NCT001575868	NCT00157586_8_T2	COMPOUND	12	12	delapril
NCT001575868	NCT00157586_8_T3	PHENOTYPE	28	29	heart failure
NCT001575868	NCT00157586_8_T4	PHENOTYPE	22	24	acute myocardial infarction
NCT0015758613	NCT00157586_13_T0	PHENOTYPE	2	2	Secondary
NCT0015758614	NCT00157586_14_T0	GENE	11	11	GFR
NCT0015758615	NCT00157586_15_T0	PHENOTYPE	1	1	secondary
NCT0015758615	NCT00157586_15_T1	PHENOTYPE	18	19	heart failure
NCT0015758615	NCT00157586_15_T2	PHENOTYPE	12	14	acute myocardial infarction
NCT001576121	NCT00157612_1_T0	PHENOTYPE	13	13	acute
NCT001576121	NCT00157612_1_T1	PHENOTYPE	6	6	complications
NCT001576123	NCT00157612_3_T0	PHENOTYPE	8	8	pneumonia
NCT001576125	NCT00157612_5_T0	PHENOTYPE	32	32	pulse
NCT001576251	NCT00157625_1_T0	PHENOTYPE	4	4	infections
NCT001576253	NCT00157625_3_T0	PHENOTYPE	28	28	infections
NCT001576255	NCT00157625_5_T0	PHENOTYPE	5	7	urinary tract infection
NCT001576256	NCT00157625_6_T0	PHENOTYPE	25	25	secondary
NCT001576256	NCT00157625_6_T1	PHENOTYPE	0	0	Secondary
NCT001576256	NCT00157625_6_T2	PHENOTYPE	22	22	bacteremia
NCT001576256	NCT00157625_6_T3	PHENOTYPE	10	12	urinary tract infection
NCT001576256	NCT00157625_6_T4	PHENOTYPE	27	29	urinary tract infection
NCT001576257	NCT00157625_7_T0	PHENOTYPE	13	15	urinary tract infection
NCT001576382	NCT00157638_2_T0	GENE	7	7	has
NCT001576383	NCT00157638_3_T0	GENE	7	7	has
NCT0015763812	NCT00157638_12_T0	PHENOTYPE	22	22	practices
NCT001576645	NCT00157664_5_T0	PHENOTYPE	0	0	Bleeding
NCT001576647	NCT00157664_7_T0	COMPOUND	10	10	calcium
NCT001576647	NCT00157664_7_T1	ORGAN	21	21	arteries
NCT001576647	NCT00157664_7_T2	ORGAN	25	25	arteries
NCT001576647	NCT00157664_7_T3	GENE	17	17	has
NCT001576901	NCT00157690_1_T0	GENE	15	15	cystic
NCT001576905	NCT00157690_5_T0	PHENOTYPE	14	14	osteopenia
NCT001576905	NCT00157690_5_T1	PHENOTYPE	16	16	osteoporosis
NCT001576906	NCT00157690_6_T0	PHENOTYPE	2	2	centres
NCT001576907	NCT00157690_7_T0	COMPOUND	9	9	alendronate
NCT0015769010	NCT00157690_10_T0	COMPOUND	9	9	calcium
NCT001577031	NCT00157703_1_T0	PHENOTYPE	30	30	toxicity
NCT001577031	NCT00157703_1_T1	GENE	36	36	reduced
NCT001577033	NCT00157703_3_T0	PHENOTYPE	14	14	focal
NCT001577033	NCT00157703_3_T1	GENE	33	33	gamma
NCT001577036	NCT00157703_6_T0	PHENOTYPE	5	5	gliosarcoma
NCT001577036	NCT00157703_6_T1	PHENOTYPE	11	11	progressive
NCT001577036	NCT00157703_6_T2	PHENOTYPE	3	4	glioblastoma multiforme
NCT001577036	NCT00157703_6_T3	PHENOTYPE	7	8	anaplastic astrocytoma
NCT001577038	NCT00157703_8_T0	GENE	5	5	1.0
NCT001577038	NCT00157703_8_T1	GENE	23	23	MRI
NCT001577038	NCT00157703_8_T2	GENE	6	6	cm
NCT001577038	NCT00157703_8_T3	GENE	14	14	cm
NCT0015770314	NCT00157703_14_T0	PHENOTYPE	4	6	negative pregnancy test
NCT0015770316	NCT00157703_16_T0	PHENOTYPE	2	2	granulocytopenia
NCT0015770316	NCT00157703_16_T1	PHENOTYPE	0	1	Acute infection
NCT0015770318	NCT00157703_18_T0	PHENOTYPE	2	2	encephalitis
NCT0015770318	NCT00157703_18_T1	PHENOTYPE	3	4	multiple sclerosis
NCT0015770318	NCT00157703_18_T2	ORGAN	7	9	central nervous system
NCT0015770319	NCT00157703_19_T0	PHENOTYPE	26	26	tumor
NCT0015770319	NCT00157703_19_T1	GENE	35	35	CSF
NCT0015770319	NCT00157703_19_T2	PHENOTYPE	0	0	Tumor
NCT0015770319	NCT00157703_19_T3	ORGAN	6	6	brainstem
NCT0015770319	NCT00157703_19_T4	GENE	5	5	ventricular
NCT0015770319	NCT00157703_19_T5	ORGAN	7	8	basal ganglia
NCT0015770320	NCT00157703_20_T0	PHENOTYPE	0	0	Tumor
NCT0015770320	NCT00157703_20_T1	GENE	29	29	ventricular
NCT0015770320	NCT00157703_20_T2	ORGAN	15	17	cerebral ventricular system
NCT0015770321	NCT00157703_21_T0	PHENOTYPE	0	0	Tumor
NCT0015770325	NCT00157703_25_T0	PHENOTYPE	0	0	HIV
NCT0015770326	NCT00157703_26_T0	COMPOUND	13	13	penciclovir
NCT0015770326	NCT00157703_26_T1	PHENOTYPE	10	10	HSV
NCT0015770326	NCT00157703_26_T2	COMPOUND	11	11	acyclovir
NCT0015770326	NCT00157703_26_T3	COMPOUND	15	15	ganciclovir
NCT0015770326	NCT00157703_26_T4	COMPOUND	14	14	famciclovir
NCT0015770326	NCT00157703_26_T5	PHENOTYPE	7	8	herpes simplex
NCT0015770327	NCT00157703_27_T0	PHENOTYPE	3	4	genital herpes
NCT0015770328	NCT00157703_28_T0	PHENOTYPE	11	11	aneurysm
NCT0015770328	NCT00157703_28_T1	GENE	4	4	MRI
NCT001577164	NCT00157716_4_T0	PHENOTYPE	14	14	ischemia
NCT001577164	NCT00157716_4_T1	PHENOTYPE	19	20	reperfusion injury
NCT001577164	NCT00157716_4_T2	PHENOTYPE	6	7	cardiovascular morbidity
NCT001577165	NCT00157716_5_T0	PHENOTYPE	5	5	complications
NCT0015771610	NCT00157716_10_T0	ORGAN	11	11	heart
NCT0015771610	NCT00157716_10_T1	PHENOTYPE	16	17	ischemia-reperfusion injury
NCT001577291	NCT00157729_1_T0	PHENOTYPE	0	0	Hypertension
NCT001577291	NCT00157729_1_T1	PHENOTYPE	10	10	complications
NCT001577291	NCT00157729_1_T2	PHENOTYPE	19	19	retinopathy
NCT001577291	NCT00157729_1_T3	PHENOTYPE	23	23	neuropathy
NCT001577291	NCT00157729_1_T4	PHENOTYPE	20	20	nephropathy
NCT001577291	NCT00157729_1_T5	PHENOTYPE	13	15	coronary artery disease
NCT001577291	NCT00157729_1_T6	PHENOTYPE	16	18	peripheral vascular disease
NCT001577292	NCT00157729_2_T0	PHENOTYPE	18	18	hypertension
NCT001577292	NCT00157729_2_T1	PHENOTYPE	21	22	diabetic complications
NCT001577294	NCT00157729_4_T0	PHENOTYPE	16	16	hypertension
NCT001577295	NCT00157729_5_T0	PHENOTYPE	14	14	toxicity
NCT001577295	NCT00157729_5_T1	GENE	8	8	B6
NCT001577295	NCT00157729_5_T2	GENE	11	11	has
NCT001577296	NCT00157729_6_T0	GENE	7	7	has
NCT001577296	NCT00157729_6_T1	PHENOTYPE	11	11	hypertension
NCT001577296	NCT00157729_6_T2	PHENOTYPE	14	14	dysfunction
NCT001577297	NCT00157729_7_T0	PHENOTYPE	21	21	hypertension
NCT001577297	NCT00157729_7_T1	GENE	28	29	type 2
NCT001577297	NCT00157729_7_T2	MOLECULAR_FUNCTION	15	16	ACE inhibitor
NCT001577552	NCT00157755_2_T0	PHENOTYPE	14	14	centers
NCT001577553	NCT00157755_3_T0	PHENOTYPE	6	6	symptoms
NCT001577553	NCT00157755_3_T1	PHENOTYPE	4	4	suffering
NCT001577553	NCT00157755_3_T2	PHENOTYPE	8	8	gastroparesis
NCT001577681	NCT00157768_1_T0	PHENOTYPE	3	5	sudden cardiac death
NCT001577683	NCT00157768_3_T0	PHENOTYPE	16	17	heart failure
NCT001577683	NCT00157768_3_T1	PHENOTYPE	11	12	myocardial infarction
NCT001577687	NCT00157768_7_T0	PHENOTYPE	10	10	infarction
NCT001577813	NCT00157781_3_T0	GENE	16	16	AT
NCT001577813	NCT00157781_3_T1	GENE	26	26	AT
NCT001577813	NCT00157781_3_T2	GENE	5	5	pts
NCT001577813	NCT00157781_3_T3	GENE	24	24	pts
NCT001577815	NCT00157781_5_T0	PHENOTYPE	26	26	symptoms
NCT001577815	NCT00157781_5_T1	GENE	20	20	AT
NCT001577815	NCT00157781_5_T2	PHENOTYPE	23	23	QOL
NCT001577817	NCT00157781_7_T0	GENE	1	1	pts
NCT001577818	NCT00157781_8_T0	GENE	16	16	AT
NCT001577819	NCT00157781_9_T0	GENE	27	27	AT
NCT001577819	NCT00157781_9_T1	GENE	18	18	ATP
NCT0015778110	NCT00157781_10_T0	GENE	1	1	CO
NCT0015778111	NCT00157781_11_T0	GENE	8	8	pts
NCT0015778111	NCT00157781_11_T1	PHENOTYPE	3	3	QOL
NCT001577942	NCT00157794_2_T0	PHENOTYPE	20	21	heart failure
NCT001577942	NCT00157794_2_T1	PHENOTYPE	16	17	cardiac diseases
NCT001577943	NCT00157794_3_T0	GENE	2	2	AV
NCT001577943	NCT00157794_3_T1	GENE	8	8	ventricular
NCT001577943	NCT00157794_3_T2	GENE	23	23	ventricular
NCT001577944	NCT00157794_4_T0	GENE	37	37	AV
NCT001577944	NCT00157794_4_T1	GENE	12	12	ventricular
NCT001577944	NCT00157794_4_T2	GENE	56	56	ventricular
NCT001577944	NCT00157794_4_T3	PHENOTYPE	21	22	atrial fibrillation
NCT001578071	NCT00157807_1_T0	PHENOTYPE	10	12	quality of life
NCT001578072	NCT00157807_2_T0	ORGAN	9	9	heart
NCT001578205	NCT00157820_5_T0	GENE	22	22	24
NCT001578205	NCT00157820_5_T1	COMPOUND	15	15	1
NCT001578205	NCT00157820_5_T2	COMPOUND	18	18	2
NCT001578205	NCT00157820_5_T3	COMPOUND	32	32	3
NCT001578205	NCT00157820_5_T4	PHENOTYPE	34	34	shocks
NCT001578205	NCT00157820_5_T5	PHENOTYPE	41	41	shocks
NCT001578205	NCT00157820_5_T6	PHENOTYPE	12	13	Adverse Events
NCT001578206	NCT00157820_6_T0	PHENOTYPE	0	0	Secondary
NCT0015782011	NCT00157820_11_T0	PHENOTYPE	12	14	ventricular ejection fraction
NCT0015782013	NCT00157820_13_T0	PHENOTYPE	11	12	heart failure
NCT0015782013	NCT00157820_13_T1	PHENOTYPE	0	2	Quality of life
NCT001578330	NCT00157833_0_T0	COMPOUND	6	6	Artekin
NCT001578330	NCT00157833_0_T1	PHENOTYPE	12	12	Malaria
NCT001578333	NCT00157833_3_T0	COMPOUND	3	3	chloroquine
NCT001578333	NCT00157833_3_T1	PHENOTYPE	6	6	P.vivax
NCT001578333	NCT00157833_3_T2	GENE	7	7	has
NCT001578334	NCT00157833_4_T0	COMPOUND	9	9	artemisinin
NCT001578334	NCT00157833_4_T1	COMPOUND	16	16	artemether_lumefantrine
NCT001578334	NCT00157833_4_T2	PHENOTYPE	19	19	P.falciparum
NCT001578335	NCT00157833_5_T0	PHENOTYPE	15	15	acute
NCT001578335	NCT00157833_5_T1	PHENOTYPE	13	13	symptoms
NCT001578335	NCT00157833_5_T2	PHENOTYPE	21	21	P.vivax
NCT001578339	NCT00157833_9_T0	GENE	40	40	eg
NCT001578461	NCT00157846_1_T0	GENE	21	21	ventricular
NCT001578592	NCT00157859_2_T0	COMPOUND	8	8	chloroquine
NCT001578592	NCT00157859_2_T1	COMPOUND	17	17	chloroquine
NCT001578592	NCT00157859_2_T2	COMPOUND	10	10	sulfadoxine_pyrimethamine
NCT001578592	NCT00157859_2_T3	PHENOTYPE	3	4	falciparum malaria
NCT001578592	NCT00157859_2_T4	PHENOTYPE	14	15	vivax malaria
NCT001578594	NCT00157859_4_T0	PHENOTYPE	7	8	falciparum malaria
NCT001578594	NCT00157859_4_T1	PHENOTYPE	13	14	vivax malaria
NCT001578853	NCT00157885_3_T0	COMPOUND	3	3	chloroquine
NCT001578853	NCT00157885_3_T1	PHENOTYPE	6	6	P.vivax
NCT001578853	NCT00157885_3_T2	GENE	7	7	has
NCT001578854	NCT00157885_4_T0	COMPOUND	11	11	amodiaquine
NCT001578854	NCT00157885_4_T1	COMPOUND	13	13	artesunate
NCT001578854	NCT00157885_4_T2	PHENOTYPE	18	18	P.falciparum
NCT001578855	NCT00157885_5_T0	PHENOTYPE	15	15	acute
NCT001578855	NCT00157885_5_T1	PHENOTYPE	13	13	symptoms
NCT001578855	NCT00157885_5_T2	PHENOTYPE	21	21	P.vivax
NCT001578858	NCT00157885_8_T0	GENE	40	40	eg
NCT001579760	NCT00157976_0_T0	PHENOTYPE	11	13	Age-Related Macular Degeneration
NCT001579893	NCT00157989_3_T0	PHENOTYPE	3	3	ventilation
NCT001579893	NCT00157989_3_T1	PHENOTYPE	9	10	tidal volume
NCT001579894	NCT00157989_4_T0	PHENOTYPE	5	6	tidal volume
NCT001579895	NCT00157989_5_T0	PHENOTYPE	11	11	initiation
NCT001579895	NCT00157989_5_T1	PHENOTYPE	14	14	ventilation
NCT001579895	NCT00157989_5_T2	PHENOTYPE	20	20	ventilation
NCT001579895	NCT00157989_5_T3	ORGAN	31	31	lungs
NCT001579895	NCT00157989_5_T4	PHENOTYPE	38	39	pulmonary injury
NCT0015798913	NCT00157989_13_T0	PHENOTYPE	4	4	5-10
NCT0015798913	NCT00157989_13_T1	GENE	10	10	pH
NCT0015798915	NCT00157989_15_T0	PHENOTYPE	0	0	Secondary
NCT0015798915	NCT00157989_15_T1	PHENOTYPE	4	4	ventilation
NCT0015798916	NCT00157989_16_T0	GENE	3	3	leak
NCT0015798916	NCT00157989_16_T1	PHENOTYPE	4	5	intraventricular haemorrhage
NCT0015798918	NCT00157989_18_T0	GENE	11	11	MSH
NCT0015798920	NCT00157989_20_T0	GENE	2	2	has
NCT0015798922	NCT00157989_22_T0	PHENOTYPE	14	14	estimation
NCT0015798922	NCT00157989_22_T1	GENE	6	6	28
NCT0015798922	NCT00157989_22_T2	BIOLOGICAL_PROCESS	9	9	gestation
NCT0015798927	NCT00157989_27_T0	GENE	28	28	has
NCT0015798927	NCT00157989_27_T1	PHENOTYPE	36	37	preterm birth
NCT0015798930	NCT00157989_30_T0	PHENOTYPE	0	0	Recruitment
NCT0015798931	NCT00157989_31_T0	GENE	11	11	envelope
NCT0015798937	NCT00157989_37_T0	ORGAN	19	19	heart
NCT0015798943	NCT00157989_43_T0	GENE	18	18	MSH
NCT0015798944	NCT00157989_44_T0	GENE	13	13	27
NCT0015798944	NCT00157989_44_T1	GENE	19	19	27
NCT0015798944	NCT00157989_44_T2	GENE	33	33	cm
NCT0015798944	NCT00157989_44_T3	BIOLOGICAL_PROCESS	15	15	gestation
NCT0015798944	NCT00157989_44_T4	BIOLOGICAL_PROCESS	21	21	gestation
NCT0015798945	NCT00157989_45_T0	ORGAN	13	13	lungs
NCT0015798949	NCT00157989_49_T0	PHENOTYPE	21	21	feels
NCT0015798961	NCT00157989_61_T0	ORGAN	18	19	chest wall
NCT0015798962	NCT00157989_62_T0	GENE	14	14	cm
NCT0015798963	NCT00157989_63_T0	PHENOTYPE	8	8	leakage
NCT0015798963	NCT00157989_63_T1	PHENOTYPE	12	14	inspiration and expiration
NCT0015798964	NCT00157989_64_T0	GENE	2	2	leak
NCT0015798964	NCT00157989_64_T1	PHENOTYPE	26	26	ventilation
NCT0015798966	NCT00157989_66_T0	GENE	3	3	has
NCT0015798969	NCT00157989_69_T0	PHENOTYPE	15	15	closed
NCT0015798970	NCT00157989_70_T0	PHENOTYPE	23	23	ventilation
NCT0015798970	NCT00157989_70_T1	ORGAN	16	16	lungs
NCT0015798971	NCT00157989_71_T0	GENE	14	14	CO2
NCT0015798971	NCT00157989_71_T1	COMPOUND	6	6	oxygen
NCT0015798978	NCT00157989_78_T0	PHENOTYPE	0	0	All
NCT0015798981	NCT00157989_81_T0	COMPOUND	1	1	oxygen
NCT0015798982	NCT00157989_82_T0	COMPOUND	1	1	oxygen
NCT0015798984	NCT00157989_84_T0	COMPOUND	12	12	oxygen
NCT0015798984	NCT00157989_84_T1	PHENOTYPE	4	5	central cyanosis
NCT0015798985	NCT00157989_85_T0	PHENOTYPE	12	12	ventilation
NCT0015798990	NCT00157989_90_T0	PHENOTYPE	15	15	hypoxia
NCT0015798990	NCT00157989_90_T1	COMPOUND	4	4	oxygen
NCT0015798991	NCT00157989_91_T0	PHENOTYPE	0	0	Mild
NCT0015798991	NCT00157989_91_T1	PHENOTYPE	1	1	hypercapnia
NCT0015798991	NCT00157989_91_T2	GENE	11	11	pH
NCT0015798991	NCT00157989_91_T3	PHENOTYPE	25	26	adverse effects
NCT0015798992	NCT00157989_92_T0	GENE	3	3	leak
NCT0015798992	NCT00157989_92_T1	ORGAN	8	8	lungs
NCT0015798993	NCT00157989_93_T0	PHENOTYPE	22	23	adverse events
NCT00157989101	NCT00157989_101_T0	GENE	5	5	CPAP
NCT001580151	NCT00158015_1_T0	GENE	15	15	CRT
NCT001580153	NCT00158015_3_T0	GENE	35	35	CRT
NCT001580153	NCT00158015_3_T1	GENE	3	3	TDI
NCT001580153	NCT00158015_3_T2	ORGAN	17	18	left ventricle
NCT001580154	NCT00158015_4_T0	GENE	16	16	ventricular
NCT001580155	NCT00158015_5_T0	GENE	7	7	CRT
NCT001580155	NCT00158015_5_T1	GENE	20	20	Paul
NCT001580156	NCT00158015_6_T0	GENE	19	19	CRT
NCT001580156	NCT00158015_6_T1	GENE	0	0	TDI
NCT001580158	NCT00158015_8_T0	PHENOTYPE	1	2	Heart failure
NCT0015801510	NCT00158015_10_T0	GENE	1	1	had
NCT0015801511	NCT00158015_11_T0	PHENOTYPE	0	0	Dyspnea
NCT0015801511	NCT00158015_11_T1	PHENOTYPE	10	11	lung disease
NCT0015801514	NCT00158015_14_T0	ORGAN	17	17	transplant
NCT0015801514	NCT00158015_14_T1	ORGAN	16	16	heart
NCT0015801515	NCT00158015_15_T0	ORGAN	4	5	heart valve
NCT0015801516	NCT00158015_16_T0	PHENOTYPE	0	2	Hypertrophic obstructive cardiomyopathy
NCT0015801518	NCT00158015_18_T0	PHENOTYPE	3	5	valvular heart disease
NCT001580282	NCT00158028_2_T0	PHENOTYPE	9	9	symptoms
NCT001580282	NCT00158028_2_T1	COMPOUND	3	3	risperidone
NCT001580282	NCT00158028_2_T2	PHENOTYPE	11	11	schizophrenia
NCT001580285	NCT00158028_5_T0	PHENOTYPE	19	19	dysphoria
NCT001580285	NCT00158028_5_T1	COMPOUND	9	9	risperidone
NCT001580285	NCT00158028_5_T2	COMPOUND	11	11	risperidone
NCT001580288	NCT00158028_8_T0	PHENOTYPE	19	20	stool guaiac
NCT001580289	NCT00158028_9_T0	GENE	50	50	II
NCT001580289	NCT00158028_9_T1	PHENOTYPE	51	51	pathology
NCT001580289	NCT00158028_9_T2	PHENOTYPE	15	16	Personality Disorder
NCT0015802815	NCT00158028_15_T0	GENE	21	21	Dr
NCT0015802821	NCT00158028_21_T0	GENE	9	9	SANS
NCT0015802825	NCT00158028_25_T0	GENE	23	23	Dr
NCT0015802830	NCT00158028_30_T0	COMPOUND	2	2	risperidone
NCT0015802830	NCT00158028_30_T1	PHENOTYPE	12	14	schizotypal personality disorder
NCT0015802833	NCT00158028_33_T0	GENE	17	17	SANS
NCT001580412	NCT00158041_2_T0	COMPOUND	6	6	amifostine
NCT001580541	NCT00158054_1_T0	PHENOTYPE	6	6	symptoms
NCT001580541	NCT00158054_1_T1	GENE	23	23	10
NCT001580542	NCT00158054_2_T0	GENE	13	13	IMPACT
NCT001580543	NCT00158054_3_T0	PHENOTYPE	8	8	focused
NCT001580548	NCT00158054_8_T0	PHENOTYPE	8	8	symptoms
NCT001580548	NCT00158054_8_T1	GENE	4	4	ACS
NCT001580548	NCT00158054_8_T2	GENE	20	20	ACS
NCT0015805410	NCT00158054_10_T0	GENE	15	15	INT
NCT0015805410	NCT00158054_10_T1	GENE	6	6	10
NCT0015805411	NCT00158054_11_T0	GENE	21	21	PST
NCT0015805411	NCT00158054_11_T1	GENE	25	25	MED
NCT0015805411	NCT00158054_11_T2	GENE	0	0	INT
NCT0015805412	NCT00158054_12_T0	COMPOUND	4	4	2
NCT0015805413	NCT00158054_13_T0	PHENOTYPE	6	6	symptoms
NCT0015805416	NCT00158054_16_T0	GENE	5	5	INT
NCT0015805417	NCT00158054_17_T0	PHENOTYPE	9	9	symptoms
NCT0015805417	NCT00158054_17_T1	PHENOTYPE	22	22	secondary
NCT0015805417	NCT00158054_17_T2	GENE	1	1	INT
NCT0015805419	NCT00158054_19_T0	PHENOTYPE	2	2	symptoms
NCT0015805419	NCT00158054_19_T1	PHENOTYPE	26	26	secondary
NCT0015805419	NCT00158054_19_T2	COMPOUND	24	24	aspirin
NCT0015805422	NCT00158054_22_T0	GENE	20	20	ACS
NCT0015805424	NCT00158054_24_T0	GENE	18	18	ACS
NCT0015805424	NCT00158054_24_T1	GENE	39	39	ACS
NCT0015805431	NCT00158054_31_T0	PHENOTYPE	32	32	disorders
NCT0015805431	NCT00158054_31_T1	PHENOTYPE	42	42	disorders
NCT0015805431	NCT00158054_31_T2	PHENOTYPE	6	6	homicidal
NCT0015805431	NCT00158054_31_T3	COMPOUND	2	2	1
NCT0015805431	NCT00158054_31_T4	COMPOUND	25	25	2
NCT0015805431	NCT00158054_31_T5	COMPOUND	43	43	3
NCT0015805431	NCT00158054_31_T6	PHENOTYPE	7	7	ideation
NCT0015805431	NCT00158054_31_T7	PHENOTYPE	34	35	depressive symptoms
NCT0015805431	NCT00158054_31_T8	PHENOTYPE	53	54	bipolar disorder
NCT0015805431	NCT00158054_31_T9	PHENOTYPE	57	58	personality disorders
NCT0015805431	NCT00158054_31_T10	PHENOTYPE	46	47	psychotic disorder
NCT0015805431	NCT00158054_31_T11	PHENOTYPE	51	52	psychotic disorder
NCT0015805431	NCT00158054_31_T12	PHENOTYPE	29	31	other substance abuse
NCT001580671	NCT00158067_1_T0	PHENOTYPE	13	13	acute
NCT001580671	NCT00158067_1_T1	GENE	9	9	has
NCT001580674	NCT00158067_4_T0	PHENOTYPE	18	18	seizure
NCT001580676	NCT00158067_6_T0	PHENOTYPE	11	11	epilepsy
NCT001580676	NCT00158067_6_T1	PHENOTYPE	5	5	seizures
NCT001580676	NCT00158067_6_T2	GENE	3	3	has
NCT001580800	NCT00158080_0_T0	PHENOTYPE	3	3	Nephropathy
NCT001580933	NCT00158093_3_T0	COMPOUND	3	3	nebivolol
NCT001580933	NCT00158093_3_T1	COMPOUND	16	16	atenolol
NCT001580933	NCT00158093_3_T2	COMPOUND	24	24	moxifloxacin
NCT001580933	NCT00158093_3_T3	PHENOTYPE	7	8	adverse event
NCT001580934	NCT00158093_4_T0	COMPOUND	10	10	nebivolol
NCT001580934	NCT00158093_4_T1	COMPOUND	20	20	nebivolol
NCT001580934	NCT00158093_4_T2	PHENOTYPE	21	21	concentrations
NCT001581060	NCT00158106_0_T0	GENE	10	10	The
NCT001581060	NCT00158106_0_T1	GENE	11	11	ACT
NCT0015810610	NCT00158106_10_T0	PHENOTYPE	6	6	aphasia
NCT0015810610	NCT00158106_10_T1	PHENOTYPE	4	4	dysarthria
NCT0015810611	NCT00158106_11_T0	PHENOTYPE	3	4	progressive dementia
NCT0015810611	NCT00158106_11_T1	PHENOTYPE	1	2	subarachnoid haemorrhage
NCT001581192	NCT00158119_2_T0	BIOLOGICAL_PROCESS	5	5	aging
NCT001581192	NCT00158119_2_T1	GENE	12	12	has
NCT001581194	NCT00158119_4_T0	PHENOTYPE	26	26	progressive
NCT001581194	NCT00158119_4_T1	ORGAN	14	15	lower extremity
NCT001581194	NCT00158119_4_T2	ORGAN	33	34	lower extremity
NCT001581196	NCT00158119_6_T0	PHENOTYPE	26	26	progressive
NCT001581321	NCT00158132_1_T0	COMPOUND	8	8	propranolol
NCT001581321	NCT00158132_1_T1	PHENOTYPE	26	27	cocaine withdrawal
NCT001581321	NCT00158132_1_T2	PHENOTYPE	20	21	cocaine addiction
NCT001581321	NCT00158132_1_T3	PHENOTYPE	27	28	withdrawal symptoms
NCT001581322	NCT00158132_2_T0	PHENOTYPE	13	13	relapse
NCT001581322	NCT00158132_2_T1	COMPOUND	15	15	cocaine
NCT001581322	NCT00158132_2_T2	COMPOUND	9	9	propranolol
NCT001581322	NCT00158132_2_T3	COMPOUND	7	7	amantadine
NCT001581325	NCT00158132_5_T0	GENE	13	13	lessen
NCT001581325	NCT00158132_5_T1	PHENOTYPE	14	14	stiffness
NCT001581325	NCT00158132_5_T2	PHENOTYPE	11	11	shaking
NCT001581327	NCT00158132_7_T0	COMPOUND	8	8	amantadine
NCT001581327	NCT00158132_7_T1	COMPOUND	7	7	dopamine
NCT001581327	NCT00158132_7_T2	PHENOTYPE	12	13	other symptoms
NCT001581327	NCT00158132_7_T3	PHENOTYPE	16	17	cocaine withdrawal
NCT001581328	NCT00158132_8_T0	ORGAN	13	13	heart
NCT001581328	NCT00158132_8_T1	PHENOTYPE	8	10	high blood pressure
NCT001581329	NCT00158132_9_T0	GENE	5	5	lessen
NCT001581329	NCT00158132_9_T1	COMPOUND	6	6	cocaine
NCT001581329	NCT00158132_9_T2	PHENOTYPE	10	12	addicted to cocaine
NCT0015813210	NCT00158132_10_T0	COMPOUND	20	20	cocaine
NCT0015813210	NCT00158132_10_T1	COMPOUND	11	11	amantadine
NCT0015813210	NCT00158132_10_T2	COMPOUND	13	13	propranolol
NCT0015813210	NCT00158132_10_T3	PHENOTYPE	24	25	cocaine withdrawal
NCT0015813210	NCT00158132_10_T4	PHENOTYPE	25	26	withdrawal symptoms
NCT0015813212	NCT00158132_12_T0	PHENOTYPE	4	5	cocaine use
NCT0015813213	NCT00158132_13_T0	COMPOUND	11	11	cocaine
NCT0015813213	NCT00158132_13_T1	PHENOTYPE	6	7	withdrawal symptoms
NCT0015813214	NCT00158132_14_T0	COMPOUND	11	11	propranolol
NCT0015813214	NCT00158132_14_T1	COMPOUND	18	18	propranolol
NCT0015813214	NCT00158132_14_T2	COMPOUND	9	9	amantadine
NCT0015813214	NCT00158132_14_T3	COMPOUND	16	16	amantadine
NCT0015813221	NCT00158132_21_T0	ORGAN	19	19	liver
NCT0015813221	NCT00158132_21_T1	GENE	8	8	axis
NCT0015813221	NCT00158132_21_T2	PHENOTYPE	5	6	sinus tachycardia
NCT0015813221	NCT00158132_21_T3	PHENOTYPE	1	4	1st degree heart block
NCT001581453	NCT00158145_3_T0	GENE	1	1	puff
NCT001581454	NCT00158145_4_T0	BIOLOGICAL_PROCESS	6	6	metabolism
NCT001581457	NCT00158145_7_T0	PHENOTYPE	3	4	lung cancer
NCT001581458	NCT00158145_8_T0	PHENOTYPE	2	3	lung cancer
NCT001581458	NCT00158145_8_T1	PHENOTYPE	16	17	lung cancer
NCT0015814510	NCT00158145_10_T0	GENE	1	1	puff
NCT0015814510	NCT00158145_10_T1	COMPOUND	8	8	nicotine
NCT001581586	NCT00158158_6_T0	PHENOTYPE	16	16	toxic
NCT001581586	NCT00158158_6_T1	PHENOTYPE	23	23	self-efficacy
NCT001581588	NCT00158158_8_T0	COMPOUND	4	4	nicotine
NCT001581589	NCT00158158_9_T0	COMPOUND	7	7	nicotine
NCT0015815810	NCT00158158_10_T0	COMPOUND	15	15	nicotine
NCT0015815811	NCT00158158_11_T0	COMPOUND	23	23	nicotine
NCT0015815815	NCT00158158_15_T0	COMPOUND	8	8	nicotine
NCT001581712	NCT00158171_2_T0	COMPOUND	11	11	nicotine
NCT001581712	NCT00158171_2_T1	COMPOUND	14	14	nicotine
NCT001581712	NCT00158171_2_T2	COMPOUND	9	9	bupropion
NCT001581712	NCT00158171_2_T3	ORGAN	15	15	gum
NCT001581715	NCT00158171_5_T0	COMPOUND	11	11	nicotine
NCT001581715	NCT00158171_5_T1	COMPOUND	14	14	nicotine
NCT001581715	NCT00158171_5_T2	COMPOUND	9	9	bupropion
NCT001581715	NCT00158171_5_T3	ORGAN	15	15	gum
NCT001581716	NCT00158171_6_T0	PHENOTYPE	16	16	toxic
NCT0015817110	NCT00158171_10_T0	COMPOUND	12	12	nicotine
NCT0015817110	NCT00158171_10_T1	COMPOUND	14	14	nicotine
NCT0015817110	NCT00158171_10_T2	COMPOUND	10	10	bupropion
NCT0015817110	NCT00158171_10_T3	ORGAN	15	15	gum
NCT0015817113	NCT00158171_13_T0	COMPOUND	3	3	nicotine
NCT0015817113	NCT00158171_13_T1	COMPOUND	6	6	nicotine
NCT0015817113	NCT00158171_13_T2	ORGAN	7	7	gum
NCT0015817114	NCT00158171_14_T0	COMPOUND	2	2	bupropion
NCT0015817116	NCT00158171_16_T0	GENE	9	9	10
NCT001581844	NCT00158184_4_T0	GENE	33	33	has
NCT001581844	NCT00158184_4_T1	PHENOTYPE	6	7	Drug Abuse
NCT001581845	NCT00158184_5_T0	GENE	6	6	has
NCT001581846	NCT00158184_6_T0	COMPOUND	12	12	oxycodone
NCT001581849	NCT00158184_9_T0	PHENOTYPE	8	8	dependence
NCT001581849	NCT00158184_9_T1	BIOLOGICAL_PROCESS	15	15	detoxification
NCT001581849	NCT00158184_9_T2	PHENOTYPE	5	6	substance abuse
NCT0015818410	NCT00158184_10_T0	COMPOUND	5	5	caffeine
NCT001581972	NCT00158197_2_T0	PHENOTYPE	6	6	reinforcement
NCT001581972	NCT00158197_2_T1	PHENOTYPE	27	27	reinforcement
NCT001581974	NCT00158197_4_T0	COMPOUND	11	11	methamphetamine
NCT001582102	NCT00158210_2_T0	COMPOUND	10	10	methamphetamine
NCT001582102	NCT00158210_2_T1	PHENOTYPE	11	11	dependence
NCT001582103	NCT00158210_3_T0	COMPOUND	11	11	rivastigmine
NCT001582103	NCT00158210_3_T1	COMPOUND	14	14	methamphetamine
NCT001582105	NCT00158210_5_T0	PHENOTYPE	0	0	Chronic
NCT001582105	NCT00158210_5_T1	COMPOUND	1	1	methamphetamine
NCT001582105	NCT00158210_5_T2	PHENOTYPE	6	7	psychotic behavior
NCT001582106	NCT00158210_6_T0	GENE	3	3	acetylcholinesterase
NCT001582106	NCT00158210_6_T1	PHENOTYPE	11	12	Alzheimer's dementia
NCT001582107	NCT00158210_7_T0	COMPOUND	11	11	rivastigmine
NCT001582107	NCT00158210_7_T1	COMPOUND	14	14	methamphetamine
NCT001582108	NCT00158210_8_T0	COMPOUND	13	13	rivastigmine
NCT001582109	NCT00158210_9_T0	COMPOUND	14	14	methamphetamine
NCT001582235	NCT00158223_5_T0	PHENOTYPE	10	10	schizophrenia
NCT001582235	NCT00158223_5_T1	GENE	1	1	has
NCT001582236	NCT00158223_6_T0	COMPOUND	22	22	clozapine
NCT001582238	NCT00158223_8_T0	GENE	6	6	has
NCT001582239	NCT00158223_9_T0	COMPOUND	13	13	clozapine
NCT001582239	NCT00158223_9_T1	PHENOTYPE	18	18	schizophrenia
NCT001582239	NCT00158223_9_T2	COMPOUND	7	7	pimozide
NCT0015822310	NCT00158223_10_T0	COMPOUND	11	11	clozapine
NCT0015822312	NCT00158223_12_T0	PHENOTYPE	12	12	severity
NCT0015822312	NCT00158223_12_T1	PHENOTYPE	13	14	cognitive ability
NCT0015822314	NCT00158223_14_T0	COMPOUND	17	17	clozapine
NCT0015822314	NCT00158223_14_T1	COMPOUND	22	22	clozapine
NCT0015822314	NCT00158223_14_T2	COMPOUND	20	20	pimozide
NCT001582362	NCT00158236_2_T0	COMPOUND	1	1	buprenorphine
NCT001582362	NCT00158236_2_T1	COMPOUND	10	10	buprenorphine
NCT001582362	NCT00158236_2_T2	PHENOTYPE	11	11	addiction
NCT001582362	NCT00158236_2_T3	COMPOUND	3	3	naloxone
NCT001582363	NCT00158236_3_T0	COMPOUND	9	9	buprenorphine
NCT001582363	NCT00158236_3_T1	COMPOUND	12	12	buprenorphine
NCT001582363	NCT00158236_3_T2	COMPOUND	14	14	naloxone
NCT001582366	NCT00158236_6_T0	PHENOTYPE	9	9	addiction
NCT001582366	NCT00158236_6_T1	PHENOTYPE	14	15	withdrawal symptoms
NCT001582367	NCT00158236_7_T0	COMPOUND	9	9	buprenorphine
NCT001582367	NCT00158236_7_T1	GENE	3	3	has
NCT001582368	NCT00158236_8_T0	PHENOTYPE	8	9	substance addiction
NCT001582369	NCT00158236_9_T0	COMPOUND	7	7	buprenorphine
NCT001582369	NCT00158236_9_T1	COMPOUND	13	13	buprenorphine
NCT0015823610	NCT00158236_10_T0	COMPOUND	12	12	buprenorphine
NCT0015823610	NCT00158236_10_T1	COMPOUND	15	15	buprenorphine
NCT0015823610	NCT00158236_10_T2	COMPOUND	17	17	naloxone
NCT0015823614	NCT00158236_14_T0	COMPOUND	2	2	naloxone
NCT0015823616	NCT00158236_16_T0	PHENOTYPE	13	14	cognitive functioning
NCT0015823618	NCT00158236_18_T0	ORGAN	0	0	Heart
NCT0015823618	NCT00158236_18_T1	ORGAN	24	24	eyes
NCT001582492	NCT00158249_2_T0	GENE	22	22	MRI
NCT001582494	NCT00158249_4_T0	PHENOTYPE	14	15	cognitive functioning
NCT001582496	NCT00158249_6_T0	BIOLOGICAL_PROCESS	9	9	metabolism
NCT001582498	NCT00158249_8_T0	PHENOTYPE	7	7	pharmacokinetics
NCT0015824910	NCT00158249_10_T0	GENE	7	7	cue
NCT0015824913	NCT00158249_13_T0	PHENOTYPE	9	9	acute
NCT0015824913	NCT00158249_13_T1	PHENOTYPE	5	5	affects
NCT0015824913	NCT00158249_13_T2	PHENOTYPE	11	11	chronic
NCT0015824916	NCT00158249_16_T0	PHENOTYPE	7	8	head trauma
NCT0015824916	NCT00158249_16_T1	PHENOTYPE	10	11	neurodegenerative disorders
NCT0015824917	NCT00158249_17_T0	GENE	1	1	has
NCT0015824917	NCT00158249_17_T1	GENE	15	15	has
NCT0015824917	NCT00158249_17_T2	PHENOTYPE	9	10	cocaine use
NCT0015824918	NCT00158249_18_T0	GENE	1	1	has
NCT0015824919	NCT00158249_19_T0	PHENOTYPE	9	9	insomnia
NCT0015824919	NCT00158249_19_T1	PHENOTYPE	19	20	cognitive function
NCT0015824920	NCT00158249_20_T0	PHENOTYPE	20	20	reward
NCT0015824920	NCT00158249_20_T1	PHENOTYPE	3	4	drug use
NCT0015824920	NCT00158249_20_T2	BIOLOGICAL_PROCESS	16	17	phospholipid metabolism
NCT0015824921	NCT00158249_21_T0	PHENOTYPE	13	13	affects
NCT0015824921	NCT00158249_21_T1	BIOLOGICAL_PROCESS	17	17	metabolism
NCT0015824922	NCT00158249_22_T0	PHENOTYPE	8	8	insights
NCT0015824922	NCT00158249_22_T1	PHENOTYPE	11	11	pathophysiology
NCT0015824922	NCT00158249_22_T2	PHENOTYPE	15	16	marijuana dependence
NCT0015824923	NCT00158249_23_T0	PHENOTYPE	11	11	disorders
NCT0015824923	NCT00158249_23_T1	PHENOTYPE	9	10	drug dependence
NCT001582622	NCT00158262_2_T0	PHENOTYPE	0	0	PTSD
NCT001582622	NCT00158262_2_T1	PHENOTYPE	10	11	psychological symptoms
NCT001582623	NCT00158262_3_T0	PHENOTYPE	7	7	trauma
NCT001582623	NCT00158262_3_T1	PHENOTYPE	3	3	PTSD
NCT001582623	NCT00158262_3_T2	PHENOTYPE	18	18	thoughts
NCT001582623	NCT00158262_3_T3	PHENOTYPE	12	12	flashback
NCT001582623	NCT00158262_3_T4	PHENOTYPE	15	15	nightmares
NCT001582623	NCT00158262_3_T5	PHENOTYPE	17	17	frightening
NCT001582624	NCT00158262_4_T0	PHENOTYPE	7	7	trauma
NCT001582624	NCT00158262_4_T1	PHENOTYPE	14	14	severity
NCT001582624	NCT00158262_4_T2	PHENOTYPE	16	16	PTSD
NCT001582624	NCT00158262_4_T3	COMPOUND	8	8	propranolol
NCT001582625	NCT00158262_5_T0	PHENOTYPE	14	14	symptoms
NCT001582625	NCT00158262_5_T1	PHENOTYPE	13	13	PTSD
NCT001582628	NCT00158262_8_T0	COMPOUND	19	19	propranolol
NCT001582628	NCT00158262_8_T1	COMPOUND	28	28	propranolol
NCT001582629	NCT00158262_9_T0	COMPOUND	13	13	propranolol
NCT0015826211	NCT00158262_11_T0	PHENOTYPE	9	9	PTSD
NCT001582881	NCT00158288_1_T0	COMPOUND	22	22	cocaine
NCT001582881	NCT00158288_1_T1	PHENOTYPE	18	19	cocaine use
NCT001582882	NCT00158288_2_T0	PHENOTYPE	12	13	cocaine use
NCT001582882	NCT00158288_2_T1	PHENOTYPE	37	38	drug use
NCT001582885	NCT00158288_5_T0	GENE	7	7	1.3
NCT001582886	NCT00158288_6_T0	GENE	7	7	1.3
NCT001582887	NCT00158288_7_T0	BIOLOGICAL_PROCESS	8	8	detoxification
NCT0015828813	NCT00158288_13_T0	PHENOTYPE	4	6	traumatic stress disorder
NCT0015828815	NCT00158288_15_T0	COMPOUND	23	23	naloxone
NCT0015828815	NCT00158288_15_T1	GENE	24	24	0.8
NCT0015828815	NCT00158288_15_T2	PHENOTYPE	4	5	opioid dependence
NCT0015828815	NCT00158288_15_T3	PHENOTYPE	14	15	opioid dependence
NCT0015828817	NCT00158288_17_T0	PHENOTYPE	8	9	cocaine dependence
NCT001583010	NCT00158301_0_T0	PHENOTYPE	5	5	Relapse
NCT001583013	NCT00158301_3_T0	PHENOTYPE	18	18	relapse
NCT0015830110	NCT00158301_10_T0	PHENOTYPE	2	3	depression symptoms
NCT0015830113	NCT00158301_13_T0	PHENOTYPE	8	9	depressive symptoms
NCT001583272	NCT00158327_2_T0	PHENOTYPE	19	20	mental health
NCT0015832710	NCT00158327_10_T0	PHENOTYPE	37	38	mental health
NCT0015832712	NCT00158327_12_T0	PHENOTYPE	17	17	symptoms
NCT0015832712	NCT00158327_12_T1	PHENOTYPE	24	26	quality of life
NCT001583402	NCT00158340_2_T0	GENE	3	3	has
NCT001583402	NCT00158340_2_T1	PHENOTYPE	11	12	emotional health
NCT001583407	NCT00158340_7_T0	PHENOTYPE	1	2	Eating Disorders
NCT001583534	NCT00158353_4_T0	GENE	10	10	PI
NCT001583534	NCT00158353_4_T1	GENE	11	11	has
NCT001583535	NCT00158353_5_T0	PHENOTYPE	11	11	strategies
NCT001583535	NCT00158353_5_T1	PHENOTYPE	4	4	self-esteem
NCT001583538	NCT00158353_8_T0	PHENOTYPE	21	21	self-esteem
NCT001583538	NCT00158353_8_T1	PHENOTYPE	29	30	substance use
NCT001583662	NCT00158366_2_T0	PHENOTYPE	0	1	Weight reduction
NCT001583663	NCT00158366_3_T0	PHENOTYPE	7	8	weight loss
NCT001583664	NCT00158366_4_T0	PHENOTYPE	13	13	schizophrenia
NCT001583665	NCT00158366_5_T0	PHENOTYPE	8	9	weight reduction
NCT0015836610	NCT00158366_10_T0	PHENOTYPE	38	39	weight loss
NCT0015836610	NCT00158366_10_T1	PHENOTYPE	55	56	weight loss
NCT0015836613	NCT00158366_13_T0	COMPOUND	16	16	glucose
NCT0015836613	NCT00158366_13_T1	ORGAN	12	12	serum
NCT0015836613	NCT00158366_13_T2	PHENOTYPE	6	7	self esteem
NCT0015836613	NCT00158366_13_T3	PHENOTYPE	3	5	quality of life
NCT001584182	NCT00158418_2_T0	PHENOTYPE	1	1	fixation
NCT001584182	NCT00158418_2_T1	PHENOTYPE	11	11	fixation
NCT001584183	NCT00158418_3_T0	GENE	20	20	humeral
NCT001584183	NCT00158418_3_T1	PHENOTYPE	22	22	fixation
NCT001584183	NCT00158418_3_T2	GENE	10	10	has
NCT001584186	NCT00158418_6_T0	PHENOTYPE	13	13	fixation
NCT001584186	NCT00158418_6_T1	PHENOTYPE	21	21	fixation
NCT001584187	NCT00158418_7_T0	GENE	16	16	humeral
NCT001584187	NCT00158418_7_T1	PHENOTYPE	13	13	fixation
NCT001584188	NCT00158418_8_T0	PHENOTYPE	5	5	centres
NCT001584189	NCT00158418_9_T0	GENE	11	11	humeral
NCT0015841811	NCT00158418_11_T0	PHENOTYPE	8	10	quality of life
NCT0015841813	NCT00158418_13_T0	PHENOTYPE	5	5	Osteoarthritis
NCT0015841813	NCT00158418_13_T1	ORGAN	22	22	Elbow
NCT0015841815	NCT00158418_15_T0	PHENOTYPE	1	1	secondary
NCT0015841816	NCT00158418_16_T0	PHENOTYPE	18	18	complications
NCT0015841816	NCT00158418_16_T1	PHENOTYPE	8	8	fixation
NCT0015841818	NCT00158418_18_T0	PHENOTYPE	48	48	dislocation
NCT0015841818	NCT00158418_18_T1	GENE	44	44	cuff
NCT0015841818	NCT00158418_18_T2	PHENOTYPE	47	47	chronic
NCT0015841818	NCT00158418_18_T3	GENE	7	7	III
NCT0015841818	NCT00158418_18_T4	PHENOTYPE	34	34	secondary
NCT0015841818	NCT00158418_18_T5	COMPOUND	31	31	1
NCT0015841818	NCT00158418_18_T6	COMPOUND	17	17	2
NCT0015841818	NCT00158418_18_T7	COMPOUND	65	65	2
NCT0015841818	NCT00158418_18_T8	PHENOTYPE	46	46	arthropathy
NCT0015841818	NCT00158418_18_T9	PHENOTYPE	54	54	arthropathy
NCT0015841818	NCT00158418_18_T10	PHENOTYPE	55	56	Charcot's arthropathy
NCT0015841818	NCT00158418_18_T11	PHENOTYPE	42	43	avascular necrosis
NCT0015841818	NCT00158418_18_T12	PHENOTYPE	39	40	joint trauma
NCT0015841818	NCT00158418_18_T13	PHENOTYPE	0	1	Primary osteoarthritis
NCT0015841818	NCT00158418_18_T14	PHENOTYPE	27	28	shoulder osteoarthritis
NCT0015841818	NCT00158418_18_T15	PHENOTYPE	50	52	rotator cuff tear
NCT0015841820	NCT00158418_20_T0	PHENOTYPE	3	4	systemic infection
NCT0015841821	NCT00158418_21_T0	PHENOTYPE	2	2	paralysis
NCT0015841824	NCT00158418_24_T0	PHENOTYPE	0	1	Psychiatric illness
NCT001584315	NCT00158431_5_T0	GENE	1	1	has
NCT001584315	NCT00158431_5_T1	PHENOTYPE	0	0	Osteoarthritis
NCT001584316	NCT00158431_6_T0	GENE	15	15	longevity
NCT001584317	NCT00158431_7_T0	PHENOTYPE	15	15	abrasion
NCT001584318	NCT00158431_8_T0	PHENOTYPE	16	16	osteoarthritis
NCT001584318	NCT00158431_8_T1	GENE	6	6	III
NCT001584319	NCT00158431_9_T0	PHENOTYPE	20	20	Osteoarthritis
NCT001584319	NCT00158431_9_T1	PHENOTYPE	8	10	quality of life
NCT0015843115	NCT00158431_15_T0	PHENOTYPE	4	4	severity
NCT0015843118	NCT00158431_18_T0	PHENOTYPE	3	3	arthritis
NCT0015843120	NCT00158431_20_T0	GENE	5	5	3.4
NCT0015843121	NCT00158431_21_T0	PHENOTYPE	20	20	distal
NCT0015843130	NCT00158431_30_T0	PHENOTYPE	0	1	Psychiatric illness
NCT001584573	NCT00158457_3_T0	GENE	2	2	has
NCT001584703	NCT00158470_3_T0	PHENOTYPE	10	10	tolerance
NCT001584707	NCT00158470_7_T0	GENE	3	3	has
NCT001584709	NCT00158470_9_T0	GENE	19	19	CD4
NCT001584709	NCT00158470_9_T1	PHENOTYPE	14	14	HIV
NCT0015847012	NCT00158470_12_T0	PHENOTYPE	13	14	opportunistic infection
NCT0015847014	NCT00158470_14_T0	PHENOTYPE	33	33	associations
NCT0015847014	NCT00158470_14_T1	BIOLOGICAL_PROCESS	23	23	behaviour
NCT0015847014	NCT00158470_14_T2	PHENOTYPE	15	16	mental well-being
NCT001584834	NCT00158483_4_T0	PHENOTYPE	36	36	HIV
NCT001584834	NCT00158483_4_T1	ORGAN	33	33	genital
NCT001584834	NCT00158483_4_T2	GENE	42	43	type 2
NCT001584834	NCT00158483_4_T3	PHENOTYPE	24	25	genital ulcers
NCT001584834	NCT00158483_4_T4	PHENOTYPE	39	40	Herpes simplex
NCT001584836	NCT00158483_6_T0	BIOLOGICAL_PROCESS	25	25	behaviour
NCT001584837	NCT00158483_7_T0	PHENOTYPE	13	14	genital ulceration
NCT001584838	NCT00158483_8_T0	PHENOTYPE	9	9	HIV
NCT001584838	NCT00158483_8_T1	GENE	14	14	has
NCT001584839	NCT00158483_9_T0	PHENOTYPE	11	11	HIV
NCT001584839	NCT00158483_9_T1	PHENOTYPE	28	28	seronegative
NCT001584839	NCT00158483_9_T2	PHENOTYPE	1	2	genital ulcers
NCT0015848310	NCT00158483_10_T0	PHENOTYPE	11	11	HIV
NCT0015848310	NCT00158483_10_T1	ORGAN	8	8	genital
NCT0015848314	NCT00158483_14_T0	PHENOTYPE	17	17	HIV
NCT0015848314	NCT00158483_14_T1	PHENOTYPE	38	38	HIV
NCT0015848314	NCT00158483_14_T2	PHENOTYPE	14	14	HSV
NCT0015848314	NCT00158483_14_T3	PHENOTYPE	36	36	HSV
NCT0015848314	NCT00158483_14_T4	PHENOTYPE	34	34	reinforcement
NCT0015848316	NCT00158483_16_T0	GENE	6	6	has
NCT0015848316	NCT00158483_16_T1	PHENOTYPE	26	27	genital ulcers
NCT0015848318	NCT00158483_18_T0	PHENOTYPE	18	18	Central
NCT0015848318	NCT00158483_18_T1	PHENOTYPE	5	6	genital ulcers
NCT0015848319	NCT00158483_19_T0	PHENOTYPE	20	20	chancroid
NCT0015848319	NCT00158483_19_T1	PHENOTYPE	22	22	syphilis
NCT0015848319	NCT00158483_19_T2	PHENOTYPE	15	16	genital ulcerations
NCT0015848323	NCT00158483_23_T0	PHENOTYPE	12	12	syphilis
NCT0015848323	NCT00158483_23_T1	GENE	9	9	D28
NCT0015848323	NCT00158483_23_T2	GENE	7	7	D2
NCT0015848323	NCT00158483_23_T3	GENE	25	25	CD4
NCT0015848323	NCT00158483_23_T4	PHENOTYPE	11	11	HIV
NCT0015848323	NCT00158483_23_T5	PHENOTYPE	19	19	HIV
NCT0015848323	NCT00158483_23_T6	ORGAN	20	20	plasma
NCT0015848324	NCT00158483_24_T0	PHENOTYPE	14	14	HIV
NCT0015848324	NCT00158483_24_T1	GENE	22	22	HSV2
NCT0015848324	NCT00158483_24_T2	ORGAN	15	15	genital
NCT0015848324	NCT00158483_24_T3	ORGAN	23	23	genital
NCT0015848325	NCT00158483_25_T0	PHENOTYPE	13	13	HIV
NCT0015848326	NCT00158483_26_T0	GENE	32	32	GUD
NCT0015848326	NCT00158483_26_T1	PHENOTYPE	14	15	genital ulcer
NCT001584960	NCT00158496_0_T0	GENE	6	6	Interferon
NCT001584960	NCT00158496_0_T1	PHENOTYPE	0	2	Chronic Hepatitis C
NCT001584962	NCT00158496_2_T0	COMPOUND	3	3	HCV
NCT001584962	NCT00158496_2_T1	GENE	16	16	Interferon
NCT001584962	NCT00158496_2_T2	GENE	9	9	has
NCT001584962	NCT00158496_2_T3	PHENOTYPE	20	20	chronic
NCT001584964	NCT00158496_4_T0	GENE	9	9	Interferon
NCT001584964	NCT00158496_4_T1	GENE	1	1	has
NCT001584965	NCT00158496_5_T0	GENE	5	5	Interferon
NCT001584965	NCT00158496_5_T1	PHENOTYPE	18	19	hepatitis C
NCT001584965	NCT00158496_5_T2	PHENOTYPE	17	18	chronic hepatitis
NCT001584967	NCT00158496_7_T0	COMPOUND	1	1	HCV
NCT001584968	NCT00158496_8_T0	GENE	2	2	has
NCT001584969	NCT00158496_9_T0	PHENOTYPE	19	20	chronic hepatitis
NCT001584969	NCT00158496_9_T1	PHENOTYPE	20	21	hepatitis C
NCT0015849610	NCT00158496_10_T0	GENE	2	2	has
NCT0015849610	NCT00158496_10_T1	GENE	14	14	interferon
NCT0015849611	NCT00158496_11_T0	COMPOUND	21	21	ribavirin
NCT0015849611	NCT00158496_11_T1	GENE	18	18	interferon
NCT0015849611	NCT00158496_11_T2	COMPOUND	35	35	HCV
NCT0015849611	NCT00158496_11_T3	PHENOTYPE	12	12	tolerance
NCT0015849611	NCT00158496_11_T4	PHENOTYPE	27	28	hepatitis C
NCT0015849611	NCT00158496_11_T5	PHENOTYPE	26	27	chronic hepatitis
NCT0015849619	NCT00158496_19_T0	COMPOUND	14	14	HCV
NCT0015849620	NCT00158496_20_T0	ORGAN	2	2	liver
NCT0015849622	NCT00158496_22_T0	COMPOUND	19	19	ribavirin
NCT0015849622	NCT00158496_22_T1	COMPOUND	4	4	HCV
NCT0015849622	NCT00158496_22_T2	GENE	8	8	PCR
NCT001585090	NCT00158509_0_T0	PHENOTYPE	12	12	HIV
NCT001585090	NCT00158509_0_T1	PHENOTYPE	7	8	Genital Herpes
NCT001585092	NCT00158509_2_T0	PHENOTYPE	2	2	symptoms
NCT001585092	NCT00158509_2_T1	ORGAN	8	8	genitals
NCT001585094	NCT00158509_4_T0	PHENOTYPE	12	12	HIV
NCT001585094	NCT00158509_4_T1	ORGAN	16	16	genital
NCT001585094	NCT00158509_4_T2	GENE	13	13	secreted
NCT001585094	NCT00158509_4_T3	PHENOTYPE	6	7	genital herpes
NCT001585097	NCT00158509_7_T0	GENE	7	7	has
NCT0015850910	NCT00158509_10_T0	PHENOTYPE	19	19	HIV
NCT0015850910	NCT00158509_10_T1	GENE	23	23	co
NCT0015850910	NCT00158509_10_T2	ORGAN	20	20	genital
NCT0015850910	NCT00158509_10_T3	PHENOTYPE	16	17	genital herpes
NCT0015850912	NCT00158509_12_T0	PHENOTYPE	4	4	HIV
NCT0015850912	NCT00158509_12_T1	PHENOTYPE	38	38	HIV
NCT0015850912	NCT00158509_12_T2	PHENOTYPE	43	43	immunity
NCT0015850912	NCT00158509_12_T3	PHENOTYPE	35	36	genital herpes
NCT0015850912	NCT00158509_12_T4	PHENOTYPE	16	17	HIV positive
NCT0015850914	NCT00158509_14_T0	PHENOTYPE	5	5	HIV
NCT0015850916	NCT00158509_16_T0	ORGAN	19	19	genital
NCT0015850920	NCT00158509_20_T0	PHENOTYPE	14	14	HIV
NCT001585220	NCT00158522_0_T0	GENE	3	3	Interferon
NCT001585220	NCT00158522_0_T1	PHENOTYPE	9	11	Acute Hepatitis C
NCT001585222	NCT00158522_2_T0	GENE	11	11	has
NCT001585222	NCT00158522_2_T1	PHENOTYPE	21	22	chronic hepatitis
NCT001585222	NCT00158522_2_T2	PHENOTYPE	3	4	Hepatitis C
NCT001585223	NCT00158522_3_T0	COMPOUND	11	11	HCV
NCT001585223	NCT00158522_3_T1	PHENOTYPE	6	7	acute hepatitis
NCT001585223	NCT00158522_3_T2	PHENOTYPE	7	8	hepatitis C
NCT001585225	NCT00158522_5_T0	GENE	10	10	Interferon
NCT001585225	NCT00158522_5_T1	GENE	1	1	has
NCT001585225	NCT00158522_5_T2	PHENOTYPE	14	15	chronic hepatitis
NCT001585225	NCT00158522_5_T3	PHENOTYPE	15	16	hepatitis C
NCT001585228	NCT00158522_8_T0	COMPOUND	1	1	HCV
NCT001585229	NCT00158522_9_T0	GENE	2	2	has
NCT001585229	NCT00158522_9_T1	PHENOTYPE	12	13	chronic hepatitis
NCT0015852210	NCT00158522_10_T0	PHENOTYPE	12	12	acute
NCT0015852211	NCT00158522_11_T0	GENE	8	8	interferon
NCT0015852211	NCT00158522_11_T1	PHENOTYPE	15	16	acute hepatitis
NCT0015852211	NCT00158522_11_T2	PHENOTYPE	16	17	hepatitis C
NCT0015852212	NCT00158522_12_T0	GENE	13	13	interferon
NCT0015852212	NCT00158522_12_T1	PHENOTYPE	10	10	tolerance
NCT0015852212	NCT00158522_12_T2	PHENOTYPE	20	21	acute hepatitis
NCT0015852212	NCT00158522_12_T3	PHENOTYPE	21	22	hepatitis C
NCT0015852218	NCT00158522_18_T0	COMPOUND	3	3	HCV
NCT0015852218	NCT00158522_18_T1	GENE	7	7	PCR
NCT001585353	NCT00158535_3_T0	PHENOTYPE	6	6	HIV
NCT001585353	NCT00158535_3_T1	PHENOTYPE	19	19	HIV
NCT001585354	NCT00158535_4_T0	PHENOTYPE	10	10	suffering
NCT001585354	NCT00158535_4_T1	COMPOUND	17	17	HCV
NCT001585354	NCT00158535_4_T2	PHENOTYPE	8	8	coinfection
NCT001585354	NCT00158535_4_T3	PHENOTYPE	13	14	liver disease
NCT001585356	NCT00158535_6_T0	ORGAN	7	7	liver
NCT001585356	NCT00158535_6_T1	COMPOUND	17	17	HCV
NCT001585356	NCT00158535_6_T2	PHENOTYPE	18	19	liver disease
NCT001585356	NCT00158535_6_T3	PHENOTYPE	10	11	HIV disease
NCT001585482	NCT00158548_2_T0	GENE	11	11	SE
NCT001585482	NCT00158548_2_T1	COMPOUND	29	29	artesunate
NCT001585482	NCT00158548_2_T2	GENE	22	22	SP
NCT001585483	NCT00158548_3_T0	COMPOUND	8	8	chloroquine
NCT001585483	NCT00158548_3_T1	COMPOUND	11	11	amodiaquine
NCT001585483	NCT00158548_3_T2	GENE	2	2	ACT
NCT001585483	NCT00158548_3_T3	COMPOUND	4	4	artesunate
NCT001585483	NCT00158548_3_T4	PHENOTYPE	15	15	malaria
NCT001585483	NCT00158548_3_T5	PHENOTYPE	23	23	malaria
NCT001585483	NCT00158548_3_T6	GENE	9	9	SP
NCT001585486	NCT00158548_6_T0	GENE	7	7	SP
NCT001585487	NCT00158548_7_T0	GENE	23	23	AS
NCT001585487	NCT00158548_7_T1	COMPOUND	22	22	artesunate
NCT001585487	NCT00158548_7_T2	GENE	9	9	SP
NCT001585488	NCT00158548_8_T0	COMPOUND	10	10	chloroquine
NCT001585488	NCT00158548_8_T1	COMPOUND	26	26	chloroquine
NCT001585488	NCT00158548_8_T2	GENE	6	6	AS
NCT001585489	NCT00158548_9_T0	COMPOUND	41	41	chloroquine
NCT001585489	NCT00158548_9_T1	COMPOUND	42	42	amodiaquine
NCT001585489	NCT00158548_9_T2	GENE	7	7	AS
NCT001585489	NCT00158548_9_T3	GENE	44	44	SP
NCT0015854810	NCT00158548_10_T0	GENE	13	13	SP
NCT0015854812	NCT00158548_12_T0	GENE	9	9	SP
NCT0015854812	NCT00158548_12_T1	GENE	22	22	SP
NCT0015854813	NCT00158548_13_T0	COMPOUND	11	11	chloroquine
NCT0015854813	NCT00158548_13_T1	PHENOTYPE	7	8	vivax malaria
NCT0015854815	NCT00158548_15_T0	GENE	12	12	ACT
NCT0015854816	NCT00158548_16_T0	COMPOUND	6	6	chloroquine
NCT0015854816	NCT00158548_16_T1	GENE	13	13	ACT
NCT0015854816	NCT00158548_16_T2	GENE	20	20	ACT
NCT0015854816	NCT00158548_16_T3	COMPOUND	15	15	artesunate
NCT0015854816	NCT00158548_16_T4	GENE	17	17	SP
NCT0015854816	NCT00158548_16_T5	PHENOTYPE	25	26	falciparum malaria
NCT0015854817	NCT00158548_17_T0	COMPOUND	14	14	chloroquine
NCT0015854817	NCT00158548_17_T1	COMPOUND	39	39	amodiaquine
NCT0015854817	NCT00158548_17_T2	GENE	12	12	AS
NCT0015854817	NCT00158548_17_T3	GENE	25	25	AS
NCT0015854817	NCT00158548_17_T4	GENE	37	37	AS
NCT0015854817	NCT00158548_17_T5	COMPOUND	22	22	primaquine
NCT0015854817	NCT00158548_17_T6	COMPOUND	11	11	artesunate
NCT0015854817	NCT00158548_17_T7	GENE	28	28	SP
NCT0015854817	NCT00158548_17_T8	GENE	30	30	SP
NCT0015854817	NCT00158548_17_T9	GENE	33	33	SP
NCT0015854817	NCT00158548_17_T10	PHENOTYPE	8	9	falciparum malaria
NCT0015854818	NCT00158548_18_T0	GENE	8	8	AS
NCT0015854818	NCT00158548_18_T1	GENE	11	11	SP
NCT0015854818	NCT00158548_18_T2	PHENOTYPE	6	7	vivax malaria
NCT0015854820	NCT00158548_20_T0	GENE	14	14	AS
NCT0015854820	NCT00158548_20_T1	PHENOTYPE	20	20	infections
NCT0015854820	NCT00158548_20_T2	PHENOTYPE	39	39	infections
NCT0015854823	NCT00158548_23_T0	PHENOTYPE	8	8	infections
NCT001585618	NCT00158561_8_T0	PHENOTYPE	2	3	Adverse events
NCT001585619	NCT00158561_9_T0	PHENOTYPE	4	4	haemolysis
NCT0015856110	NCT00158561_10_T0	PHENOTYPE	2	2	Recruitment
NCT0015856110	NCT00158561_10_T1	PHENOTYPE	5	5	Recruitment
NCT0015856116	NCT00158561_16_T0	GENE	6	6	probable
NCT0015856116	NCT00158561_16_T1	PHENOTYPE	8	8	malaria
NCT0015856126	NCT00158561_26_T0	PHENOTYPE	16	16	prick
NCT0015856126	NCT00158561_26_T1	ORGAN	15	15	thumb
NCT0015856131	NCT00158561_31_T0	GENE	0	0	NB
NCT0015856143	NCT00158561_43_T0	PHENOTYPE	2	3	reductase deficiency
NCT0015856151	NCT00158561_51_T0	PHENOTYPE	1	1	anaemia
NCT0015856152	NCT00158561_52_T0	PHENOTYPE	3	3	malaria
NCT001585741	NCT00158574_1_T0	PHENOTYPE	25	25	anaemia
NCT001585741	NCT00158574_1_T1	COMPOUND	5	5	sulfadoxine_pyrimethamine
NCT001585741	NCT00158574_1_T2	GENE	19	19	reduced
NCT001585741	NCT00158574_1_T3	PHENOTYPE	23	23	malaria
NCT001585741	NCT00158574_1_T4	GENE	6	6	SP
NCT001585741	NCT00158574_1_T5	GENE	33	33	SP
NCT001585741	NCT00158574_1_T6	GENE	17	17	EPI
NCT001585744	NCT00158574_4_T0	GENE	18	18	SP
NCT001585746	NCT00158574_6_T0	COMPOUND	34	34	amodiaquine
NCT001585746	NCT00158574_6_T1	GENE	15	15	SP
NCT001585746	NCT00158574_6_T2	GENE	32	32	SP
NCT001585748	NCT00158574_8_T0	COMPOUND	17	17	mefloquine
NCT0015857414	NCT00158574_14_T0	GENE	14	14	SP
NCT0015857414	NCT00158574_14_T1	COMPOUND	10	10	mefloquine
NCT0015857415	NCT00158574_15_T0	PHENOTYPE	16	16	measles
NCT0015857416	NCT00158574_16_T0	PHENOTYPE	28	28	malaria
NCT0015857419	NCT00158574_19_T0	GENE	14	14	SP
NCT0015857419	NCT00158574_19_T1	COMPOUND	10	10	mefloquine
NCT0015857420	NCT00158574_20_T0	PHENOTYPE	16	16	measles
NCT0015857422	NCT00158574_22_T0	GENE	15	15	EPI
NCT0015857425	NCT00158574_25_T0	PHENOTYPE	7	7	Polio
NCT0015857425	NCT00158574_25_T1	GENE	6	6	DPT
NCT0015857426	NCT00158574_26_T0	PHENOTYPE	6	6	measles
NCT0015857426	NCT00158574_26_T1	PHENOTYPE	58	58	measles
NCT0015857427	NCT00158574_27_T0	PHENOTYPE	25	25	prick
NCT0015857427	NCT00158574_27_T1	GENE	21	21	3a
NCT0015857429	NCT00158574_29_T0	PHENOTYPE	32	32	malaria
NCT0015857429	NCT00158574_29_T1	PHENOTYPE	16	16	prick
NCT0015857429	NCT00158574_29_T2	GENE	27	27	Hb
NCT0015857430	NCT00158574_30_T0	PHENOTYPE	33	33	prick
NCT0015857430	NCT00158574_30_T1	GENE	40	40	Hb
NCT0015857431	NCT00158574_31_T0	PHENOTYPE	32	32	prick
NCT0015857431	NCT00158574_31_T1	GENE	38	38	Hb
NCT0015857432	NCT00158574_32_T0	GENE	2	2	had
NCT0015857433	NCT00158574_33_T0	PHENOTYPE	20	20	prick
NCT0015857433	NCT00158574_33_T1	GENE	31	31	Hb
NCT0015857433	NCT00158574_33_T2	PHENOTYPE	36	36	malaria
NCT0015857434	NCT00158574_34_T0	PHENOTYPE	18	18	prick
NCT0015857434	NCT00158574_34_T1	GENE	42	42	Hb
NCT0015857434	NCT00158574_34_T2	PHENOTYPE	27	27	malaria
NCT0015857435	NCT00158574_35_T0	PHENOTYPE	19	19	fever
NCT0015857435	NCT00158574_35_T1	COMPOUND	46	46	quinine
NCT0015857435	NCT00158574_35_T2	GENE	15	15	has
NCT0015857435	NCT00158574_35_T3	GENE	26	26	has
NCT0015857435	NCT00158574_35_T4	PHENOTYPE	10	10	febrile
NCT0015857435	NCT00158574_35_T5	GENE	31	31	SP
NCT0015857435	NCT00158574_35_T6	PHENOTYPE	34	35	febrile illness
NCT0015857436	NCT00158574_36_T0	PHENOTYPE	14	14	fever
NCT0015857436	NCT00158574_36_T1	PHENOTYPE	7	7	malaria
NCT0015857436	NCT00158574_36_T2	GENE	26	26	SP
NCT0015857436	NCT00158574_36_T3	GENE	52	52	SP
NCT0015857436	NCT00158574_36_T4	COMPOUND	55	55	mefloquine
NCT0015857437	NCT00158574_37_T0	PHENOTYPE	9	9	blocks
NCT0015857438	NCT00158574_38_T0	GENE	25	25	SP
NCT0015857439	NCT00158574_39_T0	COMPOUND	43	43	dapsone
NCT0015857439	NCT00158574_39_T1	COMPOUND	45	45	pyrimethamine
NCT0015857439	NCT00158574_39_T2	COMPOUND	42	42	mefloquine
NCT0015857441	NCT00158574_41_T0	PHENOTYPE	15	15	malaria
NCT0015857441	NCT00158574_41_T1	PHENOTYPE	6	6	prick
NCT0015857441	NCT00158574_41_T2	GENE	29	29	SP
NCT0015857445	NCT00158574_45_T0	GENE	4	4	Tom
NCT0015857445	NCT00158574_45_T1	GENE	3	3	Dr
NCT0015857448	NCT00158574_48_T0	GENE	8	8	EPI
NCT0015857449	NCT00158574_49_T0	PHENOTYPE	11	11	blister
NCT0015857451	NCT00158574_51_T0	GENE	2	2	had
NCT0015857453	NCT00158574_53_T0	PHENOTYPE	6	6	vomiting
NCT0015857454	NCT00158574_54_T0	COMPOUND	15	15	mefloquine
NCT0015857454	NCT00158574_54_T1	PHENOTYPE	4	4	vomiting
NCT0015857456	NCT00158574_56_T0	COMPOUND	24	24	dapsone
NCT0015857456	NCT00158574_56_T1	COMPOUND	26	26	pyrimethamine
NCT0015857456	NCT00158574_56_T2	COMPOUND	23	23	mefloquine
NCT0015857457	NCT00158574_57_T0	COMPOUND	6	6	mefloquine
NCT0015857459	NCT00158574_59_T0	PHENOTYPE	22	22	fever
NCT0015857460	NCT00158574_60_T0	GENE	43	43	Hb
NCT0015857461	NCT00158574_61_T0	GENE	16	16	SP
NCT0015857461	NCT00158574_61_T1	COMPOUND	15	15	mefloquine
NCT0015857462	NCT00158574_62_T0	GENE	16	16	Hb
NCT0015857463	NCT00158574_63_T0	COMPOUND	0	0	2
NCT0015857465	NCT00158574_65_T0	COMPOUND	0	0	3
NCT0015857466	NCT00158574_66_T0	PHENOTYPE	13	13	centres
NCT0015857466	NCT00158574_66_T1	PHENOTYPE	1	2	adverse events
NCT0015857467	NCT00158574_67_T0	GENE	15	15	GSK
NCT0015857467	NCT00158574_67_T1	PHENOTYPE	2	3	adverse event
NCT0015857468	NCT00158574_68_T0	GENE	14	14	EPI
NCT0015857468	NCT00158574_68_T1	BIOLOGICAL_PROCESS	11	12	immune response
NCT0015857469	NCT00158574_69_T0	PHENOTYPE	3	3	measles
NCT0015857470	NCT00158574_70_T0	ORGAN	2	2	serum
NCT0015857470	NCT00158574_70_T1	PHENOTYPE	15	15	measles
NCT0015857471	NCT00158574_71_T0	PHENOTYPE	1	1	concentrations
NCT0015857471	NCT00158574_71_T1	GENE	3	3	DPT
NCT0015857472	NCT00158574_72_T0	PHENOTYPE	3	3	malaria
NCT0015857474	NCT00158574_74_T0	PHENOTYPE	11	11	malaria
NCT0015857474	NCT00158574_74_T1	PHENOTYPE	37	37	malaria
NCT0015857474	NCT00158574_74_T2	PHENOTYPE	2	2	prick
NCT0015857474	NCT00158574_74_T3	GENE	9	9	Hb
NCT0015857475	NCT00158574_75_T0	COMPOUND	10	10	quinine
NCT0015857475	NCT00158574_75_T1	PHENOTYPE	5	5	malaria
NCT0015857476	NCT00158574_76_T0	PHENOTYPE	23	23	anaemia
NCT0015857476	NCT00158574_76_T1	PHENOTYPE	21	21	malaria
NCT0015857477	NCT00158574_77_T0	PHENOTYPE	12	12	anaemia
NCT0015857477	NCT00158574_77_T1	PHENOTYPE	19	19	centre
NCT0015857477	NCT00158574_77_T2	PHENOTYPE	10	10	malaria
NCT0015857478	NCT00158574_78_T0	GENE	15	15	GCP
NCT0015857478	NCT00158574_78_T1	GENE	22	22	ICH
NCT0015857479	NCT00158574_79_T0	COMPOUND	3	3	SOPs
NCT0015857481	NCT00158574_81_T0	GENE	26	26	met
NCT0015857481	NCT00158574_81_T1	PHENOTYPE	19	20	adverse events
NCT0015857482	NCT00158574_82_T0	GENE	17	17	SP
NCT0015857484	NCT00158574_84_T0	PHENOTYPE	19	19	empowered
NCT0015857484	NCT00158574_84_T1	PHENOTYPE	6	7	adverse event
NCT0015857487	NCT00158574_87_T0	PHENOTYPE	26	26	Polio
NCT0015857487	NCT00158574_87_T1	GENE	24	24	DPT
NCT001585879	NCT00158587_9_T0	PHENOTYPE	14	14	relapse
NCT001585879	NCT00158587_9_T1	PHENOTYPE	16	17	vivax malaria
NCT0015858710	NCT00158587_10_T0	CELL	17	17	cells
NCT0015858719	NCT00158587_19_T0	COMPOUND	6	6	primaquine
NCT0015858719	NCT00158587_19_T1	PHENOTYPE	18	18	infections
NCT0015858721	NCT00158587_21_T0	PHENOTYPE	18	18	blister
NCT0015858727	NCT00158587_27_T0	PHENOTYPE	4	4	malaria
NCT0015858728	NCT00158587_28_T0	GENE	19	19	met
NCT0015858732	NCT00158587_32_T0	PHENOTYPE	8	8	relapse
NCT0015858734	NCT00158587_34_T0	COMPOUND	3	3	chloroquine
NCT0015858736	NCT00158587_36_T0	COMPOUND	3	3	chloroquine
NCT0015858736	NCT00158587_36_T1	COMPOUND	9	9	primaquine
NCT0015858741	NCT00158587_41_T0	PHENOTYPE	17	17	haemolysis
NCT0015858742	NCT00158587_42_T0	COMPOUND	11	11	chloroquine
NCT0015858750	NCT00158587_50_T0	PHENOTYPE	25	25	relapse
NCT0015858750	NCT00158587_50_T1	GENE	19	19	has
NCT001586002	NCT00158600_2_T0	TISSUE	16	16	tissues
NCT001586002	NCT00158600_2_T1	COMPOUND	9	9	glycogen
NCT001586002	NCT00158600_2_T2	ORGAN	18	18	heart
NCT001586002	NCT00158600_2_T3	PHENOTYPE	3	4	Pompe disease
NCT001586002	NCT00158600_2_T4	TISSUE	20	21	skeletal muscle
NCT001586003	NCT00158600_3_T0	PHENOTYPE	10	10	pharmacokinetics
NCT001586003	NCT00158600_3_T1	GENE	11	11	PK
NCT001586003	NCT00158600_3_T2	PHENOTYPE	20	21	Pompe disease
NCT001586131	NCT00158613_1_T0	GENE	2	2	met
NCT001586260	NCT00158626_0_T0	GENE	12	12	th
NCT001586260	NCT00158626_0_T1	PHENOTYPE	11	11	Prolapse
NCT001586260	NCT00158626_0_T2	PHENOTYPE	13	13	Prolapse
NCT001586260	NCT00158626_0_T3	PHENOTYPE	6	6	Symptoms
NCT001586260	NCT00158626_0_T4	ORGAN	2	3	Pelvic Floor
NCT001586264	NCT00158626_4_T0	PHENOTYPE	3	3	prolapse
NCT001586264	NCT00158626_4_T1	PHENOTYPE	5	5	backache
NCT001586264	NCT00158626_4_T2	ORGAN	9	9	bladder
NCT001586264	NCT00158626_4_T3	GENE	10	10	bowel
NCT001586264	NCT00158626_4_T4	PHENOTYPE	0	0	Symptoms
NCT001586264	NCT00158626_4_T5	PHENOTYPE	12	13	sexual dysfunction
NCT001586266	NCT00158626_6_T0	PHENOTYPE	3	3	prolapse
NCT001586267	NCT00158626_7_T0	TISSUE	5	5	fascia
NCT001586268	NCT00158626_8_T0	PHENOTYPE	4	4	recurrence
NCT001586268	NCT00158626_8_T1	PHENOTYPE	7	7	prolapse
NCT001586269	NCT00158626_9_T0	PHENOTYPE	7	7	prolapse
NCT0015862610	NCT00158626_10_T0	GENE	26	26	neuromuscular
NCT0015862610	NCT00158626_10_T1	PHENOTYPE	37	37	prolapse
NCT0015862610	NCT00158626_10_T2	PHENOTYPE	67	67	prolapse
NCT0015862610	NCT00158626_10_T3	PHENOTYPE	54	55	weight loss
NCT0015862610	NCT00158626_10_T4	ORGAN	14	15	pelvic floor
NCT0015862610	NCT00158626_10_T5	ORGAN	20	21	pelvic floor
NCT0015862611	NCT00158626_11_T0	PHENOTYPE	8	8	prolapse
NCT0015862611	NCT00158626_11_T1	ORGAN	3	4	pelvic floor
NCT0015862612	NCT00158626_12_T0	ORGAN	7	8	pelvic floor
NCT0015862613	NCT00158626_13_T0	GENE	7	7	has
NCT0015862613	NCT00158626_13_T1	PHENOTYPE	16	18	pelvic organ prolapse
NCT0015862614	NCT00158626_14_T0	PHENOTYPE	23	23	prolapse
NCT0015862615	NCT00158626_15_T0	PHENOTYPE	21	21	Centres
NCT0015862616	NCT00158626_16_T0	PHENOTYPE	19	19	symptoms
NCT0015862616	NCT00158626_16_T1	PHENOTYPE	21	21	severity
NCT0015862616	NCT00158626_16_T2	PHENOTYPE	17	17	prolapse
NCT0015862616	NCT00158626_16_T3	PHENOTYPE	20	20	prolapse
NCT0015862616	NCT00158626_16_T4	PHENOTYPE	26	26	prolapse
NCT0015862619	NCT00158626_19_T0	ORGAN	11	12	pelvic floor
NCT001586391	NCT00158639_1_T0	PHENOTYPE	9	9	hypertension
NCT001586392	NCT00158639_2_T0	GENE	1	1	BP
NCT001586392	NCT00158639_2_T1	PHENOTYPE	9	10	cardiovascular morbidity
NCT001586393	NCT00158639_3_T0	PHENOTYPE	34	34	hypertension
NCT001586395	NCT00158639_5_T0	PHENOTYPE	16	16	chronic
NCT001586396	NCT00158639_6_T0	PHENOTYPE	9	9	strategies
NCT001586397	NCT00158639_7_T0	PHENOTYPE	13	13	Chronic
NCT001586397	NCT00158639_7_T1	GENE	16	16	has
NCT001586397	NCT00158639_7_T2	GENE	34	34	has
NCT001586397	NCT00158639_7_T3	PHENOTYPE	43	43	hypertension
NCT001586397	NCT00158639_7_T4	PHENOTYPE	27	28	chronic diseases
NCT0015863911	NCT00158639_11_T0	PHENOTYPE	13	13	hypertension
NCT0015863913	NCT00158639_13_T0	GENE	12	13	group 3
NCT0015863914	NCT00158639_14_T0	PHENOTYPE	20	20	hypertension
NCT001586650	NCT00158665_0_T0	PHENOTYPE	8	8	Influenza
NCT001586650	NCT00158665_0_T1	GENE	15	15	Age
NCT001586655	NCT00158665_5_T0	PHENOTYPE	13	13	influenza
NCT001586655	NCT00158665_5_T1	PHENOTYPE	24	24	influenza
NCT001586656	NCT00158665_6_T0	BIOLOGICAL_PROCESS	13	14	immune response
NCT001586656	NCT00158665_6_T1	BIOLOGICAL_PROCESS	24	25	immune response
NCT001586659	NCT00158665_9_T0	PHENOTYPE	3	3	Acute
NCT001586659	NCT00158665_9_T1	PHENOTYPE	17	17	fever
NCT001586780	NCT00158678_0_T0	PHENOTYPE	11	11	HNSCC
NCT001586782	NCT00158678_2_T0	PHENOTYPE	14	14	xerostomia
NCT001586784	NCT00158678_4_T0	PHENOTYPE	14	14	xerostomia
NCT001586911	NCT00158691_1_T0	GENE	21	21	saliva
NCT001586913	NCT00158691_3_T0	COMPOUND	3	3	amifostine
NCT001586913	NCT00158691_3_T1	GENE	0	0	IV
NCT001586914	NCT00158691_4_T0	GENE	0	0	SC
NCT001586914	NCT00158691_4_T1	GENE	8	8	ml
NCT001587040	NCT00158704_0_T0	PHENOTYPE	11	11	Infection
NCT001587040	NCT00158704_0_T1	PHENOTYPE	10	10	HBV
NCT001587041	NCT00158704_1_T0	PHENOTYPE	1	1	Infection
NCT001587044	NCT00158704_4_T0	PHENOTYPE	1	1	secondary
NCT001587044	NCT00158704_4_T1	PHENOTYPE	12	12	chronic
NCT001587044	NCT00158704_4_T2	COMPOUND	15	16	adefovir dipivoxil
NCT001587046	NCT00158704_6_T0	GENE	3	3	has
NCT001587170	NCT00158717_0_T0	PHENOTYPE	7	7	Chronic
NCT001587170	NCT00158717_0_T1	PHENOTYPE	8	8	HBV
NCT001587173	NCT00158717_3_T0	PHENOTYPE	1	1	secondary
NCT001587173	NCT00158717_3_T1	PHENOTYPE	22	22	HBV
NCT001587173	NCT00158717_3_T2	COMPOUND	37	38	adefovir dipivoxil
NCT001587173	NCT00158717_3_T3	PHENOTYPE	18	19	hepatitis B
NCT001587173	NCT00158717_3_T4	PHENOTYPE	20	21	virus infection
NCT001587173	NCT00158717_3_T5	PHENOTYPE	17	18	chronic hepatitis
NCT001587305	NCT00158730_5_T0	GENE	15	15	IFI
NCT001587305	NCT00158730_5_T1	GENE	14	14	Probable
NCT001587430	NCT00158743_0_T0	PHENOTYPE	7	8	Severe Preeclampsia
NCT001587436	NCT00158743_6_T0	COMPOUND	13	13	magnesium
NCT001587438	NCT00158743_8_T0	COMPOUND	12	12	digoxin
NCT001587438	NCT00158743_8_T1	COMPOUND	22	22	digoxin
NCT001587438	NCT00158743_8_T2	GENE	26	27	Na/K ATPase
NCT0015874310	NCT00158743_10_T0	GENE	22	22	PE
NCT0015874310	NCT00158743_10_T1	ORGAN	11	12	fetal blood
NCT0015874311	NCT00158743_11_T0	GENE	7	7	PE
NCT0015874311	NCT00158743_11_T1	GENE	22	22	PE
NCT0015874311	NCT00158743_11_T2	PHENOTYPE	20	20	pathophysiology
NCT0015874312	NCT00158743_12_T0	GENE	9	9	fragment
NCT0015874312	NCT00158743_12_T1	GENE	8	8	FAB
NCT0015874312	NCT00158743_12_T2	PHENOTYPE	17	18	digoxin intoxication
NCT0015874313	NCT00158743_13_T0	GENE	10	10	has
NCT0015874313	NCT00158743_13_T1	PHENOTYPE	4	4	hypertension
NCT0015874313	NCT00158743_13_T2	PHENOTYPE	14	16	lower blood pressure
NCT0015874314	NCT00158743_14_T0	GENE	16	16	PE
NCT0015874314	NCT00158743_14_T1	PHENOTYPE	19	19	hypertension
NCT0015874315	NCT00158743_15_T0	GENE	28	28	PE
NCT0015874317	NCT00158743_17_T0	GENE	12	12	PE
NCT0015874319	NCT00158743_19_T0	PHENOTYPE	17	18	platelet count
NCT0015874319	NCT00158743_19_T1	ORGAN	20	21	umbilical artery
NCT0015874321	NCT00158743_21_T0	PHENOTYPE	20	20	complications
NCT0015874322	NCT00158743_22_T0	PHENOTYPE	0	1	Adverse events
NCT0015874328	NCT00158743_28_T0	PHENOTYPE	21	21	severity
NCT0015874328	NCT00158743_28_T1	PHENOTYPE	10	11	severe preeclampsia
NCT0015874331	NCT00158743_31_T0	GENE	7	7	5.7
NCT0015874333	NCT00158743_33_T0	GENE	0	0	Is
NCT0015874334	NCT00158743_34_T0	PHENOTYPE	0	0	Eclampsia
NCT0015874337	NCT00158743_37_T0	PHENOTYPE	3	4	fetal anomaly
NCT0015874338	NCT00158743_38_T0	PHENOTYPE	5	5	preeclampsia
NCT0015874338	NCT00158743_38_T1	PHENOTYPE	1	1	hypertension
NCT0015874338	NCT00158743_38_T2	PHENOTYPE	2	3	hypertension secondary
NCT0015874339	NCT00158743_39_T0	PHENOTYPE	4	5	autoimmune disease
NCT0015874340	NCT00158743_40_T0	PHENOTYPE	2	3	psychiatric disorder
NCT0015874342	NCT00158743_42_T0	PHENOTYPE	12	12	atopy
NCT0015874342	NCT00158743_42_T1	PHENOTYPE	10	10	asthma
NCT0015874342	NCT00158743_42_T2	PHENOTYPE	4	5	allergic reaction
NCT0015874343	NCT00158743_43_T0	GENE	10	10	chymopapain
NCT0015874343	NCT00158743_43_T1	PHENOTYPE	18	18	susceptible
NCT0015874343	NCT00158743_43_T2	PHENOTYPE	5	6	allergic reactions
NCT0015874343	NCT00158743_43_T3	PHENOTYPE	20	21	allergic reactions
NCT0015874345	NCT00158743_45_T0	COMPOUND	1	1	creatinine
NCT0015874345	NCT00158743_45_T1	GENE	3	3	1.5
NCT0015874345	NCT00158743_45_T2	ORGAN	0	0	Serum
NCT0015874346	NCT00158743_46_T0	PHENOTYPE	0	1	Platelet count
NCT001587691	NCT00158769_1_T0	ORGAN	9	9	liver
NCT001587692	NCT00158769_2_T0	ORGAN	17	17	livers
NCT001587821	NCT00158782_1_T0	PHENOTYPE	11	12	blood concentration
NCT001587823	NCT00158782_3_T0	PHENOTYPE	10	10	toxicity
NCT001587823	NCT00158782_3_T1	GENE	6	6	has
NCT001587824	NCT00158782_4_T0	PHENOTYPE	8	8	toxicities
NCT001587825	NCT00158782_5_T0	GENE	3	3	has
NCT001587826	NCT00158782_6_T0	PHENOTYPE	25	26	blood concentration
NCT001587827	NCT00158782_7_T0	GENE	3	3	has
NCT001587953	NCT00158795_3_T0	PHENOTYPE	7	8	general symptoms
NCT001587954	NCT00158795_4_T0	PHENOTYPE	5	5	symptoms
NCT001587955	NCT00158795_5_T0	PHENOTYPE	3	4	adverse events
NCT001588083	NCT00158808_3_T0	GENE	6	6	booster
NCT001588214	NCT00158821_4_T0	COMPOUND	9	9	tenofovir
NCT001588214	NCT00158821_4_T1	COMPOUND	16	16	efavirenz
NCT001588214	NCT00158821_4_T2	COMPOUND	14	14	lamivudine
NCT001588217	NCT00158821_7_T0	PHENOTYPE	17	17	initiation
NCT001588340	NCT00158834_0_T0	PHENOTYPE	1	1	Asthma
NCT001588340	NCT00158834_0_T1	PHENOTYPE	13	13	Asthma
NCT001588472	NCT00158847_2_T0	COMPOUND	9	9	fluticasone
NCT001588472	NCT00158847_2_T1	COMPOUND	2	2	salmeterol
NCT001588474	NCT00158847_4_T0	PHENOTYPE	17	17	symptoms
NCT001588474	NCT00158847_4_T1	PHENOTYPE	10	10	inflammation
NCT001588474	NCT00158847_4_T2	PHENOTYPE	19	21	quality of life
NCT0015884710	NCT00158847_10_T0	COMPOUND	10	10	fluticasone
NCT0015884710	NCT00158847_10_T1	COMPOUND	20	20	salmeterol
NCT0015884710	NCT00158847_10_T2	GENE	11	11	bid
NCT0015884714	NCT00158847_14_T0	PHENOTYPE	0	0	Symptoms
NCT0015884714	NCT00158847_14_T1	PHENOTYPE	2	2	QOL
NCT0015884715	NCT00158847_15_T0	PHENOTYPE	0	0	Peripheral
NCT0015884715	NCT00158847_15_T1	GENE	3	3	IgE
NCT0015884715	NCT00158847_15_T2	CELL	2	2	eosinophils
NCT0015884715	NCT00158847_15_T3	COMPOUND	10	10	methacholine
NCT0015884717	NCT00158847_17_T0	CELL	15	15	cells
NCT001588600	NCT00158860_0_T0	PHENOTYPE	10	10	Suppression
NCT001588600	NCT00158860_0_T1	PHENOTYPE	12	13	Herpes Simplex
NCT001588600	NCT00158860_0_T2	PHENOTYPE	16	17	Genital Herpes
NCT001588605	NCT00158860_5_T0	PHENOTYPE	20	21	genital herpes
NCT001588862	NCT00158886_2_T0	GENE	20	20	Gy
NCT001588862	NCT00158886_2_T1	COMPOUND	12	12	topotecan
NCT001588863	NCT00158886_3_T0	PHENOTYPE	30	30	toxicity
NCT001588863	NCT00158886_3_T1	GENE	16	16	Gy
NCT001588863	NCT00158886_3_T2	COMPOUND	5	5	topotecan
NCT001588990	NCT00158899_0_T0	GENE	9	9	Lipoprotein
NCT001589380	NCT00158938_0_T0	PHENOTYPE	7	7	Fixation
NCT001589770	NCT00158977_0_T0	GENE	3	3	AVT
NCT001589900	NCT00158990_0_T0	GENE	1	1	T3
NCT001589900	NCT00158990_0_T1	PHENOTYPE	9	10	Unipolar Depression
NCT001589907	NCT00158990_7_T0	GENE	14	14	II
NCT001589907	NCT00158990_7_T1	GENE	22	22	UPD
NCT001589907	NCT00158990_7_T2	PHENOTYPE	10	11	Bipolar Disorder
NCT001589907	NCT00158990_7_T3	PHENOTYPE	2	4	Major Depressive Episode
NCT001589907	NCT00158990_7_T4	PHENOTYPE	19	21	Major Depressive Disorder
NCT001589909	NCT00158990_9_T0	COMPOUND	11	11	2
NCT001589909	NCT00158990_9_T1	GENE	5	5	16
NCT0015899015	NCT00158990_15_T0	ORGAN	7	7	thyroid
NCT0015899015	NCT00158990_15_T1	PHENOTYPE	4	4	hypothyroidism
NCT0015899017	NCT00158990_17_T0	PHENOTYPE	4	5	physical illness
NCT0015899019	NCT00158990_19_T0	PHENOTYPE	6	7	alcohol dependence
NCT001590031	NCT00159003_1_T0	PHENOTYPE	13	13	diseases
NCT001590032	NCT00159003_2_T0	PHENOTYPE	9	9	leukemia
NCT001590033	NCT00159003_3_T0	BIOLOGICAL_PROCESS	9	9	detoxification
NCT001590035	NCT00159003_5_T0	GENE	8	8	NQO1
NCT001590035	NCT00159003_5_T1	GENE	6	6	MDR1
NCT001590035	NCT00159003_5_T2	COMPOUND	11	11	hOCT
NCT001590035	NCT00159003_5_T3	GENE	10	10	GST
NCT001590035	NCT00159003_5_T4	GENE	7	7	CYP3A4
NCT001590160	NCT00159016_0_T0	GENE	12	12	PDGFR
NCT001590160	NCT00159016_0_T1	PHENOTYPE	6	6	Tumor
NCT001590160	NCT00159016_0_T2	CELL	7	7	Cells
NCT001590162	NCT00159016_2_T0	PHENOTYPE	8	8	tumor
NCT001590162	NCT00159016_2_T1	PHENOTYPE	21	22	recurrent disease
NCT001590166	NCT00159016_6_T0	PHENOTYPE	3	4	brain tumors
NCT001590291	NCT00159029_1_T0	PHENOTYPE	7	7	malaria
NCT001590295	NCT00159029_5_T0	PHENOTYPE	7	7	malaria
NCT001590420	NCT00159042_0_T0	PHENOTYPE	4	4	Severity
NCT001590420	NCT00159042_0_T1	PHENOTYPE	6	7	Beta Thalassemia
NCT001590422	NCT00159042_2_T0	PHENOTYPE	9	9	severity
NCT001590422	NCT00159042_2_T1	PHENOTYPE	11	12	beta thalassemia
NCT001590424	NCT00159042_4_T0	PHENOTYPE	1	2	beta thalassemia
NCT001590424	NCT00159042_4_T1	GENE	4	5	beta globin
NCT001590425	NCT00159042_5_T0	PHENOTYPE	14	14	mutation
NCT001590425	NCT00159042_5_T1	GENE	21	21	East
NCT001590426	NCT00159042_6_T0	PHENOTYPE	15	15	anemia
NCT001590426	NCT00159042_6_T1	PHENOTYPE	21	21	anemia
NCT001590552	NCT00159055_2_T0	PHENOTYPE	14	14	GVHD
NCT001590552	NCT00159055_2_T1	GENE	4	4	NST
NCT001590680	NCT00159068_0_T0	PHENOTYPE	10	11	HIV Infection
NCT001590812	NCT00159081_2_T0	PHENOTYPE	9	9	relapse
NCT001590813	NCT00159081_3_T0	COMPOUND	9	9	haloperidol
NCT001590813	NCT00159081_3_T1	COMPOUND	11	11	risperidone
NCT001590813	NCT00159081_3_T2	GENE	14	14	2.4
NCT001590942	NCT00159094_2_T0	COMPOUND	11	11	vinorelbine
NCT001590942	NCT00159094_2_T1	PHENOTYPE	13	15	metastatic breast cancer
NCT001590944	NCT00159094_4_T0	PHENOTYPE	10	10	toxicity
NCT001590944	NCT00159094_4_T1	PHENOTYPE	12	13	disease progression
NCT001590945	NCT00159094_5_T0	PHENOTYPE	12	12	toxicity
NCT001590945	NCT00159094_5_T1	PHENOTYPE	4	4	Secondary
NCT001590945	NCT00159094_5_T2	PHENOTYPE	8	8	progression
NCT001590946	NCT00159094_6_T0	PHENOTYPE	10	10	pulse
NCT001590946	NCT00159094_6_T1	PHENOTYPE	6	6	dyspnea
NCT001590946	NCT00159094_6_T2	PHENOTYPE	24	24	dyspnea
NCT001590947	NCT00159094_7_T0	PHENOTYPE	19	19	symptoms
NCT001590947	NCT00159094_7_T1	PHENOTYPE	17	17	severity
NCT001590947	NCT00159094_7_T2	GENE	2	2	PPE
NCT001590948	NCT00159094_8_T0	GENE	4	4	had
NCT001590949	NCT00159094_9_T0	COMPOUND	18	18	1
NCT001590949	NCT00159094_9_T1	GENE	22	22	0.2
NCT001590949	NCT00159094_9_T2	PHENOTYPE	8	9	metastatic disease
NCT0015909410	NCT00159094_10_T0	COMPOUND	4	4	vinorelbine
NCT0015909411	NCT00159094_11_T0	PHENOTYPE	26	26	relapse/recurrence
NCT0015909411	NCT00159094_11_T1	PHENOTYPE	20	21	disease progression
NCT0015909413	NCT00159094_13_T0	PHENOTYPE	1	2	brain metastases
NCT0015909414	NCT00159094_14_T0	GENE	43	43	B6
NCT0015909414	NCT00159094_14_T1	GENE	5	5	IV
NCT0015909414	NCT00159094_14_T2	GENE	16	16	IV
NCT0015909414	NCT00159094_14_T3	GENE	28	28	IV
NCT0015909414	NCT00159094_14_T4	GENE	38	38	IV
NCT0015909414	NCT00159094_14_T5	GENE	32	32	po
NCT0015909414	NCT00159094_14_T6	GENE	46	46	po
NCT0015909416	NCT00159094_16_T0	PHENOTYPE	12	12	stomatitis
NCT0015909416	NCT00159094_16_T1	PHENOTYPE	18	18	thrombocytopenia
NCT001591071	NCT00159107_1_T0	GENE	5	5	has
NCT001591071	NCT00159107_1_T1	BIOLOGICAL_PROCESS	11	11	detoxification
NCT001591073	NCT00159107_3_T0	PHENOTYPE	9	9	relapse
NCT001591201	NCT00159120_1_T0	PHENOTYPE	3	3	prodrome
NCT001591203	NCT00159120_3_T0	PHENOTYPE	13	13	relapse
NCT001591203	NCT00159120_3_T1	PHENOTYPE	6	6	strategies
NCT001591462	NCT00159146_2_T0	GENE	1	1	has
NCT001591463	NCT00159146_3_T0	COMPOUND	11	11	pindolol
NCT001591590	NCT00159159_0_T0	GENE	12	12	de
NCT001591590	NCT00159159_0_T1	ORGAN	15	15	Transplant
NCT001591723	NCT00159172_3_T0	ORGAN	9	10	subthalamic nucleus
NCT001591724	NCT00159172_4_T0	GENE	13	13	MRI
NCT001591727	NCT00159172_7_T0	PHENOTYPE	19	19	bradykinesia
NCT001591727	NCT00159172_7_T1	PHENOTYPE	28	29	Parkinson disease
NCT0015917213	NCT00159172_13_T0	PHENOTYPE	17	19	quality of life
NCT001591855	NCT00159185_5_T0	PHENOTYPE	16	17	cardiovascular complications
NCT0015918518	NCT00159185_18_T0	PHENOTYPE	16	17	cardiovascular complications
NCT0015918519	NCT00159185_19_T0	PHENOTYPE	3	4	cardiovascular complications
NCT0015918524	NCT00159185_24_T0	GENE	4	4	PhD
NCT0015918528	NCT00159185_28_T0	GENE	10	10	has
NCT0015918530	NCT00159185_30_T0	PHENOTYPE	6	6	discomfort
NCT001591981	NCT00159198_1_T0	PHENOTYPE	1	1	adult-onset
NCT001591981	NCT00159198_1_T1	GENE	14	14	AD
NCT001591981	NCT00159198_1_T2	PHENOTYPE	12	13	autosomal dominant
NCT001591982	NCT00159198_2_T0	CELL	11	11	chromosomes
NCT001591987	NCT00159198_7_T0	GENE	21	21	AD
NCT001591988	NCT00159198_8_T0	CELL	17	17	chromosomes
NCT0015919811	NCT00159198_11_T0	ORGAN	20	21	nervous system
NCT0015919815	NCT00159198_15_T0	PHENOTYPE	29	29	pathophysiology
NCT001592111	NCT00159211_1_T0	TISSUE	15	16	abdominal fat
NCT001592111	NCT00159211_1_T1	GENE	18	19	type 2
NCT001592111	NCT00159211_1_T2	TISSUE	1	2	visceral fat
NCT001592112	NCT00159211_2_T0	GENE	15	15	insulin
NCT001592112	NCT00159211_2_T1	COMPOUND	34	34	metformin
NCT001592112	NCT00159211_2_T2	COMPOUND	17	17	pioglitazone
NCT001592112	NCT00159211_2_T3	COMPOUND	36	36	sulfonylureas
NCT001592112	NCT00159211_2_T4	TISSUE	7	8	abdominal fat
NCT001592112	NCT00159211_2_T5	GENE	20	21	type 2
NCT001592114	NCT00159211_4_T0	TISSUE	15	16	abdominal fat
NCT001592114	NCT00159211_4_T1	GENE	18	19	type 2
NCT001592114	NCT00159211_4_T2	TISSUE	1	2	visceral fat
NCT001592242	NCT00159224_2_T0	GENE	10	10	II
NCT001592242	NCT00159224_2_T1	COMPOUND	28	28	Kaletra
NCT001592503	NCT00159250_3_T0	PHENOTYPE	12	12	mutated
NCT001592503	NCT00159250_3_T1	GENE	11	11	skip
NCT001592503	NCT00159250_3_T2	GENE	13	13	dystrophin
NCT001592503	NCT00159250_3_T3	GENE	22	22	dystrophin
NCT001592503	NCT00159250_3_T4	GENE	3	3	has
NCT001592505	NCT00159250_5_T0	GENE	12	12	dystrophin
NCT001592505	NCT00159250_5_T1	COMPOUND	19	19	morpholino
NCT001592508	NCT00159250_8_T0	PHENOTYPE	9	9	weakness
NCT001592508	NCT00159250_8_T1	PHENOTYPE	6	7	muscle wasting
NCT0015925014	NCT00159250_14_T0	COMPOUND	18	18	morpholino
NCT0015925014	NCT00159250_14_T1	TISSUE	26	27	skeletal muscle
NCT0015925017	NCT00159250_17_T0	GENE	5	5	IM
NCT0015925024	NCT00159250_24_T0	GENE	13	13	grid
NCT0015925024	NCT00159250_24_T1	PHENOTYPE	12	12	cm2
NCT0015925034	NCT00159250_34_T0	TISSUE	16	16	muscles
NCT0015925041	NCT00159250_41_T0	GENE	3	3	Dr
NCT0015925043	NCT00159250_43_T0	GENE	3	3	Dr
NCT0015925044	NCT00159250_44_T0	PHENOTYPE	13	14	Mental Health
NCT0015925045	NCT00159250_45_T0	GENE	3	3	Dr
NCT0015925047	NCT00159250_47_T0	GENE	0	0	Dr
NCT0015925048	NCT00159250_48_T0	PHENOTYPE	2	2	Physiology
NCT0015925056	NCT00159250_56_T0	GENE	2	2	had
NCT0015925056	NCT00159250_56_T1	GENE	1	1	has
NCT0015925061	NCT00159250_61_T0	GENE	6	6	EDB
NCT0015925061	NCT00159250_61_T1	GENE	11	11	MRI
NCT0015925061	NCT00159250_61_T2	GENE	1	1	has
NCT0015925063	NCT00159250_63_T0	GENE	1	1	has
NCT0015925063	NCT00159250_63_T1	PHENOTYPE	3	5	forced vital capacity
NCT0015925067	NCT00159250_67_T0	GENE	1	1	has
NCT0015925071	NCT00159250_71_T0	GENE	6	6	EDB
NCT0015925071	NCT00159250_71_T1	GENE	2	2	had
NCT0015925071	NCT00159250_71_T2	GENE	1	1	has
NCT0015925073	NCT00159250_73_T0	GENE	4	4	EDB
NCT0015925073	NCT00159250_73_T1	GENE	9	9	MRI
NCT0015925073	NCT00159250_73_T2	GENE	1	1	has
NCT0015925077	NCT00159250_77_T0	GENE	1	1	has
NCT0015925077	NCT00159250_77_T1	COMPOUND	7	7	oxygen
NCT0015925077	NCT00159250_77_T2	PHENOTYPE	4	5	nocturnal hypoventilation
NCT0015925079	NCT00159250_79_T0	PHENOTYPE	14	14	ventilation
NCT0015925079	NCT00159250_79_T1	GENE	1	1	has
NCT0015925079	NCT00159250_79_T2	PHENOTYPE	3	4	respiratory insufficiency
NCT0015925081	NCT00159250_81_T0	GENE	1	1	has
NCT0015925081	NCT00159250_81_T1	PHENOTYPE	3	4	cognitive dysfunction
NCT0015925083	NCT00159250_83_T0	GENE	1	1	has
NCT0015925083	NCT00159250_83_T1	PHENOTYPE	2	3	immune deficiency
NCT0015925083	NCT00159250_83_T2	PHENOTYPE	5	6	autoimmune disease
NCT0015925085	NCT00159250_85_T0	GENE	1	1	has
NCT0015925085	NCT00159250_85_T1	GENE	7	7	has
NCT0015925085	NCT00159250_85_T2	PHENOTYPE	9	9	chronic
NCT0015925085	NCT00159250_85_T3	PHENOTYPE	4	5	bleeding disorder
NCT0015925087	NCT00159250_87_T0	COMPOUND	23	23	creatine
NCT0015925087	NCT00159250_87_T1	GENE	1	1	has
NCT0015925087	NCT00159250_87_T2	GENE	29	29	beta
NCT0015925088	NCT00159250_88_T0	GENE	2	2	had
NCT0015925088	NCT00159250_88_T1	GENE	1	1	has
NCT0015925089	NCT00159250_89_T0	GENE	1	1	has
NCT0015925090	NCT00159250_90_T0	GENE	6	6	MRI
NCT0015925090	NCT00159250_90_T1	GENE	1	1	has
NCT0015925090	NCT00159250_90_T2	GENE	9	9	has
NCT0015925091	NCT00159250_91_T0	GENE	3	3	has
NCT0015925091	NCT00159250_91_T1	GENE	7	7	has
NCT0015925091	NCT00159250_91_T2	PHENOTYPE	5	6	psychiatric disorder
NCT0015925091	NCT00159250_91_T3	PHENOTYPE	19	20	anxiety disorders
NCT0015925092	NCT00159250_92_T0	PHENOTYPE	4	4	allergies
NCT0015925092	NCT00159250_92_T1	GENE	1	1	has
NCT0015925093	NCT00159250_93_T0	GENE	1	1	has
NCT0015925093	NCT00159250_93_T1	GENE	7	7	has
NCT0015925094	NCT00159250_94_T0	GENE	1	1	has
NCT0015925094	NCT00159250_94_T1	PHENOTYPE	13	14	muscular dystrophy
NCT001592632	NCT00159263_2_T0	COMPOUND	20	20	budesonide
NCT001592632	NCT00159263_2_T1	PHENOTYPE	12	12	asthma
NCT001592632	NCT00159263_2_T2	COMPOUND	16	16	formoterol
NCT001592633	NCT00159263_3_T0	CELL	1	1	macrophages
NCT001592633	NCT00159263_3_T1	GENE	3	3	separated
NCT001592633	NCT00159263_3_T2	PHENOTYPE	6	6	adhesion
NCT001592635	NCT00159263_5_T0	GENE	3	3	MAP-kinase
NCT001592635	NCT00159263_5_T1	GENE	0	0	mRNA
NCT001592635	NCT00159263_5_T2	GENE	4	4	phosphatase
NCT001592635	NCT00159263_5_T3	GENE	7	7	IL-8
NCT001593024	NCT00159302_4_T0	PHENOTYPE	16	16	malignancy
NCT001593024	NCT00159302_4_T1	PHENOTYPE	20	21	psychiatric disease
NCT0015930224	NCT00159302_24_T0	COMPOUND	17	17	salbutamol
NCT0015930228	NCT00159302_28_T0	PHENOTYPE	0	0	Asthma
NCT0015930229	NCT00159302_29_T0	PHENOTYPE	16	16	malignancy
NCT0015930229	NCT00159302_29_T1	PHENOTYPE	20	21	psychiatric disease
NCT0015930236	NCT00159302_36_T0	PHENOTYPE	6	7	allergic asthma
NCT0015930237	NCT00159302_37_T0	PHENOTYPE	3	3	asthma
NCT0015930237	NCT00159302_37_T1	PHENOTYPE	30	30	bronchiectasis
NCT0015930237	NCT00159302_37_T2	PHENOTYPE	29	29	emphysema
NCT0015930237	NCT00159302_37_T3	PHENOTYPE	34	35	bronchopulmonary dysplasia
NCT0015930237	NCT00159302_37_T4	PHENOTYPE	31	32	cystic fibrosis
NCT0015930237	NCT00159302_37_T5	PHENOTYPE	24	25	pulmonary diseases
NCT0015930237	NCT00159302_37_T6	PHENOTYPE	27	28	chronic bronchitis
NCT0015930243	NCT00159302_43_T0	GENE	3	3	had
NCT0015930243	NCT00159302_43_T1	PHENOTYPE	5	6	skin prick
NCT0015930246	NCT00159302_46_T0	GENE	2	2	has
NCT0015930249	NCT00159302_49_T0	GENE	2	2	has
NCT0015930253	NCT00159302_53_T0	GENE	2	2	has
NCT0015930254	NCT00159302_54_T0	PHENOTYPE	6	7	Hepatitis B
NCT0015930255	NCT00159302_55_T0	GENE	2	2	has
NCT0015930255	NCT00159302_55_T1	PHENOTYPE	7	8	HIV infection
NCT0015930259	NCT00159302_59_T0	GENE	2	2	has
NCT0015930262	NCT00159302_62_T0	GENE	2	2	has
NCT0015930266	NCT00159302_66_T0	GENE	2	2	has
NCT0015930268	NCT00159302_68_T0	PHENOTYPE	10	10	sinusitis
NCT0015930268	NCT00159302_68_T1	GENE	2	2	has
NCT0015930268	NCT00159302_68_T2	PHENOTYPE	6	8	upper respiratory infection
NCT0015930271	NCT00159302_71_T0	GENE	11	11	beta-2
NCT0015930271	NCT00159302_71_T1	COMPOUND	7	7	theophylline
NCT0015930271	NCT00159302_71_T2	COMPOUND	14	14	tiotropium
NCT0015930273	NCT00159302_73_T0	PHENOTYPE	6	7	Hepatitis B
NCT0015930274	NCT00159302_74_T0	GENE	2	2	has
NCT0015930274	NCT00159302_74_T1	PHENOTYPE	7	8	HIV infection
NCT0015930278	NCT00159302_78_T0	PHENOTYPE	9	9	asthma
NCT0015930284	NCT00159302_84_T0	GENE	2	2	has
NCT0015930287	NCT00159302_87_T0	GENE	2	2	has
NCT0015930291	NCT00159302_91_T0	GENE	2	2	has
NCT0015930292	NCT00159302_92_T0	PHENOTYPE	9	9	sinusitis
NCT0015930292	NCT00159302_92_T1	GENE	2	2	has
NCT0015930292	NCT00159302_92_T2	PHENOTYPE	6	7	respiratory infection
NCT0015930293	NCT00159302_93_T0	PHENOTYPE	7	7	asthma
NCT0015930293	NCT00159302_93_T1	GENE	2	2	has
NCT0015930294	NCT00159302_94_T0	GENE	2	2	has
NCT0015930294	NCT00159302_94_T1	PHENOTYPE	10	11	hepatitis B
NCT0015930294	NCT00159302_94_T2	PHENOTYPE	24	25	hepatitis B
NCT0015930294	NCT00159302_94_T3	PHENOTYPE	6	7	hepatitis C
NCT0015930294	NCT00159302_94_T4	PHENOTYPE	20	21	hepatitis C
NCT0015930296	NCT00159302_96_T0	GENE	11	11	beta-2
NCT0015930296	NCT00159302_96_T1	COMPOUND	7	7	theophylline
NCT0015930296	NCT00159302_96_T2	COMPOUND	14	14	tiotropium
NCT0015930298	NCT00159302_98_T0	PHENOTYPE	6	7	Hepatitis B
NCT0015930299	NCT00159302_99_T0	GENE	2	2	has
NCT0015930299	NCT00159302_99_T1	PHENOTYPE	7	8	HIV infection
NCT001593152	NCT00159315_2_T0	COMPOUND	8	8	adenosine
NCT001593152	NCT00159315_2_T1	COMPOUND	12	12	adenosine
NCT001593152	NCT00159315_2_T2	GENE	14	14	AMP
NCT001593152	NCT00159315_2_T3	GENE	10	10	ATP
NCT0015931511	NCT00159315_11_T0	PHENOTYPE	0	2	Upper respiratory infection
NCT001593411	NCT00159341_1_T0	CELL	22	23	blood cells
NCT0015934112	NCT00159341_12_T0	GENE	13	13	has
NCT0015934115	NCT00159341_15_T0	ORGAN	18	18	bronchi
NCT0015934115	NCT00159341_15_T1	PHENOTYPE	23	23	infiltrating
NCT0015934115	NCT00159341_15_T2	CELL	24	24	leukocytes
NCT0015934115	NCT00159341_15_T3	GENE	1	1	has
NCT0015934115	NCT00159341_15_T4	PHENOTYPE	33	34	allergic asthma
NCT0015934115	NCT00159341_15_T5	PHENOTYPE	30	31	allergic rhinitis
NCT0015934116	NCT00159341_16_T0	GENE	13	13	allergen
NCT0015934116	NCT00159341_16_T1	TISSUE	7	8	respiratory epithelium
NCT0015934119	NCT00159341_19_T0	GENE	22	22	al
NCT0015934119	NCT00159341_19_T1	GENE	30	30	al
NCT0015934119	NCT00159341_19_T2	GENE	21	21	et
NCT0015934119	NCT00159341_19_T3	GENE	29	29	et
NCT0015934122	NCT00159341_22_T0	GENE	1	1	Sim
NCT0015934122	NCT00159341_22_T1	ORGAN	17	17	turbinates
NCT0015934124	NCT00159341_24_T0	GENE	15	15	NAC
NCT0015934124	NCT00159341_24_T1	GENE	6	6	has
NCT0015934125	NCT00159341_25_T0	CELL	26	26	cells
NCT0015934125	NCT00159341_25_T1	TISSUE	21	21	epithelium
NCT0015934125	NCT00159341_25_T2	CELL	0	0	Cells
NCT0015934129	NCT00159341_29_T0	ORGAN	12	12	turbinate
NCT0015934131	NCT00159341_31_T0	GENE	1	1	allergen
NCT0015934131	NCT00159341_31_T1	GENE	3	3	NAC
NCT0015934131	NCT00159341_31_T2	PHENOTYPE	17	17	asthma
NCT0015934131	NCT00159341_31_T3	PHENOTYPE	14	15	allergic rhinitis
NCT0015934132	NCT00159341_32_T0	GENE	5	5	allergen
NCT0015934132	NCT00159341_32_T1	GENE	0	0	NAC
NCT0015934132	NCT00159341_32_T2	GENE	1	1	has
NCT0015934137	NCT00159341_37_T0	COMPOUND	6	6	ozone
NCT0015934137	NCT00159341_37_T1	PHENOTYPE	3	4	inflammatory responses
NCT0015934140	NCT00159341_40_T0	GENE	3	3	III
NCT0015934140	NCT00159341_40_T1	GENE	7	7	phosphodiesterase
NCT0015934144	NCT00159341_44_T0	GENE	4	4	allergen
NCT0015934144	NCT00159341_44_T1	GENE	6	6	has
NCT0015934149	NCT00159341_49_T0	PHENOTYPE	4	4	toxic
NCT0015934152	NCT00159341_52_T0	GENE	1	1	Mio
NCT0015934152	NCT00159341_52_T1	GENE	3	3	al
NCT0015934152	NCT00159341_52_T2	GENE	2	2	et
NCT0015934153	NCT00159341_53_T0	CELL	6	6	neutrophil
NCT0015934153	NCT00159341_53_T1	GENE	7	7	CD11b
NCT0015934156	NCT00159341_56_T0	GENE	17	17	CD11b
NCT0015934163	NCT00159341_63_T0	GENE	13	13	has
NCT0015934166	NCT00159341_66_T0	GENE	7	7	retained
NCT0015934170	NCT00159341_70_T0	COMPOUND	1	1	2
NCT0015934175	NCT00159341_75_T0	PHENOTYPE	6	6	sinuses
NCT0015934176	NCT00159341_76_T0	PHENOTYPE	4	4	flushes
NCT0015934181	NCT00159341_81_T0	ORGAN	17	17	serum
NCT001593541	NCT00159354_1_T0	PHENOTYPE	6	7	lung disease
NCT001593548	NCT00159354_8_T0	GENE	19	19	GP
NCT001593548	NCT00159354_8_T1	PHENOTYPE	11	12	lung function
NCT0015935411	NCT00159354_11_T0	PHENOTYPE	11	12	lung function
NCT0015935413	NCT00159354_13_T0	GENE	14	14	had
NCT0015935413	NCT00159354_13_T1	PHENOTYPE	9	10	lung disease
NCT0015935415	NCT00159354_15_T0	GENE	23	23	CO
NCT0015935416	NCT00159354_16_T0	COMPOUND	12	12	prednisolone
NCT0015935420	NCT00159354_20_T0	GENE	8	8	1.2
NCT001593674	NCT00159367_4_T0	GENE	19	19	painless
NCT001593675	NCT00159367_5_T0	BIOLOGICAL_PROCESS	28	28	metabolism
NCT001593675	NCT00159367_5_T1	ORGAN	17	18	quadriceps muscle
NCT001593931	NCT00159393_1_T0	PHENOTYPE	1	1	decisions
NCT001593933	NCT00159393_3_T0	ORGAN	13	13	kidney
NCT001593933	NCT00159393_3_T1	ORGAN	24	24	kidney
NCT001593933	NCT00159393_3_T2	GENE	26	26	has
NCT001593935	NCT00159393_5_T0	ORGAN	14	14	kidney
NCT0015939310	NCT00159393_10_T0	PHENOTYPE	28	28	secondary
NCT001594064	NCT00159406_4_T0	PHENOTYPE	5	5	symptoms
NCT001594066	NCT00159406_6_T0	GENE	24	24	al
NCT001594066	NCT00159406_6_T1	GENE	23	23	et
NCT001594066	NCT00159406_6_T2	PHENOTYPE	10	11	blood loss
NCT001594066	NCT00159406_6_T3	PHENOTYPE	13	14	dilutional hyponatremia
NCT0015940614	NCT00159406_14_T0	GENE	23	23	RS
NCT0015940614	NCT00159406_14_T1	PHENOTYPE	19	19	Hai
NCT0015940614	NCT00159406_14_T2	TISSUE	13	13	prostates
NCT0015940619	NCT00159406_19_T0	PHENOTYPE	15	15	complications
NCT0015940619	NCT00159406_19_T1	GENE	1	1	extended
NCT0015940623	NCT00159406_23_T0	GENE	4	4	has
NCT001594191	NCT00159419_1_T0	PHENOTYPE	41	41	disorders
NCT001594191	NCT00159419_1_T1	PHENOTYPE	49	49	fractures
NCT001594194	NCT00159419_4_T0	ORGAN	10	10	tendons
NCT001594194	NCT00159419_4_T1	TISSUE	13	13	bones
NCT001594194	NCT00159419_4_T2	GENE	4	5	structural protein
NCT001594195	NCT00159419_5_T0	PHENOTYPE	14	14	deformity
NCT001594195	NCT00159419_5_T1	PHENOTYPE	12	12	progressive
NCT001594195	NCT00159419_5_T2	PHENOTYPE	9	10	multiple fractures
NCT001594196	NCT00159419_6_T0	PHENOTYPE	8	10	lethal in infancy
NCT001594199	NCT00159419_9_T0	PHENOTYPE	24	24	osteoporosis
NCT001594199	NCT00159419_9_T1	PHENOTYPE	14	15	osteogenesis imperfecta
NCT001594321	NCT00159432_1_T0	COMPOUND	20	20	capecitabine
NCT001594321	NCT00159432_1_T1	PHENOTYPE	12	12	tumors
NCT001594321	NCT00159432_1_T2	COMPOUND	21	21	oxaliplatin
NCT001594322	NCT00159432_2_T0	GENE	8	8	has
NCT001594322	NCT00159432_2_T1	PHENOTYPE	18	19	colorectal cancer
NCT001594323	NCT00159432_3_T0	CELL	6	6	cells
NCT001594323	NCT00159432_3_T1	PHENOTYPE	3	4	colorectal cancer
NCT001594324	NCT00159432_4_T0	GENE	4	4	has
NCT001594324	NCT00159432_4_T1	PHENOTYPE	15	16	colorectal cancer
NCT001594325	NCT00159432_5_T0	CELL	5	5	cells
NCT001594325	NCT00159432_5_T1	PHENOTYPE	3	4	colorectal cancer
NCT0015943211	NCT00159432_11_T0	PHENOTYPE	13	13	tumors
NCT001594451	NCT00159445_1_T0	COMPOUND	22	22	capecitabine
NCT001594451	NCT00159445_1_T1	PHENOTYPE	13	13	tumors
NCT001594451	NCT00159445_1_T2	COMPOUND	24	24	gemcitabine
NCT001594452	NCT00159445_2_T0	GENE	6	6	has
NCT001594452	NCT00159445_2_T1	PHENOTYPE	16	17	colorectal cancer
NCT001594455	NCT00159445_5_T0	CELL	25	25	cells
NCT001594455	NCT00159445_5_T1	PHENOTYPE	28	28	tumor
NCT001594582	NCT00159458_2_T0	COMPOUND	13	13	oxaliplatin
NCT001594582	NCT00159458_2_T1	PHENOTYPE	11	12	lung cancer
NCT001594582	NCT00159458_2_T2	PHENOTYPE	28	29	colon cancer
NCT001594583	NCT00159458_3_T0	COMPOUND	3	3	oxaliplatin
NCT001594583	NCT00159458_3_T1	COMPOUND	1	1	gemcitabine
NCT001594583	NCT00159458_3_T2	PHENOTYPE	10	11	breast cancer
NCT001594584	NCT00159458_4_T0	PHENOTYPE	13	13	tumors
NCT001594584	NCT00159458_4_T1	PHENOTYPE	11	12	breast cancer
NCT001594710	NCT00159471_0_T0	GENE	17	17	atic
NCT001594710	NCT00159471_0_T1	GENE	10	10	GTX
NCT001594710	NCT00159471_0_T2	PHENOTYPE	18	18	Cancer
NCT001594710	NCT00159471_0_T3	PHENOTYPE	14	16	Unresectable Pancreatic Cancer
NCT001594712	NCT00159471_2_T0	GENE	5	5	has
NCT001594713	NCT00159471_3_T0	PHENOTYPE	7	10	cancer of the pancreas
NCT001594714	NCT00159471_4_T0	COMPOUND	15	15	cisplatin
NCT001594714	NCT00159471_4_T1	PHENOTYPE	7	8	lung cancer
NCT001594716	NCT00159471_6_T0	PHENOTYPE	8	9	lung cancer
NCT001594717	NCT00159471_7_T0	ORGAN	16	16	rectum
NCT001594717	NCT00159471_7_T1	PHENOTYPE	11	14	cancer of the colon
NCT001594718	NCT00159471_8_T0	PHENOTYPE	11	11	tumors
NCT0015947112	NCT00159471_12_T0	PHENOTYPE	14	14	cancers
NCT0015947113	NCT00159471_13_T0	COMPOUND	10	10	capecitabine
NCT0015947113	NCT00159471_13_T1	COMPOUND	8	8	docetaxel
NCT0015947113	NCT00159471_13_T2	COMPOUND	7	7	gemcitabine
NCT001594842	NCT00159484_2_T0	GENE	6	6	has
NCT001594843	NCT00159484_3_T0	CELL	14	14	cells
NCT001594843	NCT00159484_3_T1	GENE	5	5	has
NCT001594844	NCT00159484_4_T0	PHENOTYPE	14	14	arthritis
NCT001594844	NCT00159484_4_T1	PHENOTYPE	18	19	colon polyps
NCT001594847	NCT00159484_7_T0	PHENOTYPE	10	12	effects of chemotherapy
NCT001594849	NCT00159484_9_T0	PHENOTYPE	11	13	effects of chemotherapy
NCT0015948411	NCT00159484_11_T0	PHENOTYPE	23	23	diarrhea
NCT0015948415	NCT00159484_15_T0	GENE	11	11	has
NCT0015948417	NCT00159484_17_T0	PHENOTYPE	14	14	tumors
NCT0015948420	NCT00159484_20_T0	PHENOTYPE	12	12	tumors
NCT0015948420	NCT00159484_20_T1	PHENOTYPE	25	25	tumors
NCT0015948421	NCT00159484_21_T0	PHENOTYPE	16	16	tumors
NCT0015948429	NCT00159484_29_T0	GENE	5	5	ASA
NCT001594970	NCT00159497_0_T0	BIOLOGICAL_PROCESS	0	1	Bone Remodeling
NCT001594974	NCT00159497_4_T0	COMPOUND	8	8	titanium
NCT001594978	NCT00159497_8_T0	BIOLOGICAL_PROCESS	10	11	bone remodeling
NCT0015949712	NCT00159497_12_T0	COMPOUND	8	8	titanium
NCT0015949716	NCT00159497_16_T0	BIOLOGICAL_PROCESS	10	11	bone remodeling
NCT001595101	NCT00159510_1_T0	PHENOTYPE	12	12	vasoplegia
NCT001595101	NCT00159510_1_T1	PHENOTYPE	2	2	sepsis
NCT001595101	NCT00159510_1_T2	PHENOTYPE	22	22	dysfunction
NCT001595102	NCT00159510_2_T0	GENE	16	16	MB
NCT001595102	NCT00159510_2_T1	COMPOUND	14	15	methylene blue
NCT001595102	NCT00159510_2_T2	PHENOTYPE	24	25	septic shock
NCT001595103	NCT00159510_3_T0	GENE	15	15	MB
NCT001595103	NCT00159510_3_T1	PHENOTYPE	18	20	acute lung injury
NCT001595104	NCT00159510_4_T0	GENE	15	15	MB
NCT001595104	NCT00159510_4_T1	PHENOTYPE	33	34	septic shock
NCT001595105	NCT00159510_5_T0	PHENOTYPE	7	8	septic shock
NCT001595107	NCT00159510_7_T0	GENE	0	0	MB
NCT001595109	NCT00159510_9_T0	GENE	0	0	MB
NCT0015951011	NCT00159510_11_T0	GENE	0	0	MB
NCT0015951012	NCT00159510_12_T0	GENE	14	14	0.5
NCT0015951013	NCT00159510_13_T0	GENE	14	14	Hg
NCT0015951014	NCT00159510_14_T0	PHENOTYPE	27	27	concentrations
NCT0015951014	NCT00159510_14_T1	PHENOTYPE	15	17	pulmonary artery pressure
NCT0015951019	NCT00159510_19_T0	PHENOTYPE	0	1	Severe sepsis
NCT0015951022	NCT00159510_22_T0	GENE	2	2	CI
NCT0015951022	NCT00159510_22_T1	GENE	5	5	3.5
NCT0015951022	NCT00159510_22_T2	GENE	19	19	Hg
NCT0015951022	NCT00159510_22_T3	ORGAN	7	8	pulmonary artery
NCT0015951022	NCT00159510_22_T4	PHENOTYPE	8	9	artery occlusion
NCT0015951023	NCT00159510_23_T0	GENE	24	24	balloon
NCT0015951023	NCT00159510_23_T1	ORGAN	17	18	femoral arteries
NCT0015951023	NCT00159510_23_T2	ORGAN	31	32	pulmonary artery
NCT0015951025	NCT00159510_25_T0	GENE	7	7	MB
NCT001595625	NCT00159562_5_T0	PHENOTYPE	0	0	Symptoms
NCT001595756	NCT00159575_6_T0	PHENOTYPE	4	4	infertility
NCT001595757	NCT00159575_7_T0	PHENOTYPE	10	10	PCOS
NCT001595757	NCT00159575_7_T1	PHENOTYPE	16	16	hyperandrogenism
NCT001595757	NCT00159575_7_T2	COMPOUND	12	12	metformin
NCT001595757	NCT00159575_7_T3	PHENOTYPE	18	19	insulin resistance
NCT001595759	NCT00159575_9_T0	COMPOUND	4	4	metformin
NCT001595880	NCT00159588_0_T0	PHENOTYPE	1	1	Headache
NCT001595880	NCT00159588_0_T1	PHENOTYPE	3	3	Withdrawal
NCT001595882	NCT00159588_2_T0	GENE	4	4	has
NCT001595883	NCT00159588_3_T0	PHENOTYPE	4	4	experiences
NCT001595886	NCT00159588_6_T0	GENE	9	9	probable
NCT001595886	NCT00159588_6_T1	PHENOTYPE	17	18	Headache Disorders
NCT001595888	NCT00159588_8_T0	PHENOTYPE	4	4	acute
NCT001596010	NCT00159601_0_T0	PHENOTYPE	4	5	Mental Health
NCT001596010	NCT00159601_0_T1	PHENOTYPE	0	2	Quality of Life
NCT001596013	NCT00159601_3_T0	GENE	21	21	has
NCT001596013	NCT00159601_3_T1	PHENOTYPE	10	12	Quality of Life
NCT001596016	NCT00159601_6_T0	GENE	16	16	june
NCT001596016	NCT00159601_6_T1	GENE	9	10	group 3
NCT001596270	NCT00159627_0_T0	PHENOTYPE	13	13	CHF
NCT001596270	NCT00159627_0_T1	PHENOTYPE	15	15	CHF
NCT001596270	NCT00159627_0_T2	BIOLOGICAL_PROCESS	6	6	Diuresis
NCT001596270	NCT00159627_0_T3	PHENOTYPE	10	12	Congestive Heart Failure
NCT001597182	NCT00159718_2_T0	PHENOTYPE	10	10	inflammation
NCT001597182	NCT00159718_2_T1	GENE	13	13	has
NCT001597182	NCT00159718_2_T2	COMPOUND	6	6	atorvastatin
NCT001597182	NCT00159718_2_T3	COMPOUND	8	8	amlodipine
NCT001597441	NCT00159744_1_T0	PHENOTYPE	1	1	symptoms
NCT001597441	NCT00159744_1_T1	PHENOTYPE	6	6	mania
NCT001597442	NCT00159744_2_T0	PHENOTYPE	9	9	manic
NCT001597442	NCT00159744_2_T1	PHENOTYPE	14	15	bipolar disorder
NCT001597444	NCT00159744_4_T0	COMPOUND	5	5	olanzapine
NCT001597444	NCT00159744_4_T1	COMPOUND	4	4	asenapine
NCT001597444	NCT00159744_4_T2	PHENOTYPE	17	17	mania
NCT001597571	NCT00159757_1_T0	PHENOTYPE	3	3	tolerance
NCT001597572	NCT00159757_2_T0	PHENOTYPE	33	33	satisfied
NCT001597572	NCT00159757_2_T1	PHENOTYPE	24	24	withdrawn
NCT001597572	NCT00159757_2_T2	COMPOUND	6	6	ziprasidone
NCT001597572	NCT00159757_2_T3	GENE	2	2	has
NCT001597572	NCT00159757_2_T4	GENE	21	21	has
NCT001597573	NCT00159757_3_T0	PHENOTYPE	18	18	schizophrenia
NCT001597830	NCT00159783_0_T0	PHENOTYPE	9	10	Bipolar Disorder
NCT001597832	NCT00159783_2_T0	PHENOTYPE	1	1	symptoms
NCT001597832	NCT00159783_2_T1	PHENOTYPE	6	6	mania
NCT001597833	NCT00159783_3_T0	PHENOTYPE	9	9	manic
NCT001597833	NCT00159783_3_T1	PHENOTYPE	14	15	bipolar disorder
NCT001597834	NCT00159783_4_T0	COMPOUND	23	23	olanzapine
NCT001597834	NCT00159783_4_T1	GENE	18	18	had
NCT001597834	NCT00159783_4_T2	COMPOUND	21	21	asenapine
NCT001597834	NCT00159783_4_T3	PHENOTYPE	35	35	mania
NCT001597961	NCT00159796_1_T0	PHENOTYPE	1	1	symptoms
NCT001597961	NCT00159796_1_T1	PHENOTYPE	6	6	mania
NCT001597962	NCT00159796_2_T0	PHENOTYPE	9	9	manic
NCT001597962	NCT00159796_2_T1	PHENOTYPE	14	15	bipolar disorder
NCT001597964	NCT00159796_4_T0	COMPOUND	5	5	olanzapine
NCT001597964	NCT00159796_4_T1	COMPOUND	4	4	asenapine
NCT001597964	NCT00159796_4_T2	PHENOTYPE	17	17	mania
NCT001598870	NCT00159887_0_T0	PHENOTYPE	12	14	Pulmonary Arterial Hypertension
NCT001599130	NCT00159913_0_T0	PHENOTYPE	10	12	Pulmonary Arterial Hypertension
NCT001599132	NCT00159913_2_T0	PHENOTYPE	12	12	pharmacokinetics
NCT001599132	NCT00159913_2_T1	COMPOUND	21	21	sildenafil
NCT001599132	NCT00159913_2_T2	PHENOTYPE	17	17	chronic
NCT001599134	NCT00159913_4_T0	COMPOUND	24	24	sildenafil
NCT001599261	NCT00159926_1_T0	ORGAN	11	11	kidney
NCT001599261	NCT00159926_1_T1	ORGAN	8	8	heart
NCT001599262	NCT00159926_2_T0	ORGAN	7	7	heart
NCT001599262	NCT00159926_2_T1	CELL	0	2	White blood cells
NCT001599269	NCT00159926_9_T0	PHENOTYPE	10	10	peripheral
NCT001599269	NCT00159926_9_T1	PHENOTYPE	14	14	edema
NCT001599269	NCT00159926_9_T2	ORGAN	5	5	capillary
NCT001599269	NCT00159926_9_T3	PHENOTYPE	12	12	fever
NCT001599269	NCT00159926_9_T4	BIOLOGICAL_PROCESS	11	11	vasoconstriction
NCT001599269	NCT00159926_9_T5	PHENOTYPE	15	15	diffuse
NCT001599269	NCT00159926_9_T6	PHENOTYPE	19	19	diffuse
NCT001599269	NCT00159926_9_T7	CELL	8	9	intercellular fluid
NCT001599269	NCT00159926_9_T8	PHENOTYPE	20	21	hemorrhagic diathesis
NCT001599269	NCT00159926_9_T9	PHENOTYPE	16	17	cerebral edema
NCT0015992611	NCT00159926_11_T0	PHENOTYPE	21	21	SIRS
NCT0015992611	NCT00159926_11_T1	PHENOTYPE	6	6	sequelae
NCT0015992611	NCT00159926_11_T2	GENE	8	8	CPB
NCT0015992614	NCT00159926_14_T0	CELL	21	21	cells
NCT0015992614	NCT00159926_14_T1	GENE	15	15	CPB
NCT0015992614	NCT00159926_14_T2	PHENOTYPE	27	27	circulation
NCT0015992615	NCT00159926_15_T0	PHENOTYPE	3	3	SIRS
NCT0015992615	NCT00159926_15_T1	PHENOTYPE	10	10	dysfunction
NCT0015992618	NCT00159926_18_T0	PHENOTYPE	0	0	Secondary
NCT0015992618	NCT00159926_18_T1	PHENOTYPE	16	16	complications
NCT0015992618	NCT00159926_18_T2	GENE	21	21	CPB
NCT0015992618	NCT00159926_18_T3	PHENOTYPE	1	1	Bleeding
NCT0015992619	NCT00159926_19_T0	GENE	13	13	bypass
NCT0015992619	NCT00159926_19_T1	ORGAN	11	12	coronary artery
NCT0015992623	NCT00159926_23_T0	PHENOTYPE	0	0	Anaesthesia
NCT0015992623	NCT00159926_23_T1	COMPOUND	15	15	cefuroxime
NCT001599392	NCT00159939_2_T0	GENE	3	3	has
NCT001599394	NCT00159939_4_T0	PHENOTYPE	13	13	ARDS
NCT001599395	NCT00159939_5_T0	PHENOTYPE	12	12	ARDS
NCT001599399	NCT00159939_9_T0	PHENOTYPE	21	21	severity
NCT001599399	NCT00159939_9_T1	PHENOTYPE	11	11	ARDS
NCT001599399	NCT00159939_9_T2	PHENOTYPE	23	24	respiratory failure
NCT0015993912	NCT00159939_12_T0	PHENOTYPE	43	43	severity
NCT0015993912	NCT00159939_12_T1	PHENOTYPE	45	45	ARDS
NCT0015993919	NCT00159939_19_T0	PHENOTYPE	12	12	Center
NCT0015993923	NCT00159939_23_T0	PHENOTYPE	3	3	SEVERE
NCT0015993923	NCT00159939_23_T1	GENE	8	8	GCP
NCT0015993924	NCT00159939_24_T0	PHENOTYPE	9	9	centers
NCT0015993924	NCT00159939_24_T1	PHENOTYPE	20	21	adverse events
NCT0015993925	NCT00159939_25_T0	PHENOTYPE	5	5	centers
NCT0015993928	NCT00159939_28_T0	PHENOTYPE	34	34	recruitment
NCT0015993928	NCT00159939_28_T1	PHENOTYPE	25	25	centers
NCT0015993932	NCT00159939_32_T0	GENE	13	13	al
NCT0015993935	NCT00159939_35_T0	GENE	14	14	San
NCT0015993939	NCT00159939_39_T0	PHENOTYPE	3	3	recalling
NCT0015993948	NCT00159939_48_T0	GENE	0	0	Del
NCT001599520	NCT00159952_0_T0	PHENOTYPE	2	2	Hyperglycemia
NCT001599520	NCT00159952_0_T1	GENE	4	4	PAI-1
NCT001599520	NCT00159952_0_T2	PHENOTYPE	12	13	Severe Sepsis
NCT001599520	NCT00159952_0_T3	PHENOTYPE	15	16	Septic Shock
NCT001599522	NCT00159952_2_T0	PHENOTYPE	2	2	secondary
NCT001599522	NCT00159952_2_T1	GENE	12	12	insulin
NCT001599522	NCT00159952_2_T2	PHENOTYPE	16	16	dysfunction
NCT0015995213	NCT00159952_13_T0	PHENOTYPE	18	18	ventilation
NCT0015995213	NCT00159952_13_T1	GENE	3	3	has
NCT0015995213	NCT00159952_13_T2	PHENOTYPE	16	17	tidal volume
NCT0015995217	NCT00159952_17_T0	GENE	16	16	IL6
NCT0015995217	NCT00159952_17_T1	GENE	14	14	TNF
NCT0015995220	NCT00159952_20_T0	GENE	2	2	has
NCT0015995234	NCT00159952_34_T0	PHENOTYPE	9	9	dysfunction
NCT0015995236	NCT00159952_36_T0	GENE	2	2	has
NCT0015995238	NCT00159952_38_T0	GENE	9	9	2.3
NCT0015995238	NCT00159952_38_T1	PHENOTYPE	18	19	septic shock
NCT0015995238	NCT00159952_38_T2	PHENOTYPE	15	16	severe sepsis
NCT0015995241	NCT00159952_41_T0	GENE	6	6	insulin
NCT0015995243	NCT00159952_43_T0	GENE	9	9	insulin
NCT0015995247	NCT00159952_47_T0	GENE	4	4	II
NCT0015995247	NCT00159952_47_T1	GENE	6	6	II
NCT0015995247	NCT00159952_47_T2	PHENOTYPE	1	1	Acute
NCT0015995247	NCT00159952_47_T3	GENE	5	5	SAPS
NCT0015995247	NCT00159952_47_T4	PHENOTYPE	2	2	Physiology
NCT0015995248	NCT00159952_48_T0	PHENOTYPE	7	7	severity
NCT0015995248	NCT00159952_48_T1	PHENOTYPE	2	2	Acute
NCT0015995248	NCT00159952_48_T2	PHENOTYPE	3	3	Physiology
NCT0015995250	NCT00159952_50_T0	PHENOTYPE	1	1	Sepsis
NCT0015995250	NCT00159952_50_T1	PHENOTYPE	2	3	Organ Failure
NCT0015995251	NCT00159952_51_T0	PHENOTYPE	6	6	dysfunction
NCT0015995254	NCT00159952_54_T0	GENE	9	9	1/6
NCT0015995256	NCT00159952_56_T0	PHENOTYPE	1	1	circulatory
NCT0015995256	NCT00159952_56_T1	PHENOTYPE	10	10	dysfunction
NCT0015995258	NCT00159952_58_T0	GENE	0	0	PAI-1
NCT0015995259	NCT00159952_59_T0	GENE	0	0	PAI
NCT0015995260	NCT00159952_60_T0	GENE	0	0	tPA
NCT0015995262	NCT00159952_62_T0	GENE	1	1	fragment
NCT0015995264	NCT00159952_64_T0	GENE	2	2	TAT
NCT0015995266	NCT00159952_66_T0	GENE	2	2	XII
NCT0015995267	NCT00159952_67_T0	GENE	3	3	bradykinin
NCT0015995267	NCT00159952_67_T1	BIOLOGICAL_PROCESS	0	0	Metabolism
NCT0015995269	NCT00159952_69_T0	GENE	3	3	CRP
NCT0015995270	NCT00159952_70_T0	GENE	0	0	Interleukin-6
NCT0015995270	NCT00159952_70_T1	GENE	1	1	IL-6
NCT0015995271	NCT00159952_71_T0	GENE	3	3	TNF
NCT0015995271	NCT00159952_71_T1	MOLECULAR_FUNCTION	0	2	Tumor necrosis factor
NCT0015995272	NCT00159952_72_T0	GENE	0	0	C3a
NCT0015995273	NCT00159952_73_T0	PHENOTYPE	4	4	SEVERE
NCT0015995273	NCT00159952_73_T1	GENE	9	9	GCP
NCT0015995274	NCT00159952_74_T0	PHENOTYPE	9	9	centers
NCT0015995274	NCT00159952_74_T1	PHENOTYPE	20	21	adverse events
NCT0015995278	NCT00159952_78_T0	GENE	2	2	has
NCT0015995286	NCT00159952_86_T0	PHENOTYPE	3	3	recalling
NCT0015995288	NCT00159952_88_T0	PHENOTYPE	10	10	Sepsis
NCT0015995289	NCT00159952_89_T0	GENE	3	3	69
NCT0015995291	NCT00159952_91_T0	GENE	2	2	de
NCT0015995292	NCT00159952_92_T0	PHENOTYPE	10	10	SEPSIS
NCT0015995292	NCT00159952_92_T1	GENE	7	7	al
NCT0015995292	NCT00159952_92_T2	GENE	6	6	et
NCT0015995292	NCT00159952_92_T3	PHENOTYPE	20	20	SIRS
NCT0015995292	NCT00159952_92_T4	PHENOTYPE	21	21	sepsis
NCT0015995292	NCT00159952_92_T5	PHENOTYPE	25	26	septic shock
NCT0015995292	NCT00159952_92_T6	PHENOTYPE	22	23	severe sepsis
NCT0015995296	NCT00159952_96_T0	GENE	13	13	al
NCT0015995296	NCT00159952_96_T1	GENE	12	12	et
NCT0015995296	NCT00159952_96_T2	PHENOTYPE	24	25	septic shock
NCT0015995296	NCT00159952_96_T3	PHENOTYPE	21	22	severe sepsis
NCT0015995297	NCT00159952_97_T0	GENE	7	7	345
NCT0015995299	NCT00159952_99_T0	GENE	7	7	342
NCT00159952100	NCT00159952_100_T0	GENE	14	14	al
NCT00159952100	NCT00159952_100_T1	GENE	13	13	et
NCT00159952100	NCT00159952_100_T2	COMPOUND	22	22	hydrocortisone
NCT00159952100	NCT00159952_100_T3	GENE	7	7	PE
NCT00159952100	NCT00159952_100_T4	COMPOUND	24	24	fludrocortisone
NCT00159952100	NCT00159952_100_T5	PHENOTYPE	30	31	septic shock
NCT00159952101	NCT00159952_101_T0	GENE	2	2	288
NCT00159952101	NCT00159952_101_T1	GENE	0	0	JAMA
NCT00159952102	NCT00159952_102_T0	GENE	5	5	TP
NCT00159952102	NCT00159952_102_T1	GENE	9	9	CA
NCT00159952102	NCT00159952_102_T2	GENE	11	11	RA
NCT00159952103	NCT00159952_103_T0	PHENOTYPE	11	12	severe sepsis
NCT00159952104	NCT00159952_104_T0	GENE	7	7	317
NCT00159952107	NCT00159952_107_T0	GENE	1	1	de
NCT00159952107	NCT00159952_107_T1	GENE	0	0	Van
NCT00159952107	NCT00159952_107_T2	GENE	17	17	insulin
NCT00159952107	NCT00159952_107_T3	GENE	15	15	al
NCT00159952107	NCT00159952_107_T4	GENE	14	14	et
NCT00159952107	NCT00159952_107_T5	PHENOTYPE	21	22	critically ill
NCT00159952108	NCT00159952_108_T0	GENE	3	3	med
NCT00159952108	NCT00159952_108_T1	GENE	1	1	Engl
NCT00159952109	NCT00159952_109_T0	GENE	9	9	II
NCT00159952109	NCT00159952_109_T1	PHENOTYPE	11	11	severity
NCT00159952109	NCT00159952_109_T2	GENE	5	5	DP
NCT00159952110	NCT00159952_110_T0	GENE	4	4	13
NCT00159952110	NCT00159952_110_T1	GENE	2	2	Med
NCT00159952111	NCT00159952_111_T0	GENE	2	2	de
NCT00159952112	NCT00159952_112_T0	PHENOTYPE	3	3	sepsis
NCT00159952113	NCT00159952_113_T0	GENE	2	2	Med
NCT00159952115	NCT00159952_115_T0	GENE	0	0	Br
NCT00159952115	NCT00159952_115_T1	COMPOUND	4	4	2
NCT00159952115	NCT00159952_115_T2	GENE	1	1	Med
NCT00159952116	NCT00159952_116_T0	GENE	2	2	Yan
NCT00159952116	NCT00159952_116_T1	GENE	3	3	SB
NCT00159952116	NCT00159952_116_T2	GENE	6	6	Mira
NCT00159952117	NCT00159952_117_T0	GENE	1	1	thrombomodulin
NCT00159952117	NCT00159952_117_T1	ORGAN	2	2	plasma
NCT00159952117	NCT00159952_117_T2	PHENOTYPE	13	13	sepsis
NCT00159952117	NCT00159952_117_T3	GENE	4	5	protein C
NCT00159952117	NCT00159952_117_T4	MOLECULAR_FUNCTION	9	11	activated protein C
NCT00159952118	NCT00159952_118_T0	GENE	2	2	Med
NCT00159952119	NCT00159952_119_T0	GENE	5	5	par
NCT00159952121	NCT00159952_121_T0	GENE	0	0	ICH
NCT00159952125	NCT00159952_125_T0	PHENOTYPE	1	1	hypotension
NCT001599654	NCT00159965_4_T0	PHENOTYPE	0	0	Secondary
NCT001599654	NCT00159965_4_T1	PHENOTYPE	8	8	impulsivity
NCT001599655	NCT00159965_5_T0	PHENOTYPE	7	7	electroencephalogram
NCT001599655	NCT00159965_5_T1	PHENOTYPE	32	32	symptoms
NCT001599655	NCT00159965_5_T2	GENE	4	4	NES
NCT001599655	NCT00159965_5_T3	GENE	29	29	NES
NCT0015996510	NCT00159965_10_T0	PHENOTYPE	22	22	seizure
NCT0015996512	NCT00159965_12_T0	PHENOTYPE	4	4	seizure
NCT0015996512	NCT00159965_12_T1	PHENOTYPE	11	11	seizure
NCT0015996514	NCT00159965_14_T0	COMPOUND	22	22	sertraline
NCT001599782	NCT00159978_2_T0	PHENOTYPE	5	5	tumor
NCT001599783	NCT00159978_3_T0	PHENOTYPE	7	7	tumor
NCT001599785	NCT00159978_5_T0	PHENOTYPE	5	5	hypoxia
NCT001599785	NCT00159978_5_T1	PHENOTYPE	12	12	proliferation
NCT001599786	NCT00159978_6_T0	PHENOTYPE	1	1	suffering
NCT001599786	NCT00159978_6_T1	PHENOTYPE	3	6	head and neck cancer
NCT001599788	NCT00159978_8_T0	PHENOTYPE	12	12	enabling
NCT001599788	NCT00159978_8_T1	PHENOTYPE	17	17	tumor
NCT0015997812	NCT00159978_12_T0	COMPOUND	3	3	FMISO
NCT0015997813	NCT00159978_13_T0	COMPOUND	8	8	pimonidazole
NCT0015997813	NCT00159978_13_T1	GENE	17	17	ml
NCT001599915	NCT00159991_5_T0	ORGAN	11	11	grafts
NCT001599916	NCT00159991_6_T0	ORGAN	5	5	grafts
NCT001599919	NCT00159991_9_T0	PHENOTYPE	3	3	bilateral
NCT001599919	NCT00159991_9_T1	ORGAN	14	14	grafts
NCT001599919	NCT00159991_9_T2	GENE	6	6	has
NCT001599919	NCT00159991_9_T3	GENE	4	4	IMA
NCT001599919	NCT00159991_9_T4	GENE	13	13	IMA
NCT0015999116	NCT00159991_16_T0	ORGAN	0	0	Graft
NCT0015999129	NCT00159991_29_T0	PHENOTYPE	1	1	anaesthesia
NCT0015999129	NCT00159991_29_T1	PHENOTYPE	6	6	anaesthesia
NCT0015999132	NCT00159991_32_T0	PHENOTYPE	0	0	Distal
NCT0015999134	NCT00159991_34_T0	PHENOTYPE	19	19	complications
NCT0015999134	NCT00159991_34_T1	PHENOTYPE	8	8	infarction
NCT0015999139	NCT00159991_39_T0	ORGAN	11	11	graft
NCT0015999140	NCT00159991_40_T0	GENE	13	13	bypass
NCT0015999140	NCT00159991_40_T1	ORGAN	14	14	graft
NCT0015999140	NCT00159991_40_T2	ORGAN	10	11	radial artery
NCT0015999142	NCT00159991_42_T0	ORGAN	10	10	grafts
NCT0015999142	NCT00159991_42_T1	GENE	9	9	RA
NCT0015999142	NCT00159991_42_T2	GENE	18	19	type 2
NCT001600041	NCT00160004_1_T0	GENE	6	6	2.3
NCT001600045	NCT00160004_5_T0	PHENOTYPE	16	16	weakness
NCT001600045	NCT00160004_5_T1	PHENOTYPE	20	20	progression
NCT001600045	NCT00160004_5_T2	PHENOTYPE	22	23	muscle weakness
NCT001600047	NCT00160004_7_T0	PHENOTYPE	1	1	secondary
NCT001600047	NCT00160004_7_T1	PHENOTYPE	13	13	weakness
NCT001600047	NCT00160004_7_T2	PHENOTYPE	24	24	fatigue
NCT001600047	NCT00160004_7_T3	PHENOTYPE	26	28	quality of life
NCT001600174	NCT00160017_4_T0	PHENOTYPE	6	6	complications
NCT001600434	NCT00160043_4_T0	GENE	1	1	AG
NCT001600434	NCT00160043_4_T1	GENE	10	10	AG
NCT001600434	NCT00160043_4_T2	GENE	14	14	AG
NCT001600434	NCT00160043_4_T3	GENE	3	3	has
NCT001600560	NCT00160056_0_T0	PHENOTYPE	7	7	Sensitivity
NCT001600560	NCT00160056_0_T1	PHENOTYPE	4	4	Hypoglycaemia
NCT001600562	NCT00160056_2_T0	PHENOTYPE	4	4	symptoms
NCT001600562	NCT00160056_2_T1	PHENOTYPE	6	6	hypoglycemia
NCT001600563	NCT00160056_3_T0	PHENOTYPE	19	19	unawareness
NCT001600563	NCT00160056_3_T1	PHENOTYPE	24	24	unawareness
NCT001600563	NCT00160056_3_T2	PHENOTYPE	66	66	resistant
NCT001600563	NCT00160056_3_T3	PHENOTYPE	50	50	susceptible
NCT001600563	NCT00160056_3_T4	COMPOUND	44	44	arginine
NCT001600563	NCT00160056_3_T5	GENE	5	5	receptor
NCT001600563	NCT00160056_3_T6	GENE	36	36	receptor
NCT001600563	NCT00160056_3_T7	COMPOUND	61	61	glycine
NCT001600563	NCT00160056_3_T8	PHENOTYPE	18	18	hypoglycemia
NCT001600563	NCT00160056_3_T9	PHENOTYPE	23	23	hypoglycemia
NCT001600565	NCT00160056_5_T0	PHENOTYPE	10	10	hypoglycemia
NCT001600567	NCT00160056_7_T0	PHENOTYPE	11	11	resistant
NCT001600568	NCT00160056_8_T0	PHENOTYPE	4	4	hypoglycemia
NCT001600568	NCT00160056_8_T1	GENE	19	19	reduced
NCT001600568	NCT00160056_8_T2	COMPOUND	11	11	isoproterenol
NCT001600568	NCT00160056_8_T3	ORGAN	7	7	heart
NCT001600693	NCT00160069_3_T0	GENE	1	1	AG
NCT001600693	NCT00160069_3_T1	GENE	10	10	AG
NCT001600693	NCT00160069_3_T2	GENE	14	14	AG
NCT001600693	NCT00160069_3_T3	GENE	3	3	has
NCT001600826	NCT00160082_6_T0	PHENOTYPE	3	3	secondary
NCT0016008211	NCT00160082_11_T0	PHENOTYPE	1	1	polio
NCT0016008211	NCT00160082_11_T1	ORGAN	6	7	lower extremities
NCT0016008212	NCT00160082_12_T0	ORGAN	7	7	extremity
NCT0016008216	NCT00160082_16_T0	GENE	32	32	grip
NCT0016008216	NCT00160082_16_T1	GENE	3	3	had
NCT0016008216	NCT00160082_16_T2	GENE	11	11	had
NCT0016008220	NCT00160082_20_T0	COMPOUND	3	3	BMI
NCT0016008222	NCT00160082_22_T0	GENE	7	7	had
NCT0016008224	NCT00160082_24_T0	COMPOUND	12	12	glucose
NCT0016008224	NCT00160082_24_T1	COMPOUND	14	14	fructose
NCT0016008224	NCT00160082_24_T2	COMPOUND	11	11	sorbitol
NCT0016008226	NCT00160082_26_T0	PHENOTYPE	0	2	Selective IgA deficiency
NCT0016008228	NCT00160082_28_T0	PHENOTYPE	5	5	aids
NCT0016008228	NCT00160082_28_T1	PHENOTYPE	0	2	Inability to walk
NCT0016008230	NCT00160082_30_T0	PHENOTYPE	2	2	malignancy
NCT0016008230	NCT00160082_30_T1	PHENOTYPE	6	6	malignancy
NCT0016008230	NCT00160082_30_T2	PHENOTYPE	10	10	malignancy
NCT0016008240	NCT00160082_40_T0	BIOLOGICAL_PROCESS	2	2	lactation
NCT0016008241	NCT00160082_41_T0	PHENOTYPE	0	0	Hepatitis
NCT0016008241	NCT00160082_41_T1	PHENOTYPE	2	2	HIV
NCT0016008243	NCT00160082_43_T0	GENE	1	1	kinase
NCT0016008243	NCT00160082_43_T1	GENE	2	2	10
NCT0016008244	NCT00160082_44_T0	PHENOTYPE	33	33	arteriosclerosis
NCT0016008244	NCT00160082_44_T1	COMPOUND	48	48	prednisone
NCT0016008244	NCT00160082_44_T2	PHENOTYPE	36	37	psychiatric disorder
NCT0016008244	NCT00160082_44_T3	PHENOTYPE	29	30	cardiovascular disease
NCT001600955	NCT00160095_5_T0	PHENOTYPE	12	12	proliferation
NCT001600955	NCT00160095_5_T1	PHENOTYPE	9	9	tumor
NCT001600955	NCT00160095_5_T2	PHENOTYPE	21	21	tumor
NCT001600959	NCT00160095_9_T0	PHENOTYPE	13	13	proliferation
NCT0016009515	NCT00160095_15_T0	PHENOTYPE	19	19	hypoxic
NCT0016009515	NCT00160095_15_T1	COMPOUND	17	17	nicotinamide
NCT0016009515	NCT00160095_15_T2	COMPOUND	15	15	carbogen
NCT0016009515	NCT00160095_15_T3	PHENOTYPE	28	31	carcinoma of the larynx
NCT0016009517	NCT00160095_17_T0	PHENOTYPE	38	38	hypoxia
NCT0016009517	NCT00160095_17_T1	PHENOTYPE	11	11	proliferation
NCT0016009519	NCT00160095_19_T0	PHENOTYPE	13	13	hypoxic
NCT0016009519	NCT00160095_19_T1	BIOLOGICAL_PROCESS	18	18	S-phase
NCT0016009519	NCT00160095_19_T2	COMPOUND	15	15	pimonidazole
NCT0016009520	NCT00160095_20_T0	PHENOTYPE	14	14	hypoxia
NCT0016009520	NCT00160095_20_T1	PHENOTYPE	16	16	proliferation
NCT0016009520	NCT00160095_20_T2	COMPOUND	22	22	pimonidazole
NCT0016009522	NCT00160095_22_T0	PHENOTYPE	25	25	tumors
NCT0016009525	NCT00160095_25_T0	PHENOTYPE	25	25	strategies
NCT0016009525	NCT00160095_25_T1	PHENOTYPE	6	6	tumor
NCT0016009525	NCT00160095_25_T2	PHENOTYPE	21	21	tumor
NCT001601341	NCT00160134_1_T0	COMPOUND	11	11	furosemide
NCT001601600	NCT00160160_0_T0	PHENOTYPE	8	10	Type II Diabetes
NCT001601860	NCT00160186_0_T0	COMPOUND	15	15	BMI
NCT001602120	NCT00160212_0_T0	PHENOTYPE	12	12	Hypertension
NCT001602250	NCT00160225_0_T0	PHENOTYPE	26	26	Hypertension
NCT001602250	NCT00160225_0_T1	PHENOTYPE	22	22	Nephropathy
NCT001602511	NCT00160251_1_T0	PHENOTYPE	1	1	secondary
NCT001602511	NCT00160251_1_T1	COMPOUND	17	17	boceprevir
NCT001602511	NCT00160251_1_T2	COMPOUND	7	7	ribavirin
NCT001602901	NCT00160290_1_T0	COMPOUND	12	12	lactulose
NCT001602901	NCT00160290_1_T1	PHENOTYPE	4	6	quality of life
NCT001603030	NCT00160303_0_T0	PHENOTYPE	7	8	Tennis Elbow
NCT0016030314	NCT00160303_14_T0	PHENOTYPE	7	8	lateral epicondylitis
NCT0016030315	NCT00160303_15_T0	PHENOTYPE	7	8	lateral epicondylitis
NCT0016030318	NCT00160303_18_T0	PHENOTYPE	6	7	lateral epicondylitis
NCT0016030319	NCT00160303_19_T0	PHENOTYPE	11	11	inflammation
NCT0016030319	NCT00160303_19_T1	PHENOTYPE	16	16	tendinopathies
NCT0016030319	NCT00160303_19_T2	PHENOTYPE	15	15	chronic
NCT0016030319	NCT00160303_19_T3	PHENOTYPE	19	20	lateral epicondylitis
NCT0016030320	NCT00160303_20_T0	PHENOTYPE	2	2	inflammation
NCT0016030323	NCT00160303_23_T0	PHENOTYPE	11	11	hyperglycemia
NCT0016030323	NCT00160303_23_T1	BIOLOGICAL_PROCESS	9	9	pigmentation
NCT0016030323	NCT00160303_23_T2	PHENOTYPE	8	8	atrophy
NCT0016030325	NCT00160303_25_T0	GENE	6	6	al
NCT0016030325	NCT00160303_25_T1	GENE	5	5	et
NCT0016030325	NCT00160303_25_T2	PHENOTYPE	24	25	lateral epicondylitis
NCT0016030326	NCT00160303_26_T0	GENE	2	2	al
NCT0016030326	NCT00160303_26_T1	GENE	1	1	et
NCT0016030326	NCT00160303_26_T2	PHENOTYPE	20	21	lateral epicondylitis
NCT0016030327	NCT00160303_27_T0	PHENOTYPE	22	23	lateral epicondylitis
NCT0016030328	NCT00160303_28_T0	PHENOTYPE	13	13	injuries
NCT0016030329	NCT00160303_29_T0	ORGAN	35	35	tendons
NCT0016030329	NCT00160303_29_T1	ORGAN	37	37	joints
NCT0016030329	NCT00160303_29_T2	TISSUE	34	34	ligaments
NCT0016030329	NCT00160303_29_T3	BIOLOGICAL_PROCESS	19	20	wound healing
NCT0016030332	NCT00160303_32_T0	GENE	9	9	has
NCT0016030333	NCT00160303_33_T0	ORGAN	16	17	nerve endings
NCT0016030333	NCT00160303_33_T1	TISSUE	19	20	articular ligaments
NCT0016030339	NCT00160303_39_T0	GENE	11	11	al
NCT0016030339	NCT00160303_39_T1	TISSUE	7	7	ligaments
NCT0016030339	NCT00160303_39_T2	TISSUE	30	30	ligaments
NCT0016030339	NCT00160303_39_T3	GENE	10	10	et
NCT0016030340	NCT00160303_40_T0	PHENOTYPE	14	14	proliferation
NCT0016030340	NCT00160303_40_T1	GENE	6	6	al
NCT0016030340	NCT00160303_40_T2	GENE	5	5	et
NCT0016030340	NCT00160303_40_T3	TISSUE	13	13	ligament
NCT0016030342	NCT00160303_42_T0	GENE	28	28	had
NCT0016030342	NCT00160303_42_T1	GENE	5	5	al
NCT0016030342	NCT00160303_42_T2	TISSUE	24	24	ligaments
NCT0016030342	NCT00160303_42_T3	GENE	4	4	et
NCT0016030346	NCT00160303_46_T0	COMPOUND	5	5	dextrose
NCT0016030346	NCT00160303_46_T1	COMPOUND	6	6	phenol
NCT0016030346	NCT00160303_46_T2	GENE	2	2	al
NCT0016030346	NCT00160303_46_T3	TISSUE	22	22	ligaments
NCT0016030346	NCT00160303_46_T4	GENE	1	1	et
NCT0016030348	NCT00160303_48_T0	COMPOUND	10	10	dextrose
NCT0016030348	NCT00160303_48_T1	GENE	2	2	al
NCT0016030348	NCT00160303_48_T2	GENE	1	1	et
NCT0016030348	NCT00160303_48_T3	PHENOTYPE	21	22	knee osteoarthritis
NCT0016030354	NCT00160303_54_T0	ORGAN	17	17	tendon
NCT0016030354	NCT00160303_54_T1	PHENOTYPE	26	26	proliferation
NCT0016030354	NCT00160303_54_T2	PHENOTYPE	1	2	lateral epicondylitis
NCT001603292	NCT00160329_2_T0	PHENOTYPE	15	15	hyperlipidemia
NCT001603292	NCT00160329_2_T1	GENE	40	40	ATV
NCT001603292	NCT00160329_2_T2	PHENOTYPE	18	18	HIV
NCT001603292	NCT00160329_2_T3	COMPOUND	7	7	ritonavir
NCT001603292	NCT00160329_2_T4	COMPOUND	31	31	ritonavir
NCT001603292	NCT00160329_2_T5	COMPOUND	46	46	ritonavir
NCT001603292	NCT00160329_2_T6	GENE	33	33	PI
NCT001603292	NCT00160329_2_T7	PHENOTYPE	19	19	viremia
NCT001603294	NCT00160329_4_T0	COMPOUND	6	6	ARVs
NCT001603297	NCT00160329_7_T0	GENE	7	7	CD4
NCT0016032910	NCT00160329_10_T0	GENE	22	22	CD4
NCT0016032910	NCT00160329_10_T1	PHENOTYPE	7	7	HIV
NCT0016032910	NCT00160329_10_T2	PHENOTYPE	15	15	suppression
NCT0016032911	NCT00160329_11_T0	GENE	36	36	CD4
NCT0016032911	NCT00160329_11_T1	CELL	37	37	cells
NCT0016032911	NCT00160329_11_T2	PHENOTYPE	19	19	HIV
NCT0016032911	NCT00160329_11_T3	PHENOTYPE	18	18	resistant
NCT0016032913	NCT00160329_13_T0	GENE	8	8	CD4
NCT0016032913	NCT00160329_13_T1	GENE	1	1	has
NCT0016032913	NCT00160329_13_T2	PHENOTYPE	15	15	viremia
NCT0016032914	NCT00160329_14_T0	GENE	10	10	PI
NCT0016032915	NCT00160329_15_T0	COMPOUND	9	9	LPV/r
NCT0016032915	NCT00160329_15_T1	GENE	17	17	1.3
NCT0016032916	NCT00160329_16_T0	PHENOTYPE	14	15	cardiovascular morbidity
NCT0016032917	NCT00160329_17_T0	PHENOTYPE	9	10	cardiovascular morbidity
NCT0016032917	NCT00160329_17_T1	PHENOTYPE	15	16	HIV infection
NCT0016032918	NCT00160329_18_T0	PHENOTYPE	8	8	toxicities
NCT0016032919	NCT00160329_19_T0	GENE	21	21	ATV
NCT0016032919	NCT00160329_19_T1	PHENOTYPE	14	14	toxicities
NCT0016032919	NCT00160329_19_T2	GENE	25	25	PI
NCT0016032920	NCT00160329_20_T0	COMPOUND	3	3	atazanavir
NCT0016032921	NCT00160329_21_T0	COMPOUND	13	13	LPV/r
NCT0016032921	NCT00160329_21_T1	GENE	5	5	ATV
NCT0016032922	NCT00160329_22_T0	GENE	13	13	ATV
NCT0016032922	NCT00160329_22_T1	PHENOTYPE	4	5	drug levels
NCT0016032932	NCT00160329_32_T0	GENE	0	0	Protease
NCT0016032932	NCT00160329_32_T1	GENE	2	2	PI
NCT0016032948	NCT00160329_48_T0	PHENOTYPE	3	3	azoospermia
NCT0016032949	NCT00160329_49_T0	PHENOTYPE	5	5	menopausal
NCT0016032949	NCT00160329_49_T1	GENE	0	0	FSH
NCT0016032953	NCT00160329_53_T0	PHENOTYPE	7	8	mental health
NCT0016032957	NCT00160329_57_T0	PHENOTYPE	7	7	acute
NCT0016032957	NCT00160329_57_T1	PHENOTYPE	8	9	opportunistic infection
NCT0016032958	NCT00160329_58_T0	PHENOTYPE	0	1	Chronic infections
NCT0016032966	NCT00160329_66_T0	GENE	6	6	IFN-alpha
NCT0016032966	NCT00160329_66_T1	GENE	4	4	IL-2
NCT0016032968	NCT00160329_68_T0	GENE	4	4	GM-CSF
NCT0016032970	NCT00160329_70_T0	GENE	5	5	3.4
NCT0016032970	NCT00160329_70_T1	PHENOTYPE	6	7	laboratory abnormality
NCT0016032974	NCT00160329_74_T0	PHENOTYPE	1	2	heart block
NCT0016032975	NCT00160329_75_T0	PHENOTYPE	2	3	heart block
NCT0016032976	NCT00160329_76_T0	PHENOTYPE	0	1	Pre-excitation syndromes
NCT0016032980	NCT00160329_80_T0	PHENOTYPE	2	2	syncope
NCT001603420	NCT00160342_0_T0	PHENOTYPE	9	10	Hot Flushes
NCT001603426	NCT00160342_6_T0	COMPOUND	11	11	progestins
NCT001603551	NCT00160355_1_T0	CELL	10	10	leukocyte
NCT001603553	NCT00160355_3_T0	PHENOTYPE	17	17	conditioning
NCT001603553	NCT00160355_3_T1	PHENOTYPE	6	6	toxicities
NCT001603553	NCT00160355_3_T2	GENE	11	11	reduced
NCT001603553	NCT00160355_3_T3	ORGAN	5	5	transplant
NCT001603554	NCT00160355_4_T0	CELL	8	9	stem cells
NCT001603554	NCT00160355_4_T1	CELL	13	15	white blood cells
NCT001603558	NCT00160355_8_T0	PHENOTYPE	20	20	toxicity
NCT001603558	NCT00160355_8_T1	PHENOTYPE	7	7	engraftment
NCT001603558	NCT00160355_8_T2	ORGAN	12	12	graft
NCT001603558	NCT00160355_8_T3	ORGAN	27	27	transplant
NCT001603680	NCT00160368_0_T0	COMPOUND	2	2	Potassium
NCT001603683	NCT00160368_3_T0	COMPOUND	5	6	potassium chloride
NCT001603685	NCT00160368_5_T0	COMPOUND	7	7	potassium
NCT001603685	NCT00160368_5_T1	COMPOUND	4	4	chloride
NCT001603685	NCT00160368_5_T2	GENE	8	8	has
NCT001603685	NCT00160368_5_T3	COMPOUND	18	19	potassium chloride
NCT001603686	NCT00160368_6_T0	ORGAN	25	25	kidney
NCT001603686	NCT00160368_6_T1	COMPOUND	13	13	potassium
NCT001603686	NCT00160368_6_T2	PHENOTYPE	39	39	osteoporosis
NCT001603686	NCT00160368_6_T3	ORGAN	21	22	cardiovascular system
NCT001603687	NCT00160368_7_T0	COMPOUND	11	11	potassium
NCT001603687	NCT00160368_7_T1	COMPOUND	29	29	potassium
NCT001603687	NCT00160368_7_T2	ORGAN	38	38	kidney
NCT001603687	NCT00160368_7_T3	COMPOUND	12	12	bicarbonate
NCT001603687	NCT00160368_7_T4	ORGAN	36	37	cardiovascular system
NCT001603687	NCT00160368_7_T5	COMPOUND	14	15	potassium chloride
NCT001603688	NCT00160368_8_T0	COMPOUND	4	4	potassium
NCT001603688	NCT00160368_8_T1	COMPOUND	5	5	bicarbonate
NCT001603688	NCT00160368_8_T2	COMPOUND	1	2	potassium chloride
NCT001603812	NCT00160381_2_T0	COMPOUND	13	13	asoprisnil
NCT001603812	NCT00160381_2_T1	COMPOUND	41	41	asoprisnil
NCT001603812	NCT00160381_2_T2	PHENOTYPE	32	33	uterine bleeding
NCT001603812	NCT00160381_2_T3	PHENOTYPE	36	37	uterine fibroids
NCT001603813	NCT00160381_3_T0	PHENOTYPE	5	6	uterine bleeding
NCT001603813	NCT00160381_3_T1	ORGAN	15	16	uterine artery
NCT001603944	NCT00160394_4_T0	PHENOTYPE	12	13	acne vulgaris
NCT0016039417	NCT00160394_17_T0	BIOLOGICAL_PROCESS	47	47	menarche
NCT0016039417	NCT00160394_17_T1	GENE	48	48	has
NCT0016039417	NCT00160394_17_T2	PHENOTYPE	27	29	negative pregnancy test
NCT0016039419	NCT00160394_19_T0	COMPOUND	2	2	androgen
NCT0016039421	NCT00160394_21_T0	PHENOTYPE	17	17	acne
NCT0016039425	NCT00160394_25_T0	PHENOTYPE	17	17	acne
NCT0016039427	NCT00160394_27_T0	ORGAN	10	10	liver
NCT0016039427	NCT00160394_27_T1	PHENOTYPE	4	4	diseases
NCT0016039427	NCT00160394_27_T2	PHENOTYPE	19	19	diseases
NCT0016039427	NCT00160394_27_T3	PHENOTYPE	6	6	severely
NCT0016039427	NCT00160394_27_T4	PHENOTYPE	14	15	neurological disease
NCT0016039430	NCT00160394_30_T0	PHENOTYPE	15	15	colitis
NCT0016039430	NCT00160394_30_T1	PHENOTYPE	5	6	regional enteritis
NCT0016039430	NCT00160394_30_T2	PHENOTYPE	8	9	ulcerative colitis
NCT0016039432	NCT00160394_32_T0	PHENOTYPE	6	6	photosensitivity
NCT0016039435	NCT00160394_35_T0	PHENOTYPE	15	15	recruitment
NCT001604074	NCT00160407_4_T0	GENE	19	19	San
NCT001604074	NCT00160407_4_T1	PHENOTYPE	0	0	Recruitment
NCT001604075	NCT00160407_5_T0	COMPOUND	41	41	orlistat
NCT001604075	NCT00160407_5_T1	COMPOUND	19	20	vitamin E
NCT001604075	NCT00160407_5_T2	COMPOUND	34	35	vitamin E
NCT001604075	NCT00160407_5_T3	PHENOTYPE	9	10	weight loss
NCT001604075	NCT00160407_5_T4	PHENOTYPE	30	31	weight loss
NCT001604078	NCT00160407_8_T0	GENE	19	19	TNF-alpha
NCT001604078	NCT00160407_8_T1	PHENOTYPE	10	10	inflammation
NCT001604078	NCT00160407_8_T2	PHENOTYPE	12	12	fibrosis
NCT001604079	NCT00160407_9_T0	ORGAN	1	1	liver
NCT001604203	NCT00160420_3_T0	PHENOTYPE	17	17	osteoporosis
NCT001604203	NCT00160420_3_T1	PHENOTYPE	14	15	hot flushes
NCT001604204	NCT00160420_4_T0	PHENOTYPE	22	22	endometriosis
NCT001604204	NCT00160420_4_T1	COMPOUND	12	12	asoprisnil
NCT001604205	NCT00160420_5_T0	ORGAN	9	9	endometrium
NCT001604205	NCT00160420_5_T1	PHENOTYPE	12	13	adverse events
NCT001604330	NCT00160433_0_T0	PHENOTYPE	16	16	Endometriosis
NCT001604334	NCT00160433_4_T0	PHENOTYPE	17	17	osteoporosis
NCT001604334	NCT00160433_4_T1	PHENOTYPE	14	15	hot flushes
NCT001604337	NCT00160433_7_T0	ORGAN	8	8	endometrium
NCT001604337	NCT00160433_7_T1	PHENOTYPE	11	12	adverse events
NCT001604463	NCT00160446_3_T0	PHENOTYPE	17	17	osteoporosis
NCT001604463	NCT00160446_3_T1	PHENOTYPE	14	15	hot flushes
NCT001604465	NCT00160446_5_T0	PHENOTYPE	6	6	endometriosis
NCT001604592	NCT00160459_2_T0	COMPOUND	13	13	asoprisnil
NCT001604592	NCT00160459_2_T1	PHENOTYPE	35	36	uterine fibroids
NCT001604725	NCT00160472_5_T0	PHENOTYPE	8	8	malignancy
NCT001604725	NCT00160472_5_T1	PHENOTYPE	20	20	malignancies
NCT001604725	NCT00160472_5_T2	PHENOTYPE	0	1	Ovarian cancer
NCT001604726	NCT00160472_6_T0	PHENOTYPE	8	9	ovarian cancer
NCT001604727	NCT00160472_7_T0	BIOLOGICAL_PROCESS	0	0	Angiogenesis
NCT001604727	NCT00160472_7_T1	PHENOTYPE	8	9	ovarian cancer
NCT001604729	NCT00160472_9_T0	PHENOTYPE	12	12	malignancies
NCT0016047210	NCT00160472_10_T0	GENE	3	3	VEGF
NCT0016047210	NCT00160472_10_T1	GENE	7	7	has
NCT0016047210	NCT00160472_10_T2	PHENOTYPE	23	24	ovarian cancers
NCT0016047213	NCT00160472_13_T0	PHENOTYPE	1	1	neovascularization
NCT0016047213	NCT00160472_13_T1	PHENOTYPE	6	6	malignancies
NCT0016047213	NCT00160472_13_T2	PHENOTYPE	10	11	ovarian cancer
NCT0016047213	NCT00160472_13_T3	TISSUE	23	24	smooth muscle
NCT0016047214	NCT00160472_14_T0	PHENOTYPE	24	25	benign tumors
NCT0016047214	NCT00160472_14_T1	TISSUE	6	8	vascular smooth muscle
NCT0016047215	NCT00160472_15_T0	ORGAN	24	24	microvessel
NCT0016047215	NCT00160472_15_T1	GENE	26	26	MVD
NCT0016047215	NCT00160472_15_T2	GENE	18	18	Cd34
NCT0016047215	NCT00160472_15_T3	PHENOTYPE	0	1	Malignant tumors
NCT0016047215	NCT00160472_15_T4	TISSUE	12	13	smooth muscle
NCT0016047215	NCT00160472_15_T5	PHENOTYPE	4	5	vascular resistance
NCT0016047215	NCT00160472_15_T6	GENE	13	14	muscle actin
NCT0016047217	NCT00160472_17_T0	PHENOTYPE	19	20	malignant tumors
NCT0016047218	NCT00160472_18_T0	PHENOTYPE	7	7	vascularization
NCT0016047218	NCT00160472_18_T1	PHENOTYPE	9	10	ovarian neoplasms
NCT0016047223	NCT00160472_23_T0	GENE	15	15	secreted
NCT0016047223	NCT00160472_23_T1	GENE	1	1	AVP
NCT0016047223	NCT00160472_23_T2	ORGAN	13	13	hypothalamus
NCT0016047223	NCT00160472_23_T3	MOLECULAR_FUNCTION	4	5	peptide hormone
NCT0016047223	NCT00160472_23_T4	ORGAN	18	20	posterior pituitary gland
NCT0016047226	NCT00160472_26_T0	COMPOUND	27	27	calcium
NCT0016047226	NCT00160472_26_T1	GENE	16	16	V1a
NCT0016047226	NCT00160472_26_T2	GENE	0	0	AVP
NCT0016047226	NCT00160472_26_T3	GENE	21	22	phospholipase A2
NCT0016047227	NCT00160472_27_T0	GENE	0	0	AVP
NCT0016047231	NCT00160472_31_T0	GENE	3	3	AVP
NCT0016047231	NCT00160472_31_T1	PHENOTYPE	11	11	hypertension
NCT0016047231	NCT00160472_31_T2	PHENOTYPE	20	20	hypertension
NCT0016047233	NCT00160472_33_T0	GENE	5	5	AVP
NCT0016047233	NCT00160472_33_T1	PHENOTYPE	10	10	hypertension
NCT0016047239	NCT00160472_39_T0	COMPOUND	12	12	calcium
NCT0016047239	NCT00160472_39_T1	GENE	4	4	AVP
NCT0016047242	NCT00160472_42_T0	PHENOTYPE	7	7	physiology
NCT0016047242	NCT00160472_42_T1	PHENOTYPE	10	10	constriction
NCT0016047242	NCT00160472_42_T2	PHENOTYPE	46	46	carcinogenesis
NCT0016047242	NCT00160472_42_T3	PHENOTYPE	42	42	vascularization
NCT0016047242	NCT00160472_42_T4	GENE	2	2	has
NCT0016047242	NCT00160472_42_T5	GENE	19	19	has
NCT0016047242	NCT00160472_42_T6	GENE	1	1	AVP
NCT0016047242	NCT00160472_42_T7	PHENOTYPE	44	45	ovarian cancer
NCT0016047242	NCT00160472_42_T8	GENE	38	39	angiogenic factor
NCT0016047243	NCT00160472_43_T0	GENE	18	18	receptor
NCT0016047243	NCT00160472_43_T1	GENE	13	13	AVP
NCT0016047243	NCT00160472_43_T2	PHENOTYPE	20	21	ovarian neoplasm
NCT0016047245	NCT00160472_45_T0	GENE	0	0	V1R
NCT0016047245	NCT00160472_45_T1	GENE	1	1	mRNA
NCT0016047247	NCT00160472_47_T0	GENE	3	3	mRNA
NCT0016047247	NCT00160472_47_T1	GENE	2	2	AVP
NCT0016047250	NCT00160472_50_T0	GENE	3	3	hormone
NCT0016047251	NCT00160472_51_T0	GENE	10	10	VP
NCT0016047251	NCT00160472_51_T1	GENE	16	16	AVP
NCT0016047251	NCT00160472_51_T2	ORGAN	23	24	blood vessels
NCT0016047251	NCT00160472_51_T3	PHENOTYPE	21	22	ovarian neoplasm
NCT0016047251	NCT00160472_51_T4	BIOLOGICAL_PROCESS	11	12	gene expression
NCT0016047253	NCT00160472_53_T0	ORGAN	11	11	ovaries
NCT0016047253	NCT00160472_53_T1	PHENOTYPE	0	0	PLAN
NCT0016047256	NCT00160472_56_T0	GENE	4	4	had
NCT0016047257	NCT00160472_57_T0	PHENOTYPE	4	4	malignancy
NCT0016047257	NCT00160472_57_T1	PHENOTYPE	11	11	malignancy
NCT0016047259	NCT00160472_59_T0	GENE	27	27	receptor
NCT0016047259	NCT00160472_59_T1	GENE	26	26	vasopressin
NCT0016047259	NCT00160472_59_T2	GENE	1	1	FOR
NCT0016047259	NCT00160472_59_T3	GENE	28	28	mRNA
NCT0016047259	NCT00160472_59_T4	GENE	20	20	AVP
NCT0016047259	NCT00160472_59_T5	GENE	24	24	AVP
NCT0016047262	NCT00160472_62_T0	PHENOTYPE	1	1	tumor
NCT0016047262	NCT00160472_62_T1	GENE	6	6	separated
NCT0016047262	NCT00160472_62_T2	TISSUE	10	11	connective tissue
NCT0016047264	NCT00160472_64_T0	GENE	10	10	receptor
NCT0016047264	NCT00160472_64_T1	GENE	9	9	vasopressin
NCT0016047264	NCT00160472_64_T2	PHENOTYPE	20	20	Physiology
NCT0016047264	NCT00160472_64_T3	GENE	11	11	mRNA
NCT0016047264	NCT00160472_64_T4	GENE	3	3	AVP
NCT0016047264	NCT00160472_64_T5	GENE	7	7	AVP
NCT0016047266	NCT00160472_66_T0	GENE	25	25	receptor
NCT0016047266	NCT00160472_66_T1	GENE	6	6	V1R
NCT0016047266	NCT00160472_66_T2	GENE	15	15	V1R
NCT0016047266	NCT00160472_66_T3	GENE	2	2	V2R
NCT0016047266	NCT00160472_66_T4	GENE	7	7	mRNA
NCT0016047266	NCT00160472_66_T5	PHENOTYPE	19	20	ovarian neoplasms
NCT0016047267	NCT00160472_67_T0	GENE	24	24	kit
NCT0016047267	NCT00160472_67_T1	GENE	11	11	TM
NCT0016047267	NCT00160472_67_T2	ORGAN	1	1	artery
NCT0016047267	NCT00160472_67_T3	GENE	27	27	CA
NCT0016047268	NCT00160472_68_T0	GENE	1	1	mRNA
NCT0016047268	NCT00160472_68_T1	GENE	3	3	mRNA
NCT0016047268	NCT00160472_68_T2	GENE	7	7	mRNA
NCT0016047268	NCT00160472_68_T3	GENE	2	2	V1R
NCT0016047268	NCT00160472_68_T4	GENE	0	0	VP
NCT0016047268	NCT00160472_68_T5	GENE	22	22	CA
NCT0016047268	NCT00160472_68_T6	GENE	14	14	PCR
NCT0016047268	NCT00160472_68_T7	GENE	5	6	beta actin
NCT0016047269	NCT00160472_69_T0	COMPOUND	20	20	Platinum
NCT0016047269	NCT00160472_69_T1	GENE	12	12	TM
NCT0016047269	NCT00160472_69_T2	GENE	6	6	cDNA
NCT0016047269	NCT00160472_69_T3	GENE	15	15	PCR
NCT0016047269	NCT00160472_69_T4	BIOLOGICAL_PROCESS	0	1	Reverse transcription
NCT0016047270	NCT00160472_70_T0	GENE	14	14	cDNA
NCT0016047270	NCT00160472_70_T1	ORGAN	12	13	blood vessel
NCT0016047272	NCT00160472_72_T0	GENE	14	14	3.3
NCT0016047272	NCT00160472_72_T1	GENE	5	5	mRNA
NCT0016047272	NCT00160472_72_T2	GENE	30	30	gel
NCT0016047275	NCT00160472_75_T0	COMPOUND	16	16	Acetic
NCT0016047275	NCT00160472_75_T1	COMPOUND	15	15	N
NCT0016047278	NCT00160472_78_T0	COMPOUND	16	16	HCl
NCT0016047278	NCT00160472_78_T1	GENE	14	14	1.0
NCT0016047278	NCT00160472_78_T2	COMPOUND	15	15	N
NCT0016047278	NCT00160472_78_T3	GENE	13	13	ml
NCT0016047280	NCT00160472_80_T0	COMPOUND	16	16	octadecylsilane
NCT0016047280	NCT00160472_80_T1	ORGAN	10	10	plasma
NCT0016047280	NCT00160472_80_T2	COMPOUND	27	27	ethanol
NCT001604853	NCT00160485_3_T0	PHENOTYPE	12	13	maternal hyperglycemia
NCT001604854	NCT00160485_4_T0	PHENOTYPE	2	2	GDM
NCT001604854	NCT00160485_4_T1	GENE	7	7	insulin
NCT001604854	NCT00160485_4_T2	PHENOTYPE	10	12	blood glucose levels
NCT001604855	NCT00160485_5_T0	COMPOUND	9	9	sulfonylurea
NCT001604855	NCT00160485_5_T1	GENE	19	19	insulin
NCT001604855	NCT00160485_5_T2	GENE	4	4	has
NCT0016048510	NCT00160485_10_T0	GENE	17	17	insulin
NCT0016048510	NCT00160485_10_T1	GENE	23	23	insulin
NCT0016048511	NCT00160485_11_T0	PHENOTYPE	18	18	GDM
NCT0016048511	NCT00160485_11_T1	GENE	13	13	insulin
NCT0016048514	NCT00160485_14_T0	PHENOTYPE	22	22	GDM
NCT0016048514	NCT00160485_14_T1	PHENOTYPE	20	20	complications
NCT0016048515	NCT00160485_15_T0	GENE	15	15	insulin
NCT0016048521	NCT00160485_21_T0	PHENOTYPE	12	12	GTT
NCT0016048521	NCT00160485_21_T1	PHENOTYPE	9	10	glucose tolerance
NCT0016048522	NCT00160485_22_T0	GENE	10	10	met
NCT0016048526	NCT00160485_26_T0	ORGAN	1	1	serum
NCT0016048526	NCT00160485_26_T1	GENE	3	3	hemoglobin
NCT0016048528	NCT00160485_28_T0	GENE	15	15	insulin
NCT0016048530	NCT00160485_30_T0	ORGAN	11	11	abdomen
NCT0016048533	NCT00160485_33_T0	COMPOUND	17	17	glucose
NCT0016048534	NCT00160485_34_T0	COMPOUND	8	8	glucose
NCT0016048534	NCT00160485_34_T1	GENE	15	15	hr
NCT0016048535	NCT00160485_35_T0	GENE	18	18	insulin
NCT0016048536	NCT00160485_36_T0	GENE	11	11	hemoglobin
NCT0016048537	NCT00160485_37_T0	PHENOTYPE	16	16	cord
NCT0016048538	NCT00160485_38_T0	COMPOUND	12	12	glucose
NCT0016048538	NCT00160485_38_T1	GENE	13	13	hematocrit
NCT0016048538	NCT00160485_38_T2	PHENOTYPE	7	7	cord
NCT0016048538	NCT00160485_38_T3	PHENOTYPE	14	15	insulin level
NCT0016048538	NCT00160485_38_T4	ORGAN	2	3	fetal blood
NCT0016048539	NCT00160485_39_T0	GENE	8	8	insulin
NCT0016048540	NCT00160485_40_T0	ORGAN	0	1	Cord blood
NCT0016048542	NCT00160485_42_T0	COMPOUND	17	17	glucose
NCT0016048542	NCT00160485_42_T1	PHENOTYPE	22	23	glucose tolerance
NCT001605240	NCT00160524_0_T0	GENE	11	11	CD
NCT001605240	NCT00160524_0_T1	PHENOTYPE	9	10	Crohn's Disease
NCT001605630	NCT00160563_0_T0	PHENOTYPE	13	13	Eczema
NCT001605630	NCT00160563_0_T1	PHENOTYPE	11	11	Suffering
NCT001605630	NCT00160563_0_T2	PHENOTYPE	2	2	Asthma
NCT001605630	NCT00160563_0_T3	PHENOTYPE	14	15	Atopic Dermatitis
NCT001605632	NCT00160563_2_T0	PHENOTYPE	20	20	atopic
NCT001605632	NCT00160563_2_T1	COMPOUND	10	10	levocetirizine
NCT001605632	NCT00160563_2_T2	PHENOTYPE	17	17	asthma
NCT001605760	NCT00160576_0_T0	PHENOTYPE	10	10	Dyskinesias
NCT001605760	NCT00160576_0_T1	PHENOTYPE	6	7	Parkinson's Disease
NCT001605765	NCT00160576_5_T0	COMPOUND	14	14	apomorphine
NCT001605765	NCT00160576_5_T1	COMPOUND	3	3	levodopa
NCT001605766	NCT00160576_6_T0	COMPOUND	14	14	1
NCT001605766	NCT00160576_6_T1	COMPOUND	20	20	2
NCT001605766	NCT00160576_6_T2	COMPOUND	31	31	2
NCT001605766	NCT00160576_6_T3	COMPOUND	37	37	2
NCT001605766	NCT00160576_6_T4	PHENOTYPE	53	53	waking
NCT001605766	NCT00160576_6_T5	PHENOTYPE	13	13	dyskinesias
NCT001605766	NCT00160576_6_T6	PHENOTYPE	30	30	dyskinesias
NCT001605766	NCT00160576_6_T7	PHENOTYPE	45	45	dyskinesias
NCT001605766	NCT00160576_6_T8	GENE	27	27	IV
NCT001605766	NCT00160576_6_T9	GENE	44	44	IV
NCT001605769	NCT00160576_9_T0	COMPOUND	15	15	olanzapine
NCT001605769	NCT00160576_9_T1	COMPOUND	4	4	apomorphine
NCT001605769	NCT00160576_9_T2	GENE	11	11	atypical
NCT001605769	NCT00160576_9_T3	COMPOUND	17	17	risperidone
NCT001605769	NCT00160576_9_T4	COMPOUND	14	14	clozapine
NCT0016057611	NCT00160576_11_T0	COMPOUND	8	8	domperidone
NCT0016057611	NCT00160576_11_T1	COMPOUND	6	6	dopamine
NCT001606023	NCT00160602_3_T0	GENE	3	3	MTX
NCT001606150	NCT00160615_0_T0	PHENOTYPE	10	10	Onset
NCT001606150	NCT00160615_0_T1	PHENOTYPE	11	11	Seizures
NCT001606153	NCT00160615_3_T0	PHENOTYPE	0	0	Concentration
NCT001606281	NCT00160628_1_T0	PHENOTYPE	8	8	epileptic
NCT001606802	NCT00160680_2_T0	PHENOTYPE	0	0	Concentration
NCT001606931	NCT00160693_1_T0	PHENOTYPE	22	22	CZP
NCT001606931	NCT00160693_1_T1	PHENOTYPE	10	10	Arthritis
NCT001607062	NCT00160706_2_T0	GENE	14	14	360
NCT001607065	NCT00160706_5_T0	GENE	17	17	OR
NCT001607197	NCT00160719_7_T0	ORGAN	15	15	graft
NCT001607197	NCT00160719_7_T1	ORGAN	18	18	graft
NCT001607197	NCT00160719_7_T2	ORGAN	23	23	graft
NCT001607198	NCT00160719_8_T0	ORGAN	11	11	allograft
NCT001607321	NCT00160732_1_T0	PHENOTYPE	14	14	hypoglycemia
NCT001607326	NCT00160732_6_T0	PHENOTYPE	3	3	immunosuppression
NCT001607326	NCT00160732_6_T1	ORGAN	6	7	islet cells
NCT0016073212	NCT00160732_12_T0	PHENOTYPE	3	3	malignancy
NCT0016073212	NCT00160732_12_T1	GENE	9	9	had
NCT0016073212	NCT00160732_12_T2	GENE	8	8	has
NCT0016073212	NCT00160732_12_T3	PHENOTYPE	17	18	neoplastic disease
NCT0016073213	NCT00160732_13_T0	PHENOTYPE	4	4	malignancy
NCT0016073213	NCT00160732_13_T1	ORGAN	13	13	transplant
NCT001607451	NCT00160745_1_T0	TISSUE	8	8	endothelium
NCT001607452	NCT00160745_2_T0	PHENOTYPE	5	5	hypercholesterolemia
NCT001607455	NCT00160745_5_T0	ORGAN	5	5	forearm
NCT001607456	NCT00160745_6_T0	GENE	13	13	has
NCT001607457	NCT00160745_7_T0	COMPOUND	26	26	L-NMMA
NCT001607457	NCT00160745_7_T1	COMPOUND	11	11	rosuvastatin
NCT001607457	NCT00160745_7_T2	GENE	23	24	NO synthase
NCT001607582	NCT00160758_2_T0	ORGAN	5	5	grafts
NCT001607583	NCT00160758_3_T0	ORGAN	10	10	allografts
NCT001607583	NCT00160758_3_T1	PHENOTYPE	18	18	complications
NCT001607583	NCT00160758_3_T2	ORGAN	27	27	allograft
NCT001607584	NCT00160758_4_T0	PHENOTYPE	11	11	microfractures
NCT001607586	NCT00160758_6_T0	PHENOTYPE	20	20	microfracture
NCT001607586	NCT00160758_6_T1	ORGAN	17	17	allograft
NCT001607587	NCT00160758_7_T0	ORGAN	6	6	allograft
NCT001607587	NCT00160758_7_T1	ORGAN	16	16	allograft
NCT001607841	NCT00160784_1_T0	PHENOTYPE	10	11	frozen shoulder
NCT001607843	NCT00160784_3_T0	PHENOTYPE	12	12	understood
NCT001607843	NCT00160784_3_T1	PHENOTYPE	4	5	adhesive capsulitis
NCT001607847	NCT00160784_7_T0	ORGAN	15	15	shoulders
NCT0016078410	NCT00160784_10_T0	PHENOTYPE	15	16	adhesive capsulitis
NCT0016078413	NCT00160784_13_T0	PHENOTYPE	24	25	adhesive capsulitis
NCT0016078414	NCT00160784_14_T0	GENE	4	4	CTGF
NCT0016078416	NCT00160784_16_T0	GENE	5	5	has
NCT0016078416	NCT00160784_16_T1	GENE	4	4	CTGF
NCT001607972	NCT00160797_2_T0	GENE	9	9	has
NCT001607973	NCT00160797_3_T0	GENE	12	12	MIS
NCT001607974	NCT00160797_4_T0	GENE	12	12	has
NCT001608102	NCT00160810_2_T0	PHENOTYPE	12	12	distal
NCT001608102	NCT00160810_2_T1	PHENOTYPE	21	21	fixation
NCT001608102	NCT00160810_2_T2	PHENOTYPE	13	14	radius fractures
NCT001608231	NCT00160823_1_T0	GENE	13	13	bowel
NCT001608232	NCT00160823_2_T0	GENE	10	10	bowel
NCT001608362	NCT00160836_2_T0	PHENOTYPE	9	11	bile duct stricture
NCT001608363	NCT00160836_3_T0	GENE	3	3	has
NCT001608365	NCT00160836_5_T0	PHENOTYPE	21	22	biliary stricture
NCT0016083615	NCT00160836_15_T0	GENE	9	9	has
NCT0016083616	NCT00160836_16_T0	GENE	6	6	has
NCT0016083618	NCT00160836_18_T0	PHENOTYPE	14	14	malignancy
NCT0016083618	NCT00160836_18_T1	GENE	1	1	has
NCT0016083619	NCT00160836_19_T0	PHENOTYPE	29	30	biliary stricture
NCT0016083623	NCT00160836_23_T0	GENE	9	9	envelope
NCT0016083623	NCT00160836_23_T1	PHENOTYPE	19	19	blocks
NCT0016083624	NCT00160836_24_T0	PHENOTYPE	7	8	biliary stricture
NCT0016083627	NCT00160836_27_T0	COMPOUND	5	5	iopromide
NCT0016083627	NCT00160836_27_T1	ORGAN	2	3	bile duct
NCT0016083627	NCT00160836_27_T2	PHENOTYPE	21	22	biliary stricture
NCT0016083628	NCT00160836_28_T0	PHENOTYPE	7	7	stricture
NCT0016083630	NCT00160836_30_T0	PHENOTYPE	7	8	pancreatic disease
NCT0016083632	NCT00160836_32_T0	PHENOTYPE	2	2	dilation
NCT0016083632	NCT00160836_32_T1	PHENOTYPE	1	1	stricture
NCT0016083633	NCT00160836_33_T0	PHENOTYPE	4	4	withdrawn
NCT0016083633	NCT00160836_33_T1	PHENOTYPE	8	8	stricture
NCT0016083634	NCT00160836_34_T0	PHENOTYPE	14	14	stricture
NCT0016083635	NCT00160836_35_T0	PHENOTYPE	13	13	stricture
NCT0016083635	NCT00160836_35_T1	PHENOTYPE	31	31	stricture
NCT0016083637	NCT00160836_37_T0	PHENOTYPE	6	6	agitated
NCT0016083637	NCT00160836_37_T1	GENE	9	9	ml
NCT0016083640	NCT00160836_40_T0	PHENOTYPE	7	7	stricture
NCT0016083642	NCT00160836_42_T0	PHENOTYPE	15	15	stricture
NCT0016083644	NCT00160836_44_T0	PHENOTYPE	6	6	agitated
NCT0016083644	NCT00160836_44_T1	GENE	9	9	ml
NCT0016083645	NCT00160836_45_T0	PHENOTYPE	39	39	sterile
NCT0016083645	NCT00160836_45_T1	GENE	23	23	ml
NCT0016083647	NCT00160836_47_T0	PHENOTYPE	0	0	Complications
NCT0016083655	NCT00160836_55_T0	PHENOTYPE	11	12	biliary stricture
NCT0016083657	NCT00160836_57_T0	GENE	6	6	atypical
NCT0016083657	NCT00160836_57_T1	GENE	10	10	atypical
NCT0016083662	NCT00160836_62_T0	PHENOTYPE	21	21	lymphangitis
NCT0016083663	NCT00160836_63_T0	PHENOTYPE	32	33	disease course
NCT0016083665	NCT00160836_65_T0	PHENOTYPE	38	38	Sensitivity
NCT0016083665	NCT00160836_65_T1	GENE	10	10	atypical
NCT0016083665	NCT00160836_65_T2	GENE	30	30	atypical
NCT0016083668	NCT00160836_68_T0	TISSUE	24	24	tissues
NCT0016083668	NCT00160836_68_T1	ORGAN	20	21	biliary tract
NCT001608490	NCT00160849_0_T0	PHENOTYPE	9	9	Suppression
NCT001608499	NCT00160849_9_T0	PHENOTYPE	7	7	toxicity
NCT0016084912	NCT00160849_12_T0	GENE	27	27	hs
NCT0016084912	NCT00160849_12_T1	GENE	11	12	reverse transcriptase
NCT0016084912	NCT00160849_12_T2	GENE	2	3	group 2
NCT0016084915	NCT00160849_15_T0	GENE	11	11	has
NCT0016084915	NCT00160849_15_T1	GENE	40	40	has
NCT0016084918	NCT00160849_18_T0	PHENOTYPE	15	15	HIV
NCT0016084918	NCT00160849_18_T1	GENE	2	2	has
NCT0016084918	NCT00160849_18_T2	GENE	25	25	PCR
NCT0016084918	NCT00160849_18_T3	PHENOTYPE	7	8	HIV infection
NCT0016084929	NCT00160849_29_T0	PHENOTYPE	10	12	negative pregnancy test
NCT0016084935	NCT00160849_35_T0	GENE	12	12	CD4
NCT0016084935	NCT00160849_35_T1	ORGAN	9	9	appendix
NCT0016084937	NCT00160849_37_T0	PHENOTYPE	5	5	HIV
NCT0016084939	NCT00160849_39_T0	GENE	5	5	has
NCT001608620	NCT00160862_0_T0	GENE	0	0	NK-1
NCT001608625	NCT00160862_5_T0	COMPOUND	6	6	phenylephrine
NCT001608625	NCT00160862_5_T1	GENE	7	8	substance P
NCT001608626	NCT00160862_6_T0	GENE	5	5	separated
NCT001608626	NCT00160862_6_T1	PHENOTYPE	19	19	tolerance
NCT001608626	NCT00160862_6_T2	GENE	0	1	Substance P
NCT001608628	NCT00160862_8_T0	PHENOTYPE	7	8	pulse rate
NCT001608628	NCT00160862_8_T1	PHENOTYPE	19	20	adverse events
NCT001608751	NCT00160875_1_T0	PHENOTYPE	23	23	tumors
NCT001608752	NCT00160875_2_T0	GENE	14	14	has
NCT001608752	NCT00160875_2_T1	GENE	21	21	has
NCT001608754	NCT00160875_4_T0	GENE	5	5	has
NCT001608754	NCT00160875_4_T1	PHENOTYPE	23	24	esophageal cancer
NCT001608758	NCT00160875_8_T0	GENE	2	2	II
NCT001608758	NCT00160875_8_T1	GENE	7	7	III
NCT001608759	NCT00160875_9_T0	GENE	18	18	III
NCT0016087511	NCT00160875_11_T0	GENE	25	25	had
NCT0016087513	NCT00160875_13_T0	COMPOUND	1	1	cisplatin
NCT0016087513	NCT00160875_13_T1	PHENOTYPE	13	13	tumours
NCT0016087514	NCT00160875_14_T0	GENE	6	6	has
NCT0016087514	NCT00160875_14_T1	PHENOTYPE	11	12	colorectal cancer
NCT0016087514	NCT00160875_14_T2	PHENOTYPE	17	18	esophageal cancer
NCT0016087515	NCT00160875_15_T0	PHENOTYPE	18	18	toxicity
NCT0016087515	NCT00160875_15_T1	COMPOUND	8	8	irinotecan
NCT0016087515	NCT00160875_15_T2	COMPOUND	6	6	cisplatin
NCT0016087515	NCT00160875_15_T3	PHENOTYPE	10	11	esophageal cancer
NCT0016087516	NCT00160875_16_T0	PHENOTYPE	13	13	dysphagia
NCT0016087516	NCT00160875_16_T1	GENE	34	34	has
NCT0016087520	NCT00160875_20_T0	COMPOUND	13	13	cisplatin
NCT0016087520	NCT00160875_20_T1	PHENOTYPE	11	12	esophageal cancer
NCT0016087520	NCT00160875_20_T2	PHENOTYPE	35	36	metastatic disease
NCT0016087521	NCT00160875_21_T0	PHENOTYPE	25	26	esophageal cancer
NCT001608882	NCT00160888_2_T0	GENE	1	1	II
NCT001608882	NCT00160888_2_T1	COMPOUND	14	14	L-NMMA
NCT001608882	NCT00160888_2_T2	COMPOUND	9	9	acetylcholine
NCT001608882	NCT00160888_2_T3	COMPOUND	10	11	sodium nitroprusside
NCT001608882	NCT00160888_2_T4	PHENOTYPE	3	4	venous occlusion
NCT001609012	NCT00160901_2_T0	GENE	16	16	3.5
NCT001609013	NCT00160901_3_T0	PHENOTYPE	0	0	Secondary
NCT001609013	NCT00160901_3_T1	COMPOUND	10	10	C3o
NCT001609142	NCT00160914_2_T0	GENE	2	2	has
NCT001609142	NCT00160914_2_T1	PHENOTYPE	0	1	Childhood obesity
NCT001609144	NCT00160914_4_T0	PHENOTYPE	0	0	Obese
NCT001609144	NCT00160914_4_T1	PHENOTYPE	10	11	psychological stress
NCT001609144	NCT00160914_4_T2	PHENOTYPE	13	15	disturbed body image
NCT001609146	NCT00160914_6_T0	PHENOTYPE	11	12	childhood obesity
NCT001609147	NCT00160914_7_T0	PHENOTYPE	11	12	childhood obesity
NCT001609149	NCT00160914_9_T0	PHENOTYPE	18	19	childhood obesity
NCT0016091410	NCT00160914_10_T0	PHENOTYPE	14	14	strategies
NCT0016091410	NCT00160914_10_T1	PHENOTYPE	26	26	attitudes
NCT0016091410	NCT00160914_10_T2	PHENOTYPE	21	22	childhood obesity
NCT0016091410	NCT00160914_10_T3	PHENOTYPE	30	31	childhood obesity
NCT0016091411	NCT00160914_11_T0	PHENOTYPE	29	30	childhood obesity
NCT0016091414	NCT00160914_14_T0	PHENOTYPE	21	21	attitudes
NCT0016091418	NCT00160914_18_T0	PHENOTYPE	17	18	adolescent obesity
NCT0016091419	NCT00160914_19_T0	PHENOTYPE	29	30	childhood obesity
NCT0016091420	NCT00160914_20_T0	PHENOTYPE	9	9	attitudes
NCT0016091420	NCT00160914_20_T1	PHENOTYPE	18	18	obesity
NCT0016091434	NCT00160914_34_T0	PHENOTYPE	36	37	childhood obesity
NCT0016091436	NCT00160914_36_T0	PHENOTYPE	17	18	childhood obesity
NCT0016091437	NCT00160914_37_T0	PHENOTYPE	15	16	childhood obesity
NCT0016091438	NCT00160914_38_T0	PHENOTYPE	14	14	attitudes
NCT0016091438	NCT00160914_38_T1	PHENOTYPE	19	20	childhood obesity
NCT001609272	NCT00160927_2_T0	PHENOTYPE	9	9	strain
NCT001609273	NCT00160927_3_T0	PHENOTYPE	1	1	impairment
NCT001609273	NCT00160927_3_T1	PHENOTYPE	14	16	of foot ulcer
NCT001609274	NCT00160927_4_T0	PHENOTYPE	15	15	impairment
NCT001609276	NCT00160927_6_T0	PHENOTYPE	27	27	peripheral
NCT001609276	NCT00160927_6_T1	ORGAN	28	28	arteries
NCT001609276	NCT00160927_6_T2	PHENOTYPE	22	23	peripheral neuropathy
NCT001609401	NCT00160940_1_T0	ORGAN	17	17	liver
NCT001609401	NCT00160940_1_T1	PHENOTYPE	15	15	damages
NCT001609401	NCT00160940_1_T2	PHENOTYPE	4	4	understood
NCT001609401	NCT00160940_1_T3	PHENOTYPE	12	14	autoimmune liver disease
NCT001609401	NCT00160940_1_T4	PHENOTYPE	8	10	chronic viral hepatitis
NCT001609402	NCT00160940_2_T0	PHENOTYPE	13	13	hepatoma
NCT001609402	NCT00160940_2_T1	PHENOTYPE	15	17	autoimmune liver disease
NCT001609402	NCT00160940_2_T2	PHENOTYPE	7	9	chronic viral hepatitis
NCT001609403	NCT00160940_3_T0	ORGAN	22	22	liver
NCT001609403	NCT00160940_3_T1	PHENOTYPE	29	30	liver damage
NCT001609403	NCT00160940_3_T2	CELL	17	19	white blood cells
NCT001609405	NCT00160940_5_T0	BIOLOGICAL_PROCESS	6	7	Gene Expression
NCT001609405	NCT00160940_5_T1	PHENOTYPE	19	20	disease progression
NCT001609407	NCT00160940_7_T0	ORGAN	9	9	liver
NCT0016094012	NCT00160940_12_T0	ORGAN	17	17	liver
NCT0016094012	NCT00160940_12_T1	BIOLOGICAL_PROCESS	7	8	gene expression
NCT0016094012	NCT00160940_12_T2	CELL	12	14	white blood cells
NCT0016094016	NCT00160940_16_T0	PHENOTYPE	6	7	hepatitis B
NCT0016094016	NCT00160940_16_T1	BIOLOGICAL_PROCESS	22	23	immune response
NCT0016094016	NCT00160940_16_T2	PHENOTYPE	9	10	hepatitis C
NCT0016094021	NCT00160940_21_T0	PHENOTYPE	22	23	autoimmune response
NCT0016094021	NCT00160940_21_T1	PHENOTYPE	3	5	autoimmune liver disease
NCT0016094024	NCT00160940_24_T0	GENE	22	22	structural
NCT0016094024	NCT00160940_24_T1	GENE	4	4	polyprotein
NCT0016094026	NCT00160940_26_T0	COMPOUND	4	4	HCV
NCT0016094026	NCT00160940_26_T1	GENE	26	26	East
NCT0016094027	NCT00160940_27_T0	ORGAN	8	9	immune system
NCT0016094028	NCT00160940_28_T0	GENE	13	13	IFN
NCT0016094028	NCT00160940_28_T1	PHENOTYPE	9	9	resistant
NCT0016094028	NCT00160940_28_T2	PHENOTYPE	0	1	Chronic infection
NCT0016094032	NCT00160940_32_T0	ORGAN	16	17	immune system
NCT0016094033	NCT00160940_33_T0	GENE	25	25	IFN
NCT0016094033	NCT00160940_33_T1	PHENOTYPE	9	9	acute
NCT0016094033	NCT00160940_33_T2	PHENOTYPE	7	7	persistence
NCT0016094033	NCT00160940_33_T3	COMPOUND	10	10	HCV
NCT0016094033	NCT00160940_33_T4	COMPOUND	22	22	HCV
NCT0016094035	NCT00160940_35_T0	COMPOUND	31	31	HCV
NCT0016094035	NCT00160940_35_T1	PHENOTYPE	30	30	chronic
NCT0016094035	NCT00160940_35_T2	PHENOTYPE	19	20	liver disease
NCT0016094037	NCT00160940_37_T0	PHENOTYPE	17	17	profound
NCT0016094037	NCT00160940_37_T1	COMPOUND	0	0	HCV
NCT0016094037	NCT00160940_37_T2	GENE	16	16	has
NCT0016094037	NCT00160940_37_T3	PHENOTYPE	5	6	progressive disease
NCT0016094042	NCT00160940_42_T0	GENE	13	13	PCR
NCT0016094043	NCT00160940_43_T0	GENE	14	14	2.3
NCT0016094043	NCT00160940_43_T1	ORGAN	41	41	livers
NCT0016094043	NCT00160940_43_T2	COMPOUND	39	39	HCV
NCT0016094043	NCT00160940_43_T3	PHENOTYPE	17	17	fibrosis
NCT0016094043	NCT00160940_43_T4	BIOLOGICAL_PROCESS	35	36	gene expression
NCT0016094044	NCT00160940_44_T0	BIOLOGICAL_PROCESS	11	12	gene expression
NCT0016094045	NCT00160940_45_T0	PHENOTYPE	5	5	reflected
NCT0016094045	NCT00160940_45_T1	BIOLOGICAL_PROCESS	2	3	host-virus interaction
NCT0016094046	NCT00160940_46_T0	ORGAN	4	4	liver
NCT0016094046	NCT00160940_46_T1	COMPOUND	3	3	HCV
NCT0016094047	NCT00160940_47_T0	GENE	3	3	has
NCT0016094048	NCT00160940_48_T0	PHENOTYPE	24	24	reflected
NCT0016094048	NCT00160940_48_T1	BIOLOGICAL_PROCESS	28	29	gene expression
NCT0016094055	NCT00160940_55_T0	BIOLOGICAL_PROCESS	3	4	gene expression
NCT0016094060	NCT00160940_60_T0	GENE	9	9	IFN
NCT0016094060	NCT00160940_60_T1	GENE	0	0	ISG15
NCT0016094061	NCT00160940_61_T0	GENE	8	8	NR
NCT0016094061	NCT00160940_61_T1	ORGAN	13	13	liver
NCT0016094061	NCT00160940_61_T2	ORGAN	26	26	liver
NCT0016094061	NCT00160940_61_T3	GENE	27	27	ISG15
NCT0016094061	NCT00160940_61_T4	GENE	30	30	ubiquitin
NCT0016094061	NCT00160940_61_T5	COMPOUND	25	25	HCV
NCT0016094061	NCT00160940_61_T6	GENE	31	31	Ubl
NCT0016094061	NCT00160940_61_T7	PHENOTYPE	50	51	interferon activation
NCT0016094061	NCT00160940_61_T8	BIOLOGICAL_PROCESS	22	23	immune response
NCT0016094062	NCT00160940_62_T0	GENE	14	14	E2
NCT0016094063	NCT00160940_63_T0	GENE	5	5	UBCH8
NCT0016094063	NCT00160940_63_T1	COMPOUND	25	25	HCV
NCT0016094063	NCT00160940_63_T2	GENE	11	11	activator
NCT0016094063	NCT00160940_63_T3	GENE	2	2	E2
NCT0016094063	NCT00160940_63_T4	PHENOTYPE	24	24	chronic
NCT0016094064	NCT00160940_64_T0	GENE	14	14	protease
NCT0016094064	NCT00160940_64_T1	GENE	3	3	ISG15
NCT0016094064	NCT00160940_64_T2	BIOLOGICAL_PROCESS	1	1	conjugation
NCT0016094067	NCT00160940_67_T0	COMPOUND	5	5	HCV
NCT0016094067	NCT00160940_67_T1	GENE	3	3	UBP43
NCT0016094072	NCT00160940_72_T0	ORGAN	26	26	liver
NCT0016094072	NCT00160940_72_T1	COMPOUND	24	24	HCV
NCT0016094072	NCT00160940_72_T2	BIOLOGICAL_PROCESS	7	8	viral replication
NCT0016094073	NCT00160940_73_T0	COMPOUND	6	6	HCV
NCT0016094074	NCT00160940_74_T0	PHENOTYPE	13	13	peripheral
NCT0016094074	NCT00160940_74_T1	COMPOUND	0	0	HCV
NCT0016094074	NCT00160940_74_T2	CELL	14	15	blood cells
NCT0016094076	NCT00160940_76_T0	COMPOUND	3	3	HCV
NCT0016094076	NCT00160940_76_T1	CELL	12	12	hepatocytes
NCT0016094077	NCT00160940_77_T0	COMPOUND	3	3	HCV
NCT0016094077	NCT00160940_77_T1	COMPOUND	12	12	HCV
NCT0016094077	NCT00160940_77_T2	BIOLOGICAL_PROCESS	18	19	immune response
NCT0016094077	NCT00160940_77_T3	PHENOTYPE	41	42	liver damage
NCT0016094080	NCT00160940_80_T0	COMPOUND	20	20	HCV
NCT0016094080	NCT00160940_80_T1	GENE	14	14	has
NCT0016094081	NCT00160940_81_T0	GENE	23	23	ISG15
NCT0016094081	NCT00160940_81_T1	GENE	25	25	UBP43
NCT0016094081	NCT00160940_81_T2	BIOLOGICAL_PROCESS	45	46	gene expression
NCT0016094083	NCT00160940_83_T0	CELL	19	19	cells
NCT0016094083	NCT00160940_83_T1	GENE	3	3	knockdown
NCT0016094083	NCT00160940_83_T2	COMPOUND	15	15	HCV
NCT0016094083	NCT00160940_83_T3	GENE	13	13	ISG15
NCT0016094083	NCT00160940_83_T4	GENE	11	11	UBP43
NCT0016094084	NCT00160940_84_T0	BIOLOGICAL_PROCESS	5	5	RNAi
NCT0016094084	NCT00160940_84_T1	BIOLOGICAL_PROCESS	18	19	viral replication
NCT0016094084	NCT00160940_84_T2	BIOLOGICAL_PROCESS	3	4	RNA interference
NCT0016094085	NCT00160940_85_T0	BIOLOGICAL_PROCESS	10	10	degradation
NCT0016094089	NCT00160940_89_T0	GENE	6	6	1b
NCT0016094089	NCT00160940_89_T1	GENE	13	13	IFN-a
NCT0016094089	NCT00160940_89_T2	COMPOUND	5	5	HCV
NCT0016094089	NCT00160940_89_T3	BIOLOGICAL_PROCESS	8	9	RNA replication
NCT0016094090	NCT00160940_90_T0	GENE	14	14	MxA
NCT0016094093	NCT00160940_93_T0	PHENOTYPE	15	15	strategies
NCT0016094093	NCT00160940_93_T1	GENE	9	9	ISG15
NCT0016094093	NCT00160940_93_T2	GENE	11	11	UBP43
NCT0016094095	NCT00160940_95_T0	GENE	8	8	blot
NCT0016094095	NCT00160940_95_T1	GENE	0	0	ISG15
NCT0016094095	NCT00160940_95_T2	GENE	14	14	Dr
NCT0016094095	NCT00160940_95_T3	GENE	44	44	Dr
NCT0016094095	NCT00160940_95_T4	GENE	19	19	UBP43
NCT0016094096	NCT00160940_96_T0	CELL	15	15	cells
NCT0016094096	NCT00160940_96_T1	PHENOTYPE	13	13	lysing
NCT0016094096	NCT00160940_96_T2	GENE	17	17	RIPA
NCT0016094097	NCT00160940_97_T0	GENE	18	18	IFN
NCT0016094097	NCT00160940_97_T1	GENE	9	9	ISG15
NCT0016094097	NCT00160940_97_T2	GENE	4	4	mRNA
NCT0016094097	NCT00160940_97_T3	GENE	11	11	UBP43
NCT0016094098	NCT00160940_98_T0	CELL	14	14	cells
NCT0016094099	NCT00160940_99_T0	GENE	27	27	IFNa
NCT0016094099	NCT00160940_99_T1	CELL	22	22	cells
NCT0016094099	NCT00160940_99_T2	CELL	36	36	cells
NCT0016094099	NCT00160940_99_T3	GENE	13	13	ISG15
NCT0016094099	NCT00160940_99_T4	GENE	33	33	ISG15
NCT0016094099	NCT00160940_99_T5	GENE	16	16	mRNA
NCT0016094099	NCT00160940_99_T6	GENE	24	24	PCR
NCT0016094099	NCT00160940_99_T7	GENE	15	15	UBP43
NCT00160940100	NCT00160940_100_T0	GENE	5	5	ISG15
NCT00160940100	NCT00160940_100_T1	GENE	7	7	UBP43
NCT00160940101	NCT00160940_101_T0	GENE	23	23	IFN
NCT00160940101	NCT00160940_101_T1	GENE	39	39	IFN
NCT00160940101	NCT00160940_101_T2	GENE	28	28	ISG15
NCT00160940101	NCT00160940_101_T3	COMPOUND	12	12	HCV
NCT00160940101	NCT00160940_101_T4	COMPOUND	32	32	HCV
NCT00160940101	NCT00160940_101_T5	PHENOTYPE	5	5	elimination
NCT00160940101	NCT00160940_101_T6	PHENOTYPE	26	26	elimination
NCT00160940101	NCT00160940_101_T7	GENE	7	7	UBP43
NCT00160940101	NCT00160940_101_T8	BIOLOGICAL_PROCESS	13	14	RNA replication
NCT00160940103	NCT00160940_103_T0	MOLECULAR_FUNCTION	36	37	luciferase activity
NCT00160940105	NCT00160940_105_T0	GENE	24	24	blot
NCT00160940105	NCT00160940_105_T1	GENE	7	7	mRNA
NCT00160940105	NCT00160940_105_T2	GENE	1	1	PCR
NCT00160940106	NCT00160940_106_T0	PHENOTYPE	11	11	inhibition
NCT00160940106	NCT00160940_106_T1	COMPOUND	16	16	HCV
NCT00160940106	NCT00160940_106_T2	BIOLOGICAL_PROCESS	17	18	RNA replication
NCT00160940107	NCT00160940_107_T0	GENE	23	23	IFN
NCT00160940107	NCT00160940_107_T1	GENE	39	39	IFN
NCT00160940107	NCT00160940_107_T2	GENE	28	28	ISG15
NCT00160940107	NCT00160940_107_T3	COMPOUND	12	12	HCV
NCT00160940107	NCT00160940_107_T4	COMPOUND	32	32	HCV
NCT00160940107	NCT00160940_107_T5	GENE	7	7	UBP43
NCT00160940107	NCT00160940_107_T6	BIOLOGICAL_PROCESS	13	14	RNA replication
NCT00160940108	NCT00160940_108_T0	GENE	11	11	ISG15
NCT00160940108	NCT00160940_108_T1	GENE	19	19	ISG15
NCT00160940108	NCT00160940_108_T2	GENE	0	0	UBP43
NCT00160940108	NCT00160940_108_T3	GENE	7	7	UBP43
NCT00160940109	NCT00160940_109_T0	GENE	14	14	IFNa
NCT00160940109	NCT00160940_109_T1	COMPOUND	2	2	HCV
NCT00160940109	NCT00160940_109_T2	GENE	17	17	PCR
NCT00160940112	NCT00160940_112_T0	GENE	11	11	ISG15
NCT00160940112	NCT00160940_112_T1	COMPOUND	18	18	HCV
NCT00160940112	NCT00160940_112_T2	GENE	13	13	UBP43
NCT00160940112	NCT00160940_112_T3	BIOLOGICAL_PROCESS	19	20	RNA replication
NCT00160940112	NCT00160940_112_T4	PHENOTYPE	0	2	Mechanism of action
NCT00160940113	NCT00160940_113_T0	GENE	12	12	protease
NCT00160940113	NCT00160940_113_T1	GENE	7	7	UBP43
NCT00160940114	NCT00160940_114_T0	GENE	5	5	ISG15
NCT00160940115	NCT00160940_115_T0	PHENOTYPE	23	23	inhibition
NCT00160940115	NCT00160940_115_T1	GENE	18	18	interferon
NCT00160940115	NCT00160940_115_T2	GENE	2	2	UBP43
NCT00160940115	NCT00160940_115_T3	GENE	8	8	UBP43
NCT00160940115	NCT00160940_115_T4	GENE	25	25	UBP43
NCT00160940115	NCT00160940_115_T5	COMPOUND	34	34	HCV
NCT00160940115	NCT00160940_115_T6	PHENOTYPE	6	6	elimination
NCT00160940115	NCT00160940_115_T7	MOLECULAR_FUNCTION	3	4	protease activity
NCT00160940115	NCT00160940_115_T8	BIOLOGICAL_PROCESS	13	14	viral replication
NCT00160940116	NCT00160940_116_T0	GENE	8	8	has
NCT00160940116	NCT00160940_116_T1	GENE	0	0	UBP43
NCT00160940116	NCT00160940_116_T2	MOLECULAR_FUNCTION	9	10	protease activity
NCT00160940117	NCT00160940_117_T0	COMPOUND	19	19	HCV
NCT00160940117	NCT00160940_117_T1	GENE	12	12	UBP43
NCT00160940117	NCT00160940_117_T2	MOLECULAR_FUNCTION	9	10	protease activity
NCT00160940118	NCT00160940_118_T0	GENE	8	8	protease
NCT00160940118	NCT00160940_118_T1	GENE	7	7	UBP43
NCT00160940119	NCT00160940_119_T0	PHENOTYPE	9	9	mutation
NCT00160940119	NCT00160940_119_T1	BIOLOGICAL_PROCESS	20	20	mutagenesis
NCT00160940119	NCT00160940_119_T2	GENE	4	4	UBP43
NCT00160940121	NCT00160940_121_T0	PHENOTYPE	15	15	mutated
NCT00160940121	NCT00160940_121_T1	BIOLOGICAL_PROCESS	12	12	mutagenesis
NCT00160940121	NCT00160940_121_T2	GENE	16	16	UBP43
NCT00160940121	NCT00160940_121_T3	GENE	6	6	protease
NCT00160940121	NCT00160940_121_T4	GENE	33	33	IFNa
NCT00160940121	NCT00160940_121_T5	CELL	22	22	cells
NCT00160940121	NCT00160940_121_T6	COMPOUND	25	25	HCV
NCT00160940122	NCT00160940_122_T0	GENE	2	2	protease
NCT00160940122	NCT00160940_122_T1	GENE	19	19	IFN
NCT00160940122	NCT00160940_122_T2	PHENOTYPE	12	13	dominant negative
NCT00160940123	NCT00160940_123_T0	GENE	18	18	phospholipase
NCT00160940123	NCT00160940_123_T1	GENE	22	22	ERK1
NCT00160940123	NCT00160940_123_T2	GENE	7	7	thymic
NCT00160940123	NCT00160940_123_T3	GENE	3	3	ISG15
NCT00160940123	NCT00160940_123_T4	GENE	16	16	ISG15
NCT00160940123	NCT00160940_123_T5	GENE	9	9	has
NCT00160940123	NCT00160940_123_T6	PHENOTYPE	19	19	Cg1
NCT00160940123	NCT00160940_123_T7	GENE	20	20	Jak1
NCT00160940124	NCT00160940_124_T0	CELL	6	6	cells
NCT00160940124	NCT00160940_124_T1	GENE	13	13	JAK
NCT00160940124	NCT00160940_124_T2	COMPOUND	23	23	HCV
NCT00160940124	NCT00160940_124_T3	GENE	11	11	ERK
NCT00160940125	NCT00160940_125_T0	COMPOUND	8	8	HCV
NCT00160940125	NCT00160940_125_T1	GENE	4	4	ISG15
NCT00160940125	NCT00160940_125_T2	GENE	17	17	ISG15
NCT00160940126	NCT00160940_126_T0	CELL	30	30	cells
NCT00160940126	NCT00160940_126_T1	GENE	21	21	ISG15
NCT00160940128	NCT00160940_128_T0	GENE	21	21	ISG15
NCT00160940128	NCT00160940_128_T1	GENE	5	5	gel
NCT00160940132	NCT00160940_132_T0	GENE	22	22	IFN
NCT00160940132	NCT00160940_132_T1	CELL	3	3	cells
NCT00160940132	NCT00160940_132_T2	CELL	17	17	cells
NCT00160940132	NCT00160940_132_T3	GENE	8	8	ISG15
NCT00160940133	NCT00160940_133_T0	GENE	12	12	gel
NCT00160940134	NCT00160940_134_T0	GENE	0	0	Gel
NCT00160940137	NCT00160940_137_T0	GENE	29	29	blot
NCT00160940137	NCT00160940_137_T1	GENE	1	1	MS
NCT00160940138	NCT00160940_138_T0	GENE	8	8	MS
NCT00160940139	NCT00160940_139_T0	GENE	23	23	IFN
NCT00160940139	NCT00160940_139_T1	GENE	13	13	ISG15
NCT00160940139	NCT00160940_139_T2	COMPOUND	19	19	HCV
NCT00160940139	NCT00160940_139_T3	GENE	15	15	UBP43
NCT00160940144	NCT00160940_144_T0	PHENOTYPE	12	12	acute
NCT00160940144	NCT00160940_144_T1	COMPOUND	13	13	HCV
NCT00160940144	NCT00160940_144_T2	BIOLOGICAL_PROCESS	21	22	host-virus interaction
NCT00160940145	NCT00160940_145_T0	PHENOTYPE	9	9	acute
NCT00160940145	NCT00160940_145_T1	ORGAN	1	1	liver
NCT00160940145	NCT00160940_145_T2	ORGAN	22	22	liver
NCT00160940145	NCT00160940_145_T3	PHENOTYPE	11	11	infections
NCT00160940145	NCT00160940_145_T4	COMPOUND	10	10	HCV
NCT00160940147	NCT00160940_147_T0	PHENOTYPE	9	9	peripheral
NCT00160940147	NCT00160940_147_T1	PHENOTYPE	21	21	acute
NCT00160940147	NCT00160940_147_T2	GENE	25	25	Dr
NCT00160940147	NCT00160940_147_T3	CELL	12	12	cells
NCT00160940147	NCT00160940_147_T4	COMPOUND	22	22	HCV
NCT00160940147	NCT00160940_147_T5	COMPOUND	38	38	HCV
NCT00160940147	NCT00160940_147_T6	PHENOTYPE	37	37	chronic
NCT00160940147	NCT00160940_147_T7	BIOLOGICAL_PROCESS	5	6	gene expression
NCT00160940148	NCT00160940_148_T0	PHENOTYPE	21	22	chronic infection
NCT00160940149	NCT00160940_149_T0	PHENOTYPE	5	5	recurrence
NCT00160940149	NCT00160940_149_T1	COMPOUND	7	7	HCV
NCT00160940149	NCT00160940_149_T2	PHENOTYPE	14	15	acute hepatitis
NCT00160940150	NCT00160940_150_T0	ORGAN	24	24	graft
NCT00160940150	NCT00160940_150_T1	ORGAN	7	7	liver
NCT00160940150	NCT00160940_150_T2	BIOLOGICAL_PROCESS	14	15	gene expression
NCT00160940151	NCT00160940_151_T0	PHENOTYPE	21	21	recurrence
NCT00160940151	NCT00160940_151_T1	ORGAN	4	4	liver
NCT00160940151	NCT00160940_151_T2	ORGAN	23	23	liver
NCT00160940151	NCT00160940_151_T3	ORGAN	30	30	transplant
NCT00160940151	NCT00160940_151_T4	COMPOUND	11	11	HCV
NCT00160940152	NCT00160940_152_T0	COMPOUND	10	10	HCV
NCT00160940152	NCT00160940_152_T1	PHENOTYPE	9	9	recurrent
NCT00160940155	NCT00160940_155_T0	COMPOUND	6	6	HCV
NCT00160940157	NCT00160940_157_T0	PHENOTYPE	20	20	acute
NCT00160940157	NCT00160940_157_T1	PHENOTYPE	27	27	progression
NCT00160940157	NCT00160940_157_T2	PHENOTYPE	17	17	persistence
NCT00160940157	NCT00160940_157_T3	COMPOUND	21	21	HCV
NCT00160940157	NCT00160940_157_T4	PHENOTYPE	19	19	elimination
NCT00160940157	NCT00160940_157_T5	PHENOTYPE	29	30	liver disease
NCT00160940158	NCT00160940_158_T0	COMPOUND	11	11	HCV
NCT00160940160	NCT00160940_160_T0	CELL	21	21	cells
NCT00160940160	NCT00160940_160_T1	ORGAN	25	25	liver
NCT00160940160	NCT00160940_160_T2	PHENOTYPE	15	16	acute hepatitis
NCT00160940160	NCT00160940_160_T3	BIOLOGICAL_PROCESS	3	4	gene expression
NCT00160940161	NCT00160940_161_T0	GENE	4	4	II
NCT00160940162	NCT00160940_162_T0	PHENOTYPE	17	17	acute
NCT00160940162	NCT00160940_162_T1	COMPOUND	18	18	HCV
NCT00160940162	NCT00160940_162_T2	GENE	12	12	Dr
NCT00160940162	NCT00160940_162_T3	BIOLOGICAL_PROCESS	4	5	gene expression
NCT00160940163	NCT00160940_163_T0	GENE	13	13	Dr
NCT00160940164	NCT00160940_164_T0	ORGAN	21	21	graft
NCT00160940164	NCT00160940_164_T1	ORGAN	20	20	liver
NCT00160940164	NCT00160940_164_T2	ORGAN	19	19	transplant
NCT00160940164	NCT00160940_164_T3	COMPOUND	15	15	HCV
NCT00160940164	NCT00160940_164_T4	COMPOUND	27	27	HCV
NCT00160940165	NCT00160940_165_T0	ORGAN	7	7	liver
NCT00160940165	NCT00160940_165_T1	ORGAN	16	16	transplant
NCT00160940166	NCT00160940_166_T0	COMPOUND	9	9	HCV
NCT00160940166	NCT00160940_166_T1	PHENOTYPE	8	8	chronic
NCT00160940166	NCT00160940_166_T2	BIOLOGICAL_PROCESS	14	15	gene expression
NCT00160940169	NCT00160940_169_T0	PHENOTYPE	1	1	recruitment
NCT00160940171	NCT00160940_171_T0	PHENOTYPE	0	0	Acute
NCT00160940171	NCT00160940_171_T1	COMPOUND	1	1	HCV
NCT00160940171	NCT00160940_171_T2	COMPOUND	20	20	HCV
NCT00160940171	NCT00160940_171_T3	GENE	5	5	Dr
NCT00160940172	NCT00160940_172_T0	PHENOTYPE	30	30	progression
NCT00160940172	NCT00160940_172_T1	PHENOTYPE	32	33	chronic infection
NCT00160940174	NCT00160940_174_T0	BIOLOGICAL_PROCESS	21	22	gene expression
NCT00160940177	NCT00160940_177_T0	PHENOTYPE	6	6	recurrence
NCT00160940177	NCT00160940_177_T1	ORGAN	12	12	liver
NCT00160940177	NCT00160940_177_T2	PHENOTYPE	0	0	Acute
NCT00160940177	NCT00160940_177_T3	COMPOUND	1	1	HCV
NCT00160940177	NCT00160940_177_T4	COMPOUND	5	5	HCV
NCT00160940177	NCT00160940_177_T5	COMPOUND	20	20	HCV
NCT00160940177	NCT00160940_177_T6	ORGAN	13	13	transplants
NCT00160940178	NCT00160940_178_T0	ORGAN	5	5	liver
NCT00160940178	NCT00160940_178_T1	ORGAN	6	6	transplant
NCT00160940181	NCT00160940_181_T0	ORGAN	3	3	liver
NCT00160940181	NCT00160940_181_T1	GENE	17	17	PI
NCT00160940182	NCT00160940_182_T0	ORGAN	14	14	liver
NCT00160940183	NCT00160940_183_T0	PHENOTYPE	0	0	Chronic
NCT00160940183	NCT00160940_183_T1	COMPOUND	1	1	HCV
NCT00160940183	NCT00160940_183_T2	COMPOUND	15	15	HCV
NCT00160940183	NCT00160940_183_T3	PHENOTYPE	14	14	chronic
NCT00160940183	NCT00160940_183_T4	GENE	5	5	Dr
NCT00160940185	NCT00160940_185_T0	ORGAN	6	6	liver
NCT00160940186	NCT00160940_186_T0	GENE	1	1	2.3
NCT00160940188	NCT00160940_188_T0	PHENOTYPE	10	10	acute
NCT00160940188	NCT00160940_188_T1	PHENOTYPE	23	23	acute
NCT00160940188	NCT00160940_188_T2	PHENOTYPE	2	2	Acute
NCT00160940188	NCT00160940_188_T3	COMPOUND	3	3	HCV
NCT00160940188	NCT00160940_188_T4	COMPOUND	11	11	HCV
NCT00160940188	NCT00160940_188_T5	COMPOUND	26	26	HCV
NCT00160940188	NCT00160940_188_T6	COMPOUND	42	42	HCV
NCT00160940188	NCT00160940_188_T7	PHENOTYPE	39	39	chronic
NCT00160940188	NCT00160940_188_T8	BIOLOGICAL_PROCESS	4	5	Gene expression
NCT00160940188	NCT00160940_188_T9	BIOLOGICAL_PROCESS	15	16	Gene expression
NCT00160940189	NCT00160940_189_T0	GENE	7	7	fold
NCT00160940189	NCT00160940_189_T1	GENE	15	15	fold
NCT00160940189	NCT00160940_189_T2	GENE	20	20	1.5
NCT00160940189	NCT00160940_189_T3	GENE	14	14	0.01
NCT00160940190	NCT00160940_190_T0	PHENOTYPE	11	11	acute
NCT00160940190	NCT00160940_190_T1	COMPOUND	12	12	HCV
NCT00160940190	NCT00160940_190_T2	BIOLOGICAL_PROCESS	5	6	gene expression
NCT00160940191	NCT00160940_191_T0	PHENOTYPE	8	8	progression
NCT00160940191	NCT00160940_191_T1	PHENOTYPE	33	34	chronic infection
NCT00160940191	NCT00160940_191_T2	PHENOTYPE	10	11	chronic disease
NCT00160940191	NCT00160940_191_T3	BIOLOGICAL_PROCESS	19	20	gene expression
NCT00160940192	NCT00160940_192_T0	PHENOTYPE	20	20	nearest
NCT00160940192	NCT00160940_192_T1	GENE	2	2	PCR
NCT00160940192	NCT00160940_192_T2	PHENOTYPE	39	40	chronic infection
NCT00160940193	NCT00160940_193_T0	PHENOTYPE	18	18	acute
NCT00160940193	NCT00160940_193_T1	COMPOUND	19	19	HCV
NCT00160940193	NCT00160940_193_T2	PHENOTYPE	28	29	chronic disease
NCT00160940194	NCT00160940_194_T0	COMPOUND	15	15	HCV
NCT00160940195	NCT00160940_195_T0	PHENOTYPE	16	16	acute
NCT00160940196	NCT00160940_196_T0	ORGAN	17	17	liver
NCT00160940196	NCT00160940_196_T1	PHENOTYPE	0	0	Acute
NCT00160940196	NCT00160940_196_T2	COMPOUND	1	1	HCV
NCT00160940196	NCT00160940_196_T3	COMPOUND	8	8	HCV
NCT00160940196	NCT00160940_196_T4	COMPOUND	26	26	HCV
NCT00160940196	NCT00160940_196_T5	BIOLOGICAL_PROCESS	10	11	Gene expression
NCT00160940196	NCT00160940_196_T6	BIOLOGICAL_PROCESS	4	5	gene expression
NCT00160940198	NCT00160940_198_T0	ORGAN	23	23	liver
NCT00160940198	NCT00160940_198_T1	COMPOUND	7	7	HCV
NCT00160940198	NCT00160940_198_T2	COMPOUND	15	15	HCV
NCT00160940198	NCT00160940_198_T3	COMPOUND	21	21	HCV
NCT00160940198	NCT00160940_198_T4	COMPOUND	30	30	HCV
NCT00160940198	NCT00160940_198_T5	PHENOTYPE	14	14	recurrent
NCT00160940198	NCT00160940_198_T6	PHENOTYPE	20	20	recurrent
NCT00160940202	NCT00160940_202_T0	COMPOUND	10	10	HCV
NCT00160940202	NCT00160940_202_T1	BIOLOGICAL_PROCESS	7	8	gene expression
NCT00160940205	NCT00160940_205_T0	PHENOTYPE	20	20	acute
NCT00160940205	NCT00160940_205_T1	GENE	19	19	eg
NCT00160940205	NCT00160940_205_T2	PHENOTYPE	22	22	immunosuppression
NCT00160940205	NCT00160940_205_T3	BIOLOGICAL_PROCESS	16	17	gene expression
NCT00160940206	NCT00160940_206_T0	PHENOTYPE	24	24	acute
NCT00160940206	NCT00160940_206_T1	COMPOUND	3	3	HCV
NCT00160940206	NCT00160940_206_T2	COMPOUND	26	26	HCV
NCT00160940206	NCT00160940_206_T3	COMPOUND	33	33	HCV
NCT00160940206	NCT00160940_206_T4	PHENOTYPE	32	32	chronic
NCT00160940206	NCT00160940_206_T5	BIOLOGICAL_PROCESS	20	21	gene expression
NCT00160940207	NCT00160940_207_T0	PHENOTYPE	12	12	acute
NCT00160940207	NCT00160940_207_T1	COMPOUND	13	13	HCV
NCT00160940207	NCT00160940_207_T2	BIOLOGICAL_PROCESS	17	18	gene expression
NCT00160940208	NCT00160940_208_T0	PHENOTYPE	0	0	Chronic
NCT00160940208	NCT00160940_208_T1	COMPOUND	1	1	HCV
NCT00160940208	NCT00160940_208_T2	COMPOUND	35	35	HCV
NCT00160940208	NCT00160940_208_T3	PHENOTYPE	32	32	chronic
NCT00160940208	NCT00160940_208_T4	BIOLOGICAL_PROCESS	21	22	gene expression
NCT00160940209	NCT00160940_209_T0	PHENOTYPE	12	12	acute
NCT00160940209	NCT00160940_209_T1	COMPOUND	13	13	HCV
NCT00160940213	NCT00160940_213_T0	GENE	1	1	II
NCT00160940213	NCT00160940_213_T1	PHENOTYPE	16	16	acute
NCT00160940213	NCT00160940_213_T2	COMPOUND	17	17	HCV
NCT00160940213	NCT00160940_213_T3	BIOLOGICAL_PROCESS	11	12	gene expression
NCT00160940214	NCT00160940_214_T0	PHENOTYPE	10	10	progression
NCT00160940214	NCT00160940_214_T1	PHENOTYPE	12	13	chronic disease
NCT001609660	NCT00160966_0_T0	PHENOTYPE	7	7	Nephropathy
NCT001609660	NCT00160966_0_T1	ORGAN	6	6	Transplant
NCT001609663	NCT00160966_3_T0	PHENOTYPE	9	9	understood
NCT001609664	NCT00160966_4_T0	COMPOUND	3	4	mycophenolate mofetil
NCT001609793	NCT00160979_3_T0	PHENOTYPE	6	6	tumor
NCT001609793	NCT00160979_3_T1	PHENOTYPE	21	21	tumor
NCT001609794	NCT00160979_4_T0	PHENOTYPE	4	4	tumor
NCT001609797	NCT00160979_7_T0	PHENOTYPE	4	4	hypoxia
NCT001609797	NCT00160979_7_T1	GENE	27	27	RT
NCT001609797	NCT00160979_7_T2	PHENOTYPE	12	12	tumors
NCT001609797	NCT00160979_7_T3	PHENOTYPE	19	19	tumors
NCT001609797	NCT00160979_7_T4	PHENOTYPE	18	18	hypoxic
NCT001609797	NCT00160979_7_T5	COMPOUND	3	3	oxygen
NCT001609798	NCT00160979_8_T0	PHENOTYPE	2	2	hypoxia
NCT001609798	NCT00160979_8_T1	CELL	29	29	cells
NCT0016097911	NCT00160979_11_T0	GENE	19	19	RT
NCT0016097911	NCT00160979_11_T1	GENE	26	26	RT
NCT0016097911	NCT00160979_11_T2	PHENOTYPE	3	3	tumor
NCT0016097911	NCT00160979_11_T3	COMPOUND	4	4	oxygen
NCT0016097912	NCT00160979_12_T0	ORGAN	7	7	rectum
NCT001609921	NCT00160992_1_T0	PHENOTYPE	6	6	tumor
NCT001609921	NCT00160992_1_T1	CELL	8	9	T cells
NCT001609922	NCT00160992_2_T0	CELL	3	3	cells
NCT001609923	NCT00160992_3_T0	PHENOTYPE	9	9	tumor
NCT001609923	NCT00160992_3_T1	PHENOTYPE	28	28	tumor
NCT001609923	NCT00160992_3_T2	BIOLOGICAL_PROCESS	24	25	immune response
NCT001609923	NCT00160992_3_T3	CELL	11	12	T cells
NCT001609925	NCT00160992_5_T0	CELL	6	6	lymphocytes
NCT001609925	NCT00160992_5_T1	GENE	5	5	CD8
NCT001609928	NCT00160992_8_T0	GENE	3	3	FACS
NCT001609929	NCT00160992_9_T0	PHENOTYPE	13	13	homeostatic
NCT001609929	NCT00160992_9_T1	PHENOTYPE	14	14	proliferation
NCT001609929	NCT00160992_9_T2	PHENOTYPE	20	20	proliferation
NCT001609929	NCT00160992_9_T3	GENE	7	7	CD8
NCT001609929	NCT00160992_9_T4	CELL	8	9	T cells
NCT001610051	NCT00161005_1_T0	PHENOTYPE	30	30	symptoms
NCT001610052	NCT00161005_2_T0	GENE	16	16	has
NCT001610181	NCT00161018_1_T0	COMPOUND	12	12	risperidone
NCT001610181	NCT00161018_1_T1	COMPOUND	9	9	quetiapine
NCT001610181	NCT00161018_1_T2	PHENOTYPE	36	36	schizophrenia
NCT001610181	NCT00161018_1_T3	GENE	33	33	IV
NCT001610181	NCT00161018_1_T4	COMPOUND	20	20	fluphenazine
NCT001610183	NCT00161018_3_T0	COMPOUND	7	7	quetiapine
NCT001610187	NCT00161018_7_T0	COMPOUND	8	8	risperidone
NCT001610187	NCT00161018_7_T1	COMPOUND	5	5	quetiapine
NCT001610187	NCT00161018_7_T2	COMPOUND	15	15	fluphenazine
NCT001610189	NCT00161018_9_T0	GENE	2	2	prolactin
NCT001610189	NCT00161018_9_T1	PHENOTYPE	10	11	sexual dysfunction
NCT001610189	NCT00161018_9_T2	PHENOTYPE	13	14	menstrual irregularities
NCT0016101815	NCT00161018_15_T0	PHENOTYPE	30	30	schizophrenia
NCT0016101815	NCT00161018_15_T1	PHENOTYPE	36	37	psychotic symptoms
NCT0016101819	NCT00161018_19_T0	PHENOTYPE	2	3	psychotic symptoms
NCT0016101823	NCT00161018_23_T0	PHENOTYPE	0	0	Persistence
NCT001610313	NCT00161031_3_T0	GENE	28	28	al
NCT001610313	NCT00161031_3_T1	PHENOTYPE	25	25	SCID
NCT001610313	NCT00161031_3_T2	GENE	27	27	et
NCT001610314	NCT00161031_4_T0	PHENOTYPE	13	13	SCID
NCT001610315	NCT00161031_5_T0	GENE	24	24	SANS
NCT001610315	NCT00161031_5_T1	PHENOTYPE	23	23	Symptoms
NCT001610317	NCT00161031_7_T0	PHENOTYPE	11	11	symptoms
NCT001610317	NCT00161031_7_T1	GENE	17	17	al
NCT001610317	NCT00161031_7_T2	GENE	21	21	al
NCT001610317	NCT00161031_7_T3	GENE	16	16	et
NCT001610317	NCT00161031_7_T4	GENE	20	20	et
NCT001610318	NCT00161031_8_T0	PHENOTYPE	10	10	guilt
NCT001610318	NCT00161031_8_T1	PHENOTYPE	20	20	dysphoria
NCT001610318	NCT00161031_8_T2	PHENOTYPE	11	11	feelings
NCT001610319	NCT00161031_9_T0	PHENOTYPE	2	2	hostility
NCT001610319	NCT00161031_9_T1	PHENOTYPE	11	11	hostility
NCT0016103110	NCT00161031_10_T0	GENE	17	17	1976
NCT0016103110	NCT00161031_10_T1	PHENOTYPE	14	14	Hostility
NCT0016103111	NCT00161031_11_T0	PHENOTYPE	26	26	symptoms
NCT0016103111	NCT00161031_11_T1	GENE	1	1	SANS
NCT0016103111	NCT00161031_11_T2	GENE	3	3	SANS
NCT0016103111	NCT00161031_11_T3	PHENOTYPE	10	11	inappropriate affect
NCT0016103112	NCT00161031_12_T0	PHENOTYPE	33	33	symptoms
NCT0016103112	NCT00161031_12_T1	PHENOTYPE	1	2	inappropriate affect
NCT0016103113	NCT00161031_13_T0	PHENOTYPE	4	4	severity
NCT0016103114	NCT00161031_14_T0	GENE	35	35	SEC
NCT0016103114	NCT00161031_14_T1	GENE	24	24	1976
NCT0016103114	NCT00161031_14_T2	GENE	13	13	SAS
NCT0016103114	NCT00161031_14_T3	GENE	28	28	BAS
NCT0016103114	NCT00161031_14_T4	PHENOTYPE	26	26	Akathisia
NCT0016103114	NCT00161031_14_T5	PHENOTYPE	32	33	Side Effect
NCT0016103114	NCT00161031_14_T6	PHENOTYPE	19	20	Involuntary Movement
NCT0016103115	NCT00161031_15_T0	GENE	1	1	SAS
NCT0016103115	NCT00161031_15_T1	GENE	8	8	SAS
NCT0016103115	NCT00161031_15_T2	PHENOTYPE	14	14	EPS
NCT0016103116	NCT00161031_16_T0	PHENOTYPE	21	21	judgement
NCT0016103116	NCT00161031_16_T1	ORGAN	15	15	extremity
NCT0016103118	NCT00161031_18_T0	GENE	1	1	SEC
NCT0016103119	NCT00161031_19_T0	COMPOUND	13	13	glucose
NCT0016103119	NCT00161031_19_T1	ORGAN	12	12	serum
NCT0016103122	NCT00161031_22_T0	COMPOUND	22	22	glucose
NCT0016103122	NCT00161031_22_T1	ORGAN	27	27	thyroid
NCT0016103122	NCT00161031_22_T2	ORGAN	18	18	liver
NCT0016103122	NCT00161031_22_T3	GENE	25	25	UA
NCT0016103125	NCT00161031_25_T0	COMPOUND	10	10	atomoxetine
NCT0016103128	NCT00161031_28_T0	PHENOTYPE	19	19	imbalance
NCT0016103131	NCT00161031_31_T0	GENE	17	17	log
NCT0016103134	NCT00161031_34_T0	GENE	6	6	SAS
NCT0016103134	NCT00161031_34_T1	GENE	7	7	BAS
NCT0016103134	NCT00161031_34_T2	GENE	5	5	SANS
NCT0016103137	NCT00161031_37_T0	COMPOUND	5	5	atomoxetine
NCT0016103138	NCT00161031_38_T0	GENE	8	8	1.2
NCT0016103138	NCT00161031_38_T1	GENE	13	13	3.8
NCT0016103138	NCT00161031_38_T2	COMPOUND	9	9	atomoxetine
NCT0016103138	NCT00161031_38_T3	COMPOUND	14	14	atomoxetine
NCT0016103143	NCT00161031_43_T0	COMPOUND	11	11	clozapine
NCT0016103146	NCT00161031_46_T0	COMPOUND	27	27	venlafaxine
NCT0016103146	NCT00161031_46_T1	GENE	29	30	monoamine oxidase
NCT0016103147	NCT00161031_47_T0	PHENOTYPE	19	19	akathisia
NCT0016103147	NCT00161031_47_T1	GENE	13	13	1/6
NCT0016103147	NCT00161031_47_T2	COMPOUND	12	12	lorazepam
NCT0016103147	NCT00161031_47_T3	GENE	6	6	PRN
NCT0016103147	NCT00161031_47_T4	PHENOTYPE	11	11	symptoms
NCT0016103147	NCT00161031_47_T5	PHENOTYPE	17	17	agitation
NCT0016103147	NCT00161031_47_T6	COMPOUND	7	7	benztropine
NCT0016103147	NCT00161031_47_T7	COMPOUND	21	22	chloral hydrate
NCT0016103148	NCT00161031_48_T0	GENE	6	6	PRN
NCT0016103148	NCT00161031_48_T1	GENE	19	19	PRN
NCT0016103149	NCT00161031_49_T0	PHENOTYPE	25	25	EPS
NCT0016103150	NCT00161031_50_T0	PHENOTYPE	12	12	withdrawn
NCT0016103150	NCT00161031_50_T1	COMPOUND	5	5	benztropine
NCT0016103150	NCT00161031_50_T2	COMPOUND	7	7	lorazepam
NCT0016103151	NCT00161031_51_T0	PHENOTYPE	3	3	Blind
NCT0016103156	NCT00161031_56_T0	PHENOTYPE	7	7	withdrawn
NCT0016103158	NCT00161031_58_T0	PHENOTYPE	13	14	side effect
NCT0016103160	NCT00161031_60_T0	COMPOUND	16	16	atomoxetine
NCT0016103169	NCT00161031_69_T0	PHENOTYPE	10	11	cognitive impairment
NCT001610442	NCT00161044_2_T0	COMPOUND	12	12	galantamine
NCT001610446	NCT00161044_6_T0	COMPOUND	8	8	galantamine
NCT001610446	NCT00161044_6_T1	COMPOUND	17	17	galantamine
NCT001610447	NCT00161044_7_T0	GENE	32	32	NPI
NCT001610447	NCT00161044_7_T1	GENE	44	44	AES
NCT001610447	NCT00161044_7_T2	PHENOTYPE	41	41	Apathy
NCT001610447	NCT00161044_7_T3	GENE	22	22	SANS
NCT001610447	NCT00161044_7_T4	PHENOTYPE	21	21	Symptoms
NCT001610447	NCT00161044_7_T5	PHENOTYPE	0	1	Psychiatric symptoms
NCT001610449	NCT00161044_9_T0	PHENOTYPE	3	4	adverse effects
NCT0016104411	NCT00161044_11_T0	GENE	24	24	BAS
NCT0016104411	NCT00161044_11_T1	PHENOTYPE	22	22	Akathisia
NCT0016104411	NCT00161044_11_T2	GENE	19	19	EPRS
NCT0016104411	NCT00161044_11_T3	PHENOTYPE	27	29	Abnormal Involuntary Movements
NCT0016104412	NCT00161044_12_T0	GENE	55	55	al
NCT0016104412	NCT00161044_12_T1	COMPOUND	11	11	galantamine
NCT0016104412	NCT00161044_12_T2	COMPOUND	16	16	galantamine
NCT0016104412	NCT00161044_12_T3	GENE	54	54	et
NCT0016104413	NCT00161044_13_T0	COMPOUND	16	16	galantamine
NCT0016104414	NCT00161044_14_T0	COMPOUND	36	36	galantamine
NCT001610574	NCT00161057_4_T0	PHENOTYPE	10	10	schizophrenia
NCT001610574	NCT00161057_4_T1	GENE	11	11	has
NCT001610574	NCT00161057_4_T2	PHENOTYPE	7	8	cognitive deficits
NCT001610574	NCT00161057_4_T3	PHENOTYPE	15	16	brain activity
NCT001610577	NCT00161057_7_T0	PHENOTYPE	7	7	physiology
NCT001610579	NCT00161057_9_T0	GENE	13	13	atypical
NCT0016105711	NCT00161057_11_T0	PHENOTYPE	19	19	Schizophrenia
NCT001610702	NCT00161070_2_T0	PHENOTYPE	0	0	Anticoagulation
NCT001610702	NCT00161070_2_T1	GENE	2	2	has
NCT001610702	NCT00161070_2_T2	PHENOTYPE	21	22	atrial fibrillation
NCT001610702	NCT00161070_2_T3	PHENOTYPE	16	17	cerebral ischemia
NCT001610702	NCT00161070_2_T4	PHENOTYPE	12	13	myocardial infarction
NCT001610706	NCT00161070_6_T0	GENE	0	0	ASA
NCT001610708	NCT00161070_8_T0	PHENOTYPE	13	13	bleeding
NCT001610708	NCT00161070_8_T1	PHENOTYPE	9	10	myocardial infarction
NCT001610832	NCT00161083_2_T0	PHENOTYPE	3	3	gallstone
NCT001610833	NCT00161083_3_T0	PHENOTYPE	8	8	gallstone
NCT001610833	NCT00161083_3_T1	GENE	10	10	has
NCT001610833	NCT00161083_3_T2	PHENOTYPE	4	5	biliary colic
NCT001610834	NCT00161083_4_T0	PHENOTYPE	10	10	choledocholithiasis
NCT001610834	NCT00161083_4_T1	PHENOTYPE	2	2	gallstone
NCT001610834	NCT00161083_4_T2	PHENOTYPE	12	13	acute cholecystitis
NCT001610834	NCT00161083_4_T3	PHENOTYPE	8	9	acute pancreatitis
NCT001610835	NCT00161083_5_T0	PHENOTYPE	12	12	complications
NCT001610837	NCT00161083_7_T0	PHENOTYPE	10	10	symptoms
NCT001610837	NCT00161083_7_T1	ORGAN	6	6	gallbladder
NCT001610837	NCT00161083_7_T2	PHENOTYPE	1	2	gallbladder stones
NCT001610839	NCT00161083_9_T0	ORGAN	2	2	gallbladder
NCT001610839	NCT00161083_9_T1	ORGAN	20	20	gallbladder
NCT001610839	NCT00161083_9_T2	PHENOTYPE	9	9	colics
NCT001610839	NCT00161083_9_T3	PHENOTYPE	3	3	motility
NCT001610839	NCT00161083_9_T4	PHENOTYPE	11	12	gallbladder stone
NCT0016108312	NCT00161083_12_T0	COMPOUND	8	8	UDCA
NCT0016108312	NCT00161083_12_T1	PHENOTYPE	1	2	biliary pancreatitis
NCT0016108313	NCT00161083_13_T0	ORGAN	5	5	gallbladder
NCT0016108313	NCT00161083_13_T1	GENE	15	15	mucin
NCT0016108313	NCT00161083_13_T2	COMPOUND	8	8	UDCA
NCT0016108314	NCT00161083_14_T0	PHENOTYPE	8	8	symptoms
NCT0016108314	NCT00161083_14_T1	PHENOTYPE	10	10	complications
NCT0016108314	NCT00161083_14_T2	COMPOUND	6	6	UDCA
NCT0016108315	NCT00161083_15_T0	PHENOTYPE	4	4	gallstone
NCT001610962	NCT00161096_2_T0	GENE	16	16	has
NCT001610962	NCT00161096_2_T1	PHENOTYPE	10	10	chronic
NCT001610965	NCT00161096_5_T0	PHENOTYPE	6	6	chronic
NCT001610966	NCT00161096_6_T0	COMPOUND	5	5	pantoprazole
NCT001610966	NCT00161096_6_T1	PHENOTYPE	0	0	Chronic
NCT001610967	NCT00161096_7_T0	PHENOTYPE	39	39	dependency
NCT001610967	NCT00161096_7_T1	PHENOTYPE	5	5	symptoms
NCT001610967	NCT00161096_7_T2	COMPOUND	20	20	pantoprazole
NCT001610967	NCT00161096_7_T3	COMPOUND	32	32	pantoprazole
NCT001610967	NCT00161096_7_T4	COMPOUND	18	18	1
NCT001610967	NCT00161096_7_T5	GENE	28	29	group 2
NCT001610968	NCT00161096_8_T0	PHENOTYPE	12	12	dependency
NCT001610969	NCT00161096_9_T0	PHENOTYPE	4	4	secondary
NCT001611098	NCT00161109_8_T0	PHENOTYPE	25	25	disorders
NCT001611098	NCT00161109_8_T1	PHENOTYPE	10	10	psychosis
NCT001611098	NCT00161109_8_T2	PHENOTYPE	8	8	autism
NCT001611099	NCT00161109_9_T0	PHENOTYPE	12	13	psychiatric symptoms
NCT0016110912	NCT00161109_12_T0	PHENOTYPE	7	7	SYMPTOMS
NCT0016110919	NCT00161109_19_T0	PHENOTYPE	7	7	deletion
NCT0016110922	NCT00161109_22_T0	PHENOTYPE	27	27	deletion
NCT0016110922	NCT00161109_22_T1	PHENOTYPE	17	17	autistic
NCT0016110923	NCT00161109_23_T0	PHENOTYPE	8	8	deletion
NCT001611222	NCT00161122_2_T0	PHENOTYPE	3	3	diseases
NCT001611222	NCT00161122_2_T1	PHENOTYPE	10	10	recurrent
NCT001611351	NCT00161135_1_T0	GENE	0	0	MRI
NCT001611351	NCT00161135_1_T1	PHENOTYPE	7	7	autism
NCT001611353	NCT00161135_3_T0	ORGAN	9	9	brains
NCT001611353	NCT00161135_3_T1	ORGAN	19	19	brains
NCT001611353	NCT00161135_3_T2	PHENOTYPE	5	5	autism
NCT001611357	NCT00161135_7_T0	PHENOTYPE	12	12	Autism
NCT001611357	NCT00161135_7_T1	PHENOTYPE	17	17	disorders
NCT001611359	NCT00161135_9_T0	GENE	4	4	has
NCT0016113510	NCT00161135_10_T0	GENE	21	21	has
NCT0016113510	NCT00161135_10_T1	PHENOTYPE	7	8	Developmental Disorder
NCT0016113511	NCT00161135_11_T0	PHENOTYPE	12	12	Schizophrenia
NCT0016113511	NCT00161135_11_T1	PHENOTYPE	15	15	Schizophrenia
NCT0016113513	NCT00161135_13_T0	PHENOTYPE	19	19	Schizophrenia
NCT0016113513	NCT00161135_13_T1	PHENOTYPE	14	14	autistic
NCT0016113514	NCT00161135_14_T0	PHENOTYPE	7	8	psychiatric disorders
NCT0016113515	NCT00161135_15_T0	GENE	6	6	structural
NCT0016113518	NCT00161135_18_T0	GENE	1	1	structural
NCT0016113522	NCT00161135_22_T0	PHENOTYPE	32	32	Autism
NCT0016113522	NCT00161135_22_T1	GENE	7	7	structural
NCT0016113522	NCT00161135_22_T2	PHENOTYPE	22	22	Childhood-onset
NCT0016113522	NCT00161135_22_T3	PHENOTYPE	23	23	Schizophrenia
NCT0016113526	NCT00161135_26_T0	GENE	7	7	MRI
NCT0016113526	NCT00161135_26_T1	GENE	24	24	MRI
NCT001611480	NCT00161148_0_T0	PHENOTYPE	4	6	Primary Sclerosing Cholangitis
NCT001611482	NCT00161148_2_T0	PHENOTYPE	4	5	ulcerative colitis
NCT001611483	NCT00161148_3_T0	PHENOTYPE	11	12	ulcerative colitis
NCT001611488	NCT00161148_8_T0	COMPOUND	23	23	nicotine
NCT001611488	NCT00161148_8_T1	COMPOUND	20	20	methotrexate
NCT001611488	NCT00161148_8_T2	COMPOUND	19	19	D-penicillamine
NCT0016114813	NCT00161148_13_T0	PHENOTYPE	5	5	toxic
NCT0016114814	NCT00161148_14_T0	COMPOUND	2	2	L-leucine
NCT0016114815	NCT00161148_15_T0	PHENOTYPE	11	11	colitis
NCT0016114815	NCT00161148_15_T1	PHENOTYPE	17	17	circulation
NCT0016114815	NCT00161148_15_T2	ORGAN	7	7	colon
NCT0016114818	NCT00161148_18_T0	PHENOTYPE	9	9	diseases
NCT0016114818	NCT00161148_18_T1	PHENOTYPE	15	15	pouchitis
NCT0016114818	NCT00161148_18_T2	PHENOTYPE	19	20	liver disease
NCT0016114818	NCT00161148_18_T3	PHENOTYPE	12	14	inflammatory bowel disease
NCT0016114818	NCT00161148_18_T4	PHENOTYPE	17	19	alcoholic fatty liver
NCT0016114824	NCT00161148_24_T0	COMPOUND	2	2	THE
NCT0016114824	NCT00161148_24_T1	GENE	0	0	AIM
NCT0016114824	NCT00161148_24_T2	ORGAN	16	16	liver
NCT0016114824	NCT00161148_24_T3	ORGAN	15	15	serum
NCT0016114825	NCT00161148_25_T0	PHENOTYPE	13	13	pruritus
NCT0016114825	NCT00161148_25_T1	PHENOTYPE	11	11	fatigue
NCT0016114825	NCT00161148_25_T2	PHENOTYPE	0	0	Secondary
NCT0016114827	NCT00161148_27_T0	COMPOUND	2	2	THE
NCT0016114831	NCT00161148_31_T0	PHENOTYPE	18	18	withdrawn
NCT001611612	NCT00161161_2_T0	GENE	32	32	twins
NCT001611612	NCT00161161_2_T1	GENE	43	43	twins
NCT001611612	NCT00161161_2_T2	PHENOTYPE	5	5	ADHD
NCT001611612	NCT00161161_2_T3	PHENOTYPE	15	15	ADHD
NCT001611613	NCT00161161_3_T0	PHENOTYPE	17	17	ADHD
NCT001611614	NCT00161161_4_T0	PHENOTYPE	4	4	ADHD
NCT001611616	NCT00161161_6_T0	PHENOTYPE	9	9	ADHD
NCT0016116110	NCT00161161_10_T0	PHENOTYPE	5	5	ADHD
NCT0016116110	NCT00161161_10_T1	PHENOTYPE	49	49	ADHD
NCT0016116110	NCT00161161_10_T2	GENE	56	56	CD
NCT0016116110	NCT00161161_10_T3	GENE	28	28	TRF
NCT0016116110	NCT00161161_10_T4	GENE	78	78	TRF
NCT0016116110	NCT00161161_10_T5	GENE	110	110	TRF
NCT0016116110	NCT00161161_10_T6	GENE	54	54	ODD
NCT0016116110	NCT00161161_10_T7	COMPOUND	43	43	1
NCT0016116110	NCT00161161_10_T8	COMPOUND	83	83	1
NCT0016116110	NCT00161161_10_T9	COMPOUND	113	113	1
NCT0016116110	NCT00161161_10_T10	COMPOUND	12	12	2
NCT0016116110	NCT00161161_10_T11	COMPOUND	61	61	2
NCT0016116110	NCT00161161_10_T12	COMPOUND	93	93	2
NCT0016116110	NCT00161161_10_T13	GENE	1	1	APA
NCT0016116110	NCT00161161_10_T14	GENE	86	86	APA
NCT0016116110	NCT00161161_10_T15	COMPOUND	29	29	3
NCT0016116110	NCT00161161_10_T16	GENE	10	10	DISC
NCT0016116110	NCT00161161_10_T17	GENE	59	59	DISC
NCT0016116110	NCT00161161_10_T18	GENE	91	91	DISC
NCT0016116110	NCT00161161_10_T19	PHENOTYPE	23	23	CBCL
NCT0016116110	NCT00161161_10_T20	PHENOTYPE	73	73	CBCL
NCT0016116110	NCT00161161_10_T21	PHENOTYPE	105	105	CBCL
NCT001611742	NCT00161174_2_T0	PHENOTYPE	14	14	microalbuminuria
NCT001611742	NCT00161174_2_T1	ORGAN	12	13	left ventricle
NCT001611744	NCT00161174_4_T0	COMPOUND	12	12	bleomycin
NCT001611744	NCT00161174_4_T1	COMPOUND	14	14	cisplatin
NCT001611744	NCT00161174_4_T2	PHENOTYPE	25	26	cardiovascular disease
NCT001611745	NCT00161174_5_T0	PHENOTYPE	11	11	toxicity
NCT001611747	NCT00161174_7_T0	PHENOTYPE	7	7	CVD
NCT001611747	NCT00161174_7_T1	PHENOTYPE	9	10	testicular cancer
NCT001611747	NCT00161174_7_T2	PHENOTYPE	5	6	cardiovascular disease
NCT0016117413	NCT00161174_13_T0	PHENOTYPE	4	5	testicular cancer
NCT0016117414	NCT00161174_14_T0	GENE	9	9	has
NCT0016117418	NCT00161174_18_T0	PHENOTYPE	8	9	late effects
NCT0016117418	NCT00161174_18_T1	PHENOTYPE	15	17	cardiovascular risk factor
NCT0016117419	NCT00161174_19_T0	PHENOTYPE	1	1	toxicity
NCT0016117419	NCT00161174_19_T1	PHENOTYPE	26	26	toxicity
NCT0016117420	NCT00161174_20_T0	PHENOTYPE	9	9	toxicity
NCT0016117420	NCT00161174_20_T1	PHENOTYPE	19	19	toxicity
NCT0016117422	NCT00161174_22_T0	PHENOTYPE	24	24	toxicity
NCT0016117422	NCT00161174_22_T1	GENE	31	31	TC
NCT0016117423	NCT00161174_23_T0	PHENOTYPE	15	15	secondary
NCT0016117423	NCT00161174_23_T1	PHENOTYPE	9	9	toxic
NCT0016117423	NCT00161174_23_T2	PHENOTYPE	17	17	strategies
NCT0016117423	NCT00161174_23_T3	PHENOTYPE	21	23	effects of chemotherapy
NCT001611870	NCT00161187_0_T0	CELL	2	2	Lymphocyte
NCT001611870	NCT00161187_0_T1	PHENOTYPE	14	15	Solid Tumor
NCT001611870	NCT00161187_0_T2	PHENOTYPE	10	12	Refractory Hematologic Cancer
NCT001611872	NCT00161187_2_T0	CELL	15	15	lymphocyte
NCT001611872	NCT00161187_2_T1	PHENOTYPE	28	29	solid tumor
NCT001611872	NCT00161187_2_T2	PHENOTYPE	24	26	refractory hematologic cancer
NCT001611877	NCT00161187_7_T0	CELL	5	5	lymphocyte
NCT001611878	NCT00161187_8_T0	PHENOTYPE	18	18	toxicity
NCT001611878	NCT00161187_8_T1	PHENOTYPE	14	15	disease progression
NCT001611879	NCT00161187_9_T0	CELL	12	12	cells
NCT001611879	NCT00161187_9_T1	CELL	16	16	cells
NCT001611879	NCT00161187_9_T2	CELL	22	22	cells
NCT0016118710	NCT00161187_10_T0	CELL	8	8	lymphocytes
NCT001612001	NCT00161200_1_T0	GENE	0	0	IM
NCT001612005	NCT00161200_5_T0	GENE	5	5	IM
NCT001612005	NCT00161200_5_T1	TISSUE	12	12	Epithelium
NCT001612005	NCT00161200_5_T2	PHENOTYPE	22	25	cancer of the esophagus
NCT0016120010	NCT00161200_10_T0	GENE	13	13	has
NCT0016120012	NCT00161200_12_T0	GENE	22	22	blocker
NCT0016120012	NCT00161200_12_T1	GENE	21	21	H2
NCT0016120012	NCT00161200_12_T2	GENE	17	18	proton pump
NCT0016120024	NCT00161200_24_T0	PHENOTYPE	6	6	symptoms
NCT0016120027	NCT00161200_27_T0	GENE	6	6	pH
NCT0016120027	NCT00161200_27_T1	PHENOTYPE	10	11	acid reflux
NCT0016120029	NCT00161200_29_T0	GENE	11	11	Das
NCT0016120029	NCT00161200_29_T1	GENE	10	10	Dr
NCT001612132	NCT00161213_2_T0	CELL	10	10	cells
NCT001612132	NCT00161213_2_T1	PHENOTYPE	9	9	tumor
NCT001612132	NCT00161213_2_T2	COMPOUND	4	4	imatinib
NCT001612132	NCT00161213_2_T3	COMPOUND	5	5	mesylate
NCT001612132	NCT00161213_2_T4	COMPOUND	1	1	gemcitabine
NCT001612133	NCT00161213_3_T0	GENE	3	3	II
NCT001612133	NCT00161213_3_T1	COMPOUND	13	13	imatinib
NCT001612133	NCT00161213_3_T2	COMPOUND	14	14	mesylate
NCT001612133	NCT00161213_3_T3	COMPOUND	10	10	gemcitabine
NCT001612133	NCT00161213_3_T4	PHENOTYPE	26	28	metastatic pancreatic cancer
NCT001612137	NCT00161213_7_T0	COMPOUND	3	3	hydrochloride
NCT001612137	NCT00161213_7_T1	GENE	19	19	1.5
NCT001612137	NCT00161213_7_T2	COMPOUND	15	15	imatinib
NCT001612137	NCT00161213_7_T3	COMPOUND	16	16	mesylate
NCT001612137	NCT00161213_7_T4	COMPOUND	2	2	gemcitabine
NCT001612137	NCT00161213_7_T5	GENE	4	4	IV
NCT001612138	NCT00161213_8_T0	PHENOTYPE	13	13	toxicity
NCT001612138	NCT00161213_8_T1	PHENOTYPE	9	10	disease progression
NCT001612261	NCT00161226_1_T0	PHENOTYPE	9	10	endometrial cancer
NCT001612263	NCT00161226_3_T0	PHENOTYPE	6	7	endometrial hyperplasia
NCT001612264	NCT00161226_4_T0	COMPOUND	1	1	progestins
NCT001612264	NCT00161226_4_T1	PHENOTYPE	15	15	acne
NCT001612264	NCT00161226_4_T2	PHENOTYPE	13	13	headaches
NCT001612264	NCT00161226_4_T3	PHENOTYPE	9	10	weight gain
NCT001612264	NCT00161226_4_T4	PHENOTYPE	11	12	mood changes
NCT001612265	NCT00161226_5_T0	COMPOUND	8	8	progesterone
NCT001612265	NCT00161226_5_T1	GENE	4	4	has
NCT001612267	NCT00161226_7_T0	COMPOUND	19	19	BMI
NCT001612268	NCT00161226_8_T0	GENE	10	10	25
NCT001612268	NCT00161226_8_T1	PHENOTYPE	5	5	obesity
NCT001612268	NCT00161226_8_T2	COMPOUND	0	0	BMI
NCT001612269	NCT00161226_9_T0	COMPOUND	9	9	levonorgestrel
NCT0016122613	NCT00161226_13_T0	GENE	16	16	had
NCT0016122613	NCT00161226_13_T1	PHENOTYPE	17	18	endometrial hyperplasia
NCT0016122616	NCT00161226_16_T0	PHENOTYPE	9	10	endometrial cancer
NCT0016122618	NCT00161226_18_T0	PHENOTYPE	6	7	endometrial hyperplasia
NCT0016122619	NCT00161226_19_T0	COMPOUND	1	1	progestins
NCT0016122619	NCT00161226_19_T1	PHENOTYPE	15	15	acne
NCT0016122619	NCT00161226_19_T2	PHENOTYPE	13	13	headaches
NCT0016122619	NCT00161226_19_T3	PHENOTYPE	9	10	weight gain
NCT0016122619	NCT00161226_19_T4	PHENOTYPE	11	12	mood changes
NCT0016122620	NCT00161226_20_T0	COMPOUND	8	8	progesterone
NCT0016122620	NCT00161226_20_T1	GENE	4	4	has
NCT0016122622	NCT00161226_22_T0	COMPOUND	19	19	BMI
NCT0016122623	NCT00161226_23_T0	GENE	10	10	25
NCT0016122623	NCT00161226_23_T1	PHENOTYPE	5	5	obesity
NCT0016122623	NCT00161226_23_T2	COMPOUND	0	0	BMI
NCT0016122624	NCT00161226_24_T0	COMPOUND	9	9	levonorgestrel
NCT0016122628	NCT00161226_28_T0	GENE	16	16	had
NCT0016122628	NCT00161226_28_T1	PHENOTYPE	17	18	endometrial hyperplasia
NCT0016122631	NCT00161226_31_T0	COMPOUND	3	3	BMI
NCT0016122633	NCT00161226_33_T0	PHENOTYPE	1	1	vaginosis
NCT0016122634	NCT00161226_34_T0	PHENOTYPE	3	4	inflammatory disease
NCT001612393	NCT00161239_3_T0	PHENOTYPE	13	13	lymphomas
NCT001612399	NCT00161239_9_T0	PHENOTYPE	13	13	lymphomas
NCT0016123913	NCT00161239_13_T0	PHENOTYPE	6	7	T-Cell Lymphoma
NCT0016123913	NCT00161239_13_T1	ORGAN	16	17	bone marrow
NCT001612653	NCT00161265_3_T0	GENE	24	24	M1
NCT001612653	NCT00161265_3_T1	COMPOUND	21	21	N
NCT001612653	NCT00161265_3_T2	PHENOTYPE	12	13	primary tumor
NCT001612653	NCT00161265_3_T3	PHENOTYPE	7	9	invasive breast cancer
NCT001612654	NCT00161265_4_T0	PHENOTYPE	0	1	Recurrent disease
NCT001612658	NCT00161265_8_T0	GENE	8	8	M1
NCT001612658	NCT00161265_8_T1	PHENOTYPE	6	6	recurrent
NCT001612659	NCT00161265_9_T0	GENE	6	6	M1
NCT0016126511	NCT00161265_11_T0	GENE	11	11	OR
NCT0016126511	NCT00161265_11_T1	GENE	3	3	had
NCT0016126514	NCT00161265_14_T0	PHENOTYPE	0	1	Breast tumors
NCT0016126516	NCT00161265_16_T0	PHENOTYPE	0	0	Tumors
NCT0016126516	NCT00161265_16_T1	PHENOTYPE	12	13	measurable disease
NCT0016126518	NCT00161265_18_T0	PHENOTYPE	16	17	breast cancer
NCT0016126519	NCT00161265_19_T0	COMPOUND	3	3	tamoxifen
NCT0016126519	NCT00161265_19_T1	PHENOTYPE	10	11	breast cancer
NCT001612782	NCT00161278_2_T0	COMPOUND	7	7	paclitaxel
NCT001612785	NCT00161278_5_T0	PHENOTYPE	31	31	tumors
NCT001612785	NCT00161278_5_T1	PHENOTYPE	16	17	lung cancers
NCT001612787	NCT00161278_7_T0	COMPOUND	5	5	paclitaxel
NCT0016127813	NCT00161278_13_T0	PHENOTYPE	2	2	tumor
NCT0016127815	NCT00161278_15_T0	PHENOTYPE	11	11	tumor
NCT0016127815	NCT00161278_15_T1	PHENOTYPE	26	26	tumor
NCT0016127816	NCT00161278_16_T0	PHENOTYPE	21	21	tumor
NCT0016127821	NCT00161278_21_T0	PHENOTYPE	23	23	tumor
NCT0016127822	NCT00161278_22_T0	PHENOTYPE	14	14	tumors
NCT0016127822	NCT00161278_22_T1	PHENOTYPE	11	11	nodules
NCT0016127822	NCT00161278_22_T2	TISSUE	8	9	lymph nodes
NCT0016127822	NCT00161278_22_T3	ORGAN	12	13	chest wall
NCT0016127823	NCT00161278_23_T0	PHENOTYPE	15	15	tumor
NCT0016127824	NCT00161278_24_T0	PHENOTYPE	10	10	tumor
NCT0016127826	NCT00161278_26_T0	PHENOTYPE	31	31	bleeding
NCT0016127826	NCT00161278_26_T1	PHENOTYPE	7	7	anesthesia
NCT0016127826	NCT00161278_26_T2	GENE	19	19	numb
NCT0016127827	NCT00161278_27_T0	PHENOTYPE	11	11	fits
NCT0016127831	NCT00161278_31_T0	PHENOTYPE	19	19	tumor
NCT0016127832	NCT00161278_32_T0	PHENOTYPE	6	6	tumor
NCT0016127834	NCT00161278_34_T0	GENE	7	7	cc
NCT0016127834	NCT00161278_34_T1	ORGAN	34	34	kidney
NCT0016127834	NCT00161278_34_T2	ORGAN	32	32	liver
NCT0016127834	NCT00161278_34_T3	GENE	4	4	2.3
NCT001612917	NCT00161291_7_T0	PHENOTYPE	2	4	inflammatory breast cancer
NCT001613043	NCT00161304_3_T0	PHENOTYPE	13	14	mental health
NCT001613045	NCT00161304_5_T0	PHENOTYPE	3	3	hypogonadism
NCT001613045	NCT00161304_5_T1	ORGAN	7	7	serum
NCT001613045	NCT00161304_5_T2	ORGAN	17	17	serum
NCT001613045	NCT00161304_5_T3	PHENOTYPE	8	9	testosterone level
NCT0016130413	NCT00161304_13_T0	COMPOUND	4	4	testosterone
NCT0016130413	NCT00161304_13_T1	PHENOTYPE	2	2	allergy
NCT0016130419	NCT00161304_19_T0	PHENOTYPE	2	5	alcohol abuse or dependence
NCT0016130429	NCT00161304_29_T0	GENE	3	3	20.10
NCT0016130432	NCT00161304_32_T0	PHENOTYPE	5	6	bleeding disorder
NCT0016130434	NCT00161304_34_T0	PHENOTYPE	14	14	incompetence
NCT0016130434	NCT00161304_34_T1	PHENOTYPE	17	17	comprehension
NCT001613172	NCT00161317_2_T0	PHENOTYPE	6	7	advanced cancer
NCT001613174	NCT00161317_4_T0	GENE	10	10	had
NCT001613174	NCT00161317_4_T1	PHENOTYPE	14	16	quality of life
NCT001613175	NCT00161317_5_T0	PHENOTYPE	11	13	quality of life
NCT001613177	NCT00161317_7_T0	GENE	5	5	nested
NCT001613178	NCT00161317_8_T0	PHENOTYPE	12	14	Quality of Life
NCT001613178	NCT00161317_8_T1	PHENOTYPE	7	9	quality of life
NCT0016131711	NCT00161317_11_T0	PHENOTYPE	2	4	quality of life
NCT0016131713	NCT00161317_13_T0	GENE	7	7	had
NCT0016131713	NCT00161317_13_T1	PHENOTYPE	15	17	quality of life
NCT0016131715	NCT00161317_15_T0	PHENOTYPE	16	18	quality of life
NCT001613307	NCT00161330_7_T0	GENE	5	5	al
NCT001613307	NCT00161330_7_T1	PHENOTYPE	35	35	reflux
NCT001613307	NCT00161330_7_T2	GENE	4	4	et
NCT001613307	NCT00161330_7_T3	PHENOTYPE	17	18	acute illness
NCT0016133013	NCT00161330_13_T0	COMPOUND	12	12	1
NCT0016133013	NCT00161330_13_T1	GENE	7	7	WBC
NCT0016133014	NCT00161330_14_T0	COMPOUND	14	14	CFU
NCT0016133015	NCT00161330_15_T0	GENE	4	4	NB
NCT0016133015	NCT00161330_15_T1	PHENOTYPE	12	12	fever
NCT0016133015	NCT00161330_15_T2	PHENOTYPE	0	0	Fever
NCT0016133021	NCT00161330_21_T0	PHENOTYPE	2	2	fever
NCT001613430	NCT00161343_0_T0	PHENOTYPE	1	1	HIV
NCT001613435	NCT00161343_5_T0	PHENOTYPE	9	9	HIV
NCT001613437	NCT00161343_7_T0	PHENOTYPE	12	12	HIV
NCT001613437	NCT00161343_7_T1	GENE	28	28	CTL
NCT001613437	NCT00161343_7_T2	PHENOTYPE	25	25	practices
NCT001613437	NCT00161343_7_T3	GENE	8	8	IMB
NCT001613439	NCT00161343_9_T0	PHENOTYPE	14	14	HIV
NCT001613439	NCT00161343_9_T1	PHENOTYPE	30	30	gonorrhea
NCT001613439	NCT00161343_9_T2	PHENOTYPE	28	28	STDs
NCT001613439	NCT00161343_9_T3	GENE	34	34	CTL
NCT001613439	NCT00161343_9_T4	PHENOTYPE	23	23	practices
NCT001613439	NCT00161343_9_T5	GENE	7	7	IMB
NCT0016134311	NCT00161343_11_T0	PHENOTYPE	42	42	initiation
NCT0016134311	NCT00161343_11_T1	PHENOTYPE	17	17	HIV
NCT0016134311	NCT00161343_11_T2	PHENOTYPE	46	46	HIV
NCT001613563	NCT00161356_3_T0	ORGAN	36	36	liver
NCT001613563	NCT00161356_3_T1	ORGAN	37	37	transplant
NCT001613567	NCT00161356_7_T0	ORGAN	15	15	liver
NCT001613567	NCT00161356_7_T1	COMPOUND	3	3	AmBisome
NCT001613567	NCT00161356_7_T2	ORGAN	16	16	lungs
NCT001613567	NCT00161356_7_T3	CELL	18	18	leukocytes
NCT001613567	NCT00161356_7_T4	GENE	5	5	has
NCT001613568	NCT00161356_8_T0	ORGAN	15	15	liver
NCT001613568	NCT00161356_8_T1	GENE	2	2	has
NCT001613569	NCT00161356_9_T0	ORGAN	16	16	liver
NCT001613569	NCT00161356_9_T1	COMPOUND	9	9	AmBisome
NCT001613569	NCT00161356_9_T2	PHENOTYPE	12	12	reperfusion
NCT0016135611	NCT00161356_11_T0	ORGAN	15	15	transplant
NCT0016135613	NCT00161356_13_T0	PHENOTYPE	6	7	adverse effects
NCT0016135613	NCT00161356_13_T1	PHENOTYPE	3	4	fungal infections
NCT0016135614	NCT00161356_14_T0	PHENOTYPE	7	7	ascites
NCT0016135614	NCT00161356_14_T1	COMPOUND	16	16	AmBisome
NCT0016135614	NCT00161356_14_T2	PHENOTYPE	20	21	fungal infections
NCT001613691	NCT00161369_1_T0	PHENOTYPE	25	25	atherosclerosis
NCT001613691	NCT00161369_1_T1	ORGAN	11	11	serum
NCT001613691	NCT00161369_1_T2	PHENOTYPE	14	14	Hcy
NCT001613693	NCT00161369_3_T0	PHENOTYPE	25	25	atherosclerosis
NCT001613693	NCT00161369_3_T1	ORGAN	11	11	serum
NCT001613693	NCT00161369_3_T2	PHENOTYPE	14	14	Hcy
NCT001613695	NCT00161369_5_T0	GENE	8	8	had
NCT001613697	NCT00161369_7_T0	ORGAN	4	4	plasma
NCT001613697	NCT00161369_7_T1	PHENOTYPE	5	5	Hcy
NCT001613698	NCT00161369_8_T0	PHENOTYPE	11	11	atherosclerosis
NCT001613823	NCT00161382_3_T0	PHENOTYPE	3	3	decision-making
NCT0016138211	NCT00161382_11_T0	PHENOTYPE	0	0	Intentions
NCT0016138220	NCT00161382_20_T0	PHENOTYPE	38	38	intentions
NCT0016138222	NCT00161382_22_T0	PHENOTYPE	18	18	perceived
NCT0016138222	NCT00161382_22_T1	PHENOTYPE	15	15	attitudes
NCT0016138222	NCT00161382_22_T2	PHENOTYPE	14	14	self-efficacy
NCT001613954	NCT00161395_4_T0	PHENOTYPE	18	18	subfertility
NCT001613956	NCT00161395_6_T0	BIOLOGICAL_PROCESS	35	36	menstrual cycle
NCT001613958	NCT00161395_8_T0	BIOLOGICAL_PROCESS	25	26	menstrual cycle
NCT001614082	NCT00161408_2_T0	PHENOTYPE	4	4	relapse
NCT001614210	NCT00161421_0_T0	PHENOTYPE	6	6	Pharmacokinetics
NCT001614212	NCT00161421_2_T0	COMPOUND	11	11	testosterone
NCT001614218	NCT00161421_8_T0	COMPOUND	16	16	testosterone
NCT001614218	NCT00161421_8_T1	COMPOUND	27	27	testosterone
NCT0016142111	NCT00161421_11_T0	PHENOTYPE	27	27	bloodstream
NCT0016142111	NCT00161421_11_T1	COMPOUND	6	6	testosterone
NCT0016142113	NCT00161421_13_T0	COMPOUND	13	13	testosterone
NCT0016142113	NCT00161421_13_T1	COMPOUND	26	26	testosterone
NCT0016142113	NCT00161421_13_T2	COMPOUND	4	4	Lupron
NCT0016142114	NCT00161421_14_T0	COMPOUND	11	11	testosterone
NCT0016142115	NCT00161421_15_T0	COMPOUND	12	12	testosterone
NCT0016142116	NCT00161421_16_T0	COMPOUND	11	11	testosterone
NCT0016142116	NCT00161421_16_T1	COMPOUND	18	18	testosterone
NCT0016142117	NCT00161421_17_T0	COMPOUND	5	5	testosterone
NCT001614342	NCT00161434_2_T0	GENE	9	9	GUD
NCT001614342	NCT00161434_2_T1	PHENOTYPE	0	1	Herpes simplex
NCT001614343	NCT00161434_3_T0	PHENOTYPE	26	26	HIV
NCT001614343	NCT00161434_3_T1	PHENOTYPE	35	35	HIV
NCT001614343	NCT00161434_3_T2	PHENOTYPE	15	15	suppression
NCT001614343	NCT00161434_3_T3	GENE	30	30	co
NCT001614347	NCT00161434_7_T0	GENE	25	25	CD4
NCT001614347	NCT00161434_7_T1	PHENOTYPE	17	17	HIV
NCT001614347	NCT00161434_7_T2	PHENOTYPE	29	29	HIV
NCT001614347	NCT00161434_7_T3	PHENOTYPE	19	19	HSV
NCT001614347	NCT00161434_7_T4	ORGAN	28	28	plasma
NCT001614348	NCT00161434_8_T0	ORGAN	3	3	genital
NCT0016143410	NCT00161434_10_T0	ORGAN	11	11	genital
NCT001614473	NCT00161447_3_T0	COMPOUND	14	14	acetate
NCT001614473	NCT00161447_3_T1	CELL	23	23	sperm
NCT001614473	NCT00161447_3_T2	GENE	11	11	gel
NCT001614474	NCT00161447_4_T0	PHENOTYPE	15	15	suppression
NCT001614474	NCT00161447_4_T1	PHENOTYPE	29	29	suppression
NCT001614474	NCT00161447_4_T2	BIOLOGICAL_PROCESS	31	31	spermatogenesis
NCT001614474	NCT00161447_4_T3	GENE	23	23	GnRH
NCT001614477	NCT00161447_7_T0	PHENOTYPE	6	6	blocks
NCT001614477	NCT00161447_7_T1	GENE	12	12	FSH
NCT001614477	NCT00161447_7_T2	GENE	3	3	GnRH
NCT001614479	NCT00161447_9_T0	PHENOTYPE	9	9	azoospermia
NCT001614479	NCT00161447_9_T1	PHENOTYPE	4	4	suppression
NCT001614479	NCT00161447_9_T2	BIOLOGICAL_PROCESS	6	6	spermatogenesis
NCT001614600	NCT00161460_0_T0	PHENOTYPE	0	1	Colorectal Cancer
NCT001614604	NCT00161460_4_T0	PHENOTYPE	18	19	colorectal cancer
NCT001614606	NCT00161460_6_T0	PHENOTYPE	13	14	colorectal cancer
NCT001614608	NCT00161460_8_T0	PHENOTYPE	18	18	pathology
NCT001614608	NCT00161460_8_T1	GENE	8	8	has
NCT001614609	NCT00161460_9_T0	PHENOTYPE	9	10	colorectal cancer
NCT0016146010	NCT00161460_10_T0	PHENOTYPE	10	11	colorectal cancer
NCT0016146012	NCT00161460_12_T0	PHENOTYPE	14	15	colorectal cancer
NCT0016146014	NCT00161460_14_T0	PHENOTYPE	12	12	practices
NCT001614736	NCT00161473_6_T0	PHENOTYPE	25	25	agitation
NCT001614736	NCT00161473_6_T1	GENE	6	6	had
NCT001614736	NCT00161473_6_T2	GENE	5	5	has
NCT001614736	NCT00161473_6_T3	COMPOUND	4	4	prazosin
NCT001614736	NCT00161473_6_T4	PHENOTYPE	11	13	Posttraumatic Stress Disorder
NCT001614737	NCT00161473_7_T0	PHENOTYPE	4	5	Alzheimer's disease
NCT001614866	NCT00161486_6_T0	COMPOUND	26	26	testosterone
NCT001614866	NCT00161486_6_T1	ORGAN	23	23	testes
NCT001614866	NCT00161486_6_T2	GENE	4	4	FSH
NCT001614866	NCT00161486_6_T3	ORGAN	11	12	pituitary gland
NCT001614867	NCT00161486_7_T0	COMPOUND	3	3	testosterone
NCT001614867	NCT00161486_7_T1	PHENOTYPE	2	2	blocks
NCT001614868	NCT00161486_8_T0	COMPOUND	14	14	testosterone
NCT001614868	NCT00161486_8_T1	GENE	11	11	FSH
NCT0016152512	NCT00161525_12_T0	GENE	3	3	displaced
NCT001615380	NCT00161538_0_T0	PHENOTYPE	10	10	Strategies
NCT001615380	NCT00161538_0_T1	PHENOTYPE	12	13	Atrial Fibrillation
NCT001615380	NCT00161538_0_T2	PHENOTYPE	5	7	Sick Sinus Syndrome
NCT001615384	NCT00161538_4_T0	GENE	15	15	AF
NCT001615385	NCT00161538_5_T0	GENE	6	6	AF
NCT001615386	NCT00161538_6_T0	COMPOUND	3	3	2
NCT001615386	NCT00161538_6_T1	COMPOUND	7	7	3
NCT001615386	NCT00161538_6_T2	ORGAN	5	6	atrial appendage
NCT0016153811	NCT00161538_11_T0	PHENOTYPE	20	20	complications
NCT0016153811	NCT00161538_11_T1	GENE	5	5	AF
NCT0016153811	NCT00161538_11_T2	GENE	7	7	AF
NCT0016153811	NCT00161538_11_T3	GENE	11	11	AF
NCT0016153811	NCT00161538_11_T4	PHENOTYPE	14	16	Quality of Life
NCT001615513	NCT00161551_3_T0	GENE	16	16	has
NCT001615513	NCT00161551_3_T1	GENE	10	10	ventricular
NCT001615513	NCT00161551_3_T2	PHENOTYPE	27	28	heart failure
NCT001615513	NCT00161551_3_T3	PHENOTYPE	24	25	atrial fibrillation
NCT001615513	NCT00161551_3_T4	PHENOTYPE	17	18	adverse effects
NCT001615642	NCT00161564_2_T0	PHENOTYPE	8	9	platelet count
NCT001615645	NCT00161564_5_T0	PHENOTYPE	0	0	Secondary
NCT001616031	NCT00161603_1_T0	PHENOTYPE	21	22	heart disease
NCT001616034	NCT00161603_4_T0	PHENOTYPE	8	9	psychological factors
NCT001616035	NCT00161603_5_T0	PHENOTYPE	21	22	heart disease
NCT001616038	NCT00161603_8_T0	GENE	16	16	tailor
NCT001616291	NCT00161629_1_T0	GENE	35	35	RUS
NCT001616291	NCT00161629_1_T1	PHENOTYPE	17	17	fracture
NCT001616291	NCT00161629_1_T2	PHENOTYPE	40	41	fracture displacement
NCT001616297	NCT00161629_7_T0	PHENOTYPE	16	16	fracture
NCT001616420	NCT00161642_0_T0	PHENOTYPE	6	7	Solid Tumors
NCT001616422	NCT00161642_2_T0	PHENOTYPE	13	13	tumors
NCT001616422	NCT00161642_2_T1	PHENOTYPE	12	12	affects
NCT001616945	NCT00161694_5_T0	COMPOUND	23	23	oxygen
NCT001617331	NCT00161733_1_T0	PHENOTYPE	1	1	bleeding
NCT001617331	NCT00161733_1_T1	BIOLOGICAL_PROCESS	11	11	hemostasis
NCT001617332	NCT00161733_2_T0	BIOLOGICAL_PROCESS	2	2	hemostasis
NCT001617856	NCT00161785_6_T0	GENE	24	24	has
NCT001617856	NCT00161785_6_T1	GENE	12	12	booster
NCT001618631	NCT00161863_1_T0	PHENOTYPE	7	7	fever
NCT001618632	NCT00161863_2_T0	GENE	7	7	has
NCT001618632	NCT00161863_2_T1	GENE	4	4	ml
NCT001618636	NCT00161863_6_T0	GENE	24	24	has
NCT001619151	NCT00161915_1_T0	PHENOTYPE	14	14	bleeding
NCT001619671	NCT00161967_1_T0	PHENOTYPE	22	22	concentrations
NCT001619671	NCT00161967_1_T1	GENE	7	7	has
NCT001619671	NCT00161967_1_T2	GENE	37	37	booster
NCT001619672	NCT00161967_2_T0	PHENOTYPE	5	5	persistence
NCT001619672	NCT00161967_2_T1	GENE	23	23	209
NCT001619672	NCT00161967_2_T2	GENE	43	43	209
NCT001619672	NCT00161967_2_T3	GENE	28	28	booster
NCT001619674	NCT00161967_4_T0	GENE	23	23	has
NCT001619674	NCT00161967_4_T1	GENE	11	11	booster
NCT001620322	NCT00162032_2_T0	ORGAN	7	7	heart
NCT001620840	NCT00162084_0_T0	GENE	4	4	MPI
NCT001620970	NCT00162097_0_T0	PHENOTYPE	0	0	Pharmacokinetics
NCT001620970	NCT00162097_0_T1	PHENOTYPE	8	9	Hepatic Impairment
NCT001621360	NCT00162136_0_T0	PHENOTYPE	14	14	Malignancies
NCT001621753	NCT00162175_3_T0	GENE	0	0	1.5
NCT001622140	NCT00162214_0_T0	PHENOTYPE	7	8	Solid Tumors
NCT001622270	NCT00162227_0_T0	GENE	1	1	Expanded
NCT001622270	NCT00162227_0_T1	PHENOTYPE	14	15	HIV Infection
NCT001622535	NCT00162253_5_T0	PHENOTYPE	2	2	infections
NCT001622661	NCT00162266_1_T0	PHENOTYPE	1	1	secondary
NCT001622661	NCT00162266_1_T1	PHENOTYPE	7	7	pharmacodynamic
NCT001622664	NCT00162266_4_T0	GENE	9	9	1.1
NCT0016226610	NCT00162266_10_T0	GENE	27	27	II
NCT0016226610	NCT00162266_10_T1	GENE	29	29	III
NCT0016226610	NCT00162266_10_T2	PHENOTYPE	8	8	Rheumatism
NCT0016226610	NCT00162266_10_T3	PHENOTYPE	15	16	rheumatoid arthritis
NCT0016226619	NCT00162266_19_T0	PHENOTYPE	3	3	vasculitis
NCT0016226619	NCT00162266_19_T1	PHENOTYPE	11	13	subcutaneous rheumatoid nodules
NCT0016226620	NCT00162266_20_T0	PHENOTYPE	1	1	symptoms
NCT0016226620	NCT00162266_20_T1	PHENOTYPE	4	4	progressive
NCT0016226623	NCT00162266_23_T0	PHENOTYPE	7	7	initiation
NCT0016226626	NCT00162266_26_T0	PHENOTYPE	28	28	Immunodeficiency
NCT0016226626	NCT00162266_26_T1	PHENOTYPE	30	30	HIV
NCT0016226626	NCT00162266_26_T2	PHENOTYPE	33	34	hepatitis B
NCT0016226626	NCT00162266_26_T3	PHENOTYPE	14	15	viral infections
NCT0016226627	NCT00162266_27_T0	PHENOTYPE	16	16	bronchiectasis
NCT0016226627	NCT00162266_27_T1	PHENOTYPE	9	9	pneumonia
NCT0016226627	NCT00162266_27_T2	PHENOTYPE	18	18	sinusitis
NCT0016226627	NCT00162266_27_T3	PHENOTYPE	13	14	chest infection
NCT0016226627	NCT00162266_27_T4	PHENOTYPE	5	6	chronic infections
NCT0016226627	NCT00162266_27_T5	PHENOTYPE	11	12	renal infection
NCT0016226628	NCT00162266_28_T0	PHENOTYPE	2	3	active tuberculosis
NCT001623440	NCT00162344_0_T0	ORGAN	4	4	Heart
NCT001623440	NCT00162344_0_T1	PHENOTYPE	16	16	Disease
NCT001623440	NCT00162344_0_T2	PHENOTYPE	9	9	Diabetes
NCT001623440	NCT00162344_0_T3	PHENOTYPE	13	14	Coronary Disease
NCT001623570	NCT00162357_0_T0	PHENOTYPE	5	5	Diabetes
NCT001623570	NCT00162357_0_T1	ORGAN	8	9	Coronary Artery
NCT001623702	NCT00162370_2_T0	PHENOTYPE	23	23	debility
NCT001623702	NCT00162370_2_T1	COMPOUND	26	26	dobutamine
NCT001623702	NCT00162370_2_T2	PHENOTYPE	20	21	lung disease
NCT001623832	NCT00162383_2_T0	GENE	21	21	II
NCT001623832	NCT00162383_2_T1	PHENOTYPE	11	11	encoding
NCT001623833	NCT00162383_3_T0	GENE	20	20	II
NCT001623833	NCT00162383_3_T1	GENE	5	5	ws
NCT001623961	NCT00162396_1_T0	PHENOTYPE	19	19	encoding
NCT001623962	NCT00162396_2_T0	COMPOUND	12	12	salbutamol
NCT001623964	NCT00162396_4_T0	PHENOTYPE	7	7	pulse
NCT001623964	NCT00162396_4_T1	PHENOTYPE	1	1	pharmacodynamic
NCT001623965	NCT00162396_5_T0	COMPOUND	11	11	salbutamol
NCT001623965	NCT00162396_5_T1	ORGAN	3	3	plasma
NCT001623965	NCT00162396_5_T2	ORGAN	12	12	plasma
NCT001624091	NCT00162409_1_T0	GENE	19	19	CYP2C9
NCT001624091	NCT00162409_1_T1	BIOLOGICAL_PROCESS	1	1	metabolism
NCT001624091	NCT00162409_1_T2	COMPOUND	4	4	warfarin
NCT001624091	NCT00162409_1_T3	COMPOUND	10	10	warfarin
NCT001624092	NCT00162409_2_T0	COMPOUND	16	16	warfarin
NCT001624092	NCT00162409_2_T1	COMPOUND	21	21	warfarin
NCT001624092	NCT00162409_2_T2	COMPOUND	28	28	warfarin
NCT001624092	NCT00162409_2_T3	COMPOUND	12	13	folic acid
NCT001624093	NCT00162409_3_T0	COMPOUND	14	14	warfarin
NCT001624093	NCT00162409_3_T1	COMPOUND	17	17	warfarin
NCT001624093	NCT00162409_3_T2	COMPOUND	5	6	folic acid
NCT001624222	NCT00162422_2_T0	COMPOUND	36	36	salbutamol
NCT001624224	NCT00162422_4_T0	PHENOTYPE	7	7	concentrations
NCT001624226	NCT00162422_6_T0	PHENOTYPE	21	22	drug effect
NCT001624352	NCT00162435_2_T0	GENE	8	8	VKORC1
NCT001624352	NCT00162435_2_T1	GENE	10	10	VII
NCT001624352	NCT00162435_2_T2	GENE	31	31	has
NCT001624352	NCT00162435_2_T3	COMPOUND	25	25	warfarin
NCT001624353	NCT00162435_3_T0	GENE	13	13	VKORC1
NCT001624353	NCT00162435_3_T1	GENE	12	12	CYP2C9
NCT001624353	NCT00162435_3_T2	GENE	16	16	VII
NCT001624353	NCT00162435_3_T3	PHENOTYPE	10	10	encoding
NCT001624353	NCT00162435_3_T4	COMPOUND	18	18	warfarin
NCT001624356	NCT00162435_6_T0	GENE	12	12	VKORC1
NCT001624356	NCT00162435_6_T1	GENE	11	11	CYP2C9
NCT001624356	NCT00162435_6_T2	GENE	15	15	VII
NCT001624356	NCT00162435_6_T3	PHENOTYPE	9	9	encoding
NCT001624356	NCT00162435_6_T4	COMPOUND	17	17	warfarin
NCT001624358	NCT00162435_8_T0	GENE	12	12	VKORC1
NCT001624358	NCT00162435_8_T1	GENE	11	11	CYP2C9
NCT001624358	NCT00162435_8_T2	GENE	15	15	VII
NCT001624358	NCT00162435_8_T3	GENE	24	24	reduced
NCT001624358	NCT00162435_8_T4	COMPOUND	4	4	warfarin
NCT001624610	NCT00162461_0_T0	GENE	2	2	CYP2C9
NCT001624612	NCT00162461_2_T0	GENE	9	9	CYP2C9
NCT001624614	NCT00162461_4_T0	GENE	12	12	CYP2C9
NCT001624614	NCT00162461_4_T1	COMPOUND	5	5	phenytoin
NCT001624615	NCT00162461_5_T0	GENE	6	6	CYP2C9
NCT001624615	NCT00162461_5_T1	COMPOUND	2	2	phenytoin
NCT001624741	NCT00162474_1_T0	COMPOUND	21	21	S-warfarin
NCT001624741	NCT00162474_1_T1	GENE	12	12	CYP2C9
NCT001624741	NCT00162474_1_T2	BIOLOGICAL_PROCESS	19	19	metabolism
NCT001624742	NCT00162474_2_T0	GENE	17	17	CYP2C9
NCT001624742	NCT00162474_2_T1	BIOLOGICAL_PROCESS	11	11	metabolism
NCT001624742	NCT00162474_2_T2	COMPOUND	10	10	warfarin
NCT001624743	NCT00162474_3_T0	GENE	16	16	CYP2C9
NCT001624743	NCT00162474_3_T1	BIOLOGICAL_PROCESS	22	22	metabolism
NCT001624743	NCT00162474_3_T2	COMPOUND	10	10	phenytoin
NCT001624743	NCT00162474_3_T3	COMPOUND	21	21	warfarin
NCT001624871	NCT00162487_1_T0	COMPOUND	15	15	salbutamol
NCT001624871	NCT00162487_1_T1	GENE	12	12	3.5
NCT001624871	NCT00162487_1_T2	PHENOTYPE	1	2	metabolic effects
NCT001624873	NCT00162487_3_T0	PHENOTYPE	23	24	metabolic effects
NCT001624875	NCT00162487_5_T0	PHENOTYPE	1	1	suffering
NCT001624875	NCT00162487_5_T1	PHENOTYPE	4	6	ischemic heart disease
NCT001624876	NCT00162487_6_T0	PHENOTYPE	6	6	arrhythmia
NCT001624878	NCT00162487_8_T0	COMPOUND	4	4	salbutamol
NCT001625000	NCT00162500_0_T0	PHENOTYPE	9	9	Malignancies
NCT001625000	NCT00162500_0_T1	PHENOTYPE	8	8	Tumor
NCT001625002	NCT00162500_2_T0	PHENOTYPE	29	29	TAA
NCT001625002	NCT00162500_2_T1	PHENOTYPE	26	26	Tumor
NCT001625002	NCT00162500_2_T2	GENE	25	25	MUC-1
NCT001625002	NCT00162500_2_T3	PHENOTYPE	21	22	metastatic tumors
NCT001625132	NCT00162513_2_T0	GENE	5	5	II
NCT001625132	NCT00162513_2_T1	PHENOTYPE	3	4	class I
NCT001625133	NCT00162513_3_T0	PHENOTYPE	0	0	Peripheral
NCT001625134	NCT00162513_4_T0	CELL	1	1	cells
NCT001625261	NCT00162526_1_T0	PHENOTYPE	0	0	Mucositis
NCT001625261	NCT00162526_1_T1	ORGAN	9	9	transplant
NCT001625261	NCT00162526_1_T2	PHENOTYPE	19	19	sepsis
NCT001625392	NCT00162539_2_T0	ORGAN	13	13	thyroid
NCT001625392	NCT00162539_2_T1	COMPOUND	5	5	iodine
NCT001625395	NCT00162539_5_T0	PHENOTYPE	7	8	thyroid disorders
NCT001625396	NCT00162539_6_T0	ORGAN	7	7	thyroid
NCT001625396	NCT00162539_6_T1	GENE	30	30	TSH
NCT001625396	NCT00162539_6_T2	GENE	10	10	has
NCT001625396	NCT00162539_6_T3	GENE	8	8	hormone
NCT001625398	NCT00162539_8_T0	GENE	1	1	has
NCT001625398	NCT00162539_8_T1	PHENOTYPE	10	11	iodine deficiency
NCT001625399	NCT00162539_9_T0	GENE	3	3	de
NCT001625399	NCT00162539_9_T1	GENE	2	2	Ile
NCT001625399	NCT00162539_9_T2	COMPOUND	25	25	iodine
NCT001625399	NCT00162539_9_T3	GENE	12	12	has
NCT001625399	NCT00162539_9_T4	PHENOTYPE	9	10	iodine deficiency
NCT0016253911	NCT00162539_11_T0	ORGAN	9	9	thyroid
NCT0016253911	NCT00162539_11_T1	ORGAN	24	24	thyroid
NCT0016253911	NCT00162539_11_T2	GENE	2	2	has
NCT0016253912	NCT00162539_12_T0	ORGAN	27	27	thyroid
NCT0016253912	NCT00162539_12_T1	PHENOTYPE	18	18	hypothyroidism
NCT0016253912	NCT00162539_12_T2	COMPOUND	11	11	iodine
NCT0016253912	NCT00162539_12_T3	COMPOUND	32	32	iodine
NCT0016253912	NCT00162539_12_T4	PHENOTYPE	2	3	iodine deficiency
NCT0016253914	NCT00162539_14_T0	COMPOUND	13	13	iodine
NCT001625521	NCT00162552_1_T0	PHENOTYPE	8	8	complications
NCT001625521	NCT00162552_1_T1	BIOLOGICAL_PROCESS	4	5	cytokine production
NCT001625525	NCT00162552_5_T0	PHENOTYPE	5	5	cirrhosis
NCT001625526	NCT00162552_6_T0	PHENOTYPE	3	3	carcinoma
NCT001625526	NCT00162552_6_T1	COMPOUND	8	8	pentoxifylline
NCT001625527	NCT00162552_7_T0	COMPOUND	3	3	pentoxifylline
NCT0016255213	NCT00162552_13_T0	PHENOTYPE	5	5	cirrhosis
NCT0016255214	NCT00162552_14_T0	PHENOTYPE	3	3	carcinoma
NCT0016255214	NCT00162552_14_T1	COMPOUND	8	8	pentoxifylline
NCT0016255215	NCT00162552_15_T0	COMPOUND	3	3	pentoxifylline
NCT001625651	NCT00162565_1_T0	PHENOTYPE	7	7	centers
NCT001625654	NCT00162565_4_T0	PHENOTYPE	19	20	heart failure
NCT001625655	NCT00162565_5_T0	PHENOTYPE	27	28	heart failure
NCT001625655	NCT00162565_5_T1	PHENOTYPE	31	32	pulmonary oedema
NCT0016256511	NCT00162565_11_T0	PHENOTYPE	0	0	Secondary
NCT0016256512	NCT00162565_12_T0	PHENOTYPE	2	2	centres
NCT001625781	NCT00162578_1_T0	COMPOUND	2	2	dexamethasone
NCT001625781	NCT00162578_1_T1	PHENOTYPE	13	13	sequelae
NCT001625781	NCT00162578_1_T2	GENE	6	6	has
NCT001625781	NCT00162578_1_T3	PHENOTYPE	18	19	pneumococcal meningitis
NCT001625782	NCT00162578_2_T0	COMPOUND	3	3	dexamethasone
NCT001625782	NCT00162578_2_T1	COMPOUND	8	8	vancomycin
NCT001625783	NCT00162578_3_T0	COMPOUND	27	27	dexamethasone
NCT001625783	NCT00162578_3_T1	PHENOTYPE	12	12	concentrations
NCT001625783	NCT00162578_3_T2	GENE	11	11	CSF
NCT001625783	NCT00162578_3_T3	COMPOUND	14	14	vancomycin
NCT001625783	NCT00162578_3_T4	COMPOUND	23	23	vancomycin
NCT001625783	NCT00162578_3_T5	PHENOTYPE	19	20	pneumococcal meningitis
NCT001625785	NCT00162578_5_T0	COMPOUND	9	9	dexamethasone
NCT001625785	NCT00162578_5_T1	GENE	1	1	has
NCT001625785	NCT00162578_5_T2	PHENOTYPE	18	19	pneumococcal meningitis
NCT001625786	NCT00162578_6_T0	COMPOUND	5	5	dexamethasone
NCT001625786	NCT00162578_6_T1	COMPOUND	10	10	vancomycin
NCT001625786	NCT00162578_6_T2	GENE	2	2	has
NCT001625787	NCT00162578_7_T0	COMPOUND	33	33	dexamethasone
NCT001625787	NCT00162578_7_T1	PHENOTYPE	14	14	concentrations
NCT001625787	NCT00162578_7_T2	GENE	12	12	CSF
NCT001625787	NCT00162578_7_T3	COMPOUND	13	13	vancomycin
NCT001625787	NCT00162578_7_T4	COMPOUND	31	31	vancomycin
NCT001625787	NCT00162578_7_T5	PHENOTYPE	19	20	pneumococcal meningitis
NCT001625788	NCT00162578_8_T0	COMPOUND	26	26	dexamethasone
NCT001625788	NCT00162578_8_T1	PHENOTYPE	12	12	concentrations
NCT001625788	NCT00162578_8_T2	GENE	20	20	CSF
NCT001625788	NCT00162578_8_T3	COMPOUND	14	14	vancomycin
NCT0016257813	NCT00162578_13_T0	GENE	6	6	de
NCT0016257814	NCT00162578_14_T0	PHENOTYPE	5	5	meningitis
NCT0016257814	NCT00162578_14_T1	GENE	15	15	CID
NCT0016257815	NCT00162578_15_T0	PHENOTYPE	4	4	peripheral
NCT0016257816	NCT00162578_16_T0	COMPOUND	3	3	vancomycin
NCT001625910	NCT00162591_0_T0	PHENOTYPE	4	4	Analgesia
NCT001625910	NCT00162591_0_T1	PHENOTYPE	7	7	Severely
NCT001625915	NCT00162591_5_T0	COMPOUND	11	11	remifentanil
NCT001625915	NCT00162591_5_T1	GENE	16	16	BIS
NCT001626303	NCT00162630_3_T0	COMPOUND	7	7	morphine
NCT001626432	NCT00162643_2_T0	GENE	19	19	CD4
NCT001626432	NCT00162643_2_T1	GENE	9	9	PI
NCT001626432	NCT00162643_2_T2	ORGAN	26	26	plasma
NCT001626433	NCT00162643_3_T0	GENE	9	9	protease
NCT001626433	NCT00162643_3_T1	COMPOUND	7	7	ritonavir
NCT001626434	NCT00162643_4_T0	GENE	4	4	CD4
NCT001626434	NCT00162643_4_T1	GENE	17	17	has
NCT001626435	NCT00162643_5_T0	GENE	16	16	CD4
NCT001626435	NCT00162643_5_T1	PHENOTYPE	12	12	progression
NCT001626437	NCT00162643_7_T0	COMPOUND	22	22	ritonavir
NCT001626438	NCT00162643_8_T0	GENE	26	26	CD4
NCT001626438	NCT00162643_8_T1	COMPOUND	4	4	ritonavir
NCT001626438	NCT00162643_8_T2	GENE	6	7	protease inhibitor
NCT001626560	NCT00162656_0_T0	CELL	3	3	B-cell
NCT001626562	NCT00162656_2_T0	CELL	3	3	B-cell
NCT001626562	NCT00162656_2_T1	PHENOTYPE	19	19	progressive
NCT001626563	NCT00162656_3_T0	GENE	12	12	reduced
NCT001626564	NCT00162656_4_T0	PHENOTYPE	11	11	toxicity
NCT001626564	NCT00162656_4_T1	PHENOTYPE	14	14	cardiotoxicity
NCT001626564	NCT00162656_4_T2	PHENOTYPE	18	19	secondary malignancy
NCT001626565	NCT00162656_5_T0	COMPOUND	12	12	cyclophosphamide
NCT001626565	NCT00162656_5_T1	PHENOTYPE	17	17	elimination
NCT001626569	NCT00162656_9_T0	GENE	7	7	CPM
NCT001626569	NCT00162656_9_T1	GENE	16	16	EFS
NCT001626569	NCT00162656_9_T2	GENE	25	25	EFS
NCT001626693	NCT00162669_3_T0	PHENOTYPE	19	19	tumor
NCT001626694	NCT00162669_4_T0	GENE	5	5	II
NCT001626694	NCT00162669_4_T1	PHENOTYPE	30	32	primary liver cancer
NCT001626821	NCT00162682_1_T0	PHENOTYPE	8	8	suppression
NCT001626822	NCT00162682_2_T0	PHENOTYPE	10	10	immunity
NCT001626823	NCT00162682_3_T0	PHENOTYPE	12	12	narrowing
NCT001626824	NCT00162682_4_T0	PHENOTYPE	18	19	disease progression
NCT001626826	NCT00162682_6_T0	GENE	18	18	PI
NCT001626826	NCT00162682_6_T1	PHENOTYPE	29	29	tolerance
NCT001627081	NCT00162708_1_T0	PHENOTYPE	30	30	metastases
NCT001627345	NCT00162734_5_T0	GENE	3	4	form 2
NCT001627600	NCT00162760_0_T0	PHENOTYPE	2	4	Idiopathic Pulmonary Fibrosis
NCT001627606	NCT00162760_6_T0	PHENOTYPE	9	9	leprosy
NCT001627606	NCT00162760_6_T1	COMPOUND	1	1	thalidomide
NCT001627606	NCT00162760_6_T2	PHENOTYPE	7	8	Hansen's disease
NCT001627607	NCT00162760_7_T0	PHENOTYPE	10	10	fibrosis
NCT001627609	NCT00162760_9_T0	GENE	10	10	has
NCT001627731	NCT00162773_1_T0	GENE	6	6	has
NCT001627731	NCT00162773_1_T1	PHENOTYPE	17	18	allergic asthma
NCT001627734	NCT00162773_4_T0	PHENOTYPE	10	10	irritability
NCT001627734	NCT00162773_4_T1	PHENOTYPE	17	17	edema
NCT001627734	NCT00162773_4_T2	PHENOTYPE	12	12	airflow
NCT001627735	NCT00162773_5_T0	CELL	3	3	eosinophils
NCT001627735	NCT00162773_5_T1	CELL	2	2	basophils
NCT001627735	NCT00162773_5_T2	CELL	6	6	macrophages
NCT001627735	NCT00162773_5_T3	CELL	39	39	cells
NCT001627735	NCT00162773_5_T4	PHENOTYPE	27	27	inflammation
NCT001627735	NCT00162773_5_T5	CELL	7	7	neutrophils
NCT001627735	NCT00162773_5_T6	CELL	10	11	epithelial cells
NCT001627735	NCT00162773_5_T7	CELL	0	1	Mast cells
NCT001627737	NCT00162773_7_T0	PHENOTYPE	11	11	coughing
NCT001627737	NCT00162773_7_T1	PHENOTYPE	10	10	wheezing
NCT001627737	NCT00162773_7_T2	PHENOTYPE	13	14	chest tightness
NCT001627737	NCT00162773_7_T3	PHENOTYPE	7	9	shortness of breath
NCT001627739	NCT00162773_9_T0	PHENOTYPE	1	1	asthmatics
NCT001627739	NCT00162773_9_T1	GENE	14	14	IgE
NCT0016277310	NCT00162773_10_T0	GENE	7	7	IgE
NCT0016277310	NCT00162773_10_T1	GENE	21	21	IgE
NCT0016277310	NCT00162773_10_T2	PHENOTYPE	12	12	asthma
NCT0016277310	NCT00162773_10_T3	ORGAN	6	6	serum
NCT0016277310	NCT00162773_10_T4	ORGAN	20	20	serum
NCT0016277311	NCT00162773_11_T0	PHENOTYPE	9	9	asthmatics
NCT0016277311	NCT00162773_11_T1	GENE	3	3	IgE
NCT0016277311	NCT00162773_11_T2	ORGAN	2	2	serum
NCT0016277314	NCT00162773_14_T0	PHENOTYPE	13	14	allergic asthma
NCT0016277315	NCT00162773_15_T0	PHENOTYPE	6	6	asthma
NCT0016277315	NCT00162773_15_T1	PHENOTYPE	13	13	asthma
NCT0016277315	NCT00162773_15_T2	GENE	8	8	has
NCT0016277317	NCT00162773_17_T0	PHENOTYPE	13	13	asthmatics
NCT0016277317	NCT00162773_17_T1	GENE	3	3	III
NCT0016277317	NCT00162773_17_T2	GENE	17	17	had
NCT0016277319	NCT00162773_19_T0	PHENOTYPE	16	16	asthmatics
NCT0016277320	NCT00162773_20_T0	GENE	5	5	had
NCT0016277321	NCT00162773_21_T0	PHENOTYPE	12	12	asthmatics
NCT0016277321	NCT00162773_21_T1	GENE	1	1	has
NCT0016277321	NCT00162773_21_T2	PHENOTYPE	17	17	Asthma
NCT0016277321	NCT00162773_21_T3	PHENOTYPE	18	20	Quality of Life
NCT0016277321	NCT00162773_21_T4	PHENOTYPE	7	9	quality of life
NCT0016277324	NCT00162773_24_T0	GENE	1	1	has
NCT0016277324	NCT00162773_24_T1	PHENOTYPE	17	18	allergic asthma
NCT0016277325	NCT00162773_25_T0	PHENOTYPE	8	9	allergic asthma
NCT001627867	NCT00162786_7_T0	BIOLOGICAL_PROCESS	0	0	Vision
NCT001627991	NCT00162799_1_T0	COMPOUND	3	3	salicylate
NCT001627992	NCT00162799_2_T0	COMPOUND	15	15	triflusal
NCT001627992	NCT00162799_2_T1	PHENOTYPE	11	11	obesity
NCT001627992	NCT00162799_2_T2	PHENOTYPE	12	13	insulin resistance
NCT001628122	NCT00162812_2_T0	GENE	3	3	has
NCT001628122	NCT00162812_2_T1	PHENOTYPE	17	18	breast cancer
NCT001628122	NCT00162812_2_T2	GENE	9	10	topo II
NCT001628123	NCT00162812_3_T0	GENE	4	5	topo II
NCT001628123	NCT00162812_3_T1	GENE	16	17	topo II
NCT001628124	NCT00162812_4_T0	CELL	30	30	cells
NCT001628124	NCT00162812_4_T1	PHENOTYPE	29	29	tumor
NCT001628124	NCT00162812_4_T2	GENE	18	19	topo II
NCT001628126	NCT00162812_6_T0	GENE	1	2	topo II
NCT001628126	NCT00162812_6_T1	GENE	10	11	topo II
NCT001628128	NCT00162812_8_T0	GENE	19	19	II
NCT001628128	NCT00162812_8_T1	GENE	38	38	II
NCT001628128	NCT00162812_8_T2	PHENOTYPE	41	41	tumors
NCT001628128	NCT00162812_8_T3	PHENOTYPE	22	22	tumours
NCT001628128	NCT00162812_8_T4	GENE	17	17	HER-2
NCT001628128	NCT00162812_8_T5	GENE	36	36	HER-2
NCT0016281212	NCT00162812_12_T0	PHENOTYPE	14	15	breast cancer
NCT0016281212	NCT00162812_12_T1	GENE	23	24	topo II
NCT0016281212	NCT00162812_12_T2	GENE	39	40	topo II
NCT0016281214	NCT00162812_14_T0	GENE	15	15	cm
NCT0016281214	NCT00162812_14_T1	PHENOTYPE	10	10	tumors
NCT0016281214	NCT00162812_14_T2	PHENOTYPE	6	7	breast cancer
NCT0016281214	NCT00162812_14_T3	GENE	24	25	topo II
NCT0016281215	NCT00162812_15_T0	GENE	22	22	FISH
NCT0016281215	NCT00162812_15_T1	GENE	11	12	topo II
NCT0016281216	NCT00162812_16_T0	GENE	13	13	HER-2
NCT0016281217	NCT00162812_17_T0	GENE	0	1	Topo II
NCT0016281218	NCT00162812_18_T0	COMPOUND	18	18	epirubicin
NCT0016281218	NCT00162812_18_T1	GENE	51	51	ER
NCT0016281218	NCT00162812_18_T2	GENE	49	50	estrogen receptor
NCT0016281218	NCT00162812_18_T3	PHENOTYPE	43	44	breast cancer
NCT0016281218	NCT00162812_18_T4	GENE	6	7	topo II
NCT0016281220	NCT00162812_20_T0	COMPOUND	5	5	epirubicin
NCT0016281220	NCT00162812_20_T1	GENE	11	12	topo II
NCT0016281221	NCT00162812_21_T0	PHENOTYPE	16	16	tumors
NCT0016281221	NCT00162812_21_T1	PHENOTYPE	30	30	tumors
NCT0016281221	NCT00162812_21_T2	GENE	2	2	has
NCT0016281221	NCT00162812_21_T3	GENE	13	13	ER
NCT0016281221	NCT00162812_21_T4	GENE	26	26	ER
NCT0016281222	NCT00162812_22_T0	COMPOUND	0	0	1
NCT0016281222	NCT00162812_22_T1	GENE	1	1	st
NCT0016281222	NCT00162812_22_T2	PHENOTYPE	8	8	tumors
NCT0016281222	NCT00162812_22_T3	GENE	5	5	ER
NCT0016281222	NCT00162812_22_T4	GENE	14	15	topo II
NCT0016281223	NCT00162812_23_T0	PHENOTYPE	8	8	tumors
NCT0016281223	NCT00162812_23_T1	PHENOTYPE	25	25	tumors
NCT0016281223	NCT00162812_23_T2	GENE	4	5	topo II
NCT0016281223	NCT00162812_23_T3	GENE	27	28	topo II
NCT0016281227	NCT00162812_27_T0	PHENOTYPE	3	3	tumors
NCT0016281227	NCT00162812_27_T1	PHENOTYPE	19	19	tumors
NCT0016281227	NCT00162812_27_T2	PHENOTYPE	7	7	proliferation
NCT0016281227	NCT00162812_27_T3	PHENOTYPE	23	23	proliferation
NCT0016281227	NCT00162812_27_T4	GENE	13	14	topo II
NCT0016281227	NCT00162812_27_T5	GENE	29	30	topo II
NCT0016281228	NCT00162812_28_T0	PHENOTYPE	12	12	tumors
NCT0016281228	NCT00162812_28_T1	PHENOTYPE	34	34	tumors
NCT0016281228	NCT00162812_28_T2	GENE	25	25	HER-2
NCT0016281228	NCT00162812_28_T3	GENE	4	5	topo II
NCT0016281228	NCT00162812_28_T4	GENE	17	18	topo II
NCT0016281230	NCT00162812_30_T0	PHENOTYPE	1	1	tumor
NCT0016281230	NCT00162812_30_T1	COMPOUND	17	17	oligonucleotide
NCT0016281231	NCT00162812_31_T0	PHENOTYPE	15	15	tumor
NCT0016281232	NCT00162812_32_T0	COMPOUND	17	17	epirubicin
NCT0016281233	NCT00162812_33_T0	PHENOTYPE	8	8	secondary
NCT0016281236	NCT00162812_36_T0	PHENOTYPE	2	2	mutated
NCT0016281236	NCT00162812_36_T1	PHENOTYPE	3	3	tumors
NCT0016281236	NCT00162812_36_T2	GENE	6	6	HER-2
NCT0016281236	NCT00162812_36_T3	GENE	11	12	topo II
NCT0016281237	NCT00162812_37_T0	PHENOTYPE	10	10	tumors
NCT0016281237	NCT00162812_37_T1	GENE	12	13	topo II
NCT0016281238	NCT00162812_38_T0	PHENOTYPE	31	31	tumors
NCT0016281238	NCT00162812_38_T1	COMPOUND	23	23	epirubicin
NCT0016281238	NCT00162812_38_T2	GENE	25	26	topo II
NCT0016281239	NCT00162812_39_T0	COMPOUND	13	13	epirubicin
NCT0016281239	NCT00162812_39_T1	PHENOTYPE	3	5	inflammatory breast cancer
NCT0016281241	NCT00162812_41_T0	PHENOTYPE	28	28	toxicity
NCT0016281241	NCT00162812_41_T1	COMPOUND	6	6	epirubicin
NCT0016281241	NCT00162812_41_T2	GENE	16	16	has
NCT0016281242	NCT00162812_42_T0	COMPOUND	2	2	epirubicin
NCT0016281242	NCT00162812_42_T1	GENE	21	21	has
NCT0016281244	NCT00162812_44_T0	PHENOTYPE	1	2	breast cancer
NCT0016281247	NCT00162812_47_T0	PHENOTYPE	0	0	Tumor
NCT0016281247	NCT00162812_47_T1	GENE	3	3	cm
NCT0016281251	NCT00162812_51_T0	PHENOTYPE	0	0	Multifocal
NCT0016281251	NCT00162812_51_T1	PHENOTYPE	9	9	foci
NCT0016281251	NCT00162812_51_T2	PHENOTYPE	3	4	breast tumors
NCT0016281259	NCT00162812_59_T0	PHENOTYPE	2	4	ventricular ejection fraction
NCT0016281260	NCT00162812_60_T0	PHENOTYPE	0	2	Negative pregnancy test
NCT0016281263	NCT00162812_63_T0	PHENOTYPE	0	2	Metastatic breast cancer
NCT0016281266	NCT00162812_66_T0	PHENOTYPE	2	4	invasive breast cancer
NCT0016281268	NCT00162812_68_T0	PHENOTYPE	4	5	other cancer
NCT001628251	NCT00162825_1_T0	PHENOTYPE	0	0	Psoriasis
NCT001628255	NCT00162825_5_T0	GENE	0	0	CD7
NCT001628255	NCT00162825_5_T1	CELL	1	2	T cells
NCT001628256	NCT00162825_6_T0	GENE	12	12	CD7
NCT001628256	NCT00162825_6_T1	PHENOTYPE	15	15	inflammations
NCT001628257	NCT00162825_7_T0	CELL	1	1	cells
NCT001628257	NCT00162825_7_T1	CELL	16	16	keratinocyte
NCT001628257	NCT00162825_7_T2	GENE	0	0	CD7
NCT001628258	NCT00162825_8_T0	PHENOTYPE	8	8	proliferation
NCT001628258	NCT00162825_8_T1	CELL	12	12	keratinocytes
NCT001628258	NCT00162825_8_T2	PHENOTYPE	4	5	skin inflammation
NCT0016282511	NCT00162825_11_T0	GENE	12	12	CD7
NCT001628382	NCT00162838_2_T0	ORGAN	1	1	gingiva
NCT001628382	NCT00162838_2_T1	CELL	7	8	dendritic cells
NCT001628382	NCT00162838_2_T2	TISSUE	5	6	connective tissue
NCT001628386	NCT00162838_6_T0	PHENOTYPE	10	10	maturation
NCT001628386	NCT00162838_6_T1	BIOLOGICAL_PROCESS	20	21	immune response
NCT001628387	NCT00162838_7_T0	BIOLOGICAL_PROCESS	10	11	cytokine production
NCT001628387	NCT00162838_7_T1	CELL	36	37	dendritic cells
NCT001628387	NCT00162838_7_T2	BIOLOGICAL_PROCESS	40	41	innate immunity
NCT0016283811	NCT00162838_11_T0	TISSUE	2	2	epithelium
NCT0016283811	NCT00162838_11_T1	ORGAN	26	27	immune system
NCT0016283811	NCT00162838_11_T2	CELL	17	18	Langerhans cells
NCT0016283812	NCT00162838_12_T0	CELL	0	1	Dendritic cells
NCT0016283812	NCT00162838_12_T1	CELL	6	7	antigen-presenting cells
NCT0016283813	NCT00162838_13_T0	PHENOTYPE	7	7	maturation
NCT0016283813	NCT00162838_13_T1	CELL	4	5	dendritic cells
NCT0016283815	NCT00162838_15_T0	ORGAN	1	1	gingiva
NCT0016283815	NCT00162838_15_T1	CELL	7	8	dendritic cells
NCT0016283815	NCT00162838_15_T2	TISSUE	5	6	connective tissue
NCT0016283816	NCT00162838_16_T0	TISSUE	9	9	epithelium
NCT0016283816	NCT00162838_16_T1	CELL	1	2	dendritic cells
NCT0016283816	NCT00162838_16_T2	CELL	12	13	dendritic cells
NCT0016283816	NCT00162838_16_T3	TISSUE	18	19	connective tissue
NCT0016283819	NCT00162838_19_T0	PHENOTYPE	0	0	Progression
NCT0016283819	NCT00162838_19_T1	PHENOTYPE	2	2	periodontitis
NCT0016283821	NCT00162838_21_T0	PHENOTYPE	10	10	maturation
NCT0016283821	NCT00162838_21_T1	BIOLOGICAL_PROCESS	25	26	immune response
NCT0016283822	NCT00162838_22_T0	BIOLOGICAL_PROCESS	10	11	cytokine production
NCT0016283822	NCT00162838_22_T1	CELL	36	37	dendritic cells
NCT0016283822	NCT00162838_22_T2	BIOLOGICAL_PROCESS	40	41	innate immunity
NCT001628641	NCT00162864_1_T0	PHENOTYPE	12	12	symptoms
NCT001628641	NCT00162864_1_T1	PHENOTYPE	11	11	asthma
NCT001628642	NCT00162864_2_T0	PHENOTYPE	1	1	symptoms
NCT001628642	NCT00162864_2_T1	PHENOTYPE	19	19	secondary
NCT001628642	NCT00162864_2_T2	PHENOTYPE	2	2	asthma
NCT001628642	NCT00162864_2_T3	PHENOTYPE	5	7	quality of life
NCT001628645	NCT00162864_5_T0	COMPOUND	21	21	montelukast
NCT001628645	NCT00162864_5_T1	PHENOTYPE	14	14	asthma
NCT001628645	NCT00162864_5_T2	PHENOTYPE	26	26	asthma
NCT001628645	NCT00162864_5_T3	GENE	23	23	had
NCT001628645	NCT00162864_5_T4	PHENOTYPE	3	4	lung function
NCT001628645	NCT00162864_5_T5	PHENOTYPE	7	9	quality of life
NCT001628649	NCT00162864_9_T0	COMPOUND	9	9	sodium
NCT001628649	NCT00162864_9_T1	COMPOUND	8	8	montelukast
NCT001628649	NCT00162864_9_T2	PHENOTYPE	15	15	asthma
NCT0016286411	NCT00162864_11_T0	PHENOTYPE	13	13	asthma
NCT0016286412	NCT00162864_12_T0	GENE	15	15	OR
NCT0016286414	NCT00162864_14_T0	PHENOTYPE	10	10	symptoms
NCT0016286414	NCT00162864_14_T1	PHENOTYPE	17	17	illnesses
NCT0016286414	NCT00162864_14_T2	PHENOTYPE	9	9	asthma
NCT0016286418	NCT00162864_18_T0	PHENOTYPE	25	25	asthma
NCT0016286418	NCT00162864_18_T1	PHENOTYPE	29	30	asthma attacks
NCT0016286420	NCT00162864_20_T0	PHENOTYPE	12	12	asthma
NCT0016286420	NCT00162864_20_T1	PHENOTYPE	17	17	asthma
NCT0016286420	NCT00162864_20_T2	PHENOTYPE	13	15	quality of life
NCT0016286422	NCT00162864_22_T0	PHENOTYPE	12	12	experiences
NCT0016286423	NCT00162864_23_T0	PHENOTYPE	13	13	asthma
NCT0016286423	NCT00162864_23_T1	PHENOTYPE	16	16	asthma
NCT0016286423	NCT00162864_23_T2	PHENOTYPE	14	14	QOL
NCT0016286424	NCT00162864_24_T0	PHENOTYPE	5	5	asthma
NCT0016286425	NCT00162864_25_T0	PHENOTYPE	5	5	asthma
NCT0016286426	NCT00162864_26_T0	COMPOUND	5	5	montelukast
NCT0016286427	NCT00162864_27_T0	PHENOTYPE	7	7	asthma
NCT0016286427	NCT00162864_27_T1	PHENOTYPE	5	6	lung function
NCT0016286427	NCT00162864_27_T2	PHENOTYPE	15	17	quality of life
NCT001628770	NCT00162877_0_T0	GENE	3	3	CYP2C19
NCT001628774	NCT00162877_4_T0	PHENOTYPE	20	20	recurrence
NCT001628774	NCT00162877_4_T1	PHENOTYPE	11	11	diseases
NCT001628775	NCT00162877_5_T0	GENE	5	6	proton pump
NCT001628775	NCT00162877_5_T1	PHENOTYPE	32	33	adverse effects
NCT001628775	NCT00162877_5_T2	PHENOTYPE	21	23	Helicobacter pylori infection
NCT001628776	NCT00162877_6_T0	GENE	5	5	CYP2C19
NCT001628778	NCT00162877_8_T0	PHENOTYPE	21	21	suppression
NCT001628778	NCT00162877_8_T1	COMPOUND	14	14	rabeprazole
NCT001628779	NCT00162877_9_T0	GENE	18	19	proton pump
NCT001628903	NCT00162890_3_T0	PHENOTYPE	6	6	impairment
NCT001628903	NCT00162890_3_T1	PHENOTYPE	16	17	cervical spondylosis
NCT001629031	NCT00162903_1_T0	ORGAN	15	16	ductus arteriosus
NCT001629034	NCT00162903_4_T0	COMPOUND	19	20	nitric oxide
NCT001629039	NCT00162903_9_T0	GENE	15	15	gm
NCT0016290312	NCT00162903_12_T0	PHENOTYPE	11	11	PDA
NCT0016290312	NCT00162903_12_T1	PHENOTYPE	13	13	PDA
NCT0016290314	NCT00162903_14_T0	PHENOTYPE	20	20	PDA
NCT0016290314	NCT00162903_14_T1	PHENOTYPE	22	22	PDA
NCT0016290314	NCT00162903_14_T2	PHENOTYPE	25	25	PDA
NCT0016290314	NCT00162903_14_T3	COMPOUND	31	31	indomethacin
NCT001629165	NCT00162916_5_T0	PHENOTYPE	20	20	relapse
NCT001629167	NCT00162916_7_T0	COMPOUND	21	21	citalopram
NCT001629167	NCT00162916_7_T1	PHENOTYPE	6	8	symptoms of depression
NCT001629168	NCT00162916_8_T0	PHENOTYPE	13	13	relapse
NCT001629169	NCT00162916_9_T0	COMPOUND	15	15	citalopram
NCT0016291610	NCT00162916_10_T0	PHENOTYPE	35	35	acute
NCT0016291610	NCT00162916_10_T1	PHENOTYPE	17	17	recurrence
NCT0016291610	NCT00162916_10_T2	COMPOUND	24	24	citalopram
NCT0016291610	NCT00162916_10_T3	PHENOTYPE	19	20	major depression
NCT0016291612	NCT00162916_12_T0	PHENOTYPE	14	14	severity
NCT0016291612	NCT00162916_12_T1	PHENOTYPE	5	6	major depression
NCT001629292	NCT00162929_2_T0	PHENOTYPE	3	5	recurrent breast cancer
NCT001629295	NCT00162929_5_T0	COMPOUND	4	4	1
NCT001629295	NCT00162929_5_T1	COMPOUND	15	15	2
NCT001629295	NCT00162929_5_T2	COMPOUND	21	21	3
NCT001629295	NCT00162929_5_T3	GENE	23	23	has
NCT0016292912	NCT00162929_12_T0	GENE	5	5	aromatase
NCT0016292912	NCT00162929_12_T1	COMPOUND	4	4	tamoxifen
NCT0016292920	NCT00162929_20_T0	PHENOTYPE	3	4	brain metastases
NCT001629553	NCT00162955_3_T0	PHENOTYPE	8	8	cardiotoxicity
NCT001629555	NCT00162955_5_T0	GENE	17	17	CHOP
NCT001629555	NCT00162955_5_T1	GENE	42	42	CHOP
NCT001629555	NCT00162955_5_T2	PHENOTYPE	3	4	Hodgkin's lymphoma
NCT001629556	NCT00162955_6_T0	GENE	15	15	CHOP
NCT001629683	NCT00162968_3_T0	PHENOTYPE	12	12	polyneuropathy
NCT001629683	NCT00162968_3_T1	COMPOUND	7	7	escitalopram
NCT001629689	NCT00162968_9_T0	PHENOTYPE	13	13	polyneuropathy
NCT001629689	NCT00162968_9_T1	COMPOUND	9	9	escitalopram
NCT0016296810	NCT00162968_10_T0	COMPOUND	5	5	escitalopram
NCT0016296812	NCT00162968_12_T0	GENE	12	12	tapered
NCT001629818	NCT00162981_8_T0	PHENOTYPE	14	15	intractable epilepsy
NCT001629819	NCT00162981_9_T0	PHENOTYPE	16	16	epilepsy
NCT001629819	NCT00162981_9_T1	COMPOUND	10	10	4_benzodiazepine
NCT001629943	NCT00162994_3_T0	PHENOTYPE	26	28	recurrent otitis media
NCT001629945	NCT00162994_5_T0	PHENOTYPE	10	10	symptoms
NCT001629945	NCT00162994_5_T1	PHENOTYPE	16	16	effusion
NCT001629946	NCT00162994_6_T0	PHENOTYPE	0	1	Life quality
NCT001630071	NCT00163007_1_T0	PHENOTYPE	16	16	malnutrition
NCT001630072	NCT00163007_2_T0	PHENOTYPE	6	7	acute stroke
NCT001630073	NCT00163007_3_T0	PHENOTYPE	10	11	weight loss
NCT001630075	NCT00163007_5_T0	PHENOTYPE	7	7	malnourished
NCT001630076	NCT00163007_6_T0	PHENOTYPE	3	3	dysphagia
NCT001630076	NCT00163007_6_T1	PHENOTYPE	7	8	acute stroke
NCT001630077	NCT00163007_7_T0	PHENOTYPE	13	13	malnutrition
NCT001630077	NCT00163007_7_T1	PHENOTYPE	0	0	Dysphagia
NCT001630078	NCT00163007_8_T0	PHENOTYPE	16	16	malnutrition
NCT001630079	NCT00163007_9_T0	PHENOTYPE	6	7	acute stroke
NCT0016300714	NCT00163007_14_T0	PHENOTYPE	1	3	quality of life
NCT0016300715	NCT00163007_15_T0	PHENOTYPE	13	14	weight loss
NCT0016300716	NCT00163007_16_T0	PHENOTYPE	0	0	Secondary
NCT0016300716	NCT00163007_16_T1	PHENOTYPE	9	11	quality of life
NCT001630200	NCT00163020_0_T0	GENE	10	10	PTB
NCT001630200	NCT00163020_0_T1	PHENOTYPE	8	9	Preterm Birth
NCT001630200	NCT00163020_0_T2	PHENOTYPE	14	15	Triplet Pregnancies
NCT001630203	NCT00163020_3_T0	PHENOTYPE	18	19	preterm birth
NCT001630209	NCT00163020_9_T0	COMPOUND	7	7	progesterone
NCT001630209	NCT00163020_9_T1	PHENOTYPE	14	15	preterm birth
NCT001630209	NCT00163020_9_T2	PHENOTYPE	23	24	preterm birth
NCT0016302010	NCT00163020_10_T0	PHENOTYPE	21	21	complications
NCT0016302010	NCT00163020_10_T1	GENE	2	2	has
NCT0016302010	NCT00163020_10_T2	PHENOTYPE	10	11	preterm birth
NCT0016302011	NCT00163020_11_T0	PHENOTYPE	12	13	preterm birth
NCT0016302012	NCT00163020_12_T0	COMPOUND	5	5	progesterone
NCT0016302012	NCT00163020_12_T1	BIOLOGICAL_PROCESS	21	21	gestation
NCT0016302012	NCT00163020_12_T2	PHENOTYPE	16	17	preterm birth
NCT0016302013	NCT00163020_13_T0	PHENOTYPE	14	15	triplet pregnancies
NCT0016302015	NCT00163020_15_T0	GENE	20	20	had
NCT0016302015	NCT00163020_15_T1	PHENOTYPE	22	23	preterm delivery
NCT0016302018	NCT00163020_18_T0	PHENOTYPE	31	32	preterm birth
NCT0016302020	NCT00163020_20_T0	PHENOTYPE	10	10	recruitment
NCT0016302021	NCT00163020_21_T0	PHENOTYPE	10	10	initiation
NCT0016302023	NCT00163020_23_T0	PHENOTYPE	7	8	preterm birth
NCT0016302024	NCT00163020_24_T0	BIOLOGICAL_PROCESS	5	5	placentation
NCT0016302025	NCT00163020_25_T0	BIOLOGICAL_PROCESS	5	5	placentation
NCT0016302026	NCT00163020_26_T0	TISSUE	1	1	membranes
NCT0016302027	NCT00163020_27_T0	GENE	2	2	had
NCT0016302027	NCT00163020_27_T1	BIOLOGICAL_PROCESS	11	11	placentation
NCT0016302027	NCT00163020_27_T2	GENE	1	1	has
NCT0016302031	NCT00163020_31_T0	PHENOTYPE	2	2	contractions
NCT0016302033	NCT00163020_33_T0	PHENOTYPE	21	21	exposures
NCT0016302033	NCT00163020_33_T1	PHENOTYPE	18	18	malformations
NCT0016302033	NCT00163020_33_T2	BIOLOGICAL_PROCESS	13	13	placentation
NCT0016302033	NCT00163020_33_T3	BIOLOGICAL_PROCESS	16	16	gestation
NCT0016302033	NCT00163020_33_T4	PHENOTYPE	8	9	preterm delivery
NCT0016302034	NCT00163020_34_T0	COMPOUND	9	9	progesterone
NCT0016302034	NCT00163020_34_T1	PHENOTYPE	12	12	asthma
NCT0016302034	NCT00163020_34_T2	PHENOTYPE	23	23	cholecystitis
NCT0016302034	NCT00163020_34_T3	PHENOTYPE	29	30	thromboembolic disorder
NCT0016302034	NCT00163020_34_T4	PHENOTYPE	15	16	renal insufficiency
NCT0016302034	NCT00163020_34_T5	PHENOTYPE	33	34	breast cancer
NCT0016302034	NCT00163020_34_T6	PHENOTYPE	17	18	seizure disorder
NCT0016302034	NCT00163020_34_T7	PHENOTYPE	37	38	major depression
NCT0016302034	NCT00163020_34_T8	PHENOTYPE	19	21	ischemic heart disease
NCT0016302034	NCT00163020_34_T9	PHENOTYPE	24	26	impaired liver function
NCT0016302037	NCT00163020_37_T0	GENE	9	9	NOT
NCT0016302037	NCT00163020_37_T1	PHENOTYPE	6	7	preterm birth
NCT0016302039	NCT00163020_39_T0	COMPOUND	2	2	progesterone
NCT0016302039	NCT00163020_39_T1	BIOLOGICAL_PROCESS	9	9	gestation
NCT0016302041	NCT00163020_41_T0	PHENOTYPE	0	0	Allergy
NCT0016302043	NCT00163020_43_T0	PHENOTYPE	16	16	dilation
NCT001630332	NCT00163033_2_T0	COMPOUND	15	15	estetrol
NCT001630333	NCT00163033_3_T0	PHENOTYPE	3	3	pharmacokinetics
NCT001630333	NCT00163033_3_T1	PHENOTYPE	6	6	pharmacodynamic
NCT001630334	NCT00163033_4_T0	COMPOUND	6	6	estetrol
NCT001630334	NCT00163033_4_T1	COMPOUND	13	13	estradiol
NCT001630336	NCT00163033_6_T0	COMPOUND	11	11	estetrol
NCT001630336	NCT00163033_6_T1	COMPOUND	18	18	estradiol
NCT001630337	NCT00163033_7_T0	COMPOUND	6	6	estetrol
NCT001630337	NCT00163033_7_T1	COMPOUND	20	20	estetrol
NCT001630338	NCT00163033_8_T0	COMPOUND	14	14	estetrol
NCT001630339	NCT00163033_9_T0	COMPOUND	9	9	estetrol
NCT001630339	NCT00163033_9_T1	PHENOTYPE	3	3	pharmacokinetics
NCT001630339	NCT00163033_9_T2	PHENOTYPE	6	6	pharmacodynamic
NCT0016303310	NCT00163033_10_T0	COMPOUND	11	11	estetrol
NCT0016303310	NCT00163033_10_T1	PHENOTYPE	3	3	pharmacokinetics
NCT0016303310	NCT00163033_10_T2	PHENOTYPE	5	5	pharmacodynamic
NCT0016303310	NCT00163033_10_T3	COMPOUND	22	22	estradiol
NCT001630721	NCT00163072_1_T0	PHENOTYPE	11	11	HIV
NCT001630721	NCT00163072_1_T1	PHENOTYPE	16	17	poor appetite
NCT001630723	NCT00163072_3_T0	COMPOUND	1	1	progestins
NCT001630724	NCT00163072_4_T0	COMPOUND	11	11	estrogen
NCT001630724	NCT00163072_4_T1	COMPOUND	17	17	norelgestromin
NCT001630724	NCT00163072_4_T2	COMPOUND	13	13	estradiol
NCT001630725	NCT00163072_5_T0	PHENOTYPE	4	4	pharmacokinetics
NCT001630727	NCT00163072_7_T0	GENE	5	5	IV
NCT001630727	NCT00163072_7_T1	PHENOTYPE	11	12	drug levels
NCT0016307213	NCT00163072_13_T0	GENE	8	8	half-life
NCT0016307213	NCT00163072_13_T1	GENE	31	31	1.3
NCT0016307215	NCT00163072_15_T0	GENE	11	11	transparent
NCT0016307215	NCT00163072_15_T1	GENE	8	8	gel
NCT001631110	NCT00163111_0_T0	PHENOTYPE	19	19	Candidemia
NCT001631110	NCT00163111_0_T1	ORGAN	26	26	Blood
NCT001631110	NCT00163111_0_T2	ORGAN	29	29	Blood
NCT001631110	NCT00163111_0_T3	PHENOTYPE	22	23	Fungus Infection
NCT001631760	NCT00163176_0_T0	PHENOTYPE	10	11	Neck Tumors
NCT001631762	NCT00163176_2_T0	PHENOTYPE	15	15	anaesthesia
NCT001631763	NCT00163176_3_T0	PHENOTYPE	13	13	proliferation
NCT001631764	NCT00163176_4_T0	PHENOTYPE	22	22	tumor
NCT0016317612	NCT00163176_12_T0	PHENOTYPE	6	7	primary tumor
NCT0016317614	NCT00163176_14_T0	PHENOTYPE	4	4	intent
NCT001632284	NCT00163228_4_T0	COMPOUND	4	4	TKA
NCT001632285	NCT00163228_5_T0	COMPOUND	3	3	TKA
NCT001632285	NCT00163228_5_T1	GENE	10	10	THP
NCT001632542	NCT00163254_2_T0	GENE	19	19	GP
NCT001632673	NCT00163267_3_T0	COMPOUND	18	18	clopidogrel
NCT001632673	NCT00163267_3_T1	PHENOTYPE	12	12	peripheral
NCT001632673	NCT00163267_3_T2	CELL	20	20	platelet
NCT001632673	NCT00163267_3_T3	PHENOTYPE	21	21	adhesion
NCT001632673	NCT00163267_3_T4	BIOLOGICAL_PROCESS	9	10	platelet activation
NCT001632674	NCT00163267_4_T0	COMPOUND	9	9	clopidogrel
NCT001632674	NCT00163267_4_T1	PHENOTYPE	2	2	chronic
NCT001632674	NCT00163267_4_T2	PHENOTYPE	3	5	peripheral arterial disease
NCT001632675	NCT00163267_5_T0	BIOLOGICAL_PROCESS	0	1	Platelet activation
NCT001632802	NCT00163280_2_T0	PHENOTYPE	10	10	ulceration
NCT001632802	NCT00163280_2_T1	PHENOTYPE	0	0	Mucositis
NCT001632802	NCT00163280_2_T2	PHENOTYPE	8	8	inflammation
NCT001632804	NCT00163280_4_T0	PHENOTYPE	31	31	severity
NCT001632804	NCT00163280_4_T1	PHENOTYPE	33	33	mucositis
NCT001632930	NCT00163293_0_T0	PHENOTYPE	13	13	Mild
NCT001632930	NCT00163293_0_T1	PHENOTYPE	14	16	Asthma in Children
NCT001632932	NCT00163293_2_T0	COMPOUND	7	7	ciclesonide
NCT001632934	NCT00163293_4_T0	COMPOUND	11	11	ciclesonide
NCT001632936	NCT00163293_6_T0	PHENOTYPE	10	10	asthma
NCT001633060	NCT00163306_0_T0	PHENOTYPE	11	11	Symptoms
NCT001633060	NCT00163306_0_T1	PHENOTYPE	13	14	Acid Reflux
NCT001633060	NCT00163306_0_T2	PHENOTYPE	15	17	Gastroesophageal Reflux Disease
NCT001633062	NCT00163306_2_T0	PHENOTYPE	0	0	GERD
NCT001633062	NCT00163306_2_T1	ORGAN	19	19	esophagus
NCT001633062	NCT00163306_2_T2	ORGAN	4	6	lower esophageal sphincter
NCT001633063	NCT00163306_3_T0	PHENOTYPE	18	18	symptoms
NCT001633063	NCT00163306_3_T1	PHENOTYPE	8	8	disorders
NCT001633063	NCT00163306_3_T2	PHENOTYPE	0	0	GERD
NCT001633063	NCT00163306_3_T3	PHENOTYPE	21	22	gastric reflux
NCT001633065	NCT00163306_5_T0	PHENOTYPE	1	1	refluxed
NCT001633065	NCT00163306_5_T1	ORGAN	10	10	esophagus
NCT001633065	NCT00163306_5_T2	PHENOTYPE	14	15	burning sensation
NCT001633066	NCT00163306_6_T0	PHENOTYPE	7	7	heartburn
NCT001633067	NCT00163306_7_T0	PHENOTYPE	3	3	symptoms
NCT001633067	NCT00163306_7_T1	PHENOTYPE	5	5	GERD
NCT001633068	NCT00163306_8_T0	COMPOUND	11	11	pantoprazole
NCT001633068	NCT00163306_8_T1	PHENOTYPE	17	17	GERD
NCT001633068	NCT00163306_8_T2	PHENOTYPE	15	15	remission
NCT001633069	NCT00163306_9_T0	PHENOTYPE	1	1	remission
NCT0016330612	NCT00163306_12_T0	COMPOUND	11	11	pantoprazole
NCT001633190	NCT00163319_0_T0	PHENOTYPE	13	14	Persistent Asthma
NCT001633192	NCT00163319_2_T0	COMPOUND	10	11	fluticasone propionate
NCT001633194	NCT00163319_4_T0	COMPOUND	11	11	ciclesonide
NCT001633320	NCT00163332_0_T0	PHENOTYPE	10	10	Mild
NCT001633320	NCT00163332_0_T1	PHENOTYPE	13	13	Asthma
NCT001633322	NCT00163332_2_T0	COMPOUND	7	7	ciclesonide
NCT001633322	NCT00163332_2_T1	COMPOUND	9	10	fluticasone propionate
NCT001633324	NCT00163332_4_T0	COMPOUND	11	11	ciclesonide
NCT001633450	NCT00163345_0_T0	PHENOTYPE	10	10	Asthma
NCT001633454	NCT00163345_4_T0	COMPOUND	11	11	ciclesonide
NCT001633580	NCT00163358_0_T0	PHENOTYPE	14	14	Mild
NCT001633580	NCT00163358_0_T1	PHENOTYPE	15	16	Persistent Asthma
NCT001633583	NCT00163358_3_T0	COMPOUND	11	11	ciclesonide
NCT001633710	NCT00163371_0_T0	PHENOTYPE	17	17	Mild
NCT001633710	NCT00163371_0_T1	PHENOTYPE	18	19	Persistent Asthma
NCT001633713	NCT00163371_3_T0	COMPOUND	11	11	ciclesonide
NCT001633840	NCT00163384_0_T0	PHENOTYPE	8	8	Asthma
NCT001633842	NCT00163384_2_T0	PHENOTYPE	18	18	symptoms
NCT001633842	NCT00163384_2_T1	COMPOUND	14	14	budesonide
NCT001633842	NCT00163384_2_T2	COMPOUND	12	12	ciclesonide
NCT001633842	NCT00163384_2_T3	PHENOTYPE	27	27	asthma
NCT001633843	NCT00163384_3_T0	COMPOUND	14	14	budesonide
NCT001633843	NCT00163384_3_T1	COMPOUND	10	10	ciclesonide
NCT001633970	NCT00163397_0_T0	PHENOTYPE	8	8	Asthma
NCT001633972	NCT00163397_2_T0	COMPOUND	2	2	budesonide
NCT001633974	NCT00163397_4_T0	COMPOUND	11	11	ciclesonide
NCT001634100	NCT00163410_0_T0	PHENOTYPE	15	15	Asthma
NCT001634102	NCT00163410_2_T0	COMPOUND	10	11	fluticasone propionate
NCT001634104	NCT00163410_4_T0	COMPOUND	11	11	ciclesonide
NCT001634230	NCT00163423_0_T0	PHENOTYPE	9	9	Mild
NCT001634230	NCT00163423_0_T1	PHENOTYPE	12	12	Asthma
NCT001634232	NCT00163423_2_T0	COMPOUND	10	11	fluticasone propionate
NCT001634234	NCT00163423_4_T0	COMPOUND	11	11	ciclesonide
NCT001634360	NCT00163436_0_T0	PHENOTYPE	14	14	Asthma
NCT001634490	NCT00163449_0_T0	PHENOTYPE	9	9	Asthma
NCT001634494	NCT00163449_4_T0	COMPOUND	11	11	ciclesonide
NCT001634620	NCT00163462_0_T0	PHENOTYPE	15	15	Asthma
NCT001634622	NCT00163462_2_T0	COMPOUND	13	14	fluticasone propionate
NCT001634624	NCT00163462_4_T0	COMPOUND	11	11	ciclesonide
NCT001634750	NCT00163475_0_T0	PHENOTYPE	15	15	Asthma
NCT001634752	NCT00163475_2_T0	PHENOTYPE	20	20	asthma
NCT001634752	NCT00163475_2_T1	GENE	13	13	has
NCT001634752	NCT00163475_2_T2	COMPOUND	9	11	phosphodiesterase 4 inhibitor
NCT001634753	NCT00163475_3_T0	PHENOTYPE	15	15	symptoms
NCT001634753	NCT00163475_3_T1	COMPOUND	11	11	roflumilast
NCT001634753	NCT00163475_3_T2	PHENOTYPE	25	25	asthma
NCT001634753	NCT00163475_3_T3	PHENOTYPE	13	14	lung function
NCT001634756	NCT00163475_6_T0	COMPOUND	12	12	roflumilast
NCT001634880	NCT00163488_0_T0	PHENOTYPE	13	15	Perennial Allergic Rhinitis
NCT001635010	NCT00163501_0_T0	PHENOTYPE	10	12	Perennial Allergic Rhinitis
NCT001635140	NCT00163514_0_T0	PHENOTYPE	14	16	Perennial Allergic Rhinitis
NCT001635270	NCT00163527_0_T0	PHENOTYPE	15	15	Asthma
NCT001635272	NCT00163527_2_T0	PHENOTYPE	20	20	asthma
NCT001635272	NCT00163527_2_T1	GENE	13	13	has
NCT001635272	NCT00163527_2_T2	COMPOUND	9	11	phosphodiesterase 4 inhibitor
NCT001635273	NCT00163527_3_T0	COMPOUND	11	11	roflumilast
NCT001635273	NCT00163527_3_T1	PHENOTYPE	21	22	lung function
NCT001635276	NCT00163527_6_T0	COMPOUND	12	12	roflumilast
NCT001635534	NCT00163553_4_T0	COMPOUND	43	43	buprenorphine
NCT001635534	NCT00163553_4_T1	COMPOUND	42	42	tramadol
NCT001635534	NCT00163553_4_T2	COMPOUND	45	45	methylprednisolone
NCT001635534	NCT00163553_4_T3	GENE	2	2	has
NCT001635534	NCT00163553_4_T4	COMPOUND	41	41	morphine
NCT001635538	NCT00163553_8_T0	COMPOUND	19	19	hydromorphone
NCT001635538	NCT00163553_8_T1	COMPOUND	17	17	fentanyl
NCT001635538	NCT00163553_8_T2	PHENOTYPE	40	40	analgesia
NCT001635538	NCT00163553_8_T3	COMPOUND	16	16	morphine
NCT001635539	NCT00163553_9_T0	GENE	6	6	has
NCT0016355310	NCT00163553_10_T0	COMPOUND	26	26	fentanyl
NCT0016355310	NCT00163553_10_T1	GENE	1	1	has
NCT0016355310	NCT00163553_10_T2	ORGAN	23	24	epidural space
NCT0016355311	NCT00163553_11_T0	GENE	32	32	has
NCT0016355311	NCT00163553_11_T1	COMPOUND	5	5	morphine
NCT0016355311	NCT00163553_11_T2	PHENOTYPE	12	13	respiratory depression
NCT0016355312	NCT00163553_12_T0	GENE	19	19	had
NCT0016355312	NCT00163553_12_T1	COMPOUND	34	34	morphine
NCT0016355318	NCT00163553_18_T0	PHENOTYPE	1	1	strategies
NCT0016355321	NCT00163553_21_T0	PHENOTYPE	6	6	pruritis
NCT0016355321	NCT00163553_21_T1	PHENOTYPE	4	4	vomiting
NCT0016355322	NCT00163553_22_T0	PHENOTYPE	11	11	seizures
NCT0016355322	NCT00163553_22_T1	GENE	6	6	has
NCT0016355323	NCT00163553_23_T0	PHENOTYPE	11	12	renal failure
NCT0016355325	NCT00163553_25_T0	PHENOTYPE	12	12	seizure
NCT0016355333	NCT00163553_33_T0	PHENOTYPE	2	2	anaesthesia
NCT0016355340	NCT00163553_40_T0	COMPOUND	27	27	N
NCT0016355340	NCT00163553_40_T1	GENE	18	18	ml
NCT0016355340	NCT00163553_40_T2	GENE	25	25	ml
NCT0016355341	NCT00163553_41_T0	GENE	7	7	20
NCT0016355357	NCT00163553_57_T0	GENE	1	1	unpaired
NCT0016355362	NCT00163553_62_T0	PHENOTYPE	0	1	Adverse event
NCT0016355362	NCT00163553_62_T1	PHENOTYPE	5	6	adverse events
NCT0016355364	NCT00163553_64_T0	PHENOTYPE	2	3	adverse events
NCT0016355365	NCT00163553_65_T0	GENE	28	28	TGA
NCT0016355365	NCT00163553_65_T1	PHENOTYPE	2	3	adverse event
NCT0016355366	NCT00163553_66_T0	PHENOTYPE	10	11	adverse events
NCT0016355367	NCT00163553_67_T0	PHENOTYPE	9	10	adverse event
NCT0016355368	NCT00163553_68_T0	PHENOTYPE	16	17	adverse events
NCT0016355369	NCT00163553_69_T0	PHENOTYPE	2	3	adverse events
NCT001635664	NCT00163566_4_T0	COMPOUND	1	1	testosterone
NCT001635665	NCT00163566_5_T0	GENE	4	4	has
NCT001635666	NCT00163566_6_T0	COMPOUND	16	16	fluoxymesterone
NCT001635666	NCT00163566_6_T1	COMPOUND	14	14	testosterone
NCT001635667	NCT00163566_7_T0	PHENOTYPE	14	15	adverse effects
NCT0016356610	NCT00163566_10_T0	GENE	13	13	gel
NCT0016356611	NCT00163566_11_T0	GENE	5	5	gel
NCT0016356614	NCT00163566_14_T0	COMPOUND	19	19	androgen
NCT0016356614	NCT00163566_14_T1	PHENOTYPE	0	0	Secondary
NCT0016356614	NCT00163566_14_T2	ORGAN	18	18	serum
NCT0016356614	NCT00163566_14_T3	PHENOTYPE	9	9	libido
NCT001635792	NCT00163579_2_T0	PHENOTYPE	25	26	preterm delivery
NCT001635793	NCT00163579_3_T0	PHENOTYPE	7	8	preterm delivery
NCT001635795	NCT00163579_5_T0	ORGAN	16	16	cervix
NCT001635795	NCT00163579_5_T1	GENE	7	7	has
NCT001635795	NCT00163579_5_T2	PHENOTYPE	22	22	contractions
NCT001635797	NCT00163579_7_T0	GENE	4	4	has
NCT001635799	NCT00163579_9_T0	GENE	23	23	has
NCT0016357910	NCT00163579_10_T0	GENE	4	4	has
NCT0016357911	NCT00163579_11_T0	GENE	0	0	Beta
NCT0016357911	NCT00163579_11_T1	PHENOTYPE	7	8	preterm labor
NCT0016357912	NCT00163579_12_T0	COMPOUND	6	6	calcium
NCT0016357912	NCT00163579_12_T1	GENE	16	16	receptor
NCT0016357912	NCT00163579_12_T2	COMPOUND	8	8	prostaglandin
NCT0016357913	NCT00163579_13_T0	PHENOTYPE	14	14	tremor
NCT0016357913	NCT00163579_13_T1	GENE	18	18	beta
NCT0016357914	NCT00163579_14_T0	PHENOTYPE	21	22	side effect
NCT0016357916	NCT00163579_16_T0	GENE	1	1	has
NCT0016357917	NCT00163579_17_T0	GENE	14	14	has
NCT0016357918	NCT00163579_18_T0	PHENOTYPE	6	6	inhibition
NCT0016357919	NCT00163579_19_T0	GENE	8	8	has
NCT0016357920	NCT00163579_20_T0	PHENOTYPE	17	17	contractions
NCT0016357920	NCT00163579_20_T1	PHENOTYPE	3	4	tocolytic effects
NCT0016357920	NCT00163579_20_T2	PHENOTYPE	26	27	preterm delivery
NCT0016357921	NCT00163579_21_T0	PHENOTYPE	17	17	contractions
NCT001636051	NCT00163605_1_T0	BIOLOGICAL_PROCESS	17	18	bone regeneration
NCT001636440	NCT00163644_0_T0	PHENOTYPE	12	12	QOL
NCT001636445	NCT00163644_5_T0	ORGAN	6	6	transplants
NCT001636447	NCT00163644_7_T0	COMPOUND	9	9	3
NCT001636447	NCT00163644_7_T1	PHENOTYPE	3	5	quality of life
NCT001636573	NCT00163657_3_T0	COMPOUND	3	3	HCV
NCT001636575	NCT00163657_5_T0	ORGAN	17	17	liver
NCT001636576	NCT00163657_6_T0	PHENOTYPE	20	20	complications
NCT001636576	NCT00163657_6_T1	PHENOTYPE	1	1	recurrence
NCT001636576	NCT00163657_6_T2	PHENOTYPE	36	36	recurrence
NCT001636576	NCT00163657_6_T3	ORGAN	10	10	transplant
NCT001636576	NCT00163657_6_T4	COMPOUND	3	3	HCV
NCT001636576	NCT00163657_6_T5	COMPOUND	8	8	HCV
NCT001636576	NCT00163657_6_T6	PHENOTYPE	38	39	disease progression
NCT001636577	NCT00163657_7_T0	PHENOTYPE	15	15	recurrence
NCT001636577	NCT00163657_7_T1	COMPOUND	14	14	HCV
NCT001636578	NCT00163657_8_T0	PHENOTYPE	6	6	immunosuppression
NCT001636579	NCT00163657_9_T0	PHENOTYPE	32	32	recurrence
NCT001636579	NCT00163657_9_T1	ORGAN	34	34	liver
NCT001636579	NCT00163657_9_T2	ORGAN	35	35	transplant
NCT001636579	NCT00163657_9_T3	COMPOUND	31	31	HCV
NCT001636579	NCT00163657_9_T4	ORGAN	15	15	allograft
NCT001636579	NCT00163657_9_T5	PHENOTYPE	18	19	adverse events
NCT0016365711	NCT00163657_11_T0	GENE	1	1	has
NCT0016365711	NCT00163657_11_T1	GENE	6	6	has
NCT0016365713	NCT00163657_13_T0	ORGAN	10	10	liver
NCT0016365713	NCT00163657_13_T1	ORGAN	11	11	transplant
NCT0016365713	NCT00163657_13_T2	PHENOTYPE	15	15	chronic
NCT0016365713	NCT00163657_13_T3	PHENOTYPE	16	17	Hepatitis C
NCT0016365717	NCT00163657_17_T0	ORGAN	12	12	serum
NCT0016365719	NCT00163657_19_T0	ORGAN	13	13	liver
NCT0016365719	NCT00163657_19_T1	GENE	1	1	has
NCT0016365719	NCT00163657_19_T2	ORGAN	8	9	organ transplant
NCT0016365721	NCT00163657_21_T0	ORGAN	4	4	liver
NCT0016365721	NCT00163657_21_T1	ORGAN	5	5	transplant
NCT0016365721	NCT00163657_21_T2	GENE	1	1	has
NCT0016365721	NCT00163657_21_T3	PHENOTYPE	14	15	Hepatitis C
NCT0016365721	NCT00163657_21_T4	PHENOTYPE	16	17	antibody positive
NCT0016365721	NCT00163657_21_T5	PHENOTYPE	8	9	Hepatitis B
NCT0016365723	NCT00163657_23_T0	ORGAN	14	14	liver
NCT0016365723	NCT00163657_23_T1	GENE	1	1	has
NCT0016365723	NCT00163657_23_T2	GENE	4	4	ABO
NCT0016365723	NCT00163657_23_T3	PHENOTYPE	5	6	blood group
NCT0016365725	NCT00163657_25_T0	ORGAN	11	11	liver
NCT0016365725	NCT00163657_25_T1	ORGAN	12	12	transplant
NCT0016365725	NCT00163657_25_T2	GENE	1	1	has
NCT0016365725	NCT00163657_25_T3	ORGAN	30	30	Appendix
NCT0016365725	NCT00163657_25_T4	PHENOTYPE	2	4	fulminant liver failure
NCT0016365727	NCT00163657_27_T0	ORGAN	4	4	transplant
NCT0016365727	NCT00163657_27_T1	ORGAN	23	23	transplant
NCT0016365727	NCT00163657_27_T2	GENE	1	1	has
NCT0016365727	NCT00163657_27_T3	GENE	17	17	calcineurin
NCT0016365727	NCT00163657_27_T4	PHENOTYPE	3	3	dysfunction
NCT0016365729	NCT00163657_29_T0	ORGAN	23	23	transplant
NCT0016365729	NCT00163657_29_T1	GENE	9	9	has
NCT0016365729	NCT00163657_29_T2	PHENOTYPE	13	14	blood loss
NCT0016365733	NCT00163657_33_T0	GENE	13	13	globulin
NCT0016365733	NCT00163657_33_T1	CELL	11	11	lymphocyte
NCT0016365737	NCT00163657_37_T0	GENE	1	1	has
NCT0016365738	NCT00163657_38_T0	GENE	1	1	has
NCT001636701	NCT00163670_1_T0	PHENOTYPE	11	11	accidents
NCT001636701	NCT00163670_1_T1	PHENOTYPE	5	6	sleep disorders
NCT001636701	NCT00163670_1_T2	PHENOTYPE	37	38	sleep disorders
NCT001636701	NCT00163670_1_T3	PHENOTYPE	28	30	motor vehicle accidents
NCT001636834	NCT00163683_4_T0	COMPOUND	29	29	glucose
NCT001636834	NCT00163683_4_T1	GENE	18	18	has
NCT001636834	NCT00163683_4_T2	ORGAN	22	23	blood vessels
NCT001636837	NCT00163683_7_T0	PHENOTYPE	14	14	inflammation
NCT001636962	NCT00163696_2_T0	PHENOTYPE	20	20	severity
NCT001636966	NCT00163696_6_T0	PHENOTYPE	10	10	distal
NCT001636966	NCT00163696_6_T1	PHENOTYPE	6	6	BOS
NCT001636966	NCT00163696_6_T2	PHENOTYPE	21	21	proximal
NCT001636968	NCT00163696_8_T0	GENE	5	5	has
NCT001637091	NCT00163709_1_T0	PHENOTYPE	26	26	CHF
NCT001637091	NCT00163709_1_T1	GENE	4	4	BNP
NCT001637091	NCT00163709_1_T2	PHENOTYPE	17	19	shortness of breath
NCT001637093	NCT00163709_3_T0	PHENOTYPE	17	19	shortness of breath
NCT001637095	NCT00163709_5_T0	PHENOTYPE	14	15	heart failure
NCT001637096	NCT00163709_6_T0	PHENOTYPE	21	23	shortness of breath
NCT001637097	NCT00163709_7_T0	PHENOTYPE	22	24	quality of life
NCT001637098	NCT00163709_8_T0	PHENOTYPE	15	17	shortness of breath
NCT001637221	NCT00163722_1_T0	ORGAN	3	4	immune system
NCT001637222	NCT00163722_2_T0	PHENOTYPE	18	19	acute leukaemia
NCT001637222	NCT00163722_2_T1	ORGAN	27	28	bone marrow
NCT001637223	NCT00163722_3_T0	PHENOTYPE	7	8	Invasive Aspergillosis
NCT001637223	NCT00163722_3_T1	PHENOTYPE	14	15	Invasive Aspergillosis
NCT001637225	NCT00163722_5_T0	PHENOTYPE	22	23	Invasive Aspergillosis
NCT001637226	NCT00163722_6_T0	GENE	7	7	has
NCT001637226	NCT00163722_6_T1	PHENOTYPE	23	24	drug toxicity
NCT001637228	NCT00163722_8_T0	PHENOTYPE	8	9	Invasive Aspergillosis
NCT0016372212	NCT00163722_12_T0	PHENOTYPE	27	28	drug toxicity
NCT0016372212	NCT00163722_12_T1	PHENOTYPE	24	25	Invasive Aspergillosis
NCT0016372217	NCT00163722_17_T0	PHENOTYPE	9	9	autoimmune
NCT0016372217	NCT00163722_17_T1	PHENOTYPE	4	5	HIV infection
NCT0016372220	NCT00163722_20_T0	PHENOTYPE	8	9	fungal infection
NCT001637481	NCT00163748_1_T0	PHENOTYPE	14	14	lymphoma
NCT001637483	NCT00163748_3_T0	ORGAN	16	16	transplant
NCT001637483	NCT00163748_3_T1	ORGAN	14	15	bone marrow
NCT001637485	NCT00163748_5_T0	PHENOTYPE	29	29	bleeding
NCT001637485	NCT00163748_5_T1	PHENOTYPE	18	18	toxicities
NCT001637485	NCT00163748_5_T2	CELL	36	36	platelet
NCT001637486	NCT00163748_6_T0	COMPOUND	4	4	vinorelbine
NCT001637486	NCT00163748_6_T1	PHENOTYPE	13	13	lymphoma
NCT001637486	NCT00163748_6_T2	PHENOTYPE	22	22	lymphoma
NCT001637486	NCT00163748_6_T3	COMPOUND	6	6	gemcitabine
NCT001637488	NCT00163748_8_T0	COMPOUND	21	21	vinorelbine
NCT001637488	NCT00163748_8_T1	PHENOTYPE	14	14	lymphoma
NCT001637488	NCT00163748_8_T2	COMPOUND	23	23	gemcitabine
NCT001637612	NCT00163761_2_T0	PHENOTYPE	17	17	toxicity
NCT001637614	NCT00163761_4_T0	COMPOUND	21	21	vinorelbine
NCT001637614	NCT00163761_4_T1	COMPOUND	23	23	gemcitabine
NCT001637744	NCT00163774_4_T0	GENE	12	12	CBF
NCT001637744	NCT00163774_4_T1	PHENOTYPE	2	3	head injury
NCT001637749	NCT00163774_9_T0	PHENOTYPE	25	26	head injuries
NCT001637873	NCT00163787_3_T0	PHENOTYPE	41	41	LCI
NCT001637874	NCT00163787_4_T0	PHENOTYPE	11	11	LCI
NCT001638003	NCT00163800_3_T0	PHENOTYPE	11	12	brain injury
NCT0016380011	NCT00163800_11_T0	PHENOTYPE	2	3	brain injury
NCT001638261	NCT00163826_1_T0	PHENOTYPE	36	36	complications
NCT001638261	NCT00163826_1_T1	PHENOTYPE	3	4	spinal injuries
NCT001638261	NCT00163826_1_T2	PHENOTYPE	32	33	spinal instability
NCT001638391	NCT00163839_1_T0	PHENOTYPE	25	25	severity
NCT001638391	NCT00163839_1_T1	PHENOTYPE	29	29	Angioedema
NCT001638397	NCT00163839_7_T0	GENE	6	6	cease
NCT001638398	NCT00163839_8_T0	GENE	6	6	has
NCT001638399	NCT00163839_9_T0	PHENOTYPE	3	3	severity
NCT001638399	NCT00163839_9_T1	PHENOTYPE	7	7	Angioedema
NCT001638521	NCT00163852_1_T0	PHENOTYPE	13	13	ventilation
NCT001638522	NCT00163852_2_T0	PHENOTYPE	2	2	symptoms
NCT001638522	NCT00163852_2_T1	PHENOTYPE	12	12	ventilation
NCT001638522	NCT00163852_2_T2	COMPOUND	14	14	oxygen
NCT001638522	NCT00163852_2_T3	COMPOUND	16	17	carbon dioxide
NCT001638523	NCT00163852_3_T0	PHENOTYPE	17	17	acute
NCT001638523	NCT00163852_3_T1	PHENOTYPE	14	14	hypoventilation
NCT001638523	NCT00163852_3_T2	PHENOTYPE	2	2	Acute
NCT001638523	NCT00163852_3_T3	PHENOTYPE	15	15	hypercapnia
NCT001638523	NCT00163852_3_T4	PHENOTYPE	9	9	hypovolemic
NCT001638523	NCT00163852_3_T5	PHENOTYPE	20	21	cystic fibrosis
NCT001638523	NCT00163852_3_T6	PHENOTYPE	10	11	metabolic alkalosis
NCT001638525	NCT00163852_5_T0	PHENOTYPE	19	19	symptoms
NCT001638525	NCT00163852_5_T1	COMPOUND	8	8	sodium
NCT001638525	NCT00163852_5_T2	PHENOTYPE	14	14	hypoventilation
NCT001638525	NCT00163852_5_T3	PHENOTYPE	16	16	hypercapnia
NCT001638525	NCT00163852_5_T4	COMPOUND	10	10	NaCl
NCT001638525	NCT00163852_5_T5	COMPOUND	9	9	chloride
NCT001638525	NCT00163852_5_T6	PHENOTYPE	3	4	metabolic alkalosis
NCT001638526	NCT00163852_6_T0	PHENOTYPE	7	7	ventilation
NCT001638527	NCT00163852_7_T0	PHENOTYPE	15	15	acute
NCT001638527	NCT00163852_7_T1	PHENOTYPE	12	12	hypoventilation
NCT001638527	NCT00163852_7_T2	PHENOTYPE	13	13	hypercapnia
NCT001638527	NCT00163852_7_T3	COMPOUND	3	3	NaCl
NCT001638527	NCT00163852_7_T4	PHENOTYPE	7	7	hypovolemic
NCT001638527	NCT00163852_7_T5	PHENOTYPE	18	19	cystic fibrosis
NCT001638527	NCT00163852_7_T6	PHENOTYPE	8	9	metabolic alkalosis
NCT001638650	NCT00163865_0_T0	PHENOTYPE	4	4	Boredom
NCT001638652	NCT00163865_2_T0	PHENOTYPE	14	15	mental illness
NCT001638655	NCT00163865_5_T0	PHENOTYPE	2	2	boredom
NCT001638657	NCT00163865_7_T0	PHENOTYPE	10	10	boredom
NCT001638658	NCT00163865_8_T0	PHENOTYPE	21	21	ADHD
NCT001638658	NCT00163865_8_T1	PHENOTYPE	14	15	mental illness
NCT001638659	NCT00163865_9_T0	PHENOTYPE	8	8	strategies
NCT001638659	NCT00163865_9_T1	GENE	1	1	has
NCT001638659	NCT00163865_9_T2	PHENOTYPE	20	21	mental illness
NCT0016386510	NCT00163865_10_T0	PHENOTYPE	18	19	mental illness
NCT0016386512	NCT00163865_12_T0	PHENOTYPE	14	15	Mental Health
NCT001638786	NCT00163878_6_T0	PHENOTYPE	14	15	cognitive function
NCT001638911	NCT00163891_1_T0	PHENOTYPE	13	14	chest infections
NCT001638912	NCT00163891_2_T0	ORGAN	38	38	transplant
NCT001638912	NCT00163891_2_T1	PHENOTYPE	45	46	chest infection
NCT001638917	NCT00163891_7_T0	PHENOTYPE	6	6	experiences
NCT001638918	NCT00163891_8_T0	ORGAN	18	18	transplant
NCT001638918	NCT00163891_8_T1	PHENOTYPE	19	19	centres
NCT001638918	NCT00163891_8_T2	PHENOTYPE	11	12	Cystic Fibrosis
NCT001638919	NCT00163891_9_T0	GENE	8	8	reduced
NCT001638919	NCT00163891_9_T1	PHENOTYPE	11	11	cough
NCT0016389111	NCT00163891_11_T0	ORGAN	30	30	transplant
NCT0016389111	NCT00163891_11_T1	GENE	7	7	PEP
NCT0016389112	NCT00163891_12_T0	GENE	18	18	PEP
NCT0016389114	NCT00163891_14_T0	ORGAN	16	16	transplant
NCT0016389115	NCT00163891_15_T0	GENE	41	41	null
NCT0016389115	NCT00163891_15_T1	GENE	9	9	PEP
NCT0016389115	NCT00163891_15_T2	GENE	27	27	PEP
NCT0016389115	NCT00163891_15_T3	PHENOTYPE	19	20	chest infections
NCT001639043	NCT00163904_3_T0	PHENOTYPE	15	15	progression
NCT001639043	NCT00163904_3_T1	GENE	5	5	has
NCT001639044	NCT00163904_4_T0	PHENOTYPE	29	29	severity
NCT001639044	NCT00163904_4_T1	GENE	23	23	TNF-alpha
NCT001639044	NCT00163904_4_T2	GENE	25	25	Interleukin-6
NCT001639044	NCT00163904_4_T3	GENE	26	26	IL-6
NCT001639044	NCT00163904_4_T4	ORGAN	13	13	plasma
NCT001639044	NCT00163904_4_T5	PHENOTYPE	7	8	insulin resistance
NCT001639044	NCT00163904_4_T6	GENE	20	22	Tumor Necrosis Factor-alpha
NCT001639044	NCT00163904_4_T7	PHENOTYPE	0	2	Chronic heart failure
NCT001639045	NCT00163904_5_T0	GENE	1	1	has
NCT001639046	NCT00163904_6_T0	PHENOTYPE	1	1	CHF
NCT001639046	NCT00163904_6_T1	PHENOTYPE	2	3	insulin resistance
NCT001639046	NCT00163904_6_T2	PHENOTYPE	9	11	blood glucose levels
NCT001639047	NCT00163904_7_T0	PHENOTYPE	7	7	arteriosclerosis
NCT001639047	NCT00163904_7_T1	PHENOTYPE	12	12	progression
NCT001639047	NCT00163904_7_T2	PHENOTYPE	14	15	heart failure
NCT001639047	NCT00163904_7_T3	PHENOTYPE	8	9	insulin resistance
NCT001639048	NCT00163904_8_T0	PHENOTYPE	10	10	CHF
NCT001639048	NCT00163904_8_T1	GENE	1	1	has
NCT001639048	NCT00163904_8_T2	PHENOTYPE	0	0	Hyperinsulinaemia
NCT001639049	NCT00163904_9_T0	PHENOTYPE	8	8	CHF
NCT001639049	NCT00163904_9_T1	PHENOTYPE	15	16	insulin resistance
NCT0016390411	NCT00163904_11_T0	PHENOTYPE	12	13	weight gain
NCT0016390413	NCT00163904_13_T0	PHENOTYPE	18	19	heart failure
NCT0016390413	NCT00163904_13_T1	PHENOTYPE	12	13	weight gain
NCT0016390415	NCT00163904_15_T0	PHENOTYPE	20	20	CHF
NCT0016390415	NCT00163904_15_T1	GENE	5	5	has
NCT0016390415	NCT00163904_15_T2	PHENOTYPE	9	10	disease progression
NCT0016390416	NCT00163904_16_T0	PHENOTYPE	2	2	CHF
NCT0016390416	NCT00163904_16_T1	PHENOTYPE	25	25	dyslipidemia
NCT0016390416	NCT00163904_16_T2	PHENOTYPE	21	22	insulin resistance
NCT0016390421	NCT00163904_21_T0	GENE	3	3	MUFA
NCT0016390421	NCT00163904_21_T1	PHENOTYPE	7	8	heart disease
NCT0016390422	NCT00163904_22_T0	GENE	18	18	MUFA
NCT0016390422	NCT00163904_22_T1	PHENOTYPE	23	23	obesity
NCT001639173	NCT00163917_3_T0	PHENOTYPE	3	3	analgesia
NCT001639177	NCT00163917_7_T0	COMPOUND	3	3	ketamine
NCT001639177	NCT00163917_7_T1	COMPOUND	38	38	ketamine
NCT001639177	NCT00163917_7_T2	PHENOTYPE	33	33	dreams
NCT001639177	NCT00163917_7_T3	PHENOTYPE	30	30	hallucinations
NCT001639177	NCT00163917_7_T4	PHENOTYPE	15	16	respiratory depression
NCT001639177	NCT00163917_7_T5	PHENOTYPE	28	29	respiratory depression
NCT001639177	NCT00163917_7_T6	PHENOTYPE	19	21	nausea and vomiting
NCT001639179	NCT00163917_9_T0	GENE	8	8	has
NCT0016391718	NCT00163917_18_T0	PHENOTYPE	30	31	burn injuries
NCT0016391722	NCT00163917_22_T0	PHENOTYPE	1	1	feels
NCT0016391723	NCT00163917_23_T0	PHENOTYPE	24	24	avoidance
NCT0016391723	NCT00163917_23_T1	PHENOTYPE	28	28	feelings
NCT0016391723	NCT00163917_23_T2	PHENOTYPE	22	22	arousal
NCT0016393010	NCT00163930_10_T0	GENE	1	1	VAS
NCT0016393011	NCT00163930_11_T0	PHENOTYPE	6	6	complications
NCT0016393011	NCT00163930_11_T1	PHENOTYPE	8	8	vomiting
NCT0016393011	NCT00163930_11_T2	PHENOTYPE	10	11	respiratory depression
NCT0016393013	NCT00163930_13_T0	GENE	0	0	2.1
NCT0016393013	NCT00163930_13_T1	GENE	7	7	Ken
NCT0016393013	NCT00163930_13_T2	GENE	10	10	Dr
NCT0016393018	NCT00163930_18_T0	GENE	16	16	Fax
NCT0016393021	NCT00163930_21_T0	GENE	4	4	pre
NCT0016393027	NCT00163930_27_T0	PHENOTYPE	12	12	vomiting
NCT0016393027	NCT00163930_27_T1	PHENOTYPE	9	10	respiratory depression
NCT0016393031	NCT00163930_31_T0	PHENOTYPE	12	12	analgesia
NCT0016393035	NCT00163930_35_T0	GENE	0	0	6-1
NCT001639433	NCT00163943_3_T0	COMPOUND	14	14	norepinephrine
NCT001639433	NCT00163943_3_T1	PHENOTYPE	25	25	sequelae
NCT001639433	NCT00163943_3_T2	GENE	13	13	hormone
NCT001639433	NCT00163943_3_T3	ORGAN	4	5	nervous system
NCT001639435	NCT00163943_5_T0	ORGAN	16	17	nervous system
NCT001639436	NCT00163943_6_T0	ORGAN	28	29	nervous system
NCT001639436	NCT00163943_6_T1	PHENOTYPE	7	8	weight loss
NCT001639436	NCT00163943_6_T2	PHENOTYPE	17	18	weight loss
NCT0016394310	NCT00163943_10_T0	PHENOTYPE	3	4	weight loss
NCT0016394310	NCT00163943_10_T1	PHENOTYPE	10	11	weight loss
NCT0016394312	NCT00163943_12_T0	PHENOTYPE	6	7	weight loss
NCT0016394312	NCT00163943_12_T1	PHENOTYPE	9	10	weight loss
NCT0016394315	NCT00163943_15_T0	GENE	14	14	SNS
NCT0016394315	NCT00163943_15_T1	ORGAN	11	13	sympathetic nervous system
NCT0016394316	NCT00163943_16_T0	COMPOUND	29	29	norepinephrine
NCT0016394316	NCT00163943_16_T1	GENE	8	8	MS
NCT0016394316	NCT00163943_16_T2	PHENOTYPE	15	16	weight loss
NCT0016394317	NCT00163943_17_T0	PHENOTYPE	19	20	weight loss
NCT0016394321	NCT00163943_21_T0	GENE	15	15	SNS
NCT0016394321	NCT00163943_21_T1	ORGAN	22	22	plasma
NCT0016394321	NCT00163943_21_T2	PHENOTYPE	6	7	weight loss
NCT0016394321	NCT00163943_21_T3	PHENOTYPE	20	21	metabolic rate
NCT0016394323	NCT00163943_23_T0	PHENOTYPE	7	8	weight loss
NCT0016394323	NCT00163943_23_T1	PHENOTYPE	17	18	weight loss
NCT0016394323	NCT00163943_23_T2	PHENOTYPE	28	29	weight loss
NCT0016394325	NCT00163943_25_T0	GENE	5	5	SNS
NCT0016394325	NCT00163943_25_T1	PHENOTYPE	7	8	insulin sensitivity
NCT0016394333	NCT00163943_33_T0	ORGAN	18	18	heart
NCT0016394334	NCT00163943_34_T0	GENE	6	6	max
NCT0016394335	NCT00163943_35_T0	COMPOUND	12	12	norepinephrine
NCT0016394335	NCT00163943_35_T1	GENE	1	1	SNS
NCT0016394335	NCT00163943_35_T2	PHENOTYPE	46	47	venous occlusion
NCT0016394335	NCT00163943_35_T3	PHENOTYPE	35	36	glucose tolerance
NCT0016394335	NCT00163943_35_T4	TISSUE	19	20	skeletal muscle
NCT0016394335	NCT00163943_35_T5	TISSUE	15	17	abdominal adipose tissue
NCT0016394337	NCT00163943_37_T0	ORGAN	14	14	plasma
NCT0016394337	NCT00163943_37_T1	PHENOTYPE	7	8	insulin sensitivity
NCT0016394337	NCT00163943_37_T2	PHENOTYPE	5	6	metabolic rate
NCT0016394338	NCT00163943_38_T0	PHENOTYPE	27	28	weight loss
NCT0016394338	NCT00163943_38_T1	PHENOTYPE	29	30	weight loss
NCT001639562	NCT00163956_2_T0	ORGAN	8	8	heart
NCT001639563	NCT00163956_3_T0	ORGAN	14	14	legs
NCT001639563	NCT00163956_3_T1	ORGAN	17	17	heart
NCT001639563	NCT00163956_3_T2	PHENOTYPE	9	10	blood clots
NCT001639567	NCT00163956_7_T0	PHENOTYPE	0	0	Complications
NCT0016395611	NCT00163956_11_T0	GENE	5	5	has
NCT0016395612	NCT00163956_12_T0	GENE	19	19	had
NCT0016395615	NCT00163956_15_T0	GENE	4	4	indefinite
NCT0016395617	NCT00163956_17_T0	PHENOTYPE	9	9	complication
NCT0016395618	NCT00163956_18_T0	PHENOTYPE	20	20	DVT
NCT0016395618	NCT00163956_18_T1	GENE	11	11	had
NCT0016395618	NCT00163956_18_T2	GENE	2	2	al
NCT0016395618	NCT00163956_18_T3	PHENOTYPE	19	19	recurrent
NCT0016395618	NCT00163956_18_T4	GENE	1	1	et
NCT0016395619	NCT00163956_19_T0	GENE	2	2	PE
NCT0016395621	NCT00163956_21_T0	PHENOTYPE	10	10	trauma
NCT0016395621	NCT00163956_21_T1	GENE	17	17	PE
NCT0016395621	NCT00163956_21_T2	GENE	6	6	al
NCT0016395621	NCT00163956_21_T3	GENE	5	5	et
NCT0016395623	NCT00163956_23_T0	PHENOTYPE	1	1	thrombosis
NCT0016395623	NCT00163956_23_T1	PHENOTYPE	4	4	occlusion
NCT0016395624	NCT00163956_24_T0	ORGAN	8	9	pulmonary artery
NCT0016395625	NCT00163956_25_T0	PHENOTYPE	4	4	fragmentation
NCT0016395627	NCT00163956_27_T0	GENE	5	5	has
NCT0016395630	NCT00163956_30_T0	GENE	12	12	had
NCT0016395635	NCT00163956_35_T0	PHENOTYPE	2	2	acute
NCT0016395635	NCT00163956_35_T1	PHENOTYPE	0	0	Chronic
NCT0016395635	NCT00163956_35_T2	PHENOTYPE	3	3	DVT
NCT0016395643	NCT00163956_43_T0	GENE	4	4	indefinite
NCT0016395646	NCT00163956_46_T0	PHENOTYPE	15	15	secondary
NCT0016395647	NCT00163956_47_T0	PHENOTYPE	11	11	complications
NCT0016395647	NCT00163956_47_T1	PHENOTYPE	0	0	Complications
NCT0016395647	NCT00163956_47_T2	PHENOTYPE	4	5	Adverse Events
NCT0016395649	NCT00163956_49_T0	PHENOTYPE	1	2	adverse event
NCT0016395651	NCT00163956_51_T0	PHENOTYPE	8	9	adverse event
NCT0016395656	NCT00163956_56_T0	PHENOTYPE	13	13	complications
NCT0016395656	NCT00163956_56_T1	COMPOUND	7	7	nitinol
NCT0016395656	NCT00163956_56_T2	GENE	22	22	173
NCT0016395658	NCT00163956_58_T0	GENE	1	1	SR
NCT0016395660	NCT00163956_60_T0	GENE	3	3	53
NCT0016395661	NCT00163956_61_T0	GENE	10	10	Tech
NCT0016395661	NCT00163956_61_T1	COMPOUND	8	8	LGM
NCT0016395661	NCT00163956_61_T2	GENE	1	1	SF
NCT0016395661	NCT00163956_61_T3	GENE	7	7	al
NCT0016395661	NCT00163956_61_T4	GENE	3	3	RA
NCT0016395661	NCT00163956_61_T5	GENE	6	6	et
NCT0016395664	NCT00163956_64_T0	COMPOUND	12	12	titanium
NCT0016395664	NCT00163956_64_T1	GENE	7	7	al
NCT0016395664	NCT00163956_64_T2	GENE	6	6	et
NCT0016395665	NCT00163956_65_T0	PHENOTYPE	19	19	occlusion
NCT0016395665	NCT00163956_65_T1	GENE	17	17	Is
NCT0016395665	NCT00163956_65_T2	ORGAN	6	6	Appendix
NCT0016395665	NCT00163956_65_T3	GENE	4	4	20
NCT0016395668	NCT00163956_68_T0	GENE	4	4	Is
NCT0016395668	NCT00163956_68_T1	PHENOTYPE	8	8	thrombus
NCT0016395670	NCT00163956_70_T0	PHENOTYPE	3	3	Acute
NCT0016395670	NCT00163956_70_T1	GENE	0	0	Is
NCT0016395670	NCT00163956_70_T2	PHENOTYPE	2	2	thrombus
NCT001639690	NCT00163969_0_T0	PHENOTYPE	6	6	Analgesia
NCT001639692	NCT00163969_2_T0	PHENOTYPE	12	12	acute
NCT001639692	NCT00163969_2_T1	PHENOTYPE	13	13	tolerance
NCT001639692	NCT00163969_2_T2	COMPOUND	6	6	morphine
NCT0016396912	NCT00163969_12_T0	COMPOUND	2	2	ketamine
NCT0016396913	NCT00163969_13_T0	PHENOTYPE	14	14	secondary
NCT0016396913	NCT00163969_13_T1	PHENOTYPE	6	6	dreams
NCT0016396913	NCT00163969_13_T2	PHENOTYPE	3	3	vomiting
NCT0016396913	NCT00163969_13_T3	PHENOTYPE	2	2	nausea
NCT0016396913	NCT00163969_13_T4	PHENOTYPE	0	1	Respiratory depression
NCT0016396917	NCT00163969_17_T0	COMPOUND	13	13	ketamine
NCT0016396917	NCT00163969_17_T1	COMPOUND	18	18	morphine
NCT0016396922	NCT00163969_22_T0	COMPOUND	5	5	ketamine
NCT0016396922	NCT00163969_22_T1	PHENOTYPE	1	1	allergy
NCT0016396922	NCT00163969_22_T2	COMPOUND	3	3	morphine
NCT0016396926	NCT00163969_26_T0	PHENOTYPE	0	0	Chronic
NCT0016396926	NCT00163969_26_T1	COMPOUND	1	1	morphine
NCT0016396940	NCT00163969_40_T0	COMPOUND	2	2	ketamine
NCT001640211	NCT00164021_1_T0	GENE	8	8	GOR
NCT001640213	NCT00164021_3_T0	PHENOTYPE	6	6	severity
NCT001640213	NCT00164021_3_T1	GENE	13	13	GOR
NCT001640213	NCT00164021_3_T2	GENE	26	26	pH
NCT001640213	NCT00164021_3_T3	ORGAN	22	22	transplant
NCT001640213	NCT00164021_3_T4	BIOLOGICAL_PROCESS	37	38	gastric emptying
NCT001640213	NCT00164021_3_T5	PHENOTYPE	32	34	quality of life
NCT001640214	NCT00164021_4_T0	GENE	7	7	GOR
NCT001640214	NCT00164021_4_T1	PHENOTYPE	18	19	lung function
NCT001640214	NCT00164021_4_T2	PHENOTYPE	21	23	quality of life
NCT001640217	NCT00164021_7_T0	GENE	22	22	GOR
NCT001640218	NCT00164021_8_T0	PHENOTYPE	11	12	Cystic Fibrosis
NCT0016402112	NCT00164021_12_T0	GENE	27	27	saliva
NCT0016402112	NCT00164021_12_T1	PHENOTYPE	19	19	FVC
NCT0016402112	NCT00164021_12_T2	GENE	25	25	pH
NCT0016402112	NCT00164021_12_T3	COMPOUND	5	5	BMI
NCT0016402112	NCT00164021_12_T4	PHENOTYPE	14	15	lung function
NCT0016402114	NCT00164021_14_T0	GENE	12	12	al
NCT0016402114	NCT00164021_14_T1	GENE	11	11	et
NCT0016402116	NCT00164021_16_T0	COMPOUND	14	14	antimony
NCT0016402116	NCT00164021_16_T1	GENE	3	3	pH
NCT0016402117	NCT00164021_17_T0	COMPOUND	7	7	antimony
NCT0016402117	NCT00164021_17_T1	PHENOTYPE	6	6	distal
NCT0016402117	NCT00164021_17_T2	PHENOTYPE	29	29	distal
NCT0016402117	NCT00164021_17_T3	GENE	26	26	cm
NCT0016402117	NCT00164021_17_T4	PHENOTYPE	23	23	proximal
NCT0016402117	NCT00164021_17_T5	PHENOTYPE	60	60	reflux
NCT0016402118	NCT00164021_18_T0	GENE	30	30	pH
NCT0016402118	NCT00164021_18_T1	PHENOTYPE	17	17	gastrostomy
NCT0016402121	NCT00164021_21_T0	COMPOUND	8	8	CFQ
NCT0016402121	NCT00164021_21_T1	PHENOTYPE	0	2	Quality of life
NCT001640471	NCT00164047_1_T0	PHENOTYPE	8	8	avoidance
NCT001640471	NCT00164047_1_T1	PHENOTYPE	4	4	anaesthesia
NCT001640471	NCT00164047_1_T2	PHENOTYPE	32	32	anaesthesia
NCT001640474	NCT00164047_4_T0	PHENOTYPE	12	13	postoperative nausea
NCT001640474	NCT00164047_4_T1	PHENOTYPE	13	15	nausea and vomiting
NCT001640476	NCT00164047_6_T0	PHENOTYPE	1	1	hypoxia
NCT001640477	NCT00164047_7_T0	PHENOTYPE	1	2	adverse effects
NCT001640478	NCT00164047_8_T0	PHENOTYPE	3	4	wound infection
NCT0016404712	NCT00164047_12_T0	PHENOTYPE	8	8	centres
NCT0016404715	NCT00164047_15_T0	PHENOTYPE	2	2	anaesthesia
NCT0016404718	NCT00164047_18_T0	GENE	6	6	0.3
NCT0016404718	NCT00164047_18_T1	PHENOTYPE	1	1	impairment
NCT0016404719	NCT00164047_19_T0	GENE	7	7	0.3
NCT0016404719	NCT00164047_19_T1	PHENOTYPE	4	4	ventilation
NCT0016404719	NCT00164047_19_T2	PHENOTYPE	0	0	Thoracic
NCT0016404720	NCT00164047_20_T0	GENE	6	6	eg
NCT0016404720	NCT00164047_20_T1	PHENOTYPE	7	7	volvulus
NCT0016404720	NCT00164047_20_T2	PHENOTYPE	8	9	pulmonary hypertension
NCT0016404720	NCT00164047_20_T3	PHENOTYPE	10	12	raised intracranial pressure
NCT001640601	NCT00164060_1_T0	PHENOTYPE	15	15	severity
NCT001640601	NCT00164060_1_T1	GENE	26	26	co
NCT001640601	NCT00164060_1_T2	PHENOTYPE	28	28	HIV
NCT001640601	NCT00164060_1_T3	COMPOUND	12	12	GBV-C
NCT001640601	NCT00164060_1_T4	COMPOUND	30	30	HCV
NCT001640601	NCT00164060_1_T5	PHENOTYPE	17	18	liver disease
NCT001640601	NCT00164060_1_T6	PHENOTYPE	22	23	hepatitis C
NCT001640601	NCT00164060_1_T7	PHENOTYPE	21	22	chronic hepatitis
NCT001640602	NCT00164060_2_T0	PHENOTYPE	10	10	co-infection
NCT001640605	NCT00164060_5_T0	GENE	15	15	1.2
NCT001640605	NCT00164060_5_T1	GENE	5	5	has
NCT001640606	NCT00164060_6_T0	PHENOTYPE	19	19	acute
NCT001640606	NCT00164060_6_T1	COMPOUND	0	0	GBV-C
NCT001640606	NCT00164060_6_T2	PHENOTYPE	22	22	hepatitis
NCT001640607	NCT00164060_7_T0	COMPOUND	0	0	GBV-C
NCT001640607	NCT00164060_7_T1	COMPOUND	12	12	HCV
NCT001640607	NCT00164060_7_T2	GENE	1	1	has
NCT001640607	NCT00164060_7_T3	PHENOTYPE	9	10	Hepatitis C
NCT001640608	NCT00164060_8_T0	PHENOTYPE	19	19	acute
NCT001640608	NCT00164060_8_T1	COMPOUND	1	1	GBV-C
NCT001640608	NCT00164060_8_T2	COMPOUND	5	5	HCV
NCT001640608	NCT00164060_8_T3	CELL	16	16	hepatocytes
NCT001640608	NCT00164060_8_T4	PHENOTYPE	21	22	chronic hepatitis
NCT001640609	NCT00164060_9_T0	COMPOUND	1	1	GBV-C
NCT0016406010	NCT00164060_10_T0	COMPOUND	1	1	GBV-C
NCT0016406010	NCT00164060_10_T1	GENE	29	29	E2
NCT0016406010	NCT00164060_10_T2	GENE	27	28	envelope glycoprotein
NCT0016406011	NCT00164060_11_T0	COMPOUND	10	10	GBV-C
NCT0016406011	NCT00164060_11_T1	GENE	2	2	has
NCT0016406011	NCT00164060_11_T2	PHENOTYPE	8	8	co-infection
NCT0016406011	NCT00164060_11_T3	PHENOTYPE	0	1	HIV infection
NCT0016406012	NCT00164060_12_T0	PHENOTYPE	13	13	HIV
NCT0016406012	NCT00164060_12_T1	PHENOTYPE	25	25	HIV
NCT0016406012	NCT00164060_12_T2	COMPOUND	33	33	GBV-C
NCT0016406012	NCT00164060_12_T3	PHENOTYPE	3	3	co-infection
NCT0016406012	NCT00164060_12_T4	PHENOTYPE	16	16	co-infection
NCT0016406013	NCT00164060_13_T0	COMPOUND	7	7	GBV-C
NCT0016406013	NCT00164060_13_T1	PHENOTYPE	12	13	HIV infection
NCT0016406014	NCT00164060_14_T0	COMPOUND	16	16	GBV-C
NCT0016406014	NCT00164060_14_T1	COMPOUND	26	26	HCV
NCT0016406014	NCT00164060_14_T2	PHENOTYPE	6	6	hepatitis
NCT0016406015	NCT00164060_15_T0	COMPOUND	6	6	GBV-C
NCT0016406015	NCT00164060_15_T1	COMPOUND	3	3	HCV
NCT0016406015	NCT00164060_15_T2	ORGAN	10	10	serum
NCT0016406016	NCT00164060_16_T0	COMPOUND	16	16	GBV-C
NCT0016406016	NCT00164060_16_T1	COMPOUND	7	7	HCV
NCT0016406016	NCT00164060_16_T2	PHENOTYPE	6	6	chronic
NCT0016406017	NCT00164060_17_T0	COMPOUND	17	17	GBV-C
NCT0016406017	NCT00164060_17_T1	COMPOUND	4	4	HCV
NCT0016406017	NCT00164060_17_T2	PHENOTYPE	15	15	co-infection
NCT0016406018	NCT00164060_18_T0	COMPOUND	6	6	GBV-C
NCT0016406019	NCT00164060_19_T0	ORGAN	9	9	liver
NCT0016406020	NCT00164060_20_T0	COMPOUND	21	21	GBV-C
NCT0016406020	NCT00164060_20_T1	COMPOUND	11	11	HCV
NCT0016406020	NCT00164060_20_T2	GENE	19	19	co
NCT0016406021	NCT00164060_21_T0	PHENOTYPE	14	14	HIV
NCT0016406021	NCT00164060_21_T1	COMPOUND	11	11	GBV-C
NCT0016406021	NCT00164060_21_T2	COMPOUND	12	12	HCV
NCT0016406022	NCT00164060_22_T0	PHENOTYPE	4	4	HIV
NCT0016406022	NCT00164060_22_T1	COMPOUND	6	6	GBV-C
NCT0016406022	NCT00164060_22_T2	PHENOTYPE	10	10	co-infection
NCT0016406023	NCT00164060_23_T0	COMPOUND	1	1	GBV-C
NCT0016406023	NCT00164060_23_T1	PHENOTYPE	15	16	HIV infection
NCT0016406024	NCT00164060_24_T0	COMPOUND	12	12	GBV-C
NCT0016406025	NCT00164060_25_T0	PHENOTYPE	8	8	HIV
NCT0016406025	NCT00164060_25_T1	PHENOTYPE	17	17	HIV
NCT0016406025	NCT00164060_25_T2	COMPOUND	0	0	GBV-C
NCT0016406025	NCT00164060_25_T3	COMPOUND	15	15	GBV-C
NCT0016406025	NCT00164060_25_T4	GENE	1	1	has
NCT0016406026	NCT00164060_26_T0	PHENOTYPE	12	12	Hepatitis
NCT0016406026	NCT00164060_26_T1	GENE	3	3	sera
NCT0016406026	NCT00164060_26_T2	PHENOTYPE	14	14	HIV
NCT0016406027	NCT00164060_27_T0	COMPOUND	20	20	GBV-C
NCT0016406027	NCT00164060_27_T1	GENE	8	8	has
NCT0016406027	NCT00164060_27_T2	GENE	25	25	PCR
NCT0016406028	NCT00164060_28_T0	GENE	2	2	sera
NCT0016406028	NCT00164060_28_T1	PHENOTYPE	6	6	HIV
NCT0016406028	NCT00164060_28_T2	COMPOUND	16	16	HCV
NCT0016406028	NCT00164060_28_T3	GENE	14	14	co
NCT0016406032	NCT00164060_32_T0	GENE	1	1	sera
NCT0016406032	NCT00164060_32_T1	PHENOTYPE	16	16	HIV
NCT0016406032	NCT00164060_32_T2	COMPOUND	14	14	GBV-C
NCT0016406032	NCT00164060_32_T3	COMPOUND	13	13	HCV
NCT0016406033	NCT00164060_33_T0	PHENOTYPE	13	13	progression
NCT0016406033	NCT00164060_33_T1	PHENOTYPE	15	16	liver disease
NCT0016406035	NCT00164060_35_T0	PHENOTYPE	6	6	Hepatitis
NCT0016406035	NCT00164060_35_T1	PHENOTYPE	8	8	HIV
NCT0016406037	NCT00164060_37_T0	PHENOTYPE	18	18	Hepatitis
NCT0016406037	NCT00164060_37_T1	COMPOUND	9	9	HCV
NCT0016406038	NCT00164060_38_T0	COMPOUND	8	8	HCV
NCT0016406038	NCT00164060_38_T1	GENE	2	2	has
NCT0016406041	NCT00164060_41_T0	GENE	2	2	sera
NCT0016406042	NCT00164060_42_T0	PHENOTYPE	0	0	HIV
NCT0016406042	NCT00164060_42_T1	PHENOTYPE	1	2	serology positive
NCT0016406044	NCT00164060_44_T0	COMPOUND	1	1	HCV
NCT0016406044	NCT00164060_44_T1	COMPOUND	5	5	HCV
NCT0016406044	NCT00164060_44_T2	PHENOTYPE	2	3	antibody positive
NCT0016406046	NCT00164060_46_T0	GENE	2	2	sera
NCT0016406050	NCT00164060_50_T0	PHENOTYPE	2	3	Hepatitis B
NCT0016406050	NCT00164060_50_T1	PHENOTYPE	12	13	Hepatitis B
NCT0016406050	NCT00164060_50_T2	PHENOTYPE	17	18	Hepatitis B
NCT0016406053	NCT00164060_53_T0	GENE	2	2	sera
NCT0016406053	NCT00164060_53_T1	PHENOTYPE	17	17	HIV
NCT0016406053	NCT00164060_53_T2	COMPOUND	19	19	GBV-C
NCT0016406053	NCT00164060_53_T3	COMPOUND	16	16	HCV
NCT0016406054	NCT00164060_54_T0	COMPOUND	34	34	GBV-C
NCT0016406054	NCT00164060_54_T1	COMPOUND	35	35	HCV
NCT0016406054	NCT00164060_54_T2	PHENOTYPE	37	38	HIV infection
NCT0016406056	NCT00164060_56_T0	PHENOTYPE	18	18	syndromes
NCT0016406056	NCT00164060_56_T1	PHENOTYPE	3	4	HIV infection
NCT0016406057	NCT00164060_57_T0	PHENOTYPE	15	15	HIV
NCT0016406057	NCT00164060_57_T1	COMPOUND	13	13	HCV
NCT0016406058	NCT00164060_58_T0	GENE	24	24	Interferon
NCT0016406058	NCT00164060_58_T1	PHENOTYPE	5	6	liver disease
NCT0016406059	NCT00164060_59_T0	ORGAN	8	8	liver
NCT0016406059	NCT00164060_59_T1	PHENOTYPE	15	15	cirrhosis
NCT0016406059	NCT00164060_59_T2	PHENOTYPE	13	14	chronic hepatitis
NCT0016406059	NCT00164060_59_T3	PHENOTYPE	17	18	hepatocellular cancer
NCT0016406060	NCT00164060_60_T0	COMPOUND	19	19	1
NCT0016406060	NCT00164060_60_T1	COMPOUND	21	21	1
NCT0016406060	NCT00164060_60_T2	COMPOUND	20	20	GBV-C
NCT0016406061	NCT00164060_61_T0	GENE	1	1	sera
NCT0016406061	NCT00164060_61_T1	COMPOUND	3	3	GBV-C
NCT0016406061	NCT00164060_61_T2	COMPOUND	9	9	GBV-C
NCT0016406061	NCT00164060_61_T3	GENE	6	6	E2
NCT0016406063	NCT00164060_63_T0	GENE	6	6	sera
NCT0016406064	NCT00164060_64_T0	COMPOUND	1	1	2
NCT0016406064	NCT00164060_64_T1	PHENOTYPE	2	2	HIV
NCT0016406065	NCT00164060_65_T0	GENE	0	0	CD4
NCT0016406065	NCT00164060_65_T1	GENE	2	2	buffy
NCT0016406065	NCT00164060_65_T2	PHENOTYPE	5	6	HIV positive
NCT0016406067	NCT00164060_67_T0	PHENOTYPE	0	0	HIV
NCT0016406071	NCT00164060_71_T0	PHENOTYPE	2	2	HIV/AIDS
NCT0016406071	NCT00164060_71_T1	PHENOTYPE	6	6	illnesses
NCT0016406071	NCT00164060_71_T2	PHENOTYPE	0	0	Complications
NCT0016406073	NCT00164060_73_T0	COMPOUND	0	0	HCV
NCT0016406077	NCT00164060_77_T0	PHENOTYPE	7	7	bleeding
NCT0016406077	NCT00164060_77_T1	PHENOTYPE	4	4	ascites
NCT0016406077	NCT00164060_77_T2	PHENOTYPE	0	0	Complications
NCT0016406077	NCT00164060_77_T3	PHENOTYPE	5	5	encephalopathy
NCT0016406077	NCT00164060_77_T4	PHENOTYPE	2	3	liver disease
NCT0016406077	NCT00164060_77_T5	PHENOTYPE	9	10	hepatocellular carcinoma
NCT0016406081	NCT00164060_81_T0	GENE	0	0	Alpha
NCT0016406081	NCT00164060_81_T1	GENE	3	3	AFP
NCT0016406087	NCT00164060_87_T0	PHENOTYPE	6	7	portal hypertension
NCT0016406093	NCT00164060_93_T0	GENE	32	32	co
NCT0016406093	NCT00164060_93_T1	PHENOTYPE	31	31	HIV
NCT0016406093	NCT00164060_93_T2	COMPOUND	24	24	GBV-C
NCT0016406093	NCT00164060_93_T3	COMPOUND	37	37	HCV
NCT0016406093	NCT00164060_93_T4	PHENOTYPE	21	22	liver disease
NCT0016406093	NCT00164060_93_T5	PHENOTYPE	19	20	hepatitis C
NCT0016406093	NCT00164060_93_T6	PHENOTYPE	18	19	chronic hepatitis
NCT0016406095	NCT00164060_95_T0	PHENOTYPE	9	9	HIV
NCT0016406095	NCT00164060_95_T1	COMPOUND	11	11	GBV-C
NCT0016406095	NCT00164060_95_T2	COMPOUND	7	7	HCV
NCT0016406096	NCT00164060_96_T0	PHENOTYPE	5	5	HIV
NCT0016406096	NCT00164060_96_T1	COMPOUND	7	7	GBV-C
NCT0016406096	NCT00164060_96_T2	COMPOUND	3	3	HCV
NCT0016406097	NCT00164060_97_T0	COMPOUND	2	2	HCV
NCT0016406099	NCT00164060_99_T0	GENE	7	7	al
NCT0016406099	NCT00164060_99_T1	GENE	6	6	et
NCT0016406099	NCT00164060_99_T2	PHENOTYPE	14	15	hepatitis G
NCT00164060104	NCT00164060_104_T0	GENE	3	3	Med
NCT00164060104	NCT00164060_104_T1	COMPOUND	0	0	N
NCT00164060104	NCT00164060_104_T2	GENE	1	1	Engl
NCT00164060106	NCT00164060_106_T0	GENE	7	7	al
NCT00164060106	NCT00164060_106_T1	PHENOTYPE	16	16	hepatitis
NCT00164060106	NCT00164060_106_T2	GENE	3	3	TP
NCT00164060106	NCT00164060_106_T3	GENE	6	6	et
NCT00164060107	NCT00164060_107_T0	GENE	0	0	Nat
NCT00164060107	NCT00164060_107_T1	GENE	1	1	Med
NCT00164060109	NCT00164060_109_T0	PHENOTYPE	3	4	Hepatitis G
NCT00164060109	NCT00164060_109_T1	PHENOTYPE	5	6	virus infection
NCT00164060110	NCT00164060_110_T0	GENE	0	0	Ann
NCT00164060110	NCT00164060_110_T1	GENE	2	2	Med
NCT00164060112	NCT00164060_112_T0	GENE	1	1	HL
NCT00164060112	NCT00164060_112_T1	PHENOTYPE	17	17	HIV
NCT00164060112	NCT00164060_112_T2	GENE	14	14	reduced
NCT00164060112	NCT00164060_112_T3	GENE	7	7	al
NCT00164060112	NCT00164060_112_T4	GENE	6	6	et
NCT00164060113	NCT00164060_113_T0	GENE	3	3	Med
NCT00164060113	NCT00164060_113_T1	COMPOUND	0	0	N
NCT00164060113	NCT00164060_113_T2	GENE	1	1	Engl
NCT00164060115	NCT00164060_115_T0	GENE	7	7	al
NCT00164060115	NCT00164060_115_T1	PHENOTYPE	10	10	coinfection
NCT00164060115	NCT00164060_115_T2	GENE	6	6	et
NCT00164060115	NCT00164060_115_T3	PHENOTYPE	20	21	HIV infection
NCT00164060116	NCT00164060_116_T0	GENE	3	3	Med
NCT00164060116	NCT00164060_116_T1	COMPOUND	0	0	N
NCT00164060116	NCT00164060_116_T2	GENE	1	1	Engl
NCT00164060118	NCT00164060_118_T0	PHENOTYPE	28	28	Immunodeficiency
NCT00164060118	NCT00164060_118_T1	PHENOTYPE	25	25	progression
NCT00164060118	NCT00164060_118_T2	GENE	7	7	al
NCT00164060118	NCT00164060_118_T3	GENE	6	6	et
NCT00164060118	NCT00164060_118_T4	PHENOTYPE	29	30	virus disease
NCT00164060119	NCT00164060_119_T0	PHENOTYPE	2	2	Dis
NCT00164060121	NCT00164060_121_T0	GENE	7	7	al
NCT00164060121	NCT00164060_121_T1	PHENOTYPE	15	15	chronic
NCT00164060121	NCT00164060_121_T2	GENE	6	6	et
NCT00164060121	NCT00164060_121_T3	PHENOTYPE	16	17	hepatitis C
NCT00164060121	NCT00164060_121_T4	PHENOTYPE	10	11	hepatitis G
NCT00164060121	NCT00164060_121_T5	PHENOTYPE	12	13	virus infection
NCT00164060122	NCT00164060_122_T0	GENE	0	0	Ann
NCT00164060122	NCT00164060_122_T1	GENE	2	2	Med
NCT00164060124	NCT00164060_124_T0	GENE	1	1	MP
NCT00164060124	NCT00164060_124_T1	GENE	7	7	al
NCT00164060124	NCT00164060_124_T2	GENE	6	6	et
NCT00164060124	NCT00164060_124_T3	PHENOTYPE	16	17	chronic hepatitis
NCT00164060124	NCT00164060_124_T4	PHENOTYPE	17	18	hepatitis C
NCT00164060127	NCT00164060_127_T0	GENE	1	1	MD
NCT00164060127	NCT00164060_127_T1	PHENOTYPE	21	21	Immunodeficiency
NCT00164060127	NCT00164060_127_T2	GENE	7	7	al
NCT00164060127	NCT00164060_127_T3	GENE	6	6	et
NCT00164060130	NCT00164060_130_T0	GENE	8	8	sera
NCT00164060131	NCT00164060_131_T0	PHENOTYPE	0	0	HIV
NCT00164060131	NCT00164060_131_T1	PHENOTYPE	1	2	serology positive
NCT00164060133	NCT00164060_133_T0	COMPOUND	1	1	HCV
NCT00164060133	NCT00164060_133_T1	COMPOUND	5	5	HCV
NCT00164060133	NCT00164060_133_T2	PHENOTYPE	2	3	antibody positive
NCT00164060135	NCT00164060_135_T0	GENE	2	2	sera
NCT001640731	NCT00164073_1_T0	PHENOTYPE	3	3	inflammation
NCT001640731	NCT00164073_1_T1	PHENOTYPE	5	5	fibrosis
NCT001640731	NCT00164073_1_T2	CELL	11	11	lymphocyte
NCT001640732	NCT00164073_2_T0	PHENOTYPE	12	12	toxic
NCT001640734	NCT00164073_4_T0	PHENOTYPE	7	8	hepatitis C
NCT001640734	NCT00164073_4_T1	PHENOTYPE	6	7	chronic hepatitis
NCT001640734	NCT00164073_4_T2	PHENOTYPE	28	29	adverse effects
NCT001640736	NCT00164073_6_T0	COMPOUND	14	14	HCV
NCT001640736	NCT00164073_6_T1	GENE	3	3	Interferon
NCT001640736	NCT00164073_6_T2	PHENOTYPE	13	13	chronic
NCT001640739	NCT00164073_9_T0	ORGAN	11	11	thyroid
NCT001640739	NCT00164073_9_T1	GENE	4	4	interferon
NCT001640739	NCT00164073_9_T2	GENE	23	23	interferon
NCT0016407310	NCT00164073_10_T0	PHENOTYPE	3	4	retinal haemorrhages
NCT0016407310	NCT00164073_10_T1	PHENOTYPE	0	1	Autoimmune disease
NCT0016407311	NCT00164073_11_T0	PHENOTYPE	25	25	anaemia
NCT0016407311	NCT00164073_11_T1	PHENOTYPE	13	13	dysfunction
NCT0016407311	NCT00164073_11_T2	PHENOTYPE	17	18	haemolytic anaemias
NCT0016407311	NCT00164073_11_T3	PHENOTYPE	14	15	cardiac disease
NCT0016407313	NCT00164073_13_T0	COMPOUND	12	12	HCV
NCT0016407313	NCT00164073_13_T1	GENE	8	8	has
NCT0016407314	NCT00164073_14_T0	GENE	3	3	has
NCT0016407315	NCT00164073_15_T0	PHENOTYPE	19	19	inflammation
NCT0016407315	NCT00164073_15_T1	PHENOTYPE	5	5	HBV
NCT0016407315	NCT00164073_15_T2	PHENOTYPE	9	9	HBV
NCT0016407315	NCT00164073_15_T3	PHENOTYPE	7	8	Hepatitis C
NCT0016407315	NCT00164073_15_T4	PHENOTYPE	3	4	Hepatitis B
NCT0016407316	NCT00164073_16_T0	COMPOUND	3	3	HCV
NCT0016407317	NCT00164073_17_T0	COMPOUND	3	3	HCV
NCT0016407317	NCT00164073_17_T1	GENE	6	6	has
NCT0016407317	NCT00164073_17_T2	PHENOTYPE	5	5	cirrhosis
NCT0016407317	NCT00164073_17_T3	BIOLOGICAL_PROCESS	17	18	gene expression
NCT0016407318	NCT00164073_18_T0	ORGAN	10	10	liver
NCT0016407318	NCT00164073_18_T1	PHENOTYPE	1	1	progression
NCT0016407318	NCT00164073_18_T2	COMPOUND	3	3	HCV
NCT0016407318	NCT00164073_18_T3	GENE	26	26	has
NCT0016407318	NCT00164073_18_T4	PHENOTYPE	18	19	persistent infection
NCT0016407318	NCT00164073_18_T5	BIOLOGICAL_PROCESS	6	7	gene expression
NCT0016407319	NCT00164073_19_T0	GENE	11	11	IFN-gamma
NCT0016407319	NCT00164073_19_T1	BIOLOGICAL_PROCESS	24	26	adaptive immune response
NCT0016407319	NCT00164073_19_T2	BIOLOGICAL_PROCESS	18	21	antigen processing and presentation
NCT0016407320	NCT00164073_20_T0	COMPOUND	26	26	HCV
NCT0016407322	NCT00164073_22_T0	COMPOUND	10	10	HCV
NCT0016407322	NCT00164073_22_T1	GENE	2	2	has
NCT0016407323	NCT00164073_23_T0	GENE	15	15	reduced
NCT0016407323	NCT00164073_23_T1	GENE	6	6	Interferon
NCT0016407324	NCT00164073_24_T0	CELL	3	3	cells
NCT0016407324	NCT00164073_24_T1	GENE	10	10	interleukin-8
NCT0016407324	NCT00164073_24_T2	GENE	2	2	Huh7
NCT0016407325	NCT00164073_25_T0	GENE	11	11	interferon
NCT0016407326	NCT00164073_26_T0	PHENOTYPE	8	8	peripheral
NCT0016407326	NCT00164073_26_T1	CELL	11	11	cells
NCT0016407326	NCT00164073_26_T2	PHENOTYPE	13	14	hepatitis C
NCT0016407327	NCT00164073_27_T0	PHENOTYPE	40	40	immunity
NCT0016407327	NCT00164073_27_T1	CELL	21	21	lymphocyte
NCT0016407327	NCT00164073_27_T2	CELL	8	8	cells
NCT0016407327	NCT00164073_27_T3	PHENOTYPE	42	43	hepatitis C
NCT0016407327	NCT00164073_27_T4	BIOLOGICAL_PROCESS	19	20	T-cell activation
NCT0016407327	NCT00164073_27_T5	BIOLOGICAL_PROCESS	15	18	antigen processing and presentation
NCT0016407328	NCT00164073_28_T0	COMPOUND	3	3	HCV
NCT0016407328	NCT00164073_28_T1	GENE	5	5	has
NCT0016407330	NCT00164073_30_T0	COMPOUND	20	20	HCV
NCT0016407330	NCT00164073_30_T1	PHENOTYPE	4	4	hopes
NCT0016407331	NCT00164073_31_T0	PHENOTYPE	21	21	Hepatitis
NCT0016407333	NCT00164073_33_T0	ORGAN	7	7	liver
NCT0016407338	NCT00164073_38_T0	COMPOUND	0	0	HCV
NCT0016407338	NCT00164073_38_T1	GENE	17	17	Interferon
NCT0016407340	NCT00164073_40_T0	ORGAN	1	1	liver
NCT0016407343	NCT00164073_43_T0	ORGAN	12	12	liver
NCT0016407343	NCT00164073_43_T1	PHENOTYPE	8	8	diseases
NCT0016407345	NCT00164073_45_T0	GENE	4	4	1.2
NCT0016407345	NCT00164073_45_T1	ORGAN	1	1	liver
NCT0016407345	NCT00164073_45_T2	GENE	13	13	mRNA
NCT0016407346	NCT00164073_46_T0	GENE	11	11	cDNA
NCT0016407346	NCT00164073_46_T1	GENE	3	3	mRNA
NCT0016407347	NCT00164073_47_T0	GENE	1	1	cDNA
NCT0016407348	NCT00164073_48_T0	ORGAN	4	4	liver
NCT0016407348	NCT00164073_48_T1	GENE	5	5	cDNA
NCT0016407349	NCT00164073_49_T0	GENE	14	14	cDNA
NCT0016407352	NCT00164073_52_T0	COMPOUND	2	2	1
NCT0016407352	NCT00164073_52_T1	COMPOUND	3	3	HCV
NCT0016407353	NCT00164073_53_T0	COMPOUND	3	3	2
NCT0016407353	NCT00164073_53_T1	GENE	0	0	cDNA
NCT0016407353	NCT00164073_53_T2	COMPOUND	4	4	HCV
NCT0016407354	NCT00164073_54_T0	GENE	5	5	Rx
NCT0016407354	NCT00164073_54_T1	GENE	0	0	cDNA
NCT0016407355	NCT00164073_55_T0	GENE	1	1	Rx
NCT0016407355	NCT00164073_55_T1	GENE	8	8	Rx
NCT0016407355	NCT00164073_55_T2	GENE	3	3	cDNA
NCT0016407356	NCT00164073_56_T0	GENE	1	1	Rx
NCT0016407356	NCT00164073_56_T1	GENE	9	9	Rx
NCT0016407356	NCT00164073_56_T2	GENE	3	3	cDNA
NCT0016407357	NCT00164073_57_T0	GENE	1	1	Rx
NCT0016407357	NCT00164073_57_T1	GENE	9	9	Rx
NCT0016407357	NCT00164073_57_T2	GENE	3	3	cDNA
NCT0016407358	NCT00164073_58_T0	GENE	1	1	Rx
NCT0016407358	NCT00164073_58_T1	GENE	4	4	Rx
NCT0016407358	NCT00164073_58_T2	GENE	3	3	cDNA
NCT0016407362	NCT00164073_62_T0	CELL	15	15	macrophage
NCT0016407362	NCT00164073_62_T1	GENE	8	8	IgG1
NCT0016407362	NCT00164073_62_T2	GENE	0	0	Th1
NCT0016407362	NCT00164073_62_T3	PHENOTYPE	13	13	cytotoxicity
NCT0016407370	NCT00164073_70_T0	PHENOTYPE	2	3	chronic hepatitis
NCT0016407370	NCT00164073_70_T1	PHENOTYPE	3	4	hepatitis C
NCT0016407375	NCT00164073_75_T0	COMPOUND	6	6	ribavirin
NCT0016407375	NCT00164073_75_T1	COMPOUND	3	4	interferon alfa_2b
NCT0016407375	NCT00164073_75_T2	PHENOTYPE	11	12	hepatitis C
NCT0016407379	NCT00164073_79_T0	GENE	7	7	al
NCT0016407379	NCT00164073_79_T1	PHENOTYPE	12	12	chronic
NCT0016407379	NCT00164073_79_T2	GENE	6	6	et
NCT0016407379	NCT00164073_79_T3	PHENOTYPE	13	14	hepatitis B
NCT0016407379	NCT00164073_79_T4	BIOLOGICAL_PROCESS	9	10	gene expression
NCT0016407380	NCT00164073_80_T0	GENE	2	2	120
NCT0016407382	NCT00164073_82_T0	PHENOTYPE	8	8	Insights
NCT0016407382	NCT00164073_82_T1	GENE	1	1	NA
NCT0016407382	NCT00164073_82_T2	GENE	3	3	PH
NCT0016407382	NCT00164073_82_T3	GENE	7	7	al
NCT0016407382	NCT00164073_82_T4	PHENOTYPE	16	16	cirrhosis
NCT0016407382	NCT00164073_82_T5	GENE	5	5	CA
NCT0016407382	NCT00164073_82_T6	GENE	6	6	et
NCT0016407382	NCT00164073_82_T7	PHENOTYPE	13	14	hepatitis C
NCT0016407383	NCT00164073_83_T0	GENE	4	4	160
NCT0016407385	NCT00164073_85_T0	GENE	1	1	AI
NCT0016407385	NCT00164073_85_T1	GENE	7	7	al
NCT0016407385	NCT00164073_85_T2	GENE	6	6	et
NCT0016407385	NCT00164073_85_T3	PHENOTYPE	15	16	hepatitis C
NCT0016407385	NCT00164073_85_T4	PHENOTYPE	17	18	virus infection
NCT0016407386	NCT00164073_86_T0	GENE	0	0	Proc
NCT0016407386	NCT00164073_86_T1	GENE	3	3	Sci
NCT0016407388	NCT00164073_88_T0	GENE	7	7	al
NCT0016407388	NCT00164073_88_T1	GENE	13	13	interferon
NCT0016407388	NCT00164073_88_T2	GENE	6	6	et
NCT0016407388	NCT00164073_88_T3	GENE	17	17	interleukin-8
NCT0016407388	NCT00164073_88_T4	PHENOTYPE	21	22	hepatitis C
NCT0016407389	NCT00164073_89_T0	GENE	2	2	295
NCT0016407391	NCT00164073_91_T0	GENE	15	15	interferon
NCT0016407391	NCT00164073_91_T1	GENE	6	6	et
NCT0016407391	NCT00164073_91_T2	PHENOTYPE	19	20	hepatitis C
NCT0016407391	NCT00164073_91_T3	PHENOTYPE	18	19	chronic hepatitis
NCT0016407391	NCT00164073_91_T4	BIOLOGICAL_PROCESS	10	11	gene expression
NCT0016407394	NCT00164073_94_T0	GENE	3	3	SR
NCT0016407394	NCT00164073_94_T1	GENE	15	15	gel
NCT0016407395	NCT00164073_95_T0	COMPOUND	2	2	1
NCT001640990	NCT00164099_0_T0	PHENOTYPE	7	7	Infections
NCT001640994	NCT00164099_4_T0	PHENOTYPE	9	9	infections
NCT001640995	NCT00164099_5_T0	ORGAN	24	24	intestine
NCT001640995	NCT00164099_5_T1	ORGAN	44	44	intestine
NCT001640995	NCT00164099_5_T2	PHENOTYPE	14	15	inflammatory responses
NCT001640996	NCT00164099_6_T0	PHENOTYPE	23	23	infections
NCT001640996	NCT00164099_6_T1	BIOLOGICAL_PROCESS	11	12	immune response
NCT001640997	NCT00164099_7_T0	GENE	16	16	abdominal
NCT001640999	NCT00164099_9_T0	GENE	5	5	has
NCT0016409912	NCT00164099_12_T0	PHENOTYPE	2	2	diarrhea
NCT0016409916	NCT00164099_16_T0	PHENOTYPE	14	15	site infection
NCT0016409916	NCT00164099_16_T1	PHENOTYPE	7	8	wound infection
NCT0016409917	NCT00164099_17_T0	ORGAN	34	34	intestine
NCT0016409917	NCT00164099_17_T1	PHENOTYPE	31	31	strains
NCT0016409919	NCT00164099_19_T0	PHENOTYPE	9	9	strains
NCT0016409919	NCT00164099_19_T1	GENE	6	6	LAB
NCT0016409920	NCT00164099_20_T0	GENE	9	9	LAB
NCT0016409921	NCT00164099_21_T0	CELL	29	29	cells
NCT0016409921	NCT00164099_21_T1	PHENOTYPE	8	8	focused
NCT0016409921	NCT00164099_21_T2	PHENOTYPE	34	34	resistant
NCT0016409921	NCT00164099_21_T3	GENE	6	6	has
NCT0016409921	NCT00164099_21_T4	GENE	14	14	LAB
NCT0016409922	NCT00164099_22_T0	PHENOTYPE	30	30	resistant
NCT0016409922	NCT00164099_22_T1	GENE	14	14	has
NCT0016409922	NCT00164099_22_T2	TISSUE	25	25	mucosa
NCT0016409924	NCT00164099_24_T0	GENE	6	6	LAB
NCT0016409924	NCT00164099_24_T1	TISSUE	16	17	intestinal mucosa
NCT0016409925	NCT00164099_25_T0	CELL	20	20	cells
NCT0016409925	NCT00164099_25_T1	GENE	0	0	LAB
NCT0016409927	NCT00164099_27_T0	COMPOUND	8	8	mannose
NCT0016409928	NCT00164099_28_T0	GENE	21	21	MUC2
NCT0016409928	NCT00164099_28_T1	GENE	15	15	mRNA
NCT0016409928	NCT00164099_28_T2	PHENOTYPE	8	8	adhesion
NCT0016409928	NCT00164099_28_T3	GENE	2	2	has
NCT0016409928	NCT00164099_28_T4	GENE	23	23	MUC3
NCT0016409932	NCT00164099_32_T0	GENE	4	4	LAB
NCT0016409934	NCT00164099_34_T0	PHENOTYPE	18	18	infections
NCT0016409936	NCT00164099_36_T0	PHENOTYPE	5	5	diarrhea
NCT0016409938	NCT00164099_38_T0	GENE	1	2	C-reactive protein
NCT001641121	NCT00164112_1_T0	GENE	10	10	5-1
NCT001641121	NCT00164112_1_T1	GENE	17	17	5-1
NCT001641121	NCT00164112_1_T2	GENE	4	4	has
NCT001641123	NCT00164112_3_T0	COMPOUND	23	23	levofloxacin
NCT001641123	NCT00164112_3_T1	COMPOUND	21	21	telithromycin
NCT001641123	NCT00164112_3_T2	COMPOUND	20	20	azithromycin
NCT001641123	NCT00164112_3_T3	BIOLOGICAL_PROCESS	25	25	metabolism
NCT001641124	NCT00164112_4_T0	COMPOUND	21	21	omeprazole
NCT001641124	NCT00164112_4_T1	COMPOUND	19	19	caffeine
NCT001641124	NCT00164112_4_T2	COMPOUND	22	22	midazolam
NCT001641124	NCT00164112_4_T3	COMPOUND	20	20	dextromethorphan
NCT001641124	NCT00164112_4_T4	COMPOUND	24	24	warfarin
NCT001641124	NCT00164112_4_T5	COMPOUND	26	27	vitamin K
NCT001641125	NCT00164112_5_T0	GENE	14	14	5-1
NCT001641125	NCT00164112_5_T1	GENE	20	20	5-1
NCT001641125	NCT00164112_5_T2	GENE	25	25	5-1
NCT001641125	NCT00164112_5_T3	GENE	31	31	5-1
NCT001641129	NCT00164112_9_T0	COMPOUND	8	8	levofloxacin
NCT001641129	NCT00164112_9_T1	GENE	20	20	5-1
NCT001641129	NCT00164112_9_T2	COMPOUND	6	6	telithromycin
NCT001641129	NCT00164112_9_T3	COMPOUND	5	5	azithromycin
NCT0016411213	NCT00164112_13_T0	GENE	10	10	5-1
NCT0016411213	NCT00164112_13_T1	GENE	17	17	5-1
NCT0016411213	NCT00164112_13_T2	GENE	4	4	has
NCT0016411221	NCT00164112_21_T0	GENE	8	8	CYP2C9
NCT0016411221	NCT00164112_21_T1	GENE	7	7	CYP2D6
NCT0016411221	NCT00164112_21_T2	GENE	10	10	CYP2C19
NCT0016411224	NCT00164112_24_T0	GENE	32	32	met
NCT0016411226	NCT00164112_26_T0	ORGAN	18	18	serum
NCT0016411233	NCT00164112_33_T0	GENE	10	10	5-1
NCT0016411234	NCT00164112_34_T0	GENE	2	2	5-1
NCT0016411235	NCT00164112_35_T0	PHENOTYPE	6	6	nearest
NCT0016411238	NCT00164112_38_T0	ORGAN	0	0	Plasma
NCT0016411239	NCT00164112_39_T0	GENE	1	1	INR
NCT0016411240	NCT00164112_40_T0	GENE	4	4	1.7
NCT0016411240	NCT00164112_40_T1	GENE	2	2	INR
NCT0016411240	NCT00164112_40_T2	GENE	18	18	INR
NCT0016411240	NCT00164112_40_T3	COMPOUND	8	9	vitamin K
NCT0016411242	NCT00164112_42_T0	ORGAN	8	8	plasma
NCT0016411246	NCT00164112_46_T0	GENE	19	19	CYP3A
NCT0016411246	NCT00164112_46_T1	ORGAN	8	8	plasma
NCT0016411247	NCT00164112_47_T0	COMPOUND	6	6	midazolam
NCT0016411247	NCT00164112_47_T1	GENE	14	14	0.5
NCT0016411250	NCT00164112_50_T0	GENE	5	5	5-1
NCT0016411250	NCT00164112_50_T1	GENE	20	20	5-1
NCT0016411250	NCT00164112_50_T2	COMPOUND	15	15	azithromycin
NCT0016411252	NCT00164112_52_T0	GENE	5	5	5-1
NCT0016411252	NCT00164112_52_T1	GENE	20	20	5-1
NCT0016411252	NCT00164112_52_T2	COMPOUND	15	15	telithromycin
NCT0016411254	NCT00164112_54_T0	COMPOUND	15	15	levofloxacin
NCT0016411254	NCT00164112_54_T1	GENE	5	5	5-1
NCT0016411254	NCT00164112_54_T2	GENE	20	20	5-1
NCT0016411255	NCT00164112_55_T0	GENE	18	18	1.5
NCT0016411255	NCT00164112_55_T1	COMPOUND	3	3	telithromycin
NCT0016411255	NCT00164112_55_T2	COMPOUND	2	2	azithromycin
NCT0016411255	NCT00164112_55_T3	GENE	38	38	CYP3A
NCT0016411255	NCT00164112_55_T4	COMPOUND	10	10	midazolam
NCT0016411255	NCT00164112_55_T5	COMPOUND	5	5	levofloxacin
NCT0016411255	NCT00164112_55_T6	ORGAN	7	7	plasma
NCT0016411256	NCT00164112_56_T0	GENE	1	1	5-1
NCT0016411257	NCT00164112_57_T0	GENE	15	15	5-1
NCT0016411258	NCT00164112_58_T0	COMPOUND	10	10	azithromycin
NCT0016411259	NCT00164112_59_T0	GENE	13	13	half-life
NCT0016411259	NCT00164112_59_T1	COMPOUND	4	4	azithromycin
NCT0016411259	NCT00164112_59_T2	COMPOUND	9	9	azithromycin
NCT0016411259	NCT00164112_59_T3	GENE	10	10	has
NCT0016411260	NCT00164112_60_T0	COMPOUND	6	6	caffeine
NCT0016411260	NCT00164112_60_T1	GENE	24	24	CYP1A2
NCT0016411260	NCT00164112_60_T2	GENE	27	27	NAT-2
NCT0016411261	NCT00164112_61_T0	COMPOUND	15	15	warfarin
NCT0016411261	NCT00164112_61_T1	COMPOUND	35	35	warfarin
NCT0016411261	NCT00164112_61_T2	COMPOUND	44	44	S-warfarin
NCT0016411261	NCT00164112_61_T3	GENE	42	42	CYP2C9
NCT0016411261	NCT00164112_61_T4	COMPOUND	11	11	AFMU
NCT0016411261	NCT00164112_61_T5	COMPOUND	5	6	ascorbic acid
NCT0016411261	NCT00164112_61_T6	COMPOUND	37	38	vitamin K
NCT0016411262	NCT00164112_62_T0	GENE	12	12	IV
NCT0016411264	NCT00164112_64_T0	COMPOUND	20	20	AFMU
NCT0016411266	NCT00164112_66_T0	BIOLOGICAL_PROCESS	1	1	demethylation
NCT0016411266	NCT00164112_66_T1	COMPOUND	16	16	R-warfarin
NCT0016411266	NCT00164112_66_T2	COMPOUND	21	21	R-warfarin
NCT0016411266	NCT00164112_66_T3	GENE	8	8	CYP1A2
NCT0016411266	NCT00164112_66_T4	ORGAN	23	23	plasma
NCT0016411266	NCT00164112_66_T5	GENE	9	9	NAT-2
NCT0016411268	NCT00164112_68_T0	GENE	30	30	OMP
NCT0016411268	NCT00164112_68_T1	GENE	33	33	OMP
NCT0016411268	NCT00164112_68_T2	PHENOTYPE	28	28	concentrations
NCT0016411268	NCT00164112_68_T3	GENE	1	1	3-1
NCT0016411268	NCT00164112_68_T4	ORGAN	27	27	plasma
NCT0016411269	NCT00164112_69_T0	COMPOUND	15	15	omeprazole
NCT0016411269	NCT00164112_69_T1	GENE	3	3	OMP
NCT0016411269	NCT00164112_69_T2	GENE	6	6	OMP
NCT0016411269	NCT00164112_69_T3	PHENOTYPE	41	41	concentrations
NCT0016411269	NCT00164112_69_T4	GENE	21	21	CYP2C19
NCT0016411270	NCT00164112_70_T0	GENE	9	9	CYP2D6
NCT0016411270	NCT00164112_70_T1	COMPOUND	25	25	midazolam
NCT0016411270	NCT00164112_70_T2	COMPOUND	28	28	4_hydroxymidazolam
NCT0016411270	NCT00164112_70_T3	ORGAN	22	22	plasma
NCT0016411270	NCT00164112_70_T4	COMPOUND	1	1	dextromethorphan
NCT0016411272	NCT00164112_72_T0	GENE	7	7	CYP3A
NCT0016411272	NCT00164112_72_T1	COMPOUND	19	19	midazolam
NCT0016411272	NCT00164112_72_T2	ORGAN	20	20	plasma
NCT0016411273	NCT00164112_73_T0	GENE	1	1	3-1
NCT001641381	NCT00164138_1_T0	PHENOTYPE	14	15	cystic fibrosis
NCT001641381	NCT00164138_1_T1	PHENOTYPE	7	8	urinary incontinence
NCT001641382	NCT00164138_2_T0	PHENOTYPE	1	1	coughing
NCT001641382	NCT00164138_2_T1	PHENOTYPE	17	17	understood
NCT001641382	NCT00164138_2_T2	PHENOTYPE	8	9	stress incontinence
NCT001641383	NCT00164138_3_T0	PHENOTYPE	2	2	incontinence
NCT001641383	NCT00164138_3_T1	PHENOTYPE	6	8	chronic lung disease
NCT001641383	NCT00164138_3_T2	PHENOTYPE	22	24	chronic lung disease
NCT001641386	NCT00164138_6_T0	PHENOTYPE	5	6	chronic cough
NCT001641386	NCT00164138_6_T1	PHENOTYPE	13	14	urinary incontinence
NCT001641386	NCT00164138_6_T2	PHENOTYPE	33	35	quality of life
NCT0016413811	NCT00164138_11_T0	PHENOTYPE	26	26	prolapse
NCT0016413811	NCT00164138_11_T1	PHENOTYPE	4	4	incontinence
NCT0016413811	NCT00164138_11_T2	PHENOTYPE	11	11	incontinence
NCT0016413811	NCT00164138_11_T3	PHENOTYPE	19	19	dysfunction
NCT0016413811	NCT00164138_11_T4	PHENOTYPE	28	28	enuresis
NCT0016413811	NCT00164138_11_T5	PHENOTYPE	12	13	faecal incontinence
NCT0016413811	NCT00164138_11_T6	PHENOTYPE	16	17	nocturnal enuresis
NCT0016413811	NCT00164138_11_T7	PHENOTYPE	8	9	stress incontinence
NCT0016413814	NCT00164138_14_T0	ORGAN	4	5	pelvic floor
NCT0016413817	NCT00164138_17_T0	PHENOTYPE	0	0	Severity
NCT0016413818	NCT00164138_18_T0	GENE	1	1	SF
NCT0016413819	NCT00164138_19_T0	TISSUE	8	8	muscles
NCT0016413819	NCT00164138_19_T1	ORGAN	6	7	pelvic floor
NCT0016413820	NCT00164138_20_T0	ORGAN	3	4	pelvic floor
NCT0016413822	NCT00164138_22_T0	ORGAN	13	14	pelvic floor
NCT0016413823	NCT00164138_23_T0	PHENOTYPE	25	25	coughs
NCT0016413824	NCT00164138_24_T0	PHENOTYPE	18	18	contraction
NCT0016413824	NCT00164138_24_T1	PHENOTYPE	27	27	contraction
NCT0016413824	NCT00164138_24_T2	PHENOTYPE	45	46	chronic cough
NCT0016413824	NCT00164138_24_T3	ORGAN	1	2	pelvic floor
NCT0016413824	NCT00164138_24_T4	ORGAN	38	39	pelvic floor
NCT0016413825	NCT00164138_25_T0	PHENOTYPE	12	12	coughing
NCT0016413825	NCT00164138_25_T1	PHENOTYPE	24	24	coughs
NCT0016413825	NCT00164138_25_T2	ORGAN	4	5	pelvic floor
NCT0016413826	NCT00164138_26_T0	PHENOTYPE	11	11	incontinence
NCT0016413827	NCT00164138_27_T0	PHENOTYPE	21	21	practices
NCT0016413830	NCT00164138_30_T0	ORGAN	7	7	bladder
NCT0016413830	NCT00164138_30_T1	ORGAN	0	1	Pelvic floor
NCT001641510	NCT00164151_0_T0	COMPOUND	10	10	Visicol
NCT001641640	NCT00164164_0_T0	GENE	2	2	Prep
NCT001641901	NCT00164190_1_T0	PHENOTYPE	7	7	centres
NCT001641902	NCT00164190_2_T0	PHENOTYPE	20	20	reocclusion
NCT001641902	NCT00164190_2_T1	PHENOTYPE	23	23	recurrent
NCT001641902	NCT00164190_2_T2	PHENOTYPE	24	24	ischemia
NCT001641905	NCT00164190_5_T0	BIOLOGICAL_PROCESS	19	19	transport
NCT001641908	NCT00164190_8_T0	GENE	29	29	PCI
NCT001641908	NCT00164190_8_T1	PHENOTYPE	18	18	centre
NCT001641908	NCT00164190_8_T2	PHENOTYPE	14	14	AMI
NCT0016419010	NCT00164190_10_T0	PHENOTYPE	40	40	strategies
NCT0016419010	NCT00164190_10_T1	PHENOTYPE	1	1	Plan
NCT0016419010	NCT00164190_10_T2	COMPOUND	24	24	heparin
NCT0016419010	NCT00164190_10_T3	COMPOUND	30	30	heparin
NCT0016419010	NCT00164190_10_T4	GENE	42	42	PCI
NCT0016419010	NCT00164190_10_T5	GENE	50	50	PCI
NCT0016419010	NCT00164190_10_T6	PHENOTYPE	5	6	myocardial infarction
NCT0016419011	NCT00164190_11_T0	GENE	3	3	PCI
NCT0016419011	NCT00164190_11_T1	GENE	19	19	PCI
NCT0016419011	NCT00164190_11_T2	PHENOTYPE	13	13	centre
NCT0016419013	NCT00164190_13_T0	PHENOTYPE	10	10	recurrent
NCT0016419013	NCT00164190_13_T1	PHENOTYPE	11	11	ischemia
NCT0016419013	NCT00164190_13_T2	PHENOTYPE	12	13	heart failure
NCT0016419015	NCT00164190_15_T0	GENE	3	3	PCI
NCT0016419015	NCT00164190_15_T1	GENE	19	19	PCI
NCT0016419015	NCT00164190_15_T2	PHENOTYPE	13	13	centre
NCT0016419019	NCT00164190_19_T0	PHENOTYPE	0	3	Left bundle branch block
NCT0016419021	NCT00164190_21_T0	PHENOTYPE	1	1	bleeding
NCT0016419021	NCT00164190_21_T1	PHENOTYPE	4	5	hemorrhagic diathesis
NCT0016419022	NCT00164190_22_T0	GENE	3	3	PCI
NCT0016419025	NCT00164190_25_T0	PHENOTYPE	8	8	trauma
NCT0016419029	NCT00164190_29_T0	PHENOTYPE	8	8	aneurysm
NCT0016419029	NCT00164190_29_T1	GENE	5	5	structural
NCT0016419029	NCT00164190_29_T2	PHENOTYPE	9	9	neoplasm
NCT0016419029	NCT00164190_29_T3	PHENOTYPE	10	11	arteriovenous malformation
NCT0016419029	NCT00164190_29_T4	PHENOTYPE	17	19	transient ischemic attack
NCT0016419029	NCT00164190_29_T5	ORGAN	2	4	central nervous system
NCT0016419030	NCT00164190_30_T0	COMPOUND	2	2	heparin
NCT0016419031	NCT00164190_31_T0	PHENOTYPE	1	1	allergy
NCT0016419037	NCT00164190_37_T0	GENE	1	1	bypass
NCT001642031	NCT00164203_1_T0	PHENOTYPE	10	10	impairment
NCT001642035	NCT00164203_5_T0	PHENOTYPE	10	10	symptoms
NCT001642035	NCT00164203_5_T1	GENE	1	1	1b
NCT001642037	NCT00164203_7_T0	PHENOTYPE	2	2	Self-esteem
NCT001642037	NCT00164203_7_T1	COMPOUND	1	1	3
NCT001642037	NCT00164203_7_T2	PHENOTYPE	6	6	impairment
NCT001642038	NCT00164203_8_T0	PHENOTYPE	7	7	attitudes
NCT001642161	NCT00164216_1_T0	PHENOTYPE	14	14	malaria
NCT001642165	NCT00164216_5_T0	PHENOTYPE	21	22	falciparum malaria
NCT001642290	NCT00164229_0_T0	PHENOTYPE	0	2	Fetal Alcohol Syndrome
NCT001642296	NCT00164229_6_T0	PHENOTYPE	32	32	reinforcement
NCT001642296	NCT00164229_6_T1	PHENOTYPE	10	10	arousal
NCT001642296	NCT00164229_6_T2	PHENOTYPE	20	20	arousal
NCT001642297	NCT00164229_7_T0	PHENOTYPE	15	15	arousal
NCT0016422911	NCT00164229_11_T0	PHENOTYPE	6	6	aids
NCT0016422916	NCT00164229_16_T0	PHENOTYPE	1	1	Plan
NCT001642420	NCT00164242_0_T0	PHENOTYPE	2	3	Tardive Dyskinesia
NCT001642422	NCT00164242_2_T0	GENE	4	4	TD
NCT001642422	NCT00164242_2_T1	PHENOTYPE	9	9	dysfunction
NCT001642422	NCT00164242_2_T2	CELL	12	13	cholinergic neurons
NCT001642423	NCT00164242_3_T0	GENE	11	11	TD
NCT001642423	NCT00164242_3_T1	GENE	27	27	TD
NCT001642423	NCT00164242_3_T2	GENE	3	3	cholinesterase
NCT001642423	NCT00164242_3_T3	COMPOUND	22	22	galantamine
NCT001642425	NCT00164242_5_T0	GENE	9	9	TD
NCT001642426	NCT00164242_6_T0	GENE	3	3	TD
NCT001642428	NCT00164242_8_T0	BIOLOGICAL_PROCESS	14	14	neurotransmission
NCT001642429	NCT00164242_9_T0	GENE	11	11	TD
NCT001642429	NCT00164242_9_T1	GENE	33	33	TD
NCT001642429	NCT00164242_9_T2	BIOLOGICAL_PROCESS	17	17	neurotransmission
NCT001642429	NCT00164242_9_T3	CELL	28	29	cholinergic neurons
NCT0016424211	NCT00164242_11_T0	GENE	25	25	TD
NCT0016424211	NCT00164242_11_T1	COMPOUND	19	19	galantamine
NCT0016424212	NCT00164242_12_T0	GENE	11	11	TD
NCT0016424212	NCT00164242_12_T1	COMPOUND	25	25	galantamine
NCT0016424212	NCT00164242_12_T2	PHENOTYPE	4	6	abnormal involuntary movements
NCT0016424213	NCT00164242_13_T0	COMPOUND	12	12	galantamine
NCT001642551	NCT00164255_1_T0	GENE	13	13	SP
NCT001642551	NCT00164255_1_T1	GENE	30	30	SP
NCT001642551	NCT00164255_1_T2	GENE	36	36	SP
NCT001642816	NCT00164281_6_T0	PHENOTYPE	0	0	HIV
NCT001642942	NCT00164294_2_T0	PHENOTYPE	25	26	serious injury
NCT001642944	NCT00164294_4_T0	PHENOTYPE	26	26	practices
NCT001642944	NCT00164294_4_T1	PHENOTYPE	33	34	problem drinking
NCT001642946	NCT00164294_6_T0	PHENOTYPE	16	16	practices
NCT001642946	NCT00164294_6_T1	PHENOTYPE	11	12	problem drinking
NCT001642947	NCT00164294_7_T0	PHENOTYPE	5	6	problem drinking
NCT0016429410	NCT00164294_10_T0	GENE	18	18	7-10
NCT0016429410	NCT00164294_10_T1	GENE	15	15	booster
NCT001643075	NCT00164307_5_T0	PHENOTYPE	16	16	rehearsal
NCT0016430711	NCT00164307_11_T0	PHENOTYPE	1	1	Plan
NCT001643467	NCT00164346_7_T0	PHENOTYPE	9	9	strategies
NCT0016434614	NCT00164346_14_T0	COMPOUND	4	4	1
NCT0016434614	NCT00164346_14_T1	COMPOUND	8	8	2
NCT0016434614	NCT00164346_14_T2	COMPOUND	13	13	3
NCT0016434615	NCT00164346_15_T0	PHENOTYPE	20	20	learned
NCT0016434616	NCT00164346_16_T0	GENE	7	7	booster
NCT0016434617	NCT00164346_17_T0	PHENOTYPE	1	1	Plan
NCT001643592	NCT00164359_2_T0	GENE	11	11	has
NCT001643592	NCT00164359_2_T1	PHENOTYPE	30	30	malaria
NCT001643592	NCT00164359_2_T2	PHENOTYPE	5	6	falciparum malaria
NCT001643593	NCT00164359_3_T0	PHENOTYPE	34	34	malaria
NCT001643593	NCT00164359_3_T1	PHENOTYPE	16	17	side effect
NCT001643594	NCT00164359_4_T0	COMPOUND	10	10	amodiaquine
NCT001643598	NCT00164359_8_T0	PHENOTYPE	25	25	Malaria
NCT001643722	NCT00164372_2_T0	COMPOUND	8	8	1
NCT001643722	NCT00164372_2_T1	COMPOUND	19	19	2
NCT001643722	NCT00164372_2_T2	COMPOUND	31	31	3
NCT001643722	NCT00164372_2_T3	PHENOTYPE	26	26	HIV
NCT001643722	NCT00164372_2_T4	COMPOUND	28	28	HCV
NCT001643722	NCT00164372_2_T5	COMPOUND	39	39	HCV
NCT001643722	NCT00164372_2_T6	PHENOTYPE	36	37	hepatitis C
NCT001643728	NCT00164372_8_T0	PHENOTYPE	10	10	HIV
NCT001643728	NCT00164372_8_T1	COMPOUND	12	12	HCV
NCT001643728	NCT00164372_8_T2	PHENOTYPE	13	13	seronegative
NCT001643854	NCT00164385_4_T0	PHENOTYPE	41	41	secondary
NCT001643854	NCT00164385_4_T1	PHENOTYPE	34	34	HIV
NCT001643854	NCT00164385_4_T2	PHENOTYPE	57	58	drug use
NCT001643859	NCT00164385_9_T0	PHENOTYPE	41	41	secondary
NCT001643859	NCT00164385_9_T1	PHENOTYPE	34	34	HIV
NCT001643859	NCT00164385_9_T2	PHENOTYPE	57	58	drug use
NCT0016438511	NCT00164385_11_T0	PHENOTYPE	1	2	HIV infection
NCT0016438512	NCT00164385_12_T0	PHENOTYPE	8	8	HIV
NCT0016438514	NCT00164385_14_T0	PHENOTYPE	2	2	HIV
NCT0016438514	NCT00164385_14_T1	PHENOTYPE	10	10	HIV
NCT0016438518	NCT00164385_18_T0	PHENOTYPE	2	4	borderline intellectual functioning
NCT001643981	NCT00164398_1_T0	GENE	10	10	HIP
NCT001643981	NCT00164398_1_T1	PHENOTYPE	19	19	practices
NCT001643983	NCT00164398_3_T0	PHENOTYPE	0	0	HIV
NCT001643983	NCT00164398_3_T1	PHENOTYPE	16	16	HIV
NCT001644112	NCT00164411_2_T0	PHENOTYPE	8	8	diphtheria
NCT001644242	NCT00164424_2_T0	PHENOTYPE	9	9	HIV
NCT001644242	NCT00164424_2_T1	GENE	1	1	has
NCT001644243	NCT00164424_3_T0	PHENOTYPE	26	26	HIV
NCT001644243	NCT00164424_3_T1	GENE	10	10	GUD
NCT001644243	NCT00164424_3_T2	GENE	14	14	has
NCT001644243	NCT00164424_3_T3	PHENOTYPE	7	8	genital ulcer
NCT001644243	NCT00164424_3_T4	PHENOTYPE	12	13	genital herpes
NCT001644244	NCT00164424_4_T0	GENE	12	12	GUD
NCT001644244	NCT00164424_4_T1	GENE	29	29	GUD
NCT001644244	NCT00164424_4_T2	COMPOUND	22	22	acyclovir
NCT001644246	NCT00164424_6_T0	COMPOUND	11	11	acyclovir
NCT001644247	NCT00164424_7_T0	COMPOUND	7	7	acyclovir
NCT001644248	NCT00164424_8_T0	COMPOUND	3	3	acyclovir
NCT001644249	NCT00164424_9_T0	PHENOTYPE	24	24	initiation
NCT0016442410	NCT00164424_10_T0	PHENOTYPE	20	20	HIV
NCT0016442410	NCT00164424_10_T1	PHENOTYPE	17	17	herpes
NCT0016442410	NCT00164424_10_T2	PHENOTYPE	23	24	genital ulcers
NCT0016442411	NCT00164424_11_T0	PHENOTYPE	11	11	herpes
NCT0016442411	NCT00164424_11_T1	COMPOUND	8	8	acyclovir
NCT0016442411	NCT00164424_11_T2	PHENOTYPE	20	21	genital ulcer
NCT0016442413	NCT00164424_13_T0	PHENOTYPE	37	37	HIV
NCT0016442413	NCT00164424_13_T1	GENE	8	8	GUD
NCT0016442413	NCT00164424_13_T2	PHENOTYPE	31	32	genital ulcer
NCT0016442414	NCT00164424_14_T0	PHENOTYPE	4	4	HIV
NCT0016442414	NCT00164424_14_T1	COMPOUND	1	1	acyclovir
NCT0016442418	NCT00164424_18_T0	COMPOUND	8	8	acyclovir
NCT0016442419	NCT00164424_19_T0	PHENOTYPE	17	17	chancroid
NCT0016442419	NCT00164424_19_T1	PHENOTYPE	15	15	syphilis
NCT0016442419	NCT00164424_19_T2	PHENOTYPE	3	4	genital ulcer
NCT0016442420	NCT00164424_20_T0	PHENOTYPE	30	30	HIV
NCT0016442420	NCT00164424_20_T1	PHENOTYPE	13	13	ulcer
NCT0016442420	NCT00164424_20_T2	PHENOTYPE	21	21	ulcer
NCT0016442420	NCT00164424_20_T3	PHENOTYPE	12	12	ulcers
NCT0016442421	NCT00164424_21_T0	COMPOUND	24	24	acyclovir
NCT0016442421	NCT00164424_21_T1	PHENOTYPE	27	28	ulcer healing
NCT0016442422	NCT00164424_22_T0	PHENOTYPE	10	10	HIV
NCT0016442422	NCT00164424_22_T1	PHENOTYPE	19	19	HIV
NCT0016442422	NCT00164424_22_T2	COMPOUND	7	7	acyclovir
NCT0016442422	NCT00164424_22_T3	PHENOTYPE	16	17	genital ulcers
NCT001644378	NCT00164437_8_T0	PHENOTYPE	30	30	feelings
NCT001644378	NCT00164437_8_T1	PHENOTYPE	48	48	feelings
NCT001644500	NCT00164450_0_T0	PHENOTYPE	13	13	Infection
NCT001644500	NCT00164450_0_T1	COMPOUND	0	0	TBTC
NCT001644500	NCT00164450_0_T2	GENE	3	3	PK
NCT001644500	NCT00164450_0_T3	PHENOTYPE	5	5	Pharmacokinetics
NCT001644502	NCT00164450_2_T0	COMPOUND	18	18	isoniazid
NCT001644502	NCT00164450_2_T1	GENE	36	36	2.11
NCT001644502	NCT00164450_2_T2	COMPOUND	0	0	TBTC
NCT001644502	NCT00164450_2_T3	GENE	29	29	has
NCT001644502	NCT00164450_2_T4	PHENOTYPE	26	28	latent tuberculosis infection
NCT001644503	NCT00164450_3_T0	COMPOUND	35	35	isoniazid
NCT001644503	NCT00164450_3_T1	COMPOUND	33	33	rifapentine
NCT001644506	NCT00164450_6_T0	COMPOUND	13	13	rifapentine
NCT001644506	NCT00164450_6_T1	PHENOTYPE	11	11	pharmacokinetics
NCT001644507	NCT00164450_7_T0	COMPOUND	35	35	isoniazid
NCT001644507	NCT00164450_7_T1	COMPOUND	17	17	TBTC
NCT001644507	NCT00164450_7_T2	GENE	4	4	has
NCT001644507	NCT00164450_7_T3	PHENOTYPE	43	45	latent tuberculosis infection
NCT001644507	NCT00164450_7_T4	PHENOTYPE	57	59	latent tuberculosis infection
NCT001644508	NCT00164450_8_T0	PHENOTYPE	19	19	exposures
NCT001644508	NCT00164450_8_T1	COMPOUND	6	6	rifapentine
NCT001644508	NCT00164450_8_T2	COMPOUND	15	15	rifapentine
NCT001644508	NCT00164450_8_T3	COMPOUND	21	21	rifapentine
NCT001644508	NCT00164450_8_T4	PHENOTYPE	7	7	pharmacokinetics
NCT001644509	NCT00164450_9_T0	PHENOTYPE	27	27	exposures
NCT001644509	NCT00164450_9_T1	COMPOUND	19	19	rifapentine
NCT001644509	NCT00164450_9_T2	GENE	1	1	reduced
NCT0016445010	NCT00164450_10_T0	GENE	9	9	2.11
NCT0016445010	NCT00164450_10_T1	GENE	2	2	has
NCT0016445015	NCT00164450_15_T0	COMPOUND	11	11	isoniazid
NCT0016445015	NCT00164450_15_T1	COMPOUND	24	24	isoniazid
NCT0016445015	NCT00164450_15_T2	BIOLOGICAL_PROCESS	5	5	phlebotomy
NCT0016445015	NCT00164450_15_T3	COMPOUND	13	13	rifapentine
NCT0016445015	NCT00164450_15_T4	COMPOUND	22	22	rifapentine
NCT0016445018	NCT00164450_18_T0	COMPOUND	20	20	TBTC
NCT001644630	NCT00164463_0_T0	COMPOUND	0	0	TBTC
NCT001644630	NCT00164463_0_T1	GENE	3	3	PK
NCT001644630	NCT00164463_0_T2	PHENOTYPE	5	5	Pharmacokinetics
NCT001644632	NCT00164463_2_T0	PHENOTYPE	41	41	associations
NCT001644632	NCT00164463_2_T1	PHENOTYPE	53	53	severity
NCT001644632	NCT00164463_2_T2	COMPOUND	26	26	isoniazid
NCT001644632	NCT00164463_2_T3	PHENOTYPE	51	51	tuberculosis
NCT001644632	NCT00164463_2_T4	GENE	8	8	MDR1
NCT001644632	NCT00164463_2_T5	GENE	20	20	MDR1
NCT001644632	NCT00164463_2_T6	GENE	33	33	NAT2
NCT001644632	NCT00164463_2_T7	GENE	31	31	N-acetyltransferase
NCT001644632	NCT00164463_2_T8	PHENOTYPE	38	38	regression
NCT001644632	NCT00164463_2_T9	PHENOTYPE	24	24	pharmacokinetics
NCT001644632	NCT00164463_2_T10	GENE	10	10	P-glycoprotein
NCT001644632	NCT00164463_2_T11	GENE	74	74	PK
NCT001644632	NCT00164463_2_T12	COMPOUND	43	43	moxifloxacin
NCT001644632	NCT00164463_2_T13	PHENOTYPE	62	63	lung disease
NCT001644632	NCT00164463_2_T14	GENE	77	78	C-reactive protein
NCT001644633	NCT00164463_3_T0	PHENOTYPE	16	16	ingesting
NCT001644892	NCT00164489_2_T0	PHENOTYPE	10	10	obesity
NCT001645023	NCT00164502_3_T0	PHENOTYPE	12	13	problem solving
NCT001645150	NCT00164515_0_T0	PHENOTYPE	4	4	Overweight
NCT001645153	NCT00164515_3_T0	PHENOTYPE	2	3	mobility limitations
NCT001645154	NCT00164515_4_T0	PHENOTYPE	11	11	overweight
NCT001645154	NCT00164515_4_T1	PHENOTYPE	14	15	mobility limitations
NCT001645281	NCT00164528_1_T0	PHENOTYPE	23	23	perceived
NCT001645281	NCT00164528_1_T1	PHENOTYPE	24	24	self-confidence
NCT001645281	NCT00164528_1_T2	PHENOTYPE	19	20	executive functioning
NCT0016452810	NCT00164528_10_T0	PHENOTYPE	1	1	Plan
NCT001645413	NCT00164541_3_T0	GENE	17	17	pre
NCT0016455410	NCT00164554_10_T0	GENE	2	2	has
NCT0016455415	NCT00164554_15_T0	PHENOTYPE	1	1	Plan
NCT001645678	NCT00164567_8_T0	PHENOTYPE	19	19	perceived
NCT001645678	NCT00164567_8_T1	PHENOTYPE	50	50	victimization
NCT001645807	NCT00164580_7_T0	PHENOTYPE	44	44	HIV
NCT001645807	NCT00164580_7_T1	PHENOTYPE	60	60	HIV
NCT001645807	NCT00164580_7_T2	PHENOTYPE	72	72	HIV
NCT0016458010	NCT00164580_10_T0	GENE	26	26	San
NCT0016458011	NCT00164580_11_T0	GENE	15	15	San
NCT001645933	NCT00164593_3_T0	COMPOUND	1	1	1
NCT001645933	NCT00164593_3_T1	PHENOTYPE	14	14	attachment
NCT001645933	NCT00164593_3_T2	PHENOTYPE	20	21	problem behaviors
NCT001645933	NCT00164593_3_T3	PHENOTYPE	35	36	problem solving
NCT001645934	NCT00164593_4_T0	COMPOUND	1	1	2
NCT0016459310	NCT00164593_10_T0	PHENOTYPE	10	10	fears
NCT0016459310	NCT00164593_10_T1	PHENOTYPE	11	11	perceptions
NCT0016459310	NCT00164593_10_T2	PHENOTYPE	22	23	violent behavior
NCT0016459312	NCT00164593_12_T0	GENE	4	4	YES
NCT0016459312	NCT00164593_12_T1	PHENOTYPE	44	44	victimization
NCT0016459312	NCT00164593_12_T2	COMPOUND	7	7	1
NCT0016459312	NCT00164593_12_T3	COMPOUND	16	16	2
NCT0016459312	NCT00164593_12_T4	COMPOUND	26	26	3
NCT0016459312	NCT00164593_12_T5	PHENOTYPE	28	28	perceptions
NCT001646064	NCT00164606_4_T0	PHENOTYPE	27	27	strategies
NCT001646065	NCT00164606_5_T0	PHENOTYPE	20	20	injuries
NCT001646065	NCT00164606_5_T1	PHENOTYPE	32	32	practices
NCT0016461917	NCT00164619_17_T0	PHENOTYPE	4	4	attitudes
NCT001646324	NCT00164632_4_T0	GENE	27	27	San
NCT001646324	NCT00164632_4_T1	GENE	21	21	PHCA
NCT001646324	NCT00164632_4_T2	BIOLOGICAL_PROCESS	20	20	Aging
NCT001646326	NCT00164632_6_T0	PHENOTYPE	10	10	falls
NCT0016464510	NCT00164645_10_T0	PHENOTYPE	15	16	problem solving
NCT001646582	NCT00164658_2_T0	PHENOTYPE	52	52	generalized
NCT001646584	NCT00164658_4_T0	PHENOTYPE	28	28	centers
NCT001646584	NCT00164658_4_T1	PHENOTYPE	16	16	practices
NCT001646585	NCT00164658_5_T0	PHENOTYPE	1	1	practices
NCT001646586	NCT00164658_6_T0	PHENOTYPE	2	2	practices
NCT001646586	NCT00164658_6_T1	GENE	5	6	Group 1
NCT001646587	NCT00164658_7_T0	GENE	3	4	Group 1
NCT0016465810	NCT00164658_10_T0	PHENOTYPE	22	22	perceptions
NCT001646712	NCT00164671_2_T0	GENE	24	24	San
NCT001646712	NCT00164671_2_T1	GENE	27	27	Las
NCT001646713	NCT00164671_3_T0	PHENOTYPE	14	14	attitudes
NCT001646716	NCT00164671_6_T0	PHENOTYPE	29	29	Centers
NCT001646716	NCT00164671_6_T1	PHENOTYPE	23	23	Center
NCT001646716	NCT00164671_6_T2	GENE	27	27	EMS
NCT001646716	NCT00164671_6_T3	GENE	3	3	Dr
NCT0016467110	NCT00164671_10_T0	GENE	22	22	al
NCT0016467110	NCT00164671_10_T1	GENE	21	21	et
NCT0016467114	NCT00164671_14_T0	GENE	14	14	had
NCT0016467115	NCT00164671_15_T0	PHENOTYPE	30	30	Centers
NCT0016467115	NCT00164671_15_T1	GENE	12	12	San
NCT0016467115	NCT00164671_15_T2	PHENOTYPE	23	23	gonorrhea
NCT0016467115	NCT00164671_15_T3	GENE	14	14	Las
NCT0016467115	NCT00164671_15_T4	GENE	28	28	Las
NCT0016467121	NCT00164671_21_T0	PHENOTYPE	1	1	intent
NCT0016467123	NCT00164671_23_T0	GENE	24	24	San
NCT0016467123	NCT00164671_23_T1	GENE	27	27	Las
NCT0016467124	NCT00164671_24_T0	PHENOTYPE	14	14	attitudes
NCT0016467127	NCT00164671_27_T0	PHENOTYPE	29	29	Centers
NCT0016467127	NCT00164671_27_T1	PHENOTYPE	23	23	Center
NCT0016467127	NCT00164671_27_T2	GENE	27	27	EMS
NCT0016467127	NCT00164671_27_T3	GENE	3	3	Dr
NCT0016467129	NCT00164671_29_T0	GENE	17	17	pre
NCT0016467130	NCT00164671_30_T0	GENE	0	0	EMS
NCT0016467132	NCT00164671_32_T0	PHENOTYPE	31	31	concentrations
NCT0016467132	NCT00164671_32_T1	PHENOTYPE	27	27	Gonorrhea
NCT0016467134	NCT00164671_34_T0	PHENOTYPE	17	17	attitudes
NCT0016467137	NCT00164671_37_T0	GENE	25	25	al
NCT0016467137	NCT00164671_37_T1	GENE	24	24	et
NCT0016467152	NCT00164671_52_T0	PHENOTYPE	1	1	recruitment
NCT0016467153	NCT00164671_53_T0	PHENOTYPE	5	5	recruitment
NCT0016467156	NCT00164671_56_T0	PHENOTYPE	23	23	centers
NCT0016467156	NCT00164671_56_T1	GENE	9	9	bars
NCT0016467159	NCT00164671_59_T0	PHENOTYPE	3	3	comprehension
NCT0016467165	NCT00164671_65_T0	GENE	30	30	San
NCT0016467165	NCT00164671_65_T1	GENE	33	33	Las
NCT0016467166	NCT00164671_66_T0	GENE	11	11	EMS
NCT0016467171	NCT00164671_71_T0	PHENOTYPE	16	16	attitudes
NCT0016467176	NCT00164671_76_T0	PHENOTYPE	17	17	recruitment
NCT0016467180	NCT00164671_80_T0	PHENOTYPE	8	8	recruitment
NCT0016467192	NCT00164671_92_T0	PHENOTYPE	17	17	attitudes
NCT0016467196	NCT00164671_96_T0	PHENOTYPE	2	2	strategies
NCT0016467197	NCT00164671_97_T0	PHENOTYPE	15	15	reluctance
NCT0016467197	NCT00164671_97_T1	PHENOTYPE	13	13	embarrassment
NCT0016467197	NCT00164671_97_T2	PHENOTYPE	3	4	adverse events
NCT0016467198	NCT00164671_98_T0	PHENOTYPE	1	1	said
NCT0016467198	NCT00164671_98_T1	PHENOTYPE	6	7	adverse event
NCT0016467199	NCT00164671_99_T0	GENE	0	0	Dr
NCT00164671104	NCT00164671_104_T0	PHENOTYPE	3	3	recruitment
NCT00164671107	NCT00164671_107_T0	PHENOTYPE	13	13	embarrassment
NCT00164671108	NCT00164671_108_T0	PHENOTYPE	15	15	recruitment
NCT00164671108	NCT00164671_108_T1	GENE	7	7	Dr
NCT00164671110	NCT00164671_110_T0	PHENOTYPE	15	15	recruitment
NCT00164671120	NCT00164671_120_T0	PHENOTYPE	15	15	attitudes
NCT00164671122	NCT00164671_122_T0	GENE	4	4	nested
NCT00164671126	NCT00164671_126_T0	PHENOTYPE	11	11	discomfort
NCT00164671126	NCT00164671_126_T1	PHENOTYPE	7	7	embarrassment
NCT00164671133	NCT00164671_133_T0	PHENOTYPE	18	18	Centers
NCT00164671138	NCT00164671_138_T0	PHENOTYPE	2	2	said
NCT0016469711	NCT00164697_11_T0	GENE	1	1	has
NCT001647101	NCT00164710_1_T0	GENE	5	5	has
NCT001647101	NCT00164710_1_T1	PHENOTYPE	1	1	malaria
NCT001647102	NCT00164710_2_T0	PHENOTYPE	11	11	Malaria
NCT001647102	NCT00164710_2_T1	PHENOTYPE	47	47	malaria
NCT001647103	NCT00164710_3_T0	COMPOUND	25	25	amodiaquine
NCT001647103	NCT00164710_3_T1	COMPOUND	29	29	amodiaquine
NCT001647103	NCT00164710_3_T2	COMPOUND	27	27	sulfadoxine_pyrimethamine
NCT001647103	NCT00164710_3_T3	COMPOUND	31	31	artesunate
NCT001647103	NCT00164710_3_T4	COMPOUND	35	35	artesunate
NCT001647106	NCT00164710_6_T0	PHENOTYPE	17	17	Malaria
NCT001647106	NCT00164710_6_T1	PHENOTYPE	29	29	malaria
NCT001647230	NCT00164723_0_T0	PHENOTYPE	11	11	Melena
NCT001647230	NCT00164723_0_T1	PHENOTYPE	3	5	Lower Gastrointestinal Bleeding
NCT001647233	NCT00164723_3_T0	PHENOTYPE	6	6	tumors
NCT001647233	NCT00164723_3_T1	GENE	5	5	bowel
NCT001647233	NCT00164723_3_T2	GENE	11	11	bowel
NCT001647233	NCT00164723_3_T3	COMPOUND	15	15	aspirin
NCT001647233	NCT00164723_3_T4	PHENOTYPE	12	12	ulcers
NCT001647233	NCT00164723_3_T5	PHENOTYPE	2	3	colonic cancer
NCT001647234	NCT00164723_4_T0	PHENOTYPE	9	10	peptic ulcers
NCT001647234	NCT00164723_4_T1	PHENOTYPE	15	16	GI bleeding
NCT001647236	NCT00164723_6_T0	PHENOTYPE	5	6	GI bleeding
NCT001647237	NCT00164723_7_T0	PHENOTYPE	5	6	GI bleeding
NCT001647238	NCT00164723_8_T0	PHENOTYPE	11	11	bleeding
NCT001647238	NCT00164723_8_T1	GENE	1	1	has
NCT001647239	NCT00164723_9_T0	PHENOTYPE	7	7	bleeding
NCT001647239	NCT00164723_9_T1	PHENOTYPE	4	4	complications
NCT0016472310	NCT00164723_10_T0	GENE	11	11	has
NCT0016472310	NCT00164723_10_T1	PHENOTYPE	21	22	bowel diseases
NCT0016472312	NCT00164723_12_T0	GENE	4	4	swallow
NCT0016472313	NCT00164723_13_T0	PHENOTYPE	5	5	transmitted
NCT0016472318	NCT00164723_18_T0	PHENOTYPE	17	18	tarry stool
NCT0016472318	NCT00164723_18_T1	PHENOTYPE	11	12	GI bleeding
NCT0016472319	NCT00164723_19_T0	PHENOTYPE	14	15	GI bleeding
NCT0016472321	NCT00164723_21_T0	GENE	7	7	PR
NCT0016472321	NCT00164723_21_T1	PHENOTYPE	8	8	bleeding
NCT0016472321	NCT00164723_21_T2	PHENOTYPE	2	2	melena
NCT0016472321	NCT00164723_21_T3	PHENOTYPE	4	4	melena
NCT0016472323	NCT00164723_23_T0	GENE	35	35	GI
NCT0016472323	NCT00164723_23_T1	COMPOUND	6	6	aspirin
NCT0016472323	NCT00164723_23_T2	COMPOUND	26	26	aspirin
NCT0016472323	NCT00164723_23_T3	GENE	20	20	had
NCT0016472323	NCT00164723_23_T4	PHENOTYPE	36	36	bleed
NCT0016472329	NCT00164723_29_T0	PHENOTYPE	0	0	Hematemesis
NCT0016472330	NCT00164723_30_T0	PHENOTYPE	21	21	varices
NCT0016472330	NCT00164723_30_T1	PHENOTYPE	5	5	bleeding
NCT0016472330	NCT00164723_30_T2	PHENOTYPE	17	17	bleeding
NCT0016472330	NCT00164723_30_T3	PHENOTYPE	19	19	bleeding
NCT0016472330	NCT00164723_30_T4	PHENOTYPE	25	25	bleeding
NCT0016472330	NCT00164723_30_T5	PHENOTYPE	28	28	gastropathy
NCT0016472330	NCT00164723_30_T6	PHENOTYPE	14	14	ulcers
NCT0016472330	NCT00164723_30_T7	PHENOTYPE	22	23	Mallory-Weiss tear
NCT0016472333	NCT00164723_33_T0	PHENOTYPE	1	1	bleeding
NCT0016472336	NCT00164723_36_T0	PHENOTYPE	1	1	malignancy
NCT0016472336	NCT00164723_36_T1	PHENOTYPE	6	6	malignancy
NCT0016472339	NCT00164723_39_T0	PHENOTYPE	1	3	delayed gastric emptying
NCT0016472340	NCT00164723_40_T0	GENE	2	2	bowel
NCT0016472341	NCT00164723_41_T0	COMPOUND	2	2	misoprostol
NCT0016472344	NCT00164723_44_T0	PHENOTYPE	7	7	ingestion
NCT0016472344	NCT00164723_44_T1	PHENOTYPE	2	3	swallowing disorder
NCT001647364	NCT00164736_4_T0	PHENOTYPE	8	8	HIV
NCT001647364	NCT00164736_4_T1	PHENOTYPE	15	15	HIV
NCT001647364	NCT00164736_4_T2	PHENOTYPE	35	35	HIV
NCT001647366	NCT00164736_6_T0	PHENOTYPE	10	10	HIV
NCT001647366	NCT00164736_6_T1	PHENOTYPE	18	19	weight loss
NCT001647368	NCT00164736_8_T0	PHENOTYPE	21	22	HIV infection
NCT0016473611	NCT00164736_11_T0	PHENOTYPE	26	26	HIV
NCT001647495	NCT00164749_5_T0	GENE	13	13	AD
NCT001647495	NCT00164749_5_T1	GENE	17	17	reduced
NCT001647495	NCT00164749_5_T2	COMPOUND	6	6	curcumin
NCT001647495	NCT00164749_5_T3	PHENOTYPE	28	29	cognitive deficits
NCT001647496	NCT00164749_6_T0	GENE	0	0	AD
NCT001647496	NCT00164749_6_T1	COMPOUND	11	11	curcumin
NCT001647498	NCT00164749_8_T0	GENE	27	27	beta
NCT0016474910	NCT00164749_10_T0	GENE	11	11	AD
NCT0016474910	NCT00164749_10_T1	GENE	26	26	AD
NCT0016474910	NCT00164749_10_T2	COMPOUND	9	9	curcumin
NCT0016474910	NCT00164749_10_T3	COMPOUND	24	24	curcumin
NCT0016474911	NCT00164749_11_T0	PHENOTYPE	1	1	secondary
NCT0016474911	NCT00164749_11_T1	PHENOTYPE	8	8	affects
NCT0016474911	NCT00164749_11_T2	COMPOUND	7	7	curcumin
NCT0016474912	NCT00164749_12_T0	GENE	12	12	AD
NCT0016474912	NCT00164749_12_T1	COMPOUND	7	7	curcumin
NCT0016474912	NCT00164749_12_T2	PHENOTYPE	9	10	cognitive decline
NCT0016474913	NCT00164749_13_T0	GENE	11	11	AD
NCT0016474913	NCT00164749_13_T1	PHENOTYPE	9	9	progression
NCT001647622	NCT00164762_2_T0	COMPOUND	34	34	zidovudine
NCT001647622	NCT00164762_2_T1	GENE	24	24	BAN
NCT001647622	NCT00164762_2_T2	COMPOUND	55	55	nevirapine
NCT001647622	NCT00164762_2_T3	COMPOUND	37	37	lamivudine
NCT001647622	NCT00164762_2_T4	PHENOTYPE	6	7	HIV Infection
NCT001647624	NCT00164762_4_T0	GENE	4	4	CTA
NCT001647624	NCT00164762_4_T1	PHENOTYPE	15	15	HIV
NCT001647625	NCT00164762_5_T0	PHENOTYPE	6	6	HIV
NCT001647752	NCT00164775_2_T0	PHENOTYPE	6	6	dyspepsia
NCT001647752	NCT00164775_2_T1	COMPOUND	17	17	imipramine
NCT001647753	NCT00164775_3_T0	PHENOTYPE	10	11	drug withdrawal
NCT001647754	NCT00164775_4_T0	PHENOTYPE	15	15	symptoms
NCT001647756	NCT00164775_6_T0	PHENOTYPE	4	4	dyspepsia
NCT001647756	NCT00164775_6_T1	PHENOTYPE	1	1	pathophysiology
NCT001647756	NCT00164775_6_T2	PHENOTYPE	8	8	understood
NCT001647759	NCT00164775_9_T0	PHENOTYPE	6	6	dyspepsia
NCT001647759	NCT00164775_9_T1	PHENOTYPE	27	27	dyspepsia
NCT001647759	NCT00164775_9_T2	GENE	13	13	had
NCT001647759	NCT00164775_9_T3	GENE	10	11	proton pump
NCT0016477510	NCT00164775_10_T0	PHENOTYPE	10	10	dyspepsia
NCT0016477510	NCT00164775_10_T1	PHENOTYPE	23	23	dyspepsia
NCT0016477510	NCT00164775_10_T2	PHENOTYPE	9	9	reflux
NCT0016477511	NCT00164775_11_T0	PHENOTYPE	14	14	dyspepsia
NCT0016477511	NCT00164775_11_T1	GENE	8	8	has
NCT0016477517	NCT00164775_17_T0	PHENOTYPE	20	20	dyspepsia
NCT0016477517	NCT00164775_17_T1	COMPOUND	12	12	imipramine
NCT001647880	NCT00164788_0_T0	GENE	4	4	pH
NCT001647883	NCT00164788_3_T0	PHENOTYPE	8	8	bleeding
NCT001647883	NCT00164788_3_T1	GENE	2	2	has
NCT001647884	NCT00164788_4_T0	PHENOTYPE	1	1	bleeding
NCT001647884	NCT00164788_4_T1	PHENOTYPE	0	0	Recurrent
NCT001647885	NCT00164788_5_T0	PHENOTYPE	17	17	bleeding
NCT001647885	NCT00164788_5_T1	PHENOTYPE	16	16	recurrent
NCT001647885	NCT00164788_5_T2	GENE	28	28	Med
NCT001647885	NCT00164788_5_T3	COMPOUND	25	25	N
NCT001647885	NCT00164788_5_T4	GENE	26	26	Engl
NCT001647885	NCT00164788_5_T5	GENE	10	11	proton pump
NCT001647887	NCT00164788_7_T0	COMPOUND	20	20	omeprazole
NCT001647887	NCT00164788_7_T1	COMPOUND	14	14	pentagastrin
NCT001647888	NCT00164788_8_T0	COMPOUND	15	15	esomeprazole
NCT001647889	NCT00164788_9_T0	COMPOUND	7	7	esomeprazole
NCT001647889	NCT00164788_9_T1	GENE	2	2	pH
NCT001647889	NCT00164788_9_T2	GENE	14	14	has
NCT001648010	NCT00164801_0_T0	PHENOTYPE	6	6	Hyperalgesia
NCT001648013	NCT00164801_3_T0	ORGAN	2	2	brainstem
NCT001648143	NCT00164814_3_T0	PHENOTYPE	9	11	quality of life
NCT001648145	NCT00164814_5_T0	PHENOTYPE	10	10	hyperalgesia
NCT001648146	NCT00164814_6_T0	GENE	20	20	pH
NCT001648146	NCT00164814_6_T1	PHENOTYPE	13	15	esophageal motility disorder
NCT001648146	NCT00164814_6_T2	PHENOTYPE	9	11	gastroesophageal reflux disease
NCT001648272	NCT00164827_2_T0	PHENOTYPE	5	5	bleeding
NCT001648272	NCT00164827_2_T1	PHENOTYPE	8	9	peptic ulcer
NCT001648273	NCT00164827_3_T0	PHENOTYPE	0	0	Ulcers
NCT001648273	NCT00164827_3_T1	PHENOTYPE	10	10	ulcer
NCT001648273	NCT00164827_3_T2	ORGAN	4	4	artery
NCT001648273	NCT00164827_3_T3	ORGAN	18	18	artery
NCT001648273	NCT00164827_3_T4	ORGAN	24	24	artery
NCT001648273	NCT00164827_3_T5	PHENOTYPE	30	30	thrombus
NCT001648273	NCT00164827_3_T6	PHENOTYPE	1	1	bleed
NCT001648273	NCT00164827_3_T7	PHENOTYPE	13	13	Bleeding
NCT001648274	NCT00164827_4_T0	GENE	3	3	clot
NCT001648275	NCT00164827_5_T0	GENE	20	20	fold
NCT001648275	NCT00164827_5_T1	GENE	1	1	has
NCT001648275	NCT00164827_5_T2	PHENOTYPE	12	13	ulcer bleeding
NCT001648276	NCT00164827_6_T0	PHENOTYPE	11	11	hypotension
NCT001648276	NCT00164827_6_T1	PHENOTYPE	9	9	hematemesis
NCT001648276	NCT00164827_6_T2	GENE	18	18	has
NCT001648276	NCT00164827_6_T3	PHENOTYPE	6	6	bleed
NCT001648277	NCT00164827_7_T0	GENE	4	4	clot
NCT001648279	NCT00164827_9_T0	GENE	13	13	clot
NCT001648279	NCT00164827_9_T1	PHENOTYPE	5	5	bleeding
NCT0016482710	NCT00164827_10_T0	GENE	12	12	has
NCT0016482712	NCT00164827_12_T0	PHENOTYPE	15	15	haemorrhage
NCT0016482712	NCT00164827_12_T1	PHENOTYPE	14	14	ulcer
NCT0016482721	NCT00164827_21_T0	GENE	2	2	has
NCT0016482722	NCT00164827_22_T0	ORGAN	6	6	arteries
NCT0016482722	NCT00164827_22_T1	PHENOTYPE	9	9	ulcer
NCT0016482723	NCT00164827_23_T0	PHENOTYPE	14	14	vomiting
NCT0016482723	NCT00164827_23_T1	PHENOTYPE	18	19	hemodynamic instability
NCT0016482723	NCT00164827_23_T2	PHENOTYPE	24	25	hemoglobin level
NCT0016482724	NCT00164827_24_T0	GENE	11	11	has
NCT0016482726	NCT00164827_26_T0	GENE	18	18	had
NCT0016482726	NCT00164827_26_T1	PHENOTYPE	13	13	arrhythmia
NCT0016482726	NCT00164827_26_T2	PHENOTYPE	49	49	ulcer
NCT0016482726	NCT00164827_26_T3	GENE	17	17	has
NCT0016482726	NCT00164827_26_T4	GENE	44	44	has
NCT0016482726	NCT00164827_26_T5	PHENOTYPE	38	39	blood loss
NCT0016482726	NCT00164827_26_T6	PHENOTYPE	20	21	myocardial infarction
NCT0016482729	NCT00164827_29_T0	PHENOTYPE	7	7	visualization
NCT0016482729	NCT00164827_29_T1	PHENOTYPE	17	17	bleeding
NCT0016482729	NCT00164827_29_T2	ORGAN	10	11	small intestine
NCT0016482731	NCT00164827_31_T0	PHENOTYPE	10	12	bleeding peptic ulcer
NCT001648402	NCT00164840_2_T0	GENE	3	3	has
NCT001648402	NCT00164840_2_T1	PHENOTYPE	19	21	quality of life
NCT001648531	NCT00164853_1_T0	GENE	5	5	balloon
NCT001648531	NCT00164853_1_T1	PHENOTYPE	6	6	dilation
NCT001648534	NCT00164853_4_T0	PHENOTYPE	8	8	distal
NCT001648535	NCT00164853_5_T0	GENE	11	11	balloon
NCT001648535	NCT00164853_5_T1	PHENOTYPE	12	12	dilation
NCT001648535	NCT00164853_5_T2	GENE	7	7	al
NCT001648535	NCT00164853_5_T3	GENE	6	6	et
NCT001648536	NCT00164853_6_T0	PHENOTYPE	20	20	complication
NCT001648536	NCT00164853_6_T1	GENE	11	11	balloon
NCT001648536	NCT00164853_6_T2	PHENOTYPE	12	12	dilation
NCT001648661	NCT00164866_1_T0	PHENOTYPE	7	7	bleeding
NCT001648665	NCT00164866_5_T0	COMPOUND	7	7	omeprazole
NCT001648665	NCT00164866_5_T1	PHENOTYPE	17	17	bleeding
NCT001648665	NCT00164866_5_T2	ORGAN	12	12	arteries
NCT001648665	NCT00164866_5_T3	PHENOTYPE	20	21	peptic ulcer
NCT001648666	NCT00164866_6_T0	COMPOUND	12	12	omeprazole
NCT001648667	NCT00164866_7_T0	COMPOUND	14	14	omeprazole
NCT001648667	NCT00164866_7_T1	PHENOTYPE	6	8	upper gastrointestinal bleeding
NCT001648668	NCT00164866_8_T0	PHENOTYPE	6	6	hematemesis
NCT001648668	NCT00164866_8_T1	PHENOTYPE	2	2	circulatory
NCT0016486611	NCT00164866_11_T0	PHENOTYPE	8	8	bleeding
NCT0016486611	NCT00164866_11_T1	PHENOTYPE	6	6	ulcers
NCT0016486611	NCT00164866_11_T2	PHENOTYPE	3	4	bleeding ulcers
NCT0016486612	NCT00164866_12_T0	BIOLOGICAL_PROCESS	12	12	hemostasis
NCT001648793	NCT00164879_3_T0	PHENOTYPE	18	18	obstruction
NCT001648793	NCT00164879_3_T1	GENE	9	9	bowel
NCT001648793	NCT00164879_3_T2	PHENOTYPE	8	8	edematous
NCT001648793	NCT00164879_3_T3	PHENOTYPE	13	13	anastomosis
NCT001648794	NCT00164879_4_T0	GENE	8	8	bowel
NCT001648797	NCT00164879_7_T0	PHENOTYPE	18	18	left-sided
NCT001648797	NCT00164879_7_T1	PHENOTYPE	12	13	acute obstruction
NCT001648797	NCT00164879_7_T2	PHENOTYPE	19	20	colorectal cancers
NCT001648798	NCT00164879_8_T0	PHENOTYPE	7	7	obstruction
NCT001648799	NCT00164879_9_T0	PHENOTYPE	16	16	left-sided
NCT001648799	NCT00164879_9_T1	PHENOTYPE	17	18	colorectal cancers
NCT001648922	NCT00164892_2_T0	GENE	0	0	COX-II
NCT001648922	NCT00164892_2_T1	PHENOTYPE	15	15	inflammation
NCT001648923	NCT00164892_3_T0	PHENOTYPE	5	6	stomach cancer
NCT001648924	NCT00164892_4_T0	PHENOTYPE	5	5	diseases
NCT001648924	NCT00164892_4_T1	GENE	8	8	IIIa
NCT001648926	NCT00164892_6_T0	GENE	10	10	COX-II
NCT001648926	NCT00164892_6_T1	GENE	15	15	COX-II
NCT001648926	NCT00164892_6_T2	PHENOTYPE	29	29	recurrence
NCT001648926	NCT00164892_6_T3	PHENOTYPE	12	13	stomach cancer
NCT001648926	NCT00164892_6_T4	PHENOTYPE	31	32	gastric carcinoma
NCT001648927	NCT00164892_7_T0	PHENOTYPE	8	8	toxic
NCT001648927	NCT00164892_7_T1	GENE	3	3	COX-II
NCT001648927	NCT00164892_7_T2	PHENOTYPE	11	12	side effect
NCT001649052	NCT00164905_2_T0	PHENOTYPE	8	8	acute
NCT001649052	NCT00164905_2_T1	BIOLOGICAL_PROCESS	9	9	hemostasis
NCT001649052	NCT00164905_2_T2	PHENOTYPE	11	12	bleeding ulcers
NCT001649054	NCT00164905_4_T0	PHENOTYPE	14	14	ulcer
NCT001649054	NCT00164905_4_T1	PHENOTYPE	3	3	enables
NCT001649055	NCT00164905_5_T0	PHENOTYPE	8	8	bleeding
NCT001649055	NCT00164905_5_T1	PHENOTYPE	7	7	recurrent
NCT001649056	NCT00164905_6_T0	PHENOTYPE	8	8	ulcer
NCT001649056	NCT00164905_6_T1	PHENOTYPE	18	18	ulcer
NCT001649057	NCT00164905_7_T0	PHENOTYPE	22	23	peptic ulcers
NCT001649057	NCT00164905_7_T1	PHENOTYPE	17	19	upper gastrointestinal bleeding
NCT001649059	NCT00164905_9_T0	GENE	0	0	SBP
NCT001649059	NCT00164905_9_T1	GENE	11	11	SBP
NCT001649059	NCT00164905_9_T2	PHENOTYPE	8	8	orthostatic
NCT001649059	NCT00164905_9_T3	GENE	6	6	bpm
NCT001649059	NCT00164905_9_T4	GENE	18	18	bpm
NCT001649184	NCT00164918_4_T0	PHENOTYPE	15	15	ileus
NCT001649184	NCT00164918_4_T1	PHENOTYPE	12	13	chest infection
NCT001649185	NCT00164918_5_T0	PHENOTYPE	24	24	complication
NCT001649185	NCT00164918_5_T1	PHENOTYPE	6	6	discomfort
NCT001649185	NCT00164918_5_T2	GENE	9	9	has
NCT001649185	NCT00164918_5_T3	PHENOTYPE	16	17	gastroesophageal reflux
NCT001649310	NCT00164931_0_T0	PHENOTYPE	12	14	Bleeding Peptic Ulcer
NCT001649313	NCT00164931_3_T0	PHENOTYPE	7	7	bleeding
NCT001649313	NCT00164931_3_T1	GENE	10	10	reduced
NCT001649313	NCT00164931_3_T2	BIOLOGICAL_PROCESS	29	29	hemostasis
NCT001649313	NCT00164931_3_T3	PHENOTYPE	6	6	recurrent
NCT001649315	NCT00164931_5_T0	BIOLOGICAL_PROCESS	15	15	hemostasis
NCT001649315	NCT00164931_5_T1	PHENOTYPE	8	8	recurrent
NCT001649315	NCT00164931_5_T2	PHENOTYPE	9	11	peptic ulcer bleeding
NCT001649316	NCT00164931_6_T0	PHENOTYPE	6	6	strategies
NCT001649316	NCT00164931_6_T1	PHENOTYPE	24	24	recurrent
NCT001649316	NCT00164931_6_T2	PHENOTYPE	25	27	peptic ulcer bleeding
NCT001649317	NCT00164931_7_T0	COMPOUND	10	10	omeprazole
NCT001649317	NCT00164931_7_T1	PHENOTYPE	20	20	bleeding
NCT001649317	NCT00164931_7_T2	PHENOTYPE	21	22	peptic ulcers
NCT001649443	NCT00164944_3_T0	PHENOTYPE	7	8	colorectal cancer
NCT001649446	NCT00164944_6_T0	PHENOTYPE	2	2	syndromes
NCT001649447	NCT00164944_7_T0	PHENOTYPE	8	8	sporadic
NCT001649447	NCT00164944_7_T1	PHENOTYPE	5	5	understood
NCT001649447	NCT00164944_7_T2	PHENOTYPE	9	10	colorectal cancer
NCT001649448	NCT00164944_8_T0	GENE	10	10	has
NCT001649448	NCT00164944_8_T1	PHENOTYPE	8	9	colorectal cancer
NCT001649449	NCT00164944_9_T0	PHENOTYPE	11	12	colorectal neoplasm
NCT0016494410	NCT00164944_10_T0	PHENOTYPE	7	7	adenomas
NCT0016494410	NCT00164944_10_T1	PHENOTYPE	16	17	colorectal cancer
NCT001649570	NCT00164957_0_T0	PHENOTYPE	12	12	Fed
NCT001649570	NCT00164957_0_T1	PHENOTYPE	9	9	Aspiration
NCT001649572	NCT00164957_2_T0	PHENOTYPE	16	17	aspiration pneumonia
NCT001649574	NCT00164957_4_T0	GENE	16	16	CXR
NCT0016495710	NCT00164957_10_T0	PHENOTYPE	6	6	complications
NCT0016495714	NCT00164957_14_T0	PHENOTYPE	4	4	pneumonia
NCT0016495715	NCT00164957_15_T0	PHENOTYPE	15	15	pneumonia
NCT001649705	NCT00164970_5_T0	PHENOTYPE	5	5	dementia
NCT001649706	NCT00164970_6_T0	PHENOTYPE	1	1	secondary
NCT001649706	NCT00164970_6_T1	PHENOTYPE	16	16	dementia
NCT001649708	NCT00164970_8_T0	COMPOUND	2	2	homocysteine
NCT001649708	NCT00164970_8_T1	PHENOTYPE	3	3	concentrations
NCT001649708	NCT00164970_8_T2	ORGAN	1	1	plasma
NCT001649960	NCT00164996_0_T0	PHENOTYPE	12	12	Anaesthesia
NCT001649962	NCT00164996_2_T0	PHENOTYPE	10	10	anaesthesia
NCT001650090	NCT00165009_0_T0	GENE	6	6	Heater
NCT001650092	NCT00165009_2_T0	PHENOTYPE	11	11	bleeding
NCT001650092	NCT00165009_2_T1	PHENOTYPE	10	10	recurrent
NCT001650092	NCT00165009_2_T2	PHENOTYPE	4	6	peptic ulcer bleeding
NCT001650094	NCT00165009_4_T0	COMPOUND	9	9	epinephrine
NCT001650095	NCT00165009_5_T0	PHENOTYPE	6	6	complications
NCT001650095	NCT00165009_5_T1	PHENOTYPE	11	12	myocardial ischemia
NCT001650096	NCT00165009_6_T0	PHENOTYPE	17	17	bleeding
NCT001650096	NCT00165009_6_T1	ORGAN	18	18	artery
NCT001650097	NCT00165009_7_T0	GENE	1	1	has
NCT001650099	NCT00165009_9_T0	PHENOTYPE	25	25	bleeding
NCT001650099	NCT00165009_9_T1	ORGAN	26	26	artery
NCT001650099	NCT00165009_9_T2	BIOLOGICAL_PROCESS	33	33	hemostasis
NCT001650099	NCT00165009_9_T3	GENE	17	17	clip
NCT0016500910	NCT00165009_10_T0	GENE	24	24	clip
NCT0016500910	NCT00165009_10_T1	PHENOTYPE	5	7	bleeding peptic ulcer
NCT001650221	NCT00165022_1_T0	PHENOTYPE	11	13	quality of life
NCT001650224	NCT00165022_4_T0	PHENOTYPE	3	3	GERD
NCT001650224	NCT00165022_4_T1	PHENOTYPE	4	4	QOL
NCT001650225	NCT00165022_5_T0	PHENOTYPE	1	1	GERD
NCT001650225	NCT00165022_5_T1	GENE	14	14	VAS
NCT001650226	NCT00165022_6_T0	PHENOTYPE	1	1	GERD
NCT001650226	NCT00165022_6_T1	PHENOTYPE	9	9	GERD
NCT001650226	NCT00165022_6_T2	PHENOTYPE	10	10	QOL
NCT001650227	NCT00165022_7_T0	PHENOTYPE	24	24	reflux
NCT001650227	NCT00165022_7_T1	PHENOTYPE	11	12	in remission
NCT001650228	NCT00165022_8_T0	PHENOTYPE	8	9	in remission
NCT001650350	NCT00165035_0_T0	GENE	7	7	II
NCT001650350	NCT00165035_0_T1	GENE	10	10	II
NCT001650350	NCT00165035_0_T2	PHENOTYPE	6	6	Restenosis
NCT001650350	NCT00165035_0_T3	COMPOUND	1	1	Chromium
NCT001650350	NCT00165035_0_T4	COMPOUND	0	0	Cobalt
NCT001650482	NCT00165048_2_T0	GENE	0	0	COX-II
NCT001650482	NCT00165048_2_T1	PHENOTYPE	14	14	inflammation
NCT001650483	NCT00165048_3_T0	PHENOTYPE	6	7	stomach cancer
NCT001650484	NCT00165048_4_T0	PHENOTYPE	20	20	progression
NCT001650484	NCT00165048_4_T1	GENE	27	27	span
NCT001650485	NCT00165048_5_T0	GENE	2	2	has
NCT001650487	NCT00165048_7_T0	GENE	8	8	COX-II
NCT001650487	NCT00165048_7_T1	GENE	34	34	COX-II
NCT001650487	NCT00165048_7_T2	PHENOTYPE	19	19	progression
NCT001650487	NCT00165048_7_T3	CELL	24	24	cells
NCT001650487	NCT00165048_7_T4	PHENOTYPE	10	11	stomach cancer
NCT001650487	NCT00165048_7_T5	PHENOTYPE	22	23	residual cancer
NCT001650612	NCT00165061_2_T0	PHENOTYPE	4	4	intent
NCT001650613	NCT00165061_3_T0	PHENOTYPE	15	16	oesophageal cancer
NCT001650614	NCT00165061_4_T0	PHENOTYPE	19	19	localized
NCT001650614	NCT00165061_4_T1	PHENOTYPE	20	21	oesophageal cancer
NCT001650615	NCT00165061_5_T0	PHENOTYPE	18	18	tumour
NCT001650615	NCT00165061_5_T1	PHENOTYPE	15	15	regression
NCT001650615	NCT00165061_5_T2	GENE	7	7	has
NCT001650616	NCT00165061_6_T0	PHENOTYPE	5	6	oesophageal cancer
NCT001650617	NCT00165061_7_T0	PHENOTYPE	31	32	oesophageal cancer
NCT001650618	NCT00165061_8_T0	PHENOTYPE	3	4	residual cancer
NCT001650743	NCT00165074_3_T0	PHENOTYPE	7	7	severity
NCT001650744	NCT00165074_4_T0	PHENOTYPE	11	11	recruitment
NCT001650873	NCT00165087_3_T0	PHENOTYPE	11	11	leukemia
NCT0016508710	NCT00165087_10_T0	PHENOTYPE	9	9	leukemia
NCT0016508710	NCT00165087_10_T1	COMPOUND	11	11	vincristine
NCT0016508710	NCT00165087_10_T2	GENE	14	14	asparaginase
NCT0016508710	NCT00165087_10_T3	COMPOUND	13	13	methotrexate
NCT0016508710	NCT00165087_10_T4	COMPOUND	12	12	prednisone
NCT0016508710	NCT00165087_10_T5	COMPOUND	16	16	6_mercaptopurine
NCT0016508711	NCT00165087_11_T0	PHENOTYPE	10	10	leukemia
NCT0016508711	NCT00165087_11_T1	COMPOUND	12	12	vincristine
NCT0016508711	NCT00165087_11_T2	GENE	16	16	asparaginase
NCT0016508711	NCT00165087_11_T3	GENE	34	34	asparaginase
NCT0016508711	NCT00165087_11_T4	COMPOUND	15	15	methotrexate
NCT0016508711	NCT00165087_11_T5	COMPOUND	18	18	6_mercaptopurine
NCT0016508711	NCT00165087_11_T6	COMPOUND	14	14	doxorubicin
NCT0016508711	NCT00165087_11_T7	COMPOUND	13	13	prednisone
NCT0016508714	NCT00165087_14_T0	COMPOUND	9	9	dexrazoxane
NCT0016508714	NCT00165087_14_T1	PHENOTYPE	20	20	relapse
NCT0016508714	NCT00165087_14_T2	COMPOUND	15	15	doxorubicin
NCT0016508714	NCT00165087_14_T3	ORGAN	11	11	heart
NCT0016508715	NCT00165087_15_T0	COMPOUND	12	12	dexrazoxane
NCT0016508715	NCT00165087_15_T1	COMPOUND	7	7	doxorubicin
NCT0016508715	NCT00165087_15_T2	COMPOUND	10	10	doxorubicin
NCT0016508716	NCT00165087_16_T0	PHENOTYPE	9	9	toxicity
NCT001651003	NCT00165100_3_T0	PHENOTYPE	18	18	tumors
NCT001651003	NCT00165100_3_T1	TISSUE	10	10	tissues
NCT001651262	NCT00165126_2_T0	ORGAN	10	10	bladder
NCT001651399	NCT00165139_9_T0	CELL	9	10	stem cells
NCT001651781	NCT00165178_1_T0	PHENOTYPE	10	10	learned
NCT001651785	NCT00165178_5_T0	COMPOUND	15	15	cytarabine
NCT001651785	NCT00165178_5_T1	COMPOUND	10	10	vincristine
NCT001651785	NCT00165178_5_T2	COMPOUND	18	18	hydrocortisone
NCT001651785	NCT00165178_5_T3	GENE	14	14	asparaginase
NCT001651785	NCT00165178_5_T4	COMPOUND	12	12	methotrexate
NCT001651785	NCT00165178_5_T5	COMPOUND	11	11	doxorubicin
NCT001651785	NCT00165178_5_T6	COMPOUND	9	9	prednisone
NCT001651785	NCT00165178_5_T7	COMPOUND	13	13	leucovorin
NCT001651787	NCT00165178_7_T0	COMPOUND	11	11	cytarabine
NCT001651787	NCT00165178_7_T1	COMPOUND	7	7	vincristine
NCT001651787	NCT00165178_7_T2	COMPOUND	10	10	hydrocortisone
NCT001651787	NCT00165178_7_T3	PHENOTYPE	26	26	remission
NCT001651787	NCT00165178_7_T4	COMPOUND	8	8	methotrexate
NCT001651787	NCT00165178_7_T5	COMPOUND	9	9	leucovorin
NCT001651787	NCT00165178_7_T6	GENE	4	4	MLL
NCT001651787	NCT00165178_7_T7	GENE	13	13	L-asparaginase
NCT001651788	NCT00165178_8_T0	PHENOTYPE	19	19	leukemia
NCT001651788	NCT00165178_8_T1	GENE	14	14	taps
NCT001651789	NCT00165178_9_T0	GENE	2	2	taps
NCT0016517810	NCT00165178_10_T0	COMPOUND	4	4	vincristine
NCT0016517810	NCT00165178_10_T1	COMPOUND	5	5	6_mercaptopurine
NCT0016517814	NCT00165178_14_T0	PHENOTYPE	10	10	leukemia
NCT0016517814	NCT00165178_14_T1	CELL	11	11	cells
NCT0016517814	NCT00165178_14_T2	GENE	29	29	asparaginase
NCT0016517815	NCT00165178_15_T0	COMPOUND	12	12	dexamethasone
NCT0016517815	NCT00165178_15_T1	COMPOUND	19	19	cytarabine
NCT0016517815	NCT00165178_15_T2	GENE	17	17	asparaginase
NCT0016517815	NCT00165178_15_T3	COMPOUND	14	14	methotrexate
NCT0016517815	NCT00165178_15_T4	COMPOUND	10	10	prednisone
NCT0016517817	NCT00165178_17_T0	GENE	16	16	has
NCT0016517817	NCT00165178_17_T1	PHENOTYPE	18	19	in remission
NCT0016517819	NCT00165178_19_T0	GENE	7	7	L-asparaginase
NCT0016517820	NCT00165178_20_T0	GENE	13	13	has
NCT001651913	NCT00165191_3_T0	COMPOUND	9	9	5_fluorouracil
NCT001651913	NCT00165191_3_T1	COMPOUND	5	5	doxorubicin
NCT001651913	NCT00165191_3_T2	COMPOUND	3	3	cisplatin
NCT001651917	NCT00165191_7_T0	PHENOTYPE	5	5	tumor
NCT001652047	NCT00165204_7_T0	COMPOUND	4	4	tibolone
NCT0016520412	NCT00165204_12_T0	COMPOUND	7	7	calcium
NCT0016520412	NCT00165204_12_T1	COMPOUND	9	10	vitamin D
NCT001652173	NCT00165217_3_T0	GENE	2	2	teh
NCT001652822	NCT00165282_2_T0	GENE	39	39	CD
NCT001652822	NCT00165282_2_T1	PHENOTYPE	22	22	mindfulness
NCT001652822	NCT00165282_2_T2	PHENOTYPE	33	33	mindfulness
NCT001652822	NCT00165282_2_T3	ORGAN	15	15	marrow
NCT001652822	NCT00165282_2_T4	COMPOUND	19	19	3
NCT001652822	NCT00165282_2_T5	PHENOTYPE	23	23	meditation
NCT001652822	NCT00165282_2_T6	ORGAN	16	16	transplant
NCT001652823	NCT00165282_3_T0	ORGAN	23	23	marrow
NCT001652823	NCT00165282_3_T1	PHENOTYPE	1	1	meditation
NCT001652823	NCT00165282_3_T2	ORGAN	24	24	transplant
NCT001652823	NCT00165282_3_T3	PHENOTYPE	0	0	Mindfulness
NCT001652825	NCT00165282_5_T0	PHENOTYPE	1	1	meditation
NCT001652825	NCT00165282_5_T1	GENE	2	2	has
NCT001652825	NCT00165282_5_T2	PHENOTYPE	0	0	Mindfulness
NCT001652953	NCT00165295_3_T0	GENE	3	3	has
NCT001653084	NCT00165308_4_T0	GENE	2	2	has
NCT001653084	NCT00165308_4_T1	COMPOUND	1	1	tamoxifen
NCT001653084	NCT00165308_4_T2	COMPOUND	28	28	tamoxifen
NCT001653084	NCT00165308_4_T3	PHENOTYPE	19	20	breast cancer
NCT001653348	NCT00165334_8_T0	COMPOUND	11	11	vinorelbine
NCT001653474	NCT00165347_4_T0	GENE	14	14	MRI
NCT001653474	NCT00165347_4_T1	GENE	15	15	wil
NCT001653474	NCT00165347_4_T2	PHENOTYPE	7	9	quality of life
NCT001653600	NCT00165360_0_T0	PHENOTYPE	5	5	Glioma
NCT001653730	NCT00165373_0_T0	PHENOTYPE	6	6	Cancer
NCT001653738	NCT00165373_8_T0	PHENOTYPE	9	9	tumors
NCT001653738	NCT00165373_8_T1	PHENOTYPE	5	5	gliomas
NCT001653738	NCT00165373_8_T2	ORGAN	3	4	brain stem
NCT001653739	NCT00165373_9_T0	PHENOTYPE	21	21	progressive
NCT001653996	NCT00165399_6_T0	GENE	16	16	hormone
NCT001654122	NCT00165412_2_T0	PHENOTYPE	1	1	menopausal
NCT001654122	NCT00165412_2_T1	BIOLOGICAL_PROCESS	14	15	menstrual cycle
NCT001654250	NCT00165425_0_T0	PHENOTYPE	5	6	Hodgkin's Disease
NCT001654255	NCT00165425_5_T0	ORGAN	19	19	heart
NCT001654255	NCT00165425_5_T1	ORGAN	30	30	heart
NCT001654380	NCT00165438_0_T0	PHENOTYPE	5	6	Hodgkin's Disease
NCT001654511	NCT00165451_1_T0	PHENOTYPE	12	12	tumors
NCT001654511	NCT00165451_1_T1	ORGAN	7	8	blood vessels
NCT001654515	NCT00165451_5_T0	GENE	16	16	has
NCT001654515	NCT00165451_5_T1	PHENOTYPE	14	15	disease progression
NCT001654778	NCT00165477_8_T0	GENE	3	3	MRI
NCT001654779	NCT00165477_9_T0	GENE	6	6	MRI
NCT001654779	NCT00165477_9_T1	PHENOTYPE	19	19	tumor
NCT001654906	NCT00165490_6_T0	GENE	22	22	1.5
NCT001655030	NCT00165503_0_T0	COMPOUND	7	7	Sodium
NCT001655037	NCT00165503_7_T0	PHENOTYPE	6	6	tumor
NCT001655037	NCT00165503_7_T1	COMPOUND	20	20	cisplatin
NCT001655038	NCT00165503_8_T0	COMPOUND	15	15	cisplatin
NCT001655038	NCT00165503_8_T1	ORGAN	11	12	abdominal cavity
NCT001655038	NCT00165503_8_T2	PHENOTYPE	18	19	surgical incision
NCT0016550311	NCT00165503_11_T0	GENE	9	9	1.2
NCT001655160	NCT00165516_0_T0	COMPOUND	10	10	Sodium
NCT001655163	NCT00165516_3_T0	GENE	13	13	cm3
NCT001655163	NCT00165516_3_T1	GENE	9	9	has
NCT001655164	NCT00165516_4_T0	ORGAN	30	30	abdomen
NCT001655164	NCT00165516_4_T1	PHENOTYPE	31	31	cavity
NCT001655164	NCT00165516_4_T2	COMPOUND	34	34	cisplatin
NCT001655164	NCT00165516_4_T3	PHENOTYPE	42	43	surgical incision
NCT001655166	NCT00165516_6_T0	GENE	9	9	1.2
NCT001655168	NCT00165516_8_T0	ORGAN	10	10	heart
NCT001655421	NCT00165542_1_T0	GENE	6	6	pre
NCT001655422	NCT00165542_2_T0	GENE	6	6	CSF
NCT001655427	NCT00165542_7_T0	PHENOTYPE	6	9	central nervous system tumor
NCT001655550	NCT00165555_0_T0	PHENOTYPE	7	9	Malignant Pleural Mesothelioma
NCT001655554	NCT00165555_4_T0	TISSUE	3	3	pericardium
NCT001655554	NCT00165555_4_T1	PHENOTYPE	12	12	tumor
NCT001655554	NCT00165555_4_T2	ORGAN	5	5	diaphragm
NCT0016555510	NCT00165555_10_T0	PHENOTYPE	15	15	recurrence
NCT0016555510	NCT00165555_10_T1	ORGAN	9	9	abdomen
NCT001655682	NCT00165568_2_T0	PHENOTYPE	16	16	tumor
NCT001655685	NCT00165568_5_T0	GENE	0	1	Group 1
NCT001655941	NCT00165594_1_T0	PHENOTYPE	17	17	severity
NCT001655941	NCT00165594_1_T1	GENE	1	1	IIa
NCT001655941	NCT00165594_1_T2	PHENOTYPE	13	13	secondary
NCT001655941	NCT00165594_1_T3	PHENOTYPE	23	23	pharmacokinetics
NCT001655941	NCT00165594_1_T4	PHENOTYPE	29	30	gastric cancer
NCT001655941	NCT00165594_1_T5	PHENOTYPE	19	21	adverse drug reactions
NCT001655945	NCT00165594_5_T0	CELL	0	0	Neutrophil
NCT001655946	NCT00165594_6_T0	PHENOTYPE	0	1	Platelet count
NCT001655948	NCT00165594_8_T0	GENE	2	2	AST
NCT001655948	NCT00165594_8_T1	GENE	0	1	Aspartate aminotransferase
NCT0016559411	NCT00165594_11_T0	COMPOUND	1	1	creatinine
NCT0016559411	NCT00165594_11_T1	ORGAN	0	0	Serum
NCT0016559415	NCT00165594_15_T0	COMPOUND	3	4	mitomycin C
NCT0016559418	NCT00165594_18_T0	GENE	18	18	ventricular
NCT0016559418	NCT00165594_18_T1	PHENOTYPE	7	7	arrhythmia
NCT0016559418	NCT00165594_18_T2	PHENOTYPE	28	28	hypertension
NCT0016559418	NCT00165594_18_T3	PHENOTYPE	1	2	heart disorders
NCT0016559418	NCT00165594_18_T4	PHENOTYPE	4	5	heart diseases
NCT0016559418	NCT00165594_18_T5	PHENOTYPE	13	15	left ventricular hypertrophy
NCT0016559418	NCT00165594_18_T6	PHENOTYPE	22	25	right bundle branch block
NCT0016559420	NCT00165594_20_T0	PHENOTYPE	0	1	Myocardial infarction
NCT0016559422	NCT00165594_22_T0	PHENOTYPE	0	1	Hepatic cirrhosis
NCT0016559424	NCT00165594_24_T0	PHENOTYPE	3	4	pulmonary fibrosis
NCT0016559424	NCT00165594_24_T1	PHENOTYPE	0	1	Interstitial pneumonia
NCT0016559426	NCT00165594_26_T0	PHENOTYPE	2	2	hemorrhage
NCT0016559436	NCT00165594_36_T0	GENE	0	0	WBC
NCT0016559437	NCT00165594_37_T0	CELL	0	0	Neutrophil
NCT0016559438	NCT00165594_38_T0	PHENOTYPE	0	1	Platelet count
NCT0016559440	NCT00165594_40_T0	GENE	2	2	AST
NCT0016559440	NCT00165594_40_T1	GENE	0	1	Aspartate aminotransferase
NCT0016559442	NCT00165594_42_T0	GENE	0	1	Total bilirubin
NCT0016559443	NCT00165594_43_T0	COMPOUND	1	1	creatinine
NCT0016559443	NCT00165594_43_T1	ORGAN	0	0	Serum
NCT0016559448	NCT00165594_48_T0	COMPOUND	3	4	mitomycin C
NCT0016559452	NCT00165594_52_T0	GENE	5	5	sub
NCT0016559452	NCT00165594_52_T1	PHENOTYPE	3	3	ileus
NCT0016559452	NCT00165594_52_T2	PHENOTYPE	6	6	ileus
NCT0016559453	NCT00165594_53_T0	PHENOTYPE	3	3	ascites
NCT0016559453	NCT00165594_53_T1	PHENOTYPE	7	7	cavity
NCT0016559455	NCT00165594_55_T0	GENE	19	19	ventricular
NCT0016559455	NCT00165594_55_T1	PHENOTYPE	8	8	arrhythmia
NCT0016559455	NCT00165594_55_T2	PHENOTYPE	29	29	hypertension
NCT0016559455	NCT00165594_55_T3	PHENOTYPE	0	2	Ischemic heart disease
NCT0016559455	NCT00165594_55_T4	PHENOTYPE	14	16	left ventricular hypertrophy
NCT0016559455	NCT00165594_55_T5	PHENOTYPE	4	6	other heart disease
NCT0016559455	NCT00165594_55_T6	PHENOTYPE	23	26	right bundle branch block
NCT0016559456	NCT00165594_56_T0	PHENOTYPE	0	1	Myocardial infarction
NCT0016559457	NCT00165594_57_T0	PHENOTYPE	0	1	Hepatic cirrhosis
NCT0016559458	NCT00165594_58_T0	PHENOTYPE	3	4	pulmonary fibrosis
NCT0016559458	NCT00165594_58_T1	PHENOTYPE	0	1	Interstitial pneumonia
NCT0016559459	NCT00165594_59_T0	PHENOTYPE	2	2	hemorrhage
NCT001656072	NCT00165607_2_T0	COMPOUND	7	7	calcium
NCT001656075	NCT00165607_5_T0	PHENOTYPE	2	2	osteophytes
NCT001656075	NCT00165607_5_T1	PHENOTYPE	7	7	osteophytes
NCT001656076	NCT00165607_6_T0	PHENOTYPE	2	2	hyperostosis
NCT001656076	NCT00165607_6_T1	TISSUE	4	4	ligament
NCT001656077	NCT00165607_7_T0	GENE	3	3	fusion
NCT001656078	NCT00165607_8_T0	ORGAN	7	7	spine
NCT0016562017	NCT00165620_17_T0	PHENOTYPE	3	3	acute
NCT0016562017	NCT00165620_17_T1	PHENOTYPE	8	8	symptoms
NCT0016562020	NCT00165620_20_T0	PHENOTYPE	5	5	goiter
NCT0016562020	NCT00165620_20_T1	PHENOTYPE	6	6	hyperthyroidism
NCT0016562020	NCT00165620_20_T2	PHENOTYPE	3	4	thyroid disease
NCT0016562021	NCT00165620_21_T0	PHENOTYPE	17	17	peripheral
NCT0016562021	NCT00165620_21_T1	PHENOTYPE	18	18	circulatory
NCT0016562021	NCT00165620_21_T2	ORGAN	13	13	Appendix
NCT0016562021	NCT00165620_21_T3	PHENOTYPE	3	3	cardiopathy
NCT0016562021	NCT00165620_21_T4	PHENOTYPE	16	16	cyanosis
NCT0016562021	NCT00165620_21_T5	PHENOTYPE	22	23	ventricular fibrillation
NCT0016562021	NCT00165620_21_T6	PHENOTYPE	8	9	heart failure
NCT0016562021	NCT00165620_21_T7	PHENOTYPE	6	7	class IV
NCT0016562021	NCT00165620_21_T8	PHENOTYPE	20	21	ventricular tachycardia
NCT0016562022	NCT00165620_22_T0	PHENOTYPE	9	9	hepatitis
NCT0016562022	NCT00165620_22_T1	ORGAN	32	32	Appendix
NCT0016562022	NCT00165620_22_T2	PHENOTYPE	4	4	symptoms
NCT0016562022	NCT00165620_22_T3	PHENOTYPE	3	3	hepatopathy
NCT0016562022	NCT00165620_22_T4	PHENOTYPE	6	7	liver failure
NCT0016562022	NCT00165620_22_T5	PHENOTYPE	25	27	Adverse Drug Reactions
NCT0016562022	NCT00165620_22_T6	PHENOTYPE	13	15	disturbance of consciousness
NCT0016562026	NCT00165620_26_T0	PHENOTYPE	2	3	bronchial asthma
NCT0016562027	NCT00165620_27_T0	PHENOTYPE	2	3	acute pancreatitis
NCT0016562028	NCT00165620_28_T0	PHENOTYPE	2	2	macroglobulinemia
NCT0016562029	NCT00165620_29_T0	PHENOTYPE	2	3	multiple myeloma
NCT0016562030	NCT00165620_30_T0	PHENOTYPE	2	2	tetany
NCT0016562031	NCT00165620_31_T0	PHENOTYPE	2	2	pheochromocytoma
NCT0016562031	NCT00165620_31_T1	PHENOTYPE	9	9	pheochromocytoma
NCT0016562034	NCT00165620_34_T0	PHENOTYPE	2	2	hypertension
NCT0016562036	NCT00165620_36_T0	PHENOTYPE	4	4	myasthenia
NCT001656333	NCT00165633_3_T0	COMPOUND	16	17	vitamin K2
NCT001656334	NCT00165633_4_T0	PHENOTYPE	11	11	recurrence
NCT001656338	NCT00165633_8_T0	PHENOTYPE	14	14	Oncology
NCT0016563311	NCT00165633_11_T0	PHENOTYPE	3	3	recurrence
NCT0016563311	NCT00165633_11_T1	PHENOTYPE	5	6	hepatocellular carcinoma
NCT001656462	NCT00165646_2_T0	GENE	5	5	For
NCT001656463	NCT00165646_3_T0	PHENOTYPE	3	3	heartburn
NCT001656464	NCT00165646_4_T0	PHENOTYPE	16	16	heartburn
NCT001656466	NCT00165646_6_T0	PHENOTYPE	13	14	burning sensation
NCT001656467	NCT00165646_7_T0	PHENOTYPE	13	13	bending
NCT001656467	NCT00165646_7_T1	ORGAN	22	22	abdomen
NCT001656467	NCT00165646_7_T2	BIOLOGICAL_PROCESS	11	11	eating
NCT001656468	NCT00165646_8_T0	PHENOTYPE	21	22	Reflux Esophagitis
NCT0016564610	NCT00165646_10_T0	GENE	20	20	For
NCT0016564611	NCT00165646_11_T0	PHENOTYPE	3	3	heartburn
NCT0016564613	NCT00165646_13_T0	PHENOTYPE	2	2	heartburn
NCT0016564614	NCT00165646_14_T0	PHENOTYPE	11	11	heartburn
NCT0016564619	NCT00165646_19_T0	PHENOTYPE	7	7	heartburn
NCT0016564621	NCT00165646_21_T0	PHENOTYPE	9	10	abdominal bloating
NCT0016564623	NCT00165646_23_T0	PHENOTYPE	4	4	complication
NCT0016564623	NCT00165646_23_T1	PHENOTYPE	10	11	psychosomatic disease
NCT0016564623	NCT00165646_23_T2	PHENOTYPE	13	14	manic-depressive psychosis
NCT0016564623	NCT00165646_23_T3	PHENOTYPE	15	16	obsessive-compulsive neurosis
NCT0016564627	NCT00165646_27_T0	PHENOTYPE	5	6	duodenal ulcer
NCT0016564629	NCT00165646_29_T0	PHENOTYPE	2	3	acute gastritis
NCT0016564638	NCT00165646_38_T0	GENE	3	4	proton pump
NCT0016564639	NCT00165646_39_T0	COMPOUND	12	12	aspirin
NCT0016564641	NCT00165646_41_T0	PHENOTYPE	20	20	acute
NCT0016564641	NCT00165646_41_T1	PHENOTYPE	4	4	complication
NCT0016564641	NCT00165646_41_T2	PHENOTYPE	28	28	cirrhosis
NCT0016564641	NCT00165646_41_T3	PHENOTYPE	12	13	hematological disorder
NCT0016564641	NCT00165646_41_T4	PHENOTYPE	7	8	cardiovascular disease
NCT0016564641	NCT00165646_41_T5	PHENOTYPE	10	11	myocardial infarction
NCT0016564641	NCT00165646_41_T6	PHENOTYPE	17	18	renal disease
NCT0016564641	NCT00165646_41_T7	PHENOTYPE	15	16	aplastic anemia
NCT0016564641	NCT00165646_41_T8	PHENOTYPE	25	26	hepatic disease
NCT0016564641	NCT00165646_41_T9	PHENOTYPE	22	24	chronic renal failure
NCT001656596	NCT00165659_6_T0	PHENOTYPE	10	10	infarcts
NCT001656596	NCT00165659_6_T1	PHENOTYPE	20	20	dementia
NCT001656596	NCT00165659_6_T2	PHENOTYPE	22	22	dementia
NCT001656596	NCT00165659_6_T3	PHENOTYPE	6	7	cerebral lesion
NCT001656722	NCT00165672_2_T0	GENE	5	5	For
NCT001656723	NCT00165672_3_T0	PHENOTYPE	3	3	heartburn
NCT001656724	NCT00165672_4_T0	PHENOTYPE	16	16	heartburn
NCT001656726	NCT00165672_6_T0	PHENOTYPE	13	14	burning sensation
NCT001656727	NCT00165672_7_T0	PHENOTYPE	13	13	bending
NCT001656727	NCT00165672_7_T1	ORGAN	22	22	abdomen
NCT001656727	NCT00165672_7_T2	BIOLOGICAL_PROCESS	11	11	eating
NCT001656729	NCT00165672_9_T0	PHENOTYPE	20	21	Reflux Esophagitis
NCT0016567213	NCT00165672_13_T0	GENE	19	19	For
NCT0016567214	NCT00165672_14_T0	PHENOTYPE	3	3	heartburn
NCT0016567216	NCT00165672_16_T0	PHENOTYPE	2	2	heartburn
NCT0016567217	NCT00165672_17_T0	PHENOTYPE	12	12	heartburn
NCT0016567221	NCT00165672_21_T0	GENE	17	17	pH
NCT0016567225	NCT00165672_25_T0	PHENOTYPE	8	8	heartburn
NCT0016567227	NCT00165672_27_T0	PHENOTYPE	9	10	abdominal bloating
NCT0016567229	NCT00165672_29_T0	PHENOTYPE	4	4	complication
NCT0016567229	NCT00165672_29_T1	PHENOTYPE	10	11	psychosomatic disease
NCT0016567229	NCT00165672_29_T2	PHENOTYPE	13	14	manic-depressive psychosis
NCT0016567229	NCT00165672_29_T3	PHENOTYPE	15	16	obsessive-compulsive neurosis
NCT0016567233	NCT00165672_33_T0	PHENOTYPE	5	6	duodenal ulcer
NCT0016567235	NCT00165672_35_T0	PHENOTYPE	2	3	acute gastritis
NCT0016567244	NCT00165672_44_T0	GENE	3	4	proton pump
NCT0016567245	NCT00165672_45_T0	COMPOUND	16	16	aspirin
NCT0016567247	NCT00165672_47_T0	PHENOTYPE	20	20	acute
NCT0016567247	NCT00165672_47_T1	PHENOTYPE	4	4	complication
NCT0016567247	NCT00165672_47_T2	PHENOTYPE	28	28	cirrhosis
NCT0016567247	NCT00165672_47_T3	PHENOTYPE	12	13	hematological disorder
NCT0016567247	NCT00165672_47_T4	PHENOTYPE	7	8	cardiovascular disease
NCT0016567247	NCT00165672_47_T5	PHENOTYPE	9	10	myocardial infarction
NCT0016567247	NCT00165672_47_T6	PHENOTYPE	17	18	renal disease
NCT0016567247	NCT00165672_47_T7	PHENOTYPE	15	16	aplastic anemia
NCT0016567247	NCT00165672_47_T8	PHENOTYPE	25	26	hepatic disease
NCT0016567247	NCT00165672_47_T9	PHENOTYPE	22	24	chronic renal failure
NCT001656851	NCT00165685_1_T0	PHENOTYPE	51	51	secondary
NCT001656851	NCT00165685_1_T1	GENE	48	48	TG
NCT001656851	NCT00165685_1_T2	GENE	44	44	abdominal
NCT001656851	NCT00165685_1_T3	COMPOUND	32	32	BMI
NCT001656851	NCT00165685_1_T4	PHENOTYPE	30	31	weight reduction
NCT001656851	NCT00165685_1_T5	TISSUE	38	39	subcutaneous fat
NCT001656851	NCT00165685_1_T6	TISSUE	35	36	visceral fat
NCT001657240	NCT00165724_0_T0	GENE	5	5	ALF
NCT001657240	NCT00165724_0_T1	PHENOTYPE	0	1	Alzheimer's Disease
NCT001657372	NCT00165737_2_T0	PHENOTYPE	22	22	dementia
NCT001657372	NCT00165737_2_T1	GENE	4	4	40
NCT001657372	NCT00165737_2_T2	GENE	10	10	Probable
NCT001657372	NCT00165737_2_T3	PHENOTYPE	11	11	Dementia
NCT001657372	NCT00165737_2_T4	PHENOTYPE	14	15	cerebrovascular disease
NCT001657374	NCT00165737_4_T0	PHENOTYPE	3	4	cerebrovascular disease
NCT001657377	NCT00165737_7_T0	COMPOUND	4	4	1
NCT001657377	NCT00165737_7_T1	PHENOTYPE	7	7	menopausal
NCT001657377	NCT00165737_7_T2	ORGAN	19	19	serum
NCT0016573714	NCT00165737_14_T0	PHENOTYPE	0	2	Peripheral vascular disease
NCT0016573715	NCT00165737_15_T0	GENE	15	15	bypass
NCT0016573715	NCT00165737_15_T1	GENE	20	20	bypass
NCT0016573715	NCT00165737_15_T2	ORGAN	18	19	coronary artery
NCT0016573719	NCT00165737_19_T0	ORGAN	12	12	plasma
NCT0016573719	NCT00165737_19_T1	PHENOTYPE	13	14	glucose concentration
NCT0016573721	NCT00165737_21_T0	GENE	17	17	has
NCT0016573724	NCT00165737_24_T0	COMPOUND	15	15	memantine
NCT0016573724	NCT00165737_24_T1	GENE	7	7	cholinesterase
NCT0016573726	NCT00165737_26_T0	PHENOTYPE	2	3	thyroid disease
NCT001657506	NCT00165750_6_T0	GENE	0	0	Probable
NCT001657506	NCT00165750_6_T1	PHENOTYPE	3	4	Alzheimer's Disease
NCT001657508	NCT00165750_8_T0	GENE	4	4	CDR
NCT001657508	NCT00165750_8_T1	GENE	6	6	1.2
NCT0016575010	NCT00165750_10_T0	GENE	3	3	acetylcholinesterase
NCT0016575012	NCT00165750_12_T0	PHENOTYPE	16	16	hypertension
NCT0016575014	NCT00165750_14_T0	COMPOUND	2	2	donepezil
NCT0016575014	NCT00165750_14_T1	PHENOTYPE	5	6	adverse events
NCT0016575016	NCT00165750_16_T0	COMPOUND	5	5	donepezil
NCT001657633	NCT00165763_3_T0	GENE	14	14	AD
NCT001657633	NCT00165763_3_T1	PHENOTYPE	12	13	Alzheimer's disease
NCT001657634	NCT00165763_4_T0	GENE	10	10	AD
NCT001657634	NCT00165763_4_T1	GENE	0	0	Cholinesterase
NCT001657635	NCT00165763_5_T0	GENE	8	8	cholinesterase
NCT001657635	NCT00165763_5_T1	COMPOUND	6	6	donepezil
NCT001657636	NCT00165763_6_T0	PHENOTYPE	0	1	Adverse events
NCT001657638	NCT00165763_8_T0	GENE	15	15	MRI
NCT001657638	NCT00165763_8_T1	PHENOTYPE	20	21	cerebrovascular disease
NCT001657639	NCT00165763_9_T0	GENE	3	3	has
NCT0016576315	NCT00165763_15_T0	GENE	25	25	cholinesterase
NCT0016576315	NCT00165763_15_T1	PHENOTYPE	14	14	diseases
NCT0016576315	NCT00165763_15_T2	PHENOTYPE	18	21	alcohol or drug abuse
NCT001657760	NCT00165776_0_T0	PHENOTYPE	12	13	Spasmodic Torticollis
NCT001657763	NCT00165776_3_T0	PHENOTYPE	19	20	adverse events
NCT001657763	NCT00165776_3_T1	PHENOTYPE	21	23	adverse drug reactions
NCT001657890	NCT00165789_0_T0	PHENOTYPE	30	30	Fluctuations
NCT001657890	NCT00165789_0_T1	PHENOTYPE	22	23	Parkinson's Disease
NCT001658020	NCT00165802_0_T0	PHENOTYPE	20	21	Solid Tumors
NCT001658027	NCT00165802_7_T0	GENE	10	10	has
NCT001658027	NCT00165802_7_T1	PHENOTYPE	7	8	solid tumor
NCT0016580211	NCT00165802_11_T0	PHENOTYPE	4	4	Oncology
NCT0016580215	NCT00165802_15_T0	COMPOUND	8	8	creatinine
NCT0016580215	NCT00165802_15_T1	COMPOUND	13	13	creatinine
NCT0016580215	NCT00165802_15_T2	GENE	10	10	1.5
NCT0016580215	NCT00165802_15_T3	ORGAN	7	7	serum
NCT0016580217	NCT00165802_17_T0	CELL	9	9	neutrophil
NCT0016580217	NCT00165802_17_T1	GENE	13	13	hemoglobin
NCT0016580217	NCT00165802_17_T2	ORGAN	2	3	bone marrow
NCT0016580217	NCT00165802_17_T3	PHENOTYPE	22	23	platelet count
NCT0016580224	NCT00165802_24_T0	GENE	13	13	1.11
NCT0016580224	NCT00165802_24_T1	GENE	10	10	PK
NCT0016580232	NCT00165802_32_T0	PHENOTYPE	29	29	toxic
NCT0016580232	NCT00165802_32_T1	PHENOTYPE	40	40	alopecia
NCT0016580232	NCT00165802_32_T2	ORGAN	20	21	bone marrow
NCT0016580233	NCT00165802_33_T0	GENE	17	17	has
NCT0016580233	NCT00165802_33_T1	PHENOTYPE	15	16	tumor progression
NCT0016580233	NCT00165802_33_T2	PHENOTYPE	11	12	measurable disease
NCT0016580235	NCT00165802_35_T0	GENE	3	3	had
NCT0016580241	NCT00165802_41_T0	PHENOTYPE	7	9	positive pregnancy test
NCT0016580246	NCT00165802_46_T0	PHENOTYPE	12	12	HIV
NCT0016580246	NCT00165802_46_T1	PHENOTYPE	10	10	Immunodeficiency
NCT0016580246	NCT00165802_46_T2	PHENOTYPE	16	17	hepatitis B
NCT0016580246	NCT00165802_46_T3	PHENOTYPE	20	21	hepatitis C
NCT0016580249	NCT00165802_49_T0	ORGAN	5	5	allografts
NCT0016580250	NCT00165802_50_T0	PHENOTYPE	35	35	toxicity
NCT0016580250	NCT00165802_50_T1	GENE	10	10	hormone
NCT0016580250	NCT00165802_50_T2	PHENOTYPE	42	43	Grade 1
NCT0016580253	NCT00165802_53_T0	PHENOTYPE	6	6	disorders
NCT0016580253	NCT00165802_53_T1	PHENOTYPE	4	4	diseases
NCT001658152	NCT00165815_2_T0	GENE	14	14	AD
NCT001658152	NCT00165815_2_T1	PHENOTYPE	12	12	DLB
NCT001658281	NCT00165828_1_T0	COMPOUND	22	22	zonisamide
NCT001658282	NCT00165828_2_T0	COMPOUND	9	9	zonisamide
NCT001658282	NCT00165828_2_T1	COMPOUND	16	16	zonisamide
NCT001658410	NCT00165841_0_T0	PHENOTYPE	5	5	GERD
NCT001658418	NCT00165841_8_T0	PHENOTYPE	9	9	symptoms
NCT001658418	NCT00165841_8_T1	PHENOTYPE	8	8	GERD
NCT001658419	NCT00165841_9_T0	PHENOTYPE	1	1	symptoms
NCT001658419	NCT00165841_9_T1	PHENOTYPE	14	14	symptoms
NCT001658419	NCT00165841_9_T2	PHENOTYPE	0	0	GERD
NCT001658419	NCT00165841_9_T3	PHENOTYPE	13	13	GERD
NCT001658419	NCT00165841_9_T4	PHENOTYPE	9	9	regurgitation
NCT001658419	NCT00165841_9_T5	PHENOTYPE	5	5	heartburn
NCT0016584113	NCT00165841_13_T0	PHENOTYPE	4	4	esophagitis
NCT0016584113	NCT00165841_13_T1	GENE	14	14	H2
NCT0016584113	NCT00165841_13_T2	GENE	13	13	OTC
NCT0016584113	NCT00165841_13_T3	GENE	18	18	OTC
NCT0016584113	NCT00165841_13_T4	GENE	7	8	proton pump
NCT0016584115	NCT00165841_15_T0	PHENOTYPE	24	24	severity
NCT0016584115	NCT00165841_15_T1	ORGAN	11	12	cardiovascular system
NCT0016584117	NCT00165841_17_T0	GENE	11	11	eta
NCT0016584117	NCT00165841_17_T1	COMPOUND	13	14	chorionic gonadotropin
NCT0016584117	NCT00165841_17_T2	PHENOTYPE	16	17	laboratory result
NCT0016584119	NCT00165841_19_T0	PHENOTYPE	5	5	allergy
NCT0016584119	NCT00165841_19_T1	GENE	9	10	proton pump
NCT0016584121	NCT00165841_21_T0	PHENOTYPE	19	19	obstruction
NCT0016584121	NCT00165841_21_T1	PHENOTYPE	24	24	malignancy
NCT0016584121	NCT00165841_21_T2	PHENOTYPE	17	18	malabsorption syndromes
NCT0016584121	NCT00165841_21_T3	PHENOTYPE	5	6	duodenal ulcer
NCT0016584121	NCT00165841_21_T4	PHENOTYPE	3	4	gastric ulcer
NCT0016584121	NCT00165841_21_T5	ORGAN	15	16	large intestine
NCT0016584125	NCT00165841_25_T0	PHENOTYPE	6	6	esophagitis
NCT0016584127	NCT00165841_27_T0	GENE	11	11	H2
NCT0016584127	NCT00165841_27_T1	GENE	10	10	OTC
NCT0016584127	NCT00165841_27_T2	GENE	15	15	OTC
NCT0016584127	NCT00165841_27_T3	GENE	4	5	proton pump
NCT001658544	NCT00165854_4_T0	COMPOUND	4	4	irinotecan
NCT001658544	NCT00165854_4_T1	COMPOUND	6	6	oxaliplatin
NCT001658544	NCT00165854_4_T2	GENE	2	2	FU
NCT001658544	NCT00165854_4_T3	PHENOTYPE	20	21	metastatic disease
NCT001658670	NCT00165867_0_T0	GENE	4	4	II
NCT001658670	NCT00165867_0_T1	PHENOTYPE	15	17	Metastatic Colorectal Cancer
NCT001658675	NCT00165867_5_T0	PHENOTYPE	5	5	symptoms
NCT001658675	NCT00165867_5_T1	PHENOTYPE	7	8	brain metastases
NCT001658675	NCT00165867_5_T2	PHENOTYPE	19	20	brain metastases
NCT001658678	NCT00165867_8_T0	PHENOTYPE	5	6	conjugated hyperbilirubinemia
NCT001658800	NCT00165880_0_T0	GENE	4	4	II
NCT001658804	NCT00165880_4_T0	PHENOTYPE	5	5	symptoms
NCT001658804	NCT00165880_4_T1	PHENOTYPE	7	8	brain metastases
NCT001658804	NCT00165880_4_T2	PHENOTYPE	19	20	brain metastases
NCT001659061	NCT00165906_1_T0	GENE	12	12	clot
NCT001659062	NCT00165906_2_T0	COMPOUND	8	8	heparin
NCT001659063	NCT00165906_3_T0	GENE	5	5	clot
NCT001659064	NCT00165906_4_T0	GENE	8	8	thrombin
NCT001659066	NCT00165906_6_T0	GENE	12	12	thrombin
NCT001659066	NCT00165906_6_T1	GENE	2	2	has
NCT001659067	NCT00165906_7_T0	GENE	13	13	TGC
NCT001659067	NCT00165906_7_T1	GENE	5	5	thrombin
NCT001659067	NCT00165906_7_T2	GENE	10	10	thrombin
NCT001659068	NCT00165906_8_T0	COMPOUND	13	13	heparin
NCT001659069	NCT00165906_9_T0	GENE	6	6	TGC
NCT0016590611	NCT00165906_11_T0	GENE	16	16	cc
NCT0016590611	NCT00165906_11_T1	GENE	23	23	1.2
NCT0016590612	NCT00165906_12_T0	GENE	14	14	IV
NCT0016590616	NCT00165906_16_T0	GENE	16	16	prothrombin
NCT0016590618	NCT00165906_18_T0	GENE	30	30	thrombin
NCT0016590618	NCT00165906_18_T1	GENE	4	4	prothrombin
NCT0016590618	NCT00165906_18_T2	PHENOTYPE	21	22	prothrombin level
NCT0016590620	NCT00165906_20_T0	GENE	2	2	prothrombin
NCT0016590623	NCT00165906_23_T0	GENE	14	14	thrombin
NCT0016590623	NCT00165906_23_T1	PHENOTYPE	21	21	anticoagulation
NCT0016590623	NCT00165906_23_T2	GENE	2	2	prothrombin
NCT0016590623	NCT00165906_23_T3	COMPOUND	28	28	heparin
NCT0016590623	NCT00165906_23_T4	GENE	23	23	CPB
NCT0016590623	NCT00165906_23_T5	PHENOTYPE	17	19	congenital heart disease
NCT0016590624	NCT00165906_24_T0	GENE	13	13	thrombin
NCT0016590625	NCT00165906_25_T0	COMPOUND	3	3	heparin
NCT0016590625	NCT00165906_25_T1	GENE	8	8	thrombin
NCT0016590625	NCT00165906_25_T2	GENE	17	17	CPB
NCT0016590626	NCT00165906_26_T0	GENE	21	21	thrombin
NCT0016590626	NCT00165906_26_T1	PHENOTYPE	6	8	congenital heart disease
NCT0016590628	NCT00165906_28_T0	COMPOUND	18	18	heparin
NCT0016590628	NCT00165906_28_T1	GENE	1	1	thrombin
NCT0016590628	NCT00165906_28_T2	GENE	26	26	CPB
NCT0016590628	NCT00165906_28_T3	PHENOTYPE	24	24	anticoagulation
NCT0016590629	NCT00165906_29_T0	GENE	8	8	thrombin
NCT0016590629	NCT00165906_29_T1	GENE	2	2	has
NCT0016590629	NCT00165906_29_T2	ORGAN	12	12	plasma
NCT0016590631	NCT00165906_31_T0	GENE	9	9	TGC
NCT0016590632	NCT00165906_32_T0	GENE	27	27	thrombin
NCT0016590632	NCT00165906_32_T1	PHENOTYPE	9	11	congenital heart disease
NCT0016590634	NCT00165906_34_T0	GENE	16	16	OR
NCT001659191	NCT00165919_1_T0	BIOLOGICAL_PROCESS	2	3	immune response
NCT001659191	NCT00165919_1_T1	PHENOTYPE	5	6	hepatitis C
NCT001659192	NCT00165919_2_T0	PHENOTYPE	4	4	HIV
NCT001659192	NCT00165919_2_T1	PHENOTYPE	16	16	immunity
NCT001659192	NCT00165919_2_T2	PHENOTYPE	14	15	hepatitis C
NCT001659198	NCT00165919_8_T0	PHENOTYPE	4	5	hepatitis C
NCT001659199	NCT00165919_9_T0	PHENOTYPE	6	7	hepatitis C
NCT001659199	NCT00165919_9_T1	ORGAN	13	14	immune system
NCT0016591910	NCT00165919_10_T0	PHENOTYPE	15	15	HIV
NCT0016591910	NCT00165919_10_T1	BIOLOGICAL_PROCESS	11	12	immune response
NCT0016591910	NCT00165919_10_T2	PHENOTYPE	9	10	hepatitis C
NCT0016591910	NCT00165919_10_T3	PHENOTYPE	4	5	HIV positive
NCT0016591911	NCT00165919_11_T0	PHENOTYPE	6	6	HIV
NCT0016591911	NCT00165919_11_T1	PHENOTYPE	3	4	hepatitis C
NCT0016591913	NCT00165919_13_T0	PHENOTYPE	10	10	HIV
NCT0016591913	NCT00165919_13_T1	PHENOTYPE	3	4	hepatitis C
NCT0016591914	NCT00165919_14_T0	ORGAN	3	3	liver
NCT0016591914	NCT00165919_14_T1	ORGAN	32	32	liver
NCT0016591914	NCT00165919_14_T2	PHENOTYPE	11	11	hepatitis
NCT0016591914	NCT00165919_14_T3	BIOLOGICAL_PROCESS	22	23	immune response
NCT001659323	NCT00165932_3_T0	GENE	17	17	radar
NCT001659323	NCT00165932_3_T1	GENE	6	6	TDI
NCT001659323	NCT00165932_3_T2	ORGAN	14	14	heart
NCT001659327	NCT00165932_7_T0	ORGAN	7	7	heart
NCT001659328	NCT00165932_8_T0	ORGAN	11	11	heart
NCT001659329	NCT00165932_9_T0	ORGAN	26	26	heart
NCT001659329	NCT00165932_9_T1	ORGAN	35	35	heart
NCT0016593212	NCT00165932_12_T0	PHENOTYPE	32	32	acute
NCT0016593212	NCT00165932_12_T1	PHENOTYPE	55	55	chronic
NCT0016593212	NCT00165932_12_T2	GENE	60	60	ventricular
NCT0016593212	NCT00165932_12_T3	GENE	63	63	ventricular
NCT0016593212	NCT00165932_12_T4	PHENOTYPE	50	52	congenital heart defects
NCT0016593213	NCT00165932_13_T0	GENE	17	17	TDI
NCT0016593213	NCT00165932_13_T1	GENE	19	19	has
NCT0016593213	NCT00165932_13_T2	ORGAN	39	40	right ventricles
NCT0016593216	NCT00165932_16_T0	ORGAN	12	12	heart
NCT0016593218	NCT00165932_18_T0	TISSUE	18	18	myocardium
NCT0016593224	NCT00165932_24_T0	GENE	13	13	bypass
NCT0016593224	NCT00165932_24_T1	GENE	5	5	AV
NCT0016593224	NCT00165932_24_T2	ORGAN	16	17	AV node
NCT0016593225	NCT00165932_25_T0	GENE	11	11	midline
NCT0016593225	NCT00165932_25_T1	GENE	12	12	ventricular
NCT0016593226	NCT00165932_26_T0	PHENOTYPE	26	26	SVT
NCT0016593226	NCT00165932_26_T1	PHENOTYPE	32	32	EPS
NCT0016593226	NCT00165932_26_T2	PHENOTYPE	7	7	chronic
NCT0016593226	NCT00165932_26_T3	GENE	8	8	ventricular
NCT0016593226	NCT00165932_26_T4	PHENOTYPE	23	23	WPW
NCT0016593227	NCT00165932_27_T0	GENE	15	15	midline
NCT0016593227	NCT00165932_27_T1	ORGAN	10	11	AV node
NCT0016593228	NCT00165932_28_T0	PHENOTYPE	9	9	SVT
NCT0016593228	NCT00165932_28_T1	PHENOTYPE	18	18	WPW
NCT0016593228	NCT00165932_28_T2	PHENOTYPE	14	15	ventricular preexcitation
NCT0016593230	NCT00165932_30_T0	PHENOTYPE	9	9	SVT
NCT0016593230	NCT00165932_30_T1	PHENOTYPE	13	13	EPS
NCT0016593231	NCT00165932_31_T0	PHENOTYPE	5	5	EPS
NCT0016593231	NCT00165932_31_T1	GENE	12	12	ventricular
NCT0016593232	NCT00165932_32_T0	GENE	5	5	ventricular
NCT001659451	NCT00165945_1_T0	PHENOTYPE	3	3	hoping
NCT001659451	NCT00165945_1_T1	PHENOTYPE	12	14	congenital heart disease
NCT001659453	NCT00165945_3_T0	PHENOTYPE	22	22	Visualization
NCT001659453	NCT00165945_3_T1	GENE	9	9	SGI
NCT001659453	NCT00165945_3_T2	GENE	1	1	MRI
NCT001659455	NCT00165945_5_T0	GENE	17	17	MRI
NCT001659583	NCT00165958_3_T0	PHENOTYPE	16	16	recurrence
NCT001659587	NCT00165958_7_T0	PHENOTYPE	16	16	recurrence
NCT001659711	NCT00165971_1_T0	PHENOTYPE	2	2	unconscious
NCT001659712	NCT00165971_2_T0	GENE	9	9	BIS
NCT001659716	NCT00165971_6_T0	GENE	8	8	BIS
NCT001659717	NCT00165971_7_T0	GENE	4	4	BIS
NCT001659717	NCT00165971_7_T1	PHENOTYPE	7	7	anesthesia
NCT001659719	NCT00165971_9_T0	GENE	9	9	BIS
NCT0016597112	NCT00165971_12_T0	GENE	4	4	BIS
NCT0016597114	NCT00165971_14_T0	GENE	18	18	BIS
NCT0016597114	NCT00165971_14_T1	PHENOTYPE	7	7	electroencephalogram
NCT0016597114	NCT00165971_14_T2	PHENOTYPE	5	6	brain activity
NCT0016597115	NCT00165971_15_T0	PHENOTYPE	12	12	suppression
NCT0016597115	NCT00165971_15_T1	GENE	0	0	BIS
NCT0016597115	NCT00165971_15_T2	PHENOTYPE	23	23	anesthesia
NCT0016597116	NCT00165971_16_T0	GENE	7	7	BIS
NCT0016597116	NCT00165971_16_T1	PHENOTYPE	14	14	anesthesia
NCT0016597116	NCT00165971_16_T2	PHENOTYPE	18	19	drug use
NCT0016597118	NCT00165971_18_T0	GENE	17	17	BIS
NCT0016597118	NCT00165971_18_T1	PHENOTYPE	13	13	anesthesia
NCT0016597119	NCT00165971_19_T0	GENE	0	0	BIS
NCT0016597120	NCT00165971_20_T0	GENE	6	6	BIS
NCT0016597121	NCT00165971_21_T0	GENE	18	18	BIS
NCT0016597121	NCT00165971_21_T1	PHENOTYPE	16	16	anesthesia
NCT0016597123	NCT00165971_23_T0	GENE	14	14	TNF-a
NCT0016597125	NCT00165971_25_T0	GENE	1	1	BIS
NCT0016597127	NCT00165971_27_T0	GENE	4	4	BIS
NCT001659849	NCT00165984_9_T0	PHENOTYPE	10	10	malformation
NCT001659849	NCT00165984_9_T1	PHENOTYPE	3	4	single ventricle
NCT0016598413	NCT00165984_13_T0	PHENOTYPE	24	24	circulation
NCT0016598413	NCT00165984_13_T1	PHENOTYPE	28	28	circulation
NCT0016598416	NCT00165984_16_T0	PHENOTYPE	9	10	single ventricle
NCT0016598416	NCT00165984_16_T1	PHENOTYPE	1	2	ventricular dysfunction
NCT0016598416	NCT00165984_16_T2	PHENOTYPE	21	22	myocardial ischemia
NCT0016598416	NCT00165984_16_T3	PHENOTYPE	24	26	ventricular outflow obstruction
NCT0016598417	NCT00165984_17_T0	PHENOTYPE	12	13	single ventricle
NCT0016598418	NCT00165984_18_T0	GENE	12	12	has
NCT0016598418	NCT00165984_18_T1	PHENOTYPE	30	31	single ventricle
NCT0016598419	NCT00165984_19_T0	GENE	7	7	has
NCT0016598419	NCT00165984_19_T1	PHENOTYPE	15	16	cardiovascular disease
NCT0016598420	NCT00165984_20_T0	GENE	6	6	RAS
NCT0016598421	NCT00165984_21_T0	GENE	24	24	ACE
NCT0016598421	NCT00165984_21_T1	GENE	6	6	RAS
NCT0016598421	NCT00165984_21_T2	GENE	20	20	renin
NCT0016598421	NCT00165984_21_T3	GENE	17	17	angiotensinogen
NCT0016598421	NCT00165984_21_T4	GENE	18	18	AGT
NCT0016598421	NCT00165984_21_T5	GENE	22	23	angiotensin-converting enzyme
NCT0016598422	NCT00165984_22_T0	PHENOTYPE	17	18	cardiovascular disorders
NCT0016598423	NCT00165984_23_T0	GENE	3	3	AGT
NCT0016598423	NCT00165984_23_T1	PHENOTYPE	9	10	essential hypertension
NCT0016598423	NCT00165984_23_T2	PHENOTYPE	28	30	idiopathic dilated cardiomyopathy
NCT0016598424	NCT00165984_24_T0	GENE	4	4	ACE
NCT0016598424	NCT00165984_24_T1	PHENOTYPE	13	13	deletion
NCT0016598424	NCT00165984_24_T2	GENE	15	15	has
NCT0016598427	NCT00165984_27_T0	GENE	21	21	receptor
NCT0016598427	NCT00165984_27_T1	GENE	8	8	has
NCT0016598427	NCT00165984_27_T2	GENE	5	5	ventricular
NCT0016598428	NCT00165984_28_T0	COMPOUND	12	12	norepinephrine
NCT0016598428	NCT00165984_28_T1	GENE	6	6	receptor
NCT0016598428	NCT00165984_28_T2	COMPOUND	10	10	epinephrine
NCT0016598429	NCT00165984_29_T0	PHENOTYPE	26	27	idiopathic cardiomyopathy
NCT0016598429	NCT00165984_29_T1	PHENOTYPE	14	16	congestive heart failure
NCT0016598432	NCT00165984_32_T0	GENE	11	11	eNOS
NCT0016598432	NCT00165984_32_T1	GENE	7	10	endothelial nitric oxide synthase
NCT0016598434	NCT00165984_34_T0	GENE	7	7	preproendothelin-1
NCT0016598434	NCT00165984_34_T1	GENE	11	11	has
NCT0016598434	NCT00165984_34_T2	ORGAN	20	21	mammary arteries
NCT0016598435	NCT00165984_35_T0	PHENOTYPE	8	8	overweight
NCT0016598435	NCT00165984_35_T1	PHENOTYPE	6	6	hypertension
NCT0016598437	NCT00165984_37_T0	PHENOTYPE	26	27	single ventricle
NCT001659971	NCT00165997_1_T0	PHENOTYPE	0	2	Quality of life
NCT001659973	NCT00165997_3_T0	PHENOTYPE	16	18	quality of life
NCT001659978	NCT00165997_8_T0	GENE	19	19	4.0
NCT001659978	NCT00165997_8_T1	GENE	12	12	tm
NCT001659978	NCT00165997_8_T2	PHENOTYPE	14	16	Quality of Life
NCT001660104	NCT00166010_4_T0	PHENOTYPE	9	11	congestive heart failure
NCT001660105	NCT00166010_5_T0	GENE	14	14	has
NCT001660105	NCT00166010_5_T1	PHENOTYPE	12	13	heart failure
NCT001660107	NCT00166010_7_T0	PHENOTYPE	16	17	heart failure
NCT001660108	NCT00166010_8_T0	PHENOTYPE	8	9	laboratory results
NCT001660109	NCT00166010_9_T0	GENE	8	8	BNP
NCT001660109	NCT00166010_9_T1	GENE	5	7	B-type natriuretic peptide
NCT0016601010	NCT00166010_10_T0	GENE	4	4	has
NCT0016601010	NCT00166010_10_T1	GENE	7	7	IV
NCT0016601010	NCT00166010_10_T2	GENE	17	17	IV
NCT0016601011	NCT00166010_11_T0	GENE	7	7	IV
NCT0016601019	NCT00166010_19_T0	GENE	7	7	has
NCT0016601020	NCT00166010_20_T0	GENE	7	7	BNP
NCT0016601020	NCT00166010_20_T1	GENE	23	23	BNP
NCT0016601020	NCT00166010_20_T2	GENE	4	6	B-type natriuretic peptide
NCT0016601021	NCT00166010_21_T0	GENE	0	0	BNP
NCT0016601021	NCT00166010_21_T1	GENE	3	3	secreted
NCT0016601021	NCT00166010_21_T2	ORGAN	6	7	cardiac ventricles
NCT0016601023	NCT00166010_23_T0	COMPOUND	51	51	norepinephrine
NCT0016601023	NCT00166010_23_T1	PHENOTYPE	12	12	dilation
NCT0016601023	NCT00166010_23_T2	ORGAN	25	25	capillary
NCT0016601023	NCT00166010_23_T3	COMPOUND	49	49	aldosterone
NCT0016601023	NCT00166010_23_T4	ORGAN	48	48	plasma
NCT0016601023	NCT00166010_23_T5	PHENOTYPE	26	27	wedge pressure
NCT0016601023	NCT00166010_23_T6	PHENOTYPE	32	34	systemic vascular resistance
NCT0016601024	NCT00166010_24_T0	PHENOTYPE	10	12	increased urine output
NCT0016601025	NCT00166010_25_T0	PHENOTYPE	10	10	pharmacokinetics
NCT0016601027	NCT00166010_27_T0	PHENOTYPE	13	14	heart failure
NCT0016601029	NCT00166010_29_T0	PHENOTYPE	17	17	pharmacokinetics
NCT001660230	NCT00166023_0_T0	PHENOTYPE	7	7	Endocarditis
NCT001660232	NCT00166023_2_T0	PHENOTYPE	27	27	strategies
NCT001660232	NCT00166023_2_T1	PHENOTYPE	11	11	endocarditis
NCT001660364	NCT00166036_4_T0	PHENOTYPE	20	21	heart disease
NCT001660364	NCT00166036_4_T1	PHENOTYPE	11	12	cholesterol levels
NCT001660364	NCT00166036_4_T2	PHENOTYPE	27	28	cholesterol levels
NCT001660365	NCT00166036_5_T0	ORGAN	19	19	heart
NCT001660365	NCT00166036_5_T1	ORGAN	21	22	blood vessels
NCT001660366	NCT00166036_6_T0	GENE	16	16	ROS
NCT001660366	NCT00166036_6_T1	ORGAN	10	10	arteries
NCT001660366	NCT00166036_6_T2	GENE	3	3	reduced
NCT001660366	NCT00166036_6_T3	COMPOUND	14	14	oxygen
NCT001660366	NCT00166036_6_T4	CELL	22	23	stem cells
NCT001660366	NCT00166036_6_T5	CELL	29	31	endothelial progenitor cells
NCT001660367	NCT00166036_7_T0	PHENOTYPE	16	17	heart disease
NCT001660368	NCT00166036_8_T0	COMPOUND	9	10	cholesterol lowering
NCT001660369	NCT00166036_9_T0	COMPOUND	13	13	pravastatin
NCT001660369	NCT00166036_9_T1	COMPOUND	17	17	atorvastatin
NCT001660369	NCT00166036_9_T2	PHENOTYPE	28	29	cholesterol level
NCT001660369	NCT00166036_9_T3	PHENOTYPE	31	32	heart disease
NCT0016603611	NCT00166036_11_T0	GENE	20	20	ROS
NCT0016603614	NCT00166036_14_T0	GENE	12	12	ROS
NCT0016603615	NCT00166036_15_T0	ORGAN	23	23	artery
NCT0016603615	NCT00166036_15_T1	ORGAN	22	22	forearm
NCT0016603615	NCT00166036_15_T2	ORGAN	7	8	blood vessels
NCT0016603616	NCT00166036_16_T0	COMPOUND	16	16	pravastatin
NCT0016603616	NCT00166036_16_T1	COMPOUND	13	13	atorvastatin
NCT0016603616	NCT00166036_16_T2	PHENOTYPE	23	24	cholesterol level
NCT0016603617	NCT00166036_17_T0	COMPOUND	31	31	pravastatin
NCT0016603617	NCT00166036_17_T1	GENE	28	28	ROS
NCT0016603617	NCT00166036_17_T2	COMPOUND	15	15	atorvastatin
NCT001660491	NCT00166049_1_T0	PHENOTYPE	8	9	heart failure
NCT001660496	NCT00166049_6_T0	GENE	1	1	has
NCT001660496	NCT00166049_6_T1	PHENOTYPE	11	12	problem solving
NCT001660621	NCT00166062_1_T0	PHENOTYPE	9	10	adverse events
NCT001660625	NCT00166062_5_T0	PHENOTYPE	5	5	victimization
NCT001660882	NCT00166088_2_T0	PHENOTYPE	25	26	heart disease
NCT001660883	NCT00166088_3_T0	GENE	4	4	has
NCT0016608810	NCT00166088_10_T0	PHENOTYPE	25	26	heart attacks
NCT0016608810	NCT00166088_10_T1	PHENOTYPE	7	8	heart disease
NCT0016608810	NCT00166088_10_T2	PHENOTYPE	13	14	heart disease
NCT0016608810	NCT00166088_10_T3	PHENOTYPE	20	21	heart disease
NCT0016608810	NCT00166088_10_T4	PHENOTYPE	32	33	heart disease
NCT0016608811	NCT00166088_11_T0	PHENOTYPE	16	17	heart disease
NCT0016608811	NCT00166088_11_T1	PHENOTYPE	22	23	heart disease
NCT0016608811	NCT00166088_11_T2	PHENOTYPE	26	27	heart disease
NCT0016608811	NCT00166088_11_T3	PHENOTYPE	32	33	heart disease
NCT0016608812	NCT00166088_12_T0	PHENOTYPE	42	43	heart disease
NCT0016608819	NCT00166088_19_T0	GENE	11	11	grape
NCT0016608819	NCT00166088_19_T1	COMPOUND	5	7	omega_3 fatty acid
NCT0016608821	NCT00166088_21_T0	PHENOTYPE	8	9	heart disease
NCT0016608824	NCT00166088_24_T0	PHENOTYPE	24	24	ingesting
NCT0016608825	NCT00166088_25_T0	ORGAN	15	15	Heart
NCT0016608826	NCT00166088_26_T0	PHENOTYPE	12	12	obesity
NCT001661011	NCT00166101_1_T0	COMPOUND	17	17	oxygen
NCT001661014	NCT00166101_4_T0	PHENOTYPE	8	10	hypoplastic left heart
NCT001661141	NCT00166114_1_T0	COMPOUND	22	22	norepinephrine
NCT001661141	NCT00166114_1_T1	ORGAN	28	28	brains
NCT001661141	NCT00166114_1_T2	PHENOTYPE	14	14	emotions
NCT001661142	NCT00166114_2_T0	PHENOTYPE	13	13	emotions
NCT001661271	NCT00166127_1_T0	COMPOUND	25	25	calcium
NCT001661271	NCT00166127_1_T1	BIOLOGICAL_PROCESS	26	26	sensitization
NCT001661271	NCT00166127_1_T2	ORGAN	30	30	heart
NCT001661271	NCT00166127_1_T3	PHENOTYPE	16	17	heart failure
NCT001661272	NCT00166127_2_T0	GENE	2	2	has
NCT001661272	NCT00166127_2_T1	PHENOTYPE	19	20	heart failure
NCT001661272	NCT00166127_2_T2	ORGAN	7	8	blood vessels
NCT001661275	NCT00166127_5_T0	PHENOTYPE	10	11	heart failure
NCT001661403	NCT00166140_3_T0	GENE	19	19	clot
NCT001661404	NCT00166140_4_T0	COMPOUND	3	3	heparin
NCT001661405	NCT00166140_5_T0	COMPOUND	19	19	heparin
NCT0016614010	NCT00166140_10_T0	GENE	19	19	IV
NCT0016614014	NCT00166140_14_T0	COMPOUND	2	2	heparin
NCT0016614014	NCT00166140_14_T1	PHENOTYPE	9	9	concentrations
NCT0016614014	NCT00166140_14_T2	GENE	8	8	ATIII
NCT0016614015	NCT00166140_15_T0	PHENOTYPE	11	11	concentrations
NCT0016614015	NCT00166140_15_T1	GENE	9	9	ATIII
NCT0016614016	NCT00166140_16_T0	COMPOUND	21	21	heparin
NCT0016614016	NCT00166140_16_T1	GENE	1	1	ATIII
NCT0016614018	NCT00166140_18_T0	COMPOUND	9	9	heparin
NCT0016614018	NCT00166140_18_T1	COMPOUND	25	25	heparin
NCT0016614018	NCT00166140_18_T2	GENE	38	38	CPB
NCT0016614018	NCT00166140_18_T3	GENE	5	5	ATIII
NCT0016614020	NCT00166140_20_T0	GENE	9	9	HCII
NCT0016614021	NCT00166140_21_T0	PHENOTYPE	11	11	concentrations
NCT0016614021	NCT00166140_21_T1	GENE	10	10	has
NCT0016614021	NCT00166140_21_T2	GENE	0	0	Alpha-2-macroglobulin
NCT0016614021	NCT00166140_21_T3	COMPOUND	5	7	inhibitor of thrombin
NCT0016614022	NCT00166140_22_T0	COMPOUND	19	19	heparin
NCT0016614022	NCT00166140_22_T1	GENE	13	13	thrombin
NCT0016614022	NCT00166140_22_T2	GENE	22	22	CPB
NCT0016614022	NCT00166140_22_T3	GENE	3	3	has
NCT0016614024	NCT00166140_24_T0	COMPOUND	11	11	heparin
NCT0016614024	NCT00166140_24_T1	GENE	4	4	half-life
NCT0016614024	NCT00166140_24_T2	GENE	6	6	thrombin
NCT0016614024	NCT00166140_24_T3	GENE	19	19	thrombin
NCT0016614024	NCT00166140_24_T4	GENE	23	23	CPB
NCT0016614024	NCT00166140_24_T5	GENE	13	13	ATIII
NCT0016614026	NCT00166140_26_T0	GENE	24	24	thrombin
NCT0016614026	NCT00166140_26_T1	GENE	8	8	fibrinogen
NCT0016614026	NCT00166140_26_T2	GENE	17	17	FPA
NCT0016614026	NCT00166140_26_T3	COMPOUND	15	16	fibrinopeptide A
NCT0016614027	NCT00166140_27_T0	COMPOUND	9	9	heparin
NCT0016614027	NCT00166140_27_T1	COMPOUND	41	41	heparin
NCT0016614027	NCT00166140_27_T2	COMPOUND	53	53	heparin
NCT0016614027	NCT00166140_27_T3	COMPOUND	58	58	heparin
NCT0016614027	NCT00166140_27_T4	GENE	50	50	ACT
NCT0016614027	NCT00166140_27_T5	GENE	26	26	HCII
NCT0016614027	NCT00166140_27_T6	GENE	25	25	ATIII
NCT0016614028	NCT00166140_28_T0	GENE	30	30	CPB
NCT0016614028	NCT00166140_28_T1	GENE	25	25	FPA
NCT0016614028	NCT00166140_28_T2	GENE	20	20	ATIII
NCT0016614030	NCT00166140_30_T0	COMPOUND	10	10	heparin
NCT0016614030	NCT00166140_30_T1	COMPOUND	25	25	heparin
NCT0016614030	NCT00166140_30_T2	GENE	1	1	bypass
NCT0016614030	NCT00166140_30_T3	GENE	21	21	bypass
NCT0016614030	NCT00166140_30_T4	PHENOTYPE	14	14	initiation
NCT0016614030	NCT00166140_30_T5	PHENOTYPE	8	8	anticoagulation
NCT0016614030	NCT00166140_30_T6	BIOLOGICAL_PROCESS	30	30	hemostasis
NCT0016614031	NCT00166140_31_T0	PHENOTYPE	6	6	hypercoagulability
NCT0016614035	NCT00166140_35_T0	COMPOUND	9	9	heparin
NCT0016614035	NCT00166140_35_T1	GENE	2	2	CPB
NCT0016614035	NCT00166140_35_T2	PHENOTYPE	0	0	Anticoagulation
NCT0016614037	NCT00166140_37_T0	GENE	6	6	ACT
NCT0016614038	NCT00166140_38_T0	COMPOUND	9	9	heparin
NCT0016614038	NCT00166140_38_T1	GENE	2	2	ACT
NCT0016614038	NCT00166140_38_T2	PHENOTYPE	14	14	hypothermia
NCT0016614039	NCT00166140_39_T0	GENE	13	13	CPB
NCT0016614040	NCT00166140_40_T0	PHENOTYPE	12	12	hypothermic
NCT0016614040	NCT00166140_40_T1	PHENOTYPE	24	24	hypothermic
NCT0016614041	NCT00166140_41_T0	COMPOUND	16	16	heparin
NCT0016614041	NCT00166140_41_T1	GENE	1	1	ACT
NCT0016614041	NCT00166140_41_T2	PHENOTYPE	17	17	anticoagulation
NCT0016614045	NCT00166140_45_T0	GENE	6	6	AT
NCT0016614045	NCT00166140_45_T1	GENE	7	7	III
NCT0016614046	NCT00166140_46_T0	GENE	0	0	AT
NCT0016614046	NCT00166140_46_T1	GENE	1	1	III
NCT0016614048	NCT00166140_48_T0	GENE	8	8	AT
NCT0016614048	NCT00166140_48_T1	GENE	9	9	III
NCT0016614049	NCT00166140_49_T0	GENE	22	22	ACT
NCT0016614049	NCT00166140_49_T1	PHENOTYPE	8	8	anticoagulation
NCT0016614053	NCT00166140_53_T0	GENE	10	10	bypass
NCT0016614056	NCT00166140_56_T0	GENE	9	9	CPB
NCT0016614059	NCT00166140_59_T0	GENE	3	3	CPB
NCT0016614060	NCT00166140_60_T0	GENE	5	5	CPB
NCT001661535	NCT00166153_5_T0	GENE	11	11	has
NCT001661535	NCT00166153_5_T1	GENE	19	19	has
NCT0016615314	NCT00166153_14_T0	ORGAN	8	8	transplant
NCT0016615318	NCT00166153_18_T0	PHENOTYPE	13	13	tolerance
NCT001661663	NCT00166166_3_T0	GENE	11	11	bradykinin
NCT001661663	NCT00166166_3_T1	GENE	5	5	receptor
NCT001661663	NCT00166166_3_T2	COMPOUND	9	9	acetylcholine
NCT001661663	NCT00166166_3_T3	CELL	20	22	smooth muscle cells
NCT001661665	NCT00166166_5_T0	PHENOTYPE	13	13	acute
NCT001661665	NCT00166166_5_T1	PHENOTYPE	9	9	dilation
NCT001661665	NCT00166166_5_T2	PHENOTYPE	24	24	dilation
NCT001661922	NCT00166192_2_T0	PHENOTYPE	6	6	peeling
NCT001661922	NCT00166192_2_T1	PHENOTYPE	2	2	peel
NCT001661923	NCT00166192_3_T0	PHENOTYPE	3	3	peel
NCT001661923	NCT00166192_3_T1	PHENOTYPE	7	7	sunburn
NCT001662055	NCT00166205_5_T0	GENE	2	2	has
NCT001662056	NCT00166205_6_T0	GENE	2	2	has
NCT001662183	NCT00166218_3_T0	ORGAN	8	8	lungs
NCT001662183	NCT00166218_3_T1	COMPOUND	11	11	oxygen
NCT001662184	NCT00166218_4_T0	ORGAN	7	7	heart
NCT001662185	NCT00166218_5_T0	ORGAN	5	5	heart
NCT001662186	NCT00166218_6_T0	ORGAN	12	12	lungs
NCT001662189	NCT00166218_9_T0	PHENOTYPE	16	16	pulse
NCT001662189	NCT00166218_9_T1	COMPOUND	27	27	oxygen
NCT0016621810	NCT00166218_10_T0	COMPOUND	27	27	oxygen
NCT0016621811	NCT00166218_11_T0	GENE	2	2	has
NCT0016621813	NCT00166218_13_T0	ORGAN	12	12	forehead
NCT0016621814	NCT00166218_14_T0	ORGAN	24	24	heart
NCT0016621815	NCT00166218_15_T0	ORGAN	20	20	forehead
NCT0016621817	NCT00166218_17_T0	ORGAN	17	17	groin
NCT0016621817	NCT00166218_17_T1	ORGAN	10	11	blood vessel
NCT0016621818	NCT00166218_18_T0	COMPOUND	12	12	oxygen
NCT0016621819	NCT00166218_19_T0	GENE	20	20	IV
NCT0016621820	NCT00166218_20_T0	PHENOTYPE	15	16	lactate level
NCT0016621821	NCT00166218_21_T0	COMPOUND	13	13	oxygen
NCT0016621821	NCT00166218_21_T1	PHENOTYPE	1	2	lactate level
NCT0016621824	NCT00166218_24_T0	ORGAN	8	8	forehead
NCT0016621827	NCT00166218_27_T0	ORGAN	14	14	forehead
NCT0016621830	NCT00166218_30_T0	ORGAN	13	15	superior vena cava
NCT0016621831	NCT00166218_31_T0	PHENOTYPE	19	20	lactate level
NCT0016621836	NCT00166218_36_T0	PHENOTYPE	2	3	single ventricle
NCT0016623114	NCT00166231_14_T0	GENE	11	11	has
NCT0016623115	NCT00166231_15_T0	GENE	15	15	al
NCT0016623115	NCT00166231_15_T1	GENE	14	14	et
NCT0016623117	NCT00166231_17_T0	PHENOTYPE	44	45	somatic symptoms
NCT0016623128	NCT00166231_28_T0	PHENOTYPE	6	7	heart murmur
NCT0016623129	NCT00166231_29_T0	PHENOTYPE	5	5	murmur
NCT001662444	NCT00166244_4_T0	ORGAN	33	33	plasma
NCT001662444	NCT00166244_4_T1	COMPOUND	29	30	mycophenolic acid
NCT001662446	NCT00166244_6_T0	PHENOTYPE	40	40	concentrations
NCT001662446	NCT00166244_6_T1	COMPOUND	38	39	mycophenolic acid
NCT001662446	NCT00166244_6_T2	COMPOUND	13	14	mycophenolate mofetil
NCT001662447	NCT00166244_7_T0	ORGAN	25	25	kidney
NCT001662447	NCT00166244_7_T1	ORGAN	26	26	transplant
NCT001662447	NCT00166244_7_T2	COMPOUND	11	12	mycophenolic acid
NCT001662447	NCT00166244_7_T3	COMPOUND	21	22	mycophenolate mofetil
NCT001662572	NCT00166257_2_T0	ORGAN	11	11	veins
NCT001662572	NCT00166257_2_T1	ORGAN	14	14	legs
NCT001662572	NCT00166257_2_T2	ORGAN	17	17	heart
NCT001662572	NCT00166257_2_T3	PHENOTYPE	5	6	blood clot
NCT001662574	NCT00166257_4_T0	PHENOTYPE	11	11	strategies
NCT001662576	NCT00166257_6_T0	ORGAN	5	5	heart
NCT001662579	NCT00166257_9_T0	ORGAN	29	29	groin
NCT001662579	NCT00166257_9_T1	ORGAN	17	17	heart
NCT001662579	NCT00166257_9_T2	ORGAN	36	36	heart
NCT001662579	NCT00166257_9_T3	ORGAN	25	26	blood vessel
NCT001662579	NCT00166257_9_T4	PHENOTYPE	3	5	patent foramen ovale
NCT001662701	NCT00166270_1_T0	PHENOTYPE	18	18	symptoms
NCT001662701	NCT00166270_1_T1	PHENOTYPE	17	17	fibroid
NCT001662703	NCT00166270_3_T0	PHENOTYPE	19	19	focused
NCT001662705	NCT00166270_5_T0	PHENOTYPE	2	2	fibroids
NCT001662705	NCT00166270_5_T1	ORGAN	11	11	pelvis
NCT001662705	NCT00166270_5_T2	PHENOTYPE	7	7	neoplasms
NCT001662705	NCT00166270_5_T3	PHENOTYPE	0	1	Uterine leiomyoma
NCT001662706	NCT00166270_6_T0	GENE	5	5	oval
NCT001662706	NCT00166270_6_T1	PHENOTYPE	1	2	benign tumors
NCT001662707	NCT00166270_7_T0	GENE	1	1	T2
NCT001662707	NCT00166270_7_T1	PHENOTYPE	11	12	uterine fibroids
NCT001662832	NCT00166283_2_T0	GENE	22	22	MS
NCT001662832	NCT00166283_2_T1	PHENOTYPE	10	11	cognitive deficits
NCT001662834	NCT00166283_4_T0	GENE	32	32	booster
NCT0016628311	NCT00166283_11_T0	GENE	22	22	MS
NCT0016628311	NCT00166283_11_T1	PHENOTYPE	10	11	cognitive deficits
NCT0016628314	NCT00166283_14_T0	PHENOTYPE	23	23	impairment
NCT0016628318	NCT00166283_18_T0	GENE	18	18	MS
NCT0016628318	NCT00166283_18_T1	GENE	2	2	has
NCT0016628320	NCT00166283_20_T0	GENE	20	20	AGF
NCT0016628320	NCT00166283_20_T1	GENE	11	11	NP
NCT0016628325	NCT00166283_25_T0	GENE	30	30	AGF
NCT0016628325	NCT00166283_25_T1	GENE	23	23	NP
NCT0016628325	NCT00166283_25_T2	PHENOTYPE	19	20	cognitive functioning
NCT0016628326	NCT00166283_26_T0	GENE	13	13	booster
NCT0016628327	NCT00166283_27_T0	GENE	8	8	pre
NCT0016628351	NCT00166283_51_T0	GENE	11	11	MS
NCT0016628351	NCT00166283_51_T1	GENE	6	6	has
NCT0016628351	NCT00166283_51_T2	GENE	4	4	booster
NCT0016628352	NCT00166283_52_T0	GENE	15	15	booster
NCT001662962	NCT00166296_2_T0	COMPOUND	5	5	ribavirin
NCT001662963	NCT00166296_3_T0	GENE	6	6	has
NCT001662963	NCT00166296_3_T1	GENE	4	4	interferon
NCT001662963	NCT00166296_3_T2	GENE	16	16	interferon
NCT001662963	NCT00166296_3_T3	PHENOTYPE	13	13	tolerance
NCT001662964	NCT00166296_4_T0	GENE	1	1	has
NCT001662964	NCT00166296_4_T1	PHENOTYPE	13	14	major depression
NCT001662965	NCT00166296_5_T0	PHENOTYPE	2	3	major depression
NCT001662967	NCT00166296_7_T0	PHENOTYPE	20	21	hepatitis C
NCT001662968	NCT00166296_8_T0	COMPOUND	11	11	escitalopram
NCT001662968	NCT00166296_8_T1	PHENOTYPE	22	23	hepatitis C
NCT001662968	NCT00166296_8_T2	PHENOTYPE	21	22	chronic hepatitis
NCT0016629612	NCT00166296_12_T0	GENE	15	15	interferon
NCT001663094	NCT00166309_4_T0	PHENOTYPE	6	6	bleeding
NCT001663095	NCT00166309_5_T0	GENE	8	8	has
NCT001663095	NCT00166309_5_T1	GENE	4	4	prothrombin
NCT001663096	NCT00166309_6_T0	GENE	4	4	VIIa
NCT001663096	NCT00166309_6_T1	GENE	6	6	has
NCT001663486	NCT00166348_6_T0	PHENOTYPE	20	20	strategies
NCT001663487	NCT00166348_7_T0	PHENOTYPE	4	5	problem solving
NCT001663611	NCT00166361_1_T0	PHENOTYPE	9	9	secondary
NCT001663611	NCT00166361_1_T1	PHENOTYPE	16	16	malignancy
NCT001663611	NCT00166361_1_T2	GENE	13	13	abdominal
NCT001663611	NCT00166361_1_T3	PHENOTYPE	7	8	ureteral obstruction
NCT001663614	NCT00166361_4_T0	GENE	13	13	10.5
NCT001663614	NCT00166361_4_T1	PHENOTYPE	19	19	proximal
NCT001663618	NCT00166361_8_T0	ORGAN	14	14	abdomen
NCT001663618	NCT00166361_8_T1	ORGAN	16	16	pelvis
NCT001663618	NCT00166361_8_T2	GENE	44	44	6.5
NCT001663618	NCT00166361_8_T3	PHENOTYPE	7	7	secondary
NCT001663618	NCT00166361_8_T4	GENE	23	23	has
NCT001663618	NCT00166361_8_T5	GENE	37	37	has
NCT001663618	NCT00166361_8_T6	PHENOTYPE	5	6	ureteral obstruction
NCT001663618	NCT00166361_8_T7	PHENOTYPE	20	21	urologic problem
NCT001663618	NCT00166361_8_T8	PHENOTYPE	10	11	neoplastic disease
NCT001663619	NCT00166361_9_T0	PHENOTYPE	2	3	ureteral obstructions
NCT0016636110	NCT00166361_10_T0	PHENOTYPE	7	7	obstruction
NCT0016636110	NCT00166361_10_T1	PHENOTYPE	15	15	anesthesia
NCT0016636111	NCT00166361_11_T0	BIOLOGICAL_PROCESS	19	19	degradation
NCT0016636111	NCT00166361_11_T1	PHENOTYPE	6	6	anesthesia
NCT0016636111	NCT00166361_11_T2	PHENOTYPE	15	16	iatrogenic injury
NCT0016636111	NCT00166361_11_T3	PHENOTYPE	22	24	quality of life
NCT0016636113	NCT00166361_13_T0	PHENOTYPE	30	30	malignancy
NCT0016636113	NCT00166361_13_T1	PHENOTYPE	23	23	secondary
NCT0016636113	NCT00166361_13_T2	PHENOTYPE	32	32	secondary
NCT0016636113	NCT00166361_13_T3	PHENOTYPE	45	45	malignancies
NCT0016636113	NCT00166361_13_T4	GENE	27	27	abdominal
NCT0016636113	NCT00166361_13_T5	GENE	44	44	abdominal
NCT0016636113	NCT00166361_13_T6	PHENOTYPE	21	22	ureteral obstruction
NCT0016636115	NCT00166361_15_T0	PHENOTYPE	16	16	malignancy
NCT0016636115	NCT00166361_15_T1	PHENOTYPE	9	9	secondary
NCT0016636115	NCT00166361_15_T2	PHENOTYPE	18	18	secondary
NCT0016636115	NCT00166361_15_T3	PHENOTYPE	31	31	malignancies
NCT0016636115	NCT00166361_15_T4	GENE	15	15	abdominal
NCT0016636115	NCT00166361_15_T5	GENE	30	30	abdominal
NCT0016636115	NCT00166361_15_T6	PHENOTYPE	7	8	ureteral obstruction
NCT0016636117	NCT00166361_17_T0	PHENOTYPE	12	12	malignancy
NCT0016636117	NCT00166361_17_T1	GENE	31	31	had
NCT0016636117	NCT00166361_17_T2	PHENOTYPE	6	6	secondary
NCT0016636117	NCT00166361_17_T3	PHENOTYPE	15	15	secondary
NCT0016636117	NCT00166361_17_T4	COMPOUND	5	5	1
NCT0016636117	NCT00166361_17_T5	COMPOUND	14	14	2
NCT0016636117	NCT00166361_17_T6	COMPOUND	32	32	2
NCT0016636117	NCT00166361_17_T7	COMPOUND	44	44	2
NCT0016636117	NCT00166361_17_T8	PHENOTYPE	28	28	malignancies
NCT0016636117	NCT00166361_17_T9	GENE	11	11	abdominal
NCT0016636117	NCT00166361_17_T10	GENE	27	27	abdominal
NCT0016636117	NCT00166361_17_T11	PHENOTYPE	3	4	ureteral obstruction
NCT0016636120	NCT00166361_20_T0	PHENOTYPE	8	8	anesthesia
NCT0016636121	NCT00166361_21_T0	PHENOTYPE	2	4	urinary tract infection
NCT0016636123	NCT00166361_23_T0	PHENOTYPE	0	1	Ureteral obstruction
NCT0016636124	NCT00166361_24_T0	PHENOTYPE	1	3	urinary tract abnormality
NCT0016636125	NCT00166361_25_T0	PHENOTYPE	3	4	solitary kidney
NCT001663870	NCT00166387_0_T0	PHENOTYPE	0	0	Hemophilia
NCT001663875	NCT00166387_5_T0	PHENOTYPE	49	49	associations
NCT001663875	NCT00166387_5_T1	GENE	34	34	II
NCT001663875	NCT00166387_5_T2	GENE	55	55	II
NCT001663875	NCT00166387_5_T3	PHENOTYPE	29	29	hemophilia
NCT001663875	NCT00166387_5_T4	PHENOTYPE	43	43	hemophilia
NCT0016638711	NCT00166387_11_T0	GENE	1	1	II
NCT0016638716	NCT00166387_16_T0	GENE	1	1	II
NCT001664000	NCT00166400_0_T0	PHENOTYPE	9	10	Mitral Regurgitation
NCT001664002	NCT00166400_2_T0	PHENOTYPE	5	6	progressive disease
NCT001664002	NCT00166400_2_T1	PHENOTYPE	0	1	Mitral regurgitation
NCT001664002	NCT00166400_2_T2	PHENOTYPE	4	5	slowly progressive
NCT001664003	NCT00166400_3_T0	PHENOTYPE	19	20	disease progression
NCT001664003	NCT00166400_3_T1	PHENOTYPE	17	19	mitral valve disease
NCT001664005	NCT00166400_5_T0	PHENOTYPE	24	24	enlargement
NCT001664005	NCT00166400_5_T1	GENE	7	7	has
NCT001664005	NCT00166400_5_T2	GENE	16	16	ventricular
NCT001664005	NCT00166400_5_T3	PHENOTYPE	20	20	dysfunction
NCT001664007	NCT00166400_7_T0	GENE	9	9	has
NCT001664009	NCT00166400_9_T0	PHENOTYPE	3	3	chronic
NCT0016640013	NCT00166400_13_T0	PHENOTYPE	1	1	Chronic
NCT0016640014	NCT00166400_14_T0	PHENOTYPE	28	28	enlargement
NCT0016640015	NCT00166400_15_T0	GENE	17	17	30
NCT0016640017	NCT00166400_17_T0	PHENOTYPE	6	6	acute
NCT0016640017	NCT00166400_17_T1	PHENOTYPE	10	10	tolerance
NCT0016640018	NCT00166400_18_T0	PHENOTYPE	21	21	proximal
NCT0016640022	NCT00166400_22_T0	PHENOTYPE	21	21	strategies
NCT001664130	NCT00166413_0_T0	PHENOTYPE	9	11	Primary Systemic Amyloidosis
NCT001664132	NCT00166413_2_T0	COMPOUND	12	12	dexamethasone
NCT001664134	NCT00166413_4_T0	PHENOTYPE	3	3	amyloidosis
NCT001664139	NCT00166413_9_T0	ORGAN	3	3	liver
NCT001664139	NCT00166413_9_T1	PHENOTYPE	11	12	grade 1
NCT001664139	NCT00166413_9_T2	PHENOTYPE	9	10	peripheral neuropathy
NCT001664395	NCT00166439_5_T0	ORGAN	4	4	transplant
NCT001664395	NCT00166439_5_T1	GENE	13	13	ICE
NCT001664396	NCT00166439_6_T0	ORGAN	14	14	transplant
NCT001664397	NCT00166439_7_T0	GENE	12	12	ICE
NCT001664398	NCT00166439_8_T0	GENE	6	6	II
NCT001664398	NCT00166439_8_T1	GENE	1	1	has
NCT001664399	NCT00166439_9_T0	PHENOTYPE	15	15	progression
NCT001664399	NCT00166439_9_T1	GENE	18	18	ICE
NCT0016643910	NCT00166439_10_T0	GENE	5	5	ICE
NCT0016643910	NCT00166439_10_T1	COMPOUND	20	20	cisplatin
NCT0016643910	NCT00166439_10_T2	PHENOTYPE	23	24	kidney problems
NCT0016643911	NCT00166439_11_T0	ORGAN	18	18	kidney
NCT0016643911	NCT00166439_11_T1	ORGAN	7	7	transplant
NCT0016643911	NCT00166439_11_T2	ORGAN	13	13	transplant
NCT0016643912	NCT00166439_12_T0	PHENOTYPE	19	20	kidney problems
NCT0016643912	NCT00166439_12_T1	PHENOTYPE	8	10	quality of life
NCT001664524	NCT00166452_4_T0	ORGAN	17	17	limb
NCT001664524	NCT00166452_4_T1	PHENOTYPE	16	16	distal
NCT001664524	NCT00166452_4_T2	PHENOTYPE	12	12	unilateral
NCT001664524	NCT00166452_4_T3	PHENOTYPE	3	3	CRPS
NCT001664527	NCT00166452_7_T0	ORGAN	8	8	serum
NCT001664652	NCT00166465_2_T0	GENE	1	1	II
NCT001664652	NCT00166465_2_T1	GENE	38	38	IV
NCT001664652	NCT00166465_2_T2	PHENOTYPE	17	17	tumor
NCT001664652	NCT00166465_2_T3	COMPOUND	27	27	5_fluorouracil
NCT001664652	NCT00166465_2_T4	COMPOUND	23	23	oxaliplatin
NCT001664652	NCT00166465_2_T5	COMPOUND	25	25	oxaliplatin
NCT001664652	NCT00166465_2_T6	COMPOUND	29	29	leucovorin
NCT001664652	NCT00166465_2_T7	PHENOTYPE	39	40	colorectal cancer
NCT001664654	NCT00166465_4_T0	GENE	2	2	II
NCT001664657	NCT00166465_7_T0	COMPOUND	11	11	oxaliplatin
NCT001664657	NCT00166465_7_T1	PHENOTYPE	29	31	metastatic colorectal cancer
NCT001664658	NCT00166465_8_T0	COMPOUND	6	6	oxaliplatin
NCT001664658	NCT00166465_8_T1	COMPOUND	20	20	oxaliplatin
NCT001664658	NCT00166465_8_T2	PHENOTYPE	28	29	colorectal cancer
NCT001664659	NCT00166465_9_T0	COMPOUND	16	16	oxaliplatin
NCT001664659	NCT00166465_9_T1	PHENOTYPE	24	26	metastatic colorectal cancer
NCT0016646510	NCT00166465_10_T0	COMPOUND	23	23	folate
NCT0016646510	NCT00166465_10_T1	COMPOUND	9	9	oxaliplatin
NCT0016646510	NCT00166465_10_T2	GENE	1	1	has
NCT0016646511	NCT00166465_11_T0	COMPOUND	17	17	oxaliplatin
NCT0016646511	NCT00166465_11_T1	COMPOUND	27	27	FOLFOX
NCT0016646513	NCT00166465_13_T0	GENE	8	8	IV
NCT0016646513	NCT00166465_13_T1	PHENOTYPE	9	10	colorectal cancer
NCT0016646514	NCT00166465_14_T0	GENE	3	3	VI
NCT0016646514	NCT00166465_14_T1	ORGAN	2	2	Appendix
NCT0016646514	NCT00166465_14_T2	PHENOTYPE	12	13	Colorectal Cancer
NCT0016646515	NCT00166465_15_T0	GENE	10	10	11.0
NCT0016646515	NCT00166465_15_T1	PHENOTYPE	1	2	Measurable disease
NCT0016646517	NCT00166465_17_T0	PHENOTYPE	30	30	toxic
NCT0016646517	NCT00166465_17_T1	ORGAN	13	13	Appendix
NCT0016646517	NCT00166465_17_T2	PHENOTYPE	41	41	alopecia
NCT0016646517	NCT00166465_17_T3	GENE	14	14	VII
NCT0016646517	NCT00166465_17_T4	ORGAN	9	10	bone marrow
NCT0016646517	NCT00166465_17_T5	ORGAN	18	19	Bone Marrow
NCT0016646518	NCT00166465_18_T0	PHENOTYPE	12	13	rectal cancer
NCT0016646520	NCT00166465_20_T0	GENE	21	21	has
NCT0016646520	NCT00166465_20_T1	PHENOTYPE	19	20	tumor progression
NCT0016646521	NCT00166465_21_T0	GENE	12	12	IV
NCT0016646521	NCT00166465_21_T1	ORGAN	11	11	Appendix
NCT0016646526	NCT00166465_26_T0	PHENOTYPE	0	0	Mild
NCT0016646526	NCT00166465_26_T1	COMPOUND	5	5	creatinine
NCT0016646526	NCT00166465_26_T2	PHENOTYPE	2	2	impairment
NCT0016646529	NCT00166465_29_T0	GENE	6	6	II
NCT0016646529	NCT00166465_29_T1	GENE	2	2	3/12
NCT0016646529	NCT00166465_29_T2	PHENOTYPE	20	20	neuropathy
NCT0016646529	NCT00166465_29_T3	PHENOTYPE	15	16	Grade 1
NCT0016646529	NCT00166465_29_T4	PHENOTYPE	11	12	peripheral neuropathy
NCT0016646532	NCT00166465_32_T0	COMPOUND	24	24	oxaliplatin
NCT0016646536	NCT00166465_36_T0	COMPOUND	32	32	piroxicam
NCT0016646536	NCT00166465_36_T1	COMPOUND	4	4	aspirin
NCT0016646537	NCT00166465_37_T0	GENE	2	2	VIII
NCT0016646537	NCT00166465_37_T1	ORGAN	1	1	Appendix
NCT0016646537	NCT00166465_37_T2	PHENOTYPE	10	13	central nervous system metastases
NCT0016646538	NCT00166465_38_T0	PHENOTYPE	0	0	Metastases
NCT0016646544	NCT00166465_44_T0	COMPOUND	4	4	oxaliplatin
NCT001664911	NCT00166491_1_T0	PHENOTYPE	8	10	blood sugar levels
NCT001664913	NCT00166491_3_T0	GENE	12	12	insulin
NCT001664913	NCT00166491_3_T1	PHENOTYPE	5	7	blood sugar levels
NCT001664914	NCT00166491_4_T0	GENE	11	11	insulin
NCT001664917	NCT00166491_7_T0	COMPOUND	8	8	glucose
NCT001664917	NCT00166491_7_T1	GENE	13	13	insulin
NCT001664918	NCT00166491_8_T0	GENE	7	7	has
NCT001664918	NCT00166491_8_T1	PHENOTYPE	17	18	critically ill
NCT001664919	NCT00166491_9_T0	GENE	12	12	insulin
NCT0016649110	NCT00166491_10_T0	COMPOUND	15	15	glucose
NCT0016649110	NCT00166491_10_T1	GENE	9	9	insulin
NCT0016649111	NCT00166491_11_T0	COMPOUND	13	13	glucose
NCT0016649112	NCT00166491_12_T0	COMPOUND	12	12	glucose
NCT0016649112	NCT00166491_12_T1	PHENOTYPE	13	13	concentrations
NCT0016649112	NCT00166491_12_T2	PHENOTYPE	5	6	hypoglycemic episodes
NCT0016649113	NCT00166491_13_T0	COMPOUND	21	21	glucose
NCT0016649113	NCT00166491_13_T1	GENE	5	5	insulin
NCT001665041	NCT00166504_1_T0	GENE	20	20	lipoprotein
NCT001665041	NCT00166504_1_T1	COMPOUND	32	32	atorvastatin
NCT001665561	NCT00166556_1_T0	PHENOTYPE	2	5	end stage liver disease
NCT001665562	NCT00166556_2_T0	COMPOUND	7	7	tacrolimus
NCT001665562	NCT00166556_2_T1	PHENOTYPE	5	5	immunosuppression
NCT001665563	NCT00166556_3_T0	ORGAN	29	29	graft
NCT001665563	NCT00166556_3_T1	ORGAN	28	28	liver
NCT001665563	NCT00166556_3_T2	COMPOUND	4	4	tacrolimus
NCT001665563	NCT00166556_3_T3	BIOLOGICAL_PROCESS	14	15	gene expression
NCT001665566	NCT00166556_6_T0	COMPOUND	24	24	tacrolimus
NCT001665566	NCT00166556_6_T1	ORGAN	26	26	allograft
NCT001665567	NCT00166556_7_T0	PHENOTYPE	1	1	secondary
NCT001665567	NCT00166556_7_T1	COMPOUND	8	8	tacrolimus
NCT0016655611	NCT00166556_11_T0	ORGAN	2	2	liver
NCT0016655611	NCT00166556_11_T1	ORGAN	3	3	transplant
NCT0016655612	NCT00166556_12_T0	PHENOTYPE	1	3	negative pregnancy test
NCT0016655615	NCT00166556_15_T0	TISSUE	3	3	spleen
NCT0016655616	NCT00166556_16_T0	ORGAN	1	1	transplant
NCT0016655617	NCT00166556_17_T0	ORGAN	1	1	transplant
NCT0016655618	NCT00166556_18_T0	ORGAN	2	2	transplant
NCT0016655620	NCT00166556_20_T0	ORGAN	1	1	liver
NCT0016655620	NCT00166556_20_T1	PHENOTYPE	9	10	hepatitis B
NCT0016655621	NCT00166556_21_T0	ORGAN	1	1	liver
NCT0016655621	NCT00166556_21_T1	PHENOTYPE	9	10	hepatitis C
NCT0016655622	NCT00166556_22_T0	ORGAN	1	1	liver
NCT0016655624	NCT00166556_24_T0	PHENOTYPE	14	15	hepatitis B
NCT0016655624	NCT00166556_24_T1	PHENOTYPE	0	1	Hepatitis B
NCT0016655625	NCT00166556_25_T0	PHENOTYPE	10	10	hepatitis
NCT0016655625	NCT00166556_25_T1	PHENOTYPE	0	1	Hepatitis C
NCT0016655626	NCT00166556_26_T0	GENE	1	1	III
NCT0016655626	NCT00166556_26_T1	PHENOTYPE	4	5	hepatocellular cancer
NCT0016655628	NCT00166556_28_T0	PHENOTYPE	1	2	systemic infection
NCT0016655629	NCT00166556_29_T0	PHENOTYPE	2	2	chronic
NCT0016655635	NCT00166556_35_T0	PHENOTYPE	9	10	stage 2
NCT0016655635	NCT00166556_35_T1	PHENOTYPE	7	8	hepatic encephalopathy
NCT001665693	NCT00166569_3_T0	PHENOTYPE	0	0	PCOS
NCT001665695	NCT00166569_5_T0	PHENOTYPE	2	3	phenotypic variability
NCT001665695	NCT00166569_5_T1	PHENOTYPE	7	8	associated conditions
NCT001665697	NCT00166569_7_T0	PHENOTYPE	17	17	PCOS
NCT001665698	NCT00166569_8_T0	GENE	4	4	has
NCT001665699	NCT00166569_9_T0	PHENOTYPE	9	9	PCOS
NCT0016656911	NCT00166569_11_T0	PHENOTYPE	5	5	PCOS
NCT0016656913	NCT00166569_13_T0	PHENOTYPE	2	2	PCOS
NCT0016656917	NCT00166569_17_T0	GENE	15	15	FSH
NCT0016656918	NCT00166569_18_T0	PHENOTYPE	2	3	glucose tolerance
NCT0016656919	NCT00166569_19_T0	ORGAN	11	11	ovaries
NCT0016656922	NCT00166569_22_T0	PHENOTYPE	0	0	PCOS
NCT0016656922	NCT00166569_22_T1	COMPOUND	15	15	glucose
NCT0016656922	NCT00166569_22_T2	GENE	14	14	insulin
NCT0016656922	NCT00166569_22_T3	GENE	24	24	insulin
NCT0016656924	NCT00166569_24_T0	GENE	1	1	hormone
NCT0016656931	NCT00166569_31_T0	GENE	24	24	insulin
NCT0016656931	NCT00166569_31_T1	PHENOTYPE	14	14	Endocrine
NCT0016656931	NCT00166569_31_T2	GENE	5	5	had
NCT0016656931	NCT00166569_31_T3	GENE	3	3	has
NCT0016656931	NCT00166569_31_T4	PHENOTYPE	6	7	hormone levels
NCT0016656932	NCT00166569_32_T0	PHENOTYPE	4	4	PCOS
NCT0016656932	NCT00166569_32_T1	PHENOTYPE	11	11	PCOS
NCT0016656934	NCT00166569_34_T0	GENE	40	40	prolactin
NCT0016656934	NCT00166569_34_T1	GENE	41	41	25
NCT0016656934	NCT00166569_34_T2	GENE	48	48	insulin
NCT0016656934	NCT00166569_34_T3	PHENOTYPE	35	35	hyperandrogenism
NCT0016656934	NCT00166569_34_T4	GENE	38	38	TSH
NCT0016656934	NCT00166569_34_T5	PHENOTYPE	27	27	menopausal
NCT0016656934	NCT00166569_34_T6	GENE	8	8	yrs
NCT0016656935	NCT00166569_35_T0	GENE	14	14	25
NCT0016656935	NCT00166569_35_T1	GENE	13	13	prolactin
NCT0016656935	NCT00166569_35_T2	GENE	21	21	insulin
NCT0016656935	NCT00166569_35_T3	GENE	11	11	TSH
NCT0016656935	NCT00166569_35_T4	GENE	6	6	yrs
NCT0016656937	NCT00166569_37_T0	PHENOTYPE	18	18	PCOS
NCT001665821	NCT00166582_1_T0	PHENOTYPE	13	13	asthma
NCT001665823	NCT00166582_3_T0	PHENOTYPE	16	16	asthma
NCT001665824	NCT00166582_4_T0	GENE	8	8	has
NCT001665824	NCT00166582_4_T1	PHENOTYPE	5	6	chronic illness
NCT001665825	NCT00166582_5_T0	GENE	2	2	has
NCT001665826	NCT00166582_6_T0	PHENOTYPE	20	20	asthma
NCT0016658210	NCT00166582_10_T0	GENE	23	23	SC
NCT0016658210	NCT00166582_10_T1	PHENOTYPE	1	1	asthma
NCT0016658210	NCT00166582_10_T2	PHENOTYPE	17	17	Asthma
NCT0016658212	NCT00166582_12_T0	PHENOTYPE	6	6	strategies
NCT0016658212	NCT00166582_12_T1	PHENOTYPE	13	13	asthma
NCT0016658213	NCT00166582_13_T0	PHENOTYPE	8	8	asthma
NCT0016658213	NCT00166582_13_T1	PHENOTYPE	14	14	asthma
NCT0016658214	NCT00166582_14_T0	GENE	0	0	SC
NCT0016658216	NCT00166582_16_T0	PHENOTYPE	12	12	asthma
NCT001665951	NCT00166595_1_T0	COMPOUND	14	14	risperidone
NCT001665951	NCT00166595_1_T1	BIOLOGICAL_PROCESS	29	31	response to risperidone
NCT001665953	NCT00166595_3_T0	PHENOTYPE	32	32	PDD
NCT001665953	NCT00166595_3_T1	COMPOUND	27	27	risperidone
NCT001665953	NCT00166595_3_T2	GENE	7	7	PK
NCT001665953	NCT00166595_3_T3	GENE	24	24	PK
NCT001665954	NCT00166595_4_T0	PHENOTYPE	7	7	PDD
NCT001665954	NCT00166595_4_T1	COMPOUND	27	27	risperidone
NCT001665955	NCT00166595_5_T0	GENE	15	15	PK
NCT001665955	NCT00166595_5_T1	GENE	5	5	ml
NCT001666081	NCT00166608_1_T0	PHENOTYPE	8	8	toxicity
NCT001666081	NCT00166608_1_T1	PHENOTYPE	6	6	severity
NCT001666081	NCT00166608_1_T2	PHENOTYPE	10	10	overdose
NCT001666083	NCT00166608_3_T0	PHENOTYPE	20	20	toxicity
NCT001666083	NCT00166608_3_T1	GENE	11	11	IL-10
NCT001666083	NCT00166608_3_T2	ORGAN	10	10	plasma
NCT001666084	NCT00166608_4_T0	GENE	3	3	IL-10
NCT001666084	NCT00166608_4_T1	PHENOTYPE	11	12	hepatic injury
NCT001666085	NCT00166608_5_T0	COMPOUND	11	11	APAP
NCT001666085	NCT00166608_5_T1	COMPOUND	30	30	APAP
NCT001666085	NCT00166608_5_T2	PHENOTYPE	12	12	overdose
NCT001666085	NCT00166608_5_T3	PHENOTYPE	31	31	overdose
NCT001666085	NCT00166608_5_T4	GENE	6	6	IL-10
NCT001666085	NCT00166608_5_T5	GENE	26	26	IL-10
NCT001666085	NCT00166608_5_T6	GENE	8	8	iNOS
NCT001666085	NCT00166608_5_T7	GENE	24	24	iNOS
NCT001666086	NCT00166608_6_T0	PHENOTYPE	17	17	severity
NCT001666086	NCT00166608_6_T1	GENE	14	14	IL-10
NCT001666086	NCT00166608_6_T2	PHENOTYPE	22	22	diseases
NCT001666086	NCT00166608_6_T3	GENE	12	12	iNOS
NCT001666087	NCT00166608_7_T0	GENE	7	7	IL10
NCT001666087	NCT00166608_7_T1	PHENOTYPE	21	21	overdose
NCT001666087	NCT00166608_7_T2	GENE	16	16	IL-10
NCT001666087	NCT00166608_7_T3	GENE	5	5	iNOS
NCT001666087	NCT00166608_7_T4	COMPOUND	14	14	nitrotyrosine
NCT001666087	NCT00166608_7_T5	ORGAN	11	11	plasma
NCT001666088	NCT00166608_8_T0	COMPOUND	15	15	nitrotyrosine
NCT001666089	NCT00166608_9_T0	COMPOUND	18	18	APAP
NCT001666089	NCT00166608_9_T1	PHENOTYPE	19	19	overdose
NCT0016660812	NCT00166608_12_T0	PHENOTYPE	17	17	ingestion
NCT0016660812	NCT00166608_12_T1	PHENOTYPE	21	21	ingestion
NCT0016660812	NCT00166608_12_T2	PHENOTYPE	25	25	ingestion
NCT001666212	NCT00166621_2_T0	PHENOTYPE	21	21	pharmacokinetics
NCT001666212	NCT00166621_2_T1	PHENOTYPE	11	11	autistic
NCT001666340	NCT00166634_0_T0	PHENOTYPE	5	5	Hypertension
NCT001666472	NCT00166647_2_T0	GENE	6	6	TPMT
NCT001666475	NCT00166647_5_T0	GENE	3	3	cc
NCT001666475	NCT00166647_5_T1	GENE	11	11	TPMT
NCT001666606	NCT00166660_6_T0	GENE	2	2	FGR
NCT001666607	NCT00166660_7_T0	GENE	2	2	FGR
NCT0016666010	NCT00166660_10_T0	GENE	20	20	FGR
NCT0016666010	NCT00166660_10_T1	PHENOTYPE	48	48	prematurity
NCT0016666010	NCT00166660_10_T2	GENE	44	44	CA
NCT0016666017	NCT00166660_17_T0	PHENOTYPE	11	11	individuality
NCT0016666023	NCT00166660_23_T0	GENE	2	2	FGR
NCT0016666023	NCT00166660_23_T1	GENE	16	16	CA
NCT0016666026	NCT00166660_26_T0	GENE	17	17	MRI
NCT0016666026	NCT00166660_26_T1	GENE	15	15	structural
NCT0016666027	NCT00166660_27_T0	GENE	22	22	CA
NCT0016666029	NCT00166660_29_T0	GENE	11	11	FGR
NCT001666736	NCT00166673_6_T0	COMPOUND	4	4	glucose
NCT001666738	NCT00166673_8_T0	PHENOTYPE	6	6	hyperglycemia
NCT001666738	NCT00166673_8_T1	COMPOUND	13	13	glucose
NCT001666738	NCT00166673_8_T2	PHENOTYPE	4	4	hypoglycemia
NCT001666738	NCT00166673_8_T3	GENE	1	1	has
NCT0016667310	NCT00166673_10_T0	COMPOUND	17	17	1
NCT0016667310	NCT00166673_10_T1	COMPOUND	19	19	1
NCT0016667310	NCT00166673_10_T2	COMPOUND	21	21	1
NCT0016667310	NCT00166673_10_T3	COMPOUND	23	23	1
NCT0016667310	NCT00166673_10_T4	COMPOUND	9	9	glucose
NCT0016667310	NCT00166673_10_T5	COMPOUND	13	13	2
NCT0016667310	NCT00166673_10_T6	COMPOUND	15	15	2
NCT0016667310	NCT00166673_10_T7	COMPOUND	25	25	2
NCT0016667310	NCT00166673_10_T8	COMPOUND	28	28	2
NCT0016667310	NCT00166673_10_T9	GENE	6	6	arrow
NCT0016667310	NCT00166673_10_T10	GENE	3	3	has
NCT0016667313	NCT00166673_13_T0	COMPOUND	14	14	glucose
NCT0016667313	NCT00166673_13_T1	GENE	9	9	has
NCT0016667314	NCT00166673_14_T0	GENE	2	2	has
NCT0016667321	NCT00166673_21_T0	GENE	7	7	hemoglobin
NCT0016667328	NCT00166673_28_T0	GENE	19	19	7.12
NCT0016667328	NCT00166673_28_T1	GENE	7	7	insulin
NCT0016667330	NCT00166673_30_T0	GENE	11	11	has
NCT0016667342	NCT00166673_42_T0	PHENOTYPE	12	12	decisions
NCT0016667346	NCT00166673_46_T0	GENE	7	7	has
NCT0016667352	NCT00166673_52_T0	GENE	9	9	has
NCT0016667354	NCT00166673_54_T0	GENE	5	5	insulin
NCT0016667357	NCT00166673_57_T0	GENE	5	5	13
NCT0016667357	NCT00166673_57_T1	PHENOTYPE	28	28	liked
NCT0016667366	NCT00166673_66_T0	PHENOTYPE	43	43	liked
NCT001666861	NCT00166686_1_T0	COMPOUND	11	11	clonidine
NCT001666861	NCT00166686_1_T1	PHENOTYPE	4	4	hopes
NCT001666863	NCT00166686_3_T0	PHENOTYPE	16	16	sequelae
NCT001666863	NCT00166686_3_T1	GENE	7	7	has
NCT001666863	NCT00166686_3_T2	PHENOTYPE	5	5	oncology
NCT001666865	NCT00166686_5_T0	PHENOTYPE	7	8	childhood cancer
NCT001666865	NCT00166686_5_T1	ORGAN	0	2	Central nervous system
NCT001666866	NCT00166686_6_T0	COMPOUND	6	6	clonidine
NCT001666869	NCT00166686_9_T0	COMPOUND	6	6	clonidine
NCT0016668610	NCT00166686_10_T0	GENE	0	0	PK
NCT001666990	NCT00166699_0_T0	PHENOTYPE	15	15	Anaesthesia
NCT001666993	NCT00166699_3_T0	TISSUE	22	22	bones
NCT001666993	NCT00166699_3_T1	ORGAN	25	25	spine
NCT001666995	NCT00166699_5_T0	TISSUE	11	11	bones
NCT001666997	NCT00166699_7_T0	GENE	26	26	envelope
NCT001666997	NCT00166699_7_T1	PHENOTYPE	12	13	caesarean section
NCT001666999	NCT00166699_9_T0	PHENOTYPE	29	29	anaesthesia
NCT001666999	NCT00166699_9_T1	PHENOTYPE	42	43	Caesarean section
NCT0016669915	NCT00166699_15_T0	GENE	15	15	MRI
NCT0016669915	NCT00166699_15_T1	GENE	2	2	al
NCT0016669915	NCT00166699_15_T2	GENE	1	1	et
NCT0016669916	NCT00166699_16_T0	GENE	7	7	al3
NCT0016669916	NCT00166699_16_T1	ORGAN	24	24	spine
NCT0016669916	NCT00166699_16_T2	GENE	6	6	et
NCT0016669921	NCT00166699_21_T0	PHENOTYPE	0	1	Morbid obesity
NCT0016669923	NCT00166699_23_T0	PHENOTYPE	15	15	anaesthesia
NCT0016669927	NCT00166699_27_T0	GENE	22	22	MRI
NCT0016669927	NCT00166699_27_T1	ORGAN	5	5	spine
NCT0016669927	NCT00166699_27_T2	ORGAN	27	27	spine
NCT0016669930	NCT00166699_30_T0	GENE	25	25	MRI
NCT0016669930	NCT00166699_30_T1	GENE	8	8	SHO
NCT0016669932	NCT00166699_32_T0	GENE	13	13	MRI
NCT0016669933	NCT00166699_33_T0	GENE	1	1	has
NCT0016669933	NCT00166699_33_T1	PHENOTYPE	11	11	anaesthesia
NCT0016669934	NCT00166699_34_T0	GENE	2	2	al
NCT0016669934	NCT00166699_34_T1	GENE	1	1	et
NCT0016669935	NCT00166699_35_T0	PHENOTYPE	13	13	blocks
NCT0016669935	NCT00166699_35_T1	PHENOTYPE	20	21	caesarean section
NCT0016669936	NCT00166699_36_T0	PHENOTYPE	23	23	eclampsia
NCT0016669936	NCT00166699_36_T1	PHENOTYPE	21	21	obesity
NCT0016669937	NCT00166699_37_T0	PHENOTYPE	9	10	spinal fusion
NCT0016669937	NCT00166699_37_T1	PHENOTYPE	14	16	lumbar disc prolapse
NCT0016669939	NCT00166699_39_T0	PHENOTYPE	14	15	caesarean section
NCT0016669941	NCT00166699_41_T0	GENE	21	21	envelope
NCT0016669945	NCT00166699_45_T0	GENE	11	11	CSE
NCT0016669945	NCT00166699_45_T1	GENE	28	28	has
NCT0016669947	NCT00166699_47_T0	ORGAN	12	13	epidural space
NCT0016669951	NCT00166699_51_T0	PHENOTYPE	15	15	complications
NCT0016669951	NCT00166699_51_T1	GENE	18	18	CSE
NCT0016669951	NCT00166699_51_T2	PHENOTYPE	21	21	headache
NCT0016669951	NCT00166699_51_T3	PHENOTYPE	23	23	neuropraxia
NCT0016669951	NCT00166699_51_T4	PHENOTYPE	39	40	adverse events
NCT001667121	NCT00166712_1_T0	PHENOTYPE	10	10	peripheral
NCT001667121	NCT00166712_1_T1	CELL	11	11	T-cell
NCT001667123	NCT00166712_3_T0	PHENOTYPE	7	7	immunosuppression
NCT001667124	NCT00166712_4_T0	ORGAN	1	1	transplant
NCT001667124	NCT00166712_4_T1	ORGAN	16	16	transplant
NCT001667124	NCT00166712_4_T2	COMPOUND	11	12	mycophenolate mofetil
NCT001667125	NCT00166712_5_T0	COMPOUND	11	11	tacrolimus
NCT0016671210	NCT00166712_10_T0	ORGAN	5	5	serum
NCT0016671211	NCT00166712_11_T0	PHENOTYPE	10	10	concentrations
NCT0016671215	NCT00166712_15_T0	ORGAN	5	5	kidney
NCT0016671216	NCT00166712_16_T0	ORGAN	10	10	serum
NCT0016671219	NCT00166712_19_T0	COMPOUND	6	6	tacrolimus
NCT0016671221	NCT00166712_21_T0	CELL	8	8	lymphocytes
NCT0016671221	NCT00166712_21_T1	ORGAN	11	11	serum
NCT0016671224	NCT00166712_24_T0	PHENOTYPE	8	8	diseases
NCT0016671224	NCT00166712_24_T1	PHENOTYPE	5	5	severely
NCT0016671224	NCT00166712_24_T2	PHENOTYPE	11	12	renal disease
NCT0016671225	NCT00166712_25_T0	PHENOTYPE	2	3	substance abuse
NCT0016671226	NCT00166712_26_T0	PHENOTYPE	2	3	psychiatric illness
NCT0016671228	NCT00166712_28_T0	PHENOTYPE	0	0	Malignancy
NCT0016671228	NCT00166712_28_T1	PHENOTYPE	5	6	melanoma skin
NCT0016671229	NCT00166712_29_T0	PHENOTYPE	5	5	HIV
NCT0016671231	NCT00166712_31_T0	ORGAN	7	7	transplant
NCT001667251	NCT00166725_1_T0	GENE	7	7	somatostatin
NCT001667253	NCT00166725_3_T0	GENE	3	3	18
NCT001667257	NCT00166725_7_T0	PHENOTYPE	1	1	tolerance
NCT001667257	NCT00166725_7_T1	COMPOUND	8	9	octreotide acetate
NCT0016672514	NCT00166725_14_T0	PHENOTYPE	5	5	initiation
NCT0016672515	NCT00166725_15_T0	GENE	9	9	LHRH
NCT0016672515	NCT00166725_15_T1	COMPOUND	15	15	flutamide
NCT0016672515	NCT00166725_15_T2	GENE	14	14	eg
NCT0016672515	NCT00166725_15_T3	COMPOUND	16	16	bicalutamide
NCT0016672519	NCT00166725_19_T0	PHENOTYPE	2	2	hypertension
NCT0016672520	NCT00166725_20_T0	PHENOTYPE	1	1	malignancies
NCT0016672520	NCT00166725_20_T1	PHENOTYPE	14	15	skin cancer
NCT001667384	NCT00166738_4_T0	COMPOUND	10	10	oligonucleotide
NCT001667384	NCT00166738_4_T1	GENE	13	13	span
NCT001667511	NCT00166751_1_T0	COMPOUND	21	21	barium
NCT001667511	NCT00166751_1_T1	GENE	1	1	has
NCT001667516	NCT00166751_6_T0	PHENOTYPE	3	3	occlusion
NCT001667518	NCT00166751_8_T0	PHENOTYPE	19	19	CVA
NCT0016675111	NCT00166751_11_T0	ORGAN	16	17	thyroid cartilage
NCT0016675111	NCT00166751_11_T1	ORGAN	13	14	hyoid bone
NCT0016675113	NCT00166751_13_T0	ORGAN	7	8	thyroid cartilage
NCT0016675113	NCT00166751_13_T1	ORGAN	4	5	hyoid bone
NCT0016675114	NCT00166751_14_T0	PHENOTYPE	7	7	dysphagia
NCT0016675119	NCT00166751_19_T0	GENE	3	3	swallow
NCT0016675119	NCT00166751_19_T1	PHENOTYPE	16	17	oropharyngeal dysphagia
NCT0016675121	NCT00166751_21_T0	PHENOTYPE	8	9	radiation exposure
NCT0016675122	NCT00166751_22_T0	COMPOUND	13	13	barium
NCT0016675122	NCT00166751_22_T1	PHENOTYPE	27	28	cognitive function
NCT0016675124	NCT00166751_24_T0	GENE	9	9	swallow
NCT0016675127	NCT00166751_27_T0	GENE	2	2	has
NCT0016675128	NCT00166751_28_T0	COMPOUND	21	21	barium
NCT0016675128	NCT00166751_28_T1	GENE	1	1	has
NCT0016675133	NCT00166751_33_T0	PHENOTYPE	3	3	occlusion
NCT0016675135	NCT00166751_35_T0	PHENOTYPE	19	19	CVA
NCT0016675138	NCT00166751_38_T0	ORGAN	16	17	thyroid cartilage
NCT0016675138	NCT00166751_38_T1	ORGAN	13	14	hyoid bone
NCT0016675140	NCT00166751_40_T0	ORGAN	7	8	thyroid cartilage
NCT0016675140	NCT00166751_40_T1	ORGAN	4	5	hyoid bone
NCT0016675141	NCT00166751_41_T0	PHENOTYPE	7	7	dysphagia
NCT001667641	NCT00166764_1_T0	PHENOTYPE	43	43	happiness
NCT001667641	NCT00166764_1_T1	PHENOTYPE	7	8	psychiatric symptoms
NCT001667642	NCT00166764_2_T0	PHENOTYPE	25	26	mental health
NCT001667643	NCT00166764_3_T0	PHENOTYPE	4	5	mental health
NCT001667643	NCT00166764_3_T1	PHENOTYPE	16	17	mental health
NCT001667644	NCT00166764_4_T0	PHENOTYPE	9	10	mental health
NCT001667645	NCT00166764_5_T0	PHENOTYPE	15	15	experiences
NCT001667645	NCT00166764_5_T1	PHENOTYPE	6	7	mental health
NCT001667646	NCT00166764_6_T0	PHENOTYPE	8	9	stress response
NCT001667646	NCT00166764_6_T1	PHENOTYPE	2	3	mental health
NCT001667649	NCT00166764_9_T0	PHENOTYPE	11	12	mental health
NCT001667649	NCT00166764_9_T1	PHENOTYPE	17	18	mental health
NCT0016676410	NCT00166764_10_T0	PHENOTYPE	3	3	ICC
NCT001667771	NCT00166777_1_T0	ORGAN	0	1	Vastus medialis
NCT0016677713	NCT00166777_13_T0	GENE	3	3	ANOVA
NCT001667902	NCT00166790_2_T0	PHENOTYPE	6	6	choriocarcinoma
NCT001667902	NCT00166790_2_T1	PHENOTYPE	2	3	hydatidiform mole
NCT001667902	NCT00166790_2_T2	PHENOTYPE	4	5	invasive mole
NCT001667902	NCT00166790_2_T3	PHENOTYPE	8	11	placental site trophoblastic tumor
NCT001667903	NCT00166790_3_T0	PHENOTYPE	3	4	molar pregnancies
NCT001667904	NCT00166790_4_T0	GENE	5	5	GTD
NCT001667904	NCT00166790_4_T1	PHENOTYPE	12	13	gynecologic cancer
NCT001667907	NCT00166790_7_T0	PHENOTYPE	7	7	sequelae
NCT001667907	NCT00166790_7_T1	PHENOTYPE	15	16	hydatidiform moles
NCT001667908	NCT00166790_8_T0	PHENOTYPE	31	31	recurrence
NCT001667908	NCT00166790_8_T1	GENE	23	23	1.2
NCT001667908	NCT00166790_8_T2	PHENOTYPE	11	12	metastatic disease
NCT001667909	NCT00166790_9_T0	PHENOTYPE	33	33	tumors
NCT001667909	NCT00166790_9_T1	PHENOTYPE	28	28	hopes
NCT001667909	NCT00166790_9_T2	PHENOTYPE	5	6	metastatic disease
NCT0016679010	NCT00166790_10_T0	PHENOTYPE	20	20	recurrence
NCT0016679010	NCT00166790_10_T1	PHENOTYPE	25	25	remission
NCT0016679011	NCT00166790_11_T0	ORGAN	3	3	serum
NCT0016679012	NCT00166790_12_T0	CELL	26	26	cells
NCT0016679012	NCT00166790_12_T1	PHENOTYPE	8	8	tumor
NCT0016679012	NCT00166790_12_T2	PHENOTYPE	25	25	tumor
NCT0016679012	NCT00166790_12_T3	ORGAN	13	13	serum
NCT0016679013	NCT00166790_13_T0	PHENOTYPE	29	29	tumor
NCT0016679013	NCT00166790_13_T1	GENE	20	20	GTD
NCT0016679013	NCT00166790_13_T2	COMPOUND	7	8	chorionic gonadotropin
NCT0016679014	NCT00166790_14_T0	BIOLOGICAL_PROCESS	15	15	behaviour
NCT0016679015	NCT00166790_15_T0	GENE	1	1	has
NCT0016679016	NCT00166790_16_T0	GENE	32	32	GTD
NCT0016679016	NCT00166790_16_T1	COMPOUND	22	23	chorionic gonadotropin
NCT0016679017	NCT00166790_17_T0	PHENOTYPE	20	20	tumors
NCT0016679017	NCT00166790_17_T1	PHENOTYPE	15	15	hopes
NCT0016679018	NCT00166790_18_T0	PHENOTYPE	14	15	false positive
NCT001668032	NCT00166803_2_T0	PHENOTYPE	5	5	plaques
NCT001668033	NCT00166803_3_T0	PHENOTYPE	20	20	atheroma
NCT001668033	NCT00166803_3_T1	PHENOTYPE	9	9	plaques
NCT001668036	NCT00166803_6_T0	CELL	6	6	macrophages
NCT001668036	NCT00166803_6_T1	CELL	4	4	cells
NCT001668036	NCT00166803_6_T2	PHENOTYPE	12	12	rupture
NCT001668039	NCT00166803_9_T0	ORGAN	20	20	plasma
NCT001668039	NCT00166803_9_T1	GENE	17	17	leptin
NCT001668039	NCT00166803_9_T2	PHENOTYPE	10	11	insulin resistance
NCT001668039	NCT00166803_9_T3	PHENOTYPE	27	29	lower blood pressure
NCT0016680310	NCT00166803_10_T0	PHENOTYPE	10	10	atherosclerosis
NCT0016680310	NCT00166803_10_T1	PHENOTYPE	42	42	plaque
NCT0016680310	NCT00166803_10_T2	CELL	21	21	macrophage
NCT0016680310	NCT00166803_10_T3	PHENOTYPE	14	14	inhibition
NCT0016680310	NCT00166803_10_T4	GENE	18	18	secreted
NCT0016680310	NCT00166803_10_T5	PHENOTYPE	43	43	regression
NCT0016680310	NCT00166803_10_T6	GENE	24	24	IL-6
NCT0016680310	NCT00166803_10_T7	BIOLOGICAL_PROCESS	3	4	glucose effect
NCT0016680311	NCT00166803_11_T0	COMPOUND	3	3	glucose
NCT0016680311	NCT00166803_11_T1	CELL	10	10	cells
NCT0016680312	NCT00166803_12_T0	PHENOTYPE	15	16	vascular diseases
NCT0016680313	NCT00166803_13_T0	GENE	2	2	has
NCT0016680315	NCT00166803_15_T0	PHENOTYPE	5	5	plaque
NCT0016680315	NCT00166803_15_T1	PHENOTYPE	30	30	plaque
NCT0016680315	NCT00166803_15_T2	PHENOTYPE	6	6	regression
NCT0016680317	NCT00166803_17_T0	GENE	1	1	II
NCT0016680317	NCT00166803_17_T1	GENE	16	16	10.0
NCT0016680323	NCT00166803_23_T0	PHENOTYPE	7	7	menopausal
NCT0016680323	NCT00166803_23_T1	PHENOTYPE	19	20	radiation exposure
NCT001668163	NCT00166816_3_T0	COMPOUND	4	4	cyclosporine
NCT001668163	NCT00166816_3_T1	COMPOUND	6	6	tacrolimus
NCT001668292	NCT00166829_2_T0	COMPOUND	14	14	tacrolimus
NCT001668293	NCT00166829_3_T0	COMPOUND	12	12	tacrolimus
NCT001668293	NCT00166829_3_T1	PHENOTYPE	10	10	pharmacokinetics
NCT001668424	NCT00166842_4_T0	PHENOTYPE	9	9	pharmacokinetics
NCT001668424	NCT00166842_4_T1	ORGAN	19	19	transplant
NCT001668424	NCT00166842_4_T2	ORGAN	36	36	transplant
NCT001668555	NCT00166855_5_T0	GENE	7	7	MRI
NCT001668555	NCT00166855_5_T1	GENE	18	18	MRI
NCT001668555	NCT00166855_5_T2	ORGAN	2	2	spine
NCT001668556	NCT00166855_6_T0	CELL	27	27	cells
NCT001668556	NCT00166855_6_T1	GENE	20	20	separated
NCT001668556	NCT00166855_6_T2	ORGAN	23	23	plasma
NCT001668559	NCT00166855_9_T0	ORGAN	2	2	plasma
NCT0016685513	NCT00166855_13_T0	PHENOTYPE	25	25	complications
NCT0016685513	NCT00166855_13_T1	GENE	28	28	al
NCT0016685513	NCT00166855_13_T2	GENE	27	27	et
NCT0016685516	NCT00166855_16_T0	GENE	6	6	MVD
NCT0016685516	NCT00166855_16_T1	GENE	34	34	MVD
NCT0016685516	NCT00166855_16_T2	GENE	37	37	al
NCT0016685516	NCT00166855_16_T3	GENE	1	1	has
NCT0016685516	NCT00166855_16_T4	GENE	36	36	et
NCT0016685523	NCT00166855_23_T0	ORGAN	6	6	spine
NCT0016685524	NCT00166855_24_T0	GENE	41	41	T11
NCT0016685524	NCT00166855_24_T1	ORGAN	44	44	sacrum
NCT0016685525	NCT00166855_25_T0	GENE	16	16	cm
NCT0016685526	NCT00166855_26_T0	PHENOTYPE	1	1	pulse
NCT0016685532	NCT00166855_32_T0	PHENOTYPE	9	9	flush
NCT0016685534	NCT00166855_34_T0	PHENOTYPE	10	10	interests
NCT0016685535	NCT00166855_35_T0	ORGAN	42	42	vertebra
NCT0016685535	NCT00166855_35_T1	ORGAN	29	30	bone marrow
NCT0016685535	NCT00166855_35_T2	ORGAN	38	39	bone marrow
NCT0016685537	NCT00166855_37_T0	GENE	11	11	L2
NCT0016685537	NCT00166855_37_T1	GENE	12	12	L3
NCT0016685537	NCT00166855_37_T2	GENE	14	14	L4
NCT0016685537	NCT00166855_37_T3	ORGAN	9	10	lumbar vertebrae
NCT0016685540	NCT00166855_40_T0	COMPOUND	4	4	SImax
NCT0016685541	NCT00166855_41_T0	COMPOUND	15	15	SImax
NCT0016685544	NCT00166855_44_T0	COMPOUND	6	6	SImax
NCT0016685545	NCT00166855_45_T0	COMPOUND	15	15	SImax
NCT0016685545	NCT00166855_45_T1	COMPOUND	27	27	SImax
NCT0016685547	NCT00166855_47_T0	GENE	10	10	L3
NCT0016685547	NCT00166855_47_T1	GENE	11	11	L3
NCT0016685547	NCT00166855_47_T2	GENE	13	13	L4
NCT0016685547	NCT00166855_47_T3	ORGAN	14	14	vertebrae
NCT001668682	NCT00166868_2_T0	PHENOTYPE	8	8	complication
NCT001668682	NCT00166868_2_T1	PHENOTYPE	7	7	recurrent
NCT001668682	NCT00166868_2_T2	PHENOTYPE	0	1	Ascending cholangitis
NCT001668683	NCT00166868_3_T0	PHENOTYPE	10	10	secondary
NCT001668683	NCT00166868_3_T1	PHENOTYPE	21	22	portal hypertension
NCT001668684	NCT00166868_4_T0	PHENOTYPE	14	14	recurrence
NCT001668684	NCT00166868_4_T1	GENE	4	4	had
NCT001668684	NCT00166868_4_T2	PHENOTYPE	16	17	ascending cholangitis
NCT001668685	NCT00166868_5_T0	PHENOTYPE	18	18	recurrences
NCT001668685	NCT00166868_5_T1	ORGAN	12	12	liver
NCT001668685	NCT00166868_5_T2	PHENOTYPE	5	6	ascending cholangitis
NCT001668686	NCT00166868_6_T0	GENE	14	14	had
NCT001668686	NCT00166868_6_T1	PHENOTYPE	4	4	cholangitis
NCT001668687	NCT00166868_7_T0	COMPOUND	4	4	trimethoprim_sulfamethoxazole
NCT001668687	NCT00166868_7_T1	COMPOUND	7	7	neomycin
NCT001668687	NCT00166868_7_T2	PHENOTYPE	15	16	ascending cholangitis
NCT001668689	NCT00166868_9_T0	GENE	0	0	Is
NCT0016686811	NCT00166868_11_T0	ORGAN	20	20	liver
NCT0016686811	NCT00166868_11_T1	PHENOTYPE	12	13	intestinal infection
NCT0016686811	NCT00166868_11_T2	PHENOTYPE	13	15	infection or inflammation
NCT0016686812	NCT00166868_12_T0	PHENOTYPE	17	18	ascending cholangitis
NCT0016686813	NCT00166868_13_T0	GENE	13	13	had
NCT0016686815	NCT00166868_15_T0	GENE	11	11	bid
NCT0016686818	NCT00166868_18_T0	PHENOTYPE	5	5	cholangitis
NCT0016686821	NCT00166868_21_T0	PHENOTYPE	8	8	complication
NCT0016686821	NCT00166868_21_T1	PHENOTYPE	7	7	recurrent
NCT0016686821	NCT00166868_21_T2	PHENOTYPE	0	1	Ascending cholangitis
NCT0016686822	NCT00166868_22_T0	PHENOTYPE	10	10	secondary
NCT0016686822	NCT00166868_22_T1	PHENOTYPE	21	22	portal hypertension
NCT0016686823	NCT00166868_23_T0	PHENOTYPE	14	14	recurrence
NCT0016686823	NCT00166868_23_T1	GENE	4	4	had
NCT0016686823	NCT00166868_23_T2	PHENOTYPE	16	17	ascending cholangitis
NCT0016686824	NCT00166868_24_T0	PHENOTYPE	18	18	recurrences
NCT0016686824	NCT00166868_24_T1	ORGAN	12	12	liver
NCT0016686824	NCT00166868_24_T2	PHENOTYPE	5	6	ascending cholangitis
NCT0016686825	NCT00166868_25_T0	GENE	14	14	had
NCT0016686825	NCT00166868_25_T1	PHENOTYPE	4	4	cholangitis
NCT0016686826	NCT00166868_26_T0	COMPOUND	4	4	trimethoprim_sulfamethoxazole
NCT0016686826	NCT00166868_26_T1	COMPOUND	7	7	neomycin
NCT0016686826	NCT00166868_26_T2	PHENOTYPE	15	16	ascending cholangitis
NCT0016686828	NCT00166868_28_T0	GENE	0	0	Is
NCT0016686830	NCT00166868_30_T0	ORGAN	20	20	liver
NCT0016686830	NCT00166868_30_T1	PHENOTYPE	12	13	intestinal infection
NCT0016686830	NCT00166868_30_T2	PHENOTYPE	13	15	infection or inflammation
NCT0016686831	NCT00166868_31_T0	PHENOTYPE	17	18	ascending cholangitis
NCT001668810	NCT00166881_0_T0	PHENOTYPE	4	5	Gastric Cancers
NCT001668812	NCT00166881_2_T0	GENE	12	12	PR
NCT001668812	NCT00166881_2_T1	PHENOTYPE	20	20	remission
NCT001668812	NCT00166881_2_T2	GENE	8	8	CR
NCT001668813	NCT00166881_3_T0	PHENOTYPE	7	7	remission
NCT001668814	NCT00166881_4_T0	PHENOTYPE	3	3	toxicities
NCT001668816	NCT00166881_6_T0	GENE	26	26	PR
NCT001668816	NCT00166881_6_T1	PHENOTYPE	17	17	remission
NCT001668816	NCT00166881_6_T2	GENE	24	24	CR
NCT001668817	NCT00166881_7_T0	PHENOTYPE	20	20	remission
NCT001668818	NCT00166881_8_T0	COMPOUND	9	9	irinotecan
NCT001668818	NCT00166881_8_T1	COMPOUND	7	7	docetaxel
NCT001668818	NCT00166881_8_T2	PHENOTYPE	16	17	gastric cancer
NCT0016688110	NCT00166881_10_T0	PHENOTYPE	4	5	gastric adenocarcinoma
NCT0016688111	NCT00166881_11_T0	PHENOTYPE	2	3	evaluable disease
NCT0016688118	NCT00166881_18_T0	PHENOTYPE	0	1	CNS metastasis
NCT001668943	NCT00166894_3_T0	CELL	10	10	macrophages
NCT001668943	NCT00166894_3_T1	GENE	16	16	TREM-1
NCT001668943	NCT00166894_3_T2	TISSUE	1	1	tissues
NCT001668943	NCT00166894_3_T3	PHENOTYPE	6	6	infiltrated
NCT001668943	NCT00166894_3_T4	CELL	8	8	neutrophils
NCT001668944	NCT00166894_4_T0	PHENOTYPE	13	13	disorders
NCT001668944	NCT00166894_4_T1	GENE	1	1	TREM-1
NCT001668946	NCT00166894_6_T0	GENE	7	7	TREM-1
NCT001668946	NCT00166894_6_T1	PHENOTYPE	28	28	pneumonia
NCT001668946	NCT00166894_6_T2	GENE	18	18	has
NCT001668946	NCT00166894_6_T3	GENE	4	5	soluble form
NCT001669071	NCT00166907_1_T0	COMPOUND	1	1	2
NCT001669071	NCT00166907_1_T1	PHENOTYPE	7	8	brain lesion
NCT001669072	NCT00166907_2_T0	COMPOUND	1	1	3
NCT001669073	NCT00166907_3_T0	PHENOTYPE	21	21	falls
NCT001669073	NCT00166907_3_T1	PHENOTYPE	17	17	strategies
NCT001669073	NCT00166907_3_T2	PHENOTYPE	27	28	brain lesion
NCT001669074	NCT00166907_4_T0	PHENOTYPE	28	29	brain lesion
NCT001669076	NCT00166907_6_T0	PHENOTYPE	17	17	strategies
NCT001669078	NCT00166907_8_T0	PHENOTYPE	0	0	Falls
NCT001669078	NCT00166907_8_T1	PHENOTYPE	6	6	complications
NCT001669079	NCT00166907_9_T0	PHENOTYPE	3	3	falls
NCT001669079	NCT00166907_9_T1	PHENOTYPE	20	20	falls
NCT0016690710	NCT00166907_10_T0	PHENOTYPE	13	13	falls
NCT0016690710	NCT00166907_10_T1	GENE	2	2	has
NCT0016690710	NCT00166907_10_T2	PHENOTYPE	0	1	Postural instability
NCT001669200	NCT00166920_0_T0	GENE	7	7	MRI
NCT001669200	NCT00166920_0_T1	PHENOTYPE	3	4	Oxygen Extraction
NCT001669202	NCT00166920_2_T0	COMPOUND	10	10	oxygen
NCT001669202	NCT00166920_2_T1	PHENOTYPE	7	8	metabolic rate
NCT001669204	NCT00166920_4_T0	COMPOUND	10	10	oxygen
NCT001669204	NCT00166920_4_T1	PHENOTYPE	7	8	metabolic rate
NCT001669331	NCT00166933_1_T0	PHENOTYPE	16	16	erythema
NCT001669334	NCT00166933_4_T0	PHENOTYPE	2	2	erythema
NCT001669464	NCT00166946_4_T0	COMPOUND	3	3	arsenical
NCT001669464	NCT00166946_4_T1	PHENOTYPE	4	5	skin cancer
NCT001669464	NCT00166946_4_T2	PHENOTYPE	12	16	carcinoma in situ of skin
NCT0016694610	NCT00166946_10_T0	CELL	4	4	lymphocytes
NCT0016694610	NCT00166946_10_T1	COMPOUND	14	14	arsenical
NCT0016694610	NCT00166946_10_T2	COMPOUND	3	3	arsenic
NCT0016694610	NCT00166946_10_T3	PHENOTYPE	5	5	dysfunction
NCT0016694611	NCT00166946_11_T0	CELL	18	18	cells
NCT0016694611	NCT00166946_11_T1	CELL	20	20	cells
NCT0016694611	NCT00166946_11_T2	PHENOTYPE	7	7	progression
NCT0016694611	NCT00166946_11_T3	PHENOTYPE	9	10	chemical carcinogenesis
NCT0016694612	NCT00166946_12_T0	COMPOUND	12	12	arsenic
NCT0016694612	NCT00166946_12_T1	TISSUE	16	16	epidermis
NCT0016694616	NCT00166946_16_T0	GENE	7	7	UVB
NCT0016694616	NCT00166946_16_T1	COMPOUND	5	5	arsenic
NCT0016694616	NCT00166946_16_T2	TISSUE	13	13	epidermis
NCT0016694617	NCT00166946_17_T0	CELL	9	9	cells
NCT0016694617	NCT00166946_17_T1	COMPOUND	15	15	arsenic
NCT0016694617	NCT00166946_17_T2	CELL	11	12	epidermal cells
NCT001669593	NCT00166959_3_T0	PHENOTYPE	14	14	falls
NCT001669593	NCT00166959_3_T1	GENE	3	3	has
NCT001669594	NCT00166959_4_T0	GENE	1	1	has
NCT001669594	NCT00166959_4_T1	PHENOTYPE	26	27	poor mobility
NCT001669595	NCT00166959_5_T0	PHENOTYPE	39	39	falls
NCT001669721	NCT00166972_1_T0	PHENOTYPE	24	24	metastasis
NCT001669721	NCT00166972_1_T1	GENE	5	5	trophinin
NCT001669721	NCT00166972_1_T2	PHENOTYPE	14	15	lung cancer
NCT001669723	NCT00166972_3_T0	GENE	26	26	TRO
NCT001669723	NCT00166972_3_T1	PHENOTYPE	7	7	metastasis
NCT001669723	NCT00166972_3_T2	GENE	25	25	trophinin
NCT001669723	NCT00166972_3_T3	GENE	8	8	suppressor
NCT001669723	NCT00166972_3_T4	GENE	9	9	CRMP-1
NCT001669726	NCT00166972_6_T0	GENE	3	3	trophinin
NCT001669726	NCT00166972_6_T1	PHENOTYPE	9	10	lung cancer
NCT001669852	NCT00166985_2_T0	PHENOTYPE	11	11	bilateral
NCT001669853	NCT00166985_3_T0	TISSUE	18	19	lymph node
NCT001669857	NCT00166985_7_T0	PHENOTYPE	12	12	hyperplasia
NCT001669857	NCT00166985_7_T1	PHENOTYPE	14	14	hyperplasia
NCT001669857	NCT00166985_7_T2	GENE	2	2	al
NCT001669857	NCT00166985_7_T3	GENE	1	1	et
NCT001669857	NCT00166985_7_T4	PHENOTYPE	15	16	atypical hyperplasia
NCT001669857	NCT00166985_7_T5	PHENOTYPE	20	21	endometrial carcinoma
NCT001669857	NCT00166985_7_T6	PHENOTYPE	24	25	endometrial carcinoma
NCT0016698515	NCT00166985_15_T0	GENE	8	8	MRI
NCT0016698515	NCT00166985_15_T1	PHENOTYPE	10	11	endometrial cancer
NCT0016698518	NCT00166985_18_T0	PHENOTYPE	11	11	bilateral
NCT0016698519	NCT00166985_19_T0	TISSUE	18	19	lymph node
NCT0016698523	NCT00166985_23_T0	PHENOTYPE	9	9	hyperplasia
NCT0016698523	NCT00166985_23_T1	PHENOTYPE	11	11	hyperplasia
NCT0016698523	NCT00166985_23_T2	GENE	2	2	al
NCT0016698523	NCT00166985_23_T3	GENE	23	23	has
NCT0016698523	NCT00166985_23_T4	GENE	1	1	et
NCT0016698523	NCT00166985_23_T5	PHENOTYPE	12	13	atypical hyperplasia
NCT0016698523	NCT00166985_23_T6	PHENOTYPE	17	18	endometrial carcinoma
NCT0016698523	NCT00166985_23_T7	PHENOTYPE	21	22	endometrial carcinoma
NCT0016698524	NCT00166985_24_T0	PHENOTYPE	21	21	tumors
NCT0016698524	NCT00166985_24_T1	PHENOTYPE	8	8	pulse
NCT0016698529	NCT00166985_29_T0	ORGAN	1	1	microvessel
NCT0016698529	NCT00166985_29_T1	GENE	4	4	has
NCT0016698530	NCT00166985_30_T0	PHENOTYPE	13	13	severity
NCT0016698530	NCT00166985_30_T1	PHENOTYPE	15	15	progression
NCT0016698530	NCT00166985_30_T2	ORGAN	4	4	microvessel
NCT0016698532	NCT00166985_32_T0	PHENOTYPE	0	1	Endometrial cancer
NCT0016698533	NCT00166985_33_T0	GENE	1	1	MRI
NCT0016698539	NCT00166985_39_T0	GENE	8	8	MRI
NCT0016698539	NCT00166985_39_T1	PHENOTYPE	10	11	endometrial cancer
NCT0016698540	NCT00166985_40_T0	PHENOTYPE	0	1	Endometrial cancer
NCT0016698541	NCT00166985_41_T0	PHENOTYPE	9	9	bilateral
NCT0016698541	NCT00166985_41_T1	GENE	7	7	abdominal
NCT0016698541	NCT00166985_41_T2	TISSUE	15	16	lymph node
NCT0016698542	NCT00166985_42_T0	PHENOTYPE	6	6	tumor
NCT0016698542	NCT00166985_42_T1	PHENOTYPE	20	22	lymph node metastasis
NCT0016698544	NCT00166985_44_T0	PHENOTYPE	6	6	adenocarcinoma
NCT0016698544	NCT00166985_44_T1	PHENOTYPE	8	8	adenoacanthoma
NCT0016698544	NCT00166985_44_T2	PHENOTYPE	0	0	Tumors
NCT001669981	NCT00166998_1_T0	PHENOTYPE	17	18	breast cancer
NCT0016702410	NCT00167024_10_T0	GENE	1	1	hMSH2
NCT0016702410	NCT00167024_10_T1	GENE	3	3	hMLH1
NCT0016702410	NCT00167024_10_T2	BIOLOGICAL_PROCESS	8	9	mismatch repair
NCT0016702411	NCT00167024_11_T0	GENE	1	1	XRCC3
NCT0016702411	NCT00167024_11_T1	PHENOTYPE	3	3	encoded
NCT0016702411	NCT00167024_11_T2	BIOLOGICAL_PROCESS	10	12	homologous recombinational repair
NCT001670370	NCT00167037_0_T0	PHENOTYPE	1	1	Stepping
NCT001670506	NCT00167050_6_T0	GENE	11	11	SLK
NCT001670508	NCT00167050_8_T0	GENE	12	12	CCR1
NCT001670508	NCT00167050_8_T1	GENE	16	16	CD30L
NCT001670508	NCT00167050_8_T2	GENE	6	6	chemokine
NCT001670508	NCT00167050_8_T3	GENE	20	20	MMP-1
NCT001670508	NCT00167050_8_T4	GENE	11	11	CXCR4
NCT001670508	NCT00167050_8_T5	COMPOUND	21	21	2
NCT001670508	NCT00167050_8_T6	COMPOUND	22	22	3
NCT001670508	NCT00167050_8_T7	GENE	8	8	CXCR1
NCT001670508	NCT00167050_8_T8	GENE	10	10	CXCR3
NCT001670508	NCT00167050_8_T9	GENE	9	9	CXCR2
NCT001670508	NCT00167050_8_T10	GENE	15	15	CCR5
NCT001670508	NCT00167050_8_T11	GENE	14	14	CCR4
NCT001670508	NCT00167050_8_T12	GENE	13	13	CCR3
NCT0016705014	NCT00167050_14_T0	GENE	12	12	cDNA
NCT0016705015	NCT00167050_15_T0	GENE	14	14	CCR1
NCT0016705015	NCT00167050_15_T1	GENE	19	19	CD30L
NCT0016705015	NCT00167050_15_T2	GENE	13	13	CXCR4
NCT0016705015	NCT00167050_15_T3	GENE	10	10	CXCR1
NCT0016705015	NCT00167050_15_T4	GENE	12	12	CXCR3
NCT0016705015	NCT00167050_15_T5	GENE	11	11	CXCR2
NCT0016705015	NCT00167050_15_T6	GENE	17	17	CCR5
NCT0016705015	NCT00167050_15_T7	GENE	16	16	CCR4
NCT0016705015	NCT00167050_15_T8	GENE	15	15	CCR3
NCT0016705021	NCT00167050_21_T0	GENE	11	11	cDNA
NCT0016705021	NCT00167050_21_T1	GENE	25	25	dehydrogenase
NCT0016705021	NCT00167050_21_T2	GENE	26	26	GAPDH
NCT0016705021	NCT00167050_21_T3	GENE	3	3	PCR
NCT0016705021	NCT00167050_21_T4	GENE	4	4	PCR
NCT0016705023	NCT00167050_23_T0	GENE	8	8	cDNA
NCT0016705023	NCT00167050_23_T1	GENE	18	18	PCR
NCT0016705024	NCT00167050_24_T0	GENE	4	4	chemokine
NCT0016705024	NCT00167050_24_T1	GENE	6	7	chemokine receptor
NCT0016705027	NCT00167050_27_T0	COMPOUND	16	16	agarose
NCT0016705027	NCT00167050_27_T1	GENE	9	9	separated
NCT0016705027	NCT00167050_27_T2	GENE	5	5	PCR
NCT0016705027	NCT00167050_27_T3	GENE	12	12	gel
NCT0016705027	NCT00167050_27_T4	COMPOUND	18	19	ethidium bromide
NCT0016705028	NCT00167050_28_T0	COMPOUND	2	2	agarose
NCT0016705028	NCT00167050_28_T1	GENE	3	3	gel
NCT0016705029	NCT00167050_29_T0	GENE	8	8	GAPDH
NCT0016705029	NCT00167050_29_T1	PHENOTYPE	1	2	internal control
NCT0016705033	NCT00167050_33_T0	PHENOTYPE	10	10	immersion
NCT0016705033	NCT00167050_33_T1	COMPOUND	16	16	ethanol
NCT0016705034	NCT00167050_34_T0	GENE	10	10	SA
NCT0016705036	NCT00167050_36_T0	ORGAN	6	6	serum
NCT0016705040	NCT00167050_40_T0	COMPOUND	10	10	hematoxylin
NCT001670630	NCT00167063_0_T0	PHENOTYPE	0	0	Falls
NCT001670633	NCT00167063_3_T0	PHENOTYPE	6	6	falls
NCT001670633	NCT00167063_3_T1	PHENOTYPE	18	18	falls
NCT001670633	NCT00167063_3_T2	PHENOTYPE	25	25	dysfunction
NCT001670633	NCT00167063_3_T3	PHENOTYPE	21	22	cognitive impairment
NCT001670634	NCT00167063_4_T0	PHENOTYPE	3	3	falls
NCT001670634	NCT00167063_4_T1	PHENOTYPE	10	10	falls
NCT001670634	NCT00167063_4_T2	PHENOTYPE	8	8	focused
NCT001670635	NCT00167063_5_T0	PHENOTYPE	3	3	falls
NCT001670635	NCT00167063_5_T1	PHENOTYPE	1	1	focused
NCT001670636	NCT00167063_6_T0	PHENOTYPE	15	15	falls
NCT001670637	NCT00167063_7_T0	PHENOTYPE	7	7	falls
NCT001670637	NCT00167063_7_T1	PHENOTYPE	19	19	chronic
NCT001670638	NCT00167063_8_T0	PHENOTYPE	3	3	falls
NCT001670763	NCT00167076_3_T0	PHENOTYPE	6	6	aids
NCT001670766	NCT00167076_6_T0	PHENOTYPE	33	33	aids
NCT001670769	NCT00167076_9_T0	PHENOTYPE	27	27	aids
NCT0016707611	NCT00167076_11_T0	PHENOTYPE	33	33	aids
NCT0016707611	NCT00167076_11_T1	ORGAN	21	22	lower extremities
NCT001670894	NCT00167089_4_T0	GENE	3	3	has
NCT001671025	NCT00167102_5_T0	PHENOTYPE	3	4	lymphocytic infiltrate
NCT001671026	NCT00167102_6_T0	PHENOTYPE	1	2	cellular infiltrate
NCT001671026	NCT00167102_6_T1	CELL	10	11	Langerhans cells
NCT001671029	NCT00167102_9_T0	GENE	10	10	receptor
NCT001671029	NCT00167102_9_T1	CELL	2	2	T-cells
NCT001671029	NCT00167102_9_T2	CELL	9	9	T-cell
NCT001671029	NCT00167102_9_T3	CELL	18	19	antigen-presenting cells
NCT0016710212	NCT00167102_12_T0	PHENOTYPE	26	27	alopecia areata
NCT0016710215	NCT00167102_15_T0	PHENOTYPE	0	0	Psoriasis
NCT0016710215	NCT00167102_15_T1	CELL	3	3	T-cell
NCT0016710215	NCT00167102_15_T2	PHENOTYPE	12	13	alopecia areata
NCT0016710217	NCT00167102_17_T0	COMPOUND	6	6	cyclosporine
NCT0016710217	NCT00167102_17_T1	PHENOTYPE	17	17	disorders
NCT001671153	NCT00167115_3_T0	PHENOTYPE	4	6	alcohol induced hypoglycemia
NCT001671156	NCT00167115_6_T0	PHENOTYPE	6	6	acute
NCT001671156	NCT00167115_6_T1	PHENOTYPE	21	22	glucose levels
NCT001671157	NCT00167115_7_T0	ORGAN	20	20	plasma
NCT001671158	NCT00167115_8_T0	GENE	5	6	type 2
NCT0016711510	NCT00167115_10_T0	GENE	19	19	am
NCT0016711510	NCT00167115_10_T1	PHENOTYPE	3	4	plasma glucose
NCT0016711510	NCT00167115_10_T2	PHENOTYPE	6	7	serum insulin
NCT0016711512	NCT00167115_12_T0	PHENOTYPE	9	10	plasma glucose
NCT0016711513	NCT00167115_13_T0	GENE	9	9	4-8
NCT0016711515	NCT00167115_15_T0	GENE	9	9	HDL
NCT001671542	NCT00167154_2_T0	COMPOUND	10	10	risperidone
NCT001671548	NCT00167154_8_T0	PHENOTYPE	2	4	major depressive disorder
NCT0016715413	NCT00167154_13_T0	PHENOTYPE	14	14	schizophrenia
NCT0016715413	NCT00167154_13_T1	PHENOTYPE	16	17	anxiety disorders
NCT0016715413	NCT00167154_13_T2	PHENOTYPE	12	13	bipolar disorder
NCT0016715413	NCT00167154_13_T3	PHENOTYPE	7	9	major depressive disorder
NCT0016715413	NCT00167154_13_T4	PHENOTYPE	20	22	generalized anxiety disorder
NCT0016715414	NCT00167154_14_T0	PHENOTYPE	0	1	Depressive symptoms
NCT0016715414	NCT00167154_14_T1	PHENOTYPE	6	7	substance abuse
NCT001671672	NCT00167167_2_T0	CELL	8	8	lymphocytes
NCT001671672	NCT00167167_2_T1	ORGAN	16	17	immune system
NCT001671674	NCT00167167_4_T0	CELL	2	2	lymphocytes
NCT001671675	NCT00167167_5_T0	GENE	19	19	aa
NCT001671675	NCT00167167_5_T1	CELL	18	18	lymphocytes
NCT001671675	NCT00167167_5_T2	PHENOTYPE	5	5	complications
NCT001671675	NCT00167167_5_T3	PHENOTYPE	25	26	in remission
NCT001671676	NCT00167167_6_T0	CELL	11	11	lymphocytes
NCT001671676	NCT00167167_6_T1	ORGAN	1	2	bone marrow
NCT001671677	NCT00167167_7_T0	CELL	1	1	lymphocyte
NCT001671677	NCT00167167_7_T1	ORGAN	4	5	bone marrow
NCT0016716710	NCT00167167_10_T0	CELL	13	13	leukocyte
NCT0016716710	NCT00167167_10_T1	PHENOTYPE	1	1	lymphomas
NCT0016716710	NCT00167167_10_T2	PHENOTYPE	7	7	lymphomas
NCT0016716711	NCT00167167_11_T0	PHENOTYPE	11	11	diseases
NCT0016716711	NCT00167167_11_T1	CELL	3	3	leukocytes
NCT0016716712	NCT00167167_12_T0	PHENOTYPE	6	6	disorders
NCT0016716712	NCT00167167_12_T1	PHENOTYPE	3	3	relapse
NCT0016716712	NCT00167167_12_T2	CELL	12	12	leukocyte
NCT0016716712	NCT00167167_12_T3	PHENOTYPE	0	1	Graft failure
NCT0016716713	NCT00167167_13_T0	PHENOTYPE	4	4	relapse
NCT0016716713	NCT00167167_13_T1	ORGAN	0	1	Autologous transplant
NCT0016716714	NCT00167167_14_T0	PHENOTYPE	3	3	diseases
NCT0016716714	NCT00167167_14_T1	PHENOTYPE	13	14	skin cancers
NCT001671803	NCT00167180_3_T0	CELL	10	10	cells
NCT001671803	NCT00167180_3_T1	PHENOTYPE	14	15	graft-versus-host disease
NCT001671805	NCT00167180_5_T0	CELL	9	9	cells
NCT001671805	NCT00167180_5_T1	COMPOUND	23	23	fludarabine
NCT001671805	NCT00167180_5_T2	COMPOUND	21	21	cyclophosphamide
NCT001671805	NCT00167180_5_T3	ORGAN	13	14	bone marrow
NCT001671805	NCT00167180_5_T4	ORGAN	28	29	immune system
NCT001671808	NCT00167180_8_T0	ORGAN	7	7	appendix
NCT001671808	NCT00167180_8_T1	PHENOTYPE	5	5	relapse
NCT0016718010	NCT00167180_10_T0	PHENOTYPE	3	3	relapse
NCT001672062	NCT00167206_2_T0	ORGAN	5	5	transplant
NCT001672063	NCT00167206_3_T0	ORGAN	4	4	transplant
NCT001672064	NCT00167206_4_T0	ORGAN	18	18	marrow
NCT001672064	NCT00167206_4_T1	CELL	11	12	stem cells
NCT001672065	NCT00167206_5_T0	ORGAN	1	1	transplant
NCT001672065	NCT00167206_5_T1	CELL	4	5	stem cells
NCT001672065	NCT00167206_5_T2	ORGAN	16	17	bone marrow
NCT001672067	NCT00167206_7_T0	GENE	9	9	thymic
NCT001672067	NCT00167206_7_T1	GENE	29	29	thymic
NCT001672067	NCT00167206_7_T2	GENE	4	4	has
NCT001672193	NCT00167219_3_T0	PHENOTYPE	10	10	leukemia
NCT001672193	NCT00167219_3_T1	COMPOUND	3	3	melphalan
NCT001672193	NCT00167219_3_T2	COMPOUND	1	1	cyclophosphamide
NCT001672194	NCT00167219_4_T0	ORGAN	9	10	immune system
NCT001672194	NCT00167219_4_T1	ORGAN	16	17	bone marrow
NCT001672195	NCT00167219_5_T0	ORGAN	20	20	transplant
NCT001672195	NCT00167219_5_T1	ORGAN	5	6	bone marrow
NCT001672195	NCT00167219_5_T2	ORGAN	18	19	bone marrow
NCT001672195	NCT00167219_5_T3	ORGAN	8	10	umbilical cord blood
NCT001672196	NCT00167219_6_T0	CELL	2	2	cells
NCT001672196	NCT00167219_6_T1	ORGAN	7	8	bone marrow
NCT001672321	NCT00167232_1_T0	PHENOTYPE	14	15	alcohol dependence
NCT001672324	NCT00167232_4_T0	COMPOUND	12	12	naltrexone
NCT001672324	NCT00167232_4_T1	PHENOTYPE	10	11	alcohol dependence
NCT001672325	NCT00167232_5_T0	BIOLOGICAL_PROCESS	17	17	drinking
NCT001672326	NCT00167232_6_T0	GENE	9	9	has
NCT001672326	NCT00167232_6_T1	PHENOTYPE	20	21	cocaine dependence
NCT001672328	NCT00167232_8_T0	COMPOUND	18	18	cocaine
NCT001672329	NCT00167232_9_T0	PHENOTYPE	21	21	relapse
NCT001672329	NCT00167232_9_T1	COMPOUND	23	23	cocaine
NCT0016723210	NCT00167232_10_T0	COMPOUND	15	15	cocaine
NCT001672451	NCT00167245_1_T0	PHENOTYPE	7	7	seizures
NCT001672452	NCT00167245_2_T0	GENE	1	1	has
NCT001672452	NCT00167245_2_T1	PHENOTYPE	14	15	cocaine dependence
NCT001672710	NCT00167271_0_T0	PHENOTYPE	5	5	Fibromyalgia
NCT001672715	NCT00167271_5_T0	PHENOTYPE	22	22	fibromyalgia
NCT001672716	NCT00167271_6_T0	PHENOTYPE	13	13	Center
NCT001672716	NCT00167271_6_T1	PHENOTYPE	36	36	fibromyalgia
NCT001672716	NCT00167271_6_T2	PHENOTYPE	30	32	quality of life
NCT001672717	NCT00167271_7_T0	PHENOTYPE	32	33	emotional state
NCT001672719	NCT00167271_9_T0	PHENOTYPE	24	24	Center
NCT001672719	NCT00167271_9_T1	PHENOTYPE	18	18	self-assessment
NCT0016727111	NCT00167271_11_T0	PHENOTYPE	9	9	fibromyalgia
NCT0016727112	NCT00167271_12_T0	PHENOTYPE	27	27	symptoms
NCT0016727112	NCT00167271_12_T1	PHENOTYPE	29	29	fibromyalgia
NCT0016727113	NCT00167271_13_T0	PHENOTYPE	8	8	fibromyalgia
NCT0016727113	NCT00167271_13_T1	PHENOTYPE	9	9	impairment
NCT001672843	NCT00167284_3_T0	PHENOTYPE	15	15	practices
NCT001672846	NCT00167284_6_T0	PHENOTYPE	14	16	quality of life
NCT001672971	NCT00167297_1_T0	GENE	7	7	has
NCT001672971	NCT00167297_1_T1	PHENOTYPE	20	21	substance dependence
NCT001672971	NCT00167297_1_T2	PHENOTYPE	15	17	attention deficit disorder
NCT001672972	NCT00167297_2_T0	PHENOTYPE	13	14	drug abuse
NCT001672972	NCT00167297_2_T1	PHENOTYPE	7	9	attention deficit disorder
NCT001672973	NCT00167297_3_T0	COMPOUND	7	7	cocaine
NCT001672973	NCT00167297_3_T1	PHENOTYPE	5	5	cannabis
NCT001672975	NCT00167297_5_T0	PHENOTYPE	4	4	cannabis
NCT001672975	NCT00167297_5_T1	PHENOTYPE	22	22	cannabis
NCT0016729710	NCT00167297_10_T0	GENE	1	1	PI
NCT0016729711	NCT00167297_11_T0	GENE	11	11	PI
NCT0016729713	NCT00167297_13_T0	GENE	4	4	PI
NCT0016729713	NCT00167297_13_T1	PHENOTYPE	13	14	adverse events
NCT0016729720	NCT00167297_20_T0	COMPOUND	17	17	acetate
NCT0016729720	NCT00167297_20_T1	ORGAN	7	7	diaphragm
NCT0016729721	NCT00167297_21_T0	GENE	9	9	axis
NCT0016729721	NCT00167297_21_T1	PHENOTYPE	6	7	sinus tachycardia
NCT0016729721	NCT00167297_21_T2	PHENOTYPE	2	5	1st degree heart block
NCT001673104	NCT00167310_4_T0	PHENOTYPE	30	30	severity
NCT001673104	NCT00167310_4_T1	GENE	7	7	EPA
NCT001673104	NCT00167310_4_T2	ORGAN	15	15	plasma
NCT001673106	NCT00167310_6_T0	GENE	8	8	EPA
NCT001673234	NCT00167323_4_T0	PHENOTYPE	21	22	bipolar disorder
NCT001673236	NCT00167323_6_T0	PHENOTYPE	12	12	alcoholism
NCT001673236	NCT00167323_6_T1	GENE	20	20	has
NCT001673236	NCT00167323_6_T2	PHENOTYPE	15	17	substance use disorders
NCT001673238	NCT00167323_8_T0	PHENOTYPE	11	11	alcoholism
NCT001673238	NCT00167323_8_T1	PHENOTYPE	8	9	bipolar disorder
NCT0016732310	NCT00167323_10_T0	PHENOTYPE	20	20	symptoms
NCT0016732310	NCT00167323_10_T1	PHENOTYPE	27	27	alcoholism
NCT0016732310	NCT00167323_10_T2	PHENOTYPE	24	25	bipolar disorder
NCT0016732312	NCT00167323_12_T0	PHENOTYPE	30	30	disorders
NCT0016732312	NCT00167323_12_T1	PHENOTYPE	26	26	alcoholism
NCT0016732315	NCT00167323_15_T0	PHENOTYPE	5	6	Bipolar disorder
NCT0016732315	NCT00167323_15_T1	PHENOTYPE	8	10	alcohol use disorder
NCT0016732319	NCT00167323_19_T0	PHENOTYPE	0	0	Schizophrenia
NCT0016732319	NCT00167323_19_T1	PHENOTYPE	10	11	mental retardation
NCT0016732319	NCT00167323_19_T2	PHENOTYPE	16	17	cognitive functioning
NCT0016732319	NCT00167323_19_T3	PHENOTYPE	5	6	psychotic disorder
NCT0016732319	NCT00167323_19_T4	PHENOTYPE	8	9	major depression
NCT0016732319	NCT00167323_19_T5	PHENOTYPE	1	2	schizoaffective disorder
NCT0016733622	NCT00167336_22_T0	ORGAN	20	20	hands
NCT0016733625	NCT00167336_25_T0	GENE	2	2	II
NCT001673494	NCT00167349_4_T0	GENE	2	2	has
NCT001673495	NCT00167349_5_T0	PHENOTYPE	18	18	illnesses
NCT001673495	NCT00167349_5_T1	PHENOTYPE	8	8	heterogeneous
NCT001673495	NCT00167349_5_T2	PHENOTYPE	15	16	variable severity
NCT001673624	NCT00167362_4_T0	GENE	36	36	EST
NCT001673624	NCT00167362_4_T1	GENE	38	38	EST
NCT001673624	NCT00167362_4_T2	PHENOTYPE	22	22	initiation
NCT001673624	NCT00167362_4_T3	GENE	15	15	atypical
NCT001673624	NCT00167362_4_T4	PHENOTYPE	7	8	psychotic symptoms
NCT001673625	NCT00167362_5_T0	GENE	16	16	EST
NCT001673625	NCT00167362_5_T1	GENE	20	20	CNMD
NCT001673626	NCT00167362_6_T0	GENE	26	26	PFC
NCT0016736210	NCT00167362_10_T0	GENE	36	36	The
NCT0016736210	NCT00167362_10_T1	GENE	6	6	EST
NCT0016736210	NCT00167362_10_T2	GENE	12	12	EST
NCT0016736210	NCT00167362_10_T3	PHENOTYPE	19	20	cognitive deficits
NCT0016736210	NCT00167362_10_T4	PHENOTYPE	28	29	psychotic symptoms
NCT0016736212	NCT00167362_12_T0	GENE	40	40	The
NCT0016736212	NCT00167362_12_T1	GENE	38	38	CNMD
NCT0016736213	NCT00167362_13_T0	GENE	13	13	EST
NCT0016736213	NCT00167362_13_T1	GENE	18	18	EST
NCT0016736215	NCT00167362_15_T0	GENE	6	6	EST
NCT0016736216	NCT00167362_16_T0	GENE	17	17	had
NCT0016736216	NCT00167362_16_T1	GENE	26	26	had
NCT0016736218	NCT00167362_18_T0	GENE	8	8	EST
NCT001673752	NCT00167375_2_T0	PHENOTYPE	25	26	primary insomnia
NCT001673753	NCT00167375_3_T0	PHENOTYPE	14	14	insomnia
NCT001673753	NCT00167375_3_T1	PHENOTYPE	1	2	primary insomnia
NCT001673757	NCT00167375_7_T0	PHENOTYPE	15	16	sleep apnea
NCT001673757	NCT00167375_7_T1	PHENOTYPE	18	21	periodic limb movement disorder
NCT0016737515	NCT00167375_15_T0	COMPOUND	8	8	eszopiclone
NCT0016737515	NCT00167375_15_T1	PHENOTYPE	15	15	insomnia
NCT001673882	NCT00167388_2_T0	ORGAN	12	12	intestines
NCT001673884	NCT00167388_4_T0	PHENOTYPE	16	16	hyperemia
NCT001673884	NCT00167388_4_T1	ORGAN	7	9	superior mesenteric artery
NCT001673886	NCT00167388_6_T0	ORGAN	14	16	superior mesenteric artery
NCT001673888	NCT00167388_8_T0	GENE	12	12	NPO
NCT0016738811	NCT00167388_11_T0	PHENOTYPE	23	24	premature infants
NCT0016738811	NCT00167388_11_T1	ORGAN	8	10	superior mesenteric artery
NCT0016738812	NCT00167388_12_T0	PHENOTYPE	1	1	secondary
NCT0016738813	NCT00167388_13_T0	PHENOTYPE	10	10	regression
NCT0016738813	NCT00167388_13_T1	GENE	6	6	unpaired
NCT0016738813	NCT00167388_13_T2	GENE	4	4	paired
NCT0016738816	NCT00167388_16_T0	BIOLOGICAL_PROCESS	4	4	gestation
NCT0016738816	NCT00167388_16_T1	BIOLOGICAL_PROCESS	9	9	gestation
NCT0016738818	NCT00167388_18_T0	GENE	7	7	PE
NCT0016738822	NCT00167388_22_T0	ORGAN	9	9	intestine
NCT0016738822	NCT00167388_22_T1	ORGAN	7	7	kidneys
NCT0016738822	NCT00167388_22_T2	ORGAN	5	5	heart
NCT0016738822	NCT00167388_22_T3	PHENOTYPE	1	2	congenital anomalies
NCT0016738823	NCT00167388_23_T0	PHENOTYPE	0	1	Chromosomal abnormality
NCT0016738825	NCT00167388_25_T0	PHENOTYPE	0	3	Twin to twin transfusion
NCT0016738827	NCT00167388_27_T0	PHENOTYPE	0	2	Patent ductus arteriosus
NCT0016738828	NCT00167388_28_T0	PHENOTYPE	3	4	necrotizing enterocolitis
NCT001674014	NCT00167401_4_T0	GENE	11	11	has
NCT001674015	NCT00167401_5_T0	PHENOTYPE	31	32	lung cancer
NCT001674016	NCT00167401_6_T0	PHENOTYPE	8	10	quality of life
NCT001674019	NCT00167401_9_T0	GENE	12	12	T4
NCT001674019	NCT00167401_9_T1	PHENOTYPE	16	16	diseases
NCT001674019	NCT00167401_9_T2	ORGAN	26	26	Appendix
NCT001674019	NCT00167401_9_T3	COMPOUND	14	14	N
NCT0016740110	NCT00167401_10_T0	PHENOTYPE	2	4	malignant pleural effusion
NCT0016740116	NCT00167401_16_T0	PHENOTYPE	32	32	metastasis
NCT0016740116	NCT00167401_16_T1	PHENOTYPE	3	3	enlargement
NCT0016740119	NCT00167401_19_T0	PHENOTYPE	1	1	neuropathy
NCT0016740121	NCT00167401_21_T0	PHENOTYPE	7	9	negative pregnancy test
NCT0016740123	NCT00167401_23_T0	PHENOTYPE	5	5	metastasis
NCT0016740123	NCT00167401_23_T1	GENE	7	7	IV
NCT0016740124	NCT00167401_24_T0	PHENOTYPE	2	3	measurable disease
NCT0016740127	NCT00167401_27_T0	PHENOTYPE	2	3	bilirubin elevated
NCT001674142	NCT00167414_2_T0	PHENOTYPE	28	30	quality of life
NCT001674146	NCT00167414_6_T0	PHENOTYPE	15	15	5-10
NCT001674146	NCT00167414_6_T1	PHENOTYPE	8	10	Quality of Life
NCT001674148	NCT00167414_8_T0	PHENOTYPE	12	12	metastasis
NCT001674272	NCT00167427_2_T0	PHENOTYPE	10	10	peripheral
NCT001674401	NCT00167440_1_T0	ORGAN	9	9	heart
NCT001674401	NCT00167440_1_T1	ORGAN	30	30	heart
NCT001674402	NCT00167440_2_T0	PHENOTYPE	42	42	illnesses
NCT001674402	NCT00167440_2_T1	ORGAN	10	10	heart
NCT001674402	NCT00167440_2_T2	ORGAN	35	35	heart
NCT001674403	NCT00167440_3_T0	ORGAN	10	10	heart
NCT001674404	NCT00167440_4_T0	ORGAN	9	9	heart
NCT001674405	NCT00167440_5_T0	PHENOTYPE	22	22	illnesses
NCT001674405	NCT00167440_5_T1	PHENOTYPE	38	38	outlook
NCT001674405	NCT00167440_5_T2	ORGAN	12	12	heart
NCT001674406	NCT00167440_6_T0	ORGAN	19	19	heart
NCT0016744010	NCT00167440_10_T0	PHENOTYPE	6	7	critically ill
NCT0016744014	NCT00167440_14_T0	PHENOTYPE	23	23	regression
NCT001674663	NCT00167466_3_T0	PHENOTYPE	6	6	inflammation
NCT001674663	NCT00167466_3_T1	GENE	12	12	al
NCT001674663	NCT00167466_3_T2	GENE	11	11	et
NCT001674664	NCT00167466_4_T0	GENE	46	46	1976
NCT001674664	NCT00167466_4_T1	GENE	15	15	eg
NCT001674664	NCT00167466_4_T2	PHENOTYPE	22	22	bleeding
NCT001674664	NCT00167466_4_T3	GENE	35	35	al
NCT001674664	NCT00167466_4_T4	GENE	39	39	al
NCT001674664	NCT00167466_4_T5	GENE	45	45	al
NCT001674664	NCT00167466_4_T6	GENE	49	49	al
NCT001674664	NCT00167466_4_T7	GENE	34	34	et
NCT001674664	NCT00167466_4_T8	GENE	38	38	et
NCT001674664	NCT00167466_4_T9	GENE	44	44	et
NCT001674664	NCT00167466_4_T10	GENE	48	48	et
NCT001674664	NCT00167466_4_T11	PHENOTYPE	18	19	gingival pocket
NCT001674664	NCT00167466_4_T12	PHENOTYPE	13	14	periodontal disease
NCT001674664	NCT00167466_4_T13	PHENOTYPE	28	29	periodontal disease
NCT001674666	NCT00167466_6_T0	COMPOUND	13	13	titanium
NCT001674667	NCT00167466_7_T0	PHENOTYPE	7	7	plaque
NCT001674667	NCT00167466_7_T1	PHENOTYPE	23	23	plaque
NCT001674667	NCT00167466_7_T2	GENE	8	8	has
NCT001674668	NCT00167466_8_T0	PHENOTYPE	4	4	plaque
NCT001674668	NCT00167466_8_T1	PHENOTYPE	15	15	plaque
NCT001674669	NCT00167466_9_T0	PHENOTYPE	20	20	plaque
NCT001674669	NCT00167466_9_T1	PHENOTYPE	18	18	bonding
NCT001674669	NCT00167466_9_T2	GENE	40	40	al
NCT001674669	NCT00167466_9_T3	GENE	44	44	al
NCT001674669	NCT00167466_9_T4	GENE	48	48	al
NCT001674669	NCT00167466_9_T5	GENE	39	39	et
NCT001674669	NCT00167466_9_T6	GENE	43	43	et
NCT001674669	NCT00167466_9_T7	GENE	47	47	et
NCT0016746610	NCT00167466_10_T0	GENE	20	20	al
NCT0016746610	NCT00167466_10_T1	GENE	24	24	al
NCT0016746610	NCT00167466_10_T2	GENE	19	19	et
NCT0016746610	NCT00167466_10_T3	GENE	23	23	et
NCT001674793	NCT00167479_3_T0	GENE	10	10	1.1
NCT001674793	NCT00167479_3_T1	COMPOUND	5	5	risperidone
NCT001674794	NCT00167479_4_T0	COMPOUND	28	28	zaleplon
NCT001674794	NCT00167479_4_T1	PHENOTYPE	23	23	symptoms
NCT001674794	NCT00167479_4_T2	COMPOUND	26	26	zolpidem
NCT001674794	NCT00167479_4_T3	COMPOUND	10	10	lorazepam
NCT001674794	NCT00167479_4_T4	GENE	9	9	prn
NCT001674794	NCT00167479_4_T5	GENE	25	25	prn
NCT001674794	NCT00167479_4_T6	PHENOTYPE	36	36	insomnia
NCT001674795	NCT00167479_5_T0	PHENOTYPE	10	11	psychiatric symptoms
NCT001674795	NCT00167479_5_T1	PHENOTYPE	17	18	adverse events
NCT0016747920	NCT00167479_20_T0	GENE	18	18	has
NCT0016747924	NCT00167479_24_T0	PHENOTYPE	6	7	bipolar disorder
NCT0016747926	NCT00167479_26_T0	PHENOTYPE	6	7	panic disorder
NCT0016747926	NCT00167479_26_T1	PHENOTYPE	9	11	generalized anxiety disorder
NCT0016747928	NCT00167479_28_T0	COMPOUND	12	12	lithium
NCT0016747928	NCT00167479_28_T1	COMPOUND	13	13	valproate
NCT0016747928	NCT00167479_28_T2	COMPOUND	14	14	carbamazepine
NCT0016747934	NCT00167479_34_T0	PHENOTYPE	6	6	homicidal
NCT0016747934	NCT00167479_34_T1	PHENOTYPE	7	7	ideation
NCT0016747936	NCT00167479_36_T0	PHENOTYPE	3	4	psychotic symptoms
NCT0016747938	NCT00167479_38_T0	PHENOTYPE	35	35	schizophrenia
NCT0016747938	NCT00167479_38_T1	PHENOTYPE	11	11	amnesia
NCT0016747938	NCT00167479_38_T2	PHENOTYPE	10	10	dementia
NCT0016747938	NCT00167479_38_T3	PHENOTYPE	9	9	delirium
NCT0016747938	NCT00167479_38_T4	PHENOTYPE	32	33	psychotic disorder
NCT0016747938	NCT00167479_38_T5	PHENOTYPE	21	22	substance dependence
NCT0016747938	NCT00167479_38_T6	PHENOTYPE	14	15	cognitive disorders
NCT0016747938	NCT00167479_38_T7	PHENOTYPE	37	38	schizoaffective disorder
NCT0016747940	NCT00167479_40_T0	PHENOTYPE	5	5	illnesses
NCT0016747940	NCT00167479_40_T1	PHENOTYPE	14	15	hematologic disease
NCT001674921	NCT00167492_1_T0	GENE	5	5	had
NCT001674922	NCT00167492_2_T0	ORGAN	26	27	immune system
NCT001674923	NCT00167492_3_T0	ORGAN	24	25	immune system
NCT001674924	NCT00167492_4_T0	ORGAN	16	16	liver
NCT001674927	NCT00167492_7_T0	ORGAN	10	10	liver
NCT001674928	NCT00167492_8_T0	GENE	18	18	GI
NCT001674928	NCT00167492_8_T1	GENE	10	10	has
NCT001674928	NCT00167492_8_T2	PHENOTYPE	4	4	MPA
NCT001674929	NCT00167492_9_T0	ORGAN	11	11	kidney
NCT001674929	NCT00167492_9_T1	GENE	13	13	ref
NCT001674929	NCT00167492_9_T2	GENE	3	3	has
NCT001674929	NCT00167492_9_T3	ORGAN	12	12	transplants
NCT0016749211	NCT00167492_11_T0	PHENOTYPE	17	18	adverse effects
NCT0016749217	NCT00167492_17_T0	ORGAN	22	23	immune system
NCT0016749219	NCT00167492_19_T0	GENE	21	21	CNI
NCT0016749219	NCT00167492_19_T1	PHENOTYPE	4	4	MPA
NCT0016749220	NCT00167492_20_T0	GENE	3	3	GI
NCT0016749220	NCT00167492_20_T1	PHENOTYPE	0	0	Avoidance
NCT0016749220	NCT00167492_20_T2	PHENOTYPE	9	9	MPA
NCT0016749222	NCT00167492_22_T0	PHENOTYPE	23	23	immunosuppression
NCT0016749222	NCT00167492_22_T1	PHENOTYPE	15	15	MPA
NCT0016749223	NCT00167492_23_T0	GENE	13	13	CNI
NCT0016749223	NCT00167492_23_T1	PHENOTYPE	10	11	adverse effects
NCT001675051	NCT00167505_1_T0	PHENOTYPE	6	6	avoidance
NCT0016750510	NCT00167505_10_T0	PHENOTYPE	8	8	avoidance
NCT0016750513	NCT00167505_13_T0	PHENOTYPE	2	2	avoidance
NCT0016750515	NCT00167505_15_T0	PHENOTYPE	2	2	avoidance
NCT0016750518	NCT00167505_18_T0	GENE	21	21	18
NCT0016750520	NCT00167505_20_T0	PHENOTYPE	16	16	gonorrhea
NCT0016750520	NCT00167505_20_T1	PHENOTYPE	18	18	trichomonas
NCT001675184	NCT00167518_4_T0	GENE	5	5	has
NCT001675184	NCT00167518_4_T1	PHENOTYPE	16	18	diabetic macular oedema
NCT001675185	NCT00167518_5_T0	ORGAN	42	42	eyes
NCT001675185	NCT00167518_5_T1	PHENOTYPE	24	24	focal
NCT001675185	NCT00167518_5_T2	GENE	26	26	grid
NCT001675185	NCT00167518_5_T3	COMPOUND	18	18	triamcinolone
NCT001675185	NCT00167518_5_T4	PHENOTYPE	32	34	diabetic macular oedema
NCT001675186	NCT00167518_6_T0	GENE	0	0	OCT
NCT001675186	NCT00167518_6_T1	PHENOTYPE	15	16	macular oedema
NCT001675310	NCT00167531_0_T0	PHENOTYPE	9	9	Stroke
NCT001675313	NCT00167531_3_T0	PHENOTYPE	7	9	unable to walk
NCT001675315	NCT00167531_5_T0	PHENOTYPE	11	13	unable to walk
NCT001675318	NCT00167531_8_T0	GENE	7	7	al
NCT001675318	NCT00167531_8_T1	GENE	6	6	et
NCT001675319	NCT00167531_9_T0	PHENOTYPE	8	10	unable to walk
NCT001675443	NCT00167544_3_T0	COMPOUND	18	18	hydrocortisone
NCT001675443	NCT00167544_3_T1	PHENOTYPE	26	26	BPD
NCT001675443	NCT00167544_3_T2	PHENOTYPE	20	20	ELBW
NCT001675446	NCT00167544_6_T0	PHENOTYPE	5	5	ELBW
NCT001675447	NCT00167544_7_T0	PHENOTYPE	14	14	ELBW
NCT001675447	NCT00167544_7_T1	PHENOTYPE	6	7	mental retardation
NCT001675447	NCT00167544_7_T2	PHENOTYPE	3	4	cerebral palsy
NCT001675448	NCT00167544_8_T0	PHENOTYPE	0	0	BPD
NCT001675449	NCT00167544_9_T0	PHENOTYPE	15	15	BPD
NCT001675449	NCT00167544_9_T1	GENE	11	11	reduced
NCT0016754411	NCT00167544_11_T0	COMPOUND	7	7	dexamethasone
NCT0016754411	NCT00167544_11_T1	GENE	2	2	has
NCT0016754413	NCT00167544_13_T0	COMPOUND	3	3	dexamethasone
NCT0016754413	NCT00167544_13_T1	PHENOTYPE	15	16	lung function
NCT0016754419	NCT00167544_19_T0	COMPOUND	10	10	hydrocortisone
NCT0016754420	NCT00167544_20_T0	GENE	8	8	IV
NCT0016754421	NCT00167544_21_T0	GENE	4	4	MRI
NCT0016754421	NCT00167544_21_T1	PHENOTYPE	9	9	ELBW
NCT0016754422	NCT00167544_22_T0	COMPOUND	4	4	dexamethasone
NCT0016754422	NCT00167544_22_T1	COMPOUND	2	2	indomethacin
NCT0016754426	NCT00167544_26_T0	PHENOTYPE	11	11	ELBW
NCT001675575	NCT00167557_5_T0	COMPOUND	18	18	ribavirin
NCT001675575	NCT00167557_5_T1	GENE	16	16	interferon
NCT001675575	NCT00167557_5_T2	PHENOTYPE	7	8	hepatitis C
NCT001675576	NCT00167557_6_T0	BIOLOGICAL_PROCESS	17	17	reproduction
NCT001675576	NCT00167557_6_T1	ORGAN	6	7	immune system
NCT001675577	NCT00167557_7_T0	ORGAN	20	20	liver
NCT001675579	NCT00167557_9_T0	ORGAN	18	18	liver
NCT001675579	NCT00167557_9_T1	GENE	13	13	has
NCT001675579	NCT00167557_9_T2	PHENOTYPE	4	4	hepatitis
NCT0016755714	NCT00167557_14_T0	ORGAN	4	4	liver
NCT0016755714	NCT00167557_14_T1	ORGAN	11	11	liver
NCT0016755714	NCT00167557_14_T2	ORGAN	12	12	transplant
NCT0016755717	NCT00167557_17_T0	PHENOTYPE	9	9	hepatitis
NCT0016755717	NCT00167557_17_T1	PHENOTYPE	13	13	hepatitis
NCT0016755717	NCT00167557_17_T2	PHENOTYPE	15	15	cirrhosis
NCT0016755719	NCT00167557_19_T0	PHENOTYPE	7	7	recurrence
NCT0016755719	NCT00167557_19_T1	PHENOTYPE	5	5	severity
NCT0016755719	NCT00167557_19_T2	ORGAN	18	18	graft
NCT0016755719	NCT00167557_19_T3	GENE	15	15	longevity
NCT0016755719	NCT00167557_19_T4	COMPOUND	24	24	HCV
NCT0016755721	NCT00167557_21_T0	COMPOUND	6	6	tacrolimus
NCT0016755721	NCT00167557_21_T1	COMPOUND	3	4	mycophenolate mofetil
NCT0016755722	NCT00167557_22_T0	PHENOTYPE	18	18	recurrence
NCT0016755722	NCT00167557_22_T1	COMPOUND	19	19	HCV
NCT0016755722	NCT00167557_22_T2	PHENOTYPE	20	20	cirrhosis
NCT0016755725	NCT00167557_25_T0	PHENOTYPE	15	15	recurrence
NCT0016755727	NCT00167557_27_T0	PHENOTYPE	11	11	leukopenia
NCT0016755727	NCT00167557_27_T1	COMPOUND	7	7	ribavirin
NCT0016755727	NCT00167557_27_T2	GENE	5	5	interferon
NCT0016755727	NCT00167557_27_T3	PHENOTYPE	13	13	anemia
NCT0016755730	NCT00167557_30_T0	PHENOTYPE	16	17	immune suppression
NCT0016755731	NCT00167557_31_T0	COMPOUND	21	21	HCV
NCT0016755732	NCT00167557_32_T0	COMPOUND	15	15	ribavirin
NCT0016755732	NCT00167557_32_T1	GENE	13	13	interferon
NCT0016755733	NCT00167557_33_T0	COMPOUND	17	17	HCV
NCT0016755733	NCT00167557_33_T1	PHENOTYPE	16	16	recurrent
NCT0016755734	NCT00167557_34_T0	PHENOTYPE	21	22	immune suppression
NCT0016755736	NCT00167557_36_T0	PHENOTYPE	16	16	recurrence
NCT0016755736	NCT00167557_36_T1	COMPOUND	10	10	ribavirin
NCT0016755736	NCT00167557_36_T2	GENE	7	7	PEG
NCT0016755736	NCT00167557_36_T3	COMPOUND	15	15	HCV
NCT0016755736	NCT00167557_36_T4	GENE	8	8	interferon
NCT0016755738	NCT00167557_38_T0	COMPOUND	30	30	ribavirin
NCT0016755738	NCT00167557_38_T1	GENE	10	10	PEG
NCT0016755738	NCT00167557_38_T2	GENE	27	27	PEG
NCT0016755738	NCT00167557_38_T3	PHENOTYPE	14	14	progression
NCT0016755738	NCT00167557_38_T4	PHENOTYPE	16	16	fibrosis
NCT0016755738	NCT00167557_38_T5	GENE	11	11	interferon
NCT0016755738	NCT00167557_38_T6	GENE	28	28	interferon
NCT0016755740	NCT00167557_40_T0	COMPOUND	19	19	ribavirin
NCT0016755740	NCT00167557_40_T1	GENE	16	16	PEG
NCT0016755740	NCT00167557_40_T2	COMPOUND	6	6	prednisone
NCT0016755740	NCT00167557_40_T3	GENE	17	17	interferon
NCT0016755742	NCT00167557_42_T0	PHENOTYPE	13	13	recurrence
NCT0016755742	NCT00167557_42_T1	ORGAN	15	15	transplant
NCT0016755742	NCT00167557_42_T2	COMPOUND	12	12	HCV
NCT0016755745	NCT00167557_45_T0	ORGAN	1	1	liver
NCT0016755745	NCT00167557_45_T1	ORGAN	2	2	transplant
NCT0016755745	NCT00167557_45_T2	ORGAN	15	15	transplant
NCT0016755745	NCT00167557_45_T3	COMPOUND	7	7	HCV
NCT0016755745	NCT00167557_45_T4	GENE	10	10	PCR
NCT0016755747	NCT00167557_47_T0	PHENOTYPE	3	3	acute
NCT0016755747	NCT00167557_47_T1	PHENOTYPE	5	5	chronic
NCT0016755753	NCT00167557_53_T0	COMPOUND	5	5	ribavirin
NCT0016755753	NCT00167557_53_T1	ORGAN	7	7	liver
NCT0016755753	NCT00167557_53_T2	GENE	3	3	interferon
NCT0016755754	NCT00167557_54_T0	PHENOTYPE	0	0	HIV
NCT0016755755	NCT00167557_55_T0	PHENOTYPE	0	1	Autoimmune hepatitis
NCT0016755756	NCT00167557_56_T0	PHENOTYPE	3	4	substance abuse
NCT0016755759	NCT00167557_59_T0	PHENOTYPE	2	3	retinal abnormalities
NCT001675701	NCT00167570_1_T0	COMPOUND	12	12	SFF
NCT001675701	NCT00167570_1_T1	GENE	25	25	viability
NCT001675703	NCT00167570_3_T0	COMPOUND	5	5	SFF
NCT001675707	NCT00167570_7_T0	COMPOUND	6	6	SFF
NCT001675707	NCT00167570_7_T1	GENE	9	9	extended
NCT001675708	NCT00167570_8_T0	GENE	4	4	met
NCT0016757010	NCT00167570_10_T0	COMPOUND	11	11	SFF
NCT0016757012	NCT00167570_12_T0	COMPOUND	2	2	SFF
NCT0016757019	NCT00167570_19_T0	COMPOUND	0	0	SFF
NCT0016757021	NCT00167570_21_T0	COMPOUND	12	12	SFF
NCT0016757021	NCT00167570_21_T1	GENE	25	25	viability
NCT0016757023	NCT00167570_23_T0	COMPOUND	5	5	SFF
NCT0016757027	NCT00167570_27_T0	COMPOUND	6	6	SFF
NCT0016757027	NCT00167570_27_T1	GENE	9	9	extended
NCT0016757028	NCT00167570_28_T0	GENE	4	4	met
NCT0016757030	NCT00167570_30_T0	COMPOUND	11	11	SFF
NCT0016757032	NCT00167570_32_T0	COMPOUND	2	2	SFF
NCT0016757034	NCT00167570_34_T0	GENE	8	8	K2
NCT0016757034	NCT00167570_34_T1	GENE	10	10	K3
NCT001675833	NCT00167583_3_T0	PHENOTYPE	10	10	blindness
NCT001675833	NCT00167583_3_T1	PHENOTYPE	3	3	uveitis
NCT001675833	NCT00167583_3_T2	PHENOTYPE	5	6	retinal vasculitis
NCT001675962	NCT00167596_2_T0	PHENOTYPE	13	14	severe sepsis
NCT001675963	NCT00167596_3_T0	GENE	10	10	NIR
NCT001675963	NCT00167596_3_T1	COMPOUND	19	19	oxygen
NCT001675963	NCT00167596_3_T2	GENE	18	18	hemoglobin
NCT001675964	NCT00167596_4_T0	GENE	2	2	had
NCT001675964	NCT00167596_4_T1	BIOLOGICAL_PROCESS	15	15	transport
NCT001675964	NCT00167596_4_T2	PHENOTYPE	28	29	limb ischemia
NCT001676092	NCT00167609_2_T0	COMPOUND	5	5	DHEA
NCT001676092	NCT00167609_2_T1	PHENOTYPE	14	15	myotonic dystrophy
NCT001676093	NCT00167609_3_T0	COMPOUND	16	16	DHEA
NCT001676093	NCT00167609_3_T1	PHENOTYPE	20	21	myotonic dystrophy
NCT001676223	NCT00167622_3_T0	PHENOTYPE	18	19	impaired swallowing
NCT001676223	NCT00167622_3_T1	PHENOTYPE	22	24	forced vital capacity
NCT001676224	NCT00167622_4_T0	PHENOTYPE	16	16	pneumonia
NCT001676224	NCT00167622_4_T1	PHENOTYPE	5	5	ventilation
NCT001676353	NCT00167635_3_T0	PHENOTYPE	41	41	severity
NCT001676353	NCT00167635_3_T1	PHENOTYPE	44	44	symptoms
NCT001676353	NCT00167635_3_T2	PHENOTYPE	43	43	IBS
NCT001676353	NCT00167635_3_T3	PHENOTYPE	46	47	psychological symptoms
NCT0016763510	NCT00167635_10_T0	GENE	4	4	UC
NCT001676486	NCT00167648_6_T0	COMPOUND	10	10	androgen
NCT001676486	NCT00167648_6_T1	PHENOTYPE	33	33	cancers
NCT001676486	NCT00167648_6_T2	PHENOTYPE	21	21	Oncology
NCT001676487	NCT00167648_7_T0	PHENOTYPE	0	0	Tumors
NCT001676487	NCT00167648_7_T1	ORGAN	13	14	immune system
NCT001676489	NCT00167648_9_T0	COMPOUND	14	14	estrogen
NCT001676489	NCT00167648_9_T1	COMPOUND	24	24	testosterone
NCT0016764812	NCT00167648_12_T0	PHENOTYPE	6	6	autoimmunity
NCT0016764816	NCT00167648_16_T0	COMPOUND	18	18	androgen
NCT0016764816	NCT00167648_16_T1	COMPOUND	3	3	estrogen
NCT0016764816	NCT00167648_16_T2	PHENOTYPE	12	12	immunity
NCT0016764816	NCT00167648_16_T3	COMPOUND	17	17	estradiol
NCT0016764819	NCT00167648_19_T0	PHENOTYPE	8	8	initiation
NCT0016764825	NCT00167648_25_T0	PHENOTYPE	7	7	tumor
NCT0016764826	NCT00167648_26_T0	GENE	14	14	NKG2D
NCT0016764826	NCT00167648_26_T1	COMPOUND	19	19	androgen
NCT0016764826	NCT00167648_26_T2	CELL	17	17	lymphocytes
NCT0016764826	NCT00167648_26_T3	COMPOUND	22	22	estradiol
NCT0016764826	NCT00167648_26_T4	GENE	12	13	NK receptor
NCT0016764826	NCT00167648_26_T5	CELL	6	7	NK cells
NCT0016764835	NCT00167648_35_T0	PHENOTYPE	1	1	tumor
NCT0016764839	NCT00167648_39_T0	COMPOUND	10	10	estrogen
NCT0016764839	NCT00167648_39_T1	COMPOUND	7	7	phytoestrogens
NCT0016764842	NCT00167648_42_T0	COMPOUND	4	4	testosterone
NCT0016764850	NCT00167648_50_T0	PHENOTYPE	0	0	Dementia
NCT0016764850	NCT00167648_50_T1	PHENOTYPE	3	5	altered mental status
NCT0016764855	NCT00167648_55_T0	PHENOTYPE	10	10	CVA
NCT0016764855	NCT00167648_55_T1	PHENOTYPE	6	7	myocardial infarction
NCT0016764855	NCT00167648_55_T2	PHENOTYPE	8	9	pulmonary embolism
NCT0016764859	NCT00167648_59_T0	PHENOTYPE	10	10	disorders
NCT0016764860	NCT00167648_60_T0	COMPOUND	21	21	bexarotene
NCT0016764860	NCT00167648_60_T1	COMPOUND	18	18	androgen
NCT0016764860	NCT00167648_60_T2	COMPOUND	20	20	aprepitant
NCT0016764860	NCT00167648_60_T3	COMPOUND	24	24	ketoconazole
NCT0016764860	NCT00167648_60_T4	COMPOUND	23	23	itraconazole
NCT0016764860	NCT00167648_60_T5	COMPOUND	22	22	clarithromycin
NCT001676614	NCT00167661_4_T0	ORGAN	6	6	kidney
NCT001676616	NCT00167661_6_T0	ORGAN	11	11	transplant
NCT001676618	NCT00167661_8_T0	ORGAN	8	8	transplants
NCT0016766112	NCT00167661_12_T0	ORGAN	6	6	transplant
NCT0016766114	NCT00167661_14_T0	PHENOTYPE	14	14	HIV
NCT0016766114	NCT00167661_14_T1	PHENOTYPE	9	10	hepatitis B
NCT0016766114	NCT00167661_14_T2	PHENOTYPE	7	8	hepatitis C
NCT0016766118	NCT00167661_18_T0	PHENOTYPE	13	13	lymphoma
NCT0016766118	NCT00167661_18_T1	PHENOTYPE	11	11	malignancies
NCT0016766122	NCT00167661_22_T0	ORGAN	4	4	transplant
NCT001676741	NCT00167674_1_T0	COMPOUND	15	15	nevirapine
NCT001676741	NCT00167674_1_T1	COMPOUND	13	13	zidovudine
NCT001676741	NCT00167674_1_T2	COMPOUND	14	14	lamivudine
NCT001676742	NCT00167674_2_T0	PHENOTYPE	13	13	strategies
NCT001676743	NCT00167674_3_T0	GENE	2	2	II
NCT001676744	NCT00167674_4_T0	GENE	8	8	CD4
NCT001676748	NCT00167674_8_T0	GENE	10	10	Dr
NCT001676748	NCT00167674_8_T1	GENE	27	27	Dr
NCT0016767414	NCT00167674_14_T0	GENE	2	2	CD4
NCT0016767418	NCT00167674_18_T0	BIOLOGICAL_PROCESS	11	11	gestation
NCT0016767422	NCT00167674_22_T0	GENE	5	5	CD4
NCT0016767424	NCT00167674_24_T0	COMPOUND	8	8	nevirapine
NCT0016767424	NCT00167674_24_T1	GENE	0	0	CD4
NCT0016767424	NCT00167674_24_T2	COMPOUND	9	9	zidovudine
NCT0016767425	NCT00167674_25_T0	COMPOUND	3	3	nevirapine
NCT0016767425	NCT00167674_25_T1	COMPOUND	4	4	zidovudine
NCT0016767435	NCT00167674_35_T0	GENE	16	16	CD4
NCT0016767435	NCT00167674_35_T1	ORGAN	21	21	liver
NCT0016767435	NCT00167674_35_T2	GENE	19	19	CTL
NCT0016767438	NCT00167674_38_T0	PHENOTYPE	1	1	prick
NCT0016767438	NCT00167674_38_T1	GENE	13	13	PCR
NCT001676876	NCT00167687_6_T0	COMPOUND	9	9	prazosin
NCT001676877	NCT00167687_7_T0	COMPOUND	18	18	prazosin
NCT001676878	NCT00167687_8_T0	PHENOTYPE	13	14	alcohol dependence
NCT001676879	NCT00167687_9_T0	PHENOTYPE	18	18	fluctuations
NCT0016768711	NCT00167687_11_T0	PHENOTYPE	20	20	Addiction
NCT0016768711	NCT00167687_11_T1	PHENOTYPE	8	9	chemical dependency
NCT0016768718	NCT00167687_18_T0	PHENOTYPE	12	12	orthostatic
NCT0016768718	NCT00167687_18_T1	PHENOTYPE	16	17	adverse events
NCT0016768719	NCT00167687_19_T0	PHENOTYPE	4	5	adverse events
NCT0016770010	NCT00167700_10_T0	BIOLOGICAL_PROCESS	5	6	gene expression
NCT0016770010	NCT00167700_10_T1	BIOLOGICAL_PROCESS	13	14	gene expression
NCT0016770010	NCT00167700_10_T2	PHENOTYPE	1	2	environmental exposures
NCT0016770018	NCT00167700_18_T0	COMPOUND	11	11	1st
NCT0016770020	NCT00167700_20_T0	GENE	12	12	2.4
NCT0016770020	NCT00167700_20_T1	COMPOUND	19	20	microcrystalline cellulose
NCT0016770022	NCT00167700_22_T0	PHENOTYPE	4	4	allergy
NCT0016770022	NCT00167700_22_T1	GENE	5	5	has
NCT0016770024	NCT00167700_24_T0	PHENOTYPE	7	7	atopic
NCT0016770024	NCT00167700_24_T1	PHENOTYPE	8	8	diseases
NCT0016770024	NCT00167700_24_T2	COMPOUND	41	41	longum
NCT0016770024	NCT00167700_24_T3	COMPOUND	47	47	longum
NCT0016770026	NCT00167700_26_T0	GENE	63	63	1.1
NCT0016770026	NCT00167700_26_T1	COMPOUND	40	41	microcrystalline cellulose
NCT0016770026	NCT00167700_26_T2	PHENOTYPE	21	22	congenital defects
NCT0016770029	NCT00167700_29_T0	COMPOUND	25	26	microcrystalline cellulose
NCT0016770029	NCT00167700_29_T1	PHENOTYPE	6	7	colic infants
NCT001677131	NCT00167713_1_T0	PHENOTYPE	10	10	fever
NCT001677131	NCT00167713_1_T1	PHENOTYPE	14	14	malaria
NCT001677132	NCT00167713_2_T0	PHENOTYPE	6	7	malarial fever
NCT001677133	NCT00167713_3_T0	COMPOUND	6	6	ibuprofen
NCT001677133	NCT00167713_3_T1	PHENOTYPE	9	9	fever
NCT001677133	NCT00167713_3_T2	PHENOTYPE	11	11	malaria
NCT001677134	NCT00167713_4_T0	COMPOUND	3	3	ibuprofen
NCT001677134	NCT00167713_4_T1	PHENOTYPE	5	5	fever
NCT001677134	NCT00167713_4_T2	PHENOTYPE	16	16	malaria
NCT001677136	NCT00167713_6_T0	PHENOTYPE	3	3	fever
NCT001677136	NCT00167713_6_T1	PHENOTYPE	7	7	malaria
NCT001677136	NCT00167713_6_T2	PHENOTYPE	10	12	other infectious diseases
NCT001677138	NCT00167713_8_T0	PHENOTYPE	9	10	malarial fever
NCT001677139	NCT00167713_9_T0	PHENOTYPE	10	10	fever
NCT001677139	NCT00167713_9_T1	PHENOTYPE	14	14	malaria
NCT0016771311	NCT00167713_11_T0	PHENOTYPE	32	32	infections
NCT0016771311	NCT00167713_11_T1	COMPOUND	1	1	paracetamol
NCT0016771311	NCT00167713_11_T2	GENE	22	22	TNF
NCT0016771311	NCT00167713_11_T3	COMPOUND	16	16	oxygen
NCT0016771311	NCT00167713_11_T4	BIOLOGICAL_PROCESS	26	28	innate immune response
NCT0016771311	NCT00167713_11_T5	GENE	19	21	tumour necrosis factor
NCT0016771312	NCT00167713_12_T0	COMPOUND	13	13	ibuprofen
NCT0016771312	NCT00167713_12_T1	PHENOTYPE	7	8	malarial fever
NCT0016771313	NCT00167713_13_T0	PHENOTYPE	16	16	infections
NCT0016771313	NCT00167713_13_T1	PHENOTYPE	11	11	fever
NCT0016771313	NCT00167713_13_T2	GENE	17	17	has
NCT0016771314	NCT00167713_14_T0	COMPOUND	4	4	ibuprofen
NCT0016771314	NCT00167713_14_T1	PHENOTYPE	7	7	fever
NCT0016771314	NCT00167713_14_T2	PHENOTYPE	24	24	fever
NCT0016771314	NCT00167713_14_T3	PHENOTYPE	28	28	malaria
NCT001677391	NCT00167739_1_T0	PHENOTYPE	8	9	adverse reactions
NCT001677392	NCT00167739_2_T0	COMPOUND	6	6	sulfadoxine_pyrimethamine
NCT001677393	NCT00167739_3_T0	COMPOUND	9	9	sulfadoxine_pyrimethamine
NCT001677393	NCT00167739_3_T1	COMPOUND	7	7	quinine
NCT001677393	NCT00167739_3_T2	PHENOTYPE	16	16	malaria
NCT001677396	NCT00167739_6_T0	COMPOUND	30	30	quinine
NCT001677396	NCT00167739_6_T1	GENE	12	12	has
NCT001677396	NCT00167739_6_T2	PHENOTYPE	7	7	malaria
NCT001677396	NCT00167739_6_T3	PHENOTYPE	22	22	malaria
NCT001677398	NCT00167739_8_T0	COMPOUND	4	4	quinine
NCT001677399	NCT00167739_9_T0	COMPOUND	1	1	sulfadoxine_pyrimethamine
NCT001677399	NCT00167739_9_T1	GENE	2	2	SP
NCT0016773910	NCT00167739_10_T0	GENE	2	2	has
NCT0016773911	NCT00167739_11_T0	GENE	9	9	has
NCT0016773912	NCT00167739_12_T0	GENE	6	6	SP
NCT0016773912	NCT00167739_12_T1	GENE	17	17	SP
NCT0016773912	NCT00167739_12_T2	GENE	28	28	SP
NCT0016773913	NCT00167739_13_T0	COMPOUND	10	10	quinine
NCT0016773913	NCT00167739_13_T1	COMPOUND	42	42	quinine
NCT0016773913	NCT00167739_13_T2	PHENOTYPE	54	54	malaria
NCT0016773913	NCT00167739_13_T3	GENE	35	35	SP
NCT0016773914	NCT00167739_14_T0	COMPOUND	10	10	quinine
NCT0016773914	NCT00167739_14_T1	GENE	19	19	SP
NCT0016773914	NCT00167739_14_T2	PHENOTYPE	24	25	falciparum malaria
NCT001677652	NCT00167765_2_T0	PHENOTYPE	3	4	ischemic strokes
NCT001677653	NCT00167765_3_T0	GENE	14	14	de
NCT001677654	NCT00167765_4_T0	PHENOTYPE	7	7	suffered
NCT001677656	NCT00167765_6_T0	GENE	3	3	has
NCT001677657	NCT00167765_7_T0	PHENOTYPE	15	15	waking
NCT001677657	NCT00167765_7_T1	GENE	18	18	had
NCT001677657	NCT00167765_7_T2	PHENOTYPE	9	10	lacunar stroke
NCT001677659	NCT00167765_9_T0	PHENOTYPE	16	16	infarction
NCT001677659	NCT00167765_9_T1	GENE	15	15	reduced
NCT001677659	NCT00167765_9_T2	PHENOTYPE	10	10	hypoperfusion
NCT001677659	NCT00167765_9_T3	GENE	11	11	has
NCT001677659	NCT00167765_9_T4	PHENOTYPE	3	3	reperfusion
NCT0016776510	NCT00167765_10_T0	PHENOTYPE	22	22	symptoms
NCT0016776510	NCT00167765_10_T1	GENE	2	2	IIa
NCT0016776510	NCT00167765_10_T2	PHENOTYPE	14	14	acute
NCT0016776510	NCT00167765_10_T3	PHENOTYPE	30	31	intracranial hemorrhage
NCT0016776510	NCT00167765_10_T4	PHENOTYPE	15	16	ischemic stroke
NCT0016776520	NCT00167765_20_T0	GENE	2	2	thromboplastin
NCT0016776520	NCT00167765_20_T1	GENE	24	25	factor XII
NCT0016776521	NCT00167765_21_T0	COMPOUND	8	8	heparin
NCT0016776521	NCT00167765_21_T1	COMPOUND	4	4	sulfate
NCT0016776521	NCT00167765_21_T2	GENE	3	3	protamine
NCT0016776523	NCT00167765_23_T0	GENE	3	3	INR
NCT0016777811	NCT00167778_11_T0	ORGAN	5	5	limb
NCT0016777812	NCT00167778_12_T0	COMPOUND	8	8	1
NCT0016777812	NCT00167778_12_T1	COMPOUND	30	30	2
NCT0016777812	NCT00167778_12_T2	PHENOTYPE	12	12	strategies
NCT0016777818	NCT00167778_18_T0	GENE	36	36	adaptor
NCT0016777818	NCT00167778_18_T1	PHENOTYPE	23	23	rigid
NCT0016777821	NCT00167778_21_T0	ORGAN	11	11	limb
NCT0016777821	NCT00167778_21_T1	PHENOTYPE	5	5	discomfort
NCT001677911	NCT00167791_1_T0	ORGAN	19	19	kidney
NCT001677911	NCT00167791_1_T1	ORGAN	20	20	transplant
NCT001678041	NCT00167804_1_T0	PHENOTYPE	5	5	PTSD
NCT001678042	NCT00167804_2_T0	PHENOTYPE	1	1	PTSD
NCT001678042	NCT00167804_2_T1	PHENOTYPE	13	13	PTSD
NCT001678047	NCT00167804_7_T0	GENE	18	18	TAU
NCT0016780411	NCT00167804_11_T0	PHENOTYPE	0	0	PTSD
NCT0016780411	NCT00167804_11_T1	PHENOTYPE	16	16	arousal
NCT0016780412	NCT00167804_12_T0	PHENOTYPE	7	7	PTSD
NCT0016780412	NCT00167804_12_T1	PHENOTYPE	8	8	symptoms
NCT0016780412	NCT00167804_12_T2	PHENOTYPE	6	6	chronic
NCT0016780414	NCT00167804_14_T0	PHENOTYPE	5	5	PTSD
NCT0016780415	NCT00167804_15_T0	PHENOTYPE	1	1	PTSD
NCT0016780415	NCT00167804_15_T1	PHENOTYPE	13	13	PTSD
NCT0016780418	NCT00167804_18_T0	PHENOTYPE	9	9	symptoms
NCT0016780418	NCT00167804_18_T1	PHENOTYPE	8	8	PTSD
NCT0016780419	NCT00167804_19_T0	PHENOTYPE	5	5	PTSD
NCT0016780422	NCT00167804_22_T0	GENE	18	18	TAU
NCT0016780426	NCT00167804_26_T0	ORGAN	15	15	ears
NCT0016780426	NCT00167804_26_T1	PHENOTYPE	10	10	fits
NCT0016780426	NCT00167804_26_T2	ORGAN	13	13	eyes
NCT0016780426	NCT00167804_26_T3	PHENOTYPE	8	8	HMD
NCT0016780429	NCT00167804_29_T0	PHENOTYPE	15	15	HMD
NCT0016780430	NCT00167804_30_T0	PHENOTYPE	4	4	experiences
NCT0016780433	NCT00167804_33_T0	PHENOTYPE	20	20	PTSD
NCT0016780433	NCT00167804_33_T1	GENE	2	2	TAU
NCT0016780433	NCT00167804_33_T2	PHENOTYPE	12	13	problem solving
NCT0016780434	NCT00167804_34_T0	PHENOTYPE	9	9	PTSD
NCT0016780436	NCT00167804_36_T0	PHENOTYPE	8	8	Ideation
NCT0016780438	NCT00167804_38_T0	PHENOTYPE	10	10	PTSD
NCT0016780438	NCT00167804_38_T1	PHENOTYPE	11	11	symptoms
NCT0016780438	NCT00167804_38_T2	GENE	20	20	TAU
NCT0016780439	NCT00167804_39_T0	PHENOTYPE	11	11	PTSD
NCT001678170	NCT00167817_0_T0	PHENOTYPE	13	13	Schizophrenia
NCT001678172	NCT00167817_2_T0	PHENOTYPE	14	14	schizophrenia
NCT001678172	NCT00167817_2_T1	GENE	18	18	atypical
NCT001678172	NCT00167817_2_T2	COMPOUND	20	20	aripiprazole
NCT001678172	NCT00167817_2_T3	PHENOTYPE	26	28	mechanism of action
NCT001678174	NCT00167817_4_T0	COMPOUND	11	11	aripiprazole
NCT001678175	NCT00167817_5_T0	GENE	17	17	saliva
NCT001678175	NCT00167817_5_T1	COMPOUND	18	18	cotinine
NCT001678175	NCT00167817_5_T2	PHENOTYPE	14	15	Nicotine Dependence
NCT001678176	NCT00167817_6_T0	PHENOTYPE	11	11	severity
NCT001678176	NCT00167817_6_T1	COMPOUND	5	5	glucose
NCT001678176	NCT00167817_6_T2	PHENOTYPE	0	0	Secondary
NCT001678176	NCT00167817_6_T3	ORGAN	4	4	serum
NCT001678179	NCT00167817_9_T0	PHENOTYPE	0	0	Schizophrenia
NCT0016781711	NCT00167817_11_T0	PHENOTYPE	0	0	Overweight
NCT0016781714	NCT00167817_14_T0	PHENOTYPE	2	2	schizophrenia
NCT0016781715	NCT00167817_15_T0	COMPOUND	3	3	clozapine
NCT0016781716	NCT00167817_16_T0	COMPOUND	8	8	aripiprazole
NCT001678300	NCT00167830_0_T0	PHENOTYPE	4	4	Obese
NCT001678431	NCT00167843_1_T0	COMPOUND	11	11	sulfadoxine_pyrimethamine
NCT001678432	NCT00167843_2_T0	PHENOTYPE	23	23	anemia
NCT001678434	NCT00167843_4_T0	PHENOTYPE	9	9	strategies
NCT001678434	NCT00167843_4_T1	PHENOTYPE	12	12	malaria
NCT001678435	NCT00167843_5_T0	PHENOTYPE	0	0	Malaria
NCT001678435	NCT00167843_5_T1	PHENOTYPE	21	21	malaria
NCT001678436	NCT00167843_6_T0	GENE	1	1	has
NCT001678436	NCT00167843_6_T1	PHENOTYPE	5	5	malaria
NCT001678436	NCT00167843_6_T2	PHENOTYPE	14	14	malaria
NCT001678438	NCT00167843_8_T0	GENE	31	31	reduced
NCT001678438	NCT00167843_8_T1	PHENOTYPE	20	20	malaria
NCT001678439	NCT00167843_9_T0	GENE	2	2	has
NCT001678439	NCT00167843_9_T1	GENE	13	13	has
NCT0016784312	NCT00167843_12_T0	PHENOTYPE	27	27	malaria
NCT0016784312	NCT00167843_12_T1	PHENOTYPE	47	47	malaria
NCT0016784312	NCT00167843_12_T2	GENE	6	6	extended
NCT0016784312	NCT00167843_12_T3	GENE	30	30	extended
NCT0016784314	NCT00167843_14_T0	PHENOTYPE	16	16	malaria
NCT0016784315	NCT00167843_15_T0	PHENOTYPE	3	3	malaria
NCT001678568	NCT00167856_8_T0	COMPOUND	22	22	amitriptyline
NCT001678568	NCT00167856_8_T1	COMPOUND	20	20	imipramine
NCT001678692	NCT00167869_2_T0	PHENOTYPE	17	17	hypertension
NCT001678693	NCT00167869_3_T0	GENE	2	2	has
NCT001678825	NCT00167882_5_T0	CELL	30	30	erythrocytes
NCT001678825	NCT00167882_5_T1	ORGAN	20	20	serum
NCT001678827	NCT00167882_7_T0	PHENOTYPE	3	3	IBD
NCT001678827	NCT00167882_7_T1	PHENOTYPE	4	5	in remission
NCT0016788211	NCT00167882_11_T0	PHENOTYPE	1	2	Side effects
NCT0016788214	NCT00167882_14_T0	PHENOTYPE	12	12	haematoma
NCT001678955	NCT00167895_5_T0	PHENOTYPE	10	10	inflammation
NCT001678958	NCT00167895_8_T0	CELL	9	9	fibroblasts
NCT001678958	NCT00167895_8_T1	CELL	8	8	macrophages
NCT001678958	NCT00167895_8_T2	CELL	11	11	lymphocytes
NCT0016789510	NCT00167895_10_T0	GENE	0	0	PDGF
NCT0016789510	NCT00167895_10_T1	PHENOTYPE	7	7	contraction
NCT0016789510	NCT00167895_10_T2	GENE	2	2	has
NCT001679342	NCT00167934_2_T0	ORGAN	21	21	liver
NCT001679342	NCT00167934_2_T1	COMPOUND	7	7	valproate
NCT001679342	NCT00167934_2_T2	TISSUE	23	24	adipose tissue
NCT001679342	NCT00167934_2_T3	PHENOTYPE	13	14	insulin sensitivity
NCT001679342	NCT00167934_2_T4	TISSUE	19	20	skeletal muscle
NCT001679344	NCT00167934_4_T0	PHENOTYPE	13	13	acute
NCT001679344	NCT00167934_4_T1	PHENOTYPE	16	16	complications
NCT001679345	NCT00167934_5_T0	COMPOUND	25	25	valproate
NCT001679345	NCT00167934_5_T1	GENE	13	13	atypical
NCT001679345	NCT00167934_5_T2	PHENOTYPE	9	9	schizophrenia
NCT001679470	NCT00167947_0_T0	ORGAN	4	4	Kidney
NCT001679470	NCT00167947_0_T1	ORGAN	5	5	Transplant
NCT001679733	NCT00167973_3_T0	GENE	2	2	FIX
NCT001679734	NCT00167973_4_T0	PHENOTYPE	0	1	Adverse events
NCT001680121	NCT00168012_1_T0	PHENOTYPE	1	1	secondary
NCT001680121	NCT00168012_1_T1	PHENOTYPE	7	7	infections
NCT001680251	NCT00168025_1_T0	PHENOTYPE	1	1	secondary
NCT001680251	NCT00168025_1_T1	PHENOTYPE	7	7	infections
NCT001680381	NCT00168038_1_T0	PHENOTYPE	16	17	platelet count
NCT001680510	NCT00168051_0_T0	PHENOTYPE	9	10	Hemophilia A
NCT001680642	NCT00168064_2_T0	GENE	13	13	MCH
NCT001680642	NCT00168064_2_T1	PHENOTYPE	18	19	mycosis fungoides
NCT001680643	NCT00168064_3_T0	GENE	14	14	MCH
NCT001680643	NCT00168064_3_T1	GENE	31	31	MF
NCT001680643	NCT00168064_3_T2	GENE	16	16	gel
NCT001680771	NCT00168077_1_T0	GENE	27	27	III
NCT001680771	NCT00168077_1_T1	COMPOUND	20	21	vitamin K
NCT001681037	NCT00168103_7_T0	GENE	27	27	C1-INH
NCT001681037	NCT00168103_7_T1	GENE	36	36	C1-INH
NCT001681037	NCT00168103_7_T2	GENE	44	44	C1-INH
NCT001681037	NCT00168103_7_T3	GENE	54	54	C1-INH
NCT001681037	NCT00168103_7_T4	GENE	30	30	bw
NCT001681037	NCT00168103_7_T5	GENE	39	39	bw
NCT001681037	NCT00168103_7_T6	GENE	47	47	bw
NCT001681037	NCT00168103_7_T7	GENE	57	57	bw
NCT001681038	NCT00168103_8_T0	PHENOTYPE	18	18	secondary
NCT001681038	NCT00168103_8_T1	GENE	28	28	C1-INH
NCT001681038	NCT00168103_8_T2	GENE	31	31	bw
NCT001681038	NCT00168103_8_T3	GENE	22	22	met
NCT001681551	NCT00168155_1_T0	ORGAN	10	10	liver
NCT001681551	NCT00168155_1_T1	GENE	3	3	has
NCT001681554	NCT00168155_4_T0	ORGAN	10	10	liver
NCT001681554	NCT00168155_4_T1	GENE	3	3	has
NCT0016818112	NCT00168181_12_T0	PHENOTYPE	2	2	malignancy
NCT0016818112	NCT00168181_12_T1	TISSUE	0	1	Salivary gland
NCT0016818113	NCT00168181_13_T0	PHENOTYPE	0	2	Salivary gland disease
NCT0016818119	NCT00168181_19_T0	PHENOTYPE	0	1	Recurrent disease
NCT0016818120	NCT00168181_20_T0	PHENOTYPE	0	0	Allergy
NCT001681941	NCT00168194_1_T0	PHENOTYPE	23	23	HBV
NCT001681941	NCT00168194_1_T1	CELL	14	16	white blood cells
NCT001681947	NCT00168194_7_T0	PHENOTYPE	9	9	co-infection
NCT001681947	NCT00168194_7_T1	PHENOTYPE	4	5	Hepatitis B
NCT001682071	NCT00168207_1_T0	GENE	14	14	PCR
NCT001682072	NCT00168207_2_T0	BIOLOGICAL_PROCESS	11	12	gene expression
NCT001682202	NCT00168220_2_T0	COMPOUND	15	15	nevirapine
NCT001682202	NCT00168220_2_T1	PHENOTYPE	19	19	HIV
NCT001682202	NCT00168220_2_T2	GENE	12	12	HSR
NCT001682202	NCT00168220_2_T3	COMPOUND	14	14	abacavir
NCT001682202	NCT00168220_2_T4	COMPOUND	17	17	efavirenz
NCT001682204	NCT00168220_4_T0	GENE	17	17	HSR
NCT001682204	NCT00168220_4_T1	GENE	27	27	HSR
NCT001682204	NCT00168220_4_T2	GENE	12	12	TLR
NCT001682460	NCT00168246_0_T0	PHENOTYPE	5	6	Neurological Disorders
NCT001682463	NCT00168246_3_T0	GENE	10	10	2.3
NCT001682464	NCT00168246_4_T0	PHENOTYPE	9	9	HIV
NCT001682464	NCT00168246_4_T1	PHENOTYPE	14	14	HIV
NCT001682464	NCT00168246_4_T2	PHENOTYPE	11	12	peripheral neuropathy
NCT001682467	NCT00168246_7_T0	GENE	9	9	ADC
NCT001682467	NCT00168246_7_T1	PHENOTYPE	5	5	HIV
NCT001682467	NCT00168246_7_T2	PHENOTYPE	7	7	impairment
NCT001682468	NCT00168246_8_T0	PHENOTYPE	6	8	peripheral sensory neuropathy
NCT001682590	NCT00168259_0_T0	PHENOTYPE	8	9	HIV Positive
NCT001682590	NCT00168259_0_T1	PHENOTYPE	5	6	HCMV Infection
NCT001682594	NCT00168259_4_T0	COMPOUND	6	6	HCV
NCT001682594	NCT00168259_4_T1	PHENOTYPE	0	1	HIV positive
NCT001682596	NCT00168259_6_T0	PHENOTYPE	0	1	HIV positive
NCT001682721	NCT00168272_1_T0	GENE	3	3	has
NCT001682721	NCT00168272_1_T1	GENE	18	18	has
NCT001682722	NCT00168272_2_T0	COMPOUND	7	7	rTMS
NCT001682724	NCT00168272_4_T0	GENE	38	38	TMS
NCT001682724	NCT00168272_4_T1	PHENOTYPE	36	37	left sided
NCT001682728	NCT00168272_8_T0	PHENOTYPE	16	16	remission
NCT001682729	NCT00168272_9_T0	PHENOTYPE	15	15	symptoms
NCT001682729	NCT00168272_9_T1	GENE	25	25	GAF
NCT001682729	NCT00168272_9_T2	PHENOTYPE	26	26	Global
NCT001682856	NCT00168285_6_T0	GENE	8	8	reduced
NCT001682856	NCT00168285_6_T1	PHENOTYPE	9	9	dyspnoea
NCT001682856	NCT00168285_6_T2	PHENOTYPE	12	12	tolerance
NCT001682856	NCT00168285_6_T3	PHENOTYPE	15	17	quality of life
NCT0016828513	NCT00168285_13_T0	PHENOTYPE	15	15	dyspnoea
NCT0016828513	NCT00168285_13_T1	PHENOTYPE	16	18	quality of life
NCT001683111	NCT00168311_1_T0	PHENOTYPE	12	12	symptoms
NCT001683112	NCT00168311_2_T0	COMPOUND	1	1	rTMS
NCT001683115	NCT00168311_5_T0	PHENOTYPE	4	4	pulse
NCT001683115	NCT00168311_5_T1	PHENOTYPE	27	27	inhibition
NCT001683115	NCT00168311_5_T2	GENE	5	5	TMS
NCT001683115	NCT00168311_5_T3	GENE	3	3	paired
NCT001683630	NCT00168363_0_T0	PHENOTYPE	8	8	Glaucoma
NCT001683630	NCT00168363_0_T1	PHENOTYPE	10	11	Ocular Hypertension
NCT001683761	NCT00168376_1_T0	GENE	8	8	MRI
NCT001683761	NCT00168376_1_T1	GENE	7	7	structural
NCT001683761	NCT00168376_1_T2	PHENOTYPE	5	5	localized
NCT001683761	NCT00168376_1_T3	COMPOUND	0	0	rTMS
NCT001683763	NCT00168376_3_T0	COMPOUND	0	0	rTMS
NCT001683767	NCT00168376_7_T0	PHENOTYPE	16	16	remission
NCT001683768	NCT00168376_8_T0	PHENOTYPE	15	15	symptoms
NCT001683768	NCT00168376_8_T1	GENE	25	25	GAF
NCT001683768	NCT00168376_8_T2	PHENOTYPE	26	26	Global
NCT001684672	NCT00168467_2_T0	PHENOTYPE	8	8	symptoms
NCT001684933	NCT00168493_3_T0	PHENOTYPE	13	13	relapse
NCT001684933	NCT00168493_3_T1	PHENOTYPE	10	10	suffering
NCT001684934	NCT00168493_4_T0	CELL	26	27	blood cells
NCT001684937	NCT00168493_7_T0	ORGAN	34	34	heart
NCT001684937	NCT00168493_7_T1	CELL	44	44	platelet
NCT001684937	NCT00168493_7_T2	PHENOTYPE	51	52	myocardial ischaemia
NCT001684937	NCT00168493_7_T3	PHENOTYPE	11	12	cardiac disease
NCT001684938	NCT00168493_8_T0	CELL	13	13	platelet
NCT001685060	NCT00168506_0_T0	PHENOTYPE	0	1	Panic Disorder
NCT001685062	NCT00168506_2_T0	PHENOTYPE	18	19	panic disorder
NCT001685065	NCT00168506_5_T0	PHENOTYPE	34	34	arousal
NCT001685065	NCT00168506_5_T1	PHENOTYPE	7	8	panic disorder
NCT001685065	NCT00168506_5_T2	ORGAN	31	33	sympathetic nervous system
NCT001685066	NCT00168506_6_T0	PHENOTYPE	22	22	arousal
NCT001685068	NCT00168506_8_T0	PHENOTYPE	21	22	panic disorder
NCT0016850610	NCT00168506_10_T0	PHENOTYPE	12	12	severity
NCT0016850610	NCT00168506_10_T1	PHENOTYPE	10	11	panic disorder
NCT001685194	NCT00168519_4_T0	GENE	2	3	type 2
NCT001685197	NCT00168519_7_T0	COMPOUND	10	10	nitrate
NCT0016851911	NCT00168519_11_T0	PHENOTYPE	20	20	translocation
NCT0016851911	NCT00168519_11_T1	GENE	19	19	GLUT-4
NCT0016851911	NCT00168519_11_T2	GENE	17	17	cGMP
NCT0016851911	NCT00168519_11_T3	ORGAN	0	1	Vastus lateralis
NCT0016851912	NCT00168519_12_T0	GENE	12	13	type 2
NCT0016851912	NCT00168519_12_T1	ORGAN	2	3	Vastus lateralis
NCT0016851916	NCT00168519_16_T0	GENE	16	16	Bruce
NCT0016851916	NCT00168519_16_T1	GENE	15	15	Dr
NCT0016851916	NCT00168519_16_T2	COMPOUND	2	3	nitric oxide
NCT0016851917	NCT00168519_17_T0	COMPOUND	0	0	Sodium
NCT0016851917	NCT00168519_17_T1	COMPOUND	1	1	nitroprusside
NCT0016851921	NCT00168519_21_T0	GENE	15	15	PETN
NCT0016851924	NCT00168519_24_T0	GENE	19	19	has
NCT0016851925	NCT00168519_25_T0	GENE	12	12	has
NCT0016851926	NCT00168519_26_T0	PHENOTYPE	8	8	dizziness
NCT0016851926	NCT00168519_26_T1	PHENOTYPE	6	6	headache
NCT0016851930	NCT00168519_30_T0	GENE	2	3	type 2
NCT0016851931	NCT00168519_31_T0	COMPOUND	12	12	nitrate
NCT0016851931	NCT00168519_31_T1	COMPOUND	14	15	isosorbide mononitrate
NCT0016851934	NCT00168519_34_T0	GENE	6	7	type 2
NCT0016851937	NCT00168519_37_T0	ORGAN	0	0	Plasma
NCT0016851937	NCT00168519_37_T1	COMPOUND	7	7	lactate
NCT0016851937	NCT00168519_37_T2	COMPOUND	4	4	glycerol
NCT001685321	NCT00168532_1_T0	PHENOTYPE	5	5	complications
NCT001685321	NCT00168532_1_T1	PHENOTYPE	8	8	measles
NCT001685324	NCT00168532_4_T0	PHENOTYPE	13	13	secondary
NCT001685324	NCT00168532_4_T1	PHENOTYPE	19	19	pneumonia
NCT001685324	NCT00168532_4_T2	PHENOTYPE	21	21	diarrhea
NCT001685324	NCT00168532_4_T3	PHENOTYPE	16	17	viral infections
NCT001685324	NCT00168532_4_T4	PHENOTYPE	4	6	complications of measles
NCT001685325	NCT00168532_5_T0	GENE	25	25	has
NCT001685325	NCT00168532_5_T1	PHENOTYPE	10	10	measles
NCT001685325	NCT00168532_5_T2	PHENOTYPE	40	40	measles
NCT001685326	NCT00168532_6_T0	GENE	19	19	had
NCT001685326	NCT00168532_6_T1	GENE	11	11	has
NCT001685326	NCT00168532_6_T2	PHENOTYPE	24	25	respiratory complications
NCT001685327	NCT00168532_7_T0	PHENOTYPE	25	25	symptoms
NCT001685327	NCT00168532_7_T1	COMPOUND	32	32	trimethoprim_sulfamethoxazole
NCT001685327	NCT00168532_7_T2	GENE	40	40	had
NCT001685327	NCT00168532_7_T3	PHENOTYPE	24	24	measles
NCT001685327	NCT00168532_7_T4	PHENOTYPE	43	44	bacterial infection
NCT001685328	NCT00168532_8_T0	GENE	8	8	had
NCT001685328	NCT00168532_8_T1	GENE	34	34	had
NCT001685328	NCT00168532_8_T2	PHENOTYPE	17	18	respiratory symptoms
NCT001685329	NCT00168532_9_T0	GENE	17	17	0.21
NCT001685329	NCT00168532_9_T1	GENE	16	16	0.41
NCT0016853210	NCT00168532_10_T0	PHENOTYPE	25	25	measles
NCT0016853211	NCT00168532_11_T0	PHENOTYPE	8	9	measles complications
NCT0016853212	NCT00168532_12_T0	PHENOTYPE	3	3	Measles
NCT0016853217	NCT00168532_17_T0	PHENOTYPE	23	23	measles
NCT0016853218	NCT00168532_18_T0	PHENOTYPE	16	16	measles
NCT0016853219	NCT00168532_19_T0	PHENOTYPE	0	0	Measles
NCT001685457	NCT00168545_7_T0	GENE	2	2	BCG
NCT001685459	NCT00168545_9_T0	GENE	12	12	BCG
NCT0016854511	NCT00168545_11_T0	GENE	4	4	had
NCT0016854513	NCT00168545_13_T0	GENE	12	12	had
NCT0016854514	NCT00168545_14_T0	PHENOTYPE	6	6	polio
NCT0016854514	NCT00168545_14_T1	PHENOTYPE	3	3	HBV
NCT0016854515	NCT00168545_15_T0	PHENOTYPE	15	15	measles
NCT0016854519	NCT00168545_19_T0	PHENOTYPE	11	11	malaria
NCT0016854522	NCT00168545_22_T0	GENE	3	3	BCG
NCT0016854522	NCT00168545_22_T1	PHENOTYPE	19	19	HBV
NCT0016854522	NCT00168545_22_T2	PHENOTYPE	2	2	measles
NCT0016854523	NCT00168545_23_T0	ORGAN	15	16	immune system
NCT0016854524	NCT00168545_24_T0	PHENOTYPE	11	11	measles
NCT0016854525	NCT00168545_25_T0	PHENOTYPE	31	31	measles
NCT001685585	NCT00168558_5_T0	GENE	6	6	has
NCT001685585	NCT00168558_5_T1	PHENOTYPE	4	4	measles
NCT001685585	NCT00168558_5_T2	PHENOTYPE	28	28	measles
NCT001685586	NCT00168558_6_T0	PHENOTYPE	2	2	measles
NCT001685586	NCT00168558_6_T1	GENE	9	9	Expanded
NCT001685586	NCT00168558_6_T2	GENE	13	13	EPI
NCT001685588	NCT00168558_8_T0	PHENOTYPE	17	17	measles
NCT001685589	NCT00168558_9_T0	PHENOTYPE	12	12	polio
NCT001685589	NCT00168558_9_T1	PHENOTYPE	22	22	measles
NCT001685589	NCT00168558_9_T2	PHENOTYPE	37	37	measles
NCT0016855810	NCT00168558_10_T0	PHENOTYPE	11	11	measles
NCT0016855811	NCT00168558_11_T0	PHENOTYPE	18	18	measles
NCT0016855814	NCT00168558_14_T0	PHENOTYPE	28	28	measles
NCT0016855816	NCT00168558_16_T0	PHENOTYPE	2	2	Measles
NCT0016855816	NCT00168558_16_T1	PHENOTYPE	23	23	measles
NCT0016855817	NCT00168558_17_T0	PHENOTYPE	21	21	measles
NCT0016855818	NCT00168558_18_T0	PHENOTYPE	18	18	measles
NCT0016855820	NCT00168558_20_T0	PHENOTYPE	9	9	measles
NCT0016855821	NCT00168558_21_T0	PHENOTYPE	7	7	strain
NCT0016855822	NCT00168558_22_T0	PHENOTYPE	11	11	measles
NCT0016855822	NCT00168558_22_T1	PHENOTYPE	17	17	measles
NCT0016855825	NCT00168558_25_T0	PHENOTYPE	5	5	elimination
NCT0016855825	NCT00168558_25_T1	PHENOTYPE	4	4	measles
NCT0016855826	NCT00168558_26_T0	PHENOTYPE	8	8	measles
NCT0016855826	NCT00168558_26_T1	COMPOUND	21	22	vitamin A
NCT0016855827	NCT00168558_27_T0	GENE	7	7	has
NCT0016855827	NCT00168558_27_T1	PHENOTYPE	5	5	measles
NCT0016855831	NCT00168558_31_T0	GENE	12	12	had
NCT0016855831	NCT00168558_31_T1	PHENOTYPE	18	18	measles
NCT0016855831	NCT00168558_31_T2	PHENOTYPE	33	33	measles
NCT0016855832	NCT00168558_32_T0	PHENOTYPE	14	14	measles
NCT0016855833	NCT00168558_33_T0	GENE	12	12	0.31
NCT0016855833	NCT00168558_33_T1	PHENOTYPE	4	4	measles
NCT0016855834	NCT00168558_34_T0	GENE	7	7	has
NCT0016855834	NCT00168558_34_T1	PHENOTYPE	2	2	measles
NCT0016855835	NCT00168558_35_T0	PHENOTYPE	15	15	measles
NCT0016855839	NCT00168558_39_T0	PHENOTYPE	3	3	measles
NCT0016855839	NCT00168558_39_T1	PHENOTYPE	15	15	measles
NCT0016855841	NCT00168558_41_T0	PHENOTYPE	11	11	measles
NCT001685711	NCT00168571_1_T0	PHENOTYPE	8	9	antibody titres
NCT001685712	NCT00168571_2_T0	PHENOTYPE	9	9	persistence
NCT001685712	NCT00168571_2_T1	PHENOTYPE	11	11	measles
NCT001685712	NCT00168571_2_T2	PHENOTYPE	17	17	measles
NCT001685713	NCT00168571_3_T0	PHENOTYPE	1	1	persistence
NCT001685713	NCT00168571_3_T1	PHENOTYPE	3	3	measles
NCT001685713	NCT00168571_3_T2	PHENOTYPE	10	10	measles
NCT001685715	NCT00168571_5_T0	GENE	5	5	has
NCT001685715	NCT00168571_5_T1	GENE	18	18	has
NCT001685715	NCT00168571_5_T2	PHENOTYPE	7	7	measles
NCT001685715	NCT00168571_5_T3	PHENOTYPE	16	16	measles
NCT001685716	NCT00168571_6_T0	GENE	14	14	fell
NCT001685716	NCT00168571_6_T1	PHENOTYPE	7	7	measles
NCT001685716	NCT00168571_6_T2	PHENOTYPE	33	33	measles
NCT001685717	NCT00168571_7_T0	PHENOTYPE	16	16	measles
NCT001685718	NCT00168571_8_T0	PHENOTYPE	2	2	secondary
NCT001685718	NCT00168571_8_T1	PHENOTYPE	14	14	HIV
NCT001685718	NCT00168571_8_T2	PHENOTYPE	10	10	measles
NCT001685718	NCT00168571_8_T3	PHENOTYPE	25	25	measles
NCT0016857110	NCT00168571_10_T0	PHENOTYPE	3	3	measles
NCT0016857111	NCT00168571_11_T0	PHENOTYPE	4	4	measles
NCT0016857111	NCT00168571_11_T1	PHENOTYPE	8	8	measles
NCT0016857111	NCT00168571_11_T2	PHENOTYPE	17	17	measles
NCT0016857112	NCT00168571_12_T0	PHENOTYPE	9	9	strains
NCT0016857112	NCT00168571_12_T1	PHENOTYPE	11	11	measles
NCT0016857115	NCT00168571_15_T0	PHENOTYPE	29	29	strain
NCT0016857115	NCT00168571_15_T1	PHENOTYPE	48	48	immunity
NCT0016857115	NCT00168571_15_T2	PHENOTYPE	6	6	persistence
NCT0016857115	NCT00168571_15_T3	PHENOTYPE	63	63	elimination
NCT0016857115	NCT00168571_15_T4	PHENOTYPE	8	8	measles
NCT0016857115	NCT00168571_15_T5	PHENOTYPE	39	39	measles
NCT0016857115	NCT00168571_15_T6	PHENOTYPE	60	60	measles
NCT0016857117	NCT00168571_17_T0	GENE	36	36	6/7
NCT0016857119	NCT00168571_19_T0	GENE	17	17	6/7
NCT0016857122	NCT00168571_22_T0	PHENOTYPE	3	3	measles
NCT001685841	NCT00168584_1_T0	PHENOTYPE	6	6	polio
NCT001685843	NCT00168584_3_T0	COMPOUND	12	13	vitamin A
NCT001685844	NCT00168584_4_T0	PHENOTYPE	10	10	polio
NCT001685846	NCT00168584_6_T0	GENE	2	2	VAS
NCT001685849	NCT00168584_9_T0	PHENOTYPE	6	6	polio
NCT001685849	NCT00168584_9_T1	PHENOTYPE	12	12	polio
NCT001685849	NCT00168584_9_T2	COMPOUND	21	22	vitamin A
NCT0016858410	NCT00168584_10_T0	GENE	6	6	VAS
NCT0016858411	NCT00168584_11_T0	GENE	8	8	VAS
NCT0016858411	NCT00168584_11_T1	COMPOUND	17	18	vitamin A
NCT001685970	NCT00168597_0_T0	GENE	3	3	BCG
NCT001685972	NCT00168597_2_T0	GENE	9	9	BCG
NCT001685975	NCT00168597_5_T0	COMPOUND	2	3	vitamin A
NCT001685978	NCT00168597_8_T0	COMPOUND	5	6	vitamin A
NCT001685978	NCT00168597_8_T1	PHENOTYPE	16	18	vitamin A deficiency
NCT001685978	NCT00168597_8_T2	PHENOTYPE	22	24	vitamin A deficiency
NCT0016859710	NCT00168597_10_T0	COMPOUND	6	7	vitamin A
NCT0016859712	NCT00168597_12_T0	GENE	16	16	BCG
NCT0016859712	NCT00168597_12_T1	COMPOUND	11	12	vitamin A
NCT0016859714	NCT00168597_14_T0	PHENOTYPE	5	5	diseases
NCT0016859714	NCT00168597_14_T1	PHENOTYPE	8	8	malaria
NCT0016859714	NCT00168597_14_T2	PHENOTYPE	9	9	measles
NCT0016859714	NCT00168597_14_T3	PHENOTYPE	11	12	rotavirus infections
NCT0016859715	NCT00168597_15_T0	COMPOUND	6	7	vitamin A
NCT0016859719	NCT00168597_19_T0	GENE	4	4	has
NCT0016859719	NCT00168597_19_T1	GENE	20	20	has
NCT001686100	NCT00168610_0_T0	GENE	7	7	BCG
NCT001686105	NCT00168610_5_T0	COMPOUND	2	3	vitamin A
NCT001686108	NCT00168610_8_T0	COMPOUND	5	6	vitamin A
NCT001686108	NCT00168610_8_T1	PHENOTYPE	16	18	vitamin A deficiency
NCT001686108	NCT00168610_8_T2	PHENOTYPE	22	24	vitamin A deficiency
NCT0016861010	NCT00168610_10_T0	COMPOUND	6	7	vitamin A
NCT0016861012	NCT00168610_12_T0	GENE	17	17	BCG
NCT0016861012	NCT00168610_12_T1	COMPOUND	12	13	vitamin A
NCT0016861012	NCT00168610_12_T2	PHENOTYPE	25	27	low birth weight
NCT0016861014	NCT00168610_14_T0	COMPOUND	6	7	vitamin A
NCT0016861015	NCT00168610_15_T0	COMPOUND	4	5	vitamin A
NCT0016861021	NCT00168610_21_T0	GENE	4	4	has
NCT0016861021	NCT00168610_21_T1	GENE	20	20	has
NCT0016861021	NCT00168610_21_T2	GENE	24	24	has
NCT001686231	NCT00168623_1_T0	GENE	8	8	VAS
NCT001686231	NCT00168623_1_T1	COMPOUND	12	13	vitamin A
NCT001686232	NCT00168623_2_T0	GENE	23	23	VAS
NCT001686232	NCT00168623_2_T1	PHENOTYPE	34	34	measles
NCT001686232	NCT00168623_2_T2	COMPOUND	13	14	vitamin A
NCT001686233	NCT00168623_3_T0	GENE	8	8	VAS
NCT001686237	NCT00168623_7_T0	GENE	23	23	VAS
NCT001686237	NCT00168623_7_T1	PHENOTYPE	34	34	measles
NCT001686237	NCT00168623_7_T2	COMPOUND	13	14	vitamin A
NCT001686238	NCT00168623_8_T0	GENE	8	8	VAS
NCT001686362	NCT00168636_2_T0	GENE	15	15	VAS
NCT001686364	NCT00168636_4_T0	GENE	17	17	has
NCT001686366	NCT00168636_6_T0	GENE	8	8	VAS
NCT001686367	NCT00168636_7_T0	GENE	12	12	had
NCT001686369	NCT00168636_9_T0	GENE	25	25	VAS
NCT001686369	NCT00168636_9_T1	COMPOUND	11	12	vitamin A
NCT0016863611	NCT00168636_11_T0	GENE	6	6	VAS
NCT0016863611	NCT00168636_11_T1	GENE	34	34	has
NCT001686491	NCT00168649_1_T0	COMPOUND	7	8	vitamin A
NCT001686491	NCT00168649_1_T1	BIOLOGICAL_PROCESS	13	15	response to endotoxin
NCT001686492	NCT00168649_2_T0	COMPOUND	9	10	vitamin A
NCT001686492	NCT00168649_2_T1	BIOLOGICAL_PROCESS	13	15	response to endotoxin
NCT001686493	NCT00168649_3_T0	COMPOUND	3	4	vitamin A
NCT001686495	NCT00168649_5_T0	COMPOUND	7	8	vitamin A
NCT001686495	NCT00168649_5_T1	BIOLOGICAL_PROCESS	13	15	response to endotoxin
NCT001686496	NCT00168649_6_T0	GENE	12	12	has
NCT001686496	NCT00168649_6_T1	COMPOUND	10	11	vitamin A
NCT001686496	NCT00168649_6_T2	COMPOUND	28	29	vitamin A
NCT001686496	NCT00168649_6_T3	ORGAN	17	18	immune system
NCT001686496	NCT00168649_6_T4	BIOLOGICAL_PROCESS	32	34	response to endotoxin
NCT001686498	NCT00168649_8_T0	COMPOUND	3	4	vitamin A
NCT001686499	NCT00168649_9_T0	PHENOTYPE	6	7	oxidative stress
NCT001686620	NCT00168662_0_T0	PHENOTYPE	5	5	Measles
NCT001686624	NCT00168662_4_T0	PHENOTYPE	0	0	Measles
NCT001686624	NCT00168662_4_T1	PHENOTYPE	8	8	diseases
NCT001686626	NCT00168662_6_T0	PHENOTYPE	8	8	strategies
NCT001686627	NCT00168662_7_T0	PHENOTYPE	25	25	complications
NCT001686627	NCT00168662_7_T1	PHENOTYPE	16	16	immunity
NCT001686628	NCT00168662_8_T0	GENE	8	8	has
NCT001686628	NCT00168662_8_T1	PHENOTYPE	11	11	measles
NCT001686628	NCT00168662_8_T2	PHENOTYPE	14	14	measles
NCT001686629	NCT00168662_9_T0	PHENOTYPE	20	20	measles
NCT001686629	NCT00168662_9_T1	PHENOTYPE	23	23	measles
NCT0016866211	NCT00168662_11_T0	PHENOTYPE	5	5	measles
NCT0016866212	NCT00168662_12_T0	PHENOTYPE	18	18	polio
NCT0016866212	NCT00168662_12_T1	PHENOTYPE	7	7	measles
NCT0016866212	NCT00168662_12_T2	PHENOTYPE	23	23	measles
NCT0016866213	NCT00168662_13_T0	PHENOTYPE	5	5	measles
NCT0016866214	NCT00168662_14_T0	PHENOTYPE	25	25	diarrhoea
NCT0016866214	NCT00168662_14_T1	PHENOTYPE	29	29	malaria
NCT0016866214	NCT00168662_14_T2	PHENOTYPE	7	7	measles
NCT0016866214	NCT00168662_14_T3	PHENOTYPE	26	27	respiratory infections
NCT0016866216	NCT00168662_16_T0	GENE	24	24	has
NCT0016866216	NCT00168662_16_T1	PHENOTYPE	12	12	HBV
NCT0016866216	NCT00168662_16_T2	PHENOTYPE	26	26	measles
NCT0016868811	NCT00168688_11_T0	PHENOTYPE	1	1	malaria
NCT0016868814	NCT00168688_14_T0	PHENOTYPE	8	8	malaria
NCT0016868815	NCT00168688_15_T0	PHENOTYPE	3	3	malaria
NCT001687010	NCT00168701_0_T0	GENE	6	6	MS
NCT001687016	NCT00168701_6_T0	GENE	7	7	MS
NCT001687016	NCT00168701_6_T1	GENE	15	15	al
NCT001687016	NCT00168701_6_T2	ORGAN	17	17	Appendix
NCT001687016	NCT00168701_6_T3	GENE	14	14	et
NCT001687018	NCT00168701_8_T0	GENE	8	8	5.0
NCT001687018	NCT00168701_8_T1	COMPOUND	4	4	EDSS
NCT0016870110	NCT00168701_10_T0	GENE	24	24	OR
NCT0016870110	NCT00168701_10_T1	PHENOTYPE	6	6	relapse
NCT0016870110	NCT00168701_10_T2	GENE	18	18	MRI
NCT0016870110	NCT00168701_10_T3	GENE	35	35	MRI
NCT0016870110	NCT00168701_10_T4	GENE	23	23	MS
NCT0016870114	NCT00168701_14_T0	PHENOTYPE	2	2	secondary
NCT0016870114	NCT00168701_14_T1	COMPOUND	16	16	3
NCT0016870114	NCT00168701_14_T2	GENE	7	7	MS
NCT0016870114	NCT00168701_14_T3	PHENOTYPE	1	1	progressive
NCT0016870114	NCT00168701_14_T4	PHENOTYPE	3	3	progressive
NCT0016870114	NCT00168701_14_T5	PHENOTYPE	5	5	progressive
NCT0016870114	NCT00168701_14_T6	ORGAN	15	15	Appendix
NCT0016870116	NCT00168701_16_T0	PHENOTYPE	2	2	malignancy
NCT0016870120	NCT00168701_20_T0	GENE	24	24	MS
NCT0016870120	NCT00168701_20_T1	PHENOTYPE	3	4	laboratory results
NCT0016870124	NCT00168701_24_T0	PHENOTYPE	4	5	alcohol abuse
NCT0016870126	NCT00168701_26_T0	PHENOTYPE	2	2	relapse
NCT0016870126	NCT00168701_26_T1	PHENOTYPE	22	22	relapse
NCT0016870126	NCT00168701_26_T2	GENE	1	1	MS
NCT0016870126	NCT00168701_26_T3	GENE	4	4	has
NCT0016870126	NCT00168701_26_T4	GENE	16	16	has
NCT0016870128	NCT00168701_28_T0	GENE	2	2	100
NCT0016870130	NCT00168701_30_T0	PHENOTYPE	8	9	hepatitis B
NCT0016870130	NCT00168701_30_T1	PHENOTYPE	2	3	hepatitis C
NCT001687275	NCT00168727_5_T0	PHENOTYPE	4	4	closed
NCT001687275	NCT00168727_5_T1	GENE	2	2	has
NCT001687400	NCT00168740_0_T0	PHENOTYPE	5	6	Follicular Lymphoma
NCT001687402	NCT00168740_2_T0	CELL	4	4	cells
NCT001687402	NCT00168740_2_T1	PHENOTYPE	3	3	lymphoma
NCT001687403	NCT00168740_3_T0	PHENOTYPE	2	2	recurrent
NCT001687403	NCT00168740_3_T1	PHENOTYPE	3	4	B-cell lymphoma
NCT001687404	NCT00168740_4_T0	PHENOTYPE	6	6	recurrent
NCT001687404	NCT00168740_4_T1	PHENOTYPE	7	8	B-cell lymphoma
NCT001687405	NCT00168740_5_T0	PHENOTYPE	2	2	tumors
NCT001687407	NCT00168740_7_T0	GENE	6	6	11-2
NCT001687532	NCT00168753_2_T0	GENE	15	15	IM
NCT001687532	NCT00168753_2_T1	GENE	30	30	IM
NCT0016875315	NCT00168753_15_T0	PHENOTYPE	12	12	sterile
NCT0016875322	NCT00168753_22_T0	COMPOUND	7	7	cyclosporine
NCT0016875322	NCT00168753_22_T1	COMPOUND	8	8	azathioprine
NCT0016875322	NCT00168753_22_T2	COMPOUND	6	6	methotrexate
NCT0016875322	NCT00168753_22_T3	COMPOUND	15	16	mycophenolate mofetil
NCT0016875326	NCT00168753_26_T0	PHENOTYPE	11	11	septicemia
NCT0016875326	NCT00168753_26_T1	PHENOTYPE	10	10	pneumonia
NCT0016875326	NCT00168753_26_T2	PHENOTYPE	5	5	abscess
NCT0016875326	NCT00168753_26_T3	PHENOTYPE	4	4	cellulitis
NCT0016875326	NCT00168753_26_T4	PHENOTYPE	7	8	systemic infection
NCT0016875331	NCT00168753_31_T0	PHENOTYPE	1	1	HIV
NCT0016875331	NCT00168753_31_T1	PHENOTYPE	5	5	tuberculosis
NCT0016875331	NCT00168753_31_T2	PHENOTYPE	2	3	viral hepatitis
NCT0016875334	NCT00168753_34_T0	GENE	4	4	hematocrit
NCT0016875334	NCT00168753_34_T1	CELL	5	5	platelets
NCT0016875334	NCT00168753_34_T2	GENE	3	3	hemoglobin
NCT0016875334	NCT00168753_34_T3	CELL	6	8	white blood cells
NCT0016875335	NCT00168753_35_T0	GENE	0	0	CD4
NCT0016875335	NCT00168753_35_T1	CELL	2	2	lymphocyte
NCT001687661	NCT00168766_1_T0	PHENOTYPE	15	15	relapse
NCT001687661	NCT00168766_1_T1	GENE	22	22	MRI
NCT001687661	NCT00168766_1_T2	GENE	8	8	has
NCT001687661	NCT00168766_1_T3	PHENOTYPE	17	18	brain atrophy
NCT001687664	NCT00168766_4_T0	GENE	3	3	MP
NCT001687664	NCT00168766_4_T1	GENE	7	7	po
NCT001687791	NCT00168779_1_T0	PHENOTYPE	13	13	Hypertension
NCT0016877911	NCT00168779_11_T0	PHENOTYPE	15	15	IUD
NCT0016877913	NCT00168779_13_T0	PHENOTYPE	3	4	secondary hypertension
NCT0016877915	NCT00168779_15_T0	GENE	2	2	SBP
NCT0016877915	NCT00168779_15_T1	GENE	9	9	DBP
NCT0016877917	NCT00168779_17_T0	PHENOTYPE	3	3	dysfunction
NCT0016877923	NCT00168779_23_T0	PHENOTYPE	2	2	hypokalemia
NCT0016877923	NCT00168779_23_T1	PHENOTYPE	4	4	hyperkalemia
NCT0016877925	NCT00168779_25_T0	PHENOTYPE	1	2	volume depletion
NCT0016877927	NCT00168779_27_T0	PHENOTYPE	1	2	sodium depletion
NCT0016877930	NCT00168779_30_T0	COMPOUND	1	1	fructose
NCT0016877931	NCT00168779_31_T0	PHENOTYPE	2	2	disorders
NCT0016877933	NCT00168779_33_T0	PHENOTYPE	4	5	alcohol dependency
NCT001687920	NCT00168792_0_T0	GENE	19	19	PCI
NCT001687920	NCT00168792_0_T1	GENE	25	25	PCI
NCT001687920	NCT00168792_0_T2	GENE	34	34	PCI
NCT001687920	NCT00168792_0_T3	PHENOTYPE	29	31	Acute Myocardial Infarction
NCT001688050	NCT00168805_0_T0	PHENOTYPE	17	17	Thrombosis
NCT001688570	NCT00168857_0_T0	PHENOTYPE	32	32	Nephropathy
NCT001689090	NCT00168909_0_T0	PHENOTYPE	4	4	Falls
NCT001689351	NCT00168935_1_T0	PHENOTYPE	7	7	malnutrition
NCT001689351	NCT00168935_1_T1	GENE	12	12	reduced
NCT001689351	NCT00168935_1_T2	PHENOTYPE	1	1	dysfunction
NCT001689351	NCT00168935_1_T3	PHENOTYPE	16	18	quality of life
NCT001689352	NCT00168935_2_T0	PHENOTYPE	27	29	quality of life
NCT001689611	NCT00168961_1_T0	ORGAN	4	4	liver
NCT001689612	NCT00168961_2_T0	PHENOTYPE	7	7	malnutrition
NCT001689612	NCT00168961_2_T1	PHENOTYPE	17	18	liver cirrhosis
NCT001689613	NCT00168961_3_T0	PHENOTYPE	13	13	anorexia
NCT001689613	NCT00168961_3_T1	PHENOTYPE	16	16	drowsiness
NCT001689613	NCT00168961_3_T2	GENE	3	3	has
NCT001689741	NCT00168974_1_T0	TISSUE	23	23	tissues
NCT001689741	NCT00168974_1_T1	CELL	17	19	vascular endothelial cells
NCT001689744	NCT00168974_4_T0	PHENOTYPE	7	7	severely
NCT001689744	NCT00168974_4_T1	PHENOTYPE	2	3	X-linked inheritance
NCT001689745	NCT00168974_5_T0	GENE	2	2	has
NCT001689746	NCT00168974_6_T0	PHENOTYPE	9	11	small fibre neuropathy
NCT001689749	NCT00168974_9_T0	PHENOTYPE	22	22	neuropathy
NCT001689749	NCT00168974_9_T1	PHENOTYPE	19	20	Fabry disease
NCT0016897410	NCT00168974_10_T0	PHENOTYPE	4	5	Fabry disease
NCT001689871	NCT00168987_1_T0	GENE	2	2	EPA
NCT001689871	NCT00168987_1_T1	GENE	3	3	has
NCT001689872	NCT00168987_2_T0	GENE	11	11	EPA
NCT001689872	NCT00168987_2_T1	PHENOTYPE	27	28	pancreatic carcinoma
NCT001689873	NCT00168987_3_T0	PHENOTYPE	24	24	tumors
NCT001689873	NCT00168987_3_T1	GENE	5	5	EPA
NCT001689873	NCT00168987_3_T2	PHENOTYPE	26	27	weight loss
NCT001689873	NCT00168987_3_T3	PHENOTYPE	16	18	quality of life
NCT001690001	NCT00169000_1_T0	COMPOUND	19	19	capecitabine
NCT001690001	NCT00169000_1_T1	COMPOUND	10	10	docetaxel
NCT001690001	NCT00169000_1_T2	GENE	13	13	IV
NCT001690002	NCT00169000_2_T0	COMPOUND	13	13	capecitabine
NCT001690002	NCT00169000_2_T1	CELL	21	21	cells
NCT001690002	NCT00169000_2_T2	COMPOUND	11	11	docetaxel
NCT001690002	NCT00169000_2_T3	GENE	14	14	has
NCT001690002	NCT00169000_2_T4	PHENOTYPE	19	20	breast cancer
NCT001690003	NCT00169000_3_T0	COMPOUND	1	1	capecitabine
NCT001690004	NCT00169000_4_T0	GENE	3	3	IV
NCT001690005	NCT00169000_5_T0	COMPOUND	16	16	docetaxel
NCT001690007	NCT00169000_7_T0	COMPOUND	29	29	capecitabine
NCT001690007	NCT00169000_7_T1	COMPOUND	31	31	docetaxel
NCT001690007	NCT00169000_7_T2	PHENOTYPE	3	3	tumor
NCT001690007	NCT00169000_7_T3	PHENOTYPE	11	11	tumor
NCT001690007	NCT00169000_7_T4	GENE	16	17	thymidine phosphorylase
NCT001690008	NCT00169000_8_T0	COMPOUND	5	5	capecitabine
NCT001690008	NCT00169000_8_T1	CELL	4	4	cells
NCT001690008	NCT00169000_8_T2	CELL	16	16	cells
NCT001690008	NCT00169000_8_T3	CELL	29	29	cells
NCT001690008	NCT00169000_8_T4	PHENOTYPE	2	3	breast cancer
NCT0016900010	NCT00169000_10_T0	COMPOUND	15	15	capecitabine
NCT0016900010	NCT00169000_10_T1	COMPOUND	7	7	docetaxel
NCT0016900010	NCT00169000_10_T2	PHENOTYPE	3	3	susceptible
NCT0016900010	NCT00169000_10_T3	CELL	0	0	Cells
NCT0016900013	NCT00169000_13_T0	PHENOTYPE	2	2	tumors
NCT0016900013	NCT00169000_13_T1	COMPOUND	11	11	docetaxel
NCT0016900015	NCT00169000_15_T0	COMPOUND	2	2	2
NCT0016900015	NCT00169000_15_T1	GENE	6	6	BID
NCT0016900015	NCT00169000_15_T2	GENE	5	5	po
NCT0016900016	NCT00169000_16_T0	COMPOUND	2	2	1
NCT0016900016	NCT00169000_16_T1	GENE	6	6	BID
NCT0016900016	NCT00169000_16_T2	GENE	5	5	po
NCT0016900017	NCT00169000_17_T0	GENE	6	6	BID
NCT0016900017	NCT00169000_17_T1	GENE	5	5	po
NCT0016900019	NCT00169000_19_T0	COMPOUND	4	4	capecitabine
NCT0016900019	NCT00169000_19_T1	PHENOTYPE	14	14	tumors
NCT0016900019	NCT00169000_19_T2	GENE	5	5	has
NCT0016900019	NCT00169000_19_T3	GENE	2	2	MTD
NCT0016900019	NCT00169000_19_T4	GENE	20	20	MTD
NCT0016900020	NCT00169000_20_T0	COMPOUND	5	5	5__deoxy_5_fluorouridine
NCT0016900020	NCT00169000_20_T1	GENE	26	26	Bcl-2
NCT0016900020	NCT00169000_20_T2	COMPOUND	3	3	capecitabine
NCT0016900020	NCT00169000_20_T3	COMPOUND	7	7	docetaxel
NCT0016900020	NCT00169000_20_T4	PHENOTYPE	16	16	tumor
NCT0016900020	NCT00169000_20_T5	ORGAN	2	2	plasma
NCT0016900020	NCT00169000_20_T6	PHENOTYPE	0	0	Pharmacokinetics
NCT0016900020	NCT00169000_20_T7	BIOLOGICAL_PROCESS	27	27	phosphorylation
NCT0016900021	NCT00169000_21_T0	COMPOUND	19	19	capecitabine
NCT0016900021	NCT00169000_21_T1	COMPOUND	27	27	docetaxel
NCT0016900021	NCT00169000_21_T2	PHENOTYPE	17	17	toxicities
NCT0016900022	NCT00169000_22_T0	COMPOUND	9	9	capecitabine
NCT0016900022	NCT00169000_22_T1	PHENOTYPE	0	0	Secondary
NCT0016900022	NCT00169000_22_T2	COMPOUND	11	11	docetaxel
NCT0016900022	NCT00169000_22_T3	PHENOTYPE	7	7	pharmacokinetics
NCT0016900022	NCT00169000_22_T4	PHENOTYPE	29	29	toxicities
NCT0016900022	NCT00169000_22_T5	GENE	23	23	DPD
NCT0016900022	NCT00169000_22_T6	BIOLOGICAL_PROCESS	21	21	phosphorylation
NCT001690132	NCT00169013_2_T0	ORGAN	4	4	femur
NCT001690135	NCT00169013_5_T0	PHENOTYPE	0	0	Allergy
NCT001690135	NCT00169013_5_T1	COMPOUND	2	2	gabapentin
NCT001690136	NCT00169013_6_T0	ORGAN	5	5	limb
NCT001690136	NCT00169013_6_T1	ORGAN	7	7	toes
NCT001690261	NCT00169026_1_T0	COMPOUND	4	4	clozapine
NCT001690392	NCT00169039_2_T0	COMPOUND	30	30	chlorpromazine
NCT001690392	NCT00169039_2_T1	PHENOTYPE	7	7	recruitment
NCT001690392	NCT00169039_2_T2	COMPOUND	28	28	clozapine
NCT001690392	NCT00169039_2_T3	GENE	2	2	has
NCT001690520	NCT00169052_0_T0	PHENOTYPE	10	11	Mental Illness
NCT001690523	NCT00169052_3_T0	COMPOUND	11	11	1
NCT001690523	NCT00169052_3_T1	GENE	19	19	UC
NCT001690524	NCT00169052_4_T0	COMPOUND	8	8	SMI
NCT001690524	NCT00169052_4_T1	GENE	10	10	UC
NCT001690527	NCT00169052_7_T0	PHENOTYPE	17	17	acute
NCT001690527	NCT00169052_7_T1	COMPOUND	2	2	2
NCT001690527	NCT00169052_7_T2	GENE	10	10	UC
NCT001690528	NCT00169052_8_T0	PHENOTYPE	24	24	acute
NCT001690528	NCT00169052_8_T1	COMPOUND	8	8	SMI
NCT001690528	NCT00169052_8_T2	GENE	10	10	UC
NCT001690529	NCT00169052_9_T0	GENE	3	3	reduced
NCT001690529	NCT00169052_9_T1	PHENOTYPE	21	21	practices
NCT0016905210	NCT00169052_10_T0	PHENOTYPE	6	6	secondary
NCT0016905213	NCT00169052_13_T0	PHENOTYPE	20	21	cognitive impairment
NCT0016905214	NCT00169052_14_T0	GENE	11	11	UC
NCT0016905215	NCT00169052_15_T0	COMPOUND	20	20	SMI
NCT0016905215	NCT00169052_15_T1	PHENOTYPE	18	19	mental illness
NCT0016905216	NCT00169052_16_T0	COMPOUND	18	18	SMI
NCT0016905217	NCT00169052_17_T0	GENE	3	3	SR
NCT0016905218	NCT00169052_18_T0	PHENOTYPE	25	25	acute
NCT0016905219	NCT00169052_19_T0	COMPOUND	22	22	SMI
NCT0016905220	NCT00169052_20_T0	PHENOTYPE	34	34	acute
NCT0016905220	NCT00169052_20_T1	COMPOUND	25	25	SMI
NCT0016905221	NCT00169052_21_T0	COMPOUND	25	25	SMI
NCT0016905221	NCT00169052_21_T1	GENE	11	11	UC
NCT001690652	NCT00169065_2_T0	PHENOTYPE	20	20	toxic
NCT001690652	NCT00169065_2_T1	COMPOUND	10	10	olanzapine
NCT001690652	NCT00169065_2_T2	COMPOUND	21	21	clozapine
NCT001690783	NCT00169078_3_T0	COMPOUND	26	26	chloroquine
NCT001690783	NCT00169078_3_T1	PHENOTYPE	50	50	resistant
NCT001690783	NCT00169078_3_T2	PHENOTYPE	23	23	malaria
NCT001690783	NCT00169078_3_T3	GENE	40	40	SP
NCT001690785	NCT00169078_5_T0	GENE	18	18	SP
NCT001690788	NCT00169078_8_T0	PHENOTYPE	1	1	strategies
NCT001690788	NCT00169078_8_T1	PHENOTYPE	13	14	drugs resistance
NCT001690789	NCT00169078_9_T0	PHENOTYPE	1	1	strategies
NCT001690789	NCT00169078_9_T1	PHENOTYPE	10	11	drug use
NCT0016907824	NCT00169078_24_T0	GENE	1	1	3-1
NCT0016907824	NCT00169078_24_T1	PHENOTYPE	17	17	malaria
NCT0016907824	NCT00169078_24_T2	PHENOTYPE	44	44	centres
NCT0016907825	NCT00169078_25_T0	PHENOTYPE	13	13	fever
NCT0016907825	NCT00169078_25_T1	COMPOUND	33	33	EDTA
NCT0016907825	NCT00169078_25_T2	PHENOTYPE	16	16	malaria
NCT0016907825	NCT00169078_25_T3	GENE	24	24	ml
NCT0016907826	NCT00169078_26_T0	GENE	9	9	PCV
NCT0016907826	NCT00169078_26_T1	PHENOTYPE	3	3	malaria
NCT0016907828	NCT00169078_28_T0	PHENOTYPE	13	13	centre
NCT0016907829	NCT00169078_29_T0	PHENOTYPE	9	9	spots
NCT0016907830	NCT00169078_30_T0	PHENOTYPE	17	17	malaria
NCT0016907835	NCT00169078_35_T0	PHENOTYPE	9	9	spots
NCT0016907836	NCT00169078_36_T0	PHENOTYPE	22	22	estimation
NCT0016907836	NCT00169078_36_T1	PHENOTYPE	16	16	malaria
NCT0016907837	NCT00169078_37_T0	PHENOTYPE	6	6	traps
NCT0016907839	NCT00169078_39_T0	BIOLOGICAL_PROCESS	4	4	behaviour
NCT0016907839	NCT00169078_39_T1	BIOLOGICAL_PROCESS	28	28	behaviour
NCT0016907840	NCT00169078_40_T0	GENE	0	0	3-2
NCT0016907841	NCT00169078_41_T0	PHENOTYPE	0	0	Asexual
NCT0016907841	NCT00169078_41_T1	CELL	11	13	white blood cells
NCT0016907842	NCT00169078_42_T0	GENE	8	8	pre
NCT0016907842	NCT00169078_42_T1	PHENOTYPE	16	16	spots
NCT0016907843	NCT00169078_43_T0	GENE	4	4	nested
NCT0016907843	NCT00169078_43_T1	GENE	5	5	PCR
NCT0016907844	NCT00169078_44_T0	GENE	9	9	endonuclease
NCT0016907844	NCT00169078_44_T1	GENE	7	7	Apo
NCT0016907844	NCT00169078_44_T2	COMPOUND	17	17	agarose
NCT0016907844	NCT00169078_44_T3	GENE	2	2	PCR
NCT0016907844	NCT00169078_44_T4	PHENOTYPE	5	5	digested
NCT0016907845	NCT00169078_45_T0	PHENOTYPE	12	12	mutation
NCT0016907845	NCT00169078_45_T1	COMPOUND	1	1	oligonucleotide
NCT0016907846	NCT00169078_46_T0	GENE	9	9	dhps
NCT0016907846	NCT00169078_46_T1	GENE	2	2	dhfr
NCT0016907849	NCT00169078_49_T0	PHENOTYPE	47	47	resistant
NCT0016907850	NCT00169078_50_T0	GENE	16	16	6.0
NCT0016907850	NCT00169078_50_T1	GENE	0	0	3.4
NCT0016907852	NCT00169078_52_T0	PHENOTYPE	10	10	regression
NCT0016907852	NCT00169078_52_T1	GENE	12	12	3.5
NCT0016907852	NCT00169078_52_T2	PHENOTYPE	7	7	Generalized
NCT0016907856	NCT00169078_56_T0	PHENOTYPE	4	5	severe malnutrition
NCT0016907857	NCT00169078_57_T0	PHENOTYPE	6	6	fever
NCT0016907857	NCT00169078_57_T1	PHENOTYPE	9	9	malaria
NCT0016907858	NCT00169078_58_T0	PHENOTYPE	3	3	allergy
NCT0016907860	NCT00169078_60_T0	PHENOTYPE	17	17	malaria
NCT0016907860	NCT00169078_60_T1	PHENOTYPE	19	19	vomiting
NCT001690912	NCT00169091_2_T0	GENE	4	4	tapered
NCT001691042	NCT00169104_2_T0	GENE	6	6	has
NCT001691042	NCT00169104_2_T1	PHENOTYPE	37	39	metastatic breast cancer
NCT001691049	NCT00169104_9_T0	GENE	9	9	G-CSF
NCT0016910411	NCT00169104_11_T0	GENE	16	16	G-CSF
NCT0016910411	NCT00169104_11_T1	PHENOTYPE	4	6	metastatic breast cancer
NCT0016910412	NCT00169104_12_T0	COMPOUND	25	25	vinorelbine
NCT0016910412	NCT00169104_12_T1	GENE	12	12	G-CSF
NCT0016910414	NCT00169104_14_T0	COMPOUND	4	4	MUGA
NCT0016910420	NCT00169104_20_T0	COMPOUND	8	8	1
NCT0016910420	NCT00169104_20_T1	COMPOUND	9	9	2
NCT0016910420	NCT00169104_20_T2	COMPOUND	11	11	3
NCT0016910420	NCT00169104_20_T3	COMPOUND	13	13	3
NCT0016910420	NCT00169104_20_T4	GENE	0	0	HER-2/neu
NCT0016910421	NCT00169104_21_T0	GENE	4	4	FISH
NCT001691172	NCT00169117_2_T0	PHENOTYPE	0	0	Attitudes
NCT001691178	NCT00169117_8_T0	PHENOTYPE	11	11	malaria
NCT001691178	NCT00169117_8_T1	PHENOTYPE	5	6	mosquito bites
NCT0016911710	NCT00169117_10_T0	PHENOTYPE	0	0	Attitudes
NCT0016911715	NCT00169117_15_T0	PHENOTYPE	68	68	opinions
NCT001691694	NCT00169169_4_T0	GENE	6	6	ACE
NCT001691695	NCT00169169_5_T0	GENE	16	16	R2
NCT001691695	NCT00169169_5_T1	GENE	12	12	HDC
NCT001691824	NCT00169182_4_T0	ORGAN	13	13	larynx
NCT001691828	NCT00169182_8_T0	ORGAN	13	13	larynx
NCT001692084	NCT00169208_4_T0	PHENOTYPE	3	3	strategies
NCT001692087	NCT00169208_7_T0	COMPOUND	3	3	mitoxantrone
NCT001692087	NCT00169208_7_T1	COMPOUND	9	9	fludarabine
NCT0016920812	NCT00169208_12_T0	PHENOTYPE	9	9	remission
NCT0016920812	NCT00169208_12_T1	GENE	18	18	had
NCT0016920814	NCT00169208_14_T0	PHENOTYPE	1	1	toxicity
NCT0016920816	NCT00169208_16_T0	PHENOTYPE	9	9	toxicity
NCT0016920816	NCT00169208_16_T1	PHENOTYPE	21	22	follicular lymphoma
NCT0016920817	NCT00169208_17_T0	PHENOTYPE	18	19	indolent lymphoma
NCT0016920817	NCT00169208_17_T1	PHENOTYPE	9	10	opportunistic infections
NCT0016920819	NCT00169208_19_T0	PHENOTYPE	6	6	lymphoma
NCT0016920820	NCT00169208_20_T0	COMPOUND	33	33	fludarabine
NCT0016920820	NCT00169208_20_T1	PHENOTYPE	4	6	recurrent follicular lymphoma
NCT0016920821	NCT00169208_21_T0	PHENOTYPE	3	3	progression
NCT0016920822	NCT00169208_22_T0	PHENOTYPE	0	0	Toxicity
NCT0016920826	NCT00169208_26_T0	PHENOTYPE	9	9	progression
NCT0016920827	NCT00169208_27_T0	COMPOUND	11	11	mitoxantrone
NCT0016920827	NCT00169208_27_T1	COMPOUND	9	9	fludarabine
NCT0016920828	NCT00169208_28_T0	COMPOUND	8	8	mitoxantrone
NCT0016920828	NCT00169208_28_T1	COMPOUND	34	34	dexamethasone
NCT0016920828	NCT00169208_28_T2	COMPOUND	15	15	2
NCT0016920828	NCT00169208_28_T3	COMPOUND	6	6	fludarabine
NCT0016920828	NCT00169208_28_T4	COMPOUND	49	49	fludarabine
NCT0016920828	NCT00169208_28_T5	GENE	23	23	has
NCT001692348	NCT00169234_8_T0	GENE	7	7	0.5
NCT0016923412	NCT00169234_12_T0	GENE	0	0	For
NCT0016923412	NCT00169234_12_T1	COMPOUND	11	11	prednisone
NCT001692473	NCT00169247_3_T0	ORGAN	9	9	larynx
NCT001692603	NCT00169260_3_T0	PHENOTYPE	27	27	symptoms
NCT001692603	NCT00169260_3_T1	GENE	11	11	CO
NCT001692603	NCT00169260_3_T2	GENE	14	14	CO
NCT001692603	NCT00169260_3_T3	COMPOUND	9	10	carbon monoxide
NCT001692603	NCT00169260_3_T4	PHENOTYPE	17	18	carboxyhemoglobin levels
NCT001692732	NCT00169273_2_T0	GENE	3	3	has
NCT001692732	NCT00169273_2_T1	PHENOTYPE	2	2	obesity
NCT001692733	NCT00169273_3_T0	PHENOTYPE	0	0	Obesity
NCT001692733	NCT00169273_3_T1	GENE	1	1	has
NCT001692733	NCT00169273_3_T2	PHENOTYPE	10	12	quality of life
NCT001692734	NCT00169273_4_T0	PHENOTYPE	9	9	obesity
NCT001692736	NCT00169273_6_T0	PHENOTYPE	14	14	obesity
NCT001692737	NCT00169273_7_T0	PHENOTYPE	11	12	losing weight
NCT001692737	NCT00169273_7_T1	PHENOTYPE	15	16	weight loss
NCT001692738	NCT00169273_8_T0	PHENOTYPE	23	23	obesity
NCT001692738	NCT00169273_8_T1	PHENOTYPE	12	13	weight loss
NCT001692738	NCT00169273_8_T2	PHENOTYPE	3	4	depressive disorders
NCT001692739	NCT00169273_9_T0	PHENOTYPE	13	13	obesity
NCT001692739	NCT00169273_9_T1	PHENOTYPE	23	23	obesity
NCT001692739	NCT00169273_9_T2	PHENOTYPE	31	31	obesity
NCT001692739	NCT00169273_9_T3	PHENOTYPE	36	36	obesity
NCT0016927311	NCT00169273_11_T0	GENE	6	6	30
NCT0016927311	NCT00169273_11_T1	COMPOUND	5	5	BMI
NCT0016927314	NCT00169273_14_T0	PHENOTYPE	4	4	obesity
NCT0016927315	NCT00169273_15_T0	PHENOTYPE	0	0	Secondary
NCT0016927317	NCT00169273_17_T0	PHENOTYPE	11	11	impairment
NCT0016927317	NCT00169273_17_T1	PHENOTYPE	5	5	obesity
NCT0016927319	NCT00169273_19_T0	PHENOTYPE	27	27	focused
NCT0016927319	NCT00169273_19_T1	PHENOTYPE	5	5	obesity
NCT0016927319	NCT00169273_19_T2	PHENOTYPE	16	17	weight loss
NCT0016927319	NCT00169273_19_T3	PHENOTYPE	32	33	weight loss
NCT0016927321	NCT00169273_21_T0	PHENOTYPE	8	9	weight loss
NCT0016927321	NCT00169273_21_T1	PHENOTYPE	13	14	weight loss
NCT0016927321	NCT00169273_21_T2	PHENOTYPE	29	30	weight loss
NCT0016927322	NCT00169273_22_T0	PHENOTYPE	0	0	Secondary
NCT0016927324	NCT00169273_24_T0	PHENOTYPE	27	27	impairment
NCT0016927324	NCT00169273_24_T1	PHENOTYPE	38	38	obesity
NCT0016927324	NCT00169273_24_T2	PHENOTYPE	12	13	weight loss
NCT0016927324	NCT00169273_24_T3	PHENOTYPE	18	19	weight loss
NCT0016927324	NCT00169273_24_T4	PHENOTYPE	24	25	depressive symptoms
NCT001692860	NCT00169286_0_T0	PHENOTYPE	4	5	Chronic Depression
NCT001692863	NCT00169286_3_T0	PHENOTYPE	11	12	Chronic Disease
NCT001692865	NCT00169286_5_T0	PHENOTYPE	25	25	strategies
NCT001692865	NCT00169286_5_T1	PHENOTYPE	18	18	self-efficacy
NCT001692865	NCT00169286_5_T2	PHENOTYPE	12	12	SCID
NCT001692865	NCT00169286_5_T3	GENE	6	6	SCL
NCT001692992	NCT00169299_2_T0	PHENOTYPE	10	10	symptoms
NCT001692992	NCT00169299_2_T1	COMPOUND	17	17	estrogen
NCT001692992	NCT00169299_2_T2	GENE	12	12	hormone
NCT001692995	NCT00169299_5_T0	PHENOTYPE	22	22	symptoms
NCT001692996	NCT00169299_6_T0	GENE	13	13	hormone
NCT001692997	NCT00169299_7_T0	PHENOTYPE	15	16	menopausal symptoms
NCT0016929910	NCT00169299_10_T0	GENE	21	21	has
NCT0016929910	NCT00169299_10_T1	GENE	5	5	HT
NCT0016929911	NCT00169299_11_T0	PHENOTYPE	7	7	rigors
NCT0016929912	NCT00169299_12_T0	PHENOTYPE	24	24	symptoms
NCT0016929912	NCT00169299_12_T1	GENE	26	26	peri
NCT0016929912	NCT00169299_12_T2	COMPOUND	20	20	phytoestrogens
NCT001693251	NCT00169325_1_T0	PHENOTYPE	13	13	focal
NCT001693251	NCT00169325_1_T1	ORGAN	11	12	basal ganglia
NCT001693381	NCT00169338_1_T0	PHENOTYPE	19	19	dystonia
NCT001693381	NCT00169338_1_T1	PHENOTYPE	11	11	bilateral
NCT001693381	NCT00169338_1_T2	PHENOTYPE	18	18	generalised
NCT001693381	NCT00169338_1_T3	PHENOTYPE	21	21	generalised
NCT001693381	NCT00169338_1_T4	PHENOTYPE	22	23	primary dystonia
NCT001693642	NCT00169364_2_T0	PHENOTYPE	6	6	mutation
NCT001693642	NCT00169364_2_T1	PHENOTYPE	14	14	sporadic
NCT001693642	NCT00169364_2_T2	GENE	5	5	parkin
NCT001693643	NCT00169364_3_T0	PHENOTYPE	5	5	mutation
NCT001693644	NCT00169364_4_T0	PHENOTYPE	18	18	mutation
NCT001693644	NCT00169364_4_T1	PHENOTYPE	25	25	mutation
NCT001693644	NCT00169364_4_T2	GENE	17	17	parkin
NCT001693644	NCT00169364_4_T3	GENE	24	24	parkin
NCT001693772	NCT00169377_2_T0	PHENOTYPE	1	1	pathophysiology
NCT001693773	NCT00169377_3_T0	PHENOTYPE	13	13	OCD
NCT001693773	NCT00169377_3_T1	PHENOTYPE	6	6	dysfunction
NCT001693773	NCT00169377_3_T2	ORGAN	4	5	basal ganglia
NCT001693774	NCT00169377_4_T0	PHENOTYPE	19	19	OCD
NCT001693774	NCT00169377_4_T1	ORGAN	11	12	subthalamic nucleus
NCT001693901	NCT00169390_1_T0	PHENOTYPE	13	13	peripheral
NCT001693901	NCT00169390_1_T1	COMPOUND	9	9	nicotine
NCT001693901	NCT00169390_1_T2	COMPOUND	11	11	cotinine
NCT001693901	NCT00169390_1_T3	GENE	6	6	MAO
NCT001693901	NCT00169390_1_T4	ORGAN	26	27	cord blood
NCT001693903	NCT00169390_3_T0	PHENOTYPE	8	8	concentrations
NCT001693903	NCT00169390_3_T1	GENE	14	14	MAOB
NCT001693903	NCT00169390_3_T2	COMPOUND	6	6	DOPAC
NCT001693903	NCT00169390_3_T3	GENE	10	10	MAOA
NCT001693903	NCT00169390_3_T4	COMPOUND	4	4	cotinine
NCT001693903	NCT00169390_3_T5	PHENOTYPE	9	9	reflecting
NCT001693903	NCT00169390_3_T6	CELL	13	13	platelet
NCT001693903	NCT00169390_3_T7	ORGAN	3	3	plasma
NCT001693903	NCT00169390_3_T8	ORGAN	38	39	cord blood
NCT001694031	NCT00169403_1_T0	PHENOTYPE	30	30	recurrence
NCT001694031	NCT00169403_1_T1	PHENOTYPE	34	34	symptoms
NCT001694031	NCT00169403_1_T2	COMPOUND	7	7	1
NCT001694031	NCT00169403_1_T3	COMPOUND	27	27	2
NCT001694031	NCT00169403_1_T4	PHENOTYPE	21	21	dystonia
NCT001694031	NCT00169403_1_T5	PHENOTYPE	20	20	generalised
NCT001694551	NCT00169455_1_T0	GENE	2	2	has
NCT001694551	NCT00169455_1_T1	GENE	0	0	GSK
NCT001694551	NCT00169455_1_T2	PHENOTYPE	8	9	rotavirus gastroenteritis
NCT001694682	NCT00169468_2_T0	GENE	1	1	has
NCT001694682	NCT00169468_2_T1	PHENOTYPE	10	11	B-cell lymphomas
NCT001694683	NCT00169468_3_T0	GENE	25	25	CD20
NCT001694683	NCT00169468_3_T1	PHENOTYPE	4	4	toxicity
NCT001694683	NCT00169468_3_T2	CELL	23	23	B-cell
NCT001694683	NCT00169468_3_T3	PHENOTYPE	24	24	malignancies
NCT001694683	NCT00169468_3_T4	GENE	13	13	CHOP
NCT001694686	NCT00169468_6_T0	PHENOTYPE	20	20	tolerance
NCT001694687	NCT00169468_7_T0	GENE	7	7	proteasome
NCT001694687	NCT00169468_7_T1	PHENOTYPE	19	19	myeloma
NCT001694687	NCT00169468_7_T2	GENE	10	10	has
NCT001694689	NCT00169468_9_T0	PHENOTYPE	6	6	toxicity
NCT001694689	NCT00169468_9_T1	PHENOTYPE	10	10	thrombocytopenia
NCT001694689	NCT00169468_9_T2	PHENOTYPE	8	8	neuropathy
NCT0016946813	NCT00169468_13_T0	PHENOTYPE	11	12	B-cell lymphoma
NCT0016946814	NCT00169468_14_T0	PHENOTYPE	13	13	toxicity
NCT0016946815	NCT00169468_15_T0	PHENOTYPE	14	14	toxicity
NCT0016946818	NCT00169468_18_T0	GENE	22	22	II
NCT001694943	NCT00169494_3_T0	PHENOTYPE	16	17	cervical cancer
NCT001694944	NCT00169494_4_T0	GENE	18	18	GSK
NCT001695200	NCT00169520_0_T0	PHENOTYPE	8	9	Solid Tumors
NCT001695202	NCT00169520_2_T0	COMPOUND	2	2	docetaxel
NCT001695460	NCT00169546_0_T0	PHENOTYPE	3	3	Physiology
NCT001695460	NCT00169546_0_T1	GENE	16	16	GSK
NCT001695590	NCT00169559_0_T0	PHENOTYPE	0	0	Dyslipidemia
NCT001695720	NCT00169572_0_T0	PHENOTYPE	5	5	Nausea
NCT001695980	NCT00169598_0_T0	GENE	15	15	FDG
NCT001695980	NCT00169598_0_T1	PHENOTYPE	6	6	Lymphoma
NCT001696376	NCT00169637_6_T0	BIOLOGICAL_PROCESS	4	4	digestion
NCT001696379	NCT00169637_9_T0	PHENOTYPE	0	1	Heart failure
NCT001696379	NCT00169637_9_T1	PHENOTYPE	4	5	respiratory insufficiency
NCT0016963710	NCT00169637_10_T0	PHENOTYPE	0	0	Allergy
NCT001696501	NCT00169650_1_T0	GENE	12	12	LP
NCT001696501	NCT00169650_1_T1	PHENOTYPE	6	6	centers
NCT001696502	NCT00169650_2_T0	GENE	2	2	has
NCT001696502	NCT00169650_2_T1	GENE	7	7	has
NCT001696631	NCT00169663_1_T0	GENE	2	2	has
NCT001696631	NCT00169663_1_T1	PHENOTYPE	22	23	kidney stones
NCT001696634	NCT00169663_4_T0	GENE	22	22	al
NCT001696634	NCT00169663_4_T1	PHENOTYPE	15	15	fragmentation
NCT001696634	NCT00169663_4_T2	GENE	21	21	et
NCT001696634	NCT00169663_4_T3	GENE	12	12	has
NCT001696634	NCT00169663_4_T4	PHENOTYPE	8	9	kidney stone
NCT001696634	NCT00169663_4_T5	COMPOUND	6	7	calcium phosphate
NCT001696637	NCT00169663_7_T0	GENE	25	25	al
NCT001696637	NCT00169663_7_T1	GENE	24	24	et
NCT001696637	NCT00169663_7_T2	ORGAN	12	13	urinary tract
NCT001696638	NCT00169663_8_T0	GENE	13	13	has
NCT0016966312	NCT00169663_12_T0	GENE	4	4	has
NCT001696762	NCT00169676_2_T0	GENE	13	13	LRP
NCT0016967612	NCT00169676_12_T0	TISSUE	5	7	positive surgical margins
NCT0016967613	NCT00169676_13_T0	TISSUE	9	11	positive surgical margins
NCT001697150	NCT00169715_0_T0	PHENOTYPE	4	5	Renal Diverticulum
NCT001697157	NCT00169715_7_T0	GENE	14	14	al
NCT001697157	NCT00169715_7_T1	GENE	18	18	al
NCT001697157	NCT00169715_7_T2	GENE	13	13	et
NCT001697157	NCT00169715_7_T3	GENE	17	17	et
NCT001697157	NCT00169715_7_T4	GENE	7	7	9.5
NCT001697158	NCT00169715_8_T0	PHENOTYPE	14	14	discomfort
NCT001697158	NCT00169715_8_T1	PHENOTYPE	8	11	recurrent urinary tract infections
NCT0016971510	NCT00169715_10_T0	PHENOTYPE	13	13	secondary
NCT0016971510	NCT00169715_10_T1	GENE	24	24	al
NCT0016971510	NCT00169715_10_T2	GENE	28	28	al
NCT0016971510	NCT00169715_10_T3	GENE	32	32	al
NCT0016971510	NCT00169715_10_T4	GENE	23	23	et
NCT0016971510	NCT00169715_10_T5	GENE	27	27	et
NCT0016971510	NCT00169715_10_T6	GENE	31	31	et
NCT0016971511	NCT00169715_11_T0	PHENOTYPE	28	28	diverticulum
NCT0016971511	NCT00169715_11_T1	ORGAN	24	24	infundibulum
NCT0016971511	NCT00169715_11_T2	GENE	12	12	al
NCT0016971511	NCT00169715_11_T3	GENE	16	16	al
NCT0016971511	NCT00169715_11_T4	GENE	11	11	et
NCT0016971511	NCT00169715_11_T5	GENE	15	15	et
NCT0016971512	NCT00169715_12_T0	GENE	11	11	has
NCT0016971512	NCT00169715_12_T1	PHENOTYPE	10	10	diverticula
NCT0016971515	NCT00169715_15_T0	GENE	3	3	has
NCT0016971518	NCT00169715_18_T0	PHENOTYPE	7	7	diverticula
NCT0016971520	NCT00169715_20_T0	GENE	16	16	had
NCT0016971522	NCT00169715_22_T0	PHENOTYPE	3	3	bleeding
NCT0016971524	NCT00169715_24_T0	PHENOTYPE	2	3	renal insufficiency
NCT001697411	NCT00169741_1_T0	GENE	0	0	PERC
NCT001697411	NCT00169741_1_T1	PHENOTYPE	24	24	fragmentation
NCT001697412	NCT00169741_2_T0	PHENOTYPE	17	17	trauma
NCT001697412	NCT00169741_2_T1	COMPOUND	30	30	oxygen
NCT001697413	NCT00169741_3_T0	PHENOTYPE	11	12	renal impairment
NCT001697416	NCT00169741_6_T0	PHENOTYPE	15	15	acute
NCT001697416	NCT00169741_6_T1	GENE	18	18	PERC
NCT001697418	NCT00169741_8_T0	GENE	0	0	PERC
NCT001697418	NCT00169741_8_T1	PHENOTYPE	12	12	complications
NCT001697418	NCT00169741_8_T2	GENE	7	7	has
NCT001697419	NCT00169741_9_T0	GENE	3	3	PERC
NCT001697419	NCT00169741_9_T1	GENE	4	4	has
NCT0016974110	NCT00169741_10_T0	GENE	3	3	PERC
NCT0016974110	NCT00169741_10_T1	GENE	7	7	has
NCT0016974114	NCT00169741_14_T0	COMPOUND	17	17	creatinine
NCT0016974114	NCT00169741_14_T1	GENE	23	23	PERC
NCT0016974114	NCT00169741_14_T2	GENE	29	29	PERC
NCT0016974114	NCT00169741_14_T3	GENE	2	2	has
NCT0016974119	NCT00169741_19_T0	GENE	14	14	PERC
NCT0016974119	NCT00169741_19_T1	GENE	1	1	has
NCT0016974121	NCT00169741_21_T0	PHENOTYPE	14	14	acute
NCT0016974121	NCT00169741_21_T1	GENE	17	17	PERC
NCT0016974122	NCT00169741_22_T0	GENE	10	10	PERC
NCT0016974126	NCT00169741_26_T0	GENE	15	15	pigs
NCT0016974127	NCT00169741_27_T0	COMPOUND	24	24	creatinine
NCT0016974127	NCT00169741_27_T1	GENE	8	8	PERC
NCT0016974127	NCT00169741_27_T2	GENE	12	12	has
NCT0016974127	NCT00169741_27_T3	ORGAN	23	23	serum
NCT0016974128	NCT00169741_28_T0	GENE	11	11	PERC
NCT0016974129	NCT00169741_29_T0	GENE	12	12	PERC
NCT0016974129	NCT00169741_29_T1	GENE	13	13	has
NCT001697540	NCT00169754_0_T0	PHENOTYPE	11	11	Plaque
NCT001697540	NCT00169754_0_T1	PHENOTYPE	13	13	Plaque
NCT001697540	NCT00169754_0_T2	PHENOTYPE	6	7	Renal Calculi
NCT001697544	NCT00169754_4_T0	ORGAN	13	13	limb
NCT001697544	NCT00169754_4_T1	PHENOTYPE	7	7	plaque
NCT001697544	NCT00169754_4_T2	PHENOTYPE	25	25	plaque
NCT001697544	NCT00169754_4_T3	GENE	29	29	HA
NCT001697544	NCT00169754_4_T4	GENE	33	33	al
NCT001697544	NCT00169754_4_T5	GENE	32	32	et
NCT001697546	NCT00169754_6_T0	GENE	33	33	Carr
NCT001697546	NCT00169754_6_T1	PHENOTYPE	22	22	plaque
NCT001697546	NCT00169754_6_T2	COMPOUND	13	13	calcium
NCT001697546	NCT00169754_6_T3	GENE	39	39	al
NCT001697546	NCT00169754_6_T4	COMPOUND	14	14	oxalate
NCT001697546	NCT00169754_6_T5	GENE	38	38	et
NCT001697547	NCT00169754_7_T0	GENE	2	2	has
NCT001697549	NCT00169754_9_T0	COMPOUND	19	19	calcium
NCT001697549	NCT00169754_9_T1	COMPOUND	20	20	oxalate
NCT0016975411	NCT00169754_11_T0	GENE	2	2	has
NCT0016975411	NCT00169754_11_T1	GENE	15	15	al
NCT0016975411	NCT00169754_11_T2	GENE	14	14	et
NCT0016975412	NCT00169754_12_T0	GENE	33	33	PERC
NCT0016975412	NCT00169754_12_T1	PHENOTYPE	7	8	renal calculi
NCT0016975418	NCT00169754_18_T0	PHENOTYPE	13	13	nidus
NCT0016975420	NCT00169754_20_T0	PHENOTYPE	31	31	inflammation
NCT0016975420	NCT00169754_20_T1	COMPOUND	24	25	calcium phosphate
NCT0016975421	NCT00169754_21_T0	COMPOUND	16	16	calcium
NCT0016975421	NCT00169754_21_T1	ORGAN	9	9	kidneys
NCT0016975421	NCT00169754_21_T2	COMPOUND	17	17	oxalate
NCT0016975421	NCT00169754_21_T3	COMPOUND	19	20	calcium phosphate
NCT0016975422	NCT00169754_22_T0	PHENOTYPE	18	18	plaque
NCT0016975423	NCT00169754_23_T0	PHENOTYPE	17	17	attachment
NCT0016975424	NCT00169754_24_T0	GENE	19	19	Carr
NCT0016975424	NCT00169754_24_T1	PHENOTYPE	8	8	plaque
NCT0016975426	NCT00169754_26_T0	PHENOTYPE	16	16	plaque
NCT0016975426	NCT00169754_26_T1	GENE	19	19	HA
NCT0016975427	NCT00169754_27_T0	COMPOUND	24	24	apatite
NCT0016975427	NCT00169754_27_T1	PHENOTYPE	20	20	attachment
NCT0016975427	NCT00169754_27_T2	PHENOTYPE	30	30	attachment
NCT0016975428	NCT00169754_28_T0	PHENOTYPE	31	31	plaque
NCT0016975428	NCT00169754_28_T1	PHENOTYPE	38	38	plaque
NCT0016975428	NCT00169754_28_T2	COMPOUND	23	23	calcium
NCT0016975428	NCT00169754_28_T3	GENE	15	15	HA
NCT0016975428	NCT00169754_28_T4	COMPOUND	25	25	monohydrate
NCT0016975428	NCT00169754_28_T5	COMPOUND	24	24	oxalate
NCT0016975429	NCT00169754_29_T0	PHENOTYPE	10	11	renal calculi
NCT0016975430	NCT00169754_30_T0	COMPOUND	3	3	calcium
NCT0016975430	NCT00169754_30_T1	GENE	15	15	HA
NCT0016975430	NCT00169754_30_T2	GENE	26	26	al
NCT0016975430	NCT00169754_30_T3	COMPOUND	4	4	oxalate
NCT0016975430	NCT00169754_30_T4	GENE	25	25	et
NCT0016975431	NCT00169754_31_T0	PHENOTYPE	22	22	plaque
NCT0016975431	NCT00169754_31_T1	COMPOUND	16	16	calcium
NCT0016975431	NCT00169754_31_T2	GENE	19	19	had
NCT0016975431	NCT00169754_31_T3	GENE	27	27	al
NCT0016975431	NCT00169754_31_T4	COMPOUND	17	17	oxalate
NCT0016975431	NCT00169754_31_T5	GENE	26	26	et
NCT0016975432	NCT00169754_32_T0	PHENOTYPE	10	10	plaques
NCT0016975432	NCT00169754_32_T1	GENE	24	24	al
NCT0016975432	NCT00169754_32_T2	GENE	23	23	et
NCT0016975433	NCT00169754_33_T0	GENE	13	13	PERC
NCT0016975434	NCT00169754_34_T0	GENE	13	13	PERC
NCT0016975436	NCT00169754_36_T0	COMPOUND	10	10	apatite
NCT0016975436	NCT00169754_36_T1	COMPOUND	8	8	calcium
NCT0016975436	NCT00169754_36_T2	GENE	12	12	probable
NCT0016975436	NCT00169754_36_T3	COMPOUND	9	9	oxalate
NCT0016975438	NCT00169754_38_T0	PHENOTYPE	19	19	understood
NCT0016975438	NCT00169754_38_T1	PHENOTYPE	15	16	renal calculi
NCT001697672	NCT00169767_2_T0	PHENOTYPE	15	15	complications
NCT001697672	NCT00169767_2_T1	GENE	10	10	has
NCT001697675	NCT00169767_5_T0	GENE	24	24	al
NCT001697675	NCT00169767_5_T1	GENE	1	1	has
NCT001697678	NCT00169767_8_T0	PHENOTYPE	18	18	bleeding
NCT001697678	NCT00169767_8_T1	BIOLOGICAL_PROCESS	12	12	hemostasis
NCT001697678	NCT00169767_8_T2	COMPOUND	7	7	holmium
NCT0016976712	NCT00169767_12_T0	PHENOTYPE	9	9	symptoms
NCT0016976712	NCT00169767_12_T1	PHENOTYPE	11	12	urine flow
NCT0016976718	NCT00169767_18_T0	PHENOTYPE	24	24	bleeding
NCT0016976718	NCT00169767_18_T1	ORGAN	7	7	bladder
NCT0016976718	NCT00169767_18_T2	ORGAN	18	18	bladder
NCT0016976723	NCT00169767_23_T0	PHENOTYPE	9	9	Hyperplasia
NCT0016976723	NCT00169767_23_T1	GENE	3	3	AUA
NCT0016976727	NCT00169767_27_T0	GENE	11	11	San
NCT0016976727	NCT00169767_27_T1	GENE	13	13	CA
NCT0016976728	NCT00169767_28_T0	PHENOTYPE	6	6	complications
NCT0016976728	NCT00169767_28_T1	GENE	32	32	al
NCT0016976728	NCT00169767_28_T2	GENE	31	31	et
NCT0016976728	NCT00169767_28_T3	PHENOTYPE	24	25	urine flow
NCT0016976729	NCT00169767_29_T0	GENE	11	11	has
NCT001697801	NCT00169780_1_T0	PHENOTYPE	12	12	fragmented
NCT001697803	NCT00169780_3_T0	ORGAN	14	14	kidney
NCT001697803	NCT00169780_3_T1	PHENOTYPE	22	23	kidney stone
NCT001697805	NCT00169780_5_T0	PHENOTYPE	21	22	kidney stone
NCT001697807	NCT00169780_7_T0	GENE	16	16	has
NCT0016978010	NCT00169780_10_T0	PHENOTYPE	10	11	kidney stone
NCT0016978011	NCT00169780_11_T0	GENE	17	17	has
NCT0016978012	NCT00169780_12_T0	GENE	22	22	al
NCT0016978012	NCT00169780_12_T1	GENE	26	26	al
NCT0016978012	NCT00169780_12_T2	GENE	30	30	al
NCT0016978012	NCT00169780_12_T3	GENE	11	11	has
NCT0016978012	NCT00169780_12_T4	GENE	21	21	et
NCT0016978012	NCT00169780_12_T5	GENE	25	25	et
NCT0016978012	NCT00169780_12_T6	GENE	29	29	et
NCT0016978012	NCT00169780_12_T7	ORGAN	8	9	urinary tract
NCT0016978014	NCT00169780_14_T0	ORGAN	2	3	urinary tract
NCT0016978015	NCT00169780_15_T0	PHENOTYPE	17	18	renal calculi
NCT0016978016	NCT00169780_16_T0	PHENOTYPE	7	7	fragmented
NCT0016978016	NCT00169780_16_T1	PHENOTYPE	3	4	kidney stones
NCT0016978017	NCT00169780_17_T0	PHENOTYPE	6	6	complications
NCT0016978017	NCT00169780_17_T1	GENE	17	17	al
NCT0016978017	NCT00169780_17_T2	GENE	21	21	al
NCT0016978017	NCT00169780_17_T3	PHENOTYPE	11	11	hypertension
NCT0016978017	NCT00169780_17_T4	GENE	16	16	et
NCT0016978017	NCT00169780_17_T5	GENE	20	20	et
NCT0016978017	NCT00169780_17_T6	PHENOTYPE	13	14	renal insufficiency
NCT0016978018	NCT00169780_18_T0	GENE	18	18	structural
NCT0016978018	NCT00169780_18_T1	GENE	22	22	al
NCT0016978018	NCT00169780_18_T2	PHENOTYPE	4	4	fragility
NCT0016978018	NCT00169780_18_T3	GENE	21	21	et
NCT0016978019	NCT00169780_19_T0	COMPOUND	23	23	calcium
NCT0016978019	NCT00169780_19_T1	GENE	35	35	abdominal
NCT0016978019	NCT00169780_19_T2	COMPOUND	24	24	oxalate
NCT0016978019	NCT00169780_19_T3	PHENOTYPE	7	7	fragility
NCT0016978020	NCT00169780_20_T0	COMPOUND	27	27	calcium
NCT0016978020	NCT00169780_20_T1	COMPOUND	29	29	monohydrate
NCT0016978020	NCT00169780_20_T2	GENE	36	36	fragment
NCT0016978020	NCT00169780_20_T3	COMPOUND	28	28	oxalate
NCT0016978020	NCT00169780_20_T4	PHENOTYPE	2	2	fragility
NCT0016978020	NCT00169780_20_T5	PHENOTYPE	13	13	intuition
NCT0016978026	NCT00169780_26_T0	GENE	17	17	axis
NCT0016978028	NCT00169780_28_T0	GENE	16	16	structural
NCT0016978028	NCT00169780_28_T1	PHENOTYPE	22	22	fragility
NCT0016978028	NCT00169780_28_T2	PHENOTYPE	9	10	kidney stone
NCT001697932	NCT00169793_2_T0	PHENOTYPE	17	18	kidney stone
NCT001697935	NCT00169793_5_T0	PHENOTYPE	53	53	complications
NCT001697935	NCT00169793_5_T1	ORGAN	33	33	liver
NCT001697935	NCT00169793_5_T2	GENE	3	3	mid
NCT001697935	NCT00169793_5_T3	GENE	43	43	had
NCT001697935	NCT00169793_5_T4	PHENOTYPE	24	24	anemia
NCT001697935	NCT00169793_5_T5	PHENOTYPE	27	27	nephrolithiasis
NCT001697935	NCT00169793_5_T6	PHENOTYPE	25	26	vitamin deficiencies
NCT001697935	NCT00169793_5_T7	PHENOTYPE	45	46	organ failure
NCT001697935	NCT00169793_5_T8	PHENOTYPE	21	22	adverse effects
NCT001697936	NCT00169793_6_T0	PHENOTYPE	3	3	complications
NCT001697937	NCT00169793_7_T0	COMPOUND	7	7	calcium
NCT001697938	NCT00169793_8_T0	COMPOUND	17	17	calcium
NCT001697938	NCT00169793_8_T1	COMPOUND	7	7	oxalate
NCT001697938	NCT00169793_8_T2	COMPOUND	22	22	oxalate
NCT001697938	NCT00169793_8_T3	ORGAN	13	14	large intestine
NCT001697939	NCT00169793_9_T0	ORGAN	8	8	ileum
NCT001697939	NCT00169793_9_T1	ORGAN	13	13	colon
NCT001697939	NCT00169793_9_T2	COMPOUND	22	22	oxalate
NCT001697939	NCT00169793_9_T3	TISSUE	20	20	mucosa
NCT0016979311	NCT00169793_11_T0	PHENOTYPE	35	35	complication
NCT0016979311	NCT00169793_11_T1	COMPOUND	18	18	calcium
NCT0016979311	NCT00169793_11_T2	PHENOTYPE	16	16	hyperoxaluria
NCT0016979311	NCT00169793_11_T3	ORGAN	12	12	kidney
NCT0016979311	NCT00169793_11_T4	PHENOTYPE	61	61	nephrolithiasis
NCT0016979311	NCT00169793_11_T5	COMPOUND	19	19	oxalate
NCT0016979311	NCT00169793_11_T6	PHENOTYPE	82	82	obesity
NCT0016979312	NCT00169793_12_T0	GENE	7	7	had
NCT0016979313	NCT00169793_13_T0	PHENOTYPE	25	25	complications
NCT0016979313	NCT00169793_13_T1	PHENOTYPE	49	49	learned
NCT0016979313	NCT00169793_13_T2	GENE	6	6	had
NCT0016979313	NCT00169793_13_T3	GENE	34	34	bypass
NCT0016979313	NCT00169793_13_T4	PHENOTYPE	29	29	arthritis
NCT0016979313	NCT00169793_13_T5	PHENOTYPE	30	30	urolithiasis
NCT0016979313	NCT00169793_13_T6	PHENOTYPE	32	32	nephropathy
NCT0016979313	NCT00169793_13_T7	COMPOUND	31	31	oxalate
NCT0016979313	NCT00169793_13_T8	PHENOTYPE	28	28	cirrhosis
NCT0016979314	NCT00169793_14_T0	PHENOTYPE	5	5	obesity
NCT0016979317	NCT00169793_17_T0	PHENOTYPE	19	19	hyperoxaluria
NCT0016979317	NCT00169793_17_T1	PHENOTYPE	2	3	fat malabsorption
NCT0016979317	NCT00169793_17_T2	PHENOTYPE	12	13	weight loss
NCT0016979319	NCT00169793_19_T0	PHENOTYPE	16	17	kidney stone
NCT0016979322	NCT00169793_22_T0	PHENOTYPE	12	13	kidney stones
NCT0016979323	NCT00169793_23_T0	GENE	10	10	had
NCT0016979323	NCT00169793_23_T1	PHENOTYPE	11	12	weight reduction
NCT0016979324	NCT00169793_24_T0	PHENOTYPE	6	7	kidney stone
NCT0016979332	NCT00169793_32_T0	GENE	15	15	1.4
NCT0016979332	NCT00169793_32_T1	GENE	1	1	3.4
NCT0016979332	NCT00169793_32_T2	GENE	7	7	had
NCT0016979332	NCT00169793_32_T3	GENE	16	16	had
NCT0016979332	NCT00169793_32_T4	COMPOUND	9	9	oxalate
NCT0016979332	NCT00169793_32_T5	COMPOUND	18	18	oxalate
NCT0016979332	NCT00169793_32_T6	GENE	20	21	in excess
NCT0016979334	NCT00169793_34_T0	PHENOTYPE	22	23	kidney stone
NCT0016979338	NCT00169793_38_T0	PHENOTYPE	52	52	nephrolithiasis
NCT0016979338	NCT00169793_38_T1	PHENOTYPE	55	55	nephropathy
NCT0016979338	NCT00169793_38_T2	COMPOUND	36	36	oxalate
NCT0016979338	NCT00169793_38_T3	COMPOUND	54	54	oxalate
NCT0016979340	NCT00169793_40_T0	PHENOTYPE	23	23	complications
NCT0016979341	NCT00169793_41_T0	PHENOTYPE	21	21	hyperoxaluria
NCT0016979341	NCT00169793_41_T1	PHENOTYPE	0	3	Loss of renal function
NCT0016979343	NCT00169793_43_T0	PHENOTYPE	1	1	obesity
NCT0016979343	NCT00169793_43_T1	PHENOTYPE	16	16	obesity
NCT0016979344	NCT00169793_44_T0	PHENOTYPE	18	18	complications
NCT001698062	NCT00169806_2_T0	PHENOTYPE	8	9	kidney stones
NCT001698063	NCT00169806_3_T0	PHENOTYPE	5	6	kidney stones
NCT001698063	NCT00169806_3_T1	PHENOTYPE	16	17	kidney stones
NCT001698064	NCT00169806_4_T0	PHENOTYPE	4	5	kidney stones
NCT001698065	NCT00169806_5_T0	ORGAN	18	18	kidney
NCT001698065	NCT00169806_5_T1	COMPOUND	8	8	calcium
NCT001698065	NCT00169806_5_T2	PHENOTYPE	5	6	kidney stones
NCT001698066	NCT00169806_6_T0	PHENOTYPE	8	9	kidney stones
NCT001698067	NCT00169806_7_T0	PHENOTYPE	11	11	plaques
NCT001698067	NCT00169806_7_T1	PHENOTYPE	21	22	kidney stones
NCT0016980611	NCT00169806_11_T0	PHENOTYPE	19	20	kidney stone
NCT001698191	NCT00169819_1_T0	ORGAN	23	24	coronary artery
NCT001698192	NCT00169819_2_T0	PHENOTYPE	21	21	complications
NCT001698192	NCT00169819_2_T1	PHENOTYPE	18	18	thrombocytopenia
NCT001698192	NCT00169819_2_T2	PHENOTYPE	11	12	myocardial infarction
NCT001698193	NCT00169819_3_T0	PHENOTYPE	1	1	secondary
NCT001698193	NCT00169819_3_T1	PHENOTYPE	8	9	myocardial infarction
NCT001698194	NCT00169819_4_T0	PHENOTYPE	1	1	secondary
NCT001698196	NCT00169819_6_T0	GENE	8	8	PCI
NCT001698196	NCT00169819_6_T1	PHENOTYPE	12	13	fear of
NCT001698197	NCT00169819_7_T0	GENE	25	25	balloon
NCT001698197	NCT00169819_7_T1	GENE	5	5	has
NCT001698198	NCT00169819_8_T0	GENE	10	10	PCI
NCT0016981910	NCT00169819_10_T0	PHENOTYPE	9	9	inhibition
NCT0016981910	NCT00169819_10_T1	CELL	8	8	platelet
NCT0016981914	NCT00169819_14_T0	GENE	16	16	PCI
NCT0016981915	NCT00169819_15_T0	ORGAN	18	19	coronary artery
NCT0016981919	NCT00169819_19_T0	GENE	7	7	PCI
NCT001698320	NCT00169832_0_T0	PHENOTYPE	1	1	Atherosclerosis
NCT001698324	NCT00169832_4_T0	GENE	6	6	bypass
NCT001698326	NCT00169832_6_T0	ORGAN	34	35	coronary artery
NCT001698327	NCT00169832_7_T0	COMPOUND	10	10	rosiglitazone
NCT0016983215	NCT00169832_15_T0	PHENOTYPE	13	13	sterile
NCT0016983219	NCT00169832_19_T0	PHENOTYPE	6	6	hyperglycemia
NCT0016983219	NCT00169832_19_T1	GENE	20	20	mo
NCT0016983225	NCT00169832_25_T0	GENE	31	31	ICF
NCT0016983235	NCT00169832_35_T0	ORGAN	10	11	coronary artery
NCT0016983235	NCT00169832_35_T1	ORGAN	27	28	coronary artery
NCT0016983235	NCT00169832_35_T2	ORGAN	32	33	coronary artery
NCT0016983236	NCT00169832_36_T0	GENE	2	2	AT
NCT0016983243	NCT00169832_43_T0	GENE	3	3	ACS
NCT0016983257	NCT00169832_57_T0	GENE	0	0	TG
NCT0016983258	NCT00169832_58_T0	GENE	2	2	PCI
NCT0016983260	NCT00169832_60_T0	GENE	5	5	mo
NCT0016983261	NCT00169832_61_T0	PHENOTYPE	0	0	Chronic
NCT0016983261	NCT00169832_61_T1	GENE	4	4	mo
NCT0016983261	NCT00169832_61_T2	GENE	6	6	insulin
NCT0016983261	NCT00169832_61_T3	GENE	19	19	insulin
NCT0016983262	NCT00169832_62_T0	PHENOTYPE	0	0	Allergy
NCT0016983263	NCT00169832_63_T0	GENE	17	17	mo
NCT0016983263	NCT00169832_63_T1	PHENOTYPE	3	3	anorectic
NCT0016983263	NCT00169832_63_T2	PHENOTYPE	11	11	anorectic
NCT0016983264	NCT00169832_64_T0	PHENOTYPE	13	13	recurrent
NCT0016983265	NCT00169832_65_T0	PHENOTYPE	4	5	drug abuse
NCT0016983265	NCT00169832_65_T1	PHENOTYPE	7	8	alcohol abuse
NCT0016983268	NCT00169832_68_T0	PHENOTYPE	2	2	malignancy
NCT0016983270	NCT00169832_70_T0	GENE	10	10	mo
NCT0016983275	NCT00169832_75_T0	COMPOUND	5	5	2
NCT0016983275	NCT00169832_75_T1	GENE	0	0	AT
NCT0016983276	NCT00169832_76_T0	GENE	0	0	PCI
NCT0016983278	NCT00169832_78_T0	ORGAN	5	6	coronary artery
NCT001698451	NCT00169845_1_T0	GENE	5	5	II
NCT001698451	NCT00169845_1_T1	PHENOTYPE	26	26	tumor
NCT001698451	NCT00169845_1_T2	PHENOTYPE	6	9	head and neck cancer
NCT001698452	NCT00169845_2_T0	PHENOTYPE	12	14	second primary cancers
NCT001698453	NCT00169845_3_T0	BIOLOGICAL_PROCESS	26	26	beta-carotene
NCT001698453	NCT00169845_3_T1	PHENOTYPE	32	34	second primary cancers
NCT001698453	NCT00169845_3_T2	PHENOTYPE	9	12	head and neck cancer
NCT001698455	NCT00169845_5_T0	PHENOTYPE	26	26	recurrence
NCT001698455	NCT00169845_5_T1	ORGAN	15	15	serum
NCT001698455	NCT00169845_5_T2	PHENOTYPE	29	31	second primary cancers
NCT001698455	NCT00169845_5_T3	PHENOTYPE	4	7	head and neck cancer
NCT001698458	NCT00169845_8_T0	COMPOUND	26	26	NCI
NCT001698458	NCT00169845_8_T1	ORGAN	10	10	serum
NCT001698458	NCT00169845_8_T2	COMPOUND	6	7	vitamin D
NCT001698458	NCT00169845_8_T3	COMPOUND	17	18	vitamin D
NCT001698581	NCT00169858_1_T0	GENE	11	11	35
NCT001698581	NCT00169858_1_T1	PHENOTYPE	4	5	hepatitis B
NCT001698584	NCT00169858_4_T0	PHENOTYPE	10	10	persistence
NCT001698584	NCT00169858_4_T1	COMPOUND	14	14	Engerix-B
NCT001698584	NCT00169858_4_T2	GENE	31	31	booster
NCT001698584	NCT00169858_4_T3	GENE	42	42	booster
NCT001698586	NCT00169858_6_T0	GENE	5	5	du
NCT001698586	NCT00169858_6_T1	COMPOUND	7	7	Engerix-B
NCT001698587	NCT00169858_7_T0	PHENOTYPE	4	4	thinks
NCT001698588	NCT00169858_8_T0	GENE	5	5	booster
NCT001698710	NCT00169871_0_T0	PHENOTYPE	7	7	Dyslipidemia
NCT001698714	NCT00169871_4_T0	PHENOTYPE	11	11	atherosclerosis
NCT001698714	NCT00169871_4_T1	GENE	8	8	has
NCT001698715	NCT00169871_5_T0	PHENOTYPE	19	19	plaque
NCT001698715	NCT00169871_5_T1	GENE	7	7	has
NCT001698715	NCT00169871_5_T2	GENE	6	6	CHD
NCT001698715	NCT00169871_5_T3	PHENOTYPE	20	20	rupture
NCT001698715	NCT00169871_5_T4	PHENOTYPE	26	27	coronary thrombosis
NCT001698717	NCT00169871_7_T0	GENE	5	5	CRP
NCT001698717	NCT00169871_7_T1	GENE	4	4	hs
NCT001698717	NCT00169871_7_T2	GENE	7	7	has
NCT001698717	NCT00169871_7_T3	PHENOTYPE	14	15	inflammatory responses
NCT001698719	NCT00169871_9_T0	GENE	32	32	CHD
NCT001698846	NCT00169884_6_T0	GENE	17	17	al
NCT001698846	NCT00169884_6_T1	GENE	22	22	al
NCT001698846	NCT00169884_6_T2	GENE	16	16	et
NCT001698846	NCT00169884_6_T3	GENE	21	21	et
NCT0016988416	NCT00169884_16_T0	GENE	36	36	al
NCT0016988416	NCT00169884_16_T1	GENE	35	35	et
NCT0016988422	NCT00169884_22_T0	PHENOTYPE	4	4	thoughts
NCT0016988422	NCT00169884_22_T1	PHENOTYPE	26	26	emotions
NCT0016988422	NCT00169884_22_T2	GENE	34	34	DBT
NCT0016988423	NCT00169884_23_T0	PHENOTYPE	13	14	problem solving
NCT0016988428	NCT00169884_28_T0	COMPOUND	35	35	cortisol
NCT0016988428	NCT00169884_28_T1	GENE	3	3	Van
NCT0016988428	NCT00169884_28_T2	PHENOTYPE	17	17	experiences
NCT0016988441	NCT00169884_41_T0	PHENOTYPE	36	36	self-harm
NCT0016988441	NCT00169884_41_T1	GENE	23	23	al
NCT0016988441	NCT00169884_41_T2	GENE	39	39	al
NCT0016988441	NCT00169884_41_T3	GENE	22	22	et
NCT0016988441	NCT00169884_41_T4	GENE	38	38	et
NCT0016988444	NCT00169884_44_T0	BIOLOGICAL_PROCESS	16	16	Behaviour
NCT0016988444	NCT00169884_44_T1	GENE	18	18	DBT
NCT0016988444	NCT00169884_44_T2	PHENOTYPE	11	13	borderline personality disorder
NCT0016988452	NCT00169884_52_T0	GENE	10	10	al
NCT0016988452	NCT00169884_52_T1	GENE	9	9	et
NCT0016988453	NCT00169884_53_T0	PHENOTYPE	14	14	toxic
NCT0016988453	NCT00169884_53_T1	PHENOTYPE	16	16	overdose
NCT0016988453	NCT00169884_53_T2	PHENOTYPE	11	11	depressions
NCT0016988455	NCT00169884_55_T0	GENE	7	7	DBT
NCT0016988456	NCT00169884_56_T0	GENE	12	12	DBT
NCT001698978	NCT00169897_8_T0	PHENOTYPE	8	11	chronic obstructive pulmonary disease
NCT001698979	NCT00169897_9_T0	GENE	0	0	Ann
NCT001698979	NCT00169897_9_T1	GENE	2	2	Med
NCT001698979	NCT00169897_9_T2	GENE	1	1	Int
NCT001699100	NCT00169910_0_T0	GENE	0	0	VIP
NCT001699102	NCT00169910_2_T0	GENE	1	1	CNI
NCT001699102	NCT00169910_2_T1	GENE	19	19	CNI
NCT001699102	NCT00169910_2_T2	PHENOTYPE	28	29	cardiovascular disease
NCT001699104	NCT00169910_4_T0	PHENOTYPE	15	15	Pulse
NCT001699104	NCT00169910_4_T1	PHENOTYPE	1	1	progression
NCT001699104	NCT00169910_4_T2	PHENOTYPE	19	21	Left Ventricular Hypertrophy
NCT001699232	NCT00169923_2_T0	ORGAN	5	5	kidney
NCT001699234	NCT00169923_4_T0	COMPOUND	12	12	rosiglitazone
NCT001699237	NCT00169923_7_T0	GENE	20	20	CRP
NCT001699237	NCT00169923_7_T1	GENE	22	22	CRP
NCT001699237	NCT00169923_7_T2	GENE	23	23	fetuin
NCT001699237	NCT00169923_7_T3	COMPOUND	28	28	glucose
NCT001699237	NCT00169923_7_T4	GENE	24	24	fibrinogen
NCT001699237	NCT00169923_7_T5	GENE	30	30	insulin
NCT001699237	NCT00169923_7_T6	GENE	21	21	hs
NCT001699238	NCT00169923_8_T0	PHENOTYPE	3	3	pulse
NCT001699361	NCT00169936_1_T0	ORGAN	15	15	heart
NCT001699362	NCT00169936_2_T0	PHENOTYPE	16	16	complications
NCT001699362	NCT00169936_2_T1	ORGAN	28	28	heart
NCT001699363	NCT00169936_3_T0	CELL	30	30	cells
NCT001699363	NCT00169936_3_T1	ORGAN	17	17	heart
NCT001699363	NCT00169936_3_T2	ORGAN	29	29	heart
NCT001699365	NCT00169936_5_T0	PHENOTYPE	17	17	immunosuppression
NCT001699365	NCT00169936_5_T1	ORGAN	0	0	Graft
NCT001699367	NCT00169936_7_T0	PHENOTYPE	3	3	acute
NCT001699367	NCT00169936_7_T1	PHENOTYPE	2	2	diffuse
NCT001699367	NCT00169936_7_T2	GENE	11	11	EMB
NCT001699367	NCT00169936_7_T3	PHENOTYPE	0	0	Focal
NCT001699368	NCT00169936_8_T0	PHENOTYPE	9	9	arteriopathy
NCT001699368	NCT00169936_8_T1	PHENOTYPE	13	13	chronic
NCT001699368	NCT00169936_8_T2	ORGAN	8	8	allograft
NCT001699368	NCT00169936_8_T3	GENE	2	2	CA
NCT001699369	NCT00169936_9_T0	GENE	3	3	EMB
NCT0016993610	NCT00169936_10_T0	PHENOTYPE	17	17	complications
NCT0016993611	NCT00169936_11_T0	ORGAN	19	19	heart
NCT0016993612	NCT00169936_12_T0	PHENOTYPE	2	2	acute
NCT0016993612	NCT00169936_12_T1	GENE	20	20	de
NCT0016993612	NCT00169936_12_T2	CELL	9	9	myocyte
NCT0016993612	NCT00169936_12_T3	PHENOTYPE	8	8	affects
NCT001699491	NCT00169949_1_T0	PHENOTYPE	7	7	symptoms
NCT001699491	NCT00169949_1_T1	PHENOTYPE	10	10	schizophrenia
NCT001699491	NCT00169949_1_T2	GENE	2	2	has
NCT001699492	NCT00169949_2_T0	PHENOTYPE	8	8	symptoms
NCT001699492	NCT00169949_2_T1	PHENOTYPE	16	16	symptoms
NCT001699492	NCT00169949_2_T2	PHENOTYPE	23	23	disorders
NCT001699492	NCT00169949_2_T3	PHENOTYPE	26	26	thoughts
NCT001699492	NCT00169949_2_T4	PHENOTYPE	11	12	psychotic disorders
NCT001699494	NCT00169949_4_T0	PHENOTYPE	17	17	symptoms
NCT001699494	NCT00169949_4_T1	PHENOTYPE	3	4	side effect
NCT001699495	NCT00169949_5_T0	PHENOTYPE	10	11	substance abuse
NCT001699622	NCT00169962_2_T0	PHENOTYPE	13	13	relapse
NCT001699623	NCT00169962_3_T0	PHENOTYPE	5	5	asthma
NCT001699624	NCT00169962_4_T0	PHENOTYPE	18	18	symptoms
NCT001699626	NCT00169962_6_T0	PHENOTYPE	24	24	asthmatics
NCT001699626	NCT00169962_6_T1	PHENOTYPE	34	34	acute
NCT001699626	NCT00169962_6_T2	PHENOTYPE	40	40	relapse
NCT001699629	NCT00169962_9_T0	PHENOTYPE	30	30	asthmatics
NCT001699750	NCT00169975_0_T0	PHENOTYPE	19	19	Angina
NCT001699750	NCT00169975_0_T1	PHENOTYPE	16	17	Unstable Angina
NCT001699750	NCT00169975_0_T2	PHENOTYPE	7	9	Acute Coronary Syndromes
NCT001699755	NCT00169975_5_T0	PHENOTYPE	19	19	separation
NCT001699755	NCT00169975_5_T1	GENE	15	15	grid
NCT001699759	NCT00169975_9_T0	PHENOTYPE	5	7	Acute Coronary Syndromes
NCT0016997510	NCT00169975_10_T0	PHENOTYPE	5	6	myocardial infarction
NCT0016997513	NCT00169975_13_T0	TISSUE	8	8	tissues
NCT0016997514	NCT00169975_14_T0	PHENOTYPE	19	20	Unstable Angina
NCT001699882	NCT00169988_2_T0	COMPOUND	17	17	risperidone
NCT001699882	NCT00169988_2_T1	COMPOUND	9	9	sertraline
NCT001700013	NCT00170001_3_T0	GENE	18	18	has
NCT001700014	NCT00170001_4_T0	GENE	23	23	SER
NCT001700015	NCT00170001_5_T0	PHENOTYPE	9	9	Reflux
NCT001700015	NCT00170001_5_T1	GENE	30	30	SER
NCT0017000111	NCT00170001_11_T0	PHENOTYPE	13	13	symptoms
NCT0017000111	NCT00170001_11_T1	PHENOTYPE	11	11	chronic
NCT0017000112	NCT00170001_12_T0	GENE	11	11	ENT
NCT0017000112	NCT00170001_12_T1	PHENOTYPE	15	16	Chronic Cough
NCT0017000115	NCT00170001_15_T0	COMPOUND	5	5	esomeprazole
NCT0017000117	NCT00170001_17_T0	PHENOTYPE	10	10	symptoms
NCT0017000117	NCT00170001_17_T1	PHENOTYPE	14	15	adverse events
NCT0017000118	NCT00170001_18_T0	PHENOTYPE	16	16	symptoms
NCT0017000123	NCT00170001_23_T0	PHENOTYPE	2	2	regression
NCT0017000125	NCT00170001_25_T0	PHENOTYPE	5	5	symptoms
NCT0017000128	NCT00170001_28_T0	PHENOTYPE	1	1	symptoms
NCT0017000128	NCT00170001_28_T1	ORGAN	11	11	Appendix
NCT0017000130	NCT00170001_30_T0	GENE	8	8	3.5
NCT0017000132	NCT00170001_32_T0	PHENOTYPE	13	13	chronic
NCT0017000134	NCT00170001_34_T0	PHENOTYPE	12	12	recurrent
NCT001700140	NCT00170014_0_T0	GENE	9	9	nd
NCT001700144	NCT00170014_4_T0	ORGAN	12	12	heart
NCT001700147	NCT00170014_7_T0	PHENOTYPE	40	40	suffering
NCT001700147	NCT00170014_7_T1	ORGAN	16	16	heart
NCT001700147	NCT00170014_7_T2	PHENOTYPE	42	44	acute coronary syndromes
NCT001700148	NCT00170014_8_T0	GENE	2	2	pointed
NCT0017001410	NCT00170014_10_T0	GENE	7	7	QRS
NCT0017001410	NCT00170014_10_T1	GENE	2	2	al
NCT0017001410	NCT00170014_10_T2	GENE	1	1	et
NCT001700531	NCT00170053_1_T0	COMPOUND	10	10	prednisone
NCT001700532	NCT00170053_2_T0	ORGAN	7	7	kidney
NCT001700535	NCT00170053_5_T0	ORGAN	10	10	kidney
NCT001700535	NCT00170053_5_T1	ORGAN	18	18	transplant
NCT001700538	NCT00170053_8_T0	ORGAN	21	21	kidney
NCT001700538	NCT00170053_8_T1	ORGAN	22	22	transplant
NCT001700538	NCT00170053_8_T2	PHENOTYPE	6	6	avoidance
NCT001700539	NCT00170053_9_T0	GENE	12	12	receptor
NCT001700539	NCT00170053_9_T1	GENE	11	11	IL-2
NCT001700539	NCT00170053_9_T2	GENE	17	17	globulin
NCT001700539	NCT00170053_9_T3	GENE	23	23	globulin
NCT0017005310	NCT00170053_10_T0	COMPOUND	7	7	tacrolimus
NCT0017005310	NCT00170053_10_T1	GENE	3	3	has
NCT0017005310	NCT00170053_10_T2	COMPOUND	9	10	mycophenolate mofetil
NCT0017005313	NCT00170053_13_T0	ORGAN	10	10	kidney
NCT0017005313	NCT00170053_13_T1	PHENOTYPE	7	7	acute
NCT0017005313	NCT00170053_13_T2	ORGAN	16	16	graft
NCT0017005313	NCT00170053_13_T3	ORGAN	11	11	transplant
NCT0017005317	NCT00170053_17_T0	COMPOUND	16	16	tacrolimus
NCT0017005317	NCT00170053_17_T1	GENE	17	17	TAC
NCT0017005317	NCT00170053_17_T2	PHENOTYPE	13	13	elimination
NCT0017005317	NCT00170053_17_T3	COMPOUND	19	20	mycophenolate mofetil
NCT0017005319	NCT00170053_19_T0	ORGAN	9	9	transplant
NCT0017005322	NCT00170053_22_T0	ORGAN	6	6	transplant
NCT0017005326	NCT00170053_26_T0	PHENOTYPE	0	2	Negative pregnancy test
NCT001700791	NCT00170079_1_T0	PHENOTYPE	14	14	relapse
NCT001700793	NCT00170079_3_T0	PHENOTYPE	3	3	chronic
NCT001700796	NCT00170079_6_T0	COMPOUND	15	15	cotinine
NCT001700796	NCT00170079_6_T1	COMPOUND	10	11	carbon monoxide
NCT0017007912	NCT00170079_12_T0	COMPOUND	1	1	1
NCT0017007914	NCT00170079_14_T0	COMPOUND	1	1	3
NCT0017007917	NCT00170079_17_T0	GENE	17	17	al
NCT0017007917	NCT00170079_17_T1	GENE	24	24	has
NCT0017007917	NCT00170079_17_T2	GENE	16	16	et
NCT001701055	NCT00170105_5_T0	PHENOTYPE	14	14	perceived
NCT001701059	NCT00170105_9_T0	PHENOTYPE	24	24	perceptions
NCT0017011813	NCT00170118_13_T0	ORGAN	8	8	Spine
NCT0017011813	NCT00170118_13_T1	GENE	5	5	E10
NCT0017011814	NCT00170118_14_T0	PHENOTYPE	20	20	self-efficacy
NCT0017011814	NCT00170118_14_T1	PHENOTYPE	32	32	self-efficacy
NCT0017011814	NCT00170118_14_T2	GENE	28	28	en
NCT0017011814	NCT00170118_14_T3	PHENOTYPE	24	25	Self efficacy
NCT0017011816	NCT00170118_16_T0	GENE	20	20	PhD
NCT0017011818	NCT00170118_18_T0	PHENOTYPE	10	10	self-efficacy
NCT0017011819	NCT00170118_19_T0	PHENOTYPE	26	26	self-efficacy
NCT001701447	NCT00170144_7_T0	GENE	9	9	ATP
NCT0017014415	NCT00170144_15_T0	GENE	15	15	mitochondrial
NCT0017014415	NCT00170144_15_T1	GENE	16	16	ATP
NCT0017014415	NCT00170144_15_T2	GENE	7	7	BCAA
NCT0017014416	NCT00170144_16_T0	PHENOTYPE	0	0	Secondary
NCT0017014416	NCT00170144_16_T1	GENE	13	13	ATP
NCT001701571	NCT00170157_1_T0	COMPOUND	5	5	acetate
NCT001701571	NCT00170157_1_T1	COMPOUND	7	7	flutamide
NCT001701571	NCT00170157_1_T2	GENE	11	11	lessen
NCT001701571	NCT00170157_1_T3	COMPOUND	6	6	goserelin
NCT001701571	NCT00170157_1_T4	COMPOUND	4	4	leuprolide
NCT001701571	NCT00170157_1_T5	COMPOUND	9	9	bicalutamide
NCT001701573	NCT00170157_3_T0	CELL	6	6	cells
NCT001701573	NCT00170157_3_T1	PHENOTYPE	5	5	tumor
NCT001701574	NCT00170157_4_T0	CELL	3	3	cells
NCT001701574	NCT00170157_4_T1	PHENOTYPE	2	2	tumor
NCT001701575	NCT00170157_5_T0	CELL	10	10	cells
NCT001701575	NCT00170157_5_T1	PHENOTYPE	9	9	tumor
NCT0017015716	NCT00170157_16_T0	BIOLOGICAL_PROCESS	7	8	immune response
NCT0017015720	NCT00170157_20_T0	CELL	6	6	T-cell
NCT0017015724	NCT00170157_24_T0	COMPOUND	6	6	acetate
NCT0017015724	NCT00170157_24_T1	GENE	12	12	SC
NCT0017015724	NCT00170157_24_T2	COMPOUND	10	10	goserelin
NCT0017015724	NCT00170157_24_T3	GENE	8	8	IM
NCT0017015724	NCT00170157_24_T4	COMPOUND	5	5	leuprolide
NCT0017015724	NCT00170157_24_T5	GENE	0	0	ARM
NCT0017015725	NCT00170157_25_T0	COMPOUND	4	4	flutamide
NCT0017015725	NCT00170157_25_T1	COMPOUND	10	10	bicalutamide
NCT0017015726	NCT00170157_26_T0	PHENOTYPE	31	31	toxicity
NCT0017015726	NCT00170157_26_T1	GENE	9	9	3.4
NCT0017015726	NCT00170157_26_T2	PHENOTYPE	27	28	disease progression
NCT0017015727	NCT00170157_27_T0	PHENOTYPE	13	13	initiation
NCT0017015727	NCT00170157_27_T1	GENE	3	3	IV
NCT001701831	NCT00170183_1_T0	PHENOTYPE	15	15	CHF
NCT001701831	NCT00170183_1_T1	PHENOTYPE	1	1	dysfunction
NCT001701831	NCT00170183_1_T2	PHENOTYPE	12	12	dysfunction
NCT001701833	NCT00170183_3_T0	PHENOTYPE	25	25	symptoms
NCT001701833	NCT00170183_3_T1	PHENOTYPE	13	13	CHF
NCT001701833	NCT00170183_3_T2	COMPOUND	3	3	Natrecor
NCT001701833	NCT00170183_3_T3	GENE	2	2	BNP
NCT001701833	NCT00170183_3_T4	GENE	16	16	has
NCT001701834	NCT00170183_4_T0	PHENOTYPE	16	16	CHF
NCT001701834	NCT00170183_4_T1	PHENOTYPE	25	25	CHF
NCT001701834	NCT00170183_4_T2	GENE	10	10	BNP
NCT001701834	NCT00170183_4_T3	GENE	27	27	has
NCT001701836	NCT00170183_6_T0	GENE	27	27	BNP
NCT001701836	NCT00170183_6_T1	PHENOTYPE	5	6	Heart Failure
NCT001701838	NCT00170183_8_T0	PHENOTYPE	0	0	Secondary
NCT0017018310	NCT00170183_10_T0	PHENOTYPE	32	32	acute
NCT0017018310	NCT00170183_10_T1	PHENOTYPE	11	11	dysfunction
NCT0017018311	NCT00170183_11_T0	PHENOTYPE	14	14	initiation
NCT0017018311	NCT00170183_11_T1	PHENOTYPE	8	9	heart failure
NCT0017018315	NCT00170183_15_T0	PHENOTYPE	0	1	Wt loss
NCT0017018317	NCT00170183_17_T0	COMPOUND	9	9	dopamine
NCT0017018318	NCT00170183_18_T0	PHENOTYPE	11	11	Secondary
NCT0017018320	NCT00170183_20_T0	PHENOTYPE	4	4	CHF
NCT0017018321	NCT00170183_21_T0	GENE	8	8	II
NCT0017018321	NCT00170183_21_T1	GENE	11	11	Cystatin
NCT0017018321	NCT00170183_21_T2	ORGAN	0	0	Plasma
NCT0017018321	NCT00170183_21_T3	GENE	4	4	ANP
NCT0017018321	NCT00170183_21_T4	GENE	5	5	BNP
NCT0017018321	NCT00170183_21_T5	GENE	20	20	BNP
NCT0017018321	NCT00170183_21_T6	GENE	22	22	BNP
NCT0017018321	NCT00170183_21_T7	COMPOUND	3	3	aldosterone
NCT0017018321	NCT00170183_21_T8	GENE	9	9	cGMP
NCT0017018321	NCT00170183_21_T9	MOLECULAR_FUNCTION	1	2	renin activity
NCT0017018323	NCT00170183_23_T0	COMPOUND	3	3	creatinine
NCT0017018328	NCT00170183_28_T0	COMPOUND	1	1	creatinine
NCT0017018330	NCT00170183_30_T0	COMPOUND	13	13	creatinine
NCT0017018330	NCT00170183_30_T1	COMPOUND	46	46	creatinine
NCT0017018332	NCT00170183_32_T0	COMPOUND	5	5	creatinine
NCT0017018333	NCT00170183_33_T0	COMPOUND	6	6	creatinine
NCT0017018333	NCT00170183_33_T1	COMPOUND	7	7	creatinine
NCT0017018333	NCT00170183_33_T2	GENE	29	29	BNP
NCT0017018336	NCT00170183_36_T0	PHENOTYPE	0	0	Secondary
NCT0017018337	NCT00170183_37_T0	GENE	8	8	unpaired
NCT0017018341	NCT00170183_41_T0	GENE	5	5	1.2
NCT0017018341	NCT00170183_41_T1	GENE	0	0	BNP
NCT0017018341	NCT00170183_41_T2	GENE	20	20	BNP
NCT0017018341	NCT00170183_41_T3	GENE	23	23	BNP
NCT0017018343	NCT00170183_43_T0	PHENOTYPE	8	8	initiation
NCT0017018343	NCT00170183_43_T1	GENE	10	10	BNP
NCT0017018343	NCT00170183_43_T2	GENE	11	11	BNP
NCT0017018344	NCT00170183_44_T0	COMPOUND	14	14	sodium
NCT0017018344	NCT00170183_44_T1	COMPOUND	10	10	creatinine
NCT0017018344	NCT00170183_44_T2	COMPOUND	15	15	potassium
NCT0017018344	NCT00170183_44_T3	COMPOUND	12	12	urea
NCT0017018345	NCT00170183_45_T0	GENE	9	9	II
NCT0017018345	NCT00170183_45_T1	COMPOUND	18	18	Natrecor
NCT0017018345	NCT00170183_45_T2	GENE	3	3	ANP
NCT0017018345	NCT00170183_45_T3	GENE	2	2	BNP
NCT0017018345	NCT00170183_45_T4	GENE	10	10	cGMP
NCT0017018345	NCT00170183_45_T5	GENE	4	4	PRA
NCT0017018347	NCT00170183_47_T0	GENE	13	13	BNP
NCT0017018348	NCT00170183_48_T0	PHENOTYPE	25	25	CHF
NCT0017018348	NCT00170183_48_T1	GENE	10	10	CCU
NCT0017018348	NCT00170183_48_T2	GENE	2	2	BNP
NCT0017018352	NCT00170183_52_T0	GENE	5	5	OR
NCT0017018352	NCT00170183_52_T1	PHENOTYPE	11	11	progression
NCT0017018352	NCT00170183_52_T2	PHENOTYPE	9	9	decisions
NCT001702095	NCT00170209_5_T0	GENE	3	3	has
NCT001702099	NCT00170209_9_T0	PHENOTYPE	4	6	latent tuberculosis infection
NCT0017020915	NCT00170209_15_T0	GENE	4	4	has
NCT0017020925	NCT00170209_25_T0	PHENOTYPE	6	7	adverse events
NCT0017020926	NCT00170209_26_T0	GENE	24	24	2.4
NCT0017020926	NCT00170209_26_T1	GENE	3	3	3.4
NCT0017020926	NCT00170209_26_T2	PHENOTYPE	5	6	adverse events
NCT0017020927	NCT00170209_27_T0	PHENOTYPE	2	2	hepatotoxicity
NCT0017020927	NCT00170209_27_T1	GENE	1	1	3.4
NCT0017020932	NCT00170209_32_T0	PHENOTYPE	0	0	Secondary
NCT0017020933	NCT00170209_33_T0	PHENOTYPE	4	4	HIV
NCT0017020933	NCT00170209_33_T1	GENE	24	24	TST
NCT0017020937	NCT00170209_37_T0	PHENOTYPE	2	3	adverse events
NCT0017020938	NCT00170209_38_T0	PHENOTYPE	16	16	severity
NCT0017020942	NCT00170209_42_T0	GENE	8	8	1.5
NCT0017020942	NCT00170209_42_T1	PHENOTYPE	9	10	adverse events
NCT0017020945	NCT00170209_45_T0	GENE	2	2	TST
NCT0017020945	NCT00170209_45_T1	PHENOTYPE	0	1	HIV positive
NCT0017020946	NCT00170209_46_T0	GENE	4	4	TST
NCT001702222	NCT00170222_2_T0	COMPOUND	6	6	doxycycline
NCT001702224	NCT00170222_4_T0	PHENOTYPE	7	7	acute
NCT001702354	NCT00170235_4_T0	PHENOTYPE	8	10	fear and anxiety
NCT001702358	NCT00170235_8_T0	PHENOTYPE	15	15	anxious
NCT001702358	NCT00170235_8_T1	PHENOTYPE	23	23	tumor
NCT0017023513	NCT00170235_13_T0	COMPOUND	9	9	1
NCT0017023513	NCT00170235_13_T1	COMPOUND	17	17	2
NCT0017023513	NCT00170235_13_T2	COMPOUND	23	23	3
NCT0017023513	NCT00170235_13_T3	PHENOTYPE	11	11	recruitment
NCT001702480	NCT00170248_0_T0	PHENOTYPE	5	5	Asthma
NCT001702483	NCT00170248_3_T0	PHENOTYPE	11	11	asthma
NCT001702485	NCT00170248_5_T0	PHENOTYPE	14	14	asthma
NCT001702485	NCT00170248_5_T1	PHENOTYPE	34	34	asthma
NCT001702486	NCT00170248_6_T0	PHENOTYPE	35	35	asthma
NCT0017024811	NCT00170248_11_T0	PHENOTYPE	24	24	severity
NCT0017024811	NCT00170248_11_T1	PHENOTYPE	5	5	asthma
NCT0017024812	NCT00170248_12_T0	PHENOTYPE	12	12	asthma
NCT0017024812	NCT00170248_12_T1	GENE	14	14	had
NCT0017024813	NCT00170248_13_T0	PHENOTYPE	2	2	asthma
NCT0017024813	NCT00170248_13_T1	PHENOTYPE	15	15	asthma
NCT0017024813	NCT00170248_13_T2	PHENOTYPE	21	21	asthma
NCT0017024813	NCT00170248_13_T3	PHENOTYPE	46	46	asthma
NCT0017024813	NCT00170248_13_T4	GENE	4	4	has
NCT0017024815	NCT00170248_15_T0	GENE	2	2	has
NCT0017024815	NCT00170248_15_T1	PHENOTYPE	18	19	chronic disease
NCT0017024823	NCT00170248_23_T0	PHENOTYPE	12	12	asthma
NCT0017024824	NCT00170248_24_T0	PHENOTYPE	1	1	asthma
NCT0017024824	NCT00170248_24_T1	PHENOTYPE	26	26	asthma
NCT0017024825	NCT00170248_25_T0	PHENOTYPE	3	3	asthma
NCT0017024827	NCT00170248_27_T0	PHENOTYPE	0	0	Secondary
NCT0017024828	NCT00170248_28_T0	PHENOTYPE	2	2	secondary
NCT0017024830	NCT00170248_30_T0	PHENOTYPE	13	13	asthma
NCT001702740	NCT00170274_0_T0	PHENOTYPE	12	13	Supraventricular Tachycardias
NCT001702740	NCT00170274_0_T1	PHENOTYPE	6	7	Atrial Arrhythmias
NCT001702872	NCT00170287_2_T0	PHENOTYPE	9	11	quality of life
NCT001703130	NCT00170313_0_T0	PHENOTYPE	9	9	Suffering
NCT001703130	NCT00170313_0_T1	PHENOTYPE	11	12	Heart Failure
NCT001703130	NCT00170313_0_T2	PHENOTYPE	14	15	Atrial Fibrillation
NCT001703132	NCT00170313_2_T0	PHENOTYPE	16	17	atrial fibrillation
NCT001703133	NCT00170313_3_T0	PHENOTYPE	16	16	suffering
NCT001703133	NCT00170313_3_T1	GENE	44	44	ventricular
NCT001703133	NCT00170313_3_T2	ORGAN	45	45	heart
NCT001703133	NCT00170313_3_T3	PHENOTYPE	18	19	atrial fibrillation
NCT001703133	NCT00170313_3_T4	PHENOTYPE	29	30	atrial fibrillation
NCT001703263	NCT00170326_3_T0	PHENOTYPE	30	30	suffering
NCT001703263	NCT00170326_3_T1	ORGAN	23	23	heart
NCT001703263	NCT00170326_3_T2	PHENOTYPE	10	10	LBBB
NCT001703263	NCT00170326_3_T3	PHENOTYPE	31	32	heart failure
NCT001703263	NCT00170326_3_T4	ORGAN	52	53	left ventricle
NCT001703265	NCT00170326_5_T0	PHENOTYPE	4	4	progression
NCT001703265	NCT00170326_5_T1	PHENOTYPE	12	13	ventricular dysfunction
NCT001703266	NCT00170326_6_T0	PHENOTYPE	4	4	progression
NCT001703267	NCT00170326_7_T0	GENE	0	0	ACE
NCT001703268	NCT00170326_8_T0	PHENOTYPE	19	19	progression
NCT001703397	NCT00170339_7_T0	PHENOTYPE	25	25	osteoporosis
NCT001703397	NCT00170339_7_T1	PHENOTYPE	18	18	hypogonadism
NCT001703397	NCT00170339_7_T2	GENE	7	7	has
NCT001703397	NCT00170339_7_T3	PHENOTYPE	3	3	chronic
NCT001703397	NCT00170339_7_T4	COMPOUND	33	33	methadone
NCT001703397	NCT00170339_7_T5	PHENOTYPE	27	28	sexual dysfunction
NCT001703398	NCT00170339_8_T0	COMPOUND	21	21	estrogen
NCT001703398	NCT00170339_8_T1	COMPOUND	1	1	testosterone
NCT001703398	NCT00170339_8_T2	PHENOTYPE	10	10	osteoporosis
NCT001703399	NCT00170339_9_T0	COMPOUND	15	15	methadone
NCT001703399	NCT00170339_9_T1	PHENOTYPE	24	25	sexual dysfunction
NCT0017033911	NCT00170339_11_T0	ORGAN	11	11	spine
NCT0017033912	NCT00170339_12_T0	COMPOUND	18	18	calcium
NCT0017033913	NCT00170339_13_T0	COMPOUND	16	16	testosterone
NCT0017033913	NCT00170339_13_T1	COMPOUND	6	6	methadone
NCT0017033913	NCT00170339_13_T2	COMPOUND	17	17	estradiol
NCT0017033913	NCT00170339_13_T3	PHENOTYPE	19	20	sexual dysfunction
NCT001703527	NCT00170352_7_T0	COMPOUND	13	13	oxygen
NCT001703654	NCT00170365_4_T0	PHENOTYPE	13	13	perceived
NCT001703655	NCT00170365_5_T0	PHENOTYPE	6	6	HFA
NCT001703655	NCT00170365_5_T1	PHENOTYPE	7	7	Addiction
NCT001703657	NCT00170365_7_T0	PHENOTYPE	3	3	Addiction
NCT001703658	NCT00170365_8_T0	PHENOTYPE	9	9	perceived
NCT001703658	NCT00170365_8_T1	GENE	17	17	fo
NCT001703783	NCT00170378_3_T0	PHENOTYPE	11	11	secondary
NCT001703783	NCT00170378_3_T1	PHENOTYPE	16	17	intracranial hemorrhage
NCT001703783	NCT00170378_3_T2	PHENOTYPE	2	4	traumatic brain injury
NCT001703910	NCT00170391_0_T0	PHENOTYPE	3	3	Insomnia
NCT001704043	NCT00170404_3_T0	PHENOTYPE	9	10	HIV infection
NCT001704048	NCT00170404_8_T0	PHENOTYPE	11	11	HIV
NCT001704048	NCT00170404_8_T1	PHENOTYPE	9	9	co-infection
NCT0017040411	NCT00170404_11_T0	PHENOTYPE	16	16	recruitment
NCT0017040412	NCT00170404_12_T0	BIOLOGICAL_PROCESS	7	8	immune response
NCT0017040413	NCT00170404_13_T0	BIOLOGICAL_PROCESS	9	10	immune response
NCT0017040414	NCT00170404_14_T0	GENE	23	23	es
NCT0017040420	NCT00170404_20_T0	PHENOTYPE	7	7	tuberculosis
NCT0017040427	NCT00170404_27_T0	GENE	1	1	had
NCT0017040428	NCT00170404_28_T0	COMPOUND	21	21	folate
NCT001704302	NCT00170430_2_T0	PHENOTYPE	16	16	STDs
NCT001704302	NCT00170430_2_T1	PHENOTYPE	0	1	Vaginal infections
NCT001704302	NCT00170430_2_T2	PHENOTYPE	13	15	sexually transmitted diseases
NCT001704304	NCT00170430_4_T0	PHENOTYPE	19	19	STDs
NCT001704305	NCT00170430_5_T0	COMPOUND	14	14	fluconazole
NCT001704305	NCT00170430_5_T1	COMPOUND	12	12	metronidazole
NCT001704305	NCT00170430_5_T2	PHENOTYPE	10	11	vaginal infections
NCT001704308	NCT00170430_8_T0	PHENOTYPE	9	9	strategies
NCT001704308	NCT00170430_8_T1	PHENOTYPE	15	16	vaginal infections
NCT001704309	NCT00170430_9_T0	PHENOTYPE	23	23	strategies
NCT0017043010	NCT00170430_10_T0	PHENOTYPE	14	15	vaginal infections
NCT0017043013	NCT00170430_13_T0	COMPOUND	11	11	fluconazole
NCT0017043013	NCT00170430_13_T1	COMPOUND	7	7	metronidazole
NCT0017043015	NCT00170430_15_T0	PHENOTYPE	17	17	infections
NCT0017043015	NCT00170430_15_T1	ORGAN	15	15	genital
NCT0017043015	NCT00170430_15_T2	PHENOTYPE	12	13	vaginal infections
NCT001704431	NCT00170443_1_T0	PHENOTYPE	7	8	antibody responses
NCT001704436	NCT00170443_6_T0	GENE	14	14	has
NCT001704438	NCT00170443_8_T0	PHENOTYPE	17	18	antibody responses
NCT001704561	NCT00170456_1_T0	BIOLOGICAL_PROCESS	7	8	immune response
NCT001704563	NCT00170456_3_T0	CELL	26	26	spores
NCT001704563	NCT00170456_3_T1	PHENOTYPE	0	0	Anthrax
NCT001704564	NCT00170456_4_T0	GENE	9	9	has
NCT001704564	NCT00170456_4_T1	PHENOTYPE	8	8	anthrax
NCT001704565	NCT00170456_5_T0	PHENOTYPE	20	20	infections
NCT001704565	NCT00170456_5_T1	PHENOTYPE	18	19	cutaneous anthrax
NCT001704568	NCT00170456_8_T0	COMPOUND	8	8	1
NCT001704568	NCT00170456_8_T1	COMPOUND	38	38	2
NCT0017045614	NCT00170456_14_T0	COMPOUND	4	4	BMI
NCT0017045620	NCT00170456_20_T0	GENE	88	88	had
NCT0017045620	NCT00170456_20_T1	GENE	102	102	hormone
NCT0017045620	NCT00170456_20_T2	PHENOTYPE	106	106	IUD
NCT0017045620	NCT00170456_20_T3	COMPOUND	100	100	copper
NCT0017045620	NCT00170456_20_T4	GENE	83	83	has
NCT0017045620	NCT00170456_20_T5	GENE	87	87	has
NCT0017045620	NCT00170456_20_T6	GENE	75	75	OR
NCT0017045620	NCT00170456_20_T7	GENE	79	79	OR
NCT0017045620	NCT00170456_20_T8	GENE	94	94	OR
NCT0017045620	NCT00170456_20_T9	COMPOUND	91	91	1
NCT0017045622	NCT00170456_22_T0	GENE	23	23	45
NCT0017045622	NCT00170456_22_T1	PHENOTYPE	5	5	menopausal
NCT0017045622	NCT00170456_22_T2	PHENOTYPE	21	21	menopausal
NCT0017045622	NCT00170456_22_T3	BIOLOGICAL_PROCESS	12	13	menstrual cycle
NCT0017045623	NCT00170456_23_T0	GENE	17	17	45
NCT0017045623	NCT00170456_23_T1	PHENOTYPE	15	15	menopausal
NCT0017045623	NCT00170456_23_T2	GENE	20	20	has
NCT0017045623	NCT00170456_23_T3	BIOLOGICAL_PROCESS	5	6	menstrual cycle
NCT0017045624	NCT00170456_24_T0	GENE	3	3	has
NCT0017045625	NCT00170456_25_T0	GENE	4	4	had
NCT0017045625	NCT00170456_25_T1	GENE	3	3	has
NCT0017045635	NCT00170456_35_T0	PHENOTYPE	4	5	drug abuse
NCT0017045639	NCT00170456_39_T0	GENE	20	20	OTC
NCT0017045639	NCT00170456_39_T1	GENE	27	27	OTC
NCT0017045642	NCT00170456_42_T0	PHENOTYPE	2	2	suspicion
NCT0017045646	NCT00170456_46_T0	PHENOTYPE	0	0	Immunodeficiency
NCT0017045646	NCT00170456_46_T1	PHENOTYPE	4	5	autoimmune disease
NCT0017045648	NCT00170456_48_T0	COMPOUND	12	12	cocaine
NCT0017045648	NCT00170456_48_T1	COMPOUND	11	11	methadone
NCT0017045648	NCT00170456_48_T2	PHENOTYPE	7	9	drugs of abuse
NCT0017045651	NCT00170456_51_T0	ORGAN	2	2	plasma
NCT0017045651	NCT00170456_51_T1	ORGAN	17	17	plasma
NCT0017045652	NCT00170456_52_T0	GENE	6	6	globulin
NCT0017045652	NCT00170456_52_T1	PHENOTYPE	1	1	anthrax
NCT0017045652	NCT00170456_52_T2	PHENOTYPE	4	4	anthrax
NCT0017045656	NCT00170456_56_T0	PHENOTYPE	8	8	pathology
NCT001704691	NCT00170469_1_T0	BIOLOGICAL_PROCESS	7	8	immune response
NCT001704693	NCT00170469_3_T0	CELL	26	26	spores
NCT001704693	NCT00170469_3_T1	PHENOTYPE	0	0	Anthrax
NCT001704695	NCT00170469_5_T0	GENE	13	13	has
NCT001704695	NCT00170469_5_T1	PHENOTYPE	12	12	anthrax
NCT001704696	NCT00170469_6_T0	PHENOTYPE	18	19	cutaneous anthrax
NCT001704699	NCT00170469_9_T0	PHENOTYPE	25	25	anthrax
NCT0017046910	NCT00170469_10_T0	PHENOTYPE	13	13	Anthrax
NCT0017046910	NCT00170469_10_T1	PHENOTYPE	20	20	Anthrax
NCT0017046911	NCT00170469_11_T0	PHENOTYPE	21	21	Anthrax
NCT0017046911	NCT00170469_11_T1	BIOLOGICAL_PROCESS	7	8	immune response
NCT0017046913	NCT00170469_13_T0	PHENOTYPE	12	12	symptoms
NCT0017046914	NCT00170469_14_T0	PHENOTYPE	4	4	AVA
NCT0017046914	NCT00170469_14_T1	PHENOTYPE	20	20	AVA
NCT0017046920	NCT00170469_20_T0	COMPOUND	4	4	BMI
NCT0017046922	NCT00170469_22_T0	PHENOTYPE	15	15	AVA
NCT0017046926	NCT00170469_26_T0	GENE	88	88	had
NCT0017046926	NCT00170469_26_T1	GENE	102	102	hormone
NCT0017046926	NCT00170469_26_T2	PHENOTYPE	106	106	IUD
NCT0017046926	NCT00170469_26_T3	COMPOUND	100	100	copper
NCT0017046926	NCT00170469_26_T4	GENE	83	83	has
NCT0017046926	NCT00170469_26_T5	GENE	87	87	has
NCT0017046926	NCT00170469_26_T6	GENE	75	75	OR
NCT0017046926	NCT00170469_26_T7	GENE	79	79	OR
NCT0017046926	NCT00170469_26_T8	GENE	94	94	OR
NCT0017046926	NCT00170469_26_T9	COMPOUND	91	91	1
NCT0017046928	NCT00170469_28_T0	GENE	23	23	45
NCT0017046928	NCT00170469_28_T1	GENE	42	42	45
NCT0017046928	NCT00170469_28_T2	PHENOTYPE	5	5	menopausal
NCT0017046928	NCT00170469_28_T3	PHENOTYPE	21	21	menopausal
NCT0017046928	NCT00170469_28_T4	PHENOTYPE	40	40	menopausal
NCT0017046928	NCT00170469_28_T5	GENE	45	45	has
NCT0017046928	NCT00170469_28_T6	BIOLOGICAL_PROCESS	12	13	menstrual cycle
NCT0017046928	NCT00170469_28_T7	BIOLOGICAL_PROCESS	30	31	menstrual cycle
NCT0017046929	NCT00170469_29_T0	GENE	3	3	has
NCT0017046930	NCT00170469_30_T0	GENE	4	4	had
NCT0017046930	NCT00170469_30_T1	GENE	3	3	has
NCT0017046938	NCT00170469_38_T0	PHENOTYPE	4	5	drug abuse
NCT0017046942	NCT00170469_42_T0	GENE	20	20	OTC
NCT0017046942	NCT00170469_42_T1	GENE	27	27	OTC
NCT0017046945	NCT00170469_45_T0	PHENOTYPE	2	2	suspicion
NCT0017046949	NCT00170469_49_T0	PHENOTYPE	0	0	Immunodeficiency
NCT0017046949	NCT00170469_49_T1	PHENOTYPE	4	5	autoimmune disease
NCT0017046951	NCT00170469_51_T0	COMPOUND	12	12	cocaine
NCT0017046951	NCT00170469_51_T1	COMPOUND	11	11	methadone
NCT0017046951	NCT00170469_51_T2	PHENOTYPE	7	9	drugs of abuse
NCT0017046954	NCT00170469_54_T0	ORGAN	2	2	plasma
NCT0017046954	NCT00170469_54_T1	ORGAN	17	17	plasma
NCT0017046955	NCT00170469_55_T0	GENE	6	6	globulin
NCT0017046955	NCT00170469_55_T1	PHENOTYPE	1	1	anthrax
NCT0017046955	NCT00170469_55_T2	PHENOTYPE	4	4	anthrax
NCT0017046959	NCT00170469_59_T0	PHENOTYPE	8	8	pathology
NCT001704823	NCT00170482_3_T0	BIOLOGICAL_PROCESS	5	6	immune response
NCT001704823	NCT00170482_3_T1	BIOLOGICAL_PROCESS	21	22	immune response
NCT001704829	NCT00170482_9_T0	PHENOTYPE	11	11	influenza
NCT001704829	NCT00170482_9_T1	ORGAN	0	0	Serum
NCT001704829	NCT00170482_9_T2	PHENOTYPE	9	9	immunity
NCT001704829	NCT00170482_9_T3	GENE	19	19	has
NCT001704829	NCT00170482_9_T4	ORGAN	25	25	serum
NCT001704829	NCT00170482_9_T5	PHENOTYPE	1	2	antibody titer
NCT001704829	NCT00170482_9_T6	PHENOTYPE	26	27	antibody response
NCT0017048210	NCT00170482_10_T0	PHENOTYPE	18	18	influenza
NCT0017048210	NCT00170482_10_T1	ORGAN	10	11	immune system
NCT0017048211	NCT00170482_11_T0	COMPOUND	5	5	DMID
NCT0017048212	NCT00170482_12_T0	COMPOUND	9	9	DMID
NCT0017048213	NCT00170482_13_T0	PHENOTYPE	43	43	influenza
NCT0017048220	NCT00170482_20_T0	PHENOTYPE	10	10	influenza
NCT0017048220	NCT00170482_20_T1	PHENOTYPE	44	44	influenza
NCT0017048220	NCT00170482_20_T2	GENE	26	26	IFN-gamma
NCT0017048220	NCT00170482_20_T3	GENE	3	3	ex
NCT0017048220	NCT00170482_20_T4	CELL	11	12	T cells
NCT0017048220	NCT00170482_20_T5	BIOLOGICAL_PROCESS	41	42	immune response
NCT0017048221	NCT00170482_21_T0	GENE	9	9	TNF-alpha
NCT0017048221	NCT00170482_21_T1	CELL	19	19	cells
NCT0017048221	NCT00170482_21_T2	GENE	8	8	IL-12
NCT0017048224	NCT00170482_24_T0	COMPOUND	10	10	DMID
NCT0017048224	NCT00170482_24_T1	PHENOTYPE	42	42	Influenza
NCT0017048224	NCT00170482_24_T2	PHENOTYPE	30	30	Strain
NCT0017048224	NCT00170482_24_T3	PHENOTYPE	37	37	Strain
NCT0017048224	NCT00170482_24_T4	PHENOTYPE	8	9	Infectious Diseases
NCT0017048229	NCT00170482_29_T0	PHENOTYPE	2	2	acute
NCT0017048229	NCT00170482_29_T1	PHENOTYPE	4	4	illnesses
NCT0017048229	NCT00170482_29_T2	PHENOTYPE	3	3	febrile
NCT0017048231	NCT00170482_31_T0	GENE	10	10	eg
NCT0017048231	NCT00170482_31_T1	COMPOUND	11	11	thimerosal
NCT0017048231	NCT00170482_31_T2	PHENOTYPE	1	3	allergy to eggs
NCT0017048234	NCT00170482_34_T0	PHENOTYPE	0	0	Immunosuppression
NCT001704954	NCT00170495_4_T0	PHENOTYPE	8	8	acute
NCT001704958	NCT00170495_8_T0	PHENOTYPE	8	8	severity
NCT001704958	NCT00170495_8_T1	PHENOTYPE	3	3	illnesses
NCT0017049511	NCT00170495_11_T0	PHENOTYPE	7	7	acute
NCT0017049515	NCT00170495_15_T0	PHENOTYPE	11	12	acute infection
NCT001705085	NCT00170508_5_T0	PHENOTYPE	38	38	influenza
NCT001705085	NCT00170508_5_T1	GENE	10	10	ex
NCT001705085	NCT00170508_5_T2	CELL	18	18	cells
NCT001705085	NCT00170508_5_T3	ORGAN	0	0	Serum
NCT001705085	NCT00170508_5_T4	CELL	32	33	T cells
NCT001705087	NCT00170508_7_T0	GENE	3	3	masking
NCT001705089	NCT00170508_9_T0	ORGAN	32	32	serum
NCT001705089	NCT00170508_9_T1	GENE	11	11	ml
NCT0017050811	NCT00170508_11_T0	COMPOUND	5	5	DMID
NCT0017050823	NCT00170508_23_T0	PHENOTYPE	3	5	allergy to eggs
NCT0017050825	NCT00170508_25_T0	GENE	17	17	has
NCT0017050827	NCT00170508_27_T0	PHENOTYPE	2	2	immunosuppression
NCT0017050827	NCT00170508_27_T1	GENE	0	0	Is
NCT0017050829	NCT00170508_29_T0	PHENOTYPE	3	4	neoplastic disease
NCT0017050829	NCT00170508_29_T1	PHENOTYPE	10	11	hematologic malignancy
NCT0017050831	NCT00170508_31_T0	GENE	0	0	Is
NCT0017050831	NCT00170508_31_T1	COMPOUND	12	13	beclomethasone dipropionate
NCT0017050839	NCT00170508_39_T0	PHENOTYPE	10	10	influenza
NCT0017050840	NCT00170508_40_T0	PHENOTYPE	2	3	acute illness
NCT001705212	NCT00170521_2_T0	PHENOTYPE	8	8	infections
NCT001705216	NCT00170521_6_T0	PHENOTYPE	10	11	cardiovascular morbidity
NCT001705216	NCT00170521_6_T1	PHENOTYPE	5	7	rheumatic heart disease
NCT001705218	NCT00170521_8_T0	PHENOTYPE	5	5	attributable
NCT001705218	NCT00170521_8_T1	GENE	27	27	has
NCT001705218	NCT00170521_8_T2	PHENOTYPE	7	9	rheumatic heart disease
NCT001705219	NCT00170521_9_T0	PHENOTYPE	25	25	sequelae
NCT001705219	NCT00170521_9_T1	PHENOTYPE	17	17	diseases
NCT001705219	NCT00170521_9_T2	PHENOTYPE	31	31	glomerulonephritis
NCT001705219	NCT00170521_9_T3	PHENOTYPE	28	29	rheumatic fever
NCT0017052112	NCT00170521_12_T0	PHENOTYPE	10	10	fever
NCT0017052112	NCT00170521_12_T1	PHENOTYPE	12	13	cervical lymphadenopathy
NCT0017052112	NCT00170521_12_T2	PHENOTYPE	8	9	sore throat
NCT0017052113	NCT00170521_13_T0	COMPOUND	22	22	erythromycin
NCT0017052113	NCT00170521_13_T1	COMPOUND	9	10	benzathine penicillin
NCT0017052113	NCT00170521_13_T2	PHENOTYPE	18	20	allergy to penicillin
NCT0017052115	NCT00170521_15_T0	PHENOTYPE	3	4	sore throat
NCT0017052117	NCT00170521_17_T0	PHENOTYPE	15	17	signs and symptoms
NCT0017052118	NCT00170521_18_T0	PHENOTYPE	12	12	complications
NCT0017052118	NCT00170521_18_T1	PHENOTYPE	11	11	suppurative
NCT0017052118	NCT00170521_18_T2	PHENOTYPE	7	9	acute rheumatic fever
NCT0017052119	NCT00170521_19_T0	GENE	13	13	emm
NCT0017052121	NCT00170521_21_T0	PHENOTYPE	16	16	pharyngitis
NCT0017052122	NCT00170521_22_T0	PHENOTYPE	13	13	pharyngitis
NCT0017052122	NCT00170521_22_T1	PHENOTYPE	0	0	Secondary
NCT0017052124	NCT00170521_24_T0	PHENOTYPE	10	10	pharyngitis
NCT0017052126	NCT00170521_26_T0	PHENOTYPE	7	7	pharyngitis
NCT0017052126	NCT00170521_26_T1	COMPOUND	2	2	3
NCT001705340	NCT00170534_0_T0	PHENOTYPE	3	3	STDs
NCT0017053413	NCT00170534_13_T0	PHENOTYPE	32	32	HIV
NCT001705474	NCT00170547_4_T0	PHENOTYPE	11	11	influenza
NCT0017054710	NCT00170547_10_T0	PHENOTYPE	3	3	menopausal
NCT0017054710	NCT00170547_10_T1	PHENOTYPE	11	11	sterile
NCT0017054711	NCT00170547_11_T0	PHENOTYPE	28	30	negative pregnancy test
NCT0017054719	NCT00170547_19_T0	PHENOTYPE	0	1	Chronic illness
NCT0017054723	NCT00170547_23_T0	PHENOTYPE	2	2	HIV
NCT0017054723	NCT00170547_23_T1	PHENOTYPE	3	4	hepatitis B
NCT0017054723	NCT00170547_23_T2	PHENOTYPE	7	8	hepatitis C
NCT0017054724	NCT00170547_24_T0	PHENOTYPE	3	3	influenza
NCT0017054725	NCT00170547_25_T0	PHENOTYPE	0	0	Allergy
NCT0017054725	NCT00170547_25_T1	PHENOTYPE	17	17	allergy
NCT0017054726	NCT00170547_26_T0	COMPOUND	3	3	heparin
NCT0017054726	NCT00170547_26_T1	PHENOTYPE	8	8	thrombocytopenia
NCT0017054726	NCT00170547_26_T2	GENE	6	6	has
NCT0017054726	NCT00170547_26_T3	PHENOTYPE	10	11	bleeding disorder
NCT0017054728	NCT00170547_28_T0	PHENOTYPE	0	1	Febrile illness
NCT0017054730	NCT00170547_30_T0	PHENOTYPE	2	5	alcohol or drug abuse
NCT0017056012	NCT00170560_12_T0	GENE	7	7	ml
NCT0017056014	NCT00170560_14_T0	PHENOTYPE	12	12	recruitment
NCT0017056015	NCT00170560_15_T0	PHENOTYPE	6	6	severity
NCT0017056015	NCT00170560_15_T1	GENE	12	12	hormone
NCT0017056019	NCT00170560_19_T0	GENE	3	3	II
NCT0017056019	NCT00170560_19_T1	PHENOTYPE	27	27	infections
NCT0017056019	NCT00170560_19_T2	PHENOTYPE	38	38	decisions
NCT001705731	NCT00170573_1_T0	PHENOTYPE	9	9	toxicity
NCT001705731	NCT00170573_1_T1	PHENOTYPE	16	18	quality of life
NCT001705732	NCT00170573_2_T0	PHENOTYPE	10	10	toxicity
NCT001705732	NCT00170573_2_T1	GENE	18	18	PLD
NCT001705733	NCT00170573_3_T0	PHENOTYPE	0	0	Secondary
NCT001705861	NCT00170586_1_T0	PHENOTYPE	9	9	HIV
NCT001705861	NCT00170586_1_T1	PHENOTYPE	3	4	hepatitis B
NCT001705862	NCT00170586_2_T0	PHENOTYPE	16	16	catching
NCT001705862	NCT00170586_2_T1	PHENOTYPE	22	22	catching
NCT001705863	NCT00170586_3_T0	COMPOUND	9	10	polyvinylidene fluoride
NCT001705866	NCT00170586_6_T0	ORGAN	8	8	hands
NCT001705866	NCT00170586_6_T1	PHENOTYPE	16	16	tearing
NCT001705866	NCT00170586_6_T2	PHENOTYPE	15	15	wrinkling
NCT0017058613	NCT00170586_13_T0	PHENOTYPE	9	10	pathogen transmission
NCT0017058614	NCT00170586_14_T0	BIOLOGICAL_PROCESS	40	40	sensitization
NCT0017058614	NCT00170586_14_T1	GENE	26	26	has
NCT0017058614	NCT00170586_14_T2	PHENOTYPE	35	36	contact dermatitis
NCT0017058614	NCT00170586_14_T3	PHENOTYPE	9	10	pathogen transmission
NCT0017058617	NCT00170586_17_T0	PHENOTYPE	14	14	resistant
NCT0017058619	NCT00170586_19_T0	PHENOTYPE	4	4	focused
NCT0017058619	NCT00170586_19_T1	BIOLOGICAL_PROCESS	18	19	viral penetration
NCT0017058622	NCT00170586_22_T0	PHENOTYPE	26	26	Practices
NCT0017058622	NCT00170586_22_T1	PHENOTYPE	41	41	physiology
NCT0017058622	NCT00170586_22_T2	GENE	27	27	GMP
NCT0017058623	NCT00170586_23_T0	ORGAN	33	33	hands
NCT0017058623	NCT00170586_23_T1	PHENOTYPE	30	31	skin conditions
NCT0017058628	NCT00170586_28_T0	COMPOUND	5	5	2
NCT0017058628	NCT00170586_28_T1	COMPOUND	13	13	3
NCT0017058632	NCT00170586_32_T0	GENE	3	3	2a
NCT0017058633	NCT00170586_33_T0	COMPOUND	0	0	1
NCT0017058633	NCT00170586_33_T1	COMPOUND	12	12	2
NCT0017058633	NCT00170586_33_T2	PHENOTYPE	7	7	chronic
NCT0017058633	NCT00170586_33_T3	PHENOTYPE	9	11	infectious skin disease
NCT001706122	NCT00170612_2_T0	PHENOTYPE	5	5	pneumonia
NCT001706122	NCT00170612_2_T1	PHENOTYPE	8	8	pneumoniae
NCT001706126	NCT00170612_6_T0	PHENOTYPE	25	25	Centers
NCT001706126	NCT00170612_6_T1	PHENOTYPE	14	14	tetanus
NCT001706126	NCT00170612_6_T2	PHENOTYPE	16	16	pertussis
NCT0017061220	NCT00170612_20_T0	GENE	15	15	PCV
NCT0017061220	NCT00170612_20_T1	GENE	28	28	PCV
NCT0017061220	NCT00170612_20_T2	GENE	8	8	has
NCT0017061223	NCT00170612_23_T0	PHENOTYPE	16	16	maturation
NCT0017061223	NCT00170612_23_T1	GENE	27	27	PCV
NCT0017061223	NCT00170612_23_T2	PHENOTYPE	10	10	persistence
NCT0017061227	NCT00170612_27_T0	GENE	12	12	has
NCT0017061234	NCT00170612_34_T0	PHENOTYPE	1	1	allergy
NCT0017061235	NCT00170612_35_T0	PHENOTYPE	0	1	Allergic reaction
NCT0017061235	NCT00170612_35_T1	PHENOTYPE	3	4	anaphylactoid reaction
NCT0017061237	NCT00170612_37_T0	PHENOTYPE	8	8	HIV
NCT0017061237	NCT00170612_37_T1	PHENOTYPE	0	1	HIV positive
NCT0017061241	NCT00170612_41_T0	PHENOTYPE	1	2	congenital anomaly
NCT0017061242	NCT00170612_42_T0	PHENOTYPE	0	0	Chronic
NCT0017061242	NCT00170612_42_T1	PHENOTYPE	2	2	progressive
NCT0017061243	NCT00170612_43_T0	PHENOTYPE	0	0	Seizure
NCT0017061244	NCT00170612_44_T0	PHENOTYPE	7	7	influenzae
NCT001706381	NCT00170638_1_T0	PHENOTYPE	3	3	tuberculosis
NCT001706382	NCT00170638_2_T0	CELL	5	6	blood cells
NCT001706382	NCT00170638_2_T1	CELL	14	15	blood cells
NCT001706384	NCT00170638_4_T0	CELL	16	17	blood cells
NCT001706387	NCT00170638_7_T0	PHENOTYPE	27	27	tuberculosis
NCT001706387	NCT00170638_7_T1	PHENOTYPE	51	51	meningitis
NCT001706387	NCT00170638_7_T2	GENE	28	28	Mtb
NCT001706387	NCT00170638_7_T3	PHENOTYPE	48	49	joint disease
NCT001706388	NCT00170638_8_T0	ORGAN	9	10	immune system
NCT001706774	NCT00170677_4_T0	PHENOTYPE	7	7	toxicities
NCT001706775	NCT00170677_5_T0	GENE	14	14	1.5
NCT001706775	NCT00170677_5_T1	COMPOUND	7	7	topotecan
NCT001706776	NCT00170677_6_T0	PHENOTYPE	18	18	toxicity
NCT001706776	NCT00170677_6_T1	PHENOTYPE	22	22	progression
NCT001706776	NCT00170677_6_T2	PHENOTYPE	15	15	remissions
NCT001706776	NCT00170677_6_T3	PHENOTYPE	19	21	quality of life
NCT001706901	NCT00170690_1_T0	PHENOTYPE	11	12	malignant tumours
NCT001706901	NCT00170690_1_T1	PHENOTYPE	0	1	Ovarian cancer
NCT001706902	NCT00170690_2_T0	PHENOTYPE	3	3	carcinoma
NCT001706902	NCT00170690_2_T1	PHENOTYPE	18	19	ovarian cancer
NCT001706903	NCT00170690_3_T0	PHENOTYPE	12	12	relapse
NCT001706906	NCT00170690_6_T0	PHENOTYPE	23	23	toxicity
NCT001706906	NCT00170690_6_T1	PHENOTYPE	28	28	toxicity
NCT001706906	NCT00170690_6_T2	COMPOUND	32	32	NCI
NCT001706906	NCT00170690_6_T3	GENE	30	30	3.4
NCT001706906	NCT00170690_6_T4	PHENOTYPE	35	35	progression
NCT001706906	NCT00170690_6_T5	COMPOUND	11	11	treosulfan
NCT001706906	NCT00170690_6_T6	PHENOTYPE	38	40	quality of life
NCT001707030	NCT00170703_0_T0	PHENOTYPE	14	14	Aphasia
NCT001707030	NCT00170703_0_T1	PHENOTYPE	11	12	Broca's Aphasia
NCT001707033	NCT00170703_3_T0	PHENOTYPE	21	21	strokes
NCT001707033	NCT00170703_3_T1	PHENOTYPE	5	5	Association
NCT001707033	NCT00170703_3_T2	GENE	15	15	4-8
NCT001707034	NCT00170703_4_T0	GENE	10	10	disabled
NCT001707034	NCT00170703_4_T1	PHENOTYPE	7	7	severely
NCT001707035	NCT00170703_5_T0	PHENOTYPE	18	18	aphasia
NCT001707036	NCT00170703_6_T0	PHENOTYPE	1	1	aphasia
NCT001707036	NCT00170703_6_T1	GENE	15	15	has
NCT001707036	NCT00170703_6_T2	PHENOTYPE	9	10	motor aphasia
NCT001707037	NCT00170703_7_T0	GENE	11	11	has
NCT001707037	NCT00170703_7_T1	PHENOTYPE	1	3	loss of speech
NCT001707037	NCT00170703_7_T2	PHENOTYPE	19	21	quality of life
NCT001707038	NCT00170703_8_T0	PHENOTYPE	9	9	aphasia
NCT0017070310	NCT00170703_10_T0	PHENOTYPE	2	2	aphasia
NCT0017070310	NCT00170703_10_T1	PHENOTYPE	39	39	aphasia
NCT0017070310	NCT00170703_10_T2	PHENOTYPE	8	8	impairment
NCT0017070310	NCT00170703_10_T3	PHENOTYPE	11	12	motor function
NCT0017070310	NCT00170703_10_T4	PHENOTYPE	35	36	motor function
NCT0017070311	NCT00170703_11_T0	PHENOTYPE	19	19	aphasia
NCT001707160	NCT00170716_0_T0	PHENOTYPE	15	15	Hemiparesis
NCT001707160	NCT00170716_0_T1	ORGAN	13	14	Upper Extremity
NCT001707165	NCT00170716_5_T0	PHENOTYPE	21	21	strokes
NCT001707165	NCT00170716_5_T1	PHENOTYPE	5	5	Association
NCT001707165	NCT00170716_5_T2	GENE	15	15	4-8
NCT001707167	NCT00170716_7_T0	GENE	19	19	disabled
NCT001707168	NCT00170716_8_T0	PHENOTYPE	20	20	weakness
NCT001707168	NCT00170716_8_T1	PHENOTYPE	23	23	hemiparesis
NCT001707297	NCT00170729_7_T0	COMPOUND	2	2	aspirin
NCT001707420	NCT00170742_0_T0	PHENOTYPE	15	17	Proliferative Diabetic Retinopathy
NCT0017074215	NCT00170742_15_T0	COMPOUND	22	22	glucose
NCT0017074215	NCT00170742_15_T1	GENE	17	17	insulin
NCT0017074215	NCT00170742_15_T2	PHENOTYPE	9	11	blood glucose levels
NCT0017074228	NCT00170742_28_T0	PHENOTYPE	16	16	cholelithiasis
NCT0017074228	NCT00170742_28_T1	PHENOTYPE	6	6	gallstones
NCT0017074228	NCT00170742_28_T2	GENE	10	10	had
NCT0017074232	NCT00170742_32_T0	PHENOTYPE	6	6	hypoglycemia
NCT0017074232	NCT00170742_32_T1	PHENOTYPE	7	7	unawareness
NCT0017074238	NCT00170742_38_T0	GENE	11	11	somatostatin
NCT001707940	NCT00170794_0_T0	ORGAN	11	11	Transplant
NCT001707948	NCT00170794_8_T0	GENE	13	13	retained
NCT001708200	NCT00170820_0_T0	ORGAN	14	14	Transplant
NCT001708333	NCT00170833_3_T0	COMPOUND	11	11	everolimus
NCT001708333	NCT00170833_3_T1	PHENOTYPE	0	1	Laboratory results
NCT001709240	NCT00170924_0_T0	ORGAN	18	18	Heart
NCT001709240	NCT00170924_0_T1	TISSUE	28	29	Heart Muscle
NCT001709240	NCT00170924_0_T2	PHENOTYPE	36	38	High Blood Pressure
NCT001709242	NCT00170924_2_T0	GENE	6	6	has
NCT001709242	NCT00170924_2_T1	ORGAN	5	5	heart
NCT001709242	NCT00170924_2_T2	PHENOTYPE	0	1	Diastolic Dysfunction
NCT001709243	NCT00170924_3_T0	ORGAN	14	14	heart
NCT001709243	NCT00170924_3_T1	PHENOTYPE	30	32	high blood pressure
NCT001709500	NCT00170950_0_T0	PHENOTYPE	10	11	Systolic Hypertension
NCT001709760	NCT00170976_0_T0	PHENOTYPE	22	22	Hypertension
NCT001710412	NCT00171041_2_T0	GENE	18	18	6-16
NCT001710412	NCT00171041_2_T1	COMPOUND	9	9	valsartan
NCT001710412	NCT00171041_2_T2	PHENOTYPE	12	14	high blood pressure
NCT001710540	NCT00171054_0_T0	PHENOTYPE	11	11	Hypertension
NCT001710542	NCT00171054_2_T0	PHENOTYPE	8	8	stiffness
NCT001710542	NCT00171054_2_T1	ORGAN	11	12	blood vessels
NCT001710544	NCT00171054_4_T0	COMPOUND	9	9	valsartan
NCT001710800	NCT00171080_0_T0	PHENOTYPE	19	19	Mild
NCT001710800	NCT00171080_0_T1	PHENOTYPE	22	22	Hypertension
NCT001710931	NCT00171093_1_T0	COMPOUND	15	15	simvastatin
NCT001710931	NCT00171093_1_T1	PHENOTYPE	6	6	hypertension
NCT001710931	NCT00171093_1_T2	PHENOTYPE	8	8	hypercholesterolemia
NCT001711190	NCT00171119_0_T0	PHENOTYPE	13	13	Albuminuria
NCT001711190	NCT00171119_0_T1	PHENOTYPE	5	8	Diabetes Mellitus Type II
NCT001711450	NCT00171145_0_T0	ORGAN	20	20	Bladder
NCT001711450	NCT00171145_0_T1	PHENOTYPE	17	18	Overactive Bladder
NCT001711711	NCT00171171_1_T0	COMPOUND	10	10	deferasirox
NCT001712101	NCT00171210_1_T0	COMPOUND	18	18	deferasirox
NCT001712102	NCT00171210_2_T0	COMPOUND	14	14	deferasirox
NCT001713011	NCT00171301_1_T0	ORGAN	15	15	liver
NCT001713011	NCT00171301_1_T1	COMPOUND	8	8	deferasirox
NCT001713011	NCT00171301_1_T2	ORGAN	22	22	serum
NCT001713011	NCT00171301_1_T3	PHENOTYPE	23	24	ferritin levels
NCT001713012	NCT00171301_2_T0	PHENOTYPE	7	8	adverse events
NCT001713017	NCT00171301_7_T0	PHENOTYPE	32	32	centers
NCT001713017	NCT00171301_7_T1	COMPOUND	16	16	deferasirox
NCT001713017	NCT00171301_7_T2	COMPOUND	23	23	deferasirox
NCT001713018	NCT00171301_8_T0	COMPOUND	18	18	deferiprone
NCT001713018	NCT00171301_8_T1	COMPOUND	16	16	deferoxamine
NCT001713018	NCT00171301_8_T2	PHENOTYPE	8	8	hemosiderosis
NCT001713270	NCT00171327_0_T0	PHENOTYPE	14	14	Hypertension
NCT001713270	NCT00171327_0_T1	PHENOTYPE	16	17	Endothelial Dysfunction
NCT001713272	NCT00171327_2_T0	COMPOUND	15	15	fluvastatin
NCT001713272	NCT00171327_2_T1	COMPOUND	11	11	valsartan
NCT001713400	NCT00171340_0_T0	PHENOTYPE	20	20	Cancer
NCT001713400	NCT00171340_0_T1	PHENOTYPE	9	10	Bone Loss
NCT001713400	NCT00171340_0_T2	PHENOTYPE	17	18	Breast Cancer
NCT001713660	NCT00171366_0_T0	PHENOTYPE	8	8	Hypertension
NCT001714180	NCT00171418_0_T0	PHENOTYPE	13	13	GERD
NCT001714180	NCT00171418_0_T1	PHENOTYPE	10	12	Gastroesophageal Reflux Disease
NCT001714700	NCT00171470_0_T0	PHENOTYPE	22	22	Heartburn
NCT001714700	NCT00171470_0_T1	PHENOTYPE	24	24	Heartburn
NCT001714700	NCT00171470_0_T2	PHENOTYPE	10	10	Symptoms
NCT001714830	NCT00171483_0_T0	PHENOTYPE	14	14	GERD
NCT001714830	NCT00171483_0_T1	PHENOTYPE	15	15	Symptoms
NCT001714830	NCT00171483_0_T2	PHENOTYPE	11	13	Gastroesophageal Reflux Disease
NCT001715091	NCT00171509_1_T0	COMPOUND	12	12	cyclosporine
NCT001715220	NCT00171522_0_T0	GENE	4	4	PEG
NCT001715220	NCT00171522_0_T1	PHENOTYPE	9	9	Constipation
NCT001715350	NCT00171535_0_T0	PHENOTYPE	10	10	Hypertension
NCT001715610	NCT00171561_0_T0	PHENOTYPE	7	7	Hypertension
NCT001715610	NCT00171561_0_T1	PHENOTYPE	10	10	Albuminuria
NCT001715610	NCT00171561_0_T2	PHENOTYPE	8	8	Diabetes
NCT001715613	NCT00171561_3_T0	PHENOTYPE	12	12	stiffness
NCT001715613	NCT00171561_3_T1	ORGAN	15	16	blood vessels
NCT001715741	NCT00171574_1_T0	COMPOUND	10	10	valsartan
NCT001715742	NCT00171574_2_T0	PHENOTYPE	4	4	microalbuminuria
NCT001715742	NCT00171574_2_T1	PHENOTYPE	5	5	proteinuria
NCT001715871	NCT00171587_1_T0	COMPOUND	15	15	capecitabine
NCT001715871	NCT00171587_1_T1	COMPOUND	20	20	capecitabine
NCT001715871	NCT00171587_1_T2	PHENOTYPE	30	30	tumor
NCT001715871	NCT00171587_1_T3	PHENOTYPE	13	13	pharmacokinetics
NCT001715871	NCT00171587_1_T4	PHENOTYPE	23	23	pharmacokinetics
NCT001715871	NCT00171587_1_T5	COMPOUND	10	10	vatalanib
NCT001715871	NCT00171587_1_T6	COMPOUND	25	25	vatalanib
NCT001716001	NCT00171600_1_T0	COMPOUND	12	12	lisinopril
NCT001716001	NCT00171600_1_T1	COMPOUND	10	10	valsartan
NCT001716002	NCT00171600_2_T0	PHENOTYPE	4	4	microalbuminuria
NCT001716002	NCT00171600_2_T1	PHENOTYPE	7	8	albumin/creatinine ratio
NCT001716005	NCT00171600_5_T0	PHENOTYPE	5	5	albuminuria
NCT001716395	NCT00171639_5_T0	PHENOTYPE	2	2	bilateral
NCT001717042	NCT00171704_2_T0	COMPOUND	6	6	letrozole
NCT001717042	NCT00171704_2_T1	GENE	19	19	receptor
NCT001717042	NCT00171704_2_T2	COMPOUND	8	8	tamoxifen
NCT001717042	NCT00171704_2_T3	BIOLOGICAL_PROCESS	12	13	lipid metabolism
NCT001717042	NCT00171704_2_T4	PHENOTYPE	22	23	breast cancer
NCT001717047	NCT00171704_7_T0	PHENOTYPE	6	6	malignancy
NCT001717047	NCT00171704_7_T1	GENE	2	2	had
NCT001717048	NCT00171704_8_T0	PHENOTYPE	2	3	endometrial cancer
NCT001717048	NCT00171704_8_T1	PHENOTYPE	5	7	invasive breast cancer
NCT001717049	NCT00171704_9_T0	PHENOTYPE	3	5	bilateral breast cancer
NCT001717301	NCT00171730_1_T0	COMPOUND	10	10	pasireotide
NCT001717301	NCT00171730_1_T1	PHENOTYPE	14	14	acromegaly
NCT001717820	NCT00171782_0_T0	PHENOTYPE	0	0	Hypertension
NCT001718082	NCT00171808_2_T0	COMPOUND	9	9	letrozole
NCT001718082	NCT00171808_2_T1	PHENOTYPE	16	16	recurrent
NCT001718082	NCT00171808_2_T2	GENE	17	17	hormone
NCT001718082	NCT00171808_2_T3	PHENOTYPE	19	20	endometrial cancer
NCT001718211	NCT00171821_1_T0	COMPOUND	14	14	deferasirox
NCT001718211	NCT00171821_1_T1	PHENOTYPE	23	24	iron overload
NCT001718344	NCT00171834_4_T0	GENE	19	19	II
NCT001718862	NCT00171886_2_T0	PHENOTYPE	17	17	acromegaly
NCT001718862	NCT00171886_2_T1	PHENOTYPE	24	24	acromegaly
NCT001718862	NCT00171886_2_T2	COMPOUND	9	9	octreotide
NCT001718862	NCT00171886_2_T3	PHENOTYPE	27	28	pituitary macroadenoma
NCT001719121	NCT00171912_1_T0	PHENOTYPE	23	23	malignancy
NCT001719121	NCT00171912_1_T1	PHENOTYPE	13	13	blocks
NCT001719121	NCT00171912_1_T2	COMPOUND	11	11	imatinib
NCT001719121	NCT00171912_1_T3	COMPOUND	12	12	mesylate
NCT001719125	NCT00171912_5_T0	COMPOUND	11	11	imatinib
NCT001719125	NCT00171912_5_T1	PHENOTYPE	0	0	Malignancy
NCT001719125	NCT00171912_5_T2	COMPOUND	12	12	mesylate
NCT001719125	NCT00171912_5_T3	GENE	6	7	tyrosine kinase
NCT0017191211	NCT00171912_11_T0	PHENOTYPE	16	16	mutation
NCT0017191211	NCT00171912_11_T1	GENE	14	14	KIT
NCT0017191211	NCT00171912_11_T2	PHENOTYPE	1	1	leukaemias
NCT0017191211	NCT00171912_11_T3	PHENOTYPE	10	11	systemic mastocytosis
NCT0017191211	NCT00171912_11_T4	PHENOTYPE	4	6	gastrointestinal stromal tumours
NCT0017191214	NCT00171912_14_T0	COMPOUND	6	6	imatinib
NCT0017191214	NCT00171912_14_T1	COMPOUND	7	7	mesylate
NCT0017191214	NCT00171912_14_T2	GENE	1	1	has
NCT0017191214	NCT00171912_14_T3	PHENOTYPE	23	24	clinical resistance
NCT001719251	NCT00171925_1_T0	PHENOTYPE	10	10	progression
NCT001719251	NCT00171925_1_T1	PHENOTYPE	12	13	multiple myeloma
NCT001719251	NCT00171925_1_T2	CELL	1	2	plasma cells
NCT001719252	NCT00171925_2_T0	PHENOTYPE	17	17	progression
NCT001719252	NCT00171925_2_T1	GENE	12	12	has
NCT001719252	NCT00171925_2_T2	PHENOTYPE	19	20	multiple myeloma
NCT001719252	NCT00171925_2_T3	COMPOUND	10	11	zoledronic acid
NCT001719382	NCT00171938_2_T0	PHENOTYPE	4	4	GBM
NCT001719384	NCT00171938_4_T0	GENE	5	5	PDGFR
NCT001719386	NCT00171938_6_T0	GENE	4	4	MRI
NCT001719386	NCT00171938_6_T1	PHENOTYPE	1	2	recurrent disease
NCT001719511	NCT00171951_1_T0	COMPOUND	10	10	pasireotide
NCT001719511	NCT00171951_1_T1	PHENOTYPE	14	15	Cushing's disease
NCT001719513	NCT00171951_3_T0	COMPOUND	11	11	cortisol
NCT001719640	NCT00171964_0_T0	GENE	9	9	Pts
NCT001719640	NCT00171964_0_T1	PHENOTYPE	13	14	Bone Lesions
NCT001720033	NCT00172003_3_T0	GENE	4	4	1.5
NCT001720033	NCT00172003_3_T1	GENE	1	1	dehydrogenase
NCT001720680	NCT00172068_0_T0	ORGAN	14	15	Bone Marrow
NCT001720680	NCT00172068_0_T1	PHENOTYPE	6	7	Breast Cancer
NCT001720680	NCT00172068_0_T2	PHENOTYPE	9	11	Minimal Residual Disease
NCT001720682	NCT00172068_2_T0	PHENOTYPE	15	16	breast cancer
NCT001720682	NCT00172068_2_T1	ORGAN	23	24	bone marrow
NCT001720682	NCT00172068_2_T2	COMPOUND	10	11	zoledronic acid
NCT001720682	NCT00172068_2_T3	PHENOTYPE	18	20	minimal residual disease
NCT001720810	NCT00172081_0_T0	GENE	0	0	TOP
NCT001720810	NCT00172081_0_T1	PHENOTYPE	7	7	Fracture
NCT001720810	NCT00172081_0_T2	PHENOTYPE	3	3	Parathyroid
NCT001720810	NCT00172081_0_T3	PHENOTYPE	12	13	Postmenopausal Osteoporosis
NCT001720815	NCT00172081_5_T0	GENE	5	5	PTH
NCT001720816	NCT00172081_6_T0	TISSUE	9	10	trabecular bone
NCT001720818	NCT00172081_8_T0	GENE	22	22	sc
NCT001720818	NCT00172081_8_T1	GENE	11	11	hormone
NCT0017208112	NCT00172081_12_T0	PHENOTYPE	24	24	symptoms
NCT0017208112	NCT00172081_12_T1	GENE	5	5	reduced
NCT0017208112	NCT00172081_12_T2	PHENOTYPE	4	4	severely
NCT0017208112	NCT00172081_12_T3	PHENOTYPE	10	10	fracture
NCT0017208119	NCT00172081_19_T0	COMPOUND	26	26	calcium
NCT0017208119	NCT00172081_19_T1	COMPOUND	28	29	vitamin D3
NCT0017208122	NCT00172081_22_T0	COMPOUND	5	5	prednisone
NCT0017208124	NCT00172081_24_T0	COMPOUND	4	4	pamidronate
NCT0017208124	NCT00172081_24_T1	PHENOTYPE	8	8	osteoporosis
NCT0017208126	NCT00172081_26_T0	COMPOUND	3	3	etidronate
NCT0017208128	NCT00172081_28_T0	GENE	3	3	has
NCT0017208128	NCT00172081_28_T1	COMPOUND	5	5	phenytoin
NCT0017208129	NCT00172081_29_T0	COMPOUND	18	18	phenytoin
NCT0017208134	NCT00172081_34_T0	GENE	20	20	III
NCT0017208135	NCT00172081_35_T0	COMPOUND	13	13	prednisone
NCT0017208139	NCT00172081_39_T0	PHENOTYPE	4	5	serum calcium
NCT0017208140	NCT00172081_40_T0	COMPOUND	3	3	calcium
NCT0017208140	NCT00172081_40_T1	COMPOUND	5	6	vitamin D3
NCT0017208142	NCT00172081_42_T0	PHENOTYPE	3	5	serum calcium level
NCT0017208144	NCT00172081_44_T0	PHENOTYPE	3	5	serum calcium level
NCT0017208147	NCT00172081_47_T0	COMPOUND	8	8	creatinine
NCT0017208147	NCT00172081_47_T1	COMPOUND	6	6	calcium
NCT0017208148	NCT00172081_48_T0	COMPOUND	3	3	calcium
NCT0017208148	NCT00172081_48_T1	COMPOUND	5	6	vitamin D3
NCT0017208150	NCT00172081_50_T0	COMPOUND	6	6	creatinine
NCT0017208150	NCT00172081_50_T1	COMPOUND	4	4	calcium
NCT0017208152	NCT00172081_52_T0	COMPOUND	6	6	creatinine
NCT0017208152	NCT00172081_52_T1	COMPOUND	4	4	calcium
NCT0017209423	NCT00172094_23_T0	PHENOTYPE	2	2	acute
NCT0017209423	NCT00172094_23_T1	PHENOTYPE	8	8	hypertension
NCT0017209423	NCT00172094_23_T2	PHENOTYPE	5	6	cerebrovascular disease
NCT0017209423	NCT00172094_23_T3	PHENOTYPE	12	13	hemiplegic migraines
NCT0017209429	NCT00172094_29_T0	PHENOTYPE	0	0	Migraine
NCT0017209429	NCT00172094_29_T1	PHENOTYPE	13	13	vomiting
NCT0017209429	NCT00172094_29_T2	PHENOTYPE	11	11	nausea
NCT0017209431	NCT00172094_31_T0	PHENOTYPE	1	1	acute
NCT0017209431	NCT00172094_31_T1	PHENOTYPE	3	3	chronic
NCT0017209433	NCT00172094_33_T0	COMPOUND	11	11	magnesium
NCT001721070	NCT00172107_0_T0	PHENOTYPE	21	22	Postmenopausal Osteoporosis
NCT001721072	NCT00172107_2_T0	PHENOTYPE	43	43	osteoporosis
NCT001721077	NCT00172107_7_T0	PHENOTYPE	8	8	osteopenia
NCT001721077	NCT00172107_7_T1	PHENOTYPE	17	17	osteoporosis
NCT001721077	NCT00172107_7_T2	PHENOTYPE	6	6	fracture
NCT001721077	NCT00172107_7_T3	PHENOTYPE	15	16	vertebral fractures
NCT001721079	NCT00172107_9_T0	PHENOTYPE	17	17	hypercalcemia
NCT001721079	NCT00172107_9_T1	GENE	33	33	2.0
NCT001721079	NCT00172107_9_T2	GENE	23	23	5.0
NCT001721079	NCT00172107_9_T3	GENE	10	10	has
NCT0017210713	NCT00172107_13_T0	PHENOTYPE	10	11	dose-response relationship
NCT0017210714	NCT00172107_14_T0	COMPOUND	21	21	DXA
NCT0017210715	NCT00172107_15_T0	GENE	8	8	0.5
NCT0017210716	NCT00172107_16_T0	COMPOUND	8	8	calcium
NCT0017210716	NCT00172107_16_T1	COMPOUND	12	12	calcium
NCT0017210716	NCT00172107_16_T2	COMPOUND	23	24	vitamin D
NCT0017210718	NCT00172107_18_T0	GENE	14	14	OR
NCT0017210718	NCT00172107_18_T1	GENE	37	37	11.1
NCT0017210718	NCT00172107_18_T2	GENE	23	23	0.5
NCT0017210718	NCT00172107_18_T3	PHENOTYPE	13	13	hypercalcemia
NCT0017210718	NCT00172107_18_T4	PHENOTYPE	18	19	calcium levels
NCT0017210718	NCT00172107_18_T5	PHENOTYPE	4	5	serum calcium
NCT0017210718	NCT00172107_18_T6	PHENOTYPE	42	44	serum calcium level
NCT0017210719	NCT00172107_19_T0	PHENOTYPE	9	9	hypercalcemia
NCT0017210719	NCT00172107_19_T1	GENE	10	10	OR
NCT0017210719	NCT00172107_19_T2	PHENOTYPE	32	32	withdrawn
NCT0017210719	NCT00172107_19_T3	PHENOTYPE	15	16	calcium levels
NCT001721203	NCT00172120_3_T0	ORGAN	6	7	lumbar vertebrae
NCT001721203	NCT00172120_3_T1	PHENOTYPE	1	2	anabolic effects
NCT001721204	NCT00172120_4_T0	GENE	13	13	ALX1
NCT001721204	NCT00172120_4_T1	GENE	25	25	al
NCT001721204	NCT00172120_4_T2	GENE	29	29	al
NCT001721204	NCT00172120_4_T3	GENE	24	24	et
NCT001721204	NCT00172120_4_T4	GENE	28	28	et
NCT001721206	NCT00172120_6_T0	GENE	17	17	TOP
NCT0017212010	NCT00172120_10_T0	PHENOTYPE	1	1	disorders
NCT0017212017	NCT00172120_17_T0	COMPOUND	1	1	estrogen
NCT0017212017	NCT00172120_17_T1	GENE	16	16	1.0
NCT0017212017	NCT00172120_17_T2	COMPOUND	3	3	estradiol
NCT0017212019	NCT00172120_19_T0	PHENOTYPE	0	0	Acute
NCT0017212025	NCT00172120_25_T0	GENE	11	11	TOP
NCT0017212025	NCT00172120_25_T1	COMPOUND	1	1	phenytoin
NCT0017212028	NCT00172120_28_T0	PHENOTYPE	2	3	laboratory results
NCT0017212034	NCT00172120_34_T0	GENE	4	4	20
NCT0017212035	NCT00172120_35_T0	GENE	0	0	Not
NCT0017212037	NCT00172120_37_T0	GENE	0	0	Not
NCT0017212037	NCT00172120_37_T1	PHENOTYPE	16	17	drug abuse
NCT001721331	NCT00172133_1_T0	GENE	31	31	ALX1
NCT001721334	NCT00172133_4_T0	ORGAN	7	8	lumbar vertebrae
NCT001721334	NCT00172133_4_T1	PHENOTYPE	1	2	anabolic effects
NCT001721335	NCT00172133_5_T0	GENE	13	13	ALX1
NCT0017213310	NCT00172133_10_T0	COMPOUND	16	16	calcium
NCT0017213310	NCT00172133_10_T1	GENE	21	21	D3
NCT0017213311	NCT00172133_11_T0	COMPOUND	2	2	calcium
NCT0017213312	NCT00172133_12_T0	COMPOUND	10	10	calcium
NCT0017213313	NCT00172133_13_T0	COMPOUND	2	2	calcium
NCT0017213313	NCT00172133_13_T1	GENE	5	5	D3
NCT0017213315	NCT00172133_15_T0	COMPOUND	10	10	calcium
NCT0017213315	NCT00172133_15_T1	GENE	15	15	D3
NCT0017213319	NCT00172133_19_T0	COMPOUND	5	5	calcium
NCT0017213319	NCT00172133_19_T1	GENE	8	8	D3
NCT0017213320	NCT00172133_20_T0	ORGAN	13	13	Appendix
NCT0017213321	NCT00172133_21_T0	GENE	4	4	CAB
NCT0017213327	NCT00172133_27_T0	PHENOTYPE	5	5	recurrence
NCT0017213327	NCT00172133_27_T1	GENE	3	3	had
NCT0017213327	NCT00172133_27_T2	GENE	2	2	has
NCT0017213328	NCT00172133_28_T0	PHENOTYPE	10	10	disorders
NCT0017213328	NCT00172133_28_T1	PHENOTYPE	8	8	diseases
NCT0017213328	NCT00172133_28_T2	ORGAN	0	1	Nervous system
NCT0017213331	NCT00172133_31_T0	PHENOTYPE	14	14	acute
NCT0017213331	NCT00172133_31_T1	GENE	3	3	has
NCT0017213331	NCT00172133_31_T2	GENE	36	36	met
NCT0017213333	NCT00172133_33_T0	COMPOUND	5	5	prednisone
NCT0017213346	NCT00172133_46_T0	PHENOTYPE	4	5	drug abuse
NCT0017213346	NCT00172133_46_T1	PHENOTYPE	0	1	Substance Abuse
NCT001721591	NCT00172159_1_T0	PHENOTYPE	9	10	colorectal cancer
NCT001721591	NCT00172159_1_T1	PHENOTYPE	6	7	hepatic metastasis
NCT001721592	NCT00172159_2_T0	PHENOTYPE	5	6	colorectal cancer
NCT001721592	NCT00172159_2_T1	PHENOTYPE	2	3	hepatic metastases
NCT001721593	NCT00172159_3_T0	COMPOUND	14	14	oxaliplatin
NCT001721593	NCT00172159_3_T1	COMPOUND	12	12	leucovorin
NCT001721593	NCT00172159_3_T2	PHENOTYPE	23	24	liver metastases
NCT001721594	NCT00172159_4_T0	PHENOTYPE	23	24	hepatic metastases
NCT001721595	NCT00172159_5_T0	PHENOTYPE	6	6	tumor
NCT001721595	NCT00172159_5_T1	PHENOTYPE	19	19	progression
NCT001721595	NCT00172159_5_T2	PHENOTYPE	17	18	liver metastases
NCT001721597	NCT00172159_7_T0	PHENOTYPE	21	22	colorectal cancer
NCT001721597	NCT00172159_7_T1	PHENOTYPE	18	19	hepatic metastases
NCT001721599	NCT00172159_9_T0	PHENOTYPE	9	10	colorectal cancer
NCT001721599	NCT00172159_9_T1	PHENOTYPE	6	7	hepatic metastasis
NCT0017215910	NCT00172159_10_T0	PHENOTYPE	5	6	colorectal cancer
NCT0017215910	NCT00172159_10_T1	PHENOTYPE	2	3	hepatic metastases
NCT0017215911	NCT00172159_11_T0	COMPOUND	14	14	oxaliplatin
NCT0017215911	NCT00172159_11_T1	COMPOUND	12	12	leucovorin
NCT0017215911	NCT00172159_11_T2	PHENOTYPE	23	24	liver metastases
NCT0017215912	NCT00172159_12_T0	PHENOTYPE	23	24	hepatic metastases
NCT0017215913	NCT00172159_13_T0	PHENOTYPE	6	6	tumor
NCT0017215913	NCT00172159_13_T1	PHENOTYPE	19	19	progression
NCT0017215913	NCT00172159_13_T2	PHENOTYPE	17	18	liver metastases
NCT0017215915	NCT00172159_15_T0	PHENOTYPE	21	22	colorectal cancer
NCT0017215915	NCT00172159_15_T1	PHENOTYPE	18	19	hepatic metastases
NCT0017215919	NCT00172159_19_T0	COMPOUND	3	3	1
NCT0017215919	NCT00172159_19_T1	PHENOTYPE	0	1	Primary tumor
NCT0017215922	NCT00172159_22_T0	ORGAN	7	7	rectum
NCT0017215922	NCT00172159_22_T1	PHENOTYPE	2	5	adenocarcinoma of the colon
NCT0017215924	NCT00172159_24_T0	GENE	13	13	MRI
NCT0017215927	NCT00172159_27_T0	GENE	2	2	1.5
NCT0017215927	NCT00172159_27_T1	CELL	0	0	Neutrophils
NCT0017215927	NCT00172159_27_T2	CELL	5	5	platelets
NCT0017215927	NCT00172159_27_T3	GENE	11	11	hemoglobin
NCT0017215932	NCT00172159_32_T0	PHENOTYPE	1	1	chronic
NCT0017215932	NCT00172159_32_T1	GENE	7	7	hormone
NCT0017215935	NCT00172159_35_T0	PHENOTYPE	10	11	myocardial infarction
NCT0017215935	NCT00172159_35_T1	PHENOTYPE	2	4	coronary artery disease
NCT0017215936	NCT00172159_36_T0	PHENOTYPE	2	2	subacute
NCT0017215936	NCT00172159_36_T1	PHENOTYPE	0	0	Acute
NCT0017215936	NCT00172159_36_T2	PHENOTYPE	16	17	allergic reaction
NCT0017215936	NCT00172159_36_T3	PHENOTYPE	3	4	intestinal occlusion
NCT0017215936	NCT00172159_36_T4	PHENOTYPE	8	10	inflammatory bowel disease
NCT0017215937	NCT00172159_37_T0	PHENOTYPE	1	2	drug abuse
NCT0017215937	NCT00172159_37_T1	PHENOTYPE	3	4	alcohol abuse
NCT0017215941	NCT00172159_41_T0	PHENOTYPE	2	3	peripheral neuropathy
NCT0017215942	NCT00172159_42_T0	ORGAN	14	14	cervix
NCT0017215942	NCT00172159_42_T1	PHENOTYPE	2	2	malignancy
NCT0017215942	NCT00172159_42_T2	PHENOTYPE	5	7	melanoma skin cancer
NCT0017215942	NCT00172159_42_T3	PHENOTYPE	9	13	carcinoma in situ of the
NCT001721723	NCT00172172_3_T0	ORGAN	7	8	lumbar vertebrae
NCT001721723	NCT00172172_3_T1	PHENOTYPE	1	2	anabolic effects
NCT001721724	NCT00172172_4_T0	GENE	13	13	ALX1
NCT001721726	NCT00172172_6_T0	PHENOTYPE	1	1	secondary
NCT001721726	NCT00172172_6_T1	COMPOUND	36	36	calcium
NCT001721726	NCT00172172_6_T2	COMPOUND	50	50	calcium
NCT001721726	NCT00172172_6_T3	GENE	21	21	BMC
NCT001721727	NCT00172172_7_T0	COMPOUND	18	18	calcium
NCT001721727	NCT00172172_7_T1	COMPOUND	24	24	calcium
NCT001721727	NCT00172172_7_T2	COMPOUND	31	31	calcium
NCT001721728	NCT00172172_8_T0	COMPOUND	7	8	vitamin D3
NCT001721729	NCT00172172_9_T0	GENE	17	17	sc
NCT0017217210	NCT00172172_10_T0	COMPOUND	1	1	calcium
NCT0017217211	NCT00172172_11_T0	COMPOUND	2	2	calcium
NCT0017217211	NCT00172172_11_T1	GENE	5	5	D3
NCT0017217220	NCT00172172_20_T0	PHENOTYPE	1	1	disorders
NCT0017217238	NCT00172172_38_T0	GENE	6	6	For
NCT0017217240	NCT00172172_40_T0	PHENOTYPE	12	13	drug abuse
NCT0017217240	NCT00172172_40_T1	PHENOTYPE	0	1	Substance Abuse
NCT001721850	NCT00172185_0_T0	COMPOUND	5	5	Teduglutide
NCT001721850	NCT00172185_0_T1	PHENOTYPE	9	11	Short Bowel Syndrome
NCT001721854	NCT00172185_4_T0	GENE	4	4	glucagon
NCT001721854	NCT00172185_4_T1	COMPOUND	0	0	Teduglutide
NCT001721854	NCT00172185_4_T2	CELL	18	18	neurons
NCT001721854	NCT00172185_4_T3	CELL	15	15	myofibroblasts
NCT001721854	NCT00172185_4_T4	CELL	12	13	enteroendocrine cells
NCT001721854	NCT00172185_4_T5	ORGAN	23	24	myenteric plexus
NCT001721856	NCT00172185_6_T0	GENE	5	5	III
NCT001721980	NCT00172198_0_T0	GENE	11	11	cts
NCT001721980	NCT00172198_0_T1	GENE	1	1	w-3
NCT001721986	NCT00172198_6_T0	COMPOUND	13	13	glucose
NCT001721987	NCT00172198_7_T0	GENE	22	22	am
NCT0017219814	NCT00172198_14_T0	COMPOUND	13	13	glucose
NCT0017219815	NCT00172198_15_T0	GENE	22	22	am
NCT0017219819	NCT00172198_19_T0	GENE	2	2	has
NCT001722111	NCT00172211_1_T0	PHENOTYPE	8	8	ESRD
NCT001722111	NCT00172211_1_T1	PHENOTYPE	1	2	insulin resistance
NCT001722112	NCT00172211_2_T0	PHENOTYPE	11	11	atherosclerosis
NCT001722112	NCT00172211_2_T1	PHENOTYPE	27	27	ESRD
NCT001722112	NCT00172211_2_T2	PHENOTYPE	5	6	insulin resistance
NCT001722112	NCT00172211_2_T3	PHENOTYPE	22	23	insulin resistance
NCT001722112	NCT00172211_2_T4	PHENOTYPE	2	3	oxidative stress
NCT001722112	NCT00172211_2_T5	PHENOTYPE	19	20	oxidative stress
NCT001722113	NCT00172211_3_T0	COMPOUND	4	4	glucose
NCT001722113	NCT00172211_3_T1	GENE	14	14	pH
NCT001722113	NCT00172211_3_T2	COMPOUND	11	11	lactate
NCT001722113	NCT00172211_3_T3	BIOLOGICAL_PROCESS	6	7	glucose degradation
NCT001722113	NCT00172211_3_T4	PHENOTYPE	31	32	oxidative stress
NCT001722114	NCT00172211_4_T0	GENE	8	8	pH
NCT001722114	NCT00172211_4_T1	COMPOUND	10	10	bicarbonate
NCT001722114	NCT00172211_4_T2	GENE	16	16	has
NCT001722116	NCT00172211_6_T0	PHENOTYPE	7	8	insulin resistance
NCT001722116	NCT00172211_6_T1	PHENOTYPE	4	5	oxidative stress
NCT001722117	NCT00172211_7_T0	PHENOTYPE	6	7	insulin resistance
NCT001722117	NCT00172211_7_T1	PHENOTYPE	32	33	insulin resistance
NCT001722117	NCT00172211_7_T2	PHENOTYPE	3	4	oxidative stress
NCT001722117	NCT00172211_7_T3	PHENOTYPE	29	30	oxidative stress
NCT0017221110	NCT00172211_10_T0	PHENOTYPE	13	14	insulin resistance
NCT0017221114	NCT00172211_14_T0	PHENOTYPE	10	10	atherosclerosis
NCT0017221114	NCT00172211_14_T1	PHENOTYPE	1	2	oxidative stress
NCT0017221115	NCT00172211_15_T0	PHENOTYPE	7	8	oxidative stress
NCT0017221116	NCT00172211_16_T0	COMPOUND	3	3	glucose
NCT0017221116	NCT00172211_16_T1	GENE	7	7	pH
NCT0017221116	NCT00172211_16_T2	COMPOUND	5	5	lactate
NCT0017221116	NCT00172211_16_T3	PHENOTYPE	25	26	oxidative stress
NCT0017221116	NCT00172211_16_T4	BIOLOGICAL_PROCESS	12	13	glucose degradation
NCT0017221117	NCT00172211_17_T0	GENE	7	7	pH
NCT0017221117	NCT00172211_17_T1	COMPOUND	12	12	bicarbonate
NCT0017221117	NCT00172211_17_T2	GENE	18	18	has
NCT0017221118	NCT00172211_18_T0	COMPOUND	12	12	bicarbonate
NCT0017221119	NCT00172211_19_T0	PHENOTYPE	4	5	oxidative stress
NCT0017221121	NCT00172211_21_T0	GENE	5	5	reduced
NCT0017221121	NCT00172211_21_T1	GENE	15	15	reduced
NCT0017221121	NCT00172211_21_T2	PHENOTYPE	9	10	insulin sensitivity
NCT0017221121	NCT00172211_21_T3	PHENOTYPE	6	7	oxidative stress
NCT0017221121	NCT00172211_21_T4	PHENOTYPE	16	17	oxidative stress
NCT0017221123	NCT00172211_23_T0	PHENOTYPE	6	7	insulin resistance
NCT0017221123	NCT00172211_23_T1	PHENOTYPE	32	33	insulin resistance
NCT0017221123	NCT00172211_23_T2	PHENOTYPE	3	4	oxidative stress
NCT0017221123	NCT00172211_23_T3	PHENOTYPE	29	30	oxidative stress
NCT0017221126	NCT00172211_26_T0	PHENOTYPE	1	1	ESRD
NCT0017221126	NCT00172211_26_T1	PHENOTYPE	4	5	chronic glomerulonephritis
NCT0017221126	NCT00172211_26_T2	PHENOTYPE	6	7	hypertensive nephrosclerosis
NCT0017221126	NCT00172211_26_T3	PHENOTYPE	8	9	interstitial nephritis
NCT0017221126	NCT00172211_26_T4	PHENOTYPE	10	12	polycystic kidney disease
NCT0017221129	NCT00172211_29_T0	PHENOTYPE	6	6	malignancy
NCT0017221130	NCT00172211_30_T0	PHENOTYPE	0	1	Diabetes mellitus
NCT0017221132	NCT00172211_32_T0	PHENOTYPE	1	1	peritonitis
NCT0017221132	NCT00172211_32_T1	PHENOTYPE	9	10	bacterial infections
NCT0017221133	NCT00172211_33_T0	COMPOUND	20	21	vitamin E
NCT0017221133	NCT00172211_33_T1	PHENOTYPE	7	8	oxidative stress
NCT0017221135	NCT00172211_35_T0	PHENOTYPE	7	8	rheumatoid arthritis
NCT0017221135	NCT00172211_35_T1	PHENOTYPE	3	5	systemic lupus erythematosus
NCT0017221136	NCT00172211_36_T0	COMPOUND	1	1	potassium
NCT0017221136	NCT00172211_36_T1	GENE	5	5	3.0
NCT0017221136	NCT00172211_36_T2	ORGAN	0	0	Serum
NCT001722245	NCT00172224_5_T0	PHENOTYPE	0	0	Osteopenia
NCT001722246	NCT00172224_6_T0	BIOLOGICAL_PROCESS	10	10	metabolism
NCT001722246	NCT00172224_6_T1	PHENOTYPE	7	7	ischemia
NCT001722247	NCT00172224_7_T0	PHENOTYPE	16	17	bone tumors
NCT001722248	NCT00172224_8_T0	GENE	3	3	has
NCT0017222410	NCT00172224_10_T0	PHENOTYPE	6	7	compression fractures
NCT0017222412	NCT00172224_12_T0	BIOLOGICAL_PROCESS	16	16	aging
NCT0017222412	NCT00172224_12_T1	PHENOTYPE	6	6	fractured
NCT0017222413	NCT00172224_13_T0	ORGAN	3	4	bone marrow
NCT0017222414	NCT00172224_14_T0	ORGAN	16	17	bone marrow
NCT0017222420	NCT00172224_20_T0	PHENOTYPE	0	0	Osteopenia
NCT0017222421	NCT00172224_21_T0	BIOLOGICAL_PROCESS	10	10	metabolism
NCT0017222421	NCT00172224_21_T1	PHENOTYPE	7	7	ischemia
NCT0017222422	NCT00172224_22_T0	PHENOTYPE	16	17	bone tumors
NCT0017222423	NCT00172224_23_T0	GENE	3	3	has
NCT0017222425	NCT00172224_25_T0	PHENOTYPE	6	7	compression fractures
NCT0017222427	NCT00172224_27_T0	BIOLOGICAL_PROCESS	16	16	aging
NCT0017222427	NCT00172224_27_T1	PHENOTYPE	6	6	fractured
NCT0017222428	NCT00172224_28_T0	ORGAN	3	4	bone marrow
NCT0017222429	NCT00172224_29_T0	ORGAN	16	17	bone marrow
NCT001722371	NCT00172237_1_T0	PHENOTYPE	8	10	cervical spine degeneration
NCT001722632	NCT00172263_2_T0	PHENOTYPE	7	7	myalgia
NCT001722632	NCT00172263_2_T1	PHENOTYPE	5	5	chills
NCT001722632	NCT00172263_2_T2	PHENOTYPE	4	4	fever
NCT001722632	NCT00172263_2_T3	PHENOTYPE	8	8	dyspnea
NCT001722632	NCT00172263_2_T4	PHENOTYPE	6	6	cough
NCT001722632	NCT00172263_2_T5	PHENOTYPE	10	10	diarrhea
NCT001722633	NCT00172263_3_T0	PHENOTYPE	1	1	symptoms
NCT001722633	NCT00172263_3_T1	PHENOTYPE	19	19	ventilation
NCT001722633	NCT00172263_3_T2	PHENOTYPE	14	15	respiratory failure
NCT001722635	NCT00172263_5_T0	GENE	22	22	II
NCT001722635	NCT00172263_5_T1	GENE	24	24	III
NCT001722635	NCT00172263_5_T2	PHENOTYPE	13	13	coronavirus
NCT001722635	NCT00172263_5_T3	PHENOTYPE	19	19	coronavirus
NCT001722635	NCT00172263_5_T4	GENE	20	21	group I
NCT001722639	NCT00172263_9_T0	PHENOTYPE	19	19	SARS-CoV
NCT001722762	NCT00172276_2_T0	PHENOTYPE	7	7	proteinuria
NCT001722762	NCT00172276_2_T1	PHENOTYPE	3	4	renal diseases
NCT001722763	NCT00172276_3_T0	GENE	11	11	II
NCT001722763	NCT00172276_3_T1	GENE	8	8	DD
NCT001722763	NCT00172276_3_T2	GENE	3	3	ACE
NCT001722891	NCT00172289_1_T0	PHENOTYPE	2	2	pulse
NCT001722892	NCT00172289_2_T0	PHENOTYPE	18	18	contraction
NCT001722892	NCT00172289_2_T1	TISSUE	22	23	smooth muscle
NCT001722893	NCT00172289_3_T0	PHENOTYPE	33	33	pulse
NCT001722893	NCT00172289_3_T1	TISSUE	25	26	smooth muscle
NCT001722894	NCT00172289_4_T0	PHENOTYPE	1	1	pulse
NCT001722895	NCT00172289_5_T0	PHENOTYPE	9	9	pulse
NCT001722895	NCT00172289_5_T1	ORGAN	20	21	spinal cord
NCT001722896	NCT00172289_6_T0	ORGAN	12	12	limbs
NCT001722896	NCT00172289_6_T1	PHENOTYPE	7	7	pulse
NCT001722896	NCT00172289_6_T2	PHENOTYPE	27	27	pulse
NCT001722896	NCT00172289_6_T3	PHENOTYPE	39	39	pulse
NCT001722899	NCT00172289_9_T0	ORGAN	11	12	cervical cord
NCT0017228910	NCT00172289_10_T0	ORGAN	19	20	cervical cord
NCT0017228911	NCT00172289_11_T0	PHENOTYPE	10	11	cerebrovascular accident
NCT0017228912	NCT00172289_12_T0	PHENOTYPE	17	17	pulse
NCT0017228915	NCT00172289_15_T0	PHENOTYPE	0	1	Autonomic dysfunction
NCT0017228915	NCT00172289_15_T1	PHENOTYPE	3	5	spinal cord injury
NCT0017228915	NCT00172289_15_T2	PHENOTYPE	23	25	elevated blood pressure
NCT0017228918	NCT00172289_18_T0	PHENOTYPE	9	9	sweating
NCT0017228922	NCT00172289_22_T0	PHENOTYPE	11	11	peripheral
NCT0017228922	NCT00172289_22_T1	PHENOTYPE	16	16	pulse
NCT0017228922	NCT00172289_22_T2	ORGAN	2	2	heart
NCT0017228923	NCT00172289_23_T0	PHENOTYPE	5	5	pulse
NCT0017228924	NCT00172289_24_T0	PHENOTYPE	27	27	pulse
NCT0017228925	NCT00172289_25_T0	PHENOTYPE	2	2	pulse
NCT0017228926	NCT00172289_26_T0	PHENOTYPE	18	18	contraction
NCT0017228926	NCT00172289_26_T1	TISSUE	22	23	smooth muscle
NCT0017228927	NCT00172289_27_T0	PHENOTYPE	33	33	pulse
NCT0017228927	NCT00172289_27_T1	TISSUE	25	26	smooth muscle
NCT0017228928	NCT00172289_28_T0	PHENOTYPE	1	1	pulse
NCT0017228929	NCT00172289_29_T0	PHENOTYPE	6	6	pulse
NCT0017228930	NCT00172289_30_T0	ORGAN	12	12	limbs
NCT0017228930	NCT00172289_30_T1	PHENOTYPE	7	7	pulse
NCT0017228930	NCT00172289_30_T2	PHENOTYPE	27	27	pulse
NCT0017228930	NCT00172289_30_T3	PHENOTYPE	39	39	pulse
NCT0017228933	NCT00172289_33_T0	ORGAN	11	12	cervical cord
NCT0017228934	NCT00172289_34_T0	ORGAN	19	20	cervical cord
NCT0017228935	NCT00172289_35_T0	PHENOTYPE	10	11	cerebrovascular accident
NCT0017228936	NCT00172289_36_T0	PHENOTYPE	17	17	pulse
NCT0017228937	NCT00172289_37_T0	PHENOTYPE	18	18	CVA
NCT0017228937	NCT00172289_37_T1	PHENOTYPE	6	6	pulse
NCT0017228937	NCT00172289_37_T2	PHENOTYPE	16	17	cerebrovascular accident
NCT0017228937	NCT00172289_37_T3	PHENOTYPE	20	22	spinal cord injury
NCT0017228942	NCT00172289_42_T0	ORGAN	10	11	upper extremity
NCT0017228942	NCT00172289_42_T1	ORGAN	13	14	lower extremity
NCT0017228943	NCT00172289_43_T0	ORGAN	4	5	cervical cord
NCT0017228943	NCT00172289_43_T1	ORGAN	26	27	upper extremity
NCT0017228944	NCT00172289_44_T0	PHENOTYPE	28	28	CVA
NCT001723153	NCT00172315_3_T0	PHENOTYPE	27	28	hematological diseases
NCT001723153	NCT00172315_3_T1	ORGAN	20	21	bone marrow
NCT001723154	NCT00172315_4_T0	GENE	2	2	al
NCT001723154	NCT00172315_4_T1	GENE	1	1	et
NCT001723154	NCT00172315_4_T2	ORGAN	15	16	bone marrow
NCT0017231510	NCT00172315_10_T0	PHENOTYPE	27	28	hematological diseases
NCT0017231510	NCT00172315_10_T1	ORGAN	20	21	bone marrow
NCT0017231511	NCT00172315_11_T0	GENE	2	2	al
NCT0017231511	NCT00172315_11_T1	GENE	1	1	et
NCT0017231511	NCT00172315_11_T2	ORGAN	15	16	bone marrow
NCT001723287	NCT00172328_7_T0	GENE	14	14	booster
NCT001723288	NCT00172328_8_T0	GENE	31	31	had
NCT001723288	NCT00172328_8_T1	PHENOTYPE	12	12	immunity
NCT001723288	NCT00172328_8_T2	GENE	20	20	booster
NCT001723288	NCT00172328_8_T3	PHENOTYPE	16	17	antibody response
NCT001723412	NCT00172341_2_T0	GENE	5	5	HDM
NCT001723412	NCT00172341_2_T1	GENE	9	9	cats
NCT001723412	NCT00172341_2_T2	PHENOTYPE	29	29	asthma
NCT001723413	NCT00172341_3_T0	GENE	8	8	allergen
NCT001723413	NCT00172341_3_T1	PHENOTYPE	11	11	asthma
NCT001723414	NCT00172341_4_T0	GENE	3	3	SLIT
NCT001723415	NCT00172341_5_T0	GENE	23	23	allergen
NCT001723541	NCT00172354_1_T0	PHENOTYPE	7	7	circulation
NCT001723542	NCT00172354_2_T0	GENE	20	20	ACTH
NCT001723542	NCT00172354_2_T1	ORGAN	4	4	hypothalamus
NCT001723542	NCT00172354_2_T2	ORGAN	16	17	pituitary gland
NCT001723542	NCT00172354_2_T3	GENE	8	10	corticotropin releasing hormone
NCT001723543	NCT00172354_3_T0	GENE	1	1	ACTH
NCT001723543	NCT00172354_3_T1	ORGAN	5	6	adrenal gland
NCT001723544	NCT00172354_4_T0	PHENOTYPE	8	8	bilateral
NCT001723544	NCT00172354_4_T1	GENE	10	10	had
NCT001723544	NCT00172354_4_T2	GENE	3	3	al
NCT001723544	NCT00172354_4_T3	GENE	2	2	et
NCT001723545	NCT00172354_5_T0	GENE	0	0	Karl
NCT001723547	NCT00172354_7_T0	GENE	13	13	CPR
NCT001723547	NCT00172354_7_T1	GENE	5	5	had
NCT001723547	NCT00172354_7_T2	ORGAN	2	2	serum
NCT001723547	NCT00172354_7_T3	PHENOTYPE	3	4	cortisol level
NCT001723548	NCT00172354_8_T0	GENE	10	10	ACTH
NCT001723548	NCT00172354_8_T1	GENE	7	7	had
NCT001723548	NCT00172354_8_T2	ORGAN	9	9	serum
NCT001723548	NCT00172354_8_T3	PHENOTYPE	12	13	cortisol level
NCT001723549	NCT00172354_9_T0	COMPOUND	21	21	OHCA
NCT001723549	NCT00172354_9_T1	ORGAN	3	3	serum
NCT001723549	NCT00172354_9_T2	PHENOTYPE	4	5	cortisol level
NCT0017235410	NCT00172354_10_T0	COMPOUND	9	9	hydrocortisone
NCT0017235410	NCT00172354_10_T1	COMPOUND	24	24	hydrocortisone
NCT0017235410	NCT00172354_10_T2	GENE	10	10	had
NCT0017235410	NCT00172354_10_T3	COMPOUND	16	16	epinephrine
NCT0017235412	NCT00172354_12_T0	GENE	3	3	HU
NCT0017235412	NCT00172354_12_T1	GENE	13	13	hormone
NCT0017235413	NCT00172354_13_T0	GENE	5	5	CS
NCT0017235413	NCT00172354_13_T1	GENE	1	1	CH
NCT0017235413	NCT00172354_13_T2	GENE	9	9	HA
NCT0017235413	NCT00172354_13_T3	GENE	3	3	EP
NCT0017235413	NCT00172354_13_T4	GENE	21	21	axis
NCT0017235413	NCT00172354_13_T5	GENE	30	30	Med
NCT0017235413	NCT00172354_13_T6	GENE	12	12	Fath
NCT001723674	NCT00172367_4_T0	COMPOUND	23	23	lycopene
NCT001723800	NCT00172380_0_T0	GENE	1	1	II
NCT001723800	NCT00172380_0_T1	PHENOTYPE	8	8	NSCLC
NCT001723800	NCT00172380_0_T2	GENE	10	10	III
NCT001723930	NCT00172393_0_T0	PHENOTYPE	5	6	CNS Infection
NCT001723936	NCT00172393_6_T0	PHENOTYPE	32	32	acute
NCT001723936	NCT00172393_6_T1	GENE	36	36	sera
NCT001723936	NCT00172393_6_T2	GENE	20	20	IgM
NCT001723938	NCT00172393_8_T0	GENE	5	5	had
NCT0017239312	NCT00172393_12_T0	GENE	8	8	had
NCT0017239312	NCT00172393_12_T1	ORGAN	20	21	left ventricle
NCT0017239313	NCT00172393_13_T0	GENE	13	13	had
NCT0017239313	NCT00172393_13_T1	PHENOTYPE	48	49	brainstem encephalitis
NCT0017239313	NCT00172393_13_T2	PHENOTYPE	51	52	acute illness
NCT0017239314	NCT00172393_14_T0	PHENOTYPE	24	24	coma
NCT0017239314	NCT00172393_14_T1	PHENOTYPE	26	27	aspiration pneumonia
NCT0017239314	NCT00172393_14_T2	PHENOTYPE	13	14	acute illness
NCT0017239317	NCT00172393_17_T0	PHENOTYPE	2	2	severity
NCT0017239317	NCT00172393_17_T1	PHENOTYPE	24	24	severity
NCT0017239317	NCT00172393_17_T2	PHENOTYPE	28	30	age of onset
NCT0017239319	NCT00172393_19_T0	PHENOTYPE	31	31	chronic
NCT0017239319	NCT00172393_19_T1	ORGAN	32	33	respiratory centers
NCT0017239320	NCT00172393_20_T0	PHENOTYPE	5	5	sequelae
NCT0017239320	NCT00172393_20_T1	PHENOTYPE	1	2	physical handicap
NCT0017239321	NCT00172393_21_T0	GENE	22	22	II
NCT0017239322	NCT00172393_22_T0	GENE	2	2	II
NCT0017239322	NCT00172393_22_T1	GENE	3	3	has
NCT0017239324	NCT00172393_24_T0	GENE	36	36	had
NCT0017239324	NCT00172393_24_T1	PHENOTYPE	0	1	Cognitive function
NCT0017239326	NCT00172393_26_T0	PHENOTYPE	10	11	cognitive ability
NCT0017239328	NCT00172393_28_T0	PHENOTYPE	8	8	Comprehension
NCT0017239328	NCT00172393_28_T1	PHENOTYPE	26	26	Comprehension
NCT0017239328	NCT00172393_28_T2	PHENOTYPE	31	31	Comprehension
NCT0017239328	NCT00172393_28_T3	GENE	12	12	Span
NCT0017239328	NCT00172393_28_T4	GENE	51	51	span
NCT0017239330	NCT00172393_30_T0	GENE	7	7	SAS
NCT0017239330	NCT00172393_30_T1	GENE	12	12	SAS
NCT0017239330	NCT00172393_30_T2	GENE	11	11	9.1
NCT0017239332	NCT00172393_32_T0	GENE	16	16	ANOVA
NCT0017239334	NCT00172393_34_T0	GENE	7	7	ANOVA
NCT0017239335	NCT00172393_35_T0	PHENOTYPE	15	16	cognitive function
NCT001724061	NCT00172406_1_T0	GENE	13	13	ventricular
NCT001724062	NCT00172406_2_T0	GENE	18	18	PIIINP
NCT001724062	NCT00172406_2_T1	PHENOTYPE	6	6	concentrations
NCT001724062	NCT00172406_2_T2	GENE	14	14	III
NCT001724062	NCT00172406_2_T3	ORGAN	5	5	serum
NCT001724062	NCT00172406_2_T4	PHENOTYPE	0	1	Myocardial fibrosis
NCT001724063	NCT00172406_3_T0	COMPOUND	10	10	technetium_99m
NCT001724064	NCT00172406_4_T0	GENE	15	15	53
NCT001724064	NCT00172406_4_T1	GENE	17	18	group 2
NCT001724066	NCT00172406_6_T0	GENE	13	13	0.2
NCT001724066	NCT00172406_6_T1	GENE	15	15	1.5
NCT001724066	NCT00172406_6_T2	GENE	6	6	had
NCT001724066	NCT00172406_6_T3	GENE	11	11	1.9
NCT001724066	NCT00172406_6_T4	ORGAN	8	9	right ventricle
NCT001724066	NCT00172406_6_T5	GENE	2	3	group 2
NCT001724067	NCT00172406_7_T0	PHENOTYPE	4	5	diastolic dysfunction
NCT001724068	NCT00172406_8_T0	PHENOTYPE	2	2	regression
NCT001724068	NCT00172406_8_T1	ORGAN	17	17	serum
NCT001724195	NCT00172419_5_T0	PHENOTYPE	5	5	plaques
NCT001724196	NCT00172419_6_T0	GENE	34	34	MRI
NCT001724196	NCT00172419_6_T1	PHENOTYPE	9	9	plaques
NCT001724196	NCT00172419_6_T2	GENE	24	24	pH
NCT001724197	NCT00172419_7_T0	PHENOTYPE	10	10	atheroma
NCT001724198	NCT00172419_8_T0	PHENOTYPE	16	16	plaque
NCT001724198	NCT00172419_8_T1	PHENOTYPE	28	28	initiation
NCT001724198	NCT00172419_8_T2	PHENOTYPE	18	18	regression
NCT001724198	NCT00172419_8_T3	GENE	19	19	has
NCT001724199	NCT00172419_9_T0	PHENOTYPE	16	16	plaque
NCT001724199	NCT00172419_9_T1	PHENOTYPE	17	17	regression
NCT0017241911	NCT00172419_11_T0	COMPOUND	1	1	18F-fluorodeoxyglucose
NCT0017241911	NCT00172419_11_T1	GENE	2	2	FDG
NCT0017241911	NCT00172419_11_T2	CELL	15	15	macrophages
NCT0017241911	NCT00172419_11_T3	GENE	20	20	has
NCT0017241911	NCT00172419_11_T4	CELL	17	19	smooth muscle cells
NCT0017241914	NCT00172419_14_T0	PHENOTYPE	21	21	plaque
NCT0017241914	NCT00172419_14_T1	GENE	4	4	FDG
NCT001724324	NCT00172432_4_T0	PHENOTYPE	0	1	Myocardial infarction
NCT001724325	NCT00172432_5_T0	GENE	29	29	PIIINP
NCT001724325	NCT00172432_5_T1	COMPOUND	4	4	thallium_201
NCT001724325	NCT00172432_5_T2	GENE	25	25	III
NCT001724325	NCT00172432_5_T3	ORGAN	15	15	serum
NCT001724453	NCT00172445_3_T0	PHENOTYPE	6	6	fever
NCT001724453	NCT00172445_3_T1	PHENOTYPE	9	10	cervical lymphadenopathy
NCT001724455	NCT00172445_5_T0	GENE	6	6	atypical
NCT001724455	NCT00172445_5_T1	PHENOTYPE	4	4	leucopenia
NCT001724455	NCT00172445_5_T2	PHENOTYPE	7	7	lymphocytosis
NCT001724459	NCT00172445_9_T0	PHENOTYPE	16	16	karyorrhexis
NCT001724459	NCT00172445_9_T1	PHENOTYPE	12	13	fibrinoid necrosis
NCT0017244514	NCT00172445_14_T0	PHENOTYPE	7	7	peripheral
NCT0017244514	NCT00172445_14_T1	GENE	9	9	atypical
NCT0017244514	NCT00172445_14_T2	GENE	14	14	IFN-a
NCT0017244514	NCT00172445_14_T3	COMPOUND	17	17	oligoadenylate
NCT0017244514	NCT00172445_14_T4	PHENOTYPE	10	10	lymphocytosis
NCT0017244514	NCT00172445_14_T5	ORGAN	13	13	serum
NCT0017244516	NCT00172445_16_T0	PHENOTYPE	25	26	nosocomial infection
NCT0017244516	NCT00172445_16_T1	PHENOTYPE	6	8	age of onset
NCT0017244517	NCT00172445_17_T0	PHENOTYPE	7	8	Kikuchi's disease
NCT0017244518	NCT00172445_18_T0	PHENOTYPE	8	9	Kikuchi's disease
NCT001724582	NCT00172458_2_T0	PHENOTYPE	7	7	proximal
NCT001724584	NCT00172458_4_T0	GENE	2	2	has
NCT001724586	NCT00172458_6_T0	PHENOTYPE	1	1	restenosis
NCT001724587	NCT00172458_7_T0	PHENOTYPE	20	20	restenosis
NCT001724587	NCT00172458_7_T1	GENE	5	5	balloon
NCT001724588	NCT00172458_8_T0	GENE	6	6	VAS
NCT001724588	NCT00172458_8_T1	ORGAN	12	12	artery
NCT001724589	NCT00172458_9_T0	PHENOTYPE	8	8	restenosis
NCT001724589	NCT00172458_9_T1	GENE	3	3	al
NCT001724589	NCT00172458_9_T2	GENE	2	2	et
NCT0017245810	NCT00172458_10_T0	PHENOTYPE	0	0	Restenosis
NCT0017245810	NCT00172458_10_T1	PHENOTYPE	10	12	quality of life
NCT0017245811	NCT00172458_11_T0	PHENOTYPE	8	8	restenosis
NCT0017245811	NCT00172458_11_T1	GENE	10	10	VAS
NCT0017245812	NCT00172458_12_T0	GENE	22	22	balloon
NCT0017245812	NCT00172458_12_T1	GENE	17	17	VAS
NCT0017245813	NCT00172458_13_T0	PHENOTYPE	6	6	restenosis
NCT001724711	NCT00172471_1_T0	PHENOTYPE	15	16	sleep disturbance
NCT001724713	NCT00172471_3_T0	CELL	13	13	cells
NCT001724713	NCT00172471_3_T1	GENE	7	7	has
NCT001724715	NCT00172471_5_T0	PHENOTYPE	9	9	chronic
NCT001724715	NCT00172471_5_T1	PHENOTYPE	17	18	sleep disorders
NCT001724717	NCT00172471_7_T0	ORGAN	15	15	serum
NCT001724844	NCT00172484_4_T0	PHENOTYPE	17	18	acute stroke
NCT001724844	NCT00172484_4_T1	ORGAN	11	12	upper limb
NCT001724971	NCT00172497_1_T0	PHENOTYPE	29	29	schizophrenia
NCT001724971	NCT00172497_1_T1	PHENOTYPE	42	42	schizophrenia
NCT001724971	NCT00172497_1_T2	PHENOTYPE	55	55	schizophrenia
NCT001724971	NCT00172497_1_T3	PHENOTYPE	34	34	heterogeneous
NCT001724974	NCT00172497_4_T0	PHENOTYPE	29	29	schizophrenia
NCT001724974	NCT00172497_4_T1	PHENOTYPE	42	42	schizophrenia
NCT001724974	NCT00172497_4_T2	PHENOTYPE	55	55	schizophrenia
NCT001724974	NCT00172497_4_T3	PHENOTYPE	34	34	heterogeneous
NCT001724977	NCT00172497_7_T0	PHENOTYPE	6	6	schizophrenia
NCT001724978	NCT00172497_8_T0	PHENOTYPE	10	10	insights
NCT001725104	NCT00172510_4_T0	COMPOUND	8	8	deoxycorticosterone
NCT001725104	NCT00172510_4_T1	PHENOTYPE	15	16	cortisol level
NCT001725104	NCT00172510_4_T2	PHENOTYPE	12	13	decreased aldosterone
NCT001725105	NCT00172510_5_T0	PHENOTYPE	11	11	hypertension
NCT001725105	NCT00172510_5_T1	GENE	10	10	hormone
NCT001725105	NCT00172510_5_T2	PHENOTYPE	13	14	hypokalemic alkalosis
NCT001725106	NCT00172510_6_T0	GENE	21	21	XX
NCT001725106	NCT00172510_6_T1	COMPOUND	17	17	estrogen
NCT001725106	NCT00172510_6_T2	PHENOTYPE	8	8	impairment
NCT001725106	NCT00172510_6_T3	PHENOTYPE	10	10	virilization
NCT001725107	NCT00172510_7_T0	GENE	13	13	CYP17
NCT001725107	NCT00172510_7_T1	GENE	1	1	P450c17
NCT001725107	NCT00172510_7_T2	GENE	2	2	has
NCT001725107	NCT00172510_7_T3	PHENOTYPE	10	10	encoded
NCT001725108	NCT00172510_8_T0	GENE	3	3	CYP17
NCT001725109	NCT00172510_9_T0	PHENOTYPE	10	10	pathology
NCT001725232	NCT00172523_2_T0	COMPOUND	29	29	androgen
NCT001725232	NCT00172523_2_T1	PHENOTYPE	19	19	balding
NCT001725232	NCT00172523_2_T2	PHENOTYPE	10	10	hyperandrogenism
NCT001725232	NCT00172523_2_T3	PHENOTYPE	15	15	hirsutism
NCT001725232	NCT00172523_2_T4	PHENOTYPE	0	0	PCOS
NCT001725232	NCT00172523_2_T5	PHENOTYPE	16	16	acne
NCT001725232	NCT00172523_2_T6	PHENOTYPE	5	5	anovulation
NCT001725232	NCT00172523_2_T7	ORGAN	25	25	serum
NCT001725232	NCT00172523_2_T8	PHENOTYPE	4	4	chronic
NCT001725232	NCT00172523_2_T9	PHENOTYPE	6	7	menstrual irregularities
NCT001725360	NCT00172536_0_T0	ORGAN	17	17	Graft
NCT001725360	NCT00172536_0_T1	ORGAN	14	15	Coronary Artery
NCT0017253612	NCT00172536_12_T0	PHENOTYPE	10	10	impedance
NCT0017253612	NCT00172536_12_T1	GENE	4	4	ventricular
NCT001725494	NCT00172549_4_T0	GENE	6	6	10.0
NCT001725497	NCT00172549_7_T0	PHENOTYPE	12	14	major depressive disorder
NCT001725497	NCT00172549_7_T1	PHENOTYPE	16	18	quality of life
NCT001725499	NCT00172549_9_T0	PHENOTYPE	1	3	quality of life
NCT0017254911	NCT00172549_11_T0	PHENOTYPE	3	5	quality of life
NCT0017254919	NCT00172549_19_T0	PHENOTYPE	3	3	regression
NCT0017254919	NCT00172549_19_T1	PHENOTYPE	7	9	major depressive disorder
NCT0017254919	NCT00172549_19_T2	PHENOTYPE	11	13	quality of life
NCT0017254927	NCT00172549_27_T0	PHENOTYPE	7	9	major depressive disorder
NCT0017254927	NCT00172549_27_T1	PHENOTYPE	11	13	quality of life
NCT001725625	NCT00172562_5_T0	ORGAN	1	1	microvessel
NCT001725625	NCT00172562_5_T1	GENE	3	3	MVD
NCT001725625	NCT00172562_5_T2	GENE	22	22	MVD
NCT001725625	NCT00172562_5_T3	PHENOTYPE	13	14	multiple myeloma
NCT001725625	NCT00172562_5_T4	PHENOTYPE	29	30	multiple myeloma
NCT001725625	NCT00172562_5_T5	ORGAN	6	7	bone marrow
NCT001725626	NCT00172562_6_T0	ORGAN	6	7	blood vessel
NCT0017256212	NCT00172562_12_T0	ORGAN	1	1	microvessel
NCT0017256212	NCT00172562_12_T1	GENE	3	3	MVD
NCT0017256212	NCT00172562_12_T2	GENE	22	22	MVD
NCT0017256212	NCT00172562_12_T3	PHENOTYPE	13	14	multiple myeloma
NCT0017256212	NCT00172562_12_T4	PHENOTYPE	29	30	multiple myeloma
NCT0017256212	NCT00172562_12_T5	ORGAN	6	7	bone marrow
NCT0017256213	NCT00172562_13_T0	ORGAN	6	7	blood vessel
NCT001725756	NCT00172575_6_T0	PHENOTYPE	31	31	pathology
NCT001725756	NCT00172575_6_T1	PHENOTYPE	7	7	malignancy
NCT001725756	NCT00172575_6_T2	PHENOTYPE	1	1	nodules
NCT001725880	NCT00172588_0_T0	PHENOTYPE	7	7	Adenomyosis
NCT001725880	NCT00172588_0_T1	BIOLOGICAL_PROCESS	5	5	Apoptosis
NCT001725880	NCT00172588_0_T2	CELL	3	4	Stromal Cell
NCT001725887	NCT00172588_7_T0	GENE	8	8	ESC
NCT001725887	NCT00172588_7_T1	PHENOTYPE	17	17	adenomyosis
NCT001726012	NCT00172601_2_T0	PHENOTYPE	62	62	FSS
NCT001726012	NCT00172601_2_T1	ORGAN	13	14	brachial plexus
NCT001726013	NCT00172601_3_T0	PHENOTYPE	39	39	FSS
NCT001726141	NCT00172614_1_T0	CELL	7	7	cells
NCT001726141	NCT00172614_1_T1	GENE	1	1	secreted
NCT001726141	NCT00172614_1_T2	TISSUE	3	4	adipose tissue
NCT001726147	NCT00172614_7_T0	PHENOTYPE	5	5	peripheral
NCT001726272	NCT00172627_2_T0	PHENOTYPE	22	22	carcinogenesis
NCT001726272	NCT00172627_2_T1	PHENOTYPE	11	11	cancers
NCT001726272	NCT00172627_2_T2	GENE	2	2	COX-2
NCT001726272	NCT00172627_2_T3	GENE	3	3	has
NCT001726274	NCT00172627_4_T0	PHENOTYPE	12	12	disorders
NCT001726275	NCT00172627_5_T0	GENE	8	8	COX-2
NCT001726275	NCT00172627_5_T1	GENE	11	11	GC
NCT001726277	NCT00172627_7_T0	PHENOTYPE	9	9	carcinogenesis
NCT001726277	NCT00172627_7_T1	PHENOTYPE	1	1	inflammation
NCT001726277	NCT00172627_7_T2	GENE	7	7	COX-2
NCT001726278	NCT00172627_8_T0	GENE	0	0	Interleukin-6
NCT001726278	NCT00172627_8_T1	GENE	1	1	IL-6
NCT001726278	NCT00172627_8_T2	GENE	10	10	GC
NCT001726278	NCT00172627_8_T3	PHENOTYPE	8	8	gastritis
NCT0017262710	NCT00172627_10_T0	GENE	6	6	IL-6
NCT0017262710	NCT00172627_10_T1	GENE	4	4	COX-2
NCT0017262710	NCT00172627_10_T2	GENE	8	8	GC
NCT0017262712	NCT00172627_12_T0	PHENOTYPE	11	11	pathology
NCT0017262712	NCT00172627_12_T1	GENE	8	8	GC
NCT0017262712	NCT00172627_12_T2	GENE	27	27	GC
NCT0017262713	NCT00172627_13_T0	GENE	16	16	IL-6
NCT0017262713	NCT00172627_13_T1	GENE	14	14	COX-2
NCT0017262713	NCT00172627_13_T2	GENE	9	9	GC
NCT0017262715	NCT00172627_15_T0	GENE	0	0	COX-2
NCT0017262715	NCT00172627_15_T1	GENE	4	4	PGs
NCT0017262716	NCT00172627_16_T0	CELL	5	5	cells
NCT0017262716	NCT00172627_16_T1	GENE	13	13	receptor
NCT0017262716	NCT00172627_16_T2	GENE	14	14	1.4
NCT0017262716	NCT00172627_16_T3	GENE	25	25	IL-6
NCT0017262716	NCT00172627_16_T4	GENE	23	23	COX-2
NCT0017262716	NCT00172627_16_T5	GENE	12	12	EP
NCT0017262716	NCT00172627_16_T6	GENE	4	4	GC
NCT0017262718	NCT00172627_18_T0	CELL	11	11	cells
NCT0017262718	NCT00172627_18_T1	ORGAN	18	18	xenograft
NCT0017262718	NCT00172627_18_T2	GENE	6	6	COX-2
NCT0017262718	NCT00172627_18_T3	GENE	10	10	GC
NCT0017262719	NCT00172627_19_T0	COMPOUND	4	4	celecoxib
NCT0017262719	NCT00172627_19_T1	PHENOTYPE	12	12	tumor
NCT0017262719	NCT00172627_19_T2	PHENOTYPE	13	13	blocks
NCT0017262719	NCT00172627_19_T3	GENE	20	20	IL-6
NCT0017262719	NCT00172627_19_T4	GENE	1	1	COX-2
NCT0017262720	NCT00172627_20_T0	GENE	16	16	IL-6
NCT0017262720	NCT00172627_20_T1	GENE	11	11	COX-2
NCT0017262720	NCT00172627_20_T2	GENE	18	18	GC
NCT0017262721	NCT00172627_21_T0	GENE	14	14	COX-2
NCT0017262721	NCT00172627_21_T1	GENE	20	20	GC
NCT0017262724	NCT00172627_24_T0	PHENOTYPE	22	22	carcinogenesis
NCT0017262724	NCT00172627_24_T1	PHENOTYPE	11	11	cancers
NCT0017262724	NCT00172627_24_T2	GENE	2	2	COX-2
NCT0017262724	NCT00172627_24_T3	GENE	3	3	has
NCT0017262726	NCT00172627_26_T0	PHENOTYPE	12	12	disorders
NCT0017262727	NCT00172627_27_T0	GENE	8	8	COX-2
NCT0017262727	NCT00172627_27_T1	GENE	11	11	GC
NCT0017262729	NCT00172627_29_T0	PHENOTYPE	9	9	carcinogenesis
NCT0017262729	NCT00172627_29_T1	PHENOTYPE	1	1	inflammation
NCT0017262729	NCT00172627_29_T2	GENE	7	7	COX-2
NCT0017262730	NCT00172627_30_T0	GENE	0	0	Interleukin-6
NCT0017262730	NCT00172627_30_T1	GENE	1	1	IL-6
NCT0017262730	NCT00172627_30_T2	GENE	10	10	GC
NCT0017262730	NCT00172627_30_T3	PHENOTYPE	8	8	gastritis
NCT0017262732	NCT00172627_32_T0	GENE	6	6	IL-6
NCT0017262732	NCT00172627_32_T1	GENE	4	4	COX-2
NCT0017262732	NCT00172627_32_T2	GENE	8	8	GC
NCT0017262734	NCT00172627_34_T0	PHENOTYPE	11	11	pathology
NCT0017262734	NCT00172627_34_T1	GENE	8	8	GC
NCT0017262734	NCT00172627_34_T2	GENE	27	27	GC
NCT0017262735	NCT00172627_35_T0	GENE	16	16	IL-6
NCT0017262735	NCT00172627_35_T1	GENE	14	14	COX-2
NCT0017262735	NCT00172627_35_T2	GENE	9	9	GC
NCT0017262737	NCT00172627_37_T0	GENE	0	0	COX-2
NCT0017262737	NCT00172627_37_T1	GENE	4	4	PGs
NCT0017262738	NCT00172627_38_T0	CELL	5	5	cells
NCT0017262738	NCT00172627_38_T1	GENE	13	13	receptor
NCT0017262738	NCT00172627_38_T2	GENE	14	14	1.4
NCT0017262738	NCT00172627_38_T3	GENE	25	25	IL-6
NCT0017262738	NCT00172627_38_T4	GENE	23	23	COX-2
NCT0017262738	NCT00172627_38_T5	GENE	12	12	EP
NCT0017262738	NCT00172627_38_T6	GENE	4	4	GC
NCT0017262740	NCT00172627_40_T0	CELL	11	11	cells
NCT0017262740	NCT00172627_40_T1	ORGAN	18	18	xenograft
NCT0017262740	NCT00172627_40_T2	GENE	6	6	COX-2
NCT0017262740	NCT00172627_40_T3	GENE	10	10	GC
NCT0017262741	NCT00172627_41_T0	COMPOUND	4	4	celecoxib
NCT0017262741	NCT00172627_41_T1	PHENOTYPE	12	12	tumor
NCT0017262741	NCT00172627_41_T2	PHENOTYPE	13	13	blocks
NCT0017262741	NCT00172627_41_T3	GENE	20	20	IL-6
NCT0017262741	NCT00172627_41_T4	GENE	1	1	COX-2
NCT0017262742	NCT00172627_42_T0	GENE	16	16	IL-6
NCT0017262742	NCT00172627_42_T1	GENE	11	11	COX-2
NCT0017262742	NCT00172627_42_T2	GENE	18	18	GC
NCT0017262743	NCT00172627_43_T0	GENE	14	14	COX-2
NCT0017262743	NCT00172627_43_T1	GENE	20	20	GC
NCT001726401	NCT00172640_1_T0	GENE	3	3	has
NCT001726403	NCT00172640_3_T0	PHENOTYPE	15	15	cancers
NCT001726404	NCT00172640_4_T0	PHENOTYPE	17	17	tumor
NCT001726405	NCT00172640_5_T0	GENE	1	1	has
NCT001726406	NCT00172640_6_T0	PHENOTYPE	14	15	liver cancer
NCT001726538	NCT00172653_8_T0	GENE	1	1	axis
NCT0017265318	NCT00172653_18_T0	PHENOTYPE	43	43	numbness
NCT0017265318	NCT00172653_18_T1	PHENOTYPE	45	45	tingling
NCT0017265318	NCT00172653_18_T2	PHENOTYPE	20	20	symptoms
NCT0017265318	NCT00172653_18_T3	PHENOTYPE	56	56	symptoms
NCT0017265318	NCT00172653_18_T4	BIOLOGICAL_PROCESS	17	17	reproduction
NCT0017265318	NCT00172653_18_T5	PHENOTYPE	59	60	traumatic injury
NCT0017265318	NCT00172653_18_T6	PHENOTYPE	64	65	joint dislocation
NCT0017265318	NCT00172653_18_T7	ORGAN	48	49	upper extremity
NCT0017265319	NCT00172653_19_T0	GENE	29	29	al
NCT0017265319	NCT00172653_19_T1	GENE	28	28	et
NCT0017265320	NCT00172653_20_T0	ORGAN	9	9	hands
NCT0017265321	NCT00172653_21_T0	PHENOTYPE	7	7	fibromyalgia
NCT0017265321	NCT00172653_21_T1	GENE	18	18	al
NCT0017265321	NCT00172653_21_T2	GENE	17	17	et
NCT0017265323	NCT00172653_23_T0	GENE	27	27	al
NCT0017265323	NCT00172653_23_T1	GENE	26	26	et
NCT0017265324	NCT00172653_24_T0	ORGAN	19	20	shoulder joint
NCT0017265325	NCT00172653_25_T0	PHENOTYPE	7	7	fibromyalgia
NCT0017265325	NCT00172653_25_T1	GENE	19	19	al
NCT0017265325	NCT00172653_25_T2	GENE	18	18	et
NCT0017265328	NCT00172653_28_T0	ORGAN	2	2	scapula
NCT0017265329	NCT00172653_29_T0	GENE	13	13	LSST
NCT0017265334	NCT00172653_34_T0	PHENOTYPE	17	17	disorders
NCT0017265334	NCT00172653_34_T1	PHENOTYPE	10	10	perceptions
NCT0017265336	NCT00172653_36_T0	PHENOTYPE	24	24	symptoms
NCT0017265336	NCT00172653_36_T1	PHENOTYPE	29	29	disorders
NCT0017265338	NCT00172653_38_T0	PHENOTYPE	16	16	symptoms
NCT0017265338	NCT00172653_38_T1	PHENOTYPE	21	22	musculoskeletal disorder
NCT0017265338	NCT00172653_38_T2	ORGAN	25	26	upper extremity
NCT0017265339	NCT00172653_39_T0	GENE	2	2	al
NCT0017265339	NCT00172653_39_T1	GENE	1	1	et
NCT0017265346	NCT00172653_46_T0	GENE	18	18	3-1
NCT0017265346	NCT00172653_46_T1	GENE	31	31	al
NCT0017265346	NCT00172653_46_T2	GENE	2	2	has
NCT0017265346	NCT00172653_46_T3	GENE	11	11	has
NCT0017265346	NCT00172653_46_T4	GENE	30	30	et
NCT0017265347	NCT00172653_47_T0	GENE	18	18	cm
NCT0017265347	NCT00172653_47_T1	GENE	27	27	cm
NCT0017265347	NCT00172653_47_T2	PHENOTYPE	22	24	quality of life
NCT0017265347	NCT00172653_47_T3	PHENOTYPE	0	2	Quality of life
NCT0017265347	NCT00172653_47_T4	PHENOTYPE	3	5	Quality of life
NCT0017265348	NCT00172653_48_T0	GENE	9	9	VT
NCT0017265349	NCT00172653_49_T0	PHENOTYPE	47	47	impedance
NCT0017265349	NCT00172653_49_T1	GENE	25	25	150
NCT0017265349	NCT00172653_49_T2	COMPOUND	68	68	3
NCT0017265349	NCT00172653_49_T3	COMPOUND	6	6	chloride
NCT0017265349	NCT00172653_49_T4	GENE	39	39	has
NCT0017265351	NCT00172653_51_T0	GENE	6	6	reduced
NCT0017265352	NCT00172653_52_T0	GENE	1	1	envelope
NCT0017265356	NCT00172653_56_T0	PHENOTYPE	17	17	separation
NCT0017265358	NCT00172653_58_T0	PHENOTYPE	17	17	contraction
NCT0017265359	NCT00172653_59_T0	ORGAN	12	12	sternum
NCT0017265360	NCT00172653_60_T0	PHENOTYPE	8	8	distal
NCT0017265360	NCT00172653_60_T1	ORGAN	9	9	humerus
NCT0017265369	NCT00172653_69_T0	PHENOTYPE	13	13	fatigue
NCT0017265373	NCT00172653_73_T0	GENE	30	30	kappa
NCT0017265374	NCT00172653_74_T0	GENE	28	28	kappa
NCT0017265375	NCT00172653_75_T0	GENE	13	13	rho
NCT0017265376	NCT00172653_76_T0	COMPOUND	17	17	2
NCT0017265376	NCT00172653_76_T1	GENE	13	13	LSST
NCT0017265379	NCT00172653_79_T0	GENE	9	9	axis
NCT0017265380	NCT00172653_80_T0	GENE	22	22	humeral
NCT0017265380	NCT00172653_80_T1	GENE	29	29	humeral
NCT0017265380	NCT00172653_80_T2	GENE	32	32	humeral
NCT0017265381	NCT00172653_81_T0	ORGAN	14	14	trapezius
NCT0017265381	NCT00172653_81_T1	ORGAN	16	16	trapezius
NCT0017265383	NCT00172653_83_T0	GENE	2	2	ROM
NCT0017265383	NCT00172653_83_T1	GENE	7	7	ROM
NCT0017265383	NCT00172653_83_T2	PHENOTYPE	29	29	abduction
NCT0017265383	NCT00172653_83_T3	ORGAN	5	6	shoulder joint
NCT0017265386	NCT00172653_86_T0	PHENOTYPE	3	3	symptoms
NCT0017265386	NCT00172653_86_T1	BIOLOGICAL_PROCESS	0	0	Reproduction
NCT0017265387	NCT00172653_87_T0	PHENOTYPE	2	2	tingling
NCT0017265387	NCT00172653_87_T1	PHENOTYPE	0	0	Numbness
NCT0017265387	NCT00172653_87_T2	ORGAN	5	6	upper extremity
NCT0017265388	NCT00172653_88_T0	PHENOTYPE	5	5	symptoms
NCT0017265388	NCT00172653_88_T1	PHENOTYPE	8	9	traumatic injury
NCT0017265388	NCT00172653_88_T2	PHENOTYPE	14	15	joint dislocation
NCT001726662	NCT00172666_2_T0	GENE	5	5	FasL
NCT001726662	NCT00172666_2_T1	GENE	6	6	LIGHT
NCT001726662	NCT00172666_2_T2	GENE	12	12	TNF
NCT001726662	NCT00172666_2_T3	GENE	8	8	TL1A
NCT001726662	NCT00172666_2_T4	GENE	3	4	Fas ligand
NCT001726666	NCT00172666_6_T0	PHENOTYPE	15	15	autoimmune
NCT0017266611	NCT00172666_11_T0	PHENOTYPE	2	3	multiple abnormalities
NCT0017266611	NCT00172666_11_T1	CELL	10	11	T cells
NCT0017266614	NCT00172666_14_T0	PHENOTYPE	1	1	inflammation
NCT0017266614	NCT00172666_14_T1	CELL	7	8	T cells
NCT0017266617	NCT00172666_17_T0	TISSUE	11	11	spleen
NCT0017266617	NCT00172666_17_T1	GENE	1	1	mRNA
NCT0017266617	NCT00172666_17_T2	TISSUE	8	9	lymph nodes
NCT0017266617	NCT00172666_17_T3	CELL	14	15	T cells
NCT0017266621	NCT00172666_21_T0	GENE	9	9	TR2
NCT0017266621	NCT00172666_21_T1	CELL	11	12	T cells
NCT0017266623	NCT00172666_23_T0	CELL	5	5	lymphocyte
NCT0017266623	NCT00172666_23_T1	BIOLOGICAL_PROCESS	1	2	leukocyte aggregation
NCT0017266623	NCT00172666_23_T2	GENE	11	12	soluble form
NCT0017266625	NCT00172666_25_T0	CELL	14	15	T cells
NCT0017266628	NCT00172666_28_T0	GENE	22	22	LIGHT
NCT0017266628	NCT00172666_28_T1	CELL	11	12	T cells
NCT0017266632	NCT00172666_32_T0	PHENOTYPE	31	31	autoimmunity
NCT0017266632	NCT00172666_32_T1	BIOLOGICAL_PROCESS	28	29	lymphocyte activation
NCT0017266633	NCT00172666_33_T0	PHENOTYPE	15	15	autoimmune
NCT0017266639	NCT00172666_39_T0	ORGAN	10	10	serum
NCT001726791	NCT00172679_1_T0	PHENOTYPE	12	12	falls
NCT001726791	NCT00172679_1_T1	GENE	24	24	Chi
NCT001726791	NCT00172679_1_T2	GENE	23	23	Tai
NCT001726791	NCT00172679_1_T3	PHENOTYPE	25	25	practices
NCT001726792	NCT00172679_2_T0	GENE	7	7	Chi
NCT001726792	NCT00172679_2_T1	GENE	6	6	Tai
NCT001726792	NCT00172679_2_T2	BIOLOGICAL_PROCESS	2	3	immune response
NCT001726793	NCT00172679_3_T0	GENE	12	12	Chi
NCT001726793	NCT00172679_3_T1	GENE	11	11	Tai
NCT001726796	NCT00172679_6_T0	GENE	12	12	Chi
NCT001726796	NCT00172679_6_T1	GENE	11	11	Tai
NCT001726796	NCT00172679_6_T2	COMPOUND	4	4	oxygen
NCT001726797	NCT00172679_7_T0	GENE	1	1	Chi
NCT001726797	NCT00172679_7_T1	PHENOTYPE	18	18	arthritis
NCT001726797	NCT00172679_7_T2	GENE	2	2	has
NCT001726797	NCT00172679_7_T3	GENE	0	0	Tai
NCT001726797	NCT00172679_7_T4	PHENOTYPE	14	14	hypertension
NCT001726797	NCT00172679_7_T5	PHENOTYPE	12	13	heart failure
NCT001726797	NCT00172679_7_T6	PHENOTYPE	20	21	multiple sclerosis
NCT001726797	NCT00172679_7_T7	PHENOTYPE	15	17	acute myocardial infarction
NCT001726798	NCT00172679_8_T0	PHENOTYPE	12	12	falls
NCT001726798	NCT00172679_8_T1	GENE	24	24	Chi
NCT001726798	NCT00172679_8_T2	GENE	23	23	Tai
NCT001726798	NCT00172679_8_T3	PHENOTYPE	25	25	practices
NCT001726799	NCT00172679_9_T0	GENE	7	7	Chi
NCT001726799	NCT00172679_9_T1	GENE	6	6	Tai
NCT001726799	NCT00172679_9_T2	BIOLOGICAL_PROCESS	2	3	immune response
NCT0017267910	NCT00172679_10_T0	GENE	23	23	Chi
NCT0017267910	NCT00172679_10_T1	GENE	29	29	Chi
NCT0017267910	NCT00172679_10_T2	GENE	22	22	Tai
NCT0017267910	NCT00172679_10_T3	GENE	28	28	Tai
NCT0017267910	NCT00172679_10_T4	CELL	15	16	T cells
NCT0017267912	NCT00172679_12_T0	GENE	13	13	Chi
NCT0017267912	NCT00172679_12_T1	GENE	12	12	Tai
NCT001726921	NCT00172692_1_T0	PHENOTYPE	4	4	strokes
NCT001726921	NCT00172692_1_T1	ORGAN	12	12	teeth
NCT001726921	NCT00172692_1_T2	BIOLOGICAL_PROCESS	3	3	chewing
NCT001726922	NCT00172692_2_T0	ORGAN	20	20	teeth
NCT001726923	NCT00172692_3_T0	GENE	8	8	reduced
NCT001726923	NCT00172692_3_T1	BIOLOGICAL_PROCESS	3	3	chewing
NCT001726923	NCT00172692_3_T2	BIOLOGICAL_PROCESS	12	12	chewing
NCT001726924	NCT00172692_4_T0	BIOLOGICAL_PROCESS	6	6	chewing
NCT001726924	NCT00172692_4_T1	BIOLOGICAL_PROCESS	11	11	chewing
NCT001726925	NCT00172692_5_T0	BIOLOGICAL_PROCESS	11	11	chewing
NCT001726925	NCT00172692_5_T1	BIOLOGICAL_PROCESS	13	13	chewing
NCT001726925	NCT00172692_5_T2	BIOLOGICAL_PROCESS	17	17	chewing
NCT001726925	NCT00172692_5_T3	ORGAN	12	12	gum
NCT001726927	NCT00172692_7_T0	ORGAN	0	0	Jaw
NCT001726927	NCT00172692_7_T1	BIOLOGICAL_PROCESS	11	11	chewing
NCT001726927	NCT00172692_7_T2	BIOLOGICAL_PROCESS	13	13	chewing
NCT001726927	NCT00172692_7_T3	ORGAN	12	12	gum
NCT001726928	NCT00172692_8_T0	GENE	3	3	HA
NCT001726928	NCT00172692_8_T1	BIOLOGICAL_PROCESS	11	11	chewing
NCT001726928	NCT00172692_8_T2	BIOLOGICAL_PROCESS	20	20	chewing
NCT001726928	NCT00172692_8_T3	ORGAN	7	7	gum
NCT001726929	NCT00172692_9_T0	ORGAN	15	15	jaw
NCT001726929	NCT00172692_9_T1	PHENOTYPE	27	27	regression
NCT001726929	NCT00172692_9_T2	ORGAN	7	7	teeth
NCT001726929	NCT00172692_9_T3	BIOLOGICAL_PROCESS	8	8	chewing
NCT001726929	NCT00172692_9_T4	BIOLOGICAL_PROCESS	10	10	chewing
NCT001726929	NCT00172692_9_T5	BIOLOGICAL_PROCESS	23	23	chewing
NCT0017269210	NCT00172692_10_T0	BIOLOGICAL_PROCESS	8	8	chewing
NCT0017269212	NCT00172692_12_T0	GENE	0	0	HA
NCT0017269212	NCT00172692_12_T1	ORGAN	7	7	teeth
NCT0017269212	NCT00172692_12_T2	BIOLOGICAL_PROCESS	2	2	chewing
NCT0017269212	NCT00172692_12_T3	ORGAN	3	3	gum
NCT0017269213	NCT00172692_13_T0	GENE	3	3	HA
NCT0017269213	NCT00172692_13_T1	BIOLOGICAL_PROCESS	11	11	chewing
NCT0017269213	NCT00172692_13_T2	BIOLOGICAL_PROCESS	20	20	chewing
NCT0017269213	NCT00172692_13_T3	ORGAN	7	7	gum
NCT001727185	NCT00172718_5_T0	PHENOTYPE	32	32	experiences
NCT001727311	NCT00172731_1_T0	GENE	9	9	ICF
NCT001727312	NCT00172731_2_T0	PHENOTYPE	12	12	experiences
NCT001727314	NCT00172731_4_T0	PHENOTYPE	15	15	schizophrenia
NCT0017273112	NCT00172731_12_T0	PHENOTYPE	18	18	reward
NCT0017273112	NCT00172731_12_T1	GENE	13	13	got
NCT001727442	NCT00172744_2_T0	ORGAN	13	13	premolars
NCT001727442	NCT00172744_2_T1	ORGAN	8	9	periodontal ligament
NCT001727442	NCT00172744_2_T2	CELL	0	2	Mesenchymal stem cells
NCT001727572	NCT00172757_2_T0	PHENOTYPE	14	14	polyps
NCT001727572	NCT00172757_2_T1	PHENOTYPE	11	12	colorectal cancer
NCT001727575	NCT00172757_5_T0	GENE	12	12	hMLH1
NCT001727576	NCT00172757_6_T0	GENE	10	10	E-cadherin
NCT001727578	NCT00172757_8_T0	GENE	21	21	E-cadherin
NCT001727578	NCT00172757_8_T1	GENE	3	3	has
NCT001727578	NCT00172757_8_T2	PHENOTYPE	8	9	colorectal cancer
NCT001727578	NCT00172757_8_T3	PHENOTYPE	24	25	colorectal cancer
NCT001727579	NCT00172757_9_T0	GENE	17	17	TS
NCT0017275711	NCT00172757_11_T0	GENE	28	28	TS
NCT0017275711	NCT00172757_11_T1	PHENOTYPE	34	35	colorectal cancers
NCT0017275712	NCT00172757_12_T0	PHENOTYPE	14	14	tumorigenesis
NCT0017275712	NCT00172757_12_T1	PHENOTYPE	12	13	colorectal cancer
NCT0017275712	NCT00172757_12_T2	PHENOTYPE	23	24	colorectal cancer
NCT0017275712	NCT00172757_12_T3	PHENOTYPE	40	41	colorectal cancer
NCT0017275717	NCT00172757_17_T0	PHENOTYPE	14	14	polyps
NCT0017275717	NCT00172757_17_T1	PHENOTYPE	11	12	colorectal cancer
NCT0017275721	NCT00172757_21_T0	GENE	12	12	hMLH1
NCT0017275722	NCT00172757_22_T0	GENE	10	10	E-cadherin
NCT0017275723	NCT00172757_23_T0	GENE	6	6	E-cadherin
NCT0017275723	NCT00172757_23_T1	GENE	1	1	has
NCT0017275723	NCT00172757_23_T2	CELL	15	16	cellular structure
NCT0017275726	NCT00172757_26_T0	GENE	21	21	E-cadherin
NCT0017275726	NCT00172757_26_T1	GENE	3	3	has
NCT0017275726	NCT00172757_26_T2	PHENOTYPE	8	9	colorectal cancer
NCT0017275726	NCT00172757_26_T3	PHENOTYPE	24	25	colorectal cancer
NCT0017275727	NCT00172757_27_T0	GENE	17	17	TS
NCT0017275729	NCT00172757_29_T0	GENE	9	9	TS
NCT0017275731	NCT00172757_31_T0	GENE	28	28	TS
NCT0017275731	NCT00172757_31_T1	PHENOTYPE	34	35	colorectal cancers
NCT0017275732	NCT00172757_32_T0	PHENOTYPE	14	14	tumorigenesis
NCT0017275732	NCT00172757_32_T1	PHENOTYPE	12	13	colorectal cancer
NCT0017275732	NCT00172757_32_T2	PHENOTYPE	23	24	colorectal cancer
NCT0017275732	NCT00172757_32_T3	PHENOTYPE	40	41	colorectal cancer
NCT001727701	NCT00172770_1_T0	PHENOTYPE	7	7	maladaptation
NCT001727702	NCT00172770_2_T0	PHENOTYPE	5	5	schizophrenia
NCT001727706	NCT00172770_6_T0	PHENOTYPE	10	10	schizophrenia
NCT0017277010	NCT00172770_10_T0	GENE	11	11	25.2
NCT0017277010	NCT00172770_10_T1	PHENOTYPE	9	9	psychosis
NCT0017277011	NCT00172770_11_T0	PHENOTYPE	16	16	schizophrenia
NCT0017277012	NCT00172770_12_T0	PHENOTYPE	18	18	schizophrenia
NCT001727836	NCT00172783_6_T0	GENE	12	12	1.2
NCT001727836	NCT00172783_6_T1	GENE	13	13	2.3
NCT001727838	NCT00172783_8_T0	GENE	15	15	3.4
NCT001727838	NCT00172783_8_T1	GENE	16	16	4.5
NCT0017278317	NCT00172783_17_T0	PHENOTYPE	3	3	indurations
NCT0017278318	NCT00172783_18_T0	PHENOTYPE	11	11	tuberculosis
NCT0017278318	NCT00172783_18_T1	GENE	33	33	had
NCT0017278318	NCT00172783_18_T2	GENE	40	40	TST
NCT0017278318	NCT00172783_18_T3	GENE	14	14	ml
NCT0017278318	NCT00172783_18_T4	CELL	6	7	T cells
NCT0017278319	NCT00172783_19_T0	PHENOTYPE	12	12	strain
NCT0017278319	NCT00172783_19_T1	GENE	3	3	esat-6
NCT0017278319	NCT00172783_19_T2	GENE	13	13	AN5
NCT0017278319	NCT00172783_19_T3	GENE	15	15	PCR
NCT0017278320	NCT00172783_20_T0	PHENOTYPE	3	3	transformed
NCT0017278321	NCT00172783_21_T0	PHENOTYPE	5	5	transformed
NCT0017278325	NCT00172783_25_T0	GENE	16	16	TST
NCT0017278326	NCT00172783_26_T0	CELL	8	8	cells
NCT0017278326	NCT00172783_26_T1	PHENOTYPE	15	15	spots
NCT0017278330	NCT00172783_30_T0	PHENOTYPE	0	0	Closed
NCT0017278330	NCT00172783_30_T1	GENE	10	10	CXR
NCT0017278333	NCT00172783_33_T0	PHENOTYPE	6	7	chronic cough
NCT0017278333	NCT00172783_33_T1	PHENOTYPE	11	12	febrile illness
NCT0017278334	NCT00172783_34_T0	PHENOTYPE	6	7	lung disease
NCT0017278336	NCT00172783_36_T0	GENE	18	18	10.0
NCT001727963	NCT00172796_3_T0	GENE	11	11	islet
NCT001727963	NCT00172796_3_T1	PHENOTYPE	8	9	insulin sensitivity
NCT001727966	NCT00172796_6_T0	GENE	11	11	islet
NCT001727966	NCT00172796_6_T1	PHENOTYPE	8	9	insulin sensitivity
NCT001728095	NCT00172809_5_T0	PHENOTYPE	22	23	hepatitis C
NCT001728095	NCT00172809_5_T1	PHENOTYPE	21	22	chronic hepatitis
NCT001728095	NCT00172809_5_T2	PHENOTYPE	25	28	end stage renal disease
NCT001728097	NCT00172809_7_T0	PHENOTYPE	11	11	ESRD
NCT001728097	NCT00172809_7_T1	COMPOUND	6	6	HCV
NCT001728099	NCT00172809_9_T0	PHENOTYPE	15	15	ESRD
NCT001728099	NCT00172809_9_T1	PHENOTYPE	9	9	affects
NCT001728099	NCT00172809_9_T2	PHENOTYPE	5	6	chronic hepatitis
NCT001728099	NCT00172809_9_T3	PHENOTYPE	6	7	hepatitis C
NCT0017280910	NCT00172809_10_T0	ORGAN	11	11	liver
NCT0017280910	NCT00172809_10_T1	COMPOUND	5	5	HCV
NCT0017280910	NCT00172809_10_T2	COMPOUND	19	19	HCV
NCT0017280912	NCT00172809_12_T0	COMPOUND	3	3	ribavirin
NCT0017280912	NCT00172809_12_T1	COMPOUND	9	9	HCV
NCT0017280912	NCT00172809_12_T2	GENE	1	1	interferon
NCT0017280914	NCT00172809_14_T0	GENE	27	27	interferon-alpha
NCT0017280914	NCT00172809_14_T1	COMPOUND	22	22	HCV
NCT0017280914	NCT00172809_14_T2	PHENOTYPE	10	10	SVR
NCT0017280915	NCT00172809_15_T0	GENE	22	22	interferon-alpha
NCT0017280915	NCT00172809_15_T1	GENE	38	38	interferon
NCT0017280915	NCT00172809_15_T2	PHENOTYPE	18	18	SVR
NCT0017280915	NCT00172809_15_T3	COMPOUND	12	12	HCV
NCT0017280916	NCT00172809_16_T0	GENE	16	16	PEG
NCT0017280916	NCT00172809_16_T1	GENE	8	8	interferon
NCT0017280916	NCT00172809_16_T2	GENE	21	21	interferon
NCT0017280916	NCT00172809_16_T3	COMPOUND	14	15	polyethylene glycol
NCT0017280917	NCT00172809_17_T0	COMPOUND	22	22	ribavirin
NCT0017280917	NCT00172809_17_T1	COMPOUND	13	13	HCV
NCT0017280917	NCT00172809_17_T2	GENE	9	9	has
NCT0017280917	NCT00172809_17_T3	GENE	7	7	interferon
NCT0017280918	NCT00172809_18_T0	PHENOTYPE	6	6	ESRD
NCT0017280920	NCT00172809_20_T0	GENE	8	8	interferon
NCT0017280920	NCT00172809_20_T1	PHENOTYPE	14	14	SVR
NCT0017280921	NCT00172809_21_T0	PHENOTYPE	22	23	hepatitis C
NCT0017280921	NCT00172809_21_T1	PHENOTYPE	21	22	chronic hepatitis
NCT0017280921	NCT00172809_21_T2	PHENOTYPE	25	28	end stage renal disease
NCT001728354	NCT00172835_4_T0	COMPOUND	3	3	polysaccharides
NCT001728485	NCT00172848_5_T0	GENE	12	12	had
NCT001728611	NCT00172861_1_T0	PHENOTYPE	11	11	cancers
NCT001728611	NCT00172861_1_T1	GENE	13	13	GC
NCT001728611	NCT00172861_1_T2	PHENOTYPE	4	5	chronic inflammation
NCT001728612	NCT00172861_2_T0	PHENOTYPE	19	19	cancers
NCT001728612	NCT00172861_2_T1	GENE	1	1	COX-2
NCT001728613	NCT00172861_3_T0	PHENOTYPE	8	8	carcinogenesis
NCT001728613	NCT00172861_3_T1	GENE	1	1	COX-2
NCT001728615	NCT00172861_5_T0	PHENOTYPE	5	5	carcinogenesis
NCT001728615	NCT00172861_5_T1	PHENOTYPE	9	9	strategies
NCT001728615	NCT00172861_5_T2	GENE	3	3	COX-2
NCT001728616	NCT00172861_6_T0	CELL	8	8	cells
NCT001728616	NCT00172861_6_T1	CELL	29	29	cells
NCT001728616	NCT00172861_6_T2	PHENOTYPE	3	3	LCM
NCT001728617	NCT00172861_7_T0	GENE	13	13	COX-2
NCT001728617	NCT00172861_7_T1	GENE	20	20	GC
NCT001728619	NCT00172861_9_T0	PHENOTYPE	11	11	pathology
NCT001728619	NCT00172861_9_T1	GENE	22	22	COX-2
NCT001728619	NCT00172861_9_T2	GENE	8	8	GC
NCT0017286112	NCT00172861_12_T0	CELL	13	13	cells
NCT0017286112	NCT00172861_12_T1	PHENOTYPE	15	15	LCM
NCT0017286112	NCT00172861_12_T2	GENE	8	8	GC
NCT0017286113	NCT00172861_13_T0	PHENOTYPE	7	7	LCM
NCT0017286114	NCT00172861_14_T0	TISSUE	24	24	tissues
NCT0017286114	NCT00172861_14_T1	PHENOTYPE	21	21	tumor
NCT0017286115	NCT00172861_15_T0	GENE	21	21	COX-2
NCT0017286117	NCT00172861_17_T0	GENE	12	12	COX-2
NCT0017286117	NCT00172861_17_T1	BIOLOGICAL_PROCESS	13	14	gene expression
NCT0017286119	NCT00172861_19_T0	PHENOTYPE	11	11	cancers
NCT0017286119	NCT00172861_19_T1	GENE	13	13	GC
NCT0017286119	NCT00172861_19_T2	PHENOTYPE	4	5	chronic inflammation
NCT0017286120	NCT00172861_20_T0	PHENOTYPE	19	19	cancers
NCT0017286120	NCT00172861_20_T1	GENE	1	1	COX-2
NCT0017286121	NCT00172861_21_T0	PHENOTYPE	8	8	carcinogenesis
NCT0017286121	NCT00172861_21_T1	GENE	1	1	COX-2
NCT0017286123	NCT00172861_23_T0	PHENOTYPE	5	5	carcinogenesis
NCT0017286123	NCT00172861_23_T1	PHENOTYPE	9	9	strategies
NCT0017286123	NCT00172861_23_T2	GENE	3	3	COX-2
NCT0017286124	NCT00172861_24_T0	CELL	8	8	cells
NCT0017286124	NCT00172861_24_T1	CELL	29	29	cells
NCT0017286124	NCT00172861_24_T2	PHENOTYPE	3	3	LCM
NCT0017286125	NCT00172861_25_T0	GENE	13	13	COX-2
NCT0017286125	NCT00172861_25_T1	GENE	20	20	GC
NCT0017286127	NCT00172861_27_T0	PHENOTYPE	11	11	pathology
NCT0017286127	NCT00172861_27_T1	GENE	22	22	COX-2
NCT0017286127	NCT00172861_27_T2	GENE	8	8	GC
NCT0017286130	NCT00172861_30_T0	CELL	13	13	cells
NCT0017286130	NCT00172861_30_T1	PHENOTYPE	15	15	LCM
NCT0017286130	NCT00172861_30_T2	GENE	8	8	GC
NCT0017286131	NCT00172861_31_T0	PHENOTYPE	7	7	LCM
NCT0017286132	NCT00172861_32_T0	TISSUE	24	24	tissues
NCT0017286132	NCT00172861_32_T1	PHENOTYPE	21	21	tumor
NCT0017286133	NCT00172861_33_T0	GENE	21	21	COX-2
NCT0017286135	NCT00172861_35_T0	GENE	12	12	COX-2
NCT0017286135	NCT00172861_35_T1	BIOLOGICAL_PROCESS	13	14	gene expression
NCT001728742	NCT00172874_2_T0	PHENOTYPE	10	10	SCID
NCT001728742	NCT00172874_2_T1	PHENOTYPE	5	6	eating disorder
NCT001728742	NCT00172874_2_T2	PHENOTYPE	15	16	eating disorder
NCT001728742	NCT00172874_2_T3	PHENOTYPE	18	19	eating disorder
NCT001728743	NCT00172874_3_T0	PHENOTYPE	4	5	eating disorder
NCT001728743	NCT00172874_3_T1	PHENOTYPE	19	20	eating disorders
NCT001728744	NCT00172874_4_T0	BIOLOGICAL_PROCESS	12	12	eating
NCT001728871	NCT00172887_1_T0	GENE	15	15	Act
NCT001728871	NCT00172887_1_T1	GENE	12	12	Disabled
NCT001728872	NCT00172887_2_T0	PHENOTYPE	10	10	symptoms
NCT001728872	NCT00172887_2_T1	PHENOTYPE	4	5	psychiatric illness
NCT001729136	NCT00172913_6_T0	GENE	15	15	has
NCT0017291310	NCT00172913_10_T0	ORGAN	42	42	corneas
NCT0017291314	NCT00172913_14_T0	ORGAN	1	1	eyes
NCT0017291315	NCT00172913_15_T0	PHENOTYPE	14	15	contrast sensitivity
NCT0017291320	NCT00172913_20_T0	PHENOTYPE	11	12	refractive error
NCT0017291320	NCT00172913_20_T1	PHENOTYPE	17	18	Contrast Sensitivity
NCT0017291321	NCT00172913_21_T0	ORGAN	3	3	eyes
NCT0017291321	NCT00172913_21_T1	PHENOTYPE	9	10	refractive error
NCT0017291323	NCT00172913_23_T0	PHENOTYPE	18	19	refractive errors
NCT001729261	NCT00172926_1_T0	PHENOTYPE	18	18	symptoms
NCT001729261	NCT00172926_1_T1	PHENOTYPE	23	24	laboratory results
NCT001729263	NCT00172926_3_T0	PHENOTYPE	16	16	severity
NCT001729264	NCT00172926_4_T0	PHENOTYPE	19	19	diseases
NCT001729269	NCT00172926_9_T0	PHENOTYPE	10	10	symptoms
NCT001729269	NCT00172926_9_T1	PHENOTYPE	13	14	laboratory results
NCT0017292611	NCT00172926_11_T0	PHENOTYPE	22	22	diseases
NCT001729395	NCT00172939_5_T0	PHENOTYPE	2	2	maturation
NCT001729395	NCT00172939_5_T1	CELL	17	17	keratinocytes
NCT001729395	NCT00172939_5_T2	CELL	9	9	melanosomes
NCT001729396	NCT00172939_6_T0	GENE	13	13	0.5
NCT001729396	NCT00172939_6_T1	PHENOTYPE	8	9	temperature elevation
NCT001729399	NCT00172939_9_T0	GENE	3	3	has
NCT001729399	NCT00172939_9_T1	COMPOUND	1	1	He-Ne
NCT0017293911	NCT00172939_11_T0	COMPOUND	5	5	He-Ne
NCT0017293914	NCT00172939_14_T0	BIOLOGICAL_PROCESS	9	9	regeneration
NCT0017293914	NCT00172939_14_T1	PHENOTYPE	27	27	vitiligo
NCT0017293914	NCT00172939_14_T2	GENE	24	24	IgG
NCT0017293914	NCT00172939_14_T3	COMPOUND	15	15	He-Ne
NCT0017293915	NCT00172939_15_T0	BIOLOGICAL_PROCESS	10	10	regeneration
NCT0017293915	NCT00172939_15_T1	PHENOTYPE	28	28	vitiligo
NCT0017293915	NCT00172939_15_T2	GENE	25	25	IgG
NCT0017293915	NCT00172939_15_T3	COMPOUND	16	16	He-Ne
NCT0017293917	NCT00172939_17_T0	PHENOTYPE	15	15	vitiligo
NCT0017293917	NCT00172939_17_T1	COMPOUND	10	10	He-Ne
NCT001729520	NCT00172952_0_T0	GENE	7	7	MMP
NCT001729520	NCT00172952_0_T1	GENE	5	5	ECM
NCT001729520	NCT00172952_0_T2	PHENOTYPE	13	14	High Myopia
NCT001729524	NCT00172952_4_T0	PHENOTYPE	13	14	pathologic myopia
NCT001729525	NCT00172952_5_T0	PHENOTYPE	9	9	myopia
NCT001729525	NCT00172952_5_T1	PHENOTYPE	2	2	myopic
NCT001729526	NCT00172952_6_T0	PHENOTYPE	11	11	myopia
NCT001729526	NCT00172952_6_T1	PHENOTYPE	17	18	pathological myopia
NCT001729528	NCT00172952_8_T0	PHENOTYPE	19	19	pathology
NCT001729528	NCT00172952_8_T1	GENE	5	5	collagen
NCT001729528	NCT00172952_8_T2	PHENOTYPE	15	15	myopia
NCT001729528	NCT00172952_8_T3	PHENOTYPE	21	22	high myopia
NCT001729529	NCT00172952_9_T0	PHENOTYPE	16	16	affects
NCT0017295214	NCT00172952_14_T0	PHENOTYPE	3	3	myopia
NCT0017295214	NCT00172952_14_T1	PHENOTYPE	8	9	refractive error
NCT001730040	NCT00173004_0_T0	PHENOTYPE	3	3	Hypertension
NCT001730171	NCT00173017_1_T0	PHENOTYPE	9	9	acute
NCT001730171	NCT00173017_1_T1	PHENOTYPE	8	8	Severe
NCT001730172	NCT00173017_2_T0	PHENOTYPE	1	1	dizziness
NCT001730172	NCT00173017_2_T1	PHENOTYPE	2	2	headache
NCT001730172	NCT00173017_2_T2	GENE	4	6	short of breath
NCT001730432	NCT00173043_2_T0	PHENOTYPE	20	20	PCOS
NCT001730432	NCT00173043_2_T1	PHENOTYPE	18	18	anovulation
NCT001730432	NCT00173043_2_T2	PHENOTYPE	4	5	polycystic ovaries
NCT001730435	NCT00173043_5_T0	PHENOTYPE	2	2	PCOS
NCT001730435	NCT00173043_5_T1	GENE	23	23	has
NCT001730435	NCT00173043_5_T2	PHENOTYPE	4	4	overweight
NCT001730435	NCT00173043_5_T3	PHENOTYPE	6	7	central obesity
NCT001730435	NCT00173043_5_T4	PHENOTYPE	20	21	glucose intolerance
NCT001730435	NCT00173043_5_T5	PHENOTYPE	15	16	insulin levels
NCT001730435	NCT00173043_5_T6	PHENOTYPE	17	18	insulin resistance
NCT001730439	NCT00173043_9_T0	COMPOUND	10	10	progesterone
NCT001730439	NCT00173043_9_T1	COMPOUND	27	27	metformin
NCT0017304310	NCT00173043_10_T0	PHENOTYPE	16	16	PCOS
NCT0017304310	NCT00173043_10_T1	PHENOTYPE	14	14	adiposity
NCT0017304311	NCT00173043_11_T0	BIOLOGICAL_PROCESS	10	10	ovulation
NCT0017304313	NCT00173043_13_T0	PHENOTYPE	2	2	PCOS
NCT0017304313	NCT00173043_13_T1	GENE	23	23	has
NCT0017304313	NCT00173043_13_T2	PHENOTYPE	4	4	overweight
NCT0017304313	NCT00173043_13_T3	PHENOTYPE	6	7	central obesity
NCT0017304313	NCT00173043_13_T4	PHENOTYPE	20	21	glucose intolerance
NCT0017304313	NCT00173043_13_T5	PHENOTYPE	15	16	insulin levels
NCT0017304313	NCT00173043_13_T6	PHENOTYPE	17	18	insulin resistance
NCT0017304315	NCT00173043_15_T0	GENE	8	8	adiponectin
NCT0017304315	NCT00173043_15_T1	COMPOUND	3	3	androgen
NCT0017304315	NCT00173043_15_T2	ORGAN	7	7	plasma
NCT0017304316	NCT00173043_16_T0	GENE	7	7	adiponectin
NCT0017304316	NCT00173043_16_T1	COMPOUND	3	3	testosterone
NCT0017304316	NCT00173043_16_T2	GENE	5	5	reduced
NCT0017304316	NCT00173043_16_T3	ORGAN	6	6	plasma
NCT0017304318	NCT00173043_18_T0	PHENOTYPE	15	15	PCOS
NCT0017304318	NCT00173043_18_T1	PHENOTYPE	5	5	hyperandrogenism
NCT0017304319	NCT00173043_19_T0	PHENOTYPE	3	3	hirsutism
NCT0017304319	NCT00173043_19_T1	PHENOTYPE	4	4	alopecia
NCT0017304319	NCT00173043_19_T2	PHENOTYPE	5	5	acne
NCT0017304320	NCT00173043_20_T0	COMPOUND	17	17	androgen
NCT0017304320	NCT00173043_20_T1	PHENOTYPE	35	35	PCOS
NCT0017304320	NCT00173043_20_T2	PHENOTYPE	33	33	adiposity
NCT0017304320	NCT00173043_20_T3	COMPOUND	6	6	cyproterone
NCT0017304320	NCT00173043_20_T4	ORGAN	16	16	serum
NCT0017304320	NCT00173043_20_T5	GENE	1	1	hormone
NCT0017304321	NCT00173043_21_T0	GENE	14	14	CRP
NCT0017304321	NCT00173043_21_T1	GENE	27	27	CRP
NCT0017304321	NCT00173043_21_T2	GENE	37	37	CRP
NCT0017304321	NCT00173043_21_T3	PHENOTYPE	0	0	Obese
NCT0017304321	NCT00173043_21_T4	PHENOTYPE	10	10	concentrations
NCT0017304321	NCT00173043_21_T5	COMPOUND	23	23	metformin
NCT0017304321	NCT00173043_21_T6	PHENOTYPE	3	3	PCOS
NCT0017304321	NCT00173043_21_T7	PHENOTYPE	18	18	inflammation
NCT0017304321	NCT00173043_21_T8	ORGAN	9	9	serum
NCT0017304321	NCT00173043_21_T9	GENE	12	13	C-reactive protein
NCT0017304321	NCT00173043_21_T10	PHENOTYPE	20	22	cardiovascular risk factor
NCT0017304322	NCT00173043_22_T0	COMPOUND	11	11	acetate
NCT0017304322	NCT00173043_22_T1	GENE	15	15	adiponectin
NCT0017304322	NCT00173043_22_T2	COMPOUND	8	8	metformin
NCT0017304322	NCT00173043_22_T3	GENE	2	2	am
NCT0017304322	NCT00173043_22_T4	ORGAN	14	14	serum
NCT0017304326	NCT00173043_26_T0	PHENOTYPE	8	8	severity
NCT0017304326	NCT00173043_26_T1	GENE	2	2	adiponectin
NCT0017304326	NCT00173043_26_T2	GENE	17	17	adiponectin
NCT0017304326	NCT00173043_26_T3	PHENOTYPE	22	22	PCOS
NCT0017304326	NCT00173043_26_T4	PHENOTYPE	3	3	concentrations
NCT0017304326	NCT00173043_26_T5	ORGAN	1	1	serum
NCT0017304326	NCT00173043_26_T6	PHENOTYPE	10	11	insulin resistance
NCT0017304327	NCT00173043_27_T0	GENE	19	19	adiponectin
NCT0017304327	NCT00173043_27_T1	GENE	34	34	adiponectin
NCT0017304327	NCT00173043_27_T2	PHENOTYPE	21	21	PCOS
NCT0017304327	NCT00173043_27_T3	PHENOTYPE	40	40	PCOS
NCT0017304327	NCT00173043_27_T4	GENE	4	4	al
NCT0017304327	NCT00173043_27_T5	GENE	26	26	al
NCT0017304327	NCT00173043_27_T6	GENE	3	3	et
NCT0017304327	NCT00173043_27_T7	GENE	25	25	et
NCT0017304327	NCT00173043_27_T8	PHENOTYPE	7	8	insulin sensitivity
NCT0017304327	NCT00173043_27_T9	PHENOTYPE	37	38	insulin resistance
NCT0017304329	NCT00173043_29_T0	PHENOTYPE	16	16	imbalance
NCT0017304329	NCT00173043_29_T1	COMPOUND	11	11	metformin
NCT0017304330	NCT00173043_30_T0	PHENOTYPE	0	0	Hyperinsulinemia
NCT0017304330	NCT00173043_30_T1	COMPOUND	11	11	androgen
NCT0017304330	NCT00173043_30_T2	GENE	19	19	insulin
NCT001730561	NCT00173056_1_T0	CELL	2	2	fibroblast
NCT001730561	NCT00173056_1_T1	GENE	7	7	ECM
NCT001730561	NCT00173056_1_T2	CELL	5	6	extracellular matrix
NCT001730562	NCT00173056_2_T0	CELL	10	10	cells
NCT001730562	NCT00173056_2_T1	GENE	0	0	ECM
NCT001730562	NCT00173056_2_T2	COMPOUND	11	11	HPMC
NCT001730563	NCT00173056_3_T0	COMPOUND	11	11	HPMC
NCT001730566	NCT00173056_6_T0	PHENOTYPE	4	4	peritonitis
NCT001730566	NCT00173056_6_T1	COMPOUND	8	8	HPMC
NCT001730568	NCT00173056_8_T0	COMPOUND	1	1	glucose
NCT001730568	NCT00173056_8_T1	PHENOTYPE	10	10	chronic
NCT0017305610	NCT00173056_10_T0	PHENOTYPE	1	1	pathology
NCT0017305612	NCT00173056_12_T0	PHENOTYPE	3	3	chronic
NCT0017305617	NCT00173056_17_T0	COMPOUND	12	12	glucose
NCT0017305617	NCT00173056_17_T1	PHENOTYPE	14	14	peritonitis
NCT0017305618	NCT00173056_18_T0	PHENOTYPE	8	8	acute
NCT001730691	NCT00173069_1_T0	PHENOTYPE	17	17	pathology
NCT001730691	NCT00173069_1_T1	PHENOTYPE	21	21	pathology
NCT001730691	NCT00173069_1_T2	PHENOTYPE	6	6	schizophrenia
NCT001730691	NCT00173069_1_T3	PHENOTYPE	15	15	dysfunction
NCT001730691	NCT00173069_1_T4	PHENOTYPE	12	13	cognitive impairment
NCT001730692	NCT00173069_2_T0	PHENOTYPE	1	1	pathology
NCT001730692	NCT00173069_2_T1	PHENOTYPE	8	9	psychotic symptoms
NCT001730698	NCT00173069_8_T0	GENE	9	9	PPG
NCT0017306910	NCT00173069_10_T0	GENE	19	19	PPG
NCT0017306911	NCT00173069_11_T0	PHENOTYPE	23	23	symptoms
NCT0017306911	NCT00173069_11_T1	PHENOTYPE	25	25	impairment
NCT0017306914	NCT00173069_14_T0	PHENOTYPE	8	8	impairment
NCT0017306917	NCT00173069_17_T0	PHENOTYPE	5	5	schizophrenia
NCT0017306917	NCT00173069_17_T1	PHENOTYPE	38	38	schizophrenia
NCT0017306917	NCT00173069_17_T2	GENE	42	42	has
NCT0017306917	NCT00173069_17_T3	PHENOTYPE	0	0	Recruitment
NCT0017306920	NCT00173069_20_T0	PHENOTYPE	6	6	schizophrenia
NCT0017306921	NCT00173069_21_T0	PHENOTYPE	7	7	disorders
NCT0017306921	NCT00173069_21_T1	PHENOTYPE	8	8	schizophrenia
NCT0017306921	NCT00173069_21_T2	PHENOTYPE	23	23	experiences
NCT0017306921	NCT00173069_21_T3	PHENOTYPE	10	11	schizotypal disorder
NCT0017306922	NCT00173069_22_T0	PHENOTYPE	28	29	affective symptoms
NCT0017306922	NCT00173069_22_T1	PHENOTYPE	26	27	cognitive decline
NCT0017306923	NCT00173069_23_T0	PHENOTYPE	8	8	5-10
NCT0017306927	NCT00173069_27_T0	PHENOTYPE	13	13	schizophrenia
NCT0017306929	NCT00173069_29_T0	GENE	2	2	PI
NCT0017306929	NCT00173069_29_T1	GENE	3	3	had
NCT0017306929	NCT00173069_29_T2	GENE	18	18	had
NCT0017306929	NCT00173069_29_T3	PHENOTYPE	25	26	mental health
NCT0017306929	NCT00173069_29_T4	PHENOTYPE	14	15	Mental Health
NCT0017306931	NCT00173069_31_T0	PHENOTYPE	15	15	recruitment
NCT0017306934	NCT00173069_34_T0	PHENOTYPE	51	51	symptoms
NCT0017306934	NCT00173069_34_T1	PHENOTYPE	9	9	schizophrenia
NCT0017306934	NCT00173069_34_T2	PHENOTYPE	14	14	experiences
NCT0017306936	NCT00173069_36_T0	PHENOTYPE	45	45	thoughts
NCT0017306936	NCT00173069_36_T1	GENE	54	54	neurotic
NCT0017306936	NCT00173069_36_T2	PHENOTYPE	26	26	symptoms
NCT0017306936	NCT00173069_36_T3	PHENOTYPE	55	55	symptoms
NCT0017306936	NCT00173069_36_T4	PHENOTYPE	46	46	perceptions
NCT0017306936	NCT00173069_36_T5	PHENOTYPE	11	12	cognitive deficit
NCT0017306936	NCT00173069_36_T6	PHENOTYPE	37	38	cognitive deficit
NCT0017306936	NCT00173069_36_T7	PHENOTYPE	29	30	Latent Schizophrenia
NCT0017306936	NCT00173069_36_T8	PHENOTYPE	49	50	affective symptoms
NCT0017306940	NCT00173069_40_T0	PHENOTYPE	1	1	progressing
NCT0017306950	NCT00173069_50_T0	PHENOTYPE	19	19	schizophrenia
NCT0017306950	NCT00173069_50_T1	PHENOTYPE	13	14	attention deficits
NCT0017306955	NCT00173069_55_T0	PHENOTYPE	6	6	flush
NCT0017306955	NCT00173069_55_T1	PHENOTYPE	26	26	progression
NCT0017306955	NCT00173069_55_T2	PHENOTYPE	28	28	schizophrenia
NCT0017306959	NCT00173069_59_T0	GENE	12	12	lobe
NCT0017306959	NCT00173069_59_T1	ORGAN	9	9	hippocampus
NCT0017306961	NCT00173069_61_T0	COMPOUND	6	6	niacin
NCT0017306961	NCT00173069_61_T1	PHENOTYPE	15	15	schizophrenia
NCT0017306962	NCT00173069_62_T0	PHENOTYPE	15	15	understood
NCT0017306964	NCT00173069_64_T0	PHENOTYPE	1	1	Suppression
NCT0017306964	NCT00173069_64_T1	PHENOTYPE	3	3	suppression
NCT0017306964	NCT00173069_64_T2	GENE	0	0	P50
NCT0017306964	NCT00173069_64_T3	GENE	2	2	P50
NCT0017306964	NCT00173069_64_T4	PHENOTYPE	9	9	schizophrenia
NCT0017306965	NCT00173069_65_T0	PHENOTYPE	1	1	suppression
NCT0017306965	NCT00173069_65_T1	GENE	0	0	P50
NCT0017306966	NCT00173069_66_T0	GENE	5	5	P50
NCT0017306966	NCT00173069_66_T1	PHENOTYPE	32	32	schizophrenics
NCT0017306966	NCT00173069_66_T2	PHENOTYPE	2	2	suppression
NCT0017306966	NCT00173069_66_T3	GENE	10	10	has
NCT0017306966	NCT00173069_66_T4	PHENOTYPE	19	20	chronic schizophrenia
NCT0017306967	NCT00173069_67_T0	PHENOTYPE	2	2	suppression
NCT0017306967	NCT00173069_67_T1	GENE	1	1	P50
NCT0017306968	NCT00173069_68_T0	PHENOTYPE	6	6	impairment
NCT0017306968	NCT00173069_68_T1	PHENOTYPE	5	5	suppression
NCT0017306968	NCT00173069_68_T2	GENE	4	4	P50
NCT0017306968	NCT00173069_68_T3	PHENOTYPE	16	16	schizophrenia
NCT0017306968	NCT00173069_68_T4	PHENOTYPE	12	13	information processing
NCT0017306971	NCT00173069_71_T0	PHENOTYPE	10	11	startle reflex
NCT0017306972	NCT00173069_72_T0	PHENOTYPE	10	10	schizophrenia
NCT0017306975	NCT00173069_75_T0	PHENOTYPE	9	10	Schizophrenia Disorder
NCT0017306976	NCT00173069_76_T0	GENE	4	4	HR
NCT0017306976	NCT00173069_76_T1	PHENOTYPE	35	35	schizophrenia
NCT0017306976	NCT00173069_76_T2	GENE	22	22	has
NCT0017306977	NCT00173069_77_T0	GENE	2	2	pointed
NCT0017306978	NCT00173069_78_T0	PHENOTYPE	24	24	focused
NCT0017306979	NCT00173069_79_T0	GENE	6	6	HR
NCT0017306979	NCT00173069_79_T1	PHENOTYPE	9	9	schizophrenia
NCT0017306980	NCT00173069_80_T0	GENE	34	34	HR
NCT0017306980	NCT00173069_80_T1	GENE	9	9	has
NCT0017306980	NCT00173069_80_T2	PHENOTYPE	25	26	psychotic symptoms
NCT0017306980	NCT00173069_80_T3	PHENOTYPE	20	21	mental health
NCT0017306980	NCT00173069_80_T4	PHENOTYPE	28	29	behavioral problems
NCT0017306981	NCT00173069_81_T0	PHENOTYPE	18	18	recruitment
NCT0017306981	NCT00173069_81_T1	GENE	2	2	PPG
NCT0017306981	NCT00173069_81_T2	GENE	11	11	HR
NCT0017306981	NCT00173069_81_T3	GENE	14	14	HR
NCT0017306981	NCT00173069_81_T4	PHENOTYPE	27	28	schizophrenia disorder
NCT0017306982	NCT00173069_82_T0	GENE	7	7	HR
NCT0017306982	NCT00173069_82_T1	GENE	14	14	HR
NCT0017306982	NCT00173069_82_T2	GENE	20	20	HR
NCT0017306982	NCT00173069_82_T3	PHENOTYPE	18	18	schizophrenia
NCT0017306982	NCT00173069_82_T4	PHENOTYPE	24	24	schizophrenia
NCT0017306985	NCT00173069_85_T0	GENE	15	15	HR
NCT0017306985	NCT00173069_85_T1	GENE	19	19	HR
NCT0017306986	NCT00173069_86_T0	GENE	2	2	HR
NCT0017306986	NCT00173069_86_T1	GENE	9	9	HR
NCT0017306987	NCT00173069_87_T0	PHENOTYPE	25	25	severity
NCT0017306987	NCT00173069_87_T1	PHENOTYPE	33	33	progression
NCT0017306987	NCT00173069_87_T2	PHENOTYPE	43	43	progression
NCT0017306987	NCT00173069_87_T3	GENE	22	22	HR
NCT0017306987	NCT00173069_87_T4	GENE	31	31	HR
NCT0017306987	NCT00173069_87_T5	GENE	40	40	HR
NCT0017306988	NCT00173069_88_T0	PHENOTYPE	32	32	schizophrenia
NCT0017306989	NCT00173069_89_T0	COMPOUND	1	1	2
NCT0017306989	NCT00173069_89_T1	PHENOTYPE	11	11	impairment
NCT0017306989	NCT00173069_89_T2	PHENOTYPE	25	25	schizophrenia
NCT0017306991	NCT00173069_91_T0	GENE	30	30	PPG
NCT0017306991	NCT00173069_91_T1	PHENOTYPE	16	16	schizophrenia
NCT0017306996	NCT00173069_96_T0	GENE	20	20	PPG
NCT0017306996	NCT00173069_96_T1	PHENOTYPE	16	17	Schizophrenia Disorder
NCT0017306996	NCT00173069_96_T2	PHENOTYPE	28	29	Schizophrenia Disorder
NCT0017306998	NCT00173069_98_T0	PHENOTYPE	13	13	schizophrenia
NCT00173069103	NCT00173069_103_T0	GENE	14	14	PPG
NCT00173069105	NCT00173069_105_T0	GENE	7	7	has
NCT00173069106	NCT00173069_106_T0	GENE	5	5	PPG
NCT00173069106	NCT00173069_106_T1	GENE	6	6	has
NCT00173069107	NCT00173069_107_T0	GENE	1	1	has
NCT00173069108	NCT00173069_108_T0	GENE	13	13	has
NCT00173069109	NCT00173069_109_T0	GENE	4	4	has
NCT00173069109	NCT00173069_109_T1	GENE	9	9	has
NCT00173069110	NCT00173069_110_T0	GENE	7	7	has
NCT00173069113	NCT00173069_113_T0	GENE	3	3	has
NCT00173069114	NCT00173069_114_T0	GENE	7	7	has
NCT00173069118	NCT00173069_118_T0	GENE	2	2	has
NCT00173069121	NCT00173069_121_T0	GENE	8	8	PPG
NCT00173069121	NCT00173069_121_T1	GENE	15	15	RA
NCT00173069122	NCT00173069_122_T0	GENE	5	5	RA
NCT00173069123	NCT00173069_123_T0	GENE	1	1	RA
NCT00173069126	NCT00173069_126_T0	GENE	3	3	has
NCT00173069129	NCT00173069_129_T0	GENE	6	6	PPG
NCT00173069130	NCT00173069_130_T0	GENE	12	12	has
NCT00173069132	NCT00173069_132_T0	GENE	3	3	PPG
NCT00173069138	NCT00173069_138_T0	GENE	11	11	PPG
NCT00173069143	NCT00173069_143_T0	PHENOTYPE	19	19	strategies
NCT00173069144	NCT00173069_144_T0	COMPOUND	16	16	1
NCT00173069147	NCT00173069_147_T0	COMPOUND	0	0	2
NCT00173069151	NCT00173069_151_T0	COMPOUND	0	0	3
NCT00173069158	NCT00173069_158_T0	COMPOUND	30	30	1
NCT00173069158	NCT00173069_158_T1	PHENOTYPE	16	16	strategies
NCT00173069158	NCT00173069_158_T2	GENE	13	13	has
NCT00173069160	NCT00173069_160_T0	PHENOTYPE	13	13	associations
NCT00173069161	NCT00173069_161_T0	COMPOUND	0	0	2
NCT00173069162	NCT00173069_162_T0	GENE	3	3	GAP
NCT00173069162	NCT00173069_162_T1	PHENOTYPE	0	0	Generalized
NCT00173069162	NCT00173069_162_T2	GENE	6	6	Dr
NCT00173069164	NCT00173069_164_T0	COMPOUND	0	0	3
NCT00173069180	NCT00173069_180_T0	PHENOTYPE	17	17	interests
NCT00173069181	NCT00173069_181_T0	GENE	2	2	has
NCT00173069187	NCT00173069_187_T0	CELL	21	21	lymphocyte
NCT00173069189	NCT00173069_189_T0	GENE	4	4	PPG
NCT00173069189	NCT00173069_189_T1	PHENOTYPE	13	14	Schizophrenia Disorder
NCT00173069189	NCT00173069_189_T2	PHENOTYPE	21	22	Schizophrenia Disorder
NCT00173069193	NCT00173069_193_T0	PHENOTYPE	21	21	schizophrenia
NCT00173069194	NCT00173069_194_T0	COMPOUND	14	14	niacin
NCT00173069194	NCT00173069_194_T1	PHENOTYPE	16	16	flushing
NCT00173069197	NCT00173069_197_T0	PHENOTYPE	20	20	recruitment
NCT00173069198	NCT00173069_198_T0	PHENOTYPE	3	3	schizophrenia
NCT00173069198	NCT00173069_198_T1	GENE	4	4	has
NCT00173069199	NCT00173069_199_T0	PHENOTYPE	17	17	schizophrenia
NCT00173069199	NCT00173069_199_T1	PHENOTYPE	23	23	schizophrenia
NCT00173069200	NCT00173069_200_T0	PHENOTYPE	12	12	schizophrenia
NCT00173069203	NCT00173069_203_T0	PHENOTYPE	22	22	disorders
NCT00173069206	NCT00173069_206_T0	PHENOTYPE	1	1	schizophrenia
NCT00173069208	NCT00173069_208_T0	PHENOTYPE	14	14	schizophrenia
NCT00173069208	NCT00173069_208_T1	PHENOTYPE	25	25	schizophrenia
NCT00173069211	NCT00173069_211_T0	COMPOUND	3	3	cultivate
NCT00173069213	NCT00173069_213_T0	GENE	5	5	PPG
NCT00173069215	NCT00173069_215_T0	PHENOTYPE	4	4	recruitment
NCT00173069215	NCT00173069_215_T1	PHENOTYPE	15	15	schizophrenia
NCT00173069215	NCT00173069_215_T2	GENE	16	16	has
NCT00173069216	NCT00173069_216_T0	PHENOTYPE	9	9	schizophrenia
NCT00173069216	NCT00173069_216_T1	GENE	3	3	has
NCT00173069218	NCT00173069_218_T0	GENE	6	6	has
NCT00173069220	NCT00173069_220_T0	GENE	17	17	PPG
NCT00173069221	NCT00173069_221_T0	GENE	46	46	PPG
NCT00173069222	NCT00173069_222_T0	GENE	24	24	Hua
NCT00173069222	NCT00173069_222_T1	GENE	31	31	PPG
NCT00173069222	NCT00173069_222_T2	PHENOTYPE	3	3	centers
NCT00173069224	NCT00173069_224_T0	PHENOTYPE	27	27	centers
NCT00173069227	NCT00173069_227_T0	GENE	4	4	has
NCT00173069227	NCT00173069_227_T1	PHENOTYPE	10	11	mental health
NCT00173069227	NCT00173069_227_T2	PHENOTYPE	14	15	Mental Health
NCT00173069228	NCT00173069_228_T0	PHENOTYPE	12	12	recruitment
NCT001730822	NCT00173082_2_T0	GENE	22	22	insulin
NCT001730822	NCT00173082_2_T1	CELL	19	19	cells
NCT001730822	NCT00173082_2_T2	GENE	18	18	beta
NCT001730822	NCT00173082_2_T3	PHENOTYPE	24	25	potassium depletion
NCT001730822	NCT00173082_2_T4	PHENOTYPE	9	10	primary aldosteronism
NCT001730822	NCT00173082_2_T5	PHENOTYPE	5	7	impaired glucose tolerance
NCT001730823	NCT00173082_3_T0	PHENOTYPE	17	17	hypopotassemia
NCT001730823	NCT00173082_3_T1	GENE	13	13	insulin
NCT001730823	NCT00173082_3_T2	GENE	6	6	PA
NCT001730823	NCT00173082_3_T3	GENE	27	27	PA
NCT001730823	NCT00173082_3_T4	PHENOTYPE	11	11	suppression
NCT001730823	NCT00173082_3_T5	PHENOTYPE	3	4	glucose intolerance
NCT001730823	NCT00173082_3_T6	PHENOTYPE	22	23	insulin sensitivity
NCT001730824	NCT00173082_4_T0	COMPOUND	10	10	potassium
NCT001730824	NCT00173082_4_T1	ORGAN	18	18	plasma
NCT001730824	NCT00173082_4_T2	GENE	19	19	leptin
NCT001730824	NCT00173082_4_T3	PHENOTYPE	1	2	increased insulin
NCT001730824	NCT00173082_4_T4	PHENOTYPE	22	23	primary aldosteronism
NCT001730828	NCT00173082_8_T0	GENE	22	22	insulin
NCT001730828	NCT00173082_8_T1	CELL	19	19	cells
NCT001730828	NCT00173082_8_T2	GENE	18	18	beta
NCT001730828	NCT00173082_8_T3	PHENOTYPE	24	25	potassium depletion
NCT001730828	NCT00173082_8_T4	PHENOTYPE	9	10	primary aldosteronism
NCT001730828	NCT00173082_8_T5	PHENOTYPE	5	7	impaired glucose tolerance
NCT001730829	NCT00173082_9_T0	PHENOTYPE	17	17	hypopotassemia
NCT001730829	NCT00173082_9_T1	GENE	13	13	insulin
NCT001730829	NCT00173082_9_T2	GENE	6	6	PA
NCT001730829	NCT00173082_9_T3	GENE	27	27	PA
NCT001730829	NCT00173082_9_T4	PHENOTYPE	11	11	suppression
NCT001730829	NCT00173082_9_T5	PHENOTYPE	3	4	glucose intolerance
NCT001730829	NCT00173082_9_T6	PHENOTYPE	22	23	insulin sensitivity
NCT0017308210	NCT00173082_10_T0	COMPOUND	10	10	potassium
NCT0017308210	NCT00173082_10_T1	ORGAN	18	18	plasma
NCT0017308210	NCT00173082_10_T2	GENE	19	19	leptin
NCT0017308210	NCT00173082_10_T3	PHENOTYPE	1	2	increased insulin
NCT0017308210	NCT00173082_10_T4	PHENOTYPE	22	23	primary aldosteronism
NCT0017308212	NCT00173082_12_T0	PHENOTYPE	29	30	insulin sensitivity
NCT0017308212	NCT00173082_12_T1	PHENOTYPE	8	9	primary aldosteronism
NCT0017308212	NCT00173082_12_T2	PHENOTYPE	19	20	primary aldosteronism
NCT0017308213	NCT00173082_13_T0	GENE	24	24	PA
NCT0017308213	NCT00173082_13_T1	GENE	33	33	PA
NCT0017308213	NCT00173082_13_T2	GENE	13	13	insulin
NCT0017308213	NCT00173082_13_T3	PHENOTYPE	6	7	insulin sensitivity
NCT0017308213	NCT00173082_13_T4	PHENOTYPE	30	31	glucose intolerance
NCT0017308213	NCT00173082_13_T5	PHENOTYPE	19	20	glucose tolerance
NCT0017308214	NCT00173082_14_T0	GENE	6	6	PA
NCT0017308215	NCT00173082_15_T0	GENE	10	10	cc
NCT0017308215	NCT00173082_15_T1	PHENOTYPE	13	13	ingested
NCT0017308215	NCT00173082_15_T2	COMPOUND	6	6	glucose
NCT0017308216	NCT00173082_16_T0	ORGAN	16	16	plasma
NCT0017308216	NCT00173082_16_T1	PHENOTYPE	13	14	plasma glucose
NCT0017308216	NCT00173082_16_T2	PHENOTYPE	17	18	insulin levels
NCT0017308217	NCT00173082_17_T0	COMPOUND	1	1	potassium
NCT0017308217	NCT00173082_17_T1	ORGAN	0	0	Serum
NCT0017308218	NCT00173082_18_T0	GENE	6	6	adiponectin
NCT0017308218	NCT00173082_18_T1	COMPOUND	7	7	homocystine
NCT0017308218	NCT00173082_18_T2	PHENOTYPE	13	13	adhesion
NCT0017308218	NCT00173082_18_T3	GENE	5	5	leptin
NCT0017308218	NCT00173082_18_T4	GENE	8	9	C-reactive protein
NCT001730952	NCT00173095_2_T0	PHENOTYPE	20	21	bilirubin levels
NCT001730952	NCT00173095_2_T1	PHENOTYPE	9	10	subarachnoid hemorrhage
NCT001731084	NCT00173108_4_T0	GENE	18	18	UCP
NCT001731084	NCT00173108_4_T1	PHENOTYPE	25	25	VLBW
NCT001731089	NCT00173108_9_T0	PHENOTYPE	18	18	VLBW
NCT0017310813	NCT00173108_13_T0	PHENOTYPE	5	5	VLBW
NCT0017310814	NCT00173108_14_T0	PHENOTYPE	4	4	VLBW
NCT0017310814	NCT00173108_14_T1	PHENOTYPE	13	13	chronic
NCT0017310814	NCT00173108_14_T2	PHENOTYPE	23	24	behavioral problems
NCT0017310817	NCT00173108_17_T0	PHENOTYPE	31	31	VLBW
NCT0017310818	NCT00173108_18_T0	PHENOTYPE	15	15	VLBW
NCT0017310826	NCT00173108_26_T0	PHENOTYPE	8	8	VLBW
NCT0017310830	NCT00173108_30_T0	PHENOTYPE	0	0	Generalized
NCT0017310831	NCT00173108_31_T0	PHENOTYPE	27	27	VLBW
NCT0017310832	NCT00173108_32_T0	PHENOTYPE	17	17	VLBW
NCT001731211	NCT00173121_1_T0	PHENOTYPE	23	23	strategies
NCT001731212	NCT00173121_2_T0	GENE	36	36	separated
NCT001731212	NCT00173121_2_T1	GENE	40	40	al
NCT001731212	NCT00173121_2_T2	PHENOTYPE	25	25	transmitted
NCT001731212	NCT00173121_2_T3	GENE	39	39	et
NCT001731214	NCT00173121_4_T0	TISSUE	28	28	membranes
NCT001731214	NCT00173121_4_T1	ORGAN	4	4	hands
NCT001731214	NCT00173121_4_T2	ORGAN	9	9	hands
NCT001731215	NCT00173121_5_T0	PHENOTYPE	10	11	enterovirus infection
NCT001731217	NCT00173121_7_T0	PHENOTYPE	17	18	enterovirus infection
NCT001731219	NCT00173121_9_T0	PHENOTYPE	10	10	plaque
NCT001731219	NCT00173121_9_T1	PHENOTYPE	50	50	symptoms
NCT001731219	NCT00173121_9_T2	GENE	14	14	PCR
NCT0017312111	NCT00173121_11_T0	PHENOTYPE	11	11	illnesses
NCT0017312111	NCT00173121_11_T1	PHENOTYPE	16	16	herpangina
NCT0017312113	NCT00173121_13_T0	PHENOTYPE	38	40	signs and symptoms
NCT0017312115	NCT00173121_15_T0	PHENOTYPE	3	4	enterovirus infection
NCT0017312118	NCT00173121_18_T0	GENE	6	6	pads
NCT0017312118	NCT00173121_18_T1	COMPOUND	5	5	cellulose
NCT0017312119	NCT00173121_19_T0	PHENOTYPE	33	33	sterile
NCT001731471	NCT00173147_1_T0	ORGAN	5	6	vastus medialis
NCT001731472	NCT00173147_2_T0	ORGAN	10	10	patella
NCT001731473	NCT00173147_3_T0	GENE	9	9	al
NCT001731473	NCT00173147_3_T1	GENE	8	8	et
NCT001731473	NCT00173147_3_T2	ORGAN	28	29	patellofemoral joint
NCT001731477	NCT00173147_7_T0	PHENOTYPE	19	19	attachment
NCT001731477	NCT00173147_7_T1	ORGAN	18	18	patella
NCT001731477	NCT00173147_7_T2	ORGAN	27	27	patella
NCT001731600	NCT00173160_0_T0	PHENOTYPE	3	4	Eating Disorders
NCT001731603	NCT00173160_3_T0	PHENOTYPE	18	19	eating disorders
NCT001731603	NCT00173160_3_T1	PHENOTYPE	31	32	eating disorders
NCT001731603	NCT00173160_3_T2	PHENOTYPE	39	41	other psychiatric disorders
NCT001731606	NCT00173160_6_T0	PHENOTYPE	12	12	Self-esteem
NCT001731606	NCT00173160_6_T1	GENE	14	14	RSE
NCT001731606	NCT00173160_6_T2	PHENOTYPE	7	8	Eating Disorder
NCT001731608	NCT00173160_8_T0	PHENOTYPE	14	14	severity
NCT001731608	NCT00173160_8_T1	GENE	11	11	BITE
NCT0017316010	NCT00173160_10_T0	PHENOTYPE	5	6	bulimia nervosa
NCT0017316010	NCT00173160_10_T1	PHENOTYPE	15	16	mental illness
NCT0017316010	NCT00173160_10_T2	PHENOTYPE	18	19	psychiatric diagnosis
NCT0017316012	NCT00173160_12_T0	PHENOTYPE	12	13	eating disorders
NCT0017316015	NCT00173160_15_T0	PHENOTYPE	13	14	eating disorders
NCT0017316016	NCT00173160_16_T0	PHENOTYPE	31	31	regression
NCT0017316018	NCT00173160_18_T0	PHENOTYPE	18	19	eating disorders
NCT0017316018	NCT00173160_18_T1	PHENOTYPE	31	32	eating disorders
NCT0017316018	NCT00173160_18_T2	PHENOTYPE	39	41	other psychiatric disorders
NCT0017316020	NCT00173160_20_T0	GENE	17	17	BITE
NCT0017316020	NCT00173160_20_T1	PHENOTYPE	3	4	eating disorders
NCT0017316020	NCT00173160_20_T2	PHENOTYPE	7	8	psychiatric disorders
NCT0017316021	NCT00173160_21_T0	PHENOTYPE	12	12	Self-esteem
NCT0017316021	NCT00173160_21_T1	GENE	14	14	RSE
NCT0017316021	NCT00173160_21_T2	PHENOTYPE	7	8	Eating Disorder
NCT0017316023	NCT00173160_23_T0	PHENOTYPE	14	14	severity
NCT0017316023	NCT00173160_23_T1	GENE	11	11	BITE
NCT0017316025	NCT00173160_25_T0	PHENOTYPE	5	6	bulimia nervosa
NCT0017316025	NCT00173160_25_T1	PHENOTYPE	15	16	mental illness
NCT0017316025	NCT00173160_25_T2	PHENOTYPE	18	19	psychiatric diagnosis
NCT0017316027	NCT00173160_27_T0	PHENOTYPE	12	13	eating disorders
NCT0017316030	NCT00173160_30_T0	PHENOTYPE	13	14	eating disorders
NCT0017316031	NCT00173160_31_T0	PHENOTYPE	31	31	regression
NCT001731730	NCT00173173_0_T0	PHENOTYPE	3	4	Eating Disorders
NCT001731732	NCT00173173_2_T0	GENE	27	27	BITE
NCT001731732	NCT00173173_2_T1	PHENOTYPE	12	13	eating disorders
NCT001731734	NCT00173173_4_T0	GENE	10	10	BITE
NCT001731734	NCT00173173_4_T1	PHENOTYPE	15	16	Physical Appearance
NCT001731735	NCT00173173_5_T0	PHENOTYPE	17	17	severity
NCT001731736	NCT00173173_6_T0	PHENOTYPE	11	12	eating disorders
NCT001731737	NCT00173173_7_T0	BIOLOGICAL_PROCESS	12	12	menstruation
NCT001731737	NCT00173173_7_T1	PHENOTYPE	10	10	obesity
NCT001731737	NCT00173173_7_T2	PHENOTYPE	29	29	obesity
NCT001731737	NCT00173173_7_T3	PHENOTYPE	17	18	physical abuse
NCT001731737	NCT00173173_7_T4	PHENOTYPE	31	32	psychiatric illness
NCT001731738	NCT00173173_8_T0	GENE	6	6	10.0
NCT0017317310	NCT00173173_10_T0	GENE	0	0	ANOVA
NCT0017317314	NCT00173173_14_T0	PHENOTYPE	0	0	Regression
NCT0017317314	NCT00173173_14_T1	PHENOTYPE	11	12	eating disorder
NCT0017317314	NCT00173173_14_T2	PHENOTYPE	8	9	disordered eating
NCT0017317317	NCT00173173_17_T0	GENE	27	27	BITE
NCT0017317317	NCT00173173_17_T1	PHENOTYPE	12	13	eating disorders
NCT0017317319	NCT00173173_19_T0	GENE	22	22	BITE
NCT0017317319	NCT00173173_19_T1	PHENOTYPE	27	28	Physical Appearance
NCT0017317320	NCT00173173_20_T0	PHENOTYPE	17	17	severity
NCT0017317321	NCT00173173_21_T0	PHENOTYPE	11	12	eating disorders
NCT0017317322	NCT00173173_22_T0	BIOLOGICAL_PROCESS	12	12	menstruation
NCT0017317322	NCT00173173_22_T1	PHENOTYPE	10	10	obesity
NCT0017317322	NCT00173173_22_T2	PHENOTYPE	29	29	obesity
NCT0017317322	NCT00173173_22_T3	PHENOTYPE	17	18	physical abuse
NCT0017317322	NCT00173173_22_T4	PHENOTYPE	31	32	psychiatric illness
NCT0017317323	NCT00173173_23_T0	GENE	6	6	10.0
NCT0017317325	NCT00173173_25_T0	GENE	0	0	ANOVA
NCT0017317329	NCT00173173_29_T0	PHENOTYPE	0	0	Regression
NCT0017317329	NCT00173173_29_T1	PHENOTYPE	11	12	eating disorder
NCT0017317329	NCT00173173_29_T2	PHENOTYPE	8	9	disordered eating
NCT001731861	NCT00173186_1_T0	GENE	8	8	AR
NCT001731861	NCT00173186_1_T1	GENE	10	10	AR
NCT001731863	NCT00173186_3_T0	PHENOTYPE	13	13	VSD
NCT001731864	NCT00173186_4_T0	ORGAN	4	5	aortic valve
NCT001731865	NCT00173186_5_T0	PHENOTYPE	16	16	severity
NCT001731865	NCT00173186_5_T1	GENE	19	19	AR
NCT001731865	NCT00173186_5_T2	PHENOTYPE	23	23	VSD
NCT001731865	NCT00173186_5_T3	PHENOTYPE	12	12	regression
NCT001731865	NCT00173186_5_T4	ORGAN	0	1	Aortic valve
NCT001731866	NCT00173186_6_T0	GENE	28	28	II
NCT001731866	NCT00173186_6_T1	GENE	17	17	AR
NCT001731866	NCT00173186_6_T2	GENE	26	26	AR
NCT001731866	NCT00173186_6_T3	PHENOTYPE	6	6	endocarditis
NCT001731866	NCT00173186_6_T4	GENE	18	19	Group I
NCT001731868	NCT00173186_8_T0	GENE	20	20	II
NCT001731868	NCT00173186_8_T1	PHENOTYPE	1	1	VSD
NCT001731868	NCT00173186_8_T2	ORGAN	9	10	aortic valve
NCT001731868	NCT00173186_8_T3	GENE	13	14	Group I
NCT0017318611	NCT00173186_11_T0	PHENOTYPE	2	2	VSD
NCT0017318611	NCT00173186_11_T1	ORGAN	8	9	aortic valve
NCT0017318612	NCT00173186_12_T0	GENE	3	3	AR
NCT0017318612	NCT00173186_12_T1	GENE	15	15	3.5
NCT0017318612	NCT00173186_12_T2	GENE	1	2	Group I
NCT0017318613	NCT00173186_13_T0	PHENOTYPE	7	7	VSD
NCT0017318614	NCT00173186_14_T0	GENE	1	1	AR
NCT0017318614	NCT00173186_14_T1	GENE	20	20	AR
NCT0017318614	NCT00173186_14_T2	PHENOTYPE	14	14	VSD
NCT0017318614	NCT00173186_14_T3	PHENOTYPE	35	35	VSD
NCT001731992	NCT00173199_2_T0	ORGAN	22	23	nervous system
NCT001731994	NCT00173199_4_T0	CELL	24	24	macrophage
NCT001731994	NCT00173199_4_T1	CELL	10	10	cells
NCT001731994	NCT00173199_4_T2	CELL	25	26	glial cells
NCT001731994	NCT00173199_4_T3	CELL	27	28	Schwann cells
NCT001731994	NCT00173199_4_T4	ORGAN	1	2	nervous system
NCT001731994	NCT00173199_4_T5	ORGAN	70	71	nervous system
NCT001731994	NCT00173199_4_T6	ORGAN	49	50	immune system
NCT001731994	NCT00173199_4_T7	CELL	31	33	capillary endothelial cells
NCT001731994	NCT00173199_4_T8	CELL	15	17	antigen presenting cells
NCT001731996	NCT00173199_6_T0	PHENOTYPE	1	1	disorders
NCT001731996	NCT00173199_6_T1	ORGAN	6	7	peripheral nerve
NCT001731996	NCT00173199_6_T2	ORGAN	15	16	immune system
NCT001731998	NCT00173199_8_T0	CELL	21	21	cells
NCT001731998	NCT00173199_8_T1	TISSUE	23	23	tissues
NCT001731999	NCT00173199_9_T0	CELL	13	13	cells
NCT001731999	NCT00173199_9_T1	CELL	17	17	cells
NCT001731999	NCT00173199_9_T2	ORGAN	27	27	radius
NCT001731999	NCT00173199_9_T3	GENE	2	2	hormone
NCT0017319910	NCT00173199_10_T0	BIOLOGICAL_PROCESS	18	18	transcription
NCT0017319910	NCT00173199_10_T1	BIOLOGICAL_PROCESS	20	20	translation
NCT0017319910	NCT00173199_10_T2	BIOLOGICAL_PROCESS	1	2	cytokine production
NCT0017319913	NCT00173199_13_T0	PHENOTYPE	5	5	inflammation
NCT0017319914	NCT00173199_14_T0	GENE	14	14	TNF-alpha
NCT0017319914	NCT00173199_14_T1	GENE	12	12	IL6
NCT0017319914	NCT00173199_14_T2	GENE	11	11	IL1
NCT0017319915	NCT00173199_15_T0	GENE	7	7	IL11
NCT0017319915	NCT00173199_15_T1	CELL	21	21	cells
NCT0017319915	NCT00173199_15_T2	GENE	11	11	IL8
NCT0017319915	NCT00173199_15_T3	GENE	5	5	TGF-beta
NCT0017319915	NCT00173199_15_T4	GENE	8	8	IL12
NCT0017319915	NCT00173199_15_T5	GENE	4	4	IFN-gamma
NCT0017319915	NCT00173199_15_T6	GENE	10	10	IL18
NCT0017319915	NCT00173199_15_T7	GENE	9	9	IL17
NCT0017319915	NCT00173199_15_T8	GENE	6	6	GM-CSF
NCT0017319917	NCT00173199_17_T0	PHENOTYPE	6	6	inflammation
NCT0017319918	NCT00173199_18_T0	PHENOTYPE	29	30	inflammatory responses
NCT0017319919	NCT00173199_19_T0	GENE	6	6	IL10
NCT0017319919	NCT00173199_19_T1	GENE	5	5	IL4
NCT0017319919	NCT00173199_19_T2	GENE	8	8	IL13
NCT0017319920	NCT00173199_20_T0	GENE	5	5	IFN-alpha
NCT0017319920	NCT00173199_20_T1	GENE	16	16	IL6
NCT0017319920	NCT00173199_20_T2	GENE	6	6	TGF-beta
NCT0017319920	NCT00173199_20_T3	GENE	4	4	IL16
NCT0017319920	NCT00173199_20_T4	GENE	7	7	G-CSF
NCT0017319920	NCT00173199_20_T5	GENE	14	14	TNF
NCT0017319925	NCT00173199_25_T0	CELL	1	1	cells
NCT0017319925	NCT00173199_25_T1	GENE	14	14	IL12
NCT0017319925	NCT00173199_25_T2	GENE	16	16	TNF-beta
NCT0017319925	NCT00173199_25_T3	GENE	13	13	IFN-gamma
NCT0017319925	NCT00173199_25_T4	GENE	12	12	IL2
NCT001732120	NCT00173212_0_T0	PHENOTYPE	6	6	Adenomyosis
NCT001732120	NCT00173212_0_T1	CELL	3	4	Stromal Cells
NCT001732122	NCT00173212_2_T0	PHENOTYPE	8	8	adenomyosis
NCT001732123	NCT00173212_3_T0	PHENOTYPE	23	23	adenomyosis
NCT001732123	NCT00173212_3_T1	ORGAN	19	19	endometrium
NCT001732123	NCT00173212_3_T2	CELL	12	14	natural killer cells
NCT0017321211	NCT00173212_11_T0	COMPOUND	11	11	estrogen
NCT0017321211	NCT00173212_11_T1	PHENOTYPE	13	13	adenomyosis
NCT0017321213	NCT00173212_13_T0	GENE	7	7	ESC
NCT0017321213	NCT00173212_13_T1	PHENOTYPE	8	8	proliferation
NCT0017321213	NCT00173212_13_T2	PHENOTYPE	16	16	adenomyosis
NCT0017321213	NCT00173212_13_T3	ORGAN	14	14	endometrium
NCT0017321214	NCT00173212_14_T0	TISSUE	8	8	tissues
NCT0017321214	NCT00173212_14_T1	PHENOTYPE	14	14	adenomyosis
NCT0017321214	NCT00173212_14_T2	ORGAN	20	20	endometrium
NCT001732255	NCT00173225_5_T0	PHENOTYPE	2	2	peripheral
NCT001732255	NCT00173225_5_T1	PHENOTYPE	8	8	concentrations
NCT001732255	NCT00173225_5_T2	GENE	10	10	nociceptin
NCT001732255	NCT00173225_5_T3	GENE	12	13	substance P
NCT001732256	NCT00173225_6_T0	PHENOTYPE	7	7	severity
NCT001732256	NCT00173225_6_T1	PHENOTYPE	6	6	cough
NCT001732256	NCT00173225_6_T2	COMPOUND	15	15	methacholine
NCT001732257	NCT00173225_7_T0	PHENOTYPE	17	17	symptoms
NCT001732257	NCT00173225_7_T1	PHENOTYPE	3	3	concentrations
NCT001732257	NCT00173225_7_T2	ORGAN	2	2	plasma
NCT001732257	NCT00173225_7_T3	PHENOTYPE	14	14	cough
NCT001732381	NCT00173238_1_T0	PHENOTYPE	17	17	acute
NCT001732381	NCT00173238_1_T1	PHENOTYPE	3	3	plaque
NCT001732381	NCT00173238_1_T2	PHENOTYPE	0	0	Rupture
NCT001732381	NCT00173238_1_T3	PHENOTYPE	19	19	syndromes
NCT001732381	NCT00173238_1_T4	GENE	4	4	has
NCT001732382	NCT00173238_2_T0	PHENOTYPE	23	23	acute
NCT001732383	NCT00173238_3_T0	GENE	3	3	OCT
NCT001732385	NCT00173238_5_T0	GENE	9	9	OCT
NCT001732387	NCT00173238_7_T0	PHENOTYPE	20	20	plaque
NCT001732387	NCT00173238_7_T1	PHENOTYPE	36	36	plaque
NCT001732387	NCT00173238_7_T2	PHENOTYPE	48	48	plaque
NCT001732387	NCT00173238_7_T3	PHENOTYPE	33	33	rupture
NCT001732389	NCT00173238_9_T0	GENE	0	0	OCT
NCT0017323810	NCT00173238_10_T0	GENE	8	8	OCT
NCT0017323810	NCT00173238_10_T1	TISSUE	22	22	tissues
NCT001732510	NCT00173251_0_T0	PHENOTYPE	13	13	Macromastia
NCT001732510	NCT00173251_0_T1	PHENOTYPE	15	15	Micromastia
NCT001732515	NCT00173251_5_T0	PHENOTYPE	1	1	hypertrophy
NCT001732515	NCT00173251_5_T1	PHENOTYPE	0	0	Unilateral
NCT001732515	NCT00173251_5_T2	PHENOTYPE	5	5	embarrassment
NCT001732516	NCT00173251_6_T0	ORGAN	9	9	breasts
NCT001732519	NCT00173251_9_T0	GENE	4	4	receptor
NCT001732519	NCT00173251_9_T1	PHENOTYPE	0	0	Abnormalities
NCT001732519	NCT00173251_9_T2	PHENOTYPE	11	11	pathophysiology
NCT001732519	NCT00173251_9_T3	PHENOTYPE	13	13	macromastia
NCT0017325110	NCT00173251_10_T0	GENE	10	10	receptor
NCT0017325110	NCT00173251_10_T1	GENE	22	22	receptor
NCT0017325110	NCT00173251_10_T2	PHENOTYPE	17	17	macromastia
NCT0017325110	NCT00173251_10_T3	PHENOTYPE	13	14	breast hypertrophy
NCT0017325111	NCT00173251_11_T0	PHENOTYPE	11	11	macromastia
NCT0017325111	NCT00173251_11_T1	PHENOTYPE	8	9	mammary hypertrophy
NCT001732640	NCT00173264_0_T0	PHENOTYPE	10	10	Tuberculosis
NCT001732643	NCT00173264_3_T0	GENE	8	9	heavy chain
NCT001732644	NCT00173264_4_T0	PHENOTYPE	17	17	amyloidosis
NCT001732644	NCT00173264_4_T1	PHENOTYPE	13	13	lymphoma
NCT001732644	NCT00173264_4_T2	PHENOTYPE	6	6	diseases
NCT001732644	NCT00173264_4_T3	PHENOTYPE	12	12	macroglobulinemia
NCT001732644	NCT00173264_4_T4	PHENOTYPE	29	29	MGUS
NCT001732644	NCT00173264_4_T5	PHENOTYPE	9	10	multiple myeloma
NCT001732644	NCT00173264_4_T6	PHENOTYPE	14	16	chronic lymphocytic leukemia
NCT001732644	NCT00173264_4_T7	PHENOTYPE	24	28	monoclonal gammopathy of undetermined significance
NCT001732645	NCT00173264_5_T0	PHENOTYPE	10	10	tuberculosis
NCT001732645	NCT00173264_5_T1	PHENOTYPE	4	5	monoclonal gammopathy
NCT001732646	NCT00173264_6_T0	PHENOTYPE	1	1	tuberculous
NCT001732646	NCT00173264_6_T1	PHENOTYPE	18	18	tuberculous
NCT001732647	NCT00173264_7_T0	PHENOTYPE	37	37	mutation
NCT001732647	NCT00173264_7_T1	PHENOTYPE	44	44	mutation
NCT001732647	NCT00173264_7_T2	PHENOTYPE	20	20	tuberculous
NCT001732647	NCT00173264_7_T3	PHENOTYPE	17	17	tuberculosis
NCT0017326410	NCT00173264_10_T0	PHENOTYPE	12	12	tuberculous
NCT001732774	NCT00173277_4_T0	GENE	13	13	sentinel
NCT001732774	NCT00173277_4_T1	PHENOTYPE	12	12	distal
NCT001732776	NCT00173277_6_T0	GENE	26	26	APN
NCT001732777	NCT00173277_7_T0	GENE	13	13	sentinel
NCT001732777	NCT00173277_7_T1	PHENOTYPE	12	12	distal
NCT001732905	NCT00173290_5_T0	CELL	5	6	T cells
NCT001732907	NCT00173290_7_T0	GENE	3	3	CC
NCT001732907	NCT00173290_7_T1	CELL	4	4	cells
NCT001732907	NCT00173290_7_T2	GENE	7	7	HLA-A
NCT001732907	NCT00173290_7_T3	GENE	5	5	had
NCT001732908	NCT00173290_8_T0	CELL	22	22	cells
NCT001732908	NCT00173290_8_T1	CELL	12	13	T cells
NCT001733032	NCT00173303_2_T0	GENE	7	7	reduced
NCT001733032	NCT00173303_2_T1	ORGAN	10	10	breasts
NCT001733032	NCT00173303_2_T2	PHENOTYPE	33	33	microcalcifications
NCT001733032	NCT00173303_2_T3	PHENOTYPE	32	32	faint
NCT0017330311	NCT00173303_11_T0	PHENOTYPE	6	6	SFM
NCT0017330311	NCT00173303_11_T1	PHENOTYPE	29	29	SFM
NCT001733292	NCT00173329_2_T0	PHENOTYPE	6	6	practices
NCT001733293	NCT00173329_3_T0	PHENOTYPE	4	4	diseases
NCT001733293	NCT00173329_3_T1	GENE	5	5	has
NCT001733293	NCT00173329_3_T2	GENE	6	6	shifted
NCT001733295	NCT00173329_5_T0	GENE	7	7	has
NCT001733295	NCT00173329_5_T1	PHENOTYPE	4	6	quality of life
NCT001733297	NCT00173329_7_T0	PHENOTYPE	1	3	quality of life
NCT001733298	NCT00173329_8_T0	PHENOTYPE	3	5	quality of life
NCT001733298	NCT00173329_8_T1	PHENOTYPE	11	13	quality of life
NCT001733298	NCT00173329_8_T2	PHENOTYPE	17	19	quality of life
NCT001733298	NCT00173329_8_T3	PHENOTYPE	24	26	quality of life
NCT001733298	NCT00173329_8_T4	PHENOTYPE	40	42	quality of life
NCT001733299	NCT00173329_9_T0	PHENOTYPE	13	15	quality of life
NCT0017332910	NCT00173329_10_T0	PHENOTYPE	6	6	focused
NCT0017332910	NCT00173329_10_T1	PHENOTYPE	9	9	diseases
NCT0017332911	NCT00173329_11_T0	PHENOTYPE	21	21	illnesses
NCT0017332911	NCT00173329_11_T1	PHENOTYPE	8	10	quality of life
NCT0017332911	NCT00173329_11_T2	PHENOTYPE	15	17	quality of life
NCT0017332912	NCT00173329_12_T0	PHENOTYPE	3	3	schizophrenia
NCT0017332912	NCT00173329_12_T1	PHENOTYPE	0	1	HIV infections
NCT0017332913	NCT00173329_13_T0	PHENOTYPE	2	2	illnesses
NCT0017332913	NCT00173329_13_T1	PHENOTYPE	9	9	illnesses
NCT0017332914	NCT00173329_14_T0	PHENOTYPE	6	8	signs and symptoms
NCT0017332915	NCT00173329_15_T0	PHENOTYPE	6	6	illnesses
NCT0017332915	NCT00173329_15_T1	PHENOTYPE	11	11	illnesses
NCT0017332916	NCT00173329_16_T0	PHENOTYPE	4	4	illnesses
NCT0017332916	NCT00173329_16_T1	PHENOTYPE	13	15	quality of life
NCT0017332917	NCT00173329_17_T0	PHENOTYPE	15	17	quality of life
NCT0017332919	NCT00173329_19_T0	PHENOTYPE	4	4	focused
NCT0017332919	NCT00173329_19_T1	PHENOTYPE	16	17	HIV infections
NCT0017332919	NCT00173329_19_T2	PHENOTYPE	10	12	quality of life
NCT0017332920	NCT00173329_20_T0	PHENOTYPE	22	22	schizophrenia
NCT0017332920	NCT00173329_20_T1	PHENOTYPE	24	25	HIV infections
NCT0017332920	NCT00173329_20_T2	PHENOTYPE	12	14	quality of life
NCT0017332921	NCT00173329_21_T0	PHENOTYPE	29	29	illnesses
NCT0017332921	NCT00173329_21_T1	PHENOTYPE	19	19	schizophrenia
NCT0017332921	NCT00173329_21_T2	PHENOTYPE	16	17	HIV infections
NCT0017332921	NCT00173329_21_T3	PHENOTYPE	10	12	quality of life
NCT0017332921	NCT00173329_21_T4	PHENOTYPE	24	26	quality of life
NCT001733423	NCT00173342_3_T0	PHENOTYPE	14	15	cardiac defects
NCT001733428	NCT00173342_8_T0	PHENOTYPE	40	41	ventricular arrhythmia
NCT001733550	NCT00173355_0_T0	PHENOTYPE	4	5	Dermatofibrosarcoma Protuberans
NCT001733552	NCT00173355_2_T0	GENE	13	13	had
NCT001733552	NCT00173355_2_T1	GENE	16	16	FU
NCT001733554	NCT00173355_4_T0	PHENOTYPE	6	6	DFSP
NCT001733555	NCT00173355_5_T0	GENE	4	4	had
NCT001733555	NCT00173355_5_T1	GENE	8	8	FU
NCT001733681	NCT00173368_1_T0	PHENOTYPE	8	8	complications
NCT001733683	NCT00173368_3_T0	PHENOTYPE	0	0	Choledocholithiasis
NCT001733684	NCT00173368_4_T0	TISSUE	2	2	mucosa
NCT001733685	NCT00173368_5_T0	PHENOTYPE	8	8	bleeding
NCT001733685	NCT00173368_5_T1	PHENOTYPE	9	9	complications
NCT001733813	NCT00173381_3_T0	PHENOTYPE	11	11	metastasis
NCT001733813	NCT00173381_3_T1	PHENOTYPE	3	3	metastasize
NCT001733813	NCT00173381_3_T2	PHENOTYPE	2	2	cancers
NCT001733816	NCT00173381_6_T0	PHENOTYPE	14	15	solid tumors
NCT0017338113	NCT00173381_13_T0	GENE	6	6	VEGF
NCT0017338113	NCT00173381_13_T1	GENE	13	13	VEGFR-3
NCT0017338114	NCT00173381_14_T0	GENE	8	8	VEGFR-3
NCT0017338114	NCT00173381_14_T1	GENE	1	1	VEGF-C
NCT0017338117	NCT00173381_17_T0	GENE	7	7	receptor
NCT0017338117	NCT00173381_17_T1	TISSUE	4	4	tissues
NCT0017338117	NCT00173381_17_T2	GENE	8	8	VEGFR-3
NCT0017338117	NCT00173381_17_T3	GENE	6	6	VEGF-C
NCT0017338117	NCT00173381_17_T4	GENE	9	9	FLT-4
NCT0017338124	NCT00173381_24_T0	PHENOTYPE	4	4	tumor
NCT0017338124	NCT00173381_24_T1	PHENOTYPE	22	22	tumor
NCT0017338124	NCT00173381_24_T2	COMPOUND	19	19	oxygen
NCT0017338125	NCT00173381_25_T0	PHENOTYPE	16	16	HNSCC
NCT0017338125	NCT00173381_25_T1	GENE	10	10	VEGF
NCT0017338125	NCT00173381_25_T2	PHENOTYPE	13	13	tumor
NCT0017338125	NCT00173381_25_T3	GENE	3	3	COX-2
NCT0017338125	NCT00173381_25_T4	PHENOTYPE	14	14	vascularization
NCT0017338128	NCT00173381_28_T0	GENE	0	0	IL-6
NCT0017338128	NCT00173381_28_T1	GENE	5	5	glycoprotein
NCT0017338128	NCT00173381_28_T2	GENE	3	3	secreted
NCT0017338139	NCT00173381_39_T0	PHENOTYPE	5	5	cancers
NCT0017338139	NCT00173381_39_T1	PHENOTYPE	26	26	diseases
NCT0017338139	NCT00173381_39_T2	PHENOTYPE	0	0	Metastases
NCT0017338139	NCT00173381_39_T3	TISSUE	16	17	lymph node
NCT0017338139	NCT00173381_39_T4	ORGAN	10	11	lymphatic system
NCT0017338140	NCT00173381_40_T0	GENE	13	13	IL-6
NCT0017338140	NCT00173381_40_T1	GENE	11	11	COX-2
NCT0017338140	NCT00173381_40_T2	GENE	10	10	VEGF-C
NCT0017338140	NCT00173381_40_T3	PHENOTYPE	25	26	lymphatic metastases
NCT0017338143	NCT00173381_43_T0	GENE	20	20	VEGFR-3
NCT0017338143	NCT00173381_43_T1	PHENOTYPE	18	18	inhibition
NCT0017338143	NCT00173381_43_T2	PHENOTYPE	2	2	tumors
NCT0017338143	NCT00173381_43_T3	PHENOTYPE	1	1	HNSCC
NCT0017338143	NCT00173381_43_T4	GENE	8	8	VEGF-C
NCT0017338143	NCT00173381_43_T5	PHENOTYPE	15	16	lymphatic metastasis
NCT0017338143	NCT00173381_43_T6	PHENOTYPE	29	30	lymphatic metastasis
NCT001733941	NCT00173394_1_T0	PHENOTYPE	4	5	ovarian cancer
NCT001733942	NCT00173394_2_T0	GENE	12	12	has
NCT001733942	NCT00173394_2_T1	PHENOTYPE	0	1	Ovarian cancer
NCT001733943	NCT00173394_3_T0	ORGAN	11	11	ovaries
NCT001733943	NCT00173394_3_T1	PHENOTYPE	9	9	localized
NCT001733943	NCT00173394_3_T2	PHENOTYPE	2	3	ovarian cancer
NCT001733945	NCT00173394_5_T0	PHENOTYPE	5	6	ovarian cancer
NCT001733948	NCT00173394_8_T0	PHENOTYPE	13	13	carcinomas
NCT001733948	NCT00173394_8_T1	GENE	0	0	Mesothelin
NCT001733948	NCT00173394_8_T2	CELL	6	7	epithelial cells
NCT001733949	NCT00173394_9_T0	GENE	0	0	Mesothelin
NCT001733949	NCT00173394_9_T1	GENE	1	1	has
NCT001733949	NCT00173394_9_T2	PHENOTYPE	13	14	ovarian carcinomas
NCT0017339410	NCT00173394_10_T0	GENE	11	11	A24
NCT0017339410	NCT00173394_10_T1	GENE	6	6	mesothelin
NCT0017339411	NCT00173394_11_T0	GENE	4	4	has
NCT0017339411	NCT00173394_11_T1	GENE	3	3	mesothelin
NCT0017339411	NCT00173394_11_T2	PHENOTYPE	16	17	ovarian cancer
NCT0017339413	NCT00173394_13_T0	GENE	20	20	mesothelin
NCT0017339413	NCT00173394_13_T1	GENE	26	26	mesothelin
NCT0017339413	NCT00173394_13_T2	COMPOUND	7	7	1
NCT0017339413	NCT00173394_13_T3	COMPOUND	22	22	2
NCT0017339413	NCT00173394_13_T4	CELL	16	17	T lymphocytes
NCT0017339413	NCT00173394_13_T5	PHENOTYPE	33	34	ovarian cancer
NCT0017339415	NCT00173394_15_T0	PHENOTYPE	15	16	ovarian cancer
NCT0017339416	NCT00173394_16_T0	PHENOTYPE	3	3	symptoms
NCT0017339416	NCT00173394_16_T1	PHENOTYPE	10	10	tumor
NCT0017339416	NCT00173394_16_T2	PHENOTYPE	26	27	ovarian cancer
NCT0017339416	NCT00173394_16_T3	PHENOTYPE	17	18	ovarian tumor
NCT0017339417	NCT00173394_17_T0	PHENOTYPE	13	13	malignancy
NCT0017339417	NCT00173394_17_T1	PHENOTYPE	7	7	tumor
NCT0017339417	NCT00173394_17_T2	PHENOTYPE	4	5	ovarian carcinomas
NCT0017339417	NCT00173394_17_T3	PHENOTYPE	15	16	residual tumor
NCT0017339418	NCT00173394_18_T0	PHENOTYPE	9	9	tumor
NCT0017339418	NCT00173394_18_T1	PHENOTYPE	12	13	ovarian cancer
NCT0017339419	NCT00173394_19_T0	PHENOTYPE	10	11	disease course
NCT0017339420	NCT00173394_20_T0	GENE	16	16	has
NCT0017339420	NCT00173394_20_T1	PHENOTYPE	4	5	ovarian cancer
NCT0017339421	NCT00173394_21_T0	PHENOTYPE	11	11	carcinoma
NCT0017339421	NCT00173394_21_T1	PHENOTYPE	2	3	Ovarian Cancer
NCT0017339421	NCT00173394_21_T2	ORGAN	21	22	peritoneal cavity
NCT0017339421	NCT00173394_21_T3	PHENOTYPE	4	6	Epithelial Ovarian Cancer
NCT0017339422	NCT00173394_22_T0	PHENOTYPE	5	5	tumors
NCT0017339423	NCT00173394_23_T0	ORGAN	10	10	ovaries
NCT0017339423	NCT00173394_23_T1	PHENOTYPE	8	8	localized
NCT0017339426	NCT00173394_26_T0	COMPOUND	10	10	carboplatin_paclitaxel
NCT0017339427	NCT00173394_27_T0	ORGAN	26	26	ovaries
NCT0017339429	NCT00173394_29_T0	GENE	1	1	BRCA1
NCT0017339429	NCT00173394_29_T1	GENE	3	3	BRCA2
NCT0017339430	NCT00173394_30_T0	PHENOTYPE	9	9	mutation
NCT0017339430	NCT00173394_30_T1	PHENOTYPE	13	14	ovarian cancer
NCT0017339431	NCT00173394_31_T0	GENE	8	8	BRCA1
NCT0017339431	NCT00173394_31_T1	GENE	10	10	BRCA2
NCT0017339431	NCT00173394_31_T2	PHENOTYPE	22	23	ovarian cancer
NCT0017339433	NCT00173394_33_T0	PHENOTYPE	21	22	peritoneal cancer
NCT0017339435	NCT00173394_35_T0	PHENOTYPE	8	8	strategies
NCT0017339435	NCT00173394_35_T1	PHENOTYPE	2	3	Ovarian Cancer
NCT0017339439	NCT00173394_39_T0	PHENOTYPE	33	33	tumor
NCT0017339441	NCT00173394_41_T0	GENE	0	0	Mesothelin
NCT0017339441	NCT00173394_41_T1	GENE	1	1	Mesothelin
NCT0017339441	NCT00173394_41_T2	GENE	6	6	glycoprotein
NCT0017339442	NCT00173394_42_T0	GENE	29	29	membrane-bound
NCT0017339442	NCT00173394_42_T1	GENE	20	20	secreted
NCT0017339442	NCT00173394_42_T2	COMPOUND	18	18	N
NCT0017339444	NCT00173394_44_T0	GENE	2	2	al
NCT0017339444	NCT00173394_44_T1	GENE	1	1	et
NCT0017339444	NCT00173394_44_T2	GENE	5	5	mesothelin
NCT0017339444	NCT00173394_44_T3	PHENOTYPE	9	10	ovarian carcinoma
NCT0017339445	NCT00173394_45_T0	PHENOTYPE	9	9	tumor
NCT0017339445	NCT00173394_45_T1	GENE	3	3	mesothelin
NCT0017339445	NCT00173394_45_T2	PHENOTYPE	15	16	ovarian carcinoma
NCT0017339446	NCT00173394_46_T0	GENE	2	2	Mesothelin
NCT0017339447	NCT00173394_47_T0	GENE	5	5	A24
NCT0017339448	NCT00173394_48_T0	GENE	10	10	A24
NCT0017339448	NCT00173394_48_T1	GENE	5	5	mesothelin
NCT0017339449	NCT00173394_49_T0	GENE	2	2	Mesothelin
NCT0017339450	NCT00173394_50_T0	GENE	1	1	Mesothelin
NCT0017339455	NCT00173394_55_T0	COMPOUND	7	7	1
NCT0017339455	NCT00173394_55_T1	COMPOUND	19	19	2
NCT0017339455	NCT00173394_55_T2	GENE	17	17	mesothelin
NCT0017339455	NCT00173394_55_T3	GENE	23	23	mesothelin
NCT0017339455	NCT00173394_55_T4	PHENOTYPE	30	31	ovarian cancer
NCT001734072	NCT00173407_2_T0	PHENOTYPE	10	10	tumors
NCT001734072	NCT00173407_2_T1	BIOLOGICAL_PROCESS	12	12	methylation
NCT001734072	NCT00173407_2_T2	GENE	2	2	PTEN
NCT001734072	NCT00173407_2_T3	GENE	3	3	has
NCT001734073	NCT00173407_3_T0	GENE	3	3	has
NCT001734073	NCT00173407_3_T1	PHENOTYPE	1	1	tumorigenesis
NCT001734074	NCT00173407_4_T0	BIOLOGICAL_PROCESS	22	22	methylation
NCT001734074	NCT00173407_4_T1	GENE	8	8	PTEN
NCT001734074	NCT00173407_4_T2	GENE	17	17	PTEN
NCT001734078	NCT00173407_8_T0	GENE	2	2	IGFBP-3
NCT001734078	NCT00173407_8_T1	PHENOTYPE	20	20	tumors
NCT001734078	NCT00173407_8_T2	PHENOTYPE	9	9	tumor
NCT0017340712	NCT00173407_12_T0	PHENOTYPE	10	10	tumors
NCT0017340712	NCT00173407_12_T1	BIOLOGICAL_PROCESS	12	12	methylation
NCT0017340712	NCT00173407_12_T2	GENE	2	2	PTEN
NCT0017340712	NCT00173407_12_T3	GENE	3	3	has
NCT0017340713	NCT00173407_13_T0	GENE	3	3	has
NCT0017340713	NCT00173407_13_T1	PHENOTYPE	1	1	tumorigenesis
NCT0017340714	NCT00173407_14_T0	BIOLOGICAL_PROCESS	22	22	methylation
NCT0017340714	NCT00173407_14_T1	GENE	8	8	PTEN
NCT0017340714	NCT00173407_14_T2	GENE	17	17	PTEN
NCT0017342015	NCT00173420_15_T0	PHENOTYPE	25	27	peripheral nerve diseases
NCT001734332	NCT00173433_2_T0	PHENOTYPE	8	8	relapse
NCT001734333	NCT00173433_3_T0	PHENOTYPE	2	2	tuberculosis
NCT001734333	NCT00173433_3_T1	PHENOTYPE	9	9	recurrent
NCT001734336	NCT00173433_6_T0	PHENOTYPE	13	13	tuberculosis
NCT001734337	NCT00173433_7_T0	PHENOTYPE	15	16	latent infection
NCT001734338	NCT00173433_8_T0	PHENOTYPE	4	4	focused
NCT0017343311	NCT00173433_11_T0	GENE	8	8	has
NCT0017343314	NCT00173433_14_T0	PHENOTYPE	8	8	relapse
NCT0017343315	NCT00173433_15_T0	PHENOTYPE	2	2	tuberculosis
NCT0017343315	NCT00173433_15_T1	PHENOTYPE	9	9	recurrent
NCT001734462	NCT00173446_2_T0	PHENOTYPE	13	13	inhibition
NCT001734462	NCT00173446_2_T1	COMPOUND	1	1	dopamine
NCT001734462	NCT00173446_2_T2	GENE	19	20	adenyl cyclase
NCT001734463	NCT00173446_3_T0	GENE	9	9	D5
NCT001734463	NCT00173446_3_T1	GENE	7	7	D1a
NCT001734463	NCT00173446_3_T2	GENE	6	6	D1
NCT001734463	NCT00173446_3_T3	GENE	14	14	D1
NCT001734463	NCT00173446_3_T4	COMPOUND	1	1	dopamine
NCT001734464	NCT00173446_4_T0	COMPOUND	4	4	D4
NCT001734464	NCT00173446_4_T1	GENE	8	8	D2
NCT001734464	NCT00173446_4_T2	GENE	2	2	D3
NCT001734465	NCT00173446_5_T0	PHENOTYPE	22	22	affects
NCT001734465	NCT00173446_5_T1	PHENOTYPE	7	7	hypertension
NCT001734465	NCT00173446_5_T2	PHENOTYPE	27	27	hypertension
NCT001734465	NCT00173446_5_T3	PHENOTYPE	36	36	hypertension
NCT001734465	NCT00173446_5_T4	PHENOTYPE	20	21	primary aldosteronism
NCT001734465	NCT00173446_5_T5	PHENOTYPE	12	13	primary hyperaldosteronism
NCT001734466	NCT00173446_6_T0	PHENOTYPE	6	6	hypertension
NCT001734467	NCT00173446_7_T0	GENE	11	11	APA
NCT001734467	NCT00173446_7_T1	PHENOTYPE	10	10	adenoma
NCT001734467	NCT00173446_7_T2	COMPOUND	20	20	metoclopramide
NCT001734469	NCT00173446_9_T0	GENE	9	9	APA
NCT001734469	NCT00173446_9_T1	GENE	19	19	APA
NCT001734469	NCT00173446_9_T2	GENE	16	17	D2 receptor
NCT0017344610	NCT00173446_10_T0	GENE	14	14	APA
NCT0017344610	NCT00173446_10_T1	GENE	8	8	mRNA
NCT0017344610	NCT00173446_10_T2	GENE	3	4	D2 receptor
NCT0017344610	NCT00173446_10_T3	ORGAN	18	19	adrenal glands
NCT0017344611	NCT00173446_11_T0	GENE	4	4	APA
NCT0017344611	NCT00173446_11_T1	GENE	24	24	al
NCT0017344611	NCT00173446_11_T2	GENE	7	7	D2
NCT0017344611	NCT00173446_11_T3	GENE	23	23	et
NCT0017344614	NCT00173446_14_T0	GENE	13	13	mRNA
NCT0017344614	NCT00173446_14_T1	GENE	9	9	D2
NCT0017344614	NCT00173446_14_T2	COMPOUND	11	11	D4
NCT0017344614	NCT00173446_14_T3	GENE	18	18	APA
NCT0017344614	NCT00173446_14_T4	GENE	12	12	receptor
NCT0017344614	NCT00173446_14_T5	COMPOUND	30	30	metoclopramide
NCT0017344614	NCT00173446_14_T6	ORGAN	22	23	adrenal glands
NCT001734594	NCT00173459_4_T0	PHENOTYPE	14	14	falling
NCT001734594	NCT00173459_4_T1	PHENOTYPE	4	5	lung injury
NCT001734724	NCT00173472_4_T0	GENE	10	10	EGFR
NCT0017347210	NCT00173472_10_T0	COMPOUND	11	11	irinotecan
NCT0017347210	NCT00173472_10_T1	COMPOUND	9	9	oxaliplatin
NCT0017347210	NCT00173472_10_T2	GENE	14	14	IV
NCT0017347211	NCT00173472_11_T0	COMPOUND	20	20	irinotecan
NCT0017347211	NCT00173472_11_T1	COMPOUND	7	7	FOLFOX
NCT0017347211	NCT00173472_11_T2	COMPOUND	14	14	FOLFIRI
NCT0017347212	NCT00173472_12_T0	PHENOTYPE	9	9	neurotoxicity
NCT0017347212	NCT00173472_12_T1	GENE	3	3	had
NCT0017347212	NCT00173472_12_T2	PHENOTYPE	11	11	diarrhea
NCT0017347213	NCT00173472_13_T0	PHENOTYPE	25	25	avoidance
NCT0017347216	NCT00173472_16_T0	GENE	15	15	al
NCT0017347216	NCT00173472_16_T1	GENE	16	16	Int
NCT0017347216	NCT00173472_16_T2	GENE	9	9	p53
NCT0017347216	NCT00173472_16_T3	GENE	14	14	et
NCT0017347218	NCT00173472_18_T0	GENE	16	16	MVD
NCT0017347218	NCT00173472_18_T1	GENE	18	18	EGFR
NCT0017347218	NCT00173472_18_T2	GENE	2	2	97
NCT0017347218	NCT00173472_18_T3	PHENOTYPE	15	15	MSI-H
NCT0017347219	NCT00173472_19_T0	COMPOUND	4	4	FOLFOX
NCT0017347219	NCT00173472_19_T1	COMPOUND	6	6	FOLFIRI
NCT0017347220	NCT00173472_20_T0	PHENOTYPE	2	2	tumor
NCT0017347220	NCT00173472_20_T1	BIOLOGICAL_PROCESS	9	9	metabolism
NCT0017347222	NCT00173472_22_T0	GENE	6	6	has
NCT0017347222	NCT00173472_22_T1	PHENOTYPE	9	9	MSI-H
NCT0017347222	NCT00173472_22_T2	PHENOTYPE	23	23	MSI-H
NCT0017347222	NCT00173472_22_T3	PHENOTYPE	17	18	colorectal cancer
NCT0017347222	NCT00173472_22_T4	PHENOTYPE	20	21	colorectal cancers
NCT0017347223	NCT00173472_23_T0	GENE	3	3	has
NCT0017347223	NCT00173472_23_T1	GENE	10	10	al
NCT0017347223	NCT00173472_23_T2	GENE	11	11	Int
NCT0017347223	NCT00173472_23_T3	GENE	9	9	et
NCT0017347223	NCT00173472_23_T4	PHENOTYPE	5	5	MSI-H
NCT0017347225	NCT00173472_25_T0	GENE	2	2	101
NCT0017347226	NCT00173472_26_T0	PHENOTYPE	43	43	tumors
NCT0017347226	NCT00173472_26_T1	PHENOTYPE	20	20	tumor
NCT0017347226	NCT00173472_26_T2	PHENOTYPE	27	27	tumor
NCT0017347226	NCT00173472_26_T3	GENE	17	17	DPD
NCT0017347226	NCT00173472_26_T4	GENE	32	32	DPD
NCT0017347226	NCT00173472_26_T5	PHENOTYPE	8	8	MSI-H
NCT0017347226	NCT00173472_26_T6	PHENOTYPE	45	45	MSI-H
NCT0017347226	NCT00173472_26_T7	GENE	15	15	TS
NCT0017347226	NCT00173472_26_T8	GENE	30	30	TS
NCT0017347228	NCT00173472_28_T0	GENE	12	12	MVD
NCT0017347228	NCT00173472_28_T1	GENE	10	10	EGFR
NCT0017347229	NCT00173472_29_T0	GENE	7	7	has
NCT0017347230	NCT00173472_30_T0	COMPOUND	10	10	FOLFOX
NCT0017347230	NCT00173472_30_T1	PHENOTYPE	18	19	colorectal cancer
NCT0017347234	NCT00173472_34_T0	GENE	10	10	EGFR
NCT001734851	NCT00173485_1_T0	GENE	3	3	TREM-1
NCT001734852	NCT00173485_2_T0	PHENOTYPE	6	6	peritonitis
NCT001734855	NCT00173485_5_T0	CELL	10	10	macrophages
NCT001734855	NCT00173485_5_T1	GENE	16	16	TREM-1
NCT001734855	NCT00173485_5_T2	TISSUE	1	1	tissues
NCT001734855	NCT00173485_5_T3	PHENOTYPE	6	6	infiltrated
NCT001734855	NCT00173485_5_T4	CELL	8	8	neutrophils
NCT001734856	NCT00173485_6_T0	PHENOTYPE	13	13	disorders
NCT001734856	NCT00173485_6_T1	GENE	1	1	TREM-1
NCT001734858	NCT00173485_8_T0	GENE	7	7	TREM-1
NCT001734858	NCT00173485_8_T1	PHENOTYPE	28	28	pneumonia
NCT001734858	NCT00173485_8_T2	GENE	18	18	has
NCT001734858	NCT00173485_8_T3	GENE	4	5	soluble form
NCT001734859	NCT00173485_9_T0	PHENOTYPE	3	3	progressive
NCT001734859	NCT00173485_9_T1	ORGAN	6	6	plasma
NCT001734859	NCT00173485_9_T2	PHENOTYPE	1	1	sepsis
NCT001734859	NCT00173485_9_T3	PHENOTYPE	19	19	sepsis
NCT0017348511	NCT00173485_11_T0	PHENOTYPE	6	6	peritonitis
NCT001734983	NCT00173498_3_T0	GENE	5	5	IgE
NCT001734983	NCT00173498_3_T1	ORGAN	3	3	serum
NCT001734983	NCT00173498_3_T2	PHENOTYPE	21	22	atopic dermatitis
NCT001734983	NCT00173498_3_T3	PHENOTYPE	6	7	skin prick
NCT001734984	NCT00173498_4_T0	GENE	9	9	IgE
NCT001734984	NCT00173498_4_T1	ORGAN	7	7	serum
NCT001734984	NCT00173498_4_T2	PHENOTYPE	25	26	atopic dermatitis
NCT001734984	NCT00173498_4_T3	PHENOTYPE	10	11	skin prick
NCT001735111	NCT00173511_1_T0	BIOLOGICAL_PROCESS	4	4	hemostasis
NCT001735112	NCT00173511_2_T0	PHENOTYPE	6	7	myocardial ischemia
NCT001735118	NCT00173511_8_T0	PHENOTYPE	6	7	lung disease
NCT001735118	NCT00173511_8_T1	PHENOTYPE	2	3	terminal illness
NCT001735119	NCT00173511_9_T0	PHENOTYPE	2	2	symptoms
NCT001735119	NCT00173511_9_T1	ORGAN	8	8	heart
NCT001735119	NCT00173511_9_T2	PHENOTYPE	4	5	myocardial ischemia
NCT0017351111	NCT00173511_11_T0	ORGAN	2	2	heart
NCT0017351112	NCT00173511_12_T0	BIOLOGICAL_PROCESS	8	8	hemostasis
NCT0017351113	NCT00173511_13_T0	BIOLOGICAL_PROCESS	7	7	hemostasis
NCT0017351114	NCT00173511_14_T0	PHENOTYPE	2	2	symptoms
NCT0017351114	NCT00173511_14_T1	ORGAN	8	8	heart
NCT0017351114	NCT00173511_14_T2	PHENOTYPE	4	5	myocardial ischemia
NCT001735242	NCT00173524_2_T0	PHENOTYPE	4	4	symptoms
NCT001735242	NCT00173524_2_T1	PHENOTYPE	29	29	NSCLC
NCT001735242	NCT00173524_2_T2	PHENOTYPE	6	8	quality of life
NCT001735245	NCT00173524_5_T0	GENE	5	5	EGFR
NCT001735245	NCT00173524_5_T1	PHENOTYPE	15	16	lung cancer
NCT001735370	NCT00173537_0_T0	PHENOTYPE	12	14	Primary Pulmonary Hypertension
NCT001735372	NCT00173537_2_T0	ORGAN	22	22	lungs
NCT001735372	NCT00173537_2_T1	ORGAN	1	2	pulmonary artery
NCT001735372	NCT00173537_2_T2	ORGAN	5	6	blood vessel
NCT001735372	NCT00173537_2_T3	ORGAN	12	13	right ventricle
NCT001735373	NCT00173537_3_T0	ORGAN	2	2	lungs
NCT001735373	NCT00173537_3_T1	ORGAN	29	29	aorta
NCT001735373	NCT00173537_3_T2	COMPOUND	7	7	oxygen
NCT001735373	NCT00173537_3_T3	ORGAN	17	18	left ventricle
NCT001735374	NCT00173537_4_T0	PHENOTYPE	12	14	primary pulmonary hypertension
NCT001735378	NCT00173537_8_T0	GENE	18	18	BMPR2
NCT0017353710	NCT00173537_10_T0	GENE	4	4	BMPR2
NCT0017353710	NCT00173537_10_T1	PHENOTYPE	7	9	primary pulmonary hypertension
NCT0017353713	NCT00173537_13_T0	GENE	2	2	has
NCT001735502	NCT00173550_2_T0	PHENOTYPE	11	11	osteoporosis
NCT001735502	NCT00173550_2_T1	GENE	4	4	hormone
NCT001735502	NCT00173550_2_T2	PHENOTYPE	8	9	cardiovascular disease
NCT001735503	NCT00173550_3_T0	GENE	3	3	has
NCT001735506	NCT00173550_6_T0	PHENOTYPE	25	25	osteoporosis
NCT001735506	NCT00173550_6_T1	GENE	17	17	hormone
NCT001735506	NCT00173550_6_T2	PHENOTYPE	26	27	cardiovascular disease
NCT001735506	NCT00173550_6_T3	PHENOTYPE	30	31	chronic disease
NCT001735631	NCT00173563_1_T0	PHENOTYPE	6	6	coronavirus
NCT001735631	NCT00173563_1_T1	PHENOTYPE	7	7	SARS-CoV
NCT001735633	NCT00173563_3_T0	GENE	17	17	eg
NCT001735633	NCT00173563_3_T1	PHENOTYPE	8	8	initiation
NCT001735633	NCT00173563_3_T2	CELL	1	1	monocyte
NCT001735633	NCT00173563_3_T3	BIOLOGICAL_PROCESS	10	11	immune response
NCT001735635	NCT00173563_5_T0	CELL	0	0	Monocytes
NCT001735635	NCT00173563_5_T1	BIOLOGICAL_PROCESS	7	8	immune response
NCT001735638	NCT00173563_8_T0	CELL	5	5	monocytes
NCT001735639	NCT00173563_9_T0	CELL	0	0	Monocytes
NCT001735639	NCT00173563_9_T1	PHENOTYPE	7	7	SARS-CoV
NCT0017356311	NCT00173563_11_T0	CELL	3	3	monocytes
NCT0017356311	NCT00173563_11_T1	GENE	1	1	secreted
NCT0017356313	NCT00173563_13_T0	PHENOTYPE	15	15	severity
NCT0017356313	NCT00173563_13_T1	CELL	10	10	monocytes
NCT0017356313	NCT00173563_13_T2	PHENOTYPE	6	6	SARS-CoV
NCT0017356313	NCT00173563_13_T3	PHENOTYPE	18	18	SARS-CoV
NCT001735769	NCT00173576_9_T0	PHENOTYPE	2	2	SARS-CoV
NCT001735769	NCT00173576_9_T1	PHENOTYPE	3	5	infection in children
NCT0017357610	NCT00173576_10_T0	GENE	8	8	ER
NCT0017357611	NCT00173576_11_T0	GENE	17	17	IgG
NCT0017357611	NCT00173576_11_T1	PHENOTYPE	16	16	SARS-CoV
NCT0017357611	NCT00173576_11_T2	ORGAN	9	9	serum
NCT001735890	NCT00173589_0_T0	PHENOTYPE	5	6	Atrial Fibrillation
NCT001736021	NCT00173602_1_T0	PHENOTYPE	11	13	peripheral artery occlusion
NCT001736151	NCT00173615_1_T0	GENE	18	18	CPR
NCT001736153	NCT00173615_3_T0	GENE	20	20	bypass
NCT001736284	NCT00173628_4_T0	GENE	8	8	insulin
NCT001736287	NCT00173628_7_T0	GENE	17	17	islet
NCT001736288	NCT00173628_8_T0	GENE	6	6	GAD65
NCT001736288	NCT00173628_8_T1	GENE	2	5	glutamic acid decarboxylase 65
NCT0017362811	NCT00173628_11_T0	PHENOTYPE	6	7	autoimmune thyroiditis
NCT0017362811	NCT00173628_11_T1	PHENOTYPE	2	3	autoimmune disease
NCT001736412	NCT00173641_2_T0	CELL	3	4	T cells
NCT001736414	NCT00173641_4_T0	PHENOTYPE	4	5	immune dysfunction
NCT001736416	NCT00173641_6_T0	GENE	0	0	CD4
NCT001736416	NCT00173641_6_T1	GENE	1	1	CD25
NCT001736416	NCT00173641_6_T2	CELL	3	4	T cells
NCT0017364113	NCT00173641_13_T0	GENE	24	24	GITR
NCT0017364113	NCT00173641_13_T1	GENE	22	22	Foxp3
NCT0017364113	NCT00173641_13_T2	GENE	16	16	PCR
NCT0017364114	NCT00173641_14_T0	GENE	3	3	GAD65
NCT0017364116	NCT00173641_16_T0	PHENOTYPE	25	26	autoimmune disease
NCT001736540	NCT00173654_0_T0	PHENOTYPE	0	0	Mutation
NCT001736543	NCT00173654_3_T0	COMPOUND	6	6	1
NCT001736544	NCT00173654_4_T0	GENE	17	17	has
NCT001736545	NCT00173654_5_T0	PHENOTYPE	9	10	external genitalia
NCT0017365410	NCT00173654_10_T0	COMPOUND	9	9	testosterone
NCT0017365410	NCT00173654_10_T1	COMPOUND	11	11	dihydrotestosterone
NCT0017365410	NCT00173654_10_T2	BIOLOGICAL_PROCESS	5	5	androstenedione
NCT0017365410	NCT00173654_10_T3	ORGAN	2	2	serum
NCT0017365413	NCT00173654_13_T0	GENE	1	1	HSD17B3
NCT0017365414	NCT00173654_14_T0	PHENOTYPE	2	2	mutation
NCT0017365414	NCT00173654_14_T1	PHENOTYPE	5	5	mutation
NCT0017365416	NCT00173654_16_T0	COMPOUND	14	14	testosterone
NCT0017365416	NCT00173654_16_T1	ORGAN	11	11	serum
NCT0017365417	NCT00173654_17_T0	PHENOTYPE	8	8	peripheral
NCT0017365417	NCT00173654_17_T1	PHENOTYPE	5	5	understood
NCT0017365418	NCT00173654_18_T0	PHENOTYPE	10	10	pathology
NCT001736670	NCT00173667_0_T0	PHENOTYPE	14	15	Essential Hypertension
NCT001736675	NCT00173667_5_T0	COMPOUND	9	9	nifedipine
NCT001736679	NCT00173667_9_T0	ORGAN	6	6	heart
NCT0017366710	NCT00173667_10_T0	COMPOUND	16	16	nifedipine
NCT0017366710	NCT00173667_10_T1	GENE	9	9	3/12
NCT0017366718	NCT00173667_18_T0	PHENOTYPE	17	17	hypertension
NCT0017366719	NCT00173667_19_T0	COMPOUND	10	10	nifedipine
NCT0017366719	NCT00173667_19_T1	GENE	11	11	has
NCT0017366720	NCT00173667_20_T0	COMPOUND	19	19	nifedipine
NCT0017366720	NCT00173667_20_T1	ORGAN	16	16	plasma
NCT0017366722	NCT00173667_22_T0	PHENOTYPE	26	26	hypertension
NCT0017366725	NCT00173667_25_T0	COMPOUND	9	9	nifedipine
NCT0017366725	NCT00173667_25_T1	PHENOTYPE	14	14	hypertension
NCT0017366727	NCT00173667_27_T0	COMPOUND	13	13	nifedipine
NCT0017366727	NCT00173667_27_T1	PHENOTYPE	18	18	hypertension
NCT0017366734	NCT00173667_34_T0	PHENOTYPE	11	11	hypertension
NCT0017366738	NCT00173667_38_T0	COMPOUND	10	10	nifedipine
NCT0017366738	NCT00173667_38_T1	COMPOUND	18	18	nifedipine
NCT0017366738	NCT00173667_38_T2	PHENOTYPE	16	17	Group B
NCT0017366739	NCT00173667_39_T0	COMPOUND	16	16	nifedipine
NCT0017366742	NCT00173667_42_T0	COMPOUND	9	9	nifedipine
NCT0017366746	NCT00173667_46_T0	ORGAN	6	6	heart
NCT0017366747	NCT00173667_47_T0	COMPOUND	16	16	nifedipine
NCT0017366747	NCT00173667_47_T1	GENE	9	9	3/12
NCT0017366754	NCT00173667_54_T0	PHENOTYPE	21	21	symptoms
NCT0017366754	NCT00173667_54_T1	PHENOTYPE	23	23	complications
NCT0017366754	NCT00173667_54_T2	PHENOTYPE	0	0	Withdrawal
NCT0017366757	NCT00173667_57_T0	PHENOTYPE	34	35	adverse reactions
NCT0017366757	NCT00173667_57_T1	PHENOTYPE	2	3	adverse events
NCT001736803	NCT00173680_3_T0	CELL	4	4	cells
NCT001736803	NCT00173680_3_T1	PHENOTYPE	2	2	adhesion
NCT001736803	NCT00173680_3_T2	CELL	7	8	extracellular matrix
NCT001736804	NCT00173680_4_T0	CELL	14	14	cells
NCT001736804	NCT00173680_4_T1	CELL	4	5	extracellular matrix
NCT001736805	NCT00173680_5_T0	CELL	2	2	cells
NCT001736805	NCT00173680_5_T1	PHENOTYPE	1	1	tumor
NCT001736806	NCT00173680_6_T0	GENE	22	22	mRNA
NCT001736806	NCT00173680_6_T1	BIOLOGICAL_PROCESS	19	19	splicing
NCT001736806	NCT00173680_6_T2	GENE	0	0	CD44
NCT001736807	NCT00173680_7_T0	GENE	10	10	1.5
NCT001736807	NCT00173680_7_T1	GENE	4	4	has
NCT001736808	NCT00173680_8_T0	BIOLOGICAL_PROCESS	8	8	splicing
NCT0017368010	NCT00173680_10_T0	PHENOTYPE	3	3	tumors
NCT0017368011	NCT00173680_11_T0	PHENOTYPE	10	11	tumor progression
NCT0017368011	NCT00173680_11_T1	PHENOTYPE	1	2	breast cancers
NCT0017368012	NCT00173680_12_T0	PHENOTYPE	1	2	colorectal tumors
NCT0017368015	NCT00173680_15_T0	GENE	12	12	has
NCT0017368015	NCT00173680_15_T1	GENE	7	7	CD44
NCT0017368015	NCT00173680_15_T2	PHENOTYPE	2	3	lung cancer
NCT0017368015	NCT00173680_15_T3	PHENOTYPE	10	11	tumor metastasis
NCT0017368018	NCT00173680_18_T0	PHENOTYPE	13	13	adenocarcinoma
NCT0017368021	NCT00173680_21_T0	PHENOTYPE	32	32	tumor
NCT0017368021	NCT00173680_21_T1	BIOLOGICAL_PROCESS	7	7	methylation
NCT0017368021	NCT00173680_21_T2	GENE	2	2	CD44
NCT0017368021	NCT00173680_21_T3	GENE	10	10	CD44
NCT001736930	NCT00173693_0_T0	PHENOTYPE	10	10	Fracture
NCT001736930	NCT00173693_0_T1	PHENOTYPE	7	8	Osteoporotic Fracture
NCT0017369310	NCT00173693_10_T0	PHENOTYPE	13	14	osteoporotic fracture
NCT0017369314	NCT00173693_14_T0	PHENOTYPE	8	9	osteoporotic fracture
NCT0017369330	NCT00173693_30_T0	PHENOTYPE	3	3	falls
NCT0017369337	NCT00173693_37_T0	COMPOUND	3	3	1st
NCT0017369337	NCT00173693_37_T1	GENE	2	2	FU
NCT0017369337	NCT00173693_37_T2	GENE	4	4	FU
NCT0017369339	NCT00173693_39_T0	PHENOTYPE	6	7	osteoporotic fracture
NCT0017369340	NCT00173693_40_T0	PHENOTYPE	8	8	QOL
NCT0017369342	NCT00173693_42_T0	GENE	2	2	FU
NCT0017369342	NCT00173693_42_T1	GENE	4	4	FU
NCT0017369343	NCT00173693_43_T0	PHENOTYPE	21	21	fractured
NCT0017369343	NCT00173693_43_T1	PHENOTYPE	7	7	QOL
NCT0017369343	NCT00173693_43_T2	PHENOTYPE	11	12	osteoporotic fracture
NCT0017369344	NCT00173693_44_T0	GENE	6	6	CEA
NCT0017369347	NCT00173693_47_T0	GENE	2	2	FU
NCT001737064	NCT00173706_4_T0	COMPOUND	5	5	L-carnitine
NCT001737064	NCT00173706_4_T1	PHENOTYPE	30	30	hypotension
NCT001737064	NCT00173706_4_T2	PHENOTYPE	12	12	complications
NCT001737064	NCT00173706_4_T3	GENE	36	36	reduced
NCT001737064	NCT00173706_4_T4	PHENOTYPE	26	26	symptoms
NCT001737064	NCT00173706_4_T5	CELL	43	43	cells
NCT001737064	NCT00173706_4_T6	COMPOUND	37	37	carnitine
NCT001737064	NCT00173706_4_T7	MOLECULAR_FUNCTION	39	40	transferase activity
NCT001737064	NCT00173706_4_T8	PHENOTYPE	18	19	cardiac complications
NCT001737064	NCT00173706_4_T9	GENE	38	39	palmitoyl transferase
NCT001737064	NCT00173706_4_T10	PHENOTYPE	32	33	erythropoietin-resistant anemia
NCT0017370610	NCT00173706_10_T0	COMPOUND	18	18	acetate
NCT0017370610	NCT00173706_10_T1	COMPOUND	17	17	bicarbonate
NCT0017370618	NCT00173706_18_T0	PHENOTYPE	6	8	chronic heart failure
NCT0017370620	NCT00173706_20_T0	PHENOTYPE	2	3	class IV
NCT0017370626	NCT00173706_26_T0	PHENOTYPE	2	2	diseases
NCT0017370626	NCT00173706_26_T1	PHENOTYPE	4	4	tumours
NCT0017370628	NCT00173706_28_T0	PHENOTYPE	2	5	drug and alcohol abuse
NCT0017370629	NCT00173706_29_T0	PHENOTYPE	3	3	HIV
NCT0017370633	NCT00173706_33_T0	COMPOUND	2	2	corticoid
NCT0017370635	NCT00173706_35_T0	COMPOUND	2	2	L-carnitine
NCT001737190	NCT00173719_0_T0	PHENOTYPE	12	12	Stroke
NCT001737193	NCT00173719_3_T0	GENE	25	25	al
NCT001737193	NCT00173719_3_T1	GENE	24	24	et
NCT001737320	NCT00173732_0_T0	CELL	8	8	Cell
NCT001737327	NCT00173732_7_T0	PHENOTYPE	4	4	disorders
NCT001737327	NCT00173732_7_T1	CELL	12	12	cells
NCT001737327	NCT00173732_7_T2	CELL	16	16	blastomeres
NCT001737327	NCT00173732_7_T3	GENE	0	0	PGD
NCT001737327	NCT00173732_7_T4	CELL	13	14	polar bodies
NCT0017373211	NCT00173732_11_T0	GENE	11	11	has
NCT0017373211	NCT00173732_11_T1	PHENOTYPE	25	25	degenerate
NCT0017373211	NCT00173732_11_T2	GENE	27	27	PCR
NCT0017373212	NCT00173732_12_T0	GENE	7	7	PCR
NCT0017373212	NCT00173732_12_T1	PHENOTYPE	5	5	degenerate
NCT0017373214	NCT00173732_14_T0	PHENOTYPE	0	0	Amplification
NCT0017373215	NCT00173732_15_T0	GENE	4	4	10
NCT0017373218	NCT00173732_18_T0	GENE	24	24	fragment
NCT0017373218	NCT00173732_18_T1	CELL	18	18	chromosome
NCT0017373221	NCT00173732_21_T0	PHENOTYPE	29	29	disorders
NCT0017373221	NCT00173732_21_T1	GENE	14	14	PGD
NCT0017373221	NCT00173732_21_T2	GENE	25	25	PGD
NCT0017373221	NCT00173732_21_T3	GENE	19	19	ADO
NCT001737452	NCT00173745_2_T0	PHENOTYPE	1	1	drooling
NCT001737452	NCT00173745_2_T1	PHENOTYPE	23	23	dehydration
NCT001737452	NCT00173745_2_T2	PHENOTYPE	4	5	skin maceration
NCT001737453	NCT00173745_3_T0	PHENOTYPE	14	14	drooling
NCT001737454	NCT00173745_4_T0	PHENOTYPE	11	11	complications
NCT001737455	NCT00173745_5_T0	CELL	6	6	neurons
NCT001737455	NCT00173745_5_T1	ORGAN	0	1	Nerve endings
NCT001737457	NCT00173745_7_T0	PHENOTYPE	14	14	drooling
NCT001737457	NCT00173745_7_T1	GENE	10	10	toxin
NCT001737457	NCT00173745_7_T2	GENE	4	4	had
NCT001737458	NCT00173745_8_T0	PHENOTYPE	9	10	neurological disorders
NCT001737459	NCT00173745_9_T0	PHENOTYPE	16	16	drooling
NCT001737459	NCT00173745_9_T1	GENE	12	12	toxin
NCT001737459	NCT00173745_9_T2	PHENOTYPE	20	21	cerebral palsy
NCT001737581	NCT00173758_1_T0	PHENOTYPE	12	12	interests
NCT001737582	NCT00173758_2_T0	CELL	7	7	lymphocytes
NCT001737582	NCT00173758_2_T1	CELL	11	13	natural killer cells
NCT001737583	NCT00173758_3_T0	PHENOTYPE	11	11	peripheral
NCT001737583	NCT00173758_3_T1	CELL	12	14	natural killer cells
NCT001737584	NCT00173758_4_T0	CELL	12	12	cytotrophoblasts
NCT001737586	NCT00173758_6_T0	CELL	26	26	lymphocytes
NCT001737586	NCT00173758_6_T1	GENE	16	16	IL-2
NCT001737586	NCT00173758_6_T2	GENE	5	5	IL-15
NCT001737586	NCT00173758_6_T3	GENE	14	14	IL-15
NCT001737587	NCT00173758_7_T0	CELL	13	13	lymphocytes
NCT001737587	NCT00173758_7_T1	GENE	9	9	IL-15
NCT001737588	NCT00173758_8_T0	GENE	13	13	receptor
NCT001737588	NCT00173758_8_T1	GENE	10	10	IL-15
NCT001737589	NCT00173758_9_T0	GENE	6	6	receptor
NCT001737589	NCT00173758_9_T1	GENE	5	5	IL-15
NCT001737589	NCT00173758_9_T2	GENE	31	31	IL-15
NCT001737589	NCT00173758_9_T3	CELL	11	13	natural killer cells
NCT0017375810	NCT00173758_10_T0	GENE	7	7	receptor
NCT0017375810	NCT00173758_10_T1	CELL	12	12	cells
NCT0017375810	NCT00173758_10_T2	GENE	6	6	IL-15
NCT0017375810	NCT00173758_10_T3	GENE	14	14	IL-15
NCT0017375811	NCT00173758_11_T0	CELL	12	12	cells
NCT0017375811	NCT00173758_11_T1	BIOLOGICAL_PROCESS	21	21	fertilization
NCT0017375813	NCT00173758_13_T0	PHENOTYPE	5	5	peripheral
NCT0017375816	NCT00173758_16_T0	GENE	11	11	peroxidase
NCT0017375816	NCT00173758_16_T1	GENE	4	4	IL-15
NCT0017375817	NCT00173758_17_T0	COMPOUND	6	6	hematoxylin
NCT0017375819	NCT00173758_19_T0	PHENOTYPE	7	7	peripheral
NCT0017375819	NCT00173758_19_T1	PHENOTYPE	0	0	Separation
NCT0017375819	NCT00173758_19_T2	CELL	3	3	cells
NCT0017375821	NCT00173758_21_T0	GENE	10	10	mesh
NCT0017375824	NCT00173758_24_T0	PHENOTYPE	0	0	Peripheral
NCT0017375824	NCT00173758_24_T1	CELL	3	3	cells
NCT0017375826	NCT00173758_26_T0	CELL	12	12	cells
NCT0017375826	NCT00173758_26_T1	GENE	6	6	IL-15
NCT0017375831	NCT00173758_31_T0	GENE	3	3	IL-15
NCT0017375831	NCT00173758_31_T1	GENE	6	6	mRNA
NCT0017375831	NCT00173758_31_T2	GENE	11	11	CD4
NCT0017375831	NCT00173758_31_T3	CELL	12	12	cells
NCT0017375831	NCT00173758_31_T4	CELL	14	14	cells
NCT0017375831	NCT00173758_31_T5	CELL	17	17	cells
NCT0017375831	NCT00173758_31_T6	GENE	13	13	CD8
NCT0017375831	NCT00173758_31_T7	GENE	26	26	cDNA
NCT0017375831	NCT00173758_31_T8	PHENOTYPE	24	24	transformed
NCT0017375831	NCT00173758_31_T9	GENE	1	1	PCR
NCT0017375831	NCT00173758_31_T10	BIOLOGICAL_PROCESS	28	29	reverse transcription
NCT0017375832	NCT00173758_32_T0	GENE	9	9	IL-15
NCT0017375832	NCT00173758_32_T1	GENE	14	14	PRISM
NCT0017375832	NCT00173758_32_T2	GENE	1	1	PCR
NCT0017375835	NCT00173758_35_T0	GENE	3	3	CD4
NCT0017375835	NCT00173758_35_T1	CELL	4	4	cells
NCT0017375835	NCT00173758_35_T2	CELL	6	6	cells
NCT0017375835	NCT00173758_35_T3	GENE	5	5	CD8
NCT0017375835	NCT00173758_35_T4	CELL	8	9	NK cells
NCT0017375836	NCT00173758_36_T0	PHENOTYPE	24	24	concentrations
NCT0017375836	NCT00173758_36_T1	GENE	26	26	IL-15
NCT0017375836	NCT00173758_36_T2	GENE	13	13	CD4
NCT0017375836	NCT00173758_36_T3	CELL	14	14	cells
NCT0017375836	NCT00173758_36_T4	CELL	16	16	cells
NCT0017375836	NCT00173758_36_T5	GENE	28	28	IL-2
NCT0017375836	NCT00173758_36_T6	PHENOTYPE	10	10	proliferative
NCT0017375836	NCT00173758_36_T7	GENE	15	15	CD8
NCT0017375836	NCT00173758_36_T8	PHENOTYPE	0	0	Proliferative
NCT0017375836	NCT00173758_36_T9	CELL	18	19	NK cells
NCT0017375836	NCT00173758_36_T10	PHENOTYPE	7	8	cellular proliferation
NCT0017375838	NCT00173758_38_T0	GENE	8	8	IL-10
NCT0017375838	NCT00173758_38_T1	PHENOTYPE	3	3	concentrations
NCT0017375838	NCT00173758_38_T2	PHENOTYPE	19	19	concentrations
NCT0017375838	NCT00173758_38_T3	GENE	23	23	IL-2
NCT0017375838	NCT00173758_38_T4	BIOLOGICAL_PROCESS	0	0	Secretion
NCT0017375838	NCT00173758_38_T5	GENE	21	21	IL-15
NCT0017375838	NCT00173758_38_T6	GENE	6	6	IL-6
NCT0017375841	NCT00173758_41_T0	CELL	11	11	cells
NCT0017375841	NCT00173758_41_T1	CELL	16	16	cytotrophoblasts
NCT0017375841	NCT00173758_41_T2	GENE	6	6	caspase
NCT0017375841	NCT00173758_41_T3	CELL	12	13	K562 cells
NCT0017375841	NCT00173758_41_T4	BIOLOGICAL_PROCESS	20	21	caspase activation
NCT0017375842	NCT00173758_42_T0	GENE	3	3	IL-15
NCT0017375842	NCT00173758_42_T1	ORGAN	16	16	endometrium
NCT0017375844	NCT00173758_44_T0	COMPOUND	12	12	fluorescein
NCT0017375844	NCT00173758_44_T1	COMPOUND	13	13	isothiocyanate
NCT0017375844	NCT00173758_44_T2	GENE	2	2	IL-15
NCT0017375847	NCT00173758_47_T0	GENE	25	25	biotin
NCT0017375847	NCT00173758_47_T1	GENE	22	22	Kit
NCT0017375847	NCT00173758_47_T2	GENE	3	3	IL-15
NCT0017375847	NCT00173758_47_T3	GENE	6	6	mRNA
NCT0017375847	NCT00173758_47_T4	GENE	15	15	mRNA
NCT0017375847	NCT00173758_47_T5	GENE	1	1	PCR
NCT0017375848	NCT00173758_48_T0	GENE	13	13	IL-15
NCT0017375848	NCT00173758_48_T1	GENE	3	3	cDNA
NCT0017375848	NCT00173758_48_T2	GENE	18	18	PRISM
NCT0017375848	NCT00173758_48_T3	PHENOTYPE	1	1	transforming
NCT0017375848	NCT00173758_48_T4	GENE	5	5	PCR
NCT0017375851	NCT00173758_51_T0	GENE	6	6	collagenase
NCT0017375851	NCT00173758_51_T1	PHENOTYPE	3	3	digested
NCT0017375851	NCT00173758_51_T2	GENE	7	8	type 2
NCT0017375854	NCT00173758_54_T0	PHENOTYPE	8	8	digests
NCT0017375859	NCT00173758_59_T0	CELL	2	2	cells
NCT0017375859	NCT00173758_59_T1	CELL	13	13	zygotes
NCT0017375859	NCT00173758_59_T2	ORGAN	29	29	serum
NCT0017375863	NCT00173758_63_T0	ORGAN	8	9	fetal heart
NCT0017375868	NCT00173758_68_T0	CELL	1	1	cells
NCT0017375868	NCT00173758_68_T1	PHENOTYPE	11	11	Fixation
NCT0017375868	NCT00173758_68_T2	PHENOTYPE	7	7	adhesion
NCT0017375869	NCT00173758_69_T0	COMPOUND	13	13	isothiocyanate
NCT0017375869	NCT00173758_69_T1	GENE	3	3	IL-15
NCT0017375872	NCT00173758_72_T0	GENE	3	3	IL-15
NCT0017375872	NCT00173758_72_T1	GENE	6	6	mRNA
NCT0017375872	NCT00173758_72_T2	GENE	30	30	cDNA
NCT0017375872	NCT00173758_72_T3	PHENOTYPE	28	28	transformed
NCT0017375872	NCT00173758_72_T4	GENE	1	1	PCR
NCT0017375872	NCT00173758_72_T5	BIOLOGICAL_PROCESS	32	33	reverse transcription
NCT0017375872	NCT00173758_72_T6	CELL	12	13	stromal cells
NCT0017375872	NCT00173758_72_T7	CELL	21	22	stromal cells
NCT0017375873	NCT00173758_73_T0	GENE	9	9	IL-15
NCT0017375873	NCT00173758_73_T1	GENE	14	14	PRISM
NCT0017375873	NCT00173758_73_T2	GENE	1	1	PCR
NCT001737711	NCT00173771_1_T0	GENE	5	5	had
NCT001737713	NCT00173771_3_T0	PHENOTYPE	28	28	opinions
NCT001737713	NCT00173771_3_T1	GENE	26	26	ICF
NCT001737714	NCT00173771_4_T0	GENE	19	19	reduced
NCT0017377111	NCT00173771_11_T0	GENE	10	10	had
NCT0017377111	NCT00173771_11_T1	GENE	7	7	NSC
NCT0017377113	NCT00173771_13_T0	PHENOTYPE	28	28	opinions
NCT0017377113	NCT00173771_13_T1	GENE	26	26	ICF
NCT0017377114	NCT00173771_14_T0	GENE	19	19	reduced
NCT001737845	NCT00173784_5_T0	PHENOTYPE	8	8	focused
NCT001737970	NCT00173797_0_T0	PHENOTYPE	11	11	Stroke
NCT001737977	NCT00173797_7_T0	PHENOTYPE	1	1	chronic
NCT001737978	NCT00173797_8_T0	PHENOTYPE	4	4	chronic
NCT001738106	NCT00173810_6_T0	PHENOTYPE	26	26	opinions
NCT001738106	NCT00173810_6_T1	GENE	2	2	4.5
NCT0017381010	NCT00173810_10_T0	PHENOTYPE	13	13	chronic
NCT0017381011	NCT00173810_11_T0	PHENOTYPE	22	22	transformed
NCT001738231	NCT00173823_1_T0	PHENOTYPE	7	7	CVD
NCT001738231	NCT00173823_1_T1	PHENOTYPE	28	28	CVD
NCT001738231	NCT00173823_1_T2	PHENOTYPE	14	14	ESRD
NCT001738231	NCT00173823_1_T3	PHENOTYPE	5	6	cardiovascular disease
NCT001738231	NCT00173823_1_T4	PHENOTYPE	11	13	end-stage renal disease
NCT001738232	NCT00173823_2_T0	PHENOTYPE	18	18	atherosclerosis
NCT001738232	NCT00173823_2_T1	PHENOTYPE	22	22	ESRD
NCT001738232	NCT00173823_2_T2	COMPOUND	5	5	homocysteine
NCT001738232	NCT00173823_2_T3	ORGAN	4	4	plasma
NCT001738232	NCT00173823_2_T4	PHENOTYPE	15	16	chronic inflammation
NCT001738233	NCT00173823_3_T0	PHENOTYPE	2	2	inflammation
NCT001738233	NCT00173823_3_T1	PHENOTYPE	0	0	Malnutrition
NCT001738233	NCT00173823_3_T2	PHENOTYPE	7	9	quality of life
NCT001738363	NCT00173836_3_T0	GENE	3	3	saliva
NCT001738363	NCT00173836_3_T1	GENE	21	21	saliva
NCT001738492	NCT00173849_2_T0	PHENOTYPE	20	21	oral cancer
NCT001738492	NCT00173849_2_T1	PHENOTYPE	6	8	lymph node metastases
NCT001738493	NCT00173849_3_T0	PHENOTYPE	3	4	oral cancer
NCT001738493	NCT00173849_3_T1	PHENOTYPE	15	17	lymph node metastasis
NCT001738494	NCT00173849_4_T0	CELL	17	17	cells
NCT001738494	NCT00173849_4_T1	PHENOTYPE	6	6	malignancy
NCT001738494	NCT00173849_4_T2	PHENOTYPE	16	16	tumor
NCT001738494	NCT00173849_4_T3	PHENOTYPE	0	1	Tumor metastasis
NCT001738496	NCT00173849_6_T0	CELL	10	10	cells
NCT001738496	NCT00173849_6_T1	CELL	33	33	cells
NCT001738496	NCT00173849_6_T2	PHENOTYPE	30	30	metastasis
NCT001738496	NCT00173849_6_T3	TISSUE	24	25	lymph node
NCT001738497	NCT00173849_7_T0	COMPOUND	16	16	heparin
NCT001738497	NCT00173849_7_T1	GENE	7	7	polypeptide
NCT001738498	NCT00173849_8_T0	GENE	7	7	CC
NCT001738499	NCT00173849_9_T0	CELL	11	11	cells
NCT001738499	NCT00173849_9_T1	TISSUE	6	6	tissues
NCT001738499	NCT00173849_9_T2	GENE	13	13	G-protein
NCT0017384910	NCT00173849_10_T0	PHENOTYPE	22	22	allergy
NCT0017384910	NCT00173849_10_T1	CELL	11	12	polymorphonuclear leukocytes
NCT0017384910	NCT00173849_10_T2	BIOLOGICAL_PROCESS	26	27	wound healing
NCT0017384910	NCT00173849_10_T3	PHENOTYPE	23	24	cardiovascular diseases
NCT0017384910	NCT00173849_10_T4	PHENOTYPE	20	21	viral infections
NCT0017384910	NCT00173849_10_T5	PHENOTYPE	16	17	inflammatory responses
NCT0017384913	NCT00173849_13_T0	PHENOTYPE	5	6	malignant tumors
NCT0017384914	NCT00173849_14_T0	PHENOTYPE	10	10	tumor
NCT0017384914	NCT00173849_14_T1	PHENOTYPE	8	8	immunity
NCT0017384917	NCT00173849_17_T0	GENE	0	0	SDF-1
NCT0017384917	NCT00173849_17_T1	GENE	12	12	CXCR4
NCT0017384917	NCT00173849_17_T2	GENE	4	5	CXC chemokine
NCT0017384920	NCT00173849_20_T0	GENE	14	14	SDF-1
NCT0017384920	NCT00173849_20_T1	GENE	12	12	CXCR4
NCT0017384920	NCT00173849_20_T2	GENE	9	9	mRNA
NCT0017384920	NCT00173849_20_T3	PHENOTYPE	16	17	solid tumors
NCT0017384921	NCT00173849_21_T0	PHENOTYPE	9	10	cancer progression
NCT0017384922	NCT00173849_22_T0	PHENOTYPE	20	20	tumors
NCT0017384922	NCT00173849_22_T1	PHENOTYPE	19	19	glioblastoma
NCT0017384922	NCT00173849_22_T2	PHENOTYPE	13	13	proliferation
NCT0017384922	NCT00173849_22_T3	GENE	7	7	CXCR4
NCT0017384922	NCT00173849_22_T4	GENE	2	2	al
NCT0017384922	NCT00173849_22_T5	GENE	1	1	et
NCT0017384924	NCT00173849_24_T0	CELL	17	17	cells
NCT0017384924	NCT00173849_24_T1	GENE	6	6	SDF-1
NCT0017384924	NCT00173849_24_T2	GENE	8	8	CXCR4
NCT0017384924	NCT00173849_24_T3	TISSUE	19	20	lymph node
NCT0017384924	NCT00173849_24_T4	PHENOTYPE	15	16	breast cancer
NCT0017384926	NCT00173849_26_T0	TISSUE	11	11	tissues
NCT0017384926	NCT00173849_26_T1	GENE	7	7	SDF-1
NCT0017384926	NCT00173849_26_T2	GENE	3	3	reduced
NCT0017384926	NCT00173849_26_T3	GENE	4	4	mRNA
NCT0017384927	NCT00173849_27_T0	TISSUE	18	18	tissues
NCT0017384927	NCT00173849_27_T1	MOLECULAR_FUNCTION	13	14	receptor ligand
NCT0017384928	NCT00173849_28_T0	PHENOTYPE	6	7	oral cancer
NCT0017384929	NCT00173849_29_T0	PHENOTYPE	1	1	metastasis
NCT0017384929	NCT00173849_29_T1	PHENOTYPE	12	12	metastasis
NCT0017384929	NCT00173849_29_T2	ORGAN	9	10	lymphatic system
NCT0017384929	NCT00173849_29_T3	PHENOTYPE	3	4	oral cancer
NCT0017384930	NCT00173849_30_T0	PHENOTYPE	8	8	metastasis
NCT0017384930	NCT00173849_30_T1	PHENOTYPE	23	23	metastasis
NCT0017384930	NCT00173849_30_T2	PHENOTYPE	10	11	oral cancer
NCT0017384931	NCT00173849_31_T0	PHENOTYPE	13	13	metastasis
NCT0017384931	NCT00173849_31_T1	PHENOTYPE	11	12	oral cancer
NCT0017384933	NCT00173849_33_T0	PHENOTYPE	16	16	focal
NCT001738628	NCT00173862_8_T0	GENE	0	0	GI
NCT0017386210	NCT00173862_10_T0	PHENOTYPE	4	4	infections
NCT0017386211	NCT00173862_11_T0	PHENOTYPE	9	9	toxicity
NCT0017386211	NCT00173862_11_T1	COMPOUND	7	7	NCI
NCT0017386211	NCT00173862_11_T2	PHENOTYPE	14	15	motor neuropathy
NCT0017386211	NCT00173862_11_T3	PHENOTYPE	0	1	Peripheral neuropathy
NCT0017386212	NCT00173862_12_T0	PHENOTYPE	2	2	arrhythmia
NCT001738752	NCT00173875_2_T0	GENE	18	18	receptor
NCT001738752	NCT00173875_2_T1	PHENOTYPE	7	7	strategies
NCT001738752	NCT00173875_2_T2	PHENOTYPE	9	9	inhibition
NCT001738752	NCT00173875_2_T3	COMPOUND	24	24	gefitinib
NCT001738752	NCT00173875_2_T4	GENE	13	14	tyrosine kinase
NCT001738881	NCT00173888_1_T0	PHENOTYPE	6	7	lung cancer
NCT001738883	NCT00173888_3_T0	PHENOTYPE	29	31	stage IV NSCLC
NCT001738886	NCT00173888_6_T0	PHENOTYPE	11	11	NSCLC
NCT001738886	NCT00173888_6_T1	COMPOUND	1	1	docetaxel
NCT001738886	NCT00173888_6_T2	COMPOUND	16	16	navelbine
NCT001738886	NCT00173888_6_T3	COMPOUND	18	18	gemcitabine
NCT001738888	NCT00173888_8_T0	COMPOUND	4	4	docetaxel
NCT001738888	NCT00173888_8_T1	GENE	8	8	TAX
NCT0017388810	NCT00173888_10_T0	COMPOUND	1	1	docetaxel
NCT0017388810	NCT00173888_10_T1	COMPOUND	11	11	docetaxel
NCT0017388810	NCT00173888_10_T2	COMPOUND	13	13	cisplatin
NCT0017388811	NCT00173888_11_T0	COMPOUND	7	7	docetaxel
NCT0017388811	NCT00173888_11_T1	COMPOUND	11	11	cisplatin
NCT001739012	NCT00173901_2_T0	COMPOUND	4	4	ceftazidime
NCT001739012	NCT00173901_2_T1	COMPOUND	8	8	ceftazidime
NCT001739013	NCT00173901_3_T0	COMPOUND	10	10	ceftazidime
NCT001739013	NCT00173901_3_T1	PHENOTYPE	13	15	adverse drug reaction
NCT001739140	NCT00173914_0_T0	ORGAN	7	7	Allograft
NCT001739140	NCT00173914_0_T1	PHENOTYPE	3	4	Endothelial Dysfunction
NCT001739142	NCT00173914_2_T0	GENE	4	4	CAV
NCT001739142	NCT00173914_2_T1	PHENOTYPE	9	9	progressive
NCT001739142	NCT00173914_2_T2	PHENOTYPE	7	7	diffuse
NCT001739142	NCT00173914_2_T3	ORGAN	24	24	heart
NCT001739143	NCT00173914_3_T0	ORGAN	20	20	allografts
NCT001739143	NCT00173914_3_T1	ORGAN	16	17	coronary artery
NCT001739145	NCT00173914_5_T0	COMPOUND	2	2	dipyridamole
NCT001739145	NCT00173914_5_T1	COMPOUND	16	16	dipyridamole
NCT001739147	NCT00173914_7_T0	ORGAN	0	0	Heart
NCT001739147	NCT00173914_7_T1	ORGAN	1	1	transplant
NCT001739149	NCT00173914_9_T0	GENE	10	10	III
NCT001739149	NCT00173914_9_T1	GENE	11	11	IV
NCT001739149	NCT00173914_9_T2	PHENOTYPE	0	1	Acute illness
NCT001739149	NCT00173914_9_T3	PHENOTYPE	5	7	congestive heart failure
NCT0017391410	NCT00173914_10_T0	GENE	7	7	III
NCT0017391410	NCT00173914_10_T1	GENE	13	13	al
NCT0017391410	NCT00173914_10_T2	GENE	8	8	IV
NCT0017391410	NCT00173914_10_T3	GENE	12	12	et
NCT0017391413	NCT00173914_13_T0	ORGAN	0	0	Transplant
NCT0017391414	NCT00173914_14_T0	PHENOTYPE	0	1	Endothelial dysfunction
NCT001739272	NCT00173927_2_T0	GENE	5	5	fusion
NCT001739272	NCT00173927_2_T1	PHENOTYPE	21	21	plaques
NCT001739274	NCT00173927_4_T0	CELL	19	19	monocytes
NCT001739274	NCT00173927_4_T1	PHENOTYPE	7	7	plaque
NCT001739274	NCT00173927_4_T2	PHENOTYPE	8	8	rupture
NCT001739274	NCT00173927_4_T3	BIOLOGICAL_PROCESS	15	16	gene expression
NCT001739530	NCT00173953_0_T0	BIOLOGICAL_PROCESS	3	4	Cytokine Production
NCT001739533	NCT00173953_3_T0	PHENOTYPE	5	6	chronic infection
NCT001739533	NCT00173953_3_T1	PHENOTYPE	16	17	peptic ulcer
NCT001739533	NCT00173953_3_T2	PHENOTYPE	19	20	gastric carcinoma
NCT001739533	NCT00173953_3_T3	PHENOTYPE	14	15	chronic gastritis
NCT001739534	NCT00173953_4_T0	PHENOTYPE	13	13	pathology
NCT001739534	NCT00173953_4_T1	PHENOTYPE	8	10	signs and symptoms
NCT001739661	NCT00173966_1_T0	PHENOTYPE	10	11	atrial fibrillation
NCT001739921	NCT00173992_1_T0	COMPOUND	1	1	2
NCT001739921	NCT00173992_1_T1	PHENOTYPE	7	8	brain lesion
NCT001739922	NCT00173992_2_T0	COMPOUND	1	1	3
NCT001739923	NCT00173992_3_T0	PHENOTYPE	21	21	falls
NCT001739923	NCT00173992_3_T1	PHENOTYPE	17	17	strategies
NCT001739923	NCT00173992_3_T2	PHENOTYPE	27	28	brain lesion
NCT001739924	NCT00173992_4_T0	PHENOTYPE	28	29	brain lesion
NCT001739926	NCT00173992_6_T0	PHENOTYPE	17	17	strategies
NCT001739928	NCT00173992_8_T0	PHENOTYPE	0	0	Falls
NCT001739928	NCT00173992_8_T1	PHENOTYPE	6	6	complications
NCT001739929	NCT00173992_9_T0	PHENOTYPE	3	3	falls
NCT001739929	NCT00173992_9_T1	PHENOTYPE	20	20	falls
NCT0017399210	NCT00173992_10_T0	PHENOTYPE	13	13	falls
NCT0017399210	NCT00173992_10_T1	GENE	2	2	has
NCT0017399210	NCT00173992_10_T2	PHENOTYPE	0	1	Postural instability
NCT001740441	NCT00174044_1_T0	ORGAN	29	29	limb
NCT001740441	NCT00174044_1_T1	BIOLOGICAL_PROCESS	19	19	locomotion
NCT001740442	NCT00174044_2_T0	PHENOTYPE	19	19	strokes
NCT001740445	NCT00174044_5_T0	PHENOTYPE	25	25	strokes
NCT001740448	NCT00174044_8_T0	PHENOTYPE	17	17	impairment
NCT001740448	NCT00174044_8_T1	PHENOTYPE	6	7	blood supply
NCT0017404411	NCT00174044_11_T0	PHENOTYPE	14	14	diseases
NCT0017404412	NCT00174044_12_T0	PHENOTYPE	0	0	Strokes
NCT0017404413	NCT00174044_13_T0	PHENOTYPE	4	4	strokes
NCT0017404413	NCT00174044_13_T1	PHENOTYPE	6	7	ischemic strokes
NCT0017404413	NCT00174044_13_T2	PHENOTYPE	10	12	thrombosis and embolism
NCT0017404414	NCT00174044_14_T0	PHENOTYPE	10	10	strokes
NCT0017404414	NCT00174044_14_T1	PHENOTYPE	5	6	intracerebral hemorrhage
NCT0017404414	NCT00174044_14_T2	PHENOTYPE	8	9	subarachnoid hemorrhage
NCT0017404416	NCT00174044_16_T0	PHENOTYPE	14	14	symptoms
NCT0017404416	NCT00174044_16_T1	PHENOTYPE	3	3	severity
NCT0017404418	NCT00174044_18_T0	PHENOTYPE	7	7	strokes
NCT0017404419	NCT00174044_19_T0	PHENOTYPE	18	19	neurological injury
NCT0017404420	NCT00174044_20_T0	PHENOTYPE	14	14	strokes
NCT0017404421	NCT00174044_21_T0	PHENOTYPE	8	8	strokes
NCT0017404421	NCT00174044_21_T1	PHENOTYPE	26	26	strokes
NCT0017404421	NCT00174044_21_T2	GENE	6	7	nearly normal
NCT0017404422	NCT00174044_22_T0	PHENOTYPE	9	9	strokes
NCT0017404422	NCT00174044_22_T1	PHENOTYPE	7	7	strategies
NCT0017404423	NCT00174044_23_T0	GENE	10	10	fell
NCT0017404423	NCT00174044_23_T1	PHENOTYPE	28	28	falling
NCT0017404424	NCT00174044_24_T0	PHENOTYPE	17	17	strokes
NCT0017404424	NCT00174044_24_T1	PHENOTYPE	6	6	impairment
NCT0017404424	NCT00174044_24_T2	PHENOTYPE	0	0	Falling
NCT0017404425	NCT00174044_25_T0	PHENOTYPE	22	22	falls
NCT0017404427	NCT00174044_27_T0	ORGAN	29	29	limb
NCT0017404427	NCT00174044_27_T1	BIOLOGICAL_PROCESS	19	19	locomotion
NCT0017404430	NCT00174044_30_T0	PHENOTYPE	19	19	strokes
NCT0017404432	NCT00174044_32_T0	PHENOTYPE	30	30	injuries
NCT0017404434	NCT00174044_34_T0	PHENOTYPE	25	25	strokes
NCT0017404438	NCT00174044_38_T0	GENE	3	3	0.2
NCT0017404442	NCT00174044_42_T0	GENE	3	3	45
NCT0017404446	NCT00174044_46_T0	GENE	2	2	95
NCT0017404447	NCT00174044_47_T0	COMPOUND	2	2	1
NCT001740571	NCT00174057_1_T0	PHENOTYPE	7	7	inflammation
NCT001740571	NCT00174057_1_T1	PHENOTYPE	2	3	muscle inflammation
NCT001740571	NCT00174057_1_T2	ORGAN	1	2	extraocular muscle
NCT001740572	NCT00174057_2_T0	ORGAN	17	17	thyroid
NCT001740572	NCT00174057_2_T1	GENE	5	5	had
NCT001740572	NCT00174057_2_T2	PHENOTYPE	18	19	lid retraction
NCT001740573	NCT00174057_3_T0	TISSUE	18	18	tissues
NCT001740573	NCT00174057_3_T1	PHENOTYPE	17	17	fibrosis
NCT001740573	NCT00174057_3_T2	GENE	15	15	adipose
NCT001740573	NCT00174057_3_T3	CELL	4	6	smooth muscle cells
NCT001740574	NCT00174057_4_T0	GENE	4	4	has
NCT001740574	NCT00174057_4_T1	GENE	3	3	TSHR
NCT001740574	NCT00174057_4_T2	TISSUE	11	12	connective tissue
NCT001740577	NCT00174057_7_T0	CELL	8	8	fibroblasts
NCT001740577	NCT00174057_7_T1	CELL	30	30	fibroblast
NCT001740577	NCT00174057_7_T2	GENE	18	18	had
NCT001740577	NCT00174057_7_T3	GENE	14	15	Thy-1 protein
NCT001740578	NCT00174057_8_T0	CELL	12	12	fibroblasts
NCT001740578	NCT00174057_8_T1	BIOLOGICAL_PROCESS	26	26	adipogenesis
NCT001740578	NCT00174057_8_T2	TISSUE	19	19	tissues
NCT001740578	NCT00174057_8_T3	PHENOTYPE	28	28	fibrosis
NCT001740579	NCT00174057_9_T0	GENE	2	2	CD40
NCT001740579	NCT00174057_9_T1	CELL	6	6	fibroblasts
NCT001740579	NCT00174057_9_T2	PHENOTYPE	12	13	systemic sclerosis
NCT0017405710	NCT00174057_10_T0	GENE	2	2	IGF-I
NCT0017405710	NCT00174057_10_T1	PHENOTYPE	14	14	diseases
NCT0017405710	NCT00174057_10_T2	GENE	4	4	IGF-IR
NCT0017405712	NCT00174057_12_T0	TISSUE	12	12	tissues
NCT0017405715	NCT00174057_15_T0	PHENOTYPE	8	8	edema
NCT0017405715	NCT00174057_15_T1	PHENOTYPE	19	19	inflammation
NCT0017405715	NCT00174057_15_T2	PHENOTYPE	7	7	infiltration
NCT0017405715	NCT00174057_15_T3	PHENOTYPE	10	11	interstitial fibrosis
NCT0017405715	NCT00174057_15_T4	PHENOTYPE	2	3	muscle inflammation
NCT0017405715	NCT00174057_15_T5	ORGAN	1	2	extraocular muscle
NCT0017405716	NCT00174057_16_T0	PHENOTYPE	9	9	proptosis
NCT0017405716	NCT00174057_16_T1	TISSUE	7	7	tissues
NCT0017405716	NCT00174057_16_T2	PHENOTYPE	8	8	inflammation
NCT0017405716	NCT00174057_16_T3	PHENOTYPE	10	11	lid retraction
NCT0017405716	NCT00174057_16_T4	PHENOTYPE	16	18	compressive optic neuropathy
NCT0017405717	NCT00174057_17_T0	ORGAN	17	17	thyroid
NCT0017405717	NCT00174057_17_T1	GENE	5	5	had
NCT0017405717	NCT00174057_17_T2	PHENOTYPE	18	19	lid retraction
NCT0017405718	NCT00174057_18_T0	TISSUE	18	18	tissues
NCT0017405718	NCT00174057_18_T1	PHENOTYPE	17	17	fibrosis
NCT0017405718	NCT00174057_18_T2	GENE	15	15	adipose
NCT0017405718	NCT00174057_18_T3	CELL	4	6	smooth muscle cells
NCT0017405720	NCT00174057_20_T0	GENE	5	5	putative
NCT0017405720	NCT00174057_20_T1	GENE	7	7	has
NCT0017405720	NCT00174057_20_T2	GENE	3	3	TSHR
NCT0017405720	NCT00174057_20_T3	TISSUE	14	15	connective tissue
NCT0017405721	NCT00174057_21_T0	CELL	14	14	fibroblasts
NCT0017405721	NCT00174057_21_T1	TISSUE	17	18	adipose tissue
NCT0017405723	NCT00174057_23_T0	CELL	11	11	fibroblasts
NCT0017405723	NCT00174057_23_T1	GENE	8	8	TSHR
NCT0017405725	NCT00174057_25_T0	PHENOTYPE	21	21	acute
NCT0017405725	NCT00174057_25_T1	GENE	14	14	TSHR
NCT0017405727	NCT00174057_27_T0	CELL	8	8	fibroblasts
NCT0017405727	NCT00174057_27_T1	CELL	30	30	fibroblast
NCT0017405727	NCT00174057_27_T2	PHENOTYPE	38	38	ophthalmopathy
NCT0017405727	NCT00174057_27_T3	GENE	18	18	had
NCT0017405727	NCT00174057_27_T4	GENE	14	15	Thy-1 protein
NCT0017405728	NCT00174057_28_T0	CELL	12	12	fibroblasts
NCT0017405728	NCT00174057_28_T1	BIOLOGICAL_PROCESS	26	26	adipogenesis
NCT0017405728	NCT00174057_28_T2	TISSUE	19	19	tissues
NCT0017405728	NCT00174057_28_T3	PHENOTYPE	28	28	fibrosis
NCT0017405729	NCT00174057_29_T0	CELL	22	22	fibroblasts
NCT0017405730	NCT00174057_30_T0	GENE	2	2	CD40
NCT0017405730	NCT00174057_30_T1	CELL	6	6	fibroblasts
NCT0017405730	NCT00174057_30_T2	PHENOTYPE	12	13	systemic sclerosis
NCT0017405731	NCT00174057_31_T0	GENE	2	2	IGF-I
NCT0017405731	NCT00174057_31_T1	PHENOTYPE	14	14	diseases
NCT0017405731	NCT00174057_31_T2	GENE	4	4	IGF-IR
NCT0017405733	NCT00174057_33_T0	TISSUE	20	20	tissues
NCT0017405733	NCT00174057_33_T1	PHENOTYPE	19	19	fibrosis
NCT0017405733	NCT00174057_33_T2	GENE	17	17	adipose
NCT0017405733	NCT00174057_33_T3	CELL	5	7	smooth muscle cells
NCT0017405734	NCT00174057_34_T0	PHENOTYPE	23	23	infiltrating
NCT0017405734	NCT00174057_34_T1	CELL	22	22	fibroblasts
NCT0017405734	NCT00174057_34_T2	GENE	6	6	ex
NCT0017405734	NCT00174057_34_T3	PHENOTYPE	4	4	fibrosis
NCT0017405734	NCT00174057_34_T4	GENE	2	2	adipose
NCT0017405734	NCT00174057_34_T5	CELL	25	26	muscle cells
NCT0017405735	NCT00174057_35_T0	TISSUE	12	12	tissues
NCT001740705	NCT00174070_5_T0	PHENOTYPE	11	13	acute respiratory failure
NCT001740708	NCT00174070_8_T0	PHENOTYPE	11	11	infiltrates
NCT001740708	NCT00174070_8_T1	PHENOTYPE	19	19	acute
NCT001740708	NCT00174070_8_T2	PHENOTYPE	20	20	physiology
NCT001740708	NCT00174070_8_T3	PHENOTYPE	10	10	bilateral
NCT001740708	NCT00174070_8_T4	GENE	1	1	has
NCT001740708	NCT00174070_8_T5	PHENOTYPE	6	8	acute lung injury
NCT0017407011	NCT00174070_11_T0	PHENOTYPE	10	12	acute respiratory failure
NCT0017407017	NCT00174070_17_T0	PHENOTYPE	11	13	acute respiratory failure
NCT0017407020	NCT00174070_20_T0	PHENOTYPE	11	11	infiltrates
NCT0017407020	NCT00174070_20_T1	PHENOTYPE	20	20	acute
NCT0017407020	NCT00174070_20_T2	PHENOTYPE	21	21	physiology
NCT0017407020	NCT00174070_20_T3	PHENOTYPE	10	10	bilateral
NCT0017407020	NCT00174070_20_T4	GENE	1	1	has
NCT0017407020	NCT00174070_20_T5	PHENOTYPE	6	8	acute lung injury
NCT0017407023	NCT00174070_23_T0	PHENOTYPE	10	12	acute respiratory failure
NCT0017407025	NCT00174070_25_T0	GENE	8	8	al
NCT0017407025	NCT00174070_25_T1	GENE	7	7	et
NCT0017407025	NCT00174070_25_T2	PHENOTYPE	16	17	critically ill
NCT0017407025	NCT00174070_25_T3	PHENOTYPE	12	14	acute respiratory failure
NCT0017407027	NCT00174070_27_T0	PHENOTYPE	9	9	severity
NCT0017407027	NCT00174070_27_T1	PHENOTYPE	13	13	acute
NCT0017407027	NCT00174070_27_T2	PHENOTYPE	2	2	Mets
NCT0017407027	NCT00174070_27_T3	GENE	7	7	al
NCT0017407027	NCT00174070_27_T4	GENE	6	6	et
NCT0017407027	NCT00174070_27_T5	PHENOTYPE	14	15	respiratory failure
NCT0017407028	NCT00174070_28_T0	GENE	5	5	Med
NCT0017407030	NCT00174070_30_T0	PHENOTYPE	0	2	Acute respiratory failure
NCT0017407033	NCT00174070_33_T0	GENE	0	0	JAMA
NCT0017407034	NCT00174070_34_T0	PHENOTYPE	12	12	acute
NCT0017407034	NCT00174070_34_T1	GENE	7	7	al
NCT0017407034	NCT00174070_34_T2	COMPOUND	3	3	N
NCT0017407034	NCT00174070_34_T3	GENE	6	6	et
NCT0017407035	NCT00174070_35_T0	GENE	5	5	Med
NCT0017407037	NCT00174070_37_T0	GENE	5	5	Med
NCT0017407039	NCT00174070_39_T0	PHENOTYPE	6	6	acute
NCT0017407039	NCT00174070_39_T1	PHENOTYPE	7	8	respiratory failure
NCT0017407044	NCT00174070_44_T0	PHENOTYPE	8	8	severity
NCT0017407044	NCT00174070_44_T1	PHENOTYPE	3	3	ventilation
NCT0017407044	NCT00174070_44_T2	PHENOTYPE	13	13	chronic
NCT0017407044	NCT00174070_44_T3	PHENOTYPE	20	21	acute illness
NCT0017407045	NCT00174070_45_T0	GENE	1	1	Rev
NCT0017407045	NCT00174070_45_T1	PHENOTYPE	3	3	Dis
NCT0017407046	NCT00174070_46_T0	GENE	1	1	SK
NCT0017407046	NCT00174070_46_T1	PHENOTYPE	0	0	Epstein
NCT001740831	NCT00174083_1_T0	GENE	11	11	has
NCT001740963	NCT00174096_3_T0	GENE	13	13	SCC
NCT001740963	NCT00174096_3_T1	PHENOTYPE	4	4	affects
NCT001740963	NCT00174096_3_T2	PHENOTYPE	0	2	Lymph node metastasis
NCT001740964	NCT00174096_4_T0	PHENOTYPE	3	5	lymph node metastasis
NCT001740966	NCT00174096_6_T0	CELL	17	17	cells
NCT001740966	NCT00174096_6_T1	PHENOTYPE	6	6	malignancy
NCT001740966	NCT00174096_6_T2	PHENOTYPE	16	16	tumor
NCT001740966	NCT00174096_6_T3	PHENOTYPE	0	1	Tumor metastasis
NCT001740968	NCT00174096_8_T0	CELL	8	8	cells
NCT001740968	NCT00174096_8_T1	CELL	31	31	cells
NCT001740968	NCT00174096_8_T2	PHENOTYPE	28	28	metastasis
NCT001740968	NCT00174096_8_T3	TISSUE	22	23	lymph node
NCT001740969	NCT00174096_9_T0	COMPOUND	16	16	heparin
NCT001740969	NCT00174096_9_T1	GENE	7	7	polypeptide
NCT0017409610	NCT00174096_10_T0	GENE	7	7	CC
NCT0017409611	NCT00174096_11_T0	CELL	11	11	cells
NCT0017409611	NCT00174096_11_T1	TISSUE	6	6	tissues
NCT0017409611	NCT00174096_11_T2	GENE	13	13	G-protein
NCT0017409612	NCT00174096_12_T0	PHENOTYPE	22	22	allergy
NCT0017409612	NCT00174096_12_T1	CELL	11	12	polymorphonuclear leukocytes
NCT0017409612	NCT00174096_12_T2	BIOLOGICAL_PROCESS	26	27	wound healing
NCT0017409612	NCT00174096_12_T3	PHENOTYPE	23	24	cardiovascular diseases
NCT0017409612	NCT00174096_12_T4	PHENOTYPE	20	21	viral infections
NCT0017409612	NCT00174096_12_T5	PHENOTYPE	16	17	inflammatory responses
NCT0017409615	NCT00174096_15_T0	PHENOTYPE	5	6	malignant tumors
NCT0017409616	NCT00174096_16_T0	PHENOTYPE	10	10	tumor
NCT0017409616	NCT00174096_16_T1	PHENOTYPE	8	8	immunity
NCT0017409619	NCT00174096_19_T0	GENE	0	0	SDF-1
NCT0017409619	NCT00174096_19_T1	GENE	12	12	CXCR4
NCT0017409619	NCT00174096_19_T2	GENE	4	5	CXC chemokine
NCT0017409622	NCT00174096_22_T0	GENE	14	14	SDF-1
NCT0017409622	NCT00174096_22_T1	GENE	12	12	CXCR4
NCT0017409622	NCT00174096_22_T2	GENE	9	9	mRNA
NCT0017409622	NCT00174096_22_T3	PHENOTYPE	16	17	solid tumors
NCT0017409623	NCT00174096_23_T0	PHENOTYPE	9	10	cancer progression
NCT0017409624	NCT00174096_24_T0	PHENOTYPE	18	18	tumors
NCT0017409624	NCT00174096_24_T1	PHENOTYPE	17	17	glioblastoma
NCT0017409624	NCT00174096_24_T2	PHENOTYPE	11	11	proliferation
NCT0017409624	NCT00174096_24_T3	GENE	5	5	CXCR4
NCT0017409624	NCT00174096_24_T4	GENE	2	2	al
NCT0017409624	NCT00174096_24_T5	GENE	1	1	et
NCT0017409626	NCT00174096_26_T0	CELL	17	17	cells
NCT0017409626	NCT00174096_26_T1	GENE	6	6	SDF-1
NCT0017409626	NCT00174096_26_T2	GENE	8	8	CXCR4
NCT0017409626	NCT00174096_26_T3	TISSUE	19	20	lymph node
NCT0017409626	NCT00174096_26_T4	PHENOTYPE	15	16	breast cancer
NCT0017409628	NCT00174096_28_T0	TISSUE	11	11	tissues
NCT0017409628	NCT00174096_28_T1	GENE	7	7	SDF-1
NCT0017409628	NCT00174096_28_T2	GENE	3	3	reduced
NCT0017409628	NCT00174096_28_T3	GENE	4	4	mRNA
NCT0017409629	NCT00174096_29_T0	TISSUE	18	18	tissues
NCT0017409629	NCT00174096_29_T1	MOLECULAR_FUNCTION	13	14	receptor ligand
NCT0017409630	NCT00174096_30_T0	PHENOTYPE	8	9	hypopharyngeal cancer
NCT0017409631	NCT00174096_31_T0	PHENOTYPE	13	13	metastasis
NCT0017409631	NCT00174096_31_T1	PHENOTYPE	0	0	Metastasis
NCT0017409631	NCT00174096_31_T2	ORGAN	10	11	lymphatic system
NCT0017409631	NCT00174096_31_T3	PHENOTYPE	4	5	hypopharyngeal cancer
NCT0017409632	NCT00174096_32_T0	PHENOTYPE	8	8	metastasis
NCT0017409632	NCT00174096_32_T1	PHENOTYPE	25	25	metastasis
NCT0017409632	NCT00174096_32_T2	PHENOTYPE	12	13	hypopharyngeal cancer
NCT0017409633	NCT00174096_33_T0	PHENOTYPE	15	15	metastasis
NCT0017409633	NCT00174096_33_T1	PHENOTYPE	13	14	hypopharyngeal cancer
NCT0017409635	NCT00174096_35_T0	PHENOTYPE	16	16	focal
NCT001741091	NCT00174109_1_T0	PHENOTYPE	12	12	malignancy
NCT001741091	NCT00174109_1_T1	GENE	21	21	has
NCT001741091	NCT00174109_1_T2	BIOLOGICAL_PROCESS	27	27	chewing
NCT001741091	NCT00174109_1_T3	PHENOTYPE	5	6	oral cancer
NCT001741092	NCT00174109_2_T0	PHENOTYPE	4	5	oral cancers
NCT001741093	NCT00174109_3_T0	BIOLOGICAL_PROCESS	11	11	chewing
NCT001741094	NCT00174109_4_T0	PHENOTYPE	4	5	oral cancers
NCT001741095	NCT00174109_5_T0	GENE	3	3	RAS
NCT001741095	NCT00174109_5_T1	PHENOTYPE	6	7	oral cancers
NCT001741096	NCT00174109_6_T0	PHENOTYPE	4	4	mutation
NCT001741096	NCT00174109_6_T1	GENE	3	3	RAS
NCT001741096	NCT00174109_6_T2	GENE	26	26	p53
NCT001741097	NCT00174109_7_T0	GENE	3	3	p53
NCT001741097	NCT00174109_7_T1	PHENOTYPE	6	7	oral cancers
NCT0017410910	NCT00174109_10_T0	GENE	30	30	BQ
NCT0017410910	NCT00174109_10_T1	TISSUE	36	37	oral mucosa
NCT0017410911	NCT00174109_11_T0	CELL	9	9	neuron
NCT0017410911	NCT00174109_11_T1	CELL	4	4	microtubule
NCT0017410911	NCT00174109_11_T2	CELL	21	21	cells
NCT0017410911	NCT00174109_11_T3	GENE	7	7	MAP2
NCT0017410911	NCT00174109_11_T4	GENE	5	6	protein 2
NCT0017410911	NCT00174109_11_T5	GENE	10	11	cytoskeletal protein
NCT0017410913	NCT00174109_13_T0	GENE	2	2	MAP2
NCT0017410914	NCT00174109_14_T0	GENE	5	5	MAP2
NCT001741221	NCT00174122_1_T0	PHENOTYPE	20	21	severe sepsis
NCT001741223	NCT00174122_3_T0	GENE	4	4	8.5
NCT001741224	NCT00174122_4_T0	PHENOTYPE	1	1	reflects
NCT001741224	NCT00174122_4_T1	PHENOTYPE	8	9	infectious diseases
NCT001741226	NCT00174122_6_T0	PHENOTYPE	18	18	acute
NCT001741226	NCT00174122_6_T1	PHENOTYPE	29	29	infections
NCT001741226	NCT00174122_6_T2	GENE	3	3	procalcitonin
NCT001741226	NCT00174122_6_T3	ORGAN	1	1	serum
NCT001741226	NCT00174122_6_T4	PHENOTYPE	23	24	bacterial infections
NCT001741227	NCT00174122_7_T0	PHENOTYPE	11	12	severe sepsis
NCT001741228	NCT00174122_8_T0	ORGAN	12	12	serum
NCT0017412210	NCT00174122_10_T0	GENE	9	9	procalcitonin
NCT0017412210	NCT00174122_10_T1	ORGAN	8	8	serum
NCT0017412210	NCT00174122_10_T2	PHENOTYPE	17	17	sepsis
NCT0017412211	NCT00174122_11_T0	GENE	8	8	procalcitonin
NCT0017412211	NCT00174122_11_T1	ORGAN	7	7	serum
NCT0017412211	NCT00174122_11_T2	PHENOTYPE	11	11	sepsis
NCT0017412212	NCT00174122_12_T0	PHENOTYPE	18	18	acute
NCT0017412212	NCT00174122_12_T1	GENE	7	7	procalcitonin
NCT0017412212	NCT00174122_12_T2	PHENOTYPE	20	20	febrile
NCT0017412212	NCT00174122_12_T3	PHENOTYPE	13	13	sepsis
NCT0017412213	NCT00174122_13_T0	GENE	7	7	procalcitonin
NCT001741351	NCT00174135_1_T0	PHENOTYPE	0	0	Sarcopenia
NCT001741351	NCT00174135_1_T1	BIOLOGICAL_PROCESS	17	17	aging
NCT001741352	NCT00174135_2_T0	GENE	1	1	has
NCT001741353	NCT00174135_3_T0	PHENOTYPE	9	9	sarcopenia
NCT001741354	NCT00174135_4_T0	PHENOTYPE	8	8	sarcopenia
NCT001741354	NCT00174135_4_T1	PHENOTYPE	26	26	sarcopenia
NCT001741357	NCT00174135_7_T0	PHENOTYPE	2	2	regression
NCT001741358	NCT00174135_8_T0	PHENOTYPE	19	19	sarcopenia
NCT001741359	NCT00174135_9_T0	PHENOTYPE	6	6	sarcopenia
NCT001741484	NCT00174148_4_T0	TISSUE	16	16	muscles
NCT001741488	NCT00174148_8_T0	GENE	17	17	dorsal
NCT001741488	NCT00174148_8_T1	ORGAN	10	10	Splenius
NCT001741488	NCT00174148_8_T2	GENE	29	29	ATL
NCT001741488	NCT00174148_8_T3	ORGAN	13	13	semispinalis
NCT001741488	NCT00174148_8_T4	ORGAN	16	16	multifidus
NCT001741488	NCT00174148_8_T5	ORGAN	18	19	neck muscle
NCT0017414812	NCT00174148_12_T0	PHENOTYPE	17	17	regression
NCT001741610	NCT00174161_0_T0	GENE	13	13	ity
NCT001741610	NCT00174161_0_T1	PHENOTYPE	10	12	Quality of Life
NCT001741619	NCT00174161_9_T0	PHENOTYPE	12	12	symptoms
NCT001741619	NCT00174161_9_T1	PHENOTYPE	22	22	strategies
NCT0017416113	NCT00174161_13_T0	GENE	11	11	ANOVA
NCT0017416113	NCT00174161_13_T1	PHENOTYPE	15	15	regression
NCT001741741	NCT00174174_1_T0	PHENOTYPE	6	6	sleepiness
NCT001742390	NCT00174239_0_T0	PHENOTYPE	17	17	Disease
NCT001742390	NCT00174239_0_T1	PHENOTYPE	11	11	Symptoms
NCT001742390	NCT00174239_0_T2	GENE	5	5	CR
NCT001742390	NCT00174239_0_T3	PHENOTYPE	14	15	Parkinson's Disease
NCT001742650	NCT00174265_0_T0	PHENOTYPE	9	9	Symptoms
NCT001743040	NCT00174304_0_T0	PHENOTYPE	11	11	Hypertension
NCT001743040	NCT00174304_0_T1	PHENOTYPE	13	13	Dyslipidemia
NCT001743300	NCT00174330_0_T0	PHENOTYPE	9	9	Hypertension
NCT001743300	NCT00174330_0_T1	PHENOTYPE	11	11	Dyslipidemia
NCT001743560	NCT00174356_0_T0	COMPOUND	12	12	1st
NCT001743560	NCT00174356_0_T1	PHENOTYPE	16	16	NSCLC
NCT001743560	NCT00174356_0_T2	GENE	0	0	PH
NCT001743692	NCT00174369_2_T0	CELL	13	13	cells
NCT001743694	NCT00174369_4_T0	PHENOTYPE	21	21	tumor
NCT001743694	NCT00174369_4_T1	PHENOTYPE	37	37	tumor
NCT001744210	NCT00174421_0_T0	PHENOTYPE	2	3	Short Stature
NCT001744344	NCT00174434_4_T0	PHENOTYPE	14	14	toxicity
NCT001744344	NCT00174434_4_T1	GENE	5	5	po
NCT001744862	NCT00174486_2_T0	GENE	6	6	PDE5
NCT001744999	NCT00174499_9_T0	PHENOTYPE	17	18	adverse events
NCT001745252	NCT00174525_2_T0	CELL	11	13	white blood cells
NCT001745254	NCT00174525_4_T0	MOLECULAR_FUNCTION	9	10	amyloid protein
NCT001745380	NCT00174538_0_T0	PHENOTYPE	2	4	Sickle Cell Disease
NCT001745512	NCT00174551_2_T0	PHENOTYPE	3	3	symptoms
NCT001745640	NCT00174564_0_T0	PHENOTYPE	3	5	Biliary Tract Cancer
NCT001745772	NCT00174577_2_T0	COMPOUND	8	8	1
NCT001745772	NCT00174577_2_T1	COMPOUND	7	7	risperidone
NCT001745772	NCT00174577_2_T2	GENE	2	2	met
NCT001745774	NCT00174577_4_T0	COMPOUND	25	25	risperidone
NCT001745774	NCT00174577_4_T1	GENE	3	3	met
NCT001745774	NCT00174577_4_T2	PHENOTYPE	6	7	unipolar depression
NCT001745775	NCT00174577_5_T0	GENE	4	4	2.1
NCT001745775	NCT00174577_5_T1	COMPOUND	7	7	risperidone
NCT001745777	NCT00174577_7_T0	COMPOUND	7	7	risperidone
NCT001745900	NCT00174590_0_T0	PHENOTYPE	2	4	Major Depressive Disorder
NCT001745903	NCT00174590_3_T0	GENE	7	7	has
NCT001745904	NCT00174590_4_T0	COMPOUND	6	6	risperidone
NCT001745904	NCT00174590_4_T1	PHENOTYPE	12	13	psychotic depression
NCT001745905	NCT00174590_5_T0	PHENOTYPE	10	10	psychosis
NCT001745905	NCT00174590_5_T1	PHENOTYPE	7	8	major depression
NCT001745907	NCT00174590_7_T0	GENE	17	17	HPDL
NCT001745907	NCT00174590_7_T1	COMPOUND	16	16	haloperidol
NCT001745907	NCT00174590_7_T2	COMPOUND	9	9	risperidone
NCT001745907	NCT00174590_7_T3	COMPOUND	12	12	risperidone
NCT001745907	NCT00174590_7_T4	COMPOUND	14	14	sertraline
NCT001745907	NCT00174590_7_T5	COMPOUND	19	19	sertraline
NCT001745908	NCT00174590_8_T0	PHENOTYPE	21	21	Mania
NCT001746031	NCT00174603_1_T0	COMPOUND	3	3	quetiapine
NCT001746031	NCT00174603_1_T1	PHENOTYPE	29	29	psychosis
NCT001746031	NCT00174603_1_T2	PHENOTYPE	25	27	major depressive episode
NCT001746034	NCT00174603_4_T0	GENE	16	16	al
NCT001746034	NCT00174603_4_T1	GENE	15	15	et
NCT001746034	NCT00174603_4_T2	PHENOTYPE	12	13	major depression
NCT001746035	NCT00174603_5_T0	GENE	23	23	al
NCT001746035	NCT00174603_5_T1	GENE	22	22	et
NCT001746035	NCT00174603_5_T2	PHENOTYPE	13	14	adverse effects
NCT001746037	NCT00174603_7_T0	COMPOUND	31	31	quetiapine
NCT001746037	NCT00174603_7_T1	COMPOUND	35	35	haloperidol
NCT001746037	NCT00174603_7_T2	COMPOUND	33	33	citalopram
NCT001746037	NCT00174603_7_T3	COMPOUND	37	37	citalopram
NCT001746037	NCT00174603_7_T4	PHENOTYPE	17	19	major depressive disorder
NCT001746553	NCT00174655_3_T0	TISSUE	7	8	lymph node
NCT001746555	NCT00174655_5_T0	PHENOTYPE	19	19	DCIS
NCT001746555	NCT00174655_5_T1	PHENOTYPE	13	13	adenocarcinoma
NCT001746555	NCT00174655_5_T2	PHENOTYPE	15	18	ductal carcinoma in situ
NCT001746556	NCT00174655_6_T0	PHENOTYPE	0	2	Lobular carcinoma in-situ
NCT001746557	NCT00174655_7_T0	PHENOTYPE	3	3	infiltration
NCT0017465513	NCT00174655_13_T0	ORGAN	35	35	spine
NCT0017465513	NCT00174655_13_T1	PHENOTYPE	28	28	metastases
NCT0017465513	NCT00174655_13_T2	GENE	8	8	PA
NCT0017465513	NCT00174655_13_T3	PHENOTYPE	4	4	bilateral
NCT0017465513	NCT00174655_13_T4	GENE	13	13	abdominal
NCT0017465513	NCT00174655_13_T5	PHENOTYPE	37	38	hot spots
NCT0017465513	NCT00174655_13_T6	PHENOTYPE	48	49	hot spots
NCT001747072	NCT00174707_2_T0	PHENOTYPE	13	13	adenocarcinoma
NCT001747072	NCT00174707_2_T1	PHENOTYPE	15	18	ductal carcinoma in situ
NCT001747073	NCT00174707_3_T0	PHENOTYPE	0	3	Lobular carcinoma in situ
NCT001747592	NCT00174759_2_T0	GENE	7	7	ASA
NCT001747723	NCT00174772_3_T0	PHENOTYPE	9	10	pulmonary toxicity
NCT001747850	NCT00174785_0_T0	PHENOTYPE	12	13	Atrial Fibrillation
NCT001747852	NCT00174785_2_T0	COMPOUND	3	3	dronedarone
NCT001747980	NCT00174798_0_T0	PHENOTYPE	17	18	Urinary Incontinence
NCT001747980	NCT00174798_0_T1	PHENOTYPE	13	14	Overactive Bladder
NCT001747983	NCT00174798_3_T0	PHENOTYPE	20	22	quality of life
NCT001748112	NCT00174811_2_T0	GENE	4	4	has
NCT001748242	NCT00174824_2_T0	GENE	8	8	1.5
NCT001748500	NCT00174850_0_T0	PHENOTYPE	12	13	Sexual Dysfunction
NCT001748502	NCT00174850_2_T0	PHENOTYPE	11	12	anxiety disorders
NCT001748504	NCT00174850_4_T0	PHENOTYPE	19	20	sexual dysfunction
NCT001748505	NCT00174850_5_T0	PHENOTYPE	8	8	addiction
NCT001748506	NCT00174850_6_T0	PHENOTYPE	17	17	epilepsy
NCT001748506	NCT00174850_6_T1	BIOLOGICAL_PROCESS	4	5	GABA Reuptake
NCT0017485015	NCT00174850_15_T0	PHENOTYPE	24	25	sexual dysfunction
NCT0017485017	NCT00174850_17_T0	PHENOTYPE	29	29	severity
NCT0017485018	NCT00174850_18_T0	PHENOTYPE	27	27	initiation
NCT0017485018	NCT00174850_18_T1	PHENOTYPE	20	20	anorgasmia
NCT0017485018	NCT00174850_18_T2	PHENOTYPE	19	19	impotence
NCT0017485018	NCT00174850_18_T3	PHENOTYPE	14	14	arousal
NCT0017485018	NCT00174850_18_T4	PHENOTYPE	12	13	sex drive
NCT0017485018	NCT00174850_18_T5	PHENOTYPE	22	23	delayed ejaculation
NCT0017485018	NCT00174850_18_T6	PHENOTYPE	8	9	sexual dysfunction
NCT0017485021	NCT00174850_21_T0	GENE	15	15	has
NCT0017485024	NCT00174850_24_T0	COMPOUND	12	12	tiagabine
NCT0017485027	NCT00174850_27_T0	GENE	1	1	13
NCT0017485027	NCT00174850_27_T1	GENE	7	7	am
NCT0017485030	NCT00174850_30_T0	COMPOUND	17	17	tiagabine
NCT0017485033	NCT00174850_33_T0	GENE	13	13	PE
NCT0017485035	NCT00174850_35_T0	GENE	8	8	opt
NCT0017485035	NCT00174850_35_T1	COMPOUND	11	11	tiagabine
NCT0017485042	NCT00174850_42_T0	PHENOTYPE	7	9	generalized anxiety disorder
NCT0017485044	NCT00174850_44_T0	COMPOUND	12	12	venlafaxine
NCT0017485045	NCT00174850_45_T0	PHENOTYPE	43	43	sterile
NCT0017485045	NCT00174850_45_T1	GENE	2	2	has
NCT0017485047	NCT00174850_47_T0	PHENOTYPE	18	18	sterile
NCT0017485048	NCT00174850_48_T0	GENE	19	19	met
NCT001748761	NCT00174876_1_T0	PHENOTYPE	28	28	symptoms
NCT001748761	NCT00174876_1_T1	PHENOTYPE	26	26	remission
NCT001748761	NCT00174876_1_T2	PHENOTYPE	18	18	hopes
NCT001748762	NCT00174876_2_T0	PHENOTYPE	14	14	schizophrenia
NCT001748762	NCT00174876_2_T1	GENE	6	6	has
NCT001748763	NCT00174876_3_T0	PHENOTYPE	9	10	depressive symptoms
NCT001748766	NCT00174876_6_T0	COMPOUND	7	7	dopamine
NCT001748766	NCT00174876_6_T1	PHENOTYPE	19	20	other schizophrenia
NCT001748767	NCT00174876_7_T0	ORGAN	9	9	brains
NCT001748767	NCT00174876_7_T1	COMPOUND	6	6	dopamine
NCT001748768	NCT00174876_8_T0	COMPOUND	11	11	dopamine
NCT001748769	NCT00174876_9_T0	PHENOTYPE	11	12	depressive symptoms
NCT0017487610	NCT00174876_10_T0	PHENOTYPE	25	25	elimination
NCT0017487610	NCT00174876_10_T1	PHENOTYPE	27	28	depressive symptoms
NCT0017487611	NCT00174876_11_T0	PHENOTYPE	5	6	safety issues
NCT0017487613	NCT00174876_13_T0	COMPOUND	7	7	aripiprazole
NCT0017487613	NCT00174876_13_T1	PHENOTYPE	20	21	depressive symptoms
NCT0017487614	NCT00174876_14_T0	COMPOUND	27	27	aripiprazole
NCT0017487619	NCT00174876_19_T0	PHENOTYPE	18	18	schizophrenia
NCT0017487619	NCT00174876_19_T1	PHENOTYPE	15	16	depressive symptoms
NCT0017487621	NCT00174876_21_T0	GENE	19	19	beta
NCT0017487622	NCT00174876_22_T0	GENE	25	25	opt
NCT0017487622	NCT00174876_22_T1	GENE	12	12	GABA
NCT0017487627	NCT00174876_27_T0	COMPOUND	44	44	aripiprazole
NCT0017487629	NCT00174876_29_T0	GENE	12	12	opt
NCT0017487631	NCT00174876_31_T0	PHENOTYPE	2	2	secondary
NCT0017487631	NCT00174876_31_T1	PHENOTYPE	36	36	secondary
NCT0017487631	NCT00174876_31_T2	COMPOUND	34	34	aripiprazole
NCT0017487633	NCT00174876_33_T0	PHENOTYPE	12	12	perceived
NCT001748891	NCT00174889_1_T0	COMPOUND	8	8	DHEA
NCT001748891	NCT00174889_1_T1	COMPOUND	11	11	sulfate
NCT001748891	NCT00174889_1_T2	GENE	13	13	DHEAS
NCT001748891	NCT00174889_1_T3	COMPOUND	7	7	dehydroepiandrosterone
NCT001748892	NCT00174889_2_T0	COMPOUND	6	6	DHEA
NCT001748892	NCT00174889_2_T1	COMPOUND	26	26	pregnenolone
NCT001748892	NCT00174889_2_T2	PHENOTYPE	9	9	schizophrenia
NCT001748892	NCT00174889_2_T3	PHENOTYPE	23	23	schizophrenia
NCT001748893	NCT00174889_3_T0	COMPOUND	11	11	pregnenolone
NCT001748893	NCT00174889_3_T1	PHENOTYPE	21	22	cognitive symptoms
NCT001748896	NCT00174889_6_T0	PHENOTYPE	22	23	cognitive functions
NCT001748897	NCT00174889_7_T0	COMPOUND	3	3	cortisol
NCT001748897	NCT00174889_7_T1	ORGAN	0	0	Plasma
NCT001748897	NCT00174889_7_T2	COMPOUND	1	1	pregnenolone
NCT001748898	NCT00174889_8_T0	COMPOUND	9	9	pregnenolone
NCT001749022	NCT00174902_2_T0	COMPOUND	5	5	aspirin
NCT001749022	NCT00174902_2_T1	CELL	10	10	platelets
NCT001749024	NCT00174902_4_T0	PHENOTYPE	12	13	mental stress
NCT001749025	NCT00174902_5_T0	PHENOTYPE	1	1	acute
NCT001749025	NCT00174902_5_T1	PHENOTYPE	2	3	mental stress
NCT001749028	NCT00174902_8_T0	GENE	12	12	fibrinogen
NCT001749028	NCT00174902_8_T1	ORGAN	8	8	plasma
NCT001749029	NCT00174902_9_T0	PHENOTYPE	12	12	hypertension
NCT0017490210	NCT00174902_10_T0	PHENOTYPE	19	19	acute
NCT0017490210	NCT00174902_10_T1	PHENOTYPE	9	9	chronic
NCT0017490210	NCT00174902_10_T2	PHENOTYPE	10	11	mental stress
NCT0017490210	NCT00174902_10_T3	PHENOTYPE	20	21	mental stress
NCT0017490210	NCT00174902_10_T4	PHENOTYPE	24	26	coronary heart disease
NCT0017490211	NCT00174902_11_T0	PHENOTYPE	19	19	outbursts
NCT0017490211	NCT00174902_11_T1	PHENOTYPE	11	13	acute myocardial infarction
NCT0017490212	NCT00174902_12_T0	GENE	14	14	1.4
NCT0017490212	NCT00174902_12_T1	COMPOUND	5	5	aspirin
NCT0017490212	NCT00174902_12_T2	COMPOUND	18	18	aspirin
NCT0017490212	NCT00174902_12_T3	GENE	9	9	2.9
NCT0017490213	NCT00174902_13_T0	PHENOTYPE	11	11	profound
NCT0017490213	NCT00174902_13_T1	PHENOTYPE	5	5	acute
NCT0017490213	NCT00174902_13_T2	PHENOTYPE	6	7	mental stress
NCT0017490215	NCT00174902_15_T0	PHENOTYPE	23	23	atherosclerosis
NCT0017490215	NCT00174902_15_T1	PHENOTYPE	20	21	rapid progression
NCT0017490216	NCT00174902_16_T0	COMPOUND	11	11	aspirin
NCT0017490217	NCT00174902_17_T0	PHENOTYPE	23	23	acute
NCT0017490217	NCT00174902_17_T1	COMPOUND	8	8	aspirin
NCT0017490217	NCT00174902_17_T2	PHENOTYPE	24	25	mental stress
NCT0017490218	NCT00174902_18_T0	PHENOTYPE	11	11	acute
NCT0017490218	NCT00174902_18_T1	CELL	35	35	platelets
NCT0017490218	NCT00174902_18_T2	ORGAN	17	17	plasma
NCT0017490218	NCT00174902_18_T3	PHENOTYPE	9	9	arousal
NCT0017490218	NCT00174902_18_T4	CELL	32	33	endothelial cells
NCT0017490218	NCT00174902_18_T5	PHENOTYPE	12	13	mental stress
NCT0017490218	NCT00174902_18_T6	ORGAN	6	8	central nervous system
NCT0017490228	NCT00174902_28_T0	ORGAN	9	9	plasma
NCT0017490229	NCT00174902_29_T0	GENE	6	6	ANOVA
NCT001749150	NCT00174915_0_T0	PHENOTYPE	8	8	Gout
NCT001749284	NCT00174928_4_T0	GENE	9	9	pH
NCT001749284	NCT00174928_4_T1	GENE	18	18	pH
NCT001749285	NCT00174928_5_T0	GENE	1	1	pH
NCT001749286	NCT00174928_6_T0	GENE	1	1	pH
NCT001749286	NCT00174928_6_T1	GENE	9	9	pH
NCT001749410	NCT00174941_0_T0	PHENOTYPE	7	7	Gout
NCT001749410	NCT00174941_0_T1	PHENOTYPE	10	10	Gout
NCT001749417	NCT00174941_7_T0	PHENOTYPE	24	24	tophi
NCT001749417	NCT00174941_7_T1	PHENOTYPE	7	7	acute
NCT001749417	NCT00174941_7_T2	ORGAN	27	27	joints
NCT001749417	NCT00174941_7_T3	PHENOTYPE	0	0	Gout
NCT001749417	NCT00174941_7_T4	PHENOTYPE	18	18	arthropathy
NCT001749417	NCT00174941_7_T5	GENE	31	31	structural
NCT001749417	NCT00174941_7_T6	TISSUE	26	26	bones
NCT001749417	NCT00174941_7_T7	ORGAN	43	44	urinary tract
NCT001749417	NCT00174941_7_T8	PHENOTYPE	13	14	chronic disorder
NCT001749417	NCT00174941_7_T9	COMPOUND	52	53	uric acid
NCT001749417	NCT00174941_7_T10	PHENOTYPE	8	9	inflammatory arthritis
NCT001749417	NCT00174941_7_T11	PHENOTYPE	34	35	renal impairment
NCT001749419	NCT00174941_9_T0	PHENOTYPE	19	19	hyperuricemia
NCT001749419	NCT00174941_9_T1	PHENOTYPE	23	23	gout
NCT001749419	NCT00174941_9_T2	GENE	6	7	xanthine oxidase
NCT0017494112	NCT00174941_12_T0	ORGAN	12	12	serum
NCT001749540	NCT00174954_0_T0	PHENOTYPE	6	7	Gouty Tophi
NCT001749674	NCT00174967_4_T0	PHENOTYPE	7	7	acute
NCT001749674	NCT00174967_4_T1	ORGAN	19	19	joints
NCT001749674	NCT00174967_4_T2	PHENOTYPE	0	0	Gout
NCT001749674	NCT00174967_4_T3	COMPOUND	16	16	monohydrate
NCT001749674	NCT00174967_4_T4	TISSUE	20	20	bones
NCT001749674	NCT00174967_4_T5	GENE	1	1	has
NCT001749674	NCT00174967_4_T6	PHENOTYPE	6	6	recurrent
NCT001749674	NCT00174967_4_T7	PHENOTYPE	25	26	tophaceous gout
NCT001749674	NCT00174967_4_T8	PHENOTYPE	27	28	renal impairment
NCT001749674	NCT00174967_4_T9	PHENOTYPE	10	11	inflammatory arthritis
NCT001749674	NCT00174967_4_T10	PHENOTYPE	30	32	uric acid nephrolithiasis
NCT001749675	NCT00174967_5_T0	ORGAN	1	1	serum
NCT001749675	NCT00174967_5_T1	PHENOTYPE	11	12	gouty arthritis
NCT001749675	NCT00174967_5_T2	PHENOTYPE	15	16	renal calculi
NCT001749676	NCT00174967_6_T0	COMPOUND	1	1	allopurinol
NCT001749676	NCT00174967_6_T1	GENE	5	6	xanthine oxidase
NCT001749677	NCT00174967_7_T0	PHENOTYPE	31	31	tophi
NCT001749677	NCT00174967_7_T1	ORGAN	9	9	serum
NCT001749677	NCT00174967_7_T2	COMPOUND	15	16	uric acid
NCT001749677	NCT00174967_7_T3	PHENOTYPE	24	26	impaired renal function
NCT001749677	NCT00174967_7_T4	PHENOTYPE	27	29	uric acid urolithiasis
NCT001749678	NCT00174967_8_T0	PHENOTYPE	19	19	hyperuricemia
NCT001749678	NCT00174967_8_T1	PHENOTYPE	23	23	gout
NCT001749678	NCT00174967_8_T2	GENE	6	7	xanthine oxidase
NCT001749800	NCT00174980_0_T0	COMPOUND	2	2	Oxycyte
NCT001749800	NCT00174980_0_T1	PHENOTYPE	5	7	Closed Head Injury
NCT001749803	NCT00174980_3_T0	COMPOUND	15	15	oxygen
NCT001749803	NCT00174980_3_T1	COMPOUND	7	7	Oxycyte
NCT001749803	NCT00174980_3_T2	PHENOTYPE	19	20	head injury
NCT001749805	NCT00174980_5_T0	TISSUE	30	30	tissues
NCT001749805	NCT00174980_5_T1	GENE	18	18	has
NCT001749805	NCT00174980_5_T2	COMPOUND	9	9	oxygen
NCT001749805	NCT00174980_5_T3	COMPOUND	28	28	oxygen
NCT001749805	NCT00174980_5_T4	COMPOUND	17	17	Oxycyte
NCT001749806	NCT00174980_6_T0	PHENOTYPE	30	30	Coma
NCT001749806	NCT00174980_6_T1	GENE	32	32	GCS
NCT001749806	NCT00174980_6_T2	COMPOUND	15	15	oxygen
NCT001749806	NCT00174980_6_T3	COMPOUND	18	18	Oxycyte
NCT001749806	NCT00174980_6_T4	PHENOTYPE	25	26	head injury
NCT001749807	NCT00174980_7_T0	GENE	7	7	GCS
NCT001749807	NCT00174980_7_T1	COMPOUND	13	13	oxygen
NCT001749807	NCT00174980_7_T2	PHENOTYPE	5	6	head injury
NCT001749808	NCT00174980_8_T0	COMPOUND	34	34	Oxycyte
NCT0017498010	NCT00174980_10_T0	COMPOUND	34	34	Oxycyte
NCT0017498012	NCT00174980_12_T0	GENE	17	17	PFC
NCT0017498012	NCT00174980_12_T1	COMPOUND	29	29	Oxycyte
NCT001749939	NCT00174993_9_T0	GENE	7	7	receptor
NCT001749939	NCT00174993_9_T1	CELL	5	5	peroxisome
NCT0017499310	NCT00174993_10_T0	GENE	15	15	receptor
NCT0017499310	NCT00174993_10_T1	CELL	13	13	peroxisome
NCT0017499310	NCT00174993_10_T2	GENE	9	9	Ltd
NCT001750063	NCT00175006_3_T0	PHENOTYPE	2	2	gout
NCT001750063	NCT00175006_3_T1	PHENOTYPE	6	7	progressive disease
NCT001750063	NCT00175006_3_T2	PHENOTYPE	22	23	gouty nephropathy
NCT001750063	NCT00175006_3_T3	PHENOTYPE	12	13	bone destruction
NCT001750063	NCT00175006_3_T4	PHENOTYPE	18	19	renal impairment
NCT001750065	NCT00175006_5_T0	PHENOTYPE	7	7	acute
NCT001750065	NCT00175006_5_T1	ORGAN	19	19	joints
NCT001750065	NCT00175006_5_T2	PHENOTYPE	0	0	Gout
NCT001750065	NCT00175006_5_T3	COMPOUND	16	16	monohydrate
NCT001750065	NCT00175006_5_T4	TISSUE	20	20	bones
NCT001750065	NCT00175006_5_T5	GENE	1	1	has
NCT001750065	NCT00175006_5_T6	ORGAN	34	34	serum
NCT001750065	NCT00175006_5_T7	PHENOTYPE	6	6	recurrent
NCT001750065	NCT00175006_5_T8	PHENOTYPE	46	47	gouty arthritis
NCT001750065	NCT00175006_5_T9	PHENOTYPE	25	26	tophaceous gout
NCT001750065	NCT00175006_5_T10	PHENOTYPE	50	51	renal calculi
NCT001750065	NCT00175006_5_T11	COMPOUND	30	31	uric acid
NCT001750065	NCT00175006_5_T12	PHENOTYPE	10	11	inflammatory arthritis
NCT001750065	NCT00175006_5_T13	PHENOTYPE	27	28	renal impairment
NCT001750066	NCT00175006_6_T0	COMPOUND	10	10	xanthine
NCT001750067	NCT00175006_7_T0	PHENOTYPE	13	13	hyperuricemia
NCT001750067	NCT00175006_7_T1	PHENOTYPE	17	17	gout
NCT001750068	NCT00175006_8_T0	PHENOTYPE	3	3	tophi
NCT001750068	NCT00175006_8_T1	PHENOTYPE	19	19	tophus
NCT001750068	NCT00175006_8_T2	GENE	4	4	10
NCT001750194	NCT00175019_4_T0	PHENOTYPE	0	0	Hyperuricemia
NCT001750194	NCT00175019_4_T1	ORGAN	5	5	serum
NCT001750197	NCT00175019_7_T0	PHENOTYPE	24	24	tophi
NCT001750197	NCT00175019_7_T1	PHENOTYPE	7	7	acute
NCT001750197	NCT00175019_7_T2	ORGAN	27	27	joints
NCT001750197	NCT00175019_7_T3	PHENOTYPE	0	0	Gout
NCT001750197	NCT00175019_7_T4	PHENOTYPE	18	18	arthropathy
NCT001750197	NCT00175019_7_T5	GENE	31	31	structural
NCT001750197	NCT00175019_7_T6	TISSUE	26	26	bones
NCT001750197	NCT00175019_7_T7	ORGAN	43	44	urinary tract
NCT001750197	NCT00175019_7_T8	PHENOTYPE	13	14	chronic disorder
NCT001750197	NCT00175019_7_T9	COMPOUND	51	52	uric acid
NCT001750197	NCT00175019_7_T10	PHENOTYPE	8	9	inflammatory arthritis
NCT001750197	NCT00175019_7_T11	PHENOTYPE	34	35	renal impairment
NCT001750199	NCT00175019_9_T0	PHENOTYPE	20	20	hyperuricemia
NCT001750199	NCT00175019_9_T1	PHENOTYPE	24	24	gout
NCT001750199	NCT00175019_9_T2	GENE	6	7	xanthine oxidase
NCT0017501910	NCT00175019_10_T0	COMPOUND	15	15	febuxostat
NCT0017501913	NCT00175019_13_T0	PHENOTYPE	3	3	reflects
NCT001750320	NCT00175032_0_T0	PHENOTYPE	9	9	Osteoarthritis
NCT001750326	NCT00175032_6_T0	PHENOTYPE	5	5	dyspepsia
NCT001750328	NCT00175032_8_T0	PHENOTYPE	6	6	bleeding
NCT001750328	NCT00175032_8_T1	PHENOTYPE	3	4	gastroduodenal ulcer
NCT001750450	NCT00175045_0_T0	PHENOTYPE	11	12	Erosive Esophagitis
NCT001750450	NCT00175045_0_T1	BIOLOGICAL_PROCESS	5	7	Gastric Acid Secretion
NCT001750456	NCT00175045_6_T0	GENE	2	2	had
NCT001750580	NCT00175058_0_T0	GENE	6	6	II
NCT001750580	NCT00175058_0_T1	GENE	8	8	II
NCT001750580	NCT00175058_0_T2	PHENOTYPE	0	2	Acute Myocardial Infarction
NCT001750583	NCT00175058_3_T0	GENE	17	17	II
NCT001750584	NCT00175058_4_T0	GENE	29	29	IDE
NCT001750584	NCT00175058_4_T1	GENE	10	10	AO
NCT001750584	NCT00175058_4_T2	PHENOTYPE	18	18	AMI
NCT001750584	NCT00175058_4_T3	PHENOTYPE	15	17	acute myocardial infarction
NCT001750585	NCT00175058_5_T0	PHENOTYPE	40	40	infarction
NCT001750585	NCT00175058_5_T1	GENE	11	11	AO
NCT001750585	NCT00175058_5_T2	GENE	33	33	ventricular
NCT001750585	NCT00175058_5_T3	GENE	16	16	PCI
NCT001750585	NCT00175058_5_T4	GENE	60	60	PCI
NCT001750585	NCT00175058_5_T5	PHENOTYPE	28	28	AMI
NCT001750585	NCT00175058_5_T6	PHENOTYPE	49	50	Cardiac Events
NCT001750588	NCT00175058_8_T0	PHENOTYPE	3	3	infarct
NCT001750588	NCT00175058_8_T1	GENE	30	30	AO
NCT001750588	NCT00175058_8_T2	PHENOTYPE	17	19	ST segment elevation
NCT001750589	NCT00175058_9_T0	GENE	9	9	AO
NCT001750589	NCT00175058_9_T1	GENE	27	27	AO
NCT0017505810	NCT00175058_10_T0	GENE	12	12	PCI
NCT0017505810	NCT00175058_10_T1	GENE	23	23	PCI
NCT0017505810	NCT00175058_10_T2	PHENOTYPE	7	7	AMI
NCT0017505810	NCT00175058_10_T3	GENE	16	16	AO
NCT0017505811	NCT00175058_11_T0	GENE	9	9	AO
NCT0017505812	NCT00175058_12_T0	GENE	16	16	AO
NCT0017505814	NCT00175058_14_T0	PHENOTYPE	43	43	focused
NCT0017505814	NCT00175058_14_T1	GENE	33	33	IDE
NCT0017505814	NCT00175058_14_T2	PHENOTYPE	9	9	AMI
NCT0017505815	NCT00175058_15_T0	GENE	34	34	II
NCT0017505815	NCT00175058_15_T1	PHENOTYPE	7	7	focused
NCT0017505815	NCT00175058_15_T2	GENE	1	1	has
NCT0017505815	NCT00175058_15_T3	PHENOTYPE	11	11	AMI
NCT0017505819	NCT00175058_19_T0	GENE	5	5	AO
NCT0017505819	NCT00175058_19_T1	GENE	13	13	AO
NCT0017505819	NCT00175058_19_T2	GENE	16	16	AO
NCT0017505820	NCT00175058_20_T0	GENE	6	6	II
NCT0017505820	NCT00175058_20_T1	GENE	1	1	IDE
NCT0017505823	NCT00175058_23_T0	PHENOTYPE	0	0	AMI
NCT0017505825	NCT00175058_25_T0	PHENOTYPE	5	5	AMI
NCT0017505830	NCT00175058_30_T0	GENE	4	4	PCI
NCT0017505831	NCT00175058_31_T0	GENE	4	4	II
NCT0017505831	NCT00175058_31_T1	PHENOTYPE	15	15	infarct
NCT0017505834	NCT00175058_34_T0	PHENOTYPE	4	4	VSD
NCT0017505834	NCT00175058_34_T1	PHENOTYPE	3	3	pseudoaneurysm
NCT0017505834	NCT00175058_34_T2	GENE	2	2	ventricular
NCT0017505834	NCT00175058_34_T3	ORGAN	6	7	papillary muscle
NCT0017505835	NCT00175058_35_T0	PHENOTYPE	6	7	hemorrhagic diathesis
NCT0017505837	NCT00175058_37_T0	GENE	4	4	balloon
NCT0017505838	NCT00175058_38_T0	GENE	4	4	bypass
NCT0017505838	NCT00175058_38_T1	GENE	2	2	had
NCT0017505838	NCT00175058_38_T2	GENE	1	1	has
NCT0017505844	NCT00175058_44_T0	GENE	2	2	had
NCT0017505844	NCT00175058_44_T1	GENE	1	1	has
NCT0017505844	NCT00175058_44_T2	PHENOTYPE	4	5	hemorrhagic stroke
NCT0017505848	NCT00175058_48_T0	GENE	10	10	PCI
NCT0017505850	NCT00175058_50_T0	PHENOTYPE	3	3	calcification
NCT001750712	NCT00175071_2_T0	GENE	16	16	2.3
NCT001750713	NCT00175071_3_T0	GENE	6	6	CRP
NCT001750716	NCT00175071_6_T0	PHENOTYPE	26	27	cardiovascular disease
NCT001750843	NCT00175084_3_T0	PHENOTYPE	28	28	atherosclerosis
NCT001750843	NCT00175084_3_T1	PHENOTYPE	11	11	sporadic
NCT001750843	NCT00175084_3_T2	PHENOTYPE	26	26	concentrations
NCT001750843	NCT00175084_3_T3	GENE	9	9	has
NCT001750845	NCT00175084_5_T0	GENE	46	46	lipoprotein
NCT001750845	NCT00175084_5_T1	COMPOUND	12	12	Lys-Arg
NCT001750845	NCT00175084_5_T2	BIOLOGICAL_PROCESS	49	49	metabolism
NCT001750846	NCT00175084_6_T0	PHENOTYPE	3	3	insights
NCT001750847	NCT00175084_7_T0	GENE	5	5	Arg
NCT001750847	NCT00175084_7_T1	GENE	14	14	Arg
NCT001750847	NCT00175084_7_T2	GENE	24	24	Arg
NCT001750847	NCT00175084_7_T3	GENE	31	31	has
NCT001750848	NCT00175084_8_T0	PHENOTYPE	20	20	concentrations
NCT001750848	NCT00175084_8_T1	GENE	19	19	lipoprotein
NCT001750848	NCT00175084_8_T2	COMPOUND	12	12	Lys-Arg
NCT001750848	NCT00175084_8_T3	COMPOUND	31	31	Lys-Arg
NCT001750848	NCT00175084_8_T4	PHENOTYPE	33	34	cardiovascular disease
NCT001750970	NCT00175097_0_T0	PHENOTYPE	4	4	CVD
NCT001750975	NCT00175097_5_T0	PHENOTYPE	84	84	CVD
NCT001750975	NCT00175097_5_T1	PHENOTYPE	4	4	attributable
NCT001750975	NCT00175097_5_T2	GENE	9	9	soy
NCT001750975	NCT00175097_5_T3	GENE	53	53	soy
NCT001750975	NCT00175097_5_T4	GENE	56	56	soy
NCT001750976	NCT00175097_6_T0	ORGAN	12	12	plasma
NCT001750976	NCT00175097_6_T1	GENE	18	18	soy
NCT001750976	NCT00175097_6_T2	GENE	21	21	soy
NCT001750976	NCT00175097_6_T3	PHENOTYPE	1	1	intent
NCT001751231	NCT00175123_1_T0	PHENOTYPE	9	9	malformation
NCT001751231	NCT00175123_1_T1	ORGAN	12	13	spinal cord
NCT001751232	NCT00175123_2_T0	ORGAN	5	5	bladder
NCT001751232	NCT00175123_2_T1	ORGAN	15	15	kidneys
NCT001751233	NCT00175123_3_T0	GENE	15	15	toxin
NCT001751233	NCT00175123_3_T1	COMPOUND	12	12	oxybutynin
NCT001751234	NCT00175123_4_T0	GENE	8	8	toxin
NCT001751234	NCT00175123_4_T1	COMPOUND	12	12	oxybutynin
NCT001751234	NCT00175123_4_T2	PHENOTYPE	17	18	overactive bladder
NCT001751238	NCT00175123_8_T0	ORGAN	4	4	bladder
NCT001751238	NCT00175123_8_T1	GENE	20	20	CIC
NCT001751238	NCT00175123_8_T2	PHENOTYPE	11	12	urinary incontinence
NCT001751367	NCT00175136_7_T0	PHENOTYPE	4	4	complication
NCT001751367	NCT00175136_7_T1	PHENOTYPE	8	9	aseptic loosening
NCT001751368	NCT00175136_8_T0	PHENOTYPE	4	4	fixation
NCT001751368	NCT00175136_8_T1	GENE	10	10	has
NCT0017513610	NCT00175136_10_T0	PHENOTYPE	23	23	secondary
NCT0017513610	NCT00175136_10_T1	ORGAN	3	3	tibia
NCT0017513610	NCT00175136_10_T2	GENE	18	18	probable
NCT0017513611	NCT00175136_11_T0	ORGAN	1	1	tibia
NCT0017513611	NCT00175136_11_T1	GENE	10	10	has
NCT0017513612	NCT00175136_12_T0	ORGAN	7	7	tibia
NCT0017513613	NCT00175136_13_T0	ORGAN	27	27	tibia
NCT0017513613	NCT00175136_13_T1	PHENOTYPE	26	26	proximal
NCT0017513616	NCT00175136_16_T0	COMPOUND	17	17	titanium
NCT0017513617	NCT00175136_17_T0	ORGAN	0	0	Tibia
NCT0017513619	NCT00175136_19_T0	PHENOTYPE	11	11	fatigue
NCT0017513620	NCT00175136_20_T0	PHENOTYPE	12	12	resistant
NCT0017513621	NCT00175136_21_T0	PHENOTYPE	49	49	Center
NCT0017513623	NCT00175136_23_T0	PHENOTYPE	19	19	Center
NCT001751490	NCT00175149_0_T0	PHENOTYPE	5	7	Left Ventricular Hypertrophy
NCT001751492	NCT00175149_2_T0	PHENOTYPE	3	3	LVH
NCT001751493	NCT00175149_3_T0	PHENOTYPE	9	9	LVH
NCT001751493	NCT00175149_3_T1	PHENOTYPE	5	6	secondary hyperparathyroidism
NCT001751494	NCT00175149_4_T0	PHENOTYPE	18	18	LVH
NCT001751624	NCT00175162_4_T0	PHENOTYPE	4	4	complication
NCT001751624	NCT00175162_4_T1	PHENOTYPE	8	9	aseptic loosening
NCT001751625	NCT00175162_5_T0	PHENOTYPE	4	4	fixation
NCT001751627	NCT00175162_7_T0	ORGAN	8	8	tibia
NCT0017516211	NCT00175162_11_T0	COMPOUND	17	17	titanium
NCT0017516213	NCT00175162_13_T0	TISSUE	4	4	condyles
NCT0017516213	NCT00175162_13_T1	ORGAN	3	3	tibia
NCT0017516213	NCT00175162_13_T2	TISSUE	14	15	cancellous bone
NCT0017516214	NCT00175162_14_T0	TISSUE	4	5	cancellous bone
NCT0017516215	NCT00175162_15_T0	GENE	18	18	lines
NCT0017516215	NCT00175162_15_T1	PHENOTYPE	20	20	osteolysis
NCT0017516216	NCT00175162_16_T0	TISSUE	23	23	condyles
NCT0017516216	NCT00175162_16_T1	GENE	11	11	rim
NCT0017516216	NCT00175162_16_T2	PHENOTYPE	28	28	fixation
NCT0017516217	NCT00175162_17_T0	PHENOTYPE	8	8	resistant
NCT0017516217	NCT00175162_17_T1	GENE	2	2	has
NCT0017516221	NCT00175162_21_T0	PHENOTYPE	31	31	Center
NCT0017516223	NCT00175162_23_T0	PHENOTYPE	19	19	Center
NCT001751751	NCT00175175_1_T0	PHENOTYPE	11	11	osteoporosis
NCT001751751	NCT00175175_1_T1	PHENOTYPE	24	24	osteoporosis
NCT001751751	NCT00175175_1_T2	PHENOTYPE	31	31	fracture
NCT001751753	NCT00175175_3_T0	PHENOTYPE	11	11	osteoporosis
NCT001751753	NCT00175175_3_T1	PHENOTYPE	24	24	osteoporosis
NCT001751753	NCT00175175_3_T2	PHENOTYPE	31	31	fracture
NCT001751883	NCT00175188_3_T0	GENE	8	8	PIP
NCT001751885	NCT00175188_5_T0	TISSUE	8	9	palmar plate
NCT001751886	NCT00175188_6_T0	GENE	22	22	PIP
NCT001751886	NCT00175188_6_T1	TISSUE	18	19	collateral ligaments
NCT001751887	NCT00175188_7_T0	TISSUE	29	30	collateral ligaments
NCT001751888	NCT00175188_8_T0	ORGAN	21	21	tendon
NCT001751888	NCT00175188_8_T1	PHENOTYPE	12	12	centered
NCT001751889	NCT00175188_9_T0	PHENOTYPE	9	9	osteolysis
NCT001751889	NCT00175188_9_T1	TISSUE	14	16	bone prosthesis interface
NCT0017518812	NCT00175188_12_T0	PHENOTYPE	1	1	proximal
NCT0017518812	NCT00175188_12_T1	PHENOTYPE	20	20	proximal
NCT0017518812	NCT00175188_12_T2	GENE	3	3	has
NCT0017518812	NCT00175188_12_T3	PHENOTYPE	17	17	cavity
NCT0017518813	NCT00175188_13_T0	PHENOTYPE	1	1	distal
NCT0017518813	NCT00175188_13_T1	PHENOTYPE	18	18	cavity
NCT0017518814	NCT00175188_14_T0	PHENOTYPE	11	11	sprayed
NCT0017518814	NCT00175188_14_T1	COMPOUND	13	13	titanium
NCT0017518814	NCT00175188_14_T2	ORGAN	10	10	plasma
NCT0017518822	NCT00175188_22_T0	PHENOTYPE	20	20	Center
NCT0017518824	NCT00175188_24_T0	PHENOTYPE	19	19	Center
NCT001752018	NCT00175201_8_T0	GENE	9	9	has
NCT0017520127	NCT00175201_27_T0	GENE	15	15	envelope
NCT0017520129	NCT00175201_29_T0	GENE	32	32	al
NCT0017520129	NCT00175201_29_T1	GENE	31	31	et
NCT0017520133	NCT00175201_33_T0	GENE	14	14	pre
NCT0017520136	NCT00175201_36_T0	GENE	15	15	log
NCT0017520142	NCT00175201_42_T0	PHENOTYPE	11	13	quality of life
NCT0017520145	NCT00175201_45_T0	GENE	13	13	al
NCT0017520154	NCT00175201_54_T0	GENE	11	11	DRG
NCT0017520158	NCT00175201_58_T0	PHENOTYPE	12	14	quality of life
NCT0017520161	NCT00175201_61_T0	GENE	13	13	al
NCT0017520161	NCT00175201_61_T1	GENE	12	12	et
NCT0017520162	NCT00175201_62_T0	GENE	8	8	MF
NCT0017520162	NCT00175201_62_T1	GENE	10	10	al
NCT0017520162	NCT00175201_62_T2	GENE	9	9	et
NCT001752141	NCT00175214_1_T0	GENE	21	21	calcitonin
NCT001752141	NCT00175214_1_T1	COMPOUND	19	19	raloxifene
NCT001752141	NCT00175214_1_T2	ORGAN	30	30	wrist
NCT001752141	NCT00175214_1_T3	PHENOTYPE	27	27	fracture
NCT001752141	NCT00175214_1_T4	GENE	15	15	hormone
NCT001752142	NCT00175214_2_T0	PHENOTYPE	44	44	osteoporosis
NCT001752142	NCT00175214_2_T1	PHENOTYPE	50	50	secondary
NCT0017521411	NCT00175214_11_T0	PHENOTYPE	22	22	osteoporosis
NCT0017521411	NCT00175214_11_T1	PHENOTYPE	36	36	osteoporosis
NCT0017521411	NCT00175214_11_T2	ORGAN	28	28	wrist
NCT0017521411	NCT00175214_11_T3	PHENOTYPE	25	25	fracture
NCT0017521412	NCT00175214_12_T0	GENE	22	22	calcitonin
NCT0017521412	NCT00175214_12_T1	COMPOUND	20	20	raloxifene
NCT0017521412	NCT00175214_12_T2	ORGAN	31	31	wrist
NCT0017521412	NCT00175214_12_T3	PHENOTYPE	28	28	fracture
NCT0017521412	NCT00175214_12_T4	GENE	15	15	hormone
NCT0017521413	NCT00175214_13_T0	PHENOTYPE	20	20	osteoporosis
NCT0017521414	NCT00175214_14_T0	GENE	3	3	has
NCT0017521419	NCT00175214_19_T0	PHENOTYPE	4	4	osteoporosis
NCT001752270	NCT00175227_0_T0	PHENOTYPE	3	3	Nephropathy
NCT001752275	NCT00175227_5_T0	COMPOUND	20	20	creatinine
NCT001752275	NCT00175227_5_T1	COMPOUND	29	29	creatinine
NCT001752275	NCT00175227_5_T2	GENE	21	21	OR
NCT001752275	NCT00175227_5_T3	PHENOTYPE	6	6	nephropathy
NCT001752275	NCT00175227_5_T4	ORGAN	19	19	serum
NCT001752275	NCT00175227_5_T5	ORGAN	28	28	serum
NCT001752401	NCT00175240_1_T0	PHENOTYPE	14	15	heart attacks
NCT001752404	NCT00175240_4_T0	PHENOTYPE	21	21	hyperlipidemia
NCT001752404	NCT00175240_4_T1	GENE	35	35	ACE
NCT001752404	NCT00175240_4_T2	PHENOTYPE	19	19	hypertension
NCT001752404	NCT00175240_4_T3	PHENOTYPE	5	7	acute myocardial infarction
NCT001752405	NCT00175240_5_T0	BIOLOGICAL_PROCESS	22	22	CME
NCT001752531	NCT00175253_1_T0	COMPOUND	12	12	tacrolimus
NCT001752531	NCT00175253_1_T1	PHENOTYPE	17	17	immunosuppression
NCT001752531	NCT00175253_1_T2	ORGAN	10	10	transplant
NCT001752531	NCT00175253_1_T3	ORGAN	18	18	transplant
NCT001752531	NCT00175253_1_T4	COMPOUND	14	15	mycophenolate mofetil
NCT001752532	NCT00175253_2_T0	PHENOTYPE	21	21	autoimmunity
NCT001752532	NCT00175253_2_T1	ORGAN	6	6	transplant
NCT001752534	NCT00175253_4_T0	GENE	15	15	insulin
NCT001752534	NCT00175253_4_T1	ORGAN	8	9	pancreatic islets
NCT001752535	NCT00175253_5_T0	COMPOUND	22	22	tacrolimus
NCT001752535	NCT00175253_5_T1	ORGAN	37	37	transplant
NCT001752535	NCT00175253_5_T2	PHENOTYPE	26	26	immunosuppression
NCT001752535	NCT00175253_5_T3	GENE	36	36	islet
NCT001752663	NCT00175266_3_T0	PHENOTYPE	21	21	engraftment
NCT001752663	NCT00175266_3_T1	PHENOTYPE	16	16	immunosuppression
NCT001752663	NCT00175266_3_T2	GENE	20	20	islet
NCT001752665	NCT00175266_5_T0	ORGAN	25	25	transplant
NCT001752665	NCT00175266_5_T1	GENE	24	24	islet
NCT001752792	NCT00175279_2_T0	PHENOTYPE	9	9	CHF
NCT001752792	NCT00175279_2_T1	GENE	13	13	ACE
NCT001752792	NCT00175279_2_T2	PHENOTYPE	30	30	IHD
NCT001752794	NCT00175279_4_T0	PHENOTYPE	24	24	practices
NCT001752795	NCT00175279_5_T0	PHENOTYPE	3	3	centre
NCT001752796	NCT00175279_6_T0	PHENOTYPE	15	15	CHF
NCT001752796	NCT00175279_6_T1	GENE	20	20	ACE
NCT001752796	NCT00175279_6_T2	PHENOTYPE	17	17	IHD
NCT001752797	NCT00175279_7_T0	PHENOTYPE	12	12	CHF
NCT001752797	NCT00175279_7_T1	GENE	13	13	ACE
NCT001752797	NCT00175279_7_T2	PHENOTYPE	16	16	IHD
NCT0017527910	NCT00175279_10_T0	PHENOTYPE	9	9	CHF
NCT0017527910	NCT00175279_10_T1	GENE	13	13	ACE
NCT0017527910	NCT00175279_10_T2	PHENOTYPE	30	30	IHD
NCT0017527912	NCT00175279_12_T0	PHENOTYPE	24	24	practices
NCT0017527913	NCT00175279_13_T0	PHENOTYPE	3	3	centre
NCT0017527914	NCT00175279_14_T0	PHENOTYPE	15	15	CHF
NCT0017527914	NCT00175279_14_T1	GENE	20	20	ACE
NCT0017527914	NCT00175279_14_T2	PHENOTYPE	17	17	IHD
NCT0017527915	NCT00175279_15_T0	PHENOTYPE	12	12	CHF
NCT0017527915	NCT00175279_15_T1	GENE	13	13	ACE
NCT0017527915	NCT00175279_15_T2	PHENOTYPE	16	16	IHD
NCT001752920	NCT00175292_0_T0	PHENOTYPE	11	11	Recurrence
NCT001752920	NCT00175292_0_T1	PHENOTYPE	18	18	Disease
NCT001752920	NCT00175292_0_T2	PHENOTYPE	15	16	Crohn's Disease
NCT001752922	NCT00175292_2_T0	GENE	11	11	1.1
NCT001752923	NCT00175292_3_T0	PHENOTYPE	15	15	recurrence
NCT001752926	NCT00175292_6_T0	PHENOTYPE	2	3	Crohn's disease
NCT001752927	NCT00175292_7_T0	GENE	7	7	bowel
NCT001752927	NCT00175292_7_T1	PHENOTYPE	10	10	anastomosis
NCT001752927	NCT00175292_7_T2	PHENOTYPE	3	4	Crohn's disease
NCT001752929	NCT00175292_9_T0	ORGAN	7	7	serum
NCT0017529212	NCT00175292_12_T0	PHENOTYPE	2	3	Crohn's disease
NCT0017529212	NCT00175292_12_T1	ORGAN	7	8	GI tract
NCT0017529214	NCT00175292_14_T0	PHENOTYPE	4	5	Crohn's disease
NCT0017529215	NCT00175292_15_T0	ORGAN	1	1	liver
NCT001753051	NCT00175305_1_T0	PHENOTYPE	9	9	satiety
NCT001753051	NCT00175305_1_T1	PHENOTYPE	4	5	increased appetite
NCT001753051	NCT00175305_1_T2	PHENOTYPE	13	14	compulsive behaviour
NCT001753053	NCT00175305_3_T0	GENE	6	6	ghrelin
NCT001753053	NCT00175305_3_T1	PHENOTYPE	2	2	PWS
NCT001753054	NCT00175305_4_T0	GENE	17	17	ghrelin
NCT001753054	NCT00175305_4_T1	GENE	11	11	somatostatin
NCT001753054	NCT00175305_4_T2	PHENOTYPE	33	33	PWS
NCT001753054	NCT00175305_4_T3	GENE	14	14	hormone
NCT001753056	NCT00175305_6_T0	PHENOTYPE	20	20	hyperphagia
NCT001753056	NCT00175305_6_T1	GENE	17	17	1.3
NCT001753056	NCT00175305_6_T2	PHENOTYPE	9	10	feeding problems
NCT001753056	NCT00175305_6_T3	PHENOTYPE	23	24	weight gain
NCT001753056	NCT00175305_6_T4	PHENOTYPE	6	7	central hypotonia
NCT001753056	NCT00175305_6_T5	PHENOTYPE	12	14	poor weight gain
NCT001753058	NCT00175305_8_T0	PHENOTYPE	0	0	Obesity
NCT001753058	NCT00175305_8_T1	PHENOTYPE	9	9	PWS
NCT0017530510	NCT00175305_10_T0	GENE	2	2	1.3
NCT0017530510	NCT00175305_10_T1	PHENOTYPE	6	6	PWS
NCT0017530511	NCT00175305_11_T0	PHENOTYPE	7	7	hyperphagia
NCT0017530511	NCT00175305_11_T1	PHENOTYPE	17	17	satiety
NCT0017530511	NCT00175305_11_T2	PHENOTYPE	0	0	Obesity
NCT0017530511	NCT00175305_11_T3	PHENOTYPE	9	9	hunger
NCT0017530512	NCT00175305_12_T0	PHENOTYPE	19	19	pathophysiology
NCT0017530512	NCT00175305_12_T1	PHENOTYPE	5	5	hypotonia
NCT0017530512	NCT00175305_12_T2	PHENOTYPE	21	21	obesity
NCT0017530512	NCT00175305_12_T3	PHENOTYPE	7	8	decreased energy
NCT0017530512	NCT00175305_12_T4	PHENOTYPE	8	9	energy expenditure
NCT0017530514	NCT00175305_14_T0	GENE	1	1	GH
NCT0017530515	NCT00175305_15_T0	PHENOTYPE	15	15	PWS
NCT0017530515	NCT00175305_15_T1	PHENOTYPE	1	1	obesity
NCT0017530519	NCT00175305_19_T0	GENE	10	10	ghrelin
NCT0017530519	NCT00175305_19_T1	PHENOTYPE	2	2	PWS
NCT0017530520	NCT00175305_20_T0	GENE	3	3	ghrelin
NCT0017530520	NCT00175305_20_T1	PHENOTYPE	6	6	PWS
NCT0017530521	NCT00175305_21_T0	PHENOTYPE	2	2	encoding
NCT0017530521	NCT00175305_21_T1	PHENOTYPE	12	12	PWS
NCT0017530521	NCT00175305_21_T2	PHENOTYPE	31	31	PWS
NCT0017530521	NCT00175305_21_T3	GENE	3	3	ghrelin
NCT0017530521	NCT00175305_21_T4	PHENOTYPE	35	35	deletion
NCT0017530521	NCT00175305_21_T5	CELL	7	8	chromosome 3
NCT0017530521	NCT00175305_21_T6	CELL	25	26	chromosome 15
NCT0017530521	NCT00175305_21_T7	CELL	48	49	chromosome 15
NCT0017530521	NCT00175305_21_T8	PHENOTYPE	44	45	uniparental disomy
NCT0017530522	NCT00175305_22_T0	GENE	15	15	ghrelin
NCT0017530523	NCT00175305_23_T0	GENE	3	3	ghrelin
NCT0017530523	NCT00175305_23_T1	GENE	16	16	ghrelin
NCT0017530523	NCT00175305_23_T2	PHENOTYPE	4	4	concentrations
NCT0017530523	NCT00175305_23_T3	BIOLOGICAL_PROCESS	25	25	behaviour
NCT0017530523	NCT00175305_23_T4	PHENOTYPE	7	7	PWS
NCT0017530524	NCT00175305_24_T0	GENE	12	12	ghrelin
NCT0017530524	NCT00175305_24_T1	PHENOTYPE	13	13	concentrations
NCT0017530524	NCT00175305_24_T2	GENE	14	14	has
NCT0017530524	NCT00175305_24_T3	PHENOTYPE	30	30	PWS
NCT0017530524	NCT00175305_24_T4	PHENOTYPE	9	9	hunger
NCT0017530525	NCT00175305_25_T0	COMPOUND	19	19	SST-14
NCT0017530525	NCT00175305_25_T1	COMPOUND	33	33	SST-28
NCT0017530525	NCT00175305_25_T2	ORGAN	26	26	hypothalamus
NCT0017530525	NCT00175305_25_T3	GENE	7	7	hormone
NCT0017530525	NCT00175305_25_T4	ORGAN	37	38	gastrointestinal tract
NCT0017530527	NCT00175305_27_T0	GENE	5	5	regulator
NCT0017530527	NCT00175305_27_T1	GENE	11	11	gastrin
NCT0017530527	NCT00175305_27_T2	BIOLOGICAL_PROCESS	16	17	gastric motility
NCT0017530528	NCT00175305_28_T0	COMPOUND	15	15	SST-14
NCT0017530528	NCT00175305_28_T1	GENE	1	1	somatostatin
NCT0017530528	NCT00175305_28_T2	COMPOUND	3	3	octreotide
NCT0017530530	NCT00175305_30_T0	PHENOTYPE	22	22	hyperinsulinism
NCT0017530530	NCT00175305_30_T1	GENE	8	8	somatostatin
NCT0017530530	NCT00175305_30_T2	PHENOTYPE	16	16	acromegaly
NCT0017530531	NCT00175305_31_T0	ORGAN	15	15	gallbladder
NCT0017530531	NCT00175305_31_T1	PHENOTYPE	21	22	cholesterol gallstones
NCT0017530538	NCT00175305_38_T0	COMPOUND	2	2	octreotide
NCT0017530538	NCT00175305_38_T1	PHENOTYPE	6	7	weight loss
NCT0017530538	NCT00175305_38_T2	PHENOTYPE	11	12	glucose tolerance
NCT0017530539	NCT00175305_39_T0	PHENOTYPE	2	2	reflecting
NCT0017530539	NCT00175305_39_T1	PHENOTYPE	3	4	glucose tolerance
NCT0017530540	NCT00175305_40_T0	PHENOTYPE	9	9	flatulence
NCT0017530540	NCT00175305_40_T1	PHENOTYPE	7	7	diarrhea
NCT0017530540	NCT00175305_40_T2	PHENOTYPE	4	4	nausea
NCT0017530540	NCT00175305_40_T3	PHENOTYPE	5	6	abdominal cramps
NCT0017530543	NCT00175305_43_T0	GENE	13	13	SC
NCT0017530543	NCT00175305_43_T1	GENE	26	26	ghrelin
NCT0017530543	NCT00175305_43_T2	PHENOTYPE	27	27	concentrations
NCT0017530543	NCT00175305_43_T3	GENE	20	20	al
NCT0017530543	NCT00175305_43_T4	PHENOTYPE	3	3	PWS
NCT0017530543	NCT00175305_43_T5	GENE	19	19	et
NCT0017530545	NCT00175305_45_T0	PHENOTYPE	3	3	complications
NCT0017530546	NCT00175305_46_T0	GENE	12	12	ghrelin
NCT0017530546	NCT00175305_46_T1	PHENOTYPE	13	13	concentrations
NCT0017530546	NCT00175305_46_T2	PHENOTYPE	3	3	acromegaly
NCT0017530546	NCT00175305_46_T3	COMPOUND	8	8	BMI
NCT0017530547	NCT00175305_47_T0	GENE	3	3	al
NCT0017530547	NCT00175305_47_T1	GENE	2	2	et
NCT0017530547	NCT00175305_47_T2	COMPOUND	11	11	octreotide
NCT0017530547	NCT00175305_47_T3	PHENOTYPE	23	23	obesity
NCT0017530547	NCT00175305_47_T4	PHENOTYPE	26	27	brain tumor
NCT0017530551	NCT00175305_51_T0	GENE	8	8	ghrelin
NCT0017530551	NCT00175305_51_T1	PHENOTYPE	9	9	concentrations
NCT0017530551	NCT00175305_51_T2	GENE	1	1	somatostatin
NCT0017530551	NCT00175305_51_T3	PHENOTYPE	19	19	PWS
NCT0017530552	NCT00175305_52_T0	GENE	9	9	ghrelin
NCT0017530552	NCT00175305_52_T1	GENE	16	16	ghrelin
NCT0017530552	NCT00175305_52_T2	PHENOTYPE	10	10	concentrations
NCT0017530552	NCT00175305_52_T3	PHENOTYPE	21	23	decrease in appetite
NCT001753182	NCT00175318_2_T0	GENE	10	10	had
NCT001753186	NCT00175318_6_T0	GENE	10	10	had
NCT0017531810	NCT00175318_10_T0	PHENOTYPE	13	13	caries
NCT0017531811	NCT00175318_11_T0	PHENOTYPE	1	1	secondary
NCT0017531811	NCT00175318_11_T1	PHENOTYPE	15	15	practices
NCT0017531812	NCT00175318_12_T0	GENE	10	10	has
NCT0017531812	NCT00175318_12_T1	PHENOTYPE	21	22	dental caries
NCT0017531815	NCT00175318_15_T0	PHENOTYPE	10	10	caries
NCT0017531819	NCT00175318_19_T0	COMPOUND	9	9	fluoride
NCT0017531820	NCT00175318_20_T0	COMPOUND	15	15	fluoride
NCT0017531821	NCT00175318_21_T0	GENE	22	22	30.3
NCT0017531822	NCT00175318_22_T0	PHENOTYPE	7	7	secondary
NCT0017531823	NCT00175318_23_T0	PHENOTYPE	9	9	caries
NCT0017531823	NCT00175318_23_T1	PHENOTYPE	28	28	caries
NCT001753445	NCT00175344_5_T0	GENE	3	3	had
NCT001753445	NCT00175344_5_T1	PHENOTYPE	4	5	breast cancer
NCT0017534419	NCT00175344_19_T0	PHENOTYPE	4	5	breast cancer
NCT001753573	NCT00175357_3_T0	COMPOUND	7	7	heroin
NCT001753573	NCT00175357_3_T1	COMPOUND	11	11	methadone
NCT001753573	NCT00175357_3_T2	COMPOUND	17	17	methadone
NCT001753574	NCT00175357_4_T0	COMPOUND	9	9	hydromorphone
NCT001753575	NCT00175357_5_T0	COMPOUND	27	27	hydromorphone
NCT001753575	NCT00175357_5_T1	COMPOUND	2	2	heroin
NCT001753575	NCT00175357_5_T2	COMPOUND	21	21	heroin
NCT001753577	NCT00175357_7_T0	GENE	14	14	retained
NCT0017535710	NCT00175357_10_T0	PHENOTYPE	0	0	Secondary
NCT0017535710	NCT00175357_10_T1	PHENOTYPE	12	14	quality of life
NCT0017535712	NCT00175357_12_T0	PHENOTYPE	0	1	Opioid Dependence
NCT0017535714	NCT00175357_14_T0	PHENOTYPE	5	6	opioid use
NCT0017535719	NCT00175357_19_T0	BIOLOGICAL_PROCESS	11	11	detoxification
NCT0017535719	NCT00175357_19_T1	COMPOUND	9	9	methadone
NCT0017535719	NCT00175357_19_T2	COMPOUND	30	30	methadone
NCT0017535719	NCT00175357_19_T3	PHENOTYPE	6	7	opiate addiction
NCT0017535720	NCT00175357_20_T0	COMPOUND	20	20	C-4
NCT0017535721	NCT00175357_21_T0	PHENOTYPE	2	2	fulfillment
NCT0017535724	NCT00175357_24_T0	COMPOUND	11	11	heroin
NCT0017535726	NCT00175357_26_T0	GENE	15	15	extended
NCT0017535731	NCT00175357_31_T0	GENE	1	1	II
NCT0017535731	NCT00175357_31_T1	PHENOTYPE	4	5	hepatic encephalopathy
NCT0017535732	NCT00175357_32_T0	PHENOTYPE	0	0	Chronic
NCT0017535732	NCT00175357_32_T1	PHENOTYPE	1	2	respiratory disease
NCT0017535733	NCT00175357_33_T0	PHENOTYPE	3	3	Schizophrenia
NCT0017535733	NCT00175357_33_T1	PHENOTYPE	10	11	psychotic symptoms
NCT0017535733	NCT00175357_33_T2	PHENOTYPE	6	7	psychotic disorder
NCT0017535733	NCT00175357_33_T3	PHENOTYPE	0	2	Bipolar Mood Disorder
NCT001753702	NCT00175370_2_T0	GENE	1	1	has
NCT001753705	NCT00175370_5_T0	COMPOUND	10	10	vancomycin
NCT001753705	NCT00175370_5_T1	COMPOUND	20	20	vancomycin
NCT001753705	NCT00175370_5_T2	GENE	19	19	IV
NCT001753706	NCT00175370_6_T0	COMPOUND	13	13	vancomycin
NCT001753706	NCT00175370_6_T1	COMPOUND	27	27	vancomycin
NCT001753706	NCT00175370_6_T2	GENE	12	12	IV
NCT001753706	NCT00175370_6_T3	GENE	26	26	IV
NCT001753707	NCT00175370_7_T0	COMPOUND	14	14	vancomycin
NCT001753707	NCT00175370_7_T1	GENE	13	13	IV
NCT001753707	NCT00175370_7_T2	PHENOTYPE	25	26	catheter infections
NCT001753709	NCT00175370_9_T0	PHENOTYPE	9	9	bacteremia
NCT0017537012	NCT00175370_12_T0	PHENOTYPE	10	10	infections
NCT0017537012	NCT00175370_12_T1	GENE	6	6	has
NCT0017537014	NCT00175370_14_T0	COMPOUND	18	18	vancomycin
NCT0017537014	NCT00175370_14_T1	COMPOUND	25	25	vancomycin
NCT0017537015	NCT00175370_15_T0	COMPOUND	18	18	vancomycin
NCT0017537015	NCT00175370_15_T1	PHENOTYPE	24	24	bacteremia
NCT0017537016	NCT00175370_16_T0	PHENOTYPE	9	9	bacteremia
NCT0017537018	NCT00175370_18_T0	PHENOTYPE	2	2	strains
NCT0017537018	NCT00175370_18_T1	GENE	8	8	gel
NCT001753831	NCT00175383_1_T0	GENE	0	0	TPIP
NCT001753831	NCT00175383_1_T1	GENE	1	1	has
NCT001753832	NCT00175383_2_T0	GENE	9	9	hormone
NCT001753833	NCT00175383_3_T0	GENE	10	10	LHRH
NCT001753834	NCT00175383_4_T0	GENE	1	1	LHRH
NCT001753835	NCT00175383_5_T0	GENE	1	1	LHRH
NCT001753835	NCT00175383_5_T1	GENE	11	11	TPIP
NCT001753835	NCT00175383_5_T2	COMPOUND	4	4	testosterone
NCT001753836	NCT00175383_6_T0	GENE	8	8	LHRH
NCT001753836	NCT00175383_6_T1	GENE	22	22	LHRH
NCT0017538311	NCT00175383_11_T0	COMPOUND	1	1	testosterone
NCT0017538311	NCT00175383_11_T1	COMPOUND	17	17	testosterone
NCT0017538311	NCT00175383_11_T2	PHENOTYPE	18	18	suppression
NCT0017538312	NCT00175383_12_T0	GENE	7	7	LHRH
NCT0017538312	NCT00175383_12_T1	COMPOUND	14	14	testosterone
NCT0017538314	NCT00175383_14_T0	GENE	26	26	pre
NCT0017538314	NCT00175383_14_T1	COMPOUND	3	3	testosterone
NCT0017538315	NCT00175383_15_T0	GENE	29	29	pre
NCT0017538315	NCT00175383_15_T1	COMPOUND	7	7	testosterone
NCT0017538318	NCT00175383_18_T0	GENE	9	9	T2
NCT001753965	NCT00175396_5_T0	GENE	14	14	Gy
NCT001753965	NCT00175396_5_T1	GENE	30	30	Gy
NCT001753965	NCT00175396_5_T2	COMPOUND	6	6	androgen
NCT001753965	NCT00175396_5_T3	PHENOTYPE	7	7	suppression
NCT001753966	NCT00175396_6_T0	COMPOUND	6	6	flutamide
NCT001753966	NCT00175396_6_T1	COMPOUND	3	3	androgen
NCT001753966	NCT00175396_6_T2	PHENOTYPE	1	1	suppression
NCT001753966	NCT00175396_6_T3	COMPOUND	7	7	nilutamide
NCT001753966	NCT00175396_6_T4	COMPOUND	9	9	bicalutamide
NCT001753966	NCT00175396_6_T5	COMPOUND	10	10	bicalutamide
NCT0017539613	NCT00175396_13_T0	COMPOUND	23	23	androgen
NCT0017539613	NCT00175396_13_T1	PHENOTYPE	1	1	suppression
NCT0017539613	NCT00175396_13_T2	PHENOTYPE	24	24	suppression
NCT0017539613	NCT00175396_13_T3	GENE	17	17	has
NCT0017539616	NCT00175396_16_T0	GENE	10	10	Gy
NCT0017539621	NCT00175396_21_T0	COMPOUND	16	16	androgen
NCT0017539621	NCT00175396_21_T1	PHENOTYPE	1	1	suppression
NCT0017539621	NCT00175396_21_T2	PHENOTYPE	17	17	suppression
NCT0017539621	NCT00175396_21_T3	GENE	10	10	has
NCT0017539625	NCT00175396_25_T0	PHENOTYPE	11	11	acute
NCT0017539625	NCT00175396_25_T1	PHENOTYPE	0	0	Secondary
NCT0017539625	NCT00175396_25_T2	PHENOTYPE	17	17	complications
NCT0017539625	NCT00175396_25_T3	COMPOUND	33	33	testosterone
NCT0017539625	NCT00175396_25_T4	PHENOTYPE	29	29	QOL
NCT0017539629	NCT00175396_29_T0	GENE	21	21	CS
NCT0017539629	NCT00175396_29_T1	PHENOTYPE	26	26	bilateral
NCT0017539629	NCT00175396_29_T2	GENE	30	30	GS
NCT0017539629	NCT00175396_29_T3	GENE	35	35	10
NCT0017539635	NCT00175396_35_T0	GENE	19	19	T4
NCT0017539635	NCT00175396_35_T1	ORGAN	7	8	seminal vesicle
NCT0017539643	NCT00175396_43_T0	PHENOTYPE	22	22	anesthesia
NCT0017539653	NCT00175396_53_T0	PHENOTYPE	10	10	anticoagulation
NCT0017539654	NCT00175396_54_T0	GENE	14	14	LHRH
NCT001754096	NCT00175409_6_T0	PHENOTYPE	22	22	suck
NCT001754097	NCT00175409_7_T0	PHENOTYPE	11	11	fed
NCT0017542210	NCT00175422_10_T0	PHENOTYPE	7	7	attitudes
NCT0017542214	NCT00175422_14_T0	PHENOTYPE	20	20	shaking
NCT0017548711	NCT00175487_11_T0	PHENOTYPE	0	0	Dysplasia
NCT0017548711	NCT00175487_11_T1	ORGAN	4	4	graft
NCT0017548711	NCT00175487_11_T2	GENE	2	2	structural
NCT0017548712	NCT00175487_12_T0	PHENOTYPE	10	10	centre
NCT0017548713	NCT00175487_13_T0	PHENOTYPE	3	3	osteopenia
NCT0017548713	NCT00175487_13_T1	PHENOTYPE	5	5	osteoporosis
NCT001755002	NCT00175500_2_T0	PHENOTYPE	1	1	dislocation
NCT001755003	NCT00175500_3_T0	PHENOTYPE	12	12	dislocation
NCT001755003	NCT00175500_3_T1	PHENOTYPE	4	4	dislocations
NCT001755003	NCT00175500_3_T2	PHENOTYPE	9	10	fear of
NCT001755004	NCT00175500_4_T0	PHENOTYPE	18	18	dislocation
NCT001755005	NCT00175500_5_T0	GENE	4	4	has
NCT001755009	NCT00175500_9_T0	ORGAN	15	15	femur
NCT0017550013	NCT00175500_13_T0	GENE	9	9	beaded
NCT0017550016	NCT00175500_16_T0	PHENOTYPE	7	7	dislocation
NCT0017550016	NCT00175500_16_T1	PHENOTYPE	6	6	recurrent
NCT0017550018	NCT00175500_18_T0	GENE	5	5	structural
NCT0017550018	NCT00175500_18_T1	ORGAN	3	3	acetabulum
NCT0017550018	NCT00175500_18_T2	ORGAN	6	6	allograft
NCT0017550020	NCT00175500_20_T0	ORGAN	3	3	acetabulum
NCT0017550022	NCT00175500_22_T0	ORGAN	3	3	acetabulum
NCT001755262	NCT00175526_2_T0	PHENOTYPE	4	4	severity
NCT001755262	NCT00175526_2_T1	PHENOTYPE	7	7	eclampsia
NCT001755263	NCT00175526_3_T0	PHENOTYPE	1	1	severity
NCT001755264	NCT00175526_4_T0	PHENOTYPE	19	19	eclampsia
NCT001755264	NCT00175526_4_T1	MOLECULAR_FUNCTION	30	32	activated protein C
NCT001755267	NCT00175526_7_T0	PHENOTYPE	22	22	intent
NCT001755269	NCT00175526_9_T0	PHENOTYPE	17	17	eclampsia
NCT001755269	NCT00175526_9_T1	MOLECULAR_FUNCTION	28	30	activated protein C
NCT0017552611	NCT00175526_11_T0	PHENOTYPE	10	10	opinions
NCT0017552611	NCT00175526_11_T1	PHENOTYPE	5	5	eclampsia
NCT0017552613	NCT00175526_13_T0	PHENOTYPE	4	4	severity
NCT0017552613	NCT00175526_13_T1	PHENOTYPE	7	7	eclampsia
NCT0017552614	NCT00175526_14_T0	PHENOTYPE	25	25	eclampsia
NCT0017552615	NCT00175526_15_T0	PHENOTYPE	11	11	eclampsia
NCT0017552615	NCT00175526_15_T1	PHENOTYPE	33	33	eclampsia
NCT0017552617	NCT00175526_17_T0	PHENOTYPE	1	1	severity
NCT0017552619	NCT00175526_19_T0	BIOLOGICAL_PROCESS	11	11	gestation
NCT001755390	NCT00175539_0_T0	PHENOTYPE	6	7	Sexual Arousal
NCT001755395	NCT00175539_5_T0	PHENOTYPE	17	18	sexual arousal
NCT001755396	NCT00175539_6_T0	PHENOTYPE	20	21	sexual dysfunction
NCT001755396	NCT00175539_6_T1	PHENOTYPE	42	43	sexual dysfunction
NCT001755396	NCT00175539_6_T2	PHENOTYPE	9	11	quality of life
NCT001755398	NCT00175539_8_T0	GENE	23	23	PED
NCT001755398	NCT00175539_8_T1	GENE	40	40	PED
NCT0017553910	NCT00175539_10_T0	GENE	11	11	PED
NCT0017553910	NCT00175539_10_T1	PHENOTYPE	20	21	gynecologic cancer
NCT0017553911	NCT00175539_11_T0	GENE	4	4	PED
NCT0017553911	NCT00175539_11_T1	PHENOTYPE	11	11	arousal
NCT0017553911	NCT00175539_11_T2	PHENOTYPE	9	10	sexual desire
NCT0017553911	NCT00175539_11_T3	PHENOTYPE	16	18	quality of life
NCT0017553912	NCT00175539_12_T0	GENE	8	8	PED
NCT0017553913	NCT00175539_13_T0	GENE	9	9	PED
NCT0017553914	NCT00175539_14_T0	GENE	6	6	PED
NCT0017553915	NCT00175539_15_T0	GENE	16	16	PED
NCT0017553915	NCT00175539_15_T1	GENE	28	28	PED
NCT0017553918	NCT00175539_18_T0	PHENOTYPE	9	12	Female Sexual Arousal Disorder
NCT001755653	NCT00175565_3_T0	PHENOTYPE	42	42	FVC
NCT001755653	NCT00175565_3_T1	COMPOUND	16	16	salbutamol
NCT001755653	NCT00175565_3_T2	GENE	2	2	had
NCT001755654	NCT00175565_4_T0	GENE	2	2	had
NCT001755654	NCT00175565_4_T1	GENE	8	8	10
NCT001755654	NCT00175565_4_T2	GENE	15	15	10
NCT0017556510	NCT00175565_10_T0	COMPOUND	5	5	fluticasone
NCT0017556510	NCT00175565_10_T1	COMPOUND	24	24	fluticasone
NCT0017556511	NCT00175565_11_T0	ORGAN	26	26	Heart
NCT0017556511	NCT00175565_11_T1	GENE	10	10	CRP
NCT0017556511	NCT00175565_11_T2	PHENOTYPE	27	27	Association
NCT0017556511	NCT00175565_11_T3	ORGAN	7	7	serum
NCT0017556511	NCT00175565_11_T4	GENE	8	9	C-reactive protein
NCT0017556512	NCT00175565_12_T0	GENE	6	6	interleukin-6
NCT0017556512	NCT00175565_12_T1	GENE	12	12	MCP-1
NCT0017556512	NCT00175565_12_T2	PHENOTYPE	4	4	concentrations
NCT0017556512	NCT00175565_12_T3	GENE	7	7	IL-6
NCT0017556512	NCT00175565_12_T4	ORGAN	3	3	serum
NCT0017556512	NCT00175565_12_T5	GENE	9	11	monocyte chemoattractant protein-1
NCT0017556515	NCT00175565_15_T0	GENE	11	11	CRP
NCT0017556515	NCT00175565_15_T1	GENE	14	14	log
NCT0017556516	NCT00175565_16_T0	GENE	9	9	CRP
NCT0017556516	NCT00175565_16_T1	GENE	8	8	log
NCT0017556516	NCT00175565_16_T2	GENE	3	3	paired
NCT0017556517	NCT00175565_17_T0	GENE	7	7	CRP
NCT0017556517	NCT00175565_17_T1	GENE	16	16	CRP
NCT0017556517	NCT00175565_17_T2	GENE	15	15	log
NCT0017556517	NCT00175565_17_T3	GENE	11	11	paired
NCT0017556518	NCT00175565_18_T0	GENE	10	10	CRP
NCT0017556518	NCT00175565_18_T1	COMPOUND	14	14	fluticasone
NCT0017556518	NCT00175565_18_T2	GENE	9	9	log
NCT0017556518	NCT00175565_18_T3	COMPOUND	16	16	prednisone
NCT0017556519	NCT00175565_19_T0	GENE	21	21	CRP
NCT0017556519	NCT00175565_19_T1	COMPOUND	14	14	fluticasone
NCT0017556519	NCT00175565_19_T2	COMPOUND	24	24	fluticasone
NCT0017556519	NCT00175565_19_T3	COMPOUND	6	6	prednisone
NCT0017556520	NCT00175565_20_T0	GENE	11	11	interleukin-6
NCT0017556520	NCT00175565_20_T1	GENE	14	14	CRP
NCT0017556520	NCT00175565_20_T2	GENE	13	13	log
NCT0017556520	NCT00175565_20_T3	PHENOTYPE	1	1	regression
NCT001755781	NCT00175578_1_T0	PHENOTYPE	25	26	lung cancer
NCT001755784	NCT00175578_4_T0	PHENOTYPE	17	17	tumor
NCT001756040	NCT00175604_0_T0	PHENOTYPE	10	12	Congenital Muscular Torticollis
NCT001756048	NCT00175604_8_T0	GENE	10	10	has
NCT001756431	NCT00175643_1_T0	COMPOUND	15	15	imiquimod
NCT001756431	NCT00175643_1_T1	PHENOTYPE	23	24	actinic keratoses
NCT001756434	NCT00175643_4_T0	GENE	15	15	AK
NCT001756561	NCT00175656_1_T0	PHENOTYPE	15	16	femur fracture
NCT001756562	NCT00175656_2_T0	PHENOTYPE	17	17	QOL
NCT001756562	NCT00175656_2_T1	PHENOTYPE	8	9	functional recovery
NCT001756563	NCT00175656_3_T0	PHENOTYPE	39	39	disorders
NCT001756563	NCT00175656_3_T1	PHENOTYPE	35	35	acute
NCT001756563	NCT00175656_3_T2	GENE	15	15	ASK
NCT001756563	NCT00175656_3_T3	GENE	18	18	has
NCT001756563	NCT00175656_3_T4	PHENOTYPE	37	37	chronic
NCT0017565610	NCT00175656_10_T0	PHENOTYPE	23	23	secondary
NCT001756824	NCT00175682_4_T0	GENE	15	15	AD
NCT001756825	NCT00175682_5_T0	PHENOTYPE	16	16	weakness
NCT001756825	NCT00175682_5_T1	PHENOTYPE	14	14	fatigue
NCT001756825	NCT00175682_5_T2	PHENOTYPE	13	13	dizziness
NCT001756828	NCT00175682_8_T0	GENE	8	8	AD
NCT001756829	NCT00175682_9_T0	GENE	11	11	AD
NCT001756829	NCT00175682_9_T1	CELL	21	21	sperm
NCT0017568210	NCT00175682_10_T0	PHENOTYPE	23	23	weakness
NCT0017568210	NCT00175682_10_T1	PHENOTYPE	21	21	fatigue
NCT0017568210	NCT00175682_10_T2	PHENOTYPE	20	20	dizziness
NCT0017568210	NCT00175682_10_T3	GENE	1	1	has
NCT0017568212	NCT00175682_12_T0	PHENOTYPE	26	27	autonomic dysreflexia
NCT0017568213	NCT00175682_13_T0	GENE	4	4	blocker
NCT0017568213	NCT00175682_13_T1	GENE	6	6	has
NCT0017568214	NCT00175682_14_T0	PHENOTYPE	12	12	severity
NCT0017568214	NCT00175682_14_T1	GENE	6	6	AD
NCT0017568214	NCT00175682_14_T2	PHENOTYPE	7	9	signs and symptoms
NCT001756951	NCT00175695_1_T0	PHENOTYPE	6	6	Pre-eclampsia
NCT001756951	NCT00175695_1_T1	PHENOTYPE	7	9	toxemia of pregnancy
NCT001756952	NCT00175695_2_T0	PHENOTYPE	4	4	complications
NCT001756956	NCT00175695_6_T0	PHENOTYPE	5	5	suffering
NCT001756956	NCT00175695_6_T1	PHENOTYPE	7	8	septic shock
NCT001756957	NCT00175695_7_T0	PHENOTYPE	9	9	eclampsia
NCT001756958	NCT00175695_8_T0	PHENOTYPE	5	5	eclampsia
NCT001756958	NCT00175695_8_T1	PHENOTYPE	14	14	intent
NCT001756959	NCT00175695_9_T0	PHENOTYPE	31	31	complications
NCT001756959	NCT00175695_9_T1	PHENOTYPE	7	7	eclampsia
NCT001756959	NCT00175695_9_T2	GENE	5	5	had
NCT001756959	NCT00175695_9_T3	PHENOTYPE	24	24	intent
NCT001757082	NCT00175708_2_T0	GENE	8	8	cm
NCT001757083	NCT00175708_3_T0	GENE	23	23	mat
NCT001757085	NCT00175708_5_T0	PHENOTYPE	5	5	centre
NCT001757087	NCT00175708_7_T0	PHENOTYPE	3	3	centre
NCT0017570810	NCT00175708_10_T0	GENE	10	10	cm
NCT0017570810	NCT00175708_10_T1	GENE	13	13	cm
NCT0017570814	NCT00175708_14_T0	GENE	9	9	mat
NCT0017570818	NCT00175708_18_T0	PHENOTYPE	35	35	secondary
NCT0017570818	NCT00175708_18_T1	PHENOTYPE	15	15	clubfoot
NCT0017570818	NCT00175708_18_T2	PHENOTYPE	26	26	clubfoot
NCT0017570818	NCT00175708_18_T3	PHENOTYPE	30	30	clubfoot
NCT0017570818	NCT00175708_18_T4	PHENOTYPE	32	32	clubfoot
NCT001757210	NCT00175721_0_T0	PHENOTYPE	11	11	Diabetes
NCT001757210	NCT00175721_0_T1	ORGAN	13	13	Kidney
NCT001757212	NCT00175721_2_T0	GENE	9	9	has
NCT001757215	NCT00175721_5_T0	PHENOTYPE	21	21	nidus
NCT001757216	NCT00175721_6_T0	PHENOTYPE	34	34	initiatives
NCT001757341	NCT00175734_1_T0	PHENOTYPE	12	12	concentrations
NCT001757341	NCT00175734_1_T1	GENE	11	11	hemoglobin
NCT001757341	NCT00175734_1_T2	ORGAN	5	6	blood vessels
NCT001757347	NCT00175734_7_T0	PHENOTYPE	16	16	anemia
NCT001757347	NCT00175734_7_T1	PHENOTYPE	31	32	hemoglobin levels
NCT001757349	NCT00175734_9_T0	PHENOTYPE	8	8	anemia
NCT001757349	NCT00175734_9_T1	GENE	18	18	hemoglobin
NCT001757470	NCT00175747_0_T0	GENE	2	2	IIb
NCT001757470	NCT00175747_0_T1	COMPOUND	5	6	Pulmicort Turbuhaler
NCT001757474	NCT00175747_4_T0	PHENOTYPE	27	27	peripheral
NCT001757474	NCT00175747_4_T1	PHENOTYPE	1	1	secondary
NCT001757474	NCT00175747_4_T2	COMPOUND	17	17	budesonide
NCT001757474	NCT00175747_4_T3	COMPOUND	49	49	budesonide
NCT001757474	NCT00175747_4_T4	PHENOTYPE	40	41	drug effect
NCT001757477	NCT00175747_7_T0	PHENOTYPE	2	2	peripheral
NCT001757477	NCT00175747_7_T1	PHENOTYPE	4	4	nodules
NCT0017574711	NCT00175747_11_T0	GENE	18	18	Paul
NCT0017574711	NCT00175747_11_T1	ORGAN	7	8	chest wall
NCT0017574712	NCT00175747_12_T0	PHENOTYPE	5	5	cough
NCT0017574715	NCT00175747_15_T0	CELL	0	0	Cells
NCT0017574716	NCT00175747_16_T0	GENE	7	7	1.0
NCT0017574716	NCT00175747_16_T1	GENE	2	2	had
NCT0017574721	NCT00175747_21_T0	PHENOTYPE	16	17	lung cancer
NCT0017574722	NCT00175747_22_T0	PHENOTYPE	18	18	dysplasia
NCT0017574722	NCT00175747_22_T1	PHENOTYPE	15	15	localize
NCT0017574722	NCT00175747_22_T2	GENE	25	25	Corp
NCT0017574723	NCT00175747_23_T0	GENE	13	13	1.2
NCT0017574727	NCT00175747_27_T0	CELL	6	6	cells
NCT0017574727	NCT00175747_27_T1	GENE	3	3	separated
NCT0017574728	NCT00175747_28_T0	COMPOUND	7	7	formalin
NCT0017574732	NCT00175747_32_T0	PHENOTYPE	3	3	resolved
NCT0017574736	NCT00175747_36_T0	COMPOUND	7	7	budesonide
NCT0017574736	NCT00175747_36_T1	COMPOUND	8	9	Pulmicort Turbuhaler
NCT0017574740	NCT00175747_40_T0	PHENOTYPE	9	10	adverse events
NCT0017574741	NCT00175747_41_T0	PHENOTYPE	9	9	estimation
NCT0017574743	NCT00175747_43_T0	PHENOTYPE	5	5	toxicity
NCT0017574743	NCT00175747_43_T1	PHENOTYPE	10	10	toxicity
NCT0017574743	NCT00175747_43_T2	PHENOTYPE	11	11	resolved
NCT0017574743	NCT00175747_43_T3	PHENOTYPE	13	14	grade 1
NCT001757603	NCT00175760_3_T0	PHENOTYPE	13	14	celiac disease
NCT001757606	NCT00175760_6_T0	GENE	1	1	TTG
NCT001757607	NCT00175760_7_T0	PHENOTYPE	0	0	Intermediate
NCT001757607	NCT00175760_7_T1	GENE	2	2	TTG
NCT001757608	NCT00175760_8_T0	PHENOTYPE	12	13	lactose intolerance
NCT001757732	NCT00175773_2_T0	PHENOTYPE	7	7	severity
NCT001757732	NCT00175773_2_T1	COMPOUND	17	17	epinephrine
NCT001757733	NCT00175773_3_T0	COMPOUND	2	2	epinephrine
NCT001757734	NCT00175773_4_T0	ORGAN	16	16	heart
NCT001757734	NCT00175773_4_T1	PHENOTYPE	14	14	dysfunction
NCT001757736	NCT00175773_6_T0	GENE	2	2	SSR
NCT001757737	NCT00175773_7_T0	PHENOTYPE	1	1	severity
NCT001757737	NCT00175773_7_T1	PHENOTYPE	19	20	Spinal Injury
NCT001757738	NCT00175773_8_T0	GENE	4	4	SSR
NCT001757738	NCT00175773_8_T1	PHENOTYPE	2	3	skin response
NCT0017577312	NCT00175773_12_T0	ORGAN	9	9	feet
NCT0017577312	NCT00175773_12_T1	ORGAN	7	7	hands
NCT0017577313	NCT00175773_13_T0	ORGAN	11	11	feet
NCT0017577313	NCT00175773_13_T1	ORGAN	9	9	hands
NCT0017577314	NCT00175773_14_T0	PHENOTYPE	11	11	5-10
NCT0017577314	NCT00175773_14_T1	ORGAN	1	2	median nerve
NCT0017577317	NCT00175773_17_T0	PHENOTYPE	12	12	orthostatic
NCT0017577317	NCT00175773_17_T1	PHENOTYPE	13	13	tolerance
NCT0017577320	NCT00175773_20_T0	PHENOTYPE	8	8	lightheaded
NCT0017577323	NCT00175773_23_T0	GENE	10	10	BP
NCT0017577324	NCT00175773_24_T0	GENE	20	20	3.5
NCT0017577325	NCT00175773_25_T0	ORGAN	0	0	Serum
NCT0017577330	NCT00175773_30_T0	GENE	4	4	HR
NCT0017577330	NCT00175773_30_T1	GENE	17	17	hr
NCT0017577337	NCT00175773_37_T0	PHENOTYPE	16	18	spinal cord injury
NCT0017577338	NCT00175773_38_T0	PHENOTYPE	11	11	acute
NCT0017577338	NCT00175773_38_T1	PHENOTYPE	13	13	chronic
NCT0017577340	NCT00175773_40_T0	GENE	20	20	eg
NCT0017577340	NCT00175773_40_T1	GENE	11	11	5.7
NCT0017577340	NCT00175773_40_T2	PHENOTYPE	24	24	fracture
NCT0017577343	NCT00175773_43_T0	PHENOTYPE	23	24	substance abuse
NCT001758122	NCT00175812_2_T0	PHENOTYPE	5	5	AML
NCT001758122	NCT00175812_2_T1	PHENOTYPE	4	4	resistant
NCT001758123	NCT00175812_3_T0	GENE	6	6	all-trans
NCT001758123	NCT00175812_3_T1	COMPOUND	7	8	retinoic acid
NCT001758124	NCT00175812_4_T0	PHENOTYPE	9	10	disease progression
NCT001758126	NCT00175812_6_T0	PHENOTYPE	3	3	peripheral
NCT001758126	NCT00175812_6_T1	ORGAN	6	7	bone marrow
NCT001758128	NCT00175812_8_T0	PHENOTYPE	13	13	AML
NCT001758128	NCT00175812_8_T1	PHENOTYPE	10	12	acute myelogenous leukemia
NCT0017581213	NCT00175812_13_T0	COMPOUND	2	3	retinoic acid
NCT0017581216	NCT00175812_16_T0	PHENOTYPE	10	11	disease progression
NCT0017581219	NCT00175812_19_T0	PHENOTYPE	9	9	peripheral
NCT0017581219	NCT00175812_19_T1	ORGAN	13	13	serum
NCT0017581219	NCT00175812_19_T2	ORGAN	19	20	bone marrow
NCT001758250	NCT00175825_0_T0	PHENOTYPE	15	15	Onset
NCT001758250	NCT00175825_0_T1	GENE	17	17	et
NCT001758250	NCT00175825_0_T2	PHENOTYPE	16	16	Seizures
NCT001758250	NCT00175825_0_T3	PHENOTYPE	18	18	Seizures
NCT001758383	NCT00175838_3_T0	PHENOTYPE	14	14	haemorrhage
NCT001758384	NCT00175838_4_T0	PHENOTYPE	7	7	thrombosis
NCT001758385	NCT00175838_5_T0	PHENOTYPE	13	13	symptoms
NCT001758385	NCT00175838_5_T1	COMPOUND	5	5	aspirin
NCT001758385	NCT00175838_5_T2	GENE	6	6	has
NCT001758386	NCT00175838_6_T0	PHENOTYPE	6	6	symptoms
NCT001758386	NCT00175838_6_T1	PHENOTYPE	8	8	ulceration
NCT001758386	NCT00175838_6_T2	COMPOUND	13	13	aspirin
NCT001758386	NCT00175838_6_T3	COMPOUND	18	18	aspirin
NCT001758388	NCT00175838_8_T0	PHENOTYPE	7	7	myelofibrosis
NCT001758388	NCT00175838_8_T1	PHENOTYPE	13	14	acute leukaemia
NCT001758389	NCT00175838_9_T0	COMPOUND	17	17	hydroxyurea
NCT0017583810	NCT00175838_10_T0	PHENOTYPE	15	15	acute
NCT0017583810	NCT00175838_10_T1	PHENOTYPE	11	11	thrombocythaemia
NCT0017583810	NCT00175838_10_T2	COMPOUND	23	23	hydroxyurea
NCT0017583810	NCT00175838_10_T3	GENE	24	24	has
NCT0017583812	NCT00175838_12_T0	COMPOUND	14	14	hydroxyurea
NCT0017583812	NCT00175838_12_T1	PHENOTYPE	17	18	vascular occlusion
NCT0017583813	NCT00175838_13_T0	COMPOUND	26	26	hydroxyurea
NCT0017583814	NCT00175838_14_T0	COMPOUND	8	8	hydroxyurea
NCT0017583819	NCT00175838_19_T0	PHENOTYPE	14	14	complications
NCT0017583821	NCT00175838_21_T0	GENE	2	2	has
NCT0017583821	NCT00175838_21_T1	PHENOTYPE	13	14	vascular occlusion
NCT0017583822	NCT00175838_22_T0	COMPOUND	23	23	aspirin
NCT0017583823	NCT00175838_23_T0	COMPOUND	12	12	aspirin
NCT0017583825	NCT00175838_25_T0	PHENOTYPE	21	21	acute
NCT0017583832	NCT00175838_32_T0	PHENOTYPE	10	10	menopausal
NCT0017583832	NCT00175838_32_T1	PHENOTYPE	7	8	iron deficiency
NCT001758640	NCT00175864_0_T0	PHENOTYPE	24	24	Epilepsy
NCT001758640	NCT00175864_0_T1	PHENOTYPE	26	26	Epilepsy
NCT001758640	NCT00175864_0_T2	GENE	25	25	ry
NCT001758900	NCT00175890_0_T0	GENE	11	11	Age
NCT001758900	NCT00175890_0_T1	PHENOTYPE	14	14	Onset
NCT001758900	NCT00175890_0_T2	GENE	16	16	et
NCT001758900	NCT00175890_0_T3	PHENOTYPE	15	15	Seizures
NCT001758900	NCT00175890_0_T4	PHENOTYPE	17	17	Seizures
NCT001758902	NCT00175890_2_T0	PHENOTYPE	9	9	electroencephalograms
NCT001759682	NCT00175968_2_T0	TISSUE	9	9	endothelium
NCT001759682	NCT00175968_2_T1	COMPOUND	10	10	acetylcholine
NCT001759682	NCT00175968_2_T2	COMPOUND	12	13	sodium nitroprusside
NCT001759682	NCT00175968_2_T3	PHENOTYPE	1	2	venous occlusion
NCT001759812	NCT00175981_2_T0	PHENOTYPE	2	2	concentrations
NCT001759812	NCT00175981_2_T1	ORGAN	1	1	plasma
NCT001759940	NCT00175994_0_T0	BIOLOGICAL_PROCESS	2	2	Metabolism
NCT001759940	NCT00175994_0_T1	GENE	12	12	CYP2C19
NCT001759943	NCT00175994_3_T0	BIOLOGICAL_PROCESS	5	5	metabolism
NCT001759943	NCT00175994_3_T1	GENE	8	8	has
NCT001759944	NCT00175994_4_T0	BIOLOGICAL_PROCESS	4	4	metabolism
NCT001759944	NCT00175994_4_T1	GENE	5	5	has
NCT001760072	NCT00176007_2_T0	PHENOTYPE	20	20	hypoxia
NCT001760072	NCT00176007_2_T1	PHENOTYPE	5	5	susceptible
NCT001760072	NCT00176007_2_T2	PHENOTYPE	12	12	dysfunction
NCT001760203	NCT00176020_3_T0	GENE	10	11	period 3
NCT001760331	NCT00176033_1_T0	PHENOTYPE	10	10	peripheral
NCT001760331	NCT00176033_1_T1	PHENOTYPE	8	8	concentrations
NCT001760331	NCT00176033_1_T2	PHENOTYPE	20	20	concentrations
NCT001760331	NCT00176033_1_T3	CELL	13	13	cells
NCT001760331	NCT00176033_1_T4	ORGAN	19	19	plasma
NCT001760332	NCT00176033_2_T0	COMPOUND	9	9	1
NCT001760332	NCT00176033_2_T1	COMPOUND	14	14	3
NCT001760332	NCT00176033_2_T2	PHENOTYPE	17	17	chronic
NCT001760462	NCT00176046_2_T0	CELL	24	24	lymphocytes
NCT001760462	NCT00176046_2_T1	COMPOUND	60	60	cortisol
NCT001760462	NCT00176046_2_T2	PHENOTYPE	11	12	breast cancer
NCT001760462	NCT00176046_2_T3	PHENOTYPE	84	85	breast cancer
NCT001760462	NCT00176046_2_T4	PHENOTYPE	89	91	metastatic breast cancer
NCT001760462	NCT00176046_2_T5	PHENOTYPE	25	27	quality of life
NCT001760462	NCT00176046_2_T6	PHENOTYPE	55	57	quality of life
NCT001760591	NCT00176059_1_T0	PHENOTYPE	9	9	acute
NCT001760591	NCT00176059_1_T1	ORGAN	5	5	graft
NCT001760591	NCT00176059_1_T2	ORGAN	16	16	graft
NCT001760591	NCT00176059_1_T3	PHENOTYPE	11	11	chronic
NCT001760591	NCT00176059_1_T4	PHENOTYPE	13	14	infectious diseases
NCT001760593	NCT00176059_3_T0	PHENOTYPE	12	12	acute
NCT001760593	NCT00176059_3_T1	PHENOTYPE	17	17	resistant
NCT001760593	NCT00176059_3_T2	GENE	1	1	has
NCT001760594	NCT00176059_4_T0	GENE	2	2	has
NCT001760596	NCT00176059_6_T0	PHENOTYPE	11	11	chronic
NCT001760596	NCT00176059_6_T1	PHENOTYPE	14	15	graft loss
NCT001760597	NCT00176059_7_T0	PHENOTYPE	9	9	acute
NCT001760597	NCT00176059_7_T1	ORGAN	16	16	graft
NCT001760597	NCT00176059_7_T2	PHENOTYPE	11	11	chronic
NCT001760597	NCT00176059_7_T3	PHENOTYPE	13	14	infectious diseases
NCT001760721	NCT00176072_1_T0	COMPOUND	29	29	1
NCT001760721	NCT00176072_1_T1	COMPOUND	71	71	1
NCT001760721	NCT00176072_1_T2	GENE	14	14	MB
NCT001760721	NCT00176072_1_T3	GENE	27	27	MB
NCT001760721	NCT00176072_1_T4	GENE	59	59	MB
NCT001760723	NCT00176072_3_T0	PHENOTYPE	3	3	concentrations
NCT001760723	NCT00176072_3_T1	GENE	2	2	MB
NCT001760723	NCT00176072_3_T2	GENE	18	18	MB
NCT001760723	NCT00176072_3_T3	PHENOTYPE	7	7	malaria
NCT001760724	NCT00176072_4_T0	GENE	18	18	MB
NCT001760724	NCT00176072_4_T1	GENE	23	23	MB
NCT001760725	NCT00176072_5_T0	GENE	17	17	MB
NCT001760726	NCT00176072_6_T0	COMPOUND	14	14	chloroquine
NCT001760726	NCT00176072_6_T1	PHENOTYPE	17	17	concentrations
NCT001760726	NCT00176072_6_T2	GENE	12	12	MB
NCT001760726	NCT00176072_6_T3	ORGAN	16	16	plasma
NCT001760727	NCT00176072_7_T0	GENE	19	19	MB
NCT001760983	NCT00176098_3_T0	PHENOTYPE	12	13	organic stress
NCT001760984	NCT00176098_4_T0	PHENOTYPE	16	16	anesthesia
NCT001760984	NCT00176098_4_T1	PHENOTYPE	30	30	anesthesia
NCT001761112	NCT00176111_2_T0	PHENOTYPE	23	24	nerve lesion
NCT001761114	NCT00176111_4_T0	PHENOTYPE	12	12	blocked
NCT001761115	NCT00176111_5_T0	ORGAN	26	27	peripheral nerve
NCT001761116	NCT00176111_6_T0	PHENOTYPE	9	9	excitability
NCT001761116	NCT00176111_6_T1	ORGAN	12	13	peripheral nerve
NCT001761240	NCT00176124_0_T0	CELL	0	0	Leukocyte
NCT001761240	NCT00176124_0_T1	ORGAN	5	5	Blood
NCT001761244	NCT00176124_4_T0	PHENOTYPE	5	5	centers
NCT001761245	NCT00176124_5_T0	GENE	7	7	envelope
NCT001761245	NCT00176124_5_T1	GENE	2	2	seal
NCT001761248	NCT00176124_8_T0	CELL	5	5	leukocyte
NCT0017612411	NCT00176124_11_T0	GENE	45	45	Pall
NCT0017612411	NCT00176124_11_T1	CELL	18	18	leukocyte
NCT0017612411	NCT00176124_11_T2	CELL	40	40	leukocyte
NCT0017612414	NCT00176124_14_T0	GENE	1	1	Hb
NCT0017612414	NCT00176124_14_T1	ORGAN	2	2	plasma
NCT0017612419	NCT00176124_19_T0	PHENOTYPE	12	12	hypoperfusion
NCT0017612419	NCT00176124_19_T1	PHENOTYPE	0	0	Normovolemia
NCT0017612419	NCT00176124_19_T2	PHENOTYPE	4	4	hypovolemia
NCT001761371	NCT00176137_1_T0	PHENOTYPE	4	4	progression
NCT001761374	NCT00176137_4_T0	PHENOTYPE	4	4	progression
NCT001761501	NCT00176150_1_T0	PHENOTYPE	3	3	peripheral
NCT001761501	NCT00176150_1_T1	CELL	6	6	cells
NCT001761501	NCT00176150_1_T2	PHENOTYPE	17	18	anorexia nervosa
NCT001761503	NCT00176150_3_T0	GENE	10	10	P-gp
NCT001761503	NCT00176150_3_T1	GENE	16	16	PCR
NCT001761503	NCT00176150_3_T2	GENE	12	13	reverse transcriptase
NCT001761639	NCT00176163_9_T0	PHENOTYPE	8	8	disorders
NCT001761762	NCT00176176_2_T0	PHENOTYPE	10	10	circulation
NCT001761762	NCT00176176_2_T1	PHENOTYPE	21	21	EPS
NCT001761762	NCT00176176_2_T2	PHENOTYPE	6	7	ventricular arrhythmia
NCT001761763	NCT00176176_3_T0	GENE	19	19	NSE
NCT001761763	NCT00176176_3_T1	CELL	16	16	Neuron
NCT001761763	NCT00176176_3_T2	PHENOTYPE	4	4	EPS
NCT001761763	NCT00176176_3_T3	GENE	18	18	Enolase
NCT001761890	NCT00176189_0_T0	GENE	12	12	de
NCT001761892	NCT00176189_2_T0	GENE	6	6	extended
NCT001761893	NCT00176189_3_T0	ORGAN	20	20	jaw
NCT001762022	NCT00176202_2_T0	PHENOTYPE	8	8	pathophysiology
NCT001762025	NCT00176202_5_T0	COMPOUND	2	2	lithium
NCT001762025	NCT00176202_5_T1	GENE	17	17	al
NCT001762025	NCT00176202_5_T2	GENE	16	16	et
NCT001762025	NCT00176202_5_T3	PHENOTYPE	13	14	substance abuse
NCT001762026	NCT00176202_6_T0	COMPOUND	5	5	lithium
NCT001762026	NCT00176202_6_T1	COMPOUND	4	4	sodium
NCT001762026	NCT00176202_6_T2	GENE	17	17	al
NCT001762026	NCT00176202_6_T3	COMPOUND	7	7	carbamazepine
NCT001762026	NCT00176202_6_T4	GENE	16	16	et
NCT001762027	NCT00176202_7_T0	COMPOUND	15	15	risperidone
NCT001762027	NCT00176202_7_T1	GENE	3	3	al
NCT001762027	NCT00176202_7_T2	GENE	2	2	et
NCT001762027	NCT00176202_7_T3	PHENOTYPE	10	11	antimanic effect
NCT001762029	NCT00176202_9_T0	GENE	6	6	al
NCT001762029	NCT00176202_9_T1	GENE	5	5	et
NCT0017620210	NCT00176202_10_T0	PHENOTYPE	5	5	acute
NCT0017620210	NCT00176202_10_T1	GENE	14	14	al
NCT0017620210	NCT00176202_10_T2	GENE	13	13	et
NCT0017620211	NCT00176202_11_T0	GENE	17	17	al
NCT0017620211	NCT00176202_11_T1	GENE	21	21	al
NCT0017620211	NCT00176202_11_T2	GENE	25	25	al
NCT0017620211	NCT00176202_11_T3	GENE	38	38	al
NCT0017620211	NCT00176202_11_T4	GENE	16	16	et
NCT0017620211	NCT00176202_11_T5	GENE	20	20	et
NCT0017620211	NCT00176202_11_T6	GENE	24	24	et
NCT0017620211	NCT00176202_11_T7	GENE	37	37	et
NCT001762152	NCT00176215_2_T0	ORGAN	13	13	teeth
NCT001762152	NCT00176215_2_T1	PHENOTYPE	10	10	abrasion
NCT001762281	NCT00176228_1_T0	PHENOTYPE	25	25	manic
NCT001762281	NCT00176228_1_T1	PHENOTYPE	21	22	bipolar disorder
NCT001762282	NCT00176228_2_T0	PHENOTYPE	7	7	resistant
NCT001762283	NCT00176228_3_T0	COMPOUND	11	11	lamotrigine
NCT001762283	NCT00176228_3_T1	COMPOUND	20	20	lamotrigine
NCT001762283	NCT00176228_3_T2	PHENOTYPE	9	9	dysfunction
NCT001762283	NCT00176228_3_T3	PHENOTYPE	6	7	brain activity
NCT0017622814	NCT00176228_14_T0	PHENOTYPE	9	9	symptoms
NCT0017622817	NCT00176228_17_T0	GENE	4	4	tapered
NCT0017622818	NCT00176228_18_T0	GENE	17	17	For
NCT0017622819	NCT00176228_19_T0	PHENOTYPE	4	4	symptoms
NCT0017622820	NCT00176228_20_T0	GENE	16	16	has
NCT0017622826	NCT00176228_26_T0	COMPOUND	20	20	lamotrigine
NCT0017622826	NCT00176228_26_T1	PHENOTYPE	23	24	bipolar disorder
NCT0017622827	NCT00176228_27_T0	COMPOUND	11	11	lamotrigine
NCT0017622829	NCT00176228_29_T0	COMPOUND	9	9	lamotrigine
NCT0017622837	NCT00176228_37_T0	COMPOUND	20	20	lamotrigine
NCT0017622837	NCT00176228_37_T1	PHENOTYPE	15	15	practices
NCT001762414	NCT00176241_4_T0	GENE	3	3	MTD
NCT001762414	NCT00176241_4_T1	PHENOTYPE	15	15	recurrent
NCT001762414	NCT00176241_4_T2	PHENOTYPE	18	21	head and neck cancer
NCT001762415	NCT00176241_5_T0	PHENOTYPE	0	0	Secondary
NCT001762416	NCT00176241_6_T0	PHENOTYPE	3	3	toxicities
NCT001762419	NCT00176241_9_T0	PHENOTYPE	9	9	tumor
NCT001762419	NCT00176241_9_T1	GENE	16	16	bax
NCT001762419	NCT00176241_9_T2	GENE	14	14	bcl-2
NCT001762419	NCT00176241_9_T3	GENE	11	11	p53
NCT0017624110	NCT00176241_10_T0	COMPOUND	9	9	paclitaxel
NCT0017624110	NCT00176241_10_T1	COMPOUND	8	8	gemcitabine
NCT0017624110	NCT00176241_10_T2	PHENOTYPE	14	14	recurrent
NCT0017624110	NCT00176241_10_T3	PHENOTYPE	16	19	head and neck cancer
NCT0017624119	NCT00176241_19_T0	GENE	4	4	OR
NCT0017624119	NCT00176241_19_T1	GENE	10	10	MRI
NCT0017624119	NCT00176241_19_T2	PHENOTYPE	5	6	measurable disease
NCT0017624127	NCT00176241_27_T0	PHENOTYPE	2	3	measurable disease
NCT0017624136	NCT00176241_36_T0	GENE	7	7	1.11
NCT0017624136	NCT00176241_36_T1	PHENOTYPE	0	1	Peripheral neuropathy
NCT0017624141	NCT00176241_41_T0	PHENOTYPE	19	20	fetal death
NCT001762540	NCT00176254_0_T0	PHENOTYPE	10	13	Head and Neck Cancer
NCT001762544	NCT00176254_4_T0	GENE	17	17	III
NCT001762544	NCT00176254_4_T1	GENE	7	7	has
NCT001762544	NCT00176254_4_T2	GENE	19	19	IV
NCT001762545	NCT00176254_5_T0	PHENOTYPE	10	10	remission
NCT001762546	NCT00176254_6_T0	GENE	2	2	has
NCT001762546	NCT00176254_6_T1	GENE	19	19	CR
NCT001762548	NCT00176254_8_T0	PHENOTYPE	18	18	cancers
NCT001762548	NCT00176254_8_T1	PHENOTYPE	34	34	cancers
NCT001762548	NCT00176254_8_T2	GENE	23	23	has
NCT001762549	NCT00176254_9_T0	GENE	3	3	has
NCT0017625413	NCT00176254_13_T0	PHENOTYPE	14	14	hopes
NCT0017625423	NCT00176254_23_T0	PHENOTYPE	2	2	Oncology
NCT0017625426	NCT00176254_26_T0	PHENOTYPE	2	2	tumors
NCT0017625426	NCT00176254_26_T1	GENE	22	22	MRI
NCT0017625426	NCT00176254_26_T2	GENE	16	16	cm3
NCT0017625426	NCT00176254_26_T3	GENE	1	1	T2
NCT0017625432	NCT00176254_32_T0	GENE	3	3	II
NCT0017625432	NCT00176254_32_T1	PHENOTYPE	6	6	neuropathy
NCT0017625435	NCT00176254_35_T0	GENE	8	8	MRI
NCT0017625435	NCT00176254_35_T1	PHENOTYPE	3	4	measurable disease
NCT0017625435	NCT00176254_35_T2	PHENOTYPE	13	14	evaluable disease
NCT0017625441	NCT00176254_41_T0	PHENOTYPE	11	11	recurrence
NCT0017625441	NCT00176254_41_T1	PHENOTYPE	13	13	metastases
NCT0017625441	NCT00176254_41_T2	PHENOTYPE	6	6	malignancies
NCT0017625443	NCT00176254_43_T0	PHENOTYPE	18	18	symptoms
NCT0017625443	NCT00176254_43_T1	PHENOTYPE	21	21	resolved
NCT0017625445	NCT00176254_45_T0	PHENOTYPE	5	5	allergy
NCT0017625449	NCT00176254_49_T0	PHENOTYPE	2	3	metastatic disease
NCT001762670	NCT00176267_0_T0	PHENOTYPE	12	15	Head And Neck Cancer
NCT001762674	NCT00176267_4_T0	GENE	17	17	III
NCT001762674	NCT00176267_4_T1	GENE	7	7	has
NCT001762674	NCT00176267_4_T2	GENE	19	19	IV
NCT001762675	NCT00176267_5_T0	PHENOTYPE	10	10	remission
NCT001762676	NCT00176267_6_T0	GENE	2	2	has
NCT001762676	NCT00176267_6_T1	GENE	17	17	CR
NCT001762678	NCT00176267_8_T0	PHENOTYPE	18	18	cancers
NCT001762678	NCT00176267_8_T1	PHENOTYPE	34	34	cancers
NCT001762678	NCT00176267_8_T2	GENE	23	23	has
NCT0017626715	NCT00176267_15_T0	PHENOTYPE	24	24	SCCHN
NCT0017626725	NCT00176267_25_T0	GENE	11	11	M1
NCT0017626725	NCT00176267_25_T1	PHENOTYPE	9	9	SCCHN
NCT0017626725	NCT00176267_25_T2	GENE	6	6	III
NCT0017626725	NCT00176267_25_T3	GENE	8	8	IV
NCT0017626725	NCT00176267_25_T4	GENE	5	5	T2
NCT0017626726	NCT00176267_26_T0	PHENOTYPE	2	2	tumors
NCT0017626726	NCT00176267_26_T1	GENE	22	22	MRI
NCT0017626726	NCT00176267_26_T2	GENE	16	16	cm3
NCT0017626726	NCT00176267_26_T3	GENE	1	1	T2
NCT0017626732	NCT00176267_32_T0	GENE	3	3	II
NCT0017626732	NCT00176267_32_T1	PHENOTYPE	6	6	neuropathy
NCT0017626735	NCT00176267_35_T0	GENE	8	8	MRI
NCT0017626735	NCT00176267_35_T1	PHENOTYPE	3	4	measurable disease
NCT0017626735	NCT00176267_35_T2	PHENOTYPE	13	14	evaluable disease
NCT0017626741	NCT00176267_41_T0	PHENOTYPE	11	11	recurrence
NCT0017626741	NCT00176267_41_T1	PHENOTYPE	13	13	metastases
NCT0017626741	NCT00176267_41_T2	PHENOTYPE	6	6	malignancies
NCT0017626743	NCT00176267_43_T0	PHENOTYPE	18	18	symptoms
NCT0017626743	NCT00176267_43_T1	PHENOTYPE	21	21	resolved
NCT0017626745	NCT00176267_45_T0	PHENOTYPE	5	5	allergy
NCT0017626747	NCT00176267_47_T0	PHENOTYPE	7	7	SCCHN
NCT0017626749	NCT00176267_49_T0	PHENOTYPE	2	3	metastatic disease
NCT0017626751	NCT00176267_51_T0	GENE	3	3	II
NCT0017626751	NCT00176267_51_T1	PHENOTYPE	6	7	peripheral neuropathy
NCT001762807	NCT00176280_7_T0	PHENOTYPE	0	0	Secondary
NCT0017628015	NCT00176280_15_T0	PHENOTYPE	16	16	estimation
NCT0017628015	NCT00176280_15_T1	GENE	19	19	CMP
NCT0017628015	NCT00176280_15_T2	PHENOTYPE	14	14	toxicities
NCT0017628016	NCT00176280_16_T0	ORGAN	14	14	abdomen
NCT0017628016	NCT00176280_16_T1	PHENOTYPE	17	17	tumor
NCT0017628016	NCT00176280_16_T2	GENE	10	10	CAT
NCT0017628016	NCT00176280_16_T3	ORGAN	16	16	pelvis
NCT0017628016	NCT00176280_16_T4	PHENOTYPE	20	22	quality of life
NCT0017628017	NCT00176280_17_T0	COMPOUND	9	9	1
NCT0017628017	NCT00176280_17_T1	PHENOTYPE	3	3	initiation
NCT0017628021	NCT00176280_21_T0	PHENOTYPE	4	4	recurrent
NCT0017628021	NCT00176280_21_T1	GENE	8	8	IV
NCT0017628027	NCT00176280_27_T0	GENE	3	3	18
NCT0017628028	NCT00176280_28_T0	PHENOTYPE	7	9	negative pregnancy test
NCT0017628034	NCT00176280_34_T0	PHENOTYPE	4	4	ascites
NCT0017628034	NCT00176280_34_T1	GENE	12	12	cystic
NCT0017628034	NCT00176280_34_T2	PHENOTYPE	7	8	pericardial effusions
NCT0017628034	NCT00176280_34_T3	PHENOTYPE	0	1	Bone metastases
NCT0017628050	NCT00176280_50_T0	COMPOUND	15	15	gemcitabine
NCT0017628054	NCT00176280_54_T0	PHENOTYPE	1	1	menopausal
NCT0017628058	NCT00176280_58_T0	PHENOTYPE	5	6	grade 1
NCT0017628058	NCT00176280_58_T1	PHENOTYPE	0	1	Peripheral neuropathy
NCT0017628060	NCT00176280_60_T0	PHENOTYPE	6	6	seizures
NCT0017628060	NCT00176280_60_T1	PHENOTYPE	7	10	central nervous system disorders
NCT0017629332	NCT00176293_32_T0	PHENOTYPE	3	3	symptoms
NCT0017629339	NCT00176293_39_T0	GENE	5	5	fold
NCT0017629342	NCT00176293_42_T0	PHENOTYPE	5	7	ventricular ejection fraction
NCT0017629348	NCT00176293_48_T0	GENE	3	3	18
NCT0017629361	NCT00176293_61_T0	ORGAN	8	8	Heart
NCT0017629361	NCT00176293_61_T1	GENE	10	10	II
NCT0017629361	NCT00176293_61_T2	PHENOTYPE	3	4	cardiac disease
NCT0017629361	NCT00176293_61_T3	PHENOTYPE	17	19	congestive heart failure
NCT0017629363	NCT00176293_63_T0	PHENOTYPE	21	21	initiation
NCT001763062	NCT00176306_2_T0	PHENOTYPE	19	19	concentrations
NCT001763062	NCT00176306_2_T1	COMPOUND	7	7	levofloxacin
NCT001763062	NCT00176306_2_T2	COMPOUND	18	18	levofloxacin
NCT001763062	NCT00176306_2_T3	PHENOTYPE	15	15	obesity
NCT001763063	NCT00176306_3_T0	PHENOTYPE	11	11	concentrations
NCT001763063	NCT00176306_3_T1	COMPOUND	10	10	levofloxacin
NCT001763063	NCT00176306_3_T2	PHENOTYPE	8	8	obesity
NCT001763066	NCT00176306_6_T0	COMPOUND	26	26	levofloxacin
NCT001763066	NCT00176306_6_T1	PHENOTYPE	24	24	pharmacokinetics
NCT001763066	NCT00176306_6_T2	PHENOTYPE	17	18	critical illness
NCT001763066	NCT00176306_6_T3	PHENOTYPE	20	21	severe obesity
NCT0017630624	NCT00176306_24_T0	PHENOTYPE	18	18	Center
NCT0017630626	NCT00176306_26_T0	COMPOUND	8	8	levofloxacin
NCT0017630629	NCT00176306_29_T0	COMPOUND	16	16	levofloxacin
NCT0017630629	NCT00176306_29_T1	ORGAN	1	1	serum
NCT0017630630	NCT00176306_30_T0	COMPOUND	15	15	levofloxacin
NCT0017630631	NCT00176306_31_T0	COMPOUND	21	21	levofloxacin
NCT0017630631	NCT00176306_31_T1	GENE	6	6	1.5
NCT0017630633	NCT00176306_33_T0	GENE	8	8	ml
NCT0017630634	NCT00176306_34_T0	ORGAN	12	12	serum
NCT0017630636	NCT00176306_36_T0	PHENOTYPE	20	20	elimination
NCT0017630637	NCT00176306_37_T0	COMPOUND	22	22	creatinine
NCT0017630637	NCT00176306_37_T1	COMPOUND	27	27	creatinine
NCT0017630637	NCT00176306_37_T2	COMPOUND	12	12	levofloxacin
NCT0017630638	NCT00176306_38_T0	COMPOUND	17	17	levofloxacin
NCT0017630638	NCT00176306_38_T1	ORGAN	3	3	serum
NCT0017630639	NCT00176306_39_T0	GENE	24	24	adipose
NCT0017630639	NCT00176306_39_T1	COMPOUND	14	14	potassium_40
NCT0017630642	NCT00176306_42_T0	COMPOUND	14	14	urea
NCT0017630642	NCT00176306_42_T1	COMPOUND	12	12	creatinine
NCT0017630642	NCT00176306_42_T2	PHENOTYPE	26	26	pharmacokinetics
NCT0017630642	NCT00176306_42_T3	ORGAN	11	11	serum
NCT0017630642	NCT00176306_42_T4	PHENOTYPE	20	21	concomitant disease
NCT0017630642	NCT00176306_42_T5	PHENOTYPE	34	35	infection site
NCT0017630642	NCT00176306_42_T6	PHENOTYPE	41	43	adverse drug reactions
NCT0017630643	NCT00176306_43_T0	PHENOTYPE	1	1	pharmacokinetics
NCT0017630643	NCT00176306_43_T1	GENE	17	17	Corp
NCT0017630643	NCT00176306_43_T2	PHENOTYPE	12	12	elimination
NCT0017630643	NCT00176306_43_T3	GENE	19	19	CA
NCT0017630651	NCT00176306_51_T0	COMPOUND	2	2	levofloxacin
NCT001763191	NCT00176319_1_T0	GENE	24	24	ventricular
NCT001763191	NCT00176319_1_T1	BIOLOGICAL_PROCESS	9	9	Aging
NCT001763191	NCT00176319_1_T2	BIOLOGICAL_PROCESS	35	35	metabolism
NCT001763191	NCT00176319_1_T3	PHENOTYPE	31	32	heart failure
NCT001763191	NCT00176319_1_T4	PHENOTYPE	41	42	heart failure
NCT001763191	NCT00176319_1_T5	TISSUE	33	34	skeletal muscle
NCT001763191	NCT00176319_1_T6	PHENOTYPE	5	7	Chronic heart failure
NCT001763192	NCT00176319_2_T0	PHENOTYPE	27	28	heart failure
NCT001763193	NCT00176319_3_T0	PHENOTYPE	18	18	CHF
NCT001763195	NCT00176319_5_T0	ORGAN	31	31	thigh
NCT001763195	NCT00176319_5_T1	GENE	22	22	ventricular
NCT001763195	NCT00176319_5_T2	PHENOTYPE	8	8	tolerance
NCT001763196	NCT00176319_6_T0	TISSUE	0	1	Skeletal muscle
NCT001763321	NCT00176332_1_T0	PHENOTYPE	41	41	peripheral
NCT001763321	NCT00176332_1_T1	PHENOTYPE	42	43	endothelial dysfunction
NCT001763321	NCT00176332_1_T2	TISSUE	38	39	skeletal muscle
NCT001763321	NCT00176332_1_T3	PHENOTYPE	23	25	chronic heart failure
NCT001763322	NCT00176332_2_T0	BIOLOGICAL_PROCESS	32	32	vasculogenesis
NCT001763322	NCT00176332_2_T1	PHENOTYPE	19	19	inflammation
NCT001763322	NCT00176332_2_T2	COMPOUND	14	14	rosuvastatin
NCT001763322	NCT00176332_2_T3	TISSUE	25	26	skeletal muscle
NCT001763322	NCT00176332_2_T4	PHENOTYPE	21	22	oxidative stress
NCT001763322	NCT00176332_2_T5	ORGAN	38	39	radial artery
NCT001763322	NCT00176332_2_T6	PHENOTYPE	44	46	chronic heart failure
NCT001763325	NCT00176332_5_T0	BIOLOGICAL_PROCESS	22	22	vasculogenesis
NCT001763325	NCT00176332_5_T1	PHENOTYPE	19	20	oxidative stress
NCT001763325	NCT00176332_5_T2	TISSUE	0	1	Skeletal muscle
NCT001763326	NCT00176332_6_T0	PHENOTYPE	9	9	inflammation
NCT001763326	NCT00176332_6_T1	PHENOTYPE	11	12	oxidative stress
NCT001763452	NCT00176345_2_T0	GENE	14	14	eNOS
NCT001763452	NCT00176345_2_T1	GENE	16	16	cyclooxygenase
NCT001763452	NCT00176345_2_T2	GENE	17	17	COX
NCT001763452	NCT00176345_2_T3	GENE	12	13	NO synthase
NCT001763453	NCT00176345_3_T0	GENE	17	17	bradykinin
NCT001763453	NCT00176345_3_T1	PHENOTYPE	13	14	endothelial dysfunction
NCT001763455	NCT00176345_5_T0	ORGAN	4	5	radial artery
NCT001763714	NCT00176371_4_T0	PHENOTYPE	9	10	cardiovascular diseases
NCT001763718	NCT00176371_8_T0	GENE	3	3	had
NCT001763841	NCT00176384_1_T0	PHENOTYPE	11	11	peripheral
NCT001763841	NCT00176384_1_T1	GENE	4	4	has
NCT001763841	NCT00176384_1_T2	PHENOTYPE	17	18	heart failure
NCT001763843	NCT00176384_3_T0	PHENOTYPE	20	20	peripheral
NCT001763843	NCT00176384_3_T1	PHENOTYPE	32	33	class III
NCT001763843	NCT00176384_3_T2	PHENOTYPE	26	28	chronic heart failure
NCT001763846	NCT00176384_6_T0	TISSUE	0	1	Skeletal muscle
NCT001763976	NCT00176397_6_T0	GENE	13	13	PCI
NCT001764106	NCT00176410_6_T0	COMPOUND	15	15	fluvastatin
NCT0017641017	NCT00176410_17_T0	GENE	5	5	reduced
NCT0017641017	NCT00176410_17_T1	ORGAN	0	1	Aortic valve
NCT0017641022	NCT00176410_22_T0	PHENOTYPE	1	2	aortic regurgitation
NCT0017641025	NCT00176410_25_T0	PHENOTYPE	0	2	Coronary artery disease
NCT0017641026	NCT00176410_26_T0	PHENOTYPE	2	3	arterial hypertension
NCT0017641027	NCT00176410_27_T0	PHENOTYPE	2	2	diseases
NCT001764233	NCT00176423_3_T0	PHENOTYPE	12	12	schizophrenia
NCT001764236	NCT00176423_6_T0	PHENOTYPE	6	7	cognitive impairments
NCT001764237	NCT00176423_7_T0	PHENOTYPE	11	12	cognitive impairments
NCT0017642310	NCT00176423_10_T0	ORGAN	11	11	hippocampus
NCT0017642310	NCT00176423_10_T1	ORGAN	10	10	neocortex
NCT0017642310	NCT00176423_10_T2	ORGAN	13	14	basal ganglia
NCT0017642312	NCT00176423_12_T0	GENE	12	12	P50
NCT0017642312	NCT00176423_12_T1	PHENOTYPE	18	18	schizophrenia
NCT0017642312	NCT00176423_12_T2	GENE	1	1	has
NCT0017642312	NCT00176423_12_T3	PHENOTYPE	7	8	sensory gating
NCT0017642314	NCT00176423_14_T0	GENE	20	20	receptor
NCT0017642314	NCT00176423_14_T1	GENE	9	9	acetylcholinesterase
NCT0017642314	NCT00176423_14_T2	GENE	24	25	nicotinic receptor
NCT0017642318	NCT00176423_18_T0	COMPOUND	6	6	galantamine
NCT0017642318	NCT00176423_18_T1	PHENOTYPE	10	11	psychotic symptoms
NCT0017642319	NCT00176423_19_T0	PHENOTYPE	9	9	schizophrenia
NCT0017642320	NCT00176423_20_T0	COMPOUND	15	15	olanzapine
NCT0017642320	NCT00176423_20_T1	COMPOUND	10	10	donepezil
NCT0017642323	NCT00176423_23_T0	GENE	14	14	43.1
NCT0017642323	NCT00176423_23_T1	GENE	27	27	7.2
NCT0017642324	NCT00176423_24_T0	COMPOUND	3	3	olanzapine
NCT0017642326	NCT00176423_26_T0	PHENOTYPE	7	8	sensory gating
NCT0017642327	NCT00176423_27_T0	GENE	2	2	had
NCT0017642327	NCT00176423_27_T1	GENE	4	4	P50
NCT0017642331	NCT00176423_31_T0	GENE	13	13	3.8
NCT0017642331	NCT00176423_31_T1	GENE	17	17	3.8
NCT0017642331	NCT00176423_31_T2	GENE	27	27	10.9
NCT0017642331	NCT00176423_31_T3	GENE	31	31	12.6
NCT0017642332	NCT00176423_32_T0	PHENOTYPE	20	20	schizophrenia
NCT0017642332	NCT00176423_32_T1	PHENOTYPE	15	16	cognitive impairments
NCT0017642334	NCT00176423_34_T0	PHENOTYPE	8	8	suppression
NCT0017642334	NCT00176423_34_T1	GENE	11	11	P50
NCT0017642335	NCT00176423_35_T0	COMPOUND	5	5	donepezil
NCT0017642337	NCT00176423_37_T0	COMPOUND	17	17	olanzapine
NCT0017642337	NCT00176423_37_T1	GENE	24	24	P50
NCT0017642337	NCT00176423_37_T2	GENE	30	30	al
NCT0017642337	NCT00176423_37_T3	GENE	34	34	al
NCT0017642337	NCT00176423_37_T4	GENE	29	29	et
NCT0017642337	NCT00176423_37_T5	GENE	33	33	et
NCT0017642337	NCT00176423_37_T6	PHENOTYPE	8	9	cognitive function
NCT0017642337	NCT00176423_37_T7	PHENOTYPE	26	27	cognitive function
NCT0017642338	NCT00176423_38_T0	COMPOUND	17	17	olanzapine
NCT0017642338	NCT00176423_38_T1	COMPOUND	1	1	donepezil
NCT0017642338	NCT00176423_38_T2	PHENOTYPE	7	8	cognitive function
NCT0017642344	NCT00176423_44_T0	PHENOTYPE	1	1	secondary
NCT0017642345	NCT00176423_45_T0	PHENOTYPE	12	12	symptoms
NCT0017642345	NCT00176423_45_T1	COMPOUND	4	4	galantamine
NCT0017642347	NCT00176423_47_T0	PHENOTYPE	19	19	dizziness
NCT0017642347	NCT00176423_47_T1	PHENOTYPE	15	15	anorexia
NCT0017642347	NCT00176423_47_T2	COMPOUND	4	4	galantamine
NCT0017642347	NCT00176423_47_T3	PHENOTYPE	14	14	diarrhea
NCT0017642347	NCT00176423_47_T4	PHENOTYPE	13	13	vomiting
NCT0017642347	NCT00176423_47_T5	PHENOTYPE	12	12	nausea
NCT0017642347	NCT00176423_47_T6	PHENOTYPE	16	17	weight loss
NCT0017642349	NCT00176423_49_T0	COMPOUND	3	3	galantamine
NCT0017642349	NCT00176423_49_T1	PHENOTYPE	15	16	extrapyramidal symptoms
NCT0017642351	NCT00176423_51_T0	COMPOUND	3	3	galantamine
NCT0017642352	NCT00176423_52_T0	COMPOUND	22	22	donepezil
NCT0017642352	NCT00176423_52_T1	COMPOUND	11	11	galantamine
NCT0017642352	NCT00176423_52_T2	PHENOTYPE	15	18	positive and negative symptoms
NCT0017642353	NCT00176423_53_T0	COMPOUND	3	3	galantamine
NCT0017642354	NCT00176423_54_T0	COMPOUND	11	11	galantamine
NCT0017642354	NCT00176423_54_T1	PHENOTYPE	16	17	extrapyramidal symptoms
NCT0017642355	NCT00176423_55_T0	COMPOUND	16	16	galantamine
NCT0017642356	NCT00176423_56_T0	PHENOTYPE	13	13	schizophrenia
NCT0017642356	NCT00176423_56_T1	PHENOTYPE	15	16	schizoaffective disorder
NCT0017642359	NCT00176423_59_T0	COMPOUND	11	11	galantamine
NCT0017642360	NCT00176423_60_T0	PHENOTYPE	5	6	side effect
NCT0017642362	NCT00176423_62_T0	PHENOTYPE	23	24	side effect
NCT0017642365	NCT00176423_65_T0	PHENOTYPE	4	4	schizophrenia
NCT0017642365	NCT00176423_65_T1	PHENOTYPE	6	7	schizoaffective disorder
NCT0017642368	NCT00176423_68_T0	GENE	0	0	Age
NCT0017642370	NCT00176423_70_T0	COMPOUND	13	13	olanzapine
NCT0017642370	NCT00176423_70_T1	COMPOUND	14	14	risperidone
NCT0017642370	NCT00176423_70_T2	COMPOUND	15	15	quetiapine
NCT0017642370	NCT00176423_70_T3	COMPOUND	18	18	aripiprazole
NCT0017642370	NCT00176423_70_T4	COMPOUND	16	16	ziprasidone
NCT0017642372	NCT00176423_72_T0	PHENOTYPE	9	9	severity
NCT0017642372	NCT00176423_72_T1	PHENOTYPE	7	8	cognitive impairment
NCT0017642373	NCT00176423_73_T0	PHENOTYPE	18	19	cognitive impairment
NCT0017642376	NCT00176423_76_T0	PHENOTYPE	4	5	brain disease
NCT0017642377	NCT00176423_77_T0	PHENOTYPE	5	6	substance abuse
NCT0017642377	NCT00176423_77_T1	PHENOTYPE	15	16	substance dependence
NCT0017642379	NCT00176423_79_T0	BIOLOGICAL_PROCESS	14	14	ovulation
NCT0017642381	NCT00176423_81_T0	COMPOUND	9	9	donepezil
NCT0017642381	NCT00176423_81_T1	GENE	6	6	acetylcholinesterase
NCT0017642381	NCT00176423_81_T2	COMPOUND	3	3	galantamine
NCT0017642382	NCT00176423_82_T0	GENE	8	8	AV
NCT001764361	NCT00176436_1_T0	PHENOTYPE	10	10	Schizophrenia
NCT001764361	NCT00176436_1_T1	PHENOTYPE	12	13	Schizoaffective Disorder
NCT001764363	NCT00176436_3_T0	COMPOUND	8	8	clozapine
NCT001764363	NCT00176436_3_T1	COMPOUND	23	23	BMI
NCT001764365	NCT00176436_5_T0	PHENOTYPE	12	13	lose weight
NCT001764366	NCT00176436_6_T0	COMPOUND	7	7	atomoxetine
NCT001764366	NCT00176436_6_T1	BIOLOGICAL_PROCESS	13	14	appetite suppression
NCT001764366	NCT00176436_6_T2	PHENOTYPE	22	23	lose weight
NCT001764367	NCT00176436_7_T0	COMPOUND	5	5	atomoxetine
NCT001764491	NCT00176449_1_T0	COMPOUND	18	18	nicotine
NCT001764491	NCT00176449_1_T1	COMPOUND	1	1	bupropion
NCT001764491	NCT00176449_1_T2	GENE	2	2	SR
NCT001764491	NCT00176449_1_T3	PHENOTYPE	29	30	depressive symptoms
NCT001764493	NCT00176449_3_T0	PHENOTYPE	23	23	Association
NCT001764495	NCT00176449_5_T0	COMPOUND	4	4	bupropion
NCT001764495	NCT00176449_5_T1	GENE	5	5	SR
NCT001764496	NCT00176449_6_T0	COMPOUND	7	7	nicotine
NCT001764496	NCT00176449_6_T1	COMPOUND	13	13	Nicorette
NCT001764496	NCT00176449_6_T2	ORGAN	14	14	gum
NCT001764497	NCT00176449_7_T0	ORGAN	4	4	gum
NCT001764499	NCT00176449_9_T0	GENE	17	17	had
NCT0017644911	NCT00176449_11_T0	PHENOTYPE	16	16	SCID
NCT0017644911	NCT00176449_11_T1	PHENOTYPE	21	21	Syndrome
NCT0017644912	NCT00176449_12_T0	GENE	10	10	SANS
NCT0017644912	NCT00176449_12_T1	COMPOUND	18	18	cotinine
NCT0017644912	NCT00176449_12_T2	PHENOTYPE	4	5	Nicotine Dependence
NCT0017644914	NCT00176449_14_T0	COMPOUND	1	2	carbon monoxide
NCT0017644917	NCT00176449_17_T0	GENE	11	11	14
NCT0017644917	NCT00176449_17_T1	PHENOTYPE	31	31	Temptation
NCT0017644917	NCT00176449_17_T2	PHENOTYPE	41	41	Self-Efficacy
NCT0017644920	NCT00176449_20_T0	COMPOUND	1	1	cotinine
NCT0017644920	NCT00176449_20_T1	GENE	4	4	CO
NCT0017644920	NCT00176449_20_T2	PHENOTYPE	10	11	Nicotine Dependence
NCT0017644921	NCT00176449_21_T0	PHENOTYPE	13	13	Center
NCT0017644921	NCT00176449_21_T1	PHENOTYPE	24	24	Center
NCT0017644921	NCT00176449_21_T2	PHENOTYPE	22	23	Mental Health
NCT0017644923	NCT00176449_23_T0	PHENOTYPE	3	3	Schizophrenia
NCT0017644923	NCT00176449_23_T1	PHENOTYPE	5	6	schizoaffective disorder
NCT0017644924	NCT00176449_24_T0	GENE	0	0	Age
NCT0017644926	NCT00176449_26_T0	PHENOTYPE	8	8	Dependency
NCT0017644927	NCT00176449_27_T0	PHENOTYPE	4	4	illnesses
NCT0017644927	NCT00176449_27_T1	PHENOTYPE	10	10	seizures
NCT0017644927	NCT00176449_27_T2	PHENOTYPE	0	1	Seizure disorders
NCT0017644929	NCT00176449_29_T0	PHENOTYPE	3	4	depressive episode
NCT0017644930	NCT00176449_30_T0	PHENOTYPE	1	2	substance abuse
NCT0017644931	NCT00176449_31_T0	COMPOUND	2	2	bupropion
NCT0017644933	NCT00176449_33_T0	GENE	1	1	18
NCT0017644934	NCT00176449_34_T0	COMPOUND	2	2	sodium
NCT0017644936	NCT00176449_36_T0	ORGAN	32	32	Appendix
NCT0017644936	NCT00176449_36_T1	COMPOUND	9	9	1
NCT0017644936	NCT00176449_36_T2	COMPOUND	15	15	2
NCT0017644936	NCT00176449_36_T3	COMPOUND	33	33	3
NCT0017644938	NCT00176449_38_T0	GENE	8	8	hoc
NCT0017644940	NCT00176449_40_T0	COMPOUND	11	11	cotinine
NCT0017644940	NCT00176449_40_T1	PHENOTYPE	36	36	schizophrenia
NCT0017644940	NCT00176449_40_T2	GENE	7	7	CO
NCT0017644940	NCT00176449_40_T3	COMPOUND	18	18	bupropion
NCT0017644940	NCT00176449_40_T4	GENE	19	19	SR
NCT0017644940	NCT00176449_40_T5	PHENOTYPE	4	5	Nicotine Dependence
NCT0017644943	NCT00176449_43_T0	PHENOTYPE	0	0	Secondary
NCT0017644944	NCT00176449_44_T0	GENE	1	1	SANS
NCT0017644944	NCT00176449_44_T1	GENE	2	2	EPRS
NCT0017644944	NCT00176449_44_T2	COMPOUND	14	14	bupropion
NCT0017644944	NCT00176449_44_T3	GENE	15	15	SR
NCT0017644944	NCT00176449_44_T4	PHENOTYPE	21	24	positive and negative symptoms
NCT0017644946	NCT00176449_46_T0	PHENOTYPE	12	12	Temptation
NCT0017644946	NCT00176449_46_T1	PHENOTYPE	22	22	Self-Efficacy
NCT0017644947	NCT00176449_47_T0	GENE	14	14	CO
NCT0017644947	NCT00176449_47_T1	COMPOUND	16	16	bupropion
NCT0017644948	NCT00176449_48_T0	GENE	5	5	1.2
NCT0017644951	NCT00176449_51_T0	GENE	14	14	CO
NCT0017644951	NCT00176449_51_T1	GENE	26	26	CO
NCT0017644952	NCT00176449_52_T0	COMPOUND	20	20	bupropion
NCT0017644952	NCT00176449_52_T1	COMPOUND	33	33	bupropion
NCT0017644954	NCT00176449_54_T0	PHENOTYPE	11	11	symptoms
NCT0017644954	NCT00176449_54_T1	PHENOTYPE	14	15	nicotine withdrawal
NCT0017644955	NCT00176449_55_T0	PHENOTYPE	3	3	irritability
NCT0017644955	NCT00176449_55_T1	PHENOTYPE	8	8	restlessness
NCT0017644955	NCT00176449_55_T2	PHENOTYPE	2	2	insomnia
NCT0017644955	NCT00176449_55_T3	PHENOTYPE	6	7	difficulty concentrating
NCT0017644955	NCT00176449_55_T4	PHENOTYPE	13	14	increased appetite
NCT0017644955	NCT00176449_55_T5	PHENOTYPE	9	11	decreased heart rate
NCT0017644956	NCT00176449_56_T0	PHENOTYPE	21	21	tremor
NCT0017644956	NCT00176449_56_T1	PHENOTYPE	20	20	dizziness
NCT0017644956	NCT00176449_56_T2	PHENOTYPE	19	19	insomnia
NCT0017644956	NCT00176449_56_T3	PHENOTYPE	16	16	itching
NCT0017644956	NCT00176449_56_T4	COMPOUND	6	6	bupropion
NCT0017644956	NCT00176449_56_T5	PHENOTYPE	23	23	headaches
NCT0017644956	NCT00176449_56_T6	GENE	7	7	SR
NCT0017644956	NCT00176449_56_T7	PHENOTYPE	13	14	skin rashes
NCT0017644956	NCT00176449_56_T8	PHENOTYPE	9	10	allergic reactions
NCT0017644956	NCT00176449_56_T9	PHENOTYPE	17	18	dry mouth
NCT0017644957	NCT00176449_57_T0	PHENOTYPE	5	5	insomnia
NCT0017644957	NCT00176449_57_T1	PHENOTYPE	2	3	dry mouth
NCT0017644958	NCT00176449_58_T0	PHENOTYPE	3	3	seizure
NCT0017644958	NCT00176449_58_T1	COMPOUND	8	8	bupropion
NCT0017644959	NCT00176449_59_T0	COMPOUND	1	1	bupropion
NCT0017644959	NCT00176449_59_T1	COMPOUND	5	5	dopamine
NCT0017644959	NCT00176449_59_T2	PHENOTYPE	17	17	psychosis
NCT0017644960	NCT00176449_60_T0	COMPOUND	11	11	dopamine
NCT0017644960	NCT00176449_60_T1	PHENOTYPE	20	21	psychotic symptoms
NCT0017644961	NCT00176449_61_T0	COMPOUND	17	17	bupropion
NCT0017644962	NCT00176449_62_T0	COMPOUND	14	14	bupropion
NCT0017644963	NCT00176449_63_T0	PHENOTYPE	12	12	hiccups
NCT0017644963	NCT00176449_63_T1	ORGAN	14	14	jaws
NCT0017644963	NCT00176449_63_T2	PHENOTYPE	15	15	nausea
NCT0017644963	NCT00176449_63_T3	COMPOUND	2	2	Nicorette
NCT0017644963	NCT00176449_63_T4	GENE	4	4	has
NCT0017644963	NCT00176449_63_T5	ORGAN	3	3	gum
NCT0017644963	NCT00176449_63_T6	PHENOTYPE	8	9	sore throat
NCT0017644963	NCT00176449_63_T7	PHENOTYPE	22	23	mouth ulcers
NCT0017644963	NCT00176449_63_T8	PHENOTYPE	18	19	gastrointestinal symptoms
NCT0017644964	NCT00176449_64_T0	BIOLOGICAL_PROCESS	22	22	metabolism
NCT0017644964	NCT00176449_64_T1	ORGAN	6	6	gum
NCT0017644964	NCT00176449_64_T2	ORGAN	16	17	gastrointestinal tract
NCT0017644974	NCT00176449_74_T0	PHENOTYPE	3	3	Schizophrenia
NCT0017644974	NCT00176449_74_T1	PHENOTYPE	5	6	schizoaffective disorder
NCT0017644975	NCT00176449_75_T0	GENE	0	0	Age
NCT0017644977	NCT00176449_77_T0	PHENOTYPE	8	8	Dependency
NCT0017644978	NCT00176449_78_T0	PHENOTYPE	4	4	illnesses
NCT0017644978	NCT00176449_78_T1	PHENOTYPE	10	10	seizures
NCT0017644978	NCT00176449_78_T2	PHENOTYPE	0	1	Seizure disorders
NCT0017644980	NCT00176449_80_T0	PHENOTYPE	3	4	depressive episode
NCT0017644981	NCT00176449_81_T0	PHENOTYPE	1	2	substance abuse
NCT0017644982	NCT00176449_82_T0	COMPOUND	2	2	bupropion
NCT0017644984	NCT00176449_84_T0	GENE	1	1	18
NCT001764621	NCT00176462_1_T0	PHENOTYPE	33	33	leukemia
NCT001764621	NCT00176462_1_T1	PHENOTYPE	30	30	relapse
NCT001764623	NCT00176462_3_T0	PHENOTYPE	26	26	leukemia
NCT001764623	NCT00176462_3_T1	PHENOTYPE	35	35	leukemia
NCT001764623	NCT00176462_3_T2	CELL	27	27	cells
NCT001764623	NCT00176462_3_T3	CELL	36	36	cells
NCT001764623	NCT00176462_3_T4	PHENOTYPE	16	16	remission
NCT001764623	NCT00176462_3_T5	ORGAN	39	40	bone marrow
NCT001764624	NCT00176462_4_T0	PHENOTYPE	0	0	Consolidation
NCT001764624	NCT00176462_4_T1	PHENOTYPE	8	8	remission
NCT001764625	NCT00176462_5_T0	PHENOTYPE	11	11	leukemia
NCT001764625	NCT00176462_5_T1	CELL	12	12	cells
NCT001764625	NCT00176462_5_T2	PHENOTYPE	23	23	relapse
NCT001764625	NCT00176462_5_T3	PHENOTYPE	10	10	resistant
NCT001764628	NCT00176462_8_T0	PHENOTYPE	21	21	leukemia
NCT001764628	NCT00176462_8_T1	CELL	22	22	cells
NCT001764628	NCT00176462_8_T2	ORGAN	15	15	spine
NCT001764629	NCT00176462_9_T0	GENE	16	17	spaced out
NCT001764752	NCT00176475_2_T0	CELL	6	6	cells
NCT001764753	NCT00176475_3_T0	CELL	3	3	cells
NCT001764754	NCT00176475_4_T0	CELL	3	3	lymphocytes
NCT001764754	NCT00176475_4_T1	CELL	11	11	cells
NCT001764755	NCT00176475_5_T0	CELL	15	15	lymphocytes
NCT001764755	NCT00176475_5_T1	PHENOTYPE	27	28	lymphoproliferative disease
NCT0017647511	NCT00176475_11_T0	PHENOTYPE	26	26	toxicity
NCT0017647511	NCT00176475_11_T1	CELL	16	16	lymphocyte
NCT0017647511	NCT00176475_11_T2	PHENOTYPE	22	23	disease progression
NCT0017647512	NCT00176475_12_T0	PHENOTYPE	0	0	Peripheral
NCT0017647514	NCT00176475_14_T0	CELL	3	3	lymphocytes
NCT001764881	NCT00176488_1_T0	COMPOUND	4	4	vinorelbine
NCT001764881	NCT00176488_1_T1	CELL	9	9	cells
NCT001764881	NCT00176488_1_T2	PHENOTYPE	8	8	tumor
NCT001764881	NCT00176488_1_T3	COMPOUND	1	1	epirubicin
NCT001764882	NCT00176488_2_T0	GENE	3	3	II
NCT001764882	NCT00176488_2_T1	GENE	20	20	II
NCT001764882	NCT00176488_2_T2	COMPOUND	10	10	epirubicin
NCT001764882	NCT00176488_2_T3	COMPOUND	13	13	vinorelbine
NCT001764882	NCT00176488_2_T4	PHENOTYPE	21	22	stage III
NCT001764882	NCT00176488_2_T5	PHENOTYPE	24	27	stage IV breast cancer
NCT001764884	NCT00176488_4_T0	COMPOUND	10	10	vinorelbine
NCT001764884	NCT00176488_4_T1	COMPOUND	4	4	hydrochloride
NCT001764884	NCT00176488_4_T2	COMPOUND	11	11	ditartrate
NCT001764884	NCT00176488_4_T3	COMPOUND	3	3	epirubicin
NCT001764884	NCT00176488_4_T4	GENE	5	5	IV
NCT001764884	NCT00176488_4_T5	GENE	12	12	IV
NCT001764885	NCT00176488_5_T0	COMPOUND	10	10	pegfilgrastim
NCT001764885	NCT00176488_5_T1	GENE	3	3	filgrastim
NCT001764885	NCT00176488_5_T2	GENE	4	4	G-CSF
NCT001764885	NCT00176488_5_T3	GENE	11	11	IV
NCT001764886	NCT00176488_6_T0	PHENOTYPE	29	29	toxicity
NCT001764886	NCT00176488_6_T1	GENE	5	5	T3
NCT001764886	NCT00176488_6_T2	PHENOTYPE	25	26	disease progression
NCT001764887	NCT00176488_7_T0	PHENOTYPE	19	19	toxicity
NCT001764887	NCT00176488_7_T1	GENE	4	4	IV
NCT001764887	NCT00176488_7_T2	PHENOTYPE	15	16	disease progression
NCT001764889	NCT00176488_9_T0	PHENOTYPE	3	3	tumor
NCT0017648810	NCT00176488_10_T0	GENE	12	12	blot
NCT0017648810	NCT00176488_10_T1	PHENOTYPE	0	0	Tumor
NCT0017648810	NCT00176488_10_T2	GENE	8	8	p53
NCT0017648811	NCT00176488_11_T0	CELL	0	0	Microtubule
NCT0017648811	NCT00176488_11_T1	GENE	3	3	p53
NCT001765011	NCT00176501_1_T0	GENE	3	3	II
NCT001765011	NCT00176501_1_T1	CELL	16	16	lymphocytes
NCT001765011	NCT00176501_1_T2	PHENOTYPE	22	24	metastatic kidney cancer
NCT001765014	NCT00176501_4_T0	CELL	5	5	lymphocytes
NCT001765014	NCT00176501_4_T1	GENE	6	6	IV
NCT001765015	NCT00176501_5_T0	PHENOTYPE	20	20	toxicity
NCT001765015	NCT00176501_5_T1	CELL	10	10	lymphocyte
NCT001765015	NCT00176501_5_T2	PHENOTYPE	16	17	disease progression
NCT001765016	NCT00176501_6_T0	CELL	11	11	cells
NCT001765016	NCT00176501_6_T1	CELL	23	23	cells
NCT001765144	NCT00176514_4_T0	PHENOTYPE	6	6	toxic
NCT001765144	NCT00176514_4_T1	GENE	9	9	had
NCT001765144	NCT00176514_4_T2	PHENOTYPE	32	32	HSV
NCT001765144	NCT00176514_4_T3	PHENOTYPE	31	31	thrush
NCT001765144	NCT00176514_4_T4	PHENOTYPE	12	12	mucositis
NCT001765144	NCT00176514_4_T5	PHENOTYPE	34	35	aphthous ulcers
NCT001765144	NCT00176514_4_T6	ORGAN	27	28	oral cavity
NCT001765145	NCT00176514_5_T0	PHENOTYPE	7	7	stomatitis
NCT001765145	NCT00176514_5_T1	PHENOTYPE	9	10	systemic infection
NCT001765146	NCT00176514_6_T0	PHENOTYPE	7	7	stomatitis
NCT001765146	NCT00176514_6_T1	GENE	5	5	has
NCT001765147	NCT00176514_7_T0	PHENOTYPE	8	8	vomiting
NCT0017651410	NCT00176514_10_T0	COMPOUND	15	15	prostaglandin
NCT0017651410	NCT00176514_10_T1	COMPOUND	14	14	allopurinol
NCT0017651410	NCT00176514_10_T2	PHENOTYPE	2	2	Xerostomia
NCT0017651410	NCT00176514_10_T3	COMPOUND	18	19	vitamin E
NCT001765273	NCT00176527_3_T0	COMPOUND	1	1	isotretinoin
NCT001765273	NCT00176527_3_T1	CELL	14	14	cells
NCT001765273	NCT00176527_3_T2	COMPOUND	7	7	docetaxel
NCT001765273	NCT00176527_3_T3	PHENOTYPE	13	13	tumor
NCT001765273	NCT00176527_3_T4	COMPOUND	9	9	estramustine
NCT001765273	NCT00176527_3_T5	COMPOUND	3	4	interferon alfa_2b
NCT001765277	NCT00176527_7_T0	COMPOUND	4	4	isotretinoin
NCT001765277	NCT00176527_7_T1	COMPOUND	22	22	sodium
NCT001765277	NCT00176527_7_T2	COMPOUND	30	30	docetaxel
NCT001765277	NCT00176527_7_T3	GENE	9	9	1.4
NCT001765277	NCT00176527_7_T4	GENE	18	18	1.4
NCT001765277	NCT00176527_7_T5	GENE	28	28	1.5
NCT001765277	NCT00176527_7_T6	GENE	31	31	IV
NCT001765277	NCT00176527_7_T7	COMPOUND	20	21	estramustine phosphate
NCT001765277	NCT00176527_7_T8	COMPOUND	11	12	interferon alfa_2b
NCT001765278	NCT00176527_8_T0	PHENOTYPE	13	13	toxicity
NCT001765278	NCT00176527_8_T1	PHENOTYPE	9	10	disease progression
NCT001765279	NCT00176527_9_T0	PHENOTYPE	0	0	Peripheral
NCT001765279	NCT00176527_9_T1	CELL	3	3	cells
NCT001765279	NCT00176527_9_T2	GENE	21	21	bcl-2
NCT001765401	NCT00176540_1_T0	PHENOTYPE	14	14	fatigue
NCT001765401	NCT00176540_1_T1	COMPOUND	8	8	dextromethorphan
NCT001765405	NCT00176540_5_T0	COMPOUND	4	4	hydrobromide
NCT001765405	NCT00176540_5_T1	GENE	11	11	1.7
NCT001765405	NCT00176540_5_T2	COMPOUND	3	3	dextromethorphan
NCT001765406	NCT00176540_6_T0	PHENOTYPE	16	16	toxicity
NCT001765406	NCT00176540_6_T1	PHENOTYPE	12	13	disease progression
NCT001765532	NCT00176553_2_T0	GENE	7	7	1.5
NCT001765532	NCT00176553_2_T1	GENE	11	11	BID
NCT001765534	NCT00176553_4_T0	PHENOTYPE	15	15	neurotoxicity
NCT001765534	NCT00176553_4_T1	PHENOTYPE	5	5	cough
NCT001765535	NCT00176553_5_T0	COMPOUND	17	17	methotrexate
NCT001765535	NCT00176553_5_T1	COMPOUND	3	3	dextromethorphan
NCT001765536	NCT00176553_6_T0	GENE	1	1	had
NCT001765660	NCT00176566_0_T0	GENE	2	2	II
NCT001765660	NCT00176566_0_T1	PHENOTYPE	12	13	Oral Leukoplakia
NCT001765662	NCT00176566_2_T0	PHENOTYPE	9	9	plaque
NCT001765662	NCT00176566_2_T1	PHENOTYPE	28	28	elimination
NCT001765662	NCT00176566_2_T2	TISSUE	12	13	oral mucosa
NCT001765662	NCT00176566_2_T3	PHENOTYPE	0	1	Oral leukoplakia
NCT001765662	NCT00176566_2_T4	PHENOTYPE	44	45	missing teeth
NCT001765662	NCT00176566_2_T5	PHENOTYPE	6	7	white patch
NCT001765664	NCT00176566_4_T0	PHENOTYPE	19	19	leukoplakia
NCT001765665	NCT00176566_5_T0	PHENOTYPE	19	19	leukoplakia
NCT001765797	NCT00176579_7_T0	PHENOTYPE	12	13	systemic disease
NCT001765923	NCT00176592_3_T0	GENE	37	38	interferon beta
NCT001765923	NCT00176592_3_T1	PHENOTYPE	13	14	Multiple Sclerosis
NCT001765924	NCT00176592_4_T0	GENE	16	16	MRI
NCT001765924	NCT00176592_4_T1	GENE	22	22	has
NCT001765925	NCT00176592_5_T0	PHENOTYPE	16	16	secondary
NCT001765925	NCT00176592_5_T1	PHENOTYPE	25	25	secondary
NCT001765925	NCT00176592_5_T2	GENE	8	8	MRI
NCT001765925	NCT00176592_5_T3	COMPOUND	12	12	Gadolinium
NCT001765927	NCT00176592_7_T0	GENE	12	12	MRI
NCT001765927	NCT00176592_7_T1	GENE	31	31	TR
NCT001765928	NCT00176592_8_T0	PHENOTYPE	1	1	secondary
NCT001765928	NCT00176592_8_T1	GENE	2	2	MRI
NCT001765928	NCT00176592_8_T2	GENE	23	23	TR
NCT0017659211	NCT00176592_11_T0	GENE	22	22	TR
NCT0017659211	NCT00176592_11_T1	PHENOTYPE	38	39	chronic disease
NCT0017659212	NCT00176592_12_T0	GENE	1	1	MRI
NCT0017659212	NCT00176592_12_T1	ORGAN	20	20	Appendix
NCT0017659213	NCT00176592_13_T0	GENE	15	15	MRI
NCT0017659214	NCT00176592_14_T0	PHENOTYPE	14	14	secondary
NCT0017659214	NCT00176592_14_T1	GENE	3	3	MRI
NCT0017659215	NCT00176592_15_T0	PHENOTYPE	5	5	severity
NCT0017659215	NCT00176592_15_T1	COMPOUND	23	23	EDSS
NCT0017659215	NCT00176592_15_T2	GENE	19	19	Expanded
NCT0017659215	NCT00176592_15_T3	PHENOTYPE	30	31	Multiple Sclerosis
NCT0017659216	NCT00176592_16_T0	PHENOTYPE	30	31	cognitive function
NCT001766054	NCT00176605_4_T0	COMPOUND	6	6	cyclophosphamide
NCT001766056	NCT00176605_6_T0	COMPOUND	8	8	etoposide
NCT001766316	NCT00176631_6_T0	COMPOUND	3	3	docetaxel
NCT001766316	NCT00176631_6_T1	GENE	4	4	IV
NCT001766317	NCT00176631_7_T0	PHENOTYPE	13	13	toxicity
NCT001766317	NCT00176631_7_T1	PHENOTYPE	9	10	disease progression
NCT001766441	NCT00176644_1_T0	COMPOUND	8	8	estrogen
NCT001766442	NCT00176644_2_T0	PHENOTYPE	4	4	toxicities
NCT001766442	NCT00176644_2_T1	PHENOTYPE	7	9	quality of life
NCT001766444	NCT00176644_4_T0	PHENOTYPE	13	13	Oncology
NCT001766448	NCT00176644_8_T0	PHENOTYPE	3	5	quality of life
NCT0017664412	NCT00176644_12_T0	ORGAN	14	14	abdomen
NCT0017664412	NCT00176644_12_T1	ORGAN	21	21	buttock
NCT0017664414	NCT00176644_14_T0	PHENOTYPE	3	3	falls
NCT001766571	NCT00176657_1_T0	GENE	1	1	bypass
NCT001766571	NCT00176657_1_T1	GENE	2	2	CPB
NCT001766572	NCT00176657_2_T0	ORGAN	12	12	heart
NCT001766576	NCT00176657_6_T0	CELL	4	4	platelets
NCT001766579	NCT00176657_9_T0	GENE	2	2	bypass
NCT001766579	NCT00176657_9_T1	GENE	8	8	bypass
NCT001766579	NCT00176657_9_T2	GENE	3	3	CPB
NCT001766579	NCT00176657_9_T3	PHENOTYPE	17	17	separation
NCT001766579	NCT00176657_9_T4	CELL	21	23	red blood cells
NCT0017665710	NCT00176657_10_T0	GENE	17	17	CPB
NCT0017665712	NCT00176657_12_T0	GENE	11	11	CPB
NCT0017665713	NCT00176657_13_T0	GENE	7	7	CPB
NCT0017665713	NCT00176657_13_T1	PHENOTYPE	15	15	separation
NCT0017665716	NCT00176657_16_T0	GENE	27	27	CPB
NCT001766701	NCT00176670_1_T0	PHENOTYPE	14	14	nightmares
NCT001766701	NCT00176670_1_T1	BIOLOGICAL_PROCESS	17	17	eating
NCT001766701	NCT00176670_1_T2	PHENOTYPE	15	16	separation anxiety
NCT001766701	NCT00176670_1_T3	PHENOTYPE	21	23	fear of doctors
NCT001766703	NCT00176670_3_T0	PHENOTYPE	5	5	agitated
NCT001766703	NCT00176670_3_T1	PHENOTYPE	8	8	tremble
NCT001766705	NCT00176670_5_T0	COMPOUND	23	23	1
NCT001766705	NCT00176670_5_T1	PHENOTYPE	7	7	separation
NCT001766705	NCT00176670_5_T2	PHENOTYPE	5	6	fear of
NCT001766706	NCT00176670_6_T0	COMPOUND	24	24	2
NCT001766706	NCT00176670_6_T1	GENE	23	23	PPIA
NCT001766706	NCT00176670_6_T2	PHENOTYPE	22	22	anesthesia
NCT001766706	NCT00176670_6_T3	PHENOTYPE	4	6	anxiety in children
NCT001766707	NCT00176670_7_T0	COMPOUND	10	10	3
NCT001766707	NCT00176670_7_T1	GENE	1	1	has
NCT001766707	NCT00176670_7_T2	PHENOTYPE	7	9	anxiety in children
NCT0017667010	NCT00176670_10_T0	PHENOTYPE	11	11	blowing
NCT0017667010	NCT00176670_10_T1	PHENOTYPE	6	6	focused
NCT0017667016	NCT00176670_16_T0	PHENOTYPE	14	14	nightmares
NCT0017667016	NCT00176670_16_T1	BIOLOGICAL_PROCESS	17	17	eating
NCT0017667016	NCT00176670_16_T2	PHENOTYPE	15	16	separation anxiety
NCT0017667016	NCT00176670_16_T3	PHENOTYPE	21	23	fear of doctors
NCT0017667018	NCT00176670_18_T0	PHENOTYPE	5	5	agitated
NCT0017667018	NCT00176670_18_T1	PHENOTYPE	8	8	tremble
NCT0017667020	NCT00176670_20_T0	COMPOUND	23	23	1
NCT0017667020	NCT00176670_20_T1	PHENOTYPE	7	7	separation
NCT0017667020	NCT00176670_20_T2	PHENOTYPE	5	6	fear of
NCT0017667021	NCT00176670_21_T0	COMPOUND	24	24	2
NCT0017667021	NCT00176670_21_T1	GENE	23	23	PPIA
NCT0017667021	NCT00176670_21_T2	PHENOTYPE	22	22	anesthesia
NCT0017667021	NCT00176670_21_T3	PHENOTYPE	4	6	anxiety in children
NCT0017667022	NCT00176670_22_T0	COMPOUND	10	10	3
NCT0017667022	NCT00176670_22_T1	GENE	1	1	has
NCT0017667022	NCT00176670_22_T2	PHENOTYPE	7	9	anxiety in children
NCT0017667025	NCT00176670_25_T0	PHENOTYPE	11	11	blowing
NCT0017667025	NCT00176670_25_T1	PHENOTYPE	6	6	focused
NCT0017667032	NCT00176670_32_T0	GENE	0	0	ASA
NCT0017667033	NCT00176670_33_T0	PHENOTYPE	4	4	anesthesia
NCT0017667035	NCT00176670_35_T0	PHENOTYPE	3	4	developmental disabilities
NCT0017667035	NCT00176670_35_T1	PHENOTYPE	6	7	chronic illness
NCT0017667036	NCT00176670_36_T0	GENE	3	3	had
NCT001766962	NCT00176696_2_T0	PHENOTYPE	16	16	analgesia
NCT001766969	NCT00176696_9_T0	GENE	4	4	BIS
NCT0017669611	NCT00176696_11_T0	COMPOUND	8	8	propofol
NCT0017669611	NCT00176696_11_T1	GENE	17	17	inflated
NCT0017669611	NCT00176696_11_T2	ORGAN	12	12	forearm
NCT0017669611	NCT00176696_11_T3	GENE	25	25	Hg
NCT0017669615	NCT00176696_15_T0	GENE	9	9	inflated
NCT0017669615	NCT00176696_15_T1	GENE	6	6	cuff
NCT0017669617	NCT00176696_17_T0	COMPOUND	12	12	fentanyl
NCT0017669617	NCT00176696_17_T1	COMPOUND	30	30	fentanyl
NCT0017669617	NCT00176696_17_T2	PHENOTYPE	16	16	anesthesia
NCT0017669619	NCT00176696_19_T0	PHENOTYPE	8	9	surgical incision
NCT0017669619	NCT00176696_19_T1	PHENOTYPE	16	17	surgical incision
NCT001767221	NCT00176722_1_T0	PHENOTYPE	5	5	complication
NCT001767224	NCT00176722_4_T0	GENE	11	11	bypass
NCT001767224	NCT00176722_4_T1	PHENOTYPE	4	5	visual loss
NCT001767226	NCT00176722_6_T0	PHENOTYPE	29	29	complication
NCT001767226	NCT00176722_6_T1	PHENOTYPE	19	20	visual loss
NCT001767226	NCT00176722_6_T2	PHENOTYPE	23	25	ischemic optic neuropathy
NCT001767227	NCT00176722_7_T0	PHENOTYPE	16	17	visual loss
NCT0017672211	NCT00176722_11_T0	ORGAN	12	12	spine
NCT0017672212	NCT00176722_12_T0	ORGAN	2	2	spine
NCT0017672212	NCT00176722_12_T1	PHENOTYPE	9	11	ischemic optic neuropathy
NCT0017672212	NCT00176722_12_T2	PHENOTYPE	16	19	central retinal artery occlusion
NCT0017672213	NCT00176722_13_T0	PHENOTYPE	17	18	monocular blindness
NCT0017672213	NCT00176722_13_T1	PHENOTYPE	7	8	periorbital edema
NCT0017672213	NCT00176722_13_T2	PHENOTYPE	10	12	cherry red spot
NCT0017672213	NCT00176722_13_T3	PHENOTYPE	0	3	Central retinal artery occlusion
NCT0017672219	NCT00176722_19_T0	PHENOTYPE	18	18	hypotension
NCT0017672219	NCT00176722_19_T1	PHENOTYPE	22	22	strategies
NCT0017672219	NCT00176722_19_T2	GENE	32	32	hematocrit
NCT0017672219	NCT00176722_19_T3	PHENOTYPE	13	14	blood loss
NCT0017672220	NCT00176722_20_T0	GENE	5	5	had
NCT0017672220	NCT00176722_20_T1	ORGAN	7	7	heads
NCT0017672221	NCT00176722_21_T0	PHENOTYPE	7	7	bilateral
NCT0017672221	NCT00176722_21_T1	GENE	6	6	had
NCT0017672223	NCT00176722_23_T0	ORGAN	27	27	arteries
NCT0017672223	NCT00176722_23_T1	PHENOTYPE	10	10	infarction
NCT0017672223	NCT00176722_23_T2	PHENOTYPE	29	29	anastomosis
NCT0017672223	NCT00176722_23_T3	ORGAN	22	23	ciliary arteries
NCT0017672223	NCT00176722_23_T4	PHENOTYPE	1	2	visual loss
NCT0017672227	NCT00176722_27_T0	PHENOTYPE	4	4	IOP
NCT0017672228	NCT00176722_28_T0	PHENOTYPE	8	8	IOP
NCT0017672229	NCT00176722_29_T0	ORGAN	21	21	spine
NCT0017672229	NCT00176722_29_T1	PHENOTYPE	14	15	intraocular pressure
NCT0017672233	NCT00176722_33_T0	ORGAN	4	4	pupil
NCT001767351	NCT00176735_1_T0	PHENOTYPE	11	12	pancreatic cancer
NCT001767353	NCT00176735_3_T0	PHENOTYPE	7	8	pancreatic cancer
NCT001767354	NCT00176735_4_T0	COMPOUND	26	26	capecitabine
NCT001767354	NCT00176735_4_T1	COMPOUND	10	10	gemcitabine
NCT001767354	NCT00176735_4_T2	COMPOUND	12	12	cisplatin
NCT001767355	NCT00176735_5_T0	COMPOUND	16	16	capecitabine
NCT001767356	NCT00176735_6_T0	COMPOUND	9	9	gemcitabine
NCT001767356	NCT00176735_6_T1	COMPOUND	11	11	cisplatin
NCT001767356	NCT00176735_6_T2	PHENOTYPE	20	21	pancreatic cancer
NCT001767359	NCT00176735_9_T0	PHENOTYPE	8	9	pancreatic carcinoma
NCT0017673511	NCT00176735_11_T0	PHENOTYPE	9	9	metastases
NCT0017673514	NCT00176735_14_T0	GENE	6	6	abdominal
NCT0017673514	NCT00176735_14_T1	PHENOTYPE	11	12	pancreatic cancer
NCT0017673516	NCT00176735_16_T0	ORGAN	20	20	appendix
NCT0017673523	NCT00176735_23_T0	PHENOTYPE	8	8	malignancy
NCT001767481	NCT00176748_1_T0	PHENOTYPE	0	0	Tumors
NCT001767481	NCT00176748_1_T1	ORGAN	2	3	blood vessels
NCT001767481	NCT00176748_1_T2	ORGAN	23	24	blood vessels
NCT001767482	NCT00176748_2_T0	PHENOTYPE	15	15	tumor
NCT001767482	NCT00176748_2_T1	GENE	6	6	has
NCT001767484	NCT00176748_4_T0	GENE	1	1	has
NCT001767486	NCT00176748_6_T0	COMPOUND	13	13	iodine
NCT001767486	NCT00176748_6_T1	GENE	15	15	hormone
NCT001767486	NCT00176748_6_T2	PHENOTYPE	5	6	thyroid cancer
NCT001767487	NCT00176748_7_T0	PHENOTYPE	4	5	metastatic disease
NCT0017674810	NCT00176748_10_T0	GENE	2	2	TK
NCT0017674810	NCT00176748_10_T1	GENE	24	24	TK
NCT0017674810	NCT00176748_10_T2	GENE	1	1	VEGFR
NCT0017674810	NCT00176748_10_T3	GENE	23	23	VEGFR
NCT0017674810	NCT00176748_10_T4	GENE	5	5	has
NCT0017674813	NCT00176748_13_T0	PHENOTYPE	5	5	metastases
NCT0017674813	NCT00176748_13_T1	PHENOTYPE	2	3	thyroid cancer
NCT0017674819	NCT00176748_19_T0	GENE	12	12	has
NCT0017674819	NCT00176748_19_T1	ORGAN	9	9	Appendix
NCT0017674820	NCT00176748_20_T0	GENE	23	23	met
NCT0017674820	NCT00176748_20_T1	PHENOTYPE	16	17	measurable disease
NCT0017674821	NCT00176748_21_T0	GENE	12	12	cm
NCT0017674822	NCT00176748_22_T0	GENE	13	13	0.5
NCT0017674822	NCT00176748_22_T1	GENE	1	1	cm
NCT0017674822	NCT00176748_22_T2	GENE	14	14	cm
NCT0017674829	NCT00176748_29_T0	ORGAN	8	8	Appendix
NCT0017674830	NCT00176748_30_T0	PHENOTYPE	5	5	hypertension
NCT0017674832	NCT00176748_32_T0	PHENOTYPE	2	2	hypertension
NCT0017674834	NCT00176748_34_T0	ORGAN	8	8	serum
NCT0017674837	NCT00176748_37_T0	ORGAN	9	9	veins
NCT0017674837	NCT00176748_37_T1	ORGAN	7	7	arteries
NCT0017674837	NCT00176748_37_T2	ORGAN	5	6	blood vessels
NCT0017674838	NCT00176748_38_T0	GENE	20	20	MRI
NCT0017674838	NCT00176748_38_T1	PHENOTYPE	0	0	Central
NCT0017674838	NCT00176748_38_T2	PHENOTYPE	13	13	bleed
NCT0017674838	NCT00176748_38_T3	BIOLOGICAL_PROCESS	19	19	necrosis
NCT0017674838	NCT00176748_38_T4	GENE	5	5	structural
NCT0017674838	NCT00176748_38_T5	PHENOTYPE	16	16	tumor
NCT0017674838	NCT00176748_38_T6	ORGAN	38	39	blood vessels
NCT0017674839	NCT00176748_39_T0	PHENOTYPE	2	2	hemoptysis
NCT0017674844	NCT00176748_44_T0	COMPOUND	33	33	delavirdine
NCT0017674844	NCT00176748_44_T1	COMPOUND	30	30	nelfinavir
NCT0017674844	NCT00176748_44_T2	COMPOUND	19	19	verapamil
NCT0017674844	NCT00176748_44_T3	COMPOUND	28	28	saquinavir
NCT0017674844	NCT00176748_44_T4	COMPOUND	27	27	indinavir
NCT0017674844	NCT00176748_44_T5	COMPOUND	21	21	miconazole
NCT0017674844	NCT00176748_44_T6	COMPOUND	22	22	itraconazole
NCT0017674844	NCT00176748_44_T7	COMPOUND	24	24	clarithromycin
NCT0017674844	NCT00176748_44_T8	GENE	14	14	CYP3A4
NCT0017674844	NCT00176748_44_T9	COMPOUND	31	31	lopinavir
NCT0017674844	NCT00176748_44_T10	COMPOUND	23	23	erythromycin
NCT0017674844	NCT00176748_44_T11	COMPOUND	29	29	ritonavir
NCT0017674844	NCT00176748_44_T12	COMPOUND	20	20	ketoconazole
NCT0017674846	NCT00176748_46_T0	COMPOUND	19	19	dexamethasone
NCT0017674846	NCT00176748_46_T1	COMPOUND	21	21	omeprazole
NCT0017674846	NCT00176748_46_T2	COMPOUND	25	25	rifabutin
NCT0017674846	NCT00176748_46_T3	COMPOUND	23	23	phenytoin
NCT0017674846	NCT00176748_46_T4	GENE	13	13	CYP3A4
NCT0017674846	NCT00176748_46_T5	COMPOUND	18	18	carbamazepine
NCT0017674846	NCT00176748_46_T6	COMPOUND	20	20	felbamate
NCT0017674846	NCT00176748_46_T7	COMPOUND	22	22	phenobarbital
NCT0017674846	NCT00176748_46_T8	GENE	15	15	CYP1A2
NCT0017674846	NCT00176748_46_T9	COMPOUND	24	24	primidone
NCT0017674848	NCT00176748_48_T0	PHENOTYPE	6	7	brain metastases
NCT0017674848	NCT00176748_48_T1	PHENOTYPE	1	2	seizure disorder
NCT0017674852	NCT00176748_52_T0	PHENOTYPE	3	3	malignancy
NCT0017674852	NCT00176748_52_T1	PHENOTYPE	19	19	melanoma
NCT0017674852	NCT00176748_52_T2	PHENOTYPE	13	13	intent
NCT0017674852	NCT00176748_52_T3	PHENOTYPE	32	32	intent
NCT0017674852	NCT00176748_52_T4	PHENOTYPE	15	16	skin cancer
NCT0017674852	NCT00176748_52_T5	PHENOTYPE	6	7	thyroid cancer
NCT0017674852	NCT00176748_52_T6	PHENOTYPE	25	26	cervical cancer
NCT0017674852	NCT00176748_52_T7	PHENOTYPE	35	36	other cancer
NCT0017674854	NCT00176748_54_T0	PHENOTYPE	0	0	Dementia
NCT0017674854	NCT00176748_54_T1	PHENOTYPE	3	5	altered mental status
NCT001767611	NCT00176761_1_T0	CELL	4	4	cells
NCT001767611	NCT00176761_1_T1	CELL	0	1	Dendritic cells
NCT001767611	NCT00176761_1_T2	BIOLOGICAL_PROCESS	18	19	immune response
NCT001767612	NCT00176761_2_T0	CELL	30	30	cells
NCT001767612	NCT00176761_2_T1	CELL	18	19	dendritic cells
NCT001767612	NCT00176761_2_T2	ORGAN	9	10	immune system
NCT001767613	NCT00176761_3_T0	CELL	12	12	cells
NCT001767613	NCT00176761_3_T1	CELL	22	22	cells
NCT001767613	NCT00176761_3_T2	CELL	7	8	dendritic cells
NCT001767613	NCT00176761_3_T3	CELL	16	17	dendritic cells
NCT001767613	NCT00176761_3_T4	ORGAN	25	26	immune system
NCT001767616	NCT00176761_6_T0	GENE	3	3	has
NCT0017676111	NCT00176761_11_T0	PHENOTYPE	18	19	hepatitis B
NCT0017676111	NCT00176761_11_T1	ORGAN	34	35	immune system
NCT0017676112	NCT00176761_12_T0	PHENOTYPE	29	29	tumor
NCT0017676112	NCT00176761_12_T1	GENE	23	23	has
NCT0017676113	NCT00176761_13_T0	PHENOTYPE	27	27	tetanus
NCT0017676113	NCT00176761_13_T1	PHENOTYPE	28	28	measles
NCT0017676113	NCT00176761_13_T2	PHENOTYPE	29	29	mumps
NCT0017676113	NCT00176761_13_T3	BIOLOGICAL_PROCESS	20	21	immune response
NCT0017676114	NCT00176761_14_T0	ORGAN	31	32	immune system
NCT0017676115	NCT00176761_15_T0	CELL	25	25	cells
NCT0017676115	NCT00176761_15_T1	PHENOTYPE	11	11	tumor
NCT0017676115	NCT00176761_15_T2	PHENOTYPE	19	19	tumor
NCT0017676115	NCT00176761_15_T3	PHENOTYPE	24	24	tumor
NCT0017676116	NCT00176761_16_T0	CELL	10	10	cells
NCT0017676116	NCT00176761_16_T1	GENE	7	7	has
NCT0017676116	NCT00176761_16_T2	PHENOTYPE	8	9	colorectal cancer
NCT0017676117	NCT00176761_17_T0	PHENOTYPE	9	9	tumor
NCT0017676117	NCT00176761_17_T1	GENE	5	5	has
NCT0017676121	NCT00176761_21_T0	PHENOTYPE	8	8	peripheral
NCT0017676121	NCT00176761_21_T1	CELL	1	2	dendritic cells
NCT0017676123	NCT00176761_23_T0	GENE	2	2	lines
NCT0017676123	NCT00176761_23_T1	PHENOTYPE	8	8	anesthesia
NCT0017676126	NCT00176761_26_T0	CELL	4	5	dendritic cells
NCT0017676126	NCT00176761_26_T1	CELL	17	18	dendritic cells
NCT0017676129	NCT00176761_29_T0	GENE	4	4	IL-2
NCT0017676130	NCT00176761_30_T0	CELL	20	20	cells
NCT0017676130	NCT00176761_30_T1	PHENOTYPE	19	19	tumor
NCT0017676131	NCT00176761_31_T0	CELL	24	24	cells
NCT0017676131	NCT00176761_31_T1	CELL	34	34	cells
NCT0017676131	NCT00176761_31_T2	CELL	0	2	White blood cells
NCT0017676133	NCT00176761_33_T0	GENE	22	22	has
NCT0017676134	NCT00176761_34_T0	PHENOTYPE	34	34	toxicity
NCT0017676134	NCT00176761_34_T1	GENE	3	3	has
NCT0017676134	NCT00176761_34_T2	GENE	9	9	has
NCT0017676134	NCT00176761_34_T3	CELL	25	26	dendritic cells
NCT0017676135	NCT00176761_35_T0	GENE	24	24	has
NCT0017676136	NCT00176761_36_T0	GENE	5	5	IL-2
NCT0017676137	NCT00176761_37_T0	CELL	12	12	cells
NCT0017676137	NCT00176761_37_T1	PHENOTYPE	11	11	tumor
NCT0017676138	NCT00176761_38_T0	PHENOTYPE	10	10	tumor
NCT0017676145	NCT00176761_45_T0	PHENOTYPE	3	5	metastatic colorectal cancer
NCT0017676146	NCT00176761_46_T0	GENE	9	9	had
NCT0017676149	NCT00176761_49_T0	PHENOTYPE	7	7	metastases
NCT0017676149	NCT00176761_49_T1	PHENOTYPE	24	24	ascites
NCT0017676149	NCT00176761_49_T2	TISSUE	12	13	lymph nodes
NCT0017676149	NCT00176761_49_T3	PHENOTYPE	15	16	metastatic tumor
NCT0017676149	NCT00176761_49_T4	PHENOTYPE	20	22	malignant pleural effusions
NCT0017676150	NCT00176761_50_T0	PHENOTYPE	28	28	tumor
NCT0017676156	NCT00176761_56_T0	PHENOTYPE	5	6	measurable disease
NCT0017676158	NCT00176761_58_T0	COMPOUND	4	4	1
NCT0017676158	NCT00176761_58_T1	COMPOUND	13	13	2
NCT0017676158	NCT00176761_58_T2	PHENOTYPE	5	6	platelet count
NCT0017676169	NCT00176761_69_T0	PHENOTYPE	8	8	bleeding
NCT0017676169	NCT00176761_69_T1	PHENOTYPE	10	10	hemoptysis
NCT0017676169	NCT00176761_69_T2	PHENOTYPE	11	12	GI bleeding
NCT0017676179	NCT00176761_79_T0	PHENOTYPE	2	3	HIV infection
NCT0017676181	NCT00176761_81_T0	PHENOTYPE	3	4	psychiatric illness
NCT001767741	NCT00176774_1_T0	PHENOTYPE	22	24	metastatic colorectal cancer
NCT001767742	NCT00176774_2_T0	PHENOTYPE	17	17	tumor
NCT001767747	NCT00176774_7_T0	ORGAN	7	7	serum
NCT001767871	NCT00176787_1_T0	GENE	13	13	has
NCT001767871	NCT00176787_1_T1	PHENOTYPE	19	20	rectal cancer
NCT001767872	NCT00176787_2_T0	GENE	4	4	II
NCT001767872	NCT00176787_2_T1	PHENOTYPE	22	22	tumor
NCT001767873	NCT00176787_3_T0	PHENOTYPE	10	10	tumor
NCT001767877	NCT00176787_7_T0	PHENOTYPE	3	6	adenocarcinoma of the rectum
NCT001767879	NCT00176787_9_T0	ORGAN	7	7	rectum
NCT0017678710	NCT00176787_10_T0	ORGAN	14	14	anus
NCT0017678710	NCT00176787_10_T1	GENE	11	11	cm
NCT0017678713	NCT00176787_13_T0	GENE	10	10	T4
NCT0017678713	NCT00176787_13_T1	ORGAN	19	19	pelvis
NCT0017678715	NCT00176787_15_T0	PHENOTYPE	2	3	metastatic disease
NCT0017678719	NCT00176787_19_T0	COMPOUND	9	9	capecitabine
NCT0017678719	NCT00176787_19_T1	COMPOUND	13	13	1
NCT0017678719	NCT00176787_19_T2	COMPOUND	4	4	creatinine
NCT0017678719	NCT00176787_19_T3	GENE	19	19	6-3
NCT0017678721	NCT00176787_21_T0	PHENOTYPE	26	26	initiation
NCT0017678725	NCT00176787_25_T0	PHENOTYPE	8	9	psychiatric illness
NCT001768005	NCT00176800_5_T0	GENE	5	5	TM
NCT001768005	NCT00176800_5_T1	PHENOTYPE	9	10	copper levels
NCT001768006	NCT00176800_6_T0	GENE	13	13	TM
NCT001768006	NCT00176800_6_T1	PHENOTYPE	25	26	esophageal cancer
NCT0017680016	NCT00176800_16_T0	ORGAN	2	2	esophagus
NCT0017680019	NCT00176800_19_T0	ORGAN	9	9	liver
NCT0017680019	NCT00176800_19_T1	COMPOUND	18	18	copper
NCT0017680020	NCT00176800_20_T0	GENE	3	3	1.2
NCT0017680023	NCT00176800_23_T0	COMPOUND	9	9	copper
NCT0017680024	NCT00176800_24_T0	COMPOUND	4	4	copper
NCT0017680024	NCT00176800_24_T1	GENE	5	5	has
NCT0017680025	NCT00176800_25_T0	GENE	6	6	1.2
NCT0017680027	NCT00176800_27_T0	PHENOTYPE	5	5	tumor
NCT0017680030	NCT00176800_30_T0	PHENOTYPE	5	6	esophageal cancer
NCT0017680032	NCT00176800_32_T0	GENE	5	5	abdominal
NCT0017680034	NCT00176800_34_T0	ORGAN	6	6	esophagus
NCT0017680034	NCT00176800_34_T1	TISSUE	9	10	lymph nodes
NCT0017680035	NCT00176800_35_T0	GENE	7	7	4.0
NCT0017680035	NCT00176800_35_T1	TISSUE	1	2	lymph nodes
NCT0017680036	NCT00176800_36_T0	PHENOTYPE	8	8	tumors
NCT0017680036	NCT00176800_36_T1	PHENOTYPE	11	11	distal
NCT0017680036	NCT00176800_36_T2	PHENOTYPE	3	3	enlargement
NCT0017680036	NCT00176800_36_T3	ORGAN	12	12	esophagus
NCT0017680041	NCT00176800_41_T0	PHENOTYPE	12	12	Center
NCT0017680046	NCT00176800_46_T0	CELL	13	13	granulocyte
NCT0017680046	NCT00176800_46_T1	PHENOTYPE	4	5	Platelet count
NCT0017680051	NCT00176800_51_T0	PHENOTYPE	1	1	malignancy
NCT001768132	NCT00176813_2_T0	GENE	4	4	II
NCT001768132	NCT00176813_2_T1	COMPOUND	24	24	celecoxib
NCT001768132	NCT00176813_2_T2	PHENOTYPE	16	16	tumor
NCT001768132	NCT00176813_2_T3	COMPOUND	21	21	gemcitabine
NCT001768132	NCT00176813_2_T4	COMPOUND	22	22	cisplatin
NCT001768133	NCT00176813_3_T0	PHENOTYPE	10	10	tumor
NCT001768137	NCT00176813_7_T0	PHENOTYPE	8	9	pancreatic adenocarcinoma
NCT001768139	NCT00176813_9_T0	GENE	9	9	IV
NCT001768139	NCT00176813_9_T1	PHENOTYPE	6	7	metastatic disease
NCT0017681311	NCT00176813_11_T0	PHENOTYPE	8	9	metastatic disease
NCT0017681314	NCT00176813_14_T0	GENE	6	6	0.2
NCT0017681318	NCT00176813_18_T0	CELL	8	8	neutrophil
NCT0017681318	NCT00176813_18_T1	PHENOTYPE	11	12	platelet count
NCT0017681318	NCT00176813_18_T2	ORGAN	4	5	bone marrow
NCT0017681324	NCT00176813_24_T0	PHENOTYPE	3	3	tumors
NCT0017681324	NCT00176813_24_T1	PHENOTYPE	5	8	lymphoma of the pancreas
NCT0017681326	NCT00176813_26_T0	PHENOTYPE	4	5	pancreatic cancer
NCT0017681328	NCT00176813_28_T0	PHENOTYPE	9	10	peptic ulcer
NCT0017681328	NCT00176813_28_T1	PHENOTYPE	12	13	esophageal erosions
NCT0017681330	NCT00176813_30_T0	PHENOTYPE	5	5	urticaria
NCT0017681330	NCT00176813_30_T1	COMPOUND	11	11	aspirin
NCT0017681330	NCT00176813_30_T2	PHENOTYPE	4	4	asthma
NCT0017681332	NCT00176813_32_T0	PHENOTYPE	7	7	metastases
NCT0017681332	NCT00176813_32_T1	ORGAN	3	5	central nervous system
NCT0017681334	NCT00176813_34_T0	COMPOUND	8	8	3
NCT0017681334	NCT00176813_34_T1	GENE	4	4	3.0
NCT0017681334	NCT00176813_34_T2	ORGAN	1	1	liver
NCT0017681334	NCT00176813_34_T3	COMPOUND	3	3	bilirubin
NCT0017681336	NCT00176813_36_T0	COMPOUND	3	3	creatinine
NCT0017681336	NCT00176813_36_T1	GENE	4	4	1.5
NCT0017681338	NCT00176813_38_T0	PHENOTYPE	3	3	disorders
NCT0017681340	NCT00176813_40_T0	PHENOTYPE	3	3	malignancy
NCT0017681340	NCT00176813_40_T1	PHENOTYPE	6	6	cancers
NCT0017681340	NCT00176813_40_T2	PHENOTYPE	14	14	intent
NCT0017681341	NCT00176813_41_T0	PHENOTYPE	1	2	bacterial infection
NCT0017681343	NCT00176813_43_T0	PHENOTYPE	3	3	allergy
NCT001768263	NCT00176826_3_T0	COMPOUND	8	8	busulfan
NCT001768263	NCT00176826_3_T1	COMPOUND	9	9	cyclophosphamide
NCT001768263	NCT00176826_3_T2	GENE	12	12	globulin
NCT001768264	NCT00176826_4_T0	CELL	9	10	stem cells
NCT001768264	NCT00176826_4_T1	ORGAN	11	12	bone marrow
NCT001768265	NCT00176826_5_T0	PHENOTYPE	10	10	GVHD
NCT001768267	NCT00176826_7_T0	ORGAN	21	22	bone marrow
NCT0017682611	NCT00176826_11_T0	PHENOTYPE	5	5	HLH
NCT001768390	NCT00176839_0_T0	PHENOTYPE	4	5	Hematological Malignancies
NCT001768390	NCT00176839_0_T1	CELL	0	1	Stem Cell
NCT001768394	NCT00176839_4_T0	ORGAN	5	5	transplant
NCT001768395	NCT00176839_5_T0	ORGAN	4	4	transplant
NCT001768396	NCT00176839_6_T0	ORGAN	18	18	marrow
NCT001768396	NCT00176839_6_T1	CELL	11	12	stem cells
NCT001768397	NCT00176839_7_T0	ORGAN	1	1	transplant
NCT001768397	NCT00176839_7_T1	CELL	4	5	stem cells
NCT001768397	NCT00176839_7_T2	ORGAN	16	17	bone marrow
NCT0017683910	NCT00176839_10_T0	COMPOUND	3	3	melphalan
NCT0017683910	NCT00176839_10_T1	COMPOUND	1	1	cyclophosphamide
NCT0017683911	NCT00176839_11_T0	CELL	14	15	stem cells
NCT0017683911	NCT00176839_11_T1	ORGAN	7	8	immune system
NCT0017683912	NCT00176839_12_T0	ORGAN	5	7	umbilical cord blood
NCT0017683913	NCT00176839_13_T0	CELL	2	2	cells
NCT0017683913	NCT00176839_13_T1	ORGAN	7	8	bone marrow
NCT0017683914	NCT00176839_14_T0	GENE	12	12	MTX
NCT0017683914	NCT00176839_14_T1	CELL	21	21	cells
NCT0017683916	NCT00176839_16_T0	ORGAN	12	12	marrow
NCT0017683916	NCT00176839_16_T1	ORGAN	13	13	transplant
NCT001768521	NCT00176852_1_T0	PHENOTYPE	14	14	engraftment
NCT001768521	NCT00176852_1_T1	ORGAN	13	13	transplant
NCT001768521	NCT00176852_1_T2	PHENOTYPE	19	19	graft-versus-host-disease
NCT001768522	NCT00176852_2_T0	GENE	1	1	A2
NCT001768522	NCT00176852_2_T1	GENE	2	2	has
NCT001768525	NCT00176852_5_T0	GENE	13	13	IV
NCT001768525	NCT00176852_5_T1	CELL	8	9	stem cells
NCT001768651	NCT00176865_1_T0	PHENOTYPE	14	14	engraftment
NCT001768651	NCT00176865_1_T1	ORGAN	13	13	transplant
NCT001768651	NCT00176865_1_T2	PHENOTYPE	20	20	GVHD
NCT001768651	NCT00176865_1_T3	PHENOTYPE	19	19	graft-versus-host-disease
NCT001768654	NCT00176865_4_T0	CELL	12	13	stem cells
NCT001768655	NCT00176865_5_T0	GENE	13	13	IV
NCT001768655	NCT00176865_5_T1	CELL	8	9	stem cells
NCT001768782	NCT00176878_2_T0	GENE	3	3	1.0
NCT001768782	NCT00176878_2_T1	GENE	18	18	2.0
NCT001768784	NCT00176878_4_T0	COMPOUND	1	1	fludarabine
NCT001768784	NCT00176878_4_T1	ORGAN	17	18	bone marrow
NCT001768786	NCT00176878_6_T0	COMPOUND	13	13	cyclosporin
NCT001768786	NCT00176878_6_T1	PHENOTYPE	11	11	GVHD
NCT001768786	NCT00176878_6_T2	COMPOUND	15	16	mycophenolate mofetil
NCT001768786	NCT00176878_6_T3	ORGAN	1	2	bone marrow
NCT001768787	NCT00176878_7_T0	ORGAN	31	31	marrow
NCT001768787	NCT00176878_7_T1	ORGAN	24	24	transplant
NCT001768788	NCT00176878_8_T0	ORGAN	1	2	bone marrow
NCT001768912	NCT00176891_2_T0	CELL	18	18	cells
NCT001768912	NCT00176891_2_T1	GENE	26	26	GAG
NCT001768912	NCT00176891_2_T2	GENE	7	7	IV
NCT001768913	NCT00176891_3_T0	GENE	3	3	ERT
NCT001768913	NCT00176891_3_T1	ORGAN	21	21	lungs
NCT001769044	NCT00176904_4_T0	ORGAN	12	12	marrow
NCT001769045	NCT00176904_5_T0	CELL	8	8	cells
NCT001769047	NCT00176904_7_T0	PHENOTYPE	11	11	complication
NCT001769047	NCT00176904_7_T1	CELL	24	24	cells
NCT001769047	NCT00176904_7_T2	COMPOUND	2	2	methylprednisolone
NCT001769047	NCT00176904_7_T3	PHENOTYPE	13	14	graft-versus-host disease
NCT001769174	NCT00176917_4_T0	ORGAN	12	12	marrow
NCT001769175	NCT00176917_5_T0	CELL	8	8	cells
NCT001769177	NCT00176917_7_T0	PHENOTYPE	11	11	complication
NCT001769177	NCT00176917_7_T1	CELL	24	24	cells
NCT001769177	NCT00176917_7_T2	COMPOUND	2	2	methylprednisolone
NCT001769177	NCT00176917_7_T3	PHENOTYPE	13	14	graft-versus-host disease
NCT001769303	NCT00176930_3_T0	ORGAN	5	5	transplant
NCT001769304	NCT00176930_4_T0	ORGAN	4	4	transplant
NCT001769305	NCT00176930_5_T0	ORGAN	18	18	marrow
NCT001769305	NCT00176930_5_T1	CELL	11	12	stem cells
NCT001769306	NCT00176930_6_T0	ORGAN	1	1	transplant
NCT001769306	NCT00176930_6_T1	CELL	4	5	stem cells
NCT001769306	NCT00176930_6_T2	ORGAN	16	17	bone marrow
NCT0017693010	NCT00176930_10_T0	CELL	8	8	cells
NCT0017693012	NCT00176930_12_T0	COMPOUND	6	6	busulfan
NCT0017693014	NCT00176930_14_T0	COMPOUND	5	5	2
NCT0017693014	NCT00176930_14_T1	COMPOUND	4	4	3
NCT0017693014	NCT00176930_14_T2	COMPOUND	6	6	cyclophosphamide
NCT0017693016	NCT00176930_16_T0	COMPOUND	2	2	1
NCT0017693018	NCT00176930_18_T0	CELL	5	6	stem cells
NCT0017693019	NCT00176930_19_T0	COMPOUND	7	7	1
NCT0017693019	NCT00176930_19_T1	CELL	1	1	cells
NCT0017693020	NCT00176930_20_T0	ORGAN	9	9	transplant
NCT0017693020	NCT00176930_20_T1	ORGAN	0	0	Transplant
NCT0017693020	NCT00176930_20_T2	ORGAN	7	8	bone marrow
NCT0017693022	NCT00176930_22_T0	CELL	7	8	stem cells
NCT0017693023	NCT00176930_23_T0	CELL	2	3	stem cells
NCT0017693023	NCT00176930_23_T1	ORGAN	7	8	bone marrow
NCT0017693024	NCT00176930_24_T0	CELL	8	8	cells
NCT0017693025	NCT00176930_25_T0	ORGAN	9	9	transplant
NCT0017693025	NCT00176930_25_T1	ORGAN	7	8	bone marrow
NCT0017693026	NCT00176930_26_T0	ORGAN	12	12	transplant
NCT0017693026	NCT00176930_26_T1	ORGAN	10	11	bone marrow
NCT001769431	NCT00176943_1_T0	TISSUE	21	22	hair follicle
NCT001769431	NCT00176943_1_T1	PHENOTYPE	13	14	alopecia areata
NCT001769433	NCT00176943_3_T0	CELL	24	24	cells
NCT001769433	NCT00176943_3_T1	ORGAN	7	7	scalp
NCT001769433	NCT00176943_3_T2	PHENOTYPE	14	14	affects
NCT001769434	NCT00176943_4_T0	CELL	13	13	cells
NCT001769434	NCT00176943_4_T1	PHENOTYPE	17	18	hair loss
NCT001769434	NCT00176943_4_T2	PHENOTYPE	21	22	alopecia areata
NCT001769435	NCT00176943_5_T0	PHENOTYPE	10	11	alopecia areata
NCT001769437	NCT00176943_7_T0	PHENOTYPE	8	9	Alopecia Areata
NCT001769565	NCT00176956_5_T0	GENE	17	17	AD
NCT001769691	NCT00176969_1_T0	TISSUE	11	12	hair follicles
NCT001769694	NCT00176969_4_T0	GENE	20	20	neuropeptide
NCT001769694	NCT00176969_4_T1	COMPOUND	4	4	capsaicin
NCT001769694	NCT00176969_4_T2	GENE	23	23	SP
NCT001769694	NCT00176969_4_T3	GENE	31	31	SP
NCT001769694	NCT00176969_4_T4	GENE	21	22	Substance P
NCT001769694	NCT00176969_4_T5	ORGAN	12	14	peripheral nervous system
NCT001769695	NCT00176969_5_T0	COMPOUND	10	10	capsaicin
NCT001769822	NCT00176982_2_T0	PHENOTYPE	10	10	malaria
NCT001769822	NCT00176982_2_T1	PHENOTYPE	11	12	lupus erythematosus
NCT001769822	NCT00176982_2_T2	PHENOTYPE	14	15	rheumatoid arthritis
NCT001769823	NCT00176982_3_T0	PHENOTYPE	7	7	inflammation
NCT001769823	NCT00176982_3_T1	GENE	1	1	has
NCT001769823	NCT00176982_3_T2	PHENOTYPE	18	19	alopecia areata
NCT001769825	NCT00176982_5_T0	TISSUE	11	12	hair follicle
NCT001769825	NCT00176982_5_T1	PHENOTYPE	15	16	hair loss
NCT001769825	NCT00176982_5_T2	PHENOTYPE	6	7	autoimmune disease
NCT001769825	NCT00176982_5_T3	PHENOTYPE	0	1	Alopecia areata
NCT001769829	NCT00176982_9_T0	GENE	0	1	Group I
NCT0017698210	NCT00176982_10_T0	GENE	1	1	II
NCT0017698215	NCT00176982_15_T0	COMPOUND	8	8	cyclosporin
NCT0017698215	NCT00176982_15_T1	COMPOUND	9	9	azathioprine
NCT0017698215	NCT00176982_15_T2	COMPOUND	7	7	prednisone
NCT001769953	NCT00176995_3_T0	COMPOUND	4	4	hydrochloride
NCT001769953	NCT00176995_3_T1	GENE	9	9	ODC
NCT001770081	NCT00177008_1_T0	PHENOTYPE	14	14	symptoms
NCT001770081	NCT00177008_1_T1	PHENOTYPE	16	17	social anxiety
NCT001770083	NCT00177008_3_T0	PHENOTYPE	23	23	symptoms
NCT001770083	NCT00177008_3_T1	PHENOTYPE	16	16	schizophrenia
NCT001770083	NCT00177008_3_T2	PHENOTYPE	25	26	social anxiety
NCT001770084	NCT00177008_4_T0	PHENOTYPE	14	14	symptoms
NCT001770084	NCT00177008_4_T1	PHENOTYPE	16	17	social anxiety
NCT001770085	NCT00177008_5_T0	PHENOTYPE	14	16	quality of life
NCT001770086	NCT00177008_6_T0	PHENOTYPE	11	12	sexual dysfunction
NCT001770088	NCT00177008_8_T0	PHENOTYPE	7	7	schizophrenia
NCT001770088	NCT00177008_8_T1	GENE	3	3	IV
NCT001770088	NCT00177008_8_T2	PHENOTYPE	9	10	schizoaffective disorder
NCT0017700810	NCT00177008_10_T0	PHENOTYPE	6	6	symptoms
NCT0017700810	NCT00177008_10_T1	PHENOTYPE	11	11	severity
NCT0017700810	NCT00177008_10_T2	PHENOTYPE	4	5	social anxiety
NCT0017700811	NCT00177008_11_T0	GENE	6	6	30
NCT0017700817	NCT00177008_17_T0	PHENOTYPE	9	9	schizophrenia
NCT0017700817	NCT00177008_17_T1	GENE	5	5	IV
NCT0017700817	NCT00177008_17_T2	PHENOTYPE	11	12	schizoaffective disorder
NCT0017700818	NCT00177008_18_T0	PHENOTYPE	8	8	disorders
NCT0017700818	NCT00177008_18_T1	PHENOTYPE	5	5	dementia
NCT0017700818	NCT00177008_18_T2	PHENOTYPE	14	14	dependence
NCT0017700818	NCT00177008_18_T3	PHENOTYPE	6	6	degenerative
NCT0017700818	NCT00177008_18_T4	PHENOTYPE	17	18	nicotine dependence
NCT0017700818	NCT00177008_18_T5	PHENOTYPE	20	21	alcohol abuse
NCT0017700818	NCT00177008_18_T6	PHENOTYPE	9	10	mental retardation
NCT0017700818	NCT00177008_18_T7	PHENOTYPE	11	12	substance abuse
NCT0017700820	NCT00177008_20_T0	PHENOTYPE	2	2	acute
NCT0017700823	NCT00177008_23_T0	PHENOTYPE	5	5	homicidal
NCT001770212	NCT00177021_2_T0	GENE	10	10	hormone
NCT001770213	NCT00177021_3_T0	CELL	9	9	cells
NCT001770213	NCT00177021_3_T1	TISSUE	12	13	hair follicles
NCT001770213	NCT00177021_3_T2	PHENOTYPE	17	18	alopecia areata
NCT001770215	NCT00177021_5_T0	ORGAN	20	20	scalp
NCT001770342	NCT00177034_2_T0	GENE	2	2	UVB
NCT001770342	NCT00177034_2_T1	BIOLOGICAL_PROCESS	10	11	gene expression
NCT001770346	NCT00177034_6_T0	PHENOTYPE	4	4	vitiligo
NCT001770349	NCT00177034_9_T0	CELL	24	24	cells
NCT001770349	NCT00177034_9_T1	TISSUE	17	17	epidermis
NCT001770349	NCT00177034_9_T2	ORGAN	20	21	blood vessels
NCT0017703411	NCT00177034_11_T0	CELL	9	9	keratinocyte
NCT0017703411	NCT00177034_11_T1	PHENOTYPE	12	12	vitiligo
NCT0017703412	NCT00177034_12_T0	PHENOTYPE	6	6	vitiligo
NCT0017703412	NCT00177034_12_T1	CELL	4	4	keratinocytes
NCT0017703413	NCT00177034_13_T0	CELL	0	0	Keratinocytes
NCT0017703413	NCT00177034_13_T1	PHENOTYPE	5	5	vitiligo
NCT0017703414	NCT00177034_14_T0	GENE	51	51	UVB
NCT0017703414	NCT00177034_14_T1	CELL	36	36	keratinocyte
NCT0017703414	NCT00177034_14_T2	PHENOTYPE	17	17	vitiligo
NCT0017703414	NCT00177034_14_T3	PHENOTYPE	44	44	vitiligo
NCT0017703414	NCT00177034_14_T4	CELL	8	8	keratinocytes
NCT0017703414	NCT00177034_14_T5	BIOLOGICAL_PROCESS	26	27	gene expression
NCT0017703414	NCT00177034_14_T6	BIOLOGICAL_PROCESS	37	38	gene expression
NCT001770473	NCT00177047_3_T0	ORGAN	18	18	marrow
NCT001770473	NCT00177047_3_T1	CELL	11	12	stem cells
NCT001770474	NCT00177047_4_T0	ORGAN	1	1	transplant
NCT001770474	NCT00177047_4_T1	CELL	4	5	stem cells
NCT001770474	NCT00177047_4_T2	ORGAN	16	17	bone marrow
NCT001770602	NCT00177060_2_T0	COMPOUND	5	5	hydromorphone
NCT001770602	NCT00177060_2_T1	COMPOUND	11	11	morphine
NCT001770992	NCT00177099_2_T0	GENE	19	19	immunophilin
NCT001770992	NCT00177099_2_T1	GENE	9	9	FK506
NCT001770992	NCT00177099_2_T2	BIOLOGICAL_PROCESS	28	29	hair cycle
NCT001770993	NCT00177099_3_T0	PHENOTYPE	16	16	alopecia
NCT001770993	NCT00177099_3_T1	GENE	8	8	immunophilin
NCT001770993	NCT00177099_3_T2	GENE	2	2	has
NCT001770994	NCT00177099_4_T0	ORGAN	14	14	scalp
NCT001770994	NCT00177099_4_T1	GENE	20	20	immunophilin
NCT001770994	NCT00177099_4_T2	TISSUE	15	16	hair follicles
NCT001771381	NCT00177138_1_T0	ORGAN	11	11	graft
NCT001771381	NCT00177138_1_T1	ORGAN	16	16	graft
NCT001771381	NCT00177138_1_T2	COMPOUND	39	39	tacrolimus
NCT001771381	NCT00177138_1_T3	GENE	25	26	Group 1
NCT001771382	NCT00177138_2_T0	ORGAN	17	17	kidney
NCT001771382	NCT00177138_2_T1	ORGAN	15	15	pancreas
NCT001771382	NCT00177138_2_T2	ORGAN	18	18	transplant
NCT001771382	NCT00177138_2_T3	GENE	12	12	calcineurin
NCT001771385	NCT00177138_5_T0	GENE	5	5	GI
NCT001771385	NCT00177138_5_T1	PHENOTYPE	12	12	hypertension
NCT001771385	NCT00177138_5_T2	PHENOTYPE	11	11	dysfunction
NCT001771385	NCT00177138_5_T3	PHENOTYPE	3	4	anaphylactic reactions
NCT001771385	NCT00177138_5_T4	PHENOTYPE	7	9	bone marrow suppression
NCT001771387	NCT00177138_7_T0	PHENOTYPE	4	4	infections
NCT0017713813	NCT00177138_13_T0	COMPOUND	5	5	creatinine
NCT0017713813	NCT00177138_13_T1	ORGAN	0	0	Kidney
NCT0017713814	NCT00177138_14_T0	PHENOTYPE	3	3	immunosuppression
NCT0017713816	NCT00177138_16_T0	ORGAN	1	1	kidney
NCT0017713816	NCT00177138_16_T1	ORGAN	13	13	pancreas
NCT0017713816	NCT00177138_16_T2	ORGAN	2	2	transplant
NCT0017713816	NCT00177138_16_T3	ORGAN	14	14	transplant
NCT0017713820	NCT00177138_20_T0	PHENOTYPE	7	9	negative pregnancy test
NCT0017713828	NCT00177138_28_T0	PHENOTYPE	0	1	Platelet count
NCT0017713829	NCT00177138_29_T0	PHENOTYPE	2	2	malignancy
NCT0017713829	NCT00177138_29_T1	PHENOTYPE	6	7	skin cancers
NCT0017713831	NCT00177138_31_T0	PHENOTYPE	0	1	Systemic infections
NCT0017713832	NCT00177138_32_T0	GENE	17	17	Blot
NCT0017713832	NCT00177138_32_T1	PHENOTYPE	3	4	chronic infections
NCT0017713832	NCT00177138_32_T2	PHENOTYPE	7	8	HIV infection
NCT001771641	NCT00177164_1_T0	GENE	14	14	AAP
NCT001771641	NCT00177164_1_T1	COMPOUND	6	6	risperidone
NCT001771644	NCT00177164_4_T0	PHENOTYPE	11	11	symptoms
NCT001771644	NCT00177164_4_T1	PHENOTYPE	7	8	adverse events
NCT001771645	NCT00177164_5_T0	COMPOUND	18	18	risperidone
NCT001771645	NCT00177164_5_T1	GENE	19	19	has
NCT001771647	NCT00177164_7_T0	COMPOUND	3	3	olanzapine
NCT001771647	NCT00177164_7_T1	COMPOUND	18	18	risperidone
NCT001771647	NCT00177164_7_T2	COMPOUND	22	22	risperidone
NCT001771647	NCT00177164_7_T3	COMPOUND	4	4	quetiapine
NCT001771647	NCT00177164_7_T4	COMPOUND	6	6	aripiprazole
NCT001771647	NCT00177164_7_T5	COMPOUND	5	5	ziprasidone
NCT001771647	NCT00177164_7_T6	PHENOTYPE	14	15	bipolar disorder
NCT001771649	NCT00177164_9_T0	COMPOUND	18	18	lithium
NCT001771649	NCT00177164_9_T1	COMPOUND	20	20	valproate
NCT0017716411	NCT00177164_11_T0	PHENOTYPE	1	1	PLAN
NCT0017716411	NCT00177164_11_T1	GENE	12	12	TR
NCT0017716411	NCT00177164_11_T2	PHENOTYPE	15	16	bipolar disorder
NCT0017716414	NCT00177164_14_T0	PHENOTYPE	11	11	symptoms
NCT0017716414	NCT00177164_14_T1	PHENOTYPE	7	8	adverse events
NCT0017716415	NCT00177164_15_T0	COMPOUND	18	18	risperidone
NCT0017716415	NCT00177164_15_T1	GENE	19	19	has
NCT001771771	NCT00177177_1_T0	PHENOTYPE	7	7	secondary
NCT001771771	NCT00177177_1_T1	PHENOTYPE	14	14	symptoms
NCT001771771	NCT00177177_1_T2	COMPOUND	16	16	L-carnosine
NCT001771772	NCT00177177_2_T0	COMPOUND	17	17	L-carnosine
NCT001771772	NCT00177177_2_T1	PHENOTYPE	34	35	Mental Disorders
NCT001771776	NCT00177177_6_T0	PHENOTYPE	6	6	secondary
NCT001771776	NCT00177177_6_T1	PHENOTYPE	13	13	symptoms
NCT001771776	NCT00177177_6_T2	COMPOUND	15	15	L-carnosine
NCT001771777	NCT00177177_7_T0	COMPOUND	10	10	L-carnosine
NCT001771777	NCT00177177_7_T1	PHENOTYPE	1	1	PLAN
NCT001771779	NCT00177177_9_T0	GENE	33	33	1.1
NCT001771779	NCT00177177_9_T1	COMPOUND	47	47	L-carnosine
NCT0017717710	NCT00177177_10_T0	COMPOUND	7	7	L-carnosine
NCT0017717713	NCT00177177_13_T0	PHENOTYPE	9	9	secondary
NCT0017717713	NCT00177177_13_T1	PHENOTYPE	20	20	schizophrenia
NCT0017717713	NCT00177177_13_T2	PHENOTYPE	15	18	positive and negative symptoms
NCT0017717715	NCT00177177_15_T0	PHENOTYPE	1	2	adverse effects
NCT0017717716	NCT00177177_16_T0	PHENOTYPE	6	6	schizophrenia
NCT0017717716	NCT00177177_16_T1	GENE	19	19	al
NCT0017717716	NCT00177177_16_T2	GENE	18	18	et
NCT0017717716	NCT00177177_16_T3	PHENOTYPE	1	2	Cognitive dysfunction
NCT0017717717	NCT00177177_17_T0	PHENOTYPE	3	3	nihilism
NCT0017717717	NCT00177177_17_T1	PHENOTYPE	15	15	schizophrenia
NCT0017717719	NCT00177177_19_T0	PHENOTYPE	20	20	schizophrenia
NCT0017717719	NCT00177177_19_T1	PHENOTYPE	17	18	cognitive dysfunction
NCT0017717722	NCT00177177_22_T0	COMPOUND	3	3	L-carnosine
NCT0017717722	NCT00177177_22_T1	GENE	50	50	al
NCT0017717722	NCT00177177_22_T2	PHENOTYPE	35	35	autism
NCT0017717722	NCT00177177_22_T3	GENE	49	49	et
NCT0017717722	NCT00177177_22_T4	BIOLOGICAL_PROCESS	17	18	social behavior
NCT0017717723	NCT00177177_23_T0	COMPOUND	12	12	L-carnosine
NCT0017717723	NCT00177177_23_T1	PHENOTYPE	24	24	schizophrenia
NCT0017717724	NCT00177177_24_T0	PHENOTYPE	8	8	secondary
NCT0017717724	NCT00177177_24_T1	PHENOTYPE	16	16	symptoms
NCT0017717724	NCT00177177_24_T2	COMPOUND	6	6	L-carnosine
NCT0017717724	NCT00177177_24_T3	GENE	7	7	has
NCT0017717725	NCT00177177_25_T0	COMPOUND	5	5	L-carnosine
NCT0017717725	NCT00177177_25_T1	PHENOTYPE	22	22	schizophrenia
NCT0017717725	NCT00177177_25_T2	PHENOTYPE	17	18	cognitive dysfunction
NCT001772030	NCT00177203_0_T0	COMPOUND	2	2	3
NCT001772030	NCT00177203_0_T1	PHENOTYPE	7	7	Insomnia
NCT001772034	NCT00177203_4_T0	PHENOTYPE	17	17	severity
NCT001772034	NCT00177203_4_T1	PHENOTYPE	13	13	disorders
NCT001772034	NCT00177203_4_T2	PHENOTYPE	4	4	insomnia
NCT001772034	NCT00177203_4_T3	PHENOTYPE	11	12	mental health
NCT0017720310	NCT00177203_10_T0	PHENOTYPE	21	22	side effect
NCT0017720314	NCT00177203_14_T0	PHENOTYPE	11	11	Insomnia
NCT0017720315	NCT00177203_15_T0	COMPOUND	44	44	AASM
NCT0017720315	NCT00177203_15_T1	PHENOTYPE	40	40	practices
NCT0017720315	NCT00177203_15_T2	PHENOTYPE	36	36	insomnia
NCT0017720315	NCT00177203_15_T3	COMPOUND	11	11	1
NCT0017720315	NCT00177203_15_T4	COMPOUND	21	21	2
NCT0017720317	NCT00177203_17_T0	ORGAN	3	3	wrist
NCT0017720318	NCT00177203_18_T0	CELL	11	11	cells
NCT0017720319	NCT00177203_19_T0	GENE	13	13	booster
NCT0017720322	NCT00177203_22_T0	PHENOTYPE	18	18	severity
NCT0017720322	NCT00177203_22_T1	PHENOTYPE	14	14	disorders
NCT0017720322	NCT00177203_22_T2	PHENOTYPE	5	5	insomnia
NCT0017720322	NCT00177203_22_T3	PHENOTYPE	12	13	mental health
NCT0017720324	NCT00177203_24_T0	PHENOTYPE	21	21	demented
NCT0017720324	NCT00177203_24_T1	PHENOTYPE	14	15	cognitive impairment
NCT001772165	NCT00177216_5_T0	PHENOTYPE	6	6	falling
NCT001772165	NCT00177216_5_T1	PHENOTYPE	0	0	Insomnia
NCT001772166	NCT00177216_6_T0	COMPOUND	20	20	zolpidem
NCT001772166	NCT00177216_6_T1	COMPOUND	18	18	escitalopram
NCT001772166	NCT00177216_6_T2	PHENOTYPE	3	3	insomnia
NCT001772167	NCT00177216_7_T0	PHENOTYPE	8	8	symptoms
NCT001772167	NCT00177216_7_T1	PHENOTYPE	9	9	experiences
NCT001772168	NCT00177216_8_T0	ORGAN	51	51	brains
NCT001772168	NCT00177216_8_T1	PHENOTYPE	19	19	arousal
NCT001772168	NCT00177216_8_T2	PHENOTYPE	39	39	arousal
NCT001772168	NCT00177216_8_T3	PHENOTYPE	12	12	insomnia
NCT001772168	NCT00177216_8_T4	PHENOTYPE	57	57	insomnia
NCT0017721610	NCT00177216_10_T0	GENE	0	0	PI
NCT0017721610	NCT00177216_10_T1	PHENOTYPE	2	2	insomnia
NCT0017721612	NCT00177216_12_T0	PHENOTYPE	4	5	primary insomnia
NCT0017721612	NCT00177216_12_T1	PHENOTYPE	19	20	anxiety disorders
NCT0017721613	NCT00177216_13_T0	GENE	28	28	PI
NCT0017721613	NCT00177216_13_T1	PHENOTYPE	18	18	arousal
NCT0017721613	NCT00177216_13_T2	PHENOTYPE	3	3	insomnia
NCT0017721613	NCT00177216_13_T3	PHENOTYPE	12	12	insomnia
NCT0017721614	NCT00177216_14_T0	PHENOTYPE	22	22	symptoms
NCT0017721614	NCT00177216_14_T1	GENE	8	8	PI
NCT0017721614	NCT00177216_14_T2	PHENOTYPE	14	14	dysfunction
NCT0017721616	NCT00177216_16_T0	PHENOTYPE	5	5	arousal
NCT0017721617	NCT00177216_17_T0	PHENOTYPE	15	15	arousal
NCT0017721617	NCT00177216_17_T1	PHENOTYPE	17	17	insomnia
NCT0017721618	NCT00177216_18_T0	GENE	5	5	receptor
NCT0017721618	NCT00177216_18_T1	COMPOUND	8	8	zolpidem
NCT0017721618	NCT00177216_18_T2	COMPOUND	12	12	escitalopram
NCT0017721618	NCT00177216_18_T3	COMPOUND	4	4	benzodiazepine
NCT0017721621	NCT00177216_21_T0	COMPOUND	2	2	zolpidem
NCT0017721623	NCT00177216_23_T0	COMPOUND	2	2	escitalopram
NCT0017721625	NCT00177216_25_T0	COMPOUND	18	18	zolpidem
NCT0017721626	NCT00177216_26_T0	PHENOTYPE	4	4	wakefulness
NCT0017721626	NCT00177216_26_T1	PHENOTYPE	19	19	arousal
NCT0017721626	NCT00177216_26_T2	PHENOTYPE	21	21	insomnia
NCT0017721627	NCT00177216_27_T0	PHENOTYPE	6	6	MDD
NCT0017721627	NCT00177216_27_T1	PHENOTYPE	17	18	NREM sleep
NCT0017721627	NCT00177216_27_T2	PHENOTYPE	24	25	REM sleep
NCT0017721628	NCT00177216_28_T0	PHENOTYPE	26	26	arousal
NCT0017721628	NCT00177216_28_T1	PHENOTYPE	10	10	insomnia
NCT001772293	NCT00177229_3_T0	GENE	8	8	has
NCT001772296	NCT00177229_6_T0	PHENOTYPE	22	22	focused
NCT001772296	NCT00177229_6_T1	PHENOTYPE	14	15	pediatric obesity
NCT001772296	NCT00177229_6_T2	PHENOTYPE	27	28	severe obesity
NCT001772297	NCT00177229_7_T0	PHENOTYPE	26	27	pediatric obesity
NCT0017722910	NCT00177229_10_T0	PHENOTYPE	21	21	self-esteem
NCT0017722910	NCT00177229_10_T1	PHENOTYPE	32	33	psychiatric symptoms
NCT0017722910	NCT00177229_10_T2	PHENOTYPE	26	28	quality of life
NCT0017722911	NCT00177229_11_T0	PHENOTYPE	1	1	secondary
NCT001772422	NCT00177242_2_T0	GENE	24	24	II
NCT001772422	NCT00177242_2_T1	GENE	34	34	EGFR
NCT001772422	NCT00177242_2_T2	GENE	15	15	5.9
NCT001772422	NCT00177242_2_T3	COMPOUND	19	19	gemcitabine
NCT001772422	NCT00177242_2_T4	GENE	1	1	has
NCT001772422	NCT00177242_2_T5	PHENOTYPE	7	8	pancreatic carcinoma
NCT001772422	NCT00177242_2_T6	PHENOTYPE	28	29	pancreatic tumors
NCT001772423	NCT00177242_3_T0	COMPOUND	6	6	docetaxel
NCT001772423	NCT00177242_3_T1	PHENOTYPE	13	14	pancreatic carcinoma
NCT001772423	NCT00177242_3_T2	PHENOTYPE	26	27	metastatic disease
NCT001772424	NCT00177242_4_T0	PHENOTYPE	2	2	toxicity
NCT001772428	NCT00177242_8_T0	COMPOUND	10	10	docetaxel
NCT001772555	NCT00177255_5_T0	COMPOUND	14	14	capecitabine
NCT001772555	NCT00177255_5_T1	GENE	16	16	bid
NCT001772557	NCT00177255_7_T0	COMPOUND	8	8	capecitabine
NCT001772557	NCT00177255_7_T1	COMPOUND	6	6	docetaxel
NCT001772557	NCT00177255_7_T2	PHENOTYPE	14	15	disease progression
NCT001772559	NCT00177255_9_T0	PHENOTYPE	9	10	metastatic adenocarcinoma
NCT0017725511	NCT00177255_11_T0	PHENOTYPE	4	5	evaluable disease
NCT0017725513	NCT00177255_13_T0	PHENOTYPE	18	19	metastatic disease
NCT0017725519	NCT00177255_19_T0	ORGAN	3	3	marrow
NCT0017725521	NCT00177255_21_T0	PHENOTYPE	1	2	peripheral neuropathy
NCT0017725528	NCT00177255_28_T0	PHENOTYPE	3	4	brain metastases
NCT0017725529	NCT00177255_29_T0	PHENOTYPE	7	7	seizures
NCT0017725529	NCT00177255_29_T1	PHENOTYPE	8	11	central nervous system disorders
NCT0017725533	NCT00177255_33_T0	COMPOUND	15	15	capecitabine
NCT0017725533	NCT00177255_33_T1	COMPOUND	14	14	docetaxel
NCT0017725533	NCT00177255_33_T2	PHENOTYPE	2	3	allergic reactions
NCT0017725537	NCT00177255_37_T0	PHENOTYPE	9	9	symptoms
NCT0017725537	NCT00177255_37_T1	GENE	2	2	swallow
NCT0017725538	NCT00177255_38_T0	COMPOUND	17	17	docetaxel
NCT0017725539	NCT00177255_39_T0	COMPOUND	5	5	capecitabine
NCT0017725539	NCT00177255_39_T1	COMPOUND	3	3	docetaxel
NCT0017725540	NCT00177255_40_T0	PHENOTYPE	3	3	carcinomas
NCT0017725540	NCT00177255_40_T1	PHENOTYPE	11	12	melanoma skin
NCT001772810	NCT00177281_0_T0	PHENOTYPE	8	8	Malignancies
NCT001772813	NCT00177281_3_T0	GENE	15	15	has
NCT001772815	NCT00177281_5_T0	PHENOTYPE	7	7	toxicity
NCT001772815	NCT00177281_5_T1	PHENOTYPE	5	5	severity
NCT001772816	NCT00177281_6_T0	PHENOTYPE	8	8	pharmacokinetics
NCT0017728114	NCT00177281_14_T0	COMPOUND	13	13	nitrosourea
NCT0017728114	NCT00177281_14_T1	COMPOUND	15	16	mitomycin C
NCT0017728115	NCT00177281_15_T0	PHENOTYPE	8	9	heart disease
NCT0017728117	NCT00177281_17_T0	PHENOTYPE	33	33	menopausal
NCT0017728117	NCT00177281_17_T1	PHENOTYPE	25	25	IUD
NCT0017728117	NCT00177281_17_T2	ORGAN	22	22	diaphragm
NCT0017728121	NCT00177281_21_T0	PHENOTYPE	3	3	disorientation
NCT0017728121	NCT00177281_21_T1	GENE	5	5	has
NCT0017728121	NCT00177281_21_T2	PHENOTYPE	10	11	Psychiatric illness
NCT0017728122	NCT00177281_22_T0	GENE	1	1	has
NCT0017728122	NCT00177281_22_T1	PHENOTYPE	6	7	acute infection
NCT0017728122	NCT00177281_22_T2	PHENOTYPE	2	4	signs and symptoms
NCT0017728123	NCT00177281_23_T0	GENE	1	1	has
NCT0017728124	NCT00177281_24_T0	COMPOUND	9	9	sulfate
NCT0017728124	NCT00177281_24_T1	COMPOUND	6	6	camptothecin
NCT0017728124	NCT00177281_24_T2	COMPOUND	8	8	dextran
NCT0017728124	NCT00177281_24_T3	PHENOTYPE	19	20	leptomeningeal metastasis
NCT0017728124	NCT00177281_24_T4	PHENOTYPE	3	4	allergic reactions
NCT0017728125	NCT00177281_25_T0	PHENOTYPE	9	9	suspicion
NCT0017728126	NCT00177281_26_T0	PHENOTYPE	4	4	toxicity
NCT0017728127	NCT00177281_27_T0	PHENOTYPE	4	4	metastases
NCT0017728127	NCT00177281_27_T1	PHENOTYPE	14	14	progressive
NCT0017728127	NCT00177281_27_T2	PHENOTYPE	16	16	dysfunction
NCT001772944	NCT00177294_4_T0	PHENOTYPE	26	26	symptoms
NCT001772944	NCT00177294_4_T1	PHENOTYPE	29	29	impairment
NCT001772944	NCT00177294_4_T2	PHENOTYPE	9	9	remission
NCT001772944	NCT00177294_4_T3	PHENOTYPE	35	35	chronic
NCT001772945	NCT00177294_5_T0	COMPOUND	19	19	escitalopram
NCT001772945	NCT00177294_5_T1	PHENOTYPE	9	10	major depression
NCT001772946	NCT00177294_6_T0	COMPOUND	6	6	escitalopram
NCT001772946	NCT00177294_6_T1	COMPOUND	24	24	escitalopram
NCT001772946	NCT00177294_6_T2	COMPOUND	31	31	escitalopram
NCT001772946	NCT00177294_6_T3	GENE	35	35	IPT
NCT001772947	NCT00177294_7_T0	PHENOTYPE	8	8	hopelessness
NCT001772947	NCT00177294_7_T1	PHENOTYPE	10	10	ideation
NCT001772947	NCT00177294_7_T2	PHENOTYPE	6	7	depressive symptoms
NCT001772948	NCT00177294_8_T0	PHENOTYPE	24	24	remission
NCT001773073	NCT00177307_3_T0	PHENOTYPE	17	17	toxicity
NCT001773073	NCT00177307_3_T1	GENE	7	7	has
NCT001773073	NCT00177307_3_T2	GENE	11	11	has
NCT001773074	NCT00177307_4_T0	GENE	3	3	has
NCT001773077	NCT00177307_7_T0	COMPOUND	23	23	capecitabine
NCT001773077	NCT00177307_7_T1	COMPOUND	25	25	oxaliplatin
NCT001773200	NCT00177320_0_T0	PHENOTYPE	0	1	Rheumatic Diseases
NCT001773202	NCT00177320_2_T0	PHENOTYPE	10	11	rheumatic diseases
NCT001773203	NCT00177320_3_T0	PHENOTYPE	12	13	rheumatic diseases
NCT001773205	NCT00177320_5_T0	PHENOTYPE	15	16	rheumatic diseases
NCT001773205	NCT00177320_5_T1	PHENOTYPE	33	34	rheumatic diseases
NCT001773206	NCT00177320_6_T0	PHENOTYPE	18	19	rheumatic diseases
NCT001773208	NCT00177320_8_T0	PHENOTYPE	8	9	rheumatic diseases
NCT0017732013	NCT00177320_13_T0	PHENOTYPE	16	17	rheumatic diseases
NCT0017732015	NCT00177320_15_T0	PHENOTYPE	18	19	rheumatic diseases
NCT0017732018	NCT00177320_18_T0	PHENOTYPE	13	13	5-10
NCT0017732018	NCT00177320_18_T1	PHENOTYPE	36	37	rheumatic diseases
NCT0017732019	NCT00177320_19_T0	GENE	2	2	II
NCT0017732019	NCT00177320_19_T1	PHENOTYPE	23	24	rheumatic diseases
NCT0017732021	NCT00177320_21_T0	GENE	14	14	RA
NCT0017732023	NCT00177320_23_T0	GENE	10	10	RA
NCT0017732026	NCT00177320_26_T0	PHENOTYPE	32	33	rheumatic diseases
NCT001773335	NCT00177333_5_T0	COMPOUND	9	9	doxycycline
NCT0017733311	NCT00177333_11_T0	COMPOUND	9	9	doxycycline
NCT0017733318	NCT00177333_18_T0	COMPOUND	8	8	doxycycline
NCT0017733318	NCT00177333_18_T1	COMPOUND	18	18	doxycycline
NCT0017733325	NCT00177333_25_T0	TISSUE	5	5	membranes
NCT0017733325	NCT00177333_25_T1	PHENOTYPE	8	8	dilation
NCT0017733325	NCT00177333_25_T2	PHENOTYPE	4	4	ruptured
NCT0017733325	NCT00177333_25_T3	PHENOTYPE	11	12	fetal demise
NCT0017733327	NCT00177333_27_T0	PHENOTYPE	0	0	Allergy
NCT0017733327	NCT00177333_27_T1	COMPOUND	5	5	tetracycline
NCT0017733327	NCT00177333_27_T2	COMPOUND	2	2	doxycycline
NCT0017733328	NCT00177333_28_T0	PHENOTYPE	5	5	gonorrhea
NCT0017733332	NCT00177333_32_T0	ORGAN	1	2	cardiac valve
NCT0017733332	NCT00177333_32_T1	ORGAN	5	6	cardiac valve
NCT0017733333	NCT00177333_33_T0	PHENOTYPE	8	8	endocarditis
NCT0017733335	NCT00177333_35_T0	COMPOUND	4	4	heroin
NCT0017733335	NCT00177333_35_T1	COMPOUND	6	6	cocaine
NCT001773462	NCT00177346_2_T0	ORGAN	19	20	carotid arteries
NCT001773463	NCT00177346_3_T0	PHENOTYPE	3	3	pathology
NCT001773463	NCT00177346_3_T1	ORGAN	1	2	carotid artery
NCT001773463	NCT00177346_3_T2	PHENOTYPE	11	13	carotid artery dissection
NCT001773464	NCT00177346_4_T0	PHENOTYPE	5	5	complications
NCT001773464	NCT00177346_4_T1	GENE	8	8	CEA
NCT0017734612	NCT00177346_12_T0	GENE	2	2	has
NCT0017734614	NCT00177346_14_T0	PHENOTYPE	1	1	dysfunction
NCT0017734615	NCT00177346_15_T0	PHENOTYPE	11	11	CHF
NCT0017734615	NCT00177346_15_T1	GENE	28	28	CEA
NCT0017734615	NCT00177346_15_T2	PHENOTYPE	9	10	heart failure
NCT0017734615	NCT00177346_15_T3	PHENOTYPE	1	2	class III
NCT0017734615	NCT00177346_15_T4	PHENOTYPE	19	20	pulmonary hypertension
NCT0017734619	NCT00177346_19_T0	PHENOTYPE	1	1	dysfunction
NCT0017734621	NCT00177346_21_T0	GENE	12	12	fusion
NCT0017734621	NCT00177346_21_T1	GENE	3	3	CEA
NCT0017734621	NCT00177346_21_T2	GENE	21	21	CEA
NCT0017734627	NCT00177346_27_T0	ORGAN	15	16	carotid artery
NCT0017734628	NCT00177346_28_T0	PHENOTYPE	17	17	dysfunction
NCT0017734628	NCT00177346_28_T1	PHENOTYPE	45	45	symptoms
NCT0017734628	NCT00177346_28_T2	PHENOTYPE	15	15	focal
NCT0017734628	NCT00177346_28_T3	PHENOTYPE	43	43	persistence
NCT0017734628	NCT00177346_28_T4	PHENOTYPE	35	36	completed strokes
NCT0017734628	NCT00177346_28_T5	PHENOTYPE	19	20	monocular blindness
NCT0017734628	NCT00177346_28_T6	PHENOTYPE	24	26	signs and symptoms
NCT0017734633	NCT00177346_33_T0	PHENOTYPE	3	3	MRA
NCT001773720	NCT00177372_0_T0	PHENOTYPE	4	5	Fetal Demise
NCT001773722	NCT00177372_2_T0	COMPOUND	13	13	misoprostol
NCT001773722	NCT00177372_2_T1	COMPOUND	6	6	mifepristone
NCT001773722	NCT00177372_2_T2	PHENOTYPE	2	3	early pregnancy
NCT001773723	NCT00177372_3_T0	GENE	23	23	sac
NCT001773723	NCT00177372_3_T1	COMPOUND	34	34	misoprostol
NCT001773724	NCT00177372_4_T0	COMPOUND	21	21	misoprostol
NCT001773851	NCT00177385_1_T0	PHENOTYPE	7	7	practices
NCT001773851	NCT00177385_1_T1	PHENOTYPE	27	27	practices
NCT001773982	NCT00177398_2_T0	PHENOTYPE	16	16	hyperglycemia
NCT001773985	NCT00177398_5_T0	GENE	5	5	IV
NCT001773986	NCT00177398_6_T0	PHENOTYPE	10	10	initiation
NCT001773987	NCT00177398_7_T0	PHENOTYPE	24	24	hyperglycemia
NCT001773987	NCT00177398_7_T1	COMPOUND	5	5	glucose
NCT001773987	NCT00177398_7_T2	PHENOTYPE	17	17	initiation
NCT001773988	NCT00177398_8_T0	GENE	24	24	0.01
NCT001773988	NCT00177398_8_T1	GENE	28	28	0.9
NCT001773988	NCT00177398_8_T2	PHENOTYPE	6	7	plasma glucose
NCT0017739810	NCT00177398_10_T0	GENE	17	17	SSR
NCT0017739810	NCT00177398_10_T1	GENE	10	10	insulin
NCT0017739810	NCT00177398_10_T2	GENE	18	18	insulin
NCT0017739810	NCT00177398_10_T3	GENE	0	1	Group 1
NCT0017739810	NCT00177398_10_T4	PHENOTYPE	22	24	blood glucose results
NCT0017739811	NCT00177398_11_T0	GENE	9	9	SSR
NCT0017739811	NCT00177398_11_T1	GENE	10	10	insulin
NCT001774112	NCT00177411_2_T0	COMPOUND	12	12	estrogen
NCT001774115	NCT00177411_5_T0	GENE	38	38	PTHrP
NCT001774115	NCT00177411_5_T1	PHENOTYPE	18	19	anabolic effect
NCT001774116	NCT00177411_6_T0	PHENOTYPE	20	20	Parathyroid
NCT001774117	NCT00177411_7_T0	PHENOTYPE	11	11	osteoporosis
NCT001774119	NCT00177411_9_T0	PHENOTYPE	15	15	toxicity
NCT0017741111	NCT00177411_11_T0	GENE	25	25	3.5
NCT0017741111	NCT00177411_11_T1	ORGAN	18	18	spine
NCT0017741113	NCT00177411_13_T0	GENE	34	34	2.3
NCT0017741113	NCT00177411_13_T1	ORGAN	28	28	spine
NCT0017741113	NCT00177411_13_T2	PHENOTYPE	5	5	osteoporosis
NCT0017741113	NCT00177411_13_T3	GENE	20	21	parathyroid hormone
NCT0017741114	NCT00177411_14_T0	CELL	14	14	cells
NCT0017741114	NCT00177411_14_T1	TISSUE	12	12	tissues
NCT0017741114	NCT00177411_14_T2	GENE	22	22	PTH
NCT0017741114	NCT00177411_14_T3	GENE	33	33	PTH
NCT0017741114	NCT00177411_14_T4	GENE	7	7	secreted
NCT0017741114	NCT00177411_14_T5	PHENOTYPE	0	0	Parathyroid
NCT0017741114	NCT00177411_14_T6	PHENOTYPE	20	20	Parathyroid
NCT0017741114	NCT00177411_14_T7	GENE	1	1	hormone
NCT0017741116	NCT00177411_16_T0	COMPOUND	8	8	estrogen
NCT0017741119	NCT00177411_19_T0	PHENOTYPE	27	28	anabolic effect
NCT0017741120	NCT00177411_20_T0	GENE	8	8	PTHrP
NCT0017741120	NCT00177411_20_T1	GENE	19	19	PTHrP
NCT0017741121	NCT00177411_21_T0	GENE	11	11	PTHrP
NCT0017741122	NCT00177411_22_T0	GENE	2	2	has
NCT0017741122	NCT00177411_22_T1	GENE	1	1	PTHrP
NCT0017741122	NCT00177411_22_T2	GENE	22	22	PTHrP
NCT0017741122	NCT00177411_22_T3	PHENOTYPE	27	27	osteoporosis
NCT0017741123	NCT00177411_23_T0	GENE	4	4	PTHrP
NCT0017741123	NCT00177411_23_T1	GENE	13	13	PTHrP
NCT0017741126	NCT00177411_26_T0	GENE	14	14	PTHrP
NCT0017741128	NCT00177411_28_T0	PHENOTYPE	32	32	toxicity
NCT0017741128	NCT00177411_28_T1	GENE	3	3	PTHrP
NCT0017741130	NCT00177411_30_T0	GENE	19	19	PTHrP
NCT0017741130	NCT00177411_30_T1	GENE	26	26	PTHrP
NCT0017741130	NCT00177411_30_T2	GENE	16	16	IV
NCT0017741131	NCT00177411_31_T0	GENE	8	8	PTHrP
NCT0017741131	NCT00177411_31_T1	GENE	18	18	PTHrP
NCT0017741132	NCT00177411_32_T0	COMPOUND	3	3	creatinine
NCT0017741132	NCT00177411_32_T1	COMPOUND	2	2	calcium
NCT0017741132	NCT00177411_32_T2	GENE	5	5	PTH
NCT0017741132	NCT00177411_32_T3	BIOLOGICAL_PROCESS	13	13	metabolism
NCT0017741132	NCT00177411_32_T4	COMPOUND	4	4	phosphorus
NCT0017741133	NCT00177411_33_T0	COMPOUND	17	17	creatinine
NCT0017741133	NCT00177411_33_T1	COMPOUND	16	16	calcium
NCT0017741133	NCT00177411_33_T2	BIOLOGICAL_PROCESS	23	23	metabolism
NCT0017741133	NCT00177411_33_T3	COMPOUND	18	18	phosphorus
NCT0017741135	NCT00177411_35_T0	PHENOTYPE	38	38	flush
NCT0017741135	NCT00177411_35_T1	GENE	13	13	PTHrP
NCT0017741135	NCT00177411_35_T2	GENE	23	23	PTHrP
NCT0017741135	NCT00177411_35_T3	GENE	34	34	ml
NCT0017741136	NCT00177411_36_T0	GENE	15	15	PTHrP
NCT0017741136	NCT00177411_36_T1	PHENOTYPE	10	11	adverse effects
NCT0017741138	NCT00177411_38_T0	PHENOTYPE	6	6	toxicities
NCT0017741139	NCT00177411_39_T0	ORGAN	30	30	serum
NCT0017741140	NCT00177411_40_T0	GENE	25	25	420
NCT0017741140	NCT00177411_40_T1	GENE	11	11	PTH
NCT0017741140	NCT00177411_40_T2	GENE	35	35	PTH
NCT0017741140	NCT00177411_40_T3	GENE	7	7	PTHrP
NCT0017741140	NCT00177411_40_T4	GENE	24	24	PTHrP
NCT001774248	NCT00177424_8_T0	COMPOUND	10	10	sertraline
NCT001774249	NCT00177424_9_T0	PHENOTYPE	8	9	Major Depression
NCT0017742410	NCT00177424_10_T0	PHENOTYPE	5	5	severity
NCT0017742410	NCT00177424_10_T1	PHENOTYPE	7	8	depressive symptoms
NCT0017742411	NCT00177424_11_T0	GENE	28	28	disabled
NCT001774373	NCT00177437_3_T0	GENE	16	16	PA
NCT001774374	NCT00177437_4_T0	GENE	17	17	kit
NCT001774376	NCT00177437_6_T0	PHENOTYPE	17	17	STDs
NCT001774376	NCT00177437_6_T1	PHENOTYPE	23	25	pelvic inflammatory disease
NCT001774631	NCT00177463_1_T0	PHENOTYPE	6	6	secondary
NCT001774631	NCT00177463_1_T1	PHENOTYPE	13	13	symptoms
NCT001774631	NCT00177463_1_T2	COMPOUND	15	15	L-carnosine
NCT001774632	NCT00177463_2_T0	COMPOUND	17	17	L-carnosine
NCT001774632	NCT00177463_2_T1	GENE	29	29	IV
NCT001774632	NCT00177463_2_T2	GENE	30	30	TR
NCT001774632	NCT00177463_2_T3	PHENOTYPE	31	32	bipolar disorder
NCT001774635	NCT00177463_5_T0	COMPOUND	4	4	L-carnosine
NCT001774635	NCT00177463_5_T1	PHENOTYPE	11	12	affective symptoms
NCT001774638	NCT00177463_8_T0	GENE	32	32	1.1
NCT001774638	NCT00177463_8_T1	GENE	7	7	IV
NCT001774638	NCT00177463_8_T2	COMPOUND	46	46	L-carnosine
NCT001774638	NCT00177463_8_T3	GENE	8	8	TR
NCT001774639	NCT00177463_9_T0	PHENOTYPE	32	32	euthymia
NCT001774639	NCT00177463_9_T1	PHENOTYPE	34	34	Mania
NCT001774639	NCT00177463_9_T2	PHENOTYPE	25	26	Bipolar Disorder
NCT0017746312	NCT00177463_12_T0	COMPOUND	0	0	L-carnosine
NCT0017746315	NCT00177463_15_T0	PHENOTYPE	9	9	secondary
NCT0017746315	NCT00177463_15_T1	PHENOTYPE	16	16	symptoms
NCT0017746315	NCT00177463_15_T2	PHENOTYPE	18	19	bipolar disorder
NCT0017746317	NCT00177463_17_T0	PHENOTYPE	1	2	adverse effects
NCT0017746320	NCT00177463_20_T0	PHENOTYPE	20	21	bipolar disorder
NCT001774764	NCT00177476_4_T0	COMPOUND	0	0	BMI
NCT0017747611	NCT00177476_11_T0	PHENOTYPE	1	1	hypothyroidism
NCT0017747611	NCT00177476_11_T1	PHENOTYPE	0	0	Diabetes
NCT0017747611	NCT00177476_11_T2	PHENOTYPE	9	10	energy metabolism
NCT0017747615	NCT00177476_15_T0	GENE	13	13	100
NCT0017747615	NCT00177476_15_T1	GENE	5	5	160
NCT0017747617	NCT00177476_17_T0	ORGAN	6	6	heart
NCT0017747617	NCT00177476_17_T1	ORGAN	10	10	heart
NCT0017747617	NCT00177476_17_T2	GENE	16	16	beta
NCT0017747619	NCT00177476_19_T0	PHENOTYPE	0	0	Arrhythmia
NCT0017747621	NCT00177476_21_T0	PHENOTYPE	2	3	myocardial infarction
NCT0017747621	NCT00177476_21_T1	PHENOTYPE	5	6	valvular disease
NCT0017747623	NCT00177476_23_T0	PHENOTYPE	0	1	Weight loss
NCT001774891	NCT00177489_1_T0	PHENOTYPE	21	22	Alzheimer's Disease
NCT001774894	NCT00177489_4_T0	PHENOTYPE	27	28	Alzheimer's Disease
NCT0017748910	NCT00177489_10_T0	GENE	0	0	Age
NCT0017748914	NCT00177489_14_T0	PHENOTYPE	6	6	recruitment
NCT0017748917	NCT00177489_17_T0	GENE	14	14	1.3
NCT0017748926	NCT00177489_26_T0	GENE	1	1	MD
NCT0017748926	NCT00177489_26_T1	PHENOTYPE	4	4	dementia
NCT0017748926	NCT00177489_26_T2	PHENOTYPE	6	7	cognitive impairment
NCT0017748930	NCT00177489_30_T0	PHENOTYPE	3	3	acute
NCT0017748930	NCT00177489_30_T1	PHENOTYPE	13	14	Alzheimer's Disease
NCT0017748931	NCT00177489_31_T0	PHENOTYPE	3	3	delusions
NCT0017748931	NCT00177489_31_T1	PHENOTYPE	0	0	Schizophrenia
NCT0017748931	NCT00177489_31_T2	PHENOTYPE	10	11	mental illness
NCT0017748932	NCT00177489_32_T0	GENE	5	5	probable
NCT0017748932	NCT00177489_32_T1	PHENOTYPE	3	4	head trauma
NCT0017748932	NCT00177489_32_T2	PHENOTYPE	0	1	Dementia secondary
NCT0017748933	NCT00177489_33_T0	PHENOTYPE	0	0	Blindness
NCT0017748933	NCT00177489_33_T1	PHENOTYPE	2	2	deafness
NCT001775020	NCT00177502_0_T0	PHENOTYPE	6	7	Weight Gain
NCT001775025	NCT00177502_5_T0	COMPOUND	0	0	BMI
NCT0017750212	NCT00177502_12_T0	PHENOTYPE	1	1	hypothyroidism
NCT0017750212	NCT00177502_12_T1	PHENOTYPE	0	0	Diabetes
NCT0017750212	NCT00177502_12_T2	PHENOTYPE	9	10	energy metabolism
NCT0017750216	NCT00177502_16_T0	GENE	13	13	100
NCT0017750216	NCT00177502_16_T1	GENE	5	5	160
NCT0017750218	NCT00177502_18_T0	ORGAN	6	6	heart
NCT0017750218	NCT00177502_18_T1	ORGAN	10	10	heart
NCT0017750218	NCT00177502_18_T2	GENE	16	16	beta
NCT0017750220	NCT00177502_20_T0	PHENOTYPE	0	0	Arrhythmia
NCT0017750222	NCT00177502_22_T0	PHENOTYPE	2	3	myocardial infarction
NCT0017750222	NCT00177502_22_T1	PHENOTYPE	5	6	valvular disease
NCT001775151	NCT00177515_1_T0	COMPOUND	39	39	folate
NCT001775153	NCT00177515_3_T0	GENE	13	13	has
NCT001775155	NCT00177515_5_T0	COMPOUND	18	18	folate
NCT001775157	NCT00177515_7_T0	COMPOUND	11	11	folate
NCT001775157	NCT00177515_7_T1	PHENOTYPE	14	15	birth defects
NCT001775158	NCT00177515_8_T0	COMPOUND	4	4	folate
NCT001775158	NCT00177515_8_T1	GENE	13	13	has
NCT001775158	NCT00177515_8_T2	PHENOTYPE	10	12	neural tube defects
NCT001775159	NCT00177515_9_T0	COMPOUND	11	11	folate
NCT001775159	NCT00177515_9_T1	GENE	3	3	has
NCT0017751511	NCT00177515_11_T0	COMPOUND	6	6	progesterone
NCT0017751511	NCT00177515_11_T1	GENE	7	7	has
NCT0017751512	NCT00177515_12_T0	PHENOTYPE	10	10	miscarriage
NCT0017751516	NCT00177515_16_T0	COMPOUND	23	23	folate
NCT0017751517	NCT00177515_17_T0	COMPOUND	23	23	folate
NCT001775282	NCT00177528_2_T0	COMPOUND	11	11	venlafaxine
NCT001775410	NCT00177541_0_T0	PHENOTYPE	5	5	Incontinence
NCT001775412	NCT00177541_2_T0	PHENOTYPE	31	31	incontinence
NCT001775416	NCT00177541_6_T0	TISSUE	8	8	muscles
NCT001775416	NCT00177541_6_T1	PHENOTYPE	11	11	suppression
NCT001775419	NCT00177541_9_T0	PHENOTYPE	19	20	life quality
NCT001775419	NCT00177541_9_T1	PHENOTYPE	8	10	quality of life
NCT001775419	NCT00177541_9_T2	PHENOTYPE	39	41	quality of life
NCT0017754111	NCT00177541_11_T0	PHENOTYPE	5	7	quality of life
NCT0017754112	NCT00177541_12_T0	PHENOTYPE	9	11	quality of life
NCT001775670	NCT00177567_0_T0	PHENOTYPE	4	5	Mood Disorders
NCT001775800	NCT00177580_0_T0	PHENOTYPE	3	3	Schizophrenia
NCT001775800	NCT00177580_0_T1	PHENOTYPE	1	1	Symptoms
NCT001775800	NCT00177580_0_T2	PHENOTYPE	5	6	Schizoaffective Disorder
NCT001775806	NCT00177580_6_T0	PHENOTYPE	26	26	symptoms
NCT001775806	NCT00177580_6_T1	PHENOTYPE	15	15	pulse
NCT001775806	NCT00177580_6_T2	PHENOTYPE	21	24	positive and negative symptoms
NCT001775930	NCT00177593_0_T0	PHENOTYPE	6	7	Weight Loss
NCT001775935	NCT00177593_5_T0	COMPOUND	3	3	BMI
NCT0017759312	NCT00177593_12_T0	PHENOTYPE	7	8	weight loss
NCT0017759318	NCT00177593_18_T0	GENE	13	13	bypass
NCT0017759318	NCT00177593_18_T1	ORGAN	9	9	heart
NCT0017759318	NCT00177593_18_T2	PHENOTYPE	2	3	myocardial infarction
NCT0017759320	NCT00177593_20_T0	ORGAN	5	5	heart
NCT0017759320	NCT00177593_20_T1	GENE	14	14	beta
NCT0017759322	NCT00177593_22_T0	BIOLOGICAL_PROCESS	5	5	metabolism
NCT001776066	NCT00177606_6_T0	PHENOTYPE	33	33	Center
NCT001776066	NCT00177606_6_T1	PHENOTYPE	44	44	withdrawn
NCT001776068	NCT00177606_8_T0	PHENOTYPE	11	11	withdrawn
NCT001776069	NCT00177606_9_T0	PHENOTYPE	21	21	enabling
NCT0017760610	NCT00177606_10_T0	PHENOTYPE	11	11	regression
NCT0017760613	NCT00177606_13_T0	PHENOTYPE	17	17	LST
NCT0017760613	NCT00177606_13_T1	PHENOTYPE	40	40	LST
NCT0017760615	NCT00177606_15_T0	PHENOTYPE	10	10	LST
NCT0017760617	NCT00177606_17_T0	PHENOTYPE	12	12	secondary
NCT0017760617	NCT00177606_17_T1	COMPOUND	14	14	2
NCT0017760618	NCT00177606_18_T0	PHENOTYPE	11	11	LST
NCT0017760620	NCT00177606_20_T0	GENE	8	8	H1
NCT0017760620	NCT00177606_20_T1	GENE	21	21	H2
NCT0017760622	NCT00177606_22_T0	COMPOUND	1	1	1
NCT0017760623	NCT00177606_23_T0	COMPOUND	1	1	2
NCT001776320	NCT00177632_0_T0	PHENOTYPE	9	9	Overweight
NCT001776320	NCT00177632_0_T1	PHENOTYPE	6	7	Weight Loss
NCT001776325	NCT00177632_5_T0	COMPOUND	0	0	BMI
NCT0017763214	NCT00177632_14_T0	PHENOTYPE	1	1	hypothyroidism
NCT0017763214	NCT00177632_14_T1	PHENOTYPE	0	0	Diabetes
NCT0017763214	NCT00177632_14_T2	PHENOTYPE	9	10	energy metabolism
NCT0017763219	NCT00177632_19_T0	GENE	13	13	100
NCT0017763219	NCT00177632_19_T1	GENE	5	5	160
NCT0017763221	NCT00177632_21_T0	ORGAN	6	6	heart
NCT0017763221	NCT00177632_21_T1	ORGAN	10	10	heart
NCT0017763221	NCT00177632_21_T2	GENE	16	16	beta
NCT0017763223	NCT00177632_23_T0	PHENOTYPE	0	0	Arrhythmia
NCT0017763225	NCT00177632_25_T0	PHENOTYPE	2	3	myocardial infarction
NCT0017763225	NCT00177632_25_T1	PHENOTYPE	5	6	valvular disease
NCT001776456	NCT00177645_6_T0	PHENOTYPE	32	32	cough
NCT001776456	NCT00177645_6_T1	COMPOUND	20	20	sodium
NCT001776456	NCT00177645_6_T2	COMPOUND	24	24	sodium
NCT001776456	NCT00177645_6_T3	COMPOUND	25	25	chloride
NCT001776456	NCT00177645_6_T4	COMPOUND	18	18	bicarbonate
NCT001776456	NCT00177645_6_T5	COMPOUND	21	21	bicarbonate
NCT001776456	NCT00177645_6_T6	PHENOTYPE	8	9	chronic cough
NCT001776457	NCT00177645_7_T0	COMPOUND	11	11	bicarbonate
NCT001776457	NCT00177645_7_T1	PHENOTYPE	15	15	cough
NCT001776458	NCT00177645_8_T0	PHENOTYPE	31	31	affects
NCT001776458	NCT00177645_8_T1	COMPOUND	8	8	bicarbonate
NCT001776458	NCT00177645_8_T2	PHENOTYPE	32	33	lung function
NCT001776581	NCT00177658_1_T0	PHENOTYPE	11	11	bloodstream
NCT001776581	NCT00177658_1_T1	PHENOTYPE	12	12	infections
NCT001776581	NCT00177658_1_T2	PHENOTYPE	8	9	Salmonella meningitis
NCT001776714	NCT00177671_4_T0	PHENOTYPE	5	5	strategies
NCT001776714	NCT00177671_4_T1	PHENOTYPE	23	23	impairment
NCT001776714	NCT00177671_4_T2	PHENOTYPE	17	17	progression
NCT001776714	NCT00177671_4_T3	PHENOTYPE	10	11	cognitive functioning
NCT001776716	NCT00177671_6_T0	GENE	4	4	II
NCT001776716	NCT00177671_6_T1	PHENOTYPE	20	20	progression
NCT001776716	NCT00177671_6_T2	PHENOTYPE	13	14	cognitive functions
NCT001776717	NCT00177671_7_T0	GENE	8	8	cholinesterase
NCT001776717	NCT00177671_7_T1	COMPOUND	18	18	venlafaxine
NCT001776717	NCT00177671_7_T2	COMPOUND	10	10	donepezil
NCT001776717	NCT00177671_7_T3	COMPOUND	17	17	escitalopram
NCT001776717	NCT00177671_7_T4	COMPOUND	20	20	duloxetine
NCT001776717	NCT00177671_7_T5	PHENOTYPE	26	27	cognitive functioning
NCT001776717	NCT00177671_7_T6	PHENOTYPE	35	36	major depression
NCT001776718	NCT00177671_8_T0	COMPOUND	8	8	donepezil
NCT001776718	NCT00177671_8_T1	PHENOTYPE	28	28	progression
NCT001776718	NCT00177671_8_T2	PHENOTYPE	30	31	cognitive impairment
NCT001776719	NCT00177671_9_T0	PHENOTYPE	14	15	major depression
NCT0017767110	NCT00177671_10_T0	COMPOUND	8	8	venlafaxine
NCT0017767110	NCT00177671_10_T1	COMPOUND	10	10	duloxetine
NCT0017767110	NCT00177671_10_T2	COMPOUND	7	7	citalopram
NCT001776847	NCT00177684_7_T0	ORGAN	6	6	heart
NCT0017768413	NCT00177684_13_T0	PHENOTYPE	6	6	comprehension
NCT0017768415	NCT00177684_15_T0	PHENOTYPE	17	17	sterile
NCT0017768417	NCT00177684_17_T0	GENE	5	5	ml
NCT0017768419	NCT00177684_19_T0	GENE	9	9	has
NCT0017768422	NCT00177684_22_T0	PHENOTYPE	1	1	HIV
NCT001776970	NCT00177697_0_T0	PHENOTYPE	5	6	Weight Loss
NCT001776975	NCT00177697_5_T0	COMPOUND	0	0	BMI
NCT0017769712	NCT00177697_12_T0	PHENOTYPE	1	1	hypothyroidism
NCT0017769712	NCT00177697_12_T1	PHENOTYPE	0	0	Diabetes
NCT0017769712	NCT00177697_12_T2	PHENOTYPE	9	10	energy metabolism
NCT0017769716	NCT00177697_16_T0	GENE	13	13	100
NCT0017769716	NCT00177697_16_T1	GENE	5	5	160
NCT0017769718	NCT00177697_18_T0	ORGAN	6	6	heart
NCT0017769718	NCT00177697_18_T1	ORGAN	10	10	heart
NCT0017769718	NCT00177697_18_T2	GENE	16	16	beta
NCT0017769720	NCT00177697_20_T0	PHENOTYPE	0	0	Arrhythmia
NCT0017769722	NCT00177697_22_T0	PHENOTYPE	2	3	myocardial infarction
NCT0017769722	NCT00177697_22_T1	PHENOTYPE	5	6	valvular disease
NCT001777102	NCT00177710_2_T0	GENE	12	12	1/6
NCT001777105	NCT00177710_5_T0	GENE	4	4	ml
NCT001777106	NCT00177710_6_T0	ORGAN	24	24	transplant
NCT001777106	NCT00177710_6_T1	ORGAN	5	5	serum
NCT001777106	NCT00177710_6_T2	PHENOTYPE	0	0	Concentrations
NCT001777106	NCT00177710_6_T3	COMPOUND	19	20	amphotericin B
NCT001777107	NCT00177710_7_T0	COMPOUND	29	29	urea
NCT001777107	NCT00177710_7_T1	ORGAN	19	19	serum
NCT001777107	NCT00177710_7_T2	ORGAN	28	28	serum
NCT001777107	NCT00177710_7_T3	GENE	2	2	ml
NCT001777107	NCT00177710_7_T4	COMPOUND	20	21	amphotericin B
NCT001777108	NCT00177710_8_T0	ORGAN	14	14	transplant
NCT001777109	NCT00177710_9_T0	ORGAN	18	18	transplant
NCT0017771012	NCT00177710_12_T0	PHENOTYPE	10	10	identities
NCT0017771014	NCT00177710_14_T0	PHENOTYPE	17	18	infectious diseases
NCT001777231	NCT00177723_1_T0	PHENOTYPE	21	21	toxicity
NCT001777231	NCT00177723_1_T1	PHENOTYPE	42	42	toxicity
NCT001777231	NCT00177723_1_T2	PHENOTYPE	51	51	toxicity
NCT001777231	NCT00177723_1_T3	COMPOUND	26	26	linezolid
NCT001777231	NCT00177723_1_T4	COMPOUND	44	44	linezolid
NCT001777231	NCT00177723_1_T5	PHENOTYPE	48	48	strategies
NCT001777234	NCT00177723_4_T0	COMPOUND	35	35	linezolid
NCT001777234	NCT00177723_4_T1	COMPOUND	39	39	linezolid
NCT001777234	NCT00177723_4_T2	COMPOUND	44	44	linezolid
NCT001777234	NCT00177723_4_T3	GENE	26	26	hemoglobin
NCT001777234	NCT00177723_4_T4	PHENOTYPE	23	24	platelet count
NCT001777235	NCT00177723_5_T0	COMPOUND	18	18	linezolid
NCT001777239	NCT00177723_9_T0	GENE	2	2	ml
NCT001777239	NCT00177723_9_T1	GENE	22	22	ml
NCT0017772311	NCT00177723_11_T0	PHENOTYPE	21	21	withdrawn
NCT0017772314	NCT00177723_14_T0	GENE	2	2	ml
NCT0017772314	NCT00177723_14_T1	GENE	22	22	ml
NCT0017772317	NCT00177723_17_T0	GENE	26	26	1.0
NCT0017772317	NCT00177723_17_T1	GENE	25	25	ANC
NCT0017772317	NCT00177723_17_T2	GENE	24	24	1.5
NCT0017772317	NCT00177723_17_T3	GENE	23	23	WBC
NCT0017772317	NCT00177723_17_T4	GENE	20	20	Hb
NCT0017772317	NCT00177723_17_T5	GENE	28	28	50
NCT0017772317	NCT00177723_17_T6	CELL	27	27	platelets
NCT0017772318	NCT00177723_18_T0	COMPOUND	29	29	linezolid
NCT0017772319	NCT00177723_19_T0	GENE	12	12	NOT
NCT0017772319	NCT00177723_19_T1	PHENOTYPE	2	2	decisions
NCT0017772326	NCT00177723_26_T0	PHENOTYPE	10	10	identities
NCT0017772328	NCT00177723_28_T0	GENE	9	9	Dr
NCT0017772330	NCT00177723_30_T0	GENE	9	9	Dr
NCT001777361	NCT00177736_1_T0	PHENOTYPE	24	24	concentrations
NCT001777361	NCT00177736_1_T1	PHENOTYPE	4	4	pharmacodynamics
NCT001777362	NCT00177736_2_T0	COMPOUND	11	11	cefepime
NCT001777362	NCT00177736_2_T1	GENE	5	5	has
NCT001777362	NCT00177736_2_T2	PHENOTYPE	27	27	susceptible
NCT001777363	NCT00177736_3_T0	PHENOTYPE	16	16	concentrations
NCT001777363	NCT00177736_3_T1	PHENOTYPE	21	21	concentrations
NCT001777363	NCT00177736_3_T2	COMPOUND	6	6	cefepime
NCT001777363	NCT00177736_3_T3	COMPOUND	15	15	cefepime
NCT001777365	NCT00177736_5_T0	PHENOTYPE	6	6	pneumonia
NCT001777365	NCT00177736_5_T1	COMPOUND	2	2	cefepime
NCT001777365	NCT00177736_5_T2	PHENOTYPE	8	8	bacteremia
NCT001777367	NCT00177736_7_T0	PHENOTYPE	8	8	bacteremia
NCT001777368	NCT00177736_8_T0	PHENOTYPE	9	9	pneumonia
NCT001777368	NCT00177736_8_T1	PHENOTYPE	14	14	pneumonia
NCT0017773612	NCT00177736_12_T0	GENE	7	7	IV
NCT0017773613	NCT00177736_13_T0	GENE	1	1	VAP
NCT0017773613	NCT00177736_13_T1	COMPOUND	6	6	cefepime
NCT0017773613	NCT00177736_13_T2	PHENOTYPE	7	7	resistant
NCT0017773613	NCT00177736_13_T3	PHENOTYPE	3	3	bacteremia
NCT001777490	NCT00177749_0_T0	PHENOTYPE	6	8	Invasive Fungal Infections
NCT001777492	NCT00177749_2_T0	GENE	6	6	spp
NCT001777492	NCT00177749_2_T1	COMPOUND	11	11	voriconazole
NCT001777492	NCT00177749_2_T2	PHENOTYPE	9	9	resistant
NCT001777492	NCT00177749_2_T3	COMPOUND	13	13	caspofungin
NCT001777493	NCT00177749_3_T0	PHENOTYPE	11	12	renal toxicity
NCT001777495	NCT00177749_5_T0	COMPOUND	10	10	posaconazole
NCT001777495	NCT00177749_5_T1	PHENOTYPE	1	1	intent
NCT001777495	NCT00177749_5_T2	PHENOTYPE	15	16	fungal infections
NCT001777495	NCT00177749_5_T3	PHENOTYPE	25	27	invasive fungal infections
NCT001777498	NCT00177749_8_T0	COMPOUND	10	10	posaconazole
NCT0017774911	NCT00177749_11_T0	PHENOTYPE	28	28	initiation
NCT0017774912	NCT00177749_12_T0	ORGAN	0	0	Plasma
NCT0017774912	NCT00177749_12_T1	PHENOTYPE	1	1	concentrations
NCT0017774916	NCT00177749_16_T0	COMPOUND	35	35	posaconazole
NCT0017774916	NCT00177749_16_T1	COMPOUND	1	1	1
NCT0017774916	NCT00177749_16_T2	COMPOUND	17	17	2
NCT0017774916	NCT00177749_16_T3	ORGAN	25	25	serum
NCT0017774916	NCT00177749_16_T4	PHENOTYPE	11	12	fungal infection
NCT0017774917	NCT00177749_17_T0	GENE	20	20	ml
NCT0017774919	NCT00177749_19_T0	ORGAN	16	16	serum
NCT0017774926	NCT00177749_26_T0	COMPOUND	14	14	posaconazole
NCT0017774931	NCT00177749_31_T0	PHENOTYPE	23	23	initiation
NCT0017774934	NCT00177749_34_T0	PHENOTYPE	17	17	toxicity
NCT0017774934	NCT00177749_34_T1	PHENOTYPE	48	49	adverse event
NCT0017774934	NCT00177749_34_T2	PHENOTYPE	0	1	Laboratory abnormalities
NCT0017774936	NCT00177749_36_T0	COMPOUND	3	3	posaconazole
NCT0017774936	NCT00177749_36_T1	GENE	22	22	met
NCT0017774938	NCT00177749_38_T0	COMPOUND	4	4	posaconazole
NCT0017774938	NCT00177749_38_T1	GENE	39	39	BID
NCT0017774938	NCT00177749_38_T2	COMPOUND	18	18	QID
NCT0017774939	NCT00177749_39_T0	GENE	30	30	BID
NCT0017774940	NCT00177749_40_T0	GENE	19	19	BID
NCT0017774940	NCT00177749_40_T1	COMPOUND	14	14	QID
NCT0017774942	NCT00177749_42_T0	PHENOTYPE	17	17	severity
NCT0017774942	NCT00177749_42_T1	PHENOTYPE	23	23	severity
NCT0017774942	NCT00177749_42_T2	PHENOTYPE	12	13	fungal infection
NCT0017774942	NCT00177749_42_T3	PHENOTYPE	21	22	fungal infection
NCT0017774942	NCT00177749_42_T4	PHENOTYPE	31	32	immune suppression
NCT0017774943	NCT00177749_43_T0	COMPOUND	18	18	posaconazole
NCT0017774944	NCT00177749_44_T0	COMPOUND	2	2	posaconazole
NCT0017774944	NCT00177749_44_T1	COMPOUND	24	24	posaconazole
NCT0017774951	NCT00177749_51_T0	COMPOUND	30	30	posaconazole
NCT0017774951	NCT00177749_51_T1	PHENOTYPE	14	14	resolved
NCT0017774951	NCT00177749_51_T2	PHENOTYPE	10	12	signs and symptoms
NCT0017774952	NCT00177749_52_T0	PHENOTYPE	18	18	severity
NCT0017774952	NCT00177749_52_T1	PHENOTYPE	21	22	fungal infection
NCT0017774953	NCT00177749_53_T0	COMPOUND	5	5	posaconazole
NCT0017774953	NCT00177749_53_T1	PHENOTYPE	15	17	signs and symptoms
NCT0017774954	NCT00177749_54_T0	COMPOUND	20	20	posaconazole
NCT0017774954	NCT00177749_54_T1	PHENOTYPE	6	6	bloodstream
NCT0017774954	NCT00177749_54_T2	PHENOTYPE	35	35	symptoms
NCT0017774954	NCT00177749_54_T3	PHENOTYPE	15	15	endocarditis
NCT0017774954	NCT00177749_54_T4	PHENOTYPE	13	13	candidiasis
NCT0017774954	NCT00177749_54_T5	PHENOTYPE	2	3	Candida infections
NCT001777620	NCT00177762_0_T0	PHENOTYPE	5	6	Weight Loss
NCT001777625	NCT00177762_5_T0	COMPOUND	0	0	BMI
NCT0017776212	NCT00177762_12_T0	PHENOTYPE	1	1	hypothyroidism
NCT0017776212	NCT00177762_12_T1	PHENOTYPE	0	0	Diabetes
NCT0017776212	NCT00177762_12_T2	PHENOTYPE	9	10	energy metabolism
NCT0017776216	NCT00177762_16_T0	GENE	13	13	100
NCT0017776216	NCT00177762_16_T1	GENE	5	5	160
NCT0017776218	NCT00177762_18_T0	ORGAN	6	6	heart
NCT0017776218	NCT00177762_18_T1	ORGAN	10	10	heart
NCT0017776218	NCT00177762_18_T2	GENE	16	16	beta
NCT0017776220	NCT00177762_20_T0	PHENOTYPE	0	0	Arrhythmia
NCT0017776222	NCT00177762_22_T0	PHENOTYPE	2	3	myocardial infarction
NCT0017776222	NCT00177762_22_T1	PHENOTYPE	5	6	valvular disease
NCT001777750	NCT00177775_0_T0	PHENOTYPE	16	16	Relapse
NCT001777752	NCT00177775_2_T0	PHENOTYPE	0	0	Secondary
NCT001777752	NCT00177775_2_T1	PHENOTYPE	15	15	relapse
NCT001777752	NCT00177775_2_T2	PHENOTYPE	19	19	diarrhea
NCT0017777516	NCT00177775_16_T0	PHENOTYPE	11	11	judgement
NCT0017777518	NCT00177775_18_T0	PHENOTYPE	25	26	adverse events
NCT0017777520	NCT00177775_20_T0	PHENOTYPE	7	7	relapse
NCT0017777522	NCT00177775_22_T0	PHENOTYPE	4	4	relapse
NCT0017777522	NCT00177775_22_T1	GENE	9	9	probable
NCT0017777522	NCT00177775_22_T2	PHENOTYPE	21	21	initiation
NCT0017777522	NCT00177775_22_T3	GENE	27	27	toxin
NCT0017777522	NCT00177775_22_T4	GENE	41	41	toxin
NCT0017777523	NCT00177775_23_T0	PHENOTYPE	17	17	relapse
NCT0017777526	NCT00177775_26_T0	GENE	0	0	3.3
NCT0017777528	NCT00177775_28_T0	PHENOTYPE	8	9	Infectious Disease
NCT0017777530	NCT00177775_30_T0	GENE	25	25	toxin
NCT0017777530	NCT00177775_30_T1	PHENOTYPE	32	32	relapse
NCT0017777532	NCT00177775_32_T0	PHENOTYPE	46	46	experiences
NCT0017777538	NCT00177775_38_T0	GENE	12	12	toxin
NCT0017777538	NCT00177775_38_T1	PHENOTYPE	6	6	relapse
NCT0017777538	NCT00177775_38_T2	GENE	2	2	has
NCT0017777538	NCT00177775_38_T3	PHENOTYPE	1	1	diarrhea
NCT0017777542	NCT00177775_42_T0	PHENOTYPE	25	25	perceived
NCT0017777542	NCT00177775_42_T1	PHENOTYPE	26	27	adverse events
NCT0017777543	NCT00177775_43_T0	GENE	21	21	toxin
NCT0017777543	NCT00177775_43_T1	PHENOTYPE	3	3	relapse
NCT0017777547	NCT00177775_47_T0	GENE	14	14	bowel
NCT0017777548	NCT00177775_48_T0	GENE	21	21	toxin
NCT0017777548	NCT00177775_48_T1	PHENOTYPE	3	3	relapse
NCT0017777550	NCT00177775_50_T0	PHENOTYPE	10	10	relapse
NCT0017777551	NCT00177775_51_T0	PHENOTYPE	10	10	relapse
NCT0017777552	NCT00177775_52_T0	GENE	0	0	3.4
NCT0017777552	NCT00177775_52_T1	ORGAN	8	8	serum
NCT0017777554	NCT00177775_54_T0	GENE	15	15	indefinite
NCT0017777556	NCT00177775_56_T0	PHENOTYPE	6	6	secondary
NCT0017777556	NCT00177775_56_T1	PHENOTYPE	26	26	secondary
NCT0017777557	NCT00177775_57_T0	PHENOTYPE	1	1	secondary
NCT001777881	NCT00177788_1_T0	PHENOTYPE	6	7	fungal infection
NCT001777882	NCT00177788_2_T0	COMPOUND	8	8	voriconazole
NCT001778011	NCT00177801_1_T0	PHENOTYPE	4	4	Centers
NCT001778012	NCT00177801_2_T0	GENE	2	2	has
NCT001778013	NCT00177801_3_T0	PHENOTYPE	35	36	fungal infection
NCT001778013	NCT00177801_3_T1	ORGAN	27	28	immune system
NCT001778013	NCT00177801_3_T2	PHENOTYPE	5	6	fungal infections
NCT001778014	NCT00177801_4_T0	COMPOUND	0	0	2
NCT001778014	NCT00177801_4_T1	ORGAN	6	6	serum
NCT001778014	NCT00177801_4_T2	PHENOTYPE	24	26	invasive fungal infections
NCT001778015	NCT00177801_5_T0	PHENOTYPE	19	20	viral infections
NCT001778015	NCT00177801_5_T1	PHENOTYPE	23	25	West Nile Virus
NCT001778018	NCT00177801_8_T0	ORGAN	6	6	serum
NCT001778019	NCT00177801_9_T0	PHENOTYPE	10	10	Centers
NCT001778019	NCT00177801_9_T1	PHENOTYPE	27	29	invasive fungal infections
NCT0017780111	NCT00177801_11_T0	PHENOTYPE	21	21	immunosuppression
NCT0017780113	NCT00177801_13_T0	PHENOTYPE	4	4	Infectious
NCT0017780116	NCT00177801_16_T0	ORGAN	6	6	transplant
NCT0017780117	NCT00177801_17_T0	ORGAN	29	29	transplant
NCT0017780119	NCT00177801_19_T0	PHENOTYPE	6	6	infections
NCT0017780119	NCT00177801_19_T1	ORGAN	5	5	transplant
NCT0017780121	NCT00177801_21_T0	PHENOTYPE	6	6	acute
NCT0017780121	NCT00177801_21_T1	ORGAN	20	20	transplant
NCT0017780121	NCT00177801_21_T2	PHENOTYPE	14	16	fulminant hepatic failure
NCT0017780122	NCT00177801_22_T0	ORGAN	13	13	transplant
NCT0017780128	NCT00177801_28_T0	GENE	13	13	indefinite
NCT0017780131	NCT00177801_31_T0	PHENOTYPE	20	20	conditioning
NCT0017780131	NCT00177801_31_T1	ORGAN	5	5	transplant
NCT0017780131	NCT00177801_31_T2	ORGAN	16	16	transplant
NCT0017780131	NCT00177801_31_T3	ORGAN	19	19	transplant
NCT0017780136	NCT00177801_36_T0	PHENOTYPE	3	3	fungi
NCT0017780139	NCT00177801_39_T0	GENE	5	5	eg
NCT001778271	NCT00177827_1_T0	PHENOTYPE	28	28	toxicity
NCT001778271	NCT00177827_1_T1	COMPOUND	8	8	voriconazole
NCT001778271	NCT00177827_1_T2	ORGAN	21	21	transplant
NCT001778272	NCT00177827_2_T0	PHENOTYPE	30	30	toxicity
NCT001778272	NCT00177827_2_T1	COMPOUND	12	12	voriconazole
NCT001778272	NCT00177827_2_T2	PHENOTYPE	13	13	concentrations
NCT001778272	NCT00177827_2_T3	PHENOTYPE	26	26	concentrations
NCT001778272	NCT00177827_2_T4	ORGAN	9	9	plasma
NCT001778273	NCT00177827_3_T0	COMPOUND	19	19	voriconazole
NCT001778273	NCT00177827_3_T1	ORGAN	11	11	transplant
NCT001778274	NCT00177827_4_T0	COMPOUND	18	18	voriconazole
NCT001778274	NCT00177827_4_T1	PHENOTYPE	15	15	concentrations
NCT001778274	NCT00177827_4_T2	ORGAN	27	27	plasma
NCT001778275	NCT00177827_5_T0	PHENOTYPE	38	38	toxicity
NCT001778275	NCT00177827_5_T1	PHENOTYPE	2	2	concentrations
NCT001778275	NCT00177827_5_T2	PHENOTYPE	27	27	concentrations
NCT001778275	NCT00177827_5_T3	PHENOTYPE	32	32	concentrations
NCT001778275	NCT00177827_5_T4	ORGAN	31	31	plasma
NCT001778276	NCT00177827_6_T0	PHENOTYPE	2	2	concentrations
NCT001778276	NCT00177827_6_T1	PHENOTYPE	35	35	concentrations
NCT001778276	NCT00177827_6_T2	ORGAN	32	32	plasma
NCT001778277	NCT00177827_7_T0	COMPOUND	16	16	voriconazole
NCT001778277	NCT00177827_7_T1	PHENOTYPE	14	14	pharmacokinetics
NCT001778277	NCT00177827_7_T2	ORGAN	19	19	transplant
NCT0017782714	NCT00177827_14_T0	COMPOUND	11	11	voriconazole
NCT0017782714	NCT00177827_14_T1	PHENOTYPE	12	12	pharmacokinetics
NCT001778531	NCT00177853_1_T0	PHENOTYPE	13	13	tumors
NCT001778534	NCT00177853_4_T0	PHENOTYPE	13	13	tumors
NCT001778662	NCT00177866_2_T0	COMPOUND	34	34	celecoxib
NCT001778663	NCT00177866_3_T0	COMPOUND	17	17	celecoxib
NCT001778669	NCT00177866_9_T0	PHENOTYPE	3	4	Crohn's disease
NCT0017786610	NCT00177866_10_T0	GENE	14	14	200
NCT0017786610	NCT00177866_10_T1	GENE	2	2	CDAI
NCT0017786610	NCT00177866_10_T2	GENE	10	10	CDAI
NCT0017786610	NCT00177866_10_T3	GENE	6	6	150
NCT0017786612	NCT00177866_12_T0	PHENOTYPE	21	21	IUD
NCT0017786612	NCT00177866_12_T1	PHENOTYPE	18	18	OCP
NCT0017786616	NCT00177866_16_T0	GENE	10	10	MP
NCT0017786618	NCT00177866_18_T0	PHENOTYPE	3	3	Crohn's
NCT0017786619	NCT00177866_19_T0	PHENOTYPE	2	3	Crohn's disease
NCT0017786620	NCT00177866_20_T0	COMPOUND	3	3	celecoxib
NCT0017786621	NCT00177866_21_T0	PHENOTYPE	2	2	gastritis
NCT0017786621	NCT00177866_21_T1	PHENOTYPE	6	7	peptic ulcer
NCT0017786621	NCT00177866_21_T2	PHENOTYPE	3	4	gastrointestinal bleeding
NCT0017786622	NCT00177866_22_T0	ORGAN	1	1	kidney
NCT001778792	NCT00177879_2_T0	PHENOTYPE	33	34	cognitive deficits
NCT001778794	NCT00177879_4_T0	PHENOTYPE	26	26	schizophrenia
NCT001778795	NCT00177879_5_T0	PHENOTYPE	29	30	mental illness
NCT001778923	NCT00177892_3_T0	PHENOTYPE	12	13	insulin resistance
NCT001778929	NCT00177892_9_T0	PHENOTYPE	9	9	hypoxia
NCT001778929	NCT00177892_9_T1	ORGAN	28	28	heart
NCT001778929	NCT00177892_9_T2	COMPOUND	33	33	cortisol
NCT001778929	NCT00177892_9_T3	COMPOUND	1	1	2
NCT001778929	NCT00177892_9_T4	PHENOTYPE	14	14	inflammation
NCT001778929	NCT00177892_9_T5	ORGAN	32	32	plasma
NCT001778929	NCT00177892_9_T6	PHENOTYPE	24	25	insulin resistance
NCT001778929	NCT00177892_9_T7	PHENOTYPE	11	12	oxidative stress
NCT0017789211	NCT00177892_11_T0	BIOLOGICAL_PROCESS	17	18	gene expression
NCT001779186	NCT00177918_6_T0	GENE	12	12	sera
NCT001779186	NCT00177918_6_T1	ORGAN	11	11	transplant
NCT001779186	NCT00177918_6_T2	ORGAN	1	1	serum
NCT0017791811	NCT00177918_11_T0	PHENOTYPE	7	7	pathology
NCT0017791814	NCT00177918_14_T0	PHENOTYPE	17	17	infections
NCT0017791815	NCT00177918_15_T0	PHENOTYPE	10	10	symptoms
NCT0017791816	NCT00177918_16_T0	ORGAN	19	19	transplant
NCT0017791816	NCT00177918_16_T1	ORGAN	30	30	transplant
NCT001779311	NCT00177931_1_T0	ORGAN	8	8	liver
NCT001779311	NCT00177931_1_T1	COMPOUND	6	6	cefepime
NCT001779311	NCT00177931_1_T2	ORGAN	9	9	transplant
NCT001779311	NCT00177931_1_T3	ORGAN	2	2	plasma
NCT001779313	NCT00177931_3_T0	ORGAN	30	30	liver
NCT001779313	NCT00177931_3_T1	ORGAN	31	31	transplant
NCT001779313	NCT00177931_3_T2	COMPOUND	22	22	cefepime
NCT001779315	NCT00177931_5_T0	COMPOUND	3	3	creatinine
NCT001779315	NCT00177931_5_T1	COMPOUND	9	9	creatinine
NCT001779315	NCT00177931_5_T2	COMPOUND	20	20	cefepime
NCT001779315	NCT00177931_5_T3	ORGAN	2	2	serum
NCT001779442	NCT00177944_2_T0	PHENOTYPE	9	9	infections
NCT001779442	NCT00177944_2_T1	GENE	6	6	probable
NCT001779442	NCT00177944_2_T2	PHENOTYPE	16	16	candidemia
NCT001779572	NCT00177957_2_T0	GENE	13	13	has
NCT001779576	NCT00177957_6_T0	PHENOTYPE	21	21	encoding
NCT001779576	NCT00177957_6_T1	GENE	13	13	PCR
NCT001779579	NCT00177957_9_T0	PHENOTYPE	10	10	identities
NCT001779579	NCT00177957_9_T1	GENE	24	24	has
NCT0017795715	NCT00177957_15_T0	PHENOTYPE	0	0	HIV
NCT0017797010	NCT00177970_10_T0	PHENOTYPE	12	12	PMC
NCT0017797010	NCT00177970_10_T1	PHENOTYPE	10	11	Pseudomembranous Colitis
NCT0017797012	NCT00177970_12_T0	GENE	15	15	OR
NCT0017797012	NCT00177970_12_T1	PHENOTYPE	9	9	Severity
NCT0017797012	NCT00177970_12_T2	COMPOUND	53	53	QID
NCT0017797012	NCT00177970_12_T3	GENE	46	46	IV
NCT0017797012	NCT00177970_12_T4	GENE	95	95	IV
NCT0017797012	NCT00177970_12_T5	GENE	98	98	IV
NCT0017797012	NCT00177970_12_T6	GENE	51	51	TID
NCT0017797012	NCT00177970_12_T7	COMPOUND	61	61	vancomycin
NCT0017797012	NCT00177970_12_T8	COMPOUND	73	73	vancomycin
NCT0017797012	NCT00177970_12_T9	COMPOUND	88	88	vancomycin
NCT0017797012	NCT00177970_12_T10	COMPOUND	104	104	vancomycin
NCT0017797012	NCT00177970_12_T11	COMPOUND	47	47	metronidazole
NCT0017797012	NCT00177970_12_T12	COMPOUND	96	96	metronidazole
NCT0017797012	NCT00177970_12_T13	GENE	50	50	po
NCT0017797012	NCT00177970_12_T14	GENE	64	64	po
NCT0017797012	NCT00177970_12_T15	GENE	91	91	po
NCT0017797016	NCT00177970_16_T0	PHENOTYPE	0	2	Selective IgA deficiency
NCT001779832	NCT00177983_2_T0	PHENOTYPE	16	17	mental health
NCT001780095	NCT00178009_5_T0	ORGAN	9	9	Heart
NCT001780096	NCT00178009_6_T0	GENE	15	15	ventricular
NCT001780098	NCT00178009_8_T0	ORGAN	10	10	Heart
NCT0017800910	NCT00178009_10_T0	PHENOTYPE	12	12	AHP
NCT0017800911	NCT00178009_11_T0	ORGAN	13	13	Heart
NCT0017800911	NCT00178009_11_T1	PHENOTYPE	15	15	AHP
NCT0017800912	NCT00178009_12_T0	GENE	2	2	II
NCT0017800912	NCT00178009_12_T1	PHENOTYPE	21	21	AHP
NCT0017800913	NCT00178009_13_T0	GENE	1	1	III
NCT0017800914	NCT00178009_14_T0	PHENOTYPE	3	3	self-efficacy
NCT0017800916	NCT00178009_16_T0	PHENOTYPE	3	3	self-efficacy
NCT0017800918	NCT00178009_18_T0	PHENOTYPE	11	11	HIV
NCT001780350	NCT00178035_0_T0	PHENOTYPE	6	7	Major Depression
NCT001780353	NCT00178035_3_T0	PHENOTYPE	16	16	suffering
NCT001780353	NCT00178035_3_T1	PHENOTYPE	28	29	completed suicide
NCT001780354	NCT00178035_4_T0	COMPOUND	34	34	paroxetine
NCT001780357	NCT00178035_7_T0	COMPOUND	23	23	paroxetine
NCT001780481	NCT00178048_1_T0	PHENOTYPE	6	6	insomnia
NCT001780481	NCT00178048_1_T1	PHENOTYPE	0	1	Primary insomnia
NCT001780483	NCT00178048_3_T0	PHENOTYPE	21	21	acute
NCT001780483	NCT00178048_3_T1	PHENOTYPE	37	37	acute
NCT001780484	NCT00178048_4_T0	PHENOTYPE	17	17	acute
NCT001780484	NCT00178048_4_T1	COMPOUND	20	20	paroxetine
NCT001780485	NCT00178048_5_T0	PHENOTYPE	34	34	acute
NCT001780485	NCT00178048_5_T1	GENE	16	16	1.1
NCT001780485	NCT00178048_5_T2	COMPOUND	19	19	paroxetine
NCT001780485	NCT00178048_5_T3	PHENOTYPE	6	7	primary insomnia
NCT001780743	NCT00178074_3_T0	PHENOTYPE	10	11	brain activity
NCT001780746	NCT00178074_6_T0	PHENOTYPE	14	14	Depression
NCT001780746	NCT00178074_6_T1	GENE	8	8	Dr
NCT001780747	NCT00178074_7_T0	PHENOTYPE	27	27	remission
NCT001780747	NCT00178074_7_T1	BIOLOGICAL_PROCESS	12	14	response to antidepressant
NCT0017807415	NCT00178074_15_T0	CELL	34	34	neuroreceptor
NCT0017807416	NCT00178074_16_T0	COMPOUND	1	1	glucose
NCT0017807416	NCT00178074_16_T1	GENE	25	25	al
NCT0017807416	NCT00178074_16_T2	GENE	30	30	al
NCT0017807416	NCT00178074_16_T3	GENE	10	10	has
NCT0017807416	NCT00178074_16_T4	GENE	24	24	et
NCT0017807416	NCT00178074_16_T5	GENE	29	29	et
NCT0017807417	NCT00178074_17_T0	BIOLOGICAL_PROCESS	26	26	aging
NCT001780873	NCT00178087_3_T0	GENE	21	21	AD
NCT001780873	NCT00178087_3_T1	PHENOTYPE	3	4	cognitive changes
NCT001780873	NCT00178087_3_T2	PHENOTYPE	19	20	Alzheimer's Disease
NCT001780873	NCT00178087_3_T3	PHENOTYPE	9	10	brain reserve
NCT001780876	NCT00178087_6_T0	PHENOTYPE	42	42	dementia
NCT001780876	NCT00178087_6_T1	PHENOTYPE	33	34	cognitive impairment
NCT001781004	NCT00178100_4_T0	PHENOTYPE	25	25	recurrence
NCT001781004	NCT00178100_4_T1	COMPOUND	9	9	paroxetine
NCT001781261	NCT00178126_1_T0	PHENOTYPE	44	45	pressure ulcers
NCT001781262	NCT00178126_2_T0	GENE	21	21	reduced
NCT001781262	NCT00178126_2_T1	PHENOTYPE	19	20	pressure ulcers
NCT001781262	NCT00178126_2_T2	PHENOTYPE	26	28	quality of life
NCT001781264	NCT00178126_4_T0	PHENOTYPE	0	1	Pressure ulcers
NCT001781264	NCT00178126_4_T1	PHENOTYPE	4	6	quality of life
NCT001781265	NCT00178126_5_T0	GENE	8	8	LTC
NCT001781266	NCT00178126_6_T0	PHENOTYPE	3	3	Centers
NCT001781266	NCT00178126_6_T1	GENE	9	9	CMS
NCT001781266	NCT00178126_6_T2	GENE	10	10	LTC
NCT001781266	NCT00178126_6_T3	PHENOTYPE	34	35	pressure ulcers
NCT001781267	NCT00178126_7_T0	GENE	22	22	LTC
NCT0017812611	NCT00178126_11_T0	PHENOTYPE	31	32	pressure ulcer
NCT0017812612	NCT00178126_12_T0	PHENOTYPE	23	24	pressure ulcers
NCT0017812613	NCT00178126_13_T0	PHENOTYPE	44	45	pressure ulcers
NCT0017812614	NCT00178126_14_T0	GENE	21	21	reduced
NCT0017812614	NCT00178126_14_T1	PHENOTYPE	19	20	pressure ulcers
NCT0017812614	NCT00178126_14_T2	PHENOTYPE	26	28	quality of life
NCT001781390	NCT00178139_0_T0	PHENOTYPE	8	8	Ventilation
NCT001781652	NCT00178165_2_T0	PHENOTYPE	25	25	disorders
NCT001781652	NCT00178165_2_T1	PHENOTYPE	21	22	Alzheimer's disease
NCT001781653	NCT00178165_3_T0	GENE	2	2	has
NCT001781656	NCT00178165_6_T0	PHENOTYPE	14	14	strategies
NCT001781657	NCT00178165_7_T0	PHENOTYPE	30	31	problem behavior
NCT0017816510	NCT00178165_10_T0	PHENOTYPE	1	1	strategies
NCT0017816510	NCT00178165_10_T1	GENE	24	24	al
NCT0017816510	NCT00178165_10_T2	GENE	23	23	et
NCT0017816513	NCT00178165_13_T0	PHENOTYPE	55	55	strategies
NCT0017816515	NCT00178165_15_T0	GENE	2	2	has
NCT0017816517	NCT00178165_17_T0	GENE	18	18	AD
NCT0017816522	NCT00178165_22_T0	PHENOTYPE	1	1	impairment
NCT0017816522	NCT00178165_22_T1	GENE	8	8	ADL
NCT0017816526	NCT00178165_26_T0	PHENOTYPE	3	3	acute
NCT0017816527	NCT00178165_27_T0	PHENOTYPE	3	3	delusions
NCT0017816527	NCT00178165_27_T1	PHENOTYPE	0	0	Schizophrenia
NCT0017816528	NCT00178165_28_T0	GENE	5	5	probable
NCT0017816528	NCT00178165_28_T1	PHENOTYPE	3	4	head trauma
NCT0017816528	NCT00178165_28_T2	PHENOTYPE	0	1	Dementia secondary
NCT0017816529	NCT00178165_29_T0	PHENOTYPE	0	0	Blindness
NCT0017816529	NCT00178165_29_T1	PHENOTYPE	2	2	deafness
NCT0017816532	NCT00178165_32_T0	GENE	0	0	Age
NCT0017816544	NCT00178165_44_T0	PHENOTYPE	3	3	acute
NCT0017816545	NCT00178165_45_T0	GENE	18	18	has
NCT0017816546	NCT00178165_46_T0	GENE	7	7	PI
NCT0017816547	NCT00178165_47_T0	PHENOTYPE	23	23	hesitancy
NCT0017816547	NCT00178165_47_T1	GENE	40	40	PI
NCT001781783	NCT00178178_3_T0	GENE	6	7	Group 1
NCT001781784	NCT00178178_4_T0	TISSUE	8	9	patellar tendon
NCT001781785	NCT00178178_5_T0	TISSUE	11	12	patellar tendon
NCT0017817815	NCT00178178_15_T0	TISSUE	11	12	patellar tendon
NCT0017817828	NCT00178178_28_T0	GENE	21	21	has
NCT0017817830	NCT00178178_30_T0	PHENOTYPE	16	17	medical emergencies
NCT0017817832	NCT00178178_32_T0	PHENOTYPE	9	10	adverse event
NCT0017817833	NCT00178178_33_T0	PHENOTYPE	20	20	allergy
NCT0017817838	NCT00178178_38_T0	PHENOTYPE	23	24	surgical wound
NCT0017817839	NCT00178178_39_T0	GENE	9	9	x2
NCT0017817839	NCT00178178_39_T1	COMPOUND	16	16	QID
NCT0017817840	NCT00178178_40_T0	GENE	2	2	has
NCT0017817840	NCT00178178_40_T1	GENE	10	10	prn
NCT0017817844	NCT00178178_44_T0	GENE	23	23	am
NCT001781910	NCT00178191_0_T0	PHENOTYPE	4	5	Urinary Incontinence
NCT001781913	NCT00178191_3_T0	PHENOTYPE	28	28	constipation
NCT001781913	NCT00178191_3_T1	PHENOTYPE	25	26	dry mouth
NCT001781914	NCT00178191_4_T0	PHENOTYPE	11	11	leakage
NCT001782043	NCT00178204_3_T0	PHENOTYPE	6	6	fatigue
NCT001782044	NCT00178204_4_T0	PHENOTYPE	5	5	fatigue
NCT001782044	NCT00178204_4_T1	GENE	20	20	has
NCT001782046	NCT00178204_6_T0	PHENOTYPE	12	12	fatigue
NCT001782046	NCT00178204_6_T1	PHENOTYPE	3	5	slow wave sleep
NCT001782047	NCT00178204_7_T0	PHENOTYPE	35	35	fatigue
NCT001782048	NCT00178204_8_T0	GENE	7	7	PSG
NCT0017820410	NCT00178204_10_T0	PHENOTYPE	19	19	fatigue
NCT001782175	NCT00178217_5_T0	COMPOUND	11	11	oxygen
NCT001782175	NCT00178217_5_T1	ORGAN	13	13	heart
NCT001782179	NCT00178217_9_T0	GENE	4	4	has
NCT0017821715	NCT00178217_15_T0	PHENOTYPE	0	0	Secondary
NCT0017821717	NCT00178217_17_T0	GENE	8	8	had
NCT0017821718	NCT00178217_18_T0	GENE	2	2	had
NCT001782303	NCT00178230_3_T0	GENE	5	5	interferon
NCT001782303	NCT00178230_3_T1	PHENOTYPE	8	9	lung cancer
NCT001782304	NCT00178230_4_T0	PHENOTYPE	7	8	lung cancer
NCT001782431	NCT00178243_1_T0	ORGAN	28	28	liver
NCT001782431	NCT00178243_1_T1	PHENOTYPE	18	18	tumor
NCT001782432	NCT00178243_2_T0	PHENOTYPE	20	21	liver cancer
NCT001782435	NCT00178243_5_T0	PHENOTYPE	1	2	hepatobiliary tumors
NCT001782563	NCT00178256_3_T0	COMPOUND	12	12	paclitaxel
NCT001782566	NCT00178256_6_T0	COMPOUND	10	10	paclitaxel
NCT001782566	NCT00178256_6_T1	PHENOTYPE	16	17	lung cancer
NCT001782568	NCT00178256_8_T0	PHENOTYPE	16	16	tolerance
NCT001782820	NCT00178282_0_T0	PHENOTYPE	9	10	Urinary Incontinence
NCT001782822	NCT00178282_2_T0	GENE	12	12	has
NCT001782822	NCT00178282_2_T1	PHENOTYPE	28	29	urinary incontinence
NCT001782824	NCT00178282_4_T0	PHENOTYPE	9	10	urinary incontinence
NCT001782825	NCT00178282_5_T0	PHENOTYPE	15	15	incontinence
NCT001782825	NCT00178282_5_T1	ORGAN	7	8	pelvic floor
NCT001782826	NCT00178282_6_T0	ORGAN	16	17	pelvic floor
NCT001782826	NCT00178282_6_T1	PHENOTYPE	21	22	urinary incontinence
NCT001782951	NCT00178295_1_T0	PHENOTYPE	6	6	tumors
NCT001782952	NCT00178295_2_T0	PHENOTYPE	13	14	brain tumors
NCT001782952	NCT00178295_2_T1	PHENOTYPE	8	10	effects of radiation
NCT001782953	NCT00178295_3_T0	PHENOTYPE	20	21	brain cancer
NCT001783080	NCT00178308_0_T0	ORGAN	6	6	Blood
NCT001783211	NCT00178321_1_T0	GENE	2	2	has
NCT001783212	NCT00178321_2_T0	PHENOTYPE	8	8	profound
NCT001783213	NCT00178321_3_T0	PHENOTYPE	7	7	profound
NCT001783214	NCT00178321_4_T0	GENE	4	4	has
NCT001783214	NCT00178321_4_T1	PHENOTYPE	17	18	cognitive function
NCT001783214	NCT00178321_4_T2	PHENOTYPE	9	10	cortisol levels
NCT001783215	NCT00178321_5_T0	PHENOTYPE	16	16	homeostatic
NCT001783216	NCT00178321_6_T0	PHENOTYPE	8	9	critically ill
NCT001783218	NCT00178321_8_T0	COMPOUND	4	4	cortisol
NCT001783218	NCT00178321_8_T1	COMPOUND	3	3	melatonin
NCT001783218	NCT00178321_8_T2	PHENOTYPE	6	7	immune status
NCT0017832110	NCT00178321_10_T0	PHENOTYPE	21	21	CBCL
NCT0017832113	NCT00178321_13_T0	BIOLOGICAL_PROCESS	11	12	menstrual cycle
NCT0017832115	NCT00178321_15_T0	COMPOUND	12	12	2
NCT0017832118	NCT00178321_18_T0	GENE	2	2	has
NCT0017832119	NCT00178321_19_T0	PHENOTYPE	8	8	profound
NCT0017832120	NCT00178321_20_T0	PHENOTYPE	7	7	profound
NCT0017832121	NCT00178321_21_T0	GENE	4	4	has
NCT0017832121	NCT00178321_21_T1	PHENOTYPE	17	18	cognitive function
NCT0017832121	NCT00178321_21_T2	PHENOTYPE	9	10	cortisol levels
NCT0017832122	NCT00178321_22_T0	PHENOTYPE	16	16	homeostatic
NCT0017832125	NCT00178321_25_T0	COMPOUND	4	4	cortisol
NCT0017832125	NCT00178321_25_T1	COMPOUND	3	3	melatonin
NCT0017832125	NCT00178321_25_T2	PHENOTYPE	6	7	immune status
NCT0017832127	NCT00178321_27_T0	PHENOTYPE	21	21	CBCL
NCT001783341	NCT00178334_1_T0	PHENOTYPE	9	11	quality of life
NCT001783474	NCT00178347_4_T0	ORGAN	13	13	teeth
NCT001783476	NCT00178347_6_T0	ORGAN	4	4	teeth
NCT001783477	NCT00178347_7_T0	ORGAN	1	1	teeth
NCT001783603	NCT00178360_3_T0	PHENOTYPE	20	21	emotional state
NCT0017836010	NCT00178360_10_T0	GENE	0	0	Lyric
NCT0017836013	NCT00178360_13_T0	PHENOTYPE	16	16	symptoms
NCT0017836013	NCT00178360_13_T1	PHENOTYPE	20	21	Huntington's disease
NCT0017836014	NCT00178360_14_T0	PHENOTYPE	17	18	Huntington's disease
NCT0017836015	NCT00178360_15_T0	PHENOTYPE	16	18	quality of life
NCT0017836018	NCT00178360_18_T0	GENE	12	12	PSE
NCT0017836018	NCT00178360_18_T1	GENE	8	8	RAS
NCT0017836018	NCT00178360_18_T2	GENE	18	18	TIMP
NCT0017836019	NCT00178360_19_T0	PHENOTYPE	27	27	feelings
NCT0017836020	NCT00178360_20_T0	PHENOTYPE	1	1	secondary
NCT0017836020	NCT00178360_20_T1	PHENOTYPE	12	13	Huntington's Disease
NCT0017836023	NCT00178360_23_T0	PHENOTYPE	5	5	feelings
NCT001783731	NCT00178373_1_T0	COMPOUND	4	4	modafinil
NCT001783731	NCT00178373_1_T1	PHENOTYPE	6	7	cognitive dysfunction
NCT001783732	NCT00178373_2_T0	PHENOTYPE	10	10	fatigue
NCT001783732	NCT00178373_2_T1	PHENOTYPE	22	22	fatigue
NCT001783732	NCT00178373_2_T2	COMPOUND	5	5	modafinil
NCT001783732	NCT00178373_2_T3	PHENOTYPE	30	31	cognitive dysfunction
NCT001783734	NCT00178373_4_T0	COMPOUND	21	21	1
NCT001783734	NCT00178373_4_T1	COMPOUND	37	37	2
NCT001783734	NCT00178373_4_T2	PHENOTYPE	11	11	fatigue
NCT001783734	NCT00178373_4_T3	PHENOTYPE	26	26	fatigue
NCT001783734	NCT00178373_4_T4	PHENOTYPE	47	47	fatigue
NCT001783734	NCT00178373_4_T5	COMPOUND	52	52	3
NCT001783734	NCT00178373_4_T6	PHENOTYPE	62	63	cognitive dysfunction
NCT001783735	NCT00178373_5_T0	COMPOUND	21	21	modafinil
NCT001783735	NCT00178373_5_T1	GENE	49	49	CDR
NCT001783735	NCT00178373_5_T2	PHENOTYPE	24	25	cancer fatigue
NCT001783735	NCT00178373_5_T3	PHENOTYPE	33	34	cognitive dysfunction
NCT001783736	NCT00178373_6_T0	PHENOTYPE	6	6	Fatigue
NCT001783736	NCT00178373_6_T1	PHENOTYPE	10	10	Fatigue
NCT001783736	NCT00178373_6_T2	PHENOTYPE	11	11	Severity
NCT001783736	NCT00178373_6_T3	PHENOTYPE	13	13	sleepiness
NCT001783736	NCT00178373_6_T4	PHENOTYPE	18	18	Sleepiness
NCT001783736	NCT00178373_6_T5	PHENOTYPE	29	30	psychological adjustment
NCT001783991	NCT00178399_1_T0	PHENOTYPE	12	12	affects
NCT001783992	NCT00178399_2_T0	PHENOTYPE	27	29	quality of life
NCT0017839913	NCT00178399_13_T0	PHENOTYPE	1	1	secondary
NCT001784124	NCT00178412_4_T0	PHENOTYPE	63	63	reward
NCT001784124	NCT00178412_4_T1	PHENOTYPE	18	18	loved
NCT001784124	NCT00178412_4_T2	PHENOTYPE	50	50	loved
NCT001784124	NCT00178412_4_T3	PHENOTYPE	71	71	loved
NCT001784124	NCT00178412_4_T4	PHENOTYPE	39	40	depressive symptoms
NCT001784124	NCT00178412_4_T5	PHENOTYPE	65	66	role strain
NCT0017841210	NCT00178412_10_T0	PHENOTYPE	9	9	loved
NCT0017841212	NCT00178412_12_T0	GENE	12	12	has
NCT0017841215	NCT00178412_15_T0	PHENOTYPE	1	1	secondary
NCT0017841218	NCT00178412_18_T0	GENE	33	33	had
NCT0017841218	NCT00178412_18_T1	GENE	45	45	had
NCT001784252	NCT00178425_2_T0	ORGAN	8	8	liver
NCT001784252	NCT00178425_2_T1	ORGAN	18	18	liver
NCT001784252	NCT00178425_2_T2	ORGAN	4	4	transplant
NCT001784253	NCT00178425_3_T0	ORGAN	6	6	transplants
NCT001784254	NCT00178425_4_T0	PHENOTYPE	2	3	drug levels
NCT001784257	NCT00178425_7_T0	ORGAN	8	8	liver
NCT001784257	NCT00178425_7_T1	ORGAN	18	18	liver
NCT001784257	NCT00178425_7_T2	ORGAN	4	4	transplant
NCT001784258	NCT00178425_8_T0	ORGAN	6	6	transplants
NCT001784259	NCT00178425_9_T0	PHENOTYPE	2	3	drug levels
NCT0017842510	NCT00178425_10_T0	ORGAN	4	4	liver
NCT0017842512	NCT00178425_12_T0	ORGAN	12	12	kidney
NCT0017842514	NCT00178425_14_T0	ORGAN	23	23	transplant
NCT0017842517	NCT00178425_17_T0	ORGAN	12	12	transplant
NCT0017842518	NCT00178425_18_T0	ORGAN	15	15	transplant
NCT001784383	NCT00178438_3_T0	GENE	3	3	CD
NCT001784383	NCT00178438_3_T1	GENE	8	8	bowel
NCT001784383	NCT00178438_3_T2	PHENOTYPE	1	2	Crohn's disease
NCT001784383	NCT00178438_3_T3	PHENOTYPE	23	24	Crohn's disease
NCT001784514	NCT00178451_4_T0	GENE	29	29	ACAS
NCT001784514	NCT00178451_4_T1	GENE	5	5	has
NCT001784514	NCT00178451_4_T2	ORGAN	21	22	carotid artery
NCT001784516	NCT00178451_6_T0	PHENOTYPE	12	13	vascular disease
NCT001784518	NCT00178451_8_T0	PHENOTYPE	12	12	attributable
NCT001784518	NCT00178451_8_T1	PHENOTYPE	8	8	anesthesia
NCT001784518	NCT00178451_8_T2	PHENOTYPE	15	15	ischemia
NCT001784519	NCT00178451_9_T0	PHENOTYPE	16	16	occlusion
NCT0017845110	NCT00178451_10_T0	GENE	8	8	collagen
NCT0017845110	NCT00178451_10_T1	CELL	3	3	platelets
NCT0017845117	NCT00178451_17_T0	GENE	4	4	has
NCT0017845118	NCT00178451_18_T0	CELL	16	16	platelet
NCT0017845118	NCT00178451_18_T1	GENE	17	17	glycoprotein
NCT0017845118	NCT00178451_18_T2	GENE	20	20	has
NCT0017845118	NCT00178451_18_T3	PHENOTYPE	12	14	acute myocardial infarction
NCT0017845119	NCT00178451_19_T0	PHENOTYPE	8	8	acute
NCT0017845119	NCT00178451_19_T1	PHENOTYPE	9	10	ischemic stroke
NCT0017845120	NCT00178451_20_T0	COMPOUND	8	8	heparin
NCT0017845120	NCT00178451_20_T1	PHENOTYPE	25	25	stenoses
NCT0017845120	NCT00178451_20_T2	COMPOUND	10	10	aspirin
NCT0017845120	NCT00178451_20_T3	GENE	1	1	has
NCT0017845120	NCT00178451_20_T4	PHENOTYPE	24	24	recurrent
NCT0017845120	NCT00178451_20_T5	ORGAN	12	13	carotid artery
NCT0017845121	NCT00178451_21_T0	PHENOTYPE	18	18	bleeding
NCT0017845121	NCT00178451_21_T1	CELL	4	4	platelet
NCT0017845124	NCT00178451_24_T0	PHENOTYPE	1	1	secondary
NCT001784640	NCT00178464_0_T0	PHENOTYPE	3	5	Sickle Cell Disease
NCT001784642	NCT00178464_2_T0	PHENOTYPE	10	10	infarctions
NCT001784642	NCT00178464_2_T1	GENE	16	16	MRI
NCT001784642	NCT00178464_2_T2	PHENOTYPE	6	7	cerebrovascular accidents
NCT001784646	NCT00178464_6_T0	GENE	5	5	2.0
NCT001784646	NCT00178464_6_T1	COMPOUND	16	16	aspirin
NCT001784647	NCT00178464_7_T0	GENE	3	3	5.0
NCT001784647	NCT00178464_7_T1	COMPOUND	11	11	aspirin
NCT0017846411	NCT00178464_11_T0	GENE	15	15	SS
NCT0017846411	NCT00178464_11_T1	PHENOTYPE	14	14	Hgb
NCT0017846411	NCT00178464_11_T2	PHENOTYPE	17	17	Hgb
NCT0017846411	NCT00178464_11_T3	PHENOTYPE	20	20	Thalassemia
NCT0017846421	NCT00178464_21_T0	PHENOTYPE	8	8	varicella
NCT0017846423	NCT00178464_23_T0	PHENOTYPE	0	2	Negative pregnancy tests
NCT0017846427	NCT00178464_27_T0	PHENOTYPE	6	7	cerebral hemorrhage
NCT0017846429	NCT00178464_29_T0	COMPOUND	6	6	aspirin
NCT0017846429	NCT00178464_29_T1	PHENOTYPE	3	4	allergic reaction
NCT0017846432	NCT00178464_32_T0	GENE	2	2	G-6-PD
NCT0017846432	NCT00178464_32_T1	PHENOTYPE	5	7	von Willebrand's disease
NCT0017846433	NCT00178464_33_T0	GENE	14	14	thromboplastin
NCT0017846433	NCT00178464_33_T1	GENE	9	9	prothrombin
NCT0017846433	NCT00178464_33_T2	PHENOTYPE	3	4	bleeding time
NCT0017846435	NCT00178464_35_T0	PHENOTYPE	2	3	GI bleeding
NCT0017846435	NCT00178464_35_T1	PHENOTYPE	8	9	GI bleeding
NCT0017846440	NCT00178464_40_T0	PHENOTYPE	0	0	Hypertension
NCT0017846440	NCT00178464_40_T1	GENE	1	1	BP
NCT0017846442	NCT00178464_42_T0	PHENOTYPE	3	3	chronic
NCT0017846444	NCT00178464_44_T0	GENE	4	4	MRI
NCT0017846444	NCT00178464_44_T1	PHENOTYPE	2	2	hemorrhage
NCT001784903	NCT00178490_3_T0	PHENOTYPE	13	15	high blood pressure
NCT001784905	NCT00178490_5_T0	PHENOTYPE	17	18	weight loss
NCT001784905	NCT00178490_5_T1	PHENOTYPE	37	39	high blood pressure
NCT001784907	NCT00178490_7_T0	PHENOTYPE	9	10	weight loss
NCT0017849010	NCT00178490_10_T0	GENE	3	3	has
NCT0017849010	NCT00178490_10_T1	ORGAN	8	8	heart
NCT0017849010	NCT00178490_10_T2	PHENOTYPE	4	6	high blood pressure
NCT0017849012	NCT00178490_12_T0	PHENOTYPE	4	6	high blood pressure
NCT0017849014	NCT00178490_14_T0	PHENOTYPE	7	9	high blood pressure
NCT0017849015	NCT00178490_15_T0	PHENOTYPE	17	18	weight loss
NCT0017849015	NCT00178490_15_T1	PHENOTYPE	37	39	high blood pressure
NCT0017849016	NCT00178490_16_T0	PHENOTYPE	13	15	high blood pressure
NCT0017849018	NCT00178490_18_T0	GENE	18	18	cuff
NCT0017849018	NCT00178490_18_T1	PHENOTYPE	3	5	high blood pressure
NCT0017849019	NCT00178490_19_T0	ORGAN	16	16	heart
NCT0017849019	NCT00178490_19_T1	PHENOTYPE	7	9	high blood pressure
NCT0017849022	NCT00178490_22_T0	PHENOTYPE	17	17	emotions
NCT0017849023	NCT00178490_23_T0	PHENOTYPE	20	21	weight loss
NCT0017849023	NCT00178490_23_T1	PHENOTYPE	2	4	high blood pressure
NCT0017849024	NCT00178490_24_T0	GENE	4	4	cuff
NCT0017849029	NCT00178490_29_T0	PHENOTYPE	2	4	high blood pressure
NCT0017850311	NCT00178503_11_T0	PHENOTYPE	29	29	symptoms
NCT0017850311	NCT00178503_11_T1	PHENOTYPE	28	28	ADHD
NCT0017850311	NCT00178503_11_T2	PHENOTYPE	10	10	autism
NCT0017850311	NCT00178503_11_T3	PHENOTYPE	33	34	cognitive functioning
NCT0017850313	NCT00178503_13_T0	PHENOTYPE	19	20	psychiatric disorders
NCT0017850315	NCT00178503_15_T0	COMPOUND	30	30	methylphenidate
NCT0017850315	NCT00178503_15_T1	GENE	31	31	MPH
NCT0017850316	NCT00178503_16_T0	GENE	25	25	MPH
NCT0017850316	NCT00178503_16_T1	GENE	29	29	MPH
NCT0017850317	NCT00178503_17_T0	GENE	16	16	MPH
NCT0017850319	NCT00178503_19_T0	GENE	24	24	MPH
NCT001785160	NCT00178516_0_T0	PHENOTYPE	3	4	Male Infertility
NCT001785162	NCT00178516_2_T0	GENE	25	25	eg
NCT001785162	NCT00178516_2_T1	PHENOTYPE	19	19	miscarriage
NCT001785162	NCT00178516_2_T2	CELL	10	10	sperm
NCT001785162	NCT00178516_2_T3	CELL	32	32	sperm
NCT001785162	NCT00178516_2_T4	GENE	2	2	has
NCT001785162	NCT00178516_2_T5	PHENOTYPE	13	13	infertility
NCT001785291	NCT00178529_1_T0	PHENOTYPE	22	23	psychological distress
NCT001785295	NCT00178529_5_T0	PHENOTYPE	26	26	perceived
NCT001785295	NCT00178529_5_T1	PHENOTYPE	70	70	chronic
NCT001785295	NCT00178529_5_T2	PHENOTYPE	22	24	quality of life
NCT001785299	NCT00178529_9_T0	PHENOTYPE	5	5	severity
NCT0017852910	NCT00178529_10_T0	GENE	3	3	HLM
NCT001785423	NCT00178542_3_T0	GENE	7	7	TG
NCT001785423	NCT00178542_3_T1	BIOLOGICAL_PROCESS	24	25	menstrual cycle
NCT001785554	NCT00178555_4_T0	ORGAN	21	21	trachea
NCT001785556	NCT00178555_6_T0	PHENOTYPE	4	5	difficult intubation
NCT001785557	NCT00178555_7_T0	PHENOTYPE	9	9	visualization
NCT001785557	NCT00178555_7_T1	PHENOTYPE	5	6	difficult intubation
NCT001785558	NCT00178555_8_T0	PHENOTYPE	6	6	visualization
NCT0017855513	NCT00178555_13_T0	GENE	2	2	has
NCT0017855514	NCT00178555_14_T0	GENE	1	1	has
NCT0017855516	NCT00178555_16_T0	PHENOTYPE	16	16	visualization
NCT0017855518	NCT00178555_18_T0	PHENOTYPE	7	7	distal
NCT0017855518	NCT00178555_18_T1	ORGAN	29	29	trachea
NCT0017855518	NCT00178555_18_T2	ORGAN	26	26	oropharynx
NCT0017855519	NCT00178555_19_T0	PHENOTYPE	8	9	difficult intubation
NCT001785684	NCT00178568_4_T0	PHENOTYPE	12	12	Practices
NCT001785684	NCT00178568_4_T1	PHENOTYPE	26	27	progressive dementia
NCT001785685	NCT00178568_5_T0	COMPOUND	7	7	1
NCT001785685	NCT00178568_5_T1	PHENOTYPE	19	20	progressive dementia
NCT001785686	NCT00178568_6_T0	PHENOTYPE	14	14	Practices
NCT001785686	NCT00178568_6_T1	COMPOUND	1	1	2
NCT001785686	NCT00178568_6_T2	PHENOTYPE	32	33	progressive dementia
NCT001785687	NCT00178568_7_T0	COMPOUND	1	1	3
NCT001785687	NCT00178568_7_T1	PHENOTYPE	16	17	progressive dementia
NCT001785688	NCT00178568_8_T0	COMPOUND	4	4	1
NCT001785688	NCT00178568_8_T1	COMPOUND	17	17	2
NCT001785815	NCT00178581_5_T0	GENE	2	2	bowel
NCT001785815	NCT00178581_5_T1	PHENOTYPE	1	1	tolerance
NCT001786201	NCT00178620_1_T0	GENE	21	21	clot
NCT001786201	NCT00178620_1_T1	PHENOTYPE	4	5	heart attacks
NCT001786201	NCT00178620_1_T2	PHENOTYPE	30	31	heart attack
NCT001786202	NCT00178620_2_T0	PHENOTYPE	12	13	heart attacks
NCT001786202	NCT00178620_2_T1	PHENOTYPE	2	3	heart attack
NCT001786204	NCT00178620_4_T0	GENE	4	4	EMS
NCT001786204	NCT00178620_4_T1	ORGAN	37	37	artery
NCT001786205	NCT00178620_5_T0	PHENOTYPE	5	5	symptoms
NCT001786205	NCT00178620_5_T1	PHENOTYPE	7	7	acute
NCT001786205	NCT00178620_5_T2	PHENOTYPE	14	14	acute
NCT001786205	NCT00178620_5_T3	PHENOTYPE	15	16	ST elevation
NCT001786206	NCT00178620_6_T0	PHENOTYPE	7	7	acute
NCT001786207	NCT00178620_7_T0	GENE	28	28	Hub
NCT001786208	NCT00178620_8_T0	PHENOTYPE	27	27	transmitted
NCT0017862010	NCT00178620_10_T0	GENE	19	19	PCI
NCT0017862014	NCT00178620_14_T0	GENE	5	5	MRI
NCT0017862014	NCT00178620_14_T1	PHENOTYPE	26	26	suffered
NCT0017862014	NCT00178620_14_T2	ORGAN	25	25	heart
NCT0017862014	NCT00178620_14_T3	PHENOTYPE	32	33	Heart attack
NCT0017862026	NCT00178620_26_T0	COMPOUND	1	1	cocaine
NCT0017862026	NCT00178620_26_T1	COMPOUND	3	3	amphetamine
NCT001786336	NCT00178633_6_T0	GENE	27	27	bypass
NCT001786336	NCT00178633_6_T1	PHENOTYPE	25	25	pouch
NCT001786336	NCT00178633_6_T2	GENE	30	30	SPGB
NCT001786337	NCT00178633_7_T0	PHENOTYPE	16	17	weight loss
NCT001786337	NCT00178633_7_T1	PHENOTYPE	7	8	severe obesity
NCT0017863310	NCT00178633_10_T0	PHENOTYPE	19	20	ischemic cardiomyopathy
NCT0017863310	NCT00178633_10_T1	PHENOTYPE	26	27	psychiatric disease
NCT0017863310	NCT00178633_10_T2	PHENOTYPE	13	15	coronary artery disease
NCT0017863310	NCT00178633_10_T3	PHENOTYPE	22	24	peripheral vascular disease
NCT0017863310	NCT00178633_10_T4	PHENOTYPE	16	18	congestive heart failure
NCT001786462	NCT00178646_2_T0	PHENOTYPE	13	13	imbalance
NCT001786462	NCT00178646_2_T1	PHENOTYPE	3	3	pathophysiology
NCT001786462	NCT00178646_2_T2	ORGAN	25	27	central nervous system
NCT001786463	NCT00178646_3_T0	PHENOTYPE	20	20	weakness
NCT001786463	NCT00178646_3_T1	PHENOTYPE	19	19	clonus
NCT001786463	NCT00178646_3_T2	PHENOTYPE	22	22	incoordination
NCT001786463	NCT00178646_3_T3	PHENOTYPE	1	1	spasticity
NCT001786463	NCT00178646_3_T4	PHENOTYPE	5	7	increased muscle tone
NCT001786464	NCT00178646_4_T0	PHENOTYPE	3	3	spasticity
NCT001786466	NCT00178646_6_T0	PHENOTYPE	17	17	spasticity
NCT001786466	NCT00178646_6_T1	PHENOTYPE	10	10	encephalopathy
NCT001786466	NCT00178646_6_T2	PHENOTYPE	1	2	brain injuries
NCT001786466	NCT00178646_6_T3	PHENOTYPE	6	8	traumatic brain injury
NCT001786469	NCT00178646_9_T0	GENE	10	10	toxin
NCT0017864611	NCT00178646_11_T0	PHENOTYPE	17	17	spasticity
NCT0017864612	NCT00178646_12_T0	GENE	22	22	toxin
NCT0017864613	NCT00178646_13_T0	GENE	12	12	toxin
NCT0017864616	NCT00178646_16_T0	GENE	2	2	toxin
NCT0017864617	NCT00178646_17_T0	PHENOTYPE	19	19	spasticity
NCT0017864617	NCT00178646_17_T1	ORGAN	15	15	wrist
NCT001786593	NCT00178659_3_T0	GENE	10	10	ICP
NCT001786594	NCT00178659_4_T0	GENE	15	15	ICP
NCT001786595	NCT00178659_5_T0	GENE	25	25	ICP
NCT001786596	NCT00178659_6_T0	PHENOTYPE	18	18	suffering
NCT001786596	NCT00178659_6_T1	ORGAN	15	15	serum
NCT001786596	NCT00178659_6_T2	PHENOTYPE	20	22	traumatic brain injury
NCT001786597	NCT00178659_7_T0	GENE	12	12	has
NCT001786597	NCT00178659_7_T1	PHENOTYPE	8	9	pattern recognition
NCT001786599	NCT00178659_9_T0	GENE	6	6	ICP
NCT0017865911	NCT00178659_11_T0	GENE	19	19	ICP
NCT0017865911	NCT00178659_11_T1	PHENOTYPE	3	4	brain trauma
NCT0017865914	NCT00178659_14_T0	PHENOTYPE	0	0	Fracture
NCT0017865915	NCT00178659_15_T0	PHENOTYPE	1	2	head trauma
NCT0017865919	NCT00178659_19_T0	GENE	0	0	GCS
NCT0017865920	NCT00178659_20_T0	PHENOTYPE	6	6	contusion
NCT001786721	NCT00178672_1_T0	PHENOTYPE	0	0	Secondary
NCT001786721	NCT00178672_1_T1	PHENOTYPE	20	20	Distal
NCT001786723	NCT00178672_3_T0	ORGAN	16	17	carotid arteries
NCT001786726	NCT00178672_6_T0	ORGAN	17	18	carotid arteries
NCT001786728	NCT00178672_8_T0	PHENOTYPE	21	22	adverse events
NCT0017867212	NCT00178672_12_T0	GENE	19	19	4.2
NCT0017867214	NCT00178672_14_T0	PHENOTYPE	5	5	restenosis
NCT0017867214	NCT00178672_14_T1	PHENOTYPE	12	14	carotid artery occlusion
NCT0017867215	NCT00178672_15_T0	ORGAN	3	4	carotid artery
NCT0017867216	NCT00178672_16_T0	PHENOTYPE	5	5	distal
NCT0017867216	NCT00178672_16_T1	PHENOTYPE	21	22	adverse events
NCT0017867217	NCT00178672_17_T0	PHENOTYPE	7	9	carotid artery disease
NCT0017867223	NCT00178672_23_T0	GENE	4	4	met
NCT0017867232	NCT00178672_32_T0	PHENOTYPE	31	31	dysfunction
NCT0017867232	NCT00178672_32_T1	PHENOTYPE	59	59	symptoms
NCT0017867232	NCT00178672_32_T2	PHENOTYPE	29	29	focal
NCT0017867232	NCT00178672_32_T3	PHENOTYPE	57	57	persistence
NCT0017867232	NCT00178672_32_T4	PHENOTYPE	49	50	completed strokes
NCT0017867232	NCT00178672_32_T5	PHENOTYPE	33	34	monocular blindness
NCT0017867232	NCT00178672_32_T6	ORGAN	17	18	carotid artery
NCT0017867232	NCT00178672_32_T7	PHENOTYPE	38	40	signs and symptoms
NCT0017867241	NCT00178672_41_T0	ORGAN	10	12	internal carotid artery
NCT0017867244	NCT00178672_44_T0	GENE	20	20	1.5
NCT0017867244	NCT00178672_44_T1	GENE	10	10	reduced
NCT0017867244	NCT00178672_44_T2	GENE	18	18	INR
NCT0017867244	NCT00178672_44_T3	COMPOUND	2	2	warfarin
NCT0017867247	NCT00178672_47_T0	GENE	31	31	cath
NCT0017867247	NCT00178672_47_T1	PHENOTYPE	9	11	negative pregnancy test
NCT0017867250	NCT00178672_50_T0	GENE	22	22	MRI
NCT0017867250	NCT00178672_50_T1	GENE	3	3	had
NCT0017867250	NCT00178672_50_T2	GENE	2	2	has
NCT0017867250	NCT00178672_50_T3	PHENOTYPE	5	6	intracranial hemorrhage
NCT0017867250	NCT00178672_50_T4	PHENOTYPE	7	8	hemorrhagic stroke
NCT0017867252	NCT00178672_52_T0	GENE	2	2	has
NCT0017867252	NCT00178672_52_T1	PHENOTYPE	5	6	mass lesion
NCT0017867255	NCT00178672_55_T0	COMPOUND	6	6	heparin
NCT0017867255	NCT00178672_55_T1	PHENOTYPE	4	4	allergies
NCT0017867255	NCT00178672_55_T2	COMPOUND	11	11	clopidogrel
NCT0017867255	NCT00178672_55_T3	COMPOUND	9	9	ticlopidine
NCT0017867255	NCT00178672_55_T4	GENE	2	2	has
NCT0017867257	NCT00178672_57_T0	GENE	2	2	has
NCT0017867259	NCT00178672_59_T0	PHENOTYPE	3	3	peripheral
NCT0017867259	NCT00178672_59_T1	GENE	2	2	has
NCT0017867259	NCT00178672_59_T2	PHENOTYPE	8	10	carotid artery tortuosity
NCT0017867259	NCT00178672_59_T3	ORGAN	7	9	internal carotid artery
NCT0017867263	NCT00178672_63_T0	GENE	4	4	has
NCT0017867263	NCT00178672_63_T1	PHENOTYPE	6	8	positive pregnancy test
NCT0017867265	NCT00178672_65_T0	PHENOTYPE	5	5	malformation
NCT0017867265	NCT00178672_65_T1	GENE	2	2	has
NCT001786852	NCT00178685_2_T0	PHENOTYPE	14	15	tobacco dependence
NCT001786853	NCT00178685_3_T0	PHENOTYPE	14	14	relapse
NCT001786853	NCT00178685_3_T1	PHENOTYPE	24	24	relapse
NCT001786854	NCT00178685_4_T0	PHENOTYPE	28	28	relapse
NCT001786854	NCT00178685_4_T1	GENE	7	7	extended
NCT001786859	NCT00178685_9_T0	GENE	1	1	SDT
NCT0017868516	NCT00178685_16_T0	GENE	15	15	mediator
NCT0017868518	NCT00178685_18_T0	PHENOTYPE	27	27	relapse
NCT0017868520	NCT00178685_20_T0	PHENOTYPE	9	9	regression
NCT0017868521	NCT00178685_21_T0	GENE	1	1	SDT
NCT0017868521	NCT00178685_21_T1	GENE	11	11	structural
NCT001786983	NCT00178698_3_T0	CELL	63	63	cells
NCT001786983	NCT00178698_3_T1	PHENOTYPE	28	29	lung cancer
NCT001786983	NCT00178698_3_T2	PHENOTYPE	31	32	gastric cancer
NCT001786989	NCT00178698_9_T0	PHENOTYPE	15	15	hyperthermia
NCT001786989	NCT00178698_9_T1	COMPOUND	4	4	cisplatin
NCT0017869810	NCT00178698_10_T0	BIOLOGICAL_PROCESS	22	23	immune response
NCT0017869811	NCT00178698_11_T0	COMPOUND	16	16	gemcitabine
NCT0017869811	NCT00178698_11_T1	GENE	10	10	IV
NCT0017869812	NCT00178698_12_T0	GENE	2	2	interferon-alpha
NCT0017869812	NCT00178698_12_T1	COMPOUND	4	4	gemcitabine
NCT0017869816	NCT00178698_16_T0	PHENOTYPE	10	10	discomfort
NCT0017869818	NCT00178698_18_T0	COMPOUND	11	11	gemcitabine
NCT0017869823	NCT00178698_23_T0	GENE	13	13	3.5
NCT0017869823	NCT00178698_23_T1	GENE	10	10	GM-CSF
NCT0017869823	NCT00178698_23_T2	PHENOTYPE	5	5	5-10
NCT0017869823	NCT00178698_23_T3	GENE	9	9	sargramostim
NCT0017869823	NCT00178698_23_T4	ORGAN	22	23	immune system
NCT0017869823	NCT00178698_23_T5	CELL	30	32	white blood cells
NCT0017869824	NCT00178698_24_T0	CELL	10	10	platelet
NCT0017869829	NCT00178698_29_T0	GENE	6	6	MRI
NCT001787113	NCT00178711_3_T0	PHENOTYPE	14	14	hypothermia
NCT001787114	NCT00178711_4_T0	PHENOTYPE	1	1	intent
NCT001787115	NCT00178711_5_T0	GENE	0	0	GOS
NCT001787115	NCT00178711_5_T1	PHENOTYPE	12	12	Severe
NCT0017871111	NCT00178711_11_T0	ORGAN	6	6	pupils
NCT0017871111	NCT00178711_11_T1	GENE	0	0	GCS
NCT0017871113	NCT00178711_13_T0	GENE	1	1	abdominal
NCT0017871116	NCT00178711_16_T0	PHENOTYPE	0	2	Positive pregnancy test
NCT001787242	NCT00178724_2_T0	GENE	8	8	MRI
NCT001787243	NCT00178724_3_T0	PHENOTYPE	10	12	spinal cord injury
NCT001787248	NCT00178724_8_T0	ORGAN	9	10	spinal cord
NCT0017872410	NCT00178724_10_T0	PHENOTYPE	4	4	hopes
NCT001787502	NCT00178750_2_T0	PHENOTYPE	7	7	anesthesia
NCT001787503	NCT00178750_3_T0	ORGAN	15	16	epidural space
NCT001787504	NCT00178750_4_T0	TISSUE	29	30	ligamentum flavum
NCT001787504	NCT00178750_4_T1	ORGAN	5	6	epidural space
NCT001787504	NCT00178750_4_T2	ORGAN	33	34	epidural space
NCT001787506	NCT00178750_6_T0	GENE	3	3	has
NCT001787506	NCT00178750_6_T1	ORGAN	16	17	epidural space
NCT001787507	NCT00178750_7_T0	GENE	2	2	has
NCT001787507	NCT00178750_7_T1	PHENOTYPE	1	1	anesthesia
NCT001787508	NCT00178750_8_T0	PHENOTYPE	16	16	anesthesia
NCT001787509	NCT00178750_9_T0	GENE	6	6	al
NCT001787509	NCT00178750_9_T1	PHENOTYPE	20	20	anesthesia
NCT001787509	NCT00178750_9_T2	GENE	5	5	et
NCT0017875011	NCT00178750_11_T0	GENE	1	1	has
NCT0017875012	NCT00178750_12_T0	PHENOTYPE	8	8	reflected
NCT0017875013	NCT00178750_13_T0	ORGAN	20	21	epidural space
NCT0017875015	NCT00178750_15_T0	PHENOTYPE	11	11	visualization
NCT001787631	NCT00178763_1_T0	CELL	7	7	cells
NCT001787634	NCT00178763_4_T0	PHENOTYPE	42	42	immunity
NCT001787634	NCT00178763_4_T1	PHENOTYPE	24	25	pancreas cancer
NCT001787634	NCT00178763_4_T2	PHENOTYPE	45	46	pancreas cancer
NCT001787636	NCT00178763_6_T0	PHENOTYPE	6	8	metastatic pancreatic cancer
NCT001787637	NCT00178763_7_T0	PHENOTYPE	49	49	toxicity
NCT001787637	NCT00178763_7_T1	GENE	35	35	interferon-alpha
NCT001787637	NCT00178763_7_T2	COMPOUND	29	29	HCl
NCT001787637	NCT00178763_7_T3	GENE	36	36	IFN-alpha
NCT001787637	NCT00178763_7_T4	COMPOUND	27	27	cisplatin
NCT001787637	NCT00178763_7_T5	PHENOTYPE	9	9	hyperthermia
NCT001787637	NCT00178763_7_T6	COMPOUND	28	28	gemcitabine
NCT001787637	NCT00178763_7_T7	COMPOUND	30	30	gemcitabine
NCT001787637	NCT00178763_7_T8	PHENOTYPE	53	54	pancreatic cancer
NCT001787637	NCT00178763_7_T9	PHENOTYPE	76	77	pancreatic cancer
NCT001787637	NCT00178763_7_T10	BIOLOGICAL_PROCESS	64	65	immune response
NCT001787637	NCT00178763_7_T11	PHENOTYPE	42	44	metastatic pancreas cancer
NCT001787637	NCT00178763_7_T12	PHENOTYPE	58	60	quality of life
NCT0017876311	NCT00178763_11_T0	PHENOTYPE	15	15	hyperthermia
NCT0017876312	NCT00178763_12_T0	COMPOUND	16	16	gemcitabine
NCT0017876312	NCT00178763_12_T1	GENE	10	10	IV
NCT0017876313	NCT00178763_13_T0	COMPOUND	4	4	gemcitabine
NCT0017876317	NCT00178763_17_T0	PHENOTYPE	7	7	discomfort
NCT0017876319	NCT00178763_19_T0	COMPOUND	11	11	gemcitabine
NCT0017876324	NCT00178763_24_T0	GENE	14	14	3.5
NCT0017876324	NCT00178763_24_T1	PHENOTYPE	5	5	5-10
NCT0017876324	NCT00178763_24_T2	GENE	9	9	sargramostim
NCT0017876324	NCT00178763_24_T3	ORGAN	23	24	immune system
NCT0017876324	NCT00178763_24_T4	CELL	31	33	white blood cells
NCT0017876325	NCT00178763_25_T0	CELL	0	2	White blood cells
NCT0017876326	NCT00178763_26_T0	CELL	10	10	platelet
NCT0017876331	NCT00178763_31_T0	GENE	6	6	MRI
NCT001787762	NCT00178776_2_T0	PHENOTYPE	5	6	cocaine abuse
NCT001787768	NCT00178776_8_T0	PHENOTYPE	11	12	Substance Abuse
NCT0017877611	NCT00178776_11_T0	COMPOUND	21	21	cocaine
NCT0017877615	NCT00178776_15_T0	PHENOTYPE	1	2	cocaine dependence
NCT001787891	NCT00178789_1_T0	PHENOTYPE	18	18	DVT
NCT001787891	NCT00178789_1_T1	PHENOTYPE	8	8	strategies
NCT001787891	NCT00178789_1_T2	PHENOTYPE	29	29	anticoagulation
NCT001787891	NCT00178789_1_T3	PHENOTYPE	15	17	deep venous thrombosis
NCT001787892	NCT00178789_2_T0	PHENOTYPE	11	11	DVT
NCT001787893	NCT00178789_3_T0	PHENOTYPE	16	16	DVT
NCT001787893	NCT00178789_3_T1	PHENOTYPE	15	15	proximal
NCT001787896	NCT00178789_6_T0	PHENOTYPE	30	30	DVT
NCT001787896	NCT00178789_6_T1	ORGAN	28	29	lower extremity
NCT001787897	NCT00178789_7_T0	PHENOTYPE	5	5	DVT
NCT001787897	NCT00178789_7_T1	PHENOTYPE	13	13	DVT
NCT001787898	NCT00178789_8_T0	PHENOTYPE	18	18	DVT
NCT0017878910	NCT00178789_10_T0	PHENOTYPE	9	9	DVT
NCT0017878910	NCT00178789_10_T1	GENE	25	25	2a
NCT0017878910	NCT00178789_10_T2	ORGAN	7	8	lower extremity
NCT0017878910	NCT00178789_10_T3	PHENOTYPE	1	3	signs and symptoms
NCT0017878911	NCT00178789_11_T0	GENE	11	11	2b
NCT0017878911	NCT00178789_11_T1	PHENOTYPE	7	7	DVT
NCT0017878911	NCT00178789_11_T2	GENE	10	10	OR
NCT0017878913	NCT00178789_13_T0	PHENOTYPE	3	3	DVT
NCT0017878913	NCT00178789_13_T1	ORGAN	1	2	lower extremity
NCT001788023	NCT00178802_3_T0	COMPOUND	17	17	1
NCT001788023	NCT00178802_3_T1	COMPOUND	27	27	2
NCT001788023	NCT00178802_3_T2	COMPOUND	38	38	3
NCT001788023	NCT00178802_3_T3	CELL	36	36	cells
NCT001788025	NCT00178802_5_T0	GENE	20	20	II
NCT001788025	NCT00178802_5_T1	PHENOTYPE	10	10	resistant
NCT001788025	NCT00178802_5_T2	PHENOTYPE	8	9	endometrial cancer
NCT001788027	NCT00178802_7_T0	COMPOUND	2	2	doxorubicin
NCT001788029	NCT00178802_9_T0	GENE	1	1	interferon-alpha
NCT0017880214	NCT00178802_14_T0	PHENOTYPE	13	13	tumor
NCT0017880214	NCT00178802_14_T1	ORGAN	14	14	microvasculature
NCT0017880214	NCT00178802_14_T2	ORGAN	8	9	immune system
NCT0017880216	NCT00178802_16_T0	PHENOTYPE	13	13	conscious
NCT0017880218	NCT00178802_18_T0	PHENOTYPE	10	10	discomfort
NCT0017880224	NCT00178802_24_T0	GENE	19	19	has
NCT0017880226	NCT00178802_26_T0	GENE	13	13	3.5
NCT0017880226	NCT00178802_26_T1	GENE	8	8	sargramostim
NCT0017880226	NCT00178802_26_T2	ORGAN	22	23	immune system
NCT0017880226	NCT00178802_26_T3	CELL	30	32	white blood cells
NCT0017880227	NCT00178802_27_T0	CELL	11	11	platelet
NCT0017880232	NCT00178802_32_T0	GENE	6	6	MRI
NCT0017880232	NCT00178802_32_T1	PHENOTYPE	14	14	tumor
NCT0017880232	NCT00178802_32_T2	GENE	15	15	has
NCT001788281	NCT00178828_1_T0	COMPOUND	9	9	dopamine
NCT001788282	NCT00178828_2_T0	GENE	2	2	has
NCT001788285	NCT00178828_5_T0	COMPOUND	9	9	dopamine
NCT001788286	NCT00178828_6_T0	GENE	2	2	has
NCT001788412	NCT00178841_2_T0	PHENOTYPE	9	9	localized
NCT001788415	NCT00178841_5_T0	PHENOTYPE	12	12	malignancy
NCT001788417	NCT00178841_7_T0	CELL	6	6	Peroxisome
NCT001788417	NCT00178841_7_T1	GENE	12	13	nuclear receptor
NCT001788540	NCT00178854_0_T0	GENE	8	8	SRI
NCT001788542	NCT00178854_2_T0	COMPOUND	15	15	risperidone
NCT001788543	NCT00178854_3_T0	COMPOUND	9	9	dopamine
NCT001788544	NCT00178854_4_T0	GENE	2	2	has
NCT001788801	NCT00178880_1_T0	GENE	11	11	MRI
NCT001788803	NCT00178880_3_T0	GENE	11	11	MRI
NCT001789061	NCT00178906_1_T0	PHENOTYPE	19	20	in remission
NCT001789061	NCT00178906_1_T1	PHENOTYPE	10	11	mental health
NCT001789196	NCT00178919_6_T0	PHENOTYPE	23	23	impairment
NCT001789196	NCT00178919_6_T1	PHENOTYPE	29	29	hypertension
NCT001789196	NCT00178919_6_T2	COMPOUND	8	9	nitric oxide
NCT001789196	NCT00178919_6_T3	COMPOUND	25	26	nitric oxide
NCT001789198	NCT00178919_8_T0	GENE	26	26	Hg
NCT001789198	NCT00178919_8_T1	PHENOTYPE	6	9	increase in blood pressure
NCT001789320	NCT00178932_0_T0	PHENOTYPE	3	3	Schizophrenia
NCT001789451	NCT00178945_1_T0	PHENOTYPE	8	9	cervical dystonia
NCT001789452	NCT00178945_2_T0	PHENOTYPE	4	4	chronic
NCT001789452	NCT00178945_2_T1	PHENOTYPE	0	1	Cervical dystonia
NCT001789452	NCT00178945_2_T2	PHENOTYPE	8	9	involuntary movements
NCT001789456	NCT00178945_6_T0	GENE	2	2	CD
NCT001789456	NCT00178945_6_T1	TISSUE	30	30	muscles
NCT001789456	NCT00178945_6_T2	GENE	26	26	toxin
NCT001789457	NCT00178945_7_T0	PHENOTYPE	0	0	Resistant
NCT001789458	NCT00178945_8_T0	GENE	11	11	CD
NCT001789458	NCT00178945_8_T1	GENE	1	1	toxin
NCT001789458	NCT00178945_8_T2	GENE	2	3	type A
NCT001789459	NCT00178945_9_T0	GENE	7	7	CD
NCT001789459	NCT00178945_9_T1	GENE	1	1	has
NCT0017894516	NCT00178945_16_T0	GENE	21	21	CD
NCT0017894517	NCT00178945_17_T0	GENE	25	25	CD
NCT0017894517	NCT00178945_17_T1	ORGAN	9	10	trigger points
NCT0017894518	NCT00178945_18_T0	GENE	15	15	CD
NCT0017894519	NCT00178945_19_T0	ORGAN	20	21	trigger points
NCT001789583	NCT00178958_3_T0	PHENOTYPE	10	10	schizophrenia
NCT001789583	NCT00178958_3_T1	PHENOTYPE	14	15	bipolar disorder
NCT001789583	NCT00178958_3_T2	PHENOTYPE	11	12	schizoaffective disorder
NCT0017895810	NCT00178958_10_T0	PHENOTYPE	6	7	substance dependence
NCT001789717	NCT00178971_7_T0	PHENOTYPE	10	10	Schizophrenia
NCT001789717	NCT00178971_7_T1	PHENOTYPE	12	13	Schizoaffective Disorder
NCT001789719	NCT00178971_9_T0	COMPOUND	5	5	olanzapine
NCT001789719	NCT00178971_9_T1	COMPOUND	7	7	risperidone
NCT0017897111	NCT00178971_11_T0	PHENOTYPE	6	7	neurological disorders
NCT0017897111	NCT00178971_11_T1	PHENOTYPE	3	4	brain damage
NCT0017897112	NCT00178971_12_T0	PHENOTYPE	4	5	substance dependence
NCT001789843	NCT00178984_3_T0	GENE	3	3	bowel
NCT001789844	NCT00178984_4_T0	BIOLOGICAL_PROCESS	4	5	gastric emptying
NCT001789972	NCT00178997_2_T0	ORGAN	16	16	intestines
NCT001789974	NCT00178997_4_T0	PHENOTYPE	26	27	blood supply
NCT001790103	NCT00179010_3_T0	COMPOUND	12	12	adenosine
NCT001790103	NCT00179010_3_T1	GENE	4	4	AMP
NCT001790105	NCT00179010_5_T0	COMPOUND	11	11	adenosine
NCT001790105	NCT00179010_5_T1	GENE	5	5	AMP
NCT001790106	NCT00179010_6_T0	COMPOUND	10	10	adenosine
NCT001790106	NCT00179010_6_T1	COMPOUND	22	22	adenosine
NCT001790106	NCT00179010_6_T2	GENE	12	12	AMP
NCT001790106	NCT00179010_6_T3	ORGAN	16	16	artery
NCT001790106	NCT00179010_6_T4	ORGAN	15	15	forearm
NCT001790106	NCT00179010_6_T5	ORGAN	25	25	forearm
NCT001790232	NCT00179023_2_T0	PHENOTYPE	11	12	energy expenditure
NCT001790233	NCT00179023_3_T0	GENE	4	4	SNS
NCT001790233	NCT00179023_3_T1	ORGAN	1	3	sympathetic nervous system
NCT001790234	NCT00179023_4_T0	PHENOTYPE	13	15	high blood pressure
NCT001790234	NCT00179023_4_T1	ORGAN	24	26	sympathetic nervous system
NCT001790235	NCT00179023_5_T0	COMPOUND	13	13	trimethaphan
NCT001790235	NCT00179023_5_T1	ORGAN	20	22	autonomic nervous system
NCT001790238	NCT00179023_8_T0	GENE	6	6	2.4
NCT0017902310	NCT00179023_10_T0	GENE	10	10	SNS
NCT0017902310	NCT00179023_10_T1	PHENOTYPE	19	20	energy expenditure
NCT0017902310	NCT00179023_10_T2	ORGAN	7	9	sympathetic nervous system
NCT0017902313	NCT00179023_13_T0	GENE	17	17	blocker
NCT0017902313	NCT00179023_13_T1	COMPOUND	1	1	2
NCT0017902313	NCT00179023_13_T2	COMPOUND	19	19	2
NCT0017902313	NCT00179023_13_T3	COMPOUND	24	24	3
NCT0017902313	NCT00179023_13_T4	PHENOTYPE	22	22	closed
NCT0017902313	NCT00179023_13_T5	GENE	20	20	has
NCT0017902313	NCT00179023_13_T6	PHENOTYPE	35	36	autonomic failure
NCT0017902316	NCT00179023_16_T0	PHENOTYPE	16	17	autonomic failure
NCT0017902318	NCT00179023_18_T0	PHENOTYPE	6	6	closed
NCT001790360	NCT00179036_0_T0	GENE	5	5	II
NCT001790360	NCT00179036_0_T1	PHENOTYPE	3	4	Intestinal Ischemia
NCT001790362	NCT00179036_2_T0	PHENOTYPE	18	18	hoping
NCT001790362	NCT00179036_2_T1	ORGAN	14	15	small intestine
NCT001790365	NCT00179036_5_T0	ORGAN	12	12	intestine
NCT001790365	NCT00179036_5_T1	PHENOTYPE	1	1	ischemia
NCT001790366	NCT00179036_6_T0	TISSUE	13	14	smooth muscle
NCT001790367	NCT00179036_7_T0	PHENOTYPE	10	11	mesenteric ischemia
NCT001790367	NCT00179036_7_T1	TISSUE	3	4	smooth muscle
NCT001790621	NCT00179062_1_T0	COMPOUND	16	16	glucose
NCT001790621	NCT00179062_1_T1	GENE	17	17	prolactin
NCT001790621	NCT00179062_1_T2	GENE	25	25	M3
NCT001790621	NCT00179062_1_T3	GENE	26	26	M6
NCT001790621	NCT00179062_1_T4	GENE	28	28	M12
NCT001790621	NCT00179062_1_T5	GENE	24	24	M-1
NCT001790621	NCT00179062_1_T6	PHENOTYPE	19	20	cholesterol levels
NCT001790626	NCT00179062_6_T0	PHENOTYPE	10	10	schizophrenia
NCT001790626	NCT00179062_6_T1	PHENOTYPE	19	20	psychotic symptoms
NCT001790626	NCT00179062_6_T2	PHENOTYPE	13	14	bipolar disorder
NCT001790626	NCT00179062_6_T3	PHENOTYPE	16	17	major depression
NCT001790626	NCT00179062_6_T4	PHENOTYPE	11	12	schizoaffective disorder
NCT0017906214	NCT00179062_14_T0	PHENOTYPE	21	21	schizophrenia
NCT0017906214	NCT00179062_14_T1	PHENOTYPE	46	46	psychosis
NCT0017906214	NCT00179062_14_T2	PHENOTYPE	24	25	bipolar disorder
NCT0017906214	NCT00179062_14_T3	PHENOTYPE	13	14	Mental Disorders
NCT0017906214	NCT00179062_14_T4	PHENOTYPE	22	23	schizoaffective disorder
NCT0017906214	NCT00179062_14_T5	PHENOTYPE	36	38	traumatic stress disorder
NCT0017906216	NCT00179062_16_T0	COMPOUND	6	6	olanzapine
NCT0017906216	NCT00179062_16_T1	COMPOUND	8	8	risperidone
NCT0017906216	NCT00179062_16_T2	GENE	1	1	has
NCT0017906218	NCT00179062_18_T0	COMPOUND	5	5	olanzapine
NCT0017906218	NCT00179062_18_T1	COMPOUND	7	7	risperidone
NCT0017906219	NCT00179062_19_T0	COMPOUND	8	8	olanzapine
NCT0017906219	NCT00179062_19_T1	COMPOUND	10	10	risperidone
NCT0017906221	NCT00179062_21_T0	COMPOUND	3	3	olanzapine
NCT0017906221	NCT00179062_21_T1	COMPOUND	12	12	risperidone
NCT0017906224	NCT00179062_24_T0	GENE	1	1	has
NCT0017906228	NCT00179062_28_T0	PHENOTYPE	6	7	substance dependence
NCT0017906235	NCT00179062_35_T0	PHENOTYPE	5	6	liver disease
NCT0017906238	NCT00179062_38_T0	BIOLOGICAL_PROCESS	4	4	eating
NCT0017906241	NCT00179062_41_T0	PHENOTYPE	5	6	neuroleptic malignant
NCT001791012	NCT00179101_2_T0	PHENOTYPE	4	6	quality of life
NCT001791015	NCT00179101_5_T0	PHENOTYPE	12	12	severity
NCT001791141	NCT00179114_1_T0	PHENOTYPE	0	0	Spasticity
NCT001791146	NCT00179114_6_T0	PHENOTYPE	2	2	spasticity
NCT001791147	NCT00179114_7_T0	PHENOTYPE	17	17	spasticity
NCT001791149	NCT00179114_9_T0	PHENOTYPE	8	8	spasticity
NCT001791272	NCT00179127_2_T0	GENE	7	7	insulin
NCT001791272	NCT00179127_2_T1	GENE	25	25	insulin
NCT001791272	NCT00179127_2_T2	PHENOTYPE	19	19	acidosis
NCT001791272	NCT00179127_2_T3	PHENOTYPE	16	16	DKA
NCT001791530	NCT00179153_0_T0	PHENOTYPE	7	7	Chronic
NCT001791530	NCT00179153_0_T1	PHENOTYPE	6	6	Malnourished
NCT001791535	NCT00179153_5_T0	GENE	5	5	1.0
NCT001791535	NCT00179153_5_T1	COMPOUND	10	10	urea
NCT001791536	NCT00179153_6_T0	PHENOTYPE	0	0	Progressive
NCT001791536	NCT00179153_6_T1	PHENOTYPE	2	3	weight loss
NCT001791538	NCT00179153_8_T0	PHENOTYPE	3	3	malnutrition
NCT001791539	NCT00179153_9_T0	GENE	4	4	4.0
NCT001791539	NCT00179153_9_T1	GENE	1	1	albumin
NCT001791539	NCT00179153_9_T2	ORGAN	0	0	Serum
NCT0017915310	NCT00179153_10_T0	GENE	1	1	transferrin
NCT0017915310	NCT00179153_10_T1	ORGAN	0	0	Serum
NCT0017915311	NCT00179153_11_T0	GENE	1	1	prealbumin
NCT0017915311	NCT00179153_11_T1	ORGAN	0	0	Serum
NCT001791922	NCT00179192_2_T0	PHENOTYPE	10	10	chronic
NCT001791923	NCT00179192_3_T0	PHENOTYPE	1	1	complication
NCT001791924	NCT00179192_4_T0	PHENOTYPE	12	12	thrombosis
NCT001791924	NCT00179192_4_T1	PHENOTYPE	20	20	complications
NCT001791924	NCT00179192_4_T2	GENE	26	26	longevity
NCT001791926	NCT00179192_6_T0	PHENOTYPE	21	21	thrombosis
NCT001791929	NCT00179192_9_T0	ORGAN	4	4	graft
NCT001791929	NCT00179192_9_T1	COMPOUND	3	3	polytetrafluoroethylene
NCT0017919211	NCT00179192_11_T0	PHENOTYPE	1	2	arteriovenous fistula
NCT0017919214	NCT00179192_14_T0	PHENOTYPE	0	0	Allergy
NCT0017919214	NCT00179192_14_T1	COMPOUND	2	2	iodine
NCT0017919215	NCT00179192_15_T0	PHENOTYPE	8	8	anesthesia
NCT001792055	NCT00179205_5_T0	PHENOTYPE	4	5	infectious disease
NCT001792056	NCT00179205_6_T0	PHENOTYPE	1	1	malignancy
NCT001792313	NCT00179231_3_T0	PHENOTYPE	16	16	schizophrenia
NCT001792313	NCT00179231_3_T1	PHENOTYPE	20	21	schizoaffective disorder
NCT001792316	NCT00179231_6_T0	GENE	5	5	al
NCT001792316	NCT00179231_6_T1	GENE	4	4	et
NCT0017923121	NCT00179231_21_T0	PHENOTYPE	5	5	arrhythmia
NCT0017923121	NCT00179231_21_T1	BIOLOGICAL_PROCESS	0	1	Cardiac conduction
NCT0017923123	NCT00179231_23_T0	PHENOTYPE	6	6	leukemia
NCT0017923123	NCT00179231_23_T1	PHENOTYPE	3	4	blood dyscrasia
NCT0017923125	NCT00179231_25_T0	PHENOTYPE	7	8	chronic hepatitis
NCT0017923125	NCT00179231_25_T1	PHENOTYPE	4	5	renal disease
NCT0017923131	NCT00179231_31_T0	PHENOTYPE	9	9	hypothyroidism
NCT0017923133	NCT00179231_33_T0	BIOLOGICAL_PROCESS	2	2	lactation
NCT0017923135	NCT00179231_35_T0	PHENOTYPE	2	4	substance use disorder
NCT001792442	NCT00179244_2_T0	PHENOTYPE	20	20	severity
NCT001792446	NCT00179244_6_T0	GENE	10	10	has
NCT001792446	NCT00179244_6_T1	GENE	14	14	has
NCT001792446	NCT00179244_6_T2	GENE	4	4	ER
NCT001792446	NCT00179244_6_T3	COMPOUND	3	3	bupropion
NCT001792446	NCT00179244_6_T4	GENE	5	5	extended
NCT001792447	NCT00179244_7_T0	COMPOUND	7	7	risperidone
NCT001792447	NCT00179244_7_T1	COMPOUND	22	22	risperidone
NCT001792447	NCT00179244_7_T2	PHENOTYPE	17	17	resistant
NCT001792447	NCT00179244_7_T3	GENE	10	10	ER
NCT001792447	NCT00179244_7_T4	COMPOUND	9	9	bupropion
NCT001792448	NCT00179244_8_T0	COMPOUND	26	26	risperidone
NCT001792448	NCT00179244_8_T1	GENE	29	29	ER
NCT001792448	NCT00179244_8_T2	COMPOUND	28	28	bupropion
NCT001792570	NCT00179257_0_T0	GENE	8	8	Had
NCT001792573	NCT00179257_3_T0	COMPOUND	20	20	escitalopram
NCT001792574	NCT00179257_4_T0	COMPOUND	14	14	escitalopram
NCT001792575	NCT00179257_5_T0	GENE	26	26	transporter
NCT001792575	NCT00179257_5_T1	COMPOUND	6	6	escitalopram
NCT001792575	NCT00179257_5_T2	COMPOUND	19	19	escitalopram
NCT001792575	NCT00179257_5_T3	GENE	7	7	has
NCT001792575	NCT00179257_5_T4	COMPOUND	3	3	citalopram
NCT001792575	NCT00179257_5_T5	GENE	13	14	serotonin transporter
NCT001792831	NCT00179283_1_T0	GENE	6	6	1.1
NCT001792831	NCT00179283_1_T1	COMPOUND	13	13	venlafaxine
NCT001792831	NCT00179283_1_T2	COMPOUND	11	11	sertraline
NCT001792833	NCT00179283_3_T0	GENE	6	6	1.1
NCT001792833	NCT00179283_3_T1	COMPOUND	13	13	venlafaxine
NCT001792833	NCT00179283_3_T2	COMPOUND	11	11	sertraline
NCT001792834	NCT00179283_4_T0	PHENOTYPE	27	27	symptoms
NCT001792834	NCT00179283_4_T1	PHENOTYPE	24	24	severity
NCT001792834	NCT00179283_4_T2	PHENOTYPE	38	38	acute
NCT001792834	NCT00179283_4_T3	COMPOUND	17	17	venlafaxine
NCT001792834	NCT00179283_4_T4	COMPOUND	43	43	venlafaxine
NCT001792834	NCT00179283_4_T5	COMPOUND	15	15	sertraline
NCT001792834	NCT00179283_4_T6	COMPOUND	41	41	sertraline
NCT001793091	NCT00179309_1_T0	COMPOUND	7	7	docetaxel
NCT001793091	NCT00179309_1_T1	PHENOTYPE	11	11	cancers
NCT001793091	NCT00179309_1_T2	GENE	5	5	has
NCT001793091	NCT00179309_1_T3	PHENOTYPE	13	14	breast cancer
NCT001793095	NCT00179309_5_T0	GENE	27	27	MUC-1
NCT001793095	NCT00179309_5_T1	GENE	25	25	mucin
NCT001793095	NCT00179309_5_T2	GENE	13	13	has
NCT001793095	NCT00179309_5_T3	GENE	23	23	CEA
NCT001793095	NCT00179309_5_T4	PHENOTYPE	8	10	metastatic breast cancer
NCT001793096	NCT00179309_6_T0	GENE	8	8	A2
NCT001793096	NCT00179309_6_T1	CELL	6	6	leukocyte
NCT001793097	NCT00179309_7_T0	COMPOUND	5	5	docetaxel
NCT0017930912	NCT00179309_12_T0	COMPOUND	17	17	docetaxel
NCT0017930913	NCT00179309_13_T0	CELL	16	16	cells
NCT0017930913	NCT00179309_13_T1	GENE	9	9	sargramostim
NCT0017930915	NCT00179309_15_T0	ORGAN	15	15	thigh
NCT0017930915	NCT00179309_15_T1	GENE	3	3	sargramostim
NCT0017930917	NCT00179309_17_T0	PHENOTYPE	9	11	drug side effects
NCT0017930920	NCT00179309_20_T0	COMPOUND	4	4	docetaxel
NCT0017930924	NCT00179309_24_T0	PHENOTYPE	15	16	disease progression
NCT0017930925	NCT00179309_25_T0	COMPOUND	11	11	docetaxel
NCT0017930925	NCT00179309_25_T1	GENE	7	7	pox
NCT0017930930	NCT00179309_30_T0	PHENOTYPE	11	12	metastatic disease
NCT0017930930	NCT00179309_30_T1	PHENOTYPE	1	3	Metastatic breast cancer
NCT0017930932	NCT00179309_32_T0	PHENOTYPE	26	26	Hgb
NCT0017930932	NCT00179309_32_T1	CELL	9	9	Granulocyte
NCT0017930932	NCT00179309_32_T2	GENE	25	25	hemoglobin
NCT0017930932	NCT00179309_32_T3	PHENOTYPE	17	18	Platelet count
NCT0017930934	NCT00179309_34_T0	COMPOUND	3	3	docetaxel
NCT0017930934	NCT00179309_34_T1	PHENOTYPE	16	17	disease progression
NCT0017930936	NCT00179309_36_T0	GENE	6	6	MUC-1
NCT0017930936	NCT00179309_36_T1	GENE	4	4	CEA
NCT0017930943	NCT00179309_43_T0	COMPOUND	8	8	creatinine
NCT0017930945	NCT00179309_45_T0	GENE	3	3	3.4
NCT0017930947	NCT00179309_47_T0	CELL	0	0	Granulocyte
NCT0017930948	NCT00179309_48_T0	PHENOTYPE	0	1	Platelet count
NCT0017930958	NCT00179309_58_T0	PHENOTYPE	1	2	autoimmune diseases
NCT0017930958	NCT00179309_58_T1	PHENOTYPE	9	10	autoimmune disease
NCT0017930959	NCT00179309_59_T0	PHENOTYPE	10	10	autoimmunity
NCT0017930959	NCT00179309_59_T1	PHENOTYPE	28	28	vitiligo
NCT0017930959	NCT00179309_59_T2	PHENOTYPE	22	23	thyroid disease
NCT0017930959	NCT00179309_59_T3	PHENOTYPE	13	14	endocrine disease
NCT0017932217	NCT00179322_17_T0	PHENOTYPE	20	20	alertness
NCT0017932218	NCT00179322_18_T0	PHENOTYPE	18	18	alertness
NCT0017932218	NCT00179322_18_T1	PHENOTYPE	14	14	inhibition
NCT0017932218	NCT00179322_18_T2	PHENOTYPE	2	3	decision making
NCT0017932221	NCT00179322_21_T0	PHENOTYPE	1	2	decision making
NCT0017932222	NCT00179322_22_T0	PHENOTYPE	20	21	behavioral changes
NCT001793354	NCT00179335_4_T0	GENE	11	11	am
NCT001793359	NCT00179335_9_T0	ORGAN	1	1	plasma
NCT001793359	NCT00179335_9_T1	PHENOTYPE	24	25	drug levels
NCT0017933510	NCT00179335_10_T0	GENE	6	6	ACS
NCT001793480	NCT00179348_0_T0	PHENOTYPE	13	13	Cancer
NCT001793482	NCT00179348_2_T0	PHENOTYPE	18	19	colorectal cancer
NCT001793482	NCT00179348_2_T1	PHENOTYPE	9	11	quality of life
NCT001793484	NCT00179348_4_T0	PHENOTYPE	10	10	QOL
NCT001793484	NCT00179348_4_T1	PHENOTYPE	12	13	breast cancer
NCT001793484	NCT00179348_4_T2	PHENOTYPE	7	9	quality of life
NCT001793486	NCT00179348_6_T0	PHENOTYPE	14	14	impairment
NCT001793486	NCT00179348_6_T1	PHENOTYPE	13	13	QOL
NCT001793488	NCT00179348_8_T0	PHENOTYPE	10	11	colorectal cancer
NCT0017934810	NCT00179348_10_T0	GENE	18	18	1.5
NCT0017934811	NCT00179348_11_T0	GENE	1	1	II
NCT0017934811	NCT00179348_11_T1	GENE	17	18	Group I
NCT001793611	NCT00179361_1_T0	PHENOTYPE	17	17	tumors
NCT001793612	NCT00179361_2_T0	BIOLOGICAL_PROCESS	10	11	gene expression
NCT001793613	NCT00179361_3_T0	TISSUE	15	15	tissues
NCT001793613	NCT00179361_3_T1	PHENOTYPE	12	12	tumorigenesis
NCT001793613	NCT00179361_3_T2	PHENOTYPE	18	18	understood
NCT001793613	NCT00179361_3_T3	BIOLOGICAL_PROCESS	4	5	gene expression
NCT001793616	NCT00179361_6_T0	CELL	12	12	cells
NCT001793616	NCT00179361_6_T1	PHENOTYPE	15	15	plaques
NCT001793616	NCT00179361_6_T2	TISSUE	29	29	mucosa
NCT001793617	NCT00179361_7_T0	GENE	8	8	cDNA
NCT001793617	NCT00179361_7_T1	BIOLOGICAL_PROCESS	2	3	gene expression
NCT001793618	NCT00179361_8_T0	PHENOTYPE	1	1	dysplasia
NCT0017936110	NCT00179361_10_T0	PHENOTYPE	21	21	centers
NCT001793743	NCT00179374_3_T0	GENE	18	18	2a
NCT001793748	NCT00179374_8_T0	PHENOTYPE	16	16	complications
NCT0017937411	NCT00179374_11_T0	GENE	2	2	has
NCT0017937414	NCT00179374_14_T0	GENE	18	18	2a
NCT0017937417	NCT00179374_17_T0	GENE	10	10	masking
NCT0017937421	NCT00179374_21_T0	PHENOTYPE	13	13	perceptions
NCT0017937421	NCT00179374_21_T1	PHENOTYPE	15	16	depressive symptoms
NCT001793872	NCT00179387_2_T0	PHENOTYPE	11	11	impairment
NCT001793872	NCT00179387_2_T1	PHENOTYPE	10	10	QOL
NCT001793873	NCT00179387_3_T0	PHENOTYPE	23	24	advanced cancer
NCT001793873	NCT00179387_3_T1	PHENOTYPE	17	19	quality of life
NCT001793875	NCT00179387_5_T0	PHENOTYPE	0	2	Quality of life
NCT001794002	NCT00179400_2_T0	GENE	14	14	insulin
NCT001794002	NCT00179400_2_T1	GENE	7	7	EPA
NCT001794002	NCT00179400_2_T2	PHENOTYPE	18	20	blood sugar levels
NCT001794132	NCT00179413_2_T0	PHENOTYPE	23	23	fibrosis
NCT001794133	NCT00179413_3_T0	PHENOTYPE	14	14	progression
NCT001794133	NCT00179413_3_T1	PHENOTYPE	21	22	liver failure
NCT001794133	NCT00179413_3_T2	PHENOTYPE	16	17	liver disease
NCT001794133	NCT00179413_3_T3	PHENOTYPE	24	25	liver cancer
NCT001794139	NCT00179413_9_T0	GENE	3	3	had
NCT001794139	NCT00179413_9_T1	GENE	5	5	interferon
NCT0017941312	NCT00179413_12_T0	ORGAN	5	5	liver
NCT0017941312	NCT00179413_12_T1	GENE	3	3	had
NCT0017941313	NCT00179413_13_T0	ORGAN	2	2	liver
NCT0017941315	NCT00179413_15_T0	PHENOTYPE	3	3	cirrhosis
NCT0017941315	NCT00179413_15_T1	PHENOTYPE	8	9	portal hypertension
NCT0017941317	NCT00179413_17_T0	ORGAN	6	6	liver
NCT0017941318	NCT00179413_18_T0	ORGAN	31	31	liver
NCT0017941318	NCT00179413_18_T1	PHENOTYPE	20	20	progression
NCT0017941318	NCT00179413_18_T2	PHENOTYPE	22	22	coagulopathy
NCT0017941318	NCT00179413_18_T3	GENE	39	39	Dr
NCT0017941318	NCT00179413_18_T4	GENE	38	38	PI
NCT0017941321	NCT00179413_21_T0	CELL	1	1	platelets
NCT0017941325	NCT00179413_25_T0	PHENOTYPE	10	10	initiation
NCT0017941330	NCT00179413_30_T0	GENE	3	3	has
NCT0017941330	NCT00179413_30_T1	PHENOTYPE	7	8	substance abuse
NCT0017941332	NCT00179413_32_T0	PHENOTYPE	15	15	psychoses
NCT0017941332	NCT00179413_32_T1	PHENOTYPE	17	17	ideation
NCT0017941332	NCT00179413_32_T2	PHENOTYPE	10	11	psychiatric disorder
NCT0017941333	NCT00179413_33_T0	PHENOTYPE	5	6	mild depression
NCT0017941334	NCT00179413_34_T0	PHENOTYPE	13	13	symptoms
NCT0017941334	NCT00179413_34_T1	PHENOTYPE	0	1	Mild depression
NCT0017941335	NCT00179413_35_T0	PHENOTYPE	5	5	manic
NCT001794523	NCT00179452_3_T0	PHENOTYPE	4	4	seizure
NCT001794523	NCT00179452_3_T1	PHENOTYPE	0	1	Side effects
NCT001794523	NCT00179452_3_T2	PHENOTYPE	7	9	quality of life
NCT001794527	NCT00179452_7_T0	PHENOTYPE	16	16	generalized
NCT001794527	NCT00179452_7_T1	PHENOTYPE	8	8	seizure
NCT0017945217	NCT00179452_17_T0	PHENOTYPE	5	6	atonic seizures
NCT0017945217	NCT00179452_17_T1	PHENOTYPE	1	3	primary generalized epilepsy
NCT0017945219	NCT00179452_19_T0	PHENOTYPE	4	5	status epilepticus
NCT001794654	NCT00179465_4_T0	COMPOUND	9	9	tiagabine
NCT001794783	NCT00179478_3_T0	GENE	3	3	extended
NCT001794912	NCT00179491_2_T0	GENE	23	23	bypass
NCT001794912	NCT00179491_2_T1	ORGAN	24	24	graft
NCT001794912	NCT00179491_2_T2	ORGAN	21	22	coronary artery
NCT001794915	NCT00179491_5_T0	GENE	23	23	bypass
NCT001794915	NCT00179491_5_T1	ORGAN	24	24	graft
NCT001794915	NCT00179491_5_T2	ORGAN	21	22	coronary artery
NCT001795041	NCT00179504_1_T0	GENE	11	11	RR
NCT001795043	NCT00179504_3_T0	GENE	11	11	RR
NCT001795173	NCT00179517_3_T0	PHENOTYPE	2	2	seizure
NCT001795560	NCT00179556_0_T0	PHENOTYPE	5	5	Menopausal
NCT001795560	NCT00179556_0_T1	PHENOTYPE	6	7	Hot Flashes
NCT001795562	NCT00179556_2_T0	GENE	1	1	has
NCT001795562	NCT00179556_2_T1	GENE	10	10	soy
NCT001795562	NCT00179556_2_T2	PHENOTYPE	15	16	hot flashes
NCT001795563	NCT00179556_3_T0	PHENOTYPE	21	21	symptoms
NCT001795563	NCT00179556_3_T1	PHENOTYPE	16	16	menopausal
NCT001795563	NCT00179556_3_T2	GENE	8	8	soy
NCT001795563	NCT00179556_3_T3	PHENOTYPE	19	20	hot flash
NCT001795565	NCT00179556_5_T0	GENE	1	1	has
NCT001795565	NCT00179556_5_T1	GENE	10	10	soy
NCT001795565	NCT00179556_5_T2	PHENOTYPE	15	16	hot flashes
NCT001795566	NCT00179556_6_T0	PHENOTYPE	16	16	severity
NCT001795566	NCT00179556_6_T1	COMPOUND	4	4	daidzein
NCT001795566	NCT00179556_6_T2	BIOLOGICAL_PROCESS	10	10	fermentation
NCT001795566	NCT00179556_6_T3	GENE	8	8	soy
NCT001795566	NCT00179556_6_T4	PHENOTYPE	20	21	hot flashes
NCT001795567	NCT00179556_7_T0	PHENOTYPE	16	16	severity
NCT001795567	NCT00179556_7_T1	PHENOTYPE	12	13	hot flash
NCT001795569	NCT00179556_9_T0	BIOLOGICAL_PROCESS	16	16	fermentation
NCT001795569	NCT00179556_9_T1	GENE	4	4	TM
NCT001795569	NCT00179556_9_T2	COMPOUND	27	27	ethanol
NCT0017955610	NCT00179556_10_T0	COMPOUND	5	5	daidzein
NCT0017955610	NCT00179556_10_T1	COMPOUND	7	7	daidzein
NCT0017955610	NCT00179556_10_T2	COMPOUND	9	9	genistein
NCT0017955610	NCT00179556_10_T3	COMPOUND	12	12	glycitein
NCT001795820	NCT00179582_0_T0	COMPOUND	5	5	Probiotic
NCT001795820	NCT00179582_0_T1	PHENOTYPE	9	9	Diarrhea
NCT001795820	NCT00179582_0_T2	PHENOTYPE	10	10	IBS
NCT001795950	NCT00179595_0_T0	GENE	7	7	cute
NCT001795950	NCT00179595_0_T1	PHENOTYPE	5	6	Acute Stress
NCT001795954	NCT00179595_4_T0	PHENOTYPE	22	22	meditation
NCT0017959510	NCT00179595_10_T0	PHENOTYPE	22	22	meditation
NCT001796080	NCT00179608_0_T0	PHENOTYPE	12	14	Metastatic Malignant Melanoma
NCT001796082	NCT00179608_2_T0	COMPOUND	13	13	lenalidomide
NCT001796083	NCT00179608_3_T0	COMPOUND	4	4	lenalidomide
NCT001796088	NCT00179608_8_T0	PHENOTYPE	3	4	malignant melanoma
NCT001796088	NCT00179608_8_T1	PHENOTYPE	8	9	metastatic disease
NCT001796089	NCT00179608_9_T0	GENE	18	18	II
NCT001796089	NCT00179608_9_T1	GENE	7	7	MTD
NCT001796089	NCT00179608_9_T2	ORGAN	17	17	Appendix
NCT001796089	NCT00179608_9_T3	PHENOTYPE	11	12	measurable lesion
NCT0017960810	NCT00179608_10_T0	ORGAN	9	9	Appendix
NCT0017960812	NCT00179608_12_T0	CELL	1	1	neutrophil
NCT0017960813	NCT00179608_13_T0	PHENOTYPE	0	1	Platelet count
NCT0017960814	NCT00179608_14_T0	COMPOUND	1	1	creatinine
NCT0017960814	NCT00179608_14_T1	GENE	7	7	1.5
NCT0017960814	NCT00179608_14_T2	ORGAN	0	0	Serum
NCT0017960815	NCT00179608_15_T0	GENE	7	7	1.5
NCT0017960815	NCT00179608_15_T1	GENE	0	1	Total bilirubin
NCT0017960817	NCT00179608_17_T0	ORGAN	9	9	serum
NCT0017960819	NCT00179608_19_T0	PHENOTYPE	1	1	acute
NCT0017960819	NCT00179608_19_T1	PHENOTYPE	5	5	alopecia
NCT0017960819	NCT00179608_19_T2	COMPOUND	21	21	NCI
NCT0017960819	NCT00179608_19_T3	PHENOTYPE	12	12	resolved
NCT0017960819	NCT00179608_19_T4	PHENOTYPE	2	3	adverse effects
NCT0017960819	NCT00179608_19_T5	PHENOTYPE	19	20	grade 1
NCT0017960822	NCT00179608_22_T0	PHENOTYPE	6	6	illnesses
NCT0017960825	NCT00179608_25_T0	COMPOUND	7	7	thalidomide
NCT0017960826	NCT00179608_26_T0	GENE	16	16	has
NCT0017960826	NCT00179608_26_T1	PHENOTYPE	20	21	disease progression
NCT0017960830	NCT00179608_30_T0	COMPOUND	2	2	thalidomide
NCT0017960831	NCT00179608_31_T0	COMPOUND	11	11	thalidomide
NCT0017960831	NCT00179608_31_T1	PHENOTYPE	8	9	allergic reaction
NCT0017960833	NCT00179608_33_T0	COMPOUND	4	4	lenalidomide
NCT0017960834	NCT00179608_34_T0	PHENOTYPE	4	5	other cancer
NCT0017960835	NCT00179608_35_T0	PHENOTYPE	5	5	melanoma
NCT0017960837	NCT00179608_37_T0	ORGAN	0	2	Central nervous system
NCT001796210	NCT00179621_0_T0	PHENOTYPE	8	8	Deletion
NCT001796210	NCT00179621_0_T1	PHENOTYPE	4	5	Myelodysplastic Syndromes
NCT0017962112	NCT00179621_12_T0	COMPOUND	7	7	1
NCT0017962112	NCT00179621_12_T1	COMPOUND	11	11	2
NCT0017962112	NCT00179621_12_T2	COMPOUND	16	16	3
NCT0017962114	NCT00179621_14_T0	GENE	4	4	RBC
NCT0017962114	NCT00179621_14_T1	GENE	39	39	RBC
NCT0017962114	NCT00179621_14_T2	GENE	11	11	had
NCT0017962114	NCT00179621_14_T3	GENE	18	18	had
NCT0017962114	NCT00179621_14_T4	GENE	20	20	met
NCT0017962115	NCT00179621_15_T0	GENE	1	1	RBC
NCT0017962115	NCT00179621_15_T1	GENE	14	14	RBC
NCT0017962115	NCT00179621_15_T2	GENE	3	3	had
NCT0017962116	NCT00179621_16_T0	GENE	22	22	1.28
NCT0017962116	NCT00179621_16_T1	GENE	27	27	1.28
NCT0017962116	NCT00179621_16_T2	COMPOUND	11	11	lenalidomide
NCT0017962116	NCT00179621_16_T3	COMPOUND	17	17	lenalidomide
NCT0017962119	NCT00179621_19_T0	GENE	8	8	ferritin
NCT0017962119	NCT00179621_19_T1	GENE	10	10	EPO
NCT0017962119	NCT00179621_19_T2	ORGAN	5	5	serum
NCT0017962119	NCT00179621_19_T3	ORGAN	7	7	plasma
NCT0017962120	NCT00179621_20_T0	PHENOTYPE	41	41	toxicity
NCT0017962120	NCT00179621_20_T1	PHENOTYPE	36	36	relapse
NCT0017962120	NCT00179621_20_T2	PHENOTYPE	37	38	disease progression
NCT0017962122	NCT00179621_22_T0	PHENOTYPE	20	20	relapse
NCT0017962122	NCT00179621_22_T1	COMPOUND	32	32	lenalidomide
NCT0017962122	NCT00179621_22_T2	PHENOTYPE	16	17	disease progression
NCT0017962125	NCT00179621_25_T0	PHENOTYPE	29	29	withdrawn
NCT0017962125	NCT00179621_25_T1	COMPOUND	11	11	lenalidomide
NCT0017962125	NCT00179621_25_T2	PHENOTYPE	2	3	disease progression
NCT0017962128	NCT00179621_28_T0	ORGAN	0	1	Bone marrow
NCT0017962128	NCT00179621_28_T1	PHENOTYPE	28	29	disease progression
NCT0017962129	NCT00179621_29_T0	PHENOTYPE	5	5	pathology
NCT0017962134	NCT00179621_34_T0	CELL	5	5	granulocyte
NCT0017962134	NCT00179621_34_T1	CELL	10	10	granulocyte
NCT0017962134	NCT00179621_34_T2	CELL	11	11	macrophage
NCT0017962134	NCT00179621_34_T3	GENE	8	8	G-CSF
NCT0017962134	NCT00179621_34_T4	GENE	14	14	GM-CSF
NCT001796341	NCT00179634_1_T0	PHENOTYPE	4	5	breast cancer
NCT001796344	NCT00179634_4_T0	PHENOTYPE	8	8	visualization
NCT001796348	NCT00179634_8_T0	PHENOTYPE	14	14	Response
NCT001796348	NCT00179634_8_T1	GENE	3	3	has
NCT001796348	NCT00179634_8_T2	PHENOTYPE	16	16	Imagery
NCT001796349	NCT00179634_9_T0	PHENOTYPE	15	15	anesthesia
NCT0017963410	NCT00179634_10_T0	GENE	4	4	has
NCT0017963410	NCT00179634_10_T1	PHENOTYPE	19	20	stress reactions
NCT0017963411	NCT00179634_11_T0	PHENOTYPE	16	17	breast cancer
NCT0017963413	NCT00179634_13_T0	PHENOTYPE	5	6	bone fracture
NCT0017963414	NCT00179634_14_T0	BIOLOGICAL_PROCESS	6	7	wound healing
NCT0017963414	NCT00179634_14_T1	PHENOTYPE	5	6	surgical wound
NCT0017963415	NCT00179634_15_T0	PHENOTYPE	11	12	breast cancer
NCT001796472	NCT00179647_2_T0	GENE	2	2	met
NCT001796474	NCT00179647_4_T0	COMPOUND	7	7	lenalidomide
NCT001796475	NCT00179647_5_T0	COMPOUND	6	6	dexamethasone
NCT001796475	NCT00179647_5_T1	COMPOUND	18	18	dexamethasone
NCT001796475	NCT00179647_5_T2	GENE	1	1	had
NCT001796476	NCT00179647_6_T0	COMPOUND	4	4	dexamethasone
NCT001796476	NCT00179647_6_T1	GENE	15	15	1.4
NCT001796476	NCT00179647_6_T2	PHENOTYPE	3	3	pulse
NCT001796477	NCT00179647_7_T0	COMPOUND	4	4	dexamethasone
NCT001796477	NCT00179647_7_T1	GENE	15	15	1.4
NCT001796477	NCT00179647_7_T2	PHENOTYPE	3	3	pulse
NCT001796478	NCT00179647_8_T0	COMPOUND	3	3	dexamethasone
NCT001796479	NCT00179647_9_T0	PHENOTYPE	8	9	disease progression
NCT0017964710	NCT00179647_10_T0	PHENOTYPE	23	23	toxicity
NCT0017964710	NCT00179647_10_T1	GENE	7	7	reduced
NCT0017964710	NCT00179647_10_T2	COMPOUND	2	2	lenalidomide
NCT0017964710	NCT00179647_10_T3	COMPOUND	22	22	lenalidomide
NCT0017964712	NCT00179647_12_T0	PHENOTYPE	14	14	toxicity
NCT0017964712	NCT00179647_12_T1	COMPOUND	8	8	dexamethasone
NCT0017964712	NCT00179647_12_T2	COMPOUND	13	13	dexamethasone
NCT0017964713	NCT00179647_13_T0	COMPOUND	6	6	dexamethasone
NCT0017964714	NCT00179647_14_T0	COMPOUND	35	35	lenalidomide
NCT0017964714	NCT00179647_14_T1	PHENOTYPE	23	24	disease progression
NCT0017964722	NCT00179647_22_T0	PHENOTYPE	15	15	myeloma
NCT0017964722	NCT00179647_22_T1	PHENOTYPE	8	8	progressing
NCT0017964722	NCT00179647_22_T2	GENE	19	19	has
NCT0017964722	NCT00179647_22_T3	PHENOTYPE	4	5	multiple myeloma
NCT0017964722	NCT00179647_22_T4	PHENOTYPE	22	23	progressive disease
NCT0017964724	NCT00179647_24_T0	COMPOUND	7	7	thalidomide
NCT0017964725	NCT00179647_25_T0	PHENOTYPE	26	26	satisfied
NCT0017964727	NCT00179647_27_T0	PHENOTYPE	3	3	myeloma
NCT0017964727	NCT00179647_27_T1	ORGAN	6	6	serum
NCT0017964729	NCT00179647_29_T0	PHENOTYPE	2	2	Oncology
NCT0017964731	NCT00179647_31_T0	ORGAN	9	9	serum
NCT0017964734	NCT00179647_34_T0	PHENOTYPE	4	5	laboratory abnormality
NCT0017964734	NCT00179647_34_T1	PHENOTYPE	7	8	psychiatric illness
NCT0017964738	NCT00179647_38_T0	PHENOTYPE	6	7	laboratory abnormalities
NCT0017964740	NCT00179647_40_T0	PHENOTYPE	4	5	laboratory abnormalities
NCT0017964741	NCT00179647_41_T0	GENE	6	6	1.0
NCT0017964741	NCT00179647_41_T1	GENE	3	3	ANC
NCT0017964741	NCT00179647_41_T2	CELL	1	1	neutrophil
NCT0017964742	NCT00179647_42_T0	ORGAN	14	14	marrow
NCT0017964742	NCT00179647_42_T1	CELL	16	16	cells
NCT0017964742	NCT00179647_42_T2	CELL	18	19	plasma cells
NCT0017964742	NCT00179647_42_T3	PHENOTYPE	0	1	Platelet count
NCT0017964744	NCT00179647_44_T0	CELL	14	14	cells
NCT0017964744	NCT00179647_44_T1	CELL	16	17	plasma cells
NCT0017964744	NCT00179647_44_T2	PHENOTYPE	0	1	Platelet count
NCT0017964744	NCT00179647_44_T3	ORGAN	11	12	bone marrow
NCT0017964748	NCT00179647_48_T0	GENE	3	3	2.0
NCT0017964748	NCT00179647_48_T1	ORGAN	0	0	Serum
NCT0017964748	NCT00179647_48_T2	PHENOTYPE	1	2	total bilirubin
NCT0017964753	NCT00179647_53_T0	COMPOUND	7	7	dexamethasone
NCT001796607	NCT00179660_7_T0	PHENOTYPE	1	2	Hodgkin's lymphoma
NCT001796609	NCT00179660_9_T0	PHENOTYPE	7	7	lymphoma
NCT0017966013	NCT00179660_13_T0	GENE	14	14	cm
NCT0017966013	NCT00179660_13_T1	PHENOTYPE	3	4	measurable disease
NCT0017966015	NCT00179660_15_T0	PHENOTYPE	2	2	Oncology
NCT0017966017	NCT00179660_17_T0	ORGAN	9	9	serum
NCT0017966020	NCT00179660_20_T0	PHENOTYPE	4	5	laboratory abnormalities
NCT0017966021	NCT00179660_21_T0	GENE	3	3	ANC
NCT0017966021	NCT00179660_21_T1	GENE	6	6	1.5
NCT0017966021	NCT00179660_21_T2	CELL	1	1	neutrophil
NCT0017966022	NCT00179660_22_T0	PHENOTYPE	0	1	Platelet count
NCT0017966025	NCT00179660_25_T0	GENE	3	3	2.0
NCT0017966025	NCT00179660_25_T1	ORGAN	0	0	Serum
NCT0017966025	NCT00179660_25_T2	PHENOTYPE	1	2	total bilirubin
NCT0017966026	NCT00179660_26_T0	PHENOTYPE	6	7	laboratory abnormalities
NCT0017966027	NCT00179660_27_T0	GENE	46	46	MRI
NCT0017966027	NCT00179660_27_T1	GENE	17	17	has
NCT0017966027	NCT00179660_27_T2	ORGAN	3	5	central nervous system
NCT0017966030	NCT00179660_30_T0	PHENOTYPE	4	5	laboratory abnormality
NCT0017966030	NCT00179660_30_T1	PHENOTYPE	7	8	psychiatric illness
NCT001796731	NCT00179673_1_T0	GENE	18	18	CR
NCT001796731	NCT00179673_1_T1	PHENOTYPE	10	11	disease progression
NCT001796735	NCT00179673_5_T0	PHENOTYPE	10	11	adverse events
NCT001796737	NCT00179673_7_T0	COMPOUND	19	19	lenalidomide
NCT001796737	NCT00179673_7_T1	PHENOTYPE	16	17	disease progression
NCT0017967314	NCT00179673_14_T0	PHENOTYPE	0	1	Indolent lymphoma
NCT0017967315	NCT00179673_15_T0	PHENOTYPE	2	2	lymphoma
NCT0017967316	NCT00179673_16_T0	TISSUE	6	6	mucosa
NCT0017967316	NCT00179673_16_T1	PHENOTYPE	9	9	MALT
NCT0017967316	NCT00179673_16_T2	TISSUE	7	8	lymphoid tissue
NCT0017967316	NCT00179673_16_T3	PHENOTYPE	0	4	Extranodal marginal zone B-cell lymphoma
NCT0017967317	NCT00179673_17_T0	PHENOTYPE	0	4	Nodal marginal zone B-cell lymphoma
NCT0017967318	NCT00179673_18_T0	PHENOTYPE	0	4	Splenic marginal zone B-cell lymphoma
NCT0017967319	NCT00179673_19_T0	PHENOTYPE	0	2	Small lymphocytic lymphoma
NCT0017967320	NCT00179673_20_T0	PHENOTYPE	0	1	Lymphoplasmacytoid lymphoma
NCT0017967321	NCT00179673_21_T0	PHENOTYPE	7	7	lymphoma
NCT0017967324	NCT00179673_24_T0	GENE	14	14	cm
NCT0017967324	NCT00179673_24_T1	PHENOTYPE	3	4	measurable disease
NCT0017967325	NCT00179673_25_T0	PHENOTYPE	2	2	Oncology
NCT0017967330	NCT00179673_30_T0	PHENOTYPE	4	5	laboratory abnormalities
NCT0017967331	NCT00179673_31_T0	GENE	3	3	ANC
NCT0017967331	NCT00179673_31_T1	GENE	6	6	1.5
NCT0017967331	NCT00179673_31_T2	CELL	1	1	neutrophil
NCT0017967332	NCT00179673_32_T0	PHENOTYPE	0	1	Platelet count
NCT0017967334	NCT00179673_34_T0	GENE	12	12	5.0
NCT0017967334	NCT00179673_34_T1	ORGAN	0	0	Serum
NCT0017967334	NCT00179673_34_T2	GENE	10	10	aminotransferase
NCT0017967334	NCT00179673_34_T3	ORGAN	7	7	serum
NCT0017967334	NCT00179673_34_T4	GENE	3	4	aspartate aminotransferase
NCT0017967335	NCT00179673_35_T0	GENE	3	3	2.0
NCT0017967335	NCT00179673_35_T1	ORGAN	0	0	Serum
NCT0017967335	NCT00179673_35_T2	PHENOTYPE	1	2	total bilirubin
NCT0017967336	NCT00179673_36_T0	PHENOTYPE	6	7	laboratory abnormalities
NCT0017967338	NCT00179673_38_T0	GENE	47	47	MRI
NCT0017967338	NCT00179673_38_T1	GENE	17	17	has
NCT0017967338	NCT00179673_38_T2	ORGAN	3	5	Central Nervous System
NCT0017967342	NCT00179673_42_T0	PHENOTYPE	4	5	laboratory abnormality
NCT0017967342	NCT00179673_42_T1	PHENOTYPE	7	8	psychiatric illness
NCT0017967344	NCT00179673_44_T0	PHENOTYPE	6	6	HIV
NCT0017967344	NCT00179673_44_T1	PHENOTYPE	4	4	Immunodeficiency
NCT0017967348	NCT00179673_48_T0	COMPOUND	17	17	thalidomide
NCT0017967348	NCT00179673_48_T1	COMPOUND	12	12	NCI
NCT0017967348	NCT00179673_48_T2	PHENOTYPE	10	11	Adverse Events
NCT0017967353	NCT00179673_53_T0	PHENOTYPE	2	3	Hepatitis C
NCT001796862	NCT00179686_2_T0	PHENOTYPE	4	5	disease progression
NCT001796869	NCT00179686_9_T0	COMPOUND	7	7	platinum
NCT0017968610	NCT00179686_10_T0	GENE	14	14	cm
NCT0017968610	NCT00179686_10_T1	PHENOTYPE	3	4	measurable disease
NCT0017968612	NCT00179686_12_T0	GENE	14	14	II
NCT0017968612	NCT00179686_12_T1	PHENOTYPE	2	2	Oncology
NCT0017968612	NCT00179686_12_T2	ORGAN	13	13	Appendix
NCT0017968614	NCT00179686_14_T0	ORGAN	9	9	serum
NCT0017968618	NCT00179686_18_T0	PHENOTYPE	4	5	laboratory abnormalities
NCT0017968619	NCT00179686_19_T0	GENE	3	3	ANC
NCT0017968619	NCT00179686_19_T1	GENE	6	6	1.5
NCT0017968619	NCT00179686_19_T2	CELL	1	1	neutrophil
NCT0017968620	NCT00179686_20_T0	PHENOTYPE	0	1	Platelet count
NCT0017968622	NCT00179686_22_T0	GENE	4	4	5.0
NCT0017968622	NCT00179686_22_T1	ORGAN	0	0	Serum
NCT0017968623	NCT00179686_23_T0	GENE	3	3	2.0
NCT0017968623	NCT00179686_23_T1	ORGAN	0	0	Serum
NCT0017968623	NCT00179686_23_T2	PHENOTYPE	1	2	total bilirubin
NCT0017968624	NCT00179686_24_T0	PHENOTYPE	6	7	laboratory abnormalities
NCT0017968628	NCT00179686_28_T0	PHENOTYPE	4	5	laboratory abnormality
NCT0017968628	NCT00179686_28_T1	PHENOTYPE	7	8	psychiatric illness
NCT0017968636	NCT00179686_36_T0	COMPOUND	3	3	lenalidomide
NCT001796992	NCT00179699_2_T0	PHENOTYPE	8	9	disease progression
NCT0017969910	NCT00179699_10_T0	PHENOTYPE	6	6	NSCLC
NCT0017969912	NCT00179699_12_T0	PHENOTYPE	7	7	NSCLC
NCT0017969913	NCT00179699_13_T0	GENE	8	8	cm
NCT0017969913	NCT00179699_13_T1	PHENOTYPE	3	4	measurable disease
NCT0017969917	NCT00179699_17_T0	ORGAN	7	7	Appendix
NCT0017969919	NCT00179699_19_T0	ORGAN	9	9	serum
NCT0017969922	NCT00179699_22_T0	PHENOTYPE	4	5	laboratory abnormalities
NCT0017969923	NCT00179699_23_T0	GENE	3	3	ANC
NCT0017969923	NCT00179699_23_T1	GENE	6	6	1.5
NCT0017969923	NCT00179699_23_T2	CELL	1	1	neutrophil
NCT0017969924	NCT00179699_24_T0	PHENOTYPE	0	1	Platelet count
NCT0017969925	NCT00179699_25_T0	COMPOUND	1	1	creatinine
NCT0017969925	NCT00179699_25_T1	GENE	2	2	1.5
NCT0017969925	NCT00179699_25_T2	ORGAN	0	0	Serum
NCT0017969926	NCT00179699_26_T0	GENE	4	4	3.0
NCT0017969926	NCT00179699_26_T1	ORGAN	0	0	Serum
NCT0017969927	NCT00179699_27_T0	GENE	5	5	1.5
NCT0017969927	NCT00179699_27_T1	ORGAN	0	0	Serum
NCT0017969927	NCT00179699_27_T2	PHENOTYPE	1	2	total bilirubin
NCT0017969928	NCT00179699_28_T0	PHENOTYPE	5	6	psychiatric illness
NCT0017969932	NCT00179699_32_T0	GENE	8	8	MRI
NCT0017969932	NCT00179699_32_T1	PHENOTYPE	18	18	suspicion
NCT0017969932	NCT00179699_32_T2	ORGAN	20	22	central nervous system
NCT0017969934	NCT00179699_34_T0	PHENOTYPE	7	7	NSCLC
NCT0017969936	NCT00179699_36_T0	PHENOTYPE	4	5	other cancer
NCT0017969938	NCT00179699_38_T0	COMPOUND	4	4	lenalidomide
NCT0017969944	NCT00179699_44_T0	PHENOTYPE	12	12	initiation
NCT001797128	NCT00179712_8_T0	PHENOTYPE	8	10	primary peritoneal carcinoma
NCT0017971210	NCT00179712_10_T0	PHENOTYPE	10	12	primary peritoneal carcinoma
NCT0017971211	NCT00179712_11_T0	GENE	8	8	cm
NCT0017971211	NCT00179712_11_T1	PHENOTYPE	3	4	measurable disease
NCT0017971213	NCT00179712_13_T0	COMPOUND	13	13	paclitaxel
NCT0017971213	NCT00179712_13_T1	COMPOUND	11	11	platinum
NCT0017971215	NCT00179712_15_T0	ORGAN	7	7	Appendix
NCT0017971217	NCT00179712_17_T0	PHENOTYPE	4	5	laboratory abnormalities
NCT0017971218	NCT00179712_18_T0	GENE	3	3	ANC
NCT0017971218	NCT00179712_18_T1	GENE	6	6	1.5
NCT0017971218	NCT00179712_18_T2	CELL	1	1	neutrophil
NCT0017971219	NCT00179712_19_T0	PHENOTYPE	0	1	Platelet count
NCT0017971220	NCT00179712_20_T0	COMPOUND	1	1	creatinine
NCT0017971220	NCT00179712_20_T1	GENE	2	2	1.5
NCT0017971220	NCT00179712_20_T2	ORGAN	0	0	Serum
NCT0017971221	NCT00179712_21_T0	GENE	4	4	3.0
NCT0017971221	NCT00179712_21_T1	ORGAN	0	0	Serum
NCT0017971222	NCT00179712_22_T0	GENE	3	3	2.0
NCT0017971222	NCT00179712_22_T1	ORGAN	0	0	Serum
NCT0017971222	NCT00179712_22_T2	PHENOTYPE	1	2	total bilirubin
NCT0017971223	NCT00179712_23_T0	PHENOTYPE	5	6	psychiatric illness
NCT0017971227	NCT00179712_27_T0	GENE	8	8	MRI
NCT0017971227	NCT00179712_27_T1	PHENOTYPE	18	18	suspicion
NCT0017971227	NCT00179712_27_T2	ORGAN	20	22	central nervous system
NCT0017971230	NCT00179712_30_T0	COMPOUND	3	3	platinum
NCT0017971230	NCT00179712_30_T1	COMPOUND	11	11	platinum
NCT0017971230	NCT00179712_30_T2	COMPOUND	27	27	platinum
NCT0017971232	NCT00179712_32_T0	PHENOTYPE	4	5	other cancer
NCT0017971234	NCT00179712_34_T0	COMPOUND	4	4	lenalidomide
NCT0017971239	NCT00179712_39_T0	GENE	7	7	III
NCT0017971239	NCT00179712_39_T1	ORGAN	6	6	Appendix
NCT0017971240	NCT00179712_40_T0	PHENOTYPE	14	14	initiation
NCT001797258	NCT00179725_8_T0	PHENOTYPE	8	10	primary peritoneal carcinoma
NCT0017972510	NCT00179725_10_T0	PHENOTYPE	10	12	primary peritoneal carcinoma
NCT0017972511	NCT00179725_11_T0	GENE	8	8	cm
NCT0017972511	NCT00179725_11_T1	PHENOTYPE	3	4	measurable disease
NCT0017972513	NCT00179725_13_T0	COMPOUND	13	13	paclitaxel
NCT0017972513	NCT00179725_13_T1	COMPOUND	11	11	platinum
NCT0017972515	NCT00179725_15_T0	ORGAN	7	7	Appendix
NCT0017972519	NCT00179725_19_T0	PHENOTYPE	4	5	laboratory abnormalities
NCT0017972520	NCT00179725_20_T0	GENE	3	3	ANC
NCT0017972520	NCT00179725_20_T1	GENE	6	6	1.5
NCT0017972520	NCT00179725_20_T2	CELL	1	1	neutrophil
NCT0017972521	NCT00179725_21_T0	PHENOTYPE	0	1	Platelet count
NCT0017972523	NCT00179725_23_T0	GENE	4	4	3.0
NCT0017972523	NCT00179725_23_T1	ORGAN	0	0	Serum
NCT0017972524	NCT00179725_24_T0	GENE	3	3	1.2
NCT0017972524	NCT00179725_24_T1	ORGAN	0	0	Serum
NCT0017972524	NCT00179725_24_T2	PHENOTYPE	1	2	total bilirubin
NCT0017972525	NCT00179725_25_T0	PHENOTYPE	5	6	psychiatric illness
NCT0017972529	NCT00179725_29_T0	GENE	8	8	MRI
NCT0017972529	NCT00179725_29_T1	PHENOTYPE	18	18	suspicion
NCT0017972529	NCT00179725_29_T2	ORGAN	20	22	central nervous system
NCT0017972532	NCT00179725_32_T0	COMPOUND	3	3	platinum
NCT0017972532	NCT00179725_32_T1	COMPOUND	11	11	platinum
NCT0017972532	NCT00179725_32_T2	COMPOUND	27	27	platinum
NCT0017972534	NCT00179725_34_T0	PHENOTYPE	4	5	other cancer
NCT0017972541	NCT00179725_41_T0	PHENOTYPE	14	14	initiation
NCT0017972542	NCT00179725_42_T0	ORGAN	7	7	Heart
NCT0017972542	NCT00179725_42_T1	GENE	10	10	II
NCT0017972542	NCT00179725_42_T2	ORGAN	14	14	Appendix
NCT0017972542	NCT00179725_42_T3	PHENOTYPE	2	3	cardiac disease
NCT001797380	NCT00179738_0_T0	COMPOUND	23	23	tate
NCT001797380	NCT00179738_0_T1	PHENOTYPE	24	24	Cancer
NCT001797380	NCT00179738_0_T2	PHENOTYPE	19	22	Androgen Independent Prostate Cancer
NCT0017973812	NCT00179738_12_T0	GENE	15	15	50
NCT0017973812	NCT00179738_12_T1	ORGAN	11	11	serum
NCT0017973812	NCT00179738_12_T2	PHENOTYPE	12	13	testosterone level
NCT0017973813	NCT00179738_13_T0	GENE	7	7	RH
NCT0017973820	NCT00179738_20_T0	COMPOUND	6	6	flutamide
NCT0017973820	NCT00179738_20_T1	COMPOUND	16	16	ketoconazole
NCT0017973821	NCT00179738_21_T0	COMPOUND	6	6	bicalutamide
NCT0017973824	NCT00179738_24_T0	GENE	13	13	II
NCT0017973824	NCT00179738_24_T1	PHENOTYPE	2	2	Oncology
NCT0017973824	NCT00179738_24_T2	ORGAN	12	12	Appendix
NCT0017973827	NCT00179738_27_T0	PHENOTYPE	4	5	laboratory abnormalities
NCT0017973828	NCT00179738_28_T0	GENE	3	3	ANC
NCT0017973828	NCT00179738_28_T1	GENE	6	6	1.5
NCT0017973828	NCT00179738_28_T2	CELL	1	1	neutrophil
NCT0017973829	NCT00179738_29_T0	PHENOTYPE	0	1	Platelet count
NCT0017973831	NCT00179738_31_T0	GENE	4	4	3.0
NCT0017973831	NCT00179738_31_T1	ORGAN	0	0	Serum
NCT0017973832	NCT00179738_32_T0	GENE	3	3	2.0
NCT0017973832	NCT00179738_32_T1	ORGAN	0	0	Serum
NCT0017973832	NCT00179738_32_T2	PHENOTYPE	1	2	total bilirubin
NCT0017973833	NCT00179738_33_T0	PHENOTYPE	6	7	laboratory abnormalities
NCT0017973837	NCT00179738_37_T0	PHENOTYPE	4	5	laboratory abnormality
NCT0017973837	NCT00179738_37_T1	PHENOTYPE	7	8	psychiatric illness
NCT0017973843	NCT00179738_43_T0	COMPOUND	3	3	lenalidomide
NCT0017973846	NCT00179738_46_T0	GENE	18	18	LHRH
NCT0017973846	NCT00179738_46_T1	PHENOTYPE	12	12	initiation
NCT001797519	NCT00179751_9_T0	PHENOTYPE	4	5	pancreatic carcinoma
NCT0017975111	NCT00179751_11_T0	PHENOTYPE	7	8	pancreatic carcinoma
NCT0017975112	NCT00179751_12_T0	GENE	8	8	cm
NCT0017975112	NCT00179751_12_T1	PHENOTYPE	3	4	measurable disease
NCT0017975114	NCT00179751_14_T0	COMPOUND	10	10	5_fluorouracil
NCT0017975114	NCT00179751_14_T1	PHENOTYPE	24	24	progression
NCT0017975116	NCT00179751_16_T0	ORGAN	7	7	Appendix
NCT0017975118	NCT00179751_18_T0	ORGAN	9	9	serum
NCT0017975121	NCT00179751_21_T0	PHENOTYPE	4	5	laboratory abnormalities
NCT0017975122	NCT00179751_22_T0	GENE	3	3	ANC
NCT0017975122	NCT00179751_22_T1	GENE	6	6	1.5
NCT0017975122	NCT00179751_22_T2	CELL	1	1	neutrophil
NCT0017975123	NCT00179751_23_T0	PHENOTYPE	0	1	Platelet count
NCT0017975125	NCT00179751_25_T0	GENE	4	4	3.0
NCT0017975125	NCT00179751_25_T1	ORGAN	0	0	Serum
NCT0017975126	NCT00179751_26_T0	GENE	3	3	2.0
NCT0017975126	NCT00179751_26_T1	ORGAN	0	0	Serum
NCT0017975126	NCT00179751_26_T2	PHENOTYPE	1	2	total bilirubin
NCT0017975127	NCT00179751_27_T0	PHENOTYPE	5	6	psychiatric illness
NCT0017975131	NCT00179751_31_T0	GENE	8	8	MRI
NCT0017975131	NCT00179751_31_T1	PHENOTYPE	18	18	suspicion
NCT0017975131	NCT00179751_31_T2	ORGAN	20	22	central nervous system
NCT0017975133	NCT00179751_33_T0	COMPOUND	17	17	5_fluorouracil
NCT0017975133	NCT00179751_33_T1	PHENOTYPE	9	12	carcinoma of the pancreas
NCT0017975135	NCT00179751_35_T0	PHENOTYPE	4	5	other cancer
NCT0017975137	NCT00179751_37_T0	COMPOUND	4	4	lenalidomide
NCT0017975142	NCT00179751_42_T0	PHENOTYPE	12	12	initiation
NCT001797641	NCT00179764_1_T0	ORGAN	11	11	transplant
NCT001797645	NCT00179764_5_T0	PHENOTYPE	18	18	toxic
NCT001797645	NCT00179764_5_T1	ORGAN	11	12	immune system
NCT001797645	NCT00179764_5_T2	ORGAN	21	22	bone marrow
NCT0017976412	NCT00179764_12_T0	CELL	3	4	stem cells
NCT0017976412	NCT00179764_12_T1	CELL	21	22	blood cells
NCT0017976412	NCT00179764_12_T2	CELL	15	17	bone marrow cells
NCT0017976413	NCT00179764_13_T0	ORGAN	11	11	transplant
NCT0017976413	NCT00179764_13_T1	ORGAN	30	30	Marrow
NCT0017976413	NCT00179764_13_T2	CELL	5	6	stem cells
NCT0017977710	NCT00179777_10_T0	BIOLOGICAL_PROCESS	14	14	gestation
NCT0017977715	NCT00179777_15_T0	PHENOTYPE	14	14	prick
NCT0017977715	NCT00179777_15_T1	ORGAN	0	1	Cord blood
NCT0017977717	NCT00179777_17_T0	PHENOTYPE	4	4	withdrawn
NCT001797902	NCT00179790_2_T0	ORGAN	7	7	transplant
NCT001797902	NCT00179790_2_T1	PHENOTYPE	17	17	GVHD
NCT001797902	NCT00179790_2_T2	PHENOTYPE	10	10	infertility
NCT001797902	NCT00179790_2_T3	PHENOTYPE	13	16	graft versus host disease
NCT001797903	NCT00179790_3_T0	CELL	13	13	cells
NCT001797903	NCT00179790_3_T1	ORGAN	2	2	transplant
NCT001797903	NCT00179790_3_T2	GENE	3	3	RIT
NCT001797903	NCT00179790_3_T3	ORGAN	9	10	immune system
NCT001797904	NCT00179790_4_T0	PHENOTYPE	11	11	complications
NCT001797904	NCT00179790_4_T1	ORGAN	13	13	transplant
NCT001797904	NCT00179790_4_T2	GENE	4	4	RIT
NCT001797906	NCT00179790_6_T0	GENE	0	0	ECP
NCT001797906	NCT00179790_6_T1	PHENOTYPE	11	11	lymphomas
NCT001797906	NCT00179790_6_T2	PHENOTYPE	8	8	GVHD
NCT001797907	NCT00179790_7_T0	GENE	0	0	ECP
NCT001797907	NCT00179790_7_T1	CELL	23	23	cells
NCT001797907	NCT00179790_7_T2	CELL	6	8	white blood cells
NCT001797908	NCT00179790_8_T0	CELL	9	9	cells
NCT001797908	NCT00179790_8_T1	ORGAN	2	3	immune system
NCT001797909	NCT00179790_9_T0	GENE	5	5	ECP
NCT001797909	NCT00179790_9_T1	PHENOTYPE	7	7	conditioning
NCT0017979010	NCT00179790_10_T0	GENE	16	16	ECP
NCT0017979010	NCT00179790_10_T1	GENE	24	24	RIT
NCT0017979012	NCT00179790_12_T0	COMPOUND	6	6	busulfan
NCT0017979012	NCT00179790_12_T1	CELL	9	9	thymocyte
NCT0017979012	NCT00179790_12_T2	COMPOUND	7	7	fludarabine
NCT0017979012	NCT00179790_12_T3	GENE	2	2	reduced
NCT0017979014	NCT00179790_14_T0	GENE	3	3	ECP
NCT0017979014	NCT00179790_14_T1	GENE	4	4	has
NCT0017979015	NCT00179790_15_T0	COMPOUND	13	13	8_methoxypsoralen
NCT0017979015	NCT00179790_15_T1	CELL	6	8	white blood cells
NCT0017979017	NCT00179790_17_T0	PHENOTYPE	11	11	tolerance
NCT0017979017	NCT00179790_17_T1	CELL	0	2	Antigen presenting cells
NCT0017979018	NCT00179790_18_T0	COMPOUND	9	9	busulfan
NCT0017979018	NCT00179790_18_T1	GENE	6	6	ECP
NCT0017979018	NCT00179790_18_T2	GENE	16	16	ECP
NCT0017979018	NCT00179790_18_T3	COMPOUND	7	7	fludarabine
NCT0017979018	NCT00179790_18_T4	PHENOTYPE	20	24	acute graft versus host disease
NCT0017979019	NCT00179790_19_T0	PHENOTYPE	15	15	engraftment
NCT0017979019	NCT00179790_19_T1	GENE	24	24	reduced
NCT0017979019	NCT00179790_19_T2	PHENOTYPE	18	18	GVHD
NCT0017979020	NCT00179790_20_T0	PHENOTYPE	11	11	engraftment
NCT0017979020	NCT00179790_20_T1	GENE	3	3	ECP
NCT0017979020	NCT00179790_20_T2	PHENOTYPE	8	8	immunosuppression
NCT0017979020	NCT00179790_20_T3	ORGAN	6	6	transplant
NCT0017979021	NCT00179790_21_T0	GENE	4	4	ECP
NCT0017979021	NCT00179790_21_T1	ORGAN	6	6	transplant
NCT0017979021	NCT00179790_21_T2	PHENOTYPE	17	17	GVHD
NCT0017979021	NCT00179790_21_T3	PHENOTYPE	12	12	tolerance
NCT001798030	NCT00179803_0_T0	PHENOTYPE	10	10	Tumors
NCT001798030	NCT00179803_0_T1	CELL	0	1	Stem Cell
NCT001798030	NCT00179803_0_T2	ORGAN	1	2	Cell Transplant
NCT001798030	NCT00179803_0_T3	ORGAN	6	8	Central Nervous System
NCT001798035	NCT00179803_5_T0	PHENOTYPE	2	2	GBM
NCT001798035	NCT00179803_5_T1	PHENOTYPE	5	5	astrocytoma
NCT001798035	NCT00179803_5_T2	PHENOTYPE	8	8	pineoblastoma
NCT001798035	NCT00179803_5_T3	PHENOTYPE	11	11	PNET
NCT001798035	NCT00179803_5_T4	PHENOTYPE	0	1	Group B
NCT001798035	NCT00179803_5_T5	PHENOTYPE	3	4	high grade
NCT001798035	NCT00179803_5_T6	PHENOTYPE	6	7	rhabdoid tumors
NCT001798038	NCT00179803_8_T0	CELL	5	6	Stem Cell
NCT001798039	NCT00179803_9_T0	GENE	6	6	ANC
NCT001798039	NCT00179803_9_T1	GENE	19	19	G-CSF
NCT001798039	NCT00179803_9_T2	GENE	3	3	has
NCT001798039	NCT00179803_9_T3	CELL	13	14	Stem Cell
NCT001798160	NCT00179816_0_T0	PHENOTYPE	1	1	Peripheral
NCT001798160	NCT00179816_0_T1	CELL	3	4	Stem Cell
NCT001798160	NCT00179816_0_T2	PHENOTYPE	10	11	Solid Tumors
NCT001798163	NCT00179816_3_T0	PHENOTYPE	8	8	Peripheral
NCT001798163	NCT00179816_3_T1	CELL	10	11	Stem Cell
NCT001798164	NCT00179816_4_T0	PHENOTYPE	2	2	Peripheral
NCT001798164	NCT00179816_4_T1	CELL	4	5	Stem Cell
NCT001798167	NCT00179816_7_T0	GENE	7	7	has
NCT001798167	NCT00179816_7_T1	PHENOTYPE	14	15	localized disease
NCT001798168	NCT00179816_8_T0	PHENOTYPE	12	12	remission
NCT001798168	NCT00179816_8_T1	BIOLOGICAL_PROCESS	15	15	translation
NCT001798169	NCT00179816_9_T0	PHENOTYPE	7	7	tumors
NCT0017981610	NCT00179816_10_T0	PHENOTYPE	27	27	toxicity
NCT0017981610	NCT00179816_10_T1	CELL	10	11	stem cells
NCT001798292	NCT00179829_2_T0	CELL	20	20	cells
NCT001798292	NCT00179829_2_T1	PHENOTYPE	12	12	remission
NCT001798292	NCT00179829_2_T2	GENE	13	13	CR
NCT001798293	NCT00179829_3_T0	PHENOTYPE	13	13	leukemia
NCT001798293	NCT00179829_3_T1	PHENOTYPE	23	23	leukemia
NCT001798293	NCT00179829_3_T2	GENE	24	24	has
NCT001798294	NCT00179829_4_T0	PHENOTYPE	27	28	residual disease
NCT001798294	NCT00179829_4_T1	PHENOTYPE	3	5	Minimal Residual Disease
NCT001798422	NCT00179842_2_T0	GENE	26	26	CD
NCT001798422	NCT00179842_2_T1	PHENOTYPE	32	32	peripheral
NCT001798422	NCT00179842_2_T2	GENE	12	12	CDAI
NCT001798422	NCT00179842_2_T3	PHENOTYPE	8	9	Crohn's disease
NCT001798422	NCT00179842_2_T4	CELL	34	35	lymphocyte subsets
NCT001798422	NCT00179842_2_T5	PHENOTYPE	14	16	quality of life
NCT001798424	NCT00179842_4_T0	PHENOTYPE	20	21	Crohn's disease
NCT001798424	NCT00179842_4_T1	ORGAN	17	18	immune system
NCT001798550	NCT00179855_0_T0	PHENOTYPE	3	7	Acute Graft Versus Host Disease
NCT001798553	NCT00179855_3_T0	GENE	5	5	separated
NCT001798553	NCT00179855_3_T1	GENE	11	11	buffy
NCT001798553	NCT00179855_3_T2	CELL	13	13	lymphocyte
NCT001798554	NCT00179855_4_T0	CELL	12	12	cells
NCT001798555	NCT00179855_5_T0	GENE	0	0	ECP
NCT001798556	NCT00179855_6_T0	GENE	13	13	ECP
NCT001798556	NCT00179855_6_T1	GENE	20	20	has
NCT001798559	NCT00179855_9_T0	GENE	20	20	GI
NCT001798559	NCT00179855_9_T1	PHENOTYPE	18	18	rashes
NCT001798559	NCT00179855_9_T2	PHENOTYPE	14	14	GVHD
NCT001798683	NCT00179868_3_T0	PHENOTYPE	3	3	fever
NCT001798683	NCT00179868_3_T1	PHENOTYPE	0	0	Sepsis
NCT001798683	NCT00179868_3_T2	PHENOTYPE	4	6	positive blood culture
NCT001798812	NCT00179881_2_T0	PHENOTYPE	15	15	illnesses
NCT001798812	NCT00179881_2_T1	GENE	1	1	has
NCT001798812	NCT00179881_2_T2	GENE	8	8	has
NCT001798813	NCT00179881_3_T0	CELL	8	8	cells
NCT001798815	NCT00179881_5_T0	PHENOTYPE	2	2	tumor
NCT001798815	NCT00179881_5_T1	COMPOUND	9	9	oxygen
NCT001798815	NCT00179881_5_T2	ORGAN	6	7	blood vessels
NCT001798817	NCT00179881_7_T0	PHENOTYPE	23	25	brain stem glioma
NCT001798818	NCT00179881_8_T0	PHENOTYPE	15	15	recurrent
NCT001798818	NCT00179881_8_T1	PHENOTYPE	16	18	brain stem glioma
NCT001798945	NCT00179894_5_T0	PHENOTYPE	14	14	symptoms
NCT001798945	NCT00179894_5_T1	PHENOTYPE	20	20	ADHD
NCT001798945	NCT00179894_5_T2	PHENOTYPE	16	19	Attention Deficit Hyperactivity Disorder
NCT001798948	NCT00179894_8_T0	PHENOTYPE	2	2	practices
NCT001798949	NCT00179894_9_T0	PHENOTYPE	15	15	initiation
NCT001799071	NCT00179907_1_T0	PHENOTYPE	10	11	brain tumor
NCT001799072	NCT00179907_2_T0	PHENOTYPE	6	6	complications
NCT001799076	NCT00179907_6_T0	GENE	8	8	lessen
NCT001799076	NCT00179907_6_T1	PHENOTYPE	22	22	tumor
NCT001799077	NCT00179907_7_T0	PHENOTYPE	20	21	brain tumors
NCT001799077	NCT00179907_7_T1	PHENOTYPE	14	16	quality of life
NCT0017990710	NCT00179907_10_T0	PHENOTYPE	22	22	tumor
NCT0017990711	NCT00179907_11_T0	PHENOTYPE	26	27	Group B
NCT0017990712	NCT00179907_12_T0	PHENOTYPE	16	16	tumor
NCT0017990716	NCT00179907_16_T0	PHENOTYPE	9	10	brain tumors
NCT0017990717	NCT00179907_17_T0	GENE	5	5	has
NCT0017990718	NCT00179907_18_T0	PHENOTYPE	6	7	tumor recurrence
NCT0017990719	NCT00179907_19_T0	PHENOTYPE	2	3	tumor recurrence
NCT0017990719	NCT00179907_19_T1	PHENOTYPE	9	10	primary tumor
NCT0017990721	NCT00179907_21_T0	PHENOTYPE	3	3	tumors
NCT0017990721	NCT00179907_21_T1	PHENOTYPE	5	6	glioblastoma multiforme
NCT0017990721	NCT00179907_21_T2	PHENOTYPE	8	9	tumor recurrence
NCT0017990722	NCT00179907_22_T0	GENE	2	2	has
NCT0017990722	NCT00179907_22_T1	PHENOTYPE	15	16	brain tumors
NCT0017990724	NCT00179907_24_T0	PHENOTYPE	20	20	tumor
NCT0017990726	NCT00179907_26_T0	PHENOTYPE	10	12	recurrent brain tumors
NCT0017990727	NCT00179907_27_T0	PHENOTYPE	7	7	medulloblastomas
NCT0017990727	NCT00179907_27_T1	GENE	1	1	has
NCT0017990727	NCT00179907_27_T2	PHENOTYPE	6	6	gliomas
NCT0017990727	NCT00179907_27_T3	PHENOTYPE	5	5	recurrent
NCT0017990727	NCT00179907_27_T4	PHENOTYPE	9	9	ependymomas
NCT0017990728	NCT00179907_28_T0	PHENOTYPE	2	2	tumor
NCT0017990729	NCT00179907_29_T0	GENE	14	14	Gy
NCT0017990729	NCT00179907_29_T1	PHENOTYPE	9	9	tumors
NCT0017990729	NCT00179907_29_T2	PHENOTYPE	8	8	recurrent
NCT0017990730	NCT00179907_30_T0	PHENOTYPE	12	12	edema
NCT0017990730	NCT00179907_30_T1	PHENOTYPE	9	9	complications
NCT0017990730	NCT00179907_30_T2	GENE	2	2	has
NCT0017990730	NCT00179907_30_T3	PHENOTYPE	13	14	cranial neuropathy
NCT0017990730	NCT00179907_30_T4	PHENOTYPE	16	17	radiation necrosis
NCT0017990732	NCT00179907_32_T0	GENE	2	2	has
NCT0017990732	NCT00179907_32_T1	PHENOTYPE	12	14	recurrent brain tumors
NCT0017990736	NCT00179907_36_T0	PHENOTYPE	11	11	ependymoma
NCT0017990736	NCT00179907_36_T1	PHENOTYPE	10	10	tumors
NCT0017990736	NCT00179907_36_T2	PHENOTYPE	12	12	oligodendroglioma
NCT0017990736	NCT00179907_36_T3	PHENOTYPE	6	7	malignant gliomas
NCT0017990737	NCT00179907_37_T0	PHENOTYPE	4	4	ependymoma
NCT0017990738	NCT00179907_38_T0	PHENOTYPE	12	12	symptoms
NCT0017990738	NCT00179907_38_T1	BIOLOGICAL_PROCESS	5	5	necrosis
NCT0017990738	NCT00179907_38_T2	GENE	9	9	had
NCT0017990739	NCT00179907_39_T0	PHENOTYPE	5	5	meningitis
NCT0017990740	NCT00179907_40_T0	GENE	28	28	Gy
NCT0017990740	NCT00179907_40_T1	PHENOTYPE	8	8	Center
NCT0017990740	NCT00179907_40_T2	PHENOTYPE	31	31	tumor
NCT0017990740	NCT00179907_40_T3	COMPOUND	18	18	Cobalt
NCT0017990740	NCT00179907_40_T4	PHENOTYPE	12	13	glioblastoma multiforme
NCT0017990741	NCT00179907_41_T0	GENE	13	13	Gy
NCT0017990741	NCT00179907_41_T1	GENE	7	8	Group I
NCT0017990742	NCT00179907_42_T0	GENE	5	5	II
NCT0017990742	NCT00179907_42_T1	GENE	6	6	had
NCT0017990743	NCT00179907_43_T0	PHENOTYPE	8	8	tumor
NCT0017990743	NCT00179907_43_T1	COMPOUND	1	1	Cobalt
NCT0017990744	NCT00179907_44_T0	GENE	10	10	leak
NCT0017990744	NCT00179907_44_T1	GENE	7	7	had
NCT0017990744	NCT00179907_44_T2	GENE	13	13	had
NCT0017990744	NCT00179907_44_T3	PHENOTYPE	15	16	subdural hematoma
NCT0017990745	NCT00179907_45_T0	PHENOTYPE	5	5	meningitis
NCT0017990745	NCT00179907_45_T1	PHENOTYPE	7	8	radiation necrosis
NCT0017990746	NCT00179907_46_T0	GENE	8	8	II
NCT0017990746	NCT00179907_46_T1	GENE	4	5	Group I
NCT0017990748	NCT00179907_48_T0	GENE	2	2	has
NCT0017990753	NCT00179907_53_T0	GENE	6	6	phantom
NCT0017990755	NCT00179907_55_T0	PHENOTYPE	5	5	falls
NCT0017990761	NCT00179907_61_T0	GENE	12	12	1.5
NCT0017990761	NCT00179907_61_T1	GENE	13	13	cm
NCT0017990761	NCT00179907_61_T2	GENE	16	16	cm
NCT0017990763	NCT00179907_63_T0	PHENOTYPE	7	7	cavity
NCT0017990771	NCT00179907_71_T0	PHENOTYPE	11	11	complications
NCT0017990771	NCT00179907_71_T1	ORGAN	20	21	brain stem
NCT0017990771	NCT00179907_71_T2	ORGAN	24	25	blood vessels
NCT0017990774	NCT00179907_74_T0	PHENOTYPE	8	8	tumor
NCT0017990775	NCT00179907_75_T0	PHENOTYPE	11	11	tumor
NCT0017990776	NCT00179907_76_T0	ORGAN	5	6	cranial nerves
NCT0017990777	NCT00179907_77_T0	GENE	3	3	RBE
NCT0017990778	NCT00179907_78_T0	PHENOTYPE	22	22	peripheral
NCT0017990778	NCT00179907_78_T1	PHENOTYPE	15	15	tumor
NCT0017990778	NCT00179907_78_T2	PHENOTYPE	0	0	Tumor
NCT0017990780	NCT00179907_80_T0	GENE	1	1	has
NCT0017990780	NCT00179907_80_T1	PHENOTYPE	9	10	brain tumors
NCT0017990789	NCT00179907_89_T0	PHENOTYPE	4	4	Oncology
NCT0017990789	NCT00179907_89_T1	GENE	6	6	has
NCT0017990789	NCT00179907_89_T2	PHENOTYPE	28	29	brain metastases
NCT0017990789	NCT00179907_89_T3	PHENOTYPE	25	26	brain tumors
NCT0017990793	NCT00179907_93_T0	GENE	8	8	Gy
NCT0017990793	NCT00179907_93_T1	COMPOUND	21	21	Cobalt
NCT0017990793	NCT00179907_93_T2	PHENOTYPE	15	17	adult brain tumors
NCT0017990795	NCT00179907_95_T0	PHENOTYPE	6	6	complications
NCT0017990795	NCT00179907_95_T1	GENE	30	30	has
NCT0017990798	NCT00179907_98_T0	GENE	5	5	RT
NCT0017990798	NCT00179907_98_T1	GENE	13	13	RT
NCT0017990798	NCT00179907_98_T2	PHENOTYPE	21	22	Group B
NCT00179907100	NCT00179907_100_T0	GENE	17	17	8.0
NCT00179907102	NCT00179907_102_T0	GENE	13	13	Gy
NCT00179907102	NCT00179907_102_T1	ORGAN	8	8	brainstem
NCT00179907102	NCT00179907_102_T2	ORGAN	10	11	cranial nerves
NCT00179907103	NCT00179907_103_T0	PHENOTYPE	20	20	complications
NCT00179907104	NCT00179907_104_T0	PHENOTYPE	11	11	toxicity
NCT00179907104	NCT00179907_104_T1	PHENOTYPE	9	9	acute
NCT00179907105	NCT00179907_105_T0	PHENOTYPE	1	1	toxicity
NCT00179907105	NCT00179907_105_T1	PHENOTYPE	22	22	toxicity
NCT00179907106	NCT00179907_106_T0	PHENOTYPE	7	7	toxicity
NCT00179907106	NCT00179907_106_T1	PHENOTYPE	15	15	tumor
NCT00179907108	NCT00179907_108_T0	GENE	12	12	Gy
NCT00179907108	NCT00179907_108_T1	GENE	14	14	Gy
NCT00179907108	NCT00179907_108_T2	GENE	17	17	Gy
NCT00179907108	NCT00179907_108_T3	PHENOTYPE	7	7	tumors
NCT00179907109	NCT00179907_109_T0	PHENOTYPE	7	7	tumor
NCT001799206	NCT00179920_6_T0	PHENOTYPE	7	7	tumor
NCT0017992012	NCT00179920_12_T0	ORGAN	9	9	eyes
NCT001799335	NCT00179933_5_T0	GENE	21	21	has
NCT0017993313	NCT00179933_13_T0	PHENOTYPE	17	17	CMH
NCT0017993314	NCT00179933_14_T0	GENE	9	9	34.36
NCT001799463	NCT00179946_3_T0	GENE	0	0	Is
NCT001799465	NCT00179946_5_T0	ORGAN	19	19	graft
NCT001799465	NCT00179946_5_T1	GENE	3	3	HLA-A
NCT001799465	NCT00179946_5_T2	GENE	6	6	DRB1
NCT001799467	NCT00179946_7_T0	GENE	3	3	HLA-A
NCT001799467	NCT00179946_7_T1	GENE	6	6	DRB1
NCT0017994610	NCT00179946_10_T0	CELL	3	3	cells
NCT0017994611	NCT00179946_11_T0	ORGAN	17	17	transplant
NCT0017994611	NCT00179946_11_T1	PHENOTYPE	10	11	matching testing
NCT0017994612	NCT00179946_12_T0	ORGAN	15	15	transplant
NCT0017994612	NCT00179946_12_T1	ORGAN	13	14	cord blood
NCT001799590	NCT00179959_0_T0	PHENOTYPE	12	12	Severity
NCT001799590	NCT00179959_0_T1	PHENOTYPE	14	15	Atopic Dermatitis
NCT001799590	NCT00179959_0_T2	PHENOTYPE	4	6	Staphylococcus Aureus Infection
NCT001799595	NCT00179959_5_T0	PHENOTYPE	11	11	atopic
NCT001799595	NCT00179959_5_T1	PHENOTYPE	12	12	diseases
NCT001799597	NCT00179959_7_T0	CELL	6	6	keratinocytes
NCT001799597	NCT00179959_7_T1	BIOLOGICAL_PROCESS	16	18	skin barrier function
NCT0017995911	NCT00179959_11_T0	GENE	3	3	AD
NCT0017995912	NCT00179959_12_T0	GENE	11	11	AD
NCT0017995913	NCT00179959_13_T0	PHENOTYPE	3	3	atopic
NCT0017995915	NCT00179959_15_T0	PHENOTYPE	6	6	atopic
NCT0017995915	NCT00179959_15_T1	COMPOUND	11	11	sphingosine
NCT0017995916	NCT00179959_16_T0	GENE	18	18	AD
NCT0017995916	NCT00179959_16_T1	GENE	11	11	fibronectin
NCT0017995916	NCT00179959_16_T2	GENE	9	9	laminin
NCT0017995916	NCT00179959_16_T3	PHENOTYPE	20	21	skin injury
NCT0017995917	NCT00179959_17_T0	PHENOTYPE	10	10	severity
NCT0017995917	NCT00179959_17_T1	GENE	12	12	AD
NCT0017995917	NCT00179959_17_T2	GENE	13	13	has
NCT0017995929	NCT00179959_29_T0	COMPOUND	1	1	sodium
NCT0017995929	NCT00179959_29_T1	COMPOUND	2	2	hypochlorite
NCT0017995929	NCT00179959_29_T2	GENE	4	4	has
NCT0017995930	NCT00179959_30_T0	GENE	1	1	has
NCT0017995931	NCT00179959_31_T0	PHENOTYPE	19	19	wounds
NCT0017995931	NCT00179959_31_T1	PHENOTYPE	7	7	concentrations
NCT0017995931	NCT00179959_31_T2	GENE	2	2	has
NCT0017995931	NCT00179959_31_T3	PHENOTYPE	21	21	ulcers
NCT0017995933	NCT00179959_33_T0	PHENOTYPE	13	13	severity
NCT0017995933	NCT00179959_33_T1	GENE	15	15	AD
NCT0017995937	NCT00179959_37_T0	PHENOTYPE	22	22	atopic
NCT0017995937	NCT00179959_37_T1	COMPOUND	2	2	mupirocin
NCT0017995940	NCT00179959_40_T0	GENE	9	9	AD
NCT0017995940	NCT00179959_40_T1	COMPOUND	16	16	potassium
NCT0017995940	NCT00179959_40_T2	COMPOUND	14	14	cephalexin
NCT0017995940	NCT00179959_40_T3	COMPOUND	11	11	mupirocin
NCT0017995940	NCT00179959_40_T4	COMPOUND	12	12	chlorhexidine
NCT0017995940	NCT00179959_40_T5	COMPOUND	17	17	permanganate
NCT0017995941	NCT00179959_41_T0	PHENOTYPE	11	12	atopic dermatitis
NCT0017995943	NCT00179959_43_T0	GENE	9	9	AD
NCT0017995943	NCT00179959_43_T1	GENE	20	20	AD
NCT0017995943	NCT00179959_43_T2	PHENOTYPE	15	16	secondary infections
NCT0017995944	NCT00179959_44_T0	PHENOTYPE	25	25	severity
NCT0017995944	NCT00179959_44_T1	GENE	12	12	AD
NCT0017995944	NCT00179959_44_T2	PHENOTYPE	19	20	secondary infections
NCT0017995947	NCT00179959_47_T0	PHENOTYPE	9	9	severity
NCT0017995947	NCT00179959_47_T1	GENE	11	11	AD
NCT0017995948	NCT00179959_48_T0	PHENOTYPE	13	13	severity
NCT0017995948	NCT00179959_48_T1	GENE	15	15	AD
NCT0017995949	NCT00179959_49_T0	GENE	18	18	IGA
NCT0017995949	NCT00179959_49_T1	GENE	13	13	AD
NCT0017995949	NCT00179959_49_T2	PHENOTYPE	27	27	crusting
NCT0017995949	NCT00179959_49_T3	PHENOTYPE	23	25	bacterial skin infection
NCT0017995950	NCT00179959_50_T0	COMPOUND	22	22	mupirocin
NCT0017995950	NCT00179959_50_T1	PHENOTYPE	17	17	allergy
NCT0017995953	NCT00179959_53_T0	PHENOTYPE	14	14	severely
NCT0017995954	NCT00179959_54_T0	GENE	9	9	IGA
NCT0017995954	NCT00179959_54_T1	GENE	2	2	AD
NCT0017995954	NCT00179959_54_T2	PHENOTYPE	0	0	Severity
NCT0017995956	NCT00179959_56_T0	COMPOUND	4	4	cephalexin
NCT0017995956	NCT00179959_56_T1	GENE	5	5	TID
NCT0017995957	NCT00179959_57_T0	COMPOUND	9	9	mupirocin
NCT0017995957	NCT00179959_57_T1	GENE	11	11	BID
NCT0017995958	NCT00179959_58_T0	COMPOUND	4	4	cephalexin
NCT0017995958	NCT00179959_58_T1	GENE	10	10	TID
NCT0017995959	NCT00179959_59_T0	COMPOUND	17	17	sodium
NCT0017995959	NCT00179959_59_T1	COMPOUND	9	9	mupirocin
NCT0017995959	NCT00179959_59_T2	COMPOUND	18	18	hypochlorite
NCT0017995961	NCT00179959_61_T0	PHENOTYPE	7	7	initiation
NCT0017995961	NCT00179959_61_T1	PHENOTYPE	21	21	severely
NCT0017995963	NCT00179959_63_T0	COMPOUND	2	2	sodium
NCT0017995963	NCT00179959_63_T1	COMPOUND	3	3	hypochlorite
NCT0017995970	NCT00179959_70_T0	PHENOTYPE	0	1	Adverse events
NCT0017995973	NCT00179959_73_T0	GENE	8	8	disc
NCT0017995974	NCT00179959_74_T0	PHENOTYPE	0	0	Sensitivity
NCT0017995977	NCT00179959_77_T0	COMPOUND	4	4	sodium
NCT0017995977	NCT00179959_77_T1	COMPOUND	5	5	hypochlorite
NCT0017995979	NCT00179959_79_T0	GENE	1	1	has
NCT0017995981	NCT00179959_81_T0	COMPOUND	3	3	cephalexin
NCT0017995981	NCT00179959_81_T1	PHENOTYPE	7	7	resistant
NCT0017995981	NCT00179959_81_T2	GENE	4	4	has
NCT0017995981	NCT00179959_81_T3	PHENOTYPE	9	9	strains
NCT0017995982	NCT00179959_82_T0	GENE	2	2	has
NCT0017995984	NCT00179959_84_T0	PHENOTYPE	6	6	nausea
NCT0017995984	NCT00179959_84_T1	PHENOTYPE	7	8	contact dermatitis
NCT0017995986	NCT00179959_86_T0	PHENOTYPE	4	4	concentrations
NCT0017995986	NCT00179959_86_T1	COMPOUND	0	0	Sodium
NCT0017995986	NCT00179959_86_T2	COMPOUND	1	1	hypochlorite
NCT0017995988	NCT00179959_88_T0	COMPOUND	13	13	sodium
NCT0017995988	NCT00179959_88_T1	PHENOTYPE	16	16	complication
NCT0017995988	NCT00179959_88_T2	GENE	8	8	AD
NCT0017995988	NCT00179959_88_T3	COMPOUND	14	14	hypochlorite
NCT001799723	NCT00179972_3_T0	GENE	6	6	longevity
NCT001799726	NCT00179972_6_T0	COMPOUND	24	24	oxygen
NCT001799727	NCT00179972_7_T0	GENE	17	17	reduced
NCT001799727	NCT00179972_7_T1	GENE	15	15	has
NCT0017997210	NCT00179972_10_T0	PHENOTYPE	7	7	pulse
NCT0017997210	NCT00179972_10_T1	GENE	25	25	longevity
NCT0017997210	NCT00179972_10_T2	GENE	13	13	has
NCT0017997211	NCT00179972_11_T0	PHENOTYPE	5	5	pulse
NCT0017997214	NCT00179972_14_T0	PHENOTYPE	23	23	pulse
NCT0017997214	NCT00179972_14_T1	GENE	9	9	longevity
NCT0017997216	NCT00179972_16_T0	PHENOTYPE	4	5	premature infants
NCT0017997218	NCT00179972_18_T0	GENE	6	6	longevity
NCT001799853	NCT00179985_3_T0	GENE	14	14	has
NCT001799982	NCT00179998_2_T0	PHENOTYPE	22	22	infections
NCT001799982	NCT00179998_2_T1	PHENOTYPE	14	15	lung function
NCT001799983	NCT00179998_3_T0	GENE	1	1	has
NCT001799983	NCT00179998_3_T1	PHENOTYPE	21	22	cystic fibrosis
NCT001799984	NCT00179998_4_T0	GENE	1	1	has
NCT001799984	NCT00179998_4_T1	PHENOTYPE	13	14	cystic fibrosis
NCT001799985	NCT00179998_5_T0	GENE	18	18	has
NCT001799985	NCT00179998_5_T1	PHENOTYPE	26	27	lung function
NCT001799985	NCT00179998_5_T2	PHENOTYPE	9	10	cystic fibrosis
NCT001799986	NCT00179998_6_T0	ORGAN	14	14	lungs
NCT001799986	NCT00179998_6_T1	PHENOTYPE	7	8	lung function
NCT001799986	NCT00179998_6_T2	PHENOTYPE	18	19	cystic fibrosis
NCT001799988	NCT00179998_8_T0	PHENOTYPE	8	9	cystic fibrosis
NCT0017999815	NCT00179998_15_T0	PHENOTYPE	8	9	lung function
NCT001800111	NCT00180011_1_T0	PHENOTYPE	6	6	asthma
NCT001800112	NCT00180011_2_T0	PHENOTYPE	0	0	Secondary
NCT001800112	NCT00180011_2_T1	PHENOTYPE	6	6	asthma
NCT001800112	NCT00180011_2_T2	PHENOTYPE	10	10	asthma
NCT001800112	NCT00180011_2_T3	PHENOTYPE	14	15	lung function
NCT001800112	NCT00180011_2_T4	PHENOTYPE	7	9	Quality of life
NCT001800372	NCT00180037_2_T0	GENE	14	14	II
NCT001800372	NCT00180037_2_T1	GENE	16	16	III
NCT001800372	NCT00180037_2_T2	PHENOTYPE	8	9	Parkinson's Disease
NCT001800377	NCT00180037_7_T0	GENE	6	6	Q10
NCT001800377	NCT00180037_7_T1	GENE	10	10	tid
NCT001800377	NCT00180037_7_T2	COMPOUND	5	5	Coenzyme
NCT001800378	NCT00180037_8_T0	PHENOTYPE	2	2	centers
NCT001800379	NCT00180037_9_T0	GENE	14	14	II
NCT001800379	NCT00180037_9_T1	GENE	16	16	III
NCT001800379	NCT00180037_9_T2	PHENOTYPE	8	9	Parkinson's Disease
NCT001801022	NCT00180102_2_T0	GENE	6	6	FLT3
NCT001801023	NCT00180102_3_T0	PHENOTYPE	23	23	centers
NCT001801024	NCT00180102_4_T0	COMPOUND	20	20	mitoxantrone
NCT001801028	NCT00180102_8_T0	PHENOTYPE	27	27	AML
NCT001801282	NCT00180128_2_T0	COMPOUND	15	15	mitoxantrone
NCT001801282	NCT00180128_2_T1	COMPOUND	7	7	idarubicin
NCT001801282	NCT00180128_2_T2	COMPOUND	13	13	daunorubicin
NCT001801283	NCT00180128_3_T0	COMPOUND	9	9	cytarabine
NCT001801283	NCT00180128_3_T1	GENE	4	4	WBC
NCT001801284	NCT00180128_4_T0	COMPOUND	10	10	methotrexate
NCT001801284	NCT00180128_4_T1	COMPOUND	9	9	6_mercaptopurine
NCT001801287	NCT00180128_7_T0	COMPOUND	15	15	mitoxantrone
NCT001801287	NCT00180128_7_T1	COMPOUND	7	7	idarubicin
NCT001801287	NCT00180128_7_T2	COMPOUND	13	13	daunorubicin
NCT001801288	NCT00180128_8_T0	COMPOUND	9	9	cytarabine
NCT001801288	NCT00180128_8_T1	GENE	4	4	WBC
NCT001801289	NCT00180128_9_T0	COMPOUND	10	10	methotrexate
NCT001801289	NCT00180128_9_T1	COMPOUND	9	9	6_mercaptopurine
NCT001801410	NCT00180141_0_T0	PHENOTYPE	5	6	Atopic Dermatitis
NCT001801412	NCT00180141_2_T0	COMPOUND	2	2	Elidel
NCT001801413	NCT00180141_3_T0	COMPOUND	8	8	Elidel
NCT001802450	NCT00180245_0_T0	PHENOTYPE	0	0	Tumor
NCT001802450	NCT00180245_0_T1	BIOLOGICAL_PROCESS	1	1	Metabolism
NCT001802450	NCT00180245_0_T2	PHENOTYPE	3	6	Head and Neck Cancer
NCT001802584	NCT00180258_4_T0	PHENOTYPE	13	14	heart failure
NCT001803100	NCT00180310_0_T0	GENE	1	1	II
NCT001803105	NCT00180310_5_T0	GENE	7	7	III
NCT001803232	NCT00180323_2_T0	COMPOUND	7	7	VTI
NCT001803233	NCT00180323_3_T0	COMPOUND	3	3	VTI
NCT001803233	NCT00180323_3_T1	ORGAN	9	9	heart
NCT001803233	NCT00180323_3_T2	ORGAN	23	23	heart
NCT001803360	NCT00180336_0_T0	GENE	7	7	AVT
NCT001803624	NCT00180362_4_T0	PHENOTYPE	2	2	EPS
NCT001803626	NCT00180362_6_T0	PHENOTYPE	23	23	decisions
NCT001803626	NCT00180362_6_T1	PHENOTYPE	11	13	quality of life
NCT001804013	NCT00180401_3_T0	PHENOTYPE	7	9	quality of life
NCT001804143	NCT00180414_3_T0	PHENOTYPE	30	30	symptoms
NCT001804143	NCT00180414_3_T1	PHENOTYPE	34	35	atrial arrhythmia
NCT001804143	NCT00180414_3_T2	PHENOTYPE	20	22	quality of life
NCT001804272	NCT00180427_2_T0	PHENOTYPE	18	18	arrhythmias
NCT001804272	NCT00180427_2_T1	ORGAN	2	2	heart
NCT001804272	NCT00180427_2_T2	PHENOTYPE	6	6	bradycardias
NCT001804275	NCT00180427_5_T0	GENE	22	22	IV
NCT0018045311	NCT00180453_11_T0	GENE	9	9	bypass
NCT0018045311	NCT00180453_11_T1	ORGAN	10	10	graft
NCT0018045311	NCT00180453_11_T2	ORGAN	7	8	coronary artery
NCT0018045315	NCT00180453_15_T0	GENE	7	7	had
NCT0018045315	NCT00180453_15_T1	PHENOTYPE	9	11	negative pregnancy test
NCT0018045321	NCT00180453_21_T0	GENE	13	13	3.0
NCT0018045327	NCT00180453_27_T0	GENE	17	17	CK
NCT0018045327	NCT00180453_27_T1	GENE	30	30	CK
NCT0018045327	NCT00180453_27_T2	GENE	2	2	had
NCT0018045327	NCT00180453_27_T3	GENE	1	1	has
NCT0018045327	NCT00180453_27_T4	GENE	31	31	has
NCT0018045327	NCT00180453_27_T5	PHENOTYPE	5	7	acute myocardial infarction
NCT0018045331	NCT00180453_31_T0	GENE	1	1	has
NCT0018045331	NCT00180453_31_T1	PHENOTYPE	5	7	ventricular ejection fraction
NCT0018045333	NCT00180453_33_T0	ORGAN	5	5	transplant
NCT0018045333	NCT00180453_33_T1	GENE	1	1	has
NCT0018045333	NCT00180453_33_T2	ORGAN	4	4	heart
NCT0018045333	NCT00180453_33_T3	ORGAN	9	10	organ transplant
NCT0018045333	NCT00180453_33_T4	ORGAN	19	20	organ transplant
NCT0018045337	NCT00180453_37_T0	PHENOTYPE	3	3	immunosuppression
NCT0018045337	NCT00180453_37_T1	GENE	6	6	has
NCT0018045339	NCT00180453_39_T0	COMPOUND	7	7	heparin
NCT0018045339	NCT00180453_39_T1	PHENOTYPE	4	4	anticoagulation
NCT0018045339	NCT00180453_39_T2	PHENOTYPE	3	3	chronic
NCT0018045343	NCT00180453_43_T0	GENE	11	11	WBC
NCT0018045343	NCT00180453_43_T1	GENE	1	1	has
NCT0018045343	NCT00180453_43_T2	PHENOTYPE	3	4	platelet count
NCT0018045343	NCT00180453_43_T3	PHENOTYPE	19	20	liver disease
NCT0018045345	NCT00180453_45_T0	GENE	1	1	has
NCT0018045345	NCT00180453_45_T1	PHENOTYPE	8	8	coagulopathy
NCT0018045345	NCT00180453_45_T2	PHENOTYPE	5	6	bleeding diathesis
NCT0018045346	NCT00180453_46_T0	GENE	2	2	had
NCT0018045346	NCT00180453_46_T1	GENE	1	1	has
NCT0018045346	NCT00180453_46_T2	PHENOTYPE	14	14	TIA
NCT0018045346	NCT00180453_46_T3	PHENOTYPE	6	6	CVA
NCT0018045346	NCT00180453_46_T4	PHENOTYPE	4	5	cerebrovascular accident
NCT0018045347	NCT00180453_47_T0	GENE	5	5	GI
NCT0018045347	NCT00180453_47_T1	GENE	2	2	had
NCT0018045347	NCT00180453_47_T2	GENE	1	1	has
NCT0018045347	NCT00180453_47_T3	PHENOTYPE	8	8	bleed
NCT0018045348	NCT00180453_48_T0	GENE	1	1	has
NCT0018045348	NCT00180453_48_T1	PHENOTYPE	3	5	peripheral vascular disease
NCT0018045349	NCT00180453_49_T0	GENE	1	1	has
NCT0018045349	NCT00180453_49_T1	PHENOTYPE	15	16	substance abuse
NCT0018045349	NCT00180453_49_T2	PHENOTYPE	8	10	congestive heart failure
NCT0018045350	NCT00180453_50_T0	GENE	13	13	has
NCT0018045351	NCT00180453_51_T0	GENE	1	1	has
NCT0018045359	NCT00180453_59_T0	PHENOTYPE	1	1	distal
NCT0018045360	NCT00180453_60_T0	GENE	7	7	has
NCT0018045361	NCT00180453_61_T0	GENE	20	20	balloon
NCT0018045361	NCT00180453_61_T1	PHENOTYPE	31	31	distal
NCT0018045361	NCT00180453_61_T2	GENE	15	15	PCI
NCT0018045361	NCT00180453_61_T3	GENE	7	7	has
NCT0018045363	NCT00180453_63_T0	PHENOTYPE	1	1	occlusion
NCT0018045364	NCT00180453_64_T0	PHENOTYPE	2	2	proximal
NCT0018045365	NCT00180453_65_T0	PHENOTYPE	4	4	proximal
NCT0018045366	NCT00180453_66_T0	PHENOTYPE	3	3	calcification
NCT0018045368	NCT00180453_68_T0	PHENOTYPE	4	4	thrombus
NCT0018045372	NCT00180453_72_T0	GENE	25	25	balloon
NCT0018045372	NCT00180453_72_T1	GENE	1	1	has
NCT001804661	NCT00180466_1_T0	GENE	4	4	ACS
NCT001804664	NCT00180466_4_T0	GENE	9	9	ACS
NCT001804668	NCT00180466_8_T0	GENE	6	6	ACS
NCT001804669	NCT00180466_9_T0	GENE	7	8	troponin T
NCT001804669	NCT00180466_9_T1	GENE	4	5	troponin I
NCT0018046611	NCT00180466_11_T0	COMPOUND	3	3	1
NCT0018046611	NCT00180466_11_T1	PHENOTYPE	0	1	ST depression
NCT0018046611	NCT00180466_11_T2	PHENOTYPE	23	25	left ventricular hypertrophy
NCT0018046611	NCT00180466_11_T3	PHENOTYPE	26	28	bundle branch block
NCT0018046613	NCT00180466_13_T0	COMPOUND	4	4	1
NCT0018046613	NCT00180466_13_T1	GENE	13	13	30
NCT0018046613	NCT00180466_13_T2	PHENOTYPE	1	2	ST elevation
NCT0018046617	NCT00180466_17_T0	PHENOTYPE	5	5	acute
NCT0018046617	NCT00180466_17_T1	GENE	2	2	had
NCT0018046617	NCT00180466_17_T2	GENE	1	1	has
NCT0018046617	NCT00180466_17_T3	PHENOTYPE	8	9	myocardial infarction
NCT0018046621	NCT00180466_21_T0	PHENOTYPE	1	1	hypotension
NCT0018046621	NCT00180466_21_T1	GENE	12	12	balloon
NCT0018046621	NCT00180466_21_T2	PHENOTYPE	3	4	heart failure
NCT0018046627	NCT00180466_27_T0	PHENOTYPE	2	3	cardiogenic shock
NCT0018046629	NCT00180466_29_T0	GENE	1	1	has
NCT0018046629	NCT00180466_29_T1	PHENOTYPE	5	7	ventricular ejection fraction
NCT0018046631	NCT00180466_31_T0	PHENOTYPE	15	15	fibrillation
NCT0018046631	NCT00180466_31_T1	PHENOTYPE	1	2	ventricular arrhythmia
NCT0018046631	NCT00180466_31_T2	PHENOTYPE	12	13	ventricular tachycardia
NCT0018046633	NCT00180466_33_T0	PHENOTYPE	0	0	Acute
NCT0018046634	NCT00180466_34_T0	GENE	8	8	PCI
NCT0018046634	NCT00180466_34_T1	GENE	2	2	had
NCT0018046634	NCT00180466_34_T2	GENE	1	1	has
NCT0018046635	NCT00180466_35_T0	GENE	1	1	has
NCT0018046635	NCT00180466_35_T1	PHENOTYPE	24	24	Plan
NCT0018046635	NCT00180466_35_T2	PHENOTYPE	15	16	substance abuse
NCT0018046635	NCT00180466_35_T3	PHENOTYPE	8	10	congestive heart failure
NCT0018046636	NCT00180466_36_T0	GENE	19	19	has
NCT0018047923	NCT00180479_23_T0	PHENOTYPE	13	14	Group B
NCT0018047930	NCT00180479_30_T0	COMPOUND	7	7	everolimus
NCT0018047930	NCT00180479_30_T1	PHENOTYPE	4	4	pharmacokinetics
NCT0018047930	NCT00180479_30_T2	GENE	5	5	PK
NCT0018047931	NCT00180479_31_T0	GENE	23	23	PK
NCT001804922	NCT00180492_2_T0	ORGAN	19	20	blood vessel
NCT001804923	NCT00180492_3_T0	GENE	5	5	mesh
NCT001804923	NCT00180492_3_T1	ORGAN	30	31	blood vessel
NCT001804923	NCT00180492_3_T2	PHENOTYPE	16	17	blood clots
NCT001804926	NCT00180492_6_T0	PHENOTYPE	23	26	of carotid artery disease
NCT001804927	NCT00180492_7_T0	PHENOTYPE	28	29	myocardial infarction
NCT001805053	NCT00180505_3_T0	COMPOUND	2	2	nitinol
NCT001805055	NCT00180505_5_T0	PHENOTYPE	11	11	restenosis
NCT001805056	NCT00180505_6_T0	PHENOTYPE	1	1	peripheral
NCT001805057	NCT00180505_7_T0	COMPOUND	6	6	nitinol
NCT001805057	NCT00180505_7_T1	PHENOTYPE	4	4	fracture
NCT001805058	NCT00180505_8_T0	PHENOTYPE	23	23	restenosis
NCT001805058	NCT00180505_8_T1	PHENOTYPE	10	10	fractures
NCT001805058	NCT00180505_8_T2	PHENOTYPE	21	21	fracture
NCT001805182	NCT00180518_2_T0	GENE	11	11	tm
NCT001805182	NCT00180518_2_T1	GENE	27	27	CEA
NCT001805183	NCT00180518_3_T0	GENE	23	23	CEA
NCT001805187	NCT00180518_7_T0	ORGAN	30	31	carotid artery
NCT0018051811	NCT00180518_11_T0	PHENOTYPE	25	25	acute
NCT0018051811	NCT00180518_11_T1	PHENOTYPE	0	0	Secondary
NCT0018051811	NCT00180518_11_T2	PHENOTYPE	41	41	complications
NCT0018051813	NCT00180518_13_T0	PHENOTYPE	1	2	adverse events
NCT0018051817	NCT00180518_17_T0	PHENOTYPE	5	5	TIA
NCT0018051817	NCT00180518_17_T1	PHENOTYPE	6	7	amaurosis fugax
NCT0018051817	NCT00180518_17_T2	PHENOTYPE	2	4	Transient ischemic attack
NCT0018051819	NCT00180518_19_T0	GENE	1	1	has
NCT0018051819	NCT00180518_19_T1	PHENOTYPE	7	9	negative pregnancy test
NCT0018051826	NCT00180518_26_T0	GENE	12	12	OR
NCT0018051829	NCT00180518_29_T0	ORGAN	10	11	carotid artery
NCT0018051830	NCT00180518_30_T0	GENE	4	4	bypass
NCT0018051830	NCT00180518_30_T1	ORGAN	6	7	cardiac valve
NCT0018051831	NCT00180518_31_T0	PHENOTYPE	1	1	occlusion
NCT0018051831	NCT00180518_31_T1	GENE	4	4	ICA
NCT0018051832	NCT00180518_32_T0	ORGAN	12	12	kidney
NCT0018051832	NCT00180518_32_T1	ORGAN	11	11	liver
NCT0018051832	NCT00180518_32_T2	ORGAN	9	9	heart
NCT0018051833	NCT00180518_33_T0	ORGAN	6	6	Heart
NCT0018051833	NCT00180518_33_T1	GENE	11	11	III
NCT0018051835	NCT00180518_35_T0	PHENOTYPE	1	2	renal failure
NCT0018051837	NCT00180518_37_T0	PHENOTYPE	0	0	Restenosis
NCT0018051837	NCT00180518_37_T1	GENE	3	3	CEA
NCT0018051840	NCT00180518_40_T0	PHENOTYPE	17	17	tumors
NCT0018051840	NCT00180518_40_T1	ORGAN	13	13	clavicle
NCT0018051840	NCT00180518_40_T2	GENE	9	9	C2
NCT0018051843	NCT00180518_43_T0	PHENOTYPE	1	3	laryngeal nerve paralysis
NCT0018051850	NCT00180518_50_T0	GENE	1	1	ICA
NCT0018051853	NCT00180518_53_T0	ORGAN	4	4	artery
NCT0018051853	NCT00180518_53_T1	GENE	9	9	30
NCT0018051853	NCT00180518_53_T2	GENE	13	13	30
NCT0018051855	NCT00180518_55_T0	PHENOTYPE	7	7	distal
NCT0018051855	NCT00180518_55_T1	PHENOTYPE	30	30	distal
NCT0018051855	NCT00180518_55_T2	GENE	31	31	ICA
NCT0018051855	NCT00180518_55_T3	GENE	25	25	cm
NCT0018051857	NCT00180518_57_T0	PHENOTYPE	11	11	distal
NCT0018051857	NCT00180518_57_T1	GENE	12	12	ICA
NCT0018051859	NCT00180518_59_T0	GENE	1	1	has
NCT0018051861	NCT00180518_61_T0	COMPOUND	17	17	heparin
NCT0018051861	NCT00180518_61_T1	COMPOUND	21	21	nitinol
NCT0018051861	NCT00180518_61_T2	COMPOUND	18	18	aspirin
NCT0018051861	NCT00180518_61_T3	COMPOUND	20	20	aspirin
NCT0018051861	NCT00180518_61_T4	GENE	1	1	has
NCT0018051861	NCT00180518_61_T5	PHENOTYPE	6	7	allergic reaction
NCT0018051863	NCT00180518_63_T0	COMPOUND	12	12	clopidogrel
NCT0018051863	NCT00180518_63_T1	COMPOUND	10	10	ticlopidine
NCT0018051863	NCT00180518_63_T2	GENE	1	1	has
NCT0018051863	NCT00180518_63_T3	PHENOTYPE	6	7	allergic reaction
NCT0018051865	NCT00180518_65_T0	GENE	1	1	has
NCT0018051865	NCT00180518_65_T1	PHENOTYPE	6	6	coagulopathy
NCT0018051865	NCT00180518_65_T2	PHENOTYPE	3	4	bleeding diathesis
NCT0018051867	NCT00180518_67_T0	GENE	1	1	has
NCT0018051869	NCT00180518_69_T0	PHENOTYPE	3	3	dementia
NCT0018051869	NCT00180518_69_T1	GENE	1	1	has
NCT0018051871	NCT00180518_71_T0	GENE	1	1	has
NCT0018051871	NCT00180518_71_T1	PHENOTYPE	6	7	intracranial hemorrhage
NCT0018051873	NCT00180518_73_T0	GENE	14	14	MRI
NCT0018051873	NCT00180518_73_T1	GENE	2	2	had
NCT0018051873	NCT00180518_73_T2	GENE	1	1	has
NCT0018051875	NCT00180518_75_T0	GENE	1	1	had
NCT0018051875	NCT00180518_75_T1	PHENOTYPE	6	7	ischemic stroke
NCT0018051879	NCT00180518_79_T0	GENE	12	12	IDE
NCT0018051879	NCT00180518_79_T1	GENE	14	14	has
NCT0018051879	NCT00180518_79_T2	GENE	10	10	IND
NCT0018051882	NCT00180518_82_T0	GENE	1	1	has
NCT0018051883	NCT00180518_83_T0	PHENOTYPE	4	4	symptoms
NCT0018051883	NCT00180518_83_T1	PHENOTYPE	9	9	symptoms
NCT0018051883	NCT00180518_83_T2	GENE	1	1	has
NCT0018051883	NCT00180518_83_T3	PHENOTYPE	2	3	vertebrobasilar insufficiency
NCT0018051885	NCT00180518_85_T0	GENE	5	5	GI
NCT0018051885	NCT00180518_85_T1	GENE	2	2	had
NCT0018051885	NCT00180518_85_T2	GENE	1	1	has
NCT0018051885	NCT00180518_85_T3	PHENOTYPE	6	6	bleed
NCT0018051887	NCT00180518_87_T0	PHENOTYPE	1	2	vascular tortuosity
NCT0018051889	NCT00180518_89_T0	ORGAN	8	8	graft
NCT0018051890	NCT00180518_90_T0	ORGAN	1	1	grafts
NCT0018051891	NCT00180518_91_T0	PHENOTYPE	12	12	proximal
NCT0018051891	NCT00180518_91_T1	PHENOTYPE	4	4	diffuse
NCT0018051891	NCT00180518_91_T2	ORGAN	9	10	aortic arch
NCT0018051891	NCT00180518_91_T3	ORGAN	13	15	common carotid artery
NCT0018051893	NCT00180518_93_T0	PHENOTYPE	16	16	projections
NCT0018051893	NCT00180518_93_T1	PHENOTYPE	31	31	ulcerated
NCT0018051893	NCT00180518_93_T2	PHENOTYPE	24	24	calcification
NCT001805310	NCT00180531_0_T0	GENE	13	13	CRT
NCT001805310	NCT00180531_0_T1	GENE	16	16	TR2
NCT001805310	NCT00180531_0_T2	PHENOTYPE	2	2	Arrhythmias
NCT001805310	NCT00180531_0_T3	PHENOTYPE	8	9	Heart Failure
NCT001805571	NCT00180557_1_T0	GENE	13	13	QRS
NCT001805701	NCT00180570_1_T0	PHENOTYPE	17	17	fixation
NCT001805701	NCT00180570_1_T1	GENE	2	2	has
NCT001805963	NCT00180596_3_T0	GENE	23	23	ACE
NCT001805963	NCT00180596_3_T1	GENE	9	9	CRT
NCT001805963	NCT00180596_3_T2	GENE	20	20	beta
NCT001805963	NCT00180596_3_T3	PHENOTYPE	15	16	heart failure
NCT001805964	NCT00180596_4_T0	GENE	3	3	CRT
NCT001805964	NCT00180596_4_T1	GENE	23	23	CRT
NCT001805964	NCT00180596_4_T2	PHENOTYPE	13	15	Quality of Life
NCT001805965	NCT00180596_5_T0	PHENOTYPE	15	15	complications
NCT001805965	NCT00180596_5_T1	PHENOTYPE	11	12	ventricular arrhythmias
NCT001805965	NCT00180596_5_T2	PHENOTYPE	7	8	adverse events
NCT001806094	NCT00180609_4_T0	GENE	22	22	has
NCT001806094	NCT00180609_4_T1	GENE	10	10	ventricular
NCT001806095	NCT00180609_5_T0	GENE	13	13	ventricular
NCT001806098	NCT00180609_8_T0	PHENOTYPE	5	5	centre
NCT001806221	NCT00180622_1_T0	PHENOTYPE	23	24	lung function
NCT001806482	NCT00180648_2_T0	PHENOTYPE	27	27	ingested
NCT001806482	NCT00180648_2_T1	ORGAN	14	14	intestine
NCT001806482	NCT00180648_2_T2	PHENOTYPE	10	10	dehydrated
NCT001806482	NCT00180648_2_T3	PHENOTYPE	8	8	malnourished
NCT001806484	NCT00180648_4_T0	PHENOTYPE	4	4	strain
NCT001806485	NCT00180648_5_T0	GENE	4	4	GLP-2
NCT001806485	NCT00180648_5_T1	ORGAN	35	35	intestine
NCT001806485	NCT00180648_5_T2	GENE	0	0	Glucagon
NCT001806485	NCT00180648_5_T3	GENE	9	9	hormone
NCT001806611	NCT00180661_1_T0	PHENOTYPE	9	9	asthma
NCT001806612	NCT00180661_2_T0	PHENOTYPE	10	10	inflammation
NCT001806612	NCT00180661_2_T1	PHENOTYPE	3	3	asthma
NCT001806613	NCT00180661_3_T0	PHENOTYPE	3	3	asthma
NCT001806613	NCT00180661_3_T1	PHENOTYPE	18	18	asthma
NCT001806614	NCT00180661_4_T0	PHENOTYPE	6	6	inflammation
NCT001806614	NCT00180661_4_T1	PHENOTYPE	9	9	asthma
NCT001806614	NCT00180661_4_T2	PHENOTYPE	20	20	asthma
NCT001806615	NCT00180661_5_T0	CELL	16	16	macrophage
NCT001806615	NCT00180661_5_T1	PHENOTYPE	25	25	asthma
NCT001806615	NCT00180661_5_T2	PHENOTYPE	33	33	asthma
NCT001806615	NCT00180661_5_T3	CELL	17	17	cells
NCT001806615	NCT00180661_5_T4	ORGAN	20	20	lungs
NCT001806615	NCT00180661_5_T5	CELL	11	12	blood cells
NCT001806617	NCT00180661_7_T0	PHENOTYPE	7	7	asthma
NCT001806618	NCT00180661_8_T0	GENE	9	9	SARP
NCT001806618	NCT00180661_8_T1	GENE	26	26	SARP
NCT001806618	NCT00180661_8_T2	PHENOTYPE	14	14	asthma
NCT001806618	NCT00180661_8_T3	PHENOTYPE	6	6	Asthma
NCT001806618	NCT00180661_8_T4	PHENOTYPE	21	22	bronchial hyperresponsiveness
NCT0018066111	NCT00180661_11_T0	CELL	3	3	cells
NCT0018066111	NCT00180661_11_T1	TISSUE	13	13	mucosa
NCT0018066112	NCT00180661_12_T0	PHENOTYPE	17	17	translocation
NCT0018066112	NCT00180661_12_T1	CELL	1	1	cells
NCT0018066112	NCT00180661_12_T2	GENE	15	15	receptor
NCT0018066112	NCT00180661_12_T3	GENE	25	25	histone
NCT0018066113	NCT00180661_13_T0	CELL	7	7	cells
NCT0018066113	NCT00180661_13_T1	PHENOTYPE	16	16	asthma
NCT0018066114	NCT00180661_14_T0	COMPOUND	14	14	prednisolone
NCT0018066114	NCT00180661_14_T1	COMPOUND	23	23	prednisolone
NCT0018066114	NCT00180661_14_T2	PHENOTYPE	7	7	asthma
NCT0018066116	NCT00180661_16_T0	PHENOTYPE	20	20	asthma
NCT0018066120	NCT00180661_20_T0	PHENOTYPE	6	6	symptoms
NCT0018066120	NCT00180661_20_T1	PHENOTYPE	8	8	asthma
NCT0018066121	NCT00180661_21_T0	PHENOTYPE	0	2	Quality of life
NCT0018066123	NCT00180661_23_T0	PHENOTYPE	1	2	lung function
NCT0018066124	NCT00180661_24_T0	COMPOUND	3	3	methacholine
NCT0018066125	NCT00180661_25_T0	COMPOUND	5	5	salbutamol
NCT0018066126	NCT00180661_26_T0	PHENOTYPE	5	5	symptoms
NCT0018066129	NCT00180661_29_T0	COMPOUND	2	3	nitric oxide
NCT0018066130	NCT00180661_30_T0	CELL	6	6	cells
NCT0018066132	NCT00180661_32_T0	CELL	5	5	cells
NCT0018066132	NCT00180661_32_T1	PHENOTYPE	19	19	asthma
NCT0018066133	NCT00180661_33_T0	GENE	9	9	SARP
NCT0018066134	NCT00180661_34_T0	PHENOTYPE	26	26	asthma
NCT0018066134	NCT00180661_34_T1	PHENOTYPE	2	2	Recruitment
NCT0018066142	NCT00180661_42_T0	PHENOTYPE	6	6	asthma
NCT0018066146	NCT00180661_46_T0	GENE	2	2	has
NCT0018066148	NCT00180661_48_T0	PHENOTYPE	0	0	Asthma
NCT0018066153	NCT00180661_53_T0	GENE	21	21	BTS
NCT0018066153	NCT00180661_53_T1	PHENOTYPE	39	39	asthma
NCT0018066153	NCT00180661_53_T2	PHENOTYPE	41	41	asthma
NCT0018066153	NCT00180661_53_T3	PHENOTYPE	17	17	Asthma
NCT0018066153	NCT00180661_53_T4	PHENOTYPE	26	26	symptoms
NCT0018066153	NCT00180661_53_T5	PHENOTYPE	44	44	symptoms
NCT0018066153	NCT00180661_53_T6	PHENOTYPE	24	24	Mild
NCT0018066153	NCT00180661_53_T7	COMPOUND	54	54	beclomethasone
NCT0018066154	NCT00180661_54_T0	PHENOTYPE	31	31	practices
NCT0018066154	NCT00180661_54_T1	PHENOTYPE	7	7	Asthma
NCT0018066157	NCT00180661_57_T0	PHENOTYPE	7	7	asthma
NCT0018066165	NCT00180661_65_T0	PHENOTYPE	6	6	asthma
NCT001806743	NCT00180674_3_T0	PHENOTYPE	7	7	anticoagulation
NCT001806747	NCT00180674_7_T0	PHENOTYPE	4	4	cirrhosis
NCT001806747	NCT00180674_7_T1	PHENOTYPE	0	1	Persistent infection
NCT001806747	NCT00180674_7_T2	PHENOTYPE	9	10	liver cancer
NCT001806747	NCT00180674_7_T3	PHENOTYPE	5	7	chronic liver failure
NCT0018067410	NCT00180674_10_T0	PHENOTYPE	11	12	liver fibrosis
NCT0018067411	NCT00180674_11_T0	PHENOTYPE	27	28	liver fibrosis
NCT0018067411	NCT00180674_11_T1	PHENOTYPE	35	36	hepatitis C
NCT0018067414	NCT00180674_14_T0	PHENOTYPE	3	3	anticoagulation
NCT0018067414	NCT00180674_14_T1	PHENOTYPE	15	15	fibrosis
NCT0018067414	NCT00180674_14_T2	PHENOTYPE	19	20	hepatitis C
NCT0018067414	NCT00180674_14_T3	PHENOTYPE	21	22	virus infection
NCT0018067414	NCT00180674_14_T4	PHENOTYPE	25	27	other liver diseases
NCT0018067416	NCT00180674_16_T0	PHENOTYPE	16	16	anticoagulation
NCT0018067418	NCT00180674_18_T0	PHENOTYPE	13	13	mutation
NCT0018067418	NCT00180674_18_T1	PHENOTYPE	18	18	fibrosis
NCT0018067418	NCT00180674_18_T2	COMPOUND	22	22	HCV
NCT0018067418	NCT00180674_18_T3	GENE	10	12	factor V Leiden
NCT0018067419	NCT00180674_19_T0	GENE	1	1	has
NCT0018067421	NCT00180674_21_T0	PHENOTYPE	9	9	anticoagulation
NCT0018067421	NCT00180674_21_T1	GENE	7	7	reduced
NCT0018067422	NCT00180674_22_T0	GENE	5	5	thrombin
NCT0018067422	NCT00180674_22_T1	GENE	10	10	receptor
NCT0018067422	NCT00180674_22_T2	CELL	13	13	cells
NCT0018067422	NCT00180674_22_T3	GENE	9	9	PAR1
NCT0018067426	NCT00180674_26_T0	PHENOTYPE	19	19	anticoagulation
NCT0018067426	NCT00180674_26_T1	PHENOTYPE	11	12	liver fibrosis
NCT0018067429	NCT00180674_29_T0	PHENOTYPE	3	3	anticoagulation
NCT0018067431	NCT00180674_31_T0	ORGAN	15	15	liver
NCT0018067431	NCT00180674_31_T1	COMPOUND	10	10	HCV
NCT0018067435	NCT00180674_35_T0	GENE	24	24	III
NCT0018067435	NCT00180674_35_T1	COMPOUND	10	10	bilirubin
NCT0018067435	NCT00180674_35_T2	ORGAN	0	0	Serum
NCT0018067435	NCT00180674_35_T3	ORGAN	5	5	serum
NCT0018067440	NCT00180674_40_T0	ORGAN	15	15	liver
NCT0018067440	NCT00180674_40_T1	COMPOUND	24	24	HCV
NCT0018067440	NCT00180674_40_T2	PHENOTYPE	26	27	liver disease
NCT0018067442	NCT00180674_42_T0	ORGAN	11	11	liver
NCT0018067442	NCT00180674_42_T1	PHENOTYPE	7	7	anticoagulation
NCT0018067442	NCT00180674_42_T2	GENE	20	20	INR
NCT0018067442	NCT00180674_42_T3	COMPOUND	13	14	vitamin K
NCT001806878	NCT00180687_8_T0	GENE	5	5	has
NCT001806879	NCT00180687_9_T0	PHENOTYPE	24	24	toxic
NCT001806879	NCT00180687_9_T1	PHENOTYPE	20	20	anaesthesia
NCT0018068721	NCT00180687_21_T0	PHENOTYPE	11	11	sterile
NCT0018068722	NCT00180687_22_T0	PHENOTYPE	23	23	wounds
NCT0018068722	NCT00180687_22_T1	PHENOTYPE	11	11	closed
NCT0018068722	NCT00180687_22_T2	PHENOTYPE	2	2	pneumoperitoneum
NCT001807002	NCT00180700_2_T0	PHENOTYPE	20	21	disease progression
NCT001807002	NCT00180700_2_T1	PHENOTYPE	1	2	HIV infection
NCT001807003	NCT00180700_3_T0	PHENOTYPE	11	12	disease progression
NCT001807004	NCT00180700_4_T0	PHENOTYPE	57	57	associations
NCT001807004	NCT00180700_4_T1	ORGAN	30	30	hands
NCT001807004	NCT00180700_4_T2	CELL	6	6	T-cell
NCT001807004	NCT00180700_4_T3	GENE	5	5	CD4
NCT001807004	NCT00180700_4_T4	GENE	48	48	CD4
NCT001807004	NCT00180700_4_T5	PHENOTYPE	2	2	HIV
NCT001807004	NCT00180700_4_T6	PHENOTYPE	66	66	HIV
NCT001807004	NCT00180700_4_T7	PHENOTYPE	52	53	disease progression
NCT001807004	NCT00180700_4_T8	PHENOTYPE	63	64	hormone levels
NCT001807130	NCT00180713_0_T0	PHENOTYPE	5	6	Pulmonary Hypertension
NCT001807133	NCT00180713_3_T0	ORGAN	8	8	heart
NCT001807133	NCT00180713_3_T1	PHENOTYPE	10	11	heart failure
NCT001807136	NCT00180713_6_T0	PHENOTYPE	6	6	inflammation
NCT001807136	NCT00180713_6_T1	PHENOTYPE	15	16	oxidative stress
NCT001807138	NCT00180713_8_T0	PHENOTYPE	6	7	pulmonary hypertension
NCT001807138	NCT00180713_8_T1	PHENOTYPE	15	16	disease progression
NCT001807139	NCT00180713_9_T0	GENE	20	20	reductase
NCT001807139	NCT00180713_9_T1	GENE	19	19	HMG-CoA
NCT001807261	NCT00180726_1_T0	CELL	16	16	lymphocytes
NCT001807261	NCT00180726_1_T1	PHENOTYPE	5	5	diseases
NCT001807261	NCT00180726_1_T2	CELL	13	13	eosinophils
NCT001807261	NCT00180726_1_T3	COMPOUND	40	40	corticoid
NCT001807261	NCT00180726_1_T4	PHENOTYPE	8	8	asthma
NCT001807261	NCT00180726_1_T5	PHENOTYPE	37	37	asthma
NCT001807261	NCT00180726_1_T6	CELL	14	14	macrophages
NCT001807261	NCT00180726_1_T7	CELL	10	10	cells
NCT001807261	NCT00180726_1_T8	CELL	11	11	leukocytes
NCT001807262	NCT00180726_2_T0	CELL	15	15	cells
NCT001807262	NCT00180726_2_T1	PHENOTYPE	19	19	asthma
NCT001807264	NCT00180726_4_T0	PHENOTYPE	14	14	resistant
NCT001807264	NCT00180726_4_T1	COMPOUND	10	10	corticoid
NCT001807264	NCT00180726_4_T2	PHENOTYPE	9	9	asthma
NCT001807264	NCT00180726_4_T3	PHENOTYPE	15	15	asthma
NCT001807264	NCT00180726_4_T4	BIOLOGICAL_PROCESS	6	7	gene expression
NCT001807265	NCT00180726_5_T0	CELL	7	7	macrophages
NCT001807265	NCT00180726_5_T1	CELL	6	6	cells
NCT001807265	NCT00180726_5_T2	CELL	23	23	cells
NCT001807266	NCT00180726_6_T0	CELL	4	4	leukocyte
NCT001807267	NCT00180726_7_T0	CELL	19	19	cells
NCT001807268	NCT00180726_8_T0	BIOLOGICAL_PROCESS	0	1	Gene expression
NCT0018072610	NCT00180726_10_T0	BIOLOGICAL_PROCESS	20	20	degradation
NCT0018072611	NCT00180726_11_T0	CELL	7	7	macrophages
NCT0018072611	NCT00180726_11_T1	CELL	6	6	cells
NCT0018072613	NCT00180726_13_T0	CELL	2	2	cells
NCT0018072613	NCT00180726_13_T1	CELL	20	20	cells
NCT0018072615	NCT00180726_15_T0	CELL	14	14	leukocytes
NCT0018072615	NCT00180726_15_T1	GENE	11	11	mediator
NCT0018072616	NCT00180726_16_T0	CELL	15	15	cells
NCT0018072616	NCT00180726_16_T1	PHENOTYPE	19	19	asthma
NCT0018072619	NCT00180726_19_T0	PHENOTYPE	5	6	skin prick
NCT0018072624	NCT00180726_24_T0	GENE	3	3	CXR
NCT0018072629	NCT00180726_29_T0	PHENOTYPE	3	4	skin prick
NCT0018072634	NCT00180726_34_T0	PHENOTYPE	2	4	respiratory tract infection
NCT0018072635	NCT00180726_35_T0	PHENOTYPE	15	15	asthma
NCT0018072635	NCT00180726_35_T1	PHENOTYPE	18	18	asthma
NCT0018072641	NCT00180726_41_T0	PHENOTYPE	0	2	Upper respiratory infection
NCT0018072642	NCT00180726_42_T0	PHENOTYPE	0	0	Allergy
NCT001807392	NCT00180739_2_T0	GENE	11	11	has
NCT001807392	NCT00180739_2_T1	PHENOTYPE	2	3	uterine fibroids
NCT001807395	NCT00180739_5_T0	CELL	31	31	sperm
NCT001807395	NCT00180739_5_T1	GENE	3	3	has
NCT001807522	NCT00180752_2_T0	ORGAN	12	13	quadriceps muscles
NCT001807523	NCT00180752_3_T0	ORGAN	12	13	quadriceps muscle
NCT001807524	NCT00180752_4_T0	GENE	9	9	NFkappaB
NCT001807524	NCT00180752_4_T1	GENE	12	12	HDAC
NCT001807526	NCT00180752_6_T0	PHENOTYPE	17	18	respiratory failure
NCT001807526	NCT00180752_6_T1	PHENOTYPE	21	22	idiopathic scoliosis
NCT001807653	NCT00180765_3_T0	CELL	23	23	cells
NCT001807653	NCT00180765_3_T1	PHENOTYPE	18	18	inflammation
NCT001807653	NCT00180765_3_T2	CELL	6	8	white blood cells
NCT001807654	NCT00180765_4_T0	CELL	8	8	cells
NCT001807654	NCT00180765_4_T1	PHENOTYPE	24	24	inflammation
NCT001807656	NCT00180765_6_T0	CELL	17	19	white blood cells
NCT0018076510	NCT00180765_10_T0	CELL	13	13	leukocytes
NCT0018076515	NCT00180765_15_T0	CELL	11	11	leukocytes
NCT001807784	NCT00180778_4_T0	GENE	10	10	has
NCT001807785	NCT00180778_5_T0	GENE	22	22	APS
NCT001808040	NCT00180804_0_T0	GENE	1	1	KIR
NCT001808040	NCT00180804_0_T1	GENE	4	4	HLA-C
NCT001808040	NCT00180804_0_T2	PHENOTYPE	7	8	Recurrent Miscarriages
NCT001808042	NCT00180804_2_T0	GENE	10	10	KIR
NCT001808042	NCT00180804_2_T1	PHENOTYPE	19	19	eclampsia
NCT001808042	NCT00180804_2_T2	GENE	15	15	HLA-C
NCT001808043	NCT00180804_3_T0	PHENOTYPE	14	14	suffering
NCT001808043	NCT00180804_3_T1	PHENOTYPE	16	17	recurrent miscarriages
NCT001808046	NCT00180804_6_T0	GENE	16	16	KIR
NCT001808046	NCT00180804_6_T1	PHENOTYPE	7	7	eclampsia
NCT001808046	NCT00180804_6_T2	GENE	20	20	HLA-C
NCT001808047	NCT00180804_7_T0	PHENOTYPE	13	13	miscarriages
NCT001808048	NCT00180804_8_T0	PHENOTYPE	12	12	insights
NCT001808048	NCT00180804_8_T1	PHENOTYPE	6	7	recurrent miscarriage
NCT001808170	NCT00180817_0_T0	PHENOTYPE	11	12	Antiphospholipid Antibodies
NCT001808434	NCT00180843_4_T0	PHENOTYPE	6	7	lung function
NCT001808435	NCT00180843_5_T0	PHENOTYPE	7	7	ventilation
NCT001808435	NCT00180843_5_T1	PHENOTYPE	14	15	lung function
NCT001808564	NCT00180856_4_T0	PHENOTYPE	18	18	tolerance
NCT001808564	NCT00180856_4_T1	PHENOTYPE	34	35	lung metastases
NCT001808564	NCT00180856_4_T2	PHENOTYPE	28	29	lung tumors
NCT001808564	NCT00180856_4_T3	PHENOTYPE	31	32	lung cancer
NCT001808569	NCT00180856_9_T0	PHENOTYPE	1	1	secondary
NCT001808569	NCT00180856_9_T1	PHENOTYPE	6	6	tolerance
NCT001808691	NCT00180869_1_T0	GENE	22	22	RBC
NCT001808691	NCT00180869_1_T1	GENE	27	27	RBC
NCT001808694	NCT00180869_4_T0	PHENOTYPE	6	6	tumor
NCT001808953	NCT00180895_3_T0	PHENOTYPE	1	1	secondary
NCT001808953	NCT00180895_3_T1	PHENOTYPE	7	7	toxicity
NCT001808953	NCT00180895_3_T2	GENE	32	32	CSF
NCT001808953	NCT00180895_3_T3	PHENOTYPE	25	25	pharmacokinetics
NCT001808953	NCT00180895_3_T4	PHENOTYPE	43	43	progression
NCT001808953	NCT00180895_3_T5	ORGAN	29	29	serum
NCT001808954	NCT00180895_4_T0	GENE	16	16	IV
NCT001808955	NCT00180895_5_T0	PHENOTYPE	4	4	relapse
NCT001809212	NCT00180921_2_T0	PHENOTYPE	3	3	proliferation
NCT001809212	NCT00180921_2_T1	GENE	16	16	receptor
NCT001809212	NCT00180921_2_T2	GENE	15	15	PDGF
NCT001809212	NCT00180921_2_T3	GENE	13	13	KIT
NCT001809212	NCT00180921_2_T4	GENE	6	7	tyrosine kinase
NCT001809212	NCT00180921_2_T5	GENE	11	12	c-kit receptor
NCT001809212	NCT00180921_2_T6	PHENOTYPE	31	33	adenoid cystic carcinoma
NCT001809213	NCT00180921_3_T0	GENE	17	17	KIT
NCT001809213	NCT00180921_3_T1	GENE	44	44	KIT
NCT001809213	NCT00180921_3_T2	COMPOUND	36	36	imatinib
NCT001809213	NCT00180921_3_T3	PHENOTYPE	29	31	adenoid cystic carcinoma
NCT001809213	NCT00180921_3_T4	PHENOTYPE	40	42	adenoid cystic carcinoma
NCT001809214	NCT00180921_4_T0	PHENOTYPE	20	24	adenoid cystic carcinoma of the
NCT001809214	NCT00180921_4_T1	PHENOTYPE	22	26	carcinoma of the head and
NCT001809215	NCT00180921_5_T0	PHENOTYPE	23	23	centers
NCT001809215	NCT00180921_5_T1	PHENOTYPE	8	8	malignancies
NCT001809215	NCT00180921_5_T2	TISSUE	6	7	salivary gland
NCT001809601	NCT00180960_1_T0	GENE	4	4	II
NCT001809602	NCT00180960_2_T0	TISSUE	9	9	peritoneum
NCT001809602	NCT00180960_2_T1	PHENOTYPE	3	3	tumors
NCT001809602	NCT00180960_2_T2	PHENOTYPE	12	12	tumors
NCT001809602	NCT00180960_2_T3	ORGAN	8	8	appendix
NCT001809602	NCT00180960_2_T4	ORGAN	6	6	colon
NCT001809602	NCT00180960_2_T5	ORGAN	7	7	rectum
NCT001809730	NCT00180973_0_T0	COMPOUND	11	11	THE
NCT001809730	NCT00180973_0_T1	COMPOUND	24	24	THE
NCT001809730	NCT00180973_0_T2	GENE	1	1	III
NCT001809730	NCT00180973_0_T3	PHENOTYPE	30	30	CARCINOMA
NCT001810641	NCT00181064_1_T0	PHENOTYPE	18	18	headache
NCT001810770	NCT00181077_0_T0	PHENOTYPE	4	4	Preeclampsia
NCT001810774	NCT00181077_4_T0	PHENOTYPE	22	22	seizure
NCT001810774	NCT00181077_4_T1	COMPOUND	20	20	sulfate
NCT001810774	NCT00181077_4_T2	COMPOUND	19	19	magnesium
NCT001810775	NCT00181077_5_T0	COMPOUND	14	15	Ringer's solution
NCT001810776	NCT00181077_6_T0	COMPOUND	21	21	sulfate
NCT001810776	NCT00181077_6_T1	COMPOUND	20	20	magnesium
NCT001810777	NCT00181077_7_T0	PHENOTYPE	21	21	toxicity
NCT001810777	NCT00181077_7_T1	COMPOUND	20	20	magnesium
NCT001810778	NCT00181077_8_T0	PHENOTYPE	18	19	pulmonary edema
NCT001810779	NCT00181077_9_T0	PHENOTYPE	1	1	pulse
NCT0018107710	NCT00181077_10_T0	GENE	18	18	interleukin-6
NCT0018107710	NCT00181077_10_T1	PHENOTYPE	22	22	inflammation
NCT0018107710	NCT00181077_10_T2	PHENOTYPE	11	12	platelet count
NCT0018107710	NCT00181077_10_T3	PHENOTYPE	14	15	liver enzymes
NCT0018107712	NCT00181077_12_T0	COMPOUND	1	1	sulfate
NCT001811162	NCT00181116_2_T0	COMPOUND	13	13	levetiracetam
NCT001811290	NCT00181129_0_T0	PHENOTYPE	0	0	Fatigue
NCT001811292	NCT00181129_2_T0	GENE	11	11	UC
NCT001811294	NCT00181129_4_T0	PHENOTYPE	2	2	fatigue
NCT001811294	NCT00181129_4_T1	PHENOTYPE	3	4	sleep disturbance
NCT001811294	NCT00181129_4_T2	PHENOTYPE	5	6	emotional distress
NCT001811294	NCT00181129_4_T3	PHENOTYPE	10	12	quality of life
NCT001811421	NCT00181142_1_T0	PHENOTYPE	5	5	secondary
NCT001811424	NCT00181142_4_T0	PHENOTYPE	17	17	acute
NCT001811424	NCT00181142_4_T1	GENE	24	24	IL-2
NCT001811424	NCT00181142_4_T2	GENE	21	23	interleukin 2 receptor
NCT001811552	NCT00181155_2_T0	ORGAN	17	17	heart
NCT001811552	NCT00181155_2_T1	ORGAN	21	21	heart
NCT001811552	NCT00181155_2_T2	GENE	8	9	creatine kinase
NCT001811553	NCT00181155_3_T0	COMPOUND	26	26	allopurinol
NCT001811553	NCT00181155_3_T1	GENE	23	23	IV
NCT001811553	NCT00181155_3_T2	PHENOTYPE	13	14	heart failure
NCT001811553	NCT00181155_3_T3	PHENOTYPE	15	16	dilated cardiomyopathy
NCT001811815	NCT00181181_5_T0	ORGAN	7	8	blood vessels
NCT001811816	NCT00181181_6_T0	COMPOUND	8	8	atorvastatin
NCT001811816	NCT00181181_6_T1	PHENOTYPE	4	6	high blood pressure
NCT001811819	NCT00181181_9_T0	ORGAN	7	7	kidney
NCT001811819	NCT00181181_9_T1	ORGAN	5	5	heart
NCT001811819	NCT00181181_9_T2	PHENOTYPE	9	10	liver disease
NCT0018118110	NCT00181181_10_T0	PHENOTYPE	6	6	diseases
NCT0018118113	NCT00181181_13_T0	GENE	18	18	sat
NCT0018118113	NCT00181181_13_T1	GENE	17	17	has
NCT0018118115	NCT00181181_15_T0	ORGAN	1	1	heart
NCT0018118117	NCT00181181_17_T0	ORGAN	14	14	heart
NCT0018118117	NCT00181181_17_T1	PHENOTYPE	10	11	blood supply
NCT0018118119	NCT00181181_19_T0	ORGAN	19	19	kidney
NCT0018118119	NCT00181181_19_T1	COMPOUND	16	16	glucose
NCT0018118119	NCT00181181_19_T2	ORGAN	17	17	liver
NCT0018118119	NCT00181181_19_T3	GENE	6	6	ml
NCT0018118127	NCT00181181_27_T0	GENE	13	13	has
NCT0018118132	NCT00181181_32_T0	PHENOTYPE	0	0	Pulse
NCT0018118135	NCT00181181_35_T0	ORGAN	0	1	Brachial artery
NCT0018118139	NCT00181181_39_T0	ORGAN	3	3	artery
NCT0018118141	NCT00181181_41_T0	ORGAN	3	3	artery
NCT0018118141	NCT00181181_41_T1	GENE	15	15	inflated
NCT0018118141	NCT00181181_41_T2	GENE	13	13	cuff
NCT0018118142	NCT00181181_42_T0	ORGAN	10	10	hands
NCT0018118142	NCT00181181_42_T1	PHENOTYPE	4	4	pulse
NCT0018118142	NCT00181181_42_T2	ORGAN	7	7	fingers
NCT0018118143	NCT00181181_43_T0	ORGAN	22	22	thigh
NCT0018118143	NCT00181181_43_T1	PHENOTYPE	0	0	Pulse
NCT0018118143	NCT00181181_43_T2	PHENOTYPE	15	15	pulse
NCT0018118144	NCT00181181_44_T0	ORGAN	24	24	thigh
NCT0018118145	NCT00181181_45_T0	GENE	18	18	insulin
NCT0018118145	NCT00181181_45_T1	PHENOTYPE	21	21	inflammation
NCT0018118145	NCT00181181_45_T2	CELL	23	23	platelet
NCT0018118145	NCT00181181_45_T3	GENE	6	6	ml
NCT0018118148	NCT00181181_48_T0	GENE	16	16	gel
NCT0018118149	NCT00181181_49_T0	ORGAN	7	7	heart
NCT0018118152	NCT00181181_52_T0	GENE	12	12	had
NCT0018118153	NCT00181181_53_T0	COMPOUND	17	17	adenosine
NCT0018118153	NCT00181181_53_T1	COMPOUND	22	22	adenosine
NCT0018118153	NCT00181181_53_T2	ORGAN	8	8	arteries
NCT0018118168	NCT00181181_68_T0	CELL	4	4	cells
NCT0018118176	NCT00181181_76_T0	COMPOUND	15	15	glucose
NCT0018118176	NCT00181181_76_T1	GENE	16	16	insulin
NCT0018118176	NCT00181181_76_T2	ORGAN	17	17	liver
NCT0018118176	NCT00181181_76_T3	ORGAN	19	19	kidney
NCT0018118176	NCT00181181_76_T4	PHENOTYPE	24	24	inflammation
NCT0018118176	NCT00181181_76_T5	GENE	2	2	ml
NCT0018118182	NCT00181181_82_T0	COMPOUND	25	25	metoprolol
NCT001811942	NCT00181194_2_T0	GENE	5	5	tailor
NCT001811942	NCT00181194_2_T1	PHENOTYPE	6	6	asthma
NCT001811942	NCT00181194_2_T2	PHENOTYPE	29	29	asthma
NCT001811942	NCT00181194_2_T3	PHENOTYPE	23	24	adverse effects
NCT001812074	NCT00181207_4_T0	PHENOTYPE	13	15	quality of life
NCT001812202	NCT00181220_2_T0	PHENOTYPE	16	16	tumor
NCT001812202	NCT00181220_2_T1	PHENOTYPE	11	11	lytic
NCT001812203	NCT00181220_3_T0	COMPOUND	17	17	valproate
NCT001812203	NCT00181220_3_T1	PHENOTYPE	2	3	primary tumor
NCT001812204	NCT00181220_4_T0	COMPOUND	17	17	valproate
NCT001812204	NCT00181220_4_T1	PHENOTYPE	7	7	tumor
NCT001812204	NCT00181220_4_T2	GENE	15	15	PCR
NCT001812330	NCT00181233_0_T0	PHENOTYPE	6	8	Sudden Cardiac Death
NCT001812332	NCT00181233_2_T0	GENE	25	25	MRI
NCT001812332	NCT00181233_2_T1	PHENOTYPE	42	43	sudden death
NCT001812592	NCT00181259_2_T0	GENE	14	14	reduced
NCT001812592	NCT00181259_2_T1	ORGAN	25	25	heart
NCT001812592	NCT00181259_2_T2	PHENOTYPE	16	17	heart failure
NCT001812592	NCT00181259_2_T3	PHENOTYPE	11	12	energy metabolism
NCT001812721	NCT00181272_1_T0	PHENOTYPE	31	31	obstruction
NCT001812721	NCT00181272_1_T1	PHENOTYPE	30	30	airflow
NCT001812721	NCT00181272_1_T2	COMPOUND	9	9	macrolides
NCT001812721	NCT00181272_1_T3	PHENOTYPE	27	27	inflammation
NCT001812721	NCT00181272_1_T4	PHENOTYPE	17	18	respiratory symptoms
NCT001812721	NCT00181272_1_T5	PHENOTYPE	21	23	quality of life
NCT001812727	NCT00181272_7_T0	COMPOUND	8	8	erythromycin
NCT001812727	NCT00181272_7_T1	COMPOUND	6	6	azithromycin
NCT001812727	NCT00181272_7_T2	COMPOUND	7	7	clarithromycin
NCT001812727	NCT00181272_7_T3	PHENOTYPE	11	12	bacterial infections
NCT001812728	NCT00181272_8_T0	COMPOUND	6	6	macrolides
NCT001812854	NCT00181285_4_T0	PHENOTYPE	6	6	distal
NCT001812854	NCT00181285_4_T1	PHENOTYPE	11	11	inflammation
NCT001812857	NCT00181285_7_T0	PHENOTYPE	35	35	bronchiectasis
NCT001812857	NCT00181285_7_T1	ORGAN	22	22	thorax
NCT001812857	NCT00181285_7_T2	PHENOTYPE	37	38	neuromuscular disorders
NCT001812857	NCT00181285_7_T3	ORGAN	2	3	chest wall
NCT001812857	NCT00181285_7_T4	PHENOTYPE	33	34	cystic fibrosis
NCT0018128512	NCT00181285_12_T0	PHENOTYPE	0	0	Secondary
NCT0018128512	NCT00181285_12_T1	PHENOTYPE	6	6	dyspnea
NCT0018128512	NCT00181285_12_T2	GENE	5	5	Borg
NCT001812981	NCT00181298_1_T0	PHENOTYPE	6	6	syndromes
NCT001812981	NCT00181298_1_T1	PHENOTYPE	12	13	cognitive dysfunction
NCT001812988	NCT00181298_8_T0	PHENOTYPE	8	9	cognitive function
NCT001813110	NCT00181311_0_T0	PHENOTYPE	5	5	Complications
NCT001813112	NCT00181311_2_T0	PHENOTYPE	25	25	complications
NCT001813117	NCT00181311_7_T0	PHENOTYPE	26	26	abscesses
NCT001813117	NCT00181311_7_T1	PHENOTYPE	14	14	complications
NCT001813117	NCT00181311_7_T2	PHENOTYPE	23	23	haematomas
NCT001813117	NCT00181311_7_T3	GENE	28	28	abdominal
NCT001813118	NCT00181311_8_T0	PHENOTYPE	7	7	complications
NCT001813504	NCT00181350_4_T0	GENE	7	7	SCRT
NCT001813504	NCT00181350_4_T1	PHENOTYPE	16	17	brain tumours
NCT001813505	NCT00181350_5_T0	PHENOTYPE	8	8	tumour
NCT001813505	NCT00181350_5_T1	GENE	3	3	reduced
NCT001813506	NCT00181350_6_T0	PHENOTYPE	14	14	fixation
NCT001813507	NCT00181350_7_T0	PHENOTYPE	16	16	fixation
NCT001813507	NCT00181350_7_T1	PHENOTYPE	39	39	fixation
NCT001813508	NCT00181350_8_T0	PHENOTYPE	15	15	fixation
NCT001813509	NCT00181350_9_T0	GENE	13	13	PTV
NCT0018135010	NCT00181350_10_T0	PHENOTYPE	9	9	toxicity
NCT0018135010	NCT00181350_10_T1	GENE	4	4	PTV
NCT0018135011	NCT00181350_11_T0	PHENOTYPE	13	13	fixation
NCT001813632	NCT00181363_2_T0	ORGAN	10	10	breasts
NCT001813635	NCT00181363_5_T0	GENE	14	14	PTV
NCT001813635	NCT00181363_5_T1	TISSUE	17	17	tissues
NCT001815065	NCT00181506_5_T0	PHENOTYPE	19	20	stage III
NCT001815068	NCT00181506_8_T0	PHENOTYPE	3	4	dose-effect relationship
NCT0018150610	NCT00181506_10_T0	PHENOTYPE	14	14	tolerance
NCT0018150614	NCT00181506_14_T0	GENE	10	10	OTT
NCT001815320	NCT00181532_0_T0	GENE	1	1	II
NCT001815320	NCT00181532_0_T1	PHENOTYPE	11	11	NSCLC
NCT001815322	NCT00181532_2_T0	COMPOUND	4	4	celecoxib
NCT001815322	NCT00181532_2_T1	PHENOTYPE	8	8	remission
NCT001815325	NCT00181532_5_T0	PHENOTYPE	15	15	toxicity
NCT001815327	NCT00181532_7_T0	PHENOTYPE	2	2	toxic
NCT001815327	NCT00181532_7_T1	PHENOTYPE	1	1	NSCLC
NCT0018153210	NCT00181532_10_T0	PHENOTYPE	13	13	esophagitis
NCT0018153210	NCT00181532_10_T1	PHENOTYPE	10	11	radiation pneumonitis
NCT0018153211	NCT00181532_11_T0	PHENOTYPE	11	11	tumor
NCT0018153211	NCT00181532_11_T1	GENE	8	8	COX-2
NCT0018153211	NCT00181532_11_T2	PHENOTYPE	14	15	radiation damage
NCT0018153214	NCT00181532_14_T0	ORGAN	12	12	thorax
NCT0018153214	NCT00181532_14_T1	PHENOTYPE	4	4	tumor
NCT0018153215	NCT00181532_15_T0	PHENOTYPE	1	1	tumor
NCT0018153215	NCT00181532_15_T1	PHENOTYPE	13	13	tumor
NCT001815452	NCT00181545_2_T0	PHENOTYPE	15	15	pneumonitis
NCT001815452	NCT00181545_2_T1	PHENOTYPE	17	17	esophagitis
NCT001815452	NCT00181545_2_T2	GENE	1	1	has
NCT001815454	NCT00181545_4_T0	PHENOTYPE	11	11	tumor
NCT001815455	NCT00181545_5_T0	PHENOTYPE	17	17	tumor
NCT001815457	NCT00181545_7_T0	GENE	1	1	has
NCT001815459	NCT00181545_9_T0	PHENOTYPE	5	5	pneumonitis
NCT001815459	NCT00181545_9_T1	PHENOTYPE	7	7	esophagitis
NCT0018154517	NCT00181545_17_T0	ORGAN	29	30	spinal cord
NCT0018154518	NCT00181545_18_T0	PHENOTYPE	42	43	primary tumor
NCT0018154518	NCT00181545_18_T1	ORGAN	24	25	spinal cord
NCT001815711	NCT00181571_1_T0	PHENOTYPE	2	2	ADHD
NCT001815711	NCT00181571_1_T1	PHENOTYPE	8	8	ADHD
NCT001815711	NCT00181571_1_T2	PHENOTYPE	19	19	ADHD
NCT001815714	NCT00181571_4_T0	COMPOUND	11	11	methylphenidate
NCT001815714	NCT00181571_4_T1	COMPOUND	25	25	methylphenidate
NCT001815715	NCT00181571_5_T0	COMPOUND	20	20	methylphenidate
NCT001815715	NCT00181571_5_T1	PHENOTYPE	27	27	ADHD
NCT001815715	NCT00181571_5_T2	GENE	2	2	putative
NCT001815716	NCT00181571_6_T0	PHENOTYPE	28	28	ADHD
NCT001815716	NCT00181571_6_T1	PHENOTYPE	33	34	psychiatric disorders
NCT001815717	NCT00181571_7_T0	PHENOTYPE	11	11	ADHD
NCT001815718	NCT00181571_8_T0	PHENOTYPE	17	17	ADHD
NCT0018157113	NCT00181571_13_T0	PHENOTYPE	9	9	ADHD
NCT0018157113	NCT00181571_13_T1	PHENOTYPE	5	8	attention deficit hyperactivity disorder
NCT0018157119	NCT00181571_19_T0	PHENOTYPE	3	4	anxiety disorders
NCT0018157130	NCT00181571_30_T0	PHENOTYPE	7	7	arrhythmia
NCT0018157130	NCT00181571_30_T1	PHENOTYPE	5	5	ischemia
NCT0018157132	NCT00181571_32_T0	GENE	3	3	75
NCT0018157132	NCT00181571_32_T1	PHENOTYPE	0	1	Mental retardation
NCT0018157134	NCT00181571_34_T0	PHENOTYPE	1	2	brain disorders
NCT0018157136	NCT00181571_36_T0	PHENOTYPE	2	2	tics
NCT0018157136	NCT00181571_36_T1	PHENOTYPE	0	0	Seizures
NCT0018157140	NCT00181571_40_T0	PHENOTYPE	6	6	ADHD
NCT001815843	NCT00181584_3_T0	GENE	17	17	has
NCT001815843	NCT00181584_3_T1	PHENOTYPE	18	18	osteoporosis
NCT001815844	NCT00181584_4_T0	PHENOTYPE	2	2	osteoporosis
NCT001815973	NCT00181597_3_T0	PHENOTYPE	15	16	hormone levels
NCT001816103	NCT00181610_3_T0	BIOLOGICAL_PROCESS	1	1	lactation
NCT001816104	NCT00181610_4_T0	BIOLOGICAL_PROCESS	1	1	lactation
NCT001816107	NCT00181610_7_T0	GENE	3	3	am
NCT001816107	NCT00181610_7_T1	ORGAN	18	18	breasts
NCT0018161010	NCT00181610_10_T0	PHENOTYPE	8	9	prolactin level
NCT0018161010	NCT00181610_10_T1	PHENOTYPE	44	45	prolactin level
NCT0018161012	NCT00181610_12_T0	GENE	7	7	prolactin
NCT0018161013	NCT00181610_13_T0	PHENOTYPE	15	16	prolactin level
NCT0018161015	NCT00181610_15_T0	PHENOTYPE	38	39	prolactin level
NCT0018161016	NCT00181610_16_T0	ORGAN	5	5	breasts
NCT0018161017	NCT00181610_17_T0	GENE	15	15	hr
NCT0018161020	NCT00181610_20_T0	GENE	6	6	SC
NCT0018161020	NCT00181610_20_T1	GENE	18	18	SC
NCT0018161021	NCT00181610_21_T0	GENE	6	6	SC
NCT0018161023	NCT00181610_23_T0	GENE	2	2	prolactin
NCT0018161027	NCT00181610_27_T0	PHENOTYPE	28	29	prolactin level
NCT001816232	NCT00181623_2_T0	PHENOTYPE	11	12	prolactin deficiency
NCT001816233	NCT00181623_3_T0	GENE	12	12	am
NCT001816233	NCT00181623_3_T1	PHENOTYPE	15	16	prolactin level
NCT001816234	NCT00181623_4_T0	BIOLOGICAL_PROCESS	13	13	lactation
NCT001816236	NCT00181623_6_T0	GENE	0	0	Prolactin
NCT001816237	NCT00181623_7_T0	GENE	9	9	SC
NCT001816238	NCT00181623_8_T0	PHENOTYPE	14	15	prolactin level
NCT0018162310	NCT00181623_10_T0	ORGAN	5	5	breasts
NCT0018162312	NCT00181623_12_T0	GENE	7	7	SC
NCT0018162313	NCT00181623_13_T0	GENE	6	6	SC
NCT0018162319	NCT00181623_19_T0	GENE	22	22	SC
NCT0018162319	NCT00181623_19_T1	PHENOTYPE	10	10	galactorrhea
NCT0018162319	NCT00181623_19_T2	PHENOTYPE	14	15	prolactin level
NCT0018162321	NCT00181623_21_T0	GENE	25	25	prolactin
NCT0018162322	NCT00181623_22_T0	GENE	4	4	cc
NCT0018162322	NCT00181623_22_T1	PHENOTYPE	17	18	prolactin level
NCT0018162323	NCT00181623_23_T0	PHENOTYPE	2	3	prolactin level
NCT0018162328	NCT00181623_28_T0	GENE	4	4	cc
NCT0018162328	NCT00181623_28_T1	COMPOUND	18	18	glucose
NCT0018162328	NCT00181623_28_T2	GENE	21	21	IgA
NCT0018162328	NCT00181623_28_T3	COMPOUND	19	19	lactose
NCT0018162329	NCT00181623_29_T0	PHENOTYPE	4	5	premature infants
NCT0018162332	NCT00181623_32_T0	GENE	12	12	prolactin
NCT0018162333	NCT00181623_33_T0	ORGAN	13	13	breasts
NCT0018162333	NCT00181623_33_T1	PHENOTYPE	3	4	prolactin level
NCT0018162334	NCT00181623_34_T0	GENE	27	27	prolactin
NCT001816494	NCT00181649_4_T0	COMPOUND	1	1	1
NCT001816494	NCT00181649_4_T1	COMPOUND	4	4	1
NCT001816494	NCT00181649_4_T2	BIOLOGICAL_PROCESS	28	28	lactation
NCT001816494	NCT00181649_4_T3	PHENOTYPE	7	8	prolactin level
NCT001816497	NCT00181649_7_T0	GENE	0	0	Prolactin
NCT001816499	NCT00181649_9_T0	COMPOUND	1	1	2
NCT0018164910	NCT00181649_10_T0	GENE	14	14	prolactin
NCT0018164911	NCT00181649_11_T0	GENE	11	11	SC
NCT0018164912	NCT00181649_12_T0	PHENOTYPE	27	28	prolactin level
NCT0018164914	NCT00181649_14_T0	ORGAN	4	4	breasts
NCT0018164915	NCT00181649_15_T0	GENE	7	7	SC
NCT0018164915	NCT00181649_15_T1	GENE	16	16	SC
NCT0018164916	NCT00181649_16_T0	GENE	3	3	SC
NCT0018164918	NCT00181649_18_T0	GENE	16	16	prolactin
NCT0018164920	NCT00181649_20_T0	PHENOTYPE	12	13	prolactin level
NCT0018164925	NCT00181649_25_T0	PHENOTYPE	2	3	prolactin level
NCT0018164927	NCT00181649_27_T0	GENE	2	2	cc
NCT001816621	NCT00181662_1_T0	PHENOTYPE	8	8	pharmacokinetics
NCT001816621	NCT00181662_1_T1	COMPOUND	3	3	piperine
NCT001816621	NCT00181662_1_T2	COMPOUND	10	10	curcumin
NCT001816751	NCT00181675_1_T0	COMPOUND	6	6	1
NCT001816751	NCT00181675_1_T1	PHENOTYPE	7	7	ADHD
NCT001816751	NCT00181675_1_T2	PHENOTYPE	13	13	ADHD
NCT001816751	NCT00181675_1_T3	PHENOTYPE	18	18	acute
NCT001816752	NCT00181675_2_T0	PHENOTYPE	6	6	ADHD
NCT001816752	NCT00181675_2_T1	PHENOTYPE	29	29	acute
NCT001816752	NCT00181675_2_T2	COMPOUND	1	1	2
NCT001816752	NCT00181675_2_T3	PHENOTYPE	25	27	quality of life
NCT001816753	NCT00181675_3_T0	PHENOTYPE	12	12	reflected
NCT001816753	NCT00181675_3_T1	COMPOUND	1	1	3
NCT001816755	NCT00181675_5_T0	PHENOTYPE	14	14	ADHD
NCT001816756	NCT00181675_6_T0	PHENOTYPE	17	17	ADHD
NCT001816757	NCT00181675_7_T0	PHENOTYPE	8	8	ADHD
NCT001816757	NCT00181675_7_T1	PHENOTYPE	24	26	quality of life
NCT0018167514	NCT00181675_14_T0	PHENOTYPE	10	10	ADHD
NCT0018167514	NCT00181675_14_T1	PHENOTYPE	6	7	childhood onset
NCT0018167516	NCT00181675_16_T0	PHENOTYPE	10	10	ADHD
NCT0018167518	NCT00181675_18_T0	PHENOTYPE	2	2	ADHD
NCT0018167522	NCT00181675_22_T0	PHENOTYPE	3	3	chronic
NCT0018167522	NCT00181675_22_T1	PHENOTYPE	13	14	endocrine disorders
NCT0018167522	NCT00181675_22_T2	PHENOTYPE	18	19	renal impairment
NCT0018167526	NCT00181675_26_T0	GENE	1	1	75
NCT0018167528	NCT00181675_28_T0	PHENOTYPE	1	2	brain disorders
NCT0018167530	NCT00181675_30_T0	PHENOTYPE	7	8	seizure disorders
NCT0018167538	NCT00181675_38_T0	GENE	13	13	GI
NCT0018167538	NCT00181675_38_T1	PHENOTYPE	8	10	gastroesophageal reflux disease
NCT0018167538	NCT00181675_38_T2	PHENOTYPE	5	7	peptic ulcer disease
NCT001816883	NCT00181688_3_T0	PHENOTYPE	6	6	symptoms
NCT001817017	NCT00181701_7_T0	COMPOUND	17	17	paclitaxel
NCT001817017	NCT00181701_7_T1	PHENOTYPE	7	8	allergic reaction
NCT001817018	NCT00181701_8_T0	ORGAN	15	16	abdominal cavity
NCT001817018	NCT00181701_8_T1	ORGAN	27	28	abdominal cavity
NCT001817019	NCT00181701_9_T0	PHENOTYPE	24	24	remission
NCT001817019	NCT00181701_9_T1	GENE	8	8	3.8
NCT0018170113	NCT00181701_13_T0	COMPOUND	13	13	paclitaxel
NCT0018170114	NCT00181701_14_T0	GENE	26	26	has
NCT001817141	NCT00181714_1_T0	PHENOTYPE	17	17	ADHD
NCT001817141	NCT00181714_1_T1	GENE	5	5	MPH
NCT001817147	NCT00181714_7_T0	PHENOTYPE	6	6	ADHD
NCT001817149	NCT00181714_9_T0	PHENOTYPE	4	4	ADHD
NCT001817149	NCT00181714_9_T1	GENE	29	29	OR
NCT001817149	NCT00181714_9_T2	PHENOTYPE	16	16	Severity
NCT001817149	NCT00181714_9_T3	PHENOTYPE	5	5	symptoms
NCT0018171411	NCT00181714_11_T0	PHENOTYPE	16	16	hypertension
NCT0018171411	NCT00181714_11_T1	PHENOTYPE	21	22	hematologic disease
NCT0018171411	NCT00181714_11_T2	PHENOTYPE	13	15	ischemic heart disease
NCT0018171414	NCT00181714_14_T0	PHENOTYPE	2	2	seizures
NCT0018171418	NCT00181714_18_T0	PHENOTYPE	1	2	brain disorder
NCT0018171419	NCT00181714_19_T0	PHENOTYPE	0	1	Eating disorders
NCT0018171421	NCT00181714_21_T0	PHENOTYPE	1	2	bipolar disorder
NCT0018171424	NCT00181714_24_T0	PHENOTYPE	3	3	dependence
NCT0018171424	NCT00181714_24_T1	PHENOTYPE	0	1	Substance abuse
NCT001817271	NCT00181727_1_T0	COMPOUND	11	11	Sodium
NCT001817274	NCT00181727_4_T0	PHENOTYPE	27	27	concentrations
NCT001817274	NCT00181727_4_T1	COMPOUND	7	7	Sodium
NCT001817274	NCT00181727_4_T2	GENE	31	31	GABA
NCT001817274	NCT00181727_4_T3	GENE	15	15	has
NCT001817276	NCT00181727_6_T0	COMPOUND	4	4	Sodium
NCT001817276	NCT00181727_6_T1	PHENOTYPE	25	26	bipolar disorder
NCT001817277	NCT00181727_7_T0	GENE	2	2	has
NCT0018172712	NCT00181727_12_T0	GENE	10	10	II
NCT0018172712	NCT00181727_12_T1	PHENOTYPE	49	49	Schizophrenia
NCT0018172712	NCT00181727_12_T2	GENE	54	54	al
NCT0018172712	NCT00181727_12_T3	GENE	53	53	et
NCT0018172712	NCT00181727_12_T4	PHENOTYPE	23	23	symptoms
NCT0018172712	NCT00181727_12_T5	PHENOTYPE	19	19	manic
NCT0018172712	NCT00181727_12_T6	PHENOTYPE	46	47	Affective Disorders
NCT0018172726	NCT00181727_26_T0	GENE	5	5	swallow
NCT0018172728	NCT00181727_28_T0	PHENOTYPE	3	3	ADHD
NCT0018172728	NCT00181727_28_T1	GENE	5	5	CD
NCT0018172728	NCT00181727_28_T2	GENE	4	4	ODD
NCT0018172728	NCT00181727_28_T3	PHENOTYPE	8	9	depressive disorders
NCT0018172729	NCT00181727_29_T0	PHENOTYPE	7	7	ADHD
NCT0018172734	NCT00181727_34_T0	PHENOTYPE	17	18	hematologic disease
NCT0018172734	NCT00181727_34_T1	PHENOTYPE	10	12	ischemic heart disease
NCT0018172736	NCT00181727_36_T0	PHENOTYPE	3	3	hyperthyroidism
NCT0018172736	NCT00181727_36_T1	PHENOTYPE	1	1	hypothyroidism
NCT0018172738	NCT00181727_38_T0	PHENOTYPE	3	3	allergies
NCT0018172738	NCT00181727_38_T1	PHENOTYPE	6	8	adverse drug reactions
NCT0018172740	NCT00181727_40_T0	PHENOTYPE	1	1	seizures
NCT0018172740	NCT00181727_40_T1	PHENOTYPE	6	6	resolved
NCT0018172742	NCT00181727_42_T0	PHENOTYPE	4	4	leukopenia
NCT0018172742	NCT00181727_42_T1	PHENOTYPE	0	0	Leukopenia
NCT0018172742	NCT00181727_42_T2	PHENOTYPE	9	9	resolved
NCT0018172744	NCT00181727_44_T0	COMPOUND	5	5	caffeine
NCT0018172744	NCT00181727_44_T1	COMPOUND	3	3	nicotine
NCT0018172744	NCT00181727_44_T2	PHENOTYPE	6	6	dependence
NCT0018172748	NCT00181727_48_T0	ORGAN	6	8	central nervous system
NCT0018172749	NCT00181727_49_T0	COMPOUND	9	9	Sodium
NCT0018172753	NCT00181727_53_T0	COMPOUND	44	44	MGH
NCT0018172753	NCT00181727_53_T1	GENE	66	66	has
NCT001817406	NCT00181740_6_T0	PHENOTYPE	9	9	acute
NCT001817407	NCT00181740_7_T0	GENE	1	1	II
NCT001817408	NCT00181740_8_T0	PHENOTYPE	10	10	ADHD
NCT001817408	NCT00181740_8_T1	PHENOTYPE	16	16	ADHD
NCT0018174014	NCT00181740_14_T0	PHENOTYPE	14	14	symptoms
NCT0018174014	NCT00181740_14_T1	PHENOTYPE	13	13	ADHD
NCT0018174016	NCT00181740_16_T0	PHENOTYPE	17	17	severity
NCT0018174016	NCT00181740_16_T1	PHENOTYPE	8	8	ADHD
NCT0018174020	NCT00181740_20_T0	PHENOTYPE	3	4	anxiety disorders
NCT0018174029	NCT00181740_29_T0	PHENOTYPE	7	7	allergy
NCT0018174029	NCT00181740_29_T1	PHENOTYPE	5	5	asthma
NCT0018174031	NCT00181740_31_T0	PHENOTYPE	2	2	hypercholesterolemia
NCT0018174033	NCT00181740_33_T0	PHENOTYPE	10	10	acute
NCT0018174033	NCT00181740_33_T1	PHENOTYPE	12	12	acute
NCT0018174033	NCT00181740_33_T2	PHENOTYPE	16	16	acute
NCT0018174033	NCT00181740_33_T3	PHENOTYPE	20	20	acute
NCT0018174033	NCT00181740_33_T4	PHENOTYPE	27	27	acute
NCT0018174033	NCT00181740_33_T5	PHENOTYPE	29	29	sociopathy
NCT0018174033	NCT00181740_33_T6	PHENOTYPE	13	13	OCD
NCT0018174033	NCT00181740_33_T7	PHENOTYPE	28	28	OCD
NCT0018174033	NCT00181740_33_T8	PHENOTYPE	14	15	acute mania
NCT0018174033	NCT00181740_33_T9	PHENOTYPE	18	19	bipolar disorder
NCT0018174033	NCT00181740_33_T10	PHENOTYPE	8	9	acute psychosis
NCT0018174033	NCT00181740_33_T11	PHENOTYPE	21	23	substance use disorders
NCT0018174035	NCT00181740_35_T0	PHENOTYPE	9	10	endocrine disease
NCT0018174038	NCT00181740_38_T0	PHENOTYPE	7	7	arrhythmia
NCT0018174038	NCT00181740_38_T1	PHENOTYPE	5	5	ischemia
NCT0018174040	NCT00181740_40_T0	GENE	3	3	75
NCT0018174040	NCT00181740_40_T1	PHENOTYPE	0	1	Mental retardation
NCT0018174042	NCT00181740_42_T0	PHENOTYPE	1	2	brain disorders
NCT0018174044	NCT00181740_44_T0	PHENOTYPE	2	2	tics
NCT0018174044	NCT00181740_44_T1	PHENOTYPE	0	0	Seizures
NCT0018174048	NCT00181740_48_T0	GENE	6	7	monoamine oxidase
NCT0018174048	NCT00181740_48_T1	GENE	14	15	monoamine oxidase
NCT0018174052	NCT00181740_52_T0	PHENOTYPE	6	6	ADHD
NCT001817533	NCT00181753_3_T0	PHENOTYPE	9	10	heal wounds
NCT001817536	NCT00181753_6_T0	PHENOTYPE	21	22	burn injury
NCT001817537	NCT00181753_7_T0	TISSUE	17	17	tissues
NCT001817664	NCT00181766_4_T0	PHENOTYPE	11	11	ADHD
NCT0018176614	NCT00181766_14_T0	PHENOTYPE	14	14	symptoms
NCT0018176614	NCT00181766_14_T1	PHENOTYPE	13	13	ADHD
NCT0018176616	NCT00181766_16_T0	PHENOTYPE	8	8	ADHD
NCT0018176620	NCT00181766_20_T0	PHENOTYPE	3	4	anxiety disorders
NCT0018176626	NCT00181766_26_T0	PHENOTYPE	7	7	allergy
NCT0018176626	NCT00181766_26_T1	PHENOTYPE	5	5	asthma
NCT0018176629	NCT00181766_29_T0	PHENOTYPE	2	2	hypercholesterolemia
NCT0018176631	NCT00181766_31_T0	PHENOTYPE	10	10	acute
NCT0018176631	NCT00181766_31_T1	PHENOTYPE	12	12	acute
NCT0018176631	NCT00181766_31_T2	PHENOTYPE	16	16	acute
NCT0018176631	NCT00181766_31_T3	PHENOTYPE	23	23	acute
NCT0018176631	NCT00181766_31_T4	PHENOTYPE	30	30	sociopathy
NCT0018176631	NCT00181766_31_T5	PHENOTYPE	13	13	OCD
NCT0018176631	NCT00181766_31_T6	PHENOTYPE	14	15	acute mania
NCT0018176631	NCT00181766_31_T7	PHENOTYPE	21	22	bipolar disorder
NCT0018176631	NCT00181766_31_T8	PHENOTYPE	8	9	acute psychosis
NCT0018176631	NCT00181766_31_T9	PHENOTYPE	24	26	substance use disorders
NCT0018176633	NCT00181766_33_T0	PHENOTYPE	9	10	endocrine disease
NCT0018176641	NCT00181766_41_T0	PHENOTYPE	7	7	arrhythmia
NCT0018176641	NCT00181766_41_T1	PHENOTYPE	5	5	ischemia
NCT0018176645	NCT00181766_45_T0	PHENOTYPE	1	2	brain disorders
NCT0018176649	NCT00181766_49_T0	PHENOTYPE	6	6	ADHD
NCT0018176651	NCT00181766_51_T0	GENE	13	13	had
NCT0018176653	NCT00181766_53_T0	COMPOUND	46	46	MGH
NCT0018176653	NCT00181766_53_T1	COMPOUND	13	13	1
NCT0018176653	NCT00181766_53_T2	COMPOUND	29	29	2
NCT0018176653	NCT00181766_53_T3	COMPOUND	54	54	3
NCT0018176653	NCT00181766_53_T4	GENE	68	68	has
NCT001817794	NCT00181779_4_T0	PHENOTYPE	14	14	schizophrenia
NCT001817794	NCT00181779_4_T1	GENE	17	17	has
NCT001817796	NCT00181779_6_T0	GENE	2	2	has
NCT001817796	NCT00181779_6_T1	GENE	16	16	has
NCT0018177919	NCT00181779_19_T0	GENE	10	10	II
NCT0018177919	NCT00181779_19_T1	PHENOTYPE	16	16	acute
NCT0018177919	NCT00181779_19_T2	PHENOTYPE	17	17	manic
NCT0018177919	NCT00181779_19_T3	PHENOTYPE	44	45	Affective Disorders
NCT0018177926	NCT00181779_26_T0	GENE	5	5	swallow
NCT0018177930	NCT00181779_30_T0	PHENOTYPE	17	18	hematologic disease
NCT0018177930	NCT00181779_30_T1	PHENOTYPE	10	12	ischemic heart disease
NCT0018177932	NCT00181779_32_T0	PHENOTYPE	3	3	hyperthyroidism
NCT0018177932	NCT00181779_32_T1	PHENOTYPE	1	1	hypothyroidism
NCT0018177934	NCT00181779_34_T0	PHENOTYPE	3	3	allergies
NCT0018177934	NCT00181779_34_T1	PHENOTYPE	6	8	adverse drug reactions
NCT0018177936	NCT00181779_36_T0	PHENOTYPE	1	1	seizures
NCT0018177936	NCT00181779_36_T1	PHENOTYPE	6	6	resolved
NCT0018177938	NCT00181779_38_T0	PHENOTYPE	4	4	leukopenia
NCT0018177938	NCT00181779_38_T1	PHENOTYPE	0	0	Leukopenia
NCT0018177938	NCT00181779_38_T2	PHENOTYPE	9	9	resolved
NCT0018177940	NCT00181779_40_T0	COMPOUND	5	5	caffeine
NCT0018177940	NCT00181779_40_T1	COMPOUND	3	3	nicotine
NCT0018177940	NCT00181779_40_T2	PHENOTYPE	6	6	dependence
NCT0018177944	NCT00181779_44_T0	ORGAN	6	8	central nervous system
NCT0018177946	NCT00181779_46_T0	GENE	12	12	2.12
NCT0018177946	NCT00181779_46_T1	GENE	3	4	monoamine oxidase
NCT0018177948	NCT00181779_48_T0	PHENOTYPE	7	7	ADHD
NCT001817921	NCT00181792_1_T0	PHENOTYPE	8	8	ADHD
NCT001817921	NCT00181792_1_T1	PHENOTYPE	31	31	ADHD
NCT001817921	NCT00181792_1_T2	PHENOTYPE	24	24	initiation
NCT001817921	NCT00181792_1_T3	PHENOTYPE	26	26	persistence
NCT001817923	NCT00181792_3_T0	PHENOTYPE	2	2	ADHD
NCT001817923	NCT00181792_3_T1	PHENOTYPE	32	32	ADHD
NCT001817923	NCT00181792_3_T2	PHENOTYPE	37	37	ADHD
NCT001817923	NCT00181792_3_T3	PHENOTYPE	10	10	disorders
NCT001817923	NCT00181792_3_T4	PHENOTYPE	23	23	disorders
NCT001817924	NCT00181792_4_T0	PHENOTYPE	19	19	ADHD
NCT001817924	NCT00181792_4_T1	COMPOUND	14	14	nicotine
NCT001817924	NCT00181792_4_T2	PHENOTYPE	17	17	dependence
NCT001817925	NCT00181792_5_T0	COMPOUND	3	3	1
NCT001817925	NCT00181792_5_T1	PHENOTYPE	41	41	ADHD
NCT001817925	NCT00181792_5_T2	COMPOUND	10	10	2
NCT001817925	NCT00181792_5_T3	COMPOUND	17	17	3
NCT001818052	NCT00181805_2_T0	GENE	11	11	GI
NCT001818054	NCT00181805_4_T0	PHENOTYPE	11	11	recruitment
NCT001818055	NCT00181805_5_T0	PHENOTYPE	7	7	recruitment
NCT001818056	NCT00181805_6_T0	GENE	5	5	has
NCT001818058	NCT00181805_8_T0	PHENOTYPE	3	3	compensation
NCT0018180511	NCT00181805_11_T0	PHENOTYPE	15	15	diseases
NCT001818183	NCT00181818_3_T0	PHENOTYPE	2	2	acute
NCT001818183	NCT00181818_3_T1	GENE	3	3	CHD
NCT001818185	NCT00181818_5_T0	PHENOTYPE	3	3	strategies
NCT001818186	NCT00181818_6_T0	COMPOUND	25	25	nicotine
NCT001818186	NCT00181818_6_T1	GENE	11	11	has
NCT001818187	NCT00181818_7_T0	COMPOUND	9	9	nicotine
NCT001818187	NCT00181818_7_T1	GENE	13	13	has
NCT001818187	NCT00181818_7_T2	COMPOUND	3	3	bupropion
NCT001818187	NCT00181818_7_T3	GENE	2	2	SR
NCT001818187	NCT00181818_7_T4	GENE	6	6	SR
NCT0018181810	NCT00181818_10_T0	COMPOUND	14	14	bupropion
NCT0018181810	NCT00181818_10_T1	GENE	15	15	SR
NCT0018181812	NCT00181818_12_T0	PHENOTYPE	1	1	secondary
NCT0018181813	NCT00181818_13_T0	PHENOTYPE	0	0	Secondary
NCT0018181813	NCT00181818_13_T1	PHENOTYPE	13	13	relapse
NCT0018181813	NCT00181818_13_T2	COMPOUND	6	6	bupropion
NCT0018181813	NCT00181818_13_T3	GENE	15	15	CHD
NCT0018181813	NCT00181818_13_T4	GENE	7	7	SR
NCT0018181813	NCT00181818_13_T5	PHENOTYPE	18	19	depressive symptoms
NCT0018181813	NCT00181818_13_T6	PHENOTYPE	23	25	quality of life
NCT001818311	NCT00181831_1_T0	PHENOTYPE	14	14	ADHD
NCT001818311	NCT00181831_1_T1	PHENOTYPE	11	12	bipolar disorder
NCT001818311	NCT00181831_1_T2	PHENOTYPE	33	36	Attention Deficit Hyperactivity Disorder
NCT001818312	NCT00181831_2_T0	PHENOTYPE	18	18	mania
NCT001818312	NCT00181831_2_T1	PHENOTYPE	13	14	manic symptoms
NCT001818312	NCT00181831_2_T2	ORGAN	7	8	anterior cingulate
NCT001818314	NCT00181831_4_T0	PHENOTYPE	19	19	BPD
NCT001818314	NCT00181831_4_T1	GENE	3	3	has
NCT001818314	NCT00181831_4_T2	ORGAN	10	11	anterior cingulate
NCT001818314	NCT00181831_4_T3	PHENOTYPE	16	18	bipolar affective disorder
NCT001818315	NCT00181831_5_T0	PHENOTYPE	1	1	BPD
NCT001818315	NCT00181831_5_T1	GENE	6	6	had
NCT001818315	NCT00181831_5_T2	ORGAN	10	11	anterior cingulate
NCT001818316	NCT00181831_6_T0	ORGAN	5	6	frontal lobe
NCT001818317	NCT00181831_7_T0	PHENOTYPE	11	11	mania
NCT001818317	NCT00181831_7_T1	PHENOTYPE	23	23	mania
NCT001818318	NCT00181831_8_T0	PHENOTYPE	0	0	Mania
NCT001818318	NCT00181831_8_T1	PHENOTYPE	17	17	manic
NCT001818318	NCT00181831_8_T2	ORGAN	13	14	anterior cingulate
NCT001818318	NCT00181831_8_T3	PHENOTYPE	23	25	bipolar affective disorder
NCT001818319	NCT00181831_9_T0	COMPOUND	9	9	lithium
NCT001818319	NCT00181831_9_T1	COMPOUND	18	18	lithium
NCT001818319	NCT00181831_9_T2	PHENOTYPE	17	17	acute
NCT0018183110	NCT00181831_10_T0	COMPOUND	30	30	risperidone
NCT0018183110	NCT00181831_10_T1	PHENOTYPE	10	11	manic symptoms
NCT0018183112	NCT00181831_12_T0	PHENOTYPE	14	14	ADHD
NCT0018183112	NCT00181831_12_T1	PHENOTYPE	11	12	bipolar disorder
NCT0018183112	NCT00181831_12_T2	PHENOTYPE	33	36	Attention Deficit Hyperactivity Disorder
NCT0018183113	NCT00181831_13_T0	PHENOTYPE	18	18	mania
NCT0018183113	NCT00181831_13_T1	PHENOTYPE	13	14	manic symptoms
NCT0018183113	NCT00181831_13_T2	ORGAN	7	8	anterior cingulate
NCT0018183121	NCT00181831_21_T0	GENE	11	11	II
NCT0018183121	NCT00181831_21_T1	PHENOTYPE	16	16	manic
NCT0018183122	NCT00181831_22_T0	PHENOTYPE	0	0	ADHD
NCT0018183122	NCT00181831_22_T1	PHENOTYPE	7	7	ADHD
NCT0018183122	NCT00181831_22_T2	PHENOTYPE	11	11	hyperactivity
NCT0018183126	NCT00181831_26_T0	PHENOTYPE	6	6	aneurysm
NCT0018183128	NCT00181831_28_T0	PHENOTYPE	1	1	phobia
NCT0018183129	NCT00181831_29_T0	GENE	17	17	OR
NCT0018183129	NCT00181831_29_T1	COMPOUND	11	11	risperidone
NCT0018183129	NCT00181831_29_T2	COMPOUND	22	22	risperidone
NCT0018183131	NCT00181831_31_T0	PHENOTYPE	0	0	ADHD
NCT0018183131	NCT00181831_31_T1	PHENOTYPE	7	8	bipolar disorder
NCT0018183134	NCT00181831_34_T0	PHENOTYPE	7	7	ADHD
NCT0018183134	NCT00181831_34_T1	PHENOTYPE	9	10	bipolar disorder
NCT001818441	NCT00181844_1_T0	GENE	24	24	II
NCT001818443	NCT00181844_3_T0	PHENOTYPE	28	28	disorders
NCT001818443	NCT00181844_3_T1	COMPOUND	13	13	lamotrigine
NCT001818443	NCT00181844_3_T2	PHENOTYPE	8	9	bipolar disorder
NCT001818445	NCT00181844_5_T0	GENE	2	2	12
NCT001818445	NCT00181844_5_T1	GENE	7	7	0.35
NCT001818445	NCT00181844_5_T2	PHENOTYPE	16	16	nearest
NCT001818448	NCT00181844_8_T0	PHENOTYPE	12	13	bipolar depression
NCT0018184426	NCT00181844_26_T0	GENE	5	5	swallow
NCT0018184428	NCT00181844_28_T0	PHENOTYPE	3	3	ADHD
NCT0018184428	NCT00181844_28_T1	GENE	5	5	CD
NCT0018184428	NCT00181844_28_T2	GENE	4	4	ODD
NCT0018184428	NCT00181844_28_T3	PHENOTYPE	8	9	depressive disorders
NCT0018184429	NCT00181844_29_T0	PHENOTYPE	7	7	ADHD
NCT0018184434	NCT00181844_34_T0	GENE	3	3	swallow
NCT0018184436	NCT00181844_36_T0	PHENOTYPE	17	18	hematologic disease
NCT0018184436	NCT00181844_36_T1	PHENOTYPE	10	12	ischemic heart disease
NCT0018184438	NCT00181844_38_T0	PHENOTYPE	8	8	allergies
NCT0018184438	NCT00181844_38_T1	COMPOUND	4	4	lamotrigine
NCT0018184438	NCT00181844_38_T2	PHENOTYPE	11	13	adverse drug reactions
NCT0018184440	NCT00181844_40_T0	PHENOTYPE	3	5	bone marrow depression
NCT0018184442	NCT00181844_42_T0	PHENOTYPE	3	3	rashes
NCT0018184444	NCT00181844_44_T0	COMPOUND	5	5	caffeine
NCT0018184444	NCT00181844_44_T1	COMPOUND	3	3	nicotine
NCT0018184444	NCT00181844_44_T2	PHENOTYPE	6	6	dependence
NCT0018184448	NCT00181844_48_T0	ORGAN	6	8	central nervous system
NCT0018184449	NCT00181844_49_T0	COMPOUND	8	8	lamotrigine
NCT001818578	NCT00181857_8_T0	GENE	0	0	Age
NCT0018185713	NCT00181857_13_T0	PHENOTYPE	14	14	symptoms
NCT0018185713	NCT00181857_13_T1	PHENOTYPE	13	13	ADHD
NCT0018185721	NCT00181857_21_T0	PHENOTYPE	10	10	profound
NCT0018185721	NCT00181857_21_T1	PHENOTYPE	20	20	profound
NCT0018185721	NCT00181857_21_T2	PHENOTYPE	21	21	disorders
NCT0018185721	NCT00181857_21_T3	PHENOTYPE	12	12	blindness
NCT0018185721	NCT00181857_21_T4	PHENOTYPE	11	11	deafness
NCT001818701	NCT00181870_1_T0	PHENOTYPE	27	28	Bipolar Disorder
NCT001818703	NCT00181870_3_T0	GENE	12	12	had
NCT001818703	NCT00181870_3_T1	GENE	20	20	had
NCT001818703	NCT00181870_3_T2	GENE	28	28	ER
NCT001818703	NCT00181870_3_T3	GENE	26	26	extended
NCT001818704	NCT00181870_4_T0	GENE	4	4	ER
NCT001818705	NCT00181870_5_T0	GENE	2	2	ER
NCT001818706	NCT00181870_6_T0	GENE	22	22	II
NCT001818707	NCT00181870_7_T0	PHENOTYPE	22	23	Bipolar Disorder
NCT0018187012	NCT00181870_12_T0	GENE	10	10	II
NCT0018187012	NCT00181870_12_T1	PHENOTYPE	47	47	Schizophrenia
NCT0018187012	NCT00181870_12_T2	GENE	52	52	al
NCT0018187012	NCT00181870_12_T3	GENE	51	51	et
NCT0018187012	NCT00181870_12_T4	PHENOTYPE	23	23	symptoms
NCT0018187012	NCT00181870_12_T5	PHENOTYPE	19	19	manic
NCT0018187012	NCT00181870_12_T6	PHENOTYPE	44	45	Affective Disorders
NCT0018187026	NCT00181870_26_T0	GENE	5	5	swallow
NCT0018187028	NCT00181870_28_T0	PHENOTYPE	3	3	ADHD
NCT0018187028	NCT00181870_28_T1	GENE	5	5	CD
NCT0018187028	NCT00181870_28_T2	GENE	4	4	ODD
NCT0018187028	NCT00181870_28_T3	PHENOTYPE	8	9	depressive disorders
NCT0018187029	NCT00181870_29_T0	PHENOTYPE	6	6	ADHD
NCT0018187030	NCT00181870_30_T0	PHENOTYPE	4	4	ADHD
NCT0018187035	NCT00181870_35_T0	PHENOTYPE	17	18	hematologic disease
NCT0018187035	NCT00181870_35_T1	PHENOTYPE	10	12	ischemic heart disease
NCT0018187037	NCT00181870_37_T0	PHENOTYPE	3	3	hyperthyroidism
NCT0018187037	NCT00181870_37_T1	PHENOTYPE	1	1	hypothyroidism
NCT0018187039	NCT00181870_39_T0	COMPOUND	21	21	nortriptyline
NCT0018187039	NCT00181870_39_T1	COMPOUND	19	19	protriptyline
NCT0018187039	NCT00181870_39_T2	COMPOUND	16	16	amitriptyline
NCT0018187039	NCT00181870_39_T3	COMPOUND	18	18	imipramine
NCT0018187039	NCT00181870_39_T4	COMPOUND	17	17	desipramine
NCT0018187039	NCT00181870_39_T5	COMPOUND	4	4	carbamazepine
NCT0018187040	NCT00181870_40_T0	PHENOTYPE	1	1	allergies
NCT0018187040	NCT00181870_40_T1	PHENOTYPE	4	6	adverse drug reactions
NCT0018187042	NCT00181870_42_T0	PHENOTYPE	1	1	seizures
NCT0018187042	NCT00181870_42_T1	PHENOTYPE	6	6	resolved
NCT0018187044	NCT00181870_44_T0	PHENOTYPE	3	5	bone marrow depression
NCT0018187045	NCT00181870_45_T0	COMPOUND	5	5	caffeine
NCT0018187045	NCT00181870_45_T1	COMPOUND	3	3	nicotine
NCT0018187045	NCT00181870_45_T2	PHENOTYPE	6	6	dependence
NCT0018187049	NCT00181870_49_T0	ORGAN	6	8	central nervous system
NCT0018187050	NCT00181870_50_T0	COMPOUND	8	8	carbamazepine
NCT001818961	NCT00181896_1_T0	PHENOTYPE	9	9	manic
NCT001818962	NCT00181896_2_T0	COMPOUND	14	14	bupropion
NCT001818962	NCT00181896_2_T1	GENE	15	15	SR
NCT001818962	NCT00181896_2_T2	PHENOTYPE	20	21	bipolar depression
NCT001818962	NCT00181896_2_T3	PHENOTYPE	21	23	depression in children
NCT001818965	NCT00181896_5_T0	PHENOTYPE	13	13	ADHD
NCT001818965	NCT00181896_5_T1	COMPOUND	7	7	bupropion
NCT001818965	NCT00181896_5_T2	COMPOUND	19	19	bupropion
NCT001818965	NCT00181896_5_T3	GENE	8	8	SR
NCT001818965	NCT00181896_5_T4	GENE	20	20	SR
NCT001818965	NCT00181896_5_T5	PHENOTYPE	15	16	Bipolar disorder
NCT001818965	NCT00181896_5_T6	PHENOTYPE	32	33	manic symptoms
NCT001818966	NCT00181896_6_T0	GENE	2	2	has
NCT001818966	NCT00181896_6_T1	COMPOUND	1	1	bupropion
NCT001818966	NCT00181896_6_T2	PHENOTYPE	10	11	bipolar depression
NCT001818967	NCT00181896_7_T0	COMPOUND	8	8	bupropion
NCT001818967	NCT00181896_7_T1	GENE	9	9	SR
NCT001818967	NCT00181896_7_T2	PHENOTYPE	16	17	bipolar depression
NCT001818968	NCT00181896_8_T0	PHENOTYPE	9	9	manic
NCT001818969	NCT00181896_9_T0	COMPOUND	14	14	bupropion
NCT001818969	NCT00181896_9_T1	GENE	15	15	SR
NCT001818969	NCT00181896_9_T2	PHENOTYPE	20	21	bipolar depression
NCT001818969	NCT00181896_9_T3	PHENOTYPE	21	23	depression in children
NCT001819097	NCT00181909_7_T0	PHENOTYPE	0	0	Secondary
NCT001819224	NCT00181922_4_T0	GENE	5	5	atypical
NCT001819224	NCT00181922_4_T1	GENE	18	18	5HT2
NCT001819224	NCT00181922_4_T2	GENE	16	16	D2
NCT001819226	NCT00181922_6_T0	PHENOTYPE	25	25	hyperprolactinemia
NCT001819226	NCT00181922_6_T1	GENE	3	3	has
NCT001819226	NCT00181922_6_T2	GENE	10	10	5HT2A
NCT001819226	NCT00181922_6_T3	GENE	12	13	D2 receptor
NCT001819226	NCT00181922_6_T4	PHENOTYPE	22	23	extrapyramidal symptoms
NCT0018192218	NCT00181922_18_T0	GENE	10	10	II
NCT0018192218	NCT00181922_18_T1	PHENOTYPE	16	16	acute
NCT0018192218	NCT00181922_18_T2	PHENOTYPE	17	17	manic
NCT0018192218	NCT00181922_18_T3	PHENOTYPE	44	45	Affective Disorders
NCT0018192224	NCT00181922_24_T0	GENE	5	5	swallow
NCT0018192226	NCT00181922_26_T0	COMPOUND	30	30	2
NCT0018192226	NCT00181922_26_T1	PHENOTYPE	2	2	chronic
NCT0018192226	NCT00181922_26_T2	PHENOTYPE	6	7	substance dependence
NCT0018192228	NCT00181922_28_T0	PHENOTYPE	17	18	hematologic disease
NCT0018192228	NCT00181922_28_T1	PHENOTYPE	10	12	ischemic heart disease
NCT0018192231	NCT00181922_31_T0	COMPOUND	20	20	gatifloxacin
NCT0018192231	NCT00181922_31_T1	COMPOUND	10	10	quinidine
NCT0018192231	NCT00181922_31_T2	COMPOUND	15	15	clarithromycin
NCT0018192231	NCT00181922_31_T3	COMPOUND	25	25	hydroxyzine
NCT0018192231	NCT00181922_31_T4	COMPOUND	21	21	chloroquine
NCT0018192231	NCT00181922_31_T5	COMPOUND	17	17	sparfloxacin
NCT0018192231	NCT00181922_31_T6	COMPOUND	19	19	levofloxacin
NCT0018192231	NCT00181922_31_T7	COMPOUND	14	14	erythromycin
NCT0018192231	NCT00181922_31_T8	COMPOUND	16	16	ketoconazole
NCT0018192231	NCT00181922_31_T9	COMPOUND	24	24	diphenhydramine
NCT0018192231	NCT00181922_31_T10	COMPOUND	18	18	moxifloxacin
NCT0018192233	NCT00181922_33_T0	PHENOTYPE	1	1	hypokalemia
NCT0018192233	NCT00181922_33_T1	PHENOTYPE	3	3	hypomagnesemia
NCT0018192234	NCT00181922_34_T0	PHENOTYPE	3	3	hyperthyroidism
NCT0018192234	NCT00181922_34_T1	PHENOTYPE	1	1	hypothyroidism
NCT0018192235	NCT00181922_35_T0	PHENOTYPE	3	3	allergies
NCT0018192235	NCT00181922_35_T1	PHENOTYPE	6	8	adverse drug reactions
NCT0018192236	NCT00181922_36_T0	PHENOTYPE	1	1	seizures
NCT0018192236	NCT00181922_36_T1	PHENOTYPE	6	6	resolved
NCT0018192237	NCT00181922_37_T0	PHENOTYPE	0	0	Leukopenia
NCT0018192237	NCT00181922_37_T1	PHENOTYPE	4	4	leucopenia
NCT0018192237	NCT00181922_37_T2	PHENOTYPE	9	9	resolved
NCT0018192238	NCT00181922_38_T0	COMPOUND	3	3	nicotine
NCT0018192238	NCT00181922_38_T1	COMPOUND	5	5	caffeine
NCT0018192238	NCT00181922_38_T2	PHENOTYPE	6	6	dependence
NCT0018192240	NCT00181922_40_T0	ORGAN	6	8	central nervous system
NCT0018192242	NCT00181922_42_T0	GENE	4	5	monoamine oxidase
NCT001819351	NCT00181935_1_T0	GENE	4	4	atypical
NCT001819351	NCT00181935_1_T1	PHENOTYPE	12	12	mania
NCT001819353	NCT00181935_3_T0	GENE	4	4	atypical
NCT001819353	NCT00181935_3_T1	GENE	17	17	5HT2
NCT001819353	NCT00181935_3_T2	GENE	15	15	D2
NCT001819355	NCT00181935_5_T0	COMPOUND	15	15	olanzapine
NCT001819355	NCT00181935_5_T1	PHENOTYPE	20	21	bipolar disorder
NCT0018193513	NCT00181935_13_T0	PHENOTYPE	7	7	acute
NCT0018193513	NCT00181935_13_T1	PHENOTYPE	10	11	adverse event
NCT0018193525	NCT00181935_25_T0	GENE	10	10	II
NCT0018193525	NCT00181935_25_T1	PHENOTYPE	16	16	acute
NCT0018193525	NCT00181935_25_T2	PHENOTYPE	17	17	manic
NCT0018193525	NCT00181935_25_T3	PHENOTYPE	44	45	Affective Disorders
NCT0018193533	NCT00181935_33_T0	PHENOTYPE	17	18	hematologic disease
NCT0018193533	NCT00181935_33_T1	PHENOTYPE	10	12	ischemic heart disease
NCT0018193534	NCT00181935_34_T0	PHENOTYPE	3	3	hyperthyroidism
NCT0018193534	NCT00181935_34_T1	PHENOTYPE	1	1	hypothyroidism
NCT0018193536	NCT00181935_36_T0	PHENOTYPE	3	3	allergies
NCT0018193536	NCT00181935_36_T1	PHENOTYPE	6	8	adverse drug reactions
NCT0018193538	NCT00181935_38_T0	PHENOTYPE	1	1	seizures
NCT0018193538	NCT00181935_38_T1	PHENOTYPE	6	6	resolved
NCT0018193540	NCT00181935_40_T0	PHENOTYPE	4	4	leukopenia
NCT0018193540	NCT00181935_40_T1	PHENOTYPE	0	0	Leukopenia
NCT0018193540	NCT00181935_40_T2	PHENOTYPE	9	9	resolved
NCT0018193544	NCT00181935_44_T0	ORGAN	6	8	central nervous system
NCT0018193545	NCT00181935_45_T0	COMPOUND	8	8	olanzapine
NCT0018193545	NCT00181935_45_T1	COMPOUND	6	6	risperidone
NCT0018193546	NCT00181935_46_T0	GENE	12	12	2.11
NCT0018193546	NCT00181935_46_T1	GENE	3	4	monoamine oxidase
NCT0018193547	NCT00181935_47_T0	PHENOTYPE	3	3	schizophrenia
NCT001819481	NCT00181948_1_T0	COMPOUND	6	6	1
NCT001819481	NCT00181948_1_T1	PHENOTYPE	7	7	ADHD
NCT001819481	NCT00181948_1_T2	PHENOTYPE	12	12	ADHD
NCT001819482	NCT00181948_2_T0	PHENOTYPE	19	19	ADHD
NCT001819482	NCT00181948_2_T1	COMPOUND	1	1	2
NCT001819482	NCT00181948_2_T2	GENE	12	12	1.2
NCT001819484	NCT00181948_4_T0	GENE	8	9	norepinephrine transporter
NCT001819485	NCT00181948_5_T0	PHENOTYPE	9	9	ADHD
NCT001819486	NCT00181948_6_T0	PHENOTYPE	21	21	ADHD
NCT001819610	NCT00181961_0_T0	PHENOTYPE	10	11	Sexual Dysfunction
NCT001819612	NCT00181961_2_T0	GENE	17	17	Root
NCT001819613	NCT00181961_3_T0	PHENOTYPE	13	14	sexual dysfunction
NCT001819615	NCT00181961_5_T0	GENE	15	15	Root
NCT001819615	NCT00181961_5_T1	GENE	45	45	phosphodiesterase
NCT001819615	NCT00181961_5_T2	PHENOTYPE	24	25	sexual dysfunction
NCT0018196111	NCT00181961_11_T0	GENE	17	17	has
NCT0018196115	NCT00181961_15_T0	COMPOUND	29	29	sildenafil
NCT0018196116	NCT00181961_16_T0	PHENOTYPE	26	27	sexual dysfunction
NCT0018196117	NCT00181961_17_T0	PHENOTYPE	3	4	sexual dysfunction
NCT0018196119	NCT00181961_19_T0	PHENOTYPE	11	11	symptoms
NCT0018196121	NCT00181961_21_T0	GENE	3	3	had
NCT0018196121	NCT00181961_21_T1	PHENOTYPE	5	6	sexual dysfunction
NCT0018196121	NCT00181961_21_T2	PHENOTYPE	22	23	sexual dysfunction
NCT001819743	NCT00181974_3_T0	ORGAN	11	11	autografts
NCT001819743	NCT00181974_3_T1	PHENOTYPE	6	6	wounds
NCT001819744	NCT00181974_4_T0	PHENOTYPE	5	5	bleeding
NCT001819744	NCT00181974_4_T1	PHENOTYPE	6	7	open wounds
NCT001819745	NCT00181974_5_T0	PHENOTYPE	39	39	wounds
NCT001819745	NCT00181974_5_T1	COMPOUND	12	12	1
NCT001819745	NCT00181974_5_T2	COMPOUND	20	20	2
NCT001819745	NCT00181974_5_T3	COMPOUND	29	29	3
NCT001819745	NCT00181974_5_T4	PHENOTYPE	34	34	fixation
NCT001819745	NCT00181974_5_T5	ORGAN	37	37	grafts
NCT001819745	NCT00181974_5_T6	PHENOTYPE	19	19	burns
NCT001819747	NCT00181974_7_T0	PHENOTYPE	3	3	burns
NCT001819748	NCT00181974_8_T0	COMPOUND	9	9	1
NCT001819748	NCT00181974_8_T1	COMPOUND	14	14	2
NCT001819748	NCT00181974_8_T2	PHENOTYPE	10	10	discomfort
NCT001819749	NCT00181974_9_T0	GENE	26	26	retained
NCT001819749	NCT00181974_9_T1	ORGAN	5	5	grafts
NCT0018197410	NCT00181974_10_T0	GENE	9	9	thrombin
NCT0018197410	NCT00181974_10_T1	GENE	6	6	fibrinogen
NCT0018197410	NCT00181974_10_T2	ORGAN	12	12	plasma
NCT0018197413	NCT00181974_13_T0	ORGAN	8	8	graft
NCT0018197413	NCT00181974_13_T1	PHENOTYPE	9	9	fixation
NCT0018197413	NCT00181974_13_T2	BIOLOGICAL_PROCESS	6	6	hemostasis
NCT0018197413	NCT00181974_13_T3	BIOLOGICAL_PROCESS	10	11	wound healing
NCT001819871	NCT00181987_1_T0	COMPOUND	14	14	methylphenidate
NCT001819871	NCT00181987_1_T1	PHENOTYPE	28	28	ADHD
NCT001819871	NCT00181987_1_T2	PHENOTYPE	38	38	mania
NCT001819871	NCT00181987_1_T3	PHENOTYPE	24	25	bipolar disorder
NCT001819873	NCT00181987_3_T0	PHENOTYPE	10	10	ADHD
NCT001819873	NCT00181987_3_T1	PHENOTYPE	21	21	mania
NCT001819874	NCT00181987_4_T0	PHENOTYPE	16	16	hyperactivity
NCT001819874	NCT00181987_4_T1	PHENOTYPE	13	13	talkativeness
NCT001819874	NCT00181987_4_T2	PHENOTYPE	10	10	symptoms
NCT001819874	NCT00181987_4_T3	PHENOTYPE	25	25	disorders
NCT001819876	NCT00181987_6_T0	GENE	37	37	II
NCT001819876	NCT00181987_6_T1	PHENOTYPE	44	44	ADHD
NCT001819877	NCT00181987_7_T0	COMPOUND	14	14	methylphenidate
NCT001819877	NCT00181987_7_T1	PHENOTYPE	28	28	ADHD
NCT001819877	NCT00181987_7_T2	PHENOTYPE	38	38	mania
NCT001819877	NCT00181987_7_T3	PHENOTYPE	24	25	bipolar disorder
NCT0018198720	NCT00181987_20_T0	GENE	5	5	swallow
NCT0018198724	NCT00181987_24_T0	PHENOTYPE	17	18	hematologic disease
NCT0018198724	NCT00181987_24_T1	PHENOTYPE	10	12	ischemic heart disease
NCT0018198725	NCT00181987_25_T0	PHENOTYPE	3	3	hyperthyroidism
NCT0018198725	NCT00181987_25_T1	PHENOTYPE	1	1	hypothyroidism
NCT0018198727	NCT00181987_27_T0	PHENOTYPE	3	3	allergies
NCT0018198727	NCT00181987_27_T1	PHENOTYPE	6	8	adverse drug reactions
NCT0018198729	NCT00181987_29_T0	PHENOTYPE	1	1	seizures
NCT0018198729	NCT00181987_29_T1	PHENOTYPE	6	6	resolved
NCT0018198731	NCT00181987_31_T0	PHENOTYPE	4	4	leukopenia
NCT0018198731	NCT00181987_31_T1	PHENOTYPE	0	0	Leukopenia
NCT0018198731	NCT00181987_31_T2	PHENOTYPE	9	9	resolved
NCT0018198735	NCT00181987_35_T0	ORGAN	6	8	central nervous system
NCT0018198737	NCT00181987_37_T0	PHENOTYPE	11	11	initiation
NCT0018198737	NCT00181987_37_T1	GENE	3	4	monoamine oxidase
NCT0018198738	NCT00181987_38_T0	PHENOTYPE	3	3	schizophrenia
NCT001820004	NCT00182000_4_T0	PHENOTYPE	4	4	symptoms
NCT001820004	NCT00182000_4_T1	PHENOTYPE	8	8	cognitions
NCT001820130	NCT00182013_0_T0	PHENOTYPE	10	10	Mania
NCT001820130	NCT00182013_0_T1	PHENOTYPE	19	21	Bipolar II Disorder
NCT001820393	NCT00182039_3_T0	GENE	11	11	SBP
NCT001820393	NCT00182039_3_T1	ORGAN	3	3	heart
NCT001820393	NCT00182039_3_T2	GENE	8	8	bpm
NCT001820395	NCT00182039_5_T0	COMPOUND	11	11	metoprolol
NCT001820395	NCT00182039_5_T1	GENE	12	12	CR
NCT0018203910	NCT00182039_10_T0	PHENOTYPE	30	30	recruitment
NCT0018203910	NCT00182039_10_T1	GENE	10	10	had
NCT0018203910	NCT00182039_10_T2	GENE	17	17	had
NCT001820652	NCT00182065_2_T0	PHENOTYPE	9	10	heart failure
NCT001820653	NCT00182065_3_T0	PHENOTYPE	18	18	intellect
NCT001820653	NCT00182065_3_T1	PHENOTYPE	22	23	heart failure
NCT001820656	NCT00182065_6_T0	PHENOTYPE	11	11	intellect
NCT001820657	NCT00182065_7_T0	PHENOTYPE	4	5	heart failure
NCT001820657	NCT00182065_7_T1	PHENOTYPE	14	15	heart failure
NCT0018206510	NCT00182065_10_T0	GENE	1	1	has
NCT0018206515	NCT00182065_15_T0	PHENOTYPE	7	8	adverse effects
NCT0018206517	NCT00182065_17_T0	PHENOTYPE	9	10	cognitive impairment
NCT0018206521	NCT00182065_21_T0	PHENOTYPE	1	1	secondary
NCT0018206521	NCT00182065_21_T1	PHENOTYPE	18	19	cognitive decline
NCT0018206521	NCT00182065_21_T2	PHENOTYPE	28	29	psychological symptoms
NCT0018206524	NCT00182065_24_T0	PHENOTYPE	22	22	malignancy
NCT0018206531	NCT00182065_31_T0	PHENOTYPE	4	4	acute
NCT0018206531	NCT00182065_31_T1	PHENOTYPE	7	7	falls
NCT0018206533	NCT00182065_33_T0	PHENOTYPE	12	12	symptoms
NCT001820780	NCT00182078_0_T0	PHENOTYPE	6	6	PTSD
NCT001820782	NCT00182078_2_T0	PHENOTYPE	14	16	posttraumatic stress disorder
NCT001820784	NCT00182078_4_T0	PHENOTYPE	9	9	acute
NCT001820784	NCT00182078_4_T1	COMPOUND	3	3	2
NCT001820784	NCT00182078_4_T2	COMPOUND	6	6	sertraline
NCT001820784	NCT00182078_4_T3	PHENOTYPE	12	13	burn injury
NCT001820784	NCT00182078_4_T4	PHENOTYPE	26	27	depressive symptoms
NCT001820786	NCT00182078_6_T0	PHENOTYPE	15	15	severity
NCT001820786	NCT00182078_6_T1	PHENOTYPE	22	22	acute
NCT001820786	NCT00182078_6_T2	COMPOUND	6	6	sertraline
NCT001820787	NCT00182078_7_T0	PHENOTYPE	9	10	acute stress
NCT001820787	NCT00182078_7_T1	PHENOTYPE	10	11	stress symptoms
NCT0018207811	NCT00182078_11_T0	PHENOTYPE	12	12	symptoms
NCT0018207814	NCT00182078_14_T0	GENE	6	6	tapered
NCT0018207816	NCT00182078_16_T0	COMPOUND	2	2	1
NCT0018207816	NCT00182078_16_T1	GENE	1	1	AIM
NCT0018207816	NCT00182078_16_T2	COMPOUND	8	8	sertraline
NCT0018207816	NCT00182078_16_T3	PHENOTYPE	20	21	burn injury
NCT0018207816	NCT00182078_16_T4	PHENOTYPE	27	28	burn injury
NCT0018207818	NCT00182078_18_T0	COMPOUND	2	2	2
NCT0018207818	NCT00182078_18_T1	GENE	1	1	AIM
NCT0018207818	NCT00182078_18_T2	COMPOUND	8	8	sertraline
NCT0018207819	NCT00182078_19_T0	PHENOTYPE	6	7	stress symptoms
NCT0018207820	NCT00182078_20_T0	PHENOTYPE	14	14	PTSD
NCT0018207820	NCT00182078_20_T1	PHENOTYPE	11	13	posttraumatic stress disorder
NCT0018207821	NCT00182078_21_T0	PHENOTYPE	11	11	PTSD
NCT0018207821	NCT00182078_21_T1	COMPOUND	8	8	sertraline
NCT0018207821	NCT00182078_21_T2	PHENOTYPE	25	26	burn injury
NCT0018207821	NCT00182078_21_T3	PHENOTYPE	32	33	burn injury
NCT0018207822	NCT00182078_22_T0	PHENOTYPE	12	13	developmental disorders
NCT0018207823	NCT00182078_23_T0	PHENOTYPE	15	15	PTSD
NCT0018207823	NCT00182078_23_T1	COMPOUND	12	12	sertraline
NCT0018207823	NCT00182078_23_T2	COMPOUND	23	23	sertraline
NCT0018207823	NCT00182078_23_T3	PHENOTYPE	29	30	anxiety disorders
NCT0018207823	NCT00182078_23_T4	PHENOTYPE	32	34	depression in children
NCT0018207824	NCT00182078_24_T0	PHENOTYPE	9	9	PTSD
NCT0018207824	NCT00182078_24_T1	COMPOUND	4	4	sertraline
NCT0018207825	NCT00182078_25_T0	PHENOTYPE	10	10	acute
NCT0018207830	NCT00182078_30_T0	PHENOTYPE	35	35	helplessness
NCT0018207832	NCT00182078_32_T0	COMPOUND	14	14	sertraline
NCT0018207836	NCT00182078_36_T0	COMPOUND	6	6	sertraline
NCT0018207837	NCT00182078_37_T0	COMPOUND	11	11	sertraline
NCT0018207838	NCT00182078_38_T0	GENE	9	9	tapered
NCT0018207839	NCT00182078_39_T0	PHENOTYPE	12	12	acute
NCT0018207843	NCT00182078_43_T0	GENE	16	16	had
NCT0018207850	NCT00182078_50_T0	PHENOTYPE	15	16	child abuse
NCT0018207851	NCT00182078_51_T0	COMPOUND	14	14	sertraline
NCT0018207851	NCT00182078_51_T1	PHENOTYPE	4	5	psychiatric symptoms
NCT0018207852	NCT00182078_52_T0	PHENOTYPE	6	6	PTSD
NCT0018207852	NCT00182078_52_T1	COMPOUND	1	1	sertraline
NCT0018207854	NCT00182078_54_T0	GENE	8	8	has
NCT0018207855	NCT00182078_55_T0	COMPOUND	15	15	sertraline
NCT0018207859	NCT00182078_59_T0	GENE	5	5	has
NCT0018207860	NCT00182078_60_T0	PHENOTYPE	17	17	tremor
NCT0018207860	NCT00182078_60_T1	PHENOTYPE	16	16	dizziness
NCT0018207860	NCT00182078_60_T2	PHENOTYPE	15	15	sleepiness
NCT0018207860	NCT00182078_60_T3	PHENOTYPE	9	9	diarrhea
NCT0018207860	NCT00182078_60_T4	PHENOTYPE	5	5	nausea
NCT0018207860	NCT00182078_60_T5	PHENOTYPE	12	12	insomnia
NCT0018207860	NCT00182078_60_T6	PHENOTYPE	19	19	fatigue
NCT0018207860	NCT00182078_60_T7	PHENOTYPE	6	6	headache
NCT0018207860	NCT00182078_60_T8	PHENOTYPE	13	14	sexual dysfunction
NCT0018207860	NCT00182078_60_T9	PHENOTYPE	10	11	dry mouth
NCT0018207862	NCT00182078_62_T0	COMPOUND	4	4	sertraline
NCT0018207868	NCT00182078_68_T0	PHENOTYPE	11	11	nausea
NCT0018207868	NCT00182078_68_T1	PHENOTYPE	12	12	malaise
NCT0018207868	NCT00182078_68_T2	PHENOTYPE	15	15	headaches
NCT0018207868	NCT00182078_68_T3	PHENOTYPE	16	17	mood changes
NCT0018207868	NCT00182078_68_T4	PHENOTYPE	13	14	muscle aches
NCT0018207868	NCT00182078_68_T5	PHENOTYPE	21	23	numbness and tingling
NCT0018207870	NCT00182078_70_T0	GENE	19	19	tapered
NCT0018207870	NCT00182078_70_T1	COMPOUND	14	14	sertraline
NCT0018207871	NCT00182078_71_T0	PHENOTYPE	4	4	distressed
NCT0018207872	NCT00182078_72_T0	PHENOTYPE	19	20	mental health
NCT0018207873	NCT00182078_73_T0	PHENOTYPE	7	7	distressed
NCT0018207874	NCT00182078_74_T0	PHENOTYPE	17	17	mania
NCT0018207874	NCT00182078_74_T1	PHENOTYPE	2	3	bipolar disorder
NCT0018207874	NCT00182078_74_T2	PHENOTYPE	4	5	manic-depressive illness
NCT0018207875	NCT00182078_75_T0	COMPOUND	21	21	sertraline
NCT0018207875	NCT00182078_75_T1	COMPOUND	38	38	sertraline
NCT0018207875	NCT00182078_75_T2	GENE	10	11	monoamine oxidase
NCT0018207876	NCT00182078_76_T0	COMPOUND	7	7	sertraline
NCT0018207876	NCT00182078_76_T1	PHENOTYPE	4	5	allergic reaction
NCT0018207880	NCT00182078_80_T0	COMPOUND	10	10	sertraline
NCT0018207883	NCT00182078_83_T0	GENE	12	12	has
NCT0018207885	NCT00182078_85_T0	GENE	18	18	has
NCT0018207893	NCT00182078_93_T0	PHENOTYPE	0	1	Adverse events
NCT0018207893	NCT00182078_93_T1	PHENOTYPE	36	37	Adverse Event
NCT001820911	NCT00182091_1_T0	GENE	14	14	GH
NCT001820911	NCT00182091_1_T1	PHENOTYPE	10	10	acromegaly
NCT001820916	NCT00182091_6_T0	GENE	17	17	GH
NCT001820916	NCT00182091_6_T1	GENE	27	27	GH
NCT001820916	NCT00182091_6_T2	GENE	34	34	GH
NCT001820916	NCT00182091_6_T3	PHENOTYPE	14	14	acromegaly
NCT001820916	NCT00182091_6_T4	PHENOTYPE	24	24	acromegaly
NCT001820917	NCT00182091_7_T0	GENE	0	0	GH
NCT001820917	NCT00182091_7_T1	GENE	8	8	GH
NCT001820918	NCT00182091_8_T0	GENE	3	3	GH
NCT001820918	NCT00182091_8_T1	GENE	8	8	GH
NCT001820918	NCT00182091_8_T2	GENE	16	16	GH
NCT0018209110	NCT00182091_10_T0	GENE	0	0	GH
NCT0018209110	NCT00182091_10_T1	GENE	6	6	IGF-1
NCT0018209112	NCT00182091_12_T0	GENE	15	15	GH
NCT0018209114	NCT00182091_14_T0	GENE	9	9	hormone
NCT0018209115	NCT00182091_15_T0	GENE	15	15	GH
NCT0018209115	NCT00182091_15_T1	GENE	22	22	GH
NCT0018209115	NCT00182091_15_T2	ORGAN	4	4	thyroid
NCT0018209116	NCT00182091_16_T0	GENE	10	10	GH
NCT0018209116	NCT00182091_16_T1	GENE	23	23	GH
NCT0018209116	NCT00182091_16_T2	GENE	32	32	GH
NCT0018209116	NCT00182091_16_T3	PHENOTYPE	29	29	acromegaly
NCT0018209116	NCT00182091_16_T4	GENE	33	33	has
NCT0018209118	NCT00182091_18_T0	PHENOTYPE	0	1	Cardiovascular disease
NCT0018209119	NCT00182091_19_T0	GENE	13	13	GH
NCT0018209119	NCT00182091_19_T1	PHENOTYPE	11	11	attributable
NCT0018209119	NCT00182091_19_T2	PHENOTYPE	3	3	acromegaly
NCT0018209119	NCT00182091_19_T3	PHENOTYPE	38	39	pituitary tumors
NCT0018209119	NCT00182091_19_T4	PHENOTYPE	22	23	cardiovascular morbidity
NCT0018209121	NCT00182091_21_T0	PHENOTYPE	18	18	hypopituitarism
NCT0018209122	NCT00182091_22_T0	GENE	11	11	hormone
NCT0018209122	NCT00182091_22_T1	GENE	20	20	hormone
NCT0018209122	NCT00182091_22_T2	PHENOTYPE	26	27	hormone deficiency
NCT0018209122	NCT00182091_22_T3	PHENOTYPE	3	4	endocrine disorders
NCT0018209123	NCT00182091_23_T0	GENE	10	10	fold
NCT0018209123	NCT00182091_23_T1	GENE	9	9	2.3
NCT0018209123	NCT00182091_23_T2	PHENOTYPE	4	4	Acromegaly
NCT0018209123	NCT00182091_23_T3	PHENOTYPE	3	3	acromegaly
NCT0018209124	NCT00182091_24_T0	GENE	0	0	GH
NCT0018209124	NCT00182091_24_T1	GENE	2	2	has
NCT0018209124	NCT00182091_24_T2	ORGAN	11	11	heart
NCT0018209124	NCT00182091_24_T3	ORGAN	13	14	cardiovascular system
NCT0018209126	NCT00182091_26_T0	PHENOTYPE	8	8	acromegaly
NCT0018209126	NCT00182091_26_T1	PHENOTYPE	2	3	endothelial dysfunction
NCT0018209128	NCT00182091_28_T0	GENE	3	3	has
NCT0018209128	NCT00182091_28_T1	GENE	12	12	has
NCT0018209132	NCT00182091_32_T0	PHENOTYPE	19	20	exercise intolerance
NCT0018209134	NCT00182091_34_T0	GENE	3	3	has
NCT0018209134	NCT00182091_34_T1	GENE	18	18	ventricular
NCT0018209134	NCT00182091_34_T2	PHENOTYPE	1	2	ventricular hypertrophy
NCT0018209136	NCT00182091_36_T0	GENE	41	41	somatostatin
NCT0018209136	NCT00182091_36_T1	PHENOTYPE	7	7	acromegaly
NCT0018209136	NCT00182091_36_T2	PHENOTYPE	17	17	acromegaly
NCT0018209136	NCT00182091_36_T3	PHENOTYPE	9	9	heterogeneous
NCT0018209136	NCT00182091_36_T4	ORGAN	45	45	heart
NCT0018209136	NCT00182091_36_T5	PHENOTYPE	4	5	cardiovascular disease
NCT0018209137	NCT00182091_37_T0	PHENOTYPE	6	6	acromegaly
NCT0018209137	NCT00182091_37_T1	PHENOTYPE	0	0	Dysrhythmias
NCT0018209139	NCT00182091_39_T0	GENE	8	8	GH
NCT0018209139	NCT00182091_39_T1	GENE	15	15	GH
NCT0018209139	NCT00182091_39_T2	PHENOTYPE	5	5	sequelae
NCT0018209140	NCT00182091_40_T0	GENE	12	12	has
NCT0018209140	NCT00182091_40_T1	PHENOTYPE	4	5	Cardiovascular morbidity
NCT0018209145	NCT00182091_45_T0	GENE	17	17	GH
NCT0018209145	NCT00182091_45_T1	PHENOTYPE	6	7	autonomic dysfunction
NCT0018209146	NCT00182091_46_T0	GENE	15	15	GH
NCT0018209146	NCT00182091_46_T1	PHENOTYPE	6	6	acromegaly
NCT0018209146	NCT00182091_46_T2	GENE	8	8	has
NCT0018209146	NCT00182091_46_T3	GENE	19	19	ventricular
NCT0018209147	NCT00182091_47_T0	GENE	11	11	GH
NCT0018209147	NCT00182091_47_T1	GENE	22	22	GH
NCT0018209147	NCT00182091_47_T2	PHENOTYPE	7	7	acromegaly
NCT0018209148	NCT00182091_48_T0	GENE	5	5	GH
NCT0018209148	NCT00182091_48_T1	GENE	2	2	has
NCT0018209148	NCT00182091_48_T2	GENE	7	7	has
NCT0018209148	NCT00182091_48_T3	TISSUE	0	1	Adipose tissue
NCT0018209151	NCT00182091_51_T0	GENE	1	1	GH
NCT0018209151	NCT00182091_51_T1	TISSUE	8	9	visceral fat
NCT0018209151	NCT00182091_51_T2	TISSUE	5	6	body fat
NCT0018209152	NCT00182091_52_T0	GENE	9	9	GH
NCT0018209153	NCT00182091_53_T0	GENE	0	0	GH
NCT0018209153	NCT00182091_53_T1	TISSUE	7	8	adipose tissue
NCT0018209156	NCT00182091_56_T0	GENE	18	18	HDL
NCT0018209156	NCT00182091_56_T1	GENE	20	20	GH
NCT0018209156	NCT00182091_56_T2	GENE	7	7	lipoprotein
NCT0018209156	NCT00182091_56_T3	GENE	16	16	lipoprotein
NCT0018209156	NCT00182091_56_T4	GENE	9	9	LDL
NCT0018209157	NCT00182091_57_T0	PHENOTYPE	26	26	severity
NCT0018209157	NCT00182091_57_T1	GENE	38	38	GH
NCT0018209157	NCT00182091_57_T2	PHENOTYPE	16	18	age of onset
NCT0018209159	NCT00182091_59_T0	GENE	17	17	GH
NCT0018209159	NCT00182091_59_T1	GENE	9	9	LDL
NCT0018209160	NCT00182091_60_T0	GENE	24	24	GH
NCT0018209162	NCT00182091_62_T0	PHENOTYPE	9	9	chronic
NCT0018209163	NCT00182091_63_T0	GENE	7	7	CRP
NCT0018209163	NCT00182091_63_T1	GENE	5	6	C-reactive protein
NCT0018209164	NCT00182091_64_T0	GENE	10	10	CRP
NCT0018209165	NCT00182091_65_T0	GENE	0	0	CRP
NCT0018209165	NCT00182091_65_T1	GENE	8	8	HDL
NCT0018209166	NCT00182091_66_T0	GENE	12	12	interleukin-6
NCT0018209166	NCT00182091_66_T1	PHENOTYPE	1	1	distal
NCT0018209166	NCT00182091_66_T2	GENE	13	13	IL-6
NCT0018209167	NCT00182091_67_T0	GENE	0	0	GH
NCT0018209168	NCT00182091_68_T0	PHENOTYPE	12	12	atherosclerosis
NCT0018209168	NCT00182091_68_T1	GENE	7	7	GH
NCT0018209171	NCT00182091_71_T0	GENE	14	14	CD40L
NCT0018209171	NCT00182091_71_T1	GENE	11	11	CD
NCT0018209171	NCT00182091_71_T2	PHENOTYPE	6	6	adhesion
NCT0018209171	NCT00182091_71_T3	GENE	9	9	P-selectin
NCT0018209171	NCT00182091_71_T4	GENE	8	8	ICAM-1
NCT0018209171	NCT00182091_71_T5	BIOLOGICAL_PROCESS	20	21	platelet activation
NCT0018209171	NCT00182091_71_T6	PHENOTYPE	25	26	atheromatous plaque
NCT0018209172	NCT00182091_72_T0	GENE	0	0	Myeloperoxidase
NCT0018209172	NCT00182091_72_T1	PHENOTYPE	18	19	cardiac events
NCT0018209172	NCT00182091_72_T2	PHENOTYPE	10	11	myocardial infarction
NCT0018209174	NCT00182091_74_T0	GENE	5	5	axis
NCT0018209175	NCT00182091_75_T0	PHENOTYPE	12	12	hypopituitarism
NCT0018209177	NCT00182091_77_T0	GENE	17	17	plasminogen
NCT0018209177	NCT00182091_77_T1	GENE	11	11	fibrinogen
NCT0018209177	NCT00182091_77_T2	GENE	15	15	tPA
NCT0018209177	NCT00182091_77_T3	GENE	20	20	PAI-1
NCT0018209177	NCT00182091_77_T4	GENE	12	14	tissue-type plasminogen activator
NCT0018209178	NCT00182091_78_T0	GENE	8	8	GH
NCT0018209178	NCT00182091_78_T1	GENE	26	26	GH
NCT0018209178	NCT00182091_78_T2	PHENOTYPE	19	19	acromegaly
NCT0018209178	NCT00182091_78_T3	GENE	10	10	has
NCT0018209179	NCT00182091_79_T0	GENE	10	10	GH
NCT0018209179	NCT00182091_79_T1	PHENOTYPE	15	15	acromegaly
NCT0018209179	NCT00182091_79_T2	GENE	3	3	has
NCT0018209179	NCT00182091_79_T3	PHENOTYPE	0	2	Quality of life
NCT0018209181	NCT00182091_81_T0	GENE	17	17	GH
NCT0018209181	NCT00182091_81_T1	GENE	20	20	GH
NCT0018209181	NCT00182091_81_T2	GENE	27	27	GH
NCT0018209181	NCT00182091_81_T3	GENE	31	31	GH
NCT0018209181	NCT00182091_81_T4	PHENOTYPE	16	16	acromegaly
NCT0018209181	NCT00182091_81_T5	PHENOTYPE	8	10	quality of life
NCT0018209182	NCT00182091_82_T0	PHENOTYPE	12	12	acromegaly
NCT0018209183	NCT00182091_83_T0	GENE	10	10	GH
NCT0018209183	NCT00182091_83_T1	GENE	13	13	GH
NCT0018209183	NCT00182091_83_T2	PHENOTYPE	20	20	acromegaly
NCT0018209184	NCT00182091_84_T0	GENE	4	4	GH
NCT0018209184	NCT00182091_84_T1	GENE	13	13	GH
NCT0018209185	NCT00182091_85_T0	PHENOTYPE	13	13	acromegaly
NCT0018209185	NCT00182091_85_T1	PHENOTYPE	19	19	acromegaly
NCT0018209186	NCT00182091_86_T0	GENE	2	2	has
NCT001821043	NCT00182104_3_T0	PHENOTYPE	9	9	DVT
NCT001821043	NCT00182104_3_T1	PHENOTYPE	3	3	anticoagulation
NCT001821043	NCT00182104_3_T2	ORGAN	6	7	heart valve
NCT001821044	NCT00182104_4_T0	PHENOTYPE	3	3	bleeding
NCT001821044	NCT00182104_4_T1	GENE	14	14	ASA
NCT001821300	NCT00182130_0_T0	PHENOTYPE	3	4	Rectal Cancer
NCT001821303	NCT00182130_3_T0	PHENOTYPE	14	15	tumor recurrence
NCT001821303	NCT00182130_3_T1	PHENOTYPE	3	4	rectal cancer
NCT001821304	NCT00182130_4_T0	PHENOTYPE	17	18	rectal cancer
NCT001821306	NCT00182130_6_T0	PHENOTYPE	0	0	Secondary
NCT001821306	NCT00182130_6_T1	ORGAN	9	9	bladder
NCT001821306	NCT00182130_6_T2	GENE	7	7	bowel
NCT001821306	NCT00182130_6_T3	PHENOTYPE	12	14	quality of life
NCT001821307	NCT00182130_7_T0	PHENOTYPE	12	13	rectal cancer
NCT001821308	NCT00182130_8_T0	PHENOTYPE	36	36	recurrence
NCT001821308	NCT00182130_8_T1	PHENOTYPE	35	35	tumour
NCT001821308	NCT00182130_8_T2	GENE	20	20	has
NCT001821308	NCT00182130_8_T3	PHENOTYPE	16	17	rectal cancer
NCT0018213013	NCT00182130_13_T0	PHENOTYPE	10	10	recurrence
NCT0018213013	NCT00182130_13_T1	PHENOTYPE	12	12	tumour
NCT0018213013	NCT00182130_13_T2	ORGAN	18	18	bladder
NCT0018213013	NCT00182130_13_T3	GENE	17	17	bowel
NCT0018213013	NCT00182130_13_T4	PHENOTYPE	24	26	quality of life
NCT0018213018	NCT00182130_18_T0	PHENOTYPE	9	10	rectal cancer
NCT0018213020	NCT00182130_20_T0	PHENOTYPE	0	0	Tumor
NCT0018213020	NCT00182130_20_T1	GENE	4	4	cm
NCT0018213020	NCT00182130_20_T2	PHENOTYPE	9	9	rigid
NCT001821432	NCT00182143_2_T0	PHENOTYPE	12	12	DVT
NCT001821432	NCT00182143_2_T1	PHENOTYPE	1	2	Critically ill
NCT001821432	NCT00182143_2_T2	PHENOTYPE	16	17	acute illness
NCT001821432	NCT00182143_2_T3	PHENOTYPE	9	11	deep venous thrombosis
NCT001821435	NCT00182143_5_T0	PHENOTYPE	10	10	DVT
NCT001821435	NCT00182143_5_T1	GENE	12	12	has
NCT0018214317	NCT00182143_17_T0	PHENOTYPE	0	0	Recruitment
NCT0018214323	NCT00182143_23_T0	GENE	25	25	SC
NCT0018214323	NCT00182143_23_T1	COMPOUND	15	15	dalteparin
NCT0018214323	NCT00182143_23_T2	PHENOTYPE	12	12	centres
NCT0018214326	NCT00182143_26_T0	GENE	0	0	PE
NCT0018214328	NCT00182143_28_T0	PHENOTYPE	9	9	aids
NCT0018214331	NCT00182143_31_T0	COMPOUND	21	21	dalteparin
NCT0018214337	NCT00182143_37_T0	PHENOTYPE	0	1	Ischemic stroke
NCT0018214338	NCT00182143_38_T0	PHENOTYPE	0	1	Intracranial hemorrhage
NCT0018214339	NCT00182143_39_T0	GENE	5	5	Hg
NCT0018214339	NCT00182143_39_T1	GENE	11	11	Hg
NCT0018214340	NCT00182143_40_T0	PHENOTYPE	1	1	hemorrhage
NCT0018214341	NCT00182143_41_T0	GENE	4	4	INR
NCT0018214341	NCT00182143_41_T1	PHENOTYPE	0	0	Coagulopathy
NCT0018214342	NCT00182143_42_T0	PHENOTYPE	0	0	Thrombocytopenia
NCT0018214342	NCT00182143_42_T1	PHENOTYPE	3	4	platelet count
NCT0018214345	NCT00182143_45_T0	PHENOTYPE	14	14	distal
NCT0018214345	NCT00182143_45_T1	PHENOTYPE	7	7	bilateral
NCT0018214345	NCT00182143_45_T2	ORGAN	15	15	extremity
NCT0018214345	NCT00182143_45_T3	ORGAN	3	4	lower limb
NCT001821562	NCT00182156_2_T0	PHENOTYPE	5	5	bleeding
NCT001821562	NCT00182156_2_T1	PHENOTYPE	9	10	platelet dysfunction
NCT001821563	NCT00182156_3_T0	BIOLOGICAL_PROCESS	15	15	hemostasis
NCT001821563	NCT00182156_3_T1	GENE	1	1	has
NCT001821563	NCT00182156_3_T2	PHENOTYPE	6	7	renal failure
NCT001821564	NCT00182156_4_T0	CELL	4	4	platelet
NCT001821566	NCT00182156_6_T0	PHENOTYPE	9	9	thrombocytopathy
NCT001821566	NCT00182156_6_T1	GENE	3	3	has
NCT001821566	NCT00182156_6_T2	GENE	2	2	CHD
NCT001821568	NCT00182156_8_T0	PHENOTYPE	0	1	Cardiovascular disease
NCT001821569	NCT00182156_9_T0	PHENOTYPE	15	15	inflammation
NCT001821569	NCT00182156_9_T1	PHENOTYPE	0	1	Volume overload
NCT001821569	NCT00182156_9_T2	PHENOTYPE	8	10	left ventricular hypertrophy
NCT001821569	NCT00182156_9_T3	PHENOTYPE	5	7	high blood pressure
NCT0018215610	NCT00182156_10_T0	GENE	1	1	has
NCT0018215610	NCT00182156_10_T1	GENE	0	0	SDHD
NCT0018215611	NCT00182156_11_T0	PHENOTYPE	0	0	Pulse
NCT0018215611	NCT00182156_11_T1	ORGAN	20	20	arteries
NCT0018215611	NCT00182156_11_T2	GENE	4	4	has
NCT0018216913	NCT00182169_13_T0	GENE	4	4	GH
NCT0018216919	NCT00182169_19_T0	GENE	0	0	Cor
NCT0018216920	NCT00182169_20_T0	PHENOTYPE	0	0	Acute
NCT0018216923	NCT00182169_23_T0	ORGAN	6	6	transplant
NCT0018216923	NCT00182169_23_T1	ORGAN	14	14	transplant
NCT0018216923	NCT00182169_23_T2	ORGAN	5	5	heart
NCT001821823	NCT00182182_3_T0	GENE	5	5	OR
NCT001821824	NCT00182182_4_T0	GENE	8	8	OR
NCT001821825	NCT00182182_5_T0	GENE	12	12	ventricular
NCT001821825	NCT00182182_5_T1	GENE	16	16	ventricular
NCT001821825	NCT00182182_5_T2	GENE	26	26	ventricular
NCT001821825	NCT00182182_5_T3	PHENOTYPE	13	14	systolic dysfunction
NCT001821827	NCT00182182_7_T0	PHENOTYPE	2	3	terminal illness
NCT0018218211	NCT00182182_11_T0	PHENOTYPE	15	15	ischemia
NCT0018218211	NCT00182182_11_T1	PHENOTYPE	11	12	valvular disease
NCT0018218213	NCT00182182_13_T0	COMPOUND	16	16	3
NCT001822211	NCT00182221_1_T0	GENE	14	14	PE
NCT001822212	NCT00182221_2_T0	GENE	25	25	PE
NCT001822342	NCT00182234_2_T0	PHENOTYPE	34	36	quality of life
NCT001822344	NCT00182234_4_T0	PHENOTYPE	17	18	colorectal cancers
NCT001822347	NCT00182234_7_T0	PHENOTYPE	50	50	centre
NCT001822347	NCT00182234_7_T1	PHENOTYPE	48	49	regional cancer
NCT0018223416	NCT00182234_16_T0	PHENOTYPE	9	10	psychological distress
NCT0018223416	NCT00182234_16_T1	PHENOTYPE	15	17	quality of life
NCT001822600	NCT00182260_0_T0	PHENOTYPE	13	13	GERD
NCT001822600	NCT00182260_0_T1	PHENOTYPE	12	12	Chronic
NCT001822603	NCT00182260_3_T0	PHENOTYPE	16	16	GERD
NCT001822603	NCT00182260_3_T1	PHENOTYPE	14	14	complications
NCT001822603	NCT00182260_3_T2	PHENOTYPE	11	12	respiratory symptoms
NCT001822606	NCT00182260_6_T0	PHENOTYPE	1	1	symptoms
NCT001822606	NCT00182260_6_T1	PHENOTYPE	11	11	GERD
NCT001822606	NCT00182260_6_T2	PHENOTYPE	16	16	ulceration
NCT001822606	NCT00182260_6_T3	PHENOTYPE	19	20	Barrett's esophagus
NCT001822606	NCT00182260_6_T4	PHENOTYPE	14	15	esophageal erosions
NCT001822607	NCT00182260_7_T0	PHENOTYPE	6	6	symptoms
NCT001822607	NCT00182260_7_T1	PHENOTYPE	12	12	GERD
NCT001822608	NCT00182260_8_T0	PHENOTYPE	10	10	erosions
NCT001822608	NCT00182260_8_T1	PHENOTYPE	4	4	GERD
NCT001822608	NCT00182260_8_T2	PHENOTYPE	17	17	asthma
NCT001822608	NCT00182260_8_T3	PHENOTYPE	12	13	respiratory disease
NCT001822608	NCT00182260_8_T4	PHENOTYPE	15	16	aspiration pneumonia
NCT001822608	NCT00182260_8_T5	PHENOTYPE	18	19	chronic laryngitis
NCT001822609	NCT00182260_9_T0	PHENOTYPE	2	2	GERD
NCT001822609	NCT00182260_9_T1	PHENOTYPE	7	7	reflux
NCT001822609	NCT00182260_9_T2	ORGAN	13	13	esophagus
NCT0018226010	NCT00182260_10_T0	PHENOTYPE	0	0	Reflux
NCT0018226010	NCT00182260_10_T1	GENE	18	18	LES
NCT0018226010	NCT00182260_10_T2	ORGAN	15	17	lower esophageal sphincter
NCT0018226011	NCT00182260_11_T0	GENE	12	12	reduced
NCT0018226011	NCT00182260_11_T1	PHENOTYPE	25	25	reflux
NCT0018226011	NCT00182260_11_T2	GENE	5	5	LES
NCT0018226011	NCT00182260_11_T3	GENE	10	10	LES
NCT0018226011	NCT00182260_11_T4	PHENOTYPE	11	11	hypotonia
NCT0018226011	NCT00182260_11_T5	PHENOTYPE	21	22	hiatus hernia
NCT0018226014	NCT00182260_14_T0	PHENOTYPE	6	6	symptoms
NCT0018226014	NCT00182260_14_T1	PHENOTYPE	2	2	esophagitis
NCT0018226014	NCT00182260_14_T2	PHENOTYPE	24	24	esophagitis
NCT0018226014	NCT00182260_14_T3	PHENOTYPE	22	22	inhibition
NCT0018226014	NCT00182260_14_T4	PHENOTYPE	0	0	Severity
NCT0018226014	NCT00182260_14_T5	PHENOTYPE	5	5	reflux
NCT0018226015	NCT00182260_15_T0	PHENOTYPE	5	5	GERD
NCT0018226015	NCT00182260_15_T1	GENE	6	6	has
NCT0018226015	NCT00182260_15_T2	PHENOTYPE	25	25	avoidance
NCT0018226015	NCT00182260_15_T3	PHENOTYPE	20	21	weight loss
NCT0018226016	NCT00182260_16_T0	GENE	1	1	LES
NCT0018226016	NCT00182260_16_T1	BIOLOGICAL_PROCESS	6	7	gastric emptying
NCT0018226017	NCT00182260_17_T0	ORGAN	7	7	esophagus
NCT0018226019	NCT00182260_19_T0	PHENOTYPE	3	4	gastro-esophageal reflux
NCT0018226020	NCT00182260_20_T0	PHENOTYPE	15	15	GERD
NCT001822732	NCT00182273_2_T0	PHENOTYPE	11	11	dizziness
NCT001822734	NCT00182273_4_T0	PHENOTYPE	17	17	falls
NCT001822734	NCT00182273_4_T1	PHENOTYPE	20	20	fractures
NCT001822739	NCT00182273_9_T0	GENE	13	13	ENT
NCT0018227310	NCT00182273_10_T0	GENE	2	2	has
NCT0018227312	NCT00182273_12_T0	PHENOTYPE	16	16	dizziness
NCT001822864	NCT00182286_4_T0	PHENOTYPE	31	31	centre
NCT001822867	NCT00182286_7_T0	PHENOTYPE	2	2	perceptions
NCT001822990	NCT00182299_0_T0	GENE	19	19	SIS
NCT001822990	NCT00182299_0_T1	ORGAN	10	11	Rotator Cuff
NCT001822993	NCT00182299_3_T0	PHENOTYPE	19	21	rotator cuff tears
NCT001822995	NCT00182299_5_T0	GENE	20	20	SIS
NCT001822995	NCT00182299_5_T1	ORGAN	12	13	rotator cuff
NCT001822998	NCT00182299_8_T0	GENE	10	10	SIS
NCT0018229912	NCT00182299_12_T0	GENE	25	25	cuff
NCT0018229912	NCT00182299_12_T1	PHENOTYPE	18	20	quality of life
NCT0018229914	NCT00182299_14_T0	PHENOTYPE	5	5	estimation
NCT0018229920	NCT00182299_20_T0	ORGAN	53	53	tendons
NCT0018229920	NCT00182299_20_T1	ORGAN	62	62	tendons
NCT0018229920	NCT00182299_20_T2	GENE	5	5	al
NCT0018229920	NCT00182299_20_T3	GENE	4	4	et
NCT0018229920	NCT00182299_20_T4	ORGAN	44	44	tendon
NCT0018229920	NCT00182299_20_T5	GENE	27	27	cuff
NCT0018229920	NCT00182299_20_T6	GENE	32	32	cuff
NCT0018229920	NCT00182299_20_T7	PHENOTYPE	12	14	rotator cuff tears
NCT001823123	NCT00182312_3_T0	GENE	5	5	has
NCT001823123	NCT00182312_3_T1	PHENOTYPE	11	14	very low birth weight
NCT001823124	NCT00182312_4_T0	PHENOTYPE	21	21	prematurity
NCT001823124	NCT00182312_4_T1	COMPOUND	9	9	methylxanthine
NCT001823124	NCT00182312_4_T2	PHENOTYPE	7	7	avoidance
NCT001823127	NCT00182312_7_T0	COMPOUND	7	7	adenosine
NCT001823127	NCT00182312_7_T1	PHENOTYPE	15	16	oxygen deficiency
NCT001823129	NCT00182312_9_T0	COMPOUND	13	13	oxygen
NCT0018231210	NCT00182312_10_T0	PHENOTYPE	13	16	very low birth weight
NCT0018231212	NCT00182312_12_T0	GENE	21	21	IV
NCT0018231212	NCT00182312_12_T1	GENE	31	31	IV
NCT0018231216	NCT00182312_16_T0	COMPOUND	34	34	methylxanthine
NCT0018231216	NCT00182312_16_T1	GENE	6	6	has
NCT001823252	NCT00182325_2_T0	PHENOTYPE	25	25	generalized
NCT001823252	NCT00182325_2_T1	PHENOTYPE	18	18	satisfied
NCT001823255	NCT00182325_5_T0	PHENOTYPE	25	25	generalized
NCT001823255	NCT00182325_5_T1	PHENOTYPE	18	18	satisfied
NCT001823381	NCT00182338_1_T0	PHENOTYPE	15	16	cardiovascular disease
NCT001823382	NCT00182338_2_T0	ORGAN	17	17	heart
NCT001823382	NCT00182338_2_T1	PHENOTYPE	10	12	high blood pressure
NCT001823387	NCT00182338_7_T0	PHENOTYPE	14	15	heart failure
NCT001823387	NCT00182338_7_T1	PHENOTYPE	12	13	heart attacks
NCT0018233810	NCT00182338_10_T0	PHENOTYPE	16	18	left ventricular hypertrophy
NCT0018233811	NCT00182338_11_T0	GENE	4	4	has
NCT0018233811	NCT00182338_11_T1	PHENOTYPE	20	22	congestive heart failure
NCT001823640	NCT00182364_0_T0	GENE	8	8	Pilot
NCT001823645	NCT00182364_5_T0	PHENOTYPE	7	7	DVT
NCT001823648	NCT00182364_8_T0	PHENOTYPE	21	22	critically ill
NCT0018236410	NCT00182364_10_T0	PHENOTYPE	37	37	bleeding
NCT0018236410	NCT00182364_10_T1	PHENOTYPE	50	50	recruitment
NCT0018236410	NCT00182364_10_T2	PHENOTYPE	31	32	renal insufficiency
NCT0018236410	NCT00182364_10_T3	ORGAN	45	46	lower limb
NCT0018236413	NCT00182364_13_T0	GENE	3	3	18
NCT0018236413	NCT00182364_13_T1	GENE	12	12	72
NCT0018236414	NCT00182364_14_T0	PHENOTYPE	7	7	trauma
NCT0018236414	NCT00182364_14_T1	PHENOTYPE	17	17	DVT
NCT0018236414	NCT00182364_14_T2	PHENOTYPE	29	29	thrombocytopenia
NCT0018236414	NCT00182364_14_T3	PHENOTYPE	37	37	anticoagulation
NCT0018236414	NCT00182364_14_T4	PHENOTYPE	28	28	coagulopathy
NCT0018236414	NCT00182364_14_T5	COMPOUND	30	30	creatinine
NCT0018236414	NCT00182364_14_T6	GENE	18	18	PE
NCT0018236414	NCT00182364_14_T7	PHENOTYPE	16	16	hypertension
NCT0018236414	NCT00182364_14_T8	PHENOTYPE	21	21	hemorrhage
NCT0018236416	NCT00182364_16_T0	COMPOUND	17	17	heparin
NCT0018236416	NCT00182364_16_T1	COMPOUND	11	11	dalteparin
NCT0018236420	NCT00182364_20_T0	PHENOTYPE	23	23	DVT
NCT0018236420	NCT00182364_20_T1	PHENOTYPE	4	4	bilateral
NCT0018236420	NCT00182364_20_T2	PHENOTYPE	21	21	suspicion
NCT0018236420	NCT00182364_20_T3	ORGAN	5	6	lower limb
NCT0018236421	NCT00182364_21_T0	PHENOTYPE	9	9	DVT
NCT0018236421	NCT00182364_21_T1	PHENOTYPE	8	8	proximal
NCT0018236422	NCT00182364_22_T0	GENE	3	3	PE
NCT0018236425	NCT00182364_25_T0	PHENOTYPE	16	16	bleeding
NCT0018236425	NCT00182364_25_T1	PHENOTYPE	14	14	complications
NCT0018236427	NCT00182364_27_T0	PHENOTYPE	13	13	DVT
NCT0018236427	NCT00182364_27_T1	PHENOTYPE	18	18	DVT
NCT0018236427	NCT00182364_27_T2	PHENOTYPE	21	21	bilateral
NCT0018236427	NCT00182364_27_T3	PHENOTYPE	12	12	proximal
NCT0018236427	NCT00182364_27_T4	ORGAN	22	23	lower extremity
NCT0018236434	NCT00182364_34_T0	PHENOTYPE	0	0	Trauma
NCT0018236436	NCT00182364_36_T0	PHENOTYPE	2	2	DVT
NCT0018236436	NCT00182364_36_T1	GENE	3	3	PE
NCT0018236436	NCT00182364_36_T2	PHENOTYPE	6	6	hemorrhage
NCT0018236436	NCT00182364_36_T3	PHENOTYPE	0	1	Hemorrhagic stroke
NCT0018236437	NCT00182364_37_T0	COMPOUND	5	5	2
NCT0018236437	NCT00182364_37_T1	COMPOUND	14	14	2
NCT0018236437	NCT00182364_37_T2	GENE	4	4	INR
NCT0018236437	NCT00182364_37_T3	PHENOTYPE	0	0	Coagulopathy
NCT0018236438	NCT00182364_38_T0	COMPOUND	6	6	creatinine
NCT0018236438	NCT00182364_38_T1	PHENOTYPE	0	1	Renal insufficiency
NCT0018236439	NCT00182364_39_T0	PHENOTYPE	9	9	anticoagulation
NCT0018236441	NCT00182364_41_T0	COMPOUND	2	2	2
NCT0018236443	NCT00182364_43_T0	PHENOTYPE	0	0	Withdrawal
NCT0018236447	NCT00182364_47_T0	PHENOTYPE	0	0	Bilateral
NCT0018236447	NCT00182364_47_T1	ORGAN	1	2	lower limb
NCT001823772	NCT00182377_2_T0	GENE	16	16	bypass
NCT001824031	NCT00182403_1_T0	GENE	12	12	INR
NCT001824031	NCT00182403_1_T1	COMPOUND	10	10	warfarin
NCT001824160	NCT00182416_0_T0	GENE	7	7	II
NCT001824162	NCT00182416_2_T0	PHENOTYPE	14	14	complication
NCT001824162	NCT00182416_2_T1	GENE	19	19	longevity
NCT001824162	NCT00182416_2_T2	GENE	9	9	has
NCT001824162	NCT00182416_2_T3	PHENOTYPE	24	26	quality of life
NCT001824164	NCT00182416_4_T0	PHENOTYPE	20	20	complications
NCT001824164	NCT00182416_4_T1	ORGAN	6	7	right ventricle
NCT001824165	NCT00182416_5_T0	PHENOTYPE	10	10	secondary
NCT001824165	NCT00182416_5_T1	PHENOTYPE	3	3	complications
NCT001824165	NCT00182416_5_T2	GENE	8	8	ventricular
NCT001824168	NCT00182416_8_T0	ORGAN	1	1	heart
NCT001824292	NCT00182429_2_T0	PHENOTYPE	23	23	chronic
NCT001824292	NCT00182429_2_T1	PHENOTYPE	25	25	diarrhea
NCT001824421	NCT00182442_1_T0	PHENOTYPE	7	7	schizophrenia
NCT001824422	NCT00182442_2_T0	PHENOTYPE	26	26	schizophrenia
NCT001824424	NCT00182442_4_T0	PHENOTYPE	29	29	schizophrenia
NCT001824424	NCT00182442_4_T1	GENE	17	17	has
NCT001824426	NCT00182442_6_T0	PHENOTYPE	21	21	schizophrenia
NCT001824428	NCT00182442_8_T0	PHENOTYPE	37	37	schizophrenia
NCT0018244211	NCT00182442_11_T0	PHENOTYPE	9	9	schizophrenia
NCT0018244211	NCT00182442_11_T1	PHENOTYPE	18	20	quality of life
NCT0018244211	NCT00182442_11_T2	PHENOTYPE	46	48	quality of life
NCT0018244212	NCT00182442_12_T0	PHENOTYPE	14	14	schizophrenia
NCT0018244212	NCT00182442_12_T1	PHENOTYPE	16	17	schizoaffective disorder
NCT0018244213	NCT00182442_13_T0	PHENOTYPE	28	31	Positive and negative symptoms
NCT0018244217	NCT00182442_17_T0	PHENOTYPE	17	20	perceived quality of life
NCT0018244219	NCT00182442_19_T0	PHENOTYPE	5	5	symptoms
NCT001824550	NCT00182455_0_T0	GENE	12	12	GSP
NCT001824550	NCT00182455_0_T1	PHENOTYPE	9	9	Generalized
NCT001824550	NCT00182455_0_T2	PHENOTYPE	10	11	Social Phobia
NCT001824552	NCT00182455_2_T0	PHENOTYPE	16	16	symptoms
NCT001824552	NCT00182455_2_T1	GENE	11	11	has
NCT001824552	NCT00182455_2_T2	GENE	26	26	has
NCT001824552	NCT00182455_2_T3	PHENOTYPE	18	19	social phobia
NCT001824552	NCT00182455_2_T4	PHENOTYPE	36	37	anxiety disorders
NCT001824553	NCT00182455_3_T0	GENE	17	17	GSP
NCT001824553	NCT00182455_3_T1	COMPOUND	8	8	topiramate
NCT001824682	NCT00182468_2_T0	PHENOTYPE	26	27	woman abuse
NCT001824683	NCT00182468_3_T0	PHENOTYPE	12	13	life quality
NCT001824684	NCT00182468_4_T0	PHENOTYPE	3	3	secondary
NCT001824813	NCT00182481_3_T0	PHENOTYPE	6	6	symptoms
NCT001824815	NCT00182481_5_T0	PHENOTYPE	7	7	symptoms
NCT001824818	NCT00182481_8_T0	PHENOTYPE	5	5	inflammation
NCT0018248113	NCT00182481_13_T0	PHENOTYPE	11	11	symptoms
NCT0018248113	NCT00182481_13_T1	PHENOTYPE	18	18	asthma
NCT0018248114	NCT00182481_14_T0	PHENOTYPE	19	21	quality of life
NCT0018248116	NCT00182481_16_T0	PHENOTYPE	9	9	eosinophilia
NCT0018248116	NCT00182481_16_T1	PHENOTYPE	18	18	Strategy
NCT0018248116	NCT00182481_16_T2	PHENOTYPE	25	25	Strategy
NCT0018248120	NCT00182481_20_T0	PHENOTYPE	2	2	asthma
NCT0018248126	NCT00182481_26_T0	PHENOTYPE	8	10	chronic airflow limitation
NCT0018248132	NCT00182481_32_T0	BIOLOGICAL_PROCESS	2	2	lactation
NCT001824947	NCT00182494_7_T0	COMPOUND	22	22	metformin
NCT001824947	NCT00182494_7_T1	PHENOTYPE	3	3	enables
NCT001824948	NCT00182494_8_T0	COMPOUND	7	7	metformin
NCT0018249411	NCT00182494_11_T0	PHENOTYPE	11	11	schizophrenia
NCT0018249411	NCT00182494_11_T1	GENE	21	21	IV
NCT0018249412	NCT00182494_12_T0	PHENOTYPE	9	9	relapse
NCT0018249423	NCT00182494_23_T0	ORGAN	20	20	kidney
NCT0018249423	NCT00182494_23_T1	ORGAN	18	18	liver
NCT0018249423	NCT00182494_23_T2	PHENOTYPE	6	7	liver disease
NCT0018249424	NCT00182494_24_T0	PHENOTYPE	1	1	impairment
NCT0018249424	NCT00182494_24_T1	COMPOUND	14	14	metformin
NCT0018249428	NCT00182494_28_T0	PHENOTYPE	29	29	Acromegaly
NCT0018249428	NCT00182494_28_T1	PHENOTYPE	28	28	Syndrome
NCT0018249428	NCT00182494_28_T2	ORGAN	9	9	heart
NCT0018249428	NCT00182494_28_T3	PHENOTYPE	4	4	disorders
NCT0018249428	NCT00182494_28_T4	PHENOTYPE	22	22	disorders
NCT0018249428	NCT00182494_28_T5	PHENOTYPE	31	32	chronic pancreatitis
NCT0018249428	NCT00182494_28_T6	PHENOTYPE	11	12	lung disease
NCT0018249428	NCT00182494_28_T7	BIOLOGICAL_PROCESS	24	25	glucose metabolism
NCT0018249430	NCT00182494_30_T0	PHENOTYPE	42	43	weight loss
NCT001825072	NCT00182507_2_T0	COMPOUND	10	10	olanzapine
NCT001825072	NCT00182507_2_T1	PHENOTYPE	15	16	hair pulling
NCT001825201	NCT00182520_1_T0	PHENOTYPE	12	12	OCD
NCT001825202	NCT00182520_2_T0	PHENOTYPE	19	19	OCD
NCT001825202	NCT00182520_2_T1	PHENOTYPE	22	22	OCD
NCT001825202	NCT00182520_2_T2	GENE	25	25	un
NCT001825202	NCT00182520_2_T3	GENE	23	23	has
NCT001825202	NCT00182520_2_T4	GENE	31	31	SRI
NCT001825202	NCT00182520_2_T5	COMPOUND	9	9	topiramate
NCT001825331	NCT00182533_1_T0	PHENOTYPE	17	18	social phobia
NCT001825332	NCT00182533_2_T0	PHENOTYPE	5	5	suffering
NCT001825332	NCT00182533_2_T1	PHENOTYPE	8	9	social phobia
NCT001825333	NCT00182533_3_T0	PHENOTYPE	14	14	generalized
NCT001825333	NCT00182533_3_T1	COMPOUND	9	9	sertraline
NCT001825333	NCT00182533_3_T2	PHENOTYPE	15	16	social phobia
NCT001825333	NCT00182533_3_T3	PHENOTYPE	21	22	mood disorders
NCT001825593	NCT00182559_3_T0	ORGAN	12	12	kidney
NCT001825593	NCT00182559_3_T1	ORGAN	13	13	transplant
NCT001825594	NCT00182559_4_T0	COMPOUND	28	28	cyclosporine
NCT001825594	NCT00182559_4_T1	ORGAN	23	23	kidney
NCT001825594	NCT00182559_4_T2	COMPOUND	3	3	tacrolimus
NCT001825594	NCT00182559_4_T3	ORGAN	24	24	transplant
NCT001825596	NCT00182559_6_T0	ORGAN	13	13	kidney
NCT001825596	NCT00182559_6_T1	ORGAN	14	14	transplant
NCT001825598	NCT00182559_8_T0	COMPOUND	11	11	azathioprine
NCT001825598	NCT00182559_8_T1	GENE	12	12	had
NCT0018255910	NCT00182559_10_T0	GENE	0	0	Cystatin
NCT0018255910	NCT00182559_10_T1	ORGAN	11	11	kidney
NCT0018255910	NCT00182559_10_T2	COMPOUND	6	6	creatinine
NCT0018255910	NCT00182559_10_T3	COMPOUND	23	23	creatine
NCT0018255910	NCT00182559_10_T4	ORGAN	5	5	serum
NCT0018255910	NCT00182559_10_T5	ORGAN	22	22	serum
NCT0018255910	NCT00182559_10_T6	GENE	14	15	cystatin C
NCT0018255910	NCT00182559_10_T7	BIOLOGICAL_PROCESS	28	29	glomerular filtration
NCT0018255911	NCT00182559_11_T0	COMPOUND	23	23	cyclosporine
NCT0018255911	NCT00182559_11_T1	ORGAN	17	17	graft
NCT0018255911	NCT00182559_11_T2	COMPOUND	28	28	tacrolimus
NCT0018255911	NCT00182559_11_T3	GENE	11	12	cystatin C
NCT0018255912	NCT00182559_12_T0	ORGAN	13	13	kidney
NCT0018255912	NCT00182559_12_T1	ORGAN	14	14	allograft
NCT0018255913	NCT00182559_13_T0	COMPOUND	7	7	tacrolimus
NCT0018255913	NCT00182559_13_T1	PHENOTYPE	12	12	chronic
NCT0018255916	NCT00182559_16_T0	COMPOUND	21	21	cyclosporine
NCT0018255916	NCT00182559_16_T1	ORGAN	17	17	graft
NCT0018255916	NCT00182559_16_T2	COMPOUND	23	23	tacrolimus
NCT0018255916	NCT00182559_16_T3	ORGAN	16	16	kidney
NCT0018255916	NCT00182559_16_T4	COMPOUND	1	1	2
NCT0018255916	NCT00182559_16_T5	GENE	7	8	cystatin C
NCT0018255917	NCT00182559_17_T0	ORGAN	12	12	kidney
NCT0018255917	NCT00182559_17_T1	COMPOUND	1	1	3
NCT0018255917	NCT00182559_17_T2	ORGAN	13	13	graft
NCT0018255917	NCT00182559_17_T3	GENE	18	18	2.1
NCT0018255917	NCT00182559_17_T4	COMPOUND	7	7	tacrolimus
NCT0018255918	NCT00182559_18_T0	COMPOUND	4	4	tacrolimus
NCT0018255918	NCT00182559_18_T1	COMPOUND	8	9	mycophenolate mofetil
NCT0018255919	NCT00182559_19_T0	COMPOUND	3	3	cyclosporine
NCT0018255919	NCT00182559_19_T1	PHENOTYPE	0	1	Group B
NCT0018255919	NCT00182559_19_T2	COMPOUND	7	8	mycophenolate mofetil
NCT0018255921	NCT00182559_21_T0	GENE	15	15	MDR1
NCT0018255921	NCT00182559_21_T1	GENE	19	19	ABCB1
NCT0018255921	NCT00182559_21_T2	GENE	13	13	transporter
NCT0018255922	NCT00182559_22_T0	PHENOTYPE	6	6	peripheral
NCT0018255923	NCT00182559_23_T0	GENE	6	6	polymerase
NCT0018255923	NCT00182559_23_T1	GENE	9	9	PCR
NCT0018255924	NCT00182559_24_T0	PHENOTYPE	10	10	RFLP
NCT0018255924	NCT00182559_24_T1	PHENOTYPE	6	9	restriction fragment length polymorphisms
NCT0018255926	NCT00182559_26_T0	ORGAN	6	6	transplant
NCT0018255927	NCT00182559_27_T0	PHENOTYPE	5	5	immunosuppression
NCT0018255927	NCT00182559_27_T1	COMPOUND	10	11	mycophenolate mofetil
NCT0018255928	NCT00182559_28_T0	GENE	1	1	has
NCT0018255928	NCT00182559_28_T1	ORGAN	5	5	allograft
NCT0018255929	NCT00182559_29_T0	PHENOTYPE	9	9	acute
NCT0018255929	NCT00182559_29_T1	ORGAN	4	4	graft
NCT0018255929	NCT00182559_29_T2	GENE	1	1	has
NCT0018255930	NCT00182559_30_T0	GENE	1	1	has
NCT0018255931	NCT00182559_31_T0	GENE	1	1	has
NCT0018255931	NCT00182559_31_T1	GENE	6	6	has
NCT0018255933	NCT00182559_33_T0	COMPOUND	13	13	cyclosporine
NCT0018255933	NCT00182559_33_T1	PHENOTYPE	19	19	hyperlipidemia
NCT0018255933	NCT00182559_33_T2	PHENOTYPE	11	11	suffering
NCT0018255933	NCT00182559_33_T3	GENE	1	1	has
NCT0018255933	NCT00182559_33_T4	PHENOTYPE	18	18	hypertension
NCT0018255935	NCT00182559_35_T0	PHENOTYPE	2	2	recurrence
NCT0018255935	NCT00182559_35_T1	GENE	8	8	de
NCT0018255935	NCT00182559_35_T2	GENE	1	1	has
NCT0018255935	NCT00182559_35_T3	PHENOTYPE	5	6	renal disease
NCT0018255935	NCT00182559_35_T4	PHENOTYPE	10	11	renal disease
NCT001825723	NCT00182572_3_T0	COMPOUND	8	8	heroin
NCT001825723	NCT00182572_3_T1	COMPOUND	21	21	heroin
NCT001825724	NCT00182572_4_T0	COMPOUND	10	10	heroin
NCT001825724	NCT00182572_4_T1	COMPOUND	14	14	heroin
NCT001825724	NCT00182572_4_T2	COMPOUND	27	27	heroin
NCT001825725	NCT00182572_5_T0	COMPOUND	26	26	heroin
NCT001825725	NCT00182572_5_T1	GENE	14	14	has
NCT001825726	NCT00182572_6_T0	BIOLOGICAL_PROCESS	19	19	detoxification
NCT001825729	NCT00182572_9_T0	PHENOTYPE	1	1	secondary
NCT001825729	NCT00182572_9_T1	COMPOUND	20	20	naltrexone
NCT001825729	NCT00182572_9_T2	PHENOTYPE	24	24	relapse
NCT001825729	NCT00182572_9_T3	BIOLOGICAL_PROCESS	30	30	detoxification
NCT0018257210	NCT00182572_10_T0	PHENOTYPE	12	12	relapse
NCT0018257210	NCT00182572_10_T1	PHENOTYPE	14	15	opioid use
NCT0018257211	NCT00182572_11_T0	PHENOTYPE	1	1	secondary
NCT0018257212	NCT00182572_12_T0	PHENOTYPE	10	11	drug use
NCT001825855	NCT00182585_5_T0	PHENOTYPE	18	18	HIV
NCT001825855	NCT00182585_5_T1	PHENOTYPE	26	27	substance abuse
NCT001825856	NCT00182585_6_T0	PHENOTYPE	16	16	HIV
NCT001825856	NCT00182585_6_T1	PHENOTYPE	21	21	self-efficacy
NCT001825856	NCT00182585_6_T2	PHENOTYPE	19	19	diseases
NCT001825857	NCT00182585_7_T0	PHENOTYPE	13	13	HIV
NCT0018258512	NCT00182585_12_T0	PHENOTYPE	15	15	HIV
NCT001825983	NCT00182598_3_T0	COMPOUND	18	18	buprenorphine
NCT001825984	NCT00182598_4_T0	COMPOUND	17	17	buprenorphine
NCT001825984	NCT00182598_4_T1	PHENOTYPE	18	18	HIV/AIDS
NCT001825984	NCT00182598_4_T2	PHENOTYPE	20	20	relapse
NCT001825987	NCT00182598_7_T0	COMPOUND	14	14	buprenorphine
NCT0018259811	NCT00182598_11_T0	PHENOTYPE	18	18	enabling
NCT0018259811	NCT00182598_11_T1	COMPOUND	13	13	buprenorphine
NCT0018259813	NCT00182598_13_T0	COMPOUND	16	16	buprenorphine
NCT001826111	NCT00182611_1_T0	CELL	11	11	cells
NCT001826111	NCT00182611_1_T1	PHENOTYPE	10	10	tumor
NCT001826113	NCT00182611_3_T0	COMPOUND	10	10	cisplatin
NCT001826113	NCT00182611_3_T1	PHENOTYPE	23	24	stomach cancer
NCT001826114	NCT00182611_4_T0	GENE	4	4	III
NCT001826114	NCT00182611_4_T1	COMPOUND	14	14	cisplatin
NCT001826114	NCT00182611_4_T2	PHENOTYPE	28	31	stage III stomach cancer
NCT001826118	NCT00182611_8_T0	GENE	9	9	T4
NCT001826118	NCT00182611_8_T1	GENE	7	7	T3
NCT0018261111	NCT00182611_11_T0	PHENOTYPE	12	13	disease progression
NCT001826241	NCT00182624_1_T0	TISSUE	13	13	tissues
NCT001826241	NCT00182624_1_T1	GENE	0	0	MRI
NCT001826243	NCT00182624_3_T0	GENE	15	15	MRI
NCT001826245	NCT00182624_5_T0	PHENOTYPE	12	12	pathology
NCT001826248	NCT00182624_8_T0	GENE	1	1	coil
NCT001826248	NCT00182624_8_T1	GENE	10	10	MRI
NCT001826249	NCT00182624_9_T0	ORGAN	7	7	pelvis
NCT0018262413	NCT00182624_13_T0	GENE	7	7	MRI
NCT0018262416	NCT00182624_16_T0	ORGAN	10	10	rectum
NCT0018262420	NCT00182624_20_T0	PHENOTYPE	23	23	hypoxia
NCT0018262420	NCT00182624_20_T1	GENE	6	6	MRI
NCT0018262420	NCT00182624_20_T2	GENE	18	18	MRI
NCT0018262420	NCT00182624_20_T3	GENE	21	21	MRI
NCT0018262422	NCT00182624_22_T0	GENE	9	9	3.0
NCT0018262438	NCT00182624_38_T0	PHENOTYPE	3	4	metastatic disease
NCT0018262440	NCT00182624_40_T0	GENE	11	11	LHRH
NCT0018262440	NCT00182624_40_T1	COMPOUND	6	6	androgen
NCT001826371	NCT00182637_1_T0	GENE	3	3	II
NCT001826371	NCT00182637_1_T1	COMPOUND	9	9	bortezomib
NCT001826371	NCT00182637_1_T2	PHENOTYPE	18	20	cutaneous T-cell lymphoma
NCT001826374	NCT00182637_4_T0	GENE	5	5	3.5
NCT001826374	NCT00182637_4_T1	COMPOUND	2	2	bortezomib
NCT001826374	NCT00182637_4_T2	GENE	3	3	IV
NCT001826375	NCT00182637_5_T0	PHENOTYPE	18	18	toxicity
NCT001826375	NCT00182637_5_T1	PHENOTYPE	14	15	disease progression
NCT001826376	NCT00182637_6_T0	PHENOTYPE	23	24	disease progression
NCT001826501	NCT00182650_1_T0	COMPOUND	2	2	fludarabine
NCT001826501	NCT00182650_1_T1	BIOLOGICAL_PROCESS	11	12	immune response
NCT001826501	NCT00182650_1_T2	CELL	16	18	white blood cells
NCT001826502	NCT00182650_2_T0	GENE	0	0	Interleukin-2
NCT001826502	NCT00182650_2_T1	CELL	5	7	white blood cells
NCT001826503	NCT00182650_3_T0	CELL	14	14	cells
NCT001826503	NCT00182650_3_T1	GENE	9	9	interleukin-2
NCT001826503	NCT00182650_3_T2	COMPOUND	7	7	fludarabine
NCT001826504	NCT00182650_4_T0	PHENOTYPE	22	23	Hodgkin's lymphoma
NCT0018265013	NCT00182650_13_T0	PHENOTYPE	18	18	lymphoma
NCT0018265013	NCT00182650_13_T1	PHENOTYPE	5	6	aggressive lymphoma
NCT0018265013	NCT00182650_13_T2	PHENOTYPE	16	17	high grade
NCT001826631	NCT00182663_1_T0	CELL	18	18	cells
NCT001826631	NCT00182663_1_T1	COMPOUND	4	4	thalidomide
NCT001826631	NCT00182663_1_T2	COMPOUND	6	6	clarithromycin
NCT001826631	NCT00182663_1_T3	ORGAN	10	11	immune system
NCT001826634	NCT00182663_4_T0	PHENOTYPE	2	2	toxicity
NCT001826634	NCT00182663_4_T1	ORGAN	14	14	transplant
NCT001826636	NCT00182663_6_T0	PHENOTYPE	5	6	disease progression
NCT001826639	NCT00182663_9_T0	COMPOUND	9	9	dexamethasone
NCT001826639	NCT00182663_9_T1	COMPOUND	3	3	thalidomide
NCT001826639	NCT00182663_9_T2	COMPOUND	14	14	clarithromycin
NCT001826639	NCT00182663_9_T3	GENE	18	18	BID
NCT0018266310	NCT00182663_10_T0	PHENOTYPE	13	13	toxicity
NCT0018266310	NCT00182663_10_T1	PHENOTYPE	9	10	disease progression
NCT0018266311	NCT00182663_11_T0	PHENOTYPE	12	12	toxicity
NCT0018266311	NCT00182663_11_T1	COMPOUND	2	2	thalidomide
NCT0018266311	NCT00182663_11_T2	PHENOTYPE	8	9	disease progression
NCT001826896	NCT00182689_6_T0	PHENOTYPE	6	6	toxicities
NCT0018268912	NCT00182689_12_T0	COMPOUND	5	5	platinum
NCT0018268912	NCT00182689_12_T1	COMPOUND	8	8	platinum
NCT0018268912	NCT00182689_12_T2	COMPOUND	11	11	platinum
NCT0018268913	NCT00182689_13_T0	GENE	8	8	1.28
NCT0018268913	NCT00182689_13_T1	COMPOUND	3	3	sorafenib
NCT0018268914	NCT00182689_14_T0	PHENOTYPE	13	13	toxicity
NCT0018268914	NCT00182689_14_T1	PHENOTYPE	9	10	disease progression
NCT001827026	NCT00182702_6_T0	PHENOTYPE	2	2	toxicity
NCT0018270212	NCT00182702_12_T0	COMPOUND	2	2	ixabepilone
NCT0018270212	NCT00182702_12_T1	GENE	3	3	IV
NCT0018270213	NCT00182702_13_T0	PHENOTYPE	13	13	toxicity
NCT0018270213	NCT00182702_13_T1	PHENOTYPE	9	10	disease progression
NCT0018270214	NCT00182702_14_T0	PHENOTYPE	12	13	disease progression
NCT001827151	NCT00182715_1_T0	CELL	11	11	cells
NCT001827151	NCT00182715_1_T1	PHENOTYPE	10	10	tumor
NCT001827153	NCT00182715_3_T0	CELL	6	6	cells
NCT001827153	NCT00182715_3_T1	PHENOTYPE	5	5	tumor
NCT001827154	NCT00182715_4_T0	CELL	3	3	cells
NCT001827154	NCT00182715_4_T1	PHENOTYPE	2	2	tumor
NCT001827155	NCT00182715_5_T0	PHENOTYPE	19	20	colorectal cancer
NCT001827156	NCT00182715_6_T0	GENE	4	4	III
NCT001827156	NCT00182715_6_T1	PHENOTYPE	30	32	metastatic colorectal cancer
NCT0018271513	NCT00182715_13_T0	GENE	17	17	OR
NCT0018271513	NCT00182715_13_T1	GENE	6	6	1.2
NCT0018271513	NCT00182715_13_T2	GENE	4	4	IV
NCT0018271514	NCT00182715_14_T0	PHENOTYPE	17	17	toxicity
NCT0018271514	NCT00182715_14_T1	PHENOTYPE	13	14	disease progression
NCT0018271518	NCT00182715_18_T0	PHENOTYPE	3	3	progression
NCT0018271519	NCT00182715_19_T0	PHENOTYPE	25	26	disease progression
NCT0018271520	NCT00182715_20_T0	PHENOTYPE	36	36	toxicity
NCT0018271520	NCT00182715_20_T1	PHENOTYPE	3	4	disease progression
NCT0018271520	NCT00182715_20_T2	PHENOTYPE	32	33	disease progression
NCT0018271520	NCT00182715_20_T3	PHENOTYPE	37	39	Quality of life
NCT001827281	NCT00182728_1_T0	PHENOTYPE	10	11	breast cancer
NCT001827282	NCT00182728_2_T0	GENE	3	3	II
NCT001827282	NCT00182728_2_T1	PHENOTYPE	21	23	invasive breast cancer
NCT001827287	NCT00182728_7_T0	GENE	12	12	II
NCT001827287	NCT00182728_7_T1	GENE	6	6	sentinel
NCT001827287	NCT00182728_7_T2	GENE	8	8	OR
NCT001827287	NCT00182728_7_T3	PHENOTYPE	28	28	tumor
NCT001827287	NCT00182728_7_T4	TISSUE	18	19	lymph nodes
NCT001827288	NCT00182728_8_T0	PHENOTYPE	16	16	tumor
NCT001827289	NCT00182728_9_T0	TISSUE	6	7	surgical margins
NCT001827416	NCT00182741_6_T0	COMPOUND	10	10	mitoxantrone
NCT001827416	NCT00182741_6_T1	COMPOUND	6	6	calcitriol
NCT001827416	NCT00182741_6_T2	PHENOTYPE	5	5	pulse
NCT001827416	NCT00182741_6_T3	COMPOUND	17	17	prednisone
NCT001827416	NCT00182741_6_T4	GENE	11	11	IV
NCT001827417	NCT00182741_7_T0	PHENOTYPE	18	18	toxicity
NCT001827417	NCT00182741_7_T1	PHENOTYPE	14	15	disease progression
NCT001827541	NCT00182754_1_T0	COMPOUND	6	6	octreotide
NCT001827541	NCT00182754_1_T1	PHENOTYPE	15	16	malignant ascites
NCT001827542	NCT00182754_2_T0	GENE	4	4	III
NCT001827542	NCT00182754_2_T1	COMPOUND	8	8	octreotide
NCT001827542	NCT00182754_2_T2	PHENOTYPE	23	24	malignant ascites
NCT001827549	NCT00182754_9_T0	PHENOTYPE	0	2	Quality of life
NCT001827672	NCT00182767_2_T0	CELL	11	11	cells
NCT001827672	NCT00182767_2_T1	PHENOTYPE	10	10	tumor
NCT001827679	NCT00182767_9_T0	GENE	16	16	II
NCT001827679	NCT00182767_9_T1	COMPOUND	11	11	ixabepilone
NCT0018276710	NCT00182767_10_T0	COMPOUND	2	2	ixabepilone
NCT0018276710	NCT00182767_10_T1	GENE	4	4	IV
NCT0018276710	NCT00182767_10_T2	GENE	13	13	IV
NCT0018276710	NCT00182767_10_T3	COMPOUND	11	12	doxorubicin hydrochloride
NCT0018276711	NCT00182767_11_T0	PHENOTYPE	13	13	toxicity
NCT0018276711	NCT00182767_11_T1	PHENOTYPE	9	10	disease progression
NCT001827801	NCT00182780_1_T0	PHENOTYPE	15	16	cancer fatigue
NCT001827805	NCT00182780_5_T0	GENE	9	9	II
NCT001827805	NCT00182780_5_T1	PHENOTYPE	21	21	fatigue
NCT001827805	NCT00182780_5_T2	GENE	11	11	III
NCT001827805	NCT00182780_5_T3	GENE	23	23	4.7
NCT001827805	NCT00182780_5_T4	GENE	13	13	IV
NCT001827932	NCT00182793_2_T0	CELL	6	6	cells
NCT001827932	NCT00182793_2_T1	PHENOTYPE	5	5	tumor
NCT001827933	NCT00182793_3_T0	CELL	3	3	cells
NCT001827933	NCT00182793_3_T1	PHENOTYPE	2	2	tumor
NCT001827935	NCT00182793_5_T0	CELL	8	8	cells
NCT001827935	NCT00182793_5_T1	PHENOTYPE	7	7	tumor
NCT0018279312	NCT00182793_12_T0	TISSUE	23	24	lymph nodes
NCT0018279312	NCT00182793_12_T1	ORGAN	20	21	chest wall
NCT0018279313	NCT00182793_13_T0	GENE	3	3	IV
NCT001828062	NCT00182806_2_T0	COMPOUND	7	7	gemcitabine
NCT001828063	NCT00182806_3_T0	COMPOUND	1	1	irinotecan
NCT001828063	NCT00182806_3_T1	CELL	9	9	cells
NCT001828063	NCT00182806_3_T2	PHENOTYPE	8	8	tumor
NCT001828063	NCT00182806_3_T3	COMPOUND	4	4	gemcitabine
NCT001828069	NCT00182806_9_T0	COMPOUND	2	2	irinotecan
NCT001828069	NCT00182806_9_T1	COMPOUND	13	13	gemcitabine
NCT001828069	NCT00182806_9_T2	GENE	3	3	IV
NCT001828069	NCT00182806_9_T3	GENE	14	14	IV
NCT0018280610	NCT00182806_10_T0	PHENOTYPE	13	13	toxicity
NCT0018280610	NCT00182806_10_T1	PHENOTYPE	9	10	disease progression
NCT001828190	NCT00182819_0_T0	PHENOTYPE	8	8	Gliomas
NCT001828193	NCT00182819_3_T0	COMPOUND	12	12	temozolomide
NCT001828193	NCT00182819_3_T1	PHENOTYPE	15	15	gliomas
NCT001828194	NCT00182819_4_T0	COMPOUND	18	18	temozolomide
NCT001828194	NCT00182819_4_T1	GENE	4	4	III
NCT001828194	NCT00182819_4_T2	PHENOTYPE	23	23	gliomas
NCT0018281911	NCT00182819_11_T0	PHENOTYPE	18	18	toxicity
NCT0018281911	NCT00182819_11_T1	PHENOTYPE	14	15	disease progression
NCT0018281912	NCT00182819_12_T0	PHENOTYPE	13	14	disease progression
NCT0018281912	NCT00182819_12_T1	PHENOTYPE	0	2	Quality of life
NCT001828322	NCT00182832_2_T0	PHENOTYPE	1	1	complications
NCT001828323	NCT00182832_3_T0	GENE	14	14	CI
NCT001828323	NCT00182832_3_T1	GENE	22	22	CI
NCT001828325	NCT00182832_5_T0	GENE	25	25	CI
NCT001828326	NCT00182832_6_T0	GENE	13	13	IT
NCT001828327	NCT00182832_7_T0	GENE	32	32	CI
NCT001828327	NCT00182832_7_T1	GENE	9	9	hoc
NCT001828327	NCT00182832_7_T2	PHENOTYPE	30	31	cognitive impairment
NCT001828329	NCT00182832_9_T0	GENE	19	19	CI
NCT0018283210	NCT00182832_10_T0	PHENOTYPE	23	23	initiation
NCT0018283211	NCT00182832_11_T0	PHENOTYPE	6	7	cognitive impairment
NCT0018283212	NCT00182832_12_T0	GENE	15	15	CI
NCT0018283214	NCT00182832_14_T0	PHENOTYPE	13	13	complications
NCT0018283214	NCT00182832_14_T1	PHENOTYPE	23	23	injuries
NCT0018283214	NCT00182832_14_T2	GENE	19	19	CI
NCT0018283214	NCT00182832_14_T3	GENE	28	28	IV
NCT0018283214	NCT00182832_14_T4	PHENOTYPE	22	22	falls
NCT0018283214	NCT00182832_14_T5	GENE	29	29	lines
NCT0018283214	NCT00182832_14_T6	PHENOTYPE	37	37	delirium
NCT0018283214	NCT00182832_14_T7	PHENOTYPE	33	34	pressure ulcers
NCT0018283215	NCT00182832_15_T0	GENE	7	7	CI
NCT001828452	NCT00182845_2_T0	PHENOTYPE	10	10	complications
NCT001828457	NCT00182845_7_T0	PHENOTYPE	12	12	severity
NCT001828457	NCT00182845_7_T1	PHENOTYPE	9	9	delirium
NCT001828457	NCT00182845_7_T2	PHENOTYPE	16	17	cognitive function
NCT001828457	NCT00182845_7_T3	PHENOTYPE	25	27	adverse drug effects
NCT0018284510	NCT00182845_10_T0	PHENOTYPE	5	6	Cognitive Decline
NCT001828581	NCT00182858_1_T0	GENE	47	47	saliva
NCT001828581	NCT00182858_1_T1	PHENOTYPE	49	49	sweat
NCT001828586	NCT00182858_6_T0	PHENOTYPE	20	21	blood loss
NCT001828587	NCT00182858_7_T0	TISSUE	12	12	tissues
NCT001828589	NCT00182858_9_T0	GENE	16	16	saliva
NCT001828589	NCT00182858_9_T1	ORGAN	21	21	nail
NCT001828589	NCT00182858_9_T2	PHENOTYPE	17	17	sweat
NCT0018285810	NCT00182858_10_T0	ORGAN	27	27	liver
NCT0018285810	NCT00182858_10_T1	ORGAN	20	20	abdomen
NCT0018285810	NCT00182858_10_T2	ORGAN	17	17	heart
NCT0018285810	NCT00182858_10_T3	ORGAN	29	29	heart
NCT0018285810	NCT00182858_10_T4	ORGAN	30	30	kidney
NCT0018285810	NCT00182858_10_T5	ORGAN	28	28	bladder
NCT0018285810	NCT00182858_10_T6	ORGAN	18	18	lungs
NCT0018285810	NCT00182858_10_T7	ORGAN	15	16	spinal column
NCT0018285810	NCT00182858_10_T8	TISSUE	23	24	connective tissue
NCT0018285816	NCT00182858_16_T0	PHENOTYPE	20	21	blood loss
NCT0018285817	NCT00182858_17_T0	TISSUE	12	12	tissues
NCT001828716	NCT00182871_6_T0	COMPOUND	15	15	DXA
NCT001828716	NCT00182871_6_T1	TISSUE	7	8	body fat
NCT001828843	NCT00182884_3_T0	PHENOTYPE	10	10	complications
NCT001828844	NCT00182884_4_T0	PHENOTYPE	4	4	delirium
NCT001828844	NCT00182884_4_T1	PHENOTYPE	18	18	delirium
NCT0018288410	NCT00182884_10_T0	PHENOTYPE	3	4	cognitive deficit
NCT0018288410	NCT00182884_10_T1	PHENOTYPE	10	11	adverse effects
NCT001828972	NCT00182897_2_T0	PHENOTYPE	6	6	diseases
NCT001828972	NCT00182897_2_T1	PHENOTYPE	1	1	dementia
NCT001828972	NCT00182897_2_T2	PHENOTYPE	42	42	dementia
NCT001828972	NCT00182897_2_T3	GENE	21	21	CR
NCT001828973	NCT00182897_3_T0	GENE	15	15	has
NCT001828974	NCT00182897_4_T0	PHENOTYPE	7	7	dementia
NCT001828974	NCT00182897_4_T1	PHENOTYPE	3	3	chronic
NCT001828975	NCT00182897_5_T0	GENE	2	2	has
NCT001828976	NCT00182897_6_T0	PHENOTYPE	18	18	dementia
NCT0018289710	NCT00182897_10_T0	PHENOTYPE	4	4	dementia
NCT0018289711	NCT00182897_11_T0	GENE	15	15	tailor
NCT001829231	NCT00182923_1_T0	GENE	14	14	xxx
NCT001829363	NCT00182936_3_T0	PHENOTYPE	5	5	Delirium
NCT001829363	NCT00182936_3_T1	PHENOTYPE	16	16	acute
NCT001829363	NCT00182936_3_T2	PHENOTYPE	26	26	acute
NCT001829363	NCT00182936_3_T3	PHENOTYPE	12	12	persistence
NCT001829363	NCT00182936_3_T4	PHENOTYPE	14	14	delirium
NCT001829363	NCT00182936_3_T5	PHENOTYPE	21	22	functional recovery
NCT001829364	NCT00182936_4_T0	PHENOTYPE	1	1	Delirium
NCT001829364	NCT00182936_4_T1	GENE	4	4	DAP
NCT001829364	NCT00182936_4_T2	PHENOTYPE	28	28	complications
NCT001829364	NCT00182936_4_T3	PHENOTYPE	15	15	delirium
NCT001829364	NCT00182936_4_T4	PHENOTYPE	25	25	delirium
NCT001829364	NCT00182936_4_T5	PHENOTYPE	32	32	delirium
NCT001829364	NCT00182936_4_T6	PHENOTYPE	36	36	delirious
NCT001829365	NCT00182936_5_T0	PHENOTYPE	14	14	acute
NCT001829365	NCT00182936_5_T1	PHENOTYPE	7	7	delirious
NCT001829366	NCT00182936_6_T0	GENE	1	1	DAP
NCT001829491	NCT00182949_1_T0	PHENOTYPE	17	17	diseases
NCT001829493	NCT00182949_3_T0	PHENOTYPE	28	28	diseases
NCT001829493	NCT00182949_3_T1	PHENOTYPE	15	17	diseases and disorders
NCT001829499	NCT00182949_9_T0	GENE	5	5	has
NCT0018294912	NCT00182949_12_T0	PHENOTYPE	17	17	diseases
NCT001829624	NCT00182962_4_T0	COMPOUND	15	15	1
NCT001829624	NCT00182962_4_T1	COMPOUND	24	24	2
NCT001829624	NCT00182962_4_T2	COMPOUND	28	28	2
NCT001829624	NCT00182962_4_T3	COMPOUND	48	48	2
NCT001829624	NCT00182962_4_T4	COMPOUND	58	58	2
NCT001829624	NCT00182962_4_T5	COMPOUND	42	42	3
NCT001829750	NCT00182975_0_T0	COMPOUND	3	3	DHEA
NCT001829753	NCT00182975_3_T0	COMPOUND	0	0	DHEA
NCT001829753	NCT00182975_3_T1	GENE	3	3	PPAR-alpha
NCT001829753	NCT00182975_3_T2	GENE	4	4	activator
NCT001829754	NCT00182975_4_T0	PHENOTYPE	10	10	inflammation
NCT001829754	NCT00182975_4_T1	GENE	0	0	PPAR-alpha
NCT001829754	NCT00182975_4_T2	BIOLOGICAL_PROCESS	6	7	lipid metabolism
NCT001829755	NCT00182975_5_T0	COMPOUND	0	0	DHEA
NCT001829755	NCT00182975_5_T1	PHENOTYPE	5	6	anabolic effects
NCT001829887	NCT00182988_7_T0	PHENOTYPE	5	6	Alzheimer's Disease
NCT0018298810	NCT00182988_10_T0	PHENOTYPE	8	10	quality of life
NCT0018298812	NCT00182988_12_T0	PHENOTYPE	9	10	Alzheimer's Disease
NCT0018298817	NCT00182988_17_T0	PHENOTYPE	19	19	dementia
NCT001830012	NCT00183001_2_T0	COMPOUND	6	6	calcium
NCT001830012	NCT00183001_2_T1	COMPOUND	8	9	vitamin D
NCT001830012	NCT00183001_2_T2	PHENOTYPE	20	21	bone loss
NCT001830014	NCT00183001_4_T0	PHENOTYPE	0	1	Vascular calcification
NCT001830014	NCT00183001_4_T1	COMPOUND	12	13	vitamin K
NCT001830015	NCT00183001_5_T0	COMPOUND	10	11	vitamin K
NCT001830017	NCT00183001_7_T0	ORGAN	0	0	Plasma
NCT001830017	NCT00183001_7_T1	PHENOTYPE	3	3	concentrations
NCT001830017	NCT00183001_7_T2	COMPOUND	6	6	calcium
NCT001830017	NCT00183001_7_T3	COMPOUND	8	8	sodium
NCT001830017	NCT00183001_7_T4	COMPOUND	1	2	25-hydroxyvitamin D
NCT001830019	NCT00183001_9_T0	GENE	18	18	insulin
NCT001830019	NCT00183001_9_T1	PHENOTYPE	22	22	inflammation
NCT001830019	NCT00183001_9_T2	ORGAN	16	16	plasma
NCT0018300110	NCT00183001_10_T0	COMPOUND	15	16	vitamin K
NCT001830143	NCT00183014_3_T0	PHENOTYPE	31	31	strategies
NCT001830143	NCT00183014_3_T1	PHENOTYPE	18	18	attribution
NCT001830144	NCT00183014_4_T0	PHENOTYPE	7	7	centers
NCT001830145	NCT00183014_5_T0	BIOLOGICAL_PROCESS	26	26	aging
NCT001830272	NCT00183027_2_T0	COMPOUND	4	4	1
NCT001830272	NCT00183027_2_T1	COMPOUND	5	5	1
NCT001830272	NCT00183027_2_T2	COMPOUND	12	12	1
NCT001830274	NCT00183027_4_T0	GENE	5	5	CR
NCT001830276	NCT00183027_6_T0	GENE	16	16	CR
NCT001830276	NCT00183027_6_T1	GENE	24	24	CR
NCT001830279	NCT00183027_9_T0	GENE	66	66	GI
NCT001830403	NCT00183040_3_T0	GENE	29	29	GH
NCT001830403	NCT00183040_3_T1	COMPOUND	27	27	testosterone
NCT001830403	NCT00183040_3_T2	GENE	7	7	hormone
NCT001830403	NCT00183040_3_T3	BIOLOGICAL_PROCESS	50	50	aging
NCT001830403	NCT00183040_3_T4	PHENOTYPE	14	14	contractile
NCT001830403	NCT00183040_3_T5	TISSUE	34	35	skeletal muscle
NCT001830406	NCT00183040_6_T0	COMPOUND	15	15	testosterone
NCT001830535	NCT00183053_5_T0	PHENOTYPE	13	13	falls
NCT001830535	NCT00183053_5_T1	PHENOTYPE	6	6	blocks
NCT001830536	NCT00183053_6_T0	PHENOTYPE	25	25	falls
NCT001830537	NCT00183053_7_T0	PHENOTYPE	27	27	falls
NCT001830539	NCT00183053_9_T0	PHENOTYPE	5	5	falls
NCT0018305310	NCT00183053_10_T0	PHENOTYPE	14	14	falls
NCT0018305311	NCT00183053_11_T0	PHENOTYPE	11	11	falls
NCT0018305311	NCT00183053_11_T1	GENE	2	2	has
NCT0018305312	NCT00183053_12_T0	PHENOTYPE	1	1	secondary
NCT0018305313	NCT00183053_13_T0	PHENOTYPE	15	15	falls
NCT0018305314	NCT00183053_14_T0	PHENOTYPE	6	6	falls
NCT0018305314	NCT00183053_14_T1	PHENOTYPE	18	18	decisions
NCT001830662	NCT00183066_2_T0	GENE	18	18	NIA
NCT001830662	NCT00183066_2_T1	BIOLOGICAL_PROCESS	17	17	Aging
NCT001830662	NCT00183066_2_T2	ORGAN	34	35	immune system
NCT001830662	NCT00183066_2_T3	ORGAN	26	27	bone marrow
NCT001830663	NCT00183066_3_T0	CELL	7	8	blood cells
NCT001830664	NCT00183066_4_T0	ORGAN	10	11	immune system
NCT001830664	NCT00183066_4_T1	PHENOTYPE	13	15	bone marrow failure
NCT001830792	NCT00183079_2_T0	PHENOTYPE	0	1	Heavy drinking
NCT001830793	NCT00183079_3_T0	PHENOTYPE	0	1	Heavy drinking
NCT001830794	NCT00183079_4_T0	PHENOTYPE	34	35	heavy drinking
NCT001830794	NCT00183079_4_T1	PHENOTYPE	18	20	heavy alcohol use
NCT001830795	NCT00183079_5_T0	BIOLOGICAL_PROCESS	21	21	drinking
NCT001830795	NCT00183079_5_T1	PHENOTYPE	24	25	heavy drinking
NCT001830797	NCT00183079_7_T0	GENE	4	4	reduced
NCT0018307911	NCT00183079_11_T0	BIOLOGICAL_PROCESS	40	41	drinking behavior
NCT001830926	NCT00183092_6_T0	GENE	10	10	probable
NCT001830926	NCT00183092_6_T1	COMPOUND	35	35	quinacrine
NCT001830926	NCT00183092_6_T2	PHENOTYPE	23	23	initiation
NCT001830926	NCT00183092_6_T3	PHENOTYPE	13	13	sCJD
NCT001830927	NCT00183092_7_T0	COMPOUND	11	11	quinacrine
NCT001830927	NCT00183092_7_T1	COMPOUND	23	23	quinacrine
NCT001830928	NCT00183092_8_T0	PHENOTYPE	16	16	sCJD
NCT0018309210	NCT00183092_10_T0	PHENOTYPE	25	26	medication toxicity
NCT001831052	NCT00183105_2_T0	PHENOTYPE	19	19	dependence
NCT001831052	NCT00183105_2_T1	PHENOTYPE	13	14	alcohol problems
NCT001831053	NCT00183105_3_T0	PHENOTYPE	20	20	severity
NCT001831053	NCT00183105_3_T1	PHENOTYPE	25	26	alcohol problem
NCT001831055	NCT00183105_5_T0	PHENOTYPE	10	11	alcohol problems
NCT001831055	NCT00183105_5_T1	PHENOTYPE	4	6	quality of life
NCT001831056	NCT00183105_6_T0	PHENOTYPE	17	18	chronic illnesses
NCT001831183	NCT00183118_3_T0	PHENOTYPE	2	2	HIV
NCT001831183	NCT00183118_3_T1	PHENOTYPE	13	13	HIV
NCT001831184	NCT00183118_4_T0	GENE	17	17	booster
NCT001831185	NCT00183118_5_T0	PHENOTYPE	17	17	HIV
NCT001831187	NCT00183118_7_T0	PHENOTYPE	8	8	HIV
NCT001831188	NCT00183118_8_T0	PHENOTYPE	0	0	HIV
NCT001831189	NCT00183118_9_T0	PHENOTYPE	17	17	HIV
NCT001831189	NCT00183118_9_T1	PHENOTYPE	30	30	HIV
NCT0018311810	NCT00183118_10_T0	PHENOTYPE	10	10	HIV
NCT0018311810	NCT00183118_10_T1	PHENOTYPE	7	8	substance abuse
NCT0018311812	NCT00183118_12_T0	PHENOTYPE	18	18	HIV
NCT0018311812	NCT00183118_12_T1	GENE	13	13	booster
NCT001831313	NCT00183131_3_T0	BIOLOGICAL_PROCESS	6	6	drinking
NCT001831314	NCT00183131_4_T0	PHENOTYPE	40	41	hazardous drinking
NCT001831442	NCT00183144_2_T0	PHENOTYPE	12	12	alcoholism
NCT001831442	NCT00183144_2_T1	ORGAN	2	2	heart
NCT001831442	NCT00183144_2_T2	PHENOTYPE	9	9	staggering
NCT001831442	NCT00183144_2_T3	PHENOTYPE	14	15	drug addiction
NCT001831443	NCT00183144_3_T0	PHENOTYPE	6	7	substance abuse
NCT001831443	NCT00183144_3_T1	PHENOTYPE	23	24	substance abuse
NCT001831445	NCT00183144_5_T0	COMPOUND	17	17	heroin
NCT001831445	NCT00183144_5_T1	COMPOUND	19	19	cocaine
NCT001831445	NCT00183144_5_T2	GENE	2	2	has
NCT001831446	NCT00183144_6_T0	PHENOTYPE	4	4	reinforcement
NCT0018314412	NCT00183144_12_T0	BIOLOGICAL_PROCESS	21	21	detoxification
NCT0018314413	NCT00183144_13_T0	BIOLOGICAL_PROCESS	2	2	detoxification
NCT0018314414	NCT00183144_14_T0	PHENOTYPE	16	16	reinforcement
NCT001831572	NCT00183157_2_T0	BIOLOGICAL_PROCESS	20	20	drinking
NCT001831578	NCT00183157_8_T0	BIOLOGICAL_PROCESS	20	20	drinking
NCT001831579	NCT00183157_9_T0	PHENOTYPE	25	26	drug use
NCT001831702	NCT00183170_2_T0	PHENOTYPE	17	17	symptoms
NCT001831702	NCT00183170_2_T1	PHENOTYPE	16	16	hangover
NCT001831702	NCT00183170_2_T2	PHENOTYPE	13	14	alcohol abuse
NCT001831703	NCT00183170_3_T0	PHENOTYPE	11	11	BAC
NCT001831704	NCT00183170_4_T0	PHENOTYPE	1	1	secondary
NCT001831704	NCT00183170_4_T1	PHENOTYPE	16	17	heavy drinking
NCT0018317010	NCT00183170_10_T0	PHENOTYPE	10	11	drinking problems
NCT0018317011	NCT00183170_11_T0	PHENOTYPE	7	7	symptoms
NCT0018317011	NCT00183170_11_T1	PHENOTYPE	6	6	hangover
NCT0018317013	NCT00183170_13_T0	PHENOTYPE	12	12	BAC
NCT0018317019	NCT00183170_19_T0	PHENOTYPE	24	24	BAC
NCT001831831	NCT00183183_1_T0	BIOLOGICAL_PROCESS	37	37	drinking
NCT001831833	NCT00183183_3_T0	GENE	5	5	met
NCT001831837	NCT00183183_7_T0	GENE	21	21	White
NCT001831967	NCT00183196_7_T0	COMPOUND	1	1	riboflavin
NCT001831968	NCT00183196_8_T0	COMPOUND	7	7	naltrexone
NCT001831968	NCT00183196_8_T1	COMPOUND	13	13	gabapentin
NCT001832092	NCT00183209_2_T0	PHENOTYPE	15	16	drug use
NCT001832094	NCT00183209_4_T0	PHENOTYPE	16	17	drug use
NCT001832094	NCT00183209_4_T1	PHENOTYPE	13	14	problem drinking
NCT0018320911	NCT00183209_11_T0	PHENOTYPE	15	16	drug use
NCT001832222	NCT00183222_2_T0	COMPOUND	23	23	naltrexone
NCT001832222	NCT00183222_2_T1	COMPOUND	34	34	naltrexone
NCT001832222	NCT00183222_2_T2	COMPOUND	27	27	ondansetron
NCT001832222	NCT00183222_2_T3	COMPOUND	36	36	ondansetron
NCT001832223	NCT00183222_3_T0	GENE	10	10	1.5
NCT001832224	NCT00183222_4_T0	BIOLOGICAL_PROCESS	24	24	drinking
NCT001832225	NCT00183222_5_T0	PHENOTYPE	19	20	problem drinking
NCT001832226	NCT00183222_6_T0	GENE	22	22	cue
NCT001832226	NCT00183222_6_T1	GENE	18	18	MRI
NCT0018322222	NCT00183222_22_T0	GENE	5	5	IV
NCT0018322222	NCT00183222_22_T1	PHENOTYPE	11	14	alcohol abuse or dependence
NCT0018322225	NCT00183222_25_T0	GENE	1	1	has
NCT0018322235	NCT00183222_35_T0	PHENOTYPE	12	12	symptoms
NCT0018322235	NCT00183222_35_T1	PHENOTYPE	6	6	claustrophobia
NCT0018322235	NCT00183222_35_T2	PHENOTYPE	10	11	clinical anxiety
NCT0018322241	NCT00183222_41_T0	GENE	3	3	IV
NCT0018322241	NCT00183222_41_T1	PHENOTYPE	9	10	substance dependence
NCT0018322243	NCT00183222_43_T0	PHENOTYPE	2	3	opiate abuse
NCT0018322243	NCT00183222_43_T1	PHENOTYPE	6	9	positive urine drug screen
NCT0018322245	NCT00183222_45_T0	COMPOUND	7	7	nicotine
NCT0018322245	NCT00183222_45_T1	PHENOTYPE	2	3	substance use
NCT0018322250	NCT00183222_50_T0	PHENOTYPE	5	5	homicidal
NCT0018322250	NCT00183222_50_T1	PHENOTYPE	3	3	ideation
NCT0018322250	NCT00183222_50_T2	PHENOTYPE	6	6	ideation
NCT0018322252	NCT00183222_52_T0	PHENOTYPE	4	4	acute
NCT0018322252	NCT00183222_52_T1	PHENOTYPE	11	11	seizure
NCT0018322254	NCT00183222_54_T0	COMPOUND	3	3	disulfiram
NCT0018322256	NCT00183222_56_T0	GENE	8	8	GI
NCT0018322256	NCT00183222_56_T1	PHENOTYPE	19	19	ingestion
NCT0018322256	NCT00183222_56_T2	PHENOTYPE	10	11	endocrine problem
NCT0018322258	NCT00183222_58_T0	PHENOTYPE	11	11	pancreatitis
NCT0018322258	NCT00183222_58_T1	PHENOTYPE	14	15	hepatic cirrhosis
NCT0018322258	NCT00183222_58_T2	PHENOTYPE	12	13	peptic ulcer
NCT0018322258	NCT00183222_58_T3	PHENOTYPE	9	10	gastrointestinal bleeding
NCT001832350	NCT00183235_0_T0	PHENOTYPE	6	6	Consumption
NCT001832353	NCT00183235_3_T0	COMPOUND	22	22	aripiprazole
NCT001832354	NCT00183235_4_T0	GENE	12	12	1/6
NCT001832355	NCT00183235_5_T0	BIOLOGICAL_PROCESS	24	24	drinking
NCT001832356	NCT00183235_6_T0	PHENOTYPE	19	20	problem drinking
NCT001832358	NCT00183235_8_T0	GENE	10	10	cue
NCT001832358	NCT00183235_8_T1	GENE	6	6	MRI
NCT001832359	NCT00183235_9_T0	COMPOUND	13	13	aripiprazole
NCT001832359	NCT00183235_9_T1	PHENOTYPE	16	17	alcohol cue
NCT001832359	NCT00183235_9_T2	ORGAN	21	22	nucleus accumbens
NCT0018323510	NCT00183235_10_T0	COMPOUND	4	4	aripiprazole
NCT0018323510	NCT00183235_10_T1	ORGAN	7	8	nucleus accumbens
NCT0018323513	NCT00183235_13_T0	GENE	3	3	IV
NCT0018323513	NCT00183235_13_T1	PHENOTYPE	9	10	substance dependence
NCT0018323515	NCT00183235_15_T0	COMPOUND	7	7	nicotine
NCT0018323515	NCT00183235_15_T1	PHENOTYPE	2	3	substance use
NCT0018323520	NCT00183235_20_T0	PHENOTYPE	5	5	homicidal
NCT0018323520	NCT00183235_20_T1	PHENOTYPE	3	3	ideation
NCT0018323520	NCT00183235_20_T2	PHENOTYPE	6	6	ideation
NCT0018323522	NCT00183235_22_T0	PHENOTYPE	4	4	acute
NCT0018323522	NCT00183235_22_T1	PHENOTYPE	11	11	seizure
NCT0018323524	NCT00183235_24_T0	COMPOUND	3	3	disulfiram
NCT0018323526	NCT00183235_26_T0	GENE	8	8	GI
NCT0018323526	NCT00183235_26_T1	PHENOTYPE	19	19	ingestion
NCT0018323526	NCT00183235_26_T2	PHENOTYPE	10	11	endocrine problem
NCT0018323528	NCT00183235_28_T0	PHENOTYPE	11	11	pancreatitis
NCT0018323528	NCT00183235_28_T1	PHENOTYPE	14	15	hepatic cirrhosis
NCT0018323528	NCT00183235_28_T2	PHENOTYPE	17	18	alcoholic hepatitis
NCT0018323528	NCT00183235_28_T3	PHENOTYPE	12	13	peptic ulcer
NCT0018323528	NCT00183235_28_T4	PHENOTYPE	9	10	gastrointestinal bleeding
NCT001832481	NCT00183248_1_T0	ORGAN	6	6	kidney
NCT001832481	NCT00183248_1_T1	ORGAN	28	28	kidney
NCT001832481	NCT00183248_1_T2	ORGAN	7	7	transplant
NCT001832481	NCT00183248_1_T3	CELL	24	25	stem cells
NCT001832481	NCT00183248_1_T4	ORGAN	22	23	bone marrow
NCT001832481	NCT00183248_1_T5	ORGAN	13	14	immune system
NCT001832482	NCT00183248_2_T0	PHENOTYPE	16	17	organ rejection
NCT001832484	NCT00183248_4_T0	COMPOUND	4	4	tacrolimus
NCT001832484	NCT00183248_4_T1	ORGAN	10	11	immune system
NCT001832484	NCT00183248_4_T2	ORGAN	18	19	organ transplants
NCT001832485	NCT00183248_5_T0	PHENOTYPE	18	18	leukemia
NCT001832485	NCT00183248_5_T1	CELL	11	12	T cells
NCT001832485	NCT00183248_5_T2	ORGAN	15	16	bone marrow
NCT001832486	NCT00183248_6_T0	CELL	11	13	white blood cells
NCT001832487	NCT00183248_7_T0	ORGAN	22	22	kidney
NCT001832487	NCT00183248_7_T1	ORGAN	13	13	liver
NCT001832488	NCT00183248_8_T0	ORGAN	10	10	kidney
NCT001832488	NCT00183248_8_T1	ORGAN	28	28	kidney
NCT001832488	NCT00183248_8_T2	CELL	24	25	stem cells
NCT001832488	NCT00183248_8_T3	ORGAN	4	5	immune system
NCT001832488	NCT00183248_8_T4	ORGAN	22	23	bone marrow
NCT001832489	NCT00183248_9_T0	CELL	2	3	stem cells
NCT001832489	NCT00183248_9_T1	ORGAN	0	1	Bone marrow
NCT001832489	NCT00183248_9_T2	CELL	6	7	blood cells
NCT001832489	NCT00183248_9_T3	CELL	12	13	blood cells
NCT001832489	NCT00183248_9_T4	CELL	16	17	T cells
NCT0018324814	NCT00183248_14_T0	ORGAN	3	3	kidney
NCT0018324816	NCT00183248_16_T0	COMPOUND	19	19	tacrolimus
NCT0018324816	NCT00183248_16_T1	COMPOUND	8	9	mycophenolate mofetil
NCT0018324817	NCT00183248_17_T0	ORGAN	21	21	kidney
NCT0018324817	NCT00183248_17_T1	ORGAN	39	39	transplant
NCT0018324817	NCT00183248_17_T2	CELL	16	17	stem cells
NCT0018324817	NCT00183248_17_T3	CELL	29	30	stem cells
NCT0018324817	NCT00183248_17_T4	GENE	5	6	Group 1
NCT0018324817	NCT00183248_17_T5	ORGAN	23	24	bone marrow
NCT0018324818	NCT00183248_18_T0	ORGAN	6	6	transplant
NCT0018324818	NCT00183248_18_T1	ORGAN	22	22	transplant
NCT0018324819	NCT00183248_19_T0	ORGAN	2	2	transplant
NCT0018324820	NCT00183248_20_T0	ORGAN	7	7	transplant
NCT0018324822	NCT00183248_22_T0	ORGAN	9	9	kidney
NCT0018324823	NCT00183248_23_T0	ORGAN	19	19	kidney
NCT001832610	NCT00183261_0_T0	PHENOTYPE	5	5	HIV
NCT001832610	NCT00183261_0_T1	PHENOTYPE	14	14	Acute
NCT001832610	NCT00183261_0_T2	BIOLOGICAL_PROCESS	0	1	Immune Response
NCT001832610	NCT00183261_0_T3	PHENOTYPE	17	18	HIV Infection
NCT001832613	NCT00183261_3_T0	PHENOTYPE	7	7	acute
NCT001832613	NCT00183261_3_T1	PHENOTYPE	19	19	HIV
NCT001832613	NCT00183261_3_T2	PHENOTYPE	10	11	HIV infection
NCT001832618	NCT00183261_8_T0	PHENOTYPE	2	2	HIV
NCT0018326110	NCT00183261_10_T0	PHENOTYPE	7	7	HIV
NCT0018326110	NCT00183261_10_T1	ORGAN	6	6	plasma
NCT0018326116	NCT00183261_16_T0	GENE	25	25	CD4
NCT001832748	NCT00183274_8_T0	COMPOUND	14	14	venlafaxine
NCT001832749	NCT00183274_9_T0	COMPOUND	15	15	venlafaxine
NCT0018327410	NCT00183274_10_T0	COMPOUND	5	5	venlafaxine
NCT0018327414	NCT00183274_14_T0	PHENOTYPE	14	14	secondary
NCT001832873	NCT00183287_3_T0	PHENOTYPE	19	19	complications
NCT001832873	NCT00183287_3_T1	PHENOTYPE	22	22	toxicities
NCT001832873	NCT00183287_3_T2	PHENOTYPE	15	16	HIV disease
NCT001832873	NCT00183287_3_T3	PHENOTYPE	37	38	HIV infection
NCT001833002	NCT00183300_2_T0	PHENOTYPE	0	0	PTSD
NCT001833002	NCT00183300_2_T1	PHENOTYPE	10	11	psychological symptoms
NCT001833003	NCT00183300_3_T0	PHENOTYPE	7	7	trauma
NCT001833003	NCT00183300_3_T1	PHENOTYPE	3	3	PTSD
NCT001833003	NCT00183300_3_T2	PHENOTYPE	18	18	thoughts
NCT001833003	NCT00183300_3_T3	PHENOTYPE	12	12	flashback
NCT001833003	NCT00183300_3_T4	PHENOTYPE	15	15	nightmares
NCT001833003	NCT00183300_3_T5	PHENOTYPE	17	17	frightening
NCT001833005	NCT00183300_5_T0	PHENOTYPE	22	22	symptoms
NCT001833005	NCT00183300_5_T1	GENE	13	13	PE
NCT001833005	NCT00183300_5_T2	GENE	18	18	PE
NCT001833005	NCT00183300_5_T3	PHENOTYPE	24	26	traumatic stress disorder
NCT001833006	NCT00183300_6_T0	GENE	11	11	PE
NCT001833007	NCT00183300_7_T0	GENE	4	4	PE
NCT001833008	NCT00183300_8_T0	GENE	17	17	PE
NCT001833009	NCT00183300_9_T0	GENE	25	25	PE
NCT0018330010	NCT00183300_10_T0	PHENOTYPE	11	11	symptoms
NCT0018330010	NCT00183300_10_T1	PHENOTYPE	10	10	PTSD
NCT0018330010	NCT00183300_10_T2	PHENOTYPE	15	15	PTSD
NCT0018330010	NCT00183300_10_T3	PHENOTYPE	16	16	cognitions
NCT0018330011	NCT00183300_11_T0	GENE	6	6	saliva
NCT0018330012	NCT00183300_12_T0	GENE	8	8	saliva
NCT0018330012	NCT00183300_12_T1	COMPOUND	19	19	cortisol
NCT0018330012	NCT00183300_12_T2	GENE	3	3	PE
NCT001833132	NCT00183313_2_T0	PHENOTYPE	34	34	illnesses
NCT001833132	NCT00183313_2_T1	PHENOTYPE	12	13	chronic disease
NCT001833134	NCT00183313_4_T0	PHENOTYPE	23	24	mental health
NCT001833139	NCT00183313_9_T0	PHENOTYPE	20	21	substance use
NCT001833139	NCT00183313_9_T1	PHENOTYPE	17	18	psychiatric symptoms
NCT001833262	NCT00183326_2_T0	PHENOTYPE	11	12	child abuse
NCT001833263	NCT00183326_3_T0	PHENOTYPE	3	3	symptoms
NCT001833263	NCT00183326_3_T1	PHENOTYPE	2	2	PTSD
NCT001833263	NCT00183326_3_T2	PHENOTYPE	10	11	behavioral problems
NCT001833265	NCT00183326_5_T0	PHENOTYPE	16	16	PTSD
NCT001833265	NCT00183326_5_T1	PHENOTYPE	11	12	behavioral problems
NCT001833266	NCT00183326_6_T0	PHENOTYPE	3	3	PTSD
NCT001833266	NCT00183326_6_T1	PHENOTYPE	17	17	PTSD
NCT001833266	NCT00183326_6_T2	PHENOTYPE	24	25	behavioral symptoms
NCT001833267	NCT00183326_7_T0	PHENOTYPE	10	10	PTSD
NCT001833267	NCT00183326_7_T1	PHENOTYPE	14	15	psychological symptoms
NCT001833267	NCT00183326_7_T2	PHENOTYPE	15	17	symptoms in children
NCT0018332610	NCT00183326_10_T0	PHENOTYPE	8	8	trauma
NCT0018332610	NCT00183326_10_T1	PHENOTYPE	15	15	emotions
NCT0018332611	NCT00183326_11_T0	PHENOTYPE	8	8	emotions
NCT0018332614	NCT00183326_14_T0	PHENOTYPE	10	10	symptoms
NCT0018332614	NCT00183326_14_T1	PHENOTYPE	12	12	PTSD
NCT0018332614	NCT00183326_14_T2	PHENOTYPE	16	17	behavioral problems
NCT001833393	NCT00183339_3_T0	PHENOTYPE	0	0	Autism
NCT001833393	NCT00183339_3_T1	PHENOTYPE	2	2	affects
NCT001833395	NCT00183339_5_T0	PHENOTYPE	3	4	cognitive impairments
NCT001833395	NCT00183339_5_T1	PHENOTYPE	6	7	language delays
NCT001833396	NCT00183339_6_T0	COMPOUND	13	13	fluoxetine
NCT001833396	NCT00183339_6_T1	PHENOTYPE	10	10	autistic
NCT001833396	NCT00183339_6_T2	PHENOTYPE	23	23	autism
NCT001833397	NCT00183339_7_T0	COMPOUND	11	11	fluoxetine
NCT001833522	NCT00183352_2_T0	PHENOTYPE	5	6	bipolar disorder
NCT001833522	NCT00183352_2_T1	PHENOTYPE	9	10	reproduction function
NCT001833523	NCT00183352_3_T0	PHENOTYPE	17	18	bipolar disorder
NCT001833523	NCT00183352_3_T1	PHENOTYPE	7	8	mood changes
NCT001833523	NCT00183352_3_T2	PHENOTYPE	4	5	reproductive function
NCT001833524	NCT00183352_4_T0	PHENOTYPE	6	7	bipolar disorder
NCT001833525	NCT00183352_5_T0	PHENOTYPE	7	8	mood changes
NCT001833525	NCT00183352_5_T1	PHENOTYPE	4	5	reproductive function
NCT001833527	NCT00183352_7_T0	BIOLOGICAL_PROCESS	18	18	ovulation
NCT001833527	NCT00183352_7_T1	CELL	6	7	basal body
NCT001833528	NCT00183352_8_T0	BIOLOGICAL_PROCESS	15	16	menstrual cycle
NCT0018335212	NCT00183352_12_T0	PHENOTYPE	1	2	insulin resistance
NCT001833653	NCT00183365_3_T0	GENE	17	17	PFP
NCT001833654	NCT00183365_4_T0	GENE	1	1	PFP
NCT001833657	NCT00183365_7_T0	GENE	5	5	PFP
NCT0018336512	NCT00183365_12_T0	PHENOTYPE	1	1	symptoms
NCT0018336512	NCT00183365_12_T1	PHENOTYPE	11	11	practices
NCT001833782	NCT00183378_2_T0	GENE	13	13	AD
NCT001833784	NCT00183378_4_T0	GENE	4	4	AD
NCT001833786	NCT00183378_6_T0	GENE	25	25	AD
NCT0018337810	NCT00183378_10_T0	PHENOTYPE	13	14	muscle soreness
NCT0018337817	NCT00183378_17_T0	PHENOTYPE	5	6	behavioral disturbances
NCT001833912	NCT00183391_2_T0	COMPOUND	2	2	2
NCT001833915	NCT00183391_5_T0	PHENOTYPE	18	18	dizziness
NCT001833915	NCT00183391_5_T1	PHENOTYPE	23	23	headaches
NCT001833915	NCT00183391_5_T2	PHENOTYPE	19	21	loss of appetite
NCT001833916	NCT00183391_6_T0	COMPOUND	6	6	methylphenidate
NCT001833916	NCT00183391_6_T1	PHENOTYPE	19	19	ADHD
NCT001833916	NCT00183391_6_T2	COMPOUND	10	10	atomoxetine
NCT001833916	NCT00183391_6_T3	PHENOTYPE	20	22	symptoms in children
NCT001833918	NCT00183391_8_T0	COMPOUND	13	13	norepinephrine
NCT001833918	NCT00183391_8_T1	COMPOUND	3	3	methylphenidate
NCT001833918	NCT00183391_8_T2	COMPOUND	10	10	atomoxetine
NCT001833918	NCT00183391_8_T3	COMPOUND	8	8	dopamine
NCT001833919	NCT00183391_9_T0	PHENOTYPE	16	16	ADHD
NCT001833919	NCT00183391_9_T1	GENE	1	1	has
NCT0018339110	NCT00183391_10_T0	COMPOUND	8	8	methylphenidate
NCT0018339110	NCT00183391_10_T1	COMPOUND	10	10	atomoxetine
NCT0018339117	NCT00183391_17_T0	PHENOTYPE	12	12	symptoms
NCT0018339117	NCT00183391_17_T1	PHENOTYPE	11	11	ADHD
NCT001834040	NCT00183404_0_T0	PHENOTYPE	6	6	Autism
NCT001834044	NCT00183404_4_T0	PHENOTYPE	8	8	symptoms
NCT001834044	NCT00183404_4_T1	PHENOTYPE	10	10	autism
NCT001834045	NCT00183404_5_T0	PHENOTYPE	15	15	constipation
NCT001834045	NCT00183404_5_T1	COMPOUND	4	4	haloperidol
NCT001834045	NCT00183404_5_T2	GENE	5	5	has
NCT001834045	NCT00183404_5_T3	PHENOTYPE	17	17	nausea
NCT001834045	NCT00183404_5_T4	PHENOTYPE	9	10	adverse effects
NCT001834045	NCT00183404_5_T5	PHENOTYPE	13	14	blurred vision
NCT001834047	NCT00183404_7_T0	PHENOTYPE	20	20	symptoms
NCT001834047	NCT00183404_7_T1	COMPOUND	8	8	olanzapine
NCT001834047	NCT00183404_7_T2	COMPOUND	17	17	haloperidol
NCT001834047	NCT00183404_7_T3	PHENOTYPE	22	24	autism in children
NCT001834049	NCT00183404_9_T0	COMPOUND	11	11	olanzapine
NCT0018340411	NCT00183404_11_T0	GENE	13	13	II
NCT0018340412	NCT00183404_12_T0	GENE	2	2	II
NCT0018340412	NCT00183404_12_T1	COMPOUND	6	6	olanzapine
NCT001834179	NCT00183417_9_T0	PHENOTYPE	11	11	emotions
NCT0018341711	NCT00183417_11_T0	PHENOTYPE	6	7	depressive symptoms
NCT001834303	NCT00183430_3_T0	PHENOTYPE	2	2	PTSD
NCT001834303	NCT00183430_3_T1	PHENOTYPE	6	6	thoughts
NCT001834303	NCT00183430_3_T2	PHENOTYPE	5	5	frightening
NCT001834303	NCT00183430_3_T3	GENE	17	17	numb
NCT001834304	NCT00183430_4_T0	PHENOTYPE	0	0	PTSD
NCT001834305	NCT00183430_5_T0	PHENOTYPE	17	17	trauma
NCT001834305	NCT00183430_5_T1	PHENOTYPE	8	8	PTSD
NCT001834307	NCT00183430_7_T0	PHENOTYPE	1	1	trauma
NCT001834307	NCT00183430_7_T1	PHENOTYPE	13	13	symptoms
NCT001834307	NCT00183430_7_T2	PHENOTYPE	12	12	PTSD
NCT001834307	NCT00183430_7_T3	PHENOTYPE	2	2	nightmares
NCT001834307	NCT00183430_7_T4	GENE	19	19	has
NCT001834307	NCT00183430_7_T5	PHENOTYPE	11	11	chronic
NCT001834308	NCT00183430_8_T0	PHENOTYPE	19	19	PTSD
NCT001834308	NCT00183430_8_T1	COMPOUND	2	2	paroxetine
NCT001834309	NCT00183430_9_T0	PHENOTYPE	9	9	PTSD
NCT001834309	NCT00183430_9_T1	GENE	4	4	has
NCT0018343010	NCT00183430_10_T0	PHENOTYPE	13	13	trauma
NCT0018343010	NCT00183430_10_T1	PHENOTYPE	14	14	nightmares
NCT0018343010	NCT00183430_10_T2	GENE	7	7	has
NCT0018343010	NCT00183430_10_T3	COMPOUND	6	6	prazosin
NCT0018343011	NCT00183430_11_T0	PHENOTYPE	16	16	trauma
NCT0018343011	NCT00183430_11_T1	COMPOUND	7	7	prazosin
NCT0018343011	NCT00183430_11_T2	PHENOTYPE	10	12	traumatic stress disorder
NCT0018343013	NCT00183430_13_T0	COMPOUND	11	11	prazosin
NCT0018343016	NCT00183430_16_T0	PHENOTYPE	1	1	symptoms
NCT0018343016	NCT00183430_16_T1	PHENOTYPE	3	3	severity
NCT0018343016	NCT00183430_16_T2	PHENOTYPE	0	0	PTSD
NCT0018343016	NCT00183430_16_T3	PHENOTYPE	7	8	sleep disturbances
NCT001834430	NCT00183443_0_T0	PHENOTYPE	2	2	Mania
NCT001834430	NCT00183443_0_T1	PHENOTYPE	3	3	Symptoms
NCT001834435	NCT00183443_5_T0	PHENOTYPE	8	8	schizophrenia
NCT001834435	NCT00183443_5_T1	PHENOTYPE	0	0	Symptoms
NCT001834435	NCT00183443_5_T2	PHENOTYPE	2	2	mania
NCT001834435	NCT00183443_5_T3	PHENOTYPE	10	11	bipolar disorder
NCT001834436	NCT00183443_6_T0	PHENOTYPE	13	13	paranoia
NCT001834436	NCT00183443_6_T1	PHENOTYPE	12	12	hallucinations
NCT001834436	NCT00183443_6_T2	PHENOTYPE	15	15	feelings
NCT001834436	NCT00183443_6_T3	PHENOTYPE	5	5	mania
NCT001834437	NCT00183443_7_T0	PHENOTYPE	1	1	symptoms
NCT001834437	NCT00183443_7_T1	PHENOTYPE	6	6	mania
NCT001834439	NCT00183443_9_T0	PHENOTYPE	12	12	symptoms
NCT001834439	NCT00183443_9_T1	PHENOTYPE	18	18	schizophrenia
NCT001834439	NCT00183443_9_T2	PHENOTYPE	14	14	mania
NCT0018344310	NCT00183443_10_T0	PHENOTYPE	6	6	acute
NCT0018344311	NCT00183443_11_T0	PHENOTYPE	2	2	acute
NCT0018344311	NCT00183443_11_T1	GENE	16	16	extended
NCT0018344313	NCT00183443_13_T0	COMPOUND	19	19	lithium
NCT0018344313	NCT00183443_13_T1	PHENOTYPE	2	2	acute
NCT0018344313	NCT00183443_13_T2	COMPOUND	22	22	quetiapine
NCT0018344315	NCT00183443_15_T0	PHENOTYPE	13	13	acute
NCT0018344316	NCT00183443_16_T0	PHENOTYPE	2	2	acute
NCT0018344317	NCT00183443_17_T0	PHENOTYPE	2	2	symptoms
NCT0018344317	NCT00183443_17_T1	PHENOTYPE	29	29	acute
NCT0018344317	NCT00183443_17_T2	PHENOTYPE	4	4	mania
NCT0018344319	NCT00183443_19_T0	PHENOTYPE	14	14	symptoms
NCT0018344319	NCT00183443_19_T1	PHENOTYPE	13	13	mania
NCT0018344320	NCT00183443_20_T0	PHENOTYPE	20	20	acute
NCT0018344320	NCT00183443_20_T1	PHENOTYPE	0	0	Mania
NCT0018344320	NCT00183443_20_T2	PHENOTYPE	2	4	quality of life
NCT001834696	NCT00183469_6_T0	PHENOTYPE	12	12	symptoms
NCT001834696	NCT00183469_6_T1	PHENOTYPE	11	11	mania
NCT001834696	NCT00183469_6_T2	PHENOTYPE	0	2	Bipolar disorder depression
NCT001834698	NCT00183469_8_T0	GENE	7	7	has
NCT001834698	NCT00183469_8_T1	PHENOTYPE	5	6	bipolar depression
NCT001834699	NCT00183469_9_T0	COMPOUND	5	5	lamotrigine
NCT001834699	NCT00183469_9_T1	COMPOUND	18	18	lamotrigine
NCT001834699	NCT00183469_9_T2	PHENOTYPE	15	16	depressive symptoms
NCT0018346910	NCT00183469_10_T0	PHENOTYPE	24	24	symptoms
NCT0018346910	NCT00183469_10_T1	COMPOUND	7	7	lamotrigine
NCT0018346910	NCT00183469_10_T2	PHENOTYPE	26	27	bipolar depression
NCT0018346911	NCT00183469_11_T0	COMPOUND	11	11	lamotrigine
NCT0018346911	NCT00183469_11_T1	COMPOUND	15	15	lamotrigine
NCT0018346912	NCT00183469_12_T0	PHENOTYPE	9	9	unspecified
NCT0018346913	NCT00183469_13_T0	PHENOTYPE	15	16	depressive symptoms
NCT0018348211	NCT00183482_11_T0	PHENOTYPE	13	14	depressive symptoms
NCT001834952	NCT00183495_2_T0	PHENOTYPE	16	16	irritability
NCT001834952	NCT00183495_2_T1	PHENOTYPE	3	3	BPD
NCT001834952	NCT00183495_2_T2	PHENOTYPE	9	9	mania
NCT001834952	NCT00183495_2_T3	PHENOTYPE	21	22	euphoric mood
NCT001834953	NCT00183495_3_T0	PHENOTYPE	17	17	hopelessness
NCT001834953	NCT00183495_3_T1	PHENOTYPE	1	1	manic
NCT001834953	NCT00183495_3_T2	PHENOTYPE	15	15	feelings
NCT001834953	NCT00183495_3_T3	PHENOTYPE	13	14	decreased energy
NCT001834954	NCT00183495_4_T0	PHENOTYPE	0	0	BPD
NCT001834954	NCT00183495_4_T1	PHENOTYPE	6	7	mental illness
NCT001834955	NCT00183495_5_T0	PHENOTYPE	1	1	BPD
NCT001834956	NCT00183495_6_T0	GENE	1	1	has
NCT001834956	NCT00183495_6_T1	GENE	9	9	has
NCT001834957	NCT00183495_7_T0	PHENOTYPE	13	13	BPD
NCT001834958	NCT00183495_8_T0	PHENOTYPE	13	13	attitudes
NCT0018349511	NCT00183495_11_T0	PHENOTYPE	11	11	severity
NCT0018349511	NCT00183495_11_T1	PHENOTYPE	5	5	attitudes
NCT0018349511	NCT00183495_11_T2	PHENOTYPE	20	20	addiction
NCT0018349511	NCT00183495_11_T3	PHENOTYPE	13	13	symptoms
NCT0018349511	NCT00183495_11_T4	PHENOTYPE	7	7	BPD
NCT0018349511	NCT00183495_11_T5	PHENOTYPE	15	15	mania
NCT0018349511	NCT00183495_11_T6	PHENOTYPE	9	10	psychiatric illness
NCT001835080	NCT00183508_0_T0	PHENOTYPE	3	5	Acute Stress Disorder
NCT001835214	NCT00183521_4_T0	PHENOTYPE	14	14	hyperventilation
NCT001835214	NCT00183521_4_T1	PHENOTYPE	10	10	suffocation
NCT001835214	NCT00183521_4_T2	PHENOTYPE	2	3	panic attacks
NCT001835216	NCT00183521_6_T0	PHENOTYPE	25	25	dizziness
NCT001835216	NCT00183521_6_T1	PHENOTYPE	11	11	hyperventilate
NCT001835216	NCT00183521_6_T2	PHENOTYPE	1	1	hyperventilation
NCT001835216	NCT00183521_6_T3	PHENOTYPE	31	31	hyperventilation
NCT001835216	NCT00183521_6_T4	PHENOTYPE	27	27	lightheadedness
NCT001835216	NCT00183521_6_T5	PHENOTYPE	15	16	panic attacks
NCT001835217	NCT00183521_7_T0	GENE	8	8	CO2
NCT001835217	NCT00183521_7_T1	GENE	16	16	CO2
NCT001835217	NCT00183521_7_T2	PHENOTYPE	10	11	panic attacks
NCT001835217	NCT00183521_7_T3	COMPOUND	6	7	carbon dioxide
NCT001835473	NCT00183547_3_T0	GENE	10	10	reduced
NCT001835473	NCT00183547_3_T1	BIOLOGICAL_PROCESS	5	6	giving birth
NCT001835473	NCT00183547_3_T2	PHENOTYPE	11	13	quality of life
NCT001835474	NCT00183547_4_T0	PHENOTYPE	3	4	mental health
NCT001835474	NCT00183547_4_T1	PHENOTYPE	14	15	depressive symptoms
NCT001835477	NCT00183547_7_T0	BIOLOGICAL_PROCESS	16	17	giving birth
NCT001835477	NCT00183547_7_T1	PHENOTYPE	1	2	depressive symptoms
NCT001835603	NCT00183560_3_T0	PHENOTYPE	12	12	reluctance
NCT001835604	NCT00183560_4_T0	PHENOTYPE	7	7	relapse
NCT001835608	NCT00183560_8_T0	PHENOTYPE	2	3	depression symptoms
NCT0018356012	NCT00183560_12_T0	GENE	2	3	Group 1
NCT0018356013	NCT00183560_13_T0	PHENOTYPE	12	12	relapse
NCT0018356016	NCT00183560_16_T0	PHENOTYPE	8	9	depressive symptoms
NCT001835733	NCT00183573_3_T0	PHENOTYPE	26	26	HIV
NCT001835735	NCT00183573_5_T0	PHENOTYPE	18	18	thoughts
NCT001835735	NCT00183573_5_T1	PHENOTYPE	19	19	feelings
NCT001835736	NCT00183573_6_T0	PHENOTYPE	20	20	DVD
NCT001835737	NCT00183573_7_T0	PHENOTYPE	17	17	attitudes
NCT001835860	NCT00183586_0_T0	PHENOTYPE	12	13	Anorexia Nervosa
NCT001835864	NCT00183586_4_T0	PHENOTYPE	12	12	focused
NCT001835864	NCT00183586_4_T1	PHENOTYPE	7	8	anorexia nervosa
NCT001835865	NCT00183586_5_T0	PHENOTYPE	10	11	anorexia nervosa
NCT001835866	NCT00183586_6_T0	GENE	17	17	IT
NCT001835866	NCT00183586_6_T1	GENE	7	7	FT
NCT001835866	NCT00183586_6_T2	PHENOTYPE	27	28	anorexia nervosa
NCT001835869	NCT00183586_9_T0	GENE	15	15	IT
NCT001835869	NCT00183586_9_T1	GENE	4	4	FT
NCT001835869	NCT00183586_9_T2	GENE	0	1	Group 1
NCT001835992	NCT00183599_2_T0	PHENOTYPE	25	25	irritability
NCT001835992	NCT00183599_2_T1	PHENOTYPE	8	8	addiction
NCT001835992	NCT00183599_2_T2	PHENOTYPE	23	23	restlessness
NCT001835992	NCT00183599_2_T3	PHENOTYPE	7	7	progressive
NCT001835992	NCT00183599_2_T4	PHENOTYPE	3	4	compulsive gambling
NCT001835996	NCT00183599_6_T0	GENE	0	1	Group 1
NCT0018359913	NCT00183599_13_T0	PHENOTYPE	8	9	psychiatric problems
NCT0018359913	NCT00183599_13_T1	PHENOTYPE	6	7	drug use
NCT001836123	NCT00183612_3_T0	PHENOTYPE	4	4	focused
NCT001836123	NCT00183612_3_T1	GENE	12	12	extended
NCT001836124	NCT00183612_4_T0	PHENOTYPE	8	8	pharmacodynamics
NCT001836124	NCT00183612_4_T1	PHENOTYPE	6	6	pharmacokinetics
NCT001836124	NCT00183612_4_T2	PHENOTYPE	14	15	mental health
NCT001836126	NCT00183612_6_T0	PHENOTYPE	17	17	disorders
NCT001836126	NCT00183612_6_T1	COMPOUND	9	9	olanzapine
NCT001836126	NCT00183612_6_T2	PHENOTYPE	15	16	mental health
NCT001836128	NCT00183612_8_T0	COMPOUND	4	4	olanzapine
NCT0018361210	NCT00183612_10_T0	COMPOUND	10	10	olanzapine
NCT0018361211	NCT00183612_11_T0	COMPOUND	12	12	olanzapine
NCT001836252	NCT00183625_2_T0	GENE	5	5	reduced
NCT001836252	NCT00183625_2_T1	PHENOTYPE	2	2	schizophrenia
NCT001836253	NCT00183625_3_T0	PHENOTYPE	18	18	schizophrenia
NCT001836254	NCT00183625_4_T0	COMPOUND	2	2	olanzapine
NCT001836254	NCT00183625_4_T1	COMPOUND	16	16	olanzapine
NCT001836254	NCT00183625_4_T2	COMPOUND	14	14	risperidone
NCT001836255	NCT00183625_5_T0	PHENOTYPE	4	4	schizophrenia
NCT001836256	NCT00183625_6_T0	PHENOTYPE	14	14	severity
NCT001836256	NCT00183625_6_T1	PHENOTYPE	17	17	schizophrenia
NCT001836257	NCT00183625_7_T0	PHENOTYPE	9	9	schizophrenia
NCT001836257	NCT00183625_7_T1	GENE	3	3	tapered
NCT001836258	NCT00183625_8_T0	COMPOUND	16	16	olanzapine
NCT001836258	NCT00183625_8_T1	COMPOUND	14	14	risperidone
NCT0018362511	NCT00183625_11_T0	COMPOUND	3	3	olanzapine
NCT0018362511	NCT00183625_11_T1	COMPOUND	1	1	risperidone
NCT0018362513	NCT00183625_13_T0	PHENOTYPE	14	14	symptoms
NCT0018362513	NCT00183625_13_T1	PHENOTYPE	13	13	schizophrenia
NCT001836384	NCT00183638_4_T0	PHENOTYPE	27	27	attitudes
NCT0018363813	NCT00183638_13_T0	PHENOTYPE	27	27	attitudes
NCT0018363814	NCT00183638_14_T0	PHENOTYPE	19	19	STDs
NCT0018363816	NCT00183638_16_T0	PHENOTYPE	5	5	attitudes
NCT001836513	NCT00183651_3_T0	GENE	5	5	has
NCT001836513	NCT00183651_3_T1	PHENOTYPE	14	16	borderline personality disorder
NCT001836514	NCT00183651_4_T0	PHENOTYPE	16	16	emotions
NCT001836514	NCT00183651_4_T1	PHENOTYPE	27	27	emotions
NCT001836515	NCT00183651_5_T0	GENE	7	7	DBT
NCT001836515	NCT00183651_5_T1	GENE	13	13	DBT
NCT001836516	NCT00183651_6_T0	GENE	8	8	DBT
NCT001836516	NCT00183651_6_T1	GENE	13	13	DBT
NCT001836516	NCT00183651_6_T2	GENE	18	18	DBT
NCT001836516	NCT00183651_6_T3	GENE	10	10	reduced
NCT0018365110	NCT00183651_10_T0	PHENOTYPE	7	7	thoughts
NCT001836774	NCT00183677_4_T0	PHENOTYPE	4	4	MDD
NCT001836774	NCT00183677_4_T1	PHENOTYPE	7	7	feelings
NCT001836776	NCT00183677_6_T0	PHENOTYPE	7	7	MDD
NCT001836777	NCT00183677_7_T0	GENE	2	2	has
NCT001836777	NCT00183677_7_T1	PHENOTYPE	15	15	MDD
NCT001836777	NCT00183677_7_T2	PHENOTYPE	9	10	energy metabolism
NCT001836778	NCT00183677_8_T0	PHENOTYPE	12	13	energy metabolism
NCT001836779	NCT00183677_9_T0	PHENOTYPE	9	9	MDD
NCT0018367710	NCT00183677_10_T0	PHENOTYPE	3	3	calming
NCT0018367711	NCT00183677_11_T0	COMPOUND	14	14	escitalopram
NCT0018367711	NCT00183677_11_T1	PHENOTYPE	18	18	MDD
NCT0018367711	NCT00183677_11_T2	PHENOTYPE	8	9	energy metabolism
NCT0018367712	NCT00183677_12_T0	PHENOTYPE	12	13	energy metabolism
NCT0018367713	NCT00183677_13_T0	PHENOTYPE	8	8	MDD
NCT0018367714	NCT00183677_14_T0	COMPOUND	13	13	escitalopram
NCT0018367714	NCT00183677_14_T1	PHENOTYPE	7	7	MDD
NCT0018367722	NCT00183677_22_T0	COMPOUND	5	5	escitalopram
NCT0018367722	NCT00183677_22_T1	COMPOUND	22	22	escitalopram
NCT001836900	NCT00183690_0_T0	PHENOTYPE	8	10	Post-Traumatic Stress Disorder
NCT001836904	NCT00183690_4_T0	PHENOTYPE	2	2	PTSD
NCT001836904	NCT00183690_4_T1	PHENOTYPE	6	6	thoughts
NCT001836904	NCT00183690_4_T2	PHENOTYPE	5	5	frightening
NCT001836904	NCT00183690_4_T3	GENE	16	16	numb
NCT001836906	NCT00183690_6_T0	PHENOTYPE	16	16	symptoms
NCT001836906	NCT00183690_6_T1	PHENOTYPE	18	18	PTSD
NCT001836906	NCT00183690_6_T2	GENE	2	2	PE
NCT001836906	NCT00183690_6_T3	GENE	11	11	has
NCT001836907	NCT00183690_7_T0	PHENOTYPE	11	11	PTSD
NCT001836908	NCT00183690_8_T0	PHENOTYPE	10	10	trauma
NCT001836908	NCT00183690_8_T1	PHENOTYPE	17	17	symptoms
NCT001836908	NCT00183690_8_T2	PHENOTYPE	19	19	PTSD
NCT001836908	NCT00183690_8_T3	GENE	7	7	PE
NCT001836909	NCT00183690_9_T0	PHENOTYPE	15	15	PTSD
NCT001836909	NCT00183690_9_T1	GENE	9	9	PE
NCT0018369010	NCT00183690_10_T0	GENE	12	12	PE
NCT0018369012	NCT00183690_12_T0	PHENOTYPE	3	3	symptoms
NCT0018369012	NCT00183690_12_T1	PHENOTYPE	2	2	PTSD
NCT001837032	NCT00183703_2_T0	PHENOTYPE	16	16	irritability
NCT001837032	NCT00183703_2_T1	PHENOTYPE	3	3	BPD
NCT001837032	NCT00183703_2_T2	PHENOTYPE	9	9	mania
NCT001837032	NCT00183703_2_T3	PHENOTYPE	21	22	euphoric mood
NCT001837033	NCT00183703_3_T0	PHENOTYPE	17	17	hopelessness
NCT001837033	NCT00183703_3_T1	PHENOTYPE	1	1	manic
NCT001837033	NCT00183703_3_T2	PHENOTYPE	15	15	feelings
NCT001837033	NCT00183703_3_T3	PHENOTYPE	13	14	decreased energy
NCT001837035	NCT00183703_5_T0	PHENOTYPE	5	5	manic
NCT001837036	NCT00183703_6_T0	PHENOTYPE	1	1	BPD
NCT001837037	NCT00183703_7_T0	GENE	1	1	has
NCT001837037	NCT00183703_7_T1	GENE	9	9	has
NCT001837039	NCT00183703_9_T0	PHENOTYPE	13	13	attitudes
NCT0018370311	NCT00183703_11_T0	PHENOTYPE	15	15	symptoms
NCT0018370311	NCT00183703_11_T1	PHENOTYPE	13	13	severity
NCT0018370311	NCT00183703_11_T2	PHENOTYPE	7	7	attitudes
NCT0018370311	NCT00183703_11_T3	PHENOTYPE	9	9	BPD
NCT0018370311	NCT00183703_11_T4	PHENOTYPE	17	17	mania
NCT0018370311	NCT00183703_11_T5	PHENOTYPE	11	12	psychiatric illness
NCT0018370311	NCT00183703_11_T6	PHENOTYPE	25	27	quality of life
NCT001837162	NCT00183716_2_T0	PHENOTYPE	2	2	PTSD
NCT001837162	NCT00183716_2_T1	PHENOTYPE	22	23	substance abuse
NCT001837162	NCT00183716_2_T2	PHENOTYPE	9	11	severe mental disorders
NCT001837163	NCT00183716_3_T0	PHENOTYPE	11	12	mental health
NCT001837165	NCT00183716_5_T0	PHENOTYPE	12	12	PTSD
NCT001837165	NCT00183716_5_T1	PHENOTYPE	0	0	Trauma
NCT001837165	NCT00183716_5_T2	PHENOTYPE	21	22	physical abuse
NCT001837165	NCT00183716_5_T3	PHENOTYPE	26	28	severe mental disorders
NCT001837166	NCT00183716_6_T0	PHENOTYPE	14	14	symptoms
NCT001837166	NCT00183716_6_T1	PHENOTYPE	13	13	PTSD
NCT001837166	NCT00183716_6_T2	PHENOTYPE	11	11	severity
NCT001837166	NCT00183716_6_T3	PHENOTYPE	25	26	physical abuse
NCT001837166	NCT00183716_6_T4	PHENOTYPE	18	19	mental disorders
NCT0018371611	NCT00183716_11_T0	PHENOTYPE	16	16	self-esteem
NCT0018371612	NCT00183716_12_T0	PHENOTYPE	3	3	trauma
NCT0018371612	NCT00183716_12_T1	PHENOTYPE	2	2	severity
NCT0018371612	NCT00183716_12_T2	PHENOTYPE	0	0	PTSD
NCT0018371612	NCT00183716_12_T3	PHENOTYPE	10	11	mental health
NCT0018371612	NCT00183716_12_T4	PHENOTYPE	5	6	depressive symptoms
NCT0018371612	NCT00183716_12_T5	PHENOTYPE	7	8	substance use
NCT001837295	NCT00183729_5_T0	PHENOTYPE	6	6	illnesses
NCT001837296	NCT00183729_6_T0	PHENOTYPE	12	13	depressive disorders
NCT0018372910	NCT00183729_10_T0	COMPOUND	10	10	memantine
NCT0018372910	NCT00183729_10_T1	PHENOTYPE	21	22	Alzheimer's disease
NCT0018372911	NCT00183729_11_T0	COMPOUND	1	1	memantine
NCT0018372913	NCT00183729_13_T0	PHENOTYPE	9	10	learned helplessness
NCT0018372913	NCT00183729_13_T1	PHENOTYPE	5	6	depressive symptoms
NCT0018372914	NCT00183729_14_T0	PHENOTYPE	2	4	medication side effects
NCT0018372914	NCT00183729_14_T1	PHENOTYPE	10	12	major depressive disorder
NCT001837423	NCT00183742_3_T0	PHENOTYPE	26	27	ovarian cancer
NCT001837423	NCT00183742_3_T1	PHENOTYPE	16	17	lung cancers
NCT001837552	NCT00183755_2_T0	PHENOTYPE	7	7	anhedonia
NCT001837552	NCT00183755_2_T1	PHENOTYPE	4	4	MDD
NCT001837552	NCT00183755_2_T2	PHENOTYPE	17	17	experiences
NCT001837553	NCT00183755_3_T0	PHENOTYPE	7	7	rewards
NCT001837554	NCT00183755_4_T0	PHENOTYPE	0	0	Anhedonia
NCT001837554	NCT00183755_4_T1	GENE	1	1	has
NCT001837555	NCT00183755_5_T0	PHENOTYPE	14	14	anhedonia
NCT001837555	NCT00183755_5_T1	PHENOTYPE	1	2	brain activity
NCT001837558	NCT00183755_8_T0	PHENOTYPE	19	19	reward
NCT001837558	NCT00183755_8_T1	GENE	8	8	ERP
NCT001837558	NCT00183755_8_T2	PHENOTYPE	24	24	MDD
NCT001837558	NCT00183755_8_T3	PHENOTYPE	28	28	MDD
NCT001837558	NCT00183755_8_T4	PHENOTYPE	13	14	brain activity
NCT0018375510	NCT00183755_10_T0	PHENOTYPE	27	27	MDD
NCT0018375510	NCT00183755_10_T1	PHENOTYPE	12	12	SCID
NCT0018375512	NCT00183755_12_T0	PHENOTYPE	15	15	reward
NCT0018375512	NCT00183755_12_T1	PHENOTYPE	22	22	reward
NCT0018375512	NCT00183755_12_T2	PHENOTYPE	14	14	reinforcement
NCT0018375514	NCT00183755_14_T0	GENE	5	5	ERP
NCT001837682	NCT00183768_2_T0	PHENOTYPE	13	13	HIV
NCT001837682	NCT00183768_2_T1	PHENOTYPE	3	4	drug abuse
NCT001837683	NCT00183768_3_T0	PHENOTYPE	15	15	relapse
NCT001837683	NCT00183768_3_T1	GENE	1	1	has
NCT001837685	NCT00183768_5_T0	PHENOTYPE	11	11	HIV
NCT001837685	NCT00183768_5_T1	PHENOTYPE	16	16	relapse
NCT001837685	NCT00183768_5_T2	COMPOUND	19	19	cocaine
NCT0018376810	NCT00183768_10_T0	PHENOTYPE	23	24	drug use
NCT0018376811	NCT00183768_11_T0	PHENOTYPE	10	10	HIV
NCT001837814	NCT00183781_4_T0	PHENOTYPE	8	8	HIV
NCT001837814	NCT00183781_4_T1	PHENOTYPE	9	9	HIV
NCT001837815	NCT00183781_5_T0	PHENOTYPE	3	3	helplessness
NCT001837816	NCT00183781_6_T0	COMPOUND	4	4	FITT
NCT001837816	NCT00183781_6_T1	PHENOTYPE	27	27	HIV
NCT001837817	NCT00183781_7_T0	PHENOTYPE	17	18	HIV infection
NCT001837818	NCT00183781_8_T0	COMPOUND	4	4	FITT
NCT001837818	NCT00183781_8_T1	PHENOTYPE	12	12	HIV
NCT001837818	NCT00183781_8_T2	PHENOTYPE	27	27	HIV
NCT001837819	NCT00183781_9_T0	COMPOUND	11	11	FITT
NCT001837819	NCT00183781_9_T1	PHENOTYPE	23	23	HIV
NCT0018378110	NCT00183781_10_T0	PHENOTYPE	7	7	HIV
NCT0018378111	NCT00183781_11_T0	COMPOUND	9	9	FITT
NCT0018378111	NCT00183781_11_T1	COMPOUND	21	21	FITT
NCT0018378112	NCT00183781_12_T0	COMPOUND	6	6	FITT
NCT0018378113	NCT00183781_13_T0	PHENOTYPE	0	0	HIV
NCT0018378114	NCT00183781_14_T0	PHENOTYPE	4	4	self-assessments
NCT0018378115	NCT00183781_15_T0	COMPOUND	4	4	FITT
NCT001837941	NCT00183794_1_T0	COMPOUND	12	12	docetaxel
NCT001837941	NCT00183794_1_T1	COMPOUND	14	14	gemcitabine
NCT001837941	NCT00183794_1_T2	PHENOTYPE	27	28	ovarian cancer
NCT001837942	NCT00183794_2_T0	COMPOUND	18	18	gemcitabine
NCT001837942	NCT00183794_2_T1	PHENOTYPE	16	17	lung cancer
NCT001837942	NCT00183794_2_T2	PHENOTYPE	30	31	lung cancer
NCT001837943	NCT00183794_3_T0	COMPOUND	1	1	docetaxel
NCT001837943	NCT00183794_3_T1	COMPOUND	3	3	gemcitabine
NCT001837943	NCT00183794_3_T2	PHENOTYPE	10	11	ovarian cancer
NCT001837944	NCT00183794_4_T0	PHENOTYPE	12	12	tumors
NCT001837944	NCT00183794_4_T1	PHENOTYPE	10	11	ovarian cancer
NCT001837947	NCT00183794_7_T0	PHENOTYPE	10	10	secondary
NCT001837947	NCT00183794_7_T1	PHENOTYPE	29	29	Secondary
NCT001837947	NCT00183794_7_T2	COMPOUND	15	15	docetaxel
NCT001837947	NCT00183794_7_T3	PHENOTYPE	7	7	progression
NCT001837947	NCT00183794_7_T4	COMPOUND	17	17	gemcitabine
NCT001837947	NCT00183794_7_T5	PHENOTYPE	27	28	ovarian cancer
NCT001837948	NCT00183794_8_T0	PHENOTYPE	3	3	toxicity
NCT001837948	NCT00183794_8_T1	PHENOTYPE	12	13	ovarian cancer
NCT001837949	NCT00183794_9_T0	PHENOTYPE	3	3	toxicity
NCT001837949	NCT00183794_9_T1	COMPOUND	23	23	docetaxel
NCT001837949	NCT00183794_9_T2	COMPOUND	38	38	docetaxel
NCT001837949	NCT00183794_9_T3	COMPOUND	21	21	gemcitabine
NCT001837949	NCT00183794_9_T4	COMPOUND	27	27	gemcitabine
NCT001837949	NCT00183794_9_T5	GENE	28	28	IV
NCT001837949	NCT00183794_9_T6	GENE	39	39	IV
NCT0018379410	NCT00183794_10_T0	PHENOTYPE	8	8	toxicity
NCT001838071	NCT00183807_1_T0	COMPOUND	5	5	irinotecan
NCT001838071	NCT00183807_1_T1	COMPOUND	8	8	celecoxib
NCT001838071	NCT00183807_1_T2	COMPOUND	6	6	cisplatin
NCT001838074	NCT00183807_4_T0	PHENOTYPE	12	15	cancer of the esophagus
NCT001838078	NCT00183807_8_T0	PHENOTYPE	7	7	tumors
NCT001838078	NCT00183807_8_T1	COMPOUND	4	4	irinotecan
NCT001838078	NCT00183807_8_T2	COMPOUND	6	6	cisplatin
NCT001838078	NCT00183807_8_T3	ORGAN	10	10	esophagus
NCT0018380717	NCT00183807_17_T0	GENE	5	5	ASA
NCT001838201	NCT00183820_1_T0	COMPOUND	7	7	paclitaxel
NCT001838201	NCT00183820_1_T1	COMPOUND	6	6	oxaliplatin
NCT001838201	NCT00183820_1_T2	COMPOUND	9	9	gemcitabine
NCT001838202	NCT00183820_2_T0	GENE	16	16	has
NCT001838205	NCT00183820_5_T0	GENE	3	3	IV
NCT0018382011	NCT00183820_11_T0	GENE	3	3	PE
NCT0018382012	NCT00183820_12_T0	GENE	6	6	RT
NCT0018382013	NCT00183820_13_T0	GENE	11	11	tx
NCT0018382013	NCT00183820_13_T1	PHENOTYPE	18	19	adverse effects
NCT0018382016	NCT00183820_16_T0	GENE	6	6	1.5
NCT0018382016	NCT00183820_16_T1	GENE	0	0	AGC
NCT0018382016	NCT00183820_16_T2	CELL	7	7	platelets
NCT0018382018	NCT00183820_18_T0	GENE	0	0	LDH
NCT0018382020	NCT00183820_20_T0	ORGAN	0	0	Serum
NCT0018382023	NCT00183820_23_T0	GENE	1	1	tx
NCT001838330	NCT00183833_0_T0	PHENOTYPE	9	10	Solid Tumors
NCT001838332	NCT00183833_2_T0	COMPOUND	15	15	capecitabine
NCT001838332	NCT00183833_2_T1	COMPOUND	27	27	imatinib
NCT001838332	NCT00183833_2_T2	COMPOUND	28	28	mesylate
NCT001838335	NCT00183833_5_T0	PHENOTYPE	10	11	colon cancer
NCT001838337	NCT00183833_7_T0	PHENOTYPE	15	15	tumor
NCT001838337	NCT00183833_7_T1	ORGAN	18	19	digestive tract
NCT001838337	NCT00183833_7_T2	PHENOTYPE	10	12	Gastrointestinal Stromal Tumors
NCT001838339	NCT00183833_9_T0	PHENOTYPE	9	10	colorectal cancer
NCT001838461	NCT00183846_1_T0	COMPOUND	20	20	5_fluorouracil
NCT001838462	NCT00183846_2_T0	COMPOUND	20	20	irinotecan
NCT001838463	NCT00183846_3_T0	PHENOTYPE	6	6	tumors
NCT001838592	NCT00183859_2_T0	COMPOUND	9	9	irinotecan
NCT001838592	NCT00183859_2_T1	ORGAN	17	17	abdomen
NCT001838593	NCT00183859_3_T0	COMPOUND	10	10	irinotecan
NCT001838593	NCT00183859_3_T1	ORGAN	17	18	abdominal cavity
NCT001838595	NCT00183859_5_T0	PHENOTYPE	10	11	colon cancer
NCT001838596	NCT00183859_6_T0	ORGAN	23	23	abdomen
NCT001838599	NCT00183859_9_T0	PHENOTYPE	5	5	carcinomatosis
NCT001838599	NCT00183859_9_T1	PHENOTYPE	2	3	malignant ascites
NCT001838721	NCT00183872_1_T0	PHENOTYPE	12	12	tumors
NCT001838721	NCT00183872_1_T1	COMPOUND	21	21	irinotecan
NCT001838721	NCT00183872_1_T2	COMPOUND	27	27	docetaxel
NCT001838722	NCT00183872_2_T0	GENE	5	5	has
NCT001838723	NCT00183872_3_T0	ORGAN	12	12	rectum
NCT001838723	NCT00183872_3_T1	GENE	1	1	has
NCT001838723	NCT00183872_3_T2	PHENOTYPE	7	10	cancer of the colon
NCT001838726	NCT00183872_6_T0	COMPOUND	8	8	irinotecan
NCT001838726	NCT00183872_6_T1	COMPOUND	10	10	docetaxel
NCT001838726	NCT00183872_6_T2	GENE	3	3	has
NCT001838727	NCT00183872_7_T0	PHENOTYPE	11	11	tumors
NCT001838728	NCT00183872_8_T0	COMPOUND	7	7	irinotecan
NCT001838728	NCT00183872_8_T1	COMPOUND	9	9	docetaxel
NCT001838729	NCT00183872_9_T0	PHENOTYPE	12	12	tumors
NCT001838851	NCT00183885_1_T0	ORGAN	14	14	liver
NCT001838851	NCT00183885_1_T1	ORGAN	11	11	artery
NCT001838851	NCT00183885_1_T2	COMPOUND	8	8	cisplatin
NCT001838852	NCT00183885_2_T0	ORGAN	18	18	pancreas
NCT001838852	NCT00183885_2_T1	GENE	5	5	has
NCT001838852	NCT00183885_2_T2	PHENOTYPE	13	16	cancer of the stomach
NCT001838853	NCT00183885_3_T0	CELL	7	7	cells
NCT001838854	NCT00183885_4_T0	GENE	6	6	has
NCT001838855	NCT00183885_5_T0	ORGAN	9	9	ovaries
NCT001838855	NCT00183885_5_T1	ORGAN	12	12	bladder
NCT001838855	NCT00183885_5_T2	ORGAN	11	11	esophagus
NCT001838855	NCT00183885_5_T3	PHENOTYPE	5	8	cancer of the testes
NCT001838856	NCT00183885_6_T0	CELL	7	7	cells
NCT0018388510	NCT00183885_10_T0	PHENOTYPE	13	13	tumors
NCT0018388517	NCT00183885_17_T0	PHENOTYPE	4	4	ascites
NCT0018388517	NCT00183885_17_T1	PHENOTYPE	7	7	ascites
NCT001838981	NCT00183898_1_T0	COMPOUND	20	20	capecitabine
NCT001838981	NCT00183898_1_T1	PHENOTYPE	12	12	tumors
NCT001838981	NCT00183898_1_T2	COMPOUND	21	21	oxaliplatin
NCT001838982	NCT00183898_2_T0	GENE	8	8	has
NCT001838983	NCT00183898_3_T0	ORGAN	12	12	rectum
NCT001838983	NCT00183898_3_T1	GENE	1	1	has
NCT001838983	NCT00183898_3_T2	PHENOTYPE	7	10	cancer of the colon
NCT001838985	NCT00183898_5_T0	ORGAN	12	12	rectum
NCT001838985	NCT00183898_5_T1	PHENOTYPE	7	10	cancer of the colon
NCT001838986	NCT00183898_6_T0	ORGAN	18	18	rectum
NCT001838986	NCT00183898_6_T1	PHENOTYPE	13	16	cancer of the colon
NCT001838986	NCT00183898_6_T2	PHENOTYPE	22	26	cancer of the head and
NCT001838987	NCT00183898_7_T0	COMPOUND	1	1	oxaliplatin
NCT001838987	NCT00183898_7_T1	PHENOTYPE	10	11	gastroesophageal cancer
NCT001838989	NCT00183898_9_T0	COMPOUND	22	22	capecitabine
NCT001838989	NCT00183898_9_T1	PHENOTYPE	13	13	tumors
NCT001838989	NCT00183898_9_T2	COMPOUND	20	20	oxaliplatin
NCT0018389810	NCT00183898_10_T0	PHENOTYPE	7	7	tumors
NCT0018389813	NCT00183898_13_T0	PHENOTYPE	14	14	tumors
NCT0018389821	NCT00183898_21_T0	PHENOTYPE	0	0	Ascites
NCT0018389821	NCT00183898_21_T1	PHENOTYPE	4	5	bone metastases
NCT0018389821	NCT00183898_21_T2	PHENOTYPE	1	2	pleural effusion
NCT001839111	NCT00183911_1_T0	PHENOTYPE	18	19	gastric cancer
NCT001839114	NCT00183911_4_T0	TISSUE	18	18	tissues
NCT001839114	NCT00183911_4_T1	TISSUE	20	21	lymph nodes
NCT001839115	NCT00183911_5_T0	ORGAN	15	15	abdomen
NCT001839117	NCT00183911_7_T0	COMPOUND	12	12	5_fluorouracil
NCT001839117	NCT00183911_7_T1	ORGAN	22	22	abdomen
NCT001839117	NCT00183911_7_T2	COMPOUND	14	14	leucovorin
NCT001839240	NCT00183924_0_T0	PHENOTYPE	7	10	Hormone Refractory Prostate Cancer
NCT001839243	NCT00183924_3_T0	PHENOTYPE	10	10	symptoms
NCT001839243	NCT00183924_3_T1	PHENOTYPE	24	24	toxicity
NCT001839246	NCT00183924_6_T0	PHENOTYPE	0	0	Progression
NCT001839246	NCT00183924_6_T1	PHENOTYPE	2	3	measurable disease
NCT001839248	NCT00183924_8_T0	PHENOTYPE	0	0	Progression
NCT0018392416	NCT00183924_16_T0	COMPOUND	14	14	flutamide
NCT0018392416	NCT00183924_16_T1	COMPOUND	16	16	nilutamide
NCT0018392416	NCT00183924_16_T2	COMPOUND	33	33	bicalutamide
NCT0018392416	NCT00183924_16_T3	PHENOTYPE	39	40	disease progression
NCT0018392422	NCT00183924_22_T0	GENE	0	0	WBC
NCT0018392423	NCT00183924_23_T0	CELL	1	1	neutrophil
NCT0018392424	NCT00183924_24_T0	PHENOTYPE	0	1	Platelet count
NCT001839371	NCT00183937_1_T0	GENE	10	10	proteasome
NCT001839372	NCT00183937_2_T0	GENE	3	3	proteasome
NCT001839372	NCT00183937_2_T1	CELL	6	6	cells
NCT001839372	NCT00183937_2_T2	CELL	12	12	cells
NCT0018393713	NCT00183937_13_T0	COMPOUND	14	14	flutamide
NCT0018393713	NCT00183937_13_T1	COMPOUND	16	16	nilutamide
NCT0018393724	NCT00183937_24_T0	GENE	8	8	MRI
NCT0018393724	NCT00183937_24_T1	PHENOTYPE	12	13	metastatic disease
NCT0018393724	NCT00183937_24_T2	PHENOTYPE	2	3	neurological symptoms
NCT001839500	NCT00183950_0_T0	PHENOTYPE	8	10	Non Hodgkin's Lymphoma
NCT001839500	NCT00183950_0_T1	PHENOTYPE	12	15	Chronic Lymphocytic Leukemia Refractory
NCT001839502	NCT00183950_2_T0	PHENOTYPE	19	19	tumor
NCT001839630	NCT00183963_0_T0	PHENOTYPE	17	17	DCIS
NCT001839630	NCT00183963_0_T1	PHENOTYPE	14	16	Carcinoma in Situ
NCT001839630	NCT00183963_0_T2	PHENOTYPE	12	14	Breast Ductal Carcinoma
NCT001839636	NCT00183963_6_T0	GENE	3	3	has
NCT001839637	NCT00183963_7_T0	GENE	11	11	has
NCT001839891	NCT00183989_1_T0	COMPOUND	3	3	mitoxantrone
NCT001839892	NCT00183989_2_T0	PHENOTYPE	11	11	lymphoma
NCT001839893	NCT00183989_3_T0	PHENOTYPE	10	10	tumor
NCT001839893	NCT00183989_3_T1	PHENOTYPE	16	16	lymphoma
NCT001839893	NCT00183989_3_T2	GENE	9	9	has
NCT001840022	NCT00184002_2_T0	COMPOUND	9	9	doxorubicin
NCT001840022	NCT00184002_2_T1	GENE	10	10	has
NCT001840023	NCT00184002_3_T0	PHENOTYPE	22	22	tumors
NCT001840024	NCT00184002_4_T0	PHENOTYPE	16	16	tumors
NCT001840024	NCT00184002_4_T1	PHENOTYPE	13	13	tumor
NCT001840024	NCT00184002_4_T2	GENE	18	18	reduced
NCT001840024	NCT00184002_4_T3	COMPOUND	5	5	doxorubicin
NCT001840024	NCT00184002_4_T4	GENE	8	8	has
NCT001840025	NCT00184002_5_T0	PHENOTYPE	5	6	ovarian cancer
NCT001840026	NCT00184002_6_T0	PHENOTYPE	5	5	lymphoma
NCT001840027	NCT00184002_7_T0	PHENOTYPE	19	19	tumors
NCT001840027	NCT00184002_7_T1	GENE	22	22	reduced
NCT001840027	NCT00184002_7_T2	COMPOUND	4	4	doxorubicin
NCT001840028	NCT00184002_8_T0	PHENOTYPE	23	23	tumors
NCT001840028	NCT00184002_8_T1	COMPOUND	16	16	vincristine
NCT001840028	NCT00184002_8_T2	PHENOTYPE	28	28	lymphoma
NCT001840028	NCT00184002_8_T3	COMPOUND	15	15	cyclophosphamide
NCT001840028	NCT00184002_8_T4	COMPOUND	18	18	prednisone
NCT0018400211	NCT00184002_11_T0	GENE	7	7	2.0
NCT0018400211	NCT00184002_11_T1	GENE	1	1	1.4
NCT0018400212	NCT00184002_12_T0	GENE	5	5	1.5
NCT0018400212	NCT00184002_12_T1	GENE	3	3	po
NCT0018400217	NCT00184002_17_T0	GENE	7	7	2.0
NCT0018400217	NCT00184002_17_T1	GENE	1	1	1.4
NCT0018400218	NCT00184002_18_T0	GENE	5	5	1.5
NCT0018400218	NCT00184002_18_T1	GENE	3	3	po
NCT0018400220	NCT00184002_20_T0	GENE	8	8	CR
NCT001840154	NCT00184015_4_T0	COMPOUND	17	17	bortezomib
NCT001840155	NCT00184015_5_T0	COMPOUND	13	13	bortezomib
NCT001840156	NCT00184015_6_T0	GENE	9	9	proteasome
NCT001840157	NCT00184015_7_T0	GENE	3	3	proteasome
NCT001840157	NCT00184015_7_T1	CELL	6	6	cells
NCT001840157	NCT00184015_7_T2	CELL	12	12	cells
NCT001840157	NCT00184015_7_T3	PHENOTYPE	8	8	affects
NCT001840157	NCT00184015_7_T4	COMPOUND	7	7	bortezomib
NCT001840159	NCT00184015_9_T0	PHENOTYPE	0	0	Tumors
NCT001840159	NCT00184015_9_T1	ORGAN	2	3	blood vessels
NCT001840159	NCT00184015_9_T2	ORGAN	19	20	blood vessels
NCT0018401512	NCT00184015_12_T0	COMPOUND	9	9	bortezomib
NCT001840281	NCT00184028_1_T0	COMPOUND	11	11	oxaliplatin
NCT001840419	NCT00184041_9_T0	PHENOTYPE	15	16	allergic reactions
NCT0018404110	NCT00184041_10_T0	GENE	15	15	has
NCT0018404114	NCT00184041_14_T0	PHENOTYPE	18	19	allergic reaction
NCT0018404116	NCT00184041_16_T0	GENE	7	7	has
NCT0018404118	NCT00184041_18_T0	GENE	11	11	reduced
NCT0018404118	NCT00184041_18_T1	PHENOTYPE	8	9	allergic reactions
NCT001840541	NCT00184054_1_T0	GENE	1	1	has
NCT001840542	NCT00184054_2_T0	PHENOTYPE	28	28	illnesses
NCT001840542	NCT00184054_2_T1	GENE	20	20	has
NCT001840542	NCT00184054_2_T2	COMPOUND	1	1	arsenic
NCT001840542	NCT00184054_2_T3	COMPOUND	16	16	arsenic
NCT001840542	NCT00184054_2_T4	PHENOTYPE	31	32	sleeping sickness
NCT001840543	NCT00184054_3_T0	PHENOTYPE	26	26	leukemia
NCT001840543	NCT00184054_3_T1	PHENOTYPE	27	27	lymphoma
NCT001840543	NCT00184054_3_T2	COMPOUND	6	6	arsenic
NCT001840543	NCT00184054_3_T3	PHENOTYPE	29	29	myeloma
NCT001840543	NCT00184054_3_T4	PHENOTYPE	20	20	cancers
NCT001840543	NCT00184054_3_T5	COMPOUND	11	12	arsenic trioxide
NCT001840546	NCT00184054_6_T0	GENE	10	10	has
NCT001840548	NCT00184054_8_T0	PHENOTYPE	28	28	AML
NCT001840548	NCT00184054_8_T1	COMPOUND	17	18	ascorbic acid
NCT001840548	NCT00184054_8_T2	COMPOUND	13	14	arsenic trioxide
NCT001840549	NCT00184054_9_T0	CELL	11	11	cells
NCT0018405410	NCT00184054_10_T0	CELL	14	15	blood cells
NCT0018405410	NCT00184054_10_T1	ORGAN	5	6	bone marrow
NCT0018405411	NCT00184054_11_T0	ORGAN	4	4	marrow
NCT0018405411	NCT00184054_11_T1	CELL	5	5	cells
NCT001840671	NCT00184067_1_T0	PHENOTYPE	4	4	melanoma
NCT001840671	NCT00184067_1_T1	TISSUE	11	12	lymph nodes
NCT001840672	NCT00184067_2_T0	PHENOTYPE	3	3	melanoma
NCT001840672	NCT00184067_2_T1	GENE	4	4	has
NCT001840674	NCT00184067_4_T0	PHENOTYPE	9	9	melanoma
NCT001840674	NCT00184067_4_T1	GENE	22	22	booster
NCT001840676	NCT00184067_6_T0	PHENOTYPE	12	12	melanomas
NCT001840677	NCT00184067_7_T0	GENE	12	12	MART-1
NCT001840677	NCT00184067_7_T1	GENE	3	3	tyrosinase
NCT001840677	NCT00184067_7_T2	CELL	10	11	T cells
NCT001840677	NCT00184067_7_T3	GENE	6	7	melanoma antigen
NCT001840678	NCT00184067_8_T0	GENE	8	8	ISA
NCT001840679	NCT00184067_9_T0	ORGAN	4	5	immune system
NCT0018406710	NCT00184067_10_T0	GENE	14	14	GM-CSF
NCT0018406712	NCT00184067_12_T0	GENE	13	13	GM-CSF
NCT0018406713	NCT00184067_13_T0	PHENOTYPE	19	19	melanoma
NCT0018406713	NCT00184067_13_T1	PHENOTYPE	17	17	immunity
NCT0018406713	NCT00184067_13_T2	PHENOTYPE	25	25	immunity
NCT0018406713	NCT00184067_13_T3	GENE	12	12	booster
NCT0018406714	NCT00184067_14_T0	PHENOTYPE	14	14	melanoma
NCT0018406714	NCT00184067_14_T1	PHENOTYPE	19	19	melanoma
NCT0018406714	NCT00184067_14_T2	PHENOTYPE	12	12	immunity
NCT0018406714	NCT00184067_14_T3	GENE	8	8	GM-CSF
NCT0018406715	NCT00184067_15_T0	GENE	5	5	ISA
NCT0018406716	NCT00184067_16_T0	GENE	2	2	GM-CSF
NCT0018406716	NCT00184067_16_T1	CELL	11	13	white blood cells
NCT0018406717	NCT00184067_17_T0	PHENOTYPE	10	10	melanoma
NCT0018406720	NCT00184067_20_T0	BIOLOGICAL_PROCESS	9	10	immune response
NCT0018406722	NCT00184067_22_T0	PHENOTYPE	4	4	recurrence
NCT0018406722	NCT00184067_22_T1	PHENOTYPE	7	7	melanoma
NCT001840801	NCT00184080_1_T0	GENE	1	1	has
NCT001840804	NCT00184080_4_T0	PHENOTYPE	13	13	tumors
NCT001840804	NCT00184080_4_T1	GENE	2	2	PE
NCT001841061	NCT00184106_1_T0	COMPOUND	17	17	paroxetine
NCT001841061	NCT00184106_1_T1	COMPOUND	23	23	paroxetine
NCT001841061	NCT00184106_1_T2	GENE	27	27	TAU
NCT001841062	NCT00184106_2_T0	PHENOTYPE	10	10	acute
NCT001841065	NCT00184106_5_T0	PHENOTYPE	18	18	acute
NCT0018410612	NCT00184106_12_T0	GENE	9	9	APA
NCT0018410612	NCT00184106_12_T1	PHENOTYPE	5	5	generalized
NCT0018410612	NCT00184106_12_T2	PHENOTYPE	3	4	social phobia
NCT0018410614	NCT00184106_14_T0	PHENOTYPE	0	0	Symptoms
NCT0018410618	NCT00184106_18_T0	PHENOTYPE	2	2	diseases
NCT0018410622	NCT00184106_22_T0	PHENOTYPE	0	0	Psychosis
NCT0018410623	NCT00184106_23_T0	PHENOTYPE	2	2	symptoms
NCT0018410623	NCT00184106_23_T1	PHENOTYPE	0	0	Acute
NCT0018410624	NCT00184106_24_T0	PHENOTYPE	0	2	Major depressive disorder
NCT0018410625	NCT00184106_25_T0	PHENOTYPE	4	4	PTSD
NCT0018410625	NCT00184106_25_T1	PHENOTYPE	0	2	Generalized Anxiety Disorder
NCT0018410626	NCT00184106_26_T0	PHENOTYPE	5	6	personality disorder
NCT0018410627	NCT00184106_27_T0	PHENOTYPE	3	3	dependence
NCT0018410627	NCT00184106_27_T1	PHENOTYPE	0	1	Substance abuse
NCT001841192	NCT00184119_2_T0	GENE	3	3	separated
NCT001841194	NCT00184119_4_T0	PHENOTYPE	5	5	doors
NCT001841194	NCT00184119_4_T1	PHENOTYPE	15	15	acute
NCT001841194	NCT00184119_4_T2	PHENOTYPE	20	20	closed
NCT001841195	NCT00184119_5_T0	PHENOTYPE	5	5	doors
NCT001841195	NCT00184119_5_T1	PHENOTYPE	20	20	acute
NCT001841324	NCT00184132_4_T0	GENE	2	2	had
NCT001841450	NCT00184145_0_T0	PHENOTYPE	8	8	Phobia
NCT001841450	NCT00184145_0_T1	PHENOTYPE	5	6	Specific Phobia
NCT001841581	NCT00184158_1_T0	PHENOTYPE	6	7	nerve compression
NCT001841972	NCT00184197_2_T0	GENE	9	9	MRI
NCT001841975	NCT00184197_5_T0	PHENOTYPE	2	3	cervicogenic headache
NCT001841978	NCT00184197_8_T0	TISSUE	4	4	muscles
NCT001841978	NCT00184197_8_T1	GENE	1	1	toxin
NCT001841978	NCT00184197_8_T2	PHENOTYPE	20	20	spasticity
NCT001841978	NCT00184197_8_T3	PHENOTYPE	22	22	dystonias
NCT0018419710	NCT00184197_10_T0	PHENOTYPE	16	17	cervicogenic headache
NCT0018419713	NCT00184197_13_T0	GENE	9	9	toxin
NCT0018419713	NCT00184197_13_T1	PHENOTYPE	13	14	cervicogenic headaches
NCT0018419714	NCT00184197_14_T0	PHENOTYPE	14	15	cervicogenic headache
NCT0018419718	NCT00184197_18_T0	GENE	5	5	II
NCT001842103	NCT00184210_3_T0	PHENOTYPE	18	18	tumor
NCT001842103	NCT00184210_3_T1	PHENOTYPE	7	8	clinical findings
NCT001842103	NCT00184210_3_T2	TISSUE	14	15	lymph node
NCT001842232	NCT00184223_2_T0	PHENOTYPE	0	1	Substance use
NCT001842360	NCT00184236_0_T0	PHENOTYPE	4	4	Overweight
NCT0018423610	NCT00184236_10_T0	GENE	17	17	lines
NCT001842490	NCT00184249_0_T0	PHENOTYPE	10	11	Atrial Fibrillation
NCT001842493	NCT00184249_3_T0	GENE	0	0	AF
NCT001842493	NCT00184249_3_T1	PHENOTYPE	3	5	quality of life
NCT001842495	NCT00184249_5_T0	GENE	3	3	AF
NCT001842495	NCT00184249_5_T1	GENE	7	7	III
NCT001842497	NCT00184249_7_T0	GENE	15	15	lines
NCT001842499	NCT00184249_9_T0	GENE	29	29	lines
NCT001842499	NCT00184249_9_T1	PHENOTYPE	10	10	centres
NCT001842499	NCT00184249_9_T2	ORGAN	8	8	heart
NCT0018424913	NCT00184249_13_T0	ORGAN	10	11	left atrium
NCT0018424913	NCT00184249_13_T1	ORGAN	16	17	pulmonary veins
NCT0018424917	NCT00184249_17_T0	GENE	22	22	reduced
NCT0018424917	NCT00184249_17_T1	GENE	3	3	lines
NCT0018424919	NCT00184249_19_T0	GENE	15	15	lines
NCT0018424919	NCT00184249_19_T1	ORGAN	18	19	left atrium
NCT0018424920	NCT00184249_20_T0	GENE	27	27	AF
NCT0018424920	NCT00184249_20_T1	ORGAN	19	20	left atrium
NCT001842622	NCT00184262_2_T0	PHENOTYPE	7	7	OCD
NCT001842623	NCT00184262_3_T0	GENE	5	5	ERP
NCT001843010	NCT00184301_0_T0	GENE	15	15	ty
NCT001843010	NCT00184301_0_T1	PHENOTYPE	16	16	Disorder
NCT001843010	NCT00184301_0_T2	PHENOTYPE	10	11	Eating Disorder
NCT001843010	NCT00184301_0_T3	PHENOTYPE	13	14	Personality Disorder
NCT001843013	NCT00184301_3_T0	PHENOTYPE	11	12	eating disorder
NCT001843013	NCT00184301_3_T1	PHENOTYPE	14	15	personality disorder
NCT001843016	NCT00184301_6_T0	PHENOTYPE	4	4	symptoms
NCT001843016	NCT00184301_6_T1	BIOLOGICAL_PROCESS	2	3	eating behavior
NCT001843016	NCT00184301_6_T2	PHENOTYPE	0	1	Personality disorder
NCT001843140	NCT00184314_0_T0	GENE	8	8	Period
NCT001843140	NCT00184314_0_T1	GENE	10	10	Period
NCT001843140	NCT00184314_0_T2	PHENOTYPE	2	3	Eating Disorder
NCT001843143	NCT00184314_3_T0	PHENOTYPE	9	9	symptoms
NCT001843143	NCT00184314_3_T1	PHENOTYPE	7	8	eating disorder
NCT001843143	NCT00184314_3_T2	PHENOTYPE	10	11	social intelligence
NCT001843409	NCT00184340_9_T0	PHENOTYPE	6	6	experiences
NCT001843531	NCT00184353_1_T0	GENE	2	2	3T
NCT001843533	NCT00184353_3_T0	GENE	18	18	3T
NCT001843792	NCT00184379_2_T0	GENE	8	8	has
NCT001843929	NCT00184392_9_T0	PHENOTYPE	19	19	bleeding
NCT0018439213	NCT00184392_13_T0	GENE	17	17	5.7
NCT0018439215	NCT00184392_15_T0	PHENOTYPE	6	6	rhinosinusitis
NCT001844053	NCT00184405_3_T0	PHENOTYPE	11	11	bonding
NCT001844053	NCT00184405_3_T1	PHENOTYPE	13	13	attribution
NCT001844053	NCT00184405_3_T2	PHENOTYPE	8	9	depressive symptoms
NCT001844181	NCT00184418_1_T0	PHENOTYPE	20	20	acute
NCT001844181	NCT00184418_1_T1	ORGAN	12	13	immune system
NCT001844184	NCT00184418_4_T0	PHENOTYPE	6	6	acute
NCT001844184	NCT00184418_4_T1	PHENOTYPE	23	23	acute
NCT001844185	NCT00184418_5_T0	PHENOTYPE	16	16	diseases
NCT0018441810	NCT00184418_10_T0	ORGAN	23	24	immune system
NCT001844310	NCT00184431_0_T0	PHENOTYPE	11	11	Stroke
NCT001844310	NCT00184431_0_T1	GENE	10	10	cute
NCT001844310	NCT00184431_0_T2	PHENOTYPE	8	9	Acute Stroke
NCT001844575	NCT00184457_5_T0	COMPOUND	5	5	testosterone
NCT001844575	NCT00184457_5_T1	ORGAN	4	4	serum
NCT001844702	NCT00184470_2_T0	COMPOUND	7	7	1st
NCT001844705	NCT00184470_5_T0	PHENOTYPE	17	17	trauma
NCT001844830	NCT00184483_0_T0	PHENOTYPE	8	8	Hernia
NCT001844965	NCT00184496_5_T0	PHENOTYPE	9	9	understood
NCT001844966	NCT00184496_6_T0	COMPOUND	15	15	methadone
NCT001844966	NCT00184496_6_T1	COMPOUND	13	13	morphine
NCT001844967	NCT00184496_7_T0	COMPOUND	11	11	methadone
NCT001844967	NCT00184496_7_T1	COMPOUND	6	6	morphine
NCT001844967	NCT00184496_7_T2	COMPOUND	17	17	morphine
NCT001844969	NCT00184496_9_T0	COMPOUND	5	5	methadone
NCT001844969	NCT00184496_9_T1	PHENOTYPE	21	22	ventricular arrhythmia
NCT001845093	NCT00184509_3_T0	PHENOTYPE	5	6	schizophrenic disorders
NCT001845352	NCT00184535_2_T0	ORGAN	26	27	abdominal muscles
NCT001845481	NCT00184548_1_T0	PHENOTYPE	24	24	trauma
NCT001845481	NCT00184548_1_T1	GENE	13	13	VII
NCT001845481	NCT00184548_1_T2	PHENOTYPE	22	22	severely
NCT001845481	NCT00184548_1_T3	GENE	14	15	eptacog alfa
NCT001845486	NCT00184548_6_T0	GENE	38	38	has
NCT001845873	NCT00184587_3_T0	GENE	5	5	has
NCT001845876	NCT00184587_6_T0	PHENOTYPE	13	13	headache
NCT001845877	NCT00184587_7_T0	COMPOUND	14	14	candesartan
NCT0018458711	NCT00184587_11_T0	GENE	1	1	had
NCT0018458711	NCT00184587_11_T1	PHENOTYPE	5	6	cluster headache
NCT001846131	NCT00184613_1_T0	GENE	16	16	insulin
NCT001846131	NCT00184613_1_T1	GENE	27	27	insulin
NCT001846261	NCT00184626_1_T0	PHENOTYPE	1	1	Diabetes
NCT001847171	NCT00184717_1_T0	GENE	21	21	SGA
NCT001847171	NCT00184717_1_T1	PHENOTYPE	17	20	small for gestational age
NCT001847431	NCT00184743_1_T0	MOLECULAR_FUNCTION	20	21	Growth Hormone
NCT001847431	NCT00184743_1_T1	PHENOTYPE	25	27	Growth Hormone Deficiency
NCT001847561	NCT00184756_1_T0	GENE	3	3	SGA
NCT001847561	NCT00184756_1_T1	MOLECULAR_FUNCTION	0	1	Growth hormone
NCT001847690	NCT00184769_0_T0	PHENOTYPE	14	14	CRI
NCT001847690	NCT00184769_0_T1	PHENOTYPE	16	17	Growth Retardation
NCT001847690	NCT00184769_0_T2	PHENOTYPE	0	2	Growth Hormone Treatment
NCT001847690	NCT00184769_0_T3	PHENOTYPE	11	13	Chronic Renal Insufficiency
NCT001847694	NCT00184769_4_T0	GENE	24	24	GH
NCT001847823	NCT00184782_3_T0	PHENOTYPE	3	3	tumor
NCT001847823	NCT00184782_3_T1	BIOLOGICAL_PROCESS	4	4	metabolism
NCT001847824	NCT00184782_4_T0	PHENOTYPE	17	17	tumor
NCT001847824	NCT00184782_4_T1	PHENOTYPE	23	24	liver metastases
NCT001847950	NCT00184795_0_T0	PHENOTYPE	4	5	Menopausal Symptoms
NCT001847952	NCT00184795_2_T0	PHENOTYPE	6	7	hot flashes
NCT001847953	NCT00184795_3_T0	PHENOTYPE	14	14	severity
NCT001847953	NCT00184795_3_T1	PHENOTYPE	18	18	bleeding
NCT001847953	NCT00184795_3_T2	GENE	7	7	HRT
NCT001847953	NCT00184795_3_T3	GENE	8	8	hormone
NCT001847953	NCT00184795_3_T4	PHENOTYPE	16	17	menopausal symptoms
NCT001848211	NCT00184821_1_T0	GENE	1	1	A5
NCT001848211	NCT00184821_1_T1	GENE	0	0	Annexin
NCT001848211	NCT00184821_1_T2	PHENOTYPE	13	14	forearm injury
NCT001848216	NCT00184821_6_T0	ORGAN	18	18	forearm
NCT001848216	NCT00184821_6_T1	ORGAN	28	28	forearm
NCT001848216	NCT00184821_6_T2	PHENOTYPE	30	30	preconditioning
NCT001848216	NCT00184821_6_T3	PHENOTYPE	19	20	ischemia-reperfusion injury
NCT001848218	NCT00184821_8_T0	GENE	6	6	insulin
NCT001848218	NCT00184821_8_T1	GENE	17	17	5.7
NCT001848218	NCT00184821_8_T2	PHENOTYPE	14	15	glucose levels
NCT0018482110	NCT00184821_10_T0	GENE	3	3	A5
NCT0018482110	NCT00184821_10_T1	PHENOTYPE	1	1	reperfusion
NCT0018482111	NCT00184821_11_T0	ORGAN	8	8	forearm
NCT0018482111	NCT00184821_11_T1	GENE	2	3	annexin A5
NCT0018482112	NCT00184821_12_T0	PHENOTYPE	27	27	reperfusion
NCT0018482112	NCT00184821_12_T1	PHENOTYPE	21	21	ischemia
NCT001848342	NCT00184834_2_T0	ORGAN	26	26	liver
NCT001848342	NCT00184834_2_T1	GENE	35	35	broadened
NCT001848342	NCT00184834_2_T2	PHENOTYPE	41	42	liver disease
NCT001848342	NCT00184834_2_T3	PHENOTYPE	15	17	quality of life
NCT001848345	NCT00184834_5_T0	ORGAN	2	2	liver
NCT001848346	NCT00184834_6_T0	ORGAN	20	20	liver
NCT001848472	NCT00184847_2_T0	GENE	10	10	al
NCT001848472	NCT00184847_2_T1	GENE	9	9	et
NCT001848472	NCT00184847_2_T2	PHENOTYPE	23	23	preconditioning
NCT001848472	NCT00184847_2_T3	PHENOTYPE	2	3	ischemia-reperfusion injury
NCT001848472	NCT00184847_2_T4	PHENOTYPE	16	17	endothelial dysfunction
NCT001848473	NCT00184847_3_T0	ORGAN	12	12	forearm
NCT001848473	NCT00184847_3_T1	COMPOUND	4	4	acetylcholine
NCT001848473	NCT00184847_3_T2	PHENOTYPE	13	13	ischemia
NCT001848474	NCT00184847_4_T0	COMPOUND	11	11	acetylcholine
NCT001848474	NCT00184847_4_T1	PHENOTYPE	16	17	ischemia-reperfusion injury
NCT001848475	NCT00184847_5_T0	PHENOTYPE	17	17	ischemia
NCT001848476	NCT00184847_6_T0	ORGAN	15	15	forearm
NCT001848476	NCT00184847_6_T1	PHENOTYPE	16	16	ischemia
NCT001848476	NCT00184847_6_T2	PHENOTYPE	5	6	ischemia-reperfusion injury
NCT001848477	NCT00184847_7_T0	PHENOTYPE	19	19	acute
NCT001848477	NCT00184847_7_T1	PHENOTYPE	29	29	preconditioning
NCT001848477	NCT00184847_7_T2	COMPOUND	22	22	caffeine
NCT001848477	NCT00184847_7_T3	PHENOTYPE	21	21	chronic
NCT001848477	NCT00184847_7_T4	PHENOTYPE	7	8	ischemia-reperfusion injury
NCT001848477	NCT00184847_7_T5	TISSUE	11	12	vascular endothelium
NCT001848477	NCT00184847_7_T6	GENE	24	25	adenosine receptor
NCT001848478	NCT00184847_8_T0	COMPOUND	8	8	adenosine
NCT001848478	NCT00184847_8_T1	PHENOTYPE	11	11	preconditioning
NCT001848478	NCT00184847_8_T2	TISSUE	14	15	vascular endothelium
NCT001848479	NCT00184847_9_T0	PHENOTYPE	6	6	acute
NCT001848479	NCT00184847_9_T1	COMPOUND	7	7	caffeine
NCT001848479	NCT00184847_9_T2	COMPOUND	14	14	caffeine
NCT001848479	NCT00184847_9_T3	PHENOTYPE	13	13	chronic
NCT001848479	NCT00184847_9_T4	PHENOTYPE	10	11	ischemia-reperfusion injury
NCT0018484710	NCT00184847_10_T0	PHENOTYPE	11	11	preconditioning
NCT001848603	NCT00184860_3_T0	GENE	13	13	fusion
NCT001848603	NCT00184860_3_T1	GENE	9	9	rol
NCT001848738	NCT00184873_8_T0	ORGAN	18	18	Legs
NCT0018487310	NCT00184873_10_T0	PHENOTYPE	0	0	Recruitment
NCT0018487312	NCT00184873_12_T0	PHENOTYPE	0	2	Quality of life
NCT0018487318	NCT00184873_18_T0	ORGAN	14	14	Legs
NCT001848863	NCT00184886_3_T0	COMPOUND	12	12	methotrexate
NCT001848863	NCT00184886_3_T1	GENE	16	17	adenosine receptor
NCT001848864	NCT00184886_4_T0	COMPOUND	16	16	adenosine
NCT001848865	NCT00184886_5_T0	PHENOTYPE	4	5	inflammatory arthritis
NCT001848992	NCT00184899_2_T0	PHENOTYPE	4	4	Atherosclerosis
NCT001848992	NCT00184899_2_T1	GENE	3	3	al
NCT001848992	NCT00184899_2_T2	GENE	2	2	et
NCT001848995	NCT00184899_5_T0	COMPOUND	13	13	adenosine
NCT001849121	NCT00184912_1_T0	GENE	12	12	mediator
NCT001849121	NCT00184912_1_T1	GENE	6	7	adenosine receptor
NCT001849122	NCT00184912_2_T0	COMPOUND	1	1	caffeine
NCT001849122	NCT00184912_2_T1	COMPOUND	21	21	caffeine
NCT001849122	NCT00184912_2_T2	PHENOTYPE	10	10	concentrations
NCT001849122	NCT00184912_2_T3	GENE	5	6	adenosine receptor
NCT001849123	NCT00184912_3_T0	GENE	13	13	A5
NCT001849123	NCT00184912_3_T1	ORGAN	16	16	forearm
NCT001849123	NCT00184912_3_T2	TISSUE	17	18	skeletal muscle
NCT001849124	NCT00184912_4_T0	COMPOUND	8	8	caffeine
NCT001849250	NCT00184925_0_T0	PHENOTYPE	5	5	Complications
NCT001849250	NCT00184925_0_T1	PHENOTYPE	0	2	Ventilator Associated Pneumonia
NCT001849384	NCT00184938_4_T0	PHENOTYPE	13	13	preconditioning
NCT001849386	NCT00184938_6_T0	PHENOTYPE	11	11	preconditioning
NCT001849510	NCT00184951_0_T0	PHENOTYPE	7	7	HIV
NCT001849513	NCT00184951_3_T0	PHENOTYPE	9	9	pharmacokinetics
NCT001849513	NCT00184951_3_T1	GENE	25	25	pk
NCT001849513	NCT00184951_3_T2	COMPOUND	11	11	rosuvastatin
NCT001849513	NCT00184951_3_T3	COMPOUND	22	22	rosuvastatin
NCT001849642	NCT00184964_2_T0	GENE	2	2	has
NCT001849776	NCT00184977_6_T0	PHENOTYPE	15	15	acute
NCT001849776	NCT00184977_6_T1	COMPOUND	0	0	N-acetylcysteine
NCT001849776	NCT00184977_6_T2	PHENOTYPE	20	21	cystic fibrosis
NCT001849776	NCT00184977_6_T3	PHENOTYPE	17	18	chronic bronchitis
NCT001849900	NCT00184990_0_T0	GENE	3	3	iNOS
NCT001849900	NCT00184990_0_T1	PHENOTYPE	4	4	Inhibition
NCT001849902	NCT00184990_2_T0	COMPOUND	46	46	aminoguanidine
NCT001849902	NCT00184990_2_T1	PHENOTYPE	7	7	sepsis
NCT001849902	NCT00184990_2_T2	PHENOTYPE	5	5	dysfunction
NCT001849902	NCT00184990_2_T3	GENE	22	24	inducible NO synthase
NCT001849903	NCT00184990_3_T0	COMPOUND	4	4	norepinephrine
NCT001849903	NCT00184990_3_T1	PHENOTYPE	18	18	inflammation
NCT001849903	NCT00184990_3_T2	COMPOUND	5	5	acetylcholine
NCT001849903	NCT00184990_3_T3	COMPOUND	7	8	sodium nitroprusside
NCT001849905	NCT00184990_5_T0	GENE	17	17	iNOS
NCT001849905	NCT00184990_5_T1	COMPOUND	19	19	aminoguanidine
NCT001849905	NCT00184990_5_T2	PHENOTYPE	11	11	tolerance
NCT001850030	NCT00185003_0_T0	COMPOUND	3	3	Potassium
NCT001850032	NCT00185003_2_T0	COMPOUND	12	12	norepinephrine
NCT001850032	NCT00185003_2_T1	PHENOTYPE	9	9	inhibition
NCT001850162	NCT00185016_2_T0	PHENOTYPE	0	0	Secondary
NCT001850293	NCT00185029_3_T0	PHENOTYPE	14	14	metastases
NCT001850293	NCT00185029_3_T1	GENE	13	13	nodal
NCT001850295	NCT00185029_5_T0	PHENOTYPE	10	11	false negative
NCT0018502915	NCT00185029_15_T0	GENE	1	1	MRL
NCT0018502917	NCT00185029_17_T0	PHENOTYPE	18	20	quality of life
NCT0018502919	NCT00185029_19_T0	PHENOTYPE	43	43	metastases
NCT0018502919	NCT00185029_19_T1	GENE	16	16	MRL
NCT0018502919	NCT00185029_19_T2	PHENOTYPE	33	35	lymph node metastases
NCT0018502921	NCT00185029_21_T0	GENE	2	2	MRL
NCT0018502921	NCT00185029_21_T1	GENE	18	18	MRL
NCT0018502921	NCT00185029_21_T2	GENE	31	31	MRL
NCT0018502924	NCT00185029_24_T0	PHENOTYPE	16	16	strategies
NCT0018502927	NCT00185029_27_T0	PHENOTYPE	7	7	strategies
NCT0018502927	NCT00185029_27_T1	GENE	16	16	MRL
NCT0018502934	NCT00185029_34_T0	GENE	13	13	MRI
NCT0018502934	NCT00185029_34_T1	PHENOTYPE	30	30	allergy
NCT0018502934	NCT00185029_34_T2	PHENOTYPE	16	16	claustrophobia
NCT0018502934	NCT00185029_34_T3	PHENOTYPE	39	40	asthma attack
NCT0018502934	NCT00185029_34_T4	PHENOTYPE	36	37	anaphylactic shock
NCT0018502936	NCT00185029_36_T0	GENE	13	13	MRL
NCT0018502938	NCT00185029_38_T0	GENE	45	45	coil
NCT0018502938	NCT00185029_38_T1	GENE	39	39	1.0
NCT0018502938	NCT00185029_38_T2	GENE	37	37	1.5
NCT0018502938	NCT00185029_38_T3	GENE	19	19	et
NCT0018502938	NCT00185029_38_T4	TISSUE	4	5	lymph nodes
NCT0018502942	NCT00185029_42_T0	GENE	2	2	MRL
NCT0018502945	NCT00185029_45_T0	GENE	8	8	MRI
NCT0018502946	NCT00185029_46_T0	GENE	10	10	MRL
NCT0018502949	NCT00185029_49_T0	GENE	3	3	MRL
NCT0018502951	NCT00185029_51_T0	PHENOTYPE	1	1	metastases
NCT0018502953	NCT00185029_53_T0	GENE	3	3	MRL
NCT0018502954	NCT00185029_54_T0	PHENOTYPE	3	3	metastasis
NCT0018502956	NCT00185029_56_T0	TISSUE	15	16	lymph nodes
NCT0018502956	NCT00185029_56_T1	PHENOTYPE	23	24	both sides
NCT0018502959	NCT00185029_59_T0	TISSUE	9	10	lymph nodes
NCT0018502961	NCT00185029_61_T0	GENE	10	10	grid
NCT0018502965	NCT00185029_65_T0	PHENOTYPE	34	34	metastases
NCT0018502965	NCT00185029_65_T1	TISSUE	1	2	lymph node
NCT0018502968	NCT00185029_68_T0	PHENOTYPE	2	2	secondary
NCT0018502968	NCT00185029_68_T1	GENE	16	16	MRL
NCT0018502970	NCT00185029_70_T0	PHENOTYPE	28	28	strategies
NCT0018502970	NCT00185029_70_T1	PHENOTYPE	2	4	quality of life
NCT0018502973	NCT00185029_73_T0	GENE	14	14	MRL
NCT0018502974	NCT00185029_74_T0	GENE	18	18	MRL
NCT0018502976	NCT00185029_76_T0	GENE	7	7	MRL
NCT0018502979	NCT00185029_79_T0	GENE	28	28	MRL
NCT0018502983	NCT00185029_83_T0	GENE	14	14	kappa
NCT0018502984	NCT00185029_84_T0	GENE	14	14	MRL
NCT0018502985	NCT00185029_85_T0	GENE	7	7	SAS
NCT0018502988	NCT00185029_88_T0	PHENOTYPE	5	5	strategies
NCT0018502988	NCT00185029_88_T1	GENE	9	9	MRL
NCT0018502995	NCT00185029_95_T0	GENE	22	22	MRL
NCT0018502995	NCT00185029_95_T1	GENE	39	39	MRL
NCT0018502995	NCT00185029_95_T2	PHENOTYPE	18	19	false negative
NCT0018502995	NCT00185029_95_T3	PHENOTYPE	13	14	false positive
NCT0018502998	NCT00185029_98_T0	PHENOTYPE	31	31	strategies
NCT0018502998	NCT00185029_98_T1	GENE	32	32	MRL
NCT00185029103	NCT00185029_103_T0	PHENOTYPE	29	31	quality of life
NCT00185029104	NCT00185029_104_T0	GENE	9	9	MRL
NCT00185029105	NCT00185029_105_T0	PHENOTYPE	3	3	reflecting
NCT00185029109	NCT00185029_109_T0	GENE	26	26	MRL
NCT00185029109	NCT00185029_109_T1	PHENOTYPE	23	24	false negatives
NCT00185029109	NCT00185029_109_T2	PHENOTYPE	20	21	false positives
NCT00185029117	NCT00185029_117_T0	GENE	19	19	MRL
NCT00185029118	NCT00185029_118_T0	TISSUE	17	18	lymph node
NCT00185029119	NCT00185029_119_T0	PHENOTYPE	5	7	quality of life
NCT00185029122	NCT00185029_122_T0	GENE	14	14	bowel
NCT00185029122	NCT00185029_122_T1	PHENOTYPE	9	9	dysfunction
NCT00185029127	NCT00185029_127_T0	PHENOTYPE	33	35	lymph node metastases
NCT00185029127	NCT00185029_127_T1	PHENOTYPE	14	16	quality of life
NCT00185029130	NCT00185029_130_T0	GENE	6	6	1.3
NCT00185029130	NCT00185029_130_T1	PHENOTYPE	20	20	centers
NCT00185029131	NCT00185029_131_T0	GENE	8	8	29
NCT00185029132	NCT00185029_132_T0	PHENOTYPE	2	2	centres
NCT00185029139	NCT00185029_139_T0	GENE	9	9	MRL
NCT00185029139	NCT00185029_139_T1	GENE	13	13	PPV
NCT00185029140	NCT00185029_140_T0	GENE	6	6	MRL
NCT00185029146	NCT00185029_146_T0	GENE	49	49	MRL
NCT001850423	NCT00185042_3_T0	PHENOTYPE	3	5	coronary artery disease
NCT001850425	NCT00185042_5_T0	PHENOTYPE	2	4	coronary heart disease
NCT001850426	NCT00185042_6_T0	PHENOTYPE	9	9	plaque
NCT001850426	NCT00185042_6_T1	ORGAN	5	6	coronary artery
NCT001850428	NCT00185042_8_T0	GENE	9	9	had
NCT001850429	NCT00185042_9_T0	ORGAN	1	1	heart
NCT0018504214	NCT00185042_14_T0	PHENOTYPE	1	1	CVA
NCT0018504215	NCT00185042_15_T0	GENE	8	8	III
NCT0018504215	NCT00185042_15_T1	GENE	10	10	IV
NCT0018504215	NCT00185042_15_T2	PHENOTYPE	4	5	heart failure
NCT0018504217	NCT00185042_17_T0	PHENOTYPE	1	1	hypertension
NCT0018504221	NCT00185042_21_T0	PHENOTYPE	7	7	occlusion
NCT0018504221	NCT00185042_21_T1	ORGAN	12	13	coronary artery
NCT0018504222	NCT00185042_22_T0	GENE	17	17	bypass
NCT0018504222	NCT00185042_22_T1	GENE	24	24	PCI
NCT0018504222	NCT00185042_22_T2	GENE	9	9	has
NCT0018504222	NCT00185042_22_T3	ORGAN	15	16	coronary artery
NCT001850680	NCT00185068_0_T0	PHENOTYPE	21	21	Hypertension
NCT001850680	NCT00185068_0_T1	GENE	17	17	HCT
NCT001850684	NCT00185068_4_T0	PHENOTYPE	13	13	menopausal
NCT001850684	NCT00185068_4_T1	GENE	14	14	had
NCT001850684	NCT00185068_4_T2	ORGAN	5	5	serum
NCT001850686	NCT00185068_6_T0	PHENOTYPE	7	7	TIA
NCT001850686	NCT00185068_6_T1	PHENOTYPE	0	1	Hypertensive encephalopathy
NCT001850686	NCT00185068_6_T2	PHENOTYPE	4	6	transient ischemic attack
NCT0018506812	NCT00185068_12_T0	PHENOTYPE	7	7	phaeochromocytoma
NCT0018506812	NCT00185068_12_T1	PHENOTYPE	2	3	secondary hypertension
NCT0018506812	NCT00185068_12_T2	PHENOTYPE	5	6	renal disease
NCT0018506812	NCT00185068_12_T3	PHENOTYPE	9	10	Cushing's disease
NCT0018506816	NCT00185068_16_T0	PHENOTYPE	4	4	bradycardia
NCT0018506816	NCT00185068_16_T1	PHENOTYPE	11	13	cardiac valvular disease
NCT0018506816	NCT00185068_16_T2	PHENOTYPE	5	7	congestive heart failure
NCT0018506818	NCT00185068_18_T0	PHENOTYPE	18	19	Atrial Flutter
NCT0018506818	NCT00185068_18_T1	PHENOTYPE	15	16	Atrial fibrillation
NCT0018506818	NCT00185068_18_T2	PHENOTYPE	8	9	sinoatrial block
NCT0018506818	NCT00185068_18_T3	PHENOTYPE	2	3	heart block
NCT0018506818	NCT00185068_18_T4	PHENOTYPE	10	11	Wolff-Parkinson-White Syndrome
NCT0018506818	NCT00185068_18_T5	PHENOTYPE	12	14	Sick Sinus Syndrome
NCT001850813	NCT00185081_3_T0	PHENOTYPE	6	7	primary tumor
NCT001850816	NCT00185081_6_T0	PHENOTYPE	11	12	hematologic malignancies
NCT001850817	NCT00185081_7_T0	PHENOTYPE	5	6	solid tumors
NCT0018508111	NCT00185081_11_T0	PHENOTYPE	12	12	tumor
NCT001851330	NCT00185133_0_T0	PHENOTYPE	11	11	Mild
NCT001851330	NCT00185133_0_T1	PHENOTYPE	14	14	Hypertension
NCT001851592	NCT00185159_2_T0	GENE	3	3	HDL
NCT001851592	NCT00185159_2_T1	COMPOUND	8	8	3
NCT001851592	NCT00185159_2_T2	GENE	2	2	lipoprotein
NCT001851720	NCT00185172_0_T0	PHENOTYPE	2	3	Essential Hypertension
NCT001851851	NCT00185185_1_T0	PHENOTYPE	6	6	atherosclerosis
NCT001851851	NCT00185185_1_T1	COMPOUND	3	4	olmesartan medoxomil
NCT001851981	NCT00185198_1_T0	PHENOTYPE	10	11	other symptoms
NCT001851983	NCT00185198_3_T0	GENE	1	1	AG
NCT001851983	NCT00185198_3_T1	GENE	10	10	AG
NCT001851983	NCT00185198_3_T2	GENE	3	3	has
NCT001851984	NCT00185198_4_T0	GENE	3	3	AG
NCT001852113	NCT00185211_3_T0	GENE	1	1	AG
NCT001852113	NCT00185211_3_T1	GENE	3	3	has
NCT001852241	NCT00185224_1_T0	GENE	11	11	SH
NCT001852243	NCT00185224_3_T0	GENE	1	1	AG
NCT001852243	NCT00185224_3_T1	GENE	10	10	AG
NCT001852243	NCT00185224_3_T2	GENE	14	14	AG
NCT001852243	NCT00185224_3_T3	GENE	3	3	has
NCT001852373	NCT00185237_3_T0	GENE	1	1	AG
NCT001852373	NCT00185237_3_T1	GENE	10	10	AG
NCT001852373	NCT00185237_3_T2	GENE	14	14	AG
NCT001852373	NCT00185237_3_T3	GENE	3	3	has
NCT001852505	NCT00185250_5_T0	GENE	1	1	AG
NCT001852505	NCT00185250_5_T1	GENE	10	10	AG
NCT001852505	NCT00185250_5_T2	GENE	3	3	has
NCT001852506	NCT00185250_6_T0	GENE	3	3	AG
NCT001852761	NCT00185276_1_T0	GENE	9	9	MRI
NCT001852892	NCT00185289_2_T0	GENE	1	1	AG
NCT001852892	NCT00185289_2_T1	GENE	10	10	AG
NCT001852892	NCT00185289_2_T2	GENE	14	14	AG
NCT001852892	NCT00185289_2_T3	GENE	3	3	has
NCT001853021	NCT00185302_1_T0	GENE	1	1	AG
NCT001853021	NCT00185302_1_T1	GENE	10	10	AG
NCT001853021	NCT00185302_1_T2	GENE	14	14	AG
NCT001853021	NCT00185302_1_T3	GENE	3	3	has
NCT001853150	NCT00185315_0_T0	PHENOTYPE	9	10	Pulmonary Hypertension
NCT001853153	NCT00185315_3_T0	GENE	1	1	AG
NCT001853153	NCT00185315_3_T1	GENE	9	9	AG
NCT001853153	NCT00185315_3_T2	GENE	2	2	has
NCT001853154	NCT00185315_4_T0	GENE	3	3	AG
NCT001853282	NCT00185328_2_T0	GENE	1	1	AG
NCT001853282	NCT00185328_2_T1	GENE	10	10	AG
NCT001853282	NCT00185328_2_T2	GENE	3	3	has
NCT001853283	NCT00185328_3_T0	GENE	3	3	AG
NCT001853413	NCT00185341_3_T0	GENE	1	1	AG
NCT001853413	NCT00185341_3_T1	GENE	10	10	AG
NCT001853413	NCT00185341_3_T2	GENE	3	3	has
NCT001853414	NCT00185341_4_T0	GENE	3	3	AG
NCT001853542	NCT00185354_2_T0	GENE	1	1	AG
NCT001853542	NCT00185354_2_T1	GENE	10	10	AG
NCT001853542	NCT00185354_2_T2	GENE	14	14	AG
NCT001853542	NCT00185354_2_T3	GENE	3	3	has
NCT001853672	NCT00185367_2_T0	GENE	1	1	AG
NCT001853672	NCT00185367_2_T1	GENE	10	10	AG
NCT001853672	NCT00185367_2_T2	GENE	14	14	AG
NCT001853672	NCT00185367_2_T3	GENE	3	3	has
NCT001853803	NCT00185380_3_T0	GENE	10	10	hormone
NCT001853805	NCT00185380_5_T0	GENE	1	1	AG
NCT001853805	NCT00185380_5_T1	GENE	10	10	AG
NCT001853805	NCT00185380_5_T2	GENE	3	3	has
NCT001853806	NCT00185380_6_T0	GENE	3	3	AG
NCT001853808	NCT00185380_8_T0	PHENOTYPE	8	9	Adverse Event
NCT001853930	NCT00185393_0_T0	GENE	15	15	III
NCT001853930	NCT00185393_0_T1	GENE	17	17	IV
NCT001853930	NCT00185393_0_T2	PHENOTYPE	11	13	Non Hodgkin Lymphoma
NCT001853932	NCT00185393_2_T0	PHENOTYPE	21	21	lymphoma
NCT001853934	NCT00185393_4_T0	GENE	1	1	AG
NCT001853934	NCT00185393_4_T1	GENE	10	10	AG
NCT001853934	NCT00185393_4_T2	GENE	3	3	has
NCT001853935	NCT00185393_5_T0	GENE	3	3	AG
NCT001854191	NCT00185419_1_T0	GENE	1	1	AG
NCT001854191	NCT00185419_1_T1	GENE	10	10	AG
NCT001854191	NCT00185419_1_T2	GENE	3	3	has
NCT001854192	NCT00185419_2_T0	GENE	3	3	AG
NCT001854454	NCT00185445_4_T0	GENE	9	9	AG
NCT001854454	NCT00185445_4_T1	GENE	19	19	AG
NCT001854580	NCT00185458_0_T0	GENE	23	23	HRT
NCT001854580	NCT00185458_0_T1	GENE	25	25	HRT
NCT001854582	NCT00185458_2_T0	PHENOTYPE	13	14	vaginal bleeding
NCT001854584	NCT00185458_4_T0	COMPOUND	22	22	1
NCT001854584	NCT00185458_4_T1	GENE	28	28	1.4
NCT001854584	NCT00185458_4_T2	GENE	30	30	HRT
NCT001854584	NCT00185458_4_T3	PHENOTYPE	3	4	vaginal bleeding
NCT001854585	NCT00185458_5_T0	PHENOTYPE	5	6	vaginal bleeding
NCT001854586	NCT00185458_6_T0	COMPOUND	2	2	1
NCT001854586	NCT00185458_6_T1	GENE	12	12	had
NCT001854586	NCT00185458_6_T2	GENE	16	16	HRT
NCT001854587	NCT00185458_7_T0	GENE	9	9	HRT
NCT001854587	NCT00185458_7_T1	GENE	36	36	HRT
NCT001854589	NCT00185458_9_T0	GENE	1	1	AG
NCT001854589	NCT00185458_9_T1	GENE	9	9	AG
NCT001854589	NCT00185458_9_T2	GENE	3	3	has
NCT0018545810	NCT00185458_10_T0	GENE	2	2	AG
NCT001855100	NCT00185510_0_T0	PHENOTYPE	10	11	Atopic Dermatitis
NCT001855106	NCT00185510_6_T0	GENE	1	1	AG
NCT001855106	NCT00185510_6_T1	GENE	10	10	AG
NCT001855106	NCT00185510_6_T2	GENE	3	3	has
NCT0018552311	NCT00185523_11_T0	ORGAN	4	4	veins
NCT0018552312	NCT00185523_12_T0	PHENOTYPE	6	6	hepatitis
NCT0018552313	NCT00185523_13_T0	GENE	8	8	ag
NCT0018552313	NCT00185523_13_T1	PHENOTYPE	5	6	hepatitis B
NCT0018552313	NCT00185523_13_T2	PHENOTYPE	0	1	Positive serologies
NCT0018552314	NCT00185523_14_T0	ORGAN	4	4	marrow
NCT0018552314	NCT00185523_14_T1	ORGAN	5	5	transplant
NCT0018552318	NCT00185523_18_T0	GENE	5	5	G-CSF
NCT0018552318	NCT00185523_18_T1	PHENOTYPE	2	3	allergic reaction
NCT001855363	NCT00185536_3_T0	GENE	14	14	Start
NCT001855363	NCT00185536_3_T1	PHENOTYPE	30	30	perceived
NCT001855363	NCT00185536_3_T2	GENE	8	8	3.5
NCT0018554912	NCT00185549_12_T0	PHENOTYPE	18	19	cystic fibrosis
NCT0018554912	NCT00185549_12_T1	PHENOTYPE	20	22	Quality of life
NCT0018554913	NCT00185549_13_T0	PHENOTYPE	18	18	CCC
NCT0018554913	NCT00185549_13_T1	GENE	17	17	2.0
NCT001855753	NCT00185575_3_T0	GENE	1	1	has
NCT001855754	NCT00185575_4_T0	PHENOTYPE	7	7	dysthymia
NCT001855754	NCT00185575_4_T1	COMPOUND	3	3	duloxetine
NCT001855755	NCT00185575_5_T0	PHENOTYPE	0	0	Dysthymia
NCT001855755	NCT00185575_5_T1	PHENOTYPE	4	4	chronic
NCT001855756	NCT00185575_6_T0	PHENOTYPE	28	28	hopelessness
NCT001855756	NCT00185575_6_T1	PHENOTYPE	8	8	insomnia
NCT001855756	NCT00185575_6_T2	PHENOTYPE	1	1	symptoms
NCT001855756	NCT00185575_6_T3	PHENOTYPE	16	16	fatigue
NCT001855756	NCT00185575_6_T4	PHENOTYPE	7	7	overeating
NCT001855756	NCT00185575_6_T5	PHENOTYPE	24	24	decisions
NCT001855756	NCT00185575_6_T6	PHENOTYPE	18	18	self-esteem
NCT001855756	NCT00185575_6_T7	PHENOTYPE	26	26	feelings
NCT001855756	NCT00185575_6_T8	PHENOTYPE	4	5	poor appetite
NCT001855758	NCT00185575_8_T0	PHENOTYPE	8	8	dysthymia
NCT0018557510	NCT00185575_10_T0	COMPOUND	15	15	duloxetine
NCT0018557510	NCT00185575_10_T1	PHENOTYPE	10	11	major depression
NCT0018557511	NCT00185575_11_T0	PHENOTYPE	16	16	dysthymia
NCT0018557511	NCT00185575_11_T1	COMPOUND	9	9	duloxetine
NCT0018557512	NCT00185575_12_T0	PHENOTYPE	22	22	dysthymia
NCT0018557513	NCT00185575_13_T0	COMPOUND	6	6	duloxetine
NCT0018557516	NCT00185575_16_T0	ORGAN	4	4	heart
NCT0018557517	NCT00185575_17_T0	PHENOTYPE	10	10	symptoms
NCT0018557518	NCT00185575_18_T0	COMPOUND	7	7	duloxetine
NCT0018557520	NCT00185575_20_T0	PHENOTYPE	18	18	withdrawn
NCT0018557521	NCT00185575_21_T0	COMPOUND	27	27	duloxetine
NCT0018557522	NCT00185575_22_T0	PHENOTYPE	9	9	remission
NCT0018557523	NCT00185575_23_T0	PHENOTYPE	8	8	tolerance
NCT001856013	NCT00185601_3_T0	PHENOTYPE	0	0	Diabetes
NCT001856017	NCT00185601_7_T0	PHENOTYPE	10	10	symptoms
NCT001856142	NCT00185614_2_T0	CELL	17	17	cells
NCT001856142	NCT00185614_2_T1	COMPOUND	4	4	melphalan
NCT001856142	NCT00185614_2_T2	COMPOUND	12	12	melphalan
NCT001856142	NCT00185614_2_T3	PHENOTYPE	1	1	conditioning
NCT001856142	NCT00185614_2_T4	ORGAN	18	18	transplant
NCT001856142	NCT00185614_2_T5	ORGAN	0	0	Transplant
NCT001856143	NCT00185614_3_T0	COMPOUND	10	10	melphalan
NCT001856143	NCT00185614_3_T1	GENE	3	3	filgrastim
NCT001856144	NCT00185614_4_T0	GENE	17	17	HCT
NCT001856145	NCT00185614_5_T0	CELL	11	11	leukocyte
NCT001856148	NCT00185614_8_T0	COMPOUND	10	10	hydrocortisone
NCT001856148	NCT00185614_8_T1	GENE	13	13	IV
NCT001856148	NCT00185614_8_T2	GENE	18	18	IV
NCT001856148	NCT00185614_8_T3	COMPOUND	15	15	diphenhydramine
NCT001856400	NCT00185640_0_T0	PHENOTYPE	15	16	Hematologic Malignancies
NCT001856532	NCT00185653_2_T0	PHENOTYPE	1	1	toxicity
NCT001856532	NCT00185653_2_T1	PHENOTYPE	0	0	Response
NCT001856532	NCT00185653_2_T2	PHENOTYPE	4	5	graft-versus-host disease
NCT001856534	NCT00185653_4_T0	PHENOTYPE	6	7	relapsed disease
NCT001856535	NCT00185653_5_T0	PHENOTYPE	8	8	progression
NCT001856537	NCT00185653_7_T0	PHENOTYPE	29	29	Center
NCT001856537	NCT00185653_7_T1	PHENOTYPE	19	19	pathology
NCT0018565310	NCT00185653_10_T0	PHENOTYPE	4	4	HIV
NCT001856790	NCT00185679_0_T0	ORGAN	2	2	Transplant
NCT001856792	NCT00185679_2_T0	PHENOTYPE	5	5	acute
NCT001856923	NCT00185692_3_T0	CELL	11	11	thymocyte
NCT001856923	NCT00185692_3_T1	GENE	12	12	globulin
NCT001856924	NCT00185692_4_T0	PHENOTYPE	5	5	engraftment
NCT001856924	NCT00185692_4_T1	GENE	8	8	CD34
NCT001856924	NCT00185692_4_T2	CELL	10	13	peripheral blood stem cells
NCT001856925	NCT00185692_5_T0	ORGAN	5	5	transplant
NCT001856925	NCT00185692_5_T1	PHENOTYPE	28	28	GVHD
NCT001856928	NCT00185692_8_T0	PHENOTYPE	5	5	relapse
NCT001857052	NCT00185705_2_T0	PHENOTYPE	8	8	hypertension
NCT001857053	NCT00185705_3_T0	COMPOUND	6	6	telmisartan
NCT001857053	NCT00185705_3_T1	PHENOTYPE	17	18	insulin sensitivity
NCT001857053	NCT00185705_3_T2	PHENOTYPE	13	14	insulin levels
NCT001857055	NCT00185705_5_T0	COMPOUND	4	4	glucose
NCT001857055	NCT00185705_5_T1	PHENOTYPE	14	15	insulin sensitivity
NCT001857055	NCT00185705_5_T2	PHENOTYPE	6	7	insulin levels
NCT001857057	NCT00185705_7_T0	TISSUE	14	14	tissues
NCT001857057	NCT00185705_7_T1	ORGAN	21	21	liver
NCT001857057	NCT00185705_7_T2	TISSUE	7	8	subcutaneous tissue
NCT0018570511	NCT00185705_11_T0	GENE	13	13	HDL
NCT0018570511	NCT00185705_11_T1	PHENOTYPE	0	0	Secondary
NCT0018570511	NCT00185705_11_T2	COMPOUND	8	8	telmisartan
NCT0018570511	NCT00185705_11_T3	GENE	15	15	LDL
NCT0018570511	NCT00185705_11_T4	COMPOUND	20	20	BMI
NCT0018570511	NCT00185705_11_T5	TISSUE	22	23	body fat
NCT0018570512	NCT00185705_12_T0	COMPOUND	25	25	telmisartan
NCT0018570512	NCT00185705_12_T1	PHENOTYPE	19	19	hyperinsulinemia
NCT0018570512	NCT00185705_12_T2	PHENOTYPE	17	17	obesity
NCT0018570512	NCT00185705_12_T3	PHENOTYPE	12	13	insulin sensitivity
NCT0018570513	NCT00185705_13_T0	PHENOTYPE	6	7	insulin sensitivity
NCT0018570515	NCT00185705_15_T0	COMPOUND	15	15	glucose
NCT0018570515	NCT00185705_15_T1	GENE	6	6	insulin
NCT0018570515	NCT00185705_15_T2	GENE	16	16	insulin
NCT0018570515	NCT00185705_15_T3	GENE	18	18	C-peptide
NCT0018570515	NCT00185705_15_T4	PHENOTYPE	23	24	glucose tolerance
NCT0018570515	NCT00185705_15_T5	PHENOTYPE	9	10	insulin resistance
NCT0018570517	NCT00185705_17_T0	COMPOUND	6	6	glucose
NCT0018570517	NCT00185705_17_T1	GENE	10	10	insulin
NCT0018570518	NCT00185705_18_T0	COMPOUND	20	20	telmisartan
NCT0018570518	NCT00185705_18_T1	PHENOTYPE	14	14	hypertension
NCT0018570518	NCT00185705_18_T2	PHENOTYPE	12	12	obesity
NCT0018570521	NCT00185705_21_T0	PHENOTYPE	12	12	secondary
NCT0018570521	NCT00185705_21_T1	COMPOUND	16	16	telmisartan
NCT0018570523	NCT00185705_23_T0	COMPOUND	8	8	telmisartan
NCT0018570524	NCT00185705_24_T0	GENE	10	10	MRI
NCT0018570524	NCT00185705_24_T1	TISSUE	15	17	abdominal adipose tissue
NCT0018570525	NCT00185705_25_T0	GENE	2	2	MRI
NCT0018570527	NCT00185705_27_T0	COMPOUND	18	18	telmisartan
NCT0018570529	NCT00185705_29_T0	GENE	2	2	insulin
NCT0018570529	NCT00185705_29_T1	ORGAN	1	1	plasma
NCT0018570530	NCT00185705_30_T0	GENE	1	1	insulin
NCT0018570530	NCT00185705_30_T1	PHENOTYPE	8	9	insulin resistance
NCT001857311	NCT00185731_1_T0	PHENOTYPE	21	21	toxicity
NCT001857311	NCT00185731_1_T1	CELL	14	14	cells
NCT001857311	NCT00185731_1_T2	CELL	32	32	cells
NCT001857311	NCT00185731_1_T3	GENE	30	30	oncogene
NCT001857313	NCT00185731_3_T0	PHENOTYPE	15	15	lymphomas
NCT001857313	NCT00185731_3_T1	COMPOUND	6	6	atorvastatin
NCT001857314	NCT00185731_4_T0	PHENOTYPE	9	9	lymphomas
NCT001857315	NCT00185731_5_T0	PHENOTYPE	30	30	toxicity
NCT001857315	NCT00185731_5_T1	GENE	13	13	reductase
NCT001857315	NCT00185731_5_T2	GENE	12	12	HMG-CoA
NCT001857315	NCT00185731_5_T3	PHENOTYPE	27	27	lymphoma
NCT001857315	NCT00185731_5_T4	PHENOTYPE	7	7	hypercholesterolemia
NCT001857316	NCT00185731_6_T0	PHENOTYPE	13	13	toxic
NCT001857316	NCT00185731_6_T1	PHENOTYPE	4	5	Hodgkin lymphoma
NCT001857441	NCT00185744_1_T0	PHENOTYPE	24	24	recurrences
NCT001857441	NCT00185744_1_T1	PHENOTYPE	26	26	metastases
NCT001857441	NCT00185744_1_T2	PHENOTYPE	8	8	complications
NCT001857441	NCT00185744_1_T3	PHENOTYPE	21	22	cancer recurrence
NCT001857443	NCT00185744_3_T0	PHENOTYPE	5	6	ductal carcinoma
NCT001857443	NCT00185744_3_T1	PHENOTYPE	8	11	ductal carcinoma in situ
NCT001857444	NCT00185744_4_T0	PHENOTYPE	9	11	breast cancer 3
NCT0018574412	NCT00185744_12_T0	PHENOTYPE	9	9	scleroderma
NCT0018574412	NCT00185744_12_T1	PHENOTYPE	4	6	connective tissue disorder
NCT0018574413	NCT00185744_13_T0	PHENOTYPE	0	1	Breast cancer
NCT0018574413	NCT00185744_13_T1	ORGAN	6	7	chest wall
NCT0018574414	NCT00185744_14_T0	PHENOTYPE	0	0	Multifocal
NCT0018574414	NCT00185744_14_T1	PHENOTYPE	2	4	Multicentric breast cancer
NCT0018574416	NCT00185744_16_T0	PHENOTYPE	0	0	Diffuse
NCT0018574416	NCT00185744_16_T1	PHENOTYPE	1	1	microcalcifications
NCT0018574419	NCT00185744_19_T0	TISSUE	1	2	lymph nodes
NCT0018574420	NCT00185744_20_T0	TISSUE	6	7	lymph nodes
NCT001857573	NCT00185757_3_T0	CELL	3	3	lymphocytes
NCT001857573	NCT00185757_3_T1	PHENOTYPE	13	13	GVHD
NCT001857703	NCT00185770_3_T0	PHENOTYPE	1	1	obesity
NCT001857704	NCT00185770_4_T0	PHENOTYPE	13	13	obesity
NCT001857706	NCT00185770_6_T0	GENE	4	4	has
NCT001857706	NCT00185770_6_T1	PHENOTYPE	21	21	obesity
NCT001857708	NCT00185770_8_T0	PHENOTYPE	6	6	associations
NCT001857708	NCT00185770_8_T1	PHENOTYPE	11	12	childhood obesity
NCT0018577010	NCT00185770_10_T0	PHENOTYPE	31	32	childhood obesity
NCT0018577011	NCT00185770_11_T0	PHENOTYPE	50	50	adiposity
NCT0018577013	NCT00185770_13_T0	PHENOTYPE	38	38	demoralization
NCT0018577019	NCT00185770_19_T0	COMPOUND	32	32	BMI
NCT001857831	NCT00185783_1_T0	PHENOTYPE	5	6	severe sepsis
NCT001857832	NCT00185783_2_T0	PHENOTYPE	4	5	severe sepsis
NCT001857833	NCT00185783_3_T0	PHENOTYPE	0	0	Initiation
NCT001857834	NCT00185783_4_T0	PHENOTYPE	15	15	suffering
NCT001857834	NCT00185783_4_T1	GENE	2	2	has
NCT001857834	NCT00185783_4_T2	PHENOTYPE	18	19	adrenal insufficiency
NCT001857834	NCT00185783_4_T3	PHENOTYPE	12	13	severe sepsis
NCT001857835	NCT00185783_5_T0	COMPOUND	22	22	hydrocortisone
NCT001857839	NCT00185783_9_T0	CELL	7	7	leukocyte
NCT001857839	NCT00185783_9_T1	BIOLOGICAL_PROCESS	8	9	gene expression
NCT0018578311	NCT00185783_11_T0	PHENOTYPE	24	24	suffering
NCT0018578311	NCT00185783_11_T1	PHENOTYPE	26	27	severe sepsis
NCT0018578311	NCT00185783_11_T2	PHENOTYPE	30	31	adrenal insufficiency
NCT0018578311	NCT00185783_11_T3	BIOLOGICAL_PROCESS	10	11	gene expression
NCT0018578311	NCT00185783_11_T4	CELL	14	16	white blood cells
NCT0018578312	NCT00185783_12_T0	BIOLOGICAL_PROCESS	8	9	gene expression
NCT001857968	NCT00185796_8_T0	ORGAN	3	3	marrow
NCT001857968	NCT00185796_8_T1	ORGAN	9	9	marrow
NCT001857968	NCT00185796_8_T2	PHENOTYPE	16	16	conditioning
NCT0018579613	NCT00185796_13_T0	ORGAN	3	3	marrow
NCT0018579613	NCT00185796_13_T1	ORGAN	9	9	marrow
NCT0018579613	NCT00185796_13_T2	PHENOTYPE	15	15	initiation
NCT0018579615	NCT00185796_15_T0	PHENOTYPE	3	3	dysplastic
NCT0018579617	NCT00185796_17_T0	ORGAN	0	1	Bone marrow
NCT0018579619	NCT00185796_19_T0	COMPOUND	4	4	creatinine
NCT0018579619	NCT00185796_19_T1	GENE	8	8	hr
NCT0018579621	NCT00185796_21_T0	GENE	43	43	prothrombin
NCT0018579621	NCT00185796_21_T1	PHENOTYPE	37	37	dysfunction
NCT0018579621	NCT00185796_21_T2	PHENOTYPE	45	45	ascites
NCT0018579621	NCT00185796_21_T3	PHENOTYPE	13	13	cirrhosis
NCT0018579621	NCT00185796_21_T4	ORGAN	16	16	liver
NCT0018579621	NCT00185796_21_T5	PHENOTYPE	32	33	hepatic encephalopathy
NCT0018579621	NCT00185796_21_T6	PHENOTYPE	24	25	esophageal varices
NCT0018579621	NCT00185796_21_T7	PHENOTYPE	20	21	portal hypertension
NCT0018579621	NCT00185796_21_T8	PHENOTYPE	48	49	portal hypertension
NCT0018579621	NCT00185796_21_T9	PHENOTYPE	22	23	alcoholic hepatitis
NCT0018579621	NCT00185796_21_T10	PHENOTYPE	53	54	liver abscess
NCT0018579621	NCT00185796_21_T11	PHENOTYPE	10	12	fulminant liver failure
NCT0018579621	NCT00185796_21_T12	PHENOTYPE	29	31	bleeding esophageal varices
NCT001858355	NCT00185835_5_T0	PHENOTYPE	14	14	metastases
NCT001858355	NCT00185835_5_T1	ORGAN	6	6	liver
NCT001858611	NCT00185861_1_T0	GENE	27	27	II
NCT001858611	NCT00185861_1_T1	GENE	12	12	ATO
NCT001858611	NCT00185861_1_T2	PHENOTYPE	22	23	brain tumors
NCT001858613	NCT00185861_3_T0	PHENOTYPE	3	4	malignant glioma
NCT001858614	NCT00185861_4_T0	GENE	14	14	MRI
NCT001858614	NCT00185861_4_T1	PHENOTYPE	20	20	recurrence
NCT001858614	NCT00185861_4_T2	PHENOTYPE	17	17	tumor
NCT001858614	NCT00185861_4_T3	PHENOTYPE	8	9	malignant glioma
NCT001858614	NCT00185861_4_T4	PHENOTYPE	3	5	primary brain tumor
NCT0018586111	NCT00185861_11_T0	COMPOUND	21	22	arsenic trioxide
NCT001858745	NCT00185874_5_T0	ORGAN	8	8	liver
NCT001859391	NCT00185939_1_T0	PHENOTYPE	45	45	wounds
NCT001859393	NCT00185939_3_T0	PHENOTYPE	45	45	wounds
NCT001859520	NCT00185952_0_T0	PHENOTYPE	7	8	Preterm Labor
NCT001859652	NCT00185965_2_T0	GENE	16	16	Gy
NCT001859652	NCT00185965_2_T1	PHENOTYPE	7	8	single tumor
NCT001859653	NCT00185965_3_T0	PHENOTYPE	8	8	tumor
NCT001859656	NCT00185965_6_T0	PHENOTYPE	0	1	B-cell lymphoma
NCT001859781	NCT00185978_1_T0	COMPOUND	5	5	THE
NCT001859781	NCT00185978_1_T1	COMPOUND	7	7	THE
NCT001859788	NCT00185978_8_T0	PHENOTYPE	2	2	obesity
NCT001859788	NCT00185978_8_T1	PHENOTYPE	16	16	obesity
NCT001859788	NCT00185978_8_T2	PHENOTYPE	19	19	obesity
NCT001859788	NCT00185978_8_T3	PHENOTYPE	26	26	obesity
NCT001859788	NCT00185978_8_T4	PHENOTYPE	0	0	Onset
NCT0018597810	NCT00185978_10_T0	PHENOTYPE	24	24	secondary
NCT0018597810	NCT00185978_10_T1	PHENOTYPE	18	18	Obesity
NCT0018597810	NCT00185978_10_T2	PHENOTYPE	39	39	obesity
NCT0018597811	NCT00185978_11_T0	PHENOTYPE	11	11	secondary
NCT0018597813	NCT00185978_13_T0	COMPOUND	5	5	THE
NCT0018597813	NCT00185978_13_T1	COMPOUND	7	7	THE
NCT0018597816	NCT00185978_16_T0	PHENOTYPE	22	22	demoralization
NCT001859912	NCT00185991_2_T0	GENE	7	7	1.5
NCT001859912	NCT00185991_2_T1	COMPOUND	2	2	gentamicin
NCT001859912	NCT00185991_2_T2	GENE	9	9	IV
NCT001860171	NCT00186017_1_T0	COMPOUND	7	7	olanzapine
NCT001860173	NCT00186017_3_T0	PHENOTYPE	8	8	severity
NCT001860173	NCT00186017_3_T1	COMPOUND	17	17	olanzapine
NCT001860174	NCT00186017_4_T0	COMPOUND	8	8	olanzapine
NCT001860175	NCT00186017_5_T0	COMPOUND	18	18	olanzapine
NCT001860175	NCT00186017_5_T1	GENE	11	11	BD
NCT001860178	NCT00186017_8_T0	GENE	4	4	BD
NCT001860178	NCT00186017_8_T1	PHENOTYPE	18	18	pathology
NCT001860178	NCT00186017_8_T2	GENE	11	11	has
NCT001860179	NCT00186017_9_T0	PHENOTYPE	20	20	symptoms
NCT001860179	NCT00186017_9_T1	GENE	3	3	has
NCT0018601712	NCT00186017_12_T0	COMPOUND	6	6	olanzapine
NCT0018601713	NCT00186017_13_T0	COMPOUND	7	7	olanzapine
NCT0018601715	NCT00186017_15_T0	PHENOTYPE	8	8	severity
NCT0018601715	NCT00186017_15_T1	COMPOUND	17	17	olanzapine
NCT0018601716	NCT00186017_16_T0	COMPOUND	8	8	olanzapine
NCT001860301	NCT00186030_1_T0	PHENOTYPE	8	8	trauma
NCT001860301	NCT00186030_1_T1	PHENOTYPE	25	25	trauma
NCT001860301	NCT00186030_1_T2	PHENOTYPE	32	32	avoidance
NCT001860301	NCT00186030_1_T3	PHENOTYPE	9	9	symptoms
NCT001860301	NCT00186030_1_T4	PHENOTYPE	26	26	symptoms
NCT001860301	NCT00186030_1_T5	PHENOTYPE	18	18	HIV
NCT001860301	NCT00186030_1_T6	PHENOTYPE	30	30	dissociation
NCT001860303	NCT00186030_3_T0	PHENOTYPE	4	4	trauma
NCT001860303	NCT00186030_3_T1	PHENOTYPE	8	8	HIV
NCT001860303	NCT00186030_3_T2	PHENOTYPE	15	15	HIV
NCT001860303	NCT00186030_3_T3	PHENOTYPE	5	6	stress symptoms
NCT001860305	NCT00186030_5_T0	PHENOTYPE	6	7	psychological distress
NCT001860306	NCT00186030_6_T0	PHENOTYPE	13	13	trauma
NCT001860306	NCT00186030_6_T1	PHENOTYPE	16	16	self-efficacy
NCT001860306	NCT00186030_6_T2	GENE	9	9	mediator
NCT001860306	NCT00186030_6_T3	PHENOTYPE	14	15	stress symptoms
NCT001860309	NCT00186030_9_T0	PHENOTYPE	11	11	trauma
NCT001860309	NCT00186030_9_T1	PHENOTYPE	14	14	HIV
NCT0018603010	NCT00186030_10_T0	PHENOTYPE	16	16	HIV
NCT0018603010	NCT00186030_10_T1	PHENOTYPE	29	29	HIV
NCT0018603011	NCT00186030_11_T0	PHENOTYPE	12	12	experiences
NCT0018603011	NCT00186030_11_T1	PHENOTYPE	21	22	HIV infection
NCT0018603012	NCT00186030_12_T0	PHENOTYPE	12	12	trauma
NCT001860431	NCT00186043_1_T0	COMPOUND	12	12	quetiapine
NCT001860431	NCT00186043_1_T1	PHENOTYPE	22	24	Bipolar II disorder
NCT001860433	NCT00186043_3_T0	PHENOTYPE	14	14	symptoms
NCT001860435	NCT00186043_5_T0	PHENOTYPE	5	5	centers
NCT001860435	NCT00186043_5_T1	PHENOTYPE	24	25	depressive symptoms
NCT001860436	NCT00186043_6_T0	PHENOTYPE	24	25	depressive symptoms
NCT001860437	NCT00186043_7_T0	COMPOUND	24	24	lithium
NCT001860437	NCT00186043_7_T1	GENE	27	27	al
NCT001860437	NCT00186043_7_T2	GENE	26	26	et
NCT001860437	NCT00186043_7_T3	PHENOTYPE	12	12	mania
NCT001860437	NCT00186043_7_T4	PHENOTYPE	14	15	depressive symptoms
NCT001860438	NCT00186043_8_T0	GENE	26	26	2.3
NCT001860438	NCT00186043_8_T1	PHENOTYPE	17	18	depressive symptoms
NCT001860439	NCT00186043_9_T0	GENE	1	1	II
NCT001860439	NCT00186043_9_T1	PHENOTYPE	12	13	bipolar disorder
NCT0018604311	NCT00186043_11_T0	PHENOTYPE	5	6	bipolar disorder
NCT0018604312	NCT00186043_12_T0	GENE	14	14	atypical
NCT0018604314	NCT00186043_14_T0	GENE	25	25	II
NCT0018604317	NCT00186043_17_T0	GENE	10	10	II
NCT0018604318	NCT00186043_18_T0	PHENOTYPE	18	18	symptoms
NCT0018604318	NCT00186043_18_T1	PHENOTYPE	10	11	bipolar disorder
NCT0018604319	NCT00186043_19_T0	PHENOTYPE	14	14	symptoms
NCT0018604321	NCT00186043_21_T0	PHENOTYPE	10	10	symptoms
NCT0018604322	NCT00186043_22_T0	GENE	18	18	II
NCT0018604323	NCT00186043_23_T0	GENE	18	18	II
NCT0018604323	NCT00186043_23_T1	GENE	12	12	atypical
NCT0018604327	NCT00186043_27_T0	PHENOTYPE	17	18	hormone levels
NCT001860561	NCT00186056_1_T0	PHENOTYPE	0	1	Refractory depression
NCT001860561	NCT00186056_1_T1	PHENOTYPE	5	6	clinical depression
NCT001860564	NCT00186056_4_T0	PHENOTYPE	5	6	major depression
NCT001860566	NCT00186056_6_T0	GENE	20	20	insulin
NCT001860566	NCT00186056_6_T1	ORGAN	5	5	serum
NCT001860566	NCT00186056_6_T2	PHENOTYPE	21	22	glucose tolerance
NCT0018605610	NCT00186056_10_T0	PHENOTYPE	27	28	cortisol levels
NCT0018605611	NCT00186056_11_T0	COMPOUND	15	15	mifepristone
NCT0018605612	NCT00186056_12_T0	PHENOTYPE	20	21	adverse events
NCT0018605613	NCT00186056_13_T0	GENE	76	76	insulin
NCT0018605613	NCT00186056_13_T1	COMPOUND	15	15	mifepristone
NCT0018605613	NCT00186056_13_T2	ORGAN	61	61	serum
NCT0018605613	NCT00186056_13_T3	PHENOTYPE	50	51	adverse events
NCT0018605613	NCT00186056_13_T4	PHENOTYPE	97	98	cortisol levels
NCT0018605613	NCT00186056_13_T5	PHENOTYPE	77	78	glucose tolerance
NCT0018605615	NCT00186056_15_T0	PHENOTYPE	21	22	adverse events
NCT0018605616	NCT00186056_16_T0	PHENOTYPE	14	15	cortisol levels
NCT0018605617	NCT00186056_17_T0	PHENOTYPE	23	24	adverse events
NCT0018605618	NCT00186056_18_T0	ORGAN	5	5	serum
NCT0018605620	NCT00186056_20_T0	COMPOUND	30	30	glucose
NCT0018605620	NCT00186056_20_T1	COMPOUND	32	32	potassium
NCT0018605620	NCT00186056_20_T2	PHENOTYPE	8	9	adrenal insufficiency
NCT0018605622	NCT00186056_22_T0	PHENOTYPE	16	16	IUD
NCT0018605622	NCT00186056_22_T1	ORGAN	14	14	diaphragm
NCT001860820	NCT00186082_0_T0	PHENOTYPE	7	8	Perineal Tear
NCT001860950	NCT00186095_0_T0	PHENOTYPE	4	5	Primary Amyloidosis
NCT001861081	NCT00186108_1_T0	PHENOTYPE	0	0	Secondary
NCT001861081	NCT00186108_1_T1	PHENOTYPE	34	35	disease progression
NCT001861213	NCT00186121_3_T0	PHENOTYPE	9	9	toxicity
NCT001861213	NCT00186121_3_T1	PHENOTYPE	5	6	disease progression
NCT001861216	NCT00186121_6_T0	PHENOTYPE	2	2	bilateral
NCT001861216	NCT00186121_6_T1	GENE	8	8	FSH
NCT001861216	NCT00186121_6_T2	GENE	7	7	hormone
NCT001861472	NCT00186147_2_T0	ORGAN	1	2	bone marrow
NCT001861474	NCT00186147_4_T0	ORGAN	6	6	graft
NCT001861736	NCT00186173_6_T0	PHENOTYPE	32	32	self-esteem
NCT001861736	NCT00186173_6_T1	PHENOTYPE	15	15	overweight
NCT001861736	NCT00186173_6_T2	PHENOTYPE	25	26	weight gain
NCT001861737	NCT00186173_7_T0	PHENOTYPE	20	20	overweight
NCT001861737	NCT00186173_7_T1	PHENOTYPE	14	15	weight gain
NCT001861738	NCT00186173_8_T0	GENE	20	20	has
NCT0018617310	NCT00186173_10_T0	PHENOTYPE	32	32	liking
NCT0018617310	NCT00186173_10_T1	PHENOTYPE	17	17	overweight
NCT0018617311	NCT00186173_11_T0	PHENOTYPE	16	16	overweight
NCT001861862	NCT00186186_2_T0	PHENOTYPE	17	17	affects
NCT001861862	NCT00186186_2_T1	PHENOTYPE	13	13	mania
NCT001861862	NCT00186186_2_T2	PHENOTYPE	5	6	psychiatric disorder
NCT001861862	NCT00186186_2_T3	PHENOTYPE	0	1	Bipolar disorder
NCT001861863	NCT00186186_3_T0	PHENOTYPE	18	18	recurrences
NCT001861864	NCT00186186_4_T0	PHENOTYPE	1	1	disorders
NCT001861865	NCT00186186_5_T0	PHENOTYPE	5	6	mood disorders
NCT001861866	NCT00186186_6_T0	PHENOTYPE	6	6	acute
NCT001861866	NCT00186186_6_T1	PHENOTYPE	7	7	manic
NCT001861866	NCT00186186_6_T2	PHENOTYPE	2	2	outlook
NCT001861867	NCT00186186_7_T0	GENE	25	25	indefinite
NCT001861867	NCT00186186_7_T1	COMPOUND	3	3	lithium
NCT001861867	NCT00186186_7_T2	GENE	6	6	atypical
NCT001861867	NCT00186186_7_T3	PHENOTYPE	23	23	remission
NCT001861867	NCT00186186_7_T4	PHENOTYPE	19	19	chronic
NCT001861867	NCT00186186_7_T5	PHENOTYPE	11	11	outlook
NCT001861867	NCT00186186_7_T6	PHENOTYPE	13	14	bipolar disorder
NCT001861869	NCT00186186_9_T0	PHENOTYPE	10	10	chronic
NCT001861869	NCT00186186_9_T1	PHENOTYPE	2	2	experiences
NCT0018618610	NCT00186186_10_T0	GENE	3	3	has
NCT0018618610	NCT00186186_10_T1	PHENOTYPE	18	19	bipolar depression
NCT0018618610	NCT00186186_10_T2	PHENOTYPE	7	8	bipolar disorder
NCT0018618611	NCT00186186_11_T0	PHENOTYPE	16	17	bipolar disorder
NCT0018618612	NCT00186186_12_T0	COMPOUND	9	9	sodium
NCT0018618612	NCT00186186_12_T1	GENE	4	4	extended
NCT0018618614	NCT00186186_14_T0	GENE	15	15	GABA
NCT0018618614	NCT00186186_14_T1	PHENOTYPE	18	19	bipolar disorder
NCT0018618614	NCT00186186_14_T2	PHENOTYPE	12	13	metabolic rate
NCT001862640	NCT00186264_0_T0	PHENOTYPE	8	8	Response
NCT001862640	NCT00186264_0_T1	PHENOTYPE	10	10	Response
NCT001862640	NCT00186264_0_T2	GENE	9	9	nt
NCT001862646	NCT00186264_6_T0	COMPOUND	23	23	hydrocortisone
NCT001862648	NCT00186264_8_T0	COMPOUND	17	17	cortisol
NCT001862648	NCT00186264_8_T1	COMPOUND	3	3	hydrocortisone
NCT001862648	NCT00186264_8_T2	COMPOUND	18	18	hydrocortisone
NCT001863290	NCT00186329_0_T0	GENE	0	0	BNP
NCT001863290	NCT00186329_0_T1	PHENOTYPE	4	4	Syndrome
NCT001863293	NCT00186329_3_T0	COMPOUND	18	18	Natrecor
NCT001863293	NCT00186329_3_T1	PHENOTYPE	9	10	heart failure
NCT001863293	NCT00186329_3_T2	PHENOTYPE	12	13	kidney dysfunction
NCT001863295	NCT00186329_5_T0	GENE	22	22	has
NCT001863295	NCT00186329_5_T1	PHENOTYPE	9	10	heart failure
NCT001863296	NCT00186329_6_T0	PHENOTYPE	4	5	heart failure
NCT001863297	NCT00186329_7_T0	PHENOTYPE	9	9	hypertension
NCT001863298	NCT00186329_8_T0	PHENOTYPE	9	10	heart failure
NCT001863298	NCT00186329_8_T1	PHENOTYPE	0	1	Renal insufficiency
NCT0018632911	NCT00186329_11_T0	GENE	3	3	BNP
NCT0018632911	NCT00186329_11_T1	GENE	10	10	secreted
NCT0018632911	NCT00186329_11_T2	MOLECULAR_FUNCTION	8	9	peptide hormone
NCT0018632912	NCT00186329_12_T0	GENE	1	1	has
NCT0018632913	NCT00186329_13_T0	COMPOUND	0	0	Natrecor
NCT0018632913	NCT00186329_13_T1	GENE	9	9	BNP
NCT0018632913	NCT00186329_13_T2	PHENOTYPE	16	17	heart failure
NCT0018632915	NCT00186329_15_T0	COMPOUND	9	9	Natrecor
NCT0018632915	NCT00186329_15_T1	PHENOTYPE	7	7	dyspnea
NCT0018632916	NCT00186329_16_T0	COMPOUND	10	10	Natrecor
NCT0018632916	NCT00186329_16_T1	GENE	6	6	has
NCT0018632916	NCT00186329_16_T2	ORGAN	24	24	heart
NCT0018632916	NCT00186329_16_T3	PHENOTYPE	20	21	heart failure
NCT0018632917	NCT00186329_17_T0	COMPOUND	0	0	Natrecor
NCT0018632917	NCT00186329_17_T1	PHENOTYPE	8	9	heart failure
NCT0018632917	NCT00186329_17_T2	PHENOTYPE	12	13	renal insufficiency
NCT0018632919	NCT00186329_19_T0	COMPOUND	30	30	Natrecor
NCT0018632919	NCT00186329_19_T1	PHENOTYPE	20	21	heart failure
NCT0018632919	NCT00186329_19_T2	PHENOTYPE	24	25	renal insufficiency
NCT0018632920	NCT00186329_20_T0	COMPOUND	5	5	Natrecor
NCT0018632920	NCT00186329_20_T1	GENE	6	6	has
NCT0018632922	NCT00186329_22_T0	PHENOTYPE	7	7	CHF
NCT0018632922	NCT00186329_22_T1	COMPOUND	19	19	Natrecor
NCT0018632922	NCT00186329_22_T2	COMPOUND	23	23	dextrose
NCT0018632923	NCT00186329_23_T0	COMPOUND	3	3	Natrecor
NCT0018632923	NCT00186329_23_T1	GENE	8	8	IV
NCT0018632924	NCT00186329_24_T0	PHENOTYPE	28	28	hypotension
NCT0018632924	NCT00186329_24_T1	COMPOUND	15	15	Natrecor
NCT0018632924	NCT00186329_24_T2	PHENOTYPE	13	13	initiation
NCT0018632924	NCT00186329_24_T3	BIOLOGICAL_PROCESS	6	6	diuresis
NCT0018632925	NCT00186329_25_T0	COMPOUND	17	17	dextrose
NCT0018632927	NCT00186329_27_T0	PHENOTYPE	9	9	CHF
NCT0018632927	NCT00186329_27_T1	COMPOUND	15	15	creatinine
NCT0018632930	NCT00186329_30_T0	PHENOTYPE	6	6	Center
NCT0018632930	NCT00186329_30_T1	GENE	19	19	CA
NCT0018632931	NCT00186329_31_T0	PHENOTYPE	14	14	hypotension
NCT0018632932	NCT00186329_32_T0	COMPOUND	15	15	Natrecor
NCT0018632932	NCT00186329_32_T1	GENE	13	13	half-life
NCT0018632932	NCT00186329_32_T2	GENE	5	5	IV
NCT0018632933	NCT00186329_33_T0	COMPOUND	3	3	Natrecor
NCT0018632933	NCT00186329_33_T1	GENE	4	4	has
NCT001863420	NCT00186342_0_T0	PHENOTYPE	8	9	Hematologic Malignancies
NCT001863420	NCT00186342_0_T1	ORGAN	5	6	Cell Transplant
NCT001863426	NCT00186342_6_T0	PHENOTYPE	3	3	secondary
NCT001863426	NCT00186342_6_T1	PHENOTYPE	4	4	myelodysplasia
NCT001863552	NCT00186355_2_T0	CELL	17	17	cells
NCT001863552	NCT00186355_2_T1	CELL	29	29	cells
NCT001863552	NCT00186355_2_T2	PHENOTYPE	16	16	tumor
NCT001863552	NCT00186355_2_T3	PHENOTYPE	24	24	purging
NCT001864070	NCT00186407_0_T0	PHENOTYPE	5	6	Primary Amyloidosis
NCT001864070	NCT00186407_0_T1	CELL	1	2	Stem Cell
NCT001864074	NCT00186407_4_T0	PHENOTYPE	0	1	Primary amyloidosis
NCT001864077	NCT00186407_7_T0	PHENOTYPE	14	14	Center
NCT001864077	NCT00186407_7_T1	PHENOTYPE	4	4	pathology
NCT001864079	NCT00186407_9_T0	ORGAN	4	5	bone marrow
NCT0018640715	NCT00186407_15_T0	PHENOTYPE	3	3	HIV
NCT0018640721	NCT00186407_21_T0	PHENOTYPE	2	3	multiple myeloma
NCT001864330	NCT00186433_0_T0	ORGAN	4	4	Plasma
NCT001864330	NCT00186433_0_T1	PHENOTYPE	8	9	Nasopharyngeal Carcinoma
NCT001864334	NCT00186433_4_T0	PHENOTYPE	12	12	tumors
NCT001864334	NCT00186433_4_T1	ORGAN	3	3	plasma
NCT001864461	NCT00186446_1_T0	PHENOTYPE	10	10	acute
NCT001864461	NCT00186446_1_T1	PHENOTYPE	20	20	disorders
NCT001864461	NCT00186446_1_T2	PHENOTYPE	7	8	nicotine dependence
NCT001864461	NCT00186446_1_T3	PHENOTYPE	11	12	major depression
NCT001864463	NCT00186446_3_T0	PHENOTYPE	10	10	acute
NCT001864463	NCT00186446_3_T1	PHENOTYPE	20	20	disorders
NCT001864463	NCT00186446_3_T2	PHENOTYPE	7	8	nicotine dependence
NCT001864463	NCT00186446_3_T3	PHENOTYPE	11	12	major depression
NCT001864590	NCT00186459_0_T0	PHENOTYPE	0	0	Obesity
NCT001864590	NCT00186459_0_T1	PHENOTYPE	4	5	Cardiovascular Disease
NCT001864590	NCT00186459_0_T2	PHENOTYPE	1	2	Weight Loss
NCT001864596	NCT00186459_6_T0	COMPOUND	20	20	glucose
NCT001864596	NCT00186459_6_T1	PHENOTYPE	21	21	concentrations
NCT001864596	NCT00186459_6_T2	GENE	18	18	insulin
NCT001864596	NCT00186459_6_T3	GENE	36	36	insulin
NCT001864596	NCT00186459_6_T4	PHENOTYPE	2	3	weight loss
NCT001864596	NCT00186459_6_T5	PHENOTYPE	6	7	insulin resistance
NCT001864598	NCT00186459_8_T0	PHENOTYPE	3	3	hyperinsulinemia
NCT001864598	NCT00186459_8_T1	PHENOTYPE	5	7	coronary heart disease
NCT0018645910	NCT00186459_10_T0	GENE	2	2	insulin
NCT0018645910	NCT00186459_10_T1	GENE	5	5	insulin
NCT0018645910	NCT00186459_10_T2	PHENOTYPE	3	3	resistant
NCT0018645910	NCT00186459_10_T3	PHENOTYPE	8	8	overweight
NCT0018645910	NCT00186459_10_T4	PHENOTYPE	16	17	lose weight
NCT0018645911	NCT00186459_11_T0	GENE	0	0	CHD
NCT0018645911	NCT00186459_11_T1	GENE	23	23	CHD
NCT0018645911	NCT00186459_11_T2	PHENOTYPE	6	7	weight loss
NCT0018645911	NCT00186459_11_T3	PHENOTYPE	41	42	weight loss
NCT0018645911	NCT00186459_11_T4	PHENOTYPE	18	19	insulin resistance
NCT0018645911	NCT00186459_11_T5	PHENOTYPE	33	34	insulin resistance
NCT0018645912	NCT00186459_12_T0	PHENOTYPE	3	4	weight loss
NCT0018645916	NCT00186459_16_T0	PHENOTYPE	4	4	concentrations
NCT0018645916	NCT00186459_16_T1	PHENOTYPE	21	21	concentrations
NCT0018645916	NCT00186459_16_T2	GENE	3	3	insulin
NCT0018645916	NCT00186459_16_T3	GENE	20	20	insulin
NCT0018645916	NCT00186459_16_T4	ORGAN	2	2	plasma
NCT0018645918	NCT00186459_18_T0	PHENOTYPE	7	7	PCOS
NCT0018645918	NCT00186459_18_T1	PHENOTYPE	24	24	hyperinsulinism
NCT0018645919	NCT00186459_19_T0	COMPOUND	9	9	BMI
NCT0018645922	NCT00186459_22_T0	PHENOTYPE	5	5	reflects
NCT001864722	NCT00186472_2_T0	PHENOTYPE	19	19	guilt
NCT001864722	NCT00186472_2_T1	PHENOTYPE	21	21	disappointment
NCT001864722	NCT00186472_2_T2	PHENOTYPE	6	6	emotions
NCT001864726	NCT00186472_6_T0	PHENOTYPE	27	27	symptoms
NCT001864726	NCT00186472_6_T1	GENE	21	21	has
NCT001864727	NCT00186472_7_T0	PHENOTYPE	20	21	emotional distress
NCT001864728	NCT00186472_8_T0	PHENOTYPE	18	18	symptoms
NCT0018647210	NCT00186472_10_T0	PHENOTYPE	13	13	symptoms
NCT0018647210	NCT00186472_10_T1	PHENOTYPE	27	28	psychological disorders
NCT0018647220	NCT00186472_20_T0	GENE	3	3	has
NCT001864853	NCT00186485_3_T0	COMPOUND	43	43	caffeine
NCT001864853	NCT00186485_3_T1	PHENOTYPE	35	35	dependence
NCT001864853	NCT00186485_3_T2	COMPOUND	41	41	nicotine
NCT001864853	NCT00186485_3_T3	PHENOTYPE	14	14	secondary
NCT001864853	NCT00186485_3_T4	PHENOTYPE	32	33	substance abuse
NCT001864853	NCT00186485_3_T5	PHENOTYPE	52	53	major depression
NCT001864853	NCT00186485_3_T6	PHENOTYPE	49	50	schizoaffective disorder
NCT001864853	NCT00186485_3_T7	PHENOTYPE	45	46	psychotic disorder
NCT001864853	NCT00186485_3_T8	PHENOTYPE	62	64	Obsessive compulsive disorder
NCT001864853	NCT00186485_3_T9	PHENOTYPE	67	69	Post-traumatic stress disorder
NCT001864855	NCT00186485_5_T0	GENE	2	2	II
NCT001864855	NCT00186485_5_T1	PHENOTYPE	3	4	Personality Disorder
NCT001864857	NCT00186485_7_T0	PHENOTYPE	20	20	trauma
NCT001864857	NCT00186485_7_T1	PHENOTYPE	3	3	seizure
NCT001864857	NCT00186485_7_T2	PHENOTYPE	18	18	infarctions
NCT001864857	NCT00186485_7_T3	PHENOTYPE	25	26	head trauma
NCT001864857	NCT00186485_7_T4	PHENOTYPE	28	30	loss of consciousness
NCT001864858	NCT00186485_8_T0	PHENOTYPE	17	17	Attachment
NCT001864859	NCT00186485_9_T0	PHENOTYPE	24	24	Attachment
NCT0018648512	NCT00186485_12_T0	COMPOUND	4	4	rTMS
NCT0018648513	NCT00186485_13_T0	ORGAN	4	5	Vagus Nerve
NCT0018648515	NCT00186485_15_T0	COMPOUND	2	2	fluoxetine
NCT0018648517	NCT00186485_17_T0	PHENOTYPE	10	10	Attachment
NCT0018648518	NCT00186485_18_T0	PHENOTYPE	1	1	acute
NCT0018648518	NCT00186485_18_T1	COMPOUND	19	19	2
NCT0018648519	NCT00186485_19_T0	PHENOTYPE	8	8	acute
NCT0018648519	NCT00186485_19_T1	GENE	6	6	lines
NCT0018648519	NCT00186485_19_T2	PHENOTYPE	10	11	cardiac disease
NCT0018648520	NCT00186485_20_T0	PHENOTYPE	3	3	aneurysm
NCT0018648522	NCT00186485_22_T0	PHENOTYPE	23	23	anticipation
NCT0018648522	NCT00186485_22_T1	COMPOUND	41	41	rTMS
NCT0018648523	NCT00186485_23_T0	PHENOTYPE	0	3	Positive urine drug screen
NCT0018648524	NCT00186485_24_T0	PHENOTYPE	1	4	positive urine drug screen
NCT0018648525	NCT00186485_25_T0	PHENOTYPE	2	3	laboratory abnormality
NCT001865112	NCT00186511_2_T0	PHENOTYPE	44	44	self-efficacy
NCT001865112	NCT00186511_2_T1	PHENOTYPE	17	18	breast cancer
NCT001865113	NCT00186511_3_T0	PHENOTYPE	17	17	oncology
NCT001865115	NCT00186511_5_T0	PHENOTYPE	11	11	said
NCT001865115	NCT00186511_5_T1	PHENOTYPE	28	29	breast cancer
NCT001865117	NCT00186511_7_T0	PHENOTYPE	13	13	symptoms
NCT001865117	NCT00186511_7_T1	PHENOTYPE	10	12	posttraumatic stress disorder
NCT001865118	NCT00186511_8_T0	GENE	6	6	has
NCT001865240	NCT00186524_0_T0	PHENOTYPE	15	15	Cancer
NCT001865240	NCT00186524_0_T1	PHENOTYPE	6	7	Physiological Stress
NCT001865240	NCT00186524_0_T2	PHENOTYPE	12	13	Breast Cancer
NCT001865242	NCT00186524_2_T0	GENE	18	18	has
NCT001865243	NCT00186524_3_T0	PHENOTYPE	16	17	breast cancer
NCT001865246	NCT00186524_6_T0	GENE	1	1	had
NCT001865247	NCT00186524_7_T0	GENE	15	15	San
NCT001865249	NCT00186524_9_T0	GENE	18	18	The
NCT001865249	NCT00186524_9_T1	GENE	28	28	San
NCT001865249	NCT00186524_9_T2	PHENOTYPE	24	24	CSC
NCT001865249	NCT00186524_9_T3	PHENOTYPE	7	7	weaknesses
NCT001865249	NCT00186524_9_T4	PHENOTYPE	15	16	breast cancer
NCT0018652411	NCT00186524_11_T0	PHENOTYPE	7	8	emotional distress
NCT0018652413	NCT00186524_13_T0	PHENOTYPE	6	6	recruitment
NCT0018652419	NCT00186524_19_T0	PHENOTYPE	6	6	trauma
NCT0018652419	NCT00186524_19_T1	PHENOTYPE	7	7	symptoms
NCT0018652419	NCT00186524_19_T2	PHENOTYPE	10	10	self-efficacy
NCT0018652419	NCT00186524_19_T3	PHENOTYPE	4	5	depression symptoms
NCT0018652422	NCT00186524_22_T0	PHENOTYPE	13	13	recruitment
NCT0018652423	NCT00186524_23_T0	PHENOTYPE	30	30	ideas
NCT0018652423	NCT00186524_23_T1	PHENOTYPE	18	19	breast cancer
NCT0018652424	NCT00186524_24_T0	GENE	25	25	had
NCT0018652425	NCT00186524_25_T0	PHENOTYPE	9	10	breast cancer
NCT0018652425	NCT00186524_25_T1	PHENOTYPE	23	24	breast cancer
NCT001865370	NCT00186537_0_T0	PHENOTYPE	4	5	Weight Loss
NCT001865370	NCT00186537_0_T1	PHENOTYPE	14	15	High Triglycerides
NCT001865373	NCT00186537_3_T0	PHENOTYPE	16	16	CVD
NCT001865373	NCT00186537_3_T1	GENE	38	38	TG
NCT001865373	NCT00186537_3_T2	ORGAN	36	36	plasma
NCT001865373	NCT00186537_3_T3	PHENOTYPE	31	31	dyslipidemia
NCT001865373	NCT00186537_3_T4	PHENOTYPE	6	7	compensatory hyperinsulinemia
NCT001865373	NCT00186537_3_T5	PHENOTYPE	3	4	insulin resistance
NCT001865373	NCT00186537_3_T6	PHENOTYPE	40	43	low high-density lipoprotein cholesterol
NCT001865374	NCT00186537_4_T0	GENE	2	2	lipoprotein
NCT001865374	NCT00186537_4_T1	GENE	20	20	lipoprotein
NCT001865374	NCT00186537_4_T2	GENE	21	21	LDL
NCT001865374	NCT00186537_4_T3	GENE	7	7	IRS
NCT001865374	NCT00186537_4_T4	GENE	8	8	has
NCT001865375	NCT00186537_5_T0	PHENOTYPE	21	21	CVD
NCT001865375	NCT00186537_5_T1	PHENOTYPE	9	10	compensatory hyperinsulinemia
NCT001865375	NCT00186537_5_T2	BIOLOGICAL_PROCESS	14	15	lipoprotein metabolism
NCT001865375	NCT00186537_5_T3	PHENOTYPE	6	7	insulin resistance
NCT001865376	NCT00186537_6_T0	PHENOTYPE	55	55	concentrations
NCT001865376	NCT00186537_6_T1	GENE	8	8	IRS
NCT001865376	NCT00186537_6_T2	PHENOTYPE	25	25	CVD
NCT001865376	NCT00186537_6_T3	PHENOTYPE	57	57	CVD
NCT001865376	NCT00186537_6_T4	PHENOTYPE	61	61	CVD
NCT001865376	NCT00186537_6_T5	GENE	52	52	TG
NCT001865376	NCT00186537_6_T6	ORGAN	15	15	plasma
NCT001865376	NCT00186537_6_T7	ORGAN	35	35	plasma
NCT001865376	NCT00186537_6_T8	ORGAN	51	51	plasma
NCT001865376	NCT00186537_6_T9	PHENOTYPE	4	4	dyslipidemia
NCT001865377	NCT00186537_7_T0	PHENOTYPE	14	14	CVD
NCT001865377	NCT00186537_7_T1	GENE	61	61	insulin
NCT001865377	NCT00186537_7_T2	PHENOTYPE	25	27	high blood pressure
NCT001865378	NCT00186537_8_T0	PHENOTYPE	24	24	CVD
NCT001865378	NCT00186537_8_T1	PHENOTYPE	33	33	CVD
NCT001865378	NCT00186537_8_T2	GENE	16	16	insulin
NCT001865378	NCT00186537_8_T3	PHENOTYPE	17	17	resistant
NCT001865378	NCT00186537_8_T4	GENE	19	19	had
NCT001865378	NCT00186537_8_T5	ORGAN	10	10	plasma
NCT0018653710	NCT00186537_10_T0	COMPOUND	7	7	rosiglitazone
NCT0018653710	NCT00186537_10_T1	PHENOTYPE	26	26	dyslipidemia
NCT0018653710	NCT00186537_10_T2	PHENOTYPE	16	17	insulin sensitivity
NCT0018653712	NCT00186537_12_T0	PHENOTYPE	23	23	concentrations
NCT0018653712	NCT00186537_12_T1	GENE	8	8	insulin
NCT0018653712	NCT00186537_12_T2	GENE	18	18	insulin
NCT0018653712	NCT00186537_12_T3	GENE	13	13	had
NCT0018653712	NCT00186537_12_T4	PHENOTYPE	16	17	plasma glucose
NCT0018653712	NCT00186537_12_T5	BIOLOGICAL_PROCESS	36	37	lipoprotein metabolism
NCT0018653714	NCT00186537_14_T0	GENE	13	13	insulin
NCT0018653714	NCT00186537_14_T1	PHENOTYPE	14	14	resistant
NCT0018653714	NCT00186537_14_T2	GENE	22	22	IRS
NCT0018653714	NCT00186537_14_T3	PHENOTYPE	41	41	CVD
NCT0018653714	NCT00186537_14_T4	PHENOTYPE	18	18	dyslipidemia
NCT0018653714	NCT00186537_14_T5	PHENOTYPE	31	32	weight loss
NCT001865892	NCT00186589_2_T0	COMPOUND	9	10	ibritumomab tiuxetan
NCT001865895	NCT00186589_5_T0	GENE	10	10	PR
NCT001865895	NCT00186589_5_T1	GENE	14	14	CR
NCT001865895	NCT00186589_5_T2	PHENOTYPE	19	20	disease progression
NCT001865895	NCT00186589_5_T3	PHENOTYPE	4	5	recurrent disease
NCT001865896	NCT00186589_6_T0	GENE	11	11	PR
NCT001865896	NCT00186589_6_T1	PHENOTYPE	16	16	progression
NCT001865896	NCT00186589_6_T2	GENE	13	13	CR
NCT001865898	NCT00186589_8_T0	GENE	1	1	CD20
NCT001865899	NCT00186589_9_T0	GENE	4	4	CD20
NCT0018658911	NCT00186589_11_T0	GENE	0	0	4.15
NCT0018658914	NCT00186589_14_T0	GENE	4	4	4.21
NCT0018658914	NCT00186589_14_T1	GENE	0	0	4.2
NCT0018658915	NCT00186589_15_T0	GENE	0	0	4.22
NCT0018658916	NCT00186589_16_T0	GENE	4	4	0.2
NCT0018658916	NCT00186589_16_T1	ORGAN	14	14	abdomen
NCT0018658916	NCT00186589_16_T2	GENE	0	0	4.3
NCT0018658916	NCT00186589_16_T3	ORGAN	16	16	pelvis
NCT0018658916	NCT00186589_16_T4	ORGAN	5	5	Appendix
NCT0018658918	NCT00186589_18_T0	ORGAN	25	25	abdomen
NCT0018658918	NCT00186589_18_T1	ORGAN	27	27	pelvis
NCT0018658918	NCT00186589_18_T2	GENE	13	13	al
NCT0018658918	NCT00186589_18_T3	GENE	12	12	et
NCT0018658919	NCT00186589_19_T0	GENE	0	0	4.5
NCT0018658920	NCT00186589_20_T0	ORGAN	11	12	Bone marrow
NCT0018658923	NCT00186589_23_T0	GENE	0	0	4-8
NCT0018658924	NCT00186589_24_T0	PHENOTYPE	14	14	initiation
NCT0018658929	NCT00186589_29_T0	GENE	0	0	4.15
NCT0018658938	NCT00186589_38_T0	PHENOTYPE	4	4	HIV
NCT0018658939	NCT00186589_39_T0	PHENOTYPE	9	9	dysrhythmia
NCT0018658939	NCT00186589_39_T1	PHENOTYPE	8	8	cardiomyopathy
NCT0018658939	NCT00186589_39_T2	PHENOTYPE	5	7	coronary artery disease
NCT0018658939	NCT00186589_39_T3	PHENOTYPE	11	13	congestive heart failure
NCT0018658940	NCT00186589_40_T0	PHENOTYPE	11	12	birth defects
NCT0018658941	NCT00186589_41_T0	ORGAN	10	10	marrow
NCT0018658941	NCT00186589_41_T1	GENE	0	0	4.21
NCT0018658942	NCT00186589_42_T0	GENE	0	0	4.22
NCT0018658943	NCT00186589_43_T0	PHENOTYPE	6	6	ascites
NCT0018658943	NCT00186589_43_T1	PHENOTYPE	3	4	pleural effusion
NCT001866020	NCT00186602_0_T0	PHENOTYPE	16	16	Cancer
NCT001866020	NCT00186602_0_T1	PHENOTYPE	13	14	Breast Cancer
NCT001866020	NCT00186602_0_T2	PHENOTYPE	5	7	Quality of Life
NCT001866023	NCT00186602_3_T0	PHENOTYPE	12	12	trauma
NCT001866026	NCT00186602_6_T0	PHENOTYPE	28	29	breast cancer
NCT001866026	NCT00186602_6_T1	PHENOTYPE	33	35	quality of life
NCT001866027	NCT00186602_7_T0	PHENOTYPE	7	7	listening
NCT001866027	NCT00186602_7_T1	PHENOTYPE	18	19	breast cancer
NCT0018660210	NCT00186602_10_T0	PHENOTYPE	19	20	breast cancer
NCT0018660210	NCT00186602_10_T1	PHENOTYPE	39	40	breast cancer
NCT001866541	NCT00186654_1_T0	PHENOTYPE	13	15	post partum depression
NCT001866544	NCT00186654_4_T0	PHENOTYPE	4	4	acute
NCT001866546	NCT00186654_6_T0	PHENOTYPE	29	29	relapse
NCT001866670	NCT00186667_0_T0	PHENOTYPE	8	12	Chronic Graft Versus Host Disease
NCT001866931	NCT00186693_1_T0	PHENOTYPE	14	14	inflammation
NCT001866934	NCT00186693_4_T0	PHENOTYPE	13	13	asthma
NCT001866934	NCT00186693_4_T1	PHENOTYPE	11	11	narrowing
NCT001866936	NCT00186693_6_T0	PHENOTYPE	9	9	inflammation
NCT001866938	NCT00186693_8_T0	PHENOTYPE	9	9	inflammation
NCT001866938	NCT00186693_8_T1	GENE	5	5	AHR
NCT0018669310	NCT00186693_10_T0	GENE	3	3	AHR
NCT0018669310	NCT00186693_10_T1	PHENOTYPE	6	6	understood
NCT0018669311	NCT00186693_11_T0	GENE	37	37	AHR
NCT0018669311	NCT00186693_11_T1	GENE	10	10	structural
NCT0018669311	NCT00186693_11_T2	GENE	9	9	IL-13
NCT0018669311	NCT00186693_11_T3	CELL	21	23	smooth muscle cells
NCT0018669312	NCT00186693_12_T0	PHENOTYPE	11	11	asthma
NCT0018669312	NCT00186693_12_T1	PHENOTYPE	9	9	narrowing
NCT0018669314	NCT00186693_14_T0	PHENOTYPE	13	13	asthma
NCT0018669314	NCT00186693_14_T1	ORGAN	26	27	terminal bronchioles
NCT0018669316	NCT00186693_16_T0	PHENOTYPE	28	28	obstruction
NCT0018669316	NCT00186693_16_T1	PHENOTYPE	27	27	airflow
NCT0018669316	NCT00186693_16_T2	GENE	11	11	AHR
NCT0018669317	NCT00186693_17_T0	PHENOTYPE	8	8	asthma
NCT0018669317	NCT00186693_17_T1	GENE	4	4	AHR
NCT0018669317	NCT00186693_17_T2	GENE	15	15	AHR
NCT0018669317	NCT00186693_17_T3	PHENOTYPE	19	19	inflammation
NCT0018669317	NCT00186693_17_T4	PHENOTYPE	32	32	inflammation
NCT0018669317	NCT00186693_17_T5	GENE	33	33	IL-13
NCT0018669317	NCT00186693_17_T6	GENE	34	34	IL-4
NCT0018669317	NCT00186693_17_T7	PHENOTYPE	43	43	fibrosis
NCT0018669317	NCT00186693_17_T8	GENE	35	35	IL-5
NCT0018669318	NCT00186693_18_T0	GENE	7	7	AHR
NCT0018669318	NCT00186693_18_T1	COMPOUND	20	20	methacholine
NCT0018669319	NCT00186693_19_T0	COMPOUND	2	2	methacholine
NCT001867062	NCT00186706_2_T0	GENE	13	13	GPx-1
NCT001867062	NCT00186706_2_T1	PHENOTYPE	18	19	heart disease
NCT001867063	NCT00186706_3_T0	COMPOUND	4	4	selenium
NCT001867063	NCT00186706_3_T1	GENE	8	8	GPx-1
NCT001867065	NCT00186706_5_T0	PHENOTYPE	7	7	concentrations
NCT001867065	NCT00186706_5_T1	PHENOTYPE	2	2	affects
NCT001867065	NCT00186706_5_T2	GENE	13	13	GPx-1
NCT001867066	NCT00186706_6_T0	PHENOTYPE	4	4	inflammation
NCT001867066	NCT00186706_6_T1	PHENOTYPE	14	15	respiratory disease
NCT001867067	NCT00186706_7_T0	GENE	7	7	al
NCT001867067	NCT00186706_7_T1	GENE	13	13	GPx-1
NCT001867067	NCT00186706_7_T2	GENE	6	6	et
NCT001867068	NCT00186706_8_T0	GENE	0	0	GPx-1
NCT001867068	NCT00186706_8_T1	GENE	13	13	GPx-1
NCT001867069	NCT00186706_9_T0	COMPOUND	9	9	selenium
NCT0018670610	NCT00186706_10_T0	COMPOUND	3	3	selenium
NCT0018670610	NCT00186706_10_T1	COMPOUND	11	11	selenium
NCT0018670610	NCT00186706_10_T2	PHENOTYPE	18	18	diseases
NCT0018670610	NCT00186706_10_T3	GENE	14	14	GPx
NCT0018670610	NCT00186706_10_T4	GENE	0	0	GPx-1
NCT0018670611	NCT00186706_11_T0	COMPOUND	9	9	selenium
NCT0018670615	NCT00186706_15_T0	COMPOUND	14	14	selenium
NCT0018670615	NCT00186706_15_T1	PHENOTYPE	26	27	respiratory disease
NCT0018670626	NCT00186706_26_T0	PHENOTYPE	4	4	menopausal
NCT0018670628	NCT00186706_28_T0	PHENOTYPE	6	6	acute
NCT0018670628	NCT00186706_28_T1	PHENOTYPE	9	10	chronic bronchitis
NCT0018670630	NCT00186706_30_T0	COMPOUND	7	8	vitamin A
NCT0018670630	NCT00186706_30_T1	COMPOUND	17	18	vitamin E
NCT0018670635	NCT00186706_35_T0	PHENOTYPE	4	5	cancer other
NCT0018670635	NCT00186706_35_T1	PHENOTYPE	7	9	melanoma skin cancer
NCT0018670639	NCT00186706_39_T0	COMPOUND	17	17	1
NCT0018670644	NCT00186706_44_T0	COMPOUND	1	1	niacin
NCT001867191	NCT00186719_1_T0	PHENOTYPE	7	8	lung disease
NCT0018673211	NCT00186732_11_T0	GENE	37	37	al
NCT0018673211	NCT00186732_11_T1	GENE	9	9	has
NCT0018673211	NCT00186732_11_T2	GENE	36	36	et
NCT0018673217	NCT00186732_17_T0	PHENOTYPE	5	5	secondary
NCT0018673221	NCT00186732_21_T0	PHENOTYPE	14	14	affects
NCT001867451	NCT00186745_1_T0	PHENOTYPE	0	1	Blood clots
NCT001867452	NCT00186745_2_T0	COMPOUND	11	11	heparin
NCT001867454	NCT00186745_4_T0	PHENOTYPE	31	31	bleeding
NCT001867454	NCT00186745_4_T1	ORGAN	9	9	kidneys
NCT001867454	NCT00186745_4_T2	PHENOTYPE	14	15	kidney failure
NCT001867455	NCT00186745_5_T0	ORGAN	13	13	kidneys
NCT001867455	NCT00186745_5_T1	PHENOTYPE	23	24	kidney failure
NCT001867457	NCT00186745_7_T0	PHENOTYPE	25	26	kidney failure
NCT001867457	NCT00186745_7_T1	PHENOTYPE	31	32	kidney failure
NCT0018674510	NCT00186745_10_T0	PHENOTYPE	22	23	kidney failure
NCT0018674514	NCT00186745_14_T0	PHENOTYPE	0	1	Venous thromboembolism
NCT0018674516	NCT00186745_16_T0	PHENOTYPE	21	21	bleeding
NCT0018674516	NCT00186745_16_T1	PHENOTYPE	22	22	complications
NCT0018674516	NCT00186745_16_T2	PHENOTYPE	6	7	renal insufficiency
NCT0018674517	NCT00186745_17_T0	PHENOTYPE	6	7	renal insufficiency
NCT0018674518	NCT00186745_18_T0	COMPOUND	10	10	heparin
NCT0018674520	NCT00186745_20_T0	GENE	5	5	has
NCT0018674521	NCT00186745_21_T0	PHENOTYPE	19	20	renal insufficiency
NCT0018674522	NCT00186745_22_T0	PHENOTYPE	23	24	renal insufficiency
NCT0018674524	NCT00186745_24_T0	PHENOTYPE	24	24	complication
NCT0018674524	NCT00186745_24_T1	PHENOTYPE	23	23	thrombosis
NCT0018674524	NCT00186745_24_T2	PHENOTYPE	21	21	bleeding
NCT0018674525	NCT00186745_25_T0	PHENOTYPE	40	40	bleeding
NCT0018674525	NCT00186745_25_T1	PHENOTYPE	17	18	renal insufficiency
NCT0018674527	NCT00186745_27_T0	PHENOTYPE	18	19	renal insufficiency
NCT0018674529	NCT00186745_29_T0	PHENOTYPE	11	11	acute
NCT0018674529	NCT00186745_29_T1	PHENOTYPE	25	25	anticoagulation
NCT0018674537	NCT00186745_37_T0	PHENOTYPE	10	11	renal insufficiency
NCT0018674539	NCT00186745_39_T0	PHENOTYPE	41	42	renal insufficiency
NCT0018674540	NCT00186745_40_T0	PHENOTYPE	28	29	renal insufficiency
NCT001867582	NCT00186758_2_T0	GENE	18	18	coil
NCT001867711	NCT00186771_1_T0	PHENOTYPE	6	6	symptoms
NCT001867711	NCT00186771_1_T1	PHENOTYPE	0	1	Auditory hallucinations
NCT001867713	NCT00186771_3_T0	GENE	0	0	TMS
NCT001867714	NCT00186771_4_T0	PHENOTYPE	17	17	schizophrenia
NCT001867714	NCT00186771_4_T1	GENE	11	11	TMS
NCT001867714	NCT00186771_4_T2	PHENOTYPE	14	15	auditory hallucinations
NCT001867717	NCT00186771_7_T0	ORGAN	16	16	scalp
NCT001867717	NCT00186771_7_T1	PHENOTYPE	7	8	auditory hallucinations
NCT001867841	NCT00186784_1_T0	COMPOUND	12	12	rTMS
NCT001867841	NCT00186784_1_T1	COMPOUND	21	21	rTMS
NCT001867972	NCT00186797_2_T0	CELL	17	17	platelets
NCT001867972	NCT00186797_2_T1	CELL	0	1	Stem cells
NCT001867972	NCT00186797_2_T2	CELL	4	5	blood cells
NCT001867972	NCT00186797_2_T3	CELL	10	12	red blood cells
NCT001867972	NCT00186797_2_T4	CELL	13	15	white blood cells
NCT001867973	NCT00186797_3_T0	GENE	8	8	has
NCT001867978	NCT00186797_8_T0	CELL	13	13	cells
NCT001867978	NCT00186797_8_T1	TISSUE	7	7	bones
NCT001867978	NCT00186797_8_T2	CELL	9	10	stem cells
NCT001867978	NCT00186797_8_T3	ORGAN	21	22	bone marrow
NCT001867978	NCT00186797_8_T4	ORGAN	0	1	Bone marrow
NCT001867979	NCT00186797_9_T0	CELL	1	2	stem cells
NCT0018679711	NCT00186797_11_T0	PHENOTYPE	9	9	affects
NCT001868100	NCT00186810_0_T0	CELL	0	1	Stem Cell
NCT001868100	NCT00186810_0_T1	PHENOTYPE	9	11	Sickle Cell Disease
NCT001868102	NCT00186810_2_T0	ORGAN	2	2	graft
NCT001868102	NCT00186810_2_T1	ORGAN	8	9	cord blood
NCT001868102	NCT00186810_2_T2	ORGAN	5	6	bone marrow
NCT001868103	NCT00186810_3_T0	PHENOTYPE	51	51	complication
NCT001868103	NCT00186810_3_T1	PHENOTYPE	55	55	GVHD
NCT001868103	NCT00186810_3_T2	ORGAN	49	49	transplant
NCT001868103	NCT00186810_3_T3	PHENOTYPE	44	44	toxicities
NCT001868103	NCT00186810_3_T4	CELL	30	30	platelets
NCT001868103	NCT00186810_3_T5	CELL	13	13	cells
NCT001868103	NCT00186810_3_T6	PHENOTYPE	53	53	graft-versus-host-disease
NCT001868103	NCT00186810_3_T7	ORGAN	36	37	immune system
NCT001868103	NCT00186810_3_T8	ORGAN	17	18	bone marrow
NCT001868103	NCT00186810_3_T9	CELL	23	25	red blood cells
NCT001868103	NCT00186810_3_T10	CELL	26	28	white blood cells
NCT001868230	NCT00186823_0_T0	PHENOTYPE	7	8	Hematologic Malignancies
NCT001868230	NCT00186823_0_T1	CELL	1	2	Stem Cell
NCT001868233	NCT00186823_3_T0	ORGAN	4	4	transplant
NCT001868234	NCT00186823_4_T0	PHENOTYPE	19	19	toxicity
NCT001868234	NCT00186823_4_T1	PHENOTYPE	16	16	complications
NCT001868234	NCT00186823_4_T2	PHENOTYPE	25	25	GVHD
NCT001868234	NCT00186823_4_T3	ORGAN	2	2	transplant
NCT001868234	NCT00186823_4_T4	GENE	3	3	has
NCT001868234	NCT00186823_4_T5	GENE	11	11	has
NCT001868234	NCT00186823_4_T6	PHENOTYPE	21	24	graft versus host disease
NCT001868236	NCT00186823_6_T0	CELL	21	21	cells
NCT001868236	NCT00186823_6_T1	TISSUE	10	10	tissues
NCT001868236	NCT00186823_6_T2	PHENOTYPE	0	0	GVHD
NCT001868236	NCT00186823_6_T3	CELL	5	6	T cells
NCT001868237	NCT00186823_7_T0	ORGAN	23	23	graft
NCT001868237	NCT00186823_7_T1	PHENOTYPE	9	9	GVHD
NCT001868237	NCT00186823_7_T2	GENE	10	11	too few
NCT001868237	NCT00186823_7_T3	ORGAN	16	17	immune system
NCT001868237	NCT00186823_7_T4	CELL	3	4	T cells
NCT0018682310	NCT00186823_10_T0	PHENOTYPE	16	16	engraftment
NCT0018682310	NCT00186823_10_T1	CELL	15	15	platelet
NCT0018682310	NCT00186823_10_T2	CELL	13	13	neutrophil
NCT0018682311	NCT00186823_11_T0	PHENOTYPE	7	7	complications
NCT0018682311	NCT00186823_11_T1	ORGAN	13	13	transplant
NCT0018682315	NCT00186823_15_T0	PHENOTYPE	3	3	toxicities
NCT001868361	NCT00186836_1_T0	PHENOTYPE	0	1	Hepatitis B
NCT001868362	NCT00186836_2_T0	GENE	10	10	eg
NCT001868362	NCT00186836_2_T1	PHENOTYPE	16	16	susceptible
NCT001868362	NCT00186836_2_T2	PHENOTYPE	3	3	practices
NCT001868367	NCT00186836_7_T0	PHENOTYPE	3	3	Diseases
NCT0018683610	NCT00186836_10_T0	PHENOTYPE	9	10	hepatitis A
NCT0018683610	NCT00186836_10_T1	PHENOTYPE	16	17	hepatitis A
NCT0018683610	NCT00186836_10_T2	PHENOTYPE	6	7	hepatitis B
NCT0018683610	NCT00186836_10_T3	PHENOTYPE	20	21	hepatitis B
NCT0018683611	NCT00186836_11_T0	GENE	8	8	GMT
NCT0018683613	NCT00186836_13_T0	PHENOTYPE	21	21	HBV
NCT0018683613	NCT00186836_13_T1	PHENOTYPE	19	19	susceptible
NCT0018683614	NCT00186836_14_T0	PHENOTYPE	11	11	HAV
NCT0018683614	NCT00186836_14_T1	PHENOTYPE	13	13	HBV
NCT0018683614	NCT00186836_14_T2	PHENOTYPE	20	20	HBV
NCT001868491	NCT00186849_1_T0	COMPOUND	18	18	topotecan
NCT001868492	NCT00186849_2_T0	COMPOUND	4	4	topotecan
NCT001868496	NCT00186849_6_T0	GENE	8	8	3.0
NCT0018684911	NCT00186849_11_T0	GENE	3	3	IV
NCT0018684912	NCT00186849_12_T0	COMPOUND	6	6	cyclophosphamide
NCT0018684912	NCT00186849_12_T1	GENE	3	3	IV
NCT0018684913	NCT00186849_13_T0	CELL	4	7	peripheral blood stem cells
NCT0018684915	NCT00186849_15_T0	GENE	5	5	IV
NCT0018684917	NCT00186849_17_T0	CELL	4	7	peripheral blood stem cells
NCT0018684918	NCT00186849_18_T0	PHENOTYPE	29	29	tumor
NCT0018684918	NCT00186849_18_T1	TISSUE	17	18	lymph node
NCT0018684918	NCT00186849_18_T2	PHENOTYPE	12	13	primary tumor
NCT001868621	NCT00186862_1_T0	PHENOTYPE	2	2	tumor
NCT001868621	NCT00186862_1_T1	PHENOTYPE	9	9	localized
NCT001868624	NCT00186862_4_T0	PHENOTYPE	13	13	neuroblastoma
NCT001868624	NCT00186862_4_T1	ORGAN	9	10	immune system
NCT001868625	NCT00186862_5_T0	PHENOTYPE	1	1	tumors
NCT001868625	NCT00186862_5_T1	PHENOTYPE	9	9	tumor
NCT001868625	NCT00186862_5_T2	PHENOTYPE	41	41	tumor
NCT001868625	NCT00186862_5_T3	CELL	25	25	T-cells
NCT001868626	NCT00186862_6_T0	PHENOTYPE	23	23	infiltrate
NCT001868626	NCT00186862_6_T1	CELL	16	16	cells
NCT001868626	NCT00186862_6_T2	GENE	12	12	IL-2
NCT001868626	NCT00186862_6_T3	PHENOTYPE	28	28	tumor
NCT001868626	NCT00186862_6_T4	PHENOTYPE	15	15	neuroblastoma
NCT001868626	NCT00186862_6_T5	CELL	22	22	T-cell
NCT001868626	NCT00186862_6_T6	BIOLOGICAL_PROCESS	29	30	immune response
NCT001868628	NCT00186862_8_T0	CELL	10	10	cells
NCT001868628	NCT00186862_8_T1	PHENOTYPE	9	9	tumor
NCT0018686210	NCT00186862_10_T0	GENE	2	2	had
NCT0018686211	NCT00186862_11_T0	PHENOTYPE	6	6	toxicity
NCT0018686212	NCT00186862_12_T0	PHENOTYPE	10	10	toxicity
NCT0018686212	NCT00186862_12_T1	CELL	19	19	cells
NCT0018686212	NCT00186862_12_T2	GENE	23	23	had
NCT0018686212	NCT00186862_12_T3	PHENOTYPE	11	12	progressive disease
NCT0018686213	NCT00186862_13_T0	GENE	4	4	separated
NCT001868754	NCT00186875_4_T0	PHENOTYPE	13	13	blocks
NCT001868754	NCT00186875_4_T1	PHENOTYPE	1	1	remission
NCT001868755	NCT00186875_5_T0	COMPOUND	19	19	dexamethasone
NCT001868755	NCT00186875_5_T1	COMPOUND	10	10	cytarabine
NCT001868755	NCT00186875_5_T2	COMPOUND	16	16	vincristine
NCT001868755	NCT00186875_5_T3	COMPOUND	6	6	etoposide
NCT001868755	NCT00186875_5_T4	GENE	4	4	IV
NCT001868755	NCT00186875_5_T5	GENE	14	14	IV
NCT001868756	NCT00186875_6_T0	COMPOUND	11	11	dexamethasone
NCT001868756	NCT00186875_6_T1	COMPOUND	8	8	vincristine
NCT001868757	NCT00186875_7_T0	COMPOUND	10	10	cytarabine
NCT001868757	NCT00186875_7_T1	COMPOUND	12	12	teniposide
NCT001868757	NCT00186875_7_T2	COMPOUND	8	8	methotrexate
NCT0018687515	NCT00186875_15_T0	PHENOTYPE	16	16	relapse
NCT0018687515	NCT00186875_15_T1	ORGAN	14	15	bone marrow
NCT0018687517	NCT00186875_17_T0	PHENOTYPE	11	11	remission
NCT0018687517	NCT00186875_17_T1	PHENOTYPE	4	4	Plan
NCT0018687518	NCT00186875_18_T0	PHENOTYPE	20	20	MRD
NCT0018687521	NCT00186875_21_T0	GENE	6	6	CR
NCT0018687522	NCT00186875_22_T0	GENE	12	12	max
NCT0018687522	NCT00186875_22_T1	GENE	10	10	1.5
NCT0018687523	NCT00186875_23_T0	PHENOTYPE	9	9	relapse
NCT0018687523	NCT00186875_23_T1	GENE	3	3	MHA
NCT0018687523	NCT00186875_23_T2	GENE	2	2	IT
NCT0018687523	NCT00186875_23_T3	GENE	4	4	CNS-1
NCT0018687524	NCT00186875_24_T0	COMPOUND	2	2	3
NCT0018687524	NCT00186875_24_T1	PHENOTYPE	7	7	relapse
NCT0018687525	NCT00186875_25_T0	GENE	5	5	max
NCT0018687525	NCT00186875_25_T1	GENE	15	15	MHA
NCT0018687525	NCT00186875_25_T2	GENE	14	14	IT
NCT0018687529	NCT00186875_29_T0	PHENOTYPE	16	16	Consolidation
NCT0018687529	NCT00186875_29_T1	GENE	15	15	MHA
NCT0018687529	NCT00186875_29_T2	GENE	14	14	IT
NCT0018687531	NCT00186875_31_T0	PHENOTYPE	7	7	MRD
NCT0018687534	NCT00186875_34_T0	PHENOTYPE	1	1	MRD
NCT0018687535	NCT00186875_35_T0	GENE	24	24	M1
NCT0018687535	NCT00186875_35_T1	GENE	30	30	M1
NCT0018687535	NCT00186875_35_T2	GENE	23	23	CR
NCT0018687535	NCT00186875_35_T3	GENE	29	29	CR
NCT0018687535	NCT00186875_35_T4	ORGAN	13	13	Transplant
NCT0018687535	NCT00186875_35_T5	ORGAN	25	25	marrow
NCT0018687535	NCT00186875_35_T6	ORGAN	31	31	marrow
NCT0018687535	NCT00186875_35_T7	PHENOTYPE	41	41	Consolidation
NCT0018687535	NCT00186875_35_T8	PHENOTYPE	1	1	MRD
NCT0018687536	NCT00186875_36_T0	PHENOTYPE	7	7	Consolidation
NCT0018687536	NCT00186875_36_T1	GENE	5	5	CR
NCT0018687537	NCT00186875_37_T0	GENE	5	5	CR
NCT0018687539	NCT00186875_39_T0	PHENOTYPE	17	17	MRD
NCT0018687540	NCT00186875_40_T0	GENE	15	15	2.4
NCT0018687540	NCT00186875_40_T1	PHENOTYPE	7	7	MRD
NCT0018687540	NCT00186875_40_T2	PHENOTYPE	10	10	MRD
NCT0018687541	NCT00186875_41_T0	PHENOTYPE	5	5	MRD
NCT0018687543	NCT00186875_43_T0	PHENOTYPE	6	6	MRD
NCT0018687544	NCT00186875_44_T0	PHENOTYPE	8	8	MRD
NCT0018687546	NCT00186875_46_T0	PHENOTYPE	17	17	MRD
NCT0018687547	NCT00186875_47_T0	PHENOTYPE	7	7	MRD
NCT0018687548	NCT00186875_48_T0	PHENOTYPE	1	1	MRD
NCT0018687548	NCT00186875_48_T1	ORGAN	16	16	Transplant
NCT0018687549	NCT00186875_49_T0	PHENOTYPE	9	9	Consolidation
NCT0018687551	NCT00186875_51_T0	GENE	7	7	ANC
NCT0018687551	NCT00186875_51_T1	GENE	5	5	WBC
NCT0018687551	NCT00186875_51_T2	CELL	10	10	platelets
NCT0018687552	NCT00186875_52_T0	PHENOTYPE	1	1	MRD
NCT0018687553	NCT00186875_53_T0	PHENOTYPE	8	8	MRD
NCT0018687555	NCT00186875_55_T0	GENE	15	15	II
NCT0018687555	NCT00186875_55_T1	PHENOTYPE	14	14	Consolidation
NCT0018687555	NCT00186875_55_T2	PHENOTYPE	4	4	MRD
NCT0018687555	NCT00186875_55_T3	PHENOTYPE	20	20	MRD
NCT001868885	NCT00186888_5_T0	PHENOTYPE	15	15	tumor
NCT001868886	NCT00186888_6_T0	PHENOTYPE	10	10	focal
NCT001868887	NCT00186888_7_T0	PHENOTYPE	16	16	tumor
NCT001868887	NCT00186888_7_T1	PHENOTYPE	0	0	Focal
NCT001868889	NCT00186888_9_T0	PHENOTYPE	16	16	bilateral
NCT001868889	NCT00186888_9_T1	PHENOTYPE	14	14	unilateral
NCT0018688810	NCT00186888_10_T0	COMPOUND	29	29	vincristine
NCT0018688810	NCT00186888_10_T1	GENE	31	31	G-CSF
NCT0018688810	NCT00186888_10_T2	PHENOTYPE	17	17	bilateral
NCT0018688810	NCT00186888_10_T3	COMPOUND	27	27	topotecan
NCT0018688810	NCT00186888_10_T4	PHENOTYPE	13	15	tumors in children
NCT001869011	NCT00186901_1_T0	ORGAN	14	14	spine
NCT001869011	NCT00186901_1_T1	PHENOTYPE	10	11	broken bones
NCT001869011	NCT00186901_1_T2	PHENOTYPE	1	2	bone loss
NCT001869012	NCT00186901_2_T0	PHENOTYPE	12	13	side effect
NCT001869013	NCT00186901_3_T0	PHENOTYPE	12	12	severity
NCT001869013	NCT00186901_3_T1	PHENOTYPE	15	16	side effect
NCT001869018	NCT00186901_8_T0	COMPOUND	11	11	calcium
NCT001869018	NCT00186901_8_T1	COMPOUND	13	14	vitamin D
NCT001869019	NCT00186901_9_T0	COMPOUND	11	11	calcium
NCT001869019	NCT00186901_9_T1	COMPOUND	13	14	vitamin D
NCT001869141	NCT00186914_1_T0	PHENOTYPE	3	3	osteodysplasia
NCT001869142	NCT00186914_2_T0	PHENOTYPE	8	8	Osteodysplasia
NCT001869142	NCT00186914_2_T1	ORGAN	17	17	transplant
NCT001869142	NCT00186914_2_T2	GENE	10	10	had
NCT001869142	NCT00186914_2_T3	ORGAN	15	16	bone marrow
NCT001869143	NCT00186914_3_T0	GENE	11	11	ex
NCT001869143	NCT00186914_3_T1	ORGAN	31	31	transplant
NCT001869143	NCT00186914_3_T2	CELL	14	15	stromal cells
NCT001869143	NCT00186914_3_T3	ORGAN	19	20	bone marrow
NCT001869145	NCT00186914_5_T0	GENE	6	6	ex
NCT001869145	NCT00186914_5_T1	CELL	11	11	cells
NCT001869145	NCT00186914_5_T2	ORGAN	18	19	bone marrow
NCT001869147	NCT00186914_7_T0	PHENOTYPE	11	11	toxicity
NCT0018691412	NCT00186914_12_T0	PHENOTYPE	19	19	toxicity
NCT0018691412	NCT00186914_12_T1	CELL	7	7	cells
NCT0018691412	NCT00186914_12_T2	GENE	8	8	MSC
NCT0018691413	NCT00186914_13_T0	CELL	4	4	cells
NCT0018691413	NCT00186914_13_T1	CELL	17	17	cells
NCT0018691414	NCT00186914_14_T0	PHENOTYPE	15	15	toxicity
NCT0018691415	NCT00186914_15_T0	CELL	22	24	mesenchymal stem cells
NCT001869271	NCT00186927_1_T0	PHENOTYPE	6	6	fever
NCT001869271	NCT00186927_1_T1	GENE	5	5	has
NCT001869271	NCT00186927_1_T2	PHENOTYPE	9	9	hoarseness
NCT001869271	NCT00186927_1_T3	PHENOTYPE	7	7	cough
NCT001869274	NCT00186927_4_T0	PHENOTYPE	19	19	parainfluenza
NCT001869274	NCT00186927_4_T1	PHENOTYPE	16	16	croup
NCT001869275	NCT00186927_5_T0	GENE	18	18	has
NCT001869278	NCT00186927_8_T0	PHENOTYPE	13	13	croup
NCT0018692713	NCT00186927_13_T0	PHENOTYPE	1	1	secondary
NCT0018692713	NCT00186927_13_T1	BIOLOGICAL_PROCESS	15	16	immune response
NCT0018692714	NCT00186927_14_T0	PHENOTYPE	4	4	seronegative
NCT0018692715	NCT00186927_15_T0	GENE	10	10	booster
NCT001869401	NCT00186940_1_T0	PHENOTYPE	23	23	allergies
NCT001869401	NCT00186940_1_T1	PHENOTYPE	20	20	asthma
NCT001869403	NCT00186940_3_T0	PHENOTYPE	48	48	malignancy
NCT001869403	NCT00186940_3_T1	PHENOTYPE	29	29	allergy
NCT001869403	NCT00186940_3_T2	PHENOTYPE	26	26	asthma
NCT001869403	NCT00186940_3_T3	COMPOUND	19	19	rasburicase
NCT001869403	NCT00186940_3_T4	COMPOUND	34	34	rasburicase
NCT001869403	NCT00186940_3_T5	COMPOUND	41	41	rasburicase
NCT001869403	NCT00186940_3_T6	PHENOTYPE	51	51	hyperuricemia
NCT001869403	NCT00186940_3_T7	PHENOTYPE	16	17	allergic reactions
NCT001869406	NCT00186940_6_T0	COMPOUND	15	15	rasburicase
NCT001869406	NCT00186940_6_T1	GENE	10	10	has
NCT001869530	NCT00186953_0_T0	COMPOUND	6	6	Optison
NCT001869530	NCT00186953_0_T1	PHENOTYPE	11	12	Solid Tumors
NCT001869533	NCT00186953_3_T0	GENE	8	8	dye
NCT001869534	NCT00186953_4_T0	GENE	17	17	dye
NCT001869661	NCT00186966_1_T0	PHENOTYPE	12	12	toxicity
NCT001869661	NCT00186966_1_T1	PHENOTYPE	29	29	AML
NCT001869661	NCT00186966_1_T2	COMPOUND	19	19	fludarabine
NCT001869661	NCT00186966_1_T3	COMPOUND	15	15	daunorubicin
NCT001869664	NCT00186966_4_T0	COMPOUND	11	11	daunorubicin
NCT001869669	NCT00186966_9_T0	COMPOUND	11	11	cytarabine
NCT001869790	NCT00186979_0_T0	PHENOTYPE	13	14	Solid Tumors
NCT001869794	NCT00186979_4_T0	COMPOUND	20	20	irinotecan
NCT001869795	NCT00186979_5_T0	PHENOTYPE	1	1	diarrhea
NCT001869796	NCT00186979_6_T0	GENE	3	3	reduced
NCT001869921	NCT00186992_1_T0	PHENOTYPE	12	12	tumors
NCT001869922	NCT00186992_2_T0	GENE	8	8	MRI
NCT001869922	NCT00186992_2_T1	PHENOTYPE	18	18	tumor
NCT001869923	NCT00186992_3_T0	TISSUE	18	18	tissues
NCT001869923	NCT00186992_3_T1	PHENOTYPE	12	12	tumor
NCT001870053	NCT00187005_3_T0	PHENOTYPE	10	10	remission
NCT001870055	NCT00187005_5_T0	GENE	0	0	MTX
NCT001870056	NCT00187005_6_T0	GENE	50	50	23
NCT001870056	NCT00187005_6_T1	GENE	38	38	IM
NCT001870056	NCT00187005_6_T2	GENE	20	20	1.5
NCT001870056	NCT00187005_6_T3	GENE	63	63	hr
NCT001870056	NCT00187005_6_T4	GENE	75	75	hr
NCT001870056	NCT00187005_6_T5	GENE	22	22	IV
NCT001870056	NCT00187005_6_T6	GENE	31	31	IV
NCT001870056	NCT00187005_6_T7	GENE	60	60	IV
NCT001870056	NCT00187005_6_T8	GENE	72	72	IV
NCT001870056	NCT00187005_6_T9	GENE	3	3	6/7
NCT001870056	NCT00187005_6_T10	GENE	16	16	tid
NCT001870056	NCT00187005_6_T11	GENE	35	35	L-asparaginase
NCT001870057	NCT00187005_7_T0	PHENOTYPE	34	34	relapse
NCT001870057	NCT00187005_7_T1	GENE	3	3	MHA
NCT0018700510	NCT00187005_10_T0	GENE	30	30	ANC
NCT0018700510	NCT00187005_10_T1	PHENOTYPE	33	34	platelet count
NCT0018700512	NCT00187005_12_T0	PHENOTYPE	20	20	remission
NCT0018700512	NCT00187005_12_T1	ORGAN	15	16	bone marrow
NCT0018700514	NCT00187005_14_T0	PHENOTYPE	18	18	remission
NCT001870180	NCT00187018_0_T0	ORGAN	0	0	Marrow
NCT001870180	NCT00187018_0_T1	PHENOTYPE	5	6	Osteogenesis Imperfecta
NCT001870183	NCT00187018_3_T0	PHENOTYPE	3	4	osteogenesis imperfecta
NCT001870184	NCT00187018_4_T0	GENE	28	28	had
NCT001870184	NCT00187018_4_T1	CELL	23	23	cells
NCT001870184	NCT00187018_4_T2	TISSUE	36	36	bones
NCT001870184	NCT00187018_4_T3	TISSUE	40	40	bones
NCT001870184	NCT00187018_4_T4	TISSUE	44	44	bones
NCT001870184	NCT00187018_4_T5	ORGAN	17	17	transplant
NCT001870184	NCT00187018_4_T6	ORGAN	52	52	transplant
NCT001870184	NCT00187018_4_T7	ORGAN	15	16	bone marrow
NCT001870184	NCT00187018_4_T8	ORGAN	50	51	bone marrow
NCT001870187	NCT00187018_7_T0	ORGAN	1	1	marrow
NCT001870187	NCT00187018_7_T1	CELL	2	2	cells
NCT001870187	NCT00187018_7_T2	ORGAN	16	16	transplant
NCT001870187	NCT00187018_7_T3	ORGAN	8	9	bone marrow
NCT001870187	NCT00187018_7_T4	ORGAN	14	15	bone marrow
NCT001870189	NCT00187018_9_T0	GENE	1	1	CD3
NCT001870189	NCT00187018_9_T1	CELL	2	2	cells
NCT001870189	NCT00187018_9_T2	ORGAN	9	10	bone marrow
NCT0018701810	NCT00187018_10_T0	GENE	2	2	has
NCT001870310	NCT00187031_0_T0	GENE	2	2	II
NCT001870310	NCT00187031_0_T1	PHENOTYPE	9	11	Recurrent Wilms Tumor
NCT001870312	NCT00187031_2_T0	PHENOTYPE	9	11	recurrent Wilms tumor
NCT001870313	NCT00187031_3_T0	COMPOUND	16	16	topotecan
NCT001870313	NCT00187031_3_T1	PHENOTYPE	20	22	recurrent Wilms tumor
NCT001870441	NCT00187044_1_T0	PHENOTYPE	3	3	HIV
NCT001870441	NCT00187044_1_T1	PHENOTYPE	1	1	Immunodeficiency
NCT001870441	NCT00187044_1_T2	PHENOTYPE	9	12	Acquired Immune Deficiency Syndrome
NCT001870442	NCT00187044_2_T0	PHENOTYPE	7	8	viral infections
NCT001870443	NCT00187044_3_T0	PHENOTYPE	8	8	HIV
NCT001870444	NCT00187044_4_T0	PHENOTYPE	14	14	HIV
NCT001870445	NCT00187044_5_T0	PHENOTYPE	18	18	HIV
NCT001870445	NCT00187044_5_T1	GENE	9	9	has
NCT001870446	NCT00187044_6_T0	GENE	11	11	envelope
NCT001870446	NCT00187044_6_T1	PHENOTYPE	4	4	HIV
NCT001870449	NCT00187044_9_T0	PHENOTYPE	3	3	HIV
NCT001870449	NCT00187044_9_T1	PHENOTYPE	1	1	Immunodeficiency
NCT001870449	NCT00187044_9_T2	PHENOTYPE	9	12	Acquired Immune Deficiency Syndrome
NCT0018704410	NCT00187044_10_T0	PHENOTYPE	7	8	viral infections
NCT0018704411	NCT00187044_11_T0	PHENOTYPE	8	8	HIV
NCT0018704412	NCT00187044_12_T0	PHENOTYPE	14	14	HIV
NCT0018704413	NCT00187044_13_T0	PHENOTYPE	22	22	polio
NCT0018704413	NCT00187044_13_T1	PHENOTYPE	10	10	symptoms
NCT0018704413	NCT00187044_13_T2	PHENOTYPE	24	24	measles
NCT0018704413	NCT00187044_13_T3	PHENOTYPE	20	21	hepatitis B
NCT0018704413	NCT00187044_13_T4	PHENOTYPE	15	17	other viral infections
NCT0018704414	NCT00187044_14_T0	CELL	14	14	cells
NCT0018704414	NCT00187044_14_T1	ORGAN	7	8	immune system
NCT0018704415	NCT00187044_15_T0	PHENOTYPE	17	17	HIV
NCT0018704415	NCT00187044_15_T1	PHENOTYPE	5	7	other viral infections
NCT0018704416	NCT00187044_16_T0	PHENOTYPE	18	18	HIV
NCT0018704416	NCT00187044_16_T1	GENE	9	9	has
NCT0018704417	NCT00187044_17_T0	GENE	11	11	envelope
NCT0018704417	NCT00187044_17_T1	PHENOTYPE	4	4	HIV
NCT0018704418	NCT00187044_18_T0	PHENOTYPE	17	18	HIV infection
NCT0018704419	NCT00187044_19_T0	GENE	1	1	envelope
NCT0018704419	NCT00187044_19_T1	PHENOTYPE	12	12	vaccinia
NCT0018704419	NCT00187044_19_T2	PHENOTYPE	4	4	HIV
NCT0018704419	NCT00187044_19_T3	GENE	5	5	has
NCT0018704420	NCT00187044_20_T0	PHENOTYPE	1	1	vaccinia
NCT0018704420	NCT00187044_20_T1	PHENOTYPE	26	26	smallpox
NCT0018704420	NCT00187044_20_T2	PHENOTYPE	28	28	smallpox
NCT0018704420	NCT00187044_20_T3	GENE	3	3	has
NCT0018704421	NCT00187044_21_T0	PHENOTYPE	1	1	smallpox
NCT0018704422	NCT00187044_22_T0	PHENOTYPE	18	18	vaccinia
NCT0018704422	NCT00187044_22_T1	PHENOTYPE	24	24	vaccinia
NCT0018704422	NCT00187044_22_T2	PHENOTYPE	13	13	smallpox
NCT001870573	NCT00187057_3_T0	PHENOTYPE	5	5	cancers
NCT001870574	NCT00187057_4_T0	PHENOTYPE	15	16	hematopoietic malignancies
NCT001870576	NCT00187057_6_T0	PHENOTYPE	9	9	perceptions
NCT0018705712	NCT00187057_12_T0	PHENOTYPE	0	0	Consolidation
NCT0018705712	NCT00187057_12_T1	GENE	4	4	IV
NCT0018705729	NCT00187057_29_T0	GENE	2	2	MTX
NCT0018705729	NCT00187057_29_T1	COMPOUND	3	3	hydrocortisone
NCT0018705729	NCT00187057_29_T2	GENE	1	1	MHA
NCT0018705729	NCT00187057_29_T3	GENE	0	0	IT
NCT0018705729	NCT00187057_29_T4	GENE	15	15	4-8
NCT0018705730	NCT00187057_30_T0	GENE	11	11	MTX
NCT0018705730	NCT00187057_30_T1	GENE	36	36	2.0
NCT0018705730	NCT00187057_30_T2	GENE	14	14	IM
NCT0018705730	NCT00187057_30_T3	GENE	31	31	VCR
NCT0018705730	NCT00187057_30_T4	GENE	35	35	max
NCT0018705730	NCT00187057_30_T5	GENE	32	32	1.5
NCT0018705730	NCT00187057_30_T6	GENE	16	16	IV
NCT0018705730	NCT00187057_30_T7	GENE	34	34	IV
NCT0018705730	NCT00187057_30_T8	GENE	41	41	IV
NCT0018705732	NCT00187057_32_T0	GENE	18	18	CSF
NCT0018705732	NCT00187057_32_T1	GENE	11	11	IT
NCT0018705733	NCT00187057_33_T0	GENE	10	10	MP
NCT0018705733	NCT00187057_33_T1	PHENOTYPE	0	0	Consolidation
NCT0018705733	NCT00187057_33_T2	GENE	4	4	IV
NCT0018705749	NCT00187057_49_T0	GENE	2	2	MTX
NCT0018705749	NCT00187057_49_T1	COMPOUND	3	3	hydrocortisone
NCT0018705749	NCT00187057_49_T2	GENE	1	1	MHA
NCT0018705749	NCT00187057_49_T3	GENE	0	0	IT
NCT0018705749	NCT00187057_49_T4	GENE	15	15	4-8
NCT0018705755	NCT00187057_55_T0	GENE	3	3	has
NCT001870703	NCT00187070_3_T0	GENE	37	37	1.4
NCT001870703	NCT00187070_3_T1	GENE	46	46	MHA
NCT001870703	NCT00187070_3_T2	GENE	15	15	2.4
NCT001870703	NCT00187070_3_T3	GENE	26	26	2.4
NCT001870703	NCT00187070_3_T4	COMPOUND	1	1	methotrexate
NCT001870703	NCT00187070_3_T5	COMPOUND	8	8	leucovorin
NCT001870703	NCT00187070_3_T6	GENE	34	34	IV
NCT001870703	NCT00187070_3_T7	GENE	39	39	IV
NCT001870832	NCT00187083_2_T0	PHENOTYPE	14	14	pharmacokinetics
NCT001870832	NCT00187083_2_T1	COMPOUND	8	8	asparagine
NCT001870832	NCT00187083_2_T2	GENE	16	16	L-asparaginase
NCT001870833	NCT00187083_3_T0	COMPOUND	27	27	topotecan
NCT001870833	NCT00187083_3_T1	GENE	11	12	topoisomerase II
NCT001870833	NCT00187083_3_T2	GENE	8	9	topoisomerase I
NCT001870836	NCT00187083_6_T0	GENE	4	4	2.0
NCT001870836	NCT00187083_6_T1	GENE	3	3	max
NCT001870836	NCT00187083_6_T2	GENE	1	1	1.5
NCT001870836	NCT00187083_6_T3	GENE	6	6	IV
NCT001870837	NCT00187083_7_T0	GENE	25	25	2.0
NCT001870837	NCT00187083_7_T1	GENE	24	24	max
NCT001870837	NCT00187083_7_T2	GENE	52	52	max
NCT001870837	NCT00187083_7_T3	GENE	1	1	MHA
NCT001870837	NCT00187083_7_T4	GENE	18	18	1.5
NCT001870837	NCT00187083_7_T5	GENE	49	49	1.5
NCT001870837	NCT00187083_7_T6	GENE	0	0	IT
NCT001870837	NCT00187083_7_T7	GENE	11	11	IV
NCT001870837	NCT00187083_7_T8	GENE	20	20	IV
NCT001870837	NCT00187083_7_T9	GENE	51	51	IV
NCT001870837	NCT00187083_7_T10	GENE	44	44	TID
NCT001870837	NCT00187083_7_T11	COMPOUND	3	3	1
NCT001870837	NCT00187083_7_T12	COMPOUND	7	7	1
NCT001870837	NCT00187083_7_T13	COMPOUND	9	9	1
NCT001870837	NCT00187083_7_T14	COMPOUND	14	14	1
NCT001870837	NCT00187083_7_T15	COMPOUND	23	23	1
NCT001870837	NCT00187083_7_T16	COMPOUND	57	57	1
NCT001870837	NCT00187083_7_T17	COMPOUND	16	16	2
NCT001870837	NCT00187083_7_T18	COMPOUND	28	28	2
NCT001870837	NCT00187083_7_T19	COMPOUND	53	53	2
NCT001870963	NCT00187096_3_T0	PHENOTYPE	7	7	conditioning
NCT001870968	NCT00187096_8_T0	COMPOUND	6	6	2
NCT001870968	NCT00187096_8_T1	CELL	0	1	NK Cell
NCT001870968	NCT00187096_8_T2	CELL	7	8	NK cells
NCT001871093	NCT00187109_3_T0	GENE	10	10	thrombopoietin
NCT001871093	NCT00187109_3_T1	CELL	17	17	platelet
NCT001871094	NCT00187109_4_T0	COMPOUND	17	17	ifosfamide
NCT001871094	NCT00187109_4_T1	PHENOTYPE	27	27	lymphomas
NCT001871094	NCT00187109_4_T2	COMPOUND	20	20	etoposide
NCT001871094	NCT00187109_4_T3	PHENOTYPE	24	25	solid tumors
NCT001871095	NCT00187109_5_T0	PHENOTYPE	17	19	low platelet count
NCT001871228	NCT00187122_8_T0	CELL	7	7	cells
NCT001871228	NCT00187122_8_T1	PHENOTYPE	6	6	tumor
NCT001871228	NCT00187122_8_T2	PHENOTYPE	19	19	remission
NCT001871228	NCT00187122_8_T3	PHENOTYPE	17	17	MRD
NCT001871228	NCT00187122_8_T4	PHENOTYPE	14	16	minimal residual disease
NCT0018712210	NCT00187122_10_T0	PHENOTYPE	13	13	tumor
NCT0018712210	NCT00187122_10_T1	ORGAN	8	9	bone marrow
NCT0018712212	NCT00187122_12_T0	CELL	28	28	cells
NCT0018712212	NCT00187122_12_T1	PHENOTYPE	3	3	Plan
NCT0018712212	NCT00187122_12_T2	GENE	9	9	IV
NCT0018712212	NCT00187122_12_T3	GENE	14	14	IV
NCT0018712213	NCT00187122_13_T0	GENE	25	25	IM
NCT0018712213	NCT00187122_13_T1	GENE	7	7	1.5
NCT0018712213	NCT00187122_13_T2	GENE	9	9	IV
NCT0018712213	NCT00187122_13_T3	GENE	18	18	IV
NCT0018712213	NCT00187122_13_T4	GENE	35	35	IV
NCT0018712213	NCT00187122_13_T5	GENE	43	43	IV
NCT0018712213	NCT00187122_13_T6	GENE	22	22	L-asparaginase
NCT0018712214	NCT00187122_14_T0	GENE	7	7	IT
NCT0018712215	NCT00187122_15_T0	GENE	13	13	CSF
NCT0018712215	NCT00187122_15_T1	GENE	8	8	IT
NCT0018712216	NCT00187122_16_T0	ORGAN	14	14	skull
NCT0018712216	NCT00187122_16_T1	PHENOTYPE	2	4	cranial nerve palsies
NCT0018712217	NCT00187122_17_T0	PHENOTYPE	0	0	Consolidation
NCT0018712219	NCT00187122_19_T0	GENE	7	7	IT
NCT001871356	NCT00187135_6_T0	COMPOUND	8	8	fentanyl
NCT001871483	NCT00187148_3_T0	PHENOTYPE	25	25	HIV
NCT001871484	NCT00187148_4_T0	GENE	6	6	envelope
NCT001871485	NCT00187148_5_T0	GENE	12	12	envelope
NCT001871485	NCT00187148_5_T1	PHENOTYPE	11	11	HIV
NCT001871485	NCT00187148_5_T2	BIOLOGICAL_PROCESS	7	8	immune response
NCT001871486	NCT00187148_6_T0	GENE	4	4	envelope
NCT001871486	NCT00187148_6_T1	PHENOTYPE	2	2	HIV
NCT001871489	NCT00187148_9_T0	PHENOTYPE	0	1	HIV infection
NCT001871489	NCT00187148_9_T1	PHENOTYPE	7	10	Acquired Immune Deficiency Syndrome
NCT0018714810	NCT00187148_10_T0	PHENOTYPE	7	8	viral infections
NCT0018714811	NCT00187148_11_T0	PHENOTYPE	10	10	HIV
NCT0018714812	NCT00187148_12_T0	PHENOTYPE	25	25	HIV
NCT0018714813	NCT00187148_13_T0	GENE	6	6	envelope
NCT0018714814	NCT00187148_14_T0	PHENOTYPE	20	21	HIV infection
NCT0018714817	NCT00187148_17_T0	CELL	7	7	cells
NCT0018714817	NCT00187148_17_T1	PHENOTYPE	13	13	blocks
NCT0018714818	NCT00187148_18_T0	GENE	12	12	envelope
NCT0018714818	NCT00187148_18_T1	CELL	6	6	cells
NCT0018714818	NCT00187148_18_T2	PHENOTYPE	15	15	HIV
NCT0018714818	NCT00187148_18_T3	GENE	2	2	has
NCT0018714819	NCT00187148_19_T0	CELL	9	9	cells
NCT0018714819	NCT00187148_19_T1	GENE	13	14	envelope protein
NCT0018714820	NCT00187148_20_T0	GENE	12	12	envelope
NCT0018714820	NCT00187148_20_T1	PHENOTYPE	11	11	HIV
NCT0018714820	NCT00187148_20_T2	BIOLOGICAL_PROCESS	7	8	immune response
NCT0018714821	NCT00187148_21_T0	GENE	4	4	envelope
NCT0018714821	NCT00187148_21_T1	PHENOTYPE	2	2	HIV
NCT001871612	NCT00187161_2_T0	GENE	4	4	II
NCT001871612	NCT00187161_2_T1	GENE	6	6	III
NCT001871612	NCT00187161_2_T2	PHENOTYPE	10	10	B-ALL
NCT001871612	NCT00187161_2_T3	GENE	8	8	IV
NCT001871612	NCT00187161_2_T4	PHENOTYPE	0	1	Group B
NCT001871614	NCT00187161_4_T0	GENE	0	0	G-CSF
NCT001871619	NCT00187161_9_T0	GENE	0	0	G-CSF
NCT0018716111	NCT00187161_11_T0	GENE	0	0	G-CSF
NCT0018716113	NCT00187161_13_T0	GENE	6	6	IV
NCT0018716118	NCT00187161_18_T0	GENE	0	0	G-CSF
NCT001871743	NCT00187174_3_T0	GENE	2	2	has
NCT001871743	NCT00187174_3_T1	GENE	10	10	has
NCT001871870	NCT00187187_0_T0	GENE	1	1	II
NCT001871870	NCT00187187_0_T1	GENE	10	10	II
NCT001871870	NCT00187187_0_T2	PHENOTYPE	0	0	DAVID
NCT001871870	NCT00187187_0_T3	PHENOTYPE	8	8	DAVID
NCT001871875	NCT00187187_5_T0	PHENOTYPE	6	6	DAVID
NCT001871876	NCT00187187_6_T0	PHENOTYPE	19	19	CHF
NCT001871876	NCT00187187_6_T1	PHENOTYPE	11	11	DAVID
NCT001871877	NCT00187187_7_T0	GENE	14	14	II
NCT001871877	NCT00187187_7_T1	PHENOTYPE	10	10	DAVID
NCT001871877	NCT00187187_7_T2	PHENOTYPE	25	26	heart failure
NCT001871877	NCT00187187_7_T3	PHENOTYPE	32	33	heart failure
NCT001871877	NCT00187187_7_T4	PHENOTYPE	23	24	class III
NCT0018718710	NCT00187187_10_T0	GENE	12	12	AAI
NCT0018718710	NCT00187187_10_T1	PHENOTYPE	34	36	quality of life
NCT0018718712	NCT00187187_12_T0	PHENOTYPE	17	19	congestive heart failure
NCT0018718713	NCT00187187_13_T0	PHENOTYPE	1	1	CHF
NCT0018718713	NCT00187187_13_T1	PHENOTYPE	5	5	CHF
NCT0018718713	NCT00187187_13_T2	GENE	17	17	ACE
NCT0018718713	NCT00187187_13_T3	COMPOUND	13	13	digoxin
NCT0018718713	NCT00187187_13_T4	GENE	15	16	angiotensin-converting enzyme
NCT0018718714	NCT00187187_14_T0	PHENOTYPE	7	8	Heart Failure
NCT0018718715	NCT00187187_15_T0	PHENOTYPE	2	2	symptoms
NCT0018718715	NCT00187187_15_T1	PHENOTYPE	0	1	Heart Failure
NCT0018718716	NCT00187187_16_T0	PHENOTYPE	9	9	CHF
NCT0018718722	NCT00187187_22_T0	PHENOTYPE	0	2	Quality of life
NCT0018718725	NCT00187187_25_T0	PHENOTYPE	0	0	DAVID
NCT001872001	NCT00187200_1_T0	GENE	7	7	CRT
NCT001872262	NCT00187226_2_T0	PHENOTYPE	15	16	cognitive function
NCT001872265	NCT00187226_5_T0	PHENOTYPE	17	17	tumor
NCT001872265	NCT00187226_5_T1	PHENOTYPE	7	8	brain tumors
NCT001872265	NCT00187226_5_T2	PHENOTYPE	8	10	tumors in children
NCT001872267	NCT00187226_7_T0	PHENOTYPE	26	27	cognitive deficits
NCT001872910	NCT00187291_0_T0	ORGAN	15	15	Heart
NCT001872910	NCT00187291_0_T1	PHENOTYPE	6	6	EPS
NCT001872910	NCT00187291_0_T2	GENE	17	17	ABCD
NCT001872914	NCT00187291_4_T0	PHENOTYPE	4	5	ventricular tachyarrhythmia
NCT001872918	NCT00187291_8_T0	COMPOUND	25	25	VTEs
NCT001872918	NCT00187291_8_T1	PHENOTYPE	20	20	EPS
NCT001872918	NCT00187291_8_T2	PHENOTYPE	29	31	ischemic heart disease
NCT001872918	NCT00187291_8_T3	PHENOTYPE	38	40	sustained ventricular tachycardia
NCT001872919	NCT00187291_9_T0	PHENOTYPE	22	22	EPS
NCT0018729110	NCT00187291_10_T0	PHENOTYPE	23	23	EPS
NCT0018729111	NCT00187291_11_T0	PHENOTYPE	16	16	EPS
NCT0018729111	NCT00187291_11_T1	PHENOTYPE	35	35	EPS
NCT0018729112	NCT00187291_12_T0	COMPOUND	31	31	VTEs
NCT0018729112	NCT00187291_12_T1	PHENOTYPE	27	27	EPS
NCT0018729113	NCT00187291_13_T0	COMPOUND	30	30	VTEs
NCT0018729113	NCT00187291_13_T1	PHENOTYPE	26	26	EPS
NCT0018729114	NCT00187291_14_T0	PHENOTYPE	10	10	EPS
NCT0018729114	NCT00187291_14_T1	PHENOTYPE	24	24	EPS
NCT0018729115	NCT00187291_15_T0	PHENOTYPE	1	1	secondary
NCT0018729120	NCT00187291_20_T0	PHENOTYPE	0	2	Non-sustained ventricular tachycardia
NCT0018729120	NCT00187291_20_T1	PHENOTYPE	14	16	premature ventricular contractions
NCT0018729121	NCT00187291_21_T0	PHENOTYPE	8	8	symptoms
NCT0018729121	NCT00187291_21_T1	PHENOTYPE	10	10	palpitations
NCT0018729122	NCT00187291_22_T0	PHENOTYPE	7	7	symptoms
NCT0018729122	NCT00187291_22_T1	PHENOTYPE	10	10	palpitations
NCT0018729126	NCT00187291_26_T0	PHENOTYPE	2	2	judgement
NCT0018729126	NCT00187291_26_T1	ORGAN	20	20	heart
NCT0018729126	NCT00187291_26_T2	GENE	24	24	bpm
NCT0018729128	NCT00187291_28_T0	GENE	2	2	has
NCT0018729134	NCT00187291_34_T0	PHENOTYPE	5	5	EPS
NCT0018729134	NCT00187291_34_T1	GENE	3	3	had
NCT0018729134	NCT00187291_34_T2	GENE	2	2	has
NCT0018729136	NCT00187291_36_T0	GENE	2	2	has
NCT0018729136	NCT00187291_36_T1	PHENOTYPE	4	6	coronary artery disease
NCT0018729142	NCT00187291_42_T0	PHENOTYPE	7	7	flutter
NCT0018729142	NCT00187291_42_T1	GENE	2	2	has
NCT0018729142	NCT00187291_42_T2	PHENOTYPE	3	5	persistent atrial fibrillation
NCT0018729147	NCT00187291_47_T0	PHENOTYPE	10	10	symptoms
NCT0018729147	NCT00187291_47_T1	GENE	2	2	has
NCT0018729147	NCT00187291_47_T2	GENE	6	6	IV
NCT0018729147	NCT00187291_47_T3	PHENOTYPE	7	9	congestive heart failure
NCT0018729152	NCT00187291_52_T0	GENE	2	2	has
NCT0018729152	NCT00187291_52_T1	PHENOTYPE	9	10	acute illness
NCT0018729153	NCT00187291_53_T0	PHENOTYPE	7	7	syncope
NCT0018729153	NCT00187291_53_T1	GENE	2	2	has
NCT0018729153	NCT00187291_53_T2	GENE	17	17	ventricular
NCT0018729154	NCT00187291_54_T0	GENE	2	2	has
NCT0018729155	NCT00187291_55_T0	GENE	2	2	has
NCT001873042	NCT00187304_2_T0	ORGAN	7	8	aortic valve
NCT001873043	NCT00187304_3_T0	GENE	4	4	has
NCT001873047	NCT00187304_7_T0	GENE	2	2	has
NCT0018730411	NCT00187304_11_T0	GENE	4	4	balloon
NCT0018730412	NCT00187304_12_T0	GENE	1	1	has
NCT0018730412	NCT00187304_12_T1	ORGAN	18	19	Heart Valve
NCT0018730413	NCT00187304_13_T0	GENE	2	2	ASA
NCT0018730416	NCT00187304_16_T0	PHENOTYPE	5	5	endocarditis
NCT0018730419	NCT00187304_19_T0	GENE	1	1	has
NCT0018730420	NCT00187304_20_T0	PHENOTYPE	11	11	bleeding
NCT0018730420	NCT00187304_20_T1	PHENOTYPE	4	4	coagulopathy
NCT0018730420	NCT00187304_20_T2	PHENOTYPE	7	8	GI bleeding
NCT0018730421	NCT00187304_21_T0	PHENOTYPE	4	6	peripheral vascular disease
NCT0018730422	NCT00187304_22_T0	PHENOTYPE	4	4	anticoagulation
NCT0018730422	NCT00187304_22_T1	GENE	1	1	has
NCT0018730422	NCT00187304_22_T2	PHENOTYPE	3	3	chronic
NCT001873174	NCT00187317_4_T0	PHENOTYPE	1	1	stepping
NCT001873175	NCT00187317_5_T0	PHENOTYPE	13	13	falling
NCT001873175	NCT00187317_5_T1	PHENOTYPE	1	1	impairment
NCT001873176	NCT00187317_6_T0	PHENOTYPE	13	13	impairment
NCT001873176	NCT00187317_6_T1	PHENOTYPE	16	16	stepping
NCT001873179	NCT00187317_9_T0	PHENOTYPE	14	14	stepping
NCT001873301	NCT00187330_1_T0	GENE	18	18	dye
NCT001873301	NCT00187330_1_T1	GENE	27	27	dye
NCT001873301	NCT00187330_1_T2	COMPOUND	0	0	N-acetylcysteine
NCT001873301	NCT00187330_1_T3	GENE	1	1	has
NCT001873301	NCT00187330_1_T4	PHENOTYPE	9	10	kidney damage
NCT001873301	NCT00187330_1_T5	PHENOTYPE	14	15	kidney damage
NCT001873302	NCT00187330_2_T0	PHENOTYPE	2	2	hopes
NCT001873302	NCT00187330_2_T1	ORGAN	13	13	kidneys
NCT001873303	NCT00187330_3_T0	ORGAN	4	4	kidneys
NCT001873305	NCT00187330_5_T0	COMPOUND	6	6	N-acetylcysteine
NCT001873305	NCT00187330_5_T1	PHENOTYPE	13	14	kidney problems
NCT001873307	NCT00187330_7_T0	GENE	2	2	has
NCT001873308	NCT00187330_8_T0	COMPOUND	7	7	N-acetylcysteine
NCT001873309	NCT00187330_9_T0	COMPOUND	4	4	N-acetylcysteine
NCT0018733011	NCT00187330_11_T0	PHENOTYPE	18	18	progression
NCT0018733011	NCT00187330_11_T1	PHENOTYPE	21	21	dysfunction
NCT0018733011	NCT00187330_11_T2	GENE	31	31	dye
NCT0018733011	NCT00187330_11_T3	GENE	0	0	NAC
NCT0018733011	NCT00187330_11_T4	GENE	1	1	has
NCT0018733011	NCT00187330_11_T5	PHENOTYPE	6	6	recurrent
NCT0018733011	NCT00187330_11_T6	PHENOTYPE	7	8	cardiac events
NCT0018733011	NCT00187330_11_T7	PHENOTYPE	25	27	chronic renal failure
NCT0018733014	NCT00187330_14_T0	GENE	0	0	NAC
NCT0018733014	NCT00187330_14_T1	GENE	18	18	CPB
NCT0018733014	NCT00187330_14_T2	PHENOTYPE	28	28	dysfunction
NCT0018733015	NCT00187330_15_T0	GENE	21	21	bypass
NCT0018733015	NCT00187330_15_T1	GENE	9	9	NAC
NCT0018733015	NCT00187330_15_T2	GENE	8	8	IV
NCT0018733015	NCT00187330_15_T3	PHENOTYPE	14	14	dysfunction
NCT0018733016	NCT00187330_16_T0	PHENOTYPE	20	20	dysfunction
NCT0018733016	NCT00187330_16_T1	GENE	56	56	bypass
NCT0018733016	NCT00187330_16_T2	GENE	12	12	NAC
NCT0018733016	NCT00187330_16_T3	GENE	40	40	NAC
NCT0018733016	NCT00187330_16_T4	COMPOUND	27	27	creatinine
NCT0018733016	NCT00187330_16_T5	GENE	57	57	CPB
NCT0018733016	NCT00187330_16_T6	PHENOTYPE	50	51	renal insufficiency
NCT0018733018	NCT00187330_18_T0	GENE	4	4	IV
NCT0018733018	NCT00187330_18_T1	GENE	5	5	NAC
NCT0018733018	NCT00187330_18_T2	GENE	29	29	CPB
NCT0018733018	NCT00187330_18_T3	PHENOTYPE	24	25	renal failure
NCT0018733022	NCT00187330_22_T0	PHENOTYPE	27	28	renal insufficiency
NCT0018733025	NCT00187330_25_T0	GENE	7	7	NAC
NCT0018733025	NCT00187330_25_T1	GENE	6	6	IV
NCT0018733025	NCT00187330_25_T2	GENE	15	15	IV
NCT0018733026	NCT00187330_26_T0	GENE	23	23	bypass
NCT0018733026	NCT00187330_26_T1	GENE	8	8	NAC
NCT0018733027	NCT00187330_27_T0	GENE	31	31	CPB
NCT0018733027	NCT00187330_27_T1	GENE	45	45	CPB
NCT0018733027	NCT00187330_27_T2	GENE	27	27	IV
NCT0018733028	NCT00187330_28_T0	GENE	21	21	NAC
NCT0018733028	NCT00187330_28_T1	GENE	20	20	IV
NCT0018733032	NCT00187330_32_T0	GENE	20	20	has
NCT0018733033	NCT00187330_33_T0	GENE	13	13	NAC
NCT0018733033	NCT00187330_33_T1	GENE	20	20	NAC
NCT0018733033	NCT00187330_33_T2	PHENOTYPE	24	25	adverse events
NCT0018733035	NCT00187330_35_T0	GENE	9	9	NAC
NCT0018733035	NCT00187330_35_T1	COMPOUND	19	19	creatinine
NCT0018733035	NCT00187330_35_T2	GENE	27	27	CPB
NCT0018733035	NCT00187330_35_T3	ORGAN	18	18	serum
NCT0018733038	NCT00187330_38_T0	GENE	12	12	NAC
NCT0018733038	NCT00187330_38_T1	GENE	11	11	IV
NCT0018733038	NCT00187330_38_T2	PHENOTYPE	29	30	renal failure
NCT001873432	NCT00187343_2_T0	PHENOTYPE	7	8	breast cancer
NCT001873434	NCT00187343_4_T0	PHENOTYPE	6	6	acute
NCT001873434	NCT00187343_4_T1	PHENOTYPE	12	12	erythema
NCT001873434	NCT00187343_4_T2	PHENOTYPE	15	15	desquamation
NCT001873434	NCT00187343_4_T3	PHENOTYPE	7	8	skin toxicity
NCT001873436	NCT00187343_6_T0	GENE	27	27	RR
NCT001873436	NCT00187343_6_T1	PHENOTYPE	33	33	toxicity
NCT001873436	NCT00187343_6_T2	GENE	40	40	fold
NCT001873436	NCT00187343_6_T3	PHENOTYPE	23	23	acute
NCT001873436	NCT00187343_6_T4	PHENOTYPE	25	26	skin toxicity
NCT001873436	NCT00187343_6_T5	GENE	9	10	in excess
NCT001873438	NCT00187343_8_T0	GENE	10	10	fold
NCT001873438	NCT00187343_8_T1	PHENOTYPE	2	3	hot spot
NCT0018734312	NCT00187343_12_T0	PHENOTYPE	15	15	acute
NCT0018734312	NCT00187343_12_T1	PHENOTYPE	16	17	skin toxicity
NCT0018734314	NCT00187343_14_T0	PHENOTYPE	11	11	blocked
NCT0018734314	NCT00187343_14_T1	GENE	4	4	III
NCT0018734317	NCT00187343_17_T0	PHENOTYPE	23	23	acute
NCT0018734317	NCT00187343_17_T1	PHENOTYPE	0	0	Acute
NCT0018734317	NCT00187343_17_T2	PHENOTYPE	1	2	skin toxicity
NCT0018734317	NCT00187343_17_T3	PHENOTYPE	24	25	skin toxicity
NCT0018734318	NCT00187343_18_T0	PHENOTYPE	6	6	acute
NCT0018734318	NCT00187343_18_T1	PHENOTYPE	7	8	skin toxicity
NCT0018734320	NCT00187343_20_T0	PHENOTYPE	16	16	acute
NCT0018734320	NCT00187343_20_T1	PHENOTYPE	17	18	skin toxicity
NCT001873563	NCT00187356_3_T0	GENE	15	15	bypass
NCT001873563	NCT00187356_3_T1	ORGAN	7	7	grafts
NCT001873564	NCT00187356_4_T0	ORGAN	14	15	saphenous veins
NCT001873564	NCT00187356_4_T1	ORGAN	5	6	radial arteries
NCT001873565	NCT00187356_5_T0	ORGAN	3	4	radial arteries
NCT0018735610	NCT00187356_10_T0	PHENOTYPE	17	17	strategies
NCT0018735610	NCT00187356_10_T1	ORGAN	30	31	coronary artery
NCT0018735610	NCT00187356_10_T2	ORGAN	38	39	coronary artery
NCT0018735616	NCT00187356_16_T0	ORGAN	10	10	graft
NCT0018735616	NCT00187356_16_T1	ORGAN	13	14	saphenous veins
NCT0018735616	NCT00187356_16_T2	ORGAN	0	1	Radial artery
NCT0018735619	NCT00187356_19_T0	GENE	7	7	bypass
NCT0018735619	NCT00187356_19_T1	PHENOTYPE	18	19	coronary disease
NCT0018735619	NCT00187356_19_T2	ORGAN	5	6	coronary artery
NCT0018735619	NCT00187356_19_T3	PHENOTYPE	22	24	ventricular ejection fraction
NCT001873695	NCT00187369_5_T0	GENE	1	1	twins
NCT001873697	NCT00187369_7_T0	GENE	1	1	twins
NCT001873698	NCT00187369_8_T0	PHENOTYPE	1	2	fetal anomaly
NCT001873820	NCT00187382_0_T0	GENE	9	9	MACS
NCT001873820	NCT00187382_0_T1	PHENOTYPE	6	7	Preterm Birth
NCT001873822	NCT00187382_2_T0	PHENOTYPE	11	11	impairment
NCT001873824	NCT00187382_4_T0	PHENOTYPE	23	23	impairment
NCT001873824	NCT00187382_4_T1	PHENOTYPE	16	17	Infant Development
NCT001873950	NCT00187395_0_T0	PHENOTYPE	3	3	Hypertension
NCT001873952	NCT00187395_2_T0	PHENOTYPE	11	11	centres
NCT001874087	NCT00187408_7_T0	PHENOTYPE	12	12	complication
NCT0018740810	NCT00187408_10_T0	ORGAN	15	15	tibia
NCT0018740810	NCT00187408_10_T1	ORGAN	18	18	ankle
NCT0018740810	NCT00187408_10_T2	PHENOTYPE	12	12	fractures
NCT0018740810	NCT00187408_10_T3	ORGAN	16	16	fibula
NCT0018740810	NCT00187408_10_T4	PHENOTYPE	6	7	venous thromboembolism
NCT0018740812	NCT00187408_12_T0	ORGAN	8	8	tibia
NCT0018740812	NCT00187408_12_T1	ORGAN	11	11	ankle
NCT0018740812	NCT00187408_12_T2	PHENOTYPE	5	5	fractures
NCT0018740812	NCT00187408_12_T3	ORGAN	9	9	fibula
NCT0018740813	NCT00187408_13_T0	PHENOTYPE	9	9	injuries
NCT0018740813	NCT00187408_13_T1	PHENOTYPE	5	5	fractures
NCT0018740815	NCT00187408_15_T0	PHENOTYPE	12	12	DVT
NCT0018740815	NCT00187408_15_T1	PHENOTYPE	10	10	fractures
NCT0018740816	NCT00187408_16_T0	PHENOTYPE	8	8	distal
NCT0018740816	NCT00187408_16_T1	PHENOTYPE	5	5	thrombi
NCT0018740818	NCT00187408_18_T0	PHENOTYPE	17	17	fractures
NCT0018740819	NCT00187408_19_T0	PHENOTYPE	39	39	anticoagulation
NCT0018740820	NCT00187408_20_T0	PHENOTYPE	9	9	fractures
NCT0018740820	NCT00187408_20_T1	PHENOTYPE	18	19	adverse effects
NCT0018740822	NCT00187408_22_T0	ORGAN	21	21	tibia
NCT0018740822	NCT00187408_22_T1	ORGAN	24	24	ankle
NCT0018740822	NCT00187408_22_T2	PHENOTYPE	18	18	fractures
NCT0018740822	NCT00187408_22_T3	ORGAN	22	22	fibula
NCT0018740824	NCT00187408_24_T0	GENE	2	2	has
NCT0018740825	NCT00187408_25_T0	ORGAN	10	10	tibia
NCT0018740825	NCT00187408_25_T1	ORGAN	13	13	ankle
NCT0018740825	NCT00187408_25_T2	PHENOTYPE	7	7	fractures
NCT0018740825	NCT00187408_25_T3	ORGAN	11	11	fibula
NCT0018740825	NCT00187408_25_T4	ORGAN	5	6	lower extremity
NCT0018740828	NCT00187408_28_T0	COMPOUND	8	8	dalteparin
NCT0018740829	NCT00187408_29_T0	PHENOTYPE	10	10	bleeding
NCT0018740832	NCT00187408_32_T0	GENE	14	14	12
NCT0018740833	NCT00187408_33_T0	ORGAN	22	22	tibia
NCT0018740833	NCT00187408_33_T1	COMPOUND	12	12	dalteparin
NCT0018740833	NCT00187408_33_T2	ORGAN	25	25	ankle
NCT0018740833	NCT00187408_33_T3	PHENOTYPE	19	19	fractures
NCT0018740833	NCT00187408_33_T4	ORGAN	23	23	fibula
NCT0018740834	NCT00187408_34_T0	PHENOTYPE	9	9	injuries
NCT0018740834	NCT00187408_34_T1	COMPOUND	18	18	dalteparin
NCT0018740836	NCT00187408_36_T0	PHENOTYPE	21	21	arthritis
NCT0018740836	NCT00187408_36_T1	PHENOTYPE	25	25	analgesia
NCT0018740836	NCT00187408_36_T2	COMPOUND	2	2	aspirin
NCT0018740842	NCT00187408_42_T0	PHENOTYPE	7	8	venous thromboembolism
NCT0018740843	NCT00187408_43_T0	PHENOTYPE	9	9	DVT
NCT0018740843	NCT00187408_43_T1	PHENOTYPE	24	24	DVT
NCT0018740843	NCT00187408_43_T2	GENE	11	11	PE
NCT0018740843	NCT00187408_43_T3	GENE	14	14	PE
NCT0018740843	NCT00187408_43_T4	PHENOTYPE	23	23	proximal
NCT0018740843	NCT00187408_43_T5	PHENOTYPE	20	20	fracture
NCT0018740844	NCT00187408_44_T0	PHENOTYPE	1	1	DVT
NCT0018740844	NCT00187408_44_T1	PHENOTYPE	7	7	DVT
NCT0018740846	NCT00187408_46_T0	GENE	1	1	PE
NCT0018740847	NCT00187408_47_T0	COMPOUND	9	9	2
NCT0018740847	NCT00187408_47_T1	PHENOTYPE	2	2	DVT
NCT0018740847	NCT00187408_47_T2	PHENOTYPE	1	1	proximal
NCT0018740852	NCT00187408_52_T0	PHENOTYPE	6	6	bleeding
NCT0018740852	NCT00187408_52_T1	GENE	13	13	hematocrit
NCT0018740852	NCT00187408_52_T2	PHENOTYPE	0	0	Bleeding
NCT0018740857	NCT00187408_57_T0	PHENOTYPE	5	5	bleeding
NCT0018740857	NCT00187408_57_T1	PHENOTYPE	8	9	adverse events
NCT0018740860	NCT00187408_60_T0	PHENOTYPE	2	2	thrombosis
NCT0018740860	NCT00187408_60_T1	PHENOTYPE	28	28	regression
NCT0018740860	NCT00187408_60_T2	PHENOTYPE	8	8	fractures
NCT0018740860	NCT00187408_60_T3	ORGAN	6	7	lower extremity
NCT0018740861	NCT00187408_61_T0	GENE	33	33	OR
NCT0018740861	NCT00187408_61_T1	PHENOTYPE	53	53	complications
NCT0018740861	NCT00187408_61_T2	PHENOTYPE	25	25	fracture
NCT0018740861	NCT00187408_61_T3	PHENOTYPE	28	28	fracture
NCT0018740861	NCT00187408_61_T4	PHENOTYPE	52	52	fracture
NCT0018740861	NCT00187408_61_T5	GENE	16	16	hormone
NCT0018740861	NCT00187408_61_T6	PHENOTYPE	39	39	initiation
NCT0018740861	NCT00187408_61_T7	PHENOTYPE	8	8	obesity
NCT0018740861	NCT00187408_61_T8	COMPOUND	9	9	BMI
NCT0018740861	NCT00187408_61_T9	PHENOTYPE	11	12	varicose veins
NCT0018740862	NCT00187408_62_T0	GENE	1	1	SIZE
NCT0018740869	NCT00187408_69_T0	ORGAN	4	4	tibia
NCT0018740869	NCT00187408_69_T1	PHENOTYPE	1	1	fractures
NCT0018740870	NCT00187408_70_T0	PHENOTYPE	1	1	fractures
NCT0018740870	NCT00187408_70_T1	ORGAN	4	4	fibula
NCT0018740870	NCT00187408_70_T2	ORGAN	10	10	fibula
NCT001874212	NCT00187421_2_T0	ORGAN	10	10	graft
NCT001874212	NCT00187421_2_T1	ORGAN	18	18	graft
NCT001874212	NCT00187421_2_T2	PHENOTYPE	19	19	occlusion
NCT001874213	NCT00187421_3_T0	ORGAN	11	11	graft
NCT001874213	NCT00187421_3_T1	PHENOTYPE	20	20	stenoses
NCT001874217	NCT00187421_7_T0	ORGAN	22	22	graft
NCT001874217	NCT00187421_7_T1	COMPOUND	8	8	aspirin
NCT001874218	NCT00187421_8_T0	GENE	3	3	bypass
NCT001874218	NCT00187421_8_T1	ORGAN	9	9	graft
NCT001874218	NCT00187421_8_T2	PHENOTYPE	10	10	occlusions
NCT001874219	NCT00187421_9_T0	ORGAN	3	3	graft
NCT001874219	NCT00187421_9_T1	ORGAN	13	13	graft
NCT001874219	NCT00187421_9_T2	PHENOTYPE	14	14	anastomosis
NCT0018742111	NCT00187421_11_T0	GENE	8	8	bypass
NCT0018742111	NCT00187421_11_T1	ORGAN	23	23	graft
NCT0018742111	NCT00187421_11_T2	PHENOTYPE	13	14	false positives
NCT001874342	NCT00187434_2_T0	GENE	16	16	Bubble
NCT001874342	NCT00187434_2_T1	GENE	9	9	CPAP
NCT001874342	NCT00187434_2_T2	GENE	17	17	CPAP
NCT0018743410	NCT00187434_10_T0	GENE	2	2	CPAP
NCT0018743410	NCT00187434_10_T1	GENE	26	26	CPAP
NCT0018743420	NCT00187434_20_T0	GENE	2	2	ANOVA
NCT001874471	NCT00187447_1_T0	PHENOTYPE	27	27	complications
NCT001874471	NCT00187447_1_T1	PHENOTYPE	24	24	PDA
NCT001874471	NCT00187447_1_T2	COMPOUND	11	11	indomethacin
NCT001874473	NCT00187447_3_T0	GENE	15	15	0.2
NCT001874473	NCT00187447_3_T1	GENE	1	1	28
NCT001874473	NCT00187447_3_T2	GENE	26	26	hr
NCT001874473	NCT00187447_3_T3	COMPOUND	8	8	indomethacin
NCT001874473	NCT00187447_3_T4	COMPOUND	21	21	indomethacin
NCT001874473	NCT00187447_3_T5	COMPOUND	50	50	indomethacin
NCT001874473	NCT00187447_3_T6	BIOLOGICAL_PROCESS	3	3	gestation
NCT001874474	NCT00187447_4_T0	PHENOTYPE	12	12	PDA
NCT001874474	NCT00187447_4_T1	GENE	20	20	extended
NCT001874474	NCT00187447_4_T2	COMPOUND	23	23	indomethacin
NCT001874476	NCT00187447_6_T0	GENE	21	21	hr
NCT001874476	NCT00187447_6_T1	GENE	26	26	hr
NCT001874476	NCT00187447_6_T2	COMPOUND	16	16	indomethacin
NCT001874477	NCT00187447_7_T0	GENE	26	26	hr
NCT001874477	NCT00187447_7_T1	GENE	30	30	hr
NCT001874477	NCT00187447_7_T2	BIOLOGICAL_PROCESS	9	9	gestation
NCT001874477	NCT00187447_7_T3	COMPOUND	22	22	indomethacin
NCT001874478	NCT00187447_8_T0	GENE	29	29	hr
NCT001874478	NCT00187447_8_T1	BIOLOGICAL_PROCESS	8	8	gestation
NCT001874478	NCT00187447_8_T2	COMPOUND	21	21	indomethacin
NCT0018744711	NCT00187447_11_T0	COMPOUND	13	13	indomethacin
NCT0018744712	NCT00187447_12_T0	PHENOTYPE	5	5	PDA
NCT0018744712	NCT00187447_12_T1	COMPOUND	16	16	indomethacin
NCT0018744712	NCT00187447_12_T2	PHENOTYPE	2	4	patent ductus arteriosus
NCT0018744715	NCT00187447_15_T0	CELL	0	0	Platelets
NCT0018744716	NCT00187447_16_T0	PHENOTYPE	0	1	Chromosomal disorders
NCT0018744718	NCT00187447_18_T0	PHENOTYPE	1	2	congenital anomalies
NCT0018744720	NCT00187447_20_T0	COMPOUND	2	2	indomethacin
NCT0018744721	NCT00187447_21_T0	PHENOTYPE	0	1	Necrotizing enterocolitis
NCT001874601	NCT00187460_1_T0	PHENOTYPE	1	1	acute
NCT001874601	NCT00187460_1_T1	PHENOTYPE	15	15	Feedback
NCT001874601	NCT00187460_1_T2	PHENOTYPE	20	20	Feedback
NCT001874601	NCT00187460_1_T3	PHENOTYPE	17	18	Group B
NCT001874606	NCT00187460_6_T0	PHENOTYPE	13	13	CHF
NCT001874606	NCT00187460_6_T1	PHENOTYPE	22	22	acute
NCT001874606	NCT00187460_6_T2	PHENOTYPE	8	8	AMI
NCT001874606	NCT00187460_6_T3	PHENOTYPE	10	12	congestive heart failure
NCT001874606	NCT00187460_6_T4	PHENOTYPE	5	7	acute myocardial infarction
NCT0018746011	NCT00187460_11_T0	PHENOTYPE	5	5	Feedback
NCT0018746012	NCT00187460_12_T0	PHENOTYPE	23	23	CHF
NCT0018746012	NCT00187460_12_T1	PHENOTYPE	18	18	AMI
NCT0018746013	NCT00187460_13_T0	PHENOTYPE	24	24	CHF
NCT0018746013	NCT00187460_13_T1	GENE	14	14	CCS
NCT0018746013	NCT00187460_13_T2	PHENOTYPE	22	22	AMI
NCT0018746016	NCT00187460_16_T0	PHENOTYPE	12	12	CHF
NCT0018746016	NCT00187460_16_T1	PHENOTYPE	10	10	AMI
NCT0018746017	NCT00187460_17_T0	GENE	1	1	II
NCT0018746017	NCT00187460_17_T1	PHENOTYPE	7	7	Feedback
NCT0018746017	NCT00187460_17_T2	PHENOTYPE	12	12	Feedback
NCT0018746018	NCT00187460_18_T0	GENE	17	17	II
NCT0018746018	NCT00187460_18_T1	GENE	4	4	III
NCT0018746019	NCT00187460_19_T0	ORGAN	28	28	Heart
NCT0018746020	NCT00187460_20_T0	GENE	9	9	Dr
NCT0018746021	NCT00187460_21_T0	GENE	0	0	Tu
NCT0018746021	NCT00187460_21_T1	GENE	1	1	MD
NCT0018746021	NCT00187460_21_T2	GENE	2	2	PhD
NCT001874862	NCT00187486_2_T0	GENE	5	5	II
NCT0018748610	NCT00187486_10_T0	PHENOTYPE	9	9	epileptic
NCT0018748612	NCT00187486_12_T0	PHENOTYPE	0	1	Group B
NCT0018748617	NCT00187486_17_T0	GENE	3	3	MRI
NCT001874992	NCT00187499_2_T0	PHENOTYPE	15	15	asthmatics
NCT001874994	NCT00187499_4_T0	GENE	1	1	has
NCT001874996	NCT00187499_6_T0	COMPOUND	20	20	fluticasone
NCT001874996	NCT00187499_6_T1	GENE	18	18	BID
NCT001874997	NCT00187499_7_T0	PHENOTYPE	22	22	wheeze
NCT001874997	NCT00187499_7_T1	PHENOTYPE	23	23	dyspnea
NCT001874997	NCT00187499_7_T2	PHENOTYPE	19	19	cough
NCT001874997	NCT00187499_7_T3	PHENOTYPE	17	17	symptoms
NCT001874997	NCT00187499_7_T4	PHENOTYPE	25	26	chest tightness
NCT001875124	NCT00187512_4_T0	PHENOTYPE	15	15	progression
NCT001875125	NCT00187512_5_T0	PHENOTYPE	6	7	disease progression
NCT001875127	NCT00187512_7_T0	GENE	14	14	San
NCT001875127	NCT00187512_7_T1	GENE	25	25	saliva
NCT001875127	NCT00187512_7_T2	PHENOTYPE	7	8	HIV infection
NCT0018751211	NCT00187512_11_T0	PHENOTYPE	1	1	HIV
NCT0018751212	NCT00187512_12_T0	GENE	5	5	CD4
NCT0018751212	NCT00187512_12_T1	PHENOTYPE	1	1	HIV
NCT0018751212	NCT00187512_12_T2	CELL	6	6	T-cells
NCT0018751218	NCT00187512_18_T0	PHENOTYPE	14	15	oral candidiasis
NCT0018751218	NCT00187512_18_T1	PHENOTYPE	1	2	opportunistic infection
NCT0018751218	NCT00187512_18_T2	PHENOTYPE	7	8	opportunistic infection
NCT0018751220	NCT00187512_20_T0	GENE	6	6	interferon
NCT0018751220	NCT00187512_20_T1	PHENOTYPE	3	4	hepatitis C
NCT001875250	NCT00187525_0_T0	PHENOTYPE	9	11	Frontotemporal Lobar Degeneration
NCT001875252	NCT00187525_2_T0	PHENOTYPE	19	19	FTLD
NCT001875252	NCT00187525_2_T1	PHENOTYPE	14	15	Alzheimer's Disease
NCT001875253	NCT00187525_3_T0	PHENOTYPE	15	15	symptoms
NCT001875253	NCT00187525_3_T1	PHENOTYPE	0	0	Secondary
NCT001875254	NCT00187525_4_T0	PHENOTYPE	10	11	Alzheimer's disease
NCT001875381	NCT00187538_1_T0	PHENOTYPE	11	11	osteoporosis
NCT001875382	NCT00187538_2_T0	PHENOTYPE	12	12	osteoporosis
NCT001875383	NCT00187538_3_T0	BIOLOGICAL_PROCESS	12	12	metabolism
NCT001875384	NCT00187538_4_T0	COMPOUND	12	12	calcium
NCT001875384	NCT00187538_4_T1	PHENOTYPE	15	17	increased bone resorption
NCT001875387	NCT00187538_7_T0	GENE	1	1	soy
NCT001875387	NCT00187538_7_T1	GENE	9	9	soy
NCT001875388	NCT00187538_8_T0	COMPOUND	20	20	sodium
NCT001875388	NCT00187538_8_T1	COMPOUND	18	18	calcium
NCT001875389	NCT00187538_9_T0	COMPOUND	34	34	isoflavone
NCT001875389	NCT00187538_9_T1	GENE	21	21	soy
NCT0018753810	NCT00187538_10_T0	PHENOTYPE	12	12	Center
NCT0018753812	NCT00187538_12_T0	COMPOUND	21	21	calcium
NCT0018753812	NCT00187538_12_T1	BIOLOGICAL_PROCESS	22	22	metabolism
NCT0018753813	NCT00187538_13_T0	PHENOTYPE	21	21	osteoporosis
NCT0018753815	NCT00187538_15_T0	BIOLOGICAL_PROCESS	12	12	metabolism
NCT0018753816	NCT00187538_16_T0	COMPOUND	12	12	calcium
NCT0018753816	NCT00187538_16_T1	PHENOTYPE	15	17	increased bone resorption
NCT0018753819	NCT00187538_19_T0	GENE	1	1	soy
NCT0018753819	NCT00187538_19_T1	GENE	9	9	soy
NCT0018753820	NCT00187538_20_T0	COMPOUND	20	20	sodium
NCT0018753820	NCT00187538_20_T1	COMPOUND	18	18	calcium
NCT0018753821	NCT00187538_21_T0	COMPOUND	34	34	isoflavone
NCT0018753821	NCT00187538_21_T1	GENE	21	21	soy
NCT0018753822	NCT00187538_22_T0	PHENOTYPE	12	12	Center
NCT0018753824	NCT00187538_24_T0	COMPOUND	21	21	calcium
NCT0018753824	NCT00187538_24_T1	BIOLOGICAL_PROCESS	22	22	metabolism
NCT0018753825	NCT00187538_25_T0	PHENOTYPE	21	21	osteoporosis
NCT001875513	NCT00187551_3_T0	GENE	7	7	has
NCT0018755112	NCT00187551_12_T0	ORGAN	0	0	Plasma
NCT0018755112	NCT00187551_12_T1	PHENOTYPE	8	8	HIV
NCT001875641	NCT00187564_1_T0	ORGAN	28	28	kidneys
NCT001875641	NCT00187564_1_T1	ORGAN	27	27	eyes
NCT001875641	NCT00187564_1_T2	GENE	14	14	ROS
NCT001875641	NCT00187564_1_T3	GENE	23	23	ROS
NCT001875641	NCT00187564_1_T4	GENE	1	1	has
NCT001875641	NCT00187564_1_T5	COMPOUND	12	12	oxygen
NCT001875641	NCT00187564_1_T6	PHENOTYPE	35	36	oxidative stress
NCT001875641	NCT00187564_1_T7	PHENOTYPE	4	6	high blood sugar
NCT001875646	NCT00187564_6_T0	GENE	8	8	II
NCT001875649	NCT00187564_9_T0	COMPOUND	3	3	glucose
NCT001875771	NCT00187577_1_T0	ORGAN	20	20	eyelashes
NCT001875771	NCT00187577_1_T1	PHENOTYPE	9	9	glaucoma
NCT001875775	NCT00187577_5_T0	COMPOUND	7	7	latanoprost
NCT001875775	NCT00187577_5_T1	COMPOUND	9	9	bimatoprost
NCT0018757711	NCT00187577_11_T0	PHENOTYPE	15	15	Center
NCT001875904	NCT00187590_4_T0	GENE	4	4	ER
NCT001875905	NCT00187590_5_T0	PHENOTYPE	9	10	drug use
NCT001876032	NCT00187603_2_T0	PHENOTYPE	1	1	strategies
NCT001876036	NCT00187603_6_T0	PHENOTYPE	59	59	relapse
NCT001876036	NCT00187603_6_T1	COMPOUND	8	8	1
NCT001876036	NCT00187603_6_T2	COMPOUND	30	30	2
NCT001876036	NCT00187603_6_T3	GENE	71	71	CARA
NCT001876036	NCT00187603_6_T4	COMPOUND	44	44	3
NCT001876039	NCT00187603_9_T0	PHENOTYPE	1	1	strategies
NCT0018760313	NCT00187603_13_T0	PHENOTYPE	59	59	relapse
NCT0018760313	NCT00187603_13_T1	COMPOUND	8	8	1
NCT0018760313	NCT00187603_13_T2	COMPOUND	30	30	2
NCT0018760313	NCT00187603_13_T3	GENE	71	71	CARA
NCT0018760313	NCT00187603_13_T4	COMPOUND	44	44	3
NCT001876295	NCT00187629_5_T0	CELL	17	17	cells
NCT001876295	NCT00187629_5_T1	GENE	2	2	has
NCT001876295	NCT00187629_5_T2	GENE	11	11	FGF23
NCT001876296	NCT00187629_6_T0	PHENOTYPE	9	9	wasting
NCT001876296	NCT00187629_6_T1	PHENOTYPE	11	11	osteomalacia
NCT001876296	NCT00187629_6_T2	COMPOUND	15	15	calcitriol
NCT001876296	NCT00187629_6_T3	COMPOUND	8	8	phosphate
NCT001876296	NCT00187629_6_T4	PHENOTYPE	10	10	hypophosphatemia
NCT001876296	NCT00187629_6_T5	GENE	3	3	FGF23
NCT001876297	NCT00187629_7_T0	GENE	0	0	FGF23
NCT001876298	NCT00187629_8_T0	COMPOUND	9	9	phosphate
NCT001876298	NCT00187629_8_T1	GENE	5	5	FGF23
NCT0018762910	NCT00187629_10_T0	GENE	90	90	FG
NCT0018762910	NCT00187629_10_T1	COMPOUND	59	59	phosphate
NCT0018762910	NCT00187629_10_T2	COMPOUND	77	77	phosphate
NCT0018762910	NCT00187629_10_T3	COMPOUND	96	96	phosphate
NCT0018762910	NCT00187629_10_T4	ORGAN	46	46	serum
NCT0018762910	NCT00187629_10_T5	ORGAN	89	89	serum
NCT0018762910	NCT00187629_10_T6	GENE	20	20	FGF23
NCT0018762910	NCT00187629_10_T7	GENE	31	31	FGF23
NCT0018762910	NCT00187629_10_T8	GENE	56	56	FGF23
NCT0018762910	NCT00187629_10_T9	GENE	72	72	FGF23
NCT0018762910	NCT00187629_10_T10	COMPOUND	18	18	phosphorus
NCT0018762910	NCT00187629_10_T11	COMPOUND	34	34	phosphorus
NCT0018762910	NCT00187629_10_T12	PHENOTYPE	66	67	temporal pattern
NCT0018762910	NCT00187629_10_T13	PHENOTYPE	40	41	renal failure
NCT0018762911	NCT00187629_11_T0	ORGAN	17	17	serum
NCT0018762911	NCT00187629_11_T1	GENE	18	18	FGF23
NCT0018762911	NCT00187629_11_T2	COMPOUND	24	24	phosphorus
NCT0018762911	NCT00187629_11_T3	PHENOTYPE	33	34	renal insufficiency
NCT001876551	NCT00187655_1_T0	COMPOUND	18	18	cefotaxime
NCT001876551	NCT00187655_1_T1	GENE	8	8	OAT3
NCT001876551	NCT00187655_1_T2	GENE	29	29	OAT3
NCT001876556	NCT00187655_6_T0	GENE	18	18	OAT3
NCT001876559	NCT00187655_9_T0	BIOLOGICAL_PROCESS	1	1	transport
NCT0018765510	NCT00187655_10_T0	GENE	11	11	OAT7
NCT0018765510	NCT00187655_10_T1	GENE	8	8	OAT
NCT0018765510	NCT00187655_10_T2	GENE	9	9	1.5
NCT0018765511	NCT00187655_11_T0	COMPOUND	32	32	3
NCT0018765511	NCT00187655_11_T1	CELL	17	17	cells
NCT0018765511	NCT00187655_11_T2	GENE	2	2	OAT3
NCT0018765511	NCT00187655_11_T3	PHENOTYPE	15	15	proximal
NCT0018765511	NCT00187655_11_T4	GENE	0	0	OAT1
NCT0018765511	NCT00187655_11_T5	PHENOTYPE	31	31	elimination
NCT0018765513	NCT00187655_13_T0	COMPOUND	8	8	cefotaxime
NCT0018765513	NCT00187655_13_T1	GENE	15	15	OAT3
NCT0018765513	NCT00187655_13_T2	GENE	17	17	OAT1
NCT0018765513	NCT00187655_13_T3	GENE	9	9	has
NCT0018765515	NCT00187655_15_T0	PHENOTYPE	10	11	bacterial infections
NCT0018765516	NCT00187655_16_T0	GENE	3	3	1.2
NCT0018765516	NCT00187655_16_T1	GENE	9	9	has
NCT0018765517	NCT00187655_17_T0	COMPOUND	9	9	cefotaxime
NCT0018765517	NCT00187655_17_T1	COMPOUND	10	10	DACM
NCT0018765519	NCT00187655_19_T0	COMPOUND	3	3	cefotaxime
NCT0018765519	NCT00187655_19_T1	GENE	1	1	half-life
NCT0018765519	NCT00187655_19_T2	GENE	9	9	1.5
NCT0018765519	NCT00187655_19_T3	COMPOUND	5	5	DACM
NCT0018765521	NCT00187655_21_T0	COMPOUND	8	8	cefotaxime
NCT0018765521	NCT00187655_21_T1	CELL	13	13	cells
NCT0018765521	NCT00187655_21_T2	PHENOTYPE	25	25	nephrotoxicity
NCT0018765521	NCT00187655_21_T3	GENE	21	21	reduced
NCT0018765522	NCT00187655_22_T0	GENE	1	1	PMT
NCT0018765522	NCT00187655_22_T1	GENE	3	3	has
NCT0018765523	NCT00187655_23_T0	GENE	2	2	The
NCT0018765523	NCT00187655_23_T1	TISSUE	5	5	Membrane
NCT0018765524	NCT00187655_24_T0	GENE	7	7	OAT3
NCT0018765525	NCT00187655_25_T0	GENE	27	27	OAT3
NCT0018765525	NCT00187655_25_T1	BIOLOGICAL_PROCESS	20	20	transport
NCT0018765525	NCT00187655_25_T2	PHENOTYPE	14	14	encoded
NCT0018765525	NCT00187655_25_T3	COMPOUND	21	22	estrone sulfate
NCT0018765527	NCT00187655_27_T0	CELL	25	25	chromosomes
NCT0018765527	NCT00187655_27_T1	CELL	17	17	chromosome
NCT0018765528	NCT00187655_28_T0	GENE	8	8	OAT3
NCT0018765530	NCT00187655_30_T0	BIOLOGICAL_PROCESS	6	6	transport
NCT0018765530	NCT00187655_30_T1	COMPOUND	8	9	estrone sulfate
NCT0018765531	NCT00187655_31_T0	COMPOUND	23	23	cefotaxime
NCT0018765531	NCT00187655_31_T1	GENE	13	13	OAT3
NCT0018765531	NCT00187655_31_T2	PHENOTYPE	21	21	pharmacokinetics
NCT0018765534	NCT00187655_34_T0	GENE	5	5	OAT3
NCT0018765538	NCT00187655_38_T0	PHENOTYPE	7	8	hepatic dysfunction
NCT001876686	NCT00187668_6_T0	CELL	17	17	lymphocytes
NCT001876812	NCT00187681_2_T0	ORGAN	15	15	intestine
NCT001876812	NCT00187681_2_T1	GENE	5	5	Oct1
NCT001876812	NCT00187681_2_T2	ORGAN	13	13	liver
NCT001876812	NCT00187681_2_T3	GENE	8	8	reduced
NCT001876812	NCT00187681_2_T4	COMPOUND	9	9	metformin
NCT001876813	NCT00187681_3_T0	GENE	11	11	OCT1
NCT001876814	NCT00187681_4_T0	PHENOTYPE	4	4	reflected
NCT001876814	NCT00187681_4_T1	COMPOUND	16	16	metformin
NCT001876815	NCT00187681_5_T0	COMPOUND	3	3	metformin
NCT001876816	NCT00187681_6_T0	BIOLOGICAL_PROCESS	13	15	response to metformin
NCT0018768110	NCT00187681_10_T0	COMPOUND	2	2	glucose
NCT0018768111	NCT00187681_11_T0	COMPOUND	9	9	glucose
NCT0018768111	NCT00187681_11_T1	COMPOUND	13	13	glucose
NCT0018768111	NCT00187681_11_T2	PHENOTYPE	4	5	glucose concentration
NCT0018768111	NCT00187681_11_T3	PHENOTYPE	2	4	fasting blood glucose
NCT0018768112	NCT00187681_12_T0	COMPOUND	18	18	glucose
NCT0018768112	NCT00187681_12_T1	COMPOUND	10	10	metformin
NCT0018768112	NCT00187681_12_T2	PHENOTYPE	4	5	glucose concentration
NCT0018768112	NCT00187681_12_T3	PHENOTYPE	2	4	fasting blood glucose
NCT0018768113	NCT00187681_13_T0	COMPOUND	16	16	glucose
NCT0018768113	NCT00187681_13_T1	PHENOTYPE	17	17	concentrations
NCT0018768113	NCT00187681_13_T2	COMPOUND	8	8	metformin
NCT0018768114	NCT00187681_14_T0	COMPOUND	6	6	metformin
NCT0018768114	NCT00187681_14_T1	PHENOTYPE	9	10	glucose tolerance
NCT0018768115	NCT00187681_15_T0	COMPOUND	22	22	glucose
NCT0018768115	NCT00187681_15_T1	GENE	2	2	OCT1
NCT0018768115	NCT00187681_15_T2	GENE	34	34	16
NCT0018768116	NCT00187681_16_T0	GENE	12	12	16
NCT0018768116	NCT00187681_16_T1	COMPOUND	19	19	metformin
NCT0018768117	NCT00187681_17_T0	COMPOUND	3	3	metformin
NCT0018768117	NCT00187681_17_T1	PHENOTYPE	6	7	glucose tolerance
NCT0018768118	NCT00187681_18_T0	COMPOUND	32	32	glucose
NCT0018768118	NCT00187681_18_T1	PHENOTYPE	23	23	concentrations
NCT0018768118	NCT00187681_18_T2	TISSUE	27	27	tissues
NCT0018768118	NCT00187681_18_T3	TISSUE	41	41	tissues
NCT0018768118	NCT00187681_18_T4	ORGAN	45	45	liver
NCT0018768118	NCT00187681_18_T5	COMPOUND	22	22	metformin
NCT0018768118	NCT00187681_18_T6	GENE	9	9	OCT1
NCT0018768118	NCT00187681_18_T7	GENE	18	18	OCT1
NCT0018768118	NCT00187681_18_T8	PHENOTYPE	33	33	uptakes
NCT0018768118	NCT00187681_18_T9	PHENOTYPE	5	6	glucose tolerance
NCT0018768119	NCT00187681_19_T0	COMPOUND	4	4	metformin
NCT0018768119	NCT00187681_19_T1	PHENOTYPE	12	13	insulin levels
NCT0018768120	NCT00187681_20_T0	COMPOUND	10	10	glucose
NCT0018768120	NCT00187681_20_T1	PHENOTYPE	7	8	insulin levels
NCT0018768121	NCT00187681_21_T0	GENE	17	17	OCT1
NCT0018768121	NCT00187681_21_T1	COMPOUND	1	1	metformin
NCT0018768121	NCT00187681_21_T2	PHENOTYPE	11	12	insulin levels
NCT0018768122	NCT00187681_22_T0	GENE	23	23	Oct1
NCT0018768122	NCT00187681_22_T1	COMPOUND	4	4	metformin
NCT0018768122	NCT00187681_22_T2	COMPOUND	7	7	lactate
NCT0018768123	NCT00187681_23_T0	COMPOUND	15	15	glucose
NCT0018768123	NCT00187681_23_T1	GENE	7	7	OCT1
NCT0018768123	NCT00187681_23_T2	COMPOUND	12	12	metformin
NCT0018768124	NCT00187681_24_T0	PHENOTYPE	8	8	concentrations
NCT0018768124	NCT00187681_24_T1	GENE	16	16	OCT1
NCT0018768124	NCT00187681_24_T2	COMPOUND	10	10	metformin
NCT0018768124	NCT00187681_24_T3	ORGAN	6	6	plasma
NCT0018768124	NCT00187681_24_T4	COMPOUND	7	7	lactate
NCT0018768126	NCT00187681_26_T0	PHENOTYPE	25	25	concentrations
NCT0018768126	NCT00187681_26_T1	COMPOUND	9	9	metformin
NCT001877072	NCT00187707_2_T0	COMPOUND	36	36	gabapentin
NCT001877072	NCT00187707_2_T1	GENE	28	28	OCTN1
NCT001877072	NCT00187707_2_T2	GENE	30	30	OCTN2
NCT001877073	NCT00187707_3_T0	COMPOUND	18	18	gabapentin
NCT001877073	NCT00187707_3_T1	COMPOUND	34	34	gabapentin
NCT001877073	NCT00187707_3_T2	PHENOTYPE	33	33	elimination
NCT001877201	NCT00187720_1_T0	COMPOUND	35	35	metformin
NCT001877201	NCT00187720_1_T1	GENE	10	12	organic cation transporter
NCT001877209	NCT00187720_9_T0	COMPOUND	15	15	metformin
NCT0018772010	NCT00187720_10_T0	GENE	22	22	OCT2
NCT0018772010	NCT00187720_10_T1	COMPOUND	10	10	metformin
NCT0018772011	NCT00187720_11_T0	GENE	13	13	OCT2
NCT0018772011	NCT00187720_11_T1	GENE	20	20	reduced
NCT0018772011	NCT00187720_11_T2	COMPOUND	24	24	metformin
NCT001877332	NCT00187733_2_T0	PHENOTYPE	11	11	recruitment
NCT001877333	NCT00187733_3_T0	COMPOUND	25	25	carnitine
NCT001877333	NCT00187733_3_T1	GENE	22	22	OCTN2
NCT001877333	NCT00187733_3_T2	BIOLOGICAL_PROCESS	27	28	lipid metabolism
NCT001877333	NCT00187733_3_T3	GENE	18	21	organic cation transporter 2
NCT001877335	NCT00187733_5_T0	GENE	11	11	OCTN2
NCT001877335	NCT00187733_5_T1	GENE	25	25	OCTN2
NCT001877337	NCT00187733_7_T0	GENE	8	8	OCTN2
NCT001877339	NCT00187733_9_T0	GENE	8	8	reduced
NCT001877339	NCT00187733_9_T1	BIOLOGICAL_PROCESS	12	12	transport
NCT001877339	NCT00187733_9_T2	GENE	19	19	OCTN2
NCT0018773312	NCT00187733_12_T0	COMPOUND	30	30	carnitine
NCT0018773312	NCT00187733_12_T1	GENE	8	8	OCTN2
NCT0018773312	NCT00187733_12_T2	GENE	17	17	OCTN2
NCT001877461	NCT00187746_1_T0	COMPOUND	16	16	adefovir
NCT001877462	NCT00187746_2_T0	COMPOUND	8	8	adefovir
NCT001877462	NCT00187746_2_T1	PHENOTYPE	9	9	elimination
NCT001877465	NCT00187746_5_T0	PHENOTYPE	11	11	pharmacokinetics
NCT001877466	NCT00187746_6_T0	GENE	7	7	reduced
NCT001877468	NCT00187746_8_T0	ORGAN	5	5	kidney
NCT001877468	NCT00187746_8_T1	GENE	12	12	GFR
NCT001877468	NCT00187746_8_T2	PHENOTYPE	13	13	falls
NCT001877468	NCT00187746_8_T3	BIOLOGICAL_PROCESS	9	10	glomerular filtration
NCT001877469	NCT00187746_9_T0	GENE	7	7	has
NCT001877469	NCT00187746_9_T1	PHENOTYPE	15	17	adverse drug reactions
NCT0018774610	NCT00187746_10_T0	GENE	18	18	reduced
NCT0018774610	NCT00187746_10_T1	BIOLOGICAL_PROCESS	25	26	glomerular filtration
NCT0018774611	NCT00187746_11_T0	PHENOTYPE	8	8	pharmacokinetics
NCT0018774613	NCT00187746_13_T0	GENE	1	1	OAT1
NCT0018774614	NCT00187746_14_T0	GENE	19	19	had
NCT0018774614	NCT00187746_14_T1	GENE	24	24	OAT1
NCT0018774618	NCT00187746_18_T0	COMPOUND	19	19	adefovir
NCT0018774619	NCT00187746_19_T0	PHENOTYPE	14	14	attributable
NCT0018774619	NCT00187746_19_T1	COMPOUND	10	10	adefovir
NCT0018774619	NCT00187746_19_T2	GENE	2	2	saw
NCT0018774619	NCT00187746_19_T3	GENE	16	16	OAT1
NCT0018774619	NCT00187746_19_T4	PHENOTYPE	8	8	elimination
NCT0018774622	NCT00187746_22_T0	PHENOTYPE	14	14	elimination
NCT0018774626	NCT00187746_26_T0	COMPOUND	19	19	adefovir
NCT0018774626	NCT00187746_26_T1	PHENOTYPE	21	21	elimination
NCT0018774627	NCT00187746_27_T0	COMPOUND	9	9	adefovir
NCT0018774630	NCT00187746_30_T0	GENE	14	14	55
NCT0018774630	NCT00187746_30_T1	GENE	7	7	OR
NCT001877591	NCT00187759_1_T0	PHENOTYPE	4	6	soft tissue infections
NCT001877592	NCT00187759_2_T0	PHENOTYPE	3	3	infections
NCT001877593	NCT00187759_3_T0	PHENOTYPE	10	10	abscess
NCT001877594	NCT00187759_4_T0	PHENOTYPE	15	15	infections
NCT001877594	NCT00187759_4_T1	PHENOTYPE	4	4	resistant
NCT001877595	NCT00187759_5_T0	PHENOTYPE	13	15	soft tissue infections
NCT001877597	NCT00187759_7_T0	PHENOTYPE	3	3	infections
NCT001877597	NCT00187759_7_T1	PHENOTYPE	11	11	abscess
NCT0018775910	NCT00187759_10_T0	PHENOTYPE	11	11	abscess
NCT0018775911	NCT00187759_11_T0	PHENOTYPE	8	8	infections
NCT0018775911	NCT00187759_11_T1	PHENOTYPE	9	9	resolved
NCT0018775913	NCT00187759_13_T0	PHENOTYPE	7	7	abscesses
NCT0018775914	NCT00187759_14_T0	GENE	4	4	has
NCT0018775915	NCT00187759_15_T0	PHENOTYPE	3	4	allergic reactions
NCT0018775918	NCT00187759_18_T0	PHENOTYPE	16	16	resistant
NCT0018775920	NCT00187759_20_T0	PHENOTYPE	21	21	abscesses
NCT0018775920	NCT00187759_20_T1	GENE	6	6	has
NCT0018775921	NCT00187759_21_T0	PHENOTYPE	22	22	infections
NCT0018775922	NCT00187759_22_T0	PHENOTYPE	0	0	Elimination
NCT0018775922	NCT00187759_22_T1	PHENOTYPE	7	7	infections
NCT0018775925	NCT00187759_25_T0	PHENOTYPE	23	23	infections
NCT0018775927	NCT00187759_27_T0	PHENOTYPE	14	14	severity
NCT0018775928	NCT00187759_28_T0	PHENOTYPE	9	9	severity
NCT0018775928	NCT00187759_28_T1	PHENOTYPE	2	4	soft tissue infections
NCT0018775929	NCT00187759_29_T0	GENE	12	12	met
NCT0018775929	NCT00187759_29_T1	PHENOTYPE	26	26	abscess
NCT0018775929	NCT00187759_29_T2	PHENOTYPE	29	30	foreign body
NCT0018775930	NCT00187759_30_T0	PHENOTYPE	2	2	Abscess
NCT0018775930	NCT00187759_30_T1	PHENOTYPE	4	5	open wound
NCT0018775931	NCT00187759_31_T0	PHENOTYPE	9	10	Acute onset
NCT0018775933	NCT00187759_33_T0	PHENOTYPE	4	4	tenderness
NCT0018775933	NCT00187759_33_T1	PHENOTYPE	2	2	induration
NCT0018775933	NCT00187759_33_T2	PHENOTYPE	1	1	Erythema
NCT0018775951	NCT00187759_51_T0	PHENOTYPE	0	2	Malignant otitis externa
NCT0018775953	NCT00187759_53_T0	PHENOTYPE	3	3	wounds
NCT0018775953	NCT00187759_53_T1	PHENOTYPE	10	10	gangrene
NCT0018775953	NCT00187759_53_T2	PHENOTYPE	7	8	arterial insufficiency
NCT0018775953	NCT00187759_53_T3	PHENOTYPE	0	1	Ischemic ulcers
NCT0018775961	NCT00187759_61_T0	COMPOUND	4	4	cephalexin
NCT001877727	NCT00187772_7_T0	PHENOTYPE	41	41	trauma
NCT001877727	NCT00187772_7_T1	PHENOTYPE	13	14	stress symptoms
NCT001877727	NCT00187772_7_T2	PHENOTYPE	16	17	behavior problems
NCT001877852	NCT00187785_2_T0	GENE	17	17	has
NCT001877854	NCT00187785_4_T0	GENE	22	22	retained
NCT001877981	NCT00187798_1_T0	GENE	9	9	twins
NCT001877981	NCT00187798_1_T1	COMPOUND	4	4	metformin
NCT001877981	NCT00187798_1_T2	PHENOTYPE	19	19	heredity
NCT001877981	NCT00187798_1_T3	PHENOTYPE	24	24	elimination
NCT001877982	NCT00187798_2_T0	GENE	3	3	transporter
NCT001877982	NCT00187798_2_T1	COMPOUND	18	18	metformin
NCT001877984	NCT00187798_4_T0	PHENOTYPE	26	26	heredity
NCT001877984	NCT00187798_4_T1	PHENOTYPE	18	18	elimination
NCT001877985	NCT00187798_5_T0	PHENOTYPE	8	8	elimination
NCT001877986	NCT00187798_6_T0	GENE	16	16	twins
NCT001877986	NCT00187798_6_T1	GENE	29	29	cytochrome
NCT001877986	NCT00187798_6_T2	PHENOTYPE	12	12	elimination
NCT001877989	NCT00187798_9_T0	GENE	16	16	transporter
NCT0018779810	NCT00187798_10_T0	COMPOUND	11	11	metformin
NCT0018779811	NCT00187798_11_T0	BIOLOGICAL_PROCESS	10	10	metabolism
NCT0018779811	NCT00187798_11_T1	GENE	6	6	has
NCT0018779811	NCT00187798_11_T2	ORGAN	17	17	kidneys
NCT0018779811	NCT00187798_11_T3	GENE	14	14	secreted
NCT0018779813	NCT00187798_13_T0	COMPOUND	16	16	metformin
NCT0018779814	NCT00187798_14_T0	COMPOUND	10	10	creatinine
NCT0018779814	NCT00187798_14_T1	GENE	14	14	1.5
NCT0018779814	NCT00187798_14_T2	GENE	16	16	4.2
NCT0018779815	NCT00187798_15_T0	ORGAN	10	10	kidney
NCT0018779815	NCT00187798_15_T1	COMPOUND	25	25	metformin
NCT0018779816	NCT00187798_16_T0	GENE	10	10	twins
NCT0018779816	NCT00187798_16_T1	COMPOUND	5	5	metformin
NCT0018779816	NCT00187798_16_T2	PHENOTYPE	20	20	heredity
NCT0018779816	NCT00187798_16_T3	PHENOTYPE	25	25	elimination
NCT0018779817	NCT00187798_17_T0	COMPOUND	14	14	metformin
NCT001878111	NCT00187811_1_T0	GENE	9	9	delta
NCT001878112	NCT00187811_2_T0	PHENOTYPE	10	10	recruitment
NCT001878118	NCT00187811_8_T0	PHENOTYPE	41	41	restenosis
NCT001878118	NCT00187811_8_T1	GENE	32	32	has
NCT001878119	NCT00187811_9_T0	PHENOTYPE	28	28	complications
NCT001878119	NCT00187811_9_T1	PHENOTYPE	4	4	focused
NCT001878119	NCT00187811_9_T2	GENE	2	2	has
NCT001878119	NCT00187811_9_T3	GENE	17	17	has
NCT001878119	NCT00187811_9_T4	PHENOTYPE	36	37	malignant disease
NCT0018781114	NCT00187811_14_T0	GENE	11	11	has
NCT0018781114	NCT00187811_14_T1	CELL	5	7	smooth muscle cells
NCT0018781117	NCT00187811_17_T0	PHENOTYPE	25	25	complications
NCT0018781118	NCT00187811_18_T0	PHENOTYPE	14	14	restenosis
NCT0018781118	NCT00187811_18_T1	PHENOTYPE	11	11	abscence
NCT0018781119	NCT00187811_19_T0	GENE	20	20	balloon
NCT0018781119	NCT00187811_19_T1	PHENOTYPE	32	34	peripheral vascular disease
NCT001878241	NCT00187824_1_T0	PHENOTYPE	12	12	severity
NCT001878241	NCT00187824_1_T1	PHENOTYPE	36	36	sepsis
NCT001878241	NCT00187824_1_T2	PHENOTYPE	29	30	immune dysfunction
NCT001878241	NCT00187824_1_T3	PHENOTYPE	32	33	critically ill
NCT001878241	NCT00187824_1_T4	PHENOTYPE	38	40	multiple organ failure
NCT001878243	NCT00187824_3_T0	PHENOTYPE	29	29	sepsis
NCT001878243	NCT00187824_3_T1	PHENOTYPE	21	22	critically ill
NCT001878246	NCT00187824_6_T0	PHENOTYPE	36	36	pathology
NCT001878246	NCT00187824_6_T1	COMPOUND	15	15	2
NCT001878246	NCT00187824_6_T2	GENE	48	48	has
NCT001878246	NCT00187824_6_T3	PHENOTYPE	17	18	critically ill
NCT001878247	NCT00187824_7_T0	PHENOTYPE	9	9	ventilation
NCT001878247	NCT00187824_7_T1	PHENOTYPE	25	25	ventilation
NCT001878247	NCT00187824_7_T2	PHENOTYPE	76	76	dysfunction
NCT001878247	NCT00187824_7_T3	COMPOUND	49	49	3
NCT001878247	NCT00187824_7_T4	PHENOTYPE	38	38	Sepsis
NCT001878247	NCT00187824_7_T5	PHENOTYPE	89	89	Sepsis
NCT001878247	NCT00187824_7_T6	GENE	104	104	has
NCT001878247	NCT00187824_7_T7	PHENOTYPE	46	47	septic shock
NCT001878247	NCT00187824_7_T8	PHENOTYPE	55	56	septic shock
NCT001878247	NCT00187824_7_T9	PHENOTYPE	81	82	septic shock
NCT001878247	NCT00187824_7_T10	PHENOTYPE	43	44	severe sepsis
NCT001878247	NCT00187824_7_T11	PHENOTYPE	52	53	severe sepsis
NCT001878247	NCT00187824_7_T12	PHENOTYPE	73	74	severe sepsis
NCT001878248	NCT00187824_8_T0	ORGAN	4	4	liver
NCT001878248	NCT00187824_8_T1	PHENOTYPE	3	3	chronic
NCT0018783710	NCT00187837_10_T0	GENE	3	3	1.1
NCT0018783714	NCT00187837_14_T0	GENE	8	8	wil
NCT0018783717	NCT00187837_17_T0	COMPOUND	2	3	calcium hydroxide
NCT0018783718	NCT00187837_18_T0	COMPOUND	15	15	resin
NCT0018783725	NCT00187837_25_T0	GENE	0	0	Int
NCT0018783727	NCT00187837_27_T0	PHENOTYPE	2	2	caries
NCT0018783728	NCT00187837_28_T0	GENE	7	7	ed
NCT0018783731	NCT00187837_31_T0	ORGAN	13	13	teeth
NCT0018783739	NCT00187837_39_T0	GENE	1	1	Res
NCT0018783739	NCT00187837_39_T1	PHENOTYPE	0	0	Caries
NCT0018783742	NCT00187837_42_T0	GENE	1	1	Res
NCT0018783742	NCT00187837_42_T1	PHENOTYPE	0	0	Caries
NCT0018783745	NCT00187837_45_T0	GENE	1	1	Rev
NCT0018783745	NCT00187837_45_T1	GENE	4	4	Med
NCT0018783746	NCT00187837_46_T0	GENE	1	1	AF
NCT0018783747	NCT00187837_47_T0	PHENOTYPE	4	4	inflammation
NCT0018783748	NCT00187837_48_T0	GENE	10	10	HE
NCT0018783748	NCT00187837_48_T1	ORGAN	4	5	Dental pulp
NCT0018783751	NCT00187837_51_T0	GENE	8	8	abstract
NCT0018783752	NCT00187837_52_T0	GENE	0	0	Int
NCT0018783756	NCT00187837_56_T0	ORGAN	16	16	teeth
NCT0018783758	NCT00187837_58_T0	GENE	3	3	SO
NCT0018783759	NCT00187837_59_T0	ORGAN	8	8	molars
NCT0018783760	NCT00187837_60_T0	GENE	2	2	Ass
NCT0018783760	NCT00187837_60_T1	GENE	1	1	Int
NCT0018783772	NCT00187837_72_T0	PHENOTYPE	5	5	decayed
NCT0018783772	NCT00187837_72_T1	ORGAN	9	9	teeth
NCT0018783775	NCT00187837_75_T0	COMPOUND	1	1	O
NCT0018783779	NCT00187837_79_T0	PHENOTYPE	1	1	circulation
NCT0018783780	NCT00187837_80_T0	GENE	9	9	HE
NCT0018783780	NCT00187837_80_T1	ORGAN	4	5	Dental pulp
NCT0018783782	NCT00187837_82_T0	GENE	3	3	NM
NCT001878504	NCT00187850_4_T0	GENE	2	2	CAP-2
NCT001878506	NCT00187850_6_T0	GENE	4	4	1.1
NCT0018785010	NCT00187850_10_T0	COMPOUND	2	2	resin
NCT001878764	NCT00187876_4_T0	ORGAN	14	14	tendons
NCT001878764	NCT00187876_4_T1	ORGAN	13	13	allograft
NCT001878764	NCT00187876_4_T2	TISSUE	20	20	ligament
NCT001878765	NCT00187876_5_T0	GENE	4	4	ACL
NCT001878765	NCT00187876_5_T1	TISSUE	8	8	ligament
NCT001878765	NCT00187876_5_T2	TISSUE	1	3	anterior cruciate ligament
NCT001878766	NCT00187876_6_T0	ORGAN	11	11	tendon
NCT001878766	NCT00187876_6_T1	ORGAN	2	2	tendons
NCT001878766	NCT00187876_6_T2	ORGAN	1	1	allograft
NCT001878767	NCT00187876_7_T0	ORGAN	6	6	tendons
NCT001878769	NCT00187876_9_T0	ORGAN	7	7	tendon
NCT001878769	NCT00187876_9_T1	GENE	14	14	gamma
NCT0018787610	NCT00187876_10_T0	ORGAN	17	17	tendon
NCT0018787610	NCT00187876_10_T1	ORGAN	6	6	tendons
NCT001878891	NCT00187889_1_T0	ORGAN	12	12	heart
NCT001878891	NCT00187889_1_T1	ORGAN	8	9	blood vessels
NCT001878895	NCT00187889_5_T0	COMPOUND	5	5	aldosterone
NCT001878895	NCT00187889_5_T1	COMPOUND	7	7	eplerenone
NCT001878899	NCT00187889_9_T0	COMPOUND	23	23	eplerenone
NCT0018788911	NCT00187889_11_T0	ORGAN	4	4	serum
NCT0018788912	NCT00187889_12_T0	GENE	15	15	has
NCT0018788916	NCT00187889_16_T0	GENE	5	5	Carl
NCT0018788916	NCT00187889_16_T1	GENE	7	7	MD
NCT0018788916	NCT00187889_16_T2	GENE	12	12	MD
NCT0018788916	NCT00187889_16_T3	GENE	18	18	MD
NCT0018788916	NCT00187889_16_T4	GENE	24	24	MD
NCT0018788917	NCT00187889_17_T0	PHENOTYPE	24	24	anxious
NCT001879021	NCT00187902_1_T0	COMPOUND	2	2	N
NCT001879025	NCT00187902_5_T0	GENE	30	30	ml
NCT001879027	NCT00187902_7_T0	GENE	9	9	NAAT
NCT001879027	NCT00187902_7_T1	GENE	10	10	TMA
NCT001879027	NCT00187902_7_T2	GENE	23	23	TMA
NCT001879028	NCT00187902_8_T0	GENE	9	9	NAAT
NCT001879028	NCT00187902_8_T1	GENE	10	10	TMA
NCT001879028	NCT00187902_8_T2	GENE	29	29	TMA
NCT0018790210	NCT00187902_10_T0	GENE	1	1	NAAT
NCT0018790210	NCT00187902_10_T1	GENE	7	7	NAAT
NCT0018790210	NCT00187902_10_T2	BIOLOGICAL_PROCESS	8	8	transport
NCT0018790211	NCT00187902_11_T0	GENE	8	8	70
NCT0018790213	NCT00187902_13_T0	GENE	20	20	hr
NCT001879153	NCT00187915_3_T0	PHENOTYPE	13	13	MPA
NCT001879156	NCT00187915_6_T0	PHENOTYPE	0	0	MPA
NCT001879281	NCT00187928_1_T0	PHENOTYPE	6	6	OCD
NCT001879281	NCT00187928_1_T1	GENE	10	10	has
NCT001879283	NCT00187928_3_T0	PHENOTYPE	34	34	epilepsy
NCT001879283	NCT00187928_3_T1	PHENOTYPE	15	15	seizures
NCT001879283	NCT00187928_3_T2	GENE	1	1	has
NCT001879283	NCT00187928_3_T3	PHENOTYPE	36	37	Lennox-Gastaut Syndrome
NCT001879283	NCT00187928_3_T4	PHENOTYPE	17	19	generalized tonic-clonic seizures
NCT001879289	NCT00187928_9_T0	COMPOUND	17	17	topiramate
NCT0018792815	NCT00187928_15_T0	PHENOTYPE	14	14	OCD
NCT0018792816	NCT00187928_16_T0	COMPOUND	6	6	topiramate
NCT0018792818	NCT00187928_18_T0	PHENOTYPE	5	5	OCD
NCT0018792818	NCT00187928_18_T1	PHENOTYPE	29	29	Disorders
NCT0018792823	NCT00187928_23_T0	PHENOTYPE	5	5	symptoms
NCT0018792823	NCT00187928_23_T1	PHENOTYPE	11	11	severity
NCT0018792823	NCT00187928_23_T2	PHENOTYPE	4	4	OCD
NCT0018792823	NCT00187928_23_T3	PHENOTYPE	46	46	compulsions
NCT0018792823	NCT00187928_23_T4	PHENOTYPE	44	44	obsessions
NCT0018792823	NCT00187928_23_T5	GENE	43	43	has
NCT0018792832	NCT00187928_32_T0	COMPOUND	8	8	phencyclidine
NCT0018792832	NCT00187928_32_T1	COMPOUND	9	9	cocaine
NCT0018792841	NCT00187928_41_T0	PHENOTYPE	3	3	OCD
NCT0018792844	NCT00187928_44_T0	COMPOUND	26	26	nicotine
NCT0018792844	NCT00187928_44_T1	COMPOUND	28	28	caffeine
NCT0018792844	NCT00187928_44_T2	PHENOTYPE	29	29	dependence
NCT0018792844	NCT00187928_44_T3	PHENOTYPE	18	19	substance dependence
NCT0018792846	NCT00187928_46_T0	PHENOTYPE	9	10	bipolar disorders
NCT0018792846	NCT00187928_46_T1	PHENOTYPE	13	14	psychotic disorder
NCT0018792848	NCT00187928_48_T0	PHENOTYPE	10	10	borderline
NCT0018792848	NCT00187928_48_T1	PHENOTYPE	5	6	personality disorder
NCT0018792852	NCT00187928_52_T0	PHENOTYPE	16	16	OCD
NCT0018792852	NCT00187928_52_T1	COMPOUND	5	5	topiramate
NCT0018792856	NCT00187928_56_T0	PHENOTYPE	26	26	OCD
NCT0018792856	NCT00187928_56_T1	PHENOTYPE	14	15	systemic disease
NCT0018792860	NCT00187928_60_T0	COMPOUND	4	4	creatinine
NCT0018792862	NCT00187928_62_T0	ORGAN	4	4	liver
NCT0018792863	NCT00187928_63_T0	PHENOTYPE	2	2	progressive
NCT0018792863	NCT00187928_63_T1	PHENOTYPE	4	6	degenerative neurologic disorders
NCT001879412	NCT00187941_2_T0	ORGAN	0	0	Plasma
NCT001879417	NCT00187941_7_T0	PHENOTYPE	17	17	MPA
NCT001879419	NCT00187941_9_T0	ORGAN	4	4	transplant
NCT001879419	NCT00187941_9_T1	GENE	13	13	4.5
NCT0018794110	NCT00187941_10_T0	PHENOTYPE	12	12	MPA
NCT0018794111	NCT00187941_11_T0	GENE	19	19	pk
NCT0018794116	NCT00187941_16_T0	PHENOTYPE	12	12	toxicities
NCT0018794119	NCT00187941_19_T0	GENE	7	7	4.5
NCT0018794119	NCT00187941_19_T1	GENE	5	5	pk
NCT0018794121	NCT00187941_21_T0	ORGAN	10	10	graft
NCT0018794121	NCT00187941_21_T1	PHENOTYPE	13	15	delayed graft function
NCT0018794122	NCT00187941_22_T0	ORGAN	18	18	transplant
NCT001879544	NCT00187954_4_T0	GENE	24	24	CFR
NCT001879671	NCT00187967_1_T0	GENE	13	13	bypass
NCT001879671	NCT00187967_1_T1	ORGAN	24	25	coronary artery
NCT001879931	NCT00187993_1_T0	PHENOTYPE	19	19	osteopenia
NCT001879931	NCT00187993_1_T1	GENE	0	0	GH
NCT001879931	NCT00187993_1_T2	PHENOTYPE	24	25	life quality
NCT001879932	NCT00187993_2_T0	GENE	10	10	GH
NCT001879933	NCT00187993_3_T0	GENE	11	11	GH
NCT001879935	NCT00187993_5_T0	GENE	17	17	GH
NCT001879935	NCT00187993_5_T1	BIOLOGICAL_PROCESS	8	8	metabolism
NCT001880061	NCT00188006_1_T0	BIOLOGICAL_PROCESS	11	12	complement activation
NCT001880061	NCT00188006_1_T1	PHENOTYPE	15	16	brain injury
NCT001880061	NCT00188006_1_T2	ORGAN	23	24	coronary artery
NCT001880062	NCT00188006_2_T0	BIOLOGICAL_PROCESS	5	6	complement activation
NCT001880063	NCT00188006_3_T0	GENE	12	12	bypass
NCT001880063	NCT00188006_3_T1	CELL	8	8	astrocytes
NCT001880063	NCT00188006_3_T2	BIOLOGICAL_PROCESS	15	16	complement activation
NCT001880063	NCT00188006_3_T3	PHENOTYPE	22	23	adverse events
NCT001880064	NCT00188006_4_T0	GENE	16	16	bypass
NCT001880064	NCT00188006_4_T1	PHENOTYPE	20	20	dysfunction
NCT001880064	NCT00188006_4_T2	BIOLOGICAL_PROCESS	12	13	complement activation
NCT001880064	NCT00188006_4_T3	ORGAN	8	9	cerebral arteries
NCT001880191	NCT00188019_1_T0	PHENOTYPE	13	13	mutation
NCT001880191	NCT00188019_1_T1	GENE	12	12	SDH
NCT001880191	NCT00188019_1_T2	PHENOTYPE	23	23	pheochromocytoma
NCT001880191	NCT00188019_1_T3	PHENOTYPE	21	21	paraganglioma
NCT001880192	NCT00188019_2_T0	PHENOTYPE	32	32	mutation
NCT001880192	NCT00188019_2_T1	PHENOTYPE	18	18	tumors
NCT001880192	NCT00188019_2_T2	GENE	31	31	SDH
NCT001880320	NCT00188032_0_T0	PHENOTYPE	0	0	Strategies
NCT001880320	NCT00188032_0_T1	PHENOTYPE	3	4	Pulmonary Embolism
NCT001880322	NCT00188032_2_T0	GENE	18	18	PE
NCT001880323	NCT00188032_3_T0	PHENOTYPE	49	49	decisions
NCT001880323	NCT00188032_3_T1	PHENOTYPE	27	27	PDA
NCT001880323	NCT00188032_3_T2	PHENOTYPE	11	12	pulmonary embolism
NCT001880325	NCT00188032_5_T0	PHENOTYPE	16	16	centre
NCT001880326	NCT00188032_6_T0	GENE	14	14	fold
NCT001880326	NCT00188032_6_T1	PHENOTYPE	8	8	centres
NCT001880327	NCT00188032_7_T0	GENE	18	18	PE
NCT001880327	NCT00188032_7_T1	PHENOTYPE	21	21	PDA
NCT001880327	NCT00188032_7_T2	PHENOTYPE	3	3	centres
NCT001880328	NCT00188032_8_T0	GENE	22	22	PE
NCT001880328	NCT00188032_8_T1	PHENOTYPE	17	17	PDA
NCT001880328	NCT00188032_8_T2	PHENOTYPE	10	10	centres
NCT0018803217	NCT00188032_17_T0	PHENOTYPE	22	22	PDA
NCT0018803220	NCT00188032_20_T0	PHENOTYPE	8	9	Pulmonary Embolism
NCT0018803223	NCT00188032_23_T0	GENE	7	7	al
NCT0018803223	NCT00188032_23_T1	GENE	6	6	et
NCT0018803224	NCT00188032_24_T0	GENE	0	0	Med
NCT0018803227	NCT00188032_27_T0	PHENOTYPE	5	5	strategies
NCT0018803227	NCT00188032_27_T1	PHENOTYPE	11	12	pulmonary embolism
NCT0018803230	NCT00188032_30_T0	GENE	7	7	TM
NCT0018803230	NCT00188032_30_T1	GENE	1	1	HR
NCT0018803230	NCT00188032_30_T2	GENE	9	9	MH
NCT0018803231	NCT00188032_31_T0	PHENOTYPE	4	5	thromboembolic disease
NCT0018803234	NCT00188032_34_T0	GENE	7	7	al
NCT0018803234	NCT00188032_34_T1	GENE	6	6	et
NCT0018803234	NCT00188032_34_T2	PHENOTYPE	9	10	pulmonary embolism
NCT0018803235	NCT00188032_35_T0	GENE	2	2	Med
NCT0018803237	NCT00188032_37_T0	GENE	1	1	Gal
NCT0018803237	NCT00188032_37_T1	GENE	8	8	al
NCT0018803237	NCT00188032_37_T2	GENE	7	7	et
NCT0018803237	NCT00188032_37_T3	PHENOTYPE	20	21	pulmonary embolism
NCT0018803238	NCT00188032_38_T0	GENE	0	0	Ann
NCT0018803238	NCT00188032_38_T1	GENE	2	2	Med
NCT001880583	NCT00188058_3_T0	PHENOTYPE	10	11	tidal volume
NCT001880585	NCT00188058_5_T0	PHENOTYPE	9	9	strategies
NCT001880841	NCT00188084_1_T0	CELL	8	8	cells
NCT001880842	NCT00188084_2_T0	BIOLOGICAL_PROCESS	22	22	S-phase
NCT001880842	NCT00188084_2_T1	CELL	20	20	cells
NCT001880842	NCT00188084_2_T2	CELL	14	14	clone
NCT001880842	NCT00188084_2_T3	GENE	23	23	CD45
NCT001880845	NCT00188084_5_T0	PHENOTYPE	24	24	remission
NCT001881101	NCT00188110_1_T0	PHENOTYPE	15	16	colon tumors
NCT001881362	NCT00188136_2_T0	PHENOTYPE	3	3	remission
NCT001881363	NCT00188136_3_T0	PHENOTYPE	6	6	AML
NCT001881363	NCT00188136_3_T1	PHENOTYPE	25	25	complications
NCT001881365	NCT00188136_5_T0	PHENOTYPE	9	9	remission
NCT001881366	NCT00188136_6_T0	PHENOTYPE	26	26	AML
NCT001881368	NCT00188136_8_T0	PHENOTYPE	20	20	AML
NCT001881369	NCT00188136_9_T0	PHENOTYPE	15	15	AML
NCT0018813613	NCT00188136_13_T0	ORGAN	25	25	marrow
NCT0018813616	NCT00188136_16_T0	COMPOUND	5	5	1st
NCT0018813616	NCT00188136_16_T1	PHENOTYPE	13	13	conditioning
NCT0018813616	NCT00188136_16_T2	GENE	11	11	reduced
NCT0018813616	NCT00188136_16_T3	PHENOTYPE	2	2	aplasia
NCT0018813617	NCT00188136_17_T0	COMPOUND	14	14	2
NCT0018813617	NCT00188136_17_T1	COMPOUND	16	16	melphalan
NCT0018813617	NCT00188136_17_T2	COMPOUND	3	3	fludarabine
NCT0018813618	NCT00188136_18_T0	COMPOUND	9	9	2
NCT0018813618	NCT00188136_18_T1	GENE	1	1	globulin
NCT0018813619	NCT00188136_19_T0	ORGAN	1	1	grafts
NCT0018813622	NCT00188136_22_T0	PHENOTYPE	14	14	GVHD
NCT0018813622	NCT00188136_22_T1	GENE	9	9	tapered
NCT0018813623	NCT00188136_23_T0	PHENOTYPE	0	0	Acute
NCT0018813623	NCT00188136_23_T1	COMPOUND	11	11	tacrolimus
NCT0018813623	NCT00188136_23_T2	COMPOUND	8	8	prednisone
NCT0018813623	NCT00188136_23_T3	PHENOTYPE	2	2	chronic
NCT001881491	NCT00188149_1_T0	PHENOTYPE	7	7	toxicities
NCT001881491	NCT00188149_1_T1	PHENOTYPE	13	14	second cancers
NCT001881491	NCT00188149_1_T2	PHENOTYPE	9	10	late effects
NCT001881492	NCT00188149_2_T0	GENE	23	23	HL1
NCT001881492	NCT00188149_2_T1	GENE	41	41	HL3
NCT001881492	NCT00188149_2_T2	GENE	27	27	HL2
NCT001881496	NCT00188149_6_T0	PHENOTYPE	23	23	toxicity
NCT001881496	NCT00188149_6_T1	COMPOUND	15	15	bleomycin
NCT001881496	NCT00188149_6_T2	PHENOTYPE	27	27	leukemias
NCT001881496	NCT00188149_6_T3	COMPOUND	17	17	vincristine
NCT001881496	NCT00188149_6_T4	COMPOUND	13	13	procarbazine
NCT001881496	NCT00188149_6_T5	PHENOTYPE	26	26	secondary
NCT001881496	NCT00188149_6_T6	COMPOUND	14	14	prednisolone
NCT001881496	NCT00188149_6_T7	COMPOUND	10	10	cyclophosphamide
NCT001881496	NCT00188149_6_T8	COMPOUND	30	30	etoposide
NCT001881496	NCT00188149_6_T9	COMPOUND	12	12	dacarbazine
NCT001881499	NCT00188149_9_T0	PHENOTYPE	9	9	remission
NCT0018814920	NCT00188149_20_T0	GENE	2	2	CS
NCT0018814920	NCT00188149_20_T1	GENE	3	3	III
NCT001881883	NCT00188188_3_T0	PHENOTYPE	6	7	endothelial dysfunction
NCT001881884	NCT00188188_4_T0	ORGAN	8	9	brachial artery
NCT001881886	NCT00188188_6_T0	GENE	17	17	ACE
NCT001882011	NCT00188201_1_T0	COMPOUND	10	10	HCV
NCT001882012	NCT00188201_2_T0	PHENOTYPE	25	25	neuropathy
NCT001882012	NCT00188201_2_T1	COMPOUND	35	35	HCV
NCT001882012	NCT00188201_2_T2	PHENOTYPE	21	22	liver cirrhosis
NCT001882012	NCT00188201_2_T3	ORGAN	38	40	Central Nervous System
NCT001882013	NCT00188201_3_T0	PHENOTYPE	30	31	liver cirrhosis
NCT001882013	NCT00188201_3_T1	PHENOTYPE	19	20	thinking skills
NCT001882014	NCT00188201_4_T0	PHENOTYPE	9	10	thinking skills
NCT001882015	NCT00188201_5_T0	PHENOTYPE	8	8	fatigue
NCT001882015	NCT00188201_5_T1	PHENOTYPE	15	16	thinking skills
NCT001882016	NCT00188201_6_T0	PHENOTYPE	42	42	Hepatitis
NCT001882016	NCT00188201_6_T1	PHENOTYPE	10	11	viral hepatitis
NCT001882018	NCT00188201_8_T0	PHENOTYPE	9	9	forgetfulness
NCT001882018	NCT00188201_8_T1	COMPOUND	38	38	HCV
NCT001882018	NCT00188201_8_T2	PHENOTYPE	21	21	chronic
NCT001882018	NCT00188201_8_T3	GENE	16	16	fog
NCT001882018	NCT00188201_8_T4	PHENOTYPE	30	31	cognitive impairment
NCT001882019	NCT00188201_9_T0	PHENOTYPE	6	6	impairment
NCT001882019	NCT00188201_9_T1	PHENOTYPE	29	29	HBV
NCT001882019	NCT00188201_9_T2	PHENOTYPE	20	20	QOL
NCT001882019	NCT00188201_9_T3	PHENOTYPE	26	27	Hepatitis B
NCT001882019	NCT00188201_9_T4	PHENOTYPE	17	19	quality of life
NCT0018820110	NCT00188201_10_T0	PHENOTYPE	8	9	liver inflammation
NCT0018820111	NCT00188201_11_T0	COMPOUND	22	22	HCV
NCT0018820111	NCT00188201_11_T1	COMPOUND	35	35	HCV
NCT0018820111	NCT00188201_11_T2	PHENOTYPE	24	24	HBV
NCT0018820111	NCT00188201_11_T3	PHENOTYPE	19	19	QOL
NCT0018820111	NCT00188201_11_T4	PHENOTYPE	40	41	neurocognitive dysfunction
NCT0018820111	NCT00188201_11_T5	PHENOTYPE	9	11	quality of life
NCT0018820114	NCT00188201_14_T0	COMPOUND	5	5	choline
NCT0018820114	NCT00188201_14_T1	ORGAN	14	15	white matter
NCT0018820114	NCT00188201_14_T2	ORGAN	11	12	basal ganglia
NCT0018820117	NCT00188201_17_T0	COMPOUND	3	3	choline
NCT0018820117	NCT00188201_17_T1	PHENOTYPE	28	29	cognitive dysfunction
NCT0018820118	NCT00188201_18_T0	CELL	31	31	lymphocytes
NCT0018820118	NCT00188201_18_T1	COMPOUND	4	4	HCV
NCT0018820118	NCT00188201_18_T2	COMPOUND	18	18	HCV
NCT0018820119	NCT00188201_19_T0	PHENOTYPE	20	20	peripheral
NCT0018820119	NCT00188201_19_T1	GENE	13	13	strand
NCT0018820119	NCT00188201_19_T2	CELL	23	23	cells
NCT0018820119	NCT00188201_19_T3	COMPOUND	11	11	HCV
NCT0018820119	NCT00188201_19_T4	BIOLOGICAL_PROCESS	17	18	viral replication
NCT0018820121	NCT00188201_21_T0	CELL	40	40	lymphocytes
NCT0018820121	NCT00188201_21_T1	GENE	46	46	co
NCT0018820121	NCT00188201_21_T2	PHENOTYPE	22	22	co-infection
NCT0018820121	NCT00188201_21_T3	GENE	37	37	CD4
NCT0018820121	NCT00188201_21_T4	GENE	12	12	strand
NCT0018820121	NCT00188201_21_T5	GENE	34	34	strand
NCT0018820121	NCT00188201_21_T6	CELL	43	43	cells
NCT0018820121	NCT00188201_21_T7	GENE	42	42	CD19
NCT0018820121	NCT00188201_21_T8	GENE	39	39	CD8
NCT0018820121	NCT00188201_21_T9	COMPOUND	10	10	HCV
NCT0018820121	NCT00188201_21_T10	COMPOUND	18	18	HCV
NCT0018820121	NCT00188201_21_T11	COMPOUND	32	32	HCV
NCT0018820122	NCT00188201_22_T0	CELL	11	11	lymphocytes
NCT0018820122	NCT00188201_22_T1	COMPOUND	5	5	HCV
NCT0018820122	NCT00188201_22_T2	COMPOUND	26	26	HCV
NCT0018820122	NCT00188201_22_T3	PHENOTYPE	37	37	understood
NCT0018820125	NCT00188201_25_T0	PHENOTYPE	14	14	complications
NCT0018820125	NCT00188201_25_T1	PHENOTYPE	20	20	dysfunction
NCT0018820126	NCT00188201_26_T0	GENE	31	31	HAD
NCT0018820126	NCT00188201_26_T1	PHENOTYPE	1	1	symptoms
NCT0018820126	NCT00188201_26_T2	PHENOTYPE	13	13	toxoplasmosis
NCT0018820126	NCT00188201_26_T3	PHENOTYPE	22	22	dementia
NCT0018820126	NCT00188201_26_T4	PHENOTYPE	14	14	neoplasms
NCT0018820126	NCT00188201_26_T5	PHENOTYPE	7	8	opportunistic infection
NCT0018820126	NCT00188201_26_T6	PHENOTYPE	29	30	HIV dementia
NCT0018820127	NCT00188201_27_T0	GENE	3	3	HAD
NCT0018820127	NCT00188201_27_T1	GENE	4	4	has
NCT0018820128	NCT00188201_28_T0	CELL	21	21	monocytes
NCT0018820128	NCT00188201_28_T1	PHENOTYPE	20	20	peripheral
NCT0018820128	NCT00188201_28_T2	CELL	23	23	macrophages
NCT0018820128	NCT00188201_28_T3	ORGAN	27	28	blood-brain barrier
NCT0018820129	NCT00188201_29_T0	GENE	1	1	HAD
NCT0018820132	NCT00188201_32_T0	PHENOTYPE	4	4	damages
NCT0018820132	NCT00188201_32_T1	CELL	9	9	neurons
NCT0018820132	NCT00188201_32_T2	PHENOTYPE	2	3	metabolic encephalopathy
NCT0018820134	NCT00188201_34_T0	CELL	19	19	lymphocytes
NCT0018820134	NCT00188201_34_T1	PHENOTYPE	14	14	infiltration
NCT0018820134	NCT00188201_34_T2	COMPOUND	18	18	HCV
NCT0018820134	NCT00188201_34_T3	COMPOUND	23	23	HCV
NCT0018820134	NCT00188201_34_T4	COMPOUND	49	49	HCV
NCT0018820134	NCT00188201_34_T5	PHENOTYPE	43	43	chronic
NCT0018820134	NCT00188201_34_T6	PHENOTYPE	33	34	cognitive deficits
NCT0018820138	NCT00188201_38_T0	PHENOTYPE	16	16	impairment
NCT0018820138	NCT00188201_38_T1	COMPOUND	6	6	N-acetylaspartate
NCT0018820140	NCT00188201_40_T0	PHENOTYPE	14	14	chronic
NCT0018820140	NCT00188201_40_T1	PHENOTYPE	20	20	cryoglobulinemia
NCT0018820144	NCT00188201_44_T0	GENE	1	1	II
NCT0018820144	NCT00188201_44_T1	COMPOUND	13	13	HCV
NCT0018820144	NCT00188201_44_T2	COMPOUND	25	25	HCV
NCT0018820144	NCT00188201_44_T3	ORGAN	29	29	serum
NCT0018820144	NCT00188201_44_T4	PHENOTYPE	38	39	cognitive impairment
NCT0018820146	NCT00188201_46_T0	GENE	8	8	NP
NCT0018820146	NCT00188201_46_T1	GENE	28	28	NP
NCT0018820148	NCT00188201_48_T0	ORGAN	12	12	liver
NCT0018820148	NCT00188201_48_T1	GENE	24	24	1.5
NCT0018820148	NCT00188201_48_T2	PHENOTYPE	3	3	HBV
NCT0018820149	NCT00188201_49_T0	PHENOTYPE	22	22	sequelae
NCT0018820149	NCT00188201_49_T1	COMPOUND	8	8	HCV
NCT0018820149	NCT00188201_49_T2	GENE	26	26	Interferon
NCT0018820150	NCT00188201_50_T0	COMPOUND	9	9	ribavirin
NCT0018820150	NCT00188201_50_T1	COMPOUND	20	20	ribavirin
NCT0018820150	NCT00188201_50_T2	COMPOUND	5	5	HCV
NCT0018820150	NCT00188201_50_T3	GENE	7	7	Interferon
NCT0018820150	NCT00188201_50_T4	PHENOTYPE	29	29	chronic
NCT0018820151	NCT00188201_51_T0	COMPOUND	25	25	ribavirin
NCT0018820151	NCT00188201_51_T1	GENE	7	7	interferon
NCT0018820151	NCT00188201_51_T2	COMPOUND	13	14	polyethylene glycol
NCT0018820154	NCT00188201_54_T0	GENE	9	9	IFN
NCT0018820154	NCT00188201_54_T1	COMPOUND	12	12	ribavirin
NCT0018820155	NCT00188201_55_T0	GENE	21	21	Interferon
NCT0018820158	NCT00188201_58_T0	COMPOUND	7	7	HCV
NCT0018820158	NCT00188201_58_T1	PHENOTYPE	3	3	chronic
NCT0018820158	NCT00188201_58_T2	PHENOTYPE	10	10	chronic
NCT0018820158	NCT00188201_58_T3	PHENOTYPE	14	14	HBV
NCT0018820158	NCT00188201_58_T4	PHENOTYPE	4	5	Hepatitis C
NCT0018820158	NCT00188201_58_T5	PHENOTYPE	11	12	Hepatitis B
NCT0018820161	NCT00188201_61_T0	GENE	19	19	1.0
NCT0018820161	NCT00188201_61_T1	GENE	21	21	1.5
NCT0018820161	NCT00188201_61_T2	COMPOUND	7	7	HCV
NCT0018820165	NCT00188201_65_T0	PHENOTYPE	18	19	cognitive function
NCT0018820166	NCT00188201_66_T0	GENE	13	13	TSH
NCT0018820166	NCT00188201_66_T1	GENE	12	12	Bl2
NCT0018820166	NCT00188201_66_T2	GENE	9	9	Hb
NCT0018820166	NCT00188201_66_T3	GENE	15	15	INR
NCT0018820167	NCT00188201_67_T0	COMPOUND	3	3	HCV
NCT0018820167	NCT00188201_67_T1	PHENOTYPE	5	5	HBV
NCT0018820167	NCT00188201_67_T2	PHENOTYPE	18	19	liver disease
NCT0018820168	NCT00188201_68_T0	PHENOTYPE	0	0	HBV
NCT0018820171	NCT00188201_71_T0	PHENOTYPE	22	22	hypesthesia
NCT0018820171	NCT00188201_71_T1	PHENOTYPE	20	20	dysesthesia
NCT0018820171	NCT00188201_71_T2	PHENOTYPE	18	18	cryoglobulinemia
NCT0018820171	NCT00188201_71_T3	PHENOTYPE	24	24	weakness
NCT0018820171	NCT00188201_71_T4	ORGAN	27	27	tendon
NCT0018820171	NCT00188201_71_T5	PHENOTYPE	10	11	peripheral neuropathy
NCT0018820171	NCT00188201_71_T6	PHENOTYPE	31	32	pyramidal signs
NCT0018820172	NCT00188201_72_T0	GENE	28	28	Interferon
NCT0018820174	NCT00188201_74_T0	PHENOTYPE	12	13	cognitive function
NCT0018820174	NCT00188201_74_T1	PHENOTYPE	15	16	Major Depression
NCT0018820174	NCT00188201_74_T2	PHENOTYPE	19	20	Substance Abuse
NCT0018820174	NCT00188201_74_T3	PHENOTYPE	17	18	Bipolar Disorder
NCT0018820174	NCT00188201_74_T4	PHENOTYPE	22	24	Antisocial Personality Disorder
NCT001882143	NCT00188214_3_T0	PHENOTYPE	10	10	tumour
NCT001882147	NCT00188214_7_T0	PHENOTYPE	21	21	tumor
NCT001882147	NCT00188214_7_T1	PHENOTYPE	34	34	tumor
NCT001882147	NCT00188214_7_T2	PHENOTYPE	14	14	General
NCT001882147	NCT00188214_7_T3	ORGAN	22	22	microvasculature
NCT001882148	NCT00188214_8_T0	PHENOTYPE	7	7	tumor
NCT001882149	NCT00188214_9_T0	GENE	12	12	PI
NCT001882149	NCT00188214_9_T1	GENE	24	24	PI
NCT0018821411	NCT00188214_11_T0	GENE	42	42	CR
NCT0018821411	NCT00188214_11_T1	GENE	45	45	CR
NCT0018821413	NCT00188214_13_T0	GENE	43	43	CR
NCT0018821413	NCT00188214_13_T1	GENE	46	46	CR
NCT001882274	NCT00188227_4_T0	PHENOTYPE	17	17	complications
NCT001882274	NCT00188227_4_T1	GENE	11	11	has
NCT001882274	NCT00188227_4_T2	ORGAN	9	10	bone marrow
NCT001882275	NCT00188227_5_T0	PHENOTYPE	16	16	punctures
NCT001882401	NCT00188240_1_T0	PHENOTYPE	8	9	hepatitis C
NCT001882401	NCT00188240_1_T1	PHENOTYPE	3	4	insulin resistance
NCT001882402	NCT00188240_2_T0	PHENOTYPE	23	24	liver disease
NCT001882402	NCT00188240_2_T1	PHENOTYPE	16	17	hepatitis C
NCT001882402	NCT00188240_2_T2	PHENOTYPE	11	12	insulin resistance
NCT001882404	NCT00188240_4_T0	GENE	12	12	has
NCT001882404	NCT00188240_4_T1	PHENOTYPE	6	7	hepatitis C
NCT001882404	NCT00188240_4_T2	PHENOTYPE	10	11	insulin resistance
NCT001882407	NCT00188240_7_T0	PHENOTYPE	12	13	chronic hepatitis
NCT001882407	NCT00188240_7_T1	PHENOTYPE	17	18	chronic hepatitis
NCT001882407	NCT00188240_7_T2	PHENOTYPE	18	19	hepatitis B
NCT001882407	NCT00188240_7_T3	PHENOTYPE	13	14	hepatitis C
NCT001882407	NCT00188240_7_T4	PHENOTYPE	5	6	insulin resistance
NCT001882408	NCT00188240_8_T0	PHENOTYPE	8	9	chronic hepatitis
NCT001882408	NCT00188240_8_T1	PHENOTYPE	9	10	hepatitis C
NCT001882408	NCT00188240_8_T2	PHENOTYPE	1	2	insulin resistance
NCT001882409	NCT00188240_9_T0	GENE	2	2	has
NCT0018824010	NCT00188240_10_T0	PHENOTYPE	22	22	cirrhosis
NCT0018824010	NCT00188240_10_T1	PHENOTYPE	31	31	cirrhosis
NCT0018824010	NCT00188240_10_T2	PHENOTYPE	28	29	hepatitis B
NCT0018824010	NCT00188240_10_T3	PHENOTYPE	19	20	hepatitis C
NCT0018824010	NCT00188240_10_T4	PHENOTYPE	18	19	chronic hepatitis
NCT0018824010	NCT00188240_10_T5	PHENOTYPE	27	28	chronic hepatitis
NCT0018824010	NCT00188240_10_T6	PHENOTYPE	13	14	insulin resistance
NCT0018824012	NCT00188240_12_T0	PHENOTYPE	10	11	hepatitis C
NCT0018824012	NCT00188240_12_T1	PHENOTYPE	3	4	insulin resistance
NCT0018824014	NCT00188240_14_T0	PHENOTYPE	18	19	increased insulin
NCT0018824014	NCT00188240_14_T1	PHENOTYPE	6	7	hepatitis C
NCT0018824014	NCT00188240_14_T2	PHENOTYPE	19	20	insulin resistance
NCT0018824015	NCT00188240_15_T0	PHENOTYPE	2	2	HBV
NCT0018824020	NCT00188240_20_T0	PHENOTYPE	25	26	Group B
NCT0018824022	NCT00188240_22_T0	GENE	4	4	sc
NCT0018824022	NCT00188240_22_T1	GENE	10	10	0.5
NCT0018824022	NCT00188240_22_T2	GENE	43	43	bid
NCT0018824022	NCT00188240_22_T3	GENE	20	20	po
NCT0018824028	NCT00188240_28_T0	COMPOUND	19	19	BMI
NCT0018824028	NCT00188240_28_T1	TISSUE	12	13	body fat
NCT0018824029	NCT00188240_29_T0	COMPOUND	27	27	glucose
NCT0018824029	NCT00188240_29_T1	GENE	25	25	insulin
NCT0018824029	NCT00188240_29_T2	PHENOTYPE	16	17	insulin resistance
NCT0018824030	NCT00188240_30_T0	COMPOUND	12	12	HCV
NCT0018824031	NCT00188240_31_T0	COMPOUND	23	23	HCV
NCT0018824032	NCT00188240_32_T0	COMPOUND	8	8	HCV
NCT0018824032	NCT00188240_32_T1	PHENOTYPE	15	15	SVR
NCT0018824033	NCT00188240_33_T0	PHENOTYPE	12	12	SVR
NCT0018824034	NCT00188240_34_T0	PHENOTYPE	12	12	SVR
NCT0018824035	NCT00188240_35_T0	PHENOTYPE	16	16	SVR
NCT0018824035	NCT00188240_35_T1	PHENOTYPE	17	17	SVR
NCT0018824035	NCT00188240_35_T2	PHENOTYPE	6	7	insulin resistance
NCT0018824036	NCT00188240_36_T0	GENE	10	10	4-8
NCT0018824037	NCT00188240_37_T0	GENE	10	10	PCR
NCT0018824037	NCT00188240_37_T1	GENE	19	19	PCR
NCT0018824038	NCT00188240_38_T0	PHENOTYPE	14	15	Group B
NCT0018824039	NCT00188240_39_T0	GENE	11	11	PCR
NCT0018824039	NCT00188240_39_T1	GENE	20	20	PCR
NCT0018824041	NCT00188240_41_T0	ORGAN	4	4	serum
NCT0018824041	NCT00188240_41_T1	GENE	7	7	PCR
NCT0018824042	NCT00188240_42_T0	COMPOUND	4	4	HCV
NCT0018824043	NCT00188240_43_T0	COMPOUND	4	4	HCV
NCT001882530	NCT00188253_0_T0	PHENOTYPE	18	18	Carcinoma
NCT001882530	NCT00188253_0_T1	PHENOTYPE	15	16	Nasopharyngeal Carcinoma
NCT001882533	NCT00188253_3_T0	GENE	10	10	MRI
NCT001882534	NCT00188253_4_T0	GENE	16	16	has
NCT001882537	NCT00188253_7_T0	CELL	1	1	cells
NCT001882537	NCT00188253_7_T1	CELL	10	10	cells
NCT001882537	NCT00188253_7_T2	BIOLOGICAL_PROCESS	17	17	metabolism
NCT001882538	NCT00188253_8_T0	COMPOUND	8	8	glucose
NCT001882538	NCT00188253_8_T1	CELL	2	2	cells
NCT001882538	NCT00188253_8_T2	CELL	16	16	cells
NCT001882539	NCT00188253_9_T0	COMPOUND	7	7	glucose
NCT001882539	NCT00188253_9_T1	CELL	15	15	cells
NCT0018825312	NCT00188253_12_T0	GENE	27	27	Barr
NCT0018825312	NCT00188253_12_T1	PHENOTYPE	26	26	Epstein
NCT0018825314	NCT00188253_14_T0	PHENOTYPE	22	23	disease course
NCT0018825314	NCT00188253_14_T1	PHENOTYPE	25	26	nasopharyngeal cancer
NCT0018825317	NCT00188253_17_T0	PHENOTYPE	2	3	nasopharyngeal carcinoma
NCT0018825318	NCT00188253_18_T0	GENE	0	0	MRI
NCT0018825318	NCT00188253_18_T1	PHENOTYPE	12	13	nasopharyngeal carcinoma
NCT0018825319	NCT00188253_19_T0	GENE	14	14	MRI
NCT0018825321	NCT00188253_21_T0	PHENOTYPE	10	10	recurrence
NCT0018825321	NCT00188253_21_T1	GENE	20	20	MRI
NCT0018825321	NCT00188253_21_T2	PHENOTYPE	12	13	residual disease
NCT0018825325	NCT00188253_25_T0	GENE	13	13	MRI
NCT0018825325	NCT00188253_25_T1	PHENOTYPE	21	22	recurrent disease
NCT0018825326	NCT00188253_26_T0	PHENOTYPE	20	20	tumor
NCT0018825326	NCT00188253_26_T1	PHENOTYPE	27	28	tumor recurrence
NCT0018825327	NCT00188253_27_T0	GENE	13	13	MRI
NCT0018825327	NCT00188253_27_T1	PHENOTYPE	22	23	recurrent disease
NCT0018825333	NCT00188253_33_T0	PHENOTYPE	2	3	metastatic disease
NCT0018825337	NCT00188253_37_T0	GENE	15	15	MD
NCT0018825337	NCT00188253_37_T1	PHENOTYPE	6	6	claustrophobia
NCT001882661	NCT00188266_1_T0	PHENOTYPE	10	11	gastric cancer
NCT001882662	NCT00188266_2_T0	PHENOTYPE	8	8	toxicity
NCT001882662	NCT00188266_2_T1	PHENOTYPE	7	7	acute
NCT001882662	NCT00188266_2_T2	GENE	5	5	has
NCT001882662	NCT00188266_2_T3	PHENOTYPE	19	20	gastric cancer
NCT001882669	NCT00188266_9_T0	GENE	17	17	had
NCT001882669	NCT00188266_9_T1	TISSUE	10	11	lymph nodes
NCT0018826610	NCT00188266_10_T0	PHENOTYPE	19	21	quality of life
NCT001882793	NCT00188279_3_T0	PHENOTYPE	12	12	cancers
NCT001882798	NCT00188279_8_T0	ORGAN	18	18	thorax
NCT001882798	NCT00188279_8_T1	PHENOTYPE	9	9	nodules
NCT001882798	NCT00188279_8_T2	GENE	1	1	CXR
NCT001882799	NCT00188279_9_T0	PHENOTYPE	5	5	nodules
NCT001882799	NCT00188279_9_T1	GENE	7	7	CXR
NCT001882799	NCT00188279_9_T2	GENE	20	20	CXR
NCT0018827910	NCT00188279_10_T0	PHENOTYPE	27	27	nodules
NCT0018827910	NCT00188279_10_T1	ORGAN	8	8	Thorax
NCT0018827910	NCT00188279_10_T2	GENE	29	29	CXR
NCT0018827910	NCT00188279_10_T3	PHENOTYPE	36	37	lung cancers
NCT0018827910	NCT00188279_10_T4	PHENOTYPE	16	17	lung cancer
NCT0018827911	NCT00188279_11_T0	PHENOTYPE	24	24	nodule
NCT0018827912	NCT00188279_12_T0	PHENOTYPE	23	23	nodule
NCT001882920	NCT00188292_0_T0	PHENOTYPE	3	4	Anal Cancer
NCT001882922	NCT00188292_2_T0	PHENOTYPE	6	6	HIV
NCT001882922	NCT00188292_2_T1	PHENOTYPE	12	12	HIV
NCT001882922	NCT00188292_2_T2	GENE	2	2	has
NCT001882922	NCT00188292_2_T3	PHENOTYPE	0	1	Anal cancer
NCT001882923	NCT00188292_3_T0	PHENOTYPE	1	2	anal cancer
NCT001882925	NCT00188292_5_T0	GENE	15	15	has
NCT001882925	NCT00188292_5_T1	PHENOTYPE	12	13	anal cancer
NCT001882925	NCT00188292_5_T2	PHENOTYPE	19	20	cervical cancer
NCT001882927	NCT00188292_7_T0	PHENOTYPE	10	11	anal cancer
NCT001882929	NCT00188292_9_T0	PHENOTYPE	19	19	HRA
NCT0018829210	NCT00188292_10_T0	ORGAN	8	8	anus
NCT0018829210	NCT00188292_10_T1	PHENOTYPE	0	0	HRA
NCT0018829214	NCT00188292_14_T0	PHENOTYPE	6	6	HIV
NCT0018829214	NCT00188292_14_T1	GENE	2	2	has
NCT0018829217	NCT00188292_17_T0	PHENOTYPE	10	11	anal cancer
NCT0018829225	NCT00188292_25_T0	PHENOTYPE	13	14	high grade
NCT0018829226	NCT00188292_26_T0	PHENOTYPE	0	0	Secondary
NCT001883052	NCT00188305_2_T0	ORGAN	18	18	colon
NCT001883052	NCT00188305_2_T1	GENE	28	28	has
NCT001883052	NCT00188305_2_T2	PHENOTYPE	12	13	colon cancer
NCT001883052	NCT00188305_2_T3	PHENOTYPE	34	35	breast cancer
NCT001883053	NCT00188305_3_T0	PHENOTYPE	42	42	comprehension
NCT001883053	NCT00188305_3_T1	PHENOTYPE	50	50	intent
NCT001883053	NCT00188305_3_T2	PHENOTYPE	36	37	colon cancer
NCT0018830511	NCT00188305_11_T0	PHENOTYPE	6	6	comprehension
NCT0018830516	NCT00188305_16_T0	BIOLOGICAL_PROCESS	14	14	behaviour
NCT0018830516	NCT00188305_16_T1	PHENOTYPE	16	16	comprehension
NCT0018830516	NCT00188305_16_T2	PHENOTYPE	6	7	breast cancer
NCT0018830519	NCT00188305_19_T0	ORGAN	5	5	breasts
NCT0018830520	NCT00188305_20_T0	GENE	2	2	has
NCT001883182	NCT00188318_2_T0	ORGAN	11	11	lymph
NCT001883182	NCT00188318_2_T1	PHENOTYPE	4	5	primary cancer
NCT001883183	NCT00188318_3_T0	ORGAN	3	3	lymph
NCT001883312	NCT00188331_2_T0	PHENOTYPE	33	33	symptoms
NCT001883312	NCT00188331_2_T1	PHENOTYPE	28	28	severity
NCT001883312	NCT00188331_2_T2	PHENOTYPE	4	4	fatigue
NCT001883312	NCT00188331_2_T3	PHENOTYPE	11	12	cognitive function
NCT001883314	NCT00188331_4_T0	PHENOTYPE	5	5	fatigue
NCT001883314	NCT00188331_4_T1	PHENOTYPE	7	8	cognitive decline
NCT001883316	NCT00188331_6_T0	PHENOTYPE	15	15	fatigue
NCT001883316	NCT00188331_6_T1	PHENOTYPE	22	23	cognitive function
NCT0018833110	NCT00188331_10_T0	PHENOTYPE	7	7	QOL
NCT0018833110	NCT00188331_10_T1	PHENOTYPE	4	6	quality of life
NCT0018833111	NCT00188331_11_T0	COMPOUND	6	6	homocysteine
NCT0018833111	NCT00188331_11_T1	PHENOTYPE	3	4	hormone levels
NCT001883444	NCT00188344_4_T0	GENE	6	6	balloon
NCT001883444	NCT00188344_4_T1	GENE	20	20	balloon
NCT001883444	NCT00188344_4_T2	GENE	23	23	inflated
NCT001883444	NCT00188344_4_T3	ORGAN	12	12	esophagus
NCT001883444	NCT00188344_4_T4	ORGAN	32	32	esophagus
NCT001883447	NCT00188344_7_T0	PHENOTYPE	1	1	achalasia
NCT001883447	NCT00188344_7_T1	ORGAN	8	8	esophagus
NCT001883448	NCT00188344_8_T0	ORGAN	2	2	esophagus
NCT001883449	NCT00188344_9_T0	ORGAN	9	9	esophagus
NCT001883449	NCT00188344_9_T1	ORGAN	25	25	esophagus
NCT001883449	NCT00188344_9_T2	ORGAN	12	14	lower esophageal sphincter
NCT0018834410	NCT00188344_10_T0	PHENOTYPE	0	0	Achalasia
NCT0018834413	NCT00188344_13_T0	GENE	25	25	1.2
NCT0018834414	NCT00188344_14_T0	PHENOTYPE	3	3	achalasia
NCT001883574	NCT00188357_4_T0	COMPOUND	5	5	calcium
NCT001883574	NCT00188357_4_T1	PHENOTYPE	17	17	osteoporosis
NCT001883575	NCT00188357_5_T0	COMPOUND	6	6	HIPP
NCT001883575	NCT00188357_5_T1	PHENOTYPE	22	22	lupus
NCT001883575	NCT00188357_5_T2	PHENOTYPE	30	31	heart attacks
NCT001883575	NCT00188357_5_T3	PHENOTYPE	33	34	bone loss
NCT001883575	NCT00188357_5_T4	PHENOTYPE	8	10	Systemic Lupus Erythematosus
NCT001883576	NCT00188357_6_T0	PHENOTYPE	7	7	lupus
NCT001883576	NCT00188357_6_T1	PHENOTYPE	17	17	lupus
NCT001883577	NCT00188357_7_T0	PHENOTYPE	17	17	lupus
NCT001883578	NCT00188357_8_T0	ORGAN	27	27	heart
NCT0018835712	NCT00188357_12_T0	PHENOTYPE	7	7	Mindfulness
NCT0018835714	NCT00188357_14_T0	COMPOUND	1	1	HIPP
NCT0018835714	NCT00188357_14_T1	GENE	3	3	pts
NCT0018835720	NCT00188357_20_T0	PHENOTYPE	6	6	osteoporosis
NCT0018835720	NCT00188357_20_T1	PHENOTYPE	3	4	cardiovascular disease
NCT0018835722	NCT00188357_22_T0	COMPOUND	9	9	HIPP
NCT0018835723	NCT00188357_23_T0	COMPOUND	4	4	HIPP
NCT0018835723	NCT00188357_23_T1	COMPOUND	22	22	HIPP
NCT0018835725	NCT00188357_25_T0	PHENOTYPE	24	24	lupus
NCT0018835727	NCT00188357_27_T0	COMPOUND	5	5	HIPP
NCT0018835727	NCT00188357_27_T1	COMPOUND	24	24	HIPP
NCT0018835729	NCT00188357_29_T0	COMPOUND	7	7	HIPP
NCT0018835730	NCT00188357_30_T0	PHENOTYPE	8	8	CVD
NCT0018835732	NCT00188357_32_T0	COMPOUND	5	5	HIPP
NCT0018835740	NCT00188357_40_T0	PHENOTYPE	1	1	secondary
NCT0018835741	NCT00188357_41_T0	COMPOUND	8	8	HIPP
NCT001883832	NCT00188383_2_T0	COMPOUND	12	12	amantadine
NCT001883832	NCT00188383_2_T1	COMPOUND	14	14	morphine
NCT001883838	NCT00188383_8_T0	CELL	1	1	cells
NCT0018838311	NCT00188383_11_T0	PHENOTYPE	7	7	profound
NCT0018838316	NCT00188383_16_T0	PHENOTYPE	33	33	analgesia
NCT0018838316	NCT00188383_16_T1	PHENOTYPE	24	24	pharmacokinetics
NCT0018838316	NCT00188383_16_T2	PHENOTYPE	19	20	tissue damage
NCT0018838320	NCT00188383_20_T0	PHENOTYPE	7	8	adverse effects
NCT0018838328	NCT00188383_28_T0	COMPOUND	7	7	3
NCT0018838330	NCT00188383_30_T0	COMPOUND	8	8	BMI
NCT0018838332	NCT00188383_32_T0	PHENOTYPE	15	15	sequelae
NCT0018838332	NCT00188383_32_T1	PHENOTYPE	11	11	dysfunction
NCT0018838332	NCT00188383_32_T2	ORGAN	1	3	central nervous system
NCT0018838333	NCT00188383_33_T0	PHENOTYPE	1	1	allergies
NCT0018838333	NCT00188383_33_T1	COMPOUND	10	10	amantadine
NCT0018838333	NCT00188383_33_T2	PHENOTYPE	5	6	adverse reactions
NCT0018838334	NCT00188383_34_T0	GENE	11	11	IV
NCT0018838334	NCT00188383_34_T1	PHENOTYPE	6	7	Mental Disorders
NCT0018838334	NCT00188383_34_T2	PHENOTYPE	16	17	cognitive dysfunction
NCT0018838335	NCT00188383_35_T0	PHENOTYPE	2	2	epilepsy
NCT0018838335	NCT00188383_35_T1	PHENOTYPE	5	5	seizures
NCT0018838338	NCT00188383_38_T0	COMPOUND	6	6	amantadine
NCT0018838339	NCT00188383_39_T0	PHENOTYPE	2	2	antitussive
NCT0018838339	NCT00188383_39_T1	COMPOUND	4	4	dextromethorphan
NCT0018838339	NCT00188383_39_T2	PHENOTYPE	0	0	Ingestion
NCT001883961	NCT00188396_1_T0	BIOLOGICAL_PROCESS	4	5	menstrual cycle
NCT001883961	NCT00188396_1_T1	PHENOTYPE	8	10	symptoms of depression
NCT001883962	NCT00188396_2_T0	GENE	17	17	peri
NCT001883963	NCT00188396_3_T0	COMPOUND	4	4	estrogen
NCT001883963	NCT00188396_3_T1	BIOLOGICAL_PROCESS	8	9	menstrual cycle
NCT001883963	NCT00188396_3_T2	PHENOTYPE	14	15	depressive symptoms
NCT001883964	NCT00188396_4_T0	COMPOUND	10	10	estrogen
NCT001883964	NCT00188396_4_T1	PHENOTYPE	5	6	irregular periods
NCT001883965	NCT00188396_5_T0	PHENOTYPE	16	17	Mental Disorders
NCT001883965	NCT00188396_5_T1	PHENOTYPE	23	25	major depressive disorder
NCT001883967	NCT00188396_7_T0	PHENOTYPE	15	16	depressive symptoms
NCT001883968	NCT00188396_8_T0	BIOLOGICAL_PROCESS	22	23	menstrual cycle
NCT001883968	NCT00188396_8_T1	PHENOTYPE	9	10	hormone levels
NCT001883969	NCT00188396_9_T0	ORGAN	0	0	Serum
NCT0018839610	NCT00188396_10_T0	PHENOTYPE	11	13	irregular menstrual cycles
NCT0018839611	NCT00188396_11_T0	BIOLOGICAL_PROCESS	17	18	menstrual cycle
NCT0018839614	NCT00188396_14_T0	PHENOTYPE	7	8	depressive disorders
NCT0018839617	NCT00188396_17_T0	COMPOUND	21	21	estrogen
NCT0018839618	NCT00188396_18_T0	COMPOUND	4	4	estrogen
NCT0018839618	NCT00188396_18_T1	COMPOUND	13	13	estrogen
NCT0018839619	NCT00188396_19_T0	COMPOUND	27	27	estrogen
NCT0018839619	NCT00188396_19_T1	GENE	36	36	has
NCT0018839619	NCT00188396_19_T2	BIOLOGICAL_PROCESS	21	22	menstrual cycle
NCT0018839620	NCT00188396_20_T0	PHENOTYPE	26	26	MDD
NCT0018839620	NCT00188396_20_T1	PHENOTYPE	33	34	depressive episode
NCT0018839620	NCT00188396_20_T2	PHENOTYPE	23	25	Major Depressive Disorder
NCT0018839621	NCT00188396_21_T0	PHENOTYPE	8	9	hormone levels
NCT0018839623	NCT00188396_23_T0	BIOLOGICAL_PROCESS	36	37	menstrual cycle
NCT0018839623	NCT00188396_23_T1	PHENOTYPE	19	20	depressive symptoms
NCT0018839623	NCT00188396_23_T2	PHENOTYPE	29	30	depressive symptoms
NCT0018839623	NCT00188396_23_T3	PHENOTYPE	5	7	symptoms of depression
NCT0018839624	NCT00188396_24_T0	PHENOTYPE	12	12	secondary
NCT0018839624	NCT00188396_24_T1	COMPOUND	8	8	paroxetine
NCT0018839624	NCT00188396_24_T2	COMPOUND	6	6	citalopram
NCT0018839625	NCT00188396_25_T0	PHENOTYPE	7	7	severity
NCT0018839626	NCT00188396_26_T0	PHENOTYPE	0	0	Secondary
NCT0018839626	NCT00188396_26_T1	GENE	21	21	peri
NCT0018839626	NCT00188396_26_T2	BIOLOGICAL_PROCESS	13	14	menstrual cycle
NCT0018839626	NCT00188396_26_T3	PHENOTYPE	5	7	symptoms of depression
NCT0018839627	NCT00188396_27_T0	COMPOUND	7	7	estrogen
NCT0018839627	NCT00188396_27_T1	BIOLOGICAL_PROCESS	13	14	menstrual cycle
NCT0018839629	NCT00188396_29_T0	PHENOTYPE	0	0	Secondary
NCT0018839630	NCT00188396_30_T0	COMPOUND	26	26	estrogen
NCT0018839630	NCT00188396_30_T1	COMPOUND	35	35	estrogen
NCT0018839630	NCT00188396_30_T2	PHENOTYPE	13	13	Severity
NCT0018839630	NCT00188396_30_T3	GENE	17	17	PRISM
NCT0018839630	NCT00188396_30_T4	COMPOUND	46	46	citalopram
NCT0018839630	NCT00188396_30_T5	PHENOTYPE	15	16	Menstrual Symptoms
NCT0018839630	NCT00188396_30_T6	BIOLOGICAL_PROCESS	30	31	menstrual cycle
NCT0018839633	NCT00188396_33_T0	COMPOUND	9	9	estrogen
NCT0018839634	NCT00188396_34_T0	PHENOTYPE	17	17	severity
NCT0018839635	NCT00188396_35_T0	GENE	21	21	has
NCT0018839635	NCT00188396_35_T1	BIOLOGICAL_PROCESS	16	17	menstrual cycle
NCT001884222	NCT00188422_2_T0	PHENOTYPE	12	12	metastases
NCT001884222	NCT00188422_2_T1	PHENOTYPE	11	11	nodules
NCT001884224	NCT00188422_4_T0	ORGAN	3	3	thorax
NCT001884224	NCT00188422_4_T1	PHENOTYPE	10	10	metastases
NCT001884224	NCT00188422_4_T2	PHENOTYPE	9	9	nodules
NCT001884224	NCT00188422_4_T3	GENE	12	12	CXR
NCT001884226	NCT00188422_6_T0	PHENOTYPE	11	12	lung metastases
NCT001884227	NCT00188422_7_T0	GENE	8	8	STS
NCT001884229	NCT00188422_9_T0	GENE	2	2	CXR
NCT001884229	NCT00188422_9_T1	GENE	3	3	CR
NCT0018842210	NCT00188422_10_T0	GENE	33	33	600
NCT001884350	NCT00188435_0_T0	GENE	2	2	CXR
NCT001884352	NCT00188435_2_T0	PHENOTYPE	14	14	acute
NCT001884352	NCT00188435_2_T1	GENE	9	9	CXR
NCT001884354	NCT00188435_4_T0	PHENOTYPE	15	15	nodules
NCT001884354	NCT00188435_4_T1	GENE	2	2	CXR
NCT001884354	NCT00188435_4_T2	PHENOTYPE	16	17	heart failure
NCT001884610	NCT00188461_0_T0	PHENOTYPE	3	3	Thoracic
NCT001884612	NCT00188461_2_T0	COMPOUND	10	10	3
NCT001884741	NCT00188474_1_T0	PHENOTYPE	3	5	quality of life
NCT001884743	NCT00188474_3_T0	PHENOTYPE	7	8	pleural effusions
NCT001884871	NCT00188487_1_T0	PHENOTYPE	5	5	ventilation
NCT001884871	NCT00188487_1_T1	GENE	3	3	reduced
NCT001884871	NCT00188487_1_T2	BIOLOGICAL_PROCESS	8	8	vasoconstriction
NCT001884871	NCT00188487_1_T3	BIOLOGICAL_PROCESS	7	7	reflex
NCT001884872	NCT00188487_2_T0	ORGAN	5	5	lungs
NCT001885003	NCT00188500_3_T0	PHENOTYPE	5	5	seizure
NCT001885004	NCT00188500_4_T0	COMPOUND	10	10	2
NCT001885004	NCT00188500_4_T1	GENE	23	24	group 2
NCT001885005	NCT00188500_5_T0	PHENOTYPE	1	1	seizure
NCT001885008	NCT00188500_8_T0	PHENOTYPE	5	5	ketosis
NCT001885008	NCT00188500_8_T1	PHENOTYPE	8	8	seizure
NCT001885133	NCT00188513_3_T0	TISSUE	30	30	tissues
NCT001885391	NCT00188539_1_T0	PHENOTYPE	0	0	Tumour
NCT001885391	NCT00188539_1_T1	COMPOUND	1	1	oxygen
NCT001885391	NCT00188539_1_T2	PHENOTYPE	7	7	tumours
NCT001885521	NCT00188552_1_T0	COMPOUND	18	18	oxygen
NCT001885522	NCT00188552_2_T0	PHENOTYPE	24	24	injuries
NCT001885522	NCT00188552_2_T1	COMPOUND	14	14	pentoxifylline
NCT001885522	NCT00188552_2_T2	COMPOUND	16	17	vitamin E
NCT001885651	NCT00188565_1_T0	ORGAN	7	7	rectum
NCT001885651	NCT00188565_1_T1	PHENOTYPE	3	4	colorectal carcinomas
NCT001885652	NCT00188565_2_T0	PHENOTYPE	9	9	toxicity
NCT001885652	NCT00188565_2_T1	ORGAN	5	5	pelvis
NCT001885652	NCT00188565_2_T2	PHENOTYPE	23	24	rectal carcinoma
NCT001885653	NCT00188565_3_T0	PHENOTYPE	1	1	strategies
NCT001885655	NCT00188565_5_T0	GENE	13	13	cyclooxygenase-2
NCT001885655	NCT00188565_5_T1	GENE	14	14	COX-2
NCT001885655	NCT00188565_5_T2	GENE	19	19	COX-2
NCT001885656	NCT00188565_6_T0	PHENOTYPE	15	15	arthritis
NCT001885658	NCT00188565_8_T0	GENE	6	6	COX-2
NCT001885659	NCT00188565_9_T0	COMPOUND	17	17	celecoxib
NCT001885659	NCT00188565_9_T1	GENE	1	1	has
NCT001885659	NCT00188565_9_T2	PHENOTYPE	31	32	rectal cancer
NCT0018856510	NCT00188565_10_T0	COMPOUND	14	14	celecoxib
NCT0018856510	NCT00188565_10_T1	PHENOTYPE	18	19	rectal cancer
NCT001885783	NCT00188578_3_T0	PHENOTYPE	15	15	tumor
NCT001885783	NCT00188578_3_T1	PHENOTYPE	12	12	focused
NCT001885783	NCT00188578_3_T2	PHENOTYPE	22	23	radiation damage
NCT001885913	NCT00188591_3_T0	PHENOTYPE	4	4	exposures
NCT001886041	NCT00188604_1_T0	PHENOTYPE	0	0	Secondary
NCT001886041	NCT00188604_1_T1	COMPOUND	8	8	selenium
NCT001886041	NCT00188604_1_T2	COMPOUND	23	23	selenium
NCT001886041	NCT00188604_1_T3	PHENOTYPE	20	21	adverse effects
NCT001886041	NCT00188604_1_T4	PHENOTYPE	11	13	quality of life
NCT001886172	NCT00188617_2_T0	GENE	8	8	had
NCT001886175	NCT00188617_5_T0	PHENOTYPE	3	3	pathology
NCT001886176	NCT00188617_6_T0	PHENOTYPE	27	27	complications
NCT001886178	NCT00188617_8_T0	PHENOTYPE	7	7	symptoms
NCT001886178	NCT00188617_8_T1	ORGAN	19	19	liver
NCT0018861710	NCT00188617_10_T0	PHENOTYPE	0	0	Toxicity
NCT0018861710	NCT00188617_10_T1	PHENOTYPE	20	21	measurable disease
NCT0018861711	NCT00188617_11_T0	PHENOTYPE	14	14	tumor
NCT0018861712	NCT00188617_12_T0	PHENOTYPE	6	6	pharmacodynamic
NCT0018861715	NCT00188617_15_T0	PHENOTYPE	3	3	forgets
NCT0018861716	NCT00188617_16_T0	PHENOTYPE	19	19	emesis
NCT0018861716	NCT00188617_16_T1	PHENOTYPE	2	2	vomits
NCT0018861718	NCT00188617_18_T0	GENE	8	8	III
NCT0018861719	NCT00188617_19_T0	PHENOTYPE	24	24	toxicities
NCT0018861720	NCT00188617_20_T0	PHENOTYPE	9	10	stage III
NCT0018861727	NCT00188617_27_T0	PHENOTYPE	13	13	recurrence
NCT0018861730	NCT00188617_30_T0	COMPOUND	2	2	calcium
NCT0018861730	NCT00188617_30_T1	COMPOUND	4	4	magnesium
NCT001886301	NCT00188630_1_T0	PHENOTYPE	2	2	complications
NCT001886302	NCT00188630_2_T0	PHENOTYPE	6	6	complication
NCT001886302	NCT00188630_2_T1	PHENOTYPE	0	1	Kidney failure
NCT001886303	NCT00188630_3_T0	PHENOTYPE	6	7	kidney failure
NCT001886306	NCT00188630_6_T0	PHENOTYPE	8	9	kidney injury
NCT001886307	NCT00188630_7_T0	PHENOTYPE	10	11	kidney failure
NCT001886308	NCT00188630_8_T0	GENE	1	1	NAC
NCT001886308	NCT00188630_8_T1	COMPOUND	0	0	N-acetylcysteine
NCT001886308	NCT00188630_8_T2	PHENOTYPE	12	12	overdoses
NCT001886309	NCT00188630_9_T0	GENE	18	18	dye
NCT001886309	NCT00188630_9_T1	GENE	6	6	has
NCT001886309	NCT00188630_9_T2	GENE	17	17	IV
NCT001886309	NCT00188630_9_T3	PHENOTYPE	12	13	kidney damage
NCT0018863010	NCT00188630_10_T0	GENE	5	5	NAC
NCT0018863010	NCT00188630_10_T1	GENE	12	12	dye
NCT0018863010	NCT00188630_10_T2	GENE	11	11	IV
NCT0018863010	NCT00188630_10_T3	PHENOTYPE	8	9	kidney damage
NCT0018863011	NCT00188630_11_T0	GENE	7	7	NAC
NCT0018863011	NCT00188630_11_T1	PHENOTYPE	12	13	kidney failure
NCT0018863012	NCT00188630_12_T0	GENE	0	0	NAC
NCT0018863014	NCT00188630_14_T0	GENE	11	11	NAC
NCT0018863017	NCT00188630_17_T0	ORGAN	14	14	kidney
NCT0018863017	NCT00188630_17_T1	COMPOUND	6	6	creatinine
NCT0018863018	NCT00188630_18_T0	PHENOTYPE	0	2	Reduced creatinine clearance
NCT0018863019	NCT00188630_19_T0	ORGAN	10	10	kidney
NCT0018863019	NCT00188630_19_T1	GENE	14	14	reduced
NCT0018863020	NCT00188630_20_T0	GENE	1	1	NAC
NCT0018863020	NCT00188630_20_T1	GENE	9	9	NAC
NCT0018863020	NCT00188630_20_T2	COMPOUND	3	3	creatinine
NCT0018863022	NCT00188630_22_T0	GENE	7	7	NAC
NCT0018863023	NCT00188630_23_T0	GENE	23	23	bypass
NCT0018863023	NCT00188630_23_T1	ORGAN	26	27	heart valve
NCT0018863024	NCT00188630_24_T0	PHENOTYPE	12	13	kidney failure
NCT0018863025	NCT00188630_25_T0	GENE	4	4	NAC
NCT0018863026	NCT00188630_26_T0	GENE	26	26	had
NCT0018863026	NCT00188630_26_T1	PHENOTYPE	28	29	kidney problems
NCT0018863027	NCT00188630_27_T0	COMPOUND	17	17	creatinine
NCT0018863027	NCT00188630_27_T1	GENE	9	9	TGH
NCT001886430	NCT00188643_0_T0	PHENOTYPE	9	9	Depression
NCT001886433	NCT00188643_3_T0	COMPOUND	9	9	venlafaxine
NCT001886433	NCT00188643_3_T1	COMPOUND	43	43	venlafaxine
NCT001886433	NCT00188643_3_T2	COMPOUND	12	12	lamotrigine
NCT001886433	NCT00188643_3_T3	COMPOUND	46	46	lamotrigine
NCT001886433	NCT00188643_3_T4	PHENOTYPE	36	37	side effect
NCT001886436	NCT00188643_6_T0	COMPOUND	9	9	venlafaxine
NCT001886436	NCT00188643_6_T1	COMPOUND	43	43	venlafaxine
NCT001886436	NCT00188643_6_T2	COMPOUND	12	12	lamotrigine
NCT001886436	NCT00188643_6_T3	COMPOUND	46	46	lamotrigine
NCT001886436	NCT00188643_6_T4	PHENOTYPE	36	37	side effect
NCT001886438	NCT00188643_8_T0	GENE	16	16	II
NCT001886438	NCT00188643_8_T1	PHENOTYPE	31	31	disorders
NCT001886439	NCT00188643_9_T0	GENE	10	10	16
NCT0018864324	NCT00188643_24_T0	COMPOUND	7	7	venlafaxine
NCT0018864324	NCT00188643_24_T1	COMPOUND	10	10	lamotrigine
NCT0018864327	NCT00188643_27_T0	COMPOUND	6	6	nicotine
NCT0018864327	NCT00188643_27_T1	COMPOUND	8	8	caffeine
NCT0018864327	NCT00188643_27_T2	PHENOTYPE	3	4	substance dependence
NCT0018864332	NCT00188643_32_T0	PHENOTYPE	3	3	schizophrenia
NCT0018864332	NCT00188643_32_T1	PHENOTYPE	6	7	psychotic disorders
NCT0018864333	NCT00188643_33_T0	PHENOTYPE	3	3	hyperthyroidism
NCT0018864333	NCT00188643_33_T1	PHENOTYPE	1	1	hypothyroidism
NCT001886692	NCT00188669_2_T0	PHENOTYPE	6	6	understood
NCT001886693	NCT00188669_3_T0	PHENOTYPE	9	9	mastitis
NCT001886693	NCT00188669_3_T1	PHENOTYPE	7	7	chronic
NCT001886695	NCT00188669_5_T0	COMPOUND	3	3	pentoxifylline
NCT001886695	NCT00188669_5_T1	GENE	7	7	has
NCT001886695	NCT00188669_5_T2	PHENOTYPE	15	16	radiation fibrosis
NCT001886695	NCT00188669_5_T3	COMPOUND	5	6	vitamin E
NCT001886820	NCT00188682_0_T0	GENE	15	15	ast
NCT001886824	NCT00188682_4_T0	PHENOTYPE	8	8	proliferation
NCT001886824	NCT00188682_4_T1	TISSUE	12	12	epithelium
NCT001886824	NCT00188682_4_T2	BIOLOGICAL_PROCESS	21	22	light absorption
NCT001886824	NCT00188682_4_T3	BIOLOGICAL_PROCESS	29	30	light absorption
NCT001886825	NCT00188682_5_T0	GENE	8	8	has
NCT001886826	NCT00188682_6_T0	PHENOTYPE	13	14	breast cancer
NCT001886827	NCT00188682_7_T0	GENE	2	2	has
NCT001886952	NCT00188695_2_T0	GENE	10	10	has
NCT001886952	NCT00188695_2_T1	TISSUE	14	15	lymph nodes
NCT001887081	NCT00188708_1_T0	PHENOTYPE	5	5	hypoxia
NCT001887081	NCT00188708_1_T1	PHENOTYPE	4	4	tumour
NCT001887081	NCT00188708_1_T2	PHENOTYPE	11	11	cancers
NCT001887081	NCT00188708_1_T3	PHENOTYPE	9	9	progression
NCT001887081	NCT00188708_1_T4	PHENOTYPE	16	16	resistant
NCT001887210	NCT00188721_0_T0	PHENOTYPE	27	27	Cancer
NCT001887210	NCT00188721_0_T1	PHENOTYPE	14	15	Breast Cancer
NCT001887210	NCT00188721_0_T2	PHENOTYPE	24	25	Breast Cancer
NCT001887213	NCT00188721_3_T0	PHENOTYPE	18	19	breast cancer
NCT001887214	NCT00188721_4_T0	PHENOTYPE	20	21	breast cancer
NCT001887343	NCT00188734_3_T0	PHENOTYPE	17	18	lung cancer
NCT001887475	NCT00188747_5_T0	PHENOTYPE	21	21	decisions
NCT001887476	NCT00188747_6_T0	PHENOTYPE	14	15	blood loss
NCT001887476	NCT00188747_6_T1	PHENOTYPE	18	19	adverse events
NCT001887602	NCT00188760_2_T0	PHENOTYPE	10	11	breast cancer
NCT001887603	NCT00188760_3_T0	GENE	21	21	hemoglobin
NCT001887734	NCT00188773_4_T0	PHENOTYPE	6	6	focused
NCT001887734	NCT00188773_4_T1	CELL	14	14	b-cell
NCT001887735	NCT00188773_5_T0	GENE	17	17	ROS
NCT001887735	NCT00188773_5_T1	COMPOUND	15	15	oxygen
NCT001887736	NCT00188773_6_T0	GENE	1	1	NAC
NCT001887736	NCT00188773_6_T1	COMPOUND	0	0	N-acetylcysteine
NCT001887736	NCT00188773_6_T2	GENE	8	8	has
NCT001887736	NCT00188773_6_T3	PHENOTYPE	23	24	antioxidant effects
NCT001887738	NCT00188773_8_T0	GENE	0	0	NAC
NCT001887738	NCT00188773_8_T1	PHENOTYPE	8	9	acetaminophen overdose
NCT0018877316	NCT00188773_16_T0	COMPOUND	20	20	heparin
NCT0018877316	NCT00188773_16_T1	COMPOUND	46	46	heparin
NCT0018877316	NCT00188773_16_T2	GENE	36	36	NAC
NCT0018877317	NCT00188773_17_T0	GENE	3	3	NAC
NCT0018877317	NCT00188773_17_T1	PHENOTYPE	12	13	acetaminophen overdose
NCT0018877318	NCT00188773_18_T0	COMPOUND	25	25	heparin
NCT0018877318	NCT00188773_18_T1	GENE	6	6	NAC
NCT0018877332	NCT00188773_32_T0	GENE	1	1	has
NCT0018877332	NCT00188773_32_T1	GENE	8	8	has
NCT0018877337	NCT00188773_37_T0	PHENOTYPE	14	14	allergies
NCT0018877337	NCT00188773_37_T1	PHENOTYPE	3	3	allergy
NCT0018877337	NCT00188773_37_T2	PHENOTYPE	24	25	anaphylactic reactions
NCT0018877338	NCT00188773_38_T0	PHENOTYPE	1	1	addiction
NCT001887863	NCT00188786_3_T0	ORGAN	14	14	pelvis
NCT001887994	NCT00188799_4_T0	PHENOTYPE	26	26	bleeding
NCT001887994	NCT00188799_4_T1	PHENOTYPE	25	25	discomfort
NCT001888121	NCT00188812_1_T0	COMPOUND	4	4	donepezil
NCT001888252	NCT00188825_2_T0	PHENOTYPE	0	0	Acute
NCT001888252	NCT00188825_2_T1	ORGAN	11	11	transplant
NCT001888386	NCT00188838_6_T0	GENE	3	3	II
NCT001888387	NCT00188838_7_T0	PHENOTYPE	2	3	in remission
NCT0018883811	NCT00188838_11_T0	PHENOTYPE	1	1	symptoms
NCT0018883817	NCT00188838_17_T0	PHENOTYPE	0	1	Substance dependence
NCT0018883819	NCT00188838_19_T0	PHENOTYPE	4	4	homicidal
NCT001888513	NCT00188851_3_T0	PHENOTYPE	7	7	HIV
NCT001888513	NCT00188851_3_T1	PHENOTYPE	6	6	resistant
NCT001888643	NCT00188864_3_T0	PHENOTYPE	10	11	brain metastasis
NCT001888644	NCT00188864_4_T0	PHENOTYPE	17	17	symptoms
NCT001888644	NCT00188864_4_T1	PHENOTYPE	14	14	tumour
NCT001888646	NCT00188864_6_T0	PHENOTYPE	10	11	brain metastases
NCT001888770	NCT00188877_0_T0	PHENOTYPE	5	8	Head and Neck Cancer
NCT001888772	NCT00188877_2_T0	TISSUE	15	15	tissues
NCT001888772	NCT00188877_2_T1	PHENOTYPE	11	11	tolerance
NCT001888773	NCT00188877_3_T0	TISSUE	20	20	tissues
NCT001888774	NCT00188877_4_T0	CELL	49	49	cells
NCT001888774	NCT00188877_4_T1	TISSUE	26	26	tissues
NCT001888774	NCT00188877_4_T2	PHENOTYPE	45	45	thinks
NCT001888901	NCT00188890_1_T0	PHENOTYPE	0	0	Symptoms
NCT001888902	NCT00188890_2_T0	PHENOTYPE	12	12	mesothelioma
NCT001888902	NCT00188890_2_T1	PHENOTYPE	14	15	lung cancer
NCT001888903	NCT00188890_3_T0	GENE	8	8	has
NCT001888903	NCT00188890_3_T1	PHENOTYPE	19	20	lung cancer
NCT001888904	NCT00188890_4_T0	PHENOTYPE	0	1	Malignant mesothelioma
NCT001888904	NCT00188890_4_T1	PHENOTYPE	10	11	pleural plaque
NCT001888904	NCT00188890_4_T2	PHENOTYPE	18	19	asbestos exposure
NCT0018889010	NCT00188890_10_T0	PHENOTYPE	11	11	mesothelioma
NCT0018889010	NCT00188890_10_T1	PHENOTYPE	13	14	lung cancer
NCT0018889011	NCT00188890_11_T0	PHENOTYPE	13	13	mesothelioma
NCT0018889011	NCT00188890_11_T1	PHENOTYPE	15	16	lung cancer
NCT0018889012	NCT00188890_12_T0	GENE	6	6	CAT
NCT0018889012	NCT00188890_12_T1	ORGAN	10	10	lungs
NCT0018889013	NCT00188890_13_T0	GENE	10	10	CAT
NCT0018889015	NCT00188890_15_T0	ORGAN	6	6	lungs
NCT0018889017	NCT00188890_17_T0	PHENOTYPE	2	2	plaques
NCT0018889017	NCT00188890_17_T1	ORGAN	8	8	lungs
NCT0018889017	NCT00188890_17_T2	PHENOTYPE	5	5	nodule
NCT0018889020	NCT00188890_20_T0	GENE	10	10	de
NCT0018889020	NCT00188890_20_T1	PHENOTYPE	14	14	Thoracic
NCT0018889020	NCT00188890_20_T2	GENE	8	8	Dr
NCT0018889022	NCT00188890_22_T0	PHENOTYPE	19	19	mesothelioma
NCT0018889022	NCT00188890_22_T1	PHENOTYPE	16	17	lung cancer
NCT0018889022	NCT00188890_22_T2	PHENOTYPE	28	29	lung cancer
NCT0018889023	NCT00188890_23_T0	GENE	23	23	ml
NCT0018889023	NCT00188890_23_T1	PHENOTYPE	32	33	needle stick
NCT0018889025	NCT00188890_25_T0	ORGAN	26	26	lungs
NCT0018889025	NCT00188890_25_T1	TISSUE	28	28	pleura
NCT001889030	NCT00188903_0_T0	PHENOTYPE	0	1	Diastolic Dysfunction
NCT001889030	NCT00188903_0_T1	PHENOTYPE	3	4	Atrial Fibrillation
NCT001889032	NCT00188903_2_T0	GENE	3	3	bypass
NCT001889032	NCT00188903_2_T1	ORGAN	1	2	Coronary artery
NCT001889032	NCT00188903_2_T2	PHENOTYPE	8	9	diastolic dysfunction
NCT001889033	NCT00188903_3_T0	ORGAN	3	4	left ventricle
NCT001889034	NCT00188903_4_T0	PHENOTYPE	6	6	complication
NCT001889034	NCT00188903_4_T1	GENE	2	2	AF
NCT001889034	NCT00188903_4_T2	PHENOTYPE	0	1	Atrial fibrillation
NCT001889035	NCT00188903_5_T0	GENE	0	0	AF
NCT001889035	NCT00188903_5_T1	GENE	60	60	AF
NCT001889035	NCT00188903_5_T2	GENE	9	9	has
NCT001889035	NCT00188903_5_T3	PHENOTYPE	52	53	diastolic dysfunction
NCT001889294	NCT00188929_4_T0	PHENOTYPE	22	22	tumour
NCT001889294	NCT00188929_4_T1	PHENOTYPE	21	21	lymphoma
NCT001889295	NCT00188929_5_T0	PHENOTYPE	11	11	tumour
NCT001889299	NCT00188929_9_T0	PHENOTYPE	17	17	lymphoma
NCT001889299	NCT00188929_9_T1	PHENOTYPE	18	18	tumours
NCT001889421	NCT00188942_1_T0	COMPOUND	11	11	olanzapine
NCT001889421	NCT00188942_1_T1	COMPOUND	9	9	fluoxetine
NCT001889421	NCT00188942_1_T2	GENE	14	14	MRI
NCT001889423	NCT00188942_3_T0	GENE	13	13	BD
NCT001889423	NCT00188942_3_T1	PHENOTYPE	15	15	MDD
NCT001889423	NCT00188942_3_T2	GENE	25	25	CS
NCT001889423	NCT00188942_3_T3	PHENOTYPE	43	43	imagery
NCT001889423	NCT00188942_3_T4	PHENOTYPE	6	8	major depressive episode
NCT001889424	NCT00188942_4_T0	GENE	1	1	BD
NCT001889424	NCT00188942_4_T1	PHENOTYPE	27	27	initiation
NCT001889424	NCT00188942_4_T2	PHENOTYPE	3	3	MDD
NCT001889425	NCT00188942_5_T0	PHENOTYPE	12	12	blocked
NCT001889551	NCT00188955_1_T0	COMPOUND	11	11	tacrolimus
NCT001889551	NCT00188955_1_T1	COMPOUND	12	13	mycophenolate mofetil
NCT001889554	NCT00188955_4_T0	PHENOTYPE	6	6	immunosuppression
NCT001889554	NCT00188955_4_T1	COMPOUND	9	10	mycophenolate mofetil
NCT0018895510	NCT00188955_10_T0	COMPOUND	25	25	tacrolimus
NCT0018895510	NCT00188955_10_T1	COMPOUND	41	41	tacrolimus
NCT0018895510	NCT00188955_10_T2	COMPOUND	27	27	prednisone
NCT0018895510	NCT00188955_10_T3	COMPOUND	43	43	prednisone
NCT0018895510	NCT00188955_10_T4	PHENOTYPE	28	29	Group B
NCT0018895511	NCT00188955_11_T0	ORGAN	2	2	transplant
NCT0018895516	NCT00188955_16_T0	GENE	12	12	GFR
NCT0018895520	NCT00188955_20_T0	GENE	25	25	1.5
NCT0018895520	NCT00188955_20_T1	GENE	27	27	bid
NCT0018895521	NCT00188955_21_T0	GENE	13	13	0.5
NCT0018895522	NCT00188955_22_T0	PHENOTYPE	6	6	concentrations
NCT0018895522	NCT00188955_22_T1	GENE	12	12	1.4
NCT0018895523	NCT00188955_23_T0	PHENOTYPE	3	4	Group B
NCT0018895524	NCT00188955_24_T0	PHENOTYPE	6	6	concentrations
NCT0018895524	NCT00188955_24_T1	GENE	44	44	2.0
NCT0018895524	NCT00188955_24_T2	GENE	47	47	4.0
NCT0018895524	NCT00188955_24_T3	GENE	12	12	1.4
NCT0018895524	NCT00188955_24_T4	PHENOTYPE	40	40	MPA
NCT0018895524	NCT00188955_24_T5	COMPOUND	38	39	mycophenolic acid
NCT0018895526	NCT00188955_26_T0	PHENOTYPE	19	19	hyperlipidemia
NCT0018895526	NCT00188955_26_T1	GENE	24	24	GI
NCT0018895526	NCT00188955_26_T2	PHENOTYPE	14	14	malignancy
NCT0018895526	NCT00188955_26_T3	PHENOTYPE	17	17	thrombocytopenia
NCT0018895526	NCT00188955_26_T4	PHENOTYPE	15	15	anemia
NCT0018895526	NCT00188955_26_T5	PHENOTYPE	21	21	leukopenia
NCT0018895526	NCT00188955_26_T6	PHENOTYPE	8	10	medication side effects
NCT0018895526	NCT00188955_26_T7	PHENOTYPE	2	4	signs and symptoms
NCT0018895527	NCT00188955_27_T0	PHENOTYPE	7	7	acute
NCT0018895527	NCT00188955_27_T1	PHENOTYPE	10	11	drug toxicity
NCT0018895529	NCT00188955_29_T0	ORGAN	42	42	transplant
NCT0018895529	NCT00188955_29_T1	ORGAN	2	2	allograft
NCT0018895531	NCT00188955_31_T0	PHENOTYPE	10	10	acute
NCT0018895531	NCT00188955_31_T1	PHENOTYPE	0	0	Secondary
NCT0018895531	NCT00188955_31_T2	ORGAN	12	12	graft
NCT0018895531	NCT00188955_31_T3	PHENOTYPE	7	7	proteinuria
NCT0018895533	NCT00188955_33_T0	GENE	5	5	GFR
NCT0018895533	NCT00188955_33_T1	GENE	22	22	GFR
NCT0018895534	NCT00188955_34_T0	PHENOTYPE	0	0	Proteinuria
NCT0018895534	NCT00188955_34_T1	PHENOTYPE	20	21	protein/creatinine ratio
NCT0018895536	NCT00188955_36_T0	GENE	1	1	TFR
NCT0018895536	NCT00188955_36_T1	GENE	11	11	TFR
NCT0018895538	NCT00188955_38_T0	GENE	1	1	ANOVA
NCT0018895538	NCT00188955_38_T1	GENE	14	14	ANOVA
NCT0018895539	NCT00188955_39_T0	PHENOTYPE	1	1	regression
NCT001889680	NCT00188968_0_T0	PHENOTYPE	11	11	Ventilation
NCT001889680	NCT00188968_0_T1	GENE	15	15	ure
NCT001889680	NCT00188968_0_T2	PHENOTYPE	13	14	Premature Infants
NCT001889688	NCT00188968_8_T0	PHENOTYPE	13	15	apnea of prematurity
NCT001889689	NCT00188968_9_T0	PHENOTYPE	8	10	apnea of prematurity
NCT0018896811	NCT00188968_11_T0	PHENOTYPE	17	17	ventilation
NCT0018896811	NCT00188968_11_T1	COMPOUND	41	41	methylxanthine
NCT0018896811	NCT00188968_11_T2	PHENOTYPE	44	45	premature infants
NCT0018896812	NCT00188968_12_T0	PHENOTYPE	19	20	premature infants
NCT0018896813	NCT00188968_13_T0	PHENOTYPE	1	1	secondary
NCT0018896813	NCT00188968_13_T1	COMPOUND	22	22	methylxanthine
NCT0018896814	NCT00188968_14_T0	GENE	10	10	CPAP
NCT0018896816	NCT00188968_16_T0	PHENOTYPE	13	13	decisions
NCT001889812	NCT00188981_2_T0	GENE	10	10	structural
NCT001889817	NCT00188981_7_T0	PHENOTYPE	12	12	psychosis
NCT001889818	NCT00188981_8_T0	PHENOTYPE	20	20	psychosis
NCT001889818	NCT00188981_8_T1	PHENOTYPE	13	14	psychotic episode
NCT0018898110	NCT00188981_10_T0	PHENOTYPE	25	25	centers
NCT0018898110	NCT00188981_10_T1	PHENOTYPE	35	35	centers
NCT0018898110	NCT00188981_10_T2	PHENOTYPE	39	39	interests
NCT0018898112	NCT00188981_12_T0	PHENOTYPE	12	12	psychosis
NCT0018898112	NCT00188981_12_T1	PHENOTYPE	32	32	psychosis
NCT0018898112	NCT00188981_12_T2	PHENOTYPE	40	41	Developmental Disorder
NCT0018898112	NCT00188981_12_T3	PHENOTYPE	49	51	pervasive developmental disorders
NCT0018898113	NCT00188981_13_T0	PHENOTYPE	17	17	psychosis
NCT0018898117	NCT00188981_17_T0	PHENOTYPE	2	3	psychotic episode
NCT0018898119	NCT00188981_19_T0	PHENOTYPE	0	0	Symptoms
NCT0018898119	NCT00188981_19_T1	PHENOTYPE	10	11	substance abuse
NCT0018898119	NCT00188981_19_T2	PHENOTYPE	6	8	organic mental disorder
NCT0018898121	NCT00188981_21_T0	PHENOTYPE	1	1	symptoms
NCT0018898122	NCT00188981_22_T0	GENE	3	3	reduced
NCT0018898122	NCT00188981_22_T1	PHENOTYPE	17	18	psychotic disorder
NCT0018898123	NCT00188981_23_T0	GENE	0	0	Attenuated
NCT0018898123	NCT00188981_23_T1	PHENOTYPE	1	2	psychotic symptoms
NCT0018898123	NCT00188981_23_T2	PHENOTYPE	5	6	psychotic symptoms
NCT0018898124	NCT00188981_24_T0	PHENOTYPE	22	22	remission
NCT0018898124	NCT00188981_24_T1	PHENOTYPE	4	5	psychotic symptoms
NCT0018898124	NCT00188981_24_T2	PHENOTYPE	10	11	psychotic symptoms
NCT001890071	NCT00189007_1_T0	PHENOTYPE	26	26	hypoxia
NCT001890071	NCT00189007_1_T1	COMPOUND	5	5	allopurinol
NCT001890071	NCT00189007_1_T2	COMPOUND	19	19	allopurinol
NCT001890071	NCT00189007_1_T3	PHENOTYPE	12	12	reperfusion
NCT001890071	NCT00189007_1_T4	PHENOTYPE	42	43	brain damage
NCT001890204	NCT00189020_4_T0	GENE	23	23	3-1
NCT001890204	NCT00189020_4_T1	GENE	17	17	booster
NCT001890206	NCT00189020_6_T0	GENE	15	15	reduced
NCT001890206	NCT00189020_6_T1	GENE	8	8	has
NCT001890207	NCT00189020_7_T0	GENE	1	1	reduced
NCT001890207	NCT00189020_7_T1	PHENOTYPE	10	11	herd immunity
NCT001890207	NCT00189020_7_T2	PHENOTYPE	6	8	respiratory tract infections
NCT001890209	NCT00189020_9_T0	PHENOTYPE	1	1	secondary
NCT001890209	NCT00189020_9_T1	GENE	10	10	reduced
NCT001890209	NCT00189020_9_T2	ORGAN	14	14	serum
NCT0018902019	NCT00189020_19_T0	PHENOTYPE	4	5	respiratory infections
NCT0018902020	NCT00189020_20_T0	GENE	16	16	booster
NCT001890330	NCT00189033_0_T0	GENE	10	10	Fibre
NCT001890330	NCT00189033_0_T1	GENE	13	13	Fibre
NCT001890330	NCT00189033_0_T2	PHENOTYPE	3	5	Irritable Bowel Syndrome
NCT001890332	NCT00189033_2_T0	GENE	10	10	bran
NCT001890332	NCT00189033_2_T1	PHENOTYPE	23	25	Irritable Bowel Syndrome
NCT001890333	NCT00189033_3_T0	PHENOTYPE	17	17	symptoms
NCT001890333	NCT00189033_3_T1	PHENOTYPE	16	16	IBS
NCT001890337	NCT00189033_7_T0	PHENOTYPE	6	6	IBS
NCT001890338	NCT00189033_8_T0	PHENOTYPE	11	11	symptoms
NCT001890338	NCT00189033_8_T1	PHENOTYPE	10	10	IBS
NCT001890339	NCT00189033_9_T0	PHENOTYPE	12	12	symptoms
NCT001890339	NCT00189033_9_T1	PHENOTYPE	11	11	IBS
NCT0018903310	NCT00189033_10_T0	PHENOTYPE	14	14	symptoms
NCT0018903310	NCT00189033_10_T1	PHENOTYPE	13	13	IBS
NCT0018903311	NCT00189033_11_T0	PHENOTYPE	7	7	IBS
NCT0018903314	NCT00189033_14_T0	PHENOTYPE	16	16	symptoms
NCT0018903314	NCT00189033_14_T1	PHENOTYPE	38	38	symptoms
NCT0018903314	NCT00189033_14_T2	PHENOTYPE	20	20	relapse
NCT0018903314	NCT00189033_14_T3	GENE	11	11	GP
NCT0018903314	NCT00189033_14_T4	GENE	31	31	GP
NCT0018903314	NCT00189033_14_T5	PHENOTYPE	15	15	IBS
NCT0018903314	NCT00189033_14_T6	PHENOTYPE	23	23	IBS
NCT0018903314	NCT00189033_14_T7	PHENOTYPE	34	34	IBS
NCT0018903315	NCT00189033_15_T0	GENE	18	18	II
NCT0018903315	NCT00189033_15_T1	GENE	23	23	probable
NCT0018903315	NCT00189033_15_T2	GENE	31	31	GP
NCT0018903315	NCT00189033_15_T3	PHENOTYPE	13	13	IBS
NCT0018903315	NCT00189033_15_T4	PHENOTYPE	24	24	IBS
NCT0018903315	NCT00189033_15_T5	PHENOTYPE	28	28	IBS
NCT0018903317	NCT00189033_17_T0	GENE	21	21	bran
NCT0018903319	NCT00189033_19_T0	PHENOTYPE	13	13	IBS
NCT0018903322	NCT00189033_22_T0	PHENOTYPE	2	2	constipation
NCT0018903326	NCT00189033_26_T0	GENE	15	15	GI
NCT0018903328	NCT00189033_28_T0	PHENOTYPE	10	10	IBS
NCT0018903330	NCT00189033_30_T0	PHENOTYPE	5	5	symptoms
NCT0018903330	NCT00189033_30_T1	PHENOTYPE	0	0	Secondary
NCT0018903330	NCT00189033_30_T2	PHENOTYPE	4	4	IBS
NCT0018903330	NCT00189033_30_T3	PHENOTYPE	8	10	quality of life
NCT0018903332	NCT00189033_32_T0	PHENOTYPE	21	21	symptoms
NCT0018903332	NCT00189033_32_T1	GENE	13	13	bowel
NCT0018903332	NCT00189033_32_T2	PHENOTYPE	5	5	IBS
NCT0018903332	NCT00189033_32_T3	PHENOTYPE	20	20	IBS
NCT0018903333	NCT00189033_33_T0	PHENOTYPE	16	16	IBS
NCT0018903333	NCT00189033_33_T1	PHENOTYPE	17	17	QOL
NCT0018903333	NCT00189033_33_T2	PHENOTYPE	9	11	Irritable Bowel Syndrome
NCT0018903333	NCT00189033_33_T3	PHENOTYPE	12	14	Quality of Life
NCT0018903333	NCT00189033_33_T4	PHENOTYPE	1	3	quality of life
NCT0018903335	NCT00189033_35_T0	GENE	1	1	has
NCT0018903336	NCT00189033_36_T0	GENE	0	0	Fibre
NCT0018903341	NCT00189033_41_T0	PHENOTYPE	1	1	secondary
NCT0018903342	NCT00189033_42_T0	PHENOTYPE	22	22	practices
NCT0018903346	NCT00189033_46_T0	GENE	3	3	II
NCT0018903346	NCT00189033_46_T1	PHENOTYPE	21	21	IBS
NCT0018903351	NCT00189033_51_T0	PHENOTYPE	2	2	IBS
NCT0018903351	NCT00189033_51_T1	PHENOTYPE	6	8	Quality of Life
NCT0018903352	NCT00189033_52_T0	GENE	12	12	ANOVA
NCT0018903354	NCT00189033_54_T0	PHENOTYPE	15	15	regression
NCT0018903360	NCT00189033_60_T0	GENE	18	18	II
NCT0018903360	NCT00189033_60_T1	GENE	23	23	probable
NCT0018903360	NCT00189033_60_T2	GENE	31	31	GP
NCT0018903360	NCT00189033_60_T3	PHENOTYPE	13	13	IBS
NCT0018903360	NCT00189033_60_T4	PHENOTYPE	24	24	IBS
NCT0018903360	NCT00189033_60_T5	PHENOTYPE	28	28	IBS
NCT001890725	NCT00189072_5_T0	PHENOTYPE	18	18	fatigue
NCT001890725	NCT00189072_5_T1	COMPOUND	6	6	gabapentin
NCT001890725	NCT00189072_5_T2	PHENOTYPE	16	16	somnolence
NCT001890729	NCT00189072_9_T0	PHENOTYPE	13	13	independency
NCT001890729	NCT00189072_9_T1	COMPOUND	34	34	gabapentin
NCT001890851	NCT00189085_1_T0	COMPOUND	20	20	ezetimibe
NCT0018908510	NCT00189085_10_T0	PHENOTYPE	9	10	insulin resistance
NCT0018908511	NCT00189085_11_T0	PHENOTYPE	9	9	hyperlipidemia
NCT0018908511	NCT00189085_11_T1	PHENOTYPE	4	5	insulin resistance
NCT0018908512	NCT00189085_12_T0	PHENOTYPE	1	1	hyperlipidemia
NCT0018908512	NCT00189085_12_T1	PHENOTYPE	8	9	endothelial dysfunction
NCT0018908517	NCT00189085_17_T0	COMPOUND	20	20	ezetimibe
NCT0018908517	NCT00189085_17_T1	GENE	3	3	has
NCT0018908518	NCT00189085_18_T0	PHENOTYPE	16	17	endothelial dysfunction
NCT0018908520	NCT00189085_20_T0	PHENOTYPE	1	1	secondary
NCT0018908520	NCT00189085_20_T1	COMPOUND	38	38	ezetimibe
NCT0018908520	NCT00189085_20_T2	COMPOUND	31	31	simvastatin
NCT0018908520	NCT00189085_20_T3	COMPOUND	36	36	simvastatin
NCT0018908520	NCT00189085_20_T4	PHENOTYPE	7	7	enables
NCT0018908521	NCT00189085_21_T0	COMPOUND	14	14	ezetimibe
NCT0018908521	NCT00189085_21_T1	ORGAN	6	6	plasma
NCT0018908524	NCT00189085_24_T0	PHENOTYPE	14	14	hyperlipidemia
NCT0018908524	NCT00189085_24_T1	COMPOUND	11	11	ezetimibe
NCT0018908526	NCT00189085_26_T0	COMPOUND	11	11	ezetimibe
NCT0018908536	NCT00189085_36_T0	PHENOTYPE	6	7	cerebrovascular disease
NCT0018908536	NCT00189085_36_T1	PHENOTYPE	9	11	peripheral arterial disease
NCT0018908536	NCT00189085_36_T2	PHENOTYPE	3	5	coronary heart disease
NCT001890980	NCT00189098_0_T0	PHENOTYPE	7	9	Chronic Otitis Media
NCT001890985	NCT00189098_5_T0	PHENOTYPE	25	25	otorrhea
NCT001890985	NCT00189098_5_T1	PHENOTYPE	19	19	suffering
NCT001890985	NCT00189098_5_T2	PHENOTYPE	21	23	chronic otitis media
NCT0018909811	NCT00189098_11_T0	PHENOTYPE	25	25	otorrhea
NCT0018909811	NCT00189098_11_T1	PHENOTYPE	38	38	otorrhea
NCT0018909811	NCT00189098_11_T2	PHENOTYPE	42	42	otorrhea
NCT0018909811	NCT00189098_11_T3	PHENOTYPE	24	24	resistant
NCT0018909811	NCT00189098_11_T4	GENE	41	41	had
NCT0018909812	NCT00189098_12_T0	PHENOTYPE	4	6	chronic otitis media
NCT0018909813	NCT00189098_13_T0	PHENOTYPE	24	24	otorrhea
NCT0018909813	NCT00189098_13_T1	PHENOTYPE	20	22	chronic otitis media
NCT001891110	NCT00189111_0_T0	GENE	7	7	The
NCT001891119	NCT00189111_9_T0	COMPOUND	14	14	calcium
NCT0018911111	NCT00189111_11_T0	COMPOUND	4	4	calcium
NCT0018911114	NCT00189111_14_T0	PHENOTYPE	6	6	ischemia
NCT0018911115	NCT00189111_15_T0	GENE	16	16	PCI
NCT0018911115	NCT00189111_15_T1	ORGAN	8	9	coronary artery
NCT001891376	NCT00189137_6_T0	PHENOTYPE	17	17	sarcoma
NCT001891377	NCT00189137_7_T0	PHENOTYPE	45	45	symptoms
NCT001891377	NCT00189137_7_T1	COMPOUND	3	3	docetaxel
NCT001891377	NCT00189137_7_T2	COMPOUND	35	35	docetaxel
NCT001891377	NCT00189137_7_T3	PHENOTYPE	40	40	tumor
NCT001891377	NCT00189137_7_T4	ORGAN	23	23	pancreas
NCT001891377	NCT00189137_7_T5	PHENOTYPE	19	19	cancers
NCT001891377	NCT00189137_7_T6	PHENOTYPE	20	20	cancers
NCT001891377	NCT00189137_7_T7	PHENOTYPE	29	29	cancers
NCT001891377	NCT00189137_7_T8	COMPOUND	1	1	gemcitabine
NCT001891377	NCT00189137_7_T9	COMPOUND	33	33	gemcitabine
NCT001891501	NCT00189150_1_T0	ORGAN	9	9	transplant
NCT001891502	NCT00189150_2_T0	GENE	9	9	PK
NCT001891502	NCT00189150_2_T1	COMPOUND	14	15	mycophenolate mofetil
NCT001891505	NCT00189150_5_T0	PHENOTYPE	14	14	MPA
NCT001891505	NCT00189150_5_T1	COMPOUND	12	13	mycophenolic acid
NCT001891508	NCT00189150_8_T0	GENE	23	23	reduced
NCT001891508	NCT00189150_8_T1	PHENOTYPE	4	4	neutropenia
NCT001891508	NCT00189150_8_T2	PHENOTYPE	11	11	decisions
NCT001891509	NCT00189150_9_T0	PHENOTYPE	8	8	neutropenia
NCT001891509	NCT00189150_9_T1	ORGAN	28	29	bone marrow
NCT0018915011	NCT00189150_11_T0	ORGAN	4	4	transplant
NCT0018915012	NCT00189150_12_T0	PHENOTYPE	6	6	acute
NCT0018915012	NCT00189150_12_T1	COMPOUND	16	16	1st
NCT0018915012	NCT00189150_12_T2	GENE	4	4	had
NCT0018915012	NCT00189150_12_T3	GENE	17	17	PK
NCT0018915020	NCT00189150_20_T0	ORGAN	10	10	kidney
NCT0018915020	NCT00189150_20_T1	ORGAN	12	12	heart
NCT0018915020	NCT00189150_20_T2	ORGAN	4	5	organ transplants
NCT001891630	NCT00189163_0_T0	PHENOTYPE	2	3	Hepatitis C
NCT001891632	NCT00189163_2_T0	COMPOUND	22	22	HCV
NCT001891632	NCT00189163_2_T1	COMPOUND	32	32	HCV
NCT001891632	NCT00189163_2_T2	GENE	14	14	Interferon
NCT001891632	NCT00189163_2_T3	PHENOTYPE	18	19	insulin resistance
NCT001891634	NCT00189163_4_T0	PHENOTYPE	2	3	chronic hepatitis
NCT001891634	NCT00189163_4_T1	PHENOTYPE	3	4	hepatitis C
NCT001891636	NCT00189163_6_T0	GENE	6	6	has
NCT001891636	NCT00189163_6_T1	PHENOTYPE	15	16	disease progression
NCT001891636	NCT00189163_6_T2	PHENOTYPE	4	5	hepatic steatosis
NCT001891637	NCT00189163_7_T0	PHENOTYPE	38	38	NAFLD
NCT001891637	NCT00189163_7_T1	COMPOUND	6	6	HCV
NCT001891637	NCT00189163_7_T2	PHENOTYPE	26	26	steatosis
NCT001891637	NCT00189163_7_T3	PHENOTYPE	36	37	liver disease
NCT001891637	NCT00189163_7_T4	PHENOTYPE	3	4	hepatic steatosis
NCT001891637	NCT00189163_7_T5	PHENOTYPE	12	13	insulin resistance
NCT001891637	NCT00189163_7_T6	PHENOTYPE	34	36	alcoholic fatty liver
NCT001891638	NCT00189163_8_T0	GENE	23	23	reduced
NCT001891638	NCT00189163_8_T1	PHENOTYPE	2	2	steatosis
NCT001891638	NCT00189163_8_T2	PHENOTYPE	14	14	steatosis
NCT001891638	NCT00189163_8_T3	PHENOTYPE	29	29	SVR
NCT0018916311	NCT00189163_11_T0	PHENOTYPE	10	11	hepatic steatosis
NCT0018916312	NCT00189163_12_T0	COMPOUND	13	13	pioglitazone
NCT0018916312	NCT00189163_12_T1	GENE	9	9	insulin
NCT0018916312	NCT00189163_12_T2	PHENOTYPE	16	17	insulin sensitivity
NCT0018916312	NCT00189163_12_T3	PHENOTYPE	19	20	hepatic steatosis
NCT0018916313	NCT00189163_13_T0	PHENOTYPE	22	22	SVR
NCT0018916313	NCT00189163_13_T1	COMPOUND	9	9	pioglitazone
NCT0018916313	NCT00189163_13_T2	COMPOUND	29	29	pioglitazone
NCT0018916313	NCT00189163_13_T3	PHENOTYPE	33	34	hepatitis C
NCT0018916313	NCT00189163_13_T4	PHENOTYPE	14	15	hepatic steatosis
NCT0018916313	NCT00189163_13_T5	PHENOTYPE	11	12	insulin sensitivity
NCT0018916314	NCT00189163_14_T0	GENE	12	12	insulin
NCT0018916314	NCT00189163_14_T1	PHENOTYPE	21	22	chronic hepatitis
NCT0018916314	NCT00189163_14_T2	PHENOTYPE	22	23	hepatitis C
NCT0018916317	NCT00189163_17_T0	GENE	7	7	has
NCT0018916319	NCT00189163_19_T0	PHENOTYPE	21	21	NAFLD
NCT0018916319	NCT00189163_19_T1	COMPOUND	12	12	HCV
NCT0018916319	NCT00189163_19_T2	GENE	8	8	has
NCT0018916319	NCT00189163_19_T3	PHENOTYPE	4	4	steatosis
NCT0018916319	NCT00189163_19_T4	PHENOTYPE	6	7	hepatic fibrosis
NCT0018916320	NCT00189163_20_T0	COMPOUND	11	11	HCV
NCT0018916320	NCT00189163_20_T1	COMPOUND	24	24	HCV
NCT0018916320	NCT00189163_20_T2	PHENOTYPE	30	30	steatosis
NCT0018916320	NCT00189163_20_T3	PHENOTYPE	35	35	steatosis
NCT0018916320	NCT00189163_20_T4	PHENOTYPE	3	4	hepatic steatosis
NCT0018916321	NCT00189163_21_T0	PHENOTYPE	7	7	NAFLD
NCT0018916321	NCT00189163_21_T1	COMPOUND	13	13	HCV
NCT0018916321	NCT00189163_21_T2	PHENOTYPE	25	25	steatosis
NCT0018916321	NCT00189163_21_T3	COMPOUND	21	21	BMI
NCT0018916323	NCT00189163_23_T0	PHENOTYPE	32	32	NAFLD
NCT0018916323	NCT00189163_23_T1	COMPOUND	9	9	HCV
NCT0018916323	NCT00189163_23_T2	PHENOTYPE	17	17	steatosis
NCT0018916323	NCT00189163_23_T3	PHENOTYPE	25	25	steatosis
NCT0018916323	NCT00189163_23_T4	COMPOUND	14	14	BMI
NCT0018916324	NCT00189163_24_T0	PHENOTYPE	8	9	hepatic steatosis
NCT0018916326	NCT00189163_26_T0	GENE	36	36	insulin
NCT0018916326	NCT00189163_26_T1	COMPOUND	43	43	pioglitazone
NCT0018916326	NCT00189163_26_T2	COMPOUND	7	7	HCV
NCT0018916326	NCT00189163_26_T3	PHENOTYPE	26	26	steatosis
NCT0018916326	NCT00189163_26_T4	PHENOTYPE	22	23	insulin resistance
NCT0018916333	NCT00189163_33_T0	COMPOUND	9	9	pioglitazone
NCT0018916333	NCT00189163_33_T1	PHENOTYPE	13	14	chronic hepatitis
NCT0018916333	NCT00189163_33_T2	PHENOTYPE	14	15	hepatitis C
NCT0018916334	NCT00189163_34_T0	PHENOTYPE	18	18	severity
NCT0018916334	NCT00189163_34_T1	PHENOTYPE	26	26	steatohepatitis
NCT0018916334	NCT00189163_34_T2	ORGAN	8	8	liver
NCT0018916334	NCT00189163_34_T3	PHENOTYPE	22	22	steatosis
NCT0018916334	NCT00189163_34_T4	PHENOTYPE	20	21	hepatitis C
NCT0018916335	NCT00189163_35_T0	PHENOTYPE	25	25	severity
NCT0018916335	NCT00189163_35_T1	PHENOTYPE	22	22	steatosis
NCT0018916335	NCT00189163_35_T2	PHENOTYPE	27	28	hepatitis C
NCT0018916338	NCT00189163_38_T0	PHENOTYPE	32	32	NAFLD
NCT0018916338	NCT00189163_38_T1	ORGAN	17	17	liver
NCT0018916338	NCT00189163_38_T2	ORGAN	23	23	liver
NCT0018916338	NCT00189163_38_T3	PHENOTYPE	29	30	hepatitis C
NCT0018916338	NCT00189163_38_T4	BIOLOGICAL_PROCESS	36	37	gene expression
NCT0018916339	NCT00189163_39_T0	ORGAN	15	15	liver
NCT0018916340	NCT00189163_40_T0	ORGAN	11	11	liver
NCT0018916341	NCT00189163_41_T0	COMPOUND	12	12	pioglitazone
NCT0018916341	NCT00189163_41_T1	PHENOTYPE	31	31	steatosis
NCT0018916341	NCT00189163_41_T2	BIOLOGICAL_PROCESS	15	16	gene expression
NCT0018916342	NCT00189163_42_T0	ORGAN	47	47	liver
NCT0018916342	NCT00189163_42_T1	COMPOUND	8	8	pioglitazone
NCT0018916342	NCT00189163_42_T2	PHENOTYPE	17	17	hepatotoxicity
NCT0018916342	NCT00189163_42_T3	PHENOTYPE	45	45	fibrosis
NCT0018916342	NCT00189163_42_T4	PHENOTYPE	52	52	fibrosis
NCT0018916342	NCT00189163_42_T5	PHENOTYPE	12	13	hepatitis C
NCT0018916342	NCT00189163_42_T6	PHENOTYPE	22	23	hepatitis C
NCT0018916342	NCT00189163_42_T7	PHENOTYPE	67	70	drug induced liver injury
NCT0018916344	NCT00189163_44_T0	COMPOUND	12	12	pioglitazone
NCT0018916344	NCT00189163_44_T1	PHENOTYPE	9	9	hepatotoxicity
NCT0018916344	NCT00189163_44_T2	PHENOTYPE	21	21	cirrhosis
NCT0018916344	NCT00189163_44_T3	PHENOTYPE	16	17	hepatitis C
NCT0018916346	NCT00189163_46_T0	PHENOTYPE	2	3	hepatitis C
NCT0018916347	NCT00189163_47_T0	COMPOUND	8	8	glucose
NCT0018916347	NCT00189163_47_T1	PHENOTYPE	12	13	insulin sensitivity
NCT0018916350	NCT00189163_50_T0	COMPOUND	20	20	ribavirin
NCT0018916350	NCT00189163_50_T1	GENE	18	18	interferon
NCT0018916350	NCT00189163_50_T2	PHENOTYPE	6	7	hepatitis C
NCT0018916350	NCT00189163_50_T3	PHENOTYPE	5	6	chronic hepatitis
NCT0018916352	NCT00189163_52_T0	COMPOUND	8	8	HCV
NCT0018916352	NCT00189163_52_T1	GENE	41	41	has
NCT0018916353	NCT00189163_53_T0	COMPOUND	11	11	pioglitazone
NCT0018916353	NCT00189163_53_T1	PHENOTYPE	23	23	fibrosis
NCT0018916353	NCT00189163_53_T2	PHENOTYPE	18	19	hepatic steatosis
NCT0018916354	NCT00189163_54_T0	ORGAN	24	24	liver
NCT0018916356	NCT00189163_56_T0	COMPOUND	15	15	HCV
NCT0018916356	NCT00189163_56_T1	PHENOTYPE	8	9	liver disease
NCT0018916356	NCT00189163_56_T2	PHENOTYPE	12	13	chronic infection
NCT0018916358	NCT00189163_58_T0	ORGAN	13	13	liver
NCT0018916358	NCT00189163_58_T1	PHENOTYPE	2	2	cirrhosis
NCT0018916358	NCT00189163_58_T2	PHENOTYPE	5	6	liver disease
NCT0018916360	NCT00189163_60_T0	PHENOTYPE	1	1	reflects
NCT0018916366	NCT00189163_66_T0	GENE	18	18	has
NCT0018916366	NCT00189163_66_T1	PHENOTYPE	9	10	insulin resistance
NCT001891761	NCT00189176_1_T0	PHENOTYPE	9	9	secondary
NCT001891761	NCT00189176_1_T1	PHENOTYPE	19	21	quality of life
NCT001891891	NCT00189189_1_T0	PHENOTYPE	1	1	disorders
NCT001891892	NCT00189189_2_T0	PHENOTYPE	14	14	dependence
NCT001891892	NCT00189189_2_T1	PHENOTYPE	9	10	depressive disorders
NCT001891892	NCT00189189_2_T2	PHENOTYPE	11	12	substance abuse
NCT001891893	NCT00189189_3_T0	PHENOTYPE	1	1	disorders
NCT001891893	NCT00189189_3_T1	PHENOTYPE	9	9	disorders
NCT001891897	NCT00189189_7_T0	PHENOTYPE	1	1	disorders
NCT001891898	NCT00189189_8_T0	PHENOTYPE	14	14	dependence
NCT001891898	NCT00189189_8_T1	PHENOTYPE	18	19	social maladjustment
NCT001891898	NCT00189189_8_T2	PHENOTYPE	9	10	depressive disorders
NCT001891898	NCT00189189_8_T3	PHENOTYPE	11	12	substance abuse
NCT0018918910	NCT00189189_10_T0	PHENOTYPE	1	1	disorders
NCT0018918910	NCT00189189_10_T1	PHENOTYPE	9	9	disorders
NCT0018918911	NCT00189189_11_T0	PHENOTYPE	9	10	mental health
NCT0018918912	NCT00189189_12_T0	PHENOTYPE	4	4	disorders
NCT0018918913	NCT00189189_13_T0	PHENOTYPE	3	3	oppositional
NCT0018918913	NCT00189189_13_T1	PHENOTYPE	6	7	conduct disorders
NCT0018918916	NCT00189189_16_T0	PHENOTYPE	23	23	oppositional
NCT0018918916	NCT00189189_16_T1	PHENOTYPE	26	27	conduct disorders
NCT0018918917	NCT00189189_17_T0	ORGAN	9	9	heart
NCT0018918924	NCT00189189_24_T0	GENE	12	12	DISC
NCT0018918924	NCT00189189_24_T1	PHENOTYPE	7	7	CBCL
NCT0018918924	NCT00189189_24_T2	GENE	16	16	TRF
NCT0018918927	NCT00189189_27_T0	PHENOTYPE	20	20	oppositional
NCT0018918927	NCT00189189_27_T1	PHENOTYPE	23	24	conduct disorders
NCT001892023	NCT00189202_3_T0	PHENOTYPE	5	5	avoidance
NCT001892023	NCT00189202_3_T1	PHENOTYPE	15	16	drug toxicities
NCT001892025	NCT00189202_5_T0	COMPOUND	8	8	cyclosporine
NCT001892025	NCT00189202_5_T1	GENE	6	6	reduced
NCT001892025	NCT00189202_5_T2	ORGAN	11	11	allograft
NCT001892150	NCT00189215_0_T0	ORGAN	4	5	Coronary Artery
NCT001892150	NCT00189215_0_T1	PHENOTYPE	1	2	Cognitive Decline
NCT001892153	NCT00189215_3_T0	ORGAN	11	11	heart
NCT001892154	NCT00189215_4_T0	GENE	13	13	bypass
NCT001892154	NCT00189215_4_T1	ORGAN	18	18	heart
NCT001892157	NCT00189215_7_T0	GENE	23	23	CPB
NCT001892157	NCT00189215_7_T1	PHENOTYPE	7	8	cognitive decline
NCT001892158	NCT00189215_8_T0	GENE	5	5	CPB
NCT001892159	NCT00189215_9_T0	GENE	8	8	bypass
NCT0018921510	NCT00189215_10_T0	GENE	15	15	bypass
NCT0018921510	NCT00189215_10_T1	GENE	21	21	bypass
NCT0018921511	NCT00189215_11_T0	GENE	25	25	bypass
NCT0018921511	NCT00189215_11_T1	PHENOTYPE	41	43	quality of life
NCT0018921514	NCT00189215_14_T0	PHENOTYPE	6	8	quality of life
NCT001892282	NCT00189228_2_T0	GENE	7	7	allergen
NCT001892282	NCT00189228_2_T1	PHENOTYPE	10	10	peripheral
NCT001892282	NCT00189228_2_T2	PHENOTYPE	9	9	asthma
NCT001892282	NCT00189228_2_T3	CELL	12	12	basophils
NCT001892282	NCT00189228_2_T4	CELL	16	17	mast cells
NCT001892802	NCT00189280_2_T0	COMPOUND	11	11	imiquimod
NCT001892933	NCT00189293_3_T0	PHENOTYPE	1	1	recurrence
NCT001892933	NCT00189293_3_T1	GENE	43	43	A2
NCT001893190	NCT00189319_0_T0	PHENOTYPE	8	10	Quality of Life
NCT001893190	NCT00189319_0_T1	PHENOTYPE	14	16	Paroxysmal Atrial Fibrillation
NCT001893320	NCT00189332_0_T0	PHENOTYPE	8	8	Melanoma
NCT001893320	NCT00189332_0_T1	PHENOTYPE	4	6	Metastatic Cutaneous Melanoma
NCT001893454	NCT00189345_4_T0	PHENOTYPE	3	3	cancers
NCT001893581	NCT00189358_1_T0	PHENOTYPE	0	0	Recurrence
NCT001893582	NCT00189358_2_T0	PHENOTYPE	2	2	strategies
NCT001893711	NCT00189371_1_T0	PHENOTYPE	0	0	Relapse
NCT001893713	NCT00189371_3_T0	PHENOTYPE	2	2	anemia
NCT001893713	NCT00189371_3_T1	PHENOTYPE	11	13	quality of life
NCT001893841	NCT00189384_1_T0	COMPOUND	35	35	penicillin
NCT001893841	NCT00189384_1_T1	COMPOUND	37	37	ampicillin
NCT001893841	NCT00189384_1_T2	PHENOTYPE	19	20	bacterial infections
NCT001893843	NCT00189384_3_T0	BIOLOGICAL_PROCESS	19	19	transport
NCT001893844	NCT00189384_4_T0	PHENOTYPE	24	25	bacterial infections
NCT001893845	NCT00189384_5_T0	PHENOTYPE	11	11	infections
NCT001893845	NCT00189384_5_T1	COMPOUND	32	32	gentamicin
NCT001893845	NCT00189384_5_T2	PHENOTYPE	42	42	sepsis
NCT001893846	NCT00189384_6_T0	GENE	12	12	IM
NCT001893846	NCT00189384_6_T1	GENE	18	18	IM
NCT001893846	NCT00189384_6_T2	COMPOUND	13	13	ceftriaxone
NCT001893846	NCT00189384_6_T3	PHENOTYPE	47	47	pneumonia
NCT001893846	NCT00189384_6_T4	PHENOTYPE	54	54	infections
NCT001893846	NCT00189384_6_T5	PHENOTYPE	60	60	infections
NCT001893846	NCT00189384_6_T6	COMPOUND	22	22	gentamicin
NCT001893846	NCT00189384_6_T7	COMPOUND	28	28	gentamicin
NCT001893846	NCT00189384_6_T8	PHENOTYPE	49	49	sepsis
NCT001893846	NCT00189384_6_T9	COMPOUND	19	20	procaine penicillin
NCT001893846	NCT00189384_6_T10	PHENOTYPE	45	46	bacterial infection
NCT001893848	NCT00189384_8_T0	PHENOTYPE	16	16	sepsis
NCT001893971	NCT00189397_1_T0	GENE	19	19	ABCD
NCT001893971	NCT00189397_1_T1	PHENOTYPE	17	18	contact dermatitis
NCT001893972	NCT00189397_2_T0	COMPOUND	0	0	Parthenium
NCT001893972	NCT00189397_2_T1	GENE	9	9	ABCD
NCT001893972	NCT00189397_2_T2	GENE	24	24	ABCD
NCT001893973	NCT00189397_3_T0	PHENOTYPE	1	1	dermatitis
NCT001893973	NCT00189397_3_T1	COMPOUND	0	0	Parthenium
NCT001893974	NCT00189397_4_T0	GENE	2	2	has
NCT001893974	NCT00189397_4_T1	PHENOTYPE	14	14	remissions
NCT001893976	NCT00189397_6_T0	GENE	4	4	ABCD
NCT001893977	NCT00189397_7_T0	CELL	10	11	T lymphocytes
NCT001893978	NCT00189397_8_T0	COMPOUND	15	15	azathioprine
NCT001893978	NCT00189397_8_T1	PHENOTYPE	10	10	remissions
NCT001893979	NCT00189397_9_T0	COMPOUND	4	4	azathioprine
NCT001893979	NCT00189397_9_T1	PHENOTYPE	1	2	side effect
NCT0018939710	NCT00189397_10_T0	PHENOTYPE	24	24	dermatitis
NCT0018939710	NCT00189397_10_T1	COMPOUND	23	23	Parthenium
NCT0018939710	NCT00189397_10_T2	PHENOTYPE	12	12	pulse
NCT0018939710	NCT00189397_10_T3	COMPOUND	10	10	azathioprine
NCT0018939710	NCT00189397_10_T4	COMPOUND	16	16	azathioprine
NCT0018939710	NCT00189397_10_T5	PHENOTYPE	19	19	remissions
NCT0018939716	NCT00189397_16_T0	PHENOTYPE	14	14	dermatitis
NCT001894236	NCT00189423_6_T0	GENE	0	0	CPR
NCT001894238	NCT00189423_8_T0	ORGAN	21	21	thorax
NCT001894238	NCT00189423_8_T1	GENE	15	15	CPR
NCT001894238	NCT00189423_8_T2	ORGAN	8	9	chest wall
NCT001894239	NCT00189423_9_T0	GENE	38	38	CPR
NCT001894239	NCT00189423_9_T1	GENE	42	42	CPR
NCT001894239	NCT00189423_9_T2	ORGAN	26	26	heart
NCT001894239	NCT00189423_9_T3	ORGAN	13	13	thorax
NCT001894239	NCT00189423_9_T4	ORGAN	16	17	chest wall
NCT0018942312	NCT00189423_12_T0	GENE	9	9	IDE
NCT001894496	NCT00189449_6_T0	PHENOTYPE	13	13	TAA
NCT001894496	NCT00189449_6_T1	COMPOUND	8	9	triamcinolone acetonide
NCT001894496	NCT00189449_6_T2	PHENOTYPE	31	32	allergic rhinitis
NCT001894622	NCT00189462_2_T0	GENE	9	9	has
NCT001894622	NCT00189462_2_T1	PHENOTYPE	31	31	anesthesia
NCT001894754	NCT00189475_4_T0	BIOLOGICAL_PROCESS	0	0	Phlebotomy
NCT001894754	NCT00189475_4_T1	PHENOTYPE	21	21	atopy
NCT001894754	NCT00189475_4_T2	PHENOTYPE	11	12	allergy skin
NCT001895272	NCT00189527_2_T0	PHENOTYPE	24	24	ventilation
NCT001895272	NCT00189527_2_T1	PHENOTYPE	13	13	tolerance
NCT001895272	NCT00189527_2_T2	PHENOTYPE	28	30	chronic respiratory failure
NCT001895407	NCT00189540_7_T0	PHENOTYPE	29	29	experiences
NCT001895407	NCT00189540_7_T1	PHENOTYPE	7	9	Critical Limb Ischemia
NCT001895409	NCT00189540_9_T0	PHENOTYPE	6	6	peripheral
NCT0018954011	NCT00189540_11_T0	PHENOTYPE	13	16	peripheral arterial occlusive disease
NCT0018954014	NCT00189540_14_T0	GENE	18	18	bypass
NCT0018954014	NCT00189540_14_T1	PHENOTYPE	12	14	peripheral arterial disease
NCT0018954018	NCT00189540_18_T0	COMPOUND	11	11	clopidogrel
NCT0018954018	NCT00189540_18_T1	COMPOUND	12	12	ticlopidine
NCT0018954018	NCT00189540_18_T2	COMPOUND	13	13	aspirin
NCT0018954018	NCT00189540_18_T3	CELL	8	8	platelet
NCT0018954022	NCT00189540_22_T0	COMPOUND	6	6	1
NCT0018954022	NCT00189540_22_T1	COMPOUND	13	13	2
NCT0018954022	NCT00189540_22_T2	COMPOUND	17	17	3
NCT0018954022	NCT00189540_22_T3	PHENOTYPE	11	11	menopausal
NCT0018954022	NCT00189540_22_T4	PHENOTYPE	15	15	sterile
NCT0018954028	NCT00189540_28_T0	ORGAN	25	25	ankle
NCT0018954028	NCT00189540_28_T1	PHENOTYPE	10	11	vascular disease
NCT0018954030	NCT00189540_30_T0	PHENOTYPE	5	6	Buerger's disease
NCT0018954030	NCT00189540_30_T1	PHENOTYPE	7	8	thromboangiitis obliterans
NCT0018954034	NCT00189540_34_T0	PHENOTYPE	13	13	initiation
NCT0018954034	NCT00189540_34_T1	GENE	3	3	had
NCT0018954035	NCT00189540_35_T0	COMPOUND	11	11	2
NCT0018954035	NCT00189540_35_T1	PHENOTYPE	16	16	initiation
NCT0018954035	NCT00189540_35_T2	PHENOTYPE	9	9	occluded
NCT0018954037	NCT00189540_37_T0	PHENOTYPE	26	26	initiation
NCT0018954037	NCT00189540_37_T1	PHENOTYPE	7	7	hypertension
NCT0018954039	NCT00189540_39_T0	PHENOTYPE	17	17	osteomyelitis
NCT0018954039	NCT00189540_39_T1	ORGAN	7	7	tendon
NCT0018954039	NCT00189540_39_T2	PHENOTYPE	3	3	ulcerations
NCT0018954039	NCT00189540_39_T3	PHENOTYPE	16	16	cellulitis
NCT0018954044	NCT00189540_44_T0	GENE	2	2	had
NCT0018954044	NCT00189540_44_T1	PHENOTYPE	24	24	recurrence
NCT0018954044	NCT00189540_44_T2	PHENOTYPE	4	4	tumor
NCT0018954044	NCT00189540_44_T3	PHENOTYPE	9	10	breast cancer
NCT0018954045	NCT00189540_45_T0	PHENOTYPE	26	26	recurrence
NCT0018954045	NCT00189540_45_T1	PHENOTYPE	4	4	tumor
NCT0018954045	NCT00189540_45_T2	PHENOTYPE	11	11	tumor
NCT0018954045	NCT00189540_45_T3	GENE	2	2	had
NCT0018954050	NCT00189540_50_T0	GENE	3	3	has
NCT0018954050	NCT00189540_50_T1	PHENOTYPE	7	8	hepatic cirrhosis
NCT0018954050	NCT00189540_50_T2	PHENOTYPE	9	10	viral hepatitis
NCT0018954054	NCT00189540_54_T0	PHENOTYPE	13	13	feels
NCT001895530	NCT00189553_0_T0	PHENOTYPE	15	15	Relapse
NCT001895530	NCT00189553_0_T1	PHENOTYPE	10	12	Epithelial Ovarian Cancer
NCT001895533	NCT00189553_3_T0	COMPOUND	6	6	paclitaxel
NCT001895533	NCT00189553_3_T1	PHENOTYPE	16	16	tolerance
NCT001895662	NCT00189566_2_T0	PHENOTYPE	0	0	Tolerance
NCT001895923	NCT00189592_3_T0	PHENOTYPE	12	12	acute
NCT001895923	NCT00189592_3_T1	PHENOTYPE	18	18	chronic
NCT001895923	NCT00189592_3_T2	PHENOTYPE	19	19	degeneration
NCT001895923	NCT00189592_3_T3	PHENOTYPE	10	11	plantar fasciitis
NCT001895923	NCT00189592_3_T4	PHENOTYPE	8	9	heel spurs
NCT001895927	NCT00189592_7_T0	PHENOTYPE	10	11	plantar fasciitis
NCT001895928	NCT00189592_8_T0	PHENOTYPE	12	13	progressing to
NCT0018959211	NCT00189592_11_T0	GENE	3	3	has
NCT0018959211	NCT00189592_11_T1	GENE	12	12	has
NCT0018959212	NCT00189592_12_T0	TISSUE	1	1	fascia
NCT0018959214	NCT00189592_14_T0	PHENOTYPE	5	5	sequelae
NCT0018959214	NCT00189592_14_T1	TISSUE	8	8	fascia
NCT0018959215	NCT00189592_15_T0	ORGAN	5	5	plasma
NCT0018959215	NCT00189592_15_T1	PHENOTYPE	15	15	tendinosis
NCT0018959215	NCT00189592_15_T2	PHENOTYPE	33	35	congestive heart failure
NCT0018959216	NCT00189592_16_T0	PHENOTYPE	21	21	localized
NCT0018959216	NCT00189592_16_T1	PHENOTYPE	1	3	mechanism of action
NCT0018959218	NCT00189592_18_T0	PHENOTYPE	8	8	tendinosis
NCT0018959218	NCT00189592_18_T1	ORGAN	12	12	plasma
NCT0018959220	NCT00189592_20_T0	GENE	7	7	has
NCT0018959220	NCT00189592_20_T1	PHENOTYPE	15	15	tendinosis
NCT0018959220	NCT00189592_20_T2	ORGAN	4	4	plasma
NCT0018959220	NCT00189592_20_T3	PHENOTYPE	13	13	chronic
NCT001896051	NCT00189605_1_T0	GENE	5	5	disc
NCT001896051	NCT00189605_1_T1	ORGAN	4	4	plasma
NCT001896052	NCT00189605_2_T0	PHENOTYPE	11	11	symptoms
NCT001896053	NCT00189605_3_T0	GENE	14	14	disc
NCT001896053	NCT00189605_3_T1	ORGAN	13	13	plasma
NCT001896058	NCT00189605_8_T0	GENE	10	10	disc
NCT001896058	NCT00189605_8_T1	ORGAN	9	9	plasma
NCT001896059	NCT00189605_9_T0	GENE	45	45	disc
NCT001896059	NCT00189605_9_T1	ORGAN	44	44	plasma
NCT0018960512	NCT00189605_12_T0	PHENOTYPE	5	5	focal
NCT0018960512	NCT00189605_12_T1	GENE	8	8	disc
NCT0018960512	NCT00189605_12_T2	GENE	1	1	has
NCT0018960516	NCT00189605_16_T0	PHENOTYPE	10	11	herniated disc
NCT0018960530	NCT00189605_30_T0	PHENOTYPE	9	9	peripheral
NCT0018960530	NCT00189605_30_T1	GENE	1	1	has
NCT0018960532	NCT00189605_32_T0	PHENOTYPE	0	0	Allergy
NCT0018960545	NCT00189605_45_T0	PHENOTYPE	5	5	tumor
NCT0018960545	NCT00189605_45_T1	GENE	1	1	has
NCT0018960545	NCT00189605_45_T2	PHENOTYPE	3	4	spinal fracture
NCT0018960548	NCT00189605_48_T0	ORGAN	3	4	cauda equina
NCT0018960549	NCT00189605_49_T0	PHENOTYPE	0	0	Progressive
NCT0018960550	NCT00189605_50_T0	PHENOTYPE	3	3	spondylolisthesis
NCT0018960552	NCT00189605_52_T0	PHENOTYPE	6	6	herniation
NCT0018960552	NCT00189605_52_T1	GENE	5	5	disc
NCT001896181	NCT00189618_1_T0	GENE	24	24	ASA
NCT0018961811	NCT00189618_11_T0	ORGAN	8	8	capillary
NCT0018961811	NCT00189618_11_T1	COMPOUND	20	20	oxygen
NCT0018961811	NCT00189618_11_T2	PHENOTYPE	17	18	oxygen extraction
NCT0018961813	NCT00189618_13_T0	PHENOTYPE	31	31	atherosclerosis
NCT0018961813	NCT00189618_13_T1	GENE	18	19	insulin receptor
NCT0018961814	NCT00189618_14_T0	PHENOTYPE	18	18	quality-of-life
NCT0018961814	NCT00189618_14_T1	PHENOTYPE	6	7	intermittent claudication
NCT0018961820	NCT00189618_20_T0	GENE	9	9	ASA
NCT001896310	NCT00189631_0_T0	PHENOTYPE	5	7	Metastatic Breast Cancer
NCT001896313	NCT00189631_3_T0	PHENOTYPE	0	0	Secondary
NCT001896313	NCT00189631_3_T1	PHENOTYPE	6	6	tolerance
NCT001896442	NCT00189644_2_T0	PHENOTYPE	8	8	recurrence
NCT001896442	NCT00189644_2_T1	PHENOTYPE	12	12	metastases
NCT001896442	NCT00189644_2_T2	PHENOTYPE	0	0	Secondary
NCT001896442	NCT00189644_2_T3	PHENOTYPE	14	14	tolerance
NCT001896573	NCT00189657_3_T0	PHENOTYPE	8	8	recurrence
NCT001896573	NCT00189657_3_T1	PHENOTYPE	12	12	metastases
NCT001896573	NCT00189657_3_T2	PHENOTYPE	0	0	Secondary
NCT001896573	NCT00189657_3_T3	PHENOTYPE	14	14	tolerance
NCT001896701	NCT00189670_1_T0	PHENOTYPE	4	4	secondary
NCT001896830	NCT00189683_0_T0	PHENOTYPE	5	6	Colorectal Cancer
NCT001896832	NCT00189683_2_T0	PHENOTYPE	3	3	progression
NCT001897610	NCT00189761_0_T0	PHENOTYPE	7	7	Pharmacokinetics
NCT001898262	NCT00189826_2_T0	GENE	10	10	FK506
NCT001898391	NCT00189839_1_T0	GENE	10	10	FK506
NCT001898521	NCT00189852_1_T0	PHENOTYPE	0	0	Secondary
NCT0018985210	NCT00189852_10_T0	PHENOTYPE	8	8	chronic
NCT0018985213	NCT00189852_13_T0	PHENOTYPE	4	4	affects
NCT0018985215	NCT00189852_15_T0	GENE	2	2	has
NCT0018985217	NCT00189852_17_T0	GENE	1	1	has
NCT0018985217	NCT00189852_17_T1	PHENOTYPE	12	13	heart failure
NCT0018985222	NCT00189852_22_T0	PHENOTYPE	3	3	CHF
NCT0018985228	NCT00189852_28_T0	PHENOTYPE	6	6	strategies
NCT001898782	NCT00189878_2_T0	PHENOTYPE	9	9	urticaria
NCT001898782	NCT00189878_2_T1	PHENOTYPE	16	16	severely
NCT001898782	NCT00189878_2_T2	PHENOTYPE	20	20	chronic
NCT001898782	NCT00189878_2_T3	PHENOTYPE	21	22	idiopathic urticaria
NCT001898785	NCT00189878_5_T0	COMPOUND	12	12	methotrexate
NCT001898785	NCT00189878_5_T1	COMPOUND	21	21	methotrexate
NCT001898786	NCT00189878_6_T0	COMPOUND	14	14	methotrexate
NCT001898786	NCT00189878_6_T1	COMPOUND	32	32	methotrexate
NCT001899301	NCT00189930_1_T0	PHENOTYPE	8	8	menopausal
NCT001899305	NCT00189930_5_T0	PHENOTYPE	0	2	High blood pressure
NCT001899309	NCT00189930_9_T0	PHENOTYPE	0	1	Diabetes mellitus
NCT001899309	NCT00189930_9_T1	PHENOTYPE	3	5	high blood sugar
NCT0018993011	NCT00189930_11_T0	GENE	14	14	had
NCT0018993011	NCT00189930_11_T1	GENE	1	1	has
NCT0018993011	NCT00189930_11_T2	ORGAN	16	16	heart
NCT001899560	NCT00189956_0_T0	PHENOTYPE	14	14	Smallpox
NCT001899560	NCT00189956_0_T1	GENE	16	16	pox
NCT001899694	NCT00189969_4_T0	GENE	1	1	12
NCT001899695	NCT00189969_5_T0	PHENOTYPE	6	7	atopic dermatitis
NCT001899696	NCT00189969_6_T0	PHENOTYPE	8	8	acute
NCT001899696	NCT00189969_6_T1	PHENOTYPE	10	10	disorders
NCT001899696	NCT00189969_6_T2	PHENOTYPE	2	2	chronic
NCT001899825	NCT00189982_5_T0	PHENOTYPE	3	3	bleeding
NCT001899951	NCT00189995_1_T0	PHENOTYPE	18	18	symptoms
NCT001899951	NCT00189995_1_T1	PHENOTYPE	24	24	agitation
NCT001899953	NCT00189995_3_T0	PHENOTYPE	4	4	symptoms
NCT001899954	NCT00189995_4_T0	PHENOTYPE	0	1	Violent behavior
NCT001899958	NCT00189995_8_T0	PHENOTYPE	12	12	symptoms
NCT001899958	NCT00189995_8_T1	PHENOTYPE	10	10	acute
NCT001899958	NCT00189995_8_T2	COMPOUND	16	16	olanzapine
NCT001899958	NCT00189995_8_T3	COMPOUND	14	14	risperidone
NCT001899958	NCT00189995_8_T4	GENE	20	20	5.7
NCT0018999513	NCT00189995_13_T0	PHENOTYPE	8	8	resistant
NCT001900081	NCT00190008_1_T0	GENE	15	15	GABA
NCT001900082	NCT00190008_2_T0	GENE	9	9	GABA
NCT001900084	NCT00190008_4_T0	PHENOTYPE	3	3	homeostatic
NCT001900086	NCT00190008_6_T0	COMPOUND	12	12	potassium
NCT001900086	NCT00190008_6_T1	BIOLOGICAL_PROCESS	6	6	neurotransmission
NCT001900086	NCT00190008_6_T2	GENE	1	1	has
NCT001900086	NCT00190008_6_T3	COMPOUND	10	10	piracetam
NCT001900087	NCT00190008_7_T0	GENE	11	11	TD
NCT001900088	NCT00190008_8_T0	GENE	11	11	mega
NCT0019000810	NCT00190008_10_T0	GENE	5	5	TD
NCT0019000811	NCT00190008_11_T0	PHENOTYPE	5	5	symptoms
NCT0019000811	NCT00190008_11_T1	GENE	7	7	TD
NCT0019000811	NCT00190008_11_T2	GENE	13	13	3.7
NCT0019000812	NCT00190008_12_T0	GENE	15	15	TD
NCT0019000812	NCT00190008_12_T1	COMPOUND	12	12	piracetam
NCT0019000815	NCT00190008_15_T0	GENE	39	39	had
NCT0019000815	NCT00190008_15_T1	GENE	30	30	TD
NCT0019000815	NCT00190008_15_T2	PHENOTYPE	12	13	tardive dyskinesia
NCT0019000816	NCT00190008_16_T0	PHENOTYPE	17	18	alcohol abuse
NCT0019000816	NCT00190008_16_T1	PHENOTYPE	10	11	Huntington's disease
NCT0019000816	NCT00190008_16_T2	PHENOTYPE	35	36	neurological disorders
NCT0019000816	NCT00190008_16_T3	PHENOTYPE	45	46	tardive dyskinesia
NCT0019000818	NCT00190008_18_T0	PHENOTYPE	14	14	severity
NCT0019000818	NCT00190008_18_T1	GENE	16	16	TD
NCT0019000818	NCT00190008_18_T2	PHENOTYPE	11	11	fluctuations
NCT0019000823	NCT00190008_23_T0	PHENOTYPE	2	3	tardive dyskinesia
NCT0019000826	NCT00190008_26_T0	PHENOTYPE	10	11	extrapyramidal symptoms
NCT0019000827	NCT00190008_27_T0	GENE	12	12	has
NCT0019000827	NCT00190008_27_T1	PHENOTYPE	8	9	extrapyramidal symptoms
NCT0019000827	NCT00190008_27_T2	PHENOTYPE	22	23	extrapyramidal symptoms
NCT0019000828	NCT00190008_28_T0	COMPOUND	3	3	piracetam
NCT0019000828	NCT00190008_28_T1	PHENOTYPE	24	25	movement disorders
NCT0019000828	NCT00190008_28_T2	PHENOTYPE	19	20	dependence on
NCT0019000830	NCT00190008_30_T0	COMPOUND	4	4	piracetam
NCT0019000831	NCT00190008_31_T0	PHENOTYPE	9	9	symptoms
NCT0019000831	NCT00190008_31_T1	GENE	8	8	TD
NCT0019000831	NCT00190008_31_T2	GENE	30	30	TD
NCT0019000831	NCT00190008_31_T3	GENE	19	19	3.7
NCT0019000831	NCT00190008_31_T4	COMPOUND	11	11	piracetam
NCT0019000832	NCT00190008_32_T0	GENE	19	19	TD
NCT0019000832	NCT00190008_32_T1	COMPOUND	4	4	piracetam
NCT0019000839	NCT00190008_39_T0	GENE	1	1	AH
NCT0019000843	NCT00190008_43_T0	GENE	7	7	al
NCT0019000843	NCT00190008_43_T1	COMPOUND	10	10	piracetam
NCT0019000843	NCT00190008_43_T2	GENE	6	6	et
NCT0019000844	NCT00190008_44_T0	GENE	0	0	Int
NCT0019000860	NCT00190008_60_T0	PHENOTYPE	1	1	Fahn
NCT0019000865	NCT00190008_65_T0	COMPOUND	5	5	piracetam
NCT0019000871	NCT00190008_71_T0	GENE	1	1	SK
NCT0019000872	NCT00190008_72_T0	PHENOTYPE	3	3	dyskinesia
NCT0019000875	NCT00190008_75_T0	PHENOTYPE	16	16	myoclonus
NCT0019000875	NCT00190008_75_T1	GENE	1	1	JA
NCT0019000875	NCT00190008_75_T2	GENE	7	7	al
NCT0019000875	NCT00190008_75_T3	COMPOUND	5	5	N
NCT0019000875	NCT00190008_75_T4	GENE	6	6	et
NCT0019000878	NCT00190008_78_T0	PHENOTYPE	10	10	choreoathetosis
NCT0019000878	NCT00190008_78_T1	GENE	7	7	al
NCT0019000878	NCT00190008_78_T2	GENE	6	6	et
NCT0019000882	NCT00190008_82_T0	PHENOTYPE	5	5	akathisia
NCT0019000885	NCT00190008_85_T0	PHENOTYPE	16	16	akathisia
NCT0019000885	NCT00190008_85_T1	GENE	7	7	al
NCT0019000885	NCT00190008_85_T2	COMPOUND	3	3	N
NCT0019000885	NCT00190008_85_T3	GENE	6	6	et
NCT0019000885	NCT00190008_85_T4	PHENOTYPE	13	14	tardive dyskinesia
NCT001900212	NCT00190021_2_T0	GENE	1	1	atypical
NCT001900213	NCT00190021_3_T0	COMPOUND	11	11	acetylcholine
NCT001900213	NCT00190021_3_T1	GENE	0	0	Cholinesterase
NCT001900214	NCT00190021_4_T0	GENE	27	27	7-10
NCT001900214	NCT00190021_4_T1	PHENOTYPE	20	21	behavioral disturbances
NCT001900214	NCT00190021_4_T2	PHENOTYPE	25	26	Alzheimer's disease
NCT001900215	NCT00190021_5_T0	PHENOTYPE	17	17	symptoms
NCT001900215	NCT00190021_5_T1	PHENOTYPE	10	10	disorders
NCT001900215	NCT00190021_5_T2	PHENOTYPE	20	21	visual hallucinations
NCT001900216	NCT00190021_6_T0	PHENOTYPE	22	22	severity
NCT001900216	NCT00190021_6_T1	PHENOTYPE	16	17	Alzheimer's disease
NCT001900218	NCT00190021_8_T0	COMPOUND	13	13	perphenazine
NCT001900218	NCT00190021_8_T1	COMPOUND	11	11	donepezil
NCT001900218	NCT00190021_8_T2	COMPOUND	28	28	donepezil
NCT0019002116	NCT00190021_16_T0	GENE	6	6	1.1
NCT0019002116	NCT00190021_16_T1	COMPOUND	15	15	perphenazine
NCT0019002116	NCT00190021_16_T2	COMPOUND	27	27	perphenazine
NCT0019002116	NCT00190021_16_T3	COMPOUND	20	20	donepezil
NCT0019002117	NCT00190021_17_T0	COMPOUND	11	11	perphenazine
NCT0019002117	NCT00190021_17_T1	COMPOUND	28	28	donepezil
NCT0019002119	NCT00190021_19_T0	PHENOTYPE	2	3	psychotic symptoms
NCT0019002121	NCT00190021_21_T0	GENE	21	21	GDS
NCT0019002128	NCT00190021_28_T0	GENE	1	1	LS
NCT0019002129	NCT00190021_29_T0	PHENOTYPE	5	5	dementia
NCT0019002129	NCT00190021_29_T1	PHENOTYPE	3	3	psychosis
NCT0019002133	NCT00190021_33_T0	PHENOTYPE	2	2	agitation
NCT0019002133	NCT00190021_33_T1	PHENOTYPE	4	4	dementia
NCT0019002137	NCT00190021_37_T0	PHENOTYPE	1	1	symptoms
NCT0019002145	NCT00190021_45_T0	PHENOTYPE	3	3	psychosis
NCT0019002150	NCT00190021_50_T0	GENE	0	0	Arch
NCT0019002150	NCT00190021_50_T1	GENE	2	2	Med
NCT0019002152	NCT00190021_52_T0	GENE	1	1	SP
NCT0019002153	NCT00190021_53_T0	PHENOTYPE	2	2	symptoms
NCT0019002153	NCT00190021_53_T1	PHENOTYPE	6	6	dementia
NCT0019002153	NCT00190021_53_T2	PHENOTYPE	4	4	delirium
NCT0019002156	NCT00190021_56_T0	GENE	14	14	cholinesterase
NCT0019002156	NCT00190021_56_T1	GENE	1	1	MS
NCT0019002156	NCT00190021_56_T2	GENE	0	0	Mega
NCT0019002156	NCT00190021_56_T3	GENE	5	5	SM
NCT0019002156	NCT00190021_56_T4	GENE	7	7	al
NCT0019002156	NCT00190021_56_T5	GENE	6	6	et
NCT0019002156	NCT00190021_56_T6	PHENOTYPE	18	19	Alzheimer disease
NCT0019002157	NCT00190021_57_T0	GENE	0	0	Arch
NCT0019002160	NCT00190021_60_T0	GENE	3	3	cholinesterase
NCT0019002161	NCT00190021_61_T0	GENE	2	2	Rep
NCT0019002163	NCT00190021_63_T0	GENE	5	5	SP
NCT0019002164	NCT00190021_64_T0	COMPOUND	4	4	donepezil
NCT0019002164	NCT00190021_64_T1	PHENOTYPE	1	2	visual hallucinations
NCT0019002167	NCT00190021_67_T0	GENE	3	3	LT
NCT0019002167	NCT00190021_67_T1	GENE	1	1	SL
NCT0019002168	NCT00190021_68_T0	COMPOUND	5	5	donepezil
NCT0019002170	NCT00190021_70_T0	PHENOTYPE	0	0	Dementia
NCT0019002177	NCT00190021_77_T0	BIOLOGICAL_PROCESS	1	1	Aging
NCT0019002180	NCT00190021_80_T0	PHENOTYPE	3	3	delusions
NCT0019002184	NCT00190021_84_T0	COMPOUND	2	2	tacrine
NCT0019002184	NCT00190021_84_T1	PHENOTYPE	4	5	behavioral symptoms
NCT0019002187	NCT00190021_87_T0	GENE	3	3	Ser
NCT0019002187	NCT00190021_87_T1	COMPOUND	11	11	rivastigmine
NCT0019002187	NCT00190021_87_T2	PHENOTYPE	13	13	dementia
NCT0019002187	NCT00190021_87_T3	GENE	2	2	Del
NCT0019002187	NCT00190021_87_T4	GENE	8	8	al
NCT0019002187	NCT00190021_87_T5	GENE	7	7	et
NCT0019002191	NCT00190021_91_T0	COMPOUND	3	3	donepezil
NCT0019002191	NCT00190021_91_T1	PHENOTYPE	8	9	psychotic symptoms
NCT0019002194	NCT00190021_94_T0	GENE	5	5	PR
NCT0019002194	NCT00190021_94_T1	GENE	3	3	SE
NCT0019002194	NCT00190021_94_T2	GENE	1	1	MF
NCT0019002197	NCT00190021_97_T0	GENE	2	2	Res
NCT0019002199	NCT00190021_99_T0	GENE	4	4	de
NCT0019002199	NCT00190021_99_T1	GENE	3	3	SH
NCT0019002199	NCT00190021_99_T2	GENE	12	12	GDS
NCT0019002199	NCT00190021_99_T3	GENE	8	8	al
NCT0019002199	NCT00190021_99_T4	GENE	7	7	et
NCT00190021102	NCT00190021_102_T0	PHENOTYPE	16	16	acute
NCT00190021102	NCT00190021_102_T1	GENE	1	1	BG
NCT00190021102	NCT00190021_102_T2	COMPOUND	11	11	perphenazine
NCT00190021102	NCT00190021_102_T3	GENE	7	7	al
NCT00190021102	NCT00190021_102_T4	PHENOTYPE	19	19	psychosis
NCT00190021102	NCT00190021_102_T5	GENE	6	6	et
NCT00190021102	NCT00190021_102_T6	PHENOTYPE	25	25	demented
NCT00190021102	NCT00190021_102_T7	COMPOUND	10	10	citalopram
NCT00190021102	NCT00190021_102_T8	PHENOTYPE	21	22	behavioral disturbances
NCT00190021105	NCT00190021_105_T0	GENE	3	3	BG
NCT00190021105	NCT00190021_105_T1	GENE	7	7	al
NCT00190021105	NCT00190021_105_T2	GENE	1	1	RA
NCT00190021105	NCT00190021_105_T3	GENE	6	6	et
NCT00190021108	NCT00190021_108_T0	GENE	0	0	Kay
NCT00190021109	NCT00190021_109_T0	PHENOTYPE	3	3	Syndrome
NCT00190021114	NCT00190021_114_T0	GENE	9	9	1976
NCT001900340	NCT00190034_0_T0	PHENOTYPE	2	2	Acute
NCT001900344	NCT00190034_4_T0	GENE	19	19	bypass
NCT001900344	NCT00190034_4_T1	COMPOUND	9	9	N-acetylcysteine
NCT001900344	NCT00190034_4_T2	PHENOTYPE	13	13	nephrotoxicity
NCT001900345	NCT00190034_5_T0	GENE	15	15	bypass
NCT001900346	NCT00190034_6_T0	GENE	25	25	bypass
NCT001900346	NCT00190034_6_T1	COMPOUND	8	8	N-acetylcysteine
NCT001900347	NCT00190034_7_T0	COMPOUND	1	1	creatinine
NCT001900347	NCT00190034_7_T1	ORGAN	0	0	Serum
NCT001900347	NCT00190034_7_T2	COMPOUND	4	4	urea
NCT001900348	NCT00190034_8_T0	PHENOTYPE	16	16	acute
NCT001900348	NCT00190034_8_T1	COMPOUND	8	8	N-acetylcysteine
NCT001900348	NCT00190034_8_T2	GENE	21	21	CPB
NCT001900348	NCT00190034_8_T3	PHENOTYPE	25	27	chronic renal insufficiency
NCT0019003411	NCT00190034_11_T0	PHENOTYPE	0	2	Acute renal failure
NCT0019003412	NCT00190034_12_T0	PHENOTYPE	8	10	ventricular ejection fraction
NCT0019003412	NCT00190034_12_T1	PHENOTYPE	1	4	left ventricular systolic dysfunction
NCT0019003414	NCT00190034_14_T0	PHENOTYPE	0	0	Acute
NCT0019003414	NCT00190034_14_T1	PHENOTYPE	6	6	asthma
NCT0019003414	NCT00190034_14_T2	PHENOTYPE	1	4	chronic obstructive lung disease
NCT001900471	NCT00190047_1_T0	GENE	3	3	Period
NCT001900472	NCT00190047_2_T0	PHENOTYPE	7	8	brain bleeding
NCT001900474	NCT00190047_4_T0	COMPOUND	7	7	DP-b99
NCT001900475	NCT00190047_5_T0	COMPOUND	20	20	DP-b99
NCT001900476	NCT00190047_6_T0	GENE	22	22	Period
NCT001900478	NCT00190047_8_T0	GENE	0	0	The
NCT001900479	NCT00190047_9_T0	GENE	41	41	Period
NCT001900602	NCT00190060_2_T0	PHENOTYPE	5	5	falls
NCT001900602	NCT00190060_2_T1	PHENOTYPE	6	6	fractures
NCT001900603	NCT00190060_3_T0	COMPOUND	6	6	testosterone
NCT001900603	NCT00190060_3_T1	PHENOTYPE	23	23	weakness
NCT001900603	NCT00190060_3_T2	ORGAN	5	5	serum
NCT001900603	NCT00190060_3_T3	PHENOTYPE	24	24	sarcopenia
NCT001900603	NCT00190060_3_T4	PHENOTYPE	20	21	muscle wasting
NCT001900730	NCT00190073_0_T0	PHENOTYPE	3	4	Alcoholic Neuropathy
NCT001900733	NCT00190073_3_T0	PHENOTYPE	16	17	alcoholic neuropathy
NCT001900737	NCT00190073_7_T0	GENE	22	22	RR
NCT001900737	NCT00190073_7_T1	GENE	19	19	SSR
NCT001900737	NCT00190073_7_T2	PHENOTYPE	17	18	skin response
NCT001900738	NCT00190073_8_T0	PHENOTYPE	6	6	chronic
NCT001900738	NCT00190073_8_T1	PHENOTYPE	3	4	peripheral neuropathy
NCT0019007312	NCT00190073_12_T0	COMPOUND	6	6	thiamine
NCT0019007312	NCT00190073_12_T1	COMPOUND	4	4	ethanol
NCT0019007312	NCT00190073_12_T2	PHENOTYPE	8	9	alcoholic neuropathy
NCT0019007313	NCT00190073_13_T0	COMPOUND	5	5	thiamine
NCT0019007313	NCT00190073_13_T1	GENE	14	14	has
NCT0019007313	NCT00190073_13_T2	PHENOTYPE	18	18	degeneration
NCT0019007313	NCT00190073_13_T3	PHENOTYPE	7	8	alcoholic neuropathy
NCT0019007319	NCT00190073_19_T0	PHENOTYPE	19	19	disorders
NCT0019007319	NCT00190073_19_T1	GENE	9	9	MRI
NCT0019007319	NCT00190073_19_T2	PHENOTYPE	26	28	symptoms and signs
NCT0019007321	NCT00190073_21_T0	GENE	33	33	al
NCT0019007321	NCT00190073_21_T1	GENE	32	32	et
NCT0019007321	NCT00190073_21_T2	COMPOUND	18	18	thiamine
NCT0019007322	NCT00190073_22_T0	COMPOUND	6	6	thiamine
NCT0019007323	NCT00190073_23_T0	PHENOTYPE	28	28	neuropathy
NCT0019007323	NCT00190073_23_T1	GENE	31	31	al
NCT0019007323	NCT00190073_23_T2	GENE	0	0	Age
NCT0019007323	NCT00190073_23_T3	GENE	30	30	et
NCT0019007323	NCT00190073_23_T4	PHENOTYPE	24	25	neurological disorder
NCT0019007327	NCT00190073_27_T0	PHENOTYPE	7	7	wounds
NCT0019007328	NCT00190073_28_T0	PHENOTYPE	11	11	abrasion
NCT0019007328	NCT00190073_28_T1	BIOLOGICAL_PROCESS	0	1	Wound healing
NCT0019007333	NCT00190073_33_T0	COMPOUND	24	24	1
NCT0019007333	NCT00190073_33_T1	PHENOTYPE	7	7	blocked
NCT0019007333	NCT00190073_33_T2	ORGAN	12	12	serum
NCT0019007333	NCT00190073_33_T3	GENE	19	20	PGP 9.5
NCT0019007334	NCT00190073_34_T0	GENE	12	12	IgG
NCT0019007334	NCT00190073_34_T1	GENE	27	27	CA
NCT0019007335	NCT00190073_35_T0	GENE	11	11	CA
NCT0019007336	NCT00190073_36_T0	BIOLOGICAL_PROCESS	3	3	innervation
NCT0019007338	NCT00190073_38_T0	GENE	0	0	PGP
NCT0019007338	NCT00190073_38_T1	TISSUE	6	6	epidermis
NCT0019007338	NCT00190073_38_T2	CELL	2	3	nerve fibers
NCT0019007339	NCT00190073_39_T0	TISSUE	8	8	epidermis
NCT0019007340	NCT00190073_40_T0	ORGAN	8	8	dermis
NCT0019007341	NCT00190073_41_T0	GENE	26	26	MD
NCT0019007341	NCT00190073_41_T1	TISSUE	4	4	epidermis
NCT0019007350	NCT00190073_50_T0	GENE	11	11	had
NCT0019007361	NCT00190073_61_T0	GENE	11	11	SAP
NCT0019007361	NCT00190073_61_T1	GENE	6	6	CMAP
NCT0019007361	NCT00190073_61_T2	BIOLOGICAL_PROCESS	4	5	action potential
NCT0019007361	NCT00190073_61_T3	BIOLOGICAL_PROCESS	9	10	action potential
NCT0019007362	NCT00190073_62_T0	PHENOTYPE	3	3	bilateral
NCT0019007362	NCT00190073_62_T1	ORGAN	9	10	sural nerves
NCT0019007363	NCT00190073_63_T0	PHENOTYPE	18	18	distal
NCT0019007363	NCT00190073_63_T1	GENE	15	15	reduced
NCT0019007364	NCT00190073_64_T0	GENE	18	18	al
NCT0019007364	NCT00190073_64_T1	GENE	17	17	et
NCT0019007364	NCT00190073_64_T2	PHENOTYPE	3	4	sensorimotor polyneuropathy
NCT0019007365	NCT00190073_65_T0	ORGAN	3	5	autonomic nervous system
NCT0019007366	NCT00190073_66_T0	GENE	10	10	SSR
NCT0019007366	NCT00190073_66_T1	PHENOTYPE	8	9	skin response
NCT0019007374	NCT00190073_74_T0	PHENOTYPE	5	5	disorders
NCT0019007378	NCT00190073_78_T0	PHENOTYPE	17	17	chronic
NCT0019007378	NCT00190073_78_T1	PHENOTYPE	14	15	peripheral neuropathy
NCT0019007379	NCT00190073_79_T0	GENE	17	17	SSR
NCT0019007379	NCT00190073_79_T1	GENE	11	11	punch
NCT0019007379	NCT00190073_79_T2	PHENOTYPE	4	5	neural degeneration
NCT0019007386	NCT00190073_86_T0	COMPOUND	6	6	thiamine
NCT0019007386	NCT00190073_86_T1	COMPOUND	4	4	ethanol
NCT0019007386	NCT00190073_86_T2	PHENOTYPE	8	9	alcoholic neuropathy
NCT0019007391	NCT00190073_91_T0	COMPOUND	7	7	thiamine
NCT0019007391	NCT00190073_91_T1	PHENOTYPE	9	10	alcoholic neuropathy
NCT001900860	NCT00190086_0_T0	PHENOTYPE	0	0	Syndrome
NCT001900860	NCT00190086_0_T1	PHENOTYPE	3	4	Endothelial Dysfunction
NCT0019008613	NCT00190086_13_T0	COMPOUND	17	17	nitroglycerin
NCT0019008613	NCT00190086_13_T1	PHENOTYPE	12	12	occlusion
NCT0019008613	NCT00190086_13_T2	GENE	11	11	cuff
NCT001900991	NCT00190099_1_T0	PHENOTYPE	0	0	Restenosis
NCT001900991	NCT00190099_1_T1	GENE	12	12	balloon
NCT001900993	NCT00190099_3_T0	PHENOTYPE	18	18	restenosis
NCT001900994	NCT00190099_4_T0	PHENOTYPE	5	5	restenosis
NCT001900994	NCT00190099_4_T1	PHENOTYPE	9	9	hyperplasia
NCT001900995	NCT00190099_5_T0	PHENOTYPE	5	5	restenosis
NCT001900996	NCT00190099_6_T0	GENE	8	8	balloon
NCT001900997	NCT00190099_7_T0	PHENOTYPE	15	15	restenosis
NCT0019009910	NCT00190099_10_T0	COMPOUND	4	4	paclitaxel
NCT0019009910	NCT00190099_10_T1	COMPOUND	2	2	rapamycin
NCT0019009911	NCT00190099_11_T0	COMPOUND	5	5	estrogen
NCT0019009912	NCT00190099_12_T0	GENE	19	19	eg
NCT0019009912	NCT00190099_12_T1	PHENOTYPE	16	16	proliferation
NCT0019009913	NCT00190099_13_T0	PHENOTYPE	9	11	coronary artery disease
NCT0019009915	NCT00190099_15_T0	COMPOUND	8	8	dexamethasone
NCT0019009916	NCT00190099_16_T0	PHENOTYPE	6	6	restenosis
NCT0019009916	NCT00190099_16_T1	GENE	36	36	pur
NCT0019009916	NCT00190099_16_T2	GENE	8	8	ACS
NCT0019009916	NCT00190099_16_T3	PHENOTYPE	18	19	adverse effect
NCT0019009918	NCT00190099_18_T0	PHENOTYPE	0	0	Restenosis
NCT0019009918	NCT00190099_18_T1	GENE	12	12	balloon
NCT0019009920	NCT00190099_20_T0	PHENOTYPE	18	18	restenosis
NCT0019009921	NCT00190099_21_T0	PHENOTYPE	5	5	restenosis
NCT0019009921	NCT00190099_21_T1	PHENOTYPE	9	9	hyperplasia
NCT0019009922	NCT00190099_22_T0	PHENOTYPE	5	5	restenosis
NCT0019009923	NCT00190099_23_T0	GENE	8	8	balloon
NCT0019009924	NCT00190099_24_T0	PHENOTYPE	15	15	restenosis
NCT0019009927	NCT00190099_27_T0	COMPOUND	4	4	paclitaxel
NCT0019009927	NCT00190099_27_T1	COMPOUND	2	2	rapamycin
NCT0019009928	NCT00190099_28_T0	COMPOUND	5	5	estrogen
NCT0019009929	NCT00190099_29_T0	GENE	19	19	eg
NCT0019009929	NCT00190099_29_T1	PHENOTYPE	16	16	proliferation
NCT0019009930	NCT00190099_30_T0	PHENOTYPE	9	11	coronary artery disease
NCT0019009932	NCT00190099_32_T0	COMPOUND	8	8	dexamethasone
NCT0019009933	NCT00190099_33_T0	PHENOTYPE	6	6	restenosis
NCT0019009933	NCT00190099_33_T1	GENE	36	36	pur
NCT0019009933	NCT00190099_33_T2	GENE	8	8	ACS
NCT0019009933	NCT00190099_33_T3	PHENOTYPE	18	19	adverse effect
NCT001901120	NCT00190112_0_T0	ORGAN	2	2	Heart
NCT001901120	NCT00190112_0_T1	PHENOTYPE	7	7	Sensitivity
NCT001901122	NCT00190112_2_T0	PHENOTYPE	13	13	Thoracic
NCT001901124	NCT00190112_4_T0	PHENOTYPE	1	1	imbalance
NCT001901124	NCT00190112_4_T1	GENE	10	10	has
NCT001901124	NCT00190112_4_T2	ORGAN	4	6	autonomic nervous system
NCT001901126	NCT00190112_6_T0	PHENOTYPE	10	10	severity
NCT001901126	NCT00190112_6_T1	GENE	17	17	bypass
NCT001901126	NCT00190112_6_T2	GENE	2	2	has
NCT001901126	NCT00190112_6_T3	ORGAN	15	16	coronary artery
NCT001901129	NCT00190112_9_T0	PHENOTYPE	17	17	attachment
NCT001901129	NCT00190112_9_T1	GENE	10	10	ANS
NCT001901129	NCT00190112_9_T2	BIOLOGICAL_PROCESS	4	4	innervation
NCT001901129	NCT00190112_9_T3	ORGAN	1	1	heart
NCT001901129	NCT00190112_9_T4	ORGAN	7	9	autonomic nervous system
NCT0019011210	NCT00190112_10_T0	GENE	5	5	ANS
NCT0019011210	NCT00190112_10_T1	CELL	6	7	nerve fibers
NCT0019011211	NCT00190112_11_T0	GENE	9	9	ANS
NCT0019011211	NCT00190112_11_T1	ORGAN	17	17	heart
NCT0019011212	NCT00190112_12_T0	GENE	9	9	bypass
NCT0019011212	NCT00190112_12_T1	ORGAN	7	8	coronary artery
NCT0019011213	NCT00190112_13_T0	PHENOTYPE	3	3	anesthesia
NCT0019011213	NCT00190112_13_T1	PHENOTYPE	7	7	anesthesia
NCT0019011215	NCT00190112_15_T0	ORGAN	4	4	heart
NCT0019011216	NCT00190112_16_T0	GENE	1	1	paired
NCT0019011219	NCT00190112_19_T0	PHENOTYPE	5	5	anastomoses
NCT0019011219	NCT00190112_19_T1	ORGAN	24	24	heart
NCT0019011219	NCT00190112_19_T2	ORGAN	47	48	pulmonary artery
NCT0019011219	NCT00190112_19_T3	ORGAN	33	35	superior vena cava
NCT0019011220	NCT00190112_20_T0	ORGAN	15	15	aorta
NCT0019011220	NCT00190112_20_T1	ORGAN	26	27	pulmonary artery
NCT0019011220	NCT00190112_20_T2	TISSUE	6	7	fat pads
NCT0019011220	NCT00190112_20_T3	ORGAN	11	13	superior vena cava
NCT0019011223	NCT00190112_23_T0	ORGAN	12	12	capillary
NCT0019011223	NCT00190112_23_T1	PHENOTYPE	20	21	vascular resistance
NCT0019011223	NCT00190112_23_T2	PHENOTYPE	13	14	wedge pressure
NCT0019011223	NCT00190112_23_T3	PHENOTYPE	5	7	pulmonary artery pressure
NCT0019011223	NCT00190112_23_T4	PHENOTYPE	15	17	systemic vascular resistance
NCT0019011226	NCT00190112_26_T0	GENE	13	13	5.2
NCT0019011229	NCT00190112_29_T0	PHENOTYPE	6	6	anesthesia
NCT0019011231	NCT00190112_31_T0	GENE	11	11	BIS
NCT0019011231	NCT00190112_31_T1	PHENOTYPE	7	7	anesthesia
NCT0019011232	NCT00190112_32_T0	GENE	3	3	BP
NCT0019011233	NCT00190112_33_T0	PHENOTYPE	21	21	anesthesia
NCT0019011235	NCT00190112_35_T0	GENE	33	33	SBP
NCT0019011237	NCT00190112_37_T0	GENE	11	11	r2
NCT0019011237	NCT00190112_37_T1	PHENOTYPE	2	2	regression
NCT0019011239	NCT00190112_39_T0	GENE	21	21	SBP
NCT0019011239	NCT00190112_39_T1	GENE	41	41	SBP
NCT0019011240	NCT00190112_40_T0	GENE	7	7	SBP
NCT0019011241	NCT00190112_41_T0	GENE	14	14	RR
NCT0019011241	NCT00190112_41_T1	GENE	17	17	SBP
NCT0019011241	NCT00190112_41_T2	GENE	20	20	0.5
NCT0019011241	NCT00190112_41_T3	GENE	11	11	K2
NCT0019011242	NCT00190112_42_T0	ORGAN	0	0	Heart
NCT001901253	NCT00190125_3_T0	PHENOTYPE	3	3	malnutrition
NCT001901253	NCT00190125_3_T1	PHENOTYPE	5	6	chronic inflammation
NCT001901255	NCT00190125_5_T0	PHENOTYPE	9	9	complications
NCT001901256	NCT00190125_6_T0	PHENOTYPE	13	13	malnutrition
NCT001901256	NCT00190125_6_T1	PHENOTYPE	15	15	inflammation
NCT001901381	NCT00190138_1_T0	GENE	10	10	ventricular
NCT001901381	NCT00190138_1_T1	PHENOTYPE	36	36	left-sided
NCT001901381	NCT00190138_1_T2	PHENOTYPE	38	39	conduction disorder
NCT001901381	NCT00190138_1_T3	PHENOTYPE	31	32	dilated cardiomyopathy
NCT001901381	NCT00190138_1_T4	PHENOTYPE	42	45	left bundle branch block
NCT001901381	NCT00190138_1_T5	PHENOTYPE	27	30	left ventricular systolic dysfunction
NCT001901383	NCT00190138_3_T0	PHENOTYPE	22	22	fluctuations
NCT001901383	NCT00190138_3_T1	ORGAN	17	17	heart
NCT001901384	NCT00190138_4_T0	PHENOTYPE	13	14	cardiac deaths
NCT001901385	NCT00190138_5_T0	GENE	8	8	has
NCT001901386	NCT00190138_6_T0	GENE	35	35	RV
NCT001901386	NCT00190138_6_T1	ORGAN	23	23	heart
NCT001901386	NCT00190138_6_T2	PHENOTYPE	18	19	heart failure
NCT001901389	NCT00190138_9_T0	PHENOTYPE	5	5	anastomoses
NCT0019013810	NCT00190138_10_T0	GENE	3	3	RA
NCT0019013810	NCT00190138_10_T1	ORGAN	10	11	atrial appendage
NCT0019013811	NCT00190138_11_T0	GENE	3	3	RV
NCT0019013811	NCT00190138_11_T1	GENE	9	9	RV
NCT0019013811	NCT00190138_11_T2	ORGAN	1	2	right ventricle
NCT0019013812	NCT00190138_12_T0	ORGAN	1	2	left ventricle
NCT0019013812	NCT00190138_12_T1	ORGAN	24	25	coronary artery
NCT0019013813	NCT00190138_13_T0	ORGAN	8	9	rectus abdominis
NCT0019013816	NCT00190138_16_T0	GENE	6	6	RV
NCT0019013819	NCT00190138_19_T0	ORGAN	12	12	capillary
NCT0019013819	NCT00190138_19_T1	PHENOTYPE	20	21	vascular resistance
NCT0019013819	NCT00190138_19_T2	PHENOTYPE	13	14	wedge pressure
NCT0019013819	NCT00190138_19_T3	PHENOTYPE	5	7	pulmonary artery pressure
NCT0019013819	NCT00190138_19_T4	PHENOTYPE	15	17	systemic vascular resistance
NCT0019013822	NCT00190138_22_T0	GENE	13	13	5.2
NCT0019013826	NCT00190138_26_T0	GENE	33	33	SBP
NCT0019013828	NCT00190138_28_T0	GENE	11	11	r2
NCT0019013828	NCT00190138_28_T1	PHENOTYPE	2	2	regression
NCT0019013830	NCT00190138_30_T0	GENE	21	21	SBP
NCT0019013830	NCT00190138_30_T1	GENE	41	41	SBP
NCT0019013831	NCT00190138_31_T0	GENE	7	7	SBP
NCT0019013832	NCT00190138_32_T0	GENE	14	14	RR
NCT0019013832	NCT00190138_32_T1	GENE	17	17	SBP
NCT0019013832	NCT00190138_32_T2	GENE	20	20	0.5
NCT0019013832	NCT00190138_32_T3	GENE	11	11	K2
NCT0019013833	NCT00190138_33_T0	ORGAN	0	0	Heart
NCT001901512	NCT00190151_2_T0	COMPOUND	3	3	fluoroquinolone
NCT001901512	NCT00190151_2_T1	COMPOUND	20	20	ciprofloxacin
NCT001901513	NCT00190151_3_T0	COMPOUND	10	10	ciprofloxacin
NCT001901516	NCT00190151_6_T0	COMPOUND	3	3	fluoroquinolone
NCT001901516	NCT00190151_6_T1	COMPOUND	20	20	ciprofloxacin
NCT001901517	NCT00190151_7_T0	COMPOUND	10	10	ciprofloxacin
NCT001901642	NCT00190164_2_T0	GENE	15	15	OCT
NCT001901643	NCT00190164_3_T0	PHENOTYPE	20	21	macular holes
NCT001901644	NCT00190164_4_T0	PHENOTYPE	14	15	macular holes
NCT001901647	NCT00190164_7_T0	GENE	16	16	OCT
NCT001901648	NCT00190164_8_T0	PHENOTYPE	20	21	macular holes
NCT0019016415	NCT00190164_15_T0	PHENOTYPE	1	1	secondary
NCT0019016416	NCT00190164_16_T0	PHENOTYPE	14	15	macular holes
NCT001901771	NCT00190177_1_T0	GENE	12	12	CX3CR1
NCT001901772	NCT00190177_2_T0	GENE	13	13	CX3CR1
NCT001901772	NCT00190177_2_T1	PHENOTYPE	17	17	preeclampsia
NCT001901773	NCT00190177_3_T0	PHENOTYPE	1	1	secondary
NCT001901773	NCT00190177_3_T1	PHENOTYPE	15	15	preeclampsia
NCT001901776	NCT00190177_6_T0	BIOLOGICAL_PROCESS	11	11	digestion
NCT001901776	NCT00190177_6_T1	GENE	7	7	PCR
NCT001901778	NCT00190177_8_T0	GENE	0	0	CX3CR1
NCT001901778	NCT00190177_8_T1	PHENOTYPE	3	3	preeclampsia
NCT001901903	NCT00190190_3_T0	GENE	13	13	OCT
NCT001901903	NCT00190190_3_T1	PHENOTYPE	23	23	peeling
NCT001901905	NCT00190190_5_T0	PHENOTYPE	20	20	peeling
NCT001901905	NCT00190190_5_T1	PHENOTYPE	10	11	macular holes
NCT001901906	NCT00190190_6_T0	PHENOTYPE	23	23	peeling
NCT001901906	NCT00190190_6_T1	PHENOTYPE	13	14	macular holes
NCT0019019012	NCT00190190_12_T0	GENE	13	13	OCT
NCT0019019012	NCT00190190_12_T1	PHENOTYPE	23	23	peeling
NCT0019019014	NCT00190190_14_T0	PHENOTYPE	20	20	peeling
NCT0019019014	NCT00190190_14_T1	PHENOTYPE	10	11	macular holes
NCT0019019018	NCT00190190_18_T0	GENE	15	15	Chi
NCT0019019020	NCT00190190_20_T0	PHENOTYPE	0	0	Intermediate
NCT0019019021	NCT00190190_21_T0	GENE	8	8	Lan
NCT0019019022	NCT00190190_22_T0	PHENOTYPE	23	23	peeling
NCT0019019022	NCT00190190_22_T1	PHENOTYPE	13	14	macular holes
NCT001902032	NCT00190203_2_T0	GENE	14	14	PARIS
NCT001902033	NCT00190203_3_T0	PHENOTYPE	7	7	centers
NCT001902033	NCT00190203_3_T1	GENE	25	25	PARIS
NCT001902035	NCT00190203_5_T0	PHENOTYPE	12	15	middle cerebral artery infarction
NCT001902036	NCT00190203_6_T0	PHENOTYPE	0	0	Secondary
NCT001902036	NCT00190203_6_T1	GENE	7	7	MRI
NCT001902163	NCT00190216_3_T0	PHENOTYPE	6	8	Major Depressive Disorder
NCT001902164	NCT00190216_4_T0	PHENOTYPE	5	5	resistant
NCT001902164	NCT00190216_4_T1	GENE	17	17	TMS
NCT001902164	NCT00190216_4_T2	GENE	25	25	TMS
NCT001902164	NCT00190216_4_T3	GENE	1	1	met
NCT001902165	NCT00190216_5_T0	COMPOUND	0	0	rTMS
NCT001902167	NCT00190216_7_T0	GENE	1	1	TMS
NCT001902168	NCT00190216_8_T0	GENE	6	6	cm
NCT001902292	NCT00190229_2_T0	ORGAN	17	17	heart
NCT001902292	NCT00190229_2_T1	PHENOTYPE	21	22	renal disease
NCT001902296	NCT00190229_6_T0	PHENOTYPE	12	12	bleeding
NCT001902296	NCT00190229_6_T1	PHENOTYPE	7	7	pneumonitis
NCT001902296	NCT00190229_6_T2	PHENOTYPE	6	6	myocarditis
NCT001902296	NCT00190229_6_T3	PHENOTYPE	5	5	glomerulonephritis
NCT001902297	NCT00190229_7_T0	GENE	4	4	has
NCT001902422	NCT00190242_2_T0	PHENOTYPE	3	4	vaccine immunogenicity
NCT001902424	NCT00190242_4_T0	PHENOTYPE	12	12	HIV
NCT001902424	NCT00190242_4_T1	PHENOTYPE	7	7	HAV
NCT001902426	NCT00190242_6_T0	PHENOTYPE	14	14	strategies
NCT001902426	NCT00190242_6_T1	PHENOTYPE	7	7	HAV
NCT001902427	NCT00190242_7_T0	BIOLOGICAL_PROCESS	9	10	immune response
NCT001902429	NCT00190242_9_T0	COMPOUND	16	16	O
NCT001902551	NCT00190255_1_T0	GENE	2	2	CYP2C9
NCT001902551	NCT00190255_1_T1	PHENOTYPE	7	7	elimination
NCT001902553	NCT00190255_3_T0	PHENOTYPE	20	20	elimination
NCT001902553	NCT00190255_3_T1	PHENOTYPE	13	14	gastrointestinal bleeding
NCT001902555	NCT00190255_5_T0	GENE	2	2	CYP2C9
NCT001902555	NCT00190255_5_T1	PHENOTYPE	7	7	elimination
NCT001902556	NCT00190255_6_T0	GENE	6	6	CYP2C9
NCT001902557	NCT00190255_7_T0	GENE	13	13	reduced
NCT001902558	NCT00190255_8_T0	PHENOTYPE	6	6	mutation
NCT001902558	NCT00190255_8_T1	PHENOTYPE	19	19	elimination
NCT001902558	NCT00190255_8_T2	PHENOTYPE	13	14	gastrointestinal bleeding
NCT001902559	NCT00190255_9_T0	GENE	23	23	CYP2C9
NCT0019025510	NCT00190255_10_T0	GENE	22	22	CYP2C9
NCT0019025510	NCT00190255_10_T1	PHENOTYPE	7	7	suffering
NCT0019025510	NCT00190255_10_T2	PHENOTYPE	9	10	gastrointestinal bleeding
NCT001902684	NCT00190268_4_T0	PHENOTYPE	11	11	fatigue
NCT001902684	NCT00190268_4_T1	PHENOTYPE	13	14	multiple sclerosis
NCT001902811	NCT00190281_1_T0	GENE	17	17	SU
NCT001902811	NCT00190281_1_T1	PHENOTYPE	2	2	malaria
NCT001902811	NCT00190281_1_T2	PHENOTYPE	23	23	reperfusion
NCT001902813	NCT00190281_3_T0	PHENOTYPE	32	33	acute pyelonephritis
NCT001902813	NCT00190281_3_T1	PHENOTYPE	27	29	other infectious diseases
NCT001902814	NCT00190281_4_T0	GENE	17	17	SU
NCT001902814	NCT00190281_4_T1	PHENOTYPE	2	2	malaria
NCT001902814	NCT00190281_4_T2	PHENOTYPE	23	23	reperfusion
NCT001903074	NCT00190307_4_T0	COMPOUND	17	17	aspirin
NCT001903075	NCT00190307_5_T0	PHENOTYPE	23	23	centers
NCT001903078	NCT00190307_8_T0	PHENOTYPE	28	28	acute
NCT001903078	NCT00190307_8_T1	PHENOTYPE	39	39	bleeding
NCT001903078	NCT00190307_8_T2	PHENOTYPE	52	52	bleeding
NCT001903078	NCT00190307_8_T3	PHENOTYPE	53	53	bleeding
NCT001903078	NCT00190307_8_T4	PHENOTYPE	12	12	reflecting
NCT001903078	NCT00190307_8_T5	PHENOTYPE	15	15	complications
NCT001903078	NCT00190307_8_T6	PHENOTYPE	37	37	hemorrhage
NCT001903078	NCT00190307_8_T7	PHENOTYPE	25	26	myocardial infarction
NCT001903078	NCT00190307_8_T8	PHENOTYPE	29	30	limb ischemia
NCT001903078	NCT00190307_8_T9	PHENOTYPE	47	48	cerebral hemorrhage
NCT001903078	NCT00190307_8_T10	PHENOTYPE	22	23	ischemic stroke
NCT001903078	NCT00190307_8_T11	CELL	65	67	red blood cells
NCT001903078	NCT00190307_8_T12	PHENOTYPE	32	34	deep venous thrombosis
NCT001903079	NCT00190307_9_T0	PHENOTYPE	28	28	complications
NCT001903079	NCT00190307_9_T1	COMPOUND	8	8	aspirin
NCT001903201	NCT00190320_1_T0	PHENOTYPE	1	1	secondary
NCT001903330	NCT00190333_0_T0	GENE	1	1	Transporter
NCT001903330	NCT00190333_0_T1	PHENOTYPE	5	6	Pulmonary Hypertension
NCT001903465	NCT00190346_5_T0	PHENOTYPE	24	25	respiratory acidosis
NCT001903593	NCT00190359_3_T0	GENE	3	3	IGF-1
NCT001903593	NCT00190359_3_T1	ORGAN	4	4	plasma
NCT001903593	NCT00190359_3_T2	MOLECULAR_FUNCTION	0	1	Growth hormone
NCT001903595	NCT00190359_5_T0	GENE	10	10	IGF-1
NCT001903595	NCT00190359_5_T1	ORGAN	8	8	plasma
NCT001903595	NCT00190359_5_T2	ORGAN	11	11	plasma
NCT001903595	NCT00190359_5_T3	MOLECULAR_FUNCTION	6	7	Growth hormone
NCT001903596	NCT00190359_6_T0	PHENOTYPE	4	4	severity
NCT001903596	NCT00190359_6_T1	PHENOTYPE	6	7	heart failure
NCT001903720	NCT00190372_0_T0	GENE	13	13	AD
NCT001903720	NCT00190372_0_T1	PHENOTYPE	11	12	Alzheimer's Disease
NCT001903722	NCT00190372_2_T0	PHENOTYPE	11	12	functional disorders
NCT001903724	NCT00190372_4_T0	GENE	14	14	AD
NCT001903724	NCT00190372_4_T1	GENE	23	23	has
NCT001903725	NCT00190372_5_T0	GENE	17	17	AD
NCT001903725	NCT00190372_5_T1	COMPOUND	32	32	memantine
NCT001903725	NCT00190372_5_T2	PHENOTYPE	15	16	Alzheimer's disease
NCT001903726	NCT00190372_6_T0	PHENOTYPE	0	0	Secondary
NCT001903729	NCT00190372_9_T0	GENE	7	7	DAD
NCT001903729	NCT00190372_9_T1	PHENOTYPE	12	12	Dementia
NCT001903851	NCT00190385_1_T0	PHENOTYPE	5	5	tumors
NCT001903854	NCT00190385_4_T0	ORGAN	6	6	serum
NCT001903855	NCT00190385_5_T0	PHENOTYPE	5	5	tumors
NCT001903982	NCT00190398_2_T0	PHENOTYPE	29	29	complications
NCT001903982	NCT00190398_2_T1	PHENOTYPE	15	15	anesthesia
NCT001903982	NCT00190398_2_T2	GENE	9	9	has
NCT001903982	NCT00190398_2_T3	PHENOTYPE	25	26	nerve injury
NCT001903984	NCT00190398_4_T0	PHENOTYPE	10	10	complications
NCT001903985	NCT00190398_5_T0	GENE	3	3	has
NCT001903985	NCT00190398_5_T1	PHENOTYPE	12	13	atheromatous plaque
NCT001904111	NCT00190411_1_T0	PHENOTYPE	7	7	complications
NCT001904111	NCT00190411_1_T1	GENE	4	4	yrs
NCT001904113	NCT00190411_3_T0	ORGAN	3	3	arteries
NCT001904116	NCT00190411_6_T0	COMPOUND	5	5	celiprolol
NCT001904240	NCT00190424_0_T0	PHENOTYPE	7	7	Glioblastoma
NCT001904372	NCT00190437_2_T0	PHENOTYPE	4	5	viral infections
NCT001904373	NCT00190437_3_T0	GENE	8	8	has
NCT001904374	NCT00190437_4_T0	PHENOTYPE	18	18	COLD
NCT001904503	NCT00190450_3_T0	PHENOTYPE	8	8	progression
NCT001904503	NCT00190450_3_T1	GENE	17	17	TMS
NCT001904503	NCT00190450_3_T2	GENE	12	12	M32
NCT001904503	NCT00190450_3_T3	GENE	10	10	M12
NCT001904504	NCT00190450_4_T0	PHENOTYPE	9	9	progression
NCT001904505	NCT00190450_5_T0	GENE	8	8	pre
NCT001904505	NCT00190450_5_T1	ORGAN	10	10	graft
NCT001904505	NCT00190450_5_T2	PHENOTYPE	12	12	progression
NCT001904505	NCT00190450_5_T3	GENE	11	11	TMS
NCT001904507	NCT00190450_7_T0	ORGAN	0	0	Transplants
NCT001904507	NCT00190450_7_T1	ORGAN	17	17	transplants
NCT001904508	NCT00190450_8_T0	GENE	29	29	II
NCT001904508	NCT00190450_8_T1	ORGAN	5	5	transplants
NCT001904508	NCT00190450_8_T2	PHENOTYPE	22	22	anaesthesia
NCT001904630	NCT00190463_0_T0	PHENOTYPE	8	8	Strategies
NCT001904630	NCT00190463_0_T1	PHENOTYPE	11	11	Neutropenia
NCT001904632	NCT00190463_2_T0	PHENOTYPE	4	5	fungal infections
NCT001904635	NCT00190463_5_T0	COMPOUND	24	24	galactomannan
NCT001904635	NCT00190463_5_T1	PHENOTYPE	27	27	aspergillosis
NCT001904635	NCT00190463_5_T2	GENE	5	5	has
NCT001904635	NCT00190463_5_T3	PHENOTYPE	20	21	fungal infections
NCT001904636	NCT00190463_6_T0	PHENOTYPE	36	36	toxicity
NCT001904636	NCT00190463_6_T1	COMPOUND	30	30	galactomannan
NCT001904636	NCT00190463_6_T2	GENE	42	42	has
NCT001904636	NCT00190463_6_T3	PHENOTYPE	21	21	foci
NCT001904636	NCT00190463_6_T4	PHENOTYPE	55	56	hematologic malignancies
NCT001904638	NCT00190463_8_T0	PHENOTYPE	53	53	abscesses
NCT001904638	NCT00190463_8_T1	GENE	6	6	1.1
NCT001904638	NCT00190463_8_T2	COMPOUND	56	56	galactomannan
NCT001904638	NCT00190463_8_T3	ORGAN	50	50	liver
NCT001904638	NCT00190463_8_T4	PHENOTYPE	47	47	mucositis
NCT001904638	NCT00190463_8_T5	PHENOTYPE	41	41	pneumonia
NCT001904638	NCT00190463_8_T6	PHENOTYPE	44	44	sinusitis
NCT001904638	NCT00190463_8_T7	PHENOTYPE	42	43	septic shock
NCT001904638	NCT00190463_8_T8	PHENOTYPE	21	22	persistent fever
NCT001904639	NCT00190463_9_T0	COMPOUND	9	10	amphotericin B
NCT001904639	NCT00190463_9_T1	COMPOUND	4	6	deoxycholate amphotericin B
NCT0019046310	NCT00190463_10_T0	PHENOTYPE	10	11	persistent fever
NCT0019046311	NCT00190463_11_T0	PHENOTYPE	13	13	neutropenia
NCT0019046311	NCT00190463_11_T1	CELL	6	6	neutrophil
NCT0019046312	NCT00190463_12_T0	PHENOTYPE	0	0	Secondary
NCT0019046312	NCT00190463_12_T1	PHENOTYPE	14	14	febrile
NCT0019046312	NCT00190463_12_T2	GENE	9	9	IFI
NCT0019046312	NCT00190463_12_T3	PHENOTYPE	6	8	invasive fungal infections
NCT001904760	NCT00190476_0_T0	GENE	3	3	DP
NCT001904763	NCT00190476_3_T0	COMPOUND	7	7	vinorelbine
NCT001904763	NCT00190476_3_T1	COMPOUND	5	5	gemcitabine
NCT001904765	NCT00190476_5_T0	COMPOUND	20	20	docetaxel
NCT001904765	NCT00190476_5_T1	COMPOUND	21	21	cisplatin
NCT001904766	NCT00190476_6_T0	PHENOTYPE	10	10	NSCLC
NCT001904767	NCT00190476_7_T0	PHENOTYPE	13	13	NSCLC
NCT001904767	NCT00190476_7_T1	COMPOUND	3	3	docetaxel
NCT0019047614	NCT00190476_14_T0	PHENOTYPE	4	5	primary tumor
NCT0019047618	NCT00190476_18_T0	PHENOTYPE	1	2	brain metastasis
NCT0019047619	NCT00190476_19_T0	PHENOTYPE	2	2	neoplasms
NCT0019047621	NCT00190476_21_T0	PHENOTYPE	5	5	ascites
NCT0019047621	NCT00190476_21_T1	PHENOTYPE	2	3	pleural effusion
NCT0019047622	NCT00190476_22_T0	PHENOTYPE	0	1	Bone metastasis
NCT0019047623	NCT00190476_23_T0	PHENOTYPE	1	2	systemic hypertension
NCT0019047627	NCT00190476_27_T0	PHENOTYPE	0	1	Interstitial pneumonia
NCT001904892	NCT00190489_2_T0	PHENOTYPE	12	12	nausea/vomiting
NCT001904892	NCT00190489_2_T1	GENE	2	2	3.4
NCT001904892	NCT00190489_2_T2	PHENOTYPE	3	3	toxicities
NCT001904892	NCT00190489_2_T3	PHENOTYPE	5	5	neutropenia
NCT001904892	NCT00190489_2_T4	PHENOTYPE	9	10	febrile neutropenia
NCT001904893	NCT00190489_3_T0	PHENOTYPE	3	3	toxic
NCT001904896	NCT00190489_6_T0	GENE	1	1	TTF
NCT001904896	NCT00190489_6_T1	GENE	7	7	6.4
NCT001904896	NCT00190489_6_T2	GENE	8	8	6.4
NCT001904896	NCT00190489_6_T3	GENE	10	10	6/7
NCT001904898	NCT00190489_8_T0	GENE	12	12	TTF
NCT001904899	NCT00190489_9_T0	COMPOUND	4	4	docetaxel
NCT0019048911	NCT00190489_11_T0	GENE	2	2	MBC
NCT0019048913	NCT00190489_13_T0	GENE	3	3	MBC
NCT0019048916	NCT00190489_16_T0	GENE	0	0	Age
NCT0019048917	NCT00190489_17_T0	GENE	1	1	0.3
NCT0019048918	NCT00190489_18_T0	CELL	8	8	Platelet
NCT0019048918	NCT00190489_18_T1	GENE	5	5	ANC
NCT0019048918	NCT00190489_18_T2	GENE	14	14	1.5
NCT0019048918	NCT00190489_18_T3	GENE	19	19	1.5
NCT0019048918	NCT00190489_18_T4	GENE	23	23	1.5
NCT0019048918	NCT00190489_18_T5	GENE	0	0	WBC
NCT0019048919	NCT00190489_19_T0	COMPOUND	5	5	1
NCT0019048919	NCT00190489_19_T1	COMPOUND	7	7	2
NCT0019048919	NCT00190489_19_T2	PHENOTYPE	11	11	ascites
NCT0019048919	NCT00190489_19_T3	PHENOTYPE	13	14	pericardial effusion
NCT0019048919	NCT00190489_19_T4	PHENOTYPE	8	10	malignant pleural effusion
NCT001905023	NCT00190502_3_T0	GENE	31	31	insulin
NCT001905023	NCT00190502_3_T1	GENE	38	38	insulin
NCT001905023	NCT00190502_3_T2	GENE	33	34	Group 1
NCT001905025	NCT00190502_5_T0	GENE	2	2	extended
NCT0019050210	NCT00190502_10_T0	GENE	4	5	Group 1
NCT0019050211	NCT00190502_11_T0	GENE	11	11	ml
NCT0019050212	NCT00190502_12_T0	GENE	11	11	0.2
NCT0019050212	NCT00190502_12_T1	PHENOTYPE	9	9	tolerance
NCT0019050212	NCT00190502_12_T2	GENE	12	12	ml
NCT001905150	NCT00190515_0_T0	PHENOTYPE	9	12	Stage III Colorectal Cancer
NCT001905153	NCT00190515_3_T0	PHENOTYPE	33	36	stage III colorectal cancer
NCT001905156	NCT00190515_6_T0	PHENOTYPE	6	6	secondary
NCT001905156	NCT00190515_6_T1	PHENOTYPE	12	13	adverse event
NCT0019051510	NCT00190515_10_T0	PHENOTYPE	0	0	Tumor
NCT0019051510	NCT00190515_10_T1	ORGAN	9	9	rectum
NCT0019051510	NCT00190515_10_T2	ORGAN	15	15	rectum
NCT0019051510	NCT00190515_10_T3	ORGAN	6	6	cecum
NCT0019051514	NCT00190515_14_T0	PHENOTYPE	2	3	colorectal cancer
NCT0019051516	NCT00190515_16_T0	PHENOTYPE	0	0	Tumor
NCT0019051516	NCT00190515_16_T1	GENE	3	3	D2
NCT0019051516	NCT00190515_16_T2	GENE	5	5	D3
NCT0019051516	NCT00190515_16_T3	TISSUE	6	7	lymph node
NCT0019051518	NCT00190515_18_T0	GENE	8	8	cur
NCT0019051518	NCT00190515_18_T1	PHENOTYPE	5	5	tumor
NCT0019051531	NCT00190515_31_T0	PHENOTYPE	2	2	malignancy
NCT0019051531	NCT00190515_31_T1	PHENOTYPE	6	6	malignancy
NCT0019051532	NCT00190515_32_T0	PHENOTYPE	0	0	Carcinoma
NCT0019051534	NCT00190515_34_T0	PHENOTYPE	1	2	postoperative complications
NCT0019051539	NCT00190515_39_T0	PHENOTYPE	10	11	psychiatric symptoms
NCT0019051539	NCT00190515_39_T1	PHENOTYPE	7	8	mental disorder
NCT001905283	NCT00190528_3_T0	PHENOTYPE	1	2	cervical cancer
NCT001905284	NCT00190528_4_T0	PHENOTYPE	2	3	squamous carcinoma
NCT001905285	NCT00190528_5_T0	GENE	3	3	IIa
NCT001905285	NCT00190528_5_T1	GENE	6	6	IIb
NCT001905288	NCT00190528_8_T0	GENE	0	0	Age
NCT0019052812	NCT00190528_12_T0	PHENOTYPE	7	8	other cancer
NCT0019052812	NCT00190528_12_T1	PHENOTYPE	19	21	carcinoma in situ
NCT0019052814	NCT00190528_14_T0	PHENOTYPE	2	3	psychiatric illness
NCT0019052819	NCT00190528_19_T0	PHENOTYPE	2	3	interstitial pneumonitis
NCT0019052819	NCT00190528_19_T1	PHENOTYPE	5	6	pulmonary fibrosis
NCT001905411	NCT00190541_1_T0	GENE	3	3	TME
NCT001905411	NCT00190541_1_T1	TISSUE	8	9	lymph node
NCT001905412	NCT00190541_2_T0	PHENOTYPE	8	9	rectal cancer
NCT001905414	NCT00190541_4_T0	PHENOTYPE	2	2	adenocarcinoma
NCT001905415	NCT00190541_5_T0	GENE	2	2	II
NCT001905415	NCT00190541_5_T1	GENE	4	4	III
NCT0019054118	NCT00190541_18_T0	PHENOTYPE	0	1	Cardiac infarction
NCT0019054119	NCT00190541_19_T0	PHENOTYPE	1	2	pulmonary emphysema
NCT0019054119	NCT00190541_19_T1	PHENOTYPE	4	5	pulmonary fibrosis
NCT001905670	NCT00190567_0_T0	ORGAN	5	5	Bladder
NCT001905670	NCT00190567_0_T1	PHENOTYPE	14	16	Genuine Stress Incontinence
NCT001906060	NCT00190606_0_T0	ORGAN	7	8	Pelvic Floor
NCT001906060	NCT00190606_0_T1	PHENOTYPE	14	16	Stress Urinary Incontinence
NCT001906320	NCT00190632_0_T0	PHENOTYPE	9	11	Stress Urinary Incontinence
NCT001906323	NCT00190632_3_T0	PHENOTYPE	10	10	coughing
NCT001906323	NCT00190632_3_T1	PHENOTYPE	1	2	urine leakage
NCT001906450	NCT00190645_0_T0	PHENOTYPE	9	11	Stress Urinary Incontinence
NCT001906452	NCT00190645_2_T0	PHENOTYPE	8	10	Stress Urinary Incontinence
NCT001907620	NCT00190762_0_T0	PHENOTYPE	17	17	Mesothelioma
NCT001907622	NCT00190762_2_T0	PHENOTYPE	12	12	mesothelioma
NCT001907623	NCT00190762_3_T0	PHENOTYPE	10	12	malignant pleural mesothelioma
NCT001907751	NCT00190775_1_T0	PHENOTYPE	21	21	symptoms
NCT001907751	NCT00190775_1_T1	PHENOTYPE	20	20	ADHD
NCT001907751	NCT00190775_1_T2	COMPOUND	12	12	atomoxetine
NCT001908011	NCT00190801_1_T0	PHENOTYPE	13	13	cancers
NCT001908011	NCT00190801_1_T1	GENE	1	1	has
NCT001908011	NCT00190801_1_T2	COMPOUND	5	5	cisplatin
NCT001908012	NCT00190801_2_T0	COMPOUND	9	9	pemetrexed
NCT001908012	NCT00190801_2_T1	GENE	5	5	has
NCT001908012	NCT00190801_2_T2	COMPOUND	11	11	cisplatin
NCT001908013	NCT00190801_3_T0	COMPOUND	18	18	pemetrexed
NCT001908013	NCT00190801_3_T1	GENE	28	28	had
NCT001908013	NCT00190801_3_T2	COMPOUND	20	20	cisplatin
NCT001908013	NCT00190801_3_T3	PHENOTYPE	25	26	gastric carcinoma
NCT001908014	NCT00190801_4_T0	COMPOUND	35	35	pemetrexed
NCT001908014	NCT00190801_4_T1	COMPOUND	37	37	cisplatin
NCT001908140	NCT00190814_0_T0	PHENOTYPE	9	9	Leakage
NCT001908140	NCT00190814_0_T1	GENE	16	16	ss
NCT001908140	NCT00190814_0_T2	PHENOTYPE	12	13	Physical Stress
NCT001908271	NCT00190827_1_T0	ORGAN	6	6	bladder
NCT001908271	NCT00190827_1_T1	PHENOTYPE	0	0	Incontinence
NCT001908271	NCT00190827_1_T2	PHENOTYPE	9	9	leakage
NCT001908402	NCT00190840_2_T0	COMPOUND	6	6	pemetrexed
NCT001908402	NCT00190840_2_T1	GENE	7	7	has
NCT001908402	NCT00190840_2_T2	PHENOTYPE	10	10	tolerance
NCT001908403	NCT00190840_3_T0	COMPOUND	10	10	pemetrexed
NCT001908403	NCT00190840_3_T1	GENE	2	2	has
NCT001908403	NCT00190840_3_T2	GENE	13	13	has
NCT001908405	NCT00190840_5_T0	COMPOUND	7	7	pemetrexed
NCT001908405	NCT00190840_5_T1	PHENOTYPE	33	33	NSCLC
NCT001908405	NCT00190840_5_T2	GENE	35	35	had
NCT001908405	NCT00190840_5_T3	PHENOTYPE	15	15	tolerance
NCT001908530	NCT00190853_0_T0	PHENOTYPE	12	14	Urinary Stress Incontinence
NCT001908921	NCT00190892_1_T0	PHENOTYPE	13	13	manic
NCT001908921	NCT00190892_1_T1	PHENOTYPE	4	5	bipolar disorder
NCT001908922	NCT00190892_2_T0	ORGAN	7	7	serum
NCT001908926	NCT00190892_6_T0	COMPOUND	13	13	olanzapine
NCT001908926	NCT00190892_6_T1	COMPOUND	15	15	carbamazepine
NCT001908927	NCT00190892_7_T0	PHENOTYPE	4	4	agranulocytosis
NCT001908927	NCT00190892_7_T1	CELL	6	6	neutrophil
NCT001908929	NCT00190892_9_T0	COMPOUND	7	7	caffeine
NCT001908929	NCT00190892_9_T1	COMPOUND	5	5	nicotine
NCT001908929	NCT00190892_9_T2	PHENOTYPE	2	3	substance dependence
NCT0019089211	NCT00190892_11_T0	ORGAN	9	11	central nervous system
NCT001909050	NCT00190905_0_T0	COMPOUND	6	6	HCl
NCT001909050	NCT00190905_0_T1	PHENOTYPE	13	15	Stress Urinary Incontinence
NCT001909312	NCT00190931_2_T0	PHENOTYPE	6	6	ADHD
NCT001909314	NCT00190931_4_T0	PHENOTYPE	7	7	symptoms
NCT001909318	NCT00190931_8_T0	PHENOTYPE	0	1	Laboratory results
NCT0019093112	NCT00190931_12_T0	PHENOTYPE	21	22	psychotic disorder
NCT0019093112	NCT00190931_12_T1	PHENOTYPE	14	15	bipolar disorder
NCT0019093112	NCT00190931_12_T2	PHENOTYPE	9	10	anxiety disorder
NCT0019093112	NCT00190931_12_T3	PHENOTYPE	5	6	major depression
NCT0019093116	NCT00190931_16_T0	PHENOTYPE	2	3	brain disease
NCT0019093117	NCT00190931_17_T0	PHENOTYPE	18	18	seizure
NCT0019093117	NCT00190931_17_T1	PHENOTYPE	5	6	seizure disorder
NCT0019093119	NCT00190931_19_T0	GENE	10	10	has
NCT0019093119	NCT00190931_19_T1	ORGAN	11	13	central nervous system
NCT001909441	NCT00190944_1_T0	PHENOTYPE	13	13	unilateral
NCT001909441	NCT00190944_1_T1	PHENOTYPE	19	19	distal
NCT001909441	NCT00190944_1_T2	PHENOTYPE	33	33	closed
NCT001909441	NCT00190944_1_T3	GENE	74	74	has
NCT001909441	NCT00190944_1_T4	ORGAN	20	20	radius
NCT001909441	NCT00190944_1_T5	PHENOTYPE	15	16	angulated fracture
NCT001909441	NCT00190944_1_T6	PHENOTYPE	29	31	distal radius fracture
NCT001909441	NCT00190944_1_T7	PHENOTYPE	54	56	distal radius fracture
NCT001909443	NCT00190944_3_T0	COMPOUND	1	2	strontium ranelate
NCT001909571	NCT00190957_1_T0	PHENOTYPE	6	6	ADHD
NCT001909571	NCT00190957_1_T1	PHENOTYPE	11	14	alcohol abuse or dependence
NCT001909573	NCT00190957_3_T0	BIOLOGICAL_PROCESS	2	2	drinking
NCT001909574	NCT00190957_4_T0	COMPOUND	5	5	atomoxetine
NCT001909575	NCT00190957_5_T0	PHENOTYPE	7	7	ADHD
NCT001909575	NCT00190957_5_T1	PHENOTYPE	3	4	psychiatric disorder
NCT001909575	NCT00190957_5_T2	PHENOTYPE	9	12	alcohol abuse or dependence
NCT001909960	NCT00190996_0_T0	PHENOTYPE	8	10	Stress Urinary Incontinence
NCT001910091	NCT00191009_1_T0	COMPOUND	11	11	atomoxetine
NCT001910741	NCT00191074_1_T0	GENE	4	4	had
NCT001910742	NCT00191074_2_T0	GENE	16	16	met
NCT001910745	NCT00191074_5_T0	GENE	3	3	had
NCT001910746	NCT00191074_6_T0	PHENOTYPE	2	3	Diabetes mellitus
NCT001910747	NCT00191074_7_T0	PHENOTYPE	6	6	malignancy
NCT001910870	NCT00191087_0_T0	PHENOTYPE	5	7	Stress Urinary Incontinence
NCT001911001	NCT00191100_1_T0	COMPOUND	5	5	gemcitabine
NCT001911001	NCT00191100_1_T1	COMPOUND	15	15	gemcitabine
NCT001911001	NCT00191100_1_T2	COMPOUND	7	7	cisplatin
NCT001911001	NCT00191100_1_T3	COMPOUND	17	17	cisplatin
NCT001911001	NCT00191100_1_T4	COMPOUND	24	24	cisplatin
NCT001911260	NCT00191126_0_T0	PHENOTYPE	15	15	NSCLC
NCT001911260	NCT00191126_0_T1	GENE	2	2	III
NCT001911262	NCT00191126_2_T0	PHENOTYPE	24	24	NSCLC
NCT001911262	NCT00191126_2_T1	GENE	6	6	III
NCT001911262	NCT00191126_2_T2	PHENOTYPE	20	20	progression
NCT001911263	NCT00191126_3_T0	GENE	9	9	III
NCT001912040	NCT00191204_0_T0	GENE	3	3	III
NCT001912040	NCT00191204_0_T1	PHENOTYPE	7	9	Stress Urinary Incontinence
NCT001912822	NCT00191282_2_T0	PHENOTYPE	7	7	acute
NCT001913213	NCT00191321_3_T0	PHENOTYPE	5	5	osteoporosis
NCT001913214	NCT00191321_4_T0	GENE	10	10	OR
NCT001913214	NCT00191321_4_T1	PHENOTYPE	14	15	vertebral fracture
NCT001913214	NCT00191321_4_T2	PHENOTYPE	8	9	vertebral fractures
NCT001913217	NCT00191321_7_T0	PHENOTYPE	21	21	concentrations
NCT001913217	NCT00191321_7_T1	GENE	15	15	PTH-1
NCT001913217	NCT00191321_7_T2	GENE	16	16	84
NCT001913217	NCT00191321_7_T3	PHENOTYPE	13	14	serum calcium
NCT001913217	NCT00191321_7_T4	MOLECULAR_FUNCTION	23	25	alkaline phosphatase activity
NCT001913219	NCT00191321_9_T0	PHENOTYPE	18	18	osteomalacia
NCT001913219	NCT00191321_9_T1	PHENOTYPE	2	2	diseases
NCT001913219	NCT00191321_9_T2	PHENOTYPE	27	27	hypoparathyroidism
NCT001913219	NCT00191321_9_T3	PHENOTYPE	28	28	hyperparathyroidism
NCT001913219	NCT00191321_9_T4	PHENOTYPE	23	23	osteoporosis
NCT001913219	NCT00191321_9_T5	PHENOTYPE	26	26	osteoporosis
NCT001913219	NCT00191321_9_T6	PHENOTYPE	20	20	secondary
NCT001913219	NCT00191321_9_T7	PHENOTYPE	29	29	hyperthyroidism
NCT001913219	NCT00191321_9_T8	BIOLOGICAL_PROCESS	6	6	metabolism
NCT001913219	NCT00191321_9_T9	PHENOTYPE	16	17	renal osteodystrophy
NCT001913219	NCT00191321_9_T10	PHENOTYPE	10	11	postmenopausal osteoporosis
NCT001913219	NCT00191321_9_T11	PHENOTYPE	14	15	Paget's disease
NCT0019132113	NCT00191321_13_T0	ORGAN	21	21	skeleton
NCT0019132113	NCT00191321_13_T1	PHENOTYPE	4	4	osteosarcoma
NCT0019132113	NCT00191321_13_T2	GENE	14	15	alkaline phosphatase
NCT0019132113	NCT00191321_13_T3	PHENOTYPE	5	9	Paget's disease of the bone
NCT0019132114	NCT00191321_14_T0	PHENOTYPE	1	3	impaired renal function
NCT001913471	NCT00191347_1_T0	GENE	2	2	has
NCT001913471	NCT00191347_1_T1	PHENOTYPE	13	15	metastatic breast cancer
NCT001913472	NCT00191347_2_T0	PHENOTYPE	14	14	tumor
NCT001913472	NCT00191347_2_T1	GENE	30	30	al
NCT001913472	NCT00191347_2_T2	GENE	29	29	et
NCT001913472	NCT00191347_2_T3	PHENOTYPE	25	26	breast cancer
NCT001913473	NCT00191347_3_T0	COMPOUND	10	10	pemetrexed
NCT001913473	NCT00191347_3_T1	PHENOTYPE	20	20	tumor
NCT001913473	NCT00191347_3_T2	COMPOUND	12	12	gemcitabine
NCT001913478	NCT00191347_8_T0	GENE	3	3	had
NCT001913478	NCT00191347_8_T1	PHENOTYPE	11	12	metastatic disease
NCT001913479	NCT00191347_9_T0	GENE	7	7	has
NCT0019134711	NCT00191347_11_T0	GENE	12	12	al
NCT0019134711	NCT00191347_11_T1	GENE	11	11	et
NCT0019134711	NCT00191347_11_T2	PHENOTYPE	3	4	measurable disease
NCT0019134713	NCT00191347_13_T0	PHENOTYPE	4	4	disorders
NCT0019134713	NCT00191347_13_T1	GENE	5	5	eg
NCT001913732	NCT00191373_2_T0	GENE	3	3	FISH
NCT001913732	NCT00191373_2_T1	GENE	10	10	FISH
NCT001913732	NCT00191373_2_T2	GENE	16	16	HER2
NCT001913732	NCT00191373_2_T3	PHENOTYPE	0	0	Tumors
NCT001913734	NCT00191373_4_T0	GENE	2	2	NOT
NCT001913734	NCT00191373_4_T1	PHENOTYPE	21	21	relapse
NCT001914250	NCT00191425_0_T0	COMPOUND	3	3	Teriparatide
NCT001914250	NCT00191425_0_T1	PHENOTYPE	17	18	Postmenopausal Osteoporosis
NCT001914252	NCT00191425_2_T0	COMPOUND	37	37	bisphosphonates
NCT001914252	NCT00191425_2_T1	COMPOUND	39	39	raloxifene
NCT001914252	NCT00191425_2_T2	PHENOTYPE	13	13	osteoporosis
NCT001914256	NCT00191425_6_T0	GENE	7	7	calcitonin
NCT001914256	NCT00191425_6_T1	COMPOUND	4	4	bisphosphonates
NCT001914256	NCT00191425_6_T2	COMPOUND	5	5	raloxifene
NCT001914256	NCT00191425_6_T3	COMPOUND	9	10	vitamin D
NCT001914381	NCT00191438_1_T0	PHENOTYPE	16	16	tumor
NCT001914382	NCT00191438_2_T0	PHENOTYPE	4	4	symptoms
NCT001914514	NCT00191451_4_T0	PHENOTYPE	2	4	metastatic breast cancer
NCT0019145111	NCT00191451_11_T0	COMPOUND	2	2	gemcitabine
NCT0019145114	NCT00191451_14_T0	GENE	6	6	has
NCT0019145115	NCT00191451_15_T0	PHENOTYPE	5	6	breast cancer
NCT001914643	NCT00191464_3_T0	PHENOTYPE	18	18	atherosclerosis
NCT001914643	NCT00191464_3_T1	PHENOTYPE	20	21	cardiovascular disease
NCT001914902	NCT00191490_2_T0	COMPOUND	14	14	gemcitabine
NCT001915031	NCT00191503_1_T0	PHENOTYPE	25	25	toxicity
NCT001915031	NCT00191503_1_T1	GENE	8	8	has
NCT001915032	NCT00191503_2_T0	COMPOUND	3	3	pemetrexed
NCT001915032	NCT00191503_2_T1	COMPOUND	41	41	pemetrexed
NCT001915032	NCT00191503_2_T2	PHENOTYPE	38	38	tumor
NCT001915032	NCT00191503_2_T3	COMPOUND	1	1	gemcitabine
NCT001915032	NCT00191503_2_T4	COMPOUND	43	43	gemcitabine
NCT001915420	NCT00191542_0_T0	PHENOTYPE	7	7	ADHD
NCT001915556	NCT00191555_6_T0	GENE	31	31	II
NCT001915556	NCT00191555_6_T1	PHENOTYPE	37	38	substance abuse
NCT001915556	NCT00191555_6_T2	PHENOTYPE	34	35	substance dependence
NCT001915816	NCT00191581_6_T0	GENE	4	4	1.1
NCT001915816	NCT00191581_6_T1	GENE	6	6	1.7
NCT001915818	NCT00191581_8_T0	COMPOUND	18	18	glucose
NCT001915818	NCT00191581_8_T1	GENE	7	7	insulin
NCT0019158111	NCT00191581_11_T0	COMPOUND	2	2	1
NCT0019158111	NCT00191581_11_T1	COMPOUND	10	10	sulfonylureas
NCT0019158112	NCT00191581_12_T0	COMPOUND	0	0	2
NCT0019158112	NCT00191581_12_T1	COMPOUND	8	8	2
NCT0019158112	NCT00191581_12_T2	GENE	7	7	insulin
NCT0019158113	NCT00191581_13_T0	COMPOUND	0	0	3
NCT0019158113	NCT00191581_13_T1	PHENOTYPE	9	9	hypoglycemia
NCT0019158113	NCT00191581_13_T2	PHENOTYPE	20	20	hypoglycemia
NCT0019158113	NCT00191581_13_T3	GENE	2	2	had
NCT0019158114	NCT00191581_14_T0	GENE	6	6	35
NCT001915941	NCT00191594_1_T0	BIOLOGICAL_PROCESS	9	9	menarche
NCT001916070	NCT00191607_0_T0	COMPOUND	6	6	Platinum
NCT001916070	NCT00191607_0_T1	PHENOTYPE	7	7	Resistant
NCT001916070	NCT00191607_0_T2	PHENOTYPE	15	15	Cancer
NCT001916070	NCT00191607_0_T3	PHENOTYPE	12	13	Peritoneal Cancer
NCT001916072	NCT00191607_2_T0	PHENOTYPE	8	8	progression
NCT001916072	NCT00191607_2_T1	COMPOUND	12	12	gemcitabine
NCT001916072	NCT00191607_2_T2	COMPOUND	15	15	doxorubicin
NCT001916203	NCT00191620_3_T0	COMPOUND	4	4	gemcitabine
NCT001916203	NCT00191620_3_T1	COMPOUND	25	25	gemcitabine
NCT001916203	NCT00191620_3_T2	COMPOUND	6	6	cisplatin
NCT001916203	NCT00191620_3_T3	COMPOUND	27	27	cisplatin
NCT001916460	NCT00191646_0_T0	PHENOTYPE	5	7	Fallopian Tube Cancer
NCT001916590	NCT00191659_0_T0	PHENOTYPE	10	10	ADHD
NCT001916721	NCT00191672_1_T0	GENE	8	8	lines
NCT001916850	NCT00191685_0_T0	PHENOTYPE	5	6	Melancholic Depression
NCT001916853	NCT00191685_3_T0	COMPOUND	20	20	duloxetine
NCT001916854	NCT00191685_4_T0	COMPOUND	12	12	duloxetine
NCT001916980	NCT00191698_0_T0	PHENOTYPE	10	10	ADHD
NCT001916980	NCT00191698_0_T1	GENE	12	12	ODD
NCT001917110	NCT00191711_0_T0	PHENOTYPE	13	15	Superficial Bladder Cancer
NCT001917891	NCT00191789_1_T0	COMPOUND	4	4	gemcitabine
NCT001917891	NCT00191789_1_T1	COMPOUND	6	6	cisplatin
NCT001917892	NCT00191789_2_T0	COMPOUND	12	12	gemcitabine
NCT001917892	NCT00191789_2_T1	COMPOUND	17	17	gemcitabine
NCT001917892	NCT00191789_2_T2	COMPOUND	14	14	doxorubicin
NCT001917892	NCT00191789_2_T3	COMPOUND	19	19	cisplatin
NCT001917892	NCT00191789_2_T4	PHENOTYPE	3	4	breast cancer
NCT001918281	NCT00191828_1_T0	PHENOTYPE	9	10	weight gain
NCT001918282	NCT00191828_2_T0	COMPOUND	20	20	histamine
NCT001918282	NCT00191828_2_T1	GENE	22	22	has
NCT001918282	NCT00191828_2_T2	GENE	17	17	5HT2C
NCT001918282	NCT00191828_2_T3	PHENOTYPE	5	6	weight gain
NCT001918283	NCT00191828_3_T0	COMPOUND	25	25	olanzapine
NCT001918283	NCT00191828_3_T1	PHENOTYPE	21	22	side effect
NCT001918283	NCT00191828_3_T2	PHENOTYPE	17	18	increased weight
NCT001918284	NCT00191828_4_T0	COMPOUND	7	7	olanzapine
NCT001918284	NCT00191828_4_T1	PHENOTYPE	3	4	weight gain
NCT001918285	NCT00191828_5_T0	COMPOUND	13	13	olanzapine
NCT001918285	NCT00191828_5_T1	GENE	4	4	IV
NCT001918288	NCT00191828_8_T0	COMPOUND	21	21	BMI
NCT001918410	NCT00191841_0_T0	PHENOTYPE	7	7	NSCLC
NCT001918540	NCT00191854_0_T0	GENE	8	8	Line
NCT001918540	NCT00191854_0_T1	COMPOUND	7	7	1st
NCT001918540	NCT00191854_0_T2	GENE	6	6	MBC
NCT001918540	NCT00191854_0_T3	PHENOTYPE	3	5	Metastatic Breast Cancer
NCT001918542	NCT00191854_2_T0	PHENOTYPE	26	28	metastatic breast cancer
NCT001918930	NCT00191893_0_T0	COMPOUND	3	3	Teriparatide
NCT001918932	NCT00191893_2_T0	COMPOUND	17	17	alendronate
NCT001918932	NCT00191893_2_T1	PHENOTYPE	30	30	osteoporosis
NCT001918936	NCT00191893_6_T0	PHENOTYPE	1	2	malignant neoplasm
NCT001919452	NCT00191945_2_T0	COMPOUND	20	20	atomoxetine
NCT001919453	NCT00191945_3_T0	PHENOTYPE	10	10	secondary
NCT001919457	NCT00191945_7_T0	PHENOTYPE	19	19	ADHD
NCT001919457	NCT00191945_7_T1	PHENOTYPE	9	10	Mental Disorders
NCT001919458	NCT00191945_8_T0	PHENOTYPE	9	9	ADHD
NCT001919459	NCT00191945_9_T0	GENE	9	9	1.5
NCT0019194512	NCT00191945_12_T0	PHENOTYPE	8	8	ADHD
NCT0019194515	NCT00191945_15_T0	PHENOTYPE	4	4	ADHD
NCT0019194519	NCT00191945_19_T0	PHENOTYPE	30	30	nearest
NCT001920230	NCT00192023_0_T0	PHENOTYPE	18	18	ADHD
NCT001920230	NCT00192023_0_T1	GENE	24	24	ODD
NCT001920230	NCT00192023_0_T2	GENE	26	26	ODD
NCT001920230	NCT00192023_0_T3	PHENOTYPE	21	23	Oppositional Defiant Disorder
NCT001920232	NCT00192023_2_T0	PHENOTYPE	18	18	symptoms
NCT001920232	NCT00192023_2_T1	PHENOTYPE	15	15	ADHD
NCT001920232	NCT00192023_2_T2	COMPOUND	12	12	atomoxetine
NCT001920232	NCT00192023_2_T3	GENE	17	17	ODD
NCT001920233	NCT00192023_3_T0	PHENOTYPE	14	14	ADHD
NCT001920233	NCT00192023_3_T1	COMPOUND	5	5	atomoxetine
NCT001920233	NCT00192023_3_T2	GENE	16	16	ODD
NCT001920491	NCT00192049_1_T0	GENE	12	12	has
NCT001920491	NCT00192049_1_T1	PHENOTYPE	32	34	superficial bladder cancer
NCT001920621	NCT00192062_1_T0	PHENOTYPE	3	4	measurable disease
NCT001920622	NCT00192062_2_T0	COMPOUND	7	7	vinorelbine
NCT001920623	NCT00192062_3_T0	COMPOUND	2	2	vinorelbine
NCT001920623	NCT00192062_3_T1	COMPOUND	7	7	gemcitabine
NCT001920625	NCT00192062_5_T0	GENE	17	17	has
NCT001920625	NCT00192062_5_T1	COMPOUND	8	8	designee
NCT0019206212	NCT00192062_12_T0	PHENOTYPE	16	17	breast cancer
NCT001920883	NCT00192088_3_T0	PHENOTYPE	17	17	toxicity
NCT001920886	NCT00192088_6_T0	PHENOTYPE	6	6	toxic
NCT001920886	NCT00192088_6_T1	PHENOTYPE	17	17	alopecia
NCT001921014	NCT00192101_4_T0	PHENOTYPE	7	8	disease progression
NCT001921018	NCT00192101_8_T0	GENE	2	2	has
NCT001921019	NCT00192101_9_T0	PHENOTYPE	20	20	acute
NCT001921019	NCT00192101_9_T1	PHENOTYPE	27	27	alopecia
NCT001921019	NCT00192101_9_T2	PHENOTYPE	23	23	toxicities
NCT001921019	NCT00192101_9_T3	GENE	8	8	has
NCT001921019	NCT00192101_9_T4	PHENOTYPE	3	4	disease progression
NCT0019210111	NCT00192101_11_T0	PHENOTYPE	7	7	toxic
NCT0019210111	NCT00192101_11_T1	PHENOTYPE	6	6	acute
NCT0019210111	NCT00192101_11_T2	PHENOTYPE	18	18	alopecia
NCT0019210112	NCT00192101_12_T0	GENE	17	17	has
NCT0019210112	NCT00192101_12_T1	PHENOTYPE	15	16	tumor progression
NCT0019210112	NCT00192101_12_T2	PHENOTYPE	11	12	measurable disease
NCT001921272	NCT00192127_2_T0	GENE	12	12	0.7
NCT001921272	NCT00192127_2_T1	PHENOTYPE	6	6	fever
NCT001921400	NCT00192140_0_T0	GENE	16	16	Age
NCT001921536	NCT00192153_6_T0	GENE	7	7	60
NCT001921790	NCT00192179_0_T0	GENE	2	2	II
NCT001921790	NCT00192179_0_T1	PHENOTYPE	11	11	Influenza
NCT001921793	NCT00192179_3_T0	PHENOTYPE	25	25	influenza
NCT001921793	NCT00192179_3_T1	PHENOTYPE	34	34	strain
NCT001921793	NCT00192179_3_T2	PHENOTYPE	43	43	strain
NCT001921793	NCT00192179_3_T3	PHENOTYPE	52	52	strain
NCT001921793	NCT00192179_3_T4	PHENOTYPE	28	28	Influenza
NCT001921793	NCT00192179_3_T5	PHENOTYPE	37	37	Influenza
NCT001921793	NCT00192179_3_T6	PHENOTYPE	46	46	Influenza
NCT001921793	NCT00192179_3_T7	PHENOTYPE	27	27	strains
NCT001921793	NCT00192179_3_T8	PHENOTYPE	33	33	H1N1
NCT001922183	NCT00192218_3_T0	PHENOTYPE	8	8	influenza
NCT001922310	NCT00192231_0_T0	PHENOTYPE	11	11	Influenza
NCT001922441	NCT00192244_1_T0	PHENOTYPE	15	15	influenza
NCT001922441	NCT00192244_1_T1	PHENOTYPE	25	27	acute otitis media
NCT001922570	NCT00192257_0_T0	PHENOTYPE	9	9	Influenza
NCT001922570	NCT00192257_0_T1	PHENOTYPE	14	14	Influenza
NCT001922570	NCT00192257_0_T2	PHENOTYPE	19	19	Asthma
NCT001922832	NCT00192283_2_T0	PHENOTYPE	14	16	acute otitis media
NCT001923090	NCT00192309_0_T0	GENE	1	1	II
NCT001923090	NCT00192309_0_T1	GENE	16	16	rus
NCT001923090	NCT00192309_0_T2	PHENOTYPE	13	13	Influenza
NCT001923090	NCT00192309_0_T3	BIOLOGICAL_PROCESS	9	10	Immune Response
NCT001923094	NCT00192309_4_T0	PHENOTYPE	20	20	influenza
NCT001923094	NCT00192309_4_T1	GENE	19	19	6-2
NCT001923094	NCT00192309_4_T2	PHENOTYPE	23	23	strains
NCT001923097	NCT00192309_7_T0	PHENOTYPE	16	16	influenza
NCT001923610	NCT00192361_0_T0	PHENOTYPE	11	11	Influenza
NCT001923611	NCT00192361_1_T0	GENE	3	3	2.0
NCT001923743	NCT00192374_3_T0	GENE	6	6	met
NCT001923744	NCT00192374_4_T0	GENE	10	10	has
NCT001924000	NCT00192400_0_T0	GENE	16	16	hy
NCT001924005	NCT00192400_5_T0	GENE	6	6	met
NCT001924006	NCT00192400_6_T0	GENE	10	10	has
NCT001924008	NCT00192400_8_T0	GENE	10	10	has
NCT001924132	NCT00192413_2_T0	GENE	12	12	0.5
NCT001924132	NCT00192413_2_T1	GENE	8	8	pH
NCT001924132	NCT00192413_2_T2	GENE	6	6	had
NCT001924132	NCT00192413_2_T3	GENE	10	10	7.2
NCT001924260	NCT00192426_0_T0	GENE	16	16	hy
NCT001924260	NCT00192426_0_T1	BIOLOGICAL_PROCESS	4	5	Immune Response
NCT001924264	NCT00192426_4_T0	GENE	6	6	met
NCT001924265	NCT00192426_5_T0	GENE	10	10	has
NCT001925040	NCT00192504_0_T0	PHENOTYPE	35	35	Infection
NCT001925040	NCT00192504_0_T1	PHENOTYPE	7	7	Pharmacokinetics
NCT001925432	NCT00192543_2_T0	PHENOTYPE	26	27	cardiovascular disease
NCT001925434	NCT00192543_4_T0	GENE	21	21	4.5
NCT001925434	NCT00192543_4_T1	GENE	1	1	has
NCT001925434	NCT00192543_4_T2	PHENOTYPE	9	10	kidney failure
NCT001925435	NCT00192543_5_T0	PHENOTYPE	4	4	ESRD
NCT001925435	NCT00192543_5_T1	GENE	10	10	fold
NCT001925435	NCT00192543_5_T2	PHENOTYPE	17	18	heart disease
NCT001925438	NCT00192543_8_T0	PHENOTYPE	15	16	heart attack
NCT0019254312	NCT00192543_12_T0	PHENOTYPE	0	0	Strategies
NCT001925562	NCT00192556_2_T0	PHENOTYPE	9	9	secondary
NCT001925566	NCT00192556_6_T0	PHENOTYPE	10	10	secondary
NCT001925566	NCT00192556_6_T1	PHENOTYPE	20	20	symptoms
NCT001925566	NCT00192556_6_T2	PHENOTYPE	17	18	weight gain
NCT0019255610	NCT00192556_10_T0	PHENOTYPE	12	12	tuberculosis
NCT0019255611	NCT00192556_11_T0	PHENOTYPE	3	3	tuberculosis
NCT0019255619	NCT00192556_19_T0	PHENOTYPE	1	1	learned
NCT0019255629	NCT00192556_29_T0	COMPOUND	14	14	BMI
NCT0019255634	NCT00192556_34_T0	GENE	9	9	8.0
NCT0019255638	NCT00192556_38_T0	GENE	4	4	envelope
NCT0019255645	NCT00192556_45_T0	PHENOTYPE	20	20	symptoms
NCT0019255645	NCT00192556_45_T1	PHENOTYPE	0	0	Secondary
NCT0019255645	NCT00192556_45_T2	PHENOTYPE	23	23	fever
NCT0019255645	NCT00192556_45_T3	PHENOTYPE	21	21	cough
NCT0019255645	NCT00192556_45_T4	COMPOUND	27	27	BMI
NCT0019255651	NCT00192556_51_T0	PHENOTYPE	8	8	tuberculosis
NCT001925690	NCT00192569_0_T0	PHENOTYPE	3	5	Acute Hepatitis C
NCT001925692	NCT00192569_2_T0	COMPOUND	38	38	ribavirin
NCT001925692	NCT00192569_2_T1	PHENOTYPE	26	26	HIV
NCT001925692	NCT00192569_2_T2	GENE	11	11	interferon
NCT001925692	NCT00192569_2_T3	GENE	34	34	interferon
NCT001925692	NCT00192569_2_T4	GENE	13	13	2a
NCT001925692	NCT00192569_2_T5	GENE	36	36	2a
NCT001925694	NCT00192569_4_T0	COMPOUND	22	22	ribavirin
NCT001925694	NCT00192569_4_T1	GENE	18	18	interferon
NCT001925694	NCT00192569_4_T2	GENE	20	20	2a
NCT001925694	NCT00192569_4_T3	PHENOTYPE	24	24	HIV
NCT001925694	NCT00192569_4_T4	PHENOTYPE	29	30	hepatitis C
NCT001925822	NCT00192582_2_T0	PHENOTYPE	14	15	mental health
NCT001925823	NCT00192582_3_T0	PHENOTYPE	17	18	Mental Health
NCT001925826	NCT00192582_6_T0	PHENOTYPE	5	5	symptoms
NCT001925826	NCT00192582_6_T1	PHENOTYPE	7	8	mental illness
NCT0019258211	NCT00192582_11_T0	PHENOTYPE	12	13	Mental Health
NCT0019258221	NCT00192582_21_T0	PHENOTYPE	14	14	symptoms
NCT0019258221	NCT00192582_21_T1	PHENOTYPE	19	19	strategies
NCT0019258225	NCT00192582_25_T0	PHENOTYPE	1	2	Mental Health
NCT0019258225	NCT00192582_25_T1	PHENOTYPE	34	35	Mental Health
NCT0019258226	NCT00192582_26_T0	PHENOTYPE	6	7	Mental Health
NCT0019258227	NCT00192582_27_T0	PHENOTYPE	0	0	Recruitment
NCT0019258227	NCT00192582_27_T1	PHENOTYPE	16	17	mental health
NCT0019258227	NCT00192582_27_T2	PHENOTYPE	9	10	Mental Health
NCT0019258228	NCT00192582_28_T0	PHENOTYPE	20	21	Mental Health
NCT0019258229	NCT00192582_29_T0	PHENOTYPE	9	11	chronic mental illness
NCT0019258230	NCT00192582_30_T0	PHENOTYPE	5	5	Schizophrenia
NCT0019258230	NCT00192582_30_T1	PHENOTYPE	13	13	psychoses
NCT0019258230	NCT00192582_30_T2	PHENOTYPE	6	7	Delusional disorder
NCT0019258230	NCT00192582_30_T3	PHENOTYPE	10	11	Drug psychosis
NCT0019258230	NCT00192582_30_T4	PHENOTYPE	15	16	Affective psychoses
NCT0019258230	NCT00192582_30_T5	PHENOTYPE	8	9	Schizoaffective disorder
NCT0019258231	NCT00192582_31_T0	PHENOTYPE	2	3	Intellectual disability
NCT0019258231	NCT00192582_31_T1	PHENOTYPE	6	7	brain disorders
NCT0019258233	NCT00192582_33_T0	PHENOTYPE	13	14	Mental Health
NCT0019258234	NCT00192582_34_T0	GENE	19	20	Group 1
NCT0019258239	NCT00192582_39_T0	PHENOTYPE	2	3	psychiatric diagnosis
NCT0019258242	NCT00192582_42_T0	PHENOTYPE	3	3	symptoms
NCT0019258242	NCT00192582_42_T1	PHENOTYPE	6	7	substance dependence
NCT0019258244	NCT00192582_44_T0	PHENOTYPE	12	12	Dependence
NCT0019258244	NCT00192582_44_T1	PHENOTYPE	10	10	Severity
NCT0019258244	NCT00192582_44_T2	GENE	7	7	PIH
NCT0019258246	NCT00192582_46_T0	PHENOTYPE	65	65	Strategies
NCT0019258246	NCT00192582_46_T1	PHENOTYPE	47	48	mental health
NCT0019258246	NCT00192582_46_T2	PHENOTYPE	93	94	mental health
NCT0019258246	NCT00192582_46_T3	PHENOTYPE	36	37	Mental health
NCT0019258247	NCT00192582_47_T0	PHENOTYPE	27	28	mental health
NCT0019258249	NCT00192582_49_T0	PHENOTYPE	11	12	mental illness
NCT0019258252	NCT00192582_52_T0	PHENOTYPE	4	4	symptoms
NCT0019258252	NCT00192582_52_T1	PHENOTYPE	14	14	strategies
NCT0019258253	NCT00192582_53_T0	PHENOTYPE	39	39	attitudes
NCT0019258253	NCT00192582_53_T1	GENE	34	34	had
NCT0019258255	NCT00192582_55_T0	PHENOTYPE	5	6	mental health
NCT0019258255	NCT00192582_55_T1	PHENOTYPE	25	26	Mental Health
NCT0019258256	NCT00192582_56_T0	PHENOTYPE	9	11	chronic mental illness
NCT0019258257	NCT00192582_57_T0	PHENOTYPE	5	5	Schizophrenia
NCT0019258257	NCT00192582_57_T1	PHENOTYPE	13	13	psychoses
NCT0019258257	NCT00192582_57_T2	PHENOTYPE	6	7	Delusional disorder
NCT0019258257	NCT00192582_57_T3	PHENOTYPE	15	16	Affective disorders
NCT0019258257	NCT00192582_57_T4	PHENOTYPE	10	11	Drug psychosis
NCT0019258257	NCT00192582_57_T5	PHENOTYPE	8	9	Schizoaffective disorder
NCT0019258259	NCT00192582_59_T0	PHENOTYPE	13	14	Mental Health
NCT0019258260	NCT00192582_60_T0	PHENOTYPE	12	13	Intellectual disability
NCT0019258260	NCT00192582_60_T1	PHENOTYPE	16	17	brain disorders
NCT001925950	NCT00192595_0_T0	PHENOTYPE	3	3	Coinfection
NCT001926083	NCT00192608_3_T0	COMPOUND	4	4	saquinavir
NCT001926084	NCT00192608_4_T0	COMPOUND	19	19	saquinavir
NCT001926084	NCT00192608_4_T1	GENE	12	12	has
NCT001926085	NCT00192608_5_T0	PHENOTYPE	44	44	HIV
NCT001926085	NCT00192608_5_T1	COMPOUND	27	27	atazanavir
NCT001926085	NCT00192608_5_T2	COMPOUND	42	42	atazanavir
NCT001926085	NCT00192608_5_T3	COMPOUND	12	12	saquinavir
NCT001926085	NCT00192608_5_T4	COMPOUND	22	22	saquinavir
NCT001926085	NCT00192608_5_T5	COMPOUND	39	39	saquinavir
NCT001926085	NCT00192608_5_T6	PHENOTYPE	6	7	drug levels
NCT001926085	NCT00192608_5_T7	PHENOTYPE	16	17	drug levels
NCT001926088	NCT00192608_8_T0	PHENOTYPE	11	11	HIV
NCT001926088	NCT00192608_8_T1	GENE	1	1	has
NCT001926089	NCT00192608_9_T0	GENE	21	21	protease
NCT001926089	NCT00192608_9_T1	PHENOTYPE	9	9	HIV
NCT001926089	NCT00192608_9_T2	COMPOUND	2	2	saquinavir
NCT0019260810	NCT00192608_10_T0	GENE	1	1	has
NCT0019260812	NCT00192608_12_T0	PHENOTYPE	23	23	HIV
NCT0019260812	NCT00192608_12_T1	GENE	0	0	AIM
NCT0019260812	NCT00192608_12_T2	COMPOUND	18	18	ritonavir
NCT0019260813	NCT00192608_13_T0	COMPOUND	12	12	atazanavir
NCT0019260813	NCT00192608_13_T1	COMPOUND	15	15	ritonavir
NCT0019260813	NCT00192608_13_T2	COMPOUND	13	13	saquinavir
NCT0019260813	NCT00192608_13_T3	COMPOUND	21	21	saquinavir
NCT0019260813	NCT00192608_13_T4	PHENOTYPE	7	8	drug levels
NCT0019260814	NCT00192608_14_T0	COMPOUND	6	6	saquinavir
NCT0019260814	NCT00192608_14_T1	PHENOTYPE	15	16	drug levels
NCT001926213	NCT00192621_3_T0	PHENOTYPE	23	23	HIV
NCT001926213	NCT00192621_3_T1	PHENOTYPE	25	25	lipodystrophy
NCT001926214	NCT00192621_4_T0	COMPOUND	8	8	glucose
NCT001926214	NCT00192621_4_T1	BIOLOGICAL_PROCESS	11	11	metabolism
NCT001926215	NCT00192621_5_T0	PHENOTYPE	17	17	CVD
NCT001926215	NCT00192621_5_T1	PHENOTYPE	1	1	HIV
NCT001926215	NCT00192621_5_T2	PHENOTYPE	15	16	cardiovascular disease
NCT001926216	NCT00192621_6_T0	PHENOTYPE	38	38	CVD
NCT001926216	NCT00192621_6_T1	COMPOUND	17	17	glucose
NCT001926216	NCT00192621_6_T2	PHENOTYPE	26	26	HIV
NCT001926342	NCT00192634_2_T0	COMPOUND	4	4	tenofovir_emtricitabine
NCT001926342	NCT00192634_2_T1	COMPOUND	2	2	abacavir_lamivudine
NCT001926344	NCT00192634_4_T0	PHENOTYPE	20	20	HIV
NCT001926347	NCT00192634_7_T0	PHENOTYPE	19	19	HIV
NCT001926349	NCT00192634_9_T0	GENE	2	2	cease
NCT001926349	NCT00192634_9_T1	GENE	21	21	PI
NCT0019263411	NCT00192634_11_T0	PHENOTYPE	28	28	severity
NCT0019263413	NCT00192634_13_T0	CELL	10	10	cells
NCT0019263413	NCT00192634_13_T1	ORGAN	7	7	plasma
NCT0019263413	NCT00192634_13_T2	ORGAN	8	8	serum
NCT001926600	NCT00192660_0_T0	PHENOTYPE	4	4	Abnormalities
NCT001926600	NCT00192660_0_T1	PHENOTYPE	0	1	HIV Infection
NCT001926603	NCT00192660_3_T0	BIOLOGICAL_PROCESS	25	26	glucose metabolism
NCT001926605	NCT00192660_5_T0	PHENOTYPE	21	21	CVD
NCT001926605	NCT00192660_5_T1	PHENOTYPE	1	1	HIV
NCT001926605	NCT00192660_5_T2	PHENOTYPE	19	20	cardiovascular disease
NCT001926605	NCT00192660_5_T3	BIOLOGICAL_PROCESS	9	10	glucose metabolism
NCT001926606	NCT00192660_6_T0	BIOLOGICAL_PROCESS	16	16	metabolism
NCT001926606	NCT00192660_6_T1	PHENOTYPE	35	36	cardiovascular disease
NCT0019266011	NCT00192660_11_T0	GENE	5	5	had
NCT001926731	NCT00192673_1_T0	GENE	1	1	1.3
NCT001926731	NCT00192673_1_T1	GENE	11	11	asparaginase
NCT001926734	NCT00192673_4_T0	PHENOTYPE	11	11	pharmacokinetics
NCT001926737	NCT00192673_7_T0	GENE	5	5	EFS
NCT001926737	NCT00192673_7_T1	GENE	11	11	asparaginase
NCT001926860	NCT00192686_0_T0	PHENOTYPE	3	3	Suspicion
NCT001926860	NCT00192686_0_T1	COMPOUND	6	6	TKA
NCT001927121	NCT00192712_1_T0	COMPOUND	5	5	irinotecan
NCT001927121	NCT00192712_1_T1	GENE	27	27	reduced
NCT001927121	NCT00192712_1_T2	COMPOUND	3	3	gemcitabine
NCT001927250	NCT00192725_0_T0	PHENOTYPE	3	4	Acute Mania
NCT001927253	NCT00192725_3_T0	GENE	4	4	BD
NCT001927253	NCT00192725_3_T1	PHENOTYPE	14	14	mania
NCT001927253	NCT00192725_3_T2	PHENOTYPE	2	3	bipolar disorder
NCT001927380	NCT00192738_0_T0	PHENOTYPE	5	5	Satisfaction
NCT001927382	NCT00192738_2_T0	PHENOTYPE	28	29	adverse effects
NCT001927512	NCT00192751_2_T0	PHENOTYPE	36	36	decision-making
NCT001927512	NCT00192751_2_T1	PHENOTYPE	47	48	mental illness
NCT001927514	NCT00192751_4_T0	PHENOTYPE	13	13	decision-making
NCT001927515	NCT00192751_5_T0	GENE	2	2	II
NCT001927516	NCT00192751_6_T0	PHENOTYPE	22	22	symptoms
NCT001927516	NCT00192751_6_T1	PHENOTYPE	17	17	relapse
NCT001927516	NCT00192751_6_T2	PHENOTYPE	24	24	self-efficacy
NCT001927516	NCT00192751_6_T3	PHENOTYPE	11	11	decision-making
NCT001927516	NCT00192751_6_T4	PHENOTYPE	25	27	quality of life
NCT001927641	NCT00192764_1_T0	COMPOUND	9	9	cyclophosphamide
NCT001927641	NCT00192764_1_T1	GENE	11	11	CHOP
NCT001927641	NCT00192764_1_T2	PHENOTYPE	2	4	diffuse large-cell lymphoma
NCT001927776	NCT00192777_6_T0	PHENOTYPE	5	5	malignancy
NCT001927778	NCT00192777_8_T0	PHENOTYPE	3	4	bone metastasis
NCT001927907	NCT00192790_7_T0	GENE	20	20	troponin
NCT001927907	NCT00192790_7_T1	ORGAN	7	7	heart
NCT001927907	NCT00192790_7_T2	PHENOTYPE	11	13	coronary artery disease
NCT001928421	NCT00192842_1_T0	COMPOUND	22	22	gemcitabine
NCT001928421	NCT00192842_1_T1	GENE	13	13	gr
NCT001928421	NCT00192842_1_T2	COMPOUND	15	15	curcumin
NCT001928942	NCT00192894_2_T0	GENE	5	5	has
NCT001928942	NCT00192894_2_T1	GENE	4	4	CO
NCT001928943	NCT00192894_3_T0	PHENOTYPE	33	33	anesthesia
NCT001928944	NCT00192894_4_T0	GENE	12	12	has
NCT001928944	NCT00192894_4_T1	GENE	5	5	CO
NCT001928944	NCT00192894_4_T2	ORGAN	17	18	pulmonary artery
NCT001928947	NCT00192894_7_T0	GENE	18	18	has
NCT001928947	NCT00192894_7_T1	COMPOUND	10	10	oxygen
NCT001928947	NCT00192894_7_T2	PHENOTYPE	23	24	maternal hypotension
NCT001928947	NCT00192894_7_T3	PHENOTYPE	26	27	caesarian section
NCT001928948	NCT00192894_8_T0	GENE	11	11	CO
NCT001928948	NCT00192894_8_T1	PHENOTYPE	16	16	anesthesia
NCT001929072	NCT00192907_2_T0	PHENOTYPE	2	2	complications
NCT001929072	NCT00192907_2_T1	PHENOTYPE	6	7	organ failure
NCT001929073	NCT00192907_3_T0	PHENOTYPE	21	21	complications
NCT001929461	NCT00192946_1_T0	PHENOTYPE	10	10	acute
NCT001929461	NCT00192946_1_T1	GENE	11	11	CRT
NCT001929461	NCT00192946_1_T2	ORGAN	19	19	heart
NCT001929463	NCT00192946_3_T0	GENE	12	12	CRT
NCT001929463	NCT00192946_3_T1	ORGAN	22	22	heart
NCT001929464	NCT00192946_4_T0	GENE	1	1	reduced
NCT001929464	NCT00192946_4_T1	PHENOTYPE	5	7	bundle branch block
NCT001929465	NCT00192946_5_T0	GENE	4	4	CRT
NCT001929720	NCT00192972_0_T0	PHENOTYPE	12	13	Atrial Fibrillation
NCT001929722	NCT00192972_2_T0	GENE	9	9	AF
NCT001929723	NCT00192972_3_T0	PHENOTYPE	7	7	recurrence
NCT001929723	NCT00192972_3_T1	GENE	5	5	AF
NCT001929723	NCT00192972_3_T2	PHENOTYPE	4	4	recurrent
NCT001929725	NCT00192972_5_T0	GENE	8	8	AF
NCT001929729	NCT00192972_9_T0	PHENOTYPE	6	6	recurrence
NCT001929729	NCT00192972_9_T1	GENE	4	4	AF
NCT001929729	NCT00192972_9_T2	PHENOTYPE	3	3	recurrent
NCT001929853	NCT00192985_3_T0	GENE	9	9	has
NCT001929853	NCT00192985_3_T1	ORGAN	4	5	urinary bladder
NCT001930111	NCT00193011_1_T0	GENE	3	3	has
NCT001930111	NCT00193011_1_T1	GENE	26	26	has
NCT001930111	NCT00193011_1_T2	PHENOTYPE	16	18	metastatic breast cancer
NCT001930113	NCT00193011_3_T0	COMPOUND	17	17	tamoxifen
NCT001930113	NCT00193011_3_T1	GENE	14	14	hormone
NCT001930114	NCT00193011_4_T0	COMPOUND	8	8	tamoxifen
NCT001930241	NCT00193024_1_T0	GENE	3	3	II
NCT001930241	NCT00193024_1_T1	PHENOTYPE	24	26	metastatic breast cancer
NCT001930373	NCT00193037_3_T0	PHENOTYPE	2	2	progression
NCT001930373	NCT00193037_3_T1	GENE	5	5	ARM
NCT001930373	NCT00193037_3_T2	GENE	17	17	ARM
NCT001930374	NCT00193037_4_T0	GENE	16	16	has
NCT001930501	NCT00193050_1_T0	PHENOTYPE	12	12	toxicity
NCT001930501	NCT00193050_1_T1	GENE	19	19	triplet
NCT001930501	NCT00193050_1_T2	COMPOUND	21	21	epirubicin
NCT001930501	NCT00193050_1_T3	COMPOUND	23	23	docetaxel
NCT001930501	NCT00193050_1_T4	COMPOUND	20	20	gemcitabine
NCT001930501	NCT00193050_1_T5	PHENOTYPE	30	32	inflammatory breast cancer
NCT001930502	NCT00193050_2_T0	PHENOTYPE	15	16	breast cancer
NCT001930761	NCT00193076_1_T0	COMPOUND	11	11	platinum
NCT001930761	NCT00193076_1_T1	COMPOUND	9	9	gemcitabine
NCT001930761	NCT00193076_1_T2	PHENOTYPE	17	19	metastatic breast cancer
NCT001930762	NCT00193076_2_T0	COMPOUND	7	7	gemcitabine
NCT001930762	NCT00193076_2_T1	PHENOTYPE	13	15	metastatic breast cancer
NCT001930763	NCT00193076_3_T0	COMPOUND	13	13	gemcitabine
NCT001931021	NCT00193102_1_T0	GENE	2	2	II
NCT001931021	NCT00193102_1_T1	GENE	12	12	Pearl
NCT001931152	NCT00193115_2_T0	COMPOUND	3	3	estrogen
NCT001931152	NCT00193115_2_T1	COMPOUND	9	9	estrogen
NCT001931152	NCT00193115_2_T2	COMPOUND	5	5	progesterone
NCT001931282	NCT00193128_2_T0	GENE	8	8	II
NCT001931283	NCT00193128_3_T0	GENE	10	10	II
NCT001931283	NCT00193128_3_T1	PHENOTYPE	7	7	toxic
NCT001931411	NCT00193141_1_T0	COMPOUND	10	10	paclitaxel
NCT001931411	NCT00193141_1_T1	GENE	19	19	Gy
NCT001931412	NCT00193141_2_T0	GENE	24	24	Gy
NCT001931541	NCT00193154_1_T0	GENE	9	9	II
NCT001931541	NCT00193154_1_T1	PHENOTYPE	24	25	solid tumor
NCT001932191	NCT00193219_1_T0	GENE	1	1	has
NCT001932191	NCT00193219_1_T1	PHENOTYPE	16	17	colorectal cancer
NCT001932194	NCT00193219_4_T0	COMPOUND	16	16	5_fluorouracil
NCT001932194	NCT00193219_4_T1	COMPOUND	11	11	oxaliplatin
NCT001932194	NCT00193219_4_T2	COMPOUND	38	38	leucovorin
NCT001932194	NCT00193219_4_T3	GENE	10	10	IV
NCT001932194	NCT00193219_4_T4	GENE	14	14	IV
NCT001932194	NCT00193219_4_T5	GENE	19	19	IV
NCT001932194	NCT00193219_4_T6	GENE	41	41	IV
NCT001932453	NCT00193245_3_T0	GENE	16	16	has
NCT001932581	NCT00193258_1_T0	PHENOTYPE	6	6	tumor
NCT001932581	NCT00193258_1_T1	PHENOTYPE	2	2	inhibition
NCT001932582	NCT00193258_2_T0	PHENOTYPE	29	29	toxicity
NCT001932582	NCT00193258_2_T1	GENE	7	7	has
NCT001932583	NCT00193258_3_T0	GENE	24	24	II
NCT001932840	NCT00193284_0_T0	PHENOTYPE	11	14	Head and Neck Cancer
NCT001932842	NCT00193284_2_T0	PHENOTYPE	8	8	toxicity
NCT001932842	NCT00193284_2_T1	COMPOUND	19	19	gefitinib
NCT001933102	NCT00193310_2_T0	COMPOUND	13	14	weekly paclitaxel
NCT001933102	NCT00193310_2_T1	COMPOUND	22	23	weekly paclitaxel
NCT001933103	NCT00193310_3_T0	PHENOTYPE	11	11	tumors
NCT001933103	NCT00193310_3_T1	COMPOUND	12	13	weekly paclitaxel
NCT001933105	NCT00193310_5_T0	GENE	27	27	had
NCT001933105	NCT00193310_5_T1	COMPOUND	8	9	weekly paclitaxel
NCT001933106	NCT00193310_6_T0	GENE	18	18	had
NCT001933106	NCT00193310_6_T1	COMPOUND	1	2	weekly paclitaxel
NCT001933232	NCT00193323_2_T0	GENE	16	16	has
NCT001933622	NCT00193362_2_T0	GENE	16	16	has
NCT001934142	NCT00193414_2_T0	PHENOTYPE	22	22	NSCLC
NCT001934272	NCT00193427_2_T0	PHENOTYPE	14	14	NSCLC
NCT001934401	NCT00193440_1_T0	PHENOTYPE	31	31	cytotoxicity
NCT001934401	NCT00193440_1_T1	COMPOUND	3	4	ibritumomab tiuxetan
NCT001934402	NCT00193440_2_T0	PHENOTYPE	4	4	lymphoma
NCT001934791	NCT00193479_1_T0	COMPOUND	8	8	mitoxantrone
NCT001934791	NCT00193479_1_T1	COMPOUND	9	9	vincristine
NCT001934791	NCT00193479_1_T2	COMPOUND	7	7	cyclophosphamide
NCT001934791	NCT00193479_1_T3	COMPOUND	11	11	prednisone
NCT001934792	NCT00193479_2_T0	PHENOTYPE	11	11	remission
NCT001934922	NCT00193492_2_T0	GENE	16	16	has
NCT001935181	NCT00193518_1_T0	PHENOTYPE	11	12	hematologic malignancies
NCT001935181	NCT00193518_1_T1	COMPOUND	7	8	arsenic trioxide
NCT001935182	NCT00193518_2_T0	PHENOTYPE	25	25	CLL/SLL
NCT001935182	NCT00193518_2_T1	COMPOUND	1	2	arsenic trioxide
NCT001935441	NCT00193544_1_T0	COMPOUND	8	8	thalidomide
NCT001935442	NCT00193544_2_T0	PHENOTYPE	6	8	mechanism of action
NCT001935700	NCT00193570_0_T0	PHENOTYPE	9	10	Solid Tumors
NCT001935702	NCT00193570_2_T0	PHENOTYPE	5	5	tumor
NCT001935704	NCT00193570_4_T0	GENE	16	16	has
NCT001935830	NCT00193583_0_T0	PHENOTYPE	14	15	Solid Tumors
NCT001935960	NCT00193596_0_T0	PHENOTYPE	4	7	Carcinoma of Unknown Primary
NCT001935963	NCT00193596_3_T0	PHENOTYPE	16	17	disease progression
NCT001935965	NCT00193596_5_T0	GENE	16	16	has
NCT001936090	NCT00193609_0_T0	PHENOTYPE	8	11	Carcinoma of Unknown Primary
NCT001936094	NCT00193609_4_T0	GENE	3	3	BID
NCT001936220	NCT00193622_0_T0	PHENOTYPE	9	12	Carcinoma of Unknown Primary
NCT001936222	NCT00193622_2_T0	PHENOTYPE	9	9	toxicity
NCT001936222	NCT00193622_2_T1	COMPOUND	2	2	erlotinib
NCT001936223	NCT00193622_3_T0	PHENOTYPE	22	23	solid tumor
NCT001936351	NCT00193635_1_T0	GENE	6	6	GFR
NCT001936351	NCT00193635_1_T1	PHENOTYPE	7	7	falls
NCT001936351	NCT00193635_1_T2	GENE	11	11	M2
NCT001936351	NCT00193635_1_T3	ORGAN	23	23	transplant
NCT001936354	NCT00193635_4_T0	CELL	6	6	monocytes
NCT001936354	NCT00193635_4_T1	ORGAN	3	3	kidney
NCT001936354	NCT00193635_4_T2	CELL	5	5	macrophages
NCT001936354	NCT00193635_4_T3	CELL	8	8	lymphocytes
NCT001936354	NCT00193635_4_T4	PHENOTYPE	22	22	fibrosis
NCT001936354	NCT00193635_4_T5	PHENOTYPE	0	0	Infiltration
NCT001936354	NCT00193635_4_T6	CELL	13	14	epithelial cells
NCT001936355	NCT00193635_5_T0	ORGAN	16	16	kidney
NCT001936355	NCT00193635_5_T1	PHENOTYPE	13	13	acute
NCT001936355	NCT00193635_5_T2	ORGAN	17	17	transplant
NCT001936358	NCT00193635_8_T0	GENE	11	11	GFR
NCT001936358	NCT00193635_8_T1	PHENOTYPE	3	3	uropathy
NCT001936358	NCT00193635_8_T2	GENE	16	16	M2
NCT001936359	NCT00193635_9_T0	ORGAN	18	18	kidney
NCT001936359	NCT00193635_9_T1	PHENOTYPE	8	8	tolerance
NCT0019363510	NCT00193635_10_T0	PHENOTYPE	11	11	toxicity
NCT0019363510	NCT00193635_10_T1	PHENOTYPE	23	23	progression
NCT0019363510	NCT00193635_10_T2	PHENOTYPE	25	28	end stage renal disease
NCT0019363515	NCT00193635_15_T0	CELL	11	11	macrophages
NCT0019363515	NCT00193635_15_T1	CELL	12	12	lymphocytes
NCT0019363515	NCT00193635_15_T2	CELL	16	16	cells
NCT0019363515	NCT00193635_15_T3	PHENOTYPE	5	5	infiltration
NCT0019363516	NCT00193635_16_T0	CELL	1	1	cells
NCT0019363519	NCT00193635_19_T0	GENE	13	13	had
NCT0019363519	NCT00193635_19_T1	GENE	7	7	has
NCT0019363519	NCT00193635_19_T2	COMPOUND	2	3	mycophenolate mofetil
NCT0019363520	NCT00193635_20_T0	ORGAN	4	4	kidney
NCT0019363520	NCT00193635_20_T1	PHENOTYPE	0	0	Uremia
NCT0019363520	NCT00193635_20_T2	PHENOTYPE	12	13	immunological disease
NCT0019363521	NCT00193635_21_T0	PHENOTYPE	19	19	adaptation
NCT0019363521	NCT00193635_21_T1	GENE	21	21	reduced
NCT0019363521	NCT00193635_21_T2	PHENOTYPE	9	9	hypertension
NCT0019363522	NCT00193635_22_T0	CELL	10	10	lymphocytes
NCT0019363522	NCT00193635_22_T1	PHENOTYPE	3	3	infiltration
NCT0019363523	NCT00193635_23_T0	CELL	10	10	lymphocytes
NCT0019363523	NCT00193635_23_T1	CELL	17	17	macrophage
NCT0019363523	NCT00193635_23_T2	PHENOTYPE	18	18	infiltration
NCT0019363524	NCT00193635_24_T0	PHENOTYPE	10	10	albuminuria
NCT0019363524	NCT00193635_24_T1	PHENOTYPE	12	12	glomerulosclerosis
NCT0019363527	NCT00193635_27_T0	ORGAN	19	19	transplants
NCT0019363528	NCT00193635_28_T0	PHENOTYPE	24	24	progressive
NCT0019363528	NCT00193635_28_T1	PHENOTYPE	25	28	loss of renal function
NCT0019363530	NCT00193635_30_T0	GENE	17	17	GFR
NCT0019363530	NCT00193635_30_T1	GENE	18	18	50
NCT0019363530	NCT00193635_30_T2	BIOLOGICAL_PROCESS	14	15	glomerular filtration
NCT0019363530	NCT00193635_30_T3	PHENOTYPE	27	28	obstructive uropathy
NCT0019363530	NCT00193635_30_T4	COMPOUND	6	7	mycophenolate mofetil
NCT0019363530	NCT00193635_30_T5	PHENOTYPE	30	31	reflux nephropathy
NCT0019363531	NCT00193635_31_T0	PHENOTYPE	21	21	ESRD
NCT0019363531	NCT00193635_31_T1	GENE	16	16	GFR
NCT0019363531	NCT00193635_31_T2	GENE	30	30	GFR
NCT0019363531	NCT00193635_31_T3	PHENOTYPE	13	13	progressive
NCT0019363531	NCT00193635_31_T4	GENE	31	31	50
NCT0019363531	NCT00193635_31_T5	BIOLOGICAL_PROCESS	27	28	glomerular filtration
NCT0019363531	NCT00193635_31_T6	COMPOUND	6	7	mycophenolate mofetil
NCT0019363534	NCT00193635_34_T0	GENE	10	10	structural
NCT0019363534	NCT00193635_34_T1	PHENOTYPE	1	2	obstructive uropathy
NCT0019363537	NCT00193635_37_T0	PHENOTYPE	0	0	Reflux
NCT0019363537	NCT00193635_37_T1	PHENOTYPE	1	1	nephropathy
NCT0019363541	NCT00193635_41_T0	PHENOTYPE	10	10	secondary
NCT0019363542	NCT00193635_42_T0	PHENOTYPE	5	6	urological disease
NCT0019363544	NCT00193635_44_T0	GENE	0	0	Age
NCT0019363545	NCT00193635_45_T0	PHENOTYPE	1	1	uropathy
NCT0019363549	NCT00193635_49_T0	PHENOTYPE	5	6	immunological disease
NCT0019363549	NCT00193635_49_T1	PHENOTYPE	9	10	HIV infection
NCT0019363551	NCT00193635_51_T0	GENE	14	14	GFR
NCT0019363551	NCT00193635_51_T1	PHENOTYPE	0	1	Glomerular disease
NCT0019363553	NCT00193635_53_T0	GENE	8	8	GFR
NCT0019363554	NCT00193635_54_T0	PHENOTYPE	13	13	uropathy
NCT0019363554	NCT00193635_54_T1	PHENOTYPE	30	31	kidney disease
NCT0019363561	NCT00193635_61_T0	GENE	14	14	ACE
NCT0019363562	NCT00193635_62_T0	GENE	14	14	Period
NCT0019363564	NCT00193635_64_T0	GENE	3	3	GFR
NCT0019363564	NCT00193635_64_T1	GENE	22	22	Period
NCT0019363565	NCT00193635_65_T0	GENE	3	3	GFR
NCT0019363565	NCT00193635_65_T1	GENE	18	18	GFR
NCT0019363565	NCT00193635_65_T2	GENE	7	7	M2
NCT0019363565	NCT00193635_65_T3	GENE	30	30	Period
NCT0019363565	NCT00193635_65_T4	GENE	5	5	50
NCT0019363566	NCT00193635_66_T0	GENE	9	9	GFR
NCT0019363567	NCT00193635_67_T0	PHENOTYPE	0	0	HIV
NCT0019363569	NCT00193635_69_T0	GENE	7	7	BID
NCT0019363570	NCT00193635_70_T0	GENE	6	6	BID
NCT0019363571	NCT00193635_71_T0	GENE	25	25	ANC
NCT0019363571	NCT00193635_71_T1	GENE	18	18	hematocrit
NCT0019363571	NCT00193635_71_T2	CELL	23	23	neutrophil
NCT0019363571	NCT00193635_71_T3	PHENOTYPE	17	17	anemia
NCT0019363572	NCT00193635_72_T0	PHENOTYPE	5	5	toxicity
NCT0019363572	NCT00193635_72_T1	GENE	4	4	GI
NCT0019363572	NCT00193635_72_T2	GENE	20	20	reduced
NCT0019363574	NCT00193635_74_T0	PHENOTYPE	5	5	toxicity
NCT0019363575	NCT00193635_75_T0	GENE	1	1	ANC
NCT0019363577	NCT00193635_77_T0	GENE	5	5	ACE
NCT0019363581	NCT00193635_81_T0	COMPOUND	6	7	vitamin E
NCT0019363584	NCT00193635_84_T0	PHENOTYPE	13	13	microalbuminuria
NCT0019363584	NCT00193635_84_T1	PHENOTYPE	18	18	HIV
NCT0019363584	NCT00193635_84_T2	GENE	8	8	BP
NCT0019363584	NCT00193635_84_T3	PHENOTYPE	10	11	protein/creatinine ratio
NCT0019363585	NCT00193635_85_T0	GENE	21	21	70
NCT0019363585	NCT00193635_85_T1	ORGAN	13	13	serum
NCT0019363585	NCT00193635_85_T2	PHENOTYPE	44	45	disease progression
NCT0019363586	NCT00193635_86_T0	GENE	5	5	Period
NCT0019363586	NCT00193635_86_T1	GENE	10	10	Period
NCT0019363588	NCT00193635_88_T0	PHENOTYPE	2	2	ESRD
NCT0019363588	NCT00193635_88_T1	GENE	36	36	GFR
NCT0019363588	NCT00193635_88_T2	PHENOTYPE	33	33	uropathy
NCT0019363588	NCT00193635_88_T3	GENE	37	37	50
NCT0019363589	NCT00193635_89_T0	PHENOTYPE	11	11	ESRD
NCT0019363589	NCT00193635_89_T1	ORGAN	33	33	transplant
NCT0019363592	NCT00193635_92_T0	GENE	7	7	Period
NCT001936485	NCT00193648_5_T0	GENE	2	2	R21
NCT001936485	NCT00193648_5_T1	PHENOTYPE	15	15	proteinuria
NCT001936487	NCT00193648_7_T0	GENE	25	25	II
NCT001936487	NCT00193648_7_T1	GENE	7	7	PK
NCT0019364811	NCT00193648_11_T0	PHENOTYPE	0	0	Proteinuria
NCT0019364811	NCT00193648_11_T1	PHENOTYPE	7	8	protein/creatinine ratio
NCT0019364813	NCT00193648_13_T0	COMPOUND	1	1	creatinine
NCT0019364813	NCT00193648_13_T1	GENE	4	4	GFR
NCT0019364813	NCT00193648_13_T2	ORGAN	0	0	Serum
NCT0019364814	NCT00193648_14_T0	GENE	1	1	GFR
NCT0019364817	NCT00193648_17_T0	PHENOTYPE	0	0	HIV
NCT0019364817	NCT00193648_17_T1	PHENOTYPE	1	2	Hepatitis B
NCT0019364821	NCT00193648_21_T0	COMPOUND	1	1	glucose
NCT0019364821	NCT00193648_21_T1	COMPOUND	4	4	creatinine
NCT0019364821	NCT00193648_21_T2	PHENOTYPE	5	5	concentrations
NCT0019364821	NCT00193648_21_T3	GENE	2	2	albumin
NCT0019364821	NCT00193648_21_T4	ORGAN	0	0	Serum
NCT0019364822	NCT00193648_22_T0	GENE	0	0	TNF-alpha
NCT0019364827	NCT00193648_27_T0	GENE	0	0	PK
NCT0019364828	NCT00193648_28_T0	PHENOTYPE	6	7	adverse events
NCT0019364831	NCT00193648_31_T0	GENE	3	3	ANA
NCT0019364831	NCT00193648_31_T1	GENE	1	1	albumin
NCT0019364831	NCT00193648_31_T2	ORGAN	0	0	Serum
NCT0019364831	NCT00193648_31_T3	GENE	4	4	CH50
NCT0019364832	NCT00193648_32_T0	ORGAN	1	1	serum
NCT0019364835	NCT00193648_35_T0	PHENOTYPE	6	7	adverse events
NCT0019364837	NCT00193648_37_T0	COMPOUND	1	1	creatinine
NCT0019364837	NCT00193648_37_T1	GENE	4	4	GFR
NCT0019364837	NCT00193648_37_T2	ORGAN	0	0	Serum
NCT0019364840	NCT00193648_40_T0	ORGAN	0	0	Serum
NCT0019364840	NCT00193648_40_T1	ORGAN	1	1	plasma
NCT0019364842	NCT00193648_42_T0	GENE	15	15	R21
NCT0019364842	NCT00193648_42_T1	GENE	2	2	PK
NCT0019364852	NCT00193648_52_T0	GENE	19	19	log
NCT0019364855	NCT00193648_55_T0	GENE	2	2	PPARgamma
NCT0019364857	NCT00193648_57_T0	COMPOUND	4	4	rosiglitazone
NCT0019364859	NCT00193648_59_T0	COMPOUND	41	41	rosiglitazone
NCT0019364859	NCT00193648_59_T1	COMPOUND	60	60	rosiglitazone
NCT0019364859	NCT00193648_59_T2	GENE	1	1	PK
NCT0019364859	NCT00193648_59_T3	GENE	13	13	PK
NCT0019364859	NCT00193648_59_T4	GENE	36	36	PK
NCT0019364859	NCT00193648_59_T5	GENE	65	65	PK
NCT0019364860	NCT00193648_60_T0	GENE	6	6	ml
NCT0019364861	NCT00193648_61_T0	ORGAN	6	6	serum
NCT0019364861	NCT00193648_61_T1	GENE	9	9	ml
NCT0019364861	NCT00193648_61_T2	GENE	12	12	ml
NCT0019364864	NCT00193648_64_T0	GENE	8	8	0.2
NCT0019364864	NCT00193648_64_T1	GENE	9	9	2.12
NCT0019364865	NCT00193648_65_T0	PHENOTYPE	21	22	protein/creatinine ratio
NCT0019364872	NCT00193648_72_T0	COMPOUND	20	20	2
NCT0019364872	NCT00193648_72_T1	GENE	4	4	PK
NCT0019364872	NCT00193648_72_T2	ORGAN	7	7	serum
NCT0019364874	NCT00193648_74_T0	PHENOTYPE	6	6	proteinuria
NCT0019364876	NCT00193648_76_T0	GENE	4	4	GFR
NCT0019364876	NCT00193648_76_T1	BIOLOGICAL_PROCESS	1	2	glomerular filtration
NCT0019364883	NCT00193648_83_T0	COMPOUND	35	35	prednisone
NCT0019364890	NCT00193648_90_T0	COMPOUND	4	4	levamisole
NCT0019364890	NCT00193648_90_T1	COMPOUND	2	2	cyclophosphamide
NCT0019364890	NCT00193648_90_T2	COMPOUND	5	5	methotrexate
NCT0019364890	NCT00193648_90_T3	COMPOUND	3	3	chlorambucil
NCT0019364890	NCT00193648_90_T4	COMPOUND	6	7	nitrogen mustard
NCT0019364891	NCT00193648_91_T0	BIOLOGICAL_PROCESS	0	0	Lactation
NCT0019364894	NCT00193648_94_T0	PHENOTYPE	0	0	Malignancy
NCT0019364898	NCT00193648_98_T0	PHENOTYPE	0	1	Diabetes mellitus
NCT00193648101	NCT00193648_101_T0	PHENOTYPE	0	0	Obesity
NCT00193648104	NCT00193648_104_T0	PHENOTYPE	0	0	Allergy
NCT001936610	NCT00193661_0_T0	PHENOTYPE	11	11	Hypogonadism
NCT001936740	NCT00193674_0_T0	PHENOTYPE	0	1	Habitual Abortion
NCT001936740	NCT00193674_0_T1	PHENOTYPE	11	12	Recurrent Miscarriage
NCT001937261	NCT00193726_1_T0	CELL	11	11	cells
NCT001937261	NCT00193726_1_T1	PHENOTYPE	9	10	breast cancer
NCT001937265	NCT00193726_5_T0	CELL	25	25	cells
NCT001937266	NCT00193726_6_T0	PHENOTYPE	11	11	recruitment
NCT001937266	NCT00193726_6_T1	PHENOTYPE	17	18	breast cancer
NCT0019372610	NCT00193726_10_T0	PHENOTYPE	3	3	tumour
NCT0019372610	NCT00193726_10_T1	PHENOTYPE	6	7	breast cancer
NCT0019372611	NCT00193726_11_T0	BIOLOGICAL_PROCESS	16	16	transcription
NCT0019372611	NCT00193726_11_T1	GENE	15	15	reduced
NCT0019372611	NCT00193726_11_T2	PHENOTYPE	8	8	inhibition
NCT0019372611	NCT00193726_11_T3	COMPOUND	3	3	tamoxifen
NCT0019372611	NCT00193726_11_T4	GENE	11	12	estrogen receptor
NCT0019372613	NCT00193726_13_T0	PHENOTYPE	31	31	tumours
NCT0019372613	NCT00193726_13_T1	COMPOUND	16	16	tamoxifen
NCT0019372613	NCT00193726_13_T2	PHENOTYPE	1	3	mechanism of action
NCT0019372618	NCT00193726_18_T0	CELL	3	3	cells
NCT0019372618	NCT00193726_18_T1	COMPOUND	17	17	thymidine
NCT0019372618	NCT00193726_18_T2	PHENOTYPE	7	8	breast cancer
NCT0019372618	NCT00193726_18_T3	PHENOTYPE	18	19	labeling index
NCT0019372619	NCT00193726_19_T0	CELL	11	11	cells
NCT0019372619	NCT00193726_19_T1	CELL	24	24	cells
NCT0019372619	NCT00193726_19_T2	PHENOTYPE	10	10	tumor
NCT0019372620	NCT00193726_20_T0	COMPOUND	12	12	estrogen
NCT0019372620	NCT00193726_20_T1	CELL	23	23	cells
NCT0019372620	NCT00193726_20_T2	PHENOTYPE	19	19	proliferation
NCT0019372620	NCT00193726_20_T3	PHENOTYPE	6	7	breast cancer
NCT0019372620	NCT00193726_20_T4	PHENOTYPE	21	22	breast cancer
NCT0019372625	NCT00193726_25_T0	CELL	20	20	cells
NCT0019372625	NCT00193726_25_T1	PHENOTYPE	16	16	recruitment
NCT0019372625	NCT00193726_25_T2	PHENOTYPE	18	19	breast cancer
NCT0019372629	NCT00193726_29_T0	GENE	9	9	CAF
NCT0019372629	NCT00193726_29_T1	GENE	14	14	reduced
NCT0019372630	NCT00193726_30_T0	GENE	16	16	CEF
NCT0019372630	NCT00193726_30_T1	GENE	6	6	al
NCT0019372630	NCT00193726_30_T2	GENE	5	5	et
NCT0019372630	NCT00193726_30_T3	GENE	10	10	MBC
NCT0019372631	NCT00193726_31_T0	PHENOTYPE	8	8	rages
NCT0019372631	NCT00193726_31_T1	GENE	23	23	CEF
NCT0019372633	NCT00193726_33_T0	GENE	15	15	CAF
NCT0019372633	NCT00193726_33_T1	GENE	19	19	CAF
NCT0019372633	NCT00193726_33_T2	GENE	6	6	al
NCT0019372633	NCT00193726_33_T3	GENE	5	5	et
NCT0019372633	NCT00193726_33_T4	GENE	11	11	MBC
NCT0019372634	NCT00193726_34_T0	PHENOTYPE	9	9	progression
NCT0019372635	NCT00193726_35_T0	PHENOTYPE	0	0	Toxicities
NCT0019372638	NCT00193726_38_T0	PHENOTYPE	10	11	breast cancer
NCT0019372640	NCT00193726_40_T0	GENE	5	5	has
NCT0019372641	NCT00193726_41_T0	COMPOUND	35	35	estrogen
NCT0019372641	NCT00193726_41_T1	CELL	28	28	cells
NCT0019372641	NCT00193726_41_T2	COMPOUND	9	9	tamoxifen
NCT0019372641	NCT00193726_41_T3	PHENOTYPE	26	27	breast cancer
NCT0019372641	NCT00193726_41_T4	PHENOTYPE	46	47	breast cancer
NCT0019372643	NCT00193726_43_T0	PHENOTYPE	13	13	tumour
NCT0019372643	NCT00193726_43_T1	COMPOUND	8	8	tamoxifen
NCT0019372643	NCT00193726_43_T2	COMPOUND	9	9	estradiol
NCT0019372644	NCT00193726_44_T0	COMPOUND	20	20	estradiol
NCT0019372644	NCT00193726_44_T1	PHENOTYPE	3	4	breast cancer
NCT0019372646	NCT00193726_46_T0	PHENOTYPE	7	8	breast cancer
NCT0019372648	NCT00193726_48_T0	PHENOTYPE	3	4	breast cancer
NCT0019372658	NCT00193726_58_T0	PHENOTYPE	6	7	second cancer
NCT001937391	NCT00193739_1_T0	COMPOUND	17	17	platinum
NCT001937391	NCT00193739_1_T1	GENE	15	15	RT
NCT001937391	NCT00193739_1_T2	GENE	9	9	IB2
NCT001937391	NCT00193739_1_T3	PHENOTYPE	6	7	cervical cancer
NCT001937392	NCT00193739_2_T0	GENE	18	18	NACT
NCT001937393	NCT00193739_3_T0	GENE	14	14	RT
NCT001937393	NCT00193739_3_T1	GENE	3	3	has
NCT001937397	NCT00193739_7_T0	PHENOTYPE	10	11	cervical cancer
NCT001937399	NCT00193739_9_T0	PHENOTYPE	1	1	tumours
NCT001937399	NCT00193739_9_T1	PHENOTYPE	10	12	lymph node metastases
NCT0019373910	NCT00193739_10_T0	GENE	2	2	al
NCT0019373910	NCT00193739_10_T1	GENE	1	1	et
NCT0019373912	NCT00193739_12_T0	GENE	25	25	IB1
NCT0019373912	NCT00193739_12_T1	GENE	16	16	has
NCT0019373912	NCT00193739_12_T2	PHENOTYPE	15	15	tumours
NCT0019373912	NCT00193739_12_T3	PHENOTYPE	26	26	tumours
NCT0019373913	NCT00193739_13_T0	GENE	14	14	IB2
NCT0019373913	NCT00193739_13_T1	PHENOTYPE	15	15	tumours
NCT0019373913	NCT00193739_13_T2	PHENOTYPE	26	26	tumours
NCT0019373913	NCT00193739_13_T3	PHENOTYPE	4	6	lymph node metastasis
NCT0019373914	NCT00193739_14_T0	PHENOTYPE	19	19	tumour
NCT0019373914	NCT00193739_14_T1	PHENOTYPE	10	11	cervical cancer
NCT0019373914	NCT00193739_14_T2	PHENOTYPE	24	26	lymph node metastases
NCT0019373915	NCT00193739_15_T0	PHENOTYPE	12	12	toxicity
NCT0019373915	NCT00193739_15_T1	PHENOTYPE	7	7	tumours
NCT0019373917	NCT00193739_17_T0	GENE	1	1	has
NCT0019373917	NCT00193739_17_T1	PHENOTYPE	10	11	cervical cancers
NCT0019373919	NCT00193739_19_T0	GENE	12	12	has
NCT0019373919	NCT00193739_19_T1	PHENOTYPE	18	19	cervical cancer
NCT0019373920	NCT00193739_20_T0	COMPOUND	29	29	platinum
NCT0019373920	NCT00193739_20_T1	GENE	9	9	3/12
NCT0019373920	NCT00193739_20_T2	GENE	10	10	has
NCT0019373920	NCT00193739_20_T3	PHENOTYPE	42	43	cervical cancer
NCT0019373922	NCT00193739_22_T0	GENE	1	1	has
NCT0019373922	NCT00193739_22_T1	PHENOTYPE	18	19	cervical cancer
NCT0019373923	NCT00193739_23_T0	GENE	20	20	II
NCT0019373923	NCT00193739_23_T1	GENE	17	17	IB2
NCT0019373923	NCT00193739_23_T2	PHENOTYPE	22	22	tumours
NCT0019373923	NCT00193739_23_T3	PHENOTYPE	28	28	tumours
NCT0019373923	NCT00193739_23_T4	PHENOTYPE	25	26	stage III
NCT0019373926	NCT00193739_26_T0	PHENOTYPE	7	7	tumour
NCT0019373928	NCT00193739_28_T0	GENE	3	3	NACT
NCT0019373929	NCT00193739_29_T0	GENE	4	4	NACT
NCT0019373930	NCT00193739_30_T0	GENE	12	12	NACT
NCT0019373930	NCT00193739_30_T1	CELL	23	23	clones
NCT0019373931	NCT00193739_31_T0	GENE	9	9	NACT
NCT0019373931	NCT00193739_31_T1	GENE	18	18	NACT
NCT0019373931	NCT00193739_31_T2	PHENOTYPE	15	15	cancers
NCT0019373932	NCT00193739_32_T0	CELL	18	18	clones
NCT0019373932	NCT00193739_32_T1	PHENOTYPE	4	4	tumour
NCT0019373933	NCT00193739_33_T0	GENE	2	2	has
NCT0019373937	NCT00193739_37_T0	GENE	8	8	NACT
NCT0019373937	NCT00193739_37_T1	COMPOUND	5	5	1B2
NCT0019373940	NCT00193739_40_T0	GENE	9	9	NACT
NCT0019373940	NCT00193739_40_T1	GENE	3	3	has
NCT0019373942	NCT00193739_42_T0	GENE	12	12	NACT
NCT0019373943	NCT00193739_43_T0	COMPOUND	47	47	bleomycin
NCT0019373943	NCT00193739_43_T1	COMPOUND	25	25	paclitaxel
NCT0019373943	NCT00193739_43_T2	COMPOUND	48	48	vincristine
NCT0019373943	NCT00193739_43_T3	GENE	17	17	al
NCT0019373943	NCT00193739_43_T4	GENE	44	44	al
NCT0019373943	NCT00193739_43_T5	GENE	16	16	et
NCT0019373943	NCT00193739_43_T6	GENE	43	43	et
NCT0019373943	NCT00193739_43_T7	COMPOUND	21	21	ifosfamide
NCT0019373943	NCT00193739_43_T8	COMPOUND	23	23	cisplatin
NCT0019373943	NCT00193739_43_T9	COMPOUND	50	50	cisplatin
NCT0019373943	NCT00193739_43_T10	PHENOTYPE	4	5	cervical cancer
NCT0019373944	NCT00193739_44_T0	GENE	23	23	IB2
NCT0019373944	NCT00193739_44_T1	PHENOTYPE	26	27	squamous carcinoma
NCT0019373944	NCT00193739_44_T2	PHENOTYPE	27	30	carcinoma of the cervix
NCT0019373949	NCT00193739_49_T0	PHENOTYPE	8	8	metastases
NCT0019373949	NCT00193739_49_T1	GENE	7	7	nodal
NCT0019373951	NCT00193739_51_T0	PHENOTYPE	6	7	second malignancy
NCT001937521	NCT00193752_1_T0	COMPOUND	0	0	18F-fluorodeoxyglucose
NCT001937521	NCT00193752_1_T1	GENE	6	6	has
NCT001937521	NCT00193752_1_T2	PHENOTYPE	11	12	cervical cancers
NCT001937522	NCT00193752_2_T0	GENE	4	4	has
NCT001937523	NCT00193752_3_T0	GENE	3	3	RT
NCT001937523	NCT00193752_3_T1	GENE	6	6	RT
NCT001937523	NCT00193752_3_T2	PHENOTYPE	1	1	decisions
NCT001937523	NCT00193752_3_T3	PHENOTYPE	2	2	Localized
NCT001937526	NCT00193752_6_T0	PHENOTYPE	11	11	cancers
NCT001937526	NCT00193752_6_T1	PHENOTYPE	4	5	Carcinoma Cervix
NCT0019375210	NCT00193752_10_T0	GENE	3	3	nodal
NCT0019375210	NCT00193752_10_T1	GENE	14	14	nodal
NCT0019375211	NCT00193752_11_T0	GENE	36	36	3.5
NCT0019375211	NCT00193752_11_T1	GENE	26	26	nodal
NCT0019375211	NCT00193752_11_T2	PHENOTYPE	27	27	metastasis
NCT0019375211	NCT00193752_11_T3	GENE	43	43	has
NCT0019375211	NCT00193752_11_T4	PHENOTYPE	40	41	cervical cancer
NCT0019375211	NCT00193752_11_T5	PHENOTYPE	54	56	lymph node metastasis
NCT0019375212	NCT00193752_12_T0	PHENOTYPE	19	19	recurrence
NCT0019375212	NCT00193752_12_T1	GENE	9	9	Para
NCT0019375212	NCT00193752_12_T2	PHENOTYPE	6	6	Oncology
NCT0019375212	NCT00193752_12_T3	GENE	11	11	nodal
NCT0019375213	NCT00193752_13_T0	PHENOTYPE	15	15	metastasis
NCT0019375213	NCT00193752_13_T1	GENE	14	14	nodal
NCT0019375214	NCT00193752_14_T0	GENE	15	15	nodal
NCT0019375220	NCT00193752_20_T0	GENE	11	11	FDG
NCT0019375220	NCT00193752_20_T1	GENE	20	20	nodal
NCT0019375220	NCT00193752_20_T2	PHENOTYPE	16	17	primary tumor
NCT0019375220	NCT00193752_20_T3	PHENOTYPE	28	29	recurrent disease
NCT0019375221	NCT00193752_21_T0	GENE	2	2	al
NCT0019375221	NCT00193752_21_T1	GENE	8	8	nodal
NCT0019375221	NCT00193752_21_T2	GENE	1	1	et
NCT0019375221	NCT00193752_21_T3	PHENOTYPE	31	31	metastases
NCT0019375221	NCT00193752_21_T4	PHENOTYPE	9	9	metastasis
NCT0019375221	NCT00193752_21_T5	PHENOTYPE	13	14	cervical cancer
NCT0019375221	NCT00193752_21_T6	TISSUE	34	35	lymph nodes
NCT0019375222	NCT00193752_22_T0	ORGAN	17	17	lymph
NCT0019375222	NCT00193752_22_T1	PHENOTYPE	19	19	metastasis
NCT0019375222	NCT00193752_22_T2	GENE	18	18	nodal
NCT0019375223	NCT00193752_23_T0	GENE	23	23	FDG
NCT0019375223	NCT00193752_23_T1	GENE	6	6	al
NCT0019375223	NCT00193752_23_T2	GENE	29	29	nodal
NCT0019375223	NCT00193752_23_T3	GENE	5	5	et
NCT0019375223	NCT00193752_23_T4	ORGAN	28	28	lymph
NCT0019375223	NCT00193752_23_T5	PHENOTYPE	30	30	metastasis
NCT0019375223	NCT00193752_23_T6	GENE	39	39	abdominal
NCT0019375223	NCT00193752_23_T7	PHENOTYPE	35	36	cervical cancer
NCT0019375224	NCT00193752_24_T0	GENE	2	2	al
NCT0019375224	NCT00193752_24_T1	GENE	1	1	et
NCT0019375224	NCT00193752_24_T2	TISSUE	10	11	lymph node
NCT0019375224	NCT00193752_24_T3	PHENOTYPE	33	34	cervical cancer
NCT0019375225	NCT00193752_25_T0	ORGAN	15	15	cervix
NCT0019375225	NCT00193752_25_T1	GENE	3	3	MRI
NCT0019375225	NCT00193752_25_T2	GENE	4	4	has
NCT0019375225	NCT00193752_25_T3	GENE	19	19	nodal
NCT0019375226	NCT00193752_26_T0	TISSUE	38	38	tissues
NCT0019375226	NCT00193752_26_T1	GENE	0	0	MRI
NCT0019375226	NCT00193752_26_T2	PHENOTYPE	34	34	tumor
NCT0019375226	NCT00193752_26_T3	PHENOTYPE	26	26	pulse
NCT0019375226	NCT00193752_26_T4	GENE	1	1	has
NCT0019375226	NCT00193752_26_T5	PHENOTYPE	13	14	cervical cancer
NCT0019375227	NCT00193752_27_T0	GENE	11	11	MRI
NCT0019375227	NCT00193752_27_T1	PHENOTYPE	23	24	primary tumor
NCT0019375228	NCT00193752_28_T0	GENE	13	13	MRI
NCT0019375228	NCT00193752_28_T1	GENE	6	6	al
NCT0019375228	NCT00193752_28_T2	GENE	7	7	has
NCT0019375228	NCT00193752_28_T3	GENE	5	5	et
NCT0019375228	NCT00193752_28_T4	PHENOTYPE	20	21	cervical cancer
NCT0019375229	NCT00193752_29_T0	PHENOTYPE	5	6	primary tumor
NCT0019375231	NCT00193752_31_T0	GENE	16	16	MRI
NCT0019375231	NCT00193752_31_T1	GENE	42	42	MRI
NCT0019375231	NCT00193752_31_T2	PHENOTYPE	12	12	tumor
NCT0019375231	NCT00193752_31_T3	PHENOTYPE	23	23	tumor
NCT0019375231	NCT00193752_31_T4	PHENOTYPE	38	38	tumor
NCT0019375231	NCT00193752_31_T5	GENE	47	47	nodal
NCT0019375232	NCT00193752_32_T0	PHENOTYPE	32	32	metastases
NCT0019375232	NCT00193752_32_T1	GENE	1	1	MRI
NCT0019375232	NCT00193752_32_T2	GENE	19	19	FDG
NCT0019375232	NCT00193752_32_T3	GENE	31	31	nodal
NCT0019375232	NCT00193752_32_T4	PHENOTYPE	14	15	primary tumor
NCT0019375233	NCT00193752_33_T0	PHENOTYPE	9	9	decision-making
NCT0019375234	NCT00193752_34_T0	GENE	3	3	nodal
NCT0019375234	NCT00193752_34_T1	GENE	14	14	nodal
NCT0019375235	NCT00193752_35_T0	GENE	2	2	al
NCT0019375235	NCT00193752_35_T1	GENE	10	10	nodal
NCT0019375235	NCT00193752_35_T2	GENE	1	1	et
NCT0019375235	NCT00193752_35_T3	PHENOTYPE	15	16	cervical carcinoma
NCT0019375236	NCT00193752_36_T0	GENE	5	5	has
NCT0019375236	NCT00193752_36_T1	PHENOTYPE	2	3	cervical cancer
NCT0019375236	NCT00193752_36_T2	PHENOTYPE	16	18	lymph node metastasis
NCT0019375238	NCT00193752_38_T0	PHENOTYPE	15	15	recurrence
NCT0019375238	NCT00193752_38_T1	PHENOTYPE	11	11	remission
NCT0019375239	NCT00193752_39_T0	COMPOUND	8	8	glucose
NCT0019375239	NCT00193752_39_T1	PHENOTYPE	44	44	lymphoma
NCT0019375239	NCT00193752_39_T2	GENE	12	12	FDG
NCT0019375239	NCT00193752_39_T3	PHENOTYPE	19	19	tumor
NCT0019375239	NCT00193752_39_T4	PHENOTYPE	34	34	tumor
NCT0019375239	NCT00193752_39_T5	GENE	13	13	has
NCT0019375239	NCT00193752_39_T6	PHENOTYPE	41	41	seminoma
NCT0019375239	NCT00193752_39_T7	PHENOTYPE	42	43	colorectal cancer
NCT0019375239	NCT00193752_39_T8	PHENOTYPE	39	40	breast cancer
NCT0019375239	NCT00193752_39_T9	PHENOTYPE	46	47	lung cancer
NCT0019375240	NCT00193752_40_T0	GENE	9	9	FDG
NCT0019375240	NCT00193752_40_T1	GENE	3	3	al
NCT0019375240	NCT00193752_40_T2	GENE	2	2	et
NCT0019375240	NCT00193752_40_T3	PHENOTYPE	22	23	cervical cancer
NCT0019375241	NCT00193752_41_T0	PHENOTYPE	37	37	recurrence
NCT0019375241	NCT00193752_41_T1	PHENOTYPE	19	21	lymph node disease
NCT001937650	NCT00193765_0_T0	PHENOTYPE	11	12	Squamous Carcinoma
NCT001937650	NCT00193765_0_T1	PHENOTYPE	12	15	Carcinoma of Oral Cavity
NCT001937652	NCT00193765_2_T0	PHENOTYPE	15	15	cancers
NCT001937653	NCT00193765_3_T0	PHENOTYPE	34	34	cancers
NCT001937653	NCT00193765_3_T1	GENE	12	12	has
NCT001937653	NCT00193765_3_T2	ORGAN	37	38	oral cavity
NCT001937654	NCT00193765_4_T0	PHENOTYPE	1	1	cancers
NCT001937657	NCT00193765_7_T0	PHENOTYPE	17	17	metastasis
NCT0019376510	NCT00193765_10_T0	PHENOTYPE	0	0	Secondary
NCT0019376515	NCT00193765_15_T0	PHENOTYPE	3	3	tumor
NCT0019376515	NCT00193765_15_T1	GENE	0	0	Is
NCT0019376515	NCT00193765_15_T2	GENE	15	15	Is
NCT0019376516	NCT00193765_16_T0	PHENOTYPE	21	21	metastasis
NCT0019376525	NCT00193765_25_T0	GENE	21	21	II
NCT0019376525	NCT00193765_25_T1	ORGAN	0	0	Neck
NCT0019376525	NCT00193765_25_T2	GENE	18	18	nodal
NCT0019376526	NCT00193765_26_T0	PHENOTYPE	4	4	adenopathy
NCT0019376526	NCT00193765_26_T1	PHENOTYPE	19	20	metastatic disease
NCT0019376527	NCT00193765_27_T0	PHENOTYPE	6	6	metastasis
NCT0019376528	NCT00193765_28_T0	PHENOTYPE	16	16	metastasis
NCT0019376528	NCT00193765_28_T1	PHENOTYPE	2	2	tumor
NCT0019376528	NCT00193765_28_T2	PHENOTYPE	3	3	infiltration
NCT0019376533	NCT00193765_33_T0	PHENOTYPE	3	3	metastasis
NCT0019376537	NCT00193765_37_T0	PHENOTYPE	4	4	recurrence
NCT0019376537	NCT00193765_37_T1	GENE	10	10	has
NCT0019376544	NCT00193765_44_T0	GENE	48	48	has
NCT0019376546	NCT00193765_46_T0	TISSUE	5	6	lymph nodes
NCT0019376547	NCT00193765_47_T0	GENE	21	21	pre
NCT0019376547	NCT00193765_47_T1	PHENOTYPE	9	9	metastasis
NCT0019376547	NCT00193765_47_T2	PHENOTYPE	28	28	metastasis
NCT0019376549	NCT00193765_49_T0	PHENOTYPE	18	18	metastasis
NCT0019376551	NCT00193765_51_T0	PHENOTYPE	12	12	recurrence
NCT0019376551	NCT00193765_51_T1	PHENOTYPE	19	19	secondary
NCT0019376551	NCT00193765_51_T2	GENE	24	24	has
NCT0019376553	NCT00193765_53_T0	PHENOTYPE	4	4	Recurrence
NCT0019376553	NCT00193765_53_T1	GENE	0	0	Nodal
NCT0019376553	NCT00193765_53_T2	PHENOTYPE	1	1	relapse
NCT0019376555	NCT00193765_55_T0	GENE	24	24	pre
NCT0019376556	NCT00193765_56_T0	PHENOTYPE	4	4	metastasis
NCT0019376567	NCT00193765_67_T0	PHENOTYPE	5	5	malignancy
NCT0019376569	NCT00193765_69_T0	PHENOTYPE	2	2	malignancy
NCT0019376576	NCT00193765_76_T0	PHENOTYPE	0	0	Understands
NCT0019376578	NCT00193765_78_T0	PHENOTYPE	5	5	malignancy
NCT0019376584	NCT00193765_84_T0	PHENOTYPE	3	3	tumor
NCT001937780	NCT00193778_0_T0	PHENOTYPE	8	10	Metastatic Breast Cancer
NCT001937782	NCT00193778_2_T0	PHENOTYPE	10	12	metastatic breast cancer
NCT001937784	NCT00193778_4_T0	PHENOTYPE	9	10	solid tumors
NCT001937787	NCT00193778_7_T0	PHENOTYPE	29	30	breast cancer
NCT001937787	NCT00193778_7_T1	PHENOTYPE	4	6	metastatic breast cancer
NCT0019377810	NCT00193778_10_T0	PHENOTYPE	9	9	bleeding
NCT0019377812	NCT00193778_12_T0	PHENOTYPE	8	8	understood
NCT0019377813	NCT00193778_13_T0	PHENOTYPE	13	13	metastases
NCT0019377813	NCT00193778_13_T1	PHENOTYPE	28	28	metastases
NCT0019377813	NCT00193778_13_T2	PHENOTYPE	23	24	primary tumor
NCT0019377813	NCT00193778_13_T3	PHENOTYPE	44	45	primary tumor
NCT0019377817	NCT00193778_17_T0	PHENOTYPE	2	2	suppression
NCT0019377817	NCT00193778_17_T1	PHENOTYPE	5	5	affects
NCT0019377822	NCT00193778_22_T0	PHENOTYPE	4	5	primary tumor
NCT0019377829	NCT00193778_29_T0	PHENOTYPE	13	15	metastatic breast cancer
NCT0019377831	NCT00193778_31_T0	PHENOTYPE	4	6	metastatic breast cancer
NCT0019377836	NCT00193778_36_T0	GENE	9	9	ER
NCT0019377836	NCT00193778_36_T1	GENE	7	8	estrogen receptor
NCT0019377836	NCT00193778_36_T2	GENE	10	11	progesterone receptor
NCT0019377839	NCT00193778_39_T0	PHENOTYPE	0	2	Metastatic breast cancer
NCT0019377847	NCT00193778_47_T0	PHENOTYPE	18	18	symptoms
NCT0019377847	NCT00193778_47_T1	PHENOTYPE	3	4	progressive disease
NCT0019377847	NCT00193778_47_T2	PHENOTYPE	7	8	progressive disease
NCT0019377849	NCT00193778_49_T0	PHENOTYPE	2	2	bleeding
NCT0019377849	NCT00193778_49_T1	PHENOTYPE	0	0	Ulceration
NCT0019377853	NCT00193778_53_T0	PHENOTYPE	2	2	anesthesia
NCT0019377853	NCT00193778_53_T1	PHENOTYPE	5	6	metastatic disease
NCT0019377856	NCT00193778_56_T0	PHENOTYPE	5	7	soft tissue metastasis
NCT0019377858	NCT00193778_58_T0	PHENOTYPE	10	10	metastases
NCT0019377860	NCT00193778_60_T0	PHENOTYPE	4	4	tumor
NCT0019377861	NCT00193778_61_T0	GENE	1	1	SIZE
NCT0019377861	NCT00193778_61_T1	PHENOTYPE	9	10	metastatic disease
NCT0019377861	NCT00193778_61_T2	PHENOTYPE	4	5	Breast cancer
NCT0019377866	NCT00193778_66_T0	PHENOTYPE	6	6	metastases
NCT0019377872	NCT00193778_72_T0	ORGAN	1	1	thorax
NCT0019377872	NCT00193778_72_T1	PHENOTYPE	9	9	metastasis
NCT0019377872	NCT00193778_72_T2	ORGAN	4	4	abdomen
NCT0019377874	NCT00193778_74_T0	PHENOTYPE	40	40	menopausal
NCT0019377874	NCT00193778_74_T1	GENE	35	35	ER
NCT0019377874	NCT00193778_74_T2	GENE	32	32	hormone
NCT0019377875	NCT00193778_75_T0	GENE	4	4	hormone
NCT0019377876	NCT00193778_76_T0	GENE	9	9	ER
NCT0019377876	NCT00193778_76_T1	GENE	6	6	hormone
NCT0019377877	NCT00193778_77_T0	GENE	8	8	Aromatase
NCT0019377879	NCT00193778_79_T0	PHENOTYPE	6	6	estimation
NCT0019377879	NCT00193778_79_T1	GENE	8	8	VEGF
NCT0019377879	NCT00193778_79_T2	COMPOUND	12	12	Endostatin
NCT0019377879	NCT00193778_79_T3	GENE	9	9	bFGF
NCT0019377880	NCT00193778_80_T0	COMPOUND	1	1	1
NCT0019377881	NCT00193778_81_T0	COMPOUND	1	1	2
NCT0019377882	NCT00193778_82_T0	COMPOUND	1	1	3
NCT0019377884	NCT00193778_84_T0	PHENOTYPE	1	1	metastases
NCT0019377885	NCT00193778_85_T0	ORGAN	1	1	thorax
NCT0019377885	NCT00193778_85_T1	PHENOTYPE	9	9	metastasis
NCT0019377885	NCT00193778_85_T2	ORGAN	4	4	abdomen
NCT0019377885	NCT00193778_85_T3	PHENOTYPE	17	17	progression
NCT0019377886	NCT00193778_86_T0	COMPOUND	15	15	bisphosphonates
NCT0019377886	NCT00193778_86_T1	PHENOTYPE	3	4	bony metastases
NCT0019377888	NCT00193778_88_T0	PHENOTYPE	14	14	metastasis
NCT0019377888	NCT00193778_88_T1	PHENOTYPE	2	2	tumor
NCT0019377888	NCT00193778_88_T2	PHENOTYPE	20	20	tumour
NCT0019377888	NCT00193778_88_T3	TISSUE	7	8	lymph nodes
NCT0019377888	NCT00193778_88_T4	PHENOTYPE	27	29	infiltrating lobular carcinoma
NCT0019377888	NCT00193778_88_T5	PHENOTYPE	21	23	infiltrating duct carcinoma
NCT0019377889	NCT00193778_89_T0	GENE	5	5	ER
NCT0019377893	NCT00193778_93_T0	PHENOTYPE	0	0	Progression
NCT0019377893	NCT00193778_93_T1	PHENOTYPE	3	3	Secondary
NCT0019377893	NCT00193778_93_T2	GENE	6	6	VEGF
NCT0019377893	NCT00193778_93_T3	COMPOUND	10	10	Endostatin
NCT0019377893	NCT00193778_93_T4	GENE	7	7	bFGF
NCT0019377894	NCT00193778_94_T0	PHENOTYPE	24	24	pathology
NCT00193778105	NCT00193778_105_T0	ORGAN	5	5	liver
NCT00193778105	NCT00193778_105_T1	PHENOTYPE	1	2	liver metastases
NCT00193778107	NCT00193778_107_T0	PHENOTYPE	18	18	symptoms
NCT00193778107	NCT00193778_107_T1	PHENOTYPE	3	4	progressive disease
NCT00193778107	NCT00193778_107_T2	PHENOTYPE	7	8	progressive disease
NCT00193778109	NCT00193778_109_T0	PHENOTYPE	2	2	bleeding
NCT00193778109	NCT00193778_109_T1	PHENOTYPE	0	0	Ulceration
NCT001937911	NCT00193791_1_T0	PHENOTYPE	9	10	carcinoma cervix
NCT001937913	NCT00193791_3_T0	GENE	4	4	has
NCT0019379111	NCT00193791_11_T0	PHENOTYPE	14	15	carcinoma cervix
NCT0019379113	NCT00193791_13_T0	PHENOTYPE	1	1	heterogeneous
NCT0019379114	NCT00193791_14_T0	GENE	17	17	2.3
NCT0019379114	NCT00193791_14_T1	PHENOTYPE	15	16	carcinoma cervix
NCT0019379115	NCT00193791_15_T0	PHENOTYPE	27	27	progression
NCT0019379117	NCT00193791_17_T0	PHENOTYPE	3	3	metastasis
NCT0019379119	NCT00193791_19_T0	PHENOTYPE	2	2	acute
NCT0019379119	NCT00193791_19_T1	GENE	4	4	3.4
NCT0019379119	NCT00193791_19_T2	PHENOTYPE	8	8	toxicities
NCT0019379120	NCT00193791_20_T0	PHENOTYPE	8	8	toxicity
NCT0019379121	NCT00193791_21_T0	PHENOTYPE	34	34	tumors
NCT0019379121	NCT00193791_21_T1	COMPOUND	16	16	cisplatin
NCT0019379122	NCT00193791_22_T0	PHENOTYPE	1	1	acute
NCT0019379122	NCT00193791_22_T1	GENE	3	3	3.4
NCT0019379122	NCT00193791_22_T2	PHENOTYPE	7	7	toxicities
NCT0019379122	NCT00193791_22_T3	PHENOTYPE	22	22	resolved
NCT0019379123	NCT00193791_23_T0	PHENOTYPE	8	8	toxicity
NCT0019379125	NCT00193791_25_T0	COMPOUND	7	7	cisplatin
NCT0019379126	NCT00193791_26_T0	PHENOTYPE	12	13	carcinoma cervix
NCT0019379127	NCT00193791_27_T0	PHENOTYPE	6	7	Carcinoma Cervix
NCT0019379128	NCT00193791_28_T0	PHENOTYPE	15	16	cervical cancer
NCT001938041	NCT00193804_1_T0	PHENOTYPE	20	21	cervical cancers
NCT001938042	NCT00193804_2_T0	PHENOTYPE	7	8	radiation toxicity
NCT001938043	NCT00193804_3_T0	GENE	4	4	has
NCT0019380410	NCT00193804_10_T0	GENE	9	9	nodal
NCT0019380410	NCT00193804_10_T1	PHENOTYPE	6	7	primary tumor
NCT0019380411	NCT00193804_11_T0	ORGAN	18	18	bladder
NCT0019380411	NCT00193804_11_T1	GENE	15	15	bowel
NCT0019380411	NCT00193804_11_T2	ORGAN	16	16	rectum
NCT0019380412	NCT00193804_12_T0	GENE	13	13	bowel
NCT0019380412	NCT00193804_12_T1	ORGAN	15	15	rectum
NCT0019380413	NCT00193804_13_T0	PHENOTYPE	8	8	sequelae
NCT0019380413	NCT00193804_13_T1	GENE	18	18	2.4
NCT0019380413	NCT00193804_13_T2	PHENOTYPE	13	13	enteritis
NCT0019380413	NCT00193804_13_T3	PHENOTYPE	5	5	diarrhea
NCT0019380413	NCT00193804_13_T4	PHENOTYPE	15	15	diarrhea
NCT0019380413	NCT00193804_13_T5	PHENOTYPE	10	12	small bowel obstruction
NCT0019380415	NCT00193804_15_T0	PHENOTYPE	10	10	complications
NCT0019380415	NCT00193804_15_T1	GENE	9	9	bowel
NCT0019380418	NCT00193804_18_T0	PHENOTYPE	4	4	toxicity
NCT0019380418	NCT00193804_18_T1	PHENOTYPE	9	9	complications
NCT0019380418	NCT00193804_18_T2	ORGAN	8	8	bladder
NCT0019380418	NCT00193804_18_T3	GENE	3	3	bowel
NCT0019380420	NCT00193804_20_T0	GENE	1	1	III
NCT0019380420	NCT00193804_20_T1	PHENOTYPE	5	5	proctitis
NCT0019380420	NCT00193804_20_T2	PHENOTYPE	2	3	radiation cystitis
NCT0019380423	NCT00193804_23_T0	GENE	16	16	III
NCT0019380423	NCT00193804_23_T1	GENE	24	24	III
NCT0019380423	NCT00193804_23_T2	GENE	19	19	IV
NCT0019380423	NCT00193804_23_T3	GENE	27	27	IV
NCT0019380424	NCT00193804_24_T0	PHENOTYPE	8	8	toxicities
NCT0019380425	NCT00193804_25_T0	GENE	9	9	has
NCT0019380427	NCT00193804_27_T0	PHENOTYPE	36	36	tumor
NCT0019380427	NCT00193804_27_T1	GENE	11	11	portal
NCT0019380427	NCT00193804_27_T2	GENE	20	20	portal
NCT0019380429	NCT00193804_29_T0	PHENOTYPE	34	34	severity
NCT0019380429	NCT00193804_29_T1	PHENOTYPE	36	36	acute
NCT0019380429	NCT00193804_29_T2	ORGAN	18	18	bladder
NCT0019380429	NCT00193804_29_T3	GENE	21	21	bowel
NCT0019380429	NCT00193804_29_T4	PHENOTYPE	42	42	toxicities
NCT0019380429	NCT00193804_29_T5	ORGAN	17	17	rectum
NCT0019380429	NCT00193804_29_T6	GENE	4	4	has
NCT0019380430	NCT00193804_30_T0	PHENOTYPE	14	14	toxicities
NCT0019380431	NCT00193804_31_T0	GENE	10	10	bowel
NCT0019380432	NCT00193804_32_T0	ORGAN	4	4	bladder
NCT0019380432	NCT00193804_32_T1	GENE	10	10	reduced
NCT0019380432	NCT00193804_32_T2	ORGAN	6	6	rectum
NCT0019380433	NCT00193804_33_T0	ORGAN	46	46	bladder
NCT0019380433	NCT00193804_33_T1	GENE	38	38	bowel
NCT0019380433	NCT00193804_33_T2	ORGAN	42	42	rectum
NCT0019380433	NCT00193804_33_T3	PHENOTYPE	16	17	hot spot
NCT001938171	NCT00193817_1_T0	ORGAN	14	14	esophagus
NCT001938171	NCT00193817_1_T1	TISSUE	8	9	lymph nodes
NCT001938171	NCT00193817_1_T2	PHENOTYPE	0	1	Esophageal cancer
NCT001938172	NCT00193817_2_T0	ORGAN	15	15	esophagus
NCT001938172	NCT00193817_2_T1	TISSUE	3	4	lymph nodes
NCT001938174	NCT00193817_4_T0	ORGAN	7	7	abdomen
NCT0019381714	NCT00193817_14_T0	GENE	14	14	has
NCT0019381714	NCT00193817_14_T1	PHENOTYPE	12	13	esophageal cancer
NCT0019381714	NCT00193817_14_T2	TISSUE	5	6	lymph node
NCT0019381715	NCT00193817_15_T0	GENE	1	1	has
NCT0019381720	NCT00193817_20_T0	PHENOTYPE	3	3	recurrence
NCT0019381722	NCT00193817_22_T0	PHENOTYPE	24	24	centre
NCT0019381722	NCT00193817_22_T1	PHENOTYPE	6	8	quality of life
NCT0019381723	NCT00193817_23_T0	PHENOTYPE	8	11	carcinoma of the esophagus
NCT0019381725	NCT00193817_25_T0	GENE	16	16	II
NCT0019381725	NCT00193817_25_T1	PHENOTYPE	19	19	cancers
NCT0019381725	NCT00193817_25_T2	PHENOTYPE	8	8	adenocarcinoma
NCT0019381725	NCT00193817_25_T3	GENE	17	17	CO
NCT0019381725	NCT00193817_25_T4	PHENOTYPE	9	10	esophageal cancer
NCT0019381729	NCT00193817_29_T0	PHENOTYPE	3	3	malignancy
NCT0019381737	NCT00193817_37_T0	TISSUE	3	4	lymph nodes
NCT0019381738	NCT00193817_38_T0	GENE	4	4	III
NCT0019381738	NCT00193817_38_T1	PHENOTYPE	5	5	cancers
NCT0019381739	NCT00193817_39_T0	PHENOTYPE	8	8	symptoms
NCT0019381739	NCT00193817_39_T1	PHENOTYPE	9	9	symptoms
NCT0019381740	NCT00193817_40_T0	PHENOTYPE	4	5	esophageal carcinoma
NCT0019381744	NCT00193817_44_T0	PHENOTYPE	14	15	voice change
NCT0019381749	NCT00193817_49_T0	PHENOTYPE	17	17	anesthesia
NCT0019381750	NCT00193817_50_T0	GENE	15	15	ASA
NCT0019381751	NCT00193817_51_T0	GENE	6	6	II
NCT0019381751	NCT00193817_51_T1	GENE	2	2	ASA
NCT0019381755	NCT00193817_55_T0	TISSUE	20	21	lymph nodes
NCT0019381755	NCT00193817_55_T1	PHENOTYPE	10	11	primary tumor
NCT0019381756	NCT00193817_56_T0	GENE	6	6	T4
NCT0019381756	NCT00193817_56_T1	GENE	4	4	T3
NCT0019381757	NCT00193817_57_T0	COMPOUND	1	1	N
NCT0019381760	NCT00193817_60_T0	PHENOTYPE	3	3	adenocarcinoma
NCT0019381761	NCT00193817_61_T0	GENE	12	12	pre
NCT0019381764	NCT00193817_64_T0	COMPOUND	11	11	FOB
NCT0019381764	NCT00193817_64_T1	PHENOTYPE	4	5	esophageal cancer
NCT0019381765	NCT00193817_65_T0	GENE	6	6	T4
NCT0019381765	NCT00193817_65_T1	GENE	4	4	T3
NCT0019381766	NCT00193817_66_T0	COMPOUND	1	1	N
NCT0019381769	NCT00193817_69_T0	PHENOTYPE	21	21	analgesia
NCT0019381769	NCT00193817_69_T1	PHENOTYPE	3	3	adenocarcinoma
NCT0019381769	NCT00193817_69_T2	PHENOTYPE	18	18	anesthesia
NCT0019381771	NCT00193817_71_T0	PHENOTYPE	0	0	Thoracic
NCT0019381774	NCT00193817_74_T0	ORGAN	19	19	pancreas
NCT0019381774	NCT00193817_74_T1	GENE	1	1	abdominal
NCT0019381774	NCT00193817_74_T2	ORGAN	34	34	artery
NCT0019381774	NCT00193817_74_T3	TISSUE	30	30	ligament
NCT0019381774	NCT00193817_74_T4	TISSUE	8	9	connective tissues
NCT0019381775	NCT00193817_75_T0	GENE	1	1	II
NCT0019381777	NCT00193817_77_T0	GENE	4	4	para
NCT0019381777	NCT00193817_77_T1	GENE	15	15	para
NCT0019381777	NCT00193817_77_T2	TISSUE	6	7	lymph nodes
NCT0019381777	NCT00193817_77_T3	TISSUE	9	10	lymph nodes
NCT0019381777	NCT00193817_77_T4	TISSUE	17	18	lymph nodes
NCT0019381777	NCT00193817_77_T5	PHENOTYPE	12	14	right and left
NCT0019381779	NCT00193817_79_T0	PHENOTYPE	13	13	recurrent
NCT0019381781	NCT00193817_81_T0	PHENOTYPE	15	15	recurrent
NCT0019381781	NCT00193817_81_T1	GENE	5	5	extended
NCT0019381782	NCT00193817_82_T0	GENE	1	1	III
NCT0019381784	NCT00193817_84_T0	GENE	9	9	caudal
NCT0019381784	NCT00193817_84_T1	ORGAN	16	16	clavicle
NCT0019381784	NCT00193817_84_T2	ORGAN	5	6	cricoid cartilage
NCT0019381785	NCT00193817_85_T0	GENE	21	21	II
NCT0019381785	NCT00193817_85_T1	GENE	15	15	III
NCT0019381785	NCT00193817_85_T2	TISSUE	8	9	lymph node
NCT0019381786	NCT00193817_86_T0	GENE	24	24	II
NCT0019381786	NCT00193817_86_T1	TISSUE	9	10	lymph node
NCT0019381787	NCT00193817_87_T0	PHENOTYPE	22	24	enlarged lymph nodes
NCT0019381788	NCT00193817_88_T0	PHENOTYPE	8	9	blood loss
NCT0019381789	NCT00193817_89_T0	PHENOTYPE	20	20	dependency
NCT0019381789	NCT00193817_89_T1	GENE	3	3	shifted
NCT0019381790	NCT00193817_90_T0	PHENOTYPE	6	6	ventilation
NCT0019381790	NCT00193817_90_T1	PHENOTYPE	24	24	paresis
NCT0019381790	NCT00193817_90_T2	GENE	15	15	leak
NCT0019381790	NCT00193817_90_T3	PHENOTYPE	12	12	arrhythmias
NCT0019381790	NCT00193817_90_T4	PHENOTYPE	26	26	palsy
NCT0019381790	NCT00193817_90_T5	PHENOTYPE	7	7	hemorrhage
NCT0019381790	NCT00193817_90_T6	PHENOTYPE	18	19	wound infection
NCT0019381790	NCT00193817_90_T7	ORGAN	13	14	thoracic duct
NCT0019381790	NCT00193817_90_T8	PHENOTYPE	16	17	anastomotic leak
NCT0019381790	NCT00193817_90_T9	PHENOTYPE	10	11	cardiac complications
NCT0019381790	NCT00193817_90_T10	ORGAN	21	23	recurrent laryngeal nerve
NCT0019381793	NCT00193817_93_T0	PHENOTYPE	18	19	anastomotic leak
NCT0019381797	NCT00193817_97_T0	PHENOTYPE	5	5	cord
NCT0019381797	NCT00193817_97_T1	GENE	2	2	had
NCT0019381797	NCT00193817_97_T2	PHENOTYPE	12	14	recovery of function
NCT00193817102	NCT00193817_102_T0	GENE	7	7	th
NCT00193817106	NCT00193817_106_T0	PHENOTYPE	1	1	recurrence
NCT001938306	NCT00193830_6_T0	PHENOTYPE	15	17	carcinoma of cervix
NCT001938308	NCT00193830_8_T0	PHENOTYPE	16	16	complications
NCT0019383010	NCT00193830_10_T0	PHENOTYPE	15	15	cancers
NCT0019383010	NCT00193830_10_T1	PHENOTYPE	0	2	Carcinoma of cervix
NCT0019383011	NCT00193830_11_T0	PHENOTYPE	6	7	carcinoma cervix
NCT0019383014	NCT00193830_14_T0	PHENOTYPE	12	13	carcinoma cervix
NCT0019383016	NCT00193830_16_T0	PHENOTYPE	12	14	carcinoma of cervix
NCT0019383019	NCT00193830_19_T0	GENE	8	8	OPD
NCT0019383020	NCT00193830_20_T0	PHENOTYPE	15	17	carcinoma of cervix
NCT0019383021	NCT00193830_21_T0	PHENOTYPE	16	16	complications
NCT001938430	NCT00193843_0_T0	PHENOTYPE	0	1	Oral Cancer
NCT001938433	NCT00193843_3_T0	PHENOTYPE	1	1	recurrence
NCT001938438	NCT00193843_8_T0	PHENOTYPE	11	11	toxicity
NCT0019384311	NCT00193843_11_T0	TISSUE	4	5	lymph node
NCT0019384312	NCT00193843_12_T0	TISSUE	4	5	lymph node
NCT0019384317	NCT00193843_17_T0	PHENOTYPE	2	2	tumour
NCT0019384317	NCT00193843_17_T1	GENE	5	5	nodal
NCT0019384318	NCT00193843_18_T0	GENE	10	10	Gy
NCT0019384323	NCT00193843_23_T0	COMPOUND	0	0	N
NCT0019384324	NCT00193843_24_T0	PHENOTYPE	8	9	tissue infiltration
NCT0019384324	NCT00193843_24_T1	TISSUE	4	5	Surgical margin
NCT0019384325	NCT00193843_25_T0	PHENOTYPE	0	0	Secondary
NCT0019384333	NCT00193843_33_T0	ORGAN	4	4	lymph
NCT0019384334	NCT00193843_34_T0	ORGAN	4	4	lymph
NCT0019384339	NCT00193843_39_T0	PHENOTYPE	6	7	residual disease
NCT0019384341	NCT00193843_41_T0	PHENOTYPE	3	3	metastasis
NCT0019384342	NCT00193843_42_T0	PHENOTYPE	2	2	complication
NCT0019384343	NCT00193843_43_T0	PHENOTYPE	8	9	primary tumors
NCT0019384344	NCT00193843_44_T0	PHENOTYPE	1	1	malignancy
NCT001938564	NCT00193856_4_T0	COMPOUND	11	11	androgen
NCT001938564	NCT00193856_4_T1	GENE	13	13	AD
NCT001938564	NCT00193856_4_T2	PHENOTYPE	19	19	relapse
NCT001938564	NCT00193856_4_T3	PHENOTYPE	24	24	localised
NCT001938566	NCT00193856_6_T0	PHENOTYPE	7	7	practices
NCT001938567	NCT00193856_7_T0	PHENOTYPE	4	4	osteopenia
NCT0019385612	NCT00193856_12_T0	PHENOTYPE	4	4	recruitment
NCT0019385613	NCT00193856_13_T0	GENE	29	29	AD
NCT0019385613	NCT00193856_13_T1	PHENOTYPE	24	24	relapse
NCT0019385613	NCT00193856_13_T2	GENE	25	25	had
NCT0019385618	NCT00193856_18_T0	GENE	16	16	reduced
NCT0019385618	NCT00193856_18_T1	PHENOTYPE	4	4	Oncology
NCT0019385618	NCT00193856_18_T2	GENE	11	11	indefinite
NCT0019385620	NCT00193856_20_T0	GENE	14	14	AD
NCT0019385620	NCT00193856_20_T1	PHENOTYPE	24	24	cancers
NCT0019385620	NCT00193856_20_T2	PHENOTYPE	22	23	high grade
NCT0019385623	NCT00193856_23_T0	GENE	5	5	III
NCT0019385625	NCT00193856_25_T0	COMPOUND	3	3	androgen
NCT0019385626	NCT00193856_26_T0	COMPOUND	3	3	androgen
NCT0019385627	NCT00193856_27_T0	COMPOUND	5	6	zoledronic acid
NCT0019385628	NCT00193856_28_T0	COMPOUND	5	6	zoledronic acid
NCT0019385630	NCT00193856_30_T0	COMPOUND	6	6	acetate
NCT001938693	NCT00193869_3_T0	PHENOTYPE	4	4	complication
NCT001938693	NCT00193869_3_T1	PHENOTYPE	6	6	malignancy
NCT001938693	NCT00193869_3_T2	PHENOTYPE	12	12	paralysis
NCT001938693	NCT00193869_3_T3	GENE	16	16	has
NCT001938694	NCT00193869_4_T0	GENE	0	0	Rat
NCT001938696	NCT00193869_6_T0	PHENOTYPE	47	47	toxicity
NCT001938696	NCT00193869_6_T1	GENE	36	36	hr
NCT001938697	NCT00193869_7_T0	GENE	10	10	viability
NCT001938698	NCT00193869_8_T0	COMPOUND	9	9	dexamethasone
NCT001938820	NCT00193882_0_T0	PHENOTYPE	12	12	Dysphagia
NCT001938820	NCT00193882_0_T1	PHENOTYPE	14	14	Dysphagia
NCT001938820	NCT00193882_0_T2	PHENOTYPE	1	2	Oesophageal Cancer
NCT001938820	NCT00193882_0_T3	PHENOTYPE	6	8	Quality of Life
NCT001938822	NCT00193882_2_T0	PHENOTYPE	29	29	dysphagia
NCT001938822	NCT00193882_2_T1	PHENOTYPE	43	44	oesophageal cancer
NCT001938822	NCT00193882_2_T2	PHENOTYPE	32	34	quality of life
NCT001938824	NCT00193882_4_T0	PHENOTYPE	11	11	dysphagia
NCT001938825	NCT00193882_5_T0	PHENOTYPE	4	6	quality of life
NCT001938827	NCT00193882_7_T0	PHENOTYPE	0	0	Dysphagia
NCT001938827	NCT00193882_7_T1	PHENOTYPE	8	9	local disease
NCT001938829	NCT00193882_9_T0	PHENOTYPE	2	2	dysphagia
NCT0019388211	NCT00193882_11_T0	PHENOTYPE	16	16	toxicity
NCT0019388211	NCT00193882_11_T1	PHENOTYPE	12	13	oesophageal cancer
NCT0019388211	NCT00193882_11_T2	PHENOTYPE	5	7	quality of life
NCT0019388211	NCT00193882_11_T3	PHENOTYPE	28	30	quality of life
NCT0019388212	NCT00193882_12_T0	PHENOTYPE	4	6	quality of life
NCT0019388212	NCT00193882_12_T1	PHENOTYPE	17	19	quality of life
NCT0019388212	NCT00193882_12_T2	PHENOTYPE	22	24	quality of life
NCT0019388213	NCT00193882_13_T0	PHENOTYPE	28	28	metastases
NCT0019388213	NCT00193882_13_T1	PHENOTYPE	6	6	carcinoma
NCT0019388213	NCT00193882_13_T2	PHENOTYPE	35	35	dysphagia
NCT001938951	NCT00193895_1_T0	GENE	13	13	3.4
NCT001938957	NCT00193895_7_T0	BIOLOGICAL_PROCESS	12	12	ageing
NCT001938957	NCT00193895_7_T1	PHENOTYPE	2	4	of skin cancer
NCT001938959	NCT00193895_9_T0	PHENOTYPE	7	7	recurrent
NCT001938959	NCT00193895_9_T1	PHENOTYPE	9	10	metastatic disease
NCT0019389510	NCT00193895_10_T0	PHENOTYPE	6	6	malignancy
NCT0019389510	NCT00193895_10_T1	ORGAN	9	10	parotid region
NCT0019389516	NCT00193895_16_T0	PHENOTYPE	17	17	toxicity
NCT0019389516	NCT00193895_16_T1	PHENOTYPE	1	1	tumour
NCT0019389517	NCT00193895_17_T0	PHENOTYPE	2	2	centres
NCT0019389518	NCT00193895_18_T0	GENE	1	1	has
NCT0019389519	NCT00193895_19_T0	PHENOTYPE	24	26	of skin cancer
NCT0019389520	NCT00193895_20_T0	PHENOTYPE	19	19	recurrence
NCT0019389524	NCT00193895_24_T0	PHENOTYPE	17	19	quality of life
NCT001939082	NCT00193908_2_T0	GENE	8	8	reduced
NCT001939087	NCT00193908_7_T0	GENE	8	8	reduced
NCT001939089	NCT00193908_9_T0	GENE	16	16	reduced
NCT001939089	NCT00193908_9_T1	COMPOUND	27	27	CDBC
NCT0019390810	NCT00193908_10_T0	PHENOTYPE	3	3	secondary
NCT0019390810	NCT00193908_10_T1	GENE	18	18	reduced
NCT0019390810	NCT00193908_10_T2	COMPOUND	29	29	CDBC
NCT0019392111	NCT00193921_11_T0	GENE	11	11	II
NCT0019392111	NCT00193921_11_T1	GENE	17	17	III
NCT001939341	NCT00193934_1_T0	PHENOTYPE	22	22	tumour
NCT001939342	NCT00193934_2_T0	BIOLOGICAL_PROCESS	20	20	behaviour
NCT001939342	NCT00193934_2_T1	PHENOTYPE	22	23	cervical cancer
NCT001939344	NCT00193934_4_T0	PHENOTYPE	12	13	cervical cancer
NCT001939345	NCT00193934_5_T0	PHENOTYPE	19	19	relapse
NCT0019393417	NCT00193934_17_T0	GENE	2	2	Ib
NCT0019393419	NCT00193934_19_T0	PHENOTYPE	2	2	tumour
NCT0019393421	NCT00193934_21_T0	GENE	0	0	MRI
NCT001939471	NCT00193947_1_T0	PHENOTYPE	25	25	initiation
NCT001939471	NCT00193947_1_T1	PHENOTYPE	11	11	HIV
NCT001939471	NCT00193947_1_T2	PHENOTYPE	31	31	HIV
NCT001939471	NCT00193947_1_T3	PHENOTYPE	29	29	suppression
NCT001939472	NCT00193947_2_T0	COMPOUND	7	7	nevirapine
NCT001939472	NCT00193947_2_T1	COMPOUND	23	23	nevirapine
NCT001939472	NCT00193947_2_T2	PHENOTYPE	15	15	HIV
NCT001939475	NCT00193947_5_T0	PHENOTYPE	32	32	HIV
NCT001939476	NCT00193947_6_T0	GENE	18	18	100
NCT001939476	NCT00193947_6_T1	PHENOTYPE	17	17	concentrations
NCT001939477	NCT00193947_7_T0	PHENOTYPE	1	1	elimination
NCT001939478	NCT00193947_8_T0	GENE	27	27	100
NCT001939478	NCT00193947_8_T1	PHENOTYPE	52	52	resistant
NCT001939478	NCT00193947_8_T2	ORGAN	22	22	serum
NCT0019394710	NCT00193947_10_T0	PHENOTYPE	21	21	mutation
NCT0019394710	NCT00193947_10_T1	GENE	7	8	reverse transcriptase
NCT0019394710	NCT00193947_10_T2	GENE	24	25	reverse transcriptase
NCT0019394711	NCT00193947_11_T0	PHENOTYPE	15	15	suppression
NCT0019394711	NCT00193947_11_T1	BIOLOGICAL_PROCESS	17	18	viral replication
NCT0019394711	NCT00193947_11_T2	GENE	24	25	reverse transcriptase
NCT0019394714	NCT00193947_14_T0	PHENOTYPE	12	12	suppression
NCT0019394714	NCT00193947_14_T1	PHENOTYPE	21	21	viremia
NCT0019394715	NCT00193947_15_T0	PHENOTYPE	34	34	mutants
NCT0019394715	NCT00193947_15_T1	PHENOTYPE	2	2	pharmacokinetics
NCT0019394715	NCT00193947_15_T2	PHENOTYPE	33	33	resistant
NCT0019394716	NCT00193947_16_T0	PHENOTYPE	12	12	resistant
NCT0019394717	NCT00193947_17_T0	PHENOTYPE	6	6	mutation
NCT0019394719	NCT00193947_19_T0	PHENOTYPE	1	1	resistant
NCT0019394721	NCT00193947_21_T0	PHENOTYPE	4	4	mutation
NCT0019394722	NCT00193947_22_T0	GENE	1	1	had
NCT0019394723	NCT00193947_23_T0	COMPOUND	22	22	nevirapine
NCT0019394723	NCT00193947_23_T1	PHENOTYPE	20	20	hepatotoxicity
NCT0019394723	NCT00193947_23_T2	GENE	2	2	has
NCT0019394729	NCT00193947_29_T0	PHENOTYPE	25	25	initiation
NCT0019394729	NCT00193947_29_T1	PHENOTYPE	11	11	HIV
NCT0019394729	NCT00193947_29_T2	PHENOTYPE	31	31	HIV
NCT0019394729	NCT00193947_29_T3	PHENOTYPE	29	29	suppression
NCT0019394730	NCT00193947_30_T0	COMPOUND	7	7	nevirapine
NCT0019394730	NCT00193947_30_T1	COMPOUND	23	23	nevirapine
NCT0019394730	NCT00193947_30_T2	PHENOTYPE	15	15	HIV
NCT0019394732	NCT00193947_32_T0	PHENOTYPE	0	0	HIV
NCT0019394735	NCT00193947_35_T0	COMPOUND	6	6	nevirapine
NCT0019394738	NCT00193947_38_T0	PHENOTYPE	0	0	HIV
NCT0019394739	NCT00193947_39_T0	COMPOUND	7	7	nevirapine
NCT0019394742	NCT00193947_42_T0	COMPOUND	3	3	nevirapine
NCT0019394742	NCT00193947_42_T1	PHENOTYPE	1	1	resistant
NCT001939609	NCT00193960_9_T0	PHENOTYPE	7	7	glaucoma
NCT0019396015	NCT00193960_15_T0	PHENOTYPE	13	13	glaucoma
NCT001939730	NCT00193973_0_T0	PHENOTYPE	6	8	Primary CNS Lymphoma
NCT001939733	NCT00193973_3_T0	CELL	3	3	neutrophil
NCT001939735	NCT00193973_5_T0	PHENOTYPE	5	5	lymphomas
NCT001939735	NCT00193973_5_T1	COMPOUND	19	19	methotrexate
NCT001939735	NCT00193973_5_T2	GENE	1	1	has
NCT001939735	NCT00193973_5_T3	ORGAN	9	11	blood brain barrier
NCT001939737	NCT00193973_7_T0	PHENOTYPE	23	23	neurotoxicity
NCT001939737	NCT00193973_7_T1	COMPOUND	10	10	methotrexate
NCT001939737	NCT00193973_7_T2	GENE	2	2	has
NCT001939739	NCT00193973_9_T0	COMPOUND	1	1	creatinine
NCT001939739	NCT00193973_9_T1	ORGAN	0	0	Serum
NCT001939865	NCT00193986_5_T0	PHENOTYPE	4	4	bradycardia
NCT001939992	NCT00193999_2_T0	GENE	12	12	lessen
NCT001939992	NCT00193999_2_T1	PHENOTYPE	9	9	PONV
NCT001939992	NCT00193999_2_T2	PHENOTYPE	33	33	complications
NCT001939992	NCT00193999_2_T3	PHENOTYPE	5	6	postoperative nausea
NCT001939992	NCT00193999_2_T4	PHENOTYPE	6	8	nausea and vomiting
NCT001939993	NCT00193999_3_T0	PHENOTYPE	9	9	PONV
NCT001939994	NCT00193999_4_T0	PHENOTYPE	15	17	nausea and vomiting
NCT001939995	NCT00193999_5_T0	PHENOTYPE	22	22	PONV
NCT001940124	NCT00194012_4_T0	PHENOTYPE	27	27	attributable
NCT001940124	NCT00194012_4_T1	COMPOUND	29	29	aripiprazole
NCT001940124	NCT00194012_4_T2	GENE	19	19	had
NCT001940252	NCT00194025_2_T0	ORGAN	13	13	serum
NCT001940253	NCT00194025_3_T0	GENE	11	11	reduced
NCT001940255	NCT00194025_5_T0	PHENOTYPE	43	43	schizophrenia
NCT001940255	NCT00194025_5_T1	GENE	8	8	ER
NCT001940255	NCT00194025_5_T2	PHENOTYPE	41	41	symptoms
NCT001940255	NCT00194025_5_T3	COMPOUND	4	4	valproate
NCT001940255	NCT00194025_5_T4	PHENOTYPE	19	20	bipolar disorder
NCT001940255	NCT00194025_5_T5	PHENOTYPE	21	23	manic depressive illness
NCT001940256	NCT00194025_6_T0	GENE	4	4	ER
NCT001940256	NCT00194025_6_T1	PHENOTYPE	12	13	bipolar disorder
NCT001940256	NCT00194025_6_T2	PHENOTYPE	17	18	seizure disorder
NCT001940257	NCT00194025_7_T0	PHENOTYPE	13	13	symptoms
NCT001940257	NCT00194025_7_T1	PHENOTYPE	15	15	schizophrenia
NCT001940257	NCT00194025_7_T2	GENE	10	10	ER
NCT001940382	NCT00194038_2_T0	COMPOUND	5	5	aripiprazole
NCT001940383	NCT00194038_3_T0	GENE	23	23	tapered
NCT001940383	NCT00194038_3_T1	PHENOTYPE	0	0	Initiation
NCT001940385	NCT00194038_5_T0	PHENOTYPE	19	20	bipolar disorders
NCT001940386	NCT00194038_6_T0	COMPOUND	32	32	Lithium
NCT001940386	NCT00194038_6_T1	PHENOTYPE	15	15	schizophrenia
NCT001940386	NCT00194038_6_T2	PHENOTYPE	38	38	symptoms
NCT001940386	NCT00194038_6_T3	PHENOTYPE	40	41	bipolar disorder
NCT001940387	NCT00194038_7_T0	PHENOTYPE	9	9	schizophrenia
NCT001940387	NCT00194038_7_T1	PHENOTYPE	13	14	bipolar disorder
NCT001940642	NCT00194064_2_T0	COMPOUND	10	10	lithium
NCT001940642	NCT00194064_2_T1	COMPOUND	12	12	valproate
NCT001940642	NCT00194064_2_T2	COMPOUND	14	14	carbamazepine
NCT001940644	NCT00194064_4_T0	COMPOUND	5	5	Eli
NCT001940772	NCT00194077_2_T0	COMPOUND	1	1	1
NCT001940772	NCT00194077_2_T1	COMPOUND	12	12	aripiprazole
NCT001940774	NCT00194077_4_T0	PHENOTYPE	6	6	ADHD
NCT001940774	NCT00194077_4_T1	PHENOTYPE	3	5	attention-deficit hyperactivity disorder
NCT001940777	NCT00194077_7_T0	PHENOTYPE	6	6	remission
NCT001940778	NCT00194077_8_T0	COMPOUND	1	1	2
NCT001940778	NCT00194077_8_T1	COMPOUND	28	28	2
NCT001940778	NCT00194077_8_T2	PHENOTYPE	6	6	remission
NCT001940779	NCT00194077_9_T0	PHENOTYPE	6	6	ADHD
NCT0019407711	NCT00194077_11_T0	PHENOTYPE	13	13	ADHD
NCT0019407711	NCT00194077_11_T1	PHENOTYPE	28	28	disorders
NCT0019407711	NCT00194077_11_T2	PHENOTYPE	22	22	suffering
NCT0019407713	NCT00194077_13_T0	PHENOTYPE	38	38	withdrawn
NCT0019407713	NCT00194077_13_T1	PHENOTYPE	8	8	manic
NCT0019407713	NCT00194077_13_T2	PHENOTYPE	4	6	major depressive episode
NCT001941160	NCT00194116_0_T0	GENE	10	10	II
NCT001941160	NCT00194116_0_T1	COMPOUND	3	3	Sodium
NCT001941160	NCT00194116_0_T2	PHENOTYPE	11	11	Depression
NCT001941160	NCT00194116_0_T3	GENE	4	4	ER
NCT001941162	NCT00194116_2_T0	COMPOUND	8	8	sodium
NCT001941162	NCT00194116_2_T1	GENE	9	9	ER
NCT001941293	NCT00194129_3_T0	COMPOUND	8	8	lithium
NCT001941293	NCT00194129_3_T1	COMPOUND	20	20	lithium
NCT001941294	NCT00194129_4_T0	PHENOTYPE	13	13	relapse
NCT001941295	NCT00194129_5_T0	PHENOTYPE	21	22	chemical dependency
NCT001941424	NCT00194142_4_T0	PHENOTYPE	10	10	complications
NCT001941424	NCT00194142_4_T1	PHENOTYPE	4	5	congenital infection
NCT001941424	NCT00194142_4_T2	PHENOTYPE	11	12	congenital infection
NCT001941554	NCT00194155_4_T0	PHENOTYPE	10	10	complications
NCT001941554	NCT00194155_4_T1	PHENOTYPE	11	12	congenital infection
NCT001941554	NCT00194155_4_T2	PHENOTYPE	4	5	fetal infection
NCT001941558	NCT00194155_8_T0	PHENOTYPE	10	11	placental function
NCT001941558	NCT00194155_8_T1	PHENOTYPE	1	2	pregnancy complications
NCT001941681	NCT00194168_1_T0	ORGAN	17	17	serum
NCT001941682	NCT00194168_2_T0	PHENOTYPE	14	15	ectopic pregnancy
NCT001941684	NCT00194168_4_T0	BIOLOGICAL_PROCESS	24	24	gestation
NCT001941686	NCT00194168_6_T0	ORGAN	10	11	fetal heart
NCT001941687	NCT00194168_7_T0	PHENOTYPE	1	2	ectopic pregnancy
NCT001941811	NCT00194181_1_T0	GENE	4	4	TPA
NCT001941814	NCT00194181_4_T0	GENE	9	9	envelope
NCT001941814	NCT00194181_4_T1	GENE	24	24	OR
NCT001941814	NCT00194181_4_T2	GENE	26	26	TPA
NCT001941815	NCT00194181_5_T0	GENE	6	6	TPA
NCT001941815	NCT00194181_5_T1	GENE	4	4	had
NCT001941816	NCT00194181_6_T0	GENE	6	6	TPA
NCT001941817	NCT00194181_7_T0	GENE	4	4	TPA
NCT001941947	NCT00194194_7_T0	PHENOTYPE	12	13	weight loss
NCT001941948	NCT00194194_8_T0	PHENOTYPE	4	5	weight loss
NCT0019419414	NCT00194194_14_T0	GENE	37	37	log
NCT0019419414	NCT00194194_14_T1	GENE	14	14	Pro
NCT0019419414	NCT00194194_14_T2	GENE	35	35	Pro
NCT0019419414	NCT00194194_14_T3	GENE	48	48	Pro
NCT0019419414	NCT00194194_14_T4	GENE	72	72	Pro
NCT0019419414	NCT00194194_14_T5	COMPOUND	76	76	1
NCT0019419414	NCT00194194_14_T6	COMPOUND	51	51	2
NCT0019419414	NCT00194194_14_T7	COMPOUND	3	3	3
NCT0019419414	NCT00194194_14_T8	COMPOUND	25	25	3
NCT0019419417	NCT00194194_17_T0	PHENOTYPE	17	18	weight loss
NCT0019419425	NCT00194194_25_T0	GENE	11	11	Pro
NCT0019419431	NCT00194194_31_T0	GENE	28	28	log
NCT0019419432	NCT00194194_32_T0	PHENOTYPE	30	31	weight loss
NCT0019419436	NCT00194194_36_T0	GENE	28	28	log
NCT0019419437	NCT00194194_37_T0	PHENOTYPE	28	29	weight loss
NCT0019419442	NCT00194194_42_T0	BIOLOGICAL_PROCESS	12	12	reproduction
NCT0019419453	NCT00194194_53_T0	GENE	13	13	CHOP
NCT0019419467	NCT00194194_67_T0	PHENOTYPE	4	5	weight loss
NCT0019419467	NCT00194194_67_T1	PHENOTYPE	12	13	weight loss
NCT0019419473	NCT00194194_73_T0	COMPOUND	14	14	caffeine
NCT0019419473	NCT00194194_73_T1	PHENOTYPE	1	2	metabolic rate
NCT0019419475	NCT00194194_75_T0	GENE	5	5	log
NCT0019419476	NCT00194194_76_T0	GENE	2	2	log
NCT0019419479	NCT00194194_79_T0	GENE	19	19	30
NCT0019419480	NCT00194194_80_T0	GENE	1	1	Pro
NCT0019419484	NCT00194194_84_T0	PHENOTYPE	5	6	weight loss
NCT0019419486	NCT00194194_86_T0	PHENOTYPE	4	4	disappointment
NCT0019419486	NCT00194194_86_T1	PHENOTYPE	8	8	experiences
NCT0019419488	NCT00194194_88_T0	PHENOTYPE	8	8	bruising
NCT0019419491	NCT00194194_91_T0	PHENOTYPE	12	12	recruitment
NCT0019419491	NCT00194194_91_T1	GENE	28	28	has
NCT0019419497	NCT00194194_97_T0	PHENOTYPE	5	5	complications
NCT0019419497	NCT00194194_97_T1	GENE	8	8	reduced
NCT0019419499	NCT00194194_99_T0	PHENOTYPE	24	25	weight loss
NCT001942071	NCT00194207_1_T0	ORGAN	13	13	serum
NCT001942071	NCT00194207_1_T1	COMPOUND	9	10	chorionic gonadotropin
NCT001942074	NCT00194207_4_T0	PHENOTYPE	10	10	strategies
NCT001942074	NCT00194207_4_T1	PHENOTYPE	27	27	strategies
NCT001942075	NCT00194207_5_T0	PHENOTYPE	14	14	centers
NCT001942075	NCT00194207_5_T1	GENE	9	9	has
NCT001942077	NCT00194207_7_T0	GENE	32	32	has
NCT001942079	NCT00194207_9_T0	PHENOTYPE	13	13	Attachment
NCT0019420712	NCT00194207_12_T0	PHENOTYPE	15	17	signs and symptoms
NCT0019420719	NCT00194207_19_T0	PHENOTYPE	0	1	Ectopic pregnancy
NCT0019420720	NCT00194207_20_T0	PHENOTYPE	0	0	Miscarriage
NCT0019420720	NCT00194207_20_T1	BIOLOGICAL_PROCESS	5	5	gestation
NCT001942202	NCT00194220_2_T0	CELL	10	10	cells
NCT001942202	NCT00194220_2_T1	PHENOTYPE	0	1	Oxidative stress
NCT001942203	NCT00194220_3_T0	GENE	13	13	structural
NCT001942203	NCT00194220_3_T1	BIOLOGICAL_PROCESS	10	10	aging
NCT001942206	NCT00194220_6_T0	BIOLOGICAL_PROCESS	8	8	fertilization
NCT001942206	NCT00194220_6_T1	PHENOTYPE	2	2	infertility
NCT001942208	NCT00194220_8_T0	PHENOTYPE	2	2	infertility
NCT001942331	NCT00194233_1_T0	PHENOTYPE	11	11	endometriosis
NCT001942461	NCT00194246_1_T0	GENE	16	16	ANOVA
NCT001942465	NCT00194246_5_T0	PHENOTYPE	17	18	Cue Reactivity
NCT001942468	NCT00194246_8_T0	GENE	15	15	CPT
NCT001942468	NCT00194246_8_T1	PHENOTYPE	20	21	Cue Reactivity
NCT001942469	NCT00194246_9_T0	PHENOTYPE	13	13	initiation
NCT001942469	NCT00194246_9_T1	BIOLOGICAL_PROCESS	38	38	eating
NCT001942469	NCT00194246_9_T2	PHENOTYPE	8	9	cognitive function
NCT0019424612	NCT00194246_12_T0	GENE	9	9	cue
NCT0019424612	NCT00194246_12_T1	GENE	18	18	cue
NCT0019424612	NCT00194246_12_T2	GENE	23	23	cue
NCT0019424612	NCT00194246_12_T3	GENE	27	27	cue
NCT0019424612	NCT00194246_12_T4	GENE	33	33	cue
NCT0019424612	NCT00194246_12_T5	PHENOTYPE	3	4	cue reactivity
NCT0019424613	NCT00194246_13_T0	GENE	15	15	VAS
NCT0019424613	NCT00194246_13_T1	PHENOTYPE	19	19	feelings
NCT0019424613	NCT00194246_13_T2	PHENOTYPE	21	21	hunger
NCT0019424615	NCT00194246_15_T0	GENE	12	12	cue
NCT0019424616	NCT00194246_16_T0	GENE	13	13	cue
NCT0019424617	NCT00194246_17_T0	GENE	7	7	cue
NCT0019424617	NCT00194246_17_T1	GENE	28	28	cue
NCT0019424617	NCT00194246_17_T2	ORGAN	39	39	heart
NCT0019424618	NCT00194246_18_T0	GENE	63	63	VAS
NCT0019424618	NCT00194246_18_T1	PHENOTYPE	69	69	hunger
NCT0019424618	NCT00194246_18_T2	GENE	12	12	cue
NCT0019424618	NCT00194246_18_T3	PHENOTYPE	67	67	feelings
NCT001942591	NCT00194259_1_T0	PHENOTYPE	18	18	Diabetes
NCT001942591	NCT00194259_1_T1	PHENOTYPE	10	11	weight loss
NCT001942591	NCT00194259_1_T2	PHENOTYPE	16	17	weight loss
NCT001942594	NCT00194259_4_T0	PHENOTYPE	12	13	weight loss
NCT001942596	NCT00194259_6_T0	PHENOTYPE	16	17	weight loss
NCT001942597	NCT00194259_7_T0	PHENOTYPE	16	17	weight loss
NCT0019425918	NCT00194259_18_T0	PHENOTYPE	6	6	Apnea
NCT0019425920	NCT00194259_20_T0	GENE	4	4	has
NCT0019425935	NCT00194259_35_T0	COMPOUND	13	13	RDI
NCT0019425935	NCT00194259_35_T1	COMPOUND	7	7	BMI
NCT0019425939	NCT00194259_39_T0	PHENOTYPE	14	15	weight gain
NCT0019425940	NCT00194259_40_T0	COMPOUND	14	14	RDI
NCT0019425940	NCT00194259_40_T1	PHENOTYPE	8	9	weight gain
NCT0019425941	NCT00194259_41_T0	COMPOUND	19	19	RDI
NCT0019425942	NCT00194259_42_T0	COMPOUND	12	12	RDI
NCT0019425942	NCT00194259_42_T1	COMPOUND	26	26	RDI
NCT0019425942	NCT00194259_42_T2	GENE	2	2	reduced
NCT0019425942	NCT00194259_42_T3	PHENOTYPE	16	18	increased body weight
NCT0019425947	NCT00194259_47_T0	PHENOTYPE	10	11	weight loss
NCT0019425947	NCT00194259_47_T1	PHENOTYPE	33	34	weight loss
NCT0019425952	NCT00194259_52_T0	TISSUE	9	10	abdominal fat
NCT0019425952	NCT00194259_52_T1	PHENOTYPE	17	18	weight loss
NCT0019425953	NCT00194259_53_T0	PHENOTYPE	16	17	weight loss
NCT0019425957	NCT00194259_57_T0	GENE	9	9	PSG
NCT0019425959	NCT00194259_59_T0	GENE	17	17	PSG
NCT0019425966	NCT00194259_66_T0	GENE	12	12	cm
NCT0019425966	NCT00194259_66_T1	PHENOTYPE	10	10	nearest
NCT0019425969	NCT00194259_69_T0	GENE	20	20	detached
NCT0019425969	NCT00194259_69_T1	GENE	18	18	has
NCT0019425972	NCT00194259_72_T0	GENE	2	2	separated
NCT0019425975	NCT00194259_75_T0	GENE	12	12	cm
NCT0019425975	NCT00194259_75_T1	PHENOTYPE	10	10	nearest
NCT0019425981	NCT00194259_81_T0	PHENOTYPE	5	6	sleep apnea
NCT0019425981	NCT00194259_81_T1	PHENOTYPE	0	2	Quality of life
NCT0019425982	NCT00194259_82_T0	PHENOTYPE	9	9	disorders
NCT0019425982	NCT00194259_82_T1	PHENOTYPE	11	12	excessive sleepiness
NCT0019425982	NCT00194259_82_T2	PHENOTYPE	21	23	quality of life
NCT0019425987	NCT00194259_87_T0	GENE	1	1	log
NCT0019425988	NCT00194259_88_T0	GENE	6	6	log
NCT0019425994	NCT00194259_94_T0	PHENOTYPE	14	15	sleep apnea
NCT0019425995	NCT00194259_95_T0	PHENOTYPE	16	16	decisions
NCT001942852	NCT00194285_2_T0	PHENOTYPE	33	33	complication
NCT001942855	NCT00194285_5_T0	PHENOTYPE	11	12	painful joint
NCT001942856	NCT00194285_6_T0	PHENOTYPE	17	18	painful joint
NCT001942859	NCT00194285_9_T0	PHENOTYPE	31	31	suspicion
NCT001942859	NCT00194285_9_T1	PHENOTYPE	34	35	infectious process
NCT0019428513	NCT00194285_13_T0	PHENOTYPE	31	31	suspicion
NCT0019428513	NCT00194285_13_T1	PHENOTYPE	34	35	infectious process
NCT0019428515	NCT00194285_15_T0	PHENOTYPE	4	4	suspicion
NCT0019428515	NCT00194285_15_T1	GENE	0	1	Group 1
NCT0019428517	NCT00194285_17_T0	COMPOUND	1	1	2
NCT0019428517	NCT00194285_17_T1	PHENOTYPE	4	4	suspicion
NCT0019428519	NCT00194285_19_T0	COMPOUND	1	1	3
NCT0019428519	NCT00194285_19_T1	PHENOTYPE	2	2	Intermediate
NCT0019428519	NCT00194285_19_T2	PHENOTYPE	4	4	suspicion
NCT0019428528	NCT00194285_28_T0	GENE	9	9	12
NCT0019428528	NCT00194285_28_T1	GENE	10	10	18
NCT0019428535	NCT00194285_35_T0	PHENOTYPE	19	19	complication
NCT0019428538	NCT00194285_38_T0	GENE	1	1	II
NCT0019428540	NCT00194285_40_T0	PHENOTYPE	3	3	degenerative
NCT0019428541	NCT00194285_41_T0	PHENOTYPE	29	29	disorders
NCT0019428541	NCT00194285_41_T1	PHENOTYPE	0	0	Osteoarthritis
NCT0019428541	NCT00194285_41_T2	PHENOTYPE	7	9	degenerative joint disease
NCT001942981	NCT00194298_1_T0	GENE	28	28	MRI
NCT001942982	NCT00194298_2_T0	PHENOTYPE	31	31	complication
NCT001942984	NCT00194298_4_T0	TISSUE	15	15	tissues
NCT001942984	NCT00194298_4_T1	GENE	0	0	FDG
NCT001942984	NCT00194298_4_T2	PHENOTYPE	9	10	metabolic rates
NCT001942985	NCT00194298_5_T0	PHENOTYPE	33	33	colitis
NCT001942985	NCT00194298_5_T1	PHENOTYPE	35	35	myositis
NCT001942985	NCT00194298_5_T2	GENE	7	7	FDG
NCT001942985	NCT00194298_5_T3	PHENOTYPE	13	13	disorders
NCT001942985	NCT00194298_5_T4	PHENOTYPE	44	44	infections
NCT001942985	NCT00194298_5_T5	PHENOTYPE	36	36	mastitis
NCT001942985	NCT00194298_5_T6	PHENOTYPE	37	37	vasculitis
NCT001942985	NCT00194298_5_T7	PHENOTYPE	32	32	tuberculosis
NCT001942985	NCT00194298_5_T8	PHENOTYPE	31	31	asthma
NCT001942985	NCT00194298_5_T9	PHENOTYPE	16	16	sarcoidosis
NCT001942985	NCT00194298_5_T10	PHENOTYPE	34	34	sinusitis
NCT001942985	NCT00194298_5_T11	PHENOTYPE	41	41	thyroiditis
NCT001942985	NCT00194298_5_T12	PHENOTYPE	20	21	brain abscess
NCT001942985	NCT00194298_5_T13	PHENOTYPE	24	25	renal abscess
NCT001942985	NCT00194298_5_T14	PHENOTYPE	29	30	lobar pneumonia
NCT001942985	NCT00194298_5_T15	PHENOTYPE	18	19	abdominal abscess
NCT001942985	NCT00194298_5_T16	PHENOTYPE	22	23	lung abscess
NCT001942985	NCT00194298_5_T17	PHENOTYPE	27	28	pancreatic disease
NCT001942985	NCT00194298_5_T18	PHENOTYPE	38	40	deep venous thrombosis
NCT001942986	NCT00194298_6_T0	GENE	20	20	WBC
NCT001942986	NCT00194298_6_T1	PHENOTYPE	15	16	diabetic foot
NCT001942987	NCT00194298_7_T0	GENE	5	5	has
NCT001942988	NCT00194298_8_T0	CELL	15	15	cells
NCT001942988	NCT00194298_8_T1	GENE	5	5	WBC
NCT001942989	NCT00194298_9_T0	PHENOTYPE	17	17	infiltrate
NCT001942989	NCT00194298_9_T1	CELL	6	6	leukocyte
NCT001942989	NCT00194298_9_T2	CELL	10	10	neutrophils
NCT001942989	NCT00194298_9_T3	PHENOTYPE	18	19	acute infections
NCT0019429810	NCT00194298_10_T0	PHENOTYPE	2	2	infections
NCT0019429810	NCT00194298_10_T1	PHENOTYPE	10	10	chronic
NCT0019429810	NCT00194298_10_T2	PHENOTYPE	5	6	diabetic foot
NCT0019429811	NCT00194298_11_T0	CELL	7	7	monocytes
NCT0019429811	NCT00194298_11_T1	CELL	9	9	lymphocytes
NCT0019429811	NCT00194298_11_T2	CELL	4	4	cells
NCT0019429812	NCT00194298_12_T0	CELL	12	12	monocytes
NCT0019429812	NCT00194298_12_T1	CELL	14	14	lymphocytes
NCT0019429812	NCT00194298_12_T2	CELL	2	2	leukocytes
NCT0019429812	NCT00194298_12_T3	PHENOTYPE	7	8	chronic infection
NCT0019429815	NCT00194298_15_T0	CELL	14	14	cells
NCT0019429815	NCT00194298_15_T1	PHENOTYPE	24	24	inflammation
NCT0019429816	NCT00194298_16_T0	GENE	12	12	WBC
NCT0019429821	NCT00194298_21_T0	PHENOTYPE	13	14	diabetic foot
NCT0019429822	NCT00194298_22_T0	PHENOTYPE	17	17	localizing
NCT0019429822	NCT00194298_22_T1	PHENOTYPE	19	19	infections
NCT0019429822	NCT00194298_22_T2	PHENOTYPE	29	30	diabetic foot
NCT0019429823	NCT00194298_23_T0	PHENOTYPE	5	5	inflammation
NCT0019429823	NCT00194298_23_T1	PHENOTYPE	3	3	infections
NCT0019429823	NCT00194298_23_T2	GENE	7	7	has
NCT0019429823	NCT00194298_23_T3	PHENOTYPE	25	26	diabetic foot
NCT0019429826	NCT00194298_26_T0	PHENOTYPE	13	13	osteomyelitis
NCT0019429826	NCT00194298_26_T1	PHENOTYPE	11	11	suspicion
NCT0019429826	NCT00194298_26_T2	PHENOTYPE	17	17	infections
NCT0019429826	NCT00194298_26_T3	PHENOTYPE	7	8	diabetic foot
NCT0019429826	NCT00194298_26_T4	PHENOTYPE	26	27	diabetic foot
NCT0019429827	NCT00194298_27_T0	GENE	14	14	MRI
NCT0019429827	NCT00194298_27_T1	PHENOTYPE	23	23	Neuropathy
NCT0019429827	NCT00194298_27_T2	PHENOTYPE	18	19	peripheral neuropathy
NCT0019429828	NCT00194298_28_T0	GENE	12	12	0.3
NCT0019429828	NCT00194298_28_T1	GENE	13	13	4-8
NCT0019429830	NCT00194298_30_T0	GENE	1	1	II
NCT0019429830	NCT00194298_30_T1	PHENOTYPE	13	13	osteomyelitis
NCT0019429830	NCT00194298_30_T2	PHENOTYPE	11	11	suspicion
NCT0019429830	NCT00194298_30_T3	PHENOTYPE	16	16	infections
NCT0019429830	NCT00194298_30_T4	PHENOTYPE	7	8	diabetic foot
NCT0019429830	NCT00194298_30_T5	PHENOTYPE	25	26	diabetic foot
NCT0019429832	NCT00194298_32_T0	GENE	14	14	MRI
NCT0019429832	NCT00194298_32_T1	PHENOTYPE	24	24	pulse
NCT001943501	NCT00194350_1_T0	PHENOTYPE	14	14	mutation
NCT001943631	NCT00194363_1_T0	PHENOTYPE	10	10	lymphedema
NCT001943631	NCT00194363_1_T1	PHENOTYPE	13	13	lymphedema
NCT001943633	NCT00194363_3_T0	PHENOTYPE	3	3	lymphedema
NCT001943634	NCT00194363_4_T0	PHENOTYPE	3	3	lymphedema
NCT001943634	NCT00194363_4_T1	GENE	6	6	1.5
NCT001943635	NCT00194363_5_T0	PHENOTYPE	13	13	lymphedema
NCT001943636	NCT00194363_6_T0	PHENOTYPE	4	4	lymphedema
NCT001943636	NCT00194363_6_T1	PHENOTYPE	31	31	lymphedema
NCT001943636	NCT00194363_6_T2	PHENOTYPE	37	37	lymphedema
NCT001943638	NCT00194363_8_T0	PHENOTYPE	6	6	lymphedema
NCT0019436311	NCT00194363_11_T0	PHENOTYPE	14	14	lymphedema
NCT0019436311	NCT00194363_11_T1	PHENOTYPE	29	29	lymphedema
NCT0019436312	NCT00194363_12_T0	PHENOTYPE	2	2	lymphedema
NCT0019436312	NCT00194363_12_T1	GENE	12	12	Dr
NCT0019436314	NCT00194363_14_T0	PHENOTYPE	13	13	lymphedema
NCT0019436315	NCT00194363_15_T0	PHENOTYPE	19	19	strategies
NCT0019436315	NCT00194363_15_T1	PHENOTYPE	3	3	lymphedema
NCT0019436315	NCT00194363_15_T2	PHENOTYPE	11	11	lymphedema
NCT0019436317	NCT00194363_17_T0	PHENOTYPE	2	2	lymphedema
NCT0019436320	NCT00194363_20_T0	PHENOTYPE	14	14	lymphedema
NCT0019436320	NCT00194363_20_T1	PHENOTYPE	21	21	lymphedema
NCT0019436320	NCT00194363_20_T2	PHENOTYPE	7	7	experiences
NCT0019436321	NCT00194363_21_T0	PHENOTYPE	1	1	experiences
NCT0019436323	NCT00194363_23_T0	PHENOTYPE	8	8	lymphedema
NCT0019436326	NCT00194363_26_T0	PHENOTYPE	25	25	symptoms
NCT0019436326	NCT00194363_26_T1	PHENOTYPE	24	24	lymphedema
NCT0019436334	NCT00194363_34_T0	PHENOTYPE	40	40	Center
NCT001943760	NCT00194376_0_T0	PHENOTYPE	11	11	Ventilation
NCT001943760	NCT00194376_0_T1	PHENOTYPE	2	3	Gastroesophageal Reflux
NCT001943760	NCT00194376_0_T2	PHENOTYPE	13	15	Obstructive Sleep Apnea
NCT001943762	NCT00194376_2_T0	PHENOTYPE	15	15	ventilation
NCT001943763	NCT00194376_3_T0	GENE	4	4	pH
NCT001943763	NCT00194376_3_T1	PHENOTYPE	16	16	reflux
NCT001943764	NCT00194376_4_T0	PHENOTYPE	21	21	ventilation
NCT001943764	NCT00194376_4_T1	PHENOTYPE	3	3	reflux
NCT001943764	NCT00194376_4_T2	PHENOTYPE	13	13	reflux
NCT001944021	NCT00194402_1_T0	COMPOUND	11	11	atorvastatin
NCT001944024	NCT00194402_4_T0	COMPOUND	1	1	niacin
NCT001944027	NCT00194402_7_T0	COMPOUND	19	19	glucose
NCT001944027	NCT00194402_7_T1	GENE	20	20	insulin
NCT001944027	NCT00194402_7_T2	GENE	10	10	lipoprotein
NCT001944027	NCT00194402_7_T3	GENE	17	17	LDL
NCT001944027	NCT00194402_7_T4	GENE	22	23	C-reactive protein
NCT001944028	NCT00194402_8_T0	GENE	6	6	TG
NCT001944029	NCT00194402_9_T0	GENE	3	3	32.6
NCT001944029	NCT00194402_9_T1	COMPOUND	1	1	BMI
NCT0019440210	NCT00194402_10_T0	GENE	11	11	TG
NCT0019440210	NCT00194402_10_T1	COMPOUND	3	3	atorvastatin
NCT0019440212	NCT00194402_12_T0	GENE	4	4	TG
NCT0019440213	NCT00194402_13_T0	GENE	2	2	CRP
NCT0019440213	NCT00194402_13_T1	GENE	1	1	hs
NCT0019440214	NCT00194402_14_T0	GENE	6	6	lipoprotein
NCT0019440214	NCT00194402_14_T1	COMPOUND	3	3	atorvastatin
NCT0019440214	NCT00194402_14_T2	PHENOTYPE	12	13	combined hyperlipidemia
NCT0019440215	NCT00194402_15_T0	GENE	3	3	LDL
NCT0019440215	NCT00194402_15_T1	COMPOUND	17	17	atorvastatin
NCT001944152	NCT00194415_2_T0	PHENOTYPE	14	14	HSV
NCT001944156	NCT00194415_6_T0	PHENOTYPE	8	9	herpes infection
NCT001944156	NCT00194415_6_T1	GENE	2	3	group 2
NCT001944284	NCT00194428_4_T0	GENE	3	3	0.6
NCT001944284	NCT00194428_4_T1	PHENOTYPE	9	10	weight loss
NCT001944285	NCT00194428_5_T0	GENE	14	14	1.5
NCT001944286	NCT00194428_6_T0	PHENOTYPE	9	10	weight loss
NCT001944287	NCT00194428_7_T0	GENE	13	13	1.5
NCT001944413	NCT00194441_3_T0	GENE	6	6	GOS
NCT001944416	NCT00194441_6_T0	PHENOTYPE	12	12	secondary
NCT001944416	NCT00194441_6_T1	PHENOTYPE	13	14	brain injury
NCT001944417	NCT00194441_7_T0	PHENOTYPE	13	14	brain injury
NCT0019444115	NCT00194441_15_T0	PHENOTYPE	0	0	Secondary
NCT0019444115	NCT00194441_15_T1	GENE	3	3	GOS
NCT0019444115	NCT00194441_15_T2	GENE	14	14	FIM
NCT0019444122	NCT00194441_22_T0	PHENOTYPE	13	14	brain injury
NCT0019444122	NCT00194441_22_T1	PHENOTYPE	31	32	brain injury
NCT0019444122	NCT00194441_22_T2	PHENOTYPE	9	10	critically ill
NCT0019444124	NCT00194441_24_T0	PHENOTYPE	20	21	brain injury
NCT0019444125	NCT00194441_25_T0	GENE	19	19	had
NCT0019444125	NCT00194441_25_T1	PHENOTYPE	11	12	brain injury
NCT0019444125	NCT00194441_25_T2	PHENOTYPE	21	22	brain injury
NCT001944542	NCT00194454_2_T0	GENE	56	56	5-HTTLPR
NCT001944542	NCT00194454_2_T1	PHENOTYPE	0	0	Secondary
NCT001944542	NCT00194454_2_T2	PHENOTYPE	38	39	ischemic stroke
NCT001944544	NCT00194454_4_T0	PHENOTYPE	14	14	Association
NCT001944546	NCT00194454_6_T0	PHENOTYPE	15	15	Stroke
NCT001944546	NCT00194454_6_T1	PHENOTYPE	22	22	Stroke
NCT001944546	NCT00194454_6_T2	PHENOTYPE	0	0	Secondary
NCT001944548	NCT00194454_8_T0	GENE	26	26	PSD
NCT001944548	NCT00194454_8_T1	GENE	13	13	SERT
NCT001944549	NCT00194454_9_T0	GENE	41	41	5-HTTLPR
NCT001944549	NCT00194454_9_T1	PHENOTYPE	23	24	ischemic stroke
NCT001944671	NCT00194467_1_T0	COMPOUND	4	4	valganciclovir
NCT001944673	NCT00194467_3_T0	COMPOUND	4	4	valganciclovir
NCT001944675	NCT00194467_5_T0	GENE	28	28	KS
NCT001944675	NCT00194467_5_T1	COMPOUND	1	1	valganciclovir
NCT001944675	NCT00194467_5_T2	COMPOUND	22	22	valganciclovir
NCT001944675	NCT00194467_5_T3	PHENOTYPE	26	27	Kaposi's Sarcoma
NCT001944677	NCT00194467_7_T0	COMPOUND	11	11	valganciclovir
NCT001944678	NCT00194467_8_T0	PHENOTYPE	7	8	adverse events
NCT001944679	NCT00194467_9_T0	GENE	17	17	PCR
NCT0019446710	NCT00194467_10_T0	TISSUE	9	10	oral mucosa
NCT0019446711	NCT00194467_11_T0	GENE	18	18	PCR
NCT0019446711	NCT00194467_11_T1	PHENOTYPE	15	16	adverse events
NCT001944801	NCT00194480_1_T0	PHENOTYPE	20	20	acute
NCT001944801	NCT00194480_1_T1	COMPOUND	21	21	HCV
NCT001944801	NCT00194480_1_T2	GENE	12	12	interferon
NCT001944803	NCT00194480_3_T0	GENE	1	1	interferon
NCT001944803	NCT00194480_3_T1	GENE	7	7	interferon
NCT001944804	NCT00194480_4_T0	COMPOUND	4	4	HCV
NCT001944804	NCT00194480_4_T1	COMPOUND	14	14	HCV
NCT001944804	NCT00194480_4_T2	GENE	0	0	Interferon
NCT001944804	NCT00194480_4_T3	ORGAN	10	11	immune system
NCT001944805	NCT00194480_5_T0	COMPOUND	16	16	HCV
NCT001944805	NCT00194480_5_T1	GENE	12	12	interferon
NCT001944808	NCT00194480_8_T0	GENE	5	5	interferon
NCT001944808	NCT00194480_8_T1	GENE	0	1	Group 1
NCT001944808	NCT00194480_8_T2	GENE	7	8	group 2
NCT001944809	NCT00194480_9_T0	GENE	4	4	interferon
NCT0019448010	NCT00194480_10_T0	PHENOTYPE	24	24	arthralgias
NCT0019448010	NCT00194480_10_T1	GENE	16	16	interferon
NCT0019448010	NCT00194480_10_T2	PHENOTYPE	25	25	insomnia
NCT0019448010	NCT00194480_10_T3	PHENOTYPE	23	23	myalgias
NCT0019448010	NCT00194480_10_T4	PHENOTYPE	22	22	headache
NCT0019448010	NCT00194480_10_T5	PHENOTYPE	27	28	hair loss
NCT0019448010	NCT00194480_10_T6	PHENOTYPE	9	10	adverse events
NCT001944930	NCT00194493_0_T0	PHENOTYPE	5	5	Cancer
NCT001944934	NCT00194493_4_T0	GENE	4	4	has
NCT001944938	NCT00194493_8_T0	PHENOTYPE	11	11	practices
NCT0019449315	NCT00194493_15_T0	PHENOTYPE	4	4	symptoms
NCT0019449315	NCT00194493_15_T1	PHENOTYPE	9	9	QOL
NCT0019449315	NCT00194493_15_T2	PHENOTYPE	6	8	quality of life
NCT0019449316	NCT00194493_16_T0	GENE	2	2	has
NCT0019449316	NCT00194493_16_T1	PHENOTYPE	11	11	QOL
NCT0019449320	NCT00194493_20_T0	PHENOTYPE	9	9	Oncology
NCT001945062	NCT00194506_2_T0	PHENOTYPE	39	39	Centers
NCT001945062	NCT00194506_2_T1	GENE	30	30	MIND
NCT0019450610	NCT00194506_10_T0	GENE	14	14	MIND
NCT001945190	NCT00194519_0_T0	PHENOTYPE	9	9	HIV
NCT001945190	NCT00194519_0_T1	PHENOTYPE	6	6	Suppression
NCT001945190	NCT00194519_0_T2	PHENOTYPE	10	10	Transmission
NCT001945190	NCT00194519_0_T3	PHENOTYPE	0	1	Herpes Simplex
NCT001945192	NCT00194519_2_T0	PHENOTYPE	9	9	HIV
NCT001945192	NCT00194519_2_T1	PHENOTYPE	16	16	HIV
NCT001945192	NCT00194519_2_T2	PHENOTYPE	41	41	HIV
NCT001945192	NCT00194519_2_T3	PHENOTYPE	48	48	HIV
NCT001945192	NCT00194519_2_T4	COMPOUND	35	35	acyclovir
NCT001945192	NCT00194519_2_T5	GENE	19	19	co
NCT001945192	NCT00194519_2_T6	GENE	34	34	bid
NCT001945192	NCT00194519_2_T7	GENE	24	25	type 2
NCT001945192	NCT00194519_2_T8	PHENOTYPE	21	22	herpes simplex
NCT001945193	NCT00194519_3_T0	GENE	34	34	CD4
NCT001945193	NCT00194519_3_T1	PHENOTYPE	19	19	HIV
NCT001945193	NCT00194519_3_T2	PHENOTYPE	14	14	suppression
NCT001945193	NCT00194519_3_T3	COMPOUND	17	17	acyclovir
NCT001945193	NCT00194519_3_T4	GENE	35	35	250
NCT001945194	NCT00194519_4_T0	PHENOTYPE	13	13	HIV
NCT001945194	NCT00194519_4_T1	PHENOTYPE	28	28	HIV
NCT001945194	NCT00194519_4_T2	PHENOTYPE	38	38	HIV
NCT001945194	NCT00194519_4_T3	COMPOUND	19	19	acyclovir
NCT001945194	NCT00194519_4_T4	ORGAN	12	12	genital
NCT001945194	NCT00194519_4_T5	GENE	22	22	bid
NCT001945195	NCT00194519_5_T0	GENE	21	21	CD4
NCT001945195	NCT00194519_5_T1	GENE	19	19	has
NCT001945195	NCT00194519_5_T2	GENE	23	23	250
NCT001945198	NCT00194519_8_T0	GENE	11	11	had
NCT0019451910	NCT00194519_10_T0	PHENOTYPE	14	14	HIV
NCT0019451910	NCT00194519_10_T1	GENE	22	22	2.1
NCT0019451910	NCT00194519_10_T2	PHENOTYPE	30	31	HIV infection
NCT0019451911	NCT00194519_11_T0	PHENOTYPE	16	16	HIV
NCT0019451911	NCT00194519_11_T1	PHENOTYPE	36	36	HIV
NCT0019451911	NCT00194519_11_T2	PHENOTYPE	49	49	HIV
NCT0019451911	NCT00194519_11_T3	GENE	39	39	GUD
NCT0019451911	NCT00194519_11_T4	GENE	9	9	has
NCT0019451911	NCT00194519_11_T5	PHENOTYPE	27	27	susceptible
NCT0019451913	NCT00194519_13_T0	PHENOTYPE	22	22	HIV
NCT0019451913	NCT00194519_13_T1	GENE	15	15	co
NCT0019451915	NCT00194519_15_T0	PHENOTYPE	5	5	HIV
NCT0019451915	NCT00194519_15_T1	PHENOTYPE	10	10	HIV
NCT0019451915	NCT00194519_15_T2	PHENOTYPE	39	39	HIV
NCT0019451915	NCT00194519_15_T3	PHENOTYPE	42	42	HIV
NCT001945321	NCT00194532_1_T0	COMPOUND	11	11	ciprofloxacin
NCT001945322	NCT00194532_2_T0	GENE	6	6	has
NCT001945322	NCT00194532_2_T1	PHENOTYPE	13	13	cystitis
NCT001945323	NCT00194532_3_T0	COMPOUND	11	11	cefpodoxime
NCT001945325	NCT00194532_5_T0	PHENOTYPE	24	24	acute
NCT001945325	NCT00194532_5_T1	COMPOUND	18	18	cefpodoxime
NCT001945325	NCT00194532_5_T2	PHENOTYPE	26	26	cystitis
NCT001945325	NCT00194532_5_T3	PHENOTYPE	12	12	tolerance
NCT001945325	NCT00194532_5_T4	COMPOUND	20	20	ciprofloxacin
NCT001945327	NCT00194532_7_T0	PHENOTYPE	30	30	symptoms
NCT001945328	NCT00194532_8_T0	GENE	10	10	5.9
NCT001945453	NCT00194545_3_T0	PHENOTYPE	21	21	strategies
NCT001945455	NCT00194545_5_T0	PHENOTYPE	8	8	HIV
NCT001945455	NCT00194545_5_T1	GENE	3	3	has
NCT0019454518	NCT00194545_18_T0	COMPOUND	12	12	nevirapine
NCT0019454518	NCT00194545_18_T1	COMPOUND	11	11	zidovudine
NCT0019454518	NCT00194545_18_T2	COMPOUND	14	14	lamivudine
NCT0019454526	NCT00194545_26_T0	PHENOTYPE	13	13	experiences
NCT0019454527	NCT00194545_27_T0	COMPOUND	11	11	2
NCT001945586	NCT00194558_6_T0	GENE	17	17	DCC
NCT001945586	NCT00194558_6_T1	PHENOTYPE	14	14	Diabetes
NCT0019455810	NCT00194558_10_T0	COMPOUND	2	2	glucose
NCT0019455813	NCT00194558_13_T0	GENE	20	20	DCC
NCT0019455814	NCT00194558_14_T0	PHENOTYPE	13	13	self-efficacy
NCT0019455815	NCT00194558_15_T0	PHENOTYPE	17	17	secondary
NCT001945717	NCT00194571_7_T0	PHENOTYPE	17	17	self-efficacy
NCT001945717	NCT00194571_7_T1	PHENOTYPE	27	28	behavioral problems
NCT001945843	NCT00194584_3_T0	PHENOTYPE	1	1	perceived
NCT001945843	NCT00194584_3_T1	PHENOTYPE	2	2	self-efficacy
NCT001945843	NCT00194584_3_T2	PHENOTYPE	10	10	chronic
NCT001945846	NCT00194584_6_T0	PHENOTYPE	1	2	emotional health
NCT001945847	NCT00194584_7_T0	PHENOTYPE	2	2	perceived
NCT001945847	NCT00194584_7_T1	PHENOTYPE	4	6	quality of life
NCT001945976	NCT00194597_6_T0	PHENOTYPE	8	8	gonorrhea
NCT001945977	NCT00194597_7_T0	CELL	6	8	white blood cells
NCT0019459711	NCT00194597_11_T0	PHENOTYPE	15	17	urinary tract infection
NCT0019459715	NCT00194597_15_T0	COMPOUND	3	3	2
NCT0019459720	NCT00194597_20_T0	COMPOUND	3	3	3
NCT001946102	NCT00194610_2_T0	GENE	1	1	toxin
NCT001946102	NCT00194610_2_T1	COMPOUND	9	9	acetylcholine
NCT001946102	NCT00194610_2_T2	CELL	13	14	neuromuscular junction
NCT001946102	NCT00194610_2_T3	PHENOTYPE	4	5	muscle relaxation
NCT0019461013	NCT00194610_13_T0	GENE	23	23	toxin
NCT0019461013	NCT00194610_13_T1	COMPOUND	16	16	epinephrine
NCT0019461013	NCT00194610_13_T2	COMPOUND	14	14	lidocaine
NCT0019461013	NCT00194610_13_T3	GENE	11	11	ml
NCT0019461014	NCT00194610_14_T0	ORGAN	17	17	bladder
NCT001946232	NCT00194623_2_T0	PHENOTYPE	8	9	ejaculatory dysfunction
NCT001946233	NCT00194623_3_T0	PHENOTYPE	13	15	congestive heart failure
NCT001946238	NCT00194623_8_T0	PHENOTYPE	6	6	symptoms
NCT001946238	NCT00194623_8_T1	PHENOTYPE	11	11	secondary
NCT001946238	NCT00194623_8_T2	GENE	13	13	neuromuscular
NCT0019462312	NCT00194623_12_T0	PHENOTYPE	2	2	generalized
NCT0019462312	NCT00194623_12_T1	GENE	5	5	has
NCT0019462313	NCT00194623_13_T0	GENE	4	4	neuromuscular
NCT0019462313	NCT00194623_13_T1	PHENOTYPE	7	7	generalized
NCT0019462315	NCT00194623_15_T0	GENE	10	10	toxin
NCT0019462317	NCT00194623_17_T0	GENE	9	9	midline
NCT0019462318	NCT00194623_18_T0	BIOLOGICAL_PROCESS	8	8	innervation
NCT0019462320	NCT00194623_20_T0	PHENOTYPE	5	5	symptoms
NCT0019462322	NCT00194623_22_T0	PHENOTYPE	3	4	adverse events
NCT0019462328	NCT00194623_28_T0	ORGAN	11	11	genital
NCT0019462330	NCT00194623_30_T0	ORGAN	1	1	perineum
NCT0019462330	NCT00194623_30_T1	COMPOUND	6	6	iodine
NCT0019462331	NCT00194623_31_T0	ORGAN	10	10	perineum
NCT0019462332	NCT00194623_32_T0	COMPOUND	2	2	1
NCT0019462332	NCT00194623_32_T1	COMPOUND	15	15	1
NCT0019462332	NCT00194623_32_T2	COMPOUND	7	7	2
NCT0019462332	NCT00194623_32_T3	COMPOUND	17	17	2
NCT0019462332	NCT00194623_32_T4	COMPOUND	10	10	3
NCT0019462333	NCT00194623_33_T0	TISSUE	19	19	muscles
NCT0019462334	NCT00194623_34_T0	GENE	6	6	cc
NCT0019462334	NCT00194623_34_T1	GENE	5	5	1.3
NCT0019462335	NCT00194623_35_T0	GENE	3	3	ccs
NCT001946363	NCT00194636_3_T0	PHENOTYPE	7	8	chronic prostatitis
NCT001946366	NCT00194636_6_T0	GENE	9	9	had
NCT001946367	NCT00194636_7_T0	ORGAN	5	6	nervous system
NCT001946367	NCT00194636_7_T1	ORGAN	25	27	sympathetic nervous system
NCT001946369	NCT00194636_9_T0	ORGAN	13	15	sympathetic nervous system
NCT0019463612	NCT00194636_12_T0	ORGAN	5	5	viscera
NCT0019463612	NCT00194636_12_T1	ORGAN	11	12	hypogastric plexus
NCT0019463613	NCT00194636_13_T0	GENE	3	3	has
NCT0019463614	NCT00194636_14_T0	COMPOUND	12	12	bupivacaine
NCT0019463614	NCT00194636_14_T1	ORGAN	9	10	hypogastric plexus
NCT0019463625	NCT00194636_25_T0	GENE	17	17	cc
NCT0019463625	NCT00194636_25_T1	COMPOUND	30	30	catecholamine
NCT0019463625	NCT00194636_25_T2	COMPOUND	33	33	acetylcholine
NCT0019463625	NCT00194636_25_T3	ORGAN	29	29	plasma
NCT0019463626	NCT00194636_26_T0	ORGAN	0	0	Plasma
NCT0019463626	NCT00194636_26_T1	COMPOUND	1	1	catecholamine
NCT0019463626	NCT00194636_26_T2	ORGAN	9	11	sympathetic nervous system
NCT0019463628	NCT00194636_28_T0	GENE	2	2	has
NCT0019463630	NCT00194636_30_T0	GENE	17	17	cc
NCT0019463630	NCT00194636_30_T1	ORGAN	10	10	bladder
NCT0019463631	NCT00194636_31_T0	GENE	8	8	cc
NCT0019463631	NCT00194636_31_T1	ORGAN	19	19	bladder
NCT0019463633	NCT00194636_33_T0	GENE	13	13	cc
NCT0019463633	NCT00194636_33_T1	PHENOTYPE	16	16	sterile
NCT0019463644	NCT00194636_44_T0	GENE	3	3	painless
NCT0019463648	NCT00194636_48_T0	PHENOTYPE	14	14	discomfort
NCT0019463650	NCT00194636_50_T0	ORGAN	7	9	sympathetic nervous system
NCT0019463654	NCT00194636_54_T0	ORGAN	15	15	feet
NCT0019463654	NCT00194636_54_T1	ORGAN	18	18	hands
NCT0019463656	NCT00194636_56_T0	ORGAN	10	10	wrist
NCT0019463656	NCT00194636_56_T1	ORGAN	11	12	median nerve
NCT0019463657	NCT00194636_57_T0	ORGAN	11	12	nervous system
NCT0019463657	NCT00194636_57_T1	ORGAN	0	1	Median nerve
NCT0019463658	NCT00194636_58_T0	ORGAN	5	6	median nerve
NCT0019463660	NCT00194636_60_T0	ORGAN	9	9	testicles
NCT0019463660	NCT00194636_60_T1	TISSUE	3	3	muscles
NCT0019463661	NCT00194636_61_T0	ORGAN	5	5	thigh
NCT0019463669	NCT00194636_69_T0	COMPOUND	6	6	levobupivacaine
NCT0019463669	NCT00194636_69_T1	COMPOUND	20	20	NaCl
NCT001946498	NCT00194649_8_T0	BIOLOGICAL_PROCESS	7	7	spermatogenesis
NCT001946755	NCT00194675_5_T0	COMPOUND	12	12	dutasteride
NCT001946755	NCT00194675_5_T1	PHENOTYPE	14	15	cognitive function
NCT001946882	NCT00194688_2_T0	COMPOUND	30	30	ammonia
NCT001946882	NCT00194688_2_T1	PHENOTYPE	14	15	ammonia levels
NCT001946884	NCT00194688_4_T0	COMPOUND	37	37	ammonia
NCT001947013	NCT00194701_3_T0	GENE	7	7	II
NCT001947013	NCT00194701_3_T1	GENE	9	9	III
NCT001947013	NCT00194701_3_T2	PHENOTYPE	11	12	heart failure
NCT001947015	NCT00194701_5_T0	ORGAN	32	32	Heart
NCT001947015	NCT00194701_5_T1	GENE	37	37	II
NCT001947015	NCT00194701_5_T2	GENE	39	39	III
NCT001947015	NCT00194701_5_T3	PHENOTYPE	40	41	heart failure
NCT001947015	NCT00194701_5_T4	PHENOTYPE	23	25	quality of life
NCT001947017	NCT00194701_7_T0	PHENOTYPE	27	27	symptoms
NCT001947017	NCT00194701_7_T1	PHENOTYPE	31	31	fatigue
NCT001947017	NCT00194701_7_T2	PHENOTYPE	29	29	dyspnea
NCT001947017	NCT00194701_7_T3	COMPOUND	9	9	oxygen
NCT001947017	NCT00194701_7_T4	COMPOUND	15	15	oxygen
NCT001947017	NCT00194701_7_T5	ORGAN	18	18	heart
NCT001947017	NCT00194701_7_T6	PHENOTYPE	23	25	quality of life
NCT0019470113	NCT00194701_13_T0	PHENOTYPE	0	1	Heart failure
NCT0019470114	NCT00194701_14_T0	PHENOTYPE	0	1	Heart failure
NCT0019470116	NCT00194701_16_T0	PHENOTYPE	0	1	Heart failure
NCT0019470119	NCT00194701_19_T0	PHENOTYPE	25	25	fragmented
NCT0019470119	NCT00194701_19_T1	PHENOTYPE	0	1	Heart failure
NCT0019470119	NCT00194701_19_T2	PHENOTYPE	31	32	heart failure
NCT0019470119	NCT00194701_19_T3	PHENOTYPE	27	29	slow wave sleep
NCT0019470123	NCT00194701_23_T0	PHENOTYPE	22	23	heart failure
NCT0019470123	NCT00194701_23_T1	PHENOTYPE	44	45	heart failure
NCT0019470125	NCT00194701_25_T0	COMPOUND	20	20	oxygen
NCT0019470125	NCT00194701_25_T1	ORGAN	3	3	heart
NCT0019470125	NCT00194701_25_T2	ORGAN	11	11	heart
NCT0019470125	NCT00194701_25_T3	ORGAN	25	25	heart
NCT0019470125	NCT00194701_25_T4	ORGAN	35	35	heart
NCT0019470128	NCT00194701_28_T0	PHENOTYPE	7	8	heart failure
NCT0019470129	NCT00194701_29_T0	COMPOUND	15	15	oxygen
NCT0019470129	NCT00194701_29_T1	PHENOTYPE	7	7	tolerance
NCT0019470129	NCT00194701_29_T2	ORGAN	22	22	heart
NCT0019470129	NCT00194701_29_T3	PHENOTYPE	29	31	quality of life
NCT0019470130	NCT00194701_30_T0	GENE	4	4	ANOVA
NCT0019470131	NCT00194701_31_T0	GENE	7	7	ANOVA
NCT001947140	NCT00194714_0_T0	GENE	10	10	HER2
NCT001947140	NCT00194714_0_T1	GENE	7	7	IV
NCT001947140	NCT00194714_0_T2	PHENOTYPE	14	15	Ovarian Cancer
NCT001947144	NCT00194714_4_T0	GENE	10	10	CTL
NCT001947144	NCT00194714_4_T1	GENE	7	7	HER2
NCT001947144	NCT00194714_4_T2	GENE	18	18	IV
NCT001947144	NCT00194714_4_T3	CELL	9	9	T-cell
NCT001947144	NCT00194714_4_T4	GENE	13	13	HER-2/neu
NCT001947144	NCT00194714_4_T5	PHENOTYPE	21	22	ovarian cancer
NCT001947148	NCT00194714_8_T0	GENE	15	15	CTL
NCT001947148	NCT00194714_8_T1	GENE	14	14	HER2
NCT001947272	NCT00194727_2_T0	PHENOTYPE	9	9	toxicity
NCT001947272	NCT00194727_2_T1	PHENOTYPE	13	13	toxicity
NCT001947272	NCT00194727_2_T2	PHENOTYPE	24	24	toxicity
NCT001947272	NCT00194727_2_T3	PHENOTYPE	11	11	severity
NCT001947273	NCT00194727_3_T0	PHENOTYPE	14	14	progression
NCT001947277	NCT00194727_7_T0	PHENOTYPE	12	12	tumor
NCT001947278	NCT00194727_8_T0	COMPOUND	1	1	capecitabine
NCT001947278	NCT00194727_8_T1	COMPOUND	10	10	5_fluorouracil
NCT001947279	NCT00194727_9_T0	PHENOTYPE	16	16	toxicity
NCT001947279	NCT00194727_9_T1	COMPOUND	2	2	vinorelbine
NCT001947279	NCT00194727_9_T2	PHENOTYPE	24	25	breast cancer
NCT0019472711	NCT00194727_11_T0	PHENOTYPE	6	6	toxicities
NCT0019472712	NCT00194727_12_T0	PHENOTYPE	0	0	Secondary
NCT0019472712	NCT00194727_12_T1	PHENOTYPE	11	12	enzyme levels
NCT001947401	NCT00194740_1_T0	PHENOTYPE	10	11	side effect
NCT001947402	NCT00194740_2_T0	PHENOTYPE	16	16	toxic
NCT001947402	NCT00194740_2_T1	GENE	8	8	G-CSF
NCT001947402	NCT00194740_2_T2	PHENOTYPE	25	27	metastatic breast cancer
NCT001947404	NCT00194740_4_T0	PHENOTYPE	39	39	toxicity
NCT001947404	NCT00194740_4_T1	COMPOUND	12	12	vinorelbine
NCT001947404	NCT00194740_4_T2	COMPOUND	10	10	paclitaxel
NCT001947404	NCT00194740_4_T3	PHENOTYPE	45	45	complications
NCT001947404	NCT00194740_4_T4	GENE	8	8	G-CSF
NCT001947404	NCT00194740_4_T5	GENE	31	31	G-CSF
NCT001947405	NCT00194740_5_T0	GENE	4	4	had
NCT001947405	NCT00194740_5_T1	PHENOTYPE	10	10	remissions
NCT001947406	NCT00194740_6_T0	GENE	20	20	II
NCT001947406	NCT00194740_6_T1	COMPOUND	14	14	vinorelbine
NCT001947406	NCT00194740_6_T2	COMPOUND	6	6	docetaxel
NCT001947406	NCT00194740_6_T3	GENE	16	16	27/5
NCT001947407	NCT00194740_7_T0	COMPOUND	9	9	vinorelbine
NCT001947407	NCT00194740_7_T1	COMPOUND	26	26	docetaxel
NCT001947407	NCT00194740_7_T2	GENE	16	16	G-CSF
NCT0019474010	NCT00194740_10_T0	COMPOUND	3	3	3
NCT001947532	NCT00194753_2_T0	PHENOTYPE	11	11	toxicity
NCT001947532	NCT00194753_2_T1	PHENOTYPE	9	9	severity
NCT001947532	NCT00194753_2_T2	PHENOTYPE	0	0	Toxicity
NCT001947533	NCT00194753_3_T0	PHENOTYPE	14	14	toxic
NCT001947535	NCT00194753_5_T0	PHENOTYPE	17	17	toxicity
NCT001947537	NCT00194753_7_T0	PHENOTYPE	9	9	toxicity
NCT001947537	NCT00194753_7_T1	PHENOTYPE	6	6	relapse
NCT0019475310	NCT00194753_10_T0	GENE	7	7	II
NCT0019475310	NCT00194753_10_T1	GENE	9	9	III
NCT0019475310	NCT00194753_10_T2	PHENOTYPE	10	11	breast cancer
NCT0019475312	NCT00194753_12_T0	PHENOTYPE	13	13	ICC
NCT0019475312	NCT00194753_12_T1	GENE	8	8	FISH
NCT0019475313	NCT00194753_13_T0	GENE	6	6	FISH
NCT001947664	NCT00194766_4_T0	PHENOTYPE	32	32	toxicity
NCT001947664	NCT00194766_4_T1	GENE	31	31	3.4
NCT001947666	NCT00194766_6_T0	COMPOUND	28	28	temozolomide
NCT001947666	NCT00194766_6_T1	PHENOTYPE	11	11	progression
NCT001947666	NCT00194766_6_T2	PHENOTYPE	18	19	breast cancer
NCT001947666	NCT00194766_6_T3	PHENOTYPE	21	23	soft tissue sarcoma
NCT001947668	NCT00194766_8_T0	PHENOTYPE	6	6	blocks
NCT001947669	NCT00194766_9_T0	PHENOTYPE	6	7	evaluable disease
NCT0019476614	NCT00194766_14_T0	TISSUE	23	23	bones
NCT0019476614	NCT00194766_14_T1	ORGAN	19	19	pelvis
NCT0019476614	NCT00194766_14_T2	ORGAN	20	20	spine
NCT0019476614	NCT00194766_14_T3	COMPOUND	36	37	mitomycin C
NCT0019476615	NCT00194766_15_T0	CELL	2	2	Granulocytes
NCT0019476616	NCT00194766_16_T0	PHENOTYPE	0	1	Platelet count
NCT0019476618	NCT00194766_18_T0	GENE	3	3	2.0
NCT0019476619	NCT00194766_19_T0	GENE	0	1	Total bilirubin
NCT0019476620	NCT00194766_20_T0	PHENOTYPE	10	10	metastases
NCT0019476620	NCT00194766_20_T1	PHENOTYPE	4	5	rapidly progressive
NCT0019476622	NCT00194766_22_T0	BIOLOGICAL_PROCESS	2	2	lactation
NCT0019476624	NCT00194766_24_T0	ORGAN	3	3	marrow
NCT001947792	NCT00194779_2_T0	PHENOTYPE	8	8	tumor
NCT001947793	NCT00194779_3_T0	PHENOTYPE	17	17	peripheral
NCT001947793	NCT00194779_3_T1	CELL	11	11	cells
NCT001947793	NCT00194779_3_T2	GENE	4	4	filgrastim
NCT001947793	NCT00194779_3_T3	ORGAN	14	15	bone marrow
NCT001947793	NCT00194779_3_T4	ORGAN	23	24	immune system
NCT001947793	NCT00194779_3_T5	PHENOTYPE	29	31	effects of chemotherapy
NCT001947795	NCT00194779_5_T0	GENE	31	31	G-CSF
NCT001947795	NCT00194779_5_T1	GENE	32	32	filgrastim
NCT001947795	NCT00194779_5_T2	COMPOUND	28	28	cyclophosphamide
NCT001947795	NCT00194779_5_T3	COMPOUND	22	22	doxorubicin
NCT001947795	NCT00194779_5_T4	PHENOTYPE	10	11	breast cancer
NCT001947795	NCT00194779_5_T5	COMPOUND	23	24	doxorubicin hydrochloride
NCT001947795	NCT00194779_5_T6	COMPOUND	38	39	weekly paclitaxel
NCT001947797	NCT00194779_7_T0	COMPOUND	20	20	cyclophosphamide
NCT001947797	NCT00194779_7_T1	GENE	23	23	G-CSF
NCT001947797	NCT00194779_7_T2	COMPOUND	16	16	doxorubicin
NCT001947797	NCT00194779_7_T3	PHENOTYPE	11	12	breast cancer
NCT001947799	NCT00194779_9_T0	PHENOTYPE	11	12	breast cancer
NCT001947799	NCT00194779_9_T1	COMPOUND	15	16	weekly paclitaxel
NCT0019477911	NCT00194779_11_T0	PHENOTYPE	3	3	relapse
NCT0019477911	NCT00194779_11_T1	COMPOUND	50	50	tartrate
NCT0019477911	NCT00194779_11_T2	GENE	29	29	G-CSF
NCT0019477911	NCT00194779_11_T3	COMPOUND	49	49	vinorelbine
NCT0019477911	NCT00194779_11_T4	COMPOUND	45	45	capecitabine
NCT0019477911	NCT00194779_11_T5	COMPOUND	26	26	cyclophosphamide
NCT0019477911	NCT00194779_11_T6	COMPOUND	22	22	doxorubicin
NCT0019477911	NCT00194779_11_T7	PHENOTYPE	13	14	breast cancer
NCT0019477911	NCT00194779_11_T8	COMPOUND	35	36	weekly paclitaxel
NCT0019477913	NCT00194779_13_T0	PHENOTYPE	3	3	toxicity
NCT0019477915	NCT00194779_15_T0	PHENOTYPE	6	7	breast cancer
NCT0019477917	NCT00194779_17_T0	PHENOTYPE	6	7	breast tumors
NCT0019477918	NCT00194779_18_T0	GENE	24	24	SC
NCT0019477918	NCT00194779_18_T1	GENE	22	22	filgrastim
NCT0019477918	NCT00194779_18_T2	COMPOUND	15	15	cyclophosphamide
NCT0019477918	NCT00194779_18_T3	GENE	28	28	2.7
NCT0019477918	NCT00194779_18_T4	GENE	8	8	IV
NCT0019477918	NCT00194779_18_T5	COMPOUND	5	6	doxorubicin hydrochloride
NCT0019477919	NCT00194779_19_T0	PHENOTYPE	13	13	toxicity
NCT0019477919	NCT00194779_19_T1	PHENOTYPE	9	10	disease progression
NCT0019477920	NCT00194779_20_T0	GENE	1	1	II
NCT0019477920	NCT00194779_20_T1	COMPOUND	4	4	paclitaxel
NCT0019477920	NCT00194779_20_T2	GENE	5	5	IV
NCT0019477921	NCT00194779_21_T0	PHENOTYPE	13	13	toxicity
NCT0019477921	NCT00194779_21_T1	PHENOTYPE	9	10	disease progression
NCT0019477923	NCT00194779_23_T0	GENE	1	1	III
NCT0019477923	NCT00194779_23_T1	COMPOUND	35	35	methotrexate
NCT0019477923	NCT00194779_23_T2	GENE	19	19	cm
NCT0019477923	NCT00194779_23_T3	COMPOUND	45	45	tartrate
NCT0019477923	NCT00194779_23_T4	GENE	36	36	IV
NCT0019477923	NCT00194779_23_T5	GENE	46	46	IV
NCT0019477923	NCT00194779_23_T6	COMPOUND	44	44	vinorelbine
NCT0019477923	NCT00194779_23_T7	COMPOUND	27	27	capecitabine
NCT0019477923	NCT00194779_23_T8	GENE	13	13	has
NCT0019477923	NCT00194779_23_T9	GENE	31	31	BID
NCT0019477924	NCT00194779_24_T0	PHENOTYPE	16	16	toxicity
NCT0019477924	NCT00194779_24_T1	PHENOTYPE	12	13	disease progression
NCT0019477925	NCT00194779_25_T0	GENE	24	24	II
NCT0019477925	NCT00194779_25_T1	GENE	8	8	IV
NCT0019477926	NCT00194779_26_T0	GENE	15	15	OR
NCT0019477926	NCT00194779_26_T1	GENE	30	30	III
NCT0019477926	NCT00194779_26_T2	COMPOUND	8	8	tamoxifen
NCT0019477926	NCT00194779_26_T3	COMPOUND	20	20	tamoxifen
NCT0019477926	NCT00194779_26_T4	GENE	3	3	hormone
NCT001947922	NCT00194792_2_T0	COMPOUND	16	16	estrogen
NCT001947922	NCT00194792_2_T1	COMPOUND	3	3	exemestane
NCT001947922	NCT00194792_2_T2	COMPOUND	5	6	triptorelin pamoate
NCT001947922	NCT00194792_2_T3	PHENOTYPE	9	10	breast cancer
NCT001947924	NCT00194792_4_T0	PHENOTYPE	12	12	tumor
NCT001947924	NCT00194792_4_T1	GENE	1	1	hormone
NCT001947926	NCT00194792_6_T0	PHENOTYPE	10	11	breast cancer
NCT001947928	NCT00194792_8_T0	PHENOTYPE	11	12	breast cancer
NCT0019479210	NCT00194792_10_T0	PHENOTYPE	3	3	toxicity
NCT0019479214	NCT00194792_14_T0	PHENOTYPE	6	7	breast cancer
NCT0019479216	NCT00194792_16_T0	PHENOTYPE	6	7	breast tumors
NCT0019479217	NCT00194792_17_T0	COMPOUND	5	5	exemestane
NCT0019479218	NCT00194792_18_T0	COMPOUND	20	20	exemestane
NCT0019479218	NCT00194792_18_T1	PHENOTYPE	18	18	initiation
NCT0019479218	NCT00194792_18_T2	GENE	7	7	IM
NCT0019479218	NCT00194792_18_T3	COMPOUND	4	5	triptorelin pamoate
NCT0019479219	NCT00194792_19_T0	COMPOUND	17	17	vinorelbine
NCT0019479219	NCT00194792_19_T1	COMPOUND	4	4	capecitabine
NCT0019479219	NCT00194792_19_T2	COMPOUND	18	18	ditartrate
NCT0019479219	NCT00194792_19_T3	COMPOUND	13	13	methotrexate
NCT0019479219	NCT00194792_19_T4	GENE	8	8	BID
NCT0019479219	NCT00194792_19_T5	GENE	15	15	IV
NCT0019479219	NCT00194792_19_T6	GENE	19	19	IV
NCT0019479222	NCT00194792_22_T0	COMPOUND	30	30	methotrexate
NCT0019479222	NCT00194792_22_T1	GENE	17	17	cm
NCT0019479222	NCT00194792_22_T2	GENE	31	31	IV
NCT0019479222	NCT00194792_22_T3	GENE	35	35	IV
NCT0019479222	NCT00194792_22_T4	COMPOUND	33	33	vinorelbine
NCT0019479222	NCT00194792_22_T5	COMPOUND	23	23	capecitabine
NCT0019479222	NCT00194792_22_T6	COMPOUND	34	34	ditartrate
NCT0019479222	NCT00194792_22_T7	GENE	11	11	has
NCT0019479222	NCT00194792_22_T8	GENE	25	25	BID
NCT0019479224	NCT00194792_24_T0	COMPOUND	11	11	paclitaxel
NCT0019479224	NCT00194792_24_T1	GENE	12	12	IV
NCT0019479226	NCT00194792_26_T0	PHENOTYPE	10	10	toxicity
NCT0019479226	NCT00194792_26_T1	PHENOTYPE	6	7	disease progression
NCT001948050	NCT00194805_0_T0	PHENOTYPE	2	2	Diabetes
NCT0019480511	NCT00194805_11_T0	PHENOTYPE	16	16	prick
NCT0019480526	NCT00194805_26_T0	GENE	9	9	chat
NCT0019480528	NCT00194805_28_T0	ORGAN	46	46	feet
NCT0019480528	NCT00194805_28_T1	GENE	38	38	log
NCT001948183	NCT00194818_3_T0	GENE	5	5	BID
NCT001948183	NCT00194818_3_T1	GENE	6	6	4-8
NCT001948183	NCT00194818_3_T2	GENE	12	12	4-8
NCT001948183	NCT00194818_3_T3	GENE	11	11	TID
NCT001948185	NCT00194818_5_T0	PHENOTYPE	7	8	ulcerative colitis
NCT001948186	NCT00194818_6_T0	PHENOTYPE	16	17	Ulcerative colitis
NCT001948188	NCT00194818_8_T0	GENE	3	3	0.32
NCT0019481810	NCT00194818_10_T0	PHENOTYPE	11	11	colitis
NCT0019481811	NCT00194818_11_T0	PHENOTYPE	21	21	infections
NCT0019481813	NCT00194818_13_T0	GENE	25	25	bowel
NCT0019481813	NCT00194818_13_T1	PHENOTYPE	30	30	symptoms
NCT0019481813	NCT00194818_13_T2	PHENOTYPE	0	2	Quality of life
NCT0019481813	NCT00194818_13_T3	PHENOTYPE	13	15	Inflammatory Bowel Disease
NCT0019481813	NCT00194818_13_T4	PHENOTYPE	50	52	quality of life
NCT0019481814	NCT00194818_14_T0	PHENOTYPE	4	5	in remission
NCT0019481815	NCT00194818_15_T0	GENE	15	15	BID
NCT0019481815	NCT00194818_15_T1	GENE	16	16	4-8
NCT0019481816	NCT00194818_16_T0	GENE	14	14	4-8
NCT0019481816	NCT00194818_16_T1	GENE	13	13	TID
NCT0019481821	NCT00194818_21_T0	PHENOTYPE	28	28	inflammation
NCT0019481821	NCT00194818_21_T1	GENE	21	21	lactoferrin
NCT0019481821	NCT00194818_21_T2	ORGAN	31	31	colon
NCT0019481823	NCT00194818_23_T0	PHENOTYPE	35	35	symptoms
NCT0019481824	NCT00194818_24_T0	PHENOTYPE	11	11	remission
NCT0019481825	NCT00194818_25_T0	PHENOTYPE	3	3	remission
NCT0019481825	NCT00194818_25_T1	GENE	13	13	had
NCT0019481829	NCT00194818_29_T0	PHENOTYPE	1	1	secondary
NCT0019481829	NCT00194818_29_T1	PHENOTYPE	7	9	Inflammatory Bowel Disease
NCT0019481836	NCT00194818_36_T0	PHENOTYPE	16	17	adverse events
NCT0019481838	NCT00194818_38_T0	PHENOTYPE	10	11	adverse events
NCT0019481839	NCT00194818_39_T0	GENE	23	23	midway
NCT001948441	NCT00194844_1_T0	PHENOTYPE	12	12	Miscarriage
NCT001948448	NCT00194844_8_T0	PHENOTYPE	25	26	emotional health
NCT0019484410	NCT00194844_10_T0	PHENOTYPE	11	11	Miscarriage
NCT0019484413	NCT00194844_13_T0	GENE	3	3	41
NCT0019484414	NCT00194844_14_T0	GENE	16	16	116
NCT0019484414	NCT00194844_14_T1	PHENOTYPE	14	14	Miscarriage
NCT0019484415	NCT00194844_15_T0	GENE	42	42	115
NCT0019484415	NCT00194844_15_T1	PHENOTYPE	41	41	miscarriage
NCT0019484415	NCT00194844_15_T2	GENE	15	15	MCP
NCT0019484415	NCT00194844_15_T3	PHENOTYPE	12	12	Miscarriage
NCT0019484416	NCT00194844_16_T0	PHENOTYPE	6	6	miscarriage
NCT0019484416	NCT00194844_16_T1	GENE	9	9	has
NCT0019484416	NCT00194844_16_T2	GENE	1	1	MCP
NCT0019484416	NCT00194844_16_T3	PHENOTYPE	14	15	mental health
NCT0019484418	NCT00194844_18_T0	PHENOTYPE	40	40	grieving
NCT0019484418	NCT00194844_18_T1	PHENOTYPE	14	14	miscarriage
NCT0019484418	NCT00194844_18_T2	PHENOTYPE	34	34	miscarriage
NCT0019484418	NCT00194844_18_T3	GENE	16	16	has
NCT0019484420	NCT00194844_20_T0	PHENOTYPE	41	41	miscarriage
NCT0019484423	NCT00194844_23_T0	GENE	26	26	B-1
NCT0019484423	NCT00194844_23_T1	PHENOTYPE	15	15	Miscarriage
NCT0019484426	NCT00194844_26_T0	GENE	11	12	group I
NCT0019484428	NCT00194844_28_T0	GENE	1	1	IV
NCT0019484430	NCT00194844_30_T0	PHENOTYPE	33	33	miscarriage
NCT0019484437	NCT00194844_37_T0	PHENOTYPE	1	1	associations
NCT001948573	NCT00194857_3_T0	COMPOUND	24	24	ribavirin
NCT001948573	NCT00194857_3_T1	PHENOTYPE	19	19	initiation
NCT001948573	NCT00194857_3_T2	PHENOTYPE	15	15	neutropenia
NCT001948573	NCT00194857_3_T3	GENE	22	22	interferon
NCT001948573	NCT00194857_3_T4	PHENOTYPE	13	13	anemia
NCT001948701	NCT00194870_1_T0	PHENOTYPE	27	27	seizure
NCT001948701	NCT00194870_1_T1	GENE	18	18	DBS
NCT001948703	NCT00194870_3_T0	PHENOTYPE	11	11	epilepsy
NCT001948703	NCT00194870_3_T1	PHENOTYPE	24	24	epilepsy
NCT001948703	NCT00194870_3_T2	GENE	26	26	1.2
NCT001948703	NCT00194870_3_T3	ORGAN	9	9	thalamus
NCT001948703	NCT00194870_3_T4	PHENOTYPE	29	30	recurrent seizures
NCT001948704	NCT00194870_4_T0	PHENOTYPE	11	11	seizure
NCT001948704	NCT00194870_4_T1	ORGAN	26	27	vagus nerve
NCT001948705	NCT00194870_5_T0	PHENOTYPE	12	12	seizures
NCT001948706	NCT00194870_6_T0	GENE	6	6	DBS
NCT001948707	NCT00194870_7_T0	PHENOTYPE	10	10	epilepsy
NCT001948707	NCT00194870_7_T1	GENE	7	7	DBS
NCT001948707	NCT00194870_7_T2	GENE	13	13	DBS
NCT001948707	NCT00194870_7_T3	PHENOTYPE	23	23	seizures
NCT001948708	NCT00194870_8_T0	PHENOTYPE	17	17	seizures
NCT001948708	NCT00194870_8_T1	GENE	10	10	has
NCT0019487011	NCT00194870_11_T0	PHENOTYPE	7	7	epilepsy
NCT0019487011	NCT00194870_11_T1	GENE	17	17	AN
NCT0019487011	NCT00194870_11_T2	ORGAN	20	20	thalamus
NCT0019487012	NCT00194870_12_T0	PHENOTYPE	10	10	seizure
NCT0019487012	NCT00194870_12_T1	GENE	6	6	AN
NCT0019487013	NCT00194870_13_T0	PHENOTYPE	13	13	seizure
NCT0019487013	NCT00194870_13_T1	GENE	6	6	had
NCT0019487014	NCT00194870_14_T0	PHENOTYPE	6	6	seizures
NCT0019487014	NCT00194870_14_T1	GENE	5	5	had
NCT0019487014	NCT00194870_14_T2	ORGAN	14	15	frontal lobes
NCT0019487015	NCT00194870_15_T0	PHENOTYPE	14	14	seizure
NCT0019487015	NCT00194870_15_T1	GENE	8	8	had
NCT0019487016	NCT00194870_16_T0	PHENOTYPE	24	24	seizures
NCT0019487016	NCT00194870_16_T1	GENE	1	1	AN
NCT0019487016	NCT00194870_16_T2	ORGAN	13	14	limbic system
NCT0019487017	NCT00194870_17_T0	PHENOTYPE	6	6	epilepsy
NCT0019487017	NCT00194870_17_T1	PHENOTYPE	27	27	epilepsy
NCT0019487017	NCT00194870_17_T2	GENE	35	35	1.3
NCT0019487017	NCT00194870_17_T3	GENE	9	9	CM
NCT0019487017	NCT00194870_17_T4	GENE	22	22	CM
NCT0019487017	NCT00194870_17_T5	GENE	34	34	al
NCT0019487017	NCT00194870_17_T6	GENE	28	28	has
NCT0019487017	NCT00194870_17_T7	GENE	33	33	et
NCT0019487017	NCT00194870_17_T8	ORGAN	7	8	centromedian nucleus
NCT0019487017	NCT00194870_17_T9	ORGAN	20	21	centromedian nucleus
NCT0019487018	NCT00194870_18_T0	PHENOTYPE	12	14	generalized tonic-clonic seizures
NCT0019487020	NCT00194870_20_T0	PHENOTYPE	15	17	partial complex seizures
NCT0019487020	NCT00194870_20_T1	PHENOTYPE	7	9	generalized tonic-clonic seizures
NCT0019487022	NCT00194870_22_T0	GENE	13	13	CM
NCT0019487022	NCT00194870_22_T1	PHENOTYPE	25	25	secondary
NCT0019487022	NCT00194870_22_T2	PHENOTYPE	33	33	secondary
NCT0019487022	NCT00194870_22_T3	PHENOTYPE	22	22	focal
NCT0019487022	NCT00194870_22_T4	PHENOTYPE	26	27	generalized seizures
NCT0019487022	NCT00194870_22_T5	PHENOTYPE	34	35	generalized seizures
NCT0019487022	NCT00194870_22_T6	PHENOTYPE	17	19	generalized tonic-clonic seizures
NCT0019487022	NCT00194870_22_T7	PHENOTYPE	43	45	atypical absence seizures
NCT0019487022	NCT00194870_22_T8	PHENOTYPE	39	41	generalized tonic seizures
NCT0019487023	NCT00194870_23_T0	PHENOTYPE	11	11	seizure
NCT0019487023	NCT00194870_23_T1	PHENOTYPE	19	21	partial motor seizures
NCT0019487024	NCT00194870_24_T0	PHENOTYPE	9	11	complex partial seizures
NCT0019487024	NCT00194870_24_T1	PHENOTYPE	13	15	generalized tonic seizures
NCT0019487025	NCT00194870_25_T0	PHENOTYPE	13	13	seizure
NCT0019487025	NCT00194870_25_T1	PHENOTYPE	19	19	seizure
NCT0019487025	NCT00194870_25_T2	GENE	6	6	had
NCT0019487026	NCT00194870_26_T0	GENE	11	11	al
NCT0019487026	NCT00194870_26_T1	GENE	10	10	et
NCT0019487027	NCT00194870_27_T0	GENE	16	16	CM
NCT0019487027	NCT00194870_27_T1	GENE	5	5	al
NCT0019487027	NCT00194870_27_T2	GENE	4	4	et
NCT0019487028	NCT00194870_28_T0	GENE	2	2	had
NCT0019487029	NCT00194870_29_T0	GENE	1	1	CM
NCT0019487029	NCT00194870_29_T1	GENE	6	6	AN
NCT0019487030	NCT00194870_30_T0	PHENOTYPE	6	6	epilepsy
NCT0019487030	NCT00194870_30_T1	PHENOTYPE	0	0	Electroencephalograms
NCT0019487030	NCT00194870_30_T2	PHENOTYPE	8	8	electroencephalogram
NCT0019487032	NCT00194870_32_T0	PHENOTYPE	10	10	epilepsy
NCT0019487033	NCT00194870_33_T0	PHENOTYPE	9	9	epilepsy
NCT0019487034	NCT00194870_34_T0	GENE	15	15	1.3
NCT0019487034	NCT00194870_34_T1	GENE	4	4	CM
NCT0019487034	NCT00194870_34_T2	GENE	9	9	has
NCT0019487034	NCT00194870_34_T3	ORGAN	8	8	thalamus
NCT0019487035	NCT00194870_35_T0	PHENOTYPE	10	10	epilepsy
NCT0019487035	NCT00194870_35_T1	GENE	13	13	AN
NCT0019487038	NCT00194870_38_T0	ORGAN	9	9	scalp
NCT0019487041	NCT00194870_41_T0	PHENOTYPE	11	11	epilepsy
NCT0019487046	NCT00194870_46_T0	GENE	13	13	DBS
NCT0019487050	NCT00194870_50_T0	PHENOTYPE	18	18	epilepsy
NCT0019487050	NCT00194870_50_T1	GENE	16	16	DBS
NCT0019487050	NCT00194870_50_T2	PHENOTYPE	12	14	mechanism of action
NCT0019487051	NCT00194870_51_T0	GENE	12	12	DBS
NCT001948835	NCT00194883_5_T0	PHENOTYPE	15	15	secondary
NCT001948835	NCT00194883_5_T1	GENE	4	4	GH
NCT001948835	NCT00194883_5_T2	GENE	10	10	IGF-I
NCT001948835	NCT00194883_5_T3	GENE	13	13	reduced
NCT001948835	NCT00194883_5_T4	GENE	20	20	axis
NCT0019488315	NCT00194883_15_T0	GENE	17	17	osteocalcin
NCT0019488315	NCT00194883_15_T1	BIOLOGICAL_PROCESS	14	14	metabolism
NCT0019488315	NCT00194883_15_T2	GENE	20	21	alkaline phosphatase
NCT0019488316	NCT00194883_16_T0	GENE	8	8	IGFBP-1
NCT0019488316	NCT00194883_16_T1	GENE	11	11	GH
NCT0019488316	NCT00194883_16_T2	GENE	4	4	IGF-II
NCT0019488316	NCT00194883_16_T3	GENE	3	3	IGF-I
NCT0019488316	NCT00194883_16_T4	ORGAN	0	0	Serum
NCT0019488316	NCT00194883_16_T5	PHENOTYPE	7	7	fragmented
NCT0019488316	NCT00194883_16_T6	MOLECULAR_FUNCTION	13	14	GH activity
NCT001948960	NCT00194896_0_T0	PHENOTYPE	3	5	Type 1.5 Diabetes
NCT0019489617	NCT00194896_17_T0	COMPOUND	6	6	rosiglitazone
NCT0019489620	NCT00194896_20_T0	COMPOUND	11	11	acarbose
NCT0019489620	NCT00194896_20_T1	COMPOUND	8	8	metformin
NCT0019489620	NCT00194896_20_T2	GENE	7	7	had
NCT0019489624	NCT00194896_24_T0	COMPOUND	15	15	metformin
NCT0019489624	NCT00194896_24_T1	COMPOUND	13	13	rosiglitazone
NCT0019489625	NCT00194896_25_T0	COMPOUND	2	2	acarbose
NCT0019489626	NCT00194896_26_T0	PHENOTYPE	1	1	initiation
NCT001949091	NCT00194909_1_T0	COMPOUND	11	11	sildenafil
NCT001949098	NCT00194909_8_T0	PHENOTYPE	0	0	Secondary
NCT001949098	NCT00194909_8_T1	GENE	14	14	VAS
NCT001949098	NCT00194909_8_T2	PHENOTYPE	6	8	quality of life
NCT001949099	NCT00194909_9_T0	COMPOUND	11	11	sildenafil
NCT0019490917	NCT00194909_17_T0	PHENOTYPE	0	0	Secondary
NCT0019490917	NCT00194909_17_T1	GENE	14	14	VAS
NCT0019490917	NCT00194909_17_T2	PHENOTYPE	6	8	quality of life
NCT0019490918	NCT00194909_18_T0	COMPOUND	11	11	sildenafil
NCT0019490927	NCT00194909_27_T0	GENE	12	12	VAS
NCT001949220	NCT00194922_0_T0	COMPOUND	7	7	Probiotic
NCT001949225	NCT00194922_5_T0	PHENOTYPE	14	14	constipation
NCT001949225	NCT00194922_5_T1	PHENOTYPE	16	16	diarrhea
NCT001949225	NCT00194922_5_T2	PHENOTYPE	19	20	abdominal discomfort
NCT001949226	NCT00194922_6_T0	PHENOTYPE	20	20	symptoms
NCT001949226	NCT00194922_6_T1	PHENOTYPE	22	22	IBS
NCT001949227	NCT00194922_7_T0	ORGAN	2	2	intestine
NCT001949227	NCT00194922_7_T1	ORGAN	33	34	gastrointestinal tract
NCT0019492212	NCT00194922_12_T0	PHENOTYPE	28	28	diarrhea
NCT0019492212	NCT00194922_12_T1	PHENOTYPE	18	18	IBS
NCT0019492212	NCT00194922_12_T2	PHENOTYPE	22	23	ulcerative colitis
NCT0019492212	NCT00194922_12_T3	PHENOTYPE	19	21	inflammatory bowel disease
NCT0019492222	NCT00194922_22_T0	GENE	3	3	T4
NCT0019492222	NCT00194922_22_T1	PHENOTYPE	2	2	hypothyroidism
NCT0019492222	NCT00194922_22_T2	PHENOTYPE	0	0	Hyperthyroidism
NCT0019492222	NCT00194922_22_T3	GENE	5	5	TSH
NCT001949352	NCT00194935_2_T0	COMPOUND	15	15	topotecan
NCT001949353	NCT00194935_3_T0	PHENOTYPE	4	4	toxicity
NCT001949353	NCT00194935_3_T1	COMPOUND	16	16	topotecan
NCT001949482	NCT00194948_2_T0	COMPOUND	14	14	escitalopram
NCT001949483	NCT00194948_3_T0	PHENOTYPE	21	21	remission
NCT0019496116	NCT00194961_16_T0	PHENOTYPE	33	33	progression
NCT0019496116	NCT00194961_16_T1	PHENOTYPE	37	38	renal disease
NCT0019496116	NCT00194961_16_T2	PHENOTYPE	25	28	slipped capital femoral epiphyses
NCT0019496121	NCT00194961_21_T0	PHENOTYPE	14	14	Center
NCT0019496123	NCT00194961_23_T0	PHENOTYPE	6	6	Hgb
NCT0019496123	NCT00194961_23_T1	COMPOUND	9	9	creatinine
NCT0019496123	NCT00194961_23_T2	ORGAN	10	10	liver
NCT0019496123	NCT00194961_23_T3	GENE	14	14	albumin
NCT0019496123	NCT00194961_23_T4	GENE	7	7	Hct
NCT0019496128	NCT00194961_28_T0	GENE	13	13	IL-1b
NCT0019496128	NCT00194961_28_T1	GENE	3	3	IL-1
NCT0019496128	NCT00194961_28_T2	PHENOTYPE	20	20	circulation
NCT0019496132	NCT00194961_32_T0	COMPOUND	3	3	DXA
NCT0019496138	NCT00194961_38_T0	COMPOUND	10	10	sodium
NCT0019496138	NCT00194961_38_T1	COMPOUND	12	12	citrate
NCT0019496138	NCT00194961_38_T2	COMPOUND	8	8	calcium
NCT0019496138	NCT00194961_38_T3	COMPOUND	15	15	calcitriol
NCT0019496138	NCT00194961_38_T4	COMPOUND	13	13	phosphate
NCT0019496138	NCT00194961_38_T5	GENE	7	7	erythropoietin
NCT0019496139	NCT00194961_39_T0	GENE	3	3	Time
NCT0019496140	NCT00194961_40_T0	GENE	19	19	insulin
NCT0019496140	NCT00194961_40_T1	PHENOTYPE	17	17	GTT
NCT0019496140	NCT00194961_40_T2	GENE	22	22	axis
NCT0019496140	NCT00194961_40_T3	GENE	26	26	leptin
NCT0019496140	NCT00194961_40_T4	COMPOUND	6	6	creatinine
NCT0019496140	NCT00194961_40_T5	GENE	12	12	GFR
NCT0019496140	NCT00194961_40_T6	COMPOUND	34	34	3
NCT0019496140	NCT00194961_40_T7	BIOLOGICAL_PROCESS	9	10	glomerular filtration
NCT0019496140	NCT00194961_40_T8	PHENOTYPE	14	15	Glucose Tolerance
NCT0019496141	NCT00194961_41_T0	COMPOUND	20	20	DXA
NCT001949742	NCT00194974_2_T0	PHENOTYPE	22	22	preeclampsia
NCT001949743	NCT00194974_3_T0	PHENOTYPE	25	25	complication
NCT001949743	NCT00194974_3_T1	PHENOTYPE	11	11	preeclampsia
NCT001949743	NCT00194974_3_T2	PHENOTYPE	16	18	high blood pressure
NCT001949744	NCT00194974_4_T0	PHENOTYPE	23	23	preeclampsia
NCT001949744	NCT00194974_4_T1	GENE	13	13	20
NCT001949745	NCT00194974_5_T0	PHENOTYPE	23	24	kidney disease
NCT001949745	NCT00194974_5_T1	PHENOTYPE	19	21	high blood pressure
NCT001949746	NCT00194974_6_T0	GENE	2	2	BP
NCT001949749	NCT00194974_9_T0	PHENOTYPE	10	10	strategies
NCT001949749	NCT00194974_9_T1	GENE	16	16	BP
NCT0019497410	NCT00194974_10_T0	GENE	7	7	BP
NCT0019497410	NCT00194974_10_T1	GENE	11	11	BP
NCT0019497410	NCT00194974_10_T2	GENE	27	27	BP
NCT0019497410	NCT00194974_10_T3	GENE	14	14	Hg
NCT0019497411	NCT00194974_11_T0	PHENOTYPE	13	13	preeclampsia
NCT0019497412	NCT00194974_12_T0	PHENOTYPE	4	4	preeclampsia
NCT0019497414	NCT00194974_14_T0	PHENOTYPE	3	3	chronic
NCT0019497414	NCT00194974_14_T1	PHENOTYPE	4	4	hypertension
NCT0019497416	NCT00194974_16_T0	PHENOTYPE	6	6	recruitment
NCT0019497416	NCT00194974_16_T1	BIOLOGICAL_PROCESS	11	11	gestation
NCT0019497416	NCT00194974_16_T2	GENE	9	9	6/7
NCT0019497419	NCT00194974_19_T0	GENE	23	23	90
NCT0019497419	NCT00194974_19_T1	GENE	19	19	140
NCT0019497419	NCT00194974_19_T2	GENE	17	17	Hg
NCT0019497419	NCT00194974_19_T3	GENE	21	21	Hg
NCT0019497419	NCT00194974_19_T4	GENE	25	25	Hg
NCT0019497422	NCT00194974_22_T0	GENE	20	20	DBP
NCT0019497422	NCT00194974_22_T1	GENE	21	21	90
NCT0019497422	NCT00194974_22_T2	PHENOTYPE	16	17	hypertension diastolic
NCT0019497423	NCT00194974_23_T0	COMPOUND	14	14	creatinine
NCT0019497423	NCT00194974_23_T1	ORGAN	13	13	serum
NCT0019497424	NCT00194974_24_T0	GENE	3	3	has
NCT0019497428	NCT00194974_28_T0	GENE	1	1	500
NCT0019497428	NCT00194974_28_T1	PHENOTYPE	0	0	Proteinuria
NCT0019497429	NCT00194974_29_T0	PHENOTYPE	0	2	Left ventricular hypertrophy
NCT0019497432	NCT00194974_32_T0	GENE	0	0	NB
NCT0019497439	NCT00194974_39_T0	PHENOTYPE	23	23	blocked
NCT0019497439	NCT00194974_39_T1	PHENOTYPE	26	26	blocks
NCT0019497439	NCT00194974_39_T2	GENE	14	14	Hg
NCT0019497439	NCT00194974_39_T3	GENE	18	18	Hg
NCT0019497440	NCT00194974_40_T0	PHENOTYPE	12	12	hypertension
NCT0019497449	NCT00194974_49_T0	GENE	10	10	has
NCT0019497453	NCT00194974_53_T0	PHENOTYPE	8	8	edema
NCT0019497453	NCT00194974_53_T1	PHENOTYPE	3	3	pulse
NCT0019497453	NCT00194974_53_T2	MOLECULAR_FUNCTION	10	11	urinary protein
NCT0019497456	NCT00194974_56_T0	COMPOUND	8	8	nifedipine
NCT0019497456	NCT00194974_56_T1	COMPOUND	9	9	hydralazine
NCT0019497456	NCT00194974_56_T2	COMPOUND	11	11	clonidine
NCT0019497456	NCT00194974_56_T3	COMPOUND	4	4	methyldopa
NCT0019497461	NCT00194974_61_T0	ORGAN	16	16	plasma
NCT0019497461	NCT00194974_61_T1	COMPOUND	13	14	uric acid
NCT0019497461	NCT00194974_61_T2	MOLECULAR_FUNCTION	17	18	renin activity
NCT0019497463	NCT00194974_63_T0	GENE	15	15	BP
NCT0019497464	NCT00194974_64_T0	GENE	9	9	Hg
NCT0019497464	NCT00194974_64_T1	GENE	13	13	Hg
NCT0019497468	NCT00194974_68_T0	GENE	20	20	BP
NCT0019497469	NCT00194974_69_T0	PHENOTYPE	0	0	Secondary
NCT0019497470	NCT00194974_70_T0	PHENOTYPE	4	4	preeclampsia
NCT0019497475	NCT00194974_75_T0	PHENOTYPE	10	10	hypotension
NCT0019497475	NCT00194974_75_T1	PHENOTYPE	2	2	complications
NCT0019497475	NCT00194974_75_T2	PHENOTYPE	14	14	complications
NCT0019497475	NCT00194974_75_T3	PHENOTYPE	16	16	eclampsia
NCT0019497475	NCT00194974_75_T4	PHENOTYPE	11	11	bradycardia
NCT0019497475	NCT00194974_75_T5	PHENOTYPE	8	9	intraventricular hemorrhage
NCT0019497475	NCT00194974_75_T6	PHENOTYPE	4	5	neonatal death
NCT0019497475	NCT00194974_75_T7	PHENOTYPE	20	21	organ failure
NCT0019497475	NCT00194974_75_T8	PHENOTYPE	6	7	respiratory distress
NCT0019497476	NCT00194974_76_T0	PHENOTYPE	3	3	hypertension
NCT0019497478	NCT00194974_78_T0	PHENOTYPE	6	6	recruitment
NCT0019497478	NCT00194974_78_T1	BIOLOGICAL_PROCESS	11	11	gestation
NCT0019497478	NCT00194974_78_T2	GENE	9	9	6/7
NCT0019497481	NCT00194974_81_T0	GENE	23	23	90
NCT0019497481	NCT00194974_81_T1	GENE	19	19	140
NCT0019497481	NCT00194974_81_T2	GENE	17	17	Hg
NCT0019497481	NCT00194974_81_T3	GENE	21	21	Hg
NCT0019497481	NCT00194974_81_T4	GENE	25	25	Hg
NCT0019497484	NCT00194974_84_T0	GENE	17	17	DBP
NCT0019497484	NCT00194974_84_T1	GENE	18	18	90
NCT0019497484	NCT00194974_84_T2	PHENOTYPE	16	16	hypertension
NCT0019497485	NCT00194974_85_T0	COMPOUND	14	14	creatinine
NCT0019497485	NCT00194974_85_T1	ORGAN	13	13	serum
NCT0019497486	NCT00194974_86_T0	GENE	3	3	has
NCT0019497490	NCT00194974_90_T0	GENE	1	1	500
NCT0019497490	NCT00194974_90_T1	PHENOTYPE	0	0	Proteinuria
NCT0019497491	NCT00194974_91_T0	PHENOTYPE	0	2	Left ventricular hypertrophy
NCT001950139	NCT00195013_9_T0	GENE	11	11	II
NCT001950139	NCT00195013_9_T1	GENE	12	12	III
NCT001950139	NCT00195013_9_T2	GENE	14	14	IV
NCT001950139	NCT00195013_9_T3	PHENOTYPE	7	8	breast cancer
NCT001950139	NCT00195013_9_T4	PHENOTYPE	17	18	solid tumors
NCT0019501311	NCT00195013_11_T0	COMPOUND	13	13	paclitaxel
NCT0019501311	NCT00195013_11_T1	ORGAN	27	27	Appendix
NCT0019501311	NCT00195013_11_T2	PHENOTYPE	24	25	peripheral neuropathy
NCT0019501311	NCT00195013_11_T3	COMPOUND	4	5	weekly paclitaxel
NCT0019501315	NCT00195013_15_T0	COMPOUND	3	3	1
NCT0019501327	NCT00195013_27_T0	PHENOTYPE	5	5	neuropathies
NCT0019501330	NCT00195013_30_T0	PHENOTYPE	22	22	progressive
NCT0019501330	NCT00195013_30_T1	PHENOTYPE	24	24	dysfunction
NCT0019501330	NCT00195013_30_T2	PHENOTYPE	3	4	brain metastases
NCT0019501330	NCT00195013_30_T3	PHENOTYPE	34	35	adverse events
NCT0019501334	NCT00195013_34_T0	COMPOUND	10	10	paclitaxel
NCT001950261	NCT00195026_1_T0	GENE	10	10	Corp
NCT001950261	NCT00195026_1_T1	GENE	12	12	has
NCT001950262	NCT00195026_2_T0	PHENOTYPE	13	14	breast cancer
NCT001950264	NCT00195026_4_T0	GENE	12	12	Corp
NCT001950264	NCT00195026_4_T1	GENE	14	14	has
NCT001950265	NCT00195026_5_T0	PHENOTYPE	13	14	breast cancer
NCT001950265	NCT00195026_5_T1	PHENOTYPE	24	25	breast cancer
NCT001950267	NCT00195026_7_T0	PHENOTYPE	5	6	breast cancer
NCT0019502611	NCT00195026_11_T0	PHENOTYPE	4	4	fed
NCT0019502612	NCT00195026_12_T0	ORGAN	9	9	breasts
NCT0019502613	NCT00195026_13_T0	ORGAN	10	10	breasts
NCT0019502622	NCT00195026_22_T0	PHENOTYPE	19	19	localize
NCT0019502623	NCT00195026_23_T0	PHENOTYPE	8	8	pathology
NCT0019502624	NCT00195026_24_T0	PHENOTYPE	15	16	atypical hyperplasia
NCT0019502624	NCT00195026_24_T1	PHENOTYPE	12	13	breast cancer
NCT0019502625	NCT00195026_25_T0	PHENOTYPE	7	7	pathology
NCT0019502626	NCT00195026_26_T0	PHENOTYPE	15	16	breast cancer
NCT0019502629	NCT00195026_29_T0	GENE	19	19	4.5
NCT0019502638	NCT00195026_38_T0	PHENOTYPE	16	17	breast cancer
NCT0019502639	NCT00195026_39_T0	PHENOTYPE	10	11	breast cancer
NCT0019502640	NCT00195026_40_T0	PHENOTYPE	15	16	occult cancer
NCT0019502641	NCT00195026_41_T0	GENE	4	4	has
NCT0019502642	NCT00195026_42_T0	PHENOTYPE	16	16	cancers
NCT001950392	NCT00195039_2_T0	GENE	7	7	IV
NCT001950524	NCT00195052_4_T0	PHENOTYPE	6	6	epilepsy
NCT001950524	NCT00195052_4_T1	PHENOTYPE	16	16	seizures
NCT001950524	NCT00195052_4_T2	ORGAN	26	26	neocortex
NCT001950524	NCT00195052_4_T3	ORGAN	21	22	temporal lobe
NCT001950525	NCT00195052_5_T0	PHENOTYPE	4	4	epilepsy
NCT001950525	NCT00195052_5_T1	CELL	10	10	neurons
NCT001950526	NCT00195052_6_T0	PHENOTYPE	33	33	epilepsy
NCT001950526	NCT00195052_6_T1	PHENOTYPE	25	25	understood
NCT001950527	NCT00195052_7_T0	PHENOTYPE	10	10	epilepsy
NCT001950529	NCT00195052_9_T0	PHENOTYPE	13	13	epileptic
NCT0019505211	NCT00195052_11_T0	PHENOTYPE	7	7	epilepsy
NCT001950780	NCT00195078_0_T0	PHENOTYPE	11	14	Head and Neck Cancer
NCT001950783	NCT00195078_3_T0	COMPOUND	14	14	cisplatin
NCT001950786	NCT00195078_6_T0	GENE	4	4	II
NCT001950786	NCT00195078_6_T1	PHENOTYPE	11	12	measurable disease
NCT001950914	NCT00195091_4_T0	GENE	2	2	Cp
NCT001950917	NCT00195091_7_T0	GENE	0	0	BID
NCT001950917	NCT00195091_7_T1	COMPOUND	4	4	tetrathiomolybdate
NCT0019509118	NCT00195091_18_T0	GENE	4	4	had
NCT0019509120	NCT00195091_20_T0	ORGAN	26	26	transplant
NCT0019509120	NCT00195091_20_T1	ORGAN	36	36	transplant
NCT0019509120	NCT00195091_20_T2	PHENOTYPE	38	40	metastatic breast cancer
NCT0019509121	NCT00195091_21_T0	PHENOTYPE	14	15	breast cancer
NCT0019509125	NCT00195091_25_T0	GENE	4	4	had
NCT0019509125	NCT00195091_25_T1	PHENOTYPE	10	11	breast cancer
NCT0019509128	NCT00195091_28_T0	ORGAN	17	17	abdomen
NCT0019509128	NCT00195091_28_T1	ORGAN	19	19	pelvis
NCT0019509137	NCT00195091_37_T0	PHENOTYPE	20	20	peripheral
NCT0019509139	NCT00195091_39_T0	GENE	3	3	TM
NCT0019509144	NCT00195091_44_T0	GENE	3	3	had
NCT0019509146	NCT00195091_46_T0	PHENOTYPE	3	4	breast cancer
NCT0019509148	NCT00195091_48_T0	PHENOTYPE	0	1	Carcinomatous meningitis
NCT0019509148	NCT00195091_48_T1	PHENOTYPE	7	8	brain disease
NCT0019509150	NCT00195091_50_T0	COMPOUND	1	1	creatinine
NCT0019509150	NCT00195091_50_T1	GENE	2	2	1.5
NCT0019509150	NCT00195091_50_T2	ORGAN	0	0	Serum
NCT0019509152	NCT00195091_52_T0	GENE	14	14	TM
NCT0019509152	NCT00195091_52_T1	PHENOTYPE	2	3	allergic reactions
NCT0019509154	NCT00195091_54_T0	GENE	8	8	TM
NCT0019509154	NCT00195091_54_T1	GENE	9	9	has
NCT0019509154	NCT00195091_54_T2	PHENOTYPE	16	17	abortifacient effects
NCT001951177	NCT00195117_7_T0	PHENOTYPE	4	4	perceived
NCT001951177	NCT00195117_7_T1	GENE	11	11	log
NCT001951434	NCT00195143_4_T0	GENE	19	19	DBS
NCT001951436	NCT00195143_6_T0	PHENOTYPE	15	15	nightmares
NCT001951436	NCT00195143_6_T1	PHENOTYPE	13	13	dyskinesias
NCT001951436	NCT00195143_6_T2	PHENOTYPE	10	11	involuntary movements
NCT001951437	NCT00195143_7_T0	GENE	6	6	DBS
NCT001951437	NCT00195143_7_T1	GENE	25	25	STN
NCT001951437	NCT00195143_7_T2	PHENOTYPE	17	17	hyperactive
NCT001951437	NCT00195143_7_T3	ORGAN	23	24	subthalamic nucleus
NCT001951438	NCT00195143_8_T0	GENE	11	11	GABA
NCT001951438	NCT00195143_8_T1	GENE	3	3	STN
NCT001951439	NCT00195143_9_T0	PHENOTYPE	4	4	drives
NCT001951439	NCT00195143_9_T1	GENE	26	26	GABA
NCT001951439	NCT00195143_9_T2	GENE	25	25	reduced
NCT001951439	NCT00195143_9_T3	GENE	3	3	STN
NCT001951439	NCT00195143_9_T4	PHENOTYPE	20	20	hyperactive
NCT001951439	NCT00195143_9_T5	ORGAN	14	15	substantia nigra
NCT001951439	NCT00195143_9_T6	ORGAN	10	11	globus pallidus
NCT0019514311	NCT00195143_11_T0	PHENOTYPE	30	30	symptoms
NCT0019514311	NCT00195143_11_T1	PHENOTYPE	35	35	complications
NCT0019514311	NCT00195143_11_T2	GENE	39	39	DBS
NCT0019514311	NCT00195143_11_T3	ORGAN	19	19	thalamus
NCT0019514311	NCT00195143_11_T4	ORGAN	14	15	basal ganglia
NCT001951560	NCT00195156_0_T0	PHENOTYPE	11	11	Malignancies
NCT001951560	NCT00195156_0_T1	PHENOTYPE	9	10	Solid Tumor
NCT001951566	NCT00195156_6_T0	PHENOTYPE	8	8	toxicity
NCT001951566	NCT00195156_6_T1	GENE	9	9	DLT
NCT001951691	NCT00195169_1_T0	PHENOTYPE	3	3	secondary
NCT001951691	NCT00195169_1_T1	PHENOTYPE	0	0	Secondary
NCT001951692	NCT00195169_2_T0	PHENOTYPE	9	9	perceived
NCT001951696	NCT00195169_6_T0	PHENOTYPE	6	7	myocardial infarction
NCT001951698	NCT00195169_8_T0	PHENOTYPE	6	7	myocardial infarction
NCT0019516914	NCT00195169_14_T0	PHENOTYPE	7	7	perceived
NCT0019516916	NCT00195169_16_T0	PHENOTYPE	20	22	coronary artery disease
NCT0019516916	NCT00195169_16_T1	PHENOTYPE	14	16	quality of life
NCT001951821	NCT00195182_1_T0	PHENOTYPE	5	5	perceived
NCT001951823	NCT00195182_3_T0	PHENOTYPE	11	11	perceived
NCT001951823	NCT00195182_3_T1	PHENOTYPE	3	4	psychological stress
NCT0019518211	NCT00195182_11_T0	PHENOTYPE	7	7	hypertension
NCT0019518215	NCT00195182_15_T0	PHENOTYPE	11	11	perceived
NCT0019518217	NCT00195182_17_T0	PHENOTYPE	8	8	perceived
NCT0019518217	NCT00195182_17_T1	PHENOTYPE	22	22	self-efficacy
NCT0019518217	NCT00195182_17_T2	PHENOTYPE	19	20	psychological stress
NCT0019518219	NCT00195182_19_T0	PHENOTYPE	18	18	perceived
NCT0019518219	NCT00195182_19_T1	PHENOTYPE	14	14	hypertension
NCT0019518219	NCT00195182_19_T2	PHENOTYPE	16	17	depressive symptoms
NCT0019518220	NCT00195182_20_T0	PHENOTYPE	24	24	perceived
NCT0019518220	NCT00195182_20_T1	PHENOTYPE	16	16	hypertension
NCT0019518222	NCT00195182_22_T0	PHENOTYPE	10	10	perceived
NCT0019518228	NCT00195182_28_T0	PHENOTYPE	35	35	Hypertension
NCT0019518228	NCT00195182_28_T1	GENE	41	41	140
NCT0019518228	NCT00195182_28_T2	GENE	49	49	90
NCT0019518228	NCT00195182_28_T3	PHENOTYPE	7	7	hypertension
NCT0019518228	NCT00195182_28_T4	PHENOTYPE	11	11	hypertension
NCT0019518232	NCT00195182_32_T0	PHENOTYPE	7	7	blocks
NCT0019518232	NCT00195182_32_T1	PHENOTYPE	3	5	unable to walk
NCT001952080	NCT00195208_0_T0	PHENOTYPE	11	11	GERD
NCT001952080	NCT00195208_0_T1	PHENOTYPE	13	14	Erosive Esophagitis
NCT001952210	NCT00195221_0_T0	GENE	8	8	IX
NCT001952210	NCT00195221_0_T1	PHENOTYPE	4	5	Allergic Reactions
NCT001952210	NCT00195221_0_T2	PHENOTYPE	12	13	Hemophilia B
NCT001952212	NCT00195221_2_T0	GENE	27	27	II
NCT001952212	NCT00195221_2_T1	PHENOTYPE	9	9	hemophilia
NCT001952212	NCT00195221_2_T2	GENE	29	29	III
NCT001952212	NCT00195221_2_T3	GENE	39	39	FIX
NCT001952212	NCT00195221_2_T4	PHENOTYPE	11	11	centers
NCT001952212	NCT00195221_2_T5	PHENOTYPE	30	31	allergic reactions
NCT001952341	NCT00195234_1_T0	ORGAN	11	12	immune system
NCT001952470	NCT00195247_0_T0	PHENOTYPE	6	7	Solid Tumors
NCT001952600	NCT00195260_0_T0	PHENOTYPE	7	8	Solid Tumors
NCT001952603	NCT00195260_3_T0	GENE	8	8	GI
NCT001952603	NCT00195260_3_T1	PHENOTYPE	9	9	toxicities
NCT001952603	NCT00195260_3_T2	GENE	4	4	MTD
NCT001952860	NCT00195286_0_T0	PHENOTYPE	6	6	Infections
NCT001952992	NCT00195299_2_T0	COMPOUND	11	11	temsirolimus
NCT001953121	NCT00195312_1_T0	ORGAN	11	12	immune system
NCT001953250	NCT00195325_0_T0	PHENOTYPE	9	9	Tumors
NCT001953250	NCT00195325_0_T1	PHENOTYPE	6	7	Solid Tumors
NCT001953380	NCT00195338_0_T0	PHENOTYPE	7	8	Rheumatoid Arthritis
NCT001953511	NCT00195351_1_T0	PHENOTYPE	3	5	signs and symptoms
NCT001953903	NCT00195390_3_T0	PHENOTYPE	0	1	Adverse reactions
NCT001953903	NCT00195390_3_T1	PHENOTYPE	4	5	adverse reactions
NCT001953904	NCT00195390_4_T0	PHENOTYPE	2	3	adverse reactions
NCT001954032	NCT00195403_2_T0	PHENOTYPE	1	2	adverse reactions
NCT001954032	NCT00195403_2_T1	PHENOTYPE	5	6	adverse reactions
NCT001954033	NCT00195403_3_T0	PHENOTYPE	2	3	adverse reactions
NCT001954160	NCT00195416_0_T0	PHENOTYPE	5	6	Ankylosing Spondylitis
NCT001954163	NCT00195416_3_T0	PHENOTYPE	1	2	adverse reactions
NCT001954163	NCT00195416_3_T1	PHENOTYPE	5	6	adverse reactions
NCT001954164	NCT00195416_4_T0	PHENOTYPE	5	6	adverse reactions
NCT001954550	NCT00195455_0_T0	PHENOTYPE	5	5	Symptoms
NCT001955333	NCT00195533_3_T0	PHENOTYPE	12	12	centers
NCT001955852	NCT00195585_2_T0	PHENOTYPE	0	0	Secondary
NCT001955981	NCT00195598_1_T0	COMPOUND	14	14	venlafaxine
NCT001955981	NCT00195598_1_T1	COMPOUND	28	28	paroxetine
NCT001955981	NCT00195598_1_T2	GENE	15	15	extended
NCT001955981	NCT00195598_1_T3	PHENOTYPE	22	23	panic disorder
NCT001956241	NCT00195624_1_T0	CELL	22	22	platelets
NCT001956241	NCT00195624_1_T1	GENE	0	0	SAA
NCT001956241	NCT00195624_1_T2	GENE	13	13	stops
NCT001956241	NCT00195624_1_T3	PHENOTYPE	6	7	blood disorder
NCT001956241	NCT00195624_1_T4	ORGAN	11	12	bone marrow
NCT001956241	NCT00195624_1_T5	CELL	15	17	red blood cells
NCT001956241	NCT00195624_1_T6	CELL	18	20	white blood cells
NCT001956242	NCT00195624_2_T0	CELL	14	14	lymphocytes
NCT001956242	NCT00195624_2_T1	CELL	10	12	white blood cells
NCT001956243	NCT00195624_3_T0	CELL	6	6	lymphocytes
NCT001956243	NCT00195624_3_T1	CELL	13	14	stem cells
NCT001956243	NCT00195624_3_T2	ORGAN	17	18	bone marrow
NCT001956243	NCT00195624_3_T3	PHENOTYPE	4	5	aplastic anemia
NCT001956244	NCT00195624_4_T0	CELL	3	3	lymphocytes
NCT001956244	NCT00195624_4_T1	PHENOTYPE	10	11	aplastic anemia
NCT001956245	NCT00195624_5_T0	PHENOTYPE	18	18	immunosuppression
NCT001956245	NCT00195624_5_T1	PHENOTYPE	25	25	cytopenias
NCT001956245	NCT00195624_5_T2	PHENOTYPE	21	22	rheumatoid arthritis
NCT001956245	NCT00195624_5_T3	PHENOTYPE	6	8	chronic lymphocytic leukemia
NCT001956246	NCT00195624_6_T0	GENE	20	20	has
NCT001956246	NCT00195624_6_T1	PHENOTYPE	8	10	severe aplastic anemia
NCT0019562415	NCT00195624_15_T0	COMPOUND	20	20	cyclosporine
NCT0019562415	NCT00195624_15_T1	GENE	7	7	SAA
NCT0019562415	NCT00195624_15_T2	PHENOTYPE	25	25	relapse
NCT0019562415	NCT00195624_15_T3	GENE	18	18	globulin
NCT0019562416	NCT00195624_16_T0	PHENOTYPE	1	1	secondary
NCT0019562416	NCT00195624_16_T1	PHENOTYPE	18	18	complications
NCT0019562416	NCT00195624_16_T2	PHENOTYPE	0	0	Pancytopenia
NCT0019562416	NCT00195624_16_T3	GENE	8	8	has
NCT0019562416	NCT00195624_16_T4	PHENOTYPE	6	7	aplastic anemia
NCT0019562417	NCT00195624_17_T0	CELL	21	21	monocytes
NCT0019562417	NCT00195624_17_T1	GENE	12	12	CD52
NCT0019562417	NCT00195624_17_T2	GENE	14	14	CD52
NCT0019562417	NCT00195624_17_T3	CELL	19	19	lymphocytes
NCT0019562417	NCT00195624_17_T4	GENE	6	6	IgG1
NCT0019562420	NCT00195624_20_T0	PHENOTYPE	23	23	toxicity
NCT0019562420	NCT00195624_20_T1	GENE	10	10	SAA
NCT0019562420	NCT00195624_20_T2	GENE	24	24	has
NCT0019562420	NCT00195624_20_T3	GENE	15	15	globulin
NCT0019562421	NCT00195624_21_T0	GENE	7	7	II
NCT0019562421	NCT00195624_21_T1	GENE	15	15	SAA
NCT0019562423	NCT00195624_23_T0	GENE	23	23	SAA
NCT0019562424	NCT00195624_24_T0	PHENOTYPE	0	0	Relapse
NCT0019562424	NCT00195624_24_T1	PHENOTYPE	25	25	secondary
NCT0019562424	NCT00195624_24_T2	PHENOTYPE	19	19	myelodysplasia
NCT0019562424	NCT00195624_24_T3	PHENOTYPE	16	17	clonal evolution
NCT0019562424	NCT00195624_24_T4	PHENOTYPE	21	22	acute leukemia
NCT0019562426	NCT00195624_26_T0	PHENOTYPE	5	6	Fanconi's anemia
NCT0019562427	NCT00195624_27_T0	GENE	11	11	ANC
NCT0019562427	NCT00195624_27_T1	PHENOTYPE	10	10	neutropenia
NCT001956371	NCT00195637_1_T0	ORGAN	13	13	limb
NCT001956371	NCT00195637_1_T1	TISSUE	14	14	muscles
NCT001956371	NCT00195637_1_T2	PHENOTYPE	3	3	progressive
NCT001956371	NCT00195637_1_T3	PHENOTYPE	0	0	HIBM
NCT001956371	NCT00195637_1_T4	PHENOTYPE	4	5	neuromuscular disease
NCT001956372	NCT00195637_2_T0	COMPOUND	12	13	sialic acid
NCT001956373	NCT00195637_3_T0	PHENOTYPE	3	3	HIBM
NCT001956373	NCT00195637_3_T1	COMPOUND	6	7	sialic acid
NCT001956373	NCT00195637_3_T2	PHENOTYPE	19	20	muscle weakness
NCT001956374	NCT00195637_4_T0	COMPOUND	13	14	sialic acid
NCT001956378	NCT00195637_8_T0	GENE	13	13	globulin
NCT0019563719	NCT00195637_19_T0	PHENOTYPE	12	12	mutation
NCT0019563719	NCT00195637_19_T1	GENE	10	10	kinase
NCT0019563722	NCT00195637_22_T0	BIOLOGICAL_PROCESS	16	16	sialylation
NCT0019563722	NCT00195637_22_T1	CELL	1	1	cells
NCT0019563722	NCT00195637_22_T2	GENE	6	6	reduced
NCT0019563722	NCT00195637_22_T3	PHENOTYPE	3	3	HIBM
NCT0019563722	NCT00195637_22_T4	COMPOUND	10	11	sialic acid
NCT0019563723	NCT00195637_23_T0	COMPOUND	9	10	sialic acid
NCT0019563723	NCT00195637_23_T1	CELL	23	24	muscle cells
NCT0019563723	NCT00195637_23_T2	CELL	27	28	extracellular matrix
NCT0019563731	NCT00195637_31_T0	PHENOTYPE	0	0	Secondary
NCT0019563731	NCT00195637_31_T1	GENE	9	9	grip
NCT0019563732	NCT00195637_32_T0	COMPOUND	5	6	sialic acid
NCT0019563733	NCT00195637_33_T0	BIOLOGICAL_PROCESS	7	7	sialylation
NCT001956763	NCT00195676_3_T0	COMPOUND	5	5	O
NCT001956764	NCT00195676_4_T0	COMPOUND	1	1	O
NCT001956765	NCT00195676_5_T0	GENE	5	5	had
NCT001956765	NCT00195676_5_T1	GENE	14	14	PGA
NCT001956768	NCT00195676_8_T0	PHENOTYPE	30	30	relapse
NCT001956768	NCT00195676_8_T1	COMPOUND	1	1	O
NCT001957020	NCT00195702_0_T0	PHENOTYPE	9	10	Rheumatoid Arthritis
NCT001957410	NCT00195741_0_T0	COMPOUND	6	6	Sodium
NCT001957410	NCT00195741_0_T1	PHENOTYPE	10	10	Migraine
NCT001957414	NCT00195741_4_T0	GENE	12	12	5-1
NCT001957540	NCT00195754_0_T0	GENE	2	2	III
NCT001957540	NCT00195754_0_T1	GENE	10	10	ER
NCT001957670	NCT00195767_0_T0	PHENOTYPE	12	12	Mania
NCT001957670	NCT00195767_0_T1	PHENOTYPE	15	16	Bipolar Disorder
NCT001957800	NCT00195780_0_T0	PHENOTYPE	6	6	Mania
NCT001957800	NCT00195780_0_T1	PHENOTYPE	9	11	Bipolar I Disorder
NCT001958064	NCT00195806_4_T0	PHENOTYPE	0	1	Platelet count
NCT001958190	NCT00195819_0_T0	PHENOTYPE	9	10	Ankylosing Spondylitis
NCT001958451	NCT00195845_1_T0	COMPOUND	5	5	galantamine
NCT001958580	NCT00195858_0_T0	BIOLOGICAL_PROCESS	1	1	Eating
NCT001958585	NCT00195858_5_T0	PHENOTYPE	23	23	diseases
NCT0019585814	NCT00195858_14_T0	TISSUE	12	13	body fat
NCT0019585816	NCT00195858_16_T0	PHENOTYPE	5	5	obesity
NCT0019585817	NCT00195858_17_T0	PHENOTYPE	15	15	overweight
NCT0019585818	NCT00195858_18_T0	PHENOTYPE	13	13	obesity
NCT0019585818	NCT00195858_18_T1	PHENOTYPE	38	38	obesity
NCT0019585818	NCT00195858_18_T2	PHENOTYPE	6	7	decision making
NCT001958715	NCT00195871_5_T0	CELL	7	7	cells
NCT001958718	NCT00195871_8_T0	COMPOUND	10	10	cyclophosphamide
NCT001958718	NCT00195871_8_T1	GENE	12	12	L-asparaginase
NCT0019587110	NCT00195871_10_T0	PHENOTYPE	13	13	remission
NCT0019587110	NCT00195871_10_T1	ORGAN	6	6	allograft
NCT0019587111	NCT00195871_11_T0	PHENOTYPE	23	23	remission
NCT0019587111	NCT00195871_11_T1	PHENOTYPE	4	5	chromosomal abnormalities
NCT0019587111	NCT00195871_11_T2	PHENOTYPE	34	35	residual disease
NCT0019587111	NCT00195871_11_T3	ORGAN	12	14	central nervous system
NCT001958840	NCT00195884_0_T0	PHENOTYPE	0	0	Diabetes
NCT001958843	NCT00195884_3_T0	ORGAN	6	6	Heart
NCT001958843	NCT00195884_3_T1	ORGAN	13	13	heart
NCT0019588415	NCT00195884_15_T0	COMPOUND	19	19	glucose
NCT0019588415	NCT00195884_15_T1	PHENOTYPE	15	16	insulin resistance
NCT0019588415	NCT00195884_15_T2	PHENOTYPE	11	13	increased metabolic rate
NCT0019588420	NCT00195884_20_T0	GENE	0	0	Is
NCT0019588422	NCT00195884_22_T0	COMPOUND	10	10	deuterium
NCT0019588422	NCT00195884_22_T1	PHENOTYPE	13	14	energy expenditure
NCT0019588422	NCT00195884_22_T2	PHENOTYPE	19	20	insulin resistance
NCT0019588425	NCT00195884_25_T0	GENE	10	10	insulin
NCT0019588425	NCT00195884_25_T1	GENE	6	6	LDL
NCT0019588425	NCT00195884_25_T2	GENE	11	11	apoprotein
NCT0019588425	NCT00195884_25_T3	ORGAN	9	9	plasma
NCT0019588425	NCT00195884_25_T4	GENE	30	30	BP
NCT0019588425	NCT00195884_25_T5	GENE	3	3	CHD
NCT0019588425	NCT00195884_25_T6	GENE	21	21	CHD
NCT0019588427	NCT00195884_27_T0	PHENOTYPE	4	4	QOL
NCT0019588427	NCT00195884_27_T1	PHENOTYPE	1	3	quality of life
NCT0019588428	NCT00195884_28_T0	PHENOTYPE	7	9	quality of life
NCT0019588432	NCT00195884_32_T0	PHENOTYPE	5	5	progressive
NCT0019588436	NCT00195884_36_T0	COMPOUND	20	20	glucose
NCT0019588436	NCT00195884_36_T1	GENE	23	23	BP
NCT0019588439	NCT00195884_39_T0	PHENOTYPE	9	11	quality of life
NCT001958970	NCT00195897_0_T0	PHENOTYPE	4	4	Cardiotoxicity
NCT001958972	NCT00195897_2_T0	PHENOTYPE	6	6	cardiotoxicity
NCT001958972	NCT00195897_2_T1	PHENOTYPE	14	14	impairment
NCT001958972	NCT00195897_2_T2	GENE	12	12	ventricular
NCT001958972	NCT00195897_2_T3	PHENOTYPE	19	20	heart failure
NCT001958973	NCT00195897_3_T0	PHENOTYPE	8	8	cardiotoxicity
NCT001958974	NCT00195897_4_T0	PHENOTYPE	28	28	cardiotoxicity
NCT001958974	NCT00195897_4_T1	GENE	16	16	troponin
NCT001958974	NCT00195897_4_T2	GENE	20	20	structural
NCT001959104	NCT00195910_4_T0	GENE	5	5	has
NCT001959104	NCT00195910_4_T1	GENE	15	15	hesitant
NCT001959104	NCT00195910_4_T2	GENE	25	25	IV
NCT001959104	NCT00195910_4_T3	GENE	18	18	7-10
NCT001959104	NCT00195910_4_T4	COMPOUND	21	21	morphine
NCT001959105	NCT00195910_5_T0	COMPOUND	22	22	hydromorphone
NCT001959105	NCT00195910_5_T1	COMPOUND	30	30	hydromorphone
NCT001959105	NCT00195910_5_T2	GENE	3	3	has
NCT001959105	NCT00195910_5_T3	PHENOTYPE	14	14	reluctant
NCT001959105	NCT00195910_5_T4	COMPOUND	39	39	morphine
NCT001959105	NCT00195910_5_T5	PHENOTYPE	43	43	illusion
NCT001959107	NCT00195910_7_T0	COMPOUND	19	19	hydromorphone
NCT001959230	NCT00195923_0_T0	PHENOTYPE	9	10	Perforated Appendicitis
NCT001959233	NCT00195923_3_T0	COMPOUND	6	6	ampicillin
NCT001959233	NCT00195923_3_T1	COMPOUND	7	7	gentamicin
NCT001959233	NCT00195923_3_T2	GENE	2	2	has
NCT001959233	NCT00195923_3_T3	COMPOUND	9	9	clindamycin
NCT001959234	NCT00195923_4_T0	COMPOUND	11	11	ampicillin
NCT001959234	NCT00195923_4_T1	COMPOUND	15	15	gentamicin
NCT001959234	NCT00195923_4_T2	COMPOUND	20	20	clindamycin
NCT001959234	NCT00195923_4_T3	PHENOTYPE	30	31	postoperative infection
NCT001959235	NCT00195923_5_T0	COMPOUND	1	1	gentamicin
NCT001959236	NCT00195923_6_T0	PHENOTYPE	16	16	toxicity
NCT001959236	NCT00195923_6_T1	ORGAN	8	8	serum
NCT001959238	NCT00195923_8_T0	GENE	11	11	has
NCT001959238	NCT00195923_8_T1	COMPOUND	7	7	piperacillin_tazobactam
NCT001959238	NCT00195923_8_T2	PHENOTYPE	9	10	intraabdominal infections
NCT0019592310	NCT00195923_10_T0	GENE	21	21	3.4
NCT0019592312	NCT00195923_12_T0	GENE	2	2	has
NCT0019592312	NCT00195923_12_T1	PHENOTYPE	12	13	perforated appendicitis
NCT0019592312	NCT00195923_12_T2	PHENOTYPE	8	9	intraabdominal infections
NCT0019592313	NCT00195923_13_T0	COMPOUND	1	1	ceftriaxone
NCT0019592313	NCT00195923_13_T1	COMPOUND	3	3	metronidazole
NCT0019592313	NCT00195923_13_T2	GENE	4	4	has
NCT0019592313	NCT00195923_13_T3	COMPOUND	14	14	piperacillin_tazobactam
NCT0019592313	NCT00195923_13_T4	PHENOTYPE	19	20	perforated appendicitis
NCT0019592314	NCT00195923_14_T0	PHENOTYPE	14	15	perforated appendicitis
NCT0019592315	NCT00195923_15_T0	ORGAN	14	14	serum
NCT0019592318	NCT00195923_18_T0	PHENOTYPE	21	22	perforated appendicitis
NCT0019592319	NCT00195923_19_T0	PHENOTYPE	13	14	perforated appendicitis
NCT0019592320	NCT00195923_20_T0	COMPOUND	5	5	ceftriaxone
NCT0019592322	NCT00195923_22_T0	ORGAN	11	11	appendix
NCT0019592322	NCT00195923_22_T1	PHENOTYPE	0	0	Perforation
NCT0019592322	NCT00195923_22_T2	ORGAN	21	22	abdominal cavity
NCT0019592323	NCT00195923_23_T0	GENE	3	3	has
NCT0019592323	NCT00195923_23_T1	PHENOTYPE	1	2	perforated appendicitis
NCT0019592325	NCT00195923_25_T0	PHENOTYPE	2	2	feels
NCT0019592325	NCT00195923_25_T1	GENE	0	0	Dr
NCT0019592327	NCT00195923_27_T0	COMPOUND	5	5	ceftriaxone
NCT0019592327	NCT00195923_27_T1	COMPOUND	16	16	metronidazole
NCT0019592331	NCT00195923_31_T0	PHENOTYPE	9	9	febrile
NCT0019592331	NCT00195923_31_T1	PHENOTYPE	20	20	febrile
NCT0019592334	NCT00195923_34_T0	GENE	14	14	WBC
NCT0019592334	NCT00195923_34_T1	GENE	22	22	has
NCT0019592335	NCT00195923_35_T0	GENE	2	2	WBC
NCT0019592335	NCT00195923_35_T1	GENE	11	11	WBC
NCT0019592336	NCT00195923_36_T0	ORGAN	24	24	abdomen
NCT0019592336	NCT00195923_36_T1	PHENOTYPE	3	3	fever
NCT0019592336	NCT00195923_36_T2	ORGAN	26	26	pelvis
NCT0019592336	NCT00195923_36_T3	PHENOTYPE	35	35	abscess
NCT0019592336	NCT00195923_36_T4	GENE	36	36	has
NCT0019592336	NCT00195923_36_T5	PHENOTYPE	1	1	leukocytosis
NCT0019592336	NCT00195923_36_T6	PHENOTYPE	17	18	intra-abdominal infection
NCT0019592337	NCT00195923_37_T0	PHENOTYPE	4	4	abscess
NCT0019592337	NCT00195923_37_T1	PHENOTYPE	16	16	abscess
NCT0019592338	NCT00195923_38_T0	PHENOTYPE	15	15	abscess
NCT0019592340	NCT00195923_40_T0	PHENOTYPE	52	52	complications
NCT0019592340	NCT00195923_40_T1	GENE	38	38	PhD
NCT0019592340	NCT00195923_40_T2	GENE	35	35	Dr
NCT001959363	NCT00195936_3_T0	COMPOUND	5	5	phosphate
NCT001959363	NCT00195936_3_T1	ORGAN	4	4	serum
NCT001959363	NCT00195936_3_T2	COMPOUND	9	10	vitamin D
NCT001959366	NCT00195936_6_T0	PHENOTYPE	9	9	nephrocalcinosis
NCT001959366	NCT00195936_6_T1	GENE	13	13	HPT
NCT001959366	NCT00195936_6_T2	PHENOTYPE	11	12	secondary hyperparathyroidism
NCT001959367	NCT00195936_7_T0	PHENOTYPE	7	7	hypercalcemia
NCT001959367	NCT00195936_7_T1	PHENOTYPE	6	6	hypertension
NCT001959368	NCT00195936_8_T0	PHENOTYPE	1	1	complication
NCT001959368	NCT00195936_8_T1	PHENOTYPE	3	4	secondary hyperparathyroidism
NCT001959369	NCT00195936_9_T0	GENE	3	3	PTH
NCT001959369	NCT00195936_9_T1	PHENOTYPE	9	9	circulation
NCT001959369	NCT00195936_9_T2	PHENOTYPE	14	15	serum calcium
NCT0019593612	NCT00195936_12_T0	GENE	8	8	PTH
NCT0019593612	NCT00195936_12_T1	GENE	4	4	HPT
NCT0019593612	NCT00195936_12_T2	PHENOTYPE	12	13	serum calcium
NCT0019593613	NCT00195936_13_T0	GENE	20	20	HPT
NCT0019593613	NCT00195936_13_T1	PHENOTYPE	19	19	secondary
NCT0019593613	NCT00195936_13_T2	PHENOTYPE	12	12	hypercalcemia
NCT0019593613	NCT00195936_13_T3	PHENOTYPE	16	17	parathyroid carcinoma
NCT0019593613	NCT00195936_13_T4	PHENOTYPE	24	26	chronic renal disease
NCT0019593614	NCT00195936_14_T0	COMPOUND	13	13	calcium
NCT0019593614	NCT00195936_14_T1	GENE	9	9	PTH
NCT0019593614	NCT00195936_14_T2	COMPOUND	15	15	phosphorous
NCT001959491	NCT00195949_1_T0	ORGAN	27	27	pylorus
NCT001959493	NCT00195949_3_T0	GENE	11	11	has
NCT001959498	NCT00195949_8_T0	PHENOTYPE	24	24	emesis
NCT001959622	NCT00195962_2_T0	PHENOTYPE	15	15	complications
NCT001959625	NCT00195962_5_T0	PHENOTYPE	33	33	complications
NCT001959752	NCT00195975_2_T0	PHENOTYPE	6	6	symptoms
NCT001959753	NCT00195975_3_T0	PHENOTYPE	6	6	chronic
NCT001959754	NCT00195975_4_T0	PHENOTYPE	6	6	symptoms
NCT001959754	NCT00195975_4_T1	GENE	16	16	ANS
NCT001959754	NCT00195975_4_T2	ORGAN	13	15	autonomic nervous system
NCT001959755	NCT00195975_5_T0	PHENOTYPE	0	0	Imbalance
NCT001959755	NCT00195975_5_T1	GENE	3	3	ANS
NCT001959755	NCT00195975_5_T2	GENE	4	4	has
NCT001959755	NCT00195975_5_T3	PHENOTYPE	10	11	motor function
NCT001959758	NCT00195975_8_T0	GENE	6	6	ANS
NCT001959758	NCT00195975_8_T1	PHENOTYPE	4	4	chronic
NCT0019597510	NCT00195975_10_T0	GENE	13	13	ANS
NCT0019597510	NCT00195975_10_T1	ORGAN	16	16	heart
NCT0019597511	NCT00195975_11_T0	GENE	1	1	II
NCT001959882	NCT00195988_2_T0	GENE	11	11	max
NCT001959882	NCT00195988_2_T1	GENE	0	0	FK506
NCT001959889	NCT00195988_9_T0	GENE	0	0	FK506
NCT0019598819	NCT00195988_19_T0	PHENOTYPE	4	4	acute
NCT0019598819	NCT00195988_19_T1	GENE	17	17	0.3
NCT0019598821	NCT00195988_21_T0	GENE	4	4	AR
NCT0019598821	NCT00195988_21_T1	GENE	16	16	0.3
NCT0019598823	NCT00195988_23_T0	PHENOTYPE	1	1	resistant
NCT0019598824	NCT00195988_24_T0	PHENOTYPE	1	1	resistant
NCT0019598825	NCT00195988_25_T0	PHENOTYPE	9	9	centre
NCT0019598826	NCT00195988_26_T0	PHENOTYPE	2	2	cholestasis
NCT0019598826	NCT00195988_26_T1	PHENOTYPE	7	8	bone disease
NCT0019598830	NCT00195988_30_T0	GENE	16	16	7.12
NCT0019598837	NCT00195988_37_T0	PHENOTYPE	4	4	acute
NCT0019598837	NCT00195988_37_T1	GENE	14	14	0.3
NCT0019598839	NCT00195988_39_T0	PHENOTYPE	1	1	resistant
NCT0019598840	NCT00195988_40_T0	PHENOTYPE	1	1	resistant
NCT0019598842	NCT00195988_42_T0	ORGAN	9	9	liver
NCT0019598844	NCT00195988_44_T0	PHENOTYPE	12	12	Hypertension
NCT0019598844	NCT00195988_44_T1	GENE	18	18	de
NCT0019598844	NCT00195988_44_T2	PHENOTYPE	0	0	Secondary
NCT0019598844	NCT00195988_44_T3	ORGAN	5	5	graft
NCT0019598844	NCT00195988_44_T4	PHENOTYPE	7	7	Dyslipidemia
NCT0019598847	NCT00195988_47_T0	ORGAN	1	1	liver
NCT0019598848	NCT00195988_48_T0	GENE	13	13	has
NCT0019598848	NCT00195988_48_T1	GENE	22	22	has
NCT0019598852	NCT00195988_52_T0	ORGAN	4	4	graft
NCT0019598852	NCT00195988_52_T1	ORGAN	3	3	liver
NCT0019598853	NCT00195988_53_T0	COMPOUND	15	15	tacrolimus
NCT0019598856	NCT00195988_56_T0	ORGAN	20	20	graft
NCT0019598856	NCT00195988_56_T1	ORGAN	19	19	liver
NCT0019598857	NCT00195988_57_T0	PHENOTYPE	5	5	infections
NCT0019598857	NCT00195988_57_T1	GENE	1	1	has
NCT0019598857	NCT00195988_57_T2	PHENOTYPE	9	9	vomiting
NCT0019598857	NCT00195988_57_T3	PHENOTYPE	7	8	severe diarrhea
NCT0019598857	NCT00195988_57_T4	PHENOTYPE	11	13	active peptic ulcer
NCT0019598859	NCT00195988_59_T0	GENE	4	4	has
NCT0019598859	NCT00195988_59_T1	GENE	14	14	has
NCT0019598866	NCT00195988_66_T0	ORGAN	1	1	liver
NCT0019598871	NCT00195988_71_T0	ORGAN	4	4	graft
NCT0019598871	NCT00195988_71_T1	ORGAN	3	3	liver
NCT0019598872	NCT00195988_72_T0	COMPOUND	15	15	tacrolimus
NCT0019598875	NCT00195988_75_T0	ORGAN	20	20	graft
NCT0019598875	NCT00195988_75_T1	ORGAN	19	19	liver
NCT0019598876	NCT00195988_76_T0	PHENOTYPE	5	5	infections
NCT0019598876	NCT00195988_76_T1	GENE	1	1	has
NCT0019598876	NCT00195988_76_T2	PHENOTYPE	8	8	diarrhoea
NCT0019598876	NCT00195988_76_T3	PHENOTYPE	9	9	vomiting
NCT0019598876	NCT00195988_76_T4	PHENOTYPE	11	13	active peptic ulcer
NCT0019598878	NCT00195988_78_T0	GENE	4	4	has
NCT0019598878	NCT00195988_78_T1	GENE	14	14	has
NCT001960011	NCT00196001_1_T0	GENE	8	8	ACTH
NCT001960011	NCT00196001_1_T1	GENE	14	14	CRH
NCT001960011	NCT00196001_1_T2	GENE	12	12	corticotropin
NCT001960011	NCT00196001_1_T3	GENE	16	16	hormone
NCT001960011	NCT00196001_1_T4	GENE	9	10	adrenocorticotropic hormone
NCT001960012	NCT00196001_2_T0	GENE	6	6	ACTH
NCT001960013	NCT00196001_3_T0	COMPOUND	7	7	cortisol
NCT001960013	NCT00196001_3_T1	GENE	0	0	ACTH
NCT001960013	NCT00196001_3_T2	ORGAN	3	4	adrenal glands
NCT001960014	NCT00196001_4_T0	PHENOTYPE	0	1	Cortisol levels
NCT001960014	NCT00196001_4_T1	ORGAN	11	12	adrenal gland
NCT001960015	NCT00196001_5_T0	COMPOUND	4	4	cortisol
NCT001960015	NCT00196001_5_T1	GENE	8	8	ACTH
NCT001960017	NCT00196001_7_T0	GENE	5	5	ACTH
NCT001960017	NCT00196001_7_T1	GENE	7	7	CRH
NCT001960018	NCT00196001_8_T0	COMPOUND	12	12	cortisol
NCT001960018	NCT00196001_8_T1	GENE	15	15	ACTH
NCT0019600110	NCT00196001_10_T0	GENE	8	8	ACTH
NCT0019600112	NCT00196001_12_T0	GENE	0	0	ACTH
NCT0019600112	NCT00196001_12_T1	GENE	2	2	CRH
NCT0019600114	NCT00196001_14_T0	GENE	6	6	ACTH
NCT0019600114	NCT00196001_14_T1	GENE	16	17	G protein
NCT0019600115	NCT00196001_15_T0	COMPOUND	3	3	cortisol
NCT0019600115	NCT00196001_15_T1	GENE	20	20	ACTH
NCT0019600115	NCT00196001_15_T2	GENE	5	5	hormone
NCT0019600115	NCT00196001_15_T3	ORGAN	9	10	adrenal glands
NCT0019600117	NCT00196001_17_T0	CELL	6	8	white blood cells
NCT0019600118	NCT00196001_18_T0	CELL	0	2	White blood cells
NCT0019600118	NCT00196001_18_T1	CELL	12	14	white blood cells
NCT0019600119	NCT00196001_19_T0	GENE	8	8	ACTH
NCT0019600124	NCT00196001_24_T0	GENE	20	20	Gaq
NCT0019600124	NCT00196001_24_T1	GENE	13	13	mRNA
NCT0019600124	NCT00196001_24_T2	GENE	18	19	G protein
NCT0019600125	NCT00196001_25_T0	GENE	9	9	Gaq
NCT0019600125	NCT00196001_25_T1	GENE	10	10	mRNA
NCT0019600126	NCT00196001_26_T0	CELL	22	22	cells
NCT0019600126	NCT00196001_26_T1	GENE	9	9	ACTH
NCT0019600126	NCT00196001_26_T2	GENE	15	15	CRH
NCT0019600126	NCT00196001_26_T3	GENE	13	13	corticotropin
NCT0019600126	NCT00196001_26_T4	GENE	17	17	hormone
NCT0019600126	NCT00196001_26_T5	GENE	10	11	adrenocorticotropic hormone
NCT0019600127	NCT00196001_27_T0	GENE	0	0	ACTH
NCT0019600127	NCT00196001_27_T1	GENE	2	2	CRH
NCT0019600129	NCT00196001_29_T0	GENE	12	12	ACTH
NCT0019600132	NCT00196001_32_T0	GENE	10	10	ACTH
NCT001960273	NCT00196027_3_T0	PHENOTYPE	10	12	patent foramen ovale
NCT001960403	NCT00196040_3_T0	PHENOTYPE	10	12	patent foramen ovale
NCT001960535	NCT00196053_5_T0	GENE	11	11	has
NCT001960535	NCT00196053_5_T1	COMPOUND	23	23	baclofen
NCT001960535	NCT00196053_5_T2	COMPOUND	21	21	morphine
NCT001960661	NCT00196066_1_T0	COMPOUND	7	7	nitinol
NCT001960662	NCT00196066_2_T0	ORGAN	6	6	artery
NCT001960663	NCT00196066_3_T0	CELL	7	7	cells
NCT001960922	NCT00196092_2_T0	PHENOTYPE	6	6	aneurysm
NCT001960922	NCT00196092_2_T1	GENE	15	15	cm
NCT001960924	NCT00196092_4_T0	GENE	12	12	3.5
NCT001960924	NCT00196092_4_T1	GENE	13	13	cm
NCT001960924	NCT00196092_4_T2	PHENOTYPE	3	4	iliac aneurysm
NCT001961052	NCT00196105_2_T0	PHENOTYPE	13	13	complications
NCT001961312	NCT00196131_2_T0	GENE	18	19	transporter protein
NCT001961313	NCT00196131_3_T0	PHENOTYPE	15	15	trauma
NCT001961313	NCT00196131_3_T1	COMPOUND	18	18	morphine
NCT001961313	NCT00196131_3_T2	COMPOUND	38	38	morphine
NCT001961313	NCT00196131_3_T3	PHENOTYPE	9	9	agitation
NCT001961313	NCT00196131_3_T4	PHENOTYPE	23	23	inflammation
NCT001961313	NCT00196131_3_T5	COMPOUND	41	41	glucuronide
NCT001961313	NCT00196131_3_T6	GENE	27	27	PGP
NCT001961313	NCT00196131_3_T7	ORGAN	30	32	blood brain barrier
NCT001961315	NCT00196131_5_T0	GENE	6	6	cytochrome
NCT001961315	NCT00196131_5_T1	GENE	9	9	transporter
NCT001961315	NCT00196131_5_T2	PHENOTYPE	19	20	defense mechanisms
NCT001961316	NCT00196131_6_T0	ORGAN	13	13	liver
NCT001961316	NCT00196131_6_T1	PHENOTYPE	5	5	inflammation
NCT001961316	NCT00196131_6_T2	GENE	1	1	has
NCT001961316	NCT00196131_6_T3	PHENOTYPE	21	21	severely
NCT001961318	NCT00196131_8_T0	BIOLOGICAL_PROCESS	19	19	transcription
NCT001961318	NCT00196131_8_T1	BIOLOGICAL_PROCESS	6	6	transport
NCT001961318	NCT00196131_8_T2	BIOLOGICAL_PROCESS	3	4	drug metabolism
NCT001961319	NCT00196131_9_T0	GENE	7	7	cytochrome
NCT001961319	NCT00196131_9_T1	BIOLOGICAL_PROCESS	18	18	degradation
NCT0019613112	NCT00196131_12_T0	PHENOTYPE	15	15	infections
NCT0019613113	NCT00196131_13_T0	PHENOTYPE	9	9	toxicities
NCT0019613115	NCT00196131_15_T0	PHENOTYPE	21	21	peripheral
NCT0019613115	NCT00196131_15_T1	GENE	2	2	has
NCT0019613115	NCT00196131_15_T2	PHENOTYPE	14	15	drug disposition
NCT0019613115	NCT00196131_15_T3	PHENOTYPE	8	9	inflammatory responses
NCT0019613117	NCT00196131_17_T0	GENE	14	14	PGP
NCT0019613117	NCT00196131_17_T1	GENE	12	13	transporter protein
NCT0019613118	NCT00196131_18_T0	PHENOTYPE	18	18	toxicity
NCT0019613118	NCT00196131_18_T1	GENE	12	12	PGP
NCT0019613123	NCT00196131_23_T0	ORGAN	8	8	liver
NCT0019613123	NCT00196131_23_T1	COMPOUND	14	14	glucuronide
NCT0019613123	NCT00196131_23_T2	COMPOUND	17	17	glucuronide
NCT0019613123	NCT00196131_23_T3	COMPOUND	3	3	morphine
NCT0019613124	NCT00196131_24_T0	GENE	10	10	PGP
NCT0019613124	NCT00196131_24_T1	ORGAN	13	15	blood brain barrier
NCT0019613125	NCT00196131_25_T0	PHENOTYPE	14	14	inflammation
NCT0019613125	NCT00196131_25_T1	GENE	2	2	PGP
NCT0019613125	NCT00196131_25_T2	COMPOUND	17	17	morphine
NCT0019613125	NCT00196131_25_T3	ORGAN	6	8	blood brain barrier
NCT0019613127	NCT00196131_27_T0	PHENOTYPE	21	21	agitation
NCT0019613127	NCT00196131_27_T1	COMPOUND	7	7	morphine
NCT0019613128	NCT00196131_28_T0	PHENOTYPE	23	23	agitation
NCT0019613128	NCT00196131_28_T1	PHENOTYPE	7	8	both sides
NCT0019613128	NCT00196131_28_T2	ORGAN	11	13	blood brain barrier
NCT001961570	NCT00196157_0_T0	PHENOTYPE	5	7	Persistent Atrial Fibrillation
NCT001961573	NCT00196157_3_T0	PHENOTYPE	12	12	foci
NCT001961573	NCT00196157_3_T1	PHENOTYPE	24	25	atrial fibrillation
NCT001961573	NCT00196157_3_T2	ORGAN	15	16	pulmonary veins
NCT001961702	NCT00196170_2_T0	PHENOTYPE	19	19	complication
NCT001961702	NCT00196170_2_T1	GENE	7	7	has
NCT001961702	NCT00196170_2_T2	PHENOTYPE	5	6	atrial flutter
NCT001961703	NCT00196170_3_T0	PHENOTYPE	27	28	atrial flutter
NCT001961705	NCT00196170_5_T0	PHENOTYPE	1	1	acute
NCT001961830	NCT00196183_0_T0	PHENOTYPE	4	6	Paroxysmal Atrial Fibrillation
NCT001961835	NCT00196183_5_T0	GENE	15	15	AF
NCT001961835	NCT00196183_5_T1	GENE	22	22	AF
NCT001961835	NCT00196183_5_T2	GENE	23	23	has
NCT001961837	NCT00196183_7_T0	GENE	33	33	AF
NCT001961964	NCT00196196_4_T0	ORGAN	7	7	skull
NCT001961967	NCT00196196_7_T0	ORGAN	7	7	skull
NCT001962090	NCT00196209_0_T0	PHENOTYPE	5	7	Persistent Atrial Fibrillation
NCT001962093	NCT00196209_3_T0	PHENOTYPE	11	13	persistent atrial fibrillation
NCT001962096	NCT00196209_6_T0	PHENOTYPE	11	11	complications
NCT001962222	NCT00196222_2_T0	PHENOTYPE	3	3	complication
NCT001962222	NCT00196222_2_T1	GENE	7	7	AV
NCT001962222	NCT00196222_2_T2	PHENOTYPE	8	9	conduction block
NCT001962224	NCT00196222_4_T0	GENE	13	13	AV
NCT001962224	NCT00196222_4_T1	PHENOTYPE	14	15	conduction block
NCT001963261	NCT00196326_1_T0	GENE	11	11	DR_1011
NCT001963392	NCT00196339_2_T0	PHENOTYPE	12	12	severity
NCT001963392	NCT00196339_2_T1	PHENOTYPE	14	15	hot flashes
NCT001963396	NCT00196339_6_T0	PHENOTYPE	9	10	hot flashes
NCT001963397	NCT00196339_7_T0	PHENOTYPE	12	12	severity
NCT001963397	NCT00196339_7_T1	PHENOTYPE	14	15	hot flashes
NCT001963398	NCT00196339_8_T0	PHENOTYPE	15	16	adverse events
NCT001963914	NCT00196391_4_T0	PHENOTYPE	6	6	bleeding
NCT001964173	NCT00196417_3_T0	COMPOUND	4	4	heparin
NCT001964173	NCT00196417_3_T1	COMPOUND	8	8	heparin
NCT001964175	NCT00196417_5_T0	CELL	3	3	platelet
NCT001964177	NCT00196417_7_T0	PHENOTYPE	12	12	complications
NCT001964301	NCT00196430_1_T0	PHENOTYPE	0	0	Secondary
NCT001964431	NCT00196443_1_T0	PHENOTYPE	16	16	dehydration
NCT001964431	NCT00196443_1_T1	COMPOUND	5	5	urea
NCT001964431	NCT00196443_1_T2	COMPOUND	14	14	urea
NCT001964431	NCT00196443_1_T3	COMPOUND	23	23	urea
NCT001964432	NCT00196443_2_T0	PHENOTYPE	0	0	Secondary
NCT001964432	NCT00196443_2_T1	COMPOUND	7	7	urea
NCT001964432	NCT00196443_2_T2	PHENOTYPE	23	25	chronic venous insufficiency
NCT001964561	NCT00196456_1_T0	PHENOTYPE	24	25	periodontal pocket
NCT001964562	NCT00196456_2_T0	PHENOTYPE	12	13	periodontal pocket
NCT001964951	NCT00196495_1_T0	PHENOTYPE	24	24	prolapse
NCT001964951	NCT00196495_1_T1	TISSUE	1	1	tissues
NCT001964951	NCT00196495_1_T2	GENE	22	22	Mesh
NCT001965213	NCT00196521_3_T0	PHENOTYPE	7	9	Stress Urinary Incontinence
NCT001965218	NCT00196521_8_T0	GENE	5	5	URP
NCT001965218	NCT00196521_8_T1	PHENOTYPE	2	2	prolapse
NCT001965218	NCT00196521_8_T2	PHENOTYPE	11	11	Cystocele
NCT001965343	NCT00196534_3_T0	GENE	6	6	bypass
NCT001965343	NCT00196534_3_T1	GENE	8	8	bypass
NCT001965343	NCT00196534_3_T2	PHENOTYPE	11	11	peripheral
NCT001965343	NCT00196534_3_T3	PHENOTYPE	0	0	Peripheral
NCT001965343	NCT00196534_3_T4	COMPOUND	24	24	PTFE
NCT001965343	NCT00196534_3_T5	ORGAN	21	21	grafts
NCT001965343	NCT00196534_3_T6	ORGAN	25	25	grafts
NCT001965344	NCT00196534_4_T0	ORGAN	1	1	sternum
NCT001965345	NCT00196534_5_T0	PHENOTYPE	21	21	bleeding
NCT001965345	NCT00196534_5_T1	TISSUE	9	9	tissues
NCT001965345	NCT00196534_5_T2	TISSUE	15	15	tissues
NCT001965345	NCT00196534_5_T3	ORGAN	24	24	graft
NCT001965345	NCT00196534_5_T4	PHENOTYPE	17	17	adhesions
NCT001965345	NCT00196534_5_T5	PHENOTYPE	0	0	Bleeding
NCT001965347	NCT00196534_7_T0	GENE	9	9	fusion
NCT001965347	NCT00196534_7_T1	GENE	10	10	fusion
NCT001965347	NCT00196534_7_T2	ORGAN	1	1	spine
NCT001965347	NCT00196534_7_T3	BIOLOGICAL_PROCESS	18	18	hemostasis
NCT0019653411	NCT00196534_11_T0	ORGAN	29	29	liver
NCT0019653411	NCT00196534_11_T1	GENE	9	9	bowel
NCT0019653411	NCT00196534_11_T2	ORGAN	11	11	colon
NCT0019653411	NCT00196534_11_T3	GENE	23	23	abdominal
NCT001965472	NCT00196547_2_T0	PHENOTYPE	31	31	asthma
NCT001965474	NCT00196547_4_T0	GENE	13	13	ER
NCT001965474	NCT00196547_4_T1	PHENOTYPE	15	16	acute asthma
NCT001965475	NCT00196547_5_T0	PHENOTYPE	12	12	asthma
NCT001965475	NCT00196547_5_T1	GENE	15	15	ER
NCT001965476	NCT00196547_6_T0	COMPOUND	16	16	montelukast
NCT001965476	NCT00196547_6_T1	PHENOTYPE	22	22	asthma
NCT001965476	NCT00196547_6_T2	PHENOTYPE	27	28	viral infections
NCT001965477	NCT00196547_7_T0	COMPOUND	13	13	montelukast
NCT001965478	NCT00196547_8_T0	COMPOUND	9	9	montelukast
NCT001965478	NCT00196547_8_T1	COMPOUND	27	27	montelukast
NCT001965478	NCT00196547_8_T2	PHENOTYPE	30	30	asthma
NCT001965479	NCT00196547_9_T0	COMPOUND	8	8	montelukast
NCT001965479	NCT00196547_9_T1	PHENOTYPE	13	13	asthma
NCT001965479	NCT00196547_9_T2	PHENOTYPE	28	28	asthma
NCT001965600	NCT00196560_0_T0	PHENOTYPE	5	5	Acute
NCT001965600	NCT00196560_0_T1	PHENOTYPE	6	7	Shoulder Dislocations
NCT001965604	NCT00196560_4_T0	PHENOTYPE	2	2	abduction
NCT001965731	NCT00196573_1_T0	PHENOTYPE	17	19	quality of life
NCT001965733	NCT00196573_3_T0	PHENOTYPE	24	24	tearing
NCT001965733	NCT00196573_3_T1	PHENOTYPE	21	21	dysfunction
NCT001965733	NCT00196573_3_T2	ORGAN	27	28	rotator cuff
NCT001965734	NCT00196573_4_T0	GENE	8	8	bursa
NCT001965734	NCT00196573_4_T1	ORGAN	21	21	acromion
NCT001965734	NCT00196573_4_T2	PHENOTYPE	26	26	osteophytes
NCT001965734	NCT00196573_4_T3	ORGAN	29	30	acromioclavicular joint
NCT001965734	NCT00196573_4_T4	ORGAN	12	13	coracoacromial ligament
NCT001965735	NCT00196573_5_T0	ORGAN	38	38	acromion
NCT001965735	NCT00196573_5_T1	ORGAN	19	20	rotator cuff
NCT001965735	NCT00196573_5_T2	PHENOTYPE	30	32	rotator cuff impingement
NCT001965736	NCT00196573_6_T0	ORGAN	8	8	tendon
NCT001965736	NCT00196573_6_T1	ORGAN	7	7	supraspinatus
NCT001965736	NCT00196573_6_T2	GENE	20	21	intrinsic factor
NCT001965736	NCT00196573_6_T3	ORGAN	28	29	humeral head
NCT001965737	NCT00196573_7_T0	PHENOTYPE	37	37	proximal
NCT001965737	NCT00196573_7_T1	GENE	2	2	al
NCT001965737	NCT00196573_7_T2	GENE	1	1	et
NCT001965737	NCT00196573_7_T3	ORGAN	11	12	rotator cuff
NCT001965737	NCT00196573_7_T4	ORGAN	7	8	coracoacromial ligament
NCT001965737	NCT00196573_7_T5	ORGAN	25	26	coracoacromial ligament
NCT001965737	NCT00196573_7_T6	ORGAN	20	21	humeral head
NCT001965737	NCT00196573_7_T7	ORGAN	41	42	humeral head
NCT001965738	NCT00196573_8_T0	PHENOTYPE	15	15	pathology
NCT001965738	NCT00196573_8_T1	ORGAN	36	36	acromion
NCT001965738	NCT00196573_8_T2	ORGAN	38	39	coracoacromial ligament
NCT001965738	NCT00196573_8_T3	PHENOTYPE	5	7	rotator cuff tears
NCT0019657319	NCT00196573_19_T0	PHENOTYPE	11	11	arthritis
NCT0019657319	NCT00196573_19_T1	PHENOTYPE	6	7	joint trauma
NCT0019657323	NCT00196573_23_T0	PHENOTYPE	3	5	rotator cuff tear
NCT0019657327	NCT00196573_27_T0	ORGAN	15	15	tendon
NCT0019657329	NCT00196573_29_T0	ORGAN	8	8	acromion
NCT0019657332	NCT00196573_32_T0	PHENOTYPE	18	19	psychiatric illness
NCT001965862	NCT00196586_2_T0	GENE	1	1	IL-2
NCT001965863	NCT00196586_3_T0	GENE	13	13	IL-2
NCT001965994	NCT00196599_4_T0	PHENOTYPE	0	1	Side effects
NCT001965995	NCT00196599_5_T0	GENE	4	4	CD4
NCT001965995	NCT00196599_5_T1	PHENOTYPE	9	9	HIV
NCT001965995	NCT00196599_5_T2	COMPOUND	25	25	efavirenz
NCT001965997	NCT00196599_7_T0	PHENOTYPE	0	0	Secondary
NCT001966121	NCT00196612_1_T0	COMPOUND	14	14	efavirenz
NCT001966125	NCT00196612_5_T0	COMPOUND	27	27	efavirenz
NCT001966127	NCT00196612_7_T0	PHENOTYPE	0	0	Secondary
NCT001966250	NCT00196625_0_T0	GENE	13	13	cal
NCT001966252	NCT00196625_2_T0	PHENOTYPE	0	1	Side effects
NCT001966254	NCT00196625_4_T0	COMPOUND	18	18	amprenavir
NCT001966254	NCT00196625_4_T1	GENE	44	44	had
NCT001966254	NCT00196625_4_T2	PHENOTYPE	37	37	HIV
NCT001966254	NCT00196625_4_T3	COMPOUND	16	16	lopinavir
NCT001966254	NCT00196625_4_T4	COMPOUND	25	25	ritonavir
NCT001966254	NCT00196625_4_T5	GENE	29	30	reverse transcriptase
NCT001966256	NCT00196625_6_T0	PHENOTYPE	0	1	Side effects
NCT001966258	NCT00196625_8_T0	COMPOUND	18	18	amprenavir
NCT001966258	NCT00196625_8_T1	GENE	45	45	had
NCT001966258	NCT00196625_8_T2	PHENOTYPE	38	38	HIV
NCT001966258	NCT00196625_8_T3	COMPOUND	16	16	lopinavir
NCT001966258	NCT00196625_8_T4	COMPOUND	25	25	ritonavir
NCT001966258	NCT00196625_8_T5	GENE	29	30	reverse transcriptase
NCT001966380	NCT00196638_0_T0	PHENOTYPE	9	9	Acute
NCT001966380	NCT00196638_0_T1	PHENOTYPE	5	5	Strategies
NCT001966380	NCT00196638_0_T2	PHENOTYPE	10	12	Primary HIV Infection
NCT001966385	NCT00196638_5_T0	PHENOTYPE	20	20	acute
NCT001966385	NCT00196638_5_T1	PHENOTYPE	13	13	HIV
NCT001966385	NCT00196638_5_T2	PHENOTYPE	30	30	strategies
NCT001966385	NCT00196638_5_T3	PHENOTYPE	14	14	viremia
NCT001966385	NCT00196638_5_T4	PHENOTYPE	21	23	primary HIV infection
NCT0019663810	NCT00196638_10_T0	GENE	13	13	blot
NCT0019663810	NCT00196638_10_T1	GENE	4	4	p24
NCT0019663810	NCT00196638_10_T2	PHENOTYPE	7	7	HIV
NCT0019663810	NCT00196638_10_T3	PHENOTYPE	11	11	HIV
NCT0019663810	NCT00196638_10_T4	PHENOTYPE	8	8	viremia
NCT0019663811	NCT00196638_11_T0	PHENOTYPE	13	14	autoimmune disorders
NCT0019663811	NCT00196638_11_T1	PHENOTYPE	16	17	chronic hepatitis
NCT0019663812	NCT00196638_12_T0	PHENOTYPE	0	0	Secondary
NCT0019663812	NCT00196638_12_T1	PHENOTYPE	12	12	HIV
NCT0019663812	NCT00196638_12_T2	PHENOTYPE	17	17	adhesion
NCT0019663812	NCT00196638_12_T3	BIOLOGICAL_PROCESS	13	14	immune response
NCT001966511	NCT00196651_1_T0	GENE	49	49	24
NCT001966511	NCT00196651_1_T1	GENE	70	70	24
NCT001966511	NCT00196651_1_T2	GENE	48	48	16
NCT001966511	NCT00196651_1_T3	GENE	69	69	16
NCT001966511	NCT00196651_1_T4	GENE	9	9	IL-2
NCT001966511	NCT00196651_1_T5	GENE	44	44	IL-2
NCT001966511	NCT00196651_1_T6	GENE	66	66	IL-2
NCT001966511	NCT00196651_1_T7	PHENOTYPE	19	19	HIV
NCT001966511	NCT00196651_1_T8	GENE	39	39	arm2
NCT001966512	NCT00196651_2_T0	GENE	4	4	wk
NCT001966512	NCT00196651_2_T1	ORGAN	10	10	plasma
NCT001966513	NCT00196651_3_T0	PHENOTYPE	3	3	HIV
NCT001966641	NCT00196664_1_T0	COMPOUND	13	13	paroxetine
NCT001966641	NCT00196664_1_T1	PHENOTYPE	31	32	hepatitis C
NCT001966641	NCT00196664_1_T2	PHENOTYPE	30	31	chronic hepatitis
NCT001966772	NCT00196677_2_T0	PHENOTYPE	14	14	pathology
NCT001966903	NCT00196690_3_T0	COMPOUND	16	16	donepezil
NCT001966903	NCT00196690_3_T1	PHENOTYPE	18	18	chronic
NCT001966904	NCT00196690_4_T0	COMPOUND	7	7	donepezil
NCT001966907	NCT00196690_7_T0	GENE	5	5	1.1
NCT001966907	NCT00196690_7_T1	COMPOUND	8	8	donepezil
NCT001966908	NCT00196690_8_T0	PHENOTYPE	6	6	Aphasia
NCT001966908	NCT00196690_8_T1	PHENOTYPE	12	12	Aphasia
NCT001966909	NCT00196690_9_T0	PHENOTYPE	0	0	Secondary
NCT001966909	NCT00196690_9_T1	PHENOTYPE	14	14	Aphasia
NCT001966909	NCT00196690_9_T2	PHENOTYPE	24	24	Aphasia
NCT001967032	NCT00196703_2_T0	PHENOTYPE	5	5	aphasic
NCT001967032	NCT00196703_2_T1	PHENOTYPE	4	4	chronic
NCT001967034	NCT00196703_4_T0	PHENOTYPE	21	21	aphasia
NCT001967034	NCT00196703_4_T1	COMPOUND	10	10	memantine
NCT001967034	NCT00196703_4_T2	PHENOTYPE	20	20	chronic
NCT001967034	NCT00196703_4_T3	GENE	11	11	paired
NCT001967036	NCT00196703_6_T0	PHENOTYPE	7	7	aphasia
NCT001967036	NCT00196703_6_T1	COMPOUND	4	4	memantine
NCT001967036	NCT00196703_6_T2	PHENOTYPE	14	14	dementia
NCT001967038	NCT00196703_8_T0	PHENOTYPE	9	9	aphasia
NCT001967038	NCT00196703_8_T1	GENE	12	12	has
NCT001967162	NCT00196716_2_T0	CELL	10	10	cells
NCT001967164	NCT00196716_4_T0	PHENOTYPE	22	22	symptoms
NCT001967164	NCT00196716_4_T1	COMPOUND	10	10	globotriaosylceramide
NCT001967164	NCT00196716_4_T2	TISSUE	15	15	tissues
NCT001967164	NCT00196716_4_T3	PHENOTYPE	27	28	Fabry disease
NCT001967291	NCT00196729_1_T0	ORGAN	12	12	thyroid
NCT001967291	NCT00196729_1_T1	ORGAN	22	22	thyroid
NCT001967292	NCT00196729_2_T0	ORGAN	6	6	thyroid
NCT001967292	NCT00196729_2_T1	ORGAN	14	14	thyroid
NCT001967292	NCT00196729_2_T2	GENE	17	17	TSH
NCT001967292	NCT00196729_2_T3	GENE	26	26	0.9
NCT001967292	NCT00196729_2_T4	GENE	7	7	hormone
NCT001967292	NCT00196729_2_T5	GENE	16	16	hormone
NCT001967293	NCT00196729_3_T0	ORGAN	8	8	thyroid
NCT001967293	NCT00196729_3_T1	PHENOTYPE	15	15	hypothyroid
NCT001967293	NCT00196729_3_T2	GENE	18	18	TSH
NCT001967293	NCT00196729_3_T3	GENE	9	9	hormone
NCT001967294	NCT00196729_4_T0	COMPOUND	8	8	iodine
NCT001967294	NCT00196729_4_T1	GENE	12	12	3.7
NCT001967295	NCT00196729_5_T0	ORGAN	16	16	thyroid
NCT001967295	NCT00196729_5_T1	GENE	17	17	remnants
NCT001967295	NCT00196729_5_T2	GENE	18	18	had
NCT001967299	NCT00196729_9_T0	PHENOTYPE	13	13	Hypothyroid
NCT0019672910	NCT00196729_10_T0	ORGAN	8	8	thyroid
NCT0019672910	NCT00196729_10_T1	PHENOTYPE	10	10	suppression
NCT0019672910	NCT00196729_10_T2	GENE	9	9	hormone
NCT0019672911	NCT00196729_11_T0	GENE	9	9	TSH
NCT0019672913	NCT00196729_13_T0	GENE	15	15	3.7
NCT0019672917	NCT00196729_17_T0	PHENOTYPE	4	4	Hypothyroid
NCT0019672919	NCT00196729_19_T0	GENE	10	10	3.7
NCT0019672923	NCT00196729_23_T0	PHENOTYPE	8	8	Hypothyroid
NCT001967684	NCT00196768_4_T0	PHENOTYPE	20	20	relapse
NCT001967685	NCT00196768_5_T0	PHENOTYPE	34	34	relapse
NCT001967685	NCT00196768_5_T1	GENE	10	10	nested
NCT001967685	NCT00196768_5_T2	PHENOTYPE	7	7	MRD
NCT001967685	NCT00196768_5_T3	PHENOTYPE	25	25	MRD
NCT001967685	NCT00196768_5_T4	GENE	15	15	PCR
NCT001967685	NCT00196768_5_T5	PHENOTYPE	4	6	minimal residual disease
NCT001967687	NCT00196768_7_T0	PHENOTYPE	5	5	remission
NCT001967687	NCT00196768_7_T1	GENE	3	3	ATO
NCT001967687	NCT00196768_7_T2	PHENOTYPE	14	14	remissions
NCT001967687	NCT00196768_7_T3	COMPOUND	1	2	arsenic trioxide
NCT0019676810	NCT00196768_10_T0	GENE	0	0	ATO
NCT0019676813	NCT00196768_13_T0	GENE	3	3	ATO
NCT0019676814	NCT00196768_14_T0	PHENOTYPE	1	1	remission
NCT0019676815	NCT00196768_15_T0	COMPOUND	13	13	1
NCT0019676815	NCT00196768_15_T1	COMPOUND	19	19	2
NCT0019676815	NCT00196768_15_T2	COMPOUND	25	25	3
NCT0019676815	NCT00196768_15_T3	PHENOTYPE	54	54	remission
NCT0019676815	NCT00196768_15_T4	GENE	37	37	PCR
NCT0019676816	NCT00196768_16_T0	PHENOTYPE	5	5	remission
NCT0019676816	NCT00196768_16_T1	GENE	18	18	ATO
NCT0019676820	NCT00196768_20_T0	GENE	34	34	ATO
NCT0019676820	NCT00196768_20_T1	GENE	20	20	PCR
NCT0019676820	NCT00196768_20_T2	GENE	31	31	PCR
NCT0019676821	NCT00196768_21_T0	GENE	13	13	reduced
NCT0019676821	NCT00196768_21_T1	GENE	20	20	PCR
NCT0019676824	NCT00196768_24_T0	GENE	5	5	PCR
NCT0019676825	NCT00196768_25_T0	PHENOTYPE	14	14	toxicity
NCT0019676825	NCT00196768_25_T1	GENE	16	16	ATO
NCT0019676830	NCT00196768_30_T0	GENE	5	5	nested
NCT0019676830	NCT00196768_30_T1	GENE	10	10	PCR
NCT0019676833	NCT00196768_33_T0	GENE	15	15	ATO
NCT0019676833	NCT00196768_33_T1	GENE	12	12	PCR
NCT0019676835	NCT00196768_35_T0	GENE	5	5	PCR
NCT0019676839	NCT00196768_39_T0	GENE	7	7	ATO
NCT0019676839	NCT00196768_39_T1	PHENOTYPE	2	2	MRD
NCT0019676840	NCT00196768_40_T0	GENE	15	15	2.2
NCT0019676841	NCT00196768_41_T0	PHENOTYPE	20	20	remission
NCT0019676841	NCT00196768_41_T1	PHENOTYPE	26	26	remission
NCT0019676842	NCT00196768_42_T0	PHENOTYPE	16	16	toxicity
NCT001967818	NCT00196781_8_T0	GENE	22	22	RT
NCT001967818	NCT00196781_8_T1	PHENOTYPE	3	3	Association
NCT001967818	NCT00196781_8_T2	GENE	21	21	RP
NCT0019678117	NCT00196781_17_T0	PHENOTYPE	18	18	practices
NCT0019678117	NCT00196781_17_T1	PHENOTYPE	14	16	shared decision making
NCT0019678117	NCT00196781_17_T2	PHENOTYPE	7	9	quality of life
NCT001967942	NCT00196794_2_T0	PHENOTYPE	15	15	symptoms
NCT001967942	NCT00196794_2_T1	PHENOTYPE	19	19	diarrhea
NCT001968075	NCT00196807_5_T0	GENE	9	9	atypical
NCT001968203	NCT00196820_3_T0	GENE	8	8	PR
NCT001968203	NCT00196820_3_T1	GENE	7	7	CR
NCT001968204	NCT00196820_4_T0	PHENOTYPE	5	5	toxicity
NCT001968204	NCT00196820_4_T1	COMPOUND	7	7	capecitabine
NCT001968205	NCT00196820_5_T0	COMPOUND	11	11	capecitabine
NCT001968205	NCT00196820_5_T1	PHENOTYPE	2	4	quality of life
NCT0019682011	NCT00196820_11_T0	PHENOTYPE	2	5	carcinoma of the breast
NCT0019682013	NCT00196820_13_T0	GENE	14	14	0.2
NCT0019682013	NCT00196820_13_T1	GENE	19	19	FISH
NCT0019682013	NCT00196820_13_T2	PHENOTYPE	7	8	metastatic tumour
NCT0019682017	NCT00196820_17_T0	COMPOUND	11	11	capecitabine
NCT0019682017	NCT00196820_17_T1	COMPOUND	22	22	bisphosphonates
NCT0019682018	NCT00196820_18_T0	ORGAN	15	15	Appendix
NCT0019682021	NCT00196820_21_T0	GENE	9	9	portal
NCT0019682021	NCT00196820_21_T1	PHENOTYPE	17	18	progressive disease
NCT0019682021	NCT00196820_21_T2	PHENOTYPE	1	2	measurable disease
NCT0019682023	NCT00196820_23_T0	PHENOTYPE	3	3	tumor
NCT0019682026	NCT00196820_26_T0	GENE	1	1	18
NCT0019682030	NCT00196820_30_T0	PHENOTYPE	4	6	negative pregnancy test
NCT0019682031	NCT00196820_31_T0	GENE	4	4	has
NCT0019682038	NCT00196820_38_T0	PHENOTYPE	14	14	symptoms
NCT0019682038	NCT00196820_38_T1	PHENOTYPE	1	2	brain metastases
NCT0019682042	NCT00196820_42_T0	PHENOTYPE	4	5	psychiatric illness
NCT0019682044	NCT00196820_44_T0	PHENOTYPE	3	3	malignancy
NCT0019682044	NCT00196820_44_T1	PHENOTYPE	17	19	metastatic breast cancer
NCT001968331	NCT00196833_1_T0	PHENOTYPE	19	20	breast cancer
NCT001968333	NCT00196833_3_T0	PHENOTYPE	4	5	breast cancer
NCT001968333	NCT00196833_3_T1	PHENOTYPE	26	29	pregnancy and breast cancer
NCT001968334	NCT00196833_4_T0	PHENOTYPE	8	9	breast cancer
NCT001968336	NCT00196833_6_T0	PHENOTYPE	18	19	breast cancer
NCT001968337	NCT00196833_7_T0	TISSUE	9	9	tissues
NCT001968337	NCT00196833_7_T1	PHENOTYPE	6	6	tumour
NCT001968462	NCT00196846_2_T0	ORGAN	10	11	abdominal wall
NCT001968590	NCT00196859_0_T0	GENE	8	8	ICE
NCT001968590	NCT00196859_0_T1	PHENOTYPE	6	7	Breast Cancer
NCT001968593	NCT00196859_3_T0	GENE	4	4	has
NCT001968594	NCT00196859_4_T0	COMPOUND	16	16	capecitabine
NCT001968595	NCT00196859_5_T0	PHENOTYPE	4	4	toxicity
NCT001968596	NCT00196859_6_T0	PHENOTYPE	10	10	osteoporosis
NCT001968598	NCT00196859_8_T0	PHENOTYPE	16	16	osteoporosis
NCT001968598	NCT00196859_8_T1	PHENOTYPE	18	18	recurrence
NCT001968598	NCT00196859_8_T2	COMPOUND	4	4	ibandronate
NCT001968598	NCT00196859_8_T3	PHENOTYPE	20	21	breast cancer
NCT001968599	NCT00196859_9_T0	PHENOTYPE	34	34	secondary
NCT001968599	NCT00196859_9_T1	COMPOUND	19	19	ibandronate
NCT0019685913	NCT00196859_13_T0	PHENOTYPE	4	4	bilateral
NCT0019685913	NCT00196859_13_T1	PHENOTYPE	2	2	unilateral
NCT0019685913	NCT00196859_13_T2	PHENOTYPE	5	6	primary carcinoma
NCT0019685913	NCT00196859_13_T3	PHENOTYPE	6	9	carcinoma of the breast
NCT0019685917	NCT00196859_17_T0	PHENOTYPE	12	12	tumor
NCT0019685917	NCT00196859_17_T1	PHENOTYPE	1	2	sentinel node
NCT0019685917	NCT00196859_17_T2	PHENOTYPE	8	9	sentinel node
NCT0019685920	NCT00196859_20_T0	PHENOTYPE	4	4	metastasis
NCT0019685923	NCT00196859_23_T0	PHENOTYPE	10	11	breast cancer
NCT0019685931	NCT00196859_31_T0	PHENOTYPE	3	4	breast cancer
NCT0019685932	NCT00196859_32_T0	PHENOTYPE	1	3	invasive breast carcinoma
NCT0019685936	NCT00196859_36_T0	COMPOUND	3	3	bisphosphonates
NCT0019685936	NCT00196859_36_T1	GENE	11	11	has
NCT0019685936	NCT00196859_36_T2	PHENOTYPE	5	5	osteoporosis
NCT0019685937	NCT00196859_37_T0	PHENOTYPE	3	3	tumor
NCT0019685938	NCT00196859_38_T0	PHENOTYPE	4	4	tumor
NCT001968722	NCT00196872_2_T0	COMPOUND	9	9	capecitabine
NCT001968722	NCT00196872_2_T1	PHENOTYPE	17	17	tumour
NCT001968723	NCT00196872_3_T0	COMPOUND	14	14	capecitabine
NCT001968723	NCT00196872_3_T1	GENE	3	3	III
NCT001968723	NCT00196872_3_T2	PHENOTYPE	20	22	metastatic breast cancer
NCT001968725	NCT00196872_5_T0	PHENOTYPE	17	18	breast cancer
NCT001968729	NCT00196872_9_T0	PHENOTYPE	31	32	breast cancer
NCT0019687214	NCT00196872_14_T0	COMPOUND	9	9	capecitabine
NCT0019687214	NCT00196872_14_T1	PHENOTYPE	17	17	tumour
NCT0019687215	NCT00196872_15_T0	COMPOUND	14	14	capecitabine
NCT0019687215	NCT00196872_15_T1	GENE	3	3	III
NCT0019687215	NCT00196872_15_T2	PHENOTYPE	20	22	metastatic breast cancer
NCT0019687217	NCT00196872_17_T0	PHENOTYPE	17	18	breast cancer
NCT0019687221	NCT00196872_21_T0	PHENOTYPE	31	32	breast cancer
NCT0019687222	NCT00196872_22_T0	COMPOUND	9	9	bisphosphonates
NCT0019687222	NCT00196872_22_T1	PHENOTYPE	2	4	mechanism of action
NCT0019687223	NCT00196872_23_T0	COMPOUND	26	26	1st
NCT0019687223	NCT00196872_23_T1	COMPOUND	13	13	bisphosphonates
NCT0019687224	NCT00196872_24_T0	PHENOTYPE	10	10	toxic
NCT0019687224	NCT00196872_24_T1	COMPOUND	2	2	bisphosphonates
NCT0019687224	NCT00196872_24_T2	COMPOUND	4	4	ibandronate
NCT0019687225	NCT00196872_25_T0	COMPOUND	18	18	ibandronate
NCT001968981	NCT00196898_1_T0	PHENOTYPE	24	24	complication
NCT001968981	NCT00196898_1_T1	COMPOUND	27	27	dopamine
NCT001968981	NCT00196898_1_T2	PHENOTYPE	11	13	valvular heart disease
NCT001968986	NCT00196898_6_T0	COMPOUND	22	22	dopamine
NCT001968986	NCT00196898_6_T1	PHENOTYPE	5	7	valvular heart disease
NCT001968987	NCT00196898_7_T0	GENE	16	16	pointed
NCT001968987	NCT00196898_7_T1	ORGAN	5	6	heart valve
NCT001968988	NCT00196898_8_T0	PHENOTYPE	16	18	heart valvular disease
NCT001968989	NCT00196898_9_T0	PHENOTYPE	2	3	Parkinson's disease
NCT0019689810	NCT00196898_10_T0	ORGAN	7	7	heart
NCT0019689812	NCT00196898_12_T0	COMPOUND	3	3	dopamine
NCT0019689815	NCT00196898_15_T0	GENE	3	3	II
NCT0019689815	NCT00196898_15_T1	GENE	5	5	III
NCT0019689817	NCT00196898_17_T0	GENE	4	4	II
NCT0019689817	NCT00196898_17_T1	GENE	1	1	III
NCT0019689817	NCT00196898_17_T2	PHENOTYPE	17	19	valvular heart disease
NCT0019689818	NCT00196898_18_T0	GENE	13	13	II
NCT0019689818	NCT00196898_18_T1	PHENOTYPE	2	4	valvular heart disease
NCT001969114	NCT00196911_4_T0	GENE	7	7	III
NCT001969240	NCT00196924_0_T0	PHENOTYPE	1	1	Papilloma
NCT001969240	NCT00196924_0_T1	GENE	13	13	GSK
NCT001969244	NCT00196924_4_T0	PHENOTYPE	16	17	cervical cancer
NCT001969245	NCT00196924_5_T0	GENE	9	9	GSK
NCT001969246	NCT00196924_6_T0	PHENOTYPE	13	14	hepatitis A
NCT0019692412	NCT00196924_12_T0	PHENOTYPE	1	1	acute
NCT0019692412	NCT00196924_12_T1	PHENOTYPE	3	3	chronic
NCT0019692412	NCT00196924_12_T2	PHENOTYPE	11	13	renal functional abnormality
NCT001969373	NCT00196937_3_T0	GENE	9	9	GSK
NCT001969375	NCT00196937_5_T0	GENE	4	4	extended
NCT001969762	NCT00196976_2_T0	GENE	14	14	Act
NCT001969762	NCT00196976_2_T1	GENE	3	3	has
NCT001969762	NCT00196976_2_T2	GENE	15	15	Sep
NCT0019697611	NCT00196976_11_T0	PHENOTYPE	1	1	pertussis
NCT0019697611	NCT00196976_11_T1	PHENOTYPE	15	15	pertussis
NCT001970151	NCT00197015_1_T0	GENE	14	14	Act
NCT001970151	NCT00197015_1_T1	GENE	3	3	has
NCT001970151	NCT00197015_1_T2	GENE	15	15	Sep
NCT001970281	NCT00197028_1_T0	PHENOTYPE	6	6	malaria
NCT001970282	NCT00197028_2_T0	PHENOTYPE	12	12	HBV
NCT001970282	NCT00197028_2_T1	PHENOTYPE	9	10	hepatitis B
NCT001970283	NCT00197028_3_T0	PHENOTYPE	17	17	malaria
NCT001970283	NCT00197028_3_T1	PHENOTYPE	35	35	malaria
NCT001970283	NCT00197028_3_T2	PHENOTYPE	42	42	malaria
NCT001970284	NCT00197028_4_T0	GENE	22	22	0.5
NCT001970284	NCT00197028_4_T1	GENE	29	29	has
NCT001970284	NCT00197028_4_T2	PHENOTYPE	5	5	malaria
NCT001970284	NCT00197028_4_T3	GENE	26	26	GSK
NCT001970284	NCT00197028_4_T4	GENE	9	9	Expanded
NCT001970284	NCT00197028_4_T5	GENE	23	23	ml
NCT001970284	NCT00197028_4_T6	GENE	13	13	EPI
NCT001970285	NCT00197028_5_T0	GENE	14	14	Act
NCT001970285	NCT00197028_5_T1	GENE	3	3	has
NCT001970285	NCT00197028_5_T2	GENE	15	15	Sep
NCT001970288	NCT00197028_8_T0	PHENOTYPE	43	43	symptoms
NCT001970288	NCT00197028_8_T1	COMPOUND	24	24	Engerix-B
NCT001970288	NCT00197028_8_T2	COMPOUND	39	39	Engerix-B
NCT001970288	NCT00197028_8_T3	GENE	20	20	GSK
NCT001970288	NCT00197028_8_T4	GENE	35	35	GSK
NCT001970289	NCT00197028_9_T0	PHENOTYPE	1	2	adverse events
NCT0019702810	NCT00197028_10_T0	GENE	8	8	1.2
NCT0019702810	NCT00197028_10_T1	GENE	6	6	ml
NCT0019702810	NCT00197028_10_T2	BIOLOGICAL_PROCESS	21	22	immune response
NCT001970410	NCT00197041_0_T0	PHENOTYPE	14	14	Malaria
NCT001970410	NCT00197041_0_T1	GENE	11	11	GSK
NCT001970414	NCT00197041_4_T0	PHENOTYPE	7	7	Malaria
NCT001970414	NCT00197041_4_T1	PHENOTYPE	14	14	malaria
NCT001970414	NCT00197041_4_T2	PHENOTYPE	27	27	malaria
NCT001970414	NCT00197041_4_T3	GENE	0	0	GSK
NCT001970415	NCT00197041_5_T0	PHENOTYPE	6	6	malaria
NCT001970415	NCT00197041_5_T1	PHENOTYPE	22	23	hepatitis B
NCT001970416	NCT00197041_6_T0	GENE	19	19	1.11
NCT001970416	NCT00197041_6_T1	PHENOTYPE	6	6	malaria
NCT001970417	NCT00197041_7_T0	GENE	15	15	has
NCT001970417	NCT00197041_7_T1	PHENOTYPE	10	10	malaria
NCT0019704110	NCT00197041_10_T0	PHENOTYPE	2	2	pneumonia
NCT0019704110	NCT00197041_10_T1	PHENOTYPE	9	9	pneumoniae
NCT0019704110	NCT00197041_10_T2	PHENOTYPE	4	4	meningitis
NCT001970540	NCT00197054_0_T0	PHENOTYPE	14	14	Malaria
NCT001970546	NCT00197054_6_T0	PHENOTYPE	18	18	rabies
NCT001970547	NCT00197054_7_T0	GENE	5	5	IM
NCT001970548	NCT00197054_8_T0	PHENOTYPE	11	11	symptoms
NCT001970548	NCT00197054_8_T1	PHENOTYPE	17	17	symptoms
NCT001970549	NCT00197054_9_T0	PHENOTYPE	1	2	adverse events
NCT0019705411	NCT00197054_11_T0	PHENOTYPE	19	19	malaria
NCT001970670	NCT00197067_0_T0	GENE	23	23	IM
NCT001970670	NCT00197067_0_T1	GENE	14	14	0.5
NCT001970670	NCT00197067_0_T2	GENE	9	9	GSK
NCT001970673	NCT00197067_3_T0	PHENOTYPE	6	6	malaria
NCT001970673	NCT00197067_3_T1	PHENOTYPE	22	23	hepatitis B
NCT001970674	NCT00197067_4_T0	GENE	7	7	ml
NCT001970675	NCT00197067_5_T0	GENE	15	15	0.5
NCT001970675	NCT00197067_5_T1	GENE	26	26	0.5
NCT001970675	NCT00197067_5_T2	GENE	30	30	has
NCT001970675	NCT00197067_5_T3	GENE	34	34	has
NCT001970675	NCT00197067_5_T4	GENE	6	6	EPI
NCT001970675	NCT00197067_5_T5	GENE	16	16	ml
NCT001970675	NCT00197067_5_T6	GENE	27	27	ml
NCT001970675	NCT00197067_5_T7	GENE	47	47	ml
NCT001970676	NCT00197067_6_T0	GENE	4	4	0.5
NCT001970676	NCT00197067_6_T1	GENE	5	5	ml
NCT001970676	NCT00197067_6_T2	GENE	15	15	ml
NCT001970679	NCT00197067_9_T0	BIOLOGICAL_PROCESS	13	14	immune response
NCT001970931	NCT00197093_1_T0	PHENOTYPE	7	7	concentrations
NCT001971060	NCT00197106_0_T0	PHENOTYPE	3	5	Asthma In Children
NCT001971062	NCT00197106_2_T0	GENE	10	10	bd
NCT001971062	NCT00197106_2_T1	COMPOUND	6	6	salmeterol
NCT001971062	NCT00197106_2_T2	PHENOTYPE	26	26	enables
NCT001971062	NCT00197106_2_T3	PHENOTYPE	19	20	lung function
NCT001971062	NCT00197106_2_T4	COMPOUND	7	8	fluticasone propionate
NCT001971062	NCT00197106_2_T5	PHENOTYPE	23	24	bronchial hyperreactivity
NCT001971062	NCT00197106_2_T6	PHENOTYPE	31	33	asthma in children
NCT001971190	NCT00197119_0_T0	PHENOTYPE	14	14	Hepatitis
NCT001971190	NCT00197119_0_T1	GENE	9	9	10
NCT001971194	NCT00197119_4_T0	PHENOTYPE	1	1	persistence
NCT001971194	NCT00197119_4_T1	PHENOTYPE	17	18	hepatitis A
NCT001971194	NCT00197119_4_T2	PHENOTYPE	20	21	hepatitis B
NCT001971195	NCT00197119_5_T0	PHENOTYPE	31	31	persistence
NCT001971195	NCT00197119_5_T1	PHENOTYPE	23	24	hepatitis A
NCT001971196	NCT00197119_6_T0	GENE	14	14	Act
NCT001971196	NCT00197119_6_T1	GENE	3	3	has
NCT001971196	NCT00197119_6_T2	GENE	15	15	Sep
NCT001971712	NCT00197171_2_T0	PHENOTYPE	1	1	persistence
NCT001971712	NCT00197171_2_T1	GENE	11	11	GSK
NCT001971712	NCT00197171_2_T2	PHENOTYPE	14	15	hepatitis A
NCT001971712	NCT00197171_2_T3	PHENOTYPE	17	18	hepatitis B
NCT001971713	NCT00197171_3_T0	PHENOTYPE	28	28	persistence
NCT001971713	NCT00197171_3_T1	PHENOTYPE	20	21	hepatitis A
NCT001971841	NCT00197184_1_T0	GENE	14	14	Act
NCT001971841	NCT00197184_1_T1	GENE	3	3	has
NCT001971841	NCT00197184_1_T2	GENE	15	15	Sep
NCT001971844	NCT00197184_4_T0	PHENOTYPE	1	1	persistence
NCT001971844	NCT00197184_4_T1	GENE	15	15	GSK
NCT001971844	NCT00197184_4_T2	PHENOTYPE	18	19	hepatitis A
NCT001971844	NCT00197184_4_T3	PHENOTYPE	21	22	hepatitis B
NCT001971845	NCT00197184_5_T0	PHENOTYPE	30	30	persistence
NCT001971845	NCT00197184_5_T1	PHENOTYPE	22	23	hepatitis A
NCT001972231	NCT00197223_1_T0	GENE	0	0	GSK
NCT001972232	NCT00197223_2_T0	PHENOTYPE	18	18	influenza
NCT001972232	NCT00197223_2_T1	PHENOTYPE	24	24	Influenza
NCT001972235	NCT00197223_5_T0	PHENOTYPE	5	7	negative pregnancy test
NCT001972237	NCT00197223_7_T0	PHENOTYPE	0	0	Acute
NCT001972237	NCT00197223_7_T1	PHENOTYPE	16	16	fever
NCT001972361	NCT00197236_1_T0	GENE	14	14	Act
NCT001972361	NCT00197236_1_T1	GENE	3	3	has
NCT001972361	NCT00197236_1_T2	GENE	15	15	Sep
NCT001972491	NCT00197249_1_T0	PHENOTYPE	6	6	persistence
NCT001972491	NCT00197249_1_T1	PHENOTYPE	10	10	HAV
NCT001972621	NCT00197262_1_T0	GENE	8	8	SAR
NCT001972621	NCT00197262_1_T1	PHENOTYPE	13	14	allergic rhinitis
NCT001972621	NCT00197262_1_T2	PHENOTYPE	5	7	seasonal allergic rhinitis
NCT001972622	NCT00197262_2_T0	PHENOTYPE	14	14	pruritus
NCT001972622	NCT00197262_2_T1	PHENOTYPE	15	15	rhinorrhea
NCT001972622	NCT00197262_2_T2	PHENOTYPE	19	20	red eyes
NCT001972622	NCT00197262_2_T3	PHENOTYPE	11	12	nasal congestion
NCT001972622	NCT00197262_2_T4	PHENOTYPE	4	5	hay fever
NCT001972623	NCT00197262_3_T0	GENE	42	42	SAR
NCT001972623	NCT00197262_3_T1	PHENOTYPE	39	41	seasonal allergic rhinitis
NCT001973011	NCT00197301_1_T0	BIOLOGICAL_PROCESS	30	31	immune response
NCT001973140	NCT00197314_0_T0	PHENOTYPE	11	13	Urinary Stress Incontinence
NCT001973142	NCT00197314_2_T0	TISSUE	13	13	muscles
NCT001973142	NCT00197314_2_T1	ORGAN	25	25	rectum
NCT001973142	NCT00197314_2_T2	ORGAN	22	22	eyes
NCT001973142	NCT00197314_2_T3	ORGAN	29	30	pelvic floor
NCT001973143	NCT00197314_3_T0	ORGAN	14	15	pelvic floor
NCT001973148	NCT00197314_8_T0	PHENOTYPE	14	15	stress incontinence
NCT0019731411	NCT00197314_11_T0	TISSUE	7	7	muscles
NCT0019731413	NCT00197314_13_T0	GENE	14	14	SI
NCT0019731414	NCT00197314_14_T0	PHENOTYPE	14	14	Pad
NCT0019731415	NCT00197314_15_T0	PHENOTYPE	11	11	Pad
NCT0019731415	NCT00197314_15_T1	PHENOTYPE	16	16	leakage
NCT0019731415	NCT00197314_15_T2	PHENOTYPE	24	24	leakage
NCT0019731415	NCT00197314_15_T3	PHENOTYPE	25	27	quality of life
NCT001973271	NCT00197327_1_T0	PHENOTYPE	18	18	profound
NCT001973271	NCT00197327_1_T1	PHENOTYPE	33	33	satisfied
NCT001973273	NCT00197327_3_T0	COMPOUND	6	6	bupivacaine
NCT001973273	NCT00197327_3_T1	PHENOTYPE	22	22	analgesia
NCT001973400	NCT00197340_0_T0	PHENOTYPE	16	16	Pre-Eclampsia
NCT001973400	NCT00197340_0_T1	PHENOTYPE	1	1	Chronic
NCT001973400	NCT00197340_0_T2	ORGAN	11	11	Uterus
NCT001973400	NCT00197340_0_T3	COMPOUND	4	4	ACET
NCT001973400	NCT00197340_0_T4	PHENOTYPE	18	20	Intrauterine Growth Restriction
NCT001973402	NCT00197340_2_T0	PHENOTYPE	1	1	disorders
NCT001973402	NCT00197340_2_T1	PHENOTYPE	6	6	impairment
NCT001973403	NCT00197340_3_T0	GENE	3	3	has
NCT001973406	NCT00197340_6_T0	COMPOUND	10	10	magnesium
NCT001973408	NCT00197340_8_T0	ORGAN	6	7	uterine artery
NCT0019734011	NCT00197340_11_T0	BIOLOGICAL_PROCESS	16	16	gestation
NCT0019734012	NCT00197340_12_T0	GENE	12	12	LMP
NCT0019734012	NCT00197340_12_T1	GENE	17	17	LMP
NCT0019734014	NCT00197340_14_T0	COMPOUND	14	14	1
NCT0019734016	NCT00197340_16_T0	ORGAN	2	3	uterine artery
NCT0019734018	NCT00197340_18_T0	GENE	1	1	4a
NCT0019734018	NCT00197340_18_T1	GENE	12	12	4a
NCT0019734018	NCT00197340_18_T2	GENE	13	13	4a
NCT0019734018	NCT00197340_18_T3	GENE	3	3	4b
NCT0019734020	NCT00197340_20_T0	GENE	7	7	g-l
NCT0019734020	NCT00197340_20_T1	PHENOTYPE	2	2	Proteinuria
NCT0019734021	NCT00197340_21_T0	GENE	0	0	OR
NCT0019734023	NCT00197340_23_T0	GENE	3	3	abdominal
NCT0019734024	NCT00197340_24_T0	PHENOTYPE	3	3	IUGR
NCT001973533	NCT00197353_3_T0	PHENOTYPE	3	3	focused
NCT001973534	NCT00197353_4_T0	COMPOUND	9	9	bupivacaine
NCT001973534	NCT00197353_4_T1	COMPOUND	15	15	bupivacaine
NCT001973534	NCT00197353_4_T2	COMPOUND	22	22	bupivacaine
NCT001973534	NCT00197353_4_T3	GENE	17	18	group C
NCT001973661	NCT00197366_1_T0	PHENOTYPE	9	9	resistant
NCT001973661	NCT00197366_1_T1	PHENOTYPE	11	11	strains
NCT001973662	NCT00197366_2_T0	PHENOTYPE	8	8	HIV
NCT001973662	NCT00197366_2_T1	PHENOTYPE	15	15	HIV
NCT001973663	NCT00197366_3_T0	PHENOTYPE	12	12	strain
NCT001973663	NCT00197366_3_T1	PHENOTYPE	10	10	resistant
NCT001973663	NCT00197366_3_T2	PHENOTYPE	14	14	transmitted
NCT001973665	NCT00197366_5_T0	PHENOTYPE	7	7	HIV
NCT001973666	NCT00197366_6_T0	PHENOTYPE	3	3	HIV
NCT001973668	NCT00197366_8_T0	PHENOTYPE	13	13	initiation
NCT0019736611	NCT00197366_11_T0	PHENOTYPE	4	4	transmitted
NCT0019736612	NCT00197366_12_T0	PHENOTYPE	31	31	HIV
NCT0019736613	NCT00197366_13_T0	PHENOTYPE	13	13	transmitted
NCT0019736617	NCT00197366_17_T0	PHENOTYPE	0	0	HIV
NCT001973791	NCT00197379_1_T0	GENE	8	8	has
NCT001973792	NCT00197379_2_T0	COMPOUND	4	4	roxithromycin
NCT001973792	NCT00197379_2_T1	TISSUE	12	13	hair follicle
NCT001973799	NCT00197379_9_T0	COMPOUND	5	5	roxithromycin
NCT001973799	NCT00197379_9_T1	PHENOTYPE	10	11	androgenetic alopecia
NCT001973920	NCT00197392_0_T0	GENE	7	7	TM
NCT001973922	NCT00197392_2_T0	GENE	15	15	CSF
NCT001973923	NCT00197392_3_T0	COMPOUND	16	16	clindamycin
NCT001973926	NCT00197392_6_T0	GENE	4	4	has
NCT001973929	NCT00197392_9_T0	PHENOTYPE	27	28	catheter infection
NCT0019739210	NCT00197392_10_T0	PHENOTYPE	18	19	catheter infections
NCT001974053	NCT00197405_3_T0	GENE	20	20	127
NCT001974053	NCT00197405_3_T1	GENE	5	5	COX-2
NCT001974053	NCT00197405_3_T2	PHENOTYPE	16	17	colorectal cancer
NCT001974054	NCT00197405_4_T0	PHENOTYPE	16	16	adenoma
NCT001974054	NCT00197405_4_T1	PHENOTYPE	13	14	colorectal cancer
NCT001974180	NCT00197418_0_T0	PHENOTYPE	11	11	Infection
NCT001974186	NCT00197418_6_T0	GENE	15	15	has
NCT001974310	NCT00197431_0_T0	PHENOTYPE	11	11	Cancer
NCT001974312	NCT00197431_2_T0	GENE	4	4	CYP2A6
NCT001974312	NCT00197431_2_T1	GENE	6	6	DPD
NCT001974313	NCT00197431_3_T0	GENE	13	13	CYP2A6
NCT001974313	NCT00197431_3_T1	PHENOTYPE	19	19	pharmacodynamics
NCT001974313	NCT00197431_3_T2	PHENOTYPE	17	17	pharmacokinetics
NCT001974313	NCT00197431_3_T3	GENE	15	15	DPD
NCT001974443	NCT00197444_3_T0	ORGAN	13	13	abdomen
NCT001974444	NCT00197444_4_T0	GENE	11	11	1.5
NCT001974444	NCT00197444_4_T1	GENE	24	24	1.5
NCT001974444	NCT00197444_4_T2	GENE	14	14	22.26
NCT001974444	NCT00197444_4_T3	GENE	27	27	22.26
NCT001974446	NCT00197444_6_T0	GENE	1	1	receptor
NCT001974447	NCT00197444_7_T0	PHENOTYPE	0	0	Tumor
NCT001974447	NCT00197444_7_T1	PHENOTYPE	11	12	Solid Tumors
NCT001974448	NCT00197444_8_T0	PHENOTYPE	0	0	Toxicities
NCT001974448	NCT00197444_8_T1	PHENOTYPE	10	11	Adverse Events
NCT001974448	NCT00197444_8_T2	PHENOTYPE	6	10	Common Terminology Criteria for Adverse
NCT001974573	NCT00197457_3_T0	GENE	4	4	PG
NCT001974573	NCT00197457_3_T1	GENE	23	24	proton pump
NCT001974575	NCT00197457_5_T0	GENE	7	7	II
NCT001974575	NCT00197457_5_T1	GENE	3	3	PG
NCT001974575	NCT00197457_5_T2	GENE	6	6	PG
NCT001974575	NCT00197457_5_T3	ORGAN	0	0	Serum
NCT001974576	NCT00197457_6_T0	COMPOUND	13	13	UBT
NCT001974704	NCT00197470_4_T0	CELL	13	13	cells
NCT001974704	NCT00197470_4_T1	PHENOTYPE	1	1	chronic
NCT001974704	NCT00197470_4_T2	PHENOTYPE	3	3	gastritis
NCT001974704	NCT00197470_4_T3	CELL	10	10	neutrophils
NCT001974705	NCT00197470_5_T0	TISSUE	11	12	gastric mucosa
NCT001974706	NCT00197470_6_T0	PHENOTYPE	8	9	autoimmune diseases
NCT001974831	NCT00197483_1_T0	PHENOTYPE	11	11	symptoms
NCT001974831	NCT00197483_1_T1	PHENOTYPE	20	20	schizophrenia
NCT001974831	NCT00197483_1_T2	PHENOTYPE	13	14	cognitive dysfunction
NCT001974832	NCT00197483_2_T0	PHENOTYPE	14	14	symptoms
NCT001974832	NCT00197483_2_T1	PHENOTYPE	23	23	schizophrenia
NCT001974832	NCT00197483_2_T2	COMPOUND	7	7	pergolide
NCT001974832	NCT00197483_2_T3	PHENOTYPE	16	17	cognitive impairments
NCT001974833	NCT00197483_3_T0	PHENOTYPE	14	14	symptoms
NCT001974833	NCT00197483_3_T1	PHENOTYPE	19	19	schizophrenia
NCT001974833	NCT00197483_3_T2	COMPOUND	11	11	pergolide
NCT001974833	NCT00197483_3_T3	PHENOTYPE	16	17	cognitive impairments
NCT0019749611	NCT00197496_11_T0	GENE	14	14	has
NCT0019749616	NCT00197496_16_T0	ORGAN	4	5	Lower Extremity
NCT0019749616	NCT00197496_16_T1	PHENOTYPE	9	11	quality of life
NCT001975093	NCT00197509_3_T0	PHENOTYPE	34	34	disorders
NCT001975093	NCT00197509_3_T1	GENE	19	19	has
NCT001975093	NCT00197509_3_T2	ORGAN	25	26	lower extremities
NCT001975094	NCT00197509_4_T0	PHENOTYPE	2	2	acute
NCT001975094	NCT00197509_4_T1	GENE	35	35	LTC
NCT001975095	NCT00197509_5_T0	PHENOTYPE	56	56	injuries
NCT001975095	NCT00197509_5_T1	PHENOTYPE	62	62	falls
NCT001975095	NCT00197509_5_T2	GENE	17	17	STS
NCT001975095	NCT00197509_5_T3	GENE	83	83	STS
NCT001975095	NCT00197509_5_T4	BIOLOGICAL_PROCESS	76	76	translation
NCT001975095	NCT00197509_5_T5	GENE	33	33	LTC
NCT001975095	NCT00197509_5_T6	PHENOTYPE	65	67	quality of life
NCT001975221	NCT00197522_1_T0	TISSUE	17	17	thymus
NCT001975221	NCT00197522_1_T1	TISSUE	13	14	lymph nodes
NCT001975221	NCT00197522_1_T2	CELL	0	1	Dendritic cells
NCT001975221	NCT00197522_1_T3	ORGAN	11	12	bone marrow
NCT001975221	NCT00197522_1_T4	CELL	5	7	antigen presenting cells
NCT001975222	NCT00197522_2_T0	GENE	5	5	Ad
NCT001975222	NCT00197522_2_T1	PHENOTYPE	4	4	Adenovirus
NCT001975222	NCT00197522_2_T2	PHENOTYPE	11	11	tumor
NCT001975222	NCT00197522_2_T3	PHENOTYPE	23	23	tumor
NCT001975222	NCT00197522_2_T4	PHENOTYPE	13	13	enables
NCT001975224	NCT00197522_4_T0	PHENOTYPE	15	15	melanoma
NCT001975224	NCT00197522_4_T1	PHENOTYPE	12	13	breast cancer
NCT001975225	NCT00197522_5_T0	PHENOTYPE	15	15	tumor
NCT001975226	NCT00197522_6_T0	CELL	9	9	lymphocytes
NCT001975226	NCT00197522_6_T1	CELL	15	15	cells
NCT001975226	NCT00197522_6_T2	CELL	33	33	cells
NCT001975226	NCT00197522_6_T3	PHENOTYPE	22	22	tumor
NCT001975226	NCT00197522_6_T4	PHENOTYPE	32	32	tumor
NCT001975226	NCT00197522_6_T5	PHENOTYPE	23	23	regression
NCT001975227	NCT00197522_7_T0	CELL	13	13	cells
NCT001975227	NCT00197522_7_T1	PHENOTYPE	5	5	immunity
NCT001975228	NCT00197522_8_T0	PHENOTYPE	19	19	toxicity
NCT001975228	NCT00197522_8_T1	PHENOTYPE	14	15	metastatic disease
NCT0019752211	NCT00197522_11_T0	PHENOTYPE	14	14	enabling
NCT0019752211	NCT00197522_11_T1	PHENOTYPE	5	5	tumor
NCT0019752211	NCT00197522_11_T2	ORGAN	27	28	immune system
NCT0019752213	NCT00197522_13_T0	CELL	1	1	cells
NCT0019752213	NCT00197522_13_T1	CELL	16	16	cells
NCT0019752213	NCT00197522_13_T2	PHENOTYPE	10	10	tumour
NCT0019752213	NCT00197522_13_T3	PHENOTYPE	15	15	tumour
NCT0019752215	NCT00197522_15_T0	PHENOTYPE	23	25	metastatic breast cancer
NCT0019752217	NCT00197522_17_T0	GENE	8	8	II
NCT0019752217	NCT00197522_17_T1	GENE	10	10	III
NCT0019752218	NCT00197522_18_T0	PHENOTYPE	12	13	breast cancer
NCT0019752220	NCT00197522_20_T0	PHENOTYPE	0	0	Peripheral
NCT0019752220	NCT00197522_20_T1	GENE	16	16	G-CSF
NCT0019752220	NCT00197522_20_T2	GENE	14	14	GM-CSF
NCT0019752220	NCT00197522_20_T3	CELL	2	3	progenitor cells
NCT0019752221	NCT00197522_21_T0	GENE	15	15	interleukin-4
NCT0019752221	NCT00197522_21_T1	CELL	2	2	cells
NCT0019752221	NCT00197522_21_T2	GENE	8	8	GM-CSF
NCT0019752221	NCT00197522_21_T3	GENE	1	1	CD34
NCT0019752221	NCT00197522_21_T4	GENE	11	11	Flt-3
NCT0019752222	NCT00197522_22_T0	GENE	1	1	CD34
NCT0019752222	NCT00197522_22_T1	CELL	3	4	dendritic cells
NCT0019752225	NCT00197522_25_T0	CELL	4	5	dendritic cells
NCT0019752226	NCT00197522_26_T0	PHENOTYPE	14	14	toxicity
NCT0019752226	NCT00197522_26_T1	PHENOTYPE	11	11	experiences
NCT0019752226	NCT00197522_26_T2	GENE	15	15	DLT
NCT0019752227	NCT00197522_27_T0	PHENOTYPE	3	3	experiences
NCT0019752227	NCT00197522_27_T1	GENE	4	4	DLT
NCT0019752227	NCT00197522_27_T2	GENE	24	24	DLT
NCT0019752228	NCT00197522_28_T0	GENE	29	29	fold
NCT0019752228	NCT00197522_28_T1	GENE	6	6	DLT
NCT001975485	NCT00197548_5_T0	PHENOTYPE	25	25	HIV
NCT001975485	NCT00197548_5_T1	PHENOTYPE	21	22	preterm birth
NCT001975485	NCT00197548_5_T2	PHENOTYPE	16	18	low birth weight
NCT001975486	NCT00197548_6_T0	PHENOTYPE	21	22	preterm birth
NCT001975486	NCT00197548_6_T1	PHENOTYPE	17	19	low birth weight
NCT001975610	NCT00197561_0_T0	PHENOTYPE	4	4	HIV/AIDS
NCT001975610	NCT00197561_0_T1	COMPOUND	12	12	Selenium
NCT001975610	NCT00197561_0_T2	PHENOTYPE	14	15	HIV Infection
NCT001975614	NCT00197561_4_T0	COMPOUND	9	9	nevirapine
NCT001975615	NCT00197561_5_T0	COMPOUND	7	7	selenium
NCT001975615	NCT00197561_5_T1	PHENOTYPE	19	19	HIV
NCT001975615	NCT00197561_5_T2	PHENOTYPE	22	23	disease progression
NCT001975873	NCT00197587_3_T0	COMPOUND	12	12	nevirapine
NCT001975876	NCT00197587_6_T0	PHENOTYPE	14	14	HIV
NCT001975878	NCT00197587_8_T0	PHENOTYPE	5	5	tolerance
NCT001975879	NCT00197587_9_T0	PHENOTYPE	5	5	tolerance
NCT0019758711	NCT00197587_11_T0	PHENOTYPE	19	19	HIV
NCT001976391	NCT00197639_1_T0	PHENOTYPE	4	4	HIV
NCT001976393	NCT00197639_3_T0	PHENOTYPE	18	18	HIV
NCT001976393	NCT00197639_3_T1	GENE	23	23	HSC
NCT001976395	NCT00197639_5_T0	PHENOTYPE	2	2	concentrations
NCT001976395	NCT00197639_5_T1	ORGAN	1	1	plasma
NCT001976397	NCT00197639_7_T0	GENE	20	20	VI
NCT001976397	NCT00197639_7_T1	PHENOTYPE	16	16	regression
NCT001976397	NCT00197639_7_T2	COMPOUND	7	7	ritonavir
NCT001976397	NCT00197639_7_T3	COMPOUND	5	5	indinavir
NCT001976398	NCT00197639_8_T0	PHENOTYPE	13	13	VPC
NCT001976521	NCT00197652_1_T0	COMPOUND	0	0	2
NCT001976521	NCT00197652_1_T1	PHENOTYPE	14	14	HIV
NCT001976524	NCT00197652_4_T0	PHENOTYPE	1	1	HIV
NCT001976524	NCT00197652_4_T1	GENE	6	6	PCR
NCT001976782	NCT00197678_2_T0	COMPOUND	7	7	nevirapine
NCT001976782	NCT00197678_2_T1	PHENOTYPE	15	15	HIV
NCT001976911	NCT00197691_1_T0	PHENOTYPE	8	8	diseases
NCT001976912	NCT00197691_2_T0	PHENOTYPE	16	17	respiratory disease
NCT001977040	NCT00197704_0_T0	PHENOTYPE	5	5	Tuberculosis
NCT001977043	NCT00197704_3_T0	PHENOTYPE	8	8	HIV
NCT001977043	NCT00197704_3_T1	PHENOTYPE	24	25	HIV infection
NCT001977044	NCT00197704_4_T0	BIOLOGICAL_PROCESS	13	14	immune response
NCT001977044	NCT00197704_4_T1	PHENOTYPE	7	8	vitamin deficiency
NCT001977302	NCT00197730_2_T0	PHENOTYPE	25	26	low birthweight
NCT001977303	NCT00197730_3_T0	COMPOUND	12	13	vitamin A
NCT001977303	NCT00197730_3_T1	PHENOTYPE	17	18	diarrheal disease
NCT001977304	NCT00197730_4_T0	PHENOTYPE	13	13	susceptible
NCT001977305	NCT00197730_5_T0	PHENOTYPE	3	3	HIV
NCT001977305	NCT00197730_5_T1	PHENOTYPE	17	17	malabsorption
NCT001977306	NCT00197730_6_T0	PHENOTYPE	5	5	HIV
NCT001977306	NCT00197730_6_T1	PHENOTYPE	17	17	illnesses
NCT001977307	NCT00197730_7_T0	PHENOTYPE	25	26	HIV positive
NCT001977430	NCT00197743_0_T0	PHENOTYPE	5	5	Progression
NCT001977430	NCT00197743_0_T1	PHENOTYPE	4	4	HIV
NCT001977430	NCT00197743_0_T2	PHENOTYPE	7	7	Transmission
NCT001977433	NCT00197743_3_T0	PHENOTYPE	19	19	wasting
NCT001977560	NCT00197756_0_T0	PHENOTYPE	2	2	HIV
NCT001977562	NCT00197756_2_T0	PHENOTYPE	11	11	HIV
NCT001977692	NCT00197769_2_T0	PHENOTYPE	9	9	strains
NCT001977692	NCT00197769_2_T1	PHENOTYPE	22	22	strains
NCT001977696	NCT00197769_6_T0	GENE	7	7	booster
NCT001977697	NCT00197769_7_T0	PHENOTYPE	16	16	strains
NCT001978341	NCT00197834_1_T0	GENE	27	27	NPI
NCT001978344	NCT00197834_4_T0	GENE	4	4	ER
NCT001978348	NCT00197834_8_T0	PHENOTYPE	10	10	symptoms
NCT0019783410	NCT00197834_10_T0	GENE	3	3	atypical
NCT0019783410	NCT00197834_10_T1	GENE	19	19	acetylcholinesterase
NCT0019783413	NCT00197834_13_T0	GENE	22	22	NPI
NCT0019783413	NCT00197834_13_T1	GENE	24	24	NH
NCT0019783415	NCT00197834_15_T0	GENE	15	15	1.3
NCT0019783417	NCT00197834_17_T0	GENE	20	20	NPI
NCT001978471	NCT00197847_1_T0	COMPOUND	7	7	Procalcitonin
NCT001978602	NCT00197860_2_T0	GENE	6	6	survivin
NCT001978602	NCT00197860_2_T1	GENE	8	8	telomerase
NCT001978602	NCT00197860_2_T2	PHENOTYPE	20	20	tumor
NCT001978602	NCT00197860_2_T3	CELL	10	11	dendritic cells
NCT001978602	NCT00197860_2_T4	CELL	22	23	dendritic cells
NCT001978604	NCT00197860_4_T0	CELL	1	2	dendritic cells
NCT001978605	NCT00197860_5_T0	GENE	1	1	A2
NCT001978605	NCT00197860_5_T1	GENE	12	12	survivin
NCT001978605	NCT00197860_5_T2	GENE	14	14	telomerase
NCT001978606	NCT00197860_6_T0	GENE	1	1	A2
NCT001978606	NCT00197860_6_T1	COMPOUND	7	7	KLH
NCT001978608	NCT00197860_8_T0	GENE	1	1	1.4
NCT001978731	NCT00197873_1_T0	PHENOTYPE	17	17	diarrhoea
NCT001978732	NCT00197873_2_T0	PHENOTYPE	4	5	colorectal cancer
NCT001978734	NCT00197873_4_T0	PHENOTYPE	8	8	diarrhoea
NCT001978738	NCT00197873_8_T0	COMPOUND	17	17	capecitabine
NCT001978738	NCT00197873_8_T1	PHENOTYPE	9	9	metastases
NCT001978738	NCT00197873_8_T2	COMPOUND	18	18	oxaliplatin
NCT001978738	NCT00197873_8_T3	PHENOTYPE	4	5	colorectal cancer
NCT0019787311	NCT00197873_11_T0	COMPOUND	9	9	CFU
NCT0019787312	NCT00197873_12_T0	GENE	10	10	2.4
NCT0019787312	NCT00197873_12_T1	PHENOTYPE	8	8	diarrhoea
NCT0019787313	NCT00197873_13_T0	PHENOTYPE	9	9	constipation
NCT0019787313	NCT00197873_13_T1	PHENOTYPE	8	8	bloating
NCT0019787313	NCT00197873_13_T2	PHENOTYPE	7	7	flatulence
NCT0019787313	NCT00197873_13_T3	PHENOTYPE	6	6	diarrhoea
NCT0019787313	NCT00197873_13_T4	PHENOTYPE	11	11	nausea
NCT0019787313	NCT00197873_13_T5	PHENOTYPE	0	1	Adverse effects
NCT001978862	NCT00197886_2_T0	COMPOUND	1	1	norepinephrine
NCT001978862	NCT00197886_2_T1	CELL	17	17	cells
NCT001978862	NCT00197886_2_T2	COMPOUND	14	14	oxygen
NCT001978864	NCT00197886_4_T0	COMPOUND	8	8	norepinephrine
NCT001978864	NCT00197886_4_T1	PHENOTYPE	12	12	concentrations
NCT001978864	NCT00197886_4_T2	ORGAN	18	18	rectum
NCT001978864	NCT00197886_4_T3	COMPOUND	14	15	lactic acid
NCT001978991	NCT00197899_1_T0	COMPOUND	1	1	Endotoxin
NCT001979122	NCT00197912_2_T0	GENE	7	7	survivin
NCT001979122	NCT00197912_2_T1	GENE	9	9	telomerase
NCT001979122	NCT00197912_2_T2	PHENOTYPE	21	21	tumor
NCT001979122	NCT00197912_2_T3	GENE	6	6	p53
NCT001979122	NCT00197912_2_T4	CELL	11	12	dendritic cells
NCT001979122	NCT00197912_2_T5	CELL	24	25	dendritic cells
NCT001979123	NCT00197912_3_T0	COMPOUND	16	16	celecoxib
NCT001979123	NCT00197912_3_T1	COMPOUND	2	2	cyclophosphamide
NCT001979124	NCT00197912_4_T0	GENE	6	6	Interleukin-2
NCT001979126	NCT00197912_6_T0	CELL	1	2	dendritic cells
NCT001979127	NCT00197912_7_T0	GENE	1	1	A2
NCT001979127	NCT00197912_7_T1	GENE	13	13	survivin
NCT001979127	NCT00197912_7_T2	GENE	15	15	telomerase
NCT001979127	NCT00197912_7_T3	GENE	12	12	p53
NCT001979128	NCT00197912_8_T0	GENE	1	1	A2
NCT001979128	NCT00197912_8_T1	COMPOUND	7	7	KLH
NCT0019791210	NCT00197912_10_T0	GENE	1	1	1.4
NCT0019791213	NCT00197912_13_T0	GENE	0	0	IL-2
NCT001979253	NCT00197925_3_T0	GENE	1	1	1.4
NCT001979256	NCT00197925_6_T0	GENE	6	6	sc
NCT001979256	NCT00197925_6_T1	GENE	3	3	IL-2
NCT001979382	NCT00197938_2_T0	COMPOUND	14	15	lactic acid
NCT001979382	NCT00197938_2_T1	PHENOTYPE	24	26	multiple organ failure
NCT001979643	NCT00197964_3_T0	PHENOTYPE	14	14	asthma
NCT001979644	NCT00197964_4_T0	PHENOTYPE	6	6	self-efficacy
NCT001979644	NCT00197964_4_T1	PHENOTYPE	5	5	asthma
NCT001979644	NCT00197964_4_T2	PHENOTYPE	20	20	asthma
NCT001979645	NCT00197964_5_T0	PHENOTYPE	0	0	Asthma
NCT001979774	NCT00197977_4_T0	PHENOTYPE	8	9	knee symptoms
NCT001979903	NCT00197990_3_T0	PHENOTYPE	25	25	complications
NCT001979904	NCT00197990_4_T0	PHENOTYPE	14	14	fulfillment
NCT001980162	NCT00198016_2_T0	GENE	8	8	CAF
NCT001980164	NCT00198016_4_T0	GENE	0	0	CAF
NCT001980166	NCT00198016_6_T0	PHENOTYPE	13	13	rupture
NCT001980166	NCT00198016_6_T1	PHENOTYPE	3	3	symptoms
NCT001980166	NCT00198016_6_T2	PHENOTYPE	17	17	fistula
NCT001980166	NCT00198016_6_T3	PHENOTYPE	8	9	infective endocarditis
NCT001980166	NCT00198016_6_T4	PHENOTYPE	10	11	myocardial ischemia
NCT001980166	NCT00198016_6_T5	PHENOTYPE	5	7	congestive heart failure
NCT001980167	NCT00198016_7_T0	PHENOTYPE	3	5	coronary artery fistula
NCT001980169	NCT00198016_9_T0	GENE	3	3	CAF
NCT0019801610	NCT00198016_10_T0	PHENOTYPE	11	11	occlusion
NCT0019801610	NCT00198016_10_T1	PHENOTYPE	14	14	occlusion
NCT0019801610	NCT00198016_10_T2	GENE	13	13	CAF
NCT0019801611	NCT00198016_11_T0	PHENOTYPE	12	12	fistulas
NCT001980290	NCT00198029_0_T0	ORGAN	10	10	Thumb
NCT001980290	NCT00198029_0_T1	PHENOTYPE	7	7	Osteoarthritis
NCT001980292	NCT00198029_2_T0	ORGAN	14	14	thumb
NCT001980421	NCT00198042_1_T0	ORGAN	9	9	autograft
NCT001980421	NCT00198042_1_T1	ORGAN	7	7	allografts
NCT001980421	NCT00198042_1_T2	ORGAN	14	14	autografts
NCT001980421	NCT00198042_1_T3	ORGAN	5	6	achilles tendon
NCT001980423	NCT00198042_3_T0	COMPOUND	1	1	3
NCT001980425	NCT00198042_5_T0	PHENOTYPE	7	7	fixation
NCT001980425	NCT00198042_5_T1	GENE	4	4	ACL
NCT001980427	NCT00198042_7_T0	GENE	12	12	MRI
NCT0019804210	NCT00198042_10_T0	PHENOTYPE	14	14	distal
NCT0019804210	NCT00198042_10_T1	ORGAN	18	18	tibia
NCT0019804210	NCT00198042_10_T2	ORGAN	15	15	femur
NCT0019804210	NCT00198042_10_T3	PHENOTYPE	17	17	proximal
NCT0019804210	NCT00198042_10_T4	ORGAN	6	6	spine
NCT0019804210	NCT00198042_10_T5	ORGAN	4	5	femoral neck
NCT0019804211	NCT00198042_11_T0	ORGAN	21	21	graft
NCT0019804211	NCT00198042_11_T1	PHENOTYPE	15	15	fixation
NCT0019804211	NCT00198042_11_T2	GENE	9	9	ACL
NCT0019804211	NCT00198042_11_T3	ORGAN	24	24	allograft
NCT0019804213	NCT00198042_13_T0	ORGAN	3	3	graft
NCT0019804213	NCT00198042_13_T1	ORGAN	8	8	graft
NCT0019804213	NCT00198042_13_T2	ORGAN	23	23	graft
NCT0019804213	NCT00198042_13_T3	ORGAN	11	11	allograft
NCT0019804214	NCT00198042_14_T0	PHENOTYPE	7	7	fixation
NCT0019804215	NCT00198042_15_T0	ORGAN	17	17	graft
NCT0019804215	NCT00198042_15_T1	GENE	7	7	MRI
NCT0019804220	NCT00198042_20_T0	GENE	9	9	MRI
NCT0019804220	NCT00198042_20_T1	ORGAN	16	16	tibia
NCT0019804221	NCT00198042_21_T0	GENE	3	3	MRI
NCT0019804222	NCT00198042_22_T0	PHENOTYPE	15	15	maturation
NCT0019804222	NCT00198042_22_T1	ORGAN	23	23	graft
NCT0019804222	NCT00198042_22_T2	GENE	22	22	ACL
NCT0019804227	NCT00198042_27_T0	GENE	0	0	ACL
NCT0019804231	NCT00198042_31_T0	GENE	1	1	MRI
NCT0019804233	NCT00198042_33_T0	GENE	1	1	MRI
NCT0019804236	NCT00198042_36_T0	PHENOTYPE	7	7	maturation
NCT0019804236	NCT00198042_36_T1	ORGAN	6	6	graft
NCT0019804236	NCT00198042_36_T2	GENE	0	0	MRI
NCT0019804240	NCT00198042_40_T0	GENE	1	1	MRI
NCT0019804243	NCT00198042_43_T0	GENE	1	1	MRI
NCT0019804244	NCT00198042_44_T0	GENE	13	13	ACL
NCT0019804244	NCT00198042_44_T1	ORGAN	16	17	hamstring tendons
NCT001980550	NCT00198055_0_T0	GENE	14	14	al
NCT001980550	NCT00198055_0_T1	PHENOTYPE	15	15	Disorder
NCT001980550	NCT00198055_0_T2	PHENOTYPE	11	13	Pervasive Developmental Disorder
NCT001980552	NCT00198055_2_T0	COMPOUND	6	6	aripiprazole
NCT001980552	NCT00198055_2_T1	PHENOTYPE	15	16	autistic disorder
NCT001980556	NCT00198055_6_T0	PHENOTYPE	19	19	PDD
NCT001980556	NCT00198055_6_T1	COMPOUND	7	7	dopamine
NCT001980557	NCT00198055_7_T0	GENE	15	15	atypical
NCT001980557	NCT00198055_7_T1	GENE	12	12	shifted
NCT001980558	NCT00198055_8_T0	GENE	2	2	atypical
NCT001980558	NCT00198055_8_T1	PHENOTYPE	9	10	adverse effects
NCT0019805511	NCT00198055_11_T0	COMPOUND	4	4	aripiprazole
NCT0019805511	NCT00198055_11_T1	PHENOTYPE	15	15	hyperprolactinemia
NCT0019805511	NCT00198055_11_T2	PHENOTYPE	16	17	weight gain
NCT0019805511	NCT00198055_11_T3	PHENOTYPE	13	14	extrapyramidal symptoms
NCT001980683	NCT00198068_3_T0	PHENOTYPE	15	15	recurrent
NCT001980815	NCT00198081_5_T0	GENE	0	0	COX-2
NCT001980815	NCT00198081_5_T1	PHENOTYPE	5	6	pancreatic cancers
NCT001980817	NCT00198081_7_T0	PHENOTYPE	11	11	premalignant
NCT001980817	NCT00198081_7_T1	PHENOTYPE	9	9	progression
NCT001980817	NCT00198081_7_T2	GENE	6	6	COX-2
NCT001980817	NCT00198081_7_T3	PHENOTYPE	17	17	neoplasms
NCT001980817	NCT00198081_7_T4	PHENOTYPE	21	22	intraepithelial neoplasms
NCT001980818	NCT00198081_8_T0	GENE	10	10	PC-1
NCT001980818	NCT00198081_8_T1	ORGAN	11	11	homograft
NCT001980818	NCT00198081_8_T2	GENE	1	1	COX-2
NCT001980818	NCT00198081_8_T3	PHENOTYPE	15	16	pancreatic cancer
NCT001980819	NCT00198081_9_T0	GENE	4	4	COX-2
NCT001980819	NCT00198081_9_T1	PHENOTYPE	10	11	pancreatic cancer
NCT0019808110	NCT00198081_10_T0	GENE	6	6	II
NCT0019808110	NCT00198081_10_T1	COMPOUND	17	17	celecoxib
NCT0019808110	NCT00198081_10_T2	PHENOTYPE	21	21	premalignant
NCT0019808110	NCT00198081_10_T3	GENE	15	15	COX-2
NCT0019808111	NCT00198081_11_T0	COMPOUND	7	7	celecoxib
NCT0019808112	NCT00198081_12_T0	COMPOUND	15	15	celecoxib
NCT001980941	NCT00198094_1_T0	COMPOUND	13	13	alprazolam
NCT001980941	NCT00198094_1_T1	COMPOUND	64	64	alprazolam
NCT001980941	NCT00198094_1_T2	PHENOTYPE	84	84	acute
NCT001980941	NCT00198094_1_T3	GENE	17	17	5.7
NCT001980941	NCT00198094_1_T4	PHENOTYPE	1	1	secondary
NCT001980941	NCT00198094_1_T5	COMPOUND	53	53	sertraline
NCT001980941	NCT00198094_1_T6	COMPOUND	63	63	sertraline
NCT001980941	NCT00198094_1_T7	PHENOTYPE	10	11	withdrawal symptoms
NCT001981070	NCT00198107_0_T0	PHENOTYPE	12	12	Autism
NCT001981070	NCT00198107_0_T1	PHENOTYPE	9	9	Symptoms
NCT001981073	NCT00198107_3_T0	COMPOUND	25	25	D-cycloserine
NCT001981073	NCT00198107_3_T1	COMPOUND	14	14	aripiprazole
NCT001981073	NCT00198107_3_T2	COMPOUND	23	23	aripiprazole
NCT001981078	NCT00198107_8_T0	PHENOTYPE	7	7	symptoms
NCT001981079	NCT00198107_9_T0	PHENOTYPE	16	16	autism
NCT001981079	NCT00198107_9_T1	BIOLOGICAL_PROCESS	10	11	social behavior
NCT0019810713	NCT00198107_13_T0	COMPOUND	8	8	aripiprazole
NCT0019810714	NCT00198107_14_T0	PHENOTYPE	2	2	irritability
NCT0019810715	NCT00198107_15_T0	COMPOUND	6	6	aripiprazole
NCT0019810715	NCT00198107_15_T1	COMPOUND	11	11	aripiprazole
NCT0019810716	NCT00198107_16_T0	COMPOUND	6	6	aripiprazole
NCT0019810718	NCT00198107_18_T0	PHENOTYPE	3	3	symptoms
NCT0019810718	NCT00198107_18_T1	COMPOUND	12	12	aripiprazole
NCT0019810719	NCT00198107_19_T0	COMPOUND	13	13	aripiprazole
NCT0019810721	NCT00198107_21_T0	PHENOTYPE	16	16	irritability
NCT0019810722	NCT00198107_22_T0	PHENOTYPE	19	19	autism
NCT001981200	NCT00198120_0_T0	PHENOTYPE	8	8	Autism
NCT001981204	NCT00198120_4_T0	PHENOTYPE	15	15	symptoms
NCT001981204	NCT00198120_4_T1	PHENOTYPE	23	23	impairment
NCT001981204	NCT00198120_4_T2	COMPOUND	8	8	D-cycloserine
NCT001981204	NCT00198120_4_T3	PHENOTYPE	17	17	autism
NCT001981205	NCT00198120_5_T0	PHENOTYPE	0	0	Autism
NCT001981206	NCT00198120_6_T0	PHENOTYPE	18	18	symptoms
NCT001981206	NCT00198120_6_T1	PHENOTYPE	7	7	autism
NCT001981206	NCT00198120_6_T2	PHENOTYPE	25	26	communication impairment
NCT001981208	NCT00198120_8_T0	COMPOUND	14	14	D-cycloserine
NCT001981208	NCT00198120_8_T1	PHENOTYPE	5	5	autism
NCT0019812010	NCT00198120_10_T0	COMPOUND	15	15	D-cycloserine
NCT0019812010	NCT00198120_10_T1	PHENOTYPE	23	23	autism
NCT0019812010	NCT00198120_10_T2	PHENOTYPE	20	21	other symptoms
NCT0019812012	NCT00198120_12_T0	COMPOUND	10	10	D-cycloserine
NCT0019812012	NCT00198120_12_T1	PHENOTYPE	18	18	autism
NCT0019812012	NCT00198120_12_T2	PHENOTYPE	15	16	associated symptoms
NCT0019812013	NCT00198120_13_T0	PHENOTYPE	18	18	pathophysiology
NCT0019812013	NCT00198120_13_T1	PHENOTYPE	11	11	autism
NCT0019812013	NCT00198120_13_T2	PHENOTYPE	26	26	autism
NCT0019812016	NCT00198120_16_T0	PHENOTYPE	2	2	epilepsy
NCT0019812016	NCT00198120_16_T1	COMPOUND	21	21	D-cycloserine
NCT0019812016	NCT00198120_16_T2	PHENOTYPE	7	7	seizures
NCT0019812016	NCT00198120_16_T3	PHENOTYPE	16	16	seizures
NCT0019812017	NCT00198120_17_T0	COMPOUND	0	0	D-cycloserine
NCT001981460	NCT00198146_0_T0	PHENOTYPE	3	3	Progression
NCT001981460	NCT00198146_0_T1	PHENOTYPE	2	2	Diabetes
NCT001981591	NCT00198159_1_T0	PHENOTYPE	12	12	toxicity
NCT001981596	NCT00198159_6_T0	GENE	14	14	alk
NCT001981596	NCT00198159_6_T1	GENE	19	19	alk
NCT001981596	NCT00198159_6_T2	PHENOTYPE	3	3	mets
NCT001981596	NCT00198159_6_T3	ORGAN	2	2	liver
NCT001981596	NCT00198159_6_T4	GENE	10	10	1.5
NCT001981596	NCT00198159_6_T5	GENE	0	0	Pts
NCT001981597	NCT00198159_7_T0	GENE	6	6	alk
NCT001981597	NCT00198159_7_T1	PHENOTYPE	3	3	mets
NCT001981597	NCT00198159_7_T2	ORGAN	2	2	liver
NCT001981597	NCT00198159_7_T3	GENE	0	0	Pts
NCT001981720	NCT00198172_0_T0	GENE	1	1	II
NCT001981720	NCT00198172_0_T1	PHENOTYPE	11	13	Germ Cell Tumors
NCT001981722	NCT00198172_2_T0	PHENOTYPE	9	9	progression
NCT001981850	NCT00198185_0_T0	ORGAN	12	13	Rotator Cuff
NCT001981850	NCT00198185_0_T1	ORGAN	7	8	Platelet-Rich Fibrin
NCT001981852	NCT00198185_2_T0	ORGAN	13	14	rotator cuff
NCT001981982	NCT00198198_2_T0	COMPOUND	1	1	1
NCT001981986	NCT00198198_6_T0	PHENOTYPE	15	15	BDD
NCT001981986	NCT00198198_6_T1	PHENOTYPE	13	13	Association
NCT001981989	NCT00198198_9_T0	PHENOTYPE	17	17	tolerance
NCT0019819813	NCT00198198_13_T0	COMPOUND	29	29	olanzapine
NCT0019819813	NCT00198198_13_T1	COMPOUND	32	32	haloperidol
NCT0019819813	NCT00198198_13_T2	PHENOTYPE	9	9	suffering
NCT0019819813	NCT00198198_13_T3	COMPOUND	30	30	risperidone
NCT0019819813	NCT00198198_13_T4	COMPOUND	22	22	aripiprazole
NCT0019819813	NCT00198198_13_T5	COMPOUND	31	31	ziprasidone
NCT0019819814	NCT00198198_14_T0	PHENOTYPE	3	4	substance abuse
NCT0019819814	NCT00198198_14_T1	PHENOTYPE	9	10	substance dependence
NCT001982242	NCT00198224_2_T0	ORGAN	18	18	kidney
NCT001982242	NCT00198224_2_T1	COMPOUND	4	4	morpholinoethyl
NCT001982242	NCT00198224_2_T2	PHENOTYPE	9	9	MPA
NCT001982242	NCT00198224_2_T3	COMPOUND	7	8	mycophenolic acid
NCT001982243	NCT00198224_3_T0	CELL	13	13	lymphocytes
NCT001982245	NCT00198224_5_T0	ORGAN	14	15	immune system
NCT0019822413	NCT00198224_13_T0	COMPOUND	36	36	EDTA
NCT0019822413	NCT00198224_13_T1	COMPOUND	21	21	heparin
NCT0019822413	NCT00198224_13_T2	COMPOUND	20	20	lithium
NCT0019822413	NCT00198224_13_T3	BIOLOGICAL_PROCESS	42	42	phlebotomy
NCT0019822413	NCT00198224_13_T4	GENE	34	34	purple
NCT0019822413	NCT00198224_13_T5	COMPOUND	28	29	sodium heparin
NCT0019822415	NCT00198224_15_T0	PHENOTYPE	10	11	drug levels
NCT0019822416	NCT00198224_16_T0	PHENOTYPE	18	19	drug levels
NCT0019822417	NCT00198224_17_T0	CELL	12	12	neutrophil
NCT0019822419	NCT00198224_19_T0	PHENOTYPE	14	14	secondary
NCT0019822420	NCT00198224_20_T0	GENE	8	8	CD4
NCT0019822420	NCT00198224_20_T1	CELL	19	19	lymphocytes
NCT0019822422	NCT00198224_22_T0	PHENOTYPE	8	8	initiation
NCT0019822422	NCT00198224_22_T1	BIOLOGICAL_PROCESS	10	10	phlebotomy
NCT0019822423	NCT00198224_23_T0	ORGAN	22	22	transplant
NCT0019822423	NCT00198224_23_T1	PHENOTYPE	7	8	renal disease
NCT0019822425	NCT00198224_25_T0	ORGAN	15	15	transplant
NCT0019822426	NCT00198224_26_T0	COMPOUND	3	3	cyclosporine
NCT0019822426	NCT00198224_26_T1	COMPOUND	2	2	tacrolimus
NCT0019822426	NCT00198224_26_T2	PHENOTYPE	0	1	Drug level
NCT0019822430	NCT00198224_30_T0	ORGAN	14	14	transplant
NCT0019822430	NCT00198224_30_T1	PHENOTYPE	2	3	drug levels
NCT0019822431	NCT00198224_31_T0	COMPOUND	18	18	EDTA
NCT0019822431	NCT00198224_31_T1	COMPOUND	14	14	heparin
NCT0019822431	NCT00198224_31_T2	COMPOUND	13	13	lithium
NCT0019822431	NCT00198224_31_T3	PHENOTYPE	6	6	MPA
NCT0019822432	NCT00198224_32_T0	ORGAN	0	0	Transplant
NCT0019822432	NCT00198224_32_T1	BIOLOGICAL_PROCESS	18	18	phlebotomy
NCT0019822432	NCT00198224_32_T2	COMPOUND	10	11	sodium heparin
NCT0019822434	NCT00198224_34_T0	COMPOUND	19	19	sodium
NCT0019822437	NCT00198224_37_T0	GENE	3	3	CD
NCT0019822437	NCT00198224_37_T1	GENE	6	6	CD
NCT0019822437	NCT00198224_37_T2	GENE	20	20	CD
NCT0019822437	NCT00198224_37_T3	CELL	22	22	cells
NCT0019822437	NCT00198224_37_T4	GENE	8	8	PE
NCT0019822438	NCT00198224_38_T0	GENE	3	3	CD
NCT0019822438	NCT00198224_38_T1	GENE	6	6	CD
NCT0019822438	NCT00198224_38_T2	GENE	9	9	CD
NCT0019822438	NCT00198224_38_T3	GENE	17	17	CD4
NCT0019822438	NCT00198224_38_T4	GENE	30	30	CD4
NCT0019822438	NCT00198224_38_T5	CELL	31	31	cells
NCT0019822438	NCT00198224_38_T6	GENE	8	8	PE
NCT0019822438	NCT00198224_38_T7	CELL	20	20	T-cells
NCT0019822440	NCT00198224_40_T0	COMPOUND	7	7	sodium
NCT0019822443	NCT00198224_43_T0	GENE	1	1	CD4
NCT0019822443	NCT00198224_43_T1	GENE	3	3	CD3
NCT0019822443	NCT00198224_43_T2	CELL	4	5	T cells
NCT0019822444	NCT00198224_44_T0	GENE	4	4	ATP
NCT0019822444	NCT00198224_44_T1	PHENOTYPE	2	2	lysed
NCT0019822446	NCT00198224_46_T0	ORGAN	1	1	kidney
NCT0019822446	NCT00198224_46_T1	ORGAN	2	2	transplant
NCT0019822447	NCT00198224_47_T0	PHENOTYPE	6	6	immunosuppression
NCT0019822452	NCT00198224_52_T0	ORGAN	7	7	kidney
NCT0019822452	NCT00198224_52_T1	ORGAN	10	10	kidney
NCT0019822452	NCT00198224_52_T2	ORGAN	11	11	pancreas
NCT0019822452	NCT00198224_52_T3	ORGAN	3	3	transplant
NCT0019822453	NCT00198224_53_T0	PHENOTYPE	2	3	recurrent infections
NCT001982501	NCT00198250_1_T0	PHENOTYPE	11	11	toxicity
NCT001982501	NCT00198250_1_T1	COMPOUND	14	14	hydrochloride
NCT001982501	NCT00198250_1_T2	COMPOUND	13	13	venlafaxine
NCT001982501	NCT00198250_1_T3	PHENOTYPE	34	35	breast cancer
NCT001982501	NCT00198250_1_T4	PHENOTYPE	27	28	hot flashes
NCT001982503	NCT00198250_3_T0	PHENOTYPE	21	21	distressed
NCT001982503	NCT00198250_3_T1	PHENOTYPE	0	1	Hot flashes
NCT001982504	NCT00198250_4_T0	PHENOTYPE	4	4	severity
NCT001982504	NCT00198250_4_T1	PHENOTYPE	16	17	hot flashes
NCT001982504	NCT00198250_4_T2	PHENOTYPE	21	22	breast cancer
NCT001982505	NCT00198250_5_T0	PHENOTYPE	10	10	toxicity
NCT001982505	NCT00198250_5_T1	COMPOUND	15	15	hydrochloride
NCT001982505	NCT00198250_5_T2	COMPOUND	14	14	venlafaxine
NCT001982505	NCT00198250_5_T3	GENE	18	18	po
NCT001982505	NCT00198250_5_T4	PHENOTYPE	21	22	hot flashes
NCT001982505	NCT00198250_5_T5	PHENOTYPE	28	29	breast cancer
NCT001982506	NCT00198250_6_T0	COMPOUND	14	14	norepinephrine
NCT001982506	NCT00198250_6_T1	COMPOUND	21	21	dopamine
NCT001982507	NCT00198250_7_T0	PHENOTYPE	1	1	secondary
NCT001982507	NCT00198250_7_T1	PHENOTYPE	12	13	hot flashes
NCT001982508	NCT00198250_8_T0	PHENOTYPE	14	14	symptoms
NCT001982508	NCT00198250_8_T1	PHENOTYPE	17	17	strategies
NCT0019825011	NCT00198250_11_T0	PHENOTYPE	16	16	toxicity
NCT0019825011	NCT00198250_11_T1	PHENOTYPE	12	12	severity
NCT0019825011	NCT00198250_11_T2	PHENOTYPE	40	40	fatigue
NCT0019825011	NCT00198250_11_T3	PHENOTYPE	42	43	sleep disturbance
NCT0019825011	NCT00198250_11_T4	PHENOTYPE	9	10	hot flash
NCT0019825011	NCT00198250_11_T5	PHENOTYPE	26	27	mood disturbance
NCT0019825011	NCT00198250_11_T6	PHENOTYPE	30	32	quality of life
NCT0019825012	NCT00198250_12_T0	PHENOTYPE	0	1	Hot flashes
NCT0019825014	NCT00198250_14_T0	PHENOTYPE	10	10	blister
NCT0019825016	NCT00198250_16_T0	PHENOTYPE	34	34	regression
NCT0019825017	NCT00198250_17_T0	PHENOTYPE	10	11	hot flash
NCT0019825017	NCT00198250_17_T1	PHENOTYPE	18	19	breast cancer
NCT001982630	NCT00198263_0_T0	PHENOTYPE	10	13	Head and Neck Cancer
NCT001982634	NCT00198263_4_T0	PHENOTYPE	11	11	dysfunction
NCT001982634	NCT00198263_4_T1	PHENOTYPE	3	4	solid tumors
NCT001982636	NCT00198263_6_T0	GENE	15	15	reduced
NCT001982637	NCT00198263_7_T0	PHENOTYPE	7	7	tumors
NCT001982637	NCT00198263_7_T1	PHENOTYPE	31	31	SCCHN
NCT001982639	NCT00198263_9_T0	PHENOTYPE	13	13	recurrent
NCT001982639	NCT00198263_9_T1	TISSUE	10	11	salivary gland
NCT001982639	NCT00198263_9_T2	PHENOTYPE	16	17	primary tumors
NCT001982639	NCT00198263_9_T3	ORGAN	4	5	oral cavity
NCT0019826313	NCT00198263_13_T0	GENE	0	0	Age
NCT0019826320	NCT00198263_20_T0	PHENOTYPE	7	7	waking
NCT0019826326	NCT00198263_26_T0	PHENOTYPE	2	2	tumors
NCT0019826326	NCT00198263_26_T1	GENE	21	21	MRI
NCT0019826326	NCT00198263_26_T2	ORGAN	13	14	blood vessel
NCT0019826328	NCT00198263_28_T0	PHENOTYPE	2	2	tumors
NCT0019826332	NCT00198263_32_T0	COMPOUND	12	12	bleomycin
NCT0019826334	NCT00198263_34_T0	PHENOTYPE	5	5	anesthesia
NCT0019826336	NCT00198263_36_T0	PHENOTYPE	6	6	emphysema
NCT0019826336	NCT00198263_36_T1	PHENOTYPE	8	9	pulmonary fibrosis
NCT0019826340	NCT00198263_40_T0	PHENOTYPE	6	7	cardiac arrhythmia
NCT001982765	NCT00198276_5_T0	PHENOTYPE	39	39	Adenocarcinoma
NCT001982765	NCT00198276_5_T1	PHENOTYPE	59	59	recurrences
NCT001982765	NCT00198276_5_T2	PHENOTYPE	28	28	recurrent
NCT001982765	NCT00198276_5_T3	PHENOTYPE	33	33	recurrent
NCT001982765	NCT00198276_5_T4	PHENOTYPE	32	32	BCC
NCT001982765	NCT00198276_5_T5	PHENOTYPE	38	38	Melanoma
NCT001982765	NCT00198276_5_T6	PHENOTYPE	42	42	recurrence
NCT001982765	NCT00198276_5_T7	COMPOUND	69	69	1
NCT001982765	NCT00198276_5_T8	COMPOUND	76	76	2
NCT001982765	NCT00198276_5_T9	GENE	37	37	SCC
NCT001982765	NCT00198276_5_T10	PHENOTYPE	44	45	breast cancer
NCT001982765	NCT00198276_5_T11	PHENOTYPE	54	55	solid tumors
NCT001982765	NCT00198276_5_T12	PHENOTYPE	50	51	Cutaneous Lymphoma
NCT001982765	NCT00198276_5_T13	PHENOTYPE	29	31	Basal Cell Carcinoma
NCT001982765	NCT00198276_5_T14	PHENOTYPE	34	36	Squamous Cell Carcinoma
NCT001982765	NCT00198276_5_T15	PHENOTYPE	46	48	Merkel Cell Carcinoma
NCT001982766	NCT00198276_6_T0	GENE	0	0	EPT
NCT001982766	NCT00198276_6_T1	PHENOTYPE	10	11	local disease
NCT0019827610	NCT00198276_10_T0	COMPOUND	10	11	bleomycin sulfate
NCT0019827612	NCT00198276_12_T0	COMPOUND	9	9	bleomycin
NCT0019827612	NCT00198276_12_T1	GENE	13	13	EPT
NCT0019827612	NCT00198276_12_T2	PHENOTYPE	0	0	Tumors
NCT0019827614	NCT00198276_14_T0	GENE	0	0	Age
NCT0019827621	NCT00198276_21_T0	PHENOTYPE	7	7	waking
NCT0019827627	NCT00198276_27_T0	PHENOTYPE	2	2	tumors
NCT0019827627	NCT00198276_27_T1	GENE	21	21	MRI
NCT0019827627	NCT00198276_27_T2	ORGAN	13	14	blood vessel
NCT0019827629	NCT00198276_29_T0	PHENOTYPE	2	2	tumors
NCT0019827633	NCT00198276_33_T0	COMPOUND	12	12	bleomycin
NCT0019827635	NCT00198276_35_T0	PHENOTYPE	6	6	emphysema
NCT0019827635	NCT00198276_35_T1	PHENOTYPE	8	9	pulmonary fibrosis
NCT0019827639	NCT00198276_39_T0	PHENOTYPE	6	7	cardiac arrhythmia
NCT001982890	NCT00198289_0_T0	ORGAN	12	12	Lungs
NCT001982890	NCT00198289_0_T1	PHENOTYPE	2	3	Cystic Fibrosis
NCT001983022	NCT00198302_2_T0	GENE	23	23	SAB
NCT001983022	NCT00198302_2_T1	PHENOTYPE	11	11	pharmacokinetics
NCT001983153	NCT00198315_3_T0	GENE	16	16	has
NCT001983153	NCT00198315_3_T1	PHENOTYPE	8	9	recurrent disease
NCT001983154	NCT00198315_4_T0	GENE	5	5	SCC
NCT001983154	NCT00198315_4_T1	GENE	17	17	swallow
NCT001983155	NCT00198315_5_T0	PHENOTYPE	14	14	tumors
NCT001983155	NCT00198315_5_T1	GENE	29	29	SCC
NCT001983155	NCT00198315_5_T2	PHENOTYPE	25	25	recurrent
NCT001983156	NCT00198315_6_T0	TISSUE	31	31	tonsil
NCT001983156	NCT00198315_6_T1	GENE	22	22	SCC
NCT001983156	NCT00198315_6_T2	PHENOTYPE	18	18	recurrent
NCT001983156	NCT00198315_6_T3	ORGAN	26	27	oral cavity
NCT001983156	NCT00198315_6_T4	ORGAN	28	29	soft palate
NCT001983158	NCT00198315_8_T0	TISSUE	12	12	tonsil
NCT001983158	NCT00198315_8_T1	GENE	3	3	SCC
NCT001983158	NCT00198315_8_T2	ORGAN	7	8	oral cavity
NCT001983158	NCT00198315_8_T3	ORGAN	9	10	soft palate
NCT0019831510	NCT00198315_10_T0	PHENOTYPE	0	0	Recurrent
NCT0019831514	NCT00198315_14_T0	PHENOTYPE	0	0	Tumor
NCT0019831516	NCT00198315_16_T0	GENE	0	0	Age
NCT0019831521	NCT00198315_21_T0	GENE	0	0	1.5
NCT0019831521	NCT00198315_21_T1	COMPOUND	3	4	vitamin K
NCT0019831525	NCT00198315_25_T0	PHENOTYPE	2	2	tumors
NCT0019831525	NCT00198315_25_T1	GENE	21	21	MRI
NCT0019831525	NCT00198315_25_T2	ORGAN	13	14	blood vessel
NCT0019831527	NCT00198315_27_T0	PHENOTYPE	2	2	tumors
NCT0019831533	NCT00198315_33_T0	COMPOUND	12	12	bleomycin
NCT0019831535	NCT00198315_35_T0	PHENOTYPE	5	5	anesthesia
NCT0019831537	NCT00198315_37_T0	PHENOTYPE	6	6	emphysema
NCT0019831537	NCT00198315_37_T1	PHENOTYPE	8	9	pulmonary fibrosis
NCT0019831543	NCT00198315_43_T0	COMPOUND	9	10	chorionic gonadotropin
NCT0019831545	NCT00198315_45_T0	PHENOTYPE	2	3	other cancer
NCT001983283	NCT00198328_3_T0	GENE	16	16	has
NCT001983283	NCT00198328_3_T1	PHENOTYPE	8	9	recurrent disease
NCT001983284	NCT00198328_4_T0	GENE	5	5	SCC
NCT001983284	NCT00198328_4_T1	GENE	17	17	swallow
NCT001983285	NCT00198328_5_T0	PHENOTYPE	14	14	tumors
NCT001983285	NCT00198328_5_T1	GENE	29	29	SCC
NCT001983285	NCT00198328_5_T2	PHENOTYPE	25	25	recurrent
NCT001983286	NCT00198328_6_T0	ORGAN	35	35	larynx
NCT001983286	NCT00198328_6_T1	GENE	22	22	SCC
NCT001983286	NCT00198328_6_T2	ORGAN	33	33	hypopharynx
NCT001983286	NCT00198328_6_T3	PHENOTYPE	18	18	recurrent
NCT001983288	NCT00198328_8_T0	ORGAN	16	16	larynx
NCT001983288	NCT00198328_8_T1	GENE	3	3	SCC
NCT001983288	NCT00198328_8_T2	ORGAN	14	14	hypopharynx
NCT0019832810	NCT00198328_10_T0	PHENOTYPE	0	0	Recurrent
NCT0019832814	NCT00198328_14_T0	PHENOTYPE	0	0	Tumor
NCT0019832816	NCT00198328_16_T0	GENE	0	0	Age
NCT0019832824	NCT00198328_24_T0	PHENOTYPE	2	2	tumors
NCT0019832824	NCT00198328_24_T1	GENE	21	21	MRI
NCT0019832824	NCT00198328_24_T2	ORGAN	13	14	blood vessel
NCT0019832826	NCT00198328_26_T0	PHENOTYPE	2	2	tumors
NCT0019832832	NCT00198328_32_T0	COMPOUND	12	12	bleomycin
NCT0019832834	NCT00198328_34_T0	PHENOTYPE	5	5	anesthesia
NCT0019832836	NCT00198328_36_T0	PHENOTYPE	6	6	emphysema
NCT0019832836	NCT00198328_36_T1	PHENOTYPE	8	9	pulmonary fibrosis
NCT0019832842	NCT00198328_42_T0	GENE	8	8	beta
NCT0019832842	NCT00198328_42_T1	GENE	12	12	beta
NCT0019832842	NCT00198328_42_T2	COMPOUND	10	11	chorionic gonadotropin
NCT0019832844	NCT00198328_44_T0	PHENOTYPE	2	3	other cancer
NCT001983412	NCT00198341_2_T0	PHENOTYPE	23	23	recurrences
NCT001983412	NCT00198341_2_T1	PHENOTYPE	25	26	second cancers
NCT001983413	NCT00198341_3_T0	PHENOTYPE	10	10	Oncology
NCT001983540	NCT00198354_0_T0	PHENOTYPE	2	2	NSCLC
NCT001983674	NCT00198367_4_T0	PHENOTYPE	8	8	toxicity
NCT001983674	NCT00198367_4_T1	GENE	21	21	III
NCT001983801	NCT00198380_1_T0	PHENOTYPE	7	7	tumors
NCT001983931	NCT00198393_1_T0	PHENOTYPE	23	23	associations
NCT001983931	NCT00198393_1_T1	COMPOUND	29	29	paclitaxel
NCT001983931	NCT00198393_1_T2	COMPOUND	30	30	docetaxel
NCT001983931	NCT00198393_1_T3	PHENOTYPE	16	16	Oncology
NCT001983931	NCT00198393_1_T4	COMPOUND	28	28	gemcitabine
NCT001983931	NCT00198393_1_T5	COMPOUND	32	32	cisplatin
NCT001983931	NCT00198393_1_T6	GENE	8	9	PS 2
NCT001983932	NCT00198393_2_T0	PHENOTYPE	14	14	toxicities
NCT001983933	NCT00198393_3_T0	PHENOTYPE	11	11	toxicity
NCT001983938	NCT00198393_8_T0	COMPOUND	13	13	platinum
NCT001984060	NCT00198406_0_T0	COMPOUND	4	4	THE
NCT001984060	NCT00198406_0_T1	PHENOTYPE	15	16	LUNG CANCER
NCT001984061	NCT00198406_1_T0	PHENOTYPE	0	1	LUNG CANCER
NCT001984063	NCT00198406_3_T0	GENE	12	12	pts
NCT001984063	NCT00198406_3_T1	PHENOTYPE	10	11	lung cancer
NCT001984064	NCT00198406_4_T0	GENE	16	16	oct
NCT001984064	NCT00198406_4_T1	PHENOTYPE	20	20	centers
NCT001984064	NCT00198406_4_T2	GENE	1	1	pts
NCT001984064	NCT00198406_4_T3	PHENOTYPE	9	10	lung cancer
NCT001984320	NCT00198432_0_T0	PHENOTYPE	2	2	NSCLC
NCT001984451	NCT00198445_1_T0	PHENOTYPE	1	1	secondary
NCT001985623	NCT00198562_3_T0	COMPOUND	38	38	losartan
NCT001985623	NCT00198562_3_T1	GENE	19	19	140
NCT001985623	NCT00198562_3_T2	GENE	18	18	BP
NCT001985623	NCT00198562_3_T3	GENE	28	28	BP
NCT001985623	NCT00198562_3_T4	GENE	29	29	130
NCT001985623	NCT00198562_3_T5	COMPOUND	34	34	amlodipine
NCT001985625	NCT00198562_5_T0	GENE	1	1	BP
NCT0019856210	NCT00198562_10_T0	COMPOUND	42	42	losartan
NCT0019856210	NCT00198562_10_T1	GENE	20	20	140
NCT0019856210	NCT00198562_10_T2	GENE	19	19	BP
NCT0019856210	NCT00198562_10_T3	GENE	29	29	BP
NCT0019856210	NCT00198562_10_T4	GENE	30	30	130
NCT0019856210	NCT00198562_10_T5	COMPOUND	35	35	amlodipine
NCT0019856212	NCT00198562_12_T0	GENE	1	1	BP
NCT0019857527	NCT00198575_27_T0	COMPOUND	7	7	heparin
NCT0019857527	NCT00198575_27_T1	PHENOTYPE	8	8	thrombocytopenia
NCT0019857528	NCT00198575_28_T0	PHENOTYPE	0	0	Chronic
NCT0019857528	NCT00198575_28_T1	PHENOTYPE	1	1	thrombocytopenia
NCT0019857529	NCT00198575_29_T0	PHENOTYPE	1	1	malignancy
NCT001985881	NCT00198588_1_T0	PHENOTYPE	8	9	cardiovascular diseases
NCT001985883	NCT00198588_3_T0	COMPOUND	3	3	argatroban
NCT001985884	NCT00198588_4_T0	COMPOUND	13	13	argatroban
NCT001985884	NCT00198588_4_T1	PHENOTYPE	20	21	ischemic stroke
NCT001985885	NCT00198588_5_T0	PHENOTYPE	3	3	pharmacokinetics
NCT001986141	NCT00198614_1_T0	GENE	9	9	AF
NCT001986141	NCT00198614_1_T1	GENE	14	14	has
NCT001986142	NCT00198614_2_T0	GENE	30	30	bypass
NCT001986142	NCT00198614_2_T1	GENE	7	7	blocker
NCT001986142	NCT00198614_2_T2	GENE	26	26	AF
NCT001986142	NCT00198614_2_T3	COMPOUND	18	18	metoprolol
NCT001986142	NCT00198614_2_T4	COMPOUND	3	3	carvedilol
NCT001986143	NCT00198614_3_T0	PHENOTYPE	8	9	Atrial Fibrillation
NCT001986145	NCT00198614_5_T0	GENE	8	8	AF
NCT001986147	NCT00198614_7_T0	GENE	6	6	bypass
NCT001986147	NCT00198614_7_T1	GENE	24	24	bypass
NCT001986147	NCT00198614_7_T2	PHENOTYPE	35	35	complications
NCT001986147	NCT00198614_7_T3	GENE	9	9	has
NCT001986148	NCT00198614_8_T0	PHENOTYPE	43	43	trauma
NCT001986148	NCT00198614_8_T1	GENE	15	15	AF
NCT001986149	NCT00198614_9_T0	GENE	15	15	AF
NCT001986149	NCT00198614_9_T1	GENE	25	25	AF
NCT001986149	NCT00198614_9_T2	GENE	1	1	has
NCT001986149	NCT00198614_9_T3	GENE	13	13	has
NCT0019861411	NCT00198614_11_T0	ORGAN	7	7	Heart
NCT0019861411	NCT00198614_11_T1	GENE	20	20	AF
NCT0019861412	NCT00198614_12_T0	GENE	10	10	has
NCT0019861413	NCT00198614_13_T0	GENE	14	14	has
NCT0019861413	NCT00198614_13_T1	GENE	3	3	beta
NCT0019861413	NCT00198614_13_T2	PHENOTYPE	11	12	heart failure
NCT0019861414	NCT00198614_14_T0	GENE	6	6	AF
NCT0019861414	NCT00198614_14_T1	GENE	31	31	AF
NCT0019861414	NCT00198614_14_T2	PHENOTYPE	21	21	inflammation
NCT0019861414	NCT00198614_14_T3	PHENOTYPE	3	3	pathophysiology
NCT0019861414	NCT00198614_14_T4	GENE	10	10	has
NCT0019861415	NCT00198614_15_T0	GENE	16	16	AF
NCT0019861415	NCT00198614_15_T1	COMPOUND	10	10	metoprolol
NCT0019861415	NCT00198614_15_T2	COMPOUND	11	11	carvedilol
NCT0019861415	NCT00198614_15_T3	GENE	12	12	has
NCT0019861415	NCT00198614_15_T4	PHENOTYPE	19	20	heart failure
NCT0019861416	NCT00198614_16_T0	GENE	18	18	AF
NCT0019861416	NCT00198614_16_T1	COMPOUND	6	6	carvedilol
NCT0019861417	NCT00198614_17_T0	GENE	35	35	AF
NCT0019861417	NCT00198614_17_T1	COMPOUND	27	27	metoprolol
NCT0019861417	NCT00198614_17_T2	COMPOUND	22	22	carvedilol
NCT0019861420	NCT00198614_20_T0	GENE	5	5	bypass
NCT0019861420	NCT00198614_20_T1	ORGAN	6	6	graft
NCT0019861420	NCT00198614_20_T2	ORGAN	3	4	coronary artery
NCT0019861422	NCT00198614_22_T0	GENE	12	12	balloon
NCT0019861422	NCT00198614_22_T1	PHENOTYPE	6	6	circulatory
NCT0019861425	NCT00198614_25_T0	PHENOTYPE	0	2	Acute myocardial infarction
NCT0019861427	NCT00198614_27_T0	PHENOTYPE	6	6	flutter
NCT0019861427	NCT00198614_27_T1	GENE	4	4	AF
NCT0019861427	NCT00198614_27_T2	PHENOTYPE	3	3	chronic
NCT0019861428	NCT00198614_28_T0	GENE	3	3	AF
NCT0019861429	NCT00198614_29_T0	GENE	8	9	calcium channel
NCT0019861430	NCT00198614_30_T0	ORGAN	2	2	heart
NCT0019861431	NCT00198614_31_T0	PHENOTYPE	6	6	hyperthyroidism
NCT0019861431	NCT00198614_31_T1	PHENOTYPE	4	4	pheochromocytoma
NCT0019861431	NCT00198614_31_T2	PHENOTYPE	0	1	Endocrine disorders
NCT0019861435	NCT00198614_35_T0	PHENOTYPE	3	3	asthma
NCT0019861435	NCT00198614_35_T1	PHENOTYPE	6	6	chronic
NCT0019861437	NCT00198614_37_T0	PHENOTYPE	0	1	Sick sinus
NCT0019861438	NCT00198614_38_T0	ORGAN	1	1	heart
NCT0019861441	NCT00198614_41_T0	PHENOTYPE	2	2	autoimmune
NCT0019861442	NCT00198614_42_T0	PHENOTYPE	4	4	myocarditis
NCT0019861442	NCT00198614_42_T1	PHENOTYPE	1	2	infectious diseases
NCT001986272	NCT00198627_2_T0	PHENOTYPE	9	10	neonatal infections
NCT001986277	NCT00198627_7_T0	PHENOTYPE	49	49	strategies
NCT001986277	NCT00198627_7_T1	PHENOTYPE	37	37	practices
NCT001986277	NCT00198627_7_T2	COMPOUND	8	8	1
NCT001986277	NCT00198627_7_T3	COMPOUND	23	23	2
NCT001986277	NCT00198627_7_T4	COMPOUND	55	55	3
NCT001986277	NCT00198627_7_T5	PHENOTYPE	15	16	bacterial infections
NCT001986530	NCT00198653_0_T0	PHENOTYPE	3	3	Practices
NCT001986530	NCT00198653_0_T1	PHENOTYPE	10	10	Hypothermia
NCT001986921	NCT00198692_1_T0	GENE	22	22	PAR
NCT001986921	NCT00198692_1_T1	ORGAN	11	11	limb
NCT001986921	NCT00198692_1_T2	GENE	6	6	SM
NCT001986929	NCT00198692_9_T0	GENE	10	10	SM
NCT0019869213	NCT00198692_13_T0	PHENOTYPE	7	7	secondary
NCT0019869215	NCT00198692_15_T0	ORGAN	14	14	limb
NCT0019869215	NCT00198692_15_T1	GENE	3	3	SM
NCT0019869215	NCT00198692_15_T2	GENE	5	5	has
NCT0019869217	NCT00198692_17_T0	GENE	22	22	ACA
NCT001987053	NCT00198705_3_T0	PHENOTYPE	13	13	experiences
NCT001987054	NCT00198705_4_T0	PHENOTYPE	12	12	scaling
NCT001987187	NCT00198718_7_T0	PHENOTYPE	6	6	HIV
NCT001987187	NCT00198718_7_T1	PHENOTYPE	29	29	HIV
NCT001987187	NCT00198718_7_T2	PHENOTYPE	49	49	HIV
NCT001987187	NCT00198718_7_T3	PHENOTYPE	46	46	practices
NCT001987188	NCT00198718_8_T0	BIOLOGICAL_PROCESS	23	23	hematopoiesis
NCT001987188	NCT00198718_8_T1	ORGAN	25	25	serum
NCT001987188	NCT00198718_8_T2	PHENOTYPE	11	11	anemia
NCT001987188	NCT00198718_8_T3	COMPOUND	20	21	vitamin A
NCT001987188	NCT00198718_8_T4	COMPOUND	43	44	vitamin A
NCT001987188	NCT00198718_8_T5	COMPOUND	46	47	vitamin A
NCT001987189	NCT00198718_9_T0	GENE	17	17	TAP
NCT001987189	NCT00198718_9_T1	GENE	14	14	HLA-E
NCT001987189	NCT00198718_9_T2	GENE	15	15	HLA-G
NCT001987189	NCT00198718_9_T3	PHENOTYPE	24	25	HIV infection
NCT0019871811	NCT00198718_11_T0	GENE	6	6	had
NCT0019871818	NCT00198718_18_T0	GENE	20	20	extended
NCT0019871819	NCT00198718_19_T0	PHENOTYPE	1	1	recruitment
NCT0019871819	NCT00198718_19_T1	ORGAN	5	5	plasma
NCT0019871819	NCT00198718_19_T2	ORGAN	7	7	serum
NCT0019871821	NCT00198718_21_T0	GENE	59	59	Pp
NCT0019871821	NCT00198718_21_T1	GENE	50	50	Pa
NCT0019871821	NCT00198718_21_T2	COMPOUND	18	18	palmitate
NCT0019871821	NCT00198718_21_T3	COMPOUND	17	17	retinyl
NCT0019871821	NCT00198718_21_T4	GENE	38	38	Ap
NCT0019871821	NCT00198718_21_T5	COMPOUND	14	15	vitamin A
NCT0019871821	NCT00198718_21_T6	COMPOUND	24	25	vitamin A
NCT0019871821	NCT00198718_21_T7	COMPOUND	32	33	vitamin A
NCT0019871821	NCT00198718_21_T8	COMPOUND	48	49	vitamin A
NCT0019871824	NCT00198718_24_T0	PHENOTYPE	13	13	blocks
NCT0019871826	NCT00198718_26_T0	PHENOTYPE	30	30	recruitment
NCT0019871829	NCT00198718_29_T0	GENE	7	7	mo
NCT0019871829	NCT00198718_29_T1	GENE	5	5	wk
NCT0019871833	NCT00198718_33_T0	GENE	18	18	12
NCT0019871833	NCT00198718_33_T1	GENE	15	15	18
NCT0019871834	NCT00198718_34_T0	PHENOTYPE	28	28	practices
NCT0019871835	NCT00198718_35_T0	PHENOTYPE	25	25	mastitis
NCT0019871835	NCT00198718_35_T1	PHENOTYPE	19	19	tuberculosis
NCT0019871835	NCT00198718_35_T2	PHENOTYPE	32	32	diarrhea
NCT0019871835	NCT00198718_35_T3	PHENOTYPE	6	7	acute infections
NCT0019871836	NCT00198718_36_T0	PHENOTYPE	0	0	HIV
NCT0019871839	NCT00198718_39_T0	GENE	18	18	Blot
NCT0019871839	NCT00198718_39_T1	PHENOTYPE	5	5	HIV
NCT0019871839	NCT00198718_39_T2	ORGAN	1	1	plasma
NCT0019871840	NCT00198718_40_T0	PHENOTYPE	9	9	HIV
NCT0019871841	NCT00198718_41_T0	GENE	13	13	QC
NCT0019871841	NCT00198718_41_T1	PHENOTYPE	26	26	HIV
NCT0019871842	NCT00198718_42_T0	GENE	32	32	MD
NCT0019871842	NCT00198718_42_T1	ORGAN	0	0	Serum
NCT0019871842	NCT00198718_42_T2	GENE	67	67	CA
NCT0019871843	NCT00198718_43_T0	GENE	7	7	CD4
NCT0019871843	NCT00198718_43_T1	CELL	8	8	cells
NCT0019871843	NCT00198718_43_T2	BIOLOGICAL_PROCESS	15	15	phlebotomy
NCT0019871843	NCT00198718_43_T3	PHENOTYPE	6	6	recruitment
NCT0019871843	NCT00198718_43_T4	GENE	36	36	1.5
NCT0019871843	NCT00198718_43_T5	GENE	40	40	CA
NCT0019871847	NCT00198718_47_T0	PHENOTYPE	10	10	HIV
NCT0019871848	NCT00198718_48_T0	PHENOTYPE	6	6	HIV
NCT0019871849	NCT00198718_49_T0	PHENOTYPE	29	29	empowered
NCT0019871850	NCT00198718_50_T0	PHENOTYPE	13	13	HIV
NCT0019871852	NCT00198718_52_T0	PHENOTYPE	24	24	HIV
NCT0019871854	NCT00198718_54_T0	COMPOUND	10	10	1st
NCT0019871856	NCT00198718_56_T0	PHENOTYPE	12	12	HIV
NCT0019871856	NCT00198718_56_T1	PHENOTYPE	4	4	practices
NCT001987311	NCT00198731_1_T0	PHENOTYPE	22	22	complications
NCT001987311	NCT00198731_1_T1	BIOLOGICAL_PROCESS	12	13	giving birth
NCT001987314	NCT00198731_4_T0	PHENOTYPE	14	14	complications
NCT001987316	NCT00198731_6_T0	GENE	3	3	has
NCT001987317	NCT00198731_7_T0	GENE	15	15	iceberg
NCT001987318	NCT00198731_8_T0	PHENOTYPE	19	19	diseases
NCT001987319	NCT00198731_9_T0	PHENOTYPE	14	14	illnesses
NCT0019873111	NCT00198731_11_T0	PHENOTYPE	22	22	complications
NCT0019873111	NCT00198731_11_T1	GENE	25	25	al
NCT0019873111	NCT00198731_11_T2	GENE	42	42	al
NCT0019873111	NCT00198731_11_T3	GENE	24	24	et
NCT0019873111	NCT00198731_11_T4	GENE	41	41	et
NCT0019873111	NCT00198731_11_T5	BIOLOGICAL_PROCESS	12	13	giving birth
NCT0019873112	NCT00198731_12_T0	PHENOTYPE	28	28	complication
NCT0019873114	NCT00198731_14_T0	GENE	10	10	TBA
NCT001987440	NCT00198744_0_T0	PHENOTYPE	10	11	Weight Loss
NCT001987442	NCT00198744_2_T0	PHENOTYPE	13	14	weight loss
NCT001987444	NCT00198744_4_T0	GENE	0	0	Is
NCT001987444	NCT00198744_4_T1	PHENOTYPE	27	28	weight loss
NCT001987444	NCT00198744_4_T2	TISSUE	32	33	body fat
NCT001987448	NCT00198744_8_T0	PHENOTYPE	4	5	lost weight
NCT0019874410	NCT00198744_10_T0	PHENOTYPE	9	10	weight loss
NCT0019874415	NCT00198744_15_T0	PHENOTYPE	10	11	weight loss
NCT0019874419	NCT00198744_19_T0	PHENOTYPE	9	10	weight loss
NCT0019874422	NCT00198744_22_T0	GENE	16	16	52
NCT0019874429	NCT00198744_29_T0	COMPOUND	8	8	sibutramine
NCT0019874429	NCT00198744_29_T1	COMPOUND	9	9	orlistat
NCT0019874429	NCT00198744_29_T2	COMPOUND	7	7	phentermine
NCT0019874429	NCT00198744_29_T3	PHENOTYPE	2	3	weight loss
NCT0019874437	NCT00198744_37_T0	PHENOTYPE	0	0	Chronic
NCT0019874437	NCT00198744_37_T1	PHENOTYPE	8	8	dyslipidemia
NCT0019874437	NCT00198744_37_T2	PHENOTYPE	9	9	hypertension
NCT0019874437	NCT00198744_37_T3	PHENOTYPE	6	6	obesity
NCT0019874439	NCT00198744_39_T0	ORGAN	7	7	serum
NCT001987571	NCT00198757_1_T0	PHENOTYPE	8	9	weight loss
NCT001987573	NCT00198757_3_T0	PHENOTYPE	14	15	weight loss
NCT001987575	NCT00198757_5_T0	PHENOTYPE	10	11	weight loss
NCT001987577	NCT00198757_7_T0	GENE	23	23	AF
NCT001987577	NCT00198757_7_T1	PHENOTYPE	6	7	weight loss
NCT001987577	NCT00198757_7_T2	PHENOTYPE	27	28	metabolic rate
NCT001987579	NCT00198757_9_T0	GENE	21	21	ADA
NCT001987579	NCT00198757_9_T1	PHENOTYPE	2	3	weight loss
NCT001987579	NCT00198757_9_T2	PHENOTYPE	22	23	weight loss
NCT0019875710	NCT00198757_10_T0	PHENOTYPE	10	11	weight loss
NCT0019875712	NCT00198757_12_T0	PHENOTYPE	2	3	weight loss
NCT0019875713	NCT00198757_13_T0	PHENOTYPE	12	13	weight loss
NCT0019875720	NCT00198757_20_T0	PHENOTYPE	0	0	Overweight
NCT0019875720	NCT00198757_20_T1	PHENOTYPE	8	9	weight loss
NCT0019875721	NCT00198757_21_T0	PHENOTYPE	9	9	acute
NCT0019875721	NCT00198757_21_T1	GENE	14	14	eg
NCT0019875723	NCT00198757_23_T0	COMPOUND	6	6	sibutramine
NCT0019875723	NCT00198757_23_T1	GENE	8	8	eg
NCT0019875723	NCT00198757_23_T2	COMPOUND	7	7	orlistat
NCT0019875723	NCT00198757_23_T3	COMPOUND	5	5	phentermine
NCT0019875723	NCT00198757_23_T4	PHENOTYPE	2	3	weight loss
NCT0019875727	NCT00198757_27_T0	ORGAN	14	14	diaphragm
NCT0019875730	NCT00198757_30_T0	ORGAN	6	6	serum
NCT001987700	NCT00198770_0_T0	PHENOTYPE	1	1	Compensation
NCT001987702	NCT00198770_2_T0	PHENOTYPE	34	34	opinions
NCT001987705	NCT00198770_5_T0	PHENOTYPE	6	6	compensation
NCT0019877021	NCT00198770_21_T0	PHENOTYPE	0	0	Satiety
NCT0019878317	NCT00198783_17_T0	PHENOTYPE	1	1	compensation
NCT001987961	NCT00198796_1_T0	PHENOTYPE	15	15	strain
NCT001987961	NCT00198796_1_T1	GENE	14	14	ETEC
NCT001987961	NCT00198796_1_T2	PHENOTYPE	13	13	ingest
NCT001987963	NCT00198796_3_T0	PHENOTYPE	15	15	strain
NCT001987965	NCT00198796_5_T0	PHENOTYPE	12	12	strain
NCT001987965	NCT00198796_5_T1	COMPOUND	9	9	CFU
NCT001987965	NCT00198796_5_T2	GENE	11	11	ETEC
NCT001987965	NCT00198796_5_T3	PHENOTYPE	16	16	diarrhea
NCT001987965	NCT00198796_5_T4	GENE	5	5	10.9
NCT001987965	NCT00198796_5_T5	CELL	6	8	colony forming unit
NCT001987968	NCT00198796_8_T0	ORGAN	16	16	hands
NCT001987969	NCT00198796_9_T0	PHENOTYPE	35	35	strain
NCT0019879613	NCT00198796_13_T0	GENE	2	2	45
NCT0019879614	NCT00198796_14_T0	PHENOTYPE	0	1	Chronic illness
NCT0019879614	NCT00198796_14_T1	PHENOTYPE	2	3	chemical dependency
NCT0019879615	NCT00198796_15_T0	GENE	4	4	IgA
NCT0019879615	NCT00198796_15_T1	COMPOUND	0	0	3
NCT001988090	NCT00198809_0_T0	PHENOTYPE	5	6	Weight Loss
NCT001988092	NCT00198809_2_T0	PHENOTYPE	7	7	overweight
NCT001988092	NCT00198809_2_T1	COMPOUND	8	8	BMI
NCT001988097	NCT00198809_7_T0	COMPOUND	24	24	BMI
NCT001988098	NCT00198809_8_T0	PHENOTYPE	7	8	weight reduction
NCT0019880914	NCT00198809_14_T0	PHENOTYPE	16	16	symptoms
NCT0019880914	NCT00198809_14_T1	PHENOTYPE	8	8	allergies
NCT0019880914	NCT00198809_14_T2	PHENOTYPE	13	13	GERD
NCT0019880914	NCT00198809_14_T3	PHENOTYPE	2	2	Chronic
NCT0019880914	NCT00198809_14_T4	PHENOTYPE	15	15	IBS
NCT0019880914	NCT00198809_14_T5	PHENOTYPE	7	7	obesity
NCT001988223	NCT00198822_3_T0	BIOLOGICAL_PROCESS	14	14	gestation
NCT001988229	NCT00198822_9_T0	BIOLOGICAL_PROCESS	27	27	beta-carotene
NCT001988229	NCT00198822_9_T1	COMPOUND	22	23	vitamin A
NCT0019882211	NCT00198822_11_T0	COMPOUND	13	13	1st
NCT0019882212	NCT00198822_12_T0	PHENOTYPE	17	18	birth defects
NCT0019882214	NCT00198822_14_T0	COMPOUND	25	25	1st
NCT001988611	NCT00198861_1_T0	PHENOTYPE	11	11	seronegative
NCT001988612	NCT00198861_2_T0	PHENOTYPE	18	19	executive dysfunction
NCT001988612	NCT00198861_2_T1	PHENOTYPE	35	36	drug abuse
NCT001988615	NCT00198861_5_T0	PHENOTYPE	17	17	HIV
NCT001988615	NCT00198861_5_T1	PHENOTYPE	7	8	drug abuse
NCT001988616	NCT00198861_6_T0	PHENOTYPE	21	21	associations
NCT001988617	NCT00198861_7_T0	PHENOTYPE	13	13	practices
NCT001988617	NCT00198861_7_T1	PHENOTYPE	17	18	HIV infection
NCT001988741	NCT00198874_1_T0	PHENOTYPE	26	27	drug abuse
NCT001988742	NCT00198874_2_T0	PHENOTYPE	27	27	severity
NCT001988742	NCT00198874_2_T1	PHENOTYPE	24	25	drug abuse
NCT001988742	NCT00198874_2_T2	PHENOTYPE	28	29	problem behavior
NCT001988743	NCT00198874_3_T0	PHENOTYPE	2	2	strategies
NCT001988743	NCT00198874_3_T1	PHENOTYPE	15	15	attributable
NCT001988747	NCT00198874_7_T0	GENE	3	3	has
NCT001988748	NCT00198874_8_T0	PHENOTYPE	15	15	addictions
NCT001988748	NCT00198874_8_T1	PHENOTYPE	22	23	drug abuse
NCT001988749	NCT00198874_9_T0	PHENOTYPE	27	28	problem behavior
NCT001988749	NCT00198874_9_T1	PHENOTYPE	24	25	drug use
NCT0019887410	NCT00198874_10_T0	PHENOTYPE	16	16	understood
NCT0019887413	NCT00198874_13_T0	PHENOTYPE	10	10	strategies
NCT0019887413	NCT00198874_13_T1	PHENOTYPE	14	15	drug abuse
NCT0019887416	NCT00198874_16_T0	PHENOTYPE	26	27	drug abuse
NCT0019887417	NCT00198874_17_T0	PHENOTYPE	27	27	severity
NCT0019887417	NCT00198874_17_T1	PHENOTYPE	24	25	drug abuse
NCT0019887417	NCT00198874_17_T2	PHENOTYPE	28	29	problem behavior
NCT0019887418	NCT00198874_18_T0	PHENOTYPE	2	2	strategies
NCT0019887418	NCT00198874_18_T1	PHENOTYPE	15	15	attributable
NCT0019887422	NCT00198874_22_T0	GENE	3	3	has
NCT0019887423	NCT00198874_23_T0	PHENOTYPE	15	15	addictions
NCT0019887423	NCT00198874_23_T1	PHENOTYPE	22	23	drug abuse
NCT0019887424	NCT00198874_24_T0	PHENOTYPE	27	28	problem behavior
NCT0019887424	NCT00198874_24_T1	PHENOTYPE	24	25	drug use
NCT0019887425	NCT00198874_25_T0	PHENOTYPE	16	16	understood
NCT001988872	NCT00198887_2_T0	GENE	25	25	II
NCT001988872	NCT00198887_2_T1	PHENOTYPE	4	4	learned
NCT001988872	NCT00198887_2_T2	GENE	22	22	has
NCT001988874	NCT00198887_4_T0	PHENOTYPE	7	7	focused
NCT001988875	NCT00198887_5_T0	PHENOTYPE	54	54	complications
NCT001988875	NCT00198887_5_T1	PHENOTYPE	39	39	cord
NCT001988875	NCT00198887_5_T2	COMPOUND	6	6	1
NCT001988875	NCT00198887_5_T3	COMPOUND	9	9	2
NCT001988875	NCT00198887_5_T4	PHENOTYPE	13	13	tetanus
NCT001988875	NCT00198887_5_T5	COMPOUND	12	12	3
NCT001988875	NCT00198887_5_T6	PHENOTYPE	36	36	hypothermia
NCT001988875	NCT00198887_5_T7	GENE	42	42	10
NCT001989001	NCT00198900_1_T0	GENE	1	2	type 2
NCT001989139	NCT00198913_9_T0	PHENOTYPE	20	20	pulse
NCT0019891312	NCT00198913_12_T0	GENE	12	12	log
NCT0019891312	NCT00198913_12_T1	PHENOTYPE	27	27	tolerance
NCT0019891313	NCT00198913_13_T0	PHENOTYPE	12	13	food allergies
NCT0019891319	NCT00198913_19_T0	COMPOUND	13	13	2wks
NCT0019891320	NCT00198913_20_T0	ORGAN	0	0	Appendix
NCT0019891324	NCT00198913_24_T0	GENE	7	7	log
NCT0019891325	NCT00198913_25_T0	PHENOTYPE	19	19	pulse
NCT0019891328	NCT00198913_28_T0	GENE	23	23	II
NCT001989394	NCT00198939_4_T0	PHENOTYPE	28	29	problem behavior
NCT001989394	NCT00198939_4_T1	PHENOTYPE	26	27	drug use
NCT001989394	NCT00198939_4_T2	PHENOTYPE	30	31	psychological distress
NCT001989395	NCT00198939_5_T0	PHENOTYPE	2	2	strategies
NCT001989395	NCT00198939_5_T1	PHENOTYPE	19	20	problem behavior
NCT001989397	NCT00198939_7_T0	GENE	3	3	has
NCT0019893910	NCT00198939_10_T0	PHENOTYPE	7	7	practices
NCT0019893912	NCT00198939_12_T0	PHENOTYPE	35	36	drug abuse
NCT0019893914	NCT00198939_14_T0	PHENOTYPE	10	10	strategies
NCT0019893914	NCT00198939_14_T1	PHENOTYPE	14	15	drug abuse
NCT001989650	NCT00198965_0_T0	PHENOTYPE	4	5	Weight Loss
NCT001989653	NCT00198965_3_T0	GENE	1	1	II
NCT001989654	NCT00198965_4_T0	GENE	1	1	III
NCT001989656	NCT00198965_6_T0	PHENOTYPE	17	18	weight loss
NCT001989658	NCT00198965_8_T0	GENE	0	0	The
NCT001989658	NCT00198965_8_T1	PHENOTYPE	26	26	tolerance
NCT0019896512	NCT00198965_12_T0	PHENOTYPE	7	8	weight loss
NCT0019896513	NCT00198965_13_T0	GENE	2	2	II
NCT0019896518	NCT00198965_18_T0	PHENOTYPE	5	6	losing weight
NCT0019896522	NCT00198965_22_T0	PHENOTYPE	2	2	secondary
NCT0019896522	NCT00198965_22_T1	PHENOTYPE	31	32	bioelectrical impedance
NCT0019896524	NCT00198965_24_T0	PHENOTYPE	7	8	weight loss
NCT001989781	NCT00198978_1_T0	GENE	5	5	CD20
NCT001989781	NCT00198978_1_T1	CELL	8	8	cells
NCT001989913	NCT00198991_3_T0	PHENOTYPE	5	5	MRD
NCT001989913	NCT00198991_3_T1	PHENOTYPE	2	4	minimal residual disease
NCT001989914	NCT00198991_4_T0	PHENOTYPE	21	21	MRD
NCT001990042	NCT00199004_2_T0	PHENOTYPE	2	4	minimal residual disease
NCT001990171	NCT00199017_1_T0	PHENOTYPE	16	16	relapse
NCT001990171	NCT00199017_1_T1	ORGAN	12	14	central nervous system
NCT001990302	NCT00199030_2_T0	COMPOUND	7	7	cladribine
NCT001990563	NCT00199056_3_T0	PHENOTYPE	5	5	MRD
NCT001990563	NCT00199056_3_T1	PHENOTYPE	2	4	minimal residual disease
NCT001990564	NCT00199056_4_T0	PHENOTYPE	1	1	MRD
NCT001991080	NCT00199108_0_T0	PHENOTYPE	9	9	Relapse
NCT001991080	NCT00199108_0_T1	PHENOTYPE	6	7	Aggressive Lymphoma
NCT001991080	NCT00199108_0_T2	ORGAN	11	13	Central Nervous System
NCT001991080	NCT00199108_0_T3	PHENOTYPE	2	4	Acute Lymphoblastic Leukemia
NCT001991083	NCT00199108_3_T0	GENE	8	8	2.3
NCT001991211	NCT00199121_1_T0	GENE	3	3	TDF
NCT001991341	NCT00199134_1_T0	GENE	6	6	hormone
NCT001991343	NCT00199134_3_T0	PHENOTYPE	39	39	tumor
NCT001991344	NCT00199134_4_T0	COMPOUND	25	25	letrozole
NCT001991344	NCT00199134_4_T1	PHENOTYPE	43	43	oedema
NCT001991344	NCT00199134_4_T2	PHENOTYPE	41	41	fatigue
NCT001991344	NCT00199134_4_T3	GENE	7	7	receptor
NCT001991344	NCT00199134_4_T4	PHENOTYPE	39	39	headache
NCT001991344	NCT00199134_4_T5	PHENOTYPE	9	10	breast cancer
NCT001991344	NCT00199134_4_T6	PHENOTYPE	34	35	hot flashes
NCT001991344	NCT00199134_4_T7	PHENOTYPE	36	38	nausea and vomiting
NCT001991345	NCT00199134_5_T0	COMPOUND	20	20	letrozole
NCT0019913416	NCT00199134_16_T0	GENE	11	11	II
NCT0019913416	NCT00199134_16_T1	GENE	13	13	III
NCT0019913416	NCT00199134_16_T2	PHENOTYPE	5	8	adenocarcinoma of the breast
NCT0019913417	NCT00199134_17_T0	PHENOTYPE	6	7	bone metastases
NCT0019913417	NCT00199134_17_T1	PHENOTYPE	1	3	absence of liver
NCT0019913419	NCT00199134_19_T0	GENE	6	6	cm
NCT0019913419	NCT00199134_19_T1	PHENOTYPE	0	1	Primary tumor
NCT0019913423	NCT00199134_23_T0	GENE	19	19	cDNA
NCT0019913423	NCT00199134_23_T1	GENE	21	21	EGFR
NCT0019913423	NCT00199134_23_T2	GENE	22	22	HER-2
NCT0019913423	NCT00199134_23_T3	PHENOTYPE	6	7	primary tumor
NCT0019913425	NCT00199134_25_T0	PHENOTYPE	6	7	in remission
NCT0019913425	NCT00199134_25_T1	PHENOTYPE	2	3	second malignancy
NCT0019913429	NCT00199134_29_T0	COMPOUND	8	8	MUGA
NCT0019913429	NCT00199134_29_T1	PHENOTYPE	2	4	ventricular ejection fraction
NCT0019913431	NCT00199134_31_T0	GENE	11	11	GCP
NCT001991470	NCT00199147_0_T0	PHENOTYPE	5	5	AML
NCT001991472	NCT00199147_2_T0	GENE	26	26	G-CSF
NCT001991472	NCT00199147_2_T1	CELL	8	11	peripheral blood stem cells
NCT001991600	NCT00199160_0_T0	PHENOTYPE	9	9	Recurrent
NCT001991600	NCT00199160_0_T1	PHENOTYPE	12	15	Head and Neck Cancer
NCT001992127	NCT00199212_7_T0	PHENOTYPE	4	5	breast cancer
NCT001992128	NCT00199212_8_T0	PHENOTYPE	3	4	metastatic disease
NCT0019921211	NCT00199212_11_T0	PHENOTYPE	6	7	in remission
NCT0019921211	NCT00199212_11_T1	PHENOTYPE	2	3	second malignancy
NCT0019921211	NCT00199212_11_T2	PHENOTYPE	14	16	contralateral breast cancer
NCT0019921214	NCT00199212_14_T0	ORGAN	2	4	central nervous system
NCT0019921215	NCT00199212_15_T0	PHENOTYPE	4	4	metastases
NCT0019921215	NCT00199212_15_T1	PHENOTYPE	1	2	rapidly progressive
NCT0019921217	NCT00199212_17_T0	GENE	10	10	HER-2
NCT0019921218	NCT00199212_18_T0	PHENOTYPE	9	11	metastatic breast cancer
NCT0019921219	NCT00199212_19_T0	GENE	13	13	has
NCT0019921219	NCT00199212_19_T1	GENE	2	2	MBC
NCT0019921226	NCT00199212_26_T0	PHENOTYPE	0	0	Evaluable
NCT0019921226	NCT00199212_26_T1	PHENOTYPE	3	4	measurable disease
NCT0019921226	NCT00199212_26_T2	PHENOTYPE	12	13	Solid Tumors
NCT0019921227	NCT00199212_27_T0	ORGAN	8	8	serum
NCT001992251	NCT00199225_1_T0	GENE	18	18	has
NCT001992256	NCT00199225_6_T0	PHENOTYPE	91	91	concentrations
NCT001992256	NCT00199225_6_T1	COMPOUND	49	49	moxifloxacin
NCT0019922513	NCT00199225_13_T0	COMPOUND	9	9	nicotine
NCT0019922514	NCT00199225_14_T0	PHENOTYPE	6	6	HIV
NCT0019922514	NCT00199225_14_T1	PHENOTYPE	2	3	Hepatitis B
NCT0019922515	NCT00199225_15_T0	ORGAN	6	6	serum
NCT0019922520	NCT00199225_20_T0	GENE	10	10	eg
NCT0019922520	NCT00199225_20_T1	GENE	15	15	cola
NCT0019922525	NCT00199225_25_T0	GENE	14	14	OTC
NCT0019922527	NCT00199225_27_T0	COMPOUND	5	5	calcium
NCT0019922527	NCT00199225_27_T1	COMPOUND	7	7	magnesium
NCT0019922527	NCT00199225_27_T2	COMPOUND	4	4	sodium
NCT0019922527	NCT00199225_27_T3	GENE	16	16	has
NCT0019922527	NCT00199225_27_T4	PHENOTYPE	2	3	serum potassium
NCT001992387	NCT00199238_7_T0	PHENOTYPE	7	7	pruritus
NCT001992387	NCT00199238_7_T1	PHENOTYPE	33	33	pruritus
NCT0019923810	NCT00199238_10_T0	PHENOTYPE	9	9	5-10
NCT0019923817	NCT00199238_17_T0	PHENOTYPE	7	7	pruritus
NCT0019923817	NCT00199238_17_T1	PHENOTYPE	33	33	pruritus
NCT0019923824	NCT00199238_24_T0	PHENOTYPE	0	1	Cholinergic urticaria
NCT0019923826	NCT00199238_26_T0	PHENOTYPE	0	0	Urticaria
NCT0019923826	NCT00199238_26_T1	PHENOTYPE	8	8	bites
NCT0019923828	NCT00199238_28_T0	PHENOTYPE	11	12	systemic disease
NCT0019923828	NCT00199238_28_T1	PHENOTYPE	2	3	psychiatric disorders
NCT0019923830	NCT00199238_30_T0	ORGAN	14	14	heart
NCT0019923830	NCT00199238_30_T1	PHENOTYPE	3	4	heart abnormality
NCT0019923831	NCT00199238_31_T0	PHENOTYPE	8	9	drug effect
NCT0019923833	NCT00199238_33_T0	PHENOTYPE	2	3	hereditary angioedema
NCT001992513	NCT00199251_3_T0	PHENOTYPE	34	34	pruritus
NCT001992513	NCT00199251_3_T1	PHENOTYPE	76	76	pruritus
NCT001992513	NCT00199251_3_T2	PHENOTYPE	102	102	pruritus
NCT001992513	NCT00199251_3_T3	PHENOTYPE	18	18	severity
NCT001992513	NCT00199251_3_T4	PHENOTYPE	86	86	severity
NCT001992513	NCT00199251_3_T5	GENE	113	113	VAS
NCT001992513	NCT00199251_3_T6	PHENOTYPE	60	60	wheals
NCT001992513	NCT00199251_3_T7	PHENOTYPE	84	84	wheals
NCT001992513	NCT00199251_3_T8	PHENOTYPE	20	20	symptoms
NCT001992513	NCT00199251_3_T9	PHENOTYPE	65	65	symptoms
NCT001992513	NCT00199251_3_T10	PHENOTYPE	77	77	symptoms
NCT001992513	NCT00199251_3_T11	PHENOTYPE	88	88	symptoms
NCT001992513	NCT00199251_3_T12	GENE	36	36	MPS
NCT001992513	NCT00199251_3_T13	GENE	74	74	MPS
NCT001992513	NCT00199251_3_T14	GENE	104	104	MPS
NCT001992513	NCT00199251_3_T15	PHENOTYPE	2	2	Chronic
NCT001992513	NCT00199251_3_T16	PHENOTYPE	3	4	Idiopathic Urticaria
NCT001992513	NCT00199251_3_T17	PHENOTYPE	126	127	Life Quality
NCT001992513	NCT00199251_3_T18	PHENOTYPE	142	143	adverse events
NCT001992513	NCT00199251_3_T19	PHENOTYPE	115	117	Quality of life
NCT001992516	NCT00199251_6_T0	PHENOTYPE	7	7	pruritus
NCT001992516	NCT00199251_6_T1	PHENOTYPE	33	33	pruritus
NCT001992519	NCT00199251_9_T0	PHENOTYPE	14	15	drug effect
NCT0019925115	NCT00199251_15_T0	PHENOTYPE	7	9	negative pregnancy test
NCT0019925116	NCT00199251_16_T0	PHENOTYPE	11	11	IUD
NCT0019925125	NCT00199251_25_T0	PHENOTYPE	0	1	Cholinergic urticaria
NCT0019925129	NCT00199251_29_T0	PHENOTYPE	0	0	Urticaria
NCT0019925129	NCT00199251_29_T1	PHENOTYPE	8	8	bites
NCT0019925133	NCT00199251_33_T0	PHENOTYPE	11	12	drug addiction
NCT0019925134	NCT00199251_34_T0	COMPOUND	12	12	procainamide
NCT0019925134	NCT00199251_34_T1	COMPOUND	11	11	disopyramide
NCT0019925134	NCT00199251_34_T2	COMPOUND	13	13	quinidine
NCT0019925134	NCT00199251_34_T3	COMPOUND	14	14	amiodarone
NCT0019925134	NCT00199251_34_T4	COMPOUND	15	15	sotalol
NCT0019925134	NCT00199251_34_T5	COMPOUND	16	16	thioridazine
NCT0019925134	NCT00199251_34_T6	PHENOTYPE	6	8	torsade de pointes
NCT001992643	NCT00199264_3_T0	GENE	10	10	spp
NCT001992770	NCT00199277_0_T0	PHENOTYPE	4	4	Neoplasm
NCT001992770	NCT00199277_0_T1	PHENOTYPE	6	8	Iron Deficiency Anemia
NCT001992772	NCT00199277_2_T0	GENE	17	17	ferritin
NCT001992772	NCT00199277_2_T1	ORGAN	16	16	serum
NCT001992772	NCT00199277_2_T2	COMPOUND	7	7	sucrose
NCT001992772	NCT00199277_2_T3	PHENOTYPE	21	22	postoperative complications
NCT001992776	NCT00199277_6_T0	PHENOTYPE	21	21	peritonitis
NCT001992776	NCT00199277_6_T1	GENE	2	2	has
NCT001992776	NCT00199277_6_T2	PHENOTYPE	10	10	anemia
NCT001992776	NCT00199277_6_T3	PHENOTYPE	6	7	iron deficiency
NCT001992777	NCT00199277_7_T0	PHENOTYPE	28	28	infections
NCT001992777	NCT00199277_7_T1	PHENOTYPE	1	1	anemia
NCT001992777	NCT00199277_7_T2	PHENOTYPE	18	18	anemia
NCT001992777	NCT00199277_7_T3	PHENOTYPE	26	27	postoperative complications
NCT001992777	NCT00199277_7_T4	PHENOTYPE	15	16	iron deficiency
NCT001993032	NCT00199303_2_T0	COMPOUND	9	9	dextromethorphan
NCT001993034	NCT00199303_4_T0	PHENOTYPE	8	8	analgesia
NCT001993293	NCT00199329_3_T0	COMPOUND	6	6	ondansetron
NCT001993293	NCT00199329_3_T1	COMPOUND	10	10	morphine
NCT001993424	NCT00199342_4_T0	COMPOUND	9	9	dexamethasone
NCT001993424	NCT00199342_4_T1	COMPOUND	6	6	ranitidine
NCT001993424	NCT00199342_4_T2	COMPOUND	7	7	diphenhydramine
NCT001993425	NCT00199342_5_T0	GENE	27	27	II
NCT001993425	NCT00199342_5_T1	GENE	15	15	MTD
NCT001993426	NCT00199342_6_T0	GENE	18	18	II
NCT001993426	NCT00199342_6_T1	GENE	2	2	MTD
NCT001993427	NCT00199342_7_T0	GENE	23	23	II
NCT001993427	NCT00199342_7_T1	PHENOTYPE	12	12	closed
NCT001993427	NCT00199342_7_T2	GENE	2	2	MTD
NCT0019934211	NCT00199342_11_T0	PHENOTYPE	5	6	measurable disease
NCT0019934224	NCT00199342_24_T0	ORGAN	16	16	serum
NCT0019934226	NCT00199342_26_T0	PHENOTYPE	22	22	acute
NCT0019934226	NCT00199342_26_T1	COMPOUND	17	17	nitrosourea
NCT0019934226	NCT00199342_26_T2	COMPOUND	13	14	mitomycin C
NCT0019934227	NCT00199342_27_T0	PHENOTYPE	13	13	toxicity
NCT0019934227	NCT00199342_27_T1	PHENOTYPE	12	12	acute
NCT0019934229	NCT00199342_29_T0	ORGAN	45	45	diaphragm
NCT0019934231	NCT00199342_31_T0	ORGAN	11	11	Heart
NCT0019934231	NCT00199342_31_T1	GENE	15	15	III
NCT0019934231	NCT00199342_31_T2	PHENOTYPE	3	4	cardiovascular disease
NCT0019934232	NCT00199342_32_T0	GENE	9	9	has
NCT0019934232	NCT00199342_32_T1	GENE	15	15	gamma
NCT0019934232	NCT00199342_32_T2	PHENOTYPE	5	6	brain metastases
NCT0019934235	NCT00199342_35_T0	PHENOTYPE	18	18	suspicion
NCT0019934235	NCT00199342_35_T1	PHENOTYPE	8	8	dysfunction
NCT0019934235	NCT00199342_35_T2	PHENOTYPE	52	53	treatment complications
NCT0019934236	NCT00199342_36_T0	PHENOTYPE	3	4	HIV infection
NCT0019934238	NCT00199342_38_T0	PHENOTYPE	2	3	psychiatric disorders
NCT0019934238	NCT00199342_38_T1	PHENOTYPE	5	7	altered mental status
NCT0019934240	NCT00199342_40_T0	PHENOTYPE	14	14	melanoma
NCT001993553	NCT00199355_3_T0	COMPOUND	24	24	istradefylline
NCT001993555	NCT00199355_5_T0	GENE	8	8	Step
NCT001993555	NCT00199355_5_T1	PHENOTYPE	1	2	Parkinson's Disease
NCT001993557	NCT00199355_7_T0	GENE	2	2	2.4
NCT0019935519	NCT00199355_19_T0	PHENOTYPE	13	14	Parkinson's disease
NCT0019935525	NCT00199355_25_T0	PHENOTYPE	2	2	psychosis
NCT0019935527	NCT00199355_27_T0	PHENOTYPE	3	3	Parkinsonism
NCT0019935527	NCT00199355_27_T1	PHENOTYPE	6	6	Parkinsonism
NCT0019935527	NCT00199355_27_T2	PHENOTYPE	5	5	secondary
NCT0019935527	NCT00199355_27_T3	GENE	2	2	atypical
NCT0019935537	NCT00199355_37_T0	PHENOTYPE	4	7	alcohol abuse or dependence
NCT0019935539	NCT00199355_39_T0	PHENOTYPE	2	2	seizures
NCT001993680	NCT00199368_0_T0	PHENOTYPE	5	6	Parkinson's Disease
NCT001993810	NCT00199381_0_T0	PHENOTYPE	7	8	Parkinson's Disease
NCT001993944	NCT00199394_4_T0	COMPOUND	24	24	levodopa
NCT001993944	NCT00199394_4_T1	COMPOUND	6	6	istradefylline
NCT001993947	NCT00199394_7_T0	COMPOUND	6	6	levodopa
NCT001994072	NCT00199407_2_T0	COMPOUND	16	16	istradefylline
NCT001994073	NCT00199407_3_T0	COMPOUND	24	24	istradefylline
NCT001994075	NCT00199407_5_T0	GENE	8	8	Step
NCT001994075	NCT00199407_5_T1	PHENOTYPE	1	2	Parkinson's Disease
NCT001994077	NCT00199407_7_T0	GENE	2	2	2.4
NCT001994079	NCT00199407_9_T0	COMPOUND	1	1	levodopa_carbidopa
NCT0019940723	NCT00199407_23_T0	PHENOTYPE	2	2	psychosis
NCT0019940725	NCT00199407_25_T0	PHENOTYPE	3	3	parkinsonism
NCT0019940725	NCT00199407_25_T1	GENE	2	2	atypical
NCT0019940725	NCT00199407_25_T2	PHENOTYPE	10	10	syndromes
NCT0019940725	NCT00199407_25_T3	PHENOTYPE	4	5	secondary parkinsonism
NCT0019940731	NCT00199407_31_T0	PHENOTYPE	2	2	seizures
NCT0019940733	NCT00199407_33_T0	PHENOTYPE	0	1	Clinical depression
NCT001994202	NCT00199420_2_T0	COMPOUND	16	16	istradefylline
NCT001994205	NCT00199420_5_T0	GENE	8	8	Step
NCT001994205	NCT00199420_5_T1	PHENOTYPE	1	2	Parkinson's Disease
NCT001994207	NCT00199420_7_T0	GENE	2	2	2.4
NCT001994209	NCT00199420_9_T0	COMPOUND	1	1	levodopa_carbidopa
NCT0019942023	NCT00199420_23_T0	PHENOTYPE	2	2	psychosis
NCT0019942025	NCT00199420_25_T0	PHENOTYPE	3	3	parkinsonism
NCT0019942025	NCT00199420_25_T1	GENE	2	2	atypical
NCT0019942025	NCT00199420_25_T2	PHENOTYPE	10	10	syndromes
NCT0019942025	NCT00199420_25_T3	PHENOTYPE	4	5	secondary parkinsonism
NCT0019942031	NCT00199420_31_T0	PHENOTYPE	2	2	seizures
NCT001994330	NCT00199433_0_T0	PHENOTYPE	8	9	Parkinson's Disease
NCT001994333	NCT00199433_3_T0	COMPOUND	4	4	dopamine
NCT001994333	NCT00199433_3_T1	GENE	10	11	dopamine receptor
NCT001994335	NCT00199433_5_T0	PHENOTYPE	10	11	Parkinson's disease
NCT001994339	NCT00199433_9_T0	PHENOTYPE	0	0	Mild
NCT0019943313	NCT00199433_13_T0	PHENOTYPE	0	0	Symptoms
NCT0019943313	NCT00199433_13_T1	PHENOTYPE	8	9	Parkinson's disease
NCT001994462	NCT00199446_2_T0	PHENOTYPE	18	18	discomfort
NCT001994462	NCT00199446_2_T1	ORGAN	11	11	legs
NCT001994462	NCT00199446_2_T2	PHENOTYPE	15	15	feelings
NCT001994463	NCT00199446_3_T0	PHENOTYPE	1	1	feelings
NCT001994464	NCT00199446_4_T0	PHENOTYPE	12	12	profound
NCT001994464	NCT00199446_4_T1	PHENOTYPE	17	17	fatigue
NCT001994464	NCT00199446_4_T2	PHENOTYPE	0	0	Symptoms
NCT001994464	NCT00199446_4_T3	PHENOTYPE	13	14	sleep disturbance
NCT001994591	NCT00199459_1_T0	ORGAN	11	11	serum
NCT001994593	NCT00199459_3_T0	PHENOTYPE	14	14	strategies
NCT001994595	NCT00199459_5_T0	ORGAN	5	5	serum
NCT001994596	NCT00199459_6_T0	PHENOTYPE	13	13	recurrences
NCT001994596	NCT00199459_6_T1	PHENOTYPE	21	21	strategies
NCT001994597	NCT00199459_7_T0	MOLECULAR_FUNCTION	0	1	Urinary protein
NCT001994598	NCT00199459_8_T0	ORGAN	11	11	serum
NCT0019945911	NCT00199459_11_T0	PHENOTYPE	14	14	strategies
NCT001994721	NCT00199472_1_T0	PHENOTYPE	18	18	obstruction
NCT001994852	NCT00199485_2_T0	PHENOTYPE	19	19	severity
NCT001994852	NCT00199485_2_T1	GENE	7	7	has
NCT001994852	NCT00199485_2_T2	PHENOTYPE	21	22	hot flashes
NCT001994986	NCT00199498_6_T0	PHENOTYPE	2	4	Hypertrophic Obstructive Cardiomyopathy
NCT001994988	NCT00199498_8_T0	PHENOTYPE	1	2	myocardial infarction
NCT001994989	NCT00199498_9_T0	ORGAN	4	5	tricuspid valve
NCT001995113	NCT00199511_3_T0	PHENOTYPE	7	7	hyperventilation
NCT001995113	NCT00199511_3_T1	PHENOTYPE	0	0	Strategies
NCT001995113	NCT00199511_3_T2	PHENOTYPE	3	5	raised intracranial pressure
NCT001995118	NCT00199511_8_T0	PHENOTYPE	11	11	hypotension
NCT001995118	NCT00199511_8_T1	COMPOUND	19	19	sodium
NCT001995118	NCT00199511_8_T2	COMPOUND	20	20	potassium
NCT001995118	NCT00199511_8_T3	BIOLOGICAL_PROCESS	3	3	diuresis
NCT001995118	NCT00199511_8_T4	ORGAN	16	16	serum
NCT001995118	NCT00199511_8_T5	PHENOTYPE	9	9	hypovolemia
NCT001995119	NCT00199511_9_T0	GENE	5	5	has
NCT0019951110	NCT00199511_10_T0	GENE	27	27	has
NCT0019951110	NCT00199511_10_T1	PHENOTYPE	17	19	raised intracranial pressure
NCT0019951110	NCT00199511_10_T2	PHENOTYPE	22	24	traumatic brain injury
NCT0019951111	NCT00199511_11_T0	PHENOTYPE	21	21	hypotension
NCT0019951111	NCT00199511_11_T1	BIOLOGICAL_PROCESS	14	14	diuresis
NCT0019951111	NCT00199511_11_T2	PHENOTYPE	23	23	hypovolemia
NCT0019951112	NCT00199511_12_T0	PHENOTYPE	2	2	hypernatremia
NCT0019951112	NCT00199511_12_T1	GENE	3	3	has
NCT0019951114	NCT00199511_14_T0	GENE	5	5	al
NCT0019951114	NCT00199511_14_T1	GENE	4	4	et
NCT0019951115	NCT00199511_15_T0	GENE	5	5	had
NCT0019951115	NCT00199511_15_T1	GENE	12	12	had
NCT001995632	NCT00199563_2_T0	PHENOTYPE	15	15	microalbuminuria
NCT001995632	NCT00199563_2_T1	ORGAN	9	9	forearm
NCT001995632	NCT00199563_2_T2	ORGAN	17	17	serum
NCT001995761	NCT00199576_1_T0	PHENOTYPE	6	6	complication
NCT001995761	NCT00199576_1_T1	PHENOTYPE	1	2	laryngeal edema
NCT001995762	NCT00199576_2_T0	PHENOTYPE	10	11	laryngeal edema
NCT001995764	NCT00199576_4_T0	GENE	8	8	lag
NCT001995765	NCT00199576_5_T0	PHENOTYPE	23	24	laryngeal edema
NCT001995768	NCT00199576_8_T0	PHENOTYPE	6	7	laryngeal edema
NCT001995769	NCT00199576_9_T0	PHENOTYPE	0	1	Laryngeal edema
NCT001995890	NCT00199589_0_T0	PHENOTYPE	3	3	Equinovarus
NCT001995890	NCT00199589_0_T1	PHENOTYPE	6	6	Stroke
NCT001995890	NCT00199589_0_T2	PHENOTYPE	2	2	Spastic
NCT001996156	NCT00199615_6_T0	PHENOTYPE	0	0	Recurrences
NCT001996284	NCT00199628_4_T0	PHENOTYPE	16	16	alloimmunization
NCT001996284	NCT00199628_4_T1	PHENOTYPE	10	11	neonatal diseases
NCT001996285	NCT00199628_5_T0	PHENOTYPE	4	4	diseases
NCT001996285	NCT00199628_5_T1	ORGAN	11	11	serum
NCT001996541	NCT00199654_1_T0	PHENOTYPE	5	5	relapse
NCT001996541	NCT00199654_1_T1	PHENOTYPE	8	9	colorectal cancer
NCT001996544	NCT00199654_4_T0	GENE	1	1	Up
NCT001996545	NCT00199654_5_T0	PHENOTYPE	12	12	relapse
NCT001996545	NCT00199654_5_T1	GENE	26	26	CEA
NCT001996545	NCT00199654_5_T2	PHENOTYPE	17	18	cancer relapse
NCT001996545	NCT00199654_5_T3	PHENOTYPE	16	17	colorectal cancer
NCT001996675	NCT00199667_5_T0	PHENOTYPE	17	17	MPA
NCT001996801	NCT00199680_1_T0	TISSUE	7	8	lymph node
NCT001996802	NCT00199680_2_T0	TISSUE	10	11	lymph node
NCT001996802	NCT00199680_2_T1	PHENOTYPE	2	3	cervical cancers
NCT001996803	NCT00199680_3_T0	GENE	31	31	III
NCT001996803	NCT00199680_3_T1	GENE	15	15	cm
NCT001996803	NCT00199680_3_T2	PHENOTYPE	28	28	distal
NCT001996803	NCT00199680_3_T3	PHENOTYPE	33	33	IVA
NCT001996803	NCT00199680_3_T4	PHENOTYPE	11	11	tumour
NCT001996803	NCT00199680_3_T5	PHENOTYPE	25	25	cancers
NCT001996803	NCT00199680_3_T6	PHENOTYPE	4	4	proximal
NCT001996803	NCT00199680_3_T7	TISSUE	18	19	lymph node
NCT001996804	NCT00199680_4_T0	GENE	15	15	MRI
NCT001996804	NCT00199680_4_T1	PHENOTYPE	36	36	tumour
NCT001996804	NCT00199680_4_T2	TISSUE	24	25	lymph nodes
NCT001996804	NCT00199680_4_T3	PHENOTYPE	6	7	cervical cancer
NCT001996805	NCT00199680_5_T0	GENE	7	7	MRI
NCT001996805	NCT00199680_5_T1	PHENOTYPE	20	22	lymph node metastasis
NCT001996807	NCT00199680_7_T0	GENE	16	16	MRI
NCT001996807	NCT00199680_7_T1	PHENOTYPE	7	7	enables
NCT001996807	NCT00199680_7_T2	TISSUE	12	13	lymph nodes
NCT001996807	NCT00199680_7_T3	TISSUE	21	22	lymph nodes
NCT001996808	NCT00199680_8_T0	PHENOTYPE	10	10	estimation
NCT001996809	NCT00199680_9_T0	GENE	32	32	MRI
NCT001996809	NCT00199680_9_T1	PHENOTYPE	26	27	cervical cancer
NCT001996809	NCT00199680_9_T2	PHENOTYPE	20	22	lymph node metastasis
NCT0019968011	NCT00199680_11_T0	GENE	12	12	MRI
NCT0019968012	NCT00199680_12_T0	TISSUE	22	23	lymph node
NCT001997065	NCT00199706_5_T0	COMPOUND	11	11	mannitol
NCT001997065	NCT00199706_5_T1	PHENOTYPE	26	26	hyponatremia
NCT001997065	NCT00199706_5_T2	GENE	31	31	ICP
NCT001997065	NCT00199706_5_T3	PHENOTYPE	22	22	hypovolemia
NCT001997065	NCT00199706_5_T4	PHENOTYPE	18	19	adverse effects
NCT001997065	NCT00199706_5_T5	PHENOTYPE	23	25	acute renal failure
NCT001997066	NCT00199706_6_T0	GENE	9	9	ICP
NCT001997190	NCT00199719_0_T0	PHENOTYPE	10	12	Chronic Hepatitis C
NCT001997193	NCT00199719_3_T0	COMPOUND	3	3	amantadine
NCT001997193	NCT00199719_3_T1	PHENOTYPE	15	15	SVR
NCT001997195	NCT00199719_5_T0	GENE	12	12	BW
NCT001997195	NCT00199719_5_T1	COMPOUND	7	7	HCV
NCT001997195	NCT00199719_5_T2	PHENOTYPE	5	5	SVR
NCT001997196	NCT00199719_6_T0	COMPOUND	10	10	ribavirin
NCT001997197	NCT00199719_7_T0	PHENOTYPE	9	9	concentrations
NCT001997197	NCT00199719_7_T1	GENE	2	2	has
NCT001997198	NCT00199719_8_T0	COMPOUND	10	10	ribavirin
NCT001997198	NCT00199719_8_T1	COMPOUND	18	18	ribavirin
NCT001997198	NCT00199719_8_T2	GENE	14	14	BW
NCT001997198	NCT00199719_8_T3	COMPOUND	4	4	HCV
NCT001997198	NCT00199719_8_T4	ORGAN	21	21	serum
NCT0019971910	NCT00199719_10_T0	ORGAN	0	0	Plasma
NCT0019971910	NCT00199719_10_T1	COMPOUND	4	4	ribavirin
NCT0019971911	NCT00199719_11_T0	GENE	12	12	1.5
NCT0019971912	NCT00199719_12_T0	COMPOUND	10	10	ribavirin
NCT0019971912	NCT00199719_12_T1	PHENOTYPE	1	1	concentrations
NCT0019971912	NCT00199719_12_T2	PHENOTYPE	20	20	concentrations
NCT0019971912	NCT00199719_12_T3	ORGAN	19	19	plasma
NCT0019971913	NCT00199719_13_T0	GENE	5	5	W2
NCT001997321	NCT00199732_1_T0	ORGAN	9	9	liver
NCT001997321	NCT00199732_1_T1	PHENOTYPE	4	4	reflects
NCT001997321	NCT00199732_1_T2	PHENOTYPE	5	5	HBV
NCT001997322	NCT00199732_2_T0	PHENOTYPE	9	9	HBV
NCT001997322	NCT00199732_2_T1	CELL	1	1	lymphocyte
NCT001997582	NCT00199758_2_T0	PHENOTYPE	45	45	diseases
NCT001997713	NCT00199771_3_T0	GENE	18	18	CPB
NCT001997713	NCT00199771_3_T1	GENE	31	31	IL-6
NCT001997713	NCT00199771_3_T2	COMPOUND	10	10	NaCl
NCT001997713	NCT00199771_3_T3	COMPOUND	13	13	dextran
NCT001997713	NCT00199771_3_T4	GENE	32	32	IL-8
NCT001997714	NCT00199771_4_T0	GENE	16	16	CPB
NCT001997842	NCT00199784_2_T0	PHENOTYPE	8	8	anesthesia
NCT001997971	NCT00199797_1_T0	CELL	16	16	cells
NCT001997971	NCT00199797_1_T1	PHENOTYPE	14	15	colon cancer
NCT001997972	NCT00199797_2_T0	PHENOTYPE	14	15	colorectal cancers
NCT001997972	NCT00199797_2_T1	GENE	8	9	A33 antigen
NCT001997974	NCT00199797_4_T0	PHENOTYPE	13	15	metastatic colorectal cancer
NCT001997976	NCT00199797_6_T0	GENE	13	13	IV
NCT001997976	NCT00199797_6_T1	PHENOTYPE	4	5	colorectal cancer
NCT001997977	NCT00199797_7_T0	COMPOUND	5	5	3
NCT001997977	NCT00199797_7_T1	COMPOUND	11	11	oxaliplatin
NCT001997977	NCT00199797_7_T2	COMPOUND	7	7	leucovorin
NCT001997977	NCT00199797_7_T3	COMPOUND	8	9	folinic acid
NCT001997978	NCT00199797_8_T0	PHENOTYPE	6	6	toxicity
NCT001997979	NCT00199797_9_T0	ORGAN	10	10	serum
NCT0019979710	NCT00199797_10_T0	PHENOTYPE	5	5	tumors
NCT0019979710	NCT00199797_10_T1	PHENOTYPE	3	4	measurable disease
NCT0019979712	NCT00199797_12_T0	PHENOTYPE	1	1	secondary
NCT0019979712	NCT00199797_12_T1	PHENOTYPE	23	23	tumor
NCT0019979712	NCT00199797_12_T2	COMPOUND	19	19	oxaliplatin
NCT0019979712	NCT00199797_12_T3	COMPOUND	17	17	leucovorin
NCT0019979720	NCT00199797_20_T0	PHENOTYPE	13	15	metastatic colorectal cancer
NCT0019979732	NCT00199797_32_T0	ORGAN	16	17	immune system
NCT0019979733	NCT00199797_33_T0	GENE	10	10	ml
NCT0019979735	NCT00199797_35_T0	PHENOTYPE	12	13	tumor progression
NCT0019979737	NCT00199797_37_T0	PHENOTYPE	0	2	Metastatic colorectal cancer
NCT0019979738	NCT00199797_38_T0	PHENOTYPE	4	5	colorectal cancer
NCT0019979742	NCT00199797_42_T0	GENE	3	3	0.2
NCT0019979747	NCT00199797_47_T0	GENE	18	18	MRI
NCT0019979747	NCT00199797_47_T1	PHENOTYPE	2	3	metastatic disease
NCT0019979747	NCT00199797_47_T2	ORGAN	6	8	central nervous system
NCT0019979749	NCT00199797_49_T0	PHENOTYPE	4	5	brain metastases
NCT0019979753	NCT00199797_53_T0	GENE	3	3	eg
NCT0019979753	NCT00199797_53_T1	PHENOTYPE	2	2	illnesses
NCT0019979753	NCT00199797_53_T2	PHENOTYPE	5	5	infections
NCT0019979753	NCT00199797_53_T3	PHENOTYPE	8	9	bleeding disorders
NCT0019979759	NCT00199797_59_T0	GENE	8	8	fragment
NCT0019979764	NCT00199797_64_T0	PHENOTYPE	1	1	HIV
NCT0019979764	NCT00199797_64_T1	PHENOTYPE	2	3	Hepatitis B
NCT0019979765	NCT00199797_65_T0	PHENOTYPE	0	1	Mental impairment
NCT001998100	NCT00199810_0_T0	PHENOTYPE	6	6	Preeclampsia
NCT001998231	NCT00199823_1_T0	PHENOTYPE	29	29	AMI
NCT001998231	NCT00199823_1_T1	CELL	16	18	bone marrow cells
NCT001998231	NCT00199823_1_T2	PHENOTYPE	22	24	ventricular ejection fraction
NCT001998233	NCT00199823_3_T0	PHENOTYPE	4	4	acute
NCT001998233	NCT00199823_3_T1	PHENOTYPE	13	13	acute
NCT001998233	NCT00199823_3_T2	GENE	19	19	1.1
NCT001998233	NCT00199823_3_T3	GENE	14	14	PCI
NCT001998233	NCT00199823_3_T4	GENE	31	31	PCI
NCT001998233	NCT00199823_3_T5	PHENOTYPE	10	10	STEMI
NCT001998233	NCT00199823_3_T6	PHENOTYPE	8	9	myocardial infarction
NCT001998234	NCT00199823_4_T0	PHENOTYPE	13	13	complications
NCT001998234	NCT00199823_4_T1	GENE	1	1	ventricular
NCT001998234	NCT00199823_4_T2	PHENOTYPE	9	11	quality of life
NCT001998360	NCT00199836_0_T0	PHENOTYPE	15	15	Cancer
NCT001998361	NCT00199836_1_T0	PHENOTYPE	1	1	Cancer
NCT001998365	NCT00199836_5_T0	CELL	10	10	cells
NCT001998369	NCT00199836_9_T0	PHENOTYPE	4	4	toxicity
NCT001998369	NCT00199836_9_T1	PHENOTYPE	6	7	progressive disease
NCT0019983611	NCT00199836_11_T0	PHENOTYPE	1	1	secondary
NCT0019983611	NCT00199836_11_T1	PHENOTYPE	6	6	tumor
NCT0019983611	NCT00199836_11_T2	PHENOTYPE	13	14	measurable disease
NCT001998492	NCT00199849_2_T0	GENE	16	16	psi
NCT001998492	NCT00199849_2_T1	GENE	0	0	NY-ESO-1
NCT001998493	NCT00199849_3_T0	GENE	5	5	NY-ESO-1
NCT001998497	NCT00199849_7_T0	PHENOTYPE	5	5	toxicity
NCT001998499	NCT00199849_9_T0	GENE	2	2	LAGE-1
NCT001998499	NCT00199849_9_T1	GENE	0	0	NY-ESO-1
NCT001998499	NCT00199849_9_T2	GENE	15	15	NY-ESO-1
NCT0019984910	NCT00199849_10_T0	GENE	2	2	CD4
NCT0019984910	NCT00199849_10_T1	GENE	4	4	CD8
NCT0019984910	NCT00199849_10_T2	GENE	0	0	NY-ESO-1
NCT0019984910	NCT00199849_10_T3	CELL	5	6	T cells
NCT0019984911	NCT00199849_11_T0	PHENOTYPE	17	18	measurable disease
NCT0019984921	NCT00199849_21_T0	GENE	3	3	60
NCT0019984923	NCT00199849_23_T0	ORGAN	3	3	kidney
NCT0019984923	NCT00199849_23_T1	ORGAN	4	4	liver
NCT0019984923	NCT00199849_23_T2	ORGAN	1	2	bone marrow
NCT0019984925	NCT00199849_25_T0	GENE	6	6	III
NCT0019984925	NCT00199849_25_T1	GENE	8	8	IV
NCT0019984925	NCT00199849_25_T2	PHENOTYPE	2	3	heart disease
NCT0019984927	NCT00199849_27_T0	PHENOTYPE	2	2	illnesses
NCT0019984927	NCT00199849_27_T1	ORGAN	13	13	liver
NCT0019984927	NCT00199849_27_T2	PHENOTYPE	5	5	infections
NCT0019984927	NCT00199849_27_T3	PHENOTYPE	9	10	bleeding disorders
NCT0019984927	NCT00199849_27_T4	PHENOTYPE	15	16	renal insufficiency
NCT0019984931	NCT00199849_31_T0	PHENOTYPE	1	1	HIV
NCT0019984931	NCT00199849_31_T1	PHENOTYPE	5	6	Hepatitis C
NCT0019984931	NCT00199849_31_T2	PHENOTYPE	2	3	Hepatitis B
NCT0019984937	NCT00199849_37_T0	GENE	1	1	COX-2
NCT0019984938	NCT00199849_38_T0	COMPOUND	2	2	aspirin
NCT0019984943	NCT00199849_43_T0	PHENOTYPE	0	0	Allergy
NCT0019984948	NCT00199849_48_T0	PHENOTYPE	0	1	Mental impairment
NCT001998627	NCT00199862_7_T0	GENE	7	7	IV
NCT001998627	NCT00199862_7_T1	GENE	20	20	IV
NCT0019986210	NCT00199862_10_T0	ORGAN	11	11	abdomen
NCT0019986210	NCT00199862_10_T1	GENE	14	14	1/6
NCT0019986210	NCT00199862_10_T2	ORGAN	13	13	pelvis
NCT0019986212	NCT00199862_12_T0	PHENOTYPE	4	4	tumor
NCT0019986212	NCT00199862_12_T1	PHENOTYPE	5	5	tumor
NCT0019986212	NCT00199862_12_T2	GENE	9	9	portal
NCT0019986214	NCT00199862_14_T0	PHENOTYPE	14	14	tumor
NCT0019986216	NCT00199862_16_T0	PHENOTYPE	0	0	Toxicity
NCT001998751	NCT00199875_1_T0	COMPOUND	13	13	indium_111
NCT001998759	NCT00199875_9_T0	PHENOTYPE	13	13	toxicity
NCT001998759	NCT00199875_9_T1	PHENOTYPE	31	31	decisions
NCT0019987510	NCT00199875_10_T0	PHENOTYPE	27	27	toxicity
NCT0019987520	NCT00199875_20_T0	GENE	3	3	had
NCT0019987520	NCT00199875_20_T1	PHENOTYPE	5	6	measurable disease
NCT0019987523	NCT00199875_23_T0	PHENOTYPE	10	12	negative pregnancy test
NCT0019987532	NCT00199875_32_T0	ORGAN	6	6	Heart
NCT0019987532	NCT00199875_32_T1	PHENOTYPE	2	3	cardiac disease
NCT0019987544	NCT00199875_44_T0	PHENOTYPE	0	1	Mental impairment
NCT001998885	NCT00199888_5_T0	GENE	12	12	tag
NCT0019988810	NCT00199888_10_T0	PHENOTYPE	3	4	antibody response
NCT0019988816	NCT00199888_16_T0	CELL	14	14	cells
NCT0019988816	NCT00199888_16_T1	ORGAN	6	7	immune system
NCT0019988819	NCT00199888_19_T0	CELL	14	14	cells
NCT0019988821	NCT00199888_21_T0	GENE	10	10	has
NCT0019988823	NCT00199888_23_T0	GENE	2	2	NOT
NCT0019988823	NCT00199888_23_T1	PHENOTYPE	6	7	renal cancer
NCT0019988824	NCT00199888_24_T0	PHENOTYPE	7	7	tumor
NCT0019988824	NCT00199888_24_T1	PHENOTYPE	22	22	tumor
NCT0019988824	NCT00199888_24_T2	GENE	18	18	has
NCT0019988836	NCT00199888_36_T0	PHENOTYPE	2	2	toxicity
NCT0019988841	NCT00199888_41_T0	ORGAN	2	2	Heart
NCT0019988841	NCT00199888_41_T1	PHENOTYPE	6	7	cardiac disease
NCT0019988842	NCT00199888_42_T0	PHENOTYPE	2	3	autoimmune hepatitis
NCT0019988845	NCT00199888_45_T0	PHENOTYPE	0	1	Mental impairment
NCT001999012	NCT00199901_2_T0	GENE	9	9	NY-ESO-1
NCT0019990110	NCT00199901_10_T0	PHENOTYPE	4	4	recurrence
NCT0019990110	NCT00199901_10_T1	PHENOTYPE	6	6	melanoma
NCT0019990111	NCT00199901_11_T0	PHENOTYPE	10	10	recurrence
NCT0019990111	NCT00199901_11_T1	PHENOTYPE	9	9	melanoma
NCT001999142	NCT00199914_2_T0	PHENOTYPE	1	1	affects
NCT001999146	NCT00199914_6_T0	PHENOTYPE	6	6	symptoms
NCT001999148	NCT00199914_8_T0	PHENOTYPE	13	13	symptoms
NCT001999148	NCT00199914_8_T1	COMPOUND	6	7	deep heat
NCT0019991410	NCT00199914_10_T0	GENE	9	9	null
NCT0019991412	NCT00199914_12_T0	GENE	1	1	Peri
NCT0019991413	NCT00199914_13_T0	PHENOTYPE	13	13	Osteoarthritis
NCT001999271	NCT00199927_1_T0	PHENOTYPE	2	2	ESRD
NCT001999271	NCT00199927_1_T1	PHENOTYPE	15	16	cardiovascular disease
NCT001999272	NCT00199927_2_T0	PHENOTYPE	8	8	nephropathies
NCT001999272	NCT00199927_2_T1	PHENOTYPE	16	16	ESRD
NCT001999272	NCT00199927_2_T2	PHENOTYPE	5	5	progression
NCT001999272	NCT00199927_2_T3	PHENOTYPE	7	7	chronic
NCT001999277	NCT00199927_7_T0	PHENOTYPE	11	12	Rare Disease
NCT0019992711	NCT00199927_11_T0	PHENOTYPE	13	13	ESRD
NCT0019992711	NCT00199927_11_T1	PHENOTYPE	5	5	proteinuria
NCT0019992711	NCT00199927_11_T2	PHENOTYPE	11	11	progression
NCT0019992711	NCT00199927_11_T3	PHENOTYPE	20	21	cardiovascular morbidity
NCT0019992716	NCT00199927_16_T0	COMPOUND	23	23	fluvastatin
NCT0019992717	NCT00199927_17_T0	COMPOUND	33	33	sodium
NCT001999405	NCT00199940_5_T0	PHENOTYPE	7	8	psychotic disorder
NCT0019994010	NCT00199940_10_T0	PHENOTYPE	7	7	secondary
NCT0019994011	NCT00199940_11_T0	PHENOTYPE	26	26	symptoms
NCT0019994011	NCT00199940_11_T1	PHENOTYPE	28	28	psychosis
NCT001999533	NCT00199953_3_T0	ORGAN	9	11	upper esophageal sphincter
NCT001999535	NCT00199953_5_T0	PHENOTYPE	7	7	disorders
NCT001999535	NCT00199953_5_T1	PHENOTYPE	20	20	inflammation
NCT001999535	NCT00199953_5_T2	GENE	3	3	has
NCT001999535	NCT00199953_5_T3	PHENOTYPE	18	18	chronic
NCT001999535	NCT00199953_5_T4	ORGAN	14	15	respiratory tract
NCT001999536	NCT00199953_6_T0	PHENOTYPE	8	8	symptoms
NCT001999536	NCT00199953_6_T1	PHENOTYPE	10	10	GERD
NCT001999536	NCT00199953_6_T2	PHENOTYPE	13	13	heartburn
NCT001999537	NCT00199953_7_T0	PHENOTYPE	4	4	symptoms
NCT001999537	NCT00199953_7_T1	ORGAN	7	7	larynx
NCT001999537	NCT00199953_7_T2	ORGAN	9	9	pharynx
NCT001999537	NCT00199953_7_T3	PHENOTYPE	12	13	globus pharyngeus
NCT001999538	NCT00199953_8_T0	PHENOTYPE	1	1	symptoms
NCT001999538	NCT00199953_8_T1	TISSUE	11	12	nasal epithelium
NCT001999538	NCT00199953_8_T2	ORGAN	24	26	autonomic nervous system
NCT001999663	NCT00199966_3_T0	PHENOTYPE	0	0	Secondary
NCT001999663	NCT00199966_3_T1	ORGAN	5	5	serum
NCT001999663	NCT00199966_3_T2	ORGAN	30	30	serum
NCT001999663	NCT00199966_3_T3	GENE	16	16	ER
NCT001999664	NCT00199966_4_T0	GENE	12	12	II
NCT001999664	NCT00199966_4_T1	PHENOTYPE	28	28	Mania
NCT001999665	NCT00199966_5_T0	COMPOUND	29	29	sodium
NCT001999665	NCT00199966_5_T1	COMPOUND	33	33	sodium
NCT001999665	NCT00199966_5_T2	GENE	37	37	ER
NCT001999665	NCT00199966_5_T3	GENE	34	34	extended
NCT001999666	NCT00199966_6_T0	PHENOTYPE	32	32	symptoms
NCT001999666	NCT00199966_6_T1	PHENOTYPE	34	34	mania
NCT001999920	NCT00199992_0_T0	PHENOTYPE	2	2	Acute
NCT001999920	NCT00199992_0_T1	PHENOTYPE	3	3	Wounds
NCT001999920	NCT00199992_0_T2	CELL	0	0	Platelets
NCT001999923	NCT00199992_3_T0	BIOLOGICAL_PROCESS	0	1	Wound healing
NCT002000570	NCT00200057_0_T0	PHENOTYPE	8	8	Chronic
NCT002000570	NCT00200057_0_T1	PHENOTYPE	9	10	Fecal Incontinence
NCT002000574	NCT00200057_4_T0	GENE	9	9	FI
NCT002000574	NCT00200057_4_T1	PHENOTYPE	4	4	suffering
NCT002000574	NCT00200057_4_T2	PHENOTYPE	6	6	symptoms
NCT002000574	NCT00200057_4_T3	PHENOTYPE	8	8	chronic
NCT002000574	NCT00200057_4_T4	PHENOTYPE	46	46	chronic
NCT002000574	NCT00200057_4_T5	PHENOTYPE	47	48	fecal incontinence
NCT002000576	NCT00200057_6_T0	PHENOTYPE	5	5	centers
NCT002000701	NCT00200070_1_T0	ORGAN	9	10	spinal cord
NCT002000833	NCT00200083_3_T0	PHENOTYPE	17	17	IGS
NCT002000961	NCT00200096_1_T0	PHENOTYPE	14	14	fatigue
NCT002000962	NCT00200096_2_T0	PHENOTYPE	5	5	fatigue
NCT002000962	NCT00200096_2_T1	PHENOTYPE	6	8	quality of life
NCT002000968	NCT00200096_8_T0	GENE	12	12	35
NCT002000968	NCT00200096_8_T1	GENE	21	21	hemoglobin
NCT002000968	NCT00200096_8_T2	PHENOTYPE	22	23	thyroid function
NCT0020009612	NCT00200096_12_T0	PHENOTYPE	9	9	fatigue
NCT0020009613	NCT00200096_13_T0	PHENOTYPE	12	12	symptoms
NCT0020009613	NCT00200096_13_T1	GENE	13	13	hemoglobin
NCT0020009614	NCT00200096_14_T0	PHENOTYPE	12	14	quality of life
NCT0020009616	NCT00200096_16_T0	PHENOTYPE	6	6	fatigue
NCT0020009617	NCT00200096_17_T0	PHENOTYPE	14	14	fatigue
NCT0020009619	NCT00200096_19_T0	PHENOTYPE	3	3	fatigue
NCT0020009619	NCT00200096_19_T1	PHENOTYPE	0	0	Acute
NCT0020009621	NCT00200096_21_T0	PHENOTYPE	15	15	symptoms
NCT0020009623	NCT00200096_23_T0	GENE	9	9	has
NCT002001090	NCT00200109_0_T0	PHENOTYPE	11	11	Headache
NCT002001090	NCT00200109_0_T1	PHENOTYPE	7	9	Chronic Migraine Headache
NCT002001092	NCT00200109_2_T0	GENE	23	23	CM
NCT002001093	NCT00200109_3_T0	GENE	14	14	AS
NCT002001482	NCT00200148_2_T0	PHENOTYPE	25	25	bleeding
NCT002001482	NCT00200148_2_T1	ORGAN	13	13	liver
NCT002001482	NCT00200148_2_T2	ORGAN	15	15	pancreas
NCT002001483	NCT00200148_3_T0	ORGAN	2	2	liver
NCT002001483	NCT00200148_3_T1	ORGAN	4	4	pancreas
NCT002001484	NCT00200148_4_T0	PHENOTYPE	11	11	acute
NCT002001485	NCT00200148_5_T0	ORGAN	18	18	liver
NCT002001485	NCT00200148_5_T1	ORGAN	20	20	pancreas
NCT002001485	NCT00200148_5_T2	GENE	9	9	has
NCT002001489	NCT00200148_9_T0	ORGAN	22	22	liver
NCT002001489	NCT00200148_9_T1	ORGAN	24	24	pancreas
NCT0020014810	NCT00200148_10_T0	PHENOTYPE	28	28	complication
NCT0020014811	NCT00200148_11_T0	PHENOTYPE	14	14	anesthesia
NCT0020014814	NCT00200148_14_T0	PHENOTYPE	12	12	peripheral
NCT0020014814	NCT00200148_14_T1	GENE	14	14	lines
NCT0020014816	NCT00200148_16_T0	PHENOTYPE	18	18	complications
NCT0020014817	NCT00200148_17_T0	PHENOTYPE	29	30	blood loss
NCT0020014820	NCT00200148_20_T0	PHENOTYPE	27	28	no storage
NCT0020014822	NCT00200148_22_T0	PHENOTYPE	23	23	centers
NCT002001612	NCT00200161_2_T0	COMPOUND	16	16	temozolomide
NCT002001612	NCT00200161_2_T1	COMPOUND	24	24	temozolomide
NCT002001612	NCT00200161_2_T2	PHENOTYPE	9	9	glioblastoma
NCT002001613	NCT00200161_3_T0	COMPOUND	6	6	temozolomide
NCT002001614	NCT00200161_4_T0	COMPOUND	11	11	temozolomide
NCT002001614	NCT00200161_4_T1	COMPOUND	16	16	temozolomide
NCT002001617	NCT00200161_7_T0	COMPOUND	12	12	temozolomide
NCT002001617	NCT00200161_7_T1	PHENOTYPE	25	25	tumor
NCT002001617	NCT00200161_7_T2	GENE	18	18	had
NCT002001617	NCT00200161_7_T3	PHENOTYPE	34	35	tumor progression
NCT002001619	NCT00200161_9_T0	COMPOUND	29	29	temozolomide
NCT002001619	NCT00200161_9_T1	GENE	19	19	III
NCT002001619	NCT00200161_9_T2	GENE	35	35	al
NCT002001619	NCT00200161_9_T3	GENE	34	34	et
NCT0020016110	NCT00200161_10_T0	PHENOTYPE	0	0	Secondary
NCT0020016110	NCT00200161_10_T1	GENE	13	13	MGMT
NCT0020016110	NCT00200161_10_T2	PHENOTYPE	28	29	malignant glioma
NCT0020016113	NCT00200161_13_T0	PHENOTYPE	14	15	brain tumor
NCT002001741	NCT00200174_1_T0	COMPOUND	8	8	exemestane
NCT002001741	NCT00200174_1_T1	COMPOUND	6	6	raloxifene
NCT002001742	NCT00200174_2_T0	COMPOUND	8	8	estrogen
NCT002001743	NCT00200174_3_T0	COMPOUND	8	8	estrogen
NCT002001743	NCT00200174_3_T1	ORGAN	2	2	liver
NCT002001745	NCT00200174_5_T0	GENE	1	1	has
NCT002001745	NCT00200174_5_T1	PHENOTYPE	12	12	osteoporosis
NCT002001746	NCT00200174_6_T0	PHENOTYPE	16	17	bone fractures
NCT002001748	NCT00200174_8_T0	PHENOTYPE	12	13	breast cancer
NCT002001749	NCT00200174_9_T0	PHENOTYPE	14	15	breast cancer
NCT0020017410	NCT00200174_10_T0	COMPOUND	7	7	exemestane
NCT0020017411	NCT00200174_11_T0	COMPOUND	10	10	estrogen
NCT0020017412	NCT00200174_12_T0	PHENOTYPE	12	13	breast cancer
NCT0020017417	NCT00200174_17_T0	GENE	16	16	II
NCT0020017417	NCT00200174_17_T1	GENE	18	18	III
NCT0020017417	NCT00200174_17_T2	PHENOTYPE	19	20	breast cancer
NCT0020017418	NCT00200174_18_T0	COMPOUND	12	12	estrogen
NCT0020017419	NCT00200174_19_T0	COMPOUND	20	20	estrogen
NCT0020017419	NCT00200174_19_T1	GENE	6	6	ER
NCT0020017419	NCT00200174_19_T2	PHENOTYPE	9	10	breast cancer
NCT0020017420	NCT00200174_20_T0	COMPOUND	15	15	estrogen
NCT0020017420	NCT00200174_20_T1	COMPOUND	37	37	estrogen
NCT0020017420	NCT00200174_20_T2	GENE	1	1	has
NCT0020017420	NCT00200174_20_T3	PHENOTYPE	19	20	primary tumor
NCT0020017420	NCT00200174_20_T4	PHENOTYPE	9	11	contralateral breast cancer
NCT0020017422	NCT00200174_22_T0	COMPOUND	9	9	exemestane
NCT0020017422	NCT00200174_22_T1	COMPOUND	26	26	estrogen
NCT0020017422	NCT00200174_22_T2	COMPOUND	7	7	raloxifene
NCT0020017423	NCT00200174_23_T0	COMPOUND	13	13	exemestane
NCT0020017423	NCT00200174_23_T1	GENE	33	33	lipoprotein
NCT0020017423	NCT00200174_23_T2	PHENOTYPE	48	48	pharmacodynamics
NCT0020017423	NCT00200174_23_T3	COMPOUND	11	11	raloxifene
NCT0020017423	NCT00200174_23_T4	PHENOTYPE	41	41	symptoms
NCT0020017423	NCT00200174_23_T5	COMPOUND	21	21	1
NCT0020017423	NCT00200174_23_T6	COMPOUND	30	30	2
NCT0020017423	NCT00200174_23_T7	COMPOUND	35	35	3
NCT0020017423	NCT00200174_23_T8	PHENOTYPE	46	46	pharmacokinetics
NCT0020017423	NCT00200174_23_T9	ORGAN	32	32	serum
NCT0020017423	NCT00200174_23_T10	PHENOTYPE	43	44	estrogen deficiency
NCT0020017423	NCT00200174_23_T11	PHENOTYPE	36	38	quality of life
NCT0020017424	NCT00200174_24_T0	GENE	11	11	MRI
NCT0020017426	NCT00200174_26_T0	COMPOUND	28	28	estrogen
NCT0020017426	NCT00200174_26_T1	MOLECULAR_FUNCTION	23	24	aromatase activity
NCT0020017428	NCT00200174_28_T0	COMPOUND	5	5	estrogen
NCT002001871	NCT00200187_1_T0	PHENOTYPE	16	16	anesthesia
NCT002001871	NCT00200187_1_T1	PHENOTYPE	8	9	blood loss
NCT002001872	NCT00200187_2_T0	PHENOTYPE	4	4	anesthesia
NCT002001874	NCT00200187_4_T0	PHENOTYPE	10	10	bleeding
NCT002001874	NCT00200187_4_T1	PHENOTYPE	4	6	blood pressure low
NCT002001875	NCT00200187_5_T0	PHENOTYPE	6	6	anesthesia
NCT002001876	NCT00200187_6_T0	ORGAN	10	11	spinal canal
NCT002001877	NCT00200187_7_T0	PHENOTYPE	0	0	Anesthesia
NCT002001877	NCT00200187_7_T1	GENE	8	8	numb
NCT0020018712	NCT00200187_12_T0	PHENOTYPE	5	5	anesthesia
NCT0020018716	NCT00200187_16_T0	GENE	11	11	RRP
NCT0020018718	NCT00200187_18_T0	GENE	17	17	CSE
NCT0020018720	NCT00200187_20_T0	PHENOTYPE	7	7	estimation
NCT0020018720	NCT00200187_20_T1	PHENOTYPE	22	22	anesthesia
NCT0020018720	NCT00200187_20_T2	PHENOTYPE	9	10	blood loss
NCT0020018722	NCT00200187_22_T0	GENE	13	13	8.0
NCT0020018722	NCT00200187_22_T1	GENE	10	10	hemoglobin
NCT0020018728	NCT00200187_28_T0	PHENOTYPE	2	2	Secondary
NCT0020018728	NCT00200187_28_T1	GENE	4	4	SSE
NCT0020018729	NCT00200187_29_T0	PHENOTYPE	9	9	severity
NCT0020018729	NCT00200187_29_T1	PHENOTYPE	12	12	complication
NCT0020018729	NCT00200187_29_T2	GENE	0	0	SSE
NCT0020018730	NCT00200187_30_T0	PHENOTYPE	0	1	Grade 1
NCT0020018731	NCT00200187_31_T0	GENE	6	6	TPN
NCT002002137	NCT00200213_7_T0	PHENOTYPE	10	11	food allergies
NCT002002261	NCT00200226_1_T0	ORGAN	11	11	cervix
NCT002002261	NCT00200226_1_T1	PHENOTYPE	4	4	discomfort
NCT002002262	NCT00200226_2_T0	ORGAN	13	13	cervix
NCT002002262	NCT00200226_2_T1	COMPOUND	9	9	misoprostol
NCT002002262	NCT00200226_2_T2	GENE	2	2	has
NCT002002263	NCT00200226_3_T0	ORGAN	10	10	cervix
NCT002002263	NCT00200226_3_T1	GENE	16	16	lessen
NCT002002263	NCT00200226_3_T2	PHENOTYPE	18	18	discomfort
NCT002002263	NCT00200226_3_T3	COMPOUND	5	5	misoprostol
NCT002002390	NCT00200239_0_T0	PHENOTYPE	6	7	Weight Loss
NCT002002392	NCT00200239_2_T0	GENE	6	6	has
NCT002002392	NCT00200239_2_T1	PHENOTYPE	24	25	weight loss
NCT002002393	NCT00200239_3_T0	PHENOTYPE	18	19	weight loss
NCT002002394	NCT00200239_4_T0	PHENOTYPE	7	7	obesity
NCT002002394	NCT00200239_4_T1	PHENOTYPE	14	15	weight loss
NCT002002395	NCT00200239_5_T0	PHENOTYPE	27	28	weight loss
NCT002002396	NCT00200239_6_T0	PHENOTYPE	11	11	obesity
NCT0020023910	NCT00200239_10_T0	PHENOTYPE	22	23	weight loss
NCT0020023915	NCT00200239_15_T0	COMPOUND	3	3	BMI
NCT0020023921	NCT00200239_21_T0	PHENOTYPE	1	1	allergies
NCT0020023921	NCT00200239_21_T1	COMPOUND	19	19	lactose
NCT0020023921	NCT00200239_21_T2	PHENOTYPE	13	14	lactose intolerance
NCT0020023926	NCT00200239_26_T0	PHENOTYPE	3	3	diseases
NCT0020023926	NCT00200239_26_T1	PHENOTYPE	5	7	organic brain syndromes
NCT002002522	NCT00200252_2_T0	GENE	17	17	oxytocin
NCT002002522	NCT00200252_2_T1	PHENOTYPE	22	23	blood loss
NCT002002650	NCT00200265_0_T0	BIOLOGICAL_PROCESS	1	1	Eating
NCT002002653	NCT00200265_3_T0	GENE	5	5	has
NCT002002654	NCT00200265_4_T0	PHENOTYPE	11	12	childhood obesity
NCT002002655	NCT00200265_5_T0	BIOLOGICAL_PROCESS	29	29	eating
NCT002002658	NCT00200265_8_T0	PHENOTYPE	30	31	weight loss
NCT0020026511	NCT00200265_11_T0	PHENOTYPE	32	32	reinforcement
NCT0020026511	NCT00200265_11_T1	BIOLOGICAL_PROCESS	14	14	eating
NCT0020026518	NCT00200265_18_T0	PHENOTYPE	5	5	maturation
NCT0020026518	NCT00200265_18_T1	PHENOTYPE	1	2	stage 1
NCT0020026532	NCT00200265_32_T0	PHENOTYPE	7	8	weight loss
NCT0020026536	NCT00200265_36_T0	GENE	12	12	has
NCT002002785	NCT00200278_5_T0	GENE	0	0	And
NCT002002787	NCT00200278_7_T0	PHENOTYPE	3	4	cardiovascular disease
NCT002002787	NCT00200278_7_T1	PHENOTYPE	27	29	elevated serum cholesterol
NCT0020027818	NCT00200278_18_T0	GENE	0	0	And
NCT0020027823	NCT00200278_23_T0	PHENOTYPE	50	50	asthma
NCT0020027823	NCT00200278_23_T1	GENE	21	21	had
NCT0020027823	NCT00200278_23_T2	PHENOTYPE	51	51	emphysema
NCT0020027823	NCT00200278_23_T3	PHENOTYPE	22	22	hypertension
NCT0020027823	NCT00200278_23_T4	PHENOTYPE	33	33	chronic
NCT0020027823	NCT00200278_23_T5	COMPOUND	13	13	BMI
NCT0020027823	NCT00200278_23_T6	PHENOTYPE	30	31	abnormal electrocardiogram
NCT0020027823	NCT00200278_23_T7	PHENOTYPE	34	35	infectious disease
NCT0020027823	NCT00200278_23_T8	PHENOTYPE	23	24	heart disease
NCT0020027823	NCT00200278_23_T9	PHENOTYPE	52	53	chronic bronchitis
NCT002002913	NCT00200291_3_T0	BIOLOGICAL_PROCESS	20	20	eating
NCT002002913	NCT00200291_3_T1	BIOLOGICAL_PROCESS	45	45	eating
NCT002002913	NCT00200291_3_T2	PHENOTYPE	24	25	weight loss
NCT002002914	NCT00200291_4_T0	PHENOTYPE	9	9	reinforcement
NCT002002914	NCT00200291_4_T1	PHENOTYPE	18	18	reinforcement
NCT002002914	NCT00200291_4_T2	PHENOTYPE	23	24	weight loss
NCT002002916	NCT00200291_6_T0	PHENOTYPE	17	18	weight loss
NCT002002917	NCT00200291_7_T0	PHENOTYPE	3	3	reinforcement
NCT002003040	NCT00200304_0_T0	PHENOTYPE	6	7	Weight Loss
NCT002003043	NCT00200304_3_T0	PHENOTYPE	11	12	weight loss
NCT002003043	NCT00200304_3_T1	PHENOTYPE	40	41	weight loss
NCT002003046	NCT00200304_6_T0	PHENOTYPE	0	1	Weight losses
NCT002003047	NCT00200304_7_T0	PHENOTYPE	5	6	lose weight
NCT002003048	NCT00200304_8_T0	PHENOTYPE	4	5	weight loss
NCT002003049	NCT00200304_9_T0	PHENOTYPE	13	13	overweight
NCT002003049	NCT00200304_9_T1	PHENOTYPE	20	21	weight loss
NCT0020030411	NCT00200304_11_T0	PHENOTYPE	38	38	overweight
NCT0020030411	NCT00200304_11_T1	COMPOUND	47	47	BMI
NCT0020030411	NCT00200304_11_T2	PHENOTYPE	53	54	lose weight
NCT0020030411	NCT00200304_11_T3	PHENOTYPE	9	10	weight losses
NCT0020030412	NCT00200304_12_T0	PHENOTYPE	25	26	weight loss
NCT0020030416	NCT00200304_16_T0	GENE	0	1	Group 1
NCT0020030417	NCT00200304_17_T0	PHENOTYPE	13	14	weight loss
NCT0020030418	NCT00200304_18_T0	PHENOTYPE	21	22	weight loss
NCT0020030421	NCT00200304_21_T0	PHENOTYPE	0	0	Secondary
NCT0020030421	NCT00200304_21_T1	PHENOTYPE	7	8	weight loss
NCT002003172	NCT00200317_2_T0	PHENOTYPE	3	4	cardiovascular disease
NCT002003172	NCT00200317_2_T1	PHENOTYPE	27	29	elevated serum cholesterol
NCT002003177	NCT00200317_7_T0	GENE	25	25	has
NCT0020031712	NCT00200317_12_T0	GENE	0	0	And
NCT002003302	NCT00200330_2_T0	GENE	25	25	has
NCT002003302	NCT00200330_2_T1	PHENOTYPE	20	21	weight loss
NCT002003302	NCT00200330_2_T2	PHENOTYPE	12	13	weight losses
NCT002003304	NCT00200330_4_T0	BIOLOGICAL_PROCESS	12	12	eating
NCT002003305	NCT00200330_5_T0	BIOLOGICAL_PROCESS	21	21	eating
NCT002003306	NCT00200330_6_T0	BIOLOGICAL_PROCESS	5	5	eating
NCT002003307	NCT00200330_7_T0	PHENOTYPE	25	26	weight loss
NCT0020033011	NCT00200330_11_T0	PHENOTYPE	25	26	weight loss
NCT0020033011	NCT00200330_11_T1	PHENOTYPE	32	33	weight loss
NCT0020033012	NCT00200330_12_T0	GENE	6	6	has
NCT002003430	NCT00200343_0_T0	PHENOTYPE	9	11	Chronic Hepatitis C
NCT002003432	NCT00200343_2_T0	COMPOUND	14	14	UDCA
NCT002003432	NCT00200343_2_T1	COMPOUND	26	26	UDCA
NCT002003434	NCT00200343_4_T0	COMPOUND	14	14	UDCA
NCT002003434	NCT00200343_4_T1	COMPOUND	26	26	UDCA
NCT002003435	NCT00200343_5_T0	PHENOTYPE	20	20	secondary
NCT002003435	NCT00200343_5_T1	COMPOUND	8	8	alanine
NCT002003435	NCT00200343_5_T2	ORGAN	7	7	serum
NCT002003435	NCT00200343_5_T3	ORGAN	22	22	serum
NCT002003435	NCT00200343_5_T4	COMPOUND	23	23	aspartate
NCT002003436	NCT00200343_6_T0	GENE	3	4	bile acid
NCT002003438	NCT00200343_8_T0	PHENOTYPE	12	13	chronic hepatitis
NCT002003438	NCT00200343_8_T1	PHENOTYPE	13	14	hepatitis C
NCT0020034310	NCT00200343_10_T0	PHENOTYPE	9	9	initiation
NCT0020034310	NCT00200343_10_T1	ORGAN	0	0	Serum
NCT0020034310	NCT00200343_10_T2	GENE	1	2	alanine aminotransferase
NCT0020034314	NCT00200343_14_T0	GENE	8	8	interferon
NCT0020034314	NCT00200343_14_T1	GENE	18	19	period 2
NCT0020034315	NCT00200343_15_T0	COMPOUND	11	11	cholestyramine
NCT0020034317	NCT00200343_17_T0	PHENOTYPE	3	3	cirrhosis
NCT0020034319	NCT00200343_19_T0	PHENOTYPE	12	12	neoplasia
NCT0020034319	NCT00200343_19_T1	PHENOTYPE	15	16	fulminant hepatitis
NCT0020034319	NCT00200343_19_T2	PHENOTYPE	5	6	autoimmune disease
NCT0020034319	NCT00200343_19_T3	PHENOTYPE	10	11	hepatic disorder
NCT0020034319	NCT00200343_19_T4	PHENOTYPE	18	19	peptic ulcer
NCT0020034320	NCT00200343_20_T0	ORGAN	9	9	kidney
NCT0020034320	NCT00200343_20_T1	PHENOTYPE	5	5	complications
NCT0020034320	NCT00200343_20_T2	ORGAN	11	11	pancreas
NCT0020034320	NCT00200343_20_T3	ORGAN	8	8	heart
NCT002003565	NCT00200356_5_T0	PHENOTYPE	23	23	Coma
NCT002003566	NCT00200356_6_T0	PHENOTYPE	3	3	dysfunction
NCT002003566	NCT00200356_6_T1	ORGAN	7	8	lower extremities
NCT002003568	NCT00200356_8_T0	COMPOUND	1	1	creatinine
NCT002003568	NCT00200356_8_T1	GENE	3	3	1.5
NCT002003568	NCT00200356_8_T2	ORGAN	0	0	Serum
NCT002003569	NCT00200356_9_T0	PHENOTYPE	0	1	Embolic infarction
NCT0020035610	NCT00200356_10_T0	PHENOTYPE	0	1	Intracranial haemorrhage
NCT0020035611	NCT00200356_11_T0	PHENOTYPE	1	1	infarction
NCT0020035612	NCT00200356_12_T0	PHENOTYPE	3	3	TIA
NCT0020035612	NCT00200356_12_T1	PHENOTYPE	0	2	Transient ischemic attack
NCT0020035614	NCT00200356_14_T0	COMPOUND	5	5	argatroban
NCT0020035614	NCT00200356_14_T1	COMPOUND	17	17	edaravone
NCT0020035614	NCT00200356_14_T2	COMPOUND	11	11	warfarin
NCT0020035614	NCT00200356_14_T3	COMPOUND	10	10	heparin
NCT0020035614	NCT00200356_14_T4	COMPOUND	12	12	sodium
NCT0020035614	NCT00200356_14_T5	COMPOUND	19	19	sodium
NCT0020035614	NCT00200356_14_T6	COMPOUND	15	15	hydrochloride
NCT0020035614	NCT00200356_14_T7	COMPOUND	16	16	cilostazol
NCT0020035614	NCT00200356_14_T8	COMPOUND	13	13	aspirin
NCT0020035614	NCT00200356_14_T9	COMPOUND	14	14	ticlopidine
NCT0020035614	NCT00200356_14_T10	GENE	7	9	tissue plasminogen activator
NCT0020035616	NCT00200356_16_T0	PHENOTYPE	2	2	complications
NCT0020035616	NCT00200356_16_T1	PHENOTYPE	3	3	cirrhosis
NCT0020035616	NCT00200356_16_T2	PHENOTYPE	4	5	heart failure
NCT0020035619	NCT00200356_19_T0	COMPOUND	3	3	sodium
NCT0020035619	NCT00200356_19_T1	COMPOUND	7	7	hydrochloride
NCT0020035619	NCT00200356_19_T2	COMPOUND	2	2	edaravone
NCT002003692	NCT00200369_2_T0	GENE	16	16	Ann
NCT002003692	NCT00200369_2_T1	GENE	18	18	Med
NCT002003692	NCT00200369_2_T2	GENE	17	17	Int
NCT002003693	NCT00200369_3_T0	COMPOUND	15	15	nelfinavir
NCT002003693	NCT00200369_3_T1	COMPOUND	16	16	ritonavir
NCT002003693	NCT00200369_3_T2	COMPOUND	18	18	saquinavir
NCT002003693	NCT00200369_3_T3	COMPOUND	14	14	indinavir
NCT002003695	NCT00200369_5_T0	COMPOUND	5	5	Kaletra
NCT002003696	NCT00200369_6_T0	PHENOTYPE	5	5	pharmacokinetics
NCT002003698	NCT00200369_8_T0	COMPOUND	10	10	Kaletra
NCT0020036911	NCT00200369_11_T0	COMPOUND	13	13	Kaletra
NCT0020036911	NCT00200369_11_T1	PHENOTYPE	18	19	virologic failure
NCT002004082	NCT00200408_2_T0	PHENOTYPE	27	27	tumors
NCT002004082	NCT00200408_2_T1	CELL	16	16	cells
NCT002004082	NCT00200408_2_T2	CELL	24	24	cells
NCT002004082	NCT00200408_2_T3	TISSUE	37	37	tissues
NCT002004086	NCT00200408_6_T0	PHENOTYPE	24	24	tumors
NCT002004086	NCT00200408_6_T1	PHENOTYPE	20	23	head and neck cancer
NCT002004087	NCT00200408_7_T0	PHENOTYPE	16	16	carcinogenesis
NCT0020040810	NCT00200408_10_T0	PHENOTYPE	20	20	tumors
NCT0020040810	NCT00200408_10_T1	PHENOTYPE	11	12	transversion mutations
NCT0020040811	NCT00200408_11_T0	BIOLOGICAL_PROCESS	5	6	DNA methylation
NCT0020040814	NCT00200408_14_T0	BIOLOGICAL_PROCESS	13	14	DNA methylation
NCT0020040818	NCT00200408_18_T0	BIOLOGICAL_PROCESS	12	12	methylation
NCT0020040820	NCT00200408_20_T0	BIOLOGICAL_PROCESS	5	6	DNA methylation
NCT002004210	NCT00200421_0_T0	PHENOTYPE	15	15	Mild
NCT002004210	NCT00200421_0_T1	PHENOTYPE	18	18	Hypertension
NCT002004340	NCT00200434_0_T0	PHENOTYPE	17	17	Hypertension
NCT002004342	NCT00200434_2_T0	COMPOUND	7	7	nebivolol
NCT002004343	NCT00200434_3_T0	GENE	1	1	had
NCT002004472	NCT00200447_2_T0	COMPOUND	32	32	carbidopa_levodopa
NCT002004472	NCT00200447_2_T1	COMPOUND	17	17	dopamine
NCT002004474	NCT00200447_4_T0	BIOLOGICAL_PROCESS	31	33	response to L-dopa
NCT002004475	NCT00200447_5_T0	GENE	9	9	1.2
NCT002004475	NCT00200447_5_T1	GENE	7	7	separated
NCT002004478	NCT00200447_8_T0	PHENOTYPE	6	6	initiation
NCT002004478	NCT00200447_8_T1	COMPOUND	19	19	carbidopa_levodopa
NCT002004603	NCT00200460_3_T0	COMPOUND	6	6	nebivolol
NCT002004604	NCT00200460_4_T0	GENE	1	1	had
NCT002004733	NCT00200473_3_T0	GENE	1	1	had
NCT002004860	NCT00200486_0_T0	PHENOTYPE	7	8	Neck Tumors
NCT002004862	NCT00200486_2_T0	BIOLOGICAL_PROCESS	12	13	gene expression
NCT002004863	NCT00200486_3_T0	PHENOTYPE	12	12	HNSCC
NCT002004865	NCT00200486_5_T0	BIOLOGICAL_PROCESS	12	13	gene expression
NCT002004866	NCT00200486_6_T0	GENE	28	28	has
NCT002004866	NCT00200486_6_T1	TISSUE	16	17	surgical margins
NCT002004866	NCT00200486_6_T2	PHENOTYPE	12	13	primary tumor
NCT002004866	NCT00200486_6_T3	PHENOTYPE	32	33	primary tumor
NCT002004866	NCT00200486_6_T4	PHENOTYPE	35	37	lymph node metastasis
NCT002004867	NCT00200486_7_T0	PHENOTYPE	15	15	progression
NCT002004867	NCT00200486_7_T1	PHENOTYPE	20	21	primary tumor
NCT002004868	NCT00200486_8_T0	PHENOTYPE	10	10	HNSCC
NCT0020048611	NCT00200486_11_T0	PHENOTYPE	18	18	strategies
NCT0020048611	NCT00200486_11_T1	PHENOTYPE	5	5	tumor
NCT002004991	NCT00200499_1_T0	GENE	7	7	III
NCT002004991	NCT00200499_1_T1	GENE	11	11	NEB
NCT002004994	NCT00200499_4_T0	COMPOUND	9	9	calcium
NCT002004995	NCT00200499_5_T0	COMPOUND	16	16	nebivolol
NCT002004996	NCT00200499_6_T0	COMPOUND	9	9	nebivolol
NCT002004998	NCT00200499_8_T0	COMPOUND	16	16	nebivolol
NCT002004998	NCT00200499_8_T1	GENE	20	20	NEB
NCT002005383	NCT00200538_3_T0	GENE	12	12	AD
NCT002005383	NCT00200538_3_T1	GENE	25	25	AD
NCT002005383	NCT00200538_3_T2	PHENOTYPE	10	11	Alzheimer's disease
NCT002005383	NCT00200538_3_T3	PHENOTYPE	2	3	behavioral disorders
NCT002005384	NCT00200538_4_T0	GENE	11	11	AD
NCT002005384	NCT00200538_4_T1	PHENOTYPE	1	1	affects
NCT002005386	NCT00200538_6_T0	GENE	3	3	AD
NCT002005389	NCT00200538_9_T0	GENE	19	19	AD
NCT002005389	NCT00200538_9_T1	PHENOTYPE	4	4	dysfunction
NCT0020053813	NCT00200538_13_T0	GENE	19	19	tau
NCT0020053813	NCT00200538_13_T1	BIOLOGICAL_PROCESS	15	15	phosphorylation
NCT0020053814	NCT00200538_14_T0	PHENOTYPE	24	24	pathology
NCT0020053816	NCT00200538_16_T0	GENE	11	11	II
NCT0020053821	NCT00200538_21_T0	PHENOTYPE	0	0	Secondary
NCT0020053821	NCT00200538_21_T1	GENE	10	10	NPI
NCT0020053821	NCT00200538_21_T2	GENE	34	34	DAD
NCT0020053821	NCT00200538_21_T3	PHENOTYPE	20	20	Dementia
NCT0020053821	NCT00200538_21_T4	PHENOTYPE	33	33	Dementia
NCT0020053821	NCT00200538_21_T5	PHENOTYPE	46	46	Dementia
NCT002005513	NCT00200551_3_T0	COMPOUND	16	16	cyclosporin
NCT002005513	NCT00200551_3_T1	ORGAN	12	12	serum
NCT002005513	NCT00200551_3_T2	CELL	11	11	lymphocyte
NCT002005514	NCT00200551_4_T0	ORGAN	21	21	transplant
NCT002005516	NCT00200551_6_T0	PHENOTYPE	12	12	acute
NCT002005516	NCT00200551_6_T1	ORGAN	21	21	transplant
NCT002005517	NCT00200551_7_T0	COMPOUND	18	18	tacrolimus
NCT002005517	NCT00200551_7_T1	COMPOUND	16	16	cyclosporin
NCT002005517	NCT00200551_7_T2	GENE	13	13	calcineurin
NCT002005517	NCT00200551_7_T3	ORGAN	20	20	serum
NCT002005517	NCT00200551_7_T4	PHENOTYPE	27	27	tolerance
NCT002005517	NCT00200551_7_T5	ORGAN	32	32	allograft
NCT002005519	NCT00200551_9_T0	ORGAN	17	17	transplant
NCT002005519	NCT00200551_9_T1	PHENOTYPE	28	29	cardiovascular complications
NCT0020055110	NCT00200551_10_T0	ORGAN	12	12	transplant
NCT0020055110	NCT00200551_10_T1	PHENOTYPE	0	1	Cardiovascular complications
NCT002005641	NCT00200564_1_T0	COMPOUND	14	14	ketamine
NCT002005641	NCT00200564_1_T1	PHENOTYPE	23	23	analgesia
NCT002005642	NCT00200564_2_T0	PHENOTYPE	6	6	analgesia
NCT002005642	NCT00200564_2_T1	GENE	0	0	Caudal
NCT002005642	NCT00200564_2_T2	COMPOUND	11	11	paracetamol
NCT002005642	NCT00200564_2_T3	COMPOUND	18	18	nalbuphine
NCT002005642	NCT00200564_2_T4	PHENOTYPE	1	1	anesthesia
NCT002005772	NCT00200577_2_T0	COMPOUND	0	0	2
NCT002005772	NCT00200577_2_T1	GENE	10	10	TIL
NCT002005772	NCT00200577_2_T2	GENE	13	13	IL2
NCT002005773	NCT00200577_3_T0	PHENOTYPE	11	11	tumour
NCT002005773	NCT00200577_3_T1	CELL	0	2	Tumor Infiltrating Lymphocytes
NCT002005774	NCT00200577_4_T0	GENE	0	0	TIL
NCT002005777	NCT00200577_7_T0	GENE	16	16	TIL
NCT002005777	NCT00200577_7_T1	GENE	6	6	IL2
NCT002006160	NCT00200616_0_T0	PHENOTYPE	11	11	Reflux
NCT002006160	NCT00200616_0_T1	GENE	10	10	eral
NCT002006160	NCT00200616_0_T2	PHENOTYPE	8	9	Vesico-Ureteral Reflux
NCT002006163	NCT00200616_3_T0	COMPOUND	17	17	trimethoprim_sulfamethoxazole
NCT002006163	NCT00200616_3_T1	PHENOTYPE	3	4	vesico-ureteral reflux
NCT002006292	NCT00200629_2_T0	PHENOTYPE	14	14	focused
NCT002006292	NCT00200629_2_T1	PHENOTYPE	5	7	ischemic heart disease
NCT002006292	NCT00200629_2_T2	PHENOTYPE	6	9	heart disease in women
NCT002006293	NCT00200629_3_T0	PHENOTYPE	7	9	ischemic heart disease
NCT002006293	NCT00200629_3_T1	PHENOTYPE	8	11	heart disease in women
NCT002006296	NCT00200629_6_T0	GENE	9	9	has
NCT002006296	NCT00200629_6_T1	PHENOTYPE	25	27	coronary artery disease
NCT002006297	NCT00200629_7_T0	GENE	3	3	has
NCT002006298	NCT00200629_8_T0	COMPOUND	6	6	adenosine
NCT002006298	NCT00200629_8_T1	PHENOTYPE	15	15	ischemia
NCT002006299	NCT00200629_9_T0	COMPOUND	24	24	adenosine
NCT0020062910	NCT00200629_10_T0	PHENOTYPE	10	10	symptoms
NCT0020062911	NCT00200629_11_T0	COMPOUND	51	51	adenosine
NCT0020062911	NCT00200629_11_T1	COMPOUND	58	58	adenosine
NCT0020062911	NCT00200629_11_T2	GENE	28	28	METS
NCT0020062911	NCT00200629_11_T3	PHENOTYPE	13	15	coronary artery disease
NCT002006421	NCT00200642_1_T0	PHENOTYPE	2	2	symptoms
NCT002006421	NCT00200642_1_T1	GENE	18	19	Proton pump
NCT002006429	NCT00200642_9_T0	PHENOTYPE	24	24	recurrences
NCT0020064212	NCT00200642_12_T0	PHENOTYPE	3	3	symptoms
NCT0020064212	NCT00200642_12_T1	PHENOTYPE	9	9	regurgitation
NCT0020064212	NCT00200642_12_T2	PHENOTYPE	0	0	Suffering
NCT0020064212	NCT00200642_12_T3	PHENOTYPE	5	5	reflux
NCT0020064212	NCT00200642_12_T4	PHENOTYPE	6	6	heartburn
NCT0020064212	NCT00200642_12_T5	PHENOTYPE	12	12	burns
NCT0020064213	NCT00200642_13_T0	PHENOTYPE	0	0	Symptoms
NCT0020064215	NCT00200642_15_T0	PHENOTYPE	13	13	symptoms
NCT002006551	NCT00200655_1_T0	GENE	7	8	HMG-CoA reductase
NCT002006553	NCT00200655_3_T0	BIOLOGICAL_PROCESS	12	13	lymphocyte migration
NCT002006553	NCT00200655_3_T1	ORGAN	16	18	blood brain barrier
NCT002006554	NCT00200655_4_T0	GENE	20	20	MRI
NCT002006554	NCT00200655_4_T1	GENE	8	8	MS
NCT002006555	NCT00200655_5_T0	GENE	19	19	MS
NCT002006555	NCT00200655_5_T1	GENE	16	16	putative
NCT002006555	NCT00200655_5_T2	COMPOUND	0	0	Statins
NCT002006556	NCT00200655_6_T0	GENE	11	11	MRI
NCT002006556	NCT00200655_6_T1	COMPOUND	6	6	pravastatin
NCT002006556	NCT00200655_6_T2	GENE	24	24	MS
NCT002006680	NCT00200668_0_T0	GENE	17	17	ma
NCT002006680	NCT00200668_0_T1	GENE	4	4	MRI
NCT002006680	NCT00200668_0_T2	PHENOTYPE	14	15	Multiple Myeloma
NCT002006683	NCT00200668_3_T0	GENE	6	6	MRI
NCT002006684	NCT00200668_4_T0	GENE	9	9	MRI
NCT002006685	NCT00200668_5_T0	PHENOTYPE	0	0	Sensitivity
NCT002006811	NCT00200681_1_T0	ORGAN	16	16	autograft
NCT002006811	NCT00200681_1_T1	PHENOTYPE	28	28	remission
NCT002006811	NCT00200681_1_T2	GENE	29	29	CR
NCT002007070	NCT00200707_0_T0	ORGAN	2	2	Marrow
NCT002007070	NCT00200707_0_T1	PHENOTYPE	4	6	Acute Myocardial Infarction
NCT002007072	NCT00200707_2_T0	CELL	14	14	cells
NCT002007072	NCT00200707_2_T1	GENE	18	18	viability
NCT002007203	NCT00200720_3_T0	PHENOTYPE	22	23	weight loss
NCT002007204	NCT00200720_4_T0	PHENOTYPE	8	8	Hypertension
NCT002007204	NCT00200720_4_T1	PHENOTYPE	22	24	high blood pressure
NCT0020072010	NCT00200720_10_T0	PHENOTYPE	15	16	weight loss
NCT0020072011	NCT00200720_11_T0	PHENOTYPE	4	5	weight loss
NCT0020072012	NCT00200720_12_T0	PHENOTYPE	12	13	weight loss
NCT0020072014	NCT00200720_14_T0	ORGAN	21	21	kidney
NCT0020072014	NCT00200720_14_T1	PHENOTYPE	17	18	weight loss
NCT002007463	NCT00200746_3_T0	COMPOUND	7	7	arginine
NCT002007463	NCT00200746_3_T1	ORGAN	10	10	liver
NCT002007464	NCT00200746_4_T0	COMPOUND	8	8	arginine
NCT002007464	NCT00200746_4_T1	COMPOUND	27	27	arginine
NCT002007464	NCT00200746_4_T2	ORGAN	16	16	liver
NCT002007464	NCT00200746_4_T3	PHENOTYPE	39	40	alcoholic hepatitis
NCT002007464	NCT00200746_4_T4	PHENOTYPE	36	37	liver injury
NCT002007468	NCT00200746_8_T0	COMPOUND	13	13	arginine
NCT002007468	NCT00200746_8_T1	GENE	22	22	gel
NCT0020074610	NCT00200746_10_T0	COMPOUND	12	12	arginine
NCT0020074612	NCT00200746_12_T0	ORGAN	1	1	liver
NCT0020074615	NCT00200746_15_T0	COMPOUND	7	7	leucine
NCT0020074615	NCT00200746_15_T1	ORGAN	21	21	livers
NCT0020074615	NCT00200746_15_T2	GENE	13	13	albumin
NCT0020074615	NCT00200746_15_T3	GENE	18	18	reduced
NCT0020074616	NCT00200746_16_T0	PHENOTYPE	11	11	ascites
NCT0020074616	NCT00200746_16_T1	ORGAN	6	6	abdomen
NCT0020074616	NCT00200746_16_T2	ORGAN	22	22	abdomen
NCT002007593	NCT00200759_3_T0	BIOLOGICAL_PROCESS	10	10	metabolism
NCT002007593	NCT00200759_3_T1	GENE	1	1	P450
NCT002007594	NCT00200759_4_T0	GENE	5	5	CYP
NCT002007594	NCT00200759_4_T1	GENE	3	4	cytochrome P-450
NCT002007594	NCT00200759_4_T2	BIOLOGICAL_PROCESS	11	12	drug metabolism
NCT002007595	NCT00200759_5_T0	TISSUE	28	28	tissues
NCT002007595	NCT00200759_5_T1	ORGAN	25	25	liver
NCT002007595	NCT00200759_5_T2	PHENOTYPE	1	1	pharmacokinetics
NCT002007595	NCT00200759_5_T3	GENE	21	21	CYP
NCT002007595	NCT00200759_5_T4	GENE	19	20	cytochrome P-450
NCT002007597	NCT00200759_7_T0	PHENOTYPE	10	12	urinary tract infections
NCT002007598	NCT00200759_8_T0	COMPOUND	16	16	alprazolam
NCT002007598	NCT00200759_8_T1	COMPOUND	19	19	caffeine
NCT002007598	NCT00200759_8_T2	COMPOUND	17	17	dextromethorphan
NCT002007599	NCT00200759_9_T0	PHENOTYPE	3	3	pharmacokinetics
NCT002007599	NCT00200759_9_T1	PHENOTYPE	13	14	enzyme inhibition
NCT0020075911	NCT00200759_11_T0	GENE	12	12	Clo
NCT0020075911	NCT00200759_11_T1	GENE	15	15	half-life
NCT0020075911	NCT00200759_11_T2	COMPOUND	25	25	epicatechin
NCT0020075911	NCT00200759_11_T3	COMPOUND	26	26	quercetin
NCT0020075911	NCT00200759_11_T4	ORGAN	4	4	plasma
NCT0020075911	NCT00200759_11_T5	PHENOTYPE	14	14	elimination
NCT0020075911	NCT00200759_11_T6	COMPOUND	32	32	cyanidin_3_galactoside
NCT0020075911	NCT00200759_11_T7	COMPOUND	29	30	procyanidin A2
NCT002007851	NCT00200785_1_T0	COMPOUND	15	15	allicin
NCT002007851	NCT00200785_1_T1	COMPOUND	30	30	allicin
NCT002007854	NCT00200785_4_T0	PHENOTYPE	0	0	Acute
NCT002007855	NCT00200785_5_T0	PHENOTYPE	1	1	acute
NCT002007855	NCT00200785_5_T1	COMPOUND	32	32	allicin
NCT002007857	NCT00200785_7_T0	COMPOUND	34	34	allicin
NCT002007858	NCT00200785_8_T0	PHENOTYPE	0	0	Chronic
NCT002007859	NCT00200785_9_T0	PHENOTYPE	10	10	acute
NCT002007859	NCT00200785_9_T1	CELL	3	3	platelet
NCT002007859	NCT00200785_9_T2	PHENOTYPE	15	15	chronic
NCT0020078510	NCT00200785_10_T0	GENE	6	6	8.0
NCT0020078510	NCT00200785_10_T1	GENE	37	37	8.0
NCT0020078510	NCT00200785_10_T2	COMPOUND	19	19	allicin
NCT0020078510	NCT00200785_10_T3	GENE	11	11	2.7
NCT0020078510	NCT00200785_10_T4	GENE	42	42	2.7
NCT0020078510	NCT00200785_10_T5	PHENOTYPE	1	1	chronic
NCT002007980	NCT00200798_0_T0	PHENOTYPE	5	5	Pharmacokinetics
NCT0020079812	NCT00200798_12_T0	PHENOTYPE	17	17	recruitment
NCT0020079815	NCT00200798_15_T0	ORGAN	13	13	serum
NCT0020079817	NCT00200798_17_T0	GENE	4	4	has
NCT0020079818	NCT00200798_18_T0	COMPOUND	28	28	taxifolin
NCT0020079818	NCT00200798_18_T1	GENE	33	33	MT
NCT0020079818	NCT00200798_18_T2	COMPOUND	15	15	chrysin
NCT0020079819	NCT00200798_19_T0	PHENOTYPE	4	4	Pharmacokinetics
NCT0020079821	NCT00200798_21_T0	COMPOUND	12	12	creatinine
NCT0020079821	NCT00200798_21_T1	GENE	22	22	MT
NCT0020079821	NCT00200798_21_T2	GENE	26	26	SM
NCT0020079821	NCT00200798_21_T3	GENE	30	30	SM
NCT0020079823	NCT00200798_23_T0	GENE	11	11	MT
NCT0020079824	NCT00200798_24_T0	GENE	7	7	ml
NCT0020079827	NCT00200798_27_T0	GENE	21	21	1.0
NCT0020079827	NCT00200798_27_T1	GENE	23	23	2.0
NCT0020079827	NCT00200798_27_T2	GENE	24	24	3.0
NCT0020079827	NCT00200798_27_T3	GENE	25	25	4.0
NCT0020079827	NCT00200798_27_T4	GENE	19	19	0.5
NCT0020079827	NCT00200798_27_T5	GENE	26	26	6.0
NCT0020079827	NCT00200798_27_T6	GENE	13	13	MT
NCT0020079827	NCT00200798_27_T7	GENE	22	22	1.5
NCT0020079827	NCT00200798_27_T8	GENE	27	27	8.0
NCT0020079828	NCT00200798_28_T0	GENE	2	2	TESS
NCT0020079830	NCT00200798_30_T0	GENE	15	15	Clo
NCT0020079830	NCT00200798_30_T1	GENE	17	17	SM
NCT0020079830	NCT00200798_30_T2	GENE	6	6	PK
NCT0020079830	NCT00200798_30_T3	GENE	1	1	extended
NCT0020079833	NCT00200798_33_T0	ORGAN	0	0	Plasma
NCT0020079833	NCT00200798_33_T1	ORGAN	11	11	plasma
NCT0020079833	NCT00200798_33_T2	GENE	6	6	ml
NCT0020079834	NCT00200798_34_T0	COMPOUND	5	5	silymarin
NCT0020079834	NCT00200798_34_T1	GENE	15	15	MT
NCT0020079834	NCT00200798_34_T2	GENE	27	27	MT
NCT0020079834	NCT00200798_34_T3	GENE	36	36	separated
NCT0020079834	NCT00200798_34_T4	PHENOTYPE	6	6	pharmacokinetics
NCT0020079834	NCT00200798_34_T5	GENE	21	21	span
NCT0020079834	NCT00200798_34_T6	PHENOTYPE	24	25	therapeutic range
NCT0020079835	NCT00200798_35_T0	GENE	3	3	MT
NCT0020079837	NCT00200798_37_T0	GENE	4	4	MT
NCT0020079837	NCT00200798_37_T1	GENE	53	53	al
NCT0020079837	NCT00200798_37_T2	GENE	52	52	et
NCT0020079837	NCT00200798_37_T3	GENE	14	14	SM
NCT0020079837	NCT00200798_37_T4	GENE	24	24	SM
NCT0020079837	NCT00200798_37_T5	GENE	32	32	has
NCT0020079837	NCT00200798_37_T6	PHENOTYPE	39	40	hepatic dysfunction
NCT0020079838	NCT00200798_38_T0	GENE	24	24	MT
NCT0020079838	NCT00200798_38_T1	GENE	30	30	SM
NCT0020079839	NCT00200798_39_T0	GENE	22	22	SM
NCT0020079840	NCT00200798_40_T0	GENE	19	19	SM
NCT0020079840	NCT00200798_40_T1	GENE	3	3	extended
NCT0020079841	NCT00200798_41_T0	PHENOTYPE	5	6	adverse effects
NCT0020079842	NCT00200798_42_T0	GENE	23	23	TESS
NCT0020079842	NCT00200798_42_T1	GENE	18	18	SM
NCT0020079843	NCT00200798_43_T0	COMPOUND	28	28	creatinine
NCT0020079843	NCT00200798_43_T1	GENE	14	14	MT
NCT0020079844	NCT00200798_44_T0	PHENOTYPE	16	16	concentrations
NCT0020079844	NCT00200798_44_T1	ORGAN	20	20	plasma
NCT0020079845	NCT00200798_45_T0	GENE	16	16	1.0
NCT0020079845	NCT00200798_45_T1	GENE	17	17	2.0
NCT0020079845	NCT00200798_45_T2	GENE	18	18	3.0
NCT0020079845	NCT00200798_45_T3	GENE	20	20	4.0
NCT0020079845	NCT00200798_45_T4	GENE	15	15	0.5
NCT0020079845	NCT00200798_45_T5	GENE	12	12	MT
NCT0020079845	NCT00200798_45_T6	GENE	24	24	MT
NCT0020079845	NCT00200798_45_T7	GENE	22	22	8.0
NCT0020079847	NCT00200798_47_T0	COMPOUND	14	14	creatinine
NCT0020079848	NCT00200798_48_T0	ORGAN	15	15	serum
NCT0020079849	NCT00200798_49_T0	GENE	12	12	TESS
NCT0020079849	NCT00200798_49_T1	PHENOTYPE	8	9	adverse events
NCT0020079852	NCT00200798_52_T0	GENE	8	8	has
NCT0020079853	NCT00200798_53_T0	GENE	7	7	had
NCT0020079858	NCT00200798_58_T0	GENE	18	18	MT
NCT0020079859	NCT00200798_59_T0	GENE	17	17	CYP2C9
NCT0020079859	NCT00200798_59_T1	GENE	23	23	CYP2D6
NCT0020079859	NCT00200798_59_T2	GENE	16	16	CYP1A2
NCT0020079859	NCT00200798_59_T3	GENE	15	15	CYP3A4
NCT0020079860	NCT00200798_60_T0	GENE	16	16	MT
NCT0020079861	NCT00200798_61_T0	PHENOTYPE	3	3	pharmacokinetics
NCT0020079861	NCT00200798_61_T1	PHENOTYPE	14	15	enzyme inhibition
NCT0020079862	NCT00200798_62_T0	GENE	13	13	MT
NCT0020079862	NCT00200798_62_T1	GENE	23	23	CYP
NCT0020079864	NCT00200798_64_T0	GENE	33	33	CYP2D6
NCT0020079865	NCT00200798_65_T0	PHENOTYPE	24	24	symptoms
NCT0020079865	NCT00200798_65_T1	GENE	15	15	TESS
NCT0020079865	NCT00200798_65_T2	GENE	32	32	MT
NCT0020079865	NCT00200798_65_T3	GENE	18	18	al
NCT0020079865	NCT00200798_65_T4	PHENOTYPE	13	13	Symptoms
NCT0020079865	NCT00200798_65_T5	GENE	17	17	et
NCT0020079865	NCT00200798_65_T6	PHENOTYPE	6	7	adverse events
NCT0020079867	NCT00200798_67_T0	GENE	4	4	has
NCT0020079868	NCT00200798_68_T0	GENE	1	1	CYP
NCT0020079870	NCT00200798_70_T0	GENE	24	24	TOL
NCT0020079870	NCT00200798_70_T1	GENE	21	21	CAF
NCT0020079872	NCT00200798_72_T0	GENE	7	7	ml
NCT0020079873	NCT00200798_73_T0	GENE	15	15	1.0
NCT0020079873	NCT00200798_73_T1	GENE	17	17	2.0
NCT0020079873	NCT00200798_73_T2	GENE	18	18	3.0
NCT0020079873	NCT00200798_73_T3	GENE	19	19	4.0
NCT0020079873	NCT00200798_73_T4	GENE	13	13	0.5
NCT0020079873	NCT00200798_73_T5	GENE	20	20	6.0
NCT0020079873	NCT00200798_73_T6	GENE	16	16	1.5
NCT0020079873	NCT00200798_73_T7	GENE	21	21	8.0
NCT0020079875	NCT00200798_75_T0	GENE	15	15	Clo
NCT0020079875	NCT00200798_75_T1	GENE	1	1	extended
NCT0020079876	NCT00200798_76_T0	PHENOTYPE	6	7	drug absorption
NCT0020079877	NCT00200798_77_T0	GENE	20	20	CAF
NCT0020079879	NCT00200798_79_T0	GENE	0	0	MT
NCT0020079879	NCT00200798_79_T1	GENE	9	9	MT
NCT0020079879	NCT00200798_79_T2	GENE	2	2	Period
NCT0020079879	NCT00200798_79_T3	GENE	15	15	SM
NCT0020079880	NCT00200798_80_T0	GENE	13	13	MT
NCT0020079881	NCT00200798_81_T0	PHENOTYPE	30	31	adverse events
NCT0020079882	NCT00200798_82_T0	GENE	1	1	CYP
NCT0020079884	NCT00200798_84_T0	GENE	4	4	CYP2D6
NCT0020079884	NCT00200798_84_T1	GENE	6	6	CYP1A2
NCT0020079884	NCT00200798_84_T2	GENE	36	36	MT
NCT0020079884	NCT00200798_84_T3	GENE	3	3	CYP3A4
NCT0020079885	NCT00200798_85_T0	GENE	12	12	MT
NCT0020079889	NCT00200798_89_T0	ORGAN	15	15	serum
NCT0020079890	NCT00200798_90_T0	GENE	12	12	TESS
NCT0020079890	NCT00200798_90_T1	PHENOTYPE	8	9	adverse events
NCT002008240	NCT00200824_0_T0	PHENOTYPE	7	8	Prostate Cancer
NCT002008240	NCT00200824_0_T1	PHENOTYPE	5	6	Breast Cancer
NCT002008246	NCT00200824_6_T0	GENE	7	7	soy
NCT002008246	NCT00200824_6_T1	PHENOTYPE	10	12	quality of life
NCT002008248	NCT00200824_8_T0	PHENOTYPE	15	16	blood concentrations
NCT0020082410	NCT00200824_10_T0	PHENOTYPE	6	6	concentrations
NCT0020082410	NCT00200824_10_T1	PHENOTYPE	15	16	blood concentrations
NCT0020082412	NCT00200824_12_T0	COMPOUND	8	8	isoflavone
NCT0020082416	NCT00200824_16_T0	PHENOTYPE	0	2	Quality of life
NCT002008500	NCT00200850_0_T0	PHENOTYPE	9	9	Allergy
NCT002008502	NCT00200850_2_T0	GENE	8	8	SLIT
NCT002008502	NCT00200850_2_T1	PHENOTYPE	19	19	asthma
NCT002008505	NCT00200850_5_T0	PHENOTYPE	17	17	asthma
NCT002008506	NCT00200850_6_T0	PHENOTYPE	14	14	asthma
NCT002008506	NCT00200850_6_T1	GENE	2	2	beta
NCT002008508	NCT00200850_8_T0	GENE	9	9	SLIT
NCT002008508	NCT00200850_8_T1	PHENOTYPE	25	25	asthma
NCT002008509	NCT00200850_9_T0	GENE	9	9	SLIT
NCT002008509	NCT00200850_9_T1	GENE	12	12	SLIT
NCT0020085010	NCT00200850_10_T0	PHENOTYPE	3	4	allergy skin
NCT0020085011	NCT00200850_11_T0	GENE	5	5	SLIT
NCT0020085011	NCT00200850_11_T1	GENE	15	15	SLIT
NCT0020085011	NCT00200850_11_T2	PHENOTYPE	8	9	immune tolerance
NCT002008633	NCT00200863_3_T0	PHENOTYPE	13	13	physiology
NCT002008636	NCT00200863_6_T0	PHENOTYPE	15	15	arousal
NCT002008766	NCT00200876_6_T0	GENE	8	8	painless
NCT002008892	NCT00200889_2_T0	PHENOTYPE	23	23	affects
NCT002008892	NCT00200889_2_T1	ORGAN	15	16	vagus nerve
NCT002008893	NCT00200889_3_T0	GENE	9	9	MRI
NCT002008893	NCT00200889_3_T1	GENE	14	14	MRI
NCT002009023	NCT00200902_3_T0	COMPOUND	14	14	venlafaxine
NCT002009023	NCT00200902_3_T1	COMPOUND	18	18	duloxetine
NCT002009023	NCT00200902_3_T2	COMPOUND	22	22	escitalopram
NCT002009024	NCT00200902_4_T0	COMPOUND	38	38	venlafaxine
NCT002009024	NCT00200902_4_T1	COMPOUND	40	40	duloxetine
NCT002009024	NCT00200902_4_T2	COMPOUND	42	42	escitalopram
NCT002009280	NCT00200928_0_T0	PHENOTYPE	0	0	Asthma
NCT002009280	NCT00200928_0_T1	PHENOTYPE	8	9	Bacterial Infections
NCT002009283	NCT00200928_3_T0	PHENOTYPE	18	18	atopic
NCT002009414	NCT00200941_4_T0	PHENOTYPE	4	4	tolerance
NCT002009415	NCT00200941_5_T0	PHENOTYPE	5	5	symptoms
NCT002009415	NCT00200941_5_T1	GENE	4	4	half-life
NCT002009416	NCT00200941_6_T0	GENE	1	1	has
NCT002009542	NCT00200954_2_T0	PHENOTYPE	1	1	diseases
NCT002009543	NCT00200954_3_T0	PHENOTYPE	8	8	atopic
NCT002009543	NCT00200954_3_T1	GENE	14	14	reduced
NCT002009544	NCT00200954_4_T0	PHENOTYPE	7	7	atopic
NCT002009544	NCT00200954_4_T1	PHENOTYPE	17	17	atopic
NCT002009544	NCT00200954_4_T2	GENE	24	24	has
NCT002009549	NCT00200954_9_T0	CELL	11	11	cells
NCT002009549	NCT00200954_9_T1	ORGAN	22	23	gastrointestinal tract
NCT002009549	NCT00200954_9_T2	CELL	4	5	antigen-presenting cells
NCT0020095415	NCT00200954_15_T0	PHENOTYPE	15	15	severity
NCT0020095415	NCT00200954_15_T1	PHENOTYPE	12	12	atopic
NCT0020095415	NCT00200954_15_T2	PHENOTYPE	17	17	atopic
NCT0020095417	NCT00200954_17_T0	PHENOTYPE	24	24	atopic
NCT0020095418	NCT00200954_18_T0	PHENOTYPE	8	8	severity
NCT0020095418	NCT00200954_18_T1	PHENOTYPE	12	12	atopic
NCT0020095418	NCT00200954_18_T2	BIOLOGICAL_PROCESS	10	10	sensitization
NCT0020095419	NCT00200954_19_T0	PHENOTYPE	0	0	Secondary
NCT0020095419	NCT00200954_19_T1	PHENOTYPE	5	7	change in stool
NCT002009672	NCT00200967_2_T0	COMPOUND	23	23	Gly-Gly
NCT002009672	NCT00200967_2_T1	COMPOUND	6	6	arginine
NCT002009672	NCT00200967_2_T2	GENE	18	18	receptor
NCT002009672	NCT00200967_2_T3	COMPOUND	8	8	glycine
NCT002009672	NCT00200967_2_T4	GENE	19	19	B16
NCT002009672	NCT00200967_2_T5	GENE	22	22	B16
NCT002009672	NCT00200967_2_T6	COMPOUND	20	20	Arg-Arg
NCT002009801	NCT00200980_1_T0	PHENOTYPE	8	8	asthma
NCT002009801	NCT00200980_1_T1	PHENOTYPE	25	25	asthma
NCT002009801	NCT00200980_1_T2	GENE	17	17	has
NCT002009801	NCT00200980_1_T3	PHENOTYPE	5	5	reflux
NCT002009801	NCT00200980_1_T4	PHENOTYPE	15	16	acid reflux
NCT002009802	NCT00200980_2_T0	PHENOTYPE	9	9	asthma
NCT002009802	NCT00200980_2_T1	PHENOTYPE	14	14	asthma
NCT002009802	NCT00200980_2_T2	GENE	3	3	has
NCT002009802	NCT00200980_2_T3	PHENOTYPE	7	7	reflux
NCT002009803	NCT00200980_3_T0	PHENOTYPE	27	27	strategies
NCT002009803	NCT00200980_3_T1	PHENOTYPE	26	26	suppression
NCT002009803	NCT00200980_3_T2	PHENOTYPE	14	15	acid reflux
NCT002009805	NCT00200980_5_T0	GENE	3	3	has
NCT002009808	NCT00200980_8_T0	GENE	6	6	pH
NCT002009809	NCT00200980_9_T0	PHENOTYPE	9	9	asthma
NCT002009809	NCT00200980_9_T1	PHENOTYPE	15	16	gastroesophageal reflux
NCT0020098010	NCT00200980_10_T0	GENE	10	10	pH
NCT0020098010	NCT00200980_10_T1	PHENOTYPE	8	8	impedance
NCT0020098011	NCT00200980_11_T0	PHENOTYPE	29	29	asthma
NCT0020098011	NCT00200980_11_T1	PHENOTYPE	26	27	acid reflux
NCT002009930	NCT00200993_0_T0	PHENOTYPE	0	0	Peripheral
NCT002009933	NCT00200993_3_T0	BIOLOGICAL_PROCESS	19	20	carbohydrate metabolism
NCT002009935	NCT00200993_5_T0	PHENOTYPE	15	15	peripheral
NCT002009935	NCT00200993_5_T1	PHENOTYPE	22	22	adaptations
NCT002009935	NCT00200993_5_T2	PHENOTYPE	21	21	chronic
NCT002009935	NCT00200993_5_T3	TISSUE	24	25	skeletal muscle
NCT002009936	NCT00200993_6_T0	PHENOTYPE	2	2	exposures
NCT002009936	NCT00200993_6_T1	PHENOTYPE	20	20	adaptations
NCT002009936	NCT00200993_6_T2	PHENOTYPE	24	24	understood
NCT002009937	NCT00200993_7_T0	PHENOTYPE	5	5	peripheral
NCT002009937	NCT00200993_7_T1	PHENOTYPE	10	10	chronic
NCT002009937	NCT00200993_7_T2	BIOLOGICAL_PROCESS	14	15	carbohydrate metabolism
NCT002009937	NCT00200993_7_T3	BIOLOGICAL_PROCESS	17	18	lipid metabolism
NCT002009938	NCT00200993_8_T0	GENE	42	42	ramp
NCT002009939	NCT00200993_9_T0	PHENOTYPE	21	21	peripheral
NCT002009939	NCT00200993_9_T1	ORGAN	25	25	capillary
NCT002009939	NCT00200993_9_T2	PHENOTYPE	1	1	reflecting
NCT002009939	NCT00200993_9_T3	BIOLOGICAL_PROCESS	6	7	lipid metabolism
NCT002009939	NCT00200993_9_T4	TISSUE	22	23	skeletal muscle
NCT0020099310	NCT00200993_10_T0	PHENOTYPE	8	8	peripheral
NCT0020099310	NCT00200993_10_T1	PHENOTYPE	20	20	chronic
NCT0020099310	NCT00200993_10_T2	BIOLOGICAL_PROCESS	17	18	lipid metabolism
NCT0020099311	NCT00200993_11_T0	PHENOTYPE	9	9	peripheral
NCT0020099311	NCT00200993_11_T1	PHENOTYPE	14	14	chronic
NCT0020099311	NCT00200993_11_T2	BIOLOGICAL_PROCESS	18	19	carbohydrate metabolism
NCT0020099311	NCT00200993_11_T3	BIOLOGICAL_PROCESS	21	22	lipid metabolism
NCT0020099312	NCT00200993_12_T0	ORGAN	26	26	capillary
NCT0020099312	NCT00200993_12_T1	PHENOTYPE	15	15	adaptations
NCT0020099312	NCT00200993_12_T2	TISSUE	18	19	skeletal muscle
NCT0020099312	NCT00200993_12_T3	TISSUE	30	31	skeletal muscle
NCT002010064	NCT00201006_4_T0	PHENOTYPE	15	16	lost weight
NCT002010065	NCT00201006_5_T0	GENE	2	2	has
NCT002010065	NCT00201006_5_T1	PHENOTYPE	7	8	lost weight
NCT002010067	NCT00201006_7_T0	PHENOTYPE	24	24	obesity
NCT002010069	NCT00201006_9_T0	PHENOTYPE	43	43	Condition
NCT002010069	NCT00201006_9_T1	PHENOTYPE	9	10	weight loss
NCT0020100610	NCT00201006_10_T0	COMPOUND	9	9	BMI
NCT0020100611	NCT00201006_11_T0	BIOLOGICAL_PROCESS	11	11	eating
NCT0020100611	NCT00201006_11_T1	PHENOTYPE	19	20	lost weight
NCT002010192	NCT00201019_2_T0	PHENOTYPE	9	9	hypertension
NCT002010193	NCT00201019_3_T0	PHENOTYPE	19	19	understood
NCT002010194	NCT00201019_4_T0	GENE	7	7	has
NCT002010194	NCT00201019_4_T1	GENE	5	5	BP
NCT002010195	NCT00201019_5_T0	GENE	26	26	BP
NCT002010197	NCT00201019_7_T0	PHENOTYPE	18	18	hypertension
NCT002010199	NCT00201019_9_T0	PHENOTYPE	17	17	strategies
NCT0020101910	NCT00201019_10_T0	GENE	1	1	II
NCT0020101910	NCT00201019_10_T1	PHENOTYPE	17	17	hypertension
NCT0020101910	NCT00201019_10_T2	GENE	21	21	BP
NCT0020101913	NCT00201019_13_T0	PHENOTYPE	21	21	hypertension
NCT0020101913	NCT00201019_13_T1	GENE	12	12	BP
NCT0020101914	NCT00201019_14_T0	GENE	13	13	has
NCT0020101914	NCT00201019_14_T1	PHENOTYPE	10	10	hypertension
NCT0020101914	NCT00201019_14_T2	GENE	25	25	BP
NCT002010452	NCT00201045_2_T0	GENE	0	0	BP
NCT002010453	NCT00201045_3_T0	GENE	15	15	has
NCT002010453	NCT00201045_3_T1	GENE	14	14	BP
NCT002010454	NCT00201045_4_T0	GENE	1	1	BP
NCT002010455	NCT00201045_5_T0	PHENOTYPE	16	16	satisfied
NCT002010459	NCT00201045_9_T0	PHENOTYPE	3	3	suffered
NCT0020104510	NCT00201045_10_T0	GENE	32	32	BP
NCT0020104511	NCT00201045_11_T0	PHENOTYPE	13	13	strategies
NCT0020104511	NCT00201045_11_T1	GENE	9	9	BP
NCT0020104512	NCT00201045_12_T0	GENE	20	20	BP
NCT0020104514	NCT00201045_14_T0	GENE	9	9	BP
NCT0020104515	NCT00201045_15_T0	GENE	2	2	has
NCT0020104515	NCT00201045_15_T1	GENE	10	10	BP
NCT0020104516	NCT00201045_16_T0	GENE	11	11	BP
NCT002010580	NCT00201058_0_T0	PHENOTYPE	1	1	Asthma
NCT002010582	NCT00201058_2_T0	PHENOTYPE	18	18	asthma
NCT002010583	NCT00201058_3_T0	GENE	13	13	II
NCT002010583	NCT00201058_3_T1	PHENOTYPE	24	24	relapse
NCT002010583	NCT00201058_3_T2	PHENOTYPE	33	33	recruitment
NCT002010585	NCT00201058_5_T0	PHENOTYPE	2	2	asthma
NCT002010586	NCT00201058_6_T0	PHENOTYPE	5	5	asthma
NCT002010586	NCT00201058_6_T1	GENE	13	13	grim
NCT002010587	NCT00201058_7_T0	PHENOTYPE	16	16	asthma
NCT002010588	NCT00201058_8_T0	PHENOTYPE	16	16	secondary
NCT002010589	NCT00201058_9_T0	PHENOTYPE	19	21	Quality of Life
NCT002010712	NCT00201071_2_T0	PHENOTYPE	17	17	strategies
NCT002010712	NCT00201071_2_T1	PHENOTYPE	5	5	asthma
NCT002010712	NCT00201071_2_T2	PHENOTYPE	20	20	asthma
NCT002010840	NCT00201084_0_T0	PHENOTYPE	4	4	Hypertension
NCT002010845	NCT00201084_5_T0	PHENOTYPE	8	8	hypertension
NCT002010845	NCT00201084_5_T1	GENE	16	16	BP
NCT002010847	NCT00201084_7_T0	GENE	11	11	URAD
NCT002010847	NCT00201084_7_T1	GENE	17	17	BP
NCT002010847	NCT00201084_7_T2	PHENOTYPE	12	12	practices
NCT002010848	NCT00201084_8_T0	GENE	24	24	BP
NCT0020108411	NCT00201084_11_T0	GENE	41	41	URAD
NCT0020108411	NCT00201084_11_T1	PHENOTYPE	26	26	hypertension
NCT0020108412	NCT00201084_12_T0	PHENOTYPE	0	0	Secondary
NCT0020108412	NCT00201084_12_T1	GENE	29	29	URAD
NCT0020108412	NCT00201084_12_T2	GENE	4	4	BP
NCT0020108412	NCT00201084_12_T3	GENE	45	45	BP
NCT0020108413	NCT00201084_13_T0	PHENOTYPE	2	2	secondary
NCT0020108414	NCT00201084_14_T0	GENE	3	3	has
NCT0020108414	NCT00201084_14_T1	PHENOTYPE	17	17	hypertension
NCT002011102	NCT00201110_2_T0	PHENOTYPE	0	0	CVD
NCT002011103	NCT00201110_3_T0	PHENOTYPE	10	10	CVD
NCT002011103	NCT00201110_3_T1	PHENOTYPE	9	9	chronic
NCT002011103	NCT00201110_3_T2	PHENOTYPE	21	21	decision-making
NCT002011233	NCT00201123_3_T0	PHENOTYPE	21	21	relapse
NCT002011233	NCT00201123_3_T1	PHENOTYPE	2	2	bilateral
NCT002011233	NCT00201123_3_T2	PHENOTYPE	3	4	pulmonary tuberculosis
NCT002011360	NCT00201136_0_T0	PHENOTYPE	3	3	Hypertension
NCT002011360	NCT00201136_0_T1	PHENOTYPE	7	8	Cardiovascular Disease
NCT002011364	NCT00201136_4_T0	PHENOTYPE	9	9	hypertension
NCT002011364	NCT00201136_4_T1	GENE	15	15	BP
NCT002011366	NCT00201136_6_T0	GENE	23	23	BP
NCT002011366	NCT00201136_6_T1	PHENOTYPE	11	11	obesity
NCT0020113610	NCT00201136_10_T0	GENE	23	23	BP
NCT0020113612	NCT00201136_12_T0	GENE	1	1	MD
NCT0020113613	NCT00201136_13_T0	PHENOTYPE	3	3	Hypertension
NCT0020113613	NCT00201136_13_T1	GENE	33	33	BP
NCT0020113613	NCT00201136_13_T2	GENE	6	6	HIP
NCT0020113614	NCT00201136_14_T0	PHENOTYPE	5	5	practices
NCT0020113615	NCT00201136_15_T0	PHENOTYPE	0	0	Practices
NCT0020113615	NCT00201136_15_T1	GENE	7	7	MD
NCT0020113615	NCT00201136_15_T2	GENE	12	12	MD
NCT0020113616	NCT00201136_16_T0	PHENOTYPE	2	2	practices
NCT0020113617	NCT00201136_17_T0	GENE	1	1	MD
NCT0020113619	NCT00201136_19_T0	PHENOTYPE	3	3	practices
NCT0020113620	NCT00201136_20_T0	GENE	15	15	BP
NCT0020113620	NCT00201136_20_T1	GENE	21	21	BP
NCT0020113621	NCT00201136_21_T0	GENE	0	0	BP
NCT0020113622	NCT00201136_22_T0	GENE	16	16	BP
NCT0020113624	NCT00201136_24_T0	GENE	12	12	MD
NCT0020113624	NCT00201136_24_T1	GENE	7	7	BP
NCT0020113626	NCT00201136_26_T0	GENE	23	23	0.3
NCT0020113626	NCT00201136_26_T1	PHENOTYPE	8	8	practices
NCT002011492	NCT00201149_2_T0	PHENOTYPE	13	13	hypertension
NCT002011495	NCT00201149_5_T0	PHENOTYPE	16	16	hypertension
NCT002011495	NCT00201149_5_T1	GENE	7	7	BP
NCT002011496	NCT00201149_6_T0	GENE	2	2	has
NCT002011497	NCT00201149_7_T0	PHENOTYPE	13	13	hypertension
NCT002011499	NCT00201149_9_T0	GENE	10	10	BP
NCT0020114910	NCT00201149_10_T0	PHENOTYPE	2	2	strategies
NCT0020114914	NCT00201149_14_T0	GENE	46	46	BP
NCT002011623	NCT00201162_3_T0	ORGAN	14	14	plasma
NCT002011623	NCT00201162_3_T1	GENE	8	8	soy
NCT002011623	NCT00201162_3_T2	GENE	12	12	soy
NCT002011624	NCT00201162_4_T0	GENE	15	15	lipoprotein
NCT002011624	NCT00201162_4_T1	GENE	12	12	soy
NCT002011626	NCT00201162_6_T0	GENE	11	11	LDL
NCT002011627	NCT00201162_7_T0	GENE	20	20	casein
NCT002011627	NCT00201162_7_T1	GENE	16	16	soy
NCT002011629	NCT00201162_9_T0	PHENOTYPE	27	27	menopausal
NCT002011629	NCT00201162_9_T1	GENE	13	13	LDL
NCT002011629	NCT00201162_9_T2	GENE	15	15	LDL
NCT002011629	NCT00201162_9_T3	GENE	22	22	LDL
NCT002011629	NCT00201162_9_T4	GENE	4	4	soy
NCT002011629	NCT00201162_9_T5	PHENOTYPE	28	30	quality of life
NCT0020116211	NCT00201162_11_T0	GENE	20	20	soy
NCT002011882	NCT00201188_2_T0	PHENOTYPE	0	0	Asthma
NCT002011884	NCT00201188_4_T0	PHENOTYPE	11	12	persistent asthma
NCT002011888	NCT00201188_8_T0	PHENOTYPE	8	8	understood
NCT0020118811	NCT00201188_11_T0	PHENOTYPE	15	15	asthma
NCT0020118814	NCT00201188_14_T0	PHENOTYPE	5	5	asthma
NCT0020118814	NCT00201188_14_T1	GENE	15	15	has
NCT0020118815	NCT00201188_15_T0	PHENOTYPE	15	15	asthma
NCT0020118815	NCT00201188_15_T1	PHENOTYPE	6	6	practices
NCT0020118816	NCT00201188_16_T0	PHENOTYPE	0	0	Feedback
NCT0020118817	NCT00201188_17_T0	PHENOTYPE	1	1	intent
NCT002012010	NCT00201201_0_T0	PHENOTYPE	8	8	Hypertension
NCT002012013	NCT00201201_3_T0	PHENOTYPE	16	16	self-efficacy
NCT002012016	NCT00201201_6_T0	GENE	1	1	has
NCT002012016	NCT00201201_6_T1	PHENOTYPE	8	10	adverse drug events
NCT002012019	NCT00201201_9_T0	PHENOTYPE	14	14	hypertension
NCT002012019	NCT00201201_9_T1	PHENOTYPE	9	9	practices
NCT0020120110	NCT00201201_10_T0	GENE	11	11	PEP
NCT0020120110	NCT00201201_10_T1	GENE	19	19	PEP
NCT0020120112	NCT00201201_12_T0	PHENOTYPE	7	7	strategies
NCT0020120112	NCT00201201_12_T1	GENE	23	23	has
NCT0020120112	NCT00201201_12_T2	PHENOTYPE	31	31	practices
NCT0020120116	NCT00201201_16_T0	PHENOTYPE	20	20	self-efficacy
NCT0020120116	NCT00201201_16_T1	PHENOTYPE	30	30	self-efficacy
NCT0020120116	NCT00201201_16_T2	PHENOTYPE	18	18	practices
NCT0020120117	NCT00201201_17_T0	PHENOTYPE	23	23	self-efficacy
NCT0020120117	NCT00201201_17_T1	PHENOTYPE	20	20	practices
NCT0020120119	NCT00201201_19_T0	PHENOTYPE	22	22	practices
NCT0020120120	NCT00201201_20_T0	GENE	6	6	ANOVA
NCT0020120123	NCT00201201_23_T0	GENE	18	18	ANOVA
NCT002012143	NCT00201214_3_T0	COMPOUND	5	6	nitric oxide
NCT002012144	NCT00201214_4_T0	BIOLOGICAL_PROCESS	10	11	urea cycle
NCT002012146	NCT00201214_6_T0	COMPOUND	9	9	arginine
NCT002012146	NCT00201214_6_T1	ORGAN	8	8	plasma
NCT002012146	NCT00201214_6_T2	BIOLOGICAL_PROCESS	4	5	urea cycle
NCT002012147	NCT00201214_7_T0	COMPOUND	8	8	arginine
NCT002012147	NCT00201214_7_T1	GENE	5	5	had
NCT002012148	NCT00201214_8_T0	COMPOUND	25	25	arginine
NCT002012148	NCT00201214_8_T1	ORGAN	24	24	plasma
NCT002012148	NCT00201214_8_T2	BIOLOGICAL_PROCESS	11	12	urea cycle
NCT002012148	NCT00201214_8_T3	GENE	14	17	carbamyl phosphate synthetase I
NCT002012149	NCT00201214_9_T0	BIOLOGICAL_PROCESS	10	11	urea cycle
NCT002012149	NCT00201214_9_T1	BIOLOGICAL_PROCESS	20	21	urea cycle
NCT0020121410	NCT00201214_10_T0	COMPOUND	21	21	arginine
NCT0020121410	NCT00201214_10_T1	ORGAN	20	20	plasma
NCT0020121410	NCT00201214_10_T2	COMPOUND	17	17	citrulline
NCT0020121410	NCT00201214_10_T3	BIOLOGICAL_PROCESS	8	9	urea cycle
NCT0020121410	NCT00201214_10_T4	BIOLOGICAL_PROCESS	14	15	urea cycle
NCT0020121411	NCT00201214_11_T0	GENE	26	26	bypass
NCT0020121411	NCT00201214_11_T1	PHENOTYPE	9	9	pharmacokinetics
NCT0020121411	NCT00201214_11_T2	COMPOUND	17	17	citrulline
NCT0020121411	NCT00201214_11_T3	PHENOTYPE	31	33	congenital heart defects
NCT0020121414	NCT00201214_14_T0	PHENOTYPE	0	0	VSD
NCT002012273	NCT00201227_3_T0	PHENOTYPE	11	11	practices
NCT002012279	NCT00201227_9_T0	PHENOTYPE	9	9	practices
NCT0020122713	NCT00201227_13_T0	PHENOTYPE	13	13	practices
NCT0020122717	NCT00201227_17_T0	PHENOTYPE	1	1	insights
NCT002012400	NCT00201240_0_T0	ORGAN	8	8	Transplants
NCT002012400	NCT00201240_0_T1	GENE	16	16	CTN
NCT002012400	NCT00201240_0_T2	PHENOTYPE	0	2	Acute Myeloid Leukemia
NCT002012400	NCT00201240_0_T3	PHENOTYPE	12	14	Acute Myeloid Leukemia
NCT002012400	NCT00201240_0_T4	PHENOTYPE	2	4	Leukemia T Cell
NCT002012405	NCT00201240_5_T0	PHENOTYPE	14	14	AML
NCT002012405	NCT00201240_5_T1	ORGAN	29	29	graft
NCT002012405	NCT00201240_5_T2	PHENOTYPE	21	21	remission
NCT002012405	NCT00201240_5_T3	PHENOTYPE	78	78	remission
NCT002012405	NCT00201240_5_T4	PHENOTYPE	88	88	remission
NCT002012405	NCT00201240_5_T5	ORGAN	54	54	transplant
NCT002012405	NCT00201240_5_T6	ORGAN	6	6	transplants
NCT002012406	NCT00201240_6_T0	PHENOTYPE	1	1	secondary
NCT002012406	NCT00201240_6_T1	PHENOTYPE	12	12	acute
NCT002012406	NCT00201240_6_T2	PHENOTYPE	19	19	GVHD
NCT002012406	NCT00201240_6_T3	PHENOTYPE	6	7	graft failure
NCT002012406	NCT00201240_6_T4	PHENOTYPE	16	18	chronic graft-versus-host disease
NCT002012407	NCT00201240_7_T0	GENE	12	12	CD3
NCT002012407	NCT00201240_7_T1	GENE	9	9	CD34
NCT002012407	NCT00201240_7_T2	CELL	13	14	T cells
NCT0020124013	NCT00201240_13_T0	PHENOTYPE	6	6	relapse
NCT0020124013	NCT00201240_13_T1	ORGAN	14	14	transplants
NCT0020124014	NCT00201240_14_T0	PHENOTYPE	10	10	infections
NCT0020124014	NCT00201240_14_T1	ORGAN	6	6	transplant
NCT0020124014	NCT00201240_14_T2	PHENOTYPE	9	9	reflecting
NCT0020124014	NCT00201240_14_T3	PHENOTYPE	12	12	GVHD
NCT0020124017	NCT00201240_17_T0	PHENOTYPE	13	13	AML
NCT0020124017	NCT00201240_17_T1	GENE	17	17	CR2
NCT0020124017	NCT00201240_17_T2	GENE	15	15	CR1
NCT002012533	NCT00201253_3_T0	PHENOTYPE	2	2	immunity
NCT002012536	NCT00201253_6_T0	CELL	12	12	cells
NCT002012663	NCT00201266_3_T0	GENE	11	11	mucin
NCT002012663	NCT00201266_3_T1	GENE	2	2	ABH
NCT002012663	NCT00201266_3_T2	COMPOUND	6	6	O
NCT002012665	NCT00201266_5_T0	BIOLOGICAL_PROCESS	1	1	degradation
NCT002012668	NCT00201266_8_T0	CELL	23	23	cells
NCT0020126610	NCT00201266_10_T0	PHENOTYPE	18	18	asthma
NCT002012793	NCT00201279_3_T0	PHENOTYPE	2	2	malignancies
NCT002012793	NCT00201279_3_T1	PHENOTYPE	15	18	head and neck cancer
NCT002012794	NCT00201279_4_T0	PHENOTYPE	7	7	recurrence
NCT002012794	NCT00201279_4_T1	PHENOTYPE	21	22	primary tumors
NCT002012797	NCT00201279_7_T0	PHENOTYPE	18	18	cancers
NCT002012797	NCT00201279_7_T1	GENE	2	2	al
NCT002012797	NCT00201279_7_T2	GENE	1	1	et
NCT002012797	NCT00201279_7_T3	COMPOUND	8	9	retinoic acid
NCT002012798	NCT00201279_8_T0	PHENOTYPE	7	7	cancers
NCT002012798	NCT00201279_8_T1	COMPOUND	24	25	retinoic acid
NCT002012799	NCT00201279_9_T0	GENE	18	18	had
NCT002012799	NCT00201279_9_T1	GENE	31	31	had
NCT002012799	NCT00201279_9_T2	PHENOTYPE	21	22	primary tumors
NCT002012799	NCT00201279_9_T3	PHENOTYPE	34	35	primary tumors
NCT0020127910	NCT00201279_10_T0	BIOLOGICAL_PROCESS	2	2	chewing
NCT0020127911	NCT00201279_11_T0	ORGAN	12	13	oral cavity
NCT0020127912	NCT00201279_12_T0	PHENOTYPE	5	6	primary tumors
NCT0020127913	NCT00201279_13_T0	GENE	18	18	al
NCT0020127913	NCT00201279_13_T1	GENE	3	3	RA
NCT0020127913	NCT00201279_13_T2	GENE	17	17	et
NCT0020127913	NCT00201279_13_T3	PHENOTYPE	28	28	cancers
NCT0020127913	NCT00201279_13_T4	GENE	12	12	has
NCT0020127913	NCT00201279_13_T5	PHENOTYPE	7	10	head and neck cancer
NCT0020127915	NCT00201279_15_T0	GENE	5	5	RA
NCT0020127916	NCT00201279_16_T0	PHENOTYPE	4	6	oral cavity cancer
NCT0020129211	NCT00201292_11_T0	COMPOUND	4	4	glucose
NCT0020129211	NCT00201292_11_T1	GENE	5	5	insulin
NCT0020129211	NCT00201292_11_T2	PHENOTYPE	0	0	Diabetes
NCT0020129211	NCT00201292_11_T3	GENE	6	6	leptin
NCT0020129218	NCT00201292_18_T0	PHENOTYPE	22	22	loved
NCT0020129218	NCT00201292_18_T1	PHENOTYPE	8	8	schizophrenia
NCT0020129218	NCT00201292_18_T2	PHENOTYPE	16	16	dysfunction
NCT0020129219	NCT00201292_19_T0	PHENOTYPE	9	9	symptoms
NCT0020129222	NCT00201292_22_T0	PHENOTYPE	1	1	complication
NCT0020129222	NCT00201292_22_T1	PHENOTYPE	28	28	schizophrenics
NCT0020129222	NCT00201292_22_T2	GENE	17	17	atypical
NCT0020129224	NCT00201292_24_T0	PHENOTYPE	17	17	ketoacidosis
NCT0020129231	NCT00201292_31_T0	PHENOTYPE	4	4	plethora
NCT0020129231	NCT00201292_31_T1	PHENOTYPE	12	12	secondary
NCT0020129239	NCT00201292_39_T0	PHENOTYPE	13	13	overweight
NCT0020129239	NCT00201292_39_T1	PHENOTYPE	11	11	obesity
NCT0020129242	NCT00201292_42_T0	BIOLOGICAL_PROCESS	37	37	metabolism
NCT0020129242	NCT00201292_42_T1	PHENOTYPE	29	30	insulin resistance
NCT0020129242	NCT00201292_42_T2	CELL	21	23	pancreatic beta cells
NCT0020129242	NCT00201292_42_T3	ORGAN	46	48	central nervous system
NCT0020129244	NCT00201292_44_T0	GENE	3	3	Loh
NCT0020129244	NCT00201292_44_T1	GENE	4	4	has
NCT0020129244	NCT00201292_44_T2	GENE	2	2	Dr
NCT0020129245	NCT00201292_45_T0	PHENOTYPE	8	8	alcoholism
NCT0020129245	NCT00201292_45_T1	PHENOTYPE	11	12	drug abuse
NCT0020129246	NCT00201292_46_T0	GENE	2	2	extended
NCT0020129249	NCT00201292_49_T0	GENE	15	15	atypical
NCT0020129249	NCT00201292_49_T1	PHENOTYPE	5	5	schizophrenia
NCT0020129252	NCT00201292_52_T0	PHENOTYPE	8	8	schizophrenics
NCT0020129263	NCT00201292_63_T0	GENE	0	0	III
NCT0020129264	NCT00201292_64_T0	PHENOTYPE	6	7	substance use
NCT0020129265	NCT00201292_65_T0	PHENOTYPE	53	53	schizophrenia
NCT0020129265	NCT00201292_65_T1	GENE	15	15	Dr
NCT0020129265	NCT00201292_65_T2	GENE	17	17	Lan
NCT0020129265	NCT00201292_65_T3	GENE	2	2	ADA
NCT0020129267	NCT00201292_67_T0	PHENOTYPE	25	26	glucose levels
NCT0020129270	NCT00201292_70_T0	PHENOTYPE	21	21	Diabetes
NCT0020129270	NCT00201292_70_T1	PHENOTYPE	16	17	Diabetes Mellitus
NCT0020129270	NCT00201292_70_T2	BIOLOGICAL_PROCESS	28	29	glucose metabolism
NCT0020129271	NCT00201292_71_T0	GENE	33	33	has
NCT0020129275	NCT00201292_75_T0	PHENOTYPE	19	20	plasma glucose
NCT0020129288	NCT00201292_88_T0	PHENOTYPE	3	3	susceptible
NCT0020129289	NCT00201292_89_T0	PHENOTYPE	12	12	estimation
NCT0020129289	NCT00201292_89_T1	PHENOTYPE	3	3	estimations
NCT0020129290	NCT00201292_90_T0	PHENOTYPE	10	10	centers
NCT0020129293	NCT00201292_93_T0	GENE	1	1	leptin
NCT0020129294	NCT00201292_94_T0	COMPOUND	12	12	1st
NCT0020129296	NCT00201292_96_T0	COMPOUND	7	7	2
NCT0020129298	NCT00201292_98_T0	PHENOTYPE	9	10	diabetic complications
NCT00201292100	NCT00201292_100_T0	PHENOTYPE	21	21	diseases
NCT00201292103	NCT00201292_103_T0	GENE	18	18	putative
NCT00201292107	NCT00201292_107_T0	PHENOTYPE	3	3	schizophrenia
NCT00201292107	NCT00201292_107_T1	PHENOTYPE	0	1	Diabetes mellitus
NCT00201292108	NCT00201292_108_T0	GENE	3	3	47
NCT00201292111	NCT00201292_111_T0	GENE	2	2	157
NCT00201292113	NCT00201292_113_T0	COMPOUND	1	1	O
NCT00201292115	NCT00201292_115_T0	PHENOTYPE	0	2	Metabolic Syndrome X
NCT00201292118	NCT00201292_118_T0	COMPOUND	7	7	O
NCT00201292120	NCT00201292_120_T0	GENE	2	2	59
NCT00201292123	NCT00201292_123_T0	GENE	3	3	26
NCT00201292123	NCT00201292_123_T1	PHENOTYPE	0	0	Diabetes
NCT00201292125	NCT00201292_125_T0	GENE	3	3	SS
NCT00201292128	NCT00201292_128_T0	GENE	1	1	19
NCT002013051	NCT00201305_1_T0	PHENOTYPE	12	12	toxicity
NCT002013051	NCT00201305_1_T1	PHENOTYPE	8	8	secondary
NCT002013051	NCT00201305_1_T2	PHENOTYPE	15	16	disease progression
NCT002013053	NCT00201305_3_T0	PHENOTYPE	26	26	toxicity
NCT002013053	NCT00201305_3_T1	PHENOTYPE	16	16	cancers
NCT002013053	NCT00201305_3_T2	PHENOTYPE	21	22	breast cancers
NCT002013056	NCT00201305_6_T0	ORGAN	6	6	pancreas
NCT002013056	NCT00201305_6_T1	PHENOTYPE	13	13	cancers
NCT002013056	NCT00201305_6_T2	COMPOUND	28	28	gemcitabine
NCT002013056	NCT00201305_6_T3	ORGAN	2	3	biliary tract
NCT002013056	NCT00201305_6_T4	PHENOTYPE	34	38	cancer of the biliary tract
NCT002013057	NCT00201305_7_T0	COMPOUND	10	10	gemcitabine
NCT002013057	NCT00201305_7_T1	PHENOTYPE	21	23	metastatic pancreatic adenocarcinoma
NCT002013059	NCT00201305_9_T0	PHENOTYPE	11	11	toxicity
NCT0020130510	NCT00201305_10_T0	PHENOTYPE	30	30	tumor
NCT0020130510	NCT00201305_10_T1	ORGAN	12	13	biliary tract
NCT0020130510	NCT00201305_10_T2	PHENOTYPE	8	9	metastatic carcinoma
NCT0020130512	NCT00201305_12_T0	COMPOUND	6	6	gemcitabine
NCT0020130512	NCT00201305_12_T1	COMPOUND	17	17	leucovorin
NCT0020130513	NCT00201305_13_T0	COMPOUND	3	3	gemcitabine
NCT0020130514	NCT00201305_14_T0	COMPOUND	9	9	leucovorin
NCT0020130515	NCT00201305_15_T0	PHENOTYPE	8	8	toxicity
NCT0020130516	NCT00201305_16_T0	GENE	5	5	CR
NCT0020130516	NCT00201305_16_T1	GENE	17	17	CR
NCT0020130519	NCT00201305_19_T0	PHENOTYPE	2	2	carcinoma
NCT0020130519	NCT00201305_19_T1	PHENOTYPE	11	11	cholangiocarcinoma
NCT0020130519	NCT00201305_19_T2	ORGAN	5	6	biliary tract
NCT0020130519	NCT00201305_19_T3	PHENOTYPE	8	9	gallbladder carcinoma
NCT0020130520	NCT00201305_20_T0	PHENOTYPE	19	19	metastasis
NCT0020130522	NCT00201305_22_T0	PHENOTYPE	1	2	measurable disease
NCT0020130531	NCT00201305_31_T0	GENE	3	3	70
NCT0020130531	NCT00201305_31_T1	ORGAN	0	0	Serum
NCT0020130531	NCT00201305_31_T2	PHENOTYPE	1	2	triglyceride level
NCT0020130541	NCT00201305_41_T0	PHENOTYPE	4	5	leptomeningeal metastases
NCT0020130543	NCT00201305_43_T0	PHENOTYPE	4	5	cardiac arrhythmia
NCT0020130543	NCT00201305_43_T1	PHENOTYPE	7	9	acute myocardial infarction
NCT0020130545	NCT00201305_45_T0	PHENOTYPE	5	5	diseases
NCT002013183	NCT00201318_3_T0	COMPOUND	6	6	lamivudine
NCT002013183	NCT00201318_3_T1	PHENOTYPE	11	12	hepatitis B
NCT002013183	NCT00201318_3_T2	PHENOTYPE	17	18	hepatic failure
NCT002013187	NCT00201318_7_T0	GENE	9	9	CHOP
NCT002013187	NCT00201318_7_T1	COMPOUND	3	4	CHOP regimen
NCT002013189	NCT00201318_9_T0	GENE	3	3	1.4
NCT0020131811	NCT00201318_11_T0	GENE	2	2	1.1
NCT0020131811	NCT00201318_11_T1	GENE	1	1	1.7
NCT0020131812	NCT00201318_12_T0	GENE	0	0	1.2
NCT0020131812	NCT00201318_12_T1	GENE	4	4	CR
NCT0020131813	NCT00201318_13_T0	GENE	7	7	PR
NCT0020131813	NCT00201318_13_T1	GENE	0	0	1.3
NCT0020131815	NCT00201318_15_T0	GENE	7	7	1.4
NCT0020131815	NCT00201318_15_T1	PHENOTYPE	6	6	localized
NCT0020131818	NCT00201318_18_T0	PHENOTYPE	7	7	hepatitis
NCT0020131819	NCT00201318_19_T0	COMPOUND	5	5	lamivudine
NCT0020131821	NCT00201318_21_T0	GENE	10	10	7.2
NCT0020131821	NCT00201318_21_T1	PHENOTYPE	5	5	hepatitis
NCT0020131821	NCT00201318_21_T2	PHENOTYPE	22	22	hepatitis
NCT0020131821	NCT00201318_21_T3	PHENOTYPE	24	24	resolved
NCT0020131821	NCT00201318_21_T4	COMPOUND	11	11	lamivudine
NCT0020131822	NCT00201318_22_T0	COMPOUND	1	1	lamivudine
NCT0020131823	NCT00201318_23_T0	GENE	46	46	3.0
NCT0020131823	NCT00201318_23_T1	PHENOTYPE	51	51	Toxicity
NCT0020131823	NCT00201318_23_T2	GENE	49	49	3-1
NCT0020131823	NCT00201318_23_T3	PHENOTYPE	9	9	hepatitis
NCT0020131823	NCT00201318_23_T4	CELL	67	67	Platelet
NCT0020131823	NCT00201318_23_T5	GENE	3	3	has
NCT0020131823	NCT00201318_23_T6	PHENOTYPE	12	12	HBV
NCT0020131823	NCT00201318_23_T7	PHENOTYPE	20	20	HBV
NCT0020131823	NCT00201318_23_T8	PHENOTYPE	37	37	HBV
NCT0020131823	NCT00201318_23_T9	GENE	63	63	AGC
NCT0020131823	NCT00201318_23_T10	COMPOUND	43	43	lamivudine
NCT0020131826	NCT00201318_26_T0	CELL	6	6	Platelet
NCT0020131829	NCT00201318_29_T0	PHENOTYPE	1	1	hepatitis
NCT0020131829	NCT00201318_29_T1	PHENOTYPE	3	3	hepatitis
NCT0020131829	NCT00201318_29_T2	ORGAN	19	19	serum
NCT0020131829	NCT00201318_29_T3	ORGAN	32	32	serum
NCT0020131829	NCT00201318_29_T4	PHENOTYPE	10	10	HBV
NCT0020131829	NCT00201318_29_T5	PHENOTYPE	20	20	HBV
NCT0020131829	NCT00201318_29_T6	PHENOTYPE	26	26	HBV
NCT0020131830	NCT00201318_30_T0	GENE	6	6	has
NCT0020131830	NCT00201318_30_T1	ORGAN	25	25	serum
NCT0020131830	NCT00201318_30_T2	PHENOTYPE	12	12	hepatitis
NCT0020131830	NCT00201318_30_T3	PHENOTYPE	39	39	hepatitis
NCT0020131830	NCT00201318_30_T4	PHENOTYPE	15	15	HBV
NCT0020131830	NCT00201318_30_T5	PHENOTYPE	22	22	HBV
NCT0020131830	NCT00201318_30_T6	PHENOTYPE	26	26	HBV
NCT0020131830	NCT00201318_30_T7	PHENOTYPE	43	43	HBV
NCT0020131836	NCT00201318_36_T0	PHENOTYPE	9	9	toxicity
NCT0020131836	NCT00201318_36_T1	GENE	8	8	III
NCT0020131837	NCT00201318_37_T0	PHENOTYPE	12	14	nausea and vomiting
NCT0020131838	NCT00201318_38_T0	PHENOTYPE	2	2	toxicity
NCT0020131838	NCT00201318_38_T1	GENE	7	7	III
NCT0020131838	NCT00201318_38_T2	COMPOUND	14	14	cyclophosphamide
NCT0020131838	NCT00201318_38_T3	GENE	19	19	reduced
NCT0020131838	NCT00201318_38_T4	COMPOUND	16	16	doxorubicin
NCT0020131840	NCT00201318_40_T0	GENE	7	7	II
NCT0020131840	NCT00201318_40_T1	PHENOTYPE	8	8	cardiotoxicity
NCT0020131840	NCT00201318_40_T2	COMPOUND	5	5	NCI
NCT0020131840	NCT00201318_40_T3	GENE	0	0	3.4
NCT0020131840	NCT00201318_40_T4	GENE	12	12	reduced
NCT0020131840	NCT00201318_40_T5	COMPOUND	9	9	doxorubicin
NCT0020131840	NCT00201318_40_T6	PHENOTYPE	1	1	Cardiotoxicity
NCT0020131841	NCT00201318_41_T0	PHENOTYPE	1	1	cardiotoxicity
NCT0020131841	NCT00201318_41_T1	PHENOTYPE	3	3	resolved
NCT0020131842	NCT00201318_42_T0	PHENOTYPE	6	6	cardiotoxicity
NCT0020131842	NCT00201318_42_T1	COMPOUND	3	3	NCI
NCT0020131842	NCT00201318_42_T2	GENE	5	5	III
NCT0020131842	NCT00201318_42_T3	COMPOUND	8	8	doxorubicin
NCT0020131843	NCT00201318_43_T0	PHENOTYPE	8	8	toxicity
NCT0020131843	NCT00201318_43_T1	PHENOTYPE	2	2	Toxicity
NCT0020131843	NCT00201318_43_T2	GENE	0	0	3.5
NCT0020131844	NCT00201318_44_T0	GENE	0	0	4.0
NCT0020131844	NCT00201318_44_T1	GENE	2	2	FOR
NCT0020131848	NCT00201318_48_T0	PHENOTYPE	0	0	Progressive
NCT0020131850	NCT00201318_50_T0	PHENOTYPE	4	4	toxicity
NCT0020131850	NCT00201318_50_T1	PHENOTYPE	2	2	complication
NCT0020131855	NCT00201318_55_T0	GENE	0	0	5.0
NCT0020131868	NCT00201318_68_T0	PHENOTYPE	7	7	peripheral
NCT0020131868	NCT00201318_68_T1	CELL	3	3	Platelet
NCT0020131868	NCT00201318_68_T2	GENE	0	0	AGC
NCT0020131871	NCT00201318_71_T0	GENE	1	1	aminotransferase
NCT0020131872	NCT00201318_72_T0	COMPOUND	1	1	creatinine
NCT0020131872	NCT00201318_72_T1	ORGAN	0	0	Serum
NCT0020131872	NCT00201318_72_T2	COMPOUND	5	5	urea
NCT0020131878	NCT00201318_78_T0	PHENOTYPE	4	5	brain metastasis
NCT0020131880	NCT00201318_80_T0	PHENOTYPE	8	9	liver cirrhosis
NCT0020131882	NCT00201318_82_T0	ORGAN	7	7	Heart
NCT0020131882	NCT00201318_82_T1	GENE	12	12	II
NCT0020131882	NCT00201318_82_T2	PHENOTYPE	8	8	Association
NCT002013313	NCT00201331_3_T0	PHENOTYPE	6	6	inhibition
NCT002013313	NCT00201331_3_T1	GENE	3	3	TS
NCT002013313	NCT00201331_3_T2	GENE	8	8	TS
NCT002013315	NCT00201331_5_T0	PHENOTYPE	9	10	colon adenocarcinoma
NCT002013315	NCT00201331_5_T1	PHENOTYPE	15	16	metastatic disease
NCT002013317	NCT00201331_7_T0	ORGAN	14	14	colon
NCT002013318	NCT00201331_8_T0	COMPOUND	29	29	vincristine
NCT002013318	NCT00201331_8_T1	COMPOUND	10	10	leucovorin
NCT002013318	NCT00201331_8_T2	PHENOTYPE	16	17	cancer recurrence
NCT002013318	NCT00201331_8_T3	PHENOTYPE	15	16	colon cancer
NCT002013319	NCT00201331_9_T0	GENE	35	35	II
NCT002013319	NCT00201331_9_T1	GENE	4	4	IMPACT
NCT002013319	NCT00201331_9_T2	GENE	37	37	III
NCT002013319	NCT00201331_9_T3	COMPOUND	15	15	leucovorin
NCT002013319	NCT00201331_9_T4	PHENOTYPE	38	39	colon cancer
NCT0020133111	NCT00201331_11_T0	ORGAN	17	17	colon
NCT0020133111	NCT00201331_11_T1	COMPOUND	12	12	leucovorin
NCT0020133112	NCT00201331_12_T0	GENE	2	2	had
NCT0020133112	NCT00201331_12_T1	COMPOUND	8	8	leucovorin
NCT0020133112	NCT00201331_12_T2	COMPOUND	40	40	leucovorin
NCT0020133114	NCT00201331_14_T0	COMPOUND	9	9	fluoropyrimidine
NCT0020133114	NCT00201331_14_T1	PHENOTYPE	23	24	colorectal cancer
NCT0020133116	NCT00201331_16_T0	COMPOUND	7	7	fluoropyrimidine
NCT0020133116	NCT00201331_16_T1	GENE	9	9	has
NCT0020133116	NCT00201331_16_T2	PHENOTYPE	8	8	cytotoxicity
NCT0020133116	NCT00201331_16_T3	GENE	4	4	TS
NCT0020133119	NCT00201331_19_T0	PHENOTYPE	3	4	colon cancer
NCT0020133120	NCT00201331_20_T0	ORGAN	5	5	colon
NCT0020133120	NCT00201331_20_T1	PHENOTYPE	2	2	adenocarcinoma
NCT0020133121	NCT00201331_21_T0	GENE	2	2	LN
NCT0020133125	NCT00201331_25_T0	PHENOTYPE	15	15	ESRD
NCT0020133125	NCT00201331_25_T1	PHENOTYPE	14	14	psychosis
NCT0020133125	NCT00201331_25_T2	PHENOTYPE	16	17	heart failure
NCT0020133125	NCT00201331_25_T3	PHENOTYPE	21	22	liver cirrhosis
NCT0020133125	NCT00201331_25_T4	PHENOTYPE	19	20	class III
NCT0020133126	NCT00201331_26_T0	PHENOTYPE	3	3	occlusion
NCT0020133126	NCT00201331_26_T1	PHENOTYPE	0	1	Intestinal obstruction
NCT0020133128	NCT00201331_28_T0	PHENOTYPE	0	0	Allergy
NCT0020133128	NCT00201331_28_T1	COMPOUND	4	4	leucovorin
NCT002013445	NCT00201344_5_T0	PHENOTYPE	10	13	head and neck cancer
NCT002013571	NCT00201357_1_T0	PHENOTYPE	0	0	Secondary
NCT002013571	NCT00201357_1_T1	PHENOTYPE	5	5	tumor
NCT002013571	NCT00201357_1_T2	PHENOTYPE	15	15	tumor
NCT002013571	NCT00201357_1_T3	PHENOTYPE	20	21	disease progression
NCT002013571	NCT00201357_1_T4	PHENOTYPE	27	29	quality of life
NCT002013575	NCT00201357_5_T0	COMPOUND	5	5	thalidomide
NCT002013575	NCT00201357_5_T1	COMPOUND	20	20	thalidomide
NCT002013703	NCT00201370_3_T0	PHENOTYPE	22	22	LSIL
NCT002013706	NCT00201370_6_T0	GENE	9	9	pointed
NCT002013706	NCT00201370_6_T1	PHENOTYPE	5	6	malignant disease
NCT0020137014	NCT00201370_14_T0	PHENOTYPE	22	22	LSIL
NCT0020137020	NCT00201370_20_T0	PHENOTYPE	20	20	LSIL
NCT002013831	NCT00201383_1_T0	PHENOTYPE	30	30	HNSCC
NCT002013831	NCT00201383_1_T1	PHENOTYPE	11	13	oral cavity cancer
NCT002013834	NCT00201383_4_T0	PHENOTYPE	0	0	Recurrence
NCT002013836	NCT00201383_6_T0	GENE	1	1	has
NCT002013838	NCT00201383_8_T0	PHENOTYPE	7	7	cancers
NCT002013839	NCT00201383_9_T0	GENE	19	19	III
NCT002013839	NCT00201383_9_T1	GENE	2	2	al
NCT002013839	NCT00201383_9_T2	GENE	21	21	IV
NCT002013839	NCT00201383_9_T3	GENE	1	1	et
NCT002013839	NCT00201383_9_T4	COMPOUND	9	9	cisplatin
NCT002013839	NCT00201383_9_T5	PHENOTYPE	22	25	head and neck cancer
NCT0020138312	NCT00201383_12_T0	GENE	7	7	II
NCT0020138312	NCT00201383_12_T1	GENE	2	2	al
NCT0020138312	NCT00201383_12_T2	COMPOUND	12	12	cisplatin
NCT0020138312	NCT00201383_12_T3	GENE	1	1	et
NCT0020138313	NCT00201383_13_T0	COMPOUND	19	19	cisplatin
NCT0020138314	NCT00201383_14_T0	GENE	8	8	RT
NCT0020138314	NCT00201383_14_T1	GENE	13	13	RT
NCT0020138314	NCT00201383_14_T2	GENE	16	16	has
NCT0020138316	NCT00201383_16_T0	GENE	8	8	RT
NCT0020138316	NCT00201383_16_T1	GENE	35	35	RT
NCT0020138316	NCT00201383_16_T2	PHENOTYPE	28	28	relapse
NCT0020138318	NCT00201383_18_T0	GENE	6	6	RT
NCT0020138319	NCT00201383_19_T0	GENE	0	0	Is
NCT0020138320	NCT00201383_20_T0	PHENOTYPE	0	0	Tolerance
NCT0020138321	NCT00201383_21_T0	PHENOTYPE	6	6	toxicity
NCT0020138321	NCT00201383_21_T1	PHENOTYPE	5	5	acute
NCT0020138321	NCT00201383_21_T2	GENE	11	11	RT
NCT0020138322	NCT00201383_22_T0	PHENOTYPE	23	23	leukopenia
NCT0020138322	NCT00201383_22_T1	PHENOTYPE	8	8	toxicities
NCT0020138322	NCT00201383_22_T2	PHENOTYPE	24	24	anemia
NCT0020138322	NCT00201383_22_T3	PHENOTYPE	27	27	vomiting
NCT0020138322	NCT00201383_22_T4	PHENOTYPE	25	25	nausea
NCT0020138322	NCT00201383_22_T5	PHENOTYPE	20	21	drug toxicities
NCT0020138323	NCT00201383_23_T0	PHENOTYPE	10	11	drug effect
NCT0020138325	NCT00201383_25_T0	COMPOUND	4	4	cisplatin
NCT0020138326	NCT00201383_26_T0	COMPOUND	11	11	cisplatin
NCT0020138328	NCT00201383_28_T0	PHENOTYPE	8	8	toxicity
NCT0020138329	NCT00201383_29_T0	PHENOTYPE	3	3	toxicity
NCT0020138329	NCT00201383_29_T1	GENE	14	14	extended
NCT002013964	NCT00201396_4_T0	GENE	17	17	II
NCT002013964	NCT00201396_4_T1	PHENOTYPE	13	13	metastasis
NCT002013964	NCT00201396_4_T2	GENE	4	4	has
NCT002013967	NCT00201396_7_T0	GENE	8	8	III
NCT0020139610	NCT00201396_10_T0	GENE	29	29	0.8
NCT002014096	NCT00201409_6_T0	PHENOTYPE	5	5	maturation
NCT002014096	NCT00201409_6_T1	CELL	13	13	cells
NCT002014096	NCT00201409_6_T2	PHENOTYPE	21	21	pneumonia
NCT002014096	NCT00201409_6_T3	GENE	0	0	GM-CSF
NCT002014096	NCT00201409_6_T4	CELL	9	10	alveolar macrophages
NCT002014098	NCT00201409_8_T0	TISSUE	16	16	epithelium
NCT002014098	NCT00201409_8_T1	PHENOTYPE	0	2	Acute lung injury
NCT0020140911	NCT00201409_11_T0	GENE	2	2	has
NCT0020140911	NCT00201409_11_T1	GENE	1	1	GM-CSF
NCT0020140913	NCT00201409_13_T0	GENE	22	22	has
NCT0020140913	NCT00201409_13_T1	GENE	10	10	GM-CSF
NCT0020140913	NCT00201409_13_T2	PHENOTYPE	28	29	critically ill
NCT0020140914	NCT00201409_14_T0	GENE	10	10	GM-CSF
NCT0020140915	NCT00201409_15_T0	GENE	20	20	kin
NCT0020140917	NCT00201409_17_T0	GENE	5	5	has
NCT0020140917	NCT00201409_17_T1	GENE	27	27	GM-CSF
NCT0020140917	NCT00201409_17_T2	GENE	6	6	met
NCT0020140919	NCT00201409_19_T0	GENE	7	7	met
NCT0020140920	NCT00201409_20_T0	GENE	12	12	1.2
NCT0020140920	NCT00201409_20_T1	GENE	2	2	GM-CSF
NCT0020140920	NCT00201409_20_T2	PHENOTYPE	15	16	lung injury
NCT0020140922	NCT00201409_22_T0	GENE	27	27	GM-CSF
NCT0020140923	NCT00201409_23_T0	PHENOTYPE	24	24	pneumonia
NCT0020140923	NCT00201409_23_T1	PHENOTYPE	17	17	ARDS
NCT0020140924	NCT00201409_24_T0	PHENOTYPE	12	12	ventilation
NCT002014221	NCT00201422_1_T0	PHENOTYPE	24	24	MALToma
NCT002014221	NCT00201422_1_T1	PHENOTYPE	13	13	regression
NCT002014221	NCT00201422_1_T2	PHENOTYPE	5	6	Helicobacter pylori
NCT002014221	NCT00201422_1_T3	PHENOTYPE	18	19	disease progression
NCT002014222	NCT00201422_2_T0	GENE	14	14	IE
NCT002014224	NCT00201422_4_T0	PHENOTYPE	3	3	peripheral
NCT002014224	NCT00201422_4_T1	PHENOTYPE	1	1	enlargement
NCT002014224	NCT00201422_4_T2	TISSUE	6	7	lymph node
NCT002014225	NCT00201422_5_T0	PHENOTYPE	0	0	Peripheral
NCT002014225	NCT00201422_5_T1	PHENOTYPE	7	7	lymphomatous
NCT002014226	NCT00201422_6_T0	PHENOTYPE	7	7	adenopathy
NCT002014227	NCT00201422_7_T0	ORGAN	3	3	liver
NCT002014227	NCT00201422_7_T1	TISSUE	5	5	spleen
NCT002014351	NCT00201435_1_T0	PHENOTYPE	10	12	quality of life
NCT002014354	NCT00201435_4_T0	PHENOTYPE	8	9	metastatic disease
NCT002014354	NCT00201435_4_T1	PHENOTYPE	13	14	bone metastases
NCT002014354	NCT00201435_4_T2	PHENOTYPE	1	2	breast cancer
NCT002014356	NCT00201435_6_T0	GENE	7	7	TTF
NCT002014359	NCT00201435_9_T0	COMPOUND	5	5	bisphosphonates
NCT002014359	NCT00201435_9_T1	GENE	11	11	has
NCT0020143511	NCT00201435_11_T0	PHENOTYPE	0	0	Evaluable
NCT0020143511	NCT00201435_11_T1	PHENOTYPE	1	1	metastases
NCT002014483	NCT00201448_3_T0	PHENOTYPE	10	11	Hepatitis A
NCT002014485	NCT00201448_5_T0	GENE	3	3	saliva
NCT002014485	NCT00201448_5_T1	GENE	10	10	1/6
NCT0020144818	NCT00201448_18_T0	PHENOTYPE	12	13	hepatitis A
NCT0020144819	NCT00201448_19_T0	PHENOTYPE	2	2	seronegative
NCT0020144827	NCT00201448_27_T0	GENE	6	6	sera
NCT0020144827	NCT00201448_27_T1	PHENOTYPE	0	0	Seronegative
NCT0020144834	NCT00201448_34_T0	PHENOTYPE	19	19	acute
NCT0020144834	NCT00201448_34_T1	PHENOTYPE	20	20	illnesses
NCT0020144835	NCT00201448_35_T0	GENE	1	1	saliva
NCT0020144835	NCT00201448_35_T1	ORGAN	12	12	serum
NCT0020144837	NCT00201448_37_T0	GENE	4	4	PCR
NCT0020144845	NCT00201448_45_T0	ORGAN	1	1	serum
NCT0020144847	NCT00201448_47_T0	GENE	5	5	saliva
NCT0020144853	NCT00201448_53_T0	PHENOTYPE	2	2	IUD
NCT0020144857	NCT00201448_57_T0	PHENOTYPE	1	1	bilateral
NCT0020144858	NCT00201448_58_T0	PHENOTYPE	0	0	Infertility
NCT0020144860	NCT00201448_60_T0	PHENOTYPE	0	2	Positive pregnancy test
NCT0020144862	NCT00201448_62_T0	BIOLOGICAL_PROCESS	6	6	phlebotomy
NCT0020144866	NCT00201448_66_T0	PHENOTYPE	7	8	metabolic disorders
NCT0020144866	NCT00201448_66_T1	PHENOTYPE	3	4	cardiopulmonary diseases
NCT0020144868	NCT00201448_68_T0	PHENOTYPE	7	7	psychosis
NCT002014610	NCT00201461_0_T0	PHENOTYPE	13	13	TIA
NCT002014610	NCT00201461_0_T1	PHENOTYPE	27	29	Patent Foramen Ovale
NCT002014740	NCT00201474_0_T0	PHENOTYPE	0	0	Acute
NCT002014740	NCT00201474_0_T1	PHENOTYPE	2	3	Organic Disorders
NCT002014741	NCT00201474_1_T0	PHENOTYPE	1	1	Disorders
NCT002014745	NCT00201474_5_T0	PHENOTYPE	11	11	epilepsy
NCT002014745	NCT00201474_5_T1	PHENOTYPE	14	15	brain dysfunctions
NCT002014746	NCT00201474_6_T0	GENE	12	12	axis
NCT002014746	NCT00201474_6_T1	PHENOTYPE	37	39	major depressive disorder
NCT002014749	NCT00201474_9_T0	GENE	0	0	MRI
NCT002014876	NCT00201487_6_T0	COMPOUND	5	5	choline
NCT002014877	NCT00201487_7_T0	GENE	8	8	phantom
NCT002014877	NCT00201487_7_T1	COMPOUND	15	15	choline
NCT002015000	NCT00201500_0_T0	PHENOTYPE	6	6	Preeclampsia
NCT002015131	NCT00201513_1_T0	ORGAN	9	9	spine
NCT002015132	NCT00201513_2_T0	TISSUE	2	2	muscles
NCT002015132	NCT00201513_2_T1	ORGAN	14	14	spine
NCT002015132	NCT00201513_2_T2	ORGAN	24	25	spinal column
NCT002015261	NCT00201526_1_T0	PHENOTYPE	10	10	disorders
NCT002015263	NCT00201526_3_T0	GENE	6	6	has
NCT002015264	NCT00201526_4_T0	PHENOTYPE	15	16	bipolar illness
NCT002015264	NCT00201526_4_T1	PHENOTYPE	19	21	substance use disorders
NCT002015265	NCT00201526_5_T0	PHENOTYPE	2	2	centers
NCT002015267	NCT00201526_7_T0	GENE	4	4	MRI
NCT002015392	NCT00201539_2_T0	COMPOUND	9	9	morphine
NCT002015395	NCT00201539_5_T0	PHENOTYPE	40	40	analgesia
NCT002015395	NCT00201539_5_T1	COMPOUND	30	30	morphine
NCT002015396	NCT00201539_6_T0	COMPOUND	9	9	morphine
NCT002015396	NCT00201539_6_T1	COMPOUND	15	15	morphine
NCT002015396	NCT00201539_6_T2	GENE	8	8	SR
NCT002015397	NCT00201539_7_T0	GENE	6	6	EPAC
NCT002015397	NCT00201539_7_T1	COMPOUND	15	15	morphine
NCT002015398	NCT00201539_8_T0	PHENOTYPE	16	16	analgesia
NCT002015398	NCT00201539_8_T1	COMPOUND	15	15	morphine
NCT0020153910	NCT00201539_10_T0	GENE	2	2	al
NCT0020153910	NCT00201539_10_T1	GENE	3	3	has
NCT0020153910	NCT00201539_10_T2	GENE	1	1	et
NCT0020153914	NCT00201539_14_T0	COMPOUND	18	18	morphine
NCT002015651	NCT00201565_1_T0	PHENOTYPE	22	22	atherosclerosis
NCT002015781	NCT00201578_1_T0	PHENOTYPE	16	16	toxic
NCT002015781	NCT00201578_1_T1	GENE	1	1	has
NCT002015783	NCT00201578_3_T0	PHENOTYPE	35	35	acute
NCT002015783	NCT00201578_3_T1	PHENOTYPE	37	38	viral hepatitis
NCT002015784	NCT00201578_4_T0	PHENOTYPE	14	14	hepatitis
NCT002015785	NCT00201578_5_T0	PHENOTYPE	14	15	viral hepatitis
NCT002015786	NCT00201578_6_T0	PHENOTYPE	10	10	hepatitis
NCT002015786	NCT00201578_6_T1	PHENOTYPE	4	5	adverse effects
NCT002015787	NCT00201578_7_T0	PHENOTYPE	18	19	viral hepatitis
NCT002015788	NCT00201578_8_T0	PHENOTYPE	51	52	adverse effect
NCT002015789	NCT00201578_9_T0	GENE	2	2	had
NCT0020157810	NCT00201578_10_T0	GENE	21	21	ICP
NCT0020157810	NCT00201578_10_T1	ORGAN	18	18	plasma
NCT0020157811	NCT00201578_11_T0	PHENOTYPE	16	16	trauma
NCT0020157811	NCT00201578_11_T1	PHENOTYPE	18	18	fracture
NCT0020157814	NCT00201578_14_T0	PHENOTYPE	7	8	viral hepatitis
NCT0020157817	NCT00201578_17_T0	PHENOTYPE	12	12	regression
NCT002015916	NCT00201591_6_T0	GENE	1	1	had
NCT002015918	NCT00201591_8_T0	ORGAN	0	0	Heart
NCT002015918	NCT00201591_8_T1	GENE	8	8	max
NCT002015918	NCT00201591_8_T2	GENE	2	2	HR
NCT002015918	NCT00201591_8_T3	GENE	9	9	HR
NCT002016172	NCT00201617_2_T0	COMPOUND	9	9	BAHA
NCT002016178	NCT00201617_8_T0	PHENOTYPE	0	0	Adult-onset
NCT002016178	NCT00201617_8_T1	PHENOTYPE	1	1	deafness
NCT002016302	NCT00201630_2_T0	PHENOTYPE	11	11	symptoms
NCT002016304	NCT00201630_4_T0	PHENOTYPE	1	1	symptoms
NCT002016309	NCT00201630_9_T0	COMPOUND	24	24	alfuzosin
NCT002016309	NCT00201630_9_T1	GENE	6	6	receptor
NCT002016309	NCT00201630_9_T2	COMPOUND	20	20	diaminopropyl
NCT002016309	NCT00201630_9_T3	COMPOUND	13	13	piperidine
NCT0020163010	NCT00201630_10_T0	COMPOUND	10	10	alfuzosin
NCT0020163010	NCT00201630_10_T1	GENE	6	6	receptor
NCT0020163010	NCT00201630_10_T2	GENE	19	19	receptor
NCT0020163010	NCT00201630_10_T3	COMPOUND	12	12	terazosin
NCT0020163010	NCT00201630_10_T4	COMPOUND	14	14	doxazosin
NCT0020163014	NCT00201630_14_T0	PHENOTYPE	23	23	trauma
NCT0020163014	NCT00201630_14_T1	PHENOTYPE	9	9	symptoms
NCT0020163014	NCT00201630_14_T2	PHENOTYPE	18	18	edema
NCT0020163014	NCT00201630_14_T3	PHENOTYPE	20	20	inflammation
NCT0020163022	NCT00201630_22_T0	PHENOTYPE	14	14	symptoms
NCT0020163023	NCT00201630_23_T0	PHENOTYPE	7	7	symptoms
NCT0020163023	NCT00201630_23_T1	PHENOTYPE	4	4	severity
NCT002016433	NCT00201643_3_T0	PHENOTYPE	0	1	Preterm delivery
NCT002016435	NCT00201643_5_T0	GENE	11	11	ACS
NCT002016435	NCT00201643_5_T1	PHENOTYPE	14	16	threatened preterm labor
NCT002016438	NCT00201643_8_T0	BIOLOGICAL_PROCESS	19	19	gestation
NCT002016438	NCT00201643_8_T1	PHENOTYPE	25	26	preterm delivery
NCT002016439	NCT00201643_9_T0	PHENOTYPE	33	34	preterm delivery
NCT0020164313	NCT00201643_13_T0	GENE	28	28	ANC
NCT0020164313	NCT00201643_13_T1	BIOLOGICAL_PROCESS	15	15	gestation
NCT0020164313	NCT00201643_13_T2	PHENOTYPE	19	20	preterm delivery
NCT0020164314	NCT00201643_14_T0	PHENOTYPE	4	5	preterm delivery
NCT002016562	NCT00201656_2_T0	GENE	2	2	al
NCT002016562	NCT00201656_2_T1	GENE	1	1	et
NCT002016563	NCT00201656_3_T0	GENE	15	15	27
NCT002016563	NCT00201656_3_T1	PHENOTYPE	6	6	PROM
NCT002016563	NCT00201656_3_T2	PHENOTYPE	2	5	premature rupture of membranes
NCT002016564	NCT00201656_4_T0	PHENOTYPE	0	1	Preterm birth
NCT002016564	NCT00201656_4_T1	PHENOTYPE	10	11	neonatal deaths
NCT002016564	NCT00201656_4_T2	PHENOTYPE	17	18	congenital malformations
NCT0020165610	NCT00201656_10_T0	GENE	2	2	has
NCT0020165611	NCT00201656_11_T0	PHENOTYPE	16	16	complication
NCT0020165612	NCT00201656_12_T0	PHENOTYPE	3	3	practices
NCT0020165614	NCT00201656_14_T0	TISSUE	46	46	membranes
NCT0020165614	NCT00201656_14_T1	PHENOTYPE	47	47	rupture
NCT0020165619	NCT00201656_19_T0	TISSUE	3	3	membranes
NCT0020165619	NCT00201656_19_T1	PHENOTYPE	0	1	Spontaneous rupture
NCT0020165620	NCT00201656_20_T0	BIOLOGICAL_PROCESS	3	3	gestation
NCT0020165624	NCT00201656_24_T0	PHENOTYPE	0	1	Placenta previa
NCT0020165624	NCT00201656_24_T1	PHENOTYPE	4	5	vaginal bleeding
NCT0020165628	NCT00201656_28_T0	PHENOTYPE	1	2	fetal anomaly
NCT002016692	NCT00201669_2_T0	COMPOUND	7	7	clofarabine
NCT002016692	NCT00201669_2_T1	COMPOUND	19	19	cladribine
NCT002016692	NCT00201669_2_T2	COMPOUND	17	17	fludarabine
NCT002016694	NCT00201669_4_T0	COMPOUND	4	4	clofarabine
NCT002016694	NCT00201669_4_T1	GENE	5	5	has
NCT002016694	NCT00201669_4_T2	PHENOTYPE	12	13	blood cancers
NCT002016694	NCT00201669_4_T3	PHENOTYPE	15	16	solid tumors
NCT002016695	NCT00201669_5_T0	COMPOUND	10	10	clofarabine
NCT002016695	NCT00201669_5_T1	PHENOTYPE	1	1	tumor
NCT002016695	NCT00201669_5_T2	PHENOTYPE	19	19	lymphoma
NCT002016698	NCT00201669_8_T0	COMPOUND	6	6	clofarabine
NCT002016698	NCT00201669_8_T1	PHENOTYPE	0	0	Toxicities
NCT002016698	NCT00201669_8_T2	GENE	12	12	GM-CSF
NCT002016699	NCT00201669_9_T0	GENE	0	0	GM-CSF
NCT002016699	NCT00201669_9_T1	CELL	10	12	white blood cells
NCT0020166910	NCT00201669_10_T0	PHENOTYPE	7	7	tumor
NCT0020166910	NCT00201669_10_T1	PHENOTYPE	19	19	tumor
NCT0020166910	NCT00201669_10_T2	BIOLOGICAL_PROCESS	12	13	immune response
NCT0020166911	NCT00201669_11_T0	COMPOUND	8	8	clofarabine
NCT0020166915	NCT00201669_15_T0	COMPOUND	9	9	clofarabine
NCT0020166916	NCT00201669_16_T0	COMPOUND	12	12	clofarabine
NCT0020166917	NCT00201669_17_T0	COMPOUND	15	15	clofarabine
NCT0020166917	NCT00201669_17_T1	GENE	4	4	reduced
NCT002016822	NCT00201682_2_T0	PHENOTYPE	11	11	lymphomas
NCT002016824	NCT00201682_4_T0	CELL	15	15	cells
NCT002016825	NCT00201682_5_T0	GENE	6	6	CD20
NCT002016825	NCT00201682_5_T1	CELL	16	16	B-cells
NCT002016826	NCT00201682_6_T0	CELL	14	14	B-cells
NCT002016826	NCT00201682_6_T1	ORGAN	7	8	immune system
NCT0020168210	NCT00201682_10_T0	PHENOTYPE	11	11	toxicity
NCT0020168212	NCT00201682_12_T0	CELL	5	5	cells
NCT0020168212	NCT00201682_12_T1	PHENOTYPE	4	4	tumor
NCT0020168212	NCT00201682_12_T2	ORGAN	8	9	immune system
NCT002016953	NCT00201695_3_T0	COMPOUND	4	5	arsenic trioxide
NCT002016954	NCT00201695_4_T0	GENE	22	22	has
NCT002016954	NCT00201695_4_T1	COMPOUND	4	5	arsenic trioxide
NCT002016955	NCT00201695_5_T0	GENE	15	15	II
NCT002016955	NCT00201695_5_T1	GENE	6	6	has
NCT002016955	NCT00201695_5_T2	COMPOUND	4	5	arsenic trioxide
NCT002016956	NCT00201695_6_T0	COMPOUND	13	13	dexamethasone
NCT002016956	NCT00201695_6_T1	COMPOUND	11	11	vincristine
NCT002016956	NCT00201695_6_T2	COMPOUND	10	10	doxorubicin
NCT002016956	NCT00201695_6_T3	PHENOTYPE	22	23	multiple myeloma
NCT002016956	NCT00201695_6_T4	COMPOUND	15	16	arsenic trioxide
NCT002016957	NCT00201695_7_T0	ORGAN	20	20	marrow
NCT002016957	NCT00201695_7_T1	PHENOTYPE	4	4	tumor
NCT002016958	NCT00201695_8_T0	COMPOUND	12	12	dexamethasone
NCT002016958	NCT00201695_8_T1	COMPOUND	10	10	vincristine
NCT002016958	NCT00201695_8_T2	COMPOUND	9	9	doxorubicin
NCT002016958	NCT00201695_8_T3	COMPOUND	7	8	arsenic trioxide
NCT002016959	NCT00201695_9_T0	COMPOUND	12	13	arsenic trioxide
NCT0020169511	NCT00201695_11_T0	COMPOUND	23	23	dexamethasone
NCT0020169511	NCT00201695_11_T1	COMPOUND	19	19	vincristine
NCT0020169511	NCT00201695_11_T2	COMPOUND	17	17	doxorubicin
NCT0020169511	NCT00201695_11_T3	COMPOUND	30	31	arsenic trioxide
NCT0020169514	NCT00201695_14_T0	PHENOTYPE	15	17	quality of life
NCT002017085	NCT00201708_5_T0	COMPOUND	8	8	docetaxel
NCT002017085	NCT00201708_5_T1	COMPOUND	11	11	cyclophosphamide
NCT002017085	NCT00201708_5_T2	COMPOUND	9	9	doxorubicin
NCT002017086	NCT00201708_6_T0	PHENOTYPE	15	16	breast cancer
NCT002017087	NCT00201708_7_T0	COMPOUND	3	3	docetaxel
NCT002017087	NCT00201708_7_T1	COMPOUND	7	7	cyclophosphamide
NCT002017087	NCT00201708_7_T2	COMPOUND	5	5	doxorubicin
NCT002017088	NCT00201708_8_T0	COMPOUND	3	3	docetaxel
NCT002017088	NCT00201708_8_T1	COMPOUND	7	7	cyclophosphamide
NCT002017088	NCT00201708_8_T2	COMPOUND	5	5	doxorubicin
NCT002017089	NCT00201708_9_T0	COMPOUND	7	7	docetaxel
NCT002017089	NCT00201708_9_T1	GENE	18	18	III
NCT0020170810	NCT00201708_10_T0	COMPOUND	3	3	docetaxel
NCT0020170810	NCT00201708_10_T1	PHENOTYPE	1	1	toxicities
NCT0020170813	NCT00201708_13_T0	COMPOUND	4	4	docetaxel
NCT0020170813	NCT00201708_13_T1	COMPOUND	8	8	cyclophosphamide
NCT0020170813	NCT00201708_13_T2	COMPOUND	6	6	doxorubicin
NCT0020170814	NCT00201708_14_T0	COMPOUND	4	4	docetaxel
NCT0020170814	NCT00201708_14_T1	COMPOUND	8	8	cyclophosphamide
NCT0020170814	NCT00201708_14_T2	COMPOUND	6	6	doxorubicin
NCT0020170815	NCT00201708_15_T0	COMPOUND	6	6	docetaxel
NCT0020170816	NCT00201708_16_T0	COMPOUND	9	9	cyclophosphamide
NCT0020170816	NCT00201708_16_T1	COMPOUND	7	7	doxorubicin
NCT0020170817	NCT00201708_17_T0	COMPOUND	9	9	cyclophosphamide
NCT0020170817	NCT00201708_17_T1	COMPOUND	7	7	doxorubicin
NCT0020170818	NCT00201708_18_T0	COMPOUND	6	6	docetaxel
NCT002017212	NCT00201721_2_T0	PHENOTYPE	23	23	toxicity
NCT002017212	NCT00201721_2_T1	PHENOTYPE	19	19	CLL
NCT002017212	NCT00201721_2_T2	GENE	14	14	has
NCT002017212	NCT00201721_2_T3	ORGAN	12	13	immune system
NCT002017213	NCT00201721_3_T0	COMPOUND	14	14	pentostatin
NCT002017213	NCT00201721_3_T1	COMPOUND	12	12	cyclophosphamide
NCT002017214	NCT00201721_4_T0	PHENOTYPE	13	13	CLL
NCT002017215	NCT00201721_5_T0	PHENOTYPE	20	20	CLL
NCT002017215	NCT00201721_5_T1	COMPOUND	14	14	pentostatin
NCT002017215	NCT00201721_5_T2	COMPOUND	13	13	cyclophosphamide
NCT002017216	NCT00201721_6_T0	PHENOTYPE	9	9	CLL
NCT002017345	NCT00201734_5_T0	PHENOTYPE	8	8	cancers
NCT002017346	NCT00201734_6_T0	PHENOTYPE	16	16	toxicity
NCT002017347	NCT00201734_7_T0	GENE	4	4	II
NCT002017347	NCT00201734_7_T1	COMPOUND	15	15	capecitabine
NCT002017347	NCT00201734_7_T2	COMPOUND	11	11	paclitaxel
NCT002017348	NCT00201734_8_T0	COMPOUND	11	11	paclitaxel
NCT002017348	NCT00201734_8_T1	COMPOUND	9	9	capecitabine
NCT002017349	NCT00201734_9_T0	COMPOUND	17	17	paclitaxel
NCT002017349	NCT00201734_9_T1	COMPOUND	15	15	capecitabine
NCT0020173410	NCT00201734_10_T0	GENE	2	2	II
NCT0020173411	NCT00201734_11_T0	PHENOTYPE	0	0	Toxicities
NCT0020173412	NCT00201734_12_T0	COMPOUND	8	8	capecitabine
NCT0020173412	NCT00201734_12_T1	COMPOUND	11	11	paclitaxel
NCT0020173414	NCT00201734_14_T0	COMPOUND	2	2	paclitaxel
NCT0020173416	NCT00201734_16_T0	COMPOUND	7	7	paclitaxel
NCT0020173416	NCT00201734_16_T1	COMPOUND	15	15	capecitabine
NCT0020173418	NCT00201734_18_T0	COMPOUND	16	16	paclitaxel
NCT0020173418	NCT00201734_18_T1	COMPOUND	14	14	capecitabine
NCT0020173419	NCT00201734_19_T0	GENE	15	15	II
NCT002017472	NCT00201747_2_T0	COMPOUND	14	14	irinotecan
NCT002017473	NCT00201747_3_T0	GENE	24	24	reduced
NCT002017473	NCT00201747_3_T1	GENE	5	5	has
NCT002017474	NCT00201747_4_T0	PHENOTYPE	12	12	tumor
NCT002017474	NCT00201747_4_T1	GENE	10	10	has
NCT002017474	NCT00201747_4_T2	PHENOTYPE	17	18	stomach cancers
NCT002017476	NCT00201747_6_T0	COMPOUND	8	8	irinotecan
NCT002017476	NCT00201747_6_T1	PHENOTYPE	23	24	stomach cancers
NCT002017478	NCT00201747_8_T0	COMPOUND	7	7	irinotecan
NCT0020174711	NCT00201747_11_T0	COMPOUND	10	10	irinotecan
NCT0020174712	NCT00201747_12_T0	COMPOUND	12	12	irinotecan
NCT002017604	NCT00201760_4_T0	PHENOTYPE	12	12	tumor
NCT002017604	NCT00201760_4_T1	COMPOUND	8	8	cisplatin
NCT002017605	NCT00201760_5_T0	PHENOTYPE	9	9	tumor
NCT002017605	NCT00201760_5_T1	COMPOUND	15	15	gemcitabine
NCT002017605	NCT00201760_5_T2	COMPOUND	17	17	cisplatin
NCT002017606	NCT00201760_6_T0	COMPOUND	8	8	gemcitabine
NCT002017606	NCT00201760_6_T1	COMPOUND	41	41	gemcitabine
NCT002017606	NCT00201760_6_T2	COMPOUND	11	11	cisplatin
NCT002017606	NCT00201760_6_T3	PHENOTYPE	28	29	breast cancer
NCT002017607	NCT00201760_7_T0	COMPOUND	16	16	gemcitabine
NCT002017607	NCT00201760_7_T1	COMPOUND	24	24	gemcitabine
NCT002017607	NCT00201760_7_T2	COMPOUND	27	27	cisplatin
NCT002017607	NCT00201760_7_T3	PHENOTYPE	31	33	metastatic breast cancer
NCT002017608	NCT00201760_8_T0	PHENOTYPE	0	1	Side effects
NCT0020176011	NCT00201760_11_T0	COMPOUND	5	5	gemcitabine
NCT0020176013	NCT00201760_13_T0	COMPOUND	4	4	gemcitabine
NCT0020176013	NCT00201760_13_T1	COMPOUND	7	7	cisplatin
NCT0020176014	NCT00201760_14_T0	COMPOUND	2	2	cisplatin
NCT0020176027	NCT00201760_27_T0	PHENOTYPE	10	10	initiation
NCT002017733	NCT00201773_3_T0	GENE	3	3	aromatase
NCT002017734	NCT00201773_4_T0	GENE	2	2	aromatase
NCT002017734	NCT00201773_4_T1	PHENOTYPE	4	4	blocks
NCT002017735	NCT00201773_5_T0	MOLECULAR_FUNCTION	7	8	aromatase activity
NCT002017736	NCT00201773_6_T0	COMPOUND	1	1	exemestane
NCT002017736	NCT00201773_6_T1	MOLECULAR_FUNCTION	5	6	aromatase activity
NCT002017737	NCT00201773_7_T0	GENE	13	13	COX-2
NCT002017737	NCT00201773_7_T1	PHENOTYPE	7	8	breast cancer
NCT002017739	NCT00201773_9_T0	PHENOTYPE	1	1	blocks
NCT002017739	NCT00201773_9_T1	GENE	2	2	COX-2
NCT0020177310	NCT00201773_10_T0	COMPOUND	11	11	exemestane
NCT0020177310	NCT00201773_10_T1	COMPOUND	13	13	celecoxib
NCT0020177310	NCT00201773_10_T2	PHENOTYPE	15	16	breast cancer
NCT0020177311	NCT00201773_11_T0	GENE	17	17	II
NCT0020177311	NCT00201773_11_T1	COMPOUND	10	10	exemestane
NCT0020177311	NCT00201773_11_T2	COMPOUND	12	12	celecoxib
NCT0020177311	NCT00201773_11_T3	GENE	18	18	III
NCT0020177311	NCT00201773_11_T4	GENE	20	20	IV
NCT0020177311	NCT00201773_11_T5	PHENOTYPE	21	22	breast cancer
NCT0020177313	NCT00201773_13_T0	COMPOUND	7	7	exemestane
NCT0020177313	NCT00201773_13_T1	COMPOUND	9	9	celecoxib
NCT0020177316	NCT00201773_16_T0	COMPOUND	4	4	celecoxib
NCT0020177317	NCT00201773_17_T0	COMPOUND	9	9	exemestane
NCT0020177317	NCT00201773_17_T1	COMPOUND	11	11	celecoxib
NCT0020177318	NCT00201773_18_T0	COMPOUND	24	24	exemestane
NCT0020177319	NCT00201773_19_T0	COMPOUND	4	4	exemestane
NCT0020177319	NCT00201773_19_T1	COMPOUND	6	6	celecoxib
NCT002017860	NCT00201786_0_T0	GENE	1	1	II
NCT002017860	NCT00201786_0_T1	PHENOTYPE	8	12	Acute Graft Versus Host Disease
NCT002017863	NCT00201786_3_T0	COMPOUND	4	4	pentostatin
NCT002017863	NCT00201786_3_T1	GENE	17	17	NS
NCT002017863	NCT00201786_3_T2	GENE	1	1	IV
NCT002017863	NCT00201786_3_T3	GENE	13	13	ml
NCT002017864	NCT00201786_4_T0	PHENOTYPE	2	2	nephrotoxicity
NCT002017864	NCT00201786_4_T1	GENE	8	8	ml
NCT002017864	NCT00201786_4_T2	GENE	18	18	ml
NCT002017994	NCT00201799_4_T0	CELL	15	15	cells
NCT002017994	NCT00201799_4_T1	BIOLOGICAL_PROCESS	23	24	immune response
NCT002017994	NCT00201799_4_T2	ORGAN	18	19	immune system
NCT002017996	NCT00201799_6_T0	GENE	15	15	HCT
NCT002017997	NCT00201799_7_T0	GENE	16	16	HCT
NCT0020179911	NCT00201799_11_T0	COMPOUND	4	4	cyclosporine
NCT0020179911	NCT00201799_11_T1	COMPOUND	7	7	methotrexate
NCT0020179911	NCT00201799_11_T2	ORGAN	1	1	transplant
NCT002018253	NCT00201825_3_T0	PHENOTYPE	22	22	NSCLC
NCT002018253	NCT00201825_3_T1	GENE	29	29	had
NCT002018253	NCT00201825_3_T2	COMPOUND	11	11	cisplatin
NCT002018254	NCT00201825_4_T0	PHENOTYPE	10	10	NSCLC
NCT002018255	NCT00201825_5_T0	COMPOUND	3	3	capecitabine
NCT002018255	NCT00201825_5_T1	PHENOTYPE	11	11	NSCLC
NCT002018255	NCT00201825_5_T2	COMPOUND	7	7	docetaxel
NCT002018255	NCT00201825_5_T3	GENE	8	8	has
NCT002018259	NCT00201825_9_T0	PHENOTYPE	8	8	tumors
NCT002018259	NCT00201825_9_T1	GENE	5	5	TP
NCT0020182510	NCT00201825_10_T0	COMPOUND	20	20	capecitabine
NCT0020182510	NCT00201825_10_T1	COMPOUND	18	18	docetaxel
NCT0020182510	NCT00201825_10_T2	GENE	14	14	TP
NCT0020182511	NCT00201825_11_T0	COMPOUND	19	19	capecitabine
NCT0020182511	NCT00201825_11_T1	PHENOTYPE	24	24	NSCLC
NCT0020182511	NCT00201825_11_T2	COMPOUND	21	21	docetaxel
NCT0020182511	NCT00201825_11_T3	GENE	7	7	TP
NCT0020182512	NCT00201825_12_T0	COMPOUND	10	10	capecitabine
NCT0020182512	NCT00201825_12_T1	PHENOTYPE	17	17	NSCLC
NCT0020182512	NCT00201825_12_T2	COMPOUND	8	8	docetaxel
NCT0020182513	NCT00201825_13_T0	PHENOTYPE	3	3	tumor
NCT0020182514	NCT00201825_14_T0	COMPOUND	9	9	capecitabine
NCT0020182514	NCT00201825_14_T1	COMPOUND	7	7	docetaxel
NCT002018381	NCT00201838_1_T0	COMPOUND	12	12	gemcitabine
NCT002018381	NCT00201838_1_T1	PHENOTYPE	17	18	pancreatic cancer
NCT002018382	NCT00201838_2_T0	PHENOTYPE	20	20	initiation
NCT002018382	NCT00201838_2_T1	PHENOTYPE	3	3	tumor
NCT002018386	NCT00201838_6_T0	GENE	0	0	TNF
NCT002018388	NCT00201838_8_T0	COMPOUND	6	6	gemcitabine
NCT002018388	NCT00201838_8_T1	GENE	3	3	TNF
NCT002018388	NCT00201838_8_T2	PHENOTYPE	13	14	pancreatic cancer
NCT002018389	NCT00201838_9_T0	GENE	29	29	II
NCT002018389	NCT00201838_9_T1	COMPOUND	9	9	gemcitabine
NCT002018389	NCT00201838_9_T2	GENE	2	2	has
NCT0020183810	NCT00201838_10_T0	GENE	30	30	II
NCT0020183810	NCT00201838_10_T1	COMPOUND	10	10	gemcitabine
NCT0020183810	NCT00201838_10_T2	COMPOUND	24	24	gemcitabine
NCT0020183810	NCT00201838_10_T3	PHENOTYPE	13	14	pancreatic cancer
NCT0020183811	NCT00201838_11_T0	GENE	0	0	TNF
NCT0020183812	NCT00201838_12_T0	COMPOUND	7	7	gemcitabine
NCT0020183814	NCT00201838_14_T0	COMPOUND	3	3	gemcitabine
NCT0020183817	NCT00201838_17_T0	COMPOUND	25	25	gemcitabine
NCT0020183818	NCT00201838_18_T0	GENE	20	20	II
NCT0020183819	NCT00201838_19_T0	GENE	4	4	II
NCT0020183819	NCT00201838_19_T1	COMPOUND	12	12	gemcitabine
NCT002018772	NCT00201877_2_T0	GENE	1	1	1.3
NCT002018772	NCT00201877_2_T1	GENE	3	3	IV
NCT002018774	NCT00201877_4_T0	PHENOTYPE	7	7	blocks
NCT002018775	NCT00201877_5_T0	GENE	1	1	proteasome
NCT002018775	NCT00201877_5_T1	CELL	9	9	cells
NCT002018777	NCT00201877_7_T0	PHENOTYPE	25	25	leukemia
NCT002018777	NCT00201877_7_T1	CELL	23	23	B-cells
NCT002018777	NCT00201877_7_T2	GENE	12	13	CD20 antigen
NCT002018778	NCT00201877_8_T0	CELL	14	14	B-cells
NCT002018778	NCT00201877_8_T1	ORGAN	7	8	immune system
NCT0020187713	NCT00201877_13_T0	COMPOUND	7	7	bortezomib
NCT0020187716	NCT00201877_16_T0	COMPOUND	10	10	bortezomib
NCT0020187717	NCT00201877_17_T0	PHENOTYPE	19	19	toxicity
NCT0020187719	NCT00201877_19_T0	COMPOUND	8	8	bortezomib
NCT002018900	NCT00201890_0_T0	PHENOTYPE	6	6	Lymphedema
NCT002018900	NCT00201890_0_T1	GENE	12	12	DELTA
NCT002018900	NCT00201890_0_T2	PHENOTYPE	10	11	Breast Cancer
NCT002018905	NCT00201890_5_T0	ORGAN	15	15	limb
NCT002018906	NCT00201890_6_T0	GENE	3	3	extended
NCT002018909	NCT00201890_9_T0	COMPOUND	5	5	tamoxifen
NCT002019420	NCT00201942_0_T0	COMPOUND	18	18	PREDICT
NCT002019420	NCT00201942_0_T1	PHENOTYPE	15	16	Breast Cancer
NCT002019422	NCT00201942_2_T0	COMPOUND	17	17	fluorodeoxyglucose
NCT002019422	NCT00201942_2_T1	PHENOTYPE	33	34	breast cancer
NCT002019422	NCT00201942_2_T2	PHENOTYPE	27	29	lymph node metastases
NCT002019425	NCT00201942_5_T0	PHENOTYPE	4	5	sentinel node
NCT002019426	NCT00201942_6_T0	GENE	18	18	sentinel
NCT002019426	NCT00201942_6_T1	GENE	20	20	sentinel
NCT002019426	NCT00201942_6_T2	TISSUE	22	23	lymph nodes
NCT002019427	NCT00201942_7_T0	PHENOTYPE	0	0	Sensitivity
NCT002019682	NCT00201968_2_T0	PHENOTYPE	15	15	secondary
NCT002019682	NCT00201968_2_T1	PHENOTYPE	16	16	complications
NCT002019684	NCT00201968_4_T0	TISSUE	13	13	muscles
NCT002019684	NCT00201968_4_T1	GENE	3	3	FES
NCT002019686	NCT00201968_6_T0	PHENOTYPE	19	19	secondary
NCT002019686	NCT00201968_6_T1	PHENOTYPE	20	20	complications
NCT002019686	NCT00201968_6_T2	GENE	10	10	FES
NCT002019686	NCT00201968_6_T3	ORGAN	30	30	legs
NCT002019686	NCT00201968_6_T4	PHENOTYPE	23	23	spasticity
NCT002019686	NCT00201968_6_T5	PHENOTYPE	24	25	pressure sores
NCT002019687	NCT00201968_7_T0	GENE	15	15	FES
NCT002019689	NCT00201968_9_T0	PHENOTYPE	12	14	quality of life
NCT0020196810	NCT00201968_10_T0	GENE	15	15	OR
NCT0020196810	NCT00201968_10_T1	GENE	13	13	FES
NCT0020196810	NCT00201968_10_T2	PHENOTYPE	4	4	chronic
NCT0020196811	NCT00201968_11_T0	PHENOTYPE	14	14	secondary
NCT0020196811	NCT00201968_11_T1	PHENOTYPE	15	15	complications
NCT002019942	NCT00201994_2_T0	PHENOTYPE	5	5	hyponatremia
NCT002019943	NCT00201994_3_T0	COMPOUND	4	4	sodium
NCT002019943	NCT00201994_3_T1	COMPOUND	26	26	sodium
NCT002019943	NCT00201994_3_T2	PHENOTYPE	5	5	falls
NCT002019943	NCT00201994_3_T3	ORGAN	3	3	serum
NCT002019943	NCT00201994_3_T4	ORGAN	25	25	serum
NCT002019944	NCT00201994_4_T0	PHENOTYPE	9	9	symptoms
NCT002019944	NCT00201994_4_T1	PHENOTYPE	4	4	hyponatremia
NCT002019944	NCT00201994_4_T2	PHENOTYPE	38	38	hyponatremia
NCT002019944	NCT00201994_4_T3	PHENOTYPE	45	46	heart failure
NCT002019944	NCT00201994_4_T4	PHENOTYPE	25	26	neurological damage
NCT002019949	NCT00201994_9_T0	PHENOTYPE	4	4	ascites
NCT002019949	NCT00201994_9_T1	PHENOTYPE	6	6	SIADH
NCT002019949	NCT00201994_9_T2	PHENOTYPE	2	2	cirrhosis
NCT0020199412	NCT00201994_12_T0	COMPOUND	11	11	tolvaptan
NCT0020199412	NCT00201994_12_T1	PHENOTYPE	24	24	hyponatremia
NCT0020199412	NCT00201994_12_T2	GENE	14	14	AVP
NCT0020199414	NCT00201994_14_T0	COMPOUND	9	9	sodium
NCT0020199414	NCT00201994_14_T1	GENE	10	10	135
NCT0020199414	NCT00201994_14_T2	PHENOTYPE	0	0	Hyponatremia
NCT0020199414	NCT00201994_14_T3	ORGAN	8	8	serum
NCT0020199418	NCT00201994_18_T0	PHENOTYPE	0	0	Hyponatremia
NCT0020199418	NCT00201994_18_T1	PHENOTYPE	2	2	hypovolemic
NCT0020199420	NCT00201994_20_T0	PHENOTYPE	0	0	Acute
NCT0020199420	NCT00201994_20_T1	PHENOTYPE	3	3	hyponatremia
NCT0020199420	NCT00201994_20_T2	PHENOTYPE	6	7	head trauma
NCT0020199422	NCT00201994_22_T0	PHENOTYPE	0	0	Hyponatremia
NCT0020199422	NCT00201994_22_T1	PHENOTYPE	4	4	hypothyroidism
NCT0020199422	NCT00201994_22_T2	PHENOTYPE	7	8	adrenal insufficiency
NCT0020199426	NCT00201994_26_T0	PHENOTYPE	3	4	myocardial infarction
NCT0020199428	NCT00201994_28_T0	PHENOTYPE	6	7	ventricular fibrillation
NCT0020199428	NCT00201994_28_T1	PHENOTYPE	2	4	sustained ventricular tachycardia
NCT0020199432	NCT00201994_32_T0	PHENOTYPE	3	4	cerebrovascular accident
NCT0020199434	NCT00201994_34_T0	GENE	4	4	90
NCT0020199436	NCT00201994_36_T0	PHENOTYPE	4	5	medication abuse
NCT0020199440	NCT00201994_40_T0	COMPOUND	7	7	tolvaptan
NCT0020199442	NCT00201994_42_T0	COMPOUND	1	1	creatinine
NCT0020199442	NCT00201994_42_T1	GENE	2	2	3.5
NCT0020199442	NCT00201994_42_T2	ORGAN	0	0	Serum
NCT0020199443	NCT00201994_43_T0	PHENOTYPE	9	9	symptoms
NCT0020199443	NCT00201994_43_T1	COMPOUND	1	1	sodium
NCT0020199443	NCT00201994_43_T2	PHENOTYPE	7	7	impairment
NCT0020199443	NCT00201994_43_T3	ORGAN	0	0	Serum
NCT0020199443	NCT00201994_43_T4	PHENOTYPE	12	12	apathy
NCT0020199443	NCT00201994_43_T5	GENE	2	2	120
NCT0020199444	NCT00201994_44_T0	PHENOTYPE	2	2	progressive
NCT0020199444	NCT00201994_44_T1	PHENOTYPE	9	10	multiple sclerosis
NCT0020199447	NCT00201994_47_T0	PHENOTYPE	0	0	Hyponatremia
NCT0020199448	NCT00201994_48_T0	GENE	2	2	AVP
NCT0020199449	NCT00201994_49_T0	COMPOUND	15	15	lithium
NCT0020199449	NCT00201994_49_T1	PHENOTYPE	12	12	hyponatremia
NCT0020199449	NCT00201994_49_T2	COMPOUND	14	14	demeclocycline
NCT0020199449	NCT00201994_49_T3	COMPOUND	16	16	carbonate
NCT0020199450	NCT00201994_50_T0	PHENOTYPE	12	12	hyponatremia
NCT0020199450	NCT00201994_50_T1	GENE	3	3	IV
NCT0020199451	NCT00201994_51_T0	ORGAN	1	2	pulmonary artery
NCT002020071	NCT00202007_1_T0	GENE	23	23	3.7
NCT002020076	NCT00202007_6_T0	PHENOTYPE	0	0	Schizophrenia
NCT002020076	NCT00202007_6_T1	PHENOTYPE	2	3	Acute schizophrenia
NCT002020078	NCT00202007_8_T0	GENE	0	0	Age
NCT0020200712	NCT00202007_12_T0	PHENOTYPE	6	6	Schizophrenia
NCT0020200712	NCT00202007_12_T1	PHENOTYPE	4	4	diseases
NCT0020200715	NCT00202007_15_T0	GENE	2	2	had
NCT0020200716	NCT00202007_16_T0	PHENOTYPE	7	7	dependence
NCT0020200716	NCT00202007_16_T1	PHENOTYPE	2	5	alcohol or drug abuse
NCT0020200718	NCT00202007_18_T0	GENE	3	3	had
NCT0020200719	NCT00202007_19_T0	PHENOTYPE	0	0	Allergy
NCT0020200721	NCT00202007_21_T0	PHENOTYPE	1	1	schizophrenia
NCT0020200723	NCT00202007_23_T0	PHENOTYPE	4	4	diseases
NCT0020200723	NCT00202007_23_T1	PHENOTYPE	6	6	schizophrenia
NCT0020200723	NCT00202007_23_T2	GENE	10	11	period 2
NCT002020202	NCT00202020_2_T0	GENE	47	47	1.1
NCT002020206	NCT00202020_6_T0	PHENOTYPE	3	3	experiences
NCT002020207	NCT00202020_7_T0	GENE	6	6	MRI
NCT002020209	NCT00202020_9_T0	GENE	2	2	had
NCT002020209	NCT00202020_9_T1	PHENOTYPE	3	4	cerebral infarction
NCT0020202010	NCT00202020_10_T0	GENE	13	13	MRI
NCT0020202010	NCT00202020_10_T1	PHENOTYPE	17	17	infarction
NCT0020202010	NCT00202020_10_T2	PHENOTYPE	8	9	cerebral infarction
NCT0020202014	NCT00202020_14_T0	PHENOTYPE	2	3	intracranial hemorrhage
NCT0020202015	NCT00202020_15_T0	PHENOTYPE	1	1	secondary
NCT0020202015	NCT00202020_15_T1	PHENOTYPE	3	3	cardiogenic
NCT0020202015	NCT00202020_15_T2	PHENOTYPE	4	4	embolism
NCT0020202016	NCT00202020_16_T0	PHENOTYPE	5	5	dementia
NCT0020202017	NCT00202020_17_T0	PHENOTYPE	1	1	complications
NCT0020202017	NCT00202020_17_T1	GENE	3	3	co
NCT0020202017	NCT00202020_17_T2	PHENOTYPE	8	8	hypertension
NCT0020202017	NCT00202020_17_T3	PHENOTYPE	12	13	heart failure
NCT0020202017	NCT00202020_17_T4	PHENOTYPE	10	11	diabetic acidosis
NCT0020202017	NCT00202020_17_T5	PHENOTYPE	14	15	renal failure
NCT0020202017	NCT00202020_17_T6	PHENOTYPE	17	18	malignant tumor
NCT0020202019	NCT00202020_19_T0	GENE	3	3	co
NCT0020202020	NCT00202020_20_T0	PHENOTYPE	0	2	Active peptic ulcer
NCT002020461	NCT00202046_1_T0	PHENOTYPE	8	8	lymphedema
NCT002020461	NCT00202046_1_T1	PHENOTYPE	21	21	lymphedema
NCT002020461	NCT00202046_1_T2	PHENOTYPE	23	24	breast cancer
NCT002020463	NCT00202046_3_T0	PHENOTYPE	12	12	decisions
NCT002020464	NCT00202046_4_T0	PHENOTYPE	13	13	lymphedema
NCT002020464	NCT00202046_4_T1	PHENOTYPE	4	5	side effect
NCT002020464	NCT00202046_4_T2	TISSUE	8	9	lymph node
NCT002020465	NCT00202046_5_T0	PHENOTYPE	11	11	lymphedema
NCT002020465	NCT00202046_5_T1	GENE	16	16	had
NCT002020465	NCT00202046_5_T2	PHENOTYPE	20	21	breast cancer
NCT002020466	NCT00202046_6_T0	PHENOTYPE	7	7	lymphedema
NCT002020466	NCT00202046_6_T1	PHENOTYPE	23	23	lymphedema
NCT002020466	NCT00202046_6_T2	PHENOTYPE	13	13	QOL
NCT002020466	NCT00202046_6_T3	PHENOTYPE	10	12	quality of life
NCT002020468	NCT00202046_8_T0	PHENOTYPE	6	6	lymphedema
NCT002020468	NCT00202046_8_T1	PHENOTYPE	12	12	centers
NCT002020469	NCT00202046_9_T0	PHENOTYPE	18	18	lymphedema
NCT002020469	NCT00202046_9_T1	GENE	10	10	had
NCT002020469	NCT00202046_9_T2	PHENOTYPE	2	2	oncology
NCT002020469	NCT00202046_9_T3	PHENOTYPE	11	12	breast cancer
NCT0020204611	NCT00202046_11_T0	PHENOTYPE	13	13	oncology
NCT002020594	NCT00202059_4_T0	PHENOTYPE	7	7	osteopenia
NCT002020594	NCT00202059_4_T1	GENE	0	0	CIM
NCT002020594	NCT00202059_4_T2	PHENOTYPE	10	10	osteoporosis
NCT002020594	NCT00202059_4_T3	PHENOTYPE	5	6	bone loss
NCT002020599	NCT00202059_9_T0	COMPOUND	26	26	calcium
NCT002020599	NCT00202059_9_T1	COMPOUND	27	27	carbonate
NCT002020599	NCT00202059_9_T2	COMPOUND	7	8	zoledronic acid
NCT0020205911	NCT00202059_11_T0	COMPOUND	9	9	calcium
NCT0020205911	NCT00202059_11_T1	COMPOUND	10	10	carbonate
NCT0020205911	NCT00202059_11_T2	PHENOTYPE	0	1	Group B
NCT0020205913	NCT00202059_13_T0	ORGAN	0	0	Serum
NCT0020205913	NCT00202059_13_T1	BIOLOGICAL_PROCESS	18	19	bone resorption
NCT0020205914	NCT00202059_14_T0	PHENOTYPE	24	24	symptoms
NCT0020205914	NCT00202059_14_T1	PHENOTYPE	9	9	fatigue
NCT0020205914	NCT00202059_14_T2	GENE	25	25	MD
NCT0020205914	NCT00202059_14_T3	PHENOTYPE	22	23	other cancer
NCT0020205914	NCT00202059_14_T4	PHENOTYPE	11	12	Cancer Fatigue
NCT002020723	NCT00202072_3_T0	GENE	2	2	mucin
NCT002020723	NCT00202072_3_T1	GENE	20	20	gel
NCT002020725	NCT00202072_5_T0	GENE	11	11	mucin
NCT002020725	NCT00202072_5_T1	GENE	30	30	mucin
NCT002020726	NCT00202072_6_T0	PHENOTYPE	24	24	severity
NCT002020728	NCT00202072_8_T0	GENE	13	13	MUC5B
NCT002020728	NCT00202072_8_T1	GENE	11	11	MUC5AC
NCT002020728	NCT00202072_8_T2	GENE	1	1	gel
NCT002020980	NCT00202098_0_T0	PHENOTYPE	3	3	Ventilation
NCT002020980	NCT00202098_0_T1	PHENOTYPE	12	12	ARDS
NCT002020980	NCT00202098_0_T2	ORGAN	5	6	Respiratory System
NCT002020980	NCT00202098_0_T3	PHENOTYPE	8	11	Acute Respiratory Distress Syndrome
NCT0020209810	NCT00202098_10_T0	GENE	7	7	165
NCT0020209810	NCT00202098_10_T1	GENE	5	5	Med
NCT002021112	NCT00202111_2_T0	PHENOTYPE	15	15	recruitment
NCT002021112	NCT00202111_2_T1	GENE	17	17	Jan
NCT002021115	NCT00202111_5_T0	PHENOTYPE	20	21	colon cancer
NCT002021116	NCT00202111_6_T0	GENE	2	2	has
NCT002021117	NCT00202111_7_T0	PHENOTYPE	12	13	colon cancer
NCT002021118	NCT00202111_8_T0	PHENOTYPE	13	13	centre
NCT002021119	NCT00202111_9_T0	GENE	13	13	Tom
NCT0020211110	NCT00202111_10_T0	PHENOTYPE	2	2	recruitment
NCT0020211110	NCT00202111_10_T1	GENE	4	4	Jan
NCT0020211113	NCT00202111_13_T0	ORGAN	14	14	colon
NCT0020211115	NCT00202111_15_T0	GENE	16	16	Victoria
NCT0020211116	NCT00202111_16_T0	ORGAN	5	5	colon
NCT0020211117	NCT00202111_17_T0	GENE	23	23	pre
NCT0020211117	NCT00202111_17_T1	GENE	30	30	pre
NCT0020211117	NCT00202111_17_T2	PHENOTYPE	19	19	carcinoma
NCT0020211117	NCT00202111_17_T3	GENE	13	13	abdominal
NCT0020211117	NCT00202111_17_T4	GENE	10	10	ASA
NCT0020211117	NCT00202111_17_T5	PHENOTYPE	27	28	lung function
NCT0020211119	NCT00202111_19_T0	TISSUE	7	7	peritoneum
NCT0020211120	NCT00202111_20_T0	PHENOTYPE	1	3	surgical blood loss
NCT0020211121	NCT00202111_21_T0	PHENOTYPE	6	6	tumour
NCT0020211127	NCT00202111_27_T0	PHENOTYPE	2	2	complications
NCT0020211127	NCT00202111_27_T1	PHENOTYPE	8	9	adverse events
NCT0020211129	NCT00202111_29_T0	PHENOTYPE	15	15	dependency
NCT0020211129	NCT00202111_29_T1	PHENOTYPE	35	35	ileus
NCT0020211129	NCT00202111_29_T2	PHENOTYPE	38	39	anastomotic leakage
NCT0020211129	NCT00202111_29_T3	PHENOTYPE	36	37	wound infection
NCT0020211130	NCT00202111_30_T0	GENE	6	6	TNM
NCT0020211130	NCT00202111_30_T1	PHENOTYPE	16	16	distal
NCT0020211130	NCT00202111_30_T2	PHENOTYPE	5	5	tumour
NCT0020211130	NCT00202111_30_T3	PHENOTYPE	22	22	tumour
NCT0020211130	NCT00202111_30_T4	ORGAN	13	13	colon
NCT0020211130	NCT00202111_30_T5	PHENOTYPE	14	14	proximal
NCT0020211130	NCT00202111_30_T6	GENE	8	8	ACPS
NCT0020211134	NCT00202111_34_T0	PHENOTYPE	10	10	recurrence
NCT0020211134	NCT00202111_34_T1	PHENOTYPE	3	3	wounds
NCT0020211136	NCT00202111_36_T0	ORGAN	5	5	liver
NCT0020211136	NCT00202111_36_T1	GENE	2	2	abdominal
NCT0020211137	NCT00202111_37_T0	PHENOTYPE	7	7	recurrence
NCT0020211137	NCT00202111_37_T1	PHENOTYPE	6	6	tumour
NCT0020211139	NCT00202111_39_T0	PHENOTYPE	8	8	recurrence
NCT0020211142	NCT00202111_42_T0	PHENOTYPE	16	17	colonic adenocarcinoma
NCT0020211143	NCT00202111_43_T0	PHENOTYPE	9	11	quality of life
NCT0020211144	NCT00202111_44_T0	PHENOTYPE	6	6	recurrence
NCT0020211145	NCT00202111_45_T0	PHENOTYPE	28	28	complications
NCT0020211145	NCT00202111_45_T1	PHENOTYPE	25	25	analgesia
NCT002021371	NCT00202137_1_T0	PHENOTYPE	3	3	hypertension
NCT002021372	NCT00202137_2_T0	COMPOUND	4	4	HBPM
NCT002021374	NCT00202137_4_T0	PHENOTYPE	15	15	hypertension
NCT002021375	NCT00202137_5_T0	COMPOUND	11	11	HBPM
NCT002021376	NCT00202137_6_T0	COMPOUND	2	2	HBPM
NCT0020213712	NCT00202137_12_T0	PHENOTYPE	12	12	hypertension
NCT0020213717	NCT00202137_17_T0	PHENOTYPE	22	24	lower blood pressure
NCT0020213718	NCT00202137_18_T0	PHENOTYPE	1	1	secondary
NCT0020213718	NCT00202137_18_T1	COMPOUND	5	5	HBPM
NCT0020213718	NCT00202137_18_T2	PHENOTYPE	20	20	hypertension
NCT0020213721	NCT00202137_21_T0	PHENOTYPE	37	37	hypertension
NCT0020213725	NCT00202137_25_T0	PHENOTYPE	1	1	secondary
NCT0020213725	NCT00202137_25_T1	PHENOTYPE	21	21	hypertension
NCT002021501	NCT00202150_1_T0	PHENOTYPE	11	13	quality of life
NCT002021505	NCT00202150_5_T0	PHENOTYPE	23	23	practices
NCT002021505	NCT00202150_5_T1	PHENOTYPE	47	47	practices
NCT002021509	NCT00202150_9_T0	PHENOTYPE	0	0	Secondary
NCT002021509	NCT00202150_9_T1	PHENOTYPE	6	8	quality of life
NCT0020215011	NCT00202150_11_T0	PHENOTYPE	23	23	practices
NCT0020215011	NCT00202150_11_T1	PHENOTYPE	47	47	practices
NCT0020215015	NCT00202150_15_T0	PHENOTYPE	0	0	Secondary
NCT0020215015	NCT00202150_15_T1	PHENOTYPE	6	8	quality of life
NCT0020215021	NCT00202150_21_T0	PHENOTYPE	10	10	perceived
NCT002021632	NCT00202163_2_T0	COMPOUND	14	14	DHEA
NCT002021632	NCT00202163_2_T1	COMPOUND	12	12	testosterone
NCT002021761	NCT00202176_1_T0	ORGAN	9	9	lungs
NCT002021761	NCT00202176_1_T1	ORGAN	14	14	lungs
NCT002021761	NCT00202176_1_T2	PHENOTYPE	17	18	lung hyperinflation
NCT002021891	NCT00202189_1_T0	BIOLOGICAL_PROCESS	17	18	gene expression
NCT002021893	NCT00202189_3_T0	PHENOTYPE	26	26	dyspnea
NCT002021893	NCT00202189_3_T1	PHENOTYPE	18	19	lung hyperinflation
NCT002022024	NCT00202202_4_T0	PHENOTYPE	6	6	perceived
NCT002022024	NCT00202202_4_T1	GENE	15	15	had
NCT002022025	NCT00202202_5_T0	GENE	3	3	had
NCT002022026	NCT00202202_6_T0	GENE	9	9	blanks
NCT002022156	NCT00202215_6_T0	BIOLOGICAL_PROCESS	20	20	eating
NCT002022156	NCT00202215_6_T1	BIOLOGICAL_PROCESS	45	45	eating
NCT002022156	NCT00202215_6_T2	BIOLOGICAL_PROCESS	47	47	eating
NCT002022156	NCT00202215_6_T3	BIOLOGICAL_PROCESS	22	22	behaviour
NCT002022156	NCT00202215_6_T4	PHENOTYPE	14	15	personality disorders
NCT002022281	NCT00202228_1_T0	PHENOTYPE	4	4	hyperlactatemia
NCT002022281	NCT00202228_1_T1	PHENOTYPE	1	1	acidosis
NCT002022282	NCT00202228_2_T0	PHENOTYPE	17	17	understood
NCT002022282	NCT00202228_2_T1	PHENOTYPE	6	7	mitochondrial toxicity
NCT002022282	NCT00202228_2_T2	PHENOTYPE	0	1	Lactic acidosis
NCT002022283	NCT00202228_3_T0	PHENOTYPE	43	43	HIV
NCT002022283	NCT00202228_3_T1	COMPOUND	8	8	lactate
NCT002022283	NCT00202228_3_T2	PHENOTYPE	36	37	liver steatosis
NCT002022283	NCT00202228_3_T3	PHENOTYPE	20	21	HIV positive
NCT002022284	NCT00202228_4_T0	COMPOUND	6	6	L-carnitine
NCT002022284	NCT00202228_4_T1	COMPOUND	4	4	niacin
NCT002022284	NCT00202228_4_T2	COMPOUND	3	3	thiamine
NCT002022284	NCT00202228_4_T3	GENE	18	18	mitochondrial
NCT002022284	NCT00202228_4_T4	BIOLOGICAL_PROCESS	14	15	lactate metabolism
NCT002022287	NCT00202228_7_T0	PHENOTYPE	8	8	osteopenia
NCT002022287	NCT00202228_7_T1	PHENOTYPE	7	7	hyperglycemia
NCT002022287	NCT00202228_7_T2	PHENOTYPE	6	6	hyperlipidemia
NCT002022287	NCT00202228_7_T3	PHENOTYPE	0	0	Toxicities
NCT002022287	NCT00202228_7_T4	PHENOTYPE	10	10	lipodystrophy
NCT002022288	NCT00202228_8_T0	PHENOTYPE	3	4	lactic acidosis
NCT0020222811	NCT00202228_11_T0	ORGAN	26	26	liver
NCT0020222811	NCT00202228_11_T1	COMPOUND	23	23	lactate
NCT0020222811	NCT00202228_11_T2	PHENOTYPE	3	4	lactic acidemia
NCT0020222811	NCT00202228_11_T3	PHENOTYPE	17	18	mitochondrial dysfunction
NCT0020222812	NCT00202228_12_T0	PHENOTYPE	8	8	attributable
NCT0020222812	NCT00202228_12_T1	PHENOTYPE	3	4	liver dysfunction
NCT0020222812	NCT00202228_12_T2	PHENOTYPE	10	11	mitochondrial toxicity
NCT0020222813	NCT00202228_13_T0	PHENOTYPE	12	12	chronic
NCT0020222813	NCT00202228_13_T1	BIOLOGICAL_PROCESS	7	8	lactate metabolism
NCT0020222813	NCT00202228_13_T2	PHENOTYPE	13	14	HIV infection
NCT0020222814	NCT00202228_14_T0	PHENOTYPE	7	7	HIV
NCT0020222814	NCT00202228_14_T1	PHENOTYPE	13	14	liver disease
NCT0020222815	NCT00202228_15_T0	ORGAN	11	11	forearm
NCT0020222815	NCT00202228_15_T1	COMPOUND	6	6	lactate
NCT0020222815	NCT00202228_15_T2	PHENOTYPE	12	12	ischemia
NCT0020222816	NCT00202228_16_T0	GENE	17	17	mitochondrial
NCT0020222816	NCT00202228_16_T1	BIOLOGICAL_PROCESS	13	14	lactate metabolism
NCT0020222817	NCT00202228_17_T0	COMPOUND	21	21	L-carnitine
NCT0020222817	NCT00202228_17_T1	COMPOUND	19	19	thiamine
NCT0020222818	NCT00202228_18_T0	ORGAN	18	18	liver
NCT0020222820	NCT00202228_20_T0	PHENOTYPE	18	18	HIV
NCT0020222820	NCT00202228_20_T1	PHENOTYPE	8	8	insights
NCT0020222820	NCT00202228_20_T2	BIOLOGICAL_PROCESS	13	14	lactate metabolism
NCT0020222821	NCT00202228_21_T0	COMPOUND	36	36	L-carnitine
NCT0020222821	NCT00202228_21_T1	PHENOTYPE	21	21	HIV
NCT0020222821	NCT00202228_21_T2	COMPOUND	35	35	thiamine
NCT0020222821	NCT00202228_21_T3	COMPOUND	17	17	lactate
NCT0020222821	NCT00202228_21_T4	COMPOUND	47	47	lactate
NCT0020222821	NCT00202228_21_T5	COMPOUND	63	63	lactate
NCT0020222821	NCT00202228_21_T6	COMPOUND	34	34	riboflavin
NCT0020222821	NCT00202228_21_T7	PHENOTYPE	40	41	liver disease
NCT0020222821	NCT00202228_21_T8	BIOLOGICAL_PROCESS	25	26	lactate metabolism
NCT002022411	NCT00202241_1_T0	PHENOTYPE	22	22	HIV
NCT002022411	NCT00202241_1_T1	ORGAN	15	15	serum
NCT002022411	NCT00202241_1_T2	PHENOTYPE	18	18	lipodystrophy
NCT002022414	NCT00202241_4_T0	GENE	5	5	protease
NCT002022414	NCT00202241_4_T1	PHENOTYPE	13	13	HIV
NCT002022414	NCT00202241_4_T2	GENE	1	1	has
NCT002022414	NCT00202241_4_T3	TISSUE	22	23	subcutaneous fat
NCT002022415	NCT00202241_5_T0	PHENOTYPE	7	7	understood
NCT002022415	NCT00202241_5_T1	PHENOTYPE	3	3	lipodystrophy
NCT002022418	NCT00202241_8_T0	GENE	18	18	AS
NCT002022418	NCT00202241_8_T1	PHENOTYPE	13	13	HIV
NCT002022418	NCT00202241_8_T2	PHENOTYPE	10	10	lipodystrophy
NCT0020224110	NCT00202241_10_T0	GENE	5	5	AS
NCT0020224111	NCT00202241_11_T0	PHENOTYPE	7	9	Quality of Life
NCT0020224112	NCT00202241_12_T0	ORGAN	0	0	Serum
NCT002022542	NCT00202254_2_T0	PHENOTYPE	11	11	pathology
NCT002022678	NCT00202267_8_T0	PHENOTYPE	10	10	discomfort
NCT002022678	NCT00202267_8_T1	PHENOTYPE	6	8	quality of life
NCT0020226725	NCT00202267_25_T0	PHENOTYPE	18	18	recurrence
NCT0020226725	NCT00202267_25_T1	PHENOTYPE	16	17	ulcer healing
NCT0020226725	NCT00202267_25_T2	PHENOTYPE	20	22	quality of life
NCT0020226729	NCT00202267_29_T0	COMPOUND	24	24	1st
NCT0020226729	NCT00202267_29_T1	PHENOTYPE	22	22	Ulcer
NCT0020226729	NCT00202267_29_T2	PHENOTYPE	18	18	ulcer
NCT0020226729	NCT00202267_29_T3	PHENOTYPE	27	27	ulcer
NCT0020226729	NCT00202267_29_T4	PHENOTYPE	26	26	recurrent
NCT0020226730	NCT00202267_30_T0	PHENOTYPE	7	7	ulcer
NCT0020226732	NCT00202267_32_T0	PHENOTYPE	14	14	recurrence
NCT002022800	NCT00202280_0_T0	PHENOTYPE	5	5	Psychosis
NCT002022800	NCT00202280_0_T1	GENE	10	10	B6
NCT002022807	NCT00202280_7_T0	PHENOTYPE	0	0	Secondary
NCT002022807	NCT00202280_7_T1	PHENOTYPE	12	13	side effect
NCT0020228010	NCT00202280_10_T0	PHENOTYPE	11	11	centre
NCT002022932	NCT00202293_2_T0	COMPOUND	6	6	lithium
NCT002022932	NCT00202293_2_T1	GENE	13	13	has
NCT002022932	NCT00202293_2_T2	PHENOTYPE	11	12	acute mania
NCT002022934	NCT00202293_4_T0	PHENOTYPE	15	15	hyperactivity
NCT002022934	NCT00202293_4_T1	PHENOTYPE	60	60	hyperactivity
NCT002022934	NCT00202293_4_T2	COMPOUND	18	18	lithium
NCT002022934	NCT00202293_4_T3	COMPOUND	26	26	lithium
NCT002022934	NCT00202293_4_T4	COMPOUND	31	31	chlorpromazine
NCT002022934	NCT00202293_4_T5	GENE	1	1	has
NCT002022934	NCT00202293_4_T6	PHENOTYPE	57	58	psychotic symptoms
NCT002022934	NCT00202293_4_T7	PHENOTYPE	51	52	acute mania
NCT002022936	NCT00202293_6_T0	PHENOTYPE	11	12	manic depression
NCT002022937	NCT00202293_7_T0	COMPOUND	12	12	olanzapine
NCT002022937	NCT00202293_7_T1	GENE	8	8	atypical
NCT002022937	NCT00202293_7_T2	PHENOTYPE	3	3	chronic
NCT002022938	NCT00202293_8_T0	GENE	1	1	has
NCT002022938	NCT00202293_8_T1	PHENOTYPE	16	17	tardive dyskinesia
NCT0020229310	NCT00202293_10_T0	COMPOUND	6	6	olanzapine
NCT0020229310	NCT00202293_10_T1	PHENOTYPE	9	9	mania
NCT0020229313	NCT00202293_13_T0	GENE	7	7	sparse
NCT0020229313	NCT00202293_13_T1	PHENOTYPE	5	5	mania
NCT0020229315	NCT00202293_15_T0	GENE	9	9	atypical
NCT0020229315	NCT00202293_15_T1	GENE	2	2	has
NCT0020229315	NCT00202293_15_T2	PHENOTYPE	21	21	mania
NCT0020229316	NCT00202293_16_T0	PHENOTYPE	19	19	acute
NCT0020229316	NCT00202293_16_T1	COMPOUND	6	6	olanzapine
NCT0020229316	NCT00202293_16_T2	COMPOUND	8	8	chlorpromazine
NCT0020229316	NCT00202293_16_T3	PHENOTYPE	20	21	manic episode
NCT0020229317	NCT00202293_17_T0	COMPOUND	3	3	olanzapine
NCT0020229317	NCT00202293_17_T1	COMPOUND	30	30	chlorpromazine
NCT0020229318	NCT00202293_18_T0	COMPOUND	13	13	olanzapine
NCT0020229318	NCT00202293_18_T1	PHENOTYPE	29	29	mania
NCT0020229320	NCT00202293_20_T0	COMPOUND	13	13	lithium
NCT0020229320	NCT00202293_20_T1	COMPOUND	20	20	lithium
NCT0020229320	NCT00202293_20_T2	COMPOUND	15	15	olanzapine
NCT0020229320	NCT00202293_20_T3	COMPOUND	22	22	chlorpromazine
NCT0020229321	NCT00202293_21_T0	PHENOTYPE	31	32	physical illness
NCT0020229324	NCT00202293_24_T0	PHENOTYPE	18	18	symptoms
NCT0020229324	NCT00202293_24_T1	PHENOTYPE	21	22	depressive symptoms
NCT0020229325	NCT00202293_25_T0	PHENOTYPE	4	6	quality of life
NCT0020229326	NCT00202293_26_T0	PHENOTYPE	37	37	feels
NCT0020229327	NCT00202293_27_T0	PHENOTYPE	18	18	manic
NCT0020229328	NCT00202293_28_T0	PHENOTYPE	24	24	prodrome
NCT0020229328	NCT00202293_28_T1	PHENOTYPE	26	27	bipolar disorders
NCT0020229329	NCT00202293_29_T0	PHENOTYPE	26	26	mania
NCT0020229331	NCT00202293_31_T0	PHENOTYPE	21	21	prodrome
NCT0020229331	NCT00202293_31_T1	PHENOTYPE	23	24	bipolar illness
NCT0020229332	NCT00202293_32_T0	PHENOTYPE	6	6	Recruitment
NCT0020229334	NCT00202293_34_T0	PHENOTYPE	16	16	Psychosis
NCT0020229334	NCT00202293_34_T1	PHENOTYPE	0	0	Recruitment
NCT0020229334	NCT00202293_34_T2	PHENOTYPE	30	31	psychotic episode
NCT0020229335	NCT00202293_35_T0	PHENOTYPE	12	12	mania
NCT0020229337	NCT00202293_37_T0	COMPOUND	13	13	benzodiazepine
NCT0020229338	NCT00202293_38_T0	GENE	13	13	37
NCT0020229338	NCT00202293_38_T1	PHENOTYPE	9	9	Mania
NCT0020229349	NCT00202293_49_T0	GENE	24	24	MCV
NCT0020229349	NCT00202293_49_T1	GENE	25	25	RBC
NCT0020229349	NCT00202293_49_T2	GENE	22	22	MCH
NCT0020229349	NCT00202293_49_T3	GENE	23	23	MCHC
NCT0020229349	NCT00202293_49_T4	CELL	27	27	platelets
NCT0020229352	NCT00202293_52_T0	PHENOTYPE	9	9	Psychosis
NCT0020229352	NCT00202293_52_T1	GENE	10	10	44
NCT0020229354	NCT00202293_54_T0	PHENOTYPE	15	15	agitation
NCT0020229355	NCT00202293_55_T0	PHENOTYPE	4	4	agitation
NCT0020229361	NCT00202293_61_T0	GENE	16	16	met
NCT0020229363	NCT00202293_63_T0	COMPOUND	11	11	lithium
NCT0020229364	NCT00202293_64_T0	COMPOUND	0	0	Lithium
NCT0020229364	NCT00202293_64_T1	ORGAN	1	1	serum
NCT0020229368	NCT00202293_68_T0	PHENOTYPE	11	11	manic
NCT0020229369	NCT00202293_69_T0	PHENOTYPE	18	18	recruitment
NCT0020229369	NCT00202293_69_T1	PHENOTYPE	9	9	manic
NCT0020229371	NCT00202293_71_T0	COMPOUND	1	1	lithium
NCT0020229371	NCT00202293_71_T1	COMPOUND	13	13	lithium
NCT0020229371	NCT00202293_71_T2	ORGAN	0	0	Serum
NCT0020229372	NCT00202293_72_T0	COMPOUND	1	1	lithium
NCT0020229372	NCT00202293_72_T1	ORGAN	0	0	Serum
NCT0020229373	NCT00202293_73_T0	GENE	11	11	1.0
NCT0020229373	NCT00202293_73_T1	GENE	17	17	1.0
NCT0020229373	NCT00202293_73_T2	GENE	9	9	0.5
NCT0020229373	NCT00202293_73_T3	GENE	15	15	0.8
NCT0020229373	NCT00202293_73_T4	PHENOTYPE	6	7	lithium level
NCT0020229374	NCT00202293_74_T0	GENE	12	12	49
NCT0020229374	NCT00202293_74_T1	COMPOUND	6	6	lithium
NCT0020229375	NCT00202293_75_T0	PHENOTYPE	16	16	agitation
NCT0020229376	NCT00202293_76_T0	PHENOTYPE	7	8	extrapyramidal symptoms
NCT0020229377	NCT00202293_77_T0	COMPOUND	19	19	lithium
NCT0020229377	NCT00202293_77_T1	PHENOTYPE	11	12	depressive episode
NCT0020229378	NCT00202293_78_T0	PHENOTYPE	7	8	adverse events
NCT0020229378	NCT00202293_78_T1	PHENOTYPE	44	45	Weight gain
NCT0020229379	NCT00202293_79_T0	GENE	11	11	SWN
NCT0020229379	NCT00202293_79_T1	GENE	8	8	DAI
NCT0020229380	NCT00202293_80_T0	GENE	16	16	MARS
NCT0020229381	NCT00202293_81_T0	PHENOTYPE	46	46	Secondary
NCT0020229382	NCT00202293_82_T0	PHENOTYPE	0	0	Euthymia
NCT0020229384	NCT00202293_84_T0	PHENOTYPE	29	29	symptoms
NCT0020229388	NCT00202293_88_T0	GENE	7	7	has
NCT0020229388	NCT00202293_88_T1	PHENOTYPE	4	5	functional recovery
NCT0020229389	NCT00202293_89_T0	PHENOTYPE	1	2	functional recovery
NCT002023061	NCT00202306_1_T0	PHENOTYPE	4	4	symptoms
NCT002023061	NCT00202306_1_T1	COMPOUND	27	27	lithium
NCT002023061	NCT00202306_1_T2	PHENOTYPE	17	18	mental illness
NCT002023061	NCT00202306_1_T3	PHENOTYPE	40	41	acute mania
NCT002023061	NCT00202306_1_T4	PHENOTYPE	8	9	psychotic disorders
NCT002023062	NCT00202306_2_T0	PHENOTYPE	4	4	progression
NCT002023064	NCT00202306_4_T0	COMPOUND	7	7	lithium
NCT002023064	NCT00202306_4_T1	PHENOTYPE	14	14	progression
NCT002023065	NCT00202306_5_T0	COMPOUND	18	18	lithium
NCT002023068	NCT00202306_8_T0	GENE	27	27	PACE
NCT002023068	NCT00202306_8_T1	PHENOTYPE	15	16	psychotic episode
NCT002023069	NCT00202306_9_T0	GENE	0	0	PACE
NCT002023069	NCT00202306_9_T1	GENE	22	22	GAF
NCT002023069	NCT00202306_9_T2	PHENOTYPE	15	15	psychosis
NCT002023069	NCT00202306_9_T3	PHENOTYPE	25	26	psychotic symptoms
NCT002023069	NCT00202306_9_T4	PHENOTYPE	29	30	psychotic symptoms
NCT0020230610	NCT00202306_10_T0	COMPOUND	16	16	lithium
NCT0020230612	NCT00202306_12_T0	PHENOTYPE	11	11	recruitment
NCT0020230614	NCT00202306_14_T0	PHENOTYPE	20	22	quality of life
NCT002023191	NCT00202319_1_T0	PHENOTYPE	11	11	amnesia
NCT002023191	NCT00202319_1_T1	GENE	2	2	has
NCT002023191	NCT00202319_1_T2	PHENOTYPE	14	14	tolerance
NCT002023195	NCT00202319_5_T0	PHENOTYPE	11	11	amnesia
NCT002023195	NCT00202319_5_T1	GENE	2	2	has
NCT002023195	NCT00202319_5_T2	PHENOTYPE	14	14	tolerance
NCT002023196	NCT00202319_6_T0	PHENOTYPE	14	14	amnesia
NCT002023196	NCT00202319_6_T1	PHENOTYPE	11	13	loss of consciousness
NCT0020231912	NCT00202319_12_T0	PHENOTYPE	3	3	decision-making
NCT0020231914	NCT00202319_14_T0	PHENOTYPE	10	10	ventilation
NCT0020231915	NCT00202319_15_T0	PHENOTYPE	19	19	ventilation
NCT0020231917	NCT00202319_17_T0	PHENOTYPE	20	20	discomfort
NCT0020231918	NCT00202319_18_T0	PHENOTYPE	9	9	perceptions
NCT0020231919	NCT00202319_19_T0	PHENOTYPE	35	35	ventilation
NCT0020231919	NCT00202319_19_T1	COMPOUND	12	12	1
NCT0020231919	NCT00202319_19_T2	COMPOUND	27	27	2
NCT0020231919	NCT00202319_19_T3	COMPOUND	50	50	3
NCT0020231919	NCT00202319_19_T4	PHENOTYPE	32	32	perceptions
NCT0020231919	NCT00202319_19_T5	PHENOTYPE	52	52	perceptions
NCT0020231919	NCT00202319_19_T6	PHENOTYPE	60	61	critically ill
NCT0020231923	NCT00202319_23_T0	PHENOTYPE	3	3	perceptions
NCT0020231924	NCT00202319_24_T0	PHENOTYPE	3	3	perceptions
NCT0020231924	NCT00202319_24_T1	PHENOTYPE	11	11	perceptions
NCT0020231924	NCT00202319_24_T2	PHENOTYPE	9	9	attitudes
NCT0020231925	NCT00202319_25_T0	PHENOTYPE	13	14	critically ill
NCT0020231926	NCT00202319_26_T0	PHENOTYPE	12	12	perceptions
NCT0020231926	NCT00202319_26_T1	PHENOTYPE	22	22	practices
NCT0020231927	NCT00202319_27_T0	PHENOTYPE	3	3	perceptions
NCT002023451	NCT00202345_1_T0	PHENOTYPE	19	19	anaemia
NCT002023455	NCT00202345_5_T0	PHENOTYPE	7	7	chronic
NCT002023455	NCT00202345_5_T1	PHENOTYPE	8	9	kidney disease
NCT002023455	NCT00202345_5_T2	CELL	18	20	red blood cells
NCT002023457	NCT00202345_7_T0	PHENOTYPE	16	16	anaemia
NCT002023457	NCT00202345_7_T1	COMPOUND	6	6	sucrose
NCT002023457	NCT00202345_7_T2	PHENOTYPE	20	21	stage 3
NCT002023457	NCT00202345_7_T3	PHENOTYPE	23	24	kidney disease
NCT0020234510	NCT00202345_10_T0	GENE	30	30	transferrin
NCT0020234510	NCT00202345_10_T1	COMPOUND	6	6	sucrose
NCT0020234510	NCT00202345_10_T2	PHENOTYPE	22	23	ferritin levels
NCT0020234511	NCT00202345_11_T0	COMPOUND	7	7	sucrose
NCT0020234514	NCT00202345_14_T0	COMPOUND	15	15	sucrose
NCT0020234514	NCT00202345_14_T1	PHENOTYPE	2	3	Group B
NCT0020234514	NCT00202345_14_T2	PHENOTYPE	21	22	iron levels
NCT0020234515	NCT00202345_15_T0	GENE	27	27	ferritin
NCT0020234515	NCT00202345_15_T1	GENE	29	29	transferrin
NCT0020234515	NCT00202345_15_T2	COMPOUND	19	19	sucrose
NCT0020234515	NCT00202345_15_T3	PHENOTYPE	2	3	Group B
NCT0020234517	NCT00202345_17_T0	PHENOTYPE	2	2	concentrations
NCT0020234517	NCT00202345_17_T1	GENE	1	1	Hb
NCT0020234518	NCT00202345_18_T0	GENE	1	1	GFR
NCT0020234519	NCT00202345_19_T0	COMPOUND	7	7	creatinine
NCT0020234519	NCT00202345_19_T1	GENE	12	12	Hb
NCT0020234524	NCT00202345_24_T0	PHENOTYPE	1	3	ischaemic heart disease
NCT0020234525	NCT00202345_25_T0	PHENOTYPE	2	4	congestive cardiac failure
NCT0020234526	NCT00202345_26_T0	GENE	4	4	ferritin
NCT0020234526	NCT00202345_26_T1	PHENOTYPE	0	0	Haemochromatosis
NCT0020234526	NCT00202345_26_T2	PHENOTYPE	2	3	iron overload
NCT0020234528	NCT00202345_28_T0	PHENOTYPE	0	1	Myelodysplastic syndromes
NCT0020234528	NCT00202345_28_T1	PHENOTYPE	3	4	monoclonal gammopathies
NCT0020234529	NCT00202345_29_T0	PHENOTYPE	1	1	malignancy
NCT0020234529	NCT00202345_29_T1	PHENOTYPE	3	4	gastrointestinal bleeding
NCT0020234531	NCT00202345_31_T0	PHENOTYPE	0	1	Iron deficiency
NCT0020234535	NCT00202345_35_T0	PHENOTYPE	1	2	polycystic kidney
NCT002023581	NCT00202358_1_T0	COMPOUND	4	4	atenolol
NCT002023582	NCT00202358_2_T0	ORGAN	20	20	heart
NCT002023583	NCT00202358_3_T0	COMPOUND	9	9	atenolol
NCT002023583	NCT00202358_3_T1	ORGAN	24	24	heart
NCT002023584	NCT00202358_4_T0	PHENOTYPE	4	4	inflammation
NCT002023840	NCT00202384_0_T0	GENE	3	3	MS
NCT002023840	NCT00202384_0_T1	BIOLOGICAL_PROCESS	0	1	Gene Expression
NCT002023843	NCT00202384_3_T0	GENE	15	15	MS
NCT002023973	NCT00202397_3_T0	CELL	1	1	neurons
NCT002023973	NCT00202397_3_T1	GENE	0	0	DCN
NCT002023973	NCT00202397_3_T2	GENE	17	17	DCN
NCT002023973	NCT00202397_3_T3	CELL	11	12	Purkinje neurons
NCT002023978	NCT00202397_8_T0	COMPOUND	9	9	riluzole
NCT002024102	NCT00202410_2_T0	PHENOTYPE	19	19	symptoms
NCT002024103	NCT00202410_3_T0	PHENOTYPE	28	28	Tuberculosis
NCT002024103	NCT00202410_3_T1	ORGAN	10	11	immune system
NCT002024103	NCT00202410_3_T2	ORGAN	36	37	immune system
NCT002024106	NCT00202410_6_T0	GENE	8	8	has
NCT002024107	NCT00202410_7_T0	GENE	30	30	MS
NCT002024107	NCT00202410_7_T1	GENE	15	15	poly
NCT002024109	NCT00202410_9_T0	GENE	7	7	MRI
NCT0020241011	NCT00202410_11_T0	PHENOTYPE	23	24	multiple sclerosis
NCT002024233	NCT00202423_3_T0	PHENOTYPE	25	25	suffering
NCT002024233	NCT00202423_3_T1	GENE	23	23	MS
NCT002024233	NCT00202423_3_T2	PHENOTYPE	39	39	excitability
NCT002024233	NCT00202423_3_T3	COMPOUND	11	11	Sativex
NCT002024233	NCT00202423_3_T4	PHENOTYPE	27	27	spasticity
NCT002024233	NCT00202423_3_T5	PHENOTYPE	33	33	spasticity
NCT002024233	NCT00202423_3_T6	GENE	51	51	TMS
NCT002024233	NCT00202423_3_T7	ORGAN	47	48	motor areas
NCT002024235	NCT00202423_5_T0	COMPOUND	12	12	Sativex
NCT0020242313	NCT00202423_13_T0	PHENOTYPE	5	5	secondary
NCT0020242313	NCT00202423_13_T1	PHENOTYPE	6	6	progressive
NCT0020242314	NCT00202423_14_T0	GENE	4	4	3.0
NCT0020242314	NCT00202423_14_T1	GENE	6	6	6.5
NCT0020242314	NCT00202423_14_T2	COMPOUND	1	1	EDSS
NCT0020242319	NCT00202423_19_T0	ORGAN	12	12	serum
NCT0020242321	NCT00202423_21_T0	PHENOTYPE	3	3	cannabis
NCT0020242321	NCT00202423_21_T1	PHENOTYPE	25	25	cannabis
NCT0020242322	NCT00202423_22_T0	PHENOTYPE	1	1	spasticity
NCT0020242324	NCT00202423_24_T0	GENE	4	4	MS
NCT0020242324	NCT00202423_24_T1	PHENOTYPE	3	3	progressive
NCT0020242328	NCT00202423_28_T0	PHENOTYPE	5	6	cognitive impairment
NCT0020242328	NCT00202423_28_T1	PHENOTYPE	2	3	psychiatric disorders
NCT0020242329	NCT00202423_29_T0	PHENOTYPE	5	6	substance abuse
NCT0020242330	NCT00202423_30_T0	ORGAN	8	8	thyroid
NCT0020242330	NCT00202423_30_T1	ORGAN	6	6	liver
NCT0020242330	NCT00202423_30_T2	GENE	15	15	MS
NCT0020242331	NCT00202423_31_T0	PHENOTYPE	2	2	disorders
NCT0020242331	NCT00202423_31_T1	PHENOTYPE	8	8	arrhythmias
NCT0020242331	NCT00202423_31_T2	PHENOTYPE	11	11	hypertension
NCT0020242331	NCT00202423_31_T3	PHENOTYPE	14	15	heart failure
NCT0020242331	NCT00202423_31_T4	PHENOTYPE	5	7	ischaemic heart disease
NCT0020242332	NCT00202423_32_T0	PHENOTYPE	3	3	acute
NCT0020242332	NCT00202423_32_T1	PHENOTYPE	1	1	suffering
NCT0020242332	NCT00202423_32_T2	PHENOTYPE	5	5	chronic
NCT0020242335	NCT00202423_35_T0	PHENOTYPE	8	8	anaesthesia
NCT0020242337	NCT00202423_37_T0	GENE	11	11	MS
NCT0020242338	NCT00202423_38_T0	COMPOUND	1	1	levodopa
NCT0020242339	NCT00202423_39_T0	COMPOUND	4	4	sildenafil
NCT0020242341	NCT00202423_41_T0	PHENOTYPE	3	4	adverse reaction
NCT002024493	NCT00202449_3_T0	PHENOTYPE	1	1	symptoms
NCT002024493	NCT00202449_3_T1	PHENOTYPE	6	6	symptoms
NCT002024493	NCT00202449_3_T2	PHENOTYPE	11	11	PTSD
NCT002024493	NCT00202449_3_T3	GENE	22	22	OIF
NCT002024493	NCT00202449_3_T4	PHENOTYPE	8	10	posttraumatic stress disorder
NCT002024494	NCT00202449_4_T0	PHENOTYPE	15	15	trauma
NCT002024494	NCT00202449_4_T1	GENE	11	11	reduced
NCT002024494	NCT00202449_4_T2	GENE	27	27	OIF
NCT002024494	NCT00202449_4_T3	BIOLOGICAL_PROCESS	6	6	alpha-1
NCT002024494	NCT00202449_4_T4	GENE	8	8	receptor
NCT002024494	NCT00202449_4_T5	PHENOTYPE	16	16	nightmares
NCT002024495	NCT00202449_5_T0	PHENOTYPE	15	15	trauma
NCT002024495	NCT00202449_5_T1	GENE	5	5	OIF
NCT002024495	NCT00202449_5_T2	PHENOTYPE	28	28	PTSD
NCT002024495	NCT00202449_5_T3	PHENOTYPE	16	16	nightmares
NCT002024495	NCT00202449_5_T4	PHENOTYPE	27	27	chronic
NCT002024495	NCT00202449_5_T5	COMPOUND	3	3	prazosin
NCT002024495	NCT00202449_5_T6	COMPOUND	13	13	prazosin
NCT002024495	NCT00202449_5_T7	PHENOTYPE	17	18	sleep disturbance
NCT002024496	NCT00202449_6_T0	PHENOTYPE	6	6	PTSD
NCT002024496	NCT00202449_6_T1	COMPOUND	16	16	paroxetine
NCT002024496	NCT00202449_6_T2	COMPOUND	14	14	sertraline
NCT002024497	NCT00202449_7_T0	PHENOTYPE	5	5	trauma
NCT002024497	NCT00202449_7_T1	PHENOTYPE	10	10	symptoms
NCT002024497	NCT00202449_7_T2	PHENOTYPE	6	6	PTSD
NCT002024498	NCT00202449_8_T0	PHENOTYPE	14	14	trauma
NCT002024498	NCT00202449_8_T1	PHENOTYPE	25	25	severity
NCT002024498	NCT00202449_8_T2	PHENOTYPE	23	23	PTSD
NCT002024498	NCT00202449_8_T3	COMPOUND	11	11	paroxetine
NCT002024498	NCT00202449_8_T4	PHENOTYPE	15	15	nightmares
NCT002024498	NCT00202449_8_T5	COMPOUND	7	7	prazosin
NCT002024498	NCT00202449_8_T6	PHENOTYPE	16	17	sleep disturbance
NCT002024498	NCT00202449_8_T7	PHENOTYPE	20	22	posttraumatic stress disorder
NCT0020244910	NCT00202449_10_T0	PHENOTYPE	18	18	PTSD
NCT0020244910	NCT00202449_10_T1	PHENOTYPE	19	19	pathophysiology
NCT0020244910	NCT00202449_10_T2	ORGAN	9	11	central nervous system
NCT0020244912	NCT00202449_12_T0	COMPOUND	15	15	paroxetine
NCT0020244912	NCT00202449_12_T1	COMPOUND	13	13	prazosin
NCT0020244915	NCT00202449_15_T0	COMPOUND	6	6	paroxetine
NCT0020244917	NCT00202449_17_T0	COMPOUND	6	6	paroxetine
NCT0020244919	NCT00202449_19_T0	GENE	11	11	retained
NCT0020244919	NCT00202449_19_T1	COMPOUND	6	6	paroxetine
NCT0020244919	NCT00202449_19_T2	PHENOTYPE	18	19	adverse events
NCT002024621	NCT00202462_1_T0	COMPOUND	5	5	testosterone
NCT002024621	NCT00202462_1_T1	GENE	6	6	gel
NCT002024621	NCT00202462_1_T2	GENE	11	11	gel
NCT002024622	NCT00202462_2_T0	COMPOUND	14	14	testosterone
NCT002024622	NCT00202462_2_T1	GENE	15	15	gel
NCT002024623	NCT00202462_3_T0	COMPOUND	13	13	testosterone
NCT002024623	NCT00202462_3_T1	GENE	14	14	gel
NCT002024626	NCT00202462_6_T0	COMPOUND	21	21	testosterone
NCT002024626	NCT00202462_6_T1	GENE	22	22	gel
NCT002024628	NCT00202462_8_T0	PHENOTYPE	9	9	Enjoyment
NCT002024628	NCT00202462_8_T1	PHENOTYPE	20	21	life changes
NCT002024628	NCT00202462_8_T2	PHENOTYPE	6	8	Quality of Life
NCT002024628	NCT00202462_8_T3	PHENOTYPE	18	20	quality of life
NCT0020246212	NCT00202462_12_T0	PHENOTYPE	5	7	Quality of Life
NCT0020246214	NCT00202462_14_T0	COMPOUND	3	3	testosterone
NCT002024883	NCT00202488_3_T0	GENE	13	13	IDA
NCT002024883	NCT00202488_3_T1	PHENOTYPE	15	15	resolved
NCT002024884	NCT00202488_4_T0	BIOLOGICAL_PROCESS	7	7	metabolism
NCT002024885	NCT00202488_5_T0	PHENOTYPE	9	10	iron absorption
NCT002024886	NCT00202488_6_T0	PHENOTYPE	7	7	strains
NCT002024886	NCT00202488_6_T1	PHENOTYPE	21	21	strains
NCT002024886	NCT00202488_6_T2	PHENOTYPE	29	29	gastritis
NCT002024886	NCT00202488_6_T3	PHENOTYPE	11	12	iron deficiency
NCT002024887	NCT00202488_7_T0	TISSUE	13	14	gastric mucosa
NCT002024889	NCT00202488_9_T0	GENE	10	10	IDA
NCT002024889	NCT00202488_9_T1	GENE	24	24	IDA
NCT002024889	NCT00202488_9_T2	PHENOTYPE	3	4	iron absorption
NCT002024889	NCT00202488_9_T3	PHENOTYPE	16	17	iron absorption
NCT0020248810	NCT00202488_10_T0	GENE	22	22	IDA
NCT0020248810	NCT00202488_10_T1	PHENOTYPE	10	11	iron absorption
NCT0020248810	NCT00202488_10_T2	PHENOTYPE	39	40	iron absorption
NCT0020248812	NCT00202488_12_T0	PHENOTYPE	4	4	strain
NCT0020248812	NCT00202488_12_T1	GENE	7	7	IDA
NCT0020248815	NCT00202488_15_T0	TISSUE	13	14	gastric mucosa
NCT0020248816	NCT00202488_16_T0	GENE	19	19	IDA
NCT0020248816	NCT00202488_16_T1	GENE	24	24	IDA
NCT002025013	NCT00202501_3_T0	PHENOTYPE	19	19	apnea
NCT002025013	NCT00202501_3_T1	PHENOTYPE	20	20	Hypertension
NCT002025013	NCT00202501_3_T2	PHENOTYPE	23	23	Cardiopathy
NCT002025013	NCT00202501_3_T3	PHENOTYPE	17	17	snoring
NCT002025014	NCT00202501_4_T0	PHENOTYPE	15	15	Sleepiness
NCT002025016	NCT00202501_6_T0	PHENOTYPE	33	33	recurrences
NCT002025016	NCT00202501_6_T1	GENE	23	23	BP
NCT002025016	NCT00202501_6_T2	COMPOUND	20	20	BMI
NCT002025016	NCT00202501_6_T3	PHENOTYPE	24	25	functional recovery
NCT002025016	NCT00202501_6_T4	PHENOTYPE	29	31	quality of life
NCT002025017	NCT00202501_7_T0	GENE	1	1	CPAP
NCT0020250110	NCT00202501_10_T0	PHENOTYPE	23	23	centers
NCT002025141	NCT00202514_1_T0	PHENOTYPE	5	5	symptoms
NCT002025141	NCT00202514_1_T1	PHENOTYPE	15	15	symptoms
NCT002025141	NCT00202514_1_T2	PHENOTYPE	23	23	disorders
NCT002025141	NCT00202514_1_T3	GENE	2	2	has
NCT002025141	NCT00202514_1_T4	PHENOTYPE	21	22	mental health
NCT002025141	NCT00202514_1_T5	PHENOTYPE	17	18	bipolar disorder
NCT002025141	NCT00202514_1_T6	PHENOTYPE	7	9	acute alcohol withdrawal
NCT002025142	NCT00202514_2_T0	PHENOTYPE	15	15	symptoms
NCT002025142	NCT00202514_2_T1	COMPOUND	8	8	sodium
NCT002025142	NCT00202514_2_T2	PHENOTYPE	25	25	relapse
NCT002025144	NCT00202514_4_T0	PHENOTYPE	9	10	alcohol dependence
NCT002025145	NCT00202514_5_T0	PHENOTYPE	9	9	relapse
NCT002025145	NCT00202514_5_T1	PHENOTYPE	19	19	strategies
NCT002025145	NCT00202514_5_T2	GENE	11	11	has
NCT002025145	NCT00202514_5_T3	PHENOTYPE	6	7	alcohol dependence
NCT002025146	NCT00202514_6_T0	PHENOTYPE	22	22	symptoms
NCT002025146	NCT00202514_6_T1	COMPOUND	4	4	sodium
NCT002025146	NCT00202514_6_T2	COMPOUND	8	8	valproate
NCT002025146	NCT00202514_6_T3	GENE	25	25	has
NCT002025146	NCT00202514_6_T4	PHENOTYPE	13	14	mood disorders
NCT002025148	NCT00202514_8_T0	GENE	3	3	had
NCT002025148	NCT00202514_8_T1	PHENOTYPE	13	14	anxiety disorders
NCT0020251411	NCT00202514_11_T0	GENE	10	10	extended
NCT0020251417	NCT00202514_17_T0	COMPOUND	23	23	1st
NCT0020251421	NCT00202514_21_T0	COMPOUND	9	9	sodium
NCT0020251421	NCT00202514_21_T1	GENE	10	10	extended
NCT0020251422	NCT00202514_22_T0	PHENOTYPE	11	11	Addiction
NCT0020251432	NCT00202514_32_T0	PHENOTYPE	3	4	alcohol dependence
NCT0020251434	NCT00202514_34_T0	PHENOTYPE	4	4	symptoms
NCT0020251434	NCT00202514_34_T1	PHENOTYPE	24	24	severity
NCT0020251434	NCT00202514_34_T2	PHENOTYPE	21	21	hostility
NCT0020251438	NCT00202514_38_T0	PHENOTYPE	0	1	Opioid dependence
NCT0020251440	NCT00202514_40_T0	PHENOTYPE	4	5	psychiatric disorder
NCT0020251442	NCT00202514_42_T0	COMPOUND	7	7	benzodiazepine
NCT0020251452	NCT00202514_52_T0	PHENOTYPE	0	0	Pancreatitis
NCT0020251452	NCT00202514_52_T1	PHENOTYPE	2	4	signs and symptoms
NCT0020251454	NCT00202514_54_T0	PHENOTYPE	1	1	allergy
NCT002025272	NCT00202527_2_T0	GENE	9	9	SH
NCT002025273	NCT00202527_3_T0	GENE	8	8	CPAP
NCT002025277	NCT00202527_7_T0	GENE	4	4	chi
NCT002025279	NCT00202527_9_T0	GENE	10	10	CPAP
NCT002025530	NCT00202553_0_T0	PHENOTYPE	3	3	Hypertension
NCT002025920	NCT00202592_0_T0	PHENOTYPE	3	3	Hypertension
NCT002026051	NCT00202605_1_T0	GENE	8	8	extended
NCT002026183	NCT00202618_3_T0	PHENOTYPE	17	17	microalbuminuria
NCT002026183	NCT00202618_3_T1	GENE	9	10	calcium channel
NCT002026183	NCT00202618_3_T2	GENE	5	6	angiotensin receptor
NCT002026186	NCT00202618_6_T0	COMPOUND	15	15	valsartan
NCT002026186	NCT00202618_6_T1	COMPOUND	9	9	amlodipine
NCT002026187	NCT00202618_7_T0	COMPOUND	32	32	valsartan
NCT002026187	NCT00202618_7_T1	COMPOUND	26	26	amlodipine
NCT002026310	NCT00202631_0_T0	PHENOTYPE	5	5	Tetraplegia
NCT002026313	NCT00202631_3_T0	GENE	8	8	painless
NCT002026313	NCT00202631_3_T1	PHENOTYPE	10	10	tetraplegia
NCT002026319	NCT00202631_9_T0	PHENOTYPE	7	7	cough
NCT002026319	NCT00202631_9_T1	PHENOTYPE	3	4	tidal volumes
NCT0020263110	NCT00202631_10_T0	PHENOTYPE	18	19	chest problems
NCT0020263110	NCT00202631_10_T1	PHENOTYPE	5	6	respiratory complications
NCT0020263111	NCT00202631_11_T0	PHENOTYPE	9	9	ventilation
NCT0020263111	NCT00202631_11_T1	PHENOTYPE	14	15	tidal volume
NCT0020263114	NCT00202631_14_T0	ORGAN	5	6	chest wall
NCT0020263116	NCT00202631_16_T0	PHENOTYPE	13	14	abdominal discomfort
NCT0020263116	NCT00202631_16_T1	PHENOTYPE	6	7	physiological processes
NCT0020263117	NCT00202631_17_T0	PHENOTYPE	5	5	acute
NCT0020263117	NCT00202631_17_T1	PHENOTYPE	14	14	ventilation
NCT0020263118	NCT00202631_18_T0	PHENOTYPE	12	12	ventilation
NCT0020263119	NCT00202631_19_T0	GENE	30	30	FES
NCT0020263119	NCT00202631_19_T1	PHENOTYPE	7	8	Spinal Injuries
NCT0020263120	NCT00202631_20_T0	GENE	0	0	FES
NCT0020263120	NCT00202631_20_T1	PHENOTYPE	17	17	tetraplegia
NCT0020263120	NCT00202631_20_T2	ORGAN	13	14	upper limb
NCT0020263121	NCT00202631_21_T0	GENE	4	4	FES
NCT0020263121	NCT00202631_21_T1	GENE	3	3	abdominal
NCT0020263121	NCT00202631_21_T2	PHENOTYPE	11	12	diaphragm paralysis
NCT0020263121	NCT00202631_21_T3	PHENOTYPE	16	17	tidal volume
NCT0020263123	NCT00202631_23_T0	GENE	8	8	FES
NCT0020263124	NCT00202631_24_T0	ORGAN	17	18	spinal cord
NCT002026441	NCT00202644_1_T0	CELL	3	3	cells
NCT002026441	NCT00202644_1_T1	CELL	0	0	Platelets
NCT002026441	NCT00202644_1_T2	PHENOTYPE	12	13	blood clots
NCT002026442	NCT00202644_2_T0	PHENOTYPE	17	17	bleeding
NCT002026442	NCT00202644_2_T1	CELL	5	5	platelets
NCT002026442	NCT00202644_2_T2	PHENOTYPE	11	12	blood clots
NCT002026573	NCT00202657_3_T0	GENE	8	8	had
NCT002026573	NCT00202657_3_T1	GENE	21	21	has
NCT002026573	NCT00202657_3_T2	PHENOTYPE	6	7	side effect
NCT002026573	NCT00202657_3_T3	PHENOTYPE	12	13	Parkinson's disease
NCT002026574	NCT00202657_4_T0	PHENOTYPE	13	14	adverse event
NCT002026575	NCT00202657_5_T0	COMPOUND	10	10	pergolide
NCT002026575	NCT00202657_5_T1	COMPOUND	24	24	pergolide
NCT002026575	NCT00202657_5_T2	PHENOTYPE	11	13	heart valve disease
NCT002026831	NCT00202683_1_T0	PHENOTYPE	9	9	falls
NCT002026831	NCT00202683_1_T1	PHENOTYPE	3	3	hyperventilation
NCT002026831	NCT00202683_1_T2	BIOLOGICAL_PROCESS	1	1	reflex
NCT002026831	NCT00202683_1_T3	COMPOUND	8	8	oxygen
NCT002026832	NCT00202683_2_T0	COMPOUND	8	8	oxygen
NCT002026833	NCT00202683_3_T0	PHENOTYPE	14	15	cerebral edema
NCT002026833	NCT00202683_3_T1	PHENOTYPE	19	20	severe headache
NCT002026835	NCT00202683_5_T0	PHENOTYPE	9	9	hypoxia
NCT002026835	NCT00202683_5_T1	PHENOTYPE	6	6	hyperventilation
NCT002026835	NCT00202683_5_T2	GENE	21	21	mitochondrial
NCT002026836	NCT00202683_6_T0	COMPOUND	8	8	oxygen
NCT002026839	NCT00202683_9_T0	PHENOTYPE	14	15	pulmonary edema
NCT002026839	NCT00202683_9_T1	PHENOTYPE	11	12	cerebral edema
NCT002027093	NCT00202709_3_T0	PHENOTYPE	16	16	PTSD
NCT002027093	NCT00202709_3_T1	GENE	23	23	TFT
NCT002027093	NCT00202709_3_T2	PHENOTYPE	12	12	agoraphobia
NCT002027093	NCT00202709_3_T3	PHENOTYPE	13	14	social phobia
NCT002027094	NCT00202709_4_T0	GENE	4	4	got
NCT002027095	NCT00202709_5_T0	GENE	1	1	1.2
NCT002027096	NCT00202709_6_T0	GENE	7	7	got
NCT002027222	NCT00202722_2_T0	PHENOTYPE	12	12	analgesia
NCT002027222	NCT00202722_2_T1	COMPOUND	9	9	remifentanil
NCT002027223	NCT00202722_3_T0	PHENOTYPE	3	3	analgesia
NCT002027223	NCT00202722_3_T1	COMPOUND	9	9	remifentanil
NCT002027227	NCT00202722_7_T0	GENE	12	12	STAN
NCT002027227	NCT00202722_7_T1	ORGAN	0	1	Fetal heart
NCT0020272212	NCT00202722_12_T0	COMPOUND	10	10	remifentanil
NCT0020272212	NCT00202722_12_T1	ORGAN	0	2	Umbilical cord blood
NCT0020272213	NCT00202722_13_T0	PHENOTYPE	25	25	dizziness
NCT0020272213	NCT00202722_13_T1	COMPOUND	15	15	remifentanil
NCT0020272213	NCT00202722_13_T2	PHENOTYPE	20	20	vomiting
NCT0020272213	NCT00202722_13_T3	PHENOTYPE	19	19	nausea
NCT002027350	NCT00202735_0_T0	PHENOTYPE	10	10	Recurrence
NCT002027350	NCT00202735_0_T1	PHENOTYPE	13	14	Shoulder Dislocation
NCT002027353	NCT00202735_3_T0	PHENOTYPE	7	8	anterior dislocation
NCT002027354	NCT00202735_4_T0	PHENOTYPE	3	3	recurrence
NCT002027354	NCT00202735_4_T1	PHENOTYPE	24	24	recurrence
NCT002027354	NCT00202735_4_T2	PHENOTYPE	13	13	dislocation
NCT002027356	NCT00202735_6_T0	PHENOTYPE	4	4	avulsion
NCT002027356	NCT00202735_6_T1	PHENOTYPE	17	19	anterior shoulder dislocation
NCT0020273513	NCT00202735_13_T0	PHENOTYPE	5	5	trauma
NCT0020273513	NCT00202735_13_T1	PHENOTYPE	7	7	centers
NCT0020273514	NCT00202735_14_T0	GENE	14	14	MRI
NCT0020273518	NCT00202735_18_T0	PHENOTYPE	1	1	dislocation
NCT002027484	NCT00202748_4_T0	PHENOTYPE	12	12	obesity
NCT002027877	NCT00202787_7_T0	PHENOTYPE	0	0	Recurrence
NCT002028001	NCT00202800_1_T0	COMPOUND	21	21	etoposide
NCT002028001	NCT00202800_1_T1	COMPOUND	19	19	gemcitabine
NCT002028001	NCT00202800_1_T2	GENE	8	8	oncogene
NCT002028002	NCT00202800_2_T0	GENE	2	2	II
NCT002028002	NCT00202800_2_T1	PHENOTYPE	13	15	metastatic pancreatic cancer
NCT002028004	NCT00202800_4_T0	COMPOUND	21	21	etoposide
NCT002028004	NCT00202800_4_T1	COMPOUND	19	19	gemcitabine
NCT002028004	NCT00202800_4_T2	GENE	8	8	oncogene
NCT002028006	NCT00202800_6_T0	PHENOTYPE	9	10	pancreatic cancer
NCT002028007	NCT00202800_7_T0	PHENOTYPE	11	11	toxicity
NCT002028007	NCT00202800_7_T1	PHENOTYPE	7	9	quality of life
NCT002028008	NCT00202800_8_T0	PHENOTYPE	14	15	pancreatic cancer
NCT002028009	NCT00202800_9_T0	PHENOTYPE	0	0	Secondary
NCT0020280014	NCT00202800_14_T0	PHENOTYPE	13	13	toxicity
NCT0020280014	NCT00202800_14_T1	PHENOTYPE	3	5	quality of life
NCT0020280015	NCT00202800_15_T0	PHENOTYPE	25	25	toxicity
NCT0020280015	NCT00202800_15_T1	PHENOTYPE	18	19	disease progression
NCT002028132	NCT00202813_2_T0	PHENOTYPE	13	14	critically ill
NCT002028133	NCT00202813_3_T0	PHENOTYPE	18	18	peripheral
NCT002028135	NCT00202813_5_T0	PHENOTYPE	9	9	bloodstream
NCT002028135	NCT00202813_5_T1	PHENOTYPE	10	10	infections
NCT002028135	NCT00202813_5_T2	GENE	1	1	has
NCT002028138	NCT00202813_8_T0	PHENOTYPE	26	26	infections
NCT0020281311	NCT00202813_11_T0	GENE	3	3	hub
NCT0020281313	NCT00202813_13_T0	PHENOTYPE	7	7	infections
NCT0020281316	NCT00202813_16_T0	PHENOTYPE	30	30	bloodstream
NCT0020281316	NCT00202813_16_T1	COMPOUND	19	19	minocycline
NCT0020281316	NCT00202813_16_T2	GENE	23	23	reduced
NCT0020281316	NCT00202813_16_T3	GENE	2	2	al
NCT0020281316	NCT00202813_16_T4	GENE	1	1	et
NCT002028263	NCT00202826_3_T0	PHENOTYPE	6	6	effusions
NCT002028265	NCT00202826_5_T0	PHENOTYPE	7	8	parapneumonic effusion
NCT002028268	NCT00202826_8_T0	PHENOTYPE	13	13	effusions
NCT002028269	NCT00202826_9_T0	PHENOTYPE	0	0	Insights
NCT0020282610	NCT00202826_10_T0	PHENOTYPE	16	17	parapneumonic effusion
NCT0020282611	NCT00202826_11_T0	PHENOTYPE	12	13	parapneumonic effusion
NCT002028393	NCT00202839_3_T0	ORGAN	8	8	serum
NCT002028521	NCT00202852_1_T0	GENE	11	11	MTX
NCT002028521	NCT00202852_1_T1	COMPOUND	10	10	methotrexate
NCT002028522	NCT00202852_2_T0	GENE	27	27	RA
NCT002028522	NCT00202852_2_T1	PHENOTYPE	25	26	rheumatoid arthritis
NCT002028522	NCT00202852_2_T2	PHENOTYPE	21	23	signs and symptoms
NCT0020285214	NCT00202852_14_T0	GENE	15	15	had
NCT0020285214	NCT00202852_14_T1	GENE	6	6	has
NCT0020285214	NCT00202852_14_T2	PHENOTYPE	30	31	infectious disease
NCT002028652	NCT00202865_2_T0	PHENOTYPE	28	28	nearest
NCT002029041	NCT00202904_1_T0	GENE	29	29	lipoprotein
NCT002029041	NCT00202904_1_T1	COMPOUND	19	19	atorvastatin
NCT002029041	NCT00202904_1_T2	GENE	12	12	CHD
NCT002029041	NCT00202904_1_T3	PHENOTYPE	6	7	primary hypercholesterolemia
NCT002029041	NCT00202904_1_T4	PHENOTYPE	9	11	coronary heart disease
NCT002029170	NCT00202917_0_T0	ORGAN	5	5	Grafts
NCT002029170	NCT00202917_0_T1	PHENOTYPE	9	10	Hematologic Malignancies
NCT002029304	NCT00202930_4_T0	PHENOTYPE	2	2	neuroblastoma
NCT002029306	NCT00202930_6_T0	GENE	1	1	lines
NCT002029306	NCT00202930_6_T1	PHENOTYPE	10	11	rare disorder
NCT002029307	NCT00202930_7_T0	GENE	4	4	OMS
NCT002029307	NCT00202930_7_T1	GENE	18	18	OMS
NCT002029307	NCT00202930_7_T2	PHENOTYPE	14	14	tumor
NCT002029307	NCT00202930_7_T3	PHENOTYPE	27	27	suppression
NCT002029307	NCT00202930_7_T4	PHENOTYPE	10	11	lymphocytic infiltration
NCT002029307	NCT00202930_7_T5	ORGAN	30	31	immune system
NCT002029308	NCT00202930_8_T0	GENE	8	8	CD
NCT002029308	NCT00202930_8_T1	GENE	17	17	OMS
NCT002029309	NCT00202930_9_T0	PHENOTYPE	6	6	symptoms
NCT002029309	NCT00202930_9_T1	GENE	8	8	OMS
NCT002029309	NCT00202930_9_T2	PHENOTYPE	14	14	tumor
NCT0020293010	NCT00202930_10_T0	GENE	4	4	OMS
NCT0020293011	NCT00202930_11_T0	GENE	0	0	OMS
NCT0020293012	NCT00202930_12_T0	GENE	0	0	OMS
NCT0020293013	NCT00202930_13_T0	PHENOTYPE	23	23	neuroblastoma
NCT002029432	NCT00202943_2_T0	PHENOTYPE	4	4	snore
NCT002029433	NCT00202943_3_T0	PHENOTYPE	7	9	obstructive sleep apnea
NCT002029560	NCT00202956_0_T0	PHENOTYPE	8	8	Osteoporosis
NCT002029565	NCT00202956_5_T0	ORGAN	13	13	spine
NCT002029566	NCT00202956_6_T0	GENE	8	8	ICF
NCT002029568	NCT00202956_8_T0	PHENOTYPE	9	9	secondary
NCT002029568	NCT00202956_8_T1	PHENOTYPE	6	6	scoliosis
NCT002029568	NCT00202956_8_T2	PHENOTYPE	10	10	osteoporosis
NCT002029569	NCT00202956_9_T0	PHENOTYPE	5	6	bone fracture
NCT0020295611	NCT00202956_11_T0	COMPOUND	3	3	estrogen
NCT0020295611	NCT00202956_11_T1	GENE	5	5	calcitonin
NCT0020295611	NCT00202956_11_T2	COMPOUND	8	8	ipriflavone
NCT0020295611	NCT00202956_11_T3	COMPOUND	6	6	fluoride
NCT0020295611	NCT00202956_11_T4	COMPOUND	4	4	bisphosphonates
NCT002029822	NCT00202982_2_T0	GENE	2	2	MS
NCT002029824	NCT00202982_4_T0	PHENOTYPE	8	8	relapse
NCT002029824	NCT00202982_4_T1	GENE	3	3	had
NCT002029826	NCT00202982_6_T0	GENE	17	17	MRI
NCT002029826	NCT00202982_6_T1	COMPOUND	11	11	gadolinium
NCT002029828	NCT00202982_8_T0	GENE	10	10	IM
NCT002029828	NCT00202982_8_T1	GENE	9	9	IV
NCT0020298210	NCT00202982_10_T0	GENE	7	7	IM
NCT0020298210	NCT00202982_10_T1	GENE	6	6	IV
NCT0020298214	NCT00202982_14_T0	PHENOTYPE	12	12	IUD
NCT0020298218	NCT00202982_18_T0	COMPOUND	7	7	EDSS
NCT0020298222	NCT00202982_22_T0	COMPOUND	3	4	glatiramer acetate
NCT0020298224	NCT00202982_24_T0	COMPOUND	3	3	cladribine
NCT0020298230	NCT00202982_30_T0	GENE	2	2	interferon
NCT0020298232	NCT00202982_32_T0	PHENOTYPE	0	0	Chronic
NCT0020298232	NCT00202982_32_T1	GENE	3	3	IM
NCT0020298232	NCT00202982_32_T2	GENE	2	2	IV
NCT0020298238	NCT00202982_38_T0	COMPOUND	9	9	1
NCT0020298238	NCT00202982_38_T1	PHENOTYPE	4	4	relapse
NCT0020298239	NCT00202982_39_T0	PHENOTYPE	5	5	feels
NCT002029951	NCT00202995_1_T0	GENE	8	8	MS
NCT002029951	NCT00202995_1_T1	PHENOTYPE	12	13	disease course
NCT002029952	NCT00202995_2_T0	GENE	6	6	interferon
NCT002029953	NCT00202995_3_T0	PHENOTYPE	8	8	relapse
NCT002029955	NCT00202995_5_T0	COMPOUND	1	1	gadolinium
NCT002029957	NCT00202995_7_T0	GENE	10	10	0.5
NCT002029957	NCT00202995_7_T1	COMPOUND	7	7	EDSS
NCT0020299510	NCT00202995_10_T0	PHENOTYPE	14	14	IUD
NCT0020299511	NCT00202995_11_T0	GENE	7	7	IV
NCT0020299515	NCT00202995_15_T0	COMPOUND	3	4	glatiramer acetate
NCT0020299516	NCT00202995_16_T0	COMPOUND	22	22	cladribine
NCT0020299516	NCT00202995_16_T1	ORGAN	10	10	plasma
NCT0020299518	NCT00202995_18_T0	PHENOTYPE	0	0	Chronic
NCT0020299518	NCT00202995_18_T1	GENE	3	3	IM
NCT0020299518	NCT00202995_18_T2	GENE	2	2	IV
NCT0020299521	NCT00202995_21_T0	PHENOTYPE	5	5	feels
NCT0020299521	NCT00202995_21_T1	PHENOTYPE	16	17	drug abuse
NCT0020299522	NCT00202995_22_T0	COMPOUND	4	4	gadolinium
NCT0020299522	NCT00202995_22_T1	COMPOUND	5	5	gadolinium
NCT002030211	NCT00203021_1_T0	GENE	16	16	MS
NCT002030211	NCT00203021_1_T1	PHENOTYPE	14	15	Multiple Sclerosis
NCT002030211	NCT00203021_1_T2	COMPOUND	9	10	glatiramer acetate
NCT002030340	NCT00203034_0_T0	PHENOTYPE	13	13	Fluctuations
NCT002030340	NCT00203034_0_T1	PHENOTYPE	5	6	Parkinson's Disease
NCT002030343	NCT00203034_3_T0	COMPOUND	5	5	levodopa_carbidopa
NCT002030343	NCT00203034_3_T1	COMPOUND	7	7	levodopa
NCT002030343	NCT00203034_3_T2	COMPOUND	9	9	carbidopa_levodopa
NCT002030343	NCT00203034_3_T3	COMPOUND	8	8	benserazide
NCT002030344	NCT00203034_4_T0	COMPOUND	10	10	levodopa
NCT002030349	NCT00203034_9_T0	GENE	36	36	DBS
NCT002030349	NCT00203034_9_T1	PHENOTYPE	12	12	malignancies
NCT002030349	NCT00203034_9_T2	PHENOTYPE	9	10	metabolic diseases
NCT002030349	NCT00203034_9_T3	PHENOTYPE	27	28	Parkinson's disease
NCT0020303411	NCT00203034_11_T0	GENE	10	10	DBS
NCT0020303412	NCT00203034_12_T0	COMPOUND	7	7	rasagiline
NCT0020303413	NCT00203034_13_T0	GENE	3	3	MAO
NCT0020303413	NCT00203034_13_T1	COMPOUND	6	6	methyldopa
NCT0020303413	NCT00203034_13_T2	COMPOUND	5	5	reserpine
NCT0020303413	NCT00203034_13_T3	COMPOUND	22	22	dopamine
NCT002030474	NCT00203047_4_T0	PHENOTYPE	0	0	Recruitment
NCT002030478	NCT00203047_8_T0	PHENOTYPE	37	38	false negative
NCT0020304710	NCT00203047_10_T0	GENE	8	8	Ann
NCT0020304710	NCT00203047_10_T1	GENE	13	13	Ann
NCT0020304710	NCT00203047_10_T2	PHENOTYPE	2	3	multiple sclerosis
NCT0020304713	NCT00203047_13_T0	PHENOTYPE	6	7	disease course
NCT0020304715	NCT00203047_15_T0	PHENOTYPE	8	8	relapse
NCT0020304715	NCT00203047_15_T1	GENE	3	3	had
NCT0020304719	NCT00203047_19_T0	PHENOTYPE	16	16	IUD
NCT0020304723	NCT00203047_23_T0	GENE	16	16	5.0
NCT0020304723	NCT00203047_23_T1	GENE	7	7	Expanded
NCT0020304723	NCT00203047_23_T2	COMPOUND	11	11	EDSS
NCT0020304727	NCT00203047_27_T0	GENE	18	18	MRI
NCT0020304727	NCT00203047_27_T1	COMPOUND	1	2	glatiramer acetate
NCT0020304728	NCT00203047_28_T0	GENE	17	17	MRI
NCT0020304728	NCT00203047_28_T1	COMPOUND	1	2	glatiramer acetate
NCT0020304730	NCT00203047_30_T0	COMPOUND	3	3	cladribine
NCT0020304732	NCT00203047_32_T0	COMPOUND	3	3	mitoxantrone
NCT0020304736	NCT00203047_36_T0	COMPOUND	8	8	cyclophosphamide
NCT0020304736	NCT00203047_36_T1	COMPOUND	7	7	azathioprine
NCT0020304736	NCT00203047_36_T2	COMPOUND	10	11	mycophenolate mofetil
NCT0020304738	NCT00203047_38_T0	GENE	8	8	IV
NCT0020304740	NCT00203047_40_T0	GENE	11	11	MRI
NCT0020304740	NCT00203047_40_T1	GENE	2	2	interferon
NCT0020304742	NCT00203047_42_T0	GENE	5	5	IM
NCT0020304742	NCT00203047_42_T1	GENE	17	17	MRI
NCT0020304742	NCT00203047_42_T2	GENE	3	3	IV
NCT0020304744	NCT00203047_44_T0	PHENOTYPE	0	0	Chronic
NCT0020304744	NCT00203047_44_T1	GENE	3	3	IM
NCT0020304744	NCT00203047_44_T2	GENE	2	2	IV
NCT0020304748	NCT00203047_48_T0	PHENOTYPE	25	25	feels
NCT0020304748	NCT00203047_48_T1	PHENOTYPE	6	6	affects
NCT0020304754	NCT00203047_54_T0	GENE	4	4	MRI
NCT002030730	NCT00203073_0_T0	PHENOTYPE	18	18	Sclerosis
NCT002030730	NCT00203073_0_T1	PHENOTYPE	15	16	Multiple Sclerosis
NCT002030733	NCT00203073_3_T0	GENE	8	8	Ann
NCT002030733	NCT00203073_3_T1	GENE	1	1	MS
NCT002030733	NCT00203073_3_T2	PHENOTYPE	15	16	disease course
NCT0020307311	NCT00203073_11_T0	GENE	5	5	IV
NCT0020307311	NCT00203073_11_T1	GENE	7	7	IV
NCT0020307313	NCT00203073_13_T0	COMPOUND	5	5	azathioprine
NCT0020307313	NCT00203073_13_T1	COMPOUND	3	3	methotrexate
NCT0020307315	NCT00203073_15_T0	COMPOUND	11	11	cladribine
NCT0020307315	NCT00203073_15_T1	COMPOUND	4	4	cyclophosphamide
NCT0020307317	NCT00203073_17_T0	GENE	13	13	MRI
NCT0020307325	NCT00203073_25_T0	PHENOTYPE	2	3	immune deficiency
NCT002030993	NCT00203099_3_T0	GENE	11	11	Ann
NCT002030993	NCT00203099_3_T1	GENE	10	10	al
NCT002030993	NCT00203099_3_T2	GENE	9	9	et
NCT002030993	NCT00203099_3_T3	PHENOTYPE	2	3	Multiple Sclerosis
NCT002030995	NCT00203099_5_T0	GENE	14	14	MRI
NCT002030997	NCT00203099_7_T0	PHENOTYPE	5	6	disease course
NCT002030999	NCT00203099_9_T0	PHENOTYPE	8	8	relapse
NCT002030999	NCT00203099_9_T1	GENE	3	3	had
NCT002030999	NCT00203099_9_T2	GENE	19	19	10
NCT0020309911	NCT00203099_11_T0	GENE	10	10	IM
NCT0020309911	NCT00203099_11_T1	GENE	9	9	IV
NCT0020309915	NCT00203099_15_T0	PHENOTYPE	10	10	IUD
NCT0020309919	NCT00203099_19_T0	GENE	13	13	5.0
NCT0020309919	NCT00203099_19_T1	COMPOUND	7	7	EDSS
NCT0020309923	NCT00203099_23_T0	COMPOUND	4	5	glatiramer acetate
NCT0020309925	NCT00203099_25_T0	COMPOUND	3	3	cladribine
NCT0020309925	NCT00203099_25_T1	GENE	12	12	10
NCT0020309931	NCT00203099_31_T0	GENE	2	2	interferon
NCT0020309933	NCT00203099_33_T0	PHENOTYPE	0	0	Chronic
NCT0020309933	NCT00203099_33_T1	GENE	3	3	IM
NCT0020309933	NCT00203099_33_T2	GENE	2	2	IV
NCT0020309935	NCT00203099_35_T0	GENE	6	6	NAC
NCT0020309935	NCT00203099_35_T1	PHENOTYPE	0	0	Chronic
NCT0020309940	NCT00203099_40_T0	PHENOTYPE	25	25	feels
NCT0020309940	NCT00203099_40_T1	PHENOTYPE	6	6	affects
NCT0020309942	NCT00203099_42_T0	COMPOUND	6	6	mannitol
NCT0020309943	NCT00203099_43_T0	GENE	4	4	MRI
NCT002031122	NCT00203112_2_T0	PHENOTYPE	19	19	symptoms
NCT002031122	NCT00203112_2_T1	COMPOUND	2	2	minocycline
NCT002031122	NCT00203112_2_T2	GENE	18	18	MS
NCT002031124	NCT00203112_4_T0	GENE	9	9	Ann
NCT002031124	NCT00203112_4_T1	GENE	2	2	MS
NCT002031124	NCT00203112_4_T2	GENE	8	8	al
NCT002031124	NCT00203112_4_T3	GENE	7	7	et
NCT002031126	NCT00203112_6_T0	PHENOTYPE	5	6	disease course
NCT002031128	NCT00203112_8_T0	PHENOTYPE	8	8	relapse
NCT002031128	NCT00203112_8_T1	GENE	3	3	had
NCT0020311210	NCT00203112_10_T0	GENE	17	17	MRI
NCT0020311210	NCT00203112_10_T1	COMPOUND	11	11	gadolinium
NCT0020311212	NCT00203112_12_T0	GENE	10	10	IM
NCT0020311212	NCT00203112_12_T1	GENE	9	9	IV
NCT0020311219	NCT00203112_19_T0	GENE	13	13	5.0
NCT0020311219	NCT00203112_19_T1	COMPOUND	7	7	EDSS
NCT0020311223	NCT00203112_23_T0	COMPOUND	4	5	glatiramer acetate
NCT0020311225	NCT00203112_25_T0	COMPOUND	3	3	cladribine
NCT0020311231	NCT00203112_31_T0	COMPOUND	5	5	minocycline
NCT0020311231	NCT00203112_31_T1	GENE	2	2	interferon
NCT0020311233	NCT00203112_33_T0	PHENOTYPE	0	0	Chronic
NCT0020311233	NCT00203112_33_T1	GENE	3	3	IM
NCT0020311233	NCT00203112_33_T2	GENE	2	2	IV
NCT0020311239	NCT00203112_39_T0	COMPOUND	9	9	1
NCT0020311239	NCT00203112_39_T1	PHENOTYPE	4	4	relapse
NCT0020311240	NCT00203112_40_T0	PHENOTYPE	25	25	feels
NCT0020311240	NCT00203112_40_T1	PHENOTYPE	6	6	affects
NCT0020311244	NCT00203112_44_T0	GENE	4	4	MRI
NCT002031256	NCT00203125_6_T0	PHENOTYPE	9	10	intracranial aneurysm
NCT002031381	NCT00203138_1_T0	COMPOUND	8	8	rasagiline
NCT002031514	NCT00203151_4_T0	GENE	4	4	ACR
NCT0020315112	NCT00203151_12_T0	PHENOTYPE	5	5	feels
NCT0020315114	NCT00203151_14_T0	PHENOTYPE	5	6	chronic infection
NCT0020315116	NCT00203151_16_T0	COMPOUND	7	7	DHEA
NCT002031770	NCT00203177_0_T0	GENE	13	13	opa
NCT002031770	NCT00203177_0_T1	PHENOTYPE	8	8	Fluctuations
NCT002031770	NCT00203177_0_T2	PHENOTYPE	3	4	Parkinson's Disease
NCT002031902	NCT00203190_2_T0	GENE	1	1	has
NCT002031902	NCT00203190_2_T1	PHENOTYPE	12	13	cluster headache
NCT002032031	NCT00203203_1_T0	PHENOTYPE	6	8	Ventricular Ejection Fraction
NCT002032033	NCT00203203_3_T0	GENE	30	30	ventricular
NCT002032033	NCT00203203_3_T1	GENE	9	9	has
NCT002032033	NCT00203203_3_T2	GENE	6	6	met
NCT002032033	NCT00203203_3_T3	CELL	43	44	stem cells
NCT002032033	NCT00203203_3_T4	ORGAN	56	57	left ventricle
NCT002032033	NCT00203203_3_T5	ORGAN	12	13	bone marrow
NCT0020320310	NCT00203203_10_T0	PHENOTYPE	1	1	secondary
NCT0020320310	NCT00203203_10_T1	PHENOTYPE	19	19	contractile
NCT0020320310	NCT00203203_10_T2	CELL	13	15	bone marrow cells
NCT002032164	NCT00203216_4_T0	GENE	14	14	TMS
NCT002032292	NCT00203229_2_T0	PHENOTYPE	4	4	seizure
NCT002032294	NCT00203229_4_T0	PHENOTYPE	4	5	trigeminal neuralgia
NCT002032296	NCT00203229_6_T0	COMPOUND	10	10	lamotrigine
NCT002032420	NCT00203242_0_T0	PHENOTYPE	19	19	Headaches
NCT002032420	NCT00203242_0_T1	GENE	11	11	ER
NCT002032420	NCT00203242_0_T2	PHENOTYPE	16	17	Cluster Headaches
NCT002032422	NCT00203242_2_T0	GENE	16	16	IV
NCT002032422	NCT00203242_2_T1	GENE	22	22	ER
NCT002032423	NCT00203242_3_T0	GENE	13	13	ER
NCT002032424	NCT00203242_4_T0	GENE	7	7	IV
NCT002032424	NCT00203242_4_T1	GENE	13	13	ER
NCT002032425	NCT00203242_5_T0	GENE	9	9	ER
NCT002032427	NCT00203242_7_T0	GENE	7	7	ER
NCT0020324211	NCT00203242_11_T0	PHENOTYPE	7	7	headache
NCT0020324212	NCT00203242_12_T0	PHENOTYPE	13	13	pulse
NCT0020324215	NCT00203242_15_T0	ORGAN	7	7	liver
NCT0020324215	NCT00203242_15_T1	GENE	24	24	thromboplastin
NCT0020324215	NCT00203242_15_T2	GENE	19	19	prothrombin
NCT0020324228	NCT00203242_28_T0	GENE	6	6	IV
NCT0020324230	NCT00203242_30_T0	GENE	18	18	has
NCT0020324234	NCT00203242_34_T0	GENE	26	26	ER
NCT0020324239	NCT00203242_39_T0	GENE	10	10	IV
NCT0020324242	NCT00203242_42_T0	GENE	26	26	ER
NCT0020324245	NCT00203242_45_T0	GENE	16	16	ER
NCT0020324246	NCT00203242_46_T0	GENE	14	14	OR
NCT0020324248	NCT00203242_48_T0	GENE	11	11	had
NCT0020324248	NCT00203242_48_T1	PHENOTYPE	14	14	experiences
NCT0020324249	NCT00203242_49_T0	PHENOTYPE	19	19	experiences
NCT0020324254	NCT00203242_54_T0	GENE	24	24	ER
NCT0020324255	NCT00203242_55_T0	GENE	15	15	ER
NCT0020324256	NCT00203242_56_T0	GENE	9	9	ER
NCT0020324257	NCT00203242_57_T0	GENE	14	14	OR
NCT0020324259	NCT00203242_59_T0	PHENOTYPE	14	14	symptoms
NCT0020324259	NCT00203242_59_T1	GENE	11	11	had
NCT0020324259	NCT00203242_59_T2	PHENOTYPE	20	20	experiences
NCT0020324260	NCT00203242_60_T0	PHENOTYPE	19	19	experiences
NCT0020324261	NCT00203242_61_T0	GENE	20	20	OR
NCT0020324264	NCT00203242_64_T0	PHENOTYPE	9	9	symptoms
NCT0020324264	NCT00203242_64_T1	PHENOTYPE	15	15	experiences
NCT002032551	NCT00203255_1_T0	PHENOTYPE	12	12	headaches
NCT002032551	NCT00203255_1_T1	BIOLOGICAL_PROCESS	8	9	menstrual cycle
NCT002032554	NCT00203255_4_T0	PHENOTYPE	17	17	backache
NCT002032554	NCT00203255_4_T1	PHENOTYPE	1	1	migraines
NCT002032554	NCT00203255_4_T2	PHENOTYPE	16	16	nausea
NCT002032554	NCT00203255_4_T3	BIOLOGICAL_PROCESS	5	6	menstrual cycle
NCT002032554	NCT00203255_4_T4	PHENOTYPE	19	20	breast tenderness
NCT0020325510	NCT00203255_10_T0	COMPOUND	15	15	3
NCT0020325510	NCT00203255_10_T1	COMPOUND	28	28	3
NCT0020325510	NCT00203255_10_T2	BIOLOGICAL_PROCESS	6	6	menstruation
NCT0020325510	NCT00203255_10_T3	PHENOTYPE	2	3	have headaches
NCT0020325514	NCT00203255_14_T0	PHENOTYPE	6	6	headache
NCT0020325516	NCT00203255_16_T0	GENE	21	21	hormone
NCT0020325516	NCT00203255_16_T1	GENE	27	27	hormone
NCT002032685	NCT00203268_5_T0	PHENOTYPE	20	20	allodynia
NCT002032811	NCT00203281_1_T0	COMPOUND	20	20	tacrolimus
NCT002032811	NCT00203281_1_T1	PHENOTYPE	8	8	pharmacokinetics
NCT002032811	NCT00203281_1_T2	COMPOUND	21	22	mycophenolate mofetil
NCT002032813	NCT00203281_3_T0	GENE	2	2	has
NCT002032814	NCT00203281_4_T0	ORGAN	4	4	kidney
NCT002032814	NCT00203281_4_T1	ORGAN	5	5	transplant
NCT002032815	NCT00203281_5_T0	ORGAN	13	13	transplant
NCT002032815	NCT00203281_5_T1	CELL	9	9	platelet
NCT002032816	NCT00203281_6_T0	ORGAN	24	24	kidney
NCT002032816	NCT00203281_6_T1	ORGAN	2	2	transplant
NCT002032816	NCT00203281_6_T2	ORGAN	19	20	immune system
NCT002032817	NCT00203281_7_T0	ORGAN	6	6	kidney
NCT002032818	NCT00203281_8_T0	ORGAN	4	4	transplant
NCT002032818	NCT00203281_8_T1	GENE	6	6	has
NCT002032819	NCT00203281_9_T0	ORGAN	2	2	kidney
NCT002032819	NCT00203281_9_T1	ORGAN	22	22	transplant
NCT002032819	NCT00203281_9_T2	GENE	4	4	has
NCT002032819	NCT00203281_9_T3	GENE	16	16	has
NCT002032819	NCT00203281_9_T4	GENE	23	23	has
NCT0020328111	NCT00203281_11_T0	CELL	15	15	cells
NCT0020328111	NCT00203281_11_T1	PHENOTYPE	11	11	separation
NCT0020328111	NCT00203281_11_T2	GENE	29	29	globulin
NCT0020328111	NCT00203281_11_T3	ORGAN	13	13	plasma
NCT0020328112	NCT00203281_12_T0	ORGAN	15	15	kidney
NCT0020328112	NCT00203281_12_T1	PHENOTYPE	11	11	acute
NCT0020328112	NCT00203281_12_T2	GENE	10	10	reduced
NCT0020328112	NCT00203281_12_T3	GENE	8	8	has
NCT0020328113	NCT00203281_13_T0	GENE	2	2	globulin
NCT0020328113	NCT00203281_13_T1	GENE	20	20	globulin
NCT0020328115	NCT00203281_15_T0	ORGAN	1	1	kidney
NCT0020328115	NCT00203281_15_T1	ORGAN	2	2	transplant
NCT0020328115	NCT00203281_15_T2	GENE	8	8	ABO
NCT0020328115	NCT00203281_15_T3	PHENOTYPE	9	10	blood group
NCT0020328116	NCT00203281_16_T0	ORGAN	23	23	kidney
NCT0020328116	NCT00203281_16_T1	GENE	6	6	has
NCT0020328116	NCT00203281_16_T2	ORGAN	19	20	immune system
NCT0020328116	NCT00203281_16_T3	PHENOTYPE	4	5	blood group
NCT0020328117	NCT00203281_17_T0	ORGAN	17	17	transplant
NCT0020328117	NCT00203281_17_T1	ORGAN	25	25	transplant
NCT0020328117	NCT00203281_17_T2	ORGAN	27	27	transplant
NCT0020328117	NCT00203281_17_T3	GENE	37	37	ABO
NCT0020328117	NCT00203281_17_T4	PHENOTYPE	38	39	blood group
NCT0020328118	NCT00203281_18_T0	PHENOTYPE	3	3	centered
NCT0020328118	NCT00203281_18_T1	GENE	10	10	globulin
NCT0020328119	NCT00203281_19_T0	GENE	12	12	has
NCT0020328120	NCT00203281_20_T0	GENE	50	50	ABO
NCT0020328120	NCT00203281_20_T1	GENE	0	0	Dr
NCT0020328120	NCT00203281_20_T2	ORGAN	11	11	Transplant
NCT0020328120	NCT00203281_20_T3	ORGAN	47	47	transplant
NCT0020328120	NCT00203281_20_T4	PHENOTYPE	52	53	blood groups
NCT0020328121	NCT00203281_21_T0	ORGAN	5	5	kidney
NCT0020328121	NCT00203281_21_T1	ORGAN	13	13	graft
NCT0020328121	NCT00203281_21_T2	GENE	1	1	has
NCT0020328121	NCT00203281_21_T3	GENE	28	28	ABO
NCT0020328121	NCT00203281_21_T4	ORGAN	6	6	transplants
NCT0020328122	NCT00203281_22_T0	GENE	14	14	had
NCT0020328122	NCT00203281_22_T1	PHENOTYPE	21	22	graft loss
NCT0020328123	NCT00203281_23_T0	GENE	27	27	1.5
NCT0020328123	NCT00203281_23_T1	ORGAN	30	30	transplant
NCT0020328124	NCT00203281_24_T0	PHENOTYPE	12	12	diseases
NCT0020328125	NCT00203281_25_T0	GENE	10	10	separated
NCT0020328125	NCT00203281_25_T1	ORGAN	3	3	plasma
NCT0020328125	NCT00203281_25_T2	ORGAN	14	14	plasma
NCT0020328126	NCT00203281_26_T0	GENE	6	6	1.5
NCT0020328126	NCT00203281_26_T1	ORGAN	9	9	plasma
NCT0020328127	NCT00203281_27_T0	PHENOTYPE	22	22	concentrations
NCT0020328127	NCT00203281_27_T1	ORGAN	21	21	plasma
NCT0020328130	NCT00203281_30_T0	ORGAN	23	23	graft
NCT0020328130	NCT00203281_30_T1	PHENOTYPE	38	38	illnesses
NCT002032941	NCT00203294_1_T0	GENE	1	1	has
NCT002032941	NCT00203294_1_T1	PHENOTYPE	11	11	headaches
NCT002032945	NCT00203294_5_T0	COMPOUND	15	15	lidocaine
NCT002032949	NCT00203294_9_T0	GENE	5	5	cc
NCT002033201	NCT00203320_1_T0	GENE	6	6	AD
NCT002033201	NCT00203320_1_T1	PHENOTYPE	9	9	inflammation
NCT002033201	NCT00203320_1_T2	GENE	1	1	has
NCT002033201	NCT00203320_1_T3	GENE	0	0	TNF
NCT002033202	NCT00203320_2_T0	GENE	12	12	AD
NCT002033330	NCT00203333_0_T0	PHENOTYPE	2	2	Abnormalities
NCT002033330	NCT00203333_0_T1	PHENOTYPE	7	7	Epilepsy
NCT002033330	NCT00203333_0_T2	PHENOTYPE	12	13	Sudden Death
NCT002033332	NCT00203333_2_T0	PHENOTYPE	4	4	epilepsy
NCT002033332	NCT00203333_2_T1	PHENOTYPE	23	23	epilepsy
NCT002033333	NCT00203333_3_T0	PHENOTYPE	11	11	epilepsy
NCT002033334	NCT00203333_4_T0	GENE	1	1	lines
NCT002033335	NCT00203333_5_T0	COMPOUND	5	5	1
NCT002033335	NCT00203333_5_T1	COMPOUND	19	19	2
NCT002033335	NCT00203333_5_T2	PHENOTYPE	11	12	cardiac arrhythmias
NCT002033336	NCT00203333_6_T0	PHENOTYPE	19	19	symptoms
NCT002033336	NCT00203333_6_T1	PHENOTYPE	11	11	seizure
NCT002033339	NCT00203333_9_T0	PHENOTYPE	15	15	epilepsy
NCT002033339	NCT00203333_9_T1	PHENOTYPE	7	8	cardiac arrhythmias
NCT0020333311	NCT00203333_11_T0	PHENOTYPE	11	11	seizure
NCT0020333311	NCT00203333_11_T1	PHENOTYPE	14	14	seizure
NCT0020333311	NCT00203333_11_T2	PHENOTYPE	20	20	seizure
NCT0020333311	NCT00203333_11_T3	GENE	17	17	probable
NCT0020333311	NCT00203333_11_T4	ORGAN	2	2	heart
NCT0020333311	NCT00203333_11_T5	COMPOUND	10	10	1
NCT0020333311	NCT00203333_11_T6	COMPOUND	13	13	2
NCT0020333311	NCT00203333_11_T7	COMPOUND	16	16	3
NCT0020333311	NCT00203333_11_T8	PHENOTYPE	33	33	seizures
NCT002033461	NCT00203346_1_T0	PHENOTYPE	5	6	light sensitivity
NCT002033463	NCT00203346_3_T0	COMPOUND	18	18	lidocaine
NCT002033591	NCT00203359_1_T0	GENE	6	6	AD
NCT002033591	NCT00203359_1_T1	PHENOTYPE	9	9	inflammation
NCT002033591	NCT00203359_1_T2	GENE	1	1	has
NCT002033591	NCT00203359_1_T3	GENE	0	0	TNF
NCT002033592	NCT00203359_2_T0	GENE	12	12	AD
NCT002033720	NCT00203372_0_T0	GENE	1	1	TAC
NCT002033852	NCT00203385_2_T0	PHENOTYPE	1	1	symptoms
NCT002033859	NCT00203385_9_T0	PHENOTYPE	16	16	PTSD
NCT0020338510	NCT00203385_10_T0	PHENOTYPE	19	19	PTSD
NCT0020338514	NCT00203385_14_T0	PHENOTYPE	10	10	PTSD
NCT0020338514	NCT00203385_14_T1	PHENOTYPE	4	4	acute
NCT0020338516	NCT00203385_16_T0	COMPOUND	10	10	nicotine
NCT0020338516	NCT00203385_16_T1	COMPOUND	12	12	caffeine
NCT0020338520	NCT00203385_20_T0	ORGAN	22	22	diaphragm
NCT0020338523	NCT00203385_23_T0	PHENOTYPE	7	8	cognitive disorders
NCT0020338524	NCT00203385_24_T0	PHENOTYPE	2	2	homicidal
NCT002034112	NCT00203411_2_T0	PHENOTYPE	14	14	tumor
NCT002034502	NCT00203450_2_T0	PHENOTYPE	21	21	symptoms
NCT002034503	NCT00203450_3_T0	PHENOTYPE	7	7	Mania
NCT002034503	NCT00203450_3_T1	GENE	26	26	HARS
NCT002034503	NCT00203450_3_T2	PHENOTYPE	0	0	Symptoms
NCT002034504	NCT00203450_4_T0	GENE	9	9	tapered
NCT002034508	NCT00203450_8_T0	GENE	1	1	atypical
NCT002034508	NCT00203450_8_T1	COMPOUND	4	4	aripiprazole
NCT002034508	NCT00203450_8_T2	COMPOUND	6	6	ziprasidone
NCT002034509	NCT00203450_9_T0	COMPOUND	3	3	valproate
NCT0020345010	NCT00203450_10_T0	COMPOUND	3	3	lithium
NCT0020345011	NCT00203450_11_T0	COMPOUND	3	3	carbamazepine
NCT002034632	NCT00203463_2_T0	PHENOTYPE	9	9	SCID
NCT002034637	NCT00203463_7_T0	COMPOUND	9	9	topiramate
NCT002034761	NCT00203476_1_T0	GENE	24	24	lipoprotein
NCT002034761	NCT00203476_1_T1	GENE	25	25	LDL
NCT002034761	NCT00203476_1_T2	GENE	16	16	III
NCT002034761	NCT00203476_1_T3	GENE	19	19	III
NCT002034761	NCT00203476_1_T4	GENE	18	18	ATP
NCT002034762	NCT00203476_2_T0	PHENOTYPE	13	13	rhabdomyolysis
NCT002034762	NCT00203476_2_T1	PHENOTYPE	0	0	Secondary
NCT002034762	NCT00203476_2_T2	ORGAN	7	7	liver
NCT002034762	NCT00203476_2_T3	PHENOTYPE	4	5	safety issues
NCT002034763	NCT00203476_3_T0	PHENOTYPE	15	15	secondary
NCT002034763	NCT00203476_3_T1	GENE	2	2	HDL
NCT002034765	NCT00203476_5_T0	COMPOUND	13	13	colestipol
NCT002034765	NCT00203476_5_T1	COMPOUND	10	10	ezetimibe
NCT002034765	NCT00203476_5_T2	COMPOUND	11	11	niacin
NCT002034766	NCT00203476_6_T0	COMPOUND	16	16	colestipol
NCT002034766	NCT00203476_6_T1	COMPOUND	11	11	ezetimibe
NCT002034766	NCT00203476_6_T2	COMPOUND	13	13	niacin
NCT002034768	NCT00203476_8_T0	ORGAN	11	11	liver
NCT002034769	NCT00203476_9_T0	PHENOTYPE	8	8	rhabdomyolysis
NCT002034769	NCT00203476_9_T1	PHENOTYPE	9	9	tolerance
NCT002034891	NCT00203489_1_T0	PHENOTYPE	15	16	open wound
NCT002034895	NCT00203489_5_T0	GENE	11	11	has
NCT002034896	NCT00203489_6_T0	PHENOTYPE	17	17	concentrations
NCT002034896	NCT00203489_6_T1	PHENOTYPE	31	31	resistant
NCT002034896	NCT00203489_6_T2	BIOLOGICAL_PROCESS	35	36	wound healing
NCT002034897	NCT00203489_7_T0	PHENOTYPE	25	25	resistant
NCT002034897	NCT00203489_7_T1	PHENOTYPE	21	21	chronic
NCT0020348913	NCT00203489_13_T0	GENE	5	5	has
NCT0020348917	NCT00203489_17_T0	GENE	2	2	has
NCT0020348917	NCT00203489_17_T1	PHENOTYPE	4	5	chronic ulcer
NCT0020348919	NCT00203489_19_T0	GENE	6	6	II
NCT0020348919	NCT00203489_19_T1	PHENOTYPE	8	8	ulceration
NCT0020348919	NCT00203489_19_T2	GENE	2	2	has
NCT0020348921	NCT00203489_21_T0	GENE	2	2	has
NCT0020348921	NCT00203489_21_T1	PHENOTYPE	12	13	foot ulceration
NCT0020348921	NCT00203489_21_T2	PHENOTYPE	11	12	diabetic foot
NCT0020348925	NCT00203489_25_T0	PHENOTYPE	17	18	open wound
NCT0020348925	NCT00203489_25_T1	TISSUE	9	10	surgical flap
NCT0020348927	NCT00203489_27_T0	GENE	20	20	San
NCT0020348929	NCT00203489_29_T0	PHENOTYPE	7	7	acute
NCT0020348929	NCT00203489_29_T1	PHENOTYPE	8	8	diffuse
NCT0020348929	NCT00203489_29_T2	GENE	2	2	has
NCT0020348929	NCT00203489_29_T3	PHENOTYPE	4	4	burns
NCT0020348929	NCT00203489_29_T4	PHENOTYPE	11	12	Stevens-Johnson Syndrome
NCT0020348934	NCT00203489_34_T0	GENE	2	2	has
NCT0020348934	NCT00203489_34_T1	BIOLOGICAL_PROCESS	7	8	wound healing
NCT002035021	NCT00203502_1_T0	COMPOUND	20	20	doxorubicin
NCT002035024	NCT00203502_4_T0	ORGAN	17	17	heart
NCT002035027	NCT00203502_7_T0	PHENOTYPE	5	5	strain
NCT002035029	NCT00203502_9_T0	PHENOTYPE	33	33	allergy
NCT002035029	NCT00203502_9_T1	PHENOTYPE	29	30	blood clots
NCT0020350210	NCT00203502_10_T0	GENE	20	20	had
NCT0020350210	NCT00203502_10_T1	PHENOTYPE	14	15	breast cancer
NCT0020350212	NCT00203502_12_T0	COMPOUND	11	11	docetaxel
NCT0020350212	NCT00203502_12_T1	COMPOUND	15	15	cyclophosphamide
NCT0020350213	NCT00203502_13_T0	COMPOUND	15	15	doxorubicin
NCT0020350215	NCT00203502_15_T0	ORGAN	18	18	heart
NCT0020350217	NCT00203502_17_T0	PHENOTYPE	0	0	Tumor
NCT0020350218	NCT00203502_18_T0	COMPOUND	3	3	MUGA
NCT0020350219	NCT00203502_19_T0	PHENOTYPE	3	3	tumor
NCT0020350220	NCT00203502_20_T0	ORGAN	20	20	heart
NCT002035153	NCT00203515_3_T0	PHENOTYPE	10	10	centers
NCT002035280	NCT00203528_0_T0	GENE	1	1	ER
NCT002035280	NCT00203528_0_T1	PHENOTYPE	5	6	Bipolar Disorder
NCT002035280	NCT00203528_0_T2	PHENOTYPE	9	11	Substance Use Disorder
NCT002035282	NCT00203528_2_T0	GENE	23	23	tapered
NCT002035283	NCT00203528_3_T0	GENE	27	27	1.1
NCT002035283	NCT00203528_3_T1	COMPOUND	24	24	risperidone
NCT002035285	NCT00203528_5_T0	GENE	25	25	GAF
NCT002035285	NCT00203528_5_T1	PHENOTYPE	34	35	drug use
NCT002035285	NCT00203528_5_T2	PHENOTYPE	40	41	adverse events
NCT002035285	NCT00203528_5_T3	PHENOTYPE	28	29	Drug Use
NCT002035288	NCT00203528_8_T0	GENE	8	8	BID
NCT002035288	NCT00203528_8_T1	GENE	4	4	ER
NCT002035289	NCT00203528_9_T0	COMPOUND	3	3	risperidone
NCT002035543	NCT00203554_3_T0	GENE	8	8	poly
NCT002035544	NCT00203554_4_T0	PHENOTYPE	5	5	anaesthesia
NCT002035675	NCT00203567_5_T0	PHENOTYPE	5	6	adverse events
NCT0020356710	NCT00203567_10_T0	ORGAN	16	16	diaphragm
NCT002035803	NCT00203580_3_T0	PHENOTYPE	16	17	venous thromboembolism
NCT002035803	NCT00203580_3_T1	PHENOTYPE	34	35	venous thromboembolism
NCT002035932	NCT00203593_2_T0	GENE	3	3	has
NCT002035933	NCT00203593_3_T0	GENE	11	11	reduced
NCT002035933	NCT00203593_3_T1	PHENOTYPE	12	12	orthostatic
NCT002035933	NCT00203593_3_T2	PHENOTYPE	13	13	tolerance
NCT002035933	NCT00203593_3_T3	PHENOTYPE	7	8	vasovagal syncope
NCT002035934	NCT00203593_4_T0	GENE	3	3	has
NCT002035934	NCT00203593_4_T1	PHENOTYPE	1	1	orthostatic
NCT002035934	NCT00203593_4_T2	PHENOTYPE	2	2	tolerance
NCT002035935	NCT00203593_5_T0	GENE	13	13	has
NCT002035935	NCT00203593_5_T1	PHENOTYPE	11	12	vasovagal syncope
NCT002035939	NCT00203593_9_T0	GENE	8	8	pre
NCT002035939	NCT00203593_9_T1	PHENOTYPE	0	0	Orthostatic
NCT002035939	NCT00203593_9_T2	PHENOTYPE	1	1	tolerance
NCT002036060	NCT00203606_0_T0	GENE	1	1	Interferon
NCT002036060	NCT00203606_0_T1	PHENOTYPE	16	17	Hepatitis C
NCT002036062	NCT00203606_2_T0	PHENOTYPE	8	8	cirrhosis
NCT002036062	NCT00203606_2_T1	PHENOTYPE	14	15	liver failure
NCT002036062	NCT00203606_2_T2	PHENOTYPE	17	18	liver cancer
NCT002036063	NCT00203606_3_T0	PHENOTYPE	0	0	Cirrhosis
NCT002036063	NCT00203606_3_T1	ORGAN	11	11	liver
NCT002036063	NCT00203606_3_T2	PHENOTYPE	3	4	hepatitis C
NCT002036065	NCT00203606_5_T0	PHENOTYPE	17	18	Hepatitis C
NCT002036067	NCT00203606_7_T0	COMPOUND	16	16	ribavirin
NCT002036067	NCT00203606_7_T1	GENE	14	14	interferon
NCT0020360615	NCT00203606_15_T0	COMPOUND	10	10	HCV
NCT0020360615	NCT00203606_15_T1	COMPOUND	13	13	HCV
NCT0020360615	NCT00203606_15_T2	PHENOTYPE	0	1	Chronic hepatitis
NCT0020360615	NCT00203606_15_T3	PHENOTYPE	1	2	hepatitis C
NCT0020360617	NCT00203606_17_T0	COMPOUND	5	5	HCV
NCT0020360619	NCT00203606_19_T0	COMPOUND	8	9	crack cocaine
NCT0020360620	NCT00203606_20_T0	PHENOTYPE	6	7	drug use
NCT0020360621	NCT00203606_21_T0	PHENOTYPE	11	12	cocaine use
NCT0020360621	NCT00203606_21_T1	PHENOTYPE	7	8	drug use
NCT0020360621	NCT00203606_21_T2	COMPOUND	10	11	crack cocaine
NCT0020360623	NCT00203606_23_T0	PHENOTYPE	1	2	liver disease
NCT0020360628	NCT00203606_28_T0	PHENOTYPE	20	20	bleeding
NCT0020360628	NCT00203606_28_T1	PHENOTYPE	4	4	ascites
NCT0020360628	NCT00203606_28_T2	PHENOTYPE	14	15	hepatic encephalopathy
NCT0020360634	NCT00203606_34_T0	PHENOTYPE	3	4	thyroid disease
NCT0020360635	NCT00203606_35_T0	COMPOUND	4	4	ribavirin
NCT0020360635	NCT00203606_35_T1	GENE	2	2	interferon
NCT0020360639	NCT00203606_39_T0	PHENOTYPE	1	2	hepatitis B
NCT0020360639	NCT00203606_39_T1	PHENOTYPE	0	1	Chronic hepatitis
NCT0020360640	NCT00203606_40_T0	GENE	12	12	Blot
NCT0020360640	NCT00203606_40_T1	PHENOTYPE	3	3	HIV
NCT0020360640	NCT00203606_40_T2	PHENOTYPE	6	7	positive HIV
NCT0020360642	NCT00203606_42_T0	PHENOTYPE	14	15	autoimmune disorder
NCT0020360642	NCT00203606_42_T1	PHENOTYPE	11	12	hematological malignancy
NCT0020360644	NCT00203606_44_T0	COMPOUND	11	11	cyclosporine
NCT0020360644	NCT00203606_44_T1	COMPOUND	12	12	azathioprine
NCT0020360644	NCT00203606_44_T2	COMPOUND	10	10	prednisone
NCT0020360646	NCT00203606_46_T0	PHENOTYPE	8	9	renal disease
NCT0020360648	NCT00203606_48_T0	PHENOTYPE	14	14	psychoses
NCT0020360648	NCT00203606_48_T1	PHENOTYPE	16	16	ideation
NCT0020360651	NCT00203606_51_T0	PHENOTYPE	3	4	chronic disease
NCT0020360653	NCT00203606_53_T0	ORGAN	5	5	liver
NCT0020360653	NCT00203606_53_T1	ORGAN	6	6	transplant
NCT0020360653	NCT00203606_53_T2	GENE	3	3	had
NCT002036190	NCT00203619_0_T0	PHENOTYPE	4	5	GI Bleeding
NCT002036194	NCT00203619_4_T0	GENE	2	2	1.1
NCT002036197	NCT00203619_7_T0	PHENOTYPE	2	3	GI bleeding
NCT002036198	NCT00203619_8_T0	PHENOTYPE	3	3	bleeding
NCT002036198	NCT00203619_8_T1	PHENOTYPE	13	13	bleeding
NCT002036199	NCT00203619_9_T0	PHENOTYPE	3	4	swallowing disorders
NCT0020361910	NCT00203619_10_T0	PHENOTYPE	3	5	small bowel obstruction
NCT002036326	NCT00203632_6_T0	COMPOUND	20	20	metformin
NCT002036326	NCT00203632_6_T1	COMPOUND	5	5	rosiglitazone
NCT0020363211	NCT00203632_11_T0	GENE	10	10	hormone
NCT0020363211	NCT00203632_11_T1	GENE	7	8	calcium channel
NCT0020363211	NCT00203632_11_T2	GENE	3	4	angiotensin receptor
NCT0020363212	NCT00203632_12_T0	GENE	2	2	insulin
NCT0020363213	NCT00203632_13_T0	COMPOUND	10	10	glucose
NCT002036454	NCT00203645_4_T0	PHENOTYPE	17	17	disorders
NCT002036454	NCT00203645_4_T1	PHENOTYPE	15	16	mental health
NCT002036582	NCT00203658_2_T0	PHENOTYPE	18	18	DVT
NCT002036582	NCT00203658_2_T1	GENE	2	2	has
NCT002036583	NCT00203658_3_T0	COMPOUND	16	16	heparin
NCT002036583	NCT00203658_3_T1	COMPOUND	21	21	warfarin
NCT002036712	NCT00203671_2_T0	ORGAN	12	12	graft
NCT002036717	NCT00203671_7_T0	COMPOUND	7	8	mycophenolate mofetil
NCT002036719	NCT00203671_9_T0	GENE	1	1	BID
NCT002036719	NCT00203671_9_T1	COMPOUND	5	5	QID
NCT002036719	NCT00203671_9_T2	GENE	3	3	TID
NCT0020367111	NCT00203671_11_T0	PHENOTYPE	16	17	graft loss
NCT0020367112	NCT00203671_12_T0	ORGAN	15	15	transplant
NCT0020367112	NCT00203671_12_T1	ORGAN	26	26	transplant
NCT0020367116	NCT00203671_16_T0	ORGAN	14	14	transplant
NCT0020367116	NCT00203671_16_T1	GENE	2	2	had
NCT0020367119	NCT00203671_19_T0	ORGAN	10	10	transplant
NCT0020367119	NCT00203671_19_T1	GENE	2	2	had
NCT0020367121	NCT00203671_21_T0	ORGAN	9	9	transplant
NCT0020367121	NCT00203671_21_T1	GENE	2	2	had
NCT0020367123	NCT00203671_23_T0	ORGAN	21	21	transplant
NCT0020367123	NCT00203671_23_T1	GENE	2	2	had
NCT0020367123	NCT00203671_23_T2	GENE	13	13	BID
NCT0020367123	NCT00203671_23_T3	COMPOUND	17	17	QID
NCT0020367123	NCT00203671_23_T4	GENE	15	15	TID
NCT0020367124	NCT00203671_24_T0	GENE	1	1	II
NCT0020367125	NCT00203671_25_T0	PHENOTYPE	0	0	Acute
NCT0020367126	NCT00203671_26_T0	PHENOTYPE	16	16	acute
NCT0020367130	NCT00203671_30_T0	PHENOTYPE	0	1	Graft failure
NCT0020367131	NCT00203671_31_T0	GENE	13	13	had
NCT0020367131	NCT00203671_31_T1	PHENOTYPE	14	15	graft failure
NCT0020367134	NCT00203671_34_T0	GENE	1	1	III
NCT002036842	NCT00203684_2_T0	PHENOTYPE	4	4	asthmatics
NCT002036842	NCT00203684_2_T1	PHENOTYPE	7	7	inflammation
NCT002036843	NCT00203684_3_T0	PHENOTYPE	7	7	peripheral
NCT002036844	NCT00203684_4_T0	PHENOTYPE	19	19	peripheral
NCT002036846	NCT00203684_6_T0	PHENOTYPE	5	5	inflammation
NCT002036846	NCT00203684_6_T1	GENE	15	15	has
NCT0020368410	NCT00203684_10_T0	COMPOUND	16	16	methacholine
NCT0020368410	NCT00203684_10_T1	PHENOTYPE	8	9	lung function
NCT0020368411	NCT00203684_11_T0	PHENOTYPE	10	10	inflammation
NCT0020368411	NCT00203684_11_T1	COMPOUND	1	2	nitric oxide
NCT0020368412	NCT00203684_12_T0	PHENOTYPE	8	9	lung function
NCT0020368413	NCT00203684_13_T0	CELL	14	14	cells
NCT0020368414	NCT00203684_14_T0	ORGAN	25	25	lungs
NCT0020368419	NCT00203684_19_T0	PHENOTYPE	20	22	exposure to radiation
NCT002036973	NCT00203697_3_T0	PHENOTYPE	2	2	UIP
NCT002036973	NCT00203697_3_T1	PHENOTYPE	3	5	usual interstitial pneumonitis
NCT002036974	NCT00203697_4_T0	GENE	4	4	has
NCT002036974	NCT00203697_4_T1	PHENOTYPE	0	0	UIP
NCT002036976	NCT00203697_6_T0	GENE	6	6	has
NCT002036978	NCT00203697_8_T0	GENE	5	5	has
NCT002036979	NCT00203697_9_T0	PHENOTYPE	13	13	immunosuppression
NCT002036979	NCT00203697_9_T1	PHENOTYPE	17	18	infectious disease
NCT0020369711	NCT00203697_11_T0	PHENOTYPE	2	2	strategies
NCT0020369713	NCT00203697_13_T0	COMPOUND	11	11	cyclophosphamide
NCT0020369713	NCT00203697_13_T1	COMPOUND	9	9	azathioprine
NCT0020369714	NCT00203697_14_T0	COMPOUND	10	10	cyclophosphamide
NCT0020369714	NCT00203697_14_T1	COMPOUND	8	8	azathioprine
NCT0020369715	NCT00203697_15_T0	PHENOTYPE	17	17	progression
NCT0020369722	NCT00203697_22_T0	COMPOUND	7	7	tetracycline
NCT0020369722	NCT00203697_22_T1	GENE	3	3	semi
NCT0020369724	NCT00203697_24_T0	PHENOTYPE	14	14	acne
NCT0020369724	NCT00203697_24_T1	COMPOUND	3	3	minocycline
NCT0020369724	NCT00203697_24_T2	PHENOTYPE	11	11	diseases
NCT0020369725	NCT00203697_25_T0	PHENOTYPE	13	13	leprosy
NCT0020369725	NCT00203697_25_T1	PHENOTYPE	18	18	autoimmune
NCT0020369725	NCT00203697_25_T2	PHENOTYPE	8	8	diseases
NCT0020369725	NCT00203697_25_T3	PHENOTYPE	12	12	mycobacteriosis
NCT0020369725	NCT00203697_25_T4	PHENOTYPE	24	24	prurigo
NCT0020369725	NCT00203697_25_T5	PHENOTYPE	16	17	pyoderma gangrenosum
NCT0020369725	NCT00203697_25_T6	PHENOTYPE	14	15	lyme disease
NCT0020369725	NCT00203697_25_T7	PHENOTYPE	19	20	bullous dermatitis
NCT0020369739	NCT00203697_39_T0	PHENOTYPE	0	1	Insidious onset
NCT0020369739	NCT00203697_39_T1	PHENOTYPE	5	7	dyspnea on exertion
NCT0020369740	NCT00203697_40_T0	PHENOTYPE	2	2	crackles
NCT0020369742	NCT00203697_42_T0	COMPOUND	10	10	prednisone
NCT0020369752	NCT00203697_52_T0	COMPOUND	13	13	beryllium
NCT0020369752	NCT00203697_52_T1	PHENOTYPE	4	5	environmental exposure
NCT0020369752	NCT00203697_52_T2	PHENOTYPE	9	10	pulmonary fibrosis
NCT0020369757	NCT00203697_57_T0	GENE	14	14	25
NCT0020369757	NCT00203697_57_T1	PHENOTYPE	22	23	antibodies positive
NCT0020369766	NCT00203697_66_T0	GENE	4	4	bypass
NCT0020369766	NCT00203697_66_T1	PHENOTYPE	0	1	Myocardial infarction
NCT0020369766	NCT00203697_66_T2	ORGAN	2	3	coronary artery
NCT0020369767	NCT00203697_67_T0	PHENOTYPE	0	2	Congestive heart failure
NCT0020369768	NCT00203697_68_T0	PHENOTYPE	1	1	arrhythmia
NCT0020369771	NCT00203697_71_T0	PHENOTYPE	38	38	IUD
NCT0020369771	NCT00203697_71_T1	ORGAN	11	11	serum
NCT0020369776	NCT00203697_76_T0	GENE	10	10	59
NCT0020369776	NCT00203697_76_T1	GENE	7	7	hematocrit
NCT0020369776	NCT00203697_76_T2	GENE	5	5	WBC
NCT0020369776	NCT00203697_76_T3	GENE	8	8	30
NCT0020369776	NCT00203697_76_T4	CELL	11	11	platelets
NCT0020369777	NCT00203697_77_T0	ORGAN	8	8	thyroid
NCT0020369777	NCT00203697_77_T1	GENE	0	0	TSH
NCT002037102	NCT00203710_2_T0	PHENOTYPE	6	7	foreign bodies
NCT002037102	NCT00203710_2_T1	ORGAN	14	15	blood vessels
NCT002037106	NCT00203710_6_T0	PHENOTYPE	9	9	symptoms
NCT002037109	NCT00203710_9_T0	GENE	7	7	II
NCT002037109	NCT00203710_9_T1	PHENOTYPE	18	18	complications
NCT002037109	NCT00203710_9_T2	GENE	9	9	III
NCT0020371010	NCT00203710_10_T0	PHENOTYPE	1	1	complications
NCT0020371010	NCT00203710_10_T1	PHENOTYPE	12	12	hemorrhage
NCT0020371010	NCT00203710_10_T2	PHENOTYPE	5	6	vessel perforation
NCT0020371010	NCT00203710_10_T3	PHENOTYPE	8	9	arterial dissection
NCT0020371011	NCT00203710_11_T0	PHENOTYPE	0	0	Secondary
NCT0020371012	NCT00203710_12_T0	PHENOTYPE	4	5	adverse events
NCT0020371013	NCT00203710_13_T0	PHENOTYPE	1	2	adverse events
NCT0020371021	NCT00203710_21_T0	GENE	12	12	M1
NCT0020371021	NCT00203710_21_T1	GENE	14	14	M2
NCT0020371021	NCT00203710_21_T2	PHENOTYPE	4	4	occlusion
NCT0020371021	NCT00203710_21_T3	PHENOTYPE	0	0	Angiogram
NCT0020371021	NCT00203710_21_T4	ORGAN	20	21	vertebral arteries
NCT0020371029	NCT00203710_29_T0	GENE	1	1	has
NCT0020371029	NCT00203710_29_T1	PHENOTYPE	3	4	arterial tortuosity
NCT0020371037	NCT00203710_37_T0	PHENOTYPE	5	5	allergy
NCT0020371037	NCT00203710_37_T1	GENE	1	1	has
NCT0020371042	NCT00203710_42_T0	GENE	3	3	MRI
NCT0020371042	NCT00203710_42_T1	GENE	9	9	midline
NCT002037232	NCT00203723_2_T0	PHENOTYPE	19	19	relapse
NCT002037232	NCT00203723_2_T1	GENE	4	4	TRD
NCT002037232	NCT00203723_2_T2	PHENOTYPE	16	16	remission
NCT002037232	NCT00203723_2_T3	PHENOTYPE	41	42	psychiatric illness
NCT002037232	NCT00203723_2_T4	PHENOTYPE	31	32	chronic depression
NCT002037232	NCT00203723_2_T5	PHENOTYPE	26	27	psychotic depression
NCT002037238	NCT00203723_8_T0	GENE	6	6	TRD
NCT002037238	NCT00203723_8_T1	PHENOTYPE	37	37	psychosis
NCT002037362	NCT00203736_2_T0	GENE	22	22	CAT
NCT002037363	NCT00203736_3_T0	GENE	20	20	CAT
NCT002037363	NCT00203736_3_T1	GENE	30	30	CAT
NCT002037363	NCT00203736_3_T2	PHENOTYPE	15	15	decision-making
NCT002037365	NCT00203736_5_T0	GENE	24	24	AS
NCT002037365	NCT00203736_5_T1	COMPOUND	23	23	artesunate
NCT002037365	NCT00203736_5_T2	GENE	22	22	CAT
NCT002037365	NCT00203736_5_T3	PHENOTYPE	9	9	malaria
NCT002037365	NCT00203736_5_T4	GENE	20	20	SP
NCT002037365	NCT00203736_5_T5	GENE	26	26	SP
NCT002037497	NCT00203749_7_T0	PHENOTYPE	18	18	HIV
NCT002037497	NCT00203749_7_T1	PHENOTYPE	11	13	quality of life
NCT0020374910	NCT00203749_10_T0	PHENOTYPE	6	6	strategies
NCT0020374910	NCT00203749_10_T1	GENE	3	3	has
NCT0020374911	NCT00203749_11_T0	PHENOTYPE	1	1	strategies
NCT0020374911	NCT00203749_11_T1	PHENOTYPE	12	13	HIV infection
NCT0020374913	NCT00203749_13_T0	PHENOTYPE	21	21	HIV
NCT0020374913	NCT00203749_13_T1	GENE	8	8	III
NCT002037621	NCT00203762_1_T0	GENE	40	40	ART
NCT002037621	NCT00203762_1_T1	PHENOTYPE	11	11	tuberculosis
NCT002037623	NCT00203762_3_T0	GENE	25	25	ART
NCT002037623	NCT00203762_3_T1	GENE	17	17	distracted
NCT002037625	NCT00203762_5_T0	GENE	4	4	ART
NCT002037627	NCT00203762_7_T0	GENE	10	10	ART
NCT002037882	NCT00203788_2_T0	COMPOUND	21	21	risperidone
NCT002037883	NCT00203788_3_T0	PHENOTYPE	22	22	schizophrenia
NCT002037883	NCT00203788_3_T1	PHENOTYPE	4	5	Schizophrenic Disorders
NCT002037884	NCT00203788_4_T0	PHENOTYPE	17	17	schizophrenia
NCT002037884	NCT00203788_4_T1	PHENOTYPE	26	26	schizophrenia
NCT002037884	NCT00203788_4_T2	PHENOTYPE	23	24	cognitive deficits
NCT002037886	NCT00203788_6_T0	COMPOUND	11	11	risperidone
NCT002037888	NCT00203788_8_T0	COMPOUND	22	22	risperidone
NCT002038012	NCT00203801_2_T0	GENE	22	22	CAT
NCT002038013	NCT00203801_3_T0	GENE	32	32	CAT
NCT002038013	NCT00203801_3_T1	PHENOTYPE	16	16	decision-making
NCT002038014	NCT00203801_4_T0	GENE	22	22	CAT
NCT002038014	NCT00203801_4_T1	GENE	1	1	SP
NCT002038015	NCT00203801_5_T0	COMPOUND	23	23	artemether_lumefantrine
NCT002038015	NCT00203801_5_T1	COMPOUND	19	19	artesunate
NCT002038015	NCT00203801_5_T2	GENE	1	1	CAT
NCT002038015	NCT00203801_5_T3	GENE	7	7	CAT
NCT002038015	NCT00203801_5_T4	GENE	21	21	SP
NCT002038016	NCT00203801_6_T0	GENE	8	8	CAT
NCT002038016	NCT00203801_6_T1	PHENOTYPE	5	5	malaria
NCT002038142	NCT00203814_2_T0	GENE	23	23	CAT
NCT002038142	NCT00203814_2_T1	GENE	33	33	CAT
NCT002038142	NCT00203814_2_T2	PHENOTYPE	16	16	decision-making
NCT002038144	NCT00203814_4_T0	COMPOUND	27	27	artesunate
NCT002038144	NCT00203814_4_T1	GENE	26	26	CAT
NCT002038144	NCT00203814_4_T2	PHENOTYPE	13	13	malaria
NCT002038144	NCT00203814_4_T3	GENE	24	24	SP
NCT002038144	NCT00203814_4_T4	GENE	29	29	SP
NCT002038275	NCT00203827_5_T0	GENE	7	7	Pro
NCT002038278	NCT00203827_8_T0	GENE	6	6	log
NCT002038405	NCT00203840_5_T0	GENE	7	7	Pro
NCT002038408	NCT00203840_8_T0	GENE	6	6	log
NCT002038532	NCT00203853_2_T0	GENE	7	7	has
NCT0020385311	NCT00203853_11_T0	GENE	2	2	al
NCT0020385311	NCT00203853_11_T1	GENE	1	1	et
NCT0020385320	NCT00203853_20_T0	PHENOTYPE	6	6	recalling
NCT0020385326	NCT00203853_26_T0	GENE	19	19	MEMS
NCT0020385326	NCT00203853_26_T1	ORGAN	21	21	serum
NCT0020385326	NCT00203853_26_T2	PHENOTYPE	22	23	drug levels
NCT0020385329	NCT00203853_29_T0	PHENOTYPE	11	11	dumping
NCT0020385337	NCT00203853_37_T0	ORGAN	0	0	Serum
NCT0020385337	NCT00203853_37_T1	PHENOTYPE	1	2	drug levels
NCT0020385338	NCT00203853_38_T0	PHENOTYPE	5	5	reflects
NCT0020385346	NCT00203853_46_T0	GENE	24	24	had
NCT0020385346	NCT00203853_46_T1	GENE	5	5	al
NCT0020385346	NCT00203853_46_T2	GENE	4	4	et
NCT0020385352	NCT00203853_52_T0	PHENOTYPE	1	1	reinforcement
NCT0020385353	NCT00203853_53_T0	PHENOTYPE	2	2	HIV
NCT0020385358	NCT00203853_58_T0	PHENOTYPE	5	5	HIV
NCT0020385359	NCT00203853_59_T0	PHENOTYPE	11	11	HIV
NCT0020385360	NCT00203853_60_T0	PHENOTYPE	8	8	HIV
NCT0020385360	NCT00203853_60_T1	PHENOTYPE	2	2	reflects
NCT0020385365	NCT00203853_65_T0	GENE	23	23	has
NCT0020385366	NCT00203853_66_T0	PHENOTYPE	54	54	attitudes
NCT0020385366	NCT00203853_66_T1	PHENOTYPE	29	29	HIV
NCT0020385366	NCT00203853_66_T2	PHENOTYPE	60	60	HIV
NCT0020385367	NCT00203853_67_T0	GENE	4	4	90
NCT0020385367	NCT00203853_67_T1	GENE	2	2	has
NCT0020385380	NCT00203853_80_T0	PHENOTYPE	7	7	HIV
NCT0020385380	NCT00203853_80_T1	GENE	28	28	had
NCT002038662	NCT00203866_2_T0	GENE	5	5	IL-2
NCT002038663	NCT00203866_3_T0	PHENOTYPE	11	11	metastases
NCT002038663	NCT00203866_3_T1	GENE	10	10	solitary
NCT002038664	NCT00203866_4_T0	PHENOTYPE	19	19	recurrence
NCT002038667	NCT00203866_7_T0	GENE	13	13	IL-2
NCT002038668	NCT00203866_8_T0	GENE	11	11	IL-2
NCT002038669	NCT00203866_9_T0	GENE	36	36	35
NCT002038669	NCT00203866_9_T1	GENE	29	29	IL-2
NCT002038669	NCT00203866_9_T2	GENE	24	24	CTL
NCT0020386610	NCT00203866_10_T0	GENE	26	26	36
NCT0020386610	NCT00203866_10_T1	GENE	8	8	IL-2
NCT0020386610	NCT00203866_10_T2	PHENOTYPE	23	23	tumor
NCT0020386610	NCT00203866_10_T3	PHENOTYPE	24	24	regression
NCT0020386610	NCT00203866_10_T4	PHENOTYPE	11	11	melanoma
NCT0020386610	NCT00203866_10_T5	GENE	13	13	had
NCT0020386610	NCT00203866_10_T6	GENE	20	20	CTL
NCT0020386611	NCT00203866_11_T0	GENE	9	9	IL-2
NCT0020386611	NCT00203866_11_T1	GENE	22	22	IL-2
NCT0020386611	NCT00203866_11_T2	PHENOTYPE	15	15	circulation
NCT0020386611	NCT00203866_11_T3	GENE	12	12	CTL
NCT0020386611	NCT00203866_11_T4	CELL	25	25	T-cell
NCT0020386611	NCT00203866_11_T5	PHENOTYPE	4	5	capillary leak
NCT0020386612	NCT00203866_12_T0	GENE	4	4	has
NCT0020386616	NCT00203866_16_T0	GENE	9	9	IL-2
NCT0020386618	NCT00203866_18_T0	GENE	2	2	has
NCT0020386621	NCT00203866_21_T0	GENE	26	26	IL-2
NCT0020386621	NCT00203866_21_T1	GENE	18	18	has
NCT002038791	NCT00203879_1_T0	GENE	3	4	melanoma antigen
NCT002038792	NCT00203879_2_T0	GENE	3	3	IL-2
NCT002038792	NCT00203879_2_T1	GENE	22	22	IL-2
NCT002038792	NCT00203879_2_T2	CELL	17	18	T cells
NCT002038793	NCT00203879_3_T0	PHENOTYPE	0	0	Secondary
NCT002038793	NCT00203879_3_T1	CELL	11	11	cells
NCT002038793	NCT00203879_3_T2	PHENOTYPE	10	10	melanoma
NCT002038794	NCT00203879_4_T0	GENE	35	35	perforin
NCT002038794	NCT00203879_4_T1	GENE	20	20	TAP
NCT002038794	NCT00203879_4_T2	GENE	17	17	MHC
NCT002038794	NCT00203879_4_T3	GENE	31	31	mRNA
NCT002038794	NCT00203879_4_T4	PHENOTYPE	0	0	Tumors
NCT002038794	NCT00203879_4_T5	PHENOTYPE	15	16	class I
NCT002038794	NCT00203879_4_T6	GENE	21	22	peptide transporter
NCT002038794	NCT00203879_4_T7	CELL	8	9	T cells
NCT002038794	NCT00203879_4_T8	GENE	6	7	melanoma antigen
NCT002038795	NCT00203879_5_T0	PHENOTYPE	15	15	susceptible
NCT002038795	NCT00203879_5_T1	PHENOTYPE	0	0	Tumors
NCT002038797	NCT00203879_7_T0	GENE	3	3	II
NCT002038797	NCT00203879_7_T1	PHENOTYPE	6	7	metastatic melanoma
NCT002038799	NCT00203879_9_T0	PHENOTYPE	7	7	tumor
NCT002038799	NCT00203879_9_T1	CELL	27	28	T cells
NCT002038799	NCT00203879_9_T2	BIOLOGICAL_PROCESS	37	38	gene expression
NCT0020387911	NCT00203879_11_T0	GENE	8	8	IL-2
NCT0020387911	NCT00203879_11_T1	GENE	13	13	IL-2
NCT0020387913	NCT00203879_13_T0	GENE	22	22	gp
NCT0020387915	NCT00203879_15_T0	CELL	5	5	cells
NCT0020387915	NCT00203879_15_T1	PHENOTYPE	23	23	tumor
NCT0020387915	NCT00203879_15_T2	TISSUE	15	16	lymph node
NCT0020387916	NCT00203879_16_T0	GENE	3	3	has
NCT0020387916	NCT00203879_16_T1	TISSUE	26	27	lymph node
NCT0020387917	NCT00203879_17_T0	GENE	2	2	tg
NCT0020387917	NCT00203879_17_T1	GENE	16	16	1.3
NCT0020387919	NCT00203879_19_T0	GENE	7	7	IL-2
NCT0020387920	NCT00203879_20_T0	GENE	6	6	IL-2
NCT0020387921	NCT00203879_21_T0	PHENOTYPE	6	6	peripheral
NCT0020387922	NCT00203879_22_T0	PHENOTYPE	41	41	peripheral
NCT0020387922	NCT00203879_22_T1	PHENOTYPE	38	38	melanoma
NCT0020387922	NCT00203879_22_T2	GENE	15	15	CD8
NCT0020387922	NCT00203879_22_T3	CELL	16	17	T cells
NCT0020387923	NCT00203879_23_T0	PHENOTYPE	19	19	tumor
NCT0020387923	NCT00203879_23_T1	PHENOTYPE	31	31	tumor
NCT0020387923	NCT00203879_23_T2	BIOLOGICAL_PROCESS	27	28	immune response
NCT0020387924	NCT00203879_24_T0	PHENOTYPE	18	19	residual tumors
NCT0020387925	NCT00203879_25_T0	PHENOTYPE	7	7	secondary
NCT0020387927	NCT00203879_27_T0	PHENOTYPE	2	2	metastases
NCT0020387931	NCT00203879_31_T0	PHENOTYPE	3	4	brain metastases
NCT002038922	NCT00203892_2_T0	PHENOTYPE	16	16	toxicity
NCT002038922	NCT00203892_2_T1	PHENOTYPE	12	13	progressive disease
NCT002038923	NCT00203892_3_T0	ORGAN	6	6	thigh
NCT002038923	NCT00203892_3_T1	PHENOTYPE	5	5	proximal
NCT002038925	NCT00203892_5_T0	PHENOTYPE	13	14	metastatic disease
NCT002038927	NCT00203892_7_T0	GENE	1	1	CEA
NCT002038928	NCT00203892_8_T0	PHENOTYPE	11	11	TAA
NCT002038928	NCT00203892_8_T1	GENE	8	8	CEA
NCT0020389210	NCT00203892_10_T0	GENE	7	7	GM-CSF
NCT0020389211	NCT00203892_11_T0	PHENOTYPE	7	7	tumor
NCT0020389212	NCT00203892_12_T0	GENE	6	6	Ras
NCT0020389212	NCT00203892_12_T1	GENE	2	2	al
NCT0020389212	NCT00203892_12_T2	GENE	9	9	GM-CSF
NCT0020389212	NCT00203892_12_T3	GENE	1	1	et
NCT0020389213	NCT00203892_13_T0	GENE	7	7	CTL
NCT0020389213	NCT00203892_13_T1	GENE	12	12	al
NCT0020389213	NCT00203892_13_T2	GENE	11	11	et
NCT0020389214	NCT00203892_14_T0	GENE	17	17	II
NCT0020389214	NCT00203892_14_T1	GENE	2	2	had
NCT0020389214	NCT00203892_14_T2	GENE	6	6	had
NCT0020389214	NCT00203892_14_T3	PHENOTYPE	27	28	metastatic disease
NCT0020389214	NCT00203892_14_T4	BIOLOGICAL_PROCESS	4	5	immune response
NCT0020389217	NCT00203892_17_T0	GENE	4	4	had
NCT002039052	NCT00203905_2_T0	GENE	19	19	II
NCT002039052	NCT00203905_2_T1	PHENOTYPE	47	47	recurrences
NCT002039052	NCT00203905_2_T2	PHENOTYPE	23	23	malignancies
NCT002039054	NCT00203905_4_T0	GENE	13	13	II
NCT002039055	NCT00203905_5_T0	GENE	32	32	T4
NCT002039055	NCT00203905_5_T1	GENE	35	35	T4
NCT002039055	NCT00203905_5_T2	GENE	39	39	T4
NCT002039055	NCT00203905_5_T3	GENE	57	57	N2
NCT002039055	NCT00203905_5_T4	GENE	59	59	N3
NCT002039055	NCT00203905_5_T5	GENE	26	26	nodal
NCT002039055	NCT00203905_5_T6	GENE	55	55	nodal
NCT002039055	NCT00203905_5_T7	PHENOTYPE	13	13	cancers
NCT002039058	NCT00203905_8_T0	PHENOTYPE	21	21	progression
NCT002039058	NCT00203905_8_T1	PHENOTYPE	31	31	QOL
NCT002039059	NCT00203905_9_T0	GENE	12	12	HNC
NCT0020390510	NCT00203905_10_T0	GENE	23	23	FHX
NCT0020390516	NCT00203905_16_T0	PHENOTYPE	5	5	intent
NCT002039183	NCT00203918_3_T0	PHENOTYPE	21	21	decisions
NCT002039183	NCT00203918_3_T1	PHENOTYPE	18	18	reflects
NCT002039314	NCT00203931_4_T0	GENE	5	5	has
NCT002039315	NCT00203931_5_T0	COMPOUND	33	33	pemetrexed
NCT002039315	NCT00203931_5_T1	COMPOUND	43	43	pemetrexed
NCT002039315	NCT00203931_5_T2	PHENOTYPE	11	11	progression
NCT002039317	NCT00203931_7_T0	CELL	15	15	cells
NCT002039317	NCT00203931_7_T1	PHENOTYPE	14	14	tumor
NCT0020393110	NCT00203931_10_T0	PHENOTYPE	25	25	NSCLC
NCT0020393113	NCT00203931_13_T0	COMPOUND	23	23	pemetrexed
NCT0020393114	NCT00203931_14_T0	PHENOTYPE	9	9	secondary
NCT0020393114	NCT00203931_14_T1	PHENOTYPE	7	7	progression
NCT0020393115	NCT00203931_15_T0	PHENOTYPE	7	7	secondary
NCT0020393115	NCT00203931_15_T1	COMPOUND	19	19	pemetrexed
NCT0020393115	NCT00203931_15_T2	COMPOUND	28	28	pemetrexed
NCT0020393115	NCT00203931_15_T3	PHENOTYPE	30	31	disease progression
NCT0020393117	NCT00203931_17_T0	GENE	9	9	polypeptide
NCT0020393117	NCT00203931_17_T1	ORGAN	1	1	serum
NCT0020393117	NCT00203931_17_T2	ORGAN	8	8	serum
NCT0020393117	NCT00203931_17_T3	ORGAN	17	17	serum
NCT0020393119	NCT00203931_19_T0	PHENOTYPE	12	12	inhibition
NCT0020393119	NCT00203931_19_T1	GENE	11	11	EGFR
NCT0020393119	NCT00203931_19_T2	COMPOUND	32	33	EGFR inhibitor
NCT0020393126	NCT00203931_26_T0	PHENOTYPE	13	15	negative pregnancy test
NCT002039442	NCT00203944_2_T0	GENE	27	27	met
NCT002039444	NCT00203944_4_T0	PHENOTYPE	5	5	focused
NCT002039444	NCT00203944_4_T1	GENE	3	3	has
NCT002039445	NCT00203944_5_T0	PHENOTYPE	9	10	developmentally delayed
NCT002039446	NCT00203944_6_T0	PHENOTYPE	31	31	falling
NCT002039446	NCT00203944_6_T1	PHENOTYPE	15	16	cognitive functioning
NCT002039573	NCT00203957_3_T0	COMPOUND	3	3	istradefylline
NCT002039574	NCT00203957_4_T0	COMPOUND	4	4	istradefylline
NCT002039575	NCT00203957_5_T0	PHENOTYPE	10	10	satisfied
NCT002039575	NCT00203957_5_T1	COMPOUND	1	1	istradefylline
NCT002039575	NCT00203957_5_T2	GENE	9	9	has
NCT002039577	NCT00203957_7_T0	GENE	44	44	had
NCT002039578	NCT00203957_8_T0	COMPOUND	15	15	istradefylline
NCT002039579	NCT00203957_9_T0	GENE	24	24	had
NCT002039579	NCT00203957_9_T1	PHENOTYPE	0	1	Group B
NCT0020395710	NCT00203957_10_T0	COMPOUND	12	12	1
NCT0020395710	NCT00203957_10_T1	COMPOUND	9	9	2
NCT0020395713	NCT00203957_13_T0	PHENOTYPE	7	8	adverse events
NCT0020395716	NCT00203957_16_T0	ORGAN	30	30	diaphragm
NCT0020395716	NCT00203957_16_T1	ORGAN	44	44	serum
NCT002039701	NCT00203970_1_T0	PHENOTYPE	9	9	diffuse
NCT002039703	NCT00203970_3_T0	COMPOUND	14	14	heparin
NCT002039703	NCT00203970_3_T1	PHENOTYPE	20	20	anticoagulation
NCT002039703	NCT00203970_3_T2	GENE	5	5	has
NCT002039704	NCT00203970_4_T0	PHENOTYPE	1	1	DVT
NCT002039707	NCT00203970_7_T0	PHENOTYPE	29	29	secondary
NCT002039707	NCT00203970_7_T1	PHENOTYPE	33	34	Venous Thromboembolism
NCT002039708	NCT00203970_8_T0	PHENOTYPE	42	42	DVT
NCT002039708	NCT00203970_8_T1	GENE	29	29	had
NCT002039709	NCT00203970_9_T0	PHENOTYPE	10	10	affects
NCT0020399613	NCT00203996_13_T0	COMPOUND	10	10	1
NCT0020399613	NCT00203996_13_T1	PHENOTYPE	26	26	PCOS
NCT0020399613	NCT00203996_13_T2	PHENOTYPE	23	23	hyperinsulinemia
NCT0020399613	NCT00203996_13_T3	PHENOTYPE	16	17	sleep disturbances
NCT0020399614	NCT00203996_14_T0	PHENOTYPE	14	14	PCOS
NCT0020399614	NCT00203996_14_T1	COMPOUND	24	24	pioglitazone
NCT0020399614	NCT00203996_14_T2	COMPOUND	27	27	leuprolide
NCT0020399615	NCT00203996_15_T0	COMPOUND	7	7	androgen
NCT0020399615	NCT00203996_15_T1	PHENOTYPE	10	10	PCOS
NCT0020399615	NCT00203996_15_T2	PHENOTYPE	3	4	insulin levels
NCT0020399616	NCT00203996_16_T0	COMPOUND	6	6	androgen
NCT0020399616	NCT00203996_16_T1	COMPOUND	18	18	androgen
NCT0020399616	NCT00203996_16_T2	COMPOUND	22	22	pioglitazone
NCT0020399616	NCT00203996_16_T3	GENE	16	16	insulin
NCT0020399616	NCT00203996_16_T4	COMPOUND	10	10	leuprolide
NCT0020399618	NCT00203996_18_T0	PHENOTYPE	21	21	PCOS
NCT0020399618	NCT00203996_18_T1	COMPOUND	2	2	2
NCT0020399618	NCT00203996_18_T2	PHENOTYPE	8	9	sleep disturbances
NCT0020399619	NCT00203996_19_T0	PHENOTYPE	0	0	PCOS
NCT0020399619	NCT00203996_19_T1	GENE	20	20	CPAP
NCT0020399620	NCT00203996_20_T0	PHENOTYPE	11	11	PCOS
NCT0020399621	NCT00203996_21_T0	PHENOTYPE	1	1	secondary
NCT0020399621	NCT00203996_21_T1	PHENOTYPE	11	11	PCOS
NCT0020399621	NCT00203996_21_T2	PHENOTYPE	41	41	PCOS
NCT0020399625	NCT00203996_25_T0	PHENOTYPE	14	15	REM sleep
NCT0020399629	NCT00203996_29_T0	BIOLOGICAL_PROCESS	7	7	menarche
NCT0020399632	NCT00203996_32_T0	GENE	11	11	2.4
NCT0020399632	NCT00203996_32_T1	BIOLOGICAL_PROCESS	8	9	follicular phase
NCT0020400918	NCT00204009_18_T0	GENE	4	5	type 2
NCT0020400926	NCT00204009_26_T0	PHENOTYPE	7	7	complications
NCT0020400926	NCT00204009_26_T1	PHENOTYPE	26	26	complications
NCT0020400926	NCT00204009_26_T2	PHENOTYPE	25	25	chronic
NCT0020400926	NCT00204009_26_T3	PHENOTYPE	15	16	cardiovascular disease
NCT002040220	NCT00204022_0_T0	PHENOTYPE	11	11	Nephritis
NCT002040220	NCT00204022_0_T1	PHENOTYPE	8	9	Lupus Nephritis
NCT002040224	NCT00204022_4_T0	PHENOTYPE	6	6	Nephritis
NCT002040351	NCT00204035_1_T0	PHENOTYPE	5	6	career choice
NCT002040351	NCT00204035_1_T1	PHENOTYPE	22	23	career choice
NCT002040352	NCT00204035_2_T0	PHENOTYPE	37	37	strategies
NCT002040358	NCT00204035_8_T0	PHENOTYPE	24	24	spots
NCT002040483	NCT00204048_3_T0	PHENOTYPE	33	33	centers
NCT002040486	NCT00204048_6_T0	PHENOTYPE	15	15	Center
NCT002040487	NCT00204048_7_T0	GENE	35	35	UC
NCT0020404818	NCT00204048_18_T0	PHENOTYPE	17	17	diseases
NCT0020404818	NCT00204048_18_T1	PHENOTYPE	15	15	syndromes
NCT002040612	NCT00204061_2_T0	COMPOUND	24	24	amisulpride
NCT002040612	NCT00204061_2_T1	GENE	22	22	atypical
NCT002040612	NCT00204061_2_T2	GENE	4	4	CM
NCT002040612	NCT00204061_2_T3	GENE	19	19	CM
NCT002040613	NCT00204061_3_T0	GENE	13	13	atypical
NCT002040616	NCT00204061_6_T0	PHENOTYPE	24	24	suffering
NCT002040616	NCT00204061_6_T1	PHENOTYPE	4	4	psychosis
NCT002040616	NCT00204061_6_T2	PHENOTYPE	26	27	prodromal symptoms
NCT0020406110	NCT00204061_10_T0	COMPOUND	24	24	amisulpride
NCT0020406110	NCT00204061_10_T1	GENE	22	22	atypical
NCT0020406110	NCT00204061_10_T2	GENE	4	4	CM
NCT0020406110	NCT00204061_10_T3	GENE	19	19	CM
NCT002040740	NCT00204074_0_T0	PHENOTYPE	2	3	Menstrual Migraine
NCT002040872	NCT00204087_2_T0	PHENOTYPE	8	8	schizophrenia
NCT002040874	NCT00204087_4_T0	GENE	41	41	CM
NCT002040874	NCT00204087_4_T1	PHENOTYPE	23	23	psychosis
NCT002040879	NCT00204087_9_T0	GENE	0	0	SC
NCT002041003	NCT00204100_3_T0	TISSUE	8	8	muscles
NCT002041003	NCT00204100_3_T1	TISSUE	15	15	muscles
NCT002041003	NCT00204100_3_T2	ORGAN	7	7	thigh
NCT002041003	NCT00204100_3_T3	ORGAN	14	14	buttocks
NCT002041003	NCT00204100_3_T4	TISSUE	5	6	hamstring muscles
NCT002041005	NCT00204100_5_T0	GENE	8	8	FES
NCT002041007	NCT00204100_7_T0	GENE	15	15	FES
NCT002041008	NCT00204100_8_T0	PHENOTYPE	5	7	spinal cord lesion
NCT0020410011	NCT00204100_11_T0	PHENOTYPE	39	39	progressive
NCT0020410020	NCT00204100_20_T0	PHENOTYPE	27	28	pressure sore
NCT0020410021	NCT00204100_21_T0	PHENOTYPE	10	10	centres
NCT0020410021	NCT00204100_21_T1	PHENOTYPE	22	23	Spinal Injuries
NCT0020410023	NCT00204100_23_T0	PHENOTYPE	7	7	centres
NCT0020410024	NCT00204100_24_T0	BIOLOGICAL_PROCESS	2	2	Development
NCT0020410027	NCT00204100_27_T0	GENE	6	6	FES
NCT0020410027	NCT00204100_27_T1	PHENOTYPE	4	4	progressive
NCT0020410028	NCT00204100_28_T0	PHENOTYPE	6	6	centre
NCT0020410033	NCT00204100_33_T0	PHENOTYPE	9	9	complications
NCT0020410034	NCT00204100_34_T0	ORGAN	6	6	joints
NCT0020410035	NCT00204100_35_T0	PHENOTYPE	2	2	spasticity
NCT002041131	NCT00204113_1_T0	TISSUE	13	13	muscles
NCT002041131	NCT00204113_1_T1	GENE	9	9	FES
NCT002041133	NCT00204113_3_T0	TISSUE	13	13	muscles
NCT002041133	NCT00204113_3_T1	GENE	9	9	FES
NCT002041135	NCT00204113_5_T0	GENE	4	4	FES
NCT002041135	NCT00204113_5_T1	PHENOTYPE	17	17	stepping
NCT002041136	NCT00204113_6_T0	GENE	15	15	FES
NCT002041137	NCT00204113_7_T0	PHENOTYPE	21	21	demineralisation
NCT002041137	NCT00204113_7_T1	PHENOTYPE	32	32	spasm
NCT002041138	NCT00204113_8_T0	PHENOTYPE	18	18	secondary
NCT002041138	NCT00204113_8_T1	PHENOTYPE	21	21	paralysis
NCT002041263	NCT00204126_3_T0	TISSUE	31	32	voluntary muscle
NCT002041265	NCT00204126_5_T0	TISSUE	10	11	voluntary muscle
NCT002041266	NCT00204126_6_T0	ORGAN	5	5	legs
NCT002041266	NCT00204126_6_T1	GENE	15	15	has
NCT002041269	NCT00204126_9_T0	GENE	15	15	has
NCT002041269	NCT00204126_9_T1	COMPOUND	30	30	oxygen
NCT0020412610	NCT00204126_10_T0	TISSUE	19	20	voluntary muscle
NCT0020412614	NCT00204126_14_T0	ORGAN	14	14	legs
NCT0020412616	NCT00204126_16_T0	GENE	13	13	sine
NCT0020412617	NCT00204126_17_T0	PHENOTYPE	26	26	tolerance
NCT0020412618	NCT00204126_18_T0	GENE	11	11	al
NCT0020412618	NCT00204126_18_T1	GENE	10	10	et
NCT0020412619	NCT00204126_19_T0	PHENOTYPE	22	22	fatiguing
NCT0020412621	NCT00204126_21_T0	GENE	1	1	has
NCT0020412623	NCT00204126_23_T0	PHENOTYPE	21	21	trauma
NCT0020412623	NCT00204126_23_T1	PHENOTYPE	18	18	fracture
NCT0020412623	NCT00204126_23_T2	PHENOTYPE	2	3	spinal injury
NCT0020412624	NCT00204126_24_T0	ORGAN	15	15	tibia
NCT0020412624	NCT00204126_24_T1	ORGAN	17	17	femur
NCT0020412624	NCT00204126_24_T2	ORGAN	10	10	epiphyses
NCT0020412626	NCT00204126_26_T0	PHENOTYPE	11	12	cardiovascular disease
NCT0020412628	NCT00204126_28_T0	PHENOTYPE	10	10	fracture
NCT002041395	NCT00204139_5_T0	GENE	24	24	reduced
NCT002041395	NCT00204139_5_T1	PHENOTYPE	21	22	congenital abnormalities
NCT002041395	NCT00204139_5_T2	PHENOTYPE	7	8	fetal death
NCT002041396	NCT00204139_6_T0	GENE	6	6	has
NCT002041398	NCT00204139_8_T0	BIOLOGICAL_PROCESS	10	10	gestation
NCT0020413910	NCT00204139_10_T0	PHENOTYPE	14	15	congenital abnormalities
NCT002041520	NCT00204152_0_T0	PHENOTYPE	2	3	Chronic Depression
NCT002041523	NCT00204152_3_T0	PHENOTYPE	10	10	strategies
NCT002041523	NCT00204152_3_T1	PHENOTYPE	13	14	depressive symptoms
NCT002041526	NCT00204152_6_T0	GENE	13	13	Rao
NCT002041526	NCT00204152_6_T1	GENE	15	15	al
NCT002041526	NCT00204152_6_T2	GENE	28	28	al
NCT002041526	NCT00204152_6_T3	GENE	42	42	al
NCT002041526	NCT00204152_6_T4	GENE	14	14	et
NCT002041526	NCT00204152_6_T5	GENE	27	27	et
NCT002041526	NCT00204152_6_T6	GENE	41	41	et
NCT002041526	NCT00204152_6_T7	GENE	7	7	has
NCT002041526	NCT00204152_6_T8	GENE	25	25	span
NCT002041527	NCT00204152_7_T0	PHENOTYPE	5	6	life stress
NCT002041528	NCT00204152_8_T0	PHENOTYPE	24	25	life stress
NCT002041529	NCT00204152_9_T0	PHENOTYPE	11	11	strategies
NCT002041529	NCT00204152_9_T1	PHENOTYPE	15	15	avoidance
NCT0020415213	NCT00204152_13_T0	PHENOTYPE	19	19	relapse
NCT002041782	NCT00204178_2_T0	CELL	26	26	granulocytes
NCT002041782	NCT00204178_2_T1	GENE	20	20	SOD
NCT002041782	NCT00204178_2_T2	ORGAN	1	1	kidney
NCT002041782	NCT00204178_2_T3	GENE	16	16	CAT
NCT002041782	NCT00204178_2_T4	ORGAN	2	2	transplant
NCT002041782	NCT00204178_2_T5	GENE	15	15	catalase
NCT002041782	NCT00204178_2_T6	GENE	18	19	superoxide dismutase
NCT002041782	NCT00204178_2_T7	COMPOUND	22	23	superoxide anion
NCT002041782	NCT00204178_2_T8	GENE	12	13	glutathione peroxidase
NCT002041784	NCT00204178_4_T0	ORGAN	1	1	kidney
NCT002041784	NCT00204178_4_T1	COMPOUND	16	16	creatinine
NCT002041784	NCT00204178_4_T2	ORGAN	15	15	serum
NCT002041784	NCT00204178_4_T3	PHENOTYPE	11	13	Delayed Graft Function
NCT002041913	NCT00204191_3_T0	GENE	2	2	has
NCT002041914	NCT00204191_4_T0	ORGAN	6	6	kidneys
NCT002041916	NCT00204191_6_T0	PHENOTYPE	3	3	decisions
NCT002042042	NCT00204204_2_T0	PHENOTYPE	29	29	severity
NCT002042044	NCT00204204_4_T0	PHENOTYPE	8	8	centre
NCT002042046	NCT00204204_6_T0	PHENOTYPE	11	11	pathology
NCT0020420410	NCT00204204_10_T0	PHENOTYPE	18	18	severity
NCT002042174	NCT00204217_4_T0	ORGAN	19	19	thorax
NCT002042174	NCT00204217_4_T1	PHENOTYPE	9	9	ventilation
NCT002042174	NCT00204217_4_T2	PHENOTYPE	12	12	impedance
NCT002042174	NCT00204217_4_T3	ORGAN	7	7	lungs
NCT002042175	NCT00204217_5_T0	GENE	11	11	CPR
NCT002042175	NCT00204217_5_T1	PHENOTYPE	1	1	impedance
NCT002042178	NCT00204217_8_T0	GENE	4	4	CPR
NCT002042179	NCT00204217_9_T0	PHENOTYPE	25	25	ventilation
NCT002042179	NCT00204217_9_T1	PHENOTYPE	34	34	impedance
NCT002042179	NCT00204217_9_T2	ORGAN	2	2	lungs
NCT002042179	NCT00204217_9_T3	ORGAN	23	23	esophagus
NCT002042179	NCT00204217_9_T4	GENE	8	8	ml
NCT002042301	NCT00204230_1_T0	COMPOUND	8	8	prednisolone
NCT002042303	NCT00204230_3_T0	COMPOUND	4	4	azathioprine
NCT002042303	NCT00204230_3_T1	GENE	6	6	had
NCT002042304	NCT00204230_4_T0	COMPOUND	11	11	azathioprine
NCT002042304	NCT00204230_4_T1	PHENOTYPE	9	9	elimination
NCT002042305	NCT00204230_5_T0	COMPOUND	13	13	1
NCT002042306	NCT00204230_6_T0	COMPOUND	3	3	tacrolimus
NCT002042306	NCT00204230_6_T1	GENE	13	13	FK506
NCT002042306	NCT00204230_6_T2	GENE	14	14	4.7
NCT002042309	NCT00204230_9_T0	GENE	7	7	reduced
NCT002042309	NCT00204230_9_T1	GENE	0	0	FK506
NCT002042309	NCT00204230_9_T2	PHENOTYPE	20	20	elimination
NCT002042309	NCT00204230_9_T3	GENE	8	8	ba
NCT0020423010	NCT00204230_10_T0	GENE	1	1	III
NCT002042431	NCT00204243_1_T0	COMPOUND	11	11	methadone
NCT002042432	NCT00204243_2_T0	BIOLOGICAL_PROCESS	9	9	behaviour
NCT002042432	NCT00204243_2_T1	PHENOTYPE	4	6	quality of life
NCT002042433	NCT00204243_3_T0	GENE	16	16	MMT
NCT002042433	NCT00204243_3_T1	PHENOTYPE	11	12	opioid use
NCT002042436	NCT00204243_6_T0	PHENOTYPE	4	4	relapse
NCT002042436	NCT00204243_6_T1	GENE	15	15	MMT
NCT002042436	NCT00204243_6_T2	PHENOTYPE	6	7	opiate abuse
NCT002042437	NCT00204243_7_T0	COMPOUND	22	22	naltrexone
NCT002042438	NCT00204243_8_T0	GENE	9	9	MMT
NCT002042564	NCT00204256_4_T0	COMPOUND	5	5	sucrose
NCT002042564	NCT00204256_4_T1	COMPOUND	9	9	sucrose
NCT002042565	NCT00204256_5_T0	GENE	20	20	hemoglobin
NCT002042566	NCT00204256_6_T0	GENE	7	7	ferritin
NCT002042566	NCT00204256_6_T1	PHENOTYPE	0	0	Secondary
NCT002042566	NCT00204256_6_T2	GENE	9	9	transferrin
NCT002042567	NCT00204256_7_T0	PHENOTYPE	6	7	adverse events
NCT002042691	NCT00204269_1_T0	GENE	10	10	Gel
NCT002042691	NCT00204269_1_T1	GENE	17	17	Gel
NCT002042693	NCT00204269_3_T0	GENE	10	10	Gel
NCT002042693	NCT00204269_3_T1	GENE	17	17	Gel
NCT002042821	NCT00204282_1_T0	PHENOTYPE	0	0	Diabetes
NCT002042821	NCT00204282_1_T1	GENE	32	32	toll
NCT002042822	NCT00204282_2_T0	PHENOTYPE	13	13	centers
NCT002042824	NCT00204282_4_T0	GENE	15	15	NP
NCT002042824	NCT00204282_4_T1	PHENOTYPE	37	37	Diabetes
NCT002042825	NCT00204282_5_T0	PHENOTYPE	3	5	quality of life
NCT0020428210	NCT00204282_10_T0	GENE	13	13	Alc
NCT0020428210	NCT00204282_10_T1	ORGAN	11	11	serum
NCT0020428210	NCT00204282_10_T2	GENE	22	22	ASA
NCT0020428211	NCT00204282_11_T0	GENE	13	13	SF
NCT0020428211	NCT00204282_11_T1	GENE	16	16	ADA
NCT0020428211	NCT00204282_11_T2	PHENOTYPE	9	11	quality of life
NCT0020428219	NCT00204282_19_T0	GENE	9	9	al
NCT0020428219	NCT00204282_19_T1	GENE	8	8	et
NCT0020428223	NCT00204282_23_T0	PHENOTYPE	4	5	chronic illness
NCT0020428224	NCT00204282_24_T0	PHENOTYPE	0	0	Diabetes
NCT0020428224	NCT00204282_24_T1	GENE	2	2	has
NCT002042952	NCT00204295_2_T0	GENE	3	3	MRI
NCT002042955	NCT00204295_5_T0	GENE	6	6	has
NCT002042955	NCT00204295_5_T1	COMPOUND	2	2	fluorine_18
NCT002042955	NCT00204295_5_T2	PHENOTYPE	18	19	brain tumor
NCT002042956	NCT00204295_6_T0	PHENOTYPE	12	13	brain tumors
NCT002042956	NCT00204295_6_T1	BIOLOGICAL_PROCESS	16	18	amino acid transport
NCT002042958	NCT00204295_8_T0	PHENOTYPE	20	20	glioma
NCT002042958	NCT00204295_8_T1	GENE	1	2	heavy chain
NCT002043083	NCT00204308_3_T0	GENE	1	2	reverse transcriptase
NCT002043085	NCT00204308_5_T0	GENE	20	20	reduced
NCT002043086	NCT00204308_6_T0	COMPOUND	10	10	emtricitabine
NCT002043086	NCT00204308_6_T1	COMPOUND	7	7	tenofovir
NCT002043086	NCT00204308_6_T2	GENE	8	8	TDF
NCT002043087	NCT00204308_7_T0	GENE	0	0	TDF
NCT002043088	NCT00204308_8_T0	PHENOTYPE	27	27	HIV
NCT002043089	NCT00204308_9_T0	BIOLOGICAL_PROCESS	10	10	gestation
NCT002043211	NCT00204321_1_T0	ORGAN	11	11	transplant
NCT002043211	NCT00204321_1_T1	PHENOTYPE	4	4	hypertension
NCT002043212	NCT00204321_2_T0	ORGAN	17	17	transplant
NCT002043213	NCT00204321_3_T0	PHENOTYPE	17	17	arteriosclerosis
NCT002043213	NCT00204321_3_T1	ORGAN	23	23	transplant
NCT002043213	NCT00204321_3_T2	CELL	11	12	endothelial cells
NCT002043215	NCT00204321_5_T0	COMPOUND	12	12	3
NCT002043216	NCT00204321_6_T0	ORGAN	7	7	arteries
NCT002043216	NCT00204321_6_T1	GENE	14	14	4.5
NCT002043216	NCT00204321_6_T2	PHENOTYPE	0	1	Endothelial dysfunction
NCT002043216	NCT00204321_6_T3	PHENOTYPE	12	13	cardiovascular morbidity
NCT002043217	NCT00204321_7_T0	PHENOTYPE	9	9	dysfunction
NCT002043217	NCT00204321_7_T1	ORGAN	4	6	sympathetic nervous system
NCT002043219	NCT00204321_9_T0	CELL	2	2	monocytes
NCT0020432117	NCT00204321_17_T0	ORGAN	7	9	sympathetic nervous system
NCT0020432119	NCT00204321_19_T0	PHENOTYPE	1	1	immunosuppression
NCT0020432119	NCT00204321_19_T1	CELL	6	7	endothelial cells
NCT0020432121	NCT00204321_21_T0	CELL	2	2	monocytes
NCT0020432124	NCT00204321_24_T0	PHENOTYPE	0	1	Cardiovascular complications
NCT0020432125	NCT00204321_25_T0	GENE	2	2	Soc
NCT0020432126	NCT00204321_26_T0	COMPOUND	1	1	2
NCT0020432126	NCT00204321_26_T1	COMPOUND	3	3	2
NCT0020432127	NCT00204321_27_T0	GENE	1	1	GM
NCT0020432128	NCT00204321_28_T0	PHENOTYPE	2	2	arteriosclerosis
NCT0020432128	NCT00204321_28_T1	PHENOTYPE	0	0	Atherosclerosis
NCT0020432128	NCT00204321_28_T2	PHENOTYPE	4	6	chronic renal failure
NCT0020432129	NCT00204321_29_T0	ORGAN	0	0	Kidney
NCT0020432129	NCT00204321_29_T1	GENE	1	1	Int
NCT0020432138	NCT00204321_38_T0	ORGAN	0	0	Kidney
NCT0020432138	NCT00204321_38_T1	GENE	1	1	Int
NCT0020432139	NCT00204321_39_T0	GENE	0	0	55
NCT0020432141	NCT00204321_41_T0	PHENOTYPE	19	20	cardiovascular disease
NCT0020432142	NCT00204321_42_T0	PHENOTYPE	2	2	Hypertension
NCT0020432145	NCT00204321_45_T0	ORGAN	0	0	Forearm
NCT0020432145	NCT00204321_45_T1	PHENOTYPE	2	2	hyperemia
NCT0020432146	NCT00204321_46_T0	ORGAN	0	0	Kidney
NCT0020432146	NCT00204321_46_T1	GENE	1	1	Int
NCT0020432148	NCT00204321_48_T0	GENE	4	4	Toto
NCT0020432148	NCT00204321_48_T1	GENE	7	7	CMT
NCT0020432149	NCT00204321_49_T0	PHENOTYPE	5	7	chronic renal failure
NCT0020432150	NCT00204321_50_T0	GENE	3	3	Med
NCT0020432150	NCT00204321_50_T1	COMPOUND	0	0	N
NCT0020432150	NCT00204321_50_T2	GENE	1	1	Engl
NCT0020432153	NCT00204321_53_T0	PHENOTYPE	4	6	end-stage renal disease
NCT0020432158	NCT00204321_58_T0	ORGAN	15	15	transplant
NCT0020432158	NCT00204321_58_T1	ORGAN	8	8	artery
NCT0020432163	NCT00204321_63_T0	PHENOTYPE	4	4	atherogenesis
NCT0020432163	NCT00204321_63_T1	CELL	2	2	monocytes
NCT0020432167	NCT00204321_67_T0	PHENOTYPE	1	2	inflammatory disease
NCT0020432168	NCT00204321_68_T0	GENE	3	3	Med
NCT0020432168	NCT00204321_68_T1	COMPOUND	0	0	N
NCT0020432168	NCT00204321_68_T2	GENE	1	1	Engl
NCT0020432169	NCT00204321_69_T0	GENE	1	1	Jan
NCT0020432171	NCT00204321_71_T0	GENE	3	3	HL
NCT0020432171	NCT00204321_71_T1	GENE	1	1	SM
NCT0020432172	NCT00204321_72_T0	CELL	9	9	monocytes
NCT0020432172	NCT00204321_72_T1	PHENOTYPE	6	6	proliferation
NCT0020432172	NCT00204321_72_T2	PHENOTYPE	4	4	recruitment
NCT002043342	NCT00204334_2_T0	PHENOTYPE	13	13	anemia
NCT002043343	NCT00204334_3_T0	ORGAN	14	14	graft
NCT002043343	NCT00204334_3_T1	ORGAN	4	4	artery
NCT002043343	NCT00204334_3_T2	PHENOTYPE	8	8	anemia
NCT002043343	NCT00204334_3_T3	PHENOTYPE	19	20	tubular proteinuria
NCT002043345	NCT00204334_5_T0	PHENOTYPE	10	10	anaemia
NCT002043345	NCT00204334_5_T1	ORGAN	19	19	artery
NCT002043346	NCT00204334_6_T0	ORGAN	1	1	kidney
NCT002043347	NCT00204334_7_T0	PHENOTYPE	21	21	toxic
NCT002043347	NCT00204334_7_T1	ORGAN	10	10	graft
NCT002043347	NCT00204334_7_T2	PHENOTYPE	0	0	Anemia
NCT002043347	NCT00204334_7_T3	ORGAN	4	4	kidney
NCT002043347	NCT00204334_7_T4	ORGAN	5	5	transplant
NCT002043347	NCT00204334_7_T5	GENE	16	16	erythropoietin
NCT002043347	NCT00204334_7_T6	PHENOTYPE	22	24	bone marrow depression
NCT002043348	NCT00204334_8_T0	ORGAN	8	8	kidney
NCT002043348	NCT00204334_8_T1	ORGAN	9	9	transplant
NCT002043348	NCT00204334_8_T2	PHENOTYPE	5	5	anemia
NCT002043348	NCT00204334_8_T3	PHENOTYPE	29	29	anemia
NCT002043349	NCT00204334_9_T0	TISSUE	28	28	endothelium
NCT002043349	NCT00204334_9_T1	ORGAN	10	10	transplant
NCT002043349	NCT00204334_9_T2	ORGAN	25	25	artery
NCT002043349	NCT00204334_9_T3	ORGAN	29	30	brachial artery
NCT0020433410	NCT00204334_10_T0	ORGAN	18	18	transplant
NCT0020433410	NCT00204334_10_T1	ORGAN	31	32	brachial artery
NCT0020433410	NCT00204334_10_T2	PHENOTYPE	14	15	cardiovascular morbidity
NCT0020433411	NCT00204334_11_T0	ORGAN	7	7	transplant
NCT0020433411	NCT00204334_11_T1	PHENOTYPE	4	4	anemia
NCT0020433411	NCT00204334_11_T2	PHENOTYPE	19	19	anemia
NCT0020433411	NCT00204334_11_T3	GENE	22	22	erythropoietin
NCT0020433414	NCT00204334_14_T0	PHENOTYPE	12	12	profound
NCT0020433414	NCT00204334_14_T1	ORGAN	7	7	transplant
NCT0020433415	NCT00204334_15_T0	ORGAN	49	49	kidney
NCT0020433415	NCT00204334_15_T1	ORGAN	10	10	transplant
NCT0020433415	NCT00204334_15_T2	ORGAN	50	50	transplant
NCT0020433415	NCT00204334_15_T3	ORGAN	16	16	artery
NCT0020433415	NCT00204334_15_T4	ORGAN	31	31	artery
NCT0020433415	NCT00204334_15_T5	PHENOTYPE	13	13	severely
NCT0020433416	NCT00204334_16_T0	GENE	5	5	erythropoietin
NCT0020433417	NCT00204334_17_T0	ORGAN	14	14	artery
NCT0020433417	NCT00204334_17_T1	GENE	5	5	erythropoietin
NCT0020433420	NCT00204334_20_T0	CELL	1	1	monocyte
NCT0020433420	NCT00204334_20_T1	PHENOTYPE	2	2	adhesion
NCT0020433420	NCT00204334_20_T2	CELL	4	5	endothelial cells
NCT0020433420	NCT00204334_20_T3	CELL	10	11	endothelial cells
NCT0020433421	NCT00204334_21_T0	PHENOTYPE	2	2	adhesion
NCT0020433422	NCT00204334_22_T0	PHENOTYPE	14	14	arteriosclerosis
NCT0020433422	NCT00204334_22_T1	CELL	0	0	Monocyte
NCT0020433423	NCT00204334_23_T0	PHENOTYPE	7	7	immunosuppression
NCT0020433423	NCT00204334_23_T1	PHENOTYPE	5	5	dependence
NCT0020433423	NCT00204334_23_T2	CELL	2	2	monocyte
NCT0020433423	NCT00204334_23_T3	GENE	9	9	erythropoietin
NCT0020433427	NCT00204334_27_T0	ORGAN	8	8	transplant
NCT0020433427	NCT00204334_27_T1	ORGAN	14	14	transplant
NCT0020433427	NCT00204334_27_T2	PHENOTYPE	1	1	anemia
NCT0020433427	NCT00204334_27_T3	PHENOTYPE	26	26	anemia
NCT0020433427	NCT00204334_27_T4	GENE	24	24	erythropoietin
NCT0020433428	NCT00204334_28_T0	PHENOTYPE	14	14	anemia
NCT0020433437	NCT00204334_37_T0	PHENOTYPE	7	8	cardiovascular disease
NCT0020433439	NCT00204334_39_T0	GENE	1	1	20
NCT0020433441	NCT00204334_41_T0	ORGAN	15	15	transplant
NCT0020433441	NCT00204334_41_T1	GENE	4	5	calcineurin inhibitor
NCT0020433446	NCT00204334_46_T0	GENE	3	3	55
NCT0020433446	NCT00204334_46_T1	ORGAN	0	0	Kidney
NCT0020433446	NCT00204334_46_T2	GENE	1	1	Int
NCT0020433448	NCT00204334_48_T0	COMPOUND	11	11	fluvastatin
NCT0020433448	NCT00204334_48_T1	ORGAN	19	19	arteries
NCT0020433448	NCT00204334_48_T2	ORGAN	23	23	transplant
NCT0020433448	NCT00204334_48_T3	COMPOUND	7	7	3_hydroxy_3_methylglutaryl
NCT0020433449	NCT00204334_49_T0	ORGAN	2	2	Kidney
NCT0020433449	NCT00204334_49_T1	PHENOTYPE	3	3	Dis
NCT0020433451	NCT00204334_51_T0	GENE	4	4	Boo
NCT0020433451	NCT00204334_51_T1	GENE	7	7	GP
NCT0020433451	NCT00204334_51_T2	GENE	11	11	SM
NCT0020433451	NCT00204334_51_T3	GENE	15	15	DP
NCT0020433452	NCT00204334_52_T0	GENE	9	9	p47phox
NCT0020433452	NCT00204334_52_T1	CELL	14	14	monocyte
NCT0020433452	NCT00204334_52_T2	PHENOTYPE	15	15	adhesion
NCT0020433457	NCT00204334_57_T0	PHENOTYPE	4	4	atherogenesis
NCT0020433457	NCT00204334_57_T1	CELL	2	2	monocytes
NCT0020433460	NCT00204334_60_T0	GENE	1	1	FH
NCT0020433460	NCT00204334_60_T1	GENE	11	11	SM
NCT0020433462	NCT00204334_62_T0	ORGAN	0	0	Kidney
NCT0020433462	NCT00204334_62_T1	GENE	1	1	Int
NCT002043471	NCT00204347_1_T0	PHENOTYPE	1	1	secondary
NCT002043471	NCT00204347_1_T1	PHENOTYPE	15	15	symptoms
NCT002043471	NCT00204347_1_T2	PHENOTYPE	26	26	Borderline
NCT002043471	NCT00204347_1_T3	PHENOTYPE	23	23	BPD
NCT002043476	NCT00204347_6_T0	PHENOTYPE	30	30	BPD
NCT002043602	NCT00204360_2_T0	PHENOTYPE	51	51	epilepsy
NCT002043602	NCT00204360_2_T1	GENE	22	22	eg
NCT002043602	NCT00204360_2_T2	PHENOTYPE	18	18	seizure
NCT002043602	NCT00204360_2_T3	GENE	24	24	MRI
NCT002043602	NCT00204360_2_T4	GENE	26	26	MEG
NCT002043733	NCT00204373_3_T0	PHENOTYPE	10	10	symptoms
NCT002043733	NCT00204373_3_T1	PHENOTYPE	20	20	symptoms
NCT002043733	NCT00204373_3_T2	PHENOTYPE	23	23	complications
NCT002043733	NCT00204373_3_T3	PHENOTYPE	18	18	relapse
NCT002043733	NCT00204373_3_T4	PHENOTYPE	6	7	peptic ulcers
NCT002043862	NCT00204386_2_T0	PHENOTYPE	8	8	PTSD
NCT002043863	NCT00204386_3_T0	PHENOTYPE	9	9	PTSD
NCT002043863	NCT00204386_3_T1	GENE	2	2	al
NCT002043863	NCT00204386_3_T2	GENE	1	1	et
NCT002043864	NCT00204386_4_T0	PHENOTYPE	12	12	trauma
NCT002043865	NCT00204386_5_T0	PHENOTYPE	4	4	PTSD
NCT002043865	NCT00204386_5_T1	PHENOTYPE	15	15	accidents
NCT002043865	NCT00204386_5_T2	PHENOTYPE	23	23	accidents
NCT002043865	NCT00204386_5_T3	PHENOTYPE	12	13	sexual assault
NCT002043865	NCT00204386_5_T4	PHENOTYPE	20	21	serious injury
NCT002043866	NCT00204386_6_T0	PHENOTYPE	2	2	PTSD
NCT002043867	NCT00204386_7_T0	PHENOTYPE	3	3	PTSD
NCT002043868	NCT00204386_8_T0	PHENOTYPE	4	4	PTSD
NCT002043868	NCT00204386_8_T1	PHENOTYPE	12	13	mental health
NCT002043869	NCT00204386_9_T0	PHENOTYPE	2	2	PTSD
NCT002043869	NCT00204386_9_T1	PHENOTYPE	19	19	agoraphobia
NCT002043869	NCT00204386_9_T2	PHENOTYPE	15	16	drug abuse
NCT002043869	NCT00204386_9_T3	PHENOTYPE	21	22	personality disorders
NCT002043869	NCT00204386_9_T4	PHENOTYPE	17	18	panic disorder
NCT002043869	NCT00204386_9_T5	PHENOTYPE	9	10	psychiatric disorders
NCT0020438610	NCT00204386_10_T0	PHENOTYPE	22	23	mental health
NCT002043992	NCT00204399_2_T0	PHENOTYPE	19	19	CVD
NCT002043992	NCT00204399_2_T1	GENE	9	9	has
NCT002043997	NCT00204399_7_T0	GENE	29	29	extended
NCT002043997	NCT00204399_7_T1	GENE	33	33	has
NCT002043997	NCT00204399_7_T2	GENE	60	60	has
NCT0020439911	NCT00204399_11_T0	GENE	12	12	PACE
NCT002044250	NCT00204425_0_T0	PHENOTYPE	11	11	Osteoporosis
NCT002044254	NCT00204425_4_T0	COMPOUND	1	1	estrogen
NCT002044254	NCT00204425_4_T1	PHENOTYPE	6	6	menopausal
NCT002044256	NCT00204425_6_T0	COMPOUND	10	10	estrogen
NCT002044256	NCT00204425_6_T1	COMPOUND	20	20	isoflavone
NCT002044256	NCT00204425_6_T2	GENE	15	15	soy
NCT002044256	NCT00204425_6_T3	GENE	19	19	soy
NCT002044384	NCT00204438_4_T0	ORGAN	7	8	ovarian follicles
NCT002044385	NCT00204438_5_T0	GENE	14	14	has
NCT0020443812	NCT00204438_12_T0	COMPOUND	17	17	desogestrel
NCT0020443812	NCT00204438_12_T1	COMPOUND	20	20	estradiol
NCT0020443812	NCT00204438_12_T2	BIOLOGICAL_PROCESS	29	30	follicular phase
NCT0020443812	NCT00204438_12_T3	BIOLOGICAL_PROCESS	33	34	menstrual cycle
NCT0020443814	NCT00204438_14_T0	BIOLOGICAL_PROCESS	22	23	menstrual cycle
NCT002044513	NCT00204451_3_T0	COMPOUND	10	10	progesterone
NCT002044513	NCT00204451_3_T1	COMPOUND	15	15	levonorgestrel
NCT002044514	NCT00204451_4_T0	COMPOUND	17	17	levonorgestrel
NCT0020445111	NCT00204451_11_T0	GENE	0	0	Is
NCT0020445113	NCT00204451_13_T0	PHENOTYPE	1	3	positive pregnancy test
NCT0020445116	NCT00204451_16_T0	PHENOTYPE	0	2	Irregular menstrual cycles
NCT0020445118	NCT00204451_18_T0	BIOLOGICAL_PROCESS	5	5	lactation
NCT0020445119	NCT00204451_19_T0	PHENOTYPE	2	2	suspicion
NCT0020445119	NCT00204451_19_T1	PHENOTYPE	6	7	alcohol abuse
NCT002044644	NCT00204464_4_T0	PHENOTYPE	21	21	weakness
NCT002044644	NCT00204464_4_T1	PHENOTYPE	5	6	neuromuscular diseases
NCT002044647	NCT00204464_7_T0	COMPOUND	0	0	2
NCT002044647	NCT00204464_7_T1	GENE	24	24	SERS
NCT002044647	NCT00204464_7_T2	PHENOTYPE	10	12	Amyotrophic Lateral Sclerosis
NCT002044648	NCT00204464_8_T0	PHENOTYPE	4	4	fatigue
NCT002044648	NCT00204464_8_T1	COMPOUND	0	0	3
NCT002044648	NCT00204464_8_T2	PHENOTYPE	9	9	Fatigue
NCT002044648	NCT00204464_8_T3	PHENOTYPE	10	10	Severity
NCT0020446412	NCT00204464_12_T0	PHENOTYPE	19	19	contraction
NCT0020446412	NCT00204464_12_T1	PHENOTYPE	34	34	Fatigue
NCT0020446412	NCT00204464_12_T2	PHENOTYPE	35	35	Severity
NCT0020446412	NCT00204464_12_T3	PHENOTYPE	21	23	Amyotrophic Lateral Sclerosis
NCT0020446412	NCT00204464_12_T4	PHENOTYPE	38	40	forced vital capacity
NCT002044771	NCT00204477_1_T0	PHENOTYPE	7	8	breast cancer
NCT002044772	NCT00204477_2_T0	GENE	26	26	casein
NCT002044772	NCT00204477_2_T1	GENE	9	9	soy
NCT002044777	NCT00204477_7_T0	GENE	4	4	soy
NCT0020447710	NCT00204477_10_T0	TISSUE	22	23	bone tissues
NCT002044902	NCT00204490_2_T0	GENE	3	3	soy
NCT002044902	NCT00204490_2_T1	PHENOTYPE	7	8	breast cancer
NCT002044903	NCT00204490_3_T0	GENE	2	2	has
NCT002044903	NCT00204490_3_T1	PHENOTYPE	7	8	breast cancer
NCT002044904	NCT00204490_4_T0	COMPOUND	6	6	estrogen
NCT002044909	NCT00204490_9_T0	GENE	4	4	soy
NCT0020449011	NCT00204490_11_T0	PHENOTYPE	22	23	breast cancer
NCT0020449013	NCT00204490_13_T0	ORGAN	14	14	serum
NCT0020449013	NCT00204490_13_T1	PHENOTYPE	17	18	breast cancer
NCT0020449014	NCT00204490_14_T0	COMPOUND	7	7	isoflavone
NCT0020449014	NCT00204490_14_T1	ORGAN	21	21	serum
NCT0020449014	NCT00204490_14_T2	GENE	6	6	soy
NCT0020449014	NCT00204490_14_T3	PHENOTYPE	24	25	breast cancer
NCT002045033	NCT00204503_3_T0	PHENOTYPE	23	23	disorders
NCT002045033	NCT00204503_3_T1	PHENOTYPE	6	7	bipolar depression
NCT002045033	NCT00204503_3_T2	PHENOTYPE	21	22	substance abuse
NCT002045034	NCT00204503_4_T0	COMPOUND	11	11	sodium
NCT002045034	NCT00204503_4_T1	COMPOUND	19	19	sodium
NCT002045034	NCT00204503_4_T2	PHENOTYPE	16	17	bipolar depression
NCT002045034	NCT00204503_4_T3	PHENOTYPE	13	14	alcohol abuse
NCT002045034	NCT00204503_4_T4	PHENOTYPE	34	37	alcohol abuse or dependence
NCT002045162	NCT00204516_2_T0	GENE	13	13	GP100
NCT002045162	NCT00204516_2_T1	GENE	6	6	mRNA
NCT002045162	NCT00204516_2_T2	GENE	12	12	Survivin
NCT002045162	NCT00204516_2_T3	GENE	15	15	Tyrosinase
NCT002045163	NCT00204516_3_T0	PHENOTYPE	21	21	tumor
NCT002045163	NCT00204516_3_T1	PHENOTYPE	17	17	melanoma
NCT002045164	NCT00204516_4_T0	GENE	0	0	GM-CSF
NCT002045165	NCT00204516_5_T0	PHENOTYPE	13	13	melanoma
NCT002045291	NCT00204529_1_T0	PHENOTYPE	17	17	melanoma
NCT002045557	NCT00204555_7_T0	PHENOTYPE	8	8	BCC
NCT002045558	NCT00204555_8_T0	GENE	16	16	bcl-2
NCT002045558	NCT00204555_8_T1	COMPOUND	8	8	pyrimidine
NCT002045558	NCT00204555_8_T2	GENE	6	6	p53
NCT0020455510	NCT00204555_10_T0	GENE	14	14	TNF-alpha
NCT0020455510	NCT00204555_10_T1	GENE	8	8	interleukin-12
NCT0020455510	NCT00204555_10_T2	GENE	6	6	interferon-alpha
NCT0020455510	NCT00204555_10_T3	GENE	7	7	IFN-alpha
NCT0020455510	NCT00204555_10_T4	GENE	9	9	IL-12
NCT0020455510	NCT00204555_10_T5	COMPOUND	3	3	imiquimod
NCT0020455510	NCT00204555_10_T6	GENE	28	28	Th1
NCT0020455510	NCT00204555_10_T7	BIOLOGICAL_PROCESS	29	30	immune response
NCT0020455510	NCT00204555_10_T8	GENE	11	13	tumor necrosis factor-alpha
NCT0020455511	NCT00204555_11_T0	GENE	1	1	IFN-alpha
NCT0020455511	NCT00204555_11_T1	PHENOTYPE	12	12	BCC
NCT0020455511	NCT00204555_11_T2	GENE	2	2	has
NCT0020455512	NCT00204555_12_T0	PHENOTYPE	7	7	BCC
NCT0020455513	NCT00204555_13_T0	COMPOUND	8	8	imiquimod
NCT002045681	NCT00204568_1_T0	PHENOTYPE	11	11	toxicity
NCT002045811	NCT00204581_1_T0	PHENOTYPE	5	5	metastases
NCT002045812	NCT00204581_2_T0	PHENOTYPE	12	12	recurrences
NCT002045812	NCT00204581_2_T1	PHENOTYPE	5	5	metastases
NCT002045813	NCT00204581_3_T0	GENE	0	0	IL-2
NCT002045814	NCT00204581_4_T0	GENE	8	8	IL-2
NCT002045942	NCT00204594_2_T0	GENE	8	8	CD28
NCT002045942	NCT00204594_2_T1	PHENOTYPE	11	11	melanoma
NCT002046071	NCT00204607_1_T0	GENE	7	7	GP100
NCT002046071	NCT00204607_1_T1	GENE	6	6	Survivin
NCT002046071	NCT00204607_1_T2	GENE	9	9	Tyrosinase
NCT002046072	NCT00204607_2_T0	GENE	0	0	GM-CSF
NCT002046073	NCT00204607_3_T0	PHENOTYPE	13	13	melanoma
NCT002046461	NCT00204646_1_T0	GENE	4	4	STS
NCT002046461	NCT00204646_1_T1	PHENOTYPE	13	14	metastatic disease
NCT002046462	NCT00204646_2_T0	GENE	22	22	STS
NCT002046592	NCT00204659_2_T0	PHENOTYPE	19	19	DLBCL
NCT002046592	NCT00204659_2_T1	GENE	5	5	CHOP
NCT002046592	NCT00204659_2_T2	GENE	7	7	has
NCT002046592	NCT00204659_2_T3	GENE	18	18	nodal
NCT002046594	NCT00204659_4_T0	GENE	11	11	II
NCT002046721	NCT00204672_1_T0	PHENOTYPE	9	9	asthma
NCT002046721	NCT00204672_1_T1	PHENOTYPE	17	17	asthma
NCT002046723	NCT00204672_3_T0	GENE	10	10	max
NCT002046724	NCT00204672_4_T0	GENE	16	16	max
NCT002046724	NCT00204672_4_T1	GENE	4	4	pH
NCT002046725	NCT00204672_5_T0	PHENOTYPE	7	7	suppression
NCT002046726	NCT00204672_6_T0	GENE	16	16	pH
NCT0020467210	NCT00204672_10_T0	PHENOTYPE	6	6	asthmatics
NCT0020467210	NCT00204672_10_T1	PHENOTYPE	10	10	asthmatics
NCT0020467210	NCT00204672_10_T2	PHENOTYPE	26	27	gastroesophageal reflux
NCT0020467212	NCT00204672_12_T0	GENE	1	1	BID
NCT0020467214	NCT00204672_14_T0	GENE	3	3	BID
NCT0020467216	NCT00204672_16_T0	PHENOTYPE	7	8	respiratory symptom
NCT0020467217	NCT00204672_17_T0	PHENOTYPE	13	13	bronchospasm
NCT0020467217	NCT00204672_17_T1	GENE	24	24	pH
NCT0020467217	NCT00204672_17_T2	PHENOTYPE	11	11	reflux
NCT0020467221	NCT00204672_21_T0	PHENOTYPE	3	3	asthma
NCT0020467222	NCT00204672_22_T0	PHENOTYPE	11	11	recruitment
NCT0020467223	NCT00204672_23_T0	PHENOTYPE	1	1	recruitment
NCT0020467231	NCT00204672_31_T0	PHENOTYPE	1	1	asthma
NCT002046853	NCT00204685_3_T0	PHENOTYPE	9	9	concentrations
NCT002046853	NCT00204685_3_T1	GENE	22	22	reduced
NCT002046854	NCT00204685_4_T0	PHENOTYPE	11	11	ventilation
NCT002046854	NCT00204685_4_T1	PHENOTYPE	21	21	ventilation
NCT002046983	NCT00204698_3_T0	PHENOTYPE	8	9	laryngopharyngeal reflux
NCT002046985	NCT00204698_5_T0	GENE	10	10	LPR
NCT002046986	NCT00204698_6_T0	GENE	12	12	LPR
NCT002046987	NCT00204698_7_T0	GENE	21	21	pH
NCT002046987	NCT00204698_7_T1	GENE	14	14	LPR
NCT002046988	NCT00204698_8_T0	GENE	29	29	Blot
NCT002046988	NCT00204698_8_T1	GENE	17	17	PL
NCT002046989	NCT00204698_9_T0	ORGAN	19	19	larynx
NCT002046989	NCT00204698_9_T1	GENE	33	34	proton pump
NCT002046989	NCT00204698_9_T2	PHENOTYPE	23	24	laryngopharyngeal reflux
NCT0020469810	NCT00204698_10_T0	ORGAN	13	13	larynx
NCT0020469810	NCT00204698_10_T1	GENE	27	28	proton pump
NCT0020469810	NCT00204698_10_T2	PHENOTYPE	17	18	laryngopharyngeal reflux
NCT0020469813	NCT00204698_13_T0	PHENOTYPE	14	14	initiation
NCT002047112	NCT00204711_2_T0	GENE	1	1	SNAP
NCT002047112	NCT00204711_2_T1	PHENOTYPE	37	37	anesthesia
NCT002047112	NCT00204711_2_T2	GENE	14	14	has
NCT002047112	NCT00204711_2_T3	PHENOTYPE	11	12	brain activity
NCT002047112	NCT00204711_2_T4	PHENOTYPE	27	29	loss of consciousness
NCT002047501	NCT00204750_1_T0	PHENOTYPE	9	9	recurrence
NCT002047501	NCT00204750_1_T1	PHENOTYPE	11	11	severity
NCT002047501	NCT00204750_1_T2	PHENOTYPE	13	13	dysphagia
NCT002047501	NCT00204750_1_T3	COMPOUND	19	19	rabeprazole
NCT002047503	NCT00204750_3_T0	PHENOTYPE	19	19	dilation
NCT002047503	NCT00204750_3_T1	PHENOTYPE	2	3	Schatzki's Ring
NCT002047504	NCT00204750_4_T0	COMPOUND	5	5	rabeprazole
NCT002047505	NCT00204750_5_T0	PHENOTYPE	2	2	recurrence
NCT002047505	NCT00204750_5_T1	PHENOTYPE	4	4	severity
NCT002047505	NCT00204750_5_T2	PHENOTYPE	6	6	dysphagia
NCT002047632	NCT00204763_2_T0	PHENOTYPE	20	20	motility
NCT002047634	NCT00204763_4_T0	PHENOTYPE	16	16	motility
NCT002047635	NCT00204763_5_T0	PHENOTYPE	6	6	incontinence
NCT002047635	NCT00204763_5_T1	PHENOTYPE	12	12	motility
NCT002047638	NCT00204763_8_T0	PHENOTYPE	16	16	motility
NCT002047761	NCT00204776_1_T0	GENE	2	2	has
NCT002047761	NCT00204776_1_T1	PHENOTYPE	7	8	solid tumors
NCT002047762	NCT00204776_2_T0	PHENOTYPE	11	12	breast cancer
NCT002047891	NCT00204789_1_T0	COMPOUND	7	7	DFMO
NCT002047892	NCT00204789_2_T0	GENE	28	28	TPA
NCT002047892	NCT00204789_2_T1	GENE	31	31	ODC
NCT002047892	NCT00204789_2_T2	GENE	24	24	viability
NCT002047892	NCT00204789_2_T3	COMPOUND	7	7	DFMO
NCT002047892	NCT00204789_2_T4	ORGAN	22	23	organ transplant
NCT002047892	NCT00204789_2_T5	GENE	29	30	ornithine decarboxylase
NCT002048151	NCT00204815_1_T0	COMPOUND	32	32	calcium
NCT002048671	NCT00204867_1_T0	PHENOTYPE	11	11	polyps
NCT002048800	NCT00204880_0_T0	GENE	4	4	ACE
NCT002048800	NCT00204880_0_T1	BIOLOGICAL_PROCESS	0	0	Aging
NCT002048933	NCT00204893_3_T0	COMPOUND	7	8	calcium formate
NCT002049064	NCT00204906_4_T0	PHENOTYPE	5	5	concentrations
NCT002049064	NCT00204906_4_T1	GENE	20	21	parathyroid hormone
NCT002049064	NCT00204906_4_T2	COMPOUND	3	4	vitamin D
NCT002049064	NCT00204906_4_T3	COMPOUND	18	19	vitamin D
NCT002049192	NCT00204919_2_T0	COMPOUND	12	13	vitamin D
NCT002049193	NCT00204919_3_T0	COMPOUND	11	12	vitamin D
NCT002049194	NCT00204919_4_T0	GENE	5	6	parathyroid hormone
NCT002049194	NCT00204919_4_T1	PHENOTYPE	7	8	serum calcium
NCT002049195	NCT00204919_5_T0	PHENOTYPE	1	3	quality of life
NCT002049196	NCT00204919_6_T0	GENE	3	3	paired
NCT002049321	NCT00204932_1_T0	TISSUE	7	8	body fat
NCT002049322	NCT00204932_2_T0	PHENOTYPE	1	2	weight loss
NCT002049322	NCT00204932_2_T1	PHENOTYPE	8	10	overweight and obesity
NCT002049323	NCT00204932_3_T0	PHENOTYPE	9	10	weight losses
NCT002049324	NCT00204932_4_T0	GENE	15	15	CLA
NCT002049324	NCT00204932_4_T1	GENE	30	30	CLA
NCT002049324	NCT00204932_4_T2	PHENOTYPE	42	43	weight loss
NCT002049324	NCT00204932_4_T3	TISSUE	22	23	body fat
NCT002049326	NCT00204932_6_T0	PHENOTYPE	5	6	energy expenditure
NCT002049327	NCT00204932_7_T0	COMPOUND	18	19	carbon dioxide
NCT002049328	NCT00204932_8_T0	GENE	12	12	3-2
NCT002049328	NCT00204932_8_T1	GENE	10	10	CLA
NCT002049328	NCT00204932_8_T2	GENE	28	28	gel
NCT002049329	NCT00204932_9_T0	GENE	6	6	mo
NCT002049451	NCT00204945_1_T0	ORGAN	14	14	heart
NCT002049454	NCT00204945_4_T0	ORGAN	2	3	pulmonary artery
NCT002049454	NCT00204945_4_T1	ORGAN	16	17	pulmonary artery
NCT002049455	NCT00204945_5_T0	PHENOTYPE	31	31	proximal
NCT002049455	NCT00204945_5_T1	ORGAN	32	32	aorta
NCT002049457	NCT00204945_7_T0	ORGAN	15	16	carotid arteries
NCT002049580	NCT00204958_0_T0	ORGAN	5	5	Transplant
NCT002049580	NCT00204958_0_T1	CELL	7	8	Stem Cell
NCT002049580	NCT00204958_0_T2	ORGAN	8	9	Cell Transplant
NCT002049580	NCT00204958_0_T3	ORGAN	3	4	Bone Marrow
NCT002049582	NCT00204958_2_T0	GENE	12	12	has
NCT002049582	NCT00204958_2_T1	ORGAN	17	17	intestines
NCT002049711	NCT00204971_1_T0	GENE	12	12	has
NCT002049711	NCT00204971_1_T1	ORGAN	17	17	intestines
NCT002049843	NCT00204984_3_T0	COMPOUND	14	14	hydralazine
NCT002049843	NCT00204984_3_T1	PHENOTYPE	18	19	aortic stiffness
NCT002049843	NCT00204984_3_T2	PHENOTYPE	33	34	aortic stiffness
NCT002049844	NCT00204984_4_T0	PHENOTYPE	6	6	reflected
NCT002049844	NCT00204984_4_T1	PHENOTYPE	7	7	pulse
NCT002049844	NCT00204984_4_T2	GENE	30	30	has
NCT002049844	NCT00204984_4_T3	PHENOTYPE	28	29	aortic stiffness
NCT002050362	NCT00205036_2_T0	PHENOTYPE	5	5	ingested
NCT002050362	NCT00205036_2_T1	COMPOUND	7	7	calcium
NCT002050362	NCT00205036_2_T2	ORGAN	11	11	spine
NCT002050362	NCT00205036_2_T3	COMPOUND	12	12	DXA
NCT002050362	NCT00205036_2_T4	PHENOTYPE	25	25	ingestion
NCT002050363	NCT00205036_3_T0	PHENOTYPE	16	16	ingested
NCT002050363	NCT00205036_3_T1	COMPOUND	18	18	calcium
NCT002050363	NCT00205036_3_T2	GENE	6	6	had
NCT002050363	NCT00205036_3_T3	ORGAN	8	8	spine
NCT002050363	NCT00205036_3_T4	PHENOTYPE	28	28	ingestion
NCT002050491	NCT00205049_1_T0	GENE	11	11	AAH
NCT002050491	NCT00205049_1_T1	COMPOUND	5	5	pentoxifylline
NCT002050493	NCT00205049_3_T0	GENE	11	11	AAH
NCT002050493	NCT00205049_3_T1	COMPOUND	5	5	pentoxifylline
NCT002050750	NCT00205075_0_T0	PHENOTYPE	10	10	Progression
NCT002050750	NCT00205075_0_T1	COMPOUND	9	9	HCV
NCT002050750	NCT00205075_0_T2	PHENOTYPE	6	7	Hepatitis C
NCT002050880	NCT00205088_0_T0	GENE	8	8	VP
NCT002050880	NCT00205088_0_T1	PHENOTYPE	9	10	Shunt Malfunction
NCT002051011	NCT00205101_1_T0	GENE	15	15	fusion
NCT002051011	NCT00205101_1_T1	GENE	20	20	fusion
NCT002051011	NCT00205101_1_T2	GENE	26	26	fusion
NCT002051011	NCT00205101_1_T3	GENE	27	27	PLIF
NCT002051011	NCT00205101_1_T4	ORGAN	4	4	allograft
NCT0020510119	NCT00205101_19_T0	GENE	8	8	fusion
NCT0020510119	NCT00205101_19_T1	GENE	6	6	PLIF
NCT0020510123	NCT00205101_23_T0	PHENOTYPE	0	1	Severe osteoporosis
NCT002051144	NCT00205114_4_T0	COMPOUND	0	0	2
NCT002051146	NCT00205114_6_T0	PHENOTYPE	22	22	falls
NCT002051149	NCT00205114_9_T0	PHENOTYPE	6	6	falls
NCT002051274	NCT00205127_4_T0	GENE	14	14	moe
NCT002051274	NCT00205127_4_T1	ORGAN	17	17	heart
NCT002051279	NCT00205127_9_T0	PHENOTYPE	4	4	bronchospasm
NCT002051279	NCT00205127_9_T1	COMPOUND	8	8	theophylline
NCT002051279	NCT00205127_9_T2	PHENOTYPE	6	6	asthma
NCT0020512711	NCT00205127_11_T0	PHENOTYPE	3	4	liver disease
NCT002051532	NCT00205153_2_T0	PHENOTYPE	35	35	hypertension
NCT002051532	NCT00205153_2_T1	GENE	10	10	BP
NCT002051536	NCT00205153_6_T0	GENE	7	7	BP
NCT002051660	NCT00205166_0_T0	PHENOTYPE	4	4	Sensitivity
NCT002051662	NCT00205166_2_T0	ORGAN	10	10	heart
NCT002051662	NCT00205166_2_T1	ORGAN	11	12	blood vessels
NCT002051662	NCT00205166_2_T2	PHENOTYPE	21	23	coronary artery disease
NCT002051663	NCT00205166_3_T0	COMPOUND	7	7	adenosine
NCT002051663	NCT00205166_3_T1	COMPOUND	5	5	caffeine
NCT002051663	NCT00205166_3_T2	COMPOUND	17	17	caffeine
NCT002051663	NCT00205166_3_T3	GENE	4	4	had
NCT002051663	NCT00205166_3_T4	PHENOTYPE	24	26	coronary artery disease
NCT002051664	NCT00205166_4_T0	COMPOUND	16	16	adenosine
NCT002051664	NCT00205166_4_T1	COMPOUND	6	6	caffeine
NCT002051664	NCT00205166_4_T2	PHENOTYPE	7	7	affects
NCT002051664	NCT00205166_4_T3	PHENOTYPE	12	14	coronary artery disease
NCT002051665	NCT00205166_5_T0	COMPOUND	10	10	adenosine
NCT002051665	NCT00205166_5_T1	COMPOUND	15	15	caffeine
NCT002051665	NCT00205166_5_T2	ORGAN	8	8	heart
NCT002051790	NCT00205179_0_T0	PHENOTYPE	0	1	Alzheimer's Disease
NCT002051793	NCT00205179_3_T0	COMPOUND	4	4	isoflavone
NCT002051793	NCT00205179_3_T1	PHENOTYPE	15	16	Alzheimer's disease
NCT002051793	NCT00205179_3_T2	PHENOTYPE	8	9	cognitive declines
NCT002051921	NCT00205192_1_T0	GENE	9	9	IV
NCT002051921	NCT00205192_1_T1	PHENOTYPE	11	12	heart failure
NCT002051921	NCT00205192_1_T2	PHENOTYPE	6	7	class III
NCT002051922	NCT00205192_2_T0	GENE	17	17	QRS
NCT002051926	NCT00205192_6_T0	GENE	9	9	had
NCT002052310	NCT00205231_0_T0	GENE	13	13	TNF
NCT002052310	NCT00205231_0_T1	PHENOTYPE	14	14	Inhibition
NCT002052310	NCT00205231_0_T2	PHENOTYPE	16	17	HIV Disease
NCT002052310	NCT00205231_0_T3	MOLECULAR_FUNCTION	10	12	Tumor Necrosis Factor
NCT002052441	NCT00205244_1_T0	GENE	7	7	CD
NCT002052443	NCT00205244_3_T0	PHENOTYPE	6	6	anesthesia
NCT002052443	NCT00205244_3_T1	PHENOTYPE	11	11	anesthesia
NCT002052445	NCT00205244_5_T0	PHENOTYPE	17	17	anesthesia
NCT002052571	NCT00205257_1_T0	PHENOTYPE	5	5	infiltrate
NCT002052571	NCT00205257_1_T1	ORGAN	7	7	kidney
NCT002052571	NCT00205257_1_T2	CELL	1	1	cells
NCT002052571	NCT00205257_1_T3	ORGAN	8	8	graft
NCT002052571	NCT00205257_1_T4	ORGAN	16	16	graft
NCT002052571	NCT00205257_1_T5	PHENOTYPE	14	14	damages
NCT002052572	NCT00205257_2_T0	PHENOTYPE	9	9	symptoms
NCT002052572	NCT00205257_2_T1	ORGAN	11	11	kidney
NCT002052572	NCT00205257_2_T2	PHENOTYPE	3	3	acute
NCT002052573	NCT00205257_3_T0	PHENOTYPE	2	2	symptoms
NCT002052573	NCT00205257_3_T1	PHENOTYPE	15	15	initiation
NCT002052573	NCT00205257_3_T2	PHENOTYPE	8	9	kidney damage
NCT002052574	NCT00205257_4_T0	ORGAN	0	0	Kidney
NCT002052576	NCT00205257_6_T0	CELL	7	7	cells
NCT002052577	NCT00205257_7_T0	ORGAN	15	15	kidney
NCT002052577	NCT00205257_7_T1	GENE	2	2	chemokine
NCT002052577	NCT00205257_7_T2	PHENOTYPE	11	12	immune status
NCT002052578	NCT00205257_8_T0	ORGAN	14	14	kidney
NCT002052578	NCT00205257_8_T1	GENE	6	6	chemokine
NCT002052578	NCT00205257_8_T2	PHENOTYPE	16	16	pathology
NCT002052578	NCT00205257_8_T3	ORGAN	31	31	graft
NCT002052701	NCT00205270_1_T0	PHENOTYPE	9	9	influenza
NCT002052701	NCT00205270_1_T1	ORGAN	18	18	transplant
NCT002052702	NCT00205270_2_T0	PHENOTYPE	15	16	antibody response
NCT002052704	NCT00205270_4_T0	PHENOTYPE	13	13	influenza
NCT002052705	NCT00205270_5_T0	PHENOTYPE	21	21	influenza
NCT002052705	NCT00205270_5_T1	CELL	7	7	cells
NCT002052707	NCT00205270_7_T0	ORGAN	5	5	transplant
NCT002052707	NCT00205270_7_T1	ORGAN	7	7	transplant
NCT002052708	NCT00205270_8_T0	PHENOTYPE	0	0	Influenza
NCT002052708	NCT00205270_8_T1	BIOLOGICAL_PROCESS	17	18	immune response
NCT002052708	NCT00205270_8_T2	PHENOTYPE	12	13	lung disease
NCT002053091	NCT00205309_1_T0	PHENOTYPE	12	12	trauma
NCT002053091	NCT00205309_1_T1	PHENOTYPE	0	0	Infections
NCT002053092	NCT00205309_2_T0	PHENOTYPE	8	8	infections
NCT002053092	NCT00205309_2_T1	PHENOTYPE	0	1	Nosocomial pneumonia
NCT002053221	NCT00205322_1_T0	PHENOTYPE	26	27	catheter complications
NCT002053358	NCT00205335_8_T0	PHENOTYPE	0	0	Diabetes
NCT002053359	NCT00205335_9_T0	PHENOTYPE	0	0	Diabetes
NCT0020533511	NCT00205335_11_T0	PHENOTYPE	3	3	complications
NCT0020533511	NCT00205335_11_T1	PHENOTYPE	5	5	blindness
NCT0020533511	NCT00205335_11_T2	ORGAN	7	7	heart
NCT0020533511	NCT00205335_11_T3	PHENOTYPE	9	10	kidney disease
NCT0020533515	NCT00205335_15_T0	GENE	9	9	reduced
NCT0020533522	NCT00205335_22_T0	PHENOTYPE	17	17	Diabetes
NCT0020533531	NCT00205335_31_T0	PHENOTYPE	1	1	Diabetes
NCT0020533543	NCT00205335_43_T0	GENE	12	12	4-8
NCT0020533550	NCT00205335_50_T0	PHENOTYPE	4	4	severity
NCT0020533551	NCT00205335_51_T0	PHENOTYPE	7	7	secondary
NCT0020533551	NCT00205335_51_T1	PHENOTYPE	8	8	cancers
NCT0020533551	NCT00205335_51_T2	PHENOTYPE	2	3	late effects
NCT0020533564	NCT00205335_64_T0	GENE	12	12	HSC
NCT0020533566	NCT00205335_66_T0	GENE	4	4	has
NCT0020533567	NCT00205335_67_T0	GENE	26	26	PI
NCT0020533567	NCT00205335_67_T1	GENE	4	4	had
NCT0020533567	NCT00205335_67_T2	GENE	3	3	has
NCT002053484	NCT00205348_4_T0	ORGAN	47	47	thyroid
NCT002053484	NCT00205348_4_T1	PHENOTYPE	2	3	multinodular goiter
NCT002053484	NCT00205348_4_T2	PHENOTYPE	30	31	multinodular goiter
NCT002053611	NCT00205361_1_T0	GENE	5	5	IgA
NCT002053611	NCT00205361_1_T1	PHENOTYPE	10	10	malnourished
NCT002053747	NCT00205374_7_T0	COMPOUND	9	9	cidofovir
NCT002053748	NCT00205374_8_T0	PHENOTYPE	21	21	tumor
NCT002053748	NCT00205374_8_T1	PHENOTYPE	30	30	papilloma
NCT002053748	NCT00205374_8_T2	PHENOTYPE	34	35	respiratory obstruction
NCT002053749	NCT00205374_9_T0	PHENOTYPE	24	24	recurrences
NCT002053749	NCT00205374_9_T1	COMPOUND	16	16	cidofovir
NCT002053749	NCT00205374_9_T2	GENE	19	19	has
NCT0020537411	NCT00205374_11_T0	PHENOTYPE	8	8	recurrences
NCT0020537411	NCT00205374_11_T1	GENE	7	7	RRP
NCT0020537411	NCT00205374_11_T2	COMPOUND	1	1	cidofovir
NCT0020537413	NCT00205374_13_T0	GENE	7	7	RRP
NCT0020537413	NCT00205374_13_T1	GENE	16	16	RRP
NCT0020537413	NCT00205374_13_T2	COMPOUND	1	1	cidofovir
NCT0020537413	NCT00205374_13_T3	GENE	19	19	al
NCT0020537413	NCT00205374_13_T4	GENE	18	18	et
NCT0020537415	NCT00205374_15_T0	COMPOUND	1	1	cidofovir
NCT002054001	NCT00205400_1_T0	PHENOTYPE	11	11	chronic
NCT002054001	NCT00205400_1_T1	COMPOUND	12	12	warfarin
NCT002054004	NCT00205400_4_T0	GENE	8	8	INR
NCT002054005	NCT00205400_5_T0	PHENOTYPE	2	2	bleeding
NCT002054005	NCT00205400_5_T1	PHENOTYPE	7	9	quality of life
NCT002054264	NCT00205426_4_T0	COMPOUND	0	0	Natrecor
NCT002054268	NCT00205426_8_T0	PHENOTYPE	3	4	reperfusion injury
NCT002054269	NCT00205426_9_T0	PHENOTYPE	4	5	blood supply
NCT0020542611	NCT00205426_11_T0	ORGAN	14	14	lungs
NCT0020542611	NCT00205426_11_T1	PHENOTYPE	24	25	blood supply
NCT0020542611	NCT00205426_11_T2	PHENOTYPE	7	8	pulmonary hypertension
NCT0020542611	NCT00205426_11_T3	PHENOTYPE	9	11	high blood pressure
NCT0020542615	NCT00205426_15_T0	PHENOTYPE	13	14	pulmonary hypertension
NCT0020542616	NCT00205426_16_T0	COMPOUND	3	3	Natrecor
NCT0020542616	NCT00205426_16_T1	ORGAN	13	13	transplant
NCT0020542616	NCT00205426_16_T2	GENE	4	4	has
NCT0020542616	NCT00205426_16_T3	ORGAN	12	12	heart
NCT0020542617	NCT00205426_17_T0	ORGAN	8	8	transplant
NCT002054521	NCT00205452_1_T0	PHENOTYPE	7	7	hyperparathyroidism
NCT002054521	NCT00205452_1_T1	PHENOTYPE	19	21	quality of life
NCT002054522	NCT00205452_2_T0	PHENOTYPE	0	2	Quality of life
NCT002054524	NCT00205452_4_T0	ORGAN	15	15	thyroid
NCT002054525	NCT00205452_5_T0	PHENOTYPE	17	19	quality of life
NCT002054650	NCT00205465_0_T0	PHENOTYPE	5	5	Psoriasis
NCT002054913	NCT00205491_3_T0	COMPOUND	9	9	venlafaxine
NCT002054913	NCT00205491_3_T1	BIOLOGICAL_PROCESS	13	14	norepinephrine reuptake
NCT002055049	NCT00205504_9_T0	PHENOTYPE	14	15	cardiovascular disease
NCT0020550422	NCT00205504_22_T0	COMPOUND	4	4	glucose
NCT0020550422	NCT00205504_22_T1	PHENOTYPE	0	1	Diabetes mellitus
NCT0020550422	NCT00205504_22_T2	PHENOTYPE	9	10	glucose tolerance
NCT0020550424	NCT00205504_24_T0	PHENOTYPE	2	2	thromboembolism
NCT0020550424	NCT00205504_24_T1	PHENOTYPE	10	10	coagulopathy
NCT0020550424	NCT00205504_24_T2	PHENOTYPE	7	8	vascular disease
NCT0020550424	NCT00205504_24_T3	PHENOTYPE	3	4	myocardial infarction
NCT0020550424	NCT00205504_24_T4	PHENOTYPE	5	6	cerebrovascular accident
NCT0020550425	NCT00205504_25_T0	PHENOTYPE	16	16	hypertension
NCT0020550427	NCT00205504_27_T0	COMPOUND	12	12	flutamide
NCT0020550427	NCT00205504_27_T1	COMPOUND	2	2	metformin
NCT0020550427	NCT00205504_27_T2	COMPOUND	11	11	spironolactone
NCT0020550428	NCT00205504_28_T0	PHENOTYPE	7	7	alcoholism
NCT0020550428	NCT00205504_28_T1	PHENOTYPE	4	5	drug abuse
NCT0020550429	NCT00205504_29_T0	PHENOTYPE	0	0	Ingestion
NCT0020550430	NCT00205504_30_T0	BIOLOGICAL_PROCESS	2	2	lactation
NCT002055173	NCT00205517_3_T0	PHENOTYPE	0	1	Critically ill
NCT002055174	NCT00205517_4_T0	PHENOTYPE	11	11	complications
NCT002055174	NCT00205517_4_T1	PHENOTYPE	5	5	strategies
NCT002055175	NCT00205517_5_T0	PHENOTYPE	20	20	complications
NCT002055175	NCT00205517_5_T1	PHENOTYPE	10	10	practices
NCT002055175	NCT00205517_5_T2	PHENOTYPE	16	17	respiratory failure
NCT002055176	NCT00205517_6_T0	PHENOTYPE	26	26	complications
NCT002055176	NCT00205517_6_T1	PHENOTYPE	10	10	strategies
NCT002055176	NCT00205517_6_T2	PHENOTYPE	32	32	pharmacokinetics
NCT002055177	NCT00205517_7_T0	PHENOTYPE	20	20	strategies
NCT002055177	NCT00205517_7_T1	PHENOTYPE	28	28	delirium
NCT002055177	NCT00205517_7_T2	PHENOTYPE	33	34	respiratory failure
NCT002055177	NCT00205517_7_T3	PHENOTYPE	7	8	critically ill
NCT002055178	NCT00205517_8_T0	PHENOTYPE	7	7	pharmacokinetics
NCT002055178	NCT00205517_8_T1	ORGAN	1	1	plasma
NCT002055430	NCT00205543_0_T0	ORGAN	8	8	Palate
NCT002055430	NCT00205543_0_T1	PHENOTYPE	11	13	Obstructive Sleep Apnea
NCT002055435	NCT00205543_5_T0	TISSUE	9	9	tonsils
NCT002055435	NCT00205543_5_T1	ORGAN	18	18	palate
NCT002055563	NCT00205556_3_T0	GENE	10	10	has
NCT002055565	NCT00205556_5_T0	COMPOUND	17	17	acetate
NCT002055565	NCT00205556_5_T1	GENE	7	7	ventricular
NCT002055566	NCT00205556_6_T0	COMPOUND	24	24	EDTA
NCT002055568	NCT00205556_8_T0	GENE	6	6	has
NCT002055568	NCT00205556_8_T1	PHENOTYPE	14	15	endothelial dysfunction
NCT002055568	NCT00205556_8_T2	PHENOTYPE	11	12	oxidative stress
NCT002055569	NCT00205556_9_T0	PHENOTYPE	4	4	atherosclerosis
NCT002055569	NCT00205556_9_T1	GENE	30	30	reduced
NCT002055569	NCT00205556_9_T2	GENE	9	9	ventricular
NCT002055569	NCT00205556_9_T3	PHENOTYPE	3	3	dysfunction
NCT002055569	NCT00205556_9_T4	GENE	17	17	CIMT
NCT002055569	NCT00205556_9_T5	PHENOTYPE	24	24	pulse
NCT002055569	NCT00205556_9_T6	PHENOTYPE	19	20	vascular stiffness
NCT0020555611	NCT00205556_11_T0	GENE	24	24	1/6
NCT0020555611	NCT00205556_11_T1	PHENOTYPE	9	9	chronic
NCT0020555613	NCT00205556_13_T0	GENE	4	4	CIMT
NCT0020555613	NCT00205556_13_T1	GENE	14	14	APR
NCT0020555613	NCT00205556_13_T2	PHENOTYPE	9	10	oxidative stress
NCT0020555613	NCT00205556_13_T3	PHENOTYPE	11	13	acute phase reaction
NCT0020555620	NCT00205556_20_T0	COMPOUND	20	20	homocysteine
NCT0020555620	NCT00205556_20_T1	PHENOTYPE	26	26	dysfunction
NCT0020555620	NCT00205556_20_T2	PHENOTYPE	22	23	oxidative stress
NCT0020555622	NCT00205556_22_T0	PHENOTYPE	21	21	progression
NCT0020555622	NCT00205556_22_T1	GENE	28	28	CIMT
NCT002055693	NCT00205569_3_T0	PHENOTYPE	4	4	reflects
NCT002055822	NCT00205582_2_T0	CELL	3	3	microglia
NCT002055823	NCT00205582_3_T0	PHENOTYPE	15	16	brain injury
NCT002055825	NCT00205582_5_T0	GENE	12	12	has
NCT002055825	NCT00205582_5_T1	PHENOTYPE	16	18	traumatic brain injury
NCT002055827	NCT00205582_7_T0	PHENOTYPE	10	10	suffered
NCT002055827	NCT00205582_7_T1	GENE	27	27	ICP
NCT002055827	NCT00205582_7_T2	GENE	19	19	has
NCT002055827	NCT00205582_7_T3	PHENOTYPE	12	13	head injury
NCT002055829	NCT00205582_9_T0	GENE	6	6	ICP
NCT0020558213	NCT00205582_13_T0	PHENOTYPE	8	8	peripheral
NCT0020558213	NCT00205582_13_T1	COMPOUND	10	10	benzodiazepine
NCT0020558216	NCT00205582_16_T0	PHENOTYPE	6	8	traumatic brain injury
NCT0020558218	NCT00205582_18_T0	GENE	7	7	ICP
NCT0020558225	NCT00205582_25_T0	GENE	0	0	Age
NCT0020558227	NCT00205582_27_T0	ORGAN	1	1	Skull
NCT0020558232	NCT00205582_32_T0	PHENOTYPE	1	3	exposure to radiation
NCT002055951	NCT00205595_1_T0	PHENOTYPE	7	7	inflammation
NCT002055951	NCT00205595_1_T1	PHENOTYPE	16	17	Alzheimer's disease
NCT002055951	NCT00205595_1_T2	PHENOTYPE	13	14	brain disorders
NCT002055951	NCT00205595_1_T3	PHENOTYPE	19	21	traumatic brain injury
NCT002055953	NCT00205595_3_T0	PHENOTYPE	10	10	peripheral
NCT002055953	NCT00205595_3_T1	CELL	18	18	cells
NCT002055953	NCT00205595_3_T2	CELL	22	22	macrophage
NCT002055953	NCT00205595_3_T3	GENE	26	26	al
NCT002055953	NCT00205595_3_T4	COMPOUND	11	11	benzodiazepine
NCT002055953	NCT00205595_3_T5	GENE	25	25	et
NCT002055955	NCT00205595_5_T0	CELL	5	5	cells
NCT002055955	NCT00205595_5_T1	GENE	23	23	al
NCT002055955	NCT00205595_5_T2	GENE	26	26	al
NCT002055955	NCT00205595_5_T3	PHENOTYPE	10	10	gliosis
NCT002055955	NCT00205595_5_T4	CELL	11	11	microglia
NCT002055955	NCT00205595_5_T5	GENE	22	22	et
NCT002055955	NCT00205595_5_T6	GENE	25	25	et
NCT002055956	NCT00205595_6_T0	PHENOTYPE	9	9	peripheral
NCT002055956	NCT00205595_6_T1	COMPOUND	3	3	carbon_11
NCT002055956	NCT00205595_6_T2	GENE	24	24	al
NCT002055956	NCT00205595_6_T3	GENE	30	30	al
NCT002055956	NCT00205595_6_T4	GENE	36	36	al
NCT002055956	NCT00205595_6_T5	GENE	44	44	al
NCT002055956	NCT00205595_6_T6	GENE	23	23	et
NCT002055956	NCT00205595_6_T7	GENE	29	29	et
NCT002055956	NCT00205595_6_T8	GENE	35	35	et
NCT002055956	NCT00205595_6_T9	GENE	43	43	et
NCT002055956	NCT00205595_6_T10	PHENOTYPE	27	27	encephalitis
NCT002055956	NCT00205595_6_T11	GENE	14	14	has
NCT002055956	NCT00205595_6_T12	COMPOUND	11	11	benzodiazepine
NCT002055956	NCT00205595_6_T13	ORGAN	39	40	facial nerve
NCT002055956	NCT00205595_6_T14	PHENOTYPE	32	33	multiple sclerosis
NCT002055957	NCT00205595_7_T0	GENE	7	7	has
NCT002056081	NCT00205608_1_T0	PHENOTYPE	12	12	schizophrenia
NCT002056081	NCT00205608_1_T1	CELL	9	9	microglia
NCT002056083	NCT00205608_3_T0	PHENOTYPE	0	0	Schizophrenia
NCT002056083	NCT00205608_3_T1	GENE	12	12	has
NCT002056083	NCT00205608_3_T2	ORGAN	9	10	gray matter
NCT002056083	NCT00205608_3_T3	PHENOTYPE	3	4	brain disease
NCT002056084	NCT00205608_4_T0	PHENOTYPE	1	1	pathophysiology
NCT002056084	NCT00205608_4_T1	GENE	7	7	has
NCT002056084	NCT00205608_4_T2	ORGAN	4	5	gray matter
NCT002056085	NCT00205608_5_T0	CELL	0	0	Microglia
NCT002056089	NCT00205608_9_T0	CELL	11	11	microglia
NCT002056089	NCT00205608_9_T1	PHENOTYPE	24	25	Alzheimer disease
NCT002056089	NCT00205608_9_T2	PHENOTYPE	21	22	cognitive impairment
NCT002056089	NCT00205608_9_T3	PHENOTYPE	17	19	traumatic brain damage
NCT0020560810	NCT00205608_10_T0	PHENOTYPE	17	17	schizophrenia
NCT0020560810	NCT00205608_10_T1	CELL	13	13	microglia
NCT0020560814	NCT00205608_14_T0	GENE	6	6	MRI
NCT002056214	NCT00205621_4_T0	GENE	15	15	AD
NCT002056214	NCT00205621_4_T1	PHENOTYPE	12	13	pathological process
NCT002056216	NCT00205621_6_T0	GENE	24	24	AD
NCT002056216	NCT00205621_6_T1	PHENOTYPE	15	15	concentrations
NCT002056216	NCT00205621_6_T2	GENE	17	17	extended
NCT002056217	NCT00205621_7_T0	GENE	17	17	AD
NCT002056219	NCT00205621_9_T0	GENE	21	21	AD
NCT0020562110	NCT00205621_10_T0	PHENOTYPE	10	10	resolved
NCT0020562111	NCT00205621_11_T0	GENE	28	28	AD
NCT0020562112	NCT00205621_12_T0	GENE	14	14	AD
NCT0020562120	NCT00205621_20_T0	COMPOUND	6	6	18F-FDG
NCT0020562121	NCT00205621_21_T0	GENE	2	2	MRI
NCT0020562121	NCT00205621_21_T1	GENE	8	8	CSF
NCT002056341	NCT00205634_1_T0	PHENOTYPE	10	11	respiratory infections
NCT002056342	NCT00205634_2_T0	PHENOTYPE	6	7	diffuse panbronchiolitis
NCT002056470	NCT00205647_0_T0	GENE	7	7	NAC
NCT002056470	NCT00205647_0_T1	PHENOTYPE	12	13	Chronic Bronchitis
NCT002056472	NCT00205647_2_T0	PHENOTYPE	2	4	quality of life
NCT002056473	NCT00205647_3_T0	PHENOTYPE	20	20	acute
NCT002056473	NCT00205647_3_T1	GENE	8	8	NAC
NCT002056473	NCT00205647_3_T2	PHENOTYPE	10	10	affects
NCT002056473	NCT00205647_3_T3	PHENOTYPE	14	15	chronic bronchitis
NCT002056600	NCT00205660_0_T0	PHENOTYPE	2	2	Adiposity
NCT002056602	NCT00205660_2_T0	PHENOTYPE	13	13	adiposity
NCT002056602	NCT00205660_2_T1	COMPOUND	40	40	risperidone
NCT002056602	NCT00205660_2_T2	COMPOUND	42	42	quetiapine
NCT002056602	NCT00205660_2_T3	COMPOUND	39	39	olanzapine
NCT002056602	NCT00205660_2_T4	PHENOTYPE	14	14	inflammation
NCT002056602	NCT00205660_2_T5	COMPOUND	5	5	aripiprazole
NCT002056602	NCT00205660_2_T6	ORGAN	31	31	plasma
NCT002056602	NCT00205660_2_T7	PHENOTYPE	36	36	chronic
NCT002056602	NCT00205660_2_T8	BIOLOGICAL_PROCESS	27	28	lipid metabolism
NCT002056602	NCT00205660_2_T9	GENE	18	19	C-reactive protein
NCT002056602	NCT00205660_2_T10	PHENOTYPE	24	25	insulin sensitivity
NCT002056602	NCT00205660_2_T11	BIOLOGICAL_PROCESS	21	22	glucose metabolism
NCT002056609	NCT00205660_9_T0	COMPOUND	20	20	glucose
NCT0020566012	NCT00205660_12_T0	PHENOTYPE	7	7	adiposity
NCT0020566012	NCT00205660_12_T1	PHENOTYPE	25	25	adiposity
NCT0020566012	NCT00205660_12_T2	PHENOTYPE	29	30	weight gain
NCT0020566013	NCT00205660_13_T0	COMPOUND	42	42	risperidone
NCT0020566013	NCT00205660_13_T1	COMPOUND	41	41	quetiapine
NCT0020566013	NCT00205660_13_T2	COMPOUND	44	44	ziprasidone
NCT0020566013	NCT00205660_13_T3	COMPOUND	40	40	olanzapine
NCT0020566013	NCT00205660_13_T4	COMPOUND	34	34	aripiprazole
NCT0020566013	NCT00205660_13_T5	PHENOTYPE	37	37	chronic
NCT0020566013	NCT00205660_13_T6	PHENOTYPE	28	29	metabolic effects
NCT0020566013	NCT00205660_13_T7	PHENOTYPE	17	18	glucose tolerance
NCT0020566014	NCT00205660_14_T0	PHENOTYPE	13	13	adiposity
NCT0020566014	NCT00205660_14_T1	COMPOUND	40	40	risperidone
NCT0020566014	NCT00205660_14_T2	COMPOUND	42	42	quetiapine
NCT0020566014	NCT00205660_14_T3	COMPOUND	39	39	olanzapine
NCT0020566014	NCT00205660_14_T4	PHENOTYPE	14	14	inflammation
NCT0020566014	NCT00205660_14_T5	COMPOUND	5	5	aripiprazole
NCT0020566014	NCT00205660_14_T6	ORGAN	31	31	plasma
NCT0020566014	NCT00205660_14_T7	PHENOTYPE	36	36	chronic
NCT0020566014	NCT00205660_14_T8	BIOLOGICAL_PROCESS	27	28	lipid metabolism
NCT0020566014	NCT00205660_14_T9	GENE	18	19	C-reactive protein
NCT0020566014	NCT00205660_14_T10	PHENOTYPE	24	25	insulin sensitivity
NCT0020566014	NCT00205660_14_T11	BIOLOGICAL_PROCESS	21	22	glucose metabolism
NCT0020566015	NCT00205660_15_T0	COMPOUND	1	1	1
NCT0020566015	NCT00205660_15_T1	COMPOUND	11	11	aripiprazole
NCT0020566016	NCT00205660_16_T0	COMPOUND	27	27	olanzapine
NCT0020566016	NCT00205660_16_T1	COMPOUND	6	6	aripiprazole
NCT0020566016	NCT00205660_16_T2	PHENOTYPE	24	24	chronic
NCT0020566016	NCT00205660_16_T3	PHENOTYPE	19	20	insulin sensitivity
NCT0020566016	NCT00205660_16_T4	BIOLOGICAL_PROCESS	16	17	glucose metabolism
NCT0020566018	NCT00205660_18_T0	COMPOUND	3	3	aripiprazole
NCT0020566018	NCT00205660_18_T1	COMPOUND	17	17	ziprasidone
NCT0020566019	NCT00205660_19_T0	PHENOTYPE	7	8	insulin sensitivity
NCT0020566020	NCT00205660_20_T0	COMPOUND	1	1	2
NCT0020566020	NCT00205660_20_T1	GENE	14	14	fat-free
NCT0020566020	NCT00205660_20_T2	TISSUE	7	8	abdominal fat
NCT0020566020	NCT00205660_20_T3	TISSUE	10	11	body fat
NCT0020566021	NCT00205660_21_T0	COMPOUND	20	20	olanzapine
NCT0020566021	NCT00205660_21_T1	COMPOUND	6	6	aripiprazole
NCT0020566021	NCT00205660_21_T2	TISSUE	14	15	adipose tissue
NCT0020566023	NCT00205660_23_T0	COMPOUND	3	3	aripiprazole
NCT0020566023	NCT00205660_23_T1	COMPOUND	16	16	ziprasidone
NCT0020566024	NCT00205660_24_T0	GENE	28	28	fat-free
NCT0020566024	NCT00205660_24_T1	TISSUE	25	26	abdominal fat
NCT0020566024	NCT00205660_24_T2	TISSUE	23	24	body fat
NCT002056862	NCT00205686_2_T0	COMPOUND	0	0	DHEA
NCT002056863	NCT00205686_3_T0	COMPOUND	18	18	DHEA
NCT002056864	NCT00205686_4_T0	COMPOUND	4	4	DHEA
NCT002056865	NCT00205686_5_T0	COMPOUND	7	7	DHEA
NCT002056865	NCT00205686_5_T1	COMPOUND	11	11	DHEA
NCT002056866	NCT00205686_6_T0	COMPOUND	6	6	DHEA
NCT002056866	NCT00205686_6_T1	PHENOTYPE	9	9	adaptations
NCT002056868	NCT00205686_8_T0	COMPOUND	1	1	DHEA
NCT002056868	NCT00205686_8_T1	PHENOTYPE	11	11	osteopenia
NCT002056868	NCT00205686_8_T2	PHENOTYPE	9	9	sarcopenia
NCT002056869	NCT00205686_9_T0	COMPOUND	16	16	DHEA
NCT002056869	NCT00205686_9_T1	PHENOTYPE	11	11	secondary
NCT002056869	NCT00205686_9_T2	BIOLOGICAL_PROCESS	9	9	aging
NCT0020568610	NCT00205686_10_T0	COMPOUND	13	13	DHEA
NCT0020568610	NCT00205686_10_T1	BIOLOGICAL_PROCESS	24	24	metabolism
NCT0020568612	NCT00205686_12_T0	COMPOUND	4	4	DHEA
NCT002056992	NCT00205699_2_T0	COMPOUND	5	5	glucose
NCT002056992	NCT00205699_2_T1	GENE	24	24	MRI
NCT002056992	NCT00205699_2_T2	PHENOTYPE	31	32	adverse events
NCT002056993	NCT00205699_3_T0	PHENOTYPE	18	18	decisions
NCT002056995	NCT00205699_5_T0	COMPOUND	1	1	1
NCT002056995	NCT00205699_5_T1	COMPOUND	14	14	glucose
NCT002056995	NCT00205699_5_T2	COMPOUND	17	17	glucose
NCT002056995	NCT00205699_5_T3	GENE	10	10	insulin
NCT002056995	NCT00205699_5_T4	ORGAN	16	16	liver
NCT002056995	NCT00205699_5_T5	BIOLOGICAL_PROCESS	22	22	lipolysis
NCT002056995	NCT00205699_5_T6	TISSUE	20	21	adipose tissue
NCT002056996	NCT00205699_6_T0	COMPOUND	1	1	2
NCT002056996	NCT00205699_6_T1	GENE	18	18	fat-free
NCT002056996	NCT00205699_6_T2	TISSUE	10	11	abdominal fat
NCT002056996	NCT00205699_6_T3	TISSUE	14	15	body fat
NCT002057121	NCT00205712_1_T0	PHENOTYPE	21	21	symptoms
NCT002057121	NCT00205712_1_T1	COMPOUND	9	9	ketamine
NCT002057121	NCT00205712_1_T2	PHENOTYPE	17	17	dissociation
NCT002057121	NCT00205712_1_T3	PHENOTYPE	20	20	schizophrenia
NCT002057121	NCT00205712_1_T4	PHENOTYPE	15	16	cognitive function
NCT002057121	NCT00205712_1_T5	PHENOTYPE	6	7	adverse effect
NCT002057126	NCT00205712_6_T0	GENE	4	4	has
NCT002057128	NCT00205712_8_T0	COMPOUND	15	15	dexmedetomidine
NCT002057128	NCT00205712_8_T1	GENE	19	19	alpha-2
NCT002057128	NCT00205712_8_T2	COMPOUND	24	24	ketamine
NCT002057128	NCT00205712_8_T3	PHENOTYPE	25	26	mental symptoms
NCT002057128	NCT00205712_8_T4	PHENOTYPE	26	28	symptoms in children
NCT002057129	NCT00205712_9_T0	GENE	20	20	ANOVA
NCT0020571213	NCT00205712_13_T0	COMPOUND	33	33	dexmedetomidine
NCT0020571213	NCT00205712_13_T1	GENE	30	30	alpha-2
NCT0020571213	NCT00205712_13_T2	COMPOUND	16	16	ketamine
NCT0020571213	NCT00205712_13_T3	COMPOUND	52	52	ketamine
NCT0020571213	NCT00205712_13_T4	PHENOTYPE	55	56	forearm fracture
NCT0020571214	NCT00205712_14_T0	COMPOUND	12	12	dexmedetomidine
NCT0020571214	NCT00205712_14_T1	COMPOUND	15	15	ketamine
NCT0020571214	NCT00205712_14_T2	COMPOUND	27	27	ketamine
NCT0020571214	NCT00205712_14_T3	PHENOTYPE	18	19	cognitive symptoms
NCT0020571214	NCT00205712_14_T4	PHENOTYPE	30	31	forearm fracture
NCT0020571215	NCT00205712_15_T0	COMPOUND	12	12	dexmedetomidine
NCT0020571215	NCT00205712_15_T1	COMPOUND	24	24	dexmedetomidine
NCT0020571215	NCT00205712_15_T2	COMPOUND	27	27	ketamine
NCT0020571215	NCT00205712_15_T3	PHENOTYPE	30	31	cognitive changes
NCT0020571216	NCT00205712_16_T0	COMPOUND	13	13	dexmedetomidine
NCT0020571220	NCT00205712_20_T0	GENE	9	9	II
NCT0020571220	NCT00205712_20_T1	GENE	5	5	ASA
NCT0020571221	NCT00205712_21_T0	COMPOUND	7	7	ketamine
NCT0020571221	NCT00205712_21_T1	GENE	1	1	had
NCT0020571221	NCT00205712_21_T2	PHENOTYPE	4	4	fracture
NCT0020571227	NCT00205712_27_T0	ORGAN	3	5	central nervous system
NCT0020571228	NCT00205712_28_T0	PHENOTYPE	2	2	psychosis
NCT0020571229	NCT00205712_29_T0	COMPOUND	10	10	methylphenidate
NCT0020571229	NCT00205712_29_T1	PHENOTYPE	7	8	mental function
NCT0020571229	NCT00205712_29_T2	PHENOTYPE	17	19	drugs of abuse
NCT0020571229	NCT00205712_29_T3	PHENOTYPE	12	15	attention deficit hyperactivity disorder
NCT0020571230	NCT00205712_30_T0	GENE	7	7	alpha-2
NCT0020571230	NCT00205712_30_T1	COMPOUND	12	12	clonidine
NCT0020571230	NCT00205712_30_T2	PHENOTYPE	2	2	allergy
NCT0020571230	NCT00205712_30_T3	PHENOTYPE	4	5	adverse reaction
NCT0020571232	NCT00205712_32_T0	COMPOUND	11	11	ketamine
NCT002057254	NCT00205725_4_T0	COMPOUND	20	20	olanzapine
NCT002057254	NCT00205725_4_T1	COMPOUND	7	7	glucose
NCT002057254	NCT00205725_4_T2	COMPOUND	18	18	ziprasidone
NCT002057254	NCT00205725_4_T3	PHENOTYPE	24	24	schizophrenia
NCT0020572515	NCT00205725_15_T0	COMPOUND	3	3	glucose
NCT002057384	NCT00205738_4_T0	COMPOUND	20	20	olanzapine
NCT002057384	NCT00205738_4_T1	COMPOUND	7	7	glucose
NCT002057384	NCT00205738_4_T2	COMPOUND	18	18	risperidone
NCT002057384	NCT00205738_4_T3	PHENOTYPE	24	24	schizophrenia
NCT002057386	NCT00205738_6_T0	COMPOUND	3	3	glucose
NCT0020573817	NCT00205738_17_T0	COMPOUND	3	3	glucose
NCT0020573819	NCT00205738_19_T0	PHENOTYPE	5	5	schizophrenia
NCT0020573819	NCT00205738_19_T1	PHENOTYPE	9	10	schizoaffective disorder
NCT0020573823	NCT00205738_23_T0	COMPOUND	3	3	olanzapine
NCT0020573823	NCT00205738_23_T1	COMPOUND	5	5	haloperidol
NCT0020573823	NCT00205738_23_T2	COMPOUND	4	4	risperidone
NCT0020573825	NCT00205738_25_T0	GENE	6	6	met
NCT0020573825	NCT00205738_25_T1	PHENOTYPE	3	4	psychiatric disorder
NCT0020573825	NCT00205738_25_T2	PHENOTYPE	9	11	substance use disorders
NCT0020573826	NCT00205738_26_T0	PHENOTYPE	10	10	dependence
NCT0020573826	NCT00205738_26_T1	PHENOTYPE	7	8	substance abuse
NCT002057643	NCT00205764_3_T0	GENE	14	14	PR
NCT002057643	NCT00205764_3_T1	GENE	13	13	CR
NCT002057644	NCT00205764_4_T0	PHENOTYPE	7	7	relapse
NCT002057644	NCT00205764_4_T1	PHENOTYPE	9	9	progression
NCT002057900	NCT00205790_0_T0	ORGAN	3	3	Graft
NCT0020580312	NCT00205803_12_T0	PHENOTYPE	6	6	seizure
NCT0020580312	NCT00205803_12_T1	PHENOTYPE	21	21	hydrocephalus
NCT0020580312	NCT00205803_12_T2	PHENOTYPE	20	20	encephalopathy
NCT0020580312	NCT00205803_12_T3	PHENOTYPE	15	15	disorders
NCT0020580312	NCT00205803_12_T4	PHENOTYPE	25	25	disorders
NCT0020580312	NCT00205803_12_T5	PHENOTYPE	18	19	cerebral palsy
NCT0020580312	NCT00205803_12_T6	PHENOTYPE	8	9	febrile seizure
NCT0020580312	NCT00205803_12_T7	PHENOTYPE	1	2	neurological disorder
NCT0020580313	NCT00205803_13_T0	PHENOTYPE	4	4	syndromes
NCT0020580313	NCT00205803_13_T1	PHENOTYPE	7	8	birth trauma
NCT0020580313	NCT00205803_13_T2	PHENOTYPE	11	12	Erb palsy
NCT0020580314	NCT00205803_14_T0	PHENOTYPE	0	1	Bleeding diathesis
NCT0020580314	NCT00205803_14_T1	PHENOTYPE	6	8	prolonged bleeding time
NCT0020580315	NCT00205803_15_T0	PHENOTYPE	8	8	pneumoniae
NCT0020580316	NCT00205803_16_T0	PHENOTYPE	1	2	anaphylactic reaction
NCT0020580317	NCT00205803_17_T0	PHENOTYPE	2	3	congenital malformation
NCT0020580317	NCT00205803_17_T1	PHENOTYPE	6	7	chronic disorders
NCT002058160	NCT00205816_0_T0	PHENOTYPE	7	7	Resistant
NCT002058162	NCT00205816_2_T0	PHENOTYPE	1	1	secondary
NCT002058162	NCT00205816_2_T1	COMPOUND	11	11	tigecycline
NCT002058162	NCT00205816_2_T2	PHENOTYPE	20	20	infections
NCT002058162	NCT00205816_2_T3	GENE	24	24	has
NCT002058292	NCT00205829_2_T0	PHENOTYPE	9	10	adverse event
NCT0020582910	NCT00205829_10_T0	PHENOTYPE	5	5	acute
NCT0020582912	NCT00205829_12_T0	GENE	4	4	toxin
NCT0020582912	NCT00205829_12_T1	PHENOTYPE	10	10	headache
NCT0020582914	NCT00205829_14_T0	GENE	1	1	had
NCT0020582915	NCT00205829_15_T0	PHENOTYPE	1	2	Arnold-Chiari malformation
NCT0020582918	NCT00205829_18_T0	ORGAN	7	8	spinal cord
NCT0020582919	NCT00205829_19_T0	PHENOTYPE	6	6	symptoms
NCT0020582919	NCT00205829_19_T1	PHENOTYPE	8	9	behavioral problems
NCT0020582919	NCT00205829_19_T2	PHENOTYPE	4	5	substance abuse
NCT002058422	NCT00205842_2_T0	COMPOUND	7	7	alvimopan
NCT002058422	NCT00205842_2_T1	GENE	26	26	GI
NCT002058422	NCT00205842_2_T2	GENE	35	35	bowel
NCT002058424	NCT00205842_4_T0	GENE	3	3	abdominal
NCT002058426	NCT00205842_6_T0	COMPOUND	7	7	alvimopan
NCT002058426	NCT00205842_6_T1	GENE	26	26	GI
NCT002058426	NCT00205842_6_T2	GENE	35	35	bowel
NCT002058553	NCT00205855_3_T0	GENE	2	2	has
NCT002058681	NCT00205868_1_T0	PHENOTYPE	17	17	pulse
NCT002058945	NCT00205894_5_T0	PHENOTYPE	5	5	illnesses
NCT002058945	NCT00205894_5_T1	GENE	19	19	has
NCT0020589411	NCT00205894_11_T0	PHENOTYPE	5	5	acute
NCT0020589413	NCT00205894_13_T0	GENE	4	4	toxin
NCT0020589413	NCT00205894_13_T1	PHENOTYPE	10	10	headache
NCT0020589415	NCT00205894_15_T0	GENE	1	1	had
NCT0020589416	NCT00205894_16_T0	PHENOTYPE	1	2	Arnold-Chiari malformation
NCT0020589419	NCT00205894_19_T0	ORGAN	7	8	spinal cord
NCT002059073	NCT00205907_3_T0	PHENOTYPE	13	13	inflammation
NCT002059073	NCT00205907_3_T1	GENE	22	22	extended
NCT002059075	NCT00205907_5_T0	PHENOTYPE	4	4	initiatives
NCT002059075	NCT00205907_5_T1	PHENOTYPE	13	14	lung diseases
NCT002059077	NCT00205907_7_T0	PHENOTYPE	9	9	emphysema
NCT002059078	NCT00205907_8_T0	GENE	1	1	has
NCT0020590711	NCT00205907_11_T0	PHENOTYPE	16	16	emphysema
NCT002059203	NCT00205920_3_T0	PHENOTYPE	13	13	inflammation
NCT002059203	NCT00205920_3_T1	GENE	22	22	extended
NCT002059205	NCT00205920_5_T0	PHENOTYPE	4	4	initiatives
NCT002059205	NCT00205920_5_T1	PHENOTYPE	13	14	lung diseases
NCT002059207	NCT00205920_7_T0	PHENOTYPE	9	9	emphysema
NCT002059208	NCT00205920_8_T0	GENE	1	1	has
NCT0020592011	NCT00205920_11_T0	GENE	11	11	BLVR
NCT0020592011	NCT00205920_11_T1	PHENOTYPE	17	17	emphysema
NCT002059332	NCT00205933_2_T0	PHENOTYPE	0	0	Anhedonia
NCT002059333	NCT00205933_3_T0	PHENOTYPE	19	21	Major Depressive Disorder
NCT002059335	NCT00205933_5_T0	GENE	9	9	II
NCT002059335	NCT00205933_5_T1	GENE	24	24	detached
NCT002059335	NCT00205933_5_T2	PHENOTYPE	27	28	social phobia
NCT002059335	NCT00205933_5_T3	GENE	20	21	dopamine receptor
NCT002059462	NCT00205946_2_T0	PHENOTYPE	4	4	reward
NCT002059462	NCT00205946_2_T1	PHENOTYPE	15	15	reward
NCT002059463	NCT00205946_3_T0	PHENOTYPE	15	15	reward
NCT002059463	NCT00205946_3_T1	GENE	9	9	has
NCT002059464	NCT00205946_4_T0	PHENOTYPE	28	28	reward
NCT002060240	NCT00206024_0_T0	PHENOTYPE	1	1	Heartburn
NCT002060240	NCT00206024_0_T1	PHENOTYPE	2	2	Symptoms
NCT002060242	NCT00206024_2_T0	COMPOUND	5	5	esomeprazole
NCT002060242	NCT00206024_2_T1	COMPOUND	6	6	magnesium
NCT002060242	NCT00206024_2_T2	GENE	13	13	BID
NCT002060502	NCT00206050_2_T0	PHENOTYPE	3	3	menopausal
NCT002060764	NCT00206076_4_T0	COMPOUND	22	22	cyclosporine
NCT002060764	NCT00206076_4_T1	COMPOUND	24	24	tacrolimus
NCT002060767	NCT00206076_7_T0	GENE	24	24	reduced
NCT002060767	NCT00206076_7_T1	GENE	28	28	CNI
NCT002060767	NCT00206076_7_T2	GENE	26	27	calcineurin inhibitor
NCT002060767	NCT00206076_7_T3	COMPOUND	17	18	mycophenolate mofetil
NCT002060768	NCT00206076_8_T0	COMPOUND	17	17	cyclosporine
NCT002060768	NCT00206076_8_T1	ORGAN	22	22	liver
NCT002060768	NCT00206076_8_T2	COMPOUND	19	19	tacrolimus
NCT002060768	NCT00206076_8_T3	GENE	15	15	reduced
NCT002060768	NCT00206076_8_T4	GENE	32	33	calcineurin inhibitor
NCT002060768	NCT00206076_8_T5	COMPOUND	9	10	mycophenolate mofetil
NCT002060769	NCT00206076_9_T0	ORGAN	1	1	liver
NCT002060769	NCT00206076_9_T1	PHENOTYPE	14	15	liver failure
NCT0020607611	NCT00206076_11_T0	GENE	12	12	CNI
NCT0020607611	NCT00206076_11_T1	GENE	26	26	CNI
NCT0020607611	NCT00206076_11_T2	GENE	23	24	calcineurin inhibitor
NCT0020607611	NCT00206076_11_T3	COMPOUND	8	9	mycophenolate mofetil
NCT0020607611	NCT00206076_11_T4	COMPOUND	15	16	mycophenolate mofetil
NCT0020607613	NCT00206076_13_T0	PHENOTYPE	3	3	concentrations
NCT0020607613	NCT00206076_13_T1	COMPOUND	1	2	mycophenolic acid
NCT0020607613	NCT00206076_13_T2	COMPOUND	8	9	mycophenolate mofetil
NCT002061021	NCT00206102_1_T0	GENE	10	10	IV
NCT002061151	NCT00206115_1_T0	GENE	3	3	SR
NCT002061152	NCT00206115_2_T0	GENE	1	1	SR
NCT002061281	NCT00206128_1_T0	GENE	3	3	SR
NCT002061282	NCT00206128_2_T0	GENE	1	1	SR
NCT002061800	NCT00206180_0_T0	PHENOTYPE	8	9	Erosive Esophagitis
NCT002062063	NCT00206206_3_T0	GENE	3	3	has
NCT002062064	NCT00206206_4_T0	PHENOTYPE	9	9	reluctance
NCT002062064	NCT00206206_4_T1	GENE	19	19	insulin
NCT002062066	NCT00206206_6_T0	GENE	1	1	MMH
NCT002062067	NCT00206206_7_T0	PHENOTYPE	3	3	hyperglycemia
NCT002062069	NCT00206206_9_T0	COMPOUND	27	27	glucose
NCT002062069	NCT00206206_9_T1	GENE	35	35	insulin
NCT002062069	NCT00206206_9_T2	PHENOTYPE	45	45	complications
NCT002062069	NCT00206206_9_T3	GENE	50	50	MMH
NCT002062069	NCT00206206_9_T4	PHENOTYPE	32	32	practices
NCT002062069	NCT00206206_9_T5	GENE	23	23	has
NCT002062069	NCT00206206_9_T6	GENE	42	42	has
NCT002062323	NCT00206232_3_T0	PHENOTYPE	15	15	symptoms
NCT002062323	NCT00206232_3_T1	PHENOTYPE	23	24	heart failure
NCT002062324	NCT00206232_4_T0	COMPOUND	22	22	creatinine
NCT002062324	NCT00206232_4_T1	COMPOUND	2	2	spironolactone
NCT002062324	NCT00206232_4_T2	COMPOUND	19	19	urea
NCT002062324	NCT00206232_4_T3	PHENOTYPE	13	14	adverse events
NCT002062450	NCT00206245_0_T0	PHENOTYPE	10	10	GERD
NCT002062450	NCT00206245_0_T1	GENE	3	3	IIb
NCT002062450	NCT00206245_0_T2	PHENOTYPE	13	14	Erosive Esophagitis
NCT002062453	NCT00206245_3_T0	PHENOTYPE	1	1	secondary
NCT002062453	NCT00206245_3_T1	COMPOUND	15	15	esomeprazole
NCT002062581	NCT00206258_1_T0	PHENOTYPE	17	19	high blood sugar
NCT002062585	NCT00206258_5_T0	GENE	14	14	hemoglobin
NCT002062586	NCT00206258_6_T0	GENE	5	5	fold
NCT002062586	NCT00206258_6_T1	PHENOTYPE	1	1	hypoglycemia
NCT002062587	NCT00206258_7_T0	PHENOTYPE	8	10	blood sugar level
NCT0020625810	NCT00206258_10_T0	ORGAN	16	16	liver
NCT0020625810	NCT00206258_10_T1	GENE	0	0	Amylin
NCT0020625810	NCT00206258_10_T2	GENE	10	10	glucagon
NCT0020625811	NCT00206258_11_T0	PHENOTYPE	15	15	hyperglycemia
NCT0020625811	NCT00206258_11_T1	GENE	7	7	insulin
NCT0020625811	NCT00206258_11_T2	PHENOTYPE	12	12	suppression
NCT0020625811	NCT00206258_11_T3	GENE	11	11	glucagon
NCT0020625812	NCT00206258_12_T0	GENE	1	1	glucagon
NCT0020625813	NCT00206258_13_T0	COMPOUND	21	21	glucose
NCT0020625813	NCT00206258_13_T1	COMPOUND	24	24	glucose
NCT0020625813	NCT00206258_13_T2	PHENOTYPE	13	13	hypoglycemia
NCT0020625813	NCT00206258_13_T3	GENE	1	1	glucagon
NCT0020625815	NCT00206258_15_T0	PHENOTYPE	7	7	hypoglycemia
NCT0020625815	NCT00206258_15_T1	ORGAN	14	14	heart
NCT0020625816	NCT00206258_16_T0	PHENOTYPE	1	1	hypoglycemia
NCT0020625816	NCT00206258_16_T1	GENE	12	12	glucagon
NCT0020625816	NCT00206258_16_T2	PHENOTYPE	2	2	unconsciousness
NCT0020625817	NCT00206258_17_T0	PHENOTYPE	10	10	hypoglycemia
NCT0020625819	NCT00206258_19_T0	PHENOTYPE	17	17	hyperglycemia
NCT0020625819	NCT00206258_19_T1	PHENOTYPE	24	26	hypoglycemia in children
NCT0020625819	NCT00206258_19_T2	PHENOTYPE	18	20	high blood glucose
NCT0020625820	NCT00206258_20_T0	PHENOTYPE	16	16	hyperglycemia
NCT0020625820	NCT00206258_20_T1	PHENOTYPE	24	24	hypoglycemia
NCT0020625820	NCT00206258_20_T2	GENE	11	11	glucagon
NCT0020625822	NCT00206258_22_T0	PHENOTYPE	23	23	complications
NCT0020625822	NCT00206258_22_T1	PHENOTYPE	15	15	hypoglycemia
NCT0020625827	NCT00206258_27_T0	GENE	4	4	insulin
NCT0020625827	NCT00206258_27_T1	GENE	8	8	insulin
NCT0020625829	NCT00206258_29_T0	PHENOTYPE	12	12	hypothyroidism
NCT0020625831	NCT00206258_31_T0	PHENOTYPE	4	6	negative pregnancy test
NCT0020625840	NCT00206258_40_T0	PHENOTYPE	0	2	Positive pregnancy test
NCT0020625841	NCT00206258_41_T0	PHENOTYPE	4	5	chemical abuse
NCT0020625842	NCT00206258_42_T0	PHENOTYPE	0	0	Hgb
NCT0020625842	NCT00206258_42_T1	GENE	2	2	8.0
NCT0020625844	NCT00206258_44_T0	PHENOTYPE	0	0	Allergy
NCT002062713	NCT00206271_3_T0	PHENOTYPE	9	10	stiff neck
NCT002062840	NCT00206284_0_T0	PHENOTYPE	10	10	GERD
NCT002062840	NCT00206284_0_T1	GENE	3	3	IIb
NCT002062840	NCT00206284_0_T2	PHENOTYPE	13	14	Erosive Esophagitis
NCT002062843	NCT00206284_3_T0	PHENOTYPE	1	1	secondary
NCT002062843	NCT00206284_3_T1	COMPOUND	15	15	esomeprazole
NCT002062972	NCT00206297_2_T0	COMPOUND	21	21	glucose
NCT002062972	NCT00206297_2_T1	GENE	7	7	insulin
NCT002062972	NCT00206297_2_T2	GENE	17	17	hemoglobin
NCT002062973	NCT00206297_3_T0	GENE	8	8	fold
NCT002062973	NCT00206297_3_T1	PHENOTYPE	1	1	hypoglycemia
NCT002062974	NCT00206297_4_T0	PHENOTYPE	6	8	blood sugar level
NCT002062976	NCT00206297_6_T0	GENE	7	7	insulin
NCT002062976	NCT00206297_6_T1	PHENOTYPE	12	12	suppression
NCT002062976	NCT00206297_6_T2	GENE	11	11	glucagon
NCT002062976	NCT00206297_6_T3	GENE	14	14	glucagon
NCT002062977	NCT00206297_7_T0	PHENOTYPE	3	3	hyperglycemia
NCT002062977	NCT00206297_7_T1	PHENOTYPE	4	6	high blood sugar
NCT002062978	NCT00206297_8_T0	GENE	1	1	glucagon
NCT002062979	NCT00206297_9_T0	GENE	1	1	glucagon
NCT002062979	NCT00206297_9_T1	GENE	15	15	has
NCT0020629710	NCT00206297_10_T0	COMPOUND	8	8	glucose
NCT0020629710	NCT00206297_10_T1	COMPOUND	14	14	glucose
NCT0020629711	NCT00206297_11_T0	GENE	1	1	glucagon
NCT0020629712	NCT00206297_12_T0	GENE	12	12	has
NCT0020629714	NCT00206297_14_T0	GENE	1	1	hormone
NCT0020629715	NCT00206297_15_T0	CELL	17	17	cells
NCT0020629715	NCT00206297_15_T1	GENE	13	13	insulin
NCT0020629715	NCT00206297_15_T2	GENE	20	20	insulin
NCT0020629715	NCT00206297_15_T3	ORGAN	5	5	pancreas
NCT0020629715	NCT00206297_15_T4	GENE	0	0	Amylin
NCT0020629716	NCT00206297_16_T0	GENE	0	0	Amylin
NCT0020629716	NCT00206297_16_T1	GENE	4	4	glucagon
NCT0020629717	NCT00206297_17_T0	ORGAN	3	3	liver
NCT0020629719	NCT00206297_19_T0	GENE	3	3	has
NCT0020629722	NCT00206297_22_T0	GENE	11	11	insulin
NCT0020629724	NCT00206297_24_T0	BIOLOGICAL_PROCESS	13	13	digestion
NCT0020629727	NCT00206297_27_T0	PHENOTYPE	12	12	Center
NCT0020629727	NCT00206297_27_T1	PHENOTYPE	10	10	Diabetes
NCT0020629733	NCT00206297_33_T0	GENE	4	4	insulin
NCT0020629733	NCT00206297_33_T1	GENE	8	8	insulin
NCT0020629735	NCT00206297_35_T0	PHENOTYPE	11	11	hypothyroidism
NCT0020629737	NCT00206297_37_T0	PHENOTYPE	5	7	negative pregnancy test
NCT0020629744	NCT00206297_44_T0	PHENOTYPE	0	0	Anemia
NCT0020629744	NCT00206297_44_T1	GENE	1	1	hemoglobin
NCT0020629746	NCT00206297_46_T0	PHENOTYPE	0	2	Positive pregnancy test
NCT0020629747	NCT00206297_47_T0	PHENOTYPE	4	5	chemical abuse
NCT0020629748	NCT00206297_48_T0	PHENOTYPE	0	0	Hgb
NCT0020629748	NCT00206297_48_T1	GENE	7	7	8.5
NCT002063230	NCT00206323_0_T0	PHENOTYPE	3	4	Tourette Syndrome
NCT002063239	NCT00206323_9_T0	PHENOTYPE	30	30	pulse
NCT002063239	NCT00206323_9_T1	PHENOTYPE	20	21	Tourette Syndrome
NCT0020632310	NCT00206323_10_T0	GENE	7	7	2.3
NCT0020632311	NCT00206323_11_T0	PHENOTYPE	14	15	drug use
NCT0020632315	NCT00206323_15_T0	PHENOTYPE	14	14	severity
NCT0020632315	NCT00206323_15_T1	PHENOTYPE	17	17	symptoms
NCT0020632315	NCT00206323_15_T2	PHENOTYPE	26	26	symptoms
NCT0020632315	NCT00206323_15_T3	PHENOTYPE	19	20	Tourette Syndrome
NCT0020632315	NCT00206323_15_T4	PHENOTYPE	30	33	attention deficit hyperactivity disorder
NCT0020632318	NCT00206323_18_T0	PHENOTYPE	9	9	pulse
NCT0020632322	NCT00206323_22_T0	GENE	20	20	had
NCT0020632325	NCT00206323_25_T0	COMPOUND	4	4	topiramate
NCT0020632327	NCT00206323_27_T0	COMPOUND	22	22	topiramate
NCT0020632329	NCT00206323_29_T0	COMPOUND	12	12	topiramate
NCT0020632331	NCT00206323_31_T0	COMPOUND	19	19	topiramate
NCT0020632334	NCT00206323_34_T0	COMPOUND	10	10	topiramate
NCT0020632338	NCT00206323_38_T0	COMPOUND	17	17	3
NCT0020632339	NCT00206323_39_T0	GENE	4	4	70
NCT0020632340	NCT00206323_40_T0	PHENOTYPE	9	9	pulse
NCT0020632341	NCT00206323_41_T0	GENE	18	18	had
NCT0020632343	NCT00206323_43_T0	PHENOTYPE	19	19	severity
NCT0020632344	NCT00206323_44_T0	PHENOTYPE	23	23	symptoms
NCT0020632344	NCT00206323_44_T1	PHENOTYPE	18	18	severity
NCT0020632344	NCT00206323_44_T2	PHENOTYPE	21	22	Tourette Syndrome
NCT0020632347	NCT00206323_47_T0	ORGAN	19	19	liver
NCT0020632350	NCT00206323_50_T0	GENE	15	15	had
NCT0020632353	NCT00206323_53_T0	PHENOTYPE	10	10	pulse
NCT0020632354	NCT00206323_54_T0	PHENOTYPE	17	17	symptoms
NCT0020632354	NCT00206323_54_T1	PHENOTYPE	14	14	severity
NCT0020632354	NCT00206323_54_T2	PHENOTYPE	19	20	Tourette Syndrome
NCT0020632356	NCT00206323_56_T0	GENE	18	18	had
NCT002063360	NCT00206336_0_T0	GENE	17	17	te
NCT002063360	NCT00206336_0_T1	PHENOTYPE	18	18	Syndrome
NCT002063360	NCT00206336_0_T2	PHENOTYPE	15	16	Tourette Syndrome
NCT002063365	NCT00206336_5_T0	GENE	2	2	Period
NCT002063368	NCT00206336_8_T0	PHENOTYPE	38	38	severity
NCT002063368	NCT00206336_8_T1	GENE	3	3	had
NCT002063368	NCT00206336_8_T2	PHENOTYPE	41	41	symptoms
NCT002063368	NCT00206336_8_T3	PHENOTYPE	11	11	pulse
NCT002063368	NCT00206336_8_T4	PHENOTYPE	43	44	Tourette Syndrome
NCT0020633610	NCT00206336_10_T0	ORGAN	25	25	liver
NCT0020633611	NCT00206336_11_T0	PHENOTYPE	14	14	symptoms
NCT0020633611	NCT00206336_11_T1	PHENOTYPE	18	21	attention deficit hyperactivity disorder
NCT0020633612	NCT00206336_12_T0	PHENOTYPE	19	19	symptoms
NCT0020633612	NCT00206336_12_T1	PHENOTYPE	21	21	mania
NCT0020633612	NCT00206336_12_T2	PHENOTYPE	3	5	Bipolar II Disorder
NCT0020633613	NCT00206336_13_T0	PHENOTYPE	19	19	symptoms
NCT0020633613	NCT00206336_13_T1	PHENOTYPE	5	5	OCD
NCT0020633613	NCT00206336_13_T2	PHENOTYPE	3	4	obsessive-compulsive disorder
NCT0020633614	NCT00206336_14_T0	PHENOTYPE	13	13	severity
NCT0020633615	NCT00206336_15_T0	COMPOUND	24	24	topiramate
NCT0020633617	NCT00206336_17_T0	COMPOUND	10	10	topiramate
NCT0020633617	NCT00206336_17_T1	COMPOUND	19	19	topiramate
NCT0020633619	NCT00206336_19_T0	COMPOUND	6	6	topiramate
NCT0020633620	NCT00206336_20_T0	COMPOUND	20	20	2
NCT0020633622	NCT00206336_22_T0	PHENOTYPE	9	9	pulse
NCT0020633623	NCT00206336_23_T0	GENE	18	18	had
NCT0020633627	NCT00206336_27_T0	ORGAN	19	19	liver
NCT0020633629	NCT00206336_29_T0	GENE	15	15	had
NCT0020633629	NCT00206336_29_T1	COMPOUND	29	29	topiramate
NCT0020633630	NCT00206336_30_T0	PHENOTYPE	14	14	resistant
NCT0020633630	NCT00206336_30_T1	COMPOUND	1	1	topiramate
NCT0020633631	NCT00206336_31_T0	COMPOUND	20	20	topiramate
NCT0020633632	NCT00206336_32_T0	GENE	4	4	70
NCT0020633632	NCT00206336_32_T1	COMPOUND	13	13	topiramate
NCT0020633633	NCT00206336_33_T0	COMPOUND	22	22	topiramate
NCT002063495	NCT00206349_5_T0	PHENOTYPE	16	16	exhaustion
NCT002063498	NCT00206349_8_T0	COMPOUND	10	10	glucose
NCT002063625	NCT00206362_5_T0	PHENOTYPE	16	16	exhaustion
NCT002063628	NCT00206362_8_T0	COMPOUND	10	10	glucose
NCT002063753	NCT00206375_3_T0	PHENOTYPE	11	11	hypothyroidism
NCT0020637513	NCT00206375_13_T0	GENE	9	9	T4
NCT0020637513	NCT00206375_13_T1	GENE	19	19	1.0
NCT0020637513	NCT00206375_13_T2	PHENOTYPE	8	8	hypothyroidism
NCT0020637513	NCT00206375_13_T3	GENE	12	12	5.0
NCT0020637513	NCT00206375_13_T4	GENE	22	22	TSH
NCT0020637513	NCT00206375_13_T5	GENE	14	14	dl
NCT0020637521	NCT00206375_21_T0	PHENOTYPE	3	3	chronic
NCT0020637525	NCT00206375_25_T0	GENE	17	17	has
NCT0020637530	NCT00206375_30_T0	GENE	9	9	GH
NCT0020637530	NCT00206375_30_T1	PHENOTYPE	18	18	tumor
NCT0020637530	NCT00206375_30_T2	PHENOTYPE	22	22	neurofibromatosis
NCT0020637530	NCT00206375_30_T3	PHENOTYPE	25	25	neurofibromatosis
NCT0020637530	NCT00206375_30_T4	PHENOTYPE	33	34	sleep apnea
NCT0020637530	NCT00206375_30_T5	PHENOTYPE	19	21	impaired glucose tolerance
NCT0020637530	NCT00206375_30_T6	PHENOTYPE	27	31	hypertrophy of tonsils and adenoids
NCT002063880	NCT00206388_0_T0	PHENOTYPE	6	6	Neuroblastoma
NCT002063880	NCT00206388_0_T1	TISSUE	8	9	Cortical Bone
NCT002063884	NCT00206388_4_T0	COMPOUND	11	11	cyclophosphamide
NCT002063886	NCT00206388_6_T0	PHENOTYPE	4	5	urine levels
NCT002063887	NCT00206388_7_T0	PHENOTYPE	18	18	neuroblastoma
NCT002063887	NCT00206388_7_T1	COMPOUND	11	11	cyclophosphamide
NCT002063887	NCT00206388_7_T2	PHENOTYPE	15	15	recurrent
NCT0020638810	NCT00206388_10_T0	ORGAN	8	9	immune system
NCT0020638812	NCT00206388_12_T0	PHENOTYPE	6	6	toxicity
NCT0020638812	NCT00206388_12_T1	CELL	8	8	osteoclasts
NCT0020638812	NCT00206388_12_T2	BIOLOGICAL_PROCESS	12	13	bone resorption
NCT0020638814	NCT00206388_14_T0	PHENOTYPE	19	19	progression
NCT0020638814	NCT00206388_14_T1	GENE	16	16	had
NCT0020638814	NCT00206388_14_T2	COMPOUND	35	35	pamidronate
NCT0020638814	NCT00206388_14_T3	PHENOTYPE	11	11	malignancies
NCT0020638814	NCT00206388_14_T4	PHENOTYPE	8	8	recurrent
NCT0020638814	NCT00206388_14_T5	PHENOTYPE	21	22	bone metastases
NCT0020638815	NCT00206388_15_T0	PHENOTYPE	1	1	toxicity
NCT0020638815	NCT00206388_15_T1	PHENOTYPE	12	12	hypocalcemia
NCT0020638815	NCT00206388_15_T2	GENE	7	7	has
NCT0020638815	NCT00206388_15_T3	PHENOTYPE	16	16	nausea
NCT0020638816	NCT00206388_16_T0	PHENOTYPE	3	3	toxicity
NCT0020638817	NCT00206388_17_T0	PHENOTYPE	12	12	tumors
NCT0020638817	NCT00206388_17_T1	PHENOTYPE	11	11	neuroblastoma
NCT0020638817	NCT00206388_17_T2	COMPOUND	25	25	cyclophosphamide
NCT0020638817	NCT00206388_17_T3	PHENOTYPE	6	6	progression
NCT0020638817	NCT00206388_17_T4	COMPOUND	4	4	bisphosphonates
NCT0020638818	NCT00206388_18_T0	PHENOTYPE	27	27	neuroblastoma
NCT0020638818	NCT00206388_18_T1	COMPOUND	20	20	cyclophosphamide
NCT0020638818	NCT00206388_18_T2	PHENOTYPE	24	24	recurrent
NCT0020638831	NCT00206388_31_T0	COMPOUND	16	16	nitrosourea
NCT0020638843	NCT00206388_43_T0	GENE	0	0	ANC
NCT0020638844	NCT00206388_44_T0	CELL	13	13	platelet
NCT0020638844	NCT00206388_44_T1	PHENOTYPE	0	1	Platelet count
NCT0020638845	NCT00206388_45_T0	PHENOTYPE	11	11	neuroblastoma
NCT0020638845	NCT00206388_45_T1	GENE	5	5	met
NCT0020638845	NCT00206388_45_T2	ORGAN	14	15	bone marrow
NCT0020638847	NCT00206388_47_T0	GENE	12	12	OR
NCT0020638847	NCT00206388_47_T1	BIOLOGICAL_PROCESS	0	1	Glomerular Filtration
NCT0020638849	NCT00206388_49_T0	GENE	7	7	1.5
NCT0020638849	NCT00206388_49_T1	GENE	0	1	Total bilirubin
NCT002064011	NCT00206401_1_T0	GENE	7	7	insulin
NCT002064011	NCT00206401_1_T1	GENE	12	12	insulin
NCT002064011	NCT00206401_1_T2	PHENOTYPE	2	2	IIM
NCT002064012	NCT00206401_2_T0	COMPOUND	11	11	glucose
NCT002064013	NCT00206401_3_T0	COMPOUND	9	9	glucose
NCT002064013	NCT00206401_3_T1	PHENOTYPE	37	39	blood glucose levels
NCT002064015	NCT00206401_5_T0	GENE	11	11	insulin
NCT002064016	NCT00206401_6_T0	GENE	1	1	insulin
NCT002064016	NCT00206401_6_T1	GENE	16	16	insulin
NCT002064016	NCT00206401_6_T2	PHENOTYPE	19	21	low blood glucose
NCT002064017	NCT00206401_7_T0	GENE	2	2	insulin
NCT002064017	NCT00206401_7_T1	GENE	7	7	insulin
NCT002064017	NCT00206401_7_T2	GENE	19	19	insulin
NCT002064018	NCT00206401_8_T0	GENE	5	5	insulin
NCT002064018	NCT00206401_8_T1	GENE	10	10	has
NCT002064143	NCT00206414_3_T0	PHENOTYPE	7	8	local disease
NCT002064144	NCT00206414_4_T0	PHENOTYPE	26	26	localized
NCT002064144	NCT00206414_4_T1	GENE	2	2	has
NCT002064144	NCT00206414_4_T2	PHENOTYPE	18	19	breast cancer
NCT002064145	NCT00206414_5_T0	PHENOTYPE	23	24	breast cancer
NCT002064146	NCT00206414_6_T0	PHENOTYPE	11	12	breast cancer
NCT002064146	NCT00206414_6_T1	PHENOTYPE	39	40	breast cancer
NCT002064147	NCT00206414_7_T0	GENE	3	3	has
NCT002064147	NCT00206414_7_T1	GENE	20	20	has
NCT002064147	NCT00206414_7_T2	COMPOUND	14	14	tamoxifen
NCT002064147	NCT00206414_7_T3	PHENOTYPE	30	31	Breast Cancer
NCT002064148	NCT00206414_8_T0	PHENOTYPE	16	17	breast cancer
NCT0020641412	NCT00206414_12_T0	PHENOTYPE	2	2	tumor
NCT0020641412	NCT00206414_12_T1	PHENOTYPE	32	32	enables
NCT0020641416	NCT00206414_16_T0	PHENOTYPE	5	5	localized
NCT0020641416	NCT00206414_16_T1	PHENOTYPE	6	7	breast cancer
NCT0020641418	NCT00206414_18_T0	PHENOTYPE	2	2	tumor
NCT0020641419	NCT00206414_19_T0	GENE	16	16	had
NCT0020641419	NCT00206414_19_T1	PHENOTYPE	11	12	invasive cancer
NCT0020641427	NCT00206414_27_T0	GENE	14	14	cm
NCT0020641427	NCT00206414_27_T1	PHENOTYPE	10	11	primary tumor
NCT0020641427	NCT00206414_27_T2	PHENOTYPE	5	7	invasive breast cancer
NCT0020641429	NCT00206414_29_T0	PHENOTYPE	3	5	progesterone receptor positive
NCT0020641429	NCT00206414_29_T1	PHENOTYPE	0	4	Estrogen receptor and/or progesterone receptor
NCT0020641430	NCT00206414_30_T0	PHENOTYPE	13	14	breast cancer
NCT0020641434	NCT00206414_34_T0	COMPOUND	10	10	raloxifene
NCT0020641434	NCT00206414_34_T1	GENE	4	5	estrogen receptor
NCT0020641444	NCT00206414_44_T0	PHENOTYPE	3	5	bilateral breast cancer
NCT0020641445	NCT00206414_45_T0	PHENOTYPE	3	3	tumors
NCT0020641445	NCT00206414_45_T1	PHENOTYPE	2	2	diffuse
NCT0020641445	NCT00206414_45_T2	PHENOTYPE	11	13	inflammatory breast cancer
NCT0020641447	NCT00206414_47_T0	PHENOTYPE	2	3	brain metastasis
NCT0020641452	NCT00206414_52_T0	COMPOUND	5	5	rifampicin
NCT0020641452	NCT00206414_52_T1	COMPOUND	3	3	phenytoin
NCT0020641452	NCT00206414_52_T2	COMPOUND	4	4	carbamazepine
NCT0020641453	NCT00206414_53_T0	COMPOUND	5	5	progestins
NCT0020641456	NCT00206414_56_T0	PHENOTYPE	0	1	Platelet count
NCT0020641457	NCT00206414_57_T0	PHENOTYPE	9	9	anticoagulation
NCT0020641457	NCT00206414_57_T1	PHENOTYPE	6	7	bleeding diathesis
NCT0020641459	NCT00206414_59_T0	PHENOTYPE	10	10	chronic
NCT0020641459	NCT00206414_59_T1	PHENOTYPE	5	7	interstitial lung disease
NCT0020641460	NCT00206414_60_T0	PHENOTYPE	2	4	recurrent breast cancer
NCT0020641461	NCT00206414_61_T0	PHENOTYPE	5	6	breast cancers
NCT002064274	NCT00206427_4_T0	PHENOTYPE	20	20	metastases
NCT002064274	NCT00206427_4_T1	PHENOTYPE	16	16	progression
NCT002064274	NCT00206427_4_T2	GENE	0	0	HER1
NCT002064274	NCT00206427_4_T3	PHENOTYPE	8	9	solid tumors
NCT002064275	NCT00206427_5_T0	GENE	14	14	has
NCT002064275	NCT00206427_5_T1	GENE	3	3	HER2
NCT002064275	NCT00206427_5_T2	PHENOTYPE	12	13	breast cancer
NCT002064276	NCT00206427_6_T0	GENE	22	22	receptor
NCT002064276	NCT00206427_6_T1	COMPOUND	23	23	tyrosine
NCT002064277	NCT00206427_7_T0	GENE	24	24	receptor
NCT002064277	NCT00206427_7_T1	GENE	23	23	HER2
NCT002064279	NCT00206427_9_T0	GENE	10	10	III
NCT002064279	NCT00206427_9_T1	PHENOTYPE	22	24	metastatic breast cancer
NCT0020642710	NCT00206427_10_T0	PHENOTYPE	6	7	metastatic disease
NCT0020642711	NCT00206427_11_T0	GENE	22	22	7.2
NCT0020642711	NCT00206427_11_T1	GENE	24	24	4.5
NCT0020642715	NCT00206427_15_T0	PHENOTYPE	18	18	proliferative
NCT0020642715	NCT00206427_15_T1	PHENOTYPE	10	10	cancers
NCT0020642715	NCT00206427_15_T2	PHENOTYPE	2	2	inhibition
NCT0020642723	NCT00206427_23_T0	GENE	24	24	receptor
NCT0020642723	NCT00206427_23_T1	GENE	23	23	HER2
NCT0020642724	NCT00206427_24_T0	GENE	22	22	7.2
NCT0020642724	NCT00206427_24_T1	GENE	24	24	4.5
NCT0020642733	NCT00206427_33_T0	PHENOTYPE	20	20	metastases
NCT0020642733	NCT00206427_33_T1	PHENOTYPE	16	16	progression
NCT0020642733	NCT00206427_33_T2	GENE	0	0	HER1
NCT0020642733	NCT00206427_33_T3	PHENOTYPE	8	9	solid tumors
NCT0020642734	NCT00206427_34_T0	GENE	14	14	has
NCT0020642734	NCT00206427_34_T1	GENE	3	3	HER2
NCT0020642734	NCT00206427_34_T2	PHENOTYPE	12	13	breast cancer
NCT0020642735	NCT00206427_35_T0	GENE	22	22	receptor
NCT0020642735	NCT00206427_35_T1	COMPOUND	23	23	tyrosine
NCT0020642736	NCT00206427_36_T0	GENE	24	24	receptor
NCT0020642736	NCT00206427_36_T1	GENE	23	23	HER2
NCT0020642738	NCT00206427_38_T0	GENE	10	10	III
NCT0020642738	NCT00206427_38_T1	PHENOTYPE	22	24	metastatic breast cancer
NCT0020642739	NCT00206427_39_T0	PHENOTYPE	6	7	metastatic disease
NCT0020642740	NCT00206427_40_T0	GENE	22	22	7.2
NCT0020642740	NCT00206427_40_T1	GENE	24	24	4.5
NCT0020642741	NCT00206427_41_T0	PHENOTYPE	11	12	breast cancer
NCT0020642742	NCT00206427_42_T0	PHENOTYPE	25	26	breast cancer
NCT0020642742	NCT00206427_42_T1	PHENOTYPE	20	22	mechanism of action
NCT0020642743	NCT00206427_43_T0	GENE	26	26	II
NCT0020642743	NCT00206427_43_T1	GENE	9	9	HER2
NCT0020642743	NCT00206427_43_T2	PHENOTYPE	19	20	metastatic disease
NCT0020642743	NCT00206427_43_T3	PHENOTYPE	13	14	breast cancer
NCT0020642744	NCT00206427_44_T0	PHENOTYPE	4	4	tumor
NCT0020642744	NCT00206427_44_T1	PHENOTYPE	10	10	cm2
NCT0020642744	NCT00206427_44_T2	PHENOTYPE	13	13	cm2
NCT0020642744	NCT00206427_44_T3	PHENOTYPE	16	16	cm2
NCT0020642745	NCT00206427_45_T0	PHENOTYPE	7	7	tumor
NCT0020642745	NCT00206427_45_T1	PHENOTYPE	8	8	regression
NCT0020642746	NCT00206427_46_T0	PHENOTYPE	7	7	tumor
NCT0020642746	NCT00206427_46_T1	PHENOTYPE	1	1	regression
NCT0020642746	NCT00206427_46_T2	PHENOTYPE	22	23	primary tumors
NCT0020642749	NCT00206427_49_T0	PHENOTYPE	1	1	tumors
NCT0020642750	NCT00206427_50_T0	GENE	12	12	HER2
NCT0020642750	NCT00206427_50_T1	PHENOTYPE	14	15	breast cancers
NCT0020642754	NCT00206427_54_T0	GENE	8	8	HER2
NCT0020642755	NCT00206427_55_T0	COMPOUND	1	1	1
NCT0020642755	NCT00206427_55_T1	GENE	24	24	HER2
NCT0020642755	NCT00206427_55_T2	PHENOTYPE	26	27	breast cancer
NCT0020642763	NCT00206427_63_T0	PHENOTYPE	11	12	metastatic disease
NCT0020642763	NCT00206427_63_T1	PHENOTYPE	2	3	breast cancers
NCT0020642763	NCT00206427_63_T2	PHENOTYPE	6	7	breast cancers
NCT0020642768	NCT00206427_68_T0	ORGAN	1	1	serum
NCT0020642781	NCT00206427_81_T0	PHENOTYPE	2	3	chronic illness
NCT0020642783	NCT00206427_83_T0	PHENOTYPE	0	0	Cardiomyopathy
NCT0020642787	NCT00206427_87_T0	PHENOTYPE	3	3	hypertension
NCT0020642787	NCT00206427_87_T1	PHENOTYPE	12	13	arterial disease
NCT0020642787	NCT00206427_87_T2	PHENOTYPE	6	8	congestive heart failure
NCT0020642790	NCT00206427_90_T0	PHENOTYPE	2	3	ulcerative colitis
NCT002064400	NCT00206440_0_T0	PHENOTYPE	4	4	Nausea
NCT002064402	NCT00206440_2_T0	GENE	13	13	lessen
NCT002064402	NCT00206440_2_T1	PHENOTYPE	15	17	nausea and vomiting
NCT002064403	NCT00206440_3_T0	PHENOTYPE	5	5	sickness
NCT002064405	NCT00206440_5_T0	PHENOTYPE	16	17	breast cancer
NCT002064405	NCT00206440_5_T1	PHENOTYPE	0	1	Breast Cancer
NCT002064406	NCT00206440_6_T0	PHENOTYPE	6	6	malignancy
NCT002064406	NCT00206440_6_T1	PHENOTYPE	0	1	Breast cancer
NCT002064407	NCT00206440_7_T0	PHENOTYPE	31	31	recurrence
NCT002064407	NCT00206440_7_T1	PHENOTYPE	3	4	breast cancer
NCT002064409	NCT00206440_9_T0	PHENOTYPE	19	20	breast cancer
NCT002064409	NCT00206440_9_T1	PHENOTYPE	2	3	Breast Cancer
NCT0020644011	NCT00206440_11_T0	GENE	14	14	receptor
NCT0020644011	NCT00206440_11_T1	GENE	10	10	nodal
NCT0020644011	NCT00206440_11_T2	GENE	13	13	hormone
NCT0020644012	NCT00206440_12_T0	COMPOUND	11	11	doxorubicin
NCT0020644012	NCT00206440_12_T1	PHENOTYPE	8	9	breast cancer
NCT0020644017	NCT00206440_17_T0	PHENOTYPE	5	7	Nausea and vomiting
NCT0020644018	NCT00206440_18_T0	PHENOTYPE	14	14	retching
NCT0020644018	NCT00206440_18_T1	PHENOTYPE	12	12	vomiting
NCT0020644018	NCT00206440_18_T2	PHENOTYPE	11	11	nausea
NCT0020644019	NCT00206440_19_T0	PHENOTYPE	10	10	affects
NCT0020644019	NCT00206440_19_T1	GENE	1	1	has
NCT0020644019	NCT00206440_19_T2	PHENOTYPE	11	13	quality of life
NCT0020644019	NCT00206440_19_T3	PHENOTYPE	6	8	nausea and vomiting
NCT0020644020	NCT00206440_20_T0	PHENOTYPE	13	15	quality of life
NCT0020644020	NCT00206440_20_T1	PHENOTYPE	6	8	nausea and vomiting
NCT0020644022	NCT00206440_22_T0	PHENOTYPE	5	7	nausea and vomiting
NCT0020644024	NCT00206440_24_T0	COMPOUND	4	4	1
NCT0020644024	NCT00206440_24_T1	COMPOUND	9	9	2
NCT0020644024	NCT00206440_24_T2	COMPOUND	16	16	3
NCT0020644024	NCT00206440_24_T3	PHENOTYPE	32	32	hyperemesis
NCT0020644024	NCT00206440_24_T4	PHENOTYPE	21	21	chronic
NCT0020644025	NCT00206440_25_T0	PHENOTYPE	12	12	retching
NCT0020644025	NCT00206440_25_T1	PHENOTYPE	0	0	Emesis
NCT0020644025	NCT00206440_25_T2	PHENOTYPE	10	10	vomiting
NCT0020644025	NCT00206440_25_T3	PHENOTYPE	9	9	nausea
NCT0020644026	NCT00206440_26_T0	PHENOTYPE	0	0	Nausea
NCT0020644026	NCT00206440_26_T1	PHENOTYPE	26	26	vomiting
NCT0020644026	NCT00206440_26_T2	PHENOTYPE	32	33	feeling sick
NCT0020644027	NCT00206440_27_T0	PHENOTYPE	0	0	Nausea
NCT0020644028	NCT00206440_28_T0	PHENOTYPE	0	0	Vomiting
NCT0020644028	NCT00206440_28_T1	ORGAN	13	13	jejunum
NCT0020644028	NCT00206440_28_T2	ORGAN	11	11	duodenum
NCT0020644028	NCT00206440_28_T3	ORGAN	16	17	oral cavity
NCT0020644029	NCT00206440_29_T0	PHENOTYPE	5	6	throwing up
NCT0020644030	NCT00206440_30_T0	PHENOTYPE	0	0	Retching
NCT0020644030	NCT00206440_30_T1	PHENOTYPE	9	9	vomit
NCT0020644030	NCT00206440_30_T2	PHENOTYPE	3	4	dry heaves
NCT0020644031	NCT00206440_31_T0	COMPOUND	16	16	prochlorperazine
NCT0020644031	NCT00206440_31_T1	COMPOUND	15	15	metoclopramide
NCT0020644031	NCT00206440_31_T2	COMPOUND	13	13	dopamine
NCT0020644031	NCT00206440_31_T3	PHENOTYPE	7	9	nausea and vomiting
NCT0020644032	NCT00206440_32_T0	PHENOTYPE	5	5	Oncology
NCT0020644032	NCT00206440_32_T1	GENE	7	7	has
NCT0020644032	NCT00206440_32_T2	PHENOTYPE	17	19	nausea and vomiting
NCT0020644033	NCT00206440_33_T0	PHENOTYPE	6	6	acute
NCT0020644033	NCT00206440_33_T1	PHENOTYPE	7	7	emesis
NCT0020644033	NCT00206440_33_T2	GENE	14	15	serotonin receptor
NCT0020644034	NCT00206440_34_T0	GENE	1	1	receptor
NCT0020644034	NCT00206440_34_T1	COMPOUND	6	6	ondansetron
NCT0020644034	NCT00206440_34_T2	COMPOUND	9	9	dolasetron
NCT0020644034	NCT00206440_34_T3	COMPOUND	7	7	granisetron
NCT0020644037	NCT00206440_37_T0	COMPOUND	3	3	dexamethasone
NCT0020644037	NCT00206440_37_T1	GENE	13	13	1.2
NCT0020644037	NCT00206440_37_T2	COMPOUND	16	16	metoclopramide
NCT0020644037	NCT00206440_37_T3	GENE	7	7	2.3
NCT0020644037	NCT00206440_37_T4	GENE	26	26	3.4
NCT0020644039	NCT00206440_39_T0	COMPOUND	16	16	prochlorperazine
NCT0020644039	NCT00206440_39_T1	COMPOUND	15	15	metoclopramide
NCT0020644039	NCT00206440_39_T2	COMPOUND	13	13	dopamine
NCT0020644039	NCT00206440_39_T3	PHENOTYPE	7	9	nausea and vomiting
NCT0020644040	NCT00206440_40_T0	PHENOTYPE	5	5	Oncology
NCT0020644040	NCT00206440_40_T1	GENE	7	7	has
NCT0020644040	NCT00206440_40_T2	PHENOTYPE	17	19	nausea and vomiting
NCT0020644041	NCT00206440_41_T0	PHENOTYPE	6	6	acute
NCT0020644041	NCT00206440_41_T1	PHENOTYPE	7	7	emesis
NCT0020644041	NCT00206440_41_T2	GENE	14	15	serotonin receptor
NCT0020644042	NCT00206440_42_T0	GENE	1	1	receptor
NCT0020644042	NCT00206440_42_T1	COMPOUND	6	6	ondansetron
NCT0020644042	NCT00206440_42_T2	COMPOUND	9	9	dolasetron
NCT0020644042	NCT00206440_42_T3	COMPOUND	7	7	granisetron
NCT0020644045	NCT00206440_45_T0	COMPOUND	3	3	dexamethasone
NCT0020644045	NCT00206440_45_T1	GENE	13	13	1.2
NCT0020644045	NCT00206440_45_T2	COMPOUND	16	16	metoclopramide
NCT0020644045	NCT00206440_45_T3	GENE	7	7	2.3
NCT0020644045	NCT00206440_45_T4	GENE	26	26	3.4
NCT0020644047	NCT00206440_47_T0	PHENOTYPE	13	14	breast cancer
NCT0020644049	NCT00206440_49_T0	PHENOTYPE	3	3	Vomiting
NCT0020644049	NCT00206440_49_T1	PHENOTYPE	5	5	Retching
NCT0020644049	NCT00206440_49_T2	PHENOTYPE	2	2	Nausea
NCT0020644049	NCT00206440_49_T3	PHENOTYPE	14	16	nausea and vomiting
NCT0020644050	NCT00206440_50_T0	PHENOTYPE	10	10	severity
NCT0020644050	NCT00206440_50_T1	PHENOTYPE	17	17	severity
NCT0020644050	NCT00206440_50_T2	PHENOTYPE	12	12	nausea
NCT0020644050	NCT00206440_50_T3	COMPOUND	7	7	1
NCT0020644050	NCT00206440_50_T4	COMPOUND	13	13	2
NCT0020644050	NCT00206440_50_T5	COMPOUND	20	20	3
NCT0020644050	NCT00206440_50_T6	PHENOTYPE	36	37	adverse effects
NCT0020644050	NCT00206440_50_T7	PHENOTYPE	28	30	nausea and vomiting
NCT0020644050	NCT00206440_50_T8	PHENOTYPE	32	34	quality of life
NCT0020644051	NCT00206440_51_T0	PHENOTYPE	20	22	nausea and vomiting
NCT0020644052	NCT00206440_52_T0	PHENOTYPE	12	14	nausea and vomiting
NCT0020644053	NCT00206440_53_T0	GENE	20	20	GI
NCT0020644053	NCT00206440_53_T1	PHENOTYPE	2	2	pathophysiology
NCT0020644053	NCT00206440_53_T2	PHENOTYPE	10	10	understood
NCT0020644053	NCT00206440_53_T3	TISSUE	21	21	mucosa
NCT0020644053	NCT00206440_53_T4	PHENOTYPE	4	6	nausea and vomiting
NCT0020644055	NCT00206440_55_T0	GENE	16	16	2.3
NCT0020644057	NCT00206440_57_T0	GENE	10	10	GI
NCT0020644057	NCT00206440_57_T1	PHENOTYPE	3	3	damages
NCT0020644057	NCT00206440_57_T2	TISSUE	11	11	mucosa
NCT0020644057	NCT00206440_57_T3	CELL	17	19	gastric parietal cells
NCT0020644058	NCT00206440_58_T0	COMPOUND	12	12	cytosine
NCT0020644058	NCT00206440_58_T1	GENE	3	3	has
NCT0020644058	NCT00206440_58_T2	COMPOUND	13	13	arabinoside
NCT0020644064	NCT00206440_64_T0	PHENOTYPE	19	21	gastroesophageal reflux disease
NCT0020644064	NCT00206440_64_T1	PHENOTYPE	23	25	peptic ulcer disease
NCT0020644065	NCT00206440_65_T0	GENE	14	15	proton pump
NCT0020644066	NCT00206440_66_T0	COMPOUND	20	20	methotrexate
NCT0020644066	NCT00206440_66_T1	GENE	10	10	pts
NCT0020644066	NCT00206440_66_T2	GENE	15	15	pts
NCT0020644066	NCT00206440_66_T3	COMPOUND	19	19	cyclophosphamide
NCT0020644066	NCT00206440_66_T4	PHENOTYPE	12	13	colon cancer
NCT0020644066	NCT00206440_66_T5	PHENOTYPE	7	8	breast cancer
NCT0020644067	NCT00206440_67_T0	COMPOUND	7	7	omeprazole
NCT0020644067	NCT00206440_67_T1	COMPOUND	13	13	prostaglandin
NCT0020644067	NCT00206440_67_T2	COMPOUND	11	11	misoprostol
NCT0020644068	NCT00206440_68_T0	PHENOTYPE	9	9	initiation
NCT0020644068	NCT00206440_68_T1	ORGAN	33	33	duodenum
NCT0020644069	NCT00206440_69_T0	PHENOTYPE	10	10	erosions
NCT0020644069	NCT00206440_69_T1	COMPOUND	1	1	omeprazole
NCT0020644069	NCT00206440_69_T2	COMPOUND	15	15	misoprostol
NCT0020644069	NCT00206440_69_T3	GENE	3	3	had
NCT0020644071	NCT00206440_71_T0	PHENOTYPE	13	14	colon cancer
NCT0020644072	NCT00206440_72_T0	COMPOUND	10	10	ranitidine
NCT0020644072	NCT00206440_72_T1	GENE	16	16	blocker
NCT0020644072	NCT00206440_72_T2	COMPOUND	6	6	omeprazole
NCT0020644072	NCT00206440_72_T3	GENE	15	15	H2
NCT0020644074	NCT00206440_74_T0	COMPOUND	13	13	ranitidine
NCT0020644074	NCT00206440_74_T1	COMPOUND	1	1	omeprazole
NCT0020644074	NCT00206440_74_T2	PHENOTYPE	8	8	ulcers
NCT0020644077	NCT00206440_77_T0	COMPOUND	11	11	omeprazole
NCT0020644077	NCT00206440_77_T1	GENE	8	9	proton pump
NCT0020644078	NCT00206440_78_T0	PHENOTYPE	15	15	symptoms
NCT0020644078	NCT00206440_78_T1	GENE	14	14	GI
NCT0020644078	NCT00206440_78_T2	TISSUE	2	2	mucosa
NCT0020644079	NCT00206440_79_T0	PHENOTYPE	7	7	vomiting
NCT0020644079	NCT00206440_79_T1	PHENOTYPE	5	5	nausea
NCT0020644080	NCT00206440_80_T0	COMPOUND	1	1	magnesium
NCT0020644080	NCT00206440_80_T1	GENE	9	9	has
NCT0020644080	NCT00206440_80_T2	GENE	5	6	proton pump
NCT0020644081	NCT00206440_81_T0	COMPOUND	11	11	omeprazole
NCT0020644081	NCT00206440_81_T1	COMPOUND	25	25	omeprazole
NCT0020644081	NCT00206440_81_T2	GENE	15	15	has
NCT0020644082	NCT00206440_82_T0	PHENOTYPE	19	19	acidity
NCT0020644082	NCT00206440_82_T1	GENE	2	3	proton pump
NCT0020644084	NCT00206440_84_T0	PHENOTYPE	9	10	erosive esophagitis
NCT0020644084	NCT00206440_84_T1	PHENOTYPE	13	15	gastroesophageal reflux disease
NCT0020644085	NCT00206440_85_T0	COMPOUND	19	19	amoxicillin
NCT0020644085	NCT00206440_85_T1	COMPOUND	23	23	amoxicillin
NCT0020644085	NCT00206440_85_T2	COMPOUND	21	21	clarithromycin
NCT0020644085	NCT00206440_85_T3	PHENOTYPE	7	8	Helicobacter pylori
NCT0020644085	NCT00206440_85_T4	PHENOTYPE	12	14	duodenal ulcer disease
NCT002064531	NCT00206453_1_T0	PHENOTYPE	16	17	breast cancer
NCT002064532	NCT00206453_2_T0	PHENOTYPE	15	16	breast cancer
NCT002064533	NCT00206453_3_T0	PHENOTYPE	3	4	breast cancer
NCT002064534	NCT00206453_4_T0	COMPOUND	17	17	cyclophosphamide
NCT002064534	NCT00206453_4_T1	COMPOUND	19	19	doxorubicin
NCT002064535	NCT00206453_5_T0	PHENOTYPE	14	15	breast cancer
NCT002064537	NCT00206453_7_T0	PHENOTYPE	23	24	breast cancer
NCT0020645310	NCT00206453_10_T0	PHENOTYPE	16	16	cancers
NCT0020645310	NCT00206453_10_T1	PHENOTYPE	7	8	breast cancer
NCT0020645311	NCT00206453_11_T0	PHENOTYPE	13	13	tumors
NCT0020645312	NCT00206453_12_T0	PHENOTYPE	16	17	breast cancer
NCT0020645315	NCT00206453_15_T0	PHENOTYPE	15	15	recurrence
NCT0020645315	NCT00206453_15_T1	PHENOTYPE	27	28	breast cancer
NCT0020645316	NCT00206453_16_T0	COMPOUND	12	12	paclitaxel
NCT0020645316	NCT00206453_16_T1	COMPOUND	14	14	docetaxel
NCT0020645317	NCT00206453_17_T0	PHENOTYPE	4	6	mechanism of action
NCT0020645319	NCT00206453_19_T0	PHENOTYPE	25	25	toxicity
NCT0020645320	NCT00206453_20_T0	GENE	7	7	II
NCT0020645320	NCT00206453_20_T1	COMPOUND	12	12	docetaxel
NCT0020645320	NCT00206453_20_T2	COMPOUND	36	36	docetaxel
NCT0020645320	NCT00206453_20_T3	PHENOTYPE	19	20	breast cancer
NCT0020645321	NCT00206453_21_T0	PHENOTYPE	1	1	secondary
NCT0020645321	NCT00206453_21_T1	BIOLOGICAL_PROCESS	10	11	gene expression
NCT0020645321	NCT00206453_21_T2	BIOLOGICAL_PROCESS	15	17	response to docetaxel
NCT0020645322	NCT00206453_22_T0	GENE	18	18	blot
NCT0020645322	NCT00206453_22_T1	BIOLOGICAL_PROCESS	27	28	gene expression
NCT0020645323	NCT00206453_23_T0	GENE	5	5	II
NCT0020645323	NCT00206453_23_T1	COMPOUND	15	15	docetaxel
NCT0020645323	NCT00206453_23_T2	PHENOTYPE	38	39	breast cancer
NCT0020645323	NCT00206453_23_T3	BIOLOGICAL_PROCESS	19	20	gene expression
NCT0020645324	NCT00206453_24_T0	PHENOTYPE	25	26	breast cancers
NCT0020645325	NCT00206453_25_T0	BIOLOGICAL_PROCESS	11	12	gene expression
NCT0020645327	NCT00206453_27_T0	ORGAN	6	6	kidney
NCT0020645327	NCT00206453_27_T1	ORGAN	9	9	liver
NCT0020645330	NCT00206453_30_T0	COMPOUND	11	11	docetaxel
NCT0020645333	NCT00206453_33_T0	COMPOUND	6	6	cyclophosphamide
NCT0020645333	NCT00206453_33_T1	COMPOUND	2	2	doxorubicin
NCT0020645335	NCT00206453_35_T0	PHENOTYPE	2	2	tumors
NCT0020645335	NCT00206453_35_T1	GENE	4	4	ER
NCT0020645335	NCT00206453_35_T2	COMPOUND	12	12	tamoxifen
NCT0020645342	NCT00206453_42_T0	GENE	6	6	Ki67
NCT0020645343	NCT00206453_43_T0	GENE	26	26	CD31
NCT0020645343	NCT00206453_43_T1	COMPOUND	6	6	docetaxel
NCT0020645343	NCT00206453_43_T2	GENE	22	22	VEGF
NCT0020645343	NCT00206453_43_T3	ORGAN	24	24	microvessel
NCT0020645345	NCT00206453_45_T0	PHENOTYPE	0	1	Side effects
NCT0020645346	NCT00206453_46_T0	PHENOTYPE	13	14	breast cancer
NCT0020645347	NCT00206453_47_T0	ORGAN	15	15	nail
NCT0020645347	NCT00206453_47_T1	PHENOTYPE	7	7	neutropenia
NCT0020645347	NCT00206453_47_T2	PHENOTYPE	9	9	anemia
NCT0020645347	NCT00206453_47_T3	PHENOTYPE	17	17	nausea
NCT0020645347	NCT00206453_47_T4	PHENOTYPE	19	19	fatigue
NCT0020645347	NCT00206453_47_T5	PHENOTYPE	10	10	cardiotoxicity
NCT0020645347	NCT00206453_47_T6	PHENOTYPE	14	14	alopecia
NCT0020645347	NCT00206453_47_T7	PHENOTYPE	8	8	infections
NCT0020645347	NCT00206453_47_T8	PHENOTYPE	18	18	vomiting
NCT0020645347	NCT00206453_47_T9	PHENOTYPE	11	13	congestive heart failure
NCT0020645347	NCT00206453_47_T10	PHENOTYPE	21	23	loss of appetite
NCT0020645348	NCT00206453_48_T0	PHENOTYPE	11	11	bleeding
NCT0020645348	NCT00206453_48_T1	PHENOTYPE	14	14	discomfort
NCT0020645348	NCT00206453_48_T2	PHENOTYPE	12	12	bruising
NCT0020645348	NCT00206453_48_T3	PHENOTYPE	0	1	Side effects
NCT0020645349	NCT00206453_49_T0	PHENOTYPE	0	0	Discomfort
NCT0020645349	NCT00206453_49_T1	PHENOTYPE	3	3	complications
NCT0020645354	NCT00206453_54_T0	ORGAN	1	1	serum
NCT0020645354	NCT00206453_54_T1	COMPOUND	5	6	chorionic gonadotropin
NCT0020645363	NCT00206453_63_T0	PHENOTYPE	2	3	chronic illness
NCT002064662	NCT00206466_2_T0	PHENOTYPE	14	15	breast cancer
NCT002064665	NCT00206466_5_T0	COMPOUND	11	11	docetaxel
NCT002064668	NCT00206466_8_T0	COMPOUND	6	6	cyclophosphamide
NCT002064668	NCT00206466_8_T1	COMPOUND	2	2	doxorubicin
NCT0020646610	NCT00206466_10_T0	PHENOTYPE	2	2	tumors
NCT0020646610	NCT00206466_10_T1	GENE	4	4	ER
NCT0020646610	NCT00206466_10_T2	COMPOUND	12	12	tamoxifen
NCT0020646613	NCT00206466_13_T0	GENE	7	7	has
NCT0020646613	NCT00206466_13_T1	PHENOTYPE	13	14	breast cancer
NCT0020646614	NCT00206466_14_T0	PHENOTYPE	3	4	primary tumor
NCT0020646616	NCT00206466_16_T0	GENE	13	13	ER
NCT0020646616	NCT00206466_16_T1	COMPOUND	20	20	tamoxifen
NCT0020646616	NCT00206466_16_T2	GENE	11	12	estrogen receptor
NCT0020646619	NCT00206466_19_T0	GENE	2	3	topoisomerase II
NCT0020646620	NCT00206466_20_T0	GENE	7	7	c-erbB2
NCT0020646622	NCT00206466_22_T0	PHENOTYPE	18	18	decisions
NCT0020646622	NCT00206466_22_T1	GENE	7	7	ER
NCT0020646622	NCT00206466_22_T2	PHENOTYPE	38	39	her disease
NCT0020646623	NCT00206466_23_T0	PHENOTYPE	6	6	tumors
NCT0020646623	NCT00206466_23_T1	COMPOUND	7	7	3cm
NCT0020646623	NCT00206466_23_T2	PHENOTYPE	10	11	breast cancer
NCT0020646623	NCT00206466_23_T3	PHENOTYPE	24	25	breast cancer
NCT0020646624	NCT00206466_24_T0	PHENOTYPE	17	17	tumor
NCT0020646626	NCT00206466_26_T0	PHENOTYPE	27	27	tumors
NCT0020646626	NCT00206466_26_T1	COMPOUND	22	22	cyclophosphamide
NCT0020646626	NCT00206466_26_T2	COMPOUND	20	20	doxorubicin
NCT0020646627	NCT00206466_27_T0	PHENOTYPE	13	13	tumors
NCT0020646627	NCT00206466_27_T1	GENE	17	17	cm
NCT0020646627	NCT00206466_27_T2	PHENOTYPE	27	28	progressive disease
NCT0020646628	NCT00206466_28_T0	GENE	0	0	cDNA
NCT0020646628	NCT00206466_28_T1	GENE	18	18	cDNA
NCT0020646628	NCT00206466_28_T2	BIOLOGICAL_PROCESS	6	7	Gene Expression
NCT0020646628	NCT00206466_28_T3	BIOLOGICAL_PROCESS	15	16	gene expression
NCT0020646628	NCT00206466_28_T4	PHENOTYPE	37	38	breast cancers
NCT0020646629	NCT00206466_29_T0	PHENOTYPE	8	8	leukemia
NCT0020646630	NCT00206466_30_T0	PHENOTYPE	8	9	acute leukemia
NCT0020646630	NCT00206466_30_T1	ORGAN	0	1	Bone marrow
NCT0020646632	NCT00206466_32_T0	BIOLOGICAL_PROCESS	6	7	gene expression
NCT0020646632	NCT00206466_32_T1	BIOLOGICAL_PROCESS	22	23	gene expression
NCT0020646632	NCT00206466_32_T2	PHENOTYPE	30	31	breast cancers
NCT0020646633	NCT00206466_33_T0	PHENOTYPE	14	14	initiation
NCT0020646633	NCT00206466_33_T1	PHENOTYPE	8	9	breast cancers
NCT0020646635	NCT00206466_35_T0	BIOLOGICAL_PROCESS	4	5	gene expression
NCT0020646636	NCT00206466_36_T0	GENE	10	10	PR
NCT0020646636	NCT00206466_36_T1	PHENOTYPE	5	5	tumors
NCT0020646636	NCT00206466_36_T2	GENE	12	12	NR
NCT0020646636	NCT00206466_36_T3	GENE	9	9	CR
NCT0020646641	NCT00206466_41_T0	PHENOTYPE	5	5	proliferation
NCT0020646641	NCT00206466_41_T1	GENE	10	10	MYC
NCT0020646641	NCT00206466_41_T2	GENE	9	9	ABL1
NCT0020646641	NCT00206466_41_T3	GENE	8	8	oncogene
NCT0020646641	NCT00206466_41_T4	GENE	12	12	JUNB
NCT0020646649	NCT00206466_49_T0	COMPOUND	10	10	3
NCT0020646649	NCT00206466_49_T1	GENE	11	11	cm
NCT0020646649	NCT00206466_49_T2	PHENOTYPE	1	2	breast cancers
NCT0020646651	NCT00206466_51_T0	ORGAN	1	1	serum
NCT0020646655	NCT00206466_55_T0	COMPOUND	3	3	creatinine
NCT0020646655	NCT00206466_55_T1	GENE	5	5	1.5
NCT0020646659	NCT00206466_59_T0	PHENOTYPE	3	3	acute
NCT0020646663	NCT00206466_63_T0	COMPOUND	16	16	MUGA
NCT0020646663	NCT00206466_63_T1	PHENOTYPE	10	12	ventricular ejection fraction
NCT0020646665	NCT00206466_65_T0	PHENOTYPE	2	4	metastatic breast cancer
NCT0020646671	NCT00206466_71_T0	PHENOTYPE	2	3	chronic illness
NCT0020646677	NCT00206466_77_T0	PHENOTYPE	3	3	hypertension
NCT0020646677	NCT00206466_77_T1	PHENOTYPE	15	16	arterial disease
NCT0020646677	NCT00206466_77_T2	PHENOTYPE	6	8	congestive heart failure
NCT0020646677	NCT00206466_77_T3	PHENOTYPE	9	11	acute myocardial infarction
NCT0020646679	NCT00206466_79_T0	PHENOTYPE	6	6	malignancy
NCT002064921	NCT00206492_1_T0	PHENOTYPE	12	13	breast cancer
NCT002064923	NCT00206492_3_T0	PHENOTYPE	25	26	breast cancer
NCT0020649214	NCT00206492_14_T0	BIOLOGICAL_PROCESS	17	17	transcription
NCT0020649214	NCT00206492_14_T1	GENE	8	8	has
NCT0020649214	NCT00206492_14_T2	GENE	19	20	cyclin D1
NCT0020649219	NCT00206492_19_T0	CELL	14	14	cells
NCT0020649219	NCT00206492_19_T1	PHENOTYPE	13	13	tumor
NCT0020649219	NCT00206492_19_T2	GENE	3	3	HER2
NCT0020649219	NCT00206492_19_T3	GENE	9	9	EGFR
NCT0020649223	NCT00206492_23_T0	GENE	7	7	cyclin
NCT0020649223	NCT00206492_23_T1	PHENOTYPE	2	2	progression
NCT0020649223	NCT00206492_23_T2	GENE	19	19	CDK
NCT0020649223	NCT00206492_23_T3	GENE	24	24	P27KIP1
NCT0020649223	NCT00206492_23_T4	BIOLOGICAL_PROCESS	0	1	Cell cycle
NCT0020649224	NCT00206492_24_T0	CELL	9	9	cells
NCT0020649224	NCT00206492_24_T1	GENE	2	2	CDK
NCT0020649229	NCT00206492_29_T0	PHENOTYPE	40	40	toxicity
NCT0020649229	NCT00206492_29_T1	GENE	3	3	II
NCT0020649229	NCT00206492_29_T2	GENE	15	15	had
NCT0020649229	NCT00206492_29_T3	PHENOTYPE	37	38	disease progression
NCT0020649229	NCT00206492_29_T4	PHENOTYPE	9	11	metastatic breast cancer
NCT0020649230	NCT00206492_30_T0	PHENOTYPE	9	9	toxicity
NCT0020649234	NCT00206492_34_T0	GENE	8	8	II
NCT0020649234	NCT00206492_34_T1	PHENOTYPE	3	3	toxicity
NCT0020649235	NCT00206492_35_T0	GENE	6	6	had
NCT0020649235	NCT00206492_35_T1	COMPOUND	18	18	tamoxifen
NCT0020649235	NCT00206492_35_T2	PHENOTYPE	14	15	disease progression
NCT0020649236	NCT00206492_36_T0	GENE	2	2	had
NCT0020649236	NCT00206492_36_T1	GENE	8	8	had
NCT0020649237	NCT00206492_37_T0	PHENOTYPE	4	4	toxicity
NCT0020649237	NCT00206492_37_T1	PHENOTYPE	14	14	NSCLC
NCT0020649242	NCT00206492_42_T0	GENE	11	11	cm
NCT0020649242	NCT00206492_42_T1	PHENOTYPE	16	17	metastatic disease
NCT0020649242	NCT00206492_42_T2	PHENOTYPE	1	2	breast cancers
NCT0020649244	NCT00206492_44_T0	ORGAN	1	1	serum
NCT0020649252	NCT00206492_52_T0	COMPOUND	4	4	2
NCT0020649260	NCT00206492_60_T0	PHENOTYPE	2	3	chronic illness
NCT0020649264	NCT00206492_64_T0	PHENOTYPE	3	3	hypertension
NCT0020649264	NCT00206492_64_T1	PHENOTYPE	15	16	arterial disease
NCT0020649264	NCT00206492_64_T2	PHENOTYPE	6	8	congestive heart failure
NCT0020649264	NCT00206492_64_T3	PHENOTYPE	9	11	acute myocardial infarction
NCT0020649268	NCT00206492_68_T0	PHENOTYPE	4	6	interstitial lung disease
NCT0020649270	NCT00206492_70_T0	COMPOUND	5	5	rifampicin
NCT0020649270	NCT00206492_70_T1	COMPOUND	3	3	phenytoin
NCT0020649270	NCT00206492_70_T2	COMPOUND	4	4	carbamazepine
NCT002065053	NCT00206505_3_T0	GENE	7	7	has
NCT002065053	NCT00206505_3_T1	PHENOTYPE	14	15	breast cancer
NCT002065054	NCT00206505_4_T0	PHENOTYPE	3	4	primary tumor
NCT002065056	NCT00206505_6_T0	GENE	1	1	receptor
NCT002065056	NCT00206505_6_T1	GENE	2	2	ER
NCT002065056	NCT00206505_6_T2	COMPOUND	12	12	tamoxifen
NCT002065056	NCT00206505_6_T3	GENE	4	5	progesterone receptor
NCT002065058	NCT00206505_8_T0	COMPOUND	15	15	5_fluorouracil
NCT002065058	NCT00206505_8_T1	COMPOUND	12	12	cyclophosphamide
NCT002065058	NCT00206505_8_T2	COMPOUND	13	13	methotrexate
NCT002065058	NCT00206505_8_T3	GENE	3	3	has
NCT002065058	NCT00206505_8_T4	GENE	2	2	c-erbB-2
NCT0020650513	NCT00206505_13_T0	CELL	11	11	cells
NCT0020650513	NCT00206505_13_T1	GENE	3	3	has
NCT0020650516	NCT00206505_16_T0	PHENOTYPE	17	17	tumor
NCT0020650516	NCT00206505_16_T1	GENE	2	2	has
NCT0020650517	NCT00206505_17_T0	PHENOTYPE	18	18	recurrence
NCT0020650517	NCT00206505_17_T1	PHENOTYPE	2	2	strategies
NCT0020650517	NCT00206505_17_T2	PHENOTYPE	11	12	breast cancer
NCT0020650518	NCT00206505_18_T0	PHENOTYPE	11	11	recurrence
NCT0020650519	NCT00206505_19_T0	PHENOTYPE	2	2	strategies
NCT0020650520	NCT00206505_20_T0	COMPOUND	12	12	paclitaxel
NCT0020650520	NCT00206505_20_T1	COMPOUND	14	14	docetaxel
NCT0020650526	NCT00206505_26_T0	PHENOTYPE	10	11	metastatic disease
NCT0020650526	NCT00206505_26_T1	PHENOTYPE	2	3	breast cancers
NCT0020650526	NCT00206505_26_T2	PHENOTYPE	6	7	breast cancers
NCT0020650527	NCT00206505_27_T0	PHENOTYPE	2	2	cancers
NCT0020650527	NCT00206505_27_T1	GENE	11	11	cm
NCT0020650529	NCT00206505_29_T0	ORGAN	1	1	serum
NCT0020650531	NCT00206505_31_T0	GENE	20	20	100
NCT0020650531	NCT00206505_31_T1	GENE	14	14	1.5
NCT0020650531	NCT00206505_31_T2	CELL	10	10	neutrophil
NCT0020650531	NCT00206505_31_T3	CELL	18	18	platelets
NCT0020650531	NCT00206505_31_T4	ORGAN	1	2	bone marrow
NCT0020650534	NCT00206505_34_T0	COMPOUND	2	2	bilirubin
NCT0020650534	NCT00206505_34_T1	ORGAN	1	1	serum
NCT0020650536	NCT00206505_36_T0	PHENOTYPE	3	3	acute
NCT0020650538	NCT00206505_38_T0	COMPOUND	10	10	1
NCT0020650538	NCT00206505_38_T1	COMPOUND	4	4	2
NCT0020650538	NCT00206505_38_T2	ORGAN	5	5	Appendix
NCT0020650548	NCT00206505_48_T0	PHENOTYPE	2	3	chronic illness
NCT0020650554	NCT00206505_54_T0	PHENOTYPE	3	3	hypertension
NCT0020650554	NCT00206505_54_T1	PHENOTYPE	12	13	arterial disease
NCT0020650554	NCT00206505_54_T2	PHENOTYPE	6	8	congestive heart failure
NCT002065182	NCT00206518_2_T0	PHENOTYPE	5	6	breast cancer
NCT002065185	NCT00206518_5_T0	PHENOTYPE	4	4	tumors
NCT002065185	NCT00206518_5_T1	COMPOUND	5	5	3cm
NCT002065185	NCT00206518_5_T2	PHENOTYPE	8	9	breast cancer
NCT002065185	NCT00206518_5_T3	PHENOTYPE	22	23	breast cancer
NCT002065186	NCT00206518_6_T0	PHENOTYPE	17	17	tumor
NCT002065187	NCT00206518_7_T0	GENE	7	7	has
NCT002065188	NCT00206518_8_T0	PHENOTYPE	19	19	tumor
NCT002065189	NCT00206518_9_T0	GENE	44	44	al
NCT002065189	NCT00206518_9_T1	COMPOUND	10	10	docetaxol
NCT002065189	NCT00206518_9_T2	GENE	43	43	et
NCT002065189	NCT00206518_9_T3	PHENOTYPE	59	60	breast cancer
NCT002065189	NCT00206518_9_T4	BIOLOGICAL_PROCESS	45	46	Gene expression
NCT002065189	NCT00206518_9_T5	BIOLOGICAL_PROCESS	15	16	gene expression
NCT002065189	NCT00206518_9_T6	BIOLOGICAL_PROCESS	53	55	response to docetaxel
NCT0020651812	NCT00206518_12_T0	GENE	32	32	II
NCT0020651812	NCT00206518_12_T1	BIOLOGICAL_PROCESS	24	25	gene expression
NCT0020651814	NCT00206518_14_T0	PHENOTYPE	17	18	adverse events
NCT0020651821	NCT00206518_21_T0	COMPOUND	10	10	3
NCT0020651821	NCT00206518_21_T1	GENE	11	11	cm
NCT0020651821	NCT00206518_21_T2	PHENOTYPE	1	2	breast cancers
NCT0020651823	NCT00206518_23_T0	ORGAN	1	1	serum
NCT0020651831	NCT00206518_31_T0	PHENOTYPE	3	3	acute
NCT0020651835	NCT00206518_35_T0	COMPOUND	19	19	MUGA
NCT0020651835	NCT00206518_35_T1	PHENOTYPE	10	12	ventricular ejection fraction
NCT0020651837	NCT00206518_37_T0	PHENOTYPE	2	4	metastatic breast cancer
NCT0020651843	NCT00206518_43_T0	PHENOTYPE	2	3	chronic illness
NCT0020651849	NCT00206518_49_T0	PHENOTYPE	3	3	hypertension
NCT0020651849	NCT00206518_49_T1	PHENOTYPE	15	16	arterial disease
NCT0020651849	NCT00206518_49_T2	PHENOTYPE	6	8	congestive heart failure
NCT0020651849	NCT00206518_49_T3	PHENOTYPE	9	11	acute myocardial infarction
NCT0020651851	NCT00206518_51_T0	PHENOTYPE	6	6	malignancy
NCT002065312	NCT00206531_2_T0	CELL	3	4	T cells
NCT002065313	NCT00206531_3_T0	CELL	5	5	cells
NCT002065319	NCT00206531_9_T0	CELL	20	20	T-cells
NCT002065319	NCT00206531_9_T1	CELL	38	38	T-cells
NCT0020653110	NCT00206531_10_T0	GENE	8	8	CD31
NCT0020653110	NCT00206531_10_T1	GENE	13	13	CD31
NCT0020653110	NCT00206531_10_T2	PHENOTYPE	19	19	acute
NCT0020653110	NCT00206531_10_T3	GENE	15	15	CD4
NCT0020653110	NCT00206531_10_T4	GENE	10	10	thymic
NCT0020653110	NCT00206531_10_T5	CELL	16	16	T-cells
NCT0020653110	NCT00206531_10_T6	PHENOTYPE	22	22	chronic
NCT0020653111	NCT00206531_11_T0	PHENOTYPE	28	28	acute
NCT0020653111	NCT00206531_11_T1	PHENOTYPE	31	31	chronic
NCT0020653111	NCT00206531_11_T2	PHENOTYPE	33	34	HIV infection
NCT0020653112	NCT00206531_12_T0	GENE	10	10	CD31
NCT0020653112	NCT00206531_12_T1	GENE	15	15	CD31
NCT0020653112	NCT00206531_12_T2	CELL	7	7	T-cells
NCT002065440	NCT00206544_0_T0	GENE	11	11	er
NCT002065440	NCT00206544_0_T1	PHENOTYPE	6	8	Bipolar Affective Disorder
NCT002065442	NCT00206544_2_T0	PHENOTYPE	18	19	manic symptoms
NCT002065448	NCT00206544_8_T0	COMPOUND	13	13	progesterone
NCT0020654424	NCT00206544_24_T0	COMPOUND	42	42	estrogen
NCT0020654424	NCT00206544_24_T1	COMPOUND	26	26	danazol
NCT0020654424	NCT00206544_24_T2	COMPOUND	44	44	progesterone
NCT0020654424	NCT00206544_24_T3	GENE	36	36	al
NCT0020654424	NCT00206544_24_T4	GENE	35	35	et
NCT0020654424	NCT00206544_24_T5	PHENOTYPE	9	9	mania
NCT0020654424	NCT00206544_24_T6	PHENOTYPE	31	31	mania
NCT0020654424	NCT00206544_24_T7	PHENOTYPE	49	49	mania
NCT0020654425	NCT00206544_25_T0	GENE	7	7	al
NCT0020654425	NCT00206544_25_T1	COMPOUND	12	12	tamoxifen
NCT0020654425	NCT00206544_25_T2	GENE	6	6	et
NCT0020654425	NCT00206544_25_T3	PHENOTYPE	15	16	manic symptoms
NCT0020654426	NCT00206544_26_T0	COMPOUND	18	18	lithium
NCT0020654427	NCT00206544_27_T0	PHENOTYPE	0	0	Mania
NCT0020654428	NCT00206544_28_T0	PHENOTYPE	24	24	symptoms
NCT0020654428	NCT00206544_28_T1	PHENOTYPE	26	26	mania
NCT0020654428	NCT00206544_28_T2	PHENOTYPE	11	12	affective disorder
NCT0020654429	NCT00206544_29_T0	COMPOUND	2	2	THE
NCT0020654429	NCT00206544_29_T1	PHENOTYPE	29	30	acute mania
NCT0020654431	NCT00206544_31_T0	PHENOTYPE	10	10	mania
NCT0020654431	NCT00206544_31_T1	PHENOTYPE	20	21	schizoaffective disorder
NCT0020654431	NCT00206544_31_T2	PHENOTYPE	16	18	bipolar affective disorder
NCT0020654432	NCT00206544_32_T0	GENE	12	12	has
NCT0020654443	NCT00206544_43_T0	PHENOTYPE	2	2	withdrawn
NCT0020654443	NCT00206544_43_T1	GENE	11	11	has
NCT0020654443	NCT00206544_43_T2	PHENOTYPE	12	12	resolved
NCT0020654443	NCT00206544_43_T3	PHENOTYPE	9	10	adverse event
NCT0020654451	NCT00206544_51_T0	COMPOUND	11	11	progesterone
NCT0020654456	NCT00206544_56_T0	PHENOTYPE	3	5	Medication side effects
NCT0020654459	NCT00206544_59_T0	ORGAN	20	20	appendix
NCT0020654459	NCT00206544_59_T1	GENE	5	5	FOR
NCT0020654459	NCT00206544_59_T2	GENE	17	17	al
NCT0020654459	NCT00206544_59_T3	PHENOTYPE	7	7	SCID
NCT0020654459	NCT00206544_59_T4	GENE	16	16	et
NCT0020654464	NCT00206544_64_T0	PHENOTYPE	9	9	severity
NCT0020654464	NCT00206544_64_T1	PHENOTYPE	11	11	manic
NCT0020654465	NCT00206544_65_T0	GENE	8	8	Kay
NCT0020654465	NCT00206544_65_T1	GENE	10	10	al
NCT0020654465	NCT00206544_65_T2	PHENOTYPE	3	3	SYMPTOM
NCT0020654465	NCT00206544_65_T3	GENE	9	9	et
NCT0020654472	NCT00206544_72_T0	PHENOTYPE	15	15	severity
NCT0020654473	NCT00206544_73_T0	GENE	2	2	SAS
NCT0020654473	NCT00206544_73_T1	GENE	4	4	SAS
NCT0020654474	NCT00206544_74_T0	PHENOTYPE	8	8	symptoms
NCT0020654474	NCT00206544_74_T1	PHENOTYPE	18	18	severity
NCT0020654475	NCT00206544_75_T0	PHENOTYPE	1	1	AKATHISIA
NCT0020654475	NCT00206544_75_T1	PHENOTYPE	7	7	severity
NCT0020654475	NCT00206544_75_T2	PHENOTYPE	9	9	akathisia
NCT0020654475	NCT00206544_75_T3	PHENOTYPE	23	23	Akathisia
NCT0020654476	NCT00206544_76_T0	PHENOTYPE	9	9	akathisia
NCT0020654476	NCT00206544_76_T1	PHENOTYPE	24	24	akathisia
NCT0020654476	NCT00206544_76_T2	PHENOTYPE	29	29	akathisia
NCT0020654476	NCT00206544_76_T3	PHENOTYPE	14	16	feeling of restlessness
NCT0020654477	NCT00206544_77_T0	PHENOTYPE	25	25	menopausal
NCT0020654477	NCT00206544_77_T1	GENE	1	1	CYCLE
NCT0020654477	NCT00206544_77_T2	BIOLOGICAL_PROCESS	18	19	Menstrual Cycle
NCT0020654478	NCT00206544_78_T0	BIOLOGICAL_PROCESS	10	11	menstrual cycle
NCT0020654481	NCT00206544_81_T0	BIOLOGICAL_PROCESS	16	16	menstruation
NCT0020654483	NCT00206544_83_T0	ORGAN	0	0	Serum
NCT0020654486	NCT00206544_86_T0	PHENOTYPE	7	8	Mental Health
NCT0020654488	NCT00206544_88_T0	COMPOUND	3	3	estrogen
NCT0020654488	NCT00206544_88_T1	GENE	11	11	prolactin
NCT0020654488	NCT00206544_88_T2	COMPOUND	4	4	progesterone
NCT0020654488	NCT00206544_88_T3	GENE	6	6	hormone
NCT0020654488	NCT00206544_88_T4	GENE	9	9	hormone
NCT0020654489	NCT00206544_89_T0	COMPOUND	6	6	estrogen
NCT0020654490	NCT00206544_90_T0	COMPOUND	3	3	THE
NCT0020654490	NCT00206544_90_T1	PHENOTYPE	1	1	BATTERY
NCT0020654490	NCT00206544_90_T2	GENE	2	2	FOR
NCT0020654490	NCT00206544_90_T3	PHENOTYPE	11	12	cognitive function
NCT0020654492	NCT00206544_92_T0	PHENOTYPE	5	6	adverse events
NCT0020654493	NCT00206544_93_T0	GENE	27	27	has
NCT0020654493	NCT00206544_93_T1	PHENOTYPE	28	28	resolved
NCT0020654493	NCT00206544_93_T2	PHENOTYPE	25	26	adverse event
NCT0020654493	NCT00206544_93_T3	PHENOTYPE	1	2	adverse events
NCT0020654495	NCT00206544_95_T0	GENE	3	3	has
NCT00206544100	NCT00206544_100_T0	GENE	21	21	hormone
NCT00206544100	NCT00206544_100_T1	PHENOTYPE	9	10	adverse events
NCT00206544106	NCT00206544_106_T0	GENE	4	4	retained
NCT002065570	NCT00206557_0_T0	PHENOTYPE	11	11	Schizophrenia
NCT002065574	NCT00206557_4_T0	COMPOUND	7	7	raloxifene
NCT002065574	NCT00206557_4_T1	GENE	9	9	HT
NCT002065574	NCT00206557_4_T2	COMPOUND	1	1	1
NCT002065574	NCT00206557_4_T3	COMPOUND	31	31	2
NCT002065574	NCT00206557_4_T4	PHENOTYPE	16	17	psychotic symptoms
NCT002065577	NCT00206557_7_T0	GENE	12	12	al
NCT002065577	NCT00206557_7_T1	PHENOTYPE	22	22	schizophrenia
NCT002065577	NCT00206557_7_T2	GENE	11	11	et
NCT002065577	NCT00206557_7_T3	COMPOUND	27	27	estradiol
NCT002065578	NCT00206557_8_T0	PHENOTYPE	11	11	acute
NCT002065578	NCT00206557_8_T1	COMPOUND	3	3	estrogen
NCT002065578	NCT00206557_8_T2	PHENOTYPE	12	13	psychotic symptoms
NCT0020655710	NCT00206557_10_T0	PHENOTYPE	5	5	menopausal
NCT0020655710	NCT00206557_10_T1	GENE	12	12	had
NCT0020655710	NCT00206557_10_T2	COMPOUND	10	10	estradiol
NCT0020655711	NCT00206557_11_T0	GENE	2	2	al
NCT0020655711	NCT00206557_11_T1	GENE	1	1	et
NCT0020655712	NCT00206557_12_T0	COMPOUND	6	6	estrogen
NCT0020655712	NCT00206557_12_T1	COMPOUND	25	25	estrogen
NCT0020655712	NCT00206557_12_T2	PHENOTYPE	16	16	schizophrenia
NCT0020655712	NCT00206557_12_T3	PHENOTYPE	13	13	menopausal
NCT0020655713	NCT00206557_13_T0	COMPOUND	11	11	estrogen
NCT0020655713	NCT00206557_13_T1	COMPOUND	13	13	progesterone
NCT0020655714	NCT00206557_14_T0	COMPOUND	12	12	hydrochloride
NCT0020655714	NCT00206557_14_T1	COMPOUND	11	11	raloxifene
NCT0020655714	NCT00206557_14_T2	GENE	6	7	estrogen receptor
NCT0020655716	NCT00206557_16_T0	PHENOTYPE	1	1	inference
NCT0020655716	NCT00206557_16_T1	COMPOUND	3	3	raloxifene
NCT0020655716	NCT00206557_16_T2	COMPOUND	10	10	dopamine
NCT0020655716	NCT00206557_16_T3	COMPOUND	19	20	conjugated estrogen
NCT0020655718	NCT00206557_18_T0	PHENOTYPE	7	8	cognitive impairment
NCT0020655719	NCT00206557_19_T0	COMPOUND	12	12	raloxifene
NCT0020655719	NCT00206557_19_T1	PHENOTYPE	14	15	psychotic symptoms
NCT0020655720	NCT00206557_20_T0	PHENOTYPE	26	26	schizophrenia
NCT0020655720	NCT00206557_20_T1	COMPOUND	19	19	raloxifene
NCT0020655720	NCT00206557_20_T2	PHENOTYPE	21	22	psychotic symptoms
NCT0020655721	NCT00206557_21_T0	PHENOTYPE	22	22	schizophrenia
NCT0020655721	NCT00206557_21_T1	PHENOTYPE	36	36	schizophrenia
NCT0020655721	NCT00206557_21_T2	COMPOUND	11	11	raloxifene
NCT0020655721	NCT00206557_21_T3	PHENOTYPE	40	42	quality of life
NCT002065703	NCT00206570_3_T0	PHENOTYPE	6	6	symptoms
NCT002065703	NCT00206570_3_T1	PHENOTYPE	18	18	symptoms
NCT002065703	NCT00206570_3_T2	PHENOTYPE	9	9	delusions
NCT002065703	NCT00206570_3_T3	BIOLOGICAL_PROCESS	12	12	behaviour
NCT002065703	NCT00206570_3_T4	PHENOTYPE	8	8	hallucinations
NCT002065704	NCT00206570_4_T0	PHENOTYPE	0	0	Schizophrenia
NCT002065704	NCT00206570_4_T1	PHENOTYPE	8	9	brain disorder
NCT002065706	NCT00206570_6_T0	PHENOTYPE	11	11	schizophrenia
NCT002065707	NCT00206570_7_T0	PHENOTYPE	6	6	schizophrenia
NCT002065709	NCT00206570_9_T0	PHENOTYPE	4	4	schizophrenia
NCT002065709	NCT00206570_9_T1	GENE	5	5	has
NCT0020657012	NCT00206570_12_T0	COMPOUND	9	9	estrogen
NCT0020657012	NCT00206570_12_T1	COMPOUND	32	32	estrogen
NCT0020657012	NCT00206570_12_T2	PHENOTYPE	18	18	schizophrenia
NCT0020657014	NCT00206570_14_T0	COMPOUND	11	11	estrogen
NCT0020657014	NCT00206570_14_T1	PHENOTYPE	9	9	schizophrenia
NCT0020657015	NCT00206570_15_T0	COMPOUND	17	17	estradiol
NCT0020657017	NCT00206570_17_T0	COMPOUND	1	1	estrogen
NCT0020657017	NCT00206570_17_T1	PHENOTYPE	13	14	psychotic symptoms
NCT0020657018	NCT00206570_18_T0	PHENOTYPE	24	24	schizophrenia
NCT0020657018	NCT00206570_18_T1	COMPOUND	3	3	estradiol
NCT0020657020	NCT00206570_20_T0	PHENOTYPE	2	2	Schizophrenia
NCT0020657020	NCT00206570_20_T1	COMPOUND	10	10	estradiol
NCT0020657022	NCT00206570_22_T0	GENE	10	10	has
NCT0020657033	NCT00206570_33_T0	GENE	21	21	has
NCT0020657033	NCT00206570_33_T1	PHENOTYPE	17	17	centres
NCT0020657034	NCT00206570_34_T0	PHENOTYPE	12	12	Schizophrenia
NCT0020657034	NCT00206570_34_T1	PHENOTYPE	15	16	Schizophreniform Disorder
NCT0020657038	NCT00206570_38_T0	PHENOTYPE	24	24	withdrawn
NCT0020657038	NCT00206570_38_T1	PHENOTYPE	3	4	adverse effects
NCT0020657039	NCT00206570_39_T0	PHENOTYPE	2	2	withdrawn
NCT0020657039	NCT00206570_39_T1	GENE	11	11	has
NCT0020657039	NCT00206570_39_T2	PHENOTYPE	12	12	resolved
NCT0020657039	NCT00206570_39_T3	PHENOTYPE	9	10	adverse event
NCT0020657043	NCT00206570_43_T0	COMPOUND	10	10	estradiol
NCT0020657044	NCT00206570_44_T0	COMPOUND	15	15	estrogen
NCT0020657044	NCT00206570_44_T1	BIOLOGICAL_PROCESS	7	8	menstrual cycle
NCT0020657045	NCT00206570_45_T0	COMPOUND	6	6	estrogen
NCT0020657046	NCT00206570_46_T0	GENE	4	4	Kay
NCT0020657046	NCT00206570_46_T1	GENE	6	6	al
NCT0020657046	NCT00206570_46_T2	GENE	5	5	et
NCT0020657049	NCT00206570_49_T0	ORGAN	17	17	serum
NCT0020657049	NCT00206570_49_T1	GENE	18	18	hormone
NCT0020657049	NCT00206570_49_T2	PHENOTYPE	10	11	Involuntary Movement
NCT0020657056	NCT00206570_56_T0	GENE	4	4	retained
NCT002066091	NCT00206609_1_T0	COMPOUND	6	6	oxygen
NCT002066091	NCT00206609_1_T1	PHENOTYPE	8	10	shortness of breath
NCT002066095	NCT00206609_5_T0	PHENOTYPE	1	1	strategies
NCT002066098	NCT00206609_8_T0	COMPOUND	8	8	oxygen
NCT002066098	NCT00206609_8_T1	PHENOTYPE	14	14	dyspnoea
NCT0020660910	NCT00206609_10_T0	GENE	9	9	compressed
NCT0020660910	NCT00206609_10_T1	COMPOUND	7	7	oxygen
NCT0020660910	NCT00206609_10_T2	PHENOTYPE	15	15	dyspnoea
NCT0020660912	NCT00206609_12_T0	COMPOUND	5	5	oxygen
NCT0020660912	NCT00206609_12_T1	PHENOTYPE	11	11	dyspnoea
NCT0020660912	NCT00206609_12_T2	PHENOTYPE	15	16	advanced cancer
NCT0020660914	NCT00206609_14_T0	PHENOTYPE	20	20	hypoxia
NCT0020660914	NCT00206609_14_T1	COMPOUND	5	5	oxygen
NCT0020660914	NCT00206609_14_T2	PHENOTYPE	11	11	dyspnoea
NCT0020660914	NCT00206609_14_T3	PHENOTYPE	16	17	advanced cancer
NCT0020660916	NCT00206609_16_T0	PHENOTYPE	5	5	hypoxia
NCT0020660916	NCT00206609_16_T1	COMPOUND	20	20	oxygen
NCT0020660916	NCT00206609_16_T2	PHENOTYPE	12	12	dyspnoea
NCT0020660918	NCT00206609_18_T0	GENE	9	9	compressed
NCT0020660918	NCT00206609_18_T1	PHENOTYPE	2	2	dyspnoea
NCT0020660920	NCT00206609_20_T0	PHENOTYPE	5	5	hypoxic
NCT0020660920	NCT00206609_20_T1	PHENOTYPE	14	14	hypoxic
NCT0020660920	NCT00206609_20_T2	COMPOUND	21	21	oxygen
NCT0020660920	NCT00206609_20_T3	PHENOTYPE	19	19	dyspnoea
NCT0020660922	NCT00206609_22_T0	COMPOUND	12	12	oxygen
NCT0020660922	NCT00206609_22_T1	PHENOTYPE	4	4	dyspnoea
NCT0020660922	NCT00206609_22_T2	PHENOTYPE	8	8	dyspnoea
NCT0020660924	NCT00206609_24_T0	COMPOUND	2	2	oxygen
